ID	Gene Name	Species	BBID	BIOCARTA	GOTERM_BP_DIRECT	GOTERM_CC_DIRECT	GOTERM_MF_DIRECT	INTERPRO	KEGG_PATHWAY	OMIM_DISEASE	PIR_SUPERFAMILY	SMART	UP_KW_BIOLOGICAL_PROCESS	UP_KW_CELLULAR_COMPONENT	UP_KW_DISEASE	UP_KW_DOMAIN	UP_KW_LIGAND	UP_KW_MOLECULAR_FUNCTION	UP_KW_PTM	UP_SEQ_FEATURE
OASL	2'-5'-oligoadenylate synthetase like(OASL)	Homo sapiens			GO:0009615~response to virus,GO:0045071~negative regulation of viral genome replication,GO:0045087~innate immune response,GO:0051607~defense response to virus,GO:0060700~regulation of ribonuclease activity,GO:0070106~interleukin-27-mediated signaling pathway,GO:1900246~positive regulation of RIG-I signaling pathway,	GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016020~membrane,	GO:0003677~DNA binding,GO:0003723~RNA binding,GO:0003725~double-stranded RNA binding,GO:0005515~protein binding,GO:0016779~nucleotidyltransferase activity,GO:0046966~thyroid hormone receptor binding,	IPR000626:Ubiquitin-like_dom,IPR006116:NT_2-5OAS_ClassI-CCAase,IPR006117:2-5OAS_C_CS,IPR018952:2-5-oligoAdlate_synth_1_dom2/C,IPR029071:Ubiquitin-like_domsf,IPR043518:2-5OAS_N_CS,IPR043519:NT_sf,	hsa05165:Human papillomavirus infection,			SM00213:UBQ,	KW-0051~Antiviral defense,KW-0391~Immunity,KW-0399~Innate immunity,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,		KW-0694~RNA-binding,	KW-0007~Acetylation,	DOMAIN:2'-5'-oligoadenylate synthetase 1,DOMAIN:Ubiquitin-like,DOMAIN:Ubiquitin-like 1,DOMAIN:Ubiquitin-like 2,REGION:Disordered,
DNPH1	2'-deoxynucleoside 5'-phosphate N-hydrolase 1(DNPH1)	Homo sapiens			GO:0006195~purine nucleotide catabolic process,GO:0009117~nucleotide metabolic process,GO:0009159~deoxyribonucleoside monophosphate catabolic process,GO:0030307~positive regulation of cell growth,GO:0030855~epithelial cell differentiation,GO:0043174~nucleoside salvage,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0070694~deoxyribonucleoside 5'-monophosphate N-glycosidase activity,	IPR007710:Nucleoside_deoxyribTrfase,IPR028607:DNPH1,					KW-0546~Nucleotide metabolism,	KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0326~Glycosidase,KW-0378~Hydrolase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	BINDING:in other chain,COMPBIAS:Pro residues,MUTAGEN:E->Q: Loss of deoxyribonucleoside 5'-monophosphate N-glycosidase activity.,REGION:Disordered,
HACD3	3-hydroxyacyl-CoA dehydratase 3(HACD3)	Homo sapiens			GO:0006633~fatty acid biosynthetic process,GO:0007249~I-kappaB kinase/NF-kappaB signaling,GO:0007254~JNK cascade,GO:0007264~small GTPase mediated signal transduction,GO:0007266~Rho protein signal transduction,GO:0016601~Rac protein signal transduction,GO:0030148~sphingolipid biosynthetic process,GO:0030497~fatty acid elongation,GO:0042761~very long-chain fatty acid biosynthetic process,GO:0045070~positive regulation of viral genome replication,GO:0046726~positive regulation by virus of viral protein levels in host cell,GO:1902532~negative regulation of intracellular signal transduction,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005925~focal adhesion,GO:0031965~nuclear membrane,	GO:0005096~GTPase activator activity,GO:0005515~protein binding,GO:0018812~3-hydroxyacyl-CoA dehydratase activity,GO:0019899~enzyme binding,	IPR007052:CS_dom,IPR007482:Tyr_Pase-like_PTPLA,IPR008978:HSP20-like_chaperone,	hsa00062:Fatty acid elongation,hsa01040:Biosynthesis of unsaturated fatty acids,hsa01100:Metabolic pathways,hsa01212:Fatty acid metabolism,				KW-0275~Fatty acid biosynthesis,KW-0276~Fatty acid metabolism,KW-0443~Lipid metabolism,KW-0444~Lipid biosynthesis,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0456~Lyase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:CS,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
OXCT1	3-oxoacid CoA-transferase 1(OXCT1)	Homo sapiens			GO:0042182~ketone catabolic process,GO:0046950~cellular ketone body metabolic process,GO:0046952~ketone body catabolic process,	GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,	GO:0008260~3-oxoacid CoA-transferase activity,GO:0008410~CoA-transferase activity,	IPR004163:CoA_transf_BS,IPR004164:CoA_transf_AS,IPR004165:CoA_trans_fam_I,IPR012791:3-oxoacid_CoA-transf_B,IPR012792:3-oxoacid_CoA-transf_A,IPR014388:3-oxoacid_CoA-transferase,IPR037171:NagB/RpiA_transferase-like,	hsa00280:Valine, leucine and isoleucine degradation,hsa00650:Butanoate metabolism,hsa01100:Metabolic pathways,	245050~Succinyl CoA:3-oxoacid CoA transferase deficiency,	PIRSF000858:SCOT-t,	SM00882:CoA_trans,	KW-0443~Lipid metabolism,	KW-0496~Mitochondrion,	KW-0225~Disease variant,	KW-0732~Signal,KW-0809~Transit peptide,		KW-0808~Transferase,	KW-0597~Phosphoprotein,	ACT_SITE:5-glutamyl coenzyme A thioester intermediate,TRANSIT:Mitochondrion,
PDPK1	3-phosphoinositide dependent protein kinase 1(PDPK1)	Homo sapiens	104.Insulin_signaling,105.Signaling_glucose_uptake,106.Glycogen_synthase-synthesis,107.mRNA_translation-protein_synthesis,108.Regulating_glucose_transport,83.Growth_factors_Survival_factors_Mitogens,	h_aktPathway:AKT Signaling Pathway,h_eif4Pathway:Regulation of eIF4e and p70 S6 Kinase,H_gsk3Pathway:Inactivation of Gsk3 by AKT causes accumulation of b-catenin in Alveolar Macrophages,h_igf1mtorPathway:Skeletal muscle hypertrophy is regulated via AKT/mTOR pathway,h_mtorPathway:mTOR Signaling Pathway,h_ptdinsPathway:Phosphoinositides and their downstream targets.,h_ptenPathway:PTEN dependent cell cycle arrest and apoptosis,	GO:0003323~type B pancreatic cell development,GO:0006468~protein phosphorylation,GO:0006469~negative regulation of protein kinase activity,GO:0006972~hyperosmotic response,GO:0007173~epidermal growth factor receptor signaling pathway,GO:0008286~insulin receptor signaling pathway,GO:0010518~positive regulation of phospholipase activity,GO:0010667~negative regulation of cardiac muscle cell apoptotic process,GO:0016310~phosphorylation,GO:0016477~cell migration,GO:0018105~peptidyl-serine phosphorylation,GO:0018107~peptidyl-threonine phosphorylation,GO:0019722~calcium-mediated signaling,GO:0030036~actin cytoskeleton organization,GO:0030512~negative regulation of transforming growth factor beta receptor signaling pathway,GO:0031295~T cell costimulation,GO:0032148~activation of protein kinase B activity,GO:0032869~cellular response to insulin stimulus,GO:0034122~negative regulation of toll-like receptor signaling pathway,GO:0035556~intracellular signal transduction,GO:0043122~regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043304~regulation of mast cell degranulation,GO:0043536~positive regulation of blood vessel endothelial cell migration,GO:0045766~positive regulation of angiogenesis,GO:0046777~protein autophosphorylation,GO:0048009~insulin-like growth factor receptor signaling pathway,GO:0051281~positive regulation of release of sequestered calcium ion into cytosol,GO:0051897~positive regulation of protein kinase B signaling,GO:0071364~cellular response to epidermal growth factor stimulus,GO:0097191~extrinsic apoptotic signaling pathway,GO:1903078~positive regulation of protein localization to plasma membrane,GO:1903672~positive regulation of sprouting angiogenesis,GO:1905564~positive regulation of vascular endothelial cell proliferation,GO:2000352~negative regulation of endothelial cell apoptotic process,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0014069~postsynaptic density,GO:0016020~membrane,GO:0031410~cytoplasmic vesicle,GO:0042995~cell projection,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004676~3-phosphoinositide-dependent protein kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016004~phospholipase activator activity,GO:0043274~phospholipase binding,	IPR000719:Prot_kinase_dom,IPR008271:Ser/Thr_kinase_AS,IPR011009:Kinase-like_dom_sf,IPR011993:PH-like_dom_sf,IPR017441:Protein_kinase_ATP_BS,IPR033931:PDK1-typ_PH,IPR039046:PDPK1,	hsa01524:Platinum drug resistance,hsa03320:PPAR signaling pathway,hsa04068:FoxO signaling pathway,hsa04071:Sphingolipid signaling pathway,hsa04140:Autophagy - animal,hsa04150:mTOR signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04152:AMPK signaling pathway,hsa04210:Apoptosis,hsa04360:Axon guidance,hsa04510:Focal adhesion,hsa04660:T cell receptor signaling pathway,hsa04664:Fc epsilon RI signaling pathway,hsa04722:Neurotrophin signaling pathway,hsa04910:Insulin signaling pathway,hsa04919:Thyroid hormone signaling pathway,hsa04931:Insulin resistance,hsa04960:Aldosterone-regulated sodium reabsorption,hsa05145:Toxoplasmosis,hsa05205:Proteoglycans in cancer,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05213:Endometrial cancer,hsa05215:Prostate cancer,hsa05223:Non-small cell lung cancer,hsa05231:Choline metabolism in cancer,hsa05417:Lipid and atherosclerosis,			SM00220:S_TKc,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0965~Cell junction,KW-1003~Cell membrane,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0010~Activator,KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	ACT_SITE:Proton acceptor,COMPBIAS:Polar residues,DOMAIN:PH,DOMAIN:Protein kinase,MUTAGEN:A->V: 3-fold increase in kinase activity.,MUTAGEN:R->A: No PDGF-dependent translocation to the membrane.,MUTAGEN:S->A: Abolishes phosphorylation by MAP3K5; when associated with A-394.,MUTAGEN:S->A: Abolishes phosphorylation by MAP3K5; when associated with A-398.,MUTAGEN:S->A: No activation.,MUTAGEN:S->A: No effect.,MUTAGEN:T->A: Abolishes phosphorylation by MELK.,MUTAGEN:T->E: Enhanced kinase activity towards PKB.,MUTAGEN:Y->F: Reduction in basal activity.,MUTAGEN:Y->F: Slight reduction in pervanadate-stimulated tyrosine phosphorylation.,REGION:Disordered,REGION:PIF-pocket,
NT5C	5', 3'-nucleotidase, cytosolic(NT5C)	Homo sapiens			GO:0000255~allantoin metabolic process,GO:0006204~IMP catabolic process,GO:0006249~dCMP catabolic process,GO:0009223~pyrimidine deoxyribonucleotide catabolic process,GO:0009264~deoxyribonucleotide catabolic process,GO:0016311~dephosphorylation,GO:0043605~cellular amide catabolic process,GO:0046050~UMP catabolic process,GO:0046055~dGMP catabolic process,GO:0046074~dTMP catabolic process,GO:0046079~dUMP catabolic process,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0008252~nucleotidase activity,GO:0008253~5'-nucleotidase activity,GO:0019103~pyrimidine nucleotide binding,GO:0042802~identical protein binding,GO:0046872~metal ion binding,GO:0050483~IMP 5'-nucleotidase activity,	IPR010708:5'(3')-deoxyribonucleotidase,IPR023214:HAD_sf,IPR036412:HAD-like_sf,	hsa00230:Purine metabolism,hsa00240:Pyrimidine metabolism,hsa00760:Nicotinate and nicotinamide metabolism,hsa01100:Metabolic pathways,hsa01232:Nucleotide metabolism,				KW-0546~Nucleotide metabolism,	KW-0963~Cytoplasm,			KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,	KW-0597~Phosphoprotein,	ACT_SITE:Nucleophile,ACT_SITE:Proton donor,
XRN2	5'-3' exoribonuclease 2(XRN2)	Homo sapiens			GO:0000956~nuclear-transcribed mRNA catabolic process,GO:0006364~rRNA processing,GO:0006369~termination of RNA polymerase II transcription,GO:0006396~RNA processing,GO:0006397~mRNA processing,GO:0006401~RNA catabolic process,GO:0007283~spermatogenesis,GO:0016070~RNA metabolic process,GO:0021766~hippocampus development,GO:0030182~neuron differentiation,GO:0060041~retina development in camera-type eye,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0016020~membrane,GO:0016235~aggresome,	GO:0000175~3'-5'-exoribonuclease activity,GO:0001147~transcription termination site sequence-specific DNA binding,GO:0003676~nucleic acid binding,GO:0003723~RNA binding,GO:0004518~nuclease activity,GO:0004534~5'-3' exoribonuclease activity,GO:0005515~protein binding,GO:0008409~5'-3' exonuclease activity,GO:0042802~identical protein binding,GO:0046872~metal ion binding,	IPR004859:Xrn1_N,IPR017151:Xrn2/3/4,IPR027073:5_3_exoribonuclease,IPR041412:Xrn1_helical,	hsa03008:Ribosome biogenesis in eukaryotes,hsa03018:RNA degradation,		PIRSF037239:Exonuclease_Xrn2,		KW-0507~mRNA processing,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0806~Transcription termination,	KW-0539~Nucleus,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,KW-0269~Exonuclease,KW-0378~Hydrolase,KW-0540~Nuclease,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Xrn1 N-terminal,DOMAIN:Xrn1 helical,REGION:Disordered,ZN_FING:CCHC-type,
PHYKPL	5-phosphohydroxy-L-lysine phospho-lyase(PHYKPL)	Homo sapiens				GO:0005759~mitochondrial matrix,	GO:0005515~protein binding,GO:0008483~transaminase activity,GO:0016829~lyase activity,GO:0030170~pyridoxal phosphate binding,GO:0042802~identical protein binding,	IPR005814:Aminotrans_3,IPR015421:PyrdxlP-dep_Trfase_major,IPR015422:PyrdxlP-dep_Trfase_small,IPR015424:PyrdxlP-dep_Trfase,	hsa00310:Lysine degradation,hsa01100:Metabolic pathways,	615011~Phosphohydroxylysinuria,	PIRSF000521:Transaminase_4ab_Lys_Orn,			KW-0496~Mitochondrion,	KW-0225~Disease variant,		KW-0663~Pyridoxal phosphate,	KW-0456~Lyase,		COMPBIAS:Basic and acidic residues,REGION:Disordered,
ARAF	A-Raf proto-oncogene, serine/threonine kinase(ARAF)	Homo sapiens		h_mapkPathway:MAPKinase Signaling Pathway,	GO:0000165~MAPK cascade,GO:0001934~positive regulation of protein phosphorylation,GO:0007165~signal transduction,GO:0016310~phosphorylation,GO:0032006~regulation of TOR signaling,GO:0032434~regulation of proteasomal ubiquitin-dependent protein catabolic process,GO:0033138~positive regulation of peptidyl-serine phosphorylation,GO:0036211~protein modification process,GO:0043066~negative regulation of apoptotic process,GO:1902531~regulation of intracellular signal transduction,	GO:0005739~mitochondrion,GO:0005829~cytosol,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004709~MAP kinase kinase kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0046872~metal ion binding,	IPR000719:Prot_kinase_dom,IPR001245:Ser-Thr/Tyr_kinase_cat_dom,IPR002219:PE/DAG-bd,IPR003116:RBD_dom,IPR008271:Ser/Thr_kinase_AS,IPR011009:Kinase-like_dom_sf,IPR017441:Protein_kinase_ATP_BS,IPR020454:DAG/PE-bd,IPR029071:Ubiquitin-like_domsf,IPR046349:C1-like_sf,	hsa01521:EGFR tyrosine kinase inhibitor resistance,hsa01522:Endocrine resistance,hsa04010:MAPK signaling pathway,hsa04012:ErbB signaling pathway,hsa04068:FoxO signaling pathway,hsa04270:Vascular smooth muscle contraction,hsa04650:Natural killer cell mediated cytotoxicity,hsa04720:Long-term potentiation,hsa04726:Serotonergic synapse,hsa04730:Long-term depression,hsa04810:Regulation of actin cytoskeleton,hsa04910:Insulin signaling pathway,hsa04914:Progesterone-mediated oocyte maturation,hsa04928:Parathyroid hormone synthesis, secretion and action,hsa05010:Alzheimer disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05034:Alcoholism,hsa05160:Hepatitis C,hsa05161:Hepatitis B,hsa05200:Pathways in cancer,hsa05205:Proteoglycans in cancer,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05210:Colorectal cancer,hsa05211:Renal cell carcinoma,hsa05212:Pancreatic cancer,hsa05213:Endometrial cancer,hsa05214:Glioma,hsa05215:Prostate cancer,hsa05218:Melanoma,hsa05219:Bladder cancer,hsa05220:Chronic myeloid leukemia,hsa05221:Acute myeloid leukemia,hsa05223:Non-small cell lung cancer,hsa05224:Breast cancer,hsa05225:Hepatocellular carcinoma,hsa05226:Gastric cancer,			SM00109:C1,SM00220:S_TKc,SM00455:RBD,			KW-0656~Proto-oncogene,	KW-0863~Zinc-finger,	KW-0067~ATP-binding,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,KW-0862~Zinc,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Phorbol-ester/DAG-type,DOMAIN:Protein kinase,DOMAIN:RBD,REGION:Disordered,ZN_FING:Phorbol-ester/DAG-type,
AKAP13	A-kinase anchoring protein 13(AKAP13)	Homo sapiens		h_akap13Pathway:Rho-Selective Guanine Exchange Factor AKAP13 Mediates Stress Fiber Formation,	GO:0007186~G-protein coupled receptor signaling pathway,GO:0007507~heart development,GO:0016310~phosphorylation,GO:0035023~regulation of Rho protein signal transduction,GO:0035025~positive regulation of Rho protein signal transduction,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043410~positive regulation of MAPK cascade,GO:0051056~regulation of small GTPase mediated signal transduction,GO:0055007~cardiac muscle cell differentiation,GO:0060297~regulation of sarcomere organization,GO:0060348~bone development,GO:0071875~adrenergic receptor signaling pathway,GO:0086023~adrenergic receptor signaling pathway involved in heart process,	GO:0005634~nucleus,GO:0005829~cytosol,GO:0005938~cell cortex,GO:0015629~actin cytoskeleton,GO:0016020~membrane,GO:0030864~cortical actin cytoskeleton,	GO:0005078~MAP-kinase scaffold activity,GO:0005085~guanyl-nucleotide exchange factor activity,GO:0005515~protein binding,GO:0016301~kinase activity,GO:0031267~small GTPase binding,GO:0046872~metal ion binding,GO:0051018~protein kinase A binding,GO:0060090~binding, bridging,	IPR000219:DH-domain,IPR001849:PH_domain,IPR002219:PE/DAG-bd,IPR011993:PH-like_dom_sf,IPR018459:RII-bd_1,IPR035899:DBL_dom_sf,IPR041020:PH_16,IPR046349:C1-like_sf,	hsa04928:Parathyroid hormone synthesis, secretion and action,hsa05163:Human cytomegalovirus infection,			SM00109:C1,SM00233:PH,SM00325:RhoGEF,		KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0656~Proto-oncogene,	KW-0175~Coiled coil,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0344~Guanine-nucleotide releasing factor,KW-0418~Kinase,KW-0808~Transferase,	KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:DH,DOMAIN:PH,DOMAIN:Phorbol-ester/DAG-type,DOMAIN:RII binding,MUTAGEN:A->P: Abolishes interaction with PRKAR2A and leads to constitutive activation of RHOA; when associated with P-1260.,MUTAGEN:A->P: Abolishes interaction with PRKAR2A.,MUTAGEN:D->A: Reduces guanyl nucleotide exchange activity toward RHOA.,MUTAGEN:D->Y: Abolishes guanyl nucleotide exchange activity toward RHOA.,MUTAGEN:E->A: Decreases guanyl nucleotide exchange activity toward RHOA.,MUTAGEN:F->A: Decreases guanyl nucleotide exchange activity toward RHOA.,MUTAGEN:I->P: Abolishes interaction with PRKAR2Aand leads to constitutive activation of RHOA; when associated with P-1251.,MUTAGEN:K->Y: Abolishes guanyl nucleotide exchange activity toward RHOA.,MUTAGEN:Q->Y: Abolishes guanyl nucleotide exchange activity toward RHOA.,MUTAGEN:R->A: Decreases guanyl nucleotide exchange activity toward RHOA.,MUTAGEN:R->G: Decreases guanyl nucleotide exchange activity toward RHOA.,MUTAGEN:S->A: Abolishes interaction with YWHAB, leading to constitutive activation of RHOA and MAPK14.,MUTAGEN:W->L: Impairs interaction with IKBKB.,MUTAGEN:Y->F: Loss of guanyl nucleotide exchange activity toward RHOA.,REGION:Disordered,REGION:Important for interaction with MAP2K3,REGION:Important for interaction with PRKAR2A,REGION:Interaction with ESR1,ZN_FING:Phorbol-ester/DAG-type,
AKAP9	A-kinase anchoring protein 9(AKAP9)	Homo sapiens		h_akapcentrosomePathway:Protein Kinase A at the Centrosome,	GO:0007020~microtubule nucleation,GO:0007165~signal transduction,GO:0007268~chemical synaptic transmission,GO:0016310~phosphorylation,GO:0031116~positive regulation of microtubule polymerization,GO:0031503~protein complex localization,GO:0033138~positive regulation of peptidyl-serine phosphorylation,GO:0051602~response to electrical stimulus,GO:0051661~maintenance of centrosome location,GO:0060306~regulation of membrane repolarization,GO:0060307~regulation of ventricular cardiac muscle cell membrane repolarization,GO:0071320~cellular response to cAMP,GO:0086091~regulation of heart rate by cardiac conduction,GO:0098909~regulation of cardiac muscle cell action potential involved in regulation of contraction,GO:1901018~positive regulation of potassium ion transmembrane transporter activity,GO:1903358~regulation of Golgi organization,	GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005795~Golgi stack,GO:0005801~cis-Golgi network,GO:0005813~centrosome,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0008076~voltage-gated potassium channel complex,GO:0034705~potassium channel complex,GO:0043025~neuronal cell body,GO:0043231~intracellular membrane-bounded organelle,GO:0044307~dendritic branch,GO:0097060~synaptic membrane,GO:0098978~glutamatergic synapse,	GO:0003677~DNA binding,GO:0005102~receptor binding,GO:0005515~protein binding,GO:0015459~potassium channel regulator activity,GO:0016301~kinase activity,GO:0034237~protein kinase A regulatory subunit binding,GO:0044325~ion channel binding,GO:0060090~binding, bridging,	IPR005539:ELK_dom,IPR019528:PACT_domain,IPR028745:AKAP9/Pericentrin,		611820~Long QT syndrome 11,		SM01188:ELK,		KW-0206~Cytoskeleton,KW-0333~Golgi apparatus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0454~Long QT syndrome,	KW-0175~Coiled coil,		KW-0418~Kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:ELK,DOMAIN:Pericentrin/AKAP-450 centrosomal targeting,REGION:Disordered,REGION:PKA-RII subunit binding domain,
ABRACL	ABRA C-terminal like(ABRACL)	Homo sapiens			GO:0032970~regulation of actin filament-based process,			IPR027817:Costars_dom,IPR038095:Costars_sf,IPR044302:Costars,				SM01283:Costars,							KW-0007~Acetylation,	REGION:Disordered,
ACD	ACD shelterin complex subunit and telomerase recruitment factor(ACD)	Homo sapiens			GO:0000723~telomere maintenance,GO:0001501~skeletal system development,GO:0001655~urogenital system development,GO:0006886~intracellular protein transport,GO:0007004~telomere maintenance via telomerase,GO:0016233~telomere capping,GO:0030326~embryonic limb morphogenesis,GO:0031848~protection from non-homologous end joining at telomere,GO:0032202~telomere assembly,GO:0032206~positive regulation of telomere maintenance,GO:0032211~negative regulation of telomere maintenance via telomerase,GO:0032212~positive regulation of telomere maintenance via telomerase,GO:0035282~segmentation,GO:0051973~positive regulation of telomerase activity,GO:0060381~positive regulation of single-stranded telomeric DNA binding,GO:0070198~protein localization to chromosome, telomeric region,GO:0070200~establishment of protein localization to telomere,	GO:0000781~chromosome, telomeric region,GO:0000783~nuclear telomere cap complex,GO:0005654~nucleoplasm,GO:0005697~telomerase holoenzyme complex,GO:0016604~nuclear body,GO:0070187~shelterin complex,	GO:0005515~protein binding,GO:0042162~telomeric DNA binding,GO:0044877~macromolecular complex binding,GO:0070182~DNA polymerase binding,	IPR019437:TPP1/Est3,IPR028631:ACD,		616553~Dyskeratosis congenita, autosomal dominant 6,616553~Dyskeratosis congenita, autosomal recessive 7,				KW-0158~Chromosome,KW-0539~Nucleus,KW-0779~Telomere,	KW-0225~Disease variant,KW-1011~Dyskeratosis congenita,			KW-0238~DNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Shelterin complex subunit TPP1/Est3,MOTIF:PWI,REGION:Disordered,REGION:Interaction with POT1,
ADAM10	ADAM metallopeptidase domain 10(ADAM10)	Homo sapiens		h_appPathway:Generation of amyloid b-peptide by PS1,	GO:0001701~in utero embryonic development,GO:0006468~protein phosphorylation,GO:0006508~proteolysis,GO:0006509~membrane protein ectodomain proteolysis,GO:0007162~negative regulation of cell adhesion,GO:0007219~Notch signaling pathway,GO:0007229~integrin-mediated signaling pathway,GO:0007267~cell-cell signaling,GO:0008284~positive regulation of cell proliferation,GO:0008593~regulation of Notch signaling pathway,GO:0010629~negative regulation of gene expression,GO:0010820~positive regulation of T cell chemotaxis,GO:0016485~protein processing,GO:0022617~extracellular matrix disassembly,GO:0030307~positive regulation of cell growth,GO:0030335~positive regulation of cell migration,GO:0034332~adherens junction organization,GO:0034612~response to tumor necrosis factor,GO:0038004~epidermal growth factor receptor ligand maturation,GO:0042117~monocyte activation,GO:0042987~amyloid precursor protein catabolic process,GO:0046931~pore complex assembly,GO:0051089~constitutive protein ectodomain proteolysis,GO:0051128~regulation of cellular component organization,GO:0090102~cochlea development,GO:1901342~regulation of vasculature development,GO:1901998~toxin transport,	GO:0000139~Golgi membrane,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005788~endoplasmic reticulum lumen,GO:0005794~Golgi apparatus,GO:0005798~Golgi-associated vesicle,GO:0005886~plasma membrane,GO:0005912~adherens junction,GO:0005925~focal adhesion,GO:0009986~cell surface,GO:0014069~postsynaptic density,GO:0016020~membrane,GO:0030136~clathrin-coated vesicle,GO:0030424~axon,GO:0030425~dendrite,GO:0035579~specific granule membrane,GO:0043231~intracellular membrane-bounded organelle,GO:0046930~pore complex,GO:0070062~extracellular exosome,GO:0070821~tertiary granule membrane,GO:0097038~perinuclear endoplasmic reticulum,GO:0097060~synaptic membrane,GO:0097197~tetraspanin-enriched microdomain,GO:0098978~glutamatergic synapse,	GO:0004175~endopeptidase activity,GO:0004222~metalloendopeptidase activity,GO:0005102~receptor binding,GO:0005178~integrin binding,GO:0005515~protein binding,GO:0008237~metallopeptidase activity,GO:0017124~SH3 domain binding,GO:0019901~protein kinase binding,GO:0042803~protein homodimerization activity,GO:0046872~metal ion binding,GO:0060090~binding, bridging,GO:0070573~metallodipeptidase activity,GO:1902945~metalloendopeptidase activity involved in amyloid precursor protein catabolic process,	IPR001590:Peptidase_M12B,IPR001762:Disintegrin_dom,IPR002870:Peptidase_M12B_N,IPR024079:MetalloPept_cat_dom_sf,IPR034025:ADAM10_ADAM17,IPR036436:Disintegrin_dom_sf,IPR049038:ADAM10_Cys-rich,	hsa04148:Efferocytosis,hsa05010:Alzheimer disease,hsa05120:Epithelial cell signaling in Helicobacter pylori infection,	615537~Reticulate acropigmentation of Kitamura,615590~Alzheimer disease 18, susceptibility to,		SM00050:DISIN,	KW-0914~Notch signaling pathway,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0965~Cell junction,KW-0966~Cell projection,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,	KW-0026~Alzheimer disease,KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-1008~Amyloidosis,	KW-0729~SH3-binding,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0378~Hydrolase,KW-0482~Metalloprotease,KW-0645~Protease,	KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0865~Zymogen,KW-1015~Disulfide bond,	BINDING:in inhibited form,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Pro residues,DOMAIN:Disintegrin,DOMAIN:Peptidase M12B,DOMAIN:Peptidase M12B propeptide,MOTIF:Cysteine switch,MOTIF:SH3-binding,MUTAGEN:E->A: Loss of proteolytic activity. Abrogates APP cleavage. Reduces Notch signaling.,MUTAGEN:PLAR->AAAA: Strongly reduces interaction and prevents ADAM10 maturation.,MUTAGEN:YCDVFMRCR->ACDVFMRCA: Strongly reduces interaction and ADAM10 maturation.,MUTAGEN:YCDVFMRCR->ECDVFMRCE: Strongly reduces interaction and prevents ADAM10 maturation.,REGION:Disordered,REGION:Interaction with AP2A1, AP2A2 and AP2M1,SITE:Cleavage; by furin and PCSK7,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
ADAM8	ADAM metallopeptidase domain 8(ADAM8)	Homo sapiens			GO:0000902~cell morphogenesis,GO:0001525~angiogenesis,GO:0002523~leukocyte migration involved in inflammatory response,GO:0002675~positive regulation of acute inflammatory response,GO:0002693~positive regulation of cellular extravasation,GO:0006508~proteolysis,GO:0006954~inflammatory response,GO:0007229~integrin-mediated signaling pathway,GO:0007249~I-kappaB kinase/NF-kappaB signaling,GO:0010718~positive regulation of epithelial to mesenchymal transition,GO:0010954~positive regulation of protein processing,GO:0022407~regulation of cell-cell adhesion,GO:0022617~extracellular matrix disassembly,GO:0033089~positive regulation of T cell differentiation in thymus,GO:0043410~positive regulation of MAPK cascade,GO:0043524~negative regulation of neuron apoptotic process,GO:0045089~positive regulation of innate immune response,GO:0045780~positive regulation of bone resorption,GO:0045785~positive regulation of cell adhesion,GO:0048247~lymphocyte chemotaxis,GO:0050714~positive regulation of protein secretion,GO:0051044~positive regulation of membrane protein ectodomain proteolysis,GO:0051897~positive regulation of protein kinase B signaling,GO:0070245~positive regulation of thymocyte apoptotic process,GO:0071456~cellular response to hypoxia,GO:0098609~cell-cell adhesion,GO:1901394~positive regulation of transforming growth factor beta1 activation,GO:2000309~positive regulation of tumor necrosis factor (ligand) superfamily member 11 production,GO:2000391~positive regulation of neutrophil extravasation,GO:2000415~positive regulation of fibronectin-dependent thymocyte migration,GO:2000418~positive regulation of eosinophil migration,	GO:0002102~podosome,GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,GO:0032010~phagolysosome,GO:0032127~dense core granule membrane,GO:0035579~specific granule membrane,GO:0042581~specific granule,GO:0070820~tertiary granule,GO:0070821~tertiary granule membrane,GO:0071133~alpha9-beta1 integrin-ADAM8 complex,GO:0101003~ficolin-1-rich granule membrane,	GO:0004222~metalloendopeptidase activity,GO:0004252~serine-type endopeptidase activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0008237~metallopeptidase activity,GO:0008270~zinc ion binding,GO:0043621~protein self-association,GO:0046872~metal ion binding,GO:0050839~cell adhesion molecule binding,	IPR000742:EGF-like_dom,IPR001590:Peptidase_M12B,IPR001762:Disintegrin_dom,IPR002870:Peptidase_M12B_N,IPR006586:ADAM_Cys-rich,IPR018358:Disintegrin_CS,IPR024079:MetalloPept_cat_dom_sf,IPR034027:Reprolysin_adamalysin,IPR036436:Disintegrin_dom_sf,				SM00050:DISIN,SM00608:ACR,		KW-0472~Membrane,		KW-0245~EGF-like domain,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0378~Hydrolase,KW-0401~Integrin,KW-0482~Metalloprotease,KW-0645~Protease,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Pro residues,DOMAIN:Disintegrin,DOMAIN:EGF-like,DOMAIN:Peptidase M12B,DOMAIN:Peptidase M12B propeptide,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
ARF1	ADP ribosylation factor 1(ARF1)	Homo sapiens		h_arapPathway:ADP-Ribosylation Factor,h_ptdinsPathway:Phosphoinositides and their downstream targets.,	GO:0002090~regulation of receptor internalization,GO:0006878~cellular copper ion homeostasis,GO:0006886~intracellular protein transport,GO:0015031~protein transport,GO:0016192~vesicle-mediated transport,GO:0034315~regulation of Arp2/3 complex-mediated actin nucleation,GO:0060292~long term synaptic depression,GO:0097061~dendritic spine organization,GO:0098586~cellular response to virus,GO:1990386~mitotic cleavage furrow ingression,	GO:0000139~Golgi membrane,GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0014069~postsynaptic density,GO:0030017~sarcomere,GO:0031252~cell leading edge,GO:0032991~macromolecular complex,GO:0043005~neuron projection,GO:0070062~extracellular exosome,	GO:0000287~magnesium ion binding,GO:0003723~RNA binding,GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0019904~protein domain specific binding,	IPR005225:Small_GTP-bd_dom,IPR006689:Small_GTPase_ARF/SAR,IPR024156:Small_GTPase_ARF,IPR027417:P-loop_NTPase,IPR045872:Arf1-5-like,	hsa04072:Phospholipase D signaling pathway,hsa04144:Endocytosis,hsa05110:Vibrio cholerae infection,hsa05130:Pathogenic Escherichia coli infection,hsa05131:Shigellosis,hsa05132:Salmonella infection,hsa05134:Legionellosis,	618185~Periventricular nodular heterotopia 8,		SM00175:RAB,SM00177:ARF,SM00178:SAR,	KW-0653~Protein transport,KW-0813~Transport,KW-0931~ER-Golgi transport,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0770~Synapse,KW-0771~Synaptosome,	KW-0225~Disease variant,		KW-0342~GTP-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,	KW-0007~Acetylation,KW-0449~Lipoprotein,KW-0519~Myristate,	LIPID:N-myristoyl glycine; alternate,MUTAGEN:Q->L: Inhibits GTP hydrolysis. Coatomer proteins recruitment to the Golgi membrane and formation of coated vesicles are normal. However, Golgi transport is severely reduced due to impaired vesicle uncoating.,REGION:Important for the stable binding to the membranes,
ARF6	ADP ribosylation factor 6(ARF6)	Homo sapiens			GO:0001889~liver development,GO:0006886~intracellular protein transport,GO:0007049~cell cycle,GO:0007155~cell adhesion,GO:0007399~nervous system development,GO:0010976~positive regulation of neuron projection development,GO:0016192~vesicle-mediated transport,GO:0030154~cell differentiation,GO:0030838~positive regulation of actin filament polymerization,GO:0030866~cortical actin cytoskeleton organization,GO:0032456~endocytic recycling,GO:0034394~protein localization to cell surface,GO:0035020~regulation of Rac protein signal transduction,GO:0036010~protein localization to endosome,GO:0048261~negative regulation of receptor-mediated endocytosis,GO:0048488~synaptic vesicle endocytosis,GO:0050714~positive regulation of protein secretion,GO:0051301~cell division,GO:0051489~regulation of filopodium assembly,GO:0051549~positive regulation of keratinocyte migration,GO:0060998~regulation of dendritic spine development,GO:0072659~protein localization to plasma membrane,GO:0090162~establishment of epithelial cell polarity,GO:0097178~ruffle assembly,GO:0097284~hepatocyte apoptotic process,GO:0099562~maintenance of postsynaptic density structure,GO:1902217~erythrocyte apoptotic process,GO:1903078~positive regulation of protein localization to plasma membrane,GO:1905606~regulation of presynapse assembly,GO:1990090~cellular response to nerve growth factor stimulus,GO:2000009~negative regulation of protein localization to cell surface,GO:2000171~negative regulation of dendrite development,	GO:0001726~ruffle,GO:0005737~cytoplasm,GO:0005768~endosome,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0005938~cell cortex,GO:0016020~membrane,GO:0030139~endocytic vesicle,GO:0031527~filopodium membrane,GO:0031901~early endosome membrane,GO:0032154~cleavage furrow,GO:0055038~recycling endosome membrane,GO:0070062~extracellular exosome,GO:0090543~Flemming body,GO:0098793~presynapse,GO:0098794~postsynapse,GO:0098978~glutamatergic synapse,	GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0019003~GDP binding,GO:0031996~thioesterase binding,GO:0035591~signaling adaptor activity,	IPR005225:Small_GTP-bd_dom,IPR006689:Small_GTPase_ARF/SAR,IPR024156:Small_GTPase_ARF,IPR027417:P-loop_NTPase,IPR041838:Arf6,	hsa04014:Ras signaling pathway,hsa04072:Phospholipase D signaling pathway,hsa04144:Endocytosis,hsa04666:Fc gamma R-mediated phagocytosis,hsa05130:Pathogenic Escherichia coli infection,hsa05131:Shigellosis,hsa05132:Salmonella infection,hsa05135:Yersinia infection,			SM00175:RAB,SM00177:ARF,SM00178:SAR,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0221~Differentiation,KW-0524~Neurogenesis,KW-0653~Protein transport,KW-0813~Transport,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-0967~Endosome,KW-1003~Cell membrane,			KW-0342~GTP-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,	KW-0449~Lipoprotein,KW-0519~Myristate,	LIPID:N-myristoyl glycine,LIPID:N6-myristoyl lysine,MUTAGEN:G->A: Fails to associate with membranes.,MUTAGEN:K->R: Abolished lysine-myristoylation, leading to decreased localization to membranes.,MUTAGEN:Q->L: Constitutively active. Inhibits filopodia formation and dendritic branching.,MUTAGEN:T->N: Constitutively inactivated. Fails to associate with membranes. Does not inhibit filopodia formation.,
ARFGAP2	ADP ribosylation factor GTPase activating protein 2(ARFGAP2)	Homo sapiens			GO:0015031~protein transport,GO:0048205~COPI coating of Golgi vesicle,	GO:0000139~Golgi membrane,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0005886~plasma membrane,	GO:0005096~GTPase activator activity,GO:0046872~metal ion binding,	IPR001164:ArfGAP_dom,IPR037278:ARFGAP/RecO,IPR038508:ArfGAP_dom_sf,	hsa04144:Endocytosis,			SM00105:ArfGap,	KW-0653~Protein transport,KW-0813~Transport,KW-0931~ER-Golgi transport,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0343~GTPase activation,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Arf-GAP,REGION:Disordered,REGION:Required for interaction with coatomer,ZN_FING:C4-type,
ARFGAP3	ADP ribosylation factor GTPase activating protein 3(ARFGAP3)	Homo sapiens		h_arapPathway:ADP-Ribosylation Factor,	GO:0006886~intracellular protein transport,GO:0009306~protein secretion,GO:0015031~protein transport,GO:0016192~vesicle-mediated transport,GO:0030100~regulation of endocytosis,GO:0032012~regulation of ARF protein signal transduction,GO:0048205~COPI coating of Golgi vesicle,	GO:0000139~Golgi membrane,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0016020~membrane,GO:0045202~synapse,	GO:0005096~GTPase activator activity,GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR001164:ArfGAP_dom,IPR037278:ARFGAP/RecO,IPR038508:ArfGAP_dom_sf,	hsa04144:Endocytosis,			SM00105:ArfGap,	KW-0653~Protein transport,KW-0813~Transport,KW-0931~ER-Golgi transport,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0343~GTPase activation,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Arf-GAP,REGION:Disordered,ZN_FING:C4-type,
ARFIP2	ADP ribosylation factor interacting protein 2(ARFIP2)	Homo sapiens		h_rac1Pathway:Rac 1 cell motility signaling pathway,	GO:0000423~macromitophagy,GO:0006886~intracellular protein transport,GO:0007264~small GTPase mediated signal transduction,GO:0030032~lamellipodium assembly,GO:0030036~actin cytoskeleton organization,GO:0031529~ruffle organization,GO:0034315~regulation of Arp2/3 complex-mediated actin nucleation,GO:0034497~protein localization to pre-autophagosomal structure,	GO:0001726~ruffle,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005938~cell cortex,GO:0032588~trans-Golgi network membrane,GO:0043231~intracellular membrane-bounded organelle,	GO:0005515~protein binding,GO:0005525~GTP binding,GO:0005543~phospholipid binding,GO:0019904~protein domain specific binding,GO:0030742~GTP-dependent protein binding,GO:0031267~small GTPase binding,GO:0042802~identical protein binding,GO:0045296~cadherin binding,GO:0070273~phosphatidylinositol-4-phosphate binding,	IPR010504:AH_dom,IPR027267:AH/BAR_dom_sf,IPR030798:Arfaptin_fam,				SM01015:Arfaptin,	KW-0072~Autophagy,	KW-0333~Golgi apparatus,KW-0472~Membrane,					KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:AH,MUTAGEN:W->A: Abolished ability to regulate ATG9A trafficking.,REGION:Disordered,
ARL1	ADP ribosylation factor like GTPase 1(ARL1)	Homo sapiens			GO:0006886~intracellular protein transport,GO:0007030~Golgi organization,GO:0009404~toxin metabolic process,GO:0016192~vesicle-mediated transport,GO:0031584~activation of phospholipase D activity,GO:0034067~protein localization to Golgi apparatus,GO:0042147~retrograde transport, endosome to Golgi,	GO:0000139~Golgi membrane,GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005802~trans-Golgi network,GO:0005829~cytosol,GO:0032588~trans-Golgi network membrane,	GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0008047~enzyme activator activity,GO:0019904~protein domain specific binding,GO:0046872~metal ion binding,GO:1990583~phospholipase D activator activity,	IPR005225:Small_GTP-bd_dom,IPR006689:Small_GTPase_ARF/SAR,IPR024156:Small_GTPase_ARF,IPR027417:P-loop_NTPase,				SM00175:RAB,SM00177:ARF,SM00178:SAR,		KW-0333~Golgi apparatus,KW-0472~Membrane,			KW-0342~GTP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,		KW-0449~Lipoprotein,KW-0519~Myristate,	LIPID:N-myristoyl glycine,MUTAGEN:Q->L: Altered Golgi structure with an engorged lumen. Interacts with ARFIP2, GOLGA4, RGPD8, SCOC and UNC119.,MUTAGEN:T->N: Loss of interaction with ARFIP1 and ARFIP2.,
ARL2BP	ADP ribosylation factor like GTPase 2 binding protein(ARL2BP)	Homo sapiens			GO:0007165~signal transduction,GO:0042531~positive regulation of tyrosine phosphorylation of STAT protein,GO:0045893~positive regulation of transcription, DNA-templated,GO:0051457~maintenance of protein location in nucleus,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005758~mitochondrial intermembrane space,GO:0005759~mitochondrial matrix,GO:0005813~centrosome,GO:0005819~spindle,GO:0005829~cytosol,GO:0005929~cilium,GO:0030496~midbody,	GO:0003713~transcription coactivator activity,GO:0005515~protein binding,GO:0030695~GTPase regulator activity,	IPR023379:BART_dom,IPR038849:ARL2BP,IPR042541:BART_sf,		615434~Retinitis pigmentosa with or without situs inversus,				KW-0206~Cytoskeleton,KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-0969~Cilium,	KW-0225~Disease variant,KW-1186~Ciliopathy,					DOMAIN:BART,MUTAGEN:D->A: Decreases interaction with ARL2.,MUTAGEN:E->A: Decreases interaction with ARL2.,MUTAGEN:F->A: Decreases interaction with ARL2.,MUTAGEN:L->A: Decreases interaction with ARL2.,MUTAGEN:M->A: Does not decrease interaction with ARL2.,MUTAGEN:Y->A: Decreases interaction with ARL2.,
ARL4C	ADP ribosylation factor like GTPase 4C(ARL4C)	Homo sapiens			GO:0006886~intracellular protein transport,GO:0032456~endocytic recycling,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0030175~filopodium,	GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0043014~alpha-tubulin binding,	IPR005225:Small_GTP-bd_dom,IPR006689:Small_GTPase_ARF/SAR,IPR024156:Small_GTPase_ARF,IPR027417:P-loop_NTPase,				SM00175:RAB,SM00177:ARF,SM00178:SAR,	KW-0813~Transport,	KW-0472~Membrane,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-1003~Cell membrane,			KW-0342~GTP-binding,KW-0547~Nucleotide-binding,		KW-0449~Lipoprotein,KW-0519~Myristate,	LIPID:N-myristoyl glycine,MUTAGEN:G->A: Cytoplasmic localization.,MUTAGEN:K->N: Cytoplasmic localization. Increases GDP-form.,MUTAGEN:Q->L: Does not interact with alpha tubulin. Activates transferrin transport from early endosome to recycling endosome.,MUTAGEN:T->N: Does not interact with alpha tubulin.,
ARL5A	ADP ribosylation factor like GTPase 5A(ARL5A)	Homo sapiens			GO:0006886~intracellular protein transport,GO:0016192~vesicle-mediated transport,GO:1903292~protein localization to Golgi membrane,	GO:0005737~cytoplasm,GO:0005802~trans-Golgi network,	GO:0003924~GTPase activity,GO:0005525~GTP binding,	IPR005225:Small_GTP-bd_dom,IPR006689:Small_GTPase_ARF/SAR,IPR024156:Small_GTPase_ARF,IPR027417:P-loop_NTPase,				SM00177:ARF,SM00178:SAR,					KW-0342~GTP-binding,KW-0547~Nucleotide-binding,		KW-0449~Lipoprotein,KW-0519~Myristate,	LIPID:N-myristoyl glycine,
ARL6IP4	ADP ribosylation factor like GTPase 6 interacting protein 4(ARL6IP4)	Homo sapiens			GO:0006397~mRNA processing,GO:0008380~RNA splicing,	GO:0005634~nucleus,GO:0005730~nucleolus,GO:0016607~nuclear speck,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR019532:Nucl_RNA-splicing_assoc_SR-25,					KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,					KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),REGION:Disordered,
ARL6IP6	ADP ribosylation factor like GTPase 6 interacting protein 6(ARL6IP6)	Homo sapiens				GO:0005637~nuclear inner membrane,GO:0016020~membrane,	GO:0005515~protein binding,	IPR029383:ARL6IP6,						KW-0472~Membrane,KW-0539~Nucleus,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,	REGION:Disordered,TRANSMEM:Helical,
ARL8B	ADP ribosylation factor like GTPase 8B(ARL8B)	Homo sapiens			GO:0001778~plasma membrane repair,GO:0002505~antigen processing and presentation of polysaccharide antigen via MHC class II,GO:0002747~antigen processing and presentation following phagocytosis,GO:0007059~chromosome segregation,GO:0008089~anterograde axonal transport,GO:0015031~protein transport,GO:0016197~endosomal transport,GO:0032418~lysosome localization,GO:0042267~natural killer cell mediated cytotoxicity,GO:0046754~viral exocytosis,GO:0051301~cell division,GO:0090117~endosome to lysosome transport of low-density lipoprotein particle,GO:0090385~phagosome-lysosome fusion,GO:1902774~late endosome to lysosome transport,GO:1990927~calcium ion regulated lysosome exocytosis,	GO:0005737~cytoplasm,GO:0005764~lysosome,GO:0005765~lysosomal membrane,GO:0005819~spindle,GO:0005829~cytosol,GO:0016020~membrane,GO:0030424~axon,GO:0030496~midbody,GO:0031902~late endosome membrane,GO:0045202~synapse,GO:0051233~spindle midzone,GO:0070062~extracellular exosome,GO:0101004~cytolytic granule membrane,GO:1904115~axon cytoplasm,	GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0019003~GDP binding,GO:0043014~alpha-tubulin binding,GO:0048487~beta-tubulin binding,	IPR005225:Small_GTP-bd_dom,IPR006689:Small_GTPase_ARF/SAR,IPR027417:P-loop_NTPase,IPR044154:Arl8a/8b,	hsa05132:Salmonella infection,			SM00173:RAS,SM00175:RAB,SM00177:ARF,SM00178:SAR,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0653~Protein transport,KW-0813~Transport,	KW-0206~Cytoskeleton,KW-0458~Lysosome,KW-0472~Membrane,KW-0770~Synapse,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-0967~Endosome,			KW-0342~GTP-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,	KW-0007~Acetylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),INTRAMEM:Note=Mediates targeting to membranes,MUTAGEN:ISRLLDWF->ASRALDWA: Diffuse cytoplasmic distribution and loss of localization to lysosomes. No effect on acetylation.,MUTAGEN:K->R: Abolished ubiquitination by RNF167.,MUTAGEN:L->A: Diffuse cytoplasmic distribution and loss of localization to lysosomes. No effect on acetylation.,MUTAGEN:L->F: No effect on localization and acetylation.,MUTAGEN:Missing: Alters chromosome segregation.,MUTAGEN:N->I: Loss of GTP/GDP-binding. Affects chromosome segregation.,MUTAGEN:Q->L: Prevents GTP hydrolysis. No effect on lysosomal location. Alters lysosomes cellular distribution and motility. Increases interaction with VPS41. No effect on interaction with PLEKHM1.,MUTAGEN:T->N: Preferentially binds GDP. Alters chromosome segregation. Decreases interaction with VPS41. Loss of lysosomal location. Loss of interaction with PLEKHM1.,MUTAGEN:W->R: Preferentially binds GTP.,REGION:Disordered,
AHNAK	AHNAK nucleoprotein(AHNAK)	Homo sapiens			GO:0043484~regulation of RNA splicing,GO:1901385~regulation of voltage-gated calcium channel activity,GO:1905686~positive regulation of plasma membrane repair,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005765~lysosomal membrane,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0015629~actin cytoskeleton,GO:0016020~membrane,GO:0030315~T-tubule,GO:0031982~vesicle,GO:0042383~sarcolemma,GO:0043034~costamere,GO:0044291~cell-cell contact zone,GO:0045121~membrane raft,GO:0070062~extracellular exosome,GO:0098797~plasma membrane protein complex,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0044548~S100 protein binding,GO:0045296~cadherin binding,GO:0097493~structural molecule activity conferring elasticity,	IPR001478:PDZ,IPR036034:PDZ_sf,	hsa05132:Salmonella infection,			SM00228:PDZ,		KW-0539~Nucleus,		KW-0677~Repeat,			KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:PDZ,MOTIF:Nuclear localization signal,REGION:Disordered,
AKT2	AKT serine/threonine kinase 2(AKT2)	Homo sapiens			GO:0005978~glycogen biosynthetic process,GO:0006006~glucose metabolic process,GO:0006417~regulation of translation,GO:0007165~signal transduction,GO:0008284~positive regulation of cell proliferation,GO:0008286~insulin receptor signaling pathway,GO:0008643~carbohydrate transport,GO:0010748~negative regulation of plasma membrane long-chain fatty acid transport,GO:0010907~positive regulation of glucose metabolic process,GO:0010918~positive regulation of mitochondrial membrane potential,GO:0016310~phosphorylation,GO:0018105~peptidyl-serine phosphorylation,GO:0030334~regulation of cell migration,GO:0030335~positive regulation of cell migration,GO:0032000~positive regulation of fatty acid beta-oxidation,GO:0032287~peripheral nervous system myelin maintenance,GO:0032869~cellular response to insulin stimulus,GO:0035556~intracellular signal transduction,GO:0036211~protein modification process,GO:0043066~negative regulation of apoptotic process,GO:0045444~fat cell differentiation,GO:0045725~positive regulation of glycogen biosynthetic process,GO:0046326~positive regulation of glucose import,GO:0051726~regulation of cell cycle,GO:0060644~mammary gland epithelial cell differentiation,GO:0071486~cellular response to high light intensity,GO:0072659~protein localization to plasma membrane,GO:0090314~positive regulation of protein targeting to membrane,GO:0097473~retinal rod cell apoptotic process,GO:2000147~positive regulation of cell motility,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005769~early endosome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005938~cell cortex,GO:0032587~ruffle membrane,GO:0032991~macromolecular complex,GO:0043231~intracellular membrane-bounded organelle,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0046872~metal ion binding,	IPR000719:Prot_kinase_dom,IPR000961:AGC-kinase_C,IPR001849:PH_domain,IPR008271:Ser/Thr_kinase_AS,IPR011009:Kinase-like_dom_sf,IPR011993:PH-like_dom_sf,IPR017441:Protein_kinase_ATP_BS,IPR017892:Pkinase_C,IPR034677:Akt2,IPR039026:PH_PKB,	hsa01521:EGFR tyrosine kinase inhibitor resistance,hsa01522:Endocrine resistance,hsa01524:Platinum drug resistance,hsa04010:MAPK signaling pathway,hsa04012:ErbB signaling pathway,hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04022:cGMP-PKG signaling pathway,hsa04024:cAMP signaling pathway,hsa04062:Chemokine signaling pathway,hsa04066:HIF-1 signaling pathway,hsa04068:FoxO signaling pathway,hsa04071:Sphingolipid signaling pathway,hsa04072:Phospholipase D signaling pathway,hsa04140:Autophagy - animal,hsa04150:mTOR signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04152:AMPK signaling pathway,hsa04210:Apoptosis,hsa04211:Longevity regulating pathway,hsa04213:Longevity regulating pathway - multiple species,hsa04218:Cellular senescence,hsa04261:Adrenergic signaling in cardiomyocytes,hsa04370:VEGF signaling pathway,hsa04371:Apelin signaling pathway,hsa04380:Osteoclast differentiation,hsa04510:Focal adhesion,hsa04550:Signaling pathways regulating pluripotency of stem cells,hsa04611:Platelet activation,hsa04613:Neutrophil extracellular trap formation,hsa04620:Toll-like receptor signaling pathway,hsa04625:C-type lectin receptor signaling pathway,hsa04630:JAK-STAT signaling pathway,hsa04660:T cell receptor signaling pathway,hsa04662:B cell receptor signaling pathway,hsa04664:Fc epsilon RI signaling pathway,hsa04666:Fc gamma R-mediated phagocytosis,hsa04668:TNF signaling pathway,hsa04722:Neurotrophin signaling pathway,hsa04725:Cholinergic synapse,hsa04728:Dopaminergic synapse,hsa04810:Regulation of actin cytoskeleton,hsa04910:Insulin signaling pathway,hsa04914:Progesterone-mediated oocyte maturation,hsa04915:Estrogen signaling pathway,hsa04917:Prolactin signaling pathway,hsa04919:Thyroid hormone signaling pathway,hsa04920:Adipocytokine signaling pathway,hsa04922:Glucagon signaling pathway,hsa04923:Regulation of lipolysis in adipocytes,hsa04926:Relaxin signaling pathway,hsa04929:GnRH secretion,hsa04931:Insulin resistance,hsa04932:Non-alcoholic fatty liver disease,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa04935:Growth hormone synthesis, secretion and action,hsa04936:Alcoholic liver disease,hsa04973:Carbohydrate digestion and absorption,hsa05010:Alzheimer disease,hsa05017:Spinocerebellar ataxia,hsa05131:Shigellosis,hsa05132:Salmonella infection,hsa05135:Yersinia infection,hsa05142:Chagas disease,hsa05145:Toxoplasmosis,hsa05152:Tuberculosis,hsa05160:Hepatitis C,hsa05161:Hepatitis B,hsa05162:Measles,hsa05163:Human cytomegalovirus infection,hsa05164:Influenza A,hsa05165:Human papillomavirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05200:Pathways in cancer,hsa05205:Proteoglycans in cancer,hsa05207:Chemical carcinogenesis - receptor activation,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05210:Colorectal cancer,hsa05211:Renal cell carcinoma,hsa05212:Pancreatic cancer,hsa05213:Endometrial cancer,hsa05214:Glioma,hsa05215:Prostate cancer,hsa05218:Melanoma,hsa05220:Chronic myeloid leukemia,hsa05221:Acute myeloid leukemia,hsa05222:Small cell lung cancer,hsa05223:Non-small cell lung cancer,hsa05224:Breast cancer,hsa05225:Hepatocellular carcinoma,hsa05226:Gastric cancer,hsa05230:Central carbon metabolism in cancer,hsa05231:Choline metabolism in cancer,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,hsa05415:Diabetic cardiomyopathy,hsa05417:Lipid and atherosclerosis,hsa05418:Fluid shear stress and atherosclerosis,	125853~Diabetes mellitus, type II,240900~Hypoinsulinemic hypoglycemia with hemihypertrophy,		SM00133:S_TK_X,SM00220:S_TKc,SM00233:PH,	KW-0053~Apoptosis,KW-0119~Carbohydrate metabolism,KW-0313~Glucose metabolism,KW-0320~Glycogen biosynthesis,KW-0321~Glycogen metabolism,KW-0762~Sugar transport,KW-0810~Translation regulation,KW-0813~Transport,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0967~Endosome,KW-1003~Cell membrane,	KW-0219~Diabetes mellitus,KW-0225~Disease variant,KW-0656~Proto-oncogene,		KW-0067~ATP-binding,KW-0464~Manganese,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0217~Developmental protein,KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,KW-9996~Developmental protein,	KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,	ACT_SITE:Proton acceptor,CARBOHYD:O-linked (GlcNAc) serine,CARBOHYD:O-linked (GlcNAc) threonine,COMPBIAS:Basic and acidic residues,DOMAIN:AGC-kinase C-terminal,DOMAIN:PH,DOMAIN:Protein kinase,MUTAGEN:S->A: Impairs interaction with TTC3; when associated with A-309.,MUTAGEN:S->D: Constitutively active; when associated with E-309.,MUTAGEN:T->A: Impairs interaction with TTC3; when associated with A-474.,MUTAGEN:T->E: Constitutively active; when associated with D-474.,REGION:Disordered,
ALG13	ALG13 UDP-N-acetylglucosaminyltransferase subunit(ALG13)	Homo sapiens			GO:0006488~dolichol-linked oligosaccharide biosynthetic process,GO:0006508~proteolysis,	GO:0005789~endoplasmic reticulum membrane,	GO:0003723~RNA binding,GO:0004577~N-acetylglucosaminyldiphosphodolichol N-acetylglucosaminyltransferase activity,GO:0004843~thiol-dependent ubiquitin-specific protease activity,GO:0016758~transferase activity, transferring hexosyl groups,	IPR002999:Tudor,IPR003323:OTU_dom,IPR007235:Glyco_trans_28_C,IPR038765:Papain-like_cys_pep_sf,IPR039042:Alg13-like,IPR047387:OTU_ALG13,	hsa00510:N-Glycan biosynthesis,hsa00513:Various types of N-glycan biosynthesis,hsa01100:Metabolic pathways,	300884~Developmental and epileptic encephalopathy 36,			KW-0833~Ubl conjugation pathway,	KW-0256~Endoplasmic reticulum,	KW-0225~Disease variant,KW-0887~Epilepsy,KW-0900~Congenital disorder of glycosylation,			KW-0328~Glycosyltransferase,KW-0378~Hydrolase,KW-0511~Multifunctional enzyme,KW-0645~Protease,KW-0788~Thiol protease,KW-0808~Transferase,		ACT_SITE:For deubiquitinase activity,ACT_SITE:Nucleophile; for deubiquitinase activity,COMPBIAS:Pro residues,DOMAIN:Glycosyl transferase family 28 C-terminal,DOMAIN:OTU,DOMAIN:Tudor,REGION:Deubiquitinase activity,REGION:Disordered,REGION:Glycosyltransferase activity,
ANKH	ANKH inorganic pyrophosphate transport regulator(ANKH)	Homo sapiens			GO:0001501~skeletal system development,GO:0007626~locomotory behavior,GO:0010467~gene expression,GO:0030282~bone mineralization,GO:0030500~regulation of bone mineralization,GO:0030505~inorganic diphosphate transport,GO:0035435~phosphate ion transmembrane transport,GO:0046716~muscle cell cellular homeostasis,GO:0055062~phosphate ion homeostasis,GO:0055074~calcium ion homeostasis,GO:0055085~transmembrane transport,GO:0071344~diphosphate metabolic process,GO:0071529~cementum mineralization,GO:1904383~response to sodium phosphate,GO:1904669~ATP export,	GO:0005576~extracellular region,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0019867~outer membrane,	GO:0005315~inorganic phosphate transmembrane transporter activity,GO:0005347~ATP transmembrane transporter activity,GO:0015114~phosphate ion transmembrane transporter activity,GO:0030504~inorganic diphosphate transmembrane transporter activity,	IPR009887:ANKH,		118600~Chondrocalcinosis 2,123000~Craniometaphyseal dysplasia,			KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,	KW-0209~Deafness,KW-0225~Disease variant,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,				REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
ASH1L	ASH1 like histone lysine methyltransferase(ASH1L)	Homo sapiens			GO:0000165~MAPK cascade,GO:0001501~skeletal system development,GO:0002674~negative regulation of acute inflammatory response,GO:0006338~chromatin remodeling,GO:0006355~regulation of transcription, DNA-templated,GO:0006366~transcription from RNA polymerase II promoter,GO:0006954~inflammatory response,GO:0007249~I-kappaB kinase/NF-kappaB signaling,GO:0007338~single fertilization,GO:0009791~post-embryonic development,GO:0030317~flagellated sperm motility,GO:0032259~methylation,GO:0043124~negative regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043409~negative regulation of MAPK cascade,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046697~decidualization,GO:0061038~uterus morphogenesis,GO:1903699~tarsal gland development,GO:1903709~uterine gland development,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005694~chromosome,GO:0005794~Golgi apparatus,GO:0005923~bicellular tight junction,	GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0042800~histone methyltransferase activity (H3-K4 specific),GO:0046872~metal ion binding,GO:0046974~histone methyltransferase activity (H3-K9 specific),GO:0046975~histone methyltransferase activity (H3-K36 specific),	IPR001025:BAH_dom,IPR001214:SET_dom,IPR001487:Bromodomain,IPR001965:Znf_PHD,IPR003616:Post-SET_dom,IPR006560:AWS_dom,IPR011011:Znf_FYVE_PHD,IPR013083:Znf_RING/FYVE/PHD,IPR017956:AT_hook_DNA-bd_motif,IPR019786:Zinc_finger_PHD-type_CS,IPR036427:Bromodomain-like_sf,IPR043151:BAH_sf,IPR043319:PHD_ASH1L,IPR043320:Bromo_ASH1L,IPR046341:SET_dom_sf,	hsa00310:Lysine degradation,hsa01100:Metabolic pathways,	617796~Intellectual developmental disorder, autosomal dominant 52,		SM00249:PHD,SM00297:BROMO,SM00317:SET,SM00384:AT_hook,SM00439:BAH,SM00570:AWS,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0158~Chromosome,KW-0539~Nucleus,KW-0796~Tight junction,KW-0965~Cell junction,	KW-0225~Disease variant,KW-0991~Intellectual disability,	KW-0103~Bromodomain,KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,KW-0949~S-adenosyl-L-methionine,	KW-0010~Activator,KW-0156~Chromatin regulator,KW-0489~Methyltransferase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DNA_BIND:A.T hook 1,DNA_BIND:A.T hook 2,DNA_BIND:A.T hook 3,DOMAIN:AWS,DOMAIN:BAH,DOMAIN:Bromo,DOMAIN:Post-SET,DOMAIN:SET,DOMAIN:Zinc finger PHD-type,MUTAGEN:Q->R: Abolishes methylation by N6AMT1.,REGION:Catalytic domain,REGION:Disordered,ZN_FING:PHD-type,
ARID2	AT-rich interaction domain 2(ARID2)	Homo sapiens			GO:0003007~heart morphogenesis,GO:0006337~nucleosome disassembly,GO:0006338~chromatin remodeling,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0008285~negative regulation of cell proliferation,GO:0030071~regulation of mitotic metaphase/anaphase transition,GO:0030336~negative regulation of cell migration,GO:0042592~homeostatic process,GO:0045582~positive regulation of T cell differentiation,GO:0045597~positive regulation of cell differentiation,GO:0045663~positive regulation of myoblast differentiation,GO:0048568~embryonic organ development,GO:0060038~cardiac muscle cell proliferation,GO:0060982~coronary artery morphogenesis,GO:0070316~regulation of G0 to G1 transition,GO:1905168~positive regulation of double-strand break repair via homologous recombination,GO:2000045~regulation of G1/S transition of mitotic cell cycle,GO:2000781~positive regulation of double-strand break repair,GO:2000819~regulation of nucleotide-excision repair,	GO:0000776~kinetochore,GO:0000785~chromatin,GO:0005654~nucleoplasm,GO:0005886~plasma membrane,GO:0016363~nuclear matrix,GO:0016514~SWI/SNF complex,GO:0016586~RSC complex,	GO:0003677~DNA binding,GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR001606:ARID_dom,IPR003150:DNA-bd_RFX,IPR011989:ARM-like,IPR013087:Znf_C2H2_type,IPR016024:ARM-type_fold,IPR036388:WH-like_DNA-bd_sf,IPR036390:WH_DNA-bd_sf,IPR036431:ARID_dom_sf,	hsa03082:ATP-dependent chromatin remodeling,hsa05225:Hepatocellular carcinoma,	617808~Coffin-Siris syndrome 6,		SM00501:BRIGHT,SM01014:ARID,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-0991~Intellectual disability,	KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0156~Chromatin regulator,KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DNA_BIND:RFX-type winged-helix,DOMAIN:ARID,DOMAIN:C2H2-type,DOMAIN:RFX-type winged-helix,MOTIF:LXXLL,REGION:Disordered,ZN_FING:C2H2-type,
ARID4A	AT-rich interaction domain 4A(ARID4A)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006306~DNA methylation,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0007283~spermatogenesis,GO:0010468~regulation of gene expression,GO:0030336~negative regulation of cell migration,GO:0030512~negative regulation of transforming growth factor beta receptor signaling pathway,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048821~erythrocyte development,GO:0071514~genetic imprinting,GO:0097368~establishment of Sertoli cell barrier,GO:1902455~negative regulation of stem cell population maintenance,GO:1902459~positive regulation of stem cell population maintenance,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005886~plasma membrane,GO:0016580~Sin3 complex,GO:0017053~transcriptional repressor complex,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0003677~DNA binding,GO:0003690~double-stranded DNA binding,	IPR000953:Chromo/chromo_shadow_dom,IPR001606:ARID_dom,IPR002999:Tudor,IPR012603:ARID4A/B_PWWP,IPR016197:Chromo-like_dom_sf,IPR025995:Tudor-knot,IPR036431:ARID_dom_sf,IPR047472:Tudor_ARID4A_rpt1,IPR047473:CBD_RBP1-like,				SM00298:CHROMO,SM00333:TUDOR,SM00501:BRIGHT,SM01014:ARID,	KW-0221~Differentiation,KW-0744~Spermatogenesis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0156~Chromatin regulator,KW-0238~DNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:ARID,DOMAIN:Tudor,DOMAIN:Tudor-knot,MUTAGEN:W->A: Abolishes binding to trimethylated lysines.,MUTAGEN:Y->A: Abolishes binding to trimethylated lysines.,MUTAGEN:Y->A: No effect on binding to trimethylated lysines.,MUTAGEN:Y->A: Significantly reduces affinity for trimethylated lysines.,REGION:DNA-binding,REGION:Disordered,REGION:Retinoblastoma protein binding,
ARID4B	AT-rich interaction domain 4B(ARID4B)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006306~DNA methylation,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0007283~spermatogenesis,GO:0030336~negative regulation of cell migration,GO:0030512~negative regulation of transforming growth factor beta receptor signaling pathway,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0071514~genetic imprinting,GO:0097368~establishment of Sertoli cell barrier,GO:1902455~negative regulation of stem cell population maintenance,GO:1902459~positive regulation of stem cell population maintenance,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0016580~Sin3 complex,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0003677~DNA binding,GO:0005515~protein binding,	IPR001606:ARID_dom,IPR002999:Tudor,IPR012603:ARID4A/B_PWWP,IPR016197:Chromo-like_dom_sf,IPR025995:Tudor-knot,IPR028853:ARID4B_ARID/BRIGHT,IPR036431:ARID_dom_sf,IPR047474:Tudor_ARID4B_rpt2,IPR047476:Tudor_ARID4B_rpt1,				SM00333:TUDOR,SM00501:BRIGHT,SM01014:ARID,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,		KW-0156~Chromatin regulator,KW-0238~DNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:ARID,DOMAIN:Tudor-knot,REGION:Antigenic epitope,REGION:Disordered,
ARID5A	AT-rich interaction domain 5A(ARID5A)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0002062~chondrocyte differentiation,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0032729~positive regulation of interferon-gamma production,GO:0032740~positive regulation of interleukin-17 production,GO:0032755~positive regulation of interleukin-6 production,GO:0032760~positive regulation of tumor necrosis factor production,GO:0045087~innate immune response,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0071222~cellular response to lipopolysaccharide,GO:0071391~cellular response to estrogen stimulus,GO:1901985~positive regulation of protein acetylation,GO:2000318~positive regulation of T-helper 17 type immune response,GO:2000556~positive regulation of T-helper 1 cell cytokine production,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005730~nucleolus,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003714~transcription corepressor activity,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:0030331~estrogen receptor binding,GO:0035613~RNA stem-loop binding,GO:0042802~identical protein binding,GO:0043565~sequence-specific DNA binding,GO:0046965~retinoid X receptor binding,GO:0046966~thyroid hormone receptor binding,GO:0050681~androgen receptor binding,	IPR001606:ARID_dom,IPR036431:ARID_dom_sf,				SM00501:BRIGHT,SM01014:ARID,	KW-0391~Immunity,KW-0399~Innate immunity,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0010~Activator,KW-0238~DNA-binding,KW-0678~Repressor,KW-0694~RNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:ARID,REGION:Disordered,REGION:Interaction with SOX9,
ARID5B	AT-rich interaction domain 5B(ARID5B)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001822~kidney development,GO:0001889~liver development,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006807~nitrogen compound metabolic process,GO:0008584~male gonad development,GO:0008585~female gonad development,GO:0009791~post-embryonic development,GO:0010761~fibroblast migration,GO:0030325~adrenal gland development,GO:0035264~multicellular organism growth,GO:0045444~fat cell differentiation,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0048008~platelet-derived growth factor receptor signaling pathway,GO:0048468~cell development,GO:0048644~muscle organ morphogenesis,GO:0048705~skeletal system morphogenesis,GO:0051091~positive regulation of sequence-specific DNA binding transcription factor activity,GO:0060021~palate development,GO:0060325~face morphogenesis,GO:0060612~adipose tissue development,GO:0060613~fat pad development,GO:1990830~cellular response to leukemia inhibitory factor,	GO:0005634~nucleus,GO:0005654~nucleoplasm,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0003677~DNA binding,GO:0003713~transcription coactivator activity,GO:0005515~protein binding,	IPR001606:ARID_dom,IPR030408:ARID5B_ARID/BRIGHT_DNA-bd,IPR036431:ARID_dom_sf,IPR043151:BAH_sf,				SM00501:BRIGHT,SM01014:ARID,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0010~Activator,KW-0238~DNA-binding,	KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:ARID,MUTAGEN:K->A,R: Abolishes methylation and FSK-dependent DNA-binding of the PHF2-ARID5B complex to promoters.,REGION:Disordered,
ABCF1	ATP binding cassette subfamily F member 1(ABCF1)	Homo sapiens			GO:0006412~translation,GO:0006413~translational initiation,GO:0006954~inflammatory response,GO:0045727~positive regulation of translation,	GO:0005635~nuclear envelope,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016020~membrane,GO:0042788~polysomal ribosome,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008135~translation factor activity, RNA binding,GO:0008494~translation activator activity,GO:0016887~ATPase activity,GO:0043022~ribosome binding,	IPR003439:ABC_transporter-like_ATP-bd,IPR003593:AAA+_ATPase,IPR017871:ABC_transporter-like_CS,IPR027417:P-loop_NTPase,				SM00382:AAA,		KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0010~Activator,	KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,DOMAIN:ABC transporter,DOMAIN:ABC transporter 1,DOMAIN:ABC transporter 2,MUTAGEN:E->Q: Does not inhibit ribosome binding. Reduces protein synthesis; when associated with Q-477.,MUTAGEN:E->Q: Does not inhibit ribosome binding. Reduces protein synthesis; when associated with Q-768.,MUTAGEN:G->D: Does not inhibit ribosome binding.,MUTAGEN:H->L: Does not inhibit ribosome binding.,MUTAGEN:K->M: Does not inhibit ribosome binding. Reduces ATP-binding. Inhibits ATP-binding and reduces protein synthesis; when associated with M-342. Shows a reduced association with polyribosomes; when associated with M-664. Does not inhibit IRES-mediated protein synthesis; when associated with M-664.,MUTAGEN:K->M: Does not inhibit ribosome binding. Reduces ATP-binding. Inhibits ATP-binding and reduces protein synthesis; when associated with M-664. Shows an enhanced association with polyribosomes; when associated with M-664. Does not inhibit IRES-mediated protein synthesis; when associated with M-664.,MUTAGEN:Q->E: Does not inhibit ribosome binding.,MUTAGEN:S->A: Reduces phosphorylation. Inhibits strongly phosphorylation by CK2; when associated with S-109. Does not inhibits interaction with EIF2; when associated with S-109. Does not inhibit association with ribosomes; when associated with S-109. Reduces EIF2 interaction with ribosomes; when associated with S-109. Does not inhibit protein synthesis; when associated with A-109.,MUTAGEN:S->A: Reduces phosphorylation. Inhibits strongly phosphorylation by CK2; when associated with S-140. Does not inhibit interaction with EIF2; when associated with S-140. Does not inhibit association with ribosomes; when associated with S-140. Reduces EIF2 interaction with ribosomes; when associated with S-140. Does not inhibit protein synthesis; when associated with A-140.,REGION:Disordered,
ABCF2	ATP binding cassette subfamily F member 2(ABCF2)	Homo sapiens				GO:0000786~nucleosome,GO:0005634~nucleus,GO:0005886~plasma membrane,GO:0016020~membrane,	GO:0003677~DNA binding,GO:0005524~ATP binding,GO:0016887~ATPase activity,GO:0030527~structural constituent of chromatin,GO:0046982~protein heterodimerization activity,	IPR000558:Histone_H2B,IPR003439:ABC_transporter-like_ATP-bd,IPR003593:AAA+_ATPase,IPR007125:Histone_H2A/H2B/H3,IPR009072:Histone-fold,IPR017871:ABC_transporter-like_CS,IPR027417:P-loop_NTPase,IPR032781:ABC_tran_Xtn,	hsa05130:Pathogenic Escherichia coli infection,			SM00382:AAA,SM00427:H2B,		KW-0158~Chromosome,KW-0539~Nucleus,KW-0544~Nucleosome core,		KW-0175~Coiled coil,KW-0677~Repeat,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:ABC transporter,DOMAIN:ABC transporter 1,DOMAIN:ABC transporter 2,DOMAIN:Histone H2A/H2B/H3,REGION:Disordered,
ACLY	ATP citrate lyase(ACLY)	Homo sapiens		h_malatexPathway:Shuttle for transfer of acetyl groups from mitochondria to the cytosol,	GO:0006085~acetyl-CoA biosynthetic process,GO:0006099~tricarboxylic acid cycle,GO:0006101~citrate metabolic process,GO:0006107~oxaloacetate metabolic process,GO:0006629~lipid metabolic process,GO:0006633~fatty acid biosynthetic process,GO:0006695~cholesterol biosynthetic process,GO:0008610~lipid biosynthetic process,GO:0015936~coenzyme A metabolic process,	GO:0005576~extracellular region,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016020~membrane,GO:0035578~azurophil granule lumen,GO:0070062~extracellular exosome,GO:1904813~ficolin-1-rich granule lumen,	GO:0003878~ATP citrate synthase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0046872~metal ion binding,	IPR002020:Citrate_synthase,IPR003781:CoA-bd,IPR005811:CoA_ligase,IPR014608:ATP-citrate_synthase,IPR016102:Succinyl-CoA_synth-like,IPR016143:Citrate_synth-like_sm_a-sub,IPR017440:Cit_synth/succinyl-CoA_lig_AS,IPR017866:Succ-CoA_synthase_bsu_CS,IPR032263:Citrate-bd,IPR033847:Citrt_syn/SCS-alpha_CS,IPR036291:NAD(P)-bd_dom_sf,IPR036969:Citrate_synthase_sf,	hsa00020:Citrate cycle (TCA cycle),hsa01100:Metabolic pathways,		PIRSF036511:ATP_citrt_syn,	SM00881:CoA_binding,	KW-0443~Lipid metabolism,KW-0444~Lipid biosynthesis,	KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	ACT_SITE:Tele-phosphohistidine intermediate,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin); alternate,DOMAIN:ATP-citrate synthase citrate-binding,DOMAIN:ATP-grasp,DOMAIN:CoA-binding,MUTAGEN:H->A: Reduced enzyme activity.,MUTAGEN:K->R,Q: Decreased acetylation and increased de novo lipid synthesis; when associated with R,Q-540 and R,Q-546. Abolished ubiquitination by the BCR(KLHL25) complex; when associated with R-540 and R-546.,MUTAGEN:K->R,Q: Decreased acetylation and increased de novo lipid synthesis; when associated with R,Q-540 and R,Q-554. Abolished ubiquitination by the BCR(KLHL25) complex; when associated with R-540 and R-554.,MUTAGEN:K->R,Q: Decreased acetylation and increased de novo lipid synthesis; when associated with R,Q-546 and R,Q-554. Abolished ubiquitination by the BCR(KLHL25)complex; when associated with R-546 and R-554.,REGION:Disordered,
ATP6V0B	ATPase H+ transporting V0 subunit b(ATP6V0B)	Homo sapiens			GO:0007035~vacuolar acidification,GO:0007042~lysosomal lumen acidification,GO:0016241~regulation of macroautophagy,GO:0048388~endosomal lumen acidification,GO:0051452~intracellular pH reduction,GO:0061795~Golgi lumen acidification,GO:1902600~hydrogen ion transmembrane transport,	GO:0000139~Golgi membrane,GO:0000220~vacuolar proton-transporting V-type ATPase, V0 domain,GO:0005765~lysosomal membrane,GO:0005886~plasma membrane,GO:0010008~endosome membrane,GO:0016020~membrane,GO:0030665~clathrin-coated vesicle membrane,GO:0030670~phagocytic vesicle membrane,GO:0033176~proton-transporting V-type ATPase complex,GO:0033179~proton-transporting V-type ATPase, V0 domain,GO:1902495~transmembrane transporter complex,	GO:0005515~protein binding,GO:0046961~proton-transporting ATPase activity, rotational mechanism,	IPR000245:ATPase_proteolipid_csu,IPR002379:ATPase_proteolipid_c-like_dom,IPR035921:F/V-ATP_Csub_sf,	hsa00190:Oxidative phosphorylation,hsa01100:Metabolic pathways,hsa04142:Lysosome,hsa04145:Phagosome,hsa04721:Synaptic vesicle cycle,hsa05110:Vibrio cholerae infection,hsa05120:Epithelial cell signaling in Helicobacter pylori infection,hsa05152:Tuberculosis,hsa05165:Human papillomavirus infection,hsa05323:Rheumatoid arthritis,				KW-0375~Hydrogen ion transport,KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,KW-0968~Cytoplasmic vesicle,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,				DOMAIN:V-ATPase proteolipid subunit C-like,REGION:Disordered,SITE:Essential for proton translocation,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
ATP6V0C	ATPase H+ transporting V0 subunit c(ATP6V0C)	Homo sapiens			GO:0007035~vacuolar acidification,GO:0007042~lysosomal lumen acidification,GO:0015986~ATP synthesis coupled proton transport,GO:0016241~regulation of macroautophagy,GO:0030177~positive regulation of Wnt signaling pathway,GO:0048388~endosomal lumen acidification,GO:0051452~intracellular pH reduction,GO:0061795~Golgi lumen acidification,GO:1902600~hydrogen ion transmembrane transport,	GO:0000139~Golgi membrane,GO:0000220~vacuolar proton-transporting V-type ATPase, V0 domain,GO:0005765~lysosomal membrane,GO:0005774~vacuolar membrane,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0010008~endosome membrane,GO:0016020~membrane,GO:0030665~clathrin-coated vesicle membrane,GO:0030670~phagocytic vesicle membrane,GO:0030672~synaptic vesicle membrane,GO:0033176~proton-transporting V-type ATPase complex,GO:0033179~proton-transporting V-type ATPase, V0 domain,GO:0035577~azurophil granule membrane,GO:0070062~extracellular exosome,GO:0070821~tertiary granule membrane,GO:0101003~ficolin-1-rich granule membrane,GO:1902495~transmembrane transporter complex,	GO:0005515~protein binding,GO:0031625~ubiquitin protein ligase binding,GO:0046933~proton-transporting ATP synthase activity, rotational mechanism,GO:0046961~proton-transporting ATPase activity, rotational mechanism,	IPR000245:ATPase_proteolipid_csu,IPR002379:ATPase_proteolipid_c-like_dom,IPR011555:ATPase_proteolipid_su_C_euk,IPR035921:F/V-ATP_Csub_sf,	hsa00190:Oxidative phosphorylation,hsa01100:Metabolic pathways,hsa04142:Lysosome,hsa04145:Phagosome,hsa04721:Synaptic vesicle cycle,hsa04966:Collecting duct acid secretion,hsa05110:Vibrio cholerae infection,hsa05120:Epithelial cell signaling in Helicobacter pylori infection,hsa05152:Tuberculosis,hsa05165:Human papillomavirus infection,hsa05323:Rheumatoid arthritis,	620465~Epilepsy, early-onset, 3, with or without developmental delay,			KW-0375~Hydrogen ion transport,KW-0406~Ion transport,KW-0813~Transport,KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-0770~Synapse,KW-0926~Vacuole,KW-0968~Cytoplasmic vesicle,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0832~Ubl conjugation,	DOMAIN:V-ATPase proteolipid subunit C-like,REGION:Disordered,SITE:Essential for proton translocation,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
ATP6V0D1	ATPase H+ transporting V0 subunit d1(ATP6V0D1)	Homo sapiens			GO:0006879~cellular iron ion homeostasis,GO:0007034~vacuolar transport,GO:0007035~vacuolar acidification,GO:0016241~regulation of macroautophagy,GO:0036295~cellular response to increased oxygen levels,GO:0060271~cilium assembly,GO:0097401~synaptic vesicle lumen acidification,GO:1902600~hydrogen ion transmembrane transport,	GO:0000220~vacuolar proton-transporting V-type ATPase, V0 domain,GO:0005765~lysosomal membrane,GO:0005768~endosome,GO:0005769~early endosome,GO:0005813~centrosome,GO:0010008~endosome membrane,GO:0016020~membrane,GO:0016324~apical plasma membrane,GO:0016471~vacuolar proton-transporting V-type ATPase complex,GO:0030665~clathrin-coated vesicle membrane,GO:0030670~phagocytic vesicle membrane,GO:0030672~synaptic vesicle membrane,GO:0033179~proton-transporting V-type ATPase, V0 domain,GO:0033181~plasma membrane proton-transporting V-type ATPase complex,GO:0043679~axon terminus,GO:0070062~extracellular exosome,GO:1902495~transmembrane transporter complex,	GO:0005515~protein binding,GO:0044877~macromolecular complex binding,GO:0046961~proton-transporting ATPase activity, rotational mechanism,	IPR002843:ATPase_V0-cplx_csu/dsu,IPR016727:ATPase_V0-cplx_dsu,IPR035067:V-type_ATPase_suC/d,IPR036079:ATPase_su_c/d_sf,IPR044911:V-type_ATPase_su_c/d_dom_3,	hsa00190:Oxidative phosphorylation,hsa01100:Metabolic pathways,hsa04142:Lysosome,hsa04145:Phagosome,hsa04721:Synaptic vesicle cycle,hsa04966:Collecting duct acid secretion,hsa05110:Vibrio cholerae infection,hsa05120:Epithelial cell signaling in Helicobacter pylori infection,hsa05152:Tuberculosis,hsa05165:Human papillomavirus infection,hsa05203:Viral carcinogenesis,hsa05323:Rheumatoid arthritis,		PIRSF018497:V-ATP_synth_D,		KW-0375~Hydrogen ion transport,KW-0406~Ion transport,KW-0813~Transport,KW-0970~Cilium biogenesis/degradation,	KW-0458~Lysosome,KW-0472~Membrane,KW-0968~Cytoplasmic vesicle,					KW-0597~Phosphoprotein,	REGION:Disordered,
ATP6V0E1	ATPase H+ transporting V0 subunit e1(ATP6V0E1)	Homo sapiens			GO:0007035~vacuolar acidification,GO:0016241~regulation of macroautophagy,GO:0055085~transmembrane transport,GO:1902600~hydrogen ion transmembrane transport,	GO:0005765~lysosomal membrane,GO:0010008~endosome membrane,GO:0030670~phagocytic vesicle membrane,GO:0033179~proton-transporting V-type ATPase, V0 domain,	GO:0005515~protein binding,GO:0042625~ATPase coupled ion transmembrane transporter activity,GO:0046961~proton-transporting ATPase activity, rotational mechanism,	IPR008389:ATPase_V0-cplx_e1/e2_su,IPR017385:ATPase_V0-cplx_e1/e2_su_met,	hsa00190:Oxidative phosphorylation,hsa01100:Metabolic pathways,hsa04145:Phagosome,hsa04721:Synaptic vesicle cycle,hsa04966:Collecting duct acid secretion,hsa05110:Vibrio cholerae infection,hsa05120:Epithelial cell signaling in Helicobacter pylori infection,hsa05165:Human papillomavirus infection,hsa05323:Rheumatoid arthritis,		PIRSF038097:V-ATP_synth_e1/e2,		KW-0375~Hydrogen ion transport,KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
ATP6V1A	ATPase H+ transporting V1 subunit A(ATP6V1A)	Homo sapiens			GO:0006879~cellular iron ion homeostasis,GO:0007035~vacuolar acidification,GO:0007042~lysosomal lumen acidification,GO:0015986~ATP synthesis coupled proton transport,GO:0016241~regulation of macroautophagy,GO:0036295~cellular response to increased oxygen levels,GO:0046034~ATP metabolic process,GO:0048388~endosomal lumen acidification,GO:0051452~intracellular pH reduction,GO:0061795~Golgi lumen acidification,GO:0097401~synaptic vesicle lumen acidification,GO:1902600~hydrogen ion transmembrane transport,	GO:0000139~Golgi membrane,GO:0000221~vacuolar proton-transporting V-type ATPase, V1 domain,GO:0005654~nucleoplasm,GO:0005765~lysosomal membrane,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005902~microvillus,GO:0010008~endosome membrane,GO:0016020~membrane,GO:0016324~apical plasma membrane,GO:0016469~proton-transporting two-sector ATPase complex,GO:0030133~transport vesicle,GO:0030141~secretory granule,GO:0030665~clathrin-coated vesicle membrane,GO:0033176~proton-transporting V-type ATPase complex,GO:0033180~proton-transporting V-type ATPase, V1 domain,GO:0043231~intracellular membrane-bounded organelle,GO:0070062~extracellular exosome,GO:0098850~extrinsic component of synaptic vesicle membrane,GO:1902495~transmembrane transporter complex,	GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016887~ATPase activity,GO:0046933~proton-transporting ATP synthase activity, rotational mechanism,GO:0046961~proton-transporting ATPase activity, rotational mechanism,	IPR000194:ATPase_F1/V1/A1_a/bsu_nucl-bd,IPR004100:ATPase_F1/V1/A1_a/bsu_N,IPR005725:ATPase_V1-cplx_asu,IPR020003:ATPase_a/bsu_AS,IPR022878:V-ATPase_asu,IPR023366:ATP_synth_asu-like_sf,IPR024034:ATPase_F1/V1_b/a_C,IPR027417:P-loop_NTPase,IPR031686:ATP-synth_a_Xtn,IPR036121:ATPase_F1/V1/A1_a/bsu_N_sf,	hsa00190:Oxidative phosphorylation,hsa01100:Metabolic pathways,hsa04145:Phagosome,hsa04150:mTOR signaling pathway,hsa04721:Synaptic vesicle cycle,hsa04966:Collecting duct acid secretion,hsa05110:Vibrio cholerae infection,hsa05120:Epithelial cell signaling in Helicobacter pylori infection,hsa05165:Human papillomavirus infection,hsa05323:Rheumatoid arthritis,	617403~Cutis laxa, autosomal recessive, type IID,618012~Developmental and epileptic encephalopathy 93,			KW-0375~Hydrogen ion transport,KW-0406~Ion transport,KW-0813~Transport,	KW-0458~Lysosome,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,	KW-0225~Disease variant,KW-0887~Epilepsy,		KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-1278~Translocase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:ATPase F1/V1/A1 complex alpha/beta subunit N-terminal,DOMAIN:ATPase F1/V1/A1 complex alpha/beta subunit nucleotide-binding,DOMAIN:ATPsynthase alpha/beta subunit N-terminal extension,MUTAGEN:E->Q: Complete loss of interaction with Rabies virus protein M; when associated with Q-256.,MUTAGEN:K->Q: Complete loss of interaction with Rabies virus protein M; when associated with Q-279.,
ATP6V1B2	ATPase H+ transporting V1 subunit B2(ATP6V1B2)	Homo sapiens			GO:0007035~vacuolar acidification,GO:0016241~regulation of macroautophagy,GO:0046034~ATP metabolic process,GO:0097401~synaptic vesicle lumen acidification,GO:1902600~hydrogen ion transmembrane transport,	GO:0000221~vacuolar proton-transporting V-type ATPase, V1 domain,GO:0001726~ruffle,GO:0005737~cytoplasm,GO:0005765~lysosomal membrane,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005902~microvillus,GO:0016324~apical plasma membrane,GO:0030665~clathrin-coated vesicle membrane,GO:0033180~proton-transporting V-type ATPase, V1 domain,GO:0042470~melanosome,GO:0043231~intracellular membrane-bounded organelle,GO:0070062~extracellular exosome,GO:0098850~extrinsic component of synaptic vesicle membrane,	GO:0005515~protein binding,GO:0005524~ATP binding,GO:0015078~hydrogen ion transmembrane transporter activity,GO:0046961~proton-transporting ATPase activity, rotational mechanism,	IPR000194:ATPase_F1/V1/A1_a/bsu_nucl-bd,IPR004100:ATPase_F1/V1/A1_a/bsu_N,IPR005723:ATPase_V1-cplx_bsu,IPR020003:ATPase_a/bsu_AS,IPR022879:V-ATPase_su_B/beta,IPR027417:P-loop_NTPase,	hsa00190:Oxidative phosphorylation,hsa01100:Metabolic pathways,hsa04145:Phagosome,hsa04150:mTOR signaling pathway,hsa04721:Synaptic vesicle cycle,hsa04966:Collecting duct acid secretion,hsa05110:Vibrio cholerae infection,hsa05120:Epithelial cell signaling in Helicobacter pylori infection,hsa05165:Human papillomavirus infection,hsa05323:Rheumatoid arthritis,	124480~Deafness, congenital, with onychodystrophy, autosomal dominant,616455~Zimmermann-Laband syndrome 2,	PIRSF039114:V-ATPsynth_beta/V-ATPase_B,		KW-0375~Hydrogen ion transport,KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,KW-0770~Synapse,KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,	KW-0209~Deafness,KW-0225~Disease variant,		KW-0067~ATP-binding,KW-0547~Nucleotide-binding,			DOMAIN:ATPase F1/V1/A1 complex alpha/beta subunit N-terminal,DOMAIN:ATPase F1/V1/A1 complex alpha/beta subunit nucleotide-binding,
ATP6V1D	ATPase H+ transporting V1 subunit D(ATP6V1D)	Homo sapiens			GO:0007035~vacuolar acidification,GO:0007042~lysosomal lumen acidification,GO:0016241~regulation of macroautophagy,GO:0030030~cell projection organization,GO:0048388~endosomal lumen acidification,GO:0051452~intracellular pH reduction,GO:0060271~cilium assembly,GO:0061512~protein localization to cilium,GO:0061795~Golgi lumen acidification,GO:0097401~synaptic vesicle lumen acidification,GO:1902600~hydrogen ion transmembrane transport,	GO:0000139~Golgi membrane,GO:0000221~vacuolar proton-transporting V-type ATPase, V1 domain,GO:0005654~nucleoplasm,GO:0005765~lysosomal membrane,GO:0005813~centrosome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005929~cilium,GO:0010008~endosome membrane,GO:0016020~membrane,GO:0030665~clathrin-coated vesicle membrane,GO:0033176~proton-transporting V-type ATPase complex,GO:0035579~specific granule membrane,GO:0070062~extracellular exosome,GO:0098850~extrinsic component of synaptic vesicle membrane,GO:1902495~transmembrane transporter complex,	GO:0005515~protein binding,GO:0046961~proton-transporting ATPase activity, rotational mechanism,	IPR002699:V_ATPase_D,	hsa00190:Oxidative phosphorylation,hsa01100:Metabolic pathways,hsa04145:Phagosome,hsa04150:mTOR signaling pathway,hsa04721:Synaptic vesicle cycle,hsa04966:Collecting duct acid secretion,hsa05110:Vibrio cholerae infection,hsa05120:Epithelial cell signaling in Helicobacter pylori infection,hsa05165:Human papillomavirus infection,hsa05323:Rheumatoid arthritis,				KW-0375~Hydrogen ion transport,KW-0406~Ion transport,KW-0813~Transport,KW-0970~Cilium biogenesis/degradation,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-0968~Cytoplasmic vesicle,
ATP6V1F	ATPase H+ transporting V1 subunit F(ATP6V1F)	Homo sapiens			GO:0007035~vacuolar acidification,GO:0007042~lysosomal lumen acidification,GO:0048388~endosomal lumen acidification,GO:0051452~intracellular pH reduction,GO:0061795~Golgi lumen acidification,GO:0097401~synaptic vesicle lumen acidification,GO:1902600~hydrogen ion transmembrane transport,	GO:0000139~Golgi membrane,GO:0000221~vacuolar proton-transporting V-type ATPase, V1 domain,GO:0005765~lysosomal membrane,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0010008~endosome membrane,GO:0016020~membrane,GO:0016471~vacuolar proton-transporting V-type ATPase complex,GO:0030665~clathrin-coated vesicle membrane,GO:0030672~synaptic vesicle membrane,GO:0033176~proton-transporting V-type ATPase complex,GO:0033180~proton-transporting V-type ATPase, V1 domain,GO:0070062~extracellular exosome,GO:0098793~presynapse,GO:1902495~transmembrane transporter complex,	GO:0005515~protein binding,GO:0015078~hydrogen ion transmembrane transporter activity,GO:0042625~ATPase coupled ion transmembrane transporter activity,GO:0046961~proton-transporting ATPase activity, rotational mechanism,	IPR005772:ATPase_V1-cplx_fsu_euk,IPR008218:ATPase_V1-cplx_f_g_su,IPR036906:ATPase_V1_fsu_sf,	hsa00190:Oxidative phosphorylation,hsa01100:Metabolic pathways,hsa04145:Phagosome,hsa04150:mTOR signaling pathway,hsa04721:Synaptic vesicle cycle,hsa04966:Collecting duct acid secretion,hsa05110:Vibrio cholerae infection,hsa05120:Epithelial cell signaling in Helicobacter pylori infection,hsa05165:Human papillomavirus infection,hsa05323:Rheumatoid arthritis,		PIRSF015945:ATPase_V1_F_euk,		KW-0375~Hydrogen ion transport,KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,KW-0770~Synapse,KW-0968~Cytoplasmic vesicle,
ATP6AP2	ATPase H+ transporting accessory protein 2(ATP6AP2)	Homo sapiens			GO:0002003~angiotensin maturation,GO:0007035~vacuolar acidification,GO:0007042~lysosomal lumen acidification,GO:0021626~central nervous system maturation,GO:0021903~rostrocaudal neural tube patterning,GO:0030177~positive regulation of Wnt signaling pathway,GO:0032914~positive regulation of transforming growth factor beta1 production,GO:0043408~regulation of MAPK cascade,GO:0048069~eye pigmentation,GO:0048388~endosomal lumen acidification,GO:0051452~intracellular pH reduction,GO:0060323~head morphogenesis,GO:0061795~Golgi lumen acidification,GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:0097401~synaptic vesicle lumen acidification,GO:1902600~hydrogen ion transmembrane transport,	GO:0000139~Golgi membrane,GO:0000220~vacuolar proton-transporting V-type ATPase, V0 domain,GO:0000421~autophagosome membrane,GO:0005764~lysosome,GO:0005765~lysosomal membrane,GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0010008~endosome membrane,GO:0016020~membrane,GO:0016471~vacuolar proton-transporting V-type ATPase complex,GO:0030424~axon,GO:0030665~clathrin-coated vesicle membrane,GO:0030672~synaptic vesicle membrane,GO:0032591~dendritic spine membrane,GO:0033176~proton-transporting V-type ATPase complex,GO:0045211~postsynaptic membrane,GO:0070062~extracellular exosome,GO:0070821~tertiary granule membrane,GO:0101003~ficolin-1-rich granule membrane,	GO:0005515~protein binding,GO:0038023~signaling receptor activity,	IPR012493:Renin_rcpt,IPR017850:Alkaline_phosphatase_core_sf,	hsa04614:Renin-angiotensin system,	300423~Intellectual developmental disorder, X-linked syndromic, Hedera type,300911~Parkinsonism with spasticity, X-linked,301045~Congenital disorder of glycosylation, type IIr,				KW-0256~Endoplasmic reticulum,KW-0458~Lysosome,KW-0472~Membrane,KW-0628~Postsynaptic cell membrane,KW-0770~Synapse,KW-0966~Cell projection,KW-0967~Endosome,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0887~Epilepsy,KW-0900~Congenital disorder of glycosylation,KW-0908~Parkinsonism,KW-0991~Intellectual disability,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0165~Cleavage on pair of basic residues,KW-0597~Phosphoprotein,	MOTIF:Mediates retrograde transport to the ER,MUTAGEN:K->Q: Increases cleavage and stability enhancing localization to the Golgi; when associated with Q-348.,MUTAGEN:R->Q: Increases cleavage and stability and enhancing localization to the Golgi; when associated with Q-346.,SITE:Cleavage; by furin-like protease,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
ATP1A1	ATPase Na+/K+ transporting subunit alpha 1(ATP1A1)	Homo sapiens			GO:0002026~regulation of the force of heart contraction,GO:0002028~regulation of sodium ion transport,GO:0006883~cellular sodium ion homeostasis,GO:0008217~regulation of blood pressure,GO:0009410~response to xenobiotic stimulus,GO:0010248~establishment or maintenance of transmembrane electrochemical gradient,GO:0030007~cellular potassium ion homeostasis,GO:0031947~negative regulation of glucocorticoid biosynthetic process,GO:0036376~sodium ion export from cell,GO:0045822~negative regulation of heart contraction,GO:0045823~positive regulation of heart contraction,GO:0045989~positive regulation of striated muscle contraction,GO:0055119~relaxation of cardiac muscle,GO:0071383~cellular response to steroid hormone stimulus,GO:0086002~cardiac muscle cell action potential involved in contraction,GO:0086009~membrane repolarization,GO:0086013~membrane repolarization during cardiac muscle cell action potential,GO:0086064~cell communication by electrical coupling involved in cardiac conduction,GO:1902600~hydrogen ion transmembrane transport,GO:1903416~response to glycoside,GO:1990573~potassium ion import across plasma membrane,	GO:0005783~endoplasmic reticulum,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0005890~sodium:potassium-exchanging ATPase complex,GO:0014069~postsynaptic density,GO:0016020~membrane,GO:0016323~basolateral plasma membrane,GO:0016324~apical plasma membrane,GO:0016328~lateral plasma membrane,GO:0030315~T-tubule,GO:0030424~axon,GO:0031090~organelle membrane,GO:0032991~macromolecular complex,GO:0036126~sperm flagellum,GO:0042383~sarcolemma,GO:0042470~melanosome,GO:0045121~membrane raft,GO:0060342~photoreceptor inner segment membrane,GO:0070062~extracellular exosome,GO:1903561~extracellular vesicle,	GO:0000166~nucleotide binding,GO:0005391~sodium:potassium-exchanging ATPase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008556~potassium-transporting ATPase activity,GO:0016791~phosphatase activity,GO:0016887~ATPase activity,GO:0030955~potassium ion binding,GO:0031402~sodium ion binding,GO:0046872~metal ion binding,GO:0046982~protein heterodimerization activity,GO:0051087~chaperone binding,GO:1990239~steroid hormone binding,	IPR001757:P_typ_ATPase,IPR004014:ATPase_P-typ_cation-transptr_N,IPR005775:P-type_ATPase_IIC,IPR006068:ATPase_P-typ_cation-transptr_C,IPR008250:ATPase_P-typ_transduc_dom_A_sf,IPR018303:ATPase_P-typ_P_site,IPR023214:HAD_sf,IPR023298:ATPase_P-typ_TM_dom_sf,IPR023299:ATPase_P-typ_cyto_dom_N,IPR036412:HAD-like_sf,IPR044492:P_typ_ATPase_HD_dom,	hsa04022:cGMP-PKG signaling pathway,hsa04024:cAMP signaling pathway,hsa04260:Cardiac muscle contraction,hsa04261:Adrenergic signaling in cardiomyocytes,hsa04911:Insulin secretion,hsa04918:Thyroid hormone synthesis,hsa04919:Thyroid hormone signaling pathway,hsa04925:Aldosterone synthesis and secretion,hsa04960:Aldosterone-regulated sodium reabsorption,hsa04961:Endocrine and other factor-regulated calcium reabsorption,hsa04964:Proximal tubule bicarbonate reclamation,hsa04970:Salivary secretion,hsa04971:Gastric acid secretion,hsa04972:Pancreatic secretion,hsa04973:Carbohydrate digestion and absorption,hsa04974:Protein digestion and absorption,hsa04976:Bile secretion,hsa04978:Mineral absorption,	618036~Charcot-Marie-Tooth disease, axonal, type 2DD,618314~Hypomagnesemia, seizures, and impaired intellectual development 2,		SM00831:Cation_ATPase_N,	KW-0406~Ion transport,KW-0633~Potassium transport,KW-0739~Sodium transport,KW-0740~Sodium/potassium transport,KW-0813~Transport,	KW-0472~Membrane,KW-0966~Cell projection,KW-1003~Cell membrane,	KW-0144~Charcot-Marie-Tooth disease,KW-0523~Neurodegeneration,KW-0622~Neuropathy,KW-0887~Epilepsy,KW-0982~Primary hypomagnesemia,KW-0991~Intellectual disability,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,KW-0630~Potassium,KW-0915~Sodium,	KW-1278~Translocase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:4-aspartylphosphate intermediate,COMPBIAS:Basic and acidic residues,DOMAIN:Cation-transporting P-type ATPase C-terminal,DOMAIN:Cation-transporting P-type ATPase N-terminal,REGION:Disordered,REGION:Phosphoinositide-3 kinase binding,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
ATP1B3	ATPase Na+/K+ transporting subunit beta 3(ATP1B3)	Homo sapiens			GO:0006813~potassium ion transport,GO:0006814~sodium ion transport,GO:0006883~cellular sodium ion homeostasis,GO:0030007~cellular potassium ion homeostasis,GO:0032781~positive regulation of ATPase activity,GO:0035725~sodium ion transmembrane transport,GO:0036376~sodium ion export from cell,GO:0050821~protein stabilization,GO:0071805~potassium ion transmembrane transport,GO:0072659~protein localization to plasma membrane,GO:0086009~membrane repolarization,GO:1901018~positive regulation of potassium ion transmembrane transporter activity,GO:1903278~positive regulation of sodium ion export from cell,GO:1903288~positive regulation of potassium ion import,GO:1990573~potassium ion import across plasma membrane,	GO:0005886~plasma membrane,GO:0005890~sodium:potassium-exchanging ATPase complex,GO:0016323~basolateral plasma membrane,GO:0016324~apical plasma membrane,GO:0036126~sperm flagellum,GO:0042470~melanosome,GO:0070062~extracellular exosome,	GO:0001671~ATPase activator activity,GO:0005515~protein binding,GO:0030674~protein binding, bridging,GO:0051117~ATPase binding,	IPR000402:Na/K_ATPase_sub_beta,IPR038702:Na/K_ATPase_sub_beta_sf,	hsa04022:cGMP-PKG signaling pathway,hsa04024:cAMP signaling pathway,hsa04260:Cardiac muscle contraction,hsa04261:Adrenergic signaling in cardiomyocytes,hsa04911:Insulin secretion,hsa04918:Thyroid hormone synthesis,hsa04919:Thyroid hormone signaling pathway,hsa04925:Aldosterone synthesis and secretion,hsa04960:Aldosterone-regulated sodium reabsorption,hsa04961:Endocrine and other factor-regulated calcium reabsorption,hsa04964:Proximal tubule bicarbonate reclamation,hsa04970:Salivary secretion,hsa04971:Gastric acid secretion,hsa04972:Pancreatic secretion,hsa04973:Carbohydrate digestion and absorption,hsa04974:Protein digestion and absorption,hsa04976:Bile secretion,hsa04978:Mineral absorption,				KW-0406~Ion transport,KW-0633~Potassium transport,KW-0739~Sodium transport,KW-0740~Sodium/potassium transport,KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0630~Potassium,KW-0915~Sodium,		KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,REGION:immunoglobulin-like,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
ATP2B1	ATPase plasma membrane Ca2+ transporting 1(ATP2B1)	Homo sapiens			GO:0001818~negative regulation of cytokine production,GO:0003056~regulation of vascular smooth muscle contraction,GO:0008217~regulation of blood pressure,GO:0030501~positive regulation of bone mineralization,GO:0034220~ion transmembrane transport,GO:0051480~regulation of cytosolic calcium ion concentration,GO:0051481~negative regulation of cytosolic calcium ion concentration,GO:0051928~positive regulation of calcium ion transport,GO:0055085~transmembrane transport,GO:1900076~regulation of cellular response to insulin stimulus,GO:1903779~regulation of cardiac conduction,GO:1990034~calcium ion export from cell,	GO:0001772~immunological synapse,GO:0005654~nucleoplasm,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016323~basolateral plasma membrane,GO:0030672~synaptic vesicle membrane,GO:0042734~presynaptic membrane,GO:0042995~cell projection,GO:0043231~intracellular membrane-bounded organelle,GO:0070062~extracellular exosome,GO:0098684~photoreceptor ribbon synapse,GO:0098978~glutamatergic synapse,	GO:0005388~calcium-transporting ATPase activity,GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0005524~ATP binding,GO:0015085~calcium ion transmembrane transporter activity,GO:0016887~ATPase activity,GO:0030165~PDZ domain binding,GO:0046872~metal ion binding,	IPR001757:P_typ_ATPase,IPR004014:ATPase_P-typ_cation-transptr_N,IPR006068:ATPase_P-typ_cation-transptr_C,IPR006408:P-type_ATPase_IIB,IPR008250:ATPase_P-typ_transduc_dom_A_sf,IPR018303:ATPase_P-typ_P_site,IPR022141:ATP_Ca_trans_C,IPR023214:HAD_sf,IPR023298:ATPase_P-typ_TM_dom_sf,IPR023299:ATPase_P-typ_cyto_dom_N,IPR036412:HAD-like_sf,IPR044492:P_typ_ATPase_HD_dom,	hsa04020:Calcium signaling pathway,hsa04022:cGMP-PKG signaling pathway,hsa04024:cAMP signaling pathway,hsa04261:Adrenergic signaling in cardiomyocytes,hsa04925:Aldosterone synthesis and secretion,hsa04961:Endocrine and other factor-regulated calcium reabsorption,hsa04970:Salivary secretion,hsa04972:Pancreatic secretion,hsa04978:Mineral absorption,	619910~Intellectual developmental disorder, autosomal dominant 66,		SM00831:Cation_ATPase_N,	KW-0109~Calcium transport,KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,KW-0770~Synapse,KW-0966~Cell projection,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0991~Intellectual disability,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0106~Calcium,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0112~Calmodulin-binding,KW-1278~Translocase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:4-aspartylphosphate intermediate,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Cation-transporting P-type ATPase C-terminal,DOMAIN:Cation-transporting P-type ATPase N-terminal,DOMAIN:Plasma membrane calcium transporting P-type ATPase C-terminal,REGION:Calmodulin-binding subdomain A,REGION:Disordered,REGION:Required for basolateral membrane targeting,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
ATP2B4	ATPase plasma membrane Ca2+ transporting 4(ATP2B4)	Homo sapiens			GO:0003407~neural retina development,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006874~cellular calcium ion homeostasis,GO:0007283~spermatogenesis,GO:0010629~negative regulation of gene expression,GO:0010751~negative regulation of nitric oxide mediated signal transduction,GO:0014832~urinary bladder smooth muscle contraction,GO:0016525~negative regulation of angiogenesis,GO:0021766~hippocampus development,GO:0030317~flagellated sperm motility,GO:0033138~positive regulation of peptidyl-serine phosphorylation,GO:0034220~ion transmembrane transport,GO:0043537~negative regulation of blood vessel endothelial cell migration,GO:0045019~negative regulation of nitric oxide biosynthetic process,GO:0051001~negative regulation of nitric-oxide synthase activity,GO:0051480~regulation of cytosolic calcium ion concentration,GO:0051599~response to hydrostatic pressure,GO:0070588~calcium ion transmembrane transport,GO:0070885~negative regulation of calcineurin-NFAT signaling cascade,GO:0071872~cellular response to epinephrine stimulus,GO:0071878~negative regulation of adrenergic receptor signaling pathway,GO:0097553~calcium ion transmembrane import into cytosol,GO:0098703~calcium ion import across plasma membrane,GO:0098736~negative regulation of the force of heart contraction,GO:1900082~negative regulation of arginine catabolic process,GO:1901660~calcium ion export,GO:1902083~negative regulation of peptidyl-cysteine S-nitrosylation,GO:1902305~regulation of sodium ion transmembrane transport,GO:1902548~negative regulation of cellular response to vascular endothelial growth factor stimulus,GO:1902806~regulation of cell cycle G1/S phase transition,GO:1903078~positive regulation of protein localization to plasma membrane,GO:1903243~negative regulation of cardiac muscle hypertrophy in response to stress,GO:1903249~negative regulation of citrulline biosynthetic process,GO:1903779~regulation of cardiac conduction,GO:1905145~cellular response to acetylcholine,GO:2000481~positive regulation of cAMP-dependent protein kinase activity,	GO:0005886~plasma membrane,GO:0005901~caveola,GO:0016020~membrane,GO:0016323~basolateral plasma membrane,GO:0030018~Z disc,GO:0030315~T-tubule,GO:0032991~macromolecular complex,GO:0036126~sperm flagellum,GO:0043231~intracellular membrane-bounded organelle,GO:0045121~membrane raft,GO:0048787~presynaptic active zone membrane,GO:0097228~sperm principal piece,GO:0098978~glutamatergic synapse,	GO:0005388~calcium-transporting ATPase activity,GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0005524~ATP binding,GO:0015085~calcium ion transmembrane transporter activity,GO:0016887~ATPase activity,GO:0017080~sodium channel regulator activity,GO:0019901~protein kinase binding,GO:0030165~PDZ domain binding,GO:0030346~protein phosphatase 2B binding,GO:0036487~nitric-oxide synthase inhibitor activity,GO:0046872~metal ion binding,GO:0050998~nitric-oxide synthase binding,GO:0097110~scaffold protein binding,	IPR001757:P_typ_ATPase,IPR004014:ATPase_P-typ_cation-transptr_N,IPR006068:ATPase_P-typ_cation-transptr_C,IPR006408:P-type_ATPase_IIB,IPR008250:ATPase_P-typ_transduc_dom_A_sf,IPR018303:ATPase_P-typ_P_site,IPR022141:ATP_Ca_trans_C,IPR023214:HAD_sf,IPR023298:ATPase_P-typ_TM_dom_sf,IPR023299:ATPase_P-typ_cyto_dom_N,IPR036412:HAD-like_sf,IPR044492:P_typ_ATPase_HD_dom,	hsa04020:Calcium signaling pathway,hsa04022:cGMP-PKG signaling pathway,hsa04024:cAMP signaling pathway,hsa04261:Adrenergic signaling in cardiomyocytes,hsa04925:Aldosterone synthesis and secretion,hsa04961:Endocrine and other factor-regulated calcium reabsorption,hsa04970:Salivary secretion,hsa04972:Pancreatic secretion,hsa04978:Mineral absorption,			SM00831:Cation_ATPase_N,	KW-0109~Calcium transport,KW-0406~Ion transport,KW-0813~Transport,	KW-0282~Flagellum,KW-0472~Membrane,KW-0966~Cell projection,KW-0969~Cilium,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0106~Calcium,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0112~Calmodulin-binding,KW-1278~Translocase,	KW-0597~Phosphoprotein,	ACT_SITE:4-aspartylphosphate intermediate,COMPBIAS:Basic and acidic residues,DOMAIN:Cation-transporting P-type ATPase C-terminal,DOMAIN:Cation-transporting P-type ATPase N-terminal,DOMAIN:Plasma membrane calcium transporting P-type ATPase C-terminal,MUTAGEN:D->Q: Strongly decreased calcium transport activity. Slowed decomposition of the phosphorylated intermediate.,MUTAGEN:K->L: Decreased calcium transport activity.,MUTAGEN:R->I: Mildly decreased calcium transport activity.,MUTAGEN:R->K,D,L: Decreased calcium transport activity.,MUTAGEN:V->P: Decreased calcium transport activity.,REGION:Calmodulin-binding subdomain A,REGION:Calmodulin-binding subdomain B,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
ATP2A3	ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3(ATP2A3)	Homo sapiens			GO:0006816~calcium ion transport,GO:0006874~cellular calcium ion homeostasis,GO:0006919~activation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0034220~ion transmembrane transport,GO:0070059~intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress,GO:0070588~calcium ion transmembrane transport,GO:1900121~negative regulation of receptor binding,GO:1903515~calcium ion transport from cytosol to endoplasmic reticulum,GO:1903779~regulation of cardiac conduction,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0016020~membrane,GO:0016529~sarcoplasmic reticulum,GO:0031090~organelle membrane,GO:0031095~platelet dense tubular network membrane,GO:0031965~nuclear membrane,GO:0033017~sarcoplasmic reticulum membrane,	GO:0005388~calcium-transporting ATPase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008656~cysteine-type endopeptidase activator activity involved in apoptotic process,GO:0015085~calcium ion transmembrane transporter activity,GO:0016887~ATPase activity,GO:0030899~calcium-dependent ATPase activity,GO:0044325~ion channel binding,GO:0046872~metal ion binding,	IPR001757:P_typ_ATPase,IPR004014:ATPase_P-typ_cation-transptr_N,IPR005782:P-type_ATPase_IIA,IPR006068:ATPase_P-typ_cation-transptr_C,IPR008250:ATPase_P-typ_transduc_dom_A_sf,IPR018303:ATPase_P-typ_P_site,IPR023214:HAD_sf,IPR023298:ATPase_P-typ_TM_dom_sf,IPR023299:ATPase_P-typ_cyto_dom_N,IPR036412:HAD-like_sf,IPR044492:P_typ_ATPase_HD_dom,	hsa04020:Calcium signaling pathway,hsa04022:cGMP-PKG signaling pathway,hsa04024:cAMP signaling pathway,hsa04148:Efferocytosis,hsa04260:Cardiac muscle contraction,hsa04261:Adrenergic signaling in cardiomyocytes,hsa04380:Osteoclast differentiation,hsa04919:Thyroid hormone signaling pathway,hsa04972:Pancreatic secretion,hsa05010:Alzheimer disease,hsa05017:Spinocerebellar ataxia,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05410:Hypertrophic cardiomyopathy,hsa05412:Arrhythmogenic right ventricular cardiomyopathy,hsa05414:Dilated cardiomyopathy,hsa05415:Diabetic cardiomyopathy,			SM00831:Cation_ATPase_N,	KW-0109~Calcium transport,KW-0406~Ion transport,KW-0813~Transport,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0539~Nucleus,KW-0703~Sarcoplasmic reticulum,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0106~Calcium,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-1278~Translocase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:4-aspartylphosphate intermediate,DOMAIN:Cation-transporting P-type ATPase C-terminal,DOMAIN:Cation-transporting P-type ATPase N-terminal,REGION:Disordered,REGION:Interaction with phospholamban 1,REGION:Interaction with phospholamban 2,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=10,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,TRANSMEM:Helical; Name=8,TRANSMEM:Helical; Name=9,
ATRX	ATRX chromatin remodeler(ATRX)	Homo sapiens			GO:0000212~meiotic spindle organization,GO:0006281~DNA repair,GO:0006306~DNA methylation,GO:0006325~chromatin organization,GO:0006334~nucleosome assembly,GO:0006338~chromatin remodeling,GO:0006355~regulation of transcription, DNA-templated,GO:0006366~transcription from RNA polymerase II promoter,GO:0006807~nitrogen compound metabolic process,GO:0007283~spermatogenesis,GO:0010571~positive regulation of nuclear cell cycle DNA replication,GO:0030330~DNA damage response, signal transduction by p53 class mediator,GO:0030900~forebrain development,GO:0031297~replication fork processing,GO:0031509~telomeric heterochromatin assembly,GO:0032206~positive regulation of telomere maintenance,GO:0035128~post-embryonic forelimb morphogenesis,GO:0035264~multicellular organism growth,GO:0043170~macromolecule metabolic process,GO:0044238~primary metabolic process,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0060009~Sertoli cell development,GO:0070192~chromosome organization involved in meiotic cell cycle,GO:0070198~protein localization to chromosome, telomeric region,GO:0072520~seminiferous tubule development,GO:0072711~cellular response to hydroxyurea,GO:1904908~negative regulation of maintenance of mitotic sister chromatid cohesion, telomeric,	GO:0000228~nuclear chromosome,GO:0000779~condensed chromosome, centromeric region,GO:0000781~chromosome, telomeric region,GO:0000792~heterochromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005721~pericentric heterochromatin,GO:0016604~nuclear body,GO:0016605~PML body,GO:0099115~chromosome, subtelomeric region,	GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0004386~helicase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0015616~DNA translocase activity,GO:0016887~ATPase activity,GO:0031490~chromatin DNA binding,GO:0035064~methylated histone binding,GO:0042393~histone binding,GO:0046872~metal ion binding,GO:0070087~chromo shadow domain binding,	IPR000330:SNF2_N,IPR001650:Helicase_C,IPR011011:Znf_FYVE_PHD,IPR013083:Znf_RING/FYVE/PHD,IPR014001:Helicase_ATP-bd,IPR025766:ADD,IPR027417:P-loop_NTPase,IPR038718:SNF2-like_sf,IPR041430:ADD_ATRX,IPR044574:ARIP4-like,	hsa04110:Cell cycle,	300448~Alpha-thalassemia myelodysplasia syndrome, somatic,301040~Alpha-thalassemia/impaired intellectual development syndrome,309580~Intellectual disability-hypotonic facies syndrome, X-linked,		SM00487:DEXDc,SM00490:HELICc,	KW-0227~DNA damage,KW-0234~DNA repair,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0158~Chromosome,KW-0539~Nucleus,KW-0779~Telomere,	KW-0225~Disease variant,KW-0991~Intellectual disability,	KW-0175~Coiled coil,KW-0863~Zinc-finger,	KW-0067~ATP-binding,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,KW-0862~Zinc,	KW-0156~Chromatin regulator,KW-0238~DNA-binding,KW-0347~Helicase,KW-0378~Hydrolase,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:ADD,DOMAIN:ATRX ADD,DOMAIN:Helicase ATP-binding,DOMAIN:Helicase C-terminal,DOMAIN:PHD-type,MOTIF:DEGH box,MOTIF:PxVxL motif,MUTAGEN:D->A: Impairs interaction with histone H3 peptides trimethylated at 'Lys-10' (H3K9me3) and reduces localization to pericentromeric heterochromatin foci.,MUTAGEN:D->A: Impairs interaction with histone H3 peptides trimethylated at 'Lys-10' (H3K9me3).,MUTAGEN:D->A: Impairs interaction with histone H3 peptides trimethylated at 'Lys-10' (H3K9me3); loss of heterochromatic localization.,MUTAGEN:E->A: Impairs interaction with histone H3 peptides unmethylated at 'Lys-5' (H3K4me0); reduces pericentromeric localization.,MUTAGEN:E->L: Impairs interaction with histone H3 peptides and reduces localization to pericentromeric heterochromatin foci.,MUTAGEN:H->N: Impairs interaction with histone H3 peptides and reduces localization to pericentromeric heterochromatin foci.,MUTAGEN:I->A: Impairs interaction with histone H3 peptides trimethylated at 'Lys-10' (H3K9me3).,MUTAGEN:K->R: Abolishes ATPAse activity, no effect on pericentromeric heterochromatin localization.,MUTAGEN:Y->A,K: Impairs interaction with histone H3 peptides trimethylated at 'Lys-10' (H3K9me3); loss of heterochromatic localization.,MUTAGEN:Y->A: Impairs interaction with histone H3 peptides trimethylated at 'Lys-10' (H3K9me3) and reduces localization to pericentromeric heterochromatin foci.,REGION:Disordered,REGION:Interaction with DAXX,REGION:Interaction with MECP2,ZN_FING:GATA-type; atypical,ZN_FING:PHD-type; atypical,
AHI1	Abelson helper integration site 1(AHI1)	Homo sapiens			GO:0001738~morphogenesis of a polarized epithelium,GO:0001947~heart looping,GO:0002092~positive regulation of receptor internalization,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0007417~central nervous system development,GO:0008104~protein localization,GO:0010842~retina layer formation,GO:0016192~vesicle-mediated transport,GO:0030862~positive regulation of polarized epithelial cell differentiation,GO:0030902~hindbrain development,GO:0035844~cloaca development,GO:0035845~photoreceptor cell outer segment organization,GO:0039008~pronephric nephron tubule morphogenesis,GO:0039023~pronephric duct morphogenesis,GO:0043066~negative regulation of apoptotic process,GO:0044458~motile cilium assembly,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0050795~regulation of behavior,GO:0060271~cilium assembly,GO:0065001~specification of axis polarity,GO:0070121~Kupffer's vesicle development,GO:0070986~left/right axis specification,GO:0071599~otic vesicle development,	GO:0005813~centrosome,GO:0005814~centriole,GO:0005829~cytosol,GO:0005911~cell-cell junction,GO:0005912~adherens junction,GO:0005929~cilium,GO:0036038~MKS complex,GO:0036064~ciliary basal body,GO:0097730~non-motile cilium,	GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR001452:SH3_domain,IPR001680:WD40_rpt,IPR015943:WD40/YVTN_repeat-like_dom_sf,IPR035832:AHI1_SH3,IPR036028:SH3-like_dom_sf,IPR036322:WD40_repeat_dom_sf,		608629~Joubert syndrome 3,		SM00320:WD40,SM00326:SH3,	KW-0221~Differentiation,KW-0970~Cilium biogenesis/degradation,	KW-0206~Cytoskeleton,KW-0963~Cytoplasm,KW-0965~Cell junction,KW-0966~Cell projection,KW-0969~Cilium,	KW-0225~Disease variant,KW-0979~Joubert syndrome,KW-1186~Ciliopathy,	KW-0175~Coiled coil,KW-0677~Repeat,KW-0728~SH3 domain,KW-0853~WD repeat,		KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:SH3,REGION:Disordered,REGION:Interaction with HAP1,REPEAT:WD,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,REPEAT:WD 7,
ARAP2	ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 2(ARAP2)	Homo sapiens		h_arapPathway:ADP-Ribosylation Factor,	GO:0007165~signal transduction,	GO:0005737~cytoplasm,	GO:0005096~GTPase activator activity,GO:0005547~phosphatidylinositol-3,4,5-trisphosphate binding,GO:0046872~metal ion binding,	IPR000159:RA_dom,IPR000198:RhoGAP_dom,IPR001164:ArfGAP_dom,IPR001660:SAM,IPR001849:PH_domain,IPR008936:Rho_GTPase_activation_prot,IPR011993:PH-like_dom_sf,IPR013761:SAM/pointed_sf,IPR037278:ARFGAP/RecO,IPR037858:RhoGAP_ARAP,IPR038508:ArfGAP_dom_sf,	hsa04144:Endocytosis,			SM00105:ArfGap,SM00233:PH,SM00324:RhoGAP,SM00454:SAM,		KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0343~GTPase activation,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:Arf-GAP,DOMAIN:PH,DOMAIN:PH 1,DOMAIN:PH 2,DOMAIN:PH 3,DOMAIN:PH 4,DOMAIN:PH 5,DOMAIN:Ras-associating,DOMAIN:Rho-GAP,DOMAIN:SAM,REGION:Disordered,ZN_FING:C4-type,
ACAP1	ArfGAP with coiled-coil, ankyrin repeat and PH domains 1(ACAP1)	Homo sapiens			GO:0015031~protein transport,	GO:0010008~endosome membrane,GO:0016020~membrane,GO:0055038~recycling endosome membrane,	GO:0005096~GTPase activator activity,GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR001164:ArfGAP_dom,IPR001849:PH_domain,IPR002110:Ankyrin_rpt,IPR004148:BAR_dom,IPR011993:PH-like_dom_sf,IPR027267:AH/BAR_dom_sf,IPR036770:Ankyrin_rpt-contain_sf,IPR037278:ARFGAP/RecO,IPR038508:ArfGAP_dom_sf,IPR045258:ACAP1/2/3-like,	hsa04144:Endocytosis,			SM00105:ArfGap,SM00233:PH,SM00248:ANK,	KW-0653~Protein transport,KW-0813~Transport,	KW-0472~Membrane,KW-0967~Endosome,		KW-0040~ANK repeat,KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0343~GTPase activation,	KW-0597~Phosphoprotein,KW-0944~Nitration,	DOMAIN:Arf-GAP,DOMAIN:BAR,DOMAIN:PH,MUTAGEN:F->A: Reduced membrane binding and ability to induce liposome tubulation.,MUTAGEN:F->E: Almost abolishes membrane binding.,MUTAGEN:F->W: Preserves membrane binding and ability to tubulate liposomes.,MUTAGEN:K->N: Loss of binding to PIP2 and PIP3. Loss of association with endosomal tubules when coexpressed with PIP5K1C.,MUTAGEN:R->Q: Loss of GAP activity. No effect on GULP1 binding or association with endosomal tubules when coexpressed with PIP5K1C.,MUTAGEN:S->A: Loss of phosphorylation at S-554, interaction with ITGB1 and ITGB1-dependent cell migration.,MUTAGEN:S->A: Loss of phosphorylation by PKB, interaction with ITGB1 and ITGB1-dependent cell migration.,MUTAGEN:S->A: No effect on interaction with ITGB1.,MUTAGEN:S->D: Enhances interaction with ITGB1.,MUTAGEN:T->A: No effect on interaction with ITGB1.,MUTAGEN:Y->F: No effect on interaction with ITGB1.,REGION:Disordered,REGION:Prevents interaction with ITGB1 when S-554 is not phosphorylated,REGION:Required for formation of endosomal tubules when overexpressed with PIP5K1C,REGION:Required for interaction with GULP1,REPEAT:ANK 1,REPEAT:ANK 2,REPEAT:ANK 3,ZN_FING:C4-type,
BCAP31	B cell receptor associated protein 31(BCAP31)	Homo sapiens			GO:0006626~protein targeting to mitochondrion,GO:0006886~intracellular protein transport,GO:0006888~ER to Golgi vesicle-mediated transport,GO:0006915~apoptotic process,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0007283~spermatogenesis,GO:0032471~negative regulation of endoplasmic reticulum calcium ion concentration,GO:0034976~response to endoplasmic reticulum stress,GO:0035584~calcium-mediated signaling using intracellular calcium source,GO:0043280~positive regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0051561~positive regulation of mitochondrial calcium ion concentration,GO:0070973~protein localization to endoplasmic reticulum exit site,GO:1903071~positive regulation of ER-associated ubiquitin-dependent protein catabolic process,GO:1904154~positive regulation of retrograde protein transport, ER to cytosol,GO:1904294~positive regulation of ERAD pathway,GO:2000060~positive regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process,GO:2001244~positive regulation of intrinsic apoptotic signaling pathway,	GO:0000139~Golgi membrane,GO:0005739~mitochondrion,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005811~lipid particle,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0030136~clathrin-coated vesicle,GO:0032580~Golgi cisterna membrane,GO:0033116~endoplasmic reticulum-Golgi intermediate compartment membrane,GO:0044233~ER-mitochondrion membrane contact site,GO:0097038~perinuclear endoplasmic reticulum,GO:0098553~lumenal side of endoplasmic reticulum membrane,	GO:0005515~protein binding,GO:0042288~MHC class I protein binding,GO:0044877~macromolecular complex binding,	IPR008417:BAP29/BAP31,IPR040463:BAP29/BAP31_N,IPR041672:Bap31/Bap29_C,	hsa04141:Protein processing in endoplasmic reticulum,hsa05165:Human papillomavirus infection,	300475~Deafness, dystonia, and cerebral hypomyelination,			KW-0053~Apoptosis,KW-0653~Protein transport,KW-0813~Transport,KW-0931~ER-Golgi transport,KW-0945~Host-virus interaction,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,	KW-0209~Deafness,KW-0991~Intellectual disability,KW-1023~Dystonia,	KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,		DOMAIN:BAP29/BAP31 transmembrane,DOMAIN:Bap31/Bap29 cytoplasmic coiled-coil,MOTIF:Di-lysine motif,MUTAGEN:D->A: Abolishes cleavage by caspases, inhibits apoptotic membrane blebbing and release of cytochrome c from mitochondria; when associated with A-164.,MUTAGEN:D->A: Abolishes cleavage by caspases, inhibits apoptotic membrane blebbing and release of cytochrome c from mitochondria; when associated with A-238.,SITE:Cleavage; by caspase-8,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
BDP1	B double prime 1, subunit of RNA polymerase III transcription initiation factor IIIB(BDP1)	Homo sapiens			GO:0070898~RNA polymerase III transcriptional preinitiation complex assembly,	GO:0000126~transcription factor TFIIIB complex,GO:0005654~nucleoplasm,	GO:0001156~TFIIIC-class transcription factor binding,GO:0005515~protein binding,	IPR001005:SANT/Myb,IPR009057:Homeobox-like_sf,IPR039467:TFIIIB_B''_Myb,		618257~Deafness, autosomal recessive 112,		SM00717:SANT,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0209~Deafness,KW-1010~Non-syndromic deafness,	KW-0175~Coiled coil,KW-0677~Repeat,		KW-0010~Activator,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,DOMAIN:Myb-like,MUTAGEN:S->A: Not phosphorylated by CSNK2A1; when associated with A-390; A-426; A-431 and A-437. CK2 treatment constitutively activates for U6 transcription; when associated with A-390; A-426; A-431 and A-437.,MUTAGEN:S->A: Not phosphorylated by CSNK2A1; when associated with A-390; A-426; A-437 and A-446. CK2 treatment constitutively activates for U6 transcription; when associated with A-390; A-426; A-437 and A-446.,MUTAGEN:S->A: Not phosphorylated by CSNK2A1; when associated with A-390; A-431; A-437 and A-446. CK2 treatment constitutively activates for U6 transcription; when associated with A-390; A-431; A-437 and A-446.,MUTAGEN:S->A: Not phosphorylated by CSNK2A1; when associated with A-426; A-431; A-437 and A-446. CK2 treatment constitutively activates for U6 transcription; when associated with A-426; A-431; A-437 and A-446.,MUTAGEN:T->A: Not phosphorylated by CSNK2A1; when associated with A-390; A-426; A-431 and A-446. CK2 treatment constitutively activates for U6 transcription; when associated with A-390; A-426; A-431 and A-446.,REGION:9 X 55 AA repeats of G-R-R-X-I-S-P-X-E-N-G-X-E-E-V-K-P-X-X-E-M-E-T-D-L-K-X-T-G-R-E-X-X-X-R-E-K-T-X-E-X-X-D-A-X-E-E-I-D-X-D-L-E-E-T,REGION:Disordered,REGION:Interaction with ZBTB43,REGION:Required for phosphorylation by CSNK2A1,REPEAT:1; approximate,REPEAT:2,REPEAT:3,REPEAT:4,REPEAT:5,REPEAT:6,REPEAT:7,REPEAT:8; approximate,REPEAT:9; approximate,
BCL7B	BAF chromatin remodeling complex subunit BCL7B(BCL7B)	Homo sapiens			GO:0006338~chromatin remodeling,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006915~apoptotic process,GO:0008284~positive regulation of cell proliferation,GO:0016055~Wnt signaling pathway,GO:0030071~regulation of mitotic metaphase/anaphase transition,GO:0030154~cell differentiation,GO:0045596~negative regulation of cell differentiation,GO:0070316~regulation of G0 to G1 transition,GO:1902459~positive regulation of stem cell population maintenance,GO:2000045~regulation of G1/S transition of mitotic cell cycle,GO:2000781~positive regulation of double-strand break repair,GO:2000819~regulation of nucleotide-excision repair,	GO:0000785~chromatin,GO:0016514~SWI/SNF complex,	GO:0003779~actin binding,GO:0005515~protein binding,	IPR006804:BCL7,	hsa03082:ATP-dependent chromatin remodeling,				KW-0053~Apoptosis,KW-0221~Differentiation,KW-0879~Wnt signaling pathway,		KW-0020~Allergen,KW-0856~Williams-Beuren syndrome,				KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,REGION:Disordered,
BANF1	BAF nuclear assembly factor 1(BANF1)	Homo sapiens			GO:0006325~chromatin organization,GO:0006979~response to oxidative stress,GO:0007084~mitotic nuclear envelope reassembly,GO:0009615~response to virus,GO:0010836~negative regulation of protein ADP-ribosylation,GO:0015074~DNA integration,GO:0032480~negative regulation of type I interferon production,GO:0045071~negative regulation of viral genome replication,GO:0045824~negative regulation of innate immune response,GO:0051276~chromosome organization,	GO:0000785~chromatin,GO:0000793~condensed chromosome,GO:0005634~nucleus,GO:0005635~nuclear envelope,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0003677~DNA binding,GO:0003690~double-stranded DNA binding,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,	IPR004122:BAF_prot,IPR036617:BAF_sf,		614008~Nestor-Guillermo progeria syndrome,		SM01023:BAF,	KW-0945~Host-virus interaction,	KW-0158~Chromosome,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,			KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:HhH,MUTAGEN:C->A: No effect on histone H1/H3 and LEMD3/MAN1 binding.,MUTAGEN:D->A: Reduces binding to dsDNA, LEMD3/MAN1 and histone H1/H3. Reduced interaction with PARP1.,MUTAGEN:G->E: Abolishes homodimerization, preventing ability to cross-bridge DNA. Abolished ability to mediate nuclear membrane reformation at the end of mitosis. Abolished ability to outcompete CGAS for DNA-binding, leading to innate immune activation. Complete loss of EMD, histone H1/H3 and LEMD3/MAN1 binding.,MUTAGEN:G->E: Complete loss of dsDNA, EMD, histone H1/H3 and LEMD3/MAN1 binding.,MUTAGEN:G->E: Fails to bind dsDNA.,MUTAGEN:G->Q: Complete loss of EMD binding and reduces dsDNA binding.,MUTAGEN:G->Q: Reduces binding to dsDNA.,MUTAGEN:I->A: Reduces histone H1/H3 and LEMD3/MAN1 binding. Fails to promote HIV-1 genome integration.,MUTAGEN:I->K: Fails to promote HIV-1 genome integration.,MUTAGEN:K->A: Complete loss of LEMD3/MAN1 and histone H1/H3 binding.,MUTAGEN:K->A: No effect on LEMD3/MAN1 binding. Enhances histone H1/H3 binding.,MUTAGEN:K->A: No effect on histone H1/H3 and LEMD3/MAN1 binding.,MUTAGEN:K->A: No effect on histone H1/H3 binding.,MUTAGEN:K->A: Reduces LEMD3/MAN1 binding. No effect on histone H1/H3 binding.,MUTAGEN:K->E: Complete loss of EMD binding. Reduces LEMD3/MAN1 binding. Enhances histone H1/H3 binding.,MUTAGEN:K->E: Complete loss of dsDNA and LEMD3/MAN1 binding.,MUTAGEN:K->E: Enhances histone H1/H3 binding.,MUTAGEN:K->E: No effect on histone H1/H3 binding.,MUTAGEN:K->E: Reduces binding to dsDNA.,MUTAGEN:K->E: Reduces histone H1/H3 binding.,MUTAGEN:L->A: Reduces LEMD3/MAN1 binding. No effect on Histone H1/H3 binding.,MUTAGEN:L->E: Complete loss of dsDNA, histone H1/H3 and LEMD3/MAN1 binding.,MUTAGEN:L->K: Fails to promote HIV-1 genome integration.,MUTAGEN:L->R: Abolishes interaction with LEM domain-containing proteins without affecting homodimerization and DNA-binding. Does not affect its involvement in nuclear membrane reformation at the end of mitosis. Does not affect ability to outcompete CGAS for DNA-binding.,MUTAGEN:P->A: No effect on LEMD3/MAN1 and enhances histone H1/H3 binding.,MUTAGEN:R->A: Enhances histone H1/H3 binding.,MUTAGEN:R->A: No effect on histone H1/H3 binding.,MUTAGEN:R->E: Complete loss of LEMD3/MAN1 binding.,MUTAGEN:R->E: No effect on histone H1/H3 binding.,MUTAGEN:R->E: Reduces LEMD3/MAN1 binding.,MUTAGEN:R->E: Reduces binding to dsDNA. No effect on histone H1/H3 binding.,MUTAGEN:S->A: Delayed phosphorylation with a 10-fold decrease in the initial phosphorylation rate. 71% loss of binding to lamin A.,MUTAGEN:S->D: 75% cytoplasmic localization.,MUTAGEN:S->E: Complete loss of phosphorylation and mislocalization of EMD in nucleus.,MUTAGEN:TT->AA: No effect on the initial rate of phosphorylation but a second slow phase of phosphorylation is absent.,MUTAGEN:TTS->AAA: 95% nuclear localization. Loss of BAF phosphorylation and ability to suppress vaccinia virus DNA replication.,MUTAGEN:TTS->DDD: 85% cytoplasmic localization.,MUTAGEN:V->A: No effect on histone H1/H3 binding.,MUTAGEN:V->E: Complete loss of EMD, and histone H1/H3 binding. Reduces dsDNA and LEMD3/MAN1 binding.,MUTAGEN:W->A: Complete loss of LEMD3/MAN1 binding. Enhances histone H1/H3 binding.,REGION:Disordered,
BAG1	BAG cochaperone 1(BAG1)	Homo sapiens			GO:0006915~apoptotic process,GO:0007166~cell surface receptor signaling pathway,GO:0034393~positive regulation of smooth muscle cell apoptotic process,GO:0043066~negative regulation of apoptotic process,GO:0050821~protein stabilization,GO:0051085~chaperone mediated protein folding requiring cofactor,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016020~membrane,	GO:0000774~adenyl-nucleotide exchange factor activity,GO:0005515~protein binding,GO:0031625~ubiquitin protein ligase binding,GO:0051087~chaperone binding,	IPR000626:Ubiquitin-like_dom,IPR003103:BAG_domain,IPR017093:BAG-1,IPR029071:Ubiquitin-like_domsf,IPR036533:BAG_dom_sf,IPR039773:BAG_chaperone_regulator,	hsa04141:Protein processing in endoplasmic reticulum,		PIRSF037029:BAG_1,	SM00213:UBQ,SM00264:BAG,	KW-0053~Apoptosis,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0677~Repeat,		KW-0143~Chaperone,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:BAG,DOMAIN:Ubiquitin-like,MUTAGEN:RK->AA: Significant loss of interaction with HSPA8.,REGION:7 X 6 AA tandem repeat of E-E-X(4),REGION:Disordered,REGION:Interaction with HSPA8,REGION:Interaction with PPP1R15A,REPEAT:1,REPEAT:2,REPEAT:3,REPEAT:4,REPEAT:5,REPEAT:6,REPEAT:7,
BBX	BBX high mobility group box domain containing(BBX)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0060348~bone development,	GO:0000785~chromatin,GO:0005634~nucleus,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003677~DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR009071:HMG_box_dom,IPR019102:TF_HMG_box_BBX_DUF2028,IPR036910:HMG_box_dom_sf,				SM00398:HMG,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0175~Coiled coil,		KW-0238~DNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DNA_BIND:HMG box,DOMAIN:HMG box,REGION:Disordered,
BAX	BCL2 associated X, apoptosis regulator(BAX)	Homo sapiens	127.Mito-stress,152.altered_synaptic_signalling-neurodegenerative_disorders,46.P13K_PTEN,	h_badPathway:Regulation of BAD phosphorylation,h_ceramidePathway:Ceramide Signaling Pathway,h_chemicalPathway:Apoptotic Signaling in Response to DNA Damage,h_mitochondriaPathway:Role of Mitochondria in Apoptotic Signaling,h_p53hypoxiaPathway:Hypoxia and p53 in the Cardiovascular system,h_p53Pathway:p53 Signaling Pathway,	GO:0001541~ovarian follicle development,GO:0001764~neuron migration,GO:0001777~T cell homeostatic proliferation,GO:0001782~B cell homeostasis,GO:0001783~B cell apoptotic process,GO:0001822~kidney development,GO:0001836~release of cytochrome c from mitochondria,GO:0001844~protein insertion into mitochondrial membrane involved in apoptotic signaling pathway,GO:0001974~blood vessel remodeling,GO:0002262~myeloid cell homeostasis,GO:0002352~B cell negative selection,GO:0002358~B cell homeostatic proliferation,GO:0002904~positive regulation of B cell apoptotic process,GO:0006687~glycosphingolipid metabolic process,GO:0006808~regulation of nitrogen utilization,GO:0006915~apoptotic process,GO:0006919~activation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0006950~response to stress,GO:0007281~germ cell development,GO:0008053~mitochondrial fusion,GO:0008625~extrinsic apoptotic signaling pathway via death domain receptors,GO:0008630~intrinsic apoptotic signaling pathway in response to DNA damage,GO:0008635~activation of cysteine-type endopeptidase activity involved in apoptotic process by cytochrome c,GO:0008637~apoptotic mitochondrial changes,GO:0009566~fertilization,GO:0009636~response to toxic substance,GO:0009651~response to salt stress,GO:0010248~establishment or maintenance of transmembrane electrochemical gradient,GO:0010332~response to gamma radiation,GO:0010524~positive regulation of calcium ion transport into cytosol,GO:0010917~negative regulation of mitochondrial membrane potential,GO:0021854~hypothalamus development,GO:0021987~cerebral cortex development,GO:0031334~positive regulation of protein complex assembly,GO:0032091~negative regulation of protein binding,GO:0032469~endoplasmic reticulum calcium ion homeostasis,GO:0032471~negative regulation of endoplasmic reticulum calcium ion concentration,GO:0032976~release of matrix enzymes from mitochondria,GO:0033137~negative regulation of peptidyl-serine phosphorylation,GO:0033599~regulation of mammary gland epithelial cell proliferation,GO:0034620~cellular response to unfolded protein,GO:0034644~cellular response to UV,GO:0035234~ectopic germ cell programmed cell death,GO:0042475~odontogenesis of dentin-containing tooth,GO:0042981~regulation of apoptotic process,GO:0043065~positive regulation of apoptotic process,GO:0043524~negative regulation of neuron apoptotic process,GO:0043525~positive regulation of neuron apoptotic process,GO:0043653~mitochondrial fragmentation involved in apoptotic process,GO:0045136~development of secondary sexual characteristics,GO:0046666~retinal cell programmed cell death,GO:0048087~positive regulation of developmental pigmentation,GO:0048147~negative regulation of fibroblast proliferation,GO:0048515~spermatid differentiation,GO:0048597~post-embryonic camera-type eye morphogenesis,GO:0048678~response to axon injury,GO:0048873~homeostasis of number of cells within a tissue,GO:0051204~protein insertion into mitochondrial membrane,GO:0051209~release of sequestered calcium ion into cytosol,GO:0051281~positive regulation of release of sequestered calcium ion into cytosol,GO:0051726~regulation of cell cycle,GO:0051881~regulation of mitochondrial membrane potential,GO:0060011~Sertoli cell proliferation,GO:0060041~retina development in camera-type eye,GO:0060057~apoptotic process involved in mammary gland involution,GO:0060058~positive regulation of apoptotic process involved in mammary gland involution,GO:0060068~vagina development,GO:0060402~calcium ion transport into cytosol,GO:0070059~intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress,GO:0070242~thymocyte apoptotic process,GO:0070584~mitochondrion morphogenesis,GO:0072332~intrinsic apoptotic signaling pathway by p53 class mediator,GO:0090200~positive regulation of release of cytochrome c from mitochondria,GO:0097049~motor neuron apoptotic process,GO:0097190~apoptotic signaling pathway,GO:0097191~extrinsic apoptotic signaling pathway,GO:0097192~extrinsic apoptotic signaling pathway in absence of ligand,GO:0097193~intrinsic apoptotic signaling pathway,GO:0097435~supramolecular fiber organization,GO:0098586~cellular response to virus,GO:1900103~positive regulation of endoplasmic reticulum unfolded protein response,GO:1902110~positive regulation of mitochondrial membrane permeability involved in apoptotic process,GO:1902262~apoptotic process involved in blood vessel morphogenesis,GO:1902263~apoptotic process involved in embryonic digit morphogenesis,GO:1902445~regulation of mitochondrial membrane permeability involved in programmed necrotic cell death,GO:1902512~positive regulation of apoptotic DNA fragmentation,GO:1903896~positive regulation of IRE1-mediated unfolded protein response,GO:1904019~epithelial cell apoptotic process,GO:1904037~positive regulation of epithelial cell apoptotic process,GO:1990117~B cell receptor apoptotic signaling pathway,GO:2000243~positive regulation of reproductive process,GO:2000673~positive regulation of motor neuron apoptotic process,GO:2001233~regulation of apoptotic signaling pathway,GO:2001234~negative regulation of apoptotic signaling pathway,GO:2001244~positive regulation of intrinsic apoptotic signaling pathway,	GO:0005634~nucleus,GO:0005635~nuclear envelope,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005741~mitochondrial outer membrane,GO:0005757~mitochondrial permeability transition pore complex,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0016020~membrane,GO:0046930~pore complex,GO:0070062~extracellular exosome,GO:0071944~cell periphery,GO:0097136~Bcl-2 family protein complex,GO:0097144~BAX complex,GO:0097145~BAK complex,	GO:0005515~protein binding,GO:0008289~lipid binding,GO:0015267~channel activity,GO:0030544~Hsp70 protein binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0046982~protein heterodimerization activity,GO:0051434~BH3 domain binding,	IPR002475:Bcl2-like,IPR020717:Bcl2_BH1_motif_CS,IPR020726:Bcl2_BH2_motif_CS,IPR020728:Bcl2_BH3_motif_CS,IPR026298:Bcl-2_fam,IPR036834:Bcl-2-like_sf,IPR046371:Bcl-2_BH1-3,	hsa01521:EGFR tyrosine kinase inhibitor resistance,hsa01522:Endocrine resistance,hsa01524:Platinum drug resistance,hsa04071:Sphingolipid signaling pathway,hsa04115:p53 signaling pathway,hsa04141:Protein processing in endoplasmic reticulum,hsa04210:Apoptosis,hsa04211:Longevity regulating pathway,hsa04215:Apoptosis - multiple species,hsa04217:Necroptosis,hsa04722:Neurotrophin signaling pathway,hsa04932:Non-alcoholic fatty liver disease,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05130:Pathogenic Escherichia coli infection,hsa05131:Shigellosis,hsa05132:Salmonella infection,hsa05152:Tuberculosis,hsa05160:Hepatitis C,hsa05161:Hepatitis B,hsa05162:Measles,hsa05163:Human cytomegalovirus infection,hsa05164:Influenza A,hsa05165:Human papillomavirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05200:Pathways in cancer,hsa05202:Transcriptional misregulation in cancer,hsa05203:Viral carcinogenesis,hsa05210:Colorectal cancer,hsa05212:Pancreatic cancer,hsa05213:Endometrial cancer,hsa05214:Glioma,hsa05216:Thyroid cancer,hsa05217:Basal cell carcinoma,hsa05218:Melanoma,hsa05220:Chronic myeloid leukemia,hsa05222:Small cell lung cancer,hsa05223:Non-small cell lung cancer,hsa05224:Breast cancer,hsa05225:Hepatocellular carcinoma,hsa05226:Gastric cancer,hsa05417:Lipid and atherosclerosis,	114500~Colorectal cancer, somatic,613065~T-cell acute lymphoblastic leukemia, somatic,		SM00337:BCL,	KW-0053~Apoptosis,KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1000~Mitochondrion outer membrane,	KW-0043~Tumor suppressor,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:Bcl-2 Bcl-2 homology region 1-3,MOTIF:BH1,MOTIF:BH2,MOTIF:BH3,MUTAGEN:K->E: Reduces interaction with BCL2L11, homooligomerization and triggering of apoptosis.,MUTAGEN:K->R: No loss of polyubiquitination.,MUTAGEN:K->R: Partial loss of polyubiquitination.,MUTAGEN:M->D,E: Strongly reduced interaction with MCL1, BCL2, BCL2L1 and BCL2L2. No effect on cytochrome c release and subsequent apoptosis triggered by etoposide.,MUTAGEN:Missing: Enhanced fiber formation with humanin.,MUTAGEN:S->D,E,H,K: Constitutive cytoplasmic location.,MUTAGEN:S->V: Constitutive mitochondrial location. Enhanced fiber formation with humanin.,REGION:Disordered,TRANSMEM:Helical,
BCLAF1	BCL2 associated transcription factor 1(BCLAF1)	Homo sapiens			GO:0000184~nuclear-transcribed mRNA catabolic process, nonsense-mediated decay,GO:0006397~mRNA processing,GO:0006417~regulation of translation,GO:0006915~apoptotic process,GO:0006974~cellular response to DNA damage stimulus,GO:0008380~RNA splicing,GO:0043065~positive regulation of apoptotic process,GO:0043620~regulation of DNA-templated transcription in response to stress,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051028~mRNA transport,GO:1990830~cellular response to leukemia inhibitory factor,GO:2000144~positive regulation of DNA-templated transcription, initiation,GO:2001244~positive regulation of intrinsic apoptotic signaling pathway,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0016592~mediator complex,GO:0016607~nuclear speck,GO:0035145~exon-exon junction complex,	GO:0003677~DNA binding,GO:0003712~transcription cofactor activity,GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0005515~protein binding,	IPR018545:Btz_dom,IPR029199:THRAP3_BCLAF1,					KW-0507~mRNA processing,KW-0508~mRNA splicing,KW-0509~mRNA transport,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0810~Translation regulation,KW-0813~Transport,	KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0238~DNA-binding,KW-0678~Repressor,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0164~Citrullination,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:Btz,REGION:Disordered,
BNIP2	BCL2 interacting protein 2(BNIP2)	Homo sapiens			GO:0006915~apoptotic process,GO:0043066~negative regulation of apoptotic process,GO:0090649~response to oxygen-glucose deprivation,	GO:0005635~nuclear envelope,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0043231~intracellular membrane-bounded organelle,GO:0048471~perinuclear region of cytoplasm,	GO:0005096~GTPase activator activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,	IPR001251:CRAL-TRIO_dom,IPR022181:Bcl2-/adenovirus-E1B,IPR036865:CRAL-TRIO_dom_sf,				SM00516:SEC14,	KW-0053~Apoptosis,	KW-0963~Cytoplasm,					KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,DOMAIN:CRAL-TRIO,REGION:Disordered,
BNIP3L	BCL2 interacting protein 3 like(BNIP3L)	Homo sapiens			GO:0010917~negative regulation of mitochondrial membrane potential,GO:0016239~positive regulation of macroautophagy,GO:0019222~regulation of metabolic process,GO:0035694~mitochondrial protein catabolic process,GO:0035794~positive regulation of mitochondrial membrane permeability,GO:0043065~positive regulation of apoptotic process,GO:0043066~negative regulation of apoptotic process,GO:0043067~regulation of programmed cell death,GO:0043069~negative regulation of programmed cell death,GO:0051607~defense response to virus,GO:0071456~cellular response to hypoxia,GO:0097345~mitochondrial outer membrane permeabilization,GO:1901524~regulation of macromitophagy,GO:1903146~regulation of mitophagy,GO:1903214~regulation of protein targeting to mitochondrion,	GO:0005634~nucleus,GO:0005635~nuclear envelope,GO:0005739~mitochondrion,GO:0005740~mitochondrial envelope,GO:0005741~mitochondrial outer membrane,GO:0005783~endoplasmic reticulum,GO:0016020~membrane,GO:0016607~nuclear speck,	GO:0005515~protein binding,GO:0005521~lamin binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,	IPR010548:BNIP3,	hsa04137:Mitophagy - animal,				KW-0053~Apoptosis,KW-0945~Host-virus interaction,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0496~Mitochondrion,KW-0539~Nucleus,KW-1000~Mitochondrion outer membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,MOTIF:BH3,REGION:Disordered,TRANSMEM:Helical,
BID	BH3 interacting domain death agonist(BID)	Homo sapiens	127.Mito-stress,150.caspase_and_NFKB_activation,46.P13K_PTEN,	h_chemicalPathway:Apoptotic Signaling in Response to DNA Damage,h_deathPathway:Induction of apoptosis through DR3 and DR4/5 Death Receptors ,h_hivnefPathway:HIV-I Nef: negative effector of Fas and TNF,h_mitochondriaPathway:Role of Mitochondria in Apoptotic Signaling,	GO:0001836~release of cytochrome c from mitochondria,GO:0006626~protein targeting to mitochondrion,GO:0006915~apoptotic process,GO:0006919~activation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0006950~response to stress,GO:0008625~extrinsic apoptotic signaling pathway via death domain receptors,GO:0008637~apoptotic mitochondrial changes,GO:0010918~positive regulation of mitochondrial membrane potential,GO:0031334~positive regulation of protein complex assembly,GO:0042129~regulation of T cell proliferation,GO:0042770~signal transduction in response to DNA damage,GO:0042775~mitochondrial ATP synthesis coupled electron transport,GO:0043065~positive regulation of apoptotic process,GO:0050678~regulation of epithelial cell proliferation,GO:0051402~neuron apoptotic process,GO:0065003~macromolecular complex assembly,GO:0090150~establishment of protein localization to membrane,GO:0090200~positive regulation of release of cytochrome c from mitochondria,GO:0097191~extrinsic apoptotic signaling pathway,GO:0097284~hepatocyte apoptotic process,GO:0097345~mitochondrial outer membrane permeabilization,GO:0097435~supramolecular fiber organization,GO:1902230~negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage,GO:2000045~regulation of G1/S transition of mitotic cell cycle,GO:2000271~positive regulation of fibroblast apoptotic process,GO:2001233~regulation of apoptotic signaling pathway,GO:2001235~positive regulation of apoptotic signaling pathway,GO:2001238~positive regulation of extrinsic apoptotic signaling pathway,GO:2001244~positive regulation of intrinsic apoptotic signaling pathway,	GO:0005739~mitochondrion,GO:0005741~mitochondrial outer membrane,GO:0005829~cytosol,GO:0016020~membrane,	GO:0005123~death receptor binding,GO:0005515~protein binding,GO:0031625~ubiquitin protein ligase binding,GO:0043028~cysteine-type endopeptidase regulator activity involved in apoptotic process,	IPR010479:BID,IPR020728:Bcl2_BH3_motif_CS,IPR036834:Bcl-2-like_sf,	hsa01524:Platinum drug resistance,hsa04071:Sphingolipid signaling pathway,hsa04115:p53 signaling pathway,hsa04210:Apoptosis,hsa04215:Apoptosis - multiple species,hsa04217:Necroptosis,hsa04650:Natural killer cell mediated cytotoxicity,hsa04932:Non-alcoholic fatty liver disease,hsa05010:Alzheimer disease,hsa05014:Amyotrophic lateral sclerosis,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05152:Tuberculosis,hsa05160:Hepatitis C,hsa05161:Hepatitis B,hsa05162:Measles,hsa05163:Human cytomegalovirus infection,hsa05164:Influenza A,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05200:Pathways in cancer,hsa05416:Viral myocarditis,hsa05417:Lipid and atherosclerosis,		PIRSF038018:BID,		KW-0053~Apoptosis,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0963~Cytoplasm,KW-1000~Mitochondrion outer membrane,					KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,MOTIF:BH3,REGION:Disordered,SITE:Cleavage,SITE:Cleavage; by CASP6,SITE:Cleavage;by CASP6,
BORCS5	BLOC-1 related complex subunit 5(BORCS5)	Homo sapiens			GO:0032418~lysosome localization,GO:0051036~regulation of endosome size,GO:0072384~organelle transport along microtubule,GO:1903744~positive regulation of anterograde synaptic vesicle transport,	GO:0005765~lysosomal membrane,GO:0005873~plus-end kinesin complex,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0030672~synaptic vesicle membrane,GO:0043231~intracellular membrane-bounded organelle,GO:0098574~cytoplasmic side of lysosomal membrane,GO:0099078~BORC complex,	GO:0005515~protein binding,	IPR018780:TBORCS5,						KW-0458~Lysosome,KW-0472~Membrane,					KW-0449~Lipoprotein,KW-0519~Myristate,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,LIPID:N-myristoyl glycine,MUTAGEN:G->A: Loss of myristoylation and loss of localization to lysosomal membranes.,REGION:Disordered,
BCCIP	BRCA2 and CDKN1A interacting protein(BCCIP)	Homo sapiens			GO:0000079~regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0000132~establishment of mitotic spindle orientation,GO:0000226~microtubule cytoskeleton organization,GO:0006281~DNA repair,GO:0007049~cell cycle,GO:0007052~mitotic spindle organization,GO:0034453~microtubule anchoring,GO:0061101~neuroendocrine cell differentiation,GO:0090307~mitotic spindle assembly,	GO:0000922~spindle pole,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005813~centrosome,GO:0005814~centriole,GO:0005829~cytosol,GO:0019908~nuclear cyclin-dependent protein kinase holoenzyme complex,GO:0097431~mitotic spindle pole,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0015631~tubulin binding,GO:0019207~kinase regulator activity,	IPR025602:BCP1_family,			PIRSF028983:BCP1,		KW-0131~Cell cycle,KW-0227~DNA damage,KW-0234~DNA repair,	KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,					KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,REGION:Disordered,REGION:Interaction with BRCA2,REGION:Interaction with CDKN1A,
BRK1	BRICK1 subunit of SCAR/WAVE actin nucleating complex(BRK1)	Homo sapiens			GO:0001701~in utero embryonic development,GO:0007015~actin filament organization,GO:0008064~regulation of actin polymerization or depolymerization,GO:0010592~positive regulation of lamellipodium assembly,GO:0016601~Rac protein signal transduction,GO:0031334~positive regulation of protein complex assembly,GO:0048144~fibroblast proliferation,GO:0048146~positive regulation of fibroblast proliferation,GO:0048870~cell motility,GO:2000601~positive regulation of Arp2/3 complex-mediated actin nucleation,	GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0030027~lamellipodium,GO:0031209~SCAR complex,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0031267~small GTPase binding,GO:0042802~identical protein binding,GO:0044877~macromolecular complex binding,	IPR033378:BRICK1,	hsa04810:Regulation of actin cytoskeleton,hsa05130:Pathogenic Escherichia coli infection,hsa05132:Salmonella infection,					KW-0206~Cytoskeleton,KW-0963~Cytoplasm,		KW-0175~Coiled coil,			KW-0007~Acetylation,
BRMS1	BRMS1 transcriptional repressor and anoikis regulator(BRMS1)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006915~apoptotic process,GO:0030336~negative regulation of cell migration,GO:0030512~negative regulation of transforming growth factor beta receptor signaling pathway,GO:0032088~negative regulation of NF-kappaB transcription factor activity,GO:0042981~regulation of apoptotic process,GO:0045892~negative regulation of transcription, DNA-templated,GO:0090312~positive regulation of protein deacetylation,GO:1902455~negative regulation of stem cell population maintenance,GO:1902459~positive regulation of stem cell population maintenance,GO:2000210~positive regulation of anoikis,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0016580~Sin3 complex,GO:0070822~Sin3-type complex,	GO:0005515~protein binding,GO:0042826~histone deacetylase binding,GO:0051059~NF-kappaB binding,	IPR013907:Sds3,				SM01401:Sds3,	KW-0053~Apoptosis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0043~Tumor suppressor,	KW-0175~Coiled coil,		KW-0678~Repressor,	KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),REGION:Disordered,
BACH1	BTB domain and CNC homolog 1(BACH1)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006281~DNA repair,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0019222~regulation of metabolic process,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0090575~RNA polymerase II transcription factor complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0020037~heme binding,GO:0098531~transcription factor activity, direct ligand regulated sequence-specific DNA binding,	IPR000210:BTB/POZ_dom,IPR004826:bZIP_Maf,IPR004827:bZIP,IPR008917:TF_DNA-bd_sf,IPR011333:SKP1/BTB/POZ_sf,IPR043321:bZIP_BACH,IPR046347:bZIP_sf,IPR047167:NFE2-like,				SM00225:BTB,SM00338:BRLZ,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0010~Activator,KW-0238~DNA-binding,KW-0678~Repressor,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:BTB,DOMAIN:BZIP,DOMAIN:bZIP,REGION:Basic motif,REGION:Disordered,REGION:Leucine-zipper,
BTG2	BTG anti-proliferation factor 2(BTG2)	Homo sapiens		h_btg2Pathway:BTG family proteins and cell cycle regulation,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006281~DNA repair,GO:0006974~cellular response to DNA damage stimulus,GO:0007405~neuroblast proliferation,GO:0007406~negative regulation of neuroblast proliferation,GO:0008285~negative regulation of cell proliferation,GO:0008306~associative learning,GO:0009612~response to mechanical stimulus,GO:0009952~anterior/posterior pattern specification,GO:0014070~response to organic cyclic compound,GO:0017148~negative regulation of translation,GO:0021542~dentate gyrus development,GO:0021954~central nervous system neuron development,GO:0031175~neuron projection development,GO:0035914~skeletal muscle cell differentiation,GO:0043434~response to peptide hormone,GO:0043524~negative regulation of neuron apoptotic process,GO:0045930~negative regulation of mitotic cell cycle,GO:0051602~response to electrical stimulus,GO:0060213~positive regulation of nuclear-transcribed mRNA poly(A) tail shortening,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0003714~transcription corepressor activity,GO:0005515~protein binding,	IPR002087:Anti_prolifrtn,IPR033332:BTG,IPR036054:BTG-like_sf,	hsa03018:RNA degradation,			SM00099:btg1,	KW-0804~Transcription,KW-0805~Transcription regulation,						KW-0597~Phosphoprotein,	MUTAGEN:D->A: Abolishes interaction with CNOT7 and CNOT8.,MUTAGEN:D->A: Impairs interaction with CNOT7 and CNOT8.,MUTAGEN:E->A: Impairs interaction with CNOT7. Inhibits CNOT7 mRNA deadenylase activity.,MUTAGEN:H->A: Impairs interaction with CNOT7 and CNOT8.,MUTAGEN:P->A: Impairs PIN1-binding.,MUTAGEN:S->A: Impairs phosphorylation by MAPK1 and MAPK3, and decreases PIN1-binding.,MUTAGEN:S->A: Impairs phosphorylation by MAPK14, and decreases PIN1-binding.,MUTAGEN:W->A: Abolishes interaction with CNOT7 and CNOT8; impairs anti-proliferative activity.,MUTAGEN:Y->A: Abolishes interaction with CNOT7 and CNOT8.,
BTG3	BTG anti-proliferation factor 3(BTG3)	Homo sapiens			GO:0008285~negative regulation of cell proliferation,GO:0045930~negative regulation of mitotic cell cycle,	GO:0005634~nucleus,GO:0005737~cytoplasm,	GO:0005515~protein binding,	IPR002087:Anti_prolifrtn,IPR033332:BTG,IPR036054:BTG-like_sf,	hsa03018:RNA degradation,			SM00099:btg1,								DOMAIN:Anti-proliferative protein,REGION:Disordered,
BANP	BTG3 associated nuclear protein(BANP)	Homo sapiens			GO:0006325~chromatin organization,GO:0007049~cell cycle,GO:0034504~protein localization to nucleus,GO:0042177~negative regulation of protein catabolic process,GO:0045893~positive regulation of transcription, DNA-templated,	GO:0005654~nucleoplasm,GO:0016020~membrane,GO:0016604~nuclear body,	GO:0003677~DNA binding,GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR018379:BEN_domain,IPR042343:BANP,				SM01025:BEN,	KW-0131~Cell cycle,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0472~Membrane,KW-0539~Nucleus,	KW-0043~Tumor suppressor,	KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0156~Chromatin regulator,KW-0217~Developmental protein,KW-0238~DNA-binding,KW-0678~Repressor,KW-9996~Developmental protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:BEN,REGION:DNA-binding,REGION:Disordered,REGION:Interaction with CUX1 and HDAC1,TRANSMEM:Helical,
BUD31	BUD31 homolog(BUD31)	Homo sapiens			GO:0000398~mRNA splicing, via spliceosome,GO:0045893~positive regulation of transcription, DNA-templated,GO:2000825~positive regulation of androgen receptor activity,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005681~spliceosomal complex,GO:0071007~U2-type catalytic step 2 spliceosome,	GO:0005515~protein binding,GO:0016922~ligand-dependent nuclear receptor binding,GO:0030374~ligand-dependent nuclear receptor transcription coactivator activity,	IPR001748:BUD31,IPR018230:BUD31/G10-rel_CS,	hsa03040:Spliceosome,				KW-0507~mRNA processing,KW-0508~mRNA splicing,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0747~Spliceosome,					KW-0007~Acetylation,	MOTIF:Nuclear localization signal,REGION:Disordered,REGION:Interaction with AR,
BET1L	Bet1 golgi vesicular membrane trafficking protein like(BET1L)	Homo sapiens			GO:0015031~protein transport,GO:0042147~retrograde transport, endosome to Golgi,GO:0061025~membrane fusion,GO:2000156~regulation of retrograde vesicle-mediated transport, Golgi to ER,	GO:0000139~Golgi membrane,GO:0005768~endosome,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0016020~membrane,GO:0031201~SNARE complex,	GO:0005484~SNAP receptor activity,	IPR000727:T_SNARE_dom,IPR039899:BET1_SNARE,	hsa04130:SNARE interactions in vesicular transport,				KW-0653~Protein transport,KW-0813~Transport,	KW-0333~Golgi apparatus,KW-0472~Membrane,		KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:T-SNARE coiled-coil homology,DOMAIN:t-SNARE coiled-coil homology,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,TRANSMEM:Helical; Anchor for type IV membrane protein,
CCL5	C-C motif chemokine ligand 5(CCL5)	Homo sapiens	109.Chemokine_families,18.Cytokine_astocytes,22.Cytokine-chemokine_CNS,33.GProt-coupled_Rec_T_Cell_med_Inflamm,34.Chemokines_in_EAE,	h_eosinophilsPathway:The Role of Eosinophils in the Chemokine Network of Allergy,	GO:0002407~dendritic cell chemotaxis,GO:0002548~monocyte chemotaxis,GO:0002676~regulation of chronic inflammatory response,GO:0006816~calcium ion transport,GO:0006874~cellular calcium ion homeostasis,GO:0006887~exocytosis,GO:0006935~chemotaxis,GO:0006954~inflammatory response,GO:0006955~immune response,GO:0007159~leukocyte cell-cell adhesion,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007267~cell-cell signaling,GO:0009615~response to virus,GO:0009636~response to toxic substance,GO:0010536~positive regulation of activation of Janus kinase activity,GO:0010759~positive regulation of macrophage chemotaxis,GO:0010820~positive regulation of T cell chemotaxis,GO:0014911~positive regulation of smooth muscle cell migration,GO:0030335~positive regulation of cell migration,GO:0030593~neutrophil chemotaxis,GO:0031328~positive regulation of cellular biosynthetic process,GO:0031584~activation of phospholipase D activity,GO:0033634~positive regulation of cell-cell adhesion mediated by integrin,GO:0034112~positive regulation of homotypic cell-cell adhesion,GO:0034612~response to tumor necrosis factor,GO:0042102~positive regulation of T cell proliferation,GO:0042119~neutrophil activation,GO:0042327~positive regulation of phosphorylation,GO:0042531~positive regulation of tyrosine phosphorylation of STAT protein,GO:0043547~positive regulation of GTPase activity,GO:0043922~negative regulation by host of viral transcription,GO:0044344~cellular response to fibroblast growth factor stimulus,GO:0045070~positive regulation of viral genome replication,GO:0045071~negative regulation of viral genome replication,GO:0045089~positive regulation of innate immune response,GO:0045744~negative regulation of G-protein coupled receptor protein signaling pathway,GO:0045785~positive regulation of cell adhesion,GO:0045948~positive regulation of translational initiation,GO:0046427~positive regulation of JAK-STAT cascade,GO:0048245~eosinophil chemotaxis,GO:0048246~macrophage chemotaxis,GO:0048247~lymphocyte chemotaxis,GO:0048661~positive regulation of smooth muscle cell proliferation,GO:0050673~epithelial cell proliferation,GO:0050679~positive regulation of epithelial cell proliferation,GO:0050796~regulation of insulin secretion,GO:0050863~regulation of T cell activation,GO:0050918~positive chemotaxis,GO:0051897~positive regulation of protein kinase B signaling,GO:0051928~positive regulation of calcium ion transport,GO:0070098~chemokine-mediated signaling pathway,GO:0070100~negative regulation of chemokine-mediated signaling pathway,GO:0070233~negative regulation of T cell apoptotic process,GO:0070234~positive regulation of T cell apoptotic process,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0071346~cellular response to interferon-gamma,GO:0071347~cellular response to interleukin-1,GO:0071356~cellular response to tumor necrosis factor,GO:0090026~positive regulation of monocyte chemotaxis,GO:0098586~cellular response to virus,GO:2000110~negative regulation of macrophage apoptotic process,GO:2000406~positive regulation of T cell migration,GO:2000503~positive regulation of natural killer cell chemotaxis,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005737~cytoplasm,	GO:0004435~phosphatidylinositol phospholipase C activity,GO:0004672~protein kinase activity,GO:0005515~protein binding,GO:0008009~chemokine activity,GO:0016004~phospholipase activator activity,GO:0030298~receptor signaling protein tyrosine kinase activator activity,GO:0031726~CCR1 chemokine receptor binding,GO:0031729~CCR4 chemokine receptor binding,GO:0031730~CCR5 chemokine receptor binding,GO:0042056~chemoattractant activity,GO:0042379~chemokine receptor binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0043621~protein self-association,GO:0046817~chemokine receptor antagonist activity,GO:0048020~CCR chemokine receptor binding,	IPR000827:Chemokine_CC_CS,IPR001811:Chemokine_IL8-like_dom,IPR036048:Interleukin_8-like_sf,IPR039809:Chemokine_b/g/d,	hsa04060:Cytokine-cytokine receptor interaction,hsa04061:Viral protein interaction with cytokine and cytokine receptor,hsa04062:Chemokine signaling pathway,hsa04620:Toll-like receptor signaling pathway,hsa04621:NOD-like receptor signaling pathway,hsa04623:Cytosolic DNA-sensing pathway,hsa04668:TNF signaling pathway,hsa05020:Prion disease,hsa05120:Epithelial cell signaling in Helicobacter pylori infection,hsa05131:Shigellosis,hsa05142:Chagas disease,hsa05163:Human cytomegalovirus infection,hsa05164:Influenza A,hsa05168:Herpes simplex virus 1 infection,hsa05323:Rheumatoid arthritis,hsa05417:Lipid and atherosclerosis,	609423~HIV-1 disease, delayed progression of,609423~HIV-1 disease, rapid progression of,		SM00199:SCY,	KW-0145~Chemotaxis,KW-0395~Inflammatory response,	KW-0964~Secreted,		KW-0732~Signal,		KW-0202~Cytokine,	KW-0325~Glycoprotein,KW-0558~Oxidation,KW-1015~Disulfide bond,	CARBOHYD:O-linked (GalNAc...) serine; partial,DOMAIN:Chemokine interleukin-8-like,MUTAGEN:E->A: No effect on inhibition of activity by tick evasin-4.,MUTAGEN:G->A,K: No effect on inhibition of activity by tick evasin-4.,MUTAGEN:H->A: No effect on inhibition of activity by tick evasin-4.,MUTAGEN:KKWVR->AAWVA: No effect on inhibition of activity by tick evasin-4.,MUTAGEN:RKNR->AANA: No effect on inhibition of activity by tick evasin-4.,MUTAGEN:T->A: No effect on inhibition of activity by tick evasin-4.,MUTAGEN:T->A: Reduced inhibition of activity by tick evasin-4.,SITE:Cleavage; by DPP4,
CCR7	C-C motif chemokine receptor 7(CCR7)	Homo sapiens	14.chemokine_receptor-ligand,15.T-cell_polarization-chemokine_receptors,16.Chemokines-rec-T-cells,	h_nktPathway:Selective expression of chemokine receptors during T-cell polarization,	GO:0001768~establishment of T cell polarity,GO:0001954~positive regulation of cell-matrix adhesion,GO:0002407~dendritic cell chemotaxis,GO:0002408~myeloid dendritic cell chemotaxis,GO:0002606~positive regulation of dendritic cell antigen processing and presentation,GO:0002885~positive regulation of hypersensitivity,GO:0002922~positive regulation of humoral immune response,GO:0006935~chemotaxis,GO:0006954~inflammatory response,GO:0006955~immune response,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0019722~calcium-mediated signaling,GO:0030838~positive regulation of actin filament polymerization,GO:0031274~positive regulation of pseudopodium assembly,GO:0031529~ruffle organization,GO:0032496~response to lipopolysaccharide,GO:0032649~regulation of interferon-gamma production,GO:0032651~regulation of interleukin-1 beta production,GO:0032695~negative regulation of interleukin-12 production,GO:0032735~positive regulation of interleukin-12 production,GO:0034695~response to prostaglandin E,GO:0038115~chemokine (C-C motif) ligand 19 signaling pathway,GO:0038116~chemokine (C-C motif) ligand 21 signaling pathway,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0045060~negative thymic T cell selection,GO:0045785~positive regulation of cell adhesion,GO:0045860~positive regulation of protein kinase activity,GO:0046330~positive regulation of JNK cascade,GO:0048872~homeostasis of number of cells,GO:0050862~positive regulation of T cell receptor signaling pathway,GO:0051209~release of sequestered calcium ion into cytosol,GO:0051491~positive regulation of filopodium assembly,GO:0051897~positive regulation of protein kinase B signaling,GO:0060326~cell chemotaxis,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0071345~cellular response to cytokine stimulus,GO:0071731~response to nitric oxide,GO:0090023~positive regulation of neutrophil chemotaxis,GO:0097022~lymphocyte migration into lymph node,GO:0097029~mature conventional dendritic cell differentiation,GO:2000147~positive regulation of cell motility,GO:2000510~positive regulation of dendritic cell chemotaxis,GO:2000522~positive regulation of immunological synapse formation,GO:2000525~positive regulation of T cell costimulation,GO:2000526~positive regulation of glycoprotein biosynthetic process involved in immunological synapse formation,GO:2000547~regulation of dendritic cell dendrite assembly,GO:2000669~negative regulation of dendritic cell apoptotic process,	GO:0005739~mitochondrion,GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,	GO:0004930~G-protein coupled receptor activity,GO:0016493~C-C chemokine receptor activity,GO:0035757~chemokine (C-C motif) ligand 19 binding,GO:0035758~chemokine (C-C motif) ligand 21 binding,GO:0038117~C-C motif chemokine 19 receptor activity,GO:0038121~C-C motif chemokine 21 receptor activity,	IPR000276:GPCR_Rhodpsn,IPR000355:Chemokine_rcpt,IPR001718:Chemokine_CCR7,IPR017452:GPCR_Rhodpsn_7TM,	hsa04060:Cytokine-cytokine receptor interaction,hsa04061:Viral protein interaction with cytokine and cytokine receptor,hsa04062:Chemokine signaling pathway,					KW-0472~Membrane,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:G-protein coupled receptors family 1 profile,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
CXCR3	C-X-C motif chemokine receptor 3(CXCR3)	Homo sapiens	14.chemokine_receptor-ligand,15.T-cell_polarization-chemokine_receptors,16.Chemokines-rec-T-cells,	h_il12Pathway:IL12 and Stat4 Dependent Signaling Pathway in Th1 Development,h_mCalpainPathway:mCalpain and friends in Cell motility,h_nktPathway:Selective expression of chemokine receptors during T-cell polarization,h_no2il12Pathway:NO2-dependent IL 12 Pathway in NK cells,	GO:0001525~angiogenesis,GO:0001937~negative regulation of endothelial cell proliferation,GO:0002685~regulation of leukocyte migration,GO:0006915~apoptotic process,GO:0006935~chemotaxis,GO:0006954~inflammatory response,GO:0006955~immune response,GO:0007155~cell adhesion,GO:0007166~cell surface receptor signaling pathway,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007189~adenylate cyclase-activating G-protein coupled receptor signaling pathway,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0008284~positive regulation of cell proliferation,GO:0016525~negative regulation of angiogenesis,GO:0019722~calcium-mediated signaling,GO:0030155~regulation of cell adhesion,GO:0045766~positive regulation of angiogenesis,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0050921~positive regulation of chemotaxis,GO:0051281~positive regulation of release of sequestered calcium ion into cytosol,GO:0060326~cell chemotaxis,GO:0070098~chemokine-mediated signaling pathway,GO:1900118~negative regulation of execution phase of apoptosis,GO:1900119~positive regulation of execution phase of apoptosis,	GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,	GO:0004950~chemokine receptor activity,GO:0005515~protein binding,GO:0016493~C-C chemokine receptor activity,GO:0016494~C-X-C chemokine receptor activity,GO:0019956~chemokine binding,GO:0019957~C-C chemokine binding,GO:0019958~C-X-C chemokine binding,GO:0038023~signaling receptor activity,	IPR000276:GPCR_Rhodpsn,IPR000355:Chemokine_rcpt,IPR004070:Chemokine_CXCR3,IPR017452:GPCR_Rhodpsn_7TM,	hsa04060:Cytokine-cytokine receptor interaction,hsa04061:Viral protein interaction with cytokine and cytokine receptor,hsa04062:Chemokine signaling pathway,				KW-0037~Angiogenesis,KW-0053~Apoptosis,KW-0145~Chemotaxis,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-0765~Sulfation,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:G-protein coupled receptors family 1 profile,MUTAGEN:D->A: Abolishes binding to CXCL10 and CXCL11 and CXCL11-induced chemotaxis. Reduces CXCL9 and CXCL10-induced chemotaxis.,MUTAGEN:D->A: Abolishes binding to CXCL10 and CXCL11. Reduces CXCL9-, CXCL10- and CXCL11-induced chemotaxis.,MUTAGEN:D->A: Reduces binding to CXCL10 and CXCL9-, CXCL10- and CXCL11-induced chemotaxis. Abolishes binding to CXCL11.,MUTAGEN:D->K: Abolishes binding to CXCL10 and CXCL11 and CXCL10- and CXCL11-induced chemotaxis. Reduces CXCL9-induced chemotaxis.,MUTAGEN:D->K: Abolishes binding to CXCL10 and CXCL11 and CXCL9-, CXCL10- and CXCL11-induced chemotaxis.,MUTAGEN:D->K: Reduces binding to CXCL10 and CXCL11 and CXCL9-, CXCL10- and CXCL11-induced chemotaxis.,MUTAGEN:E->A: Reduces binding to CXCL10 and CXCL9- and CXCL11-induced chemotaxis. Abolishes binding to CXCL11 and CXCL10-induced chemotaxis.,MUTAGEN:E->K: Abolishes binding to CXCL10 and CXCL11 and CXCL9-, CXCL10- and CXCL11-induced chemotaxis.,MUTAGEN:E->K: Does not affect binding to CXCL9, CXCL10 and CXCL11 or activation.,MUTAGEN:E->K: Reduces slightly CXCL9-, CXCL10- and CXCL11-induced chemotaxis.,MUTAGEN:Missing: Reduces binding to CXCL10 and CXCL11, and reduces CXCL10- and CXCL11-induced chemotaxis and activation. Does not affect CXCL9-induced chemotaxis and activation.,MUTAGEN:R->A: Abolishes CXCL10-induced chemotaxis. Reduces CXCL9- and CXCL11-induced chemotaxis. Does not affect binding to CXCL10 and CXCL11.,MUTAGEN:R->A: Abolishes binding to CXCL10 and CXCL11 and CXCL9-, CXCL10- and CXCL11-induced chemotaxis. Reduces ligand-induced receptor internalization.,MUTAGEN:R->A: Reduces CXCL9-, CXCL10- and CXCL11-induced chemotaxis. Does not affect binding to CXCL10 and CXCL11 or receptor internalization.,MUTAGEN:Y->F: Reduces sulfation and CXCL9-, CXCL10- and CXCL11-induced chemotaxis. Abolishes binding to CXCL10. Abolishes sulfation, binding to CXCL11, ligand-induced receptor internalization and CXCL9-, CXCL10- and CXCL11-induced chemotaxis; when associated with F-29.,MUTAGEN:Y->F: Reduces sulfation, binding to CXCL10 and CXCL9-, CXCL10- and CXCL11-induced chemotaxis. Abolishes sulfation, binding to CXCL10 and CXCL11 and CXCL9-, CXCL10- and CXCL11-induced chemotaxis; when associated with F-27.,MUTAGEN:YDY->ADA: Abolishes binding to CXCL10 and CXCL11 and CXCL9-, CXCL10- and CXCL11-induced chemotaxis.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
CXCR4	C-X-C motif chemokine receptor 4(CXCR4)	Homo sapiens	14.chemokine_receptor-ligand,15.T-cell_polarization-chemokine_receptors,	h_ccr5Pathway:Pertussis toxin-insensitive CCR5 Signaling in Macrophage,h_cxcr4Pathway:CXCR4 Signaling Pathway,h_nktPathway:Selective expression of chemokine receptors during T-cell polarization,h_vifPathway:HIV-1 defeats host-mediated resistance by CEM15,	GO:0001666~response to hypoxia,GO:0001764~neuron migration,GO:0002064~epithelial cell development,GO:0002407~dendritic cell chemotaxis,GO:0006915~apoptotic process,GO:0006935~chemotaxis,GO:0006954~inflammatory response,GO:0006955~immune response,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0007420~brain development,GO:0008038~neuron recognition,GO:0009615~response to virus,GO:0014823~response to activity,GO:0019722~calcium-mediated signaling,GO:0022008~neurogenesis,GO:0022029~telencephalon cell migration,GO:0030155~regulation of cell adhesion,GO:0030335~positive regulation of cell migration,GO:0035470~positive regulation of vascular wound healing,GO:0038160~CXCL12-activated CXCR4 signaling pathway,GO:0043067~regulation of programmed cell death,GO:0043217~myelin maintenance,GO:0045446~endothelial cell differentiation,GO:0046718~viral entry into host cell,GO:0048714~positive regulation of oligodendrocyte differentiation,GO:0050792~regulation of viral process,GO:0050920~regulation of chemotaxis,GO:0050921~positive regulation of chemotaxis,GO:0050965~detection of temperature stimulus involved in sensory perception of pain,GO:0050966~detection of mechanical stimulus involved in sensory perception of pain,GO:0051924~regulation of calcium ion transport,GO:0060048~cardiac muscle contraction,GO:0060326~cell chemotaxis,GO:0061154~endothelial tube morphogenesis,GO:0071345~cellular response to cytokine stimulus,GO:0071417~cellular response to organonitrogen compound,GO:0071466~cellular response to xenobiotic stimulus,GO:1901327~response to tacrolimus,GO:1903861~positive regulation of dendrite extension,GO:1904018~positive regulation of vasculature development,GO:1905322~positive regulation of mesenchymal stem cell migration,GO:1990478~response to ultrasound,GO:2000448~positive regulation of macrophage migration inhibitory factor signaling pathway,	GO:0005737~cytoplasm,GO:0005764~lysosome,GO:0005769~early endosome,GO:0005770~late endosome,GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,GO:0031252~cell leading edge,GO:0031410~cytoplasmic vesicle,GO:0032991~macromolecular complex,GO:0070062~extracellular exosome,GO:0070161~anchoring junction,	GO:0001618~virus receptor activity,GO:0003779~actin binding,GO:0004930~G-protein coupled receptor activity,GO:0004950~chemokine receptor activity,GO:0005515~protein binding,GO:0015026~coreceptor activity,GO:0016493~C-C chemokine receptor activity,GO:0016494~C-X-C chemokine receptor activity,GO:0019955~cytokine binding,GO:0019957~C-C chemokine binding,GO:0031625~ubiquitin protein ligase binding,GO:0032027~myosin light chain binding,GO:0036094~small molecule binding,GO:0038147~C-X-C motif chemokine 12 receptor activity,GO:0043130~ubiquitin binding,	IPR000276:GPCR_Rhodpsn,IPR000355:Chemokine_rcpt,IPR001277:CXCR4/ACKR2,IPR017452:GPCR_Rhodpsn_7TM,IPR022726:Chemokine_CXCR4_N_dom,	hsa03250:Viral life cycle - HIV-1,hsa03260:Virion - Human immunodeficiency virus,hsa04020:Calcium signaling pathway,hsa04060:Cytokine-cytokine receptor interaction,hsa04061:Viral protein interaction with cytokine and cytokine receptor,hsa04062:Chemokine signaling pathway,hsa04144:Endocytosis,hsa04360:Axon guidance,hsa04670:Leukocyte transendothelial migration,hsa04672:Intestinal immune network for IgA production,hsa04810:Regulation of actin cytoskeleton,hsa05163:Human cytomegalovirus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05200:Pathways in cancer,	193670~Myelokathexis, isolated,193670~WHIM syndrome 1,			KW-0945~Host-virus interaction,	KW-0458~Lysosome,KW-0472~Membrane,KW-0965~Cell junction,KW-0967~Endosome,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,KW-1183~Host cell receptor for virus entry,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0654~Proteoglycan,KW-0765~Sulfation,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,KW-1017~Isopeptide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (Xyl...) (chondroitin sulfate) serine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:G-protein coupled receptors family 1 profile,MOTIF:Important for signaling,MUTAGEN:D->A,S,N: Greatly reduced coreceptor activity for HIV-1 isolate NDK. Reduced coreceptor activity for several other HIV-1 isolates.,MUTAGEN:D->A: Markedly reduced coreceptor activity for HIV-1 isolate LAI.,MUTAGEN:D->A: Reduced CXCL12 binding. Abolishes signaling.,MUTAGEN:D->N: No reduction of agonist-induced G-protein activation.,MUTAGEN:D->N: Reduced CXCL12 binding. Abolishes signaling. Markedly reduced coreceptor activity for HIV-1 isolate LAI.,MUTAGEN:D->N: Reduced coreceptor activity for HIV-1 isolate NDK.,MUTAGEN:D->R: Abolishes coreceptor activity for HIV-1 isolate NDK. Reduced coreceptor activity for several other HIV-1 isolates.,MUTAGEN:E->A: Markedly reduced coreceptor activity for HIV-1 isolate NDK. Less effect for HIV-1 isolate LAI.,MUTAGEN:E->Q: Reduced CXCL12 binding. Impaired signaling. Reduced coreceptor activity for HIV-1 isolate LAI. Enhanced coreceptor activity for HIV-1 isolate NDK.,MUTAGEN:EE->AA: Reduced CXCL12 binding. Reduced coreceptor activity for HIV-1 isolate NDK.,MUTAGEN:K->R: Loss of ubiquitination by RNF113A.,MUTAGEN:K->R: No effect on ubiquitination by RNF113A.,MUTAGEN:L->W: Increased thermostability.,MUTAGEN:Missing: Reduced CXCL12 binding. Abolishes signaling.,MUTAGEN:Missing: Reduced CXCL12 binding. Impaired signaling. Reduced coreceptor activity for HIV-1 isolates LAI and NDK.,MUTAGEN:Missing: Reduced CXCL12 binding. No effect on signaling.,MUTAGEN:N->A: Enhanced coreceptor activity on R5 HIV-1 isolate Envs; when associated with A-11.,MUTAGEN:N->A: Reduced molecular weight. Enhanced coreceptor activity on R5 HIV-1 isolate Envs. Slight further enhancement of coreceptor activity; when associated with A-13.,MUTAGEN:N->D: No reduction of agonist-induced G-protein activation.,MUTAGEN:N->K: Loss of agonist-induced G-protein activation.,MUTAGEN:N->S: Constitutive G-protein activation, with further activation induced by agonist.,MUTAGEN:R->A: Loss of agonist-induced G-protein activation.,MUTAGEN:R->A: Reduced coreceptor activity for several HIV-1 isolates.,MUTAGEN:S->A: Moderate degradation. About 60% reduction in binding ITCH and no ubiquitination nor protein degradation; when associated with A-324.,MUTAGEN:S->A: Moderate degradation. About 60% reduction in binding ITCH and no ubiquitination nor protein degradation; when associated with A-325.,MUTAGEN:S->A: No effect on binding to ITCH.,MUTAGEN:S->A: No effect on sulfate incorporation; when associated with A-8 and A-13.,MUTAGEN:S->A: Sulfate incorporation greatly reduced; when associated with F-21. Moderate reduction in sulfate incorporation; when associated with F-7 and F-12. No sulfate incorporation and binding SDF-1alpha greatly reduced; when associated with F-7; F-12; and F-21.,MUTAGEN:S->D: Enhanced binding to ITCH. Enhanced binding to ITCH and greatly increased protein degradation; when associated with D-324.,MUTAGEN:S->D: Enhanced binding to ITCH. Enhanced binding to ITCH and greatly increased protein degradation; when associated with D-325.,MUTAGEN:T->A: Enhanced coreceptor activity on R5 HIV-1 isolate Envs. No effect on sulfate incorporation; when associated with A-8 and A-9.,MUTAGEN:T->A: No effect on sulfate incorporation; when associated with A-9 and A-13.,MUTAGEN:T->P: Retains ligand-binding affinity but abolishes signaling.,MUTAGEN:Y->A: Greatly reduced coreceptor activity for HIV-1 isolates LAI and NDK; when associated with A-7.,MUTAGEN:Y->A: No reduction of agonist-induced G-protein activation.,MUTAGEN:Y->A: Reduced CXCL12 binding. Reduced coreceptor activity for HIV-1 isolates LAI and NDk.,MUTAGEN:Y->A: Reduced coreceptor activity for HIV-1 isolates LAI and NDK. Greatly reduced coreceptor activity for HIV-1 isolates LAI and NDK; when associated with A-12.,MUTAGEN:Y->F: Sulfate incorporation greatly reduced; when associated with F-12 and F-21. Moderate reduction in sulfate incorporation; when associated with F-12 and A-18. No sulfate incorporation and binding SDF-1alpha greatly reduced; when associated with F-12; A-18 and F-21.,MUTAGEN:Y->F: Sulfate incorporation greatly reduced; when associated with F-7 and F-12. Sulfate incorporation greatly reduced; when associated with A-18. No sulfate incorporation and binding SDF-1alpha greatly reduced; when associated with F-7; F-12 and A-18.,MUTAGEN:Y->F: Sulfate incorporation greatly reduced; when associated with F-7 and F-21. Moderate reduction in sulfate incorporation; when associated with F-7 and A-18. No sulfate incorporation and binding SDF-1alpha greatly reduced; when associated with F-7; A-18 and F-21.,REGION:Chemokine binding,REGION:Chemokine binding, important for signaling and HIV-1 coreceptor activity,REGION:Disordered,REGION:Important for chemokine binding, signaling and HIV-1 coreceptor activity,REGION:Involved in dimerization,REGION:Involved in dimerization; when bound to chemokine,SITE:Chemokine binding,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
CXCR6	C-X-C motif chemokine receptor 6(CXCR6)	Homo sapiens			GO:0006935~chemotaxis,GO:0006954~inflammatory response,GO:0006955~immune response,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0019079~viral genome replication,GO:0019722~calcium-mediated signaling,GO:0060326~cell chemotaxis,GO:0070098~chemokine-mediated signaling pathway,	GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,	GO:0004930~G-protein coupled receptor activity,GO:0015026~coreceptor activity,GO:0016493~C-C chemokine receptor activity,GO:0016494~C-X-C chemokine receptor activity,GO:0019957~C-C chemokine binding,	IPR000276:GPCR_Rhodpsn,IPR000355:Chemokine_rcpt,IPR002235:Chemokine_CXCR6,IPR017452:GPCR_Rhodpsn_7TM,	hsa04060:Cytokine-cytokine receptor interaction,hsa04062:Chemokine signaling pathway,					KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:G-protein coupled receptors family 1 profile,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
CMC1	C-X9-C motif containing 1(CMC1)	Homo sapiens				GO:0005739~mitochondrion,	GO:0046872~metal ion binding,	IPR013892:Cyt_c_biogenesis_Cmc1-like,						KW-0496~Mitochondrion,			KW-0186~Copper,KW-0479~Metal-binding,		KW-0007~Acetylation,KW-1015~Disulfide bond,	DOMAIN:CHCH,MOTIF:Cx9C motif 1,MOTIF:Cx9C motif 2,REGION:Disordered,
CMC2	C-X9-C motif containing 2(CMC2)	Homo sapiens				GO:0005739~mitochondrion,	GO:0005515~protein binding,	IPR013892:Cyt_c_biogenesis_Cmc1-like,						KW-0496~Mitochondrion,					KW-1015~Disulfide bond,	DOMAIN:CHCH,MOTIF:Cx9C motif 1,MOTIF:Cx9C motif 2,REGION:Disordered,
CSK	C-terminal Src kinase(CSK)	Homo sapiens		h_cell2cellPathway:Cell to Cell Adhesion Signaling,h_cskPathway:Activation of Csk by cAMP-dependent Protein Kinase Inhibits Signaling through the T Cell Receptor,h_integrinPathway:Integrin Signaling Pathway,h_srcRPTPPathway:Activation of Src by Protein-tyrosine phosphatase alpha,	GO:0002250~adaptive immune response,GO:0006468~protein phosphorylation,GO:0008285~negative regulation of cell proliferation,GO:0010989~negative regulation of low-density lipoprotein particle clearance,GO:0016310~phosphorylation,GO:0031295~T cell costimulation,GO:0032715~negative regulation of interleukin-6 production,GO:0034332~adherens junction organization,GO:0042997~negative regulation of Golgi to plasma membrane protein transport,GO:0045779~negative regulation of bone resorption,GO:0048709~oligodendrocyte differentiation,GO:0050765~negative regulation of phagocytosis,GO:0050852~T cell receptor signaling pathway,GO:0060368~regulation of Fc receptor mediated stimulatory signaling pathway,GO:0070373~negative regulation of ERK1 and ERK2 cascade,GO:0071375~cellular response to peptide hormone stimulus,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005911~cell-cell junction,GO:0070062~extracellular exosome,	GO:0004713~protein tyrosine kinase activity,GO:0004715~non-membrane spanning protein tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0019903~protein phosphatase binding,GO:0034236~protein kinase A catalytic subunit binding,GO:0042802~identical protein binding,GO:0046872~metal ion binding,GO:0070064~proline-rich region binding,GO:1990782~protein tyrosine kinase binding,	IPR000719:Prot_kinase_dom,IPR000980:SH2,IPR001245:Ser-Thr/Tyr_kinase_cat_dom,IPR001452:SH3_domain,IPR008266:Tyr_kinase_AS,IPR011009:Kinase-like_dom_sf,IPR017441:Protein_kinase_ATP_BS,IPR020635:Tyr_kinase_cat_dom,IPR035027:Csk-like_SH2,IPR036028:SH3-like_dom_sf,IPR036860:SH2_dom_sf,	hsa05120:Epithelial cell signaling in Helicobacter pylori infection,			SM00219:TyrKc,SM00252:SH2,SM00326:SH3,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0727~SH2 domain,KW-0728~SH3 domain,	KW-0067~ATP-binding,KW-0460~Magnesium,KW-0464~Manganese,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0808~Transferase,KW-0829~Tyrosine-protein kinase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,DOMAIN:Protein kinase,DOMAIN:SH2,DOMAIN:SH3,MUTAGEN:S->A: Strong decrease of phosphorylation by PRKACA (catalytic subunit of PKA).,MUTAGEN:Y->F: Abolishes phosphorylation.,MUTAGEN:Y->F: Decreases activity by two-thirds and alters conformation.,REGION:Interaction with PTPN22,
CLEC2B	C-type lectin domain family 2 member B(CLEC2B)	Homo sapiens				GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,	GO:0005515~protein binding,GO:0030246~carbohydrate binding,GO:0042802~identical protein binding,	IPR001304:C-type_lectin-like,IPR016186:C-type_lectin-like/link_sf,IPR016187:CTDL_fold,IPR033992:NKR-like_CTLD,	hsa05167:Kaposi sarcoma-associated herpesvirus infection,			SM00034:CLECT,		KW-0472~Membrane,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0430~Lectin,		KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:C-type lectin,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
CFLAR	CASP8 and FADD like apoptosis regulator(CFLAR)	Homo sapiens	36.Death_of_Key_Intracellular_Targets,86.Apoptosis_Nematode&_Vert,	h_deathPathway:Induction of apoptosis through DR3 and DR4/5 Death Receptors ,h_fasPathway:FAS signaling pathway ( CD95 ),h_hivnefPathway:HIV-I Nef: negative effector of Fas and TNF,h_il2rbPathway:IL-2 Receptor Beta Chain in T cell Activation,	GO:0006508~proteolysis,GO:0006915~apoptotic process,GO:0007519~skeletal muscle tissue development,GO:0010667~negative regulation of cardiac muscle cell apoptotic process,GO:0010976~positive regulation of neuron projection development,GO:0014732~skeletal muscle atrophy,GO:0014842~regulation of skeletal muscle satellite cell proliferation,GO:0014866~skeletal myofibril assembly,GO:0030182~neuron differentiation,GO:0030216~keratinocyte differentiation,GO:0030218~erythrocyte differentiation,GO:0032869~cellular response to insulin stimulus,GO:0033574~response to testosterone,GO:0042060~wound healing,GO:0042981~regulation of apoptotic process,GO:0043065~positive regulation of apoptotic process,GO:0043066~negative regulation of apoptotic process,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043403~skeletal muscle tissue regeneration,GO:0043525~positive regulation of neuron apoptotic process,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0060544~regulation of necroptotic process,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0071364~cellular response to epidermal growth factor stimulus,GO:0071392~cellular response to estradiol stimulus,GO:0071456~cellular response to hypoxia,GO:0071549~cellular response to dexamethasone stimulus,GO:0071732~cellular response to nitric oxide,GO:0072126~positive regulation of glomerular mesangial cell proliferation,GO:0097194~execution phase of apoptosis,GO:1901740~negative regulation of myoblast fusion,GO:1902042~negative regulation of extrinsic apoptotic signaling pathway via death domain receptors,GO:1903055~positive regulation of extracellular matrix organization,GO:1903427~negative regulation of reactive oxygen species biosynthetic process,GO:1903845~negative regulation of cellular response to transforming growth factor beta stimulus,GO:1903944~negative regulation of hepatocyte apoptotic process,GO:2000347~positive regulation of hepatocyte proliferation,GO:2001237~negative regulation of extrinsic apoptotic signaling pathway,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0031264~death-inducing signaling complex,GO:0031265~CD95 death-inducing signaling complex,GO:0097342~ripoptosome,	GO:0002020~protease binding,GO:0004197~cysteine-type endopeptidase activity,GO:0005123~death receptor binding,GO:0005515~protein binding,GO:0008047~enzyme activator activity,GO:0044877~macromolecular complex binding,GO:0097153~cysteine-type endopeptidase activity involved in apoptotic process,GO:0097199~cysteine-type endopeptidase activity involved in apoptotic signaling pathway,GO:0097200~cysteine-type endopeptidase activity involved in execution phase of apoptosis,	IPR001309:Pept_C14_p20,IPR001875:DED_dom,IPR011029:DEATH-like_dom_sf,IPR011600:Pept_C14_caspase,IPR015917:Pept_C14A,IPR029030:Caspase-like_dom_sf,	hsa04064:NF-kappa B signaling pathway,hsa04140:Autophagy - animal,hsa04210:Apoptosis,hsa04217:Necroptosis,hsa04668:TNF signaling pathway,hsa05142:Chagas disease,hsa05160:Hepatitis C,			SM00031:DED,SM00115:CASc,	KW-0053~Apoptosis,KW-0945~Host-virus interaction,			KW-0677~Repeat,				DOMAIN:Caspase family p20,DOMAIN:DED,DOMAIN:DED 1,DOMAIN:DED 2,MUTAGEN:D->N,A: Abolishes proteolytic processing.,MUTAGEN:Y->F: Decreases apoptosis-inducing activity. Reduces interaction with caspase-3 and proteolytic processing.,REGION:Caspase,REGION:Interaction with CASP3,REGION:Interaction with CASP8,REGION:Interaction with CASP8 propeptide,REGION:Interaction with CASP8 subunits p18 and p10,REGION:Interaction with FADD,REGION:Interaction with TRAF1 and TRAF2,REGION:Not proteolytically processed and involved in apoptosis inhibition,SITE:Cleavage; by CASP8,
CEBPG	CCAAT enhancer binding protein gamma(CEBPG)	Homo sapiens			GO:0001889~liver development,GO:0006351~transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006955~immune response,GO:0016071~mRNA metabolic process,GO:0030183~B cell differentiation,GO:0032729~positive regulation of interferon-gamma production,GO:0042267~natural killer cell mediated cytotoxicity,GO:0043353~enucleate erythrocyte differentiation,GO:0043388~positive regulation of DNA binding,GO:0043433~negative regulation of sequence-specific DNA binding transcription factor activity,GO:0045739~positive regulation of DNA repair,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051091~positive regulation of sequence-specific DNA binding transcription factor activity,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0090575~RNA polymerase II transcription factor complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0043565~sequence-specific DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR004827:bZIP,IPR031106:C/EBP,IPR046347:bZIP_sf,	hsa05152:Tuberculosis,			SM00338:BRLZ,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0010~Activator,KW-0238~DNA-binding,	KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:bZIP,REGION:Basic motif,REGION:Disordered,REGION:Leucine-zipper,
CEBPZ	CCAAT enhancer binding protein zeta(CEBPZ)	Homo sapiens			GO:0045944~positive regulation of transcription from RNA polymerase II promoter,	GO:0005634~nucleus,GO:0016602~CCAAT-binding factor complex,GO:0043231~intracellular membrane-bounded organelle,	GO:0003713~transcription coactivator activity,GO:0003723~RNA binding,	IPR005612:CCAAT-binding_factor,IPR016024:ARM-type_fold,IPR040155:CEBPZ/Mak21-like,					KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0010~Activator,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,DOMAIN:CCAAT-binding factor,REGION:Disordered,
CNBP	CCHC-type zinc finger nucleic acid binding protein(CNBP)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006355~regulation of transcription, DNA-templated,GO:0008284~positive regulation of cell proliferation,GO:0042632~cholesterol homeostasis,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0071919~G-quadruplex DNA formation,GO:2000767~positive regulation of cytoplasmic translation,	GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,	GO:0003676~nucleic acid binding,GO:0003723~RNA binding,GO:0003727~single-stranded RNA binding,GO:0003729~mRNA binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0045182~translation regulator activity,GO:0051880~G-quadruplex DNA binding,	IPR001878:Znf_CCHC,IPR036875:Znf_CCHC_sf,		602668~Myotonic dystrophy 2,		SM00343:ZnF_C2HC,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0256~Endoplasmic reticulum,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,KW-0678~Repressor,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	DOMAIN:CCHC-type,MUTAGEN:R->K: Significantly reduces methylation; when associated with K-25.,MUTAGEN:R->K: Significantly reduces methylation; when associated with K-27.,REGION:RNA-binding Arg/Gly-rich region (RGG-box),ZN_FING:CCHC-type 1,ZN_FING:CCHC-type 2,ZN_FING:CCHC-type 3,ZN_FING:CCHC-type 4,ZN_FING:CCHC-type 5,ZN_FING:CCHC-type 6,ZN_FING:CCHC-type 7,
CNOT1	CCR4-NOT transcription complex subunit 1(CNOT1)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0000288~nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay,GO:0000289~nuclear-transcribed mRNA poly(A) tail shortening,GO:0001829~trophectodermal cell differentiation,GO:0010606~positive regulation of cytoplasmic mRNA processing body assembly,GO:0017148~negative regulation of translation,GO:0033147~negative regulation of intracellular estrogen receptor signaling pathway,GO:0035195~gene silencing by miRNA,GO:0048387~negative regulation of retinoic acid receptor signaling pathway,GO:0060213~positive regulation of nuclear-transcribed mRNA poly(A) tail shortening,GO:0061014~positive regulation of mRNA catabolic process,GO:1900153~positive regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay,GO:2000036~regulation of stem cell population maintenance,	GO:0000932~P-body,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005778~peroxisomal membrane,GO:0005829~cytosol,GO:0016020~membrane,GO:0030014~CCR4-NOT complex,GO:0030015~CCR4-NOT core complex,	GO:0003723~RNA binding,GO:0004535~poly(A)-specific ribonuclease activity,GO:0005515~protein binding,GO:0019904~protein domain specific binding,GO:0030331~estrogen receptor binding,GO:0042974~retinoic acid receptor binding,GO:0060090~binding, bridging,GO:0070016~armadillo repeat domain binding,	IPR007196:CCR4-Not_Not1_C,IPR024557:CNOT1_dom_4,IPR032191:CNOT1_CAF1_bind,IPR032193:CNOT1_TTP_bind,IPR032194:CNOT1_HEAT,IPR038535:CNOT1_TTP_bind_sf,IPR040398:Not1,	hsa03018:RNA degradation,	618500~Holoprosencephaly 12, with or without pancreatic agenesis,619033~Vissers-Bodmer syndrome,			KW-0804~Transcription,KW-0805~Transcription regulation,KW-0810~Translation regulation,KW-0943~RNA-mediated gene silencing,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0370~Holoprosencephaly,KW-0991~Intellectual disability,KW-1268~Autism spectrum disorder,			KW-0217~Developmental protein,KW-0678~Repressor,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:CCR4-NOT transcription complex subunit 1,DOMAIN:CCR4-NOT transcription complex subunit 1 CAF1-binding,DOMAIN:CCR4-NOT transcription complex subunit 1 HEAT repeat,DOMAIN:CCR4-NOT transcription complex subunit 1 TTP binding,DOMAIN:CCR4-Not complex component Not1 C-terminal,MOTIF:LXXLL,MUTAGEN:H->Y: Impairs interaction with CNOT7; when associated with E-1208 and E-1218.,MUTAGEN:K->E: Impairs interaction with CNOT7; when associated with E-1208 and Y-1212.,MUTAGEN:K->E: Impairs interaction with CNOT7; when associated with Y-1212 and E-1218.,MUTAGEN:P->Y: Abolishes interaction with CNOT7; when associated with Y-1209.,MUTAGEN:P->Y: Abolishes interaction with CNOT7; when associated with Y-1257.,MUTAGEN:V->R: Abolishes interaction with CNOT7.,REGION:Disordered,REGION:Interaction with CNOT6, CNOT6L, CNOT7 and CNOT8,REGION:Interaction with ZFP36,
CNOT4	CCR4-NOT transcription complex subunit 4(CNOT4)	Homo sapiens			GO:0000289~nuclear-transcribed mRNA poly(A) tail shortening,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0016567~protein ubiquitination,GO:0045652~regulation of megakaryocyte differentiation,GO:0051865~protein autoubiquitination,	GO:0005634~nucleus,GO:0005829~cytosol,GO:0030014~CCR4-NOT complex,	GO:0003723~RNA binding,GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR000504:RRM_dom,IPR000571:Znf_CCCH,IPR001841:Znf_RING,IPR003954:RRM_dom_euk,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR013083:Znf_RING/FYVE/PHD,IPR034261:CNOT4_RRM,IPR035979:RBD_domain_sf,IPR039515:NOT4_mRING-HC-C4C4,IPR039780:Mot2,	hsa03018:RNA degradation,			SM00361:RRM_1,	KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0694~RNA-binding,KW-0808~Transferase,	KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,DOMAIN:C3H1-type,DOMAIN:RING-type,DOMAIN:RRM,MUTAGEN:C->A: Abolishes interaction with E2 ubiquitin ligases.,MUTAGEN:C->R: Abolishes interaction with E2 ubiquitin ligases.,MUTAGEN:E->A: Strongly reduces interaction with E2 ubiquitin ligases.,MUTAGEN:E->K: Strongly reduced interaction with UBE2D2.,MUTAGEN:I->A,W: Strongly reduces interaction with E2 ubiquitin ligases.,MUTAGEN:L->A,E: Abolishes interaction with E2 ubiquitin ligases.,MUTAGEN:M->A: Strongly reduces interaction with E2 ubiquitin ligases.,MUTAGEN:P->A: Strongly reduces interaction with E2 ubiquitin ligases.,MUTAGEN:R->A,E: Strongly reduces interaction with E2 ubiquitin ligases.,MUTAGEN:W->A: Strongly reduces interaction with E2 ubiquitin ligases.,REGION:Disordered,ZN_FING:C3H1-type,ZN_FING:RING-type; degenerate,
CNOT6L	CCR4-NOT transcription complex subunit 6 like(CNOT6L)	Homo sapiens			GO:0000289~nuclear-transcribed mRNA poly(A) tail shortening,GO:0006397~mRNA processing,GO:0006417~regulation of translation,GO:0008284~positive regulation of cell proliferation,GO:0010606~positive regulation of cytoplasmic mRNA processing body assembly,GO:0031047~gene silencing by RNA,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0030014~CCR4-NOT complex,	GO:0004535~poly(A)-specific ribonuclease activity,GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR001611:Leu-rich_rpt,IPR003591:Leu-rich_rpt_typical-subtyp,IPR005135:Endo/exonuclease/phosphatase,IPR032675:LRR_dom_sf,IPR034967:Deadenylase_CCR4b,IPR036691:Endo/exonu/phosph_ase_sf,	hsa03018:RNA degradation,			SM00369:LRR_TYP,	KW-0507~mRNA processing,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0810~Translation regulation,KW-0943~RNA-mediated gene silencing,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0433~Leucine-rich repeat,KW-0677~Repeat,	KW-0460~Magnesium,KW-0479~Metal-binding,	KW-0269~Exonuclease,KW-0378~Hydrolase,KW-0540~Nuclease,		ACT_SITE:Proton donor/acceptor,DOMAIN:Endonuclease/exonuclease/phosphatase,MUTAGEN:D->A: Loss of deadenylase activity.,MUTAGEN:E->A: Loss of deadenylase activity.,MUTAGEN:F->A: Loss of deadenylase activity.,MUTAGEN:H->A: Loss of deadenylase activity.,MUTAGEN:P->A: Decreased deadenylase activity.,REGION:Nuclease domain,REGION:Required for interaction with CNOT1, CNOT3 and CNOT7,REPEAT:LRR 1,REPEAT:LRR 2,REPEAT:LRR 3,REPEAT:LRR 4,
CNOT7	CCR4-NOT transcription complex subunit 7(CNOT7)	Homo sapiens			GO:0000289~nuclear-transcribed mRNA poly(A) tail shortening,GO:0000290~deadenylation-dependent decapping of nuclear-transcribed mRNA,GO:0006402~mRNA catabolic process,GO:0006417~regulation of translation,GO:0008284~positive regulation of cell proliferation,GO:0008285~negative regulation of cell proliferation,GO:0010629~negative regulation of gene expression,GO:0031047~gene silencing by RNA,GO:0033962~cytoplasmic mRNA processing body assembly,GO:0035195~gene silencing by miRNA,GO:0042509~regulation of tyrosine phosphorylation of STAT protein,GO:0043928~exonucleolytic nuclear-transcribed mRNA catabolic process involved in deadenylation-dependent decay,GO:0045070~positive regulation of viral genome replication,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051607~defense response to virus,GO:0060213~positive regulation of nuclear-transcribed mRNA poly(A) tail shortening,GO:0060339~negative regulation of type I interferon-mediated signaling pathway,GO:0061014~positive regulation of mRNA catabolic process,GO:1900153~positive regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay,	GO:0000932~P-body,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016020~membrane,GO:0016604~nuclear body,GO:0016607~nuclear speck,GO:0030014~CCR4-NOT complex,GO:0030015~CCR4-NOT core complex,GO:0043232~intracellular non-membrane-bounded organelle,	GO:0000175~3'-5'-exoribonuclease activity,GO:0003676~nucleic acid binding,GO:0003714~transcription corepressor activity,GO:0003723~RNA binding,GO:0004532~exoribonuclease activity,GO:0004535~poly(A)-specific ribonuclease activity,GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR006941:RNase_CAF1,IPR012337:RNaseH-like_sf,IPR036397:RNaseH_sf,IPR039637:CNOT7/CNOT8/Pop2,	hsa03018:RNA degradation,				KW-0804~Transcription,KW-0805~Transcription regulation,KW-0810~Translation regulation,KW-0943~RNA-mediated gene silencing,	KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0460~Magnesium,KW-0479~Metal-binding,	KW-0269~Exonuclease,KW-0378~Hydrolase,KW-0540~Nuclease,KW-0678~Repressor,KW-0694~RNA-binding,		MUTAGEN:D->N: Abolishes RNA deadenylase activity.,MUTAGEN:D->N: Abolishes RNA deadenylase activity. Drastically reduces the rate of deadenylation and decay of CBEP3-tethered mRNA.,MUTAGEN:E->K: Abolishes interaction with CNOT1; when associated with K-138 and Y-142.,MUTAGEN:E->K: Abolishes interaction with CNOT1; when associated with Y-142 and K-149.,MUTAGEN:E->Q: Abolishes RNA deadenylase activity.,MUTAGEN:H->A: Abolishes RNA deadenylase activity.,MUTAGEN:K->A: Abolishes interaction with TOB1.,MUTAGEN:M->R: Abolishes interaction with CNOT1.,MUTAGEN:T->Y: Abolishes interaction with CNOT1; when associated with K-138 and K-149.,
CNOT8	CCR4-NOT transcription complex subunit 8(CNOT8)	Homo sapiens			GO:0000289~nuclear-transcribed mRNA poly(A) tail shortening,GO:0006402~mRNA catabolic process,GO:0006417~regulation of translation,GO:0008284~positive regulation of cell proliferation,GO:0035195~gene silencing by miRNA,GO:0043928~exonucleolytic nuclear-transcribed mRNA catabolic process involved in deadenylation-dependent decay,GO:0061014~positive regulation of mRNA catabolic process,	GO:0000932~P-body,GO:0005634~nucleus,GO:0005829~cytosol,GO:0030014~CCR4-NOT complex,GO:0030015~CCR4-NOT core complex,	GO:0000175~3'-5'-exoribonuclease activity,GO:0003676~nucleic acid binding,GO:0003723~RNA binding,GO:0004535~poly(A)-specific ribonuclease activity,GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR006941:RNase_CAF1,IPR012337:RNaseH-like_sf,IPR036397:RNaseH_sf,IPR039637:CNOT7/CNOT8/Pop2,	hsa03018:RNA degradation,				KW-0804~Transcription,KW-0805~Transcription regulation,KW-0810~Translation regulation,KW-0943~RNA-mediated gene silencing,	KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0479~Metal-binding,	KW-0269~Exonuclease,KW-0378~Hydrolase,KW-0540~Nuclease,KW-0678~Repressor,KW-0694~RNA-binding,		MUTAGEN:D->A: Impairs deadenylation and decay of mRNAi-targeted mRNA; when associated with A-42.,MUTAGEN:E->A: Impairs deadenylation and decay of mRNAi-targeted mRNA; when associated with A-40.,
CD151	CD151 molecule (Raph blood group)(CD151)	Homo sapiens	73.Integrins_and_other_cell-surface_receptors,		GO:0007155~cell adhesion,GO:0016477~cell migration,GO:0030335~positive regulation of cell migration,GO:0042098~T cell proliferation,GO:0044319~wound healing, spreading of cells,GO:0045807~positive regulation of endocytosis,	GO:0005604~basement membrane,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0009986~cell surface,GO:0016020~membrane,	GO:0005178~integrin binding,GO:0005515~protein binding,	IPR000301:Tetraspanin_animals,IPR008952:Tetraspanin_EC2_sf,IPR018499:Tetraspanin/Peripherin,IPR018503:Tetraspanin_CS,		179620~Blood group, Raph,609057~Epidermolysis bullosa simplex 7, with nephropathy and deafness,	PIRSF002419:Tetraspanin,		KW-0945~Host-virus interaction,	KW-0472~Membrane,	KW-0209~Deafness,KW-0263~Epidermolysis bullosa,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0095~Blood group antigen,	KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0564~Palmitate,	CARBOHYD:N-linked (GlcNAc...) asparagine,LIPID:S-palmitoyl cysteine,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CD164	CD164 molecule(CD164)	Homo sapiens			GO:0006955~immune response,GO:0007155~cell adhesion,GO:0007157~heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules,GO:0007162~negative regulation of cell adhesion,GO:0007165~signal transduction,GO:0007517~muscle organ development,GO:0030097~hemopoiesis,	GO:0005576~extracellular region,GO:0005764~lysosome,GO:0005765~lysosomal membrane,GO:0005768~endosome,GO:0005886~plasma membrane,GO:0010008~endosome membrane,GO:0016020~membrane,	GO:0005515~protein binding,	IPR007947:CD164_MGC24,	hsa04142:Lysosome,	616969~Deafness, autosomal dominant 66,			KW-0130~Cell adhesion,KW-0517~Myogenesis,	KW-0458~Lysosome,KW-0472~Membrane,KW-0964~Secreted,KW-0967~Endosome,KW-1003~Cell membrane,	KW-0209~Deafness,KW-1010~Non-syndromic deafness,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0654~Proteoglycan,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (Xyl...) (glycosaminoglycan) serine,REGION:Disordered,REGION:Required for endosomal and lysosomal localization,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CD2BP2	CD2 cytoplasmic tail binding protein 2(CD2BP2)	Homo sapiens			GO:0000244~spliceosomal tri-snRNP complex assembly,	GO:0001650~fibrillar center,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005682~U5 snRNP,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016607~nuclear speck,	GO:0005515~protein binding,GO:0043021~ribonucleoprotein complex binding,	IPR003169:GYF,IPR035445:GYF-like_dom_sf,IPR039905:CD2BP2/Lin1,				SM00444:GYF,	KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,KW-0963~Cytoplasm,					KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:GYF,REGION:Disordered,
CD2	CD2 molecule(CD2)	Homo sapiens	150.caspase_and_NFKB_activation,7.IL17_hematopoesis,81.Structure_of_Caps_and_SMACs,90.IB_and-cat-Arm_processing_of_Ci,99.NF-kB_activation,	h_dcPathway:Dendritic cells in regulating TH1 and TH2 Development,h_il17Pathway:IL 17 Signaling Pathway,h_no2il12Pathway:NO2-dependent IL 12 Pathway in NK cells,h_stathminPathway:Stathmin and breast cancer resistance to antimicrotubule agents,h_tcytotoxicPathway:T Cytotoxic Cell Surface Molecules,h_thelperPathway:T Helper Cell Surface Molecules,	GO:0001766~membrane raft polarization,GO:0006915~apoptotic process,GO:0007166~cell surface receptor signaling pathway,GO:0030101~natural killer cell activation,GO:0030887~positive regulation of myeloid dendritic cell activation,GO:0032729~positive regulation of interferon-gamma production,GO:0032757~positive regulation of interleukin-8 production,GO:0032760~positive regulation of tumor necrosis factor production,GO:0034113~heterotypic cell-cell adhesion,GO:0042110~T cell activation,GO:0042267~natural killer cell mediated cytotoxicity,GO:0045580~regulation of T cell differentiation,GO:0098609~cell-cell adhesion,	GO:0005576~extracellular region,GO:0005654~nucleoplasm,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0005911~cell-cell junction,GO:0009897~external side of plasma membrane,GO:0009898~cytoplasmic side of plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,GO:0032991~macromolecular complex,	GO:0005102~receptor binding,GO:0005515~protein binding,GO:0030971~receptor tyrosine kinase binding,GO:0038023~signaling receptor activity,GO:0042802~identical protein binding,GO:0043621~protein self-association,	IPR008424:Ig_C2-set,IPR013106:Ig_V-set,IPR013783:Ig-like_fold,IPR015632:CD2,IPR036179:Ig-like_dom_sf,	hsa04514:Cell adhesion molecules,hsa04640:Hematopoietic cell lineage,				KW-0130~Cell adhesion,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,DOMAIN:Ig-like C2-type,DOMAIN:Ig-like V-type,DOMAIN:Immunoglobulin C2-set,DOMAIN:Immunoglobulin V-set,MUTAGEN:D->H: Loss of CD58 and CD59 binding.,MUTAGEN:K->R: Loss of CD58 binding.,MUTAGEN:Q->K: Loss of CD58 binding.,MUTAGEN:Y->D: Loss of CD58 and CD59 binding.,REGION:CD58 binding region 1,REGION:CD58 binding region 2,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CD247	CD247 molecule(CD247)	Homo sapiens		h_cskPathway:Activation of Csk by cAMP-dependent Protein Kinase Inhibits Signaling through the T Cell Receptor,h_ctla4Pathway:The Co-Stimulatory Signal During T-cell Activation,h_ctlPathway:CTL mediated immune response against target cells ,h_il12Pathway:IL12 and Stat4 Dependent Signaling Pathway in Th1 Development,h_il17Pathway:IL 17 Signaling Pathway,h_no2il12Pathway:NO2-dependent IL 12 Pathway in NK cells,h_stathminPathway:Stathmin and breast cancer resistance to antimicrotubule agents,h_tcapoptosisPathway:HIV Induced T Cell Apoptosis,h_tcraPathway:Lck and Fyn tyrosine kinases in initiation of TCR Activation,h_tcrmolecule:T Cell Receptor and CD3 Complex,h_tcrPathway:T Cell Receptor Signaling Pathway,h_tcytotoxicPathway:T Cytotoxic Cell Surface Molecules,h_thelperPathway:T Helper Cell Surface Molecules,h_tob1Pathway:Role of Tob in T-cell activation,	GO:0002250~adaptive immune response,GO:0007166~cell surface receptor signaling pathway,GO:0038094~Fc-gamma receptor signaling pathway,GO:0046629~gamma-delta T cell activation,GO:0046631~alpha-beta T cell activation,GO:0050852~T cell receptor signaling pathway,GO:0051259~protein oligomerization,GO:0065003~macromolecular complex assembly,GO:2000010~positive regulation of protein localization to cell surface,	GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0033001~Fc-gamma receptor III complex,GO:0042101~T cell receptor complex,GO:0042105~alpha-beta T cell receptor complex,GO:0042106~gamma-delta T cell receptor complex,GO:0098797~plasma membrane protein complex,	GO:0004888~transmembrane signaling receptor activity,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0046982~protein heterodimerization activity,GO:1990782~protein tyrosine kinase binding,	IPR003110:Phos_immunorcpt_sig_ITAM,IPR021663:CD3_zeta/IgE_Fc_rcpt_gamma,IPR024128:T-cell_CD3_zeta,	hsa04650:Natural killer cell mediated cytotoxicity,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04660:T cell receptor signaling pathway,hsa05142:Chagas disease,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,	610163~Immunodeficiency 25,		SM00077:ITAM,	KW-0391~Immunity,KW-0945~Host-virus interaction,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:ITAM 1,DOMAIN:ITAM 2,DOMAIN:ITAM 3,MUTAGEN:D->E,L,V: Decreases cell surface expression of IgG Fc receptor complex.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CD27	CD27 molecule(CD27)	Homo sapiens			GO:0007166~cell surface receptor signaling pathway,GO:0016064~immunoglobulin mediated immune response,GO:0043066~negative regulation of apoptotic process,GO:0045471~response to ethanol,GO:0045579~positive regulation of B cell differentiation,GO:0045582~positive regulation of T cell differentiation,GO:0046330~positive regulation of JNK cascade,GO:0070233~negative regulation of T cell apoptotic process,GO:0097191~extrinsic apoptotic signaling pathway,GO:1901224~positive regulation of NIK/NF-kappaB signaling,	GO:0005576~extracellular region,GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,	GO:0004888~transmembrane signaling receptor activity,GO:0005515~protein binding,GO:0043027~cysteine-type endopeptidase inhibitor activity involved in apoptotic process,	IPR001368:TNFR/NGFR_Cys_rich_reg,IPR022328:TNFR_7,IPR034000:TNFRSF7_N,	hsa04060:Cytokine-cytokine receptor interaction,	615122~Lymphoproliferative syndrome 2,		SM00208:TNFR,	KW-0053~Apoptosis,	KW-0472~Membrane,	KW-0225~Disease variant,	KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (GalNAc...) serine,COMPBIAS:Basic and acidic residues,REGION:Disordered,REPEAT:TNFR-Cys 1,REPEAT:TNFR-Cys 2,REPEAT:TNFR-Cys 3,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CD28	CD28 molecule(CD28)	Homo sapiens	3.T_cell_receptor,50.Hypothesis_of_bronchial_asthma,55.Allergen_recognition_by_Th2_or_Th0_cell,	h_asbcellPathway:Antigen Dependent B Cell Activation,h_bbcellPathway:Bystander B Cell Activation,h_ctla4Pathway:The Co-Stimulatory Signal During T-cell Activation,h_nktPathway:Selective expression of chemokine receptors during T-cell polarization,h_tcapoptosisPathway:HIV Induced T Cell Apoptosis,h_tcytotoxicPathway:T Cytotoxic Cell Surface Molecules,h_th1th2Pathway:Th1/Th2 Differentiation,h_thelperPathway:T Helper Cell Surface Molecules,h_tob1Pathway:Role of Tob in T-cell activation,	GO:0001819~positive regulation of cytokine production,GO:0002863~positive regulation of inflammatory response to antigenic stimulus,GO:0006366~transcription from RNA polymerase II promoter,GO:0006959~humoral immune response,GO:0007166~cell surface receptor signaling pathway,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0031295~T cell costimulation,GO:0032733~positive regulation of interleukin-10 production,GO:0032743~positive regulation of interleukin-2 production,GO:0032753~positive regulation of interleukin-4 production,GO:0035739~CD4-positive, alpha-beta T cell proliferation,GO:0042102~positive regulation of T cell proliferation,GO:0042110~T cell activation,GO:0042129~regulation of T cell proliferation,GO:0043066~negative regulation of apoptotic process,GO:0043491~protein kinase B signaling,GO:0045060~negative thymic T cell selection,GO:0045066~regulatory T cell differentiation,GO:0045070~positive regulation of viral genome replication,GO:0045589~regulation of regulatory T cell differentiation,GO:0045727~positive regulation of translation,GO:0045840~positive regulation of mitotic nuclear division,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048304~positive regulation of isotype switching to IgG isotypes,GO:0050852~T cell receptor signaling pathway,GO:0051897~positive regulation of protein kinase B signaling,GO:0097190~apoptotic signaling pathway,GO:2000563~positive regulation of CD4-positive, alpha-beta T cell proliferation,	GO:0001772~immunological synapse,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,GO:0098636~protein complex involved in cell adhesion,	GO:0002020~protease binding,GO:0005515~protein binding,GO:0015026~coreceptor activity,GO:0019901~protein kinase binding,GO:0042802~identical protein binding,	IPR008093:CD28,IPR013106:Ig_V-set,IPR013783:Ig-like_fold,IPR036179:Ig-like_dom_sf,IPR040216:CTLA4/CD28,	hsa04514:Cell adhesion molecules,hsa04660:T cell receptor signaling pathway,hsa04672:Intestinal immune network for IgA production,hsa04940:Type I diabetes mellitus,hsa05162:Measles,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,hsa05320:Autoimmune thyroid disease,hsa05322:Systemic lupus erythematosus,hsa05323:Rheumatoid arthritis,hsa05330:Allograft rejection,hsa05332:Graft-versus-host disease,hsa05416:Viral myocarditis,			SM00406:IGv,		KW-0472~Membrane,		KW-0393~Immunoglobulin domain,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like V-type,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CD3D	CD3 delta subunit of T-cell receptor complex(CD3D)	Homo sapiens		h_cskPathway:Activation of Csk by cAMP-dependent Protein Kinase Inhibits Signaling through the T Cell Receptor,h_ctla4Pathway:The Co-Stimulatory Signal During T-cell Activation,h_ctlPathway:CTL mediated immune response against target cells ,h_il12Pathway:IL12 and Stat4 Dependent Signaling Pathway in Th1 Development,h_il17Pathway:IL 17 Signaling Pathway,h_no2il12Pathway:NO2-dependent IL 12 Pathway in NK cells,h_stathminPathway:Stathmin and breast cancer resistance to antimicrotubule agents,h_tcapoptosisPathway:HIV Induced T Cell Apoptosis,h_tcraPathway:Lck and Fyn tyrosine kinases in initiation of TCR Activation,h_tcrmolecule:T Cell Receptor and CD3 Complex,h_tcrPathway:T Cell Receptor Signaling Pathway,h_tcytotoxicPathway:T Cytotoxic Cell Surface Molecules,h_thelperPathway:T Helper Cell Surface Molecules,h_tob1Pathway:Role of Tob in T-cell activation,	GO:0002250~adaptive immune response,GO:0007166~cell surface receptor signaling pathway,GO:0045059~positive thymic T cell selection,GO:0046631~alpha-beta T cell activation,GO:0050852~T cell receptor signaling pathway,	GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0016020~membrane,GO:0030669~clathrin-coated endocytic vesicle membrane,GO:0042101~T cell receptor complex,GO:0042105~alpha-beta T cell receptor complex,	GO:0004888~transmembrane signaling receptor activity,GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR003110:Phos_immunorcpt_sig_ITAM,IPR013783:Ig-like_fold,IPR015484:CD3_esu/gsu/dsu,IPR032052:Ig_4,IPR036179:Ig-like_dom_sf,	hsa04640:Hematopoietic cell lineage,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04660:T cell receptor signaling pathway,hsa05142:Chagas disease,hsa05162:Measles,hsa05166:Human T-cell leukemia virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,hsa05340:Primary immunodeficiency,	615617~Immunodeficiency 19, severe combined,		SM00077:ITAM,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-1003~Cell membrane,	KW-0705~SCID,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:CD3 gamma/delta subunit Ig-like,DOMAIN:ITAM,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CD3E	CD3 epsilon subunit of T-cell receptor complex(CD3E)	Homo sapiens		h_cskPathway:Activation of Csk by cAMP-dependent Protein Kinase Inhibits Signaling through the T Cell Receptor,h_ctla4Pathway:The Co-Stimulatory Signal During T-cell Activation,h_ctlPathway:CTL mediated immune response against target cells ,h_il12Pathway:IL12 and Stat4 Dependent Signaling Pathway in Th1 Development,h_il17Pathway:IL 17 Signaling Pathway,h_no2il12Pathway:NO2-dependent IL 12 Pathway in NK cells,h_stathminPathway:Stathmin and breast cancer resistance to antimicrotubule agents,h_tcapoptosisPathway:HIV Induced T Cell Apoptosis,h_tcraPathway:Lck and Fyn tyrosine kinases in initiation of TCR Activation,h_tcrmolecule:T Cell Receptor and CD3 Complex,h_tcrPathway:T Cell Receptor Signaling Pathway,h_tcytotoxicPathway:T Cytotoxic Cell Surface Molecules,h_thelperPathway:T Helper Cell Surface Molecules,h_tob1Pathway:Role of Tob in T-cell activation,	GO:0001954~positive regulation of cell-matrix adhesion,GO:0002250~adaptive immune response,GO:0002669~positive regulation of T cell anergy,GO:0002870~T cell anergy,GO:0007166~cell surface receptor signaling pathway,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0007172~signal complex assembly,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007224~smoothened signaling pathway,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0016358~dendrite development,GO:0019722~calcium-mediated signaling,GO:0021549~cerebellum development,GO:0031295~T cell costimulation,GO:0032729~positive regulation of interferon-gamma production,GO:0032743~positive regulation of interleukin-2 production,GO:0032753~positive regulation of interleukin-4 production,GO:0033634~positive regulation of cell-cell adhesion mediated by integrin,GO:0035739~CD4-positive, alpha-beta T cell proliferation,GO:0042102~positive regulation of T cell proliferation,GO:0042110~T cell activation,GO:0042981~regulation of apoptotic process,GO:0045059~positive thymic T cell selection,GO:0045060~negative thymic T cell selection,GO:0045879~negative regulation of smoothened signaling pathway,GO:0046629~gamma-delta T cell activation,GO:0046631~alpha-beta T cell activation,GO:0050731~positive regulation of peptidyl-tyrosine phosphorylation,GO:0050850~positive regulation of calcium-mediated signaling,GO:0050852~T cell receptor signaling pathway,GO:0065003~macromolecular complex assembly,GO:0097190~apoptotic signaling pathway,GO:2000563~positive regulation of CD4-positive, alpha-beta T cell proliferation,	GO:0001772~immunological synapse,GO:0005783~endoplasmic reticulum,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0005911~cell-cell junction,GO:0009897~external side of plasma membrane,GO:0042101~T cell receptor complex,GO:0042105~alpha-beta T cell receptor complex,GO:0042106~gamma-delta T cell receptor complex,GO:0043197~dendritic spine,GO:0044297~cell body,	GO:0004888~transmembrane signaling receptor activity,GO:0005515~protein binding,GO:0017124~SH3 domain binding,GO:0019901~protein kinase binding,GO:0030159~receptor signaling complex scaffold activity,GO:0042608~T cell receptor binding,GO:0042802~identical protein binding,	IPR003110:Phos_immunorcpt_sig_ITAM,IPR003598:Ig_sub2,IPR013783:Ig-like_fold,IPR015484:CD3_esu/gsu/dsu,IPR036179:Ig-like_dom_sf,	hsa04640:Hematopoietic cell lineage,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04660:T cell receptor signaling pathway,hsa05142:Chagas disease,hsa05162:Measles,hsa05166:Human T-cell leukemia virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,hsa05340:Primary immunodeficiency,	615615~Immunodeficiency 18,615615~Immunodeficiency 18, SCID variant,		SM00077:ITAM,SM00408:IGc2,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	DOMAIN:ITAM,DOMAIN:Ig-like,DOMAIN:Immunoglobulin subtype 2,REGION:Disordered,REGION:NUMB-binding region,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CD3G	CD3 gamma subunit of T-cell receptor complex(CD3G)	Homo sapiens		h_cskPathway:Activation of Csk by cAMP-dependent Protein Kinase Inhibits Signaling through the T Cell Receptor,h_ctla4Pathway:The Co-Stimulatory Signal During T-cell Activation,h_ctlPathway:CTL mediated immune response against target cells ,h_il12Pathway:IL12 and Stat4 Dependent Signaling Pathway in Th1 Development,h_il17Pathway:IL 17 Signaling Pathway,h_no2il12Pathway:NO2-dependent IL 12 Pathway in NK cells,h_stathminPathway:Stathmin and breast cancer resistance to antimicrotubule agents,h_tcapoptosisPathway:HIV Induced T Cell Apoptosis,h_tcraPathway:Lck and Fyn tyrosine kinases in initiation of TCR Activation,h_tcrmolecule:T Cell Receptor and CD3 Complex,h_tcrPathway:T Cell Receptor Signaling Pathway,h_tcytotoxicPathway:T Cytotoxic Cell Surface Molecules,h_thelperPathway:T Helper Cell Surface Molecules,h_tob1Pathway:Role of Tob in T-cell activation,	GO:0002250~adaptive immune response,GO:0007163~establishment or maintenance of cell polarity,GO:0007166~cell surface receptor signaling pathway,GO:0015031~protein transport,GO:0042110~T cell activation,GO:0045059~positive thymic T cell selection,GO:0046629~gamma-delta T cell activation,GO:0046631~alpha-beta T cell activation,GO:0050852~T cell receptor signaling pathway,GO:0065003~macromolecular complex assembly,GO:0070228~regulation of lymphocyte apoptotic process,	GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0030669~clathrin-coated endocytic vesicle membrane,GO:0042105~alpha-beta T cell receptor complex,GO:0042106~gamma-delta T cell receptor complex,	GO:0004888~transmembrane signaling receptor activity,GO:0005515~protein binding,GO:0030159~receptor signaling complex scaffold activity,GO:0042608~T cell receptor binding,GO:0042802~identical protein binding,	IPR003110:Phos_immunorcpt_sig_ITAM,IPR003598:Ig_sub2,IPR013783:Ig-like_fold,IPR015484:CD3_esu/gsu/dsu,IPR032052:Ig_4,IPR036179:Ig-like_dom_sf,	hsa04640:Hematopoietic cell lineage,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04660:T cell receptor signaling pathway,hsa05142:Chagas disease,hsa05162:Measles,hsa05166:Human T-cell leukemia virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,	615607~Immunodeficiency 17, CD3 gamma deficient,		SM00077:ITAM,SM00408:IGc2,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:ITAM,DOMAIN:Ig-like,DOMAIN:Immunoglobulin subtype 2,MOTIF:Di-leucine motif,MUTAGEN:L->A: Abolishes lysosomal targeting.,MUTAGEN:L->A: Diminished but persistent lysosomal targeting.,MUTAGEN:L->I: Diminished but persistent lysosomal targeting.,MUTAGEN:L->I: No effect.,MUTAGEN:Y->A: Abolishes lysosomal targeting.,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CD37	CD37 molecule(CD37)	Homo sapiens	73.Integrins_and_other_cell-surface_receptors,			GO:0001772~immunological synapse,GO:0016020~membrane,GO:0070062~extracellular exosome,	GO:0005515~protein binding,	IPR000301:Tetraspanin_animals,IPR008952:Tetraspanin_EC2_sf,IPR018499:Tetraspanin/Peripherin,IPR018503:Tetraspanin_CS,	hsa04640:Hematopoietic cell lineage,		PIRSF002419:Tetraspanin,			KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CD4	CD4 molecule(CD4)	Homo sapiens	124.GH-IGF1_thymopoiesis,125.T_Cells_CNS-APCs,3.T_cell_receptor,50.Hypothesis_of_bronchial_asthma,54.T-cell_anergy,55.Allergen_recognition_by_Th2_or_Th0_cell,59.L-type_Ca2+_Tat_immune_cells,62.G1-phase_progression_by_Myc,63.LAT_couples_T-cell_receptor,67.Ikaros_and_signaling_inhibitors,7.IL17_hematopoesis,78.B_Cell_Development,81.Structure_of_Caps_and_SMACs,97.Immune_injury_MS-lesions_MS_antigen,	h_asbcellPathway:Antigen Dependent B Cell Activation,h_bbcellPathway:Bystander B Cell Activation,h_cskPathway:Activation of Csk by cAMP-dependent Protein Kinase Inhibits Signaling through the T Cell Receptor,h_il17Pathway:IL 17 Signaling Pathway,h_il5Pathway:IL 5 Signaling Pathway,h_inflamPathway:Cytokines and Inflammatory Response,h_nktPathway:Selective expression of chemokine receptors during T-cell polarization,h_no2il12Pathway:NO2-dependent IL 12 Pathway in NK cells,h_stemPathway:Regulation of hematopoiesis by cytokines,h_tcapoptosisPathway:HIV Induced T Cell Apoptosis,h_tcraPathway:Lck and Fyn tyrosine kinases in initiation of TCR Activation,h_thelperPathway:T Helper Cell Surface Molecules,h_vifPathway:HIV-1 defeats host-mediated resistance by CEM15,	GO:0001934~positive regulation of protein phosphorylation,GO:0002250~adaptive immune response,GO:0006955~immune response,GO:0007155~cell adhesion,GO:0007165~signal transduction,GO:0007166~cell surface receptor signaling pathway,GO:0007167~enzyme linked receptor protein signaling pathway,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0019722~calcium-mediated signaling,GO:0030217~T cell differentiation,GO:0030225~macrophage differentiation,GO:0032507~maintenance of protein location in cell,GO:0032743~positive regulation of interleukin-2 production,GO:0033674~positive regulation of kinase activity,GO:0035397~helper T cell enhancement of adaptive immune response,GO:0035723~interleukin-15-mediated signaling pathway,GO:0042110~T cell activation,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043410~positive regulation of MAPK cascade,GO:0045058~T cell selection,GO:0045657~positive regulation of monocyte differentiation,GO:0045860~positive regulation of protein kinase activity,GO:0045893~positive regulation of transcription, DNA-templated,GO:0046598~positive regulation of viral entry into host cell,GO:0046718~viral entry into host cell,GO:0050731~positive regulation of peptidyl-tyrosine phosphorylation,GO:0050829~defense response to Gram-negative bacterium,GO:0050850~positive regulation of calcium-mediated signaling,GO:0050863~regulation of T cell activation,GO:0050870~positive regulation of T cell activation,GO:0051924~regulation of calcium ion transport,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0097011~cellular response to granulocyte macrophage colony-stimulating factor stimulus,	GO:0005769~early endosome,GO:0005788~endoplasmic reticulum lumen,GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0030669~clathrin-coated endocytic vesicle membrane,GO:0042101~T cell receptor complex,GO:0045121~membrane raft,	GO:0001618~virus receptor activity,GO:0004888~transmembrane signaling receptor activity,GO:0005201~extracellular matrix structural constituent,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0008289~lipid binding,GO:0015026~coreceptor activity,GO:0019899~enzyme binding,GO:0019901~protein kinase binding,GO:0023026~MHC class II protein complex binding,GO:0038023~signaling receptor activity,GO:0042011~interleukin-16 binding,GO:0042012~interleukin-16 receptor activity,GO:0042289~MHC class II protein binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:1990782~protein tyrosine kinase binding,	IPR000973:CD4,IPR003598:Ig_sub2,IPR003599:Ig_sub,IPR007110:Ig-like_dom,IPR008424:Ig_C2-set,IPR013106:Ig_V-set,IPR013151:Immunoglobulin,IPR013783:Ig-like_fold,IPR015274:CD4-extracel,IPR021963:Tcell_CD4_Cterm,IPR036179:Ig-like_dom_sf,	hsa03250:Viral life cycle - HIV-1,hsa03260:Virion - Human immunodeficiency virus,hsa04060:Cytokine-cytokine receptor interaction,hsa04514:Cell adhesion molecules,hsa04612:Antigen processing and presentation,hsa04640:Hematopoietic cell lineage,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04660:T cell receptor signaling pathway,hsa05135:Yersinia infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,hsa05340:Primary immunodeficiency,	613949~OKT4 epitope deficiency,619238~Immunodeficiency 79,		SM00406:IGv,SM00408:IGc2,SM00409:IG,	KW-0391~Immunity,KW-0945~Host-virus interaction,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,KW-1183~Host cell receptor for virus entry,	KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:CD4 extracellular,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,DOMAIN:Ig-like C2-type 3,DOMAIN:Ig-like V-type,DOMAIN:Immunoglobulin C2-set,DOMAIN:Immunoglobulin subtype,DOMAIN:T cell CD4 receptor C-terminal region,LIPID:S-palmitoyl cysteine,MUTAGEN:C->A: Loss of homodimerization; when associated with A-445.,MUTAGEN:C->A: Loss of homodimerization; when associated with A-447.,MUTAGEN:D->R: Increases the affinity for MHCII; when associated with Y-65; W-70 and R-85.,MUTAGEN:F->I: Abrogates the interaction with MHCII and T cell activation.,MUTAGEN:LL->AA: Loss of Nef-induced CD4 down-modulation.,MUTAGEN:M->T: No effect.,MUTAGEN:Missing: Abolished interaction with SPG21 and induced T-cell activation.,MUTAGEN:Q->Y: Increases the affinity for MHCII; when associated with W-70; R-85 and R-88.,MUTAGEN:R->A: Has no effect on the interaction with MHCII. Impairs recognition by OKT4 antibody.,MUTAGEN:S->A: About 75% loss of internalization.,MUTAGEN:S->A: No effect.,MUTAGEN:S->L: No effect.,MUTAGEN:S->R: Increases the affinity for MHCII; when associated with Y-65; W-70 and R-88.,MUTAGEN:T->W: Increases the affinity for MHCII; when associated with Y-65; R-85 and R-88.,REGION:Disordered,REGION:HIV-1 Vpu-susceptibility domain,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CD47	CD47 molecule(CD47)	Homo sapiens	66.Prot_Interac_w_integrin_domains,72.IAP_interaction_with_cell_death_pathways,74.CD47-IAP_with_avB3,83.Growth_factors_Survival_factors_Mitogens,		GO:0001525~angiogenesis,GO:0006915~apoptotic process,GO:0006954~inflammatory response,GO:0007155~cell adhesion,GO:0007229~integrin-mediated signaling pathway,GO:0008284~positive regulation of cell proliferation,GO:0016477~cell migration,GO:0022409~positive regulation of cell-cell adhesion,GO:0032649~regulation of interferon-gamma production,GO:0032653~regulation of interleukin-10 production,GO:0032655~regulation of interleukin-12 production,GO:0032675~regulation of interleukin-6 production,GO:0032680~regulation of tumor necrosis factor production,GO:0034113~heterotypic cell-cell adhesion,GO:0045428~regulation of nitric oxide biosynthetic process,GO:0050729~positive regulation of inflammatory response,GO:0050765~negative regulation of phagocytosis,GO:0050766~positive regulation of phagocytosis,GO:0050870~positive regulation of T cell activation,GO:0051496~positive regulation of stress fiber assembly,GO:0060368~regulation of Fc receptor mediated stimulatory signaling pathway,GO:0071346~cellular response to interferon-gamma,GO:0071347~cellular response to interleukin-1,GO:0071349~cellular response to interleukin-12,GO:1904669~ATP export,GO:2000439~positive regulation of monocyte extravasation,	GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0035579~specific granule membrane,GO:0070062~extracellular exosome,GO:0070821~tertiary granule membrane,	GO:0005515~protein binding,GO:0070053~thrombospondin receptor activity,GO:0086080~protein binding involved in heterotypic cell-cell adhesion,GO:0098632~protein binding involved in cell-cell adhesion,	IPR006704:CD47,IPR007110:Ig-like_dom,IPR013147:CD47-like_TM,IPR013270:CD47_Vset,IPR013783:Ig-like_fold,IPR036179:Ig-like_dom_sf,IPR037805:IgV_CD47,	hsa04148:Efferocytosis,hsa04512:ECM-receptor interaction,				KW-0037~Angiogenesis,KW-0053~Apoptosis,KW-0130~Cell adhesion,KW-0395~Inflammatory response,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0873~Pyrrolidone carboxylic acid,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:CD47-like transmembrane,DOMAIN:Ig-like,DOMAIN:Ig-like V-type,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CD48	CD48 molecule(CD48)	Homo sapiens			GO:0006952~defense response,	GO:0005886~plasma membrane,GO:0016020~membrane,GO:0045121~membrane raft,GO:0070062~extracellular exosome,GO:0098552~side of membrane,	GO:0005515~protein binding,	IPR003599:Ig_sub,IPR007110:Ig-like_dom,IPR013106:Ig_V-set,IPR013783:Ig-like_fold,IPR036179:Ig-like_dom_sf,	hsa04650:Natural killer cell mediated cytotoxicity,			SM00409:IG,		KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0336~GPI-anchor,KW-0449~Lipoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,LIPID:GPI-anchor amidated serine,PROPEP:Removed in mature form,TRANSMEM:Helical,
CD5	CD5 molecule(CD5)	Homo sapiens		h_dcPathway:Dendritic cells in regulating TH1 and TH2 Development,	GO:0008037~cell recognition,GO:0031295~T cell costimulation,GO:0097190~apoptotic signaling pathway,	GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0016020~membrane,	GO:0005515~protein binding,GO:0038023~signaling receptor activity,	IPR001190:SRCR,IPR003566:Tcell_CD5,IPR017448:SRCR-like_dom,IPR036772:SRCR-like_dom_sf,	hsa04640:Hematopoietic cell lineage,			SM00202:SR,		KW-0472~Membrane,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Pro residues,DOMAIN:SRCR,DOMAIN:SRCR 1,DOMAIN:SRCR 2,DOMAIN:SRCR 3,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CD52	CD52 molecule(CD52)	Homo sapiens			GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0045730~respiratory burst,	GO:0005576~extracellular region,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0097225~sperm midpiece,GO:0098552~side of membrane,		IPR026643:CAMPATH-1,						KW-0472~Membrane,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0336~GPI-anchor,KW-0449~Lipoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,LIPID:GPI-anchor amidated serine,PEPTIDE:CAMPATH-1 antigen,PROPEP:Removed in mature form,TRANSMEM:Helical,
CD53	CD53 molecule(CD53)	Homo sapiens			GO:0007165~signal transduction,GO:1901741~positive regulation of myoblast fusion,	GO:0001772~immunological synapse,GO:0005886~plasma membrane,GO:0005911~cell-cell junction,GO:0009986~cell surface,GO:0016020~membrane,GO:0035579~specific granule membrane,GO:0070062~extracellular exosome,GO:0070821~tertiary granule membrane,	GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR000301:Tetraspanin_animals,IPR008952:Tetraspanin_EC2_sf,IPR018499:Tetraspanin/Peripherin,IPR018503:Tetraspanin_CS,			PIRSF002419:Tetraspanin,			KW-0472~Membrane,KW-0965~Cell junction,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CD55	CD55 molecule (Cromer blood group)(CD55)	Homo sapiens			GO:0002726~positive regulation of T cell cytokine production,GO:0006958~complement activation, classical pathway,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0030449~regulation of complement activation,GO:0031664~regulation of lipopolysaccharide-mediated signaling pathway,GO:0045087~innate immune response,GO:0045730~respiratory burst,GO:0045916~negative regulation of complement activation,GO:0046718~viral entry into host cell,GO:1903659~regulation of complement-dependent cytotoxicity,GO:2000516~positive regulation of CD4-positive, alpha-beta T cell activation,GO:2000563~positive regulation of CD4-positive, alpha-beta T cell proliferation,	GO:0000139~Golgi membrane,GO:0005576~extracellular region,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0030133~transport vesicle,GO:0030667~secretory granule membrane,GO:0033116~endoplasmic reticulum-Golgi intermediate compartment membrane,GO:0045121~membrane raft,GO:0070062~extracellular exosome,GO:0098552~side of membrane,GO:0101003~ficolin-1-rich granule membrane,	GO:0001618~virus receptor activity,GO:0005515~protein binding,GO:0008289~lipid binding,	IPR000436:Sushi_SCR_CCP_dom,IPR035976:Sushi/SCR/CCP_sf,	hsa04610:Complement and coagulation cascades,hsa04640:Hematopoietic cell lineage,hsa05416:Viral myocarditis,	226300~Complement hyperactivation, angiopathic thrombosis, and protein-losing enteropathy,613793~Blood group Cromer,		SM00032:CCP,	KW-0180~Complement pathway,KW-0391~Immunity,KW-0399~Innate immunity,KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0677~Repeat,KW-0732~Signal,KW-0768~Sushi,		KW-0095~Blood group antigen,KW-0675~Receptor,KW-1183~Host cell receptor for virus entry,	KW-0325~Glycoprotein,KW-0336~GPI-anchor,KW-0449~Lipoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:Sushi,DOMAIN:Sushi 1,DOMAIN:Sushi 2,DOMAIN:Sushi 3,DOMAIN:Sushi 4,LIPID:GPI-anchor amidated serine,PROPEP:Removed in mature form,REGION:Disordered,
CD58	CD58 molecule(CD58)	Homo sapiens	7.IL17_hematopoesis,	h_il17Pathway:IL 17 Signaling Pathway,	GO:0032757~positive regulation of interleukin-8 production,GO:0034113~heterotypic cell-cell adhesion,GO:0071346~cellular response to interferon-gamma,GO:0071356~cellular response to tumor necrosis factor,GO:0098609~cell-cell adhesion,	GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,GO:0030667~secretory granule membrane,GO:0070062~extracellular exosome,GO:0101003~ficolin-1-rich granule membrane,	GO:0005102~receptor binding,GO:0005515~protein binding,	IPR013783:Ig-like_fold,IPR036179:Ig-like_dom_sf,	hsa04514:Cell adhesion molecules,hsa05169:Epstein-Barr virus infection,					KW-0472~Membrane,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like,MUTAGEN:F->S: No effect on CD2-binding.,MUTAGEN:L->G: No effect on CD2-binding.,MUTAGEN:T->S: No effect on CD2-binding.,MUTAGEN:V->K: No effect on CD2-binding.,MUTAGEN:V->Q: No effect on CD2-binding.,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CD59	CD59 molecule (CD59 blood group)(CD59)	Homo sapiens			GO:0001971~negative regulation of activation of membrane attack complex,GO:0007166~cell surface receptor signaling pathway,GO:0007596~blood coagulation,GO:0030449~regulation of complement activation,GO:1903659~regulation of complement-dependent cytotoxicity,	GO:0000139~Golgi membrane,GO:0005615~extracellular space,GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0012507~ER to Golgi transport vesicle membrane,GO:0016020~membrane,GO:0030133~transport vesicle,GO:0031982~vesicle,GO:0033116~endoplasmic reticulum-Golgi intermediate compartment membrane,GO:0035579~specific granule membrane,GO:0070062~extracellular exosome,GO:0070821~tertiary granule membrane,GO:0098552~side of membrane,	GO:0001848~complement binding,GO:0005515~protein binding,	IPR016054:LY6_UPA_recep-like,IPR018363:CD59_antigen_CS,IPR045860:Snake_toxin-like_sf,	hsa04610:Complement and coagulation cascades,hsa04640:Hematopoietic cell lineage,	612300~Hemolytic anemia, CD59-mediated, with or without immune-mediated polyneuropathy,		SM00134:LU,		KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0360~Hereditary hemolytic anemia,	KW-0732~Signal,			KW-0325~Glycoprotein,KW-0336~GPI-anchor,KW-0449~Lipoprotein,KW-0971~Glycation,KW-1015~Disulfide bond,	CARBOHYD:N-linked (Glc) (glycation) lysine,CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (GalNAc...) threonine,DOMAIN:UPAR/Ly6,LIPID:GPI-anchor amidated asparagine,MUTAGEN:D->R: Loss of function. Lysis.,MUTAGEN:D->R: No loss of function.,MUTAGEN:E->R: Almost complete loss of function. Lysis.,MUTAGEN:F->E: Almost complete loss of function. Lysis.,MUTAGEN:F->K: No loss of function.,MUTAGEN:F->R: Some loss of function. Some lysis.,MUTAGEN:H->Q: Loss of glycation mediated inactivation.,MUTAGEN:K->D: No loss of function.,MUTAGEN:K->E: No loss of function.,MUTAGEN:K->Q: Loss of glycation mediated inactivation.,MUTAGEN:L->D: No loss of function.,MUTAGEN:L->E: No loss of function.,MUTAGEN:N->K: No loss of function.,MUTAGEN:N->R,Q: No loss of function.,MUTAGEN:R->E: Loss of function. Lysis.,MUTAGEN:W->E: Complete loss of function. Lysis.,MUTAGEN:Y->R: No loss of function.,PROPEP:Removed in mature form,
CD6	CD6 molecule(CD6)	Homo sapiens			GO:0001771~immunological synapse formation,GO:0001934~positive regulation of protein phosphorylation,GO:0002250~adaptive immune response,GO:0002438~acute inflammatory response to antigenic stimulus,GO:0007157~heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules,GO:0031663~lipopolysaccharide-mediated signaling pathway,GO:0032496~response to lipopolysaccharide,GO:0042102~positive regulation of T cell proliferation,GO:0045087~innate immune response,GO:1900017~positive regulation of cytokine production involved in inflammatory response,	GO:0001772~immunological synapse,GO:0005576~extracellular region,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,GO:0042101~T cell receptor complex,	GO:0001530~lipopolysaccharide binding,GO:0005515~protein binding,GO:0019901~protein kinase binding,GO:0042802~identical protein binding,GO:0070891~lipoteichoic acid binding,	IPR001190:SRCR,IPR017448:SRCR-like_dom,IPR036772:SRCR-like_dom_sf,	hsa04514:Cell adhesion molecules,			SM00202:SR,	KW-0130~Cell adhesion,KW-0391~Immunity,KW-0399~Innate immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:SRCR,DOMAIN:SRCR 1,DOMAIN:SRCR 2,DOMAIN:SRCR 3,MUTAGEN:D->A: Strongly reduces interaction with ALCAM.,MUTAGEN:E->A: Nearly abolishes interaction with ALCAM.,MUTAGEN:E->A: Reduces interaction with ALCAM.,MUTAGEN:L->A: Reduces interaction with ALCAM.,MUTAGEN:N->A: Strongly reduces interaction with ALCAM.,MUTAGEN:Q->A: Reduces interaction with ALCAM.,MUTAGEN:R->A: Reduces interaction with ALCAM.,MUTAGEN:S->A: Reduces interaction with ALCAM.,MUTAGEN:Y->A: Abolishes interaction with ALCAM.,MUTAGEN:Y->A: Nearly abolishes interaction with ALCAM.,MUTAGEN:Y->F: Reduces tyrosine phosphorylation. Reduces affinity for LCP2. Impairs activation of T-cells.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CD63	CD63 molecule(CD63)	Homo sapiens	57.Post-Golgi&endo_trans_MHC_class_II,73.Integrins_and_other_cell-surface_receptors,		GO:0002092~positive regulation of receptor internalization,GO:0007160~cell-matrix adhesion,GO:0015031~protein transport,GO:0016477~cell migration,GO:0035646~endosome to melanosome transport,GO:0048757~pigment granule maturation,GO:1900746~regulation of vascular endothelial growth factor signaling pathway,GO:1901379~regulation of potassium ion transmembrane transport,GO:2001046~positive regulation of integrin-mediated signaling pathway,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005654~nucleoplasm,GO:0005765~lysosomal membrane,GO:0005771~multivesicular body,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0010008~endosome membrane,GO:0016020~membrane,GO:0031088~platelet dense granule membrane,GO:0031902~late endosome membrane,GO:0031904~endosome lumen,GO:0032585~multivesicular body membrane,GO:0035577~azurophil granule membrane,GO:0042470~melanosome,GO:0043231~intracellular membrane-bounded organelle,GO:0070062~extracellular exosome,GO:0097487~multivesicular body, internal vesicle,	GO:0005515~protein binding,	IPR000301:Tetraspanin_animals,IPR008952:Tetraspanin_EC2_sf,IPR018499:Tetraspanin/Peripherin,IPR018503:Tetraspanin_CS,IPR042028:CD63_LEL,	hsa04142:Lysosome,hsa05205:Proteoglycans in cancer,		PIRSF002419:Tetraspanin,		KW-0653~Protein transport,KW-0813~Transport,	KW-0458~Lysosome,KW-0472~Membrane,KW-0964~Secreted,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0564~Palmitate,	CARBOHYD:N-linked (GlcNAc...) asparagine,MOTIF:Lysosomal targeting motif,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CD69	CD69 molecule(CD69)	Homo sapiens	60.IL-15_rheumatoid-arthritis_synovitis,		GO:0071466~cellular response to xenobiotic stimulus,	GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0016020~membrane,GO:0032991~macromolecular complex,	GO:0004888~transmembrane signaling receptor activity,GO:0005515~protein binding,GO:0030246~carbohydrate binding,GO:0042802~identical protein binding,	IPR001304:C-type_lectin-like,IPR016186:C-type_lectin-like/link_sf,IPR016187:CTDL_fold,IPR033992:NKR-like_CTLD,				SM00034:CLECT,		KW-0472~Membrane,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0430~Lectin,		KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DISULFID:Interchain,DOMAIN:C-type lectin,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
CD7	CD7 molecule(CD7)	Homo sapiens		h_dcPathway:Dendritic cells in regulating TH1 and TH2 Development,	GO:0002250~adaptive immune response,GO:0006955~immune response,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0042110~T cell activation,	GO:0005886~plasma membrane,GO:0016020~membrane,	GO:0005515~protein binding,GO:0038023~signaling receptor activity,	IPR003599:Ig_sub,IPR007110:Ig-like_dom,IPR013106:Ig_V-set,IPR013783:Ig-like_fold,IPR036179:Ig-like_dom_sf,IPR039090:CD7,	hsa04640:Hematopoietic cell lineage,			SM00406:IGv,SM00409:IG,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0564~Palmitate,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like,LIPID:S-palmitoyl cysteine,REGION:4 X 9 AA tandem repeats, potential spacer function,REGION:Disordered,REPEAT:1,REPEAT:2,REPEAT:3,REPEAT:4,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CD74	CD74 molecule(CD74)	Homo sapiens		h_mhcPathway:Antigen Processing and Presentation,	GO:0001516~prostaglandin biosynthetic process,GO:0001934~positive regulation of protein phosphorylation,GO:0001961~positive regulation of cytokine-mediated signaling pathway,GO:0002286~T cell activation involved in immune response,GO:0002606~positive regulation of dendritic cell antigen processing and presentation,GO:0002792~negative regulation of peptide secretion,GO:0002830~positive regulation of type 2 immune response,GO:0002906~negative regulation of mature B cell apoptotic process,GO:0006886~intracellular protein transport,GO:0006955~immune response,GO:0010628~positive regulation of gene expression,GO:0016064~immunoglobulin mediated immune response,GO:0019882~antigen processing and presentation,GO:0019883~antigen processing and presentation of endogenous antigen,GO:0019886~antigen processing and presentation of exogenous peptide antigen via MHC class II,GO:0030336~negative regulation of cell migration,GO:0030890~positive regulation of B cell proliferation,GO:0031394~positive regulation of prostaglandin biosynthetic process,GO:0032722~positive regulation of chemokine production,GO:0032755~positive regulation of interleukin-6 production,GO:0032757~positive regulation of interleukin-8 production,GO:0033674~positive regulation of kinase activity,GO:0034341~response to interferon-gamma,GO:0035691~macrophage migration inhibitory factor signaling pathway,GO:0043030~regulation of macrophage activation,GO:0043066~negative regulation of apoptotic process,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043410~positive regulation of MAPK cascade,GO:0043518~negative regulation of DNA damage response, signal transduction by p53 class mediator,GO:0045058~T cell selection,GO:0045059~positive thymic T cell selection,GO:0045060~negative thymic T cell selection,GO:0045581~negative regulation of T cell differentiation,GO:0045582~positive regulation of T cell differentiation,GO:0045657~positive regulation of monocyte differentiation,GO:0045893~positive regulation of transcription, DNA-templated,GO:0046597~negative regulation of viral entry into host cell,GO:0046598~positive regulation of viral entry into host cell,GO:0048146~positive regulation of fibroblast proliferation,GO:0050731~positive regulation of peptidyl-tyrosine phosphorylation,GO:0050821~protein stabilization,GO:0051085~chaperone mediated protein folding requiring cofactor,GO:0060907~positive regulation of macrophage cytokine production,GO:0065003~macromolecular complex assembly,GO:0070206~protein trimerization,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0090023~positive regulation of neutrophil chemotaxis,GO:1902166~negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator,GO:2000343~positive regulation of chemokine (C-X-C motif) ligand 2 production,GO:2000448~positive regulation of macrophage migration inhibitory factor signaling pathway,	GO:0000139~Golgi membrane,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005764~lysosome,GO:0005765~lysosomal membrane,GO:0005770~late endosome,GO:0005771~multivesicular body,GO:0005773~vacuole,GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0012507~ER to Golgi transport vesicle membrane,GO:0016020~membrane,GO:0030658~transport vesicle membrane,GO:0030666~endocytic vesicle membrane,GO:0030669~clathrin-coated endocytic vesicle membrane,GO:0032588~trans-Golgi network membrane,GO:0032991~macromolecular complex,GO:0035692~macrophage migration inhibitory factor receptor complex,GO:0035693~NOS2-CD74 complex,GO:0042613~MHC class II protein complex,GO:0043202~lysosomal lumen,GO:0070062~extracellular exosome,GO:0098553~lumenal side of endoplasmic reticulum membrane,	GO:0001540~beta-amyloid binding,GO:0004896~cytokine receptor activity,GO:0005515~protein binding,GO:0019955~cytokine binding,GO:0023026~MHC class II protein complex binding,GO:0035718~macrophage migration inhibitory factor binding,GO:0042289~MHC class II protein binding,GO:0042609~CD4 receptor binding,GO:0042658~MHC class II protein binding, via antigen binding groove,GO:0042802~identical protein binding,GO:0044183~protein binding involved in protein folding,GO:0050998~nitric-oxide synthase binding,	IPR000716:Thyroglobulin_1,IPR011988:MHC_II-assoc_invariant_trimer,IPR015386:MHC_II-assoc_invar/CLIP_MHC-bd,IPR022339:MHC_II-assoc_invar_chain,IPR036613:MHCII_invariant_trimer_sf,IPR036857:Thyroglobulin_1_sf,IPR043530:CD74_antigen,	hsa04612:Antigen processing and presentation,hsa05152:Tuberculosis,hsa05168:Herpes simplex virus 1 infection,		PIRSF001992:CD74_antigen,	SM00211:TY,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0458~Lysosome,KW-0472~Membrane,KW-0964~Secreted,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0143~Chaperone,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0654~Proteoglycan,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (GalNAc...) serine,CARBOHYD:O-linked (GalNAc...) threonine,CARBOHYD:O-linked (Xyl...) (chondroitin sulfate) serine,DOMAIN:MHC class II-associated invariant chain/CLIP MHC II-interacting,DOMAIN:Thyroglobulin type-1,MUTAGEN:PG->RR,DD: Decreases inhibition of Ebola virus infection.,MUTAGEN:PG->TT: No effect on inhibition of Ebola virus infection.,PEPTIDE:Class-II-associated invariant chain peptide,REGION:Disordered,REGION:Required for interaction with CTSL,SITE:Breakpoint for translocation to form a CD74-ROS1 fusion protein,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
CD8A	CD8 subunit alpha(CD8A)	Homo sapiens	124.GH-IGF1_thymopoiesis,58.(CD40L)_immnosurveillance,59.L-type_Ca2+_Tat_immune_cells,67.Ikaros_and_signaling_inhibitors,7.IL17_hematopoesis,78.B_Cell_Development,81.Structure_of_Caps_and_SMACs,97.Immune_injury_MS-lesions_MS_antigen,	h_il17Pathway:IL 17 Signaling Pathway,h_stemPathway:Regulation of hematopoiesis by cytokines,h_tcytotoxicPathway:T Cytotoxic Cell Surface Molecules,	GO:0002250~adaptive immune response,GO:0002456~T cell mediated immunity,GO:0006955~immune response,GO:0007166~cell surface receptor signaling pathway,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0019882~antigen processing and presentation,GO:0042110~T cell activation,GO:0045065~cytotoxic T cell differentiation,GO:0050852~T cell receptor signaling pathway,	GO:0005576~extracellular region,GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0042101~T cell receptor complex,GO:0043235~receptor complex,GO:0044853~plasma membrane raft,	GO:0005515~protein binding,GO:0015026~coreceptor activity,GO:0023024~MHC class I protein complex binding,GO:0042288~MHC class I protein binding,	IPR003599:Ig_sub,IPR007110:Ig-like_dom,IPR013106:Ig_V-set,IPR013783:Ig-like_fold,IPR015468:CD8_asu,IPR036179:Ig-like_dom_sf,	hsa04514:Cell adhesion molecules,hsa04612:Antigen processing and presentation,hsa04640:Hematopoietic cell lineage,hsa04660:T cell receptor signaling pathway,hsa05135:Yersinia infection,hsa05340:Primary immunodeficiency,	608957~Immunodeficiency 116,		SM00406:IGv,SM00409:IG,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0393~Immunoglobulin domain,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0564~Palmitate,KW-1015~Disulfide bond,	DOMAIN:Ig-like,DOMAIN:Ig-like V-type,DOMAIN:Immunoglobulin V-set,LIPID:S-palmitoyl cysteine,MUTAGEN:C->A: Complete loss of palmitoylation.,MUTAGEN:G->R: Prevents CD8 expression.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CD82	CD82 molecule(CD82)	Homo sapiens	73.Integrins_and_other_cell-surface_receptors,			GO:0005886~plasma membrane,GO:0016020~membrane,GO:0070062~extracellular exosome,	GO:0005515~protein binding,	IPR000301:Tetraspanin_animals,IPR008952:Tetraspanin_EC2_sf,IPR018499:Tetraspanin/Peripherin,IPR018503:Tetraspanin_CS,	hsa04115:p53 signaling pathway,		PIRSF002419:Tetraspanin,			KW-0472~Membrane,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CD83	CD83 molecule(CD83)	Homo sapiens			GO:0006952~defense response,GO:0006959~humoral immune response,GO:0007165~signal transduction,GO:0014070~response to organic cyclic compound,GO:0032713~negative regulation of interleukin-4 production,GO:0032733~positive regulation of interleukin-10 production,GO:0032743~positive regulation of interleukin-2 production,GO:0043367~CD4-positive, alpha-beta T cell differentiation,GO:0043372~positive regulation of CD4-positive, alpha-beta T cell differentiation,	GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0016020~membrane,	GO:0005515~protein binding,	IPR003599:Ig_sub,IPR007110:Ig-like_dom,IPR013106:Ig_V-set,IPR013151:Immunoglobulin,IPR013783:Ig-like_fold,IPR036179:Ig-like_dom_sf,				SM00409:IG,		KW-0472~Membrane,		KW-0393~Immunoglobulin domain,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:Ig-like V-type,DOMAIN:Immunoglobulin,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CD96	CD96 molecule(CD96)	Homo sapiens			GO:0002728~negative regulation of natural killer cell cytokine production,GO:0006954~inflammatory response,GO:0006955~immune response,GO:0007155~cell adhesion,GO:0007160~cell-matrix adhesion,GO:0032496~response to lipopolysaccharide,GO:0032689~negative regulation of interferon-gamma production,	GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0016020~membrane,		IPR003599:Ig_sub,IPR007110:Ig-like_dom,IPR013783:Ig-like_fold,IPR036179:Ig-like_dom_sf,IPR042381:CD96,		211750~C syndrome,		SM00409:IG,	KW-0130~Cell adhesion,	KW-0472~Membrane,	KW-0225~Disease variant,KW-0989~Craniosynostosis,	KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type,DOMAIN:Ig-like V-type 1,DOMAIN:Ig-like V-type 2,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CLK1	CDC like kinase 1(CLK1)	Homo sapiens			GO:0016310~phosphorylation,GO:0018108~peptidyl-tyrosine phosphorylation,GO:0043484~regulation of RNA splicing,	GO:0005634~nucleus,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0004713~protein tyrosine kinase activity,GO:0004715~non-membrane spanning protein tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,	IPR000719:Prot_kinase_dom,IPR008271:Ser/Thr_kinase_AS,IPR011009:Kinase-like_dom_sf,IPR017441:Protein_kinase_ATP_BS,	hsa05134:Legionellosis,			SM00220:S_TKc,		KW-0539~Nucleus,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,KW-0829~Tyrosine-protein kinase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,DOMAIN:Protein kinase,REGION:Disordered,
CDC42EP3	CDC42 effector protein 3(CDC42EP3)	Homo sapiens			GO:0007165~signal transduction,GO:0007266~Rho protein signal transduction,GO:0008360~regulation of cell shape,GO:0030838~positive regulation of actin filament polymerization,GO:0031274~positive regulation of pseudopodium assembly,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0012505~endomembrane system,GO:0015629~actin cytoskeleton,	GO:0005515~protein binding,GO:0005519~cytoskeletal regulatory protein binding,GO:0031267~small GTPase binding,	IPR000095:CRIB_dom,IPR029273:Cdc42_effect-like,				SM00285:PBD,	KW-0133~Cell shape,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0963~Cytoplasm,					KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:CRIB,REGION:Disordered,
CDC42SE1	CDC42 small effector 1(CDC42SE1)	Homo sapiens			GO:0006909~phagocytosis,GO:0007165~signal transduction,GO:0008360~regulation of cell shape,GO:0035023~regulation of Rho protein signal transduction,	GO:0005737~cytoplasm,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0030054~cell junction,	GO:0005095~GTPase inhibitor activity,GO:0031267~small GTPase binding,	IPR000095:CRIB_dom,IPR036936:CRIB_dom_sf,IPR039056:SPEC,					KW-0133~Cell shape,KW-0581~Phagocytosis,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,					KW-0449~Lipoprotein,KW-0564~Palmitate,	DOMAIN:CRIB,LIPID:S-palmitoyl cysteine,MUTAGEN:CC->AA: Prevents targeting to the activated TCR.,MUTAGEN:H->A: Abolishes interaction with CDC42, induces a decrease in blocking CDC42-induced JNK activation but does not affect targeting to the activated TCR; when associated with A-33 and A-38.,MUTAGEN:H->A: Abolishes interaction with CDC42, induces a decrease in blocking CDC42-induced JNK activation but does not affect targeting to the activated TCR; when associated with A-33 and A-41.,MUTAGEN:K->A: Abolishes interaction with CDC42 and induces a decrease in blocking CDC42-induced JNK activation; when associated with A-62.,MUTAGEN:P->A: Abolishes interaction with CDC42, induces a decrease in blocking CDC42-induced JNK activation but does not affect targeting to the activated TCR; when associated with A-38 and A-41.,MUTAGEN:Q->A: Abolishes interaction with CDC42 and induces a decrease in blocking CDC42-induced JNK activation; when associated with A-66.,REGION:Disordered,REGION:Mediates phosphoinositide-binding,
CISD2	CDGSH iron sulfur domain 2(CISD2)	Homo sapiens			GO:0000422~mitophagy,GO:0006914~autophagy,GO:0010506~regulation of autophagy,	GO:0005741~mitochondrial outer membrane,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0016020~membrane,GO:0032991~macromolecular complex,GO:0043231~intracellular membrane-bounded organelle,GO:0097038~perinuclear endoplasmic reticulum,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0042803~protein homodimerization activity,GO:0046872~metal ion binding,GO:0051537~2 iron, 2 sulfur cluster binding,	IPR018967:FeS-contain_CDGSH-typ,IPR019610:FeS-contain_mitoNEET_N,IPR042216:MitoNEET_CISD,IPR045131:CISD1/2,		604928~Wolfram syndrome 2,		SM00704:ZnF_CDGSH,	KW-0072~Autophagy,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0496~Mitochondrion,KW-1000~Mitochondrion outer membrane,	KW-0209~Deafness,KW-0219~Diabetes mellitus,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0001~2Fe-2S,KW-0408~Iron,KW-0411~Iron-sulfur,KW-0479~Metal-binding,			COMPBIAS:Basic and acidic residues,DOMAIN:Iron sulphur,DOMAIN:Iron-binding zinc finger CDGSH type,MUTAGEN:C->S: Has the same optical signature of the native protein and improves yields of purified protein and a decreased tendency to aggregate.,MUTAGEN:C->S: Impairs interaction with BCL2; when associated with S-101; S-110 and Q-114.,MUTAGEN:C->S: Impairs interaction with BCL2; when associated with S-99; S-101 and Q-114.,MUTAGEN:C->S: Impairs interaction with BCL2; when associated with S-99; S-110 and Q-114.,MUTAGEN:H->Q: Impairs interaction with BCL2; when associated with S-99; S-101 and S-110.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
CDS2	CDP-diacylglycerol synthase 2(CDS2)	Homo sapiens			GO:0006655~phosphatidylglycerol biosynthetic process,GO:0016024~CDP-diacylglycerol biosynthetic process,	GO:0005743~mitochondrial inner membrane,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0016020~membrane,	GO:0004605~phosphatidate cytidylyltransferase activity,GO:0005515~protein binding,	IPR000374:PC_trans,IPR016720:PC_Trfase_euk,	hsa00564:Glycerophospholipid metabolism,hsa01100:Metabolic pathways,hsa04070:Phosphatidylinositol signaling system,		PIRSF018269:PC_trans_euk,		KW-0443~Lipid metabolism,KW-0444~Lipid biosynthesis,KW-0594~Phospholipid biosynthesis,KW-1208~Phospholipid metabolism,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0548~Nucleotidyltransferase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,REGION:Disordered,TRANSMEM:Helical,
CDIPT	CDP-diacylglycerol--inositol 3-phosphatidyltransferase(CDIPT)	Homo sapiens			GO:0006661~phosphatidylinositol biosynthetic process,GO:0008654~phospholipid biosynthetic process,	GO:0005789~endoplasmic reticulum membrane,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0016020~membrane,	GO:0003881~CDP-diacylglycerol-inositol 3-phosphatidyltransferase activity,GO:0005515~protein binding,GO:0016740~transferase activity,GO:0016780~phosphotransferase activity, for other substituted phosphate groups,GO:0046872~metal ion binding,	IPR000462:CDP-OH_P_trans,IPR014387:CDP_diag_ino_3_P_euk,IPR043130:CDP-OH_PTrfase_TM_dom,IPR048254:CDP_ALCOHOL_P_TRANSF_CS,	hsa00562:Inositol phosphate metabolism,hsa00564:Glycerophospholipid metabolism,hsa01100:Metabolic pathways,hsa04070:Phosphatidylinositol signaling system,		PIRSF000848:CDP_diag_ino_3_P,		KW-0443~Lipid metabolism,KW-0444~Lipid biosynthesis,KW-0594~Phospholipid biosynthesis,KW-1208~Phospholipid metabolism,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0460~Magnesium,KW-0464~Manganese,KW-0479~Metal-binding,	KW-0808~Transferase,		ACT_SITE:Proton acceptor,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
CGGBP1	CGG triplet repeat binding protein 1(CGGBP1)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0010468~regulation of gene expression,GO:0040029~regulation of gene expression, epigenetic,	GO:0005634~nucleus,GO:0005654~nucleoplasm,	GO:0003690~double-stranded DNA binding,GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR033375:Cggbp1,					KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0238~DNA-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,MOTIF:Nuclear localization signal,REGION:Disordered,
CMTM3	CKLF like MARVEL transmembrane domain containing 3(CMTM3)	Homo sapiens			GO:0001835~blastocyst hatching,GO:0006935~chemotaxis,GO:0007165~signal transduction,GO:0050861~positive regulation of B cell receptor signaling pathway,	GO:0005615~extracellular space,GO:0005829~cytosol,GO:0016020~membrane,GO:0031410~cytoplasmic vesicle,GO:0031965~nuclear membrane,	GO:0005125~cytokine activity,GO:0005515~protein binding,	IPR008253:Marvel,					KW-0145~Chemotaxis,	KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0202~Cytokine,		COMPBIAS:Pro residues,DOMAIN:MARVEL,REGION:Disordered,TRANSMEM:Helical,
CMTM6	CKLF like MARVEL transmembrane domain containing 6(CMTM6)	Homo sapiens			GO:0015031~protein transport,GO:0031647~regulation of protein stability,GO:0032456~endocytic recycling,	GO:0005886~plasma membrane,GO:0016020~membrane,GO:0031901~early endosome membrane,GO:0035577~azurophil granule membrane,GO:0035579~specific granule membrane,GO:0055038~recycling endosome membrane,	GO:0005515~protein binding,	IPR008253:Marvel,					KW-0813~Transport,	KW-0472~Membrane,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:MARVEL,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CMTM7	CKLF like MARVEL transmembrane domain containing 7(CMTM7)	Homo sapiens			GO:0002337~B-1a B cell differentiation,GO:0006935~chemotaxis,GO:0007165~signal transduction,	GO:0005615~extracellular space,GO:0016020~membrane,	GO:0005125~cytokine activity,GO:0005515~protein binding,	IPR008253:Marvel,					KW-0145~Chemotaxis,	KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0202~Cytokine,		DOMAIN:MARVEL,REGION:Disordered,TRANSMEM:Helical,
CLPTM1	CLPTM1 regulator of GABA type A receptor forward trafficking(CLPTM1)	Homo sapiens			GO:0030154~cell differentiation,GO:0033081~regulation of T cell differentiation in thymus,	GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0012505~endomembrane system,GO:0016020~membrane,	GO:0005515~protein binding,GO:0050811~GABA receptor binding,	IPR008429:CLPTM1,					KW-0221~Differentiation,	KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
COMMD2	COMM domain containing 2(COMMD2)	Homo sapiens				GO:0005737~cytoplasm,	GO:0005515~protein binding,	IPR017920:COMM,IPR037354:Commd2,					KW-0804~Transcription,KW-0805~Transcription regulation,KW-0833~Ubl conjugation pathway,	KW-0963~Cytoplasm,						DOMAIN:COMM,
COPS3	COP9 signalosome subunit 3(COPS3)	Homo sapiens			GO:0000338~protein deneddylation,GO:0001701~in utero embryonic development,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0007165~signal transduction,GO:0009416~response to light stimulus,GO:0045116~protein neddylation,GO:1902162~regulation of DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator,GO:2000434~regulation of protein neddylation,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0008180~COP9 signalosome,GO:0032991~macromolecular complex,GO:0048471~perinuclear region of cytoplasm,	GO:0005515~protein binding,	IPR000717:PCI_dom,IPR036388:WH-like_DNA-bd_sf,IPR036390:WH_DNA-bd_sf,IPR048621:CSN3_C,				SM00088:PINT,		KW-0539~Nucleus,KW-0736~Signalosome,KW-0963~Cytoplasm,					KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:PCI,REGION:Disordered,
COPS5	COP9 signalosome subunit 5(COPS5)	Homo sapiens		h_hifPathway:Hypoxia-Inducible Factor in the Cardiovascular System,	GO:0000338~protein deneddylation,GO:0006412~translation,GO:0006413~translational initiation,GO:0006508~proteolysis,GO:0016579~protein deubiquitination,GO:0043066~negative regulation of apoptotic process,GO:0043687~post-translational protein modification,GO:0045116~protein neddylation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046328~regulation of JNK cascade,GO:0051091~positive regulation of sequence-specific DNA binding transcription factor activity,GO:0051726~regulation of cell cycle,GO:1903894~regulation of IRE1-mediated unfolded protein response,GO:1990182~exosomal secretion,GO:2000434~regulation of protein neddylation,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005852~eukaryotic translation initiation factor 3 complex,GO:0008021~synaptic vesicle,GO:0008180~COP9 signalosome,GO:0048471~perinuclear region of cytoplasm,	GO:0003713~transcription coactivator activity,GO:0003743~translation initiation factor activity,GO:0005515~protein binding,GO:0008237~metallopeptidase activity,GO:0019784~NEDD8-specific protease activity,GO:0019899~enzyme binding,GO:0035718~macrophage migration inhibitory factor binding,GO:0046872~metal ion binding,	IPR000555:JAMM/MPN+_dom,IPR037518:MPN,IPR040961:CSN5_C,				SM00232:JAB_MPN,		KW-0539~Nucleus,KW-0736~Signalosome,KW-0770~Synapse,KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,			KW-0479~Metal-binding,KW-0862~Zinc,	KW-0378~Hydrolase,KW-0482~Metalloprotease,KW-0645~Protease,	KW-0007~Acetylation,	DOMAIN:MPN,MOTIF:JAMM motif,MUTAGEN:H->Q: Abolishes ability to deneddylate cullins, without affecting the 'Lys-63'-specific deubiquitination associated with the COP9 signalosome complex.,
COPA	COPI coat complex subunit alpha(COPA)	Homo sapiens		h_arapPathway:ADP-Ribosylation Factor,	GO:0006886~intracellular protein transport,GO:0006888~ER to Golgi vesicle-mediated transport,GO:0006890~retrograde vesicle-mediated transport, Golgi to ER,GO:0006891~intra-Golgi vesicle-mediated transport,GO:0007165~signal transduction,GO:0016192~vesicle-mediated transport,GO:0030157~pancreatic juice secretion,	GO:0000139~Golgi membrane,GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0016020~membrane,GO:0030117~membrane coat,GO:0030126~COPI vesicle coat,GO:0030133~transport vesicle,GO:0030426~growth cone,GO:0030663~COPI-coated vesicle membrane,GO:0070062~extracellular exosome,	GO:0005179~hormone activity,GO:0005198~structural molecule activity,GO:0005515~protein binding,	IPR001680:WD40_rpt,IPR006692:Coatomer_WD-assoc_reg,IPR010714:Coatomer_asu_C,IPR011048:Haem_d1_sf,IPR015943:WD40/YVTN_repeat-like_dom_sf,IPR016391:Coatomer_asu,IPR019775:WD40_repeat_CS,IPR020472:G-protein_beta_WD-40_rep,IPR036322:WD40_repeat_dom_sf,IPR047312:Coatomer_alpha_WD-assoc_reg,		616414~Autoimmune interstitial lung, joint, and kidney disease,	PIRSF003354:Coatomer_alpha_subunit,	SM00320:WD40,	KW-0653~Protein transport,KW-0813~Transport,KW-0931~ER-Golgi transport,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0964~Secreted,KW-0968~Cytoplasmic vesicle,	KW-0225~Disease variant,	KW-0677~Repeat,KW-0853~WD repeat,		KW-0372~Hormone,	KW-0488~Methylation,KW-0597~Phosphoprotein,	DOMAIN:Coatomer WD associated region,DOMAIN:Coatomer alpha subunit C-terminal,PEPTIDE:Proxenin,PEPTIDE:Xenin,REGION:Disordered,REPEAT:WD,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,REPEAT:WD 7,
COPB1	COPI coat complex subunit beta 1(COPB1)	Homo sapiens			GO:0006886~intracellular protein transport,GO:0006888~ER to Golgi vesicle-mediated transport,GO:0006891~intra-Golgi vesicle-mediated transport,GO:0016192~vesicle-mediated transport,	GO:0000139~Golgi membrane,GO:0005789~endoplasmic reticulum membrane,GO:0005793~endoplasmic reticulum-Golgi intermediate compartment,GO:0005794~Golgi apparatus,GO:0005798~Golgi-associated vesicle,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0030117~membrane coat,GO:0030126~COPI vesicle coat,GO:0030133~transport vesicle,GO:0030667~secretory granule membrane,GO:0043231~intracellular membrane-bounded organelle,GO:0070821~tertiary granule membrane,GO:0101003~ficolin-1-rich granule membrane,	GO:0005198~structural molecule activity,GO:0005515~protein binding,	IPR002553:Clathrin/coatomer_adapt-like_N,IPR011710:Coatomer_bsu_C,IPR011989:ARM-like,IPR016024:ARM-type_fold,IPR016460:COPB1,IPR029446:COPB1_appendage_platform_dom,		619255~Baralle-Macken syndrome,	PIRSF005727:Coatomer_beta_subunit,		KW-0653~Protein transport,KW-0813~Transport,KW-0931~ER-Golgi transport,KW-0945~Host-virus interaction,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0898~Cataract,KW-0991~Intellectual disability,	KW-0677~Repeat,			KW-0007~Acetylation,	DOMAIN:Clathrin/coatomer adaptor adaptin-like N-terminal,REPEAT:HEAT 1,REPEAT:HEAT 2,REPEAT:HEAT 3,REPEAT:HEAT 4,REPEAT:HEAT 5,REPEAT:HEAT 6,
COPB2	COPI coat complex subunit beta 2(COPB2)	Homo sapiens			GO:0006886~intracellular protein transport,GO:0006888~ER to Golgi vesicle-mediated transport,GO:0006890~retrograde vesicle-mediated transport, Golgi to ER,GO:0006891~intra-Golgi vesicle-mediated transport,GO:0016192~vesicle-mediated transport,	GO:0000139~Golgi membrane,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0030117~membrane coat,GO:0030126~COPI vesicle coat,GO:0030133~transport vesicle,GO:0030663~COPI-coated vesicle membrane,	GO:0005198~structural molecule activity,GO:0005515~protein binding,	IPR001680:WD40_rpt,IPR006692:Coatomer_WD-assoc_reg,IPR011044:Quino_amine_DH_bsu,IPR015943:WD40/YVTN_repeat-like_dom_sf,IPR016453:COPB2,IPR020472:G-protein_beta_WD-40_rep,IPR036322:WD40_repeat_dom_sf,		617800~Microcephaly 19, primary, autosomal recessive,619884~Osteoporosis, childhood- or juvenile-onset, with developmental delay,	PIRSF005567:Coatomer_beta'_subunit,	SM00320:WD40,	KW-0653~Protein transport,KW-0813~Transport,KW-0931~ER-Golgi transport,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,	KW-0905~Primary microcephaly,	KW-0175~Coiled coil,KW-0677~Repeat,KW-0853~WD repeat,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:Coatomer WD associated region,REGION:Disordered,REPEAT:WD,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,
COPZ1	COPI coat complex subunit zeta 1(COPZ1)	Homo sapiens			GO:0006886~intracellular protein transport,GO:0006890~retrograde vesicle-mediated transport, Golgi to ER,GO:0006891~intra-Golgi vesicle-mediated transport,GO:0015031~protein transport,	GO:0000139~Golgi membrane,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0030126~COPI vesicle coat,GO:0030133~transport vesicle,		IPR000804:Clathrin_sm-chain_CS,IPR011012:Longin-like_dom_sf,IPR022775:AP_mu_sigma_su,IPR039652:Coatomer_zeta,					KW-0653~Protein transport,KW-0813~Transport,KW-0931~ER-Golgi transport,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,					KW-0007~Acetylation,	COMPBIAS:Polar residues,DOMAIN:AP complex mu/sigma subunit,MUTAGEN:EI->KA: Reduced interaction with gamma subunit.,MUTAGEN:EL->KA: Reduced interaction with gamma subunit.,REGION:Disordered,
CREBBP	CREB binding protein(CREBBP)	Homo sapiens	139.Fig1CD_Eukaryotic_transcriptional_control,140.Fig2_assembly_model_transcription,141.Fig3_pre-assembly_model_initiation,142.Fig4AB_signal-mediated_transfer_model,143.Fig4CD_signal-mediated_transfer_model,85.Nuc_Rec-Coact_Complex,99.NF-kB_activation,	h_carm-erPathway:CARM1 and Regulation of the Estrogen Receptor,h_carm1Pathway:Transcription Regulation by Methyltransferase of CARM1,h_cskPathway:Activation of Csk by cAMP-dependent Protein Kinase Inhibits Signaling through the T Cell Receptor,h_huntingtonPathway:Inhibition of Huntington's disease neurodegeneration by histone deacetylase inhibitors,h_il7Pathway:IL-7 Signal Transduction,h_nfatPathway:NFAT and Hypertrophy of the heart (Transcription in the broken heart),h_nthiPathway:NFkB activation by Nontypeable Hemophilus influenzae,h_pcafPathway:The information-processing pathway at the IFN-beta enhancer,h_pelp1Pathway:Pelp1 Modulation of Estrogen Receptor Activity,h_pitx2Pathway:Multi-step Regulation of Transcription by Pitx2,h_pmlPathway:Regulation of transcriptional activity by PML,h_PparaPathway:Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha),h_PPARgPathway:Role of PPAR-gamma Coactivators in Obesity and Thermogenesis,h_relaPathway:Acetylation and Deacetylation of RelA in The Nucleus,h_setPathway:Granzyme A mediated Apoptosis Pathway,h_tgfbPathway:TGF beta signaling pathway,h_vdrPathway:Control of Gene Expression by Vitamin D Receptor,h_wntPathway:WNT Signaling Pathway,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001666~response to hypoxia,GO:0002223~stimulatory C-type lectin receptor signaling pathway,GO:0006338~chromatin remodeling,GO:0006355~regulation of transcription, DNA-templated,GO:0006473~protein acetylation,GO:0007165~signal transduction,GO:0008589~regulation of smoothened signaling pathway,GO:0016479~negative regulation of transcription from RNA polymerase I promoter,GO:0018076~N-terminal peptidyl-lysine acetylation,GO:0030511~positive regulation of transforming growth factor beta receptor signaling pathway,GO:0031648~protein destabilization,GO:0031669~cellular response to nutrient levels,GO:0034644~cellular response to UV,GO:0038061~NIK/NF-kappaB signaling,GO:0042592~homeostatic process,GO:0042733~embryonic digit morphogenesis,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048511~rhythmic process,GO:0065003~macromolecular complex assembly,GO:1900034~regulation of cellular response to heat,GO:1900182~positive regulation of protein localization to nucleus,	GO:0000123~histone acetyltransferase complex,GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016604~nuclear body,	GO:0001223~transcription coactivator binding,GO:0002039~p53 binding,GO:0003682~chromatin binding,GO:0003684~damaged DNA binding,GO:0003712~transcription cofactor activity,GO:0003713~transcription coactivator activity,GO:0003714~transcription corepressor activity,GO:0004402~histone acetyltransferase activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0016407~acetyltransferase activity,GO:0031490~chromatin DNA binding,GO:0034212~peptide N-acetyltransferase activity,GO:0043426~MRF binding,GO:0043993~histone acetyltransferase activity (H3-K18 specific),GO:0044017~histone acetyltransferase activity (H3-K27 specific),GO:0046872~metal ion binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:0061733~peptide-lysine-N-acetyltransferase activity,	IPR000197:Znf_TAZ,IPR000433:Znf_ZZ,IPR001487:Bromodomain,IPR003101:KIX_dom,IPR009110:Nuc_rcpt_coact,IPR010303:RING_CBP-p300,IPR011011:Znf_FYVE_PHD,IPR013083:Znf_RING/FYVE/PHD,IPR013178:Histone_AcTrfase_Rtt109/CBP,IPR014744:Nuc_rcpt_coact_CREBbp,IPR018359:Bromodomain_CS,IPR031162:CBP_P300_HAT,IPR035898:TAZ_dom_sf,IPR036427:Bromodomain-like_sf,IPR036529:KIX_dom_sf,IPR037073:Nuc_rcpt_coact_CREBbp_sf,IPR038547:RING_CBP-p300_sf,IPR043145:Znf_ZZ_sf,	hsa03083:Polycomb repressive complex,hsa03250:Viral life cycle - HIV-1,hsa04024:cAMP signaling pathway,hsa04066:HIF-1 signaling pathway,hsa04068:FoxO signaling pathway,hsa04110:Cell cycle,hsa04310:Wnt signaling pathway,hsa04330:Notch signaling pathway,hsa04350:TGF-beta signaling pathway,hsa04520:Adherens junction,hsa04630:JAK-STAT signaling pathway,hsa04720:Long-term potentiation,hsa04916:Melanogenesis,hsa04919:Thyroid hormone signaling pathway,hsa04922:Glucagon signaling pathway,hsa04935:Growth hormone synthesis, secretion and action,hsa05016:Huntington disease,hsa05152:Tuberculosis,hsa05161:Hepatitis B,hsa05164:Influenza A,hsa05165:Human papillomavirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05200:Pathways in cancer,hsa05203:Viral carcinogenesis,hsa05206:MicroRNAs in cancer,hsa05211:Renal cell carcinoma,hsa05215:Prostate cancer,	180849~Rubinstein-Taybi syndrome 1,618332~Menke-Hennekam syndrome 1,		SM00291:ZnF_ZZ,SM00297:BROMO,SM00551:ZnF_TAZ,SM01250:KAT11,	KW-0090~Biological rhythms,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0991~Intellectual disability,	KW-0103~Bromodomain,KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0012~Acyltransferase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1),DOMAIN:Bromo,DOMAIN:CBP/p300-type HAT,DOMAIN:KIX,DOMAIN:TAZ-type,DOMAIN:ZZ-type,MUTAGEN:D->R: Impairs binding to acetylated histones.,MUTAGEN:E->R: Abolishes interaction with ASF1A.,MUTAGEN:F->A: Impairs binding to acetylated histones.,MUTAGEN:K->E: Abolishes interaction with ASF1A.,MUTAGEN:K->E: Impairs binding to acetylated histones.,MUTAGEN:N->E,R: Abolishes interaction with ASF1A.,MUTAGEN:S->I: Impairs interaction with ASF1A.,MUTAGEN:W->A: Abolishes interaction with ASF1A.,REGION:Disordered,REGION:Interaction with ASF1A,REGION:Interaction with SRCAP,REGION:Interaction with TRERF1,REGION:Interaction with histone,SITE:Breakpoint for translocation to form KAT6A-CREBBP,SITE:Breakpoint for translocation to form KAT6B-CREBBP,ZN_FING:TAZ-type,ZN_FING:TAZ-type 1,ZN_FING:TAZ-type 2,ZN_FING:ZZ-type,
CREBZF	CREB/ATF bZIP transcription factor(CREBZF)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0009615~response to virus,GO:0036500~ATF6-mediated unfolded protein response,GO:0045814~negative regulation of gene expression, epigenetic,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051090~regulation of sequence-specific DNA binding transcription factor activity,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005739~mitochondrion,GO:0090575~RNA polymerase II transcription factor complex,	GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR004827:bZIP,IPR020850:GED_dom,IPR046347:bZIP_sf,					KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0175~Coiled coil,			KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:BZIP,DOMAIN:GED,DOMAIN:bZIP,MOTIF:HCFC1-binding motif (HBM),MUTAGEN:D->A: Significantly reduced binding to HCFC1.,MUTAGEN:H->A: Significantly reduced binding to HCFC1.,MUTAGEN:Y->A: Does not interact with HCFC1 and is inefficient at inhibiting CREB3 transcriptional activity. Does not colocalize with CREB3 in promyelocytic leukemia protein nuclear bodies (PML-NB).,REGION:Basic motif,REGION:Disordered,REGION:Leucine-zipper,
CTDNEP1	CTD nuclear envelope phosphatase 1(CTDNEP1)	Homo sapiens			GO:0006470~protein dephosphorylation,GO:0006998~nuclear envelope organization,GO:0007077~mitotic nuclear envelope disassembly,GO:0007276~gamete generation,GO:0007498~mesoderm development,GO:0010867~positive regulation of triglyceride biosynthetic process,GO:0034504~protein localization to nucleus,GO:0060070~canonical Wnt signaling pathway,GO:0090263~positive regulation of canonical Wnt signaling pathway,	GO:0005635~nuclear envelope,GO:0005737~cytoplasm,GO:0005789~endoplasmic reticulum membrane,GO:0005811~lipid particle,GO:0016020~membrane,GO:0031965~nuclear membrane,GO:0071595~Nem1-Spo7 phosphatase complex,	GO:0004722~protein serine/threonine phosphatase activity,GO:0005515~protein binding,GO:0017018~myosin phosphatase activity,	IPR004274:FCP1_dom,IPR011948:Dullard_phosphatase,IPR023214:HAD_sf,IPR036412:HAD-like_sf,				SM00577:CPDc,		KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0539~Nucleus,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0378~Hydrolase,KW-0904~Protein phosphatase,		DOMAIN:FCP1 homology,MUTAGEN:D->N,E: Abolishes phosphatase activity.,TRANSMEM:Helical,
CTR9	CTR9 homolog, Paf1/RNA polymerase II complex component(CTR9)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001711~endodermal cell fate commitment,GO:0001826~inner cell mass cell differentiation,GO:0001829~trophectodermal cell differentiation,GO:0001832~blastocyst growth,GO:0001835~blastocyst hatching,GO:0006355~regulation of transcription, DNA-templated,GO:0006368~transcription elongation from RNA polymerase II promoter,GO:0007259~JAK-STAT cascade,GO:0016055~Wnt signaling pathway,GO:0019827~stem cell population maintenance,GO:0045638~negative regulation of myeloid cell differentiation,GO:0045814~negative regulation of gene expression, epigenetic,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0070102~interleukin-6-mediated signaling pathway,GO:0071222~cellular response to lipopolysaccharide,	GO:0000791~euchromatin,GO:0005654~nucleoplasm,GO:0016593~Cdc73/Paf1 complex,GO:0016607~nuclear speck,GO:0032991~macromolecular complex,GO:0043231~intracellular membrane-bounded organelle,	GO:0000993~RNA polymerase II core binding,GO:0005515~protein binding,GO:0042169~SH2 domain binding,	IPR011990:TPR-like_helical_dom_sf,IPR019734:TPR_repeat,IPR031101:Ctr9,				SM00028:TPR,	KW-0804~Transcription,KW-0805~Transcription regulation,KW-0879~Wnt signaling pathway,	KW-0539~Nucleus,		KW-0175~Coiled coil,KW-0677~Repeat,KW-0802~TPR repeat,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,REPEAT:TPR,REPEAT:TPR 1,REPEAT:TPR 10,REPEAT:TPR 11,REPEAT:TPR 12,REPEAT:TPR 13,REPEAT:TPR 14,REPEAT:TPR 15,REPEAT:TPR 16,REPEAT:TPR 2,REPEAT:TPR 3,REPEAT:TPR 4,REPEAT:TPR 5,REPEAT:TPR 6,REPEAT:TPR 7,REPEAT:TPR 8,REPEAT:TPR 9,
CELF1	CUGBP Elav-like family member 1(CELF1)	Homo sapiens			GO:0000381~regulation of alternative mRNA splicing, via spliceosome,GO:0006376~mRNA splice site selection,GO:0006397~mRNA processing,GO:0007281~germ cell development,GO:0007286~spermatid development,GO:0008285~negative regulation of cell proliferation,GO:0009792~embryo development ending in birth or egg hatching,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0016441~posttranscriptional gene silencing,GO:0017148~negative regulation of translation,GO:0021987~cerebral cortex development,GO:0035194~posttranscriptional gene silencing by RNA,GO:0040018~positive regulation of multicellular organism growth,GO:0043484~regulation of RNA splicing,GO:0050727~regulation of inflammatory response,GO:0061157~mRNA destabilization,	GO:0001673~male germ cell nucleus,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0010494~cytoplasmic stress granule,GO:0016020~membrane,GO:0097356~perinucleolar compartment,GO:1990904~ribonucleoprotein complex,	GO:0000900~translation repressor activity, nucleic acid binding,GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0003730~mRNA 3'-UTR binding,GO:0005515~protein binding,GO:0031369~translation initiation factor binding,GO:0036002~pre-mRNA binding,GO:0042835~BRE binding,	IPR000504:RRM_dom,IPR002343:Hud_Sxl_RNA,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR034196:CELF1/2_RRM1,IPR034198:CELF1/2_RRM2,IPR034199:CELF1/2_RRM3,IPR035979:RBD_domain_sf,				SM00360:RRM,	KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,		KW-0010~Activator,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:RRM,DOMAIN:RRM 1,DOMAIN:RRM 2,DOMAIN:RRM 3,MUTAGEN:F->L: Does not reduce RNA-binding; when associated with D-331 and F-472. Abolishes ARE/EDEN-dependent deadenylation; when associated with D-331 and F-472.,MUTAGEN:G->D: Does not reduce RNA-binding; when associated with L-63 and F-472. Abolishes ARE/EDEN-dependent deadenylation; when associated with D-331 and F-472.,MUTAGEN:L->F: Does not reduce RNA-binding; when associated with L-63 and D-331. Abolishes ARE/EDEN-dependent deadenylation; when associated with D-331 and F-472.,REGION:Disordered,
CELF2	CUGBP Elav-like family member 2(CELF2)	Homo sapiens			GO:0000381~regulation of alternative mRNA splicing, via spliceosome,GO:0006376~mRNA splice site selection,GO:0006396~RNA processing,GO:0006397~mRNA processing,GO:0008016~regulation of heart contraction,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0043231~intracellular membrane-bounded organelle,GO:0090543~Flemming body,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003730~mRNA 3'-UTR binding,GO:0036002~pre-mRNA binding,	IPR000504:RRM_dom,IPR002343:Hud_Sxl_RNA,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR034196:CELF1/2_RRM1,IPR034198:CELF1/2_RRM2,IPR034199:CELF1/2_RRM3,IPR035979:RBD_domain_sf,		619561~Developmental and epileptic encephalopathy 97,		SM00360:RRM,	KW-0507~mRNA processing,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0887~Epilepsy,KW-0991~Intellectual disability,	KW-0677~Repeat,		KW-0678~Repressor,KW-0694~RNA-binding,		COMPBIAS:Polar residues,DOMAIN:RRM,DOMAIN:RRM 1,DOMAIN:RRM 2,DOMAIN:RRM 3,REGION:Disordered,REGION:Necessary for RNA-binding, TNNT2 exon 5 and NMDA R1 exon 21 inclusion,
CWC15	CWC15 spliceosome associated protein homolog(CWC15)	Homo sapiens			GO:0000398~mRNA splicing, via spliceosome,GO:0045292~mRNA cis splicing, via spliceosome,	GO:0000974~Prp19 complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005681~spliceosomal complex,GO:0005739~mitochondrion,GO:0016607~nuclear speck,GO:0071007~U2-type catalytic step 2 spliceosome,GO:0071013~catalytic step 2 spliceosome,	GO:0003723~RNA binding,GO:0005515~protein binding,	IPR006973:Cwf_Cwc_15,	hsa03040:Spliceosome,				KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,KW-0747~Spliceosome,		KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,REGION:Disordered,
CWC22	CWC22 spliceosome associated protein homolog(CWC22)	Homo sapiens			GO:0000398~mRNA splicing, via spliceosome,GO:0048024~regulation of mRNA splicing, via spliceosome,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005681~spliceosomal complex,GO:0005829~cytosol,GO:0016607~nuclear speck,GO:0071005~U2-type precatalytic spliceosome,GO:0071006~U2-type catalytic step 1 spliceosome,GO:0071007~U2-type catalytic step 2 spliceosome,GO:0071013~catalytic step 2 spliceosome,	GO:0003723~RNA binding,GO:0005515~protein binding,	IPR003890:MIF4G-like_typ-3,IPR003891:Initiation_fac_eIF4g_MI,IPR016024:ARM-type_fold,				SM00543:MIF4G,SM00544:MA3,	KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,KW-0747~Spliceosome,					KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:MI,DOMAIN:MIF4G,MUTAGEN:G->Y: No effect on EIF4A3 incorporation into EJCs.,MUTAGEN:NK->DE: Loss of EIF4A3-binding.,MUTAGEN:NKVN->AAVA: Loss of EIF4A3-binding.,MUTAGEN:R->A: Decreased EIF4A3-binding; when associated with A-334.,MUTAGEN:Y->A: Decreased EIF4A3-binding; when associated with A-331.,REGION:Disordered,
CXXC1	CXXC finger protein 1(CXXC1)	Homo sapiens			GO:0006355~regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0016363~nuclear matrix,GO:0016607~nuclear speck,GO:0035097~histone methyltransferase complex,GO:0048188~Set1C/COMPASS complex,	GO:0000987~core promoter proximal region sequence-specific DNA binding,GO:0003677~DNA binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0035064~methylated histone binding,GO:0045322~unmethylated CpG binding,GO:0046872~metal ion binding,	IPR001965:Znf_PHD,IPR002857:Znf_CXXC,IPR011011:Znf_FYVE_PHD,IPR013083:Znf_RING/FYVE/PHD,IPR019786:Zinc_finger_PHD-type_CS,IPR019787:Znf_PHD-finger,IPR022056:CpG-bd_C,IPR037869:Spp1/CFP1,				SM00249:PHD,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0175~Coiled coil,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:CXXC-type,DOMAIN:PHD-type,MUTAGEN:C->A: Complete loss of DNA binding activity. No effect on localization in nuclear speckles.,REGION:Disordered,ZN_FING:CXXC-type,ZN_FING:PHD-type,
CYLD	CYLD lysine 63 deubiquitinase(CYLD)	Homo sapiens			GO:0006508~proteolysis,GO:0007049~cell cycle,GO:0007346~regulation of mitotic cell cycle,GO:0010803~regulation of tumor necrosis factor-mediated signaling pathway,GO:0016055~Wnt signaling pathway,GO:0016579~protein deubiquitination,GO:0032088~negative regulation of NF-kappaB transcription factor activity,GO:0032480~negative regulation of type I interferon production,GO:0035872~nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway,GO:0043369~CD4-positive or CD8-positive, alpha-beta T cell lineage commitment,GO:0045087~innate immune response,GO:0045577~regulation of B cell differentiation,GO:0045582~positive regulation of T cell differentiation,GO:0046329~negative regulation of JNK cascade,GO:0048872~homeostasis of number of cells,GO:0050727~regulation of inflammatory response,GO:0050728~negative regulation of inflammatory response,GO:0050862~positive regulation of T cell receptor signaling pathway,GO:0060544~regulation of necroptotic process,GO:0070266~necroptotic process,GO:0070423~nucleotide-binding oligomerization domain containing signaling pathway,GO:0070507~regulation of microtubule cytoskeleton organization,GO:0070536~protein K63-linked deubiquitination,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:1901026~ripoptosome assembly involved in necroptotic process,GO:1901223~negative regulation of NIK/NF-kappaB signaling,GO:1902017~regulation of cilium assembly,GO:1903753~negative regulation of p38MAPK cascade,GO:1903829~positive regulation of cellular protein localization,GO:1990108~protein linear deubiquitination,GO:2000493~negative regulation of interleukin-18-mediated signaling pathway,GO:2001238~positive regulation of extrinsic apoptotic signaling pathway,GO:2001242~regulation of intrinsic apoptotic signaling pathway,	GO:0005813~centrosome,GO:0005819~spindle,GO:0005829~cytosol,GO:0005874~microtubule,GO:0005881~cytoplasmic microtubule,GO:0005886~plasma membrane,GO:0009898~cytoplasmic side of plasma membrane,GO:0030496~midbody,GO:0036064~ciliary basal body,GO:0042995~cell projection,GO:0048471~perinuclear region of cytoplasm,GO:0097542~ciliary tip,	GO:0004843~thiol-dependent ubiquitin-specific protease activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0019901~protein kinase binding,GO:0061578~Lys63-specific deubiquitinase activity,GO:0061815~ubiquitinyl hydrolase activity, acting on linear ubiquitin,GO:0070064~proline-rich region binding,GO:1990380~Lys48-specific deubiquitinase activity,	IPR000938:CAP-Gly_domain,IPR001394:Peptidase_C19_UCH,IPR018200:USP_CS,IPR028889:USP_dom,IPR036859:CAP-Gly_dom_sf,IPR038765:Papain-like_cys_pep_sf,	hsa04064:NF-kappa B signaling pathway,hsa04217:Necroptosis,hsa04380:Osteoclast differentiation,hsa04622:RIG-I-like receptor signaling pathway,hsa04625:C-type lectin receptor signaling pathway,hsa04668:TNF signaling pathway,	132700~Cylindromatosis, familial,601606~Trichoepithelioma, multiple familial, 1,605041~Brooke-Spiegler syndrome,619132~Frontotemporal dementia and/or amyotrophic lateral sclerosis 8,		SM01052:CAP_GLY,	KW-0131~Cell cycle,KW-0391~Immunity,KW-0399~Innate immunity,KW-0833~Ubl conjugation pathway,KW-0879~Wnt signaling pathway,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0493~Microtubule,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-1003~Cell membrane,	KW-0036~Amyotrophic lateral sclerosis,KW-0043~Tumor suppressor,KW-0225~Disease variant,KW-0523~Neurodegeneration,	KW-0677~Repeat,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0378~Hydrolase,KW-0645~Protease,KW-0788~Thiol protease,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	ACT_SITE:Nucleophile,ACT_SITE:Proton acceptor,COMPBIAS:Polar residues,DOMAIN:CAP-Gly,DOMAIN:CAP-Gly 1,DOMAIN:CAP-Gly 2,DOMAIN:CAP-Gly 3,DOMAIN:USP,MUTAGEN:C->A,S: Loss of deubiquitinating activity.,MUTAGEN:H->N: Loss of deubiquitinating activity.,MUTAGEN:L->D: Impaired interaction with SPATA2.,MUTAGEN:S->A: Abolishes binding to TRAF2.,MUTAGEN:S->A: Loss of phosphorylation; when associated with A-418; A-422; A-432; A-436; A-439 and A-441.,MUTAGEN:S->A: Loss of phosphorylation; when associated with A-418; A-422; A-432; A-436; A-439 and A-444.,MUTAGEN:S->A: Loss of phosphorylation; when associated with A-418; A-422; A-432; A-436; A-441 and A-444.,MUTAGEN:S->A: Reduced phosphorylation; when associated with A-418; A-432 and A-436. Loss of phosphorylation; when associated with A-418; A-432; A-436; A-439; A-441 and A-444.,MUTAGEN:S->A: Reduced phosphorylation; when associated with A-422; A-432 and A-436. Loss of phosphorylation; when associated with A-422; A-432; A-436; A-439; A-441 and A-444.,MUTAGEN:S->A: Slightly reduced phosphorylation; when associated with A-432. Reduced phosphorylation; when associated with A-418; A-422 and A-432. Loss of phosphorylation; when associated with A-418; A-422; A-432; A-439; A-441 and A-444.,MUTAGEN:S->A: Slightly reduced phosphorylation; when associated with A-436. Reduced phosphorylation; when associated with A-418; A-422 and A-436. Loss of phosphorylation; when associated with A-418; A-422; A-436; A-439; A-441 and A-444.,MUTAGEN:S->E: Abolishes deubiquitination of TRAF2; when associated with E-418; E-422; E-432; E-436; E-439 and E-441.,MUTAGEN:S->E: Abolishes deubiquitination of TRAF2; when associated with E-418; E-422; E-432; E-436; E-439 and E-444.,MUTAGEN:S->E: Abolishes deubiquitination of TRAF2; when associated with E-418; E-422; E-432; E-436; E-441 and E-444.,MUTAGEN:S->E: Abolishes deubiquitination of TRAF2; when associated with E-418; E-422; E-432; E-439; E-441 and E-444.,MUTAGEN:S->E: Abolishes deubiquitination of TRAF2; when associated with E-418; E-422; E-436; E-439; E-441 and E-444.,MUTAGEN:S->E: Abolishes deubiquitination of TRAF2; when associated with E-418; E-432; E-436; E-439; E-441 and E-444.,MUTAGEN:S->E: Abolishes deubiquitination of TRAF2; when associated with E-422; E-432; E-436; E-439; E-441 and E-444.,REGION:B-box,REGION:Disordered,REGION:Interaction with IKBKG/NEMO,REGION:Interaction with TRAF2,REGION:Interaction with TRIP,
CBLB	Cbl proto-oncogene B(CBLB)	Homo sapiens			GO:0002669~positive regulation of T cell anergy,GO:0002870~T cell anergy,GO:0006607~NLS-bearing protein import into nucleus,GO:0006955~immune response,GO:0007165~signal transduction,GO:0007166~cell surface receptor signaling pathway,GO:0007175~negative regulation of epidermal growth factor-activated receptor activity,GO:0016567~protein ubiquitination,GO:0023051~regulation of signaling,GO:0030163~protein catabolic process,GO:0031398~positive regulation of protein ubiquitination,GO:0035556~intracellular signal transduction,GO:0035739~CD4-positive, alpha-beta T cell proliferation,GO:0045732~positive regulation of protein catabolic process,GO:0050852~T cell receptor signaling pathway,GO:0050860~negative regulation of T cell receptor signaling pathway,GO:2000562~negative regulation of CD4-positive, alpha-beta T cell proliferation,GO:2000583~regulation of platelet-derived growth factor receptor-alpha signaling pathway,	GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0045121~membrane raft,	GO:0001784~phosphotyrosine binding,GO:0004842~ubiquitin-protein transferase activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0017124~SH3 domain binding,GO:0030971~receptor tyrosine kinase binding,GO:0061630~ubiquitin protein ligase activity,	IPR001841:Znf_RING,IPR003153:Adaptor_Cbl_N_hlx,IPR009060:UBA-like_sf,IPR011992:EF-hand-dom_pair,IPR013083:Znf_RING/FYVE/PHD,IPR014741:Adaptor_Cbl_EF_hand-like,IPR014742:Adaptor_Cbl_SH2-like,IPR015940:UBA,IPR017907:Znf_RING_CS,IPR018957:Znf_C3HC4_RING-type,IPR024159:Cbl_PTB,IPR024162:Adaptor_Cbl,IPR036537:Adaptor_Cbl_N_dom_sf,IPR036860:SH2_dom_sf,IPR039520:CBL-B_RING-HC,	hsa04012:ErbB signaling pathway,hsa04120:Ubiquitin mediated proteolysis,hsa04144:Endocytosis,hsa04625:C-type lectin receptor signaling pathway,hsa04660:T cell receptor signaling pathway,hsa04910:Insulin signaling pathway,hsa05162:Measles,	620430~Autoimmune disease, multisystem, infantile-onset, 3,		SM00165:UBA,SM00184:RING,	KW-0833~Ubl conjugation pathway,	KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0106~Calcium,KW-0479~Metal-binding,KW-0862~Zinc,	KW-0808~Transferase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Cbl-PTB,DOMAIN:RING-type,DOMAIN:UBA,MUTAGEN:A->E: Loss of ubiquitin binding. Reduced levels of tyrosine phosphorylation.,MUTAGEN:C->A: Abolishes E3 activity but does not affect binding to substrates.,MUTAGEN:F->A: Loss of ubiquitin binding. Reduced levels of tyrosine phosphorylation.,MUTAGEN:G->E: Inhibits interaction with SYK. No effect on E3 activity.,MUTAGEN:GY->AQ: Abolishes interaction with ubiquitinated proteins.,MUTAGEN:I->E: Interferes with dimerization. Reduced E3 ubiquitin-protein ligase activity. Reduced levels of tyrosine phosphorylation.,MUTAGEN:K->A: No effect on interaction with SH3KBP1. Reduced interaction with CD2AP. Strongly reduced interaction with CD2AP; when associated with A-911.,MUTAGEN:L->A: No effect on interaction with ubiquitinated proteins.,MUTAGEN:M->A: Loss of ubiquitin binding. Reduced levels of tyrosine phosphorylation.,MUTAGEN:R->A: No effect on interaction with CD2AP. Reduced interaction with SH3KBP1. Strongly reduced interaction with SH3KBP1; when associated with A-911.,MUTAGEN:R->A: Reduced interaction with CD2AP and with SH3KBP1. Strongly reduced interaction with CD2AP; when associated with A-907. Strongly reduced interaction with SH3KBP1; when associated with A-904.,MUTAGEN:Y->E: Decreases affinity for E2 ubiquitin-conjugating enzymes.,MUTAGEN:Y->F: Inhibits interaction with CRKL. Abolishes interaction with CRKL; when associated with F-665.,MUTAGEN:Y->F: Slightly inhibits interaction with CRKL. Abolishes interaction with CRKL; when associated with F-709.,REGION:4H,REGION:Disordered,REGION:EF-hand-like,REGION:Interaction with SH3KBP1,REGION:Interaction with VAV1,REGION:Linker,REGION:SH2-like,ZN_FING:RING-type,
DCAF13	DDB1 and CUL4 associated factor 13(DCAF13)	Homo sapiens			GO:0000462~maturation of SSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA),GO:0001555~oocyte growth,GO:0006364~rRNA processing,GO:0007056~spindle assembly involved in female meiosis,GO:0016567~protein ubiquitination,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0044725~chromatin reprogramming in the zygote,GO:0046697~decidualization,	GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005813~centrosome,GO:0005829~cytosol,GO:0030054~cell junction,GO:0032040~small-subunit processome,GO:0080008~Cul4-RING E3 ubiquitin ligase complex,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0030331~estrogen receptor binding,GO:1990756~protein binding, bridging involved in substrate recognition for ubiquitination,	IPR001680:WD40_rpt,IPR007287:Sof1,IPR013979:TIF_beta_prop-like,IPR015943:WD40/YVTN_repeat-like_dom_sf,IPR019775:WD40_repeat_CS,IPR036322:WD40_repeat_dom_sf,				SM00320:WD40,	KW-0690~Ribosome biogenesis,KW-0698~rRNA processing,KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,		KW-0677~Repeat,KW-0853~WD repeat,		KW-0687~Ribonucleoprotein,	KW-0007~Acetylation,	COMPBIAS:Pro residues,DOMAIN:Sof1-like protein,DOMAIN:Translation initiation factor beta propellor-like,REGION:Disordered,REGION:Required for nucleolar location,REPEAT:WD,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,REPEAT:WD 7,
DDRGK1	DDRGK domain containing 1(DDRGK1)	Homo sapiens			GO:0008284~positive regulation of cell proliferation,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0030335~positive regulation of cell migration,GO:0031647~regulation of protein stability,GO:0032435~negative regulation of proteasomal ubiquitin-dependent protein catabolic process,GO:0032436~positive regulation of proteasomal ubiquitin-dependent protein catabolic process,GO:0033146~regulation of intracellular estrogen receptor signaling pathway,GO:0034976~response to endoplasmic reticulum stress,GO:0043066~negative regulation of apoptotic process,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0051216~cartilage development,GO:0061709~reticulophagy,GO:0070972~protein localization to endoplasmic reticulum,GO:0071569~protein ufmylation,GO:1901800~positive regulation of proteasomal protein catabolic process,GO:1902808~positive regulation of cell cycle G1/S phase transition,GO:1903721~positive regulation of I-kappaB phosphorylation,GO:1903895~negative regulation of IRE1-mediated unfolded protein response,GO:1905050~positive regulation of metallopeptidase activity,GO:1905552~positive regulation of protein localization to endoplasmic reticulum,GO:1905636~positive regulation of RNA polymerase II regulatory region sequence-specific DNA binding,GO:1990592~protein K69-linked ufmylation,	GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,	GO:0005515~protein binding,GO:0044389~ubiquitin-like protein ligase binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,	IPR019153:DDRGK_dom-contain,IPR036388:WH-like_DNA-bd_sf,IPR036390:WH_DNA-bd_sf,		602557~Spondyloepimetaphyseal dysplasia, Shohat type,		SM01128:DDRGK,	KW-0833~Ubl conjugation pathway,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,	KW-0242~Dwarfism,	KW-0732~Signal,			KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in UFM1),DOMAIN:PCI,MUTAGEN:K->R: Impairs interaction with UFL1 and ufmylation. Impairs interaction with ERN1/IRE1-alpha and ability to regulate its stability. Does not affect ability to promote reticulophagy. Impairs some post-translational modification without affecting interaction with UFL1; when associated with 116-R--R-128, R-146, R-176, R-193, 224-R--R-227 and R-267.,MUTAGEN:K->R: Impairs some post-translational modification without affecting interaction with UFL1; when associated with 116-R--R-128, R-146, R-193, 224-R--R-227 and R-267.,MUTAGEN:K->R: Impairs some post-translational modification without affecting interaction with UFL1; when associated with 116-R--R-128, R-176, R-193, 224-R--R-227 and R-267.,MUTAGEN:K->R: Weak or no effect on ufmylation.,MUTAGEN:K->R: Weak or no effect on ufmylation. Impairs some post-translational modification without affecting interaction with UFL1; when associated with 116-R--R-128, R-146, R-176, 224-R--R-227 and R-267.,MUTAGEN:KIGAKKLRKLEEK->RIGARRLRRLEER: Impairs some post-translational modification without affecting interaction with UFL1; when associated with R-146, R-176, R-193, 224-R--R-227 and R-267.,MUTAGEN:KQSK->RQSR: Impairs some post-translational modification without affecting interaction with UFL1; when associated with 116-R--R-128, R-146, R-176, R-193 and R-267.,REGION:Disordered,REGION:Mediates interaction with CDK5RAP3,REGION:Mediates interaction with TRIP4,REGION:Mediates interaction with UFL1,
DDX17	DEAD-box helicase 17(DDX17)	Homo sapiens			GO:0000380~alternative mRNA splicing, via spliceosome,GO:0000381~regulation of alternative mRNA splicing, via spliceosome,GO:0001837~epithelial to mesenchymal transition,GO:0002376~immune system process,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006364~rRNA processing,GO:0006396~RNA processing,GO:0010586~miRNA metabolic process,GO:0030520~intracellular estrogen receptor signaling pathway,GO:0030521~androgen receptor signaling pathway,GO:0031047~gene silencing by RNA,GO:0045445~myoblast differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051607~defense response to virus,GO:2001014~regulation of skeletal muscle cell differentiation,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016020~membrane,GO:0016607~nuclear speck,GO:1990904~ribonucleoprotein complex,	GO:0003676~nucleic acid binding,GO:0003713~transcription coactivator activity,GO:0003723~RNA binding,GO:0003724~RNA helicase activity,GO:0003730~mRNA 3'-UTR binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008186~RNA-dependent ATPase activity,GO:0016787~hydrolase activity,GO:0016887~ATPase activity,GO:0043021~ribonucleoprotein complex binding,	IPR000629:RNA-helicase_DEAD-box_CS,IPR001650:Helicase_C,IPR011545:DEAD/DEAH_box_helicase_dom,IPR014001:Helicase_ATP-bd,IPR014014:RNA_helicase_DEAD_Q_motif,IPR027417:P-loop_NTPase,IPR046330:DDX17_ATP-bd-dom,				SM00487:DEXDc,SM00490:HELICc,	KW-0051~Antiviral defense,KW-0391~Immunity,KW-0507~mRNA processing,KW-0508~mRNA splicing,KW-0698~rRNA processing,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0943~RNA-mediated gene silencing,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0732~Signal,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0347~Helicase,KW-0378~Hydrolase,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:DEAD-box RNA helicase Q,DOMAIN:Helicase ATP-binding,DOMAIN:Helicase C-terminal,MOTIF:DEAD box,MOTIF:Q motif,MUTAGEN:D->H: Small decrease in CD44 alternative splicing.,MUTAGEN:D->N: Loss of helicase activity. No effect on ESR1 coactivation.,MUTAGEN:K->N: No effect on transcription activation, when assayed in luciferase reporter gene assays using MDM2 or FOS promoters, either alone or in the presence of EP300 and KAT2B.,MUTAGEN:K->R: Impaired sumoylation and decreased stability. Impairs interaction with HDAC1, but not with HDAC2, nor HDAC3. No effect on EP300-, ESR1-, DDX5- and YAP1-binding.,MUTAGEN:K->R: Loss of helicase activity. Loss of splicing regulation in the estrogen signaling pathway. Reduced CD44 alternative splicing regulation. Does not promote ZCH3HAV1-mediated RNA degradation.,MUTAGEN:K->R: No effect on HDAC1-, HDAC2- nor HDAC3-binding, decreased ESR1 coactivation, strongly decreased TP53 coactivation. Complete loss of lysine acetylation, decreased stability, loss of ESR1 and TP53 coactivation and loss of HDAC1- and HDAC3-binding, no effect on HDAC2-binding; when associated with 108-R-R-109.,MUTAGEN:KK->RR: No effect on HDAC1-, HDAC2- nor HDAC3-binding, small decrease in ESR1 coactivation, decreased TP53 coactivation. Complete loss of lysine acetylation, decreased stability, loss of ESR1 and TP53 coactivation and loss of HDAC1- and HDAC3-binding, no effect on HDAC2-binding; when associated with R-121.,MUTAGEN:S->L: Small decrease in CD44 alternative splicing.,MUTAGEN:T->A: Decreased CD44 alternative splicing.,MUTAGEN:W->G: Small decrease in CD44 alternative splicing.,REGION:Disordered,REGION:Interaction with YAP1,REGION:Transactivation domain,
DDX18	DEAD-box helicase 18(DDX18)	Homo sapiens			GO:0000463~maturation of LSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA),	GO:0005694~chromosome,GO:0005730~nucleolus,GO:0016020~membrane,	GO:0003723~RNA binding,GO:0003724~RNA helicase activity,GO:0004386~helicase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016787~hydrolase activity,GO:0016887~ATPase activity,	IPR000629:RNA-helicase_DEAD-box_CS,IPR001650:Helicase_C,IPR011545:DEAD/DEAH_box_helicase_dom,IPR014001:Helicase_ATP-bd,IPR025313:DUF4217,IPR027417:P-loop_NTPase,IPR044773:DDX18/Has1_DEADc,				SM00487:DEXDc,SM00490:HELICc,SM01178:DUF4217,		KW-0158~Chromosome,KW-0539~Nucleus,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0347~Helicase,KW-0378~Hydrolase,KW-0694~RNA-binding,		COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Helicase ATP-binding,DOMAIN:Helicase C-terminal,MOTIF:DEAD box,MOTIF:Q motif,REGION:Disordered,
DDX23	DEAD-box helicase 23(DDX23)	Homo sapiens			GO:0000354~cis assembly of pre-catalytic spliceosome,GO:0000375~RNA splicing, via transesterification reactions,GO:0000398~mRNA splicing, via spliceosome,GO:0008380~RNA splicing,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005682~U5 snRNP,GO:0005730~nucleolus,GO:0046540~U4/U6 x U5 tri-snRNP complex,GO:0070062~extracellular exosome,GO:0071013~catalytic step 2 spliceosome,	GO:0003676~nucleic acid binding,GO:0003723~RNA binding,GO:0003724~RNA helicase activity,GO:0003729~mRNA binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016787~hydrolase activity,GO:0016887~ATPase activity,	IPR000629:RNA-helicase_DEAD-box_CS,IPR001650:Helicase_C,IPR011545:DEAD/DEAH_box_helicase_dom,IPR014001:Helicase_ATP-bd,IPR014014:RNA_helicase_DEAD_Q_motif,IPR027417:P-loop_NTPase,	hsa03040:Spliceosome,			SM00487:DEXDc,SM00490:HELICc,	KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0158~Chromosome,KW-0539~Nucleus,KW-0747~Spliceosome,		KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0347~Helicase,KW-0378~Hydrolase,KW-0694~RNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:DEAD-box RNA helicase Q,DOMAIN:Helicase ATP-binding,DOMAIN:Helicase C-terminal,MOTIF:DEAD box,MOTIF:Q motif,REGION:Disordered,
DDX24	DEAD-box helicase 24(DDX24)	Homo sapiens			GO:0016070~RNA metabolic process,	GO:0005730~nucleolus,GO:0016020~membrane,	GO:0003723~RNA binding,GO:0003724~RNA helicase activity,GO:0004386~helicase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016787~hydrolase activity,GO:0016887~ATPase activity,	IPR000629:RNA-helicase_DEAD-box_CS,IPR001650:Helicase_C,IPR011545:DEAD/DEAH_box_helicase_dom,IPR014001:Helicase_ATP-bd,IPR014014:RNA_helicase_DEAD_Q_motif,IPR027417:P-loop_NTPase,				SM00487:DEXDc,SM00490:HELICc,					KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0347~Helicase,KW-0378~Hydrolase,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:DEAD-box RNA helicase Q,DOMAIN:Helicase ATP-binding,DOMAIN:Helicase C-terminal,MOTIF:DEAD box,MOTIF:Q motif,REGION:Disordered,
DDX3X	DEAD-box helicase 3 X-linked(DDX3X)	Homo sapiens			GO:0006413~translational initiation,GO:0007059~chromosome segregation,GO:0007276~gamete generation,GO:0008625~extrinsic apoptotic signaling pathway via death domain receptors,GO:0009615~response to virus,GO:0010501~RNA secondary structure unwinding,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0016055~Wnt signaling pathway,GO:0017148~negative regulation of translation,GO:0030154~cell differentiation,GO:0030307~positive regulation of cell growth,GO:0030308~negative regulation of cell growth,GO:0031333~negative regulation of protein complex assembly,GO:0031954~positive regulation of protein autophosphorylation,GO:0032481~positive regulation of type I interferon production,GO:0032508~DNA duplex unwinding,GO:0032727~positive regulation of interferon-alpha production,GO:0032728~positive regulation of interferon-beta production,GO:0034063~stress granule assembly,GO:0034157~positive regulation of toll-like receptor 7 signaling pathway,GO:0034161~positive regulation of toll-like receptor 8 signaling pathway,GO:0035556~intracellular signal transduction,GO:0036493~positive regulation of translation in response to endoplasmic reticulum stress,GO:0042256~mature ribosome assembly,GO:0043065~positive regulation of apoptotic process,GO:0043066~negative regulation of apoptotic process,GO:0043154~negative regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0043280~positive regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0045070~positive regulation of viral genome replication,GO:0045087~innate immune response,GO:0045727~positive regulation of translation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0045948~positive regulation of translational initiation,GO:0055088~lipid homeostasis,GO:0071243~cellular response to arsenic-containing substance,GO:0071470~cellular response to osmotic stress,GO:0071651~positive regulation of chemokine (C-C motif) ligand 5 production,GO:0071902~positive regulation of protein serine/threonine kinase activity,GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:0097193~intrinsic apoptotic signaling pathway,GO:0098586~cellular response to virus,GO:1900087~positive regulation of G1/S transition of mitotic cell cycle,GO:1900227~positive regulation of NLRP3 inflammasome complex assembly,GO:1901223~negative regulation of NIK/NF-kappaB signaling,GO:1901224~positive regulation of NIK/NF-kappaB signaling,GO:1901985~positive regulation of protein acetylation,GO:1902042~negative regulation of extrinsic apoptotic signaling pathway via death domain receptors,GO:1902523~positive regulation of protein K63-linked ubiquitination,GO:1903608~protein localization to cytoplasmic stress granule,GO:2001243~negative regulation of intrinsic apoptotic signaling pathway,	GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005829~cytosol,GO:0005852~eukaryotic translation initiation factor 3 complex,GO:0005886~plasma membrane,GO:0010494~cytoplasmic stress granule,GO:0016020~membrane,GO:0022627~cytosolic small ribosomal subunit,GO:0030027~lamellipodium,GO:0031252~cell leading edge,GO:0034774~secretory granule lumen,GO:0043186~P granule,GO:0070062~extracellular exosome,GO:0072559~NLRP3 inflammasome complex,GO:1904813~ficolin-1-rich granule lumen,	GO:0003676~nucleic acid binding,GO:0003677~DNA binding,GO:0003678~DNA helicase activity,GO:0003723~RNA binding,GO:0003724~RNA helicase activity,GO:0003729~mRNA binding,GO:0003924~GTPase activity,GO:0004386~helicase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008134~transcription factor binding,GO:0008143~poly(A) binding,GO:0008190~eukaryotic initiation factor 4E binding,GO:0016787~hydrolase activity,GO:0016887~ATPase activity,GO:0017111~nucleoside-triphosphatase activity,GO:0031369~translation initiation factor binding,GO:0033592~RNA strand annealing activity,GO:0035591~signaling adaptor activity,GO:0035613~RNA stem-loop binding,GO:0043015~gamma-tubulin binding,GO:0043024~ribosomal small subunit binding,GO:0043273~CTPase activity,GO:0043539~protein serine/threonine kinase activator activity,GO:0045296~cadherin binding,GO:0048027~mRNA 5'-UTR binding,	IPR000629:RNA-helicase_DEAD-box_CS,IPR001650:Helicase_C,IPR011545:DEAD/DEAH_box_helicase_dom,IPR014001:Helicase_ATP-bd,IPR014014:RNA_helicase_DEAD_Q_motif,IPR027417:P-loop_NTPase,	hsa04622:RIG-I-like receptor signaling pathway,hsa05161:Hepatitis B,hsa05203:Viral carcinogenesis,	300958~Intellectual developmental disorder, X-linked syndromic, Snijders Blok type,		SM00487:DEXDc,SM00490:HELICc,	KW-0053~Apoptosis,KW-0159~Chromosome partition,KW-0391~Immunity,KW-0399~Innate immunity,KW-0690~Ribosome biogenesis,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0810~Translation regulation,KW-0945~Host-virus interaction,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-1003~Cell membrane,KW-1271~Inflammasome,	KW-0225~Disease variant,KW-0991~Intellectual disability,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0238~DNA-binding,KW-0347~Helicase,KW-0378~Hydrolase,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:DEAD-box RNA helicase Q,DOMAIN:Helicase ATP-binding,DOMAIN:Helicase C-terminal,MOTIF:DEAD box,MOTIF:Nuclear export signal,MOTIF:Q motif,MUTAGEN:D->A: No effect on general translation; when associated with A-200; A-207; A-230 and A-348.,MUTAGEN:DEAD->AEAA: Loss of ATPase activity.,MUTAGEN:E->A: No effect on general translation; when associated with A-200; A-207; A-230 and A-347.,MUTAGEN:E->Q: Loss of both ATPase and RNA helicase activities; decreased up-regulation of CDKN1A promoter activity and HNF4A-mediated MTTP transcriptional activation; no effect on the repression of cap- and IRES-dependent translation, WNT/beta catenin signaling, nor on stress granule assembly. Does not promote the translation of HIV-1 RNA.,MUTAGEN:FF->AA: Loss of interaction with VACV protein K7, IRF3 activation and IFNB1 promoter induction.,MUTAGEN:K->A: No effect on general translation; when associated with A-200; A-207; A-347 and A-348.,MUTAGEN:K->E: Complete loss of ATPase and RNA-unwinding activities. Loss of HIV-1 mRNA nuclear export. Does not promote the translation of HIV-1 RNA. No effect on IFNB1 induction. No effect on RNA-binding. Loss of inhibition of NF-kappa-B-mediated transcriptional activity.,MUTAGEN:L->A: Impaired interaction with EIF4E; decreased repression of cap-dependent translation. Fails to induce stress granule assembly and to rescue cell viability after stress. No effect on translation of HIV-1 RNA; when associated with A-38.,MUTAGEN:LDL->ADA: Impairs nuclear export and interaction with XPO1/CMR1.,MUTAGEN:LDQQFAGLDL->ADQQAAGADA: Impairs nuclear export and interaction with XPO1/CMR1.,MUTAGEN:PSE->ASA: Loss of interaction with TRAF3, reduced TRAF3 'K-63'-linked autoubiquitination.,MUTAGEN:Q->A: Does not promote the translation of HIV-1 RNA. No effect on general translation; when associated with A-200; A-230: A-347 and A-348.,MUTAGEN:S->A: Greatly impairs phosphorylation by TBK1 and fails to synergize with TBK1 in IFN-beta induction; when associated with A-181; A-183 and A-240.,MUTAGEN:S->A: Greatly impairs phosphorylation by TBK1 and fails to synergize with TBK1 in IFN-beta induction; when associated with A-181; A-183 and A-269.,MUTAGEN:S->A: Greatly impairs phosphorylation by TBK1 and fails to synergize with TBK1 in IFN-beta induction; when associated with A-181; A-240 and A-269.,MUTAGEN:S->A: Greatly impairs phosphorylation by TBK1 and fails to synergize with TBK1 in IFNB1 induction; when associated with A-183; A-240 and A-269.,MUTAGEN:S->A: Impairs phosphorylation by TBK1 and fails to synergize with TBK1 in IFN-beta induction; when associated with A-429; A-438; A-442 and A-456.,MUTAGEN:S->A: Impairs phosphorylation by TBK1 and fails to synergize with TBK1 in IFN-beta induction; when associated with A-429; A-438; A-442 and A-520.,MUTAGEN:S->A: Impairs phosphorylation by TBK1 and fails to synergize with TBK1 in IFN-beta induction; when associated with A-429; A-438; A-456 and A-520.,MUTAGEN:S->A: Impairs phosphorylation by TBK1 and fails to synergize with TBK1 in IFN-beta induction; when associated with A-438; A-442; A-456 and A-520.,MUTAGEN:S->A: Reduces total phosphorylation by 30%. Abolishes interaction with IRF3 and fails to enhance IFNB promoter induction. No effect on interaction with IKBKE.,MUTAGEN:S->A: Reduces total phosphorylation by 60%. No effect on interaction with IKBKE.,MUTAGEN:S->D: Interacts with IRF3 and enhances IFNB promoter induction.,MUTAGEN:S->L: Strong decrease in ATPase activity and RNA-unwinding activity. Does not promote the translation of mRNAs containing long structured 5'UTRs, including that of CCNE1. No effect on the translation of HIV-1 RNA.,MUTAGEN:SAT->AAA: Loss of RNA helicase, but not ATPase activity; no effect on the repression of cap- and IRES-dependent translation, WNT/beta catenin signaling, up-regulation of CDKN1A promoter activity, HNF4A-mediated MTTP transcriptional activation, nor on stress granule assembly.,MUTAGEN:SS->AA: Reduces total phosphorylation by 50%. No effect on interaction with IKBKE.,MUTAGEN:T->A: Impairs phosphorylation by TBK1 and fails to synergize with TBK1 in IFN-beta induction; when associated with A-429; A-442; A-456 and A-520.,MUTAGEN:TRE->RRV: Increased NF-kappa-B-mediated transcriptional activity, contrary to wild-type which is inhibitory in this experimental setting.,MUTAGEN:Y->A: Impaired interaction with EIF4E; impaired stress granule formation, decreased repression of cap-dependent translation and decreased ability to enhance IRES-mediated translation. No effect on translation of HIV-1 RNA; when associated with A-43.,MUTAGEN:Y->A: No effect on general translation; when associated with A-207; A-230; A-347 and A-348.,REGION:Disordered,REGION:Interaction with CHUK,REGION:Interaction with EIF4E,REGION:Interaction with GSK3B,REGION:Interaction with HCV core protein,REGION:Interaction with IKBKE,REGION:Interaction with NXF1,REGION:Interaction with VACV protein K7,REGION:Involved in binding to RNA G-quadruplex,REGION:Involved in stimulation of ATPase activity by DNA and RNA, nucleic acid binding and unwinding and HIV-1 replication,REGION:Required for TBK1 and IKBKE-dependent IFNB1 activation,TRANSMEM:Helical,
DDX46	DEAD-box helicase 46(DDX46)	Homo sapiens			GO:0000398~mRNA splicing, via spliceosome,GO:1903241~U2-type prespliceosome assembly,	GO:0001650~fibrillar center,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005681~spliceosomal complex,GO:0005684~U2-type spliceosomal complex,GO:0005686~U2 snRNP,GO:0015030~Cajal body,GO:0016020~membrane,GO:0016607~nuclear speck,	GO:0003676~nucleic acid binding,GO:0003723~RNA binding,GO:0003724~RNA helicase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016787~hydrolase activity,GO:0016887~ATPase activity,	IPR000629:RNA-helicase_DEAD-box_CS,IPR001650:Helicase_C,IPR011545:DEAD/DEAH_box_helicase_dom,IPR014001:Helicase_ATP-bd,IPR014014:RNA_helicase_DEAD_Q_motif,IPR027417:P-loop_NTPase,	hsa03040:Spliceosome,			SM00487:DEXDc,SM00490:HELICc,	KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,KW-0747~Spliceosome,		KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0347~Helicase,KW-0378~Hydrolase,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0449~Lipoprotein,KW-0519~Myristate,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:DEAD-box RNA helicase Q,DOMAIN:Helicase ATP-binding,DOMAIN:Helicase C-terminal,LIPID:N-myristoyl glycine,MOTIF:DEAD box,MOTIF:Q motif,REGION:Disordered,
DDX5	DEAD-box helicase 5(DDX5)	Homo sapiens		h_akap95Pathway:AKAP95 role in mitosis and chromosome dynamics,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0000380~alternative mRNA splicing, via spliceosome,GO:0000381~regulation of alternative mRNA splicing, via spliceosome,GO:0000398~mRNA splicing, via spliceosome,GO:0000956~nuclear-transcribed mRNA catabolic process,GO:0001837~epithelial to mesenchymal transition,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0008380~RNA splicing,GO:0009299~mRNA transcription,GO:0030509~BMP signaling pathway,GO:0030520~intracellular estrogen receptor signaling pathway,GO:0030521~androgen receptor signaling pathway,GO:0031053~primary miRNA processing,GO:0043517~positive regulation of DNA damage response, signal transduction by p53 class mediator,GO:0045069~regulation of viral genome replication,GO:0045445~myoblast differentiation,GO:0045667~regulation of osteoblast differentiation,GO:0048511~rhythmic process,GO:0060765~regulation of androgen receptor signaling pathway,GO:0061614~pri-miRNA transcription from RNA polymerase II promoter,GO:0072332~intrinsic apoptotic signaling pathway by p53 class mediator,GO:2001014~regulation of skeletal muscle cell differentiation,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005681~spliceosomal complex,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016020~membrane,GO:0016607~nuclear speck,GO:0070062~extracellular exosome,GO:0071013~catalytic step 2 spliceosome,GO:1990904~ribonucleoprotein complex,	GO:0003676~nucleic acid binding,GO:0003723~RNA binding,GO:0003724~RNA helicase activity,GO:0003730~mRNA 3'-UTR binding,GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0005524~ATP binding,GO:0016787~hydrolase activity,GO:0016887~ATPase activity,GO:0019899~enzyme binding,GO:0035500~MH2 domain binding,GO:0036002~pre-mRNA binding,GO:0043021~ribonucleoprotein complex binding,GO:0046332~SMAD binding,GO:0048306~calcium-dependent protein binding,GO:0050681~androgen receptor binding,GO:0070412~R-SMAD binding,GO:0070878~primary miRNA binding,GO:1990841~promoter-specific chromatin binding,	IPR000629:RNA-helicase_DEAD-box_CS,IPR001650:Helicase_C,IPR011545:DEAD/DEAH_box_helicase_dom,IPR012587:P68_rpt,IPR014001:Helicase_ATP-bd,IPR014014:RNA_helicase_DEAD_Q_motif,IPR027417:P-loop_NTPase,	hsa03040:Spliceosome,hsa05202:Transcriptional misregulation in cancer,hsa05205:Proteoglycans in cancer,			SM00487:DEXDc,SM00490:HELICc,SM01414:P68HR,	KW-0090~Biological rhythms,KW-0507~mRNA processing,KW-0508~mRNA splicing,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0747~Spliceosome,KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0347~Helicase,KW-0378~Hydrolase,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:DEAD-box RNA helicase Q,DOMAIN:DEAD/DEAH box helicase,DOMAIN:Helicase ATP-binding,DOMAIN:Helicase C-terminal,MOTIF:DEAD box,MOTIF:Q motif,MUTAGEN:E->A: Abolishes sumoylation.,MUTAGEN:K->R: Abolishes RNA helicase activity.,MUTAGEN:K->R: Abolishes sumoylation, abolishes interaction with HDAC1, increases TP53 coactivation and promotes polyubiquitination.,MUTAGEN:R->L: Binds to the tau stem-loop-containing RNA. Inhibits tau exon 10 inclusion and RNA cleavage. Does not inhibit interaction with RBM4.,REGION:Disordered,REGION:Transactivation domain,
DDX54	DEAD-box helicase 54(DDX54)	Homo sapiens			GO:0006364~rRNA processing,GO:0006396~RNA processing,GO:0016070~RNA metabolic process,GO:0030520~intracellular estrogen receptor signaling pathway,GO:0045892~negative regulation of transcription, DNA-templated,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005794~Golgi apparatus,GO:0016020~membrane,	GO:0003676~nucleic acid binding,GO:0003714~transcription corepressor activity,GO:0003723~RNA binding,GO:0003724~RNA helicase activity,GO:0005102~receptor binding,GO:0005524~ATP binding,GO:0016787~hydrolase activity,GO:0016887~ATPase activity,GO:0030331~estrogen receptor binding,	IPR000629:RNA-helicase_DEAD-box_CS,IPR001650:Helicase_C,IPR011545:DEAD/DEAH_box_helicase_dom,IPR012541:DBP10_C,IPR014001:Helicase_ATP-bd,IPR014014:RNA_helicase_DEAD_Q_motif,IPR027417:P-loop_NTPase,IPR033517:DDX54/DBP10_DEAD-box_helicase,				SM00487:DEXDc,SM00490:HELICc,SM01123:DBP10CT,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0347~Helicase,KW-0378~Hydrolase,KW-0694~RNA-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,DOMAIN:DBP10 C-terminal,DOMAIN:DEAD-box RNA helicase Q,DOMAIN:Helicase ATP-binding,DOMAIN:Helicase C-terminal,MOTIF:DEAD box,MOTIF:Q motif,REGION:Disordered,REGION:Interaction with nuclear receptors,
DDX6	DEAD-box helicase 6(DDX6)	Homo sapiens			GO:0017148~negative regulation of translation,GO:0019074~viral RNA genome packaging,GO:0019827~stem cell population maintenance,GO:0030182~neuron differentiation,GO:0033962~cytoplasmic mRNA processing body assembly,GO:0034063~stress granule assembly,GO:0035278~miRNA mediated inhibition of translation,GO:0045665~negative regulation of neuron differentiation,	GO:0000932~P-body,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0010494~cytoplasmic stress granule,GO:0016020~membrane,GO:0016442~RISC complex,GO:0036464~cytoplasmic ribonucleoprotein granule,	GO:0003676~nucleic acid binding,GO:0003723~RNA binding,GO:0003724~RNA helicase activity,GO:0003729~mRNA binding,GO:0004386~helicase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016787~hydrolase activity,GO:0016887~ATPase activity,GO:0019904~protein domain specific binding,GO:0045296~cadherin binding,	IPR000629:RNA-helicase_DEAD-box_CS,IPR001650:Helicase_C,IPR011545:DEAD/DEAH_box_helicase_dom,IPR014001:Helicase_ATP-bd,IPR014014:RNA_helicase_DEAD_Q_motif,IPR027417:P-loop_NTPase,	hsa03018:RNA degradation,	618653~Intellectual developmental disorder with impaired language and dysmorphic facies,		SM00487:DEXDc,SM00490:HELICc,		KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0656~Proto-oncogene,KW-0991~Intellectual disability,		KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0347~Helicase,KW-0378~Hydrolase,KW-0694~RNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,DOMAIN:DEAD-box RNA helicase Q,DOMAIN:Helicase ATP-binding,DOMAIN:Helicase C-terminal,MOTIF:DEAD box,MOTIF:Q motif,MUTAGEN:C->A: In CL-AA; abolishes interaction with PATL1 and reduces interaction with GIGYF1 and GIGYF2, but has no affect on interaction with EDC3, EIF4ENIF1 and LSM14A; when associated with A-328. In 4xmut; abolishes interaction with EDC3; when associated with A-328, A-349 and A-353.,MUTAGEN:E->Q: Abolished helicase activity and ability to regulate RNA metabolism.,MUTAGEN:H->A: Abolishes interaction with EDC3; when associated with A-320; A-327 and A-331.,MUTAGEN:K->A: In LK-AA; abolishes interaction with PATL1 and reduces interaction with GIGYF1, GIGYF2, EDC3, EIF4ENIF1 and LSM14A; when associated with A-349. In 4xmut; abolishes interaction with EDC3; when associated with A-324; A-328 and A-349.,MUTAGEN:L->A: In CL-AA; abolishes interaction with PATL1 and reduces interaction with GIGYF1 and GIGYF2, but has no affect on interaction with EDC3, EIF4ENIF1 and LSM14A; when associated with A-324. In 4xmut; abolishes interaction with EDC3; when associated with A-324, A-349 and A-353.,MUTAGEN:L->A: In LK-AA; abolishes interaction with PATL1 and reduces interaction with GIGYF1, GIGYF2, EDC3, EIF4ENIF1 and LSM14A; when associated with A-353. In 4xmut; abolishes interaction with EDC3; when associated with A-324, A-328 and A-353.,MUTAGEN:Q->A: Abolishes interaction with EDC3; when associated with A-323; A-327 and A-331.,MUTAGEN:R->A: Abolishes interaction with EDC3; when associated with A-320; A-323 and A-327.,MUTAGEN:R->E: Abolished ability to regulate RNA metabolism.,MUTAGEN:T->A: Abolishes interaction with EDC3; when associated with A-320; A-323 and A-331.,REGION:Disordered,REGION:Gyf binding,REGION:RecA-like domain 2,
DHX36	DEAH-box helicase 36(DHX36)	Homo sapiens			GO:0001503~ossification,GO:0002735~positive regulation of myeloid dendritic cell cytokine production,GO:0006359~regulation of transcription from RNA polymerase III promoter,GO:0007283~spermatogenesis,GO:0010501~RNA secondary structure unwinding,GO:0010628~positive regulation of gene expression,GO:0017148~negative regulation of translation,GO:0030154~cell differentiation,GO:0031442~positive regulation of mRNA 3'-end processing,GO:0032206~positive regulation of telomere maintenance,GO:0032508~DNA duplex unwinding,GO:0032727~positive regulation of interferon-alpha production,GO:0034605~cellular response to heat,GO:0034644~cellular response to UV,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043330~response to exogenous dsRNA,GO:0043488~regulation of mRNA stability,GO:0044806~G-quadruplex DNA unwinding,GO:0045087~innate immune response,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0045995~regulation of embryonic development,GO:0051607~defense response to virus,GO:0051891~positive regulation of cardioblast differentiation,GO:0060261~positive regulation of transcription initiation from RNA polymerase II promoter,GO:0061003~positive regulation of dendritic spine morphogenesis,GO:0061158~3'-UTR-mediated mRNA destabilization,GO:0090669~telomerase RNA stabilization,GO:1900153~positive regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay,GO:1901534~positive regulation of hematopoietic progenitor cell differentiation,GO:1903843~cellular response to arsenite ion,GO:1904358~positive regulation of telomere maintenance via telomere lengthening,GO:1904582~positive regulation of intracellular mRNA localization,GO:2000767~positive regulation of cytoplasmic translation,	GO:0000781~chromosome, telomeric region,GO:0005622~intracellular,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0010494~cytoplasmic stress granule,GO:0016020~membrane,GO:0016607~nuclear speck,GO:0030424~axon,GO:0030425~dendrite,GO:0043204~perikaryon,GO:0070062~extracellular exosome,	GO:0000287~magnesium ion binding,GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0002151~G-quadruplex RNA binding,GO:0003676~nucleic acid binding,GO:0003678~DNA helicase activity,GO:0003697~single-stranded DNA binding,GO:0003723~RNA binding,GO:0003724~RNA helicase activity,GO:0003725~double-stranded RNA binding,GO:0003730~mRNA 3'-UTR binding,GO:0004386~helicase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008094~DNA-dependent ATPase activity,GO:0016787~hydrolase activity,GO:0016887~ATPase activity,GO:0035925~mRNA 3'-UTR AU-rich region binding,GO:0042826~histone deacetylase binding,GO:0048027~mRNA 5'-UTR binding,GO:0051880~G-quadruplex DNA binding,GO:0070034~telomerase RNA binding,GO:0070883~pre-miRNA binding,	IPR001650:Helicase_C,IPR002464:DNA/RNA_helicase_DEAH_CS,IPR007502:Helicase-assoc_dom,IPR011545:DEAD/DEAH_box_helicase_dom,IPR011709:DEAD-box_helicase_OB_fold,IPR014001:Helicase_ATP-bd,IPR027417:P-loop_NTPase,IPR048333:HA2_WH,	hsa03018:RNA degradation,			SM00487:DEXDc,SM00490:HELICc,SM00847:HA2,	KW-0051~Antiviral defense,KW-0221~Differentiation,KW-0391~Immunity,KW-0399~Innate immunity,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0810~Translation regulation,KW-0813~Transport,	KW-0158~Chromosome,KW-0472~Membrane,KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0779~Telomere,KW-0963~Cytoplasm,KW-0966~Cell projection,		KW-0175~Coiled coil,KW-0677~Repeat,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0010~Activator,KW-0217~Developmental protein,KW-0238~DNA-binding,KW-0347~Helicase,KW-0378~Hydrolase,KW-0678~Repressor,KW-0694~RNA-binding,KW-9996~Developmental protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:DEAD-box helicase OB fold,DOMAIN:Helicase ATP-binding,DOMAIN:Helicase C-terminal,DOMAIN:Helicase-associated,MOTIF:DEAH box,MOTIF:Nuclear localization signal,MUTAGEN:E->A: Loss of ATPase activity; results in an increased in G4-DNA- and G4-RNA-binding stabilities, increases localization in cytoplasmic stress granules and loss of mRNA deadenylation and mRNA decay.,MUTAGEN:G->A: Reduces G4-RNA-binding; when associated with G-54, A-57, A-59 and A-62.,MUTAGEN:G->A: Reduces G4-RNA-binding; when associated with G-54, A-57, A-62 and A-63.,MUTAGEN:G->L: Inhibits G4-DNA-binding; when associated with L-55 and L-59.,MUTAGEN:G->L: Inhibits G4-DNA-binding; when associated with L-55 and L-63.,MUTAGEN:G->L: Inhibits G4-DNA-binding; when associated with L-59 and L-63.,MUTAGEN:G->P: Greatly reduces G4-RNA-binding; when associated with P-59.,MUTAGEN:G->P: Greatly reduces G4-RNA-binding; when associated with P-63.,MUTAGEN:I->A: Reduces G4-RNA-binding; when associated with G-54, A-57, A-59 and A-63.,MUTAGEN:L->A: Reduces G4-RNA-binding; when associated with G-54, A-59, A-62 and A-63.,MUTAGEN:P->G: Reduces G4-RNA binding; when associated with A-57, A-59, A-62 and A-63.,MUTAGEN:W->A: Does not inhibit G4-DNA-binding; when associated with A-66.,MUTAGEN:Y->A: Does not inhibit G4-DNA-binding; when associated with A-65.,REGION:DSM (DHX36-specific motif),REGION:Disordered,REGION:Necessary for interaction with single-stranded DNA at the 3'-end of the G4-DNA structure,REGION:Necessary for nuclear and nucleolar caps localizations,REGION:OB-fold-like subdomains,REGION:RecA-like domain 1,REGION:RecA-like domain 2,REGION:Required for G4-DNA- and G4-RNA-binding,REGION:Required for recruitment to cytoplasmic stress granules,REGION:Required for the pre-miR-134 transport,REGION:WH domain,TRANSMEM:Helical,
DEF6	DEF6 guanine nucleotide exchange factor(DEF6)	Homo sapiens			GO:0051056~regulation of small GTPase mediated signal transduction,GO:0098876~vesicle-mediated transport to the plasma membrane,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0030175~filopodium,GO:0048471~perinuclear region of cytoplasm,	GO:0005085~guanyl-nucleotide exchange factor activity,GO:0005515~protein binding,	IPR001849:PH_domain,IPR011992:EF-hand-dom_pair,IPR011993:PH-like_dom_sf,		619573~Immunodeficiency 87 and autoimmunity,		SM00233:PH,		KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-1003~Cell membrane,	KW-0225~Disease variant,				KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:PH,MUTAGEN:KR->AA: Abolishes PtdInsP3 binding.,MUTAGEN:L->N: Abolishes interaction with RAC1.,MUTAGEN:LKV->NKS: Abolishes interaction with RAC1.,MUTAGEN:R->C: Abolishes PtdInsP3 binding.,MUTAGEN:RR->AA: Abolishes PtdInsP3 binding.,MUTAGEN:Y->F: Loss of phosphorylation by LCK and abolition of PtdInsP3 binding.,REGION:Disordered,
DEK	DEK proto-oncogene(DEK)	Homo sapiens			GO:0006325~chromatin organization,GO:0006338~chromatin remodeling,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0007165~signal transduction,GO:0019079~viral genome replication,GO:0035066~positive regulation of histone acetylation,GO:0045943~positive regulation of transcription from RNA polymerase I promoter,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0045945~positive regulation of transcription from RNA polymerase III promoter,GO:2000779~regulation of double-strand break repair,GO:2001032~regulation of double-strand break repair via nonhomologous end joining,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0043292~contractile fiber,	GO:0003677~DNA binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0042393~histone binding,	IPR003034:SAP_dom,IPR014876:DEK_C,IPR036361:SAP_dom_sf,IPR044198:DEK,		Leukemia, acute nonlymphocytic~Leukemia, acute nonlymphocytic,		SM00513:SAP,		KW-0539~Nucleus,	KW-0656~Proto-oncogene,			KW-0156~Chromatin regulator,KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0013~ADP-ribosylation,KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,DOMAIN:DEK-C,DOMAIN:SAP,MOTIF:Nuclear localization signal,REGION:Disordered,
DDA1	DET1 and DDB1 associated 1(DDA1)	Homo sapiens			GO:0000209~protein polyubiquitination,GO:0032436~positive regulation of proteasomal ubiquitin-dependent protein catabolic process,	GO:0005654~nucleoplasm,GO:0080008~Cul4-RING E3 ubiquitin ligase complex,	GO:0005515~protein binding,	IPR018276:DDA1_N,IPR033575:DDA1,					KW-0833~Ubl conjugation pathway,						KW-0007~Acetylation,KW-0597~Phosphoprotein,	REGION:Disordered,
DDX21	DExD-box helicase 21(DDX21)	Homo sapiens			GO:0001649~osteoblast differentiation,GO:0002735~positive regulation of myeloid dendritic cell cytokine production,GO:0006338~chromatin remodeling,GO:0006364~rRNA processing,GO:0006366~transcription from RNA polymerase II promoter,GO:0016479~negative regulation of transcription from RNA polymerase I promoter,GO:0035066~positive regulation of histone acetylation,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043330~response to exogenous dsRNA,GO:0045087~innate immune response,GO:0045943~positive regulation of transcription from RNA polymerase I promoter,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0045945~positive regulation of transcription from RNA polymerase III promoter,GO:0051607~defense response to virus,	GO:0005654~nucleoplasm,GO:0005694~chromosome,GO:0005730~nucleolus,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0016020~membrane,	GO:0003723~RNA binding,GO:0003724~RNA helicase activity,GO:0003725~double-stranded RNA binding,GO:0003729~mRNA binding,GO:0004386~helicase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016787~hydrolase activity,GO:0016887~ATPase activity,GO:0019843~rRNA binding,GO:0030515~snoRNA binding,GO:0035198~miRNA binding,GO:0042802~identical protein binding,GO:0097322~7SK snRNA binding,	IPR001650:Helicase_C,IPR011545:DEAD/DEAH_box_helicase_dom,IPR012562:GUCT,IPR014001:Helicase_ATP-bd,IPR027417:P-loop_NTPase,IPR035979:RBD_domain_sf,				SM00487:DEXDc,SM00490:HELICc,	KW-0051~Antiviral defense,KW-0391~Immunity,KW-0399~Innate immunity,KW-0698~rRNA processing,KW-0804~Transcription,	KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0347~Helicase,KW-0378~Hydrolase,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:Helicase ATP-binding,DOMAIN:Helicase C-terminal,MOTIF:DEAD box,MOTIF:Q motif,MUTAGEN:DE->HG: In mutant DEV; loss of helicase activity. Defects in release of P-TEFb from inhibitory 7SK snRNP.,MUTAGEN:K->Q: Mimics acetylation; impaired ability to resolve R-loops; when associated with Q-137 and Q-600.,MUTAGEN:K->Q: Mimics acetylation; impaired ability to resolve R-loops; when associated with Q-18 and Q-137.,MUTAGEN:K->Q: Mimics acetylation; impaired ability to resolve R-loops; when associated with Q-18 and Q-600.,MUTAGEN:SA->LE: In mutant SAT; ATPase defective. Defects in release of P-TEFb from inhibitory 7SK snRNP.,REGION:3 X 5 AA repeats,REGION:Disordered,REPEAT:1,REPEAT:2,REPEAT:3,
DDX39A	DExD-box helicase 39A(DDX39A)	Homo sapiens			GO:0000398~mRNA splicing, via spliceosome,GO:0006405~RNA export from nucleus,GO:0006406~mRNA export from nucleus,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0016020~membrane,GO:0016607~nuclear speck,	GO:0003676~nucleic acid binding,GO:0003723~RNA binding,GO:0003724~RNA helicase activity,GO:0003729~mRNA binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016787~hydrolase activity,GO:0016887~ATPase activity,GO:0042802~identical protein binding,	IPR001650:Helicase_C,IPR011545:DEAD/DEAH_box_helicase_dom,IPR014001:Helicase_ATP-bd,IPR014014:RNA_helicase_DEAD_Q_motif,IPR027417:P-loop_NTPase,				SM00487:DEXDc,SM00490:HELICc,	KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0347~Helicase,KW-0378~Hydrolase,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:DEAD-box RNA helicase Q,DOMAIN:Helicase ATP-binding,DOMAIN:Helicase C-terminal,MOTIF:DECD box,MOTIF:Q motif,REGION:Disordered,
DDX50	DExD-box helicase 50(DDX50)	Homo sapiens				GO:0005730~nucleolus,GO:0005886~plasma membrane,GO:0016020~membrane,	GO:0003723~RNA binding,GO:0003724~RNA helicase activity,GO:0003729~mRNA binding,GO:0005524~ATP binding,GO:0016787~hydrolase activity,GO:0016887~ATPase activity,	IPR001650:Helicase_C,IPR011545:DEAD/DEAH_box_helicase_dom,IPR012562:GUCT,IPR014001:Helicase_ATP-bd,IPR027417:P-loop_NTPase,IPR035979:RBD_domain_sf,				SM00487:DEXDc,SM00490:HELICc,		KW-0539~Nucleus,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0347~Helicase,KW-0378~Hydrolase,KW-0694~RNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Helicase ATP-binding,DOMAIN:Helicase C-terminal,MOTIF:DEVD box,MOTIF:Q motif,REGION:Disordered,
DHX9	DExH-box helicase 9(DHX9)	Homo sapiens			GO:0000380~alternative mRNA splicing, via spliceosome,GO:0001649~osteoblast differentiation,GO:0006260~DNA replication,GO:0006353~DNA-templated transcription, termination,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006954~inflammatory response,GO:0010501~RNA secondary structure unwinding,GO:0032508~DNA duplex unwinding,GO:0032727~positive regulation of interferon-alpha production,GO:0032728~positive regulation of interferon-beta production,GO:0032741~positive regulation of interleukin-18 production,GO:0032755~positive regulation of interleukin-6 production,GO:0032760~positive regulation of tumor necrosis factor production,GO:0035195~gene silencing by miRNA,GO:0039695~DNA-templated viral transcription,GO:0044806~G-quadruplex DNA unwinding,GO:0045087~innate immune response,GO:0045089~positive regulation of innate immune response,GO:0045739~positive regulation of DNA repair,GO:0045740~positive regulation of DNA replication,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046833~positive regulation of RNA export from nucleus,GO:0048146~positive regulation of fibroblast proliferation,GO:0048511~rhythmic process,GO:0050434~positive regulation of viral transcription,GO:0050684~regulation of mRNA processing,GO:0050691~regulation of defense response to virus by host,GO:0050729~positive regulation of inflammatory response,GO:0051028~mRNA transport,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0060760~positive regulation of response to cytokine stimulus,GO:0065003~macromolecular complex assembly,GO:0070269~pyroptosis,GO:0070922~small RNA loading onto RISC,GO:0070934~CRD-mediated mRNA stabilization,GO:0071356~cellular response to tumor necrosis factor,GO:0071360~cellular response to exogenous dsRNA,GO:1900152~negative regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay,GO:1903608~protein localization to cytoplasmic stress granule,GO:1904973~positive regulation of viral translation,GO:1905698~positive regulation of polysome binding,GO:2000373~positive regulation of DNA topoisomerase (ATP-hydrolyzing) activity,GO:2000765~regulation of cytoplasmic translation,GO:2000767~positive regulation of cytoplasmic translation,	GO:0005622~intracellular,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005726~perichromatin fibrils,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005829~cytosol,GO:0005844~polysome,GO:0015629~actin cytoskeleton,GO:0016020~membrane,GO:0016442~RISC complex,GO:0016604~nuclear body,GO:0032991~macromolecular complex,GO:0036464~cytoplasmic ribonucleoprotein granule,GO:0042788~polysomal ribosome,GO:0070578~RISC-loading complex,GO:0070937~CRD-mediated mRNA stability complex,GO:0097165~nuclear stress granule,GO:1990904~ribonucleoprotein complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000993~RNA polymerase II core binding,GO:0001069~regulatory region RNA binding,GO:0003677~DNA binding,GO:0003678~DNA helicase activity,GO:0003688~DNA replication origin binding,GO:0003690~double-stranded DNA binding,GO:0003697~single-stranded DNA binding,GO:0003712~transcription cofactor activity,GO:0003713~transcription coactivator activity,GO:0003723~RNA binding,GO:0003724~RNA helicase activity,GO:0003725~double-stranded RNA binding,GO:0003727~single-stranded RNA binding,GO:0003729~mRNA binding,GO:0004386~helicase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016787~hydrolase activity,GO:0016887~ATPase activity,GO:0017111~nucleoside-triphosphatase activity,GO:0031490~chromatin DNA binding,GO:0033679~3'-5' DNA/RNA helicase activity,GO:0034458~3'-5' RNA helicase activity,GO:0035197~siRNA binding,GO:0035613~RNA stem-loop binding,GO:0043022~ribosome binding,GO:0043138~3'-5' DNA helicase activity,GO:0045142~triplex DNA binding,GO:0046872~metal ion binding,GO:0047429~nucleoside-triphosphate diphosphatase activity,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:0061676~importin-alpha family protein binding,GO:0070063~RNA polymerase binding,GO:1905172~RISC complex binding,GO:1905538~polysome binding,GO:1990518~single-stranded DNA-dependent ATP-dependent 3'-5' DNA helicase activity,GO:1990825~sequence-specific mRNA binding,GO:1990841~promoter-specific chromatin binding,	IPR001650:Helicase_C,IPR002464:DNA/RNA_helicase_DEAH_CS,IPR007502:Helicase-assoc_dom,IPR011545:DEAD/DEAH_box_helicase_dom,IPR011709:DEAD-box_helicase_OB_fold,IPR014001:Helicase_ATP-bd,IPR014720:dsRBD_dom,IPR027417:P-loop_NTPase,IPR044445:DHX9_DSRM_1,IPR044446:DHX9_DSRM_2,IPR044447:DHX9_DEXHc,IPR048333:HA2_WH,				SM00358:DSRM,SM00487:DEXDc,SM00490:HELICc,SM00847:HA2,	KW-0090~Biological rhythms,KW-0235~DNA replication,KW-0391~Immunity,KW-0395~Inflammatory response,KW-0399~Innate immunity,KW-0507~mRNA processing,KW-0508~mRNA splicing,KW-0509~mRNA transport,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0806~Transcription termination,KW-0810~Translation regulation,KW-0813~Transport,KW-0943~RNA-mediated gene silencing,KW-0945~Host-virus interaction,	KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,	KW-0067~ATP-binding,KW-0464~Manganese,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0010~Activator,KW-0238~DNA-binding,KW-0347~Helicase,KW-0378~Hydrolase,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:DRBM,DOMAIN:DRBM 1,DOMAIN:DRBM 2,DOMAIN:Helicase ATP-binding,DOMAIN:Helicase C-terminal,DOMAIN:Helicase-associated,MOTIF:DEIH box,MOTIF:Nuclear localization signal (NLS1),MOTIF:Nuclear localization signal (NLS2),MUTAGEN:D->A: Does not inhibit binding to origins of DNA replication; when associated with A-512.,MUTAGEN:E->A: Does not inhibit binding to origins of DNA replication; when associated with A-511.,MUTAGEN:H->A: Reduces siRNA-binding and interaction with AGO2.,MUTAGEN:I->A: Reduces NUP98-induced mRNA transcription and alternative splicing activities.,MUTAGEN:K->A: Inhibits siRNA-binding and decreases interaction with AGO2; when associated with A-53 and A-54.,MUTAGEN:K->A: Inhibits siRNA-binding and decreases interaction with AGO2; when associated with A-53 and A-55.,MUTAGEN:K->A: Inhibits siRNA-binding and interaction with AGO2; when associated with A-234 and A-235.,MUTAGEN:K->A: Inhibits siRNA-binding and interaction with AGO2; when associated with A-234 and A-236.,MUTAGEN:K->A: Localizes in the cytoplasm and does not interact with the importin complex.,MUTAGEN:K->A: Reduces siRNA-binding and interaction with AGO2.,MUTAGEN:K->A: Reduces siRNA-binding and interaction with AGO2; when associated with A-6.,MUTAGEN:K->R,N: Inhibits interaction with AGO2, DICER1 and TARBP2. Abrogates helicase activity and transcriptional activation. Does not inhibit binding to origins of DNA replication.,MUTAGEN:K->R: Reduces NUP98-induced mRNA transcription and alternative splicing activities.,MUTAGEN:Missing: Abolishes nuclear localization.,MUTAGEN:N->A: Does not reduce siRNA-binding and interaction with AGO2.,MUTAGEN:N->A: Inhibits siRNA-binding and decreases interaction with AGO2; when associated with A-54 and A-55.,MUTAGEN:N->A: Inhibits siRNA-binding and interaction with AGO2; when associated with A-235 and A-236.,MUTAGEN:N->A: Reduces siRNA-binding and interaction with AGO2; when associated with A-187.,MUTAGEN:N->A: Reduces siRNA-binding; when associated with A-5.,MUTAGEN:Q->A: Reduces siRNA-binding and interaction with AGO2; when associated with A-186.,MUTAGEN:R->A: Localizes in the nucleus and interacts with the importin complex.,MUTAGEN:R->A: Localizes in the nucleus and the cytoplasm and interacts weakly with the importin complex.,MUTAGEN:R->L: Abolishes nuclear localization.,MUTAGEN:S->L: Does not inhibit binding to origins of DNA replication.,MUTAGEN:W->A: Abrogates transcriptional activation and RNA polymerase II binding by the MTAD region. No change in ATP binding and ATPase activities.,MUTAGEN:W->A: Abrogates transcriptional activation by the MTAD region. No change in RNA polymerase II holoenzyme binding.,MUTAGEN:Y->A: Inhibits siRNA-binding and interaction with AGO2.,REGION:Core helicase,REGION:Disordered,REGION:HA2,REGION:Interaction with BRCA1,REGION:Interaction with CREBBP,REGION:MTAD,REGION:Necessary for interaction with H2AX,REGION:Necessary for interaction with RNA polymerase II holoenzyme,REGION:OB-fold,REGION:RGG,REGION:siRNA-binding,
DDIT4	DNA damage inducible transcript 4(DDIT4)	Homo sapiens			GO:0001666~response to hypoxia,GO:0001764~neuron migration,GO:0006915~apoptotic process,GO:0007420~brain development,GO:0009968~negative regulation of signal transduction,GO:0030182~neuron differentiation,GO:0032007~negative regulation of TOR signaling,GO:0032984~macromolecular complex disassembly,GO:0035556~intracellular signal transduction,GO:0042771~intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator,GO:0045820~negative regulation of glycolytic process,GO:0048011~neurotrophin TRK receptor signaling pathway,GO:0051607~defense response to virus,GO:0071549~cellular response to dexamethasone stimulus,GO:0072593~reactive oxygen species metabolic process,	GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,	GO:0005515~protein binding,GO:0071889~14-3-3 protein binding,	IPR012918:RTP801-like,IPR038281:RTP801-like_C_sf,	hsa04140:Autophagy - animal,hsa04150:mTOR signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa05206:MicroRNAs in cancer,				KW-0051~Antiviral defense,KW-0053~Apoptosis,	KW-0496~Mitochondrion,KW-0963~Cytoplasm,					KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,MUTAGEN:C->S: Mildly reduces inhibition of mTORC1.,MUTAGEN:K->A: Reduces inhibition of mTORC1. Abolishes inhibition of mTORC1; when associated with A-222.,MUTAGEN:L->A: Reduces inhibition of mTORC1.,MUTAGEN:P->A: Abolishes inhibition of mTORC1.,MUTAGEN:R->A: No effect on inhibition of mTORC1.,MUTAGEN:S->A,D: No effect on inhibition of mTORC1.,MUTAGEN:S->A: Strongly inhibits proteasomal degradation.,MUTAGEN:S->L,W: No effect on inhibition of mTORC1.,MUTAGEN:T->A: Strongly inhibits proteasomal degradation. Strongly inhibits proteasomal degradation; when associated with A-25.,MUTAGEN:T->A: Strongly inhibits proteasomal degradation; when associated with A-23.,MUTAGEN:Y->A: Reduces inhibition of mTORC1. Abolishes inhibition of mTORC1; when associated with A-219.,REGION:Disordered,
DNMT1	DNA methyltransferase 1(DNMT1)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006346~methylation-dependent chromatin silencing,GO:0006351~transcription, DNA-templated,GO:0010424~DNA methylation on cytosine within a CG sequence,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0032259~methylation,GO:0043045~DNA methylation involved in embryo development,GO:0044027~hypermethylation of CpG island,GO:0071230~cellular response to amino acid stimulus,GO:0090116~C-5 methylation of cytosine,GO:1903926~cellular response to bisphenol A,GO:1904707~positive regulation of vascular smooth muscle cell proliferation,GO:1905460~negative regulation of vascular associated smooth muscle cell apoptotic process,GO:1905931~negative regulation of vascular smooth muscle cell differentiation involved in phenotypic switching,	GO:0001674~female germ cell nucleus,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005657~replication fork,GO:0005721~pericentric heterochromatin,	GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003723~RNA binding,GO:0003886~DNA (cytosine-5-)-methyltransferase activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0008327~methyl-CpG binding,GO:0008757~S-adenosylmethionine-dependent methyltransferase activity,GO:0009008~DNA-methyltransferase activity,GO:1990841~promoter-specific chromatin binding,	IPR001025:BAH_dom,IPR001525:C5_MeTfrase,IPR002857:Znf_CXXC,IPR010506:DMAP1-bd,IPR017198:DNMT1-like,IPR018117:C5_DNA_meth_AS,IPR022702:Cytosine_MeTrfase1_RFD,IPR029063:SAM-dependent_MTases_sf,IPR031303:C5_meth_CS,IPR043151:BAH_sf,	hsa00270:Cysteine and methionine metabolism,hsa01100:Metabolic pathways,hsa05206:MicroRNAs in cancer,	604121~Cerebellar ataxia, deafness, and narcolepsy, autosomal dominant,614116~Neuropathy, hereditary sensory, type IE,	PIRSF037404:DNMT1,	SM00439:BAH,SM01137:DMAP_binding,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0209~Deafness,KW-0225~Disease variant,KW-0622~Neuropathy,	KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,KW-0949~S-adenosyl-L-methionine,	KW-0010~Activator,KW-0156~Chromatin regulator,KW-0238~DNA-binding,KW-0489~Methyltransferase,KW-0678~Repressor,KW-0808~Transferase,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:BAH,DOMAIN:BAH 1,DOMAIN:BAH 2,DOMAIN:CXXC-type,DOMAIN:DMAP1-binding,DOMAIN:SAM-dependent MTase C5-type,MOTIF:Nuclear localization signal,MUTAGEN:A->S: No loss of interaction with PCNA.,MUTAGEN:C->A: Loss of activity.,MUTAGEN:C->F: Reduces activity about 10-fold; when associated with G-653; G-656; G-659; G-667 and G-670.,MUTAGEN:C->G: Reduces activity about 10-fold; when associated with G-653; G-656; G-659; G-664 and G-667.,MUTAGEN:C->G: Reduces activity about 10-fold; when associated with G-653; G-656; G-659; G-664 and G-670.,MUTAGEN:C->G: Reduces activity about 10-fold; when associated with G-653; G-656; G-664; G-667 and G-670.,MUTAGEN:C->G: Reduces activity about 10-fold; when associated with G-653; G-659; G-664; G-667 and G-670.,MUTAGEN:C->G: Reduces activity about 10-fold; when associated with G-656; G-659; G-664; G-667 and G-670.,MUTAGEN:F->V: Abolishes interaction with PCNA.,MUTAGEN:H->V: Abolishes interaction with PCNA.,MUTAGEN:I->A: Abolishes interaction with PCNA.,MUTAGEN:K->A: Loss of interaction with L3MBTL3 and DCAF5. Loss of ubiquitination by the CRL4-DCAF5 E3 ubiquitin ligase complex.,MUTAGEN:K->A: No loss of interaction with PCNA.,MUTAGEN:Q->A: Abolishes interaction with PCNA.,MUTAGEN:R->A: Abolishes interaction with PCNA.,MUTAGEN:S->A: No loss of interaction with PCNA.,MUTAGEN:T->A: Abolishes interaction with PCNA.,REGION:6 X 2 AA tandem repeats of K-G,REGION:Autoinhibitory linker,REGION:Catalytic,REGION:DNA replication foci-targeting sequence,REGION:Disordered,REGION:Homodimerization,REGION:Interaction with DMAP1,REGION:Interaction with DNMT3A,REGION:Interaction with DNMT3B,REGION:Interaction with PCNA,REGION:Interaction with the PRC2/EED-EZH2 complex,REGION:Required for activity,REPEAT:1,REPEAT:2,REPEAT:3,REPEAT:4,REPEAT:5,REPEAT:6; approximate,SITE:Important for activity,ZN_FING:CXXC-type,
POLDIP2	DNA polymerase delta interacting protein 2(POLDIP2)	Homo sapiens			GO:0007005~mitochondrion organization,GO:0016242~negative regulation of macroautophagy,GO:0045931~positive regulation of mitotic cell cycle,GO:0051894~positive regulation of focal adhesion assembly,GO:0070584~mitochondrion morphogenesis,GO:0070987~error-free translesion synthesis,GO:0090307~mitotic spindle assembly,GO:1903490~positive regulation of mitotic cytokinesis,GO:1990874~vascular smooth muscle cell proliferation,	GO:0005634~nucleus,GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0005911~cell-cell junction,GO:0030496~midbody,GO:0042645~mitochondrial nucleoid,GO:0072686~mitotic spindle,	GO:0003677~DNA binding,GO:0005515~protein binding,	IPR007474:ApaG_domain,IPR011722:Hemimethylated_DNA-bd_dom,IPR036623:Hemimethylated_DNA-bd_sf,IPR036767:ApaG_sf,				SM00992:YccV-like,	KW-0227~DNA damage,KW-0234~DNA repair,	KW-0496~Mitochondrion,KW-0539~Nucleus,		KW-0809~Transit peptide,			KW-0597~Phosphoprotein,	DOMAIN:ApaG,TRANSIT:Mitochondrion,
POLE4	DNA polymerase epsilon 4, accessory subunit(POLE4)	Homo sapiens			GO:0006261~DNA-dependent DNA replication,GO:0071897~DNA biosynthetic process,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0008622~epsilon DNA polymerase complex,	GO:0003677~DNA binding,GO:0003887~DNA-directed DNA polymerase activity,GO:0005515~protein binding,GO:0046982~protein heterodimerization activity,	IPR003958:CBFA_NFYB_domain,IPR009072:Histone-fold,	hsa03030:DNA replication,hsa03410:Base excision repair,hsa03420:Nucleotide excision repair,					KW-0539~Nucleus,				KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	REGION:Disordered,
TOP1	DNA topoisomerase I(TOP1)	Homo sapiens			GO:0006260~DNA replication,GO:0006265~DNA topological change,GO:0006338~chromatin remodeling,GO:0007059~chromosome segregation,GO:0007623~circadian rhythm,GO:0009410~response to xenobiotic stimulus,GO:0012501~programmed cell death,GO:0016310~phosphorylation,GO:0018105~peptidyl-serine phosphorylation,GO:0032922~circadian regulation of gene expression,GO:0040016~embryonic cleavage,	GO:0000228~nuclear chromosome,GO:0000932~P-body,GO:0001650~fibrillar center,GO:0001673~male germ cell nucleus,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005694~chromosome,GO:0005730~nucleolus,GO:0032993~protein-DNA complex,GO:0043204~perikaryon,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003690~double-stranded DNA binding,GO:0003697~single-stranded DNA binding,GO:0003723~RNA binding,GO:0003917~DNA topoisomerase type I activity,GO:0004674~protein serine/threonine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008301~DNA binding, bending,GO:0019904~protein domain specific binding,GO:0097100~supercoiled DNA binding,	IPR001631:TopoI,IPR008336:TopoI_DNA-bd_euk,IPR011010:DNA_brk_join_enz,IPR013030:DNA_topo_DNA_db_N_dom2,IPR013034:DNA_topo_DNA_db_N_dom1,IPR013499:TopoI_euk,IPR013500:TopoI_cat_euk,IPR014711:TopoI_cat_a-hlx-sub_euk,IPR014727:TopoI_cat_a/b-sub_euk,IPR018521:TopoI_AS,IPR025834:TopoI_C_dom,IPR036202:TopoI_DNA-bd_euk_N_sf,IPR048045:Topoisomer_I_DNA-bd,		DNA topoisomerase I, camptothecin-resistant~DNA topoisomerase I, camptothecin-resistant,		SM00435:TOPEUc,	KW-0090~Biological rhythms,KW-0945~Host-virus interaction,	KW-0539~Nucleus,	KW-0656~Proto-oncogene,	KW-0175~Coiled coil,		KW-0238~DNA-binding,KW-0413~Isomerase,KW-0799~Topoisomerase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	ACT_SITE:O-(3'-phospho-DNA)-tyrosine intermediate,COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:DNA topoisomerase I eukaryotic-type,DOMAIN:Topo IB-type catalytic,MUTAGEN:K->A: Almost abolishes enzyme activity.,MUTAGEN:K->R: 5-fold decrease in sumoylation. Localizes in both nucleoplasm and nucleoli; when associated with or without R-103 or R-153. Almost complete loss of sumoylation, concentrates in nucleoli and no clearing from nucleoli on CPT treatment; when associated with R-103 and R-153.,MUTAGEN:K->R: Localizes in both nucleoplasm and nucleoli; when associated with R-103 or R-117. Almost complete loss of sumoylation, concentrates in nucleoli and no clearing from nucleoli on CPT treatment; when associated with R-103 and R-117.,MUTAGEN:K->R: Localizes in both nucleoplasm and nucleoli; when associated with R-117 or R-153. Almost complete loss of sumoylation, concentrates in nucleoli and no clearing from nucleoli on CPT treatment; when associated with R-117 and R-153.,MUTAGEN:K->R: Strongly reduced enzyme activity.,MUTAGEN:Y->F: No change in CPT-induced clearing from nuclei.,REGION:Disordered,REGION:Interaction with DNA,SITE:Interaction with DNA,
DGCR6L	DiGeorge syndrome critical region gene 6 like(DGCR6L)	Homo sapiens			GO:0007155~cell adhesion,GO:0009887~animal organ morphogenesis,	GO:0005634~nucleus,GO:0031012~extracellular matrix,	GO:0005515~protein binding,	IPR010849:Gonadal,						KW-0539~Nucleus,		KW-0175~Coiled coil,			KW-0597~Phosphoprotein,	REGION:Disordered,
DNAJB1	DnaJ heat shock protein family (Hsp40) member B1(DNAJB1)	Homo sapiens		h_p53hypoxiaPathway:Hypoxia and p53 in the Cardiovascular system,h_prionPathway:Prion Pathway,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006457~protein folding,GO:0006986~response to unfolded protein,GO:0030900~forebrain development,GO:0032781~positive regulation of ATPase activity,GO:0034605~cellular response to heat,GO:0051085~chaperone mediated protein folding requiring cofactor,GO:0090084~negative regulation of inclusion body assembly,GO:1900034~regulation of cellular response to heat,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0014069~postsynaptic density,GO:0043025~neuronal cell body,GO:0043197~dendritic spine,GO:0061827~sperm head,GO:0070062~extracellular exosome,GO:0098978~glutamatergic synapse,	GO:0001671~ATPase activator activity,GO:0003714~transcription corepressor activity,GO:0005515~protein binding,GO:0030544~Hsp70 protein binding,GO:0044183~protein binding involved in protein folding,GO:0045296~cadherin binding,GO:0051082~unfolded protein binding,GO:0051087~chaperone binding,GO:0051117~ATPase binding,	IPR001623:DnaJ_domain,IPR002939:DnaJ_C,IPR008971:HSP40/DnaJ_pept-bd,IPR018253:DnaJ_domain_CS,IPR036869:J_dom_sf,	hsa04141:Protein processing in endoplasmic reticulum,hsa05164:Influenza A,			SM00271:DnaJ,	KW-0346~Stress response,	KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0143~Chaperone,	KW-0597~Phosphoprotein,	DOMAIN:Chaperone DnaJ C-terminal,DOMAIN:J,REGION:Disordered,
DNAJB11	DnaJ heat shock protein family (Hsp40) member B11(DNAJB11)	Homo sapiens			GO:0006457~protein folding,GO:0016556~mRNA modification,GO:0032781~positive regulation of ATPase activity,GO:0050768~negative regulation of neurogenesis,GO:0051604~protein maturation,	GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005783~endoplasmic reticulum,GO:0005788~endoplasmic reticulum lumen,GO:0016020~membrane,GO:0034663~endoplasmic reticulum chaperone complex,GO:0101031~chaperone complex,	GO:0005102~receptor binding,GO:0005515~protein binding,GO:0051082~unfolded protein binding,GO:0051787~misfolded protein binding,	IPR001623:DnaJ_domain,IPR002939:DnaJ_C,IPR008971:HSP40/DnaJ_pept-bd,IPR018253:DnaJ_domain_CS,IPR036869:J_dom_sf,	hsa04141:Protein processing in endoplasmic reticulum,	618061~Polycystic kidney disease 6 with or without polycystic liver disease,		SM00271:DnaJ,		KW-0256~Endoplasmic reticulum,	KW-0225~Disease variant,	KW-0732~Signal,		KW-0143~Chaperone,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:J,MUTAGEN:C->S: Drastic loss of interaction with denatured substrates.,MUTAGEN:H->Q: Loss of HSPA5-binding, but no effect on interaction with denatured substrates.,
DNAJB14	DnaJ heat shock protein family (Hsp40) member B14(DNAJB14)	Homo sapiens			GO:0051085~chaperone mediated protein folding requiring cofactor,GO:0065003~macromolecular complex assembly,GO:0071218~cellular response to misfolded protein,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0016020~membrane,GO:0031965~nuclear membrane,	GO:0005515~protein binding,GO:0030544~Hsp70 protein binding,	IPR001623:DnaJ_domain,IPR015399:DUF1977_DnaJ-like,IPR018253:DnaJ_domain_CS,IPR036869:J_dom_sf,				SM00271:DnaJ,	KW-0945~Host-virus interaction,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0539~Nucleus,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0143~Chaperone,		COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:J,MUTAGEN:H->Q: Abolishes interaction with HSPA8/Hsc70.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
DNAJB6	DnaJ heat shock protein family (Hsp40) member B6(DNAJB6)	Homo sapiens		h_prionPathway:Prion Pathway,	GO:0006457~protein folding,GO:0030036~actin cytoskeleton organization,GO:0030198~extracellular matrix organization,GO:0032880~regulation of protein localization,GO:0034504~protein localization to nucleus,GO:0043154~negative regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0045109~intermediate filament organization,GO:0045892~negative regulation of transcription, DNA-templated,GO:0060710~chorio-allantoic fusion,GO:0060715~syncytiotrophoblast cell differentiation involved in labyrinthine layer development,GO:0060717~chorion development,GO:0061077~chaperone-mediated protein folding,GO:0090084~negative regulation of inclusion body assembly,GO:1900034~regulation of cellular response to heat,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016020~membrane,GO:0030018~Z disc,GO:0048471~perinuclear region of cytoplasm,	GO:0001671~ATPase activator activity,GO:0003677~DNA binding,GO:0005515~protein binding,GO:0030544~Hsp70 protein binding,GO:0031072~heat shock protein binding,GO:0042802~identical protein binding,GO:0044183~protein binding involved in protein folding,GO:0051082~unfolded protein binding,GO:0051087~chaperone binding,	IPR001623:DnaJ_domain,IPR018253:DnaJ_domain_CS,IPR036869:J_dom_sf,IPR043183:DNJB2/6-like,		603511~Muscular dystrophy, limb-girdle, autosomal dominant 1,		SM00271:DnaJ,		KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0947~Limb-girdle muscular dystrophy,			KW-0143~Chaperone,	KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:J,REGION:Disordered,REGION:Interaction with HSP70,REGION:Interaction with KRT18,
DNAJB9	DnaJ heat shock protein family (Hsp40) member B9(DNAJB9)	Homo sapiens			GO:0002639~positive regulation of immunoglobulin production,GO:0006986~response to unfolded protein,GO:0030183~B cell differentiation,GO:0030433~ubiquitin-dependent ERAD pathway,GO:0034976~response to endoplasmic reticulum stress,GO:0036503~ERAD pathway,GO:1903895~negative regulation of IRE1-mediated unfolded protein response,	GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005788~endoplasmic reticulum lumen,GO:0005789~endoplasmic reticulum membrane,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0030544~Hsp70 protein binding,GO:0051087~chaperone binding,GO:0051787~misfolded protein binding,	IPR001623:DnaJ_domain,IPR018253:DnaJ_domain_CS,IPR036869:J_dom_sf,				SM00271:DnaJ,	KW-0834~Unfolded protein response,	KW-0256~Endoplasmic reticulum,		KW-0732~Signal,		KW-0143~Chaperone,	KW-0597~Phosphoprotein,	DOMAIN:J,REGION:Divergent targeting domain,
DNAJC3	DnaJ heat shock protein family (Hsp40) member C3(DNAJC3)	Homo sapiens		h_rnaPathway:Double Stranded RNA Induced Gene Expression,	GO:0006986~response to unfolded protein,GO:0034975~protein folding in endoplasmic reticulum,GO:0036494~positive regulation of translation initiation in response to endoplasmic reticulum stress,GO:0043066~negative regulation of apoptotic process,GO:0051603~proteolysis involved in cellular protein catabolic process,GO:0051607~defense response to virus,GO:0070417~cellular response to cold,GO:1903912~negative regulation of endoplasmic reticulum stress-induced eIF2 alpha phosphorylation,	GO:0005576~extracellular region,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005788~endoplasmic reticulum lumen,GO:0005790~smooth endoplasmic reticulum,GO:0005829~cytosol,GO:0016020~membrane,GO:0035578~azurophil granule lumen,GO:0070062~extracellular exosome,GO:1903561~extracellular vesicle,	GO:0004860~protein kinase inhibitor activity,GO:0019901~protein kinase binding,GO:0051087~chaperone binding,GO:0051787~misfolded protein binding,	IPR001440:TPR_1,IPR001623:DnaJ_domain,IPR011990:TPR-like_helical_dom_sf,IPR019734:TPR_repeat,IPR036869:J_dom_sf,	hsa04141:Protein processing in endoplasmic reticulum,hsa05164:Influenza A,	616192~Ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus,		SM00028:TPR,SM00271:DnaJ,	KW-0051~Antiviral defense,KW-0346~Stress response,KW-0810~Translation regulation,KW-0834~Unfolded protein response,	KW-0256~Endoplasmic reticulum,	KW-0209~Deafness,KW-0219~Diabetes mellitus,KW-0523~Neurodegeneration,KW-0622~Neuropathy,	KW-0677~Repeat,KW-0732~Signal,KW-0802~TPR repeat,		KW-0143~Chaperone,KW-0678~Repressor,	KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	DOMAIN:J,REGION:Disordered,REGION:Flexible linker,REPEAT:TPR,REPEAT:TPR 1,REPEAT:TPR 2,REPEAT:TPR 3,REPEAT:TPR 4,REPEAT:TPR 5,REPEAT:TPR 6,REPEAT:TPR 7,REPEAT:TPR 8,REPEAT:TPR 9,
DNAJC7	DnaJ heat shock protein family (Hsp40) member C7(DNAJC7)	Homo sapiens			GO:0006457~protein folding,GO:0051085~chaperone mediated protein folding requiring cofactor,GO:1900034~regulation of cellular response to heat,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0016020~membrane,GO:0070062~extracellular exosome,	GO:0001671~ATPase activator activity,GO:0005515~protein binding,GO:0031072~heat shock protein binding,	IPR001440:TPR_1,IPR001623:DnaJ_domain,IPR011990:TPR-like_helical_dom_sf,IPR019734:TPR_repeat,IPR036869:J_dom_sf,IPR047150:SGT,				SM00028:TPR,SM00271:DnaJ,		KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0802~TPR repeat,		KW-0143~Chaperone,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:J,MUTAGEN:H->A: Predominantly nuclear localization. Abolishes interaction with HSP90AA1 and HSPA1A/B; when associated with A-101 and A-333.,MUTAGEN:R->A: Impairs interaction with HSP90AA1 and HSPA1A/B. Abolishes interaction with HSP90AA1 and HSPA1A/B; when associated with A-101 and A-409.,MUTAGEN:R->A: Impairs interaction with HSP90AA1 and HSPA1A/B. Abolishes interaction with HSP90AA1 and HSPA1A/B; when associated with A-333 and A-409.,REGION:Disordered,REPEAT:TPR,REPEAT:TPR 1,REPEAT:TPR 2,REPEAT:TPR 3,REPEAT:TPR 4,REPEAT:TPR 5,REPEAT:TPR 6,REPEAT:TPR 7,REPEAT:TPR 8,REPEAT:TPR 9,
DNAJC9	DnaJ heat shock protein family (Hsp40) member C9(DNAJC9)	Homo sapiens			GO:0006334~nucleosome assembly,GO:0032781~positive regulation of ATPase activity,	GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0101031~chaperone complex,	GO:0005515~protein binding,GO:0031072~heat shock protein binding,GO:0042393~histone binding,GO:0051087~chaperone binding,	IPR001623:DnaJ_domain,IPR018253:DnaJ_domain_CS,IPR036869:J_dom_sf,				SM00271:DnaJ,		KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0175~Coiled coil,		KW-0143~Chaperone,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:J,MUTAGEN:C->S: Does not affect interaction with histones.,MUTAGEN:EEAKEA->AAAKAE: Reduces the co-chaperone complex formation with MCM2; histone H3.3 and H4.,MUTAGEN:FL->AA: Reduces the formation of the co-chaperone complex with MCM2 and histones H3.3 and H4.,MUTAGEN:HPD->QPN: Increased binding to histones H3 and H4. Less integration of histones H3 and H4 in chromatin. Increased recruitment of histone deposition factors to chromatin. Trapped on chromatin throughout the cell cycle in a manner depending on histone-binding. Released from chromatin trap; when associated with Ala-224; Ala-227; Ala-238 and Ala-242.,MUTAGEN:LKAAI->AKAAA: Disrupts the formation of the co-chaperone complex with MCM2 and histones H3.3 and H4.,MUTAGEN:MEAKY->AEAKA: Partial loss of histone dimer H3-H4 interaction. Reduces the co-chaperone complex formation with MCM2; histone H3.3 and H4.,MUTAGEN:QKDR->AKDA: Partial loss of histone dimer H3-H4 interaction. Reduces the formation of the co-chaperone complex with MCM2 and histones H3.3 and H4.,MUTAGEN:QKDRQKEMDNFLAQMEAKY->AKDAQKEMDNFLAQAEAKA: Abolishes the interaction with MCM2, TONSL and histones H3.3 and H4. Disrupts the formation of the co-chaperone complex with MCM2 and histones H3.3 and H4.,REGION:Disordered,REGION:Required for histone binding,
EP300	E1A binding protein p300(EP300)	Homo sapiens		h_carm-erPathway:CARM1 and Regulation of the Estrogen Receptor,h_carm1Pathway:Transcription Regulation by Methyltransferase of CARM1,h_g2Pathway:Cell Cycle: G2/M Checkpoint,h_her2Pathway:Role of ERBB2 in Signal Transduction and Oncology,h_hifPathway:Hypoxia-Inducible Factor in the Cardiovascular System,h_il7Pathway:IL-7 Signal Transduction,h_mef2dPathway:Role of MEF2D in T-cell Apoptosis,h_melanocytePathway:Melanocyte Development and Pigmentation Pathway,h_nthiPathway:NFkB activation by Nontypeable Hemophilus influenzae,h_p53hypoxiaPathway:Hypoxia and p53 in the Cardiovascular system,h_pelp1Pathway:Pelp1 Modulation of Estrogen Receptor Activity,h_pitx2Pathway:Multi-step Regulation of Transcription by Pitx2,h_PparaPathway:Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha),h_PPARgPathway:Role of PPAR-gamma Coactivators in Obesity and Thermogenesis,h_relaPathway:Acetylation and Deacetylation of RelA in The Nucleus,h_tgfbPathway:TGF beta signaling pathway,h_vdrPathway:Control of Gene Expression by Vitamin D Receptor,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001666~response to hypoxia,GO:0001756~somitogenesis,GO:0001966~thigmotaxis,GO:0002209~behavioral defense response,GO:0002223~stimulatory C-type lectin receptor signaling pathway,GO:0006110~regulation of glycolytic process,GO:0006355~regulation of transcription, DNA-templated,GO:0006366~transcription from RNA polymerase II promoter,GO:0006473~protein acetylation,GO:0006475~internal protein amino acid acetylation,GO:0006915~apoptotic process,GO:0007049~cell cycle,GO:0007249~I-kappaB kinase/NF-kappaB signaling,GO:0007399~nervous system development,GO:0007507~heart development,GO:0007519~skeletal muscle tissue development,GO:0007611~learning or memory,GO:0007623~circadian rhythm,GO:0009887~animal organ morphogenesis,GO:0010506~regulation of autophagy,GO:0010507~negative regulation of autophagy,GO:0010628~positive regulation of gene expression,GO:0010742~macrophage derived foam cell differentiation,GO:0010821~regulation of mitochondrion organization,GO:0010976~positive regulation of neuron projection development,GO:0018076~N-terminal peptidyl-lysine acetylation,GO:0018393~internal peptidyl-lysine acetylation,GO:0018394~peptidyl-lysine acetylation,GO:0030183~B cell differentiation,GO:0030220~platelet formation,GO:0030324~lung development,GO:0030511~positive regulation of transforming growth factor beta receptor signaling pathway,GO:0031333~negative regulation of protein complex assembly,GO:0031648~protein destabilization,GO:0031669~cellular response to nutrient levels,GO:0034644~cellular response to UV,GO:0035264~multicellular organism growth,GO:0035855~megakaryocyte development,GO:0036268~swimming,GO:0042307~positive regulation of protein import into nucleus,GO:0042771~intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator,GO:0043627~response to estrogen,GO:0043923~positive regulation by host of viral transcription,GO:0045444~fat cell differentiation,GO:0045721~negative regulation of gluconeogenesis,GO:0045815~positive regulation of gene expression, epigenetic,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046427~positive regulation of JAK-STAT cascade,GO:0048511~rhythmic process,GO:0050821~protein stabilization,GO:0050896~response to stimulus,GO:0051091~positive regulation of sequence-specific DNA binding transcription factor activity,GO:0060325~face morphogenesis,GO:0060765~regulation of androgen receptor signaling pathway,GO:0071233~cellular response to leucine,GO:0090043~regulation of tubulin deacetylation,GO:1900034~regulation of cellular response to heat,GO:1901796~regulation of signal transduction by p53 class mediator,GO:1904263~positive regulation of TORC1 signaling,	GO:0000123~histone acetyltransferase complex,GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0032993~protein-DNA complex,	GO:0001221~transcription cofactor binding,GO:0001223~transcription coactivator binding,GO:0002039~p53 binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003684~damaged DNA binding,GO:0003712~transcription cofactor activity,GO:0003713~transcription coactivator activity,GO:0004402~histone acetyltransferase activity,GO:0004468~lysine N-acetyltransferase activity, acting on acetyl phosphate as donor,GO:0005515~protein binding,GO:0008013~beta-catenin binding,GO:0008270~zinc ion binding,GO:0010484~H3 histone acetyltransferase activity,GO:0010485~H4 histone acetyltransferase activity,GO:0016407~acetyltransferase activity,GO:0016746~transferase activity, transferring acyl groups,GO:0016922~ligand-dependent nuclear receptor binding,GO:0031490~chromatin DNA binding,GO:0034212~peptide N-acetyltransferase activity,GO:0043993~histone acetyltransferase activity (H3-K18 specific),GO:0044013~H2B histone acetyltransferase activity,GO:0044017~histone acetyltransferase activity (H3-K27 specific),GO:0046872~metal ion binding,GO:0048156~tau protein binding,GO:0050681~androgen receptor binding,GO:0051059~NF-kappaB binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:0061733~peptide-lysine-N-acetyltransferase activity,GO:0097157~pre-mRNA intronic binding,GO:0097677~STAT family protein binding,	IPR000197:Znf_TAZ,IPR000433:Znf_ZZ,IPR001487:Bromodomain,IPR003101:KIX_dom,IPR009110:Nuc_rcpt_coact,IPR010303:RING_CBP-p300,IPR013083:Znf_RING/FYVE/PHD,IPR013178:Histone_AcTrfase_Rtt109/CBP,IPR014744:Nuc_rcpt_coact_CREBbp,IPR018359:Bromodomain_CS,IPR031162:CBP_P300_HAT,IPR035898:TAZ_dom_sf,IPR036427:Bromodomain-like_sf,IPR036529:KIX_dom_sf,IPR037073:Nuc_rcpt_coact_CREBbp_sf,IPR038547:RING_CBP-p300_sf,IPR043145:Znf_ZZ_sf,	hsa03083:Polycomb repressive complex,hsa03250:Viral life cycle - HIV-1,hsa04024:cAMP signaling pathway,hsa04066:HIF-1 signaling pathway,hsa04068:FoxO signaling pathway,hsa04110:Cell cycle,hsa04310:Wnt signaling pathway,hsa04330:Notch signaling pathway,hsa04350:TGF-beta signaling pathway,hsa04520:Adherens junction,hsa04630:JAK-STAT signaling pathway,hsa04720:Long-term potentiation,hsa04916:Melanogenesis,hsa04919:Thyroid hormone signaling pathway,hsa04922:Glucagon signaling pathway,hsa04935:Growth hormone synthesis, secretion and action,hsa05016:Huntington disease,hsa05152:Tuberculosis,hsa05161:Hepatitis B,hsa05164:Influenza A,hsa05165:Human papillomavirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05200:Pathways in cancer,hsa05203:Viral carcinogenesis,hsa05206:MicroRNAs in cancer,hsa05211:Renal cell carcinoma,hsa05215:Prostate cancer,	114500~Colorectal cancer, somatic,613684~Rubinstein-Taybi syndrome 2,618333~Menke-Hennekam syndrome 2,		SM00291:ZnF_ZZ,SM00297:BROMO,SM00551:ZnF_TAZ,SM01250:KAT11,	KW-0090~Biological rhythms,KW-0131~Cell cycle,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0158~Chromosome,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0991~Intellectual disability,	KW-0103~Bromodomain,KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0012~Acyltransferase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0164~Citrullination,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO),DOMAIN:Bromo,DOMAIN:CBP/p300-type HAT,DOMAIN:KIX,DOMAIN:TAZ-type,DOMAIN:ZZ-type,MOTIF:Nuclear localization signal,MUTAGEN:C->R: Increased acetyltransferase activity.,MUTAGEN:D->R: 70% decrease in activity; when associated with R-1625. 90% decrease in activity; when associated with E-1505 and R-1625. 90% decrease in activity; when associated with R-1357; R-1505 and R-1625.,MUTAGEN:D->R: 70% decrease in activity; when associated with R-1628. 90% decrease in activity; when associated with R-1505 and R-1628. 90% decrease in activity; when associated with R-1357; R-1505 and R-1628.,MUTAGEN:D->Y: Abolished acetyltransferase and acyltransferase activities. Abolishes autoacetylation. Does not interact with TFAP2A and inhibits transcriptional coactivation of TFAP2A by CITED2. Does not inhibit interaction with CITED2, DNA-binding of TFAP2A or nuclear localization of TFAP2A or CITED2. No enhancement of FOXO1-mediated transcriptional activity. No inhibition of insulin-mediated translocation to the cytoplasm. No acetylation of RXRA.,MUTAGEN:E->K: Increased acetyltransferase activity.,MUTAGEN:E->R: 90% decrease in activity; when associated with R-1625 and R-1628. 90% decrease in activity; when associated with R-1357; R-1625 and R-1628.,MUTAGEN:F->A: Abolished acetyltransferase activity.,MUTAGEN:F->E: Increased acetyltransferase activity.,MUTAGEN:K->A: Abolishes sumoylation and transcriptional repression when associated with A-1024.,MUTAGEN:K->A: Abolishes sumoylation and transcriptional repression; when associated with A-1020.,MUTAGEN:K->R: Abolishes sumoylation and transcriptional repression; when associated with R-1020.,MUTAGEN:K->R: Abolishes sumoylation and transcriptional repression; when associated with R-1024.,MUTAGEN:L->A: Inhibits interaction with HIF1A and transcription activation; when associated with A-344.,MUTAGEN:L->A: Inhibits interaction with HIF1A and transcription activation; when associated with A-345.,MUTAGEN:R->K: Abolishes interaction with NCOA2.,MUTAGEN:R->K: No effect on interaction with NCOA2.,MUTAGEN:R->K: Strongly reduces interaction with NCOA2.,MUTAGEN:RR->EE: Increased acetyltransferase activity.,MUTAGEN:S->A: Abolishes AMPK-mediated phosphorylation.,MUTAGEN:S->D: Phosphomimetic mutant that leads to descreased interaction with nuclear receptors.,MUTAGEN:S->R: Loss of activity; when associated with R-1397.,MUTAGEN:S->W: Loss of activity; when associated with W-1396.,MUTAGEN:T->L: 40% decrease in activity.,MUTAGEN:T->R: 40% decrease in activity. 90% decrease in activity; when associated with R-1505; R-1625 and R-1628.,MUTAGEN:TMKNVL->NAAIRS: Inhibits interaction with HIF1A. Reduces interaction with CITED2.,MUTAGEN:VCLPLK->NAAIRS: Inhibits interaction with HIF1A. Does not inhibit interaction with CITED2.,MUTAGEN:Y->F: Abolishes autoacetylation. Loss of acetyltransferase activity.,MUTAGEN:Y->R: Loss of activity; when associated with R-1396.,MUTAGEN:Y->W: Loss of activity; when associated with W-1397.,REGION:Binding region for E1A adenovirus,REGION:CRD1; mediates transcriptional repression,REGION:Disordered,REGION:Interaction with ALX1,REGION:Interaction with HTLV-1 Tax,REGION:Interaction with NCOA2,REGION:Interaction with RORA,REGION:Interaction with histone,SITE:Breakpoint for translocation to form KAT6A-EP300 and EP300-KAT6A,SITE:Interaction with NCOA2,ZN_FING:TAZ-type,ZN_FING:TAZ-type 1,ZN_FING:TAZ-type 2,ZN_FING:ZZ-type,
ELF1	E74 like ETS transcription factor 1(ELF1)	Homo sapiens			GO:0001817~regulation of cytokine production,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0030154~cell differentiation,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0050860~negative regulation of T cell receptor signaling pathway,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0043565~sequence-specific DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000418:Ets_dom,IPR022084:TF_Elf_N,IPR036388:WH-like_DNA-bd_sf,IPR036390:WH_DNA-bd_sf,IPR046328:ETS_fam,				SM00413:ETS,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0010~Activator,KW-0238~DNA-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DNA_BIND:ETS,DOMAIN:ETS,DOMAIN:Transcription factor Elf N-terminal,REGION:Disordered,
ELF2	E74 like ETS transcription factor 2(ELF2)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0030154~cell differentiation,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0016604~nuclear body,	GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0043565~sequence-specific DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000418:Ets_dom,IPR022084:TF_Elf_N,IPR036388:WH-like_DNA-bd_sf,IPR036390:WH_DNA-bd_sf,IPR046328:ETS_fam,				SM00413:ETS,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0010~Activator,KW-0238~DNA-binding,	KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DNA_BIND:ETS,DOMAIN:ETS,DOMAIN:Transcription factor Elf N-terminal,REGION:Disordered,
EBNA1BP2	EBNA1 binding protein 2(EBNA1BP2)	Homo sapiens			GO:0006364~rRNA processing,GO:0042254~ribosome biogenesis,GO:0042273~ribosomal large subunit biogenesis,	GO:0005694~chromosome,GO:0005730~nucleolus,GO:0030687~preribosome, large subunit precursor,GO:0034399~nuclear periphery,	GO:0003723~RNA binding,GO:0005515~protein binding,	IPR008610:Ebp2,					KW-0690~Ribosome biogenesis,	KW-0539~Nucleus,		KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),REGION:Disordered,
EFCAB14	EF-hand calcium binding domain 14(EFCAB14)	Homo sapiens				GO:0016020~membrane,	GO:0005509~calcium ion binding,	IPR002048:EF_hand_dom,IPR011992:EF-hand-dom_pair,IPR042352:EFCAB14,						KW-0472~Membrane,		KW-0677~Repeat,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-0597~Phosphoprotein,	DOMAIN:EF-hand,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,REGION:Disordered,TRANSMEM:Helical,
EFHD2	EF-hand domain family member D2(EFHD2)	Homo sapiens				GO:0045121~membrane raft,	GO:0005509~calcium ion binding,GO:0045296~cadherin binding,	IPR002048:EF_hand_dom,IPR011992:EF-hand-dom_pair,IPR040365:EFHD1/2,IPR049025:AIF-1_EF_pair,				SM00054:EFh,		KW-0472~Membrane,		KW-0677~Repeat,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:EF-hand,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,REGION:Disordered,
EFR3A	EFR3 homolog A(EFR3A)	Homo sapiens			GO:0046854~phosphatidylinositol phosphorylation,GO:0072659~protein localization to plasma membrane,	GO:0005829~cytosol,GO:0005886~plasma membrane,		IPR016024:ARM-type_fold,IPR049152:EFR3-like_ARM,						KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,	KW-1268~Autism spectrum disorder,KW-1269~Autism,				KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,	MUTAGEN:CCCC->SSSS: Induces localization to the cytosol.,
EHD1	EH domain containing 1(EHD1)	Homo sapiens			GO:0006886~intracellular protein transport,GO:0006897~endocytosis,GO:0010886~positive regulation of cholesterol storage,GO:0010976~positive regulation of neuron projection development,GO:0016197~endosomal transport,GO:0031175~neuron projection development,GO:0032456~endocytic recycling,GO:0034383~low-density lipoprotein particle clearance,GO:0042632~cholesterol homeostasis,GO:0051260~protein homooligomerization,GO:0060271~cilium assembly,GO:0061512~protein localization to cilium,GO:0072659~protein localization to plasma membrane,GO:1901741~positive regulation of myoblast fusion,GO:1990090~cellular response to nerve growth factor stimulus,GO:2001137~positive regulation of endocytic recycling,	GO:0005737~cytoplasm,GO:0005769~early endosome,GO:0005811~lipid particle,GO:0005886~plasma membrane,GO:0010008~endosome membrane,GO:0016020~membrane,GO:0020018~ciliary pocket membrane,GO:0030139~endocytic vesicle,GO:0031095~platelet dense tubular network membrane,GO:0031901~early endosome membrane,GO:0048471~perinuclear region of cytoplasm,GO:0055038~recycling endosome membrane,GO:0070062~extracellular exosome,	GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0005525~GTP binding,GO:0031267~small GTPase binding,GO:0042802~identical protein binding,GO:0045296~cadherin binding,	IPR000261:EH_dom,IPR002048:EF_hand_dom,IPR011992:EF-hand-dom_pair,IPR018247:EF_Hand_1_Ca_BS,IPR027417:P-loop_NTPase,IPR030381:G_DYNAMIN_dom,IPR031692:EHD_N,IPR040990:DUF5600,IPR045063:Dynamin_N,	hsa04144:Endocytosis,			SM00027:EH,	KW-0653~Protein transport,KW-0813~Transport,KW-0970~Cilium biogenesis/degradation,	KW-0472~Membrane,KW-0966~Cell projection,KW-0967~Endosome,KW-0969~Cilium,KW-1003~Cell membrane,		KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0106~Calcium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,		KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:Dynamin-type G,DOMAIN:EF-hand,DOMAIN:EH,MUTAGEN:G->R: Abolishes ATP-binding and localizes to cytoplasm.,MUTAGEN:K->A: Loss of interaction with MICALL1.,MUTAGEN:K->E: Loss of accumulation at the ciliary pocket. Loss of function in ciliogenesis. Loss of association with tubulovesicular structures and altered MICALL1 localization. No effect on MICALL1 localization; when associated with A-485.,MUTAGEN:V->P: Greatly reduces oligomerization and interaction with RAB11FIP2.,MUTAGEN:W->A: Loss of accumulation at the ciliary pocket. Loss of function in ciliogenesis. Abolishes interaction with RAB11FIP2. No effect on MICALL1 localization; when associated with E-483.,REGION:G1 motif,REGION:G2 motif,REGION:G3 motif,REGION:G4 motif,REGION:G5 motif,
ELAVL1	ELAV like RNA binding protein 1(ELAVL1)	Homo sapiens		h_vegfPathway:VEGF, Hypoxia, and Angiogenesis,	GO:0006606~protein import into nucleus,GO:0016441~posttranscriptional gene silencing,GO:0032930~positive regulation of superoxide anion generation,GO:0045727~positive regulation of translation,GO:0048255~mRNA stabilization,GO:0051260~protein homooligomerization,GO:0060965~negative regulation of gene silencing by miRNA,GO:0061157~mRNA destabilization,GO:0070935~3'-UTR-mediated mRNA stabilization,GO:2000036~regulation of stem cell population maintenance,	GO:0000932~P-body,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0010494~cytoplasmic stress granule,GO:0016020~membrane,GO:0016528~sarcoplasm,GO:0031410~cytoplasmic vesicle,GO:0098794~postsynapse,GO:0098978~glutamatergic synapse,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003725~double-stranded RNA binding,GO:0003729~mRNA binding,GO:0003730~mRNA 3'-UTR binding,GO:0005515~protein binding,GO:0019901~protein kinase binding,GO:0035198~miRNA binding,GO:0035925~mRNA 3'-UTR AU-rich region binding,GO:0042803~protein homodimerization activity,	IPR000504:RRM_dom,IPR002343:Hud_Sxl_RNA,IPR006548:ELAD_HU_SF,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR034996:HuR_RRM2,IPR035979:RBD_domain_sf,	hsa04152:AMPK signaling pathway,hsa04657:IL-17 signaling pathway,			SM00360:RRM,		KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,		KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:RRM,DOMAIN:RRM 1,DOMAIN:RRM 2,DOMAIN:RRM 3,MUTAGEN:S->A: Decreases phosphorylation by PRKCD.,MUTAGEN:S->A: Decreases phosphorylation by PRKCD. Nearly abolishes phosphorylation by PRKCD and translocation from the nucleus into the cytoplasm; when associated with A-221.,MUTAGEN:S->A: Decreases phosphorylation by PRKCD. Nearly abolishes phosphorylation by PRKCD and translocation from the nucleus into the cytoplasm; when associated with A-318.,REGION:Disordered,
ELOVL1	ELOVL fatty acid elongase 1(ELOVL1)	Homo sapiens			GO:0006636~unsaturated fatty acid biosynthetic process,GO:0019367~fatty acid elongation, saturated fatty acid,GO:0030148~sphingolipid biosynthetic process,GO:0030497~fatty acid elongation,GO:0034625~fatty acid elongation, monounsaturated fatty acid,GO:0034626~fatty acid elongation, polyunsaturated fatty acid,GO:0035338~long-chain fatty-acyl-CoA biosynthetic process,GO:0036109~alpha-linolenic acid metabolic process,GO:0042761~very long-chain fatty acid biosynthetic process,GO:0043651~linoleic acid metabolic process,GO:0046513~ceramide biosynthetic process,GO:0061436~establishment of skin barrier,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0016020~membrane,	GO:0005515~protein binding,GO:0009922~fatty acid elongase activity,	IPR002076:ELO_fam,IPR030457:ELO_CS,IPR033681:ELOVL1,	hsa00062:Fatty acid elongation,hsa01040:Biosynthesis of unsaturated fatty acids,hsa01100:Metabolic pathways,hsa01212:Fatty acid metabolism,	618527~Ichthyotic keratoderma, spasticity, hypomyelination, and dysmorphic facies,			KW-0275~Fatty acid biosynthesis,KW-0276~Fatty acid metabolism,KW-0443~Lipid metabolism,KW-0444~Lipid biosynthesis,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,	KW-0225~Disease variant,KW-0977~Ichthyosis,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0808~Transferase,	KW-0007~Acetylation,	MOTIF:Di-lysine motif,TRANSMEM:Helical,
EML4	EMAP like 4(EML4)	Homo sapiens			GO:0000226~microtubule cytoskeleton organization,GO:0000278~mitotic cell cycle,GO:0007017~microtubule-based process,GO:0007080~mitotic metaphase plate congression,GO:0008608~attachment of spindle microtubules to kinetochore,GO:0051301~cell division,	GO:0005737~cytoplasm,GO:0005815~microtubule organizing center,GO:0005829~cytosol,GO:0005874~microtubule,GO:0015630~microtubule cytoskeleton,GO:0016020~membrane,GO:0030496~midbody,GO:0072686~mitotic spindle,	GO:0005515~protein binding,GO:0008017~microtubule binding,GO:0043014~alpha-tubulin binding,GO:0043621~protein self-association,GO:0048487~beta-tubulin binding,	IPR001680:WD40_rpt,IPR005108:HELP,IPR011047:Quinoprotein_ADH-like_supfam,IPR015943:WD40/YVTN_repeat-like_dom_sf,IPR036322:WD40_repeat_dom_sf,	hsa05200:Pathways in cancer,hsa05223:Non-small cell lung cancer,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,			SM00320:WD40,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,	KW-0206~Cytoskeleton,KW-0493~Microtubule,KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0677~Repeat,KW-0853~WD repeat,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:HELP,MUTAGEN:S->A: Phosphorylation-deficient mutant which shows increased localization to microtubules during mitosis, increased microtubule stability and impaired chromosome congression; when associated with A-144.,MUTAGEN:S->A: Phosphorylation-deficient mutant which shows increased localization to microtubules during mitosis, increased microtubule stability and impaired chromosome congression; when associated with A-146.,MUTAGEN:S->D: Phosphomimetic mutant which shows reduced localization to microtubules during interphase; when associated with D-144.,MUTAGEN:S->D: Phosphomimetic mutant which shows reduced localization to microtubules during interphase; when associated with D-146.,REGION:Disordered,REGION:Microtubule-binding,REPEAT:WD,REPEAT:WD 1,REPEAT:WD 10,REPEAT:WD 11,REPEAT:WD 12,REPEAT:WD 13,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,REPEAT:WD 7,REPEAT:WD 8,REPEAT:WD 9,SITE:Breakpoint for translocation to form the EML4-ALK fusion protein (variant 1),SITE:Breakpoint for translocation to form the EML4-ALK fusion protein (variant 2),
ENY2	ENY2 transcription and export complex 2 subunit(ENY2)	Homo sapiens			GO:0006282~regulation of DNA repair,GO:0006325~chromatin organization,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006368~transcription elongation from RNA polymerase II promoter,GO:0006406~mRNA export from nucleus,GO:0015031~protein transport,GO:0016578~histone deubiquitination,GO:0016973~poly(A)+ mRNA export from nucleus,GO:0043484~regulation of RNA splicing,GO:0045893~positive regulation of transcription, DNA-templated,GO:0061179~negative regulation of insulin secretion involved in cellular response to glucose stimulus,	GO:0000124~SAGA complex,GO:0005643~nuclear pore,GO:0005654~nucleoplasm,GO:0005739~mitochondrion,GO:0033276~transcription factor TFTC complex,GO:0044615~nuclear pore nuclear basket,GO:0070390~transcription export complex 2,GO:0071819~DUBm complex,	GO:0003682~chromatin binding,GO:0003713~transcription coactivator activity,GO:0005515~protein binding,GO:0030374~ligand-dependent nuclear receptor transcription coactivator activity,	IPR018783:TF_ENY2,IPR038212:TF_EnY2_sf,					KW-0509~mRNA transport,KW-0653~Protein transport,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0811~Translocation,KW-0813~Transport,	KW-0539~Nucleus,				KW-0010~Activator,KW-0156~Chromatin regulator,	KW-0007~Acetylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),
EID1	EP300 interacting inhibitor of differentiation 1(EID1)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0007049~cell cycle,GO:0030154~cell differentiation,GO:0045892~negative regulation of transcription, DNA-templated,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0036464~cytoplasmic ribonucleoprotein granule,	GO:0003714~transcription corepressor activity,GO:0005515~protein binding,GO:0035035~histone acetyltransferase binding,	IPR033258:EID,					KW-0131~Cell cycle,KW-0221~Differentiation,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0678~Repressor,	KW-0832~Ubl conjugation,	COMPBIAS:Acidic residues,MOTIF:LXCXE motif,MUTAGEN:C->G: Abolishes RB1 binding.,MUTAGEN:E->Q: Abolishes RB1 binding.,MUTAGEN:L->S: Abolishes RB1 binding.,REGION:Disordered,REGION:Interaction with NR0B2,
EDEM3	ER degradation enhancing alpha-mannosidase like protein 3(EDEM3)	Homo sapiens			GO:0005975~carbohydrate metabolic process,GO:0006058~mannoprotein catabolic process,GO:0006486~protein glycosylation,GO:0006986~response to unfolded protein,GO:0036503~ERAD pathway,GO:1904380~endoplasmic reticulum mannose trimming,GO:1904382~mannose trimming involved in glycoprotein ERAD pathway,	GO:0005783~endoplasmic reticulum,GO:0005788~endoplasmic reticulum lumen,GO:0016020~membrane,GO:0044322~endoplasmic reticulum quality control compartment,	GO:0004571~mannosyl-oligosaccharide 1,2-alpha-mannosidase activity,GO:0005509~calcium ion binding,	IPR001382:Glyco_hydro_47,IPR003137:PA_domain,IPR012341:6hp_glycosidase-like_sf,IPR036026:Seven-hairpin_glycosidases,IPR037322:EDEM3_PA,IPR044674:EDEM1/2/3,IPR046450:PA_dom_sf,	hsa04141:Protein processing in endoplasmic reticulum,	619493~Congenital disorder of glycosylation, type IIv,			KW-0834~Unfolded protein response,	KW-0256~Endoplasmic reticulum,	KW-0900~Congenital disorder of glycosylation,	KW-0732~Signal,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0326~Glycosidase,KW-0378~Hydrolase,	KW-0325~Glycoprotein,	ACT_SITE:Proton donor,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:PA,MOTIF:Prevents secretion from ER,REGION:Disordered,
EMC10	ER membrane protein complex subunit 10(EMC10)	Homo sapiens			GO:0001525~angiogenesis,GO:0001938~positive regulation of endothelial cell proliferation,GO:0010595~positive regulation of endothelial cell migration,GO:0045050~protein insertion into ER membrane by stop-transfer membrane-anchor sequence,GO:0045766~positive regulation of angiogenesis,GO:0071816~tail-anchored membrane protein insertion into ER membrane,	GO:0005576~extracellular region,GO:0005789~endoplasmic reticulum membrane,GO:0016020~membrane,GO:0072546~ER membrane protein complex,	GO:0032977~membrane insertase activity,			619264~Neurodevelopmental disorder with dysmorphic facies and variable seizures,			KW-0037~Angiogenesis,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0964~Secreted,	KW-0991~Intellectual disability,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
EMC8	ER membrane protein complex subunit 8(EMC8)	Homo sapiens			GO:0045050~protein insertion into ER membrane by stop-transfer membrane-anchor sequence,GO:0071816~tail-anchored membrane protein insertion into ER membrane,	GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005794~Golgi apparatus,GO:0016020~membrane,GO:0072546~ER membrane protein complex,	GO:0005515~protein binding,GO:0032977~membrane insertase activity,	IPR005366:EMC8/9,IPR037518:MPN,						KW-0256~Endoplasmic reticulum,KW-0472~Membrane,						DOMAIN:MPN,
ERGIC2	ERGIC and golgi 2(ERGIC2)	Homo sapiens			GO:0006888~ER to Golgi vesicle-mediated transport,GO:0006890~retrograde vesicle-mediated transport, Golgi to ER,	GO:0000139~Golgi membrane,GO:0005634~nucleus,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005793~endoplasmic reticulum-Golgi intermediate compartment,GO:0005794~Golgi apparatus,GO:0016020~membrane,GO:0030134~ER to Golgi transport vesicle,GO:0033116~endoplasmic reticulum-Golgi intermediate compartment membrane,GO:0043231~intracellular membrane-bounded organelle,GO:1990351~transporter complex,	GO:0005515~protein binding,	IPR012936:Erv_C,IPR039542:Erv_N,IPR045888:Erv,					KW-0813~Transport,KW-0931~ER-Golgi transport,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				DOMAIN:Endoplasmic reticulum vesicle transporter C-terminal,DOMAIN:Endoplasmic reticulum vesicle transporter N-terminal,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
ERH	ERH mRNA splicing and mitosis factor(ERH)	Homo sapiens			GO:0006139~nucleobase-containing compound metabolic process,GO:0006213~pyrimidine nucleoside metabolic process,GO:0007049~cell cycle,	GO:0005634~nucleus,GO:0030496~midbody,GO:0034709~methylosome,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0008327~methyl-CpG binding,	IPR000781:ERH,IPR035912:EHR_sf,			PIRSF016393:Enh_rudimentary,		KW-0131~Cell cycle,	KW-0539~Nucleus,					KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),
ETHE1	ETHE1 persulfide dioxygenase(ETHE1)	Homo sapiens			GO:0006749~glutathione metabolic process,GO:0070813~hydrogen sulfide metabolic process,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,	GO:0005506~iron ion binding,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0050313~sulfur dioxygenase activity,	IPR001279:Metallo-B-lactamas,IPR036866:RibonucZ/Hydroxyglut_hydro,IPR044528:POD-like_MBL-fold,	hsa00920:Sulfur metabolism,hsa01100:Metabolic pathways,	602473~Ethylmalonic encephalopathy,		SM00849:Lactamase_B,		KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,	KW-0809~Transit peptide,	KW-0408~Iron,KW-0479~Metal-binding,	KW-0223~Dioxygenase,KW-0560~Oxidoreductase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:Metallo-beta-lactamase,TRANSIT:Mitochondrion,
ETS1	ETS proto-oncogene 1, transcription factor(ETS1)	Homo sapiens		h_etsPathway:METS affect on Macrophage Differentiation,h_keratinocytePathway:Keratinocyte Differentiation,	GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0006955~immune response,GO:0008285~negative regulation of cell proliferation,GO:0010595~positive regulation of endothelial cell migration,GO:0010628~positive regulation of gene expression,GO:0030154~cell differentiation,GO:0030578~PML body organization,GO:0042981~regulation of apoptotic process,GO:0043536~positive regulation of blood vessel endothelial cell migration,GO:0045648~positive regulation of erythrocyte differentiation,GO:0045765~regulation of angiogenesis,GO:0045766~positive regulation of angiogenesis,GO:0045786~negative regulation of cell cycle,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046677~response to antibiotic,GO:0048870~cell motility,GO:0050729~positive regulation of inflammatory response,GO:1902895~positive regulation of pri-miRNA transcription from RNA polymerase II promoter,GO:1904996~positive regulation of leukocyte adhesion to vascular endothelial cell,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001222~transcription corepressor binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003676~nucleic acid binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0030374~ligand-dependent nuclear receptor transcription coactivator activity,GO:0042802~identical protein binding,GO:0043565~sequence-specific DNA binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000418:Ets_dom,IPR003118:Pointed_dom,IPR013761:SAM/pointed_sf,IPR016311:Transform_prot_C-ets,IPR036388:WH-like_DNA-bd_sf,IPR036390:WH_DNA-bd_sf,IPR041886:SAM_PNT-ETS-1,IPR045688:Ets1_N_flank,IPR046328:ETS_fam,	hsa04014:Ras signaling pathway,hsa04218:Cellular senescence,hsa05166:Human T-cell leukemia virus 1 infection,hsa05200:Pathways in cancer,hsa05211:Renal cell carcinoma,		PIRSF001698:Transforming_factor_C-ets,	SM00251:SAM_PNT,SM00413:ETS,	KW-0391~Immunity,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0656~Proto-oncogene,			KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DNA_BIND:ETS,DOMAIN:ETS,DOMAIN:PNT,REGION:Activation domain; required for transcription activation,REGION:Disordered,REGION:Helix H4,REGION:Helix H5,REGION:Helix HI-1,REGION:Helix HI-2,
EWSR1	EWS RNA binding protein 1(EWSR1)	Homo sapiens			GO:0006355~regulation of transcription, DNA-templated,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0015030~Cajal body,	GO:0003712~transcription cofactor activity,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0042802~identical protein binding,GO:0046872~metal ion binding,	IPR000504:RRM_dom,IPR001876:Znf_RanBP2,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR034869:EWS_RRM,IPR034870:TET_fam,IPR035979:RBD_domain_sf,IPR036443:Znf_RanBP2_sf,	hsa05202:Transcriptional misregulation in cancer,	612219~Ewing sarcoma,612219~Neuroepithelioma,		SM00360:RRM,SM00547:ZnF_RBZ,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,	KW-0656~Proto-oncogene,	KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0112~Calmodulin-binding,KW-0678~Repressor,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:IQ,DOMAIN:RRM,DOMAIN:RanBP2-type,MOTIF:Nuclear localization signal,MUTAGEN:D->A: No effect on nuclear targeting.,MUTAGEN:P->A: Cytoplasmic localization.,MUTAGEN:R->A: Cytoplasmic localization.,MUTAGEN:R->A: No effect on nuclear targeting.,MUTAGEN:R->K: No effect on nuclear targeting.,MUTAGEN:Y->A: Cytoplasmic localization.,REGION:31 X approximate tandem repeats,REGION:Disordered,REGION:EAD (Gln/Pro/Thr-rich),REPEAT:1,REPEAT:10,REPEAT:11,REPEAT:12,REPEAT:13,REPEAT:14,REPEAT:15,REPEAT:16,REPEAT:17,REPEAT:18,REPEAT:19,REPEAT:2,REPEAT:20,REPEAT:21,REPEAT:22,REPEAT:23,REPEAT:24,REPEAT:25,REPEAT:26,REPEAT:27,REPEAT:28,REPEAT:29,REPEAT:3,REPEAT:30,REPEAT:31,REPEAT:4,REPEAT:5,REPEAT:6,REPEAT:7,REPEAT:8,REPEAT:9,SITE:Breakpoint for insertion to form EWSR1-FEV fusion protein,SITE:Breakpoint for translocation to form chimeric EWSR1/ATF1 protein,ZN_FING:RanBP2-type,
FBXW11	F-box and WD repeat domain containing 11(FBXW11)	Homo sapiens			GO:0000132~establishment of mitotic spindle orientation,GO:0000209~protein polyubiquitination,GO:0006470~protein dephosphorylation,GO:0007097~nuclear migration,GO:0007281~germ cell development,GO:0008090~retrograde axonal transport,GO:0016055~Wnt signaling pathway,GO:0016567~protein ubiquitination,GO:0031023~microtubule organizing center organization,GO:0031146~SCF-dependent proteasomal ubiquitin-dependent protein catabolic process,GO:0031648~protein destabilization,GO:0042753~positive regulation of circadian rhythm,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0045862~positive regulation of proteolysis,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0047496~vesicle transport along microtubule,GO:0048511~rhythmic process,GO:0048854~brain morphogenesis,GO:1901223~negative regulation of NIK/NF-kappaB signaling,	GO:0000151~ubiquitin ligase complex,GO:0000776~kinetochore,GO:0005634~nucleus,GO:0005635~nuclear envelope,GO:0005813~centrosome,GO:0005829~cytosol,GO:0005875~microtubule associated complex,GO:0005881~cytoplasmic microtubule,GO:0019005~SCF ubiquitin ligase complex,GO:0043005~neuron projection,GO:0043025~neuronal cell body,GO:1904115~axon cytoplasm,	GO:0005515~protein binding,GO:0046983~protein dimerization activity,GO:0051010~microtubule plus-end binding,GO:0061630~ubiquitin protein ligase activity,GO:0070840~dynein complex binding,GO:1990756~protein binding, bridging involved in substrate recognition for ubiquitination,	IPR001680:WD40_rpt,IPR001810:F-box_dom,IPR015943:WD40/YVTN_repeat-like_dom_sf,IPR019775:WD40_repeat_CS,IPR020472:G-protein_beta_WD-40_rep,IPR021977:Beta-TrCP_D,IPR036047:F-box-like_dom_sf,IPR036322:WD40_repeat_dom_sf,	hsa04114:Oocyte meiosis,hsa04120:Ubiquitin mediated proteolysis,hsa04218:Cellular senescence,hsa04310:Wnt signaling pathway,hsa04340:Hedgehog signaling pathway,hsa04390:Hippo signaling pathway,hsa04710:Circadian rhythm,hsa05131:Shigellosis,hsa05170:Human immunodeficiency virus 1 infection,	618914~Neurodevelopmental, jaw, eye, and digital syndrome,		SM00256:FBOX,SM00320:WD40,SM01028:Beta-TrCP_D,	KW-0090~Biological rhythms,KW-0131~Cell cycle,KW-0833~Ubl conjugation pathway,KW-0879~Wnt signaling pathway,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,	KW-0677~Repeat,KW-0853~WD repeat,				DOMAIN:F-box,REGION:Disordered,REGION:Homodimerization domain D,REPEAT:WD,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,REPEAT:WD 7,
FBXW2	F-box and WD repeat domain containing 2(FBXW2)	Homo sapiens			GO:0006508~proteolysis,GO:0036211~protein modification process,	GO:0005829~cytosol,	GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,	IPR001680:WD40_rpt,IPR001810:F-box_dom,IPR015943:WD40/YVTN_repeat-like_dom_sf,IPR019775:WD40_repeat_CS,IPR020472:G-protein_beta_WD-40_rep,IPR036047:F-box-like_dom_sf,IPR036322:WD40_repeat_dom_sf,IPR042627:FBXW2,				SM00256:FBOX,SM00320:WD40,	KW-0833~Ubl conjugation pathway,			KW-0677~Repeat,KW-0853~WD repeat,			KW-0007~Acetylation,	DOMAIN:F-box,REPEAT:WD,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,REPEAT:WD 7,
FBXW5	F-box and WD repeat domain containing 5(FBXW5)	Homo sapiens			GO:0007088~regulation of mitotic nuclear division,GO:0010824~regulation of centrosome duplication,GO:0016567~protein ubiquitination,GO:0031146~SCF-dependent proteasomal ubiquitin-dependent protein catabolic process,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0019005~SCF ubiquitin ligase complex,GO:0080008~Cul4-RING E3 ubiquitin ligase complex,	GO:0005515~protein binding,GO:0019901~protein kinase binding,	IPR001680:WD40_rpt,IPR001810:F-box_dom,IPR015943:WD40/YVTN_repeat-like_dom_sf,IPR036047:F-box-like_dom_sf,IPR036322:WD40_repeat_dom_sf,IPR042508:FBXW5,				SM00256:FBOX,SM00320:WD40,	KW-0833~Ubl conjugation pathway,	KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0853~WD repeat,			KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	DOMAIN:F-box,MOTIF:D-box,MUTAGEN:S->A: Impairs phosphorylation by PLK4 and enhances ubiquitination of SASS6.,REPEAT:WD,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,REPEAT:WD 7,
FBXO21	F-box protein 21(FBXO21)	Homo sapiens			GO:0006511~ubiquitin-dependent protein catabolic process,	GO:0000151~ubiquitin ligase complex,GO:0005829~cytosol,	GO:0003677~DNA binding,GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,	IPR001810:F-box_dom,IPR011722:Hemimethylated_DNA-bd_dom,IPR032698:SirB1_N,IPR036047:F-box-like_dom_sf,IPR036623:Hemimethylated_DNA-bd_sf,				SM00992:YccV-like,	KW-0833~Ubl conjugation pathway,							DOMAIN:F-box,DOMAIN:Hemimethylated DNA-binding,
FBXO34	F-box protein 34(FBXO34)	Homo sapiens					GO:0005515~protein binding,	IPR001810:F-box_dom,IPR036047:F-box-like_dom_sf,IPR039594:FBXO34/46,					KW-0833~Ubl conjugation pathway,							COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:F-box,REGION:Disordered,
FBXO7	F-box protein 7(FBXO7)	Homo sapiens			GO:0000422~mitophagy,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0006626~protein targeting to mitochondrion,GO:0010975~regulation of neuron projection development,GO:0016567~protein ubiquitination,GO:0019222~regulation of metabolic process,GO:0030098~lymphocyte differentiation,GO:0031647~regulation of protein stability,GO:0040012~regulation of locomotion,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0045620~negative regulation of lymphocyte differentiation,GO:0070936~protein K48-linked ubiquitination,GO:1901526~positive regulation of macromitophagy,GO:1903377~negative regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway,GO:1903599~positive regulation of mitophagy,GO:2000134~negative regulation of G1/S transition of mitotic cell cycle,	GO:0000151~ubiquitin ligase complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0019005~SCF ubiquitin ligase complex,GO:0032991~macromolecular complex,GO:0097409~glial cytoplasmic inclusion,GO:0097414~classical Lewy body,GO:0097462~Lewy neurite,GO:1990037~Lewy body core,GO:1990038~Lewy body corona,	GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0019901~protein kinase binding,GO:0031625~ubiquitin protein ligase binding,GO:0043130~ubiquitin binding,GO:0046982~protein heterodimerization activity,GO:1990756~protein binding, bridging involved in substrate recognition for ubiquitination,	IPR001810:F-box_dom,IPR021625:PI31_Prot_N,IPR029071:Ubiquitin-like_domsf,IPR036047:F-box-like_dom_sf,IPR047118:Fbxo7,		260300~Parkinson disease 15, autosomal recessive,		SM00256:FBOX,	KW-0833~Ubl conjugation pathway,	KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0907~Parkinson disease,KW-0908~Parkinsonism,				KW-0488~Methylation,	COMPBIAS:Polar residues,DOMAIN:F-box,MOTIF:RFDP motif,MUTAGEN:R->G: Loss of SIRT7 ubiquitination.,MUTAGEN:T->M: Impairs interaction with PRKN.,MUTAGEN:V->E: Abolishes interaction with PSMF1.,REGION:Disordered,REGION:Important for dimerization and interaction with PSMF1,REGION:Important for interaction with CDK6,REGION:Important for interaction with PINK1,REGION:Ubiquitin-like,
FAAP20	FA core complex associated protein 20(FAAP20)	Homo sapiens			GO:0006513~protein monoubiquitination,GO:0006974~cellular response to DNA damage stimulus,GO:0019985~translesion synthesis,GO:0036297~interstrand cross-link repair,	GO:0000785~chromatin,GO:0005654~nucleoplasm,GO:0005694~chromosome,GO:0005829~cytosol,GO:0016604~nuclear body,GO:0030054~cell junction,GO:0043240~Fanconi anaemia nuclear complex,	GO:0005515~protein binding,GO:0031593~polyubiquitin binding,GO:0043130~ubiquitin binding,GO:0046872~metal ion binding,GO:0070530~K63-linked polyubiquitin binding,	IPR031490:UBZ2_FAAP20,IPR031491:FANCA_interact,					KW-0227~DNA damage,KW-0234~DNA repair,	KW-0158~Chromosome,KW-0539~Nucleus,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0597~Phosphoprotein,	DOMAIN:UBZ2-type,MUTAGEN:C->A: Abolishes binding to ubiquitin.,MUTAGEN:C->A: Abolishes binding to ubiquitin. Abolishes binding to ubiquitin; when associated with A-150.,MUTAGEN:C->A: Abolishes binding to ubiquitin; when associated with A-147.,MUTAGEN:D->A: Abolishes binding to ubiquitin.,REGION:Disordered,ZN_FING:UBZ2-type,
FERMT3	FERM domain containing kindlin 3(FERMT3)	Homo sapiens			GO:0007155~cell adhesion,GO:0007159~leukocyte cell-cell adhesion,GO:0007160~cell-matrix adhesion,GO:0007229~integrin-mediated signaling pathway,GO:0030335~positive regulation of cell migration,GO:0033622~integrin activation,GO:0033632~regulation of cell-cell adhesion mediated by integrin,GO:0034446~substrate adhesion-dependent cell spreading,GO:0070527~platelet aggregation,	GO:0002102~podosome,GO:0005576~extracellular region,GO:0016020~membrane,GO:0030055~cell-substrate junction,GO:0031093~platelet alpha granule lumen,GO:0042995~cell projection,GO:0070062~extracellular exosome,GO:0070161~anchoring junction,	GO:0005178~integrin binding,GO:0008289~lipid binding,	IPR001849:PH_domain,IPR011993:PH-like_dom_sf,IPR014352:FERM/acyl-CoA-bd_prot_sf,IPR019747:FERM_CS,IPR019748:FERM_central,IPR019749:Band_41_domain,IPR035963:FERM_2,IPR037837:PH_Kindlin/fermitin,IPR037843:Kindlin/fermitin,IPR040790:Kindlin_2_N,	hsa04611:Platelet activation,	612840~Leukocyte adhesion deficiency, type III,		SM00233:PH,SM00295:B41,	KW-0130~Cell adhesion,	KW-0965~Cell junction,KW-0966~Cell projection,	KW-0225~Disease variant,				KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:Band 4.1,DOMAIN:FERM,DOMAIN:FERM central,DOMAIN:Kindlin-2 N-terminal,DOMAIN:PH,REGION:Disordered,
FIBP	FGF1 intracellular binding protein(FIBP)	Homo sapiens			GO:0008543~fibroblast growth factor receptor signaling pathway,GO:0070527~platelet aggregation,	GO:0005634~nucleus,GO:0005739~mitochondrion,GO:0012505~endomembrane system,GO:0016020~membrane,GO:0016607~nuclear speck,	GO:0017134~fibroblast growth factor binding,	IPR008614:FIBP,		617107~Thauvin-Robinet-Faivre syndrome,				KW-0472~Membrane,KW-0539~Nucleus,	KW-0225~Disease variant,				KW-0007~Acetylation,
FKBP1A	FKBP prolyl isomerase 1A(FKBP1A)	Homo sapiens		h_mtorPathway:mTOR Signaling Pathway,h_nfatPathway:NFAT and Hypertrophy of the heart (Transcription in the broken heart),	GO:0000413~protein peptidyl-prolyl isomerization,GO:0003007~heart morphogenesis,GO:0006457~protein folding,GO:0006458~'de novo' protein folding,GO:0022417~protein maturation by protein folding,GO:0030512~negative regulation of transforming growth factor beta receptor signaling pathway,GO:0032092~positive regulation of protein binding,GO:0032515~negative regulation of phosphoprotein phosphatase activity,GO:0032880~regulation of protein localization,GO:0032926~negative regulation of activin receptor signaling pathway,GO:0042026~protein refolding,GO:0042110~T cell activation,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0050776~regulation of immune response,GO:0055010~ventricular cardiac muscle tissue morphogenesis,GO:0060314~regulation of ryanodine-sensitive calcium-release channel activity,GO:0060347~heart trabecula formation,GO:0070588~calcium ion transmembrane transport,GO:0097435~supramolecular fiber organization,GO:1902991~regulation of amyloid precursor protein catabolic process,GO:1990000~amyloid fibril formation,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0014802~terminal cisterna,GO:0016020~membrane,GO:0016529~sarcoplasmic reticulum,GO:0030018~Z disc,GO:0033017~sarcoplasmic reticulum membrane,GO:0098562~cytoplasmic side of membrane,GO:1990425~ryanodine receptor complex,	GO:0003755~peptidyl-prolyl cis-trans isomerase activity,GO:0005160~transforming growth factor beta receptor binding,GO:0005515~protein binding,GO:0005527~macrolide binding,GO:0005528~FK506 binding,GO:0030547~receptor inhibitor activity,GO:0034713~type I transforming growth factor beta receptor binding,GO:0044325~ion channel binding,GO:0070411~I-SMAD binding,GO:0070697~activin receptor binding,	IPR001179:PPIase_FKBP_dom,IPR046357:PPIase_dom_sf,						KW-0472~Membrane,KW-0703~Sarcoplasmic reticulum,KW-0963~Cytoplasm,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0413~Isomerase,KW-0697~Rotamase,	KW-0007~Acetylation,	DOMAIN:PPIase FKBP-type,REGION:Disordered,TRANSMEM:Helical,
FKBP2	FKBP prolyl isomerase 2(FKBP2)	Homo sapiens			GO:0061077~chaperone-mediated protein folding,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0016020~membrane,	GO:0003755~peptidyl-prolyl cis-trans isomerase activity,GO:0005515~protein binding,GO:0005528~FK506 binding,	IPR001179:PPIase_FKBP_dom,IPR044609:FKBP2/11,IPR046357:PPIase_dom_sf,						KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0413~Isomerase,KW-0697~Rotamase,		DOMAIN:PPIase FKBP-type,MOTIF:Prevents secretion from ER,TRANSMEM:Helical,
FKBP5	FKBP prolyl isomerase 5(FKBP5)	Homo sapiens			GO:0000413~protein peptidyl-prolyl isomerization,GO:0006457~protein folding,GO:0009617~response to bacterium,GO:0061077~chaperone-mediated protein folding,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016020~membrane,GO:0070062~extracellular exosome,	GO:0003755~peptidyl-prolyl cis-trans isomerase activity,GO:0005515~protein binding,GO:0005528~FK506 binding,GO:0031072~heat shock protein binding,	IPR001179:PPIase_FKBP_dom,IPR001440:TPR_1,IPR011990:TPR-like_helical_dom_sf,IPR019734:TPR_repeat,IPR046357:PPIase_dom_sf,	hsa04915:Estrogen signaling pathway,	608516~Major depressive disorder and accelerated response to antidepressant drug treatment,		SM00028:TPR,		KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0802~TPR repeat,		KW-0143~Chaperone,KW-0413~Isomerase,KW-0697~Rotamase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:PPIase FKBP-type,DOMAIN:PPIase FKBP-type 1,DOMAIN:PPIase FKBP-type 2,MUTAGEN:K->Q: Mimics acetylation; impaired interaction with AKT1 and PHLPP1; when associated with Q-155.,MUTAGEN:K->Q: Mimics acetylation; impaired interaction with AKT1 and PHLPP1; when associated with Q-28.,MUTAGEN:K->R: Decreased acetylation; promotes interaction with AKT1 and PHLPP1; when associated with R-155.,MUTAGEN:K->R: Decreased acetylation; promotes interaction with AKT1 and PHLPP1; when associated with R-28.,REGION:Disordered,REPEAT:TPR,REPEAT:TPR 1,REPEAT:TPR 2,REPEAT:TPR 3,
FKBP8	FKBP prolyl isomerase 8(FKBP8)	Homo sapiens			GO:0001933~negative regulation of protein phosphorylation,GO:0006457~protein folding,GO:0006915~apoptotic process,GO:0007224~smoothened signaling pathway,GO:0010468~regulation of gene expression,GO:0021904~dorsal/ventral neural tube patterning,GO:0030509~BMP signaling pathway,GO:0030513~positive regulation of BMP signaling pathway,GO:0035264~multicellular organism growth,GO:0035556~intracellular signal transduction,GO:0043010~camera-type eye development,GO:0043066~negative regulation of apoptotic process,GO:0048665~neuron fate specification,GO:0070585~protein localization to mitochondrion,GO:1903146~regulation of mitophagy,	GO:0005739~mitochondrion,GO:0005740~mitochondrial envelope,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0012505~endomembrane system,GO:0016020~membrane,GO:0031966~mitochondrial membrane,GO:0032991~macromolecular complex,	GO:0003755~peptidyl-prolyl cis-trans isomerase activity,GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0042802~identical protein binding,GO:0044183~protein binding involved in protein folding,GO:0046872~metal ion binding,GO:0097718~disordered domain specific binding,	IPR001179:PPIase_FKBP_dom,IPR001440:TPR_1,IPR011990:TPR-like_helical_dom_sf,IPR013105:TPR_2,IPR019734:TPR_repeat,IPR046357:PPIase_dom_sf,	hsa04137:Mitophagy - animal,			SM00028:TPR,	KW-0053~Apoptosis,KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-0496~Mitochondrion,		KW-0677~Repeat,KW-0802~TPR repeat,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0413~Isomerase,KW-0697~Rotamase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:PPIase FKBP-type,MUTAGEN:D->N: Abolishes calcium-binding and reduces affinity for BCL2; when associated with Asn-149.,MUTAGEN:D->N: Abolishes calcium-binding and reduces affinity for BCL2; when associated with Asn-151.,REGION:Disordered,REPEAT:TPR,REPEAT:TPR 1,REPEAT:TPR 2,REPEAT:TPR 3,TRANSMEM:Helical,
FLII	FLII actin remodeling protein(FLII)	Homo sapiens			GO:0008154~actin polymerization or depolymerization,GO:0030239~myofibril assembly,GO:0051014~actin filament severing,GO:0051016~barbed-end actin filament capping,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005903~brush border,GO:0005925~focal adhesion,GO:0015629~actin cytoskeleton,GO:0034451~centriolar satellite,	GO:0003779~actin binding,GO:0005515~protein binding,GO:0005546~phosphatidylinositol-4,5-bisphosphate binding,GO:0051015~actin filament binding,	IPR001611:Leu-rich_rpt,IPR003591:Leu-rich_rpt_typical-subtyp,IPR007122:Villin/Gelsolin,IPR007123:Gelsolin-like_dom,IPR025875:Leu-rich_rpt_4,IPR029006:ADF-H/Gelsolin-like_dom_sf,IPR032675:LRR_dom_sf,		620635~Cardiomyopathy, dilated, 2J,		SM00262:GEL,SM00364:LRR_BAC,SM00365:LRR_SD22,SM00369:LRR_TYP,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0965~Cell junction,		KW-0433~Leucine-rich repeat,KW-0677~Repeat,		KW-0009~Actin-binding,KW-0010~Activator,KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:Gelsolin-like,MUTAGEN:E->K: No change in ESR1 binding but reduced binding to ACTL6A and reduced coactivator function.,MUTAGEN:G->S: No change in binding to ACTL6A or in coactivator function.,REGION:Disordered,REGION:Interaction with ACTL6A,REGION:Interaction with LRRFIP1 and LRRFIP2,REPEAT:Gelsolin-like 1,REPEAT:Gelsolin-like 2,REPEAT:Gelsolin-like 3,REPEAT:Gelsolin-like 4,REPEAT:Gelsolin-like 5,REPEAT:LRR 1,REPEAT:LRR 10,REPEAT:LRR 11,REPEAT:LRR 12,REPEAT:LRR 13,REPEAT:LRR 14,REPEAT:LRR 15,REPEAT:LRR 2,REPEAT:LRR 3,REPEAT:LRR 4,REPEAT:LRR 5,REPEAT:LRR 6,REPEAT:LRR 7,REPEAT:LRR 8,REPEAT:LRR 9,
FXR1	FMR1 autosomal homolog 1(FXR1)	Homo sapiens			GO:0000381~regulation of alternative mRNA splicing, via spliceosome,GO:0001934~positive regulation of protein phosphorylation,GO:0006417~regulation of translation,GO:0006915~apoptotic process,GO:0007283~spermatogenesis,GO:0007286~spermatid development,GO:0007517~muscle organ development,GO:0017148~negative regulation of translation,GO:0021542~dentate gyrus development,GO:0032720~negative regulation of tumor necrosis factor production,GO:0043488~regulation of mRNA stability,GO:0045187~regulation of circadian sleep/wake cycle, sleep,GO:0045727~positive regulation of translation,GO:0048170~positive regulation of long-term neuronal synaptic plasticity,GO:0048513~animal organ development,GO:0048856~anatomical structure development,GO:0050728~negative regulation of inflammatory response,GO:0050767~regulation of neurogenesis,GO:0051028~mRNA transport,GO:0051292~nuclear pore complex assembly,GO:0051489~regulation of filopodium assembly,GO:0051664~nuclear pore localization,GO:0051966~regulation of synaptic transmission, glutamatergic,GO:0060538~skeletal muscle organ development,GO:0061157~mRNA destabilization,GO:0099577~regulation of translation at presynapse, modulating synaptic transmission,GO:1900272~negative regulation of long-term synaptic potentiation,GO:2000637~positive regulation of gene silencing by miRNA,	GO:0005634~nucleus,GO:0005635~nuclear envelope,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005840~ribosome,GO:0005844~polysome,GO:0010494~cytoplasmic stress granule,GO:0014069~postsynaptic density,GO:0016020~membrane,GO:0030424~axon,GO:0030426~growth cone,GO:0036464~cytoplasmic ribonucleoprotein granule,GO:0043005~neuron projection,GO:0043025~neuronal cell body,GO:0043034~costamere,GO:0043197~dendritic spine,GO:0043232~intracellular non-membrane-bounded organelle,GO:0044326~dendritic spine neck,GO:0048471~perinuclear region of cytoplasm,GO:0098793~presynapse,GO:0098794~postsynapse,GO:0098978~glutamatergic synapse,GO:1902737~dendritic filopodium,	GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0003730~mRNA 3'-UTR binding,GO:0005515~protein binding,GO:0033592~RNA strand annealing activity,GO:0035925~mRNA 3'-UTR AU-rich region binding,GO:0042803~protein homodimerization activity,GO:0045182~translation regulator activity,GO:0046982~protein heterodimerization activity,GO:1905538~polysome binding,	IPR004087:KH_dom,IPR004088:KH_dom_type_1,IPR008395:Agenet-like_dom,IPR022034:FMR1-like_C_core,IPR032172:FXR1_C1,IPR032177:FXR_C3,IPR036612:KH_dom_type_1_sf,IPR040148:FMR1,IPR040472:FMRP_KH0,IPR041560:Tudor_FRM1,IPR047425:Tudor_Agenet_FXR1_rpt1,IPR047427:Tudor_Agenet_FXR1_rpt2,IPR047494:KH_I_FXR1_rpt1,IPR047495:KH_I_FXR1_rpt2,IPR047496:KH_I_FXR1_rpt3,		618822~Congenital myopathy 9A with respiratory insufficiency and bone fractures,618823~Congenital myopathy 9B, proximal, with minicore lesions,		SM00322:KH,	KW-0221~Differentiation,KW-0517~Myogenesis,KW-0744~Spermatogenesis,	KW-0539~Nucleus,KW-0770~Synapse,KW-0963~Cytoplasm,KW-0966~Cell projection,		KW-0677~Repeat,KW-0732~Signal,		KW-0217~Developmental protein,KW-0694~RNA-binding,KW-9996~Developmental protein,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Agenet-like,DOMAIN:Agenet-like 1,DOMAIN:Agenet-like 2,DOMAIN:Fragile X messenger ribonucleoprotein 1-like C-terminal core,DOMAIN:Fragile X-related 1 protein C-terminal region 3,DOMAIN:Fragile X-related protein 1 C-terminal region 1,DOMAIN:KH 1,DOMAIN:KH 2,MUTAGEN:EY->AA: Reduced binding to PAK1.,MUTAGEN:GN->DA: Does not affect binding to PAK1.,MUTAGEN:I->N: Abolished binding to PAK1.,MUTAGEN:QVLLE->KVLLA: Abolished binding to PAK1.,MUTAGEN:S->A: Abolished phosphorylation by PAK1, leading to impaired activity.,MUTAGEN:S->D: Mimics phosphorylation state; leading to increased activity.,REGION:Disordered,REGION:RNA-binding RGG-box,
FOSL2	FOS like 2, AP-1 transcription factor subunit(FOSL2)	Homo sapiens		h_ranklPathway:Bone Remodelling,	GO:0000902~cell morphogenesis,GO:0001649~osteoblast differentiation,GO:0001666~response to hypoxia,GO:0001865~NK T cell differentiation,GO:0002062~chondrocyte differentiation,GO:0002437~inflammatory response to antigenic stimulus,GO:0003334~keratinocyte development,GO:0003417~growth plate cartilage development,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0008219~cell death,GO:0009410~response to xenobiotic stimulus,GO:0010467~gene expression,GO:0030183~B cell differentiation,GO:0030223~neutrophil differentiation,GO:0030225~macrophage differentiation,GO:0030282~bone mineralization,GO:0030316~osteoclast differentiation,GO:0032496~response to lipopolysaccharide,GO:0032964~collagen biosynthetic process,GO:0035264~multicellular organism growth,GO:0035962~response to interleukin-13,GO:0035988~chondrocyte proliferation,GO:0036446~myofibroblast differentiation,GO:0040014~regulation of multicellular organism growth,GO:0042100~B cell proliferation,GO:0042593~glucose homeostasis,GO:0045087~innate immune response,GO:0045444~fat cell differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048146~positive regulation of fibroblast proliferation,GO:0048745~smooth muscle tissue development,GO:0048771~tissue remodeling,GO:0048873~homeostasis of number of cells within a tissue,GO:0050852~T cell receptor signaling pathway,GO:0051384~response to glucocorticoid,GO:0060427~lung connective tissue development,GO:0060613~fat pad development,GO:0061144~alveolar secondary septum development,GO:0070254~mucus secretion,GO:0098760~response to interleukin-7,GO:1901142~insulin metabolic process,GO:1904606~fat cell apoptotic process,GO:1904760~regulation of myofibroblast differentiation,GO:1904975~response to bleomycin,GO:1990823~response to leukemia inhibitory factor,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0090575~RNA polymerase II transcription factor complex,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,	IPR000837:AP-1,IPR004827:bZIP,IPR046347:bZIP_sf,	hsa04380:Osteoclast differentiation,			SM00338:BRLZ,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:BZIP,DOMAIN:bZIP,REGION:Basic motif,REGION:Disordered,REGION:Leucine-zipper,
FRYL	FRY like transcription coactivator(FRYL)	Homo sapiens			GO:0000902~cell morphogenesis,GO:0031175~neuron projection development,	GO:0005938~cell cortex,GO:0030427~site of polarized growth,		IPR016024:ARM-type_fold,IPR025481:Cell_Morphogen_C,IPR025614:Cell_morpho_N,IPR029473:MOR2-PAG1_mid,IPR039867:Furry/Tao3/Mor2,IPR045842:Fry_C,					KW-0804~Transcription,KW-0805~Transcription regulation,			KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Polar residues,DOMAIN:Cell morphogenesis central region,DOMAIN:Cell morphogenesis protein C-terminal,DOMAIN:Cell morphogenesis protein N-terminal,DOMAIN:Protein furry C-terminal,REGION:Disordered,SITE:Breakpoint for insertion to form KMT2A/MLL1-AFF4 fusion protein,
FRG1	FSHD region gene 1(FRG1)	Homo sapiens			GO:0000398~mRNA splicing, via spliceosome,GO:0006364~rRNA processing,GO:0007517~muscle organ development,	GO:0005730~nucleolus,GO:0015030~Cajal body,GO:0030018~Z disc,GO:0055120~striated muscle dense body,GO:0071013~catalytic step 2 spliceosome,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0051015~actin filament binding,	IPR008999:Actin-crosslinking,IPR010414:FRG1,					KW-0507~mRNA processing,KW-0508~mRNA splicing,KW-0517~Myogenesis,KW-0690~Ribosome biogenesis,KW-0698~rRNA processing,	KW-0539~Nucleus,KW-0747~Spliceosome,KW-0963~Cytoplasm,				KW-0009~Actin-binding,KW-0694~RNA-binding,		COMPBIAS:Polar residues,MOTIF:Bipartite nuclear localization signal,MOTIF:Nuclear localization signal,REGION:Disordered,
FUNDC2	FUN14 domain containing 2(FUNDC2)	Homo sapiens			GO:0000422~mitophagy,GO:0010543~regulation of platelet activation,GO:0035356~cellular triglyceride homeostasis,	GO:0005634~nucleus,GO:0005739~mitochondrion,GO:0005741~mitochondrial outer membrane,	GO:0005515~protein binding,GO:0005547~phosphatidylinositol-3,4,5-trisphosphate binding,	IPR007014:FUN14,					KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0539~Nucleus,KW-1000~Mitochondrion outer membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,	TOPO_DOM:Cytoplasmic,TOPO_DOM:Mitochondrial intermembrane,TRANSMEM:Helical,
FUS	FUS RNA binding protein(FUS)	Homo sapiens			GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0008380~RNA splicing,GO:0043484~regulation of RNA splicing,GO:0045893~positive regulation of transcription, DNA-templated,GO:0048255~mRNA stabilization,GO:0051260~protein homooligomerization,GO:1905168~positive regulation of double-strand break repair via homologous recombination,GO:1990000~amyloid fibril formation,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0016020~membrane,GO:0043232~intracellular non-membrane-bounded organelle,	GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003712~transcription cofactor activity,GO:0003713~transcription coactivator activity,GO:0003723~RNA binding,GO:0003730~mRNA 3'-UTR binding,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0046872~metal ion binding,	IPR000504:RRM_dom,IPR001876:Znf_RanBP2,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR034870:TET_fam,IPR035979:RBD_domain_sf,IPR036443:Znf_RanBP2_sf,	hsa03015:mRNA surveillance pathway,hsa03040:Spliceosome,hsa05014:Amyotrophic lateral sclerosis,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05202:Transcriptional misregulation in cancer,	608030~Amyotrophic lateral sclerosis 6, with or without frontotemporal dementia,614782~Essential tremor, hereditary, 4,		SM00360:RRM,SM00547:ZnF_RBZ,		KW-0472~Membrane,KW-0539~Nucleus,	KW-0036~Amyotrophic lateral sclerosis,KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0656~Proto-oncogene,	KW-0677~Repeat,KW-0812~Transmembrane,KW-0863~Zinc-finger,KW-1133~Transmembrane helix,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,KW-0694~RNA-binding,	KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:RRM,DOMAIN:RanBP2-type,REGION:Disordered,SITE:Breakpoint for translocation to form FUS/TLS-CHOP oncogene,SITE:Breakpoint for translocation to form chimeric FUS/ATF1 protein,TRANSMEM:Helical,ZN_FING:RanBP2-type,
FXYD5	FXYD domain containing ion transport regulator 5(FXYD5)	Homo sapiens			GO:0006811~ion transport,GO:0030033~microvillus assembly,GO:0034220~ion transmembrane transport,GO:0043269~regulation of ion transport,GO:0046588~negative regulation of calcium-dependent cell-cell adhesion,GO:2000649~regulation of sodium ion transmembrane transporter activity,	GO:0016020~membrane,	GO:0003779~actin binding,GO:0005515~protein binding,GO:0017080~sodium channel regulator activity,GO:0045296~cadherin binding,GO:0099106~ion channel regulator activity,	IPR000272:Ion-transport_regulator_FXYD,IPR047297:FXYD_motif,					KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0407~Ion channel,	KW-0325~Glycoprotein,	COMPBIAS:Polar residues,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
FGD3	FYVE, RhoGEF and PH domain containing 3(FGD3)	Homo sapiens			GO:0007010~cytoskeleton organization,GO:0008360~regulation of cell shape,GO:0030036~actin cytoskeleton organization,GO:0043087~regulation of GTPase activity,GO:0046847~filopodium assembly,GO:0051056~regulation of small GTPase mediated signal transduction,	GO:0001726~ruffle,GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0030027~lamellipodium,	GO:0005085~guanyl-nucleotide exchange factor activity,GO:0031267~small GTPase binding,GO:0046872~metal ion binding,	IPR000219:DH-domain,IPR000306:Znf_FYVE,IPR001849:PH_domain,IPR011011:Znf_FYVE_PHD,IPR011993:PH-like_dom_sf,IPR013083:Znf_RING/FYVE/PHD,IPR017455:Znf_FYVE-rel,IPR035899:DBL_dom_sf,IPR035941:FGD1-4_PH2,	hsa04810:Regulation of actin cytoskeleton,			SM00064:FYVE,SM00233:PH,SM00325:RhoGEF,		KW-0206~Cytoskeleton,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0344~Guanine-nucleotide releasing factor,	KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:DH,DOMAIN:FYVE-type,DOMAIN:PH,DOMAIN:PH 1,DOMAIN:PH 2,REGION:Disordered,ZN_FING:FYVE-type,
FAS	Fas cell surface death receptor(FAS)	Homo sapiens	38.Cell_cycle_arrest_and_apoptosis_ceramide,39.Deg_of_Chromosomal_DNA,46.P13K_PTEN,58.(CD40L)_immnosurveillance,72.IAP_interaction_with_cell_death_pathways,97.Immune_injury_MS-lesions_MS_antigen,	h_asbcellPathway:Antigen Dependent B Cell Activation,h_bbcellPathway:Bystander B Cell Activation,h_ctlPathway:CTL mediated immune response against target cells ,h_fasPathway:FAS signaling pathway ( CD95 ),h_hivnefPathway:HIV-I Nef: negative effector of Fas and TNF,h_hsp27Pathway:Stress Induction of HSP Regulation,h_il2rbPathway:IL-2 Receptor Beta Chain in T cell Activation,h_keratinocytePathway:Keratinocyte Differentiation,h_pmlPathway:Regulation of transcriptional activity by PML,h_tcapoptosisPathway:HIV Induced T Cell Apoptosis,	GO:0001934~positive regulation of protein phosphorylation,GO:0006915~apoptotic process,GO:0006924~activation-induced cell death of T cells,GO:0006955~immune response,GO:0007165~signal transduction,GO:0032872~regulation of stress-activated MAPK cascade,GO:0033209~tumor necrosis factor-mediated signaling pathway,GO:0034198~cellular response to amino acid starvation,GO:0036337~Fas signaling pathway,GO:0042981~regulation of apoptotic process,GO:0043065~positive regulation of apoptotic process,GO:0043066~negative regulation of apoptotic process,GO:0065003~macromolecular complex assembly,GO:0071260~cellular response to mechanical stimulus,GO:0071455~cellular response to hyperoxia,GO:0097049~motor neuron apoptotic process,GO:0097191~extrinsic apoptotic signaling pathway,GO:0097192~extrinsic apoptotic signaling pathway in absence of ligand,GO:0097527~necroptotic signaling pathway,GO:2001235~positive regulation of apoptotic signaling pathway,GO:2001269~positive regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway,	GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,GO:0016604~nuclear body,GO:0031264~death-inducing signaling complex,GO:0031265~CD95 death-inducing signaling complex,GO:0045121~membrane raft,GO:0070062~extracellular exosome,	GO:0004888~transmembrane signaling receptor activity,GO:0005031~tumor necrosis factor-activated receptor activity,GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0019900~kinase binding,GO:0038023~signaling receptor activity,GO:0042802~identical protein binding,	IPR000488:Death_domain,IPR001368:TNFR/NGFR_Cys_rich_reg,IPR008063:Fas_rcpt,IPR011029:DEATH-like_dom_sf,IPR033998:TNFRSF6_death,IPR033999:TNFRSF6_N,	hsa01524:Platinum drug resistance,hsa04010:MAPK signaling pathway,hsa04060:Cytokine-cytokine receptor interaction,hsa04115:p53 signaling pathway,hsa04210:Apoptosis,hsa04217:Necroptosis,hsa04650:Natural killer cell mediated cytotoxicity,hsa04668:TNF signaling pathway,hsa04932:Non-alcoholic fatty liver disease,hsa04936:Alcoholic liver disease,hsa04940:Type I diabetes mellitus,hsa05010:Alzheimer disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05130:Pathogenic Escherichia coli infection,hsa05142:Chagas disease,hsa05143:African trypanosomiasis,hsa05160:Hepatitis C,hsa05161:Hepatitis B,hsa05162:Measles,hsa05163:Human cytomegalovirus infection,hsa05164:Influenza A,hsa05165:Human papillomavirus infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05200:Pathways in cancer,hsa05205:Proteoglycans in cancer,hsa05320:Autoimmune thyroid disease,hsa05330:Allograft rejection,hsa05332:Graft-versus-host disease,hsa05417:Lipid and atherosclerosis,	601859~Autoimmune lymphoproliferative syndrome,601859~Autoimmune lymphoproliferative syndrome, type IA,Squamous cell carcinoma, burn scar-related, somatic~Squamous cell carcinoma, burn scar-related, somatic,		SM00005:DEATH,SM00208:TNFR,	KW-0053~Apoptosis,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0112~Calmodulin-binding,KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:(Microbial infection) N-beta-linked (GlcNAc) arginine,CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (GalNAc...) threonine,DOMAIN:Death,DOMAIN:TNFR-Cys,LIPID:S-palmitoyl cysteine,MUTAGEN:C->V: Loss of palmitoylation.,MUTAGEN:E->K: Loss of interaction with FADD.,MUTAGEN:I->D: Constitutive activation. Promotes apoptosis, both in the presence and in the absence of stimulation by a ligand.,MUTAGEN:K->D: Strongly decreased interaction with FADD.,MUTAGEN:Q->K: Loss of interaction with FADD.,MUTAGEN:R->A: Abolished GlcNAcylation by E.coli NleB1.,MUTAGEN:R->E: Strongly decreased interaction with FADD.,MUTAGEN:Y->D: Decreased interaction with FADD.,REGION:Interaction with CALM,REGION:Interaction with HIPK3,REPEAT:TNFR-Cys,REPEAT:TNFR-Cys 1,REPEAT:TNFR-Cys 2,REPEAT:TNFR-Cys 3,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
FOS	Fos proto-oncogene, AP-1 transcription factor subunit(FOS)	Homo sapiens	3.T_cell_receptor,67.Ikaros_and_signaling_inhibitors,92.Ancient_Host_Defense_Pathways,	h_arenrf2Pathway:Oxidative Stress Induced Gene Expression Via Nrf2,h_bcellsurvivalPathway:B Cell Survival Pathway,h_bcrPathway:BCR Signaling Pathway,h_cardiacEGFPathway:Role of EGF Receptor Transactivation by GPCRs in Cardiac Hypertrophy,h_ccr5Pathway:Pertussis toxin-insensitive CCR5 Signaling in Macrophage,h_cdmacPathway:Cadmium induces DNA synthesis and proliferation in macrophages,h_dreamPathway:Repression of Pain Sensation by the Transcriptional Regulator DREAM,h_egfPathway:EGF Signaling Pathway,h_epoPathway:EPO Signaling Pathway,h_etsPathway:METS affect on Macrophage Differentiation,h_fcer1Pathway:Fc Epsilon Receptor I Signaling in Mast Cells,h_gleevecPathway:Inhibition of Cellular Proliferation by Gleevec,h_gpcrPathway:Signaling Pathway from G-Protein Families,h_igf1Pathway:IGF-1 Signaling Pathway,h_il2Pathway:IL 2 signaling pathway,h_il2rbPathway:IL-2 Receptor Beta Chain in T cell Activation,h_il3Pathway:IL 3 signaling pathway,h_il6Pathway:IL 6 signaling pathway,h_insulinPathway:Insulin Signaling Pathway,h_keratinocytePathway:Keratinocyte Differentiation,h_mapkPathway:MAPKinase Signaling Pathway,h_metPathway:Signaling of Hepatocyte Growth Factor Receptor,h_ngfPathway:Nerve growth factor pathway (NGF),h_pdgfPathway:PDGF Signaling Pathway,h_ranklPathway:Bone Remodelling,h_tcrPathway:T Cell Receptor Signaling Pathway,h_tollPathway:Toll-Like Receptor Pathway,h_tpoPathway:TPO Signaling Pathway,h_tsp1Pathway:TSP-1 Induced Apoptosis in Microvascular Endothelial Cell ,	GO:0001661~conditioned taste aversion,GO:0006306~DNA methylation,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0006954~inflammatory response,GO:0007179~transforming growth factor beta receptor signaling pathway,GO:0007399~nervous system development,GO:0007565~female pregnancy,GO:0009410~response to xenobiotic stimulus,GO:0009416~response to light stimulus,GO:0009629~response to gravity,GO:0009636~response to toxic substance,GO:0014823~response to activity,GO:0014856~skeletal muscle cell proliferation,GO:0030316~osteoclast differentiation,GO:0032496~response to lipopolysaccharide,GO:0032570~response to progesterone,GO:0032868~response to insulin,GO:0034224~cellular response to zinc ion starvation,GO:0034614~cellular response to reactive oxygen species,GO:0035902~response to immobilization stress,GO:0035914~skeletal muscle cell differentiation,GO:0035994~response to muscle stretch,GO:0045471~response to ethanol,GO:0045672~positive regulation of osteoclast differentiation,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051412~response to corticosterone,GO:0051450~myoblast proliferation,GO:0051591~response to cAMP,GO:0060395~SMAD protein signal transduction,GO:0071276~cellular response to cadmium ion,GO:0071277~cellular response to calcium ion,GO:0071356~cellular response to tumor necrosis factor,GO:0071364~cellular response to epidermal growth factor stimulus,GO:0071374~cellular response to parathyroid hormone stimulus,GO:0071456~cellular response to hypoxia,GO:0071560~cellular response to transforming growth factor beta stimulus,GO:1902895~positive regulation of pri-miRNA transcription from RNA polymerase II promoter,GO:1903131~mononuclear cell differentiation,GO:1904628~cellular response to phorbol 13-acetate 12-myristate,GO:1990646~cellular response to prolactin,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0032993~protein-DNA complex,GO:0035976~transcription factor AP-1 complex,GO:0090575~RNA polymerase II transcription factor complex,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000979~RNA polymerase II core promoter sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001221~transcription cofactor binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:0070412~R-SMAD binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000837:AP-1,IPR004827:bZIP,IPR046347:bZIP_sf,	hsa01522:Endocrine resistance,hsa04010:MAPK signaling pathway,hsa04024:cAMP signaling pathway,hsa04210:Apoptosis,hsa04380:Osteoclast differentiation,hsa04620:Toll-like receptor signaling pathway,hsa04657:IL-17 signaling pathway,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04660:T cell receptor signaling pathway,hsa04662:B cell receptor signaling pathway,hsa04668:TNF signaling pathway,hsa04713:Circadian entrainment,hsa04725:Cholinergic synapse,hsa04728:Dopaminergic synapse,hsa04915:Estrogen signaling pathway,hsa04917:Prolactin signaling pathway,hsa04921:Oxytocin signaling pathway,hsa04926:Relaxin signaling pathway,hsa04928:Parathyroid hormone synthesis, secretion and action,hsa04932:Non-alcoholic fatty liver disease,hsa04935:Growth hormone synthesis, secretion and action,hsa05031:Amphetamine addiction,hsa05130:Pathogenic Escherichia coli infection,hsa05132:Salmonella infection,hsa05133:Pertussis,hsa05135:Yersinia infection,hsa05140:Leishmaniasis,hsa05142:Chagas disease,hsa05161:Hepatitis B,hsa05162:Measles,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05171:Coronavirus disease - COVID-19,hsa05200:Pathways in cancer,hsa05207:Chemical carcinogenesis - receptor activation,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05210:Colorectal cancer,hsa05224:Breast cancer,hsa05231:Choline metabolism in cancer,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,hsa05323:Rheumatoid arthritis,hsa05417:Lipid and atherosclerosis,hsa05418:Fluid shear stress and atherosclerosis,			SM00338:BRLZ,		KW-0256~Endoplasmic reticulum,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0656~Proto-oncogene,	KW-0175~Coiled coil,		KW-0238~DNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:BZIP,DOMAIN:bZIP,MUTAGEN:K->R: Abolishes sumoylation. No change in nuclear location nor on protein stability. Increased AP1 transactivation activity when heterodimerized with cJUN.,MUTAGEN:K->R: No change in sumoylation.,MUTAGEN:S->A: Loss of protein stability. Reduced MOS/MAPK-mediated transforming ability; when associated with A-374.,MUTAGEN:S->A: No change in sumoylation levels. Loss of protein stability. Reduced MOS/MAPK-mediated transforming ability; when associated with A-362.,MUTAGEN:S->D: Increased protein stability. Increased MOS/MAPK-mediated transforming ability and no change in sumoylation levels; when associated with D-362.,MUTAGEN:S->D: Increased protein stability. Increased MOS/MAPK-mediated transforming ability and no change in sumoylation levels; when associated with D-374.,MUTAGEN:T->D: Decreased sumoylation levels.,MUTAGEN:T->D: No change in sumoylation levels.,MUTAGEN:Y->E: Loss of activation of phospholipid synthesis; when associated with E-10.,MUTAGEN:Y->E: Loss of activation of phospholipid synthesis; when associated with E-30.,MUTAGEN:Y->F: No effect on Tyr-phosphorylation. Loss of endoplasmic reticulum localization in quiescent cells.,MUTAGEN:Y->F: Overall loss of Tyr-phosphorylation, including that of Y-10 phosphorylation. Localizes to the endoplasmic reticulum in quiescent cells. Activates phospholipid synthesis in growing cells.,MUTAGEN:Y->F: Overall loss of Tyr-phosphorylation, including that of Y-30 phosphorylation. Localizes to the endoplasmic reticulum in quiescent cells. Activates phospholipid synthesis in growing cells.,REGION:Basic motif; required for the activation of phospholipid synthesis, but not for CDS1-binding,REGION:Disordered,REGION:Leucine-zipper,
FTSJ1	FtsJ RNA 2'-O-methyltransferase 1(FTSJ1)	Homo sapiens			GO:0002128~tRNA nucleoside ribose methylation,GO:0002130~wobble position ribose methylation,GO:0002181~cytoplasmic translation,GO:0006400~tRNA modification,GO:0022008~neurogenesis,GO:0030488~tRNA methylation,GO:0032259~methylation,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0005515~protein binding,GO:0008171~O-methyltransferase activity,GO:0008175~tRNA methyltransferase activity,GO:0008757~S-adenosylmethionine-dependent methyltransferase activity,GO:0016423~tRNA (guanine) methyltransferase activity,GO:1904047~S-adenosyl-L-methionine binding,	IPR002877:RNA_MeTrfase_FtsJ_dom,IPR015507:rRNA-MeTfrase_E,IPR025786:Mononega_L_MeTrfase,IPR028590:RNA_methyltr_E_TRM7,IPR029063:SAM-dependent_MTases_sf,		309549~Intellectual developmental disorder, X-linked 9,			KW-0819~tRNA processing,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0991~Intellectual disability,		KW-0949~S-adenosyl-L-methionine,	KW-0489~Methyltransferase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,DOMAIN:Mononegavirus-type SAM-dependent 2'-O-MTase,DOMAIN:Ribosomal RNA methyltransferase FtsJ,REGION:Required for binding to WDR6,
GNL1	G protein nucleolar 1 (putative)(GNL1)	Homo sapiens			GO:0002456~T cell mediated immunity,GO:0006974~cellular response to DNA damage stimulus,GO:0007165~signal transduction,	GO:0005615~extracellular space,GO:0005634~nucleus,	GO:0000166~nucleotide binding,GO:0003924~GTPase activity,GO:0005198~structural molecule activity,GO:0005525~GTP binding,	IPR006073:GTP-bd,IPR027417:P-loop_NTPase,IPR030378:G_CP_dom,IPR043358:GNL1-like,									KW-0342~GTP-binding,KW-0547~Nucleotide-binding,		KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,DOMAIN:CP-type G,DOMAIN:G,REGION:Disordered,
GNL2	G protein nucleolar 2(GNL2)	Homo sapiens			GO:0042254~ribosome biogenesis,	GO:0005634~nucleus,GO:0005730~nucleolus,GO:0016020~membrane,	GO:0003723~RNA binding,GO:0003924~GTPase activity,GO:0005525~GTP binding,	IPR006073:GTP-bd,IPR012971:NOG2_N_dom,IPR023179:GTP-bd_ortho_bundle_sf,IPR024929:GNL2_CP_dom,IPR027417:P-loop_NTPase,IPR030378:G_CP_dom,	hsa03008:Ribosome biogenesis in eukaryotes,				KW-0690~Ribosome biogenesis,	KW-0472~Membrane,KW-0539~Nucleus,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0342~GTP-binding,KW-0547~Nucleotide-binding,		KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:CP-type G,MUTAGEN:D->A: Loss of GTP-binding. Punctate pattern throughout the nucleus, including nucleoli.,MUTAGEN:GET->AEA: No effect on GTP-binding, nor on nucleolar localization.,MUTAGEN:K->A: No effect on GTP-binding, nor on nucleolar localization.,MUTAGEN:KKK->AAA: No effect on nucleolar localization Predominantly cytoplasmic, with some nucleolar staining; when associated with 682-AAA-684. Strong nucleolar localization, with some cytoplasmic staining; when associated with 724-AAA-726. Diffused localization to both cytoplasm and nucleus; when associated with 682-AAA-684 and 724-AAA-726.,MUTAGEN:P->A: No effect on nucleolar localization; when associated with A-463.,MUTAGEN:P->A: No effect on nucleolar localization; when associated with A-475.,MUTAGEN:PG->AA: No effect on GTP-binding, nor on nucleolar localization.,MUTAGEN:RDP->AAA: Loss of GTP-binding. Efficient localization to the nucleus, but excluded from nucleoli.,MUTAGEN:RDR->ADA: Diffused nuclear localization, loss of nucleolar localization.,MUTAGEN:RKK->AAA: No effect on nucleolar localization. Strong nucleolar localization, with some cytoplasmic staining; when associated with 711-AAA-713. Diffused localization to both cytoplasm and nucleus; when associated with 682-AAA-684 and 711-AAA-713.,MUTAGEN:RR->AA: Diffused nuclear localization, loss of nucleolar localization.,MUTAGEN:RR->AA: No effect on nucleolar localization.,MUTAGEN:RRR->AAA: No effect on nucleolar localization. Predominantly cytoplasmic, with some nucleolar staining; when associated with 711-AAA-713. Diffused localization to both cytoplasm and nucleus; when associated with 711-AAA-713 and 724-AAA-726.,MUTAGEN:S->A: No effect on GTP-binding, nor on nucleolar localization.,REGION:Disordered,TRANSMEM:Helical,
GNL3	G protein nucleolar 3(GNL3)	Homo sapiens			GO:0017145~stem cell division,GO:0019827~stem cell population maintenance,GO:0032206~positive regulation of telomere maintenance,GO:0033235~positive regulation of protein sumoylation,GO:0042127~regulation of cell proliferation,GO:1902895~positive regulation of pri-miRNA transcription from RNA polymerase II promoter,GO:1904816~positive regulation of protein localization to chromosome, telomeric region,	GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005694~chromosome,GO:0005730~nucleolus,GO:0016020~membrane,GO:0016604~nuclear body,GO:0030496~midbody,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0048027~mRNA 5'-UTR binding,	IPR006073:GTP-bd,IPR014813:Gnl3_N_dom,IPR027417:P-loop_NTPase,IPR030378:G_CP_dom,	hsa03008:Ribosome biogenesis in eukaryotes,					KW-0539~Nucleus,		KW-0175~Coiled coil,	KW-0342~GTP-binding,KW-0547~Nucleotide-binding,		KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:CP-type G,DOMAIN:Guanine nucleotide-binding protein-like 3 N-terminal,REGION:Acidic,REGION:Basic,REGION:Disordered,REGION:Intermediate,
GPS1	G protein pathway suppressor 1(GPS1)	Homo sapiens			GO:0000338~protein deneddylation,GO:0007254~JNK cascade,GO:0045116~protein neddylation,GO:2000434~regulation of protein neddylation,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0008180~COP9 signalosome,GO:0032991~macromolecular complex,	GO:0005095~GTPase inhibitor activity,GO:0005515~protein binding,	IPR000717:PCI_dom,IPR019585:Rpn7/CSN1,IPR036390:WH_DNA-bd_sf,IPR045135:Rpn7_N,IPR048624:CSN1_C,				SM00088:PINT,		KW-0539~Nucleus,KW-0736~Signalosome,KW-0963~Cytoplasm,					KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:26S proteasome regulatory subunit Rpn7 N-terminal,DOMAIN:PCI,REGION:Disordered,
GPS2	G protein pathway suppressor 2(GPS2)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007254~JNK cascade,GO:0010804~negative regulation of tumor necrosis factor-mediated signaling pathway,GO:0010875~positive regulation of cholesterol efflux,GO:0019216~regulation of lipid metabolic process,GO:0030183~B cell differentiation,GO:0034122~negative regulation of toll-like receptor signaling pathway,GO:0035360~positive regulation of peroxisome proliferator activated receptor signaling pathway,GO:0045598~regulation of fat cell differentiation,GO:0045599~negative regulation of fat cell differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046329~negative regulation of JNK cascade,GO:0050728~negative regulation of inflammatory response,GO:0050859~negative regulation of B cell receptor signaling pathway,GO:0098780~response to mitochondrial depolarisation,GO:1900045~negative regulation of protein K63-linked ubiquitination,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0017053~transcriptional repressor complex,	GO:0003712~transcription cofactor activity,GO:0003713~transcription coactivator activity,GO:0003714~transcription corepressor activity,GO:0005095~GTPase inhibitor activity,GO:0005515~protein binding,GO:0030332~cyclin binding,	IPR026094:GPS2,	hsa05166:Human T-cell leukemia virus 1 infection,				KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0043~Tumor suppressor,	KW-0175~Coiled coil,		KW-0010~Activator,KW-0678~Repressor,	KW-0488~Methylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1),MUTAGEN:F->A: Abolishes methylation.,MUTAGEN:HRHI->AEHA: Abolishes interaction with TBL1X.,MUTAGEN:IL->AA: Weakly affects interaction with sumoylated NR1H2 and NR5A2 proteins.,MUTAGEN:K->A: Decreases methylation.,MUTAGEN:K->R: Abolishes sumoylation; when associated with R-45.,MUTAGEN:K->R: Abolishes sumoylation; when associated with R-71.,MUTAGEN:LFLQL->RFRQR: Weakly affects interaction with sumoylated NR1H2 and NR5A2 proteins.,MUTAGEN:LLAL->RRAR: Weakly affects interaction with sumoylated NR1H2 and NR5A2 proteins.,MUTAGEN:Missing: Abolishes interaction with sumoylated NR1H2 and NR5A2 proteins.,MUTAGEN:N->A: Strongly decreases methylation.,MUTAGEN:P->A: Strongly decreases methylation.,MUTAGEN:Q->A: Does not affect methylation.,MUTAGEN:S->A: Does not affect methylation.,MUTAGEN:Y->A: Abolishes methylation.,REGION:Disordered,REGION:interaction with SUMO,
GNA13	G protein subunit alpha 13(GNA13)	Homo sapiens		h_myosinPathway:PKC-catalyzed phosphorylation of inhibitory phosphoprotein of myosin phosphatase,h_par1pathway:Thrombin signaling and protease-activated receptors,	GO:0001569~branching involved in blood vessel morphogenesis,GO:0001701~in utero embryonic development,GO:0007165~signal transduction,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007188~adenylate cyclase-modulating G-protein coupled receptor signaling pathway,GO:0007189~adenylate cyclase-activating G-protein coupled receptor signaling pathway,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0007266~Rho protein signal transduction,GO:0008217~regulation of blood pressure,GO:0008360~regulation of cell shape,GO:0010762~regulation of fibroblast migration,GO:0030154~cell differentiation,GO:0030168~platelet activation,GO:0051056~regulation of small GTPase mediated signal transduction,GO:1904706~negative regulation of vascular smooth muscle cell proliferation,GO:1904753~negative regulation of vascular associated smooth muscle cell migration,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005834~heterotrimeric G-protein complex,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0016020~membrane,GO:0031526~brush border membrane,GO:0042470~melanosome,GO:0070062~extracellular exosome,	GO:0001664~G-protein coupled receptor binding,GO:0003924~GTPase activity,GO:0005085~guanyl-nucleotide exchange factor activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0031683~G-protein beta/gamma-subunit complex binding,GO:0031752~D5 dopamine receptor binding,GO:0046872~metal ion binding,	IPR000469:Gprotein_alpha_12/13,IPR001019:Gprotein_alpha_su,IPR011025:GproteinA_insert,IPR027417:P-loop_NTPase,	hsa04022:cGMP-PKG signaling pathway,hsa04071:Sphingolipid signaling pathway,hsa04072:Phospholipase D signaling pathway,hsa04270:Vascular smooth muscle contraction,hsa04371:Apelin signaling pathway,hsa04611:Platelet activation,hsa04730:Long-term depression,hsa04810:Regulation of actin cytoskeleton,hsa04928:Parathyroid hormone synthesis, secretion and action,hsa05130:Pathogenic Escherichia coli infection,hsa05163:Human cytomegalovirus infection,hsa05200:Pathways in cancer,			SM00275:G_alpha,		KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,			KW-0342~GTP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0807~Transducer,	KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,	DOMAIN:G-alpha,LIPID:S-palmitoyl cysteine,MUTAGEN:C->S: Fails to localize to plasma membranes and failed to activate Rho-dependent serum response factor-mediated transcription and actin stress fiber formation.,MUTAGEN:T->A: Abolishes phosphorylation by PKA; disrupts heterotrimer stability.,REGION:G1 motif,REGION:G2 motif,REGION:G3 motif,REGION:G4 motif,REGION:G5 motif,
GNAI2	G protein subunit alpha i2(GNAI2)	Homo sapiens			GO:0001973~adenosine receptor signaling pathway,GO:0007049~cell cycle,GO:0007165~signal transduction,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007188~adenylate cyclase-modulating G-protein coupled receptor signaling pathway,GO:0007189~adenylate cyclase-activating G-protein coupled receptor signaling pathway,GO:0007193~adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway,GO:0007194~negative regulation of adenylate cyclase activity,GO:0007213~G-protein coupled acetylcholine receptor signaling pathway,GO:0007214~gamma-aminobutyric acid signaling pathway,GO:0007584~response to nutrient,GO:0008283~cell proliferation,GO:0008284~positive regulation of cell proliferation,GO:0030335~positive regulation of cell migration,GO:0032930~positive regulation of superoxide anion generation,GO:0035810~positive regulation of urine volume,GO:0043434~response to peptide hormone,GO:0045955~negative regulation of calcium ion-dependent exocytosis,GO:0046628~positive regulation of insulin receptor signaling pathway,GO:0050805~negative regulation of synaptic transmission,GO:0051301~cell division,GO:0051924~regulation of calcium ion transport,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:1904707~positive regulation of vascular smooth muscle cell proliferation,GO:2000179~positive regulation of neural precursor cell proliferation,GO:2001234~negative regulation of apoptotic signaling pathway,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005829~cytosol,GO:0005834~heterotrimeric G-protein complex,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0030425~dendrite,GO:0030496~midbody,GO:0044297~cell body,GO:0045202~synapse,GO:0070062~extracellular exosome,GO:0098992~neuronal dense core vesicle,GO:1903561~extracellular vesicle,	GO:0001664~G-protein coupled receptor binding,GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0031683~G-protein beta/gamma-subunit complex binding,GO:0046872~metal ion binding,	IPR001019:Gprotein_alpha_su,IPR001408:Gprotein_alpha_I,IPR011025:GproteinA_insert,IPR027417:P-loop_NTPase,	hsa04015:Rap1 signaling pathway,hsa04022:cGMP-PKG signaling pathway,hsa04024:cAMP signaling pathway,hsa04062:Chemokine signaling pathway,hsa04071:Sphingolipid signaling pathway,hsa04261:Adrenergic signaling in cardiomyocytes,hsa04360:Axon guidance,hsa04371:Apelin signaling pathway,hsa04540:Gap junction,hsa04611:Platelet activation,hsa04670:Leukocyte transendothelial migration,hsa04713:Circadian entrainment,hsa04723:Retrograde endocannabinoid signaling,hsa04724:Glutamatergic synapse,hsa04725:Cholinergic synapse,hsa04726:Serotonergic synapse,hsa04727:GABAergic synapse,hsa04728:Dopaminergic synapse,hsa04730:Long-term depression,hsa04914:Progesterone-mediated oocyte maturation,hsa04915:Estrogen signaling pathway,hsa04916:Melanogenesis,hsa04921:Oxytocin signaling pathway,hsa04923:Regulation of lipolysis in adipocytes,hsa04924:Renin secretion,hsa04926:Relaxin signaling pathway,hsa04928:Parathyroid hormone synthesis, secretion and action,hsa04934:Cushing syndrome,hsa04935:Growth hormone synthesis, secretion and action,hsa04971:Gastric acid secretion,hsa05012:Parkinson disease,hsa05030:Cocaine addiction,hsa05032:Morphine addiction,hsa05034:Alcoholism,hsa05133:Pertussis,hsa05142:Chagas disease,hsa05145:Toxoplasmosis,hsa05163:Human cytomegalovirus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05200:Pathways in cancer,hsa05207:Chemical carcinogenesis - receptor activation,	192605~Ventricular tachycardia, idiopathic,Pituitary adenoma, ACTH-secreting, somatic~Pituitary adenoma, ACTH-secreting, somatic,		SM00275:G_alpha,	KW-0131~Cell cycle,KW-0132~Cell division,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,			KW-0342~GTP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0807~Transducer,	KW-0013~ADP-ribosylation,KW-0449~Lipoprotein,KW-0519~Myristate,KW-0564~Palmitate,	COMPBIAS:Polar residues,DOMAIN:G-alpha,LIPID:N-myristoyl glycine,LIPID:S-palmitoyl cysteine,REGION:Disordered,REGION:G1 motif,REGION:G2 motif,REGION:G3 motif,REGION:G4 motif,REGION:G5 motif,
GNAI3	G protein subunit alpha i3(GNAI3)	Homo sapiens			GO:0007049~cell cycle,GO:0007188~adenylate cyclase-modulating G-protein coupled receptor signaling pathway,GO:0007193~adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway,GO:0007194~negative regulation of adenylate cyclase activity,GO:0007212~dopamine receptor signaling pathway,GO:0016239~positive regulation of macroautophagy,GO:0046039~GTP metabolic process,GO:0051301~cell division,	GO:0000139~Golgi membrane,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005765~lysosomal membrane,GO:0005789~endoplasmic reticulum membrane,GO:0005794~Golgi apparatus,GO:0005813~centrosome,GO:0005834~heterotrimeric G-protein complex,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0030496~midbody,GO:0070062~extracellular exosome,	GO:0001664~G-protein coupled receptor binding,GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0019003~GDP binding,GO:0031683~G-protein beta/gamma-subunit complex binding,GO:0046872~metal ion binding,	IPR001019:Gprotein_alpha_su,IPR001408:Gprotein_alpha_I,IPR011025:GproteinA_insert,IPR027417:P-loop_NTPase,	hsa04015:Rap1 signaling pathway,hsa04022:cGMP-PKG signaling pathway,hsa04024:cAMP signaling pathway,hsa04062:Chemokine signaling pathway,hsa04071:Sphingolipid signaling pathway,hsa04261:Adrenergic signaling in cardiomyocytes,hsa04360:Axon guidance,hsa04371:Apelin signaling pathway,hsa04540:Gap junction,hsa04611:Platelet activation,hsa04670:Leukocyte transendothelial migration,hsa04713:Circadian entrainment,hsa04723:Retrograde endocannabinoid signaling,hsa04724:Glutamatergic synapse,hsa04725:Cholinergic synapse,hsa04726:Serotonergic synapse,hsa04727:GABAergic synapse,hsa04728:Dopaminergic synapse,hsa04730:Long-term depression,hsa04914:Progesterone-mediated oocyte maturation,hsa04915:Estrogen signaling pathway,hsa04916:Melanogenesis,hsa04921:Oxytocin signaling pathway,hsa04923:Regulation of lipolysis in adipocytes,hsa04924:Renin secretion,hsa04926:Relaxin signaling pathway,hsa04928:Parathyroid hormone synthesis, secretion and action,hsa04934:Cushing syndrome,hsa04935:Growth hormone synthesis, secretion and action,hsa04971:Gastric acid secretion,hsa05012:Parkinson disease,hsa05030:Cocaine addiction,hsa05032:Morphine addiction,hsa05034:Alcoholism,hsa05133:Pertussis,hsa05142:Chagas disease,hsa05145:Toxoplasmosis,hsa05163:Human cytomegalovirus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05200:Pathways in cancer,hsa05207:Chemical carcinogenesis - receptor activation,	602483~Auriculocondylar syndrome 1,		SM00275:G_alpha,	KW-0131~Cell cycle,KW-0132~Cell division,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,	KW-0225~Disease variant,		KW-0342~GTP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0807~Transducer,	KW-0013~ADP-ribosylation,KW-0449~Lipoprotein,KW-0519~Myristate,KW-0564~Palmitate,	DOMAIN:G-alpha,LIPID:N-myristoyl glycine,LIPID:S-palmitoyl cysteine,MUTAGEN:F->A: Decreased affinity for CCDC88C and PLCD4.,MUTAGEN:F->A: No effect on binding to PLCD4.,MUTAGEN:G->R: Decreased affinity for PLCD4.,MUTAGEN:I->A: No effect on binding to PLCD4.,MUTAGEN:K->A: Decreased affinity for PLCD4.,MUTAGEN:K->A: No effect on binding to PLCD4.,MUTAGEN:K->M: No effect on binding to CCDC88C.,MUTAGEN:L->A: Decreased affinity for PLCD4.,MUTAGEN:L->A: Increased affinity for PLCD4.,MUTAGEN:L->A: No effect on binding to PLCD4.,MUTAGEN:L->H: Decreased affinity for PLCD4.,MUTAGEN:L->V: No effect on binding to PLCD4.,MUTAGEN:N->A: Decreased affinity for PLCD4.,MUTAGEN:N->E: Decreased affinity for PLCD4.,MUTAGEN:S->A: Increased affinity for PLCD4.,MUTAGEN:S->D: Decreased affinity for PLCD4.,MUTAGEN:V->A: No effect on binding to PLCD4.,MUTAGEN:W->A: Decreased affinity for CCDC88C and PLCD4.,MUTAGEN:W->F: Increased affinity for PLCD4. No effect on binding to CCDC88C.,REGION:G1 motif,REGION:G2 motif,REGION:G3 motif,REGION:G4 motif,REGION:G5 motif,
GNB2	G protein subunit beta 2(GNB2)	Homo sapiens			GO:0007165~signal transduction,GO:0007186~G-protein coupled receptor signaling pathway,GO:1901379~regulation of potassium ion transmembrane transport,	GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0005765~lysosomal membrane,GO:0005829~cytosol,GO:0005834~heterotrimeric G-protein complex,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0016020~membrane,GO:0031982~vesicle,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,	GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0030159~receptor signaling complex scaffold activity,GO:0044877~macromolecular complex binding,GO:0051020~GTPase binding,	IPR001632:Gprotein_B,IPR001680:WD40_rpt,IPR015943:WD40/YVTN_repeat-like_dom_sf,IPR016346:Guanine_nucleotide-bd_bsu,IPR019775:WD40_repeat_CS,IPR020472:G-protein_beta_WD-40_rep,IPR036322:WD40_repeat_dom_sf,	hsa04014:Ras signaling pathway,hsa04062:Chemokine signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04371:Apelin signaling pathway,hsa04713:Circadian entrainment,hsa04723:Retrograde endocannabinoid signaling,hsa04724:Glutamatergic synapse,hsa04725:Cholinergic synapse,hsa04726:Serotonergic synapse,hsa04727:GABAergic synapse,hsa04728:Dopaminergic synapse,hsa04926:Relaxin signaling pathway,hsa05032:Morphine addiction,hsa05034:Alcoholism,hsa05163:Human cytomegalovirus infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05200:Pathways in cancer,	619464~Sick sinus syndrome 4,619503~Neurodevelopmental disorder with hypotonia and dysmorphic facies,	PIRSF002394:GN-bd_beta,	SM00320:WD40,		KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0991~Intellectual disability,	KW-0677~Repeat,KW-0853~WD repeat,		KW-0807~Transducer,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	REPEAT:WD,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,REPEAT:WD 7,
GNB5	G protein subunit beta 5(GNB5)	Homo sapiens			GO:0007165~signal transduction,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007212~dopamine receptor signaling pathway,GO:0036367~light adaption,GO:0043547~positive regulation of GTPase activity,GO:1901386~negative regulation of voltage-gated calcium channel activity,GO:1990603~dark adaptation,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005834~heterotrimeric G-protein complex,GO:0098793~presynapse,GO:1902773~GTPase activator complex,	GO:0003924~GTPase activity,GO:0005096~GTPase activator activity,GO:0005515~protein binding,GO:0030159~receptor signaling complex scaffold activity,GO:0031682~G-protein gamma-subunit binding,GO:0051087~chaperone binding,	IPR001632:Gprotein_B,IPR001680:WD40_rpt,IPR015943:WD40/YVTN_repeat-like_dom_sf,IPR016346:Guanine_nucleotide-bd_bsu,IPR019775:WD40_repeat_CS,IPR020472:G-protein_beta_WD-40_rep,IPR036322:WD40_repeat_dom_sf,	hsa04014:Ras signaling pathway,hsa04062:Chemokine signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04371:Apelin signaling pathway,hsa04713:Circadian entrainment,hsa04723:Retrograde endocannabinoid signaling,hsa04724:Glutamatergic synapse,hsa04725:Cholinergic synapse,hsa04726:Serotonergic synapse,hsa04727:GABAergic synapse,hsa04728:Dopaminergic synapse,hsa04926:Relaxin signaling pathway,hsa05032:Morphine addiction,hsa05034:Alcoholism,hsa05163:Human cytomegalovirus infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05200:Pathways in cancer,	617173~Lodder-Merla syndrome, type 1, with impaired intellectual development and cardiac arrhythmia,617182~Lodder-Merla syndrome, type 2, with developmental delay and with or without cardiac arrhythmia,	PIRSF002394:GN-bd_beta,	SM00320:WD40,		KW-0472~Membrane,	KW-0225~Disease variant,KW-0991~Intellectual disability,	KW-0175~Coiled coil,KW-0677~Repeat,KW-0853~WD repeat,		KW-0807~Transducer,		REPEAT:WD,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,REPEAT:WD 7,
GPR108	G protein-coupled receptor 108(GPR108)	Homo sapiens			GO:0006810~transport,GO:0034122~negative regulation of toll-like receptor signaling pathway,GO:0050776~regulation of immune response,	GO:0000139~Golgi membrane,GO:0005794~Golgi apparatus,GO:0005802~trans-Golgi network,GO:0016020~membrane,GO:0033106~cis-Golgi network membrane,	GO:0005515~protein binding,	IPR009637:GPR107/GPR108-like,					KW-0945~Host-virus interaction,	KW-0333~Golgi apparatus,KW-0472~Membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,REGION:Disordered,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
GPR137B	G protein-coupled receptor 137B(GPR137B)	Homo sapiens			GO:0006914~autophagy,GO:0010506~regulation of autophagy,GO:0043030~regulation of macrophage activation,GO:0043087~regulation of GTPase activity,GO:0045671~negative regulation of osteoclast differentiation,GO:0045779~negative regulation of bone resorption,GO:1904263~positive regulation of TORC1 signaling,	GO:0005765~lysosomal membrane,GO:0005886~plasma membrane,GO:0016020~membrane,	GO:0005515~protein binding,	IPR029723:GPR137,					KW-0072~Autophagy,	KW-0458~Lysosome,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Pro residues,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
GPR171	G protein-coupled receptor 171(GPR171)	Homo sapiens			GO:0007186~G-protein coupled receptor signaling pathway,GO:0007188~adenylate cyclase-modulating G-protein coupled receptor signaling pathway,GO:0007218~neuropeptide signaling pathway,GO:0035589~G-protein coupled purinergic nucleotide receptor signaling pathway,GO:0045638~negative regulation of myeloid cell differentiation,GO:0051930~regulation of sensory perception of pain,GO:0060259~regulation of feeding behavior,	GO:0005886~plasma membrane,GO:0016020~membrane,	GO:0004930~G-protein coupled receptor activity,GO:0008188~neuropeptide receptor activity,GO:0008528~G-protein coupled peptide receptor activity,GO:0042923~neuropeptide binding,GO:0045028~G-protein coupled purinergic nucleotide receptor activity,	IPR000276:GPCR_Rhodpsn,IPR017452:GPCR_Rhodpsn_7TM,IPR048077:GPR171,						KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
GPR183	G protein-coupled receptor 183(GPR183)	Homo sapiens			GO:0002250~adaptive immune response,GO:0002312~B cell activation involved in immune response,GO:0002313~mature B cell differentiation involved in immune response,GO:0002407~dendritic cell chemotaxis,GO:0006955~immune response,GO:0006959~humoral immune response,GO:0007186~G-protein coupled receptor signaling pathway,GO:0010818~T cell chemotaxis,GO:0030316~osteoclast differentiation,GO:0030595~leukocyte chemotaxis,GO:0030890~positive regulation of B cell proliferation,GO:0036145~dendritic cell homeostasis,GO:0061470~T follicular helper cell differentiation,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:2000458~regulation of astrocyte chemotaxis,	GO:0005886~plasma membrane,	GO:0004930~G-protein coupled receptor activity,GO:0008142~oxysterol binding,	IPR000276:GPCR_Rhodpsn,IPR017452:GPCR_Rhodpsn_7TM,IPR047160:GP183-like,				SM01381:7TM_GPCR_Srsx,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	MUTAGEN:C->A: Abolishes localization to the cell membrane without affecting protein expression levels.,MUTAGEN:C->A: Increased receptor activation.,MUTAGEN:C->A: Strongly reduced localization to the cell membrane and reduced protein expression levels.,MUTAGEN:D->A: Loss of receptor activation without affecting oxysterol agonist-binding.,MUTAGEN:D->R: Strong decrease in oxysterol agonist-binding and receptor activation.,MUTAGEN:E->A: Strong reduction in ligand potency.,MUTAGEN:F->A,Y: 500-fold decrease of IC(50) for GSK682753A. No effect on oxysterol agonist-binding and receptor activation.,MUTAGEN:F->A: Increased receptor activation. Strongly reduced localization to the cell membrane.,MUTAGEN:H->A: 10-fold reduction in receptor activation.,MUTAGEN:H->A: Reduced localization to the cell membrane and reduced receptor function.,MUTAGEN:I->A: Reduced localization to the cell membrane and reduced receptor function.,MUTAGEN:L->A: Reduced localization to the cell membrane and reduced receptor function.,MUTAGEN:M->A: Reduced localization to the cell membrane and reduced receptor function, without affecting oxysterol agonist-binding.,MUTAGEN:M->I: Reduced localization to the cell membrane and reduced receptor function. Reduced oxysterol agonist-binding.,MUTAGEN:N->A: Strongly reduced localization to the cell membrane.,MUTAGEN:P->A: Strongly reduced localization to the cell membrane.,MUTAGEN:Q->A: 10-fold reduction in receptor activation.,MUTAGEN:R->A: Strong decrease in oxysterol agonist-binding and receptor activation.,MUTAGEN:R->K: Slight decrease in oxysterol agonist-binding and receptor activation.,MUTAGEN:R->W: Slight decrease in oxysterol agonist-binding and receptor activation.,MUTAGEN:T->A,F: No effect.,MUTAGEN:V->A: Reduced localization to the cell membrane and reduced receptor function.,MUTAGEN:Y->A,F: No effect.,MUTAGEN:Y->A,F: Strong decrease in oxysterol agonist-binding and receptor activation.,MUTAGEN:Y->A: 10-fold reduction in receptor activation. Strongly reduced localization to the cell membrane.,REGION:Disordered,REGION:Interaction with G proteins,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
GPATCH8	G-patch domain containing 8(GPATCH8)	Homo sapiens				GO:0005634~nucleus,	GO:0003676~nucleic acid binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR000467:G_patch_dom,IPR013087:Znf_C2H2_type,IPR022755:Znf_C2H2_jaz,IPR036236:Znf_C2H2_sf,				SM00443:G_patch,				KW-0175~Coiled coil,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:C2H2-type,DOMAIN:G-patch,REGION:Disordered,ZN_FING:C2H2-type,
GRSF1	G-rich RNA sequence binding factor 1(GRSF1)	Homo sapiens			GO:0000957~mitochondrial RNA catabolic process,GO:0000962~positive regulation of mitochondrial RNA catabolic process,GO:0006378~mRNA polyadenylation,GO:0008033~tRNA processing,GO:0009952~anterior/posterior pattern specification,GO:0016331~morphogenesis of embryonic epithelium,GO:0043484~regulation of RNA splicing,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0035770~ribonucleoprotein granule,GO:0042645~mitochondrial nucleoid,GO:1990904~ribonucleoprotein complex,	GO:0002151~G-quadruplex RNA binding,GO:0003676~nucleic acid binding,GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0005515~protein binding,	IPR000504:RRM_dom,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR034424:GRSF-1_RRM2,IPR034425:GRSF1_RRM1,IPR034426:GRSF1_RRM3,IPR035979:RBD_domain_sf,				SM00360:RRM,	KW-0507~mRNA processing,KW-0819~tRNA processing,	KW-0496~Mitochondrion,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0809~Transit peptide,		KW-0694~RNA-binding,	KW-0597~Phosphoprotein,	DOMAIN:RRM,DOMAIN:RRM 1,DOMAIN:RRM 2,DOMAIN:RRM 3,MUTAGEN:E->A: Impairs RNA-binding and melting of G-quadruplex RNA structures; when associated with A-155; A-159; A-223; A-255; A-259; A-320; A-406 and A-410.,MUTAGEN:E->A: Impairs RNA-binding and melting of G-quadruplex RNA structures; when associated with A-155; A-159; A-223; A-255; A-259; A-406; A-410 and A-470.,MUTAGEN:E->A: Impairs RNA-binding and melting of G-quadruplex RNA structures; when associated with A-155; A-159; A-255; A-259; A-320; A-406; A-410 and A-470.,MUTAGEN:F->A: Impairs RNA-binding and melting of G-quadruplex RNA structures; when associated with A-155; A-159; A-223; A-255; A-259; A-320; A-406 and A-470.,MUTAGEN:Q->A: Impairs RNA-binding and melting of G-quadruplex RNA structures; when associated with A-159; A-223; A-255; A-259; A-320; A-406; A-410 and A-470.,MUTAGEN:R->A: Impairs RNA-binding and melting of G-quadruplex RNA structures; when associated with A-155; A-159; A-223; A-255; A-259; A-320; A-410 and A-470.,MUTAGEN:R->A: Impairs RNA-binding and melting of G-quadruplex RNA structures; when associated with A-155; A-159; A-223; A-259; A-320; A-406; A-410 and A-470.,MUTAGEN:W->A: Impairs RNA-binding and melting of G-quadruplex RNA structures; when associated with A-155; A-223; A-255; A-259; A-320; A-406; A-410 and A-470.,MUTAGEN:Y->A: Impairs RNA-binding and melting of G-quadruplex RNA structures; when associated with A-155; A-159; A-223; A-255; A-320; A-406; A-410 and A-470.,REGION:Disordered,TRANSIT:Mitochondrion,
GSPT1	G1 to S phase transition 1(GSPT1)	Homo sapiens			GO:0000082~G1/S transition of mitotic cell cycle,GO:0000184~nuclear-transcribed mRNA catabolic process, nonsense-mediated decay,GO:0006412~translation,GO:0006415~translational termination,GO:0006449~regulation of translational termination,GO:0006479~protein methylation,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0018444~translation release factor complex,GO:0022626~cytosolic ribosome,	GO:0003723~RNA binding,GO:0003747~translation release factor activity,GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,	IPR000795:T_Tr_GTP-bd_dom,IPR004160:Transl_elong_EFTu/EF1A_C,IPR004161:EFTu-like_2,IPR009000:Transl_B-barrel_sf,IPR009001:Transl_elong_EF1A/Init_IF2_C,IPR027417:P-loop_NTPase,IPR031157:G_TR_CS,	hsa03015:mRNA surveillance pathway,				KW-0648~Protein biosynthesis,KW-0866~Nonsense-mediated mRNA decay,				KW-0342~GTP-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,		COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Tr-type G,DOMAIN:tr-type G,REGION:Disordered,REGION:G1,REGION:G2,REGION:G3,REGION:G4,REGION:G5,
G3BP1	G3BP stress granule assembly factor 1(G3BP1)	Homo sapiens			GO:0007265~Ras protein signal transduction,GO:0032481~positive regulation of type I interferon production,GO:0032508~DNA duplex unwinding,GO:0034063~stress granule assembly,GO:0045087~innate immune response,GO:0051607~defense response to virus,GO:0090090~negative regulation of canonical Wnt signaling pathway,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005925~focal adhesion,GO:0010494~cytoplasmic stress granule,GO:0016020~membrane,GO:0043204~perikaryon,GO:0043226~organelle,GO:0043229~intracellular organelle,GO:1990904~ribonucleoprotein complex,	GO:0003676~nucleic acid binding,GO:0003677~DNA binding,GO:0003678~DNA helicase activity,GO:0003723~RNA binding,GO:0003724~RNA helicase activity,GO:0003729~mRNA binding,GO:0004519~endonuclease activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016887~ATPase activity,GO:0033677~DNA/RNA helicase activity,GO:0043024~ribosomal small subunit binding,	IPR000504:RRM_dom,IPR002075:NTF2_dom,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR018222:Nuclear_transport_factor_2_euk,IPR032710:NTF2-like_dom_sf,IPR034374:G3BP1_RRM,IPR035979:RBD_domain_sf,IPR039539:Ras_GTPase_bind_prot,IPR042987:ARHGEF39,	hsa04623:Cytosolic DNA-sensing pathway,			SM00360:RRM,	KW-0391~Immunity,KW-0399~Innate immunity,KW-0813~Transport,KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0238~DNA-binding,KW-0255~Endonuclease,KW-0347~Helicase,KW-0378~Hydrolase,KW-0540~Nuclease,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin); alternate,DOMAIN:NTF2,DOMAIN:Nuclear transport factor 2,DOMAIN:RRM,MUTAGEN:F->W: Abolished interaction with CAPRIN1 and ability to undergo liquid-liquid phase separation. Abolished interaction with USP10.,MUTAGEN:F->W: Decreased interaction with USP10.,MUTAGEN:F->W: Does not affect interaction with USP10.,MUTAGEN:FGF->GDG: Abolished mRNA-binding and ability to undergo liquid-liquid phase separation.,MUTAGEN:K->R: In 10KR; abolished ubiquitination in response to heat shock, leading to decreased stress granule disassembly when associated with R-36, R-50, R-59, R-64, R-123, R-353, R-357, R-376 and R-393. In 6KR; strongly decreased ubiquitination in response to heat shock, leading to decreased stress granule disassembly; when associated with R-36, R-50, R-59, R-64 and R-123.,MUTAGEN:K->R: In 10KR; abolished ubiquitination in response to heat shock, leading to decreased stress granule disassembly when associated with R-36, R-50, R-59, R-64, R-76, R-123, R-353, R-357 and R-376.,MUTAGEN:K->R: In 10KR; abolished ubiquitination in response to heat shock, leading to decreased stress granule disassembly when associated with R-36, R-50, R-59, R-64, R-76, R-123, R-353, R-357 and R-393.,MUTAGEN:K->R: In 10KR; abolished ubiquitination in response to heat shock, leading to decreased stress granule disassembly when associated with R-36, R-50, R-59, R-64, R-76, R-123, R-353, R-376 and R-393.,MUTAGEN:K->R: In 10KR; abolished ubiquitination in response to heat shock, leading to decreased stress granule disassembly when associated with R-36, R-50, R-59, R-64, R-76, R-123,R-357, R-376 and R-393.,MUTAGEN:K->R: In 10KR; abolished ubiquitination in response to heat shock, leading to decreased stress granule disassembly when associated with R-36, R-50, R-59, R-64, R-76, R-353, R-357, R-376 and R-393. In 6KR; strongly decreased ubiquitination in response to heat shock, leading to decreased stress granule disassembly; when associated with R-36, R-50, R-59, R-64 and R-76.,MUTAGEN:K->R: In 10KR; abolished ubiquitination in response to heat shock, leading to decreased stress granule disassembly when associated with R-36, R-50, R-59, R-76, R-123, R-353, R-357, R-376 and R-393. In 6KR; strongly decreased ubiquitination in response to heat shock, leading to decreased stress granule disassembly; when associated with R-36, R-50, R-59, R-76 and R-123. In 4KR; decreased ubiquitination in response to heat shock, leading to slightly decreased stress granule disassembly; when associated with R-36, R-50 and R-59.,MUTAGEN:K->R: In 10KR; abolished ubiquitination in response to heat shock, leading to decreased stress granule disassembly when associated with R-36, R-50, R-64, R-76, R-123, R-353, R-357, R-376 and R-393. In 6KR; strongly decreased ubiquitination in response to heat shock, leading to decreased stress granule disassembly; when associated with R-36, R-50, R-64, R-76 and R-123. In 4KR; decreased ubiquitination in response to heat shock, leading to slightly decreased stress granule disassembly; when associated with R-36, R-50 and R-64.,MUTAGEN:K->R: In 10KR; abolished ubiquitination in response to heat shock, leading to decreased stress granule disassembly when associated with R-36, R-59, R-64, R-76, R-123, R-353, R-357, R-376 and R-393. In 6KR; strongly decreased ubiquitination in response to heat shock, leading to decreased stress granule disassembly; when associated with R-36, R-59, R-64, R-76 and R-123. In 4KR; decreased ubiquitination in response to heat shock, leading to slightly decreased stress granule disassembly; when associated with R-36, R-59 and R-64.,MUTAGEN:K->R: In 10KR; abolished ubiquitination in response to heat shock, leading to decreased stress granule disassembly when associated with R-50, R-59, R-64, R-76, R-123, R-353, R-357, R-376 and R-393. In 6KR; strongly decreased ubiquitination in response to heat shock, leading to decreased stress granule disassembly; when associated with R-50, R-59, R-64, R-76 and R-123. In 4KR; decreased ubiquitination in response to heat shock, leading to slightly decreased stress granule disassembly; when associated with R-50, R-59 and R-64.,MUTAGEN:Q->G: Loss of cleavage by human enterovirus 71 protease 3C.,MUTAGEN:S->A: Slightly increased ability to undergo liquid-liquid phase separation. Increased ability to undergo liquid-liquid phase separation; when associated with A-232. Cytoplasmic.,MUTAGEN:S->A: Slightly increased ability to undergo liquid-liquid phase separation; when associated with A-149. Cytoplasmic. Partially nuclear; when associated with E-149.,MUTAGEN:S->E: Cytoplasmic. Partially nuclear; when associated with E-149.,MUTAGEN:S->E: Mimics phosphorylation; decreased ability to undergo liquid-liquid phase separation. Cytoplasmic and nuclear; no assembly of stress granules; no homo-oligomerization.,REGION:Acidic disordered region,REGION:Disordered,REGION:RG-rich region,SITE:Cleavage; by human enterovirus 71 protease 3C,TRANSMEM:Helical,
G3BP2	G3BP stress granule assembly factor 2(G3BP2)	Homo sapiens			GO:0007253~cytoplasmic sequestering of NF-kappaB,GO:0007265~Ras protein signal transduction,GO:0034063~stress granule assembly,GO:0045087~innate immune response,GO:0051028~mRNA transport,GO:0051260~protein homooligomerization,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0010494~cytoplasmic stress granule,GO:0043229~intracellular organelle,GO:1990904~ribonucleoprotein complex,	GO:0003676~nucleic acid binding,GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0005515~protein binding,GO:0030159~receptor signaling complex scaffold activity,	IPR000504:RRM_dom,IPR002075:NTF2_dom,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR018222:Nuclear_transport_factor_2_euk,IPR032710:NTF2-like_dom_sf,IPR034376:G3BP2_RRM,IPR035979:RBD_domain_sf,IPR039539:Ras_GTPase_bind_prot,				SM00360:RRM,	KW-0391~Immunity,KW-0399~Innate immunity,KW-0509~mRNA transport,KW-0813~Transport,KW-0945~Host-virus interaction,	KW-0963~Cytoplasm,				KW-0694~RNA-binding,	KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:NTF2,DOMAIN:RRM,REGION:Acidic disordered region,REGION:Disordered,REGION:RG-rich region,
GABARAPL1	GABA type A receptor associated protein like 1(GABARAPL1)	Homo sapiens			GO:0000045~autophagosome assembly,GO:0000422~mitophagy,GO:0006914~autophagy,GO:0006995~cellular response to nitrogen starvation,GO:0016236~macroautophagy,GO:0061723~glycophagy,GO:0097352~autophagosome maturation,	GO:0000421~autophagosome membrane,GO:0005739~mitochondrion,GO:0005776~autophagosome,GO:0005783~endoplasmic reticulum,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0005874~microtubule,GO:0016020~membrane,GO:0030659~cytoplasmic vesicle membrane,	GO:0005515~protein binding,GO:0005543~phospholipid binding,GO:0008429~phosphatidylethanolamine binding,GO:0030957~Tat protein binding,GO:0031625~ubiquitin protein ligase binding,GO:0048487~beta-tubulin binding,GO:0050811~GABA receptor binding,	IPR004241:Atg8-like,IPR029071:Ubiquitin-like_domsf,	hsa04068:FoxO signaling pathway,hsa04136:Autophagy - other,hsa04137:Mitophagy - animal,hsa04140:Autophagy - animal,hsa04621:NOD-like receptor signaling pathway,hsa04727:GABAergic synapse,				KW-0072~Autophagy,KW-0945~Host-virus interaction,	KW-0206~Cytoskeleton,KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0493~Microtubule,KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,				KW-0675~Receptor,	KW-0449~Lipoprotein,	LIPID:Phosphatidylethanolamine amidated glycine; alternate,LIPID:Phosphatidylserine amidated glycine; alternate,MUTAGEN:G->A: No processing of precursor.,MUTAGEN:H->A: Abolished interaction with ATG4B.,MUTAGEN:R->A: Abolished interaction with ATG4B.,MUTAGEN:R->A: Does not affect interaction with ATG4B.,PROPEP:Removed in mature form,SITE:(Microbial infection) Cleavage; by RavZ,SITE:Cleavage; by ATG4B,
GABARAPL2	GABA type A receptor associated protein like 2(GABARAPL2)	Homo sapiens			GO:0000045~autophagosome assembly,GO:0000422~mitophagy,GO:0006891~intra-Golgi vesicle-mediated transport,GO:0006914~autophagy,GO:0006995~cellular response to nitrogen starvation,GO:0015031~protein transport,GO:0016236~macroautophagy,GO:0032781~positive regulation of ATPase activity,GO:0070972~protein localization to endoplasmic reticulum,GO:0097352~autophagosome maturation,GO:1901799~negative regulation of proteasomal protein catabolic process,	GO:0000139~Golgi membrane,GO:0000421~autophagosome membrane,GO:0005737~cytoplasm,GO:0005776~autophagosome,GO:0005789~endoplasmic reticulum membrane,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0016020~membrane,GO:0031410~cytoplasmic vesicle,	GO:0000149~SNARE binding,GO:0005515~protein binding,GO:0008017~microtubule binding,GO:0008429~phosphatidylethanolamine binding,GO:0031625~ubiquitin protein ligase binding,GO:0048487~beta-tubulin binding,GO:0050811~GABA receptor binding,GO:0051117~ATPase binding,	IPR004241:Atg8-like,IPR029071:Ubiquitin-like_domsf,	hsa04068:FoxO signaling pathway,hsa04136:Autophagy - other,hsa04137:Mitophagy - animal,hsa04140:Autophagy - animal,hsa04621:NOD-like receptor signaling pathway,hsa04727:GABAergic synapse,				KW-0072~Autophagy,KW-0653~Protein transport,KW-0813~Transport,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0968~Cytoplasmic vesicle,				KW-0675~Receptor,	KW-0007~Acetylation,KW-0449~Lipoprotein,KW-0597~Phosphoprotein,	LIPID:Phosphatidylethanolamine amidated glycine; alternate,LIPID:Phosphatidylserine amidated glycine; alternate,MUTAGEN:G->A: Impairs localization at the autophagosomal membrane.,MUTAGEN:R->A: Strongly reduced interaction with UBA5.,MUTAGEN:S->D: Phospho-mimetic mutant; abolished localization to autophagosomes.,MUTAGEN:SS->AA: Impaired phosphorylation by TBK1.,MUTAGEN:SS->DD: Phospho-mimetic mutant; impaired interaction with ATG4 proteins, preventing cleavage at the C-terminus, conjugation to phosphatidylethanolamine.,PROPEP:Removed in mature form,SITE:Cleavage; by ATG4,
GABARAP	GABA type A receptor-associated protein(GABARAP)	Homo sapiens		h_gabaPathway:Gamma-aminobutyric Acid Receptor Life Cycle,	GO:0000045~autophagosome assembly,GO:0000226~microtubule cytoskeleton organization,GO:0000422~mitophagy,GO:0006605~protein targeting,GO:0006914~autophagy,GO:0006995~cellular response to nitrogen starvation,GO:0007268~chemical synaptic transmission,GO:0008625~extrinsic apoptotic signaling pathway via death domain receptors,GO:0015031~protein transport,GO:0016236~macroautophagy,GO:0032436~positive regulation of proteasomal ubiquitin-dependent protein catabolic process,GO:0035020~regulation of Rac protein signal transduction,GO:0097352~autophagosome maturation,GO:1902524~positive regulation of protein K48-linked ubiquitination,	GO:0000139~Golgi membrane,GO:0000421~autophagosome membrane,GO:0005764~lysosome,GO:0005776~autophagosome,GO:0005790~smooth endoplasmic reticulum,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0005874~microtubule,GO:0005875~microtubule associated complex,GO:0005886~plasma membrane,GO:0005930~axoneme,GO:0015629~actin cytoskeleton,GO:0016020~membrane,GO:0031410~cytoplasmic vesicle,GO:0045202~synapse,GO:0097225~sperm midpiece,	GO:0005515~protein binding,GO:0008017~microtubule binding,GO:0008429~phosphatidylethanolamine binding,GO:0031625~ubiquitin protein ligase binding,GO:0048487~beta-tubulin binding,GO:0050811~GABA receptor binding,	IPR004241:Atg8-like,IPR029071:Ubiquitin-like_domsf,	hsa04068:FoxO signaling pathway,hsa04136:Autophagy - other,hsa04137:Mitophagy - animal,hsa04140:Autophagy - animal,hsa04621:NOD-like receptor signaling pathway,hsa04727:GABAergic synapse,				KW-0053~Apoptosis,KW-0072~Autophagy,KW-0653~Protein transport,KW-0813~Transport,	KW-0206~Cytoskeleton,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0493~Microtubule,KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,				KW-0675~Receptor,	KW-0449~Lipoprotein,	LIPID:Phosphatidylethanolamine amidated glycine; alternate,LIPID:Phosphatidylserine amidated glycine; alternate,MUTAGEN:D->H: No effect on WDFY3-binding. Impaired WDFY3-binding, but no effect on SQSTM1-binding; when associated with Q-24 and H-25.,MUTAGEN:G->A: Impairs localization at the autophagosomal membrane.,MUTAGEN:K->Q: No effect on WDFY3-binding. Impaired WDFY3-binding, but no effect on SQSTM1-binding; when associated with H-25 and H-54.,MUTAGEN:R->A: No effect on interaction with TECPR2.,MUTAGEN:Y->H: No effect on WDFY3-binding. Impaired WDFY3-binding, but no effect on SQSTM1-binding; when associated with Q-24 and H-54.,MUTAGEN:YL->AA: Inhibits interaction with TECPR2.,PROPEP:Removed in mature form,REGION:Disordered,REGION:Interaction with GABRG2,REGION:Interaction with GPHN,REGION:Interaction with beta-tubulin,SITE:Cleavage; by ATG4B,
GADD45GIP1	GADD45G interacting protein 1(GADD45GIP1)	Homo sapiens			GO:0007049~cell cycle,GO:0032543~mitochondrial translation,	GO:0005654~nucleoplasm,GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005759~mitochondrial matrix,GO:0005762~mitochondrial large ribosomal subunit,	GO:0005515~protein binding,	IPR018472:Ribosomal_mL64,IPR043035:Ribosomal_mL64_sf,					KW-0131~Cell cycle,KW-0945~Host-virus interaction,	KW-0496~Mitochondrion,KW-0539~Nucleus,		KW-0175~Coiled coil,		KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,		MOTIF:Nuclear localization signal,REGION:Disordered,
GATA3	GATA binding protein 3(GATA3)	Homo sapiens	78.B_Cell_Development,80.T_cell_Activation,89.CD4_T_Cell_Differentiation,	h_gata3Pathway:GATA3 participate in activating the Th2 cytokine genes expression,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001701~in utero embryonic development,GO:0001709~cell fate determination,GO:0001764~neuron migration,GO:0001817~regulation of cytokine production,GO:0001822~kidney development,GO:0001823~mesonephros development,GO:0002088~lens development in camera-type eye,GO:0002520~immune system development,GO:0002572~pro-T cell differentiation,GO:0003180~aortic valve morphogenesis,GO:0003215~cardiac right ventricle morphogenesis,GO:0003281~ventricular septum development,GO:0006338~chromatin remodeling,GO:0006366~transcription from RNA polymerase II promoter,GO:0006952~defense response,GO:0006954~inflammatory response,GO:0006959~humoral immune response,GO:0007165~signal transduction,GO:0007411~axon guidance,GO:0008283~cell proliferation,GO:0008285~negative regulation of cell proliferation,GO:0008584~male gonad development,GO:0009615~response to virus,GO:0009653~anatomical structure morphogenesis,GO:0009791~post-embryonic development,GO:0009967~positive regulation of signal transduction,GO:0010595~positive regulation of endothelial cell migration,GO:0010719~negative regulation of epithelial to mesenchymal transition,GO:0010975~regulation of neuron projection development,GO:0030101~natural killer cell activation,GO:0030217~T cell differentiation,GO:0030218~erythrocyte differentiation,GO:0030225~macrophage differentiation,GO:0030856~regulation of epithelial cell differentiation,GO:0031929~TOR signaling,GO:0032689~negative regulation of interferon-gamma production,GO:0032703~negative regulation of interleukin-2 production,GO:0032736~positive regulation of interleukin-13 production,GO:0032753~positive regulation of interleukin-4 production,GO:0032754~positive regulation of interleukin-5 production,GO:0033600~negative regulation of mammary gland epithelial cell proliferation,GO:0035162~embryonic hemopoiesis,GO:0035457~cellular response to interferon-alpha,GO:0035799~ureter maturation,GO:0035898~parathyroid hormone secretion,GO:0042421~norepinephrine biosynthetic process,GO:0042472~inner ear morphogenesis,GO:0043491~protein kinase B signaling,GO:0043523~regulation of neuron apoptotic process,GO:0043583~ear development,GO:0043627~response to estrogen,GO:0045061~thymic T cell selection,GO:0045064~T-helper 2 cell differentiation,GO:0045087~innate immune response,GO:0045165~cell fate commitment,GO:0045582~positive regulation of T cell differentiation,GO:0045622~regulation of T-helper cell differentiation,GO:0045786~negative regulation of cell cycle,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048469~cell maturation,GO:0048485~sympathetic nervous system development,GO:0048538~thymus development,GO:0048568~embryonic organ development,GO:0048589~developmental growth,GO:0048646~anatomical structure formation involved in morphogenesis,GO:0050728~negative regulation of inflammatory response,GO:0050852~T cell receptor signaling pathway,GO:0051216~cartilage development,GO:0051897~positive regulation of protein kinase B signaling,GO:0060017~parathyroid gland development,GO:0060037~pharyngeal system development,GO:0060065~uterus development,GO:0060231~mesenchymal to epithelial transition,GO:0060374~mast cell differentiation,GO:0060676~ureteric bud formation,GO:0061290~canonical Wnt signaling pathway involved in metanephric kidney development,GO:0071353~cellular response to interleukin-4,GO:0071356~cellular response to tumor necrosis factor,GO:0071599~otic vesicle development,GO:0071773~cellular response to BMP stimulus,GO:0072107~positive regulation of ureteric bud formation,GO:0072178~nephric duct morphogenesis,GO:0072179~nephric duct formation,GO:0072182~regulation of nephron tubule epithelial cell differentiation,GO:0072197~ureter morphogenesis,GO:0072676~lymphocyte migration,GO:1901536~negative regulation of DNA demethylation,GO:1902895~positive regulation of pri-miRNA transcription from RNA polymerase II promoter,GO:2000114~regulation of establishment of cell polarity,GO:2000146~negative regulation of cell motility,GO:2000352~negative regulation of endothelial cell apoptotic process,GO:2000553~positive regulation of T-helper 2 cell cytokine production,GO:2000607~negative regulation of cell proliferation involved in mesonephros development,GO:2000611~positive regulation of thyroid hormone generation,GO:2000679~positive regulation of transcription regulatory region DNA binding,GO:2000683~regulation of cellular response to X-ray,GO:2000703~negative regulation of fibroblast growth factor receptor signaling pathway involved in ureteric bud formation,GO:2000734~negative regulation of glial cell-derived neurotrophic factor receptor signaling pathway involved in ureteric bud formation,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0000987~core promoter proximal region sequence-specific DNA binding,GO:0001223~transcription coactivator binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005134~interleukin-2 receptor binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0042802~identical protein binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:0070888~E-box binding,GO:0071837~HMG box domain binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000679:Znf_GATA,IPR013088:Znf_NHR/GATA,IPR016374:TF_GATA-2/3,IPR039355:Transcription_factor_GATA,	hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04928:Parathyroid hormone synthesis, secretion and action,hsa05321:Inflammatory bowel disease,	146255~Hypoparathyroidism, sensorineural deafness, and renal dysplasia,	PIRSF003027:TF_GATA-1/2/3,	SM00401:ZnF_GATA,	KW-0391~Immunity,KW-0399~Innate immunity,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0209~Deafness,KW-0225~Disease variant,	KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0238~DNA-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,MOTIF:YxKxHxxxRP,REGION:Disordered,REGION:Flexible linker,REGION:Interaction with TBX21,ZN_FING:GATA-type 1,ZN_FING:GATA-type 2,
GATAD2B	GATA zinc finger domain containing 2B(GATAD2B)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006338~chromatin remodeling,GO:0042659~regulation of cell fate specification,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:2000736~regulation of stem cell differentiation,	GO:0000781~chromosome, telomeric region,GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0016581~NuRD complex,GO:0016607~nuclear speck,GO:0032991~macromolecular complex,	GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0031492~nucleosomal DNA binding,GO:0043565~sequence-specific DNA binding,	IPR000679:Znf_GATA,IPR013088:Znf_NHR/GATA,IPR032346:P66_CC,IPR040386:P66,	hsa03082:ATP-dependent chromatin remodeling,	615074~GAND syndrome,			KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0158~Chromosome,KW-0539~Nucleus,	KW-0991~Intellectual disability,	KW-0175~Coiled coil,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0678~Repressor,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:GATA-type,DOMAIN:Transcriptional repressor p66 coiled-coil MBD2-interaction,REGION:CR1; interaction with MBD2 and MBD3,REGION:CR2; histone tail-binding,REGION:Disordered,ZN_FING:GATA-type,
GPBP1L1	GC-rich promoter binding protein 1 like 1(GPBP1L1)	Homo sapiens			GO:0006351~transcription, DNA-templated,GO:0006355~regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,	GO:0005634~nucleus,	GO:0003677~DNA binding,GO:0003723~RNA binding,GO:0005515~protein binding,	IPR028128:Vasculin_fam,					KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0238~DNA-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,
GDI1	GDP dissociation inhibitor 1(GDI1)	Homo sapiens			GO:0007165~signal transduction,GO:0007264~small GTPase mediated signal transduction,GO:0015031~protein transport,GO:0016192~vesicle-mediated transport,GO:0032482~Rab protein signal transduction,GO:0045773~positive regulation of axon extension,GO:0050771~negative regulation of axonogenesis,GO:0051592~response to calcium ion,GO:0090315~negative regulation of protein targeting to membrane,	GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0030424~axon,GO:0030496~midbody,GO:0032991~macromolecular complex,GO:0043025~neuronal cell body,GO:0043209~myelin sheath,GO:0099523~presynaptic cytosol,	GO:0005092~GDP-dissociation inhibitor activity,GO:0005093~Rab GDP-dissociation inhibitor activity,GO:0005096~GTPase activator activity,GO:0005515~protein binding,GO:0031267~small GTPase binding,	IPR000806:RabGDI,IPR018203:GDP_dissociation_inhibitor,IPR036188:FAD/NAD-bd_sf,		300849~Intellectual developmental disorder, X-linked 41,				KW-0333~Golgi apparatus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0991~Intellectual disability,			KW-0343~GTPase activation,		COMPBIAS:Polar residues,REGION:Disordered,
GID8	GID complex subunit 8 homolog(GID8)	Homo sapiens			GO:0008284~positive regulation of cell proliferation,GO:0016055~Wnt signaling pathway,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0090263~positive regulation of canonical Wnt signaling pathway,	GO:0000151~ubiquitin ligase complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0030054~cell junction,	GO:0005515~protein binding,GO:0042803~protein homodimerization activity,	IPR006594:LisH,IPR006595:CTLH_C,IPR013144:CRA_dom,IPR024964:CTLH/CRA,				SM00667:LisH,SM00668:CTLH,SM00757:CRA,	KW-0879~Wnt signaling pathway,	KW-0539~Nucleus,KW-0963~Cytoplasm,					KW-0832~Ubl conjugation,	DOMAIN:CTLH,DOMAIN:LisH,REGION:Interaction with CTNNB1,
GIT2	GIT ArfGAP 2(GIT2)	Homo sapiens		h_agrPathway:Agrin in Postsynaptic Differentiation,	GO:0007420~brain development,GO:0008277~regulation of G-protein coupled receptor protein signaling pathway,GO:0016310~phosphorylation,GO:0032012~regulation of ARF protein signal transduction,GO:0036465~synaptic vesicle recycling,	GO:0005654~nucleoplasm,GO:0005925~focal adhesion,GO:0045202~synapse,GO:0098793~presynapse,	GO:0005096~GTPase activator activity,GO:0005515~protein binding,GO:0016301~kinase activity,GO:0031267~small GTPase binding,GO:0046872~metal ion binding,	IPR001164:ArfGAP_dom,IPR002110:Ankyrin_rpt,IPR013724:GIT_SHD,IPR022018:GIT1_C,IPR032352:GIT1/2_CC,IPR036770:Ankyrin_rpt-contain_sf,IPR037278:ARFGAP/RecO,IPR038508:ArfGAP_dom_sf,IPR047161:GIT-like,	hsa04144:Endocytosis,hsa05135:Yersinia infection,			SM00105:ArfGap,SM00248:ANK,SM00555:GIT,				KW-0040~ANK repeat,KW-0175~Coiled coil,KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0343~GTPase activation,KW-0418~Kinase,KW-0675~Receptor,KW-0808~Transferase,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:ARF GTPase-activating protein GIT1 C-terminal,DOMAIN:Arf GTPase-activating protein GIT1/2 coiled-coil,DOMAIN:Arf-GAP,DOMAIN:GIT Spa2 homology (SHD),REGION:Disordered,REPEAT:ANK,REPEAT:ANK 1,REPEAT:ANK 2,REPEAT:ANK 3,ZN_FING:C4-type,
GLIPR1	GLI pathogenesis related 1(GLIPR1)	Homo sapiens				GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0035577~azurophil granule membrane,	GO:0005515~protein binding,	IPR001283:CRISP-related,IPR002413:V5_allergen-like,IPR014044:CAP_domain,IPR018244:Allrgn_V5/Tpx1_CS,IPR034121:SCP_GLIPR-1-like,IPR035940:CAP_sf,				SM00198:SCP,		KW-0472~Membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,				DOMAIN:SCP,TRANSMEM:Helical,
GNAS	GNAS complex locus(GNAS)	Homo sapiens		h_agpcrPathway:Attenuation of GPCR Signaling,h_bArr-mapkPathway:Role of ï¿½-arrestins in the activation and targeting of MAP kinases,h_bArrestin-srcPathway:Roles of ï¿½-arrestin-dependent Recruitment of Src Kinases in GPCR Signaling,h_bArrestinPathway:ï¿½-arrestins in GPCR Desensitization,h_ccr3Pathway:CCR3 signaling in Eosinophils,h_cftrPathway:Cystic fibrosis transmembrane conductance regulator (CFTR) and beta 2 adrenergic receptor (b2AR) pathway,h_chrebpPathway:ChREBP regulation by carbohydrates and cAMP,h_crebPathway:Transcription factor CREB and its extracellular signals,h_cremPathway:Regulation of Spermatogenesis by CREM,h_cskPathway:Activation of Csk by cAMP-dependent Protein Kinase Inhibits Signaling through the T Cell Receptor,h_erkPathway:Erk1/Erk2 Mapk Signaling pathway,h_gcrpathway:Corticosteroids and cardioprotection,h_gpcrPathway:Signaling Pathway from G-Protein Families,h_gsPathway:Activation of cAMP-dependent protein kinase, PKA,h_mPRPathway:How Progesterone Initiates the Oocyte Maturation,h_plcePathway:Phospholipase C-epsilon pathway,h_raccPathway:Ion Channels and Their Functional Role in Vascular Endothelium,	GO:0007186~G-protein coupled receptor signaling pathway,GO:0007189~adenylate cyclase-activating G-protein coupled receptor signaling pathway,GO:0007190~activation of adenylate cyclase activity,GO:0007191~adenylate cyclase-activating dopamine receptor signaling pathway,GO:0007565~female pregnancy,GO:0007606~sensory perception of chemical stimulus,GO:0007608~sensory perception of smell,GO:0009306~protein secretion,GO:0009966~regulation of signal transduction,GO:0040015~negative regulation of multicellular organism growth,GO:0043547~positive regulation of GTPase activity,GO:0043950~positive regulation of cAMP-mediated signaling,GO:0046907~intracellular transport,GO:0048589~developmental growth,GO:0050890~cognition,GO:0060348~bone development,GO:0060789~hair follicle placode formation,GO:0070527~platelet aggregation,GO:0071107~response to parathyroid hormone,GO:0071380~cellular response to prostaglandin E stimulus,GO:0071870~cellular response to catecholamine stimulus,GO:0071880~adenylate cyclase-activating adrenergic receptor signaling pathway,	GO:0001726~ruffle,GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005834~heterotrimeric G-protein complex,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016324~apical plasma membrane,GO:0030133~transport vesicle,GO:0032588~trans-Golgi network membrane,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,	GO:0003924~GTPase activity,GO:0005159~insulin-like growth factor receptor binding,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0010856~adenylate cyclase activator activity,GO:0019001~guanyl nucleotide binding,GO:0031683~G-protein beta/gamma-subunit complex binding,GO:0031698~beta-2 adrenergic receptor binding,GO:0031748~D1 dopamine receptor binding,GO:0031852~mu-type opioid receptor binding,GO:0035255~ionotropic glutamate receptor binding,GO:0046872~metal ion binding,GO:0051430~corticotropin-releasing hormone receptor 1 binding,	IPR000367:Gprotein_alpha_S,IPR001019:Gprotein_alpha_su,IPR009434:NESP55,IPR011025:GproteinA_insert,IPR027417:P-loop_NTPase,	hsa01522:Endocrine resistance,hsa04015:Rap1 signaling pathway,hsa04020:Calcium signaling pathway,hsa04024:cAMP signaling pathway,hsa04072:Phospholipase D signaling pathway,hsa04261:Adrenergic signaling in cardiomyocytes,hsa04270:Vascular smooth muscle contraction,hsa04540:Gap junction,hsa04611:Platelet activation,hsa04713:Circadian entrainment,hsa04714:Thermogenesis,hsa04724:Glutamatergic synapse,hsa04726:Serotonergic synapse,hsa04728:Dopaminergic synapse,hsa04730:Long-term depression,hsa04750:Inflammatory mediator regulation of TRP channels,hsa04911:Insulin secretion,hsa04912:GnRH signaling pathway,hsa04913:Ovarian steroidogenesis,hsa04915:Estrogen signaling pathway,hsa04916:Melanogenesis,hsa04918:Thyroid hormone synthesis,hsa04921:Oxytocin signaling pathway,hsa04922:Glucagon signaling pathway,hsa04923:Regulation of lipolysis in adipocytes,hsa04924:Renin secretion,hsa04925:Aldosterone synthesis and secretion,hsa04926:Relaxin signaling pathway,hsa04927:Cortisol synthesis and secretion,hsa04928:Parathyroid hormone synthesis, secretion and action,hsa04934:Cushing syndrome,hsa04935:Growth hormone synthesis, secretion and action,hsa04961:Endocrine and other factor-regulated calcium reabsorption,hsa04962:Vasopressin-regulated water reabsorption,hsa04970:Salivary secretion,hsa04971:Gastric acid secretion,hsa04972:Pancreatic secretion,hsa04976:Bile secretion,hsa05012:Parkinson disease,hsa05030:Cocaine addiction,hsa05031:Amphetamine addiction,hsa05032:Morphine addiction,hsa05034:Alcoholism,hsa05110:Vibrio cholerae infection,hsa05142:Chagas disease,hsa05146:Amoebiasis,hsa05163:Human cytomegalovirus infection,hsa05165:Human papillomavirus infection,hsa05200:Pathways in cancer,hsa05207:Chemical carcinogenesis - receptor activation,hsa05414:Dilated cardiomyopathy,	103580~Pseudohypoparathyroidism Ia,166350~Osseous heteroplasia, progressive,219080~ACTH-independent macronodular adrenal hyperplasia,603233~Pseudohypoparathyroidism Ib,612462~Pseudohypoparathyroidism Ic,612463~Pseudopseudohypoparathyroidism,617686~Pituitary adenoma 3, multiple types, somatic,McCune-Albright syndrome, somatic, mosaic 174800~McCune-Albright syndrome, somatic, mosaic 174800,		SM00275:G_alpha,		KW-0472~Membrane,KW-0964~Secreted,KW-0966~Cell projection,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0242~Dwarfism,KW-0550~Obesity,KW-0656~Proto-oncogene,KW-1062~Cushing syndrome,	KW-0175~Coiled coil,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0342~GTP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0807~Transducer,	KW-0013~ADP-ribosylation,KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-0654~Proteoglycan,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:G-alpha,LIPID:N-palmitoyl glycine,LIPID:S-palmitoyl cysteine,MUTAGEN:D->N: Increases binding to GAS2L2; when associated with L-227.,MUTAGEN:Q->A: Increases GDP release but does not affect receptor-mediated activation.,MUTAGEN:Q->L: Increases binding to GAS2L2; when associated with N-295.,MUTAGEN:R->A: Increases GDP release and impairs receptor-mediated activation; markedly elevated intrinsic GTPase rate which will lead to more rapid inactivation.,PEPTIDE:GPIPIRRH peptide,PEPTIDE:LHAL tetrapeptide,REGION:Disordered,REGION:G1 motif,REGION:G2 motif,REGION:G3 motif,REGION:G4 motif,REGION:G5 motif,TRANSMEM:Helical,
GPN1	GPN-loop GTPase 1(GPN1)	Homo sapiens				GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,	GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0016787~hydrolase activity,GO:0016887~ATPase activity,	IPR003593:AAA+_ATPase,IPR004130:Gpn,IPR027417:P-loop_NTPase,IPR030230:Gpn1/Npa3/XAB1,				SM00382:AAA,		KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0342~GTP-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:AAA+ ATPase,MOTIF:Gly-Pro-Asn (GPN)-loop; involved in dimer interface,MUTAGEN:GSGK->AAAA: Abolishes GTPase activity and decreases association with GPN3.,REGION:Disordered,SITE:Stabilizes the phosphate intermediate; shared with dimeric partner,
GRAMD1A	GRAM domain containing 1A(GRAMD1A)	Homo sapiens			GO:0006869~lipid transport,GO:0006914~autophagy,GO:0032366~intracellular sterol transport,GO:0071397~cellular response to cholesterol,	GO:0005776~autophagosome,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0031410~cytoplasmic vesicle,GO:0044232~organelle membrane contact site,	GO:0005515~protein binding,GO:0015485~cholesterol binding,	IPR004182:GRAM,IPR011993:PH-like_dom_sf,IPR031968:VASt,				SM00568:GRAM,	KW-0072~Autophagy,KW-0445~Lipid transport,KW-0813~Transport,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0446~Lipid-binding,		KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:GRAM,DOMAIN:VASt,REGION:Disordered,TRANSMEM:Helical,
GIGYF2	GRB10 interacting GYF protein 2(GIGYF2)	Homo sapiens			GO:0007631~feeding behavior,GO:0008344~adult locomotory behavior,GO:0009791~post-embryonic development,GO:0016441~posttranscriptional gene silencing,GO:0017148~negative regulation of translation,GO:0021522~spinal cord motor neuron differentiation,GO:0031571~mitotic G1 DNA damage checkpoint,GO:0035264~multicellular organism growth,GO:0045947~negative regulation of translational initiation,GO:0048009~insulin-like growth factor receptor signaling pathway,GO:0048873~homeostasis of number of cells within a tissue,GO:0050881~musculoskeletal movement,GO:0050885~neuromuscular process controlling balance,GO:0060339~negative regulation of type I interferon-mediated signaling pathway,GO:0061157~mRNA destabilization,GO:0072344~rescue of stalled ribosome,	GO:0005768~endosome,GO:0005783~endoplasmic reticulum,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0010494~cytoplasmic stress granule,GO:0016020~membrane,GO:0031982~vesicle,GO:0032991~macromolecular complex,GO:0043204~perikaryon,GO:1990635~proximal dendrite,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0045296~cadherin binding,GO:0060090~binding, bridging,GO:0070064~proline-rich region binding,	IPR003169:GYF,IPR035445:GYF-like_dom_sf,		607688~Parkinson disease 11,		SM00444:GYF,			KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0907~Parkinson disease,KW-0908~Parkinsonism,				KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:GYF,MOTIF:4EHP-binding motif,MOTIF:DDX6 binding motif,MUTAGEN:F->A: Abolishes interaction with DDX6; when associated with A-300.,MUTAGEN:F->A: Abolishes interaction with DDX6; when associated with A-306.,MUTAGEN:W->A: Abolishes interaction with DDX6.,MUTAGEN:YRYGREEML->ARAGREEAA: Abolishes interaction with EIF4E2.,REGION:Disordered,REGION:Required for GRB10-binding,REGION:Required for interaction with SARS-CoV-2 non-structural protein 2 (nsp2),
GCC2	GRIP and coiled-coil domain containing 2(GCC2)	Homo sapiens			GO:0006622~protein targeting to lysosome,GO:0031023~microtubule organizing center organization,GO:0034067~protein localization to Golgi apparatus,GO:0034453~microtubule anchoring,GO:0034499~late endosome to Golgi transport,GO:0042147~retrograde transport, endosome to Golgi,GO:0070861~regulation of protein exit from endoplasmic reticulum,GO:0071955~recycling endosome to Golgi transport,GO:0090161~Golgi ribbon formation,	GO:0005654~nucleoplasm,GO:0005794~Golgi apparatus,GO:0005802~trans-Golgi network,GO:0005829~cytosol,GO:0016020~membrane,	GO:0005515~protein binding,GO:0031267~small GTPase binding,GO:0042802~identical protein binding,	IPR000237:GRIP_dom,IPR032023:GCC2_Rab_bind,	hsa05132:Salmonella infection,			SM00755:Grip,	KW-0653~Protein transport,KW-0813~Transport,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0963~Cytoplasm,		KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:GRIP,MUTAGEN:I->A: Slightly decreases RAB6A binding affinity. Decreases RAB9A binding affinity by 2-fold. Strongly decreases RAB6A or RAB9A binding affinity and abolishes Golgi localization; when associated with A-1595.,MUTAGEN:L->A: Decreases RAB6A binding affinity by 2-fold. Strongly decreases RAB9A binding affinity. Strongly decreases RAB6A or RAB9A binding affinity and abolishes Golgi localization; when associated with A-1588.,MUTAGEN:Y->A: No effect on interaction with RAB6A and RAB9A.,REGION:Disordered,REGION:Mediates interaction with RAB6A,REGION:Mediates interaction with RAB9A,
GCHFR	GTP cyclohydrolase I feedback regulator(GCHFR)	Homo sapiens			GO:0006809~nitric oxide biosynthetic process,GO:0009890~negative regulation of biosynthetic process,GO:0045428~regulation of nitric oxide biosynthetic process,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0030425~dendrite,GO:0031965~nuclear membrane,GO:0042470~melanosome,	GO:0005515~protein binding,GO:0016787~hydrolase activity,GO:0044549~GTP cyclohydrolase binding,	IPR009112:GTP_CycHdrlase_I_reg,IPR036717:GFRP_sf,						KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0378~Hydrolase,		REGION:Disordered,
GIMAP4	GTPase, IMAP family member 4(GIMAP4)	Homo sapiens				GO:0005829~cytosol,GO:0043231~intracellular membrane-bounded organelle,	GO:0005525~GTP binding,	IPR006703:G_AIG1,IPR027417:P-loop_NTPase,IPR045058:GIMA/IAN/Toc,						KW-0963~Cytoplasm,		KW-0175~Coiled coil,	KW-0342~GTP-binding,KW-0547~Nucleotide-binding,		KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:AIG1-type G,DOMAIN:IQ,REGION:Disordered,REGION:G1,REGION:G2,REGION:G3,REGION:G4,REGION:G5,
GIMAP7	GTPase, IMAP family member 7(GIMAP7)	Homo sapiens			GO:0046039~GTP metabolic process,	GO:0005783~endoplasmic reticulum,GO:0005794~Golgi apparatus,GO:0005811~lipid particle,	GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,	IPR006703:G_AIG1,IPR027417:P-loop_NTPase,IPR045058:GIMA/IAN/Toc,						KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0551~Lipid droplet,KW-0963~Cytoplasm,		KW-0175~Coiled coil,	KW-0342~GTP-binding,KW-0547~Nucleotide-binding,			DOMAIN:AIG1-type G,MUTAGEN:E->W: Impairs dimerization and abolishes GTPase activity. No effect on GTP binding.,MUTAGEN:R->D: Abolishes GTPase activity. No effect on GTP binding and on dimerization.,REGION:G1,REGION:G2,REGION:G3,REGION:G4,REGION:G5,SITE:Important for catalytic activity,
GRPEL1	GrpE like 1, mitochondrial(GRPEL1)	Homo sapiens			GO:0006457~protein folding,GO:0006886~intracellular protein transport,GO:0030150~protein import into mitochondrial matrix,	GO:0001405~presequence translocase-associated import motor,GO:0005654~nucleoplasm,GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005744~mitochondrial inner membrane presequence translocase complex,GO:0005759~mitochondrial matrix,	GO:0000774~adenyl-nucleotide exchange factor activity,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0051082~unfolded protein binding,GO:0051087~chaperone binding,	IPR000740:GrpE,IPR009012:GrpE_head,IPR013805:GrpE_coiled_coil,						KW-0496~Mitochondrion,		KW-0175~Coiled coil,KW-0809~Transit peptide,		KW-0143~Chaperone,	KW-0007~Acetylation,	COMPBIAS:Polar residues,REGION:Disordered,TRANSIT:Mitochondrion,
HAX1	HCLS1 associated protein X-1(HAX1)	Homo sapiens			GO:0030833~regulation of actin filament polymerization,GO:0030854~positive regulation of granulocyte differentiation,GO:0038158~granulocyte colony-stimulating factor signaling pathway,GO:0042981~regulation of apoptotic process,GO:0043066~negative regulation of apoptotic process,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0050731~positive regulation of peptidyl-tyrosine phosphorylation,GO:0051897~positive regulation of protein kinase B signaling,GO:0071345~cellular response to cytokine stimulus,GO:1903146~regulation of mitophagy,GO:1903214~regulation of protein targeting to mitochondrion,	GO:0000932~P-body,GO:0005635~nuclear envelope,GO:0005667~transcription factor complex,GO:0005739~mitochondrion,GO:0005741~mitochondrial outer membrane,GO:0005758~mitochondrial intermembrane space,GO:0005759~mitochondrial matrix,GO:0005783~endoplasmic reticulum,GO:0005938~cell cortex,GO:0015629~actin cytoskeleton,GO:0016324~apical plasma membrane,GO:0016529~sarcoplasmic reticulum,GO:0030027~lamellipodium,GO:0030136~clathrin-coated vesicle,GO:0031410~cytoplasmic vesicle,GO:0031965~nuclear membrane,	GO:0005515~protein binding,GO:0019966~interleukin-1 binding,GO:0035591~signaling adaptor activity,	IPR017248:HAX-1,		610738~Neutropenia, severe congenital 3, autosomal recessive,	PIRSF037634:HS1-associating_X-1,			KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0703~Sarcoplasmic reticulum,KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,	KW-0225~Disease variant,				KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,REGION:Involved in ATP2A2 binding,REGION:Involved in CASP9 binding,REGION:Involved in GNA13 binding,REGION:Involved in HCLS1 binding,REGION:Involved in PKD2 binding,REGION:Involved in PLN binding,REGION:Mediates interaction with UCP3,REGION:Required for ITGB6 binding,REGION:Required for localization in mitochondria,REGION:Required for localization in sarcoplasmic reticulum,SITE:Cleavage; by caspase-3,
HDDC2	HD domain containing 2(HDDC2)	Homo sapiens					GO:0002953~5'-deoxynucleotidase activity,GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR003607:HD/PDEase_dom,IPR006674:HD_domain,IPR039356:YfbR/HDDC2,	hsa00230:Purine metabolism,hsa00240:Pyrimidine metabolism,hsa01100:Metabolic pathways,hsa01232:Nucleotide metabolism,			SM00471:HDc,					KW-0170~Cobalt,KW-0460~Magnesium,KW-0464~Manganese,KW-0479~Metal-binding,	KW-0378~Hydrolase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:HD,
HERC1	HECT and RLD domain containing E3 ubiquitin protein ligase family member 1(HERC1)	Homo sapiens			GO:0006914~autophagy,GO:0010507~negative regulation of autophagy,GO:0016567~protein ubiquitination,GO:0021702~cerebellar Purkinje cell differentiation,GO:0022038~corpus callosum development,GO:0031175~neuron projection development,GO:0050885~neuromuscular process controlling balance,	GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0016020~membrane,	GO:0004842~ubiquitin-protein transferase activity,GO:0005085~guanyl-nucleotide exchange factor activity,	IPR000408:Reg_chr_condens,IPR000569:HECT_dom,IPR001680:WD40_rpt,IPR001870:B30.2/SPRY,IPR003877:SPRY_dom,IPR009091:RCC1/BLIP-II,IPR013320:ConA-like_dom_sf,IPR015943:WD40/YVTN_repeat-like_dom_sf,IPR019775:WD40_repeat_CS,IPR035768:SPRY_HERC1,IPR035983:Hect_E3_ubiquitin_ligase,IPR036322:WD40_repeat_dom_sf,IPR043136:B30.2/SPRY_sf,	hsa04120:Ubiquitin mediated proteolysis,	617011~Macrocephaly, dysmorphic facies, and psychomotor retardation,		SM00119:HECTc,SM00320:WD40,SM00449:SPRY,	KW-0813~Transport,KW-0833~Ubl conjugation pathway,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0991~Intellectual disability,	KW-0677~Repeat,KW-0853~WD repeat,		KW-0344~Guanine-nucleotide releasing factor,KW-0808~Transferase,	KW-0597~Phosphoprotein,	ACT_SITE:Glycyl thioester intermediate,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:B30.2/SPRY,DOMAIN:HECT,REGION:Disordered,REPEAT:RCC1,REPEAT:RCC1 1,REPEAT:RCC1 10,REPEAT:RCC1 11,REPEAT:RCC1 12,REPEAT:RCC1 13,REPEAT:RCC1 14,REPEAT:RCC1 2,REPEAT:RCC1 3,REPEAT:RCC1 4,REPEAT:RCC1 5,REPEAT:RCC1 6,REPEAT:RCC1 7,REPEAT:RCC1 8,REPEAT:RCC1 9,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,REPEAT:WD 7,
HECTD1	HECT domain E3 ubiquitin protein ligase 1(HECTD1)	Homo sapiens			GO:0003170~heart valve development,GO:0003281~ventricular septum development,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0016567~protein ubiquitination,GO:0032436~positive regulation of proteasomal ubiquitin-dependent protein catabolic process,GO:0035904~aorta development,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0048856~anatomical structure development,GO:0070534~protein K63-linked ubiquitination,	GO:0016607~nuclear speck,	GO:0005515~protein binding,GO:0046872~metal ion binding,GO:0061630~ubiquitin protein ligase activity,	IPR000569:HECT_dom,IPR002110:Ankyrin_rpt,IPR008979:Galactose-bd-like_sf,IPR010606:Mib_Herc2,IPR011989:ARM-like,IPR012919:SUN_dom,IPR016024:ARM-type_fold,IPR035983:Hect_E3_ubiquitin_ligase,IPR036770:Ankyrin_rpt-contain_sf,IPR037252:Mib_Herc2_sf,IPR041200:FKBP3_BTHB,IPR045322:HECTD1/TRIP12-like,				SM00119:HECTc,SM00248:ANK,	KW-0833~Ubl conjugation pathway,			KW-0040~ANK repeat,KW-0677~Repeat,		KW-0808~Transferase,	KW-0597~Phosphoprotein,	ACT_SITE:Glycyl thioester intermediate,COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:HECT,DOMAIN:MIB/HERC2,DOMAIN:SUN,MUTAGEN:C->G: Abolished E3 ubiquitin-protein ligase activity.,REGION:Disordered,REGION:K-box,REPEAT:ANK,REPEAT:ANK 1,REPEAT:ANK 2,REPEAT:ANK 3,REPEAT:ANK 4,
HERPUD2	HERPUD family member 2(HERPUD2)	Homo sapiens			GO:0007283~spermatogenesis,GO:0030968~endoplasmic reticulum unfolded protein response,	GO:0016020~membrane,	GO:0005515~protein binding,	IPR000626:Ubiquitin-like_dom,IPR029071:Ubiquitin-like_domsf,IPR039751:HERPUD1/2,				SM00213:UBQ,	KW-0834~Unfolded protein response,	KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				COMPBIAS:Polar residues,DOMAIN:Ubiquitin-like,REGION:Disordered,TRANSMEM:Helical,
HEXIM1	HEXIM P-TEFb complex subunit 1(HEXIM1)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0002218~activation of innate immune response,GO:0007507~heart development,GO:0032897~negative regulation of viral transcription,GO:0034244~negative regulation of transcription elongation from RNA polymerase II promoter,GO:0045087~innate immune response,GO:0045736~negative regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0045892~negative regulation of transcription, DNA-templated,GO:1901798~positive regulation of signal transduction by p53 class mediator,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0043231~intracellular membrane-bounded organelle,	GO:0004860~protein kinase inhibitor activity,GO:0004861~cyclin-dependent protein serine/threonine kinase inhibitor activity,GO:0005515~protein binding,GO:0017069~snRNA binding,GO:0042802~identical protein binding,GO:0097322~7SK snRNA binding,	IPR024872:HEXIM,					KW-0391~Immunity,KW-0399~Innate immunity,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,		KW-0678~Repressor,	KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,MUTAGEN:F->A,D,K: Partial loss of function.,MUTAGEN:KHRR->ILAA: Abolishes interaction with 7SK snRNA.,MUTAGEN:L->A: Loss of oligomerization; when associated with A-287; A-294 and A-332.,MUTAGEN:L->A: Loss of oligomerization; when associated with A-287; A-294 and A-339.,MUTAGEN:L->A: Loss of oligomerization; when associated with A-287; A-332 and A-339. Loss of function and interaction with P-TEFb; when associated with A-287.,MUTAGEN:L->A: Loss of oligomerization; when associated with A-294; A-332 and A-339. Loss of function and interaction with P-TEFb; when associated with A-294.,MUTAGEN:RRR->AAA: Abolishes interaction with 7SK snRNA.,MUTAGEN:T->D: Abolishes interaction with P-TEFb. Same effect; when associated with D-203.,MUTAGEN:Y->A,E: Loss of function.,MUTAGEN:Y->D: Abolishes interaction with P-TEFb; when associated with D-205.,REGION:Autoinhibitory acidic region; in absence of 7SK snRNA interacts with the basic region preventing interaction with P-TEFb and modulating subcellular localization,REGION:Basic region; mediates nuclear localization and interaction with 7SK snRNA and NR3C1,REGION:Disordered,REGION:Interaction with P-TEFb,REGION:Mediates interaction with CCNT1,REGION:Required for inhibition of ESR1-dependent transcription,
HTATIP2	HIV-1 Tat interactive protein 2(HTATIP2)	Homo sapiens			GO:0001525~angiogenesis,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006915~apoptotic process,GO:0030154~cell differentiation,GO:0043066~negative regulation of apoptotic process,GO:0043068~positive regulation of programmed cell death,GO:0045765~regulation of angiogenesis,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046777~protein autophosphorylation,GO:0051170~nuclear import,	GO:0005634~nucleus,GO:0005635~nuclear envelope,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016020~membrane,	GO:0003713~transcription coactivator activity,GO:0004674~protein serine/threonine kinase activity,GO:0005515~protein binding,GO:0016491~oxidoreductase activity,	IPR016040:NAD(P)-bd_dom,IPR036291:NAD(P)-bd_dom_sf,					KW-0037~Angiogenesis,KW-0053~Apoptosis,KW-0221~Differentiation,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0043~Tumor suppressor,		KW-0521~NADP,	KW-0217~Developmental protein,KW-0560~Oxidoreductase,KW-9996~Developmental protein,	KW-0007~Acetylation,	ACT_SITE:Proton acceptor,DOMAIN:NAD(P)-binding,MUTAGEN:GETG->VETA: Loss of proapoptotic and metastatis-inhibiting effect.,MUTAGEN:R->H: Loss of association with nucleus.,
HTATSF1	HIV-1 Tat specific factor 1(HTATSF1)	Homo sapiens			GO:0000398~mRNA splicing, via spliceosome,GO:0000724~double-strand break repair via homologous recombination,GO:0006325~chromatin organization,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0019079~viral genome replication,GO:0032784~regulation of DNA-templated transcription, elongation,GO:1903241~U2-type prespliceosome assembly,GO:1990166~protein localization to site of double-strand break,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005681~spliceosomal complex,GO:0005684~U2-type spliceosomal complex,GO:0005686~U2 snRNP,GO:0035861~site of double-strand break,	GO:0003723~RNA binding,GO:0005515~protein binding,	IPR000504:RRM_dom,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR034392:TatSF1-like_RRM1,IPR034393:TatSF1-like,IPR035979:RBD_domain_sf,				SM00360:RRM,	KW-0227~DNA damage,KW-0234~DNA repair,KW-0507~mRNA processing,KW-0508~mRNA splicing,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0158~Chromosome,KW-0539~Nucleus,KW-0747~Spliceosome,		KW-0677~Repeat,		KW-0010~Activator,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:RRM,DOMAIN:RRM 1,DOMAIN:RRM 2,MUTAGEN:KF->AA: In 4A mutant; abolished binding to poly-ADP-ribosylated RPA1 and recruitment to DNA damage sites; when associated with 155-A-A-156.,MUTAGEN:KF->AA: In 4A mutant; abolished binding to poly-ADP-ribosylated RPA1 and recruitment to DNA damage sites; when associated with 297-A-A-298.,MUTAGEN:S->A: Impaired phosphorylation by CK2, leading to abolish interaction with TOPBP1.,MUTAGEN:Y->D: Loss of interaction with U snRNPs.,REGION:Disordered,REGION:Mediates interaction with the P-TEFb complex,REGION:U2AF homology motif (UHM),
HPS1	HPS1 biogenesis of lysosomal organelles complex 3 subunit 1(HPS1)	Homo sapiens			GO:0007040~lysosome organization,GO:0007601~visual perception,GO:0016192~vesicle-mediated transport,GO:0046907~intracellular transport,GO:0050896~response to stimulus,GO:0060155~platelet dense granule organization,GO:1903232~melanosome assembly,	GO:0005737~cytoplasm,GO:0005764~lysosome,GO:0005829~cytosol,GO:0031085~BLOC-3 complex,GO:0031410~cytoplasmic vesicle,	GO:0005085~guanyl-nucleotide exchange factor activity,GO:0005515~protein binding,GO:0046983~protein dimerization activity,	IPR026053:HPS1,IPR043970:FUZ/MON1/HPS1_longin_3,IPR043971:FUZ/MON1/HPS1_longin_2,IPR043972:FUZ/MON1/HPS1_longin_1,		203300~Hermansky-Pudlak syndrome 1,			KW-0716~Sensory transduction,KW-0844~Vision,		KW-0015~Albinism,KW-0225~Disease variant,KW-0363~Hermansky-Pudlak syndrome,	KW-0677~Repeat,		KW-0344~Guanine-nucleotide releasing factor,		COMPBIAS:Polar residues,DOMAIN:FUZ/MON1/HPS1 first Longin,DOMAIN:FUZ/MON1/HPS1 second Longin,DOMAIN:FUZ/MON1/HPS1 third Longin,MOTIF:Melanosome targeting signal,REGION:Disordered,REPEAT:[DE]-X(4)-L-L 1,REPEAT:[DE]-X(4)-L-L 2,REPEAT:[DE]-X(4)-L-L 3,REPEAT:[DE]-X(4)-L-L 4,
HTRA2	HtrA serine peptidase 2(HTRA2)	Homo sapiens			GO:0006508~proteolysis,GO:0006672~ceramide metabolic process,GO:0007005~mitochondrion organization,GO:0007628~adult walking behavior,GO:0008630~intrinsic apoptotic signaling pathway in response to DNA damage,GO:0009635~response to herbicide,GO:0010822~positive regulation of mitochondrion organization,GO:0012501~programmed cell death,GO:0016540~protein autoprocessing,GO:0019742~pentacyclic triterpenoid metabolic process,GO:0030163~protein catabolic process,GO:0030900~forebrain development,GO:0034599~cellular response to oxidative stress,GO:0034605~cellular response to heat,GO:0035458~cellular response to interferon-beta,GO:0040014~regulation of multicellular organism growth,GO:0043065~positive regulation of apoptotic process,GO:0043280~positive regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0043524~negative regulation of neuron apoptotic process,GO:0045786~negative regulation of cell cycle,GO:0048666~neuron development,GO:0051402~neuron apoptotic process,GO:0071300~cellular response to retinoic acid,GO:0071363~cellular response to growth factor stimulus,GO:0097193~intrinsic apoptotic signaling pathway,GO:0097194~execution phase of apoptosis,GO:1902176~negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway,GO:1903146~regulation of mitophagy,GO:1903955~positive regulation of protein targeting to mitochondrion,GO:1904924~negative regulation of mitophagy in response to mitochondrial depolarization,GO:2001241~positive regulation of extrinsic apoptotic signaling pathway in absence of ligand,GO:2001269~positive regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005739~mitochondrion,GO:0005758~mitochondrial intermembrane space,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0009898~cytoplasmic side of plasma membrane,GO:0016020~membrane,GO:0031966~mitochondrial membrane,GO:0035631~CD40 receptor complex,GO:1905370~serine-type endopeptidase complex,	GO:0004252~serine-type endopeptidase activity,GO:0005515~protein binding,GO:0008233~peptidase activity,GO:0008236~serine-type peptidase activity,GO:0042802~identical protein binding,GO:0051082~unfolded protein binding,	IPR001478:PDZ,IPR001940:Peptidase_S1C,IPR009003:Peptidase_S1_PA,IPR036034:PDZ_sf,IPR041489:PDZ_6,	hsa04210:Apoptosis,hsa04215:Apoptosis - multiple species,hsa05012:Parkinson disease,hsa05022:Pathways of neurodegeneration - multiple diseases,	610297~Parkinson disease 13,617248~3-methylglutaconic aciduria, type VIII,		SM00228:PDZ,	KW-0053~Apoptosis,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0496~Mitochondrion,	KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0887~Epilepsy,KW-0907~Parkinson disease,KW-0908~Parkinsonism,	KW-0809~Transit peptide,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0378~Hydrolase,KW-0645~Protease,KW-0720~Serine protease,	KW-0068~Autocatalytic cleavage,KW-0865~Zymogen,	ACT_SITE:Charge relay system,COMPBIAS:Polar residues,DOMAIN:PDZ,MOTIF:IAP-binding motif,MUTAGEN:A->M: Loss of interaction with XIAP. Loss of inhibition of XIAP activity.,MUTAGEN:S->A: Loss of protease activity.,REGION:Disordered,REGION:Serine protease,TRANSIT:Mitochondrion,TRANSMEM:Helical,
IGFLR1	IGF like family receptor 1(IGFLR1)	Homo sapiens				GO:0005654~nucleoplasm,GO:0005886~plasma membrane,	GO:0005515~protein binding,	IPR011029:DEATH-like_dom_sf,IPR042355:IGFLR1,						KW-0472~Membrane,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,		COMPBIAS:Polar residues,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
IK	IK cytokine(IK)	Homo sapiens			GO:0000278~mitotic cell cycle,GO:0000398~mRNA splicing, via spliceosome,GO:0007094~mitotic spindle assembly checkpoint,GO:0034501~protein localization to kinetochore,	GO:0000228~nuclear chromosome,GO:0000922~spindle pole,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005694~chromosome,GO:0005737~cytoplasm,GO:0016607~nuclear speck,GO:0071005~U2-type precatalytic spliceosome,GO:0097431~mitotic spindle pole,	GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR012492:RED_C,IPR012916:RED_N,IPR039896:Red-like,					KW-0507~mRNA processing,KW-0508~mRNA splicing,KW-0945~Host-virus interaction,	KW-0158~Chromosome,KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0747~Spliceosome,KW-0963~Cytoplasm,		KW-0677~Repeat,			KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Protein RED C-terminal,DOMAIN:RED-like N-terminal,REGION:17 X 2 AA tandem repeats of R-[ED],REGION:Disordered,REPEAT:1,REPEAT:10,REPEAT:11,REPEAT:12,REPEAT:13,REPEAT:14,REPEAT:15,REPEAT:16,REPEAT:17,REPEAT:2,REPEAT:3,REPEAT:4,REPEAT:5,REPEAT:6,REPEAT:7,REPEAT:8,REPEAT:9,
IKZF1	IKAROS family zinc finger 1(IKZF1)	Homo sapiens			GO:0006325~chromatin organization,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007049~cell cycle,GO:0007498~mesoderm development,GO:0030098~lymphocyte differentiation,GO:0030218~erythrocyte differentiation,GO:0045892~negative regulation of transcription, DNA-templated,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005721~pericentric heterochromatin,GO:0005829~cytosol,GO:0032991~macromolecular complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0019904~protein domain specific binding,GO:0042802~identical protein binding,GO:0046872~metal ion binding,	IPR013087:Znf_C2H2_type,IPR028440:TRPS1,IPR036236:Znf_C2H2_sf,		616873~Immunodeficiency, common variable, 13,		SM00355:ZnF_C2H2,	KW-0131~Cell cycle,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,	KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0156~Chromatin regulator,KW-0217~Developmental protein,KW-0238~DNA-binding,KW-0678~Repressor,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO),DOMAIN:C2H2-type,MUTAGEN:H->R: Abolishes binding to DNA and has diffuse nuclear localization.,MUTAGEN:N->A: Abolishes binding to DNA and has diffuse nuclear localization.,REGION:Disordered,REGION:Required for binding PP1CC,REGION:Required for both high-affinity DNA binding and pericentromeric heterochromatin localization,SITE:Required for both pericentromeric heterochromatin localization and DNA binding,SITE:Required for both pericentromeric heterochromatin localization and complete DNA binding,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4,ZN_FING:C2H2-type 5,ZN_FING:C2H2-type 6,
IKZF3	IKAROS family zinc finger 3(IKZF3)	Homo sapiens		h_il2rbPathway:IL-2 Receptor Beta Chain in T cell Activation,	GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007498~mesoderm development,GO:0009617~response to bacterium,GO:0030183~B cell differentiation,GO:0030217~T cell differentiation,GO:0030888~regulation of B cell proliferation,GO:0042981~regulation of apoptotic process,GO:0045577~regulation of B cell differentiation,GO:0045619~regulation of lymphocyte differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0042826~histone deacetylase binding,GO:0043565~sequence-specific DNA binding,GO:0046872~metal ion binding,GO:0046982~protein heterodimerization activity,GO:1990841~promoter-specific chromatin binding,	IPR013087:Znf_C2H2_type,IPR036236:Znf_C2H2_sf,		619437~Immunodeficiency 84,		SM00355:ZnF_C2H2,	KW-0075~B-cell activation,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,	KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:C2H2-type,REGION:Disordered,REGION:Mediates homodimerization and heterodimerization,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4; atypical,ZN_FING:C2H2-type 5,ZN_FING:C2H2-type 6; atypical,
ITK	IL2 inducible T cell kinase(ITK)	Homo sapiens		h_ctla4Pathway:The Co-Stimulatory Signal During T-cell Activation,	GO:0001819~positive regulation of cytokine production,GO:0001865~NK T cell differentiation,GO:0002250~adaptive immune response,GO:0006468~protein phosphorylation,GO:0006968~cellular defense response,GO:0007165~signal transduction,GO:0007202~activation of phospholipase C activity,GO:0016310~phosphorylation,GO:0035556~intracellular signal transduction,GO:0042110~T cell activation,GO:0046629~gamma-delta T cell activation,GO:0050852~T cell receptor signaling pathway,GO:0050853~B cell receptor signaling pathway,	GO:0005634~nucleus,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005911~cell-cell junction,	GO:0004715~non-membrane spanning protein tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0046872~metal ion binding,	IPR000719:Prot_kinase_dom,IPR000980:SH2,IPR001245:Ser-Thr/Tyr_kinase_cat_dom,IPR001452:SH3_domain,IPR001562:Znf_Btk_motif,IPR001849:PH_domain,IPR008266:Tyr_kinase_AS,IPR011009:Kinase-like_dom_sf,IPR011993:PH-like_dom_sf,IPR017441:Protein_kinase_ATP_BS,IPR020635:Tyr_kinase_cat_dom,IPR035583:ITK_SH3,IPR036028:SH3-like_dom_sf,IPR036860:SH2_dom_sf,IPR042785:ITK_PTKc,IPR043539:Grb2-like,	hsa04062:Chemokine signaling pathway,hsa04660:T cell receptor signaling pathway,hsa04670:Leukocyte transendothelial migration,	613011~Lymphoproliferative syndrome 1,		SM00107:BTK,SM00219:TyrKc,SM00233:PH,SM00252:SH2,SM00326:SH3,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,	KW-0727~SH2 domain,KW-0728~SH3 domain,KW-0863~Zinc-finger,	KW-0067~ATP-binding,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,KW-0862~Zinc,	KW-0418~Kinase,KW-0808~Transferase,KW-0829~Tyrosine-protein kinase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	ACT_SITE:Proton acceptor,DOMAIN:PH,DOMAIN:Protein kinase,DOMAIN:SH2,DOMAIN:SH3,MUTAGEN:P->G: Complete loss of interaction with PPIA/CYPA.,REGION:Disordered,ZN_FING:Btk-type,
INO80E	INO80 complex subunit E(INO80E)	Homo sapiens			GO:0000723~telomere maintenance,GO:0006275~regulation of DNA replication,GO:0006281~DNA repair,GO:0006282~regulation of DNA repair,GO:0006310~DNA recombination,GO:0006338~chromatin remodeling,GO:0033044~regulation of chromosome organization,GO:0045739~positive regulation of DNA repair,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045995~regulation of embryonic development,GO:0051726~regulation of cell cycle,GO:0060382~regulation of DNA strand elongation,GO:1904507~positive regulation of telomere maintenance in response to DNA damage,	GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0031011~Ino80 complex,	GO:0005515~protein binding,	IPR026678:INO80E,	hsa03082:ATP-dependent chromatin remodeling,				KW-0227~DNA damage,KW-0233~DNA recombination,KW-0234~DNA repair,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0175~Coiled coil,			KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),REGION:Disordered,
IQGAP1	IQ motif containing GTPase activating protein 1(IQGAP1)	Homo sapiens			GO:0001817~regulation of cytokine production,GO:0007165~signal transduction,GO:0007173~epidermal growth factor receptor signaling pathway,GO:0007346~regulation of mitotic cell cycle,GO:0008543~fibroblast growth factor receptor signaling pathway,GO:0010761~fibroblast migration,GO:0016477~cell migration,GO:0035305~negative regulation of dephosphorylation,GO:0036120~cellular response to platelet-derived growth factor stimulus,GO:0043410~positive regulation of MAPK cascade,GO:0045860~positive regulation of protein kinase activity,GO:0048008~platelet-derived growth factor receptor signaling pathway,GO:0071277~cellular response to calcium ion,GO:0071364~cellular response to epidermal growth factor stimulus,GO:0072015~glomerular visceral epithelial cell development,GO:1903479~mitotic actomyosin contractile ring assembly actin filament organization,GO:1990138~neuron projection extension,	GO:0001726~ruffle,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005874~microtubule,GO:0005884~actin filament,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0005938~cell cortex,GO:0009898~cytoplasmic side of plasma membrane,GO:0015629~actin cytoskeleton,GO:0015630~microtubule cytoskeleton,GO:0016323~basolateral plasma membrane,GO:0016324~apical plasma membrane,GO:0016328~lateral plasma membrane,GO:0030424~axon,GO:0030426~growth cone,GO:0030496~midbody,GO:0030667~secretory granule membrane,GO:0030864~cortical actin cytoskeleton,GO:0036057~slit diaphragm,GO:0036464~cytoplasmic ribonucleoprotein granule,GO:0043005~neuron projection,GO:0070062~extracellular exosome,GO:1990904~ribonucleoprotein complex,	GO:0005078~MAP-kinase scaffold activity,GO:0005095~GTPase inhibitor activity,GO:0005096~GTPase activator activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0005547~phosphatidylinositol-3,4,5-trisphosphate binding,GO:0019901~protein kinase binding,GO:0019903~protein phosphatase binding,GO:0019904~protein domain specific binding,GO:0031267~small GTPase binding,GO:0043539~protein serine/threonine kinase activator activity,GO:0044548~S100 protein binding,GO:0045296~cadherin binding,GO:0051015~actin filament binding,GO:0060090~binding, bridging,	IPR000048:IQ_motif_EF-hand-BS,IPR000593:RasGAP_C,IPR001202:WW_dom,IPR001715:CH_dom,IPR001936:RasGAP_dom,IPR008936:Rho_GTPase_activation_prot,IPR023152:RasGAP_CS,IPR027417:P-loop_NTPase,IPR036872:CH_dom_sf,	hsa04520:Adherens junction,hsa04810:Regulation of actin cytoskeleton,hsa05205:Proteoglycans in cancer,			SM00015:IQ,SM00033:CH,SM00323:RasGAP,SM00456:WW,	KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0175~Coiled coil,KW-0677~Repeat,KW-0732~Signal,		KW-0112~Calmodulin-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:Calponin-homology (CH),DOMAIN:IQ 1,DOMAIN:IQ 2,DOMAIN:IQ 3,DOMAIN:IQ 4,DOMAIN:Ras-GAP,DOMAIN:WW,MUTAGEN:S->A: Abolishes neurite outgrowth promoting activity; when associated with A-1441.,MUTAGEN:S->A: Abolishes neurite outgrowth promoting activity; when associated with A-1443.,MUTAGEN:S->D: Strongly enhances neurite outgrowth promoting activity; when associated with A-1441.,MUTAGEN:S->E: Strongly enhances neurite outgrowth promoting activity; when associated with A-1443.,REGION:C1,REGION:C2,REGION:Disordered,
IST1	IST1 factor associated with ESCRT-III(IST1)	Homo sapiens			GO:0008104~protein localization,GO:0009838~abscission,GO:0015031~protein transport,GO:0019076~viral release from host cell,GO:0036258~multivesicular body assembly,GO:0045184~establishment of protein localization,GO:0045862~positive regulation of proteolysis,GO:0046745~viral capsid secondary envelopment,GO:0048668~collateral sprouting,GO:0048672~positive regulation of collateral sprouting,GO:0051301~cell division,GO:0061640~cytoskeleton-dependent cytokinesis,GO:1904903~ESCRT III complex disassembly,	GO:0000785~chromatin,GO:0005576~extracellular region,GO:0005635~nuclear envelope,GO:0005793~endoplasmic reticulum-Golgi intermediate compartment,GO:0005813~centrosome,GO:0005829~cytosol,GO:0030496~midbody,GO:0035578~azurophil granule lumen,GO:0043231~intracellular membrane-bounded organelle,GO:0070062~extracellular exosome,GO:0090543~Flemming body,	GO:0005515~protein binding,GO:0019904~protein domain specific binding,GO:0042802~identical protein binding,GO:0044877~macromolecular complex binding,GO:0045296~cadherin binding,GO:0090541~MIT domain binding,	IPR005061:Ist1,IPR042277:IST1-like,	hsa04144:Endocytosis,				KW-0131~Cell cycle,KW-0132~Cell division,	KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,		KW-0175~Coiled coil,			KW-0597~Phosphoprotein,	MOTIF:MIT-interacting motif,MOTIF:Type-2 MIT-interacting motif,MUTAGEN:L->A: Diminishes interaction with VPS4A. Greatly diminishes interaction with VPS4A and abolishes interaction with VTA1; when associated with D-326. Greatly diminishes interaction with VPS4A; when associated with D-323.,MUTAGEN:L->A: Diminishes interaction with VPS4A. Greatly diminishes interaction with VPS4A; when associated with D-326.,MUTAGEN:L->D: Diminishes interaction with VPS4A. Greatly diminishes interaction with VPS4A and abolishes interaction with VTA1; when associated with A-353. Greatly diminishes interaction with VPS4A; when associated with A-360.,MUTAGEN:L->D: Diminishes interaction with VPS4A. Greatly diminishes interaction with VPS4A; when associated with A-353.,MUTAGEN:LK->AA: Abolishes interaction with VTA1, MITD1 and USP8; diminishes interaction with VPS4A.,REGION:Disordered,REGION:Interaction with CHMP1A and CHMP1B,REGION:Interaction with VPS37B,REGION:Interaction with VPS4A, VTA1, MITD1 STAMBP and USP8,REGION:Interaction with VTA1,
JKAMP	JNK1/MAPK8 associated membrane protein(JKAMP)	Homo sapiens			GO:0006986~response to unfolded protein,GO:0030433~ubiquitin-dependent ERAD pathway,GO:0036503~ERAD pathway,	GO:0005789~endoplasmic reticulum membrane,GO:0016020~membrane,	GO:0031625~ubiquitin protein ligase binding,	IPR008485:JAMP,					KW-0834~Unfolded protein response,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0832~Ubl conjugation,	CARBOHYD:N-linked (GlcNAc...) asparagine,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
JAK1	Janus kinase 1(JAK1)	Homo sapiens	12.IL-6_type_cytok-signal-transduct,48.mice_minus_JAKs_and_STATs,75.Stats_activators_of_Apoptosis,	h_egfPathway:EGF Signaling Pathway,h_ifnaPathway:IFN alpha signaling pathway,h_ifngPathway:IFN gamma signaling pathway ,h_il10Pathway:IL-10 Anti-inflammatory Signaling Pathway,h_il22bpPathway:IL22 Soluble Receptor Signaling Pathway ,h_il2Pathway:IL 2 signaling pathway,h_il2rbPathway:IL-2 Receptor Beta Chain in T cell Activation,h_il4Pathway:IL 4 signaling pathway,h_il6Pathway:IL 6 signaling pathway,h_il7Pathway:IL-7 Signal Transduction,h_pdgfPathway:PDGF Signaling Pathway,h_stat3Pathway:Stat3 Signaling Pathway,	GO:0006468~protein phosphorylation,GO:0007259~JAK-STAT cascade,GO:0007260~tyrosine phosphorylation of STAT protein,GO:0016310~phosphorylation,GO:0019221~cytokine-mediated signaling pathway,GO:0030154~cell differentiation,GO:0030155~regulation of cell adhesion,GO:0034112~positive regulation of homotypic cell-cell adhesion,GO:0035556~intracellular signal transduction,GO:0035723~interleukin-15-mediated signaling pathway,GO:0035771~interleukin-4-mediated signaling pathway,GO:0038110~interleukin-2-mediated signaling pathway,GO:0038113~interleukin-9-mediated signaling pathway,GO:0038154~interleukin-11-mediated signaling pathway,GO:0038196~type III interferon signaling pathway,GO:0046677~response to antibiotic,GO:0051239~regulation of multicellular organismal process,GO:0060333~interferon-gamma-mediated signaling pathway,GO:0060337~type I interferon signaling pathway,GO:0060397~JAK-STAT cascade involved in growth hormone signaling pathway,GO:0070102~interleukin-6-mediated signaling pathway,GO:0072540~T-helper 17 cell lineage commitment,GO:0098586~cellular response to virus,GO:1900182~positive regulation of protein localization to nucleus,GO:1903672~positive regulation of sprouting angiogenesis,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005768~endosome,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0009898~cytoplasmic side of plasma membrane,GO:0012505~endomembrane system,GO:0016020~membrane,GO:0031234~extrinsic component of cytoplasmic side of plasma membrane,	GO:0004713~protein tyrosine kinase activity,GO:0004715~non-membrane spanning protein tyrosine kinase activity,GO:0005131~growth hormone receptor binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0019903~protein phosphatase binding,GO:0031625~ubiquitin protein ligase binding,GO:0031730~CCR5 chemokine receptor binding,GO:0046872~metal ion binding,	IPR000299:FERM_domain,IPR000719:Prot_kinase_dom,IPR000980:SH2,IPR001245:Ser-Thr/Tyr_kinase_cat_dom,IPR008266:Tyr_kinase_AS,IPR011009:Kinase-like_dom_sf,IPR016251:Tyr_kinase_non-rcpt_Jak/Tyk2,IPR017441:Protein_kinase_ATP_BS,IPR019748:FERM_central,IPR019749:Band_41_domain,IPR020635:Tyr_kinase_cat_dom,IPR020776:Tyr_kinase_non-rcpt_Jak1,IPR035963:FERM_2,IPR036860:SH2_dom_sf,IPR041046:FERM_F2,IPR041155:FERM_F1,IPR041381:JAK1-3/TYK2_PHL_dom,	hsa01521:EGFR tyrosine kinase inhibitor resistance,hsa04151:PI3K-Akt signaling pathway,hsa04217:Necroptosis,hsa04380:Osteoclast differentiation,hsa04550:Signaling pathways regulating pluripotency of stem cells,hsa04620:Toll-like receptor signaling pathway,hsa04621:NOD-like receptor signaling pathway,hsa04630:JAK-STAT signaling pathway,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa05140:Leishmaniasis,hsa05145:Toxoplasmosis,hsa05152:Tuberculosis,hsa05160:Hepatitis C,hsa05161:Hepatitis B,hsa05162:Measles,hsa05163:Human cytomegalovirus infection,hsa05164:Influenza A,hsa05165:Human papillomavirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05171:Coronavirus disease - COVID-19,hsa05200:Pathways in cancer,hsa05203:Viral carcinogenesis,hsa05212:Pancreatic cancer,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,	618999~Autoinflammation, immune dysregulation, and eosinophilia,	PIRSF000636:TyrPK_Jak,	SM00219:TyrKc,SM00252:SH2,SM00295:B41,		KW-0472~Membrane,	KW-0225~Disease variant,	KW-0677~Repeat,KW-0727~SH2 domain,	KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0808~Transferase,KW-0829~Tyrosine-protein kinase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	ACT_SITE:Proton acceptor,DOMAIN:FERM,DOMAIN:Protein kinase,DOMAIN:Protein kinase 1,DOMAIN:Protein kinase 2,DOMAIN:SH2,MUTAGEN:K->A: Loss of protein tyrosine kinase activity.,MUTAGEN:V->F: Constitutively active. Increased receptor signaling pathway via JAK-STAT.,
JOSD1	Josephin domain containing 1(JOSD1)	Homo sapiens			GO:0006508~proteolysis,GO:0016579~protein deubiquitination,	GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016020~membrane,	GO:0004843~thiol-dependent ubiquitin-specific protease activity,GO:0005515~protein binding,	IPR006155:Josephin,IPR040053:JOSD1/2,				SM01246:Josephin,	KW-0833~Ubl conjugation pathway,	KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,				KW-0378~Hydrolase,KW-0645~Protease,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	ACT_SITE:Nucleophile,ACT_SITE:Proton acceptor,DOMAIN:Josephin,MUTAGEN:C->A: Loss of deubiquitination activity, no change in subcellular location.,REGION:Disordered,
JUN	Jun proto-oncogene, AP-1 transcription factor subunit(JUN)	Homo sapiens	114.Genomic_reformatting_Brain_Ischemia,3.T_cell_receptor,67.Ikaros_and_signaling_inhibitors,77.IkBa_Kinase_JNK_MEKK1,92.Ancient_Host_Defense_Pathways,	h_41BBPathway:The 4-1BB-dependent immune response,h_agrPathway:Agrin in Postsynaptic Differentiation,h_arenrf2Pathway:Oxidative Stress Induced Gene Expression Via Nrf2,h_at1rPathway:Angiotensin II mediated activation of JNK Pathway via Pyk2 dependent signaling,h_atmPathway:ATM Signaling Pathway,h_bcrPathway:BCR Signaling Pathway,h_cardiacEGFPathway:Role of EGF Receptor Transactivation by GPCRs in Cardiac Hypertrophy,h_ccr5Pathway:Pertussis toxin-insensitive CCR5 Signaling in Macrophage,h_cdmacPathway:Cadmium induces DNA synthesis and proliferation in macrophages,h_d4gdiPathway:D4-GDI Signaling Pathway,h_dreamPathway:Repression of Pain Sensation by the Transcriptional Regulator DREAM,h_egfPathway:EGF Signaling Pathway,h_epoPathway:EPO Signaling Pathway,h_etsPathway:METS affect on Macrophage Differentiation,h_fasPathway:FAS signaling pathway ( CD95 ),h_fcer1Pathway:Fc Epsilon Receptor I Signaling in Mast Cells,h_gleevecPathway:Inhibition of Cellular Proliferation by Gleevec,h_gpcrPathway:Signaling Pathway from G-Protein Families,h_hifPathway:Hypoxia-Inducible Factor in the Cardiovascular System,h_igf1Pathway:IGF-1 Signaling Pathway,h_il12Pathway:IL12 and Stat4 Dependent Signaling Pathway in Th1 Development,h_il1rPathway:Signal transduction through IL1R,h_il2Pathway:IL 2 signaling pathway,h_il6Pathway:IL 6 signaling pathway,h_insulinPathway:Insulin Signaling Pathway,h_integrinPathway:Integrin Signaling Pathway,h_keratinocytePathway:Keratinocyte Differentiation,h_mapkPathway:MAPKinase Signaling Pathway,h_metPathway:Signaling of Hepatocyte Growth Factor Receptor,h_ngfPathway:Nerve growth factor pathway (NGF),h_pcafPathway:The information-processing pathway at the IFN-beta enhancer,h_pdgfPathway:PDGF Signaling Pathway,h_PparaPathway:Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha),h_pyk2Pathway:Links between Pyk2 and Map Kinases,h_stressPathway:TNF/Stress Related Signaling,h_tcrPathway:T Cell Receptor Signaling Pathway,h_tnfr1Pathway:TNFR1 Signaling Pathway,h_tollPathway:Toll-Like Receptor Pathway,h_tpoPathway:TPO Signaling Pathway,h_tsp1Pathway:TSP-1 Induced Apoptosis in Microvascular Endothelial Cell ,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007179~transforming growth factor beta receptor signaling pathway,GO:0019046~release from viral latency,GO:0034614~cellular response to reactive oxygen species,GO:0034976~response to endoplasmic reticulum stress,GO:0042127~regulation of cell proliferation,GO:0043065~positive regulation of apoptotic process,GO:0043392~negative regulation of DNA binding,GO:0043922~negative regulation by host of viral transcription,GO:0043923~positive regulation by host of viral transcription,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051726~regulation of cell cycle,GO:0060395~SMAD protein signal transduction,GO:0071276~cellular response to cadmium ion,GO:1902895~positive regulation of pri-miRNA transcription from RNA polymerase II promoter,GO:1904707~positive regulation of vascular smooth muscle cell proliferation,GO:1990441~negative regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress,GO:2000144~positive regulation of DNA-templated transcription, initiation,	GO:0000228~nuclear chromosome,GO:0000785~chromatin,GO:0000791~euchromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0035976~transcription factor AP-1 complex,GO:0090575~RNA polymerase II transcription factor complex,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003690~double-stranded DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0003723~RNA binding,GO:0005096~GTPase activator activity,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:0019899~enzyme binding,GO:0031625~ubiquitin protein ligase binding,GO:0035497~cAMP response element binding,GO:0042802~identical protein binding,GO:0044389~ubiquitin-like protein ligase binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:0070412~R-SMAD binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR002112:Leuzip_Jun,IPR004827:bZIP,IPR005643:JNK,IPR008917:TF_DNA-bd_sf,IPR046347:bZIP_sf,	hsa01522:Endocrine resistance,hsa04010:MAPK signaling pathway,hsa04012:ErbB signaling pathway,hsa04024:cAMP signaling pathway,hsa04137:Mitophagy - animal,hsa04210:Apoptosis,hsa04310:Wnt signaling pathway,hsa04380:Osteoclast differentiation,hsa04510:Focal adhesion,hsa04530:Tight junction,hsa04620:Toll-like receptor signaling pathway,hsa04621:NOD-like receptor signaling pathway,hsa04625:C-type lectin receptor signaling pathway,hsa04657:IL-17 signaling pathway,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04660:T cell receptor signaling pathway,hsa04662:B cell receptor signaling pathway,hsa04668:TNF signaling pathway,hsa04722:Neurotrophin signaling pathway,hsa04912:GnRH signaling pathway,hsa04915:Estrogen signaling pathway,hsa04921:Oxytocin signaling pathway,hsa04926:Relaxin signaling pathway,hsa04932:Non-alcoholic fatty liver disease,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa05030:Cocaine addiction,hsa05031:Amphetamine addiction,hsa05120:Epithelial cell signaling in Helicobacter pylori infection,hsa05130:Pathogenic Escherichia coli infection,hsa05131:Shigellosis,hsa05132:Salmonella infection,hsa05133:Pertussis,hsa05135:Yersinia infection,hsa05140:Leishmaniasis,hsa05142:Chagas disease,hsa05161:Hepatitis B,hsa05162:Measles,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05171:Coronavirus disease - COVID-19,hsa05200:Pathways in cancer,hsa05203:Viral carcinogenesis,hsa05207:Chemical carcinogenesis - receptor activation,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05210:Colorectal cancer,hsa05211:Renal cell carcinoma,hsa05224:Breast cancer,hsa05231:Choline metabolism in cancer,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,hsa05321:Inflammatory bowel disease,hsa05323:Rheumatoid arthritis,hsa05417:Lipid and atherosclerosis,hsa05418:Fluid shear stress and atherosclerosis,			SM00338:BRLZ,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0656~Proto-oncogene,	KW-0175~Coiled coil,		KW-0010~Activator,KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:BZIP,DOMAIN:bZIP,MUTAGEN:Missing: Abolishes activation of FASLG/CD95L transcription.,MUTAGEN:R->V: Abolishes the synergistic activity with SMAD3 to activate TGF-beta-mediated transcription.,MUTAGEN:S->A: Abolishes phosphorylation by DYRK2. Abolishes phosphorylation by GSK3B at Thr-239.,MUTAGEN:S->A: Greatly reduced ATF7-mediated transcriptional activity; when associated with A-63. Abolishes interaction with FBXW7; when associated with A-63; A-91 and A-93.,MUTAGEN:S->A: Greatly reduced ATF7-mediated transcriptional activity; when associated with A-73. Abolishes interaction with FBXW7; when associated with A-73; A-91 and A-93.,MUTAGEN:T->A: Abolishes interaction with FBXW7; when associated with A-63; A-73 and A-91.,MUTAGEN:T->A: Abolishes interaction with FBXW7; when associated with A-63; A-73 and A-93.,MUTAGEN:T->A: Complete loss of PAK2-mediated phosphorylation; when associated with A-2; A-89; A-93; and A-286.,MUTAGEN:T->A: Complete loss of PAK2-mediated phosphorylation; when associated with A-2; A-8; A-89; and A-286.,MUTAGEN:T->A: Complete loss of PAK2-mediated phosphorylation; when associated with A-2; A-8; A-89; and A-93.,MUTAGEN:T->A: Complete loss of PAK2-mediated phosphorylation; when associated with A-2; A-8; A-93; and A-286.,MUTAGEN:T->A: Complete loss of PAK2-mediated phosphorylation; when associated with A-8; A-89; A-93; and A-286.,REGION:Basic motif,REGION:Interaction with PAGE4,REGION:Leucine-zipper,SITE:Necessary for synergistic transcriptional activity with SMAD3,
JUNB	JunB proto-oncogene, AP-1 transcription factor subunit(JUNB)	Homo sapiens	114.Genomic_reformatting_Brain_Ischemia,	h_gata3Pathway:GATA3 participate in activating the Th2 cytokine genes expression,	GO:0001570~vasculogenesis,GO:0001649~osteoblast differentiation,GO:0001829~trophectodermal cell differentiation,GO:0002158~osteoclast proliferation,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0030316~osteoclast differentiation,GO:0033687~osteoblast proliferation,GO:0042127~regulation of cell proliferation,GO:0045597~positive regulation of cell differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046697~decidualization,GO:0051726~regulation of cell cycle,GO:0060136~embryonic process involved in female pregnancy,GO:0060716~labyrinthine layer blood vessel development,GO:0071277~cellular response to calcium ion,GO:2000319~regulation of T-helper 17 cell differentiation,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0035976~transcription factor AP-1 complex,GO:0090575~RNA polymerase II transcription factor complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003690~double-stranded DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR002112:Leuzip_Jun,IPR004827:bZIP,IPR005643:JNK,IPR008917:TF_DNA-bd_sf,IPR046347:bZIP_sf,	hsa04380:Osteoclast differentiation,hsa04668:TNF signaling pathway,hsa04935:Growth hormone synthesis, secretion and action,			SM00338:BRLZ,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0175~Coiled coil,		KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:BZIP,DOMAIN:bZIP,REGION:Basic motif,REGION:Disordered,REGION:Leucine-zipper,
JUND	JunD proto-oncogene, AP-1 transcription factor subunit(JUND)	Homo sapiens		h_bcellsurvivalPathway:B Cell Survival Pathway,h_fosbPathway:FOSB gene expression and drug abuse,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0002076~osteoblast development,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0010467~gene expression,GO:0042127~regulation of cell proliferation,GO:0045669~positive regulation of osteoblast differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051726~regulation of cell cycle,GO:0071277~cellular response to calcium ion,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0017053~transcriptional repressor complex,GO:0035976~transcription factor AP-1 complex,GO:0090575~RNA polymerase II transcription factor complex,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001221~transcription cofactor binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003690~double-stranded DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:0019899~enzyme binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR002112:Leuzip_Jun,IPR004827:bZIP,IPR005643:JNK,IPR008917:TF_DNA-bd_sf,IPR046347:bZIP_sf,	hsa04010:MAPK signaling pathway,hsa04380:Osteoclast differentiation,hsa04657:IL-17 signaling pathway,hsa04928:Parathyroid hormone synthesis, secretion and action,			SM00338:BRLZ,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0175~Coiled coil,		KW-0010~Activator,KW-0238~DNA-binding,	KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	DISULFID:Interchain (with C-172 in FOSB),DOMAIN:BZIP,DOMAIN:bZIP,MOTIF:MAP kinase docking motif; essential for its phosphorylation,MOTIF:Menin-binding motif (MBM),MUTAGEN:A->R: Reduced interaction with MEN1.,MUTAGEN:F->A: Loss of interaction with MEN1.,MUTAGEN:G->R: Loss of interaction with MEN1.,MUTAGEN:K->A: Loss of phosphorylation; when associated with A-46.,MUTAGEN:K->A: Loss of phosphorylation; when associated with A-47.,MUTAGEN:K->E: Reduced interaction with MEN1; when associated with E-46.,MUTAGEN:K->E: Reduced interaction with MEN1; when associated with E-47.,MUTAGEN:L->A: Loss of phosphorylation; when associated with A-52.,MUTAGEN:L->A: Loss of phosphorylation; when associated with A-54.,MUTAGEN:L->A: Reduced interaction with MEN1.,MUTAGEN:P->A: Loss of interaction with MEN1.,MUTAGEN:P->A: Reduced interaction with MEN1.,MUTAGEN:R->A: Reduced interaction with MEN1.,REGION:Basic motif,REGION:Disordered,REGION:Leucine-zipper,
KANSL1	KAT8 regulatory NSL complex subunit 1(KANSL1)	Homo sapiens			GO:0006325~chromatin organization,GO:0045893~positive regulation of transcription, DNA-templated,GO:0051571~positive regulation of histone H3-K4 methylation,	GO:0000123~histone acetyltransferase complex,GO:0000776~kinetochore,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0044545~NSL complex,GO:0071339~MLL1 complex,	GO:0005515~protein binding,GO:0035035~histone acetyltransferase binding,	IPR026180:NSL1,IPR029332:PEHE_dom,		610443~Koolen-De Vries syndrome,		SM01300:PEHE,		KW-0137~Centromere,KW-0158~Chromosome,KW-0539~Nucleus,KW-0995~Kinetochore,	KW-0225~Disease variant,KW-0991~Intellectual disability,	KW-0175~Coiled coil,		KW-0156~Chromatin regulator,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:PEHE,MUTAGEN:E->R: Abolishes interaction with KAT8.,MUTAGEN:F->R: No effect on interaction with KAT8.,MUTAGEN:FDIN->AAAA: Strongly reduces KAT8 histone acetyltransferase activity.,MUTAGEN:GESS->AAAA: Strongly reduces KAT8 histone acetyltransferase activity.,MUTAGEN:H->R: Abolishes interaction with KAT8.,MUTAGEN:NIVI->AAAA: Abolishes KAT8 histone acetyltransferase activity.,MUTAGEN:PMSV->AAAA: Reduces KAT8 histone acetyltransferase activity.,MUTAGEN:RRRR->AAAA: Abolishes KAT8 histone acetyltransferase activity.,REGION:Disordered,REGION:Required for activation of KAT8 histone acetyltransferase activity,REGION:Sufficient for interaction with KAT8,
KDELR1	KDEL endoplasmic reticulum protein retention receptor 1(KDELR1)	Homo sapiens		h_arapPathway:ADP-Ribosylation Factor,	GO:0006621~protein retention in ER lumen,GO:0006888~ER to Golgi vesicle-mediated transport,GO:0006890~retrograde vesicle-mediated transport, Golgi to ER,GO:0015031~protein transport,GO:0030217~T cell differentiation,GO:0070231~T cell apoptotic process,	GO:0000139~Golgi membrane,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005793~endoplasmic reticulum-Golgi intermediate compartment,GO:0005801~cis-Golgi network,GO:0030133~transport vesicle,GO:0030663~COPI-coated vesicle membrane,GO:0033116~endoplasmic reticulum-Golgi intermediate compartment membrane,	GO:0005046~KDEL sequence binding,GO:0005515~protein binding,GO:0046923~ER retention sequence binding,	IPR000133:ER_ret_rcpt,	hsa05110:Vibrio cholerae infection,				KW-0653~Protein transport,KW-0813~Transport,KW-0931~ER-Golgi transport,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0968~Cytoplasmic vesicle,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0597~Phosphoprotein,	MUTAGEN:D->N: Loss of recycling together with cargo proteins containing the sequence motif K-D-E-L from the Golgi to the endoplasmic reticulum.,MUTAGEN:DT->AA: Decreased binding to the sequence motif K-D-E-L.,MUTAGEN:E->A,Q: Loss of recycling together with cargo proteins containing the sequence motif K-D-E-L from the Golgi to the endoplasmic reticulum.,MUTAGEN:H->A: Loss of recycling together with cargo proteins containing the sequence motif K-D-E-L from the Golgi to the endoplasmic reticulum.,MUTAGEN:I->A: Decreased binding to the sequence motif K-D-E-L.,MUTAGEN:KGKK->AGAA: Loss of recycling together with cargo proteins containing the sequence motif K-D-E-L from the Golgi to the endoplasmic reticulum.,MUTAGEN:R->K: Loss of recycling together with cargo proteins containing the sequence motif K-D-E-L from the Golgi to the endoplasmic reticulum.,MUTAGEN:S->A: Inhibits coatomer/ARF-GAP recruitment, receptor redistribution, and intracellular retention of KDEL ligands.,MUTAGEN:S->D: Redistribution to the ER is not affected upon PKA inactivation.,MUTAGEN:Y->F: Loss of recycling together with cargo proteins containing the sequence motif K-D-E-L from the Golgi to the endoplasmic reticulum.,REGION:Important for recycling of cargo proteins with the sequence motif K-D-E-L from the Golgi to the endoplasmic reticulum,REGION:Interaction with the K-D-E-L motif on target proteins,SITE:Important for recycling of cargo proteins with the sequence motif K-D-E-L from the Golgi to the endoplasmic reticulum,SITE:Interaction with the K-D-E-L motif on target proteins,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
KDELR2	KDEL endoplasmic reticulum protein retention receptor 2(KDELR2)	Homo sapiens		h_arapPathway:ADP-Ribosylation Factor,	GO:0006621~protein retention in ER lumen,GO:0006888~ER to Golgi vesicle-mediated transport,GO:0006890~retrograde vesicle-mediated transport, Golgi to ER,GO:0015031~protein transport,GO:0035437~maintenance of protein localization in endoplasmic reticulum,	GO:0000139~Golgi membrane,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005801~cis-Golgi network,GO:0016020~membrane,GO:0030133~transport vesicle,GO:0030663~COPI-coated vesicle membrane,	GO:0005046~KDEL sequence binding,GO:0046923~ER retention sequence binding,	IPR000133:ER_ret_rcpt,	hsa05110:Vibrio cholerae infection,	619131~Osteogenesis imperfecta, type XXI,			KW-0653~Protein transport,KW-0813~Transport,KW-0931~ER-Golgi transport,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0968~Cytoplasmic vesicle,	KW-0225~Disease variant,KW-1065~Osteogenesis imperfecta,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,		REGION:Important for recycling of cargo proteins with the sequence motif K-D-E-L from the Golgi to the endoplasmic reticulum,REGION:Interaction with the K-D-E-L motif on target proteins,SITE:Important for recycling of cargo proteins with the sequence motif K-D-E-L from the Golgi to the endoplasmic reticulum,SITE:Interaction with the K-D-E-L motif on target proteins,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
KHDRBS1	KH RNA binding domain containing, signal transduction associated 1(KHDRBS1)	Homo sapiens		h_sam68Pathway:Regulation of Splicing through Sam68,	GO:0000082~G1/S transition of mitotic cell cycle,GO:0000086~G2/M transition of mitotic cell cycle,GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0000381~regulation of alternative mRNA splicing, via spliceosome,GO:0006397~mRNA processing,GO:0007283~spermatogenesis,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045948~positive regulation of translational initiation,GO:0046831~regulation of RNA export from nucleus,GO:0046833~positive regulation of RNA export from nucleus,GO:0050852~T cell receptor signaling pathway,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016020~membrane,GO:0032991~macromolecular complex,GO:0070618~Grb2-Sos complex,	GO:0003677~DNA binding,GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0005515~protein binding,GO:0008143~poly(A) binding,GO:0008266~poly(U) RNA binding,GO:0017124~SH3 domain binding,GO:0019904~protein domain specific binding,GO:0035591~signaling adaptor activity,GO:0042169~SH2 domain binding,GO:0042802~identical protein binding,GO:0044877~macromolecular complex binding,GO:1990782~protein tyrosine kinase binding,	IPR004087:KH_dom,IPR004088:KH_dom_type_1,IPR032335:Sam68-YY,IPR032571:Qua1_dom,IPR036612:KH_dom_type_1_sf,IPR045071:BBP-like,				SM00322:KH,	KW-0131~Cell cycle,KW-0507~mRNA processing,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0729~SH3-binding,		KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:K Homology,DOMAIN:KH,MUTAGEN:E->A: Impairs homodimerization.,MUTAGEN:E->K: Disrupts interaction with APC.,MUTAGEN:F->S: Disrupts homodimerization, impairs influence on alternative splicing.,MUTAGEN:V->F: Disrupts binding to poly(A). Decreased binding to the BCL2L1 mRNA. Loss of function in BCL2L1 splicing. Changed nuclear localization.,MUTAGEN:Y->E: Fails to influence alternative splicing of CD44, NRXN2 and NRXN3.,MUTAGEN:Y->F: Completely blocks nuclear localization.,MUTAGEN:Y->F: No effect on the nuclear localization.,MUTAGEN:Y->K: Impairs interaction with APC.,MUTAGEN:Y->S: Impairs homodimerization.,REGION:Disordered,REGION:Interaction with HNRNPA1,REGION:Interaction with ZBTB7A,REGION:Involved in homodimerization,
KIAA0319L	KIAA0319 like(KIAA0319L)	Homo sapiens			GO:0001764~neuron migration,	GO:0000139~Golgi membrane,GO:0005730~nucleolus,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0031410~cytoplasmic vesicle,	GO:0005515~protein binding,	IPR000601:PKD_dom,IPR013783:Ig-like_fold,IPR013980:MANSC_dom,IPR022409:PKD/Chitinase_dom,IPR029865:KIAA0319-like,IPR035986:PKD_dom_sf,				SM00089:PKD,	KW-0945~Host-virus interaction,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:MANSC,DOMAIN:PKD,DOMAIN:PKD 1,DOMAIN:PKD 2,DOMAIN:PKD 3,DOMAIN:PKD 4,DOMAIN:PKD 5,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
KIAA1191	KIAA1191(KIAA1191)	Homo sapiens				GO:0005737~cytoplasm,	GO:0005515~protein binding,GO:0016491~oxidoreductase activity,	IPR026759:P33MONOX,						KW-0963~Cytoplasm,			KW-0521~NADP,	KW-0560~Oxidoreductase,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,MOTIF:Flavin-containing monooxygenase motif,REGION:Disordered,
KLF6	KLF transcription factor 6(KLF6)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0030183~B cell differentiation,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,	GO:0000785~chromatin,GO:0001650~fibrillar center,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005829~cytosol,GO:0043231~intracellular membrane-bounded organelle,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0005515~protein binding,GO:0046872~metal ion binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR013087:Znf_C2H2_type,IPR036236:Znf_C2H2_sf,		176807~Prostate cancer, somatic,613659~Gastric cancer, somatic,		SM00355:ZnF_C2H2,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0238~DNA-binding,		COMPBIAS:Polar residues,DOMAIN:C2H2-type,MOTIF:9aaTAD; inactive,REGION:Disordered,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,
KXD1	KxDL motif containing 1(KXD1)	Homo sapiens			GO:0016192~vesicle-mediated transport,GO:0032418~lysosome localization,GO:0051036~regulation of endosome size,GO:0072384~organelle transport along microtubule,	GO:0005765~lysosomal membrane,GO:0031083~BLOC-1 complex,GO:0098574~cytoplasmic side of lysosomal membrane,GO:0099078~BORC complex,	GO:0005515~protein binding,	IPR019371:KxDL_dom,IPR039843:KXD1-like,						KW-0458~Lysosome,KW-0472~Membrane,					KW-0007~Acetylation,	COMPBIAS:Polar residues,DOMAIN:KxDL,REGION:Disordered,
LAGE3	L antigen family member 3(LAGE3)	Homo sapiens			GO:0008033~tRNA processing,GO:0070525~tRNA threonylcarbamoyladenosine metabolic process,	GO:0000408~EKC/KEOPS complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0016604~nuclear body,	GO:0005515~protein binding,	IPR015419:CTAG/Pcc1,		301006~Galloway-Mowat syndrome 2, X-linked,			KW-0819~tRNA processing,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0887~Epilepsy,KW-0991~Intellectual disability,					REGION:Disordered,
LBH	LBH regulator of WNT signaling pathway(LBH)	Homo sapiens			GO:0006355~regulation of transcription, DNA-templated,GO:0033147~negative regulation of intracellular estrogen receptor signaling pathway,GO:0043408~regulation of MAPK cascade,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0060644~mammary gland epithelial cell differentiation,GO:1904674~positive regulation of somatic stem cell population maintenance,GO:1904677~positive regulation of somatic stem cell division,GO:2000103~positive regulation of mammary stem cell proliferation,GO:2000737~negative regulation of stem cell differentiation,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0032991~macromolecular complex,	GO:0005515~protein binding,	IPR013294:LBH,IPR038990:LBH_dom,IPR042945:LBH_dom_prot,			PIRSF008130:LBH,		KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,	DOMAIN:LBH,REGION:Disordered,
LCK	LCK proto-oncogene, Src family tyrosine kinase(LCK)	Homo sapiens	3.T_cell_receptor,54.T-cell_anergy,63.LAT_couples_T-cell_receptor,67.Ikaros_and_signaling_inhibitors,81.Structure_of_Caps_and_SMACs,	h_cskPathway:Activation of Csk by cAMP-dependent Protein Kinase Inhibits Signaling through the T Cell Receptor,h_ctla4Pathway:The Co-Stimulatory Signal During T-cell Activation,h_il2Pathway:IL 2 signaling pathway,h_il7Pathway:IL-7 Signal Transduction,h_tcraPathway:Lck and Fyn tyrosine kinases in initiation of TCR Activation,h_tcrPathway:T Cell Receptor Signaling Pathway,	GO:0006468~protein phosphorylation,GO:0006882~cellular zinc ion homeostasis,GO:0006919~activation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0009410~response to xenobiotic stimulus,GO:0016310~phosphorylation,GO:0018108~peptidyl-tyrosine phosphorylation,GO:0030097~hemopoiesis,GO:0030168~platelet activation,GO:0030217~T cell differentiation,GO:0031295~T cell costimulation,GO:0034116~positive regulation of heterotypic cell-cell adhesion,GO:0035556~intracellular signal transduction,GO:0038083~peptidyl-tyrosine autophosphorylation,GO:0038094~Fc-gamma receptor signaling pathway,GO:0045087~innate immune response,GO:0050852~T cell receptor signaling pathway,GO:0050853~B cell receptor signaling pathway,GO:0050862~positive regulation of T cell receptor signaling pathway,GO:0050870~positive regulation of T cell activation,GO:0050900~leukocyte migration,GO:0051209~release of sequestered calcium ion into cytosol,GO:0051249~regulation of lymphocyte activation,GO:1903039~positive regulation of leukocyte cell-cell adhesion,GO:2001244~positive regulation of intrinsic apoptotic signaling pathway,	GO:0000242~pericentriolar material,GO:0001772~immunological synapse,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0031234~extrinsic component of cytoplasmic side of plasma membrane,GO:0045121~membrane raft,GO:0070062~extracellular exosome,	GO:0001784~phosphotyrosine binding,GO:0004713~protein tyrosine kinase activity,GO:0004715~non-membrane spanning protein tyrosine kinase activity,GO:0004722~protein serine/threonine phosphatase activity,GO:0005102~receptor binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016004~phospholipase activator activity,GO:0019901~protein kinase binding,GO:0019903~protein phosphatase binding,GO:0042169~SH2 domain binding,GO:0042608~T cell receptor binding,GO:0042609~CD4 receptor binding,GO:0042610~CD8 receptor binding,GO:0042802~identical protein binding,GO:0043274~phospholipase binding,GO:0043548~phosphatidylinositol 3-kinase binding,GO:0051117~ATPase binding,	IPR000719:Prot_kinase_dom,IPR000980:SH2,IPR001245:Ser-Thr/Tyr_kinase_cat_dom,IPR001452:SH3_domain,IPR008266:Tyr_kinase_AS,IPR011009:Kinase-like_dom_sf,IPR017441:Protein_kinase_ATP_BS,IPR020635:Tyr_kinase_cat_dom,IPR035749:Lck_SH3,IPR035850:Lck_SH2,IPR036028:SH3-like_dom_sf,IPR036860:SH2_dom_sf,IPR043539:Grb2-like,	hsa04064:NF-kappa B signaling pathway,hsa04380:Osteoclast differentiation,hsa04650:Natural killer cell mediated cytotoxicity,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04660:T cell receptor signaling pathway,hsa05135:Yersinia infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,hsa05340:Primary immunodeficiency,	615758~Immunodeficiency 22,		SM00219:TyrKc,SM00252:SH2,SM00326:SH3,	KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0656~Proto-oncogene,	KW-0727~SH2 domain,KW-0728~SH3 domain,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0808~Transferase,KW-0829~Tyrosine-protein kinase,	KW-0449~Lipoprotein,KW-0519~Myristate,KW-0564~Palmitate,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,DOMAIN:Protein kinase,DOMAIN:SH2,DOMAIN:SH3,LIPID:N-myristoyl glycine,LIPID:S-palmitoyl cysteine,MUTAGEN:R->K: No effect on interaction with SQSTM1.,MUTAGEN:S->E: Allows interaction with SQSTM1.,REGION:Disordered,REGION:Interaction with PTPRH,REGION:Interactions with CD4 and CD8,
LRP10	LDL receptor related protein 10(LRP10)	Homo sapiens			GO:0006629~lipid metabolic process,GO:0006869~lipid transport,GO:0006897~endocytosis,GO:0048839~inner ear development,	GO:0005886~plasma membrane,GO:0005905~clathrin-coated pit,GO:0016020~membrane,	GO:0005041~low-density lipoprotein receptor activity,GO:0005515~protein binding,	IPR000859:CUB_dom,IPR002172:LDrepeatLR_classA_rpt,IPR023415:LDLR_class-A_CS,IPR035914:Sperma_CUB_dom_sf,IPR036055:LDL_receptor-like_sf,				SM00042:CUB,SM00192:LDLa,	KW-0254~Endocytosis,	KW-0168~Coated pit,KW-0472~Membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:CUB,DOMAIN:CUB 1,DOMAIN:CUB 2,DOMAIN:LDL-receptor class A 1,DOMAIN:LDL-receptor class A 2,DOMAIN:LDL-receptor class A 3,DOMAIN:LDL-receptor class A 4,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
LRPAP1	LDL receptor related protein associated protein 1(LRPAP1)	Homo sapiens			GO:0002091~negative regulation of receptor internalization,GO:0007165~signal transduction,GO:0010916~negative regulation of very-low-density lipoprotein particle clearance,GO:0032091~negative regulation of protein binding,GO:0048259~regulation of receptor-mediated endocytosis,GO:1900116~extracellular negative regulation of signal transduction,GO:1900222~negative regulation of beta-amyloid clearance,GO:1900223~positive regulation of beta-amyloid clearance,	GO:0005576~extracellular region,GO:0005768~endosome,GO:0005783~endoplasmic reticulum,GO:0005793~endoplasmic reticulum-Golgi intermediate compartment,GO:0005794~Golgi apparatus,GO:0005796~Golgi lumen,GO:0005801~cis-Golgi network,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0012505~endomembrane system,GO:0031904~endosome lumen,GO:0048237~rough endoplasmic reticulum lumen,	GO:0001540~beta-amyloid binding,GO:0005102~receptor binding,GO:0005515~protein binding,GO:0008201~heparin binding,GO:0035473~lipase binding,GO:0048018~receptor agonist activity,GO:0048019~receptor antagonist activity,GO:0050750~low-density lipoprotein particle receptor binding,GO:0070326~very-low-density lipoprotein particle receptor binding,	IPR009066:MG_RAP_rcpt_1,IPR010483:Alpha_2_MRAP_C,IPR036744:RAP_sf,IPR037999:RAP_D3,IPR038001:RAP_D2,IPR038003:A2-macroglobuin_RAP,	hsa04979:Cholesterol metabolism,	615431~Myopia 23, autosomal recessive,				KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0967~Endosome,		KW-0175~Coiled coil,KW-0732~Signal,		KW-0358~Heparin-binding,KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,DOMAIN:Alpha-2-macroglobulin RAP C-terminal,DOMAIN:Alpha-2-macroglobulin receptor-associated protein,MOTIF:Prevents secretion from ER,MUTAGEN:H->A: Strongly reduced interaction with LRP1; when associated with A-283; A-291; A-293; A-302 and A-307.,MUTAGEN:H->A: Strongly reduced interaction with LRP1; when associated with A-283; A-291; A-293; A-302 and A-341.,MUTAGEN:H->A: Strongly reduced interaction with LRP1; when associated with A-283; A-291; A-293; A-307 and A-341.,MUTAGEN:H->A: Strongly reduced interaction with LRP1; when associated with A-283; A-291; A-302; A-307 and A-341.,MUTAGEN:H->A: Strongly reduced interaction with LRP1; when associated with A-283; A-293; A-302; A-307 and A-341.,MUTAGEN:H->A: Strongly reduced interaction with LRP1; when associated with A-291; A-293; A-302; A-307 and A-341.,MUTAGEN:K->A: Reduces competition with MAPT for binding to LRP1; when associated with A-290.,MUTAGEN:K->A: Reduces competition with MAPT for binding to LRP1; when associated with A-304.,REGION:Disordered,REGION:LDL receptor binding,
LASP1	LIM and SH3 protein 1(LASP1)	Homo sapiens			GO:0006811~ion transport,GO:0034220~ion transmembrane transport,	GO:0005737~cytoplasm,GO:0005856~cytoskeleton,GO:0005925~focal adhesion,GO:0005938~cell cortex,GO:0030864~cortical actin cytoskeleton,	GO:0003779~actin binding,GO:0005515~protein binding,GO:0015075~ion transmembrane transporter activity,GO:0045296~cadherin binding,GO:0046872~metal ion binding,GO:0051015~actin filament binding,	IPR000900:Nebulin_repeat,IPR001452:SH3_domain,IPR001781:Znf_LIM,IPR035630:Lasp1_SH3,IPR036028:SH3-like_dom_sf,				SM00132:LIM,SM00227:NEBU,SM00326:SH3,	KW-0406~Ion transport,KW-0813~Transport,	KW-0206~Cytoskeleton,KW-0963~Cytoplasm,		KW-0440~LIM domain,KW-0677~Repeat,KW-0728~SH3 domain,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0009~Actin-binding,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:LIM zinc-binding,DOMAIN:SH3,REGION:Disordered,REPEAT:Nebulin 1,REPEAT:Nebulin 2,
LIMA1	LIM domain and actin binding 1(LIMA1)	Homo sapiens		h_s1pPathway:SREBP control of lipid synthesis,	GO:0008203~cholesterol metabolic process,GO:0016477~cell migration,GO:0030299~intestinal cholesterol absorption,GO:0030835~negative regulation of actin filament depolymerization,GO:0031529~ruffle organization,GO:0042632~cholesterol homeostasis,GO:0051017~actin filament bundle assembly,	GO:0001725~stress fiber,GO:0001726~ruffle,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0015629~actin cytoskeleton,GO:0031526~brush border membrane,GO:0032154~cleavage furrow,	GO:0003785~actin monomer binding,GO:0005515~protein binding,GO:0045296~cadherin binding,GO:0046872~metal ion binding,GO:0051015~actin filament binding,	IPR001781:Znf_LIM,IPR028740:EPLIN_Lim_dom,		618079~Low density lipoprotein cholesterol level QTL 8,		SM00132:LIM,	KW-0153~Cholesterol metabolism,KW-0443~Lipid metabolism,KW-0753~Steroid metabolism,KW-1207~Sterol metabolism,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0965~Cell junction,KW-1003~Cell membrane,		KW-0440~LIM domain,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0009~Actin-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:LIM zinc-binding,MOTIF:Required for interaction with NPC1L1,REGION:Disordered,REGION:Required for interaction with MYO5B,
LIMD2	LIM domain containing 2(LIMD2)	Homo sapiens			GO:0051017~actin filament bundle assembly,	GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0015629~actin cytoskeleton,	GO:0005515~protein binding,GO:0046872~metal ion binding,GO:0051015~actin filament binding,	IPR001781:Znf_LIM,IPR044115:LIM_LIMD2,				SM00132:LIM,		KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0440~LIM domain,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0007~Acetylation,	DOMAIN:LIM zinc-binding,REGION:Disordered,
LIMS1	LIM zinc finger domain containing 1(LIMS1)	Homo sapiens			GO:0010628~positive regulation of gene expression,GO:0010811~positive regulation of cell-substrate adhesion,GO:0033209~tumor necrosis factor-mediated signaling pathway,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043547~positive regulation of GTPase activity,GO:0045184~establishment of protein localization,GO:0045216~cell-cell junction organization,GO:0045892~negative regulation of transcription, DNA-templated,GO:0051894~positive regulation of focal adhesion assembly,GO:0071560~cellular response to transforming growth factor beta stimulus,GO:0098609~cell-cell adhesion,GO:1900026~positive regulation of substrate adhesion-dependent cell spreading,GO:2001046~positive regulation of integrin-mediated signaling pathway,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005911~cell-cell junction,GO:0005925~focal adhesion,GO:0048471~perinuclear region of cytoplasm,	GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0019901~protein kinase binding,GO:0046872~metal ion binding,	IPR001781:Znf_LIM,IPR017351:PINCH-1-4-like,IPR047944:LIMS1/2-like_LIM1,IPR047946:PINCH-1/2-like,			PIRSF038003:PINCH,	SM00132:LIM,		KW-0472~Membrane,KW-0965~Cell junction,KW-1003~Cell membrane,		KW-0440~LIM domain,KW-0677~Repeat,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0007~Acetylation,	DOMAIN:LIM zinc-binding,DOMAIN:LIM zinc-binding 1,DOMAIN:LIM zinc-binding 2,DOMAIN:LIM zinc-binding 3,DOMAIN:LIM zinc-binding 4,DOMAIN:LIM zinc-binding 5,MUTAGEN:D->A: Alters interaction with ILK.,MUTAGEN:F->A: Loss of interaction with ILK and loss of localization to focal adhesion.,MUTAGEN:H->D: Alters interaction with ILK.,MUTAGEN:L->D: Alters interaction with ILK.,MUTAGEN:R->A: Alters interaction with ILK.,REGION:Disordered,
LMBRD1	LMBR1 domain containing 1(LMBRD1)	Homo sapiens			GO:0007369~gastrulation,GO:0038016~insulin receptor internalization,GO:0061462~protein localization to lysosome,GO:0072583~clathrin-dependent endocytosis,	GO:0005765~lysosomal membrane,GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0030136~clathrin-coated vesicle,GO:0043231~intracellular membrane-bounded organelle,GO:0045334~clathrin-coated endocytic vesicle,	GO:0005158~insulin receptor binding,GO:0005515~protein binding,GO:0031419~cobalamin binding,GO:0032050~clathrin heavy chain binding,GO:0035612~AP-2 adaptor complex binding,	IPR006876:LMBR1-like_membr_prot,	hsa04977:Vitamin digestion and absorption,	277380~Methylmalonic aciduria and homocystinuria, cblF type,			KW-0254~Endocytosis,KW-0306~Gastrulation,KW-0813~Transport,KW-0945~Host-virus interaction,	KW-0256~Endoplasmic reticulum,KW-0458~Lysosome,KW-0472~Membrane,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0170~Cobalt,KW-0846~Cobalamin,	KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,MOTIF:WTKF motif; mediates interaction with adapter protein complex 2 and is essential for its function in clathrin-mediated endocytosis of INSR,MOTIF:YERL motif; mediates interaction with adapter protein complex 2 and is essential for its function in clathrin-mediated endocytosis of INSR,MUTAGEN:N->Q: Affects glycosylation status. Affects glycosylation status; when associated with Q-448.,MUTAGEN:N->Q: Affects glycosylation status; when associated with Q-457.,MUTAGEN:N->Q: Does not affect glycosylation status; when associated with Q-78.,MUTAGEN:N->Q: Does not affect glycosylation status; when associated with Q-88.,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,TRANSMEM:Helical; Name=8,TRANSMEM:Helical; Name=9,
LRBA	LPS responsive beige-like anchor protein(LRBA)	Homo sapiens			GO:0000423~macromitophagy,GO:0008104~protein localization,GO:0034497~protein localization to pre-autophagosomal structure,	GO:0005765~lysosomal membrane,GO:0005789~endoplasmic reticulum membrane,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016020~membrane,	GO:0005515~protein binding,GO:0019901~protein kinase binding,	IPR000409:BEACH_dom,IPR001680:WD40_rpt,IPR010508:NBEA-like_DUF1088,IPR011989:ARM-like,IPR011993:PH-like_dom_sf,IPR013320:ConA-like_dom_sf,IPR015943:WD40/YVTN_repeat-like_dom_sf,IPR016024:ARM-type_fold,IPR023362:PH-BEACH_dom,IPR031570:NBEA/BDCP_DUF4704,IPR036322:WD40_repeat_dom_sf,IPR036372:BEACH_dom_sf,IPR046851:NBCH_WD40,IPR046852:Neurobeachin_a-sol,		614700~Immunodeficiency, common variable, 8, with autoimmunity,		SM00320:WD40,SM01026:Beach,		KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0458~Lysosome,KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0175~Coiled coil,KW-0677~Repeat,KW-0812~Transmembrane,KW-0853~WD repeat,KW-1133~Transmembrane helix,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:BEACH,DOMAIN:BEACH-type PH,DOMAIN:DUF4704,DOMAIN:Neurobeachin alpha-solenoid region,DOMAIN:Neurobeachin beta-propeller,REGION:Disordered,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,TRANSMEM:Helical,
LRRFIP2	LRR binding FLII interacting protein 2(LRRFIP2)	Homo sapiens			GO:0006355~regulation of transcription, DNA-templated,GO:0016055~Wnt signaling pathway,		GO:0005515~protein binding,GO:0030275~LRR domain binding,	IPR019139:LRRFIP1/2,					KW-0879~Wnt signaling pathway,			KW-0175~Coiled coil,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,MUTAGEN:S->A: No change in LPS-induced NFKB activity.,MUTAGEN:S->A: Reduction in LPS-induced NFKB activity.,MUTAGEN:S->E: No change in LPS-induced NFKB activity. Interacts with MYD88 in an LPS-inducible manner.,REGION:DVL3-binding,REGION:Disordered,
LSM8	LSM8 homolog, U6 small nuclear RNA associated(LSM8)	Homo sapiens			GO:0000398~mRNA splicing, via spliceosome,GO:0043066~negative regulation of apoptotic process,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005681~spliceosomal complex,GO:0005688~U6 snRNP,GO:0005737~cytoplasm,GO:0031417~NatC complex,GO:0046540~U4/U6 x U5 tri-snRNP complex,GO:0071005~U2-type precatalytic spliceosome,GO:0071011~precatalytic spliceosome,	GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0005515~protein binding,GO:0017070~U6 snRNA binding,	IPR001163:Sm_dom_euk/arc,IPR010920:LSM_dom_sf,IPR034103:Lsm8,IPR034110:LSMD1_Sm,IPR044642:PTHR15588,IPR047575:Sm,	hsa03018:RNA degradation,hsa03040:Spliceosome,			SM00651:Sm,	KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,KW-0747~Spliceosome,KW-0963~Cytoplasm,		KW-0175~Coiled coil,		KW-0687~Ribonucleoprotein,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:Sm,REGION:Disordered,
LUC7L2	LUC7 like 2, pre-mRNA splicing factor(LUC7L2)	Homo sapiens			GO:0006376~mRNA splice site selection,	GO:0005685~U1 snRNP,GO:0016607~nuclear speck,GO:0071004~U2-type prespliceosome,	GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0005515~protein binding,GO:0019899~enzyme binding,	IPR004882:Luc7-rel,						KW-0539~Nucleus,		KW-0175~Coiled coil,			KW-0379~Hydroxylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,MUTAGEN:K->R: Induces a decrease in lysyl-hydroxylation. Abolishes lysyl-hydroxylation; when associated with R-266.,MUTAGEN:K->R: Induces a decrease in lysyl-hydroxylation. Abolishes lysyl-hydroxylation; when associated with R-269.,REGION:Disordered,
LUC7L3	LUC7 like 3 pre-mRNA splicing factor(LUC7L3)	Homo sapiens			GO:0006376~mRNA splice site selection,GO:0008380~RNA splicing,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005685~U1 snRNP,GO:0016607~nuclear speck,GO:0071004~U2-type prespliceosome,	GO:0003677~DNA binding,GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0005515~protein binding,	IPR004882:Luc7-rel,					KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,		KW-0175~Coiled coil,		KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,REGION:Disordered,
LARP1	La ribonucleoprotein 1, translational regulator(LARP1)	Homo sapiens			GO:0006413~translational initiation,GO:0008283~cell proliferation,GO:0010608~posttranscriptional regulation of gene expression,GO:0016239~positive regulation of macroautophagy,GO:0017148~negative regulation of translation,GO:0031929~TOR signaling,GO:0038202~TORC1 signaling,GO:0045070~positive regulation of viral genome replication,GO:0045727~positive regulation of translation,GO:0045947~negative regulation of translational initiation,GO:0045948~positive regulation of translational initiation,GO:0048255~mRNA stabilization,GO:0072752~cellular response to rapamycin,GO:1990928~response to amino acid starvation,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0010494~cytoplasmic stress granule,GO:0016020~membrane,GO:0031931~TORC1 complex,GO:1990904~ribonucleoprotein complex,	GO:0000339~RNA cap binding,GO:0000340~RNA 7-methylguanosine cap binding,GO:0003723~RNA binding,GO:0003730~mRNA 3'-UTR binding,GO:0005515~protein binding,GO:0008190~eukaryotic initiation factor 4E binding,GO:0008494~translation activator activity,GO:0031369~translation initiation factor binding,GO:0043024~ribosomal small subunit binding,GO:0045296~cadherin binding,GO:0048027~mRNA 5'-UTR binding,	IPR006607:DM15,IPR006630:La_HTH,IPR036388:WH-like_DNA-bd_sf,IPR036390:WH_DNA-bd_sf,IPR045180:La_dom_prot,				SM00684:DM15,SM00715:LA,	KW-0648~Protein biosynthesis,KW-0810~Translation regulation,	KW-0963~Cytoplasm,				KW-0678~Repressor,KW-0687~Ribonucleoprotein,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:HTH La-type RNA-binding,MUTAGEN:E->R: Strongly decreased RNA binding.,MUTAGEN:F->A: No effect on interaction with RPTOR.,MUTAGEN:F->A: Strongly reduced interaction with PABPC1.,MUTAGEN:Missing: Loss of interaction with RPTOR.,MUTAGEN:Missing: Strongly reduced interaction with PABPC1.,MUTAGEN:R->E: Abolishes RNA binding. Abolishes inhibition of EIF4G1 binding to mRNA molecules with a 5'TOP motif; when associated with A-960.,MUTAGEN:S->A: Loss of phosphorylation by MTOR; when associated with A-769. Decreased interaction with RPTOR and impaired dissociation from the 5'UTR of mRNA molecules; when associated with A-769; A-847 and A-1058.,MUTAGEN:S->A: Strongly reduced phosphorylation mediated by AKT and RPS6KB1. Decreased interaction with RPTOR and impaired dissociation from the 5'UTR of mRNA molecules; when associated with A-766; A-769 and A-847.,MUTAGEN:S->A: Strongly reduced phosphorylation mediated by Akt and RPS6KB1. Decreased interaction with RPTOR and impaired dissociation from the 5'UTR of mRNA molecules; when associated with A-766; A-769 and A-1058.,MUTAGEN:T->A: Loss of phosphorylation by MTOR; when associated with A-766. Decreased interaction with RPTOR and impaired dissociation from the 5'UTR of mRNA molecules; when associated with A-766; A-847 and A-1058.,MUTAGEN:Y->A: Abolishes RNA binding. Abolishes translational repression of mRNAs with a 5'TOP motif. Abolishes inhibition of EIF4G1 binding to mRNA molecules with a 5'TOP motif; when associated with E-917.,MUTAGEN:Y->A: Strongly decreased RNA binding.,REGION:Disordered,REGION:Interaction with 7-methylguanosine mRNA cap structure,REGION:Interaction with mRNA,REGION:Required for interaction with PABPC1,REGION:Required for interaction with RPTOR and for repression of mRNAs with a 5'TOP motif,
LYAR	Ly1 antibody reactive(LYAR)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006364~rRNA processing,GO:0045087~innate immune response,GO:0045824~negative regulation of innate immune response,GO:0045943~positive regulation of transcription from RNA polymerase I promoter,GO:0048821~erythrocyte development,GO:0050766~positive regulation of phagocytosis,	GO:0001750~photoreceptor outer segment,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,	GO:0003677~DNA binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0046872~metal ion binding,	IPR014898:Znf_C2H2_LYAR,IPR036236:Znf_C2H2_sf,IPR039999:LYAR,IPR041010:Znf-ACC,					KW-0391~Immunity,KW-0399~Innate immunity,KW-0698~rRNA processing,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0966~Cell projection,		KW-0175~Coiled coil,KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,KW-0678~Repressor,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Acetyl-coA carboxylase zinc finger,DOMAIN:Zinc finger C2H2 LYAR-type,MUTAGEN:Missing: Decreases the production of 28S rRNA and the formation of pre-60S particle.,REGION:Disordered,ZN_FING:C2HC LYAR-type 1,ZN_FING:C2HC LYAR-type 2,
LYSMD2	LysM domain containing 2(LYSMD2)	Homo sapiens						IPR018392:LysM_dom,IPR036779:LysM_dom_sf,IPR045030:LYSM1-4,				SM00257:LysM,							KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:LysM,REGION:Disordered,
MPHOSPH8	M-phase phosphoprotein 8(MPHOSPH8)	Homo sapiens			GO:0044027~hypermethylation of CpG island,GO:0044030~regulation of DNA methylation,GO:0045814~negative regulation of gene expression, epigenetic,GO:0045869~negative regulation of single stranded viral RNA replication via double stranded DNA intermediate,GO:0045892~negative regulation of transcription, DNA-templated,GO:0090309~positive regulation of methylation-dependent chromatin silencing,	GO:0000786~nucleosome,GO:0000792~heterochromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,	GO:0003682~chromatin binding,GO:0005515~protein binding,GO:0035064~methylated histone binding,	IPR000953:Chromo/chromo_shadow_dom,IPR002110:Ankyrin_rpt,IPR016197:Chromo-like_dom_sf,IPR023779:Chromodomain_CS,IPR023780:Chromo_domain,IPR036770:Ankyrin_rpt-contain_sf,				SM00248:ANK,SM00298:CHROMO,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0158~Chromosome,KW-0539~Nucleus,		KW-0040~ANK repeat,KW-0677~Repeat,		KW-0678~Repressor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:Chromo,MUTAGEN:S->A: In STA mutant; fails to dissociate from chromatin during early mitosis; when associated with A-149; A-334 and A-385.,MUTAGEN:S->A: In STA mutant; fails to dissociate from chromatin during early mitosis; when associated with A-164; A-334 and A-385.,MUTAGEN:T->A: In STA mutant; fails to dissociate from chromatin during early mitosis; when associated with A-149; A-164 and A-385.,MUTAGEN:T->A: In STA mutant; fails to dissociate from chromatin during early mitosis; when associated with A-149; A-164; and A-334.,MUTAGEN:W->A: Abolishes interaction with histone H3K9me3 and prevents recruitment of the HUSH complex to heterochromatin. Impaired ability to mediate silencing of unintegrated retroviral DNA.,REGION:Disordered,REGION:Histone H3K9me3 binding,REGION:Interaction with humanin,REPEAT:ANK 1,REPEAT:ANK 2,REPEAT:ANK 3,REPEAT:ANK 4,SITE:Interaction with histone H3K9me3,
MAF1	MAF1 homolog, negative regulator of RNA polymerase III(MAF1)	Homo sapiens			GO:0016479~negative regulation of transcription from RNA polymerase I promoter,GO:0016480~negative regulation of transcription from RNA polymerase III promoter,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0000994~RNA polymerase III core binding,GO:0001002~RNA polymerase III type 1 promoter sequence-specific DNA binding,GO:0001003~RNA polymerase III type 2 promoter sequence-specific DNA binding,GO:0001006~RNA polymerase III type 3 promoter sequence-specific DNA binding,GO:0005515~protein binding,	IPR015257:Maf1,IPR038564:Maf1_sf,			PIRSF037240:RNA_polIII_Trep_MAF1,		KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0678~Repressor,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1 and SUMO2),MUTAGEN:K->R: No interaction with RNA pol III and impaired recruitment to tRNA gene promoters.,MUTAGEN:S->A: Stronger repressive effect on RNA polymerase III transcription. Stronger repressive effect on RNA polymerase III transcription; when associated with A-60 and A-68. Much stronger repressive effect on RNA polymerase III transcription and loss of phosphorylation; when associated with A-60, A-64 and A-68.,MUTAGEN:S->A: Stronger repressive effect on RNA polymerase III transcription; when associated with A-60 and A-75. Much stronger repressive effect on RNA polymerase III transcription and loss of phosphorylation; when associated with A-60, A-64 and A-75.,MUTAGEN:S->A: Stronger repressive effect on RNA polymerase III transcription; when associated with A-68 and A-75. Much stronger repressive effect on RNA polymerase III transcription and loss of phosphorylation; when associated with A-64, A-68 and A-75.,MUTAGEN:S->D: No change. Weaker repressive effect on RNA polymerase III transcription; when associated with D-60 and D-68.,MUTAGEN:S->D: No change. Weaker repressive effect on RNA polymerase III transcription; when associated with D-60 and D-75.,MUTAGEN:S->D: No change. Weaker repressive effect on RNA polymerase III transcription; when associated with D-68 and D-75.,MUTAGEN:T->A: Much stronger repressive effect on RNA polymerase III transcription and loss of phosphorylation; when associated with A-60, A-68 and A-75.,REGION:Disordered,
MKNK2	MAPK interacting serine/threonine kinase 2(MKNK2)	Homo sapiens		h_erkPathway:Erk1/Erk2 Mapk Signaling pathway,h_mapkPathway:MAPKinase Signaling Pathway,	GO:0006417~regulation of translation,GO:0006468~protein phosphorylation,GO:0007166~cell surface receptor signaling pathway,GO:0016310~phosphorylation,GO:0018105~peptidyl-serine phosphorylation,GO:0030097~hemopoiesis,GO:0035556~intracellular signal transduction,GO:0046777~protein autophosphorylation,GO:0071243~cellular response to arsenic-containing substance,GO:0097192~extrinsic apoptotic signaling pathway in absence of ligand,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0016604~nuclear body,GO:0016605~PML body,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004683~calmodulin-dependent protein kinase activity,GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0005524~ATP binding,GO:0009931~calcium-dependent protein serine/threonine kinase activity,GO:0016301~kinase activity,GO:0046872~metal ion binding,	IPR000719:Prot_kinase_dom,IPR008271:Ser/Thr_kinase_AS,IPR011009:Kinase-like_dom_sf,IPR017441:Protein_kinase_ATP_BS,	hsa04010:MAPK signaling pathway,hsa04066:HIF-1 signaling pathway,hsa04910:Insulin signaling pathway,			SM00220:S_TKc,	KW-0053~Apoptosis,KW-0810~Translation regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,KW-0862~Zinc,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,COMPBIAS:Polar residues,DOMAIN:Protein kinase,MOTIF:MAP kinase binding,MOTIF:Nuclear localization signal,MUTAGEN:D->G: Reduced phosphorylation.,MUTAGEN:T->A: Loss of kinase activity; when associated with T-244.,MUTAGEN:T->A: Loss of kinase activity; when associated with T-249.,MUTAGEN:T->D: Constitutively active.,REGION:Disordered,
MARCKSL1	MARCKS like 1(MARCKSL1)	Homo sapiens			GO:0007015~actin filament organization,GO:0007417~central nervous system development,GO:0008283~cell proliferation,GO:0008284~positive regulation of cell proliferation,	GO:0005737~cytoplasm,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0051015~actin filament binding,	IPR002101:MARCKS,	hsa04666:Fc gamma R-mediated phagocytosis,hsa05140:Leishmaniasis,					KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,				KW-0009~Actin-binding,KW-0112~Calmodulin-binding,	KW-0449~Lipoprotein,KW-0519~Myristate,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,LIPID:N-myristoyl glycine,REGION:Disordered,REGION:Effector domain involved in lipid-binding and calmodulin-binding,
MLX	MAX dimerization protein MLX(MLX)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0031965~nuclear membrane,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0042803~protein homodimerization activity,GO:0046982~protein heterodimerization activity,GO:0046983~protein dimerization activity,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR011598:bHLH_dom,IPR036638:HLH_DNA-bd_sf,	hsa04931:Insulin resistance,hsa04932:Non-alcoholic fatty liver disease,			SM00353:HLH,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,		KW-0010~Activator,KW-0238~DNA-binding,KW-0678~Repressor,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:BHLH,DOMAIN:bHLH,REGION:Disordered,REGION:Leucine-zipper,
MIS18BP1	MIS18 binding protein 1(MIS18BP1)	Homo sapiens			GO:0007049~cell cycle,GO:0051301~cell division,	GO:0000775~chromosome, centromeric region,GO:0005654~nucleoplasm,	GO:0003677~DNA binding,GO:0005515~protein binding,	IPR001005:SANT/Myb,IPR009057:Homeobox-like_sf,IPR015216:SANTA,IPR017884:SANT_dom,IPR039110:KNL2-like,				SM00717:SANT,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,	KW-0137~Centromere,KW-0158~Chromosome,KW-0539~Nucleus,				KW-0238~DNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:SANT,DOMAIN:SANTA,REGION:Disordered,
MLLT3	MLLT3 super elongation complex subunit(MLLT3)	Homo sapiens			GO:0006355~regulation of transcription, DNA-templated,GO:0007379~segment specification,GO:0009952~anterior/posterior pattern specification,GO:0010467~gene expression,GO:0045893~positive regulation of transcription, DNA-templated,GO:0060218~hematopoietic stem cell differentiation,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:1902275~regulation of chromatin organization,GO:2000035~regulation of stem cell division,GO:2000096~positive regulation of Wnt signaling pathway, planar cell polarity pathway,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005694~chromosome,GO:0005829~cytosol,GO:0008023~transcription elongation factor complex,GO:0070062~extracellular exosome,	GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0005515~protein binding,GO:0042393~histone binding,GO:0060090~binding, bridging,GO:0070577~lysine-acetylated histone binding,	IPR005033:YEATS,IPR038704:YEAST_sf,IPR040930:AF-9_AHD,	hsa03250:Viral life cycle - HIV-1,hsa05202:Transcriptional misregulation in cancer,				KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0158~Chromosome,KW-0539~Nucleus,	KW-0656~Proto-oncogene,			KW-0010~Activator,KW-0238~DNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:AF-9 ANC1 homology,DOMAIN:YEATS,MOTIF:Nuclear localization signal,MUTAGEN:D->A: Decreased binding to acetylated histone H3.,MUTAGEN:F->A: Decreased binding to acetylated histone H3.,MUTAGEN:F->A: Decreased binding to crotonylated histone H3. Decreased binding to acetylated histone H3.,MUTAGEN:F->A: Strongly decreased binding to crotonylated histone H3. Decreased binding to acetylated histone H3.,MUTAGEN:G->A: Decreased binding to crotonylated histone H3. Decreased binding to acetylated histone H3.,MUTAGEN:H->A: Decreased binding to crotonylated histone H3. Decreased binding to acetylated histone H3.,MUTAGEN:RPKRVCK->EPERVCE: Decreased DNA-binding.,MUTAGEN:S->A: Decreased binding to crotonylated histone H3. Decreased binding to acetylated histone H3.,MUTAGEN:Y->A: Strongly decreased binding to crotonylated histone H3. Decreased binding to acetylated histone H3.,MUTAGEN:Y->W: Does not affect ability to discriminate between acetylated and crotonylated histone H3.,MUTAGEN:YA->WG: Binds equally well acetylated and crotonylated histone H3.,REGION:Disordered,REGION:Histone H3K9cr binding,SITE:Histone H3K9cr binding,SITE:KMT2A/MLL1 fusion point (in acute myeloid leukemia patient CO),SITE:KMT2A/MLL1 fusion point (in acute myeloid leukemia patient F1),
MOB4	MOB family member 4, phocein(MOB4)	Homo sapiens				GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0032580~Golgi cisterna membrane,GO:0043025~neuronal cell body,GO:0043197~dendritic spine,GO:0048471~perinuclear region of cytoplasm,	GO:0005515~protein binding,GO:0019900~kinase binding,GO:0046872~metal ion binding,	IPR005301:MOB_kinase_act_fam,IPR036703:MOB_kinase_act_sf,				SM01388:Mob1_phocein,	KW-0813~Transport,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0963~Cytoplasm,			KW-0479~Metal-binding,KW-0862~Zinc,		KW-0597~Phosphoprotein,
MOB1A	MOB kinase activator 1A(MOB1A)	Homo sapiens			GO:0001934~positive regulation of protein phosphorylation,GO:0031952~regulation of protein autophosphorylation,GO:0035329~hippo signaling,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0019209~kinase activator activity,GO:0019900~kinase binding,GO:0030295~protein kinase activator activity,GO:0046872~metal ion binding,	IPR005301:MOB_kinase_act_fam,IPR036703:MOB_kinase_act_sf,	hsa04390:Hippo signaling pathway,hsa04392:Hippo signaling pathway - multiple species,			SM01388:Mob1_phocein,		KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0479~Metal-binding,KW-0862~Zinc,		KW-0007~Acetylation,KW-0597~Phosphoprotein,	REGION:Disordered,
MOB2	MOB kinase activator 2(MOB2)	Homo sapiens			GO:0001934~positive regulation of protein phosphorylation,GO:0007165~signal transduction,GO:0016310~phosphorylation,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0048471~perinuclear region of cytoplasm,	GO:0005515~protein binding,GO:0016301~kinase activity,GO:0030295~protein kinase activator activity,GO:0046872~metal ion binding,	IPR005301:MOB_kinase_act_fam,IPR036703:MOB_kinase_act_sf,				SM01388:Mob1_phocein,		KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0479~Metal-binding,KW-0862~Zinc,	KW-0418~Kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	REGION:Disordered,
MORC3	MORC family CW-type zinc finger 3(MORC3)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006468~protein phosphorylation,GO:0009791~post-embryonic development,GO:0018105~peptidyl-serine phosphorylation,GO:0032688~negative regulation of interferon-beta production,GO:0048147~negative regulation of fibroblast proliferation,GO:0050821~protein stabilization,GO:0051457~maintenance of protein location in nucleus,GO:2000774~positive regulation of cellular senescence,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0016363~nuclear matrix,GO:0016605~PML body,	GO:0003677~DNA binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0016887~ATPase activity,GO:0030674~protein binding, bridging,GO:0035064~methylated histone binding,	IPR011124:Znf_CW,IPR036890:HATPase_C_sf,IPR041006:Morc_S5,IPR045261:MORC_ATPase,					KW-0391~Immunity,KW-0399~Innate immunity,KW-0945~Host-virus interaction,	KW-0158~Chromosome,KW-0539~Nucleus,		KW-0175~Coiled coil,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0694~RNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:CW-type,MUTAGEN:D->N: Forms nuclear bodies, but rapidly diffuses throughout the nucleus under conditions of ATP depletion.,MUTAGEN:E->A: Fails to localize to PML nuclear bodies and activate TP53.,MUTAGEN:E->A: Strong decrease of binding to NS1.,MUTAGEN:G->A: Diffuse nuclear localization. Fails to form nuclear bodies in the presence of ATP.,MUTAGEN:K->R: Loss of sumoylation; when associated with R-597; R-650; R-651 and R-740.,MUTAGEN:K->R: Loss of sumoylation; when associated with R-597; R-650; R-651 and R-794.,MUTAGEN:K->R: Loss of sumoylation; when associated with R-597; R-650; R-740 and R-794.,MUTAGEN:K->R: Loss of sumoylation; when associated with R-597; R-651; R-740 and R-794.,MUTAGEN:K->R: Loss of sumoylation; when associated with R-650; R-651; R-740 and R-794.,MUTAGEN:W->A: About threefold increase in catalytic activity.,MUTAGEN:W->A: Diffuse nuclear localization, possibly due to loss of DNA or nucleosome binding.,REGION:Disordered,REGION:Nuclear matrix binding,REGION:RNA binding,ZN_FING:CW-type,
MSL3	MSL complex subunit 3(MSL3)	Homo sapiens			GO:0006325~chromatin organization,GO:0006338~chromatin remodeling,GO:0006355~regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0035267~NuA4 histone acetyltransferase complex,GO:0072487~MSL complex,	GO:0003677~DNA binding,GO:0005515~protein binding,GO:0035064~methylated histone binding,GO:0046972~histone acetyltransferase activity (H4-K16 specific),	IPR000953:Chromo/chromo_shadow_dom,IPR008676:MRG,IPR016197:Chromo-like_dom_sf,IPR025995:Tudor-knot,IPR026541:MRG_dom,IPR038217:MRG_C_sf,		301032~Basilicata-Akhtar syndrome,		SM00298:CHROMO,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0991~Intellectual disability,			KW-0156~Chromatin regulator,KW-0238~DNA-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Chromo,DOMAIN:MRG,DOMAIN:Tudor-knot,MUTAGEN:F->A: Abolishes interaction with histone H4 monomethylated at 'Lys-20'(H4K20Me1).,MUTAGEN:H->A: Diminishes DNA-binding; when associated with A-65.,MUTAGEN:R->A: Diminishes DNA-binding; when associated with A-55.,MUTAGEN:W->G: Diminishes DNA-binding.,MUTAGEN:Y->A: Diminishes interaction with histone H4 monomethylated at 'Lys-20'(H4K20Me1).,REGION:Disordered,REGION:Required for the histone acetyltransferase activity of the MSL complex,
MTRNR2L12	MT-RNR2 like 12 (pseudogene)(MTRNR2L12)	Homo sapiens			GO:1900118~negative regulation of execution phase of apoptosis,	GO:0005576~extracellular region,GO:0005737~cytoplasm,	GO:0048019~receptor antagonist activity,	IPR028139:Humanin,						KW-0963~Cytoplasm,KW-0964~Secreted,
MTRNR2L8	MT-RNR2 like 8 (pseudogene)(MTRNR2L8)	Homo sapiens			GO:1900118~negative regulation of execution phase of apoptosis,	GO:0005576~extracellular region,GO:0005737~cytoplasm,	GO:0048019~receptor antagonist activity,	IPR028139:Humanin,						KW-0963~Cytoplasm,KW-0964~Secreted,
MAZ	MYC associated zinc finger protein(MAZ)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006367~transcription initiation from RNA polymerase II promoter,GO:0006369~termination of RNA polymerase II transcription,GO:0008284~positive regulation of cell proliferation,GO:0010628~positive regulation of gene expression,GO:0030335~positive regulation of cell migration,GO:0045893~positive regulation of transcription, DNA-templated,GO:0051897~positive regulation of protein kinase B signaling,GO:2001234~negative regulation of apoptotic signaling pathway,	GO:0005634~nucleus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR013087:Znf_C2H2_type,IPR036236:Znf_C2H2_sf,				SM00355:ZnF_C2H2,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,KW-0694~RNA-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:C2H2-type,REGION:Disordered,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4,ZN_FING:C2H2-type 5,ZN_FING:C2H2-type 6; atypical,
MYCBP2	MYC binding protein 2(MYCBP2)	Homo sapiens			GO:0007411~axon guidance,GO:0008582~regulation of synaptic growth at neuromuscular junction,GO:0016567~protein ubiquitination,GO:0021785~branchiomotor neuron axon guidance,GO:0021952~central nervous system projection neuron axonogenesis,GO:0031398~positive regulation of protein ubiquitination,GO:0032880~regulation of protein localization,GO:0032922~circadian regulation of gene expression,GO:0042177~negative regulation of protein catabolic process,GO:0050905~neuromuscular process,GO:0051493~regulation of cytoskeleton organization,GO:0070936~protein K48-linked ubiquitination,GO:1902667~regulation of axon guidance,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0015630~microtubule cytoskeleton,GO:0016020~membrane,GO:0030424~axon,GO:0043231~intracellular membrane-bounded organelle,	GO:0005085~guanyl-nucleotide exchange factor activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0031267~small GTPase binding,GO:0042802~identical protein binding,GO:0046872~metal ion binding,GO:0061630~ubiquitin protein ligase activity,	IPR000408:Reg_chr_condens,IPR001841:Znf_RING,IPR004939:APC_su10/DOC_dom,IPR008979:Galactose-bd-like_sf,IPR009091:RCC1/BLIP-II,IPR012983:PHR,IPR013083:Znf_RING/FYVE/PHD,IPR013783:Ig-like_fold,IPR014756:Ig_E-set,IPR017868:Filamin/ABP280_repeat-like,IPR038648:PHR_sf,				SM00184:RING,SM01337:APC10,	KW-0090~Biological rhythms,KW-0833~Ubl conjugation pathway,	KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0966~Cell projection,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0344~Guanine-nucleotide releasing factor,KW-0808~Transferase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,DOMAIN:DOC,DOMAIN:RING-type,MUTAGEN:C->A: Increased thiol-sensitive adduct formation.,MUTAGEN:C->S: Abolished E3 ubiquitin-protein ligase activity.,MUTAGEN:C->S: Retains activity while also forming a discrete monoubiquitin adduct that is resistant to thiolysis but is reversible after base treatment.,MUTAGEN:E->A,Q: Does not affect E3 ubiquitin-protein ligase activity.,MUTAGEN:F->A: Reduced E3 ubiquitin-protein ligase activity in threonine discharge assay.,MUTAGEN:H->N: Abolished E3 ubiquitin-protein ligase activity in threonine discharge assay, associated with enhanced thiol-sensitive ubiquitin adduct formation.,REGION:Disordered,REGION:PHR domain 1,REGION:PHR domain 2,REGION:RAE1 binding,REGION:Tandem cysteine domain,REPEAT:Filamin,REPEAT:RCC1,REPEAT:RCC1 1,REPEAT:RCC1 2,REPEAT:RCC1 3,REPEAT:RCC1 4,REPEAT:RCC1 5,SITE:Important for catalysis,ZN_FING:RING-type; atypical,
MYD88	MYD88 innate immune signal transduction adaptor(MYD88)	Homo sapiens	92.Ancient_Host_Defense_Pathways,	H_gsk3Pathway:Inactivation of Gsk3 by AKT causes accumulation of b-catenin in Alveolar Macrophages,h_il1rPathway:Signal transduction through IL1R,h_nfkbPathway:NF-kB Signaling Pathway,h_nthiPathway:NFkB activation by Nontypeable Hemophilus influenzae,h_tollPathway:Toll-Like Receptor Pathway,	GO:0002238~response to molecule of fungal origin,GO:0002269~leukocyte activation involved in inflammatory response,GO:0002283~neutrophil activation involved in immune response,GO:0002755~MyD88-dependent toll-like receptor signaling pathway,GO:0006338~chromatin remodeling,GO:0006909~phagocytosis,GO:0006915~apoptotic process,GO:0006954~inflammatory response,GO:0007165~signal transduction,GO:0007166~cell surface receptor signaling pathway,GO:0007249~I-kappaB kinase/NF-kappaB signaling,GO:0007254~JNK cascade,GO:0008063~Toll signaling pathway,GO:0009682~induced systemic resistance,GO:0010467~gene expression,GO:0010628~positive regulation of gene expression,GO:0014004~microglia differentiation,GO:0014070~response to organic cyclic compound,GO:0014075~response to amine,GO:0016064~immunoglobulin mediated immune response,GO:0031663~lipopolysaccharide-mediated signaling pathway,GO:0032481~positive regulation of type I interferon production,GO:0032494~response to peptidoglycan,GO:0032722~positive regulation of chemokine production,GO:0032731~positive regulation of interleukin-1 beta production,GO:0032740~positive regulation of interleukin-17 production,GO:0032747~positive regulation of interleukin-23 production,GO:0032755~positive regulation of interleukin-6 production,GO:0032757~positive regulation of interleukin-8 production,GO:0032760~positive regulation of tumor necrosis factor production,GO:0034142~toll-like receptor 4 signaling pathway,GO:0034158~toll-like receptor 8 signaling pathway,GO:0038172~interleukin-33-mediated signaling pathway,GO:0042742~defense response to bacterium,GO:0042832~defense response to protozoan,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043200~response to amino acid,GO:0043588~skin development,GO:0045087~innate immune response,GO:0045471~response to ethanol,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046330~positive regulation of JNK cascade,GO:0048661~positive regulation of smooth muscle cell proliferation,GO:0050671~positive regulation of lymphocyte proliferation,GO:0050727~regulation of inflammatory response,GO:0050830~defense response to Gram-positive bacterium,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0051607~defense response to virus,GO:0060337~type I interferon signaling pathway,GO:0060907~positive regulation of macrophage cytokine production,GO:0070498~interleukin-1-mediated signaling pathway,GO:0070555~response to interleukin-1,GO:0070935~3'-UTR-mediated mRNA stabilization,GO:0070944~neutrophil mediated killing of bacterium,GO:0071222~cellular response to lipopolysaccharide,GO:0071260~cellular response to mechanical stimulus,GO:0090557~establishment of endothelial intestinal barrier,GO:1900017~positive regulation of cytokine production involved in inflammatory response,GO:1900227~positive regulation of NLRP3 inflammasome complex assembly,GO:1902622~regulation of neutrophil migration,GO:2000338~regulation of chemokine (C-X-C motif) ligand 1 production,GO:2000341~regulation of chemokine (C-X-C motif) ligand 2 production,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0010008~endosome membrane,GO:0019897~extrinsic component of plasma membrane,GO:0031234~extrinsic component of cytoplasmic side of plasma membrane,GO:0032991~macromolecular complex,	GO:0005121~Toll binding,GO:0005123~death receptor binding,GO:0005149~interleukin-1 receptor binding,GO:0005515~protein binding,GO:0035325~Toll-like receptor binding,GO:0035591~signaling adaptor activity,GO:0042802~identical protein binding,GO:0043621~protein self-association,GO:0060090~binding, bridging,GO:0070976~TIR domain binding,	IPR000157:TIR_dom,IPR000488:Death_domain,IPR011029:DEATH-like_dom_sf,IPR017281:Myelin_different_resp_MyD88,IPR034249:MyD88_Death,IPR035897:Toll_tir_struct_dom_sf,	hsa04010:MAPK signaling pathway,hsa04064:NF-kappa B signaling pathway,hsa04620:Toll-like receptor signaling pathway,hsa04621:NOD-like receptor signaling pathway,hsa04936:Alcoholic liver disease,hsa05130:Pathogenic Escherichia coli infection,hsa05131:Shigellosis,hsa05132:Salmonella infection,hsa05133:Pertussis,hsa05134:Legionellosis,hsa05135:Yersinia infection,hsa05140:Leishmaniasis,hsa05142:Chagas disease,hsa05143:African trypanosomiasis,hsa05144:Malaria,hsa05145:Toxoplasmosis,hsa05152:Tuberculosis,hsa05161:Hepatitis B,hsa05162:Measles,hsa05164:Influenza A,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05171:Coronavirus disease - COVID-19,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,hsa05417:Lipid and atherosclerosis,	153600~Macroglobulinemia, Waldenstrom, somatic,612260~Immunodeficiency 68,	PIRSF037756:MyD88,	SM00005:DEATH,SM00255:TIR,	KW-0051~Antiviral defense,KW-0391~Immunity,KW-0395~Inflammatory response,KW-0399~Innate immunity,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,				KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	DOMAIN:Death,DOMAIN:TIR,MUTAGEN:C->S: Abolished interaction with E.coli TcpC without affecting ability to promote Toll-like receptor (TLR)-mediated cytokine production; when associated with S-203.,MUTAGEN:C->S: Abolished interaction with E.coli TcpC without affecting ability to promote Toll-like receptor (TLR)-mediated cytokine production; when associated with S-280.,MUTAGEN:D->A: Slightly reduced activity.,MUTAGEN:I->N: In Pococurante (Poc); abolished MYD88-dependent sensing of most Toll-like receptor (TLR) ligands.,MUTAGEN:K->A: Slightly reduced activity.,MUTAGEN:R->A: Reduced interaction with TIRAP, and strongly reduced activity. Strongly reduced interaction with TIRAP; when associated with A-288.,MUTAGEN:R->A: Slightly reduced activity, and reduced interaction with TIRAP. Strongly reduced interaction with TIRAP; when associated with A-196.,MUTAGEN:R->A: Strongly reduced activity.,REGION:Disordered,REGION:Intermediate domain,
MEAF6	MYST/Esa1 associated factor 6(MEAF6)	Homo sapiens			GO:0001558~regulation of cell growth,GO:0006275~regulation of DNA replication,GO:0006325~chromatin organization,GO:0006338~chromatin remodeling,GO:0006355~regulation of transcription, DNA-templated,GO:0042981~regulation of apoptotic process,GO:0045893~positive regulation of transcription, DNA-templated,GO:0050793~regulation of developmental process,GO:0051726~regulation of cell cycle,GO:1903706~regulation of hemopoiesis,GO:1905168~positive regulation of double-strand break repair via homologous recombination,GO:2000278~regulation of DNA biosynthetic process,GO:2000779~regulation of double-strand break repair,	GO:0000123~histone acetyltransferase complex,GO:0000776~kinetochore,GO:0000786~nucleosome,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0035267~NuA4 histone acetyltransferase complex,GO:0070776~MOZ/MORF histone acetyltransferase complex,	GO:0005515~protein binding,GO:0036408~histone acetyltransferase activity (H3-K14 specific),GO:0043995~histone acetyltransferase activity (H4-K5 specific),GO:0043996~histone acetyltransferase activity (H4-K8 specific),GO:0043997~histone acetyltransferase activity (H4-K12 specific),	IPR015418:Eaf6,	hsa03082:ATP-dependent chromatin remodeling,				KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0137~Centromere,KW-0158~Chromosome,KW-0539~Nucleus,KW-0995~Kinetochore,		KW-0175~Coiled coil,		KW-0010~Activator,KW-0156~Chromatin regulator,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,REGION:Disordered,
MRFAP1L1	Morf4 family associated protein 1 like 1(MRFAP1L1)	Homo sapiens					GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR029254:MRFAP1,								KW-0175~Coiled coil,
MRFAP1	Morf4 family associated protein 1(MRFAP1)	Homo sapiens				GO:0005654~nucleoplasm,GO:0048471~perinuclear region of cytoplasm,	GO:0005515~protein binding,	IPR029254:MRFAP1,						KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,
NAGK	N-acetylglucosamine kinase(NAGK)	Homo sapiens			GO:0006044~N-acetylglucosamine metabolic process,GO:0006051~N-acetylmannosamine metabolic process,GO:0019262~N-acetylneuraminate catabolic process,GO:0032495~response to muramyl dipeptide,GO:0042742~defense response to bacterium,GO:0045087~innate immune response,GO:0046835~carbohydrate phosphorylation,GO:0070434~positive regulation of nucleotide-binding oligomerization domain containing 2 signaling pathway,	GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0005524~ATP binding,GO:0045127~N-acetylglucosamine kinase activity,	IPR002731:ATPase_BadF,IPR039758:NAGK_prok_euk,IPR043129:ATPase_NBD,	hsa00520:Amino sugar and nucleotide sugar metabolism,hsa01100:Metabolic pathways,hsa01250:Biosynthesis of nucleotide sugars,				KW-0391~Immunity,KW-0399~Innate immunity,				KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:ATPase BadF/BadG/BcrA/BcrD type,MUTAGEN:D->V: Abolished ability to phosphorylate muramyl dipeptide.,REGION:Disordered,
GNPTG	N-acetylglucosamine-1-phosphate transferase subunit gamma(GNPTG)	Homo sapiens			GO:0016256~N-glycan processing to lysosome,GO:0046835~carbohydrate phosphorylation,	GO:0000139~Golgi membrane,GO:0005794~Golgi apparatus,GO:0070062~extracellular exosome,GO:0070622~UDP-N-acetylglucosamine-lysosomal-enzyme N-acetylglucosaminephosphotransferase complex,	GO:0003976~UDP-N-acetylglucosamine-lysosomal-enzyme N-acetylglucosaminephosphotransferase activity,GO:0005515~protein binding,GO:0042803~protein homodimerization activity,	IPR009011:Man6P_isomerase_rcpt-bd_dom_sf,IPR010506:DMAP1-bd,IPR012913:OS9-like_dom,IPR039794:Gtb1-like,IPR044865:MRH_dom,	hsa04142:Lysosome,	252605~Mucolipidosis III gamma,		SM01137:DMAP_binding,		KW-0333~Golgi apparatus,KW-0964~Secreted,	KW-0225~Disease variant,KW-0942~Mucolipidosis,	KW-0732~Signal,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,DISULFID:Interchain,DOMAIN:DMAP1-binding,DOMAIN:MRH,REGION:Disordered,
NAA38	N-alpha-acetyltransferase 38, NatC auxiliary subunit(NAA38)	Homo sapiens			GO:0043066~negative regulation of apoptotic process,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0031417~NatC complex,	GO:0003723~RNA binding,GO:0005515~protein binding,	IPR001163:Sm_dom_euk/arc,IPR010920:LSM_dom_sf,IPR034110:LSMD1_Sm,IPR047575:Sm,				SM00651:Sm,		KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:Sm,REGION:Disordered,
NAA60	N-alpha-acetyltransferase 60, NatF catalytic subunit(NAA60)	Homo sapiens			GO:0006334~nucleosome assembly,GO:0006474~N-terminal protein amino acid acetylation,GO:0007059~chromosome segregation,GO:0008283~cell proliferation,GO:0017196~N-terminal peptidyl-methionine acetylation,	GO:0000139~Golgi membrane,	GO:0004402~histone acetyltransferase activity,GO:0004596~peptide alpha-N-acetyltransferase activity,GO:0005515~protein binding,GO:0010485~H4 histone acetyltransferase activity,GO:0042803~protein homodimerization activity,	IPR000182:GNAT_dom,IPR016181:Acyl_CoA_acyltransferase,IPR045141:NAA60-like,					KW-0159~Chromosome partition,	KW-0333~Golgi apparatus,KW-0472~Membrane,				KW-0012~Acyltransferase,KW-0156~Chromatin regulator,KW-0808~Transferase,	KW-0007~Acetylation,	DOMAIN:N-acetyltransferase,INTRAMEM:Helical,MUTAGEN:C->S: Does not affect localization to the Golgi apparatus; when associated with S-19; S-132; S-207 and S-222.,MUTAGEN:C->S: Does not affect localization to the Golgi apparatus; when associated with S-19; S-30; S-132 and S-207.,MUTAGEN:C->S: Does not affect localization to the Golgi apparatus; when associated with S-19; S-30; S-132 and S-222.,MUTAGEN:C->S: Does not affect localization to the Golgi apparatus; when associated with S-19; S-30; S-207 and S-222.,MUTAGEN:C->S: Does not affect localization to the Golgi apparatus; when associated with S-30; S-132; S-207 and S-222.,MUTAGEN:D->A: Slightly increased acetyltransferase activity.,MUTAGEN:E->A,F: Only slightly affects acetyltransferase activity.,MUTAGEN:E->A: Slightly increased acetyltransferase activity.,MUTAGEN:F->A: Abolished acetyltransferase activity.,MUTAGEN:G->A: Abolishes acetyltransferase activity.,MUTAGEN:H->A,F: Abolished acetyltransferase activity.,MUTAGEN:I->A: Reduced acetyltransferase activity.,MUTAGEN:I->A: Slightly altered acetyltransferase activity.,MUTAGEN:K->A: Slightly reduced acetyltransferase activity.,MUTAGEN:K->R,Q: Increased acetyltransferase activity.,MUTAGEN:K->R: Decreased acetyltransferase activity; when associated with R-105, R-109, R-121 and R-156.,MUTAGEN:K->R: Decreased acetyltransferase activity; when associated with R-79, R-105, R-109 and R-156.,MUTAGEN:K->R: Decreased acetyltransferase activity; when associated with R-79, R-105, R-121 and R-156.,MUTAGEN:K->R: Decreased acetyltransferase activity; when associated with R-79, R-109, R-121 and R-156.,MUTAGEN:K->R: Decreased histone acetyltransferase activity; when associated with R-79, R-105, R-109 and R-121.,MUTAGEN:L->A: Decreased acetyltransferase activity.,MUTAGEN:LL->AA: Does not affect localization to the Golgi apparatus.,MUTAGEN:N->A: Strongly reduced acetyltransferase activity.,MUTAGEN:P->A: Reduced acetyltransferase activity.,MUTAGEN:Y->A,F: Abolished acetyltransferase activity.,MUTAGEN:Y->A,F: Slightly altered acetyltransferase activity.,MUTAGEN:Y->A,F: Strongly reduced acetyltransferase activity.,MUTAGEN:Y->A: Strongly reduced acetyltransferase activity.,REGION:Required for homodimerization,SITE:Required to position thioacetyl group,TOPO_DOM:Cytoplasmic,
NGLY1	N-glycanase 1(NGLY1)	Homo sapiens			GO:0006457~protein folding,GO:0006515~misfolded or incompletely synthesized protein catabolic process,GO:0006516~glycoprotein catabolic process,GO:0006517~protein deglycosylation,GO:0006950~response to stress,GO:0019538~protein metabolic process,GO:0036503~ERAD pathway,GO:0071712~ER-associated misfolded protein catabolic process,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0000224~peptide-N4-(N-acetyl-beta-glucosaminyl)asparagine amidase activity,GO:0005515~protein binding,GO:0016787~hydrolase activity,GO:0046872~metal ion binding,	IPR002931:Transglutaminase-like,IPR006588:Peptide_N_glycanase_PAW_dom,IPR008979:Galactose-bd-like_sf,IPR018325:Rad4/PNGase_transGLS-fold,IPR018997:PUB_domain,IPR036339:PUB-like_dom_sf,IPR038680:PAW_sf,IPR038765:Papain-like_cys_pep_sf,	hsa04141:Protein processing in endoplasmic reticulum,	615273~Congenital disorder of deglycosylation 1,		SM00460:TGc,SM00580:PUG,SM00613:PAW,		KW-0963~Cytoplasm,			KW-0479~Metal-binding,KW-0862~Zinc,	KW-0378~Hydrolase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Nucleophile,COMPBIAS:Polar residues,DOMAIN:PAW,DOMAIN:PUB,REGION:Disordered,
MPG	N-methylpurine DNA glycosylase(MPG)	Homo sapiens			GO:0006284~base-excision repair,GO:0006307~DNA dealkylation involved in DNA repair,GO:0045007~depurination,	GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0016020~membrane,GO:0042645~mitochondrial nucleoid,	GO:0003677~DNA binding,GO:0003684~damaged DNA binding,GO:0003905~alkylbase DNA N-glycosylase activity,GO:0005515~protein binding,GO:0008725~DNA-3-methyladenine glycosylase activity,GO:0019104~DNA N-glycosylase activity,GO:0043916~DNA-7-methylguanine glycosylase activity,GO:0052821~DNA-7-methyladenine glycosylase activity,GO:0052822~DNA-3-methylguanine glycosylase activity,	IPR003180:MPG,IPR011034:Formyl_transferase-like_C_sf,IPR036995:MPG_sf,	hsa03410:Base excision repair,				KW-0227~DNA damage,KW-0234~DNA repair,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1135~Mitochondrion nucleoid,		KW-0809~Transit peptide,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0378~Hydrolase,	KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,REGION:Disordered,TRANSIT:Mitochondrion,TRANSMEM:Helical,
NMI	N-myc and STAT interactor(NMI)	Homo sapiens		h_il2rbPathway:IL-2 Receptor Beta Chain in T cell Activation,h_il7Pathway:IL-7 Signal Transduction,	GO:0002281~macrophage activation involved in immune response,GO:0007259~JAK-STAT cascade,GO:0008285~negative regulation of cell proliferation,GO:0009615~response to virus,GO:0032687~negative regulation of interferon-alpha production,GO:0032688~negative regulation of interferon-beta production,GO:0034142~toll-like receptor 4 signaling pathway,GO:0045087~innate immune response,GO:0045089~positive regulation of innate immune response,GO:0045824~negative regulation of innate immune response,GO:0050729~positive regulation of inflammatory response,GO:0070936~protein K48-linked ubiquitination,GO:1901223~negative regulation of NIK/NF-kappaB signaling,GO:1901224~positive regulation of NIK/NF-kappaB signaling,GO:1902524~positive regulation of protein K48-linked ubiquitination,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016020~membrane,	GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR009909:Nmi/IFP35_dom,IPR009938:Nmi/IFP35_N,IPR012677:Nucleotide-bd_a/b_plait_sf,					KW-0391~Immunity,KW-0399~Innate immunity,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0964~Secreted,		KW-0175~Coiled coil,			KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:NID,DOMAIN:NID 1,DOMAIN:NID 2,DOMAIN:Nmi/IFP 35,MUTAGEN:K->R: Loss of TRIM21-mediated ubiquitination and loss of Sendai virus-triggered type I IFN-beta production. Loss of TRIM21-mediated ubiquitination and decreased Sendai virus-triggered type I IFN-beta production; when associated with R-27.,MUTAGEN:K->R: No change in TRIM21-mediated ubiquitination and no change in Sendai virus-triggered type I IFN-beta production. Loss of TRIM21-mediated ubiquitination and decreased Sendai virus-triggered type I IFN-beta production; when associated with R-22.,MUTAGEN:K->R: No change in TRIM21-mediated ubiquitination; when associated with R-176.,MUTAGEN:K->R: No change in TRIM21-mediated ubiquitination; when associated with R-183.,MUTAGEN:K->R: No change in TRIM21-mediated ubiquitination; when associated with R-56.,MUTAGEN:K->R: No change in TRIM21-mediated ubiquitination; when associated with R-61.,REGION:Disordered,
NDRG1	N-myc downstream regulated 1(NDRG1)	Homo sapiens			GO:0007165~signal transduction,GO:0008285~negative regulation of cell proliferation,GO:0010038~response to metal ion,GO:0030330~DNA damage response, signal transduction by p53 class mediator,GO:0032287~peripheral nervous system myelin maintenance,GO:0045576~mast cell activation,GO:0071456~cellular response to hypoxia,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005829~cytosol,GO:0005874~microtubule,GO:0005886~plasma membrane,GO:0005912~adherens junction,GO:0015630~microtubule cytoskeleton,GO:0048471~perinuclear region of cytoplasm,GO:0055038~recycling endosome membrane,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0008017~microtubule binding,GO:0031267~small GTPase binding,GO:0043015~gamma-tubulin binding,GO:0045296~cadherin binding,	IPR004142:NDRG,IPR029058:AB_hydrolase,		601455~Charcot-Marie-Tooth disease, type 4D,				KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0493~Microtubule,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,	KW-0144~Charcot-Marie-Tooth disease,KW-0523~Neurodegeneration,KW-0622~Neuropathy,	KW-0677~Repeat,KW-0732~Signal,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:3 X 10 AA tandem repeats of G-T-R-S-R-S-H-T-S-E,REGION:Disordered,REPEAT:1,REPEAT:2,REPEAT:3,
NMT1	N-myristoyltransferase 1(NMT1)	Homo sapiens			GO:0001701~in utero embryonic development,GO:0018008~N-terminal peptidyl-glycine N-myristoylation,GO:0022400~regulation of rhodopsin mediated signaling pathway,GO:0042180~cellular ketone metabolic process,GO:0072657~protein localization to membrane,GO:1900740~positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway,	GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0005886~plasma membrane,	GO:0004379~glycylpeptide N-tetradecanoyltransferase activity,GO:0005515~protein binding,GO:0018030~peptidyl-lysine N6-myristoyltransferase activity,GO:0019107~myristoyltransferase activity,	IPR000903:NMT,IPR016181:Acyl_CoA_acyltransferase,IPR022676:NMT_N,IPR022677:NMT_C,IPR022678:NMT_CS,			PIRSF015892:N-myristl_transf,			KW-0472~Membrane,KW-0963~Cytoplasm,				KW-0012~Acyltransferase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:Glycylpeptide N-tetradecanoyltransferase C-terminal,DOMAIN:Glycylpeptide N-tetradecanoyltransferase N-terminal,MUTAGEN:G->D,K: Reduced activity.,MUTAGEN:V->L: Reduced glycine N-myristoyltransferase activity.,MUTAGEN:Y->A: Reduced glycine N-myristoyltransferase activity.,MUTAGEN:Y->P: Abolished glycine- and lysine-myristoyltransferase activities.,REGION:Disordered,
NDUFS3	NADH:ubiquinone oxidoreductase core subunit S3(NDUFS3)	Homo sapiens			GO:0006120~mitochondrial electron transport, NADH to ubiquinone,GO:0009060~aerobic respiration,GO:0021762~substantia nigra development,GO:0030308~negative regulation of cell growth,GO:0032981~mitochondrial respiratory chain complex I assembly,GO:0042776~mitochondrial ATP synthesis coupled proton transport,GO:0072593~reactive oxygen species metabolic process,GO:2001243~negative regulation of intrinsic apoptotic signaling pathway,	GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005747~mitochondrial respiratory chain complex I,GO:0005759~mitochondrial matrix,GO:0016604~nuclear body,GO:0031966~mitochondrial membrane,	GO:0003954~NADH dehydrogenase activity,GO:0005515~protein binding,GO:0008137~NADH dehydrogenase (ubiquinone) activity,GO:0009055~electron carrier activity,	IPR001268:NADH_UbQ_OxRdtase_30kDa_su,IPR010218:NADH_DH_suC,IPR020396:NADH_UbQ_OxRdtase_CS,IPR037232:NADH_quin_OxRdtase_su_C/D-like,	hsa00190:Oxidative phosphorylation,hsa01100:Metabolic pathways,hsa04714:Thermogenesis,hsa04723:Retrograde endocannabinoid signaling,hsa04932:Non-alcoholic fatty liver disease,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05415:Diabetic cardiomyopathy,	618230~Mitochondrial complex I deficiency, nuclear type 8,			KW-0249~Electron transport,KW-0679~Respiratory chain,KW-0813~Transport,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,	KW-0225~Disease variant,KW-1274~Primary mitochondrial disease,	KW-0732~Signal,KW-0809~Transit peptide,	KW-0520~NAD,KW-0830~Ubiquinone,	KW-0560~Oxidoreductase,KW-1278~Translocase,		DOMAIN:NADH:ubiquinone oxidoreductase 30kDa subunit,TRANSIT:Mitochondrion,
NDUFV2	NADH:ubiquinone oxidoreductase core subunit V2(NDUFV2)	Homo sapiens			GO:0006120~mitochondrial electron transport, NADH to ubiquinone,GO:0007399~nervous system development,GO:0009060~aerobic respiration,GO:0042776~mitochondrial ATP synthesis coupled proton transport,GO:0048738~cardiac muscle tissue development,	GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005747~mitochondrial respiratory chain complex I,	GO:0003954~NADH dehydrogenase activity,GO:0005515~protein binding,GO:0008137~NADH dehydrogenase (ubiquinone) activity,GO:0009055~electron carrier activity,GO:0016491~oxidoreductase activity,GO:0046872~metal ion binding,GO:0051537~2 iron, 2 sulfur cluster binding,	IPR002023:NuoE-like,IPR036249:Thioredoxin-like_sf,IPR041921:NuoE_N,IPR042128:NuoE_dom,	hsa00190:Oxidative phosphorylation,hsa01100:Metabolic pathways,hsa04714:Thermogenesis,hsa04723:Retrograde endocannabinoid signaling,hsa04932:Non-alcoholic fatty liver disease,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05415:Diabetic cardiomyopathy,	618229~Mitochondrial complex I deficiency, nuclear type 7,	PIRSF000216:NADH_DH_24kDa,		KW-0249~Electron transport,KW-0679~Respiratory chain,KW-0813~Transport,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,	KW-1274~Primary mitochondrial disease,	KW-0809~Transit peptide,	KW-0001~2Fe-2S,KW-0408~Iron,KW-0411~Iron-sulfur,KW-0479~Metal-binding,KW-0520~NAD,KW-0830~Ubiquinone,	KW-0560~Oxidoreductase,KW-1278~Translocase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	REGION:Disordered,TRANSIT:Mitochondrion,
NDUFA10	NADH:ubiquinone oxidoreductase subunit A10(NDUFA10)	Homo sapiens			GO:0006120~mitochondrial electron transport, NADH to ubiquinone,GO:0009060~aerobic respiration,GO:0032981~mitochondrial respiratory chain complex I assembly,GO:0042776~mitochondrial ATP synthesis coupled proton transport,	GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005747~mitochondrial respiratory chain complex I,GO:0005759~mitochondrial matrix,	GO:0008137~NADH dehydrogenase (ubiquinone) activity,	IPR015828:NDUFA10,IPR027417:P-loop_NTPase,IPR031314:DNK_dom,	hsa00190:Oxidative phosphorylation,hsa01100:Metabolic pathways,hsa04714:Thermogenesis,hsa04723:Retrograde endocannabinoid signaling,hsa04932:Non-alcoholic fatty liver disease,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05415:Diabetic cardiomyopathy,	618243~Mitochondrial complex I deficiency, nuclear type 22,	PIRSF000543:NADH_UQ_42KD,		KW-0249~Electron transport,KW-0679~Respiratory chain,KW-0813~Transport,	KW-0496~Mitochondrion,	KW-0225~Disease variant,KW-1274~Primary mitochondrial disease,	KW-0732~Signal,KW-0809~Transit peptide,	KW-0274~FAD,KW-0285~Flavoprotein,KW-0830~Ubiquinone,		KW-0597~Phosphoprotein,	DOMAIN:Deoxynucleoside kinase,REGION:Disordered,TRANSIT:Mitochondrion,
NDUFA11	NADH:ubiquinone oxidoreductase subunit A11(NDUFA11)	Homo sapiens			GO:0009060~aerobic respiration,GO:0032981~mitochondrial respiratory chain complex I assembly,GO:0042776~mitochondrial ATP synthesis coupled proton transport,	GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005747~mitochondrial respiratory chain complex I,	GO:0005515~protein binding,	IPR039205:NDUFA11,	hsa00190:Oxidative phosphorylation,hsa01100:Metabolic pathways,hsa04714:Thermogenesis,hsa04723:Retrograde endocannabinoid signaling,hsa04932:Non-alcoholic fatty liver disease,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05415:Diabetic cardiomyopathy,	618236~Mitochondrial complex I deficiency, nuclear type 14,			KW-0249~Electron transport,KW-0679~Respiratory chain,KW-0813~Transport,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,	KW-1274~Primary mitochondrial disease,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,	TRANSMEM:Helical,
NDUFA12	NADH:ubiquinone oxidoreductase subunit A12(NDUFA12)	Homo sapiens			GO:0006979~response to oxidative stress,GO:0007585~respiratory gaseous exchange,GO:0009060~aerobic respiration,GO:0032981~mitochondrial respiratory chain complex I assembly,GO:0042775~mitochondrial ATP synthesis coupled electron transport,GO:0042776~mitochondrial ATP synthesis coupled proton transport,	GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005747~mitochondrial respiratory chain complex I,GO:0005829~cytosol,GO:0016020~membrane,GO:0070469~respiratory chain,	GO:0005515~protein binding,GO:0008137~NADH dehydrogenase (ubiquinone) activity,	IPR007763:NDUFA12,	hsa00190:Oxidative phosphorylation,hsa01100:Metabolic pathways,hsa04714:Thermogenesis,hsa04723:Retrograde endocannabinoid signaling,hsa04932:Non-alcoholic fatty liver disease,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05415:Diabetic cardiomyopathy,	618244~Mitochondrial complex I deficiency, nuclear type 23,			KW-0249~Electron transport,KW-0679~Respiratory chain,KW-0813~Transport,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,	KW-0225~Disease variant,KW-1274~Primary mitochondrial disease,				KW-0007~Acetylation,
NDUFA2	NADH:ubiquinone oxidoreductase subunit A2(NDUFA2)	Homo sapiens			GO:0001835~blastocyst hatching,GO:0006120~mitochondrial electron transport, NADH to ubiquinone,GO:0009060~aerobic respiration,GO:0032981~mitochondrial respiratory chain complex I assembly,GO:0042776~mitochondrial ATP synthesis coupled proton transport,	GO:0005743~mitochondrial inner membrane,GO:0005747~mitochondrial respiratory chain complex I,GO:0031966~mitochondrial membrane,	GO:0008137~NADH dehydrogenase (ubiquinone) activity,	IPR007741:Ribosomal_mL43/mS25/NADH_DH,IPR016464:NADH_Ub_cplx-1_asu_su-2,IPR036249:Thioredoxin-like_sf,	hsa00190:Oxidative phosphorylation,hsa01100:Metabolic pathways,hsa04714:Thermogenesis,hsa04723:Retrograde endocannabinoid signaling,hsa04932:Non-alcoholic fatty liver disease,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05415:Diabetic cardiomyopathy,	618235~Mitochondrial complex I deficiency, nuclear type 13,	PIRSF005822:NDUA2,	SM00916:L51_S25_CI-B8,	KW-0249~Electron transport,KW-0679~Respiratory chain,KW-0813~Transport,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,	KW-1274~Primary mitochondrial disease,				KW-0007~Acetylation,KW-1015~Disulfide bond,	DISULFID:Redox-active,
NDUFB3	NADH:ubiquinone oxidoreductase subunit B3(NDUFB3)	Homo sapiens			GO:0006120~mitochondrial electron transport, NADH to ubiquinone,GO:0009060~aerobic respiration,GO:0022900~electron transport chain,GO:0032981~mitochondrial respiratory chain complex I assembly,GO:0042776~mitochondrial ATP synthesis coupled proton transport,	GO:0005743~mitochondrial inner membrane,GO:0005747~mitochondrial respiratory chain complex I,GO:0070469~respiratory chain,	GO:0008137~NADH dehydrogenase (ubiquinone) activity,	IPR012576:NDUFB3,	hsa00190:Oxidative phosphorylation,hsa01100:Metabolic pathways,hsa04714:Thermogenesis,hsa04723:Retrograde endocannabinoid signaling,hsa04932:Non-alcoholic fatty liver disease,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05415:Diabetic cardiomyopathy,	618246~Mitochondrial complex I deficiency, nuclear type 25,			KW-0249~Electron transport,KW-0679~Respiratory chain,KW-0813~Transport,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,	KW-0225~Disease variant,KW-1274~Primary mitochondrial disease,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,KW-0488~Methylation,	MUTAGEN:HGHEH->RGHER: Abolished histidine methylation by METTL9.,TRANSMEM:Helical,
NDUFC1	NADH:ubiquinone oxidoreductase subunit C1(NDUFC1)	Homo sapiens			GO:0006120~mitochondrial electron transport, NADH to ubiquinone,GO:0009060~aerobic respiration,GO:0032981~mitochondrial respiratory chain complex I assembly,GO:0042776~mitochondrial ATP synthesis coupled proton transport,	GO:0005743~mitochondrial inner membrane,GO:0005747~mitochondrial respiratory chain complex I,	GO:0008137~NADH dehydrogenase (ubiquinone) activity,	IPR026192:NDUFC1,	hsa00190:Oxidative phosphorylation,hsa01100:Metabolic pathways,hsa04714:Thermogenesis,hsa04723:Retrograde endocannabinoid signaling,hsa04932:Non-alcoholic fatty liver disease,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05415:Diabetic cardiomyopathy,				KW-0249~Electron transport,KW-0679~Respiratory chain,KW-0813~Transport,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,		KW-0809~Transit peptide,KW-0812~Transmembrane,KW-1133~Transmembrane helix,				TRANSIT:Mitochondrion,TRANSMEM:Helical,
NCK1	NCK adaptor protein 1(NCK1)	Homo sapiens		h_actinYPathway:Y branching of actin filaments,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006417~regulation of translation,GO:0006930~substrate-dependent cell migration, cell extension,GO:0007015~actin filament organization,GO:0007165~signal transduction,GO:0007172~signal complex assembly,GO:0010976~positive regulation of neuron projection development,GO:0016477~cell migration,GO:0030032~lamellipodium assembly,GO:0030334~regulation of cell migration,GO:0030838~positive regulation of actin filament polymerization,GO:0033137~negative regulation of peptidyl-serine phosphorylation,GO:0034976~response to endoplasmic reticulum stress,GO:0036493~positive regulation of translation in response to endoplasmic reticulum stress,GO:0042102~positive regulation of T cell proliferation,GO:0042110~T cell activation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046627~negative regulation of insulin receptor signaling pathway,GO:0048013~ephrin receptor signaling pathway,GO:0051707~response to other organism,GO:0070262~peptidyl-serine dephosphorylation,GO:1902237~positive regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway,GO:1902310~positive regulation of peptidyl-serine dephosphorylation,GO:1903676~positive regulation of cap-dependent translational initiation,GO:1903679~positive regulation of cap-independent translational initiation,GO:1903898~negative regulation of PERK-mediated unfolded protein response,GO:1903912~negative regulation of endoplasmic reticulum stress-induced eIF2 alpha phosphorylation,GO:1990441~negative regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress,	GO:0000164~protein phosphatase type 1 complex,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0005840~ribosome,GO:0005886~plasma membrane,GO:0005911~cell-cell junction,GO:0012506~vesicle membrane,	GO:0004860~protein kinase inhibitor activity,GO:0005102~receptor binding,GO:0005515~protein binding,GO:0008093~cytoskeletal adaptor activity,GO:0019904~protein domain specific binding,GO:0030159~receptor signaling complex scaffold activity,GO:0030674~protein binding, bridging,GO:0030971~receptor tyrosine kinase binding,GO:0035591~signaling adaptor activity,GO:0045296~cadherin binding,GO:0046875~ephrin receptor binding,GO:0071074~eukaryotic initiation factor eIF2 binding,	IPR000980:SH2,IPR001452:SH3_domain,IPR017304:NCK,IPR035562:Nck1_SH3_1,IPR035564:Nck1_SH3_2,IPR035565:Nck1_SH3_3,IPR035882:Nck1_SH2,IPR036028:SH3-like_dom_sf,IPR036860:SH2_dom_sf,IPR039801:EPS8-like,	hsa04012:ErbB signaling pathway,hsa04360:Axon guidance,hsa04660:T cell receptor signaling pathway,hsa05130:Pathogenic Escherichia coli infection,		PIRSF037874:Cytoplasmic_NCK,	SM00252:SH2,SM00326:SH3,	KW-0810~Translation regulation,	KW-0256~Endoplasmic reticulum,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0727~SH2 domain,KW-0728~SH3 domain,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:SH2,DOMAIN:SH3,DOMAIN:SH3 1,DOMAIN:SH3 2,DOMAIN:SH3 3,MUTAGEN:R->K: No effect on RASA1-binding.,MUTAGEN:W->K: No effect on RASA1-binding. Almost complete loss of RASA1-binding; when associated with K-38 and K-229.,MUTAGEN:W->K: Small decrease in RASA1-binding. Almost complete loss of RASA1-binding; when associated with K-143 and K-229.,MUTAGEN:W->K: Small decrease in RASA1-binding. Almost complete loss of RASA1-binding; when associated with K-38 and K-229.,
N4BP1	NEDD4 binding protein 1(N4BP1)	Homo sapiens			GO:0001818~negative regulation of cytokine production,GO:0031397~negative regulation of protein ubiquitination,GO:0032435~negative regulation of proteasomal ubiquitin-dependent protein catabolic process,GO:0034644~cellular response to UV,GO:0045071~negative regulation of viral genome replication,GO:0045087~innate immune response,GO:0045088~regulation of innate immune response,	GO:0005634~nucleus,GO:0005730~nucleolus,GO:0005829~cytosol,GO:0016605~PML body,	GO:0003729~mRNA binding,GO:0004540~ribonuclease activity,GO:0005515~protein binding,GO:0043130~ubiquitin binding,	IPR021869:RNase_Zc3h12_NYN,					KW-0391~Immunity,KW-0399~Innate immunity,	KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0378~Hydrolase,KW-0540~Nuclease,KW-0694~RNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	DOMAIN:KH-like,DOMAIN:RNase NYN,MUTAGEN:D->N: Abolished ability to degrade HIV-1 mRNAs.,MUTAGEN:P->A: Abolished ability to interact with ubiquitin.,MUTAGEN:R->A: Abolished cleavage by MALT1.,REGION:CoCUN,REGION:Disordered,SITE:Cleavage,SITE:Cleavage; by CASP8,SITE:Cleavage; by MALT1,
NEDD8	NEDD8 ubiquitin like modifier(NEDD8)	Homo sapiens		h_p27Pathway:Regulation of p27 Phosphorylation during Cell Cycle Progression,	GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006508~proteolysis,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0008104~protein localization,GO:0009653~anatomical structure morphogenesis,GO:0019941~modification-dependent protein catabolic process,GO:0030162~regulation of proteolysis,GO:0036211~protein modification process,GO:0045116~protein neddylation,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0031386~protein tag,GO:0031625~ubiquitin protein ligase binding,	IPR000626:Ubiquitin-like_dom,IPR019954:Ubiquitin_CS,IPR019956:Ubiquitin_dom,IPR029071:Ubiquitin-like_domsf,IPR038738:Nedd8-like,				SM00213:UBQ,	KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,					KW-0007~Acetylation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Gly-Lys) (interchain with K-? in acceptor proteins),DOMAIN:Ubiquitin-like,MUTAGEN:A->R: Prevents adenylation by UBE1C.,MUTAGEN:E->Q: Decreased interaction with B.pseudomallei Cif protein, leading to slightly decreased deamidation.,MUTAGEN:H->A: Decreased interaction with B.pseudomallei Cif protein, leading to slightly decreased deamidation.,MUTAGEN:K->A: Decreased interaction with B.pseudomallei Cif protein, leading to decreased deamidation.,MUTAGEN:Q->E: Impaired ability to activate cullin-RING-based E3 ubiquitin-protein ligase complexes.,MUTAGEN:TLT->ALA: Decreased interaction with B.pseudomallei Cif protein, leading to decreased deamidation.,REGION:Interaction with UBE1C,SITE:Interaction with UBE1C,
NFE2L2	NFE2 like bZIP transcription factor 2(NFE2L2)	Homo sapiens		h_arenrf2Pathway:Oxidative Stress Induced Gene Expression Via Nrf2,h_prionPathway:Prion Pathway,	GO:0002931~response to ischemia,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006954~inflammatory response,GO:0006979~response to oxidative stress,GO:0010499~proteasomal ubiquitin-independent protein catabolic process,GO:0010628~positive regulation of gene expression,GO:0010667~negative regulation of cardiac muscle cell apoptotic process,GO:0010976~positive regulation of neuron projection development,GO:0016567~protein ubiquitination,GO:0030194~positive regulation of blood coagulation,GO:0030968~endoplasmic reticulum unfolded protein response,GO:0034599~cellular response to oxidative stress,GO:0036003~positive regulation of transcription from RNA polymerase II promoter in response to stress,GO:0036499~PERK-mediated unfolded protein response,GO:0042149~cellular response to glucose starvation,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0043536~positive regulation of blood vessel endothelial cell migration,GO:0045088~regulation of innate immune response,GO:0045454~cell redox homeostasis,GO:0045766~positive regulation of angiogenesis,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0045995~regulation of embryonic development,GO:0046223~aflatoxin catabolic process,GO:0046326~positive regulation of glucose import,GO:0070301~cellular response to hydrogen peroxide,GO:0071280~cellular response to copper ion,GO:0071356~cellular response to tumor necrosis factor,GO:0071456~cellular response to hypoxia,GO:0071466~cellular response to xenobiotic stimulus,GO:0071498~cellular response to fluid shear stress,GO:0071499~cellular response to laminar fluid shear stress,GO:1900038~negative regulation of cellular response to hypoxia,GO:1900407~regulation of cellular response to oxidative stress,GO:1902037~negative regulation of hematopoietic stem cell differentiation,GO:1902176~negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway,GO:1903071~positive regulation of ER-associated ubiquitin-dependent protein catabolic process,GO:1903788~positive regulation of glutathione biosynthetic process,GO:1904294~positive regulation of ERAD pathway,GO:1904385~cellular response to angiotensin,GO:1904753~negative regulation of vascular associated smooth muscle cell migration,GO:2000060~positive regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process,GO:2000121~regulation of removal of superoxide radicals,GO:2000352~negative regulation of endothelial cell apoptotic process,GO:2000379~positive regulation of reactive oxygen species metabolic process,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005813~centrosome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0032993~protein-DNA complex,GO:0090575~RNA polymerase II transcription factor complex,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001221~transcription cofactor binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0019904~protein domain specific binding,GO:0031625~ubiquitin protein ligase binding,GO:0043565~sequence-specific DNA binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,	IPR004826:bZIP_Maf,IPR004827:bZIP,IPR008917:TF_DNA-bd_sf,IPR046347:bZIP_sf,IPR047167:NFE2-like,	hsa04141:Protein processing in endoplasmic reticulum,hsa05012:Parkinson disease,hsa05200:Pathways in cancer,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05225:Hepatocellular carcinoma,hsa05417:Lipid and atherosclerosis,hsa05418:Fluid shear stress and atherosclerosis,	617744~Immunodeficiency, developmental delay, and hypohomocysteinemia,		SM00338:BRLZ,	KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,	KW-0175~Coiled coil,		KW-0010~Activator,KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-0971~Glycation,	CARBOHYD:N-linked (Glc) (glycation) arginine,CARBOHYD:N-linked (Glc) (glycation) lysine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:BZIP,DOMAIN:bZIP,MOTIF:DLG motif,MOTIF:ETGE motif,MUTAGEN:E->G: Abolished interaction with KEAP1.,MUTAGEN:K->A: Loss of function; when associated with A-462; A-472; A-499; A-569 and A-587.,MUTAGEN:K->A: Loss of function; when associated with A-462; A-487; A-499; A-569 and A-587.,MUTAGEN:K->A: Loss of function; when associated with A-472; A-487; A-499; A-569 and A-587.,MUTAGEN:Missing: Abolished interaction with KEAP1.,MUTAGEN:R->A: Loss of function; when associated with A-462; A-472; A-487; A-499 and A-569.,MUTAGEN:R->A: Loss of function; when associated with A-462; A-472; A-487; A-499 and A-587.,MUTAGEN:R->A: Loss of function; when associated with A-462; A-472; A-487; A-569 and A-587.,MUTAGEN:T->A: Loss of interaction with KEAP1.,REGION:Basic motif,REGION:Disordered,REGION:Leucine-zipper,REGION:Mediates interaction with CHD6 and is necessary to activate transcription,
NKAP	NFKB activating protein(NKAP)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0007219~Notch signaling pathway,GO:0030851~granulocyte differentiation,GO:0033077~T cell differentiation in thymus,GO:0035019~somatic stem cell population maintenance,GO:0045892~negative regulation of transcription, DNA-templated,GO:0046638~positive regulation of alpha-beta T cell differentiation,GO:0071425~hematopoietic stem cell proliferation,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,	GO:0003682~chromatin binding,GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0005515~protein binding,GO:0031490~chromatin DNA binding,GO:0060090~binding, bridging,	IPR009269:NKAP_C,IPR040466:NKAP,		301039~Intellectual developmental disorder, X-linked syndromic, Hackman-Di Donato type,			KW-0804~Transcription,KW-0805~Transcription regulation,KW-0914~Notch signaling pathway,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-0991~Intellectual disability,			KW-0678~Repressor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:NF-kappa-B-activating protein C-terminal,REGION:Disordered,REGION:Necessary for interaction with CIR1,REGION:Necessary for interaction with HDAC3 and transcriptional repression,
NFKBIA	NFKB inhibitor alpha(NFKBIA)	Homo sapiens	17.Activators-CAM,77.IkBa_Kinase_JNK_MEKK1,90.IB_and-cat-Arm_processing_of_Ci,	h_41BBPathway:The 4-1BB-dependent immune response,h_aktPathway:AKT Signaling Pathway,h_atmPathway:ATM Signaling Pathway,h_cd40Pathway:CD40L Signaling Pathway,h_cdmacPathway:Cadmium induces DNA synthesis and proliferation in macrophages,h_deathPathway:Induction of apoptosis through DR3 and DR4/5 Death Receptors ,h_eponfkbPathway:Erythropoietin mediated neuroprotection through NF-kB,h_fmlpPathway:fMLP induced chemokine gene expression in HMC-1 cells,h_hivnefPathway:HIV-I Nef: negative effector of Fas and TNF,h_il1rPathway:Signal transduction through IL1R,h_keratinocytePathway:Keratinocyte Differentiation,h_mapkPathway:MAPKinase Signaling Pathway,h_nfkbPathway:NF-kB Signaling Pathway,h_nthiPathway:NFkB activation by Nontypeable Hemophilus influenzae,h_pkcPathway:Activation of PKC through G protein coupled receptor,h_PparaPathway:Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha),h_raccycdPathway:Influence of Ras and Rho proteins on G1 to S Transition,h_relaPathway:Acetylation and Deacetylation of RelA in The Nucleus,h_rnaPathway:Double Stranded RNA Induced Gene Expression,h_stressPathway:TNF/Stress Related Signaling,h_tcrPathway:T Cell Receptor Signaling Pathway,h_tidPathway:Chaperones modulate interferon Signaling Pathway,h_tnfr2Pathway:TNFR2 Signaling Pathway,h_tollPathway:Toll-Like Receptor Pathway,h_vipPathway:Neuropeptides VIP and PACAP inhibit the apoptosis of activated T cells,	GO:0006606~protein import into nucleus,GO:0006915~apoptotic process,GO:0007219~Notch signaling pathway,GO:0007249~I-kappaB kinase/NF-kappaB signaling,GO:0007253~cytoplasmic sequestering of NF-kappaB,GO:0010745~negative regulation of macrophage derived foam cell differentiation,GO:0010875~positive regulation of cholesterol efflux,GO:0010888~negative regulation of lipid storage,GO:0031663~lipopolysaccharide-mediated signaling pathway,GO:0032088~negative regulation of NF-kappaB transcription factor activity,GO:0032495~response to muramyl dipeptide,GO:0033209~tumor necrosis factor-mediated signaling pathway,GO:0034142~toll-like receptor 4 signaling pathway,GO:0035994~response to muscle stretch,GO:0038061~NIK/NF-kappaB signaling,GO:0042127~regulation of cell proliferation,GO:0043124~negative regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043330~response to exogenous dsRNA,GO:0045638~negative regulation of myeloid cell differentiation,GO:0045746~negative regulation of Notch signaling pathway,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0050729~positive regulation of inflammatory response,GO:0050853~B cell receptor signaling pathway,GO:0051247~positive regulation of protein metabolic process,GO:0060261~positive regulation of transcription initiation from RNA polymerase II promoter,GO:0070417~cellular response to cold,GO:0070427~nucleotide-binding oligomerization domain containing 1 signaling pathway,GO:0070431~nucleotide-binding oligomerization domain containing 2 signaling pathway,GO:0070498~interleukin-1-mediated signaling pathway,GO:0071356~cellular response to tumor necrosis factor,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0033256~I-kappaB/NF-kappaB complex,	GO:0005515~protein binding,GO:0008139~nuclear localization sequence binding,GO:0019899~enzyme binding,GO:0031625~ubiquitin protein ligase binding,GO:0042802~identical protein binding,GO:0051059~NF-kappaB binding,	IPR002110:Ankyrin_rpt,IPR036770:Ankyrin_rpt-contain_sf,	hsa04024:cAMP signaling pathway,hsa04062:Chemokine signaling pathway,hsa04064:NF-kappa B signaling pathway,hsa04210:Apoptosis,hsa04380:Osteoclast differentiation,hsa04620:Toll-like receptor signaling pathway,hsa04621:NOD-like receptor signaling pathway,hsa04622:RIG-I-like receptor signaling pathway,hsa04623:Cytosolic DNA-sensing pathway,hsa04625:C-type lectin receptor signaling pathway,hsa04657:IL-17 signaling pathway,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04660:T cell receptor signaling pathway,hsa04662:B cell receptor signaling pathway,hsa04668:TNF signaling pathway,hsa04722:Neurotrophin signaling pathway,hsa04920:Adipocytokine signaling pathway,hsa04926:Relaxin signaling pathway,hsa04931:Insulin resistance,hsa04936:Alcoholic liver disease,hsa05120:Epithelial cell signaling in Helicobacter pylori infection,hsa05130:Pathogenic Escherichia coli infection,hsa05131:Shigellosis,hsa05132:Salmonella infection,hsa05134:Legionellosis,hsa05135:Yersinia infection,hsa05140:Leishmaniasis,hsa05142:Chagas disease,hsa05145:Toxoplasmosis,hsa05160:Hepatitis C,hsa05161:Hepatitis B,hsa05162:Measles,hsa05163:Human cytomegalovirus infection,hsa05164:Influenza A,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05171:Coronavirus disease - COVID-19,hsa05200:Pathways in cancer,hsa05203:Viral carcinogenesis,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05215:Prostate cancer,hsa05220:Chronic myeloid leukemia,hsa05222:Small cell lung cancer,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,hsa05417:Lipid and atherosclerosis,	612132~Ectodermal dysplasia and immunodeficiency 2,		SM00248:ANK,	KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0038~Ectodermal dysplasia,KW-0225~Disease variant,	KW-0040~ANK repeat,KW-0677~Repeat,			KW-0379~Hydroxylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin); alternate,MOTIF:Destruction motif,MOTIF:Nuclear export signal,MOTIF:Nuclear import signal,MUTAGEN:D->A: Loss in phosphorylation; when associated with A-31.,MUTAGEN:D->A: Loss of phosphorylation; when associated with A-35.,MUTAGEN:D->G: No change neither in phosphorylation, nor on degradation.,MUTAGEN:K->R: Little change in Tax-stimulated transactivation. No change in Tax-stimulated transactivation; when associated with R-38.,MUTAGEN:K->R: Little change in Tax-stimulated transactivation. No sumoylation. Greatly reduced Tax- or cytokine-stimulated transactivation and decrease in ubiquitination and degradation; when associated with R-21. Does not affect activation by FK506.,MUTAGEN:K->R: Little change in Tax-stimulated transactivation. No sumoylation. Greatly reduced Tax- or cytokine-stimulated transactivation and decrease in ubiquitination and degradation; when associated with R-22. Does not affect activation by FK506.,MUTAGEN:K->R: No change in Tax-stimulated transactivation. No change in Tax-stimulated transactivation; when associated with R-47.,MUTAGEN:LHLAVI->AHAAVA: Greatly reduced nuclear localization. Great reduction in its ability to inhibit DNA binding of RELA.,MUTAGEN:MVKELQEI->AAKEAQEA: No nuclear export.,MUTAGEN:N->A: Almost abolished ability to inhibit NF-kappa-B DNA-binding activity; when associated with A-210.,MUTAGEN:N->A: Almost abolished ability to inhibit NF-kappa-B DNA-binding activity; when associated with A-244.,MUTAGEN:S->A: Loss of phosphorylation, ubiquitination and degradation; when associated with A-36. Abolished activation by FK506.,MUTAGEN:S->A: Loss of phosphorylation, ubiquitination, and degradation; when associated with A-32. Does not affect activation by FK506.,MUTAGEN:S->A: No inducible ubiquitination nor protein degradation.,MUTAGEN:S->E: Mimics phosphorylation; promoting ubiquitination and degradation; when associated with E-32.,MUTAGEN:S->E: Mimics phosphorylation; promoting ubiquitination and degradation; when associated with E-36.,MUTAGEN:S->T: Decrease in phosphorylation and degradation; when associated with T-32.,MUTAGEN:S->T: Decrease in phosphorylation and degradation; when associated with T-36.,MUTAGEN:T->A: No inducible ubiquitination nor protein degradation.,MUTAGEN:Y->F: No phosphorylation.,REGION:Disordered,REPEAT:ANK,REPEAT:ANK 1,REPEAT:ANK 2,REPEAT:ANK 3,REPEAT:ANK 4,REPEAT:ANK 5,
NFKBIB	NFKB inhibitor beta(NFKBIB)	Homo sapiens		h_p53hypoxiaPathway:Hypoxia and p53 in the Cardiovascular system,	GO:0006351~transcription, DNA-templated,GO:0006954~inflammatory response,GO:0007165~signal transduction,GO:0043122~regulation of I-kappaB kinase/NF-kappaB signaling,GO:0045893~positive regulation of transcription, DNA-templated,GO:0071222~cellular response to lipopolysaccharide,	GO:0005634~nucleus,GO:0005829~cytosol,	GO:0003713~transcription coactivator activity,GO:0005515~protein binding,	IPR002110:Ankyrin_rpt,IPR036770:Ankyrin_rpt-contain_sf,	hsa04062:Chemokine signaling pathway,hsa04621:NOD-like receptor signaling pathway,hsa04622:RIG-I-like receptor signaling pathway,hsa04623:Cytosolic DNA-sensing pathway,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04660:T cell receptor signaling pathway,hsa04662:B cell receptor signaling pathway,hsa04722:Neurotrophin signaling pathway,hsa04920:Adipocytokine signaling pathway,hsa05130:Pathogenic Escherichia coli infection,hsa05131:Shigellosis,hsa05140:Leishmaniasis,hsa05145:Toxoplasmosis,hsa05162:Measles,hsa05164:Influenza A,hsa05169:Epstein-Barr virus infection,hsa05171:Coronavirus disease - COVID-19,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,			SM00248:ANK,		KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0040~ANK repeat,KW-0677~Repeat,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,MUTAGEN:S->A: No degradation; when associated with A-19.,MUTAGEN:S->A: No degradation; when associated with A-23.,REGION:Disordered,REPEAT:ANK,REPEAT:ANK 1,REPEAT:ANK 2,REPEAT:ANK 3,REPEAT:ANK 4,REPEAT:ANK 5,REPEAT:ANK 6,
NFU1	NFU1 iron-sulfur cluster scaffold(NFU1)	Homo sapiens			GO:0016226~iron-sulfur cluster assembly,GO:0097428~protein maturation by iron-sulfur cluster transfer,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,	GO:0005506~iron ion binding,GO:0005515~protein binding,GO:0051536~iron-sulfur cluster binding,GO:0051539~4 iron, 4 sulfur cluster binding,	IPR001075:NIF_FeS_clus_asmbl_NifU_C,IPR014824:Nfu/NifU_N,IPR034904:FSCA_dom_sf,IPR035433:NFU1-like,IPR036498:Nfu/NifU_N_sf,		605711~Multiple mitochondrial dysfunctions syndrome 1,	PIRSF036773:HIRIP5,	SM00932:Nfu_N,		KW-0496~Mitochondrion,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-1274~Primary mitochondrial disease,	KW-0809~Transit peptide,	KW-0408~Iron,KW-0411~Iron-sulfur,KW-0479~Metal-binding,			DOMAIN:NIF system FeS cluster assembly NifU C-terminal,MUTAGEN:G->A: Alters protein structure. Increases likelihood of existing as monomer. Decreases ability to receive a Fe/S clusters from donor proteins. Decreases delivery rates of [2Fe-2S] cluster to target proteins.,MUTAGEN:G->K: Alters protein structure. Increases likelihood of existing as monomer. Decreases ability to receive a Fe/S clusters from donor proteins. Decreases delivery rates of [2Fe-2S] cluster to target proteins.,REGION:Disordered,REGION:NifU,TRANSIT:Mitochondrion,
NHP2	NHP2 ribonucleoprotein(NHP2)	Homo sapiens			GO:0000470~maturation of LSU-rRNA,GO:0007004~telomere maintenance via telomerase,GO:0031118~rRNA pseudouridine synthesis,GO:0031120~snRNA pseudouridine synthesis,GO:1904874~positive regulation of telomerase RNA localization to Cajal body,	GO:0000781~chromosome, telomeric region,GO:0005654~nucleoplasm,GO:0005697~telomerase holoenzyme complex,GO:0005730~nucleolus,GO:0005732~small nucleolar ribonucleoprotein complex,GO:0022625~cytosolic large ribosomal subunit,GO:0031429~box H/ACA snoRNP complex,GO:0072589~box H/ACA scaRNP complex,GO:0090661~box H/ACA telomerase RNP complex,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0034513~box H/ACA snoRNA binding,GO:0070034~telomerase RNA binding,	IPR002415:H/ACA_rnp_Nhp2-like,IPR004038:Ribosomal_eL8/eL30/eS12/Gad45,IPR018492:Ribosomal_eL8/Nhp2,IPR029064:Ribosomal_eL30-like_sf,	hsa03008:Ribosome biogenesis in eukaryotes,	613987~Dyskeratosis congenita, autosomal recessive 2,			KW-0690~Ribosome biogenesis,KW-0698~rRNA processing,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-1011~Dyskeratosis congenita,			KW-0687~Ribonucleoprotein,KW-0694~RNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:Ribosomal protein eL8/eL30/eS12/Gadd45,
NEK7	NIMA related kinase 7(NEK7)	Homo sapiens			GO:0006468~protein phosphorylation,GO:0007346~regulation of mitotic cell cycle,GO:0016310~phosphorylation,GO:0018105~peptidyl-serine phosphorylation,GO:0032212~positive regulation of telomere maintenance via telomerase,GO:0035865~cellular response to potassium ion,GO:0051225~spindle assembly,GO:0051973~positive regulation of telomerase activity,GO:1900227~positive regulation of NLRP3 inflammasome complex assembly,GO:1904355~positive regulation of telomere capping,	GO:0000922~spindle pole,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005815~microtubule organizing center,GO:0005874~microtubule,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0046872~metal ion binding,	IPR000719:Prot_kinase_dom,IPR001245:Ser-Thr/Tyr_kinase_cat_dom,IPR008271:Ser/Thr_kinase_AS,IPR011009:Kinase-like_dom_sf,IPR017441:Protein_kinase_ATP_BS,	hsa04621:NOD-like receptor signaling pathway,		PIRSF000654:Integrin-linked_kinase,	SM00220:S_TKc,		KW-0206~Cytoskeleton,KW-0493~Microtubule,KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,DOMAIN:Protein kinase,MUTAGEN:D->A: Does not affect interaction with NEK9.,MUTAGEN:D->R: Does not affect interaction with NLRP3.,MUTAGEN:E->V,R: Does not affect interaction with NLRP3.,MUTAGEN:H->A: Does not affect interaction with NEK9.,MUTAGEN:I->F: Does not affect interaction with NEK9.,MUTAGEN:K->A,E: Does not affect interaction with NEK9.,MUTAGEN:K->E: Does not affect interaction with NLRP3.,MUTAGEN:K->E: Strongly increased protein kinase activity.,MUTAGEN:L->A: Significant decrease in catalytic activity; when associated with A-28.,MUTAGEN:L->D: Abolished interaction with NEK9 and subsequent activation of NEK7 kinase activity.,MUTAGEN:L->W: Does not affect interaction with NEK9.,MUTAGEN:M->A,R: Decreased interaction with NEK9 and subsequent activation of NEK7 kinase activity.,MUTAGEN:N->A: Reduced protein kinase activity.,MUTAGEN:N->D: Significant decrease in catalytic activity.,MUTAGEN:N->R,K: Strongly reduced protein kinase activity.,MUTAGEN:Q->R: Decreased interaction with NLRP3.,MUTAGEN:R->A,D: Abolished interaction with NEK9 and subsequent activation of NEK7 kinase activity.,MUTAGEN:R->E: Decreased interaction with NLRP3.,MUTAGEN:R->E: Does not affect interaction with NLRP3.,MUTAGEN:R->E: Strongly reduced protein kinase activity.,MUTAGEN:S->A: Abolished phosphorylation with NEK9 and protein kinase activity.,MUTAGEN:SD->AR: Decreased interaction with NLRP3.,MUTAGEN:SDHYSE->ARHYSR: Decreased interaction with NLRP3.,MUTAGEN:T->A: Does not affect interaction with NEK9.,MUTAGEN:Y->A: 5-fold increase in catalytic activity.,MUTAGEN:Y->A: Significant decrease in catalytic activity; when associated with A-31.,MUTAGEN:Y->F,L: Moderate increase in catalytic activity.,REGION:Disordered,REGION:NTE motif,SITE:Autoinhibitory,
NOB1	NIN1 (RPN12) binding protein 1 homolog(NOB1)	Homo sapiens			GO:0006364~rRNA processing,GO:0007601~visual perception,GO:0030490~maturation of SSU-rRNA,GO:0042274~ribosomal small subunit biogenesis,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0030688~preribosome, small subunit precursor,	GO:0004518~nuclease activity,GO:0004521~endoribonuclease activity,GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR002716:PIN_dom,IPR014881:NOB1_Zn-bd,IPR017117:Nob1_euk,IPR033411:Ribonuclease_PIN,IPR033461:WRNPLPNID,IPR036283:NOB1_Zf-like_sf,IPR039907:NOB1,	hsa03008:Ribosome biogenesis in eukaryotes,		PIRSF037125:D-site_20S_pre-rRNA_nuclease,	SM00670:PINc,		KW-0539~Nucleus,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0255~Endonuclease,KW-0378~Hydrolase,KW-0540~Nuclease,	KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,DOMAIN:PIN,DOMAIN:PINc,DOMAIN:Ribonuclease PIN,REGION:Disordered,ZN_FING:NOB1,
NIPA2	NIPA magnesium transporter 2(NIPA2)	Homo sapiens			GO:0015693~magnesium ion transport,GO:1903830~magnesium ion transmembrane transport,	GO:0005769~early endosome,GO:0005886~plasma membrane,GO:0016020~membrane,	GO:0015095~magnesium ion transmembrane transporter activity,	IPR008521:Mg_trans_NIPA,					KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,KW-0967~Endosome,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0460~Magnesium,			TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
NME2	NME/NM23 nucleoside diphosphate kinase 2(NME2)	Homo sapiens		h_ndkDynaminPathway:Endocytotic role of NDK, Phosphins and Dynamin,	GO:0002762~negative regulation of myeloid leukocyte differentiation,GO:0006183~GTP biosynthetic process,GO:0006228~UTP biosynthetic process,GO:0006241~CTP biosynthetic process,GO:0007155~cell adhesion,GO:0007189~adenylate cyclase-activating G-protein coupled receptor signaling pathway,GO:0007229~integrin-mediated signaling pathway,GO:0009142~nucleoside triphosphate biosynthetic process,GO:0010976~positive regulation of neuron projection development,GO:0016310~phosphorylation,GO:0034599~cellular response to oxidative stress,GO:0042981~regulation of apoptotic process,GO:0043066~negative regulation of apoptotic process,GO:0045618~positive regulation of keratinocyte differentiation,GO:0045682~regulation of epidermis development,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0050679~positive regulation of epithelial cell proliferation,GO:0060416~response to growth hormone,GO:0071333~cellular response to glucose stimulus,GO:0071398~cellular response to fatty acid,	GO:0001726~ruffle,GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005882~intermediate filament,GO:0030027~lamellipodium,GO:0031966~mitochondrial membrane,GO:0034774~secretory granule lumen,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,GO:0071944~cell periphery,GO:1904813~ficolin-1-rich granule lumen,	GO:0003677~DNA binding,GO:0003713~transcription coactivator activity,GO:0004550~nucleoside diphosphate kinase activity,GO:0004673~protein histidine kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0005504~fatty acid binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0019003~GDP binding,GO:0019215~intermediate filament binding,GO:0019899~enzyme binding,GO:0042802~identical protein binding,GO:0046872~metal ion binding,GO:0051880~G-quadruplex DNA binding,	IPR001564:Nucleoside_diP_kinase,IPR023005:Nucleoside_diP_kinase_AS,IPR034907:NDK-like_dom,IPR036850:NDK-like_dom_sf,	hsa00230:Purine metabolism,hsa00240:Pyrimidine metabolism,hsa00983:Drug metabolism - other enzymes,hsa01100:Metabolic pathways,hsa01232:Nucleotide metabolism,hsa01240:Biosynthesis of cofactors,			SM00562:NDK,	KW-0546~Nucleotide metabolism,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0966~Cell projection,			KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0010~Activator,KW-0238~DNA-binding,KW-0418~Kinase,KW-0808~Transferase,		ACT_SITE:Pros-phosphohistidine intermediate,DOMAIN:Nucleoside diphosphate kinase-like,MUTAGEN:R->A: Decreased single-stranded DNA-binding and nucleotide-binding activity. No effect on 3D-structure.,REGION:Interaction with AKAP13,
NME3	NME/NM23 nucleoside diphosphate kinase 3(NME3)	Homo sapiens			GO:0006183~GTP biosynthetic process,GO:0006228~UTP biosynthetic process,GO:0006241~CTP biosynthetic process,GO:0006281~DNA repair,GO:0006915~apoptotic process,GO:0008053~mitochondrial fusion,GO:0009142~nucleoside triphosphate biosynthetic process,GO:0016310~phosphorylation,	GO:0005737~cytoplasm,GO:0005741~mitochondrial outer membrane,GO:0005829~cytosol,GO:0036064~ciliary basal body,	GO:0004550~nucleoside diphosphate kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0046872~metal ion binding,	IPR001564:Nucleoside_diP_kinase,IPR023005:Nucleoside_diP_kinase_AS,IPR034907:NDK-like_dom,IPR036850:NDK-like_dom_sf,	hsa00230:Purine metabolism,hsa00240:Pyrimidine metabolism,hsa00983:Drug metabolism - other enzymes,hsa01100:Metabolic pathways,hsa01232:Nucleotide metabolism,hsa01240:Biosynthesis of cofactors,			SM00562:NDK,	KW-0053~Apoptosis,KW-0546~Nucleotide metabolism,				KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0808~Transferase,		ACT_SITE:Pros-phosphohistidine intermediate,DOMAIN:Nucleoside diphosphate kinase-like,REGION:Disordered,
NOP16	NOP16 nucleolar protein(NOP16)	Homo sapiens			GO:0042273~ribosomal large subunit biogenesis,	GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0043231~intracellular membrane-bounded organelle,	GO:0003723~RNA binding,	IPR019002:Ribosome_biogenesis_Nop16,						KW-0539~Nucleus,					KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),REGION:Disordered,
NOP56	NOP56 ribonucleoprotein(NOP56)	Homo sapiens			GO:0006364~rRNA processing,GO:0042254~ribosome biogenesis,GO:0042274~ribosomal small subunit biogenesis,	GO:0001650~fibrillar center,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005732~small nucleolar ribonucleoprotein complex,GO:0005737~cytoplasm,GO:0016020~membrane,GO:0031428~box C/D snoRNP complex,GO:0032040~small-subunit processome,GO:0070761~pre-snoRNP complex,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0030515~snoRNA binding,GO:0045296~cadherin binding,GO:1990226~histone methyltransferase binding,	IPR002687:Nop_dom,IPR012974:NOP58/56_N,IPR012976:NOSIC,IPR036070:Nop_dom_sf,IPR042239:Nop_C,IPR045056:Nop56/Nop58,	hsa03008:Ribosome biogenesis in eukaryotes,hsa05017:Spinocerebellar ataxia,	614153~Spinocerebellar ataxia 36,		SM00931:NOSIC,	KW-0690~Ribosome biogenesis,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0523~Neurodegeneration,KW-0950~Spinocerebellar ataxia,	KW-0175~Coiled coil,		KW-0687~Ribonucleoprotein,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:NOSIC,DOMAIN:Nop,REGION:Disordered,
NOP58	NOP58 ribonucleoprotein(NOP58)	Homo sapiens			GO:0006364~rRNA processing,GO:0042274~ribosomal small subunit biogenesis,GO:0048254~snoRNA localization,	GO:0001650~fibrillar center,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005732~small nucleolar ribonucleoprotein complex,GO:0005829~cytosol,GO:0015030~Cajal body,GO:0016020~membrane,GO:0031428~box C/D snoRNP complex,GO:0032040~small-subunit processome,GO:0070761~pre-snoRNP complex,	GO:0001094~TFIID-class transcription factor binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0030515~snoRNA binding,GO:0051117~ATPase binding,	IPR002687:Nop_dom,IPR012974:NOP58/56_N,IPR012976:NOSIC,IPR036070:Nop_dom_sf,IPR042239:Nop_C,IPR045056:Nop56/Nop58,	hsa03008:Ribosome biogenesis in eukaryotes,			SM00931:NOSIC,	KW-0690~Ribosome biogenesis,	KW-0539~Nucleus,				KW-0687~Ribonucleoprotein,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:NOSIC,DOMAIN:Nop,DOMAIN:Nucleolar protein 58/56 N-terminal,MUTAGEN:A->P: Restricted to nucleoplasm. Abolishes interaction with NOPCHAP1.,MUTAGEN:KHAA->AHAR: Restricted to nucleoplasm. Decreases interaction with NOPCHAP1.,REGION:Disordered,REGION:Sufficient for interaction with NOPCHAP1,
NPC2	NPC intracellular cholesterol transporter 2(NPC2)	Homo sapiens			GO:0008203~cholesterol metabolic process,GO:0009615~response to virus,GO:0010467~gene expression,GO:0010878~cholesterol storage,GO:0015914~phospholipid transport,GO:0016125~sterol metabolic process,GO:0019747~regulation of isoprenoid metabolic process,GO:0030301~cholesterol transport,GO:0032366~intracellular sterol transport,GO:0032367~intracellular cholesterol transport,GO:0033344~cholesterol efflux,GO:0042632~cholesterol homeostasis,GO:0046836~glycolipid transport,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005764~lysosome,GO:0005783~endoplasmic reticulum,GO:0035578~azurophil granule lumen,GO:0043202~lysosomal lumen,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0015485~cholesterol binding,GO:0019899~enzyme binding,GO:0032934~sterol binding,	IPR003172:ML_dom,IPR014756:Ig_E-set,IPR033916:ML_Npc2-like,IPR039670:NPC2-like,	hsa04142:Lysosome,hsa04979:Cholesterol metabolism,	607625~Niemann-pick disease, type C2,		SM00737:ML,	KW-0153~Cholesterol metabolism,KW-0443~Lipid metabolism,KW-0445~Lipid transport,KW-0753~Steroid metabolism,KW-0813~Transport,KW-1207~Sterol metabolism,	KW-0256~Endoplasmic reticulum,KW-0458~Lysosome,KW-0964~Secreted,	KW-0225~Disease variant,KW-1054~Niemann-Pick disease,	KW-0732~Signal,			KW-0007~Acetylation,KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:MD-2-related lipid-recognition,
NSMCE1	NSE1 homolog, SMC5-SMC6 complex component(NSMCE1)	Homo sapiens			GO:0000724~double-strand break repair via homologous recombination,GO:0006281~DNA repair,GO:0006310~DNA recombination,GO:0006974~cellular response to DNA damage stimulus,GO:0016925~protein sumoylation,GO:0032204~regulation of telomere maintenance,	GO:0000781~chromosome, telomeric region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0030915~Smc5-Smc6 complex,GO:0043231~intracellular membrane-bounded organelle,	GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0046872~metal ion binding,GO:0046983~protein dimerization activity,GO:0061630~ubiquitin protein ligase activity,	IPR001841:Znf_RING,IPR002219:PE/DAG-bd,IPR011513:Nse1,IPR013083:Znf_RING/FYVE/PHD,IPR014857:Nse1_RING_C4HC3-type,IPR036388:WH-like_DNA-bd_sf,					KW-0227~DNA damage,KW-0233~DNA recombination,KW-0234~DNA repair,KW-0833~Ubl conjugation pathway,	KW-0158~Chromosome,KW-0539~Nucleus,KW-0779~Telomere,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0808~Transferase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	DOMAIN:Phorbol-ester/DAG-type,DOMAIN:RING-type,REGION:Disordered,REGION:Interaction with NSMCE3,ZN_FING:RING-type; atypical,
NSMCE3	NSE3 homolog, SMC5-SMC6 complex component(NSMCE3)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0000724~double-strand break repair via homologous recombination,GO:0006281~DNA repair,GO:0016925~protein sumoylation,GO:0031398~positive regulation of protein ubiquitination,GO:0032204~regulation of telomere maintenance,GO:0034644~cellular response to UV,GO:0071478~cellular response to radiation,GO:0072711~cellular response to hydroxyurea,	GO:0000781~chromosome, telomeric region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0030915~Smc5-Smc6 complex,	GO:0005515~protein binding,GO:0046983~protein dimerization activity,	IPR002190:MHD_dom,IPR037445:MAGE,IPR041898:MAGE_WH1,IPR041899:MAGE_WH2,		617241~Lung disease, immunodeficiency, and chromosome breakage syndrome,		SM01373:MAGE,	KW-0227~DNA damage,KW-0233~DNA recombination,KW-0234~DNA repair,KW-0341~Growth regulation,KW-0833~Ubl conjugation pathway,	KW-0158~Chromosome,KW-0539~Nucleus,KW-0779~Telomere,KW-0963~Cytoplasm,	KW-0225~Disease variant,			KW-0825~Tumor antigen,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:MAGE,MUTAGEN:F->A: Abolishes interaction with EID3.,MUTAGEN:I->A: Abolishes interaction with EID3.,MUTAGEN:L->A: Abolishes interaction with EID3.,MUTAGEN:LL->AA: Decreases interaction with NSMCE1, no effect on interaction with NSMCE4A, abolishes in vitro promotion of NSMCE1 ubiquitin ligase activity.,MUTAGEN:M->A: Abolishes interaction with EID3.,MUTAGEN:V->A: Abolishes interaction with EID3.,REGION:Disordered,REGION:Interaction with NSMCE1,
NAPA	NSF attachment protein alpha(NAPA)	Homo sapiens			GO:0006886~intracellular protein transport,GO:0006891~intra-Golgi vesicle-mediated transport,GO:0007420~brain development,GO:0010807~regulation of synaptic vesicle priming,GO:0016082~synaptic vesicle priming,GO:0016192~vesicle-mediated transport,GO:0030182~neuron differentiation,GO:0035249~synaptic transmission, glutamatergic,GO:0035494~SNARE complex disassembly,GO:0045176~apical protein localization,GO:0061025~membrane fusion,	GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0070044~synaptobrevin 2-SNAP-25-syntaxin-1a complex,GO:0070062~extracellular exosome,GO:0098793~presynapse,GO:0098978~glutamatergic synapse,	GO:0000149~SNARE binding,GO:0005483~soluble NSF attachment protein activity,GO:0005515~protein binding,GO:0019905~syntaxin binding,GO:0044877~macromolecular complex binding,	IPR000744:NSF_attach,IPR011990:TPR-like_helical_dom_sf,	hsa04721:Synaptic vesicle cycle,				KW-0653~Protein transport,KW-0813~Transport,KW-0931~ER-Golgi transport,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	MUTAGEN:K->A: Does not affect interaction with GNA12.,MUTAGEN:K->A: Increases interaction with GNA12.,
NSFL1C	NSFL1 cofactor(NSFL1C)	Homo sapiens			GO:0000045~autophagosome assembly,GO:0000132~establishment of mitotic spindle orientation,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0007030~Golgi organization,GO:0031468~nuclear envelope reassembly,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0046604~positive regulation of mitotic centrosome separation,GO:0061025~membrane fusion,GO:1904780~negative regulation of protein localization to centrosome,	GO:0005634~nucleus,GO:0005694~chromosome,GO:0005737~cytoplasm,GO:0005795~Golgi stack,GO:0005813~centrosome,GO:0005829~cytosol,GO:1990730~VCP-NSFL1C complex,	GO:0005515~protein binding,GO:0008289~lipid binding,GO:0043130~ubiquitin binding,	IPR001012:UBX_dom,IPR009060:UBA-like_sf,IPR012989:SEP_domain,IPR029071:Ubiquitin-like_domsf,IPR036241:NSFL1C_SEP_dom_sf,	hsa04141:Protein processing in endoplasmic reticulum,			SM00166:UBX,SM00553:SEP,		KW-0158~Chromosome,KW-0206~Cytoskeleton,KW-0333~Golgi apparatus,KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0446~Lipid-binding,		KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:SEP,DOMAIN:UBX,MOTIF:Nuclear localization signal,REGION:Disordered,
NUBP2	NUBP iron-sulfur cluster assembly factor 2, cytosolic(NUBP2)	Homo sapiens			GO:0016226~iron-sulfur cluster assembly,GO:0030030~cell projection organization,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005814~centriole,GO:0005829~cytosol,GO:0005929~cilium,GO:0031616~spindle pole centrosome,	GO:0000166~nucleotide binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0046872~metal ion binding,GO:0051536~iron-sulfur cluster binding,GO:0051539~4 iron, 4 sulfur cluster binding,	IPR000808:Mrp-like_CS,IPR019591:Mrp/NBP35_ATP-bd,IPR027417:P-loop_NTPase,IPR028600:NUBP2/Cfd1_eukaryotes,IPR033756:YlxH/NBP35,					KW-0970~Cilium biogenesis/degradation,	KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-0969~Cilium,			KW-0004~4Fe-4S,KW-0067~ATP-binding,KW-0408~Iron,KW-0411~Iron-sulfur,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,		KW-0007~Acetylation,	REGION:Disordered,
NUTM2B-AS1	NUTM2B antisense RNA 1(NUTM2B-AS1)	Homo sapiens								618637~Oculopharyngeal myopathy with leukoencephalopathy 1,
NUDCD2	NudC domain containing 2(NUDCD2)	Homo sapiens			GO:0006457~protein folding,	GO:0000776~kinetochore,GO:0000922~spindle pole,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005829~cytosol,GO:0015630~microtubule cytoskeleton,GO:0045171~intercellular bridge,GO:0072686~mitotic spindle,	GO:0005515~protein binding,GO:0051082~unfolded protein binding,	IPR007052:CS_dom,IPR008978:HSP20-like_chaperone,IPR037898:NudC_fam,IPR037902:p23_NUDCD2,						KW-0137~Centromere,KW-0158~Chromosome,KW-0206~Cytoskeleton,KW-0963~Cytoplasm,KW-0995~Kinetochore,					KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:CS,REGION:Disordered,
OGT	O-linked N-acetylglucosamine (GlcNAc) transferase(OGT)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0000423~macromitophagy,GO:0000432~positive regulation of transcription from RNA polymerase II promoter by glucose,GO:0006110~regulation of glycolytic process,GO:0006111~regulation of gluconeogenesis,GO:0006325~chromatin organization,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006493~protein O-linked glycosylation,GO:0006915~apoptotic process,GO:0007165~signal transduction,GO:0007584~response to nutrient,GO:0016485~protein processing,GO:0030097~hemopoiesis,GO:0030336~negative regulation of cell migration,GO:0030512~negative regulation of transforming growth factor beta receptor signaling pathway,GO:0031397~negative regulation of protein ubiquitination,GO:0032435~negative regulation of proteasomal ubiquitin-dependent protein catabolic process,GO:0032868~response to insulin,GO:0032922~circadian regulation of gene expression,GO:0035020~regulation of Rac protein signal transduction,GO:0045727~positive regulation of translation,GO:0045862~positive regulation of proteolysis,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046626~regulation of insulin receptor signaling pathway,GO:0046889~positive regulation of lipid biosynthetic process,GO:0048511~rhythmic process,GO:0051571~positive regulation of histone H3-K4 methylation,GO:0051963~regulation of synapse assembly,GO:0060544~regulation of necroptotic process,GO:0071333~cellular response to glucose stimulus,GO:1902455~negative regulation of stem cell population maintenance,GO:1902459~positive regulation of stem cell population maintenance,GO:1904263~positive regulation of TORC1 signaling,	GO:0000123~histone acetyltransferase complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016580~Sin3 complex,GO:0017122~protein N-acetylglucosaminyltransferase complex,GO:0031966~mitochondrial membrane,GO:0032991~macromolecular complex,GO:0042995~cell projection,GO:0044545~NSL complex,GO:0098978~glutamatergic synapse,	GO:0005515~protein binding,GO:0005547~phosphatidylinositol-3,4,5-trisphosphate binding,GO:0008375~acetylglucosaminyltransferase activity,GO:0016757~transferase activity, transferring glycosyl groups,GO:0031490~chromatin DNA binding,GO:0097363~protein O-GlcNAc transferase activity,	IPR001440:TPR_1,IPR011990:TPR-like_helical_dom_sf,IPR019734:TPR_repeat,IPR029489:OGT/SEC/SPY_C,IPR037919:OGT,	hsa00514:Other types of O-glycan biosynthesis,hsa03083:Polycomb repressive complex,hsa04931:Insulin resistance,	300997~Intellectual developmental disorder, X-linked 106,		SM00028:TPR,	KW-0053~Apoptosis,KW-0090~Biological rhythms,KW-0833~Ubl conjugation pathway,KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0991~Intellectual disability,	KW-0677~Repeat,KW-0802~TPR repeat,	KW-0446~Lipid-binding,	KW-0156~Chromatin regulator,KW-0328~Glycosyltransferase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	ACT_SITE:Proton acceptor,CARBOHYD:O-linked (GlcNAc) serine,CARBOHYD:O-linked (GlcNAc) serine; alternate,CARBOHYD:O-linked (GlcNAc) serine; by autocatalysis,CARBOHYD:O-linked (GlcNAc) threonine,DOMAIN:O-GlcNAc transferase C-terminal,MOTIF:DFP motif,MOTIF:Nuclear localization signal,MUTAGEN:DFP->AAA: Impaired localization to the nucleus.,MUTAGEN:H->A: Loss of enzyme activity.,MUTAGEN:H->A: Loss of enzyme activity. Moderate increase in KMT2E ubiquitination. Moderate increase in KMT2E ubiquitination; when associated with A-508.,MUTAGEN:H->A: Reduces enzyme activity by about 95%. Moderate increase in KMT2E ubiquitination; when associated with A-508.,MUTAGEN:H->A: Reduces enzyme activity by over 90%.,MUTAGEN:I->D: Abolishes homodimerization of the TPR domain. Slightly reduced enzyme activity; when associated with E-208.,MUTAGEN:S->A: Does not affect global auto-O-GlcNAcylation.,MUTAGEN:S->A: Increased auto-O-GlcNAcylation.,MUTAGEN:S->A: Reduced autoglycosylation.,MUTAGEN:S->A: Reduced autoglycosylation. Reduced localization to the nucleus.,MUTAGEN:T->A: Abolished phosphorylation by AMPK. Does not affect ability to regulate mTORC1.,MUTAGEN:T->A: Decreased auto-O-GlcNAcylation.,MUTAGEN:T->A: Does not affect global auto-O-GlcNAcylation.,MUTAGEN:T->E: Affects substrate selectivity. Mimics phosphorylation; does not affect ability to regulate mTORC1.,MUTAGEN:T->V: Reduced autoglycosylation.,MUTAGEN:W->E: Abolishes homodimerization of the TPR domain. Slightly reduced enzyme activity; when associated with D-211.,MUTAGEN:WLAI->ELAD: Abolished homooligomerization.,REGION:Required for phosphatidylinositol 3,4,5-triphosphate binding,REPEAT:TPR,REPEAT:TPR 1,REPEAT:TPR 10,REPEAT:TPR 11,REPEAT:TPR 12,REPEAT:TPR 13; truncated,REPEAT:TPR 2,REPEAT:TPR 3,REPEAT:TPR 4,REPEAT:TPR 5,REPEAT:TPR 6,REPEAT:TPR 7,REPEAT:TPR 8,REPEAT:TPR 9,
OSGEP	O-sialoglycoprotein endopeptidase(OSGEP)	Homo sapiens			GO:0002949~tRNA threonylcarbamoyladenosine modification,GO:0006400~tRNA modification,GO:0070525~tRNA threonylcarbamoyladenosine metabolic process,	GO:0000408~EKC/KEOPS complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0005515~protein binding,GO:0046872~metal ion binding,GO:0061711~N(6)-L-threonylcarbamoyladenine synthase,	IPR000905:Gcp-like_dom,IPR017860:Peptidase_M22_CS,IPR017861:KAE1/TsaD,IPR034680:Kae1_archaea_euk,IPR043129:ATPase_NBD,		617729~Galloway-Mowat syndrome 3,			KW-0819~tRNA processing,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0887~Epilepsy,KW-0991~Intellectual disability,		KW-0479~Metal-binding,	KW-0012~Acyltransferase,KW-0808~Transferase,		DOMAIN:Gcp-like,
OCIAD1	OCIA domain containing 1(OCIAD1)	Homo sapiens			GO:0006897~endocytosis,GO:0046427~positive regulation of JAK-STAT cascade,GO:0061484~hematopoietic stem cell homeostasis,GO:2000736~regulation of stem cell differentiation,	GO:0005764~lysosome,GO:0005768~endosome,GO:0005794~Golgi apparatus,GO:0016020~membrane,	GO:0005515~protein binding,	IPR009764:OCIA_dom,IPR040187:OCAD1/2,						KW-0967~Endosome,					KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:OCIA,REGION:Disordered,
OCIAD2	OCIA domain containing 2(OCIAD2)	Homo sapiens			GO:0006897~endocytosis,GO:0009617~response to bacterium,GO:0046427~positive regulation of JAK-STAT cascade,GO:0061484~hematopoietic stem cell homeostasis,	GO:0005764~lysosome,GO:0005768~endosome,GO:0005794~Golgi apparatus,		IPR009764:OCIA_dom,IPR040187:OCAD1/2,						KW-0967~Endosome,					KW-0007~Acetylation,	DOMAIN:OCIA,REGION:Disordered,
OFD1	OFD1 centriole and centriolar satellite protein(OFD1)	Homo sapiens			GO:0060271~cilium assembly,GO:0060287~epithelial cilium movement involved in determination of left/right asymmetry,	GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005813~centrosome,GO:0005814~centriole,GO:0005829~cytosol,GO:0005929~cilium,GO:0015630~microtubule cytoskeleton,GO:0016020~membrane,GO:0031514~motile cilium,GO:0034451~centriolar satellite,GO:0036064~ciliary basal body,	GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0043014~alpha-tubulin binding,GO:0043015~gamma-tubulin binding,GO:0060090~binding, bridging,	IPR006594:LisH,		300209~Simpson-Golabi-Behmel syndrome, type 2,300424~Retinitis pigmentosa 23,300804~Joubert syndrome 10,311200~Orofaciodigital syndrome I,		SM00667:LisH,	KW-0970~Cilium biogenesis/degradation,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-0969~Cilium,	KW-0225~Disease variant,KW-0682~Retinitis pigmentosa,KW-0979~Joubert syndrome,KW-1186~Ciliopathy,	KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:LisH,MUTAGEN:E->G: Increased protein stability.,MUTAGEN:S->A: Loss of phosphorylation by PKA. Loss of cAMP-dependent interaction with TBC1D31. Loss of ubiquitin-mediated proteasomal degradation. Loss of function in cilium assembly. Dominant negative effect.,REGION:Disordered,REGION:Mediates homooligomerization,REGION:Mediates the interaction with SDCCAG8,TRANSMEM:Helical,
ORMDL1	ORMDL sphingolipid biosynthesis regulator 1(ORMDL1)	Homo sapiens			GO:0006672~ceramide metabolic process,GO:0006686~sphingomyelin biosynthetic process,GO:0030148~sphingolipid biosynthetic process,GO:0042552~myelination,GO:0044255~cellular lipid metabolic process,GO:0061744~motor behavior,GO:0090156~cellular sphingolipid homeostasis,GO:1900060~negative regulation of ceramide biosynthetic process,GO:2000303~regulation of ceramide biosynthetic process,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0035339~SPOTS complex,	GO:0005515~protein binding,	IPR007203:ORMDL,			PIRSF018147:ORMDL,			KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
ORMDL2	ORMDL sphingolipid biosynthesis regulator 2(ORMDL2)	Homo sapiens			GO:0006672~ceramide metabolic process,GO:0030148~sphingolipid biosynthetic process,GO:0044255~cellular lipid metabolic process,GO:0090156~cellular sphingolipid homeostasis,GO:1900060~negative regulation of ceramide biosynthetic process,GO:2000303~regulation of ceramide biosynthetic process,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0035339~SPOTS complex,	GO:0005515~protein binding,	IPR007203:ORMDL,			PIRSF018147:ORMDL,			KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
ORMDL3	ORMDL sphingolipid biosynthesis regulator 3(ORMDL3)	Homo sapiens			GO:0002903~negative regulation of B cell apoptotic process,GO:0006672~ceramide metabolic process,GO:0006686~sphingomyelin biosynthetic process,GO:0006940~regulation of smooth muscle contraction,GO:0010508~positive regulation of autophagy,GO:0030148~sphingolipid biosynthetic process,GO:0042552~myelination,GO:0044255~cellular lipid metabolic process,GO:0061744~motor behavior,GO:0090156~cellular sphingolipid homeostasis,GO:1900060~negative regulation of ceramide biosynthetic process,GO:1900182~positive regulation of protein localization to nucleus,GO:2000303~regulation of ceramide biosynthetic process,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0030667~secretory granule membrane,GO:0035339~SPOTS complex,GO:0035579~specific granule membrane,	GO:0005515~protein binding,	IPR007203:ORMDL,			PIRSF018147:ORMDL,			KW-0256~Endoplasmic reticulum,KW-0472~Membrane,	KW-1058~Asthma,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0379~Hydroxylation,KW-0832~Ubl conjugation,	MUTAGEN:F->P: Impaired negative regulation of SPT complex activity in the presence of ceramides.,MUTAGEN:F->R: Impaired negative regulation of SPT complex activity in the presence of ceramides.,MUTAGEN:H->A: No effect on the negative regulation of SPT complex activity in the presence of ceramides.,MUTAGEN:I->R: Impaired negative regulation of SPT complex activity in the presence of ceramides.,MUTAGEN:Missing: Impaired negative regulation of SPT complex activity in the presence of ceramides.,MUTAGEN:N->A: Disrupted ceramide binding; impaired negative regulation of SPT complex activity in the presence of ceramides; in the absence of ceramides, reduced affinity of SPT complex towards palmitoyl-CoA.,MUTAGEN:P->A: Increased protein levels; decreased ubiquitination; increased negative regulation of SPT complex activity.,MUTAGEN:V->R: Impaired negative regulation of SPT complex activity in the presence of ceramides.,REGION:Important for ceramide level-sensing,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
OS9	OS9 endoplasmic reticulum lectin(OS9)	Homo sapiens			GO:0006511~ubiquitin-dependent protein catabolic process,GO:0006605~protein targeting,GO:0006621~protein retention in ER lumen,GO:0016567~protein ubiquitination,GO:0030433~ubiquitin-dependent ERAD pathway,GO:0030968~endoplasmic reticulum unfolded protein response,GO:0030970~retrograde protein transport, ER to cytosol,GO:0034976~response to endoplasmic reticulum stress,GO:0036503~ERAD pathway,GO:1904153~negative regulation of retrograde protein transport, ER to cytosol,	GO:0000836~Hrd1p ubiquitin ligase complex,GO:0005783~endoplasmic reticulum,GO:0005788~endoplasmic reticulum lumen,GO:0005789~endoplasmic reticulum membrane,	GO:0002020~protease binding,GO:0005515~protein binding,GO:0030246~carbohydrate binding,	IPR009011:Man6P_isomerase_rcpt-bd_dom_sf,IPR012913:OS9-like_dom,IPR044865:MRH_dom,IPR045149:OS-9-like,	hsa04141:Protein processing in endoplasmic reticulum,					KW-0256~Endoplasmic reticulum,		KW-0732~Signal,	KW-0430~Lectin,		KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,DOMAIN:MRH,DOMAIN:Protein OS9-like,MUTAGEN:R->A: Loss of glycan-binding activity and partial inhibition of ERAD of the misfolded glycoprotein NHK (PubMed:19346256). Reduced interaction with SEL1L (PubMed:18264092) not confirmed in (PubMed:19346256).,REGION:Disordered,
OTUB1	OTU deubiquitinase, ubiquitin aldehyde binding 1(OTUB1)	Homo sapiens			GO:0002250~adaptive immune response,GO:0006281~DNA repair,GO:0006508~proteolysis,GO:0006974~cellular response to DNA damage stimulus,GO:0016579~protein deubiquitination,GO:0071108~protein K48-linked deubiquitination,GO:1904263~positive regulation of TORC1 signaling,GO:2000780~negative regulation of double-strand break repair,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0004843~thiol-dependent ubiquitin-specific protease activity,GO:0005515~protein binding,GO:0008234~cysteine-type peptidase activity,GO:0019784~NEDD8-specific protease activity,GO:0031625~ubiquitin protein ligase binding,GO:0043130~ubiquitin binding,GO:0055105~ubiquitin-protein transferase inhibitor activity,	IPR003323:OTU_dom,IPR016615:Otubain,IPR019400:Peptidase_C65_otubain,IPR038765:Papain-like_cys_pep_sf,IPR042467:Peptidase_C65_otubain_sub2,IPR042468:Peptidase_C65_otubain_sub1,			PIRSF013503:Ubiquitin_thioesterase_Otubain,		KW-0227~DNA damage,KW-0234~DNA repair,KW-0391~Immunity,KW-0833~Ubl conjugation pathway,KW-1064~Adaptive immunity,	KW-0963~Cytoplasm,				KW-0378~Hydrolase,KW-0645~Protease,KW-0788~Thiol protease,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Nucleophile,COMPBIAS:Polar residues,DOMAIN:OTU,MUTAGEN:A->T: Does not affect ability to inhibit UBE2N/UBC13.,MUTAGEN:C->A: Abolishes only ubiquitin-vinylsulfone adduct formation.,MUTAGEN:C->A: No effect on RNF128.,MUTAGEN:C->A: Prevents RNF128 autoubiquitination, and stabilizes RNF128 in vivo. Abolishes both ubiquitin-binding and adduct formation with ubiquitin-vinylsulfone. Does not affect ability to deubiquitinate RPTOR; when associated with A-88 and A-265.,MUTAGEN:C->S: Abolishes hydrolase activity in vitro. Does not affect ability to inhibit RNF168. Does not affect ability to deubiquitinate DEPTOR. Abolishes ability to inhibit RNF168; when associated with E-88 and A-265.,MUTAGEN:C->S: Does not affect ability to deubiquitinate DEPTOR.,MUTAGEN:D->A: Abolished ability to deubiquitinate DEPTOR. Does not affect ability to deubiquitinate RPTOR; when associated with A-91 and A-265.,MUTAGEN:D->E: Abolishes hydrolase activity in vitro. Abolishes ability to inhibit RNF168; when associated with S-91 and A-265.,MUTAGEN:D->G: Impairs inhibition of UBE2N/UBC13.,MUTAGEN:F->S: Fails to inhibit ubiquitin conjugation by UBE2N/UBC13.,MUTAGEN:H->A: Abolishes ability to inhibit RNF168; when associated with A-88 and S-91. Does not affect ability to deubiquitinate RPTOR; when associated with A-88 and A-91.,MUTAGEN:H->R: Abolishes hydrolase activity in vitro.,MUTAGEN:I->T: Impairs inhibition of UBE2N/UBC13.,MUTAGEN:P->G: Slightly improves ability to cleave 'K63'-linked ubiquitin.,MUTAGEN:P->L: Fails to inhibit ubiquitin conjugation by UBE2N/UBC13.,MUTAGEN:Q->L: Does not affect activity in DNA repair and ability to inhibit UBE2N/UBC13.,MUTAGEN:Q->R: Impairs inhibition of UBE2N/UBC13.,MUTAGEN:R->L: No effect on RNF128.,MUTAGEN:T->R: Impairs inhibition of UBE2N/UBC13.,MUTAGEN:Y->A: Abolished ability to deubiquitinate RPTOR.,MUTAGEN:Y->H: Impairs inhibition of UBE2N/UBC13.,REGION:Disordered,REGION:Free ubiquitin binding,REGION:Ubiquitin-conjugating enzyme E2 binding,SITE:Interacts with free ubiquitin,SITE:Required for proximal ubiquitin-binding,
OVCA2	OVCA2 serine hydrolase domain containing(OVCA2)	Homo sapiens			GO:0032526~response to retinoic acid,	GO:0005634~nucleus,GO:0005737~cytoplasm,	GO:0016787~hydrolase activity,	IPR005645:FSH_dom,IPR029058:AB_hydrolase,										KW-0378~Hydrolase,		ACT_SITE:Charge relay system,REGION:Disordered,
OLA1	Obg like ATPase 1(OLA1)	Homo sapiens			GO:0046034~ATP metabolic process,	GO:0005576~extracellular region,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005829~cytosol,GO:0016020~membrane,GO:0031093~platelet alpha granule lumen,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0005524~ATP binding,GO:0005525~GTP binding,GO:0016887~ATPase activity,GO:0043023~ribosomal large subunit binding,GO:0045296~cadherin binding,GO:0046872~metal ion binding,	IPR004095:TGS,IPR004396:ATPase_YchF/OLA1,IPR006073:GTP-bd,IPR012675:Beta-grasp_dom_sf,IPR012676:TGS-like,IPR013029:YchF_C,IPR023192:TGS-like_dom_sf,IPR027417:P-loop_NTPase,IPR031167:G_OBG,IPR041706:YchF_N,			PIRSF006641:CHP00092,			KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,	KW-0007~Acetylation,	DOMAIN:OBG-type G,DOMAIN:TGS,MOTIF:Nuclear export signal,MUTAGEN:F->A: Loss of ATP-binding.,MUTAGEN:LSE->KSD: Retention of ATP-binding specificity.,MUTAGEN:N->A: Loss of ATP-binding.,REGION:Disordered,
P2RY10	P2Y receptor family member 10(P2RY10)	Homo sapiens			GO:0007200~phospholipase C-activating G-protein coupled receptor signaling pathway,GO:0035025~positive regulation of Rho protein signal transduction,	GO:0005886~plasma membrane,GO:0016020~membrane,	GO:0004930~G-protein coupled receptor activity,	IPR000276:GPCR_Rhodpsn,IPR017452:GPCR_Rhodpsn_7TM,	hsa04080:Neuroactive ligand-receptor interaction,					KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:G-protein coupled receptors family 1 profile,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
PAF1	PAF1 homolog, Paf1/RNA polymerase II complex component(PAF1)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001711~endodermal cell fate commitment,GO:0006368~transcription elongation from RNA polymerase II promoter,GO:0006378~mRNA polyadenylation,GO:0016055~Wnt signaling pathway,GO:0019827~stem cell population maintenance,GO:0031124~mRNA 3'-end processing,GO:0031442~positive regulation of mRNA 3'-end processing,GO:0034504~protein localization to nucleus,GO:0045638~negative regulation of myeloid cell differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0071222~cellular response to lipopolysaccharide,GO:1902808~positive regulation of cell cycle G1/S phase transition,	GO:0001650~fibrillar center,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0016020~membrane,GO:0016593~Cdc73/Paf1 complex,GO:0043231~intracellular membrane-bounded organelle,	GO:0000993~RNA polymerase II core binding,GO:0003682~chromatin binding,GO:0005515~protein binding,	IPR007133:RNA_pol_II-assoc_Paf1,					KW-0804~Transcription,KW-0805~Transcription regulation,KW-0879~Wnt signaling pathway,	KW-0539~Nucleus,	KW-0043~Tumor suppressor,	KW-0175~Coiled coil,			KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),REGION:Disordered,REGION:Interaction with PINT87aa,
PATL1	PAT1 homolog 1, processing body mRNA decay factor(PATL1)	Homo sapiens			GO:0000290~deadenylation-dependent decapping of nuclear-transcribed mRNA,GO:0033962~cytoplasmic mRNA processing body assembly,	GO:0000932~P-body,GO:0005829~cytosol,GO:0016605~PML body,GO:0016607~nuclear speck,GO:0030014~CCR4-NOT complex,GO:0036464~cytoplasmic ribonucleoprotein granule,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0008266~poly(U) RNA binding,GO:0034046~poly(G) binding,	IPR019167:PAT1_dom,IPR039900:Pat1-like,	hsa03018:RNA degradation,					KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0694~RNA-binding,	KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,MOTIF:Nuclear export signal,MUTAGEN:E->A: In mut2; Abolishes interaction with the decapping machinery and localization to P-body; when associated with S-523; A-530 and S-534.,MUTAGEN:I->A: Loss of nuclear export; when associated with A-86, A-90 and A-93.,MUTAGEN:K->A: In mut1; Abolishes RNA-binding, localization to P-body and interaction with the decapping machinery; when associated with A-519; A-520; A-591; A-595 and A-625.,MUTAGEN:K->A: In mut1; Abolishes RNA-binding, localization to P-body and interaction with the decapping machinery; when associated with A-519; A-520; A-591; A-595 and A-626.,MUTAGEN:L->A: In mut2; Abolishes interaction with the decapping machinery and localization to P-body; when associated with A-527; A-530 and S-534.,MUTAGEN:L->A: Loss of nuclear export; when associated with A-86, A-93 and A-95.,MUTAGEN:L->A: Loss of nuclear export; when associated with A-90, A-93 and A-95.,MUTAGEN:L->S: In mut2; Abolishes interaction with the decapping machinery and localization to P-body; when associated with S-523; A-527 and A-530.,MUTAGEN:M->A: Loss of nuclear export; when associated with A-86, A-90 and A-95.,MUTAGEN:R->A: In mut1; Abolishes RNA-binding, localization to P-body and interaction with the decapping machinery; when associated with A-519; A-520; A-591; A-625 and A-626.,MUTAGEN:R->A: In mut1; Abolishes RNA-binding, localization to P-body and interaction with the decapping machinery; when associated with A-519; A-520; A-595; A-625 and A-626.,MUTAGEN:R->A: In mut1; Abolishes RNA-binding, localization to P-body and interaction with the decapping machinery; when associated with A-519; A-591; A-595; A-625 and A-626.,MUTAGEN:R->A: In mut1; Abolishes RNA-binding, localization to P-body and interaction with the decapping machinery; when associated with A-520; A-591; A-595; A-625 and A-626.,MUTAGEN:Y->A: In mut2; Abolishes interaction with the decapping machinery and localization to P-body; when associated with S-523; A-527 and S-534.,MUTAGEN:YERRYLLSLEEERPALMDD->GSGSGSG: In mut3; does not affect neither RNA-binding,interaction with the decapping machinery, nor localization to P-body.,REGION:Disordered,REGION:Involved in RNA-binding,REGION:Involved in nuclear foci localization,REGION:Involved in nuclear speckle localization,REGION:Region A; interaction with DDX6/RCK,REGION:Region C,REGION:Region H,REGION:Region N; interaction with decapping machinery,
PBX4	PBX homeobox 4(PBX4)	Homo sapiens			GO:0001654~eye development,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007420~brain development,GO:0009887~animal organ morphogenesis,GO:0045893~positive regulation of transcription, DNA-templated,GO:0048568~embryonic organ development,GO:0048666~neuron development,	GO:0000785~chromatin,GO:0001741~XY body,GO:0005634~nucleus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0043565~sequence-specific DNA binding,	IPR001356:Homeobox_dom,IPR005542:PBX_PBC_dom,IPR008422:Homeobox_KN_domain,IPR009057:Homeobox-like_sf,				SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0010~Activator,KW-0238~DNA-binding,		COMPBIAS:Polar residues,DNA_BIND:Homeobox; TALE-type,DOMAIN:PBC,REGION:Disordered,REGION:PBC-A,REGION:PBC-B,
PBXIP1	PBX homeobox interacting protein 1(PBXIP1)	Homo sapiens			GO:0002532~production of molecular mediator involved in inflammatory response,GO:0007155~cell adhesion,GO:0016477~cell migration,GO:0022617~extracellular matrix disassembly,GO:0030097~hemopoiesis,GO:0030177~positive regulation of Wnt signaling pathway,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:1901148~gene expression involved in extracellular matrix organization,GO:1902732~positive regulation of chondrocyte proliferation,GO:2001106~regulation of Rho guanyl-nucleotide exchange factor activity,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005829~cytosol,GO:0005874~microtubule,GO:0016020~membrane,	GO:0003713~transcription coactivator activity,GO:0003714~transcription corepressor activity,GO:0005515~protein binding,							KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0493~Microtubule,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,MOTIF:Nuclear localization signal,MUTAGEN:LASLL->AASAA: Reduces interaction with ESR1.,REGION:Disordered,TRANSMEM:Helical,
PCED1B	PC-esterase domain containing 1B(PCED1B)	Homo sapiens					GO:0005515~protein binding,GO:0016740~transferase activity,	IPR036514:SGNH_hydro_sf,												COMPBIAS:Pro residues,REGION:Disordered,
PSIP1	PC4 and SRSF1 interacting protein 1(PSIP1)	Homo sapiens			GO:0000395~mRNA 5'-splice site recognition,GO:0006338~chromatin remodeling,GO:0006979~response to oxidative stress,GO:0009408~response to heat,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,	GO:0000791~euchromatin,GO:0000792~heterochromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0034399~nuclear periphery,	GO:0003682~chromatin binding,GO:0003713~transcription coactivator activity,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0097100~supercoiled DNA binding,	IPR000313:PWWP_dom,IPR021567:LEDGF_IBD,IPR035441:TFIIS/LEDGF_dom_sf,IPR036218:HIVI-bd_sf,	hsa03250:Viral life cycle - HIV-1,			SM00293:PWWP,	KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0539~Nucleus,		KW-0175~Coiled coil,		KW-0238~DNA-binding,	KW-0164~Citrullination,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:PWWP,MOTIF:Nuclear localization signal,MUTAGEN:D->A: Loss of interaction with human HIV-1 integrase; no effect on interaction with CDCA7L and POGZ.,MUTAGEN:D->N: Loss of interaction with human HIV-1 integrase; no effect on interaction with KMT2A.,MUTAGEN:F->A: Loss of interaction with human HIV-1 integrase and POGZ; reduced interaction with CDCA7L.,MUTAGEN:I->A: Loss of interaction with human HIV-1 integrase; reduced interaction with POGZ and CDCA7L.,MUTAGEN:K->A: Reduced interaction with POGZ, CDCA7L and human HIV-1 integrase.,MUTAGEN:K->D: Reduced interaction with KMT2A. Significant loss of interaction with KMT2A; when associated with A-368.,MUTAGEN:L->A: Reduced interaction with KMT2A. Significant loss of interaction with KMT2A; when associated with D-407.,MUTAGEN:R->D: Significant loss of interaction with KMT2A; when associated with D-404.,MUTAGEN:R->D: Significant loss of interaction with KMT2A; when associated with D-405.,MUTAGEN:V->A: Reduced interaction with POGZ, CDCA7L and human HIV-1 integrase.,MUTAGEN:V->A: Reduced interaction with human HIV-1 integrase; no effect on interaction with POGZ and CDCA7L.,REGION:Disordered,REGION:Integrase-binding domain (IBD),
PCF11	PCF11 cleavage and polyadenylation factor subunit(PCF11)	Homo sapiens			GO:0006369~termination of RNA polymerase II transcription,GO:0006378~mRNA polyadenylation,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005849~mRNA cleavage factor complex,	GO:0000993~RNA polymerase II core binding,GO:0003729~mRNA binding,	IPR006569:CID_dom,IPR008942:ENTH_VHS,IPR021605:Pcf11_Clp1-ID,IPR045154:PCF11-like,IPR047415:Pcf11_CID,IPR048829:PCF11_RFEG_rpt,IPR048830:PCF11_helical,IPR048832:PCF11_charged,	hsa03015:mRNA surveillance pathway,			SM00582:RPR,	KW-0507~mRNA processing,	KW-0539~Nucleus,		KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:CID,DOMAIN:Pcf11 Clp1-ID,MUTAGEN:ST->AA: Abolished phosphorylation by WNK1, leading to mRNA retention in the nucleus and in prolonged association with polyadenylated mRNAs at transcription loci.,REGION:Disordered,
PDAP1	PDGFA associated protein 1(PDAP1)	Homo sapiens			GO:0007165~signal transduction,	GO:0005576~extracellular region,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:1904813~ficolin-1-rich granule lumen,	GO:0003723~RNA binding,GO:0005515~protein binding,	IPR019380:Casein_kinase_sb_PP28,IPR039876:HAP28,											KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),REGION:Disordered,
PHF1	PHD finger protein 1(PHF1)	Homo sapiens			GO:0006325~chromatin organization,GO:0006355~regulation of transcription, DNA-templated,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005813~centrosome,GO:0005829~cytosol,GO:0035098~ESC/E(Z) complex,GO:0035861~site of double-strand break,	GO:0001222~transcription corepressor binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0005515~protein binding,GO:0035064~methylated histone binding,GO:0042802~identical protein binding,GO:0046872~metal ion binding,GO:1990226~histone methyltransferase binding,	IPR001965:Znf_PHD,IPR002999:Tudor,IPR011011:Znf_FYVE_PHD,IPR013083:Znf_RING/FYVE/PHD,IPR019786:Zinc_finger_PHD-type_CS,IPR019787:Znf_PHD-finger,IPR025894:Mtf2_C_dom,IPR031202:PHF1_PDH-finger1,IPR040477:KDM4-like_Tudor,IPR047010:PHF1_PHD-finger2,IPR047399:Tudor_PHF1,	hsa03083:Polycomb repressive complex,			SM00249:PHD,SM00333:TUDOR,	KW-0227~DNA damage,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0156~Chromatin regulator,KW-0678~Repressor,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Lysine-specific demethylase 4-like Tudor,DOMAIN:PHD-type,DOMAIN:Polycomb-like MTF2 factor 2 C-terminal,DOMAIN:Tudor,MUTAGEN:E->K: Impairs histone H3K36me3-binding.,MUTAGEN:F->A: Abolishes histone H3K36me3-binding.,MUTAGEN:W->A: Abolishes histone H3K36me3-binding and localization at double-strand breaks (DSBs).,MUTAGEN:Y->A: Abolishes histone H3K36me3-binding.,REGION:Disordered,ZN_FING:PHD-type 1,ZN_FING:PHD-type 2,
PHF20L1	PHD finger protein 20 like 1(PHF20L1)	Homo sapiens			GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0032435~negative regulation of proteasomal ubiquitin-dependent protein catabolic process,GO:0042177~negative regulation of protein catabolic process,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0044545~NSL complex,	GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR002999:Tudor,IPR004092:Mbt,IPR011011:Znf_FYVE_PHD,IPR013083:Znf_RING/FYVE/PHD,IPR014002:Agenet_dom_plant,IPR019786:Zinc_finger_PHD-type_CS,IPR040477:KDM4-like_Tudor,IPR043449:PHF20-like,IPR047405:Tudor_PHF20L1,				SM00333:TUDOR,SM00743:Agenet,		KW-0539~Nucleus,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Agenet,DOMAIN:Lysine-specific demethylase 4-like Tudor,DOMAIN:Tudor,DOMAIN:Tudor 1,DOMAIN:Tudor 2,REGION:Disordered,ZN_FING:PHD-type,
PHF20	PHD finger protein 20(PHF20)	Homo sapiens			GO:0006325~chromatin organization,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0045893~positive regulation of transcription, DNA-templated,GO:0051571~positive regulation of histone H3-K4 methylation,	GO:0000123~histone acetyltransferase complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0031965~nuclear membrane,GO:0044545~NSL complex,GO:0071339~MLL1 complex,	GO:0003677~DNA binding,GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR001965:Znf_PHD,IPR002999:Tudor,IPR004092:Mbt,IPR011011:Znf_FYVE_PHD,IPR013083:Znf_RING/FYVE/PHD,IPR013087:Znf_C2H2_type,IPR019786:Zinc_finger_PHD-type_CS,IPR022255:PHF20_AT-hook,IPR041297:Crb2_Tudor,IPR043449:PHF20-like,				SM00249:PHD,SM00333:TUDOR,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0156~Chromatin regulator,KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,DISULFID:Interchain (with C-100),DISULFID:Interchain (with C-96),DNA_BIND:A.T hook,DOMAIN:C2H2-type,DOMAIN:PHD finger protein 20 AT hook,DOMAIN:Tudor 1,DOMAIN:Tudor 2,MUTAGEN:C->S: Abolishes homodimerization.,MUTAGEN:W->A: Abolishes interaction with methylated p53.,MUTAGEN:Y->A: Abolishes interaction with methylated p53.,REGION:Disordered,ZN_FING:C2H2-type,ZN_FING:PHD-type,
PHF5A	PHD finger protein 5A(PHF5A)	Homo sapiens			GO:0000398~mRNA splicing, via spliceosome,GO:0045893~positive regulation of transcription, DNA-templated,GO:0048863~stem cell differentiation,GO:1903241~U2-type prespliceosome assembly,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005681~spliceosomal complex,GO:0005684~U2-type spliceosomal complex,GO:0005686~U2 snRNP,GO:0005689~U12-type spliceosomal complex,GO:0016363~nuclear matrix,GO:0016607~nuclear speck,GO:0071005~U2-type precatalytic spliceosome,GO:0071011~precatalytic spliceosome,	GO:0003677~DNA binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,	IPR005345:PHF5,	hsa03040:Spliceosome,		PIRSF016468:PHF5,		KW-0507~mRNA processing,KW-0508~mRNA splicing,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0747~Spliceosome,			KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0238~DNA-binding,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	MUTAGEN:Y->C: No apparent effect on cell growth, localization of SF3B1 protein or formation of nuclear speckles. Alters the structure of the presumed branchpoint (BP) adenosine binding pocket within the splicing factor SF3B complex which may lead to decreased binding affinity and thus affect pre-mRNA splicing.,MUTAGEN:Y->E,S,A: Alters the structure of the presumed branchpoint (BP) adenosine binding pocket within the splicing factor SF3B complex which may lead to decreased binding affinity and thus affect pre-mRNA splicing.,REGION:Interaction with SF3B1 and SF3B3,REGION:Interaction with SF3B3,SITE:Interaction with RNA,SITE:Interaction with SF3B3,
PYURF	PIGY upstream open reading frame(PYURF)	Homo sapiens			GO:0050821~protein stabilization,	GO:0005739~mitochondrion,GO:0005789~endoplasmic reticulum membrane,	GO:0005515~protein binding,	IPR005651:Trm112-like,						KW-0496~Mitochondrion,		KW-0809~Transit peptide,				COMPBIAS:Basic and acidic residues,DOMAIN:TRM112,MUTAGEN:C->A: Reduces interaction with NDUFAF5.,MUTAGEN:I->S: Reduces interaction with NDUFAF5.,MUTAGEN:L->K: Loss of interaction with NDUFAF5.,REGION:Disordered,TRANSIT:Mitochondrion,
PITHD1	PITH domain containing 1(PITHD1)	Homo sapiens			GO:0007286~spermatid development,GO:0007341~penetration of zona pellucida,GO:0045654~positive regulation of megakaryocyte differentiation,GO:0045893~positive regulation of transcription, DNA-templated,GO:0061136~regulation of proteasomal protein catabolic process,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0097598~sperm cytoplasmic droplet,		IPR008979:Galactose-bd-like_sf,IPR010400:PITH_dom,IPR037047:PITH_dom_sf,IPR045099:PITH1-like,					KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0963~Cytoplasm,				KW-0010~Activator,	KW-0597~Phosphoprotein,	DOMAIN:PITH,
PML	PML nuclear body scaffold(PML)	Homo sapiens		h_pmlPathway:Regulation of transcriptional activity by PML,	GO:0001666~response to hypoxia,GO:0002230~positive regulation of defense response to virus by host,GO:0006355~regulation of transcription, DNA-templated,GO:0006605~protein targeting,GO:0006606~protein import into nucleus,GO:0006915~apoptotic process,GO:0006977~DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest,GO:0007179~transforming growth factor beta receptor signaling pathway,GO:0008285~negative regulation of cell proliferation,GO:0008630~intrinsic apoptotic signaling pathway in response to DNA damage,GO:0008631~intrinsic apoptotic signaling pathway in response to oxidative stress,GO:0009411~response to UV,GO:0010332~response to gamma radiation,GO:0010522~regulation of calcium ion transport into cytosol,GO:0010761~fibroblast migration,GO:0016525~negative regulation of angiogenesis,GO:0016925~protein sumoylation,GO:0030099~myeloid cell differentiation,GO:0030155~regulation of cell adhesion,GO:0030308~negative regulation of cell growth,GO:0030578~PML body organization,GO:0031065~positive regulation of histone deacetylation,GO:0031503~protein complex localization,GO:0032206~positive regulation of telomere maintenance,GO:0032211~negative regulation of telomere maintenance via telomerase,GO:0032469~endoplasmic reticulum calcium ion homeostasis,GO:0032691~negative regulation of interleukin-1 beta production,GO:0032922~circadian regulation of gene expression,GO:0032938~negative regulation of translation in response to oxidative stress,GO:0034097~response to cytokine,GO:0042752~regulation of circadian rhythm,GO:0042771~intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator,GO:0043153~entrainment of circadian clock by photoperiod,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0044790~negative regulation by host of viral release from host cell,GO:0045087~innate immune response,GO:0045165~cell fate commitment,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045930~negative regulation of mitotic cell cycle,GO:0048146~positive regulation of fibroblast proliferation,GO:0048384~retinoic acid receptor signaling pathway,GO:0050821~protein stabilization,GO:0051457~maintenance of protein location in nucleus,GO:0051726~regulation of cell cycle,GO:0051974~negative regulation of telomerase activity,GO:0060058~positive regulation of apoptotic process involved in mammary gland involution,GO:0060395~SMAD protein signal transduction,GO:0060444~branching involved in mammary gland duct morphogenesis,GO:0065003~macromolecular complex assembly,GO:0070059~intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress,GO:0071353~cellular response to interleukin-4,GO:0090398~cellular senescence,GO:0090402~oncogene-induced cell senescence,GO:0097191~extrinsic apoptotic signaling pathway,GO:1901798~positive regulation of signal transduction by p53 class mediator,GO:1904816~positive regulation of protein localization to chromosome, telomeric region,GO:1990830~cellular response to leukemia inhibitory factor,GO:2000059~negative regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process,GO:2000758~positive regulation of peptidyl-lysine acetylation,GO:2000779~regulation of double-strand break repair,GO:2001238~positive regulation of extrinsic apoptotic signaling pathway,	GO:0000781~chromosome, telomeric region,GO:0000792~heterochromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0016363~nuclear matrix,GO:0016605~PML body,GO:0031901~early endosome membrane,GO:0031965~nuclear membrane,	GO:0003677~DNA binding,GO:0003713~transcription coactivator activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0019789~SUMO transferase activity,GO:0031625~ubiquitin protein ligase binding,GO:0032183~SUMO binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0046332~SMAD binding,GO:0046982~protein heterodimerization activity,GO:0050897~cobalt ion binding,GO:0060090~binding, bridging,GO:0061659~ubiquitin-like protein ligase activity,	IPR000315:Znf_B-box,IPR001841:Znf_RING,IPR013083:Znf_RING/FYVE/PHD,IPR017907:Znf_RING_CS,IPR018957:Znf_C3HC4_RING-type,IPR021978:PML-like_CC,IPR047153:TRIM45/56/19,	hsa04120:Ubiquitin mediated proteolysis,hsa04144:Endocytosis,hsa05164:Influenza A,hsa05168:Herpes simplex virus 1 infection,hsa05200:Pathways in cancer,hsa05202:Transcriptional misregulation in cancer,hsa05221:Acute myeloid leukemia,	Leukemia, acute promyelocytic, PML/RARA type~Leukemia, acute promyelocytic, PML/RARA type,		SM00184:RING,SM00336:BBOX,	KW-0051~Antiviral defense,KW-0053~Apoptosis,KW-0090~Biological rhythms,KW-0391~Immunity,KW-0399~Innate immunity,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0967~Endosome,	KW-0043~Tumor suppressor,KW-0656~Proto-oncogene,	KW-0175~Coiled coil,KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0238~DNA-binding,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in /SUMO5); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1P1/SUMO5); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin); alternate,DOMAIN:B box-type,DOMAIN:PML-like coiled-coil,DOMAIN:RING-type,MOTIF:Nuclear localization signal,MUTAGEN:C->S: No nuclear microspeckle location, no sumoylation and loss of intrinsic transcriptional repressor activity of PML-RARA oncoprotein; when associated with R-89.,MUTAGEN:C->S: Strongly reduced sumoylation; when associated with S-57.,MUTAGEN:C->S: Strongly reduced sumoylation; when associated with S-60.,MUTAGEN:K->A: Loss of nuclear localization; when associated with A-487.,MUTAGEN:K->A: Loss of nuclear localization; when associated with A-490.,MUTAGEN:K->R: Abolished conjugation of one SUMO1P1/SUMO5. Loss of 2 sumoylations; when associated with R-65 with or without R-133. No effect on nuclear body formation; when associated with R-65. No sumoylation nor nuclear body formation; when associated with R-65 and R-160. Loss the ability to be conjugated by SUMO1P1/SUMO5 but could be conjugated by SUMO1; when associated with R-65 and R-160.,MUTAGEN:K->R: Compromised the formation of high molecular weight species of SUMO1P1/SUMO5 conjugation on PML. Loss of 2 sumoylations; when associated with or without R-65. No sumoylation nor nuclear body formation; when associated with or without R-65 and R-490. Loss the ability to be conjugated by SUMO1P1/SUMO5 but could be conjugated by SUMO1; when associated with R-65 and R-490.,MUTAGEN:K->R: Does not affect SUMO1P1/SUMO5 conjugation.,MUTAGEN:K->R: Loss of 2 sumoylations; when associated with R-65 and R-490.,MUTAGEN:K->R: Loss of 2 sumoylations; when associated with R-65 with or without R-133. No effect on nuclear body formation; when associated with R-65. No sumoylation nor nuclear body formation; when associated with R-65 and R-160.,MUTAGEN:K->R: Loss of 2 sumoylations; when associated with or without R-65. No sumoylation nor nuclear body formation; when associated with or without R-65 and R-490.,MUTAGEN:K->R: Loss of nuclear localization. Reduced acetylation. Further decrease in acetylation; when associated with R-515.,MUTAGEN:K->R: Loss of one sumoylation. No effect on nuclear body formation. Loss of 2 sumoylations; when associated with R-490 with or without R-133 or R-150. No effect on nuclear body formation; when associated with R-490. Loss the ability to be conjugated by SUMO1P1/SUMO5 but could be conjugated by SUMO1; when associated with R-160 and R-490.,MUTAGEN:K->R: Loss of one sumoylation. No effect on nuclear body formation. Loss of 2 sumoylations; when associated with R-490 with or without R-133 or R-150. No effect on nuclear body formation; when associated with R-490. No sumoylation nor nuclear body formation; when associated with R-160 and R-490.,MUTAGEN:K->R: No effect on sumoylation levels.,MUTAGEN:K->R: Slightly reduced acetylation. Further decrease in acetylation; when associated with R-487.,MUTAGEN:P->R: No nuclear microspeckle location, no sumoylation and loss of intrinsic transcriptional repressor activity of PML-RARA oncoprotein; when associated with S-88.,MUTAGEN:Q->A: Loss of cleavage by enterovirus 71 protease 3C.,MUTAGEN:S->A: Abolishes ubiquitination by the BCR(KLHL20) E3 ubiquitin ligase complex.,MUTAGEN:VVVI->AAAS: Abolishes SUMO1 binding.,REGION:Disordered,REGION:Interaction with PER2,REGION:Sumo interaction motif (SIM),SITE:(Microbial infection) Cleavage by protease 3C of enterovirus 71,SITE:Breakpoint for translocation to form PML-RARA oncogene in type A APL,SITE:Breakpoint for translocation to form PML-RARA oncogene in type B APL,ZN_FING:B box-type 1; atypical,ZN_FING:B box-type 2,ZN_FING:RING-type,
PNMA1	PNMA family member 1(PNMA1)	Homo sapiens			GO:0002437~inflammatory response to antigenic stimulus,GO:0043065~positive regulation of apoptotic process,	GO:0005730~nucleolus,GO:0005737~cytoplasm,	GO:0005515~protein binding,	IPR026523:PNMA,IPR048270:PNMA_C,IPR048271:PNMA_N,						KW-0539~Nucleus,		KW-0175~Coiled coil,		KW-0825~Tumor antigen,		DOMAIN:Paraneoplastic antigen Ma-like C-terminal,DOMAIN:Paraneoplastic antigen Ma-like N-terminal,
PNISR	PNN interacting serine and arginine rich protein(PNISR)	Homo sapiens				GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016607~nuclear speck,GO:0048786~presynaptic active zone,	GO:0003723~RNA binding,	IPR031937:PNISR,						KW-0539~Nucleus,		KW-0175~Coiled coil,			KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),REGION:Disordered,
POP7	POP7 homolog, ribonuclease P/MRP subunit(POP7)	Homo sapiens			GO:0001682~tRNA 5'-leader removal,GO:0006364~rRNA processing,GO:0008033~tRNA processing,	GO:0000172~ribonuclease MRP complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005655~nucleolar ribonuclease P complex,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0030681~multimeric ribonuclease P complex,GO:0043231~intracellular membrane-bounded organelle,	GO:0003676~nucleic acid binding,GO:0003723~RNA binding,GO:0004526~ribonuclease P activity,GO:0005515~protein binding,GO:0033204~ribonuclease P RNA binding,	IPR014612:Pop7/Rpp20,IPR036882:Alba-like_dom_sf,	hsa03008:Ribosome biogenesis in eukaryotes,		PIRSF036572:RPP20,		KW-0698~rRNA processing,KW-0819~tRNA processing,	KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0694~RNA-binding,		MUTAGEN:N->Q: Strongly reduced interaction with RPP25.,
PRDM1	PR/SET domain 1(PRDM1)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001763~morphogenesis of a branching structure,GO:0001822~kidney development,GO:0001893~maternal placenta development,GO:0002250~adaptive immune response,GO:0003170~heart valve development,GO:0003281~ventricular septum development,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007281~germ cell development,GO:0009791~post-embryonic development,GO:0010467~gene expression,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0032259~methylation,GO:0032823~regulation of natural killer cell differentiation,GO:0033082~regulation of extrathymic T cell differentiation,GO:0035904~aorta development,GO:0042127~regulation of cell proliferation,GO:0042462~eye photoreceptor cell development,GO:0045087~innate immune response,GO:0045165~cell fate commitment,GO:0048844~artery morphogenesis,GO:0051136~regulation of NK T cell differentiation,GO:0060040~retinal bipolar neuron differentiation,GO:0060576~intestinal epithelial cell development,GO:0060707~trophoblast giant cell differentiation,GO:0060976~coronary vasculature development,GO:1990654~sebum secreting cell proliferation,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0008168~methyltransferase activity,GO:0046872~metal ion binding,GO:1990226~histone methyltransferase binding,GO:1990837~sequence-specific double-stranded DNA binding,GO:1990841~promoter-specific chromatin binding,	IPR001214:SET_dom,IPR013087:Znf_C2H2_type,IPR016608:PRDM1,IPR036236:Znf_C2H2_sf,IPR044413:PRDM1_PR-SET,IPR046341:SET_dom_sf,			PIRSF013212:PRDM1,	SM00317:SET,SM00355:ZnF_C2H2,	KW-0391~Immunity,KW-0399~Innate immunity,KW-0804~Transcription,KW-0805~Transcription regulation,KW-1064~Adaptive immunity,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,KW-0949~S-adenosyl-L-methionine,	KW-0238~DNA-binding,KW-0489~Methyltransferase,KW-0678~Repressor,KW-0808~Transferase,	KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:C2H2-type,DOMAIN:SET,MUTAGEN:I->G,K: Protein instability caused by increased susceptibility to proteasomal degradation.,MUTAGEN:P->G,K: Protein instability caused by increased susceptibility to proteasomal degradation.,REGION:Disordered,REGION:Interaction with PIAS1,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4,
PRELID1	PRELI domain containing 1(PRELID1)	Homo sapiens			GO:0006915~apoptotic process,GO:0010917~negative regulation of mitochondrial membrane potential,GO:0010950~positive regulation of endopeptidase activity,GO:0015914~phospholipid transport,GO:0043066~negative regulation of apoptotic process,GO:0045580~regulation of T cell differentiation,GO:0051881~regulation of mitochondrial membrane potential,GO:0070234~positive regulation of T cell apoptotic process,GO:0090201~negative regulation of release of cytochrome c from mitochondria,GO:0097035~regulation of membrane lipid distribution,GO:1901857~positive regulation of cellular respiration,GO:2001140~positive regulation of phospholipid transport,	GO:0005654~nucleoplasm,GO:0005739~mitochondrion,GO:0005758~mitochondrial intermembrane space,GO:0032991~macromolecular complex,	GO:0005515~protein binding,GO:1990050~phosphatidic acid transporter activity,	IPR006797:PRELI/MSF1_dom,IPR037365:Slowmo/Ups,					KW-0053~Apoptosis,KW-0445~Lipid transport,KW-0813~Transport,	KW-0496~Mitochondrion,		KW-0809~Transit peptide,				COMPBIAS:Basic residues,COMPBIAS:Polar residues,DOMAIN:PRELI/MSF1,REGION:Disordered,TRANSIT:Mitochondrion,
PTTG1IP	PTTG1 interacting protein(PTTG1IP)	Homo sapiens			GO:0006606~protein import into nucleus,GO:0031398~positive regulation of protein ubiquitination,GO:0043518~negative regulation of DNA damage response, signal transduction by p53 class mediator,GO:1902254~negative regulation of intrinsic apoptotic signaling pathway by p53 class mediator,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0016020~membrane,GO:0070062~extracellular exosome,	GO:0002039~p53 binding,GO:0005515~protein binding,	IPR016201:PSI,				SM00423:PSI,		KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:PSI,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
PTTG1	PTTG1 regulator of sister chromatid separation, securin(PTTG1)	Homo sapiens			GO:0006281~DNA repair,GO:0007283~spermatogenesis,GO:0045143~homologous chromosome segregation,GO:0051276~chromosome organization,GO:0051301~cell division,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0004869~cysteine-type endopeptidase inhibitor activity,GO:0005515~protein binding,GO:0017124~SH3 domain binding,	IPR006940:Securin_separation_inhibitor,	hsa04110:Cell cycle,hsa04114:Oocyte meiosis,hsa05166:Human T-cell leukemia virus 1 infection,				KW-0131~Cell cycle,KW-0132~Cell division,KW-0159~Chromosome partition,KW-0227~DNA damage,KW-0234~DNA repair,KW-0498~Mitosis,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0656~Proto-oncogene,	KW-0677~Repeat,KW-0729~SH3-binding,			KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,MOTIF:D-box,MOTIF:SH3-binding,MOTIF:TEK-box 1,MOTIF:TEK-box 2,MUTAGEN:L->A: Abolishes ubiquitination and subsequent degradation; when associated with A-61.,MUTAGEN:P->A: Strongly reduces transforming capability; when associated with L-170; A-172 and L-173.,MUTAGEN:PSPP->LSAL: Strongly reduces transforming capability; when associated with A-163.,MUTAGEN:R->A: Abolishes ubiquitination and subsequent degradation; when associated with A-64.,MUTAGEN:S->A: Abolishes phosphorylation.,REGION:Disordered,
PWP1	PWP1 homolog, endonuclein(PWP1)	Homo sapiens			GO:0006351~transcription, DNA-templated,GO:0006364~rRNA processing,GO:0033140~negative regulation of peptidyl-serine phosphorylation of STAT protein,GO:1901838~positive regulation of transcription of nuclear large rRNA transcript from RNA polymerase I promoter,GO:2000738~positive regulation of stem cell differentiation,	GO:0005634~nucleus,GO:0005694~chromosome,GO:0005730~nucleolus,GO:0005794~Golgi apparatus,	GO:1990889~H4K20me3 modified histone binding,	IPR001680:WD40_rpt,IPR015943:WD40/YVTN_repeat-like_dom_sf,IPR019775:WD40_repeat_CS,IPR020472:G-protein_beta_WD-40_rep,IPR036322:WD40_repeat_dom_sf,IPR044285:PWP1,				SM00320:WD40,	KW-0690~Ribosome biogenesis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0158~Chromosome,KW-0539~Nucleus,		KW-0677~Repeat,KW-0853~WD repeat,			KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,REGION:Disordered,REPEAT:WD,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,REPEAT:WD 7,
PIM2	Pim-2 proto-oncogene, serine/threonine kinase(PIM2)	Homo sapiens			GO:0000082~G1/S transition of mitotic cell cycle,GO:0006468~protein phosphorylation,GO:0007346~regulation of mitotic cell cycle,GO:0008285~negative regulation of cell proliferation,GO:0008637~apoptotic mitochondrial changes,GO:0009615~response to virus,GO:0010508~positive regulation of autophagy,GO:0016236~macroautophagy,GO:0016239~positive regulation of macroautophagy,GO:0043066~negative regulation of apoptotic process,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0045893~positive regulation of transcription, DNA-templated,GO:0046777~protein autophosphorylation,GO:0050821~protein stabilization,	GO:0005737~cytoplasm,	GO:0004674~protein serine/threonine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,	IPR000719:Prot_kinase_dom,IPR008271:Ser/Thr_kinase_AS,IPR011009:Kinase-like_dom_sf,IPR017348:PIM1/2/3,IPR017441:Protein_kinase_ATP_BS,	hsa05200:Pathways in cancer,hsa05221:Acute myeloid leukemia,		PIRSF037993:STPK_Pim-1,	SM00220:S_TKc,	KW-0053~Apoptosis,KW-0131~Cell cycle,		KW-0656~Proto-oncogene,		KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,COMPBIAS:Pro residues,DOMAIN:Protein kinase,REGION:Disordered,
R3HDM4	R3H domain containing 4(R3HDM4)	Homo sapiens				GO:0005634~nucleus,	GO:0003676~nucleic acid binding,	IPR001374:R3H_dom,IPR025952:R3H-assoc_dom,IPR036867:R3H_dom_sf,IPR039629:R3HDM4,						KW-0539~Nucleus,						DOMAIN:R3H,REGION:Disordered,
RABGAP1L	RAB GTPase activating protein 1 like(RABGAP1L)	Homo sapiens			GO:0006897~endocytosis,GO:0015031~protein transport,GO:0032880~regulation of protein localization,GO:0043087~regulation of GTPase activity,	GO:0005634~nucleus,GO:0005769~early endosome,GO:0005794~Golgi apparatus,GO:0005929~cilium,GO:0016020~membrane,	GO:0005096~GTPase activator activity,GO:0031267~small GTPase binding,	IPR000195:Rab-GAP-TBC_dom,IPR006020:PTB/PI_dom,IPR011993:PH-like_dom_sf,IPR022164:Kinesin-like,IPR035969:Rab-GAP_TBC_sf,				SM00164:TBC,SM00462:PTB,	KW-0254~Endocytosis,KW-0653~Protein transport,KW-0813~Transport,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0967~Endosome,KW-0968~Cytoplasmic vesicle,		KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0343~GTPase activation,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Kinesin-like,DOMAIN:PID,DOMAIN:Rab-GAP TBC,REGION:Disordered,SITE:Arginine finger,SITE:Glutamine finger,TRANSMEM:Helical,
RABIF	RAB interacting factor(RABIF)	Homo sapiens			GO:0006892~post-Golgi vesicle-mediated transport,GO:0007264~small GTPase mediated signal transduction,GO:0015031~protein transport,GO:0061025~membrane fusion,	GO:0005829~cytosol,GO:0016020~membrane,	GO:0005085~guanyl-nucleotide exchange factor activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,	IPR007515:Mss4,IPR011057:Mss4-like_sf,IPR011323:Mss4/transl-control_tumour,					KW-0653~Protein transport,KW-0813~Transport,				KW-0479~Metal-binding,KW-0862~Zinc,	KW-0344~Guanine-nucleotide releasing factor,	KW-0007~Acetylation,	DOMAIN:MSS4,
RAB10	RAB10, member RAS oncogene family(RAB10)	Homo sapiens			GO:0006893~Golgi to plasma membrane transport,GO:0007409~axonogenesis,GO:0016192~vesicle-mediated transport,GO:0016197~endosomal transport,GO:0019882~antigen processing and presentation,GO:0030859~polarized epithelial cell differentiation,GO:0032869~cellular response to insulin stimulus,GO:0043001~Golgi to plasma membrane protein transport,GO:0045055~regulated exocytosis,GO:0045200~establishment of neuroblast polarity,GO:0071786~endoplasmic reticulum tubular network organization,GO:0072659~protein localization to plasma membrane,GO:0090150~establishment of protein localization to membrane,GO:0097051~establishment of protein localization to endoplasmic reticulum membrane,GO:0098609~cell-cell adhesion,GO:1903361~protein localization to basolateral plasma membrane,	GO:0000139~Golgi membrane,GO:0000145~exocyst,GO:0005768~endosome,GO:0005789~endoplasmic reticulum membrane,GO:0005794~Golgi apparatus,GO:0005802~trans-Golgi network,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0005912~adherens junction,GO:0005925~focal adhesion,GO:0005929~cilium,GO:0010008~endosome membrane,GO:0030659~cytoplasmic vesicle membrane,GO:0030667~secretory granule membrane,GO:0030670~phagocytic vesicle membrane,GO:0032593~insulin-responsive compartment,GO:0048471~perinuclear region of cytoplasm,GO:0055037~recycling endosome,GO:0055038~recycling endosome membrane,GO:0070062~extracellular exosome,GO:0070382~exocytic vesicle,GO:0071782~endoplasmic reticulum tubular network,	GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0019003~GDP binding,GO:0031489~myosin V binding,GO:0098641~cadherin binding involved in cell-cell adhesion,	IPR001806:Small_GTPase,IPR005225:Small_GTP-bd_dom,IPR027417:P-loop_NTPase,	hsa04144:Endocytosis,hsa04152:AMPK signaling pathway,			SM00173:RAS,SM00174:RHO,SM00175:RAB,SM00176:RAN,SM00177:ARF,	KW-0653~Protein transport,KW-0813~Transport,	KW-0206~Cytoskeleton,KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-0967~Endosome,KW-0968~Cytoplasmic vesicle,	KW-0523~Neurodegeneration,		KW-0342~GTP-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,	KW-0007~Acetylation,KW-0449~Lipoprotein,KW-0597~Phosphoprotein,KW-0636~Prenylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),LIPID:S-geranylgeranyl cysteine,MOTIF:Effector region,MUTAGEN:Q->L: Probable constitutively active mutant unable to hydrolyze GTP; accumulates at the base of the primary cilium and alters the basolateral recycling pathway in epithelial cells. No effect on endoplasmic reticulum recruitment to the Legionella-containing vacuole. Increased WDR44-positive tubulation.,MUTAGEN:T->A: Loss of phosphorylation. No effect on GDI1 and GDI2 binding. Increases localization to the cytosol.,MUTAGEN:T->E: Phosphomimetic mutant. Loss of GDI1 and GDI2 binding. Increases localization to the Golgi complex.,MUTAGEN:T->N: Probable dominant negative mutant locked in the inactive GDP-bound form; alters the basolateral recycling pathway in epithelial cells and endoplasmic reticulum membrane morphology. Reduces endoplasmic reticulum recruitment to the Legionella-containing vacuole. Decreased WDR44-positive tubulation. Loss of E-cadherin and MMP14 export and decreased CFTR export.,
RAB11FIP1	RAB11 family interacting protein 1(RAB11FIP1)	Homo sapiens			GO:0015031~protein transport,GO:0045055~regulated exocytosis,GO:0070164~negative regulation of adiponectin secretion,	GO:0005829~cytosol,GO:0016020~membrane,GO:0030670~phagocytic vesicle membrane,GO:0043231~intracellular membrane-bounded organelle,GO:0055037~recycling endosome,	GO:0031267~small GTPase binding,	IPR000008:C2_dom,IPR019018:Rab-bd_FIP-RBD,IPR035892:C2_domain_sf,IPR037245:FIP-RBD_C_sf,IPR037789:FIP_classI,	hsa04144:Endocytosis,			SM00239:C2,	KW-0653~Protein transport,KW-0813~Transport,	KW-0472~Membrane,KW-0967~Endosome,KW-0968~Cytoplasmic vesicle,					KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:C2,DOMAIN:FIP-RBD,MUTAGEN:D->N: Does not abolish the interaction with RAB11A, homooligomerization and subcellular location. Reduces the interaction with RAB4A.,MUTAGEN:I->E: Abolishes the interaction with RAB11A and RAB4A, homooligomerization and subcellular location.,MUTAGEN:Y->F: Does not abolish the interaction with RAB11A, homooligomerization and subcellular location. Reduces the interaction with RAB4A.,REGION:Disordered,REGION:Necessary for interaction with RAB4A and RAB11A, subcellular location and endosomal recycling,
RAB11A	RAB11A, member RAS oncogene family(RAB11A)	Homo sapiens		h_rabPathway:Rab GTPases Mark Targets In The Endocytotic Machinery,	GO:0006887~exocytosis,GO:0007080~mitotic metaphase plate congression,GO:0010634~positive regulation of epithelial cell migration,GO:0010796~regulation of multivesicular body size,GO:0010971~positive regulation of G2/M transition of mitotic cell cycle,GO:0016192~vesicle-mediated transport,GO:0030953~astral microtubule organization,GO:0031175~neuron projection development,GO:0032402~melanosome transport,GO:0032465~regulation of cytokinesis,GO:0034394~protein localization to cell surface,GO:0036258~multivesicular body assembly,GO:0048227~plasma membrane to endosome transport,GO:0051650~establishment of vesicle localization,GO:0060627~regulation of vesicle-mediated transport,GO:0061512~protein localization to cilium,GO:0072594~establishment of protein localization to organelle,GO:0072659~protein localization to plasma membrane,GO:0090150~establishment of protein localization to membrane,GO:0090307~mitotic spindle assembly,GO:0098887~neurotransmitter receptor transport, endosome to postsynaptic membrane,GO:1902017~regulation of cilium assembly,GO:1902954~regulation of early endosome to recycling endosome transport,GO:1904779~regulation of protein localization to centrosome,GO:1990182~exosomal secretion,GO:2001135~regulation of endocytic recycling,	GO:0000139~Golgi membrane,GO:0000922~spindle pole,GO:0005771~multivesicular body,GO:0005794~Golgi apparatus,GO:0005802~trans-Golgi network,GO:0005813~centrosome,GO:0005814~centriole,GO:0005828~kinetochore microtubule,GO:0005829~cytosol,GO:0030133~transport vesicle,GO:0030659~cytoplasmic vesicle membrane,GO:0030666~endocytic vesicle membrane,GO:0031410~cytoplasmic vesicle,GO:0031982~vesicle,GO:0032154~cleavage furrow,GO:0032588~trans-Golgi network membrane,GO:0032991~macromolecular complex,GO:0034451~centriolar satellite,GO:0043231~intracellular membrane-bounded organelle,GO:0045335~phagocytic vesicle,GO:0055037~recycling endosome,GO:0055038~recycling endosome membrane,GO:0070062~extracellular exosome,GO:0098837~postsynaptic recycling endosome,GO:0098978~glutamatergic synapse,	GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0008017~microtubule binding,GO:0019905~syntaxin binding,GO:0031489~myosin V binding,GO:0051959~dynein light intermediate chain binding,	IPR001806:Small_GTPase,IPR005225:Small_GTP-bd_dom,IPR027417:P-loop_NTPase,	hsa04144:Endocytosis,hsa04961:Endocrine and other factor-regulated calcium reabsorption,hsa04962:Vasopressin-regulated water reabsorption,hsa04972:Pancreatic secretion,hsa05164:Influenza A,			SM00173:RAS,SM00174:RHO,SM00175:RAB,SM00176:RAN,	KW-0131~Cell cycle,KW-0653~Protein transport,KW-0813~Transport,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0967~Endosome,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,			KW-0342~GTP-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,	KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0488~Methylation,KW-0636~Prenylation,	CARBOHYD:(Microbial infection) N-beta-linked (GlcNAc) arginine,LIPID:S-geranylgeranyl cysteine,MOTIF:Effector region,MUTAGEN:F->A: Nearly abolishes SH3BP5-mediated guanine nucleotide exchange.,MUTAGEN:I->A: Abolishes SH3BP5-mediated guanine nucleotide exchange.,MUTAGEN:K->A: Mildly decreases SH3BP5-mediated guanine nucleotide exchange.,MUTAGEN:K->N: Abolishes SH3BP5-mediated guanine nucleotide exchange.,MUTAGEN:K->P: Abolishes SH3BP5-mediated guanine nucleotide exchange.,MUTAGEN:K->R: Impairs protein folding and decreases affinity for guanine nucleotides.,MUTAGEN:L->P: Decreases SH3BP5-mediated guanine nucleotide exchange.,MUTAGEN:L->P: Nearly abolishes SH3BP5-mediated guanine nucleotide exchange.,MUTAGEN:Q->L: Constitutively active mutant. Decreases GTPase activity. Disrupts the trafficking of CDH1 to the plasma membrane and promotes accumulation of CDH1 in RAB11A endosomes in nonpolarized cells. Promotes mistargeting of CDH1 to the apical membrane in polarized cells.,MUTAGEN:R->C: Decreases SH3BP5-mediated guanine nucleotide exchange.,MUTAGEN:S->F: Nearly abolishes SH3BP5-mediated guanine nucleotide exchange.,MUTAGEN:S->L: Impairs protein folding.,MUTAGEN:S->N: Dominant-negative mutant. Induces increased number of binucleated cells, indicating defects in cytokinesis. Inhibits the transport of NPC1L1 to the plama membrane. Disrupts the trafficking of CDH1 to the plasma membrane and promotes accumulation of CDH1 in RAB11A endosomes in nonpolarized cells. Promotes mistargeting of CDH1 to the apical membrane in polarized cells. Increased interaction with ATP9A. Loss of interaction with WDR44, decreased WDR44-positive tubules and loss of E-cadherin export.,MUTAGEN:V->M: Impairs protein folding.,PROPEP:Removed in mature form,REGION:Disordered,
RAB11B	RAB11B, member RAS oncogene family(RAB11B)	Homo sapiens			GO:0001881~receptor recycling,GO:0032402~melanosome transport,GO:0032456~endocytic recycling,GO:0033572~transferrin transport,GO:0035773~insulin secretion involved in cellular response to glucose stimulus,GO:0044070~regulation of anion transport,GO:0045054~constitutive secretory pathway,GO:0045055~regulated exocytosis,GO:0071468~cellular response to acidic pH,GO:0090150~establishment of protein localization to membrane,GO:2000008~regulation of protein localization to cell surface,GO:2001135~regulation of endocytic recycling,	GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0008021~synaptic vesicle,GO:0030670~phagocytic vesicle membrane,GO:0030672~synaptic vesicle membrane,GO:0045335~phagocytic vesicle,GO:0055037~recycling endosome,GO:0055038~recycling endosome membrane,GO:0070062~extracellular exosome,	GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0019003~GDP binding,GO:0031489~myosin V binding,GO:0045296~cadherin binding,	IPR001806:Small_GTPase,IPR005225:Small_GTP-bd_dom,IPR027417:P-loop_NTPase,	hsa04144:Endocytosis,hsa04152:AMPK signaling pathway,hsa04962:Vasopressin-regulated water reabsorption,hsa05164:Influenza A,	617807~Neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matter,		SM00173:RAS,SM00174:RHO,SM00175:RAB,SM00176:RAN,	KW-0653~Protein transport,KW-0813~Transport,	KW-0472~Membrane,KW-0770~Synapse,KW-0967~Endosome,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0991~Intellectual disability,		KW-0342~GTP-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,	KW-0007~Acetylation,KW-0164~Citrullination,KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0488~Methylation,KW-0636~Prenylation,	COMPBIAS:Polar residues,LIPID:S-geranylgeranyl cysteine,MOTIF:Effector region,MUTAGEN:Q->L: Constitutively active mutant locked in the active GTP-bound form; alters apical recycling.,MUTAGEN:S->N: Dominant negative mutant locked in the inactive GDP-bound form; alters apical recycling. Does not interact with ZFYV2E and KIF5A.,PROPEP:Removed in mature form,REGION:Disordered,
RAB14	RAB14, member RAS oncogene family(RAB14)	Homo sapiens			GO:0006886~intracellular protein transport,GO:0006895~Golgi to endosome transport,GO:0008543~fibroblast growth factor receptor signaling pathway,GO:0016192~vesicle-mediated transport,GO:0032456~endocytic recycling,GO:0032880~regulation of protein localization,GO:0042742~defense response to bacterium,GO:0045995~regulation of embryonic development,GO:0046907~intracellular transport,GO:0090382~phagosome maturation,GO:0090387~phagolysosome assembly involved in apoptotic cell clearance,	GO:0000139~Golgi membrane,GO:0005764~lysosome,GO:0005765~lysosomal membrane,GO:0005769~early endosome,GO:0005770~late endosome,GO:0005791~rough endoplasmic reticulum,GO:0005795~Golgi stack,GO:0005802~trans-Golgi network,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0012505~endomembrane system,GO:0030140~trans-Golgi network transport vesicle,GO:0031901~early endosome membrane,GO:0042175~nuclear outer membrane-endoplasmic reticulum membrane network,GO:0043231~intracellular membrane-bounded organelle,GO:0045335~phagocytic vesicle,GO:0048471~perinuclear region of cytoplasm,GO:0055037~recycling endosome,GO:0055038~recycling endosome membrane,GO:0070062~extracellular exosome,GO:0070821~tertiary granule membrane,	GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0019003~GDP binding,GO:0031489~myosin V binding,	IPR001806:Small_GTPase,IPR005225:Small_GTP-bd_dom,IPR027417:P-loop_NTPase,IPR030702:Rab14,	hsa04148:Efferocytosis,hsa04152:AMPK signaling pathway,			SM00173:RAS,SM00174:RHO,SM00175:RAB,SM00176:RAN,	KW-0653~Protein transport,KW-0813~Transport,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0967~Endosome,KW-0968~Cytoplasmic vesicle,			KW-0342~GTP-binding,KW-0547~Nucleotide-binding,		KW-0007~Acetylation,KW-0449~Lipoprotein,KW-0488~Methylation,KW-0636~Prenylation,	LIPID:S-geranylgeranyl cysteine,MOTIF:Effector region,REGION:Disordered,
RAB18	RAB18, member RAS oncogene family(RAB18)	Homo sapiens			GO:0001654~eye development,GO:0006886~intracellular protein transport,GO:0007264~small GTPase mediated signal transduction,GO:0007420~brain development,GO:0034389~lipid particle organization,GO:0071786~endoplasmic reticulum tubular network organization,	GO:0005789~endoplasmic reticulum membrane,GO:0005794~Golgi apparatus,GO:0005811~lipid particle,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0012505~endomembrane system,GO:0016324~apical plasma membrane,GO:0030667~secretory granule membrane,GO:0071782~endoplasmic reticulum tubular network,	GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0019003~GDP binding,	IPR001806:Small_GTPase,IPR005225:Small_GTP-bd_dom,IPR025662:Sigma_54_int_dom_ATP-bd_1,IPR027417:P-loop_NTPase,		614222~Warburg micro syndrome 3,		SM00173:RAS,SM00174:RHO,SM00175:RAB,SM00176:RAN,SM00177:ARF,	KW-0653~Protein transport,KW-0813~Transport,KW-0945~Host-virus interaction,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0551~Lipid droplet,KW-1003~Cell membrane,			KW-0342~GTP-binding,KW-0547~Nucleotide-binding,	KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0007~Acetylation,KW-0449~Lipoprotein,KW-0488~Methylation,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-0636~Prenylation,	LIPID:S-geranylgeranyl cysteine,LIPID:S-palmitoyl cysteine,MOTIF:Effector region,MUTAGEN:Q->L: No loss of localization to lipid droplets and interaction with ZFYVE1.,MUTAGEN:S->N: Loss of localization to lipid droplets and interaction with ZFYVE1.,PROPEP:Removed in mature form,REGION:Disordered,
RAB1A	RAB1A, member RAS oncogene family(RAB1A)	Homo sapiens		h_rabPathway:Rab GTPases Mark Targets In The Endocytotic Machinery,	GO:0000045~autophagosome assembly,GO:0006886~intracellular protein transport,GO:0006888~ER to Golgi vesicle-mediated transport,GO:0006897~endocytosis,GO:0006914~autophagy,GO:0007030~Golgi organization,GO:0016192~vesicle-mediated transport,GO:0016477~cell migration,GO:0019068~virion assembly,GO:0030252~growth hormone secretion,GO:0032402~melanosome transport,GO:0032757~positive regulation of interleukin-8 production,GO:0034446~substrate adhesion-dependent cell spreading,GO:0042742~defense response to bacterium,GO:0047496~vesicle transport along microtubule,GO:0090110~cargo loading into COPII-coated vesicle,GO:1903020~positive regulation of glycoprotein metabolic process,	GO:0000139~Golgi membrane,GO:0005769~early endosome,GO:0005783~endoplasmic reticulum,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0012505~endomembrane system,GO:0030658~transport vesicle membrane,GO:0042470~melanosome,GO:0070062~extracellular exosome,	GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0045296~cadherin binding,	IPR001806:Small_GTPase,IPR005225:Small_GTP-bd_dom,IPR027417:P-loop_NTPase,	hsa04140:Autophagy - animal,hsa05014:Amyotrophic lateral sclerosis,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05130:Pathogenic Escherichia coli infection,hsa05134:Legionellosis,			SM00173:RAS,SM00174:RHO,SM00175:RAB,SM00176:RAN,SM00177:ARF,	KW-0072~Autophagy,KW-0653~Protein transport,KW-0813~Transport,KW-0931~ER-Golgi transport,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0967~Endosome,			KW-0342~GTP-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,	KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0597~Phosphoprotein,KW-0636~Prenylation,	CARBOHYD:(Microbial infection) N-beta-linked (GlcNAc) arginine,COMPBIAS:Polar residues,LIPID:S-geranylgeranyl cysteine,MOTIF:Effector region,MUTAGEN:N->I: Dominant negative mutant. Strongly reduces the levels of CASR present at the cell-surface.,MUTAGEN:R->A: Abolished arginine GlcNAcylation; when associated with A-74 and A-111. Abolished arginine GlcNAcylation; when associated with 72-A--A-74 and A-111.,MUTAGEN:R->A: Abolished arginine GlcNAcylation; when associated with A-74 and A-82. Abolished arginine GlcNAcylation; when associated with 72-A--A-74 and A-82.,MUTAGEN:R->A: Abolished arginine GlcNAcylation; when associated with A-82 and A-111.,MUTAGEN:RFR->AFA: Abolished arginine GlcNAcylation; when associated with A-82 and A-111.,REGION:Disordered,
RAB27A	RAB27A, member RAS oncogene family(RAB27A)	Homo sapiens		h_rabPathway:Rab GTPases Mark Targets In The Endocytotic Machinery,	GO:0006887~exocytosis,GO:0007596~blood coagulation,GO:0010628~positive regulation of gene expression,GO:0019882~antigen processing and presentation,GO:0030318~melanocyte differentiation,GO:0032400~melanosome localization,GO:0032402~melanosome transport,GO:0036257~multivesicular body organization,GO:0043316~cytotoxic T cell degranulation,GO:0043320~natural killer cell degranulation,GO:0045921~positive regulation of exocytosis,GO:0048489~synaptic vesicle transport,GO:0050766~positive regulation of phagocytosis,GO:0071985~multivesicular body sorting pathway,GO:0097278~complement-dependent cytotoxicity,GO:1903307~positive regulation of regulated secretory pathway,GO:1903428~positive regulation of reactive oxygen species biosynthetic process,GO:1903435~positive regulation of constitutive secretory pathway,GO:1990182~exosomal secretion,	GO:0001750~photoreceptor outer segment,GO:0005576~extracellular region,GO:0005764~lysosome,GO:0005770~late endosome,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0016020~membrane,GO:0016324~apical plasma membrane,GO:0030141~secretory granule,GO:0030425~dendrite,GO:0032585~multivesicular body membrane,GO:0033093~Weibel-Palade body,GO:0033162~melanosome membrane,GO:0035580~specific granule lumen,GO:0042470~melanosome,GO:0070062~extracellular exosome,GO:0070382~exocytic vesicle,	GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0019003~GDP binding,GO:0019904~protein domain specific binding,GO:0031489~myosin V binding,	IPR001806:Small_GTPase,IPR005225:Small_GTP-bd_dom,IPR027417:P-loop_NTPase,IPR041837:Rab27a/b,		607624~Griscelli syndrome, type 2,		SM00173:RAS,SM00174:RHO,SM00175:RAB,SM00176:RAN,	KW-0268~Exocytosis,	KW-0458~Lysosome,KW-0472~Membrane,KW-0967~Endosome,	KW-0225~Disease variant,		KW-0342~GTP-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,	KW-0007~Acetylation,KW-0449~Lipoprotein,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0636~Prenylation,KW-1015~Disulfide bond,	LIPID:S-geranylgeranyl cysteine,MOTIF:Effector region,MUTAGEN:A->V: Abolishes interaction with SYTL2.,MUTAGEN:L->P: Abolishes interaction with SYTL2.,MUTAGEN:Q->L: GTP-locked. decreases interaction with DENND10.,MUTAGEN:T->N: GDP-locked. Abolishes interaction with UNC13D and localization to lysosomes. Increases interaction with DENND10. Disrupts late endocytic pathway homeostasis.,
RAB29	RAB29, member RAS oncogene family(RAB29)	Homo sapiens			GO:0001921~positive regulation of receptor recycling,GO:0006886~intracellular protein transport,GO:0007005~mitochondrion organization,GO:0007030~Golgi organization,GO:0007416~synapse assembly,GO:0009617~response to bacterium,GO:0010977~negative regulation of neuron projection development,GO:0016192~vesicle-mediated transport,GO:0030154~cell differentiation,GO:0032438~melanosome organization,GO:0042110~T cell activation,GO:0042147~retrograde transport, endosome to Golgi,GO:0044788~modulation by host of viral process,GO:0050862~positive regulation of T cell receptor signaling pathway,GO:0072657~protein localization to membrane,GO:0090316~positive regulation of intracellular protein transport,GO:1901998~toxin transport,GO:1903441~protein localization to ciliary membrane,GO:1905279~regulation of retrograde transport, endosome to Golgi,	GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005769~early endosome,GO:0005773~vacuole,GO:0005794~Golgi apparatus,GO:0005801~cis-Golgi network,GO:0005802~trans-Golgi network,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0012505~endomembrane system,GO:0016020~membrane,GO:0031982~vesicle,GO:0042470~melanosome,GO:0043231~intracellular membrane-bounded organelle,GO:0048471~perinuclear region of cytoplasm,GO:0055037~recycling endosome,GO:0070062~extracellular exosome,GO:0097708~intracellular vesicle,	GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0019003~GDP binding,GO:0019894~kinesin binding,GO:0031267~small GTPase binding,GO:0070840~dynein complex binding,	IPR001806:Small_GTPase,IPR005225:Small_GTP-bd_dom,IPR027417:P-loop_NTPase,IPR030697:Rab29/Rab38/Rab32,				SM00173:RAS,SM00174:RHO,SM00175:RAB,SM00176:RAN,	KW-0221~Differentiation,KW-0653~Protein transport,KW-0813~Transport,	KW-0206~Cytoskeleton,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0926~Vacuole,KW-0963~Cytoplasm,KW-1003~Cell membrane,			KW-0342~GTP-binding,KW-0547~Nucleotide-binding,		KW-0449~Lipoprotein,KW-0597~Phosphoprotein,KW-0636~Prenylation,	LIPID:S-geranylgeranyl cysteine,MOTIF:Effector region,MUTAGEN:M->S: Loss of LRRK2 binding. Does not stimulate LRRK2 kinase activity. Localized to the cytosol.,MUTAGEN:R->S: Loss of LRRK2 binding. Does not stimulate LRRK2 kinase activity. Localized to the cytosol.,MUTAGEN:S->A: Loss of phosphorylation by LRRK2.,MUTAGEN:S->E: Loss of phosphorylation by LRRK2. Does not stimulate LRRK2 kinase activity; when associated with E-71.,MUTAGEN:T->A: Loss of phosphorylation by LRRK2.,MUTAGEN:T->E: Loss of phosphorylation by LRRK2. Does not stimulate LRRK2 kinase activity; when associated with E-72.,SITE:Cleavage; by S.Typhimurium viral protease GtgE,
RAB2A	RAB2A, member RAS oncogene family(RAB2A)	Homo sapiens		h_rabPathway:Rab GTPases Mark Targets In The Endocytotic Machinery,	GO:0006888~ER to Golgi vesicle-mediated transport,GO:0007030~Golgi organization,GO:0015031~protein transport,GO:0016192~vesicle-mediated transport,	GO:0000139~Golgi membrane,GO:0001669~acrosomal vesicle,GO:0005634~nucleus,GO:0005765~lysosomal membrane,GO:0005789~endoplasmic reticulum membrane,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0033116~endoplasmic reticulum-Golgi intermediate compartment membrane,GO:0042470~melanosome,GO:0070062~extracellular exosome,	GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0019003~GDP binding,	IPR001806:Small_GTPase,IPR005225:Small_GTP-bd_dom,IPR027417:P-loop_NTPase,	hsa04152:AMPK signaling pathway,			SM00173:RAS,SM00174:RHO,SM00175:RAB,SM00176:RAN,	KW-0653~Protein transport,KW-0813~Transport,KW-0931~ER-Golgi transport,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0968~Cytoplasmic vesicle,			KW-0342~GTP-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,	KW-0007~Acetylation,KW-0449~Lipoprotein,KW-0636~Prenylation,	LIPID:S-geranylgeranyl cysteine,MOTIF:Effector region,REGION:Required for interaction with PRKCI,
RAB3GAP1	RAB3 GTPase activating protein catalytic subunit 1(RAB3GAP1)	Homo sapiens			GO:0007420~brain development,GO:0021854~hypothalamus development,GO:0034389~lipid particle organization,GO:0043010~camera-type eye development,GO:0043087~regulation of GTPase activity,GO:0043547~positive regulation of GTPase activity,GO:0048172~regulation of short-term neuronal synaptic plasticity,GO:0060079~excitatory postsynaptic potential,GO:0060325~face morphogenesis,GO:0061646~positive regulation of glutamate neurotransmitter secretion in response to membrane depolarization,GO:0097051~establishment of protein localization to endoplasmic reticulum membrane,GO:1903061~positive regulation of protein lipidation,GO:1903233~regulation of calcium ion-dependent exocytosis of neurotransmitter,GO:1903373~positive regulation of endoplasmic reticulum tubular network organization,GO:2000786~positive regulation of autophagosome assembly,	GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005794~Golgi apparatus,GO:0005811~lipid particle,GO:0005829~cytosol,GO:0032991~macromolecular complex,GO:0070062~extracellular exosome,GO:0071782~endoplasmic reticulum tubular network,GO:0098794~postsynapse,	GO:0005085~guanyl-nucleotide exchange factor activity,GO:0005096~GTPase activator activity,GO:0005515~protein binding,GO:0031267~small GTPase binding,	IPR026147:Rab3GAP1_conserved,IPR045698:Rab3GAP1_C,IPR045700:Rab3GAP1,		600118~Warburg micro syndrome 1,619420~Martsolf syndrome 2,				KW-0256~Endoplasmic reticulum,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0898~Cataract,KW-0991~Intellectual disability,			KW-0343~GTPase activation,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Rab3GAP catalytic subunit C-terminal,DOMAIN:Rab3GAP catalytic subunit conserved,MUTAGEN:R->A: Loss of function.,MUTAGEN:R->A: No effect.,REGION:Disordered,
RAB35	RAB35, member RAS oncogene family(RAB35)	Homo sapiens			GO:0000281~mitotic cytokinesis,GO:0008104~protein localization,GO:0015031~protein transport,GO:0016197~endosomal transport,GO:0019882~antigen processing and presentation,GO:0031175~neuron projection development,GO:0032456~endocytic recycling,GO:0032482~Rab protein signal transduction,GO:0036010~protein localization to endosome,GO:0048227~plasma membrane to endosome transport,GO:1990090~cellular response to nerve growth factor stimulus,	GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005905~clathrin-coated pit,GO:0010008~endosome membrane,GO:0030669~clathrin-coated endocytic vesicle membrane,GO:0031253~cell projection membrane,GO:0042470~melanosome,GO:0045171~intercellular bridge,GO:0045334~clathrin-coated endocytic vesicle,GO:0055038~recycling endosome membrane,GO:0070062~extracellular exosome,	GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0005546~phosphatidylinositol-4,5-bisphosphate binding,GO:0019003~GDP binding,	IPR001806:Small_GTPase,IPR005225:Small_GTP-bd_dom,IPR027417:P-loop_NTPase,IPR041815:Rab35,	hsa04144:Endocytosis,			SM00173:RAS,SM00174:RHO,SM00175:RAB,SM00176:RAN,SM00177:ARF,	KW-0653~Protein transport,KW-0813~Transport,	KW-0168~Coated pit,KW-0472~Membrane,KW-0967~Endosome,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,			KW-0342~GTP-binding,KW-0547~Nucleotide-binding,		KW-0449~Lipoprotein,KW-0597~Phosphoprotein,KW-0636~Prenylation,	COMPBIAS:Basic and acidic residues,LIPID:S-geranylgeranyl cysteine,MOTIF:Effector region,MUTAGEN:Q->L: Loss of GTPase activity. Increased fast recycling.,MUTAGEN:S->N: Destabilization of the intercellular bridge during cytokinesis. Strong reduction in fast recycling.,MUTAGEN:T->A: Loss of phosphorylation. No effect on binding to GDI1 and GDI2.,MUTAGEN:T->E: Phosphomimetic mutant. Loss of binding to GDI1, GDI2, CHM and CHML.,REGION:Disordered,
RAB4A	RAB4A, member RAS oncogene family(RAB4A)	Homo sapiens		h_rabPathway:Rab GTPases Mark Targets In The Endocytotic Machinery,	GO:0015031~protein transport,GO:0016192~vesicle-mediated transport,GO:0019882~antigen processing and presentation,GO:0030100~regulation of endocytosis,GO:0032482~Rab protein signal transduction,	GO:0005768~endosome,GO:0005886~plasma membrane,GO:0030659~cytoplasmic vesicle membrane,GO:0031901~early endosome membrane,GO:0031982~vesicle,GO:0032593~insulin-responsive compartment,GO:0048471~perinuclear region of cytoplasm,GO:0055038~recycling endosome membrane,GO:0070062~extracellular exosome,GO:0098837~postsynaptic recycling endosome,	GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0019003~GDP binding,	IPR001806:Small_GTPase,IPR005225:Small_GTP-bd_dom,IPR027417:P-loop_NTPase,IPR041819:Rab4,	hsa04144:Endocytosis,			SM00173:RAS,SM00174:RHO,SM00175:RAB,SM00176:RAN,SM00177:ARF,	KW-0653~Protein transport,KW-0813~Transport,	KW-0472~Membrane,KW-0963~Cytoplasm,KW-0967~Endosome,			KW-0342~GTP-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,	KW-0449~Lipoprotein,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0636~Prenylation,	LIPID:S-geranylgeranyl cysteine,MOTIF:Effector region,MUTAGEN:G->A: 10-fold decrease in ZFYVE20 binding affinity.,MUTAGEN:G->L: 10-fold decrease in ZFYVE20 binding affinity.,
RAB5C	RAB5C, member RAS oncogene family(RAB5C)	Homo sapiens			GO:0006886~intracellular protein transport,GO:0006897~endocytosis,GO:0048227~plasma membrane to endosome transport,	GO:0005765~lysosomal membrane,GO:0005768~endosome,GO:0005811~lipid particle,GO:0005886~plasma membrane,GO:0012505~endomembrane system,GO:0031901~early endosome membrane,GO:0035577~azurophil granule membrane,GO:0042470~melanosome,GO:0070062~extracellular exosome,	GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0019003~GDP binding,	IPR001806:Small_GTPase,IPR005225:Small_GTP-bd_dom,IPR027417:P-loop_NTPase,	hsa04014:Ras signaling pathway,hsa04137:Mitophagy - animal,hsa04144:Endocytosis,hsa04145:Phagosome,hsa04148:Efferocytosis,hsa04962:Vasopressin-regulated water reabsorption,hsa05132:Salmonella infection,hsa05146:Amoebiasis,hsa05152:Tuberculosis,			SM00173:RAS,SM00174:RHO,SM00175:RAB,SM00176:RAN,	KW-0653~Protein transport,KW-0813~Transport,	KW-0472~Membrane,KW-0967~Endosome,KW-1003~Cell membrane,			KW-0342~GTP-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,	KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0597~Phosphoprotein,KW-0636~Prenylation,	COMPBIAS:Polar residues,LIPID:S-geranylgeranyl cysteine,MOTIF:Effector region,MUTAGEN:S->A: Loss of phosphorylation. No effect on GDI1, GDI2, CHML and CHM binding.,MUTAGEN:S->E: Phosphomimetic mutant. Loss of GDI1, GDI2, CHML and CHM binding.,REGION:Disordered,
RAB6A	RAB6A, member RAS oncogene family(RAB6A)	Homo sapiens		h_rabPathway:Rab GTPases Mark Targets In The Endocytotic Machinery,	GO:0006886~intracellular protein transport,GO:0006890~retrograde vesicle-mediated transport, Golgi to ER,GO:0006891~intra-Golgi vesicle-mediated transport,GO:0018125~peptidyl-cysteine methylation,GO:0019882~antigen processing and presentation,GO:0031175~neuron projection development,GO:0034067~protein localization to Golgi apparatus,GO:0034498~early endosome to Golgi transport,GO:0042147~retrograde transport, endosome to Golgi,GO:0051179~localization,GO:0072385~minus-end-directed organelle transport along microtubule,GO:1903292~protein localization to Golgi membrane,	GO:0000139~Golgi membrane,GO:0002080~acrosomal membrane,GO:0005789~endoplasmic reticulum membrane,GO:0005794~Golgi apparatus,GO:0005802~trans-Golgi network,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0012505~endomembrane system,GO:0016020~membrane,GO:0030667~secretory granule membrane,GO:0031410~cytoplasmic vesicle,GO:0032588~trans-Golgi network membrane,GO:0070062~extracellular exosome,GO:0070381~endosome to plasma membrane transport vesicle,	GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0019904~protein domain specific binding,GO:0031489~myosin V binding,	IPR001806:Small_GTPase,IPR005225:Small_GTP-bd_dom,IPR027417:P-loop_NTPase,				SM00173:RAS,SM00174:RHO,SM00175:RAB,SM00176:RAN,	KW-0653~Protein transport,KW-0813~Transport,KW-0931~ER-Golgi transport,KW-0945~Host-virus interaction,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0968~Cytoplasmic vesicle,			KW-0342~GTP-binding,KW-0547~Nucleotide-binding,		KW-0007~Acetylation,KW-0449~Lipoprotein,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0636~Prenylation,	LIPID:S-geranylgeranyl cysteine,MOTIF:Effector region,MUTAGEN:I->E: Loss of RAB6IP1-binding.,MUTAGEN:Q->L: Loss of GTPase activity. Interacts with APBA1.,MUTAGEN:T->N: Loss of APBA1-binding. No loss of RIC1- and RGP1-binding.,
RAB7A	RAB7A, member RAS oncogene family(RAB7A)	Homo sapiens		h_rabPathway:Rab GTPases Mark Targets In The Endocytotic Machinery,	GO:0000045~autophagosome assembly,GO:0006622~protein targeting to lysosome,GO:0006897~endocytosis,GO:0007174~epidermal growth factor catabolic process,GO:0008333~endosome to lysosome transport,GO:0009617~response to bacterium,GO:0015031~protein transport,GO:0016042~lipid catabolic process,GO:0019076~viral release from host cell,GO:0022615~protein to membrane docking,GO:0042147~retrograde transport, endosome to Golgi,GO:0045022~early endosome to late endosome transport,GO:0045453~bone resorption,GO:0045732~positive regulation of protein catabolic process,GO:0046907~intracellular transport,GO:0048524~positive regulation of viral process,GO:0051650~establishment of vesicle localization,GO:0061724~lipophagy,GO:0090382~phagosome maturation,GO:0090383~phagosome acidification,GO:0090385~phagosome-lysosome fusion,GO:0099638~endosome to plasma membrane protein transport,GO:1903542~negative regulation of exosomal secretion,GO:1903543~positive regulation of exosomal secretion,GO:1905366~negative regulation of intralumenal vesicle formation,	GO:0000421~autophagosome membrane,GO:0005739~mitochondrion,GO:0005764~lysosome,GO:0005765~lysosomal membrane,GO:0005770~late endosome,GO:0005794~Golgi apparatus,GO:0005811~lipid particle,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0010008~endosome membrane,GO:0030667~secretory granule membrane,GO:0030670~phagocytic vesicle membrane,GO:0030672~synaptic vesicle membrane,GO:0030904~retromer complex,GO:0031902~late endosome membrane,GO:0031966~mitochondrial membrane,GO:0033162~melanosome membrane,GO:0034045~pre-autophagosomal structure membrane,GO:0045335~phagocytic vesicle,GO:0070062~extracellular exosome,GO:0097208~alveolar lamellar body,	GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0019003~GDP binding,GO:0031267~small GTPase binding,GO:1905394~retromer complex binding,	IPR001806:Small_GTPase,IPR005225:Small_GTP-bd_dom,IPR027417:P-loop_NTPase,	hsa04137:Mitophagy - animal,hsa04140:Autophagy - animal,hsa04144:Endocytosis,hsa04145:Phagosome,hsa04148:Efferocytosis,hsa05132:Salmonella infection,hsa05146:Amoebiasis,hsa05152:Tuberculosis,	600882~Charcot-Marie-Tooth disease, type 2B,		SM00173:RAS,SM00174:RHO,SM00175:RAB,SM00176:RAN,	KW-0072~Autophagy,KW-0442~Lipid degradation,KW-0443~Lipid metabolism,KW-0653~Protein transport,KW-0813~Transport,KW-0945~Host-virus interaction,	KW-0458~Lysosome,KW-0472~Membrane,KW-0496~Mitochondrion,KW-0551~Lipid droplet,KW-0967~Endosome,KW-0968~Cytoplasmic vesicle,	KW-0144~Charcot-Marie-Tooth disease,KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0622~Neuropathy,		KW-0342~GTP-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,	KW-0007~Acetylation,KW-0449~Lipoprotein,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0636~Prenylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),LIPID:S-geranylgeranyl cysteine,MOTIF:Effector region,MUTAGEN:K->A: Abolishes interaction with RILP and localization to late endosomal/lysosomal compartments.,MUTAGEN:L->A: Abolishes interaction with RILP and reduces its localization to late endosomal/lysosomal compartments.,MUTAGEN:L->A: Does not abolish interaction with RILP and localization to late endosomal/lysosomal compartments. Does not abolish interaction with RILP and localization to late endosomal/lysosomal compartments; when associated with A-183.,MUTAGEN:Q->L: Does not abolish localization on late endosomes, lysosomes and phagosomes and does not reduce phagosomal fusions. No loss of interaction with CLN5 and VPS13A. Increases interaction with PRPH. Inhibits SARS-CoV-2 infection.,MUTAGEN:T->N: Abolishes localization on late endosomes, lysosomes and phagosomes and reduces phagosomal fusions. Abolishes association of RILP with the phagosomes. No loss of interaction with CLN5. No loss of interaction with PRPH. Reduced interaction with VPS13A. Inhibits SARS-CoV-2 infection.,MUTAGEN:V->A: Abolishes interaction with RILP and localization to late endosomal/lysosomal compartments.,MUTAGEN:Y->A: Does not abolish interaction with RILP and localization to late endosomal/lysosomal compartments. Does not abolish interaction with RILP and localization to late endosomal/lysosomal compartments; when associated with A-182.,
RAB8A	RAB8A, member RAS oncogene family(RAB8A)	Homo sapiens		h_rabPathway:Rab GTPases Mark Targets In The Endocytotic Machinery,	GO:0006904~vesicle docking involved in exocytosis,GO:0006914~autophagy,GO:0007030~Golgi organization,GO:0007409~axonogenesis,GO:0009306~protein secretion,GO:0010506~regulation of autophagy,GO:0017157~regulation of exocytosis,GO:0032456~endocytic recycling,GO:0032869~cellular response to insulin stimulus,GO:0048169~regulation of long-term neuronal synaptic plasticity,GO:0048210~Golgi vesicle fusion to target membrane,GO:0051223~regulation of protein transport,GO:0060271~cilium assembly,GO:0061512~protein localization to cilium,GO:0072659~protein localization to plasma membrane,GO:0098887~neurotransmitter receptor transport, endosome to postsynaptic membrane,GO:0098969~neurotransmitter receptor transport to postsynaptic membrane,GO:0099003~vesicle-mediated transport in synapse,	GO:0000139~Golgi membrane,GO:0005768~endosome,GO:0005813~centrosome,GO:0005814~centriole,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005929~cilium,GO:0008021~synaptic vesicle,GO:0010008~endosome membrane,GO:0014069~postsynaptic density,GO:0030140~trans-Golgi network transport vesicle,GO:0030496~midbody,GO:0030670~phagocytic vesicle membrane,GO:0032588~trans-Golgi network membrane,GO:0036064~ciliary basal body,GO:0043025~neuronal cell body,GO:0043197~dendritic spine,GO:0045335~phagocytic vesicle,GO:0055038~recycling endosome membrane,GO:0060170~ciliary membrane,GO:0070062~extracellular exosome,GO:0097546~ciliary base,GO:0097730~non-motile cilium,GO:0098978~glutamatergic synapse,	GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0019003~GDP binding,GO:0031267~small GTPase binding,GO:0031489~myosin V binding,GO:1990782~protein tyrosine kinase binding,	IPR001806:Small_GTPase,IPR005225:Small_GTP-bd_dom,IPR027417:P-loop_NTPase,	hsa04140:Autophagy - animal,hsa04144:Endocytosis,hsa04152:AMPK signaling pathway,hsa04530:Tight junction,hsa04972:Pancreatic secretion,hsa05014:Amyotrophic lateral sclerosis,hsa05022:Pathways of neurodegeneration - multiple diseases,			SM00173:RAS,SM00174:RHO,SM00175:RAB,SM00176:RAN,SM00177:ARF,	KW-0072~Autophagy,KW-0653~Protein transport,KW-0813~Transport,KW-0970~Cilium biogenesis/degradation,	KW-0206~Cytoskeleton,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-0967~Endosome,KW-0968~Cytoplasmic vesicle,KW-0969~Cilium,KW-1003~Cell membrane,	KW-0656~Proto-oncogene,		KW-0342~GTP-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,	KW-0449~Lipoprotein,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0636~Prenylation,	LIPID:S-geranylgeranyl cysteine,MOTIF:Effector region,MUTAGEN:Q->L: Probable constitutively active mutant locked in the active GTP-bound form. Stimulates interaction with MICALL1. Increased WDR44-positive tubulation.,MUTAGEN:T->A: Loss of phosphorylation. No effect on the binding of GDP or GTP. Localizes primarily to the Golgi complex but does not affect membrane localization.,MUTAGEN:T->E: Phosphomimetic mutant. No effect on the binding of GDP or GTP. Loss of GDI1, GDI2, CHM, CHML, RABGGTA, RABGGTB, RAB3IP, TBC1D15, and INPP5B binding. Increases localization to the cell membrane.,MUTAGEN:T->N: Loss of interaction with MICAL1. Loss of GRAF1/ARHGAP26 and GRAF2/ARHGAP10 tubular localization. Loss of E-cadherin and MMP14 export.,PROPEP:Removed in mature form,
RAB8B	RAB8B, member RAS oncogene family(RAB8B)	Homo sapiens			GO:0006904~vesicle docking involved in exocytosis,GO:0009306~protein secretion,GO:0017157~regulation of exocytosis,GO:0019882~antigen processing and presentation,GO:0031346~positive regulation of cell projection organization,GO:0032456~endocytic recycling,GO:0045046~protein import into peroxisome membrane,GO:0048210~Golgi vesicle fusion to target membrane,GO:0051461~positive regulation of corticotropin secretion,GO:0072659~protein localization to plasma membrane,	GO:0005768~endosome,GO:0005778~peroxisomal membrane,GO:0005886~plasma membrane,GO:0008021~synaptic vesicle,GO:0010008~endosome membrane,GO:0030140~trans-Golgi network transport vesicle,GO:0030670~phagocytic vesicle membrane,GO:0045335~phagocytic vesicle,GO:0048471~perinuclear region of cytoplasm,GO:0051286~cell tip,GO:0055038~recycling endosome membrane,GO:0070062~extracellular exosome,	GO:0003924~GTPase activity,GO:0005102~receptor binding,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0019003~GDP binding,GO:0030911~TPR domain binding,	IPR001806:Small_GTPase,IPR005225:Small_GTP-bd_dom,IPR027417:P-loop_NTPase,	hsa04530:Tight junction,			SM00173:RAS,SM00174:RHO,SM00175:RAB,SM00176:RAN,SM00177:ARF,	KW-0653~Protein transport,KW-0813~Transport,	KW-0472~Membrane,KW-0967~Endosome,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,			KW-0342~GTP-binding,KW-0547~Nucleotide-binding,		KW-0449~Lipoprotein,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0636~Prenylation,	LIPID:S-geranylgeranyl cysteine,MOTIF:Effector region,MUTAGEN:T->A: Loss of phosphorylation. No effect on GDI1 and GDI2 binding. Reduced binding to CHM and CHML.,MUTAGEN:T->E: Phosphomimetic mutant. Loss of binding to GDI1, GDI2, CHM, and CHML.,PROPEP:Removed in mature form,
RANBP1	RAN binding protein 1(RANBP1)	Homo sapiens		h_ranMSPathway:Role of Ran in mitotic spindle regulation,h_ranPathway:Cycling of Ran in nucleocytoplasmic transport,	GO:0006913~nucleocytoplasmic transport,GO:0007051~spindle organization,GO:0007165~signal transduction,GO:0046604~positive regulation of mitotic centrosome separation,GO:0046907~intracellular transport,	GO:0005634~nucleus,GO:0005635~nuclear envelope,GO:0005643~nuclear pore,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005829~cytosol,	GO:0005092~GDP-dissociation inhibitor activity,GO:0005096~GTPase activator activity,GO:0005515~protein binding,GO:0031267~small GTPase binding,GO:0045296~cadherin binding,	IPR000156:Ran_bind_dom,IPR011993:PH-like_dom_sf,IPR045255:RanBP1-like,IPR045256:RanBP1_RanBD,	hsa05166:Human T-cell leukemia virus 1 infection,hsa05203:Viral carcinogenesis,			SM00160:RanBD,						KW-0343~GTPase activation,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:RanBD1,REGION:Disordered,
RANBP2	RAN binding protein 2(RANBP2)	Homo sapiens		h_npcPathway:Mechanism of Protein Import into the Nucleus,h_ranbp2Pathway:Sumoylation by RanBP2 Regulates Transcriptional Repression,h_ranPathway:Cycling of Ran in nucleocytoplasmic transport,	GO:0001975~response to amphetamine,GO:0006111~regulation of gluconeogenesis,GO:0006457~protein folding,GO:0006607~NLS-bearing protein import into nucleus,GO:0006913~nucleocytoplasmic transport,GO:0016925~protein sumoylation,GO:0046907~intracellular transport,GO:0051028~mRNA transport,GO:0051168~nuclear export,GO:0051642~centrosome localization,	GO:0005635~nuclear envelope,GO:0005642~annulate lamellae,GO:0005643~nuclear pore,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016020~membrane,GO:0031965~nuclear membrane,GO:0042405~nuclear inclusion body,GO:0043231~intracellular membrane-bounded organelle,GO:0044614~nuclear pore cytoplasmic filaments,GO:0044615~nuclear pore nuclear basket,GO:1990723~cytoplasmic periphery of the nuclear pore complex,	GO:0003723~RNA binding,GO:0003755~peptidyl-prolyl cis-trans isomerase activity,GO:0005096~GTPase activator activity,GO:0005515~protein binding,GO:0019789~SUMO transferase activity,GO:0031267~small GTPase binding,GO:0044877~macromolecular complex binding,GO:0046872~metal ion binding,GO:0061665~SUMO ligase activity,	IPR000156:Ran_bind_dom,IPR001876:Znf_RanBP2,IPR002130:Cyclophilin-type_PPIase_dom,IPR011990:TPR-like_helical_dom_sf,IPR011993:PH-like_dom_sf,IPR019734:TPR_repeat,IPR020892:Cyclophilin-type_PPIase_CS,IPR022011:IR1-M,IPR029000:Cyclophilin-like_dom_sf,IPR036443:Znf_RanBP2_sf,IPR045255:RanBP1-like,	hsa03013:Nucleocytoplasmic transport,hsa03250:Viral life cycle - HIV-1,hsa05014:Amyotrophic lateral sclerosis,	608033~Encephalopathy, acute, infection-induced, 3, susceptibility to,		SM00028:TPR,SM00160:RanBD,SM00547:ZnF_RBZ,	KW-0509~mRNA transport,KW-0653~Protein transport,KW-0811~Translocation,KW-0813~Transport,KW-0833~Ubl conjugation pathway,	KW-0472~Membrane,KW-0539~Nucleus,KW-0906~Nuclear pore complex,		KW-0677~Repeat,KW-0802~TPR repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0413~Isomerase,KW-0694~RNA-binding,KW-0697~Rotamase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:PPIase cyclophilin-type,DOMAIN:RanBD1,DOMAIN:RanBD1 1,DOMAIN:RanBD1 2,DOMAIN:RanBD1 3,DOMAIN:RanBD1 4,DOMAIN:RanBP2-type,MUTAGEN:C->S,A: Impairs SUMO E3 ligase activity.,MUTAGEN:D->A: Impairs SUMO E3 ligase activity.,MUTAGEN:F->A: Abolishes binding to UBE2I and SUMO E3 ligase activity.,MUTAGEN:F->A: Impairs SUMO E3 ligase activity.,MUTAGEN:I->K: Abolishes interaction with sumoylated RANGAP1.,MUTAGEN:K->A: No effect on SUMO E3 ligase activity.,MUTAGEN:L->A: Abolishes binding to UBE2I and SUMO E3 ligase activity.,MUTAGEN:P->A: Impairs SUMO E3 ligase activity.,MUTAGEN:P->A: No effect on SUMO E3 ligase activity.,MUTAGEN:T->A: Impairs SUMO E3 ligase activity.,MUTAGEN:V->K: Abolishes interaction with sumoylated RANGAP1.,MUTAGEN:Y->A: Impairs SUMO E3 ligase activity.,REGION:2 X 50 AA approximate repeats,REGION:22 X 2 AA repeats of F-G,REGION:Disordered,REGION:Interaction with BICD2,REGION:Interaction with SUMO1,REGION:Interaction with UBE2I,REGION:Interaction with sumoylated RANGAP1,REGION:Required for E3 SUMO-ligase activity,REPEAT:1,REPEAT:10,REPEAT:11,REPEAT:12,REPEAT:13,REPEAT:14,REPEAT:15,REPEAT:16,REPEAT:17,REPEAT:18,REPEAT:19,REPEAT:2,REPEAT:20,REPEAT:21,REPEAT:22,REPEAT:3,REPEAT:4,REPEAT:5,REPEAT:6,REPEAT:7,REPEAT:8,REPEAT:9,REPEAT:TPR,REPEAT:TPR 1,REPEAT:TPR 2,REPEAT:TPR 3,REPEAT:TPR 4,REPEAT:TPR 5,REPEAT:TPR 6,REPEAT:TPR 7,SITE:Breakpoint for translocation to form RANBP2-FGFR1 protein,ZN_FING:RanBP2-type 1,ZN_FING:RanBP2-type 2,ZN_FING:RanBP2-type 3,ZN_FING:RanBP2-type 4,ZN_FING:RanBP2-type 5,ZN_FING:RanBP2-type 6,ZN_FING:RanBP2-type 7,ZN_FING:RanBP2-type 8,
RANBP3	RAN binding protein 3(RANBP3)	Homo sapiens			GO:0006611~protein export from nucleus,GO:0046907~intracellular transport,	GO:0005634~nucleus,GO:0005643~nuclear pore,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,	GO:0005096~GTPase activator activity,GO:0005515~protein binding,GO:0031267~small GTPase binding,GO:0070412~R-SMAD binding,	IPR000156:Ran_bind_dom,IPR011993:PH-like_dom_sf,IPR045255:RanBP1-like,	hsa05166:Human T-cell leukemia virus 1 infection,			SM00160:RanBD,	KW-0653~Protein transport,KW-0813~Transport,	KW-0539~Nucleus,KW-0963~Cytoplasm,					KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:RanBD1,REGION:Disordered,
RBCK1	RANBP2-type and C3HC4-type zinc finger containing 1(RBCK1)	Homo sapiens			GO:0000209~protein polyubiquitination,GO:0016567~protein ubiquitination,GO:0032088~negative regulation of NF-kappaB transcription factor activity,GO:0042742~defense response to bacterium,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0050852~T cell receptor signaling pathway,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0051220~cytoplasmic sequestering of protein,GO:0060546~negative regulation of necroptotic process,GO:0097039~protein linear polyubiquitination,GO:1901224~positive regulation of NIK/NF-kappaB signaling,GO:2001238~positive regulation of extrinsic apoptotic signaling pathway,	GO:0005829~cytosol,GO:0071797~LUBAC complex,	GO:0003713~transcription coactivator activity,GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0043130~ubiquitin binding,GO:0046872~metal ion binding,GO:1990757~ubiquitin ligase activator activity,	IPR000626:Ubiquitin-like_dom,IPR001841:Znf_RING,IPR001876:Znf_RanBP2,IPR013083:Znf_RING/FYVE/PHD,IPR017907:Znf_RING_CS,IPR027370:Znf-RING_euk,IPR029071:Ubiquitin-like_domsf,IPR036443:Znf_RanBP2_sf,IPR044066:TRIAD_supradom,IPR047557:Rcat_RBR_HOIL1,IPR047558:BRcat_RBR_HOIL1,IPR047559:HOIL1_RBR_mRING-HC-C3HC3D,	hsa04217:Necroptosis,hsa04621:NOD-like receptor signaling pathway,hsa05131:Shigellosis,	615895~Polyglucosan body myopathy 1 with or without immunodeficiency,		SM00184:RING,SM00547:ZnF_RBZ,	KW-0833~Ubl conjugation pathway,KW-0945~Host-virus interaction,		KW-0225~Disease variant,	KW-0175~Coiled coil,KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:RING-type,DOMAIN:RanBP2-type,DOMAIN:Ubiquitin-like,MUTAGEN:C->S: Binds to IREB2 in iron-treated cells. Reversed iron-induced down-regulation of IREB2. No ubiquitination of heme-loaded IREB2; when associated with S-282.,MUTAGEN:C->S: Binds to IREB2 in iron-treated cells. Reversed iron-induced down-regulation of IREB2. No ubiquitination of heme-loaded IREB2; when associated with S-285.,REGION:Disordered,REGION:Interaction with IRF3,REGION:Interaction with RNF31,REGION:Interaction with TAB2,REGION:TRIAD supradomain,ZN_FING:IBR-type,ZN_FING:RING-type 1,ZN_FING:RING-type 2; atypical,ZN_FING:RanBP2-type,
RAP1A	RAP1A, member of RAS oncogene family(RAP1A)	Homo sapiens		h_integrinPathway:Integrin Signaling Pathway,h_metPathway:Signaling of Hepatocyte Growth Factor Receptor,	GO:0007399~nervous system development,GO:0010976~positive regulation of neuron projection development,GO:0016079~synaptic vesicle exocytosis,GO:0032486~Rap protein signal transduction,GO:0038180~nerve growth factor signaling pathway,GO:0043547~positive regulation of GTPase activity,GO:0045860~positive regulation of protein kinase activity,GO:0061028~establishment of endothelial barrier,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0071320~cellular response to cAMP,GO:0072659~protein localization to plasma membrane,GO:1901888~regulation of cell junction assembly,GO:1990090~cellular response to nerve growth factor stimulus,GO:2000301~negative regulation of synaptic vesicle exocytosis,GO:2001214~positive regulation of vasculogenesis,	GO:0005737~cytoplasm,GO:0005769~early endosome,GO:0005770~late endosome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0010008~endosome membrane,GO:0016020~membrane,GO:0030054~cell junction,GO:0032045~guanyl-nucleotide exchange factor complex,GO:0035579~specific granule membrane,GO:0043005~neuron projection,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,GO:0070161~anchoring junction,GO:0097225~sperm midpiece,GO:0098793~presynapse,GO:0098978~glutamatergic synapse,	GO:0003924~GTPase activity,GO:0005085~guanyl-nucleotide exchange factor activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0019003~GDP binding,GO:0031267~small GTPase binding,GO:0044877~macromolecular complex binding,	IPR001806:Small_GTPase,IPR005225:Small_GTP-bd_dom,IPR020849:Small_GTPase_Ras-type,IPR027417:P-loop_NTPase,IPR038851:Rap1,	hsa04010:MAPK signaling pathway,hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04024:cAMP signaling pathway,hsa04062:Chemokine signaling pathway,hsa04510:Focal adhesion,hsa04520:Adherens junction,hsa04530:Tight junction,hsa04611:Platelet activation,hsa04670:Leukocyte transendothelial migration,hsa04720:Long-term potentiation,hsa04722:Neurotrophin signaling pathway,hsa04934:Cushing syndrome,hsa04972:Pancreatic secretion,hsa05211:Renal cell carcinoma,hsa05417:Lipid and atherosclerosis,			SM00173:RAS,SM00174:RHO,SM00175:RAB,SM00176:RAN,	KW-0524~Neurogenesis,	KW-0472~Membrane,KW-0963~Cytoplasm,KW-0965~Cell junction,KW-0967~Endosome,KW-1003~Cell membrane,	KW-0043~Tumor suppressor,		KW-0342~GTP-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,	KW-0449~Lipoprotein,KW-0488~Methylation,KW-0636~Prenylation,	LIPID:S-geranylgeranyl cysteine,MOTIF:Effector region,PROPEP:Removed in mature form,
RAP1B	RAP1B, member of RAS oncogene family(RAP1B)	Homo sapiens		h_ephA4Pathway:Eph Kinases and ephrins support platelet aggregation,h_metPathway:Signaling of Hepatocyte Growth Factor Receptor,	GO:0007165~signal transduction,GO:0008283~cell proliferation,GO:0017156~calcium ion regulated exocytosis,GO:0032486~Rap protein signal transduction,GO:0033625~positive regulation of integrin activation,GO:0045955~negative regulation of calcium ion-dependent exocytosis,GO:0051649~establishment of localization in cell,GO:0061028~establishment of endothelial barrier,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0071320~cellular response to cAMP,GO:0099010~modification of postsynaptic structure,GO:1901888~regulation of cell junction assembly,GO:2000114~regulation of establishment of cell polarity,GO:2000301~negative regulation of synaptic vesicle exocytosis,	GO:0005811~lipid particle,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005911~cell-cell junction,GO:0016020~membrane,GO:0035577~azurophil granule membrane,GO:0070062~extracellular exosome,GO:0098978~glutamatergic synapse,	GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0019003~GDP binding,GO:0044877~macromolecular complex binding,	IPR001806:Small_GTPase,IPR005225:Small_GTP-bd_dom,IPR020849:Small_GTPase_Ras-type,IPR027417:P-loop_NTPase,IPR038851:Rap1,	hsa04010:MAPK signaling pathway,hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04024:cAMP signaling pathway,hsa04062:Chemokine signaling pathway,hsa04510:Focal adhesion,hsa04520:Adherens junction,hsa04611:Platelet activation,hsa04670:Leukocyte transendothelial migration,hsa04720:Long-term potentiation,hsa04722:Neurotrophin signaling pathway,hsa04934:Cushing syndrome,hsa04972:Pancreatic secretion,hsa05211:Renal cell carcinoma,hsa05417:Lipid and atherosclerosis,	620654~Thrombocytopenia 11 with multiple congenital anomalies and dysmorphic facies,		SM00173:RAS,SM00174:RHO,SM00175:RAB,SM00176:RAN,		KW-0472~Membrane,KW-0963~Cytoplasm,KW-0965~Cell junction,KW-1003~Cell membrane,			KW-0342~GTP-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,	KW-0013~ADP-ribosylation,KW-0449~Lipoprotein,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0636~Prenylation,	LIPID:S-geranylgeranyl cysteine,MOTIF:Effector region,MUTAGEN:D->A: Impairs interaction with KRIT1.,MUTAGEN:E->A: Strong reduction in nucleotide exchange with EPAC2.,MUTAGEN:F->A: Abolishes complex formation with RAP1GAP. Loss GTPase activity.,MUTAGEN:G->V: Constitutively activated.,MUTAGEN:Q->A: Impairs interaction with KRIT1.,MUTAGEN:Q->E: Abolishes complex formation with RAP1GAP. Loss GTPase activity.,MUTAGEN:S->A: Abolishes phosphorylation by PKA.,MUTAGEN:Y->A: 25-fold reduction in RAP1GAP-stimulated GTPase activity.,MUTAGEN:Y->F: 2-fold reduction in RAP1GAP-stimulated GTPase activity.,PROPEP:Removed in mature form,REGION:Interaction with KRIT1,
RAP2B	RAP2B, member of RAS oncogene family(RAP2B)	Homo sapiens		h_plcePathway:Phospholipase C-epsilon pathway,	GO:0007165~signal transduction,GO:0030168~platelet activation,GO:0030336~negative regulation of cell migration,GO:0031954~positive regulation of protein autophosphorylation,GO:0032486~Rap protein signal transduction,GO:0061097~regulation of protein tyrosine kinase activity,GO:0070527~platelet aggregation,	GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005923~bicellular tight junction,GO:0016020~membrane,GO:0035579~specific granule membrane,GO:0044291~cell-cell contact zone,GO:0045121~membrane raft,GO:0055038~recycling endosome membrane,GO:0070062~extracellular exosome,GO:0070821~tertiary granule membrane,	GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0019003~GDP binding,GO:0019904~protein domain specific binding,	IPR001806:Small_GTPase,IPR005225:Small_GTP-bd_dom,IPR020849:Small_GTPase_Ras-type,IPR027417:P-loop_NTPase,IPR041840:Rap2,				SM00173:RAS,SM00174:RHO,SM00175:RAB,		KW-0472~Membrane,KW-0967~Endosome,			KW-0342~GTP-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,	KW-0449~Lipoprotein,KW-0488~Methylation,KW-0564~Palmitate,KW-0636~Prenylation,	LIPID:S-geranylgeranyl cysteine,LIPID:S-palmitoyl cysteine,MOTIF:Effector region,PROPEP:Removed in mature form,
RORA	RAR related orphan receptor A(RORA)	Homo sapiens			GO:0001525~angiogenesis,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006805~xenobiotic metabolic process,GO:0006809~nitric oxide biosynthetic process,GO:0008589~regulation of smoothened signaling pathway,GO:0010575~positive regulation of vascular endothelial growth factor production,GO:0010906~regulation of glucose metabolic process,GO:0019218~regulation of steroid metabolic process,GO:0021702~cerebellar Purkinje cell differentiation,GO:0021930~cerebellar granule cell precursor proliferation,GO:0030522~intracellular receptor signaling pathway,GO:0032922~circadian regulation of gene expression,GO:0036315~cellular response to sterol,GO:0042632~cholesterol homeostasis,GO:0042692~muscle cell differentiation,GO:0042753~positive regulation of circadian rhythm,GO:0043030~regulation of macrophage activation,GO:0043124~negative regulation of I-kappaB kinase/NF-kappaB signaling,GO:0045599~negative regulation of fat cell differentiation,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046068~cGMP metabolic process,GO:0050728~negative regulation of inflammatory response,GO:0070328~triglyceride homeostasis,GO:0071347~cellular response to interleukin-1,GO:0071356~cellular response to tumor necrosis factor,GO:0071456~cellular response to hypoxia,GO:0072539~T-helper 17 cell differentiation,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001221~transcription cofactor binding,GO:0001222~transcription corepressor binding,GO:0001223~transcription coactivator binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0004879~RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding,GO:0005515~protein binding,GO:0008013~beta-catenin binding,GO:0008142~oxysterol binding,GO:0008270~zinc ion binding,GO:0043565~sequence-specific DNA binding,GO:0098531~transcription factor activity, direct ligand regulated sequence-specific DNA binding,	IPR000536:Nucl_hrmn_rcpt_lig-bd,IPR001628:Znf_hrmn_rcpt,IPR001723:Nuclear_hrmn_rcpt,IPR003079:ROR_rcpt,IPR013088:Znf_NHR/GATA,IPR035500:NHR-like_dom_sf,IPR044101:NR_DBD_ROR,	hsa04659:Th17 cell differentiation,hsa04710:Circadian rhythm,hsa05017:Spinocerebellar ataxia,hsa05321:Inflammatory bowel disease,	618060~Intellectual developmental disorder with or without epilepsy or cerebellar ataxia,		SM00399:ZnF_C4,SM00430:HOLI,	KW-0090~Biological rhythms,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-0887~Epilepsy,KW-0991~Intellectual disability,	KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0217~Developmental protein,KW-0238~DNA-binding,KW-0675~Receptor,KW-9996~Developmental protein,	KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO),DNA_BIND:Nuclear receptor,DOMAIN:NR LBD,DOMAIN:Nuclear receptor,MOTIF:AF-2,MUTAGEN:A->L: About 80% loss of transcriptional activity.,MUTAGEN:A->Q: Almost total loss of transcriptional activity.,MUTAGEN:C->L: About 60% loss of transcriptional activity.,MUTAGEN:C->Q: Less effect on transcriptional activity with cholesterol sulfate as substrate as compared to cholesterol as substrate.,MUTAGEN:E->K: Abolishes transcriptional activity. Protects from protein degradation.,MUTAGEN:F->W: Slight loss of transcriptional activity.,MUTAGEN:H->W: Almost total loss of transcriptional activity.,MUTAGEN:K->A: Complete loss of transcriptional activity; when associated with A-507.,MUTAGEN:K->A: Increased transcriptional activity. No effect on protein degradation.,MUTAGEN:K->R: Loss of sumoylation.,MUTAGEN:K->R: No effect on sumoylation.,MUTAGEN:L->F: Small reduction in transcriptional activity. No protein degradation.,MUTAGEN:LF->AA: Decreases interaction with NCOA2. Loss of interaction with FOXP3.,MUTAGEN:T->A: Greatly increased transcriptional activity. Decrease in repression by NR1D1.,MUTAGEN:T->D,E: Some increase in transcriptional activity. No change in repression by NR1D1.,MUTAGEN:T->R: Attenuates transcriptional activity.,MUTAGEN:T->V,I: Some increase in transcriptional activity.,MUTAGEN:V->G: Greatly reduced transcriptional activity. Protects from protein degradation.,MUTAGEN:V->R: Strongly decreases interaction with NCOA2 and MED1.,MUTAGEN:Y->A: Complete loss of transcriptional activity; when associated with A-339.,MUTAGEN:Y->F: About 40% loss of transcriptional activity.,REGION:Disordered,ZN_FING:NR C4-type,
RASGRP1	RAS guanyl releasing protein 1(RASGRP1)	Homo sapiens			GO:0001934~positive regulation of protein phosphorylation,GO:0002437~inflammatory response to antigenic stimulus,GO:0007165~signal transduction,GO:0007264~small GTPase mediated signal transduction,GO:0007265~Ras protein signal transduction,GO:0030101~natural killer cell activation,GO:0030154~cell differentiation,GO:0032252~secretory granule localization,GO:0032725~positive regulation of granulocyte macrophage colony-stimulating factor production,GO:0032729~positive regulation of interferon-gamma production,GO:0032760~positive regulation of tumor necrosis factor production,GO:0032825~positive regulation of natural killer cell differentiation,GO:0033089~positive regulation of T cell differentiation in thymus,GO:0042098~T cell proliferation,GO:0042100~B cell proliferation,GO:0042110~T cell activation,GO:0042113~B cell activation,GO:0043303~mast cell degranulation,GO:0043406~positive regulation of MAP kinase activity,GO:0043547~positive regulation of GTPase activity,GO:0045954~positive regulation of natural killer cell mediated cytotoxicity,GO:0046330~positive regulation of JNK cascade,GO:0046579~positive regulation of Ras protein signal transduction,GO:0047496~vesicle transport along microtubule,GO:0051896~regulation of protein kinase B signaling,GO:0070372~regulation of ERK1 and ERK2 cascade,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0090630~activation of GTPase activity,	GO:0000139~Golgi membrane,GO:0005789~endoplasmic reticulum membrane,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016020~membrane,	GO:0005085~guanyl-nucleotide exchange factor activity,GO:0005509~calcium ion binding,GO:0008270~zinc ion binding,GO:0008289~lipid binding,GO:0019992~diacylglycerol binding,GO:0031210~phosphatidylcholine binding,GO:0042802~identical protein binding,	IPR000651:Ras-like_Gua-exchang_fac_N,IPR001895:RASGEF_cat_dom,IPR002048:EF_hand_dom,IPR002219:PE/DAG-bd,IPR008937:Ras-like_GEF,IPR011992:EF-hand-dom_pair,IPR018247:EF_Hand_1_Ca_BS,IPR020454:DAG/PE-bd,IPR023578:Ras_GEF_dom_sf,IPR036964:RASGEF_cat_dom_sf,IPR046349:C1-like_sf,	hsa04010:MAPK signaling pathway,hsa04014:Ras signaling pathway,hsa04611:Platelet activation,hsa04660:T cell receptor signaling pathway,hsa05200:Pathways in cancer,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,	618534~Immunodeficiency 64,		SM00054:EFh,SM00109:C1,SM00147:RasGEF,SM00229:RasGEFN,	KW-0221~Differentiation,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0772~Systemic lupus erythematosus,	KW-0175~Coiled coil,KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0106~Calcium,KW-0479~Metal-binding,KW-0862~Zinc,	KW-0344~Guanine-nucleotide releasing factor,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:EF-hand,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,DOMAIN:N-terminal Ras-GEF,DOMAIN:Phorbol-ester/DAG-type,DOMAIN:Ras-GEF,MUTAGEN:DHDQD->AHAQA: Decrease of Ras activation indicated by decrease of ERK phosphorylation.,MUTAGEN:E->A: Decrease of Ras activation indicated by decrease of ERK phosphorylation.,MUTAGEN:F->D: Increase of Ras activation indicated by increase of ERK phosphorylation.,MUTAGEN:R->E: Loss of function; prevents Ras activation.,MUTAGEN:V->D: Increase of Ras activation indicated by increase of ERK phosphorylation.,MUTAGEN:Y->F: Loss of localization to the endoplasmic reticulum and the Golgi apparatus.,REGION:Disordered,REGION:PT region; mediates the BCR-dependent translocation to plasma membrane,REGION:Ras exchanger motif region; required for transforming activity,REGION:Suppress the PT region-mediated translocation to plasma membrane,ZN_FING:Phorbol-ester/DAG-type,
RALA	RAS like proto-oncogene A(RALA)	Homo sapiens		h_rasPathway:Ras Signaling Pathway,	GO:0001843~neural tube closure,GO:0006887~exocytosis,GO:0006935~chemotaxis,GO:0007049~cell cycle,GO:0007165~signal transduction,GO:0007265~Ras protein signal transduction,GO:0017157~regulation of exocytosis,GO:0031623~receptor internalization,GO:0032956~regulation of actin cytoskeleton organization,GO:0045742~positive regulation of epidermal growth factor receptor signaling pathway,GO:0051301~cell division,GO:0051491~positive regulation of filopodium assembly,GO:0051665~membrane raft localization,GO:0072655~establishment of protein localization to mitochondrion,GO:0090141~positive regulation of mitochondrial fission,	GO:0005739~mitochondrion,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0009986~cell surface,GO:0016020~membrane,GO:0030139~endocytic vesicle,GO:0030659~cytoplasmic vesicle membrane,GO:0032154~cleavage furrow,GO:0070062~extracellular exosome,GO:0090543~Flemming body,GO:0097060~synaptic membrane,GO:0098685~Schaffer collateral - CA1 synapse,	GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0017022~myosin binding,GO:0019003~GDP binding,GO:0031625~ubiquitin protein ligase binding,GO:0031755~Edg-2 lysophosphatidic acid receptor binding,GO:0051117~ATPase binding,	IPR001806:Small_GTPase,IPR005225:Small_GTP-bd_dom,IPR020849:Small_GTPase_Ras-type,IPR027417:P-loop_NTPase,	hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04072:Phospholipase D signaling pathway,hsa05132:Salmonella infection,hsa05200:Pathways in cancer,hsa05210:Colorectal cancer,hsa05212:Pancreatic cancer,	619311~Hiatt-Neu-Cooper neurodevelopmental syndrome,		SM00173:RAS,SM00174:RHO,SM00175:RAB,SM00176:RAN,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0268~Exocytosis,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0991~Intellectual disability,		KW-0342~GTP-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,	KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0636~Prenylation,	CARBOHYD:(Microbial infection) O-linked (Glc) threonine; by P.sordellii toxin TcsL,LIPID:S-geranylgeranyl cysteine,MOTIF:Effector region,MUTAGEN:A->W: Impaired cytokinesis, as shown by increased number of binucleate cells. No effect on cytokinesis; when associated with V-23. Decreased interaction with EXOC2 and EXOC8; when associated with V-23.,MUTAGEN:A->W: Strongly reduces interaction with EXOC8.,MUTAGEN:C->S: Loss of geranylgeranylation and membrane localization.,MUTAGEN:D->E: No effect on cytokinesis; when associated with L-72.,MUTAGEN:D->N: No effect on cytokinesis. Impaired cytokinesis, as shown by increased number of binucleate cells; when associated with L-72.,MUTAGEN:E->R: Impaired cytokinesis, as shown by increased number of binucleate cells. No effect on cytokinesis; when associated with V-23. Decreased interaction with EXOC2 and EXOC8; when associated with V-23.,MUTAGEN:G->V: Impaired cytokinesis, as shown by increased number of binucleate cells. No effect on interaction with EXOC2 and EXOC8. No effect on cytokinesis; when associated with R-38 or W-48. Decreased interaction with EXOC2 and EXOC8; when associated with R-38 or W-48.,MUTAGEN:K->E: Strongly reduces interaction with EXOC8.,MUTAGEN:K->I: No effect on interaction with EXOC8.,MUTAGEN:L->S: Converts geranyl-geranylation to farnesylation. No effect on membrane localization. Fails to deflect GGTI-induced apoptosis of adherent cell cultures, but rescues anchorage-independent cell proliferation.,MUTAGEN:Missing: Impaired cytokinesis, as shown by increased number of binucleate cells. Impaired cytokinesis; when associated with L-72.,MUTAGEN:N->A: No effect on interaction with EXOC8.,MUTAGEN:N->R: Strongly reduces interaction with EXOC8.,MUTAGEN:Q->L: Impaired cytokinesis, as shown by increased number of binucleate cells. Impaired cytokinesis; when associated with N-49 or 1-M--S-11. No effect on cytokinesis; when associated with E-49.,MUTAGEN:R->A: Strongly reduces interaction with EXOC8.,MUTAGEN:R->W: No effect on interaction with EXOC8.,MUTAGEN:S->A: Decreased localization to mitochondrion. Loss of function in mitochondrial fission.,MUTAGEN:S->D: Increased localization to mitochondrion.,MUTAGEN:S->W: Strongly reduces interaction with EXOC8.,MUTAGEN:T->A: Abolished monoglucosylation by P.sordellii toxin TcsL.,PROPEP:Removed in mature form,
RASA2	RAS p21 protein activator 2(RASA2)	Homo sapiens			GO:0007165~signal transduction,GO:0035556~intracellular signal transduction,GO:0046580~negative regulation of Ras protein signal transduction,	GO:0005829~cytosol,GO:0048471~perinuclear region of cytoplasm,	GO:0005096~GTPase activator activity,GO:0005543~phospholipid binding,GO:0046872~metal ion binding,	IPR000008:C2_dom,IPR001562:Znf_Btk_motif,IPR001849:PH_domain,IPR001936:RasGAP_dom,IPR008936:Rho_GTPase_activation_prot,IPR011993:PH-like_dom_sf,IPR023152:RasGAP_CS,IPR035892:C2_domain_sf,IPR037773:RASA2_PH,IPR039360:Ras_GTPase,	hsa04010:MAPK signaling pathway,hsa04014:Ras signaling pathway,hsa05203:Viral carcinogenesis,			SM00107:BTK,SM00233:PH,SM00239:C2,SM00323:RasGAP,		KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0343~GTPase activation,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:C2 1,DOMAIN:C2 2,DOMAIN:PH,DOMAIN:Ras-GAP,REGION:Disordered,ZN_FING:Btk-type,
RASAL3	RAS protein activator like 3(RASAL3)	Homo sapiens			GO:0046580~negative regulation of Ras protein signal transduction,GO:0051142~positive regulation of NK T cell proliferation,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005938~cell cortex,GO:0016020~membrane,GO:0070062~extracellular exosome,GO:0098562~cytoplasmic side of membrane,	GO:0005096~GTPase activator activity,GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR000008:C2_dom,IPR001936:RasGAP_dom,IPR008936:Rho_GTPase_activation_prot,IPR023152:RasGAP_CS,IPR035892:C2_domain_sf,IPR039360:Ras_GTPase,	hsa04014:Ras signaling pathway,			SM00323:RasGAP,		KW-0963~Cytoplasm,		KW-0175~Coiled coil,		KW-0343~GTPase activation,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:C2,DOMAIN:PH,DOMAIN:Ras-GAP,REGION:Disordered,
RBBP8	RB binding protein 8, endonuclease(RBBP8)	Homo sapiens		h_atmPathway:ATM Signaling Pathway,	GO:0000082~G1/S transition of mitotic cell cycle,GO:0000724~double-strand break repair via homologous recombination,GO:0001835~blastocyst hatching,GO:0006281~DNA repair,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0010792~DNA double-strand break processing involved in repair via single-strand annealing,GO:0035825~reciprocal DNA recombination,GO:0044818~mitotic G2/M transition checkpoint,GO:0045892~negative regulation of transcription, DNA-templated,GO:0051301~cell division,GO:0051321~meiotic cell cycle,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005694~chromosome,GO:0017053~transcriptional repressor complex,GO:0043231~intracellular membrane-bounded organelle,GO:0070533~BRCA1-C complex,	GO:0000014~single-stranded DNA endodeoxyribonuclease activity,GO:0003677~DNA binding,GO:0003684~damaged DNA binding,GO:0003714~transcription corepressor activity,GO:0004519~endonuclease activity,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0046872~metal ion binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,	IPR013882:Ctp1_C,IPR019518:CtIP_N,IPR033316:RBBP8-like,	hsa03440:Homologous recombination,	251255~Jawad syndrome,606744~Seckel syndrome 2,Pancreatic carcinoma, somatic~Pancreatic carcinoma, somatic,			KW-0131~Cell cycle,KW-0132~Cell division,KW-0227~DNA damage,KW-0234~DNA repair,KW-0469~Meiosis,KW-0498~Mitosis,	KW-0158~Chromosome,KW-0539~Nucleus,	KW-0225~Disease variant,KW-0242~Dwarfism,KW-0991~Intellectual disability,	KW-0175~Coiled coil,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,KW-0255~Endonuclease,KW-0378~Hydrolase,KW-0540~Nuclease,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:DNA endonuclease Ctp1 N-terminal,DOMAIN:DNA endonuclease activator Ctp1 C-terminal,MOTIF:KLHL15-binding,MOTIF:PXDLS motif,MUTAGEN:C->A: Reduces Zn(2+) content; when associated with A-89.,MUTAGEN:C->A: Reduces Zn(2+) content; when associated with A-92.,MUTAGEN:F->A: Decreased CUL3/KLHL15-mediated proteasomal degradation.,MUTAGEN:H->A: No effect on RPA focus formation on DNA damage.,MUTAGEN:K->A: Abolishes damage recruitment capability.,MUTAGEN:K->A: Impaired FZR1-binding and APC/C-mediated polyubiquitination. Increased stability. No effect on MRE11-binding, nor on CUL3/KLHL15-mediated proteasomal degradation. No effect on DNA-en resection activity.,MUTAGEN:K->A: No effect on FZR1-binding.,MUTAGEN:K->A: No effect on RPA focus formation on DNA damage.,MUTAGEN:K->R: In K12R; defects in ability to promoting DNA resection and homologous recombination; when associated with R-62; R-115; R-132; R-133; R-404; R-572; R-578; R-640; R-759; R-760 and R-782. In K5R; defects in ability to promoting DNA resection and homologous recombination; when associated with R-62; R-115; R-132 and R-133.,MUTAGEN:K->R: In K12R; defects in ability to promoting DNA resection and homologous recombination; when associated with R-62; R-78; R-115; R-132; R-133; R-404; R-572; R-578; R-640; R-759 and R-760.,MUTAGEN:K->R: In K12R; defects in ability to promoting DNA resection and homologous recombination; when associated with R-62; R-78; R-115; R-132; R-133; R-404; R-572; R-578; R-640; R-759 and R-782.,MUTAGEN:K->R: In K12R; defects in ability to promoting DNA resection and homologous recombination; when associated with R-62; R-78; R-115; R-132; R-133; R-404; R-572; R-578; R-640; R-760 and R-782.,MUTAGEN:K->R: In K12R; defects in ability to promoting DNA resection and homologous recombination; when associated with R-62; R-78; R-115; R-132; R-133; R-404; R-572; R-578; R-759; R-760 and R-782.,MUTAGEN:K->R: In K12R; defects in ability to promoting DNA resection and homologous recombination; when associated with R-62; R-78; R-115; R-132; R-133; R-404; R-572; R-640; R-759; R-760 and R-782.,MUTAGEN:K->R: In K12R; defects in ability to promoting DNA resection and homologous recombination; when associated with R-62; R-78; R-115; R-132; R-133; R-404; R-578; R-640; R-759; R-760 and R-782.,MUTAGEN:K->R: In K12R; defects in ability to promoting DNA resection and homologous recombination; when associated with R-62; R-78; R-115; R-132; R-133; R-572; R-578; R-640; R-759; R-760 and R-782.,MUTAGEN:K->R: In K12R; defects in ability to promoting DNA resection and homologous recombination; when associated with R-62; R-78; R-115; R-133; R-404; R-572; R-578; R-640; R-759; R-760 and R-782. In K5R; defects in ability to promoting DNA resection and homologous recombination; when associated with R-62; R-78; R-115 and R-132.,MUTAGEN:K->R: In K12R; defects in ability to promoting DNA resection and homologous recombination; when associated with R-62; R-78; R-115; R-133; R-404; R-572; R-578; R-640; R-759; R-760 and R-782. In K5R; defects in ability to promoting DNA resection and homologous recombination; when associated with R-62; R-78; R-115 and R-133.,MUTAGEN:K->R: In K12R; defects in ability to promoting DNA resection and homologous recombination; when associated with R-62; R-78; R-132; R-133; R-404; R-572; R-578; R-640; R-759; R-760 and R-782. In K5R; defects in ability to promoting DNA resection and homologous recombination; when associated with R-62; R-78; R-132 and R-133.,MUTAGEN:K->R: In K12R; defects in ability to promoting DNA resection and homologous recombination; when associated with R-78; R-115; R-132; R-133; R-404; R-572; R-578; R-640; R-759; R-760 and R-782. In K5R; defects in ability to promoting DNA resection and homologous recombination; when associated with R-78; R-115; R-132 and R-133.,MUTAGEN:L->A: No effect on RPA focus formation on DNA damage.,MUTAGEN:L->E: Can form homodimers but not homotetramers. Abolishes ability to promote homologous recombination and DNA resection. Defective binding to DNA. Defective in localizing to sites of DNA damage. Does not affect interaction with MRN complex components MRE11, NBN or RAD50.,MUTAGEN:R->A: Defective binding to DNA. No effect on CUL3/KLHL15-mediated proteasomal degradation. Does not affect tetramerization.,MUTAGEN:S->A: Abolishes BRCA1 interaction and ubiquitination. No activation of CHEK1 after DNA damage.,MUTAGEN:S->A: Abrogates dissociation of BRCA1.,MUTAGEN:S->A: No effect on PIN1-binding. Impaired PIN1-binding, partially decreased CUL3/KLHL15-mediated proteasomal degradation, no effect on BRCA1-, MRE11-, nor on KLHL15-binding; when associated with A-315.,MUTAGEN:T->A: Decreased PIN1-binding. Impaired PIN1-binding, partially decreased CUL3/KLHL15-mediated proteasomal degradation, no effect on BRCA1-, MRE11-, nor on KLHL15-binding; when associated with A-276.,MUTAGEN:T->A: Impairs DNA resection.,MUTAGEN:T->E: Mimics constitutive phosphorylation.,MUTAGEN:V->A: No effect on RPA focus formation on DNA damage.,MUTAGEN:Y->A: Decreased interaction with KLHL15, decreased polyubiquitination and CUL3/KLHL15-mediated proteasomal degradation. No effect on DNA-end resection activity.,MUTAGEN:Y->F: No effect on KLHL15-binding, nor on CUL3/KLHL15-mediated proteasomal degradation.,REGION:Damage-recruitment motif,REGION:Disordered,REGION:Essential for binding to the MRN complex and for RPA focus formation on DNA damage,REGION:Required for interaction with LMO4, probably by making physical contact with LMO4,REGION:Required for interaction with LMO4, probably by stabilizing the interaction through RPPB8 dimerization,
RBL2	RB transcriptional corepressor like 2(RBL2)	Homo sapiens		h_etsPathway:METS affect on Macrophage Differentiation,	GO:0006325~chromatin organization,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007049~cell cycle,GO:0010629~negative regulation of gene expression,GO:0030154~cell differentiation,GO:0043550~regulation of lipid kinase activity,GO:0051726~regulation of cell cycle,GO:2000134~negative regulation of G1/S transition of mitotic cell cycle,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005694~chromosome,GO:0005730~nucleolus,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0005515~protein binding,GO:1990841~promoter-specific chromatin binding,	IPR002719:RB_B,IPR002720:RB_A,IPR013763:Cyclin-like_dom,IPR015030:RB_C,IPR024599:RB_N,IPR028309:RB_fam,IPR036915:Cyclin-like_sf,	hsa04068:FoxO signaling pathway,hsa04110:Cell cycle,hsa04151:PI3K-Akt signaling pathway,hsa04218:Cellular senescence,hsa05165:Human papillomavirus infection,hsa05203:Viral carcinogenesis,	619690~Brunet-Wagner neurodevelopmental syndrome,		SM00385:CYCLIN,SM01367:DUF3452,SM01368:RB_A,SM01369:Rb_C,	KW-0131~Cell cycle,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0539~Nucleus,	KW-0043~Tumor suppressor,KW-0225~Disease variant,KW-0991~Intellectual disability,			KW-0156~Chromatin regulator,KW-0238~DNA-binding,KW-0678~Repressor,	KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Cyclin-like,DOMAIN:Retinoblastoma-associated protein A-box,DOMAIN:Retinoblastoma-associated protein C-terminal,DOMAIN:Retinoblastoma-associated protein N-terminal,REGION:Disordered,REGION:Domain A,REGION:Domain B,REGION:Pocket; binds E1A,REGION:Spacer,
RB1CC1	RB1 inducible coiled-coil 1(RB1CC1)	Homo sapiens		h_stathminPathway:Stathmin and breast cancer resistance to antimicrotubule agents,	GO:0000045~autophagosome assembly,GO:0000422~mitophagy,GO:0001889~liver development,GO:0001934~positive regulation of protein phosphorylation,GO:0006914~autophagy,GO:0007049~cell cycle,GO:0007507~heart development,GO:0008285~negative regulation of cell proliferation,GO:0010508~positive regulation of autophagy,GO:0030242~pexophagy,GO:0034517~ribophagy,GO:0034727~piecemeal microautophagy of nucleus,GO:0045793~positive regulation of cell size,GO:0046330~positive regulation of JNK cascade,GO:0061709~reticulophagy,GO:0061723~glycophagy,GO:0097191~extrinsic apoptotic signaling pathway,GO:1903059~regulation of protein lipidation,GO:2001237~negative regulation of extrinsic apoptotic signaling pathway,	GO:0000407~pre-autophagosomal structure,GO:0000421~autophagosome membrane,GO:0005764~lysosome,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0031965~nuclear membrane,GO:0034045~pre-autophagosomal structure membrane,GO:1990316~ATG1/ULK1 kinase complex,	GO:0005515~protein binding,GO:0019901~protein kinase binding,GO:0043495~protein anchor,GO:0060090~binding, bridging,	IPR019460:Atg11_C,IPR040040:ATG11,	hsa04140:Autophagy - animal,hsa04211:Longevity regulating pathway,hsa05010:Alzheimer disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05017:Spinocerebellar ataxia,hsa05022:Pathways of neurodegeneration - multiple diseases,	114480~Breast cancer, somatic,			KW-0072~Autophagy,KW-0131~Cell cycle,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0458~Lysosome,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0043~Tumor suppressor,	KW-0175~Coiled coil,			KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:Autophagy-related protein 11 C-terminal,MOTIF:FFAT,MOTIF:Nuclear localization signal,REGION:Disordered,
RCAN3	RCAN family member 3(RCAN3)	Homo sapiens			GO:0009653~anatomical structure morphogenesis,GO:0019722~calcium-mediated signaling,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0003676~nucleic acid binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0008597~calcium-dependent protein serine/threonine phosphatase regulator activity,GO:0019902~phosphatase binding,GO:0031013~troponin I binding,	IPR006931:Calcipressin,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR035979:RBD_domain_sf,												COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Calcineurin-binding,REGION:Disordered,
REST	RE1 silencing transcription factor(REST)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0000381~regulation of alternative mRNA splicing, via spliceosome,GO:0001666~response to hypoxia,GO:0002244~hematopoietic progenitor cell differentiation,GO:0002931~response to ischemia,GO:0006338~chromatin remodeling,GO:0006355~regulation of transcription, DNA-templated,GO:0008285~negative regulation of cell proliferation,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0032348~negative regulation of aldosterone biosynthetic process,GO:0035019~somatic stem cell population maintenance,GO:0043065~positive regulation of apoptotic process,GO:0043068~positive regulation of programmed cell death,GO:0043280~positive regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0043922~negative regulation by host of viral transcription,GO:0045665~negative regulation of neuron differentiation,GO:0045666~positive regulation of neuron differentiation,GO:0045667~regulation of osteoblast differentiation,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0045955~negative regulation of calcium ion-dependent exocytosis,GO:0046676~negative regulation of insulin secretion,GO:0050768~negative regulation of neurogenesis,GO:0050877~neurological system process,GO:0050885~neuromuscular process controlling balance,GO:0050910~detection of mechanical stimulus involved in sensory perception of sound,GO:0060088~auditory receptor cell stereocilium organization,GO:0060379~cardiac muscle cell myoblast differentiation,GO:0071257~cellular response to electrical stimulus,GO:0071385~cellular response to glucocorticoid stimulus,GO:0071466~cellular response to xenobiotic stimulus,GO:0097150~neuronal stem cell population maintenance,GO:0099563~modification of synaptic structure,GO:1902459~positive regulation of stem cell population maintenance,GO:1902894~negative regulation of pri-miRNA transcription from RNA polymerase II promoter,GO:2000065~negative regulation of cortisol biosynthetic process,GO:2000678~negative regulation of transcription regulatory region DNA binding,GO:2000706~negative regulation of dense core granule biogenesis,GO:2000740~negative regulation of mesenchymal stem cell differentiation,GO:2000798~negative regulation of amniotic stem cell differentiation,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0017053~transcriptional repressor complex,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000979~RNA polymerase II core promoter sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003682~chromatin binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0046872~metal ion binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,	IPR013087:Znf_C2H2_type,IPR036236:Znf_C2H2_sf,	hsa04550:Signaling pathways regulating pluripotency of stem cells,hsa05016:Huntington disease,	612431~Deafness, autosomal dominant 27,616806~Wilms tumor 6, susceptibility to,617626~Fibromatosis, gingival, 5,		SM00355:ZnF_C2H2,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0209~Deafness,KW-0225~Disease variant,KW-1010~Non-syndromic deafness,	KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0678~Repressor,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,DOMAIN:C2H2-type,MUTAGEN:A->T: Does not change transcriptional repression activity.,MUTAGEN:E->A: Loss of interaction with BTRC.,MUTAGEN:E->G: Does not change transcriptional repression activity.,MUTAGEN:EGIHS->AGIHA: Loss of interaction with BTRC. Reduced ubiquitination. Decreased proteasomal degradation in G2. Decreased average time from nuclear envelope breakdown to anaphase onset. Increased number of lagging chromosomes and chromosome bridges in anaphase and prematurely separated sister chromatids. Reduced MAD2 levels.,MUTAGEN:H->Y: Does not change transcriptional repression activity.,MUTAGEN:KFSKTKKSKRK->AFSKTADSMDA: No effect on nuclear localization.,MUTAGEN:KFSKTKKSKRK->GS: Reduced nuclear localization.,MUTAGEN:M->T: Inhibits transcriptional repression activity.,MUTAGEN:Missing: No effect on nuclear localization.,MUTAGEN:S->A: Lack of deubiquitination by USP7.,MUTAGEN:S->A: Loss of interaction with BTRC.,MUTAGEN:S->A: No impact on deubiquitination by USP7.,MUTAGEN:S->N: Does not change transcriptional repression activity.,REGION:Disordered,REGION:Interaction with RCOR1,REGION:Interaction with SIN3A,REGION:Interaction with SIN3B,REGION:Interaction with ZFP90,REGION:Required for binding to the neuron-restrictive silencer element,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4,ZN_FING:C2H2-type 5,ZN_FING:C2H2-type 6,ZN_FING:C2H2-type 7,ZN_FING:C2H2-type 8,ZN_FING:C2H2-type 9,
REL	REL proto-oncogene, NF-kB subunit(REL)	Homo sapiens	79.B_cell_Activation,		GO:0006954~inflammatory response,GO:0007249~I-kappaB kinase/NF-kappaB signaling,GO:0010629~negative regulation of gene expression,GO:0032688~negative regulation of interferon-beta production,GO:0033554~cellular response to stress,GO:0034097~response to cytokine,GO:0038061~NIK/NF-kappaB signaling,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0045087~innate immune response,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0071159~NF-kappaB complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,	IPR000451:NFkB/Dor,IPR002909:IPT_dom,IPR008967:p53-like_TF_DNA-bd_sf,IPR011539:RHD_DNA_bind_dom,IPR013783:Ig-like_fold,IPR014756:Ig_E-set,IPR030492:RHD_CS,IPR032397:RHD_dimer,IPR033926:IPT_NFkappaB,IPR037059:RHD_DNA_bind_dom_sf,IPR042845:RHD-n_c-Rel,	hsa04014:Ras signaling pathway,hsa05202:Transcriptional misregulation in cancer,hsa05203:Viral carcinogenesis,	619652~Immunodeficiency 92,		SM00429:IPT,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0656~Proto-oncogene,			KW-0010~Activator,KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:RHD,MOTIF:Nuclear localization signal,REGION:Disordered,
RELB	RELB proto-oncogene, NF-kB subunit(RELB)	Homo sapiens			GO:0006954~inflammatory response,GO:0007249~I-kappaB kinase/NF-kappaB signaling,GO:0019882~antigen processing and presentation,GO:0030098~lymphocyte differentiation,GO:0032688~negative regulation of interferon-beta production,GO:0032922~circadian regulation of gene expression,GO:0033554~cellular response to stress,GO:0034097~response to cytokine,GO:0038061~NIK/NF-kappaB signaling,GO:0043011~myeloid dendritic cell differentiation,GO:0045063~T-helper 1 cell differentiation,GO:0045087~innate immune response,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0071470~cellular response to osmotic stress,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005829~cytosol,GO:0017053~transcriptional repressor complex,GO:0032991~macromolecular complex,GO:0045202~synapse,GO:0071159~NF-kappaB complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0019901~protein kinase binding,GO:0042802~identical protein binding,	IPR000451:NFkB/Dor,IPR002909:IPT_dom,IPR008967:p53-like_TF_DNA-bd_sf,IPR011539:RHD_DNA_bind_dom,IPR013783:Ig-like_fold,IPR014756:Ig_E-set,IPR030492:RHD_CS,IPR030496:RelB_RHD_N,IPR032397:RHD_dimer,IPR032399:RelB_leu_zip,IPR032400:RelB_transact,IPR033926:IPT_NFkappaB,IPR037059:RHD_DNA_bind_dom_sf,	hsa04010:MAPK signaling pathway,hsa04064:NF-kappa B signaling pathway,hsa04380:Osteoclast differentiation,hsa04625:C-type lectin receptor signaling pathway,hsa05166:Human T-cell leukemia virus 1 infection,hsa05169:Epstein-Barr virus infection,	617585~Immunodeficiency 53,		SM00429:IPT,	KW-0090~Biological rhythms,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,			KW-0010~Activator,KW-0238~DNA-binding,KW-0678~Repressor,	KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:RHD,DOMAIN:RelB leucine zipper,DOMAIN:RelB transactivation,MOTIF:Nuclear localization signal,REGION:Disordered,REGION:Leucine-zipper,
RIC8A	RIC8 guanine nucleotide exchange factor A(RIC8A)	Homo sapiens			GO:0001701~in utero embryonic development,GO:0001944~vasculature development,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007193~adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway,GO:0008542~visual learning,GO:0042074~cell migration involved in gastrulation,GO:0070586~cell-cell adhesion involved in gastrulation,GO:0071711~basement membrane organization,	GO:0005737~cytoplasm,GO:0005886~plasma membrane,	GO:0001965~G-protein alpha-subunit binding,GO:0005085~guanyl-nucleotide exchange factor activity,GO:0005515~protein binding,	IPR008376:Synembryn,IPR011989:ARM-like,IPR016024:ARM-type_fold,IPR019318:Gua_nucleotide_exch_fac_Ric8,						KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,				KW-0344~Guanine-nucleotide releasing factor,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,
RTCB	RNA 2',3'-cyclic phosphate and 5'-OH ligase(RTCB)	Homo sapiens			GO:0000971~tRNA exon ligation utilizing 2',3' cyclic phosphate of 5'-exon as source of linkage phosphate,GO:0001701~in utero embryonic development,GO:0001890~placenta development,GO:0006388~tRNA splicing, via endonucleolytic cleavage and ligation,GO:0008033~tRNA processing,	GO:0005634~nucleus,GO:0005635~nuclear envelope,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0043231~intracellular membrane-bounded organelle,GO:0072669~tRNA-splicing ligase complex,	GO:0003723~RNA binding,GO:0003972~RNA ligase (ATP) activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0008452~RNA ligase activity,GO:0017166~vinculin binding,GO:0046872~metal ion binding,	IPR001233:RtcB,IPR027513:RtcB_euk,IPR036025:RtcB-like_sf,					KW-0819~tRNA processing,	KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0342~GTP-binding,KW-0464~Manganese,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0436~Ligase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	ACT_SITE:GMP-histidine intermediate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),MUTAGEN:C->A: Abolishes tRNA ligase activity.,
RBM17	RNA binding motif protein 17(RBM17)	Homo sapiens			GO:0000380~alternative mRNA splicing, via spliceosome,GO:0045292~mRNA cis splicing, via spliceosome,	GO:0005654~nucleoplasm,GO:0005681~spliceosomal complex,	GO:0003676~nucleic acid binding,GO:0003723~RNA binding,GO:0005515~protein binding,	IPR000467:G_patch_dom,IPR000504:RRM_dom,IPR003954:RRM_dom_euk,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR034653:SPF45_RRM,IPR035979:RBD_domain_sf,IPR040052:RBM17,	hsa03040:Spliceosome,		PIRSF031066:Splicing_factor_SPF45,	SM00361:RRM_1,SM00443:G_patch,	KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,KW-0747~Spliceosome,				KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:G-patch,DOMAIN:RRM,MUTAGEN:D->A: Impairs interaction with SF1; has minor effect on interaction with SF3B1 and U2AF2.,MUTAGEN:D->K: Abolishes interaction with SF3B1, SF1 and U2AF2. Abolishes regulation of alternative splicing.,MUTAGEN:F->A: Impairs interaction with SF1 and U2AF2 and abolishes interaction with SF3B1. Abolishes regulation of alternative splicing.,MUTAGEN:R->A: Impairs interaction with SF3B1, SF1 and U2AF2. Abolishes regulation of alternative splicing.,MUTAGEN:Y->A: Impairs interaction with SF3B1, SF1 and U2AF2. Abolishes regulation of alternative splicing.,REGION:Disordered,
RBM18	RNA binding motif protein 18(RBM18)	Homo sapiens				GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0045171~intercellular bridge,	GO:0003723~RNA binding,	IPR000504:RRM_dom,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR035979:RBD_domain_sf,IPR039157:RBM18_RRM,				SM00360:RRM,						KW-0694~RNA-binding,		DOMAIN:RRM,REGION:Disordered,
RBM23	RNA binding motif protein 23(RBM23)	Homo sapiens			GO:0006397~mRNA processing,GO:0008380~RNA splicing,GO:0045893~positive regulation of transcription, DNA-templated,GO:0048024~regulation of mRNA splicing, via spliceosome,	GO:0005634~nucleus,GO:0016020~membrane,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:1990446~U1 snRNP binding,	IPR000504:RRM_dom,IPR006509:RBM39_SF,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR029123:RBM39_linker,IPR035979:RBD_domain_sf,				SM00360:RRM,	KW-0507~mRNA processing,KW-0508~mRNA splicing,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0677~Repeat,		KW-0694~RNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,DOMAIN:RRM,DOMAIN:RRM 1,DOMAIN:RRM 2,DOMAIN:Splicing factor RBM39 linker,MUTAGEN:FCMQL->ACMQA: In M1; abolished ability to regulate steroid hormone receptor-mediated transcription, without affecting the pre-mRNA splicing factor activity.,MUTAGEN:LMAKL->AMAKA: In M3; reduced pre-mRNA splicing factor activity without affecting steroid hormone receptor-mediated transcription.,MUTAGEN:YVGSL->AVGSA: In M2; reduced pre-mRNA splicing factor activity without affecting steroid hormone receptor-mediated transcription.,REGION:Disordered,
RBM3	RNA binding motif protein 3(RBM3)	Homo sapiens			GO:0006396~RNA processing,GO:0006417~regulation of translation,GO:0045727~positive regulation of translation,GO:0048026~positive regulation of mRNA splicing, via spliceosome,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005681~spliceosomal complex,GO:0005737~cytoplasm,GO:0015934~large ribosomal subunit,GO:0030425~dendrite,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0043023~ribosomal large subunit binding,	IPR000504:RRM_dom,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR034278:RBM3/CIRBP_RRM,IPR035979:RBD_domain_sf,				SM00360:RRM,	KW-0346~Stress response,	KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0966~Cell projection,		KW-0732~Signal,		KW-0694~RNA-binding,	KW-0488~Methylation,KW-0597~Phosphoprotein,	DOMAIN:RRM,REGION:Disordered,
RBM33	RNA binding motif protein 33(RBM33)	Homo sapiens			GO:0006405~RNA export from nucleus,GO:0035553~oxidative single-stranded RNA demethylation,GO:0043488~regulation of mRNA stability,	GO:0005634~nucleus,GO:0005737~cytoplasm,	GO:0003723~RNA binding,GO:0030674~protein binding, bridging,GO:1990247~N6-methyladenosine-containing RNA binding,	IPR000504:RRM_dom,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR035979:RBD_domain_sf,IPR039878:RBM33,				SM00360:RRM,				KW-0175~Coiled coil,		KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:RRM,REGION:Disordered,
RBM39	RNA binding motif protein 39(RBM39)	Homo sapiens			GO:0006396~RNA processing,GO:0006397~mRNA processing,GO:0008380~RNA splicing,GO:0048024~regulation of mRNA splicing, via spliceosome,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0015630~microtubule cytoskeleton,GO:0016607~nuclear speck,GO:0032991~macromolecular complex,GO:0034451~centriolar satellite,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0050733~RS domain binding,GO:1990446~U1 snRNP binding,	IPR000504:RRM_dom,IPR003954:RRM_dom_euk,IPR006509:RBM39_SF,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR029123:RBM39_linker,IPR035979:RBD_domain_sf,				SM00360:RRM,SM00361:RRM_1,	KW-0507~mRNA processing,KW-0508~mRNA splicing,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0677~Repeat,		KW-0010~Activator,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:RRM,DOMAIN:RRM 1,DOMAIN:RRM 2,DOMAIN:RRM 3,DOMAIN:Splicing factor RBM39 linker,REGION:Activating domain,REGION:Disordered,REGION:Interaction with ESR1 and ESR2,REGION:Interaction with JUN,REGION:Interaction with NCOA6,
RBM4	RNA binding motif protein 4(RBM4)	Homo sapiens			GO:0000381~regulation of alternative mRNA splicing, via spliceosome,GO:0000398~mRNA splicing, via spliceosome,GO:0002190~cap-independent translational initiation,GO:0002192~IRES-dependent translational initiation,GO:0006396~RNA processing,GO:0006397~mRNA processing,GO:0006417~regulation of translation,GO:0007623~circadian rhythm,GO:0008380~RNA splicing,GO:0010628~positive regulation of gene expression,GO:0017148~negative regulation of translation,GO:0031016~pancreas development,GO:0032055~negative regulation of translation in response to stress,GO:0032922~circadian regulation of gene expression,GO:0035278~miRNA mediated inhibition of translation,GO:0035773~insulin secretion involved in cellular response to glucose stimulus,GO:0035883~enteroendocrine cell differentiation,GO:0043153~entrainment of circadian clock by photoperiod,GO:0045727~positive regulation of translation,GO:0045947~negative regulation of translational initiation,GO:0046626~regulation of insulin receptor signaling pathway,GO:0046685~response to arsenic-containing substance,GO:0046822~regulation of nucleocytoplasmic transport,GO:0051149~positive regulation of muscle cell differentiation,GO:0097167~circadian regulation of translation,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0010494~cytoplasmic stress granule,GO:0016607~nuclear speck,GO:0032991~macromolecular complex,GO:0048471~perinuclear region of cytoplasm,	GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0003730~mRNA 3'-UTR binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0030332~cyclin binding,GO:0035198~miRNA binding,GO:0046872~metal ion binding,GO:0097157~pre-mRNA intronic binding,GO:0097158~pre-mRNA intronic pyrimidine-rich binding,	IPR000504:RRM_dom,IPR001878:Znf_CCHC,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR034897:RBM4_RRM1,IPR034898:RBM4_RRM2,IPR035979:RBD_domain_sf,				SM00343:ZnF_C2HC,SM00360:RRM,	KW-0221~Differentiation,KW-0507~mRNA processing,KW-0508~mRNA splicing,KW-0943~RNA-mediated gene silencing,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0694~RNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:CCHC-type,DOMAIN:RRM,DOMAIN:RRM 1,DOMAIN:RRM 2,MUTAGEN:F->A: Abrogates regulation of alternative splice site selection; when associated with A-37; A-113 and A-115.,MUTAGEN:F->A: Abrogates regulation of alternative splice site selection; when associated with A-37; A-39 and A-113.,MUTAGEN:S->A: Inhibits IRES-mediated mRNA translation. Does not inhibit interaction with EIF4A1. Inhibits localization in cytoplasm and cytoplasmic granules upon cell muscle differentiation. Inhibits negative regulation of translation involved in gene silencing by miRNA.,MUTAGEN:Y->A: Abrogates regulation of alternative splice site selection; when associated with A-37; A-39 and A-115.,MUTAGEN:Y->A: Abrogates regulation of alternative splice site selection; when associated with A-39; A-113 and A-115.,REGION:Interaction with TNPO3,ZN_FING:CCHC-type,
RBM42	RNA binding motif protein 42(RBM42)	Homo sapiens			GO:0000398~mRNA splicing, via spliceosome,GO:0048025~negative regulation of mRNA splicing, via spliceosome,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0046540~U4/U6 x U5 tri-snRNP complex,	GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0005515~protein binding,	IPR000504:RRM_dom,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR034215:RBM42_RRM,IPR035979:RBD_domain_sf,				SM00360:RRM,		KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,DOMAIN:RRM,REGION:Disordered,REGION:Necessary for interaction with HNRNPK,
RBM5	RNA binding motif protein 5(RBM5)	Homo sapiens			GO:0000245~spliceosomal complex assembly,GO:0000381~regulation of alternative mRNA splicing, via spliceosome,GO:0000398~mRNA splicing, via spliceosome,GO:0006396~RNA processing,GO:0006397~mRNA processing,GO:0006915~apoptotic process,GO:0008285~negative regulation of cell proliferation,GO:0008380~RNA splicing,GO:0043065~positive regulation of apoptotic process,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005681~spliceosomal complex,	GO:0003676~nucleic acid binding,GO:0003677~DNA binding,GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR000467:G_patch_dom,IPR000504:RRM_dom,IPR001876:Znf_RanBP2,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR013087:Znf_C2H2_type,IPR034991:RBM5_RRM1,IPR034993:RBM5_RRM2,IPR035979:RBD_domain_sf,IPR036443:Znf_RanBP2_sf,IPR041591:OCRE,				SM00360:RRM,SM00443:G_patch,SM00547:ZnF_RBZ,	KW-0053~Apoptosis,KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,KW-0747~Spliceosome,		KW-0175~Coiled coil,KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0694~RNA-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:C2H2-type,DOMAIN:G-patch,DOMAIN:RRM,DOMAIN:RRM 1,DOMAIN:RRM 2,DOMAIN:RanBP2-type,REGION:Disordered,REGION:Required for interaction with U2AF2,REGION:Sufficient for interaction with ACIN1, PRPF8, SFRS3, SNRPB, SNRPN, SNRNP70 and SNRNP200,ZN_FING:C2H2-type; atypical,ZN_FING:RanBP2-type,
RBMX	RNA binding motif protein X-linked(RBMX)	Homo sapiens			GO:0000381~regulation of alternative mRNA splicing, via spliceosome,GO:0000398~mRNA splicing, via spliceosome,GO:0001649~osteoblast differentiation,GO:0006366~transcription from RNA polymerase II promoter,GO:0006509~membrane protein ectodomain proteolysis,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048025~negative regulation of mRNA splicing, via spliceosome,GO:0048026~positive regulation of mRNA splicing, via spliceosome,GO:0051260~protein homooligomerization,GO:0071347~cellular response to interleukin-1,	GO:0000791~euchromatin,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005681~spliceosomal complex,GO:0016020~membrane,GO:0032991~macromolecular complex,GO:0044530~supraspliceosomal complex,GO:0070062~extracellular exosome,GO:0071013~catalytic step 2 spliceosome,GO:1990904~ribonucleoprotein complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0003682~chromatin binding,GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0005515~protein binding,GO:0019904~protein domain specific binding,GO:0042802~identical protein binding,	IPR000504:RRM_dom,IPR003954:RRM_dom_euk,IPR012604:RBM1CTR,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR035979:RBD_domain_sf,	hsa03040:Spliceosome,	300238~Intellectual developmental disorder, X-linked syndromic, Shashi type,309555~Intellectual developmental disorder, X-linked syndromic, Gustavson type,		SM00360:RRM,SM00361:RRM_1,	KW-0507~mRNA processing,KW-0508~mRNA splicing,KW-0804~Transcription,	KW-0539~Nucleus,KW-0747~Spliceosome,	KW-0043~Tumor suppressor,KW-0991~Intellectual disability,			KW-0010~Activator,KW-0678~Repressor,KW-0687~Ribonucleoprotein,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:RBM1CTR,DOMAIN:RRM,MUTAGEN:K->A: Promotes cell proliferation. Inhibits transcriptional up-regulation of the TXNIP promoter.,REGION:Disordered,REGION:Necessary for RNA-binding,REGION:Necessary for the association to nascent RNAPII transcripts and nuclear localization,
RNPS1	RNA binding protein with serine rich domain 1(RNPS1)	Homo sapiens			GO:0000184~nuclear-transcribed mRNA catabolic process, nonsense-mediated decay,GO:0000381~regulation of alternative mRNA splicing, via spliceosome,GO:0000398~mRNA splicing, via spliceosome,GO:0006351~transcription, DNA-templated,GO:0008380~RNA splicing,GO:0043065~positive regulation of apoptotic process,GO:0048025~negative regulation of mRNA splicing, via spliceosome,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016607~nuclear speck,GO:0035145~exon-exon junction complex,GO:0061574~ASAP complex,	GO:0003723~RNA binding,GO:0003730~mRNA 3'-UTR binding,GO:0005515~protein binding,	IPR000504:RRM_dom,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR014010:REJ_dom,IPR034201:RNPS1_RRM,IPR035979:RBD_domain_sf,	hsa03013:Nucleocytoplasmic transport,hsa03015:mRNA surveillance pathway,			SM00360:RRM,	KW-0507~mRNA processing,KW-0508~mRNA splicing,KW-0866~Nonsense-mediated mRNA decay,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:REJ,DOMAIN:RRM,MUTAGEN:N->R: Impairs interaction with SAP18.,MUTAGEN:S->A: Abolishes phosphorylation by CSNK2A1 and partially reduces splicing stimulation. Does not abolish interaction with CSNK2A1 and subcellular localization.,MUTAGEN:S->E: Partially reduces splicing stimulation. Does not abolish interaction with CSNK2A1 and subcellular localization.,MUTAGEN:Y->A: Abolishes exon-skipping.,REGION:Disordered,REGION:Interaction with SAP18 and ACIN1,REGION:Necessary for interaction with PNN and exon-skipping,REGION:Necessary for interaction with SRP54, nuclear localization and exon-skipping,REGION:Necessary for interaction with TRA2B, nuclear localization and exon-skipping,REGION:Necessary for interaction with the cleaved p110 isoform of CDC2L1,REGION:Necessary for interactions with UPF2 and UPF3B and UPF2-dependent NMD,
POLR2A	RNA polymerase II subunit A(POLR2A)	Homo sapiens		h_carm-erPathway:CARM1 and Regulation of the Estrogen Receptor,h_dreamPathway:Repression of Pain Sensation by the Transcriptional Regulator DREAM,h_hSWI-SNFpathway:Chromatin Remodeling by hSWI/SNF ATP-dependent Complexes,h_pcafPathway:The information-processing pathway at the IFN-beta enhancer,h_rarrxrPathway:Nuclear receptors coordinate the activities of chromatin remodeling complexes and coactivators to facilitate initiation of transcription in carcinoma cells,h_telPathway:Telomeres, Telomerase, Cellular Aging, and  Immortality,	GO:0001172~transcription, RNA-templated,GO:0006353~DNA-templated transcription, termination,GO:0006355~regulation of transcription, DNA-templated,GO:0006366~transcription from RNA polymerase II promoter,GO:0014070~response to organic cyclic compound,GO:0033120~positive regulation of RNA splicing,GO:0071453~cellular response to oxygen levels,	GO:0000428~DNA-directed RNA polymerase complex,GO:0000791~euchromatin,GO:0000974~Prp19 complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005665~DNA-directed RNA polymerase II, core complex,GO:0005694~chromosome,GO:0005737~cytoplasm,	GO:0001046~core promoter sequence-specific DNA binding,GO:0001055~RNA polymerase II activity,GO:0003677~DNA binding,GO:0003723~RNA binding,GO:0003899~DNA-directed 5'-3' RNA polymerase activity,GO:0003968~RNA-directed 5'-3' RNA polymerase activity,GO:0005515~protein binding,GO:0019900~kinase binding,GO:0031625~ubiquitin protein ligase binding,GO:0046872~metal ion binding,GO:0050436~microfibril binding,GO:1990841~promoter-specific chromatin binding,	IPR000684:RNA_pol_II_repeat_euk,IPR000722:RNA_pol_asu,IPR006592:RNA_pol_N,IPR007066:RNA_pol_Rpb1_3,IPR007073:RNA_pol_Rpb1_7,IPR007075:RNA_pol_Rpb1_6,IPR007080:RNA_pol_Rpb1_1,IPR007081:RNA_pol_Rpb1_5,IPR007083:RNA_pol_Rpb1_4,IPR038120:Rpb1_funnel_sf,IPR038593:RNA_pol_Rpb1_7_sf,IPR042102:RNA_pol_Rpb1_3_sf,IPR044893:RNA_pol_Rpb1_clamp_domain,IPR045867:DNA-dir_RpoC_beta_prime,	hsa03020:RNA polymerase,hsa03420:Nucleotide excision repair,hsa05016:Huntington disease,	618603~Neurodevelopmental disorder with hypotonia and variable intellectual and behavioral abnormalities,		SM00663:RPOLA_N,	KW-0804~Transcription,KW-0945~Host-virus interaction,	KW-0158~Chromosome,KW-0240~DNA-directed RNA polymerase,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-9994~DNA-directed RNA polymerase,	KW-0225~Disease variant,KW-0991~Intellectual disability,	KW-0677~Repeat,	KW-0460~Magnesium,KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,KW-0548~Nucleotidyltransferase,KW-0696~RNA-directed RNA polymerase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin); by NEDD4,DOMAIN:RNA polymerase N-terminal,MUTAGEN:K->R: Impairs ubiquitination, interaction with the TFIIH complex, and its degradation during transcription stress.,MUTAGEN:K->R: Loss of acetylation and loss of regulation of growth-factor-induced gene expression; when associated with R-1838; R-1859; R-1866; R-1873; R-1887; R-1908 and R-1922.,MUTAGEN:K->R: Loss of acetylation and loss of regulation of growth-factor-induced gene expression; when associated with R-1838; R-1859; R-1866; R-1873; R-1887; R-1908 and R-1936.,MUTAGEN:K->R: Loss of acetylation and loss of regulation of growth-factor-induced gene expression; when associated with R-1838; R-1859; R-1866; R-1873; R-1908; R-1922 and R-1936.,MUTAGEN:K->R: Loss of acetylation and loss of regulation of growth-factor-induced gene expression; when associated with R-1838; R-1859; R-1866; R-1887; R-1908; R-1922 and R-1936.,MUTAGEN:K->R: Loss of acetylation and loss of regulation of growth-factor-induced gene expression; when associated with R-1838; R-1866; R-1873; R-1887; R-1908; R-1922 and R-1936.,MUTAGEN:K->R: Loss of acetylation and loss of regulation of growth-factor-induced gene expression; when associated with R-1859; R-1859; R-1873; R-1887; R-1908; R-1922 and R-1936.,MUTAGEN:K->R: Loss of acetylation and loss of regulation of growth-factor-induced gene expression; when associated with R-1859; R-1866; R-1873; R-1887; R-1908; R-1922 and R-1936.,MUTAGEN:K->R: Loss of acetylation and loss of regulation of growth-factor-induced gene expression; when associated with R.1838; R-1859; R-1866; R-1873; R-1887; R-1922 and R-1936.,MUTAGEN:Missing: Decreases cell viability.,MUTAGEN:R->A: Misexpression of a variety of small nuclear RNAs and small nucleolar RNAs. Loss of interaction with TDRD3 and SMN1/SMN2.,REGION:Bridging helix,REGION:C-terminal domain (CTD); 52 X 7 AA approximate tandem repeats of Y-[ST]-P-[STQ]-[ST]-P-[SRTEVKGN],REGION:Disordered,REPEAT:1,REPEAT:10,REPEAT:11,REPEAT:12,REPEAT:13,REPEAT:14,REPEAT:15,REPEAT:16,REPEAT:17,REPEAT:18,REPEAT:19,REPEAT:20,REPEAT:21,REPEAT:22,REPEAT:23,REPEAT:24,REPEAT:25,REPEAT:26,REPEAT:27,REPEAT:28,REPEAT:29,REPEAT:2; approximate,REPEAT:3,REPEAT:30,REPEAT:31,REPEAT:32,REPEAT:33,REPEAT:34,REPEAT:35,REPEAT:36,REPEAT:37,REPEAT:38,REPEAT:39,REPEAT:4,REPEAT:40,REPEAT:41,REPEAT:42,REPEAT:43,REPEAT:44,REPEAT:45,REPEAT:46,REPEAT:47,REPEAT:48,REPEAT:49,REPEAT:5,REPEAT:50,REPEAT:51; approximate,REPEAT:52; approximate,REPEAT:6,REPEAT:7,REPEAT:8,REPEAT:9,
POLR2E	RNA polymerase II, I and III subunit E(POLR2E)	Homo sapiens			GO:0006351~transcription, DNA-templated,GO:0006360~transcription from RNA polymerase I promoter,GO:0006362~transcription elongation from RNA polymerase I promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0006383~transcription from RNA polymerase III promoter,GO:0042797~tRNA transcription from RNA polymerase III promoter,GO:0050821~protein stabilization,	GO:0000428~DNA-directed RNA polymerase complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005665~DNA-directed RNA polymerase II, core complex,GO:0005666~DNA-directed RNA polymerase III complex,GO:0005736~DNA-directed RNA polymerase I complex,GO:0005829~cytosol,GO:0055029~nuclear DNA-directed RNA polymerase complex,GO:1990062~RPAP3/R2TP/prefoldin-like complex,	GO:0001054~RNA polymerase I activity,GO:0001055~RNA polymerase II activity,GO:0001056~RNA polymerase III activity,GO:0003677~DNA binding,GO:0003899~DNA-directed 5'-3' RNA polymerase activity,GO:0005515~protein binding,	IPR000783:RNA_pol_subH/Rpb5_C,IPR005571:RNA_pol_Rpb5_N,IPR014381:Arch_Rpo5/euc_Rpb5,IPR020608:RNA_pol_subH/Rpb5_CS,IPR035913:RPB5-like_sf,IPR036710:RNA_pol_Rpb5_N_sf,	hsa03020:RNA polymerase,hsa03420:Nucleotide excision repair,hsa04623:Cytosolic DNA-sensing pathway,hsa05016:Huntington disease,		PIRSF000747:RPB5,		KW-0804~Transcription,KW-0945~Host-virus interaction,	KW-0240~DNA-directed RNA polymerase,KW-0539~Nucleus,KW-9994~DNA-directed RNA polymerase,					KW-0007~Acetylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:RNA polymerase Rpb5 N-terminal,DOMAIN:RNA polymerase subunit H/Rpb5 C-terminal,REGION:Disordered,
POLR3E	RNA polymerase III subunit E(POLR3E)	Homo sapiens			GO:0006351~transcription, DNA-templated,GO:0042797~tRNA transcription from RNA polymerase III promoter,GO:0045087~innate immune response,GO:0051607~defense response to virus,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005666~DNA-directed RNA polymerase III complex,GO:0005829~cytosol,		IPR006886:RNA_pol_III_Rpc5,IPR045576:RPC5_C,	hsa03020:RNA polymerase,hsa04623:Cytosolic DNA-sensing pathway,				KW-0051~Antiviral defense,KW-0391~Immunity,KW-0399~Innate immunity,KW-0804~Transcription,	KW-0240~DNA-directed RNA polymerase,KW-0539~Nucleus,KW-9994~DNA-directed RNA polymerase,					KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:DNA-directed RNA polymerase III subunit RPC5 C-terminal,REGION:Disordered,REGION:Required for Pol III complex stability,
RPAIN	RPA interacting protein(RPAIN)	Homo sapiens			GO:0006606~protein import into nucleus,GO:0009411~response to UV,	GO:0001650~fibrillar center,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0016605~PML body,	GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR028155:RPA_interact_central,IPR028156:RIP,IPR028158:RPA_interact_N_dom,IPR028159:RPA_interact_C_dom,						KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO); in isoform 2,DOMAIN:RPA-interacting protein N-terminal,MUTAGEN:K->R: Abolishes sumoylation; when associated with R-114 and R-121.,MUTAGEN:K->R: Abolishes sumoylation; when associated with R-121 and R-142.,MUTAGEN:K->R: Induces a strong decrease in sumoylation; when associated with N-103. Abolishes sumoylation; when associated with R-114 and R-142.,REGION:Mediates nuclear export,ZN_FING:RIP-type,
RTF1	RTF1 homolog, Paf1/RNA polymerase II complex component(RTF1)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001711~endodermal cell fate commitment,GO:0001832~blastocyst growth,GO:0006325~chromatin organization,GO:0006368~transcription elongation from RNA polymerase II promoter,GO:0016055~Wnt signaling pathway,GO:0019827~stem cell population maintenance,	GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0016593~Cdc73/Paf1 complex,	GO:0003677~DNA binding,GO:0003697~single-stranded DNA binding,GO:0003723~RNA binding,GO:0005515~protein binding,	IPR004343:Plus-3_dom,IPR036128:Plus3-like_sf,				SM00719:Plus3,	KW-0804~Transcription,KW-0805~Transcription regulation,KW-0879~Wnt signaling pathway,	KW-0539~Nucleus,		KW-0175~Coiled coil,		KW-0010~Activator,KW-0238~DNA-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,DOMAIN:Plus3,MUTAGEN:E->K: Reduced binding to single-stranded DNA.,MUTAGEN:Q->A: Reduced binding to single-stranded DNA.,MUTAGEN:R->E: Loss of binding to single-stranded DNA.,REGION:Disordered,
RWDD1	RWD domain containing 1(RWDD1)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0030521~androgen receptor signaling pathway,GO:0034599~cellular response to oxidative stress,GO:0071394~cellular response to testosterone stimulus,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005844~polysome,	GO:0005515~protein binding,	IPR006575:RWD-domain,IPR016135:UBQ-conjugating_enzyme/RWD,IPR032378:ZC3H15/TMA46_C,IPR040213:GIR2-like,				SM00591:RWD,				KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,DOMAIN:RWD,REGION:Disordered,REGION:Interaction with DRG2,
RABAC1	Rab acceptor 1(RABAC1)	Homo sapiens				GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0008021~synaptic vesicle,GO:0016020~membrane,	GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0051020~GTPase binding,GO:0070064~proline-rich region binding,	IPR004895:Prenylated_rab_accept_PRA1,						KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0770~Synapse,KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				REGION:Homodimerization,REGION:Required for interaction with GDI1,REGION:Required for interaction with prenylated RAB3A and VAMP2,TOPO_DOM:Cytoplasmic,TRANSMEM:Helical,
RABGGTB	Rab geranylgeranyltransferase subunit beta(RABGGTB)	Homo sapiens			GO:0007601~visual perception,GO:0018344~protein geranylgeranylation,GO:0036211~protein modification process,	GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005968~Rab-protein geranylgeranyltransferase complex,	GO:0004663~Rab geranylgeranyltransferase activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0008318~protein prenyltransferase activity,GO:0031267~small GTPase binding,GO:0046872~metal ion binding,	IPR001330:PFTB_repeat,IPR008930:Terpenoid_cyclase/PrenylTrfase,IPR026873:Ptb1,IPR045089:PGGT1B-like,								KW-0677~Repeat,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0637~Prenyltransferase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	REPEAT:PFTB 1,REPEAT:PFTB 2,REPEAT:PFTB 3,REPEAT:PFTB 4,REPEAT:PFTB 5,REPEAT:PFTB 6,
RILPL2	Rab interacting lysosomal protein like 2(RILPL2)	Homo sapiens			GO:0003382~epithelial cell morphogenesis,GO:0060271~cilium assembly,GO:1903445~protein transport from ciliary membrane to plasma membrane,	GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005829~cytosol,GO:0005929~cilium,GO:0016020~membrane,GO:0036064~ciliary basal body,	GO:0005515~protein binding,GO:0031267~small GTPase binding,GO:0042802~identical protein binding,GO:0046983~protein dimerization activity,GO:0051959~dynein light intermediate chain binding,	IPR021563:RILP_dimer,IPR034743:RH1,IPR034744:RH2,					KW-0653~Protein transport,KW-0813~Transport,	KW-0206~Cytoskeleton,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-0969~Cilium,		KW-0175~Coiled coil,			KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,DOMAIN:RH1,DOMAIN:RH2,MUTAGEN:K->E: Loss of interaction with RAB8A, RAB10 and RAB12.,MUTAGEN:R->E: Loss of interaction with RAB8A, RAB10 and RAB12.,REGION:Disordered,
RAC1	Rac family small GTPase 1(RAC1)	Homo sapiens	102.Cholesterol_Stress_Response,	h_actinYPathway:Y branching of actin filaments,h_agrPathway:Agrin in Postsynaptic Differentiation,h_arfPathway:Tumor Suppressor Arf Inhibits Ribosomal Biogenesis,h_at1rPathway:Angiotensin II mediated activation of JNK Pathway via Pyk2 dependent signaling,h_bcrPathway:BCR Signaling Pathway,h_cdc42racPathway:Role of PI3K subunit p85 in regulation of Actin Organization and Cell Migration,h_crebPathway:Transcription factor CREB and its extracellular signals,h_edg1Pathway:Phospholipids as signalling intermediaries,h_fmlpPathway:fMLP induced chemokine gene expression in HMC-1 cells,h_malPathway:Role of MAL in Rho-Mediated Activation of SRF,h_mapkPathway:MAPKinase Signaling Pathway,h_nkcellsPathway:Ras-Independent pathway in NK cell-mediated cytotoxicity,h_p38mapkPathway:p38 MAPK Signaling Pathway ,h_ptdinsPathway:Phosphoinositides and their downstream targets.,h_pyk2Pathway:Links between Pyk2 and Map Kinases,h_rac1Pathway:Rac 1 cell motility signaling pathway,h_raccycdPathway:Influence of Ras and Rho proteins on G1 to S Transition,h_rasPathway:Ras Signaling Pathway,h_salmonellaPathway:How does salmonella hijack a cell,h_tcrPathway:T Cell Receptor Signaling Pathway,h_uCalpainPathway:uCalpain and friends in Cell spread,	GO:0001764~neuron migration,GO:0001934~positive regulation of protein phosphorylation,GO:0003376~sphingosine-1-phosphate signaling pathway,GO:0006935~chemotaxis,GO:0006954~inflammatory response,GO:0007015~actin filament organization,GO:0007155~cell adhesion,GO:0007160~cell-matrix adhesion,GO:0007163~establishment or maintenance of cell polarity,GO:0007165~signal transduction,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007264~small GTPase mediated signal transduction,GO:0008045~motor neuron axon guidance,GO:0008360~regulation of cell shape,GO:0008361~regulation of cell size,GO:0009611~response to wounding,GO:0009653~anatomical structure morphogenesis,GO:0010310~regulation of hydrogen peroxide metabolic process,GO:0010591~regulation of lamellipodium assembly,GO:0010592~positive regulation of lamellipodium assembly,GO:0010595~positive regulation of endothelial cell migration,GO:0010764~negative regulation of fibroblast migration,GO:0010810~regulation of cell-substrate adhesion,GO:0010811~positive regulation of cell-substrate adhesion,GO:0016477~cell migration,GO:0016601~Rac protein signal transduction,GO:0030031~cell projection assembly,GO:0030032~lamellipodium assembly,GO:0030036~actin cytoskeleton organization,GO:0030041~actin filament polymerization,GO:0030334~regulation of cell migration,GO:0030865~cortical cytoskeleton organization,GO:0031116~positive regulation of microtubule polymerization,GO:0031529~ruffle organization,GO:0032707~negative regulation of interleukin-23 production,GO:0032956~regulation of actin cytoskeleton organization,GO:0034446~substrate adhesion-dependent cell spreading,GO:0035025~positive regulation of Rho protein signal transduction,GO:0035556~intracellular signal transduction,GO:0042129~regulation of T cell proliferation,GO:0043131~erythrocyte enucleation,GO:0043304~regulation of mast cell degranulation,GO:0043652~engulfment of apoptotic cell,GO:0045428~regulation of nitric oxide biosynthetic process,GO:0045453~bone resorption,GO:0045730~respiratory burst,GO:0048012~hepatocyte growth factor receptor signaling pathway,GO:0048261~negative regulation of receptor-mediated endocytosis,GO:0048870~cell motility,GO:0051179~localization,GO:0051492~regulation of stress fiber assembly,GO:0051496~positive regulation of stress fiber assembly,GO:0051668~localization within membrane,GO:0051894~positive regulation of focal adhesion assembly,GO:0060071~Wnt signaling pathway, planar cell polarity pathway,GO:0060263~regulation of respiratory burst,GO:0060326~cell chemotaxis,GO:0060753~regulation of mast cell chemotaxis,GO:0070662~mast cell proliferation,GO:0070668~positive regulation of mast cell proliferation,GO:0071526~semaphorin-plexin signaling pathway,GO:0071593~lymphocyte aggregation,GO:0090023~positive regulation of neutrophil chemotaxis,GO:0097178~ruffle assembly,GO:1900026~positive regulation of substrate adhesion-dependent cell spreading,GO:1902622~regulation of neutrophil migration,GO:1903955~positive regulation of protein targeting to mitochondrion,	GO:0005634~nucleus,GO:0005635~nuclear envelope,GO:0005737~cytoplasm,GO:0005741~mitochondrial outer membrane,GO:0005789~endoplasmic reticulum membrane,GO:0005802~trans-Golgi network,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005884~actin filament,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0005938~cell cortex,GO:0016020~membrane,GO:0030027~lamellipodium,GO:0030667~secretory granule membrane,GO:0030670~phagocytic vesicle membrane,GO:0031410~cytoplasmic vesicle,GO:0032587~ruffle membrane,GO:0036464~cytoplasmic ribonucleoprotein granule,GO:0042470~melanosome,GO:0043020~NADPH oxidase complex,GO:0043197~dendritic spine,GO:0055038~recycling endosome membrane,GO:0070062~extracellular exosome,GO:0098794~postsynapse,GO:0098978~glutamatergic synapse,GO:0101003~ficolin-1-rich granule membrane,	GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0019887~protein kinase regulator activity,GO:0019899~enzyme binding,GO:0019901~protein kinase binding,GO:0031996~thioesterase binding,GO:0044877~macromolecular complex binding,GO:0051022~Rho GDP-dissociation inhibitor binding,	IPR001806:Small_GTPase,IPR003578:Small_GTPase_Rho,IPR005225:Small_GTP-bd_dom,IPR027417:P-loop_NTPase,	hsa04010:MAPK signaling pathway,hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04024:cAMP signaling pathway,hsa04062:Chemokine signaling pathway,hsa04071:Sphingolipid signaling pathway,hsa04145:Phagosome,hsa04148:Efferocytosis,hsa04151:PI3K-Akt signaling pathway,hsa04310:Wnt signaling pathway,hsa04360:Axon guidance,hsa04370:VEGF signaling pathway,hsa04380:Osteoclast differentiation,hsa04510:Focal adhesion,hsa04520:Adherens junction,hsa04530:Tight junction,hsa04613:Neutrophil extracellular trap formation,hsa04620:Toll-like receptor signaling pathway,hsa04650:Natural killer cell mediated cytotoxicity,hsa04662:B cell receptor signaling pathway,hsa04664:Fc epsilon RI signaling pathway,hsa04666:Fc gamma R-mediated phagocytosis,hsa04670:Leukocyte transendothelial migration,hsa04722:Neurotrophin signaling pathway,hsa04810:Regulation of actin cytoskeleton,hsa04932:Non-alcoholic fatty liver disease,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa04972:Pancreatic secretion,hsa05014:Amyotrophic lateral sclerosis,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05100:Bacterial invasion of epithelial cells,hsa05120:Epithelial cell signaling in Helicobacter pylori infection,hsa05130:Pathogenic Escherichia coli infection,hsa05131:Shigellosis,hsa05132:Salmonella infection,hsa05135:Yersinia infection,hsa05163:Human cytomegalovirus infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05200:Pathways in cancer,hsa05203:Viral carcinogenesis,hsa05205:Proteoglycans in cancer,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05210:Colorectal cancer,hsa05211:Renal cell carcinoma,hsa05212:Pancreatic cancer,hsa05231:Choline metabolism in cancer,hsa05415:Diabetic cardiomyopathy,hsa05416:Viral myocarditis,hsa05417:Lipid and atherosclerosis,hsa05418:Fluid shear stress and atherosclerosis,	617751~Intellectual developmental disorder, autosomal dominant 48,		SM00173:RAS,SM00174:RHO,SM00175:RAB,SM00176:RAN,		KW-0472~Membrane,KW-0539~Nucleus,KW-0770~Synapse,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0991~Intellectual disability,		KW-0342~GTP-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,	KW-0007~Acetylation,KW-0013~ADP-ribosylation,KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0488~Methylation,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-0636~Prenylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CARBOHYD:(Microbial infection) O-alpha-linked (GlcNAc) threonine; by C.novyi toxin TcdA; alternate,CARBOHYD:(Microbial infection) O-linked (Glc) threonine; by C.difficile toxins TcdA and TcdB, and by P.sordellii toxin TcsL; alternate,CARBOHYD:(Microbial infection) O-linked (GlcNAc) tyrosine; by Photorhabdus PAU_02230; alternate,CARBOHYD:O-linked (GlcNAc) tyrosine; by Photorhabdus PAU_02230,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),LIPID:(Microbial infection) N6-palmitoyl lysine,LIPID:S-geranylgeranyl cysteine,MOTIF:Effector region,MOTIF:Polybasic region; required for nuclear import,MUTAGEN:C->W: Abolishes in vitro prenylation.,MUTAGEN:F->A: Strongly reduced interaction with PLCB2.,MUTAGEN:G->V: Constitutively active. Interacts with PARD6 proteins. Increases nuclear localization and up-regulates transcriptional activity of NR3C2. Doesn't interact with CYRIB. Increases interaction with GARRE1.,MUTAGEN:G->V: No interaction with PPP5C; when associated with L-61. Translocates to the plasma membrane; also when associated with L-61.,MUTAGEN:K->A: Decreased palmitoylation by the V.cholerae toxin RtxA.,MUTAGEN:K->A: Slightly decreased palmitoylation by the V.cholerae toxin RtxA.,MUTAGEN:K->R: Loss of FBXL19-induced polyubiquitination.,MUTAGEN:KKRKRK->AARARA: In 4KA mutant; abolished palmitoylation by the V.cholerae toxin RtxA.,MUTAGEN:L->A: Strongly reduced interaction with PLCB2.,MUTAGEN:Q->L: Constitutively active. Interacts with PARD6 proteins. Interacts with PPP5C, activates its phosphatase activity and translocates PPP5C to the plasma membrane. No effect on interaction with RAPH1. Interacts with CYRIB. No interaction with PPP5C; when associated with V-30 or S-35. Translocates to the plasma membrane; also when associated with V-30 or S-35.,MUTAGEN:RKR->AKA: In 2RA mutant; does not affect palmitoylation by the V.cholerae toxin RtxA.,MUTAGEN:S->A: Loss of AKT-mediated phosphorylation and FBXL19-induced polyubiquitination.,MUTAGEN:T->A: Abolishes AMPylation by Vibrio VopS.,MUTAGEN:T->N: Constitutively inactivated. Abolishes interaction with PARD6 proteins. No effect on NR3C2 transcriptional activity. No interaction with PPP5C. Doesn't activate PPP5C phosphatase activity and translocate PPP5C to the plasma membrane. Doesn't interact with CYRIB.,MUTAGEN:T->S: No interaction with PPP5C; when associated with L-61. Translocates to the plasma membrane; also when associated with L-61.,MUTAGEN:W->A: Strongly reduced interaction with PLCB2.,MUTAGEN:Y->F: Abolishes AMPylation by Haemophilus IbpA.,PROPEP:Removed in mature form,REGION:Disordered,
RAF1	Raf-1 proto-oncogene, serine/threonine kinase(RAF1)	Homo sapiens	100.MAPK_signaling_cascades,102.Cholesterol_Stress_Response,104.Insulin_signaling,105.Signaling_glucose_uptake,106.Glycogen_synthase-synthesis,107.mRNA_translation-protein_synthesis,2.Cytokine_Receptors,54.T-cell_anergy,67.Ikaros_and_signaling_inhibitors,68.Mitogen_signaling_in_growth_control,83.Growth_factors_Survival_factors_Mitogens,	h_at1rPathway:Angiotensin II mediated activation of JNK Pathway via Pyk2 dependent signaling,h_bArr-mapkPathway:Role of ï¿½-arrestins in the activation and targeting of MAP kinases,h_bArrestin-srcPathway:Roles of ï¿½-arrestin-dependent Recruitment of Src Kinases in GPCR Signaling,h_bcrPathway:BCR Signaling Pathway,h_biopeptidesPathway:Bioactive Peptide Induced Signaling Pathway,h_ccr3Pathway:CCR3 signaling in Eosinophils,h_cdk5Pathway:Phosphorylation of MEK1 by cdk5/p35 down regulates the MAP kinase pathway,h_cdmacPathway:Cadmium induces DNA synthesis and proliferation in macrophages,h_ceramidePathway:Ceramide Signaling Pathway,h_cxcr4Pathway:CXCR4 Signaling Pathway,h_ecmPathway:Erk and PI-3 Kinase Are Necessary for Collagen Binding in Corneal Epithelia,h_egfPathway:EGF Signaling Pathway,h_epoPathway:EPO Signaling Pathway,h_erkPathway:Erk1/Erk2 Mapk Signaling pathway,h_fcer1Pathway:Fc Epsilon Receptor I Signaling in Mast Cells,h_fmlpPathway:fMLP induced chemokine gene expression in HMC-1 cells,h_ghPathway:Growth Hormone Signaling Pathway,h_gleevecPathway:Inhibition of Cellular Proliferation by Gleevec,h_gpcrPathway:Signaling Pathway from G-Protein Families,h_her2Pathway:Role of ERBB2 in Signal Transduction and Oncology,h_igf1Pathway:IGF-1 Signaling Pathway,h_igf1rPathway:Multiple antiapoptotic pathways from IGF-1R signaling lead to BAD phosphorylation,h_il2Pathway:IL 2 signaling pathway,h_il2rbPathway:IL-2 Receptor Beta Chain in T cell Activation,h_il3Pathway:IL 3 signaling pathway,h_il6Pathway:IL 6 signaling pathway,h_insulinPathway:Insulin Signaling Pathway,h_integrinPathway:Integrin Signaling Pathway,h_keratinocytePathway:Keratinocyte Differentiation,h_malPathway:Role of MAL in Rho-Mediated Activation of SRF,h_mapkPathway:MAPKinase Signaling Pathway,h_metPathway:Signaling of Hepatocyte Growth Factor Receptor,h_nfatPathway:NFAT and Hypertrophy of the heart (Transcription in the broken heart),h_ngfPathway:Nerve growth factor pathway (NGF),h_pdgfPathway:PDGF Signaling Pathway,h_pyk2Pathway:Links between Pyk2 and Map Kinases,h_raccycdPathway:Influence of Ras and Rho proteins on G1 to S Transition,h_rasPathway:Ras Signaling Pathway,h_sppaPathway:Aspirin Blocks Signaling Pathway Involved in Platelet Activation,h_spryPathway:Sprouty regulation of tyrosine kinase signals,h_tcrPathway:T Cell Receptor Signaling Pathway,h_tpoPathway:TPO Signaling Pathway,	GO:0000165~MAPK cascade,GO:0001934~positive regulation of protein phosphorylation,GO:0006468~protein phosphorylation,GO:0006915~apoptotic process,GO:0007165~signal transduction,GO:0007190~activation of adenylate cyclase activity,GO:0008285~negative regulation of cell proliferation,GO:0008286~insulin receptor signaling pathway,GO:0008625~extrinsic apoptotic signaling pathway via death domain receptors,GO:0010604~positive regulation of macromolecule metabolic process,GO:0014044~Schwann cell development,GO:0016310~phosphorylation,GO:0030878~thyroid gland development,GO:0031333~negative regulation of protein complex assembly,GO:0031399~regulation of protein modification process,GO:0033138~positive regulation of peptidyl-serine phosphorylation,GO:0035019~somatic stem cell population maintenance,GO:0035023~regulation of Rho protein signal transduction,GO:0035773~insulin secretion involved in cellular response to glucose stimulus,GO:0035994~response to muscle stretch,GO:0036211~protein modification process,GO:0038133~ERBB2-ERBB3 signaling pathway,GO:0042060~wound healing,GO:0042552~myelination,GO:0042981~regulation of apoptotic process,GO:0043066~negative regulation of apoptotic process,GO:0043154~negative regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0043410~positive regulation of MAPK cascade,GO:0044342~type B pancreatic cell proliferation,GO:0045104~intermediate filament cytoskeleton organization,GO:0045595~regulation of cell differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048009~insulin-like growth factor receptor signaling pathway,GO:0048011~neurotrophin TRK receptor signaling pathway,GO:0048538~thymus development,GO:0051173~positive regulation of nitrogen compound metabolic process,GO:0060324~face development,GO:0060333~interferon-gamma-mediated signaling pathway,GO:0071550~death-inducing signaling complex assembly,GO:1902042~negative regulation of extrinsic apoptotic signaling pathway via death domain receptors,GO:1902531~regulation of intracellular signal transduction,GO:2000145~regulation of cell motility,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005741~mitochondrial outer membrane,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0031143~pseudopodium,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004709~MAP kinase kinase kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0019899~enzyme binding,GO:0031267~small GTPase binding,GO:0042802~identical protein binding,GO:0046872~metal ion binding,	IPR000719:Prot_kinase_dom,IPR001245:Ser-Thr/Tyr_kinase_cat_dom,IPR002219:PE/DAG-bd,IPR003116:RBD_dom,IPR008271:Ser/Thr_kinase_AS,IPR011009:Kinase-like_dom_sf,IPR017441:Protein_kinase_ATP_BS,IPR020454:DAG/PE-bd,IPR029071:Ubiquitin-like_domsf,IPR046349:C1-like_sf,	hsa01521:EGFR tyrosine kinase inhibitor resistance,hsa01522:Endocrine resistance,hsa04010:MAPK signaling pathway,hsa04012:ErbB signaling pathway,hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04022:cGMP-PKG signaling pathway,hsa04024:cAMP signaling pathway,hsa04062:Chemokine signaling pathway,hsa04068:FoxO signaling pathway,hsa04071:Sphingolipid signaling pathway,hsa04072:Phospholipase D signaling pathway,hsa04140:Autophagy - animal,hsa04150:mTOR signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04210:Apoptosis,hsa04218:Cellular senescence,hsa04270:Vascular smooth muscle contraction,hsa04360:Axon guidance,hsa04370:VEGF signaling pathway,hsa04371:Apelin signaling pathway,hsa04510:Focal adhesion,hsa04540:Gap junction,hsa04550:Signaling pathways regulating pluripotency of stem cells,hsa04613:Neutrophil extracellular trap formation,hsa04625:C-type lectin receptor signaling pathway,hsa04630:JAK-STAT signaling pathway,hsa04650:Natural killer cell mediated cytotoxicity,hsa04660:T cell receptor signaling pathway,hsa04662:B cell receptor signaling pathway,hsa04664:Fc epsilon RI signaling pathway,hsa04666:Fc gamma R-mediated phagocytosis,hsa04720:Long-term potentiation,hsa04722:Neurotrophin signaling pathway,hsa04726:Serotonergic synapse,hsa04730:Long-term depression,hsa04810:Regulation of actin cytoskeleton,hsa04910:Insulin signaling pathway,hsa04912:GnRH signaling pathway,hsa04914:Progesterone-mediated oocyte maturation,hsa04915:Estrogen signaling pathway,hsa04916:Melanogenesis,hsa04917:Prolactin signaling pathway,hsa04919:Thyroid hormone signaling pathway,hsa04921:Oxytocin signaling pathway,hsa04926:Relaxin signaling pathway,hsa04928:Parathyroid hormone synthesis, secretion and action,hsa04929:GnRH secretion,hsa04935:Growth hormone synthesis, secretion and action,hsa05010:Alzheimer disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05034:Alcoholism,hsa05132:Salmonella infection,hsa05152:Tuberculosis,hsa05160:Hepatitis C,hsa05161:Hepatitis B,hsa05163:Human cytomegalovirus infection,hsa05164:Influenza A,hsa05165:Human papillomavirus infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05200:Pathways in cancer,hsa05205:Proteoglycans in cancer,hsa05206:MicroRNAs in cancer,hsa05207:Chemical carcinogenesis - receptor activation,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05210:Colorectal cancer,hsa05211:Renal cell carcinoma,hsa05212:Pancreatic cancer,hsa05213:Endometrial cancer,hsa05214:Glioma,hsa05215:Prostate cancer,hsa05218:Melanoma,hsa05219:Bladder cancer,hsa05220:Chronic myeloid leukemia,hsa05221:Acute myeloid leukemia,hsa05223:Non-small cell lung cancer,hsa05224:Breast cancer,hsa05225:Hepatocellular carcinoma,hsa05226:Gastric cancer,hsa05230:Central carbon metabolism in cancer,hsa05231:Choline metabolism in cancer,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,	611553~Noonan syndrome 5,611554~LEOPARD syndrome 2,615916~Cardiomyopathy, dilated, 1NN,	PIRSF000654:Integrin-linked_kinase,	SM00109:C1,SM00220:S_TKc,SM00455:RBD,		KW-0472~Membrane,KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,	KW-0122~Cardiomyopathy,KW-0209~Deafness,KW-0225~Disease variant,KW-0656~Proto-oncogene,	KW-0863~Zinc-finger,	KW-0067~ATP-binding,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,KW-0862~Zinc,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0488~Methylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,COMPBIAS:Polar residues,DOMAIN:Phorbol-ester/DAG-type,DOMAIN:Protein kinase,DOMAIN:RBD,MUTAGEN:K->W: Catalytically inactive.,MUTAGEN:R->K: Loss of methylation. Increased stability and catalytic activity in response to EGF treatment.,MUTAGEN:S->D: Increased kinase activity but can still be inhibited by PPP5C; when associated with D-491.,MUTAGEN:SS->AA: Reduced kinase activity; when associated with 340-D-D-341.,MUTAGEN:SS->DE: Non-inhibited by PPP5C. Constitutively active and non-inhibited by PPP5C; when associated with 340-D-D-341.,MUTAGEN:T->D: Increased kinase activity but can still be inhibited by PPP5C; when associated with D-494.,MUTAGEN:YY->DD: Constitutively active and highly phosphorylated on S-338, inhibited by PPP5C. Reduced kinase activity; when associated with 338-A-A-339. Constitutively active and non-inhibited by PPP5C; when associated with 338-D-E-339.,REGION:Disordered,REGION:Interaction with PEBP1/RKIP,ZN_FING:Phorbol-ester/DAG-type,
RALGAPA1	Ral GTPase activating protein catalytic subunit alpha 1(RALGAPA1)	Homo sapiens			GO:0051056~regulation of small GTPase mediated signal transduction,GO:0090630~activation of GTPase activity,	GO:0005634~nucleus,GO:0005737~cytoplasm,	GO:0005096~GTPase activator activity,GO:0046982~protein heterodimerization activity,	IPR000331:Rap/Ran_GAP_dom,IPR016024:ARM-type_fold,IPR027107:Tuberin/Ral-act_asu,IPR035974:Rap/Ran-GAP_sf,IPR046859:RGPA/RALGAPB_N,	hsa04014:Ras signaling pathway,	618797~Neurodevelopmental disorder with hypotonia, neonatal respiratory insufficiency, and thermodysregulation,				KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,	KW-0175~Coiled coil,KW-0732~Signal,		KW-0343~GTPase activation,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Rap-GAP,MUTAGEN:N->K: Has no effect on interaction with RALGAPB but causes loss of activity.,REGION:Disordered,REGION:Minimal domain that binds to TCF3/E12,
RANGAP1	Ran GTPase activating protein 1(RANGAP1)	Homo sapiens		h_npcPathway:Mechanism of Protein Import into the Nucleus,h_ranbp2Pathway:Sumoylation by RanBP2 Regulates Transcriptional Repression,h_ranMSPathway:Role of Ran in mitotic spindle regulation,h_ranPathway:Cycling of Ran in nucleocytoplasmic transport,	GO:0006913~nucleocytoplasmic transport,GO:0007165~signal transduction,GO:0016925~protein sumoylation,GO:0046826~negative regulation of protein export from nucleus,GO:0048678~response to axon injury,GO:0051168~nuclear export,GO:0090630~activation of GTPase activity,GO:1904117~cellular response to vasopressin,	GO:0000776~kinetochore,GO:0005634~nucleus,GO:0005635~nuclear envelope,GO:0005643~nuclear pore,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016235~aggresome,GO:0030425~dendrite,GO:0031965~nuclear membrane,GO:0043231~intracellular membrane-bounded organelle,GO:0044614~nuclear pore cytoplasmic filaments,GO:0048471~perinuclear region of cytoplasm,GO:0072686~mitotic spindle,GO:1904115~axon cytoplasm,GO:1990723~cytoplasmic periphery of the nuclear pore complex,	GO:0003723~RNA binding,GO:0005096~GTPase activator activity,GO:0005515~protein binding,GO:0031267~small GTPase binding,GO:0031625~ubiquitin protein ligase binding,GO:0045296~cadherin binding,	IPR001611:Leu-rich_rpt,IPR009109:Ran_GTPase_activating_1_C,IPR032675:LRR_dom_sf,IPR036720:RanGAP1_C_sf,	hsa03013:Nucleocytoplasmic transport,			SM00368:LRR_RI,		KW-0137~Centromere,KW-0158~Chromosome,KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0995~Kinetochore,		KW-0433~Leucine-rich repeat,KW-0677~Repeat,		KW-0343~GTPase activation,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:Ran-GTPase activating protein 1 C-terminal,MOTIF:SUMO conjugation,MUTAGEN:K->R: Loss of cross-link to SUMO1. Abolishes association with nuclear pores during interphase, and with mitotic spindles during mitosis.,MUTAGEN:R->A: Abolishes RAN GTPase activation.,MUTAGEN:S->A: No effect on phosphorylation.,MUTAGEN:S->A: Strongly decreased phosphorylation. No effect on sumoylation.,REGION:Disordered,REPEAT:LRR 1,REPEAT:LRR 2,REPEAT:LRR 3,REPEAT:LRR 4,REPEAT:LRR 5,REPEAT:LRR 6,SITE:Hydrophobic interaction with UBE2I,
RAP1GDS1	Rap1 GTPase-GDP dissociation stimulator 1(RAP1GDS1)	Homo sapiens			GO:0003300~cardiac muscle hypertrophy,GO:0010821~regulation of mitochondrion organization,GO:0014829~vascular smooth muscle contraction,GO:0031034~myosin filament assembly,GO:0032471~negative regulation of endoplasmic reticulum calcium ion concentration,GO:0034504~protein localization to nucleus,GO:0051561~positive regulation of mitochondrial calcium ion concentration,GO:0070376~regulation of ERK5 cascade,GO:0080120~CAAX-box protein maturation,GO:0086098~angiotensin-activated signaling pathway involved in heart process,GO:1904464~regulation of matrix metallopeptidase secretion,	GO:0005634~nucleus,GO:0005739~mitochondrion,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0005085~guanyl-nucleotide exchange factor activity,GO:0005515~protein binding,	IPR000225:Armadillo,IPR011989:ARM-like,IPR016024:ARM-type_fold,IPR040144:RAP1GDS1,		620655~Alfadhel syndrome,		SM00185:ARM,		KW-0256~Endoplasmic reticulum,KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,		KW-0344~Guanine-nucleotide releasing factor,	KW-0007~Acetylation,	COMPBIAS:Basic and acidic residues,MOTIF:Nuclear export signal (NES),REGION:Critical for catalytic activity,REGION:Disordered,REGION:Interacts with polybasic regions in GTPases,REGION:Prevents binding to prenylated RHOA,REPEAT:ARM,REPEAT:ARM 1,REPEAT:ARM 2,REPEAT:ARM 3,REPEAT:ARM 4,REPEAT:ARM 5,SITE:Breakpoint for translocation to form the NUP98-RAP1GDS1 fusion protein,
RASSF1	Ras association domain family member 1(RASSF1)	Homo sapiens			GO:0006974~cellular response to DNA damage stimulus,GO:0007049~cell cycle,GO:0007165~signal transduction,GO:0007265~Ras protein signal transduction,GO:0031398~positive regulation of protein ubiquitination,GO:0050821~protein stabilization,GO:0051726~regulation of cell cycle,GO:1902806~regulation of cell cycle G1/S phase transition,	GO:0000922~spindle pole,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005874~microtubule,GO:0015630~microtubule cytoskeleton,	GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0042802~identical protein binding,GO:0046872~metal ion binding,	IPR000159:RA_dom,IPR002219:PE/DAG-bd,IPR011524:SARAH_dom,IPR029071:Ubiquitin-like_domsf,IPR033600:RASSF1_RA,IPR033614:RASSF1-6,IPR046349:C1-like_sf,	hsa04014:Ras signaling pathway,hsa04390:Hippo signaling pathway,hsa04392:Hippo signaling pathway - multiple species,hsa05200:Pathways in cancer,hsa05206:MicroRNAs in cancer,hsa05219:Bladder cancer,hsa05223:Non-small cell lung cancer,			SM00109:C1,SM00314:RA,	KW-0131~Cell cycle,	KW-0206~Cytoskeleton,KW-0493~Microtubule,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0043~Tumor suppressor,	KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:Phorbol-ester/DAG-type,DOMAIN:Ras-associating,DOMAIN:SARAH,REGION:Disordered,REGION:MOAP1-binding,REGION:Mediates interaction with E4F1,ZN_FING:Phorbol-ester/DAG-type,
RASSF5	Ras association domain family member 5(RASSF5)	Homo sapiens			GO:0006915~apoptotic process,GO:0007165~signal transduction,GO:0031398~positive regulation of protein ubiquitination,GO:0046651~lymphocyte proliferation,GO:0050672~negative regulation of lymphocyte proliferation,GO:1900180~regulation of protein localization to nucleus,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005874~microtubule,	GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0046872~metal ion binding,	IPR000159:RA_dom,IPR002219:PE/DAG-bd,IPR011524:SARAH_dom,IPR029071:Ubiquitin-like_domsf,IPR033614:RASSF1-6,IPR033623:RASSF5_RA,IPR046349:C1-like_sf,	hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04218:Cellular senescence,hsa04670:Leukocyte transendothelial migration,hsa05200:Pathways in cancer,hsa05223:Non-small cell lung cancer,			SM00109:C1,SM00314:RA,	KW-0053~Apoptosis,	KW-0206~Cytoskeleton,KW-0493~Microtubule,KW-0963~Cytoplasm,	KW-0043~Tumor suppressor,	KW-0175~Coiled coil,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Phorbol-ester/DAG-type,DOMAIN:Ras-associating,DOMAIN:SARAH,REGION:Disordered,ZN_FING:Phorbol-ester/DAG-type,
RRAGA	Ras related GTP binding A(RRAGA)	Homo sapiens			GO:0006915~apoptotic process,GO:0008104~protein localization,GO:0009267~cellular response to starvation,GO:0010507~negative regulation of autophagy,GO:0031669~cellular response to nutrient levels,GO:0032008~positive regulation of TOR signaling,GO:0033209~tumor necrosis factor-mediated signaling pathway,GO:0034198~cellular response to amino acid starvation,GO:0035556~intracellular signal transduction,GO:0042593~glucose homeostasis,GO:0061462~protein localization to lysosome,GO:0071230~cellular response to amino acid stimulus,GO:0072657~protein localization to membrane,GO:1904263~positive regulation of TORC1 signaling,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005764~lysosome,GO:0005765~lysosomal membrane,GO:0005829~cytosol,GO:1990130~Iml1 complex,GO:1990131~Gtr1-Gtr2 GTPase complex,GO:1990877~Lst4-Lst7 complex,	GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0031625~ubiquitin protein ligase binding,GO:0042803~protein homodimerization activity,GO:0043495~protein anchor,GO:0046982~protein heterodimerization activity,GO:0051219~phosphoprotein binding,	IPR006762:Gtr1_RagA,IPR027417:P-loop_NTPase,IPR039397:RagA/B,	hsa04140:Autophagy - animal,hsa04150:mTOR signaling pathway,hsa05131:Shigellosis,				KW-0053~Apoptosis,KW-0945~Host-virus interaction,	KW-0458~Lysosome,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0342~GTP-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),MUTAGEN:A->F: In RA3 mutant; abolished interaction with RPTOR without affecting GTP-binding; when associated with Y-35 and A-46.,MUTAGEN:D->A: In RA2 mutant; abolished interaction with RPTOR without affecting GTP-binding; when associated with A-46. Does not affect interaction with TFE3 and TFEB; when associated with A-46.,MUTAGEN:D->Y: In RA3 mutant; abolished interaction with RPTOR without affecting GTP-binding; when associated with F-29 and A-46.,MUTAGEN:E->A: Abolished interaction with TFE3 and TFEB without affecting interaction with RPTOR.,MUTAGEN:E->A: In RA2 mutant; abolished interaction with RPTOR without affecting GTP-binding; when associated with A-35. In RA3 mutant; abolished interaction with RPTOR without affecting GTP-binding; when associated with F-29 and Y-35. Abolished interaction with RPTOR without affecting interaction with TFE3 and TFEB. Does not affect interaction with TFE3 and TFEB; when associated with A-35.,MUTAGEN:H->A: Abolished interaction with TFE3 and TFEB without affecting interaction with RPTOR.,MUTAGEN:K->R: Prevents RRAGA ubiquitination and alters interaction and regulation by GATOR1; when associated with R-142, R-230 and R-244.,MUTAGEN:K->R: Prevents RRAGA ubiquitination and alters interaction and regulation by GATOR1; when associated with R-220, R-230 and R-244.,MUTAGEN:K->R: Prevents RRAGA ubiquitination and alters interaction and regulation by GATOR1; when associated with RR-142, R-220 and R-230.,MUTAGEN:K->R: Prevents RRAGA ubiquitination and alters interaction and regulation by GATOR1; when associated with RR-142, R-220 and R-244.,MUTAGEN:L->A: Abolished interaction with TFE3 and TFEB without affecting interaction with RPTOR.,MUTAGEN:P->A: Abolished interaction with TFE3 and TFEB without affecting interaction with RPTOR.,MUTAGEN:Q->A: Abolished interaction with TFE3 and TFEB without affecting interaction with RPTOR.,MUTAGEN:Q->L: Maintains GTP-bound state, leading to activate mTORC1.,MUTAGEN:R->A: Abolished interaction with TFE3 and TFEB without affecting interaction with RPTOR.,MUTAGEN:T->N: Reduced affinity for all nucleotides, but with preferential binding of GDP over GTP.,MUTAGEN:Y->A: In RA1 mutant; abolished interaction with RPTOR without affecting GTP-binding. Does not affect interaction with TFE3 and TFEB.,
RSU1	Ras suppressor protein 1(RSU1)	Homo sapiens			GO:0007165~signal transduction,GO:0010811~positive regulation of cell-substrate adhesion,GO:0043547~positive regulation of GTPase activity,	GO:0005829~cytosol,GO:0005925~focal adhesion,GO:0070062~extracellular exosome,	GO:0005515~protein binding,	IPR001611:Leu-rich_rpt,IPR003591:Leu-rich_rpt_typical-subtyp,IPR025875:Leu-rich_rpt_4,IPR032675:LRR_dom_sf,				SM00364:LRR_BAC,SM00369:LRR_TYP,				KW-0433~Leucine-rich repeat,KW-0677~Repeat,			KW-0007~Acetylation,	COMPBIAS:Basic and acidic residues,REGION:Disordered,REPEAT:LRR 1,REPEAT:LRR 2,REPEAT:LRR 3,REPEAT:LRR 4,REPEAT:LRR 5,REPEAT:LRR 6,REPEAT:LRR 7,
ARHGDIA	Rho GDP dissociation inhibitor alpha(ARHGDIA)	Homo sapiens			GO:0007266~Rho protein signal transduction,GO:0032880~regulation of protein localization,GO:0035023~regulation of Rho protein signal transduction,GO:0043066~negative regulation of apoptotic process,GO:0071526~semaphorin-plexin signaling pathway,	GO:0001772~immunological synapse,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0016020~membrane,GO:0070062~extracellular exosome,GO:0098685~Schaffer collateral - CA1 synapse,	GO:0005094~Rho GDP-dissociation inhibitor activity,GO:0005096~GTPase activator activity,GO:0005515~protein binding,	IPR000406:Rho_GDI,IPR014756:Ig_E-set,IPR024792:RhoGDI_dom_sf,	hsa04722:Neurotrophin signaling pathway,hsa04962:Vasopressin-regulated water reabsorption,	615244~Nephrotic syndrome, type 8,				KW-0963~Cytoplasm,	KW-0225~Disease variant,			KW-0343~GTPase activation,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,MUTAGEN:D->A: Loss of RHOA interaction; when associated with A-185.,MUTAGEN:D->A: Loss of RHOA interaction; when associated with A-45.,MUTAGEN:K->A: Loss of interaction with NGFR.,REGION:Disordered,
ARHGDIB	Rho GDP dissociation inhibitor beta(ARHGDIB)	Homo sapiens		h_caspasePathway:Caspase Cascade in Apoptosis,h_d4gdiPathway:D4-GDI Signaling Pathway,h_fasPathway:FAS signaling pathway ( CD95 ),h_hivnefPathway:HIV-I Nef: negative effector of Fas and TNF,h_tnfr1Pathway:TNFR1 Signaling Pathway,	GO:0007266~Rho protein signal transduction,GO:0035023~regulation of Rho protein signal transduction,GO:0071461~cellular response to redox state,GO:1901164~negative regulation of trophoblast cell migration,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0016020~membrane,GO:0031410~cytoplasmic vesicle,GO:0070062~extracellular exosome,	GO:0003924~GTPase activity,GO:0005094~Rho GDP-dissociation inhibitor activity,GO:0005096~GTPase activator activity,GO:0005515~protein binding,GO:0031267~small GTPase binding,	IPR000406:Rho_GDI,IPR014756:Ig_E-set,IPR024792:RhoGDI_dom_sf,	hsa04722:Neurotrophin signaling pathway,hsa04962:Vasopressin-regulated water reabsorption,					KW-0963~Cytoplasm,				KW-0343~GTPase activation,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	REGION:Disordered,
ARHGAP15	Rho GTPase activating protein 15(ARHGAP15)	Homo sapiens			GO:0007165~signal transduction,GO:0008360~regulation of cell shape,GO:0043087~regulation of GTPase activity,GO:0051056~regulation of small GTPase mediated signal transduction,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,	GO:0005096~GTPase activator activity,	IPR000198:RhoGAP_dom,IPR001849:PH_domain,IPR008936:Rho_GTPase_activation_prot,IPR011993:PH-like_dom_sf,				SM00233:PH,SM00324:RhoGAP,		KW-0472~Membrane,KW-0963~Cytoplasm,				KW-0343~GTPase activation,	KW-0597~Phosphoprotein,	DOMAIN:PH,DOMAIN:Rho-GAP,REGION:Disordered,
ARHGAP25	Rho GTPase activating protein 25(ARHGAP25)	Homo sapiens			GO:0006911~phagocytosis, engulfment,GO:0007015~actin filament organization,GO:0007165~signal transduction,GO:0051058~negative regulation of small GTPase mediated signal transduction,GO:0090630~activation of GTPase activity,	GO:0001891~phagocytic cup,	GO:0005096~GTPase activator activity,	IPR000198:RhoGAP_dom,IPR001849:PH_domain,IPR008936:Rho_GTPase_activation_prot,IPR011993:PH-like_dom_sf,				SM00233:PH,SM00324:RhoGAP,		KW-0963~Cytoplasm,		KW-0175~Coiled coil,		KW-0343~GTPase activation,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:PH,DOMAIN:Rho-GAP,REGION:Disordered,
ARHGAP30	Rho GTPase activating protein 30(ARHGAP30)	Homo sapiens			GO:0007165~signal transduction,GO:0007264~small GTPase mediated signal transduction,GO:0051056~regulation of small GTPase mediated signal transduction,	GO:0005829~cytosol,GO:0031410~cytoplasmic vesicle,GO:0043231~intracellular membrane-bounded organelle,	GO:0005096~GTPase activator activity,GO:0005515~protein binding,	IPR000198:RhoGAP_dom,IPR008936:Rho_GTPase_activation_prot,				SM00324:RhoGAP,		KW-0968~Cytoplasmic vesicle,				KW-0343~GTPase activation,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Rho-GAP,REGION:Disordered,
ARHGAP4	Rho GTPase activating protein 4(ARHGAP4)	Homo sapiens		h_rhoPathway:Rho cell motility signaling pathway,	GO:0007010~cytoskeleton organization,GO:0007165~signal transduction,GO:0007266~Rho protein signal transduction,GO:0007399~nervous system development,GO:0010764~negative regulation of fibroblast migration,GO:0030336~negative regulation of cell migration,GO:0030517~negative regulation of axon extension,GO:0051056~regulation of small GTPase mediated signal transduction,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005874~microtubule,GO:0030426~growth cone,	GO:0005096~GTPase activator activity,GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR000198:RhoGAP_dom,IPR001060:FCH_dom,IPR001452:SH3_domain,IPR008936:Rho_GTPase_activation_prot,IPR027267:AH/BAR_dom_sf,IPR031160:F_BAR,IPR035678:srGAP4_SH3,IPR036028:SH3-like_dom_sf,				SM00055:FCH,SM00324:RhoGAP,SM00326:SH3,		KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0728~SH3 domain,		KW-0343~GTPase activation,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:F-BAR,DOMAIN:Rho-GAP,DOMAIN:SH3,REGION:Disordered,
ARHGEF1	Rho guanine nucleotide exchange factor 1(ARHGEF1)	Homo sapiens		h_myosinPathway:PKC-catalyzed phosphorylation of inhibitory phosphoprotein of myosin phosphatase,h_par1pathway:Thrombin signaling and protease-activated receptors,h_rhoPathway:Rho cell motility signaling pathway,	GO:0007186~G-protein coupled receptor signaling pathway,GO:0007266~Rho protein signal transduction,GO:0051056~regulation of small GTPase mediated signal transduction,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016020~membrane,	GO:0001664~G-protein coupled receptor binding,GO:0003723~RNA binding,GO:0005085~guanyl-nucleotide exchange factor activity,GO:0005096~GTPase activator activity,GO:0005515~protein binding,	IPR000219:DH-domain,IPR001849:PH_domain,IPR011993:PH-like_dom_sf,IPR015212:RGS-like_dom,IPR035899:DBL_dom_sf,IPR036305:RGS_sf,IPR037887:p115RhoGEF_RGS,IPR041020:PH_16,IPR044926:RGS_subdomain_2,	hsa04270:Vascular smooth muscle contraction,hsa04611:Platelet activation,hsa04810:Regulation of actin cytoskeleton,hsa04928:Parathyroid hormone synthesis, secretion and action,hsa05130:Pathogenic Escherichia coli infection,hsa05135:Yersinia infection,hsa05163:Human cytomegalovirus infection,hsa05200:Pathways in cancer,hsa05205:Proteoglycans in cancer,hsa05417:Lipid and atherosclerosis,	618459~Immunodeficiency 62,		SM00233:PH,SM00325:RhoGEF,		KW-0472~Membrane,KW-0963~Cytoplasm,		KW-0175~Coiled coil,		KW-0343~GTPase activation,KW-0344~Guanine-nucleotide releasing factor,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:ARHGEF1-like PH,DOMAIN:DH,DOMAIN:PH,DOMAIN:RGSL,DOMAIN:Regulator of G protein signalling-like,MUTAGEN:Y->F: Lowers the exchange activity.,MUTAGEN:Y->F: No effect.,REGION:Disordered,
SKP1	S-phase kinase associated protein 1(SKP1)	Homo sapiens	84.Ubiquitination_Pathways_Cell_Cycle,	h_eradPathway:ERï¿½associated degradation (ERAD) Pathway,h_fbw7Pathway:Cyclin E Destruction Pathway,h_p27Pathway:Regulation of p27 Phosphorylation during Cell Cycle Progression,h_skp2e2fPathway:E2F1 Destruction Pathway,	GO:0000209~protein polyubiquitination,GO:0006338~chromatin remodeling,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0006513~protein monoubiquitination,GO:0016567~protein ubiquitination,GO:0031146~SCF-dependent proteasomal ubiquitin-dependent protein catabolic process,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0051457~maintenance of protein location in nucleus,GO:0070936~protein K48-linked ubiquitination,GO:1904668~positive regulation of ubiquitin protein ligase activity,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005829~cytosol,GO:0019005~SCF ubiquitin ligase complex,GO:0031467~Cul7-RING ubiquitin ligase complex,GO:0031519~PcG protein complex,	GO:0005515~protein binding,GO:0008013~beta-catenin binding,GO:0019904~protein domain specific binding,GO:0097602~cullin family protein binding,GO:1990444~F-box domain binding,GO:1990756~protein binding, bridging involved in substrate recognition for ubiquitination,	IPR001232:SKP1-like,IPR011333:SKP1/BTB/POZ_sf,IPR016072:Skp1_comp_dimer,IPR016073:Skp1_comp_POZ,IPR016897:SKP1,IPR036296:SKP1-like_dim_sf,	hsa03083:Polycomb repressive complex,hsa04110:Cell cycle,hsa04114:Oocyte meiosis,hsa04120:Ubiquitin mediated proteolysis,hsa04141:Protein processing in endoplasmic reticulum,hsa04310:Wnt signaling pathway,hsa04350:TGF-beta signaling pathway,hsa04710:Circadian rhythm,hsa05131:Shigellosis,hsa05132:Salmonella infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05200:Pathways in cancer,		PIRSF028729:E3_ubiquit_lig_SCF_Skp,	SM00512:Skp1,	KW-0833~Ubl conjugation pathway,KW-0945~Host-virus interaction,						KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1),DOMAIN:SKP1 component POZ,DOMAIN:SKP1 component dimerisation,REGION:Disordered,REGION:Interaction with the F-box domain of F-box proteins,
S100A10	S100 calcium binding protein A10(S100A10)	Homo sapiens			GO:0001765~membrane raft assembly,GO:0006900~membrane budding,GO:0010756~positive regulation of plasminogen activation,GO:0042789~mRNA transcription from RNA polymerase II promoter,GO:0043547~positive regulation of GTPase activity,GO:0045921~positive regulation of exocytosis,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0050767~regulation of neurogenesis,GO:0051496~positive regulation of stress fiber assembly,GO:0051894~positive regulation of focal adhesion assembly,GO:0072659~protein localization to plasma membrane,GO:1900026~positive regulation of substrate adhesion-dependent cell spreading,GO:1905686~positive regulation of plasma membrane repair,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,GO:0016363~nuclear matrix,GO:0045121~membrane raft,GO:0070062~extracellular exosome,GO:0090575~RNA polymerase II transcription factor complex,GO:0098797~plasma membrane protein complex,GO:1990665~AnxA2-p11 complex,	GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0042803~protein homodimerization activity,GO:0044325~ion channel binding,GO:0048306~calcium-dependent protein binding,	IPR001751:S100/CaBP7/8-like_CS,IPR011992:EF-hand-dom_pair,IPR013787:S100_Ca-bd_sub,IPR028476:S100-A10,	hsa05132:Salmonella infection,			SM01394:S_100,		KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:S100/CaBP-9k-type calcium binding subdomain,REGION:Ancestral calcium site,TRANSMEM:Helical,
S100A11	S100 calcium binding protein A11(S100A11)	Homo sapiens			GO:0007165~signal transduction,GO:0008156~negative regulation of DNA replication,GO:0008285~negative regulation of cell proliferation,GO:0014911~positive regulation of smooth muscle cell migration,GO:0042127~regulation of cell proliferation,GO:0098609~cell-cell adhesion,	GO:0001726~ruffle,GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005912~adherens junction,GO:0034774~secretory granule lumen,GO:0070062~extracellular exosome,	GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0042803~protein homodimerization activity,GO:0044548~S100 protein binding,GO:0048306~calcium-dependent protein binding,GO:0098641~cadherin binding involved in cell-cell adhesion,	IPR001751:S100/CaBP7/8-like_CS,IPR002048:EF_hand_dom,IPR011992:EF-hand-dom_pair,IPR013787:S100_Ca-bd_sub,IPR018247:EF_Hand_1_Ca_BS,IPR028482:S100A11,				SM00054:EFh,SM01394:S_100,		KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	DISULFID:Interchain,DOMAIN:EF-hand,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,
S100A4	S100 calcium binding protein A4(S100A4)	Homo sapiens			GO:0001837~epithelial to mesenchymal transition,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0050918~positive chemotaxis,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,	GO:0003723~RNA binding,GO:0003779~actin binding,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0042056~chemoattractant activity,GO:0042802~identical protein binding,GO:0046914~transition metal ion binding,GO:0048306~calcium-dependent protein binding,GO:0050786~RAGE receptor binding,	IPR001751:S100/CaBP7/8-like_CS,IPR002048:EF_hand_dom,IPR011992:EF-hand-dom_pair,IPR013787:S100_Ca-bd_sub,IPR018247:EF_Hand_1_Ca_BS,IPR034325:S-100_dom,				SM00054:EFh,SM01394:S_100,		KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0964~Secreted,		KW-0677~Repeat,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-0007~Acetylation,	DOMAIN:EF-hand,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,
S100A6	S100 calcium binding protein A6(S100A6)	Homo sapiens			GO:0007165~signal transduction,GO:0007409~axonogenesis,GO:0034220~ion transmembrane transport,GO:0048146~positive regulation of fibroblast proliferation,	GO:0001726~ruffle,GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005635~nuclear envelope,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0009898~cytoplasmic side of plasma membrane,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,	GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0005523~tropomyosin binding,GO:0008270~zinc ion binding,GO:0015075~ion transmembrane transporter activity,GO:0042803~protein homodimerization activity,GO:0044548~S100 protein binding,GO:0048306~calcium-dependent protein binding,	IPR001751:S100/CaBP7/8-like_CS,IPR002048:EF_hand_dom,IPR011992:EF-hand-dom_pair,IPR013787:S100_Ca-bd_sub,IPR018247:EF_Hand_1_Ca_BS,IPR034118:S-100A6,				SM00054:EFh,SM01394:S_100,		KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0677~Repeat,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:EF-hand,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,
SACM1L	SAC1 like phosphatidylinositide phosphatase(SACM1L)	Homo sapiens			GO:0006661~phosphatidylinositol biosynthetic process,GO:0046856~phosphatidylinositol dephosphorylation,	GO:0000139~Golgi membrane,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005794~Golgi apparatus,GO:0016020~membrane,	GO:0004438~phosphatidylinositol-3-phosphatase activity,GO:0005515~protein binding,GO:0016791~phosphatase activity,GO:0034596~phosphatidylinositol phosphate 4-phosphatase activity,GO:0043812~phosphatidylinositol-4-phosphate phosphatase activity,	IPR002013:SAC_dom,	hsa00562:Inositol phosphate metabolism,hsa01100:Metabolic pathways,hsa04070:Phosphatidylinositol signaling system,				KW-0443~Lipid metabolism,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0378~Hydrolase,	KW-0007~Acetylation,	DOMAIN:SAC,MUTAGEN:C->S: Loss of phosphatidylinositol-4-phosphate phosphatase activity.,REGION:Essential for phosphatidylinositol-4-phosphate phosphatase activity,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
SLTM	SAFB like transcription modulator(SLTM)	Homo sapiens			GO:0001886~endothelial cell morphogenesis,GO:0001889~liver development,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006909~phagocytosis,GO:0006915~apoptotic process,GO:0007165~signal transduction,GO:0007166~cell surface receptor signaling pathway,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0007399~nervous system development,GO:0010507~negative regulation of autophagy,GO:0016310~phosphorylation,GO:0016477~cell migration,GO:0030182~neuron differentiation,GO:0031016~pancreas development,GO:0031116~positive regulation of microtubule polymerization,GO:0035024~negative regulation of Rho protein signal transduction,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048754~branching morphogenesis of an epithelial tube,GO:0050684~regulation of mRNA processing,GO:0050918~positive chemotaxis,GO:0051497~negative regulation of stress fiber assembly,GO:0061436~establishment of skin barrier,GO:0070495~negative regulation of thrombin-activated receptor signaling pathway,GO:0071526~semaphorin-plexin signaling pathway,GO:1901299~negative regulation of hydrogen peroxide-mediated programmed cell death,GO:1905098~negative regulation of guanyl-nucleotide exchange factor activity,GO:2001028~positive regulation of endothelial cell chemotaxis,	GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005886~plasma membrane,GO:0009925~basal plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,GO:0016604~nuclear body,GO:0043235~receptor complex,	GO:0003676~nucleic acid binding,GO:0003723~RNA binding,GO:0004672~protein kinase activity,GO:0004713~protein tyrosine kinase activity,GO:0005008~hepatocyte growth factor-activated receptor activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0017154~semaphorin receptor activity,GO:0019903~protein phosphatase binding,GO:0042802~identical protein binding,GO:0043565~sequence-specific DNA binding,	IPR000504:RRM_dom,IPR000719:Prot_kinase_dom,IPR001245:Ser-Thr/Tyr_kinase_cat_dom,IPR001627:Semap_dom,IPR002165:Plexin_repeat,IPR002909:IPT_dom,IPR003034:SAP_dom,IPR008266:Tyr_kinase_AS,IPR011009:Kinase-like_dom_sf,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR013783:Ig-like_fold,IPR014756:Ig_E-set,IPR015943:WD40/YVTN_repeat-like_dom_sf,IPR016201:PSI,IPR016244:Tyr_kinase_HGF/MSP_rcpt,IPR017441:Protein_kinase_ATP_BS,IPR020635:Tyr_kinase_cat_dom,IPR031148:Plexin,IPR035979:RBD_domain_sf,IPR036352:Semap_dom_sf,IPR036361:SAP_dom_sf,			PIRSF000617:TyrPK_HGF-R,	SM00219:TyrKc,SM00360:RRM,SM00423:PSI,SM00429:IPT,SM00513:SAP,SM00630:Sema,	KW-0053~Apoptosis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0472~Membrane,KW-0539~Nucleus,KW-0964~Secreted,	KW-0209~Deafness,KW-0225~Disease variant,KW-0656~Proto-oncogene,KW-1010~Non-syndromic deafness,	KW-0175~Coiled coil,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0675~Receptor,KW-0678~Repressor,KW-0694~RNA-binding,KW-0808~Transferase,KW-0829~Tyrosine-protein kinase,	KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,KW-1017~Isopeptide bond,	ACT_SITE:Proton acceptor,CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (Man) threonine,COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:IPT/TIG 1,DOMAIN:IPT/TIG 2,DOMAIN:IPT/TIG 3,DOMAIN:Protein kinase,DOMAIN:RRM,DOMAIN:SAP,DOMAIN:Sema,DOMAIN:Serine-threonine/tyrosine-protein kinase catalytic,MUTAGEN:Y->F: Complete loss of kinase activity and of ligand-induced ubiquitination. Alters interaction with PTPN1 and PTPN2. Loss of interaction with PTPN1 and PTPN2; when associated with F-1235.,MUTAGEN:Y->F: Complete loss of kinase activity. Alters interaction with PTPN1 and PTPN2. Loss of interaction with PTPN1 and PTPN2; when associated with F-1234.,MUTAGEN:Y->F: No effect on ligand-induced CBL-mediated ubiquitination; when associated with F-1313, F-1349 and F-1356.,MUTAGEN:Y->F: No effect on ligand-induced CBL-mediated ubiquitination; when associated with F-1313, F-1349 and F-1365.,MUTAGEN:Y->F: No effect on ligand-induced CBL-mediated ubiquitination; when associated with F-1313, F-1356 and F-1365.,MUTAGEN:Y->F: No effect on ligand-induced CBL-mediated ubiquitination; when associated with F-1349, F-1356 and F-1365.,REGION:Disordered,REGION:Interaction with MUC20,REGION:Interaction with RANBP9,SITE:Breakpoint for translocation to form TPR-MET oncogene,SITE:Cleavage,SITE:Required for ligand-induced CBL-mediated ubiquitination,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SASH3	SAM and SH3 domain containing 3(SASH3)	Homo sapiens			GO:0001782~B cell homeostasis,GO:0002639~positive regulation of immunoglobulin production,GO:0002726~positive regulation of T cell cytokine production,GO:0002821~positive regulation of adaptive immune response,GO:0030890~positive regulation of B cell proliferation,GO:0032729~positive regulation of interferon-gamma production,GO:0032733~positive regulation of interleukin-10 production,GO:0032743~positive regulation of interleukin-2 production,GO:0032753~positive regulation of interleukin-4 production,GO:0032760~positive regulation of tumor necrosis factor production,GO:0042098~T cell proliferation,GO:0042100~B cell proliferation,GO:0042102~positive regulation of T cell proliferation,GO:0043367~CD4-positive, alpha-beta T cell differentiation,GO:0043372~positive regulation of CD4-positive, alpha-beta T cell differentiation,GO:0046622~positive regulation of organ growth,GO:0048873~homeostasis of number of cells within a tissue,	GO:0005634~nucleus,GO:0005737~cytoplasm,		IPR001452:SH3_domain,IPR001660:SAM,IPR013761:SAM/pointed_sf,IPR021090:SPIDER,IPR035721:SASH3_SH3,IPR036028:SH3-like_dom_sf,		301082~Immunodeficiency 102,		SM00326:SH3,SM00454:SAM,			KW-0225~Disease variant,	KW-0728~SH3 domain,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:SAM,DOMAIN:SH3,REGION:Disordered,
SAMSN1	SAM domain, SH3 domain and nuclear localization signals 1(SAMSN1)	Homo sapiens			GO:0002820~negative regulation of adaptive immune response,GO:0050732~negative regulation of peptidyl-tyrosine phosphorylation,GO:0050869~negative regulation of B cell activation,	GO:0001726~ruffle,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0001784~phosphotyrosine binding,GO:0003723~RNA binding,	IPR001452:SH3_domain,IPR001660:SAM,IPR013761:SAM/pointed_sf,IPR021090:SPIDER,IPR036028:SH3-like_dom_sf,IPR037623:SAMSN1_SAM,				SM00326:SH3,SM00454:SAM,		KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0966~Cell projection,		KW-0728~SH3 domain,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:SAM,DOMAIN:SH3,DOMAIN:SLy proteins associated disordered region,MOTIF:Important for interaction with 14-3-3 proteins,REGION:Disordered,
SAP30BP	SAP30 binding protein(SAP30BP)	Homo sapiens			GO:0006355~regulation of transcription, DNA-templated,GO:0009615~response to virus,GO:0052472~modulation by host of symbiont transcription,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0045111~intermediate filament cytoskeleton,	GO:0005515~protein binding,	IPR012479:SAP30BP,					KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0678~Repressor,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),REGION:Disordered,
SATB1	SATB homeobox 1(SATB1)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006325~chromatin organization,GO:0006338~chromatin remodeling,GO:0006357~regulation of transcription from RNA polymerase II promoter,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0016363~nuclear matrix,GO:0016604~nuclear body,GO:0016605~PML body,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003690~double-stranded DNA binding,GO:0005515~protein binding,GO:0043565~sequence-specific DNA binding,	IPR001356:Homeobox_dom,IPR003350:CUT_dom,IPR009057:Homeobox-like_sf,IPR010982:Lambda_DNA-bd_dom_sf,IPR032355:CUTL,IPR032392:ULD,IPR038216:SATB_CUTL_sf,IPR038224:SATB_ULD_sf,IPR039673:SATB1/SATB2,		619228~Developmental delay with dysmorphic facies and dental anomalies,619229~den Hoed-de Boer-Voisin syndrome,		SM00389:HOX,SM01109:CUT,	KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-0991~Intellectual disability,	KW-0371~Homeobox,KW-0677~Repeat,		KW-0156~Chromatin regulator,KW-0238~DNA-binding,KW-0678~Repressor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DNA_BIND:CUT 1,DNA_BIND:CUT 2,DNA_BIND:Homeobox,DOMAIN:CUTL,DOMAIN:ULD,MOTIF:Nuclear localization signal,MOTIF:Protein interaction,MUTAGEN:D->A: CASP6-resistant.,MUTAGEN:E->A: Normal nuclear localization.,MUTAGEN:FQN->AAA: Reduced interaction with matrix attachment region (MAR) DNA.,MUTAGEN:G->A: Impaired MAR-DNA-binding.,MUTAGEN:K->A,Q,R: No acetylation.,MUTAGEN:K->A: Loss of nuclear localization, cytoplasmic.,MUTAGEN:K->N: Impaired MAR-DNA-binding.,MUTAGEN:K->N: Reduced MAR-DNA-binding.,MUTAGEN:K->R: Loss of sumoylation.,MUTAGEN:K->R: Normal sumoylation.,MUTAGEN:N->A: Normal nuclear localization.,MUTAGEN:Q->A: Impaired MAR-DNA-binding.,MUTAGEN:R->A: Loss of nuclear localization, cytoplasmic.,MUTAGEN:R->A: Reduced interaction with matrix attachment region (MAR) DNA; when associated with A-646.,MUTAGEN:R->A: Reduced interaction with matrix attachment region (MAR) DNA; when associated with A-648.,MUTAGEN:R->N: Impaired MAR-DNA-binding.,MUTAGEN:R->N: Reduced MAR-DNA-binding.,MUTAGEN:S->A: Impaired MAR-DNA-binding.,MUTAGEN:S->A: No phosphorylation.,MUTAGEN:S->A: Slightly reduced MAR-DNA-binding.,REGION:Disordered,REGION:Nuclear matrix targeting sequence (NMTS),SITE:Cleavage; by caspases,
SDAD1	SDA1 domain containing 1(SDAD1)	Homo sapiens			GO:0000055~ribosomal large subunit export from nucleus,GO:0015031~protein transport,GO:0042273~ribosomal large subunit biogenesis,	GO:0005654~nucleoplasm,GO:0005730~nucleolus,		IPR007949:SDA1_MD,IPR012977:SDA1_N,IPR016024:ARM-type_fold,IPR027312:Sda1,IPR048292:SDA1_C,					KW-0653~Protein transport,KW-0690~Ribosome biogenesis,KW-0813~Transport,	KW-0539~Nucleus,		KW-0175~Coiled coil,			KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,DOMAIN:SDA1 C-terminal,DOMAIN:SDA1 N-terminal,DOMAIN:SDA1 middle,REGION:Disordered,
SEC11A	SEC11 homolog A, signal peptidase complex subunit(SEC11A)	Homo sapiens			GO:0006465~signal peptide processing,	GO:0005787~signal peptidase complex,GO:0005789~endoplasmic reticulum membrane,GO:0016020~membrane,	GO:0004252~serine-type endopeptidase activity,GO:0005515~protein binding,GO:0008233~peptidase activity,	IPR001733:Peptidase_S26B,IPR015927:Peptidase_S24_S26A/B/C,IPR019533:Peptidase_S26,IPR019756:Pept_S26A_signal_pept_1_Ser-AS,IPR019758:Pept_S26A_signal_pept_1_CS,IPR036286:LexA/Signal_pep-like_sf,	hsa03060:Protein export,					KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0378~Hydrolase,KW-0645~Protease,		ACT_SITE:Charge relay system,DOMAIN:Peptidase S24/S26A/S26B/S26C,MUTAGEN:D->N: Loss of catalytic activity. Slight reduction in protein stability.,MUTAGEN:D->N: Moderate reduction in catalytic activity. Reduces protein stability.,MUTAGEN:D->N: No effect on catalytic activity or protein stability.,MUTAGEN:D->R: Slight reduction in catalytic activity; when associated with D-97.,MUTAGEN:R->D: Slight reduction in catalytic activity; when associated with R-116.,MUTAGEN:S->A: Loss of catalytic activity.,REGION:C-terminal short (CTS) helix,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
SEC11C	SEC11 homolog C, signal peptidase complex subunit(SEC11C)	Homo sapiens			GO:0006465~signal peptide processing,	GO:0005787~signal peptidase complex,GO:0005789~endoplasmic reticulum membrane,GO:0016020~membrane,	GO:0004252~serine-type endopeptidase activity,GO:0005515~protein binding,GO:0008233~peptidase activity,	IPR001733:Peptidase_S26B,IPR015927:Peptidase_S24_S26A/B/C,IPR019533:Peptidase_S26,IPR019756:Pept_S26A_signal_pept_1_Ser-AS,IPR019758:Pept_S26A_signal_pept_1_CS,IPR036286:LexA/Signal_pep-like_sf,	hsa03060:Protein export,					KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0378~Hydrolase,KW-0645~Protease,		ACT_SITE:Charge relay system,DOMAIN:Peptidase S24/S26A/S26B/S26C,MUTAGEN:D->N: Loss of catalytic activity. Slight reduction in protein stability.,MUTAGEN:D->N: Moderate reduction in catalytic activity. Reduces protein stability.,MUTAGEN:D->N: No effect on catalytic activity or protein stability.,MUTAGEN:D->R: Slight reduction in catalytic activity; when associated with D-109.,MUTAGEN:R->D: Slight reduction in catalytic activity; when associated with R-128.,MUTAGEN:S->A: Loss of catalytic activity.,REGION:C-terminal short (CTS) helix,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
SEC13	SEC13 homolog, nuclear pore and COPII coat complex component(SEC13)	Homo sapiens			GO:0006606~protein import into nucleus,GO:0006886~intracellular protein transport,GO:0006913~nucleocytoplasmic transport,GO:0015031~protein transport,GO:0031669~cellular response to nutrient levels,GO:0032008~positive regulation of TOR signaling,GO:0032527~protein exit from endoplasmic reticulum,GO:0051028~mRNA transport,GO:0090110~cargo loading into COPII-coated vesicle,GO:0090114~COPII-coated vesicle budding,GO:1904262~negative regulation of TORC1 signaling,GO:1904263~positive regulation of TORC1 signaling,	GO:0000776~kinetochore,GO:0005635~nuclear envelope,GO:0005643~nuclear pore,GO:0005654~nucleoplasm,GO:0005765~lysosomal membrane,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0012507~ER to Golgi transport vesicle membrane,GO:0030127~COPII vesicle coat,GO:0031080~nuclear pore outer ring,GO:0043231~intracellular membrane-bounded organelle,GO:0061700~GATOR2 complex,GO:0070062~extracellular exosome,	GO:0005198~structural molecule activity,GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR001680:WD40_rpt,IPR015943:WD40/YVTN_repeat-like_dom_sf,IPR036322:WD40_repeat_dom_sf,IPR037363:Sec13/Seh1_fam,	hsa03013:Nucleocytoplasmic transport,hsa04141:Protein processing in endoplasmic reticulum,hsa04150:mTOR signaling pathway,hsa05014:Amyotrophic lateral sclerosis,			SM00320:WD40,	KW-0509~mRNA transport,KW-0653~Protein transport,KW-0811~Translocation,KW-0813~Transport,KW-0931~ER-Golgi transport,	KW-0256~Endoplasmic reticulum,KW-0458~Lysosome,KW-0472~Membrane,KW-0539~Nucleus,KW-0906~Nuclear pore complex,KW-0968~Cytoplasmic vesicle,		KW-0677~Repeat,KW-0853~WD repeat,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	REPEAT:WD,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,
SEC14L1	SEC14 like lipid binding 1(SEC14L1)	Homo sapiens			GO:0015871~choline transport,GO:0039536~negative regulation of RIG-I signaling pathway,GO:0045087~innate immune response,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005758~mitochondrial intermembrane space,GO:0005794~Golgi apparatus,GO:0005829~cytosol,	GO:0005515~protein binding,GO:0039552~RIG-I binding,	IPR001251:CRAL-TRIO_dom,IPR006797:PRELI/MSF1_dom,IPR009038:GOLD_dom,IPR011074:CRAL/TRIO_N_dom,IPR036273:CRAL/TRIO_N_dom_sf,IPR036598:GOLD_dom_sf,IPR036865:CRAL-TRIO_dom_sf,IPR037365:Slowmo/Ups,				SM00516:SEC14,SM01100:CRAL_TRIO_N,	KW-0391~Immunity,KW-0399~Innate immunity,	KW-0333~Golgi apparatus,KW-0963~Cytoplasm,				KW-0734~Signal transduction inhibitor,	KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:CRAL-TRIO,DOMAIN:GOLD,DOMAIN:PRELI/MSF1,REGION:Disordered,REGION:Required for interaction and inhibitory function toward RIGI,
SEC22B	SEC22 homolog B, vesicle trafficking protein(SEC22B)	Homo sapiens			GO:0006888~ER to Golgi vesicle-mediated transport,GO:0006890~retrograde vesicle-mediated transport, Golgi to ER,GO:0015031~protein transport,GO:0045732~positive regulation of protein catabolic process,GO:0048280~vesicle fusion with Golgi apparatus,GO:1902902~negative regulation of autophagosome assembly,	GO:0000139~Golgi membrane,GO:0005737~cytoplasm,GO:0005789~endoplasmic reticulum membrane,GO:0005793~endoplasmic reticulum-Golgi intermediate compartment,GO:0005794~Golgi apparatus,GO:0012507~ER to Golgi transport vesicle membrane,GO:0016020~membrane,GO:0030133~transport vesicle,GO:0030670~phagocytic vesicle membrane,GO:0031201~SNARE complex,GO:0033116~endoplasmic reticulum-Golgi intermediate compartment membrane,GO:0042470~melanosome,	GO:0005484~SNAP receptor activity,GO:0005515~protein binding,	IPR001388:Synaptobrevin-like,IPR010908:Longin_dom,IPR011012:Longin-like_dom_sf,IPR042855:V_SNARE_CC,IPR044565:Sec22,	hsa04130:SNARE interactions in vesicular transport,hsa04145:Phagosome,hsa05134:Legionellosis,			SM01270:Longin,	KW-0653~Protein transport,KW-0813~Transport,KW-0931~ER-Golgi transport,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,		KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:Longin,DOMAIN:V-SNARE coiled-coil homology,DOMAIN:v-SNARE coiled-coil homology,TOPO_DOM:Cytoplasmic,TRANSMEM:Helical,TRANSMEM:Helical; Anchor for type IV membrane protein,
SEC31A	SEC31 homolog A, COPII coat complex component(SEC31A)	Homo sapiens			GO:0006886~intracellular protein transport,GO:0006888~ER to Golgi vesicle-mediated transport,GO:0007029~endoplasmic reticulum organization,GO:0051592~response to calcium ion,GO:0090110~cargo loading into COPII-coated vesicle,	GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0012507~ER to Golgi transport vesicle membrane,GO:0030120~vesicle coat,GO:0030127~COPII vesicle coat,GO:0030134~ER to Golgi transport vesicle,GO:0043231~intracellular membrane-bounded organelle,GO:0048471~perinuclear region of cytoplasm,GO:0070971~endoplasmic reticulum exit site,	GO:0005198~structural molecule activity,GO:0005515~protein binding,GO:0048306~calcium-dependent protein binding,	IPR001680:WD40_rpt,IPR015943:WD40/YVTN_repeat-like_dom_sf,IPR024298:ACE1_Sec16_Sec31,IPR036322:WD40_repeat_dom_sf,IPR040251:SEC31-like,	hsa04141:Protein processing in endoplasmic reticulum,	618651~Halperin-Birk syndrome,		SM00320:WD40,	KW-0653~Protein transport,KW-0813~Transport,KW-0931~ER-Golgi transport,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,	KW-0656~Proto-oncogene,	KW-0677~Repeat,KW-0732~Signal,KW-0853~WD repeat,			KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:Ancestral coatomer element 1 Sec16/Sec31,MOTIF:ALG-2-binding site motif-2 (ABS-2),,MUTAGEN:K->R: Does not abolish monoubiquitination by the BCR(KLHL12) E3 ubiquitin ligase complex, revealing flexibility of ubiquitination sites; when associated with R-1217.,MUTAGEN:K->R: Does not abolish monoubiquitination by the BCR(KLHL12) E3 ubiquitin ligase complex, revealing flexibility of ubiquitination sites; when associated with R-647.,REGION:Disordered,REGION:Interaction with PDCD6,REGION:Interaction with SEC13,REPEAT:WD,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,REPEAT:WD 7,REPEAT:WD 8; interaction with SEC13,
SEC61A1	SEC61 translocon subunit alpha 1(SEC61A1)	Homo sapiens		h_eradPathway:ERï¿½associated degradation (ERAD) Pathway,	GO:0006613~cotranslational protein targeting to membrane,GO:0006614~SRP-dependent cotranslational protein targeting to membrane,GO:0006616~SRP-dependent cotranslational protein targeting to membrane, translocation,GO:0006620~posttranslational protein targeting to membrane,GO:0007029~endoplasmic reticulum organization,GO:0015031~protein transport,GO:0031204~posttranslational protein targeting to membrane, translocation,GO:0039019~pronephric nephron development,GO:0045047~protein targeting to ER,GO:0045048~protein insertion into ER membrane,GO:0070588~calcium ion transmembrane transport,	GO:0005783~endoplasmic reticulum,GO:0005784~Sec61 translocon complex,GO:0005789~endoplasmic reticulum membrane,GO:0016020~membrane,	GO:0005048~signal sequence binding,GO:0005262~calcium channel activity,GO:0005515~protein binding,GO:0008320~protein transmembrane transporter activity,GO:0043022~ribosome binding,	IPR002208:SecY/SEC61-alpha,IPR019561:Translocon_Sec61/SecY_plug_dom,IPR023201:SecY_dom_sf,IPR030659:SecY_CS,	hsa03060:Protein export,hsa04141:Protein processing in endoplasmic reticulum,hsa04145:Phagosome,hsa05110:Vibrio cholerae infection,	617056~Tubulointerstitial kidney disease, autosomal dominant, 5,620670~Immunodeficiency, common variable, 15,620674~Neutropenia, severe congenital, 11, autosomal dominant,	PIRSF004557:SecY,		KW-0653~Protein transport,KW-0811~Translocation,KW-0813~Transport,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,	KW-0225~Disease variant,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0143~Chaperone,		DOMAIN:Translocon Sec61/SecY plug,MUTAGEN:Y->H: Reduces cotranslational translocation of APLN precursor/preproapelin.,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
SEC61B	SEC61 translocon subunit beta(SEC61B)	Homo sapiens			GO:0006616~SRP-dependent cotranslational protein targeting to membrane, translocation,GO:0006886~intracellular protein transport,GO:0030433~ubiquitin-dependent ERAD pathway,GO:0030970~retrograde protein transport, ER to cytosol,GO:0031204~posttranslational protein targeting to membrane, translocation,GO:0036503~ERAD pathway,	GO:0005783~endoplasmic reticulum,GO:0005784~Sec61 translocon complex,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0016020~membrane,GO:0031205~endoplasmic reticulum Sec complex,GO:0044322~endoplasmic reticulum quality control compartment,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0043022~ribosome binding,GO:0048408~epidermal growth factor binding,	IPR016482:SecG/Sec61-beta/Sbh,IPR030671:Sec61-beta/Sbh,	hsa03060:Protein export,hsa04141:Protein processing in endoplasmic reticulum,hsa04145:Phagosome,hsa05110:Vibrio cholerae infection,		PIRSF006398:Sec61_beta_euk,		KW-0653~Protein transport,KW-0811~Translocation,KW-0813~Transport,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,LIPID:S-palmitoyl cysteine,MUTAGEN:C->S: Abolishes S-acylation.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
SEC61G	SEC61 translocon subunit gamma(SEC61G)	Homo sapiens			GO:0031204~posttranslational protein targeting to membrane, translocation,GO:0045047~protein targeting to ER,	GO:0005829~cytosol,GO:0016020~membrane,GO:0071261~Ssh1 translocon complex,	GO:0005515~protein binding,GO:0008320~protein transmembrane transporter activity,GO:0043022~ribosome binding,	IPR001901:Translocase_SecE/Sec61-g,IPR008158:Translocase_Sec61-g,IPR023391:Prot_translocase_SecE_dom_sf,	hsa03060:Protein export,hsa04141:Protein processing in endoplasmic reticulum,hsa04145:Phagosome,hsa05110:Vibrio cholerae infection,				KW-0653~Protein transport,KW-0811~Translocation,KW-0813~Transport,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SEC62	SEC62 homolog, preprotein translocation factor(SEC62)	Homo sapiens			GO:0006613~cotranslational protein targeting to membrane,GO:0006620~posttranslational protein targeting to membrane,GO:0015031~protein transport,GO:0031204~posttranslational protein targeting to membrane, translocation,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005791~rough endoplasmic reticulum,GO:0016020~membrane,	GO:0038023~signaling receptor activity,	IPR004728:Sec62,IPR036388:WH-like_DNA-bd_sf,	hsa03060:Protein export,hsa04141:Protein processing in endoplasmic reticulum,				KW-0653~Protein transport,KW-0811~Translocation,KW-0813~Transport,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
SECISBP2L	SECIS binding protein 2 like(SECISBP2L)	Homo sapiens			GO:0001514~selenocysteine incorporation,	GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003730~mRNA 3'-UTR binding,GO:0005515~protein binding,GO:0035368~selenocysteine insertion sequence binding,GO:0043021~ribonucleoprotein complex binding,	IPR004038:Ribosomal_eL8/eL30/eS12/Gad45,IPR029064:Ribosomal_eL30-like_sf,IPR040051:SECISBP2,								KW-0175~Coiled coil,			KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Ribosomal protein eL8/eL30/eS12/Gadd45,MUTAGEN:G->R: Loss of binding to SELV and TXNRD1 SECIS elements.,REGION:Disordered,
SEL1L	SEL1L adaptor subunit of SYVN1 ubiquitin ligase(SEL1L)	Homo sapiens			GO:0006641~triglyceride metabolic process,GO:0007219~Notch signaling pathway,GO:0009306~protein secretion,GO:0030433~ubiquitin-dependent ERAD pathway,GO:0030970~retrograde protein transport, ER to cytosol,GO:0036503~ERAD pathway,GO:0050821~protein stabilization,	GO:0000836~Hrd1p ubiquitin ligase complex,GO:0000839~Hrd1p ubiquitin ligase ERAD-L complex,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0016020~membrane,GO:0036513~Derlin-1 retrotranslocation complex,	GO:0005515~protein binding,	IPR000562:FN_type2_dom,IPR006597:Sel1-like,IPR011990:TPR-like_helical_dom_sf,IPR013806:Kringle-like,IPR036943:FN_type2_sf,	hsa04141:Protein processing in endoplasmic reticulum,			SM00059:FN2,SM00671:SEL1,	KW-0914~Notch signaling pathway,KW-0945~Host-virus interaction,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,DOMAIN:Fibronectin type-II,REGION:Disordered,REGION:Important for homodimerization and oligomerization,REGION:Interaction with ERLEC1, OS9 and SYVN1,REGION:Interaction with SYVN1,REGION:Mediates retention in the endoplasmic reticulum,REPEAT:Sel1-like 1,REPEAT:Sel1-like 10,REPEAT:Sel1-like 11,REPEAT:Sel1-like 2,REPEAT:Sel1-like 3,REPEAT:Sel1-like 4,REPEAT:Sel1-like 5,REPEAT:Sel1-like 6,REPEAT:Sel1-like 7,REPEAT:Sel1-like 8,REPEAT:Sel1-like 9,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
SERTAD1	SERTA domain containing 1(SERTAD1)	Homo sapiens			GO:0000079~regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0008284~positive regulation of cell proliferation,GO:0030308~negative regulation of cell growth,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0016528~sarcoplasm,	GO:0005515~protein binding,	IPR009263:SERTA_dom,					KW-0804~Transcription,KW-0805~Transcription regulation,						KW-0832~Ubl conjugation,	DOMAIN:SERTA,REGION:Disordered,
SETD2	SET domain containing 2, histone lysine methyltransferase(SETD2)	Homo sapiens			GO:0001525~angiogenesis,GO:0001763~morphogenesis of a branching structure,GO:0001843~neural tube closure,GO:0006298~mismatch repair,GO:0006355~regulation of transcription, DNA-templated,GO:0006368~transcription elongation from RNA polymerase II promoter,GO:0010038~response to metal ion,GO:0010468~regulation of gene expression,GO:0010508~positive regulation of autophagy,GO:0010569~regulation of double-strand break repair via homologous recombination,GO:0010793~regulation of mRNA export from nucleus,GO:0014070~response to organic cyclic compound,GO:0018023~peptidyl-lysine trimethylation,GO:0030900~forebrain development,GO:0032259~methylation,GO:0032465~regulation of cytokinesis,GO:0032727~positive regulation of interferon-alpha production,GO:0034340~response to type I interferon,GO:0034728~nucleosome organization,GO:0035441~cell migration involved in vasculogenesis,GO:0035987~endodermal cell differentiation,GO:0043279~response to alkaloid,GO:0045778~positive regulation of ossification,GO:0048332~mesoderm morphogenesis,GO:0048701~embryonic cranial skeleton morphogenesis,GO:0048863~stem cell differentiation,GO:0048864~stem cell development,GO:0051607~defense response to virus,GO:0060039~pericardium development,GO:0060669~embryonic placenta morphogenesis,GO:0060977~coronary vasculature morphogenesis,GO:1902850~microtubule cytoskeleton organization involved in mitosis,GO:1905634~regulation of protein localization to chromatin,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005694~chromosome,GO:0005737~cytoplasm,	GO:0005515~protein binding,GO:0016279~protein-lysine N-methyltransferase activity,GO:0043014~alpha-tubulin binding,GO:0046872~metal ion binding,GO:0046975~histone methyltransferase activity (H3-K36 specific),	IPR001202:WW_dom,IPR001214:SET_dom,IPR003616:Post-SET_dom,IPR006560:AWS_dom,IPR009078:Ferritin-like_SF,IPR013257:SRI,IPR035441:TFIIS/LEDGF_dom_sf,IPR036020:WW_dom_sf,IPR038190:SRI_sf,IPR042294:SETD2_animal,IPR044437:SETD2/Set2_SET,IPR046341:SET_dom_sf,	hsa00310:Lysine degradation,hsa01100:Metabolic pathways,	616831~Luscan-Lumish syndrome,620155~Rabin-Pappas syndrome,620157~Intellectual developmental disorder, autosomal dominant 70,		SM00317:SET,SM00456:WW,SM00508:PostSET,SM00570:AWS,	KW-0051~Antiviral defense,KW-0221~Differentiation,KW-0227~DNA damage,KW-0234~DNA repair,KW-0391~Immunity,KW-0399~Innate immunity,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0158~Chromosome,KW-0539~Nucleus,	KW-0043~Tumor suppressor,KW-0225~Disease variant,KW-0991~Intellectual disability,KW-1268~Autism spectrum disorder,	KW-0175~Coiled coil,	KW-0479~Metal-binding,KW-0862~Zinc,KW-0949~S-adenosyl-L-methionine,	KW-0010~Activator,KW-0156~Chromatin regulator,KW-0217~Developmental protein,KW-0489~Methyltransferase,KW-0808~Transferase,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:AWS,DOMAIN:Post-SET,DOMAIN:SET,DOMAIN:WW,MUTAGEN:C->A: Does not affect methyltransferase activity.,MUTAGEN:E->A: Increased methyltransferase activity.,MUTAGEN:E->A: Increases interaction with hyperphosphorylated POLR2A; when associated with A-2528.,MUTAGEN:E->A: Increases interaction with hyperphosphorylated POLR2A; when associated with A-2531.,MUTAGEN:F->A: Does not affect interaction with hyperphosphorylated POLR2A.,MUTAGEN:F->A: Strongly reduced methyltransferase activity.,MUTAGEN:G->A,T: Does not affect interaction with hyperphosphorylated POLR2A.,MUTAGEN:H->A: Impairs interaction with hyperphosphorylated POLR2A.,MUTAGEN:K->A: Does not affect interaction with hyperphosphorylated POLR2A.,MUTAGEN:K->A: Impairs interaction with hyperphosphorylated POLR2A.,MUTAGEN:Q->A: Does not affect interaction with hyperphosphorylated POLR2A.,MUTAGEN:Q->A: Loss of methyltransferase activity.,MUTAGEN:R->A,V,L,I,F: Impaired methyltransferase activity.,MUTAGEN:R->A: Does not affect interaction with hyperphosphorylated POLR2A.,MUTAGEN:R->A: Impairs interaction with hyperphosphorylated POLR2A.,MUTAGEN:R->H,G: Loss of methyltransferase activity. Abolishes ability to monomethylate STAT1.,MUTAGEN:R->P,W,K,Q: Loss of methyltransferase activity.,MUTAGEN:T->A: Increased methyltransferase activity.,MUTAGEN:V->A: Impairs interaction with hyperphosphorylated POLR2A.,MUTAGEN:Y->A: Increased methyltransferase activity.,MUTAGEN:Y->A: Strongly reduced methyltransferase activity.,REGION:Disordered,REGION:Interaction with POLR2A,REGION:Interaction with TUBA1A,REGION:Low charge region,
SETD5	SET domain containing 5(SETD5)	Homo sapiens			GO:0006338~chromatin remodeling,GO:0006355~regulation of transcription, DNA-templated,GO:0016480~negative regulation of transcription from RNA polymerase III promoter,GO:0032259~methylation,GO:0032784~regulation of DNA-templated transcription, elongation,GO:0050890~cognition,GO:0051963~regulation of synapse assembly,GO:1902275~regulation of chromatin organization,	GO:0000785~chromatin,GO:0000791~euchromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0034967~Set3 complex,GO:0070210~Rpd3L-Expanded complex,	GO:0003714~transcription corepressor activity,GO:0035064~methylated histone binding,GO:0046974~histone methyltransferase activity (H3-K9 specific),GO:0046975~histone methyltransferase activity (H3-K36 specific),	IPR001214:SET_dom,IPR044433:SETD5_SET,IPR046341:SET_dom_sf,		615761~Intellectual developmental disorder, autosomal dominant 23,		SM00317:SET,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0158~Chromosome,KW-0539~Nucleus,	KW-0225~Disease variant,KW-0991~Intellectual disability,KW-1268~Autism spectrum disorder,KW-1269~Autism,			KW-0156~Chromatin regulator,KW-0489~Methyltransferase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,DOMAIN:SET,REGION:Disordered,
SET	SET nuclear proto-oncogene(SET)	Homo sapiens		h_setPathway:Granzyme A mediated Apoptosis Pathway,	GO:0006260~DNA replication,GO:0006334~nucleosome assembly,GO:0006337~nucleosome disassembly,GO:0035067~negative regulation of histone acetylation,GO:0043524~negative regulation of neuron apoptotic process,GO:0045892~negative regulation of transcription, DNA-templated,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005811~lipid particle,GO:0005829~cytosol,GO:0032991~macromolecular complex,GO:0048471~perinuclear region of cytoplasm,	GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0004864~protein phosphatase inhibitor activity,GO:0005515~protein binding,GO:0019888~protein phosphatase regulator activity,GO:0042393~histone binding,	IPR002164:NAP_family,IPR037231:NAP-like_sf,		618106~Intellectual developmental disorder, autosomal dominant 58,			KW-0945~Host-virus interaction,	KW-0256~Endoplasmic reticulum,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0656~Proto-oncogene,KW-0991~Intellectual disability,	KW-0175~Coiled coil,		KW-0143~Chaperone,KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),REGION:Dimerization,REGION:Disordered,REGION:Earmuff domain,SITE:Breakpoint for translocation to form SET-CAN oncogene,
SFT2D1	SFT2 domain containing 1(SFT2D1)	Homo sapiens			GO:0015031~protein transport,GO:0016192~vesicle-mediated transport,	GO:0005737~cytoplasm,GO:0012505~endomembrane system,GO:0016020~membrane,GO:0043231~intracellular membrane-bounded organelle,	GO:0005515~protein binding,	IPR007305:Vesicle_transpt_Got1/SFT2,IPR011691:Vesicle_transpt_SFT2,					KW-0653~Protein transport,KW-0813~Transport,	KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,	TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,
SUGT1	SGT1 homolog, MIS12 kinetochore complex assembly cochaperone(SUGT1)	Homo sapiens			GO:0007051~spindle organization,GO:0014841~skeletal muscle satellite cell proliferation,GO:0031647~regulation of protein stability,GO:0051382~kinetochore assembly,	GO:0000151~ubiquitin ligase complex,GO:0000776~kinetochore,GO:0005634~nucleus,GO:0005829~cytosol,GO:0032991~macromolecular complex,	GO:0005515~protein binding,GO:0051087~chaperone binding,	IPR007052:CS_dom,IPR007699:SGS_dom,IPR008978:HSP20-like_chaperone,IPR011990:TPR-like_helical_dom_sf,IPR019734:TPR_repeat,IPR044563:Sgt1-like,	hsa04621:NOD-like receptor signaling pathway,			SM00028:TPR,	KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0802~TPR repeat,			KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:CS,DOMAIN:SGS,REPEAT:TPR,REPEAT:TPR 1,REPEAT:TPR 2,REPEAT:TPR 3,
SH2D1A	SH2 domain containing 1A(SH2D1A)	Homo sapiens	61.Myc_network,84.Ubiquitination_Pathways_Cell_Cycle,		GO:0002250~adaptive immune response,GO:0006959~humoral immune response,GO:0006968~cellular defense response,GO:0007267~cell-cell signaling,GO:0042267~natural killer cell mediated cytotoxicity,GO:0045954~positive regulation of natural killer cell mediated cytotoxicity,GO:0050776~regulation of immune response,GO:0050860~negative regulation of T cell receptor signaling pathway,	GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0005515~protein binding,	IPR000980:SH2,IPR017289:SH2_prot_1A,IPR035876:SH2D1A_SH2,IPR036860:SH2_dom_sf,	hsa04650:Natural killer cell mediated cytotoxicity,	308240~Lymphoproliferative syndrome, X-linked, 1,	PIRSF037828:SH2_p1A,	SM00252:SH2,	KW-0391~Immunity,KW-0399~Innate immunity,KW-1064~Adaptive immunity,	KW-0963~Cytoplasm,	KW-0225~Disease variant,	KW-0727~SH2 domain,			KW-0007~Acetylation,	DOMAIN:SH2,MUTAGEN:R->E: Disrupts interaction with FYN.,MUTAGEN:R->Q: Strongly reduced affinity for SLAMF1.,REGION:Disordered,REGION:Interaction with FYN SH3 domain,
SH2D2A	SH2 domain containing 2A(SH2D2A)	Homo sapiens			GO:0001525~angiogenesis,GO:0007165~signal transduction,GO:0030154~cell differentiation,GO:0042098~T cell proliferation,	GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0005515~protein binding,GO:0017124~SH3 domain binding,	IPR000980:SH2,IPR035884:SH2D2A_SH2,IPR036860:SH2_dom_sf,	hsa04370:VEGF signaling pathway,			SM00252:SH2,	KW-0037~Angiogenesis,KW-0221~Differentiation,	KW-0963~Cytoplasm,		KW-0727~SH2 domain,KW-0729~SH3-binding,		KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:SH2,MOTIF:SH3-binding,REGION:Disordered,
SH3BGRL	SH3 domain binding glutamate rich protein like(SH3BGRL)	Homo sapiens			GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:1904690~positive regulation of cytoplasmic translational initiation,	GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0070062~extracellular exosome,	GO:0017124~SH3 domain binding,GO:1990756~protein binding, bridging involved in substrate recognition for ubiquitination,	IPR006993:Glut_rich_SH3-bd,IPR036249:Thioredoxin-like_sf,			PIRSF008142:SH3-bind_E-rich_L,			KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0729~SH3-binding,				MOTIF:SH3-binding,REGION:Required for interaction with HER2,REGION:Required for interaction with PFN1, HER2, and ATG12,
SH3GLB1	SH3 domain containing GRB2 like, endophilin B1(SH3GLB1)	Homo sapiens		h_cblPathway:CBL mediated ligand-induced downregulation of EGF receptors,	GO:0006914~autophagy,GO:0006915~apoptotic process,GO:0010508~positive regulation of autophagy,GO:0016241~regulation of macroautophagy,GO:0031334~positive regulation of protein complex assembly,GO:0031647~regulation of protein stability,GO:0032465~regulation of cytokinesis,GO:0032801~receptor catabolic process,GO:0034198~cellular response to amino acid starvation,GO:0042149~cellular response to glucose starvation,GO:0048102~autophagic cell death,GO:0061024~membrane organization,GO:0090148~membrane fission,GO:1903527~positive regulation of membrane tubulation,GO:1903778~protein localization to vacuolar membrane,GO:1903955~positive regulation of protein targeting to mitochondrion,GO:2000786~positive regulation of autophagosome assembly,	GO:0000139~Golgi membrane,GO:0000421~autophagosome membrane,GO:0005737~cytoplasm,GO:0005741~mitochondrial outer membrane,GO:0005829~cytosol,GO:0016020~membrane,GO:0030496~midbody,GO:0031410~cytoplasmic vesicle,GO:0032991~macromolecular complex,	GO:0005515~protein binding,GO:0008289~lipid binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0045296~cadherin binding,	IPR001452:SH3_domain,IPR004148:BAR_dom,IPR027267:AH/BAR_dom_sf,IPR028503:SH3GLB_SH3,IPR035695:SH3GLB1_BAR,IPR036028:SH3-like_dom_sf,	hsa04140:Autophagy - animal,hsa04144:Endocytosis,			SM00326:SH3,SM00721:BAR,	KW-0053~Apoptosis,KW-0072~Autophagy,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0496~Mitochondrion,KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,KW-1000~Mitochondrion outer membrane,		KW-0175~Coiled coil,KW-0728~SH3 domain,	KW-0446~Lipid-binding,		KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:BAR,DOMAIN:SH3,MUTAGEN:T->A: Reduced CDK5-mediated phosphorylation and impaired dimerization.,MUTAGEN:T->E: Spontaneous dimerization.,MUTAGEN:V->M: Abolishes interaction with BAX.,REGION:Membrane-binding amphipathic helix,REGION:Required for membrane binding,
SHARPIN	SHANK associated RH domain interactor(SHARPIN)	Homo sapiens			GO:0007005~mitochondrion organization,GO:0010803~regulation of tumor necrosis factor-mediated signaling pathway,GO:0016567~protein ubiquitination,GO:0030262~apoptotic nuclear changes,GO:0031424~keratinization,GO:0042742~defense response to bacterium,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0050728~negative regulation of inflammatory response,GO:0097039~protein linear polyubiquitination,GO:2000348~regulation of CD40 signaling pathway,	GO:0005829~cytosol,GO:0030425~dendrite,GO:0045202~synapse,GO:0071797~LUBAC complex,	GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0030674~protein binding, bridging,GO:0031593~polyubiquitin binding,GO:0042802~identical protein binding,GO:0043130~ubiquitin binding,GO:0044877~macromolecular complex binding,GO:0046872~metal ion binding,	IPR001876:Znf_RanBP2,IPR011993:PH-like_dom_sf,IPR029071:Ubiquitin-like_domsf,IPR031912:Sharpin_PH,IPR036443:Znf_RanBP2_sf,	hsa04217:Necroptosis,hsa04621:NOD-like receptor signaling pathway,hsa05131:Shigellosis,			SM00547:ZnF_RBZ,	KW-0833~Ubl conjugation pathway,	KW-0770~Synapse,KW-0963~Cytoplasm,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0597~Phosphoprotein,	COMPBIAS:Pro residues,DOMAIN:RanBP2-type,DOMAIN:Ubiquitin-like,MUTAGEN:C->S: Abolishes binding to ubiquitin without affecting interaction with RNF31; when associated with S-354.,MUTAGEN:C->S: Abolishes binding to ubiquitin without affecting interaction with RNF31; when associated with S-357.,MUTAGEN:C->S: Abolishes binding to ubiquitin without affecting interaction with RNF31; when associated with S-368.,MUTAGEN:C->S: Abolishes binding to ubiquitin without affecting interaction with RNF31; when associated with S-371.,MUTAGEN:I->A: Abolishes interaction with RNF31 and ability to mediate linear polyubiquitination.,MUTAGEN:TF->LV: Abolishes binding to ubiquitin and ability to mediate linear polyubiquitination.,MUTAGEN:V->D: Abolishes homodimerization.,REGION:Disordered,REGION:Interaction with SHANK1,REGION:Self-association,ZN_FING:RanBP2-type,
SHOC2	SHOC2 leucine rich repeat scaffold protein(SHOC2)	Homo sapiens			GO:0007165~signal transduction,GO:0007265~Ras protein signal transduction,GO:0008543~fibroblast growth factor receptor signaling pathway,GO:0010976~positive regulation of neuron projection development,GO:0038180~nerve growth factor signaling pathway,GO:0045665~negative regulation of neuron differentiation,GO:0045666~positive regulation of neuron differentiation,GO:0046579~positive regulation of Ras protein signal transduction,GO:0071378~cellular response to growth hormone stimulus,GO:2000178~negative regulation of neural precursor cell proliferation,	GO:0000164~protein phosphatase type 1 complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0005515~protein binding,GO:0008157~protein phosphatase 1 binding,GO:0019888~protein phosphatase regulator activity,GO:0019903~protein phosphatase binding,	IPR001611:Leu-rich_rpt,IPR003591:Leu-rich_rpt_typical-subtyp,IPR032675:LRR_dom_sf,	hsa04014:Ras signaling pathway,	607721~Noonan syndrome-like with loose anagen hair 1,		SM00364:LRR_BAC,SM00365:LRR_SD22,SM00369:LRR_TYP,		KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,	KW-0433~Leucine-rich repeat,KW-0677~Repeat,				COMPBIAS:Basic and acidic residues,REGION:Disordered,REPEAT:LRR 1,REPEAT:LRR 10,REPEAT:LRR 11,REPEAT:LRR 12,REPEAT:LRR 13,REPEAT:LRR 14,REPEAT:LRR 15,REPEAT:LRR 16,REPEAT:LRR 17,REPEAT:LRR 18,REPEAT:LRR 19,REPEAT:LRR 2,REPEAT:LRR 20,REPEAT:LRR 3,REPEAT:LRR 4,REPEAT:LRR 5,REPEAT:LRR 6,REPEAT:LRR 7,REPEAT:LRR 8,REPEAT:LRR 9,
SIVA1	SIVA1 apoptosis inducing factor(SIVA1)	Homo sapiens			GO:0006915~apoptotic process,GO:0006924~activation-induced cell death of T cells,GO:0032088~negative regulation of NF-kappaB transcription factor activity,GO:0046718~viral entry into host cell,GO:0097191~extrinsic apoptotic signaling pathway,GO:0097193~intrinsic apoptotic signaling pathway,GO:1901030~positive regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,	GO:0001618~virus receptor activity,GO:0005164~tumor necrosis factor receptor binding,GO:0005175~CD27 receptor binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0046872~metal ion binding,GO:0051537~2 iron, 2 sulfur cluster binding,	IPR006058:2Fe2S_fd_BS,IPR022773:Siva,	hsa04115:p53 signaling pathway,		PIRSF038096:Siva_cd27_bd,		KW-0053~Apoptosis,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0479~Metal-binding,KW-0862~Zinc,		KW-0597~Phosphoprotein,	MUTAGEN:Y->F: Abolishes phosphorylation and apoptotic activity.,MUTAGEN:Y->F: No effect on phosphorylation or apoptotic activity.,REGION:Interaction with BCL2L1 isoform Bcl-x(L) and inhibition of BCL2L1 anti-apoptotic activity,REGION:Interaction with coxsackievirus B3 VP2,
SKIL	SKI like proto-oncogene(SKIL)	Homo sapiens		h_tgfbPathway:TGF beta signaling pathway,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001825~blastocyst formation,GO:0002260~lymphocyte homeostasis,GO:0007179~transforming growth factor beta receptor signaling pathway,GO:0007283~spermatogenesis,GO:0007519~skeletal muscle tissue development,GO:0008625~extrinsic apoptotic signaling pathway via death domain receptors,GO:0008630~intrinsic apoptotic signaling pathway in response to DNA damage,GO:0030512~negative regulation of transforming growth factor beta receptor signaling pathway,GO:0030514~negative regulation of BMP signaling pathway,GO:0034097~response to cytokine,GO:0045596~negative regulation of cell differentiation,GO:0046677~response to antibiotic,GO:0050772~positive regulation of axonogenesis,GO:0051726~regulation of cell cycle,GO:0070306~lens fiber cell differentiation,GO:0070848~response to growth factor,GO:1902043~positive regulation of extrinsic apoptotic signaling pathway via death domain receptors,GO:1902231~positive regulation of intrinsic apoptotic signaling pathway in response to DNA damage,	GO:0001669~acrosomal vesicle,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005737~cytoplasm,GO:0016605~PML body,GO:0032991~macromolecular complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003682~chromatin binding,GO:0005515~protein binding,GO:0019904~protein domain specific binding,GO:0042802~identical protein binding,GO:0044877~macromolecular complex binding,GO:0046332~SMAD binding,	IPR003380:SKI/SNO/DAC,IPR009061:DNA-bd_dom_put_sf,IPR010919:SAND-like_dom_sf,IPR014890:c-SKI_SMAD4-bd_dom,IPR023216:Tscrpt_reg_SKI_SnoN,IPR037000:Ski_DNA-bd_sf,	hsa04350:TGF-beta signaling pathway,hsa04550:Signaling pathways regulating pluripotency of stem cells,			SM01046:c-SKI_SMAD_bind,				KW-0175~Coiled coil,			KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:c-SKI SMAD4-binding,REGION:Disordered,
SLU7	SLU7 homolog, splicing factor(SLU7)	Homo sapiens			GO:0000375~RNA splicing, via transesterification reactions,GO:0000380~alternative mRNA splicing, via spliceosome,GO:0000389~mRNA 3'-splice site recognition,GO:0000398~mRNA splicing, via spliceosome,GO:0006886~intracellular protein transport,GO:0008380~RNA splicing,GO:0034605~cellular response to heat,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005681~spliceosomal complex,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016020~membrane,GO:0016607~nuclear speck,GO:0030532~small nuclear ribonucleoprotein complex,GO:0043231~intracellular membrane-bounded organelle,GO:0071013~catalytic step 2 spliceosome,	GO:0000386~second spliceosomal transesterification activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0030628~pre-mRNA 3'-splice site binding,	IPR021715:Slu7_dom,IPR039974:Splicing_factor_SLU7,	hsa03040:Spliceosome,				KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,KW-0747~Spliceosome,KW-0963~Cytoplasm,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Pre-mRNA-splicing factor SLU7,MOTIF:Bipartite nuclear localization signal,MUTAGEN:AM->VP: Does not affect nuclear localization.,MUTAGEN:C->S: Induces a cytoplasmic localization; when associated with S-120; G-128 and S-133.,MUTAGEN:C->S: Induces a cytoplasmic localization; when associated with S-120; S-123 and G-128.,MUTAGEN:C->S: Induces a cytoplasmic localization; when associated with S-123; G-128 and S-133.,MUTAGEN:H->G: Induces a cytoplasmic localization; when associated with S-120; S-123 and S-133.,MUTAGEN:K->N: Abolishes nuclear localization.,MUTAGEN:R->N: Abolishes nuclear localization.,REGION:Disordered,ZN_FING:CCHC-type,
SMAD2	SMAD family member 2(SMAD2)	Homo sapiens		h_tgfbPathway:TGF beta signaling pathway,	GO:0001657~ureteric bud development,GO:0001701~in utero embryonic development,GO:0001706~endoderm formation,GO:0001707~mesoderm formation,GO:0003140~determination of left/right asymmetry in lateral mesoderm,GO:0003180~aortic valve morphogenesis,GO:0003184~pulmonary valve morphogenesis,GO:0003203~endocardial cushion morphogenesis,GO:0006351~transcription, DNA-templated,GO:0006355~regulation of transcription, DNA-templated,GO:0007179~transforming growth factor beta receptor signaling pathway,GO:0007352~zygotic specification of dorsal/ventral axis,GO:0007369~gastrulation,GO:0008285~negative regulation of cell proliferation,GO:0009653~anatomical structure morphogenesis,GO:0009749~response to glucose,GO:0009791~post-embryonic development,GO:0009880~embryonic pattern specification,GO:0009952~anterior/posterior pattern specification,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0010718~positive regulation of epithelial to mesenchymal transition,GO:0017015~regulation of transforming growth factor beta receptor signaling pathway,GO:0023019~signal transduction involved in regulation of gene expression,GO:0030073~insulin secretion,GO:0030154~cell differentiation,GO:0030324~lung development,GO:0030325~adrenal gland development,GO:0030513~positive regulation of BMP signaling pathway,GO:0031016~pancreas development,GO:0031053~primary miRNA processing,GO:0032924~activin receptor signaling pathway,GO:0035265~organ growth,GO:0035556~intracellular signal transduction,GO:0038092~nodal signaling pathway,GO:0045165~cell fate commitment,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048340~paraxial mesoderm morphogenesis,GO:0048617~embryonic foregut morphogenesis,GO:0048701~embryonic cranial skeleton morphogenesis,GO:0051098~regulation of binding,GO:0060039~pericardium development,GO:0060395~SMAD protein signal transduction,GO:0070723~response to cholesterol,GO:0071333~cellular response to glucose stimulus,GO:0071895~odontoblast differentiation,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016020~membrane,GO:0032444~activin responsive factor complex,GO:0032991~macromolecular complex,GO:0071141~SMAD protein complex,GO:0071142~SMAD2 protein complex,GO:0071144~SMAD2-SMAD3 protein complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0000987~core promoter proximal region sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003690~double-stranded DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005160~transforming growth factor beta receptor binding,GO:0005515~protein binding,GO:0019902~phosphatase binding,GO:0031625~ubiquitin protein ligase binding,GO:0034713~type I transforming growth factor beta receptor binding,GO:0042802~identical protein binding,GO:0046332~SMAD binding,GO:0046872~metal ion binding,GO:0048156~tau protein binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:0070410~co-SMAD binding,GO:0070411~I-SMAD binding,GO:0070412~R-SMAD binding,GO:0097718~disordered domain specific binding,	IPR001132:SMAD_dom_Dwarfin-type,IPR003619:MAD_homology1_Dwarfin-type,IPR008984:SMAD_FHA_dom_sf,IPR013019:MAD_homology_MH1,IPR013790:Dwarfin,IPR017855:SMAD-like_dom_sf,IPR036578:SMAD_MH1_sf,	hsa04110:Cell cycle,hsa04144:Endocytosis,hsa04218:Cellular senescence,hsa04350:TGF-beta signaling pathway,hsa04371:Apelin signaling pathway,hsa04390:Hippo signaling pathway,hsa04550:Signaling pathways regulating pluripotency of stem cells,hsa04659:Th17 cell differentiation,hsa04926:Relaxin signaling pathway,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa05142:Chagas disease,hsa05166:Human T-cell leukemia virus 1 infection,hsa05200:Pathways in cancer,hsa05205:Proteoglycans in cancer,hsa05210:Colorectal cancer,hsa05212:Pancreatic cancer,hsa05225:Hepatocellular carcinoma,hsa05226:Gastric cancer,hsa05321:Inflammatory bowel disease,hsa05415:Diabetic cardiomyopathy,	619656~Loeys-Dietz syndrome 6,619657~Congenital heart defects, multiple types, 8, with or without heterotaxy,		SM00523:DWA,SM00524:DWB,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-1056~Heterotaxy,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,DOMAIN:MH1,DOMAIN:MH2,MOTIF:PY-motif,MUTAGEN:K->R: Loss of acetylation.,MUTAGEN:K->R: No effect on acetylation.,MUTAGEN:Missing: Loss of binding to SMURF2.,MUTAGEN:N->S: Loss of binding to SARA.,MUTAGEN:S->A: Loss of phosphorylation by TGFBR1; when associated with A-465 and A-467.,MUTAGEN:S->A: No change in binding to PPM1A. Loss of phosphorylation by TGFBR1; when associated with A-464 and A-465.,MUTAGEN:S->A: No change in binding to PPM1A. Loss of phosphorylation by TGFBR1; when associated with A-464 and A-467.,MUTAGEN:S->D: No change in binding to PPM1A.,MUTAGEN:SMS->AMA: Binds RANBP3.,MUTAGEN:SMS->DMD: Greatly reduced RANBP2 binding.,MUTAGEN:V->R: Increased binding to PPM1A.,MUTAGEN:W->A: Loss of interaction with PMEPA1.,REGION:Disordered,TRANSMEM:Helical,
SMU1	SMU1 DNA replication regulator and spliceosomal factor(SMU1)	Homo sapiens			GO:0000381~regulation of alternative mRNA splicing, via spliceosome,GO:0000398~mRNA splicing, via spliceosome,GO:0008380~RNA splicing,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0016607~nuclear speck,GO:0071005~U2-type precatalytic spliceosome,GO:0071011~precatalytic spliceosome,	GO:0005515~protein binding,	IPR001680:WD40_rpt,IPR006594:LisH,IPR006595:CTLH_C,IPR015943:WD40/YVTN_repeat-like_dom_sf,IPR019775:WD40_repeat_CS,IPR020472:G-protein_beta_WD-40_rep,IPR036322:WD40_repeat_dom_sf,IPR045184:SMU1,				SM00320:WD40,SM00667:LisH,SM00668:CTLH,	KW-0507~mRNA processing,KW-0508~mRNA splicing,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0853~WD repeat,			KW-0007~Acetylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:CTLH,DOMAIN:LisH,REGION:Required for interaction with IK and with influenza A virus RNA polymerase,REPEAT:WD,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,REPEAT:WD 7,
SNAPIN	SNAP associated protein(SNAPIN)	Homo sapiens			GO:0006886~intracellular protein transport,GO:0007040~lysosome organization,GO:0007042~lysosomal lumen acidification,GO:0007269~neurotransmitter secretion,GO:0008089~anterograde axonal transport,GO:0008090~retrograde axonal transport,GO:0008333~endosome to lysosome transport,GO:0010977~negative regulation of neuron projection development,GO:0016079~synaptic vesicle exocytosis,GO:0016188~synaptic vesicle maturation,GO:0031175~neuron projection development,GO:0031503~protein complex localization,GO:0031629~synaptic vesicle fusion to presynaptic active zone membrane,GO:0032418~lysosome localization,GO:0032438~melanosome organization,GO:0043393~regulation of protein binding,GO:0048489~synaptic vesicle transport,GO:0048490~anterograde synaptic vesicle transport,GO:0051036~regulation of endosome size,GO:0051604~protein maturation,GO:0070050~neuron cellular homeostasis,GO:0072384~organelle transport along microtubule,GO:0072553~terminal button organization,GO:0097352~autophagosome maturation,GO:1902774~late endosome to lysosome transport,GO:1902824~positive regulation of late endosome to lysosome transport,GO:2000300~regulation of synaptic vesicle exocytosis,	GO:0000139~Golgi membrane,GO:0001669~acrosomal vesicle,GO:0002177~manchette,GO:0005829~cytosol,GO:0008021~synaptic vesicle,GO:0030141~secretory granule,GO:0030672~synaptic vesicle membrane,GO:0031083~BLOC-1 complex,GO:0045202~synapse,GO:0048471~perinuclear region of cytoplasm,GO:0098574~cytoplasmic side of lysosomal membrane,GO:0099078~BORC complex,GO:1904115~axon cytoplasm,	GO:0000149~SNARE binding,GO:0005515~protein binding,	IPR017246:Snapin,IPR028119:Snapin/Pallidin/Snn1,			PIRSF037631:Snapin,		KW-0268~Exocytosis,KW-0945~Host-virus interaction,	KW-0333~Golgi apparatus,KW-0458~Lysosome,KW-0472~Membrane,KW-0770~Synapse,KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,		KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	REGION:Interaction with TOR1A,
SNRK	SNF related kinase(SNRK)	Homo sapiens			GO:0006468~protein phosphorylation,GO:0007049~cell cycle,GO:0016310~phosphorylation,GO:0030099~myeloid cell differentiation,GO:0035556~intracellular signal transduction,GO:0051301~cell division,	GO:0005634~nucleus,	GO:0000287~magnesium ion binding,GO:0004674~protein serine/threonine kinase activity,GO:0005524~ATP binding,	IPR000719:Prot_kinase_dom,IPR008271:Ser/Thr_kinase_AS,IPR011009:Kinase-like_dom_sf,IPR015940:UBA,IPR017441:Protein_kinase_ATP_BS,IPR030616:Aur-like,				SM00220:S_TKc,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,	KW-0539~Nucleus,			KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0488~Methylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Protein kinase,DOMAIN:UBA,MUTAGEN:T->A,E: Prevents phosphorylation and activation by STK11/LKB1 complex.,REGION:Disordered,
SNF8	SNF8 subunit of ESCRT-II(SNF8)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0010628~positive regulation of gene expression,GO:0016236~macroautophagy,GO:0032456~endocytic recycling,GO:0036258~multivesicular body assembly,GO:0042176~regulation of protein catabolic process,GO:0043328~protein targeting to vacuole involved in ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway,GO:0045022~early endosome to late endosome transport,GO:0045732~positive regulation of protein catabolic process,GO:0051179~localization,GO:0061635~regulation of protein complex stability,GO:0071985~multivesicular body sorting pathway,GO:0090148~membrane fission,GO:1903543~positive regulation of exosomal secretion,	GO:0000814~ESCRT II complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0010008~endosome membrane,GO:0016020~membrane,GO:0031902~late endosome membrane,GO:0048471~perinuclear region of cytoplasm,GO:0055037~recycling endosome,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0008289~lipid binding,GO:0016247~channel regulator activity,GO:0042803~protein homodimerization activity,	IPR016689:ESCRT-2_cplx_Snf8,IPR036388:WH-like_DNA-bd_sf,IPR036390:WH_DNA-bd_sf,IPR040608:Snf8/Vps36,	hsa04144:Endocytosis,		PIRSF017215:ESCRT2_Vps22,		KW-0653~Protein transport,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0813~Transport,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0967~Endosome,		KW-0175~Coiled coil,			KW-0488~Methylation,
SNW1	SNW domain containing 1(SNW1)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0000398~mRNA splicing, via spliceosome,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0030511~positive regulation of transforming growth factor beta receptor signaling pathway,GO:0042771~intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator,GO:0043923~positive regulation by host of viral transcription,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048026~positive regulation of mRNA splicing, via spliceosome,GO:0048384~retinoic acid receptor signaling pathway,GO:0048385~regulation of retinoic acid receptor signaling pathway,GO:0050769~positive regulation of neurogenesis,GO:0070562~regulation of vitamin D receptor signaling pathway,GO:0070564~positive regulation of vitamin D receptor signaling pathway,GO:0071300~cellular response to retinoic acid,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005681~spliceosomal complex,GO:0008024~cyclin/CDK positive transcription elongation factor complex,GO:0016363~nuclear matrix,GO:0016604~nuclear body,GO:0016607~nuclear speck,GO:0071007~U2-type catalytic step 2 spliceosome,GO:0071013~catalytic step 2 spliceosome,	GO:0003713~transcription coactivator activity,GO:0003714~transcription corepressor activity,GO:0003723~RNA binding,GO:0005112~Notch binding,GO:0005515~protein binding,GO:0016922~ligand-dependent nuclear receptor binding,GO:0019899~enzyme binding,GO:0042809~vitamin D receptor binding,GO:0042974~retinoic acid receptor binding,GO:0046332~SMAD binding,GO:0050681~androgen receptor binding,	IPR004015:SKI-int_prot_SKIP_SNW-dom,IPR017862:SKI-int_prot_SKIP,	hsa03040:Spliceosome,hsa04330:Notch signaling pathway,hsa05169:Epstein-Barr virus infection,hsa05203:Viral carcinogenesis,				KW-0507~mRNA processing,KW-0508~mRNA splicing,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0747~Spliceosome,					KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:SKI-interacting protein SKIP SNW,MUTAGEN:E->A,R: Abolishes interaction with PPIL1.,MUTAGEN:M->A: Abolishes interaction with PPIL1.,REGION:Disordered,REGION:Interaction with PPIL1,REGION:SNW,
SON	SON DNA and RNA binding protein(SON)	Homo sapiens			GO:0000226~microtubule cytoskeleton organization,GO:0000281~mitotic cytokinesis,GO:0006397~mRNA processing,GO:0008380~RNA splicing,GO:0043066~negative regulation of apoptotic process,GO:0043484~regulation of RNA splicing,GO:0048024~regulation of mRNA splicing, via spliceosome,GO:0051726~regulation of cell cycle,	GO:0016607~nuclear speck,	GO:0003677~DNA binding,GO:0003723~RNA binding,GO:0005515~protein binding,	IPR000467:G_patch_dom,IPR014720:dsRBD_dom,IPR032922:SON,IPR036322:WD40_repeat_dom_sf,		617140~ZTTK syndrome,		SM00358:DSRM,SM00443:G_patch,	KW-0131~Cell cycle,KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-0991~Intellectual disability,	KW-0677~Repeat,		KW-0238~DNA-binding,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:DRBM,DOMAIN:G-patch,REGION:11 X 7 AA tandem repeats of [DR]-P-Y-R-[LI][AG][QHP],REGION:14 X 6 AA repeats of [ED]-R-S-M-M-S,REGION:17 X 10 AA tandem repeats of L-A-[ST]-[NSG]-[TS]-MDSQM,REGION:2 X 19 AA repeats of P-S-R-R-R-R-S-R-S-V-V-R-R-R-S-F-S-I-S,REGION:3 X 11 AA tandem repats of P-P-L-P-P-E-E-P-P-[TME]-[MTG],REGION:3 X tandem repeats of [ST]-P-[VLI]-R-[RL]-[RK]-[RF]-S-R,REGION:4 X 8 AA tandem repeats of V-L-E-SS-[AVT]-VT,REGION:7 X 7 AA repeats of P-S-R-R-S-R-[TS],REGION:Disordered,REPEAT:1-1,REPEAT:1-10,REPEAT:1-11,REPEAT:1-12,REPEAT:1-13,REPEAT:1-14,REPEAT:1-2,REPEAT:1-3,REPEAT:1-4,REPEAT:1-5,REPEAT:1-6,REPEAT:1-7,REPEAT:1-8,REPEAT:1-9,REPEAT:2-1,REPEAT:2-2,REPEAT:2-3,REPEAT:2-4,REPEAT:2-5,REPEAT:2-6,REPEAT:2-7,REPEAT:3-1,REPEAT:3-2,
SP100	SP100 nuclear antigen(SP100)	Homo sapiens		h_pmlPathway:Regulation of transcriptional activity by PML,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0000723~telomere maintenance,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006978~DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator,GO:0010596~negative regulation of endothelial cell migration,GO:0030330~DNA damage response, signal transduction by p53 class mediator,GO:0032526~response to retinoic acid,GO:0032897~negative regulation of viral transcription,GO:0034097~response to cytokine,GO:0034340~response to type I interferon,GO:0034341~response to interferon-gamma,GO:0043392~negative regulation of DNA binding,GO:0043433~negative regulation of sequence-specific DNA binding transcription factor activity,GO:0045185~maintenance of protein location,GO:0045765~regulation of angiogenesis,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046826~negative regulation of protein export from nucleus,GO:0048384~retinoic acid receptor signaling pathway,GO:0051091~positive regulation of sequence-specific DNA binding transcription factor activity,GO:0060333~interferon-gamma-mediated signaling pathway,GO:0060337~type I interferon signaling pathway,GO:1902041~regulation of extrinsic apoptotic signaling pathway via death domain receptors,GO:1902044~regulation of Fas signaling pathway,	GO:0000781~chromosome, telomeric region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0016604~nuclear body,GO:0016605~PML body,GO:0030870~Mre11 complex,GO:0034399~nuclear periphery,	GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003677~DNA binding,GO:0005515~protein binding,GO:0019900~kinase binding,GO:0019904~protein domain specific binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0046872~metal ion binding,GO:0046983~protein dimerization activity,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:0070087~chromo shadow domain binding,	IPR000770:SAND_dom,IPR001487:Bromodomain,IPR001965:Znf_PHD,IPR004865:HSR_dom,IPR009071:HMG_box_dom,IPR010919:SAND-like_dom_sf,IPR011011:Znf_FYVE_PHD,IPR013083:Znf_RING/FYVE/PHD,IPR019786:Zinc_finger_PHD-type_CS,IPR019787:Znf_PHD-finger,IPR030411:Sp140_Bromo,IPR036427:Bromodomain-like_sf,IPR036910:HMG_box_dom_sf,IPR043563:Sp110/Sp140/Sp140L-like,	hsa05168:Herpes simplex virus 1 infection,hsa05203:Viral carcinogenesis,			SM00249:PHD,SM00258:SAND,SM00297:BROMO,SM00398:HMG,	KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0677~Repeat,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DNA_BIND:HMG box,DNA_BIND:HMG box 1,DNA_BIND:HMG box 2,DOMAIN:HMG box,DOMAIN:HSR,DOMAIN:PHD-type,DOMAIN:SAND,MOTIF:D-box; recognition signal for CDC20-mediated degradation,MOTIF:Nuclear localization signal,MOTIF:PxVxL motif,MUTAGEN:L->A: Prevents CDC20-mediated degradation; when associated with Ala-165.,MUTAGEN:R->A: Prevents CDC20-mediated degradation; when associated with Ala-168.,REGION:Disordered,REGION:Sufficient to mediate interaction with ETS1,
SP140	SP140 nuclear body protein(SP140)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006952~defense response,	GO:0001650~fibrillar center,GO:0005634~nucleus,GO:0005739~mitochondrion,GO:0016605~PML body,	GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003677~DNA binding,GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR000770:SAND_dom,IPR001487:Bromodomain,IPR001965:Znf_PHD,IPR004865:HSR_dom,IPR010919:SAND-like_dom_sf,IPR011011:Znf_FYVE_PHD,IPR013083:Znf_RING/FYVE/PHD,IPR019786:Zinc_finger_PHD-type_CS,IPR019787:Znf_PHD-finger,IPR030411:Sp140_Bromo,IPR036427:Bromodomain-like_sf,IPR043563:Sp110/Sp140/Sp140L-like,				SM00249:PHD,SM00258:SAND,SM00297:BROMO,		KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0103~Bromodomain,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,DOMAIN:Bromo,DOMAIN:HSR,DOMAIN:PHD-type,DOMAIN:SAND,MOTIF:Nuclear localization signal,REGION:Disordered,ZN_FING:PHD-type,
SPOCK2	SPARC (osteonectin), cwcv and kazal like domains proteoglycan 2(SPOCK2)	Homo sapiens			GO:0007416~synapse assembly,GO:0010811~positive regulation of cell-substrate adhesion,GO:0010951~negative regulation of endopeptidase activity,GO:0030198~extracellular matrix organization,GO:0045595~regulation of cell differentiation,GO:1990830~cellular response to leukemia inhibitory factor,GO:2000147~positive regulation of cell motility,	GO:0005576~extracellular region,GO:0031012~extracellular matrix,	GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0005539~glycosaminoglycan binding,GO:0008191~metalloendopeptidase inhibitor activity,GO:0050840~extracellular matrix binding,	IPR000716:Thyroglobulin_1,IPR002350:Kazal_dom,IPR011992:EF-hand-dom_pair,IPR019577:SPARC/Testican_Ca-bd-dom,IPR036058:Kazal_dom_sf,IPR036857:Thyroglobulin_1_sf,				SM00211:TY,SM00280:KAZAL,		KW-0272~Extracellular matrix,KW-0964~Secreted,		KW-0732~Signal,	KW-0106~Calcium,		KW-0325~Glycoprotein,KW-0357~Heparan sulfate,KW-0597~Phosphoprotein,KW-0654~Proteoglycan,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (Xyl...) (glycosaminoglycan) serine,COMPBIAS:Acidic residues,COMPBIAS:Basic residues,DOMAIN:Kazal-like,DOMAIN:Thyroglobulin type-1,REGION:Disordered,
SPG21	SPG21 abhydrolase domain containing, maspardin(SPG21)	Homo sapiens			GO:0050851~antigen receptor-mediated signaling pathway,	GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0010008~endosome membrane,GO:0030140~trans-Golgi network transport vesicle,GO:0043231~intracellular membrane-bounded organelle,	GO:0005515~protein binding,GO:0042609~CD4 receptor binding,	IPR000073:AB_hydrolase_1,IPR026151:Maspardin,IPR029058:AB_hydrolase,	hsa04144:Endocytosis,	248900~Mast syndrome,				KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0967~Endosome,	KW-0523~Neurodegeneration,KW-0890~Hereditary spastic paraplegia,				KW-0597~Phosphoprotein,	DOMAIN:AB hydrolase-1,MUTAGEN:S->A: Abolishes interaction with CD4.,
SPG7	SPG7 matrix AAA peptidase subunit, paraplegin(SPG7)	Homo sapiens			GO:0006508~proteolysis,GO:0007399~nervous system development,GO:0008089~anterograde axonal transport,GO:0034982~mitochondrial protein processing,GO:0046902~regulation of mitochondrial membrane permeability,GO:1902686~mitochondrial outer membrane permeabilization involved in programmed cell death,	GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005745~m-AAA complex,GO:0005757~mitochondrial permeability transition pore complex,GO:0016020~membrane,GO:1904115~axon cytoplasm,	GO:0004176~ATP-dependent peptidase activity,GO:0004222~metalloendopeptidase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008233~peptidase activity,GO:0008270~zinc ion binding,GO:0016887~ATPase activity,GO:0051082~unfolded protein binding,	IPR000642:Peptidase_M41,IPR003593:AAA+_ATPase,IPR003959:ATPase_AAA_core,IPR005936:FtsH,IPR011546:Pept_M41_FtsH_extracell,IPR027417:P-loop_NTPase,IPR037219:Peptidase_M41-like,IPR041569:AAA_lid_3,		607259~Spastic paraplegia 7, autosomal recessive,		SM00382:AAA,		KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,	KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0890~Hereditary spastic paraplegia,KW-1065~Osteogenesis imperfecta,	KW-0175~Coiled coil,KW-0732~Signal,KW-0809~Transit peptide,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,KW-0862~Zinc,	KW-0378~Hydrolase,KW-0482~Metalloprotease,KW-0645~Protease,	KW-0944~Nitration,	COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,DOMAIN:AAA ATPase AAA+ lid,DOMAIN:AAA+ ATPase,DOMAIN:ATPase AAA-type core,DOMAIN:Peptidase M41,DOMAIN:Peptidase M41 FtsH extracellular,MUTAGEN:E->G: Loss of proteolytic activity but no loss of interaction with PPIF; when associated with G-574 and S-577.,MUTAGEN:G->S: No loss of interaction with PPIF. Loss of proteolytic activity but no loss of interaction with PPIF; when associated with G-574 and G-575.,MUTAGEN:H->G: Loss of proteolytic activity but no loss of interaction with PPIF; when associated with G-575 and S-577.,PROPEP:Removed in mature form,REGION:Disordered,REGION:Interaction with PPIF,TOPO_DOM:Mitochondrial intermembrane,TOPO_DOM:Mitochondrial matrix,TRANSIT:Mitochondrion,TRANSMEM:Helical,
SPNS1	SPNS lysolipid transporter 1, lysophospholipid(SPNS1)	Homo sapiens			GO:0007165~signal transduction,GO:0033700~phospholipid efflux,GO:0035751~regulation of lysosomal lumen pH,GO:0051977~lysophospholipid transport,GO:0055085~transmembrane transport,	GO:0005743~mitochondrial inner membrane,GO:0005765~lysosomal membrane,GO:0016020~membrane,	GO:0005215~transporter activity,GO:0005515~protein binding,GO:0022857~transmembrane transporter activity,	IPR008359:Linker_for_activat_Tcells_prot,IPR011701:MFS,IPR020846:MFS_dom,IPR036259:MFS_trans_sf,IPR044770:MFS_spinster-like,					KW-0445~Lipid transport,KW-0813~Transport,	KW-0458~Lysosome,KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:Major facilitator superfamily (MFS) profile,REGION:Disordered,TRANSMEM:Helical,
SUPT16H	SPT16 homolog, facilitates chromatin remodeling subunit(SUPT16H)	Homo sapiens		h_vdrPathway:Control of Gene Expression by Vitamin D Receptor,	GO:0006260~DNA replication,GO:0006281~DNA repair,GO:0006334~nucleosome assembly,GO:0006337~nucleosome disassembly,GO:0006366~transcription from RNA polymerase II promoter,GO:0006368~transcription elongation from RNA polymerase II promoter,GO:0032786~positive regulation of DNA-templated transcription, elongation,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0035101~FACT complex,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0031491~nucleosome binding,	IPR000994:Pept_M24,IPR011993:PH-like_dom_sf,IPR013719:RTT106/SPT16-like_middle_dom,IPR013953:FACT_Spt16,IPR029148:FACT-Spt16_Nlobe,IPR029149:Creatin/AminoP/Spt16_NTD,IPR033825:Spt16_M24,IPR036005:Creatinase/aminopeptidase-like,IPR040258:Spt16,IPR048969:SPT16_C,		619480~Neurodevelopmental disorder with dysmorphic facies and thin corpus callosum,		SM01285:FACT-Spt16_Nlob,SM01286:SPT16,SM01287:Rtt106,	KW-0227~DNA damage,KW-0234~DNA repair,KW-0235~DNA replication,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0158~Chromosome,KW-0539~Nucleus,	KW-0991~Intellectual disability,	KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0013~ADP-ribosylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:FACT complex subunit Spt16 N-terminal lobe,REGION:Disordered,
SUPT4H1	SPT4 homolog, DSIF elongation factor subunit(SUPT4H1)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006325~chromatin organization,GO:0006355~regulation of transcription, DNA-templated,GO:0006368~transcription elongation from RNA polymerase II promoter,GO:0032785~negative regulation of DNA-templated transcription, elongation,GO:0032786~positive regulation of DNA-templated transcription, elongation,GO:0034243~regulation of transcription elongation from RNA polymerase II promoter,GO:0034244~negative regulation of transcription elongation from RNA polymerase II promoter,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0032044~DSIF complex,	GO:0000993~RNA polymerase II core binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0046982~protein heterodimerization activity,	IPR009287:Spt4,IPR022800:Spt4/RpoE2_Znf,IPR029040:RPABC4/Spt4,IPR038510:Spt4_sf,	hsa03250:Viral life cycle - HIV-1,		PIRSF025023:Spt4,	SM01389:Spt4,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0678~Repressor,	KW-0007~Acetylation,	DOMAIN:Spt4/RpoE2 zinc finger,REGION:Interaction with SUPT5H,ZN_FING:C4-type,
SUPT5H	SPT5 homolog, DSIF elongation factor subunit(SUPT5H)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006354~DNA-templated transcription, elongation,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006368~transcription elongation from RNA polymerase II promoter,GO:0016239~positive regulation of macroautophagy,GO:0032784~regulation of DNA-templated transcription, elongation,GO:0032785~negative regulation of DNA-templated transcription, elongation,GO:0032786~positive regulation of DNA-templated transcription, elongation,GO:0034243~regulation of transcription elongation from RNA polymerase II promoter,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0032044~DSIF complex,	GO:0003682~chromatin binding,GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0003746~translation elongation factor activity,GO:0005515~protein binding,GO:0019899~enzyme binding,GO:0046982~protein heterodimerization activity,	IPR005100:NGN-domain,IPR005824:KOW,IPR006645:NGN-like_dom,IPR008991:Translation_prot_SH3-like_sf,IPR014722:Rib_uL2_dom2,IPR017071:TF_Spt5_eukaryote,IPR022581:Spt5_N,IPR024945:Spt5_C_dom,IPR036735:NGN_dom_sf,IPR039385:NGN_Euk,IPR039659:SPT5,IPR041973:KOW_Spt5_1,IPR041975:KOW_Spt5_2,IPR041976:KOW_Spt5_3,IPR041977:KOW_Spt5_4,IPR041978:KOW_Spt5_5,IPR041980:KOW_Spt5_6,	hsa03250:Viral life cycle - HIV-1,		PIRSF036945:Spt5,	SM00738:NGN,SM00739:KOW,SM01104:CTD,	KW-0648~Protein biosynthesis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0677~Repeat,		KW-0010~Activator,KW-0251~Elongation factor,KW-0678~Repressor,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:KOW,DOMAIN:KOW 1,DOMAIN:KOW 2,DOMAIN:KOW 3,DOMAIN:KOW 4,DOMAIN:KOW 5,DOMAIN:NGN,DOMAIN:NusG-like N-terminal,DOMAIN:Spt5 C-terminal,DOMAIN:Spt5 transcription elongation factor N-terminal,MUTAGEN:G->D: Defective in regulation of transcriptional elongation.,MUTAGEN:R->A: Enhances interactions with CDK9 and RNA polymerase II and enhances transcriptional elongation; when associated with A-681 and A-698.,MUTAGEN:R->A: Enhances interactions with CDK9 and RNA polymerase II and enhances transcriptional elongation; when associated with A-696 and A-698.,MUTAGEN:R->A: Enhances transcriptional elongation. Enhances interactions with CDK9 and RNA polymerase II and enhances transcriptional elongation; when associated with A-681 and A-696.,MUTAGEN:R->K: Increases promoter association and enhances transcriptional elongation; when associated with K-681 and K-696.,MUTAGEN:R->K: Increases promoter association and enhances transcriptional elongation; when associated with K-681 and K-698.,MUTAGEN:R->K: Increases promoter association and enhances transcriptional elongation; when associated with K-696 and K-698.,REGION:10 X 8 AA approximate tandem repeats of P-[TS]-P-S-P-[QA]-[SG]-Y, motif CTR2,REGION:9 X 7 AA approximate tandem repeats of G-S-[QR]-T-P-X-[YQ], motif CTR1,REGION:Disordered,REGION:Interaction with RNA polymerase II,REGION:Interaction with SUPT4H1,REPEAT:CTR1-1; approximate,REPEAT:CTR1-2,REPEAT:CTR1-3,REPEAT:CTR1-4,REPEAT:CTR1-5,REPEAT:CTR1-6,REPEAT:CTR1-7,REPEAT:CTR1-8,REPEAT:CTR1-9,REPEAT:CTR2-1,REPEAT:CTR2-10,REPEAT:CTR2-2; approximate,REPEAT:CTR2-3; approximate,REPEAT:CTR2-4; half-length,REPEAT:CTR2-5; approximate,REPEAT:CTR2-6,REPEAT:CTR2-7; approximate,REPEAT:CTR2-8,REPEAT:CTR2-9,
SUPT7L	SPT7 like, STAGA complex subunit gamma(SUPT7L)	Homo sapiens			GO:0006282~regulation of DNA repair,GO:0043484~regulation of RNA splicing,GO:0045893~positive regulation of transcription, DNA-templated,GO:0051457~maintenance of protein location in nucleus,	GO:0000124~SAGA complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,	GO:0003713~transcription coactivator activity,GO:0005515~protein binding,GO:0046982~protein heterodimerization activity,	IPR006565:BTP,IPR009072:Histone-fold,IPR039460:SUPT7L,				SM00576:BTP,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,					KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),REGION:Disordered,
SCAF4	SR-related CTD associated factor 4(SCAF4)	Homo sapiens			GO:2000805~negative regulation of termination of RNA polymerase II transcription, poly(A)-coupled,	GO:0005634~nucleus,GO:0005654~nucleoplasm,	GO:0003723~RNA binding,GO:1990269~RNA polymerase II C-terminal domain phosphoserine binding,	IPR000504:RRM_dom,IPR006569:CID_dom,IPR008942:ENTH_VHS,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR034369:SCAF4_RRM,IPR035979:RBD_domain_sf,		620511~Fliedner-Zweier syndrome,		SM00360:RRM,SM00582:RPR,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:CID,DOMAIN:RRM,REGION:Disordered,
SLIRP	SRA stem-loop interacting RNA binding protein(SLIRP)	Homo sapiens			GO:0000961~negative regulation of mitochondrial RNA catabolic process,GO:0007005~mitochondrion organization,GO:0007286~spermatid development,GO:0007338~single fertilization,GO:0030317~flagellated sperm motility,GO:0070584~mitochondrion morphogenesis,	GO:0001669~acrosomal vesicle,GO:0005634~nucleus,GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0036126~sperm flagellum,GO:0048471~perinuclear region of cytoplasm,GO:1990904~ribonucleoprotein complex,	GO:0003676~nucleic acid binding,GO:0003723~RNA binding,GO:0005515~protein binding,	IPR000504:RRM_dom,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR034152:SLIRP_RRM,IPR035979:RBD_domain_sf,				SM00360:RRM,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0496~Mitochondrion,KW-0539~Nucleus,		KW-0809~Transit peptide,		KW-0678~Repressor,KW-0694~RNA-binding,	KW-0597~Phosphoprotein,	DOMAIN:RRM,MUTAGEN:L->A: Impairs SRA-mediated repression; when associated with 24-A-A-25.,MUTAGEN:R->A: Impairs corepressor activity; when associated with 13-A-A-14.,MUTAGEN:RR->AA: Impairs SRA-mediated repression; when associated with A-62.,MUTAGEN:RR->AA: Impairs corepressor activity; when associated with A-7.,REGION:Disordered,TRANSIT:Mitochondrion,
SREK1IP1	SREK1 interacting protein 1(SREK1IP1)	Homo sapiens			GO:0006397~mRNA processing,GO:0008380~RNA splicing,		GO:0003676~nucleic acid binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,	IPR001878:Znf_CCHC,					KW-0507~mRNA processing,KW-0508~mRNA splicing,			KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,REGION:Disordered,ZN_FING:CCHC-type,
SRPRA	SRP receptor subunit alpha(SRPRA)	Homo sapiens			GO:0006613~cotranslational protein targeting to membrane,GO:0006614~SRP-dependent cotranslational protein targeting to membrane,GO:0006617~SRP-dependent cotranslational protein targeting to membrane, signal sequence recognition,GO:0006886~intracellular protein transport,GO:0045047~protein targeting to ER,	GO:0005785~signal recognition particle receptor complex,GO:0005789~endoplasmic reticulum membrane,GO:0016020~membrane,GO:0070062~extracellular exosome,	GO:0003723~RNA binding,GO:0003924~GTPase activity,GO:0005047~signal recognition particle binding,GO:0005525~GTP binding,GO:0016887~ATPase activity,	IPR000897:SRP54_GTPase_dom,IPR003593:AAA+_ATPase,IPR007222:Sig_recog_particle_rcpt_asu_N,IPR011012:Longin-like_dom_sf,IPR013822:Signal_recog_particl_SRP54_hlx,IPR027417:P-loop_NTPase,IPR036225:SRP/SRP_N,IPR042101:SRP54_N_sf,	hsa03060:Protein export,			SM00382:AAA,SM00962:SRP54,SM00963:SRP54_N,		KW-0256~Endoplasmic reticulum,KW-0472~Membrane,			KW-0342~GTP-binding,KW-0547~Nucleotide-binding,	KW-0675~Receptor,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:SRP54-type proteins GTP-binding,MUTAGEN:R->A: Reduced SR compaction. Impaired interaction with SRP. Impaired detachement from ribosome. Does not impair GTP hydrolysis by the SRP-SR complex.,REGION:Disordered,REGION:NG domain,
SRPK1	SRSF protein kinase 1(SRPK1)	Homo sapiens			GO:0000245~spliceosomal complex assembly,GO:0006468~protein phosphorylation,GO:0007059~chromosome segregation,GO:0008380~RNA splicing,GO:0016310~phosphorylation,GO:0018105~peptidyl-serine phosphorylation,GO:0035092~sperm chromatin condensation,GO:0035556~intracellular signal transduction,GO:0045070~positive regulation of viral genome replication,GO:0045071~negative regulation of viral genome replication,GO:0045087~innate immune response,GO:0048024~regulation of mRNA splicing, via spliceosome,GO:0050684~regulation of mRNA processing,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016363~nuclear matrix,GO:0016607~nuclear speck,	GO:0000287~magnesium ion binding,GO:0003723~RNA binding,GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,	IPR000719:Prot_kinase_dom,IPR008271:Ser/Thr_kinase_AS,IPR011009:Kinase-like_dom_sf,IPR017441:Protein_kinase_ATP_BS,	hsa05168:Herpes simplex virus 1 infection,			SM00220:S_TKc,	KW-0159~Chromosome partition,KW-0221~Differentiation,KW-0507~mRNA processing,KW-0508~mRNA splicing,KW-0945~Host-virus interaction,	KW-0158~Chromosome,KW-0256~Endoplasmic reticulum,KW-0492~Microsome,KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Protein kinase,MUTAGEN:S->A: No effect on protein phosphorylation.,MUTAGEN:S->A: Protein phosphorylation impaired at this position.,MUTAGEN:S->G: No effect on protein phosphorylation.,REGION:Disordered,
SRPK2	SRSF protein kinase 2(SRPK2)	Homo sapiens			GO:0000245~spliceosomal complex assembly,GO:0001525~angiogenesis,GO:0006468~protein phosphorylation,GO:0008284~positive regulation of cell proliferation,GO:0008380~RNA splicing,GO:0010628~positive regulation of gene expression,GO:0018105~peptidyl-serine phosphorylation,GO:0030154~cell differentiation,GO:0035063~nuclear speck organization,GO:0035556~intracellular signal transduction,GO:0043525~positive regulation of neuron apoptotic process,GO:0045070~positive regulation of viral genome replication,GO:0045071~negative regulation of viral genome replication,GO:0045087~innate immune response,GO:0045787~positive regulation of cell cycle,GO:0048024~regulation of mRNA splicing, via spliceosome,GO:0050684~regulation of mRNA processing,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016607~nuclear speck,	GO:0000287~magnesium ion binding,GO:0003723~RNA binding,GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0071889~14-3-3 protein binding,	IPR000719:Prot_kinase_dom,IPR008271:Ser/Thr_kinase_AS,IPR011009:Kinase-like_dom_sf,IPR017441:Protein_kinase_ATP_BS,				SM00220:S_TKc,	KW-0221~Differentiation,KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0158~Chromosome,KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Protein kinase,REGION:Disordered,SITE:Cleavage; by caspase-3,
SOX4	SRY-box transcription factor 4(SOX4)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001666~response to hypoxia,GO:0002328~pro-B cell differentiation,GO:0003183~mitral valve morphogenesis,GO:0003215~cardiac right ventricle morphogenesis,GO:0003289~atrial septum primum morphogenesis,GO:0003357~noradrenergic neuron differentiation,GO:0006355~regulation of transcription, DNA-templated,GO:0007399~nervous system development,GO:0007420~brain development,GO:0007507~heart development,GO:0008284~positive regulation of cell proliferation,GO:0008285~negative regulation of cell proliferation,GO:0009653~anatomical structure morphogenesis,GO:0010467~gene expression,GO:0014009~glial cell proliferation,GO:0021510~spinal cord development,GO:0021782~glial cell development,GO:0030154~cell differentiation,GO:0030182~neuron differentiation,GO:0030217~T cell differentiation,GO:0031018~endocrine pancreas development,GO:0031397~negative regulation of protein ubiquitination,GO:0031647~regulation of protein stability,GO:0032024~positive regulation of insulin secretion,GO:0035019~somatic stem cell population maintenance,GO:0035910~ascending aorta morphogenesis,GO:0042593~glucose homeostasis,GO:0043065~positive regulation of apoptotic process,GO:0043516~regulation of DNA damage response, signal transduction by p53 class mediator,GO:0045588~positive regulation of gamma-delta T cell differentiation,GO:0045662~negative regulation of myoblast differentiation,GO:0045663~positive regulation of myoblast differentiation,GO:0045727~positive regulation of translation,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048485~sympathetic nervous system development,GO:0048593~camera-type eye morphogenesis,GO:0050821~protein stabilization,GO:0060412~ventricular septum morphogenesis,GO:0060485~mesenchyme development,GO:0060563~neuroepithelial cell differentiation,GO:0060993~kidney morphogenesis,GO:0061484~hematopoietic stem cell homeostasis,GO:0071333~cellular response to glucose stimulus,GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:2000761~positive regulation of N-terminal peptidyl-lysine acetylation,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005737~cytoplasm,GO:0005739~mitochondrion,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0035198~miRNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR009071:HMG_box_dom,IPR017386:SOX-12/11/4,IPR036910:HMG_box_dom_sf,	hsa05206:MicroRNAs in cancer,	618506~Coffin-Siris syndrome 10,	PIRSF038098:SOX-12/11/4a,	SM00398:HMG,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-0991~Intellectual disability,			KW-0010~Activator,KW-0238~DNA-binding,	KW-0007~Acetylation,	COMPBIAS:Polar residues,DNA_BIND:HMG box,MOTIF:9aaTAD,MUTAGEN:K->R: Abolished acetylation by KAT5.,MUTAGEN:K->R: Does not affect acetylation by KAT5.,REGION:Disordered,
SSNA1	SS nuclear autoantigen 1(SSNA1)	Homo sapiens			GO:0000226~microtubule cytoskeleton organization,GO:0007020~microtubule nucleation,GO:0007049~cell cycle,GO:0007409~axonogenesis,GO:0042073~intraciliary transport,GO:0043113~receptor clustering,GO:0048675~axon extension,GO:0051301~cell division,	GO:0005634~nucleus,GO:0005813~centrosome,GO:0005814~centriole,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005930~axoneme,GO:0030424~axon,GO:0030496~midbody,GO:0031514~motile cilium,GO:0036064~ciliary basal body,GO:0099512~supramolecular fiber,	GO:0005515~protein binding,GO:0008017~microtubule binding,GO:0042802~identical protein binding,GO:0043621~protein self-association,	IPR033362:SSNA1_fam,					KW-0131~Cell cycle,KW-0132~Cell division,KW-0524~Neurogenesis,	KW-0206~Cytoskeleton,KW-0282~Flagellum,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-0969~Cilium,		KW-0175~Coiled coil,			KW-0007~Acetylation,	MUTAGEN:C->S: Does not affect oligomer formation; when associated with S-18 and S-23.,MUTAGEN:C->S: Does not affect oligomer formation; when associated with S-18 and S-30.,MUTAGEN:C->S: Does not affect oligomer formation; when associated with S-23 and S-30.,REGION:Disordered,REGION:Important for localization to the centrosome,
SS18L2	SS18 like 2(SS18L2)	Homo sapiens					GO:0003713~transcription coactivator activity,GO:0005515~protein binding,	IPR007726:SS18_N,IPR044779:SS18,												MOTIF:SH2-binding,
SSU72	SSU72 homolog, RNA polymerase II CTD phosphatase(SSU72)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006369~termination of RNA polymerase II transcription,GO:0006378~mRNA polyadenylation,GO:0006397~mRNA processing,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0005847~mRNA cleavage and polyadenylation specificity factor complex,	GO:0005515~protein binding,GO:0008420~CTD phosphatase activity,GO:0017018~myosin phosphatase activity,	IPR006811:RNA_pol_II_suA,IPR036196:Ptyr_pPase_sf,	hsa03015:mRNA surveillance pathway,				KW-0507~mRNA processing,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,		KW-0378~Hydrolase,KW-0904~Protein phosphatase,		MUTAGEN:C->S: Abolishes phosphatase activity.,
ST13	ST13 Hsp70 interacting protein(ST13)	Homo sapiens			GO:0006457~protein folding,GO:0009617~response to bacterium,GO:0051085~chaperone mediated protein folding requiring cofactor,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0030544~Hsp70 protein binding,GO:0030674~protein binding, bridging,GO:0046983~protein dimerization activity,	IPR006636:STI1_HS-bd,IPR011990:TPR-like_helical_dom_sf,IPR019734:TPR_repeat,IPR034649:Hip_N,IPR041243:STI1/HOP_DP,				SM00028:TPR,SM00727:STI1,		KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0732~Signal,KW-0802~TPR repeat,		KW-0143~Chaperone,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:Hsp70-interacting protein N-terminal,DOMAIN:STI1,REGION:Disordered,REPEAT:TPR,REPEAT:TPR 1,REPEAT:TPR 2,REPEAT:TPR 3,
ST3GAL1	ST3 beta-galactoside alpha-2,3-sialyltransferase 1(ST3GAL1)	Homo sapiens			GO:0002319~memory B cell differentiation,GO:0006054~N-acetylneuraminate metabolic process,GO:0006486~protein glycosylation,GO:0006487~protein N-linked glycosylation,GO:0010706~ganglioside biosynthetic process via lactosylceramide,GO:0016266~O-glycan processing,GO:0018146~keratan sulfate biosynthetic process,GO:0019082~viral protein processing,GO:0036211~protein modification process,GO:0097503~sialylation,GO:1905403~negative regulation of activated CD8-positive, alpha-beta T cell apoptotic process,GO:1990743~protein sialylation,	GO:0000139~Golgi membrane,GO:0005794~Golgi apparatus,GO:0016020~membrane,GO:0032588~trans-Golgi network membrane,GO:0070062~extracellular exosome,GO:1990675~Golgi medial cisterna membrane,GO:1990676~Golgi trans cisterna membrane,	GO:0003836~beta-galactoside (CMP) alpha-2,3-sialyltransferase activity,GO:0008373~sialyltransferase activity,GO:0047288~monosialoganglioside sialyltransferase activity,	IPR001675:Glyco_trans_29,IPR012163:Sialyl_trans,IPR038578:GT29-like_sf,	hsa00512:Mucin type O-glycan biosynthesis,hsa00533:Glycosaminoglycan biosynthesis - keratan sulfate,hsa00603:Glycosphingolipid biosynthesis - globo and isoglobo series,hsa00604:Glycosphingolipid biosynthesis - ganglio series,hsa01100:Metabolic pathways,		PIRSF005557:Sialyl_trans,		KW-0443~Lipid metabolism,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0964~Secreted,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0328~Glycosyltransferase,KW-0808~Transferase,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,MUTAGEN:C->S: Has no effect on the catalytic efficiency; when associated with S-59.,MUTAGEN:C->S: Has no effect on the catalytic efficiency; when associated with S-64.,MUTAGEN:C->S: Loss of the catalytic activity; when associated with S-139.,MUTAGEN:C->S: Loss of the catalytic activity; when associated with S-142.,MUTAGEN:C->S: Loss of the catalytic activity; when associated with S-281.,MUTAGEN:C->S: Loss of the catalytic activity; when associated with S-61.,MUTAGEN:N->A: Decreases the affinity and the catalytic efficiency for both donor and acceptor substrates.,MUTAGEN:N->S: Decreases the affinity and the specific activity for both donor and acceptor substrates. Decreases the catalytic efficiency for the donor and acceptor substrates by 17- and 32-fold, respectively.,MUTAGEN:S->A: Decreases the affinity for the donor and acceptor substrates by 4.5- and 4-fold, respectively. Almost no change in specific activity.,MUTAGEN:V->A: Decreases the catalytic efficiency for the donor and acceptor substrates by 5- and 70-fold, respectively.,MUTAGEN:V->Y: Drastic decrease of the catalytic efficiency for both donor and acceptor substrates by 67- and 344-fold, respectively. Does not change the enzyme regioselectivity.,MUTAGEN:Y->A: Decreases the catalytic efficiency for the donor and acceptor substrates by 2.5- and 35-fold, respectively.,MUTAGEN:Y->A: Drastic decrease of the catalytic efficiency for both donor and acceptor substrates by 44- and 115-fold, respectively.,MUTAGEN:Y->F: Decreases the catalytic efficiency for the donor and acceptor substrates by 2- and 12-fold, respectively.,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
STAG1	STAG1 cohesin complex component(STAG1)	Homo sapiens			GO:0007059~chromosome segregation,GO:0007062~sister chromatid cohesion,GO:0034087~establishment of mitotic sister chromatid cohesion,GO:0051179~localization,GO:0051301~cell division,GO:0090307~mitotic spindle assembly,	GO:0000775~chromosome, centromeric region,GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005694~chromosome,GO:0005829~cytosol,GO:0008278~cohesin complex,GO:0016363~nuclear matrix,GO:0016604~nuclear body,GO:0030892~mitotic cohesin complex,GO:0097431~mitotic spindle pole,	GO:0003682~chromatin binding,GO:0005515~protein binding,	IPR013721:STAG,IPR016024:ARM-type_fold,IPR020839:SCD,IPR039662:Cohesin_Scc3/SA,	hsa04110:Cell cycle,	617635~Intellectual developmental disorder, autosomal dominant 47,			KW-0131~Cell cycle,KW-0132~Cell division,KW-0159~Chromosome partition,KW-0498~Mitosis,	KW-0137~Centromere,KW-0158~Chromosome,KW-0539~Nucleus,	KW-0225~Disease variant,KW-0991~Intellectual disability,	KW-0175~Coiled coil,			KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:SCD,DOMAIN:STAG,REGION:Disordered,
STAG2	STAG2 cohesin complex component(STAG2)	Homo sapiens			GO:0007059~chromosome segregation,GO:0007062~sister chromatid cohesion,GO:0034087~establishment of mitotic sister chromatid cohesion,GO:0051301~cell division,GO:0051321~meiotic cell cycle,GO:0090307~mitotic spindle assembly,	GO:0000775~chromosome, centromeric region,GO:0000785~chromatin,GO:0001650~fibrillar center,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005694~chromosome,GO:0005730~nucleolus,GO:0005829~cytosol,GO:0008278~cohesin complex,GO:0016020~membrane,GO:0016363~nuclear matrix,GO:0030892~mitotic cohesin complex,GO:0097431~mitotic spindle pole,	GO:0003682~chromatin binding,GO:0005515~protein binding,	IPR013721:STAG,IPR016024:ARM-type_fold,IPR020839:SCD,IPR039662:Cohesin_Scc3/SA,	hsa04110:Cell cycle,	301022~Mullegama-Klein-Martinez syndrome,301043~Holoprosencephaly 13, X-linked,			KW-0131~Cell cycle,KW-0132~Cell division,KW-0159~Chromosome partition,KW-0469~Meiosis,KW-0498~Mitosis,	KW-0137~Centromere,KW-0158~Chromosome,KW-0539~Nucleus,	KW-0225~Disease variant,KW-0370~Holoprosencephaly,	KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:SCD,DOMAIN:STAG,REGION:Disordered,
STUB1	STIP1 homology and U-box containing protein 1(STUB1)	Homo sapiens			GO:0000165~MAPK cascade,GO:0000209~protein polyubiquitination,GO:0002931~response to ischemia,GO:0006281~DNA repair,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0006513~protein monoubiquitination,GO:0006515~misfolded or incompletely synthesized protein catabolic process,GO:0016567~protein ubiquitination,GO:0030433~ubiquitin-dependent ERAD pathway,GO:0030512~negative regulation of transforming growth factor beta receptor signaling pathway,GO:0030968~endoplasmic reticulum unfolded protein response,GO:0031398~positive regulation of protein ubiquitination,GO:0031647~regulation of protein stability,GO:0031943~regulation of glucocorticoid metabolic process,GO:0032436~positive regulation of proteasomal ubiquitin-dependent protein catabolic process,GO:0034392~negative regulation of smooth muscle cell apoptotic process,GO:0034393~positive regulation of smooth muscle cell apoptotic process,GO:0034605~cellular response to heat,GO:0036503~ERAD pathway,GO:0038128~ERBB2 signaling pathway,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0045862~positive regulation of proteolysis,GO:0050821~protein stabilization,GO:0051604~protein maturation,GO:0051865~protein autoubiquitination,GO:0061684~chaperone-mediated autophagy,GO:0070534~protein K63-linked ubiquitination,GO:0071218~cellular response to misfolded protein,GO:0071456~cellular response to hypoxia,GO:0090035~positive regulation of chaperone-mediated protein complex assembly,GO:1901526~positive regulation of macromitophagy,GO:1904294~positive regulation of ERAD pathway,	GO:0000151~ubiquitin ligase complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0030018~Z disc,GO:0031371~ubiquitin conjugating enzyme complex,GO:0042405~nuclear inclusion body,GO:0101031~chaperone complex,	GO:0001664~G-protein coupled receptor binding,GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0019899~enzyme binding,GO:0019900~kinase binding,GO:0030544~Hsp70 protein binding,GO:0030674~protein binding, bridging,GO:0030911~TPR domain binding,GO:0031072~heat shock protein binding,GO:0031625~ubiquitin protein ligase binding,GO:0034450~ubiquitin-ubiquitin ligase activity,GO:0042803~protein homodimerization activity,GO:0046332~SMAD binding,GO:0048156~tau protein binding,GO:0051087~chaperone binding,GO:0051787~misfolded protein binding,GO:0051879~Hsp90 protein binding,GO:0061630~ubiquitin protein ligase activity,GO:0070412~R-SMAD binding,	IPR003613:Ubox_domain,IPR011990:TPR-like_helical_dom_sf,IPR013083:Znf_RING/FYVE/PHD,IPR019734:TPR_repeat,IPR041312:CHIP_TPR_N,IPR045200:CHIP,IPR045202:CHIP_RING-Ubox,	hsa04120:Ubiquitin mediated proteolysis,hsa04141:Protein processing in endoplasmic reticulum,	615768~Spinocerebellar ataxia, autosomal recessive 16,618093~Spinocerebellar ataxia 48,		SM00028:TPR,SM00504:Ubox,	KW-0227~DNA damage,KW-0234~DNA repair,KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0950~Spinocerebellar ataxia,	KW-0175~Coiled coil,KW-0677~Repeat,KW-0802~TPR repeat,		KW-0808~Transferase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:CHIP N-terminal tetratricopeptide repeat,DOMAIN:U-box,MUTAGEN:H->Q: Loss of ability to ubiquitinate FOXP3 and SIRT6.,MUTAGEN:K->A: Loss of interaction with FOXP3 and its ability to ubiquitinate FOXP3. Loss of interaction with SMAD3, HSPA8, HSP90AA1 and HSP90AB1.,MUTAGEN:P->A: Abolishes E3 ligase activity.,REGION:Disordered,REPEAT:TPR,REPEAT:TPR 1,REPEAT:TPR 2,REPEAT:TPR 3,
STT3A	STT3 oligosaccharyltransferase complex catalytic subunit A(STT3A)	Homo sapiens			GO:0006486~protein glycosylation,GO:0006487~protein N-linked glycosylation,GO:0018279~protein N-linked glycosylation via asparagine,GO:0043686~co-translational protein modification,GO:0043687~post-translational protein modification,	GO:0005789~endoplasmic reticulum membrane,GO:0008250~oligosaccharyltransferase complex,GO:0016020~membrane,GO:0035000~oligosaccharyltransferase III complex,	GO:0004579~dolichyl-diphosphooligosaccharide-protein glycotransferase activity,GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR003674:Oligo_trans_STT3,IPR048307:STT3_N,IPR048999:STT3-PglB_core,	hsa00510:N-Glycan biosynthesis,hsa00513:Various types of N-glycan biosynthesis,hsa01100:Metabolic pathways,hsa04141:Protein processing in endoplasmic reticulum,	615596~Congenital disorder of glycosylation, type Iw, autosomal recessive,619714~Congenital disorder of glycosylation, type Iw, autosomal dominant,				KW-0256~Endoplasmic reticulum,KW-0472~Membrane,	KW-0225~Disease variant,KW-0900~Congenital disorder of glycosylation,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0460~Magnesium,KW-0464~Manganese,KW-0479~Metal-binding,	KW-0328~Glycosyltransferase,KW-0808~Transferase,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) (high mannose) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Oligosaccharyl transferase STT3 N-terminal,MOTIF:DK motif,MOTIF:DXD motif 1,MOTIF:DXD motif 2,MOTIF:SVSE motif,MOTIF:WWDYG motif,REGION:Interacts with target acceptor peptide in protein substrate,SITE:Important for catalytic activity,SITE:Interacts with target acceptor peptide in protein substrate,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
SENP6	SUMO specific peptidase 6(SENP6)	Homo sapiens			GO:0006508~proteolysis,GO:0016925~protein sumoylation,GO:0016926~protein desumoylation,GO:0070646~protein modification by small protein removal,GO:0090169~regulation of spindle assembly,GO:0090234~regulation of kinetochore assembly,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0005515~protein binding,GO:0008234~cysteine-type peptidase activity,GO:0070139~SUMO-specific endopeptidase activity,	IPR003653:Peptidase_C48_C,IPR038765:Papain-like_cys_pep_sf,					KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,				KW-0378~Hydrolase,KW-0645~Protease,KW-0788~Thiol protease,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Ubiquitin-like protease family profile,MUTAGEN:C->S: Abolishes enzymatic activity.,REGION:Disordered,REGION:Protease,
SZRD1	SUZ RNA binding domain containing 1(SZRD1)	Homo sapiens						IPR024642:SUZ-C,IPR024771:SUZ,IPR039228:SZRD1,											KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:SUZ,DOMAIN:SUZ-C,REGION:Disordered,
SMARCA2	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2(SMARCA2)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006338~chromatin remodeling,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007286~spermatid development,GO:0007399~nervous system development,GO:0008284~positive regulation of cell proliferation,GO:0008285~negative regulation of cell proliferation,GO:0030071~regulation of mitotic metaphase/anaphase transition,GO:0030308~negative regulation of cell growth,GO:0045582~positive regulation of T cell differentiation,GO:0045596~negative regulation of cell differentiation,GO:0045597~positive regulation of cell differentiation,GO:0045663~positive regulation of myoblast differentiation,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0070316~regulation of G0 to G1 transition,GO:1902459~positive regulation of stem cell population maintenance,GO:2000045~regulation of G1/S transition of mitotic cell cycle,GO:2000781~positive regulation of double-strand break repair,GO:2000819~regulation of nucleotide-excision repair,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0016514~SWI/SNF complex,GO:0016586~RSC complex,GO:0035060~brahma complex,GO:0043231~intracellular membrane-bounded organelle,GO:0045111~intermediate filament cytoskeleton,GO:0070603~SWI/SNF superfamily-type complex,GO:0071564~npBAF complex,GO:0071565~nBAF complex,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003713~transcription coactivator activity,GO:0004386~helicase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008094~DNA-dependent ATPase activity,GO:0016787~hydrolase activity,GO:0042393~histone binding,	IPR000330:SNF2_N,IPR001487:Bromodomain,IPR001650:Helicase_C,IPR006576:BRK_domain,IPR014001:Helicase_ATP-bd,IPR014012:HSA_dom,IPR014978:Gln-Leu-Gln_QLQ,IPR018359:Bromodomain_CS,IPR027417:P-loop_NTPase,IPR029295:SnAC,IPR036427:Bromodomain-like_sf,IPR037259:BRK_sf,IPR037382:Rsc/polybromo,IPR038718:SNF2-like_sf,	hsa03082:ATP-dependent chromatin remodeling,hsa04714:Thermogenesis,hsa05225:Hepatocellular carcinoma,	601358~Nicolaides-Baraitser syndrome,619293~Blepharophimosis-impaired intellectual development syndrome,		SM00297:BROMO,SM00487:DEXDc,SM00490:HELICc,SM00573:HSA,SM00592:BRK,SM00951:QLQ,SM01314:SnAC,	KW-0524~Neurogenesis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-0991~Intellectual disability,KW-1063~Hypotrichosis,KW-1211~Schizophrenia,	KW-0103~Bromodomain,KW-0732~Signal,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0010~Activator,KW-0238~DNA-binding,KW-0347~Helicase,KW-0378~Hydrolase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Bromo,DOMAIN:HSA,DOMAIN:Helicase ATP-binding,DOMAIN:Helicase C-terminal,DOMAIN:QLQ,MOTIF:DEGH box,REGION:Disordered,
SMARCA5	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 5(SMARCA5)	Homo sapiens			GO:0000183~chromatin silencing at rDNA,GO:0006275~regulation of DNA replication,GO:0006281~DNA repair,GO:0006325~chromatin organization,GO:0006334~nucleosome assembly,GO:0006338~chromatin remodeling,GO:0006352~DNA-templated transcription, initiation,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006974~cellular response to DNA damage stimulus,GO:0016479~negative regulation of transcription from RNA polymerase I promoter,GO:0031062~positive regulation of histone methylation,GO:0031065~positive regulation of histone deacetylation,GO:0031507~heterochromatin assembly,GO:0035066~positive regulation of histone acetylation,GO:0044030~regulation of DNA methylation,GO:0045740~positive regulation of DNA replication,GO:0045943~positive regulation of transcription from RNA polymerase I promoter,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0045945~positive regulation of transcription from RNA polymerase III promoter,GO:1905213~negative regulation of mitotic chromosome condensation,GO:1990830~cellular response to leukemia inhibitory factor,	GO:0000793~condensed chromosome,GO:0001650~fibrillar center,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005677~chromatin silencing complex,GO:0005721~pericentric heterochromatin,GO:0005730~nucleolus,GO:0008623~CHRAC,GO:0016589~NURF complex,GO:0016590~ACF complex,GO:0031213~RSF complex,GO:0035861~site of double-strand break,GO:0043596~nuclear replication fork,GO:0090535~WICH complex,GO:0090536~NoRC complex,	GO:0003677~DNA binding,GO:0004386~helicase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008094~DNA-dependent ATPase activity,GO:0016787~hydrolase activity,GO:0016887~ATPase activity,GO:0031491~nucleosome binding,GO:0042393~histone binding,	IPR000330:SNF2_N,IPR001005:SANT/Myb,IPR001650:Helicase_C,IPR009057:Homeobox-like_sf,IPR014001:Helicase_ATP-bd,IPR015194:ISWI_HAND-dom,IPR015195:SLIDE,IPR017884:SANT_dom,IPR027417:P-loop_NTPase,IPR036306:ISWI_HAND-dom_sf,IPR038718:SNF2-like_sf,	hsa03082:ATP-dependent chromatin remodeling,			SM00487:DEXDc,SM00490:HELICc,SM00717:SANT,	KW-0945~Host-virus interaction,	KW-0158~Chromosome,KW-0539~Nucleus,		KW-0175~Coiled coil,KW-0677~Repeat,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0156~Chromatin regulator,KW-0347~Helicase,KW-0378~Hydrolase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Helicase ATP-binding,DOMAIN:Helicase C-terminal,DOMAIN:SANT,DOMAIN:SANT 1,DOMAIN:SANT 2,MOTIF:DEAH box,MUTAGEN:K->R: Abolishes ATP hydrolysis. Binds to chromatin itself, but abolishes the chromatin binding of the cohesin complex component RAD21.,REGION:Disordered,
SUN2	Sad1 and UNC84 domain containing 2(SUN2)	Homo sapiens			GO:0007052~mitotic spindle organization,GO:0007097~nuclear migration,GO:0021817~nucleokinesis involved in cell motility in cerebral cortex radial glia guided migration,GO:0030335~positive regulation of cell migration,GO:0031022~nuclear migration along microfilament,GO:0051321~meiotic cell cycle,GO:0051642~centrosome localization,GO:0090292~nuclear matrix anchoring at nuclear membrane,	GO:0000781~chromosome, telomeric region,GO:0000794~condensed nuclear chromosome,GO:0005635~nuclear envelope,GO:0005637~nuclear inner membrane,GO:0010008~endosome membrane,GO:0016020~membrane,GO:0031965~nuclear membrane,GO:0034993~LINC complex,	GO:0005515~protein binding,GO:0005521~lamin binding,GO:0008017~microtubule binding,GO:0042802~identical protein binding,GO:0043495~protein anchor,	IPR012919:SUN_dom,IPR040994:Sun_CC2,IPR045119:SUN1-5,					KW-0469~Meiosis,	KW-0472~Membrane,KW-0539~Nucleus,KW-0967~Endosome,		KW-0175~Coiled coil,KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DISULFID:Interchain (with C-6862 in SYNE2),DOMAIN:SUN,MUTAGEN:A->E: Decreases interaction with SYNE2. Disrupts interaction with SYNE2; when associated with E-641 and E-703.,MUTAGEN:C->A: Decreases stability of the SUN2:SYNE2/KASH2 complex under tensile forces and inhibits force transmission through the complex.,MUTAGEN:D->N: Disrupts interaction with SYNE2.,MUTAGEN:G->D: Decreases interaction with SYNE2.,MUTAGEN:H->A: Disrupts interaction with SYNE2.,MUTAGEN:L->D: Disrupts interaction with SYNE2.,MUTAGEN:Missing: Disrupts interaction with SYNE2.,MUTAGEN:S->E: Decreases interaction with SYNE2. Disrupts interaction with SYNE2; when associated with E-603 and E-703.,MUTAGEN:Y->E: Decreases interaction with SYNE2. Disrupts interaction with SYNE2; when associated with E-603 and E-641.,MUTAGEN:Y->F: Disrupts interaction with SYNE2, impairs localization to the nuclear envelope.,REGION:Disordered,REGION:LMNA-binding,REGION:Sufficient for interaction with SYNE1 and SYNE2,TOPO_DOM:Nuclear,TOPO_DOM:Perinuclear space,TRANSMEM:Helical,
SAP18	Sin3A associated protein 18(SAP18)	Homo sapiens			GO:0000381~regulation of alternative mRNA splicing, via spliceosome,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006397~mRNA processing,GO:0008380~RNA splicing,GO:0043065~positive regulation of apoptotic process,GO:0045892~negative regulation of transcription, DNA-templated,GO:0048025~negative regulation of mRNA splicing, via spliceosome,	GO:0000118~histone deacetylase complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0016604~nuclear body,GO:0016607~nuclear speck,GO:0035145~exon-exon junction complex,GO:0061574~ASAP complex,	GO:0003714~transcription corepressor activity,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0008134~transcription factor binding,	IPR010516:SAP18,IPR017250:Hist_deAcase_cplx_SAP18,IPR042534:SAP18_sf,	hsa03013:Nucleocytoplasmic transport,hsa03015:mRNA surveillance pathway,		PIRSF037637:HDAC_SAP18,		KW-0507~mRNA processing,KW-0508~mRNA splicing,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0678~Repressor,	KW-0007~Acetylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),MUTAGEN:D->A: Abolishes splicing regulation activity and interaction with RNPS1 and ACIN1; when associated with A-121.,MUTAGEN:K->A: No effect on splicing regulation activity.,MUTAGEN:T->A: Abolishes splicing regulation activity and interaction with RNPS1 and ACIN1; when associated with A-118.,REGION:Disordered,REGION:Involved in splicing regulation activity,
SLA2	Src like adaptor 2(SLA2)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0019724~B cell mediated immunity,GO:0042110~T cell activation,GO:0046854~phosphatidylinositol phosphorylation,GO:0050776~regulation of immune response,GO:0050849~negative regulation of calcium-mediated signaling,GO:0050851~antigen receptor-mediated signaling pathway,GO:0050860~negative regulation of T cell receptor signaling pathway,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005770~late endosome,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005942~phosphatidylinositol 3-kinase complex,GO:0010008~endosome membrane,GO:0043231~intracellular membrane-bounded organelle,	GO:0005515~protein binding,GO:0035591~signaling adaptor activity,GO:0046935~1-phosphatidylinositol-3-kinase regulator activity,	IPR000980:SH2,IPR001452:SH3_domain,IPR035052:SLAP_SH2,IPR036028:SH3-like_dom_sf,IPR036860:SH2_dom_sf,IPR043539:Grb2-like,				SM00252:SH2,SM00326:SH3,		KW-0472~Membrane,KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,		KW-0727~SH2 domain,KW-0728~SH3 domain,			KW-0449~Lipoprotein,KW-0519~Myristate,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:SH2,DOMAIN:SH3,LIPID:N-myristoyl glycine,MUTAGEN:G->A: Abolishes localization to membranes.,REGION:Disordered,REGION:SLA C-terminal,
SLA	Src like adaptor(SLA)	Homo sapiens			GO:0007165~signal transduction,GO:0043408~regulation of MAPK cascade,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005768~endosome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0008180~COP9 signalosome,	GO:0001784~phosphotyrosine binding,GO:0005154~epidermal growth factor receptor binding,GO:0005515~protein binding,	IPR000980:SH2,IPR001452:SH3_domain,IPR035052:SLAP_SH2,IPR035596:SLAP_SH3,IPR036028:SH3-like_dom_sf,IPR036860:SH2_dom_sf,IPR043539:Grb2-like,				SM00252:SH2,SM00326:SH3,		KW-0963~Cytoplasm,KW-0967~Endosome,		KW-0727~SH2 domain,KW-0728~SH3 domain,			KW-0449~Lipoprotein,KW-0519~Myristate,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:SH2,DOMAIN:SH3,LIPID:N-myristoyl glycine,MUTAGEN:L->S: Abolishes interaction with CBL. Does not affect dimerization; when associated with S-218 and S-224.,MUTAGEN:L->S: Abolishes interaction with CBL. Does not affect dimerization; when associated with S-218 and S-229.,MUTAGEN:L->S: Abolishes interaction with CBL. Does not affect dimerization; when associated with S-224 and S-229.,MUTAGEN:LSL->QSQ: Abolishes interaction with CBL. Slightly affects dimerization.,MUTAGEN:R->K: Strongly reduces interaction with ZAP70, CD3Z, SYK and LAT.,REGION:Disordered,REGION:SLA C-terminal,
STARD7	StAR related lipid transfer domain containing 7(STARD7)	Homo sapiens				GO:0005741~mitochondrial outer membrane,	GO:0005515~protein binding,GO:0008289~lipid binding,	IPR002913:START_lipid-bd_dom,IPR023393:START-like_dom_sf,IPR041949:START_STARD7,		607876~Epilepsy, familial adult myoclonic, 2,		SM00234:START,		KW-0496~Mitochondrion,		KW-0175~Coiled coil,KW-0809~Transit peptide,				COMPBIAS:Polar residues,DOMAIN:START,REGION:Disordered,SITE:Cleavage; by PARL,TRANSIT:Mitochondrion,
TRAC	T cell receptor alpha constant(TRAC)	Homo sapiens	124.GH-IGF1_thymopoiesis,150.caspase_and_NFKB_activation,3.T_cell_receptor,5.B7_CD40_B-cell_activa,50.Hypothesis_of_bronchial_asthma,54.T-cell_anergy,55.Allergen_recognition_by_Th2_or_Th0_cell,63.LAT_couples_T-cell_receptor,67.Ikaros_and_signaling_inhibitors,80.T_cell_Activation,81.Structure_of_Caps_and_SMACs,		GO:0002250~adaptive immune response,GO:0009617~response to bacterium,GO:0046631~alpha-beta T cell activation,GO:0050852~T cell receptor signaling pathway,	GO:0005886~plasma membrane,GO:0016020~membrane,GO:0042105~alpha-beta T cell receptor complex,		IPR013783:Ig-like_fold,IPR015370:TCR_alpha_C,IPR036179:Ig-like_dom_sf,		615387~Immunodeficiency 7, TCR-alpha/beta deficient,			KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-1003~Cell membrane,KW-1279~T cell receptor,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DISULFID:Interchain (with C-130 in TRBC1 or TRBC2),DOMAIN:Ig-like C1-type,DOMAIN:T-cell receptor alpha chain constant,MUTAGEN:N->L,F: Impairs TR-CD3 complex assembly.,REGION:Connecting peptide,TOPO_DOM:Cytoplasmic,TRANSMEM:Helical,
TRAT1	T cell receptor associated transmembrane adaptor 1(TRAT1)	Homo sapiens			GO:0001920~negative regulation of receptor recycling,GO:0002250~adaptive immune response,GO:0006968~cellular defense response,GO:0007165~signal transduction,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0050850~positive regulation of calcium-mediated signaling,GO:0050862~positive regulation of T cell receptor signaling pathway,GO:0051051~negative regulation of transport,	GO:0005886~plasma membrane,GO:0034451~centriolar satellite,GO:0042101~T cell receptor complex,GO:0072686~mitotic spindle,	GO:0005068~transmembrane receptor protein tyrosine kinase adaptor activity,GO:0005515~protein binding,	IPR020399:T-cell_rcpt-assoc_TM_adapter-1,					KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DISULFID:Interchain,MUTAGEN:Y->F: Abolishes interaction with PIK3R1.,REGION:Disordered,REGION:Interaction with PIK3R1,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical; Signal-anchor for type III membrane protein,
TRBC1	T cell receptor beta constant 1(TRBC1)	Homo sapiens			GO:0002250~adaptive immune response,GO:0006955~immune response,GO:0046631~alpha-beta T cell activation,GO:0050852~T cell receptor signaling pathway,	GO:0005886~plasma membrane,GO:0016020~membrane,GO:0042105~alpha-beta T cell receptor complex,		IPR003597:Ig_C1-set,IPR007110:Ig-like_dom,IPR013783:Ig-like_fold,IPR036179:Ig-like_dom_sf,				SM00407:IGc1,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-1003~Cell membrane,KW-1279~T cell receptor,		KW-0393~Immunoglobulin domain,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DISULFID:Interchain (with C-94 in TRAC),DOMAIN:Ig-like,DOMAIN:Ig-like C1-type,MUTAGEN:Q->F: Impairs signal transduction in response to antigenic stimulation.,MUTAGEN:V->F: Reduces TR-CD3 complex assembly.,REGION:Connecting peptide,TOPO_DOM:Cytoplasmic,TRANSMEM:Helical,
TBK1	TANK binding kinase 1(TBK1)	Homo sapiens			GO:0002218~activation of innate immune response,GO:0002753~cytoplasmic pattern recognition receptor signaling pathway,GO:0006468~protein phosphorylation,GO:0006954~inflammatory response,GO:0007249~I-kappaB kinase/NF-kappaB signaling,GO:0009615~response to virus,GO:0010508~positive regulation of autophagy,GO:0010629~negative regulation of gene expression,GO:0016239~positive regulation of macroautophagy,GO:0018105~peptidyl-serine phosphorylation,GO:0018107~peptidyl-threonine phosphorylation,GO:0032479~regulation of type I interferon production,GO:0032481~positive regulation of type I interferon production,GO:0032727~positive regulation of interferon-alpha production,GO:0032728~positive regulation of interferon-beta production,GO:0033138~positive regulation of peptidyl-serine phosphorylation,GO:0034142~toll-like receptor 4 signaling pathway,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0044565~dendritic cell proliferation,GO:0045087~innate immune response,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0050830~defense response to Gram-positive bacterium,GO:0051607~defense response to virus,GO:0060337~type I interferon signaling pathway,GO:0060340~positive regulation of type I interferon-mediated signaling pathway,GO:1904262~negative regulation of TORC1 signaling,GO:1904263~positive regulation of TORC1 signaling,GO:1904417~positive regulation of xenophagy,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0043231~intracellular membrane-bounded organelle,GO:1902554~serine/threonine protein kinase complex,	GO:0003676~nucleic acid binding,GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0019903~protein phosphatase binding,GO:0042802~identical protein binding,GO:0051219~phosphoprotein binding,	IPR000719:Prot_kinase_dom,IPR001245:Ser-Thr/Tyr_kinase_cat_dom,IPR011009:Kinase-like_dom_sf,IPR017441:Protein_kinase_ATP_BS,IPR041087:TBK1_ULD,IPR041309:TBK1_CCD1,	hsa04014:Ras signaling pathway,hsa04137:Mitophagy - animal,hsa04140:Autophagy - animal,hsa04620:Toll-like receptor signaling pathway,hsa04621:NOD-like receptor signaling pathway,hsa04622:RIG-I-like receptor signaling pathway,hsa04623:Cytosolic DNA-sensing pathway,hsa04657:IL-17 signaling pathway,hsa04936:Alcoholic liver disease,hsa05014:Amyotrophic lateral sclerosis,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05131:Shigellosis,hsa05135:Yersinia infection,hsa05160:Hepatitis C,hsa05161:Hepatitis B,hsa05162:Measles,hsa05163:Human cytomegalovirus infection,hsa05164:Influenza A,hsa05165:Human papillomavirus infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05171:Coronavirus disease - COVID-19,hsa05417:Lipid and atherosclerosis,	616439~Frontotemporal dementia and/or amyotrophic lateral sclerosis 4,617900~Encephalopathy, acute, infection-induced (herpes-specific), susceptibility to, 8,		SM00220:S_TKc,	KW-0051~Antiviral defense,KW-0391~Immunity,KW-0399~Innate immunity,KW-0945~Host-virus interaction,	KW-0963~Cytoplasm,	KW-0036~Amyotrophic lateral sclerosis,KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0955~Glaucoma,	KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	ACT_SITE:Proton acceptor,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:Protein kinase,DOMAIN:TANK binding kinase 1 ubiquitin-like,DOMAIN:TANK-binding kinase 1 coiled-coil,DOMAIN:Ubiquitin-like,MUTAGEN:D->A: Decreases phosphorylation and kinase activity.,MUTAGEN:D->N: Loss of kinase activity.,MUTAGEN:E->A: Decreases kinase activity.,MUTAGEN:E->R: Decreases phosphorylation and kinase activity. Abolishes dimerization; when associated with A-357 or R-448.,MUTAGEN:E->R: Decreases phosphorylation and kinase activity. Abolishes dimerization; when associated with R-355.,MUTAGEN:F->E: Abolishes dimerization and decreases kinase activity but no effect on phosphorylation; when associated with E-459 and E-466.,MUTAGEN:H->E: Abolishes dimerization and decreases kinase activity but no effect on phosphorylation; when associated with E-466 and E-470.,MUTAGEN:I->A: Decreases kinase activity.,MUTAGEN:I->E: Abolishes dimerization and decreases kinase activity but no effect on phosphorylation; when associated with E-459 and E-470.,MUTAGEN:K->A: Loss of kinase activity.,MUTAGEN:K->D: Decreases phosphorylation and kinase activity.,MUTAGEN:K->E: Strongly decreases interaction with TANK and TBKBP1. No effect on phosphorylation.,MUTAGEN:K->R: Abrogates both 'Lys-48'-linked and 'Lys-33'-linked ubiquitination.,MUTAGEN:K->R: Decreases ubiquitination. Abolishes ubiquitination, phosphorylation and kinase activity; when associated with R-30.,MUTAGEN:K->R: Decreases ubiquitination. Abolishes ubiquitination, phosphorylation and kinase activity; when associated with R-401.,MUTAGEN:L->A: Almost abolishes interaction with TANK.,MUTAGEN:L->A: Strongly decreases interaction with AZI2, TANK and TBKBP1. No effect on phosphorylation.,MUTAGEN:L->E: Decreases kinase activity. No effect on phosphorylation.,MUTAGEN:M->A: Decreases interaction with TANK.,MUTAGEN:N->A: Decreases interaction with TANK.,MUTAGEN:N->A: Reduced phosphorylation of STING1.,MUTAGEN:Q->A: Reduced phosphorylation of STING1.,MUTAGEN:R->A: Decreases phosphorylation and kinase activity. Abolishes dimerization; when associated with R-355.,MUTAGEN:R->D: Decreases phosphorylation and kinase activity. Abolishes dimerization.,MUTAGEN:S->A: Loss of kinase activity. No effect on dimerization. Loss of USP38-mediated degradation.,MUTAGEN:S->E: Decreased kinase activity.,MUTAGEN:Y->A: Decreases kinase activity. Reduced phosphorylation of STING1.,MUTAGEN:Y->E: Abolishes phosphorylation and kinase activity.,REGION:Disordered,REGION:Interaction with AZI2, TANK and TBKBP1,
TAOK3	TAO kinase 3(TAOK3)	Homo sapiens			GO:0000165~MAPK cascade,GO:0006281~DNA repair,GO:0006468~protein phosphorylation,GO:0006974~cellular response to DNA damage stimulus,GO:0007095~mitotic G2 DNA damage checkpoint,GO:0016310~phosphorylation,GO:0032874~positive regulation of stress-activated MAPK cascade,GO:0043408~regulation of MAPK cascade,GO:0043507~positive regulation of JUN kinase activity,GO:0046329~negative regulation of JNK cascade,GO:0046330~positive regulation of JNK cascade,GO:0046777~protein autophosphorylation,GO:0048812~neuron projection morphogenesis,	GO:0005737~cytoplasm,GO:0005886~plasma membrane,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004860~protein kinase inhibitor activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016301~kinase activity,GO:0016740~transferase activity,	IPR000719:Prot_kinase_dom,IPR008271:Ser/Thr_kinase_AS,IPR011009:Kinase-like_dom_sf,IPR017441:Protein_kinase_ATP_BS,	hsa04010:MAPK signaling pathway,			SM00220:S_TKc,	KW-0227~DNA damage,KW-0234~DNA repair,	KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Protein kinase,MUTAGEN:D->A: Loss of serine/threonine-protein kinase activity.,MUTAGEN:S->A: Inhibits activation of the p38/MAPK14 stress-activated MAPK cascade in response to DNA damage.,MUTAGEN:T->A: No autophosphorylation and no kinase activity; when associated with F-183.,MUTAGEN:Y->F: No autophosphorylation and no kinase activity; when associated with A-181.,REGION:Disordered,
TMF1	TATA element modulatory factor 1(TMF1)	Homo sapiens			GO:0001675~acrosome assembly,GO:0001819~positive regulation of cytokine production,GO:0007289~spermatid nucleus differentiation,GO:0010629~negative regulation of gene expression,GO:0030317~flagellated sperm motility,GO:0030521~androgen receptor signaling pathway,GO:0032275~luteinizing hormone secretion,GO:0033327~Leydig cell differentiation,GO:0042742~defense response to bacterium,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0061136~regulation of proteasomal protein catabolic process,GO:1904019~epithelial cell apoptotic process,GO:1904036~negative regulation of epithelial cell apoptotic process,GO:2000845~positive regulation of testosterone secretion,	GO:0000139~Golgi membrane,GO:0005634~nucleus,GO:0005783~endoplasmic reticulum,GO:0005794~Golgi apparatus,GO:0005829~cytosol,	GO:0003677~DNA binding,GO:0005515~protein binding,GO:0030374~ligand-dependent nuclear receptor transcription coactivator activity,GO:0050681~androgen receptor binding,	IPR022091:TMF_TATA-bd,IPR022092:TMF_DNA-bd,					KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,		KW-0238~DNA-binding,KW-0678~Repressor,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:TATA element modulatory factor 1 TATA binding,MUTAGEN:SLD->AAA: Strongly reduced the ubiquitination directing activity of the protein.,REGION:Disordered,REGION:Interaction with Elongin BC complex,
TAF12	TATA-box binding protein associated factor 12(TAF12)	Homo sapiens			GO:0006282~regulation of DNA repair,GO:0006352~DNA-templated transcription, initiation,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0006367~transcription initiation from RNA polymerase II promoter,GO:0042789~mRNA transcription from RNA polymerase II promoter,GO:0043484~regulation of RNA splicing,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051123~RNA polymerase II transcriptional preinitiation complex assembly,GO:0060261~positive regulation of transcription initiation from RNA polymerase II promoter,	GO:0000124~SAGA complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005669~transcription factor TFIID complex,GO:0033276~transcription factor TFTC complex,GO:0046695~SLIK (SAGA-like) complex,	GO:0003677~DNA binding,GO:0003713~transcription coactivator activity,GO:0005515~protein binding,GO:0017025~TBP-class protein binding,GO:0046982~protein heterodimerization activity,	IPR003228:TFIID_TAF12_dom,IPR009072:Histone-fold,IPR037794:TAF12,	hsa03022:Basal transcription factors,				KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,					KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Histone-fold,DOMAIN:Transcription initiation factor TFIID subunit 12,MUTAGEN:ACQLA->RCQLR: Drastically reduces binding to TAF4.,MUTAGEN:IADDF->EADDK: Drastically reduces binding to TAF4.,MUTAGEN:VV->EK: Drastically reduces binding to TAF4.,REGION:Disordered,
TAF15	TATA-box binding protein associated factor 15(TAF15)	Homo sapiens			GO:0006355~regulation of transcription, DNA-templated,GO:0008380~RNA splicing,GO:0045893~positive regulation of transcription, DNA-templated,GO:0048255~mRNA stabilization,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,	GO:0003677~DNA binding,GO:0003712~transcription cofactor activity,GO:0003723~RNA binding,GO:0003730~mRNA 3'-UTR binding,GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR000504:RRM_dom,IPR001876:Znf_RanBP2,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR034870:TET_fam,IPR035979:RBD_domain_sf,IPR036443:Znf_RanBP2_sf,	hsa03022:Basal transcription factors,hsa05202:Transcriptional misregulation in cancer,	612237~Chondrosarcoma, extraskeletal myxoid,		SM00360:RRM,SM00547:ZnF_RBZ,		KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0656~Proto-oncogene,	KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0013~ADP-ribosylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:RRM,DOMAIN:RanBP2-type,REGION:21 X approximate tandem repeats of D-R-[S,G](0,3)-G-G-Y-G-G,REGION:Disordered,REPEAT:1,REPEAT:10,REPEAT:11,REPEAT:12,REPEAT:13,REPEAT:14,REPEAT:15,REPEAT:16,REPEAT:17,REPEAT:18,REPEAT:19,REPEAT:2,REPEAT:20,REPEAT:21,REPEAT:3,REPEAT:4,REPEAT:5,REPEAT:6,REPEAT:7,REPEAT:8,REPEAT:9,ZN_FING:RanBP2-type,
TAF3	TATA-box binding protein associated factor 3(TAF3)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0042789~mRNA transcription from RNA polymerase II promoter,GO:0043433~negative regulation of sequence-specific DNA binding transcription factor activity,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051123~RNA polymerase II transcriptional preinitiation complex assembly,GO:0051457~maintenance of protein location in nucleus,GO:0060261~positive regulation of transcription initiation from RNA polymerase II promoter,	GO:0001673~male germ cell nucleus,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005669~transcription factor TFIID complex,GO:0031965~nuclear membrane,	GO:0002039~p53 binding,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:0046872~metal ion binding,GO:0046982~protein heterodimerization activity,	IPR001965:Znf_PHD,IPR006565:BTP,IPR009072:Histone-fold,IPR011011:Znf_FYVE_PHD,IPR013083:Znf_RING/FYVE/PHD,IPR019786:Zinc_finger_PHD-type_CS,IPR019787:Znf_PHD-finger,	hsa03022:Basal transcription factors,			SM00249:PHD,SM00576:BTP,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Bromodomain associated,DOMAIN:PHD-type,MUTAGEN:W->R: Loss of interaction with TAF10.,REGION:Disordered,ZN_FING:PHD-type,
TAF9	TATA-box binding protein associated factor 9(TAF9)	Homo sapiens			GO:0000492~box C/D snoRNP assembly,GO:0006282~regulation of DNA repair,GO:0006338~chromatin remodeling,GO:0006352~DNA-templated transcription, initiation,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006974~cellular response to DNA damage stimulus,GO:0032435~negative regulation of proteasomal ubiquitin-dependent protein catabolic process,GO:0042789~mRNA transcription from RNA polymerase II promoter,GO:0043066~negative regulation of apoptotic process,GO:0043484~regulation of RNA splicing,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0050821~protein stabilization,GO:0051123~RNA polymerase II transcriptional preinitiation complex assembly,GO:0060261~positive regulation of transcription initiation from RNA polymerase II promoter,GO:0060760~positive regulation of response to cytokine stimulus,GO:0070555~response to interleukin-1,GO:1902065~response to L-glutamate,GO:1902166~negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator,	GO:0000124~SAGA complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005669~transcription factor TFIID complex,GO:0033276~transcription factor TFTC complex,GO:0070761~pre-snoRNP complex,GO:0071339~MLL1 complex,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0002039~p53 binding,GO:0003677~DNA binding,GO:0003713~transcription coactivator activity,GO:0004402~histone acetyltransferase activity,GO:0005515~protein binding,GO:0046982~protein heterodimerization activity,GO:0051117~ATPase binding,GO:0070742~C2H2 zinc finger domain binding,	IPR003162:TFIID-31,IPR009072:Histone-fold,	hsa03022:Basal transcription factors,				KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	REGION:Disordered,
TAF1D	TATA-box binding protein associated factor, RNA polymerase I subunit D(TAF1D)	Homo sapiens			GO:0006355~regulation of transcription, DNA-templated,	GO:0005654~nucleoplasm,GO:0005668~RNA polymerase transcription factor SL1 complex,GO:0005730~nucleolus,GO:0005829~cytosol,GO:0034451~centriolar satellite,GO:0072686~mitotic spindle,	GO:0003677~DNA binding,GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR027976:TAF1D,					KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0238~DNA-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,REGION:Disordered,
TBPL1	TATA-box binding protein like 1(TBPL1)	Homo sapiens			GO:0001675~acrosome assembly,GO:0006235~dTTP biosynthetic process,GO:0006352~DNA-templated transcription, initiation,GO:0006366~transcription from RNA polymerase II promoter,GO:0007289~spermatid nucleus differentiation,	GO:0001673~male germ cell nucleus,GO:0005672~transcription factor TFIIA complex,GO:0005737~cytoplasm,	GO:0000979~RNA polymerase II core promoter sequence-specific DNA binding,GO:0003677~DNA binding,GO:0005515~protein binding,	IPR000814:TBP,IPR012295:TBP_dom_sf,IPR015445:TBP-like,	hsa03022:Basal transcription factors,hsa05016:Huntington disease,hsa05017:Spinocerebellar ataxia,hsa05165:Human papillomavirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05203:Viral carcinogenesis,				KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0238~DNA-binding,
TBC1D10C	TBC1 domain family member 10C(TBC1D10C)	Homo sapiens			GO:0033173~calcineurin-NFAT signaling cascade,GO:0042113~B cell activation,GO:0042147~retrograde transport, endosome to Golgi,GO:0050869~negative regulation of B cell activation,GO:0070371~ERK1 and ERK2 cascade,GO:0070373~negative regulation of ERK1 and ERK2 cascade,GO:0070885~negative regulation of calcineurin-NFAT signaling cascade,GO:0090630~activation of GTPase activity,	GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0031527~filopodium membrane,GO:0101003~ficolin-1-rich granule membrane,	GO:0005096~GTPase activator activity,GO:0005515~protein binding,	IPR000195:Rab-GAP-TBC_dom,IPR035969:Rab-GAP_TBC_sf,				SM00164:TBC,						KW-0343~GTPase activation,		COMPBIAS:Polar residues,DOMAIN:Rab-GAP TBC,MUTAGEN:R->A: Loss of GAP activity.,REGION:Disordered,REGION:Interaction with calcineurin,SITE:Arginine finger,SITE:Glutamine finger,
TBC1D4	TBC1 domain family member 4(TBC1D4)	Homo sapiens			GO:0016192~vesicle-mediated transport,GO:0031339~negative regulation of vesicle fusion,GO:0032869~cellular response to insulin stimulus,GO:0090630~activation of GTPase activity,	GO:0005829~cytosol,GO:0031982~vesicle,	GO:0005096~GTPase activator activity,GO:0005515~protein binding,	IPR000195:Rab-GAP-TBC_dom,IPR006020:PTB/PI_dom,IPR011993:PH-like_dom_sf,IPR021785:DUF3350,IPR035969:Rab-GAP_TBC_sf,	hsa04919:Thyroid hormone signaling pathway,hsa04931:Insulin resistance,hsa05415:Diabetic cardiomyopathy,	616087~Diabetes mellitus, noninsulin-dependent, 5,		SM00164:TBC,SM00462:PTB,		KW-0963~Cytoplasm,	KW-0219~Diabetes mellitus,	KW-0175~Coiled coil,KW-0677~Repeat,		KW-0343~GTPase activation,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:PID,DOMAIN:PID 1,DOMAIN:PID 2,DOMAIN:Rab-GAP TBC,MUTAGEN:R->K: Loss of Rab GTPase activation. Only 20% reduction of GLUT4 translocation; even when associated with A-318; A-588; A-642 and A-751.,MUTAGEN:S->A: 80% reduction of insulin-stimulated GLUT4 translocation; when associated with A-318; A-588 and A-642.,MUTAGEN:S->A: 80% reduction of insulin-stimulated GLUT4 translocation; when associated with A-318; A-642 and A-751.,MUTAGEN:S->A: 80% reduction of insulin-stimulated GLUT4 translocation; when associated with A-588; A-642 and A-751.,MUTAGEN:T->A: 80% reduction of insulin-stimulated GLUT4 translocation; when associated with A-318; A-588 and A-751.,REGION:Disordered,
TIPARP	TCDD inducible poly(ADP-ribose) polymerase(TIPARP)	Homo sapiens			GO:0001570~vasculogenesis,GO:0001822~kidney development,GO:0006807~nitrogen compound metabolic process,GO:0008209~androgen metabolic process,GO:0008210~estrogen metabolic process,GO:0008585~female gonad development,GO:0009791~post-embryonic development,GO:0010629~negative regulation of gene expression,GO:0030097~hemopoiesis,GO:0045732~positive regulation of protein catabolic process,GO:0048008~platelet-derived growth factor receptor signaling pathway,GO:0048705~skeletal system morphogenesis,GO:0048745~smooth muscle tissue development,GO:0060021~palate development,GO:0060325~face morphogenesis,GO:0071407~cellular response to organic cyclic compound,GO:1904612~response to 2,3,7,8-tetrachlorodibenzodioxine,	GO:0005634~nucleus,	GO:0000987~core promoter proximal region sequence-specific DNA binding,GO:0003950~NAD+ ADP-ribosyltransferase activity,GO:0016779~nucleotidyltransferase activity,GO:0046872~metal ion binding,GO:1990404~protein ADP-ribosylase activity,	IPR000571:Znf_CCCH,IPR004170:WWE-dom,IPR012317:Poly(ADP-ribose)pol_cat_dom,IPR037197:WWE_dom_sf,						KW-0539~Nucleus,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0520~NAD,KW-0862~Zinc,	KW-0328~Glycosyltransferase,KW-0548~Nucleotidyltransferase,KW-0808~Transferase,	KW-0013~ADP-ribosylation,	DOMAIN:C3H1-type,DOMAIN:PARP catalytic,DOMAIN:WWE,MOTIF:Nuclear localization signal,MUTAGEN:C->A: Relocalization to the cytosol.,MUTAGEN:C->A: Slight reduction of auto-mono-ADP-ribosylation.,MUTAGEN:H->A: Abolishes ADP-ribosyltransferase activity.,MUTAGEN:I->A: Does not affect ADP-ribosyltransferase activity.,MUTAGEN:K->A: Partial relocalization to the cytoplasm.,MUTAGEN:Y->A: Abolishes ADP-ribosyltransferase activity.,REGION:Disordered,ZN_FING:C3H1-type,
TINF2	TERF1 interacting nuclear factor 2(TINF2)	Homo sapiens			GO:0010836~negative regulation of protein ADP-ribosylation,GO:0016233~telomere capping,GO:0032202~telomere assembly,GO:0032206~positive regulation of telomere maintenance,GO:0032211~negative regulation of telomere maintenance via telomerase,GO:0050680~negative regulation of epithelial cell proliferation,GO:0070198~protein localization to chromosome, telomeric region,GO:1904356~regulation of telomere maintenance via telomere lengthening,	GO:0000781~chromosome, telomeric region,GO:0000783~nuclear telomere cap complex,GO:0005654~nucleoplasm,GO:0010370~perinucleolar chromocenter,GO:0016363~nuclear matrix,GO:0016604~nuclear body,GO:0070187~shelterin complex,	GO:0005515~protein binding,GO:0042162~telomeric DNA binding,	IPR029400:TINF2_N,IPR039098:TINF2,		268130~Revesz syndrome,613990~Dyskeratosis congenita, autosomal dominant 3,				KW-0158~Chromosome,KW-0539~Nucleus,KW-0779~Telomere,	KW-0225~Disease variant,KW-1011~Dyskeratosis congenita,				KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:TERF1-interacting nuclear factor 2 N-terminal,MOTIF:Nuclear localization signal,MOTIF:TBM,MUTAGEN:F->A: Abolishes interaction with TERF1.,MUTAGEN:P->A: Does not effect interaction with TERF1.,REGION:Disordered,
TERF2IP	TERF2 interacting protein(TERF2IP)	Homo sapiens			GO:0000723~telomere maintenance,GO:0001933~negative regulation of protein phosphorylation,GO:0006355~regulation of transcription, DNA-templated,GO:0007004~telomere maintenance via telomerase,GO:0010569~regulation of double-strand break repair via homologous recombination,GO:0010833~telomere maintenance via telomere lengthening,GO:0016233~telomere capping,GO:0031848~protection from non-homologous end joining at telomere,GO:0032204~regulation of telomere maintenance,GO:0032205~negative regulation of telomere maintenance,GO:0032206~positive regulation of telomere maintenance,GO:0035556~intracellular signal transduction,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0048239~negative regulation of DNA recombination at telomere,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0070198~protein localization to chromosome, telomeric region,GO:1901224~positive regulation of NIK/NF-kappaB signaling,	GO:0000228~nuclear chromosome,GO:0000781~chromosome, telomeric region,GO:0000783~nuclear telomere cap complex,GO:0001673~male germ cell nucleus,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0016604~nuclear body,GO:0070187~shelterin complex,	GO:0005515~protein binding,GO:0019902~phosphatase binding,GO:0042162~telomeric DNA binding,GO:0098505~G-rich strand telomeric DNA binding,	IPR001357:BRCT_dom,IPR009057:Homeobox-like_sf,IPR015010:Rap1_Myb_dom,IPR021661:Rap1_C,IPR036420:BRCT_dom_sf,IPR038104:Rap1_C_sf,IPR039595:TE2IP/Rap1,					KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0158~Chromosome,KW-0539~Nucleus,KW-0779~Telomere,KW-0963~Cytoplasm,				KW-0010~Activator,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:BRCT,DOMAIN:Myb-like,DOMAIN:Rap1 Myb,MOTIF:Nuclear localization signal,REGION:Disordered,
TAB2	TGF-beta activated kinase 1 (MAP3K7) binding protein 2(TAB2)	Homo sapiens		h_tollPathway:Toll-Like Receptor Pathway,	GO:0006954~inflammatory response,GO:0007507~heart development,GO:0010507~negative regulation of autophagy,GO:0016310~phosphorylation,GO:0032496~response to lipopolysaccharide,GO:0038061~NIK/NF-kappaB signaling,GO:0042742~defense response to bacterium,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0045860~positive regulation of protein kinase activity,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005765~lysosomal membrane,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0010008~endosome membrane,	GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0016301~kinase activity,GO:0043130~ubiquitin binding,GO:0046872~metal ion binding,GO:0060090~binding, bridging,GO:0070530~K63-linked polyubiquitin binding,	IPR001876:Znf_RanBP2,IPR003892:CUE,IPR036443:Znf_RanBP2_sf,IPR041911:TAB2/3_CUE,	hsa04010:MAPK signaling pathway,hsa04064:NF-kappa B signaling pathway,hsa04380:Osteoclast differentiation,hsa04620:Toll-like receptor signaling pathway,hsa04621:NOD-like receptor signaling pathway,hsa04657:IL-17 signaling pathway,hsa04668:TNF signaling pathway,hsa04936:Alcoholic liver disease,hsa05130:Pathogenic Escherichia coli infection,hsa05131:Shigellosis,hsa05132:Salmonella infection,hsa05135:Yersinia infection,hsa05140:Leishmaniasis,hsa05145:Toxoplasmosis,hsa05161:Hepatitis B,hsa05162:Measles,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05171:Coronavirus disease - COVID-19,hsa05417:Lipid and atherosclerosis,	614980~Congenital heart defects, nonsyndromic, 2,		SM00546:CUE,SM00547:ZnF_RBZ,		KW-0458~Lysosome,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0967~Endosome,	KW-0225~Disease variant,	KW-0175~Coiled coil,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0418~Kinase,KW-0808~Transferase,	KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:CUE,DOMAIN:RanBP2-type,MUTAGEN:C->L,M: Abolished Cys methylation and ability to bind 'Lys-63'-linked ubiquitin.,MUTAGEN:C->S: Disrupted zinc-finger; abolished methylation at C-673.,MUTAGEN:E->A: Abolishes ubiquitin binding.,MUTAGEN:F->A: Abolishes ubiquitin binding.,MUTAGEN:H->A: Abolishes ubiquitin binding.,MUTAGEN:K->R: Loss of TRIM35-mediated ubiquitination.,MUTAGEN:K->R: Loss of TRIM60-mediated SUMOylation; when associated with R-329.,MUTAGEN:K->R: Loss of TRIM60-mediated SUMOylation; when associated with R-562.,MUTAGEN:L->A: Abolishes ubiquitin binding.,REGION:Disordered,REGION:Interaction with polyubiquitin,ZN_FING:RanBP2-type,
TGIF1	TGFB induced factor homeobox 1(TGIF1)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006355~regulation of transcription, DNA-templated,GO:0009410~response to xenobiotic stimulus,GO:0010629~negative regulation of gene expression,GO:0071363~cellular response to growth factor stimulus,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0070410~co-SMAD binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeobox_dom,IPR008422:Homeobox_KN_domain,IPR009057:Homeobox-like_sf,	hsa04350:TGF-beta signaling pathway,	142946~Holoprosencephaly 4,		SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-0370~Holoprosencephaly,	KW-0371~Homeobox,		KW-0238~DNA-binding,KW-0678~Repressor,		COMPBIAS:Polar residues,DNA_BIND:Homeobox,DNA_BIND:Homeobox; TALE-type,DOMAIN:Homeobox,DOMAIN:Homeobox KN,MOTIF:CTBP-binding motif,REGION:Disordered,
THAP7	THAP domain containing 7(THAP7)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006325~chromatin organization,GO:0006355~regulation of transcription, DNA-templated,GO:0045892~negative regulation of transcription, DNA-templated,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0016607~nuclear speck,GO:0031965~nuclear membrane,GO:0043231~intracellular membrane-bounded organelle,	GO:0001222~transcription corepressor binding,GO:0003677~DNA binding,GO:0005515~protein binding,GO:0035064~methylated histone binding,GO:0042393~histone binding,GO:0042802~identical protein binding,GO:0042826~histone deacetylase binding,GO:0046872~metal ion binding,GO:0070577~lysine-acetylated histone binding,GO:0070742~C2H2 zinc finger domain binding,	IPR006612:THAP_Znf,IPR026519:THAP7,				SM00692:DM3,SM00980:THAP,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0158~Chromosome,KW-0539~Nucleus,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,	KW-0597~Phosphoprotein,	MOTIF:HCFC1-binding motif (HBM),REGION:Disordered,ZN_FING:THAP-type,
THOC7	THO complex subunit 7(THOC7)	Homo sapiens			GO:0006397~mRNA processing,GO:0006406~mRNA export from nucleus,GO:0008380~RNA splicing,GO:0046784~viral mRNA export from host cell nucleus,	GO:0000346~transcription export complex,GO:0000347~THO complex,GO:0000445~THO complex part of transcription export complex,GO:0000781~chromosome, telomeric region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016607~nuclear speck,	GO:0003723~RNA binding,GO:0005515~protein binding,	IPR008501:THOC7/Mft1,	hsa03013:Nucleocytoplasmic transport,				KW-0507~mRNA processing,KW-0508~mRNA splicing,KW-0509~mRNA transport,KW-0813~Transport,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,		KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	REGION:Disordered,REGION:Interaction with NIF3L1,REGION:Interaction with THOC5,
THUMPD1	THUMP domain containing 1(THUMPD1)	Homo sapiens			GO:0006400~tRNA modification,	GO:0005654~nucleoplasm,	GO:0003723~RNA binding,GO:0005515~protein binding,	IPR004114:THUMP_dom,IPR040183:THUMPD1-like,		619989~Neurodevelopmental disorder with speech delay and variable ocular anomalies,		SM00981:THUMP,			KW-0225~Disease variant,KW-0991~Intellectual disability,			KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:THUMP,REGION:Disordered,
TIAL1	TIA1 cytotoxic granule associated RNA binding protein like 1(TIAL1)	Homo sapiens		h_WNVpathway:West Nile Virus,	GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006915~apoptotic process,GO:0006952~defense response,GO:0007281~germ cell development,GO:0008285~negative regulation of cell proliferation,GO:0017145~stem cell division,GO:0035332~positive regulation of hippo signaling,GO:0072089~stem cell proliferation,GO:2000637~positive regulation of gene silencing by miRNA,GO:2000648~positive regulation of stem cell proliferation,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005764~lysosome,GO:0005829~cytosol,GO:0010494~cytoplasmic stress granule,GO:0044194~cytolytic granule,	GO:0003677~DNA binding,GO:0003723~RNA binding,GO:0003730~mRNA 3'-UTR binding,GO:0005515~protein binding,GO:0035925~mRNA 3'-UTR AU-rich region binding,	IPR000504:RRM_dom,IPR003954:RRM_dom_euk,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR034492:TIAR_RRM1,IPR034494:TIAR_RRM2,IPR034496:TIAR_RRM3,IPR035979:RBD_domain_sf,				SM00360:RRM,SM00361:RRM_1,	KW-0053~Apoptosis,	KW-0458~Lysosome,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,		KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:RRM,DOMAIN:RRM 1,DOMAIN:RRM 2,DOMAIN:RRM 3,REGION:Disordered,
TIMP1	TIMP metallopeptidase inhibitor 1(TIMP1)	Homo sapiens		h_reckPathway:Inhibition of Matrix Metalloproteinases,	GO:0002248~connective tissue replacement involved in inflammatory response wound healing,GO:0007165~signal transduction,GO:0008284~positive regulation of cell proliferation,GO:0009725~response to hormone,GO:0010951~negative regulation of endopeptidase activity,GO:0034097~response to cytokine,GO:0043066~negative regulation of apoptotic process,GO:0043086~negative regulation of catalytic activity,GO:0043434~response to peptide hormone,GO:0051045~negative regulation of membrane protein ectodomain proteolysis,GO:0051216~cartilage development,GO:0071492~cellular response to UV-A,GO:1901164~negative regulation of trophoblast cell migration,GO:1905049~negative regulation of metallopeptidase activity,GO:2001044~regulation of integrin-mediated signaling pathway,	GO:0005576~extracellular region,GO:0005581~collagen trimer,GO:0005604~basement membrane,GO:0005615~extracellular space,GO:0005788~endoplasmic reticulum lumen,GO:0031012~extracellular matrix,GO:0031093~platelet alpha granule lumen,GO:0070062~extracellular exosome,	GO:0002020~protease binding,GO:0005125~cytokine activity,GO:0005515~protein binding,GO:0008083~growth factor activity,GO:0008191~metalloendopeptidase inhibitor activity,GO:0008270~zinc ion binding,GO:0030414~peptidase inhibitor activity,GO:0046872~metal ion binding,	IPR001134:Netrin_domain,IPR001820:TIMP,IPR008993:TIMP-like_OB-fold,IPR027465:TIMP_C,IPR030490:TIMP_CS,	hsa04066:HIF-1 signaling pathway,			SM00206:NTR,		KW-0964~Secreted,		KW-0176~Collagen,KW-0732~Signal,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0339~Growth factor,KW-0481~Metalloenzyme inhibitor,KW-0483~Metalloprotease inhibitor,KW-0646~Protease inhibitor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) (complex) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:NTR,MUTAGEN:H->A: Nearly abolishes metalloproteinase inhibition.,MUTAGEN:Q->A: Nearly abolishes metalloproteinase inhibition.,MUTAGEN:T->E,G,K,Q,R: Reduced interaction with metalloproteinase.,MUTAGEN:T->L: Decreases protein flexibility and increases affinity for MMP14.,MUTAGEN:T->V: Normal interaction with metalloproteinase.,REGION:Disordered,REGION:Involved in metalloproteinase-binding,SITE:Involved in metalloproteinase-binding,
TM2D2	TM2 domain containing 2(TM2D2)	Homo sapiens				GO:0016020~membrane,	GO:0005515~protein binding,	IPR007829:TM2,						KW-0472~Membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,REGION:Disordered,TRANSMEM:Helical,
TM2D3	TM2 domain containing 3(TM2D3)	Homo sapiens			GO:0045747~positive regulation of Notch signaling pathway,GO:0046331~lateral inhibition,	GO:0005886~plasma membrane,GO:0016020~membrane,		IPR007829:TM2,						KW-0472~Membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:TM2,TRANSMEM:Helical,
TMEM9B	TMEM9 domain family member B(TMEM9B)	Homo sapiens			GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,	GO:0005765~lysosomal membrane,GO:0031901~early endosome membrane,	GO:0005515~protein binding,	IPR008853:TMEM9/TMEM9B,						KW-0458~Lysosome,KW-0472~Membrane,KW-0967~Endosome,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,TRANSMEM:Helical,
TNFAIP3	TNF alpha induced protein 3(TNFAIP3)	Homo sapiens		h_cd40Pathway:CD40L Signaling Pathway,h_nfkbPathway:NF-kB Signaling Pathway,h_tnfr2Pathway:TNFR2 Signaling Pathway,	GO:0001922~B-1 B cell homeostasis,GO:0002237~response to molecule of bacterial origin,GO:0002634~regulation of germinal center formation,GO:0002677~negative regulation of chronic inflammatory response,GO:0006508~proteolysis,GO:0006915~apoptotic process,GO:0006954~inflammatory response,GO:0007010~cytoskeleton organization,GO:0010803~regulation of tumor necrosis factor-mediated signaling pathway,GO:0016477~cell migration,GO:0016579~protein deubiquitination,GO:0030177~positive regulation of Wnt signaling pathway,GO:0031397~negative regulation of protein ubiquitination,GO:0032088~negative regulation of NF-kappaB transcription factor activity,GO:0032495~response to muramyl dipeptide,GO:0032691~negative regulation of interleukin-1 beta production,GO:0032703~negative regulation of interleukin-2 production,GO:0032715~negative regulation of interleukin-6 production,GO:0032720~negative regulation of tumor necrosis factor production,GO:0034136~negative regulation of toll-like receptor 2 signaling pathway,GO:0034140~negative regulation of toll-like receptor 3 signaling pathway,GO:0034144~negative regulation of toll-like receptor 4 signaling pathway,GO:0034148~negative regulation of toll-like receptor 5 signaling pathway,GO:0035523~protein K29-linked deubiquitination,GO:0035871~protein K11-linked deubiquitination,GO:0035872~nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway,GO:0043124~negative regulation of I-kappaB kinase/NF-kappaB signaling,GO:0045732~positive regulation of protein catabolic process,GO:0045779~negative regulation of bone resorption,GO:0045824~negative regulation of innate immune response,GO:0048662~negative regulation of smooth muscle cell proliferation,GO:0050691~regulation of defense response to virus by host,GO:0050728~negative regulation of inflammatory response,GO:0050869~negative regulation of B cell activation,GO:0061043~regulation of vascular wound healing,GO:0070301~cellular response to hydrogen peroxide,GO:0070423~nucleotide-binding oligomerization domain containing signaling pathway,GO:0070429~negative regulation of nucleotide-binding oligomerization domain containing 1 signaling pathway,GO:0070433~negative regulation of nucleotide-binding oligomerization domain containing 2 signaling pathway,GO:0070536~protein K63-linked deubiquitination,GO:0070936~protein K48-linked ubiquitination,GO:0071108~protein K48-linked deubiquitination,GO:0071222~cellular response to lipopolysaccharide,GO:0071947~protein deubiquitination involved in ubiquitin-dependent protein catabolic process,GO:0072573~tolerance induction to lipopolysaccharide,GO:0072666~establishment of protein localization to vacuole,GO:0090291~negative regulation of osteoclast proliferation,GO:1902042~negative regulation of extrinsic apoptotic signaling pathway via death domain receptors,GO:1990168~protein K33-linked deubiquitination,GO:2000347~positive regulation of hepatocyte proliferation,GO:2000349~negative regulation of CD40 signaling pathway,GO:2000352~negative regulation of endothelial cell apoptotic process,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005764~lysosome,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0002020~protease binding,GO:0003677~DNA binding,GO:0004842~ubiquitin-protein transferase activity,GO:0004843~thiol-dependent ubiquitin-specific protease activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0019900~kinase binding,GO:0042802~identical protein binding,GO:0043130~ubiquitin binding,GO:0043621~protein self-association,GO:0061578~Lys63-specific deubiquitinase activity,GO:0070530~K63-linked polyubiquitin binding,	IPR002653:Znf_A20,IPR003323:OTU_dom,	hsa04064:NF-kappa B signaling pathway,hsa04217:Necroptosis,hsa04621:NOD-like receptor signaling pathway,hsa04657:IL-17 signaling pathway,hsa04668:TNF signaling pathway,hsa05162:Measles,hsa05169:Epstein-Barr virus infection,	616744~Autoinflammatory syndrome, familial, Behcet-like 1,		SM00259:ZnF_A20,	KW-0053~Apoptosis,KW-0395~Inflammatory response,KW-0833~Ubl conjugation pathway,	KW-0458~Lysosome,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,	KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,KW-0378~Hydrolase,KW-0511~Multifunctional enzyme,KW-0645~Protease,KW-0788~Thiol protease,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Nucleophile,ACT_SITE:Proton acceptor,COMPBIAS:Polar residues,DOMAIN:A20-type,DOMAIN:OTU,MUTAGEN:C->A: Impairs polyubiquitin binding, abolishes inhibition of IKK activation; when associated with A-779.,MUTAGEN:C->A: Impairs polyubiquitin binding, abolishes inhibition of IKK activation; when associated with A-782.,MUTAGEN:C->A: Loss of deubiquitinase activity.,MUTAGEN:C->A: Marked attenuation of ubiquitin ligase activity and inhibition of RIPK1 degradation; when associated with A-624.,MUTAGEN:C->A: Marked attenuation of ubiquitin ligase activity and inhibition of RIPK1 degradation; when associated with A-627.,MUTAGEN:C->A: No effect on ubiquitin ligase activity; when associated with A-521.,MUTAGEN:C->A: No effect on ubiquitin ligase activity; when associated with A-524.,MUTAGEN:C->S: Loss of 'Lys-63' deubiquitinating activity. Down-regulation of TNF-induced NF-kappa-B activity less effective.,MUTAGEN:D->A: Minor effect on 'Lys-48' deubiquitinase activity. Strongly reduced 'Lys-63' deubiquitinase activity.,MUTAGEN:D->A: Strongly reduced deubiquitinase activity.,MUTAGEN:E->A: Strongly reduced 'Lys-48' deubiquitinase activity.,MUTAGEN:F->A: Impairs ubiquitination activity. Loss of down-regulation of NF-kappa-B activity; when associated with A-614.,MUTAGEN:F->A: Strongly reduced 'Lys-48' deubiquitinase activity.,MUTAGEN:FG->AA: Impairs polyubiquitin binding, abolishes inhibition of IKK activation.,MUTAGEN:H->A: Loss of deubiquitinase activity.,MUTAGEN:H->A: Reduces deubiquitinase activity.,MUTAGEN:L->A: Strongly reduced 'Lys-48' deubiquitinase activity.,MUTAGEN:L->R: Impairs ubiquitination activity. Loss of down-regulation of NF-kappa-B activity; when associated with A-614.,MUTAGEN:R->A: Abolishes interactionj with YWHAZ and YWHAH; no effect on inhibitory activity of TNF-induced NF-kappa-B activation.,MUTAGEN:S->A: Abolishes interactionj with YWHAZ and YWHAH; no effect on inhibitory activity of TNF-induced NF-kappa-B activation.,MUTAGEN:S->A: Strongly reduced 'Lys-48' deubiquitinase activity.,MUTAGEN:T->A: Minor effect on 'Lys-48' deubiquitinase activity.,MUTAGEN:Y->A: Impairs ubiquitination activity. Loss of down-regulation of NF-kappa-B activity; when associated with A-615 or R-626.,MUTAGEN:Y->A: Strongly reduced 'Lys-48' deubiquitinase activity.,REGION:Disordered,REGION:Interaction with RIPK1,REGION:Interaction with TNIP1,REGION:Interaction with ubiquitin,REGION:Required for lysosomal localization and for TRAF2 lysosomal degradation,REGION:Required for proteasomal degradation of UBE2N and UBE2D3, TRAF6 deubiquitination, and TAX1BP1 interaction with UBE2N,REGION:Sufficient for inhibitory activity of TNF-induced NF-kappa-B activity,REGION:TRAF-binding,SITE:Cleavage; by MALT1,ZN_FING:A20-type 1,ZN_FING:A20-type 2,ZN_FING:A20-type 3,ZN_FING:A20-type 4,ZN_FING:A20-type 5,ZN_FING:A20-type 6,ZN_FING:A20-type 7,
TNFAIP8	TNF alpha induced protein 8(TNFAIP8)	Homo sapiens			GO:0006915~apoptotic process,GO:0042981~regulation of apoptotic process,GO:0043065~positive regulation of apoptotic process,GO:0043066~negative regulation of apoptotic process,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,	GO:0005515~protein binding,GO:0043027~cysteine-type endopeptidase inhibitor activity involved in apoptotic process,	IPR008477:TNFAIP8-like,IPR038355:TNFAIP8_sf,					KW-0053~Apoptosis,	KW-0963~Cytoplasm,		KW-0175~Coiled coil,				COMPBIAS:Polar residues,REGION:Disordered,
TRAF1	TNF receptor associated factor 1(TRAF1)	Homo sapiens	51.CD40_and_EBV,	h_hivnefPathway:HIV-I Nef: negative effector of Fas and TNF,h_tnfr2Pathway:TNFR2 Signaling Pathway,	GO:0006915~apoptotic process,GO:0016310~phosphorylation,GO:0033209~tumor necrosis factor-mediated signaling pathway,GO:0043122~regulation of I-kappaB kinase/NF-kappaB signaling,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0065003~macromolecular complex assembly,GO:0070534~protein K63-linked ubiquitination,GO:2001236~regulation of extrinsic apoptotic signaling pathway,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0009898~cytoplasmic side of plasma membrane,GO:0098802~plasma membrane receptor complex,	GO:0005164~tumor necrosis factor receptor binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0016301~kinase activity,GO:0031625~ubiquitin protein ligase binding,GO:0031996~thioesterase binding,GO:0042802~identical protein binding,	IPR002083:MATH/TRAF_dom,IPR008974:TRAF-like,IPR012227:TNF_rcpt-assoc_TRAF_met,IPR032070:TRAF_BIRC3-bd,IPR037306:TRAF1_MATH,IPR049342:TRAF_MEP1_MATH_dom,	hsa04064:NF-kappa B signaling pathway,hsa04210:Apoptosis,hsa04668:TNF signaling pathway,hsa05200:Pathways in cancer,hsa05202:Transcriptional misregulation in cancer,hsa05203:Viral carcinogenesis,hsa05222:Small cell lung cancer,		PIRSF015614:TRAF,	SM00061:MATH,	KW-0053~Apoptosis,			KW-0175~Coiled coil,		KW-0418~Kinase,KW-0675~Receptor,KW-0808~Transferase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:MATH,MUTAGEN:D->A: Abolishes CASP8-mediated cleavage.,MUTAGEN:K->R: Nearly abolished ubiquitination; when associated with R-185.,MUTAGEN:K->R: Nearly abolished ubiquitination; when associated with R-193.,REGION:Disordered,SITE:Cleavage; by CASP8,
TRAF3	TNF receptor associated factor 3(TRAF3)	Homo sapiens	51.CD40_and_EBV,	h_cd40Pathway:CD40L Signaling Pathway,h_tall1Pathway:TACI and BCMA stimulation of B cell immune responses.,h_tnfr2Pathway:TNFR2 Signaling Pathway,	GO:0001817~regulation of cytokine production,GO:0002224~toll-like receptor signaling pathway,GO:0006915~apoptotic process,GO:0007165~signal transduction,GO:0008063~Toll signaling pathway,GO:0030162~regulation of proteolysis,GO:0032088~negative regulation of NF-kappaB transcription factor activity,GO:0032481~positive regulation of type I interferon production,GO:0032648~regulation of interferon-beta production,GO:0033209~tumor necrosis factor-mediated signaling pathway,GO:0034142~toll-like receptor 4 signaling pathway,GO:0035666~TRIF-dependent toll-like receptor signaling pathway,GO:0042981~regulation of apoptotic process,GO:0043122~regulation of I-kappaB kinase/NF-kappaB signaling,GO:0045087~innate immune response,GO:0048584~positive regulation of response to stimulus,GO:0050688~regulation of defense response to virus,GO:0051607~defense response to virus,GO:0060337~type I interferon signaling pathway,GO:0070534~protein K63-linked ubiquitination,	GO:0000151~ubiquitin ligase complex,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005768~endosome,GO:0005829~cytosol,GO:0009898~cytoplasmic side of plasma membrane,GO:0010008~endosome membrane,GO:0035631~CD40 receptor complex,GO:0098802~plasma membrane receptor complex,GO:1902554~serine/threonine protein kinase complex,	GO:0004842~ubiquitin-protein transferase activity,GO:0005164~tumor necrosis factor receptor binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0019899~enzyme binding,GO:0019901~protein kinase binding,GO:0019903~protein phosphatase binding,GO:0031625~ubiquitin protein ligase binding,GO:0031996~thioesterase binding,GO:0042802~identical protein binding,GO:0046872~metal ion binding,GO:0061630~ubiquitin protein ligase activity,	IPR001293:Znf_TRAF,IPR001841:Znf_RING,IPR002083:MATH/TRAF_dom,IPR008974:TRAF-like,IPR012227:TNF_rcpt-assoc_TRAF_met,IPR013083:Znf_RING/FYVE/PHD,IPR017907:Znf_RING_CS,IPR027128:TRAF3_RING-HC,IPR037304:TRAF3_MATH,IPR049342:TRAF_MEP1_MATH_dom,IPR049440:TRAF3/5_RING,	hsa04064:NF-kappa B signaling pathway,hsa04620:Toll-like receptor signaling pathway,hsa04621:NOD-like receptor signaling pathway,hsa04622:RIG-I-like receptor signaling pathway,hsa04657:IL-17 signaling pathway,hsa04668:TNF signaling pathway,hsa04936:Alcoholic liver disease,hsa05160:Hepatitis C,hsa05161:Hepatitis B,hsa05162:Measles,hsa05164:Influenza A,hsa05165:Human papillomavirus infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05171:Coronavirus disease - COVID-19,hsa05200:Pathways in cancer,hsa05203:Viral carcinogenesis,hsa05222:Small cell lung cancer,hsa05417:Lipid and atherosclerosis,	614849~Encephalopathy, acute, infection-induced (herpes-specific), susceptibility to, 5,	PIRSF015614:TRAF,	SM00061:MATH,	KW-0053~Apoptosis,KW-0391~Immunity,KW-0833~Ubl conjugation pathway,KW-0945~Host-virus interaction,	KW-0496~Mitochondrion,KW-0963~Cytoplasm,KW-0967~Endosome,	KW-0225~Disease variant,	KW-0175~Coiled coil,KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0808~Transferase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-0882~Thioester bond,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl cysteine thioester (Cys-Gly) (interchain with G-Cter in ubiquitin),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:MATH,DOMAIN:RING-type,DOMAIN:TRAF-type,MUTAGEN:C->A: Loss of ubiquitination activity on ASC; when associated with A-70.,MUTAGEN:C->A: Strong increase in both 'Lys-48' and 'Lys-63'-linked ubiquitination.,MUTAGEN:CGH->AGA: Loss of ubiquitination activity, impaired interaction with MAVS and IRF3. No effect on interaction with IKBKE, nor with DDX3X.,MUTAGEN:F->A: Abolishes interaction with LTBR, CD40 and TANK.,MUTAGEN:F->E: Abolishes interaction with LTBR, CD40 and TANK.,MUTAGEN:G->A: Confers resistance to cleavage by enterovirus D68 protease 2A.,MUTAGEN:H->A: Loss of ubiquitination activity on ASC; when associated with A-68.,MUTAGEN:K->R: Abolishes interaction with RALGDS.,MUTAGEN:Q->A: Abolishes interaction with RNF216; when associated with A-441.,MUTAGEN:Y->A: Abolishes interaction with LTBR, CD40 and TANK.,MUTAGEN:Y->A: Abolishes interaction with RNF216; when associated with A-443.,REGION:(Microbial infection) Interaction with glycoprotein N of Andes and New York hantaviruses,REGION:Disordered,ZN_FING:RING-type,ZN_FING:TRAF-type,ZN_FING:TRAF-type 1,ZN_FING:TRAF-type 2,
TNFRSF14	TNF receptor superfamily member 14(TNFRSF14)	Homo sapiens			GO:0002250~adaptive immune response,GO:0002720~positive regulation of cytokine production involved in immune response,GO:0006955~immune response,GO:0007166~cell surface receptor signaling pathway,GO:0031295~T cell costimulation,GO:0033209~tumor necrosis factor-mediated signaling pathway,GO:0045087~innate immune response,GO:0046642~negative regulation of alpha-beta T cell proliferation,GO:0046718~viral entry into host cell,GO:0050731~positive regulation of peptidyl-tyrosine phosphorylation,GO:0050829~defense response to Gram-negative bacterium,GO:0050830~defense response to Gram-positive bacterium,GO:1905675~negative regulation of adaptive immune memory response,GO:2000406~positive regulation of T cell migration,	GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0016020~membrane,	GO:0001618~virus receptor activity,GO:0005031~tumor necrosis factor-activated receptor activity,GO:0005515~protein binding,GO:0019955~cytokine binding,GO:0031625~ubiquitin protein ligase binding,	IPR001368:TNFR/NGFR_Cys_rich_reg,IPR022332:TNFR_14,IPR034031:TNFRSF14/UL144_N,	hsa03266:Virion - Herpesvirus,hsa04060:Cytokine-cytokine receptor interaction,hsa04061:Viral protein interaction with cytokine and cytokine receptor,hsa05168:Herpes simplex virus 1 infection,			SM00208:TNFR,	KW-0391~Immunity,KW-0399~Innate immunity,KW-0945~Host-virus interaction,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,KW-1183~Host cell receptor for virus entry,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:TNFR-Cys,MUTAGEN:Y->A: Abolishes cis interactions with BTLA.,MUTAGEN:Y->F: Does not affect cis interactions with BTLA.,REGION:Disordered,REPEAT:TNFR-Cys,REPEAT:TNFR-Cys 1,REPEAT:TNFR-Cys 2,REPEAT:TNFR-Cys 3,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
TNFRSF18	TNF receptor superfamily member 18(TNFRSF18)	Homo sapiens			GO:0002687~positive regulation of leukocyte migration,GO:0006915~apoptotic process,GO:0007165~signal transduction,GO:0033209~tumor necrosis factor-mediated signaling pathway,GO:0042531~positive regulation of tyrosine phosphorylation of STAT protein,GO:0043066~negative regulation of apoptotic process,GO:0045785~positive regulation of cell adhesion,	GO:0005576~extracellular region,GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,	GO:0005031~tumor necrosis factor-activated receptor activity,GO:0005515~protein binding,	IPR001368:TNFR/NGFR_Cys_rich_reg,IPR022318:TNFR_18,IPR034018:TNFRSF18_N,	hsa04060:Cytokine-cytokine receptor interaction,			SM00208:TNFR,	KW-0053~Apoptosis,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,DOMAIN:TNFR-Cys,REGION:Disordered,REPEAT:TNFR-Cys 1,REPEAT:TNFR-Cys 2,REPEAT:TNFR-Cys 3,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
TNFRSF1A	TNF receptor superfamily member 1A(TNFRSF1A)	Homo sapiens	150.caspase_and_NFKB_activation,40.Deg_of_Chrom_DNA_TNF-ind_apoptosis,46.P13K_PTEN,72.IAP_interaction_with_cell_death_pathways,99.NF-kB_activation,	h_ceramidePathway:Ceramide Signaling Pathway,h_hivnefPathway:HIV-I Nef: negative effector of Fas and TNF,h_keratinocytePathway:Keratinocyte Differentiation,h_nfkbPathway:NF-kB Signaling Pathway,h_pmlPathway:Regulation of transcriptional activity by PML,h_relaPathway:Acetylation and Deacetylation of RelA in The Nucleus,h_soddPathway:SODD/TNFR1 Signaling Pathway,h_stressPathway:TNF/Stress Related Signaling,h_tidPathway:Chaperones modulate interferon Signaling Pathway,h_tnfr1Pathway:TNFR1 Signaling Pathway,	GO:0003176~aortic valve development,GO:0003177~pulmonary valve development,GO:0003332~negative regulation of extracellular matrix constituent secretion,GO:0006366~transcription from RNA polymerase II promoter,GO:0006693~prostaglandin metabolic process,GO:0006915~apoptotic process,GO:0006954~inflammatory response,GO:0007165~signal transduction,GO:0008625~extrinsic apoptotic signaling pathway via death domain receptors,GO:0008630~intrinsic apoptotic signaling pathway in response to DNA damage,GO:0010614~negative regulation of cardiac muscle hypertrophy,GO:0010803~regulation of tumor necrosis factor-mediated signaling pathway,GO:0019221~cytokine-mediated signaling pathway,GO:0033209~tumor necrosis factor-mediated signaling pathway,GO:0034250~positive regulation of cellular amide metabolic process,GO:0042531~positive regulation of tyrosine phosphorylation of STAT protein,GO:0042742~defense response to bacterium,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0045834~positive regulation of lipid metabolic process,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0050728~negative regulation of inflammatory response,GO:0050729~positive regulation of inflammatory response,GO:0071260~cellular response to mechanical stimulus,GO:0072659~protein localization to plasma membrane,GO:1900119~positive regulation of execution phase of apoptosis,GO:1902339~positive regulation of apoptotic process involved in morphogenesis,GO:1903140~regulation of establishment of endothelial barrier,GO:1905038~regulation of membrane lipid metabolic process,	GO:0000139~Golgi membrane,GO:0002947~tumor necrosis factor receptor superfamily complex,GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,GO:0043235~receptor complex,GO:0045121~membrane raft,	GO:0005031~tumor necrosis factor-activated receptor activity,GO:0005515~protein binding,GO:0043120~tumor necrosis factor binding,	IPR000488:Death_domain,IPR001368:TNFR/NGFR_Cys_rich_reg,IPR011029:DEATH-like_dom_sf,IPR020419:TNFR_1A,IPR033993:TNFRSF1A_N,IPR033994:TNFRSF1A_death,	hsa04010:MAPK signaling pathway,hsa04060:Cytokine-cytokine receptor interaction,hsa04061:Viral protein interaction with cytokine and cytokine receptor,hsa04064:NF-kappa B signaling pathway,hsa04071:Sphingolipid signaling pathway,hsa04150:mTOR signaling pathway,hsa04210:Apoptosis,hsa04215:Apoptosis - multiple species,hsa04217:Necroptosis,hsa04380:Osteoclast differentiation,hsa04668:TNF signaling pathway,hsa04920:Adipocytokine signaling pathway,hsa04931:Insulin resistance,hsa04932:Non-alcoholic fatty liver disease,hsa04936:Alcoholic liver disease,hsa05010:Alzheimer disease,hsa05014:Amyotrophic lateral sclerosis,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05130:Pathogenic Escherichia coli infection,hsa05131:Shigellosis,hsa05132:Salmonella infection,hsa05142:Chagas disease,hsa05145:Toxoplasmosis,hsa05152:Tuberculosis,hsa05160:Hepatitis C,hsa05163:Human cytomegalovirus infection,hsa05164:Influenza A,hsa05165:Human papillomavirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05171:Coronavirus disease - COVID-19,hsa05417:Lipid and atherosclerosis,hsa05418:Fluid shear stress and atherosclerosis,	142680~Periodic fever, familial,614810~Multiple sclerosis, susceptibility to, 5,		SM00005:DEATH,SM00208:TNFR,	KW-0053~Apoptosis,KW-0945~Host-virus interaction,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-1008~Amyloidosis,	KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:(Microbial infection) N-beta-linked (GlcNAc) arginine,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:Death,DOMAIN:TNFR-Cys,MUTAGEN:R->A: Abolished GlcNAcylation by E.coli NleB1.,REGION:Disordered,REGION:N-SMase activation domain (NSD),REPEAT:TNFR-Cys,REPEAT:TNFR-Cys 1,REPEAT:TNFR-Cys 2,REPEAT:TNFR-Cys 3,REPEAT:TNFR-Cys 4,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
TNFRSF1B	TNF receptor superfamily member 1B(TNFRSF1B)	Homo sapiens	72.IAP_interaction_with_cell_death_pathways,	h_hivnefPathway:HIV-I Nef: negative effector of Fas and TNF,h_keratinocytePathway:Keratinocyte Differentiation,h_nfkbPathway:NF-kB Signaling Pathway,h_pmlPathway:Regulation of transcriptional activity by PML,h_relaPathway:Acetylation and Deacetylation of RelA in The Nucleus,h_soddPathway:SODD/TNFR1 Signaling Pathway,h_tidPathway:Chaperones modulate interferon Signaling Pathway,h_tnfr2Pathway:TNFR2 Signaling Pathway,	GO:0002718~regulation of cytokine production involved in immune response,GO:0002724~regulation of T cell cytokine production,GO:0003176~aortic valve development,GO:0003177~pulmonary valve development,GO:0003332~negative regulation of extracellular matrix constituent secretion,GO:0006954~inflammatory response,GO:0006955~immune response,GO:0008630~intrinsic apoptotic signaling pathway in response to DNA damage,GO:0010614~negative regulation of cardiac muscle hypertrophy,GO:0031641~regulation of myelination,GO:0031643~positive regulation of myelination,GO:0033209~tumor necrosis factor-mediated signaling pathway,GO:0042129~regulation of T cell proliferation,GO:0048714~positive regulation of oligodendrocyte differentiation,GO:0050779~RNA destabilization,GO:0051044~positive regulation of membrane protein ectodomain proteolysis,GO:0071222~cellular response to lipopolysaccharide,GO:0071363~cellular response to growth factor stimulus,GO:0097191~extrinsic apoptotic signaling pathway,GO:1902339~positive regulation of apoptotic process involved in morphogenesis,	GO:0002947~tumor necrosis factor receptor superfamily complex,GO:0005576~extracellular region,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0035579~specific granule membrane,GO:0043025~neuronal cell body,GO:0043196~varicosity,GO:0045121~membrane raft,GO:0048471~perinuclear region of cytoplasm,	GO:0005031~tumor necrosis factor-activated receptor activity,GO:0005515~protein binding,GO:0016787~hydrolase activity,GO:0031625~ubiquitin protein ligase binding,GO:0043120~tumor necrosis factor binding,	IPR001368:TNFR/NGFR_Cys_rich_reg,IPR020411:TNFR_1B,IPR033996:TNFRSF1B_N,	hsa04060:Cytokine-cytokine receptor interaction,hsa04061:Viral protein interaction with cytokine and cytokine receptor,hsa04668:TNF signaling pathway,hsa04920:Adipocytokine signaling pathway,hsa05014:Amyotrophic lateral sclerosis,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05170:Human immunodeficiency virus 1 infection,			SM00208:TNFR,	KW-0053~Apoptosis,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0378~Hydrolase,KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (GalNAc...) serine,CARBOHYD:O-linked (GalNAc...) threonine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:TNFR-Cys,REGION:Disordered,REPEAT:TNFR-Cys,REPEAT:TNFR-Cys 1,REPEAT:TNFR-Cys 2,REPEAT:TNFR-Cys 3,REPEAT:TNFR-Cys 4,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
TNFRSF25	TNF receptor superfamily member 25(TNFRSF25)	Homo sapiens		h_deathPathway:Induction of apoptosis through DR3 and DR4/5 Death Receptors ,	GO:0006915~apoptotic process,GO:0007165~signal transduction,GO:0007166~cell surface receptor signaling pathway,GO:0033209~tumor necrosis factor-mediated signaling pathway,GO:0042981~regulation of apoptotic process,GO:0097190~apoptotic signaling pathway,	GO:0005576~extracellular region,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016020~membrane,	GO:0005031~tumor necrosis factor-activated receptor activity,GO:0038023~signaling receptor activity,	IPR000488:Death_domain,IPR001368:TNFR/NGFR_Cys_rich_reg,IPR011029:DEATH-like_dom_sf,IPR022329:TNFR_25,IPR034050:TNFRSF25_N,	hsa04060:Cytokine-cytokine receptor interaction,			SM00005:DEATH,SM00208:TNFR,	KW-0053~Apoptosis,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:(Microbial infection) N-beta-linked (GlcNAc) arginine,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Death,DOMAIN:TNFR-Cys,MUTAGEN:D->A: Suppresses homodimerization, and TNFR1 interaction.,MUTAGEN:L->A: Suppresses homodimerization, TNFR1 interaction, and apoptosis induction.,MUTAGEN:L->A: Suppresses homodimerization, and TNFR1 interaction.,REPEAT:TNFR-Cys,REPEAT:TNFR-Cys 1,REPEAT:TNFR-Cys 2,REPEAT:TNFR-Cys 3,REPEAT:TNFR-Cys 4,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
TNFRSF4	TNF receptor superfamily member 4(TNFRSF4)	Homo sapiens		h_ox40Pathway:OX40 Signaling Pathway,	GO:0002639~positive regulation of immunoglobulin production,GO:0006954~inflammatory response,GO:0006955~immune response,GO:0030890~positive regulation of B cell proliferation,GO:0033209~tumor necrosis factor-mediated signaling pathway,GO:0042098~T cell proliferation,GO:0043433~negative regulation of sequence-specific DNA binding transcription factor activity,GO:0045892~negative regulation of transcription, DNA-templated,GO:0046718~viral entry into host cell,	GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,	GO:0001618~virus receptor activity,GO:0005031~tumor necrosis factor-activated receptor activity,GO:0005515~protein binding,	IPR001368:TNFR/NGFR_Cys_rich_reg,IPR020445:TNFR_4,IPR034022:TNFRSF4_N,	hsa04060:Cytokine-cytokine receptor interaction,	615593~Immunodeficiency 16,		SM00208:TNFR,SM01411:Ephrin_rec_like,	KW-0945~Host-virus interaction,	KW-0472~Membrane,	KW-0225~Disease variant,	KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,KW-1183~Host cell receptor for virus entry,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:TNFR-Cys,REGION:Disordered,REPEAT:TNFR-Cys,REPEAT:TNFR-Cys 1,REPEAT:TNFR-Cys 2,REPEAT:TNFR-Cys 3; truncated,REPEAT:TNFR-Cys 4,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
TNFSF10	TNF superfamily member 10(TNFSF10)	Homo sapiens		h_deathPathway:Induction of apoptosis through DR3 and DR4/5 Death Receptors ,	GO:0006915~apoptotic process,GO:0006955~immune response,GO:0007165~signal transduction,GO:0007267~cell-cell signaling,GO:0008584~male gonad development,GO:0032868~response to insulin,GO:0043065~positive regulation of apoptotic process,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043280~positive regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0090200~positive regulation of release of cytochrome c from mitochondria,GO:2001238~positive regulation of extrinsic apoptotic signaling pathway,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0070062~extracellular exosome,	GO:0005102~receptor binding,GO:0005125~cytokine activity,GO:0005164~tumor necrosis factor receptor binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0042802~identical protein binding,GO:0045569~TRAIL binding,GO:0046872~metal ion binding,	IPR006052:TNF_dom,IPR008983:Tumour_necrosis_fac-like_dom,IPR017355:TNF_ligand_10/11,IPR021184:TNF_CS,	hsa04060:Cytokine-cytokine receptor interaction,hsa04061:Viral protein interaction with cytokine and cytokine receptor,hsa04068:FoxO signaling pathway,hsa04210:Apoptosis,hsa04217:Necroptosis,hsa04650:Natural killer cell mediated cytotoxicity,hsa05130:Pathogenic Escherichia coli infection,hsa05132:Salmonella infection,hsa05164:Influenza A,hsa05417:Lipid and atherosclerosis,		PIRSF038013:TNF10_TNF11,	SM00207:TNF,	KW-0053~Apoptosis,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0202~Cytokine,	KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:TNF family profile,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
TNIP1	TNFAIP3 interacting protein 1(TNIP1)	Homo sapiens			GO:0002755~MyD88-dependent toll-like receptor signaling pathway,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006412~translation,GO:0006952~defense response,GO:0006954~inflammatory response,GO:0007159~leukocyte cell-cell adhesion,GO:0009101~glycoprotein biosynthetic process,GO:0043124~negative regulation of I-kappaB kinase/NF-kappaB signaling,GO:0045071~negative regulation of viral genome replication,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0050729~positive regulation of inflammatory response,GO:0070373~negative regulation of ERK1 and ERK2 cascade,GO:0071222~cellular response to lipopolysaccharide,GO:1903003~positive regulation of protein deubiquitination,	GO:0005654~nucleoplasm,GO:0005829~cytosol,	GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0051019~mitogen-activated protein kinase binding,	IPR032419:CC2-LZ_dom,	hsa05131:Shigellosis,				KW-0395~Inflammatory response,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,			KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:NF-kappa-B essential modulator NEMO CC2-LZ,MOTIF:Nuclear localization signal,MUTAGEN:D->N: Abolishes binding to polyubiquitin ('K-63'-linked and linear).,MUTAGEN:Y->F: Abolishes interaction with PI3K p85 regulatory subunit and abolishes interaction between SELPLG and PI3K p85 regulatory subunit.,REGION:Disordered,REGION:Interaction with Nef,REGION:Interaction with Shigella flexneri ipah9.8,REGION:Required for inhibitory activity of TNF-induced NF-kappa-B activation,REGION:Ubiquitin-binding domain (UBD),
TNIP2	TNFAIP3 interacting protein 2(TNIP2)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006915~apoptotic process,GO:0006954~inflammatory response,GO:0023035~CD40 signaling pathway,GO:0034134~toll-like receptor 2 signaling pathway,GO:0034138~toll-like receptor 3 signaling pathway,GO:0034162~toll-like receptor 9 signaling pathway,GO:0043032~positive regulation of macrophage activation,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0050821~protein stabilization,GO:0050871~positive regulation of B cell activation,GO:0070498~interleukin-1-mediated signaling pathway,GO:0071222~cellular response to lipopolysaccharide,GO:2000352~negative regulation of endothelial cell apoptotic process,	GO:0005654~nucleoplasm,GO:0005829~cytosol,	GO:0005515~protein binding,GO:0019901~protein kinase binding,GO:0031593~polyubiquitin binding,GO:0046872~metal ion binding,GO:0070530~K63-linked polyubiquitin binding,	IPR022008:EABR,IPR034735:NEMO_ZF,					KW-0053~Apoptosis,KW-0395~Inflammatory response,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Basic and acidic residues,DOMAIN:CCHC NOA-type,MUTAGEN:DF->NA: Abolishes ubiquitin binding.,MUTAGEN:ER->AA: Abolishes ubiquitin binding; loss of inhibitory activity on NF-kappa-B activation.,MUTAGEN:S->A: Reduces phosphorylation.,MUTAGEN:S->A: Reduces phosphorylation; reduces CHUK-mediated NF-kappa-B activation.,REGION:Disordered,REGION:Ubiquitin-binding domain (UBD),ZN_FING:CCHC NOA-type,
TOX4	TOX high mobility group box family member 4(TOX4)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,	GO:0000781~chromosome, telomeric region,GO:0000785~chromatin,GO:0005634~nucleus,GO:0072357~PTW/PP1 phosphatase complex,	GO:0003677~DNA binding,GO:0005515~protein binding,GO:0031490~chromatin DNA binding,	IPR009071:HMG_box_dom,IPR036910:HMG_box_dom_sf,				SM00398:HMG,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0732~Signal,		KW-0238~DNA-binding,	KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,DNA_BIND:HMG box,DOMAIN:HMG box,MOTIF:Nuclear localization signal,REGION:Disordered,
TRIAP1	TP53 regulated inhibitor of apoptosis 1(TRIAP1)	Homo sapiens			GO:0006915~apoptotic process,GO:0006977~DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest,GO:0015914~phospholipid transport,GO:0030330~DNA damage response, signal transduction by p53 class mediator,GO:0034644~cellular response to UV,GO:0043066~negative regulation of apoptotic process,GO:0043154~negative regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0045332~phospholipid translocation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0090201~negative regulation of release of cytochrome c from mitochondria,GO:0097035~regulation of membrane lipid distribution,GO:1902166~negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator,GO:2001140~positive regulation of phospholipid transport,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005739~mitochondrion,GO:0005758~mitochondrial intermembrane space,GO:0032991~macromolecular complex,	GO:0002039~p53 binding,GO:0005515~protein binding,GO:1990050~phosphatidic acid transporter activity,	IPR007918:MDM35_apoptosis,					KW-0053~Apoptosis,KW-0445~Lipid transport,KW-0813~Transport,	KW-0496~Mitochondrion,		KW-0175~Coiled coil,			KW-0007~Acetylation,KW-1015~Disulfide bond,	DOMAIN:CHCH,MOTIF:Cx9C motif 1,MOTIF:Cx9C motif 2,MUTAGEN:F->A: Impairs interaction with PRELID3A.,SITE:Important for interaction with PRELID3A,
TANK	TRAF family member associated NFKB activator(TANK)	Homo sapiens		h_stressPathway:TNF/Stress Related Signaling,h_tnfr2Pathway:TNFR2 Signaling Pathway,	GO:0006974~cellular response to DNA damage stimulus,GO:0007165~signal transduction,GO:0007249~I-kappaB kinase/NF-kappaB signaling,GO:0010804~negative regulation of tumor necrosis factor-mediated signaling pathway,GO:0032481~positive regulation of type I interferon production,GO:0043124~negative regulation of I-kappaB kinase/NF-kappaB signaling,GO:0051607~defense response to virus,GO:0060337~type I interferon signaling pathway,GO:0071347~cellular response to interleukin-1,GO:0071356~cellular response to tumor necrosis factor,GO:0071479~cellular response to ionizing radiation,GO:1903003~positive regulation of protein deubiquitination,GO:2000158~positive regulation of ubiquitin-specific protease activity,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0032991~macromolecular complex,GO:1902554~serine/threonine protein kinase complex,	GO:0004843~thiol-dependent ubiquitin-specific protease activity,GO:0005515~protein binding,GO:0031625~ubiquitin protein ligase binding,GO:0035800~deubiquitinase activator activity,GO:0046872~metal ion binding,GO:0060090~binding, bridging,	IPR024581:TBD,IPR039669:TANK,IPR041641:CALCOCO1/2_Zn_UBZ1,	hsa04140:Autophagy - animal,hsa04621:NOD-like receptor signaling pathway,hsa04622:RIG-I-like receptor signaling pathway,hsa05014:Amyotrophic lateral sclerosis,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05417:Lipid and atherosclerosis,				KW-0227~DNA damage,KW-0945~Host-virus interaction,	KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:Tbk1/Ikki binding,DOMAIN:UBZ1-type,MUTAGEN:D->A: Abolishes interaction with TRAF2; greatly diminishes interaction with TRAF3.,MUTAGEN:D->A: Diminishes interaction with TRAF2 and TRAF3.,MUTAGEN:E->A: Complete loss of cleavage by Seneca Valley virus protease 3C.,MUTAGEN:E->A: No effect on cleavage by Seneca Valley virus protease 3C.,MUTAGEN:F->A: Diminishes interaction with TRAF2 and TRAF3.,MUTAGEN:H->A: No effect on cleavage by Seneca Valley virus protease 3C.,MUTAGEN:Q->A: Abolishes interaction with TRAF2 and TRAF3.,MUTAGEN:Q->A: Complete loss of cleavage by Seneca Valley virus protease 3C.,MUTAGEN:Q->A: No effect on cleavage by Seneca Valley virus protease 3C.,MUTAGEN:T->A: Abolishes interaction with TRAF2 and TRAF3.,REGION:Disordered,REGION:Interaction with TBK1 and IKBKE,REGION:Necessary for interaction with TRAF6,REGION:Necessary for interaction with ZC3H12A,REGION:TRAF family member interaction,SITE:(Microbial infection) Cleavage; by viral Seneca Valley virus protease 3C,SITE:Cleavage by EMCV protease 3C,ZN_FING:UBZ1-type,
TNIK	TRAF2 and NCK interacting kinase(TNIK)	Homo sapiens			GO:0000165~MAPK cascade,GO:0001934~positive regulation of protein phosphorylation,GO:0006468~protein phosphorylation,GO:0007010~cytoskeleton organization,GO:0010243~response to organonitrogen compound,GO:0016055~Wnt signaling pathway,GO:0030033~microvillus assembly,GO:0030036~actin cytoskeleton organization,GO:0035556~intracellular signal transduction,GO:0043408~regulation of MAPK cascade,GO:0046330~positive regulation of JNK cascade,GO:0046777~protein autophosphorylation,GO:0048812~neuron projection morphogenesis,GO:0048814~regulation of dendrite morphogenesis,GO:0072659~protein localization to plasma membrane,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0016324~apical plasma membrane,GO:0048471~perinuclear region of cytoplasm,GO:0055037~recycling endosome,GO:0070062~extracellular exosome,GO:0098793~presynapse,GO:0098978~glutamatergic synapse,GO:0099092~postsynaptic density, intracellular component,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,	IPR000719:Prot_kinase_dom,IPR001180:CNH_dom,IPR008271:Ser/Thr_kinase_AS,IPR011009:Kinase-like_dom_sf,IPR017441:Protein_kinase_ATP_BS,		617028~Intellectual developmental disorder, autosomal recessive 54,		SM00036:CNH,SM00220:S_TKc,	KW-0524~Neurogenesis,KW-0879~Wnt signaling pathway,	KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0967~Endosome,	KW-0991~Intellectual disability,		KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:CNH,DOMAIN:Protein kinase,MUTAGEN:DF->AA: Loss of autophosphorylation.,MUTAGEN:K->A: Kinase dead. Loss of autophosphorylation and loss of function in cytoskeleton regulation.,MUTAGEN:RD->AA: Loss of autophosphorylation.,REGION:Disordered,REGION:Mediates interaction with NEDD4,
TRAF3IP3	TRAF3 interacting protein 3(TRAF3IP3)	Homo sapiens			GO:0002753~cytoplasmic pattern recognition receptor signaling pathway,GO:0032481~positive regulation of type I interferon production,	GO:0000139~Golgi membrane,GO:0005739~mitochondrion,GO:0005741~mitochondrial outer membrane,GO:0005765~lysosomal membrane,GO:0005886~plasma membrane,GO:0016020~membrane,	GO:0005515~protein binding,GO:0060090~binding, bridging,							KW-0333~Golgi apparatus,KW-0458~Lysosome,KW-0472~Membrane,KW-0496~Mitochondrion,KW-1000~Mitochondrion outer membrane,KW-1003~Cell membrane,		KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,				COMPBIAS:Polar residues,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Anchor for type IV membrane protein,
TSC22D3	TSC22 domain family member 3(TSC22D3)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006970~response to osmotic stress,GO:0070236~negative regulation of activation-induced cell death of T cells,	GO:0005634~nucleus,GO:0005829~cytosol,	GO:0005515~protein binding,	IPR000580:TSC22/Bun,IPR047862:TSC22/BUN_CS,						KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,			KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,REGION:AP1-binding,REGION:Disordered,REGION:Leucine-zipper,
TSC22D4	TSC22 domain family member 4(TSC22D4)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006970~response to osmotic stress,GO:0042593~glucose homeostasis,GO:0045892~negative regulation of transcription, DNA-templated,GO:0070050~neuron cellular homeostasis,GO:1990138~neuron projection extension,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0030425~dendrite,GO:0045202~synapse,	GO:0005515~protein binding,	IPR000580:TSC22/Bun,IPR042553:TSC22D4,IPR047862:TSC22/BUN_CS,					KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0770~Synapse,KW-0963~Cytoplasm,KW-0966~Cell projection,		KW-0175~Coiled coil,		KW-0678~Repressor,	KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,REGION:Disordered,REGION:Leucine-zipper,
TSPYL1	TSPY like 1(TSPYL1)	Homo sapiens			GO:0006334~nucleosome assembly,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,	GO:0003682~chromatin binding,GO:0019899~enzyme binding,GO:0042393~histone binding,GO:0042802~identical protein binding,	IPR002164:NAP_family,IPR037231:NAP-like_sf,		608800~Sudden infant death with dysgenesis of the testes syndrome,				KW-0539~Nucleus,					KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),REGION:Disordered,
TSPYL2	TSPY like 2(TSPYL2)	Homo sapiens			GO:0006334~nucleosome assembly,GO:0007049~cell cycle,GO:0008156~negative regulation of DNA replication,GO:0009966~regulation of signal transduction,GO:0030308~negative regulation of cell growth,GO:0045786~negative regulation of cell cycle,GO:0045859~regulation of protein kinase activity,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,	GO:0000182~rDNA binding,GO:0003682~chromatin binding,GO:0005515~protein binding,GO:0042393~histone binding,	IPR002164:NAP_family,IPR037231:NAP-like_sf,					KW-0131~Cell cycle,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0156~Chromatin regulator,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),MUTAGEN:S->A: Impairs effect on cell proliferation; when associated with A-340.,MUTAGEN:T->A: Impairs effect on cell proliferation; when associated with A-20.,REGION:Disordered,
TSR2	TSR2 ribosome maturation factor(TSR2)	Homo sapiens			GO:0000462~maturation of SSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA),	GO:0005634~nucleus,	GO:0005515~protein binding,	IPR019398:Pre-rRNA_process_TSR2,		300946~Diamond-Blackfan anemia 14 with mandibulofacial dysostosis,			KW-0698~rRNA processing,		KW-0225~Disease variant,KW-1024~Diamond-Blackfan anemia,					REGION:Disordered,
TAX1BP1	Tax1 binding protein 1(TAX1BP1)	Homo sapiens			GO:0006914~autophagy,GO:0006915~apoptotic process,GO:0032088~negative regulation of NF-kappaB transcription factor activity,GO:0034144~negative regulation of toll-like receptor 4 signaling pathway,GO:0039532~negative regulation of viral-induced cytoplasmic pattern recognition receptor signaling pathway,GO:0043066~negative regulation of apoptotic process,GO:0045087~innate immune response,GO:1905161~protein localization to phagocytic vesicle,	GO:0000407~pre-autophagosomal structure,GO:0005739~mitochondrion,GO:0005776~autophagosome,GO:0005829~cytosol,GO:0031410~cytoplasmic vesicle,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0019900~kinase binding,GO:0030674~protein binding, bridging,GO:0046872~metal ion binding,	IPR012852:CALCOCO1-like,IPR041611:SKICH,IPR041641:CALCOCO1/2_Zn_UBZ1,	hsa04137:Mitophagy - animal,hsa04140:Autophagy - animal,				KW-0053~Apoptosis,KW-0072~Autophagy,KW-0391~Immunity,KW-0399~Innate immunity,KW-0945~Host-virus interaction,	KW-0496~Mitochondrion,KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,		KW-0175~Coiled coil,KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:SKICH,DOMAIN:UBZ1-type,MUTAGEN:A->Q: Complete loss of TBK1 and RB1CC1 binding.,MUTAGEN:E->A: Reduced affinity for ubiquitin.,MUTAGEN:F->A: Reduced affinity for ubiquitin.,MUTAGEN:Q->A: Normal affinity for ubiquitin.,MUTAGEN:Q->A: Reduced affinity for ubiquitin.,MUTAGEN:R->A: Normal affinity for ubiquitin.,MUTAGEN:V->S: Complete loss of MAP1LC3B binding.,MUTAGEN:V->S: Reduced affinity for ubiquitin.,REGION:Disordered,REGION:Oligomerization,ZN_FING:UBZ1-type 1,ZN_FING:UBZ1-type 2,
TRABD	TraB domain containing(TRABD)	Homo sapiens						IPR002816:TraB/PrgY/GumN_fam,IPR046345:TraB_PrgY-like,											KW-0007~Acetylation,KW-0597~Phosphoprotein,	REGION:Disordered,
TUFM	Tu translation elongation factor, mitochondrial(TUFM)	Homo sapiens			GO:0006414~translational elongation,GO:0045471~response to ethanol,GO:0070125~mitochondrial translational elongation,	GO:0005739~mitochondrion,GO:0005741~mitochondrial outer membrane,GO:0016020~membrane,GO:0042645~mitochondrial nucleoid,GO:0045202~synapse,GO:0070062~extracellular exosome,	GO:0003723~RNA binding,GO:0003746~translation elongation factor activity,GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,	IPR000795:T_Tr_GTP-bd_dom,IPR004160:Transl_elong_EFTu/EF1A_C,IPR004161:EFTu-like_2,IPR004541:Transl_elong_EFTu/EF1A_bac/org,IPR009000:Transl_B-barrel_sf,IPR009001:Transl_elong_EF1A/Init_IF2_C,IPR027417:P-loop_NTPase,IPR031157:G_TR_CS,IPR033720:EFTU_2,IPR041709:EF-Tu_GTP-bd,		610678~Combined oxidative phosphorylation deficiency 4,			KW-0648~Protein biosynthesis,KW-0945~Host-virus interaction,	KW-0496~Mitochondrion,	KW-0225~Disease variant,KW-1274~Primary mitochondrial disease,	KW-0809~Transit peptide,	KW-0342~GTP-binding,KW-0547~Nucleotide-binding,	KW-0251~Elongation factor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:Tr-type G,DOMAIN:tr-type G,REGION:G1,REGION:G2,REGION:G3,REGION:G4,REGION:G5,TRANSIT:Mitochondrion,
U2AF2	U2 small nuclear RNA auxiliary factor 2(U2AF2)	Homo sapiens			GO:0000245~spliceosomal complex assembly,GO:0000398~mRNA splicing, via spliceosome,GO:0006397~mRNA processing,GO:0008380~RNA splicing,GO:0031397~negative regulation of protein ubiquitination,GO:0033120~positive regulation of RNA splicing,GO:0048025~negative regulation of mRNA splicing, via spliceosome,	GO:0000243~commitment complex,GO:0000974~Prp19 complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005681~spliceosomal complex,GO:0016607~nuclear speck,GO:0071004~U2-type prespliceosome,GO:0089701~U2AF,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0008187~poly-pyrimidine tract binding,GO:0019899~enzyme binding,GO:0030628~pre-mRNA 3'-splice site binding,GO:0070742~C2H2 zinc finger domain binding,	IPR000504:RRM_dom,IPR006529:U2AF_lg,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR035979:RBD_domain_sf,	hsa03040:Spliceosome,	620535~Developmental delay, dysmorphic facies, and brain anomalies,		SM00360:RRM,	KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,KW-0747~Spliceosome,		KW-0677~Repeat,		KW-0678~Repressor,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0379~Hydroxylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:RRM,DOMAIN:RRM 1,DOMAIN:RRM 2,DOMAIN:RRM 3,MUTAGEN:DDEE->AAAA: Reduces interaction with SF1.,MUTAGEN:DDEE->RRKK: Reduces interaction with SF1.,MUTAGEN:EE->AA: No effect.,MUTAGEN:EE->GA: Reduces interaction with SF1.,MUTAGEN:EE->KK: Reduces interaction with SF1.,MUTAGEN:EE->RR: Reduces interaction with SF1.,MUTAGEN:F->A: Reduces interaction with SF1.,MUTAGEN:P->G: Decreases affinity for UAF1 by 2 orders of magnitude.,MUTAGEN:W->A: Decreases affinity for UAF1 by 3 orders of magnitude.,REGION:Disordered,REGION:Necessary and sufficient to stimulate pre-mRNAs 3'-end cleavage in a CFIm complex-dependent manner,REGION:Required for interaction with PRPF19,
U2SURP	U2 snRNP associated SURP domain containing(U2SURP)	Homo sapiens			GO:0006396~RNA processing,	GO:0005634~nucleus,GO:0005654~nucleoplasm,	GO:0003723~RNA binding,GO:0005515~protein binding,	IPR000061:Surp,IPR000504:RRM_dom,IPR006569:CID_dom,IPR008942:ENTH_VHS,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR013170:mRNA_splic_Cwf21_dom,IPR035009:SR140_RRM,IPR035967:SWAP/Surp_sf,IPR035979:RBD_domain_sf,IPR047488:SR140_cwf21,	hsa03040:Spliceosome,			SM00360:RRM,SM00582:RPR,SM00648:SWAP,SM01115:cwf21,		KW-0539~Nucleus,		KW-0175~Coiled coil,		KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:CID,DOMAIN:CWF21,DOMAIN:RRM,DOMAIN:SURP motif,REGION:Disordered,REPEAT:SURP motif,
UHMK1	U2AF homology motif kinase 1(UHMK1)	Homo sapiens		h_stathminPathway:Stathmin and breast cancer resistance to antimicrotubule agents,	GO:0018105~peptidyl-serine phosphorylation,GO:0031175~neuron projection development,GO:0045948~positive regulation of translational initiation,GO:0046777~protein autophosphorylation,GO:0046825~regulation of protein export from nucleus,GO:0051726~regulation of cell cycle,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0016607~nuclear speck,GO:0030424~axon,GO:0032839~dendrite cytoplasm,GO:0043231~intracellular membrane-bounded organelle,GO:0071598~neuronal ribonucleoprotein granule,	GO:0003723~RNA binding,GO:0004674~protein serine/threonine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016740~transferase activity,GO:0019899~enzyme binding,GO:0043021~ribonucleoprotein complex binding,GO:1990935~splicing factor binding,	IPR000504:RRM_dom,IPR000719:Prot_kinase_dom,IPR011009:Kinase-like_dom_sf,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR034372:UHMK1,IPR035979:RBD_domain_sf,				SM00220:S_TKc,SM00360:RRM,		KW-0539~Nucleus,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0694~RNA-binding,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,		ACT_SITE:Proton acceptor,DOMAIN:Protein kinase,DOMAIN:RRM,MUTAGEN:K->A: Loss of kinase activity.,
USB1	U6 snRNA biogenesis phosphodiesterase 1(USB1)	Homo sapiens			GO:0008380~RNA splicing,GO:0034472~snRNA 3'-end processing,GO:0034477~U6 snRNA 3'-end processing,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0045171~intercellular bridge,	GO:0000175~3'-5'-exoribonuclease activity,GO:0004518~nuclease activity,GO:0005515~protein binding,GO:0016829~lyase activity,GO:1990838~poly(U)-specific exoribonuclease activity, producing 3' uridine cyclic phosphate ends,	IPR027521:Usb1,		604173~Poikiloderma with neutropenia,				KW-0539~Nucleus,				KW-0378~Hydrolase,KW-0456~Lyase,KW-0540~Nuclease,		ACT_SITE:Proton acceptor,ACT_SITE:Proton donor,ACT_SITE:Proton donor/acceptor,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,MUTAGEN:H->A: Abolishes exoribonuclease activity. Does not rescue the molecular phenotype caused by USB1 depletion. Does not restore U6 snRNA processing when expressed in deleted mpn1 yeast cells; when associated with A-120. Increases the accumulation of unspliced pre-mRNAs when expressed in deleted mpn1 yeast cells; when associated with A-120. Slows growth in the cold when expressed in deleted mpn1 yeast cells; when associated with A-120. Abolishes exoribonuclease activity; when associated with A-120. Decreases U6 and U6atac motility.,MUTAGEN:H->A: Abolishes exoribonuclease activity. Does not restore U6 snRNA processing when expressed in deleted mpn1 yeast cells; when associated with A-208. Increases the accumulation of unspliced pre-mRNAs when expressed in deleted mpn1 yeast cells; when associated with A-208. Slows growth in the cold when expressed in deleted mpn1 yeast cells; when associated with A-208. Abolishes exoribonuclease activity; when associated with A-208. Decreases U6 and U6atac motility.,MUTAGEN:H->N: Loss of exonuclease activity.,MUTAGEN:H->N: Significantly decreases exonuclease activity.,MUTAGEN:H->Q: Loss of exonuclease activity.,MUTAGEN:S->C: Significantly decreases exonuclease activity.,MUTAGEN:Y->A: Significantly decreases exonuclease activity.,REGION:Disordered,
UBALD1	UBA like domain containing 1(UBALD1)	Homo sapiens					GO:0005515~protein binding,	IPR009060:UBA-like_sf,IPR039310:UBALD1/2,												COMPBIAS:Polar residues,COMPBIAS:Pro residues,REGION:Disordered,
UBXN1	UBX domain protein 1(UBXN1)	Homo sapiens			GO:0031397~negative regulation of protein ubiquitination,GO:0032435~negative regulation of proteasomal ubiquitin-dependent protein catabolic process,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:1903094~negative regulation of protein K48-linked deubiquitination,GO:1904293~negative regulation of ERAD pathway,GO:2000157~negative regulation of ubiquitin-specific protease activity,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0034098~VCP-NPL4-UFD1 AAA ATPase complex,	GO:0005515~protein binding,GO:0031593~polyubiquitin binding,GO:0031625~ubiquitin protein ligase binding,GO:0036435~K48-linked polyubiquitin binding,GO:0043130~ubiquitin binding,GO:0051117~ATPase binding,GO:0071796~K6-linked polyubiquitin binding,GO:1904855~proteasome regulatory particle binding,	IPR001012:UBX_dom,IPR009060:UBA-like_sf,IPR015940:UBA,IPR029071:Ubiquitin-like_domsf,IPR041923:UBA_UBXN1,	hsa04141:Protein processing in endoplasmic reticulum,			SM00165:UBA,SM00166:UBX,	KW-0945~Host-virus interaction,	KW-0963~Cytoplasm,		KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,DOMAIN:UBA,DOMAIN:UBX,MUTAGEN:M->T: Abolishes binding to 'Lys-6'-linked polyubiquitin chains and ability to inhibit E3 ubiquitin-protein ligase activity of the BRCA1-BARD1 heterodimer.,MUTAGEN:R->A: Does not affect binding to 'Lys-6'-linked polyubiquitin chains and ability to inhibit E3 ubiquitin-protein ligase activity of the BRCA1-BARD1 heterodimer.,REGION:Disordered,REGION:Interaction with BRCA1,
UBXN4	UBX domain protein 4(UBXN4)	Homo sapiens			GO:0006986~response to unfolded protein,GO:0030433~ubiquitin-dependent ERAD pathway,GO:0036503~ERAD pathway,	GO:0005635~nuclear envelope,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,	GO:0005515~protein binding,	IPR001012:UBX_dom,IPR029071:Ubiquitin-like_domsf,IPR036249:Thioredoxin-like_sf,	hsa04141:Protein processing in endoplasmic reticulum,			SM00166:UBX,	KW-0834~Unfolded protein response,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0539~Nucleus,					KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:UBX,REGION:Disordered,REGION:Interaction with UBQLN1,TOPO_DOM:Cytoplasmic,
B3GNT2	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2(B3GNT2)	Homo sapiens			GO:0006493~protein O-linked glycosylation,GO:0007411~axon guidance,GO:0007608~sensory perception of smell,GO:0016266~O-glycan processing,GO:0018146~keratan sulfate biosynthetic process,GO:0030311~poly-N-acetyllactosamine biosynthetic process,GO:1990830~cellular response to leukemia inhibitory factor,	GO:0000139~Golgi membrane,GO:0016020~membrane,	GO:0005515~protein binding,GO:0008457~beta-galactosyl-N-acetylglucosaminylgalactosylglucosyl-ceramide beta-1,3-acetylglucosaminyltransferase activity,GO:0008499~UDP-galactose:beta-N-acetylglucosamine beta-1,3-galactosyltransferase activity,GO:0008532~N-acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase activity,	IPR002659:Glyco_trans_31,	hsa00533:Glycosaminoglycan biosynthesis - keratan sulfate,hsa00601:Glycosphingolipid biosynthesis - lacto and neolacto series,hsa01100:Metabolic pathways,					KW-0333~Golgi apparatus,KW-0472~Membrane,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0464~Manganese,	KW-0328~Glycosyltransferase,KW-0808~Transferase,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,MUTAGEN:D->A: Loss of enzymatic activity, no loss of B3GNT8-binding.,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
UGP2	UDP-glucose pyrophosphorylase 2(UGP2)	Homo sapiens			GO:0005977~glycogen metabolic process,GO:0005978~glycogen biosynthetic process,GO:0006011~UDP-glucose metabolic process,GO:0007420~brain development,GO:0019255~glucose 1-phosphate metabolic process,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0003983~UTP:glucose-1-phosphate uridylyltransferase activity,GO:0005515~protein binding,GO:0005536~glucose binding,GO:0032557~pyrimidine ribonucleotide binding,GO:0042802~identical protein binding,GO:0046872~metal ion binding,GO:0070569~uridylyltransferase activity,	IPR002618:UDPGP_fam,IPR016267:UDPGP_trans,IPR029044:Nucleotide-diphossugar_trans,	hsa00040:Pentose and glucuronate interconversions,hsa00052:Galactose metabolism,hsa00500:Starch and sucrose metabolism,hsa00520:Amino sugar and nucleotide sugar metabolism,hsa01100:Metabolic pathways,hsa01240:Biosynthesis of cofactors,hsa01250:Biosynthesis of nucleotide sugars,	618744~Developmental and epileptic encephalopathy 83,	PIRSF000806:UDPGP,			KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0887~Epilepsy,		KW-0460~Magnesium,KW-0479~Metal-binding,	KW-0548~Nucleotidyltransferase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	MUTAGEN:C->S: No significant loss of activity.,MUTAGEN:H->R: No significant loss of activity.,MUTAGEN:NL->PE: Abolishes oligomerization and significantly increases enzymatic activity.,MUTAGEN:R->H: Loss of activity; possibly due to folding defect.,MUTAGEN:R->H: No significant loss of activity.,MUTAGEN:W->S: Loss of activity; possibly due to folding defect.,MUTAGEN:W->S: No significant loss of activity.,REGION:Critical for end-to-end subunit interaction,REGION:Oligomerization,
UXS1	UDP-glucuronate decarboxylase 1(UXS1)	Homo sapiens			GO:0033320~UDP-D-xylose biosynthetic process,GO:0042732~D-xylose metabolic process,	GO:0005737~cytoplasm,GO:0032580~Golgi cisterna membrane,GO:0070062~extracellular exosome,GO:1902494~catalytic complex,	GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0048040~UDP-glucuronate decarboxylase activity,GO:0070403~NAD+ binding,	IPR001509:Epimerase_deHydtase,IPR016040:NAD(P)-bd_dom,IPR021761:UXS1_N,IPR036291:NAD(P)-bd_dom_sf,IPR044516:UXS,	hsa00520:Amino sugar and nucleotide sugar metabolism,hsa01100:Metabolic pathways,hsa01250:Biosynthesis of nucleotide sugars,					KW-0333~Golgi apparatus,KW-0472~Membrane,		KW-0732~Signal,KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0520~NAD,	KW-0210~Decarboxylase,KW-0456~Lyase,	KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:NAD(P)-binding,DOMAIN:NAD-dependent epimerase/dehydratase,DOMAIN:UDP-glucuronate decarboxylase N-terminal,MUTAGEN:E->A: Reduced UDP-glucuronic acid decarboxylase activity.,MUTAGEN:R->H: Strongly reduced UDP-glucuronic acid decarboxylase activity, caused by a local unfolding of the active site that allows for a rotation of the dimer interface, leading to the formation of a homohexamer.,MUTAGEN:R->Q: Strongly reduced UDP-glucuronic acid decarboxylase activity.,MUTAGEN:Y->F: Abolished UDP-glucuronic acid decarboxylase activity.,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
UPF2	UPF2 regulator of nonsense mediated mRNA decay(UPF2)	Homo sapiens			GO:0000184~nuclear-transcribed mRNA catabolic process, nonsense-mediated decay,GO:0001889~liver development,GO:0006406~mRNA export from nucleus,GO:0031100~animal organ regeneration,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005844~polysome,GO:0035145~exon-exon junction complex,GO:0036464~cytoplasmic ribonucleoprotein granule,GO:0048471~perinuclear region of cytoplasm,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0042162~telomeric DNA binding,	IPR003890:MIF4G-like_typ-3,IPR007193:Upf2/Nmd2_C,IPR016024:ARM-type_fold,IPR039762:Nmd2/UPF2,	hsa03013:Nucleocytoplasmic transport,hsa03015:mRNA surveillance pathway,			SM00543:MIF4G,	KW-0866~Nonsense-mediated mRNA decay,	KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0677~Repeat,		KW-0694~RNA-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,DOMAIN:MIF4G 1,DOMAIN:MIF4G 2,DOMAIN:MIF4G 3,MUTAGEN:D->K: Does not abolish interaction with UPF3B.,MUTAGEN:E->R: Abolishes interaction with UPF3B and association with SMG1 and RBM8A; reduces phosphorylation of UPF1.,MUTAGEN:E->R: Decreases interaction with UPF1.,MUTAGEN:ED->KR: Does not abolish interaction with UPF3B. Does not abolish interaction with UPF3B; when associated with D-854.,MUTAGEN:F->E: Abolishes interaction with UPF1.,MUTAGEN:F->E: Abolishes interaction with UPF1; reduces NMD efficiency.,MUTAGEN:F->E: Greatly reduces NMD efficiency; when associated with E-1173 and E-1174.,MUTAGEN:L->E: Abolishes interaction with UPF1; reduces NMD efficiency.,MUTAGEN:L->E: Greatly reduces NMD efficiency; when associated with E-1171 and E-1173.,MUTAGEN:M->E: Abolishes interaction with UPF1.,MUTAGEN:M->E: Decreases interaction with UPF1.,MUTAGEN:M->E: Decreases interaction with UPF1; does not reduce NMD efficiency.,MUTAGEN:M->E: Greatly reduces NMD efficiency; when associated with E-1171 and E-1174.,MUTAGEN:R->D: Does not abolish interaction with UPF3B; when associated with K-851 and R-852.,MUTAGEN:R->E: Decreases interaction with UPF1.,MUTAGEN:RK->EE: Strongly impairs RNA-binding.,MUTAGEN:Y->A: Does not impair RNA-binding; when associated with A-894.,MUTAGEN:Y->A: Does not impair RNA-binding; when associated with A-932.,REGION:Binds to UPF3B,REGION:Disordered,REGION:Interaction with UPF1,REGION:Necessary for interaction with UPF1,REGION:Sufficient for interaction with EIF4A1 and EIF1,REGION:Sufficient for interaction with UPF1,REGION:Sufficient for interaction with UPF1 C-terminus,REGION:Sufficient for interaction with UPF3A and UPF3B,
UPF3B	UPF3B regulator of nonsense mediated mRNA decay(UPF3B)	Homo sapiens			GO:0000184~nuclear-transcribed mRNA catabolic process, nonsense-mediated decay,GO:0007420~brain development,GO:0031175~neuron projection development,GO:0045666~positive regulation of neuron differentiation,GO:0045727~positive regulation of translation,GO:0051028~mRNA transport,GO:1905746~positive regulation of mRNA cis splicing, via spliceosome,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0034451~centriolar satellite,GO:0035145~exon-exon junction complex,GO:0043025~neuronal cell body,	GO:0003676~nucleic acid binding,GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0005515~protein binding,	IPR005120:UPF3_dom,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR034979:UPF3B_RRM-like,IPR035979:RBD_domain_sf,IPR039722:Upf3,	hsa03013:Nucleocytoplasmic transport,hsa03015:mRNA surveillance pathway,	300676~Intellectual developmental disorder, X-linked syndromic 14,			KW-0509~mRNA transport,KW-0813~Transport,KW-0866~Nonsense-mediated mRNA decay,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0991~Intellectual disability,			KW-0694~RNA-binding,	KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:UPF3,MUTAGEN:D->A: Reduces NMD.,MUTAGEN:K->A: Reduces NMD.,MUTAGEN:K->E: Abolishes interaction with UPF2.,MUTAGEN:L->F: Reduces NMD.,MUTAGEN:Missing: Abolishes NMD.,MUTAGEN:R->A: Impairs association with EJC.,MUTAGEN:R->A: Reduces NMD.,MUTAGEN:R->E: Abolishes NMD; when associated with E-447 and E-449.,MUTAGEN:R->E: Abolishes NMD; when associated with E-447 and E-451.,MUTAGEN:R->E: Abolishes NMD; when associated with E-449 and E-451.,MUTAGEN:R->E: Does not abolish interaction with UPF2.,MUTAGEN:VVIRRL->AVARRA: Abolishes interaction with UPF2.,MUTAGEN:Y->A: Impairs association with EJC.,MUTAGEN:YVF->DVD: Abolishes interaction with UPF2.,REGION:Binds to UPF2,REGION:Disordered,REGION:Necessary for interaction with RBM8A and for activating NMD,REGION:Necessary for interaction with UPF2,REGION:Sufficient for association with EJC core,
VAPA	VAMP associated protein A(VAPA)	Homo sapiens			GO:0006686~sphingomyelin biosynthetic process,GO:0006888~ER to Golgi vesicle-mediated transport,GO:0015914~phospholipid transport,GO:0015918~sterol transport,GO:0019076~viral release from host cell,GO:0030301~cholesterol transport,GO:0031175~neuron projection development,GO:0035627~ceramide transport,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0044828~negative regulation by host of viral genome replication,GO:0044829~positive regulation by host of viral genome replication,GO:0061025~membrane fusion,GO:0061817~endoplasmic reticulum-plasma membrane tethering,GO:0070972~protein localization to endoplasmic reticulum,GO:0090114~COPII-coated vesicle budding,	GO:0000139~Golgi membrane,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005923~bicellular tight junction,GO:0015630~microtubule cytoskeleton,GO:0031965~nuclear membrane,GO:0031982~vesicle,GO:0035577~azurophil granule membrane,GO:0048471~perinuclear region of cytoplasm,	GO:0005515~protein binding,GO:0008017~microtubule binding,GO:0019904~protein domain specific binding,GO:0033149~FFAT motif binding,GO:0042803~protein homodimerization activity,GO:0045296~cadherin binding,GO:0046982~protein heterodimerization activity,	IPR000535:MSP_dom,IPR008962:PapD-like_sf,IPR013783:Ig-like_fold,IPR016763:VAP,	hsa04979:Cholesterol metabolism,		PIRSF019693:VAMP-associated,		KW-0945~Host-virus interaction,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0539~Nucleus,KW-0796~Tight junction,KW-0965~Cell junction,KW-1003~Cell membrane,		KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	DISULFID:Interchain,DOMAIN:MSP,MUTAGEN:K->D: Alters interaction with ZFYVE27, impairs interaction with WDR44 and prevents binding to the FFAT motif in target proteins; when associated with D-96.,MUTAGEN:K->L: Impairs the interaction of the MSP domain with the phosphorylated FFAT motif of STARD3. Does not affect its ability to interact with the conventional FFAT motif of OSBPL1A.,MUTAGEN:M->D: Alters interaction with ZFYVE27, impairs interaction with WDR44 and prevents binding to the FFAT motif in target proteins; when associated with D-94.,MUTAGEN:Missing: Impaired interaction with WDR44.,REGION:Disordered,REGION:phosphorylated FFAT motif binding,SITE:Involved in binding the phosphorylated serine of the phospho-FFAT motif,TOPO_DOM:Cytoplasmic,TRANSMEM:Helical; Anchor for type IV membrane protein,
VBP1	VHL binding protein 1(VBP1)	Homo sapiens			GO:0006457~protein folding,GO:0007017~microtubule-based process,GO:0007021~tubulin complex assembly,GO:0061077~chaperone-mediated protein folding,GO:1905907~negative regulation of amyloid fibril formation,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005844~polysome,GO:0016272~prefoldin complex,GO:0043231~intracellular membrane-bounded organelle,	GO:0001540~beta-amyloid binding,GO:0005515~protein binding,GO:0015631~tubulin binding,GO:0051082~unfolded protein binding,	IPR004127:Prefoldin_subunit_alpha,IPR009053:Prefoldin,IPR016655:PFD3,			PIRSF016396:Prefoldin_subunit_3,			KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,		KW-0143~Chaperone,	KW-0007~Acetylation,
VOPP1	VOPP1 WW domain binding protein(VOPP1)	Homo sapiens				GO:0005764~lysosome,GO:0005765~lysosomal membrane,GO:0005768~endosome,GO:0005770~late endosome,GO:0030659~cytoplasmic vesicle membrane,GO:0031090~organelle membrane,GO:0031902~late endosome membrane,	GO:0005515~protein binding,GO:0019899~enzyme binding,	IPR026229:VOPP1,					KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0458~Lysosome,KW-0472~Membrane,KW-0967~Endosome,KW-0968~Cytoplasmic vesicle,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,				COMPBIAS:Polar residues,COMPBIAS:Pro residues,MUTAGEN:Y->A: Does not affect binding to WWOX.,MUTAGEN:Y->A: Reduces binding to WWOX.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
VPS26B	VPS26 retromer complex component B(VPS26B)	Homo sapiens			GO:0006886~intracellular protein transport,GO:0016241~regulation of macroautophagy,GO:0042147~retrograde transport, endosome to Golgi,GO:0071346~cellular response to interferon-gamma,	GO:0005768~endosome,GO:0005769~early endosome,GO:0005770~late endosome,GO:0005829~cytosol,GO:0016020~membrane,GO:0030904~retromer complex,GO:0030906~retromer, cargo-selective complex,GO:0045335~phagocytic vesicle,	GO:0005515~protein binding,	IPR014752:Arrestin-like_C,IPR028934:Vps26-related,	hsa04144:Endocytosis,				KW-0653~Protein transport,KW-0813~Transport,	KW-0472~Membrane,KW-0963~Cytoplasm,KW-0967~Endosome,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,	TRANSMEM:Helical,
VPS28	VPS28 subunit of ESCRT-I(VPS28)	Homo sapiens			GO:0015031~protein transport,GO:0016236~macroautophagy,GO:0031397~negative regulation of protein ubiquitination,GO:0032509~endosome transport via multivesicular body sorting pathway,GO:0036258~multivesicular body assembly,GO:0039702~viral budding via host ESCRT complex,GO:0043162~ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway,GO:0043328~protein targeting to vacuole involved in ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway,GO:0045732~positive regulation of protein catabolic process,GO:0090148~membrane fission,GO:2000397~positive regulation of ubiquitin-dependent endocytosis,	GO:0000813~ESCRT I complex,GO:0005737~cytoplasm,GO:0005768~endosome,GO:0005769~early endosome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0010008~endosome membrane,GO:0031902~late endosome membrane,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0043130~ubiquitin binding,GO:0044877~macromolecular complex binding,	IPR007143:Vps28,IPR017898:VPS28_N,IPR017899:VPS28_C,IPR037202:ESCRT_assembly_dom,IPR037206:VPS28_C_sf,IPR038358:VPS28_N_sf,	hsa04144:Endocytosis,		PIRSF017535:VPS28,		KW-0653~Protein transport,KW-0813~Transport,	KW-0472~Membrane,KW-0967~Endosome,KW-1003~Cell membrane,					KW-0007~Acetylation,	DOMAIN:VPS28 C-terminal,DOMAIN:VPS28 N-terminal,
VPS29	VPS29 retromer complex component(VPS29)	Homo sapiens			GO:0006886~intracellular protein transport,GO:0015031~protein transport,GO:0032456~endocytic recycling,GO:0042147~retrograde transport, endosome to Golgi,	GO:0005768~endosome,GO:0005769~early endosome,GO:0005770~late endosome,GO:0005829~cytosol,GO:0010008~endosome membrane,GO:0030904~retromer complex,GO:0030906~retromer, cargo-selective complex,GO:0043231~intracellular membrane-bounded organelle,	GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR000979:Phosphodiesterase_MJ0936/Vps29,IPR004843:Calcineurin-like_PHP_ApaH,IPR024654:Calcineurin-like_PHP_lpxH,IPR028661:Vps29,IPR029052:Metallo-depent_PP-like,	hsa04144:Endocytosis,				KW-0653~Protein transport,KW-0813~Transport,KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-0963~Cytoplasm,KW-0967~Endosome,			KW-0479~Metal-binding,KW-0862~Zinc,		KW-0007~Acetylation,	DOMAIN:Calcineurin-like phosphoesterase,MUTAGEN:D->A,N: Loss of in vitro protein phosphatase activity.,MUTAGEN:D->A: Loss of in vitro protein phosphatase activity.,MUTAGEN:H->A: Loss of in vitro protein phosphatase activity.,MUTAGEN:I->D: Disrupts interaction with VPS35.,MUTAGEN:L->E: Disrupts interaction with TBC1D5.,MUTAGEN:N->A: Loss of in vitro protein phosphatase activity.,MUTAGEN:N->D: No effect on in vitro protein phosphatase activity.,MUTAGEN:V->D: Decreases interaction with VPS35.,REGION:Disordered,
VPS35	VPS35 retromer complex component(VPS35)	Homo sapiens			GO:0006886~intracellular protein transport,GO:0007040~lysosome organization,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0010821~regulation of mitochondrion organization,GO:0015031~protein transport,GO:0016055~Wnt signaling pathway,GO:0016241~regulation of macroautophagy,GO:0031647~regulation of protein stability,GO:0031648~protein destabilization,GO:0032456~endocytic recycling,GO:0032463~negative regulation of protein homooligomerization,GO:0036010~protein localization to endosome,GO:0042147~retrograde transport, endosome to Golgi,GO:0043653~mitochondrial fragmentation involved in apoptotic process,GO:0045056~transcytosis,GO:0045732~positive regulation of protein catabolic process,GO:0050728~negative regulation of inflammatory response,GO:0050804~modulation of synaptic transmission,GO:0050882~voluntary musculoskeletal movement,GO:0051246~regulation of protein metabolic process,GO:0060161~positive regulation of dopamine receptor signaling pathway,GO:0061357~positive regulation of Wnt protein secretion,GO:0090128~regulation of synapse maturation,GO:0090141~positive regulation of mitochondrial fission,GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:0090326~positive regulation of locomotion involved in locomotory behavior,GO:0098887~neurotransmitter receptor transport, endosome to postsynaptic membrane,GO:0099003~vesicle-mediated transport in synapse,GO:0099074~mitochondrion to lysosome transport,GO:0099639~neurotransmitter receptor transport, endosome to plasma membrane,GO:1902823~negative regulation of late endosome to lysosome transport,GO:1902950~regulation of dendritic spine maintenance,GO:1903181~positive regulation of dopamine biosynthetic process,GO:1903828~negative regulation of cellular protein localization,GO:1904377~positive regulation of protein localization to cell periphery,GO:1905166~negative regulation of lysosomal protein catabolic process,GO:1905606~regulation of presynapse assembly,GO:2000331~regulation of terminal button organization,	GO:0005739~mitochondrion,GO:0005764~lysosome,GO:0005765~lysosomal membrane,GO:0005768~endosome,GO:0005769~early endosome,GO:0005770~late endosome,GO:0005829~cytosol,GO:0010008~endosome membrane,GO:0014069~postsynaptic density,GO:0030904~retromer complex,GO:0030906~retromer, cargo-selective complex,GO:0043005~neuron projection,GO:0043025~neuronal cell body,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,GO:0097422~tubular endosome,GO:0098793~presynapse,GO:0098978~glutamatergic synapse,GO:0099073~mitochondrion-derived vesicle,	GO:0005515~protein binding,GO:0031748~D1 dopamine receptor binding,	IPR005378:Vps35,IPR016024:ARM-type_fold,IPR042491:Vps35_C,	hsa04144:Endocytosis,	614203~Parkinson disease 17,	PIRSF009375:Retromer_Vps35,		KW-0653~Protein transport,KW-0813~Transport,KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-0963~Cytoplasm,KW-0967~Endosome,	KW-0523~Neurodegeneration,KW-0907~Parkinson disease,KW-0908~Parkinsonism,				KW-0597~Phosphoprotein,	MUTAGEN:H->R: Disrupts interaction with VPS29. Does not effect interaction with VPS26.,MUTAGEN:L->P: Disrupts interaction with VPS26; no effect on interaction with VPS29.,REGION:Disordered,REGION:Interaction with IGF2R cytoplasmic domain,REGION:Interaction with SLC11A2,REGION:Interaction with SNX3,
VPS37B	VPS37B subunit of ESCRT-I(VPS37B)	Homo sapiens			GO:0006612~protein targeting to membrane,GO:0006623~protein targeting to vacuole,GO:0009056~catabolic process,GO:0015031~protein transport,GO:0016236~macroautophagy,GO:0019076~viral release from host cell,GO:0036258~multivesicular body assembly,GO:0039702~viral budding via host ESCRT complex,GO:0043162~ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway,GO:0043328~protein targeting to vacuole involved in ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway,GO:0090148~membrane fission,GO:1903774~positive regulation of viral budding via host ESCRT complex,	GO:0000813~ESCRT I complex,GO:0005737~cytoplasm,GO:0005768~endosome,GO:0005886~plasma membrane,GO:0010008~endosome membrane,GO:0030496~midbody,GO:0031902~late endosome membrane,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0048306~calcium-dependent protein binding,	IPR009851:Mod_r,IPR029012:Helix_hairpin_bin_sf,IPR037202:ESCRT_assembly_dom,	hsa04144:Endocytosis,				KW-0653~Protein transport,KW-0813~Transport,	KW-0472~Membrane,KW-0967~Endosome,		KW-0732~Signal,			KW-0488~Methylation,	COMPBIAS:Pro residues,DOMAIN:VPS37 C-terminal,REGION:Disordered,REGION:Interaction with IST1,
VRK3	VRK serine/threonine kinase 3(VRK3)	Homo sapiens			GO:0007165~signal transduction,GO:0007519~skeletal muscle tissue development,GO:0016310~phosphorylation,GO:0018105~peptidyl-serine phosphorylation,GO:0070373~negative regulation of ERK1 and ERK2 cascade,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0043231~intracellular membrane-bounded organelle,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016301~kinase activity,GO:0019903~protein phosphatase binding,	IPR000719:Prot_kinase_dom,IPR011009:Kinase-like_dom_sf,IPR026870:Zinc_ribbon_dom,				SM00220:S_TKc,		KW-0539~Nucleus,			KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:Protein kinase,DOMAIN:Zinc-ribbon,MOTIF:Nuclear localization signal,REGION:Disordered,
WAPL	WAPL cohesin release factor(WAPL)	Homo sapiens			GO:0000070~mitotic sister chromatid segregation,GO:0008156~negative regulation of DNA replication,GO:0035562~negative regulation of chromatin binding,GO:0045875~negative regulation of sister chromatid cohesion,GO:0051301~cell division,GO:0071168~protein localization to chromatin,GO:0071922~regulation of cohesin loading,	GO:0000775~chromosome, centromeric region,GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005694~chromosome,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0043231~intracellular membrane-bounded organelle,GO:0045171~intercellular bridge,GO:0072686~mitotic spindle,	GO:0005515~protein binding,	IPR011989:ARM-like,IPR012502:WAPL_dom,IPR016024:ARM-type_fold,IPR022771:WAPL_C,IPR039874:WAPL,	hsa04110:Cell cycle,				KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,KW-0945~Host-virus interaction,	KW-0158~Chromosome,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,DOMAIN:WAPL,MOTIF:FGF motif 1,MOTIF:FGF motif 2,MOTIF:FGF motif 3,MUTAGEN:DD->KK: Impaired sister chromatid cohesion and resolution.,MUTAGEN:E->K: No effect.,MUTAGEN:FGF->EGE: Loss of interaction with PDS5B; when associated with 429-E--E-431 and 453-E--E-455.,MUTAGEN:FGF->EGE: Loss of interaction with PDS5B; when associated with 73-E--E-75 and 429-E--E-431.,MUTAGEN:FGF->EGE: Loss of interaction with PDS5B; when associated with 73-E--E-75 and 453-E--E-455.,MUTAGEN:I->A: Impaired sister chromatid cohesion and resolution; when associated with A-1116.,MUTAGEN:M->A: Impaired sister chromatid cohesion and resolution; when associated with A-1120.,MUTAGEN:T->A: No effect.,MUTAGEN:VK->AE: Impaired sister chromatid cohesion and resolution.,REGION:Disordered,REGION:Mediates interaction with the cohesin complex,
WHAMM	WASP homolog associated with actin, golgi membranes and microtubules(WHAMM)	Homo sapiens			GO:0006888~ER to Golgi vesicle-mediated transport,GO:0007015~actin filament organization,GO:0030032~lamellipodium assembly,GO:0034314~Arp2/3 complex-mediated actin nucleation,GO:0048041~focal adhesion assembly,GO:0051127~positive regulation of actin nucleation,GO:0097320~plasma membrane tubulation,	GO:0000139~Golgi membrane,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005874~microtubule,GO:0030659~cytoplasmic vesicle membrane,GO:0033116~endoplasmic reticulum-Golgi intermediate compartment membrane,	GO:0003779~actin binding,GO:0008017~microtubule binding,GO:0031267~small GTPase binding,GO:0071933~Arp2/3 complex binding,	IPR003124:WH2_dom,IPR031738:JMY/WHAMM,IPR031808:JMY/WHAMM_N,	hsa04530:Tight junction,					KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0493~Microtubule,KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,		KW-0175~Coiled coil,KW-0677~Repeat,		KW-0009~Actin-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:WH2 1,DOMAIN:WH2 2,MUTAGEN:W->A: Decreases nucleation-promoting factor activity and Arp2/3 complex activation.,REGION:Disordered,REGION:Mediates actin nucleation,REGION:Mediates association with membranes,REGION:Mediates interaction with microtubules,
WSB1	WD repeat and SOCS box containing 1(WSB1)	Homo sapiens			GO:0000209~protein polyubiquitination,GO:0016310~phosphorylation,GO:0016567~protein ubiquitination,GO:0035556~intracellular signal transduction,GO:0044314~protein K27-linked ubiquitination,	GO:0005829~cytosol,	GO:0005515~protein binding,GO:0016301~kinase activity,GO:0061630~ubiquitin protein ligase activity,	IPR001496:SOCS_box,IPR001680:WD40_rpt,IPR011047:Quinoprotein_ADH-like_supfam,IPR015943:WD40/YVTN_repeat-like_dom_sf,IPR019775:WD40_repeat_CS,IPR020472:G-protein_beta_WD-40_rep,IPR036036:SOCS_box-like_dom_sf,IPR036322:WD40_repeat_dom_sf,				SM00253:SOCS,SM00320:WD40,SM00969:SOCS_box,	KW-0833~Ubl conjugation pathway,			KW-0677~Repeat,KW-0732~Signal,KW-0853~WD repeat,		KW-0418~Kinase,KW-0808~Transferase,		DOMAIN:SOCS box,REGION:Disordered,REPEAT:WD,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,
WRAP73	WD repeat containing, antisense to TP73(WRAP73)	Homo sapiens			GO:0030030~cell projection organization,GO:0090307~mitotic spindle assembly,GO:1902857~positive regulation of non-motile cilium assembly,	GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005814~centriole,GO:0005815~microtubule organizing center,GO:0034451~centriolar satellite,GO:0036064~ciliary basal body,GO:0072686~mitotic spindle,GO:1990811~Msd1-Wdr8-Pkl1 complex,	GO:0005515~protein binding,	IPR001680:WD40_rpt,IPR015943:WD40/YVTN_repeat-like_dom_sf,IPR036322:WD40_repeat_dom_sf,				SM00320:WD40,	KW-0970~Cilium biogenesis/degradation,	KW-0206~Cytoskeleton,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0853~WD repeat,			KW-0597~Phosphoprotein,	REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,
WDR18	WD repeat domain 18(WDR18)	Homo sapiens			GO:0006261~DNA-dependent DNA replication,GO:0006364~rRNA processing,	GO:0005654~nucleoplasm,GO:0005656~nuclear pre-replicative complex,GO:0005730~nucleolus,GO:0097344~Rix1 complex,	GO:0005515~protein binding,	IPR001680:WD40_rpt,IPR015943:WD40/YVTN_repeat-like_dom_sf,IPR019775:WD40_repeat_CS,IPR020472:G-protein_beta_WD-40_rep,IPR026987:Wdr18_C_dom,IPR036322:WD40_repeat_dom_sf,IPR045227:WDR18/Ipi3/RID3,				SM00320:WD40,	KW-0698~rRNA processing,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0853~WD repeat,		KW-0217~Developmental protein,KW-9996~Developmental protein,		DOMAIN:WD repeat-containing protein 18 C-terminal,REPEAT:WD,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,
WDR33	WD repeat domain 33(WDR33)	Homo sapiens			GO:0006301~postreplication repair,GO:0006378~mRNA polyadenylation,GO:0007283~spermatogenesis,GO:0031124~mRNA 3'-end processing,	GO:0001650~fibrillar center,GO:0005581~collagen trimer,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005847~mRNA cleavage and polyadenylation specificity factor complex,	GO:0003723~RNA binding,	IPR001680:WD40_rpt,IPR008160:Collagen,IPR015943:WD40/YVTN_repeat-like_dom_sf,IPR036322:WD40_repeat_dom_sf,IPR045245:Pfs2-like,	hsa03015:mRNA surveillance pathway,			SM00320:WD40,	KW-0507~mRNA processing,	KW-0539~Nucleus,		KW-0176~Collagen,KW-0677~Repeat,KW-0853~WD repeat,			KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Collagen-like,REGION:Disordered,REPEAT:WD,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,REPEAT:WD 7,
WDR45	WD repeat domain 45(WDR45)	Homo sapiens			GO:0000045~autophagosome assembly,GO:0000422~mitophagy,GO:0006497~protein lipidation,GO:0006914~autophagy,GO:0009267~cellular response to starvation,GO:0030242~pexophagy,GO:0034497~protein localization to pre-autophagosomal structure,GO:0044804~nucleophagy,GO:0061723~glycophagy,GO:2000786~positive regulation of autophagosome assembly,	GO:0000407~pre-autophagosomal structure,GO:0005829~cytosol,GO:0019898~extrinsic component of membrane,GO:0034045~pre-autophagosomal structure membrane,	GO:0005515~protein binding,GO:0019901~protein kinase binding,GO:0032266~phosphatidylinositol-3-phosphate binding,GO:0080025~phosphatidylinositol-3,5-bisphosphate binding,GO:1901981~phosphatidylinositol phosphate binding,	IPR001680:WD40_rpt,IPR015943:WD40/YVTN_repeat-like_dom_sf,IPR036322:WD40_repeat_dom_sf,IPR048720:PROPPIN,	hsa04140:Autophagy - animal,	300894~Neurodegeneration with brain iron accumulation 5,		SM00320:WD40,	KW-0072~Autophagy,	KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0523~Neurodegeneration,	KW-0677~Repeat,KW-0853~WD repeat,	KW-0446~Lipid-binding,			MOTIF:L/FRRG motif,MUTAGEN:D->A: Decreased interaction with ATG2A. Loss of interaction with ATG2A; when associated with A-15.,MUTAGEN:D->A: Loss of interaction with AMPK. No effect on interaction with ATG2A.,MUTAGEN:E->A: No effect on interaction with ATG2A.,MUTAGEN:H->A: No effect on interaction with ATG2A.,MUTAGEN:K->A: No effect on interaction with ATG2A.,MUTAGEN:N->A: Decreased interaction with ATG2A. Loss of interaction with ATG2A; when associated with A-17.,MUTAGEN:Q->A: No effect on interaction with ATG2A.,MUTAGEN:R->A: No effect on interaction with ATG2A.,MUTAGEN:RR->AA: No effect on interaction with ATG2A.,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,REPEAT:WD 7,
WDR46	WD repeat domain 46(WDR46)	Homo sapiens			GO:0000462~maturation of SSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA),GO:0042274~ribosomal small subunit biogenesis,	GO:0005581~collagen trimer,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005840~ribosome,GO:0032040~small-subunit processome,	GO:0003723~RNA binding,	IPR001680:WD40_rpt,IPR012952:BING4_C_dom,IPR015943:WD40/YVTN_repeat-like_dom_sf,IPR036322:WD40_repeat_dom_sf,IPR040315:WDR46/Utp7,				SM00320:WD40,SM01033:BING4CT,		KW-0539~Nucleus,		KW-0176~Collagen,KW-0677~Repeat,KW-0853~WD repeat,		KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:BING4 C-terminal,REGION:Disordered,REPEAT:WD,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,
WDR48	WD repeat domain 48(WDR48)	Homo sapiens			GO:0000724~double-strand break repair via homologous recombination,GO:0006974~cellular response to DNA damage stimulus,GO:0007283~spermatogenesis,GO:0007338~single fertilization,GO:0035264~multicellular organism growth,GO:0043588~skin development,GO:0046427~positive regulation of JAK-STAT cascade,GO:0048568~embryonic organ development,GO:0048705~skeletal system morphogenesis,GO:0048872~homeostasis of number of cells,GO:0050679~positive regulation of epithelial cell proliferation,GO:0072520~seminiferous tubule development,GO:1902525~regulation of protein monoubiquitination,GO:1905168~positive regulation of double-strand break repair via homologous recombination,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005764~lysosome,GO:0005770~late endosome,GO:0005829~cytosol,GO:0043231~intracellular membrane-bounded organelle,	GO:0003677~DNA binding,GO:0003690~double-stranded DNA binding,GO:0003697~single-stranded DNA binding,GO:0005515~protein binding,GO:0035800~deubiquitinase activator activity,GO:0043130~ubiquitin binding,	IPR001680:WD40_rpt,IPR015943:WD40/YVTN_repeat-like_dom_sf,IPR019775:WD40_repeat_CS,IPR020472:G-protein_beta_WD-40_rep,IPR021772:WDR48/Bun107,IPR036322:WD40_repeat_dom_sf,	hsa03460:Fanconi anemia pathway,			SM00320:WD40,	KW-0227~DNA damage,KW-0234~DNA repair,KW-0833~Ubl conjugation pathway,KW-0945~Host-virus interaction,	KW-0458~Lysosome,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0967~Endosome,		KW-0677~Repeat,KW-0853~WD repeat,		KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	MUTAGEN:H->A: Does not affect interaction with RAD51AP1.,MUTAGEN:I->A: In UAF1(11A); impaired DNA-binding; when associated with A-30, A-50, A-117, A-161, A-168, A-230, A-272, A-274, A-275 and A-318. In UAF1(11A); does not affect ability to promote USP1-mediated deubiquitination of FANCD2 and stimulate RAD51-mediated homologous recombination, because of DNA-binding mediated by RAD51AP1; when associated with A-30, A-50, A-117, A-161, A-168, A-230, A-272, A-274, A-275 and A-318.,MUTAGEN:K->A: In UAF1(11A); impaired DNA-binding; when associated with A-30, A-50, A-117, A-161, A-168, A-230, A-272, A-274, A-275 and A-363. In UAF1(11A); does not affect ability to promote USP1-mediated deubiquitination of FANCD2 and stimulate RAD51-mediated homologous recombination, because of DNA-binding mediated by RAD51AP1; when associated with A-30, A-50, A-117, A-161, A-168, A-230, A-272, A-274, A-275 and A-363.,MUTAGEN:K->A: In UAF1(11A); impaired DNA-binding; when associated with A-30, A-50, A-117, A-161, A-168, A-230, A-272, A-274, A-318 and A-363. In UAF1(11A); does not affect ability to promote USP1-mediated deubiquitination of FANCD2 and stimulate RAD51-mediated homologous recombination, because of DNA-binding mediated by RAD51AP1; when associated with A-30, A-50, A-117, A-161, A-168, A-230, A-272, A-274, A-318 and A-363.,MUTAGEN:K->A: In UAF1(11A); impaired DNA-binding; when associated with A-30, A-50, A-161, A-168, A-230, A-272, A-274, A-275, A-318 and A-363. In UAF1(11A); does not affect ability to promote USP1-mediated deubiquitination of FANCD2 and stimulate RAD51-mediated homologous recombination, because of DNA-binding mediated by RAD51AP1; when associated with A-30, A-50, A-161, A-168, A-230, A-272, A-274, A-275, A-318 and A-363.,MUTAGEN:K->A: In UAF1(3A); impaired DNA-binding; when associated with A-30 and A-50. In UAF1(3A); does not affect ability to promote USP1-mediated deubiquitination of FANCD2 and stimulate RAD51-mediated homologous recombination, because of DNA-binding mediated by RAD51AP1; when associated with A-30 and A-50. In UAF1(11A); impaired DNA-binding; when associated with A-30, A-50, A-117, A-161, A-230, A-272, A-274, A-275, A-318 and A-363. In UAF1(11A); does not affect ability to promote USP1-mediated deubiquitination of FANCD2 and stimulate RAD51-mediated homologous recombination, because of DNA-binding mediated by RAD51AP1; when associated with A-30, A-50, A-117, A-161, A-230, A-272, A-274, A-275, A-318 and A-363.,MUTAGEN:K->E: Decreased interaction with RAD51AP1.,MUTAGEN:K->E: Does not affect interaction with RAD51AP1.,MUTAGEN:K->E: Strongly reduces interaction with USP12 or USP46 and abolishes stimulation of their enzyme activity; when associated with A-256 and D-272.,MUTAGEN:KVMEH->EVMEA: Decreased interaction with RAD51AP1.,MUTAGEN:L->F: Impaired binding to PHLPP1. Defective in stabilizing PHLPP1.,MUTAGEN:R->A: In UAF1(11A); impaired DNA-binding; when associated with A-30, A-50, A-117, A-161, A-168, A-230, A-272, A-275, A-318 and A-363. In UAF1(11A); does not affect ability to promote USP1-mediated deubiquitination of FANCD2 and stimulate RAD51-mediated homologous recombination, because of DNA-binding mediated by RAD51AP1; when associated with A-30, A-50, A-117, A-161, A-168, A-230, A-272, A-275, A-318 and A-363.,MUTAGEN:R->A: In UAF1(11A); impaired DNA-binding; when associated with A-30, A-50, A-117, A-161, A-168, A-230, A-274, A-275, A-318 and A-363. In UAF1(11A); does not affect ability to promote USP1-mediated deubiquitination of FANCD2 and stimulate RAD51-mediated homologous recombination, because of DNA-binding mediated by RAD51AP1; when associated with A-30, A-50, A-117, A-161, A-168, A-230, A-274, A-275, A-318 and A-363.,MUTAGEN:R->A: In UAF1(3A); impaired DNA-binding; when associated with A-30 and A-168. In UAF1(3A); does not affect ability to promote USP1-mediated deubiquitination of FANCD2 and stimulate RAD51-mediated homologous recombination, because of DNA-binding mediated by RAD51AP1; when associated with A-30 and A-168. In UAF1(11A); impaired DNA-binding; when associated with A-30, A-117, A-161, A-168, A-230, A-272, A-274, A-275, A-318 and A-363. In UAF1(11A); does not affect ability to promote USP1-mediated deubiquitination of FANCD2 and stimulate RAD51-mediated homologous recombination, because of DNA-binding mediated by RAD51AP1; when associated with A-30, A-117, A-161, A-168, A-230, A-272, A-274, A-275, A-318 and A-363.,MUTAGEN:R->A: In UAF1(3A); impaired DNA-binding; when associated with A-50 and A-168. In UAF1(3A); does not affect ability to promote USP1-mediated deubiquitination of FANCD2 and stimulate RAD51-mediated homologous recombination, because of DNA-binding mediated by RAD51AP1; when associated with A-50 and A-168. In UAF1(11A); impaired DNA-binding; when associated with A-50, A-117, A-161, A-168, A-230, A-272, A-274, A-275, A-318 and A-363. In UAF1(11A); does not affect ability to promote USP1-mediated deubiquitination of FANCD2 and stimulate RAD51-mediated homologous recombination, because of DNA-binding mediated by RAD51AP1; when associated with A-50, A-117, A-161, A-168, A-230, A-272, A-274, A-275, A-318 and A-363.,MUTAGEN:R->D: Strongly reduces interaction with USP12 or USP46 and abolishes stimulation of their enzyme activity; when associated with E-214 and A-256.,MUTAGEN:S->A: In UAF1(11A); impaired DNA-binding; when associated with A-30, A-50, A-117, A-161, A-168, A-272, A-274, A-275, A-318 and A-363. In UAF1(11A); does not affect ability to promote USP1-mediated deubiquitination of FANCD2 and stimulate RAD51-mediated homologous recombination, because of DNA-binding mediated by RAD51AP1; when associated with A-30, A-50, A-117, A-161, A-168, A-272, A-274, A-275, A-318 and A-363.,MUTAGEN:S->Y: Strongly reduces interaction with USP46 and abolishes stimulation of USP46 enzyme activity.,MUTAGEN:T->A: In UAF1(11A); impaired DNA-binding; when associated with A-30, A-50, A-117, A-168, A-230, A-272, A-274, A-275, A-318 and A-363. In UAF1(11A); does not affect ability to promote USP1-mediated deubiquitination of FANCD2 and stimulate RAD51-mediated homologous recombination, because of DNA-binding mediated by RAD51AP1; when associated with A-30, A-50, A-117, A-168, A-230, A-272, A-274, A-275, A-318 and A-363.,MUTAGEN:W->A: Impaired binding to USP12; when associated with Ala-256.,MUTAGEN:W->A: Strongly reduces interaction with USP12 or USP46 and abolishes stimulation of their enzyme activity; when associated with E-214 and D-272. Impaired binding to USP12; when associated with Ala-77.,MUTAGEN:Y->A: Impaired binding to USP12; when associated with Ala-119.,MUTAGEN:Y->A: Impaired binding to USP12; when associated with Ala-172.,REGION:Disordered,REPEAT:WD,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,REPEAT:WD 7,REPEAT:WD 8,
WDR83OS	WD repeat domain 83 opposite strand(WDR83OS)	Homo sapiens			GO:0006457~protein folding,GO:0045048~protein insertion into ER membrane,	GO:0005789~endoplasmic reticulum membrane,GO:0101031~chaperone complex,	GO:0005515~protein binding,GO:0044183~protein binding involved in protein folding,	IPR005351:ASTER,						KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0143~Chaperone,	KW-0007~Acetylation,	REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
WIPI2	WD repeat domain, phosphoinositide interacting 2(WIPI2)	Homo sapiens			GO:0000045~autophagosome assembly,GO:0000422~mitophagy,GO:0006497~protein lipidation,GO:0009267~cellular response to starvation,GO:0030242~pexophagy,GO:0034497~protein localization to pre-autophagosomal structure,GO:0044804~nucleophagy,GO:0061723~glycophagy,GO:0098792~xenophagy,	GO:0000407~pre-autophagosomal structure,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0016020~membrane,GO:0019898~extrinsic component of membrane,GO:0032991~macromolecular complex,GO:0034045~pre-autophagosomal structure membrane,	GO:0005515~protein binding,GO:0010314~phosphatidylinositol-5-phosphate binding,GO:0032266~phosphatidylinositol-3-phosphate binding,GO:0080025~phosphatidylinositol-3,5-bisphosphate binding,	IPR001680:WD40_rpt,IPR015943:WD40/YVTN_repeat-like_dom_sf,IPR036322:WD40_repeat_dom_sf,IPR048720:PROPPIN,	hsa04136:Autophagy - other,hsa04140:Autophagy - animal,hsa05010:Alzheimer disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05017:Spinocerebellar ataxia,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05131:Shigellosis,	618453~Intellectual developmental disorder with short stature and variable skeletal anomalies,		SM00320:WD40,	KW-0072~Autophagy,	KW-0472~Membrane,	KW-0225~Disease variant,KW-0991~Intellectual disability,	KW-0677~Repeat,KW-0853~WD repeat,	KW-0446~Lipid-binding,		KW-0597~Phosphoprotein,	MOTIF:L/FRRG motif,MUTAGEN:R->E: Decreasess interaction with ATG16L1.,MUTAGEN:R->E: Impairs interaction with ATG16L1.,MUTAGEN:R->T: Impairs preautophagosomal localization; when associated with T-242.,MUTAGEN:R->T: Impairs preautophagosomal localization; when associated with T-243.,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,REPEAT:WD 7,
WNK1	WNK lysine deficient protein kinase 1(WNK1)	Homo sapiens			GO:0002028~regulation of sodium ion transport,GO:0003084~positive regulation of systemic arterial blood pressure,GO:0006468~protein phosphorylation,GO:0006811~ion transport,GO:0006884~cell volume homeostasis,GO:0007165~signal transduction,GO:0007507~heart development,GO:0010507~negative regulation of autophagy,GO:0010766~negative regulation of sodium ion transport,GO:0010793~regulation of mRNA export from nucleus,GO:0010820~positive regulation of T cell chemotaxis,GO:0016310~phosphorylation,GO:0018105~peptidyl-serine phosphorylation,GO:0018107~peptidyl-threonine phosphorylation,GO:0030644~cellular chloride ion homeostasis,GO:0031397~negative regulation of protein ubiquitination,GO:0033633~negative regulation of cell-cell adhesion mediated by integrin,GO:0034115~negative regulation of heterotypic cell-cell adhesion,GO:0034260~negative regulation of GTPase activity,GO:0035556~intracellular signal transduction,GO:0035725~sodium ion transmembrane transport,GO:0038116~chemokine (C-C motif) ligand 21 signaling pathway,GO:0045050~protein insertion into ER membrane by stop-transfer membrane-anchor sequence,GO:0045766~positive regulation of angiogenesis,GO:0048666~neuron development,GO:0050852~T cell receptor signaling pathway,GO:0055075~potassium ion homeostasis,GO:0055080~cation homeostasis,GO:0071474~cellular hyperosmotic response,GO:0090188~negative regulation of pancreatic juice secretion,GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:0097022~lymphocyte migration into lymph node,GO:1902305~regulation of sodium ion transmembrane transport,GO:1903038~negative regulation of leukocyte cell-cell adhesion,GO:1903077~negative regulation of protein localization to plasma membrane,GO:1903490~positive regulation of mitotic cytokinesis,GO:1904062~regulation of cation transmembrane transport,GO:1904595~positive regulation of termination of RNA polymerase II transcription,GO:1990869~cellular response to chemokine,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016020~membrane,GO:0032991~macromolecular complex,GO:0043232~intracellular non-membrane-bounded organelle,GO:0072686~mitotic spindle,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016301~kinase activity,GO:0019901~protein kinase binding,GO:0019902~phosphatase binding,GO:0030295~protein kinase activator activity,	IPR000719:Prot_kinase_dom,IPR008271:Ser/Thr_kinase_AS,IPR011009:Kinase-like_dom_sf,IPR024678:Kinase_OSR1/WNK_CCT,		201300~Neuropathy, hereditary sensory and autonomic, type II,614492~Pseudohypoaldosteronism, type IIC,		SM00220:S_TKc,		KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0523~Neurodegeneration,KW-0622~Neuropathy,		KW-0067~ATP-binding,KW-0547~Nucleotide-binding,KW-0868~Chloride,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	ACT_SITE:Proton acceptor,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Protein kinase,MOTIF:RFXV motif 1,MOTIF:RFXV motif 2,MOTIF:RFXV motif 3,MOTIF:RFXV motif 4,MUTAGEN:D->A,K: Abolished interaction with EMC2.,MUTAGEN:D->A,K: Does not affect interaction with EMC2.,MUTAGEN:D->A: Abolished serine/threonine-protein kinase activity.,MUTAGEN:D->K: Does not affect interaction with EMC2.,MUTAGEN:F->A: Slightly decreased binding to OXSR1/OSR1 and STK39/SPAK; when associated with A-1258. Abolished binding to OXSR1/OSR1 and STK39/SPAK; when associated with A-1258, A-1946 and A-1958.,MUTAGEN:F->A: Slightly decreased binding to OXSR1/OSR1 and STK39/SPAK; when associated with A-1860. Abolished binding to OXSR1/OSR1 and STK39/SPAK; when associated with A-1860, A-1946 and A-1958.,MUTAGEN:F->A: Slightly decreased binding to OXSR1/OSR1 and STK39/SPAK; when associated with A-1946. Abolished binding to OXSR1/OSR1 and STK39/SPAK; when associated with A-1258, A-1860 and A-1946.,MUTAGEN:F->A: Slightly decreased binding to OXSR1/OSR1 and STK39/SPAK; when associated with A-1958. Abolished binding to OXSR1/OSR1 and STK39/SPAK; when associated with A-1257, A-1860 and A-1958.,MUTAGEN:F->K: Abolished interaction with EMC2.,MUTAGEN:G->R,N,D,C,Q,H,I,L,K,M,F,P,S,T,W,Y,V: Does not affect binding to OXSR1/OSR1.,MUTAGEN:H->K: Does not affect interaction with EMC2.,MUTAGEN:K->M: Abolished serine/threonine-protein kinase activity. Does not affect ability to activate SGK1.,MUTAGEN:L->K: Abolished interaction with EMC2.,MUTAGEN:Missing: Abolished interaction with EMC2.,MUTAGEN:R->A,N,C,E,Q,H,I,L,K,M,F,S,T,W,Y,V: Does not affect binding to OXSR1/OSR1.,MUTAGEN:S->A: Decreased autophosphorylation, preventing activation of the serine/threonine-protein kinase activity.,MUTAGEN:V->E: Does not affect ability to phosphorylate OXSR1/OSR1.,MUTAGEN:W->K,L,A: Abolished interaction with EMC2.,REGION:Amphipathic alpha-helix,REGION:Autoinhibitory domain,REGION:Disordered,REGION:Interaction with KLHL3,
WTAP	WT1 associated protein(WTAP)	Homo sapiens			GO:0000381~regulation of alternative mRNA splicing, via spliceosome,GO:0006397~mRNA processing,GO:0007049~cell cycle,GO:0008380~RNA splicing,GO:0080009~mRNA methylation,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0016607~nuclear speck,GO:0031965~nuclear membrane,GO:0036396~MIS complex,	GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR033757:WTAP,					KW-0131~Cell cycle,KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,		KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,REGION:Disordered,
WBP11	WW domain binding protein 11(WBP11)	Homo sapiens			GO:0006364~rRNA processing,GO:0006396~RNA processing,GO:0006397~mRNA processing,GO:0008380~RNA splicing,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0043231~intracellular membrane-bounded organelle,	GO:0003697~single-stranded DNA binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0050699~WW domain binding,	IPR019007:WW_dom-bd_prot_11,	hsa03040:Spliceosome,	619227~Vertebral, cardiac, tracheoesophageal, renal, and limb defects,			KW-0507~mRNA processing,KW-0508~mRNA splicing,KW-0698~rRNA processing,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,	KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),MOTIF:PGR,MUTAGEN:K->A: Loss of PQBP1-binding; when associated with A-192 and A-197.,MUTAGEN:R->A: Loss of PQBP1-binding; when associated with A-192 and A-198.,MUTAGEN:R->A: Loss of PQBP1-binding; when associated with A-197 and A-198.,REGION:Disordered,REGION:Interaction with PP1,REGION:Required for nuclear import,
WBP2	WW domain binding protein 2(WBP2)	Homo sapiens			GO:0032570~response to progesterone,GO:0033148~positive regulation of intracellular estrogen receptor signaling pathway,GO:0043627~response to estrogen,GO:0045815~positive regulation of gene expression, epigenetic,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0050847~progesterone receptor signaling pathway,GO:0071169~establishment of protein localization to chromatin,GO:0071391~cellular response to estrogen stimulus,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0003713~transcription coactivator activity,GO:0005515~protein binding,GO:0030331~estrogen receptor binding,GO:0031490~chromatin DNA binding,	IPR004182:GRAM,IPR011993:PH-like_dom_sf,IPR044852:WBP2-like,		617639~Deafness, autosomal recessive 107,				KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0209~Deafness,KW-0225~Disease variant,KW-1010~Non-syndromic deafness,	KW-0677~Repeat,			KW-0597~Phosphoprotein,	COMPBIAS:Pro residues,DOMAIN:GRAM,MOTIF:PPxY motif 1,MOTIF:PPxY motif 2,MUTAGEN:PPPPY->AAAPA: Loss of coactivator activity in presence of estrogen.,MUTAGEN:Y->F: No effect on phosphorylation induced by EGF.,MUTAGEN:Y->F: Strongly decreases phosphorylation induced by EGF. Abolishes phosphorylation in response to EGF, estrogen and progesterone; when associated with F-231.,REGION:Disordered,
WAC	WW domain containing adaptor with coiled-coil(WAC)	Homo sapiens			GO:0006325~chromatin organization,GO:0006338~chromatin remodeling,GO:0006974~cellular response to DNA damage stimulus,GO:0010506~regulation of autophagy,GO:0016239~positive regulation of macroautophagy,GO:0031571~mitotic G1 DNA damage checkpoint,GO:0032435~negative regulation of proteasomal ubiquitin-dependent protein catabolic process,GO:0045893~positive regulation of transcription, DNA-templated,GO:1904263~positive regulation of TORC1 signaling,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005681~spliceosomal complex,GO:0016607~nuclear speck,	GO:0000993~RNA polymerase II core binding,GO:0003682~chromatin binding,GO:0005515~protein binding,	IPR001202:WW_dom,IPR036020:WW_dom_sf,IPR038867:WAC,		616708~Desanto-Shinawi syndrome,		SM00456:WW,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0175~Coiled coil,		KW-0156~Chromatin regulator,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:WW,REGION:Disordered,
XBP1	X-box binding protein 1(XBP1)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001525~angiogenesis,GO:0001558~regulation of cell growth,GO:0001889~liver development,GO:0001934~positive regulation of protein phosphorylation,GO:0001935~endothelial cell proliferation,GO:0002639~positive regulation of immunoglobulin production,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0006633~fatty acid biosynthetic process,GO:0006914~autophagy,GO:0006915~apoptotic process,GO:0006955~immune response,GO:0006996~organelle organization,GO:0007517~muscle organ development,GO:0008284~positive regulation of cell proliferation,GO:0010508~positive regulation of autophagy,GO:0010832~negative regulation of myotube differentiation,GO:0015031~protein transport,GO:0030335~positive regulation of cell migration,GO:0030512~negative regulation of transforming growth factor beta receptor signaling pathway,GO:0030968~endoplasmic reticulum unfolded protein response,GO:0031062~positive regulation of histone methylation,GO:0031647~regulation of protein stability,GO:0031648~protein destabilization,GO:0031670~cellular response to nutrient,GO:0032008~positive regulation of TOR signaling,GO:0032755~positive regulation of interleukin-6 production,GO:0032869~cellular response to insulin stimulus,GO:0034599~cellular response to oxidative stress,GO:0034976~response to endoplasmic reticulum stress,GO:0035356~cellular triglyceride homeostasis,GO:0035470~positive regulation of vascular wound healing,GO:0035924~cellular response to vascular endothelial growth factor stimulus,GO:0036498~IRE1-mediated unfolded protein response,GO:0036500~ATF6-mediated unfolded protein response,GO:0036503~ERAD pathway,GO:0042149~cellular response to glucose starvation,GO:0042307~positive regulation of protein import into nucleus,GO:0042632~cholesterol homeostasis,GO:0043066~negative regulation of apoptotic process,GO:0043491~protein kinase B signaling,GO:0045348~positive regulation of MHC class II biosynthetic process,GO:0045579~positive regulation of B cell differentiation,GO:0045582~positive regulation of T cell differentiation,GO:0045600~positive regulation of fat cell differentiation,GO:0045766~positive regulation of angiogenesis,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048010~vascular endothelial growth factor receptor signaling pathway,GO:0048666~neuron development,GO:0051897~positive regulation of protein kinase B signaling,GO:0055089~fatty acid homeostasis,GO:0055092~sterol homeostasis,GO:0060612~adipose tissue development,GO:0070373~negative regulation of ERK1 and ERK2 cascade,GO:0071073~positive regulation of phospholipid biosynthetic process,GO:0071222~cellular response to lipopolysaccharide,GO:0071230~cellular response to amino acid stimulus,GO:0071332~cellular response to fructose stimulus,GO:0071333~cellular response to glucose stimulus,GO:0071353~cellular response to interleukin-4,GO:0071375~cellular response to peptide hormone stimulus,GO:0071498~cellular response to fluid shear stress,GO:0071499~cellular response to laminar fluid shear stress,GO:1900100~positive regulation of plasma cell differentiation,GO:1900102~negative regulation of endoplasmic reticulum unfolded protein response,GO:1900103~positive regulation of endoplasmic reticulum unfolded protein response,GO:1901985~positive regulation of protein acetylation,GO:1902236~negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway,GO:1903071~positive regulation of ER-associated ubiquitin-dependent protein catabolic process,GO:1903489~positive regulation of lactation,GO:1904707~positive regulation of vascular smooth muscle cell proliferation,GO:1904754~positive regulation of vascular associated smooth muscle cell migration,GO:1990418~response to insulin-like growth factor stimulus,GO:1990440~positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress,GO:2000347~positive regulation of hepatocyte proliferation,GO:2000353~positive regulation of endothelial cell apoptotic process,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0090575~RNA polymerase II transcription factor complex,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0000987~core promoter proximal region sequence-specific DNA binding,GO:0002020~protease binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0019901~protein kinase binding,GO:0030331~estrogen receptor binding,GO:0031490~chromatin DNA binding,GO:0031625~ubiquitin protein ligase binding,GO:0042802~identical protein binding,GO:0046982~protein heterodimerization activity,GO:1990837~sequence-specific double-stranded DNA binding,	IPR004827:bZIP,IPR046347:bZIP_sf,	hsa04141:Protein processing in endoplasmic reticulum,hsa04932:Non-alcoholic fatty liver disease,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05017:Spinocerebellar ataxia,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05417:Lipid and atherosclerosis,	612371~Major affective disorder-7, susceptibility to,		SM00338:BRLZ,	KW-0037~Angiogenesis,KW-0053~Apoptosis,KW-0072~Autophagy,KW-0221~Differentiation,KW-0346~Stress response,KW-0443~Lipid metabolism,KW-0444~Lipid biosynthesis,KW-0517~Myogenesis,KW-0653~Protein transport,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0813~Transport,KW-0834~Unfolded protein response,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0553~Oncogene,	KW-0175~Coiled coil,KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0010~Activator,KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,	KW-0007~Acetylation,KW-0165~Cleavage on pair of basic residues,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Basic and acidic residues,DOMAIN:BZIP,DOMAIN:bZIP,MUTAGEN:C->N: Induces glycosylation.,MUTAGEN:I->D: Reduces endoplasmic reticulum localization of its own mRNA; when associated with E-194 and E-205.,MUTAGEN:L->A: Reduces translational pausing, membrane targeting and cytoplasmic splicing of its own mRNA.,MUTAGEN:L->D: Reduces endoplasmic reticulum localization of its own mRNA; when associated with E-189 and E-193.,MUTAGEN:L->E: Reduces endoplasmic reticulum localization of its own mRNA; when associated with D-198 and E-205.,MUTAGEN:Q->L: Inhibits HM13/SPP-mediated degradation of XBP1; when associated with L-197; L-200 and L-203.,MUTAGEN:Q->L: Inhibits HM13/SPP-mediated degradation of XBP1; when associated with L-199; L-200 and L-203.,MUTAGEN:R->N: Induces glycosylation.,MUTAGEN:S->A: Increases translational pausing of its own mRNA.,MUTAGEN:S->L: Inhibits HM13/SPP-mediated degradation of XBP1; when associated with L-197; L-199 and L-200.,MUTAGEN:S->L: Inhibits HM13/SPP-mediated degradation of XBP1; when associated with L-197; L-199 and L-203.,MUTAGEN:T->N: Does not induce glycosylation.,MUTAGEN:V->E: Reduces endoplasmic reticulum localization of its own mRNA; when associated with E-189 and D-196.,MUTAGEN:W->A: Reduces translational pausing, membrane targeting and cytoplasmic splicing of its own mRNA.,MUTAGEN:W->E: Reduces endoplasmic reticulum localization of its own mRNA; when associated with E-193 and D-196.,MUTAGEN:W->E: Reduces endoplasmic reticulum localization of its own mRNA; when associated with E-194 and D-198.,REGION:Basic motif,REGION:Disordered,REGION:Leucine-zipper,REGION:Necessary for the translational pausing of its own mRNA,REGION:Nuclear localization signal (NLS); in isoforms 1 and isoform 2,SITE:Cleavage; by HM13/SPP,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
XRCC5	X-ray repair cross complementing 5(XRCC5)	Homo sapiens		h_telPathway:Telomeres, Telomerase, Cellular Aging, and  Immortality,	GO:0000723~telomere maintenance,GO:0000725~recombinational repair,GO:0002218~activation of innate immune response,GO:0006302~double-strand break repair,GO:0006303~double-strand break repair via nonhomologous end joining,GO:0006310~DNA recombination,GO:0006974~cellular response to DNA damage stimulus,GO:0009410~response to xenobiotic stimulus,GO:0022008~neurogenesis,GO:0032204~regulation of telomere maintenance,GO:0032212~positive regulation of telomere maintenance via telomerase,GO:0032508~DNA duplex unwinding,GO:0034462~small-subunit processome assembly,GO:0043085~positive regulation of catalytic activity,GO:0045087~innate immune response,GO:0045860~positive regulation of protein kinase activity,GO:0045892~negative regulation of transcription, DNA-templated,GO:0048660~regulation of smooth muscle cell proliferation,GO:0050769~positive regulation of neurogenesis,GO:0051973~positive regulation of telomerase activity,GO:0060218~hematopoietic stem cell differentiation,GO:0070198~protein localization to chromosome, telomeric region,GO:0071398~cellular response to fatty acid,GO:0071425~hematopoietic stem cell proliferation,GO:0071475~cellular hyperosmotic salinity response,GO:0071480~cellular response to gamma radiation,GO:0071481~cellular response to X-ray,GO:1904430~negative regulation of t-circle formation,GO:1990830~cellular response to leukemia inhibitory factor,	GO:0000781~chromosome, telomeric region,GO:0000783~nuclear telomere cap complex,GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005958~DNA-dependent protein kinase-DNA ligase 4 complex,GO:0016020~membrane,GO:0032040~small-subunit processome,GO:0032991~macromolecular complex,GO:0032993~protein-DNA complex,GO:0034774~secretory granule lumen,GO:0043564~Ku70:Ku80 complex,GO:0070418~DNA-dependent protein kinase complex,GO:0070419~nonhomologous end joining complex,GO:0090734~site of DNA damage,GO:1990904~ribonucleoprotein complex,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0003677~DNA binding,GO:0003678~DNA helicase activity,GO:0003684~damaged DNA binding,GO:0003690~double-stranded DNA binding,GO:0003691~double-stranded telomeric DNA binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008047~enzyme activator activity,GO:0008094~DNA-dependent ATPase activity,GO:0016787~hydrolase activity,GO:0016887~ATPase activity,GO:0031625~ubiquitin protein ligase binding,GO:0034511~U3 snoRNA binding,GO:0042162~telomeric DNA binding,GO:0044877~macromolecular complex binding,GO:0045027~DNA end binding,GO:0051575~5'-deoxyribose-5-phosphate lyase activity,	IPR002035:VWF_A,IPR005160:Ku_C,IPR005161:Ku_N,IPR006164:Ku70/Ku80_beta-barrel_dom,IPR014893:Ku_PK_bind,IPR016194:SPOC-like_C_dom_sf,IPR024193:Ku80,IPR036465:vWFA_dom_sf,IPR036494:Ku_C_sf,	hsa03450:Non-homologous end-joining,		PIRSF016570:Ku80,	SM00327:VWA,SM00559:Ku78,	KW-0227~DNA damage,KW-0233~DNA recombination,KW-0234~DNA repair,KW-0391~Immunity,KW-0399~Innate immunity,KW-0690~Ribosome biogenesis,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0158~Chromosome,KW-0539~Nucleus,	KW-0772~Systemic lupus erythematosus,		KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0010~Activator,KW-0238~DNA-binding,KW-0347~Helicase,KW-0378~Hydrolase,	KW-0007~Acetylation,KW-0013~ADP-ribosylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Ku,DOMAIN:Ku70/Ku80 N-terminal alpha/beta,MOTIF:EEXXXDL motif,MUTAGEN:DD->AA: Abolishes interaction with PRKDC and its recruitment to sites of DNA damage.,MUTAGEN:EE->AA: Abolishes interaction with PRKDC and its recruitment to sites of DNA damage.,REGION:Disordered,REGION:Leucine-zipper,
XRCC6	X-ray repair cross complementing 6(XRCC6)	Homo sapiens		h_telPathway:Telomeres, Telomerase, Cellular Aging, and  Immortality,	GO:0000723~telomere maintenance,GO:0000725~recombinational repair,GO:0002218~activation of innate immune response,GO:0006266~DNA ligation,GO:0006303~double-strand break repair via nonhomologous end joining,GO:0006310~DNA recombination,GO:0032508~DNA duplex unwinding,GO:0045087~innate immune response,GO:0045621~positive regulation of lymphocyte differentiation,GO:0045860~positive regulation of protein kinase activity,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048660~regulation of smooth muscle cell proliferation,GO:0071475~cellular hyperosmotic salinity response,GO:0071480~cellular response to gamma radiation,GO:0071481~cellular response to X-ray,GO:0097680~double-strand break repair via classical nonhomologous end joining,	GO:0000781~chromosome, telomeric region,GO:0000783~nuclear telomere cap complex,GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005730~nucleolus,GO:0005829~cytosol,GO:0005958~DNA-dependent protein kinase-DNA ligase 4 complex,GO:0016020~membrane,GO:0032991~macromolecular complex,GO:0032993~protein-DNA complex,GO:0034774~secretory granule lumen,GO:0043564~Ku70:Ku80 complex,GO:0070418~DNA-dependent protein kinase complex,GO:0070419~nonhomologous end joining complex,GO:1904813~ficolin-1-rich granule lumen,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0003677~DNA binding,GO:0003678~DNA helicase activity,GO:0003684~damaged DNA binding,GO:0003690~double-stranded DNA binding,GO:0003691~double-stranded telomeric DNA binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008094~DNA-dependent ATPase activity,GO:0016787~hydrolase activity,GO:0016887~ATPase activity,GO:0030332~cyclin binding,GO:0042162~telomeric DNA binding,GO:0044877~macromolecular complex binding,GO:0045027~DNA end binding,GO:0051575~5'-deoxyribose-5-phosphate lyase activity,GO:0097110~scaffold protein binding,	IPR003034:SAP_dom,IPR005160:Ku_C,IPR005161:Ku_N,IPR006164:Ku70/Ku80_beta-barrel_dom,IPR006165:Ku70,IPR016194:SPOC-like_C_dom_sf,IPR027388:Ku70_bridge/pillars_dom_sf,IPR036361:SAP_dom_sf,IPR036465:vWFA_dom_sf,IPR047087:KU70_core_dom,	hsa03450:Non-homologous end-joining,		PIRSF003033:Ku70,	SM00513:SAP,SM00559:Ku78,	KW-0227~DNA damage,KW-0233~DNA recombination,KW-0234~DNA repair,KW-0391~Immunity,KW-0399~Innate immunity,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0158~Chromosome,KW-0539~Nucleus,	KW-0772~Systemic lupus erythematosus,		KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0010~Activator,KW-0238~DNA-binding,KW-0347~Helicase,KW-0378~Hydrolase,KW-0456~Lyase,KW-0511~Multifunctional enzyme,	KW-0007~Acetylation,KW-0013~ADP-ribosylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	ACT_SITE:Schiff-base intermediate with DNA; for 5'-deoxyribose-5-phosphate lyase activity,COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Ku,DOMAIN:SAP,MUTAGEN:K->A: Abolishes adduct formation; when associated with A-31 and A-160.,MUTAGEN:K->A: Abolishes adduct formation; when associated with A-31 and A-164.,MUTAGEN:K->A: Diminishes the ability to form a Schiff base. Abolishes adduct formation; when associated with A-160 and A-164.,REGION:Disordered,REGION:Interaction with DEAF1,
XAB2	XPA binding protein 2(XAB2)	Homo sapiens			GO:0000349~generation of catalytic spliceosome for first transesterification step,GO:0000398~mRNA splicing, via spliceosome,GO:0001824~blastocyst development,GO:0006283~transcription-coupled nucleotide-excision repair,GO:0006351~transcription, DNA-templated,	GO:0000974~Prp19 complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0016020~membrane,GO:0043231~intracellular membrane-bounded organelle,GO:0071007~U2-type catalytic step 2 spliceosome,GO:0071013~catalytic step 2 spliceosome,GO:0071014~post-mRNA release spliceosomal complex,	GO:0005515~protein binding,	IPR003107:HAT,IPR011990:TPR-like_helical_dom_sf,IPR019734:TPR_repeat,IPR045075:Syf1-like,	hsa03040:Spliceosome,			SM00028:TPR,SM00386:HAT,	KW-0227~DNA damage,KW-0234~DNA repair,KW-0507~mRNA processing,KW-0508~mRNA splicing,KW-0804~Transcription,	KW-0539~Nucleus,KW-0747~Spliceosome,		KW-0677~Repeat,KW-0802~TPR repeat,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,REGION:Disordered,REPEAT:HAT 1,REPEAT:HAT 10,REPEAT:HAT 11,REPEAT:HAT 12,REPEAT:HAT 13,REPEAT:HAT 14,REPEAT:HAT 2,REPEAT:HAT 3,REPEAT:HAT 4,REPEAT:HAT 5,REPEAT:HAT 6,REPEAT:HAT 7,REPEAT:HAT 8,REPEAT:HAT 9,REPEAT:TPR,
YBX1	Y-box binding protein 1(YBX1)	Homo sapiens		h_dbpbPathway:Transcriptional activation of dbpb from mRNA,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001701~in utero embryonic development,GO:0006355~regulation of transcription, DNA-templated,GO:0006397~mRNA processing,GO:0008380~RNA splicing,GO:0008544~epidermis development,GO:0010468~regulation of gene expression,GO:0017148~negative regulation of translation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048255~mRNA stabilization,GO:0048598~embryonic morphogenesis,GO:0050658~RNA transport,GO:0051031~tRNA transport,GO:0051154~negative regulation of striated muscle cell differentiation,GO:0051781~positive regulation of cell division,GO:0070934~CRD-mediated mRNA stabilization,GO:0098761~cellular response to interleukin-7,GO:1900152~negative regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay,GO:1903608~protein localization to cytoplasmic stress granule,GO:1990428~miRNA transport,GO:2000767~positive regulation of cytoplasmic translation,GO:2000773~negative regulation of cellular senescence,	GO:0000932~P-body,GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005689~U12-type spliceosomal complex,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0010494~cytoplasmic stress granule,GO:0043231~intracellular membrane-bounded organelle,GO:0045202~synapse,GO:0070062~extracellular exosome,GO:0070937~CRD-mediated mRNA stability complex,GO:0071204~histone pre-mRNA 3'end processing complex,GO:1990124~messenger ribonucleoprotein complex,GO:1990904~ribonucleoprotein complex,	GO:0003676~nucleic acid binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003690~double-stranded DNA binding,GO:0003697~single-stranded DNA binding,GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0005515~protein binding,GO:0035198~miRNA binding,GO:0051020~GTPase binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR002059:CSP_DNA-bd,IPR011129:CSD,IPR012340:NA-bd_OB-fold,IPR019844:CSD_1,				SM00357:CSP,	KW-0507~mRNA processing,KW-0508~mRNA splicing,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0964~Secreted,				KW-0010~Activator,KW-0238~DNA-binding,KW-0497~Mitogen,KW-0678~Repressor,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:CSD,MUTAGEN:K->A: Abrogates unconventional secretion.,MUTAGEN:S->A: Loss of phosphorylation by PKB/AKT1. Inhibits translocation to the nucleus and tumor cell growth.,MUTAGEN:W->A: Abolished binding to C5-methylcytosine (m5C)-containing mRNAs.,MUTAGEN:W->F: Decreased binding to C5-methylcytosine (m5C)-containing mRNAs. Decreased ability to discriminate between m5C-containing and unmethylated mRNAs.,REGION:C5-methylcytosine binding,REGION:Disordered,REGION:Interaction with ss-DNA,SITE:Cleavage; by 20S proteasomal protease,SITE:Important for C5-methylcytosine-recognition,
YKT6	YKT6 v-SNARE homolog(YKT6)	Homo sapiens			GO:0006888~ER to Golgi vesicle-mediated transport,GO:0006903~vesicle targeting,GO:0006904~vesicle docking involved in exocytosis,GO:0015031~protein transport,GO:0042147~retrograde transport, endosome to Golgi,GO:0061025~membrane fusion,	GO:0000139~Golgi membrane,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005768~endosome,GO:0005783~endoplasmic reticulum,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0030133~transport vesicle,GO:0030659~cytoplasmic vesicle membrane,GO:0031201~SNARE complex,GO:0033116~endoplasmic reticulum-Golgi intermediate compartment membrane,GO:0043025~neuronal cell body,GO:0097440~apical dendrite,GO:0097441~basilar dendrite,	GO:0005484~SNAP receptor activity,GO:0019706~protein-cysteine S-palmitoyltransferase activity,GO:0045296~cadherin binding,	IPR010908:Longin_dom,IPR011012:Longin-like_dom_sf,IPR042855:V_SNARE_CC,IPR045848:R-SNARE_YKT6,	hsa04130:SNARE interactions in vesicular transport,hsa04140:Autophagy - animal,			SM01270:Longin,	KW-0653~Protein transport,KW-0813~Transport,KW-0931~ER-Golgi transport,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,		KW-0175~Coiled coil,		KW-0808~Transferase,	KW-0449~Lipoprotein,KW-0488~Methylation,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-0636~Prenylation,	DOMAIN:Longin,DOMAIN:V-SNARE coiled-coil homology,DOMAIN:v-SNARE coiled-coil homology,LIPID:S-farnesyl cysteine,LIPID:S-palmitoyl cysteine,MUTAGEN:C->S: Decreases palmitoylation by 55%. Prevents palmitoylation; when associated with S-195. Targeted to Golgi and cytosol; when associated with E-42.,MUTAGEN:C->S: Prevents farnesylation. Targeted to cytosol; when associated with E-42. Decreases palmitoylation by 13%. Prevents palmitoylation; when associated with S-194.,MUTAGEN:F->E: Increases palmitoylation. Targeted to Golgi membranes. Targeted to Golgi and cytosol; when associated with S-194. Targeted to cytosol; when associated with S-195.,PROPEP:Removed in mature form,
YME1L1	YME1 like 1 ATPase(YME1L1)	Homo sapiens			GO:0006508~proteolysis,GO:0006515~misfolded or incompletely synthesized protein catabolic process,GO:0007005~mitochondrion organization,GO:0008283~cell proliferation,GO:0034214~protein hexamerization,GO:0034982~mitochondrial protein processing,GO:0035694~mitochondrial protein catabolic process,GO:0043066~negative regulation of apoptotic process,	GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0016020~membrane,GO:0016604~nuclear body,	GO:0004176~ATP-dependent peptidase activity,GO:0004222~metalloendopeptidase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016887~ATPase activity,GO:0046872~metal ion binding,	IPR000642:Peptidase_M41,IPR003593:AAA+_ATPase,IPR003959:ATPase_AAA_core,IPR003960:ATPase_AAA_CS,IPR005936:FtsH,IPR027417:P-loop_NTPase,IPR037219:Peptidase_M41-like,IPR041569:AAA_lid_3,		617302~Optic atrophy 11,		SM00382:AAA,		KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,	KW-0225~Disease variant,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,KW-0862~Zinc,	KW-0378~Hydrolase,KW-0482~Metalloprotease,KW-0645~Protease,		DOMAIN:AAA+ ATPase,DOMAIN:ATPase AAA-type core,MUTAGEN:E->Q: Loss of ATPase and protease activity. Loss of PRELID1 degradation. Cannot restore OMA1 degradation in YME1L-depleted cells.,MUTAGEN:E->Q: Loss of protease activity. Cannot restore OMA1 degradation in YME1L-depleted cells.,REGION:Disordered,TOPO_DOM:Mitochondrial intermembrane,TOPO_DOM:Mitochondrial matrix,TRANSMEM:Helical,
YTHDF2	YTH N6-methyladenosine RNA binding protein F2(YTHDF2)	Homo sapiens			GO:0001556~oocyte maturation,GO:0006402~mRNA catabolic process,GO:0006959~humoral immune response,GO:0007049~cell cycle,GO:0007276~gamete generation,GO:0007284~spermatogonial cell division,GO:0030155~regulation of cell adhesion,GO:0034063~stress granule assembly,GO:0043488~regulation of mRNA stability,GO:0045087~innate immune response,GO:0045746~negative regulation of Notch signaling pathway,GO:0048598~embryonic morphogenesis,GO:0050767~regulation of neurogenesis,GO:0060339~negative regulation of type I interferon-mediated signaling pathway,GO:0061157~mRNA destabilization,GO:0070925~organelle assembly,GO:0071425~hematopoietic stem cell proliferation,GO:0098508~endothelial to hematopoietic transition,GO:1902036~regulation of hematopoietic stem cell differentiation,GO:1903538~regulation of meiotic cell cycle process involved in oocyte maturation,GO:1903679~positive regulation of cap-independent translational initiation,GO:2000232~regulation of rRNA processing,GO:2000737~negative regulation of stem cell differentiation,	GO:0000932~P-body,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0010494~cytoplasmic stress granule,GO:0034451~centriolar satellite,GO:0036464~cytoplasmic ribonucleoprotein granule,	GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0005515~protein binding,GO:1990247~N6-methyladenosine-containing RNA binding,	IPR007275:YTH_domain,IPR045168:YTH_prot,					KW-0131~Cell cycle,KW-0132~Cell division,KW-0221~Differentiation,KW-0391~Immunity,KW-0399~Innate immunity,KW-0498~Mitosis,KW-0744~Spermatogenesis,KW-0896~Oogenesis,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,DOMAIN:YTH,MUTAGEN:K->A: Decreased binding to RNAs.,MUTAGEN:R->A: Decreased binding to RNAs.,MUTAGEN:R->A: Slightly decreased binding to RNAs.,MUTAGEN:W->A: Reduced binding to N6-methyladenosine (m6A)-containing RNAs.,MUTAGEN:W->A: Reduced binding to N6-methyladenosine (m6A)-containing RNAs. Reduced ability to undergo liquid-liquid phase separation. Reduced binding to C5-methylcytosine (m5C)-containing RNAs.,MUTAGEN:W->A: Reduced binding to N6-methyladenosine (m6A)-containing RNAs. Reduced ability to undergo liquid-liquid phase separation; when associated with A-432.,REGION:Disordered,REGION:Interaction with m6A-containing mRNAs,REGION:Localization to mRNA processing bodies (P-bodies),
YY1AP1	YY1 associated protein 1(YY1AP1)	Homo sapiens			GO:0006355~regulation of transcription, DNA-templated,GO:0008283~cell proliferation,GO:0030154~cell differentiation,GO:0051726~regulation of cell cycle,	GO:0001650~fibrillar center,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0031011~Ino80 complex,	GO:0003712~transcription cofactor activity,GO:0005515~protein binding,			602531~Grange syndrome,			KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,					KW-0597~Phosphoprotein,	REGION:Disordered,
YY1	YY1 transcription factor(YY1)	Homo sapiens		h_prc2Pathway:The PRC2 Complex Sets Long-term Gene Silencing Through Modification of Histone Tails,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0000723~telomere maintenance,GO:0000724~double-strand break repair via homologous recombination,GO:0006275~regulation of DNA replication,GO:0006282~regulation of DNA repair,GO:0006338~chromatin remodeling,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006403~RNA localization,GO:0006974~cellular response to DNA damage stimulus,GO:0007283~spermatogenesis,GO:0009952~anterior/posterior pattern specification,GO:0010225~response to UV-C,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0030183~B cell differentiation,GO:0032688~negative regulation of interferon-beta production,GO:0033044~regulation of chromosome organization,GO:0034644~cellular response to UV,GO:0034696~response to prostaglandin F,GO:0045739~positive regulation of DNA repair,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0045995~regulation of embryonic development,GO:0048593~camera-type eye morphogenesis,GO:0051726~regulation of cell cycle,GO:0060382~regulation of DNA strand elongation,GO:0061052~negative regulation of cell growth involved in cardiac muscle cell development,GO:0071347~cellular response to interleukin-1,GO:0071707~immunoglobulin heavy chain V-D-J recombination,GO:1902894~negative regulation of pri-miRNA transcription from RNA polymerase II promoter,GO:1904507~positive regulation of telomere maintenance in response to DNA damage,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005677~chromatin silencing complex,GO:0016363~nuclear matrix,GO:0031011~Ino80 complex,GO:0031519~PcG protein complex,	GO:0000400~four-way junction DNA binding,GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0000987~core promoter proximal region sequence-specific DNA binding,GO:0001217~bacterial-type RNA polymerase transcriptional repressor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0046332~SMAD binding,GO:0046872~metal ion binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR013087:Znf_C2H2_type,IPR017114:YY1-like,IPR036236:Znf_C2H2_sf,	hsa03082:ATP-dependent chromatin remodeling,hsa03083:Polycomb repressive complex,	617557~Gabriele-de Vries syndrome,	PIRSF037113:TF_Yin_yang,	SM00355:ZnF_C2H2,	KW-0221~Differentiation,KW-0227~DNA damage,KW-0233~DNA recombination,KW-0234~DNA repair,KW-0744~Spermatogenesis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-0991~Intellectual disability,	KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0238~DNA-binding,KW-0678~Repressor,	KW-0013~ADP-ribosylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:C2H2-type,MUTAGEN:S->A: Abolished phosphorylation by CK2, leading to increased cleavage by caspase-7 (CASP7).,REGION:Binding to DNA,REGION:Disordered,REGION:Interaction with the SMAD1/SMAD4 complex,REGION:Involved in masking transactivation domain,REGION:Involved in nuclear matrix association,REGION:Involved in repression of activated transcription,SITE:Cleavage; by caspase-7,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4,
YDJC	YdjC chitooligosaccharide deacetylase homolog(YDJC)	Homo sapiens			GO:0005975~carbohydrate metabolic process,		GO:0000287~magnesium ion binding,GO:0019213~deacetylase activity,	IPR006879:YdjC-like,IPR011330:Glyco_hydro/deAcase_b/a-brl,					KW-0119~Carbohydrate metabolism,				KW-0460~Magnesium,KW-0479~Metal-binding,	KW-0378~Hydrolase,		ACT_SITE:Proton acceptor,
YIPF4	Yip1 domain family member 4(YIPF4)	Homo sapiens			GO:0006888~ER to Golgi vesicle-mediated transport,GO:0048280~vesicle fusion with Golgi apparatus,	GO:0005783~endoplasmic reticulum,GO:0005794~Golgi apparatus,GO:0005802~trans-Golgi network,GO:0005886~plasma membrane,GO:0043231~intracellular membrane-bounded organelle,	GO:0005515~protein binding,	IPR006977:Yip1_dom,IPR045231:Yip1/4-like,					KW-0945~Host-virus interaction,	KW-0333~Golgi apparatus,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
YIPF5	Yip1 domain family member 5(YIPF5)	Homo sapiens			GO:0006888~ER to Golgi vesicle-mediated transport,GO:0015031~protein transport,GO:0030070~insulin processing,GO:0048280~vesicle fusion with Golgi apparatus,GO:0060628~regulation of ER to Golgi vesicle-mediated transport,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005794~Golgi apparatus,GO:0005802~trans-Golgi network,GO:0016020~membrane,GO:0030134~ER to Golgi transport vesicle,GO:0043231~intracellular membrane-bounded organelle,GO:0070971~endoplasmic reticulum exit site,	GO:0005515~protein binding,	IPR006977:Yip1_dom,IPR045231:Yip1/4-like,		619278~Microcephaly, epilepsy, and diabetes syndrome 2,			KW-0653~Protein transport,KW-0813~Transport,KW-0931~ER-Golgi transport,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0968~Cytoplasmic vesicle,	KW-0219~Diabetes mellitus,KW-0225~Disease variant,KW-0887~Epilepsy,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,				DOMAIN:Yip1,REGION:Interaction with Sec23,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
ZFP36L1	ZFP36 ring finger protein like 1(ZFP36L1)	Homo sapiens			GO:0000165~MAPK cascade,GO:0000288~nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay,GO:0001570~vasculogenesis,GO:0003342~proepicardium development,GO:0006397~mRNA processing,GO:0006417~regulation of translation,GO:0006915~apoptotic process,GO:0007507~heart development,GO:0008283~cell proliferation,GO:0009611~response to wounding,GO:0010468~regulation of gene expression,GO:0010837~regulation of keratinocyte proliferation,GO:0021915~neural tube development,GO:0031086~nuclear-transcribed mRNA catabolic process, deadenylation-independent decay,GO:0031440~regulation of mRNA 3'-end processing,GO:0032869~cellular response to insulin stimulus,GO:0033077~T cell differentiation in thymus,GO:0035264~multicellular organism growth,GO:0038066~p38MAPK cascade,GO:0043488~regulation of mRNA stability,GO:0043491~protein kinase B signaling,GO:0044344~cellular response to fibroblast growth factor stimulus,GO:0045577~regulation of B cell differentiation,GO:0045600~positive regulation of fat cell differentiation,GO:0045616~regulation of keratinocyte differentiation,GO:0045647~negative regulation of erythrocyte differentiation,GO:0045657~positive regulation of monocyte differentiation,GO:0045661~regulation of myoblast differentiation,GO:0048382~mesendoderm development,GO:0051028~mRNA transport,GO:0060710~chorio-allantoic fusion,GO:0060712~spongiotrophoblast layer development,GO:0061158~3'-UTR-mediated mRNA destabilization,GO:0070371~ERK1 and ERK2 cascade,GO:0071320~cellular response to cAMP,GO:0071356~cellular response to tumor necrosis factor,GO:0071364~cellular response to epidermal growth factor stimulus,GO:0071375~cellular response to peptide hormone stimulus,GO:0071385~cellular response to glucocorticoid stimulus,GO:0071456~cellular response to hypoxia,GO:0071472~cellular response to salt stress,GO:0071560~cellular response to transforming growth factor beta stimulus,GO:0072091~regulation of stem cell proliferation,GO:0097403~cellular response to raffinose,GO:1900153~positive regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay,GO:1901991~negative regulation of mitotic cell cycle phase transition,GO:1902172~regulation of keratinocyte apoptotic process,GO:1904582~positive regulation of intracellular mRNA localization,	GO:0000932~P-body,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:1990904~ribonucleoprotein complex,	GO:0003677~DNA binding,GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0005515~protein binding,GO:0035925~mRNA 3'-UTR AU-rich region binding,GO:0046872~metal ion binding,GO:0071889~14-3-3 protein binding,	IPR000571:Znf_CCCH,IPR007635:Tis11B_N,IPR036855:Znf_CCCH_sf,IPR045877:ZFP36-like,	hsa04218:Cellular senescence,			SM00356:ZnF_C3H1,	KW-0507~mRNA processing,KW-0509~mRNA transport,KW-0813~Transport,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0217~Developmental protein,KW-0238~DNA-binding,KW-0687~Ribonucleoprotein,KW-0694~RNA-binding,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:C3H1-type,DOMAIN:Tis11B-like protein N-terminal,MUTAGEN:C->R: Reduces binding to ARE-containing mRNAs and ARE-mediated mRNA decay. Inhibits binding to ARE-containing mRNAs and ARE-mediated mRNA decay; when associated with R-120.,MUTAGEN:C->R: Reduces binding to ARE-containing mRNAs and ARE-mediated mRNA decay. Inhibits binding to ARE-containing mRNAs and ARE-mediated mRNA decay; when associated with R-158.,MUTAGEN:S->A: Inhibits MAPKAPK2-mediated ARE-containing mRNA stabilization; when associated with A-54 and A-203. Inhibits interaction with 14-3-3 proteins and AKT1-mediated ARE-containing mRNA stabilization; when associated with A-203. Inhibits interaction with 14-3-3 proteins and AKT1-mediated ARE-containing mRNA stabilization, but does not affect ARE binding; when associated with A-90.,MUTAGEN:S->A: Inhibits MAPKAPK2-mediated ARE-containing mRNA stabilization; when associated with A-92 and A-203.,MUTAGEN:S->A: Inhibits interaction with 14-3-3 proteins and AKT1-mediated ARE-containing mRNA stabilization, but does not affect ARE binding; when associated with A-92.,MUTAGEN:S->A: Inhibits interaction with 14-3-3 proteins and AKT1-mediated ARE-containing mRNA stabilization; when associated with A-92. Inhibits MAPKAPK2-mediated ARE-containing mRNA stabilization; when associated with A-54 and A-92.,MUTAGEN:S->A: Inhibits p38 MAPK-mediated LDLR mRNA stabilization, but does not inhibit interaction with CNOT1 and CNOT7; when associated with A-334.,MUTAGEN:S->A: Inhibits p38 MAPK-mediated LDLR mRNA stabilization, but does not inhibit interaction with CNOT1 and CNOT7; when associated with A-336.,REGION:Disordered,REGION:Necessary and sufficient for the association with mRNA decay enzymes and mRNA decay activation,REGION:Necessary for mRNA decay activation,ZN_FING:C3H1-type,ZN_FING:C3H1-type 1,ZN_FING:C3H1-type 2,
ZFP36L2	ZFP36 ring finger protein like 2(ZFP36L2)	Homo sapiens			GO:0000288~nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay,GO:0006402~mRNA catabolic process,GO:0006417~regulation of translation,GO:0009611~response to wounding,GO:0030097~hemopoiesis,GO:0033077~T cell differentiation in thymus,GO:0035019~somatic stem cell population maintenance,GO:0043488~regulation of mRNA stability,GO:0044344~cellular response to fibroblast growth factor stimulus,GO:0045577~regulation of B cell differentiation,GO:0045599~negative regulation of fat cell differentiation,GO:0048103~somatic stem cell division,GO:0060216~definitive hemopoiesis,GO:0061158~3'-UTR-mediated mRNA destabilization,GO:0070371~ERK1 and ERK2 cascade,GO:0071356~cellular response to tumor necrosis factor,GO:0071364~cellular response to epidermal growth factor stimulus,GO:0071385~cellular response to glucocorticoid stimulus,GO:0071560~cellular response to transforming growth factor beta stimulus,GO:0097011~cellular response to granulocyte macrophage colony-stimulating factor stimulus,GO:1900153~positive regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay,GO:1901991~negative regulation of mitotic cell cycle phase transition,GO:2000737~negative regulation of stem cell differentiation,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0035925~mRNA 3'-UTR AU-rich region binding,GO:0046872~metal ion binding,	IPR000571:Znf_CCCH,IPR007635:Tis11B_N,IPR036855:Znf_CCCH_sf,IPR045877:ZFP36-like,	hsa04218:Cellular senescence,	620154~Oocyte/zygote/embryo maturation arrest 13,		SM00356:ZnF_C3H1,		KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,	KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0217~Developmental protein,KW-0687~Ribonucleoprotein,KW-0694~RNA-binding,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,MOTIF:RNA-binding,MUTAGEN:E->K: Impaired mRNA-binding; when associated with R-157.,MUTAGEN:E->R: Impaired mRNA-binding; when associated with K-195.,REGION:Disordered,REGION:RNA-binding,ZN_FING:C3H1-type 1,ZN_FING:C3H1-type 2,
ZFP36	ZFP36 ring finger protein(ZFP36)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0000165~MAPK cascade,GO:0000288~nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay,GO:0000289~nuclear-transcribed mRNA poly(A) tail shortening,GO:0006402~mRNA catabolic process,GO:0009611~response to wounding,GO:0010837~regulation of keratinocyte proliferation,GO:0030099~myeloid cell differentiation,GO:0031086~nuclear-transcribed mRNA catabolic process, deadenylation-independent decay,GO:0032680~regulation of tumor necrosis factor production,GO:0032703~negative regulation of interleukin-2 production,GO:0032897~negative regulation of viral transcription,GO:0035278~miRNA mediated inhibition of translation,GO:0038066~p38MAPK cascade,GO:0042594~response to starvation,GO:0043488~regulation of mRNA stability,GO:0044344~cellular response to fibroblast growth factor stimulus,GO:0045600~positive regulation of fat cell differentiation,GO:0045616~regulation of keratinocyte differentiation,GO:0045647~negative regulation of erythrocyte differentiation,GO:0050728~negative regulation of inflammatory response,GO:0051028~mRNA transport,GO:0060213~positive regulation of nuclear-transcribed mRNA poly(A) tail shortening,GO:0060218~hematopoietic stem cell differentiation,GO:0061158~3'-UTR-mediated mRNA destabilization,GO:0070935~3'-UTR-mediated mRNA stabilization,GO:0071222~cellular response to lipopolysaccharide,GO:0071356~cellular response to tumor necrosis factor,GO:0071364~cellular response to epidermal growth factor stimulus,GO:0071385~cellular response to glucocorticoid stimulus,GO:0097011~cellular response to granulocyte macrophage colony-stimulating factor stimulus,GO:1900153~positive regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay,GO:1901835~positive regulation of deadenylation-independent decapping of nuclear-transcribed mRNA,GO:1902037~negative regulation of hematopoietic stem cell differentiation,GO:1902172~regulation of keratinocyte apoptotic process,GO:1904246~negative regulation of polynucleotide adenylyltransferase activity,GO:1904582~positive regulation of intracellular mRNA localization,GO:2000637~positive regulation of gene silencing by miRNA,	GO:0000932~P-body,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0010494~cytoplasmic stress granule,GO:0030014~CCR4-NOT complex,GO:1990904~ribonucleoprotein complex,	GO:0003677~DNA binding,GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0005515~protein binding,GO:0019899~enzyme binding,GO:0019901~protein kinase binding,GO:0019957~C-C chemokine binding,GO:0031072~heat shock protein binding,GO:0035925~mRNA 3'-UTR AU-rich region binding,GO:0044877~macromolecular complex binding,GO:0046872~metal ion binding,GO:0070063~RNA polymerase binding,GO:0071889~14-3-3 protein binding,	IPR000571:Znf_CCCH,IPR036855:Znf_CCCH_sf,IPR045877:ZFP36-like,	hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,			SM00356:ZnF_C3H1,	KW-0509~mRNA transport,KW-0813~Transport,KW-0943~RNA-mediated gene silencing,KW-0945~Host-virus interaction,	KW-0271~Exosome,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,KW-0687~Ribonucleoprotein,KW-0694~RNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,DOMAIN:C3H1-type,MUTAGEN:C->R: Inhibits binding to ARE-containing transcripts. Inhibits binding to and deadenylation activities of ARE-containing mRNAs. Inhibits localization of ARE-containing mRNAs to processing bodies (PBs).,MUTAGEN:C->R: Inhibits both ARE-binding and mRNA deadenylation activities.,MUTAGEN:F->A: Abolishes interaction with CNOT1 and impairs TNF mRNA deadenylation.,MUTAGEN:F->N: Inhibits ARE-containing RNA-binding, deadenylation and RNA decapping activities.,MUTAGEN:P->V: Inhibits interaction with SH3KBP1.,MUTAGEN:R->A: Abolishes interaction with CNOT1.,MUTAGEN:S->A: Inhibits PKM-induced ZFP36 degradation through a p38 MAPK signaling pathway.,REGION:Disordered,REGION:Interaction with CNOT1,REGION:Necessary and sufficient for the association with mRNA decay enzymes and mRNA decay activation,REGION:Necessary for RNA-binding,REGION:Necessary for interaction with PABPN1,REGION:Necessary for localization of ARE-containing mRNAs to processing bodies (PBs),REGION:Necessary for mRNA decay activation,REGION:Necessary for nuclear export,REGION:Necessary for nuclear localization,REPEAT:P-P-P-P-G,ZN_FING:C3H1-type,ZN_FING:C3H1-type 1,ZN_FING:C3H1-type 2,
ZFAS1	ZNFX1 antisense RNA 1(ZFAS1)	Homo sapiens				GO:0005634~nucleus,GO:0005737~cytoplasm,
ZPR1	ZPR1 zinc finger(ZPR1)	Homo sapiens			GO:0000226~microtubule cytoskeleton organization,GO:0001833~inner cell mass cell proliferation,GO:0001834~trophectodermal cell proliferation,GO:0006260~DNA replication,GO:0006397~mRNA processing,GO:0006457~protein folding,GO:0007165~signal transduction,GO:0008283~cell proliferation,GO:0008380~RNA splicing,GO:0010628~positive regulation of gene expression,GO:0021510~spinal cord development,GO:0030576~Cajal body organization,GO:0031641~regulation of myelination,GO:0033120~positive regulation of RNA splicing,GO:0042023~DNA endoreduplication,GO:0042307~positive regulation of protein import into nucleus,GO:0045787~positive regulation of cell cycle,GO:0045927~positive regulation of growth,GO:0061564~axon development,GO:0071364~cellular response to epidermal growth factor stimulus,GO:1902742~apoptotic process involved in development,GO:1990261~pre-mRNA catabolic process,GO:2000672~negative regulation of motor neuron apoptotic process,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0015030~Cajal body,GO:0030424~axon,GO:0030426~growth cone,GO:0043025~neuronal cell body,GO:0043204~perikaryon,GO:0048471~perinuclear region of cytoplasm,GO:0097504~Gemini of coiled bodies,	GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0030971~receptor tyrosine kinase binding,GO:0031369~translation initiation factor binding,GO:0044183~protein binding involved in protein folding,	IPR004457:Znf_ZPR1,IPR040141:ZPR1,IPR042451:ZPR1_A/B_dom,IPR042452:ZPR1_Znf1/2,		619321~Growth restriction, hypoplastic kidneys, alopecia, and distinctive facies,		SM00709:Zpr1,	KW-0221~Differentiation,KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0966~Cell projection,	KW-0209~Deafness,KW-0242~Dwarfism,KW-1063~Hypotrichosis,	KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,			COMPBIAS:Pro residues,DOMAIN:Zinc finger ZPR1-type,REGION:Disordered,ZN_FING:C4-type 1,ZN_FING:C4-type 2,
ABHD14B	abhydrolase domain containing 14B(ABHD14B)	Homo sapiens			GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0050427~3'-phosphoadenosine 5'-phosphosulfate metabolic process,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0016787~hydrolase activity,GO:0061733~peptide-lysine-N-acetyltransferase activity,	IPR000073:AB_hydrolase_1,IPR029058:AB_hydrolase,						KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0012~Acyltransferase,KW-0378~Hydrolase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Charge relay system,DOMAIN:AB hydrolase-1,MUTAGEN:S->A: Abolished protein-lysine deacetylase activity in vitro.,
ABHD17A	abhydrolase domain containing 17A, depalmitoylase(ABHD17A)	Homo sapiens			GO:0002084~protein depalmitoylation,GO:0072657~protein localization to membrane,GO:1902817~negative regulation of protein localization to microtubule,GO:1905668~positive regulation of protein localization to endosome,	GO:0005886~plasma membrane,GO:0010008~endosome membrane,GO:0016020~membrane,GO:0016607~nuclear speck,GO:0043197~dendritic spine,GO:0043231~intracellular membrane-bounded organelle,GO:0055038~recycling endosome membrane,GO:0098839~postsynaptic density membrane,GO:0098944~postsynaptic recycling endosome membrane,GO:0098978~glutamatergic synapse,	GO:0005515~protein binding,GO:0008474~palmitoyl-(protein) hydrolase activity,	IPR022742:Hydrolase_4,IPR029058:AB_hydrolase,						KW-0472~Membrane,KW-0628~Postsynaptic cell membrane,KW-0770~Synapse,KW-0966~Cell projection,KW-0967~Endosome,KW-1003~Cell membrane,				KW-0378~Hydrolase,	KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,	ACT_SITE:Charge relay system,COMPBIAS:Polar residues,DOMAIN:Serine aminopeptidase S33,MUTAGEN:Missing: Reduces catalytic activity. Loss of membrane localization. No effect on NRAS plasma membrane localization.,MUTAGEN:S->A: Loss of catalytic activity. No effect on its localization. No effect on NRAS plasma membrane localization.,REGION:Disordered,
ABI1	abl interactor 1(ABI1)	Homo sapiens			GO:0001756~somitogenesis,GO:0001764~neuron migration,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0008154~actin polymerization or depolymerization,GO:0008285~negative regulation of cell proliferation,GO:0035855~megakaryocyte development,GO:0048813~dendrite morphogenesis,GO:0061098~positive regulation of protein tyrosine kinase activity,GO:0072673~lamellipodium morphogenesis,	GO:0005634~nucleus,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0014069~postsynaptic density,GO:0030027~lamellipodium,GO:0030175~filopodium,GO:0030426~growth cone,GO:0031209~SCAR complex,GO:0032433~filopodium tip,GO:0070062~extracellular exosome,GO:0098858~actin-based cell projection,	GO:0005515~protein binding,GO:0008092~cytoskeletal protein binding,GO:0017124~SH3 domain binding,GO:0030296~protein tyrosine kinase activator activity,GO:0035591~signaling adaptor activity,GO:0045296~cadherin binding,	IPR000727:T_SNARE_dom,IPR001452:SH3_domain,IPR012849:Abl-interactor_HHR_dom,IPR028457:ABI,IPR035725:Abi1_SH3,IPR036028:SH3-like_dom_sf,	hsa05130:Pathogenic Escherichia coli infection,hsa05132:Salmonella infection,			SM00326:SH3,	KW-0945~Host-virus interaction,	KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0770~Synapse,KW-0963~Cytoplasm,KW-0966~Cell projection,		KW-0175~Coiled coil,KW-0728~SH3 domain,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:SH3,DOMAIN:T-SNARE coiled-coil homology,DOMAIN:t-SNARE coiled-coil homology,REGION:Disordered,REGION:Required for binding to WASF1,SITE:Breakpoint for translocation to form KMT2A/MLL1-ABI1,
ACAA1	acetyl-CoA acyltransferase 1(ACAA1)	Homo sapiens			GO:0000038~very long-chain fatty acid metabolic process,GO:0006635~fatty acid beta-oxidation,GO:0008206~bile acid metabolic process,GO:0010124~phenylacetate catabolic process,GO:0033540~fatty acid beta-oxidation using acyl-CoA oxidase,GO:0036109~alpha-linolenic acid metabolic process,	GO:0005576~extracellular region,GO:0005777~peroxisome,GO:0005782~peroxisomal matrix,GO:0005829~cytosol,GO:0016020~membrane,GO:0035580~specific granule lumen,	GO:0003985~acetyl-CoA C-acetyltransferase activity,GO:0003988~acetyl-CoA C-acyltransferase activity,GO:0005515~protein binding,GO:0008775~acetate CoA-transferase activity,GO:0016401~palmitoyl-CoA oxidase activity,GO:0016747~transferase activity, transferring acyl groups other than amino-acyl groups,GO:0050633~acetyl-CoA C-myristoyltransferase activity,	IPR002155:Thiolase,IPR016039:Thiolase-like,IPR020610:Thiolase_AS,IPR020613:Thiolase_CS,IPR020615:Thiolase_acyl_enz_int_AS,IPR020616:Thiolase_N,IPR020617:Thiolase_C,	hsa00071:Fatty acid degradation,hsa00280:Valine, leucine and isoleucine degradation,hsa00592:alpha-Linolenic acid metabolism,hsa01040:Biosynthesis of unsaturated fatty acids,hsa01100:Metabolic pathways,hsa01212:Fatty acid metabolism,hsa03320:PPAR signaling pathway,hsa04146:Peroxisome,		PIRSF000429:Ac-CoA_Ac_transf,		KW-0276~Fatty acid metabolism,KW-0443~Lipid metabolism,	KW-0576~Peroxisome,		KW-0809~Transit peptide,		KW-0012~Acyltransferase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	ACT_SITE:Acyl-thioester intermediate,ACT_SITE:Proton acceptor,DOMAIN:Thiolase C-terminal,DOMAIN:Thiolase N-terminal,MUTAGEN:G->D,R,L: Does not affect localization to peroxisomes.,MUTAGEN:H->E: In S3E mutant; Abolished localization to peroxisomes.,MUTAGEN:L->D,K: Does not affect localization to peroxisomes.,MUTAGEN:Q->D,K,L: Does not affect localization to peroxisomes.,MUTAGEN:V->D,K: Abolished localization to peroxisomes.,MUTAGEN:V->D: Abolished localization to peroxisomes.,MUTAGEN:V->K: Does not affect localization to peroxisomes.,REGION:PTS2-type peroxisomal targeting signal,TRANSIT:Peroxisome,
ACP1	acid phosphatase 1(ACP1)	Homo sapiens				GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0009898~cytoplasmic side of plasma membrane,GO:0016020~membrane,GO:0042383~sarcolemma,GO:0070062~extracellular exosome,	GO:0003993~acid phosphatase activity,GO:0004721~phosphoprotein phosphatase activity,GO:0004725~protein tyrosine phosphatase activity,GO:0004726~non-membrane spanning protein tyrosine phosphatase activity,GO:0005515~protein binding,	IPR002115:Tyr_Pase_low_mol_wt_mml,IPR017867:Tyr_phospatase_low_mol_wt,IPR023485:Ptyr_pPase,IPR036196:Ptyr_pPase_sf,	hsa00730:Thiamine metabolism,hsa00740:Riboflavin metabolism,hsa01100:Metabolic pathways,hsa04520:Adherens junction,hsa05208:Chemical carcinogenesis - reactive oxygen species,			SM00226:LMWPc,		KW-0472~Membrane,KW-0963~Cytoplasm,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0378~Hydrolase,KW-0904~Protein phosphatase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Nucleophile,ACT_SITE:Proton donor,DOMAIN:Phosphotyrosine protein phosphatase I,MUTAGEN:C->S: Inactive.,MUTAGEN:Y->F: Reduced phosphorylation and activity.,MUTAGEN:Y->F: Reduced phosphorylation. No effect on activity.,TRANSMEM:Helical,
ANP32E	acidic nuclear phosphoprotein 32 family member E(ANP32E)	Homo sapiens			GO:0006325~chromatin organization,GO:0006457~protein folding,GO:0042981~regulation of apoptotic process,	GO:0000812~Swr1 complex,GO:0005634~nucleus,GO:0031410~cytoplasmic vesicle,	GO:0005515~protein binding,GO:0019212~phosphatase inhibitor activity,GO:0042393~histone binding,GO:0044183~protein binding involved in protein folding,	IPR001611:Leu-rich_rpt,IPR025875:Leu-rich_rpt_4,IPR032675:LRR_dom_sf,IPR045081:AN32,						KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0433~Leucine-rich repeat,KW-0677~Repeat,		KW-0143~Chaperone,KW-0156~Chromatin regulator,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:LRRCT,MUTAGEN:DDDY->ADAA: In ANP32E-m2; abolished ability to interact with the H2A.Z/H2AZ1-H2B dimer.,MUTAGEN:LSYLM->ASYAA: In ANP32E-m1; abolished ability to interact with the H2A.Z/H2AZ1-H2B dimer.,REGION:Disordered,REGION:ZID domain,REPEAT:LRR 1,REPEAT:LRR 2,REPEAT:LRR 3,REPEAT:LRR 4,
ACO2	aconitase 2(ACO2)	Homo sapiens			GO:0001889~liver development,GO:0006091~generation of precursor metabolites and energy,GO:0006099~tricarboxylic acid cycle,GO:0006101~citrate metabolic process,GO:0006102~isocitrate metabolic process,GO:0035900~response to isolation stress,	GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0005829~cytosol,	GO:0003994~aconitate hydratase activity,GO:0005506~iron ion binding,GO:0046872~metal ion binding,GO:0051536~iron-sulfur cluster binding,GO:0051538~3 iron, 4 sulfur cluster binding,GO:0051539~4 iron, 4 sulfur cluster binding,	IPR000573:AconitaseA/IPMdHydase_ssu_swvl,IPR001030:Acoase/IPM_deHydtase_lsu_aba,IPR006248:Aconitase_mito-like,IPR015928:Aconitase/3IPM_dehydase_swvl,IPR015931:Acnase/IPM_dHydase_lsu_aba_1/3,IPR015932:Aconitase_dom2,IPR018136:Aconitase_4Fe-4S_BS,IPR036008:Aconitase_4Fe-4S_dom,	hsa00020:Citrate cycle (TCA cycle),hsa00630:Glyoxylate and dicarboxylate metabolism,hsa01100:Metabolic pathways,hsa01200:Carbon metabolism,hsa01210:2-Oxocarboxylic acid metabolism,hsa01230:Biosynthesis of amino acids,	614559~Infantile cerebellar-retinal degeneration,616289~Optic atrophy 9,			KW-0816~Tricarboxylic acid cycle,	KW-0496~Mitochondrion,	KW-0225~Disease variant,KW-0523~Neurodegeneration,	KW-0809~Transit peptide,	KW-0004~4Fe-4S,KW-0408~Iron,KW-0411~Iron-sulfur,KW-0479~Metal-binding,	KW-0456~Lyase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Aconitase A/isopropylmalate dehydratase small subunit swivel,DOMAIN:Aconitase/3-isopropylmalate dehydratase large subunit alpha/beta/alpha,REGION:Disordered,TRANSIT:Mitochondrion,
ACTG1	actin gamma 1(ACTG1)	Homo sapiens		h_hivnefPathway:HIV-I Nef: negative effector of Fas and TNF,	GO:0001525~angiogenesis,GO:0001738~morphogenesis of a polarized epithelium,GO:0007409~axonogenesis,GO:0010628~positive regulation of gene expression,GO:0030335~positive regulation of cell migration,GO:0035633~maintenance of permeability of blood-brain barrier,GO:0045214~sarcomere organization,GO:0048870~cell motility,GO:0051492~regulation of stress fiber assembly,GO:0051893~regulation of focal adhesion assembly,GO:0070527~platelet aggregation,GO:0071346~cellular response to interferon-gamma,GO:0090303~positive regulation of wound healing,GO:0098974~postsynaptic actin cytoskeleton organization,GO:1900242~regulation of synaptic vesicle endocytosis,GO:1902396~protein localization to bicellular tight junction,	GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005884~actin filament,GO:0005886~plasma membrane,GO:0005911~cell-cell junction,GO:0005925~focal adhesion,GO:0016020~membrane,GO:0030016~myofibril,GO:0030424~axon,GO:0031941~filamentous actin,GO:0035267~NuA4 histone acetyltransferase complex,GO:0043296~apical junction complex,GO:0044305~calyx of Held,GO:0045202~synapse,GO:0045335~phagocytic vesicle,GO:0070062~extracellular exosome,GO:0072562~blood microparticle,GO:0097433~dense body,GO:0098685~Schaffer collateral - CA1 synapse,	GO:0005200~structural constituent of cytoskeleton,GO:0005515~protein binding,GO:0005522~profilin binding,GO:0005524~ATP binding,GO:0016787~hydrolase activity,GO:0019901~protein kinase binding,GO:0031625~ubiquitin protein ligase binding,GO:0042802~identical protein binding,GO:0098973~structural constituent of postsynaptic actin cytoskeleton,	IPR004000:Actin,IPR004001:Actin_CS,IPR020902:Actin/actin-like_CS,IPR043129:ATPase_NBD,	hsa03082:ATP-dependent chromatin remodeling,hsa04015:Rap1 signaling pathway,hsa04145:Phagosome,hsa04210:Apoptosis,hsa04390:Hippo signaling pathway,hsa04510:Focal adhesion,hsa04520:Adherens junction,hsa04530:Tight junction,hsa04611:Platelet activation,hsa04613:Neutrophil extracellular trap formation,hsa04670:Leukocyte transendothelial migration,hsa04714:Thermogenesis,hsa04810:Regulation of actin cytoskeleton,hsa04814:Motor proteins,hsa04919:Thyroid hormone signaling pathway,hsa04921:Oxytocin signaling pathway,hsa04971:Gastric acid secretion,hsa05014:Amyotrophic lateral sclerosis,hsa05100:Bacterial invasion of epithelial cells,hsa05110:Vibrio cholerae infection,hsa05130:Pathogenic Escherichia coli infection,hsa05131:Shigellosis,hsa05132:Salmonella infection,hsa05135:Yersinia infection,hsa05164:Influenza A,hsa05205:Proteoglycans in cancer,hsa05225:Hepatocellular carcinoma,hsa05410:Hypertrophic cardiomyopathy,hsa05412:Arrhythmogenic right ventricular cardiomyopathy,hsa05414:Dilated cardiomyopathy,hsa05416:Viral myocarditis,hsa05418:Fluid shear stress and atherosclerosis,	604717~Deafness, autosomal dominant 20/26,614583~Baraitser-Winter syndrome 2,		SM00268:ACTIN,		KW-0206~Cytoskeleton,KW-0963~Cytoplasm,	KW-0209~Deafness,KW-0225~Disease variant,KW-0991~Intellectual disability,KW-1010~Non-syndromic deafness,		KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,	KW-0007~Acetylation,KW-0488~Methylation,KW-0558~Oxidation,KW-1017~Isopeptide bond,	CROSSLNK:(Microbial infection) Isoglutamyl lysine isopeptide (Glu-Lys) (interchain with K-50); by Vibrio toxins RtxA and VgrG1,CROSSLNK:(Microbial infection) Isoglutamyl lysine isopeptide (Lys-Glu) (interchain with E-270); by Vibrio toxins RtxA and VgrG1,
ACTR1A	actin related protein 1A(ACTR1A)	Homo sapiens			GO:0016192~vesicle-mediated transport,	GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005829~cytosol,GO:0005869~dynactin complex,GO:0005875~microtubule associated complex,GO:0005938~cell cortex,GO:0015630~microtubule cytoskeleton,GO:0070062~extracellular exosome,GO:0099738~cell cortex region,	GO:0005515~protein binding,GO:0005524~ATP binding,	IPR004000:Actin,IPR004001:Actin_CS,IPR020902:Actin/actin-like_CS,IPR043129:ATPase_NBD,	hsa04814:Motor proteins,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05132:Salmonella infection,			SM00268:ACTIN,		KW-0206~Cytoskeleton,KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,		KW-0007~Acetylation,
ACTR1B	actin related protein 1B(ACTR1B)	Homo sapiens				GO:0005576~extracellular region,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005829~cytosol,GO:0005869~dynactin complex,GO:0015630~microtubule cytoskeleton,GO:0016020~membrane,GO:0034774~secretory granule lumen,GO:0070062~extracellular exosome,GO:1904813~ficolin-1-rich granule lumen,	GO:0005515~protein binding,GO:0005524~ATP binding,	IPR004000:Actin,IPR004001:Actin_CS,IPR020902:Actin/actin-like_CS,IPR043129:ATPase_NBD,	hsa04814:Motor proteins,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05132:Salmonella infection,			SM00268:ACTIN,		KW-0206~Cytoskeleton,KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,		KW-0007~Acetylation,KW-0944~Nitration,
ACTR2	actin related protein 2(ACTR2)	Homo sapiens		h_actinYPathway:Y branching of actin filaments,h_cdc42racPathway:Role of PI3K subunit p85 in regulation of Actin Organization and Cell Migration,h_mPRPathway:How Progesterone Initiates the Oocyte Maturation,h_rhoPathway:Rho cell motility signaling pathway,h_salmonellaPathway:How does salmonella hijack a cell,	GO:0007163~establishment or maintenance of cell polarity,GO:0008356~asymmetric cell division,GO:0010592~positive regulation of lamellipodium assembly,GO:0016344~meiotic chromosome movement towards spindle pole,GO:0016482~cytosolic transport,GO:0033206~meiotic cytokinesis,GO:0034314~Arp2/3 complex-mediated actin nucleation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051653~spindle localization,GO:0060271~cilium assembly,GO:0071346~cellular response to interferon-gamma,GO:1905168~positive regulation of double-strand break repair via homologous recombination,	GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005885~Arp2/3 protein complex,GO:0005925~focal adhesion,GO:0015629~actin cytoskeleton,GO:0016020~membrane,GO:0030478~actin cap,GO:0035578~azurophil granule lumen,GO:0035861~site of double-strand break,GO:0042995~cell projection,GO:0070062~extracellular exosome,GO:1904813~ficolin-1-rich granule lumen,	GO:0003779~actin binding,GO:0005200~structural constituent of cytoskeleton,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0051015~actin filament binding,	IPR004000:Actin,IPR020902:Actin/actin-like_CS,IPR043129:ATPase_NBD,	hsa04144:Endocytosis,hsa04530:Tight junction,hsa04666:Fc gamma R-mediated phagocytosis,hsa04810:Regulation of actin cytoskeleton,hsa05100:Bacterial invasion of epithelial cells,hsa05130:Pathogenic Escherichia coli infection,hsa05131:Shigellosis,hsa05132:Salmonella infection,hsa05135:Yersinia infection,			SM00268:ACTIN,		KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0966~Cell projection,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0009~Actin-binding,	KW-0007~Acetylation,
ARPC1B	actin related protein 2/3 complex subunit 1B(ARPC1B)	Homo sapiens		h_actinYPathway:Y branching of actin filaments,h_cdc42racPathway:Role of PI3K subunit p85 in regulation of Actin Organization and Cell Migration,h_mPRPathway:How Progesterone Initiates the Oocyte Maturation,h_rhoPathway:Rho cell motility signaling pathway,h_salmonellaPathway:How does salmonella hijack a cell,	GO:0032355~response to estradiol,GO:0034314~Arp2/3 complex-mediated actin nucleation,GO:0043627~response to estrogen,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005885~Arp2/3 protein complex,GO:0005925~focal adhesion,GO:0015629~actin cytoskeleton,GO:0036284~tubulobulbar complex,GO:0070062~extracellular exosome,	GO:0003779~actin binding,GO:0005200~structural constituent of cytoskeleton,GO:0005515~protein binding,GO:0044877~macromolecular complex binding,GO:0051015~actin filament binding,	IPR001680:WD40_rpt,IPR015943:WD40/YVTN_repeat-like_dom_sf,IPR017383:ARPC1,IPR036322:WD40_repeat_dom_sf,	hsa04144:Endocytosis,hsa04530:Tight junction,hsa04666:Fc gamma R-mediated phagocytosis,hsa04810:Regulation of actin cytoskeleton,hsa05100:Bacterial invasion of epithelial cells,hsa05130:Pathogenic Escherichia coli infection,hsa05131:Shigellosis,hsa05132:Salmonella infection,hsa05135:Yersinia infection,	617718~Immunodeficiency 71 with inflammatory disease and congenital thrombocytopenia,	PIRSF038093:ARP2/3_su1,	SM00320:WD40,		KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,	KW-0677~Repeat,KW-0853~WD repeat,		KW-0009~Actin-binding,		REGION:Disordered,REPEAT:WD,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,
ARPC2	actin related protein 2/3 complex subunit 2(ARPC2)	Homo sapiens		h_actinYPathway:Y branching of actin filaments,h_cdc42racPathway:Role of PI3K subunit p85 in regulation of Actin Organization and Cell Migration,h_mPRPathway:How Progesterone Initiates the Oocyte Maturation,h_rhoPathway:Rho cell motility signaling pathway,h_salmonellaPathway:How does salmonella hijack a cell,	GO:0010592~positive regulation of lamellipodium assembly,GO:0030041~actin filament polymerization,GO:0030838~positive regulation of actin filament polymerization,GO:0034314~Arp2/3 complex-mediated actin nucleation,GO:0070358~actin polymerization-dependent cell motility,GO:1900026~positive regulation of substrate adhesion-dependent cell spreading,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005768~endosome,GO:0005829~cytosol,GO:0005885~Arp2/3 protein complex,GO:0005925~focal adhesion,GO:0015629~actin cytoskeleton,GO:0030027~lamellipodium,GO:0031252~cell leading edge,GO:0035861~site of double-strand break,GO:0036195~muscle cell projection membrane,GO:0042995~cell projection,GO:0043005~neuron projection,GO:0045202~synapse,GO:0070062~extracellular exosome,GO:0098978~glutamatergic synapse,	GO:0003779~actin binding,GO:0005200~structural constituent of cytoskeleton,GO:0005515~protein binding,GO:0051015~actin filament binding,	IPR007188:ARPC2,IPR034666:ARPC2/4,	hsa04144:Endocytosis,hsa04530:Tight junction,hsa04666:Fc gamma R-mediated phagocytosis,hsa04810:Regulation of actin cytoskeleton,hsa05100:Bacterial invasion of epithelial cells,hsa05130:Pathogenic Escherichia coli infection,hsa05131:Shigellosis,hsa05132:Salmonella infection,hsa05135:Yersinia infection,					KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0770~Synapse,KW-0771~Synaptosome,KW-0963~Cytoplasm,KW-0966~Cell projection,				KW-0009~Actin-binding,	KW-0007~Acetylation,
ATF4	activating transcription factor 4(ATF4)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006094~gluconeogenesis,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0006874~cellular calcium ion homeostasis,GO:0007214~gamma-aminobutyric acid signaling pathway,GO:0009636~response to toxic substance,GO:0010575~positive regulation of vascular endothelial growth factor production,GO:0010628~positive regulation of gene expression,GO:0030182~neuron differentiation,GO:0030282~bone mineralization,GO:0030968~endoplasmic reticulum unfolded protein response,GO:0031667~response to nutrient levels,GO:0032057~negative regulation of translational initiation in response to stress,GO:0032922~circadian regulation of gene expression,GO:0034198~cellular response to amino acid starvation,GO:0034599~cellular response to oxidative stress,GO:0034644~cellular response to UV,GO:0034976~response to endoplasmic reticulum stress,GO:0035162~embryonic hemopoiesis,GO:0036003~positive regulation of transcription from RNA polymerase II promoter in response to stress,GO:0036091~positive regulation of transcription from RNA polymerase II promoter in response to oxidative stress,GO:0036499~PERK-mediated unfolded protein response,GO:0042149~cellular response to glucose starvation,GO:0042789~mRNA transcription from RNA polymerase II promoter,GO:0043065~positive regulation of apoptotic process,GO:0043267~negative regulation of potassium ion transport,GO:0043525~positive regulation of neuron apoptotic process,GO:0045667~regulation of osteoblast differentiation,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045943~positive regulation of transcription from RNA polymerase I promoter,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048167~regulation of synaptic plasticity,GO:0070059~intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress,GO:0070169~positive regulation of biomineral tissue development,GO:0070309~lens fiber cell morphogenesis,GO:0070982~L-asparagine metabolic process,GO:0071456~cellular response to hypoxia,GO:1903377~negative regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway,GO:1905461~positive regulation of vascular associated smooth muscle cell apoptotic process,GO:1990253~cellular response to leucine starvation,GO:1990440~positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress,GO:1990737~response to manganese-induced endoplasmic reticulum stress,GO:2000120~positive regulation of sodium-dependent phosphate transport,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005829~cytosol,GO:0016607~nuclear speck,GO:0032590~dendrite membrane,GO:0032991~macromolecular complex,GO:0034399~nuclear periphery,GO:0043005~neuron projection,GO:0090575~RNA polymerase II transcription factor complex,GO:1990037~Lewy body core,GO:1990589~ATF4-CREB1 transcription factor complex,GO:1990590~ATF1-ATF4 transcription factor complex,GO:1990617~CHOP-ATF4 complex,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0008140~cAMP response element binding protein binding,GO:0019901~protein kinase binding,GO:0042802~identical protein binding,GO:0043522~leucine zipper domain binding,GO:0043565~sequence-specific DNA binding,GO:0046982~protein heterodimerization activity,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:1990837~sequence-specific double-stranded DNA binding,GO:1990841~promoter-specific chromatin binding,	IPR004827:bZIP,IPR046347:bZIP_sf,	hsa04010:MAPK signaling pathway,hsa04022:cGMP-PKG signaling pathway,hsa04137:Mitophagy - animal,hsa04141:Protein processing in endoplasmic reticulum,hsa04151:PI3K-Akt signaling pathway,hsa04210:Apoptosis,hsa04211:Longevity regulating pathway,hsa04261:Adrenergic signaling in cardiomyocytes,hsa04668:TNF signaling pathway,hsa04720:Long-term potentiation,hsa04722:Neurotrophin signaling pathway,hsa04725:Cholinergic synapse,hsa04728:Dopaminergic synapse,hsa04911:Insulin secretion,hsa04912:GnRH signaling pathway,hsa04915:Estrogen signaling pathway,hsa04918:Thyroid hormone synthesis,hsa04922:Glucagon signaling pathway,hsa04925:Aldosterone synthesis and secretion,hsa04926:Relaxin signaling pathway,hsa04927:Cortisol synthesis and secretion,hsa04928:Parathyroid hormone synthesis, secretion and action,hsa04932:Non-alcoholic fatty liver disease,hsa04934:Cushing syndrome,hsa04935:Growth hormone synthesis, secretion and action,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05030:Cocaine addiction,hsa05031:Amphetamine addiction,hsa05034:Alcoholism,hsa05161:Hepatitis B,hsa05163:Human cytomegalovirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05203:Viral carcinogenesis,hsa05207:Chemical carcinogenesis - receptor activation,hsa05215:Prostate cancer,hsa05417:Lipid and atherosclerosis,			SM00338:BRLZ,	KW-0090~Biological rhythms,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0175~Coiled coil,		KW-0010~Activator,KW-0238~DNA-binding,KW-0678~Repressor,	KW-0007~Acetylation,KW-0379~Hydroxylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:BZIP,DOMAIN:bZIP,MOTIF:BetaTrCP degron motif,MUTAGEN:K->R: Decreased acetylation without affecting ubiquitination by SCF(BTRC).,MUTAGEN:P->A: Increased stability in low oxygen conditions; when associated with A-156, A-162, A-164 and A-167.,MUTAGEN:P->A: Increased stability in low oxygen conditions; when associated with A-156, A-162, A-164 and A-174.,MUTAGEN:P->A: Increased stability in low oxygen conditions; when associated with A-156, A-162, A-167 and A-174.,MUTAGEN:P->A: Increased stability in low oxygen conditions; when associated with A-156, A-164, A-167 and A-174.,MUTAGEN:P->A: Increased stability in low oxygen conditions; when associated with A-162, A-164, A-167 and A-174.,MUTAGEN:S->A: Abolished phosphorylation by CK2 leading to increased stability.,MUTAGEN:S->A: Abolished phosphorylation by RPS6KA3/RSK2.,MUTAGEN:S->N: Abolished phosphorylation on the betaTrCP degron motif, interaction with BTRC and subsequent ubiquitination.,MUTAGEN:T->A: Does not affect phosphorylation by CK2.,REGION:Basic motif,REGION:Disordered,REGION:Interaction with GABBR1,REGION:Leucine-zipper,
ATF6B	activating transcription factor 6 beta(ATF6B)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007165~signal transduction,GO:0030968~endoplasmic reticulum unfolded protein response,GO:0034976~response to endoplasmic reticulum stress,GO:0036500~ATF6-mediated unfolded protein response,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:1903892~negative regulation of ATF6-mediated unfolded protein response,GO:1990440~positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress,	GO:0000139~Golgi membrane,GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005789~endoplasmic reticulum membrane,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0032993~protein-DNA complex,GO:0090575~RNA polymerase II transcription factor complex,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR004827:bZIP,IPR046347:bZIP_sf,	hsa04022:cGMP-PKG signaling pathway,hsa04141:Protein processing in endoplasmic reticulum,hsa04151:PI3K-Akt signaling pathway,hsa04211:Longevity regulating pathway,hsa04261:Adrenergic signaling in cardiomyocytes,hsa04668:TNF signaling pathway,hsa04728:Dopaminergic synapse,hsa04911:Insulin secretion,hsa04915:Estrogen signaling pathway,hsa04918:Thyroid hormone synthesis,hsa04925:Aldosterone synthesis and secretion,hsa04926:Relaxin signaling pathway,hsa04927:Cortisol synthesis and secretion,hsa04928:Parathyroid hormone synthesis, secretion and action,hsa04934:Cushing syndrome,hsa04935:Growth hormone synthesis, secretion and action,hsa05020:Prion disease,hsa05030:Cocaine addiction,hsa05031:Amphetamine addiction,hsa05034:Alcoholism,hsa05161:Hepatitis B,hsa05163:Human cytomegalovirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05203:Viral carcinogenesis,hsa05207:Chemical carcinogenesis - receptor activation,			SM00338:BRLZ,	KW-0804~Transcription,KW-0805~Transcription regulation,KW-0834~Unfolded protein response,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0539~Nucleus,		KW-0175~Coiled coil,KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0010~Activator,KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:BZIP,DOMAIN:bZIP,REGION:Basic motif,REGION:Disordered,REGION:Leucine-zipper,REGION:Transcription activation,SITE:Cleavage; by MBTPS1,SITE:Important for cleavage by MBTPS2,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
ATF7IP	activating transcription factor 7 interacting protein(ATF7IP)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006306~DNA methylation,GO:0006355~regulation of transcription, DNA-templated,GO:0031647~regulation of protein stability,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045898~regulation of RNA polymerase II transcriptional preinitiation complex assembly,GO:0050821~protein stabilization,GO:0090309~positive regulation of methylation-dependent chromatin silencing,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005829~cytosol,GO:0016604~nuclear body,	GO:0003712~transcription cofactor activity,GO:0003714~transcription corepressor activity,GO:0005515~protein binding,GO:0016887~ATPase activity,	IPR003961:FN3_dom,IPR013783:Ig-like_fold,IPR026085:ATF7-int,IPR031870:ATF7IP_BD,IPR036116:FN3_sf,					KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0539~Nucleus,		KW-0175~Coiled coil,		KW-0010~Activator,KW-0678~Repressor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:ATF7-interacting protein protein binding,DOMAIN:Fibronectin type-III,MOTIF:Nuclear localization signal,MUTAGEN:D->A: Abolishes the interaction with SUMO.,MUTAGEN:L->A: Abolishes the interaction with SUMO.,MUTAGEN:L->R: Abolishes interaction with MBD1 and subsequent transcriptional repression.,REGION:Disordered,REGION:Interaction with MBD1,REGION:Interaction with SETDB1,REGION:Interaction with SUMO,
ABT1	activator of basal transcription 1(ABT1)	Homo sapiens			GO:0000447~endonucleolytic cleavage in ITS1 to separate SSU-rRNA from 5.8S rRNA and LSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA),GO:0000472~endonucleolytic cleavage to generate mature 5'-end of SSU-rRNA from (SSU-rRNA, 5.8S rRNA, LSU-rRNA),GO:0000480~endonucleolytic cleavage in 5'-ETS of tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA),GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0021522~spinal cord motor neuron differentiation,GO:0034462~small-subunit processome assembly,GO:0045893~positive regulation of transcription, DNA-templated,	GO:0005634~nucleus,GO:0005667~transcription factor complex,GO:0005730~nucleolus,	GO:0003677~DNA binding,GO:0003713~transcription coactivator activity,GO:0003723~RNA binding,GO:0005515~protein binding,	IPR012677:Nucleotide-bd_a/b_plait_sf,IPR034353:ABT1/ESF2_RRM,IPR035979:RBD_domain_sf,IPR039119:ABT1/Esf2,					KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0175~Coiled coil,		KW-0238~DNA-binding,KW-0694~RNA-binding,	KW-0007~Acetylation,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,DOMAIN:RRM,REGION:Disordered,
AUTS2	activator of transcription and developmental regulator AUTS2(AUTS2)	Homo sapiens			GO:0001764~neuron migration,GO:0010592~positive regulation of lamellipodium assembly,GO:0030036~actin cytoskeleton organization,GO:0035022~positive regulation of Rac protein signal transduction,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048675~axon extension,GO:0051571~positive regulation of histone H3-K4 methylation,GO:0097484~dendrite extension,GO:2000620~positive regulation of histone H4-K16 acetylation,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005856~cytoskeleton,GO:0015629~actin cytoskeleton,GO:0030426~growth cone,	GO:0003682~chromatin binding,GO:0005515~protein binding,	IPR023246:AUTS2,	hsa03083:Polycomb repressive complex,	615834~Intellectual developmental disorder, autosomal dominant 26,			KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0966~Cell projection,	KW-0991~Intellectual disability,KW-1268~Autism spectrum disorder,KW-1269~Autism,				KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,REGION:Disordered,REGION:Important for regulation of lamellipodia formation,
ACADVL	acyl-CoA dehydrogenase very long chain(ACADVL)	Homo sapiens		h_nos1Pathway:Nitric Oxide Signaling Pathway,h_PDZsPathway:Synaptic Proteins at the Synaptic Junction,	GO:0001659~temperature homeostasis,GO:0009409~response to cold,GO:0015980~energy derivation by oxidation of organic compounds,GO:0030855~epithelial cell differentiation,GO:0033539~fatty acid beta-oxidation using acyl-CoA dehydrogenase,GO:0045717~negative regulation of fatty acid biosynthetic process,GO:0046322~negative regulation of fatty acid oxidation,GO:0090181~regulation of cholesterol metabolic process,	GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005759~mitochondrial matrix,GO:0031966~mitochondrial membrane,GO:0042645~mitochondrial nucleoid,	GO:0000062~fatty-acyl-CoA binding,GO:0003995~acyl-CoA dehydrogenase activity,GO:0004466~long-chain-acyl-CoA dehydrogenase activity,GO:0005515~protein binding,GO:0016627~oxidoreductase activity, acting on the CH-CH group of donors,GO:0017099~very-long-chain-acyl-CoA dehydrogenase activity,GO:0042802~identical protein binding,GO:0050660~flavin adenine dinucleotide binding,	IPR006089:Acyl-CoA_DH_CS,IPR006091:Acyl-CoA_Oxase/DH_mid-dom,IPR009075:AcylCo_DH/oxidase_C,IPR009100:AcylCoA_DH/oxidase_NM_dom_sf,IPR013786:AcylCoA_DH/ox_N,IPR036250:AcylCo_DH-like_C,IPR037069:AcylCoA_DH/ox_N_sf,IPR046373:Acyl-CoA_Oxase/DH_mid-dom_sf,	hsa00071:Fatty acid degradation,hsa01100:Metabolic pathways,hsa01212:Fatty acid metabolism,hsa04936:Alcoholic liver disease,	201475~VLCAD deficiency,			KW-0276~Fatty acid metabolism,KW-0443~Lipid metabolism,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,	KW-0122~Cardiomyopathy,KW-0225~Disease variant,	KW-0809~Transit peptide,	KW-0274~FAD,KW-0285~Flavoprotein,	KW-0560~Oxidoreductase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0702~S-nitrosylation,	ACT_SITE:Proton acceptor,COMPBIAS:Basic and acidic residues,DOMAIN:Acyl-CoA dehydrogenase/oxidase C-terminal,DOMAIN:Acyl-CoA dehydrogenase/oxidase N-terminal,DOMAIN:Acyl-CoA oxidase/dehydrogenase middle,MUTAGEN:A->G,V,S,D,H: Changed substrate specificity with decreased affinity for tetradecanoyl-CoA and hexadecanoyl-CoA.,MUTAGEN:E->D: Decreased acyl-CoA dehydrogenase activity. No effect on affinity for acyl-CoA. No effect on FAD cofactor-binding.,MUTAGEN:E->Q: Loss of acyl-CoA dehydrogenase activity. No effect on FAD cofactor-binding.,MUTAGEN:F->T: Decreased acyl-CoA dehydrogenase activity. Decreased affinity for acyl-CoA. No effect on FAD cofactor-binding.,MUTAGEN:F->V: Loss of acyl-CoA dehydrogenase activity. Loss of FAD cofactor-binding.,MUTAGEN:F->Y: Decreased acyl-CoA dehydrogenase activity. No effect on affinity for acyl-CoA. Decreased FAD cofactor-binding.,REGION:Catalytic,REGION:Disordered,REGION:Membrane-anchoring,TRANSIT:Mitochondrion,
AP1G2	adaptor related protein complex 1 subunit gamma 2(AP1G2)	Homo sapiens			GO:0006886~intracellular protein transport,GO:0006896~Golgi to vacuole transport,GO:0016192~vesicle-mediated transport,	GO:0000139~Golgi membrane,GO:0005794~Golgi apparatus,GO:0005798~Golgi-associated vesicle,GO:0010008~endosome membrane,GO:0012505~endomembrane system,GO:0016020~membrane,GO:0030117~membrane coat,GO:0030121~AP-1 adaptor complex,GO:0030133~transport vesicle,GO:0097708~intracellular vesicle,	GO:0005515~protein binding,GO:0035615~clathrin adaptor activity,	IPR002553:Clathrin/coatomer_adapt-like_N,IPR008152:Clathrin_a/b/g-adaptin_app_Ig,IPR008153:GAE_dom,IPR011989:ARM-like,IPR013041:Clathrin_app_Ig-like_sf,IPR016024:ARM-type_fold,IPR017107:AP1_complex_gsu,	hsa04142:Lysosome,hsa05170:Human immunodeficiency virus 1 infection,		PIRSF037094:AP1_complex_gamma,	SM00809:Alpha_adaptinC2,	KW-0653~Protein transport,KW-0813~Transport,KW-0945~Host-virus interaction,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0967~Endosome,KW-0968~Cytoplasmic vesicle,						DOMAIN:Clathrin/coatomer adaptor adaptin-like N-terminal,DOMAIN:GAE,MUTAGEN:A->G: Greatly diminishes interaction with ubiquitin; when associated with G-369.,MUTAGEN:A->G: Greatly diminishes interaction with ubiquitin; when associated with G-376.,MUTAGEN:L->G: Greatly diminishes interaction with ubiquitin; when associated with G-372.,MUTAGEN:S->G: Greatly diminishes interaction with ubiquitin; when associated with G-372.,REGION:Disordered,REGION:Essential for ubiquitin-binding,
AP2B1	adaptor related protein complex 2 subunit beta 1(AP2B1)	Homo sapiens			GO:0001822~kidney development,GO:0003281~ventricular septum development,GO:0006886~intracellular protein transport,GO:0016192~vesicle-mediated transport,GO:0035904~aorta development,GO:0048488~synaptic vesicle endocytosis,GO:0060976~coronary vasculature development,GO:0072583~clathrin-dependent endocytosis,GO:0098884~postsynaptic neurotransmitter receptor internalization,	GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0009898~cytoplasmic side of plasma membrane,GO:0016020~membrane,GO:0030117~membrane coat,GO:0030122~AP-2 adaptor complex,GO:0030131~clathrin adaptor complex,GO:0030666~endocytic vesicle membrane,GO:0030669~clathrin-coated endocytic vesicle membrane,GO:0031090~organelle membrane,GO:0031410~cytoplasmic vesicle,GO:0036020~endolysosome membrane,GO:0045334~clathrin-coated endocytic vesicle,GO:0098793~presynapse,GO:0098794~postsynapse,GO:0098978~glutamatergic synapse,	GO:0005048~signal sequence binding,GO:0005515~protein binding,GO:0030276~clathrin binding,GO:0035615~clathrin adaptor activity,	IPR000225:Armadillo,IPR002553:Clathrin/coatomer_adapt-like_N,IPR008152:Clathrin_a/b/g-adaptin_app_Ig,IPR009028:Coatomer/calthrin_app_sub_C,IPR011989:ARM-like,IPR012295:TBP_dom_sf,IPR013037:Clathrin_b-adaptin_app_Ig-like,IPR013041:Clathrin_app_Ig-like_sf,IPR015151:B-adaptin_app_sub_C,IPR016024:ARM-type_fold,IPR016342:AP_complex_bsu_1_2_4,IPR026739:AP_beta,	hsa04144:Endocytosis,hsa04721:Synaptic vesicle cycle,hsa04961:Endocrine and other factor-regulated calcium reabsorption,hsa05016:Huntington disease,		PIRSF002291:AP_complex_beta,	SM00185:ARM,SM00809:Alpha_adaptinC2,SM01020:B2-adapt-app_C,	KW-0254~Endocytosis,KW-0653~Protein transport,KW-0813~Transport,	KW-0168~Coated pit,KW-0472~Membrane,KW-1003~Cell membrane,					KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:Beta-adaptin appendage C-terminal subdomain,DOMAIN:Clathrin adaptor alpha/beta/gamma-adaptin appendage Ig-like subdomain,DOMAIN:Clathrin/coatomer adaptor adaptin-like N-terminal,MUTAGEN:E->A: Strongly reduces interaction with LDLRAP1 and ARRB1. No effect on DENND1B-binding.,MUTAGEN:E->A: Strongly reduces interaction with LDLRAP1, ARRB1 and EPN1. No effect on DENND1B-binding.,MUTAGEN:K->E: Strongly reduces interaction with ARRB1.,MUTAGEN:K->Q: Strongly reduces interaction with LDLRAP1. SNAP91 and clathrin. Reduces interaction with EPN1. No effect on EPS15 binding.,MUTAGEN:Q->A: Strongly reduces interaction with ARRB1.,MUTAGEN:R->A: No effect on interaction with ARRB1.,MUTAGEN:R->E: Strongly reduces interaction with EPN1. Reduces interaction with SNAP91 and clathrin. No effect on EPS15 binding.,MUTAGEN:W->A: Abolishes interaction with LDLRAP1 and ARRB1. Greatly reduces DENND1B-binding.,MUTAGEN:Y->A: Strongly reduces interaction with SNAP91, EPS15, AMPH and BIN1 and clathrin heavy chain.,MUTAGEN:Y->V: Strongly reduces interaction with SNAP91, EPN1 and clathrin. No effect on EPS15 binding. Abolishes interaction with ARRB1 and with DENND1B.,REGION:Disordered,REGION:Interaction with ARRB1,
AP2M1	adaptor related protein complex 2 subunit mu 1(AP2M1)	Homo sapiens		h_bArrestinPathway:ï¿½-arrestins in GPCR Desensitization,h_ndkDynaminPathway:Endocytotic role of NDK, Phosphins and Dynamin,h_ptdinsPathway:Phosphoinositides and their downstream targets.,	GO:0002092~positive regulation of receptor internalization,GO:0006886~intracellular protein transport,GO:0006897~endocytosis,GO:0006900~membrane budding,GO:0016192~vesicle-mediated transport,GO:0031623~receptor internalization,GO:0048488~synaptic vesicle endocytosis,GO:0065003~macromolecular complex assembly,GO:0072583~clathrin-dependent endocytosis,GO:0097494~regulation of vesicle size,GO:0098884~postsynaptic neurotransmitter receptor internalization,GO:1900244~positive regulation of synaptic vesicle endocytosis,GO:1903077~negative regulation of protein localization to plasma membrane,	GO:0005765~lysosomal membrane,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005905~clathrin-coated pit,GO:0009898~cytoplasmic side of plasma membrane,GO:0030122~AP-2 adaptor complex,GO:0030131~clathrin adaptor complex,GO:0030666~endocytic vesicle membrane,GO:0030669~clathrin-coated endocytic vesicle membrane,GO:0031410~cytoplasmic vesicle,GO:0036020~endolysosome membrane,GO:0045334~clathrin-coated endocytic vesicle,GO:0070062~extracellular exosome,GO:0098794~postsynapse,GO:0098894~extrinsic component of presynaptic endocytic zone membrane,GO:0098978~glutamatergic synapse,	GO:0005048~signal sequence binding,GO:0005515~protein binding,GO:0008289~lipid binding,GO:0035615~clathrin adaptor activity,GO:0044325~ion channel binding,GO:0050750~low-density lipoprotein particle receptor binding,GO:0097718~disordered domain specific binding,	IPR001392:Clathrin_mu,IPR011012:Longin-like_dom_sf,IPR018240:Clathrin_mu_CS,IPR022775:AP_mu_sigma_su,IPR028565:MHD,IPR036168:AP2_Mu_C_sf,IPR043512:Mu2_C,IPR043532:AP2_Mu_N,	hsa04144:Endocytosis,hsa04721:Synaptic vesicle cycle,hsa04961:Endocrine and other factor-regulated calcium reabsorption,hsa05016:Huntington disease,	618587~Intellectual developmental disorder 60 with seizures,	PIRSF005992:Clathrin_mu,		KW-0254~Endocytosis,KW-0653~Protein transport,KW-0813~Transport,	KW-0168~Coated pit,KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0887~Epilepsy,KW-0991~Intellectual disability,		KW-0446~Lipid-binding,		KW-0597~Phosphoprotein,	DOMAIN:AP complex mu/sigma subunit,DOMAIN:MHD,REGION:Disordered,
AP2S1	adaptor related protein complex 2 subunit sigma 1(AP2S1)	Homo sapiens			GO:0006886~intracellular protein transport,GO:0016192~vesicle-mediated transport,GO:0030100~regulation of endocytosis,GO:0048268~clathrin coat assembly,GO:0048488~synaptic vesicle endocytosis,GO:0072583~clathrin-dependent endocytosis,GO:0098884~postsynaptic neurotransmitter receptor internalization,	GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0009898~cytoplasmic side of plasma membrane,GO:0030117~membrane coat,GO:0030122~AP-2 adaptor complex,GO:0030666~endocytic vesicle membrane,GO:0030669~clathrin-coated endocytic vesicle membrane,GO:0036020~endolysosome membrane,GO:0043231~intracellular membrane-bounded organelle,GO:0045334~clathrin-coated endocytic vesicle,GO:0098793~presynapse,GO:0098794~postsynapse,	GO:0005515~protein binding,GO:0035615~clathrin adaptor activity,	IPR000804:Clathrin_sm-chain_CS,IPR011012:Longin-like_dom_sf,IPR016635:AP_complex_ssu,IPR022775:AP_mu_sigma_su,IPR027156:APS2,	hsa04144:Endocytosis,hsa04721:Synaptic vesicle cycle,hsa04961:Endocrine and other factor-regulated calcium reabsorption,hsa05016:Huntington disease,	600740~Hypocalciuric hypercalcemia, type III,	PIRSF015588:AP_complex_sigma,		KW-0254~Endocytosis,KW-0653~Protein transport,KW-0813~Transport,	KW-0168~Coated pit,KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,				KW-0597~Phosphoprotein,	DOMAIN:AP complex mu/sigma subunit,
AP3B1	adaptor related protein complex 3 subunit beta 1(AP3B1)	Homo sapiens			GO:0000902~cell morphogenesis,GO:0002224~toll-like receptor signaling pathway,GO:0002244~hematopoietic progenitor cell differentiation,GO:0003016~respiratory system process,GO:0006622~protein targeting to lysosome,GO:0006882~cellular zinc ion homeostasis,GO:0006886~intracellular protein transport,GO:0006954~inflammatory response,GO:0007040~lysosome organization,GO:0007283~spermatogenesis,GO:0007338~single fertilization,GO:0007596~blood coagulation,GO:0008089~anterograde axonal transport,GO:0016192~vesicle-mediated transport,GO:0030851~granulocyte differentiation,GO:0032438~melanosome organization,GO:0034394~protein localization to cell surface,GO:0035654~cargo loading into clathrin-coated vesicle, AP-3-mediated,GO:0036211~protein modification process,GO:0042789~mRNA transcription from RNA polymerase II promoter,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046907~intracellular transport,GO:0048007~antigen processing and presentation, exogenous lipid antigen via MHC class Ib,GO:0048490~anterograde synaptic vesicle transport,GO:0048872~homeostasis of number of cells,GO:0051138~positive regulation of NK T cell differentiation,GO:0060155~platelet dense granule organization,GO:0060425~lung morphogenesis,GO:0090152~establishment of protein localization to mitochondrial membrane involved in mitochondrial fission,GO:0098773~skin epidermis development,GO:1903232~melanosome assembly,	GO:0005739~mitochondrion,GO:0005765~lysosomal membrane,GO:0005769~early endosome,GO:0005794~Golgi apparatus,GO:0016020~membrane,GO:0030117~membrane coat,GO:0030123~AP-3 adaptor complex,GO:0030131~clathrin adaptor complex,GO:0030665~clathrin-coated vesicle membrane,GO:1904115~axon cytoplasm,	GO:0005515~protein binding,GO:0019903~protein phosphatase binding,GO:0030276~clathrin binding,GO:0030742~GTP-dependent protein binding,	IPR002553:Clathrin/coatomer_adapt-like_N,IPR011989:ARM-like,IPR015151:B-adaptin_app_sub_C,IPR016024:ARM-type_fold,IPR016342:AP_complex_bsu_1_2_4,IPR026739:AP_beta,IPR026740:AP3_beta,IPR029390:AP3B_C,IPR029394:AP3B1_Ser,	hsa04142:Lysosome,	608233~Hermansky-Pudlak syndrome 2,	PIRSF002291:AP_complex_beta,PIRSF037096:AP3_complex_beta,	SM01020:B2-adapt-app_C,SM01355:AP3B1_C,	KW-0653~Protein transport,KW-0813~Transport,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0968~Cytoplasmic vesicle,	KW-0015~Albinism,KW-0225~Disease variant,KW-0363~Hermansky-Pudlak syndrome,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,DOMAIN:AP-3 complex subunit beta 1 serine-rich,DOMAIN:AP-3 complex subunit beta C-terminal,DOMAIN:Beta-adaptin appendage C-terminal subdomain,DOMAIN:Clathrin/coatomer adaptor adaptin-like N-terminal,REGION:Disordered,TRANSMEM:Helical,
AP3S1	adaptor related protein complex 3 subunit sigma 1(AP3S1)	Homo sapiens			GO:0006886~intracellular protein transport,GO:0006896~Golgi to vacuole transport,GO:0008089~anterograde axonal transport,GO:0008286~insulin receptor signaling pathway,GO:0016183~synaptic vesicle coating,GO:0016192~vesicle-mediated transport,GO:0035654~cargo loading into clathrin-coated vesicle, AP-3-mediated,GO:0036465~synaptic vesicle recycling,GO:0046907~intracellular transport,GO:0048490~anterograde synaptic vesicle transport,GO:0060155~platelet dense granule organization,GO:1903232~melanosome assembly,	GO:0005769~early endosome,GO:0005794~Golgi apparatus,GO:0030119~AP-type membrane coat adaptor complex,GO:0030123~AP-3 adaptor complex,GO:0030133~transport vesicle,GO:0030659~cytoplasmic vesicle membrane,GO:0043231~intracellular membrane-bounded organelle,GO:0098793~presynapse,GO:1904115~axon cytoplasm,	GO:0005515~protein binding,	IPR000804:Clathrin_sm-chain_CS,IPR011012:Longin-like_dom_sf,IPR016635:AP_complex_ssu,IPR022775:AP_mu_sigma_su,IPR027155:APS3,	hsa04142:Lysosome,		PIRSF015588:AP_complex_sigma,		KW-0653~Protein transport,KW-0813~Transport,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0968~Cytoplasmic vesicle,					KW-0597~Phosphoprotein,	DOMAIN:AP complex mu/sigma subunit,
ADD1	adducin 1(ADD1)	Homo sapiens		h_PDZsPathway:Synaptic Proteins at the Synaptic Junction,	GO:0000902~cell morphogenesis,GO:0001701~in utero embryonic development,GO:0006884~cell volume homeostasis,GO:0007010~cytoskeleton organization,GO:0020027~hemoglobin metabolic process,GO:0030036~actin cytoskeleton organization,GO:0030218~erythrocyte differentiation,GO:0032092~positive regulation of protein binding,GO:0035264~multicellular organism growth,GO:0048873~homeostasis of number of cells within a tissue,GO:0051016~barbed-end actin filament capping,GO:0051017~actin filament bundle assembly,GO:0071277~cellular response to calcium ion,GO:1903142~positive regulation of establishment of endothelial barrier,GO:1903393~positive regulation of adherens junction organization,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0005912~adherens junction,GO:0005925~focal adhesion,GO:0008290~F-actin capping protein complex,GO:0014069~postsynaptic density,GO:0016604~nuclear body,	GO:0003723~RNA binding,GO:0003779~actin binding,GO:0005200~structural constituent of cytoskeleton,GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0030507~spectrin binding,GO:0042803~protein homodimerization activity,GO:0045296~cadherin binding,GO:0046982~protein heterodimerization activity,GO:0046983~protein dimerization activity,GO:0051015~actin filament binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,	IPR001303:Aldolase_II/adducin_N,IPR036409:Aldolase_II/adducin_N_sf,		145500~Hypertension, essential, salt-sensitive,		SM01007:Aldolase_II,		KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,				KW-0009~Actin-binding,KW-0112~Calmodulin-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Class II aldolase/adducin N-terminal,MUTAGEN:T->D: Abolishes phosphorylation by ROCK2; when associated with D-445.,MUTAGEN:T->D: Abolishes phosphorylation by ROCK2; when associated with D-480.,REGION:Disordered,REGION:Interaction with calmodulin,
ADD3	adducin 3(ADD3)	Homo sapiens			GO:0007010~cytoskeleton organization,GO:0009410~response to xenobiotic stimulus,GO:0045907~positive regulation of vasoconstriction,GO:0051016~barbed-end actin filament capping,GO:0051495~positive regulation of cytoskeleton organization,	GO:0000794~condensed nuclear chromosome,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0005903~brush border,GO:0005911~cell-cell junction,GO:0005938~cell cortex,GO:0014069~postsynaptic density,GO:0016020~membrane,	GO:0005080~protein kinase C binding,GO:0005200~structural constituent of cytoskeleton,GO:0005516~calmodulin binding,GO:0051015~actin filament binding,	IPR001303:Aldolase_II/adducin_N,IPR036409:Aldolase_II/adducin_N_sf,		617008~Cerebral palsy, spastic quadriplegic, 3,		SM01007:Aldolase_II,		KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,	KW-0225~Disease variant,			KW-0009~Actin-binding,KW-0112~Calmodulin-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Class II aldolase/adducin N-terminal,REGION:Disordered,REGION:Interaction with calmodulin,SITE:Cleavage by asparagine endopeptidase (AEP),
APRT	adenine phosphoribosyltransferase(APRT)	Homo sapiens			GO:0006166~purine ribonucleoside salvage,GO:0006168~adenine salvage,GO:0007625~grooming behavior,GO:0032263~GMP salvage,GO:0032264~IMP salvage,GO:0044209~AMP salvage,	GO:0005576~extracellular region,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0034774~secretory granule lumen,GO:0070062~extracellular exosome,	GO:0002055~adenine binding,GO:0003999~adenine phosphoribosyltransferase activity,GO:0005515~protein binding,GO:0016208~AMP binding,GO:0016757~transferase activity, transferring glycosyl groups,	IPR000836:PRibTrfase_dom,IPR005764:Ade_phspho_trans,IPR029057:PRTase-like,	hsa00230:Purine metabolism,hsa01100:Metabolic pathways,hsa01232:Nucleotide metabolism,	614723~Adenine phosphoribosyltransferase deficiency,			KW-0660~Purine salvage,	KW-0963~Cytoplasm,	KW-0225~Disease variant,			KW-0328~Glycosyltransferase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:Phosphoribosyltransferase,
ADAR	adenosine deaminase RNA specific(ADAR)	Homo sapiens		h_antisensePathway:RNA polymerase III transcription,	GO:0001649~osteoblast differentiation,GO:0002244~hematopoietic progenitor cell differentiation,GO:0002566~somatic diversification of immune receptors via somatic mutation,GO:0006382~adenosine to inosine editing,GO:0006396~RNA processing,GO:0006397~mRNA processing,GO:0006606~protein import into nucleus,GO:0006611~protein export from nucleus,GO:0009615~response to virus,GO:0016553~base conversion or substitution editing,GO:0030218~erythrocyte differentiation,GO:0031054~pre-miRNA processing,GO:0035455~response to interferon-alpha,GO:0044387~negative regulation of protein kinase activity by regulation of protein phosphorylation,GO:0045070~positive regulation of viral genome replication,GO:0045087~innate immune response,GO:0051607~defense response to virus,GO:0060216~definitive hemopoiesis,GO:0060339~negative regulation of type I interferon-mediated signaling pathway,GO:0061484~hematopoietic stem cell homeostasis,GO:0070922~small RNA loading onto RISC,GO:0097284~hepatocyte apoptotic process,GO:0098586~cellular response to virus,GO:1900369~negative regulation of RNA interference,GO:1903944~negative regulation of hepatocyte apoptotic process,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016020~membrane,GO:0044530~supraspliceosomal complex,	GO:0003677~DNA binding,GO:0003723~RNA binding,GO:0003725~double-stranded RNA binding,GO:0003726~double-stranded RNA adenosine deaminase activity,GO:0005515~protein binding,GO:0008251~tRNA-specific adenosine deaminase activity,GO:0046872~metal ion binding,	IPR002466:A_deamin,IPR014720:dsRBD_dom,IPR036388:WH-like_DNA-bd_sf,IPR036390:WH_DNA-bd_sf,IPR042371:Z_dom,IPR044456:ADAR1_DSRM_1,IPR044457:ADAR1_DSRM_3,	hsa04622:RIG-I-like receptor signaling pathway,hsa04623:Cytosolic DNA-sensing pathway,hsa05162:Measles,hsa05164:Influenza A,hsa05171:Coronavirus disease - COVID-19,	127400~Dyschromatosis symmetrica hereditaria,615010~Aicardi-Goutieres syndrome 6,		SM00358:DSRM,SM00550:Zalpha,SM00552:ADEAMc,	KW-0051~Antiviral defense,KW-0391~Immunity,KW-0399~Innate immunity,KW-0507~mRNA processing,KW-0943~RNA-mediated gene silencing,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0948~Aicardi-Goutieres syndrome,	KW-0677~Repeat,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,KW-0378~Hydrolase,KW-0694~RNA-binding,	KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	ACT_SITE:Proton donor,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:A to I editase,DOMAIN:DRBM,DOMAIN:DRBM 1,DOMAIN:DRBM 2,DOMAIN:DRBM 3,DOMAIN:Z-binding,DOMAIN:Z-binding 1,DOMAIN:Z-binding 2,MUTAGEN:E->A: No effect on nuclear location; when associated with A-721 and A-724.,MUTAGEN:I->N: Disrupts the bi-partite nuclear localization signal and abolishes nuclear location; when associated with S-719 and N-723.,MUTAGEN:K->R: Abolishes sumoylation.,MUTAGEN:KK->AA: Strongly impaired RNA binding. No effect on nuclear location.,MUTAGEN:KVRK->AVAA: No effect on nuclear location. No effect on RNA binding.,MUTAGEN:L->N: Disrupts the bi-partite nuclear localization signal and abolishes nuclear location; when associated with N-716 and S-719.,MUTAGEN:L->S: Disrupts the bi-partite nuclear localization signal and abolishes nuclear location; when associated with N-716 and N-723.,MUTAGEN:MMP->AMA: Decreased nuclear and partially cytoplasmic location.,MUTAGEN:Missing: Abolishes nuclear location.,MUTAGEN:Missing: Disrupts nuclear localization signal. No effect on RNA binding.,MUTAGEN:Missing: Disrupts the bi-partite nuclear localization signal and abolishes nuclear location.,MUTAGEN:N->A: No effect on nuclear location; when associated with A-718 and A-721.,MUTAGEN:R->A: Abolishes interaction with TNPO1, TNPO1-mediated nuclear import and nuclear location.,MUTAGEN:R->A: No effect on nuclear location; when associated with A-721 and A-724.,REGION:C-terminal extension of DRBM 3 and constituent of a bi-partite nuclear localization signal,REGION:Disordered,REGION:Interaction with Z-DNA,REGION:N-terminal extension of DRBM 3 and constituent of a bi-partite nuclear localization signal,
ADK	adenosine kinase(ADK)	Homo sapiens			GO:0006144~purine nucleobase metabolic process,GO:0006166~purine ribonucleoside salvage,GO:0006175~dATP biosynthetic process,GO:0009156~ribonucleoside monophosphate biosynthetic process,GO:0016310~phosphorylation,GO:0032263~GMP salvage,GO:0044209~AMP salvage,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,	GO:0003723~RNA binding,GO:0004001~adenosine kinase activity,GO:0004136~deoxyadenosine kinase activity,GO:0005524~ATP binding,GO:0046872~metal ion binding,	IPR001805:Adenokinase,IPR002173:Carboh/pur_kinase_PfkB_CS,IPR011611:PfkB_dom,IPR029056:Ribokinase-like,	hsa00230:Purine metabolism,hsa01100:Metabolic pathways,hsa01232:Nucleotide metabolism,	614300~Hypermethioninemia due to adenosine kinase deficiency,			KW-0660~Purine salvage,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,		KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,DOMAIN:Carbohydrate kinase PfkB,MOTIF:Nuclear localization signal,MUTAGEN:KK->AA,AD: Abolishes nuclear localization.,
AK3	adenylate kinase 3(AK3)	Homo sapiens			GO:0006172~ADP biosynthetic process,GO:0007596~blood coagulation,GO:0009142~nucleoside triphosphate biosynthetic process,GO:0016310~phosphorylation,GO:0046033~AMP metabolic process,GO:0046039~GTP metabolic process,GO:0046041~ITP metabolic process,GO:0046051~UTP metabolic process,	GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,	GO:0004017~adenylate kinase activity,GO:0004550~nucleoside diphosphate kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0005525~GTP binding,GO:0046899~nucleoside triphosphate adenylate kinase activity,	IPR000850:Adenylat/UMP-CMP_kin,IPR006259:Adenyl_kin_sub,IPR007862:Adenylate_kinase_lid-dom,IPR027417:P-loop_NTPase,IPR028586:AK3/Ak4_mitochondrial,IPR033690:Adenylat_kinase_CS,IPR036193:ADK_active_lid_dom_sf,	hsa00230:Purine metabolism,hsa01232:Nucleotide metabolism,hsa01240:Biosynthesis of cofactors,					KW-0496~Mitochondrion,			KW-0342~GTP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:Adenylate kinase active site lid,REGION:LID,REGION:NMP,REGION:NMPbind,
AK6	adenylate kinase 6(AK6)	Homo sapiens			GO:0015949~nucleobase-containing small molecule interconversion,GO:0016310~phosphorylation,GO:0046940~nucleoside monophosphate phosphorylation,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0015030~Cajal body,GO:0016020~membrane,GO:0016607~nuclear speck,	GO:0004017~adenylate kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016887~ATPase activity,GO:0050145~nucleoside phosphate kinase activity,	IPR020618:Adenyl_kinase_AK6,IPR027417:P-loop_NTPase,	hsa00230:Purine metabolism,hsa01100:Metabolic pathways,hsa01232:Nucleotide metabolism,hsa01240:Biosynthesis of cofactors,hsa03008:Ribosome biogenesis in eukaryotes,					KW-0539~Nucleus,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0808~Transferase,		MUTAGEN:H->G: Induces homodimerization. Reduces adenylate kinase activity by 72% and ATPase activity by 76%. Significantly changes Cajal body organization in the nucleus, resulting in enhanced apoptosis and reduced proliferation.,REGION:LID,REGION:NMP,
ADSL	adenylosuccinate lyase(ADSL)	Homo sapiens			GO:0001666~response to hypoxia,GO:0006164~purine nucleotide biosynthetic process,GO:0006167~AMP biosynthetic process,GO:0006177~GMP biosynthetic process,GO:0006189~'de novo' IMP biosynthetic process,GO:0007584~response to nutrient,GO:0009060~aerobic respiration,GO:0014850~response to muscle activity,GO:0042594~response to starvation,GO:0044208~'de novo' AMP biosynthetic process,GO:0044209~AMP salvage,GO:0044281~small molecule metabolic process,GO:0097294~'de novo' XMP biosynthetic process,	GO:0005829~cytosol,GO:0032991~macromolecular complex,	GO:0003824~catalytic activity,GO:0004018~N6-(1,2-dicarboxyethyl)AMP AMP-lyase (fumarate-forming) activity,GO:0016829~lyase activity,GO:0042802~identical protein binding,GO:0070626~(S)-2-(5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxamido)succinate AMP-lyase (fumarate-forming) activity,	IPR000362:Fumarate_lyase_fam,IPR004769:Pur_lyase,IPR008948:L-Aspartase-like,IPR019468:AdenyloSucc_lyase_C,IPR020557:Fumarate_lyase_CS,IPR022761:Fumarate_lyase_N,IPR024083:Fumarase/histidase_N,	hsa00230:Purine metabolism,hsa00250:Alanine, aspartate and glutamate metabolism,hsa01100:Metabolic pathways,hsa01232:Nucleotide metabolism,hsa01240:Biosynthesis of cofactors,	103050~Adenylosuccinase deficiency,		SM00998:ADSL_C,	KW-0658~Purine biosynthesis,		KW-0225~Disease variant,KW-0887~Epilepsy,			KW-0456~Lyase,	KW-0007~Acetylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	ACT_SITE:Proton donor/acceptor,BINDING:in other chain,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1),DOMAIN:Adenylosuccinate lyase C-terminal,DOMAIN:Fumarate lyase N-terminal,
ADGRE5	adhesion G protein-coupled receptor E5(ADGRE5)	Homo sapiens			GO:0006954~inflammatory response,GO:0006955~immune response,GO:0007155~cell adhesion,GO:0007166~cell surface receptor signaling pathway,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007189~adenylate cyclase-activating G-protein coupled receptor signaling pathway,GO:0007267~cell-cell signaling,	GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0016020~membrane,GO:0030667~secretory granule membrane,GO:0070062~extracellular exosome,	GO:0004888~transmembrane signaling receptor activity,GO:0004930~G-protein coupled receptor activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,	IPR000152:EGF-type_Asp/Asn_hydroxyl_site,IPR000203:GPS,IPR000742:EGF-like_dom,IPR000832:GPCR_2_secretin-like,IPR001881:EGF-like_Ca-bd_dom,IPR003056:GPCR_2_ADGRE2_ADGRE5,IPR009030:Growth_fac_rcpt_cys_sf,IPR017981:GPCR_2-like_7TM,IPR017983:GPCR_2_secretin-like_CS,IPR018097:EGF_Ca-bd_CS,IPR046338:GAIN_dom_sf,				SM00179:EGF_CA,SM00181:EGF,SM00303:GPS,	KW-0130~Cell adhesion,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0245~EGF-like domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,	KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:EGF-like,DOMAIN:EGF-like 1,DOMAIN:EGF-like 2; calcium-binding,DOMAIN:EGF-like 3; calcium-binding,DOMAIN:EGF-like 4; calcium-binding,DOMAIN:EGF-like 5; calcium-binding,DOMAIN:G-protein coupled receptors family 2 profile 2,DOMAIN:GPS,REGION:Disordered,SITE:Cleavage,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
AFTPH	aftiphilin(AFTPH)	Homo sapiens			GO:0015031~protein transport,GO:0046907~intracellular transport,	GO:0005654~nucleoplasm,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0030121~AP-1 adaptor complex,GO:0032588~trans-Golgi network membrane,GO:0043231~intracellular membrane-bounded organelle,GO:0048471~perinuclear region of cytoplasm,	GO:0030276~clathrin binding,	IPR029205:Clathrin-bd,IPR046359:Aftin-like,					KW-0653~Protein transport,KW-0813~Transport,	KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,		KW-0677~Repeat,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Aftiphilin clathrin-binding box,MOTIF:CLTCL1/Clathrin-binding,MOTIF:WXXF motif 1,MOTIF:WXXF motif 2,MOTIF:WXXF motif 3 (partial),MOTIF:WXXF motif 4,MUTAGEN:YQW->SQS: Abolishes the interaction with CLTCL1/Clathrin.,REGION:Clathrin-binding,REGION:Disordered,REGION:Interaction with AP1G1,REGION:Interaction with AP1G1, AP1G2, GGA1 and GGA3,
AKIRIN1	akirin 1(AKIRIN1)	Homo sapiens			GO:0010592~positive regulation of lamellipodium assembly,GO:0010759~positive regulation of macrophage chemotaxis,GO:0014839~myoblast migration involved in skeletal muscle regeneration,GO:0045663~positive regulation of myoblast differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:1902723~negative regulation of skeletal muscle satellite cell proliferation,GO:1902725~negative regulation of satellite cell differentiation,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0031965~nuclear membrane,	GO:0003712~transcription cofactor activity,GO:0005515~protein binding,	IPR024132:Akirin,						KW-0539~Nucleus,					KW-0597~Phosphoprotein,	COMPBIAS:Pro residues,MOTIF:Nuclear localization signal,MOTIF:SYVS motif,REGION:Disordered,
AKIRIN2	akirin 2(AKIRIN2)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0002250~adaptive immune response,GO:0002821~positive regulation of adaptive immune response,GO:0006606~protein import into nucleus,GO:0008284~positive regulation of cell proliferation,GO:0009792~embryo development ending in birth or egg hatching,GO:0010629~negative regulation of gene expression,GO:0021987~cerebral cortex development,GO:0031144~proteasome localization,GO:0032496~response to lipopolysaccharide,GO:0032755~positive regulation of interleukin-6 production,GO:0042742~defense response to bacterium,GO:0045087~innate immune response,GO:0045089~positive regulation of innate immune response,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0050871~positive regulation of B cell activation,GO:0051147~regulation of muscle cell differentiation,GO:0071630~ubiquitin-dependent catabolism of misfolded proteins by nucleus-associated proteasome,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0016020~membrane,GO:0017053~transcriptional repressor complex,	GO:0003712~transcription cofactor activity,GO:0005515~protein binding,GO:0019899~enzyme binding,GO:0030674~protein binding, bridging,GO:0042802~identical protein binding,	IPR024132:Akirin,					KW-0391~Immunity,KW-0399~Innate immunity,KW-0653~Protein transport,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0813~Transport,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0217~Developmental protein,KW-0678~Repressor,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,	MOTIF:Nuclear localization signal,MOTIF:SYVS motif,MUTAGEN:Missing: Abolished association with the 20S and 26S proteasomes.,REGION:Disordered,
AKR7A2	aldo-keto reductase family 7 member A2(AKR7A2)	Homo sapiens		h_arenrf2Pathway:Oxidative Stress Induced Gene Expression Via Nrf2,	GO:0005975~carbohydrate metabolic process,GO:0006081~cellular aldehyde metabolic process,GO:0006629~lipid metabolic process,GO:0022900~electron transport chain,GO:0044597~daunorubicin metabolic process,GO:0044598~doxorubicin metabolic process,	GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0004032~alditol:NADP+ 1-oxidoreductase activity,GO:0004033~aldo-keto reductase (NADP) activity,GO:0005515~protein binding,GO:0009055~electron carrier activity,GO:0019119~phenanthrene-9,10-epoxide hydrolase activity,	IPR023210:NADP_OxRdtase_dom,IPR036812:NADP_OxRdtase_dom_sf,	hsa00980:Metabolism of xenobiotics by cytochrome P450,				KW-0443~Lipid metabolism,	KW-0333~Golgi apparatus,KW-0496~Mitochondrion,KW-0963~Cytoplasm,		KW-0809~Transit peptide,	KW-0521~NADP,	KW-0560~Oxidoreductase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton donor,DOMAIN:NADP-dependent oxidoreductase,REGION:Disordered,SITE:Lowers pKa of active site Tyr,TRANSIT:Mitochondrion,
ALDOA	aldolase, fructose-bisphosphate A(ALDOA)	Homo sapiens		h_mta3Pathway:Downregulated of MTA-3 in ER-negative Breast Tumors,	GO:0006000~fructose metabolic process,GO:0006096~glycolytic process,GO:0006754~ATP biosynthetic process,GO:0006941~striated muscle contraction,GO:0007015~actin filament organization,GO:0007339~binding of sperm to zona pellucida,GO:0008360~regulation of cell shape,GO:0030388~fructose 1,6-bisphosphate metabolic process,GO:0046716~muscle cell cellular homeostasis,GO:0051289~protein homotetramerization,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005829~cytosol,GO:0015629~actin cytoskeleton,GO:0016020~membrane,GO:0031093~platelet alpha granule lumen,GO:0031430~M band,GO:0031674~I band,GO:0034774~secretory granule lumen,GO:0061827~sperm head,GO:0070062~extracellular exosome,GO:1904724~tertiary granule lumen,GO:1904813~ficolin-1-rich granule lumen,	GO:0003723~RNA binding,GO:0003779~actin binding,GO:0004332~fructose-bisphosphate aldolase activity,GO:0005515~protein binding,GO:0008092~cytoskeletal protein binding,GO:0015631~tubulin binding,GO:0042802~identical protein binding,GO:0045296~cadherin binding,GO:0070061~fructose binding,	IPR000741:FBA_I,IPR013785:Aldolase_TIM,IPR029768:Aldolase_I_AS,	hsa00010:Glycolysis / Gluconeogenesis,hsa00030:Pentose phosphate pathway,hsa00051:Fructose and mannose metabolism,hsa01100:Metabolic pathways,hsa01200:Carbon metabolism,hsa01230:Biosynthesis of amino acids,hsa04066:HIF-1 signaling pathway,	611881~Glycogen storage disease XII,			KW-0324~Glycolysis,	KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0322~Glycogen storage disease,KW-0360~Hereditary hemolytic anemia,		KW-0704~Schiff base,	KW-0456~Lyase,	KW-0007~Acetylation,KW-0379~Hydroxylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	ACT_SITE:Proton acceptor,ACT_SITE:Schiff-base intermediate with dihydroxyacetone-P,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,SITE:Necessary for preference for fructose 1,6-bisphosphate over fructose 1-phosphate,
ALKBH7	alkB homolog 7(ALKBH7)	Homo sapiens			GO:0006631~fatty acid metabolic process,GO:0006974~cellular response to DNA damage stimulus,GO:0010883~regulation of lipid storage,GO:1902445~regulation of mitochondrial membrane permeability involved in programmed necrotic cell death,	GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,	GO:0005515~protein binding,GO:0046872~metal ion binding,GO:0051213~dioxygenase activity,	IPR027450:AlkB-like,IPR032870:ALKBH7-like,IPR037151:AlkB-like_sf,					KW-1210~Necrosis,	KW-0496~Mitochondrion,		KW-0809~Transit peptide,	KW-0408~Iron,KW-0479~Metal-binding,	KW-0223~Dioxygenase,KW-0560~Oxidoreductase,		DOMAIN:Alpha-ketoglutarate-dependent dioxygenase AlkB-like,MUTAGEN:L->Q: Does not affect ability to trigger programmed necrosis.,TRANSIT:Mitochondrion,
ATRAID	all-trans retinoic acid induced differentiation factor(ATRAID)	Homo sapiens			GO:0006855~drug transmembrane transport,GO:0010468~regulation of gene expression,GO:0030154~cell differentiation,GO:0030501~positive regulation of bone mineralization,GO:0033689~negative regulation of osteoblast proliferation,GO:0042177~negative regulation of protein catabolic process,GO:0045669~positive regulation of osteoblast differentiation,	GO:0005635~nuclear envelope,GO:0005765~lysosomal membrane,GO:0005886~plasma membrane,GO:0043231~intracellular membrane-bounded organelle,GO:0048471~perinuclear region of cytoplasm,	GO:0005515~protein binding,GO:0042910~xenobiotic transporter activity,	IPR000742:EGF-like_dom,IPR032675:LRR_dom_sf,IPR042350:ATRAID,					KW-0221~Differentiation,	KW-0458~Lysosome,KW-0472~Membrane,KW-0539~Nucleus,KW-1003~Cell membrane,		KW-0245~EGF-like domain,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:EGF-like,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
MGAT1	alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase(MGAT1)	Homo sapiens			GO:0001701~in utero embryonic development,GO:0006049~UDP-N-acetylglucosamine catabolic process,GO:0006486~protein glycosylation,GO:0006487~protein N-linked glycosylation,GO:0018279~protein N-linked glycosylation via asparagine,GO:0019082~viral protein processing,	GO:0000139~Golgi membrane,GO:0005794~Golgi apparatus,GO:0016020~membrane,GO:0033116~endoplasmic reticulum-Golgi intermediate compartment membrane,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,GO:1903561~extracellular vesicle,	GO:0003827~alpha-1,3-mannosylglycoprotein 2-beta-N-acetylglucosaminyltransferase activity,GO:0005515~protein binding,GO:0008375~acetylglucosaminyltransferase activity,GO:0030145~manganese ion binding,	IPR004139:Glyco_trans_13,IPR029044:Nucleotide-diphossugar_trans,	hsa00510:N-Glycan biosynthesis,hsa00513:Various types of N-glycan biosynthesis,hsa01100:Metabolic pathways,					KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0963~Cytoplasm,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0464~Manganese,KW-0479~Metal-binding,	KW-0328~Glycosyltransferase,KW-0808~Transferase,	KW-1015~Disulfide bond,	ACT_SITE:Proton acceptor,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
MGAT4A	alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase A(MGAT4A)	Homo sapiens			GO:0006486~protein glycosylation,GO:0006487~protein N-linked glycosylation,GO:0006491~N-glycan processing,GO:0019082~viral protein processing,GO:0046487~glyoxylate metabolic process,	GO:0000139~Golgi membrane,GO:0005777~peroxisome,GO:0005783~endoplasmic reticulum,GO:0005788~endoplasmic reticulum lumen,GO:0005793~endoplasmic reticulum-Golgi intermediate compartment,GO:0005795~Golgi stack,GO:0070062~extracellular exosome,	GO:0008375~acetylglucosaminyltransferase activity,GO:0008453~alanine-glyoxylate transaminase activity,GO:0008454~alpha-1,3-mannosylglycoprotein 4-beta-N-acetylglucosaminyltransferase activity,GO:0016757~transferase activity, transferring glycosyl groups,GO:0042803~protein homodimerization activity,GO:0046872~metal ion binding,	IPR006759:Glyco_transf_54,	hsa00510:N-Glycan biosynthesis,hsa00513:Various types of N-glycan biosynthesis,hsa01100:Metabolic pathways,					KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0964~Secreted,		KW-0175~Coiled coil,KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0479~Metal-binding,	KW-0328~Glycosyltransferase,KW-0808~Transferase,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
MGAT2	alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase(MGAT2)	Homo sapiens			GO:0006486~protein glycosylation,GO:0006487~protein N-linked glycosylation,GO:0009312~oligosaccharide biosynthetic process,GO:0018279~protein N-linked glycosylation via asparagine,GO:0019082~viral protein processing,	GO:0000139~Golgi membrane,GO:0005794~Golgi apparatus,GO:0005795~Golgi stack,GO:0016020~membrane,	GO:0008455~alpha-1,6-mannosylglycoprotein 2-beta-N-acetylglucosaminyltransferase activity,GO:0030145~manganese ion binding,GO:0042803~protein homodimerization activity,GO:0046872~metal ion binding,	IPR007754:GlcNAc_II,IPR029044:Nucleotide-diphossugar_trans,	hsa00510:N-Glycan biosynthesis,hsa00513:Various types of N-glycan biosynthesis,hsa01100:Metabolic pathways,	212066~Congenital disorder of glycosylation, type IIa,				KW-0333~Golgi apparatus,KW-0472~Membrane,	KW-0225~Disease variant,KW-0900~Congenital disorder of glycosylation,	KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0464~Manganese,KW-0479~Metal-binding,	KW-0328~Glycosyltransferase,KW-0808~Transferase,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,MUTAGEN:D->A: Loss of catalytic activity.,MUTAGEN:D->A: Nearly abolishes catalytic activity.,MUTAGEN:E->A: Loss of catalytic activity.,MUTAGEN:N->A: Strongly decreased catalytic activity and affinity for UDP-GlcNAc.,MUTAGEN:R->A: Strongly decreased catalytic activity and affinity for UDP-GlcNAc.,MUTAGEN:W->A: Loss of catalytic activity.,MUTAGEN:Y->A: Nearly abolishes catalytic activity and strongly decreases affinity for UDP-GlcNAc.,MUTAGEN:Y->A: Strongly decreased catalytic activity and affinity for UDP-GlcNAc.,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
AIMP1	aminoacyl tRNA synthetase complex interacting multifunctional protein 1(AIMP1)	Homo sapiens			GO:0001525~angiogenesis,GO:0001937~negative regulation of endothelial cell proliferation,GO:0006412~translation,GO:0006915~apoptotic process,GO:0006954~inflammatory response,GO:0007165~signal transduction,GO:0007267~cell-cell signaling,GO:0050900~leukocyte migration,GO:0051607~defense response to virus,GO:0070094~positive regulation of glucagon secretion,	GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005783~endoplasmic reticulum,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0009986~cell surface,GO:0016020~membrane,GO:0017101~aminoacyl-tRNA synthetase multienzyme complex,	GO:0000049~tRNA binding,GO:0005125~cytokine activity,GO:0005515~protein binding,GO:0042803~protein homodimerization activity,GO:0051020~GTPase binding,	IPR002547:tRNA-bd_dom,IPR012340:NA-bd_OB-fold,		260600~Leukodystrophy, hypomyelinating, 3,			KW-0037~Angiogenesis,KW-0053~Apoptosis,KW-0395~Inflammatory response,KW-0648~Protein biosynthesis,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0964~Secreted,	KW-1026~Leukodystrophy,	KW-0175~Coiled coil,		KW-0202~Cytokine,KW-0694~RNA-binding,KW-0820~tRNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1),DOMAIN:TRNA-binding,DOMAIN:tRNA-binding,REGION:Disordered,REGION:Interaction with HSP90B1,REGION:Required for endothelial cell death,REGION:Required for endothelial cell migration,REGION:Required for fibroblast proliferation,
AASDHPPT	aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferase(AASDHPPT)	Homo sapiens			GO:0009258~10-formyltetrahydrofolate catabolic process,GO:0015939~pantothenate metabolic process,GO:0019878~lysine biosynthetic process via aminoadipic acid,GO:0051604~protein maturation,	GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0000287~magnesium ion binding,GO:0005515~protein binding,GO:0008897~holo-[acyl-carrier-protein] synthase activity,	IPR008278:4-PPantetheinyl_Trfase_dom,IPR037143:4-PPantetheinyl_Trfase_dom_sf,	hsa00770:Pantothenate and CoA biosynthesis,hsa01100:Metabolic pathways,					KW-0963~Cytoplasm,			KW-0460~Magnesium,KW-0479~Metal-binding,	KW-0808~Transferase,	KW-0597~Phosphoprotein,	DOMAIN:4'-phosphopantetheinyl transferase,MUTAGEN:D->A: Reduces affinity for magnesium by 10-fold, and holo-[acyl-carrier-protein] synthase activity by 30000-fold.,MUTAGEN:E->A: Reduces affinity for magnesium by 40-fold, and holo-[acyl-carrier-protein] synthase activity by 32000-fold.,MUTAGEN:E->Q: Reduces affinity for magnesium by 20-fold, and holo-[acyl-carrier-protein] synthase activity by 6500-fold.,MUTAGEN:H->A: Reduces affinity for magnesium by 75-fold, and holo-[acyl-carrier-protein] synthase activity by 150-fold.,MUTAGEN:K->A: Reduces holo-[acyl-carrier-protein] synthase activity by 2000-fold, with only minor change in the affinity for magnesium and coenzyme A.,MUTAGEN:Q->E: Reduces affinity for magnesium by 200-fold and abolishes holo-[acyl-carrier-protein] synthase activity; when associated with Q-181.,MUTAGEN:R->A: Reduces affinity for magnesium and coenzyme A, and reduces holo-[acyl-carrier-protein] synthase activity by 7-fold.,MUTAGEN:R->A: Reduces affinity for magnesium by 7-fold, and holo-[acyl-carrier-protein] synthase activity by 2-fold.,
APLP2	amyloid beta precursor like protein 2(APLP2)	Homo sapiens			GO:0007186~G-protein coupled receptor signaling pathway,GO:0007409~axonogenesis,GO:0007417~central nervous system development,	GO:0005634~nucleus,GO:0005788~endoplasmic reticulum lumen,GO:0005886~plasma membrane,GO:0012505~endomembrane system,GO:0016020~membrane,GO:0031092~platelet alpha granule membrane,GO:0070062~extracellular exosome,	GO:0003677~DNA binding,GO:0004867~serine-type endopeptidase inhibitor activity,GO:0005515~protein binding,GO:0008201~heparin binding,GO:0042802~identical protein binding,GO:0046914~transition metal ion binding,	IPR002223:Kunitz_BPTI,IPR008154:Amyloid_glyco_extra,IPR008155:Amyloid_glyco,IPR011178:Amyloid_glyco_Cu-bd,IPR011993:PH-like_dom_sf,IPR015849:Amyloid_glyco_heparin-bd,IPR019543:APP_amyloid_C,IPR019744:APP_CUBD_CS,IPR019745:Amyloid_glyco_intracell_CS,IPR020901:Prtase_inh_Kunz-CS,IPR024329:Amyloid_glyco_E2_domain,IPR036176:E2_sf,IPR036454:Amyloid_glyco_heparin-bd_sf,IPR036669:Amyloid_Cu-bd_sf,IPR036880:Kunitz_BPTI_sf,				SM00006:A4_EXTRA,SM00131:KU,		KW-0472~Membrane,KW-0539~Nucleus,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0186~Copper,KW-0479~Metal-binding,	KW-0238~DNA-binding,KW-0646~Protease inhibitor,KW-0722~Serine protease inhibitor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0654~Proteoglycan,KW-1015~Disulfide bond,	CARBOHYD:O-linked (Xyl...) (chondroitin sulfate) serine,COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,DOMAIN:BPTI/Kunitz inhibitor,DOMAIN:E1,DOMAIN:E2,MOTIF:NPXY motif,REGION:CuBD subdomain,REGION:Disordered,REGION:GFLD subdomain,REGION:Interaction with DAB2,SITE:Reactive bond,SITE:Required for Cu(2+) reduction,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
ANAPC11	anaphase promoting complex subunit 11(ANAPC11)	Homo sapiens			GO:0000278~mitotic cell cycle,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0007346~regulation of mitotic cell cycle,GO:0016567~protein ubiquitination,GO:0031145~anaphase-promoting complex-dependent catabolic process,GO:0045842~positive regulation of mitotic metaphase/anaphase transition,GO:0051301~cell division,GO:0051445~regulation of meiotic cell cycle,GO:0070979~protein K11-linked ubiquitination,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005680~anaphase-promoting complex,GO:0005730~nucleolus,GO:0005829~cytosol,	GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0034450~ubiquitin-ubiquitin ligase activity,GO:0061630~ubiquitin protein ligase activity,GO:0097602~cullin family protein binding,	IPR001841:Znf_RING,IPR013083:Znf_RING/FYVE/PHD,IPR024991:RING-H2_APC11,	hsa04110:Cell cycle,hsa04114:Oocyte meiosis,hsa04120:Ubiquitin mediated proteolysis,hsa04914:Progesterone-mediated oocyte maturation,hsa05166:Human T-cell leukemia virus 1 infection,				KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0832~Ubl conjugation,	DOMAIN:Anaphase-promoting complex subunit 11 RING-H2 finger,MUTAGEN:C->S: Greatly reduces autoubiquitination activity; in isoform 1.,MUTAGEN:C->S: Slightly reduces autoubiquitination activity; in isoform 1.,MUTAGEN:H->S: Greatly reduces autoubiquitination activity; in isoform 1.,MUTAGEN:H->S: Slightly reduces autoubiquitination activity; in isoform 1.,ZN_FING:RING-type,
ANAPC16	anaphase promoting complex subunit 16(ANAPC16)	Homo sapiens			GO:0007049~cell cycle,GO:0007346~regulation of mitotic cell cycle,GO:0016567~protein ubiquitination,GO:0031145~anaphase-promoting complex-dependent catabolic process,GO:0051301~cell division,GO:0051445~regulation of meiotic cell cycle,	GO:0000776~kinetochore,GO:0005654~nucleoplasm,GO:0005680~anaphase-promoting complex,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0005515~protein binding,	IPR029641:APC16,	hsa04110:Cell cycle,hsa04114:Oocyte meiosis,hsa04120:Ubiquitin mediated proteolysis,hsa04914:Progesterone-mediated oocyte maturation,hsa05166:Human T-cell leukemia virus 1 infection,				KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,KW-0833~Ubl conjugation pathway,	KW-0137~Centromere,KW-0158~Chromosome,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0995~Kinetochore,					KW-0007~Acetylation,	COMPBIAS:Polar residues,REGION:Disordered,
ANAPC5	anaphase promoting complex subunit 5(ANAPC5)	Homo sapiens			GO:0007049~cell cycle,GO:0007346~regulation of mitotic cell cycle,GO:0016567~protein ubiquitination,GO:0031145~anaphase-promoting complex-dependent catabolic process,GO:0045842~positive regulation of mitotic metaphase/anaphase transition,GO:0051301~cell division,GO:0051445~regulation of meiotic cell cycle,GO:0070979~protein K11-linked ubiquitination,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005680~anaphase-promoting complex,GO:0005819~spindle,GO:0005829~cytosol,	GO:0019903~protein phosphatase binding,	IPR011990:TPR-like_helical_dom_sf,IPR019734:TPR_repeat,IPR026000:Apc5_dom,IPR037679:Apc5,IPR048968:Apc5_N,	hsa04110:Cell cycle,hsa04114:Oocyte meiosis,hsa04120:Ubiquitin mediated proteolysis,hsa04657:IL-17 signaling pathway,hsa04914:Progesterone-mediated oocyte maturation,hsa05166:Human T-cell leukemia virus 1 infection,			SM00028:TPR,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,KW-0833~Ubl conjugation pathway,	KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0802~TPR repeat,			KW-0597~Phosphoprotein,	DOMAIN:Anaphase-promoting complex subunit 5,DOMAIN:Anaphase-promoting complex subunit 5 N-terminal,REPEAT:TPR 1,REPEAT:TPR 10,REPEAT:TPR 11,REPEAT:TPR 12,REPEAT:TPR 13,REPEAT:TPR 2,REPEAT:TPR 3,REPEAT:TPR 4,REPEAT:TPR 5,REPEAT:TPR 6,REPEAT:TPR 7,REPEAT:TPR 8,REPEAT:TPR 9,
AGGF1	angiogenic factor with G-patch and FHA domains 1(AGGF1)	Homo sapiens			GO:0001525~angiogenesis,GO:0001570~vasculogenesis,GO:0001938~positive regulation of endothelial cell proliferation,GO:0007155~cell adhesion,GO:0045766~positive regulation of angiogenesis,	GO:0005576~extracellular region,GO:0005737~cytoplasm,GO:0048471~perinuclear region of cytoplasm,	GO:0003676~nucleic acid binding,GO:0005515~protein binding,	IPR000253:FHA_dom,IPR000467:G_patch_dom,IPR008984:SMAD_FHA_dom_sf,IPR035624:AGGF1_OCRE,IPR041591:OCRE,				SM00240:FHA,SM00443:G_patch,	KW-0037~Angiogenesis,KW-0221~Differentiation,	KW-0963~Cytoplasm,KW-0964~Secreted,		KW-0175~Coiled coil,		KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:FHA,DOMAIN:G-patch,REGION:Disordered,
ANKRD10	ankyrin repeat domain 10(ANKRD10)	Homo sapiens				GO:0005654~nucleoplasm,	GO:0005515~protein binding,	IPR002110:Ankyrin_rpt,IPR036770:Ankyrin_rpt-contain_sf,				SM00248:ANK,				KW-0040~ANK repeat,KW-0677~Repeat,				COMPBIAS:Polar residues,REGION:Disordered,REPEAT:ANK,REPEAT:ANK 1,REPEAT:ANK 2,REPEAT:ANK 3,REPEAT:ANK 4,
ANKRD12	ankyrin repeat domain 12(ANKRD12)	Homo sapiens				GO:0005654~nucleoplasm,GO:0005829~cytosol,		IPR002110:Ankyrin_rpt,IPR036770:Ankyrin_rpt-contain_sf,				SM00248:ANK,		KW-0539~Nucleus,	KW-0225~Disease variant,	KW-0040~ANK repeat,KW-0677~Repeat,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,REGION:Disordered,REPEAT:ANK,REPEAT:ANK 1,REPEAT:ANK 2,REPEAT:ANK 3,
ANKRD17	ankyrin repeat domain 17(ANKRD17)	Homo sapiens			GO:0001955~blood vessel maturation,GO:0006275~regulation of DNA replication,GO:0042742~defense response to bacterium,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0045087~innate immune response,GO:0045787~positive regulation of cell cycle,GO:0051151~negative regulation of smooth muscle cell differentiation,GO:1900087~positive regulation of G1/S transition of mitotic cell cycle,GO:1900245~positive regulation of MDA-5 signaling pathway,GO:1900246~positive regulation of RIG-I signaling pathway,	GO:0000785~chromatin,GO:0001673~male germ cell nucleus,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0016020~membrane,GO:0031965~nuclear membrane,	GO:0003682~chromatin binding,GO:0003723~RNA binding,GO:0005515~protein binding,	IPR002110:Ankyrin_rpt,IPR004087:KH_dom,IPR004088:KH_dom_type_1,IPR036612:KH_dom_type_1_sf,IPR036770:Ankyrin_rpt-contain_sf,IPR047375:KH-I_ANKRD17,		619504~Chopra-Amiel-Gordon syndrome,		SM00248:ANK,SM00322:KH,	KW-0391~Immunity,KW-0399~Innate immunity,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0991~Intellectual disability,	KW-0040~ANK repeat,KW-0175~Coiled coil,KW-0677~Repeat,		KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:K Homology,DOMAIN:KH,REGION:Disordered,REPEAT:ANK,REPEAT:ANK 1,REPEAT:ANK 10,REPEAT:ANK 11,REPEAT:ANK 12,REPEAT:ANK 13,REPEAT:ANK 14,REPEAT:ANK 15,REPEAT:ANK 16,REPEAT:ANK 17,REPEAT:ANK 18,REPEAT:ANK 19,REPEAT:ANK 2,REPEAT:ANK 20,REPEAT:ANK 21,REPEAT:ANK 22,REPEAT:ANK 23,REPEAT:ANK 24,REPEAT:ANK 25,REPEAT:ANK 3,REPEAT:ANK 4,REPEAT:ANK 5,REPEAT:ANK 6,REPEAT:ANK 7,REPEAT:ANK 8,REPEAT:ANK 9,
ANKRD44	ankyrin repeat domain 44(ANKRD44)	Homo sapiens					GO:0005515~protein binding,	IPR002110:Ankyrin_rpt,IPR036770:Ankyrin_rpt-contain_sf,				SM00248:ANK,				KW-0040~ANK repeat,KW-0677~Repeat,				REPEAT:ANK,REPEAT:ANK 1,REPEAT:ANK 10,REPEAT:ANK 11,REPEAT:ANK 12,REPEAT:ANK 13,REPEAT:ANK 14,REPEAT:ANK 15,REPEAT:ANK 16,REPEAT:ANK 17,REPEAT:ANK 18,REPEAT:ANK 19,REPEAT:ANK 2,REPEAT:ANK 20,REPEAT:ANK 21,REPEAT:ANK 22,REPEAT:ANK 23,REPEAT:ANK 24,REPEAT:ANK 25,REPEAT:ANK 26,REPEAT:ANK 27,REPEAT:ANK 28,REPEAT:ANK 3,REPEAT:ANK 4,REPEAT:ANK 5,REPEAT:ANK 6,REPEAT:ANK 7,REPEAT:ANK 8,REPEAT:ANK 9,
ANKRD11	ankyrin repeat domain containing 11(ANKRD11)	Homo sapiens			GO:0042475~odontogenesis of dentin-containing tooth,GO:0048705~skeletal system morphogenesis,GO:0060325~face morphogenesis,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,	GO:0042802~identical protein binding,	IPR002110:Ankyrin_rpt,IPR036770:Ankyrin_rpt-contain_sf,IPR042636:ANKRD11,		148050~KBG syndrome,		SM00248:ANK,		KW-0539~Nucleus,	KW-0225~Disease variant,KW-0242~Dwarfism,KW-0991~Intellectual disability,	KW-0040~ANK repeat,KW-0677~Repeat,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,REGION:Disordered,REGION:Important for protein degradation,REPEAT:ANK,REPEAT:ANK 1,REPEAT:ANK 2,REPEAT:ANK 3,REPEAT:ANK 4,
ANXA1	annexin A1(ANXA1)	Homo sapiens		h_gcrpathway:Corticosteroids and cardioprotection,	GO:0001780~neutrophil homeostasis,GO:0002250~adaptive immune response,GO:0002548~monocyte chemotaxis,GO:0002685~regulation of leukocyte migration,GO:0006909~phagocytosis,GO:0006954~inflammatory response,GO:0007165~signal transduction,GO:0007166~cell surface receptor signaling pathway,GO:0007187~G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger,GO:0008360~regulation of cell shape,GO:0010165~response to X-ray,GO:0014839~myoblast migration involved in skeletal muscle regeneration,GO:0018149~peptide cross-linking,GO:0030036~actin cytoskeleton organization,GO:0030073~insulin secretion,GO:0030216~keratinocyte differentiation,GO:0030850~prostate gland development,GO:0031018~endocrine pancreas development,GO:0031340~positive regulation of vesicle fusion,GO:0031394~positive regulation of prostaglandin biosynthetic process,GO:0032355~response to estradiol,GO:0032508~DNA duplex unwinding,GO:0032652~regulation of interleukin-1 production,GO:0032717~negative regulation of interleukin-8 production,GO:0032743~positive regulation of interleukin-2 production,GO:0033031~positive regulation of neutrophil apoptotic process,GO:0035924~cellular response to vascular endothelial growth factor stimulus,GO:0042063~gliogenesis,GO:0042102~positive regulation of T cell proliferation,GO:0042119~neutrophil activation,GO:0042127~regulation of cell proliferation,GO:0043066~negative regulation of apoptotic process,GO:0043434~response to peptide hormone,GO:0045087~innate immune response,GO:0045627~positive regulation of T-helper 1 cell differentiation,GO:0045629~negative regulation of T-helper 2 cell differentiation,GO:0045920~negative regulation of exocytosis,GO:0046632~alpha-beta T cell differentiation,GO:0046883~regulation of hormone secretion,GO:0050482~arachidonic acid secretion,GO:0050727~regulation of inflammatory response,GO:0051179~localization,GO:0070301~cellular response to hydrogen peroxide,GO:0070365~hepatocyte differentiation,GO:0070459~prolactin secretion,GO:0070555~response to interleukin-1,GO:0071385~cellular response to glucocorticoid stimulus,GO:0071621~granulocyte chemotaxis,GO:0090050~positive regulation of cell migration involved in sprouting angiogenesis,GO:0090303~positive regulation of wound healing,GO:0097350~neutrophil clearance,GO:0098609~cell-cell adhesion,GO:1900087~positive regulation of G1/S transition of mitotic cell cycle,	GO:0001533~cornified envelope,GO:0001891~phagocytic cup,GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005768~endosome,GO:0005769~early endosome,GO:0005829~cytosol,GO:0005884~actin filament,GO:0005886~plasma membrane,GO:0005912~adherens junction,GO:0005925~focal adhesion,GO:0005929~cilium,GO:0009986~cell surface,GO:0010008~endosome membrane,GO:0016323~basolateral plasma membrane,GO:0016324~apical plasma membrane,GO:0016328~lateral plasma membrane,GO:0031514~motile cilium,GO:0031901~early endosome membrane,GO:0031982~vesicle,GO:0042383~sarcolemma,GO:0070062~extracellular exosome,	GO:0001786~phosphatidylserine binding,GO:0005102~receptor binding,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0005543~phospholipid binding,GO:0005544~calcium-dependent phospholipid binding,GO:0008289~lipid binding,GO:0019834~phospholipase A2 inhibitor activity,GO:0048306~calcium-dependent protein binding,GO:0098641~cadherin binding involved in cell-cell adhesion,	IPR001464:Annexin,IPR002388:ANX1,IPR018252:Annexin_repeat_CS,IPR018502:Annexin_repeat,IPR037104:Annexin_sf,				SM00335:ANX,	KW-0391~Immunity,KW-0395~Inflammatory response,KW-0399~Innate immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0964~Secreted,KW-0966~Cell projection,KW-0967~Endosome,KW-0968~Cytoplasmic vesicle,KW-0969~Cilium,KW-1003~Cell membrane,		KW-0041~Annexin,KW-0677~Repeat,	KW-0106~Calcium,KW-0111~Calcium/phospholipid-binding,KW-0479~Metal-binding,	KW-0593~Phospholipase A2 inhibitor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,CROSSLNK:Isoglutamyl lysine isopeptide (Gln-Lys) (interchain with K-?),MUTAGEN:S->A: Abolishes secretion and modulation of exocytosis.,MUTAGEN:S->A: Abolishes secretion and nearly abolishes modulation of exocytosis.,MUTAGEN:S->A: No effect on secretion and modulation of exocytosis.,PEPTIDE:Annexin Ac2-26,REPEAT:Annexin 1,REPEAT:Annexin 2,REPEAT:Annexin 3,REPEAT:Annexin 4,SITE:Cleavage; by CTSG,
ANXA11	annexin A11(ANXA11)	Homo sapiens			GO:0006909~phagocytosis,GO:0032506~cytokinetic process,GO:0051592~response to calcium ion,	GO:0005635~nuclear envelope,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005819~spindle,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0030496~midbody,GO:0042470~melanosome,GO:0042581~specific granule,GO:0042582~azurophil granule,GO:0045335~phagocytic vesicle,GO:0070062~extracellular exosome,	GO:0001786~phosphatidylserine binding,GO:0003723~RNA binding,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0005544~calcium-dependent phospholipid binding,GO:0008429~phosphatidylethanolamine binding,GO:0023026~MHC class II protein complex binding,GO:0044548~S100 protein binding,GO:0048306~calcium-dependent protein binding,	IPR001464:Annexin,IPR008157:ANX11,IPR018252:Annexin_repeat_CS,IPR018502:Annexin_repeat,IPR037104:Annexin_sf,	hsa05014:Amyotrophic lateral sclerosis,	617839~Amyotrophic lateral sclerosis 23,619733~Inclusion body myopathy and brain white matter abnormalities,		SM00335:ANX,	KW-0131~Cell cycle,KW-0132~Cell division,	KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0036~Amyotrophic lateral sclerosis,KW-0225~Disease variant,KW-0523~Neurodegeneration,	KW-0041~Annexin,KW-0677~Repeat,	KW-0106~Calcium,KW-0111~Calcium/phospholipid-binding,		KW-0007~Acetylation,	COMPBIAS:Pro residues,REGION:Disordered,REPEAT:Annexin 1,REPEAT:Annexin 2,REPEAT:Annexin 3,REPEAT:Annexin 4,
ANXA5	annexin A5(ANXA5)	Homo sapiens			GO:0007165~signal transduction,GO:0007596~blood coagulation,GO:0010033~response to organic substance,GO:0043066~negative regulation of apoptotic process,GO:0050819~negative regulation of coagulation,	GO:0005576~extracellular region,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005925~focal adhesion,GO:0009897~external side of plasma membrane,GO:0016020~membrane,GO:0042383~sarcolemma,GO:0042589~zymogen granule membrane,GO:0070062~extracellular exosome,GO:0072563~endothelial microparticle,	GO:0001786~phosphatidylserine binding,GO:0004859~phospholipase inhibitor activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0005543~phospholipid binding,GO:0005544~calcium-dependent phospholipid binding,	IPR001464:Annexin,IPR002391:ANX4,IPR002392:ANX5,IPR018252:Annexin_repeat_CS,IPR018502:Annexin_repeat,IPR037104:Annexin_sf,		614391~Pregnancy loss, recurrent, susceptibility to, 3,		SM00335:ANX,	KW-0094~Blood coagulation,KW-0356~Hemostasis,			KW-0041~Annexin,KW-0677~Repeat,	KW-0106~Calcium,KW-0111~Calcium/phospholipid-binding,		KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0702~S-nitrosylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,MOTIF:[IL]-x-C-x-x-[DE] motif,REPEAT:Annexin 1,REPEAT:Annexin 2,REPEAT:Annexin 3,REPEAT:Annexin 4,
ANXA7	annexin A7(ANXA7)	Homo sapiens			GO:0006914~autophagy,GO:0010629~negative regulation of gene expression,GO:0030855~epithelial cell differentiation,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0042584~chromaffin granule membrane,GO:0070062~extracellular exosome,	GO:0001786~phosphatidylserine binding,GO:0003723~RNA binding,GO:0005178~integrin binding,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0005544~calcium-dependent phospholipid binding,GO:0048306~calcium-dependent protein binding,	IPR001464:Annexin,IPR018252:Annexin_repeat_CS,IPR018502:Annexin_repeat,IPR037104:Annexin_sf,	hsa05014:Amyotrophic lateral sclerosis,			SM00335:ANX,				KW-0041~Annexin,KW-0677~Repeat,	KW-0106~Calcium,KW-0111~Calcium/phospholipid-binding,		KW-0007~Acetylation,	COMPBIAS:Pro residues,REGION:3 X 5 AA tandem repeats of G-Y-P-P-X,REGION:Disordered,REGION:Repeat-rich region,REPEAT:Annexin 1,REPEAT:Annexin 2,REPEAT:Annexin 3,REPEAT:Annexin 4,
ASF1A	anti-silencing function 1A histone chaperone(ASF1A)	Homo sapiens			GO:0001649~osteoblast differentiation,GO:0006281~DNA repair,GO:0006334~nucleosome assembly,GO:0006335~DNA replication-dependent nucleosome assembly,GO:0031297~replication fork processing,GO:0042692~muscle cell differentiation,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0032991~macromolecular complex,GO:0035861~site of double-strand break,	GO:0003682~chromatin binding,GO:0005515~protein binding,GO:0042393~histone binding,	IPR006818:ASF1-like,IPR036747:ASF1-like_sf,					KW-0227~DNA damage,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0158~Chromosome,KW-0539~Nucleus,				KW-0143~Chaperone,KW-0156~Chromatin regulator,	KW-0597~Phosphoprotein,	MOTIF:Required for interaction with HIRA,MUTAGEN:D->A: Abrogates interaction with CHAF1B and HIRA.,MUTAGEN:D->A: Loss of interaction with TLK2. Reduced phosphorylation.,MUTAGEN:D->R: Reduces interaction with histone H3.,MUTAGEN:E->A: Loss of interaction with TLK2.,MUTAGEN:ED->AA: Abrogates interaction with HIRA and induction of senescence-associated heterochromatin foci.,MUTAGEN:R->E: Reduces interaction with histone H3.,MUTAGEN:S->A: Abolished phosphorylation in response to DNA damage.,MUTAGEN:S->A: Does not affect phosphorylation in response to DNA damage.,MUTAGEN:S->D: Mimics phosphorylation; promoting recruitment to chromatin in response to DNA damage.,MUTAGEN:V->R: Abrogates interaction with histone H3 and histone H4. Loss of interaction with TLK2. Reduced phosphorylation.,MUTAGEN:VGP->AAA: Abrogates interaction with HIRA and induction of senescence-associated heterochromatin foci.,REGION:Interaction with histone H3, CHAF1B, and HIRA,REGION:Required for interaction with HIRA,
ATOX1	antioxidant 1 copper chaperone(ATOX1)	Homo sapiens			GO:0006825~copper ion transport,GO:0006878~cellular copper ion homeostasis,GO:0006979~response to oxidative stress,	GO:0005829~cytosol,	GO:0005507~copper ion binding,GO:0005515~protein binding,GO:0016530~metallochaperone activity,GO:0016531~copper chaperone activity,GO:0031956~medium-chain fatty acid-CoA ligase activity,GO:0032767~copper-dependent protein binding,GO:0046872~metal ion binding,GO:0047760~butyrate-CoA ligase activity,GO:1903136~cuprous ion binding,	IPR006121:HMA_dom,IPR017969:Heavy-metal-associated_CS,IPR036163:HMA_dom_sf,	hsa04978:Mineral absorption,				KW-0187~Copper transport,KW-0406~Ion transport,KW-0813~Transport,				KW-0186~Copper,KW-0479~Metal-binding,	KW-0143~Chaperone,KW-0436~Ligase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:HMA,MUTAGEN:C->A: Impairs Cu(+)-bridged heterodimer formation with ATP7A.,MUTAGEN:R->E: Has no overall effect on Cu(+)-bridged heterodimer formation with ATP7A.,MUTAGEN:T->A: Has no overall effect on Cu(+)-bridged heterodimer formation with ATP7A.,MUTAGEN:V->A: Has no overall effect on Cu(+)-bridged heterodimer formation with ATP7A.,
AZIN1	antizyme inhibitor 1(AZIN1)	Homo sapiens			GO:0006596~polyamine biosynthetic process,GO:0033387~putrescine biosynthetic process from ornithine,GO:0042177~negative regulation of protein catabolic process,GO:1902269~positive regulation of polyamine transmembrane transport,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0003824~catalytic activity,GO:0004586~ornithine decarboxylase activity,GO:0005515~protein binding,GO:0042978~ornithine decarboxylase activator activity,	IPR000183:Orn/DAP/Arg_de-COase,IPR002433:Orn_de-COase,IPR009006:Ala_racemase/Decarboxylase_C,IPR022643:De-COase2_C,IPR022644:De-COase2_N,IPR022657:De-COase2_CS,IPR029066:PLP-binding_barrel,IPR031178:Azin1,					KW-0620~Polyamine biosynthesis,	KW-0539~Nucleus,			KW-0663~Pyridoxal phosphate,		KW-0832~Ubl conjugation,	ACT_SITE:Proton donor,DOMAIN:Orn/DAP/Arg decarboxylase 2 C-terminal,DOMAIN:Orn/DAP/Arg decarboxylase 2 N-terminal,SITE:Not modified,
APOBEC3C	apolipoprotein B mRNA editing enzyme catalytic subunit 3C(APOBEC3C)	Homo sapiens			GO:0009972~cytidine deamination,GO:0010526~negative regulation of transposition, RNA-mediated,GO:0016554~cytidine to uridine editing,GO:0044355~clearance of foreign intracellular DNA,GO:0045071~negative regulation of viral genome replication,GO:0045087~innate immune response,GO:0045869~negative regulation of single stranded viral RNA replication via double stranded DNA intermediate,GO:0051607~defense response to virus,GO:0070383~DNA cytosine deamination,GO:0080111~DNA demethylation,	GO:0000932~P-body,GO:0005634~nucleus,GO:0005737~cytoplasm,	GO:0003723~RNA binding,GO:0004126~cytidine deaminase activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0016787~hydrolase activity,GO:0047844~deoxycytidine deaminase activity,	IPR002125:CMP_dCMP_dom,IPR016192:APOBEC/CMP_deaminase_Zn-bd,IPR016193:Cytidine_deaminase-like,	hsa03250:Viral life cycle - HIV-1,hsa05170:Human immunodeficiency virus 1 infection,				KW-0051~Antiviral defense,KW-0391~Immunity,KW-0399~Innate immunity,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0479~Metal-binding,KW-0862~Zinc,	KW-0378~Hydrolase,	KW-0449~Lipoprotein,	ACT_SITE:Proton donor,DOMAIN:CMP/dCMP-type deaminase,MUTAGEN:A->K: Resistant to HIV-1 Vif.,MUTAGEN:C->K: Resistant to HIV-1 Vif and reduces Vif binding.,MUTAGEN:E->K: Remains sensitive to HIV-1 Vif but abolishes Vif binding.,MUTAGEN:E->K: Resistant to HIV-1 Vif and reduces Vif binding.,MUTAGEN:F->D: Resistant to HIV-1 Vif and abolishes Vif binding.,MUTAGEN:F->W: Resistant to HIV-1 Vif and reduces Vif binding.,MUTAGEN:H->D: Resistant to HIV-1 Vif and reduces Vif binding.,MUTAGEN:I->A: Resistant to HIV-1 Vif and reduces Vif binding.,MUTAGEN:L->A: Resistant to HIV-1 Vif and reduces Vif binding.,MUTAGEN:L->D: Resistant to HIV-1 Vif and abolishes Vif binding.,MUTAGEN:P->A: No effect on Vif binding.,MUTAGEN:S->P: Resistant to HIV-1 Vif and reduces Vif binding.,MUTAGEN:Y->A: Resistant to HIV-1 Vif and abolishes Vif binding.,REGION:(Microbial infection) Required for interaction with human foamy virus protein Bet,
APOBEC3G	apolipoprotein B mRNA editing enzyme catalytic subunit 3G(APOBEC3G)	Homo sapiens			GO:0002230~positive regulation of defense response to virus by host,GO:0009972~cytidine deamination,GO:0010526~negative regulation of transposition, RNA-mediated,GO:0016553~base conversion or substitution editing,GO:0016554~cytidine to uridine editing,GO:0045071~negative regulation of viral genome replication,GO:0045087~innate immune response,GO:0045869~negative regulation of single stranded viral RNA replication via double stranded DNA intermediate,GO:0048525~negative regulation of viral process,GO:0051607~defense response to virus,GO:0070383~DNA cytosine deamination,GO:0080111~DNA demethylation,	GO:0000932~P-body,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0030895~apolipoprotein B mRNA editing enzyme complex,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0004126~cytidine deaminase activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0008829~dCTP deaminase activity,GO:0042802~identical protein binding,GO:0047844~deoxycytidine deaminase activity,	IPR002125:CMP_dCMP_dom,IPR016192:APOBEC/CMP_deaminase_Zn-bd,IPR016193:Cytidine_deaminase-like,	hsa03250:Viral life cycle - HIV-1,hsa05170:Human immunodeficiency virus 1 infection,				KW-0051~Antiviral defense,KW-0391~Immunity,KW-0399~Innate immunity,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0378~Hydrolase,	KW-0449~Lipoprotein,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	ACT_SITE:Proton donor,DOMAIN:CMP/dCMP-type deaminase,DOMAIN:CMP/dCMP-type deaminase 1,DOMAIN:CMP/dCMP-type deaminase 2,MUTAGEN:C->A,S: Decreases cytidine deaminase activity.,MUTAGEN:C->A: Decreases cytidine deaminase activity.,MUTAGEN:C->S: Does not decrease cytidine deaminase activity.,MUTAGEN:D->K: Resistant to HIV-1 Vif with complete loss of Vif-induced degradation and Vif binding.,MUTAGEN:E->A: Loss of cytidine deaminase activity and significant decrease in antiviral activity.,MUTAGEN:E->A: Loss of cytidine deaminase activity and significant decrease in antiviral activity; when associated with A-259.,MUTAGEN:E->A: Loss of cytidine deaminase activity and significant decrease in antiviral activity; when associated with A-67.,MUTAGEN:E->A: No effect on cytidine deaminase and antiviral activity.,MUTAGEN:E->K: Modifies the spectrum of action against mobile genetic elements; when associated with K-247.,MUTAGEN:E->Q: Decreases cytidine deaminase activity and antiviral activity.,MUTAGEN:E->Q: Decreases cytidine deaminase activity.,MUTAGEN:E->Q: Does not decrease cytidine deaminase activity.,MUTAGEN:F->K: Remains sensitive to HIV-1 Vif and able to bind Vif.,MUTAGEN:F->W: Remains sensitive to HIV-1 Vif and able to bind Vif.,MUTAGEN:H->A: Decreases cytidine deaminase activity.,MUTAGEN:L->D: Remains sensitive to HIV-1 Vif and able to bind Vif.,MUTAGEN:N->A: Abolishes enzyme activity.,MUTAGEN:P->K: Modifies the spectrum of action against mobile genetic elements; when associated with K-217.,MUTAGEN:R->A,E: Abolishes enzyme activity.,MUTAGEN:R->A: Slightly reduces enzyme activity.,MUTAGEN:R->E: Reduces enzyme activity.,MUTAGEN:R->E: Strongly reduces enzyme activity.,MUTAGEN:T->A: Loss of phosphorylation. No effect on cytidine deaminase activity or HIV-1 restriction activity.,MUTAGEN:T->E: Phosphomimetic mutant which shows loss of cytidine deaminase activity and HIV-1 restriction activity.,MUTAGEN:W->A: Abolishes enzyme activity.,MUTAGEN:Y->A: Abolishes enzyme activity.,MUTAGEN:Y->A: Remains sensitive to HIV-1 Vif and able to bind Vif.,REGION:Essential for cytoplasmic localization,REGION:Interaction with DNA,REGION:Necessary for homooligomerization,SITE:Interaction with DNA,
AATF	apoptosis antagonizing transcription factor(AATF)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006974~cellular response to DNA damage stimulus,GO:0007155~cell adhesion,GO:0007346~regulation of mitotic cell cycle,GO:0032929~negative regulation of superoxide anion generation,GO:0040016~embryonic cleavage,GO:0042274~ribosomal small subunit biogenesis,GO:0042985~negative regulation of amyloid precursor protein biosynthetic process,GO:0043066~negative regulation of apoptotic process,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:2000378~negative regulation of reactive oxygen species metabolic process,GO:2001234~negative regulation of apoptotic signaling pathway,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0032040~small-subunit processome,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0019901~protein kinase binding,GO:0043522~leucine zipper domain binding,GO:0048156~tau protein binding,	IPR012617:AATF_C,IPR025160:AATF,IPR039223:AATF/Bfr2,						KW-0539~Nucleus,					KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:AATF leucine zipper-containing,DOMAIN:Apoptosis-antagonizing transcription factor C-terminal,REGION:Disordered,REGION:POLR2J binding,REGION:RB1 and SP1 binding,REGION:RB1 binding,
API5	apoptosis inhibitor 5(API5)	Homo sapiens			GO:0043066~negative regulation of apoptotic process,GO:0044346~fibroblast apoptotic process,GO:0051179~localization,GO:2000270~negative regulation of fibroblast apoptotic process,	GO:0005634~nucleus,GO:0005681~spliceosomal complex,GO:0005737~cytoplasm,GO:0016020~membrane,GO:0016607~nuclear speck,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0017134~fibroblast growth factor binding,	IPR008383:API5,IPR011989:ARM-like,IPR016024:ARM-type_fold,					KW-0053~Apoptosis,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,			KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,MOTIF:Nuclear localization signal,REGION:ARM-like and Heat-like helical repeats,REGION:Disordered,REGION:Leucine-zipper,
ACIN1	apoptotic chromatin condensation inducer 1(ACIN1)	Homo sapiens			GO:0006397~mRNA processing,GO:0008380~RNA splicing,GO:0030218~erythrocyte differentiation,GO:0030263~apoptotic chromosome condensation,GO:0043065~positive regulation of apoptotic process,GO:0045657~positive regulation of monocyte differentiation,GO:0048025~negative regulation of mRNA splicing, via spliceosome,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016607~nuclear speck,GO:0061574~ASAP complex,	GO:0003676~nucleic acid binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0016887~ATPase activity,GO:0019899~enzyme binding,	IPR003034:SAP_dom,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR032552:RSB_motif,IPR034257:Acinus_RRM,IPR035979:RBD_domain_sf,IPR036361:SAP_dom_sf,	hsa03013:Nucleocytoplasmic transport,hsa03015:mRNA surveillance pathway,hsa03040:Spliceosome,			SM00513:SAP,	KW-0053~Apoptosis,KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,				KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:SAP,MUTAGEN:D->A: Abolishes cleavage by CASP3 and chromatin condensation activity.,REGION:Disordered,REGION:Sufficient for interaction with RNPS1 and SAP18 and formation of the ASAP complex,SITE:Cleavage; by caspase-3,
APEX1	apurinic/apyrimidinic endodeoxyribonuclease 1(APEX1)	Homo sapiens		h_setPathway:Granzyme A mediated Apoptosis Pathway,	GO:0000723~telomere maintenance,GO:0006281~DNA repair,GO:0006284~base-excision repair,GO:0006287~base-excision repair, gap-filling,GO:0006308~DNA catabolic process,GO:0006310~DNA recombination,GO:0042981~regulation of apoptotic process,GO:0043488~regulation of mRNA stability,GO:0045454~cell redox homeostasis,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0080111~DNA demethylation,GO:0097698~telomere maintenance via base-excision repair,	GO:0000781~chromosome, telomeric region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005783~endoplasmic reticulum,GO:0005813~centrosome,GO:0005840~ribosome,GO:0016607~nuclear speck,GO:0048471~perinuclear region of cytoplasm,	GO:0003677~DNA binding,GO:0003684~damaged DNA binding,GO:0003691~double-stranded telomeric DNA binding,GO:0003713~transcription coactivator activity,GO:0003714~transcription corepressor activity,GO:0003723~RNA binding,GO:0003906~DNA-(apurinic or apyrimidinic site) lyase activity,GO:0004519~endonuclease activity,GO:0004520~endodeoxyribonuclease activity,GO:0004523~RNA-DNA hybrid ribonuclease activity,GO:0004528~phosphodiesterase I activity,GO:0004844~uracil DNA N-glycosylase activity,GO:0005515~protein binding,GO:0008081~phosphoric diester hydrolase activity,GO:0008296~3'-5'-exodeoxyribonuclease activity,GO:0008309~double-stranded DNA exodeoxyribonuclease activity,GO:0008311~double-stranded DNA 3'-5' exodeoxyribonuclease activity,GO:0008408~3'-5' exonuclease activity,GO:0016491~oxidoreductase activity,GO:0016890~site-specific endodeoxyribonuclease activity, specific for altered base,GO:0031490~chromatin DNA binding,GO:0046872~metal ion binding,GO:0052720~apurinic/apyrimidinic endodeoxyribonuclease activity,GO:0090580~phosphodiesterase activity, acting on 3'-phosphoglycolate-terminated DNA strands,	IPR004808:AP_endonuc_1,IPR005135:Endo/exonuclease/phosphatase,IPR020847:AP_endonuclease_F1_BS,IPR020848:AP_endonuclease_F1_CS,IPR036691:Endo/exonu/phosph_ase_sf,	hsa03410:Base excision repair,				KW-0227~DNA damage,KW-0233~DNA recombination,KW-0234~DNA repair,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0256~Endoplasmic reticulum,KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0460~Magnesium,KW-0464~Manganese,KW-0479~Metal-binding,	KW-0010~Activator,KW-0238~DNA-binding,KW-0255~Endonuclease,KW-0269~Exonuclease,KW-0378~Hydrolase,KW-0540~Nuclease,KW-0678~Repressor,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0165~Cleavage on pair of basic residues,KW-0597~Phosphoprotein,KW-0702~S-nitrosylation,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,	ACT_SITE:Proton acceptor,ACT_SITE:Proton donor/acceptor,COMPBIAS:Basic and acidic residues,DISULFID:Alternate,DOMAIN:Endonuclease/exonuclease/phosphatase,MOTIF:Nuclear export signal (NES),MOTIF:Nuclear localization signal (NLS),MUTAGEN:C->A: Abolishes partially the redox activity.,MUTAGEN:C->A: Abolishes the redox activity. Does not abolish the AP endodeoxyribonuclease and phosphodiesterase activities. Reduces protection from granzyme A-mediated cell death; when associated with A-31 and A-210.,MUTAGEN:C->A: Does not abolish the redox activity.,MUTAGEN:C->S: Does not abolish NO-induced nitrosylation. Abolishes NO-induced nitrosylation and translocation from the nucleus to the cytoplasm; when associated with S-310.,MUTAGEN:C->S: Does not abolish NO-induced nitrosylation. Abolishes NO-induced nitrosylation and translocation from the nucleus to the cytoplasm; when associated with S-93.,MUTAGEN:C->S: Does not abolish NO-induced nitrosylation. Enhances NO-induced nuclear export.,MUTAGEN:D->A,N: Abolishes the AP endodeoxyribonuclease activity. Reduces protection from granzyme A-mediated cell death; when associated with A-31 and A-65.,MUTAGEN:D->A: Reduces AP endodeoxyribonuclease activity. Nearly abolishes AP endodeoxyribonuclease activity; when associated with A-283.,MUTAGEN:D->A: Reduces nuclear localization; when associated with A-12.,MUTAGEN:D->A: Strongly reduces AP endodeoxyribonuclease activity, but does not affect RNA cleavage activity. Nearly abolishes AP endodeoxyribonuclease activity; when associated with A-308.,MUTAGEN:D->A: Strongly reduces AP endodeoxyribonuclease activity.,MUTAGEN:E->A: Lacks MYC CRD RNA cleavage activity.,MUTAGEN:E->A: Reduces nuclear localization; when associated with A-13.,MUTAGEN:F->A: Strongly reduces AP endodeoxyribonuclease activity.,MUTAGEN:H->N,S: Abolishes AP endodeoxyribonuclease activity. Lacks MYC CRD RNA cleavage activity.,MUTAGEN:K->A: Enhances the interaction with TOMM20. Does not inhibit redox and AP endodeoyribonuclease activities. Inhibits rRNA binding, interaction with NPM1, nuclear localization and modulates its endodeoxyribonuclease activity; when associated with A-24; A-25; A-27 and A-32. Reduces protection from granzyme A-mediated cell death; when associated with A-65 and A-210.,MUTAGEN:K->A: Enhances the interaction with TOMM20. Inhibits rRNA binding, interaction with NPM1, nuclear localization and modulates its endodeoxyribonuclease activity; when associated with A-24; A-27; A-31 and A-32. Inhibits ubiquitination; when associated with K-24 and K-27.,MUTAGEN:K->A: Enhances the interaction with TOMM20. Inhibits rRNA binding, interaction with NPM1, nuclear localization and modulates its endodeoxyribonuclease activity; when associated with A-25; A-27; A-31 and A-32. Inhibits ubiquitination; when associated with K-25 and K-27.,MUTAGEN:K->A: Enhances the interaction with TOMM20. Inhibits rRNA binding, interaction with NPM1, nuclear localization and modulates its endodeoyribonuclease activity; when associated with A-24; A-25; A-31 and A-32. Inhibits ubiquitination; when associated with K-24 and K-25.,MUTAGEN:K->A: Inhibits rRNA binding, interaction with NPM1, nuclear localization and modulates its endodeoxyribonuclease activity; when associated with A-24; A-25; A-27 and A-31.,MUTAGEN:K->A: Reduces the interaction with TOMM20.,MUTAGEN:K->A: Reduces the interaction with TOMM20. Abolishes localization in the mitochondria; when associated with A-301.,MUTAGEN:K->R: Lack of acetylation and does not stimulate the YBX1-mediated MDR1 promoter activity and alter nuclear subcellular localization; when associated with R-6.,MUTAGEN:K->R: Lack of acetylation, does not stimulate the YBX1-mediated MDR1 promoter activity and alter nuclear subcellular localization; when associated with R-7. Does not inhibit interaction with HDAC1, HDAC2 and HDAC3. Absence of increase in nCaRE binding activity.,MUTAGEN:N->A: Abolishes AP endodeoxyribonuclease activity.,MUTAGEN:N->A: Nearly abolishes AP endodeoxyribonuclease activity.,MUTAGEN:N->Q,D: Decreases AP endodeoxyribonuclease activity.,MUTAGEN:R->A: Reduces the interaction with TOMM20. Abolishes localization in the mitochondria; when associated with A-299.,MUTAGEN:Y->A,F,H: Abolishes the AP endodeoxyribonuclease activity.,REGION:Disordered,REGION:Mitochondrial targeting sequence (MTS),REGION:Necessary for interaction with NPM1 and for efficient rRNA binding,REGION:Necessary for interaction with YBX1, binding to RNA, NPM1-dependent association with rRNA, endoribonuclease activity on abasic RNA and localization in the nucleoli,SITE:Cleavage; by granzyme A,SITE:Important for catalytic activity,SITE:Interaction with DNA substrate,SITE:Transition state stabilizer,
AQP3	aquaporin 3 (Gill blood group)(AQP3)	Homo sapiens			GO:0002684~positive regulation of immune system process,GO:0002931~response to ischemia,GO:0003091~renal water homeostasis,GO:0006833~water transport,GO:0015793~glycerol transport,GO:0032526~response to retinoic acid,GO:0033280~response to vitamin D,GO:0042476~odontogenesis,GO:0045616~regulation of keratinocyte differentiation,GO:0051592~response to calcium ion,GO:0051649~establishment of localization in cell,GO:0070295~renal water absorption,GO:0071456~cellular response to hypoxia,GO:0071918~urea transmembrane transport,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0005911~cell-cell junction,GO:0016020~membrane,GO:0016323~basolateral plasma membrane,	GO:0005515~protein binding,GO:0015204~urea transmembrane transporter activity,GO:0015250~water channel activity,GO:0015254~glycerol channel activity,GO:0042802~identical protein binding,	IPR000425:MIP,IPR022357:MIP_CS,IPR023271:Aquaporin-like,IPR023275:Aquaporin_3,	hsa04962:Vasopressin-regulated water reabsorption,	607457~Blood group GIL,			KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0095~Blood group antigen,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,INTRAMEM:Discontinuously helical,MOTIF:NPA 1,MOTIF:NPA 2,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
ALOX5AP	arachidonate 5-lipoxygenase activating protein(ALOX5AP)	Homo sapiens		h_eicosanoidPathway:Eicosanoid Metabolism,	GO:0002540~leukotriene production involved in inflammatory response,GO:0002675~positive regulation of acute inflammatory response,GO:0019370~leukotriene biosynthetic process,GO:0019372~lipoxygenase pathway,GO:0070207~protein homotrimerization,GO:0071277~cellular response to calcium ion,GO:0098869~cellular oxidant detoxification,	GO:0005635~nuclear envelope,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0016020~membrane,GO:0031965~nuclear membrane,	GO:0004051~arachidonate 5-lipoxygenase activity,GO:0004364~glutathione transferase activity,GO:0004464~leukotriene-C4 synthase activity,GO:0004602~glutathione peroxidase activity,GO:0005515~protein binding,GO:0008047~enzyme activator activity,GO:0019899~enzyme binding,GO:0042802~identical protein binding,GO:0044877~macromolecular complex binding,GO:0050544~arachidonic acid binding,	IPR001129:Membr-assoc_MAPEG,IPR001446:5_LipOase_AP,IPR018295:FLAP/GST2/LTC4S_CS,IPR023352:MAPEG-like_dom_sf,	hsa04664:Fc epsilon RI signaling pathway,	601367~Stroke, susceptibility to,			KW-0434~Leukotriene biosynthesis,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0539~Nucleus,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				MUTAGEN:A->V: Strongly decreased affinity for the inhibitor MK-591.,MUTAGEN:D->A: Decreased affinity for the inhibitor MK-591.,MUTAGEN:F->A: Decreased affinity for the inhibitor MK-591.,MUTAGEN:I->A: Increased affinity for the inhibitor MK-591.,MUTAGEN:K->A: Strongly increased affinity for the inhibitor MK-591.,MUTAGEN:T->A: Strongly decreased affinity for the inhibitor MK-591.,MUTAGEN:V->A: Increased affinity for the inhibitor MK-591.,MUTAGEN:V->A: Strongly decreased affinity for the inhibitor MK-591.,MUTAGEN:Y->A: Strongly decreased affinity for the inhibitor MK-591.,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
ARGLU1	arginine and glutamate rich 1(ARGLU1)	Homo sapiens				GO:0005654~nucleoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,	GO:0005515~protein binding,GO:0045296~cadherin binding,	IPR033371:ARGLU1,					KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,					KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,REGION:Disordered,
RSRC2	arginine and serine rich coiled-coil 2(RSRC2)	Homo sapiens					GO:0003723~RNA binding,GO:0005515~protein binding,	IPR028124:SMAP_dom,								KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:Small acidic protein-like,REGION:Disordered,
RSRP1	arginine and serine rich protein 1(RSRP1)	Homo sapiens			GO:0000245~spliceosomal complex assembly,	GO:0005634~nucleus,	GO:0005515~protein binding,	IPR029656:RSRP1,						KW-0539~Nucleus,					KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic residues,COMPBIAS:Polar residues,MUTAGEN:S->A: No effect on interaction with spliceosome factors.,MUTAGEN:SPS->APA: Reduces interaction with spliceosome factors.,REGION:Disordered,
ARIH1	ariadne RBR E3 ubiquitin protein ligase 1(ARIH1)	Homo sapiens			GO:0000209~protein polyubiquitination,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0016567~protein ubiquitination,GO:0032436~positive regulation of proteasomal ubiquitin-dependent protein catabolic process,GO:0039585~PKR signal transduction,	GO:0000151~ubiquitin ligase complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0015030~Cajal body,GO:0016604~nuclear body,GO:0019005~SCF ubiquitin ligase complex,GO:0031462~Cul2-RING ubiquitin ligase complex,GO:0031463~Cul3-RING ubiquitin ligase complex,GO:0031464~Cul4A-RING E3 ubiquitin ligase complex,GO:0097413~Lewy body,	GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0019787~ubiquitin-like protein transferase activity,GO:0031624~ubiquitin conjugating enzyme binding,GO:0031625~ubiquitin protein ligase binding,GO:0061630~ubiquitin protein ligase activity,	IPR001841:Znf_RING,IPR002867:IBR_dom,IPR013083:Znf_RING/FYVE/PHD,IPR018957:Znf_C3HC4_RING-type,IPR031127:E3_UB_ligase_RBR,IPR044066:TRIAD_supradom,IPR045840:Ariadne,IPR048962:ARIH1-like_UBL,	hsa04137:Mitophagy - animal,			SM00184:RING,SM00647:IBR,	KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,	KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0808~Transferase,	KW-0007~Acetylation,	COMPBIAS:Acidic residues,DOMAIN:Ariadne,DOMAIN:E3 ubiquitin-protein ligase ARIH1-like UBA-like,DOMAIN:IBR,MUTAGEN:C->A,H: Loss of interaction with UBE2L3.,MUTAGEN:C->A,S: Does not affect zinc binding and folding. Abolishes ability to transfer ubiquitin and E3 ubiquitin-protein ligase activity.,MUTAGEN:C->A: Impairs E3 ubiquitin-protein ligase activity.,MUTAGEN:C->A: Impairs zinc-binding and folding. Abolishes E3 ubiquitin-protein ligase activity.,MUTAGEN:E->A: Hyperactive 'open' mutant that displays enhanced E3 ubiquitin-protein ligase activity.,MUTAGEN:E->A: Relieves autoinhibition of the E3 ligase activity by the ariadne domain; when associated with 430-A-A-431. Hyperactive 'open' mutant that displays enhanced E3 ubiquitin-protein ligase activity; when associated with 430-A-A-431. Hyperactive 'open' mutant that displays enhanced E3 ubiquitin-protein ligase activity; when associated with 420-A--A-423.,MUTAGEN:F->A: Disrupts the hydrophobic network. Abolishes E3 ubiquitin-protein ligase activity.,MUTAGEN:F->A: Slightly relieves autoinhibition of the E3 ligase activity by the ariadne domain.,MUTAGEN:F->A: Strongly decreased ability to initiate ubiquitination of cullin-RING complexes.,MUTAGEN:FE->AA: Relieves autoinhibition of the E3 ligase activity by the ariadne domain; when associated with A-503. Hyperactive 'open' mutant that displays enhanced E3 ubiquitin-protein ligase activity; when associated with A-503.,MUTAGEN:GSA->AAD: Defects in ligation.,MUTAGEN:H->A: Defects in ligation. Does not affect zinc binding, folding. Does not impair E3 ubiquitin-protein ligase activity.,MUTAGEN:H->A: Impaired interaction with UBE2L3 without affecting interaction with neddylated cullin-RING complexes.,MUTAGEN:I->A: Disrupts the hydrophobic network. Abolishes E3 ubiquitin-protein ligase activity.,MUTAGEN:I->A: Loss of interaction with UBE2L3. Decreased E3 ligase activity. Strongly decreased ability to initiate ubiquitination of cullin-RING complexes.,MUTAGEN:IE->AA: Strongly decreased ability to initiate ubiquitination of cullin-RING complexes.,MUTAGEN:KE->AA: Strongly decreased ability to initiate ubiquitination of cullin-RING complexes.,MUTAGEN:KLF->AAA: Strongly decreased ability to initiate ubiquitination of cullin-RING complexes.,MUTAGEN:KY->AAA: Strongly decreased ability to initiate ubiquitination of cullin-RING complexes.,MUTAGEN:N->A: Defects in ligation.,MUTAGEN:N->A: Hyperactive 'open' mutant that displays enhanced E3 ubiquitin-protein ligase activity.,MUTAGEN:NT->AA: Strongly decreased ability to initiate ubiquitination of cullin-RING complexes.,MUTAGEN:PW->AA: Defects in ligation.,MUTAGEN:Q->A: Hyperactive 'open' mutant that displays enhanced E3 ubiquitin-protein ligase activity.,MUTAGEN:QI->HV: No loss of interaction with UBE2L3.,MUTAGEN:RYMN->AYMA: Slightly relieves autoinhibition of the E3 ligase activity by the ariadne domain. Hyperactive 'open' mutant that displays enhanced E3 ubiquitin-protein ligase activity; when associated with A-503.,MUTAGEN:S->A: Slightly relieves autoinhibition of the E3 ligase activity by the ariadne domain.,MUTAGEN:SFV->AAA: Strongly decreased ability to initiate ubiquitination of cullin-RING complexes.,MUTAGEN:V->A: Strongly decreased ability to initiate ubiquitination of cullin-RING complexes.,MUTAGEN:W->A: Abolishes E3 ubiquitin-protein ligase activity.,MUTAGEN:W->A: Does not affect E3 ubiquitin-protein ligase activity.,MUTAGEN:W->A: Does not affect E3 ubiquitin-protein ligase activity. Strongly decreased ability to initiate ubiquitination of cullin-RING complexes.,MUTAGEN:Y->A: Hyperactive 'open' mutant that displays enhanced E3 ubiquitin-protein ligase activity.,MUTAGEN:Y->A: No loss of interaction with UBE2L3.,MUTAGEN:Y->A: Strongly decreased ability to initiate ubiquitination of cullin-RING complexes.,REGION:Ariadne domain,REGION:Disordered,REGION:TRIAD supradomain,REGION:UBA-like,ZN_FING:IBR-type,ZN_FING:RING-type 1,ZN_FING:RING-type 2; atypical,
ARIH2	ariadne RBR E3 ubiquitin protein ligase 2(ARIH2)	Homo sapiens			GO:0000209~protein polyubiquitination,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0016567~protein ubiquitination,GO:0032436~positive regulation of proteasomal ubiquitin-dependent protein catabolic process,GO:0048588~developmental cell growth,GO:0070534~protein K63-linked ubiquitination,GO:0070936~protein K48-linked ubiquitination,GO:0071425~hematopoietic stem cell proliferation,GO:1903955~positive regulation of protein targeting to mitochondrion,	GO:0000151~ubiquitin ligase complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0031466~Cul5-RING ubiquitin ligase complex,	GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0031624~ubiquitin conjugating enzyme binding,GO:0061630~ubiquitin protein ligase activity,	IPR001841:Znf_RING,IPR002867:IBR_dom,IPR013083:Znf_RING/FYVE/PHD,IPR017907:Znf_RING_CS,IPR031127:E3_UB_ligase_RBR,IPR044066:TRIAD_supradom,IPR045840:Ariadne,IPR047555:BRcat_RBR_TRIAD1,IPR047556:Rcat_RBR_TRIAD1,				SM00184:RING,SM00647:IBR,	KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0808~Transferase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Acidic residues,DOMAIN:RING-type,MUTAGEN:C->A: Abolishes E3 ubiquitin-protein ligase activity.,MUTAGEN:C->A: Does not affect interaction with UBE2L3.,MUTAGEN:C->A: Loss of effect in myelopoiesis.,MUTAGEN:H->A: Loss of effect in myelopoiesis. Abolishes interaction with UBE2L3.,MUTAGEN:LKV->AKA: Reduced interaction with neddylated CUL5; when associated with A-100.,MUTAGEN:W->A: Reduced interaction with neddylated CUL5; when associated with 84-A--A-86.,REGION:Ariadne domain,REGION:Disordered,REGION:TRIAD supradomain,REGION:UBA-like,ZN_FING:IBR-type,ZN_FING:RING-type 1,ZN_FING:RING-type 2; atypical,
ARMC10	armadillo repeat containing 10(ARMC10)	Homo sapiens			GO:0040010~positive regulation of growth rate,GO:0043066~negative regulation of apoptotic process,GO:1902254~negative regulation of intrinsic apoptotic signaling pathway by p53 class mediator,	GO:0005739~mitochondrion,GO:0005741~mitochondrial outer membrane,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0016020~membrane,	GO:0002039~p53 binding,GO:0050692~DBD domain binding,	IPR006911:ARM-rpt_dom,IPR011989:ARM-like,IPR016024:ARM-type_fold,					KW-0341~Growth regulation,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0496~Mitochondrion,KW-1000~Mitochondrion outer membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:Armadillo repeat-containing,REGION:Disordered,REPEAT:ARM,TRANSMEM:Helical,
ARMC8	armadillo repeat containing 8(ARMC8)	Homo sapiens			GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,	GO:0000151~ubiquitin ligase complex,GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0034657~GID complex,GO:0035580~specific granule lumen,GO:0043231~intracellular membrane-bounded organelle,GO:1904724~tertiary granule lumen,	GO:0005515~protein binding,	IPR000225:Armadillo,IPR011989:ARM-like,IPR016024:ARM-type_fold,IPR038739:ARMC8/Vid28,				SM00185:ARM,		KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	REPEAT:ARM,REPEAT:ARM 1,REPEAT:ARM 10,REPEAT:ARM 11,REPEAT:ARM 12,REPEAT:ARM 13,REPEAT:ARM 14,REPEAT:ARM 2,REPEAT:ARM 3,REPEAT:ARM 4,REPEAT:ARM 5,REPEAT:ARM 6,REPEAT:ARM 7,REPEAT:ARM 8,REPEAT:ARM 9,
ARRDC1	arrestin domain containing 1(ARRDC1)	Homo sapiens			GO:0006511~ubiquitin-dependent protein catabolic process,GO:0006858~extracellular transport,GO:0015031~protein transport,GO:0016567~protein ubiquitination,GO:0045746~negative regulation of Notch signaling pathway,	GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0031410~cytoplasmic vesicle,GO:0070062~extracellular exosome,GO:1903561~extracellular vesicle,	GO:0005515~protein binding,GO:0031625~ubiquitin protein ligase binding,GO:0042802~identical protein binding,GO:1990756~protein binding, bridging involved in substrate recognition for ubiquitination,GO:1990763~arrestin family protein binding,	IPR011021:Arrestin-like_N,IPR011022:Arrestin_C-like,IPR014752:Arrestin-like_C,IPR014756:Ig_E-set,				SM01017:Arrestin_C,		KW-0472~Membrane,KW-1003~Cell membrane,					KW-0832~Ubl conjugation,	COMPBIAS:Pro residues,DOMAIN:Arrestin C-terminal-like,DOMAIN:Arrestin-like N-terminal,MOTIF:PPxY motif 1,MOTIF:PPxY motif 2,MUTAGEN:F->L: Loss of localization to the cell membrane and extracellular vesicles. Localizes to the cytoplasm.,MUTAGEN:G->A: Decreased localization to the cell membrane and extracellular vesicles.,MUTAGEN:N->D: Decreased localization to the cell membrane and extracellular vesicles.,MUTAGEN:P->A: Loss of interaction with ITCH; when associated with A-403.,MUTAGEN:P->A: Loss of interaction with ITCH; when associated with A-416.,MUTAGEN:S->A: Decreased interaction with TSG101. No effect on localization to the cell membrane. Loss of localization to extracellular vesicles.,REGION:Disordered,
ARRDC2	arrestin domain containing 2(ARRDC2)	Homo sapiens			GO:0015031~protein transport,	GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0031410~cytoplasmic vesicle,	GO:0005515~protein binding,	IPR011021:Arrestin-like_N,IPR011022:Arrestin_C-like,IPR014752:Arrestin-like_C,IPR014756:Ig_E-set,				SM01017:Arrestin_C,								DOMAIN:Arrestin C-terminal-like,
AHR	aryl hydrocarbon receptor(AHR)	Homo sapiens		h_acrPathway:Ahr Signal Transduction Pathway,	GO:0001568~blood vessel development,GO:0002819~regulation of adaptive immune response,GO:0002841~negative regulation of T cell mediated immune response to tumor cell,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006805~xenobiotic metabolic process,GO:0006915~apoptotic process,GO:0007049~cell cycle,GO:0009410~response to xenobiotic stimulus,GO:0009636~response to toxic substance,GO:0010468~regulation of gene expression,GO:0019933~cAMP-mediated signaling,GO:0030522~intracellular receptor signaling pathway,GO:0030888~regulation of B cell proliferation,GO:0032922~circadian regulation of gene expression,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048511~rhythmic process,GO:0050728~negative regulation of inflammatory response,GO:0071219~cellular response to molecule of bacterial origin,GO:0071320~cellular response to cAMP,GO:1904322~cellular response to forskolin,GO:1904613~cellular response to 2,3,7,8-tetrachlorodibenzodioxine,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0032991~macromolecular complex,GO:0034751~aryl hydrocarbon receptor complex,GO:0034752~cytosolic aryl hydrocarbon receptor complex,GO:0034753~nuclear aryl hydrocarbon receptor complex,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0000987~core promoter proximal region sequence-specific DNA binding,GO:0001094~TFIID-class transcription factor binding,GO:0001223~transcription coactivator binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0004879~RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding,GO:0005515~protein binding,GO:0017025~TBP-class protein binding,GO:0042803~protein homodimerization activity,GO:0046982~protein heterodimerization activity,GO:0046983~protein dimerization activity,GO:0051879~Hsp90 protein binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:0070888~E-box binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000014:PAS,IPR001610:PAC,IPR011598:bHLH_dom,IPR013655:PAS_fold_3,IPR013767:PAS_fold,IPR033348:AHR_bHLH,IPR035965:PAS-like_dom_sf,IPR036638:HLH_DNA-bd_sf,	hsa04659:Th17 cell differentiation,hsa04934:Cushing syndrome,hsa05207:Chemical carcinogenesis - receptor activation,hsa05208:Chemical carcinogenesis - reactive oxygen species,	618345~Retinitis pigmentosa 85,		SM00086:PAC,SM00091:PAS,SM00353:HLH,	KW-0090~Biological rhythms,KW-0131~Cell cycle,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0682~Retinitis pigmentosa,	KW-0677~Repeat,		KW-0010~Activator,KW-0238~DNA-binding,KW-0675~Receptor,KW-0678~Repressor,	KW-0007~Acetylation,KW-0013~ADP-ribosylation,	COMPBIAS:Polar residues,DOMAIN:BHLH,DOMAIN:PAC,DOMAIN:PAS,DOMAIN:PAS 1,DOMAIN:PAS 2,DOMAIN:bHLH,MOTIF:Nuclear export signal,MOTIF:Nuclear localization signal 1,MOTIF:Nuclear localization signal 2,MUTAGEN:A->D: Abolishes transcription factor activity; when associated with D-50 and D-82.,MUTAGEN:F->D: Abolishes transcription factor activity; when associated with D-50 and D-79.,MUTAGEN:F->D: Interferes with transcription factor activity.,MUTAGEN:H->G: Almost abolishes transcription factor activity. No effect on nuclear translocation upon ligand binding.,MUTAGEN:I->D: Interferes with transcription factor activity.,MUTAGEN:L->D: Abolishes transcription factor activity; when associated with D-79 and D-82.,MUTAGEN:L->D: Interferes with transcription factor activity.,MUTAGEN:LLQAL->ELQDE: Strongly reduces transcription factor activity.,MUTAGEN:R->D: Abolishes transcription factor activity. Alters on nuclear translocation upon ligand binding.,MUTAGEN:S->G: Strongly reduces transcription factor activity.,MUTAGEN:V->A: Increases specific ligand binding.,MUTAGEN:V->D: Abolishes specific ligand binding.,MUTAGEN:V->D: Interferes with transcription factor activity.,MUTAGEN:V->L,G: No effect on specific ligand binding.,REGION:DNA-binding,REGION:Disordered,REGION:Required for maintaining the overall integrity of the AHR:ARNT heterodimer and its transcriptional activity,
ASNSD1	asparagine synthetase domain containing 1(ASNSD1)	Homo sapiens			GO:0006529~asparagine biosynthetic process,GO:0006541~glutamine metabolic process,		GO:0004066~asparagine synthase (glutamine-hydrolyzing) activity,	IPR001962:Asn_synthase,IPR014729:Rossmann-like_a/b/a_fold,IPR017932:GATase_2_dom,IPR029055:Ntn_hydrolases_N,					KW-0028~Amino-acid biosynthesis,KW-0061~Asparagine biosynthesis,			KW-0315~Glutamine amidotransferase,				ACT_SITE:For GATase activity,DOMAIN:Asparagine synthetase,DOMAIN:Glutamine amidotransferase type-2,
ATXN1	ataxin 1(ATXN1)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006396~RNA processing,GO:0007399~nervous system development,GO:0007420~brain development,GO:0007612~learning,GO:0007613~memory,GO:0035176~social behavior,GO:0045892~negative regulation of transcription, DNA-templated,GO:0051168~nuclear export,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016363~nuclear matrix,GO:0042405~nuclear inclusion body,	GO:0003677~DNA binding,GO:0005515~protein binding,GO:0008266~poly(U) RNA binding,GO:0034046~poly(G) binding,GO:0042802~identical protein binding,GO:0043621~protein self-association,	IPR003652:Ataxin_AXH_dom,IPR020997:Ataxin-1_N,IPR036096:Ataxin_AXH_dom_sf,IPR043404:ATAXIN1-like,	hsa04330:Notch signaling pathway,hsa05017:Spinocerebellar ataxia,hsa05022:Pathways of neurodegeneration - multiple diseases,	164400~Spinocerebellar ataxia 1,		SM00536:AXH,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0523~Neurodegeneration,KW-0950~Spinocerebellar ataxia,			KW-0238~DNA-binding,KW-0678~Repressor,KW-0694~RNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO),DOMAIN:AXH,MOTIF:Nuclear localization signal,MUTAGEN:K->R: No effect on sumoylation.,MUTAGEN:K->R: Sumoylation reduced to 40% of wild-type.,MUTAGEN:K->R: Sumoylation reduced to 42% of wild-type.,MUTAGEN:K->R: Sumoylation reduced to 43% of wild-type.,MUTAGEN:K->R: Sumoylation reduced to 44% of wild-type.,MUTAGEN:K->R: Sumoylation reduced to 46% of wild-type.,MUTAGEN:K->R: Sumoylation reduced to 53% of wild-type.,MUTAGEN:K->R: Sumoylation reduced to 57% of wild-type.,MUTAGEN:K->R: Sumoylation reduced to 62% of wild-type.,MUTAGEN:K->R: Sumoylation reduced to 68% of wild-type.,MUTAGEN:S->A: Reduces phosphorylation but does not affect nuclear localization.,REGION:Disordered,REGION:Interaction with USP7,REGION:RNA-binding,REGION:Self-association,
ATXN2L	ataxin 2 like(ATXN2L)	Homo sapiens			GO:0016071~mRNA metabolic process,GO:0034063~stress granule assembly,	GO:0005829~cytosol,GO:0010494~cytoplasmic stress granule,GO:0016020~membrane,GO:0016607~nuclear speck,	GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0005515~protein binding,GO:0045296~cadherin binding,	IPR009604:LsmAD_domain,IPR009818:Ataxin-2_C,IPR025852:SM_dom_ATX,IPR045117:ATXN2-like,IPR047575:Sm,	hsa05014:Amyotrophic lateral sclerosis,hsa05017:Spinocerebellar ataxia,hsa05022:Pathways of neurodegeneration - multiple diseases,			SM01272:LsmAD,		KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Ataxin 2 SM,DOMAIN:Sm,MUTAGEN:R->Q: No effect on localization to stress granules under stress conditions.,REGION:Disordered,REGION:Interaction with MPL,TRANSMEM:Helical,
AURKAIP1	aurora kinase A interacting protein 1(AURKAIP1)	Homo sapiens			GO:0032543~mitochondrial translation,GO:0045839~negative regulation of mitotic nuclear division,GO:0045862~positive regulation of proteolysis,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005759~mitochondrial matrix,GO:0005763~mitochondrial small ribosomal subunit,GO:0043231~intracellular membrane-bounded organelle,	GO:0005515~protein binding,	IPR013177:Ribosomal_mS38_C,				SM01155:DUF1713,		KW-0496~Mitochondrion,KW-0539~Nucleus,				KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,		DOMAIN:Ribosomal protein mS38 C-terminal,REGION:Disordered,
ATG101	autophagy related 101(ATG101)	Homo sapiens			GO:0000045~autophagosome assembly,GO:0006914~autophagy,GO:0008285~negative regulation of cell proliferation,GO:0010508~positive regulation of autophagy,GO:1903059~regulation of protein lipidation,	GO:0000407~pre-autophagosomal structure,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:1990316~ATG1/ULK1 kinase complex,	GO:0005515~protein binding,GO:0019901~protein kinase binding,GO:0042802~identical protein binding,GO:0044877~macromolecular complex binding,	IPR012445:ATG101,	hsa04136:Autophagy - other,hsa04140:Autophagy - animal,hsa04211:Longevity regulating pathway,hsa05010:Alzheimer disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05017:Spinocerebellar ataxia,hsa05022:Pathways of neurodegeneration - multiple diseases,				KW-0072~Autophagy,	KW-0963~Cytoplasm,						MUTAGEN:D->R: Impairs interaction with ATG13; when associated with S-31.,MUTAGEN:H->S: Impairs interaction with ATG13; when associated with R-54.,MUTAGEN:I->D: Abolishes interaction with ATG13; when associated with D-152 and D-156.,MUTAGEN:I->D: Abolishes interaction with ATG13; when associated with D-153 and D-156.,MUTAGEN:V->D: Abolishes interaction with ATG13; when associated with D-152 and D-152.,REGION:Important for interaction with ATG13,
ATG3	autophagy related 3(ATG3)	Homo sapiens			GO:0000045~autophagosome assembly,GO:0000422~mitophagy,GO:0006612~protein targeting to membrane,GO:0006914~autophagy,GO:0015031~protein transport,GO:0016567~protein ubiquitination,GO:0043653~mitochondrial fragmentation involved in apoptotic process,GO:0044804~nucleophagy,GO:0050765~negative regulation of phagocytosis,GO:0061723~glycophagy,GO:1902017~regulation of cilium assembly,	GO:0000407~pre-autophagosomal structure,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0034274~Atg12-Atg5-Atg16 complex,	GO:0005515~protein binding,GO:0019776~Atg8 ligase activity,GO:0019777~Atg12 transferase activity,GO:0019787~ubiquitin-like protein transferase activity,GO:0019899~enzyme binding,	IPR007135:Atg3/Atg10,IPR046962:Atg3,	hsa04136:Autophagy - other,hsa04140:Autophagy - animal,hsa05167:Kaposi sarcoma-associated herpesvirus infection,				KW-0072~Autophagy,KW-0653~Protein transport,KW-0813~Transport,KW-0833~Ubl conjugation pathway,	KW-0963~Cytoplasm,				KW-0808~Transferase,	KW-0007~Acetylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	ACT_SITE:Glycyl thioester intermediate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ATG12),MOTIF:Caspase cleavage motif LETD,MUTAGEN:C->S: Instead of the formation of an intermediate complex with a thiol ester bond between ATG3 (E2-like enzyme) and GABARAPL1/APG8L (substrate), a stable complex with an O-ester bond is formed.,REGION:Disordered,SITE:Cleavage; by CASP8,
ATG5	autophagy related 5(ATG5)	Homo sapiens			GO:0000045~autophagosome assembly,GO:0000422~mitophagy,GO:0000423~macromitophagy,GO:0001974~blood vessel remodeling,GO:0002718~regulation of cytokine production involved in immune response,GO:0006325~chromatin organization,GO:0006914~autophagy,GO:0006995~cellular response to nitrogen starvation,GO:0009267~cellular response to starvation,GO:0009410~response to xenobiotic stimulus,GO:0009620~response to fungus,GO:0010040~response to iron(II) ion,GO:0010659~cardiac muscle cell apoptotic process,GO:0010667~negative regulation of cardiac muscle cell apoptotic process,GO:0016236~macroautophagy,GO:0016567~protein ubiquitination,GO:0019883~antigen processing and presentation of endogenous antigen,GO:0031397~negative regulation of protein ubiquitination,GO:0032480~negative regulation of type I interferon production,GO:0034727~piecemeal microautophagy of nucleus,GO:0035973~aggrephagy,GO:0039689~negative stranded viral RNA replication,GO:0042311~vasodilation,GO:0043687~post-translational protein modification,GO:0044804~nucleophagy,GO:0045060~negative thymic T cell selection,GO:0045824~negative regulation of innate immune response,GO:0048840~otolith development,GO:0050687~negative regulation of defense response to virus,GO:0050765~negative regulation of phagocytosis,GO:0051279~regulation of release of sequestered calcium ion into cytosol,GO:0051649~establishment of localization in cell,GO:0055015~ventricular cardiac muscle cell development,GO:0060047~heart contraction,GO:0061684~chaperone-mediated autophagy,GO:0061739~protein lipidation involved in autophagosome assembly,GO:0070254~mucus secretion,GO:0070257~positive regulation of mucus secretion,GO:0071500~cellular response to nitrosative stress,GO:1901096~regulation of autophagosome maturation,GO:1902017~regulation of cilium assembly,GO:1902617~response to fluoride,GO:1904093~negative regulation of autophagic cell death,GO:1904973~positive regulation of viral translation,GO:2000378~negative regulation of reactive oxygen species metabolic process,	GO:0005737~cytoplasm,GO:0005776~autophagosome,GO:0005829~cytosol,GO:0005930~axoneme,GO:0016020~membrane,GO:0030424~axon,GO:0030670~phagocytic vesicle membrane,GO:0032991~macromolecular complex,GO:0034045~pre-autophagosomal structure membrane,GO:0034274~Atg12-Atg5-Atg16 complex,GO:0044233~ER-mitochondrion membrane contact site,GO:1990234~transferase complex,	GO:0005515~protein binding,GO:0019776~Atg8 ligase activity,	IPR007239:Atg5,IPR042526:Atg5_HR,IPR042527:Atg5_UblA_dom_sf,IPR048318:ATG5_UblB,IPR048939:ATG5_UblA,IPR048940:ATG5_HBR,	hsa04136:Autophagy - other,hsa04140:Autophagy - animal,hsa04211:Longevity regulating pathway,hsa04213:Longevity regulating pathway - multiple species,hsa04216:Ferroptosis,hsa04621:NOD-like receptor signaling pathway,hsa04622:RIG-I-like receptor signaling pathway,hsa05131:Shigellosis,	617584~Spinocerebellar ataxia, autosomal recessive 25,			KW-0053~Apoptosis,KW-0072~Autophagy,KW-0391~Immunity,KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0523~Neurodegeneration,	KW-0732~Signal,			KW-0007~Acetylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ATG12),DOMAIN:Autophagy protein ATG5 UblA,DOMAIN:Autophagy protein ATG5 UblB,DOMAIN:Autophagy protein ATG5 alpha-helical bundle region,MUTAGEN:K->R: Loss of conjugaction with ATG12. Does affect interaction with DHX58, nor with MAVS.,REGION:Disordered,
BIRC2	baculoviral IAP repeat containing 2(BIRC2)	Homo sapiens		h_caspasePathway:Caspase Cascade in Apoptosis,h_deathPathway:Induction of apoptosis through DR3 and DR4/5 Death Receptors ,h_hivnefPathway:HIV-I Nef: negative effector of Fas and TNF,h_mitochondriaPathway:Role of Mitochondria in Apoptotic Signaling,	GO:0000209~protein polyubiquitination,GO:0001666~response to hypoxia,GO:0001890~placenta development,GO:0006915~apoptotic process,GO:0007166~cell surface receptor signaling pathway,GO:0007249~I-kappaB kinase/NF-kappaB signaling,GO:0031398~positive regulation of protein ubiquitination,GO:0033209~tumor necrosis factor-mediated signaling pathway,GO:0034121~regulation of toll-like receptor signaling pathway,GO:0038061~NIK/NF-kappaB signaling,GO:0039535~regulation of RIG-I signaling pathway,GO:0042127~regulation of cell proliferation,GO:0042981~regulation of apoptotic process,GO:0043066~negative regulation of apoptotic process,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0045088~regulation of innate immune response,GO:0045471~response to ethanol,GO:0045595~regulation of cell differentiation,GO:0045893~positive regulation of transcription, DNA-templated,GO:0050727~regulation of inflammatory response,GO:0051591~response to cAMP,GO:0051726~regulation of cell cycle,GO:0060544~regulation of necroptotic process,GO:0060546~negative regulation of necroptotic process,GO:0070266~necroptotic process,GO:0070424~regulation of nucleotide-binding oligomerization domain containing signaling pathway,GO:1901222~regulation of NIK/NF-kappaB signaling,GO:1902443~negative regulation of ripoptosome assembly involved in necroptotic process,GO:1902523~positive regulation of protein K63-linked ubiquitination,GO:1902524~positive regulation of protein K48-linked ubiquitination,GO:1902527~positive regulation of protein monoubiquitination,GO:2000116~regulation of cysteine-type endopeptidase activity,GO:2000377~regulation of reactive oxygen species metabolic process,	GO:0001741~XY body,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0009898~cytoplasmic side of plasma membrane,GO:0035631~CD40 receptor complex,	GO:0003713~transcription coactivator activity,GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0016740~transferase activity,GO:0042802~identical protein binding,GO:0043027~cysteine-type endopeptidase inhibitor activity involved in apoptotic process,GO:0043130~ubiquitin binding,GO:0044877~macromolecular complex binding,GO:0046872~metal ion binding,GO:0051087~chaperone binding,GO:0061630~ubiquitin protein ligase activity,GO:0098770~FBXO family protein binding,	IPR001315:CARD,IPR001370:BIR_rpt,IPR001841:Znf_RING,IPR011029:DEATH-like_dom_sf,IPR013083:Znf_RING/FYVE/PHD,IPR041933:BIRC2/BIRC3_UBA,IPR048875:BIRC2-3-like_UBA,	hsa01524:Platinum drug resistance,hsa04064:NF-kappa B signaling pathway,hsa04120:Ubiquitin mediated proteolysis,hsa04210:Apoptosis,hsa04215:Apoptosis - multiple species,hsa04217:Necroptosis,hsa04390:Hippo signaling pathway,hsa04510:Focal adhesion,hsa04621:NOD-like receptor signaling pathway,hsa04668:TNF signaling pathway,hsa05132:Salmonella infection,hsa05145:Toxoplasmosis,hsa05168:Herpes simplex virus 1 infection,hsa05200:Pathways in cancer,hsa05202:Transcriptional misregulation in cancer,hsa05222:Small cell lung cancer,			SM00114:CARD,SM00184:RING,SM00238:BIR,	KW-0053~Apoptosis,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0808~Transferase,	KW-0832~Ubl conjugation,	DOMAIN:CARD,DOMAIN:RING-type,REGION:Disordered,REPEAT:BIR 1,REPEAT:BIR 2,REPEAT:BIR 3,ZN_FING:RING-type,
BIRC3	baculoviral IAP repeat containing 3(BIRC3)	Homo sapiens		h_caspasePathway:Caspase Cascade in Apoptosis,h_deathPathway:Induction of apoptosis through DR3 and DR4/5 Death Receptors ,h_hivnefPathway:HIV-I Nef: negative effector of Fas and TNF,h_mitochondriaPathway:Role of Mitochondria in Apoptotic Signaling,h_soddPathway:SODD/TNFR1 Signaling Pathway,	GO:0006915~apoptotic process,GO:0007166~cell surface receptor signaling pathway,GO:0007249~I-kappaB kinase/NF-kappaB signaling,GO:0007283~spermatogenesis,GO:0031398~positive regulation of protein ubiquitination,GO:0033209~tumor necrosis factor-mediated signaling pathway,GO:0034121~regulation of toll-like receptor signaling pathway,GO:0038061~NIK/NF-kappaB signaling,GO:0039535~regulation of RIG-I signaling pathway,GO:0042981~regulation of apoptotic process,GO:0043066~negative regulation of apoptotic process,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0045088~regulation of innate immune response,GO:0050727~regulation of inflammatory response,GO:0051726~regulation of cell cycle,GO:0060544~regulation of necroptotic process,GO:0060546~negative regulation of necroptotic process,GO:0070424~regulation of nucleotide-binding oligomerization domain containing signaling pathway,GO:2000116~regulation of cysteine-type endopeptidase activity,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0032991~macromolecular complex,	GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0016740~transferase activity,GO:0043027~cysteine-type endopeptidase inhibitor activity involved in apoptotic process,GO:0044877~macromolecular complex binding,GO:0046872~metal ion binding,GO:0061630~ubiquitin protein ligase activity,	IPR001315:CARD,IPR001370:BIR_rpt,IPR001841:Znf_RING,IPR011029:DEATH-like_dom_sf,IPR048875:BIRC2-3-like_UBA,	hsa01524:Platinum drug resistance,hsa04064:NF-kappa B signaling pathway,hsa04120:Ubiquitin mediated proteolysis,hsa04210:Apoptosis,hsa04215:Apoptosis - multiple species,hsa04217:Necroptosis,hsa04390:Hippo signaling pathway,hsa04510:Focal adhesion,hsa04621:NOD-like receptor signaling pathway,hsa04668:TNF signaling pathway,hsa05132:Salmonella infection,hsa05145:Toxoplasmosis,hsa05168:Herpes simplex virus 1 infection,hsa05200:Pathways in cancer,hsa05202:Transcriptional misregulation in cancer,hsa05222:Small cell lung cancer,			SM00114:CARD,SM00184:RING,SM00238:BIR,	KW-0053~Apoptosis,KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0808~Transferase,	KW-0832~Ubl conjugation,	DOMAIN:CARD,DOMAIN:RING-type,REPEAT:BIR 1,REPEAT:BIR 2,REPEAT:BIR 3,SITE:Breakpoint for translocation to form BIRC3-MALT1,ZN_FING:RING-type,
BIRC6	baculoviral IAP repeat containing 6(BIRC6)	Homo sapiens			GO:0006468~protein phosphorylation,GO:0006915~apoptotic process,GO:0007049~cell cycle,GO:0008283~cell proliferation,GO:0008284~positive regulation of cell proliferation,GO:0016567~protein ubiquitination,GO:0032465~regulation of cytokinesis,GO:0042127~regulation of cell proliferation,GO:0042981~regulation of apoptotic process,GO:0043066~negative regulation of apoptotic process,GO:0051301~cell division,GO:0060711~labyrinthine layer development,GO:0060712~spongiotrophoblast layer development,GO:2001237~negative regulation of extrinsic apoptotic signaling pathway,	GO:0000922~spindle pole,GO:0005634~nucleus,GO:0005768~endosome,GO:0005802~trans-Golgi network,GO:0005813~centrosome,GO:0005815~microtubule organizing center,GO:0005829~cytosol,GO:0016020~membrane,GO:0030496~midbody,GO:0090543~Flemming body,	GO:0004842~ubiquitin-protein transferase activity,GO:0004869~cysteine-type endopeptidase inhibitor activity,GO:0005515~protein binding,GO:0061631~ubiquitin conjugating enzyme activity,	IPR000608:UBQ-conjugat_E2,IPR001370:BIR_rpt,IPR016135:UBQ-conjugating_enzyme/RWD,IPR022103:BIRC6,	hsa04120:Ubiquitin mediated proteolysis,hsa04140:Autophagy - animal,hsa04215:Apoptosis - multiple species,			SM00212:UBCc,SM00238:BIR,	KW-0053~Apoptosis,KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,KW-0833~Ubl conjugation pathway,	KW-0206~Cytoskeleton,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0967~Endosome,		KW-0175~Coiled coil,		KW-0646~Protease inhibitor,KW-0789~Thiol protease inhibitor,KW-0808~Transferase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	ACT_SITE:Glycyl thioester intermediate,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:UBC core,REGION:Disordered,REPEAT:BIR,
BHLHE40	basic helix-loop-helix family member e40(BHLHE40)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007623~circadian rhythm,GO:0009952~anterior/posterior pattern specification,GO:0032922~circadian regulation of gene expression,GO:0042752~regulation of circadian rhythm,GO:0043153~entrainment of circadian clock by photoperiod,GO:0043433~negative regulation of sequence-specific DNA binding transcription factor activity,GO:0045892~negative regulation of transcription, DNA-templated,GO:0050767~regulation of neurogenesis,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0016604~nuclear body,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0019904~protein domain specific binding,GO:0042803~protein homodimerization activity,GO:0043425~bHLH transcription factor binding,GO:0043426~MRF binding,GO:0046982~protein heterodimerization activity,GO:0046983~protein dimerization activity,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:0070888~E-box binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR003650:Orange_dom,IPR011598:bHLH_dom,IPR036638:HLH_DNA-bd_sf,	hsa04710:Circadian rhythm,			SM00353:HLH,SM00511:ORANGE,	KW-0090~Biological rhythms,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0238~DNA-binding,KW-0678~Repressor,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1, SUMO2 and SUMO3),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1, SUMO2 and SUMO3); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:BHLH,DOMAIN:Orange,DOMAIN:bHLH,MUTAGEN:H->A: No effect on its interaction with BMAL1 or its repressor activity against the CLOCK-BMAL1 heterodimer. Significant reduction in E-box binding.,MUTAGEN:K->R: Partial loss of sumoylation. Complete loss of sumoylation; when associated with R-159.,MUTAGEN:K->R: Partial loss of sumoylation. Complete loss of sumoylation; when associated with R-279.,MUTAGEN:LL->AA: Abolishes RXRA repression.,MUTAGEN:P->A: No loss of repressor activity against NR0B2.,MUTAGEN:R->A: Loss of interaction with BMAL1 and E-box binding. Significant reduction in its repressor activity against the CLOCK-BMAL1 heterodimer.,MUTAGEN:R->A: Loss of repressor activity against NR0B2.,REGION:Disordered,REGION:Essential for interaction with BMAL1, E-box binding and repressor activity against the CLOCK-BMAL1 heterodimer,REGION:Necessary for interaction with RXRA and repressor activity against RXRA,
BTF3L4	basic transcription factor 3 like 4(BTF3L4)	Homo sapiens					GO:0005515~protein binding,	IPR002715:Nas_poly-pep-assoc_cplx_dom,IPR038187:NAC_A/B_dom_sf,IPR039370:BTF3,				SM01407:NAC,							KW-0488~Methylation,KW-0597~Phosphoprotein,	DOMAIN:NAC-A/B,REGION:Disordered,
BSG	basigin (Ok blood group)(BSG)	Homo sapiens			GO:0001525~angiogenesis,GO:0003407~neural retina development,GO:0007155~cell adhesion,GO:0007166~cell surface receptor signaling pathway,GO:0007411~axon guidance,GO:0007566~embryo implantation,GO:0010575~positive regulation of vascular endothelial growth factor production,GO:0010595~positive regulation of endothelial cell migration,GO:0030593~neutrophil chemotaxis,GO:0032755~positive regulation of interleukin-6 production,GO:0042475~odontogenesis of dentin-containing tooth,GO:0043434~response to peptide hormone,GO:0045494~photoreceptor cell maintenance,GO:0046598~positive regulation of viral entry into host cell,GO:0046689~response to mercury ion,GO:0046697~decidualization,GO:0046718~viral entry into host cell,GO:0051591~response to cAMP,GO:0061154~endothelial tube morphogenesis,GO:0072659~protein localization to plasma membrane,GO:1904466~positive regulation of matrix metallopeptidase secretion,	GO:0000139~Golgi membrane,GO:0001750~photoreceptor outer segment,GO:0001917~photoreceptor inner segment,GO:0002080~acrosomal membrane,GO:0005739~mitochondrion,GO:0005768~endosome,GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0016020~membrane,GO:0016323~basolateral plasma membrane,GO:0042383~sarcolemma,GO:0042470~melanosome,GO:0043231~intracellular membrane-bounded organelle,GO:0070062~extracellular exosome,	GO:0001618~virus receptor activity,GO:0005515~protein binding,GO:0005537~mannose binding,GO:0038023~signaling receptor activity,GO:0045296~cadherin binding,	IPR003598:Ig_sub2,IPR003599:Ig_sub,IPR007110:Ig-like_dom,IPR013783:Ig-like_fold,IPR036179:Ig-like_dom_sf,IPR043204:Basigin-like,	hsa04148:Efferocytosis,	111380~Blood group, OK,		SM00408:IGc2,SM00409:IG,	KW-0037~Angiogenesis,KW-0945~Host-virus interaction,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0966~Cell projection,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0430~Lectin,KW-0465~Mannose-binding,	KW-0095~Blood group antigen,KW-0675~Receptor,KW-1183~Host cell receptor for virus entry,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type,DOMAIN:Ig-like V-type,MUTAGEN:C->M: Loss of ability to stimulate interleukin-6 secretion.,MUTAGEN:D->A: Reduced interaction with KDR/VEGFR2.,MUTAGEN:D->E: No effect on the interaction with P.falciparum RH5.,MUTAGEN:F->L: Severe reduction in the interaction with P.falciparum RH5.,MUTAGEN:H->HH: Severe reduction in the interaction with P.falciparum RH5.,MUTAGEN:K->E: No effect on the interaction with P.falciparum RH5.,MUTAGEN:N->D: No effect on the interaction with P.falciparum RH5; when associated with D-160 and D-268.,MUTAGEN:N->D: No effect on the interaction with P.falciparum RH5; when associated with D-160 and D-302.,MUTAGEN:N->D: No effect on the interaction with P.falciparum RH5; when associated with D-268 and D-302.,MUTAGEN:P->A: Loss of interaction with PPIL2.,MUTAGEN:PG->AA: Loss of its ability to mediate chemotactic activity of PPIA/CYPA.,MUTAGEN:Q->A: Reduced interaction with KDR/VEGFR2. Complete loss of interaction with KDR/VEGFR2 when associated with A-199.,MUTAGEN:Q->A: Reduced interaction with KDR/VEGFR2. Significant loss of interaction with KDR/VEGFR2; when associated with A-184.,MUTAGEN:Q->K: Severe reduction in the interaction with P.falciparum RH5.,MUTAGEN:R->A: Reduced interaction with KDR/VEGFR2. Significant loss of interaction with KDR/VEGFR2; when associated with A-182.,MUTAGEN:T->A: Reduced interaction with KDR/VEGFR2. Complete loss of interaction with KDR/VEGFR2; when associated with A-195.,REGION:Disordered,REGION:Essential for interaction with KDR/VEGFR2,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
B4GALT3	beta-1,4-galactosyltransferase 3(B4GALT3)	Homo sapiens			GO:0005975~carbohydrate metabolic process,GO:0006486~protein glycosylation,GO:0006682~galactosylceramide biosynthetic process,GO:0070085~glycosylation,	GO:0000139~Golgi membrane,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0016020~membrane,GO:0032580~Golgi cisterna membrane,GO:0070062~extracellular exosome,	GO:0003831~beta-N-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase activity,GO:0003945~N-acetyllactosamine synthase activity,GO:0008378~galactosyltransferase activity,GO:0016757~transferase activity, transferring glycosyl groups,GO:0046872~metal ion binding,	IPR003859:Galactosyl_T,IPR027791:Galactosyl_T_C,IPR027995:Galactosyl_T_N,IPR029044:Nucleotide-diphossugar_trans,	hsa00510:N-Glycan biosynthesis,hsa00513:Various types of N-glycan biosynthesis,hsa00514:Other types of O-glycan biosynthesis,hsa00515:Mannose type O-glycan biosynthesis,hsa00533:Glycosaminoglycan biosynthesis - keratan sulfate,hsa00601:Glycosphingolipid biosynthesis - lacto and neolacto series,hsa01100:Metabolic pathways,				KW-0443~Lipid metabolism,	KW-0333~Golgi apparatus,KW-0472~Membrane,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0464~Manganese,KW-0479~Metal-binding,	KW-0328~Glycosyltransferase,KW-0808~Transferase,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:Galactosyltransferase C-terminal,DOMAIN:Galactosyltransferase N-terminal,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
B2M	beta-2-microglobulin(B2M)	Homo sapiens		h_ctlPathway:CTL mediated immune response against target cells ,h_mhcPathway:Antigen Processing and Presentation,h_nkcellsPathway:Ras-Independent pathway in NK cell-mediated cytotoxicity,	GO:0001913~T cell mediated cytotoxicity,GO:0001916~positive regulation of T cell mediated cytotoxicity,GO:0002237~response to molecule of bacterial origin,GO:0002474~antigen processing and presentation of peptide antigen via MHC class I,GO:0002481~antigen processing and presentation of exogenous protein antigen via MHC class Ib, TAP-dependent,GO:0002502~peptide antigen assembly with MHC class I protein complex,GO:0002503~peptide antigen assembly with MHC class II protein complex,GO:0002726~positive regulation of T cell cytokine production,GO:0006826~iron ion transport,GO:0006879~cellular iron ion homeostasis,GO:0006955~immune response,GO:0007608~sensory perception of smell,GO:0007611~learning or memory,GO:0010977~negative regulation of neuron projection development,GO:0019885~antigen processing and presentation of endogenous peptide antigen via MHC class I,GO:0019886~antigen processing and presentation of exogenous peptide antigen via MHC class II,GO:0032092~positive regulation of protein binding,GO:0033077~T cell differentiation in thymus,GO:0034756~regulation of iron ion transport,GO:0042026~protein refolding,GO:0045646~regulation of erythrocyte differentiation,GO:0048260~positive regulation of receptor-mediated endocytosis,GO:0050680~negative regulation of epithelial cell proliferation,GO:0050768~negative regulation of neurogenesis,GO:0050778~positive regulation of immune response,GO:0050870~positive regulation of T cell activation,GO:0051289~protein homotetramerization,GO:0060586~multicellular organismal iron ion homeostasis,GO:0071281~cellular response to iron ion,GO:0071283~cellular response to iron(III) ion,GO:0071316~cellular response to nicotine,GO:1900121~negative regulation of receptor binding,GO:1900122~positive regulation of receptor binding,GO:1904434~positive regulation of ferrous iron binding,GO:1904437~positive regulation of transferrin receptor binding,GO:1990000~amyloid fibril formation,GO:2000774~positive regulation of cellular senescence,GO:2000978~negative regulation of forebrain neuron differentiation,	GO:0000139~Golgi membrane,GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005765~lysosomal membrane,GO:0005783~endoplasmic reticulum,GO:0005788~endoplasmic reticulum lumen,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0009897~external side of plasma membrane,GO:0012507~ER to Golgi transport vesicle membrane,GO:0016020~membrane,GO:0030670~phagocytic vesicle membrane,GO:0031901~early endosome membrane,GO:0031902~late endosome membrane,GO:0031905~early endosome lumen,GO:0035580~specific granule lumen,GO:0042612~MHC class I protein complex,GO:0042613~MHC class II protein complex,GO:0042824~MHC class I peptide loading complex,GO:0055038~recycling endosome membrane,GO:0070062~extracellular exosome,GO:1904724~tertiary granule lumen,GO:1990712~HFE-transferrin receptor complex,	GO:0005198~structural molecule activity,GO:0005515~protein binding,GO:0023026~MHC class II protein complex binding,GO:0042605~peptide antigen binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,	IPR003006:Ig/MHC_CS,IPR003597:Ig_C1-set,IPR003599:Ig_sub,IPR007110:Ig-like_dom,IPR013106:Ig_V-set,IPR013783:Ig-like_fold,IPR015370:TCR_alpha_C,IPR015707:B2Microglobulin,IPR036179:Ig-like_dom_sf,	hsa04612:Antigen processing and presentation,hsa05163:Human cytomegalovirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,	105200~Amyloidosis, familial visceral,241600~Immunodeficiency 43,		SM00406:IGv,SM00407:IGc1,SM00409:IG,	KW-0391~Immunity,	KW-0034~Amyloid,KW-0490~MHC I,KW-0964~Secreted,	KW-0225~Disease variant,KW-1008~Amyloidosis,	KW-0393~Immunoglobulin domain,KW-0732~Signal,			KW-0325~Glycoprotein,KW-0873~Pyrrolidone carboxylic acid,KW-0971~Glycation,KW-1015~Disulfide bond,	CARBOHYD:N-linked (Glc) (glycation) isoleucine; in hemodialysis-associated amyloidosis,CARBOHYD:N-linked (Glc) (glycation) lysine; in vitro,DOMAIN:Ig-like,DOMAIN:Ig-like C1-type,DOMAIN:Immunoglobulin C1-set,MUTAGEN:D->P: Increases tendency towards amyloid formation.,MUTAGEN:W->G: Decreases tendency towards amyloid formation.,MUTAGEN:W->V: Increases tendency towards amyloid formation.,
BFAR	bifunctional apoptosis regulator(BFAR)	Homo sapiens			GO:0000209~protein polyubiquitination,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0006915~apoptotic process,GO:0043066~negative regulation of apoptotic process,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0051865~protein autoubiquitination,GO:0070534~protein K63-linked ubiquitination,GO:0070936~protein K48-linked ubiquitination,GO:1903895~negative regulation of IRE1-mediated unfolded protein response,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0016020~membrane,	GO:0005515~protein binding,GO:0030674~protein binding, bridging,GO:0046872~metal ion binding,GO:0061630~ubiquitin protein ligase activity,GO:0089720~caspase binding,	IPR001660:SAM,IPR001841:Znf_RING,IPR013083:Znf_RING/FYVE/PHD,IPR013761:SAM/pointed_sf,IPR017907:Znf_RING_CS,				SM00184:RING,SM00454:SAM,	KW-0053~Apoptosis,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0812~Transmembrane,KW-0863~Zinc-finger,KW-1133~Transmembrane helix,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:RING-type,DOMAIN:SAM,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,ZN_FING:RING-type,
BLOC1S6	biogenesis of lysosomal organelles complex 1 subunit 6(BLOC1S6)	Homo sapiens		h_AnthraxPathway:Anthrax Toxin Mechanism of Action,	GO:0007596~blood coagulation,GO:0008089~anterograde axonal transport,GO:0016081~synaptic vesicle docking,GO:0030318~melanocyte differentiation,GO:0031175~neuron projection development,GO:0032402~melanosome transport,GO:0032438~melanosome organization,GO:0032816~positive regulation of natural killer cell activation,GO:0033299~secretion of lysosomal enzymes,GO:0035646~endosome to melanosome transport,GO:0046907~intracellular transport,GO:0048490~anterograde synaptic vesicle transport,GO:0050942~positive regulation of pigment cell differentiation,GO:0061025~membrane fusion,	GO:0005737~cytoplasm,GO:0005768~endosome,GO:0005829~cytosol,GO:0016020~membrane,GO:0030133~transport vesicle,GO:0031083~BLOC-1 complex,GO:0031201~SNARE complex,GO:0043227~membrane-bounded organelle,GO:0098793~presynapse,GO:1904115~axon cytoplasm,	GO:0005515~protein binding,GO:0019905~syntaxin binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0051015~actin filament binding,	IPR017242:BLOC-1_pallidin,IPR028119:Snapin/Pallidin/Snn1,		614171~Hermansky-Pudlak syndrome 9,	PIRSF037609:BLOC-1_complex_pallidin,			KW-0472~Membrane,KW-0963~Cytoplasm,	KW-0015~Albinism,KW-0225~Disease variant,KW-0363~Hermansky-Pudlak syndrome,	KW-0175~Coiled coil,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,
BRIX1	biogenesis of ribosomes BRX1(BRIX1)	Homo sapiens			GO:0000027~ribosomal large subunit assembly,GO:0006364~rRNA processing,	GO:0005694~chromosome,GO:0005730~nucleolus,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0019843~rRNA binding,	IPR007109:Brix,IPR026532:BRX1,				SM00879:Brix,	KW-0690~Ribosome biogenesis,	KW-0539~Nucleus,					KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Brix,REGION:Disordered,
BOD1L1	biorientation of chromosomes in cell division 1 like 1(BOD1L1)	Homo sapiens			GO:0006281~DNA repair,GO:0006974~cellular response to DNA damage stimulus,GO:0007049~cell cycle,GO:0031297~replication fork processing,GO:0051301~cell division,	GO:0005654~nucleoplasm,GO:0005694~chromosome,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0048188~Set1C/COMPASS complex,	GO:0005515~protein binding,	IPR026955:Bod1-like,IPR043244:BOD1L1,					KW-0227~DNA damage,KW-0234~DNA repair,	KW-0158~Chromosome,KW-0206~Cytoskeleton,KW-0963~Cytoplasm,					KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DNA_BIND:A.T hook,REGION:Disordered,
BST2	bone marrow stromal cell antigen 2(BST2)	Homo sapiens			GO:0002737~negative regulation of plasmacytoid dendritic cell cytokine production,GO:0009615~response to virus,GO:0030308~negative regulation of cell growth,GO:0030336~negative regulation of cell migration,GO:0032956~regulation of actin cytoskeleton organization,GO:0034341~response to interferon-gamma,GO:0035455~response to interferon-alpha,GO:0035456~response to interferon-beta,GO:0042113~B cell activation,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0045071~negative regulation of viral genome replication,GO:0045087~innate immune response,GO:0051607~defense response to virus,GO:0070665~positive regulation of leukocyte proliferation,GO:1901253~negative regulation of intracellular transport of viral material,	GO:0005737~cytoplasm,GO:0005771~multivesicular body,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,GO:0016324~apical plasma membrane,GO:0035577~azurophil granule membrane,GO:0043231~intracellular membrane-bounded organelle,GO:0045121~membrane raft,GO:0070062~extracellular exosome,GO:0098552~side of membrane,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0008191~metalloendopeptidase inhibitor activity,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,	IPR024886:BST2,	hsa03250:Viral life cycle - HIV-1,hsa05168:Herpes simplex virus 1 infection,hsa05170:Human immunodeficiency virus 1 infection,				KW-0051~Antiviral defense,KW-0075~B-cell activation,KW-0391~Immunity,KW-0399~Innate immunity,KW-0945~Host-virus interaction,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0175~Coiled coil,KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0336~GPI-anchor,KW-0449~Lipoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,KW-1017~Isopeptide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DISULFID:Interchain,LIPID:GPI-anchor amidated serine,MUTAGEN:C->A: Prevents homodimerization and inhibition of SARS-CoV, HCoV-229E, and HIV-1 viral particles production ex vivo; when associated with A-53 and A-63.,MUTAGEN:C->A: Prevents homodimerization and inhibition of SARS-CoV, HCoV-229E, and HIV-1 viral particles production ex vivo; when associated with A-53 and A-91.,MUTAGEN:C->A: Prevents homodimerization and inhibition of SARS-CoV, HCoV-229E, and HIV-1 viral particles production ex vivo; when associated with A-63 and A-91.,MUTAGEN:K->R: Abolishes redistribution to late endosomes in cells expressing KSH virus E3 ubiquitin-protein ligase K5.,MUTAGEN:K->R: No effect on redistribution to late endosomes in cells expressing KSH virus E3 ubiquitin-protein ligase K5.,MUTAGEN:N->A: Loss of glycosylation site.,MUTAGEN:N->A: Loss of glycosylation site. Impairs anti-viral activity.,MUTAGEN:STS->AAA: Partial resistance to Vpu.,MUTAGEN:Y->A: Partial resistance to Vpu and significantly reduced activation of NF-kB; when associated with A-6.,MUTAGEN:Y->A: Partial resistance to Vpu and significantly reduced activation of NF-kB; when associated with A-8.,PROPEP:Removed in mature form,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
BIN1	bridging integrator 1(BIN1)	Homo sapiens	62.G1-phase_progression_by_Myc,		GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006897~endocytosis,GO:0006997~nucleus organization,GO:0007010~cytoskeleton organization,GO:0008333~endosome to lysosome transport,GO:0010564~regulation of cell cycle process,GO:0030100~regulation of endocytosis,GO:0030838~positive regulation of actin filament polymerization,GO:0033292~T-tubule organization,GO:0043065~positive regulation of apoptotic process,GO:0045664~regulation of neuron differentiation,GO:0045807~positive regulation of endocytosis,GO:0048488~synaptic vesicle endocytosis,GO:0048711~positive regulation of astrocyte differentiation,GO:0051647~nucleus localization,GO:0060988~lipid tube assembly,GO:0086091~regulation of heart rate by cardiac conduction,GO:1901380~negative regulation of potassium ion transmembrane transport,GO:1902430~negative regulation of beta-amyloid formation,GO:1902960~negative regulation of aspartic-type endopeptidase activity involved in amyloid precursor protein catabolic process,GO:1903946~negative regulation of ventricular cardiac muscle cell action potential,GO:1904878~negative regulation of calcium ion transmembrane transport via high voltage-gated calcium channel,	GO:0005634~nucleus,GO:0005635~nuclear envelope,GO:0005737~cytoplasm,GO:0005768~endosome,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0008021~synaptic vesicle,GO:0015629~actin cytoskeleton,GO:0016020~membrane,GO:0030018~Z disc,GO:0030315~T-tubule,GO:0030424~axon,GO:0030425~dendrite,GO:0031674~I band,GO:0031982~vesicle,GO:0033268~node of Ranvier,GO:0043194~axon initial segment,GO:0043196~varicosity,GO:0043679~axon terminus,GO:0044300~cerebellar mossy fiber,GO:0060987~lipid tube,GO:0090571~RNA polymerase II transcription repressor complex,GO:0098850~extrinsic component of synaptic vesicle membrane,GO:0098978~glutamatergic synapse,	GO:0002020~protease binding,GO:0005515~protein binding,GO:0005543~phospholipid binding,GO:0019828~aspartic-type endopeptidase inhibitor activity,GO:0030276~clathrin binding,GO:0042802~identical protein binding,GO:0048156~tau protein binding,GO:0051015~actin filament binding,GO:0051020~GTPase binding,GO:0051087~chaperone binding,GO:0070063~RNA polymerase binding,	IPR001452:SH3_domain,IPR003005:Amphiphysin,IPR003023:Amphiphysin_2,IPR004148:BAR_dom,IPR027267:AH/BAR_dom_sf,IPR035471:Amphiphysin-2_SH3,IPR036028:SH3-like_dom_sf,	hsa04144:Endocytosis,hsa04666:Fc gamma R-mediated phagocytosis,	255200~Centronuclear myopathy 2,		SM00326:SH3,SM00721:BAR,	KW-0221~Differentiation,KW-0254~Endocytosis,KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0967~Endosome,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0175~Coiled coil,KW-0728~SH3 domain,		KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:BAR,DOMAIN:SH3,REGION:Clathrin-binding,REGION:Disordered,REGION:Interaction with BIN2,
BPTF	bromodomain PHD finger transcription factor(BPTF)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001892~embryonic placenta development,GO:0006338~chromatin remodeling,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007420~brain development,GO:0007492~endoderm development,GO:0009952~anterior/posterior pattern specification,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:1990090~cellular response to nerve growth factor stimulus,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0016589~NURF complex,GO:0030425~dendrite,GO:0044297~cell body,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,GO:1904949~ATPase complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0005515~protein binding,GO:0008094~DNA-dependent ATPase activity,GO:0035064~methylated histone binding,GO:0043565~sequence-specific DNA binding,GO:0046872~metal ion binding,	IPR001487:Bromodomain,IPR001965:Znf_PHD,IPR011011:Znf_FYVE_PHD,IPR013083:Znf_RING/FYVE/PHD,IPR018359:Bromodomain_CS,IPR018501:DDT_dom,IPR019786:Zinc_finger_PHD-type_CS,IPR019787:Znf_PHD-finger,IPR028941:WHIM2_dom,IPR036427:Bromodomain-like_sf,IPR038028:BPTF,	hsa03082:ATP-dependent chromatin remodeling,	617755~Neurodevelopmental disorder with dysmorphic facies and distal limb anomalies,		SM00249:PHD,SM00297:BROMO,SM00571:DDT,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0991~Intellectual disability,	KW-0103~Bromodomain,KW-0175~Coiled coil,KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0156~Chromatin regulator,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Bromo,DOMAIN:DDT,DOMAIN:PHD-type,MUTAGEN:D->N,A: Abolishes binding to histone H3K4me3.,MUTAGEN:G->E,L: Strongly reduces binding to histone H3K4me3.,MUTAGEN:Q->K: Strongly reduces binding to histone H3K4me3.,MUTAGEN:W->E,F: Abolishes binding to histone H3K4me3.,MUTAGEN:Y->E: Induces binding to histone H3K4me2.,MUTAGEN:Y->S: Abolishes binding to histone H3K4me3.,MUTAGEN:Y->T: Abolishes binding to histone H3K4me3.,MUTAGEN:Y->T: Strongly reduces binding to histone H3K4me3.,REGION:Disordered,REGION:Interaction with KEAP1,REGION:Interaction with MAZ,SITE:Histone H3K4me3 binding,ZN_FING:PHD-type 1,ZN_FING:PHD-type 2,
BAZ1B	bromodomain adjacent to zinc finger domain 1B(BAZ1B)	Homo sapiens		h_vdrPathway:Control of Gene Expression by Vitamin D Receptor,	GO:0006338~chromatin remodeling,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006974~cellular response to DNA damage stimulus,GO:0016310~phosphorylation,GO:0035066~positive regulation of histone acetylation,GO:0043687~post-translational protein modification,GO:0045943~positive regulation of transcription from RNA polymerase I promoter,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0045945~positive regulation of transcription from RNA polymerase III promoter,GO:1905213~negative regulation of mitotic chromosome condensation,	GO:0000793~condensed chromosome,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005721~pericentric heterochromatin,GO:0005730~nucleolus,GO:0043596~nuclear replication fork,GO:0090535~WICH complex,	GO:0004715~non-membrane spanning protein tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008270~zinc ion binding,GO:0035173~histone kinase activity,GO:0042393~histone binding,	IPR001487:Bromodomain,IPR001841:Znf_RING,IPR001965:Znf_PHD,IPR011011:Znf_FYVE_PHD,IPR013083:Znf_RING/FYVE/PHD,IPR013136:WSTF_Acf1_Cbp146,IPR018359:Bromodomain_CS,IPR018501:DDT_dom,IPR019786:Zinc_finger_PHD-type_CS,IPR019787:Znf_PHD-finger,IPR028941:WHIM2_dom,IPR028942:WHIM1_dom,IPR036427:Bromodomain-like_sf,IPR037375:BAZ1B_Bromo,IPR047174:BAZ1B,IPR047256:BAZ1B_PHD,	hsa03082:ATP-dependent chromatin remodeling,			SM00249:PHD,SM00297:BROMO,SM00571:DDT,	KW-0227~DNA damage,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0856~Williams-Beuren syndrome,	KW-0103~Bromodomain,KW-0175~Coiled coil,KW-0863~Zinc-finger,	KW-0067~ATP-binding,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,KW-0862~Zinc,	KW-0418~Kinase,KW-0808~Transferase,KW-0829~Tyrosine-protein kinase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:Bromo,DOMAIN:DDT,DOMAIN:WAC,MOTIF:C motif,MUTAGEN:C->A: Loss of tyrosine-protein kinase activity.,REGION:Disordered,ZN_FING:PHD-type,
BAZ2A	bromodomain adjacent to zinc finger domain 2A(BAZ2A)	Homo sapiens			GO:0000183~chromatin silencing at rDNA,GO:0001188~RNA polymerase I transcriptional preinitiation complex assembly,GO:0006306~DNA methylation,GO:0006338~chromatin remodeling,GO:0006351~transcription, DNA-templated,GO:0006355~regulation of transcription, DNA-templated,GO:0016479~negative regulation of transcription from RNA polymerase I promoter,GO:0031062~positive regulation of histone methylation,GO:0031065~positive regulation of histone deacetylation,GO:0031507~heterochromatin assembly,GO:0044030~regulation of DNA methylation,	GO:0005634~nucleus,GO:0005677~chromatin silencing complex,GO:0005730~nucleolus,GO:0005829~cytosol,GO:0016607~nuclear speck,GO:0033553~rDNA heterochromatin,GO:0090536~NoRC complex,	GO:0001164~RNA polymerase I CORE element sequence-specific DNA binding,GO:0003677~DNA binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0016922~ligand-dependent nuclear receptor binding,GO:0042393~histone binding,GO:0046872~metal ion binding,GO:0070577~lysine-acetylated histone binding,	IPR001487:Bromodomain,IPR001739:Methyl_CpG_DNA-bd,IPR001965:Znf_PHD,IPR011011:Znf_FYVE_PHD,IPR013083:Znf_RING/FYVE/PHD,IPR016177:DNA-bd_dom_sf,IPR017956:AT_hook_DNA-bd_motif,IPR018359:Bromodomain_CS,IPR018501:DDT_dom,IPR019787:Znf_PHD-finger,IPR028940:PHD_BAZ2A,IPR028941:WHIM2_dom,IPR028942:WHIM1_dom,IPR036427:Bromodomain-like_sf,IPR037374:BAZ2A/B_Bromo,	hsa03082:ATP-dependent chromatin remodeling,			SM00249:PHD,SM00297:BROMO,SM00384:AT_hook,SM00391:MBD,SM00571:DDT,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0103~Bromodomain,KW-0175~Coiled coil,KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0156~Chromatin regulator,KW-0238~DNA-binding,KW-0678~Repressor,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DNA_BIND:A.T hook 1,DNA_BIND:A.T hook 2,DNA_BIND:A.T hook 3,DNA_BIND:A.T hook 4,DOMAIN:Bromo,DOMAIN:DDT,DOMAIN:MBD,DOMAIN:PHD-type,DOMAIN:WHIM2,REGION:Disordered,ZN_FING:PHD-type,
CMIP	c-Maf inducing protein(CMIP)	Homo sapiens			GO:0001701~in utero embryonic development,	GO:0005654~nucleoplasm,GO:0005829~cytosol,	GO:0005515~protein binding,	IPR032675:LRR_dom_sf,						KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0433~Leucine-rich repeat,KW-0677~Repeat,			KW-0597~Phosphoprotein,	DOMAIN:PH,REGION:Disordered,REPEAT:LRR 1,REPEAT:LRR 2,REPEAT:LRR 3,REPEAT:LRR 4,
ARPP19	cAMP regulated phosphoprotein 19(ARPP19)	Homo sapiens			GO:0000086~G2/M transition of mitotic cell cycle,GO:0000278~mitotic cell cycle,GO:0007049~cell cycle,GO:0035308~negative regulation of protein dephosphorylation,GO:0045722~positive regulation of gluconeogenesis,GO:0046326~positive regulation of glucose import,GO:0051301~cell division,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,	GO:0004864~protein phosphatase inhibitor activity,GO:0005102~receptor binding,GO:0005515~protein binding,GO:0015459~potassium channel regulator activity,GO:0019212~phosphatase inhibitor activity,GO:0019888~protein phosphatase regulator activity,GO:0051721~protein phosphatase 2A binding,	IPR006760:Endosulphine,					KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,	KW-0963~Cytoplasm,				KW-0650~Protein phosphatase inhibitor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,
CREB1	cAMP responsive element binding protein 1(CREB1)	Homo sapiens		h_arenrf2Pathway:Oxidative Stress Induced Gene Expression Via Nrf2,h_CaCaMPathway:Ca++/ Calmodulin-dependent Protein Kinase Activation,h_carm1Pathway:Transcription Regulation by Methyltransferase of CARM1,h_crebPathway:Transcription factor CREB and its extracellular signals,h_dreamPathway:Repression of Pain Sensation by the Transcriptional Regulator DREAM,h_erk5Pathway:Role of Erk5 in Neuronal Survival,h_gpcrPathway:Signaling Pathway from G-Protein Families,h_hbxPathway:Calcium Signaling by HBx of Hepatitis B virus,h_hcmvPathway:Human Cytomegalovirus and Map Kinase Pathways,h_hifPathway:Hypoxia-Inducible Factor in the Cardiovascular System,h_huntingtonPathway:Inhibition of Huntington's disease neurodegeneration by histone deacetylase inhibitors,h_mapkPathway:MAPKinase Signaling Pathway,h_melanocytePathway:Melanocyte Development and Pigmentation Pathway,h_p38mapkPathway:p38 MAPK Signaling Pathway ,	GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006468~protein phosphorylation,GO:0007165~signal transduction,GO:0007409~axonogenesis,GO:0007595~lactation,GO:0007613~memory,GO:0007623~circadian rhythm,GO:0008361~regulation of cell size,GO:0009410~response to xenobiotic stimulus,GO:0010033~response to organic substance,GO:0010944~negative regulation of transcription by competitive promoter binding,GO:0014074~response to purine-containing compound,GO:0019933~cAMP-mediated signaling,GO:0021983~pituitary gland development,GO:0030316~osteoclast differentiation,GO:0033363~secretory granule organization,GO:0033762~response to glucagon,GO:0035729~cellular response to hepatocyte growth factor stimulus,GO:0040018~positive regulation of multicellular organism growth,GO:0042789~mRNA transcription from RNA polymerase II promoter,GO:0043066~negative regulation of apoptotic process,GO:0045600~positive regulation of fat cell differentiation,GO:0045672~positive regulation of osteoclast differentiation,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046879~hormone secretion,GO:0046887~positive regulation of hormone secretion,GO:0046889~positive regulation of lipid biosynthetic process,GO:0050821~protein stabilization,GO:0050896~response to stimulus,GO:0055025~positive regulation of cardiac muscle tissue development,GO:0060430~lung saccule development,GO:0060509~Type I pneumocyte differentiation,GO:0071294~cellular response to zinc ion,GO:0071300~cellular response to retinoic acid,GO:1904322~cellular response to forskolin,GO:1990830~cellular response to leukemia inhibitory factor,GO:2000224~regulation of testosterone biosynthetic process,	GO:0000785~chromatin,GO:0000791~euchromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0090575~RNA polymerase II transcription factor complex,GO:1990589~ATF4-CREB1 transcription factor complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0019899~enzyme binding,GO:0035497~cAMP response element binding,GO:0042802~identical protein binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001630:Leuzip_CREB,IPR003102:CREB1-like_pKID,IPR004827:bZIP,IPR046347:bZIP_sf,	hsa04022:cGMP-PKG signaling pathway,hsa04024:cAMP signaling pathway,hsa04148:Efferocytosis,hsa04151:PI3K-Akt signaling pathway,hsa04152:AMPK signaling pathway,hsa04211:Longevity regulating pathway,hsa04261:Adrenergic signaling in cardiomyocytes,hsa04380:Osteoclast differentiation,hsa04612:Antigen processing and presentation,hsa04668:TNF signaling pathway,hsa04710:Circadian rhythm,hsa04713:Circadian entrainment,hsa04714:Thermogenesis,hsa04725:Cholinergic synapse,hsa04728:Dopaminergic synapse,hsa04911:Insulin secretion,hsa04915:Estrogen signaling pathway,hsa04916:Melanogenesis,hsa04918:Thyroid hormone synthesis,hsa04922:Glucagon signaling pathway,hsa04924:Renin secretion,hsa04925:Aldosterone synthesis and secretion,hsa04926:Relaxin signaling pathway,hsa04927:Cortisol synthesis and secretion,hsa04928:Parathyroid hormone synthesis, secretion and action,hsa04931:Insulin resistance,hsa04934:Cushing syndrome,hsa04935:Growth hormone synthesis, secretion and action,hsa04962:Vasopressin-regulated water reabsorption,hsa05016:Huntington disease,hsa05020:Prion disease,hsa05030:Cocaine addiction,hsa05031:Amphetamine addiction,hsa05034:Alcoholism,hsa05152:Tuberculosis,hsa05161:Hepatitis B,hsa05163:Human cytomegalovirus infection,hsa05165:Human papillomavirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05203:Viral carcinogenesis,hsa05207:Chemical carcinogenesis - receptor activation,hsa05215:Prostate cancer,	612160~Histiocytoma, angiomatoid fibrous, somatic,		SM00338:BRLZ,	KW-0090~Biological rhythms,KW-0221~Differentiation,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0539~Nucleus,		KW-0175~Coiled coil,		KW-0010~Activator,KW-0238~DNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:BZIP,DOMAIN:KID,DOMAIN:bZIP,MUTAGEN:K->R: Decreased sumoylation, in vivo and in vitro.,MUTAGEN:K->R: Decreased sumoylation, in vivo and in vitro. Loss of nuclear localization.,MUTAGEN:K->R: No effect on sumoylation.,MUTAGEN:S->A: Does not interact with TOX3 and inhibits induction of transcription by TOX3. Loss of phosphorylation by CaMK4. Loss of phosphorylation by TSSK4.,MUTAGEN:S->A: Impaired phosphorylation by HIPK2 and subsequent transactivation.,MUTAGEN:S->E: Potentiated transactivation.,REGION:Basic motif,REGION:Disordered,REGION:Leucine-zipper,SITE:Required for binding TORCs,
CREB3	cAMP responsive element binding protein 3(CREB3)	Homo sapiens			GO:0001558~regulation of cell growth,GO:0002230~positive regulation of defense response to virus by host,GO:0006351~transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006935~chemotaxis,GO:0019043~establishment of viral latency,GO:0019046~release from viral latency,GO:0030335~positive regulation of cell migration,GO:0030968~endoplasmic reticulum unfolded protein response,GO:0042127~regulation of cell proliferation,GO:0042981~regulation of apoptotic process,GO:0042994~cytoplasmic sequestering of transcription factor,GO:0045786~negative regulation of cell cycle,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0050930~induction of positive chemotaxis,GO:0051928~positive regulation of calcium ion transport,GO:0090026~positive regulation of monocyte chemotaxis,GO:0090045~positive regulation of deacetylase activity,GO:1902236~negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway,	GO:0000139~Golgi membrane,GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0016020~membrane,GO:0016604~nuclear body,GO:0043025~neuronal cell body,GO:0090575~RNA polymerase II transcription factor complex,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001221~transcription cofactor binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0008140~cAMP response element binding protein binding,GO:0031726~CCR1 chemokine receptor binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0046983~protein dimerization activity,GO:1990837~sequence-specific double-stranded DNA binding,	IPR004827:bZIP,IPR046347:bZIP_sf,	hsa04022:cGMP-PKG signaling pathway,hsa04024:cAMP signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04152:AMPK signaling pathway,hsa04211:Longevity regulating pathway,hsa04261:Adrenergic signaling in cardiomyocytes,hsa04668:TNF signaling pathway,hsa04714:Thermogenesis,hsa04725:Cholinergic synapse,hsa04728:Dopaminergic synapse,hsa04911:Insulin secretion,hsa04915:Estrogen signaling pathway,hsa04916:Melanogenesis,hsa04918:Thyroid hormone synthesis,hsa04922:Glucagon signaling pathway,hsa04925:Aldosterone synthesis and secretion,hsa04926:Relaxin signaling pathway,hsa04927:Cortisol synthesis and secretion,hsa04928:Parathyroid hormone synthesis, secretion and action,hsa04931:Insulin resistance,hsa04934:Cushing syndrome,hsa04935:Growth hormone synthesis, secretion and action,hsa04962:Vasopressin-regulated water reabsorption,hsa05016:Huntington disease,hsa05020:Prion disease,hsa05030:Cocaine addiction,hsa05031:Amphetamine addiction,hsa05034:Alcoholism,hsa05161:Hepatitis B,hsa05163:Human cytomegalovirus infection,hsa05165:Human papillomavirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05203:Viral carcinogenesis,hsa05207:Chemical carcinogenesis - receptor activation,hsa05215:Prostate cancer,			SM00338:BRLZ,	KW-0145~Chemotaxis,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0834~Unfolded protein response,KW-0945~Host-virus interaction,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0677~Repeat,KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0010~Activator,KW-0238~DNA-binding,KW-0678~Repressor,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:BZIP,DOMAIN:bZIP,MOTIF:HCFC1-binding-motif (HBM),MOTIF:LXXLL motif 1,MOTIF:LXXLL motif 2,MUTAGEN:DHTY->AAAA: Inhibits interaction with HCFC1. Reduces transcriptional activation. Inhibits strongly transcriptional activation; when associated with 12-A-A-13 and 56-A-A-57. Colocalizes with HCFC1 in the nucleus (isoform 1).,MUTAGEN:LL->AA: Does not affect the transcriptional activation of the glucocorticoid receptor NR3C1; when associated with 16-A-A-17 (isoform 2).,MUTAGEN:LL->AA: Does not affect the transcriptional activation of the glucocorticoid receptor NR3C1; when associated with 57-A-A-58 (isoform 2).,MUTAGEN:LL->AA: Does not inhibit interaction with HCFC1. Reduces transcriptional activation. Inhibits strongly transcriptional activation; when associated with 12-A-A-13 and 78-A--A-81 (isoform 1).,MUTAGEN:LL->AA: Does not inhibit interaction with HCFC1. Reduces transcriptional activation. Inhibits strongly transcriptional activation; when associated with 56-A-A-57 and 78-A--A-81 (isoform 1).,MUTAGEN:N->G: Does not bind to DNA but retains its ability to interact with HCFC1. Reduces transcriptional activation of unfolded protein response elements (UPRE)-containing promoter. Colocalizes with HCFC1 in the ER membrane.,MUTAGEN:R->A: Does not inhibit proteolytic cleavage and transcriptional activation.,MUTAGEN:R->G: Inhibits proteolytic cleavage and transcriptional activation.,MUTAGEN:Y->A: Does not retain HCFC1 in the cytoplasm, does not interact with HCFC1, does not activate promoter and fail to protect cells from a productive infection by HSV-1.,REGION:Basic motif,REGION:Leucine-zipper,REGION:Transcription activation (acidic),SITE:Cleavage; by PS1,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
CREM	cAMP responsive element modulator(CREM)	Homo sapiens		h_cremPathway:Regulation of Spermatogenesis by CREM,h_dreamPathway:Repression of Pain Sensation by the Transcriptional Regulator DREAM,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006687~glycosphingolipid metabolic process,GO:0007165~signal transduction,GO:0007283~spermatogenesis,GO:0030154~cell differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048511~rhythmic process,GO:0050896~response to stimulus,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:1990589~ATF4-CREB1 transcription factor complex,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0008140~cAMP response element binding protein binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001630:Leuzip_CREB,IPR003102:CREB1-like_pKID,IPR004827:bZIP,IPR046347:bZIP_sf,	hsa04261:Adrenergic signaling in cardiomyocytes,			SM00338:BRLZ,	KW-0090~Biological rhythms,KW-0221~Differentiation,KW-0744~Spermatogenesis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,		KW-0010~Activator,KW-0217~Developmental protein,KW-0238~DNA-binding,KW-0678~Repressor,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,DOMAIN:BZIP,DOMAIN:KID,DOMAIN:bZIP,REGION:Basic motif,REGION:Disordered,REGION:Leucine-zipper,
CIB1	calcium and integrin binding 1(CIB1)	Homo sapiens			GO:0001525~angiogenesis,GO:0001933~negative regulation of protein phosphorylation,GO:0001934~positive regulation of protein phosphorylation,GO:0001954~positive regulation of cell-matrix adhesion,GO:0002931~response to ischemia,GO:0006302~double-strand break repair,GO:0006915~apoptotic process,GO:0006974~cellular response to DNA damage stimulus,GO:0007026~negative regulation of microtubule depolymerization,GO:0007113~endomitotic cell cycle,GO:0007155~cell adhesion,GO:0007286~spermatid development,GO:0008284~positive regulation of cell proliferation,GO:0008285~negative regulation of cell proliferation,GO:0010977~negative regulation of neuron projection development,GO:0030220~platelet formation,GO:0030307~positive regulation of cell growth,GO:0030335~positive regulation of cell migration,GO:0031122~cytoplasmic microtubule organization,GO:0033630~positive regulation of cell adhesion mediated by integrin,GO:0038163~thrombopoietin-mediated signaling pathway,GO:0042127~regulation of cell proliferation,GO:0043066~negative regulation of apoptotic process,GO:0043085~positive regulation of catalytic activity,GO:0045653~negative regulation of megakaryocyte differentiation,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0051301~cell division,GO:0051302~regulation of cell division,GO:0051898~negative regulation of protein kinase B signaling,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0070886~positive regulation of calcineurin-NFAT signaling cascade,GO:0071356~cellular response to tumor necrosis factor,GO:0071363~cellular response to growth factor stimulus,GO:0071902~positive regulation of protein serine/threonine kinase activity,GO:0090050~positive regulation of cell migration involved in sprouting angiogenesis,GO:0090314~positive regulation of protein targeting to membrane,GO:0097191~extrinsic apoptotic signaling pathway,GO:1900026~positive regulation of substrate adhesion-dependent cell spreading,GO:1903078~positive regulation of protein localization to plasma membrane,GO:1990090~cellular response to nerve growth factor stimulus,GO:2000256~positive regulation of male germ cell proliferation,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005794~Golgi apparatus,GO:0005813~centrosome,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016324~apical plasma membrane,GO:0030027~lamellipodium,GO:0030424~axon,GO:0030426~growth cone,GO:0031982~vesicle,GO:0032433~filopodium tip,GO:0032587~ruffle membrane,GO:0042383~sarcolemma,GO:0043005~neuron projection,GO:0043025~neuronal cell body,GO:0043204~perikaryon,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,GO:0071944~cell periphery,	GO:0000287~magnesium ion binding,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0008427~calcium-dependent protein kinase inhibitor activity,GO:0030291~protein serine/threonine kinase inhibitor activity,GO:0031267~small GTPase binding,GO:0043495~protein anchor,GO:0044325~ion channel binding,	IPR002048:EF_hand_dom,IPR011992:EF-hand-dom_pair,IPR018247:EF_Hand_1_Ca_BS,		618267~Epidermodysplasia verruciformis 3,		SM00054:EFh,	KW-0037~Angiogenesis,KW-0053~Apoptosis,KW-0130~Cell adhesion,KW-0131~Cell cycle,KW-0132~Cell division,KW-0221~Differentiation,KW-0744~Spermatogenesis,	KW-0206~Cytoskeleton,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-1003~Cell membrane,		KW-0677~Repeat,	KW-0106~Calcium,KW-0460~Magnesium,KW-0479~Metal-binding,		KW-0449~Lipoprotein,KW-0519~Myristate,KW-0597~Phosphoprotein,	DOMAIN:EF-hand,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,LIPID:N-myristoyl glycine,MUTAGEN:D->N: Cytoplasmic localization.,MUTAGEN:E->Q: Cytoplasmic localization.,MUTAGEN:F->A: Loss of binding to ITGA2B.,MUTAGEN:F->A: Loss of binding to ITGA2B. Does not inhibit interaction with PAK1.,MUTAGEN:G->A: Inhibits translocation to the plasma membrane. Increased apoptosis after TNF stimulation.,MUTAGEN:I->A: Loss of binding to ITGA2B.,MUTAGEN:IFDF->AAAA: Loss of binding to ITGAV.,MUTAGEN:L->A,T: Loss of binding to ITGA2B.,MUTAGEN:LI->AA: Loss of binding to ITGA2B.,MUTAGEN:S->A: Loss of phosphorylation by PKD/PRKD2; in isoform 2.,MUTAGEN:S->E: Phosphomimetic; promotes tumor growth by an indirect mechanism; in isoform 2.,MUTAGEN:T->A: No effect on phosphorylation by PKD/PRKD2; in isoform 2.,
CALCOCO2	calcium binding and coiled-coil domain 2(CALCOCO2)	Homo sapiens			GO:0016032~viral process,GO:0034341~response to interferon-gamma,GO:0098792~xenophagy,GO:1901098~positive regulation of autophagosome maturation,	GO:0000421~autophagosome membrane,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005776~autophagosome,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0016020~membrane,GO:0016605~PML body,GO:0031410~cytoplasmic vesicle,GO:0043231~intracellular membrane-bounded organelle,GO:0048471~perinuclear region of cytoplasm,	GO:0005515~protein binding,GO:0042803~protein homodimerization activity,GO:0046872~metal ion binding,	IPR041611:SKICH,IPR041641:CALCOCO1/2_Zn_UBZ1,	hsa04137:Mitophagy - animal,hsa04140:Autophagy - animal,hsa05131:Shigellosis,hsa05164:Influenza A,				KW-0072~Autophagy,KW-0945~Host-virus interaction,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,		KW-0175~Coiled coil,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0597~Phosphoprotein,	DOMAIN:SKICH,MOTIF:CLIR,MOTIF:LIR-like,MUTAGEN:C->A: Does not affect interaction with MYO6.,MUTAGEN:C->A: Fails interact with MYO6 and to promote maturation of autophagosomes.,MUTAGEN:DYWE->AAAA: Abrogates interaction with MAPLC3A, MAPLC3B and GABARAPL2.,MUTAGEN:L->A: Severely reduces affinity for LGALS8.,MUTAGEN:N->A: Prevents interaction with LGALS8.,MUTAGEN:V->S: Abrogates the interaction with MAP1LC3C.,MUTAGEN:Y->A,F: Severely reduced affinity for LGALS8.,MUTAGEN:Y->A: Severely reduces affinity for LGALS8.,REGION:Disordered,REGION:Interaction with LGALS8,REGION:Interaction with MYO6,ZN_FING:UBZ1-type,
CAMLG	calcium modulating ligand(CAMLG)	Homo sapiens			GO:0001782~B cell homeostasis,GO:0001881~receptor recycling,GO:0006952~defense response,GO:0007165~signal transduction,GO:0007173~epidermal growth factor receptor signaling pathway,GO:0016192~vesicle-mediated transport,GO:0031397~negative regulation of protein ubiquitination,GO:0032435~negative regulation of proteasomal ubiquitin-dependent protein catabolic process,GO:0045048~protein insertion into ER membrane,GO:0050821~protein stabilization,GO:0071816~tail-anchored membrane protein insertion into ER membrane,	GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0016020~membrane,GO:0043529~GET complex,	GO:0005515~protein binding,GO:0031625~ubiquitin protein ligase binding,	IPR016719:CAMLG,		620201~Congenital disorder of glycosylation, type IIz,	PIRSF018259:CAML,		KW-0813~Transport,KW-0931~ER-Golgi transport,KW-0945~Host-virus interaction,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,	KW-0900~Congenital disorder of glycosylation,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	COMPBIAS:Polar residues,MUTAGEN:RRRK->EEEE: Abolishes binding to GET3.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
CAMK4	calcium/calmodulin dependent protein kinase IV(CAMK4)	Homo sapiens	103.Ca2-calmodulin_PK_cascade,	h_CaCaMPathway:Ca++/ Calmodulin-dependent Protein Kinase Activation,h_nfatPathway:NFAT and Hypertrophy of the heart (Transcription in the broken heart),h_pgc1aPathway:Regulation of PGC-1a,h_stathminPathway:Stathmin and breast cancer resistance to antimicrotubule agents,	GO:0002250~adaptive immune response,GO:0006468~protein phosphorylation,GO:0006954~inflammatory response,GO:0007165~signal transduction,GO:0007616~long-term memory,GO:0016310~phosphorylation,GO:0018105~peptidyl-serine phosphorylation,GO:0033081~regulation of T cell differentiation in thymus,GO:0035556~intracellular signal transduction,GO:0043011~myeloid dendritic cell differentiation,GO:0045670~regulation of osteoclast differentiation,GO:0045893~positive regulation of transcription, DNA-templated,GO:0046777~protein autophosphorylation,	GO:0001650~fibrillar center,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0070062~extracellular exosome,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004683~calmodulin-dependent protein kinase activity,GO:0005516~calmodulin binding,GO:0005524~ATP binding,GO:0009931~calcium-dependent protein serine/threonine kinase activity,	IPR000719:Prot_kinase_dom,IPR008271:Ser/Thr_kinase_AS,IPR011009:Kinase-like_dom_sf,IPR017441:Protein_kinase_ATP_BS,	hsa04020:Calcium signaling pathway,hsa04024:cAMP signaling pathway,hsa04211:Longevity regulating pathway,hsa04371:Apelin signaling pathway,hsa04380:Osteoclast differentiation,hsa04720:Long-term potentiation,hsa04722:Neurotrophin signaling pathway,hsa04725:Cholinergic synapse,hsa04921:Oxytocin signaling pathway,hsa04925:Aldosterone synthesis and secretion,hsa05031:Amphetamine addiction,hsa05034:Alcoholism,hsa05214:Glioma,			SM00220:S_TKc,	KW-0391~Immunity,KW-0395~Inflammatory response,KW-1064~Adaptive immunity,	KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0106~Calcium,KW-0547~Nucleotide-binding,	KW-0112~Calmodulin-binding,KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,CARBOHYD:O-linked (GlcNAc) serine,CARBOHYD:O-linked (GlcNAc) threonine,COMPBIAS:Basic and acidic residues,DOMAIN:Protein kinase,MUTAGEN:FN->DD: Fully active Ca2+/CaM-independent kinase; when associated with 309-A--A-312. Loss of interaction with PPP2CA/PPP2CB.,MUTAGEN:HMDT->DEDD: Fully active Ca2+/CaM-independent kinase; when associated with 320-A-A-321.,MUTAGEN:K->E: Loss of activity; dominant negative form.,MUTAGEN:S->A: Increases phosphorylation of CREB1 2-fold. Decreases total O-linked glycosylation 2-fold. Increases ATP-binding affinity.,MUTAGEN:S->A: Loss of activity.,MUTAGEN:T->A: Loss of activation by CaMKK1 or CaMKK2.,MUTAGEN:TS->AA: Loss of phosphorylation of CREB1.,REGION:Autoinhibitory domain,REGION:Calmodulin-binding,REGION:Disordered,REGION:PP2A-binding,
CACYBP	calcyclin binding protein(CACYBP)	Homo sapiens			GO:0007507~heart development,GO:1990830~cellular response to leukemia inhibitory factor,	GO:0005634~nucleus,GO:0005641~nuclear envelope lumen,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0019005~SCF ubiquitin ligase complex,GO:0030877~beta-catenin destruction complex,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0015631~tubulin binding,GO:0019904~protein domain specific binding,GO:0031625~ubiquitin protein ligase binding,GO:0042803~protein homodimerization activity,GO:0044548~S100 protein binding,	IPR007052:CS_dom,IPR007699:SGS_dom,IPR008978:HSP20-like_chaperone,IPR015120:Siah-Interact_N,IPR037201:CacyBP_N,IPR037893:CS_CacyBP,	hsa04310:Wnt signaling pathway,				KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:CS,DOMAIN:SGS,DOMAIN:Siah interacting protein N-terminal,MUTAGEN:KRVR->AAVA: Abolishes interaction with SIAH1.,MUTAGEN:P->N: Abolishes interaction with SIAH1; when associated with N-64.,MUTAGEN:V->N: Abolishes interaction with SIAH1; when associated with N-66.,REGION:Interaction with S100A6,REGION:Interaction with SIAH1,REGION:Interaction with SKP1,
CALM1	calmodulin 1(CALM1)	Homo sapiens		h_at1rPathway:Angiotensin II mediated activation of JNK Pathway via Pyk2 dependent signaling,h_bcrPathway:BCR Signaling Pathway,h_biopeptidesPathway:Bioactive Peptide Induced Signaling Pathway,h_CaCaMPathway:Ca++/ Calmodulin-dependent Protein Kinase Activation,h_calcineurinPathway:Effects of calcineurin in Keratinocyte Differentiation,h_ccr5Pathway:Pertussis toxin-insensitive CCR5 Signaling in Macrophage,h_fcer1Pathway:Fc Epsilon Receptor I Signaling in Mast Cells,h_fmlpPathway:fMLP induced chemokine gene expression in HMC-1 cells,h_gcrpathway:Corticosteroids and cardioprotection,h_gpcrPathway:Signaling Pathway from G-Protein Families,h_hdacPathway:Control of skeletal myogenesis by HDAC & calcium/calmodulin-dependent kinase (CaMK),h_mef2dPathway:Role of MEF2D in T-cell Apoptosis,h_ndkDynaminPathway:Endocytotic role of NDK, Phosphins and Dynamin,h_nfatPathway:NFAT and Hypertrophy of the heart (Transcription in the broken heart),h_no1Pathway:Actions of Nitric Oxide in the Heart,h_nos1Pathway:Nitric Oxide Signaling Pathway,h_pgc1aPathway:Regulation of PGC-1a,h_pyk2Pathway:Links between Pyk2 and Map Kinases,h_tcrPathway:T Cell Receptor Signaling Pathway,h_vipPathway:Neuropeptides VIP and PACAP inhibit the apoptosis of activated T cells,	GO:0000086~G2/M transition of mitotic cell cycle,GO:0002027~regulation of heart rate,GO:0005513~detection of calcium ion,GO:0007186~G-protein coupled receptor signaling pathway,GO:0010800~positive regulation of peptidyl-threonine phosphorylation,GO:0010801~negative regulation of peptidyl-threonine phosphorylation,GO:0010880~regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum,GO:0010881~regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion,GO:0016240~autophagosome docking,GO:0016310~phosphorylation,GO:0021762~substantia nigra development,GO:0031954~positive regulation of protein autophosphorylation,GO:0032465~regulation of cytokinesis,GO:0032516~positive regulation of phosphoprotein phosphatase activity,GO:0035307~positive regulation of protein dephosphorylation,GO:0035458~cellular response to interferon-beta,GO:0046427~positive regulation of JAK-STAT cascade,GO:0050848~regulation of calcium-mediated signaling,GO:0051343~positive regulation of cyclic-nucleotide phosphodiesterase activity,GO:0051592~response to calcium ion,GO:0055117~regulation of cardiac muscle contraction,GO:0060314~regulation of ryanodine-sensitive calcium-release channel activity,GO:0060315~negative regulation of ryanodine-sensitive calcium-release channel activity,GO:0060316~positive regulation of ryanodine-sensitive calcium-release channel activity,GO:0071346~cellular response to interferon-gamma,GO:0071902~positive regulation of protein serine/threonine kinase activity,GO:0098901~regulation of cardiac muscle cell action potential,GO:1901842~negative regulation of high voltage-gated calcium channel activity,GO:1901844~regulation of cell communication by electrical coupling involved in cardiac conduction,GO:1905913~negative regulation of calcium ion export from cell,GO:1990456~mitochondrion-ER tethering,	GO:0000922~spindle pole,GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005829~cytosol,GO:0005876~spindle microtubule,GO:0005886~plasma membrane,GO:0008076~voltage-gated potassium channel complex,GO:0030017~sarcomere,GO:0031982~vesicle,GO:0032991~macromolecular complex,GO:0034704~calcium channel complex,GO:0043209~myelin sheath,GO:0097225~sperm midpiece,GO:1902494~catalytic complex,	GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0010856~adenylate cyclase activator activity,GO:0016301~kinase activity,GO:0019855~calcium channel inhibitor activity,GO:0019901~protein kinase binding,GO:0031432~titin binding,GO:0043539~protein serine/threonine kinase activator activity,GO:0044325~ion channel binding,GO:0048306~calcium-dependent protein binding,GO:0072542~protein phosphatase activator activity,	IPR002048:EF_hand_dom,IPR011992:EF-hand-dom_pair,IPR018247:EF_Hand_1_Ca_BS,	hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04020:Calcium signaling pathway,hsa04022:cGMP-PKG signaling pathway,hsa04024:cAMP signaling pathway,hsa04070:Phosphatidylinositol signaling system,hsa04114:Oocyte meiosis,hsa04218:Cellular senescence,hsa04261:Adrenergic signaling in cardiomyocytes,hsa04270:Vascular smooth muscle contraction,hsa04371:Apelin signaling pathway,hsa04625:C-type lectin receptor signaling pathway,hsa04713:Circadian entrainment,hsa04720:Long-term potentiation,hsa04722:Neurotrophin signaling pathway,hsa04728:Dopaminergic synapse,hsa04740:Olfactory transduction,hsa04744:Phototransduction,hsa04750:Inflammatory mediator regulation of TRP channels,hsa04910:Insulin signaling pathway,hsa04912:GnRH signaling pathway,hsa04915:Estrogen signaling pathway,hsa04916:Melanogenesis,hsa04921:Oxytocin signaling pathway,hsa04922:Glucagon signaling pathway,hsa04924:Renin secretion,hsa04925:Aldosterone synthesis and secretion,hsa04970:Salivary secretion,hsa04971:Gastric acid secretion,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05031:Amphetamine addiction,hsa05034:Alcoholism,hsa05133:Pertussis,hsa05152:Tuberculosis,hsa05163:Human cytomegalovirus infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05200:Pathways in cancer,hsa05214:Glioma,hsa05417:Lipid and atherosclerosis,hsa05418:Fluid shear stress and atherosclerosis,	614916~Ventricular tachycardia, catecholaminergic polymorphic, 4,616247~Long QT syndrome 14,		SM00054:EFh,	KW-0945~Host-virus interaction,	KW-0206~Cytoskeleton,KW-0282~Flagellum,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-0969~Cilium,	KW-0225~Disease variant,KW-0454~Long QT syndrome,	KW-0677~Repeat,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0418~Kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin); alternate,DOMAIN:EF-hand,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,DOMAIN:EF-hand 3,DOMAIN:EF-hand 4,REGION:Necessary and sufficient for interaction with PCP4,
CAMTA1	calmodulin binding transcription activator 1(CAMTA1)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0035307~positive regulation of protein dephosphorylation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0050885~neuromuscular process controlling balance,GO:0051171~regulation of nitrogen compound metabolic process,GO:0060255~regulation of macromolecule metabolic process,GO:0070886~positive regulation of calcineurin-NFAT signaling cascade,GO:0080090~regulation of primary metabolic process,	GO:0005634~nucleus,GO:0005730~nucleolus,GO:0005829~cytosol,	GO:0003677~DNA binding,GO:0003690~double-stranded DNA binding,GO:0003712~transcription cofactor activity,GO:0043565~sequence-specific DNA binding,	IPR000048:IQ_motif_EF-hand-BS,IPR002110:Ankyrin_rpt,IPR002909:IPT_dom,IPR005559:CG-1_dom,IPR013783:Ig-like_fold,IPR014756:Ig_E-set,IPR027417:P-loop_NTPase,IPR036770:Ankyrin_rpt-contain_sf,		614756~Cerebellar dysfunction with variable cognitive and behavioral abnormalities,		SM01076:CG-1,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0991~Intellectual disability,	KW-0040~ANK repeat,KW-0677~Repeat,		KW-0010~Activator,		COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DNA_BIND:CG-1,DOMAIN:CG-1,DOMAIN:IPT/TIG,DOMAIN:IQ 1,DOMAIN:IQ 2,DOMAIN:IQ 3,MOTIF:Nuclear localization signal,REGION:Disordered,REPEAT:ANK,REPEAT:ANK 1,REPEAT:ANK 2,REPEAT:ANK 3,
CANX	calnexin(CANX)	Homo sapiens		h_eradPathway:ERï¿½associated degradation (ERAD) Pathway,	GO:0006457~protein folding,GO:0009306~protein secretion,GO:0019082~viral protein processing,GO:0030433~ubiquitin-dependent ERAD pathway,GO:0034975~protein folding in endoplasmic reticulum,GO:0036503~ERAD pathway,GO:0048488~synaptic vesicle endocytosis,GO:0072583~clathrin-dependent endocytosis,	GO:0005783~endoplasmic reticulum,GO:0005788~endoplasmic reticulum lumen,GO:0005789~endoplasmic reticulum membrane,GO:0016020~membrane,GO:0031965~nuclear membrane,GO:0031966~mitochondrial membrane,GO:0033162~melanosome membrane,GO:0042470~melanosome,GO:0044233~ER-mitochondrion membrane contact site,GO:0044322~endoplasmic reticulum quality control compartment,GO:0070062~extracellular exosome,GO:0098553~lumenal side of endoplasmic reticulum membrane,GO:0098793~presynapse,	GO:0003723~RNA binding,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0030246~carbohydrate binding,GO:0051082~unfolded protein binding,	IPR001580:Calret/calnex,IPR009033:Calreticulin/calnexin_P_dom_sf,IPR013320:ConA-like_dom_sf,IPR018124:Calret/calnex_CS,	hsa04141:Protein processing in endoplasmic reticulum,hsa04145:Phagosome,hsa04612:Antigen processing and presentation,hsa04918:Thyroid hormone synthesis,hsa05166:Human T-cell leukemia virus 1 infection,				KW-0945~Host-virus interaction,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0496~Mitochondrion,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0430~Lectin,KW-0479~Metal-binding,	KW-0143~Chaperone,	KW-0007~Acetylation,KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,LIPID:S-palmitoyl cysteine,REGION:4 X approximate repeats,REGION:Disordered,REGION:Interaction with PPIB,REGION:P domain (Extended arm),REGION:Sufficient to mediate interaction with SGIP1,REPEAT:1-1,REPEAT:1-2,REPEAT:1-3,REPEAT:1-4,REPEAT:2-1,REPEAT:2-2,REPEAT:2-3,REPEAT:2-4,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
CAPN1	calpain 1(CAPN1)	Homo sapiens		h_integrinPathway:Integrin Signaling Pathway,h_mCalpainPathway:mCalpain and friends in Cell motility,h_p35AlzheimersPathway:Deregulation of CDK5 in Alzheimers Disease,h_uCalpainPathway:uCalpain and friends in Cell spread,	GO:0006508~proteolysis,GO:0008284~positive regulation of cell proliferation,GO:0016241~regulation of macroautophagy,GO:0032801~receptor catabolic process,GO:0050790~regulation of catalytic activity,GO:0060056~mammary gland involution,GO:0097264~self proteolysis,GO:2000310~regulation of NMDA receptor activity,	GO:0001533~cornified envelope,GO:0005576~extracellular region,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005764~lysosome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0016020~membrane,GO:0070062~extracellular exosome,GO:1904813~ficolin-1-rich granule lumen,	GO:0004198~calcium-dependent cysteine-type endopeptidase activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0008233~peptidase activity,	IPR000169:Pept_cys_AS,IPR001300:Peptidase_C2_calpain_cat,IPR002048:EF_hand_dom,IPR011992:EF-hand-dom_pair,IPR018247:EF_Hand_1_Ca_BS,IPR022682:Calpain_domain_III,IPR022683:Calpain_III,IPR022684:Calpain_cysteine_protease,IPR033883:C2_III,IPR036213:Calpain_III_sf,IPR038765:Papain-like_cys_pep_sf,	hsa04141:Protein processing in endoplasmic reticulum,hsa04210:Apoptosis,hsa04217:Necroptosis,hsa04218:Cellular senescence,hsa05010:Alzheimer disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05131:Shigellosis,	616907~Spastic paraplegia 76, autosomal recessive,		SM00230:CysPc,SM00720:calpain_III,		KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0890~Hereditary spastic paraplegia,	KW-0677~Repeat,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0378~Hydrolase,KW-0645~Protease,KW-0788~Thiol protease,	KW-0007~Acetylation,KW-0068~Autocatalytic cleavage,KW-0597~Phosphoprotein,	DOMAIN:Calpain catalytic,DOMAIN:EF-hand,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,DOMAIN:EF-hand 3,DOMAIN:EF-hand 4,REGION:Domain III,REGION:Domain IV,REGION:Linker,SITE:Cleavage; for 75 kDa form,SITE:Cleavage; for 78 kDa form,
CAPN2	calpain 2(CAPN2)	Homo sapiens		h_mCalpainPathway:mCalpain and friends in Cell motility,h_mef2dPathway:Role of MEF2D in T-cell Apoptosis,	GO:0001666~response to hypoxia,GO:0001824~blastocyst development,GO:0006508~proteolysis,GO:0007520~myoblast fusion,GO:0007565~female pregnancy,GO:0009612~response to mechanical stimulus,GO:0010666~positive regulation of cardiac muscle cell apoptotic process,GO:0016540~protein autoprocessing,GO:0032675~regulation of interleukin-6 production,GO:0035458~cellular response to interferon-beta,GO:0042542~response to hydrogen peroxide,GO:0048266~behavioral response to pain,GO:0051493~regulation of cytoskeleton organization,GO:0051603~proteolysis involved in cellular protein catabolic process,GO:0071222~cellular response to lipopolysaccharide,GO:0071230~cellular response to amino acid stimulus,GO:1901741~positive regulation of myoblast fusion,GO:2001247~positive regulation of phosphatidylcholine biosynthetic process,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005764~lysosome,GO:0005783~endoplasmic reticulum,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0009897~external side of plasma membrane,GO:0030425~dendrite,GO:0030864~cortical actin cytoskeleton,GO:0031143~pseudopodium,GO:0043025~neuronal cell body,GO:0045121~membrane raft,GO:0070062~extracellular exosome,GO:0097038~perinuclear endoplasmic reticulum,	GO:0004198~calcium-dependent cysteine-type endopeptidase activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0008092~cytoskeletal protein binding,GO:0008234~cysteine-type peptidase activity,GO:0019899~enzyme binding,GO:0044877~macromolecular complex binding,	IPR000169:Pept_cys_AS,IPR001300:Peptidase_C2_calpain_cat,IPR002048:EF_hand_dom,IPR011992:EF-hand-dom_pair,IPR018247:EF_Hand_1_Ca_BS,IPR022682:Calpain_domain_III,IPR022683:Calpain_III,IPR022684:Calpain_cysteine_protease,IPR033883:C2_III,IPR036213:Calpain_III_sf,IPR038765:Papain-like_cys_pep_sf,IPR042736:EFh_PEF_CAPN2,	hsa04141:Protein processing in endoplasmic reticulum,hsa04210:Apoptosis,hsa04217:Necroptosis,hsa04218:Cellular senescence,hsa04510:Focal adhesion,hsa05010:Alzheimer disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05131:Shigellosis,			SM00230:CysPc,SM00720:calpain_III,		KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0677~Repeat,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0378~Hydrolase,KW-0645~Protease,KW-0788~Thiol protease,	KW-0007~Acetylation,	DOMAIN:Calpain catalytic,DOMAIN:EF-hand,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,DOMAIN:EF-hand 3,PROPEP:Anchors to the small subunit,REGION:Disordered,REGION:Domain III,REGION:Domain IV,REGION:Linker,
CAST	calpastatin(CAST)	Homo sapiens			GO:0097340~inhibition of cysteine-type endopeptidase activity,GO:1990709~presynaptic active zone organization,GO:2000675~negative regulation of type B pancreatic cell apoptotic process,	GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0016020~membrane,	GO:0003723~RNA binding,GO:0004866~endopeptidase inhibitor activity,GO:0004869~cysteine-type endopeptidase inhibitor activity,GO:0005515~protein binding,GO:0010859~calcium-dependent cysteine-type endopeptidase inhibitor activity,GO:0045296~cadherin binding,	IPR001259:Prot_inh_calpain,IPR026998:Calpastatin,	hsa05131:Shigellosis,	616295~Peeling skin with leukonychia, acral punctate keratoses, cheilitis, and knuckle pads,					KW-1007~Palmoplantar keratoderma,	KW-0677~Repeat,		KW-0646~Protease inhibitor,KW-0789~Thiol protease inhibitor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),REGION:Disordered,REPEAT:Inhibitory domain 1,REPEAT:Inhibitory domain 2,REPEAT:Inhibitory domain 3,REPEAT:Inhibitory domain 4,
CALR	calreticulin(CALR)	Homo sapiens		h_nfatPathway:NFAT and Hypertrophy of the heart (Transcription in the broken heart),	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0002502~peptide antigen assembly with MHC class I protein complex,GO:0006355~regulation of transcription, DNA-templated,GO:0006457~protein folding,GO:0006611~protein export from nucleus,GO:0006874~cellular calcium ion homeostasis,GO:0007283~spermatogenesis,GO:0008284~positive regulation of cell proliferation,GO:0009410~response to xenobiotic stimulus,GO:0010595~positive regulation of endothelial cell migration,GO:0010628~positive regulation of gene expression,GO:0017148~negative regulation of translation,GO:0022417~protein maturation by protein folding,GO:0030433~ubiquitin-dependent ERAD pathway,GO:0030866~cortical actin cytoskeleton organization,GO:0032355~response to estradiol,GO:0033144~negative regulation of intracellular steroid hormone receptor signaling pathway,GO:0033574~response to testosterone,GO:0034504~protein localization to nucleus,GO:0034975~protein folding in endoplasmic reticulum,GO:0036503~ERAD pathway,GO:0040020~regulation of meiotic nuclear division,GO:0042921~glucocorticoid receptor signaling pathway,GO:0042981~regulation of apoptotic process,GO:0045665~negative regulation of neuron differentiation,GO:0045787~positive regulation of cell cycle,GO:0045892~negative regulation of transcription, DNA-templated,GO:0048387~negative regulation of retinoic acid receptor signaling pathway,GO:0050766~positive regulation of phagocytosis,GO:0050821~protein stabilization,GO:0051208~sequestering of calcium ion,GO:0055007~cardiac muscle cell differentiation,GO:0071257~cellular response to electrical stimulus,GO:0071285~cellular response to lithium ion,GO:0071310~cellular response to organic substance,GO:0090398~cellular senescence,GO:0098586~cellular response to virus,GO:1900026~positive regulation of substrate adhesion-dependent cell spreading,GO:1901164~negative regulation of trophoblast cell migration,GO:1901224~positive regulation of NIK/NF-kappaB signaling,GO:1903416~response to glycoside,GO:2000510~positive regulation of dendritic cell chemotaxis,	GO:0001669~acrosomal vesicle,GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005635~nuclear envelope,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005788~endoplasmic reticulum lumen,GO:0005789~endoplasmic reticulum membrane,GO:0005790~smooth endoplasmic reticulum,GO:0005829~cytosol,GO:0005840~ribosome,GO:0005844~polysome,GO:0005925~focal adhesion,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,GO:0016529~sarcoplasmic reticulum,GO:0030670~phagocytic vesicle membrane,GO:0033018~sarcoplasmic reticulum lumen,GO:0033116~endoplasmic reticulum-Golgi intermediate compartment membrane,GO:0042824~MHC class I peptide loading complex,GO:0044194~cytolytic granule,GO:0044322~endoplasmic reticulum quality control compartment,GO:0048471~perinuclear region of cytoplasm,GO:0060473~cortical granule,GO:0070062~extracellular exosome,GO:0071682~endocytic vesicle lumen,GO:0098553~lumenal side of endoplasmic reticulum membrane,	GO:0001849~complement component C1q binding,GO:0003677~DNA binding,GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0005049~nuclear export signal receptor activity,GO:0005178~integrin binding,GO:0005506~iron ion binding,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0030246~carbohydrate binding,GO:0031625~ubiquitin protein ligase binding,GO:0042277~peptide binding,GO:0042562~hormone binding,GO:0044183~protein binding involved in protein folding,GO:0050681~androgen receptor binding,GO:0051082~unfolded protein binding,GO:0051087~chaperone binding,	IPR001580:Calret/calnex,IPR009033:Calreticulin/calnexin_P_dom_sf,IPR009169:Calreticulin,IPR013320:ConA-like_dom_sf,IPR018124:Calret/calnex_CS,	hsa04141:Protein processing in endoplasmic reticulum,hsa04145:Phagosome,hsa04148:Efferocytosis,hsa04612:Antigen processing and presentation,hsa05142:Chagas disease,hsa05163:Human cytomegalovirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,	187950~Thrombocythemia, somatic,254450~Myelofibrosis, somatic,	PIRSF002356:Calreticulin,			KW-0256~Endoplasmic reticulum,KW-0272~Extracellular matrix,KW-0458~Lysosome,KW-0703~Sarcoplasmic reticulum,KW-0963~Cytoplasm,KW-0964~Secreted,KW-0968~Cytoplasmic vesicle,		KW-0677~Repeat,KW-0732~Signal,	KW-0106~Calcium,KW-0430~Lectin,KW-0479~Metal-binding,KW-0862~Zinc,	KW-0143~Chaperone,	KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0379~Hydroxylation,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,MOTIF:Prevents secretion from ER,REGION:3 X approximate repeats,REGION:4 X approximate repeats,REGION:C-domain,REGION:Disordered,REGION:Interaction with PPIB,REGION:N-domain,REGION:P-domain,REPEAT:1-1,REPEAT:1-2,REPEAT:1-3,REPEAT:1-4,REPEAT:2-1,REPEAT:2-2,REPEAT:2-3,
CNPY3	canopy FGF signaling regulator 3(CNPY3)	Homo sapiens			GO:0045087~innate immune response,	GO:0005788~endoplasmic reticulum lumen,	GO:0005102~receptor binding,GO:0005515~protein binding,	IPR021852:DUF3456,		617929~Developmental and epileptic encephalopathy 60,			KW-0391~Immunity,KW-0399~Innate immunity,	KW-0256~Endoplasmic reticulum,	KW-0225~Disease variant,KW-0887~Epilepsy,	KW-0175~Coiled coil,KW-0732~Signal,		KW-0143~Chaperone,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,DOMAIN:Saposin B-type,REGION:Disordered,
CAPZA1	capping actin protein of muscle Z-line subunit alpha 1(CAPZA1)	Homo sapiens			GO:0030036~actin cytoskeleton organization,GO:0034329~cell junction assembly,GO:0051016~barbed-end actin filament capping,GO:0065003~macromolecular complex assembly,	GO:0005576~extracellular region,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0008290~F-actin capping protein complex,GO:0015629~actin cytoskeleton,GO:0070062~extracellular exosome,GO:0071203~WASH complex,	GO:0003779~actin binding,GO:0005515~protein binding,GO:0045296~cadherin binding,GO:0051015~actin filament binding,	IPR002189:CapZ_alpha,IPR017865:F-actin_cap_asu_CS,IPR037282:CapZ_alpha/beta,IPR042276:CapZ_alpha/beta_2,IPR042489:CapZ_alpha_1,	hsa04144:Endocytosis,hsa04814:Motor proteins,					KW-0206~Cytoskeleton,KW-0963~Cytoplasm,		KW-0175~Coiled coil,		KW-0009~Actin-binding,KW-0117~Actin capping,	KW-0007~Acetylation,KW-0597~Phosphoprotein,
CAPZA2	capping actin protein of muscle Z-line subunit alpha 2(CAPZA2)	Homo sapiens			GO:0030036~actin cytoskeleton organization,GO:0051016~barbed-end actin filament capping,GO:0065003~macromolecular complex assembly,	GO:0005576~extracellular region,GO:0005829~cytosol,GO:0005903~brush border,GO:0008290~F-actin capping protein complex,GO:0015629~actin cytoskeleton,GO:0016020~membrane,GO:0030863~cortical cytoskeleton,GO:0070062~extracellular exosome,	GO:0003779~actin binding,GO:0005515~protein binding,GO:0051015~actin filament binding,	IPR002189:CapZ_alpha,IPR017865:F-actin_cap_asu_CS,IPR037282:CapZ_alpha/beta,IPR042276:CapZ_alpha/beta_2,IPR042489:CapZ_alpha_1,	hsa04144:Endocytosis,hsa04814:Motor proteins,					KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0009~Actin-binding,KW-0117~Actin capping,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	TRANSMEM:Helical,
CAPZB	capping actin protein of muscle Z-line subunit beta(CAPZB)	Homo sapiens			GO:0000902~cell morphogenesis,GO:0007010~cytoskeleton organization,GO:0008154~actin polymerization or depolymerization,GO:0010591~regulation of lamellipodium assembly,GO:0022604~regulation of cell morphogenesis,GO:0030032~lamellipodium assembly,GO:0030036~actin cytoskeleton organization,GO:0051016~barbed-end actin filament capping,GO:0051490~negative regulation of filopodium assembly,	GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005903~brush border,GO:0008290~F-actin capping protein complex,GO:0014069~postsynaptic density,GO:0015629~actin cytoskeleton,GO:0016020~membrane,GO:0030017~sarcomere,GO:0030027~lamellipodium,GO:0030863~cortical cytoskeleton,GO:0070062~extracellular exosome,GO:0071203~WASH complex,GO:0097224~sperm connecting piece,GO:0098685~Schaffer collateral - CA1 synapse,GO:0098686~hippocampal mossy fiber to CA3 synapse,	GO:0003779~actin binding,GO:0005515~protein binding,GO:0045296~cadherin binding,GO:0051015~actin filament binding,	IPR001698:CAPZB,IPR019771:F-actin_capping_bsu_CS,IPR037282:CapZ_alpha/beta,IPR042276:CapZ_alpha/beta_2,IPR043175:CAPZB_N,	hsa04144:Endocytosis,hsa04814:Motor proteins,					KW-0206~Cytoskeleton,KW-0963~Cytoplasm,				KW-0009~Actin-binding,KW-0117~Actin capping,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	REGION:Disordered,
CAPG	capping actin protein, gelsolin like(CAPG)	Homo sapiens			GO:0007417~central nervous system development,GO:0008154~actin polymerization or depolymerization,GO:0030031~cell projection assembly,GO:0051014~actin filament severing,GO:0051016~barbed-end actin filament capping,GO:0065003~macromolecular complex assembly,	GO:0001726~ruffle,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005814~centriole,GO:0008290~F-actin capping protein complex,GO:0015629~actin cytoskeleton,GO:0030027~lamellipodium,GO:0042470~melanosome,GO:0070062~extracellular exosome,GO:0072686~mitotic spindle,GO:0090543~Flemming body,	GO:0005515~protein binding,GO:0005546~phosphatidylinositol-4,5-bisphosphate binding,GO:0019904~protein domain specific binding,GO:0044877~macromolecular complex binding,GO:0045296~cadherin binding,GO:0051015~actin filament binding,	IPR007122:Villin/Gelsolin,IPR007123:Gelsolin-like_dom,IPR029006:ADF-H/Gelsolin-like_dom_sf,				SM00262:GEL,		KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0966~Cell projection,		KW-0677~Repeat,		KW-0009~Actin-binding,KW-0117~Actin capping,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:Gelsolin-like,MOTIF:Nuclear localization signal,REGION:Disordered,REPEAT:Gelsolin-like 1,REPEAT:Gelsolin-like 2,REPEAT:Gelsolin-like 3,
CNDP2	carnosine dipeptidase 2(CNDP2)	Homo sapiens			GO:0006508~proteolysis,	GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0004180~carboxypeptidase activity,GO:0016787~hydrolase activity,GO:0016805~dipeptidase activity,GO:0046872~metal ion binding,GO:0070573~metallodipeptidase activity,GO:0103046~alanylglutamate dipeptidase activity,	IPR001261:ArgE/DapE_CS,IPR002933:Peptidase_M20,IPR011650:Peptidase_M20_dimer,IPR017153:CNDP/DUG1,	hsa00330:Arginine and proline metabolism,hsa00340:Histidine metabolism,hsa00410:beta-Alanine metabolism,hsa01100:Metabolic pathways,		PIRSF037242:CNDP_dipeptidase,			KW-0963~Cytoplasm,			KW-0464~Manganese,KW-0479~Metal-binding,	KW-0121~Carboxypeptidase,KW-0378~Hydrolase,KW-0482~Metalloprotease,KW-0645~Protease,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,BINDING:in other chain,DOMAIN:Peptidase M20 dimerisation,REGION:Disordered,SITE:Important for catalytic activity,
CRTAP	cartilage associated protein(CRTAP)	Homo sapiens			GO:0007283~spermatogenesis,GO:0018400~peptidyl-proline hydroxylation to 3-hydroxy-L-proline,GO:0030199~collagen fibril organization,GO:0050821~protein stabilization,GO:0061077~chaperone-mediated protein folding,GO:1901874~negative regulation of post-translational protein modification,	GO:0005615~extracellular space,GO:0005783~endoplasmic reticulum,GO:0005788~endoplasmic reticulum lumen,GO:0032991~macromolecular complex,	GO:0005515~protein binding,GO:0005518~collagen binding,	IPR011990:TPR-like_helical_dom_sf,		610682~Osteogenesis imperfecta, type VII,				KW-0272~Extracellular matrix,KW-0964~Secreted,	KW-0225~Disease variant,KW-0242~Dwarfism,KW-1065~Osteogenesis imperfecta,	KW-0732~Signal,			KW-0325~Glycoprotein,KW-0379~Hydroxylation,	CARBOHYD:N-linked (GlcNAc...) asparagine,
CSNK1A1	casein kinase 1 alpha 1(CSNK1A1)	Homo sapiens		h_nfatPathway:NFAT and Hypertrophy of the heart (Transcription in the broken heart),h_p35AlzheimersPathway:Deregulation of CDK5 in Alzheimers Disease,h_p53hypoxiaPathway:Hypoxia and p53 in the Cardiovascular system,h_wntPathway:WNT Signaling Pathway,	GO:0006468~protein phosphorylation,GO:0007030~Golgi organization,GO:0007049~cell cycle,GO:0007165~signal transduction,GO:0007166~cell surface receptor signaling pathway,GO:0016055~Wnt signaling pathway,GO:0016310~phosphorylation,GO:0018105~peptidyl-serine phosphorylation,GO:0019082~viral protein processing,GO:0031670~cellular response to nutrient,GO:0032436~positive regulation of proteasomal ubiquitin-dependent protein catabolic process,GO:0035025~positive regulation of Rho protein signal transduction,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0045104~intermediate filament cytoskeleton organization,GO:0051301~cell division,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:1900226~negative regulation of NLRP3 inflammasome complex assembly,GO:1904263~positive regulation of TORC1 signaling,	GO:0000776~kinetochore,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005819~spindle,GO:0005829~cytosol,GO:0005847~mRNA cleavage and polyadenylation specificity factor complex,GO:0005929~cilium,GO:0016020~membrane,GO:0016607~nuclear speck,GO:0030877~beta-catenin destruction complex,GO:0036064~ciliary basal body,GO:0045095~keratin filament,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,	IPR000719:Prot_kinase_dom,IPR008271:Ser/Thr_kinase_AS,IPR011009:Kinase-like_dom_sf,IPR017441:Protein_kinase_ATP_BS,	hsa04310:Wnt signaling pathway,hsa04340:Hedgehog signaling pathway,hsa05010:Alzheimer disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05165:Human papillomavirus infection,hsa05224:Breast cancer,hsa05225:Hepatocellular carcinoma,hsa05226:Gastric cancer,			SM00220:S_TKc,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,KW-0879~Wnt signaling pathway,	KW-0137~Centromere,KW-0158~Chromosome,KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-0995~Kinetochore,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,COMPBIAS:Polar residues,DOMAIN:Protein kinase,REGION:Disordered,
CSNK1D	casein kinase 1 delta(CSNK1D)	Homo sapiens		h_ck1Pathway:Regulation of ck1/cdk5 by type 1 glutamate receptors,h_p35AlzheimersPathway:Deregulation of CDK5 in Alzheimers Disease,h_p53hypoxiaPathway:Hypoxia and p53 in the Cardiovascular system,h_wntPathway:WNT Signaling Pathway,	GO:0001934~positive regulation of protein phosphorylation,GO:0006468~protein phosphorylation,GO:0006897~endocytosis,GO:0007020~microtubule nucleation,GO:0007030~Golgi organization,GO:0007165~signal transduction,GO:0016055~Wnt signaling pathway,GO:0016310~phosphorylation,GO:0018105~peptidyl-serine phosphorylation,GO:0032436~positive regulation of proteasomal ubiquitin-dependent protein catabolic process,GO:0032922~circadian regulation of gene expression,GO:0034067~protein localization to Golgi apparatus,GO:0042752~regulation of circadian rhythm,GO:0048208~COPII vesicle coating,GO:0051225~spindle assembly,GO:0061512~protein localization to cilium,GO:0071539~protein localization to centrosome,GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:1904948~midbrain dopaminergic neuron differentiation,GO:1905515~non-motile cilium assembly,GO:1990090~cellular response to nerve growth factor stimulus,GO:2000052~positive regulation of non-canonical Wnt signaling pathway,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005813~centrosome,GO:0005819~spindle,GO:0005829~cytosol,GO:0005876~spindle microtubule,GO:0005886~plasma membrane,GO:0033116~endoplasmic reticulum-Golgi intermediate compartment membrane,GO:0036064~ciliary basal body,GO:0048471~perinuclear region of cytoplasm,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0045296~cadherin binding,GO:0050321~tau-protein kinase activity,	IPR000719:Prot_kinase_dom,IPR008271:Ser/Thr_kinase_AS,IPR011009:Kinase-like_dom_sf,IPR017441:Protein_kinase_ATP_BS,	hsa04340:Hedgehog signaling pathway,hsa04390:Hippo signaling pathway,hsa04540:Gap junction,hsa04710:Circadian rhythm,	615224~Advanced sleep-phase syndrome, familial, 2,		SM00220:S_TKc,	KW-0090~Biological rhythms,KW-0879~Wnt signaling pathway,	KW-0206~Cytoskeleton,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,	KW-0225~Disease variant,		KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0488~Methylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Protein kinase,MUTAGEN:K->M: Impaired kinase activity and abnormal subcellular localization with exclusive accumulation to the nucleus.,MUTAGEN:T->I: Impaired kinase activity and abnormal subcellular localization with exclusive accumulation to the nucleus.,REGION:Autoinhibitory,REGION:Centrosomal localization signal (CLS),REGION:Disordered,
CSNK2A1	casein kinase 2 alpha 1(CSNK2A1)	Homo sapiens		h_egfPathway:EGF Signaling Pathway,h_epoPathway:EPO Signaling Pathway,h_igf1Pathway:IGF-1 Signaling Pathway,h_il2Pathway:IL 2 signaling pathway,h_il6Pathway:IL 6 signaling pathway,h_insulinPathway:Insulin Signaling Pathway,h_Lis1Pathway:Lissencephaly gene (LIS1) in neuronal migration and development,h_ngfPathway:Nerve growth factor pathway (NGF),h_pdgfPathway:PDGF Signaling Pathway,h_tpoPathway:TPO Signaling Pathway,h_wntPathway:WNT Signaling Pathway,	GO:0006302~double-strand break repair,GO:0006468~protein phosphorylation,GO:0006915~apoptotic process,GO:0006974~cellular response to DNA damage stimulus,GO:0007049~cell cycle,GO:0007165~signal transduction,GO:0008284~positive regulation of cell proliferation,GO:0016055~Wnt signaling pathway,GO:0016310~phosphorylation,GO:0017148~negative regulation of translation,GO:0018105~peptidyl-serine phosphorylation,GO:0018107~peptidyl-threonine phosphorylation,GO:0030177~positive regulation of Wnt signaling pathway,GO:0030307~positive regulation of cell growth,GO:0043154~negative regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0045732~positive regulation of protein catabolic process,GO:0048511~rhythmic process,GO:0050821~protein stabilization,GO:0051726~regulation of cell cycle,GO:0061077~chaperone-mediated protein folding,GO:0075342~disruption by symbiont of host cell PML body,GO:1905337~positive regulation of aggrephagy,GO:1905818~regulation of chromosome separation,GO:2000059~negative regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process,GO:2001234~negative regulation of apoptotic signaling pathway,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005956~protein kinase CK2 complex,GO:0016605~PML body,GO:0031519~PcG protein complex,GO:0070822~Sin3-type complex,	GO:0004674~protein serine/threonine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016301~kinase activity,GO:0042802~identical protein binding,GO:0051879~Hsp90 protein binding,	IPR000719:Prot_kinase_dom,IPR001245:Ser-Thr/Tyr_kinase_cat_dom,IPR008271:Ser/Thr_kinase_AS,IPR011009:Kinase-like_dom_sf,IPR017441:Protein_kinase_ATP_BS,IPR045216:CK2_alpha,	hsa03008:Ribosome biogenesis in eukaryotes,hsa04064:NF-kappa B signaling pathway,hsa04137:Mitophagy - animal,hsa04310:Wnt signaling pathway,hsa04520:Adherens junction,hsa05010:Alzheimer disease,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05162:Measles,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,	617062~Okur-Chung neurodevelopmental syndrome,		SM00220:S_TKc,	KW-0053~Apoptosis,KW-0090~Biological rhythms,KW-0131~Cell cycle,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0879~Wnt signaling pathway,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-0991~Intellectual disability,		KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,COMPBIAS:Polar residues,DOMAIN:Protein kinase,REGION:Disordered,REGION:Interaction with beta subunit,
CSNK2B	casein kinase 2 beta(CSNK2B)	Homo sapiens			GO:0007165~signal transduction,GO:0008285~negative regulation of cell proliferation,GO:0016055~Wnt signaling pathway,GO:0016310~phosphorylation,GO:0018107~peptidyl-threonine phosphorylation,GO:0032927~positive regulation of activin receptor signaling pathway,GO:0033211~adiponectin-activated signaling pathway,GO:0043537~negative regulation of blood vessel endothelial cell migration,GO:0051101~regulation of DNA binding,GO:0060391~positive regulation of SMAD protein import into nucleus,GO:0061154~endothelial tube morphogenesis,GO:0065003~macromolecular complex assembly,GO:0075342~disruption by symbiont of host cell PML body,GO:1903901~negative regulation of viral life cycle,	GO:0000785~chromatin,GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005956~protein kinase CK2 complex,GO:0016605~PML body,GO:0031519~PcG protein complex,GO:0034774~secretory granule lumen,GO:0070062~extracellular exosome,GO:1904813~ficolin-1-rich granule lumen,	GO:0003682~chromatin binding,GO:0004674~protein serine/threonine kinase activity,GO:0005102~receptor binding,GO:0005515~protein binding,GO:0016301~kinase activity,GO:0019887~protein kinase regulator activity,GO:0019904~protein domain specific binding,GO:0030674~protein binding, bridging,GO:0042802~identical protein binding,GO:0046872~metal ion binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,	IPR000704:Casein_kinase_II_reg-sub,IPR016149:Casein_kin_II_reg-sub_N,IPR035991:Casein_kinase_II_beta-like,IPR038773:LY6G5B,	hsa03008:Ribosome biogenesis in eukaryotes,hsa03083:Polycomb repressive complex,hsa04064:NF-kappa B signaling pathway,hsa04137:Mitophagy - animal,hsa04310:Wnt signaling pathway,hsa04520:Adherens junction,hsa05010:Alzheimer disease,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05162:Measles,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,	618732~Poirier-Bienvenu neurodevelopmental syndrome,		SM01085:CK_II_beta,	KW-0879~Wnt signaling pathway,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-0887~Epilepsy,KW-0991~Intellectual disability,		KW-0479~Metal-binding,KW-0862~Zinc,	KW-0418~Kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,MOTIF:KSSR motif,MUTAGEN:KSSR->AAAA: No effect on interaction alpha subunit CSNK2A1. Loss on interaction with ARK2N and Epstein-Barr virus EBNA1.,REGION:Disordered,REGION:Interaction with alpha subunit,
CLPP	caseinolytic mitochondrial matrix peptidase proteolytic subunit(CLPP)	Homo sapiens			GO:0006508~proteolysis,GO:0006515~misfolded or incompletely synthesized protein catabolic process,GO:0033619~membrane protein proteolysis,GO:0051603~proteolysis involved in cellular protein catabolic process,	GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0009368~endopeptidase Clp complex,	GO:0004175~endopeptidase activity,GO:0004176~ATP-dependent peptidase activity,GO:0004252~serine-type endopeptidase activity,GO:0005515~protein binding,GO:0008233~peptidase activity,GO:0042802~identical protein binding,GO:0051117~ATPase binding,	IPR001907:ClpP,IPR018215:ClpP_Ser_AS,IPR023562:ClpP/TepA,IPR029045:ClpP/crotonase-like_dom_sf,IPR033135:ClpP_His_AS,		614129~Perrault syndrome 3,				KW-0496~Mitochondrion,	KW-0209~Deafness,KW-0225~Disease variant,	KW-0809~Transit peptide,		KW-0378~Hydrolase,KW-0645~Protease,KW-0720~Serine protease,	KW-0007~Acetylation,	ACT_SITE:Nucleophile,COMPBIAS:Basic and acidic residues,MUTAGEN:Missing: Abolishes protease activity.,MUTAGEN:S->A,C: Abolishes protease activity.,REGION:Disordered,TRANSIT:Mitochondrion,
CASP3	caspase 3(CASP3)	Homo sapiens	126.Apoptosis-Bcl-2,127.Mito-stress,150.caspase_and_NFKB_activation,38.Cell_cycle_arrest_and_apoptosis_ceramide,46.P13K_PTEN,72.IAP_interaction_with_cell_death_pathways,86.Apoptosis_Nematode&_Vert,	h_bcellsurvivalPathway:B Cell Survival Pathway,h_caspasePathway:Caspase Cascade in Apoptosis,h_chemicalPathway:Apoptotic Signaling in Response to DNA Damage,h_d4gdiPathway:D4-GDI Signaling Pathway,h_deathPathway:Induction of apoptosis through DR3 and DR4/5 Death Receptors ,h_DNAfragmentPathway:Apoptotic DNA fragmentation and tissue homeostasis,h_fasPathway:FAS signaling pathway ( CD95 ),h_hivnefPathway:HIV-I Nef: negative effector of Fas and TNF,h_hsp27Pathway:Stress Induction of HSP Regulation,h_mitochondriaPathway:Role of Mitochondria in Apoptotic Signaling,h_tnfr1Pathway:TNFR1 Signaling Pathway,h_tsp1Pathway:TSP-1 Induced Apoptosis in Microvascular Endothelial Cell ,	GO:0001554~luteolysis,GO:0001666~response to hypoxia,GO:0001782~B cell homeostasis,GO:0001818~negative regulation of cytokine production,GO:0006508~proteolysis,GO:0006915~apoptotic process,GO:0006974~cellular response to DNA damage stimulus,GO:0007413~axonal fasciculation,GO:0007507~heart development,GO:0007605~sensory perception of sound,GO:0007611~learning or memory,GO:0008627~intrinsic apoptotic signaling pathway in response to osmotic stress,GO:0009410~response to xenobiotic stimulus,GO:0009411~response to UV,GO:0009611~response to wounding,GO:0009749~response to glucose,GO:0010165~response to X-ray,GO:0016241~regulation of macroautophagy,GO:0016485~protein processing,GO:0021766~hippocampus development,GO:0030163~protein catabolic process,GO:0030182~neuron differentiation,GO:0030216~keratinocyte differentiation,GO:0030218~erythrocyte differentiation,GO:0030220~platelet formation,GO:0030889~negative regulation of B cell proliferation,GO:0031647~regulation of protein stability,GO:0032025~response to cobalt ion,GO:0032355~response to estradiol,GO:0032496~response to lipopolysaccharide,GO:0034349~glial cell apoptotic process,GO:0034612~response to tumor necrosis factor,GO:0035094~response to nicotine,GO:0042542~response to hydrogen peroxide,GO:0043029~T cell homeostasis,GO:0043065~positive regulation of apoptotic process,GO:0043200~response to amino acid,GO:0043525~positive regulation of neuron apoptotic process,GO:0044346~fibroblast apoptotic process,GO:0045165~cell fate commitment,GO:0045786~negative regulation of cell cycle,GO:0046007~negative regulation of activated T cell proliferation,GO:0048011~neurotrophin TRK receptor signaling pathway,GO:0051146~striated muscle cell differentiation,GO:0051384~response to glucocorticoid,GO:0051402~neuron apoptotic process,GO:0051604~protein maturation,GO:0061713~anterior neural tube closure,GO:0070269~pyroptosis,GO:0071887~leukocyte apoptotic process,GO:0072734~cellular response to staurosporine,GO:0097190~apoptotic signaling pathway,GO:0097193~intrinsic apoptotic signaling pathway,GO:0097194~execution phase of apoptosis,GO:1902004~positive regulation of beta-amyloid formation,GO:1904019~epithelial cell apoptotic process,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0031264~death-inducing signaling complex,GO:0032991~macromolecular complex,GO:0043025~neuronal cell body,	GO:0002020~protease binding,GO:0004190~aspartic-type endopeptidase activity,GO:0004197~cysteine-type endopeptidase activity,GO:0004861~cyclin-dependent protein serine/threonine kinase inhibitor activity,GO:0005123~death receptor binding,GO:0005515~protein binding,GO:0008047~enzyme activator activity,GO:0008233~peptidase activity,GO:0016005~phospholipase A2 activator activity,GO:0044877~macromolecular complex binding,GO:0097153~cysteine-type endopeptidase activity involved in apoptotic process,GO:0097199~cysteine-type endopeptidase activity involved in apoptotic signaling pathway,GO:0097200~cysteine-type endopeptidase activity involved in execution phase of apoptosis,	IPR001309:Pept_C14_p20,IPR002138:Pept_C14_p10,IPR002398:Pept_C14,IPR011600:Pept_C14_caspase,IPR015917:Pept_C14A,IPR016129:Caspase_his_AS,IPR029030:Caspase-like_dom_sf,IPR033139:Caspase_cys_AS,	hsa01524:Platinum drug resistance,hsa04010:MAPK signaling pathway,hsa04115:p53 signaling pathway,hsa04148:Efferocytosis,hsa04210:Apoptosis,hsa04215:Apoptosis - multiple species,hsa04623:Cytosolic DNA-sensing pathway,hsa04650:Natural killer cell mediated cytotoxicity,hsa04657:IL-17 signaling pathway,hsa04668:TNF signaling pathway,hsa04726:Serotonergic synapse,hsa04932:Non-alcoholic fatty liver disease,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa04936:Alcoholic liver disease,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05120:Epithelial cell signaling in Helicobacter pylori infection,hsa05130:Pathogenic Escherichia coli infection,hsa05132:Salmonella infection,hsa05133:Pertussis,hsa05134:Legionellosis,hsa05145:Toxoplasmosis,hsa05146:Amoebiasis,hsa05152:Tuberculosis,hsa05160:Hepatitis C,hsa05161:Hepatitis B,hsa05162:Measles,hsa05163:Human cytomegalovirus infection,hsa05164:Influenza A,hsa05165:Human papillomavirus infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05200:Pathways in cancer,hsa05203:Viral carcinogenesis,hsa05205:Proteoglycans in cancer,hsa05206:MicroRNAs in cancer,hsa05210:Colorectal cancer,hsa05222:Small cell lung cancer,hsa05416:Viral myocarditis,hsa05417:Lipid and atherosclerosis,			SM00115:CASc,	KW-0053~Apoptosis,	KW-0963~Cytoplasm,				KW-0378~Hydrolase,KW-0645~Protease,KW-0788~Thiol protease,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0702~S-nitrosylation,KW-0865~Zymogen,	DOMAIN:Caspase family p20,MUTAGEN:D->A: In P3-D3A mutant; abolished cleavage and activation, leading to prevent thiol protease activity; when associated with A-28 and A-175.,MUTAGEN:D->A: In P3-D3A mutant; abolished cleavage and activation, leading to prevent thiol protease activity; when associated with A-9 and A-175.,MUTAGEN:D->A: In P3-D3A mutant; abolished cleavage and activation, leading to prevent thiol protease activity; when associated with A-9 and A-28.,MUTAGEN:R->A: Abolished ADP-riboxanation by C.violaceum CopC.,REGION:Disordered,
CASP4	caspase 4(CASP4)	Homo sapiens		h_caspasePathway:Caspase Cascade in Apoptosis,	GO:0006508~proteolysis,GO:0006915~apoptotic process,GO:0006954~inflammatory response,GO:0016540~protein autoprocessing,GO:0042742~defense response to bacterium,GO:0042981~regulation of apoptotic process,GO:0043525~positive regulation of neuron apoptotic process,GO:0045087~innate immune response,GO:0050727~regulation of inflammatory response,GO:0050729~positive regulation of inflammatory response,GO:0050830~defense response to Gram-positive bacterium,GO:0051604~protein maturation,GO:0070059~intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress,GO:0070269~pyroptosis,GO:0097193~intrinsic apoptotic signaling pathway,GO:0097194~execution phase of apoptosis,GO:1903265~positive regulation of tumor necrosis factor-mediated signaling pathway,GO:1904646~cellular response to beta-amyloid,GO:2000494~positive regulation of interleukin-18-mediated signaling pathway,	GO:0005576~extracellular region,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0032991~macromolecular complex,GO:0061702~inflammasome complex,GO:0072558~NLRP1 inflammasome complex,	GO:0001530~lipopolysaccharide binding,GO:0004197~cysteine-type endopeptidase activity,GO:0005515~protein binding,GO:0050700~CARD domain binding,GO:0097200~cysteine-type endopeptidase activity involved in execution phase of apoptosis,	IPR001309:Pept_C14_p20,IPR001315:CARD,IPR002138:Pept_C14_p10,IPR002398:Pept_C14,IPR011029:DEATH-like_dom_sf,IPR011600:Pept_C14_caspase,IPR015917:Pept_C14A,IPR016129:Caspase_his_AS,IPR029030:Caspase-like_dom_sf,IPR033139:Caspase_cys_AS,	hsa04613:Neutrophil extracellular trap formation,hsa04621:NOD-like receptor signaling pathway,hsa05130:Pathogenic Escherichia coli infection,hsa05131:Shigellosis,hsa05132:Salmonella infection,		PIRSF038001:Caspase_ICE,	SM00114:CARD,SM00115:CASc,	KW-0391~Immunity,KW-0395~Inflammatory response,KW-0399~Innate immunity,KW-1210~Necrosis,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0496~Mitochondrion,KW-0963~Cytoplasm,KW-0964~Secreted,KW-1271~Inflammasome,				KW-0378~Hydrolase,KW-0645~Protease,KW-0788~Thiol protease,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0865~Zymogen,	DOMAIN:CARD,DOMAIN:Caspase family p10,MUTAGEN:C->A: Loss of enzymatic activity. Loss of LPS-induced pyroptosis. No effect on the interaction with LPS. Decrease in cell death induced by TMEM214 overexpression. Does not support IL1B and IL18 secretion following UVB irradiation.,MUTAGEN:C->S: Loss of autocatalysis.,MUTAGEN:D->A: Abolished autoprocessing and ability to form a heterotetramer composed of Caspase-4 subunit p10 and Caspase-4 subunit p20, preventing ability to cleave GSDMD and induce pyroptosis.,MUTAGEN:R->A: Abolished ability to cleave Gasdermin-D (GSDMD).,MUTAGEN:V->N: Abolished interaction with Gasdermin-D (GSDMD) and ability to mediate its cleavage.,MUTAGEN:W->L,N: Abolished interaction with Gasdermin-D (GSDMD) and ability to mediate its cleavage.,REGION:Disordered,REGION:Required for LPS-binding,SITE:Cleavage; by autolysis,
CASP8	caspase 8(CASP8)	Homo sapiens	150.caspase_and_NFKB_activation,39.Deg_of_Chromosomal_DNA,40.Deg_of_Chrom_DNA_TNF-ind_apoptosis,44.Sig_Trans_TNFR1-DR3-DR4_DR5,46.P13K_PTEN,72.IAP_interaction_with_cell_death_pathways,86.Apoptosis_Nematode&_Vert,	h_caspasePathway:Caspase Cascade in Apoptosis,h_ceramidePathway:Ceramide Signaling Pathway,h_d4gdiPathway:D4-GDI Signaling Pathway,h_deathPathway:Induction of apoptosis through DR3 and DR4/5 Death Receptors ,h_fasPathway:FAS signaling pathway ( CD95 ),h_hivnefPathway:HIV-I Nef: negative effector of Fas and TNF,h_mitochondriaPathway:Role of Mitochondria in Apoptotic Signaling,h_soddPathway:SODD/TNFR1 Signaling Pathway,h_tnfr1Pathway:TNFR1 Signaling Pathway,	GO:0001525~angiogenesis,GO:0001817~regulation of cytokine production,GO:0006508~proteolysis,GO:0006915~apoptotic process,GO:0006919~activation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0007507~heart development,GO:0008625~extrinsic apoptotic signaling pathway via death domain receptors,GO:0010803~regulation of tumor necrosis factor-mediated signaling pathway,GO:0030101~natural killer cell activation,GO:0030225~macrophage differentiation,GO:0030335~positive regulation of cell migration,GO:0032025~response to cobalt ion,GO:0032355~response to estradiol,GO:0032496~response to lipopolysaccharide,GO:0032731~positive regulation of interleukin-1 beta production,GO:0034612~response to tumor necrosis factor,GO:0036462~TRAIL-activated apoptotic signaling pathway,GO:0042110~T cell activation,GO:0042113~B cell activation,GO:0042981~regulation of apoptotic process,GO:0043065~positive regulation of apoptotic process,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043124~negative regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043525~positive regulation of neuron apoptotic process,GO:0045088~regulation of innate immune response,GO:0045471~response to ethanol,GO:0045651~positive regulation of macrophage differentiation,GO:0045862~positive regulation of proteolysis,GO:0051603~proteolysis involved in cellular protein catabolic process,GO:0051604~protein maturation,GO:0060546~negative regulation of necroptotic process,GO:0060715~syncytiotrophoblast cell differentiation involved in labyrinthine layer development,GO:0070269~pyroptosis,GO:0071260~cellular response to mechanical stimulus,GO:0071407~cellular response to organic cyclic compound,GO:0097190~apoptotic signaling pathway,GO:0097191~extrinsic apoptotic signaling pathway,GO:0097194~execution phase of apoptosis,GO:0097202~activation of cysteine-type endopeptidase activity,GO:0097264~self proteolysis,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005741~mitochondrial outer membrane,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0030027~lamellipodium,GO:0031264~death-inducing signaling complex,GO:0031265~CD95 death-inducing signaling complex,GO:0032991~macromolecular complex,GO:0044297~cell body,GO:0097342~ripoptosome,	GO:0004197~cysteine-type endopeptidase activity,GO:0005123~death receptor binding,GO:0005164~tumor necrosis factor receptor binding,GO:0005515~protein binding,GO:0008233~peptidase activity,GO:0008234~cysteine-type peptidase activity,GO:0031625~ubiquitin protein ligase binding,GO:0035877~death effector domain binding,GO:0042802~identical protein binding,GO:0044877~macromolecular complex binding,GO:0097110~scaffold protein binding,GO:0097153~cysteine-type endopeptidase activity involved in apoptotic process,GO:0097199~cysteine-type endopeptidase activity involved in apoptotic signaling pathway,	IPR001309:Pept_C14_p20,IPR001875:DED_dom,IPR002138:Pept_C14_p10,IPR011029:DEATH-like_dom_sf,IPR011600:Pept_C14_caspase,IPR015917:Pept_C14A,IPR016129:Caspase_his_AS,IPR029030:Caspase-like_dom_sf,IPR033139:Caspase_cys_AS,IPR033170:Caspase-8_DED1,	hsa01524:Platinum drug resistance,hsa04115:p53 signaling pathway,hsa04210:Apoptosis,hsa04215:Apoptosis - multiple species,hsa04217:Necroptosis,hsa04620:Toll-like receptor signaling pathway,hsa04621:NOD-like receptor signaling pathway,hsa04622:RIG-I-like receptor signaling pathway,hsa04623:Cytosolic DNA-sensing pathway,hsa04625:C-type lectin receptor signaling pathway,hsa04657:IL-17 signaling pathway,hsa04668:TNF signaling pathway,hsa04932:Non-alcoholic fatty liver disease,hsa04936:Alcoholic liver disease,hsa05010:Alzheimer disease,hsa05016:Huntington disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05130:Pathogenic Escherichia coli infection,hsa05132:Salmonella infection,hsa05134:Legionellosis,hsa05142:Chagas disease,hsa05145:Toxoplasmosis,hsa05152:Tuberculosis,hsa05160:Hepatitis C,hsa05161:Hepatitis B,hsa05162:Measles,hsa05163:Human cytomegalovirus infection,hsa05164:Influenza A,hsa05165:Human papillomavirus infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05200:Pathways in cancer,hsa05203:Viral carcinogenesis,hsa05416:Viral myocarditis,hsa05417:Lipid and atherosclerosis,	114480~Breast cancer, protection against,114550~Hepatocellular carcinoma, somatic,211980~Lung cancer, protection against,607271~Caspase 8 lymphadenopathy syndrome,	PIRSF038001:Caspase_ICE,	SM00031:DED,SM00115:CASc,	KW-0053~Apoptosis,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,	KW-0677~Repeat,		KW-0378~Hydrolase,KW-0645~Protease,KW-0788~Thiol protease,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0865~Zymogen,	DOMAIN:Caspase family p10,DOMAIN:Caspase family p20,DOMAIN:DED,DOMAIN:DED 1,DOMAIN:DED 2,MUTAGEN:C->S: Abolishes interaction with UBR2.,MUTAGEN:D->A: Abolishes binding to FLASH. Induces NF-kappa-B activation.,MUTAGEN:R->A: Abolished ADP-riboxanation by C.violaceum CopC.,MUTAGEN:S->A: Impaired CDK1-mediated phosphorylation and enhanced apoptosis.,REGION:Disordered,SITE:Cleavage; by CASP6,SITE:Cleavage; by autocatalytic cleavage,
COMT	catechol-O-methyltransferase(COMT)	Homo sapiens			GO:0001662~behavioral fear response,GO:0001666~response to hypoxia,GO:0001963~synaptic transmission, dopaminergic,GO:0001964~startle response,GO:0001975~response to amphetamine,GO:0002001~renin secretion into blood stream,GO:0005977~glycogen metabolic process,GO:0006584~catecholamine metabolic process,GO:0006629~lipid metabolic process,GO:0006693~prostaglandin metabolic process,GO:0006979~response to oxidative stress,GO:0007613~memory,GO:0008542~visual learning,GO:0009410~response to xenobiotic stimulus,GO:0009611~response to wounding,GO:0009636~response to toxic substance,GO:0010035~response to inorganic substance,GO:0010467~gene expression,GO:0014046~dopamine secretion,GO:0016036~cellular response to phosphate starvation,GO:0021696~cerebellar cortex morphogenesis,GO:0032094~response to food,GO:0032259~methylation,GO:0032502~developmental process,GO:0032835~glomerulus development,GO:0033344~cholesterol efflux,GO:0034097~response to cytokine,GO:0035264~multicellular organism growth,GO:0035640~exploration behavior,GO:0035812~renal sodium excretion,GO:0042415~norepinephrine metabolic process,GO:0042417~dopamine metabolic process,GO:0042420~dopamine catabolic process,GO:0042424~catecholamine catabolic process,GO:0046959~habituation,GO:0048243~norepinephrine secretion,GO:0050965~detection of temperature stimulus involved in sensory perception of pain,GO:0051412~response to corticosterone,GO:0060840~artery development,GO:0071314~cellular response to cocaine,GO:0071626~mastication,GO:0097018~renal albumin absorption,GO:0097205~renal filtration,GO:1903350~response to dopamine,GO:1990776~response to angiotensin,	GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0030424~axon,GO:0030425~dendrite,GO:0043231~intracellular membrane-bounded organelle,GO:0045202~synapse,GO:0070062~extracellular exosome,	GO:0000287~magnesium ion binding,GO:0005515~protein binding,GO:0008168~methyltransferase activity,GO:0008171~O-methyltransferase activity,GO:0008757~S-adenosylmethionine-dependent methyltransferase activity,GO:0016206~catechol O-methyltransferase activity,GO:0102084~L-dopa O-methyltransferase activity,	IPR002935:SAM_O-MeTrfase,IPR017128:Catechol_O-MeTrfase_euk,IPR029063:SAM-dependent_MTases_sf,	hsa00140:Steroid hormone biosynthesis,hsa00350:Tyrosine metabolism,hsa01100:Metabolic pathways,hsa04728:Dopaminergic synapse,	167870~Panic disorder, susceptibility to,181500~Schizophrenia, susceptibility to,	PIRSF037177:Catechol_O-mtfrase_euk,		KW-0128~Catecholamine metabolism,KW-0443~Lipid metabolism,KW-0531~Neurotransmitter degradation,	KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,	KW-1211~Schizophrenia,	KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0460~Magnesium,KW-0479~Metal-binding,KW-0949~S-adenosyl-L-methionine,	KW-0489~Methyltransferase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
CTNNB1	catenin beta 1(CTNNB1)	Homo sapiens		h_alkPathway:ALK in cardiac myocytes,h_cell2cellPathway:Cell to Cell Adhesion Signaling,H_gsk3Pathway:Inactivation of Gsk3 by AKT causes accumulation of b-catenin in Alveolar Macrophages,h_pitx2Pathway:Multi-step Regulation of Transcription by Pitx2,h_ps1Pathway:Presenilin action in Notch and Wnt signaling,h_tffPathway:Trefoil Factors Initiate  Mucosal Healing,h_wntPathway:WNT Signaling Pathway,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0000165~MAPK cascade,GO:0000209~protein polyubiquitination,GO:0000578~embryonic axis specification,GO:0001569~branching involved in blood vessel morphogenesis,GO:0001649~osteoblast differentiation,GO:0001658~branching involved in ureteric bud morphogenesis,GO:0001701~in utero embryonic development,GO:0001702~gastrulation with mouth forming second,GO:0001708~cell fate specification,GO:0001711~endodermal cell fate commitment,GO:0001764~neuron migration,GO:0001837~epithelial to mesenchymal transition,GO:0001840~neural plate development,GO:0002052~positive regulation of neuroblast proliferation,GO:0002053~positive regulation of mesenchymal cell proliferation,GO:0002062~chondrocyte differentiation,GO:0002089~lens morphogenesis in camera-type eye,GO:0003151~outflow tract morphogenesis,GO:0003266~regulation of secondary heart field cardioblast proliferation,GO:0003338~metanephros morphogenesis,GO:0003340~negative regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis,GO:0006366~transcription from RNA polymerase II promoter,GO:0007155~cell adhesion,GO:0007160~cell-matrix adhesion,GO:0007249~I-kappaB kinase/NF-kappaB signaling,GO:0007268~chemical synaptic transmission,GO:0007398~ectoderm development,GO:0007403~glial cell fate determination,GO:0007405~neuroblast proliferation,GO:0008284~positive regulation of cell proliferation,GO:0008285~negative regulation of cell proliferation,GO:0008543~fibroblast growth factor receptor signaling pathway,GO:0009410~response to xenobiotic stimulus,GO:0009948~anterior/posterior axis specification,GO:0009950~dorsal/ventral axis specification,GO:0009954~proximal/distal pattern formation,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0010718~positive regulation of epithelial to mesenchymal transition,GO:0010909~positive regulation of heparan sulfate proteoglycan biosynthetic process,GO:0016525~negative regulation of angiogenesis,GO:0019827~stem cell population maintenance,GO:0021819~layer formation in cerebral cortex,GO:0021854~hypothalamus development,GO:0022009~central nervous system vasculogenesis,GO:0030316~osteoclast differentiation,GO:0030539~male genitalia development,GO:0030902~hindbrain development,GO:0030997~regulation of centriole-centriole cohesion,GO:0031016~pancreas development,GO:0031069~hair follicle morphogenesis,GO:0031396~regulation of protein ubiquitination,GO:0031641~regulation of myelination,GO:0032212~positive regulation of telomere maintenance via telomerase,GO:0032331~negative regulation of chondrocyte differentiation,GO:0032355~response to estradiol,GO:0032968~positive regulation of transcription elongation from RNA polymerase II promoter,GO:0033077~T cell differentiation in thymus,GO:0033234~negative regulation of protein sumoylation,GO:0034333~adherens junction assembly,GO:0034394~protein localization to cell surface,GO:0035050~embryonic heart tube development,GO:0035112~genitalia morphogenesis,GO:0035115~embryonic forelimb morphogenesis,GO:0035116~embryonic hindlimb morphogenesis,GO:0035315~hair cell differentiation,GO:0035995~detection of muscle stretch,GO:0036023~embryonic skeletal limb joint morphogenesis,GO:0036520~astrocyte-dopaminergic neuron signaling,GO:0042129~regulation of T cell proliferation,GO:0042475~odontogenesis of dentin-containing tooth,GO:0042733~embryonic digit morphogenesis,GO:0043065~positive regulation of apoptotic process,GO:0043066~negative regulation of apoptotic process,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0043410~positive regulation of MAPK cascade,GO:0043525~positive regulation of neuron apoptotic process,GO:0044338~canonical Wnt signaling pathway involved in mesenchymal stem cell differentiation,GO:0045453~bone resorption,GO:0045597~positive regulation of cell differentiation,GO:0045603~positive regulation of endothelial cell differentiation,GO:0045669~positive regulation of osteoblast differentiation,GO:0045671~negative regulation of osteoclast differentiation,GO:0045743~positive regulation of fibroblast growth factor receptor signaling pathway,GO:0045765~regulation of angiogenesis,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0045976~negative regulation of mitotic cell cycle, embryonic,GO:0048145~regulation of fibroblast proliferation,GO:0048469~cell maturation,GO:0048489~synaptic vesicle transport,GO:0048538~thymus development,GO:0048599~oocyte development,GO:0048617~embryonic foregut morphogenesis,GO:0048643~positive regulation of skeletal muscle tissue development,GO:0048660~regulation of smooth muscle cell proliferation,GO:0048664~neuron fate determination,GO:0048709~oligodendrocyte differentiation,GO:0048715~negative regulation of oligodendrocyte differentiation,GO:0050767~regulation of neurogenesis,GO:0050808~synapse organization,GO:0051145~smooth muscle cell differentiation,GO:0051450~myoblast proliferation,GO:0051884~regulation of timing of anagen,GO:0051963~regulation of synapse assembly,GO:0060066~oviduct development,GO:0060070~canonical Wnt signaling pathway,GO:0060440~trachea formation,GO:0060441~epithelial tube branching involved in lung morphogenesis,GO:0060484~lung-associated mesenchyme development,GO:0060487~lung epithelial cell differentiation,GO:0060492~lung induction,GO:0060742~epithelial cell differentiation involved in prostate gland development,GO:0060767~epithelial cell proliferation involved in prostate gland development,GO:0060769~positive regulation of epithelial cell proliferation involved in prostate gland development,GO:0060789~hair follicle placode formation,GO:0060856~establishment of blood-brain barrier,GO:0060916~mesenchymal cell proliferation involved in lung development,GO:0061047~positive regulation of branching involved in lung morphogenesis,GO:0061154~endothelial tube morphogenesis,GO:0061198~fungiform papilla formation,GO:0061549~sympathetic ganglion development,GO:0061550~cranial ganglion development,GO:0070602~regulation of centromeric sister chromatid cohesion,GO:0071363~cellular response to growth factor stimulus,GO:0071681~cellular response to indole-3-methanol,GO:0072033~renal vesicle formation,GO:0072053~renal inner medulla development,GO:0072054~renal outer medulla development,GO:0072079~nephron tubule formation,GO:0072089~stem cell proliferation,GO:0072182~regulation of nephron tubule epithelial cell differentiation,GO:0072497~mesenchymal stem cell differentiation,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:0090279~regulation of calcium ion import,GO:0090425~acinar cell differentiation,GO:0097091~synaptic vesicle clustering,GO:0097190~apoptotic signaling pathway,GO:0098609~cell-cell adhesion,GO:1901331~positive regulation of odontoblast differentiation,GO:1903377~negative regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway,GO:1904888~cranial skeletal system development,GO:1904948~midbrain dopaminergic neuron differentiation,GO:1990138~neuron projection extension,GO:1990403~embryonic brain development,GO:1990791~dorsal root ganglion development,GO:1990963~establishment of blood-retinal barrier,GO:2000008~regulation of protein localization to cell surface,GO:2000017~positive regulation of determination of dorsal identity,GO:2000288~positive regulation of myoblast proliferation,GO:2000648~positive regulation of stem cell proliferation,	GO:0000791~euchromatin,GO:0000922~spindle pole,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005911~cell-cell junction,GO:0005912~adherens junction,GO:0005916~fascia adherens,GO:0005923~bicellular tight junction,GO:0005925~focal adhesion,GO:0005938~cell cortex,GO:0016020~membrane,GO:0016323~basolateral plasma membrane,GO:0016327~apicolateral plasma membrane,GO:0016328~lateral plasma membrane,GO:0016342~catenin complex,GO:0016600~flotillin complex,GO:0030018~Z disc,GO:0030027~lamellipodium,GO:0030054~cell junction,GO:0030877~beta-catenin destruction complex,GO:0031528~microvillus membrane,GO:0032991~macromolecular complex,GO:0032993~protein-DNA complex,GO:0034750~Scrib-APC-beta-catenin complex,GO:0042734~presynaptic membrane,GO:0045177~apical part of cell,GO:0045202~synapse,GO:0045211~postsynaptic membrane,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,GO:0070369~beta-catenin-TCF7L2 complex,GO:0071944~cell periphery,GO:0098685~Schaffer collateral - CA1 synapse,GO:0098831~presynaptic active zone cytoplasmic component,GO:0098978~glutamatergic synapse,GO:0099092~postsynaptic density, intracellular component,GO:1990711~Beta-catenin-ICAT complex,GO:1990907~beta-catenin-TCF complex,GO:1990909~Wnt signalosome,	GO:0001221~transcription cofactor binding,GO:0001222~transcription corepressor binding,GO:0003682~chromatin binding,GO:0003713~transcription coactivator activity,GO:0005102~receptor binding,GO:0005515~protein binding,GO:0016922~ligand-dependent nuclear receptor binding,GO:0019899~enzyme binding,GO:0019900~kinase binding,GO:0019901~protein kinase binding,GO:0019903~protein phosphatase binding,GO:0030331~estrogen receptor binding,GO:0031625~ubiquitin protein ligase binding,GO:0044325~ion channel binding,GO:0045294~alpha-catenin binding,GO:0045296~cadherin binding,GO:0046332~SMAD binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:0070411~I-SMAD binding,GO:0097718~disordered domain specific binding,GO:1990226~histone methyltransferase binding,	IPR000225:Armadillo,IPR011989:ARM-like,IPR013284:Beta-catenin,IPR016024:ARM-type_fold,	hsa04015:Rap1 signaling pathway,hsa04310:Wnt signaling pathway,hsa04390:Hippo signaling pathway,hsa04510:Focal adhesion,hsa04520:Adherens junction,hsa04550:Signaling pathways regulating pluripotency of stem cells,hsa04670:Leukocyte transendothelial migration,hsa04916:Melanogenesis,hsa04919:Thyroid hormone signaling pathway,hsa04934:Cushing syndrome,hsa04936:Alcoholic liver disease,hsa05010:Alzheimer disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05100:Bacterial invasion of epithelial cells,hsa05132:Salmonella infection,hsa05160:Hepatitis C,hsa05163:Human cytomegalovirus infection,hsa05165:Human papillomavirus infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05200:Pathways in cancer,hsa05205:Proteoglycans in cancer,hsa05210:Colorectal cancer,hsa05213:Endometrial cancer,hsa05215:Prostate cancer,hsa05216:Thyroid cancer,hsa05217:Basal cell carcinoma,hsa05224:Breast cancer,hsa05225:Hepatocellular carcinoma,hsa05226:Gastric cancer,hsa05412:Arrhythmogenic right ventricular cardiomyopathy,hsa05418:Fluid shear stress and atherosclerosis,	114500~Colorectal cancer, somatic,114550~Hepatocellular carcinoma, somatic,132600~Pilomatricoma, somatic,155255~Medulloblastoma, somatic,167000~Ovarian cancer, somatic,615075~Neurodevelopmental disorder with spastic diplegia and visual defects,617572~Exudative vitreoretinopathy 7,		SM00185:ARM,	KW-0130~Cell adhesion,KW-0524~Neurogenesis,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0879~Wnt signaling pathway,KW-0945~Host-virus interaction,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0539~Nucleus,KW-0770~Synapse,KW-0963~Cytoplasm,KW-0965~Cell junction,KW-0966~Cell projection,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0991~Intellectual disability,	KW-0677~Repeat,		KW-0010~Activator,	KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0702~S-nitrosylation,KW-0832~Ubl conjugation,	CARBOHYD:O-linked (GlcNAc) serine; alternate,COMPBIAS:Polar residues,MUTAGEN:F->A: Abolishes CTNNBIP1 binding; when associated with A-661.,MUTAGEN:F->A: Abolishes or strongly reduces AXIN2 binding.,MUTAGEN:H->A: Abolishes TCF7L2 binding, and strongly reduces or abolishes LEF1 binding.,MUTAGEN:H->A: Abolishes or strongly reduces AXIN1 and AXIN2 binding. Strongly reduces phosphorylation and degradation; when associated with A-386 and A-383.,MUTAGEN:K->A: Abolishes APC binding.,MUTAGEN:K->A: Abolishes TCF7L2 and LEF1 binding.,MUTAGEN:K->A: Abolishes or strongly reduces AXIN1 and AXIN2 binding.,MUTAGEN:K->A: Strongly reduces or abolishes LEF1 binding.,MUTAGEN:K->E: Abolishes TCF7L2 binding.,MUTAGEN:L->A: Abolishes interaction with BCL9 but no effect on interaction with CDH3; when associated with A-159.,MUTAGEN:L->A: No effect on interaction with BCL9 and CDH3.,MUTAGEN:L->A: No effect on interaction with BCL9 and CDH3. Abolishes interaction with BCL9 but no effect on interaction with CDH3; when associated with A-156.,MUTAGEN:N->A: Abolishes TCF7L2 and LEF1 binding.,MUTAGEN:R->A: Abolishes CTNNBIP1 binding; when associated with A-660.,MUTAGEN:R->A: Abolishes TCF7L2 binding, and strongly reduces or abolishes LEF1 binding.,MUTAGEN:R->A: Strongly reduces APC binding. Strongly reduces phosphorylation and degradation; when associated with A-260 and A-383.,MUTAGEN:S->F: No effect.,MUTAGEN:W->A: Abolishes APC binding. Strongly reduces phosphorylation and degradation; when associated with A-260 and A-386.,MUTAGEN:Y->E: No effect on interaction with BCL9 and BCL9L.,MUTAGEN:Y->F: Abolished phosphorylation by SRC and interaction with isoform M2 of PKM (PKM2).,MUTAGEN:Y->F: Abolishes phosphorylation by PTK6.,REGION:Disordered,REGION:Interaction with BCL9,REGION:Interaction with SCRIB,REGION:Interaction with VCL,REPEAT:ARM,REPEAT:ARM 1,REPEAT:ARM 10,REPEAT:ARM 11,REPEAT:ARM 12,REPEAT:ARM 2,REPEAT:ARM 3,REPEAT:ARM 4,REPEAT:ARM 5,REPEAT:ARM 6,REPEAT:ARM 7,REPEAT:ARM 8,REPEAT:ARM 9,
CTSA	cathepsin A(CTSA)	Homo sapiens			GO:0006508~proteolysis,GO:0006886~intracellular protein transport,GO:0031647~regulation of protein stability,GO:1904714~regulation of chaperone-mediated autophagy,GO:1904715~negative regulation of chaperone-mediated autophagy,	GO:0005576~extracellular region,GO:0005764~lysosome,GO:0005783~endoplasmic reticulum,GO:0016020~membrane,GO:0035578~azurophil granule lumen,GO:0043202~lysosomal lumen,GO:0043231~intracellular membrane-bounded organelle,GO:0070062~extracellular exosome,GO:0098575~lumenal side of lysosomal membrane,	GO:0004180~carboxypeptidase activity,GO:0004185~serine-type carboxypeptidase activity,GO:0008047~enzyme activator activity,	IPR001563:Peptidase_S10,IPR018202:Ser_caboxypep_ser_AS,IPR029058:AB_hydrolase,IPR033124:Ser_caboxypep_his_AS,	hsa04142:Lysosome,hsa04614:Renin-angiotensin system,	256540~Galactosialidosis,				KW-0458~Lysosome,	KW-0225~Disease variant,	KW-0732~Signal,		KW-0121~Carboxypeptidase,KW-0378~Hydrolase,KW-0645~Protease,	KW-0325~Glycoprotein,KW-0865~Zymogen,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,MUTAGEN:H->Q: Inactivates the enzyme.,MUTAGEN:S->A: Inactivates the enzyme.,REGION:Disordered,
CTSB	cathepsin B(CTSB)	Homo sapiens			GO:0006508~proteolysis,GO:0006590~thyroid hormone generation,GO:0030574~collagen catabolic process,GO:0030855~epithelial cell differentiation,GO:0042981~regulation of apoptotic process,GO:0046697~decidualization,GO:0046718~viral entry into host cell,GO:0051603~proteolysis involved in cellular protein catabolic process,GO:0097067~cellular response to thyroid hormone stimulus,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005764~lysosome,GO:0009897~external side of plasma membrane,GO:0016324~apical plasma membrane,GO:0036021~endolysosome lumen,GO:0042470~melanosome,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,GO:1904090~peptidase inhibitor complex,GO:1904813~ficolin-1-rich granule lumen,	GO:0004197~cysteine-type endopeptidase activity,GO:0005515~protein binding,GO:0005518~collagen binding,GO:0008233~peptidase activity,GO:0008234~cysteine-type peptidase activity,GO:0043394~proteoglycan binding,	IPR000169:Pept_cys_AS,IPR000668:Peptidase_C1A_C,IPR012599:Propeptide_C1A,IPR013128:Peptidase_C1A,IPR025660:Pept_his_AS,IPR025661:Pept_asp_AS,IPR038765:Papain-like_cys_pep_sf,	hsa04140:Autophagy - animal,hsa04142:Lysosome,hsa04210:Apoptosis,hsa04612:Antigen processing and presentation,hsa04621:NOD-like receptor signaling pathway,hsa04924:Renin secretion,	148370~Keratolytic winter erythema,		SM00645:Pept_C1,		KW-0458~Lysosome,KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0732~Signal,		KW-0378~Hydrolase,KW-0645~Protease,KW-0788~Thiol protease,	KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0865~Zymogen,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:Peptidase C1A papain C-terminal,DOMAIN:Peptidase C1A propeptide,PROPEP:Activation peptide,REGION:Disordered,
CTSC	cathepsin C(CTSC)	Homo sapiens			GO:0001913~T cell mediated cytotoxicity,GO:0006508~proteolysis,GO:0006915~apoptotic process,GO:0006955~immune response,GO:0010033~response to organic substance,GO:0031642~negative regulation of myelination,GO:0051603~proteolysis involved in cellular protein catabolic process,GO:1903052~positive regulation of proteolysis involved in cellular protein catabolic process,GO:1903980~positive regulation of microglial cell activation,GO:2001235~positive regulation of apoptotic signaling pathway,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005654~nucleoplasm,GO:0005764~lysosome,GO:0005788~endoplasmic reticulum lumen,GO:0005813~centrosome,GO:0016020~membrane,GO:0030134~ER to Golgi transport vesicle,GO:0033116~endoplasmic reticulum-Golgi intermediate compartment membrane,GO:0035578~azurophil granule lumen,GO:0043231~intracellular membrane-bounded organelle,GO:0070062~extracellular exosome,	GO:0004197~cysteine-type endopeptidase activity,GO:0004252~serine-type endopeptidase activity,GO:0005515~protein binding,GO:0008234~cysteine-type peptidase activity,GO:0008239~dipeptidyl-peptidase activity,GO:0016505~peptidase activator activity involved in apoptotic process,GO:0019902~phosphatase binding,GO:0031404~chloride ion binding,GO:0042802~identical protein binding,GO:0043621~protein self-association,GO:0051087~chaperone binding,	IPR000169:Pept_cys_AS,IPR000668:Peptidase_C1A_C,IPR013128:Peptidase_C1A,IPR014882:CathepsinC_exc,IPR025660:Pept_his_AS,IPR025661:Pept_asp_AS,IPR036496:CathepsinC_exc_dom_sf,IPR038765:Papain-like_cys_pep_sf,IPR039412:CatC,	hsa04142:Lysosome,hsa04210:Apoptosis,	170650~Periodontitis 1, juvenile,245000~Papillon-Lefevre syndrome,245010~Haim-Munk syndrome,		SM00645:Pept_C1,		KW-0458~Lysosome,	KW-0225~Disease variant,KW-1007~Palmoplantar keratoderma,	KW-0732~Signal,	KW-0868~Chloride,	KW-0378~Hydrolase,KW-0645~Protease,KW-0788~Thiol protease,	KW-0325~Glycoprotein,KW-0865~Zymogen,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Cathepsin C exclusion,DOMAIN:Peptidase C1A papain C-terminal,REGION:Disordered,
CTSD	cathepsin D(CTSD)	Homo sapiens		h_mta3Pathway:Downregulated of MTA-3 in ER-negative Breast Tumors,	GO:0000045~autophagosome assembly,GO:0006508~proteolysis,GO:0019886~antigen processing and presentation of exogenous peptide antigen via MHC class II,GO:0038020~insulin receptor recycling,GO:0042159~lipoprotein catabolic process,GO:0043065~positive regulation of apoptotic process,GO:0043280~positive regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0070201~regulation of establishment of protein localization,GO:1901143~insulin catabolic process,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005764~lysosome,GO:0005765~lysosomal membrane,GO:0010008~endosome membrane,GO:0031904~endosome lumen,GO:0035580~specific granule lumen,GO:0042470~melanosome,GO:0043202~lysosomal lumen,GO:0045121~membrane raft,GO:0070062~extracellular exosome,GO:1904724~tertiary granule lumen,GO:1904813~ficolin-1-rich granule lumen,	GO:0004190~aspartic-type endopeptidase activity,GO:0004197~cysteine-type endopeptidase activity,GO:0005515~protein binding,GO:0008233~peptidase activity,GO:0070001~aspartic-type peptidase activity,	IPR001461:Aspartic_peptidase_A1,IPR001969:Aspartic_peptidase_AS,IPR012848:Aspartic_peptidase_N,IPR021109:Peptidase_aspartic_dom_sf,IPR033121:PEPTIDASE_A1,IPR033144:Cathepsin_D,	hsa04071:Sphingolipid signaling pathway,hsa04140:Autophagy - animal,hsa04142:Lysosome,hsa04210:Apoptosis,hsa04915:Estrogen signaling pathway,hsa05152:Tuberculosis,hsa05415:Diabetic cardiomyopathy,	610127~Ceroid lipofuscinosis, neuronal, 10,				KW-0458~Lysosome,KW-0964~Secreted,	KW-0026~Alzheimer disease,KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0525~Neuronal ceroid lipofuscinosis,	KW-0732~Signal,		KW-0064~Aspartyl protease,KW-0378~Hydrolase,KW-0645~Protease,	KW-0325~Glycoprotein,KW-0865~Zymogen,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (GalNAc...) threonine,COMPBIAS:Polar residues,DOMAIN:Peptidase A1,PROPEP:Activation peptide,REGION:Disordered,
CTSS	cathepsin S(CTSS)	Homo sapiens			GO:0002224~toll-like receptor signaling pathway,GO:0002250~adaptive immune response,GO:0006508~proteolysis,GO:0006915~apoptotic process,GO:0006955~immune response,GO:0010447~response to acidic pH,GO:0010952~positive regulation of peptidase activity,GO:0016485~protein processing,GO:0019882~antigen processing and presentation,GO:0019886~antigen processing and presentation of exogenous peptide antigen via MHC class II,GO:0022617~extracellular matrix disassembly,GO:0030574~collagen catabolic process,GO:0034769~basement membrane disassembly,GO:0048002~antigen processing and presentation of peptide antigen,GO:0051603~proteolysis involved in cellular protein catabolic process,GO:0097067~cellular response to thyroid hormone stimulus,GO:2001235~positive regulation of apoptotic signaling pathway,GO:2001259~positive regulation of cation channel activity,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005764~lysosome,GO:0005770~late endosome,GO:0036021~endolysosome lumen,GO:0043202~lysosomal lumen,GO:0043231~intracellular membrane-bounded organelle,GO:0045335~phagocytic vesicle,GO:1904724~tertiary granule lumen,GO:1904813~ficolin-1-rich granule lumen,	GO:0001968~fibronectin binding,GO:0004197~cysteine-type endopeptidase activity,GO:0004252~serine-type endopeptidase activity,GO:0005518~collagen binding,GO:0008234~cysteine-type peptidase activity,GO:0008656~cysteine-type endopeptidase activator activity involved in apoptotic process,GO:0043236~laminin binding,GO:0043394~proteoglycan binding,	IPR000169:Pept_cys_AS,IPR000668:Peptidase_C1A_C,IPR013128:Peptidase_C1A,IPR013201:Prot_inhib_I29,IPR025660:Pept_his_AS,IPR025661:Pept_asp_AS,IPR038765:Papain-like_cys_pep_sf,IPR039417:Peptidase_C1A_papain-like,	hsa04142:Lysosome,hsa04145:Phagosome,hsa04210:Apoptosis,hsa04612:Antigen processing and presentation,hsa05152:Tuberculosis,			SM00645:Pept_C1,SM00848:Inhibitor_I29,		KW-0458~Lysosome,KW-0964~Secreted,KW-0968~Cytoplasmic vesicle,		KW-0732~Signal,		KW-0378~Hydrolase,KW-0645~Protease,KW-0788~Thiol protease,	KW-0325~Glycoprotein,KW-0865~Zymogen,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Cathepsin propeptide inhibitor,DOMAIN:Peptidase C1A papain C-terminal,MUTAGEN:N->Q: Abolishes glycosylation.,PROPEP:Activation peptide,
CTSW	cathepsin W(CTSW)	Homo sapiens			GO:0006508~proteolysis,GO:0006955~immune response,GO:0051603~proteolysis involved in cellular protein catabolic process,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005764~lysosome,GO:0005783~endoplasmic reticulum,GO:0016020~membrane,GO:0031089~platelet dense granule lumen,	GO:0004197~cysteine-type endopeptidase activity,GO:0008234~cysteine-type peptidase activity,	IPR000668:Peptidase_C1A_C,IPR013128:Peptidase_C1A,IPR013201:Prot_inhib_I29,IPR025660:Pept_his_AS,IPR025661:Pept_asp_AS,IPR038765:Papain-like_cys_pep_sf,IPR039417:Peptidase_C1A_papain-like,	hsa04142:Lysosome,hsa04210:Apoptosis,			SM00645:Pept_C1,SM00848:Inhibitor_I29,		KW-0256~Endoplasmic reticulum,		KW-0732~Signal,		KW-0378~Hydrolase,KW-0645~Protease,KW-0788~Thiol protease,	KW-0325~Glycoprotein,KW-0865~Zymogen,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Cathepsin propeptide inhibitor,DOMAIN:Peptidase C1A papain C-terminal,REGION:Disordered,
CCAR2	cell cycle and apoptosis regulator 2(CCAR2)	Homo sapiens			GO:0006355~regulation of transcription, DNA-templated,GO:0006397~mRNA processing,GO:0006974~cellular response to DNA damage stimulus,GO:0007049~cell cycle,GO:0008380~RNA splicing,GO:0009411~response to UV,GO:0016055~Wnt signaling pathway,GO:0030308~negative regulation of cell growth,GO:0031647~regulation of protein stability,GO:0032435~negative regulation of proteasomal ubiquitin-dependent protein catabolic process,GO:0032784~regulation of DNA-templated transcription, elongation,GO:0042752~regulation of circadian rhythm,GO:0043065~positive regulation of apoptotic process,GO:0043086~negative regulation of catalytic activity,GO:0043653~mitochondrial fragmentation involved in apoptotic process,GO:0045892~negative regulation of transcription, DNA-templated,GO:0048511~rhythmic process,GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:0090311~regulation of protein deacetylation,GO:1902230~negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage,GO:2000003~positive regulation of DNA damage checkpoint,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005759~mitochondrial matrix,GO:0005819~spindle,GO:0044609~DBIRD complex,	GO:0000774~adenyl-nucleotide exchange factor activity,GO:0000993~RNA polymerase II core binding,GO:0003723~RNA binding,GO:0004857~enzyme inhibitor activity,GO:0005515~protein binding,GO:0019899~enzyme binding,GO:0051082~unfolded protein binding,	IPR011992:EF-hand-dom_pair,IPR025223:S1-like_RNA-bd_dom,IPR025224:CCAR1/CCAR2,IPR025954:DBC1/CARP1_inactive_NUDIX_dom,IPR045353:LAIKA,IPR045354:BURAN,	hsa04310:Wnt signaling pathway,			SM01122:DBC1,	KW-0053~Apoptosis,KW-0090~Biological rhythms,KW-0131~Cell cycle,KW-0227~DNA damage,KW-0507~mRNA processing,KW-0508~mRNA splicing,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0879~Wnt signaling pathway,	KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0043~Tumor suppressor,	KW-0175~Coiled coil,		KW-0010~Activator,KW-0481~Metalloenzyme inhibitor,KW-0678~Repressor,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2 and SUMO3); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:DBC1/CARP1 catalytically inactive NUDIX hydrolase,DOMAIN:S1-like RNA binding,MUTAGEN:K->R: Loss of sumoylation.,MUTAGEN:K->R: No effect on sumoylation.,MUTAGEN:Missing: Abolishes binding to SIRT1.,MUTAGEN:T->A: Significantly reduces association with SIRT1. Decreases sumoylation and the interaction of the sumoylated form with SIRT1. Inhibits CCAR2-PSIA3 interaction. Increases CCAR2-SENP1 interaction. Down-regulation of the signals related with the epithelial-mesenchymal transition of gastric cancer cells.,MUTAGEN:T->D: Significantly increases association with SIRT1 and induces p53 acetylation and apoptosis. Increases sumoylation and the interaction of the sumoylated form with SIRT1. Promotes CCAR2-PSIA3 interaction. Decreases CCAR2-SENP1 interaction.,REGION:Disordered,REGION:Interaction with MCC,REGION:Interaction with NR1D1,
CCPG1	cell cycle progression 1(CCPG1)	Homo sapiens			GO:0007049~cell cycle,GO:0008284~positive regulation of cell proliferation,GO:0045787~positive regulation of cell cycle,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:2001106~regulation of Rho guanyl-nucleotide exchange factor activity,	GO:0016020~membrane,	GO:0005515~protein binding,						KW-0131~Cell cycle,	KW-0472~Membrane,		KW-0175~Coiled coil,KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,REGION:Interaction with MCF2L and SRC,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
CDC123	cell division cycle 123(CDC123)	Homo sapiens			GO:0006457~protein folding,GO:0007049~cell cycle,GO:0008284~positive regulation of cell proliferation,GO:0045948~positive regulation of translational initiation,GO:0051301~cell division,GO:0051726~regulation of cell cycle,GO:1905143~eukaryotic translation initiation factor 2 complex assembly,	GO:0005737~cytoplasm,	GO:0000287~magnesium ion binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0044183~protein binding involved in protein folding,	IPR009772:CDC123,			PIRSF007807:Cdc123,			KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0143~Chaperone,	KW-0597~Phosphoprotein,	MUTAGEN:D->A: Severely disrupts assembly factor activity.,REGION:Disordered,
CDC25B	cell division cycle 25B(CDC25B)	Homo sapiens		H_cdc25Pathway:cdc25 and chk1 Regulatory Pathway in response to DNA damage,h_g2Pathway:Cell Cycle: G2/M Checkpoint,h_ptc1Pathway:Sonic Hedgehog (SHH) Receptor Ptc1 Regulates cell cycle,h_rbPathway:RB Tumor Suppressor/Checkpoint Signaling in response to DNA damage,h_srcRPTPPathway:Activation of Src by Protein-tyrosine phosphatase alpha,	GO:0000086~G2/M transition of mitotic cell cycle,GO:0000278~mitotic cell cycle,GO:0001556~oocyte maturation,GO:0006468~protein phosphorylation,GO:0007049~cell cycle,GO:0007144~female meiosis I,GO:0008284~positive regulation of cell proliferation,GO:0010971~positive regulation of G2/M transition of mitotic cell cycle,GO:0032467~positive regulation of cytokinesis,GO:0045931~positive regulation of mitotic cell cycle,GO:0051301~cell division,GO:1902751~positive regulation of cell cycle G2/M phase transition,	GO:0000922~spindle pole,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005829~cytosol,	GO:0004721~phosphoprotein phosphatase activity,GO:0004725~protein tyrosine phosphatase activity,GO:0005515~protein binding,GO:0019901~protein kinase binding,	IPR000751:MPI_Phosphatase,IPR001763:Rhodanese-like_dom,IPR036873:Rhodanese-like_dom_sf,	hsa04010:MAPK signaling pathway,hsa04110:Cell cycle,hsa04914:Progesterone-mediated oocyte maturation,hsa05206:MicroRNAs in cancer,			SM00450:RHOD,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,	KW-0206~Cytoskeleton,KW-0963~Cytoplasm,				KW-0378~Hydrolase,KW-0904~Protein phosphatase,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Rhodanese,REGION:Disordered,
CDC26	cell division cycle 26(CDC26)	Homo sapiens			GO:0007049~cell cycle,GO:0007346~regulation of mitotic cell cycle,GO:0031145~anaphase-promoting complex-dependent catabolic process,GO:0051301~cell division,GO:0051445~regulation of meiotic cell cycle,GO:0070979~protein K11-linked ubiquitination,	GO:0005654~nucleoplasm,GO:0005680~anaphase-promoting complex,GO:0005829~cytosol,	GO:0005515~protein binding,	IPR018860:APC_suCDC26,	hsa04110:Cell cycle,hsa04114:Oocyte meiosis,hsa04120:Ubiquitin mediated proteolysis,hsa04914:Progesterone-mediated oocyte maturation,hsa05166:Human T-cell leukemia virus 1 infection,				KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,		KW-0175~Coiled coil,			KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,REGION:Disordered,
CDC37L1	cell division cycle 37 like 1, HSP90 cochaperone(CDC37L1)	Homo sapiens			GO:0006457~protein folding,GO:0050821~protein stabilization,	GO:0005576~extracellular region,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0031089~platelet dense granule lumen,	GO:0005515~protein binding,GO:0031072~heat shock protein binding,GO:0051082~unfolded protein binding,GO:0051087~chaperone binding,	IPR004918:Cdc37,IPR013874:Cdc37_Hsp90-bd,IPR038189:Cdc37_Hsp90-bd_sf,				SM01070:CDC37_M,		KW-0963~Cytoplasm,		KW-0175~Coiled coil,		KW-0143~Chaperone,	KW-0597~Phosphoprotein,	DOMAIN:Cdc37 Hsp90 binding,REGION:Disordered,REGION:Interaction with Hsp70,REGION:Required for interaction with STIP1,REGION:Self-association,REGION:Self-association and interaction with Hsp90,
CDC37	cell division cycle 37, HSP90 cochaperone(CDC37)	Homo sapiens			GO:0000079~regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0006457~protein folding,GO:0006605~protein targeting,GO:0010608~posttranscriptional regulation of gene expression,GO:0050821~protein stabilization,GO:0060334~regulation of interferon-gamma-mediated signaling pathway,GO:0060338~regulation of type I interferon-mediated signaling pathway,GO:0098779~positive regulation of macromitophagy in response to mitochondrial depolarization,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0070062~extracellular exosome,GO:0101031~chaperone complex,GO:1990565~HSP90-CDC37 chaperone complex,	GO:0005515~protein binding,GO:0019887~protein kinase regulator activity,GO:0019900~kinase binding,GO:0019901~protein kinase binding,GO:0031072~heat shock protein binding,GO:0051082~unfolded protein binding,GO:0051087~chaperone binding,GO:0051879~Hsp90 protein binding,GO:0097110~scaffold protein binding,	IPR004918:Cdc37,IPR013855:Cdc37_N_dom,IPR013873:Cdc37_C,IPR013874:Cdc37_Hsp90-bd,IPR038189:Cdc37_Hsp90-bd_sf,	hsa04151:PI3K-Akt signaling pathway,			SM01069:CDC37_C,SM01070:CDC37_M,SM01071:CDC37_N,		KW-0963~Cytoplasm,		KW-0175~Coiled coil,		KW-0143~Chaperone,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Basic and acidic residues,DOMAIN:Cdc37 C-terminal,DOMAIN:Cdc37 Hsp90 binding,DOMAIN:Cdc37 N-terminal,REGION:Disordered,
CDC40	cell division cycle 40(CDC40)	Homo sapiens			GO:0000398~mRNA splicing, via spliceosome,GO:1990403~embryonic brain development,	GO:0005654~nucleoplasm,GO:0016607~nuclear speck,GO:0071007~U2-type catalytic step 2 spliceosome,GO:0071013~catalytic step 2 spliceosome,	GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0005515~protein binding,	IPR001680:WD40_rpt,IPR015943:WD40/YVTN_repeat-like_dom_sf,IPR019775:WD40_repeat_CS,IPR032847:PRPF17,IPR036322:WD40_repeat_dom_sf,	hsa03040:Spliceosome,	619302~Pontocerebellar hypoplasia, type 15,		SM00320:WD40,	KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,KW-0747~Spliceosome,	KW-0225~Disease variant,KW-0991~Intellectual disability,	KW-0677~Repeat,KW-0853~WD repeat,			KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,MUTAGEN:P->A: Loss of isomerization. Can rescue splicing defects when transfected in knockout cells.,REGION:Disordered,REPEAT:WD,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,REPEAT:WD 7,
CDC5L	cell division cycle 5 like(CDC5L)	Homo sapiens			GO:0000077~DNA damage checkpoint,GO:0000398~mRNA splicing, via spliceosome,GO:0006281~DNA repair,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007049~cell cycle,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051301~cell division,	GO:0000974~Prp19 complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005662~DNA replication factor A complex,GO:0005681~spliceosomal complex,GO:0005737~cytoplasm,GO:0016020~membrane,GO:0016607~nuclear speck,GO:0071007~U2-type catalytic step 2 spliceosome,GO:0071013~catalytic step 2 spliceosome,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0071987~WD40-repeat domain binding,	IPR001005:SANT/Myb,IPR009057:Homeobox-like_sf,IPR017930:Myb_dom,IPR021786:Cdc5p/Cef1_C,IPR047240:SANT_CDC5L_II,IPR047242:CDC5L/Cef1,	hsa03040:Spliceosome,			SM00717:SANT,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0227~DNA damage,KW-0234~DNA repair,KW-0507~mRNA processing,KW-0508~mRNA splicing,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0747~Spliceosome,KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0677~Repeat,		KW-0010~Activator,KW-0238~DNA-binding,KW-0694~RNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DNA_BIND:H-T-H motif,DOMAIN:HTH myb-type,DOMAIN:HTH myb-type 1,DOMAIN:HTH myb-type 2,DOMAIN:Myb-like,MOTIF:Nuclear localization signal,MUTAGEN:S->A: Abolishes phosphorylation. No effect on homodimerization nor on nuclear localization; when associated with A-227; A-303; A-358; A-385; A-404; A-411; A-424 and A-438.,MUTAGEN:S->A: Abolishes phosphorylation. No effect on homodimerization nor on nuclear localization; when associated with A-227; A-303; A-385; A-404; A-411; A-417; A-424 and A-438.,MUTAGEN:S->A: Abolishes phosphorylation. No effect on homodimerization nor on nuclear localization; when associated with A-227; A-358; A-385; A-404; A-411; A-417; A-424 and A-438.,MUTAGEN:T->A: Abolishes phosphorylation. Markedly diminished pre-mRNA splicing activity; when associated with A-411. No effect on homodimerization nor on nuclear localization; when associated with A-227; A-303; A-358; A-385; A-404; A-411; A-417 and A-424.,MUTAGEN:T->A: Abolishes phosphorylation. Markedly diminished pre-mRNA splicing activity; when associated with A-438. No effect on homodimerization nor on nuclear localization; when associated with A-227; A-303; A-358; A-385; A-404; A-417; A-424 and A-438.,MUTAGEN:T->A: Abolishes phosphorylation. No effect on homodimerization nor on nuclear localization; when associated with A-227; A-303; A-358; A-385; A-404; A-411; A-417 and A-438.,MUTAGEN:T->A: Abolishes phosphorylation. No effect on homodimerization nor on nuclear localization; when associated with A-227; A-303; A-358; A-385; A-411; A-417; A-424 and A-438.,MUTAGEN:T->A: Abolishes phosphorylation. No effect on homodimerization nor on nuclear localization; when associated with A-303; A-358; A-385; A-404; A-411; A-417; A-424 and A-438.,MUTAGEN:W->G: Abolishes DNA-binding; when associated with G-31 and G-53.,MUTAGEN:W->G: Abolishes DNA-binding; when associated with G-31 and G-82.,MUTAGEN:W->G: Abolishes DNA-binding; when associated with G-53 and G-82.,REGION:Disordered,REGION:Interaction with DAPK3,REGION:Interaction with PLRG1,REGION:Interaction with PPP1R8,REGION:Required for interaction with CTNNBL1,SITE:Breakpoint for translocation,
CCAR1	cell division cycle and apoptosis regulator 1(CCAR1)	Homo sapiens			GO:0006355~regulation of transcription, DNA-templated,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0006915~apoptotic process,GO:0007049~cell cycle,GO:0008284~positive regulation of cell proliferation,GO:0016567~protein ubiquitination,GO:0030335~positive regulation of cell migration,GO:0043065~positive regulation of apoptotic process,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,	GO:0005634~nucleus,GO:0005641~nuclear envelope lumen,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0048471~perinuclear region of cytoplasm,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0003713~transcription coactivator activity,GO:0003714~transcription corepressor activity,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0030374~ligand-dependent nuclear receptor transcription coactivator activity,GO:0061630~ubiquitin protein ligase activity,	IPR003034:SAP_dom,IPR011992:EF-hand-dom_pair,IPR012340:NA-bd_OB-fold,IPR025223:S1-like_RNA-bd_dom,IPR025224:CCAR1/CCAR2,IPR025954:DBC1/CARP1_inactive_NUDIX_dom,IPR036361:SAP_dom_sf,IPR045353:LAIKA,IPR045354:BURAN,				SM00513:SAP,SM01122:DBC1,	KW-0053~Apoptosis,KW-0131~Cell cycle,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0963~Cytoplasm,		KW-0175~Coiled coil,		KW-0010~Activator,KW-0678~Repressor,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:DBC1/CARP1 catalytically inactive NUDIX hydrolase,DOMAIN:S1-like RNA binding,DOMAIN:SAP,REGION:Disordered,REGION:Interaction with AR,REGION:Interaction with GATA1,REGION:Interaction with GATA2,
CDCA4	cell division cycle associated 4(CDCA4)	Homo sapiens				GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,	GO:0005515~protein binding,	IPR009263:SERTA_dom,						KW-0539~Nucleus,						DOMAIN:SERTA,
CNTRL	centriolin(CNTRL)	Homo sapiens			GO:0001822~kidney development,GO:0003281~ventricular septum development,GO:0007049~cell cycle,GO:0035904~aorta development,GO:0051301~cell division,GO:0060976~coronary vasculature development,	GO:0005813~centrosome,GO:0005815~microtubule organizing center,GO:0005829~cytosol,GO:0016020~membrane,GO:0034451~centriolar satellite,GO:0048471~perinuclear region of cytoplasm,GO:0090543~Flemming body,GO:0090619~meiotic spindle pole,GO:0097431~mitotic spindle pole,	GO:0005515~protein binding,	IPR001611:Leu-rich_rpt,IPR003591:Leu-rich_rpt_typical-subtyp,IPR032675:LRR_dom_sf,				SM00365:LRR_SD22,SM00369:LRR_TYP,	KW-0131~Cell cycle,KW-0132~Cell division,	KW-0206~Cytoskeleton,KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0433~Leucine-rich repeat,KW-0677~Repeat,			KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:LRRCT,REGION:Disordered,REGION:Required for centrosome localization,REGION:Sufficient for interaction with HOOK2,REPEAT:LRR 1,REPEAT:LRR 2,REPEAT:LRR 3,REPEAT:LRR 4,SITE:Breakpoint for translocation to form CEP110-FGFR1,
CENPC	centromere protein C(CENPC)	Homo sapiens			GO:0000278~mitotic cell cycle,GO:0007059~chromosome segregation,GO:0051301~cell division,GO:0051315~attachment of mitotic spindle microtubules to kinetochore,GO:0051382~kinetochore assembly,GO:0051455~attachment of spindle microtubules to kinetochore involved in homologous chromosome segregation,	GO:0000776~kinetochore,GO:0000779~condensed chromosome, centromeric region,GO:0000939~condensed chromosome inner kinetochore,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005721~pericentric heterochromatin,GO:0005829~cytosol,GO:0016604~nuclear body,GO:0030496~midbody,	GO:0003677~DNA binding,GO:0005515~protein binding,GO:0019237~centromeric DNA binding,GO:0042802~identical protein binding,	IPR011051:RmlC_Cupin_sf,IPR014710:RmlC-like_jellyroll,IPR025974:Mif2/CENP-C_cupin,IPR028052:CENP-C_N_dom,IPR028386:CENP-C/Mif2/cnp3,IPR028931:CENP-C_mid,					KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,	KW-0137~Centromere,KW-0158~Chromosome,KW-0539~Nucleus,KW-0995~Kinetochore,				KW-0238~DNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:CENP-C middle DNMT3B-binding,DOMAIN:Kinetochore assembly subunit CENP-C N-terminal,MOTIF:Nuclear localization signal,REGION:Disordered,REGION:MIF2 homology domain II,REGION:MIF2 homology domain III,
CEP57	centrosomal protein 57(CEP57)	Homo sapiens			GO:0007286~spermatid development,GO:0008543~fibroblast growth factor receptor signaling pathway,GO:0051260~protein homooligomerization,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005813~centrosome,GO:0005829~cytosol,GO:0005874~microtubule,GO:0034451~centriolar satellite,	GO:0005515~protein binding,GO:0008017~microtubule binding,GO:0017134~fibroblast growth factor binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0043015~gamma-tubulin binding,	IPR024957:Cep57_MT-bd_dom,IPR025913:Cep57_CLD,		614114~Mosaic variegated aneuploidy syndrome 2,				KW-0206~Cytoskeleton,KW-0493~Microtubule,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Cep57 centrosome localisation,DOMAIN:Cep57 centrosome microtubule-binding,REGION:Disordered,REGION:Mediates interaction with microtubules,REGION:centrosome localization domain (CLD),
CERS2	ceramide synthase 2(CERS2)	Homo sapiens			GO:0019216~regulation of lipid metabolic process,GO:0030148~sphingolipid biosynthetic process,GO:0035902~response to immobilization stress,GO:0046513~ceramide biosynthetic process,GO:0048681~negative regulation of axon regeneration,GO:1900148~negative regulation of Schwann cell migration,GO:1905045~negative regulation of Schwann cell proliferation involved in axon regeneration,	GO:0005634~nucleus,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0016020~membrane,	GO:0003677~DNA binding,GO:0005515~protein binding,GO:0050291~sphingosine N-acyltransferase activity,	IPR001356:Homeobox_dom,IPR006634:TLC-dom,IPR009057:Homeobox-like_sf,IPR016439:Lag1/Lac1-like,	hsa00600:Sphingolipid metabolism,hsa01100:Metabolic pathways,hsa04071:Sphingolipid signaling pathway,		PIRSF005225:LAG1_LAC1,	SM00724:TLC,	KW-0443~Lipid metabolism,KW-0444~Lipid biosynthesis,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0808~Transferase,	KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DNA_BIND:Homeobox,DOMAIN:Homeobox,DOMAIN:TLC,MOTIF:Last loop motif,MUTAGEN:R->A: Abolished inhibition by sphingosine-1-phosphate; when associated with A-230.,MUTAGEN:R->A: Abolished inhibition by sphingosine-1-phosphate; when associated with A-325.,MUTAGEN:SDREETESS->ADREEAEAA: Strongly decreased phosphorylation leading to reduced ceramide synthase activity.,REGION:Disordered,REGION:Homeobox-like,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
CRBN	cereblon(CRBN)	Homo sapiens			GO:0016567~protein ubiquitination,GO:0030177~positive regulation of Wnt signaling pathway,GO:0031333~negative regulation of protein complex assembly,GO:0031334~positive regulation of protein complex assembly,GO:0034766~negative regulation of ion transmembrane transport,GO:0035641~locomotory exploration behavior,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016020~membrane,GO:0031464~Cul4A-RING E3 ubiquitin ligase complex,GO:0048471~perinuclear region of cytoplasm,	GO:0005515~protein binding,GO:0044325~ion channel binding,GO:0046872~metal ion binding,	IPR003111:Lon_prtase_N,IPR004910:Yippee/Mis18/Cereblon,IPR015947:PUA-like_sf,IPR034750:CULT,IPR046336:Lon_prtase_N_sf,		607417~Intellectual developmental disorder, autosomal recessive 2,		SM00464:LON,	KW-0833~Ubl conjugation pathway,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0991~Intellectual disability,		KW-0479~Metal-binding,KW-0862~Zinc,		KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	DOMAIN:CULT,DOMAIN:Lon N-terminal,MUTAGEN:Missing: Fails to rescue increased BK channel activity and decreased probability of neurotransmission in a mouse hippocampal neuron model.,MUTAGEN:W->A: Abolishes thalidomide-binding without affecting DCX protein ligase complex activity; when associated with A-384. Abolishes pomalidomide-induced change in substrate specificity and abolishes pomalidomide-induced decrease in cell viability that is brought about by increased degradation of MYC, IRF4 and IKZF3.,MUTAGEN:Y->A: Abolishes thalidomide-binding without affecting DCX protein ligase complex activity; when associated with A-386.,REGION:Disordered,
CCT2	chaperonin containing TCP1 subunit 2(CCT2)	Homo sapiens			GO:0006457~protein folding,GO:0007339~binding of sperm to zona pellucida,GO:0032212~positive regulation of telomere maintenance via telomerase,GO:0050821~protein stabilization,GO:0051086~chaperone mediated protein folding independent of cofactor,GO:0051131~chaperone-mediated protein complex assembly,GO:0051973~positive regulation of telomerase activity,GO:0061077~chaperone-mediated protein folding,GO:0090666~scaRNA localization to Cajal body,GO:1904851~positive regulation of establishment of protein localization to telomere,GO:1904871~positive regulation of protein localization to Cajal body,GO:1904874~positive regulation of telomerase RNA localization to Cajal body,	GO:0002199~zona pellucida receptor complex,GO:0005576~extracellular region,GO:0005829~cytosol,GO:0005832~chaperonin-containing T-complex,GO:0005874~microtubule,GO:0035578~azurophil granule lumen,GO:0044297~cell body,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016887~ATPase activity,GO:0031625~ubiquitin protein ligase binding,GO:0044183~protein binding involved in protein folding,GO:0051082~unfolded protein binding,	IPR002194:Chaperonin_TCP-1_CS,IPR002423:Cpn60/GroEL/TCP-1,IPR012716:Chap_CCT_beta,IPR017998:Chaperone_TCP-1,IPR027409:GroEL-like_apical_dom_sf,IPR027410:TCP-1-like_intermed_sf,IPR027413:GROEL-like_equatorial_sf,						KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0143~Chaperone,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),
CCT3	chaperonin containing TCP1 subunit 3(CCT3)	Homo sapiens			GO:0006457~protein folding,GO:0007339~binding of sperm to zona pellucida,GO:0032212~positive regulation of telomere maintenance via telomerase,GO:0050821~protein stabilization,GO:0061077~chaperone-mediated protein folding,GO:1904851~positive regulation of establishment of protein localization to telomere,GO:1904871~positive regulation of protein localization to Cajal body,GO:1904874~positive regulation of telomerase RNA localization to Cajal body,	GO:0002199~zona pellucida receptor complex,GO:0005829~cytosol,GO:0005832~chaperonin-containing T-complex,GO:0005856~cytoskeleton,GO:0005874~microtubule,GO:0044297~cell body,GO:0070062~extracellular exosome,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016887~ATPase activity,GO:0044183~protein binding involved in protein folding,GO:0051082~unfolded protein binding,	IPR002194:Chaperonin_TCP-1_CS,IPR002423:Cpn60/GroEL/TCP-1,IPR012719:Chap_CCT_gamma,IPR017998:Chaperone_TCP-1,IPR027409:GroEL-like_apical_dom_sf,IPR027410:TCP-1-like_intermed_sf,IPR027413:GROEL-like_equatorial_sf,						KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0143~Chaperone,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),REGION:Disordered,
CCT4	chaperonin containing TCP1 subunit 4(CCT4)	Homo sapiens	85.Nuc_Rec-Coact_Complex,	h_bcellsurvivalPathway:B Cell Survival Pathway,	GO:0006457~protein folding,GO:0007339~binding of sperm to zona pellucida,GO:0032212~positive regulation of telomere maintenance via telomerase,GO:0050821~protein stabilization,GO:0051973~positive regulation of telomerase activity,GO:0061077~chaperone-mediated protein folding,GO:0090666~scaRNA localization to Cajal body,GO:1904851~positive regulation of establishment of protein localization to telomere,GO:1904871~positive regulation of protein localization to Cajal body,GO:1904874~positive regulation of telomerase RNA localization to Cajal body,	GO:0002199~zona pellucida receptor complex,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005829~cytosol,GO:0005832~chaperonin-containing T-complex,GO:0005874~microtubule,GO:0042470~melanosome,GO:0042995~cell projection,GO:0044297~cell body,GO:0070062~extracellular exosome,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016887~ATPase activity,GO:0044183~protein binding involved in protein folding,GO:0051082~unfolded protein binding,	IPR002194:Chaperonin_TCP-1_CS,IPR002423:Cpn60/GroEL/TCP-1,IPR012717:Chap_CCT_delta,IPR017998:Chaperone_TCP-1,IPR027409:GroEL-like_apical_dom_sf,IPR027410:TCP-1-like_intermed_sf,IPR027413:GROEL-like_equatorial_sf,						KW-0206~Cytoskeleton,KW-0963~Cytoplasm,KW-0966~Cell projection,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0143~Chaperone,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	REGION:Disordered,
CCT6A	chaperonin containing TCP1 subunit 6A(CCT6A)	Homo sapiens			GO:0006457~protein folding,GO:0032212~positive regulation of telomere maintenance via telomerase,GO:0050821~protein stabilization,GO:0061077~chaperone-mediated protein folding,GO:1904851~positive regulation of establishment of protein localization to telomere,GO:1904871~positive regulation of protein localization to Cajal body,GO:1904874~positive regulation of telomerase RNA localization to Cajal body,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005832~chaperonin-containing T-complex,GO:0005874~microtubule,GO:0070062~extracellular exosome,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016887~ATPase activity,GO:0044183~protein binding involved in protein folding,GO:0051082~unfolded protein binding,GO:0071987~WD40-repeat domain binding,	IPR002194:Chaperonin_TCP-1_CS,IPR002423:Cpn60/GroEL/TCP-1,IPR012722:Chap_CCT_zeta,IPR017998:Chaperone_TCP-1,IPR027409:GroEL-like_apical_dom_sf,IPR027410:TCP-1-like_intermed_sf,IPR027413:GROEL-like_equatorial_sf,						KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0143~Chaperone,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),
CCT8	chaperonin containing TCP1 subunit 8(CCT8)	Homo sapiens			GO:0006457~protein folding,GO:0007339~binding of sperm to zona pellucida,GO:0032212~positive regulation of telomere maintenance via telomerase,GO:0050821~protein stabilization,GO:0061077~chaperone-mediated protein folding,GO:1904851~positive regulation of establishment of protein localization to telomere,GO:1904871~positive regulation of protein localization to Cajal body,GO:1904874~positive regulation of telomerase RNA localization to Cajal body,	GO:0002199~zona pellucida receptor complex,GO:0005576~extracellular region,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005829~cytosol,GO:0005832~chaperonin-containing T-complex,GO:0005874~microtubule,GO:0005929~cilium,GO:0034774~secretory granule lumen,GO:0035578~azurophil granule lumen,GO:0044297~cell body,GO:0045111~intermediate filament cytoskeleton,GO:0070062~extracellular exosome,GO:1904813~ficolin-1-rich granule lumen,	GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016887~ATPase activity,GO:0044183~protein binding involved in protein folding,GO:0045296~cadherin binding,GO:0051082~unfolded protein binding,	IPR002194:Chaperonin_TCP-1_CS,IPR002423:Cpn60/GroEL/TCP-1,IPR012721:Chap_CCT_theta,IPR017998:Chaperone_TCP-1,IPR027409:GroEL-like_apical_dom_sf,IPR027410:TCP-1-like_intermed_sf,IPR027413:GROEL-like_equatorial_sf,						KW-0206~Cytoskeleton,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-0969~Cilium,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0143~Chaperone,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),REGION:Disordered,
CHMP1A	charged multivesicular body protein 1A(CHMP1A)	Homo sapiens			GO:0001778~plasma membrane repair,GO:0006914~autophagy,GO:0006997~nucleus organization,GO:0007076~mitotic chromosome condensation,GO:0007080~mitotic metaphase plate congression,GO:0010629~negative regulation of gene expression,GO:0010824~regulation of centrosome duplication,GO:0015031~protein transport,GO:0016192~vesicle-mediated transport,GO:0031468~nuclear envelope reassembly,GO:0032509~endosome transport via multivesicular body sorting pathway,GO:0036258~multivesicular body assembly,GO:0039702~viral budding via host ESCRT complex,GO:0043162~ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway,GO:0045324~late endosome to vacuole transport,GO:0046761~viral budding from plasma membrane,GO:0051301~cell division,GO:0051469~vesicle fusion with vacuole,GO:0061763~multivesicular body-lysosome fusion,GO:0071985~multivesicular body sorting pathway,GO:0090148~membrane fission,GO:0097352~autophagosome maturation,GO:1901673~regulation of mitotic spindle assembly,GO:1902774~late endosome to lysosome transport,GO:1904903~ESCRT III complex disassembly,	GO:0000421~autophagosome membrane,GO:0000776~kinetochore,GO:0000794~condensed nuclear chromosome,GO:0000815~ESCRT III complex,GO:0005643~nuclear pore,GO:0005654~nucleoplasm,GO:0005765~lysosomal membrane,GO:0005769~early endosome,GO:0005771~multivesicular body,GO:0005813~centrosome,GO:0005815~microtubule organizing center,GO:0005828~kinetochore microtubule,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0012505~endomembrane system,GO:0016363~nuclear matrix,GO:0030496~midbody,GO:0032585~multivesicular body membrane,GO:0070062~extracellular exosome,GO:1904930~amphisome membrane,	GO:0005515~protein binding,GO:0008237~metallopeptidase activity,GO:0008270~zinc ion binding,GO:0019904~protein domain specific binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,	IPR005024:Snf7_fam,	hsa04144:Endocytosis,hsa04217:Necroptosis,	614961~Pontocerebellar hypoplasia, type 8,			KW-0131~Cell cycle,KW-0132~Cell division,KW-0653~Protein transport,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0813~Transport,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0967~Endosome,	KW-0523~Neurodegeneration,	KW-0175~Coiled coil,		KW-0678~Repressor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,MOTIF:MIT-interacting motif,MUTAGEN:L->A: No effect on interaction with IST1; when associated with L-194.,REGION:Disordered,
CHMP1B	charged multivesicular body protein 1B(CHMP1B)	Homo sapiens			GO:0001778~plasma membrane repair,GO:0006914~autophagy,GO:0006997~nucleus organization,GO:0007080~mitotic metaphase plate congression,GO:0010824~regulation of centrosome duplication,GO:0015031~protein transport,GO:0031468~nuclear envelope reassembly,GO:0032509~endosome transport via multivesicular body sorting pathway,GO:0036258~multivesicular body assembly,GO:0039702~viral budding via host ESCRT complex,GO:0043162~ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway,GO:0045184~establishment of protein localization,GO:0045324~late endosome to vacuole transport,GO:0046761~viral budding from plasma membrane,GO:0051301~cell division,GO:0051469~vesicle fusion with vacuole,GO:0061763~multivesicular body-lysosome fusion,GO:0071985~multivesicular body sorting pathway,GO:0090148~membrane fission,GO:0097352~autophagosome maturation,GO:1901673~regulation of mitotic spindle assembly,GO:1902774~late endosome to lysosome transport,GO:1904903~ESCRT III complex disassembly,	GO:0000421~autophagosome membrane,GO:0000776~kinetochore,GO:0000815~ESCRT III complex,GO:0005643~nuclear pore,GO:0005654~nucleoplasm,GO:0005765~lysosomal membrane,GO:0005771~multivesicular body,GO:0005828~kinetochore microtubule,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0010008~endosome membrane,GO:0030117~membrane coat,GO:0030496~midbody,GO:0032585~multivesicular body membrane,GO:0070062~extracellular exosome,GO:1904930~amphisome membrane,	GO:0005515~protein binding,GO:0019904~protein domain specific binding,GO:0042802~identical protein binding,GO:0090541~MIT domain binding,	IPR005024:Snf7_fam,	hsa04144:Endocytosis,hsa04217:Necroptosis,				KW-0131~Cell cycle,KW-0132~Cell division,KW-0653~Protein transport,KW-0813~Transport,	KW-0472~Membrane,KW-0963~Cytoplasm,KW-0967~Endosome,		KW-0175~Coiled coil,				COMPBIAS:Polar residues,MOTIF:MIT-interacting motif,MUTAGEN:A->R: Abolishes interaction with SPAScT and no effect on interaction with VPS4A; when associated with R-178 and R-184.,MUTAGEN:DE->AA: Diminishes interaction with VPS4B.,MUTAGEN:E->A: Decreases interaction with SPAST.,MUTAGEN:E->R: Abolishes interaction with SPAST and no effect on interaction with VPS4A; when associated with R-178 and R-181.,MUTAGEN:L->A: Abolishes interaction with SPAST and VPS4A; when associated with A-188.,MUTAGEN:L->A: Abolishes interaction with SPAST and VPS4A; when associated with A-192.,MUTAGEN:L->A: Abolishes interaction with VPS4B.,MUTAGEN:T->R: Abolishes interaction with SPAST and no effect on interaction with VPS4A; when associated with R-181 and R-184.,REGION:Disordered,REGION:Interaction with IST1,REGION:Interaction with SPAST,REGION:Interaction with VPS4A, MITD1 and STAMBP,REGION:Interaction with VPS4B,REGION:Interaction with VTA1,
CHMP2A	charged multivesicular body protein 2A(CHMP2A)	Homo sapiens			GO:0001778~plasma membrane repair,GO:0006914~autophagy,GO:0006997~nucleus organization,GO:0007080~mitotic metaphase plate congression,GO:0010324~membrane invagination,GO:0010458~exit from mitosis,GO:0010824~regulation of centrosome duplication,GO:0015031~protein transport,GO:0016236~macroautophagy,GO:0019076~viral release from host cell,GO:0031468~nuclear envelope reassembly,GO:0032509~endosome transport via multivesicular body sorting pathway,GO:0036258~multivesicular body assembly,GO:0039702~viral budding via host ESCRT complex,GO:0043162~ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway,GO:0045184~establishment of protein localization,GO:0045324~late endosome to vacuole transport,GO:0046761~viral budding from plasma membrane,GO:0051258~protein polymerization,GO:0051260~protein homooligomerization,GO:0051469~vesicle fusion with vacuole,GO:0061763~multivesicular body-lysosome fusion,GO:0071985~multivesicular body sorting pathway,GO:0090148~membrane fission,GO:0097352~autophagosome maturation,GO:1901673~regulation of mitotic spindle assembly,GO:1902774~late endosome to lysosome transport,GO:1903543~positive regulation of exosomal secretion,GO:1903723~negative regulation of centriole elongation,GO:1904903~ESCRT III complex disassembly,	GO:0000421~autophagosome membrane,GO:0000776~kinetochore,GO:0000785~chromatin,GO:0000815~ESCRT III complex,GO:0005635~nuclear envelope,GO:0005643~nuclear pore,GO:0005765~lysosomal membrane,GO:0005771~multivesicular body,GO:0005828~kinetochore microtubule,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0030117~membrane coat,GO:0030496~midbody,GO:0032585~multivesicular body membrane,GO:0070062~extracellular exosome,GO:1904930~amphisome membrane,	GO:0005515~protein binding,GO:0019904~protein domain specific binding,GO:0031210~phosphatidylcholine binding,	IPR005024:Snf7_fam,	hsa04144:Endocytosis,hsa04217:Necroptosis,				KW-0653~Protein transport,KW-0813~Transport,KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-0539~Nucleus,KW-0967~Endosome,		KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	MOTIF:MIT-interacting motif,MUTAGEN:DE->AA: Diminishes interaction with VPS4B.,MUTAGEN:L->A: Diminishes interaction with VTA1.,MUTAGEN:Missing: Abolishes interaction with VTA1.,MUTAGEN:Missing: Membrane association; releases autoinhibition.,REGION:Interaction with VPS4B,REGION:Interaction with VTA1,
CHMP2B	charged multivesicular body protein 2B(CHMP2B)	Homo sapiens			GO:0001778~plasma membrane repair,GO:0006914~autophagy,GO:0006997~nucleus organization,GO:0007032~endosome organization,GO:0007080~mitotic metaphase plate congression,GO:0010824~regulation of centrosome duplication,GO:0015031~protein transport,GO:0016236~macroautophagy,GO:0019076~viral release from host cell,GO:0031468~nuclear envelope reassembly,GO:0032509~endosome transport via multivesicular body sorting pathway,GO:0036258~multivesicular body assembly,GO:0039702~viral budding via host ESCRT complex,GO:0043162~ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway,GO:0045324~late endosome to vacuole transport,GO:0046761~viral budding from plasma membrane,GO:0050804~modulation of synaptic transmission,GO:0050890~cognition,GO:0051469~vesicle fusion with vacuole,GO:0061763~multivesicular body-lysosome fusion,GO:0070050~neuron cellular homeostasis,GO:0071985~multivesicular body sorting pathway,GO:0090148~membrane fission,GO:0097352~autophagosome maturation,GO:1901673~regulation of mitotic spindle assembly,GO:1902774~late endosome to lysosome transport,GO:1904903~ESCRT III complex disassembly,	GO:0000421~autophagosome membrane,GO:0000776~kinetochore,GO:0000815~ESCRT III complex,GO:0005643~nuclear pore,GO:0005737~cytoplasm,GO:0005764~lysosome,GO:0005765~lysosomal membrane,GO:0005768~endosome,GO:0005770~late endosome,GO:0005771~multivesicular body,GO:0005828~kinetochore microtubule,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0014069~postsynaptic density,GO:0030496~midbody,GO:0032585~multivesicular body membrane,GO:0070062~extracellular exosome,GO:0098978~glutamatergic synapse,GO:1904930~amphisome membrane,	GO:0005515~protein binding,GO:0019904~protein domain specific binding,GO:0045296~cadherin binding,	IPR005024:Snf7_fam,	hsa04144:Endocytosis,hsa04217:Necroptosis,hsa05014:Amyotrophic lateral sclerosis,hsa05022:Pathways of neurodegeneration - multiple diseases,	600795~Frontotemporal dementia and/or amyotrophic lateral sclerosis 7,			KW-0653~Protein transport,KW-0813~Transport,	KW-0472~Membrane,KW-0963~Cytoplasm,KW-0967~Endosome,	KW-0036~Amyotrophic lateral sclerosis,KW-0225~Disease variant,KW-0523~Neurodegeneration,	KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	MOTIF:MIT-interacting motif,REGION:Disordered,
CHMP4B	charged multivesicular body protein 4B(CHMP4B)	Homo sapiens			GO:0000281~mitotic cytokinesis,GO:0001778~plasma membrane repair,GO:0006620~posttranslational protein targeting to membrane,GO:0006900~membrane budding,GO:0006914~autophagy,GO:0006997~nucleus organization,GO:0007080~mitotic metaphase plate congression,GO:0010458~exit from mitosis,GO:0010506~regulation of autophagy,GO:0010824~regulation of centrosome duplication,GO:0015031~protein transport,GO:0016236~macroautophagy,GO:0031468~nuclear envelope reassembly,GO:0032511~late endosome to vacuole transport via multivesicular body sorting pathway,GO:0036258~multivesicular body assembly,GO:0036438~maintenance of lens transparency,GO:0039702~viral budding via host ESCRT complex,GO:0043162~ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway,GO:0046755~viral budding,GO:0046761~viral budding from plasma membrane,GO:0050877~neurological system process,GO:0051258~protein polymerization,GO:0051469~vesicle fusion with vacuole,GO:0061763~multivesicular body-lysosome fusion,GO:0071985~multivesicular body sorting pathway,GO:0090148~membrane fission,GO:0090611~ubiquitin-independent protein catabolic process via the multivesicular body sorting pathway,GO:0097352~autophagosome maturation,GO:1901673~regulation of mitotic spindle assembly,GO:1902774~late endosome to lysosome transport,	GO:0000421~autophagosome membrane,GO:0000776~kinetochore,GO:0000815~ESCRT III complex,GO:0005634~nucleus,GO:0005635~nuclear envelope,GO:0005643~nuclear pore,GO:0005737~cytoplasm,GO:0005765~lysosomal membrane,GO:0005768~endosome,GO:0005771~multivesicular body,GO:0005828~kinetochore microtubule,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0009898~cytoplasmic side of plasma membrane,GO:0030117~membrane coat,GO:0030496~midbody,GO:0031982~vesicle,GO:0032585~multivesicular body membrane,GO:0070062~extracellular exosome,GO:1904930~amphisome membrane,	GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0045296~cadherin binding,	IPR005024:Snf7_fam,	hsa03250:Viral life cycle - HIV-1,hsa04144:Endocytosis,hsa04217:Necroptosis,	605387~Cataract 31, multiple types,			KW-0653~Protein transport,KW-0813~Transport,KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0967~Endosome,	KW-0225~Disease variant,KW-0898~Cataract,	KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	REGION:Disordered,
CHMP5	charged multivesicular body protein 5(CHMP5)	Homo sapiens			GO:0001778~plasma membrane repair,GO:0001919~regulation of receptor recycling,GO:0006900~membrane budding,GO:0006914~autophagy,GO:0006997~nucleus organization,GO:0007080~mitotic metaphase plate congression,GO:0010824~regulation of centrosome duplication,GO:0015031~protein transport,GO:0030218~erythrocyte differentiation,GO:0031468~nuclear envelope reassembly,GO:0032511~late endosome to vacuole transport via multivesicular body sorting pathway,GO:0036258~multivesicular body assembly,GO:0039702~viral budding via host ESCRT complex,GO:0043162~ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway,GO:0046755~viral budding,GO:0046761~viral budding from plasma membrane,GO:0051469~vesicle fusion with vacuole,GO:0061763~multivesicular body-lysosome fusion,GO:0071222~cellular response to lipopolysaccharide,GO:0071225~cellular response to muramyl dipeptide,GO:0071985~multivesicular body sorting pathway,GO:0090148~membrane fission,GO:0097352~autophagosome maturation,GO:1901673~regulation of mitotic spindle assembly,GO:1902774~late endosome to lysosome transport,GO:1904903~ESCRT III complex disassembly,	GO:0000421~autophagosome membrane,GO:0000776~kinetochore,GO:0005643~nuclear pore,GO:0005765~lysosomal membrane,GO:0005771~multivesicular body,GO:0005828~kinetochore microtubule,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0030496~midbody,GO:0032585~multivesicular body membrane,GO:0070062~extracellular exosome,GO:1904930~amphisome membrane,	GO:0005515~protein binding,GO:0045296~cadherin binding,	IPR005024:Snf7_fam,	hsa04144:Endocytosis,hsa04217:Necroptosis,				KW-0653~Protein transport,KW-0813~Transport,	KW-0472~Membrane,KW-0963~Cytoplasm,KW-0967~Endosome,		KW-0175~Coiled coil,			KW-0449~Lipoprotein,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	LIPID:(Microbial infection) N6-stearoyl lysine,MUTAGEN:K->R: Decreased stearoylation in response to S.flexneri infection.,MUTAGEN:KAKPK->RARPR: Decreased stearoylation in response to S.flexneri infection.,REGION:Disordered,REGION:Interaction with VTA1,
CHMP7	charged multivesicular body protein 7(CHMP7)	Homo sapiens			GO:0001778~plasma membrane repair,GO:0006900~membrane budding,GO:0006914~autophagy,GO:0006997~nucleus organization,GO:0007080~mitotic metaphase plate congression,GO:0010458~exit from mitosis,GO:0015031~protein transport,GO:0031468~nuclear envelope reassembly,GO:0032511~late endosome to vacuole transport via multivesicular body sorting pathway,GO:0036258~multivesicular body assembly,GO:0039702~viral budding via host ESCRT complex,GO:0043162~ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway,GO:0045324~late endosome to vacuole transport,GO:0046761~viral budding from plasma membrane,GO:0051469~vesicle fusion with vacuole,GO:0061763~multivesicular body-lysosome fusion,GO:0071168~protein localization to chromatin,GO:0071985~multivesicular body sorting pathway,GO:0090148~membrane fission,GO:0097352~autophagosome maturation,GO:1901673~regulation of mitotic spindle assembly,GO:1902774~late endosome to lysosome transport,GO:1904903~ESCRT III complex disassembly,	GO:0000421~autophagosome membrane,GO:0000776~kinetochore,GO:0000785~chromatin,GO:0000815~ESCRT III complex,GO:0005635~nuclear envelope,GO:0005643~nuclear pore,GO:0005654~nucleoplasm,GO:0005765~lysosomal membrane,GO:0005771~multivesicular body,GO:0005828~kinetochore microtubule,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0009898~cytoplasmic side of plasma membrane,GO:0030496~midbody,GO:0032585~multivesicular body membrane,GO:1904930~amphisome membrane,	GO:0005515~protein binding,	IPR005024:Snf7_fam,	hsa04144:Endocytosis,hsa04217:Necroptosis,				KW-0653~Protein transport,KW-0813~Transport,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,			KW-0597~Phosphoprotein,	REGION:Disordered,
CLIC1	chloride intracellular channel 1(CLIC1)	Homo sapiens			GO:0006821~chloride transport,GO:0007165~signal transduction,GO:0045669~positive regulation of osteoblast differentiation,GO:0051881~regulation of mitochondrial membrane potential,GO:0070527~platelet aggregation,GO:1902476~chloride transmembrane transport,	GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005635~nuclear envelope,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005783~endoplasmic reticulum,GO:0005886~plasma membrane,GO:0005903~brush border,GO:0016020~membrane,GO:0031965~nuclear membrane,GO:0031982~vesicle,GO:0034707~chloride channel complex,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,GO:0072562~blood microparticle,	GO:0005254~chloride channel activity,GO:0005515~protein binding,GO:0045296~cadherin binding,	IPR002946:CLIC,IPR004045:Glutathione_S-Trfase_N,IPR010987:Glutathione-S-Trfase_C-like,IPR030259:CLIC-1_C,IPR036249:Thioredoxin-like_sf,IPR036282:Glutathione-S-Trfase_C_sf,IPR040079:Glutathione_S-Trfase,					KW-0406~Ion transport,KW-0813~Transport,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0868~Chloride,	KW-0407~Ion channel,KW-0851~Voltage-gated channel,KW-0869~Chloride channel,	KW-0007~Acetylation,KW-0318~Glutathionylation,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	DISULFID:Alternate,DOMAIN:GST C-terminal,MUTAGEN:C->S: Loss of dimerization and of ion transport activity.,REGION:Required for insertion into the membrane,TRANSMEM:Helical; Note=After insertion into the membrane,
CLNS1A	chloride nucleotide-sensitive channel 1A(CLNS1A)	Homo sapiens			GO:0000387~spliceosomal snRNP assembly,GO:0006821~chloride transport,GO:0006884~cell volume homeostasis,GO:0008380~RNA splicing,GO:0045292~mRNA cis splicing, via spliceosome,GO:0048026~positive regulation of mRNA splicing, via spliceosome,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005681~spliceosomal complex,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0034709~methylosome,GO:0034715~pICln-Sm protein complex,	GO:0003723~RNA binding,GO:0005515~protein binding,	IPR003521:ICln,IPR011993:PH-like_dom_sf,IPR039924:ICln/Lot5/Saf5,					KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,					KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,REGION:Disordered,
CSGALNACT2	chondroitin sulfate N-acetylgalactosaminyltransferase 2(CSGALNACT2)	Homo sapiens			GO:0030166~proteoglycan biosynthetic process,GO:0030206~chondroitin sulfate biosynthetic process,GO:0050650~chondroitin sulfate proteoglycan biosynthetic process,GO:0050651~dermatan sulfate proteoglycan biosynthetic process,GO:0050652~dermatan sulfate proteoglycan biosynthetic process, polysaccharide chain biosynthetic process,GO:0050653~chondroitin sulfate proteoglycan biosynthetic process, polysaccharide chain biosynthetic process,	GO:0000139~Golgi membrane,GO:0016020~membrane,GO:0032580~Golgi cisterna membrane,	GO:0005515~protein binding,GO:0008376~acetylgalactosaminyltransferase activity,GO:0046872~metal ion binding,GO:0047237~glucuronylgalactosylproteoglycan 4-beta-N-acetylgalactosaminyltransferase activity,GO:0047238~glucuronosyl-N-acetylgalactosaminyl-proteoglycan 4-beta-N-acetylgalactosaminyltransferase activity,	IPR008428:Chond_GalNAc,IPR029044:Nucleotide-diphossugar_trans,	hsa00532:Glycosaminoglycan biosynthesis - chondroitin sulfate / dermatan sulfate,hsa01100:Metabolic pathways,					KW-0333~Golgi apparatus,KW-0472~Membrane,		KW-0175~Coiled coil,KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0479~Metal-binding,	KW-0808~Transferase,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
CHTOP	chromatin target of PRMT1(CHTOP)	Homo sapiens			GO:0006338~chromatin remodeling,GO:0006406~mRNA export from nucleus,GO:0032781~positive regulation of ATPase activity,GO:0051096~positive regulation of helicase activity,	GO:0000346~transcription export complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0016607~nuclear speck,	GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0005515~protein binding,GO:0008327~methyl-CpG binding,	IPR025715:FoP_C,				SM01218:FoP_duplication,	KW-0509~mRNA transport,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0813~Transport,	KW-0539~Nucleus,				KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Chromatin target of PRMT1 protein C-terminal,MOTIF:GAR motif; involved in 5hmC binding,MUTAGEN:R->A: Loss of 5hmc binding; when associated with A-195; A-197; A-199 and A-201.,MUTAGEN:R->A: Loss of 5hmc binding; when associated with A-195; A-197; A-199 and A-203.,MUTAGEN:R->A: Loss of 5hmc binding; when associated with A-195; A-197; A-201 and A-203.,MUTAGEN:R->A: Loss of 5hmc binding; when associated with A-195; A-199; A-201 and A-203.,MUTAGEN:R->A: Loss of 5hmc binding; when associated with A-197; A-199; A-201 and A-203.,REGION:Disordered,REGION:Interaction with PRMT1,
CBX3	chromobox 3(CBX3)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006325~chromatin organization,GO:0006338~chromatin remodeling,GO:0006974~cellular response to DNA damage stimulus,GO:0031507~heterochromatin assembly,GO:0045892~negative regulation of transcription, DNA-templated,GO:0048511~rhythmic process,	GO:0000775~chromosome, centromeric region,GO:0000779~condensed chromosome, centromeric region,GO:0000781~chromosome, telomeric region,GO:0000785~chromatin,GO:0000791~euchromatin,GO:0000792~heterochromatin,GO:0005634~nucleus,GO:0005635~nuclear envelope,GO:0005637~nuclear inner membrane,GO:0005654~nucleoplasm,GO:0005721~pericentric heterochromatin,GO:0005819~spindle,GO:0061793~chromatin lock complex,GO:0090575~RNA polymerase II transcription factor complex,GO:0090734~site of DNA damage,	GO:0001221~transcription cofactor binding,GO:0003682~chromatin binding,GO:0005515~protein binding,GO:0019899~enzyme binding,GO:0019904~protein domain specific binding,GO:0035064~methylated histone binding,GO:0042802~identical protein binding,GO:1990226~histone methyltransferase binding,	IPR000953:Chromo/chromo_shadow_dom,IPR008251:Chromo_shadow_dom,IPR016197:Chromo-like_dom_sf,IPR017984:Chromo_dom_subgr,IPR023779:Chromodomain_CS,IPR023780:Chromo_domain,IPR038033:CBX3_chromo_domain,	hsa03083:Polycomb repressive complex,hsa05131:Shigellosis,			SM00298:CHROMO,SM00300:ChSh,	KW-0090~Biological rhythms,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0677~Repeat,		KW-0156~Chromatin regulator,KW-0678~Repressor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:Chromo,DOMAIN:Chromo 1,DOMAIN:Chromo 2; shadow subtype,REGION:Disordered,
CHD1	chromodomain helicase DNA binding protein 1(CHD1)	Homo sapiens			GO:0006338~chromatin remodeling,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0034728~nucleosome organization,GO:0043923~positive regulation by host of viral transcription,	GO:0000228~nuclear chromosome,GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,	GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0004386~helicase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016887~ATPase activity,GO:0035064~methylated histone binding,GO:0042393~histone binding,	IPR000330:SNF2_N,IPR000953:Chromo/chromo_shadow_dom,IPR001650:Helicase_C,IPR014001:Helicase_ATP-bd,IPR016197:Chromo-like_dom_sf,IPR023779:Chromodomain_CS,IPR023780:Chromo_domain,IPR025260:CHD1-like_C,IPR027417:P-loop_NTPase,IPR038718:SNF2-like_sf,IPR039880:CHCT1-like,IPR040793:CDH1_2_SANT_HL1,		617682~Pilarowski-Bjornsson syndrome,		SM00298:CHROMO,SM00487:DEXDc,SM00490:HELICc,SM01176:DUF4208,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0991~Intellectual disability,	KW-0677~Repeat,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0156~Chromatin regulator,KW-0238~DNA-binding,KW-0347~Helicase,KW-0378~Hydrolase,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,DOMAIN:Chromo,DOMAIN:Chromo 1,DOMAIN:Chromo 2,DOMAIN:Chromodomain-helicase-DNA-binding protein 1-like C-terminal,DOMAIN:Helicase ATP-binding,DOMAIN:Helicase C-terminal,MOTIF:DEAH box,MUTAGEN:KERMRPVK->AERMAPVA: Abolishes DNA-binding.,MUTAGEN:KHAIKK->AHAIAA: Abolishes DNA-binding.,MUTAGEN:KQLDRPEK->AQLDAPEA: Abolishes DNA-binding.,MUTAGEN:RKLHK->AALHA: Abolishes DNA-binding.,REGION:3 X 5 AA repeats of H-S-D-H-R,REGION:CHD1 helical C-terminal domain (CHCT),REGION:Disordered,REPEAT:1,REPEAT:2,REPEAT:3,
CHD2	chromodomain helicase DNA binding protein 2(CHD2)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006974~cellular response to DNA damage stimulus,GO:0007517~muscle organ development,GO:0010467~gene expression,GO:0034728~nucleosome organization,GO:0060218~hematopoietic stem cell differentiation,	GO:0000785~chromatin,GO:0005634~nucleus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003723~RNA binding,GO:0004386~helicase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016887~ATPase activity,GO:0042393~histone binding,	IPR000330:SNF2_N,IPR000953:Chromo/chromo_shadow_dom,IPR001650:Helicase_C,IPR009057:Homeobox-like_sf,IPR014001:Helicase_ATP-bd,IPR016197:Chromo-like_dom_sf,IPR023779:Chromodomain_CS,IPR023780:Chromo_domain,IPR025260:CHD1-like_C,IPR027417:P-loop_NTPase,IPR038718:SNF2-like_sf,IPR040793:CDH1_2_SANT_HL1,		615369~Developmental and epileptic encephalopathy 94,		SM00298:CHROMO,SM00487:DEXDc,SM00490:HELICc,SM01176:DUF4208,	KW-0517~Myogenesis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-0887~Epilepsy,	KW-0677~Repeat,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0156~Chromatin regulator,KW-0238~DNA-binding,KW-0347~Helicase,KW-0378~Hydrolase,	KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,DOMAIN:Chromo,DOMAIN:Chromo 1,DOMAIN:Chromo 2,DOMAIN:Helicase ATP-binding,DOMAIN:Helicase C-terminal,MOTIF:DEAH box,REGION:CHD1 helical C-terminal domain (CHCT),REGION:Disordered,
CHD4	chromodomain helicase DNA binding protein 4(CHD4)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0000724~double-strand break repair via homologous recombination,GO:0006338~chromatin remodeling,GO:0010629~negative regulation of gene expression,GO:0042659~regulation of cell fate specification,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0051963~regulation of synapse assembly,GO:0072553~terminal button organization,GO:2000736~regulation of stem cell differentiation,	GO:0000781~chromosome, telomeric region,GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0016020~membrane,GO:0016581~NuRD complex,GO:0032991~macromolecular complex,GO:0090575~RNA polymerase II transcription factor complex,GO:0090734~site of DNA damage,	GO:0001221~transcription cofactor binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003714~transcription corepressor activity,GO:0004386~helicase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008270~zinc ion binding,GO:0016787~hydrolase activity,GO:0016887~ATPase activity,GO:0031492~nucleosomal DNA binding,GO:0042393~histone binding,GO:0042826~histone deacetylase binding,GO:0046872~metal ion binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,	IPR000330:SNF2_N,IPR000953:Chromo/chromo_shadow_dom,IPR001650:Helicase_C,IPR001965:Znf_PHD,IPR002464:DNA/RNA_helicase_DEAH_CS,IPR009462:CHD_II_SANT-like,IPR009463:DUF1087,IPR011011:Znf_FYVE_PHD,IPR012957:CHD_C2,IPR012958:CHD_N,IPR013083:Znf_RING/FYVE/PHD,IPR014001:Helicase_ATP-bd,IPR016197:Chromo-like_dom_sf,IPR019786:Zinc_finger_PHD-type_CS,IPR019787:Znf_PHD-finger,IPR023780:Chromo_domain,IPR027417:P-loop_NTPase,IPR038718:SNF2-like_sf,	hsa03082:ATP-dependent chromatin remodeling,hsa05165:Human papillomavirus infection,hsa05203:Viral carcinogenesis,	617159~Sifrim-Hitz-Weiss syndrome,		SM00249:PHD,SM00298:CHROMO,SM00487:DEXDc,SM00490:HELICc,SM01146:DUF1086,SM01147:DUF1087,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0991~Intellectual disability,	KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0067~ATP-binding,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,KW-0862~Zinc,	KW-0156~Chromatin regulator,KW-0238~DNA-binding,KW-0347~Helicase,KW-0378~Hydrolase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:CHD C-terminal 2,DOMAIN:CHD N-terminal,DOMAIN:CHD subfamily II SANT-like,DOMAIN:Chromo,DOMAIN:Chromo 1,DOMAIN:Chromo 2,DOMAIN:DUF1087,DOMAIN:Helicase ATP-binding,DOMAIN:Helicase C-terminal,DOMAIN:PHD-type,MOTIF:DEAH box,REGION:Disordered,REGION:Required for interaction with PCNT,ZN_FING:PHD-type 1,ZN_FING:PHD-type 2,
C11ORF58	chromosome 11 open reading frame 58(C11orf58)	Homo sapiens						IPR026714:SMAP,IPR028124:SMAP_dom,											KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Small acidic protein-like,REGION:Disordered,
C12ORF57	chromosome 12 open reading frame 57(C12orf57)	Homo sapiens			GO:0009791~post-embryonic development,GO:0014819~regulation of skeletal muscle contraction,GO:0021540~corpus callosum morphogenesis,GO:0021678~third ventricle development,GO:0036343~psychomotor behavior,GO:0048593~camera-type eye morphogenesis,GO:0050890~cognition,	GO:0005737~cytoplasm,GO:0016607~nuclear speck,	GO:0005515~protein binding,	IPR026317:P_C10,		218340~Temtamy syndrome,				KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0991~Intellectual disability,				KW-0007~Acetylation,	REGION:Disordered,
C17ORF49	chromosome 17 open reading frame 49(C17orf49)	Homo sapiens			GO:0006325~chromatin organization,	GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0016589~NURF complex,GO:0071339~MLL1 complex,	GO:0003677~DNA binding,GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR001005:SANT/Myb,IPR009057:Homeobox-like_sf,	hsa03082:ATP-dependent chromatin remodeling,					KW-0539~Nucleus,				KW-0156~Chromatin regulator,KW-0238~DNA-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Pro residues,DOMAIN:SANT,REGION:Disordered,
C18ORF32	chromosome 18 open reading frame 32(C18orf32)	Homo sapiens			GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,	GO:0005783~endoplasmic reticulum,GO:0005811~lipid particle,	GO:0005515~protein binding,	IPR026776:UPF0729,		619985~Glycosylphosphatidylinositol biosynthesis defect 25,				KW-0256~Endoplasmic reticulum,KW-0551~Lipid droplet,						REGION:Disordered,REGION:Necessary for its localzation to the endoplasmic reticulum and lipid droplets,
C3ORF38	chromosome 3 open reading frame 38(C3orf38)	Homo sapiens			GO:0006915~apoptotic process,GO:0043065~positive regulation of apoptotic process,	GO:0005634~nucleus,		IPR026698:UPF_C3orf38,IPR032710:NTF2-like_dom_sf,					KW-0053~Apoptosis,						KW-0007~Acetylation,
C4ORF3	chromosome 4 open reading frame 3(C4orf3)	Homo sapiens				GO:0005789~endoplasmic reticulum membrane,		IPR038780:C4orf3,	hsa04020:Calcium signaling pathway,					KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,	COMPBIAS:Basic and acidic residues,REGION:Disordered,TRANSMEM:Helical,
C5ORF15	chromosome 5 open reading frame 15(C5orf15)	Homo sapiens				GO:0016020~membrane,		IPR037645:KCT2,						KW-0472~Membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
C6ORF62	chromosome 6 open reading frame 62(C6orf62)	Homo sapiens						IPR027903:DUF4566,
C9ORF78	chromosome 9 open reading frame 78(C9orf78)	Homo sapiens			GO:0000398~mRNA splicing, via spliceosome,GO:0007059~chromosome segregation,GO:0045292~mRNA cis splicing, via spliceosome,GO:0060629~regulation of homologous chromosome segregation,	GO:0000775~chromosome, centromeric region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005681~spliceosomal complex,GO:0005829~cytosol,	GO:0005515~protein binding,GO:0030623~U5 snRNA binding,	IPR010756:Tls1-like,					KW-0159~Chromosome partition,KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0137~Centromere,KW-0158~Chromosome,KW-0539~Nucleus,KW-0747~Spliceosome,				KW-0694~RNA-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,MUTAGEN:F->A: Decreases binding to SNRNP200.,MUTAGEN:R->A: Abolishes binding to SNRNP200.,REGION:Disordered,REGION:Interaction with SNRNP200,
CHTF8	chromosome transmission fidelity factor 8(CHTF8)	Homo sapiens			GO:0006260~DNA replication,GO:0007064~mitotic sister chromatid cohesion,GO:0032508~DNA duplex unwinding,GO:1900264~positive regulation of DNA-directed DNA polymerase activity,	GO:0005654~nucleoplasm,GO:0031390~Ctf18 RFC-like complex,	GO:0003677~DNA binding,GO:0003689~DNA clamp loader activity,GO:0017116~single-stranded DNA-dependent ATP-dependent DNA helicase activity,	IPR018607:Ctf8,					KW-0131~Cell cycle,KW-0235~DNA replication,	KW-0539~Nucleus,				KW-0238~DNA-binding,
CHURC1	churchill domain containing 1(CHURC1)	Homo sapiens			GO:0008543~fibroblast growth factor receptor signaling pathway,GO:0045893~positive regulation of transcription, DNA-templated,		GO:0005515~protein binding,GO:0008270~zinc ion binding,	IPR009508:Transcrpt_activator_Churchill,IPR038543:Churchill_sf,					KW-0804~Transcription,KW-0805~Transcription regulation,				KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0217~Developmental protein,KW-9996~Developmental protein,
CS	citrate synthase(CS)	Homo sapiens		h_malatexPathway:Shuttle for transfer of acetyl groups from mitochondria to the cytosol,	GO:0005975~carbohydrate metabolic process,GO:0006099~tricarboxylic acid cycle,GO:0006101~citrate metabolic process,	GO:0005634~nucleus,GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0016020~membrane,GO:0070062~extracellular exosome,	GO:0003723~RNA binding,GO:0004108~citrate (Si)-synthase activity,GO:0046912~transferase activity, transferring acyl groups, acyl groups converted into alkyl on transfer,	IPR002020:Citrate_synthase,IPR010109:Citrate_synthase_euk,IPR016142:Citrate_synth-like_lrg_a-sub,IPR016143:Citrate_synth-like_sm_a-sub,IPR019810:Citrate_synthase_AS,IPR036969:Citrate_synthase_sf,	hsa00020:Citrate cycle (TCA cycle),hsa00630:Glyoxylate and dicarboxylate metabolism,hsa01100:Metabolic pathways,hsa01200:Carbon metabolism,hsa01210:2-Oxocarboxylic acid metabolism,hsa01230:Biosynthesis of amino acids,				KW-0816~Tricarboxylic acid cycle,	KW-0472~Membrane,KW-0496~Mitochondrion,		KW-0809~Transit peptide,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0808~Transferase,	KW-0007~Acetylation,KW-0488~Methylation,	MUTAGEN:K->R: Does not inhibit methylation.,MUTAGEN:K->R: Inhibits methylation.,TRANSIT:Mitochondrion,TRANSMEM:Helical,
CLTC	clathrin heavy chain(CLTC)	Homo sapiens			GO:0000278~mitotic cell cycle,GO:0001649~osteoblast differentiation,GO:0006886~intracellular protein transport,GO:0006898~receptor-mediated endocytosis,GO:0006914~autophagy,GO:0016192~vesicle-mediated transport,GO:0031623~receptor internalization,GO:0033572~transferrin transport,GO:0042147~retrograde transport, endosome to Golgi,GO:0048268~clathrin coat assembly,GO:0051301~cell division,GO:0060236~regulation of mitotic spindle organization,GO:0072318~clathrin coat disassembly,GO:0072583~clathrin-dependent endocytosis,GO:0090307~mitotic spindle assembly,GO:1900126~negative regulation of hyaluronan biosynthetic process,GO:1903077~negative regulation of protein localization to plasma membrane,	GO:0005764~lysosome,GO:0005768~endosome,GO:0005819~spindle,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0012505~endomembrane system,GO:0016020~membrane,GO:0030118~clathrin coat,GO:0030130~clathrin coat of trans-Golgi network vesicle,GO:0030132~clathrin coat of coated pit,GO:0030136~clathrin-coated vesicle,GO:0030669~clathrin-coated endocytic vesicle membrane,GO:0031523~Myb complex,GO:0032588~trans-Golgi network membrane,GO:0032991~macromolecular complex,GO:0036020~endolysosome membrane,GO:0042470~melanosome,GO:0045334~clathrin-coated endocytic vesicle,GO:0070062~extracellular exosome,GO:0071439~clathrin complex,GO:0072686~mitotic spindle,GO:1903561~extracellular vesicle,GO:1990498~mitotic spindle microtubule,	GO:0003723~RNA binding,GO:0003725~double-stranded RNA binding,GO:0005198~structural molecule activity,GO:0005515~protein binding,GO:0019901~protein kinase binding,GO:0032051~clathrin light chain binding,GO:0050750~low-density lipoprotein particle receptor binding,GO:0097718~disordered domain specific binding,GO:1990381~ubiquitin-specific protease binding,	IPR000547:Clathrin_H-chain/VPS_repeat,IPR011990:TPR-like_helical_dom_sf,IPR012331:Clathrin_H-chain_linker,IPR015348:Clathrin_H-chain_linker_core,IPR016024:ARM-type_fold,IPR016025:Clathrin_H-chain_N,IPR016341:Clathrin_heavy_chain,IPR022365:Clathrin_H-chain_propeller_rpt,	hsa04142:Lysosome,hsa04144:Endocytosis,hsa04721:Synaptic vesicle cycle,hsa04961:Endocrine and other factor-regulated calcium reabsorption,hsa05016:Huntington disease,hsa05100:Bacterial invasion of epithelial cells,	617854~Intellectual developmental disorder, autosomal dominant 56,	PIRSF002290:Clathrin_H_chain,	SM00299:CLH,	KW-0072~Autophagy,KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,	KW-0168~Coated pit,KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,	KW-0225~Disease variant,KW-0991~Intellectual disability,	KW-0175~Coiled coil,KW-0677~Repeat,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:Clathrin heavy chain linker core motif,MUTAGEN:K->E: Disrupts spindle localization.,MUTAGEN:K->E: Disrupts spindle localization; when associated with E-444, E-445, E-500 and E-506.,MUTAGEN:K->E: Disrupts spindle localization; when associated with E-444, E-445, E-500 and E-507.,MUTAGEN:K->E: Disrupts spindle localization; when associated with E-444, E-445, E-506 and E-507.,MUTAGEN:K->E: Disrupts spindle localization; when associated with E-444, E-500, E-506 and E-507.,MUTAGEN:K->E: Disrupts spindle localization; when associated with E-481, E-487, E-500 and E-506.,MUTAGEN:K->E: Disrupts spindle localization; when associated with E-481, E-487, E-500 and E-507.,MUTAGEN:K->E: Disrupts spindle localization; when associated with E-481, E-487, E-506 and E-507.,MUTAGEN:K->E: Disrupts spindle localization; when associated with E-481, E-500, E-506 and E-507.,MUTAGEN:LRANV->ERGQC: Disrupts spindle localization and interaction with TACC3.,MUTAGEN:P->N: Disrupts spindle localization.,MUTAGEN:Q->A: Disrupts spindle localization.,MUTAGEN:R->E: Disrupts spindle localization; when associated with E-445, E-500 E-506 and E-507.,MUTAGEN:R->E: Disrupts spindle localization; when associated with E-487, E-500, E-506 and E-507.,MUTAGEN:S->G: Disrupts spindle localization.,MUTAGEN:T->A: Disrupts spindle localization.,REGION:Binding site for the uncoating ATPase, involved in lattice disassembly,REGION:Distal segment,REGION:Flexible linker,REGION:Globular terminal domain,REGION:Heavy chain arm,REGION:Involved in binding clathrin light chain,REGION:Involved in spindle localization and interaction with TACC3,REGION:Proximal segment,REGION:Trimerization,REGION:WD40-like repeat 1,REGION:WD40-like repeat 2,REGION:WD40-like repeat 3,REGION:WD40-like repeat 4,REGION:WD40-like repeat 5,REGION:WD40-like repeat 6,REGION:WD40-like repeat 7,REPEAT:CHCR,REPEAT:CHCR 1,REPEAT:CHCR 2,REPEAT:CHCR 3,REPEAT:CHCR 4,REPEAT:CHCR 5,REPEAT:CHCR 6,REPEAT:CHCR 7,
CLTB	clathrin light chain B(CLTB)	Homo sapiens		h_arapPathway:ADP-Ribosylation Factor,	GO:0006886~intracellular protein transport,GO:0016192~vesicle-mediated transport,GO:0072583~clathrin-dependent endocytosis,	GO:0005802~trans-Golgi network,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0030118~clathrin coat,GO:0030125~clathrin vesicle coat,GO:0030130~clathrin coat of trans-Golgi network vesicle,GO:0030132~clathrin coat of coated pit,GO:0030672~synaptic vesicle membrane,GO:0043231~intracellular membrane-bounded organelle,GO:0045334~clathrin-coated endocytic vesicle,GO:0060170~ciliary membrane,GO:0098835~presynaptic endocytic zone membrane,GO:0099631~postsynaptic endocytic zone cytoplasmic component,	GO:0005198~structural molecule activity,GO:0005515~protein binding,GO:0032050~clathrin heavy chain binding,GO:0042277~peptide binding,	IPR000996:Clathrin_L-chain,	hsa04142:Lysosome,hsa04144:Endocytosis,hsa04721:Synaptic vesicle cycle,hsa04961:Endocrine and other factor-regulated calcium reabsorption,hsa05016:Huntington disease,hsa05100:Bacterial invasion of epithelial cells,					KW-0168~Coated pit,KW-0472~Membrane,KW-0968~Cytoplasmic vesicle,			KW-0106~Calcium,		KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,REGION:Involved in binding clathrin heavy chain,
CLDND1	claudin domain containing 1(CLDND1)	Homo sapiens				GO:0009986~cell surface,GO:0016020~membrane,GO:0016324~apical plasma membrane,	GO:0005515~protein binding,	IPR004031:PMP22/EMP/MP20/Claudin,IPR042356:CLDN1,						KW-0472~Membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,TRANSMEM:Helical,
CPSF7	cleavage and polyadenylation specific factor 7(CPSF7)	Homo sapiens			GO:0006397~mRNA processing,GO:0031124~mRNA 3'-end processing,GO:0051262~protein tetramerization,GO:0051290~protein heterotetramerization,GO:1990120~messenger ribonucleoprotein complex assembly,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005847~mRNA cleavage and polyadenylation specificity factor complex,GO:0005849~mRNA cleavage factor complex,GO:0016020~membrane,	GO:0003676~nucleic acid binding,GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0005515~protein binding,	IPR000504:RRM_dom,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR034772:CPSF6/7,IPR034773:CPSF7_RRM,IPR035979:RBD_domain_sf,	hsa03015:mRNA surveillance pathway,hsa03250:Viral life cycle - HIV-1,			SM00360:RRM,	KW-0507~mRNA processing,	KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0694~RNA-binding,	KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:RRM,REGION:Arg/Ser-rich domain,REGION:Disordered,
COTL1	coactosin like F-actin binding protein 1(COTL1)	Homo sapiens			GO:0030833~regulation of actin filament polymerization,GO:0050832~defense response to fungus,	GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005829~cytosol,GO:0005884~actin filament,GO:0030427~site of polarized growth,GO:0030864~cortical actin cytoskeleton,GO:0034774~secretory granule lumen,GO:0070062~extracellular exosome,GO:1904813~ficolin-1-rich granule lumen,	GO:0003779~actin binding,GO:0005515~protein binding,GO:0019899~enzyme binding,GO:0051015~actin filament binding,	IPR002108:ADF-H,IPR029006:ADF-H/Gelsolin-like_dom_sf,				SM00102:ADF,		KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0009~Actin-binding,KW-0143~Chaperone,	KW-0007~Acetylation,	DOMAIN:ADF-H,MUTAGEN:K->A: Abolishes 5LO-binding activity.,MUTAGEN:K->A: Abolishes actin-binding activity.,MUTAGEN:K->A: No effect on 5LO-binding activity.,MUTAGEN:K->E: Abolishes 5LO-binding activity.,MUTAGEN:K->R: No effect on 5LO-binding activity.,REGION:Flexible and important for F-actin binding,
COQ10B	coenzyme Q10B(COQ10B)	Homo sapiens			GO:0006744~ubiquinone biosynthetic process,GO:0045333~cellular respiration,	GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,	GO:0048039~ubiquinone binding,	IPR005031:COQ10_START,IPR023393:START-like_dom_sf,IPR044996:COQ10-like,						KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,		KW-0809~Transit peptide,				DOMAIN:Coenzyme Q-binding protein COQ10 START,TRANSIT:Mitochondrion,
CFL1	cofilin 1(CFL1)	Homo sapiens		h_ccr3Pathway:CCR3 signaling in Eosinophils,h_rac1Pathway:Rac 1 cell motility signaling pathway,h_rhoPathway:Rho cell motility signaling pathway,	GO:0000281~mitotic cytokinesis,GO:0007010~cytoskeleton organization,GO:0007266~Rho protein signal transduction,GO:0009615~response to virus,GO:0022604~regulation of cell morphogenesis,GO:0030036~actin cytoskeleton organization,GO:0030042~actin filament depolymerization,GO:0030043~actin filament fragmentation,GO:0040019~positive regulation of embryonic development,GO:0043066~negative regulation of apoptotic process,GO:0044794~positive regulation by host of viral process,GO:0051014~actin filament severing,GO:0051293~establishment of spindle localization,GO:0061001~regulation of dendritic spine morphogenesis,	GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005925~focal adhesion,GO:0015629~actin cytoskeleton,GO:0016020~membrane,GO:0016363~nuclear matrix,GO:0030027~lamellipodium,GO:0030426~growth cone,GO:0031258~lamellipodium membrane,GO:0031982~vesicle,GO:0032587~ruffle membrane,GO:0070062~extracellular exosome,	GO:0003779~actin binding,GO:0005515~protein binding,GO:0051015~actin filament binding,	IPR002108:ADF-H,IPR017904:ADF/Cofilin,IPR029006:ADF-H/Gelsolin-like_dom_sf,	hsa04360:Axon guidance,hsa04666:Fc gamma R-mediated phagocytosis,hsa04810:Regulation of actin cytoskeleton,hsa05133:Pertussis,hsa05170:Human immunodeficiency virus 1 infection,			SM00102:ADF,	KW-0945~Host-virus interaction,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-1003~Cell membrane,				KW-0009~Actin-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:ADF-H,MOTIF:Nuclear localization signal,REGION:Disordered,
CCDC107	coiled-coil domain containing 107(CCDC107)	Homo sapiens				GO:0016020~membrane,	GO:0005515~protein binding,	IPR038779:CCDC107,						KW-0472~Membrane,		KW-0175~Coiled coil,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,				REGION:Disordered,TRANSMEM:Helical,
CCDC115	coiled-coil domain containing 115(CCDC115)	Homo sapiens			GO:0006879~cellular iron ion homeostasis,GO:0007042~lysosomal lumen acidification,GO:0036295~cellular response to increased oxygen levels,GO:0070072~vacuolar proton-transporting V-type ATPase complex assembly,GO:1905146~lysosomal protein catabolic process,	GO:0005764~lysosome,GO:0005768~endosome,GO:0005783~endoplasmic reticulum,GO:0005793~endoplasmic reticulum-Golgi intermediate compartment,GO:0016020~membrane,GO:0016471~vacuolar proton-transporting V-type ATPase complex,GO:0030137~COPI-coated vesicle,	GO:0005515~protein binding,GO:0051082~unfolded protein binding,	IPR040357:Vma22/CCDC115,		616828~Congenital disorder of glycosylation, type IIo,				KW-0256~Endoplasmic reticulum,KW-0458~Lysosome,KW-0967~Endosome,KW-0968~Cytoplasmic vesicle,	KW-0225~Disease variant,KW-0900~Congenital disorder of glycosylation,	KW-0175~Coiled coil,				COMPBIAS:Basic and acidic residues,REGION:Disordered,
CCDC124	coiled-coil domain containing 124(CCDC124)	Homo sapiens			GO:0006366~transcription from RNA polymerase II promoter,GO:0007049~cell cycle,GO:0045893~positive regulation of transcription, DNA-templated,GO:0051301~cell division,	GO:0005634~nucleus,GO:0005813~centrosome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0030496~midbody,	GO:0003713~transcription coactivator activity,GO:0003723~RNA binding,	IPR010422:Ccdc124/Oxs1,					KW-0131~Cell cycle,KW-0132~Cell division,	KW-0206~Cytoskeleton,KW-0963~Cytoplasm,		KW-0175~Coiled coil,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,REGION:Disordered,
CCDC174	coiled-coil domain containing 174(CCDC174)	Homo sapiens				GO:0005634~nucleus,GO:0005654~nucleoplasm,	GO:0005515~protein binding,	IPR025066:CCDC174-like,		616816~Hypotonia, infantile, with psychomotor retardation,				KW-0539~Nucleus,		KW-0175~Coiled coil,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,
CCDC28A	coiled-coil domain containing 28A(CCDC28A)	Homo sapiens					GO:0005515~protein binding,	IPR025271:CCDC28,								KW-0175~Coiled coil,		KW-0675~Receptor,		COMPBIAS:Polar residues,REGION:Disordered,SITE:Breakpoint for translocation to form NUP98-CCDC28A,
CCDC47	coiled-coil domain containing 47(CCDC47)	Homo sapiens			GO:0001649~osteoblast differentiation,GO:0006457~protein folding,GO:0006983~ER overload response,GO:0009791~post-embryonic development,GO:0030433~ubiquitin-dependent ERAD pathway,GO:0032469~endoplasmic reticulum calcium ion homeostasis,GO:0036503~ERAD pathway,GO:0045048~protein insertion into ER membrane,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0016020~membrane,GO:0030867~rough endoplasmic reticulum membrane,GO:0101031~chaperone complex,	GO:0003723~RNA binding,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0043022~ribosome binding,GO:0044183~protein binding involved in protein folding,	IPR012879:CCDC47,		618268~Trichohepatoneurodevelopmental syndrome,				KW-0256~Endoplasmic reticulum,KW-0472~Membrane,	KW-0225~Disease variant,	KW-0175~Coiled coil,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0143~Chaperone,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
CCDC90B	coiled-coil domain containing 90B(CCDC90B)	Homo sapiens				GO:0005739~mitochondrion,GO:0016020~membrane,GO:0031966~mitochondrial membrane,	GO:0005515~protein binding,	IPR024461:CCDC90-like,						KW-0472~Membrane,KW-0496~Mitochondrion,		KW-0175~Coiled coil,KW-0809~Transit peptide,KW-0812~Transmembrane,KW-1133~Transmembrane helix,				COMPBIAS:Polar residues,REGION:Disordered,TRANSIT:Mitochondrion,TRANSMEM:Helical,
CCSER2	coiled-coil serine rich protein 2(CCSER2)	Homo sapiens			GO:0001578~microtubule bundle formation,	GO:0005737~cytoplasm,GO:0015630~microtubule cytoskeleton,	GO:0008017~microtubule binding,	IPR029627:CCSER,						KW-0206~Cytoskeleton,KW-0963~Cytoplasm,		KW-0175~Coiled coil,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,
CHCHD3	coiled-coil-helix-coiled-coil-helix domain containing 3(CHCHD3)	Homo sapiens			GO:0007007~inner mitochondrial membrane organization,GO:0008053~mitochondrial fusion,GO:0042407~cristae formation,	GO:0001401~mitochondrial sorting and assembly machinery complex,GO:0005634~nucleus,GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0044284~mitochondrial crista junction,GO:0061617~MICOS complex,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0019902~phosphatase binding,GO:0060090~binding, bridging,	IPR007964:MIC19/MIC25,					KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0999~Mitochondrion inner membrane,		KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0678~Repressor,	KW-0007~Acetylation,KW-0449~Lipoprotein,KW-0519~Myristate,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	COMPBIAS:Polar residues,DOMAIN:CHCH,LIPID:N-myristoyl glycine,MOTIF:Cx9C motif 1,MOTIF:Cx9C motif 2,REGION:Disordered,TRANSMEM:Helical,
CHCHD7	coiled-coil-helix-coiled-coil-helix domain containing 7(CHCHD7)	Homo sapiens			GO:0033108~mitochondrial respiratory chain complex assembly,	GO:0005739~mitochondrion,GO:0005758~mitochondrial intermembrane space,		IPR009069:Cys_alpha_HP_mot_SF,IPR048280:COX6B-like,						KW-0496~Mitochondrion,					KW-1015~Disulfide bond,	DOMAIN:CHCH,MOTIF:Cx9C motif 1,MOTIF:Cx9C motif 2,
CSDE1	cold shock domain containing E1(CSDE1)	Homo sapiens			GO:0006446~regulation of translational initiation,GO:0008584~male gonad development,GO:0034063~stress granule assembly,GO:0070934~CRD-mediated mRNA stabilization,GO:0070966~nuclear-transcribed mRNA catabolic process, no-go decay,GO:0075522~IRES-dependent viral translational initiation,GO:1900152~negative regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay,GO:2000767~positive regulation of cytoplasmic translation,	GO:0000932~P-body,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0010494~cytoplasmic stress granule,GO:0070937~CRD-mediated mRNA stability complex,	GO:0003676~nucleic acid binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0035613~RNA stem-loop binding,GO:1905172~RISC complex binding,	IPR002059:CSP_DNA-bd,IPR011129:CSD,IPR012340:NA-bd_OB-fold,IPR019844:CSD_1,IPR024642:SUZ-C,				SM00357:CSP,		KW-0963~Cytoplasm,		KW-0677~Repeat,		KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:CSD,DOMAIN:CSD 1,DOMAIN:CSD 2; truncated,DOMAIN:CSD 3,DOMAIN:CSD 4; truncated,DOMAIN:CSD 5,DOMAIN:CSD 6,DOMAIN:CSD 7,DOMAIN:CSD 8,DOMAIN:CSD 9,DOMAIN:SUZ-C,REGION:Disordered,
C1QBP	complement C1q binding protein(C1QBP)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006397~mRNA processing,GO:0006915~apoptotic process,GO:0006955~immune response,GO:0006958~complement activation, classical pathway,GO:0008380~RNA splicing,GO:0030449~regulation of complement activation,GO:0032689~negative regulation of interferon-gamma production,GO:0032695~negative regulation of interleukin-12 production,GO:0039534~negative regulation of MDA-5 signaling pathway,GO:0039536~negative regulation of RIG-I signaling pathway,GO:0042256~mature ribosome assembly,GO:0043065~positive regulation of apoptotic process,GO:0043491~protein kinase B signaling,GO:0045087~innate immune response,GO:0045785~positive regulation of cell adhesion,GO:0048025~negative regulation of mRNA splicing, via spliceosome,GO:0050687~negative regulation of defense response to virus,GO:0051897~positive regulation of protein kinase B signaling,GO:0070131~positive regulation of mitochondrial translation,GO:0090023~positive regulation of neutrophil chemotaxis,GO:1900026~positive regulation of substrate adhesion-dependent cell spreading,GO:1901165~positive regulation of trophoblast cell migration,GO:2000510~positive regulation of dendritic cell chemotaxis,	GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,	GO:0001849~complement component C1q binding,GO:0003714~transcription corepressor activity,GO:0003729~mRNA binding,GO:0005515~protein binding,GO:0005540~hyaluronic acid binding,GO:0008134~transcription factor binding,GO:0030984~kininogen binding,GO:0031690~adrenergic receptor binding,GO:0097177~mitochondrial ribosome binding,	IPR003428:MAM33,IPR036561:MAM33_sf,		617713~Combined oxidative phosphorylation deficiency 33,			KW-0053~Apoptosis,KW-0180~Complement pathway,KW-0391~Immunity,KW-0399~Innate immunity,KW-0507~mRNA processing,KW-0508~mRNA splicing,KW-0690~Ribosome biogenesis,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0964~Secreted,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-1274~Primary mitochondrial disease,	KW-0809~Transit peptide,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	MUTAGEN:G->D: Impairs HIV RNA splicing in mouse cells.,REGION:C1q binding,REGION:Disordered,REGION:Interaction with MAVS,TRANSIT:Mitochondrion,
CPNE1	copine 1(CPNE1)	Homo sapiens			GO:0006508~proteolysis,GO:0006629~lipid metabolic process,GO:0010629~negative regulation of gene expression,GO:0016192~vesicle-mediated transport,GO:0043122~regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043392~negative regulation of DNA binding,GO:0045666~positive regulation of neuron differentiation,GO:0051897~positive regulation of protein kinase B signaling,GO:0071277~cellular response to calcium ion,GO:1901223~negative regulation of NIK/NF-kappaB signaling,GO:1903265~positive regulation of tumor necrosis factor-mediated signaling pathway,GO:1990138~neuron projection extension,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0031965~nuclear membrane,GO:0035577~azurophil granule membrane,GO:0070062~extracellular exosome,	GO:0001786~phosphatidylserine binding,GO:0004175~endopeptidase activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0005544~calcium-dependent phospholipid binding,GO:0042802~identical protein binding,GO:0051059~NF-kappaB binding,	IPR000008:C2_dom,IPR002035:VWF_A,IPR010734:Copine_C,IPR035892:C2_domain_sf,IPR036465:vWFA_dom_sf,IPR037768:C2B_Copine,IPR045052:Copine,				SM00239:C2,SM00327:VWA,	KW-0221~Differentiation,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0677~Repeat,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0678~Repressor,	KW-0007~Acetylation,	COMPBIAS:Polar residues,DOMAIN:C2,DOMAIN:C2 1,DOMAIN:C2 2,DOMAIN:Copine C-terminal,DOMAIN:VWFA,MUTAGEN:D->A: Inhibits translocation to the cell membrane in a calcium-dependent manner and does not inhibit neuronal progenitor cell differentiation; when associated with A-21.,MUTAGEN:D->A: Inhibits translocation to the cell membrane in a calcium-dependent manner and does not inhibit neuronal progenitor cell differentiation; when associated with A-216.,MUTAGEN:D->A: Inhibits translocation to the cell membrane in a calcium-dependent manner and does not inhibit neuronal progenitor cell differentiation; when associated with A-222.,MUTAGEN:D->A: Inhibits translocation to the cell membrane in a calcium-dependent manner and does not inhibit neuronal progenitor cell differentiation; when associated with A-90.,REGION:Disordered,
CPNE3	copine 3(CPNE3)	Homo sapiens			GO:0030335~positive regulation of cell migration,GO:0038128~ERBB2 signaling pathway,GO:0071277~cellular response to calcium ion,GO:0071363~cellular response to growth factor stimulus,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0030054~cell junction,GO:0035577~azurophil granule membrane,GO:0070062~extracellular exosome,	GO:0003723~RNA binding,GO:0004674~protein serine/threonine kinase activity,GO:0005515~protein binding,GO:0005544~calcium-dependent phospholipid binding,GO:0030971~receptor tyrosine kinase binding,GO:0046872~metal ion binding,GO:0048306~calcium-dependent protein binding,	IPR000008:C2_dom,IPR002035:VWF_A,IPR010734:Copine_C,IPR035892:C2_domain_sf,IPR036465:vWFA_dom_sf,IPR037768:C2B_Copine,IPR045052:Copine,				SM00239:C2,SM00327:VWA,		KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0965~Cell junction,KW-1003~Cell membrane,		KW-0677~Repeat,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-0597~Phosphoprotein,	DOMAIN:C2,DOMAIN:C2 1,DOMAIN:C2 2,DOMAIN:VWFA,
CCS	copper chaperone for superoxide dismutase(CCS)	Homo sapiens			GO:0006801~superoxide metabolic process,GO:0015680~intracellular copper ion transport,GO:0019430~removal of superoxide radicals,GO:0034599~cellular response to oxidative stress,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0005507~copper ion binding,GO:0005515~protein binding,GO:0015035~protein disulfide oxidoreductase activity,GO:0016532~superoxide dismutase copper chaperone activity,GO:0045296~cadherin binding,	IPR001424:SOD_Cu_Zn_dom,IPR006121:HMA_dom,IPR018152:SOD_Cu/Zn_BS,IPR024134:SOD_Cu/Zn_/chaperone,IPR036163:HMA_dom_sf,IPR036423:SOD-like_Cu/Zn_dom_sf,	hsa05014:Amyotrophic lateral sclerosis,hsa05022:Pathways of neurodegeneration - multiple diseases,					KW-0963~Cytoplasm,			KW-0186~Copper,KW-0479~Metal-binding,KW-0862~Zinc,	KW-0143~Chaperone,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:HMA,DOMAIN:Superoxide dismutase copper/zinc binding,MUTAGEN:C->S: Reduces copper binding by half; when associated with S-22. Negligible effect on zinc binding.,MUTAGEN:C->S: Reduces copper binding by half; when associated with S-244. Negligible effect on zinc binding.,MUTAGEN:C->S: Reduces copper binding by half; when associated with S-246. Negligible effect on zinc binding.,MUTAGEN:C->S: Reduces copper binding by half; when associated with S-25. Negligible effect on zinc binding.,REGION:Disordered,REGION:Superoxide dismutase-like,
COMMD1	copper metabolism domain containing 1(COMMD1)	Homo sapiens			GO:0006289~nucleotide-excision repair,GO:0006893~Golgi to plasma membrane transport,GO:0015031~protein transport,GO:0031398~positive regulation of protein ubiquitination,GO:0032088~negative regulation of NF-kappaB transcription factor activity,GO:0032434~regulation of proteasomal ubiquitin-dependent protein catabolic process,GO:0048227~plasma membrane to endosome transport,GO:0055070~copper ion homeostasis,GO:1902306~negative regulation of sodium ion transmembrane transport,GO:2000009~negative regulation of protein localization to cell surface,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005768~endosome,GO:0005769~early endosome,GO:0005829~cytosol,GO:0010008~endosome membrane,GO:0031462~Cul2-RING ubiquitin ligase complex,GO:0055037~recycling endosome,	GO:0005507~copper ion binding,GO:0005515~protein binding,GO:0005546~phosphatidylinositol-4,5-bisphosphate binding,GO:0005547~phosphatidylinositol-3,4,5-trisphosphate binding,GO:0019871~sodium channel inhibitor activity,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0043325~phosphatidylinositol-3,4-bisphosphate binding,GO:0070300~phosphatidic acid binding,GO:0080025~phosphatidylinositol-3,5-bisphosphate binding,	IPR017920:COMM,IPR033776:COMMD1_N,IPR037351:Murr1,					KW-0653~Protein transport,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0813~Transport,KW-0833~Ubl conjugation pathway,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0967~Endosome,KW-0968~Cytoplasmic vesicle,			KW-0186~Copper,KW-0446~Lipid-binding,KW-0479~Metal-binding,		KW-0007~Acetylation,KW-0832~Ubl conjugation,	DOMAIN:COMM,DOMAIN:COMMD1 N-terminal,MUTAGEN:H->A: Reduces copper-induced fluorescence change.,MUTAGEN:M->A: Reduces copper-induced fluorescence change.,REGION:Required for binding to PtdIns(4,5)P2,REGION:Sufficient for interaction with SLC12A2,
CIR1	corepressor interacting with RBPJ, CIR1(CIR1)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001701~in utero embryonic development,GO:0006397~mRNA processing,GO:0008380~RNA splicing,GO:0045892~negative regulation of transcription, DNA-templated,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0016607~nuclear speck,GO:0032991~macromolecular complex,	GO:0003714~transcription corepressor activity,GO:0005515~protein binding,GO:0019901~protein kinase binding,GO:0042826~histone deacetylase binding,GO:0044877~macromolecular complex binding,	IPR019339:CIR_N_dom,IPR040014:CIR1,	hsa04330:Notch signaling pathway,hsa05169:Epstein-Barr virus infection,			SM01083:Cir_N,	KW-0507~mRNA processing,KW-0508~mRNA splicing,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0678~Repressor,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:CBF1-interacting co-repressor CIR N-terminal,MOTIF:Nuclear localization signal,REGION:Disordered,REGION:Interaction with RBPJ,REGION:Interaction with RP9,
CNIH4	cornichon family member 4(CNIH4)	Homo sapiens			GO:0006888~ER to Golgi vesicle-mediated transport,GO:0015031~protein transport,GO:0016192~vesicle-mediated transport,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005793~endoplasmic reticulum-Golgi intermediate compartment,GO:0016020~membrane,GO:0030134~ER to Golgi transport vesicle,	GO:0005515~protein binding,GO:0031730~CCR5 chemokine receptor binding,	IPR003377:Cornichon,				SM01398:Cornichon,	KW-0653~Protein transport,KW-0813~Transport,KW-0931~ER-Golgi transport,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				TRANSMEM:Helical,
CORO1B	coronin 1B(CORO1B)	Homo sapiens			GO:0007015~actin filament organization,GO:0016477~cell migration,GO:0030036~actin cytoskeleton organization,GO:0031529~ruffle organization,GO:0034315~regulation of Arp2/3 complex-mediated actin nucleation,GO:0034316~negative regulation of Arp2/3 complex-mediated actin nucleation,GO:0035767~endothelial cell chemotaxis,GO:0036120~cellular response to platelet-derived growth factor stimulus,GO:0042060~wound healing,GO:0051017~actin filament bundle assembly,GO:0071672~negative regulation of smooth muscle cell chemotaxis,GO:0090135~actin filament branching,GO:1902463~protein localization to cell leading edge,GO:2000394~positive regulation of lamellipodium morphogenesis,	GO:0001725~stress fiber,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005884~actin filament,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0030027~lamellipodium,GO:0031252~cell leading edge,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,GO:0071944~cell periphery,	GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0045296~cadherin binding,GO:0051015~actin filament binding,GO:0071933~Arp2/3 complex binding,	IPR001680:WD40_rpt,IPR015048:DUF1899,IPR015505:Coronin,IPR015943:WD40/YVTN_repeat-like_dom_sf,IPR019775:WD40_repeat_CS,IPR036322:WD40_repeat_dom_sf,				SM00320:WD40,SM01166:DUF1899,SM01167:DUF1900,		KW-0206~Cytoskeleton,KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0677~Repeat,KW-0853~WD repeat,		KW-0009~Actin-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:DUF1899,MUTAGEN:S->A: Stronger interaction with the Arp2/3 complex. Does not affect homo-oligomerization. Enhanced ruffling in response to phorbol 12-myristate 13-acetate (PMA) and increased speed in fibroblasts.,MUTAGEN:S->D: Weaker interaction with the Arp2/3 complex. Does not affect homo-oligomerization. Attenuated PMA-induced ruffling and slower speed in fibroblasts.,REGION:Disordered,REPEAT:WD,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,
CUL1	cullin 1(CUL1)	Homo sapiens		h_eradPathway:ERï¿½associated degradation (ERAD) Pathway,h_fbw7Pathway:Cyclin E Destruction Pathway,h_p27Pathway:Regulation of p27 Phosphorylation during Cell Cycle Progression,h_skp2e2fPathway:E2F1 Destruction Pathway,	GO:0000082~G1/S transition of mitotic cell cycle,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0006513~protein monoubiquitination,GO:0006915~apoptotic process,GO:0008283~cell proliferation,GO:0009887~animal organ morphogenesis,GO:0016567~protein ubiquitination,GO:0031146~SCF-dependent proteasomal ubiquitin-dependent protein catabolic process,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0070936~protein K48-linked ubiquitination,GO:0097193~intrinsic apoptotic signaling pathway,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0019005~SCF ubiquitin ligase complex,GO:0031461~cullin-RING ubiquitin ligase complex,GO:1990452~Parkin-FBXW7-Cul1 ubiquitin ligase complex,	GO:0005515~protein binding,GO:0030674~protein binding, bridging,GO:0031625~ubiquitin protein ligase binding,	IPR001373:Cullin_N,IPR016157:Cullin_CS,IPR016158:Cullin_homology,IPR016159:Cullin_repeat-like_dom_sf,IPR019559:Cullin_neddylation_domain,IPR036317:Cullin_homology_sf,IPR036388:WH-like_DNA-bd_sf,IPR036390:WH_DNA-bd_sf,IPR045093:Cullin,	hsa04110:Cell cycle,hsa04114:Oocyte meiosis,hsa04120:Ubiquitin mediated proteolysis,hsa04141:Protein processing in endoplasmic reticulum,hsa04310:Wnt signaling pathway,hsa04340:Hedgehog signaling pathway,hsa04350:TGF-beta signaling pathway,hsa04710:Circadian rhythm,hsa05131:Shigellosis,hsa05170:Human immunodeficiency virus 1 infection,hsa05200:Pathways in cancer,			SM00182:CULLIN,SM00884:Cullin_Nedd8,	KW-0833~Ubl conjugation pathway,KW-0945~Host-virus interaction,						KW-0488~Methylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in NEDD8),DOMAIN:Cullin N-terminal,DOMAIN:Cullin family profile,REGION:Disordered,
CUL4A	cullin 4A(CUL4A)	Homo sapiens			GO:0000082~G1/S transition of mitotic cell cycle,GO:0001701~in utero embryonic development,GO:0006281~DNA repair,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0006974~cellular response to DNA damage stimulus,GO:0007283~spermatogenesis,GO:0008283~cell proliferation,GO:0008284~positive regulation of cell proliferation,GO:0016567~protein ubiquitination,GO:0030097~hemopoiesis,GO:0030853~negative regulation of granulocyte differentiation,GO:0034644~cellular response to UV,GO:0035019~somatic stem cell population maintenance,GO:0042110~T cell activation,GO:0042254~ribosome biogenesis,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0045732~positive regulation of protein catabolic process,GO:0048511~rhythmic process,GO:0097193~intrinsic apoptotic signaling pathway,GO:1900087~positive regulation of G1/S transition of mitotic cell cycle,GO:2000001~regulation of DNA damage checkpoint,GO:2000819~regulation of nucleotide-excision repair,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0031461~cullin-RING ubiquitin ligase complex,GO:0031464~Cul4A-RING E3 ubiquitin ligase complex,GO:0080008~Cul4-RING E3 ubiquitin ligase complex,	GO:0005515~protein binding,GO:0031625~ubiquitin protein ligase binding,GO:0061630~ubiquitin protein ligase activity,	IPR001373:Cullin_N,IPR016157:Cullin_CS,IPR016158:Cullin_homology,IPR016159:Cullin_repeat-like_dom_sf,IPR019559:Cullin_neddylation_domain,IPR036317:Cullin_homology_sf,IPR036388:WH-like_DNA-bd_sf,IPR036390:WH_DNA-bd_sf,IPR045093:Cullin,	hsa03420:Nucleotide excision repair,hsa04120:Ubiquitin mediated proteolysis,hsa05170:Human immunodeficiency virus 1 infection,			SM00182:CULLIN,SM00884:Cullin_Nedd8,	KW-0090~Biological rhythms,KW-0227~DNA damage,KW-0234~DNA repair,KW-0833~Ubl conjugation pathway,KW-0945~Host-virus interaction,						KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in NEDD8),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:Cullin N-terminal,DOMAIN:Cullin family profile,MUTAGEN:LYQAV->AAAAA: Largely reduces interaction with DDB1; abolishes interaction with DDB2.,MUTAGEN:WQDH->AADA: Largely reduces interaction with DDB1; abolishes interaction with DDB2.,
CAND1	cullin associated and neddylation dissociated 1(CAND1)	Homo sapiens			GO:0010265~SCF complex assembly,GO:0016567~protein ubiquitination,GO:0030154~cell differentiation,GO:0043086~negative regulation of catalytic activity,GO:0045899~positive regulation of RNA polymerase II transcriptional preinitiation complex assembly,	GO:0000151~ubiquitin ligase complex,GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0016020~membrane,GO:0031461~cullin-RING ubiquitin ligase complex,GO:0034774~secretory granule lumen,GO:0070062~extracellular exosome,GO:1904813~ficolin-1-rich granule lumen,	GO:0005515~protein binding,GO:0017025~TBP-class protein binding,	IPR011989:ARM-like,IPR013932:TATA-bd_TIP120,IPR016024:ARM-type_fold,IPR039852:CAND1/CAND2,					KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,DOMAIN:TATA-binding protein interacting (TIP20),REGION:Disordered,REPEAT:HEAT 1,REPEAT:HEAT 10,REPEAT:HEAT 11,REPEAT:HEAT 12,REPEAT:HEAT 13,REPEAT:HEAT 14,REPEAT:HEAT 15,REPEAT:HEAT 16,REPEAT:HEAT 17,REPEAT:HEAT 18,REPEAT:HEAT 19,REPEAT:HEAT 2,REPEAT:HEAT 20,REPEAT:HEAT 21,REPEAT:HEAT 22,REPEAT:HEAT 23,REPEAT:HEAT 24,REPEAT:HEAT 25,REPEAT:HEAT 26,REPEAT:HEAT 27,REPEAT:HEAT 3,REPEAT:HEAT 4,REPEAT:HEAT 5,REPEAT:HEAT 6,REPEAT:HEAT 7,REPEAT:HEAT 8,REPEAT:HEAT 9,
CUTA	cutA divalent cation tolerance homolog(CUTA)	Homo sapiens			GO:0008104~protein localization,GO:0010038~response to metal ion,	GO:0016020~membrane,GO:0070062~extracellular exosome,	GO:0005507~copper ion binding,GO:0005515~protein binding,GO:0019899~enzyme binding,	IPR004323:Ion_tolerance_CutA,IPR011322:N-reg_PII-like_a/b,IPR015867:N-reg_PII/ATP_PRibTrfase_C,						KW-0472~Membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	COMPBIAS:Polar residues,REGION:Disordered,REGION:O-glycosylated at one site,TRANSMEM:Helical,
CAP1	cyclase associated actin cytoskeleton regulatory protein 1(CAP1)	Homo sapiens	81.Structure_of_Caps_and_SMACs,	h_mPRPathway:How Progesterone Initiates the Oocyte Maturation,	GO:0000902~cell morphogenesis,GO:0001667~ameboidal-type cell migration,GO:0006898~receptor-mediated endocytosis,GO:0007010~cytoskeleton organization,GO:0007015~actin filament organization,GO:0007163~establishment or maintenance of cell polarity,GO:0007165~signal transduction,GO:0007190~activation of adenylate cyclase activity,GO:0019933~cAMP-mediated signaling,	GO:0005576~extracellular region,GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0030864~cortical actin cytoskeleton,GO:0035578~azurophil granule lumen,GO:0070062~extracellular exosome,	GO:0003779~actin binding,GO:0005515~protein binding,GO:0008179~adenylate cyclase binding,	IPR001837:Adenylate_cyclase-assoc_CAP,IPR006599:CARP_motif,IPR013912:Adenylate_cyclase-assoc_CAP_C,IPR013992:Adenylate_cyclase-assoc_CAP_N,IPR016098:CAP/MinC_C,IPR017901:C-CAP_CF_C-like,IPR018106:CAP_CS_N,IPR028417:CAP_CS_C,IPR036222:CAP_N_sf,IPR036223:CAP_C_sf,				SM00673:CARP,		KW-0472~Membrane,KW-1003~Cell membrane,		KW-0732~Signal,		KW-0009~Actin-binding,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1),DOMAIN:Adenylate cyclase-associated CAP N-terminal,DOMAIN:C-CAP/cofactor C-like,REGION:Disordered,
CCND2	cyclin D2(CCND2)	Homo sapiens		h_cellcyclePathway:Cyclins and Cell Cycle Regulation,	GO:0000079~regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0000082~G1/S transition of mitotic cell cycle,GO:0001934~positive regulation of protein phosphorylation,GO:0007616~long-term memory,GO:0008284~positive regulation of cell proliferation,GO:0008344~adult locomotory behavior,GO:0043066~negative regulation of apoptotic process,GO:0044772~mitotic cell cycle phase transition,GO:0045737~positive regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0051301~cell division,GO:0071481~cellular response to X-ray,GO:1900087~positive regulation of G1/S transition of mitotic cell cycle,	GO:0000307~cyclin-dependent protein kinase holoenzyme complex,GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005829~cytosol,GO:0031965~nuclear membrane,GO:0097129~cyclin D2-CDK4 complex,	GO:0005515~protein binding,GO:0016538~cyclin-dependent protein serine/threonine kinase regulator activity,GO:0019901~protein kinase binding,GO:0061575~cyclin-dependent protein serine/threonine kinase activator activity,	IPR004367:Cyclin_C-dom,IPR006671:Cyclin_N,IPR013763:Cyclin-like_dom,IPR036915:Cyclin-like_sf,IPR039361:Cyclin,IPR048258:Cyclins_cyclin-box,	hsa04068:FoxO signaling pathway,hsa04110:Cell cycle,hsa04115:p53 signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04218:Cellular senescence,hsa04310:Wnt signaling pathway,hsa04340:Hedgehog signaling pathway,hsa04390:Hippo signaling pathway,hsa04510:Focal adhesion,hsa04630:JAK-STAT signaling pathway,hsa04917:Prolactin signaling pathway,hsa05162:Measles,hsa05165:Human papillomavirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05200:Pathways in cancer,hsa05202:Transcriptional misregulation in cancer,hsa05203:Viral carcinogenesis,hsa05206:MicroRNAs in cancer,	615938~Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 3,		SM00385:CYCLIN,SM01332:Cyclin_C,	KW-0131~Cell cycle,KW-0132~Cell division,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,			KW-0195~Cyclin,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Basic and acidic residues,DOMAIN:Cyclin C-terminal,DOMAIN:Cyclin N-terminal,DOMAIN:Cyclin-like,REGION:Disordered,
CCND3	cyclin D3(CCND3)	Homo sapiens		h_cellcyclePathway:Cyclins and Cell Cycle Regulation,	GO:0000079~regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0000082~G1/S transition of mitotic cell cycle,GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001934~positive regulation of protein phosphorylation,GO:0007165~signal transduction,GO:0042098~T cell proliferation,GO:0042127~regulation of cell proliferation,GO:0044772~mitotic cell cycle phase transition,GO:0045737~positive regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0051301~cell division,GO:1900087~positive regulation of G1/S transition of mitotic cell cycle,	GO:0000307~cyclin-dependent protein kinase holoenzyme complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005829~cytosol,GO:0097130~cyclin D3-CDK4 complex,	GO:0004693~cyclin-dependent protein serine/threonine kinase activity,GO:0005515~protein binding,GO:0016538~cyclin-dependent protein serine/threonine kinase regulator activity,GO:0019901~protein kinase binding,GO:0061575~cyclin-dependent protein serine/threonine kinase activator activity,	IPR004367:Cyclin_C-dom,IPR006671:Cyclin_N,IPR013763:Cyclin-like_dom,IPR036915:Cyclin-like_sf,IPR039361:Cyclin,IPR048258:Cyclins_cyclin-box,	hsa04110:Cell cycle,hsa04115:p53 signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04218:Cellular senescence,hsa04310:Wnt signaling pathway,hsa04390:Hippo signaling pathway,hsa04510:Focal adhesion,hsa04630:JAK-STAT signaling pathway,hsa05162:Measles,hsa05164:Influenza A,hsa05165:Human papillomavirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05200:Pathways in cancer,hsa05203:Viral carcinogenesis,hsa05207:Chemical carcinogenesis - receptor activation,			SM00385:CYCLIN,SM01332:Cyclin_C,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0195~Cyclin,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,DOMAIN:Cyclin C-terminal,DOMAIN:Cyclin N-terminal,DOMAIN:Cyclin-like,REGION:Disordered,
GAK	cyclin G associated kinase(GAK)	Homo sapiens			GO:0006898~receptor-mediated endocytosis,GO:0007029~endoplasmic reticulum organization,GO:0007030~Golgi organization,GO:0007049~cell cycle,GO:0010977~negative regulation of neuron projection development,GO:0016191~synaptic vesicle uncoating,GO:0016310~phosphorylation,GO:0034067~protein localization to Golgi apparatus,GO:0046907~intracellular transport,GO:0048268~clathrin coat assembly,GO:0051085~chaperone mediated protein folding requiring cofactor,GO:0072318~clathrin coat disassembly,GO:0072583~clathrin-dependent endocytosis,GO:0072659~protein localization to plasma membrane,GO:0090160~Golgi to lysosome transport,GO:1905443~regulation of clathrin coat assembly,	GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0005925~focal adhesion,GO:0016020~membrane,GO:0030136~clathrin-coated vesicle,GO:0031982~vesicle,GO:0043231~intracellular membrane-bounded organelle,GO:0048471~perinuclear region of cytoplasm,GO:0098793~presynapse,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016301~kinase activity,GO:0030276~clathrin binding,GO:0030332~cyclin binding,GO:0051087~chaperone binding,	IPR000719:Prot_kinase_dom,IPR001623:DnaJ_domain,IPR008271:Ser/Thr_kinase_AS,IPR011009:Kinase-like_dom_sf,IPR014020:Tensin_C2-dom,IPR029021:Prot-tyrosine_phosphatase-like,IPR029023:Tensin_phosphatase,IPR035892:C2_domain_sf,IPR036869:J_dom_sf,				SM00220:S_TKc,SM00271:DnaJ,SM01326:PTEN_C2,	KW-0131~Cell cycle,	KW-0333~Golgi apparatus,KW-0963~Cytoplasm,KW-0965~Cell junction,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:C2 tensin-type,DOMAIN:J,DOMAIN:Phosphatase tensin-type,DOMAIN:Protein kinase,REGION:Disordered,
CCNG1	cyclin G1(CCNG1)	Homo sapiens	26.cyclin-CDK_complexes,		GO:0000079~regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0006949~syncytium formation,GO:0007095~mitotic G2 DNA damage checkpoint,GO:0009629~response to gravity,GO:0010243~response to organonitrogen compound,GO:0043066~negative regulation of apoptotic process,GO:0044772~mitotic cell cycle phase transition,GO:0051301~cell division,	GO:0000307~cyclin-dependent protein kinase holoenzyme complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0030425~dendrite,GO:0043025~neuronal cell body,GO:0048471~perinuclear region of cytoplasm,	GO:0005515~protein binding,GO:0016538~cyclin-dependent protein serine/threonine kinase regulator activity,	IPR006671:Cyclin_N,IPR013763:Cyclin-like_dom,IPR036915:Cyclin-like_sf,IPR039361:Cyclin,	hsa04115:p53 signaling pathway,hsa05206:MicroRNAs in cancer,			SM00385:CYCLIN,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,	KW-0539~Nucleus,				KW-0195~Cyclin,		DOMAIN:Cyclin N-terminal,DOMAIN:Cyclin-like,
CCNH	cyclin H(CCNH)	Homo sapiens		h_cellcyclePathway:Cyclins and Cell Cycle Regulation,h_ptc1Pathway:Sonic Hedgehog (SHH) Receptor Ptc1 Regulates cell cycle,	GO:0000079~regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0006351~transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0006367~transcription initiation from RNA polymerase II promoter,GO:0007049~cell cycle,GO:0050821~protein stabilization,GO:2000045~regulation of G1/S transition of mitotic cell cycle,	GO:0000307~cyclin-dependent protein kinase holoenzyme complex,GO:0000439~core TFIIH complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005675~holo TFIIH complex,GO:0019907~cyclin-dependent protein kinase activating kinase holoenzyme complex,GO:0070516~CAK-ERCC2 complex,GO:0070985~TFIIK complex,	GO:0005515~protein binding,GO:0016538~cyclin-dependent protein serine/threonine kinase regulator activity,	IPR006671:Cyclin_N,IPR013763:Cyclin-like_dom,IPR027081:CyclinH/Ccl1,IPR031658:Cyclin_C_2,IPR036915:Cyclin-like_sf,IPR043198:Cyclin/Ssn8,	hsa03022:Basal transcription factors,hsa03420:Nucleotide excision repair,hsa04110:Cell cycle,			SM00385:CYCLIN,	KW-0131~Cell cycle,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0195~Cyclin,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:Cyclin-like,MUTAGEN:S->A: No effect on the transcriptional activity of the reconstituted TFIIH complex.,REGION:Disordered,
CCNK	cyclin K(CCNK)	Homo sapiens			GO:0000079~regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0006974~cellular response to DNA damage stimulus,GO:0007049~cell cycle,GO:0009966~regulation of signal transduction,GO:0032786~positive regulation of DNA-templated transcription, elongation,GO:0032968~positive regulation of transcription elongation from RNA polymerase II promoter,GO:0044828~negative regulation by host of viral genome replication,GO:0051301~cell division,	GO:0000307~cyclin-dependent protein kinase holoenzyme complex,GO:0002944~cyclin K-CDK12 complex,GO:0002945~cyclin K-CDK13 complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0008024~cyclin/CDK positive transcription elongation factor complex,	GO:0004693~cyclin-dependent protein serine/threonine kinase activity,GO:0005515~protein binding,GO:0008353~RNA polymerase II carboxy-terminal domain kinase activity,GO:0016538~cyclin-dependent protein serine/threonine kinase regulator activity,GO:0019901~protein kinase binding,GO:0061575~cyclin-dependent protein serine/threonine kinase activator activity,	IPR004367:Cyclin_C-dom,IPR006671:Cyclin_N,IPR013763:Cyclin-like_dom,IPR036915:Cyclin-like_sf,IPR043198:Cyclin/Ssn8,		618147~Intellectual developmental disorder with hypertelorism and distinctive facies,	PIRSF028758:Cyclin, C/H/G types,PIRSF036580:Cyclin_L,	SM00385:CYCLIN,SM01332:Cyclin_C,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-0991~Intellectual disability,			KW-0195~Cyclin,	KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Cyclin C-terminal,DOMAIN:Cyclin N-terminal,DOMAIN:Cyclin-like,REGION:Disordered,
CCNL2	cyclin L2(CCNL2)	Homo sapiens	14.chemokine_receptor-ligand,		GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0042981~regulation of apoptotic process,GO:0043484~regulation of RNA splicing,GO:0046605~regulation of centrosome cycle,GO:0051726~regulation of cell cycle,	GO:0000307~cyclin-dependent protein kinase holoenzyme complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0016607~nuclear speck,GO:0043231~intracellular membrane-bounded organelle,	GO:0005515~protein binding,GO:0016538~cyclin-dependent protein serine/threonine kinase regulator activity,	IPR004367:Cyclin_C-dom,IPR006671:Cyclin_N,IPR013763:Cyclin-like_dom,IPR036915:Cyclin-like_sf,IPR043198:Cyclin/Ssn8,			PIRSF036580:Cyclin_L,	SM00385:CYCLIN,SM01332:Cyclin_C,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0677~Repeat,		KW-0195~Cyclin,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Cyclin C-terminal,DOMAIN:Cyclin N-terminal,REGION:Cyclin-like 1,REGION:Cyclin-like 2,REGION:Disordered,REGION:RS,
CNPPD1	cyclin Pas1/PHO80 domain containing 1(CNPPD1)	Homo sapiens				GO:0000307~cyclin-dependent protein kinase holoenzyme complex,GO:0005634~nucleus,GO:0016020~membrane,	GO:0016538~cyclin-dependent protein serine/threonine kinase regulator activity,GO:0019901~protein kinase binding,	IPR013922:Cyclin_PHO80-like,						KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				TRANSMEM:Helical,
CCNT1	cyclin T1(CCNT1)	Homo sapiens			GO:0000079~regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0007049~cell cycle,GO:0009410~response to xenobiotic stimulus,GO:0032786~positive regulation of DNA-templated transcription, elongation,GO:0032968~positive regulation of transcription elongation from RNA polymerase II promoter,GO:0043923~positive regulation by host of viral transcription,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051301~cell division,	GO:0000307~cyclin-dependent protein kinase holoenzyme complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0008024~cyclin/CDK positive transcription elongation factor complex,GO:0070691~P-TEFb complex,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0005515~protein binding,GO:0016538~cyclin-dependent protein serine/threonine kinase regulator activity,GO:0019901~protein kinase binding,GO:0061575~cyclin-dependent protein serine/threonine kinase activator activity,GO:0070063~RNA polymerase binding,GO:0097322~7SK snRNA binding,	IPR006671:Cyclin_N,IPR013763:Cyclin-like_dom,IPR036915:Cyclin-like_sf,IPR043198:Cyclin/Ssn8,IPR047320:CYCLIN_CCNT1_rpt2,	hsa03250:Viral life cycle - HIV-1,hsa05202:Transcriptional misregulation in cancer,			SM00385:CYCLIN,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0539~Nucleus,		KW-0175~Coiled coil,		KW-0195~Cyclin,	KW-0007~Acetylation,KW-0013~ADP-ribosylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Cyclin-like,MOTIF:Nuclear localization signal, and interaction with Tat-TAR RNA,MUTAGEN:C->Y: Loss of HIV-1 Tat transactivation.,MUTAGEN:HHHHHNHHSHK->AAAAANAASAKA: In mutant 9A; impaired formation of phase-separated liquid droplets, leading to decreased ability to activate CDK9.,REGION:Disordered,REGION:Histidine-rich domain (HRD),REGION:Required for interaction with ZMYND8,SITE:Essential for interacting with HIV-1 Tat,
CDK11B	cyclin dependent kinase 11B(CDK11B)	Homo sapiens		h_hivnefPathway:HIV-I Nef: negative effector of Fas and TNF,	GO:0000278~mitotic cell cycle,GO:0001558~regulation of cell growth,GO:0006355~regulation of transcription, DNA-templated,GO:0006468~protein phosphorylation,GO:0006915~apoptotic process,GO:0007346~regulation of mitotic cell cycle,GO:0016310~phosphorylation,GO:0042981~regulation of apoptotic process,GO:0043484~regulation of RNA splicing,GO:0046605~regulation of centrosome cycle,GO:0050684~regulation of mRNA processing,GO:0051726~regulation of cell cycle,	GO:0000307~cyclin-dependent protein kinase holoenzyme complex,GO:0005634~nucleus,GO:0005737~cytoplasm,	GO:0003723~RNA binding,GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004693~cyclin-dependent protein serine/threonine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016301~kinase activity,	IPR000719:Prot_kinase_dom,IPR008271:Ser/Thr_kinase_AS,IPR011009:Kinase-like_dom_sf,IPR045267:CDK11/PITSLRE_STKc,				SM00220:S_TKc,	KW-0053~Apoptosis,KW-0131~Cell cycle,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	ACT_SITE:Proton acceptor,COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Protein kinase,REGION:Disordered,
CDK12	cyclin dependent kinase 12(CDK12)	Homo sapiens			GO:0006366~transcription from RNA polymerase II promoter,GO:0006397~mRNA processing,GO:0006468~protein phosphorylation,GO:0008380~RNA splicing,GO:0016310~phosphorylation,GO:0032968~positive regulation of transcription elongation from RNA polymerase II promoter,GO:0043405~regulation of MAP kinase activity,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046777~protein autophosphorylation,GO:0051726~regulation of cell cycle,GO:2000737~negative regulation of stem cell differentiation,	GO:0002944~cyclin K-CDK12 complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0008024~cyclin/CDK positive transcription elongation factor complex,GO:0016607~nuclear speck,GO:0019908~nuclear cyclin-dependent protein kinase holoenzyme complex,	GO:0004672~protein kinase activity,GO:0004693~cyclin-dependent protein serine/threonine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008353~RNA polymerase II carboxy-terminal domain kinase activity,GO:0016301~kinase activity,GO:0019901~protein kinase binding,GO:0030332~cyclin binding,	IPR000719:Prot_kinase_dom,IPR008271:Ser/Thr_kinase_AS,IPR011009:Kinase-like_dom_sf,IPR017441:Protein_kinase_ATP_BS,				SM00220:S_TKc,	KW-0507~mRNA processing,KW-0508~mRNA splicing,KW-0945~Host-virus interaction,	KW-0539~Nucleus,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	ACT_SITE:Proton acceptor,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Protein kinase,MUTAGEN:D->N: Abolishes kinase activity.,REGION:Disordered,
CDK16	cyclin dependent kinase 16(CDK16)	Homo sapiens			GO:0000083~regulation of transcription involved in G1/S transition of mitotic cell cycle,GO:0006468~protein phosphorylation,GO:0006887~exocytosis,GO:0007283~spermatogenesis,GO:0010508~positive regulation of autophagy,GO:0030252~growth hormone secretion,GO:0031175~neuron projection development,GO:0051726~regulation of cell cycle,GO:0061178~regulation of insulin secretion involved in cellular response to glucose stimulus,	GO:0000307~cyclin-dependent protein kinase holoenzyme complex,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0008021~synaptic vesicle,GO:0009898~cytoplasmic side of plasma membrane,GO:0015630~microtubule cytoskeleton,GO:0043005~neuron projection,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004693~cyclin-dependent protein serine/threonine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,	IPR000719:Prot_kinase_dom,IPR008271:Ser/Thr_kinase_AS,IPR011009:Kinase-like_dom_sf,IPR017441:Protein_kinase_ATP_BS,				SM00220:S_TKc,	KW-0221~Differentiation,KW-0744~Spermatogenesis,	KW-0472~Membrane,KW-0770~Synapse,KW-0771~Synaptosome,KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,COMPBIAS:Polar residues,DOMAIN:Protein kinase,MUTAGEN:K->A: Loss of kinase activity. Abolishes effect on insulin secretion.,MUTAGEN:K->R: Loss of kinase activity.,MUTAGEN:S->A: Abolishes phosphorylation by BRSK2. Abolishes effect on insulin secretion.,MUTAGEN:S->A: Constitutively activated, due to loss of an inhibitory phosphorylation site. Increases interaction with CCNY.,MUTAGEN:S->A: Strongly reduces interaction with CCNY.,MUTAGEN:S->D: Abolishes interaction with CCNY.,REGION:Disordered,
CDK17	cyclin dependent kinase 17(CDK17)	Homo sapiens			GO:0000083~regulation of transcription involved in G1/S transition of mitotic cell cycle,GO:0006468~protein phosphorylation,GO:0016310~phosphorylation,GO:0051726~regulation of cell cycle,	GO:0005634~nucleus,GO:0005737~cytoplasm,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004693~cyclin-dependent protein serine/threonine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,	IPR000719:Prot_kinase_dom,IPR008271:Ser/Thr_kinase_AS,IPR011009:Kinase-like_dom_sf,IPR017441:Protein_kinase_ATP_BS,				SM00220:S_TKc,					KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,COMPBIAS:Polar residues,DOMAIN:Protein kinase,REGION:Disordered,
CDK4	cyclin dependent kinase 4(CDK4)	Homo sapiens	26.cyclin-CDK_complexes,4.cyclins_&_p27_cell_cycle,83.Growth_factors_Survival_factors_Mitogens,94.E2F_transcriptional_activity_cell_cycle,	h_cellcyclePathway:Cyclins and Cell Cycle Regulation,h_EfpPathway:Estrogen-responsive protein Efp controls cell cycle and breast tumors growth,h_g1Pathway:Cell Cycle: G1/S Check Point ,h_p53Pathway:p53 Signaling Pathway,h_raccycdPathway:Influence of Ras and Rho proteins on G1 to S Transition,h_rbPathway:RB Tumor Suppressor/Checkpoint Signaling in response to DNA damage,	GO:0000082~G1/S transition of mitotic cell cycle,GO:0006468~protein phosphorylation,GO:0007165~signal transduction,GO:0008284~positive regulation of cell proliferation,GO:0009410~response to xenobiotic stimulus,GO:0010033~response to organic substance,GO:0010389~regulation of G2/M transition of mitotic cell cycle,GO:0010468~regulation of gene expression,GO:0010971~positive regulation of G2/M transition of mitotic cell cycle,GO:0016310~phosphorylation,GO:0048146~positive regulation of fibroblast proliferation,GO:0051301~cell division,GO:0051726~regulation of cell cycle,GO:0060260~regulation of transcription initiation from RNA polymerase II promoter,GO:0061469~regulation of type B pancreatic cell proliferation,GO:0071222~cellular response to lipopolysaccharide,GO:0071353~cellular response to interleukin-4,GO:1904628~cellular response to phorbol 13-acetate 12-myristate,GO:1904637~cellular response to ionomycin,	GO:0000307~cyclin-dependent protein kinase holoenzyme complex,GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005923~bicellular tight junction,GO:0031965~nuclear membrane,GO:0097128~cyclin D1-CDK4 complex,GO:0097129~cyclin D2-CDK4 complex,GO:0097130~cyclin D3-CDK4 complex,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004693~cyclin-dependent protein serine/threonine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016301~kinase activity,GO:0016538~cyclin-dependent protein serine/threonine kinase regulator activity,GO:0030332~cyclin binding,	IPR000719:Prot_kinase_dom,IPR008271:Ser/Thr_kinase_AS,IPR011009:Kinase-like_dom_sf,IPR017441:Protein_kinase_ATP_BS,	hsa01522:Endocrine resistance,hsa04110:Cell cycle,hsa04115:p53 signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04218:Cellular senescence,hsa04530:Tight junction,hsa04660:T cell receptor signaling pathway,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa04934:Cushing syndrome,hsa05160:Hepatitis C,hsa05162:Measles,hsa05163:Human cytomegalovirus infection,hsa05164:Influenza A,hsa05165:Human papillomavirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05169:Epstein-Barr virus infection,hsa05200:Pathways in cancer,hsa05203:Viral carcinogenesis,hsa05212:Pancreatic cancer,hsa05214:Glioma,hsa05218:Melanoma,hsa05219:Bladder cancer,hsa05220:Chronic myeloid leukemia,hsa05222:Small cell lung cancer,hsa05223:Non-small cell lung cancer,hsa05224:Breast cancer,hsa05225:Hepatocellular carcinoma,	609048~Melanoma, cutaneous malignant, 3,		SM00220:S_TKc,	KW-0131~Cell cycle,KW-0132~Cell division,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,		KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,DOMAIN:Protein kinase,MUTAGEN:P->S: No effect on in vitro phosphorylation by CDK7. Greatly reduced T-172 phosphorylation and enzyme activity.,MUTAGEN:T->A: Weak enzyme activity towards RB1, but no effect on binding of CCDN1 nor CCDN3.,MUTAGEN:T->E: Retains moderate enzyme activity.,REGION:Required for binding D-type cyclins,
CDK6	cyclin dependent kinase 6(CDK6)	Homo sapiens	26.cyclin-CDK_complexes,4.cyclins_&_p27_cell_cycle,71.Id_proteins_G0-to-S_cell_cycle,83.Growth_factors_Survival_factors_Mitogens,94.E2F_transcriptional_activity_cell_cycle,	h_cellcyclePathway:Cyclins and Cell Cycle Regulation,h_EfpPathway:Estrogen-responsive protein Efp controls cell cycle and breast tumors growth,h_g1Pathway:Cell Cycle: G1/S Check Point ,h_raccycdPathway:Influence of Ras and Rho proteins on G1 to S Transition,	GO:0000082~G1/S transition of mitotic cell cycle,GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001954~positive regulation of cell-matrix adhesion,GO:0003323~type B pancreatic cell development,GO:0006468~protein phosphorylation,GO:0007165~signal transduction,GO:0007219~Notch signaling pathway,GO:0008285~negative regulation of cell proliferation,GO:0009615~response to virus,GO:0010033~response to organic substance,GO:0010389~regulation of G2/M transition of mitotic cell cycle,GO:0010468~regulation of gene expression,GO:0010628~positive regulation of gene expression,GO:0014002~astrocyte development,GO:0021542~dentate gyrus development,GO:0021670~lateral ventricle development,GO:0033077~T cell differentiation in thymus,GO:0042063~gliogenesis,GO:0043697~cell dedifferentiation,GO:0045596~negative regulation of cell differentiation,GO:0045638~negative regulation of myeloid cell differentiation,GO:0045646~regulation of erythrocyte differentiation,GO:0045656~negative regulation of monocyte differentiation,GO:0045668~negative regulation of osteoblast differentiation,GO:0045786~negative regulation of cell cycle,GO:0048146~positive regulation of fibroblast proliferation,GO:0048699~generation of neurons,GO:0050680~negative regulation of epithelial cell proliferation,GO:0051301~cell division,GO:0051726~regulation of cell cycle,GO:0060218~hematopoietic stem cell differentiation,GO:1902036~regulation of hematopoietic stem cell differentiation,GO:2000145~regulation of cell motility,GO:2000773~negative regulation of cellular senescence,	GO:0000307~cyclin-dependent protein kinase holoenzyme complex,GO:0001726~ruffle,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005829~cytosol,GO:0097132~cyclin D2-CDK6 complex,	GO:0004693~cyclin-dependent protein serine/threonine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0030332~cyclin binding,GO:0098770~FBXO family protein binding,	IPR000719:Prot_kinase_dom,IPR008271:Ser/Thr_kinase_AS,IPR011009:Kinase-like_dom_sf,IPR017441:Protein_kinase_ATP_BS,IPR028788:CDK6,	hsa04110:Cell cycle,hsa04115:p53 signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04218:Cellular senescence,hsa04934:Cushing syndrome,hsa05160:Hepatitis C,hsa05162:Measles,hsa05163:Human cytomegalovirus infection,hsa05164:Influenza A,hsa05165:Human papillomavirus infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05169:Epstein-Barr virus infection,hsa05200:Pathways in cancer,hsa05203:Viral carcinogenesis,hsa05206:MicroRNAs in cancer,hsa05212:Pancreatic cancer,hsa05214:Glioma,hsa05218:Melanoma,hsa05220:Chronic myeloid leukemia,hsa05222:Small cell lung cancer,hsa05223:Non-small cell lung cancer,hsa05224:Breast cancer,hsa05225:Hepatocellular carcinoma,	616080~Microcephaly 12, primary, autosomal recessive,		SM00220:S_TKc,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0221~Differentiation,	KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0966~Cell projection,	KW-0225~Disease variant,KW-0905~Primary microcephaly,		KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,DOMAIN:Protein kinase,
CDKN1A	cyclin dependent kinase inhibitor 1A(CDKN1A)	Homo sapiens	1.RBphosphoE2F,108.Regulating_glucose_transport,157.14-3-3_Cell_Cycle,26.cyclin-CDK_complexes,94.E2F_transcriptional_activity_cell_cycle,	h_atmPathway:ATM Signaling Pathway,h_calcineurinPathway:Effects of calcineurin in Keratinocyte Differentiation,h_cellcyclePathway:Cyclins and Cell Cycle Regulation,h_eponfkbPathway:Erythropoietin mediated neuroprotection through NF-kB,h_g1Pathway:Cell Cycle: G1/S Check Point ,h_g2Pathway:Cell Cycle: G2/M Checkpoint,h_p53hypoxiaPathway:Hypoxia and p53 in the Cardiovascular system,h_p53Pathway:p53 Signaling Pathway,h_raccycdPathway:Influence of Ras and Rho proteins on G1 to S Transition,	GO:0000079~regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0000082~G1/S transition of mitotic cell cycle,GO:0001701~in utero embryonic development,GO:0001933~negative regulation of protein phosphorylation,GO:0001934~positive regulation of protein phosphorylation,GO:0006606~protein import into nucleus,GO:0006974~cellular response to DNA damage stimulus,GO:0006977~DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest,GO:0006978~DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator,GO:0007095~mitotic G2 DNA damage checkpoint,GO:0007265~Ras protein signal transduction,GO:0007346~regulation of mitotic cell cycle,GO:0007507~heart development,GO:0008285~negative regulation of cell proliferation,GO:0009410~response to xenobiotic stimulus,GO:0009636~response to toxic substance,GO:0010165~response to X-ray,GO:0010243~response to organonitrogen compound,GO:0010389~regulation of G2/M transition of mitotic cell cycle,GO:0010629~negative regulation of gene expression,GO:0016310~phosphorylation,GO:0030216~keratinocyte differentiation,GO:0030308~negative regulation of cell growth,GO:0030890~positive regulation of B cell proliferation,GO:0031100~animal organ regeneration,GO:0031668~cellular response to extracellular stimulus,GO:0032091~negative regulation of protein binding,GO:0034198~cellular response to amino acid starvation,GO:0034605~cellular response to heat,GO:0042060~wound healing,GO:0042246~tissue regeneration,GO:0042326~negative regulation of phosphorylation,GO:0042771~intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator,GO:0043066~negative regulation of apoptotic process,GO:0043068~positive regulation of programmed cell death,GO:0043616~keratinocyte proliferation,GO:0045736~negative regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0045740~positive regulation of DNA replication,GO:0045860~positive regulation of protein kinase activity,GO:0046685~response to arsenic-containing substance,GO:0048144~fibroblast proliferation,GO:0048146~positive regulation of fibroblast proliferation,GO:0051171~regulation of nitrogen compound metabolic process,GO:0051412~response to corticosterone,GO:0051726~regulation of cell cycle,GO:0055093~response to hyperoxia,GO:0060255~regulation of macromolecule metabolic process,GO:0060574~intestinal epithelial cell maturation,GO:0071479~cellular response to ionizing radiation,GO:0071480~cellular response to gamma radiation,GO:0071493~cellular response to UV-B,GO:0072331~signal transduction by p53 class mediator,GO:0080090~regulation of primary metabolic process,GO:0090398~cellular senescence,GO:0090399~replicative senescence,GO:0090400~stress-induced premature senescence,GO:0090402~oncogene-induced cell senescence,GO:0097193~intrinsic apoptotic signaling pathway,GO:1902806~regulation of cell cycle G1/S phase transition,GO:1904030~negative regulation of cyclin-dependent protein kinase activity,GO:1904044~response to aldosterone,GO:1904706~negative regulation of vascular smooth muscle cell proliferation,GO:1905179~negative regulation of cardiac muscle tissue regeneration,GO:2000045~regulation of G1/S transition of mitotic cell cycle,GO:2000134~negative regulation of G1/S transition of mitotic cell cycle,GO:2000279~negative regulation of DNA biosynthetic process,GO:2000379~positive regulation of reactive oxygen species metabolic process,	GO:0000307~cyclin-dependent protein kinase holoenzyme complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005829~cytosol,GO:0016604~nuclear body,GO:0032991~macromolecular complex,GO:0048471~perinuclear region of cytoplasm,GO:0070557~PCNA-p21 complex,	GO:0004860~protein kinase inhibitor activity,GO:0004861~cyclin-dependent protein serine/threonine kinase inhibitor activity,GO:0005515~protein binding,GO:0016301~kinase activity,GO:0019901~protein kinase binding,GO:0019912~cyclin-dependent protein kinase activating kinase activity,GO:0030332~cyclin binding,GO:0031625~ubiquitin protein ligase binding,GO:0044877~macromolecular complex binding,GO:0046872~metal ion binding,	IPR003175:CDI_dom,IPR029841:CDKN1A,IPR044898:CDI_dom_sf,	hsa01522:Endocrine resistance,hsa01524:Platinum drug resistance,hsa04012:ErbB signaling pathway,hsa04066:HIF-1 signaling pathway,hsa04068:FoxO signaling pathway,hsa04110:Cell cycle,hsa04115:p53 signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04218:Cellular senescence,hsa04630:JAK-STAT signaling pathway,hsa04921:Oxytocin signaling pathway,hsa04928:Parathyroid hormone synthesis, secretion and action,hsa04934:Cushing syndrome,hsa05160:Hepatitis C,hsa05161:Hepatitis B,hsa05163:Human cytomegalovirus infection,hsa05165:Human papillomavirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05169:Epstein-Barr virus infection,hsa05200:Pathways in cancer,hsa05202:Transcriptional misregulation in cancer,hsa05203:Viral carcinogenesis,hsa05205:Proteoglycans in cancer,hsa05206:MicroRNAs in cancer,hsa05210:Colorectal cancer,hsa05211:Renal cell carcinoma,hsa05212:Pancreatic cancer,hsa05213:Endometrial cancer,hsa05214:Glioma,hsa05215:Prostate cancer,hsa05216:Thyroid cancer,hsa05217:Basal cell carcinoma,hsa05218:Melanoma,hsa05219:Bladder cancer,hsa05220:Chronic myeloid leukemia,hsa05222:Small cell lung cancer,hsa05223:Non-small cell lung cancer,hsa05224:Breast cancer,hsa05225:Hepatocellular carcinoma,hsa05226:Gastric cancer,				KW-0131~Cell cycle,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0418~Kinase,KW-0649~Protein kinase inhibitor,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl serine ester (Ser-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:Cyclin-dependent kinase inhibitor,MOTIF:Nuclear localization signal,MOTIF:PIP-box K+4 motif,MUTAGEN:K->A: Loss of interaction with TRIM39.,MUTAGEN:KRR->AAA: Abolishes degradation by the proteasome without affecting the interaction with PCNA.,MUTAGEN:MTDFY->ATDAAA: Abolishes interaction with PCNA and subsequent degradation by the proteasome.,MUTAGEN:QTSMTDF->ATSATDA: Abolishes interaction with PCNA and subsequent degradation by the proteasome.,MUTAGEN:S->A: No change in interaction with PCNA. Abolishes UV radiation-induced phosphorylation and subsequent degradation.,MUTAGEN:S->D: Reduces interaction with PCNA.,MUTAGEN:S->E: Phosphomimetic mutant, increases ubiquitination by the DCX(DTL) complex.,MUTAGEN:T->A: Abolishes UV radiation-induced phosphorylation and subsequent degradation.,MUTAGEN:T->A: Reduces phosphorylation by Akt; no change in interaction with PCNA, CDK2 or CDK4; no change in subcellular location.,MUTAGEN:T->D: No interaction with PCNA; 59% inhibition of CDK2 binding; modest inhibition of CDK4 binding; no change in subcellular location.,REGION:Disordered,REGION:Interaction with TRIM39,REGION:Required for binding CDKs,REGION:Required for binding cyclins,ZN_FING:C4-type,
CSTB	cystatin B(CSTB)	Homo sapiens			GO:0008344~adult locomotory behavior,GO:0010466~negative regulation of peptidase activity,GO:0045861~negative regulation of proteolysis,GO:1990000~amyloid fibril formation,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0034774~secretory granule lumen,GO:0070062~extracellular exosome,GO:1904724~tertiary granule lumen,GO:1904813~ficolin-1-rich granule lumen,	GO:0002020~protease binding,GO:0003723~RNA binding,GO:0004866~endopeptidase inhibitor activity,GO:0004869~cysteine-type endopeptidase inhibitor activity,	IPR000010:Cystatin_dom,IPR001713:Prot_inh_stefin,IPR018073:Prot_inh_cystat_CS,IPR046350:Cystatin_sf,		254800~Epilepsy, progressive myoclonic 1A (Unverricht and Lundborg),		SM00043:CY,		KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0887~Epilepsy,			KW-0646~Protease inhibitor,KW-0789~Thiol protease inhibitor,	KW-0007~Acetylation,	DOMAIN:Cystatin,MOTIF:Secondary area of contact,REGION:Disordered,SITE:Reactive site,
CST7	cystatin F(CST7)	Homo sapiens			GO:0006955~immune response,GO:0010466~negative regulation of peptidase activity,GO:0031643~positive regulation of myelination,GO:0097340~inhibition of cysteine-type endopeptidase activity,GO:1903979~negative regulation of microglial cell activation,	GO:0005615~extracellular space,GO:0005764~lysosome,GO:0005768~endosome,GO:0005770~late endosome,GO:0005771~multivesicular body,GO:0005783~endoplasmic reticulum,GO:0005794~Golgi apparatus,GO:0031410~cytoplasmic vesicle,	GO:0004866~endopeptidase inhibitor activity,GO:0004869~cysteine-type endopeptidase inhibitor activity,GO:0005515~protein binding,GO:0030414~peptidase inhibitor activity,GO:0042803~protein homodimerization activity,	IPR000010:Cystatin_dom,IPR042886:Cystatin-F,IPR046350:Cystatin_sf,				SM00043:CY,		KW-0963~Cytoplasm,KW-0964~Secreted,		KW-0732~Signal,		KW-0646~Protease inhibitor,KW-0789~Thiol protease inhibitor,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DISULFID:Interchain (with C-26),DISULFID:Interchain (with C-63),MOTIF:Secondary area of contact,SITE:Reactive site,
CSRP1	cysteine and glycine rich protein 1(CSRP1)	Homo sapiens			GO:0045214~sarcomere organization,GO:0060537~muscle tissue development,GO:0070527~platelet aggregation,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005925~focal adhesion,GO:0030018~Z disc,GO:0070062~extracellular exosome,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0008307~structural constituent of muscle,GO:0042805~actinin binding,GO:0046872~metal ion binding,	IPR001781:Znf_LIM,				SM00132:LIM,		KW-0539~Nucleus,		KW-0440~LIM domain,KW-0677~Repeat,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:LIM zinc-binding,DOMAIN:LIM zinc-binding 1,DOMAIN:LIM zinc-binding 2,MOTIF:Nuclear localization signal,
CHORDC1	cysteine and histidine rich domain containing 1(CHORDC1)	Homo sapiens			GO:0001578~microtubule bundle formation,GO:0001933~negative regulation of protein phosphorylation,GO:0006469~negative regulation of protein kinase activity,GO:0006611~protein export from nucleus,GO:0006813~potassium ion transport,GO:0007264~small GTPase mediated signal transduction,GO:0010824~regulation of centrosome duplication,GO:0010923~negative regulation of phosphatase activity,GO:0022406~membrane docking,GO:0031122~cytoplasmic microtubule organization,GO:0031397~negative regulation of protein ubiquitination,GO:0031953~negative regulation of protein autophosphorylation,GO:0032088~negative regulation of NF-kappaB transcription factor activity,GO:0032417~positive regulation of sodium:proton antiporter activity,GO:0042308~negative regulation of protein import into nucleus,GO:0050821~protein stabilization,GO:0051222~positive regulation of protein transport,GO:0051298~centrosome duplication,GO:0051453~regulation of intracellular pH,GO:0060050~positive regulation of protein glycosylation,GO:0061024~membrane organization,GO:0061025~membrane fusion,GO:0061077~chaperone-mediated protein folding,GO:0070885~negative regulation of calcineurin-NFAT signaling cascade,GO:0071073~positive regulation of phospholipid biosynthetic process,GO:0071468~cellular response to acidic pH,GO:0090314~positive regulation of protein targeting to membrane,GO:1900034~regulation of cellular response to heat,	GO:0000139~Golgi membrane,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005793~endoplasmic reticulum-Golgi intermediate compartment,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0015630~microtubule cytoskeleton,GO:0030133~transport vesicle,GO:0045121~membrane raft,GO:0070062~extracellular exosome,GO:1990351~transporter complex,	GO:0004860~protein kinase inhibitor activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008017~microtubule binding,GO:0008270~zinc ion binding,GO:0015385~sodium:proton antiporter activity,GO:0015459~potassium channel regulator activity,GO:0019900~kinase binding,GO:0043531~ADP binding,GO:0046872~metal ion binding,GO:0048306~calcium-dependent protein binding,GO:0051879~Hsp90 protein binding,	IPR002048:EF_hand_dom,IPR007051:CHORD_dom,IPR007052:CS_dom,IPR008978:HSP20-like_chaperone,IPR011992:EF-hand-dom_pair,IPR039790:CHRD1,				SM00054:EFh,	KW-0346~Stress response,KW-0653~Protein transport,KW-0813~Transport,	KW-0206~Cytoskeleton,KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0523~Neurodegeneration,	KW-0677~Repeat,	KW-0106~Calcium,KW-0479~Metal-binding,KW-0862~Zinc,	KW-0143~Chaperone,KW-0649~Protein kinase inhibitor,	KW-0007~Acetylation,KW-0449~Lipoprotein,KW-0519~Myristate,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:CHORD,DOMAIN:CHORD 1,DOMAIN:CHORD 2,DOMAIN:CS,DOMAIN:EF-hand,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,DOMAIN:EF-hand 3,DOMAIN:EF-hand 4,LIPID:N-myristoyl glycine,MOTIF:Necessary for association with microtubule and interaction with GAPDH,MOTIF:Nuclear export signal 1,MOTIF:Nuclear export signal 2,MUTAGEN:D->A: Does not reduce calcium-binding, colocalization and interaction with SLC9A1.,MUTAGEN:E->A: Reduces calcium-binding and SLC9A1-dependent Na(+)/H(+) exchange activity. Does not reduce colocalization and interaction with SLC9A1. Reduces colocalization and interaction with SLC9A1; when associated with A-134.,MUTAGEN:E->A: Reduces calcium-binding and SLC9A1-dependent Na(+)/H(+) exchange activity. Does not reduce colocalization and interaction with SLC9A1. Reduces colocalization and interaction with SLC9A1; when associated with A-175.,MUTAGEN:I->A: Inhibits translocation to the cytoplasm; when associated with A-143; A-145; A-183 and A-185.,MUTAGEN:R->A: Does not affect sodium:proton antiporter activity.,MUTAGEN:V->A: Inhibits translocation to the cytoplasm; when associated with A-143; A-145; A-147 and A-183.,MUTAGEN:V->A: Inhibits translocation to the cytoplasm; when associated with A-143; A-145; A-147 and A-185.,MUTAGEN:V->A: Inhibits translocation to the cytoplasm; when associated with A-143; A-147; A-183 and A-185.,MUTAGEN:V->A: Inhibits translocation to the cytoplasm; when associated with A-145; A-147; A-183 and A-185.,REGION:Disordered,REGION:Interaction with HSP90AA1 and HSP90AB1,REGION:Interaction with PPP5C,REGION:Necessary for nuclear export signal,
CRIP1	cysteine rich protein 1(CRIP1)	Homo sapiens			GO:0006955~immune response,GO:0007507~heart development,GO:0008630~intrinsic apoptotic signaling pathway in response to DNA damage,GO:0010033~response to organic substance,GO:0010043~response to zinc ion,GO:0010468~regulation of gene expression,GO:0060741~prostate gland stromal morphogenesis,GO:0071236~cellular response to antibiotic,GO:0071493~cellular response to UV-B,	GO:0005737~cytoplasm,	GO:0008270~zinc ion binding,GO:0042277~peptide binding,	IPR001781:Znf_LIM,				SM00132:LIM,				KW-0440~LIM domain,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0007~Acetylation,KW-0488~Methylation,	DOMAIN:LIM zinc-binding,
CYSTM1	cysteine rich transmembrane module containing 1(CYSTM1)	Homo sapiens				GO:0005886~plasma membrane,GO:0016020~membrane,GO:0070062~extracellular exosome,GO:0070821~tertiary granule membrane,	GO:0005515~protein binding,	IPR043240:CYSTM1-like,						KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				COMPBIAS:Pro residues,REGION:Disordered,TRANSMEM:Helical,
CMPK1	cytidine/uridine monophosphate kinase 1(CMPK1)	Homo sapiens			GO:0006207~'de novo' pyrimidine nucleobase biosynthetic process,GO:0006221~pyrimidine nucleotide biosynthetic process,GO:0006222~UMP biosynthetic process,GO:0006225~UDP biosynthetic process,GO:0009117~nucleotide metabolic process,GO:0009123~nucleoside monophosphate metabolic process,GO:0009220~pyrimidine ribonucleotide biosynthetic process,GO:0015949~nucleobase-containing small molecule interconversion,GO:0016310~phosphorylation,GO:0046705~CDP biosynthetic process,GO:0046940~nucleoside monophosphate phosphorylation,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0004127~cytidylate kinase activity,GO:0004550~nucleoside diphosphate kinase activity,GO:0004849~uridine kinase activity,GO:0005524~ATP binding,GO:0009041~uridylate kinase activity,GO:0033862~UMP kinase activity,GO:0036430~CMP kinase activity,GO:0036431~dCMP kinase activity,GO:0050145~nucleoside phosphate kinase activity,	IPR000850:Adenylat/UMP-CMP_kin,IPR006266:UMP_CMP_kinase,IPR027417:P-loop_NTPase,IPR033690:Adenylat_kinase_CS,	hsa00240:Pyrimidine metabolism,hsa00983:Drug metabolism - other enzymes,hsa01100:Metabolic pathways,hsa01232:Nucleotide metabolism,hsa01240:Biosynthesis of cofactors,				KW-0665~Pyrimidine biosynthesis,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0732~Signal,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),REGION:LID,REGION:NMP,REGION:NMPbind,
CYP20A1	cytochrome P450 family 20 subfamily A member 1(CYP20A1)	Homo sapiens				GO:0016020~membrane,	GO:0004497~monooxygenase activity,GO:0005506~iron ion binding,GO:0016705~oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen,GO:0020037~heme binding,	IPR001128:Cyt_P450,IPR002401:Cyt_P450_E_grp-I,IPR036396:Cyt_P450_sf,						KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0349~Heme,KW-0408~Iron,KW-0479~Metal-binding,	KW-0503~Monooxygenase,KW-0560~Oxidoreductase,		BINDING:axial binding residue,TRANSMEM:Helical,
CYB5R3	cytochrome b5 reductase 3(CYB5R3)	Homo sapiens			GO:0006695~cholesterol biosynthetic process,GO:0006809~nitric oxide biosynthetic process,GO:0008015~blood circulation,	GO:0005576~extracellular region,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005741~mitochondrial outer membrane,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005811~lipid particle,GO:0005829~cytosol,GO:0005833~hemoglobin complex,GO:0016020~membrane,GO:0031966~mitochondrial membrane,GO:0035578~azurophil granule lumen,GO:1903958~nitric-oxide synthase complex,	GO:0004128~cytochrome-b5 reductase activity, acting on NAD(P)H,GO:0005515~protein binding,GO:0016208~AMP binding,GO:0016491~oxidoreductase activity,GO:0043531~ADP binding,GO:0050421~nitrite reductase (NO-forming) activity,GO:0051287~NAD binding,GO:0071949~FAD binding,	IPR001433:OxRdtase_FAD/NAD-bd,IPR001709:Flavoprot_Pyr_Nucl_cyt_Rdtase,IPR001834:CBR-like,IPR008333:Cbr1-like_FAD-bd_dom,IPR017927:FAD-bd_FR_type,IPR017938:Riboflavin_synthase-like_b-brl,IPR039261:FNR_nucleotide-bd,	hsa00520:Amino sugar and nucleotide sugar metabolism,	250800~Methemoglobinemia, type I,250800~Methemoglobinemia, type II,			KW-0152~Cholesterol biosynthesis,KW-0153~Cholesterol metabolism,KW-0443~Lipid metabolism,KW-0444~Lipid biosynthesis,KW-0752~Steroid biosynthesis,KW-0753~Steroid metabolism,KW-0756~Sterol biosynthesis,KW-1207~Sterol metabolism,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0496~Mitochondrion,KW-0963~Cytoplasm,KW-1000~Mitochondrion outer membrane,	KW-0225~Disease variant,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0274~FAD,KW-0285~Flavoprotein,KW-0520~NAD,	KW-0560~Oxidoreductase,	KW-0007~Acetylation,KW-0449~Lipoprotein,KW-0519~Myristate,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:FAD-binding FR-type,LIPID:N-myristoyl glycine,MUTAGEN:C->A: Loss of 30% of NADH-cytochrome b5 reductase activity.,MUTAGEN:C->A: Loss of 80% of NADH-cytochrome b5 reductase activity.,MUTAGEN:C->S: No effect on NADH-cytochrome b5 reductase activity.,MUTAGEN:F->A: Decreases protein stability and slightly decreases NADH-cytochrome b5 reductase activity.,MUTAGEN:F->L: No effect on protein stability and NADH-cytochrome b5 reductase activity.,MUTAGEN:FVF->LVL: No effect on protein stability and NADH-cytochrome b5 reductase activity.,MUTAGEN:S->A: Decreased NADH-cytochrome b5 reductase activity, highly increases Km for NADH and decreases Kcat.,REGION:Disordered,TRANSMEM:Helical,
CYB5R4	cytochrome b5 reductase 4(CYB5R4)	Homo sapiens			GO:0003032~detection of oxygen,GO:0006091~generation of precursor metabolites and energy,GO:0006801~superoxide metabolic process,GO:0015701~bicarbonate transport,GO:0030073~insulin secretion,GO:0042593~glucose homeostasis,GO:0046677~response to antibiotic,GO:0048468~cell development,GO:0072593~reactive oxygen species metabolic process,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0048471~perinuclear region of cytoplasm,	GO:0004128~cytochrome-b5 reductase activity, acting on NAD(P)H,GO:0016174~NAD(P)H oxidase activity,GO:0016653~oxidoreductase activity, acting on NAD(P)H, heme protein as acceptor,GO:0020037~heme binding,GO:0046872~metal ion binding,	IPR001199:Cyt_B5-like_heme/steroid-bd,IPR001433:OxRdtase_FAD/NAD-bd,IPR007052:CS_dom,IPR008333:Cbr1-like_FAD-bd_dom,IPR008978:HSP20-like_chaperone,IPR017927:FAD-bd_FR_type,IPR017938:Riboflavin_synthase-like_b-brl,IPR018506:Cyt_B5_heme-BS,IPR036400:Cyt_B5-like_heme/steroid_sf,IPR037908:p23_NCB5OR,IPR039261:FNR_nucleotide-bd,	hsa00520:Amino sugar and nucleotide sugar metabolism,			SM01117:Cyt-b5,		KW-0256~Endoplasmic reticulum,			KW-0274~FAD,KW-0285~Flavoprotein,KW-0349~Heme,KW-0408~Iron,KW-0479~Metal-binding,KW-0520~NAD,	KW-0560~Oxidoreductase,	KW-0007~Acetylation,	BINDING:axial binding residue,COMPBIAS:Polar residues,DOMAIN:CS,DOMAIN:Cytochrome b5 heme-binding,DOMAIN:FAD-binding FR-type,REGION:Disordered,
COA4	cytochrome c oxidase assembly factor 4 homolog(COA4)	Homo sapiens			GO:0033617~mitochondrial respiratory chain complex IV assembly,	GO:0005739~mitochondrion,GO:0005758~mitochondrial intermembrane space,		IPR010625:CHCH,IPR039870:Coa4-like,	hsa04714:Thermogenesis,					KW-0496~Mitochondrion,					KW-1015~Disulfide bond,	DOMAIN:CHCH,MOTIF:Cx9C motif 1,MOTIF:Cx9C motif 2,REGION:Disordered,
COX16	cytochrome c oxidase assembly factor COX16(COX16)	Homo sapiens			GO:0033617~mitochondrial respiratory chain complex IV assembly,	GO:0005743~mitochondrial inner membrane,	GO:0005515~protein binding,	IPR020164:Cyt_c_Oxase_assmbl_COX16,	hsa04714:Thermogenesis,	619355~Mitochondrial complex IV deficiency, nuclear type 22,				KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,	KW-0225~Disease variant,KW-1274~Primary mitochondrial disease,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,				REGION:Disordered,TOPO_DOM:Mitochondrial intermembrane,TOPO_DOM:Mitochondrial matrix,TRANSMEM:Helical,
COX20	cytochrome c oxidase assembly factor COX20(COX20)	Homo sapiens			GO:0033617~mitochondrial respiratory chain complex IV assembly,	GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,	GO:0005515~protein binding,	IPR022533:Cox20,	hsa04714:Thermogenesis,	619054~Mitochondrial complex IV deficiency, nuclear type 11,				KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,	KW-0225~Disease variant,KW-1274~Primary mitochondrial disease,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,	TOPO_DOM:Mitochondrial intermembrane,TOPO_DOM:Mitochondrial matrix,TRANSMEM:Helical,
COX17	cytochrome c oxidase copper chaperone COX17(COX17)	Homo sapiens			GO:0006091~generation of precursor metabolites and energy,GO:0006825~copper ion transport,GO:0008284~positive regulation of cell proliferation,GO:0033617~mitochondrial respiratory chain complex IV assembly,GO:1904960~positive regulation of cytochrome-c oxidase activity,	GO:0005737~cytoplasm,GO:0005758~mitochondrial intermembrane space,	GO:0005507~copper ion binding,GO:0005515~protein binding,GO:0008047~enzyme activator activity,GO:0016531~copper chaperone activity,GO:0043167~ion binding,GO:1903136~cuprous ion binding,	IPR007745:Cyt_c_oxidase_Cu-chaperone,IPR009069:Cys_alpha_HP_mot_SF,	hsa00190:Oxidative phosphorylation,hsa01100:Metabolic pathways,hsa04714:Thermogenesis,					KW-0496~Mitochondrion,KW-0963~Cytoplasm,			KW-0186~Copper,KW-0479~Metal-binding,	KW-0143~Chaperone,	KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	DOMAIN:CHCH,MOTIF:Cx9C motif 1,MOTIF:Cx9C motif 2,REGION:Disordered,
COX7A2	cytochrome c oxidase subunit 7A2(COX7A2)	Homo sapiens			GO:0002082~regulation of oxidative phosphorylation,GO:0006123~mitochondrial electron transport, cytochrome c to oxygen,GO:0045333~cellular respiration,GO:0097250~mitochondrial respiratory chain supercomplex assembly,	GO:0005746~mitochondrial respiratory chain,GO:0005751~mitochondrial respiratory chain complex IV,GO:0031966~mitochondrial membrane,	GO:0005515~protein binding,GO:0016491~oxidoreductase activity,	IPR003177:Cytc_oxidase_su7a_met,IPR036539:Cyt_c_oxidase_su7a_sf,IPR039297:COX7a,	hsa00190:Oxidative phosphorylation,hsa01100:Metabolic pathways,hsa04260:Cardiac muscle contraction,hsa04714:Thermogenesis,hsa04932:Non-alcoholic fatty liver disease,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05415:Diabetic cardiomyopathy,					KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,		KW-0809~Transit peptide,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0560~Oxidoreductase,	KW-0007~Acetylation,	TOPO_DOM:Mitochondrial intermembrane,TOPO_DOM:Mitochondrial matrix,TRANSIT:Mitochondrion,TRANSMEM:Helical,
COX7B	cytochrome c oxidase subunit 7B(COX7B)	Homo sapiens			GO:0006123~mitochondrial electron transport, cytochrome c to oxygen,GO:0007417~central nervous system development,GO:0045333~cellular respiration,GO:1902600~hydrogen ion transmembrane transport,	GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005746~mitochondrial respiratory chain,GO:0005751~mitochondrial respiratory chain complex IV,GO:0031966~mitochondrial membrane,GO:0045277~respiratory chain complex IV,	GO:0004129~cytochrome-c oxidase activity,GO:0005515~protein binding,	IPR008433:Cyt_c_oxidase_suVIIB,IPR023272:Cyt_c_oxidase_suVIIB_dom_sf,	hsa00190:Oxidative phosphorylation,hsa01100:Metabolic pathways,hsa04260:Cardiac muscle contraction,hsa04714:Thermogenesis,hsa04932:Non-alcoholic fatty liver disease,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05415:Diabetic cardiomyopathy,	300887~Linear skin defects with multiple congenital anomalies 2,				KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,		KW-0809~Transit peptide,KW-0812~Transmembrane,KW-1133~Transmembrane helix,				TOPO_DOM:Mitochondrial intermembrane,TOPO_DOM:Mitochondrial matrix,TRANSIT:Mitochondrion,TRANSMEM:Helical,
CYCS	cytochrome c, somatic(CYCS)	Homo sapiens		h_aifPathway:Opposing roles of AIF in Apoptosis and Cell Survival,h_caspasePathway:Caspase Cascade in Apoptosis,h_ceramidePathway:Ceramide Signaling Pathway,h_chemicalPathway:Apoptotic Signaling in Response to DNA Damage,h_d4gdiPathway:D4-GDI Signaling Pathway,h_deathPathway:Induction of apoptosis through DR3 and DR4/5 Death Receptors ,h_etcPathway:Electron Transport Reaction in Mitochondria,h_hivnefPathway:HIV-I Nef: negative effector of Fas and TNF,h_hsp27Pathway:Stress Induction of HSP Regulation,h_mitochondriaPathway:Role of Mitochondria in Apoptotic Signaling,h_tffPathway:Trefoil Factors Initiate  Mucosal Healing,	GO:0006122~mitochondrial electron transport, ubiquinol to cytochrome c,GO:0006123~mitochondrial electron transport, cytochrome c to oxygen,GO:0006915~apoptotic process,GO:0008635~activation of cysteine-type endopeptidase activity involved in apoptotic process by cytochrome c,GO:0043280~positive regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0045333~cellular respiration,GO:0097193~intrinsic apoptotic signaling pathway,	GO:0005634~nucleus,GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005758~mitochondrial intermembrane space,GO:0005829~cytosol,GO:0043293~apoptosome,GO:0070469~respiratory chain,	GO:0005515~protein binding,GO:0009055~electron carrier activity,GO:0020037~heme binding,GO:0046872~metal ion binding,	IPR002327:Cyt_c_1A/1B,IPR009056:Cyt_c-like_dom,IPR036909:Cyt_c-like_dom_sf,	hsa00190:Oxidative phosphorylation,hsa01100:Metabolic pathways,hsa01524:Platinum drug resistance,hsa04115:p53 signaling pathway,hsa04210:Apoptosis,hsa04215:Apoptosis - multiple species,hsa04932:Non-alcoholic fatty liver disease,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05017:Spinocerebellar ataxia,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05130:Pathogenic Escherichia coli infection,hsa05131:Shigellosis,hsa05132:Salmonella infection,hsa05134:Legionellosis,hsa05145:Toxoplasmosis,hsa05152:Tuberculosis,hsa05160:Hepatitis C,hsa05161:Hepatitis B,hsa05162:Measles,hsa05163:Human cytomegalovirus infection,hsa05164:Influenza A,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05200:Pathways in cancer,hsa05210:Colorectal cancer,hsa05222:Small cell lung cancer,hsa05416:Viral myocarditis,hsa05417:Lipid and atherosclerosis,	612004~Thrombocytopenia 4,			KW-0053~Apoptosis,KW-0249~Electron transport,KW-0679~Respiratory chain,KW-0813~Transport,	KW-0496~Mitochondrion,	KW-0225~Disease variant,		KW-0349~Heme,KW-0408~Iron,KW-0479~Metal-binding,		KW-0007~Acetylation,KW-0597~Phosphoprotein,	BINDING:axial binding residue,BINDING:covalent,DOMAIN:Cytochrome c,MUTAGEN:C->A: Decreased covalent heme attachment.,MUTAGEN:C->S: Decreased covalent heme attachment.,MUTAGEN:F->A: Decreased covalent heme attachment.,MUTAGEN:F->Y: No effect on covalent heme attachment.,MUTAGEN:H->A: Loss of covalent heme attachment.,MUTAGEN:K->A,D,R: No effect on covalent heme attachment.,
POR	cytochrome p450 oxidoreductase(POR)	Homo sapiens		h_arenrf2Pathway:Oxidative Stress Induced Gene Expression Via Nrf2,	GO:0006805~xenobiotic metabolic process,GO:0009725~response to hormone,GO:0022900~electron transport chain,GO:0032770~positive regulation of monooxygenase activity,GO:0090346~cellular organofluorine metabolic process,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0016020~membrane,GO:0043231~intracellular membrane-bounded organelle,	GO:0003958~NADPH-hemoprotein reductase activity,GO:0005515~protein binding,GO:0010181~FMN binding,GO:0016491~oxidoreductase activity,GO:0050660~flavin adenine dinucleotide binding,GO:0050661~NADP binding,	IPR001094:Flavdoxin-like,IPR001433:OxRdtase_FAD/NAD-bd,IPR001709:Flavoprot_Pyr_Nucl_cyt_Rdtase,IPR003097:CysJ-like_FAD-binding,IPR008254:Flavodoxin/NO_synth,IPR017927:FAD-bd_FR_type,IPR017938:Riboflavin_synthase-like_b-brl,IPR023173:NADPH_Cyt_P450_Rdtase_alpha,IPR023208:P450R,IPR029039:Flavoprotein-like_sf,IPR039261:FNR_nucleotide-bd,		201750~Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis,613571~Disordered steroidogenesis due to cytochrome P450 oxidoreductase,	PIRSF000208:P450R,			KW-0256~Endoplasmic reticulum,KW-0472~Membrane,	KW-0225~Disease variant,KW-0954~Congenital adrenal hyperplasia,KW-0989~Craniosynostosis,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0274~FAD,KW-0285~Flavoprotein,KW-0288~FMN,KW-0521~NADP,	KW-0560~Oxidoreductase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:FAD-binding FR-type,DOMAIN:Flavodoxin-like,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
CYTH1	cytohesin 1(CYTH1)	Homo sapiens		h_arapPathway:ADP-Ribosylation Factor,	GO:0016192~vesicle-mediated transport,GO:0030155~regulation of cell adhesion,GO:0032012~regulation of ARF protein signal transduction,GO:0090162~establishment of epithelial cell polarity,	GO:0000139~Golgi membrane,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005912~adherens junction,GO:0005923~bicellular tight junction,GO:0009898~cytoplasmic side of plasma membrane,	GO:0005085~guanyl-nucleotide exchange factor activity,GO:0005515~protein binding,GO:0008289~lipid binding,	IPR000904:Sec7_dom,IPR001849:PH_domain,IPR011993:PH-like_dom_sf,IPR023394:Sec7_C_sf,IPR035999:Sec7_dom_sf,	hsa04072:Phospholipase D signaling pathway,hsa04144:Endocytosis,hsa05130:Pathogenic Escherichia coli infection,hsa05131:Shigellosis,hsa05132:Salmonella infection,			SM00222:Sec7,SM00233:PH,		KW-0472~Membrane,KW-0796~Tight junction,KW-0963~Cytoplasm,KW-0965~Cell junction,KW-1003~Cell membrane,		KW-0175~Coiled coil,	KW-0446~Lipid-binding,	KW-0344~Guanine-nucleotide releasing factor,	KW-0007~Acetylation,KW-0832~Ubl conjugation,	DOMAIN:PH,DOMAIN:SEC7,MUTAGEN:E->A,K: Reduces guanine exchange factor activity by over 90%.,MUTAGEN:M->A: Reduces guanine exchange factor activity by over 90%.,MUTAGEN:Y->A: Reduces guanine exchange factor activity by over 90%.,REGION:C-terminal autoinhibitory region,
CYTH2	cytohesin 2(CYTH2)	Homo sapiens	108.Regulating_glucose_transport,	h_arapPathway:ADP-Ribosylation Factor,	GO:0006897~endocytosis,GO:0030036~actin cytoskeleton organization,GO:0032012~regulation of ARF protein signal transduction,	GO:0000139~Golgi membrane,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005912~adherens junction,GO:0005923~bicellular tight junction,GO:0016020~membrane,GO:0030426~growth cone,	GO:0005085~guanyl-nucleotide exchange factor activity,GO:0005515~protein binding,GO:0008289~lipid binding,GO:0070679~inositol 1,4,5 trisphosphate binding,	IPR000904:Sec7_dom,IPR001849:PH_domain,IPR011993:PH-like_dom_sf,IPR023394:Sec7_C_sf,IPR035999:Sec7_dom_sf,	hsa04072:Phospholipase D signaling pathway,hsa04144:Endocytosis,hsa05130:Pathogenic Escherichia coli infection,hsa05131:Shigellosis,hsa05132:Salmonella infection,			SM00222:Sec7,SM00233:PH,		KW-0472~Membrane,KW-0796~Tight junction,KW-0963~Cytoplasm,KW-0965~Cell junction,KW-0966~Cell projection,KW-1003~Cell membrane,		KW-0175~Coiled coil,	KW-0446~Lipid-binding,	KW-0344~Guanine-nucleotide releasing factor,		DOMAIN:PH,DOMAIN:SEC7,MUTAGEN:E->D: Inhibits GTP GDP exchange activity. Abolishes recruitment of ARF6 to the plasma membrane.,MUTAGEN:I->A: Reduces ARL4D GTP-dependent interaction and targeting to the plasma membrane mediated by ARL4C, ARL4C and ARL4D.,MUTAGEN:K->A: Reduces ARL4D GTP-dependent interaction and targeting to the plasma membrane mediated by ARL4C, ARL4C and ARL4D.,MUTAGEN:K->R: Does not reduce ARL4D GTP-dependent interaction but inhibits targeting to the plasma membrane mediated by ARL4C, ARL4C and ARL4D.,MUTAGEN:R->D: Does not reduce ARL4D GTP-dependent interaction but inhibits targeting to the plasma membrane mediated by ARL4C, ARL4C and ARL4D.,REGION:C-terminal autoinhibitory region,REGION:Disordered,
CRLF3	cytokine receptor like factor 3(CRLF3)	Homo sapiens			GO:0030308~negative regulation of cell growth,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046427~positive regulation of JAK-STAT cascade,GO:2000134~negative regulation of G1/S transition of mitotic cell cycle,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016020~membrane,	GO:0003677~DNA binding,GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR003961:FN3_dom,IPR013783:Ig-like_fold,IPR036116:FN3_sf,						KW-0472~Membrane,KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,	DOMAIN:Fibronectin type-III,TRANSMEM:Helical,
CYFIP2	cytoplasmic FMR1 interacting protein 2(CYFIP2)	Homo sapiens			GO:0000902~cell morphogenesis,GO:0006915~apoptotic process,GO:0007411~axon guidance,GO:0030031~cell projection assembly,GO:0030833~regulation of actin filament polymerization,GO:0045862~positive regulation of proteolysis,GO:0051388~positive regulation of neurotrophin TRK receptor signaling pathway,GO:0097202~activation of cysteine-type endopeptidase activity,GO:0097484~dendrite extension,GO:0098609~cell-cell adhesion,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016020~membrane,GO:0031209~SCAR complex,GO:0043005~neuron projection,GO:0045202~synapse,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0031267~small GTPase binding,	IPR008081:Cytoplasmic_FMR1-int,IPR009828:CYRIA/CYRIB_Rac1-bd,	hsa04810:Regulation of actin cytoskeleton,hsa05130:Pathogenic Escherichia coli infection,hsa05132:Salmonella infection,	618008~Developmental and epileptic encephalopathy 65,	PIRSF008153:FMR1_interacting,		KW-0053~Apoptosis,KW-0130~Cell adhesion,	KW-0539~Nucleus,KW-0770~Synapse,KW-0771~Synaptosome,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0887~Epilepsy,				KW-0007~Acetylation,	DOMAIN:CYRIA/CYRIB Rac1 binding,
CKAP2	cytoskeleton associated protein 2(CKAP2)	Homo sapiens			GO:0000281~mitotic cytokinesis,GO:0006915~apoptotic process,GO:0007026~negative regulation of microtubule depolymerization,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,	GO:0000922~spindle pole,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005874~microtubule,GO:0015630~microtubule cytoskeleton,GO:0072686~mitotic spindle,		IPR026165:CKAP2_fam,IPR029197:CKAP2_C,					KW-0053~Apoptosis,KW-0131~Cell cycle,	KW-0206~Cytoskeleton,KW-0493~Microtubule,KW-0963~Cytoplasm,					KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Cytoskeleton-associated protein 2 C-terminal,REGION:Disordered,
CIAO1	cytosolic iron-sulfur assembly component 1(CIAO1)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007059~chromosome segregation,GO:0008284~positive regulation of cell proliferation,GO:0016226~iron-sulfur cluster assembly,GO:0097428~protein maturation by iron-sulfur cluster transfer,	GO:0005737~cytoplasm,GO:0071817~MMXD complex,GO:0097361~CIA complex,	GO:0005515~protein binding,	IPR001680:WD40_rpt,IPR015943:WD40/YVTN_repeat-like_dom_sf,IPR019775:WD40_repeat_CS,IPR028608:CIAO1/Cia1,IPR036322:WD40_repeat_dom_sf,				SM00320:WD40,	KW-0159~Chromosome partition,	KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0853~WD repeat,				MOTIF:LYR motif; required for interaction with HSC20,MUTAGEN:IWK->AAA: Does not affect binding to HSC20.,MUTAGEN:LYR->AAA: Abolishes binding to HSC20.,REPEAT:WD,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,REPEAT:WD 7,
CTLA4	cytotoxic T-lymphocyte associated protein 4(CTLA4)	Homo sapiens	3.T_cell_receptor,5.B7_CD40_B-cell_activa,	h_ctla4Pathway:The Co-Stimulatory Signal During T-cell Activation,	GO:0002250~adaptive immune response,GO:0006955~immune response,GO:0006974~cellular response to DNA damage stimulus,GO:0030889~negative regulation of B cell proliferation,GO:0042129~regulation of T cell proliferation,GO:0042130~negative regulation of T cell proliferation,GO:0043065~positive regulation of apoptotic process,GO:0045590~negative regulation of regulatory T cell differentiation,GO:0050852~T cell receptor signaling pathway,GO:0050853~B cell receptor signaling pathway,	GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0045334~clathrin-coated endocytic vesicle,GO:0048471~perinuclear region of cytoplasm,GO:0098636~protein complex involved in cell adhesion,	GO:0005515~protein binding,	IPR003599:Ig_sub,IPR008096:CTLA4,IPR013106:Ig_V-set,IPR013783:Ig-like_fold,IPR036179:Ig-like_dom_sf,IPR040216:CTLA4/CD28,	hsa04514:Cell adhesion molecules,hsa04660:T cell receptor signaling pathway,hsa05320:Autoimmune thyroid disease,hsa05323:Rheumatoid arthritis,	140300~Hashimoto thyroiditis,152700~Systemic lupus erythematosus, susceptibility to,601388~Diabetes mellitus, insulin-dependent, 12,609755~Celiac disease, susceptibility to, 3,616100~Immune dysregulation with autoimmunity, immunodeficiency, and lymphoproliferation,		SM00406:IGv,SM00409:IG,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-1003~Cell membrane,	KW-0219~Diabetes mellitus,KW-0225~Disease variant,KW-0772~Systemic lupus erythematosus,	KW-0393~Immunoglobulin domain,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DISULFID:Interchain,DOMAIN:Ig-like V-type,DOMAIN:Immunoglobulin V-set,DOMAIN:Immunoglobulin subtype,MUTAGEN:E->A,R: Strongly reduced interaction with CD80, CD86 and ICOSLG.,MUTAGEN:I->A,D: Strongly reduced interaction with CD80, CD86 and ICOSLG.,MUTAGEN:K->A,D: Strongly reduced interaction with CD80, CD86 and ICOSLG.,MUTAGEN:L->D: Strongly reduced interaction with CD80, CD86 and ICOSLG.,MUTAGEN:R->A,D: Strongly reduced interaction with CD80, CD86 and ICOSLG.,MUTAGEN:S->A: Strongly reduced interaction with CD80, CD86 and ICOSLG.,MUTAGEN:V->D: Strongly reduced interaction with CD80, CD86 and ICOSLG.,MUTAGEN:Y->A,D: Strongly reduced interaction with CD80, CD86 and ICOSLG.,REGION:Disordered,REGION:Homodimerization,REGION:Important for interaction with CD80 and CD86,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
DDB1	damage specific DNA binding protein 1(DDB1)	Homo sapiens			GO:0006281~DNA repair,GO:0006289~nucleotide-excision repair,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0006915~apoptotic process,GO:0006974~cellular response to DNA damage stimulus,GO:0007056~spindle assembly involved in female meiosis,GO:0010498~proteasomal protein catabolic process,GO:0016055~Wnt signaling pathway,GO:0016567~protein ubiquitination,GO:0019076~viral release from host cell,GO:0034644~cellular response to UV,GO:0035234~ectopic germ cell programmed cell death,GO:0042752~regulation of circadian rhythm,GO:0043066~negative regulation of apoptotic process,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0044725~chromatin reprogramming in the zygote,GO:0045070~positive regulation of viral genome replication,GO:0045722~positive regulation of gluconeogenesis,GO:0045732~positive regulation of protein catabolic process,GO:0046726~positive regulation by virus of viral protein levels in host cell,GO:0048511~rhythmic process,GO:0051093~negative regulation of developmental process,GO:0051702~interaction with symbiont,GO:0070914~UV-damage excision repair,GO:1901990~regulation of mitotic cell cycle phase transition,GO:2000242~negative regulation of reproductive process,	GO:0000781~chromosome, telomeric region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0031464~Cul4A-RING E3 ubiquitin ligase complex,GO:0031465~Cul4B-RING E3 ubiquitin ligase complex,GO:0032991~macromolecular complex,GO:0035861~site of double-strand break,GO:0070062~extracellular exosome,GO:0080008~Cul4-RING E3 ubiquitin ligase complex,	GO:0003676~nucleic acid binding,GO:0003677~DNA binding,GO:0003684~damaged DNA binding,GO:0005515~protein binding,GO:0030674~protein binding, bridging,GO:0044877~macromolecular complex binding,GO:0071987~WD40-repeat domain binding,GO:0097602~cullin family protein binding,	IPR004871:Cleavage/polyA-sp_fac_asu_C,IPR011047:Quinoprotein_ADH-like_supfam,IPR015943:WD40/YVTN_repeat-like_dom_sf,IPR018846:Cleavage/polyA-sp_fac_asu_N,IPR036322:WD40_repeat_dom_sf,	hsa03420:Nucleotide excision repair,hsa04120:Ubiquitin mediated proteolysis,hsa05161:Hepatitis B,hsa05170:Human immunodeficiency virus 1 infection,hsa05203:Viral carcinogenesis,	619426~White-Kernohan syndrome,			KW-0090~Biological rhythms,KW-0227~DNA damage,KW-0234~DNA repair,KW-0833~Ubl conjugation pathway,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0991~Intellectual disability,	KW-0677~Repeat,		KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Cleavage/polyadenylation specificity factor A subunit C-terminal,DOMAIN:Cleavage/polyadenylation specificity factor A subunit N-terminal,MUTAGEN:E->A: Slightly impairs interaction with CUL4A.,MUTAGEN:EAE->AAA: Impairs interaction with AMBRA1, DTL, DET1, DCAF1, DCAF5, DCAF11 and DCAF8.,MUTAGEN:MALY->AAAA: Impairs interaction with AMBRA1, DTL and DCAF5.,MUTAGEN:W->A: Impairs interaction with AMBRA1, ERCC8, DCAF5 and DCAF11.,MUTAGEN:W->A: Strongly impairs interaction with CUL4A.,MUTAGEN:YLDN->ALAA: Impairs interaction with DDA1.,REGION:Interaction with CDT1,REGION:Interaction with CDT1 and CUL4A,REGION:WD repeat beta-propeller A,REGION:WD repeat beta-propeller B; Interaction with CUL4A,REGION:WD repeat beta-propeller C,
DAP3	death associated protein 3(DAP3)	Homo sapiens			GO:0006915~apoptotic process,GO:0032543~mitochondrial translation,GO:0097190~apoptotic signaling pathway,	GO:0005654~nucleoplasm,GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005761~mitochondrial ribosome,GO:0005763~mitochondrial small ribosomal subunit,GO:0005840~ribosome,GO:0015935~small ribosomal subunit,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,GO:0005525~GTP binding,	IPR008092:Ribosomal_mS29_met,IPR019368:Ribosomal_mS29,IPR027417:P-loop_NTPase,					KW-0053~Apoptosis,	KW-0496~Mitochondrion,		KW-0809~Transit peptide,	KW-0342~GTP-binding,KW-0547~Nucleotide-binding,	KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0007~Acetylation,	COMPBIAS:Basic and acidic residues,REGION:Disordered,TRANSIT:Mitochondrion,
DAXX	death domain associated protein(DAXX)	Homo sapiens		h_fasPathway:FAS signaling pathway ( CD95 ),h_hivnefPathway:HIV-I Nef: negative effector of Fas and TNF,h_hsp27Pathway:Stress Induction of HSP Regulation,h_keratinocytePathway:Keratinocyte Differentiation,h_mapkPathway:MAPKinase Signaling Pathway,h_p38mapkPathway:p38 MAPK Signaling Pathway ,h_pmlPathway:Regulation of transcriptional activity by PML,	GO:0001934~positive regulation of protein phosphorylation,GO:0006325~chromatin organization,GO:0006334~nucleosome assembly,GO:0006338~chromatin remodeling,GO:0006355~regulation of transcription, DNA-templated,GO:0006915~apoptotic process,GO:0007254~JNK cascade,GO:0008625~extrinsic apoptotic signaling pathway via death domain receptors,GO:0010468~regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0030521~androgen receptor signaling pathway,GO:0031396~regulation of protein ubiquitination,GO:0034605~cellular response to heat,GO:0034620~cellular response to unfolded protein,GO:0036480~neuron intrinsic apoptotic signaling pathway in response to oxidative stress,GO:0042981~regulation of apoptotic process,GO:0045860~positive regulation of protein kinase activity,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0071276~cellular response to cadmium ion,GO:0071280~cellular response to copper ion,GO:0072738~cellular response to diamide,GO:1903936~cellular response to sodium arsenite,	GO:0000775~chromosome, centromeric region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016604~nuclear body,GO:0016605~PML body,	GO:0002039~p53 binding,GO:0003713~transcription coactivator activity,GO:0003714~transcription corepressor activity,GO:0005515~protein binding,GO:0019899~enzyme binding,GO:0019901~protein kinase binding,GO:0030295~protein kinase activator activity,GO:0031072~heat shock protein binding,GO:0031625~ubiquitin protein ligase binding,GO:0042393~histone binding,GO:0042803~protein homodimerization activity,GO:0050681~androgen receptor binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,	IPR031333:Daxx_N,IPR038298:Daxx_N_sf,IPR046378:DAXX_histone-bd,IPR046426:DAXX_histone-bd_sf,	hsa04010:MAPK signaling pathway,hsa04210:Apoptosis,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05168:Herpes simplex virus 1 infection,				KW-0053~Apoptosis,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0137~Centromere,KW-0158~Chromosome,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,		KW-0143~Chaperone,KW-0156~Chromatin regulator,KW-0678~Repressor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Daxx N-terminal Rassf1C-interacting,DOMAIN:Daxx histone-binding,MOTIF:Nuclear localization signal,MUTAGEN:D->A: Abolishes interaction with histones H3 and H4.,MUTAGEN:E->L: Impairs interaction with histones H3 and H4.,MUTAGEN:F->A: Abolishes interaction with histones H3 and H4.,MUTAGEN:K->A,L: Impairs interaction with histones H3 and H4.,MUTAGEN:K->A: Abolishes sumoylation; when associated with A-630.,MUTAGEN:K->A: Abolishes sumoylation; when associated with A-631.,MUTAGEN:Missing: Abolishes sumoylation.,MUTAGEN:Q->L: Impairs interaction with histones H3 and H4.,MUTAGEN:R->A: Abolishes interaction with histones H3 and H4.,MUTAGEN:S->A: Abolishes interaction with histones H3 and H4.,MUTAGEN:S->A: No effect on cytosol translocation. upon glucose deprivation.,MUTAGEN:S->A: No translocation to the cytosol upon glucose deprivation.,MUTAGEN:Y->A,S: Abolishes interaction with histones H3 and H4.,MUTAGEN:Y->E: Abolishes interaction with histone H3.3.,REGION:(Microbial infection) Interaction with Puumala hantavirus nucleoprotein,REGION:Disordered,REGION:Interaction with MAP3K5,REGION:Interaction with SPOP,REGION:Interaction with histone H3.3,REGION:Necessary for interaction with USP7,REGION:Necessary for interaction with USP7 and ATRX,REGION:Sumo interaction motif (SIM),
DEDD2	death effector domain containing 2(DEDD2)	Homo sapiens			GO:0006396~RNA processing,GO:0006915~apoptotic process,GO:0008625~extrinsic apoptotic signaling pathway via death domain receptors,GO:0016075~rRNA catabolic process,GO:0019725~cellular homeostasis,GO:0030262~apoptotic nuclear changes,GO:0035556~intracellular signal transduction,GO:0042981~regulation of apoptotic process,GO:0045892~negative regulation of transcription, DNA-templated,GO:2001238~positive regulation of extrinsic apoptotic signaling pathway,	GO:0005654~nucleoplasm,GO:0005730~nucleolus,	GO:0003677~DNA binding,GO:0005515~protein binding,GO:0030159~receptor signaling complex scaffold activity,	IPR001875:DED_dom,IPR011029:DEATH-like_dom_sf,IPR038856:DEDD/DEDD2,IPR049341:TRADD-like_N,				SM00031:DED,	KW-0053~Apoptosis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0238~DNA-binding,		COMPBIAS:Basic residues,COMPBIAS:Polar residues,DOMAIN:DED,MOTIF:Bipartite nuclear localization signal,MOTIF:Nuclear localization signal,REGION:Disordered,
DEDD	death effector domain containing(DEDD)	Homo sapiens			GO:0006915~apoptotic process,GO:0007283~spermatogenesis,GO:0008625~extrinsic apoptotic signaling pathway via death domain receptors,GO:0042177~negative regulation of protein catabolic process,GO:0042981~regulation of apoptotic process,GO:0046697~decidualization,GO:1901837~negative regulation of transcription of nuclear large rRNA transcript from RNA polymerase I promoter,	GO:0005730~nucleolus,GO:0005737~cytoplasm,	GO:0003677~DNA binding,GO:0005515~protein binding,	IPR001875:DED_dom,IPR011029:DEATH-like_dom_sf,IPR038856:DEDD/DEDD2,IPR049341:TRADD-like_N,				SM00031:DED,	KW-0053~Apoptosis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0238~DNA-binding,KW-0678~Repressor,	KW-0832~Ubl conjugation,	COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,DOMAIN:DED,REGION:Disordered,
DCP1B	decapping mRNA 1B(DCP1B)	Homo sapiens			GO:0000184~nuclear-transcribed mRNA catabolic process, nonsense-mediated decay,GO:0000290~deadenylation-dependent decapping of nuclear-transcribed mRNA,GO:0031087~deadenylation-independent decapping of nuclear-transcribed mRNA,	GO:0000932~P-body,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016020~membrane,GO:0043229~intracellular organelle,GO:0043231~intracellular membrane-bounded organelle,	GO:0003729~mRNA binding,GO:0005515~protein binding,GO:0008047~enzyme activator activity,	IPR010334:Dcp1,IPR011993:PH-like_dom_sf,IPR031953:mRNA_decap_C,	hsa03018:RNA degradation,				KW-0866~Nonsense-mediated mRNA decay,	KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0378~Hydrolase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,REGION:Disordered,
DCP2	decapping mRNA 2(DCP2)	Homo sapiens			GO:0000184~nuclear-transcribed mRNA catabolic process, nonsense-mediated decay,GO:0000290~deadenylation-dependent decapping of nuclear-transcribed mRNA,GO:0006402~mRNA catabolic process,GO:0032211~negative regulation of telomere maintenance via telomerase,GO:0043488~regulation of mRNA stability,GO:0043928~exonucleolytic nuclear-transcribed mRNA catabolic process involved in deadenylation-dependent decay,GO:0071044~histone mRNA catabolic process,GO:1904872~regulation of telomerase RNA localization to Cajal body,	GO:0000932~P-body,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016442~RISC complex,GO:0030054~cell junction,GO:0036464~cytoplasmic ribonucleoprotein granule,	GO:0003723~RNA binding,GO:0004534~5'-3' exoribonuclease activity,GO:0005515~protein binding,GO:0016787~hydrolase activity,GO:0016896~exoribonuclease activity, producing 5'-phosphomonoesters,GO:0030145~manganese ion binding,GO:0070034~telomerase RNA binding,	IPR000086:NUDIX_hydrolase_dom,IPR007722:DCP2_BoxA,IPR015797:NUDIX_hydrolase-like_dom_sf,IPR020084:NUDIX_hydrolase_CS,IPR036189:DCP2_BoxA_sf,IPR044099:Dcp2_NUDIX,	hsa03018:RNA degradation,			SM01125:DCP2,	KW-0866~Nonsense-mediated mRNA decay,	KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0464~Manganese,KW-0479~Metal-binding,	KW-0378~Hydrolase,KW-0694~RNA-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:Nudix hydrolase,DOMAIN:mRNA decapping protein 2 Box A,MOTIF:Nudix box,MUTAGEN:E->Q: Loss of decapping activity; when associated with Q-148.,MUTAGEN:E->Q: Strongly reduced decapping activity.,MUTAGEN:S->A: Leads to the accumulation of autophagosomes under normal growth conditions.,MUTAGEN:S->D: Leads to reduced autophagosome formation under autophagy-inducing conditions.,REGION:Disordered,
DOCK10	dedicator of cytokinesis 10(DOCK10)	Homo sapiens			GO:0001782~B cell homeostasis,GO:0002315~marginal zone B cell differentiation,GO:0007264~small GTPase mediated signal transduction,GO:0030334~regulation of cell migration,GO:0043547~positive regulation of GTPase activity,GO:0060997~dendritic spine morphogenesis,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016020~membrane,GO:0043197~dendritic spine,GO:0070062~extracellular exosome,GO:0098978~glutamatergic synapse,	GO:0005085~guanyl-nucleotide exchange factor activity,GO:0005515~protein binding,GO:0031267~small GTPase binding,	IPR001849:PH_domain,IPR011993:PH-like_dom_sf,IPR021816:DOCK_C/D_N,IPR026791:DOCK,IPR027007:C2_DOCK-type_domain,IPR027357:DOCKER_dom,IPR035892:C2_domain_sf,IPR037809:C2_Dock-D,IPR043161:DOCK_C_lobe_A,IPR043162:DOCK_C_lobe_C,IPR046769:DOCKER_Lobe_A,IPR046770:DOCKER_Lobe_B,IPR046773:DOCKER_Lobe_C,				SM00233:PH,		KW-0539~Nucleus,KW-0770~Synapse,KW-0963~Cytoplasm,KW-0966~Cell projection,				KW-0344~Guanine-nucleotide releasing factor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:C2 DOCK-type,DOMAIN:DOCKER,DOMAIN:Dedicator of cytokinesis C/D N-terminal,DOMAIN:PH,REGION:Disordered,
DOCK8	dedicator of cytokinesis 8(DOCK8)	Homo sapiens			GO:0001771~immunological synapse formation,GO:0007264~small GTPase mediated signal transduction,GO:0036336~dendritic cell migration,GO:0043547~positive regulation of GTPase activity,GO:0051056~regulation of small GTPase mediated signal transduction,GO:0061485~memory T cell proliferation,GO:0070233~negative regulation of T cell apoptotic process,GO:1903905~positive regulation of establishment of T cell polarity,GO:1990869~cellular response to chemokine,GO:2000406~positive regulation of T cell migration,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0031252~cell leading edge,GO:0031256~leading edge membrane,GO:0031258~lamellipodium membrane,	GO:0005085~guanyl-nucleotide exchange factor activity,GO:0005515~protein binding,	IPR016024:ARM-type_fold,IPR021816:DOCK_C/D_N,IPR026791:DOCK,IPR027007:C2_DOCK-type_domain,IPR027357:DOCKER_dom,IPR035892:C2_domain_sf,IPR037808:C2_Dock-C,IPR043161:DOCK_C_lobe_A,IPR043162:DOCK_C_lobe_C,IPR046769:DOCKER_Lobe_A,IPR046770:DOCKER_Lobe_B,IPR046773:DOCKER_Lobe_C,		243700~Hyper-IgE syndrome 2, autosomal recessive, with recurrent infections,				KW-0472~Membrane,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0991~Intellectual disability,			KW-0344~Guanine-nucleotide releasing factor,	KW-0597~Phosphoprotein,	DOMAIN:C2 DOCK-type,DOMAIN:DOCKER,DOMAIN:Dedicator of cytokinesis C/D N-terminal,MUTAGEN:S->A: Abolishes phosphorylation. No migration in response to chemokine CXCL12/SDF-1-alpha stimulation; when associated with A-2077 and A-2082.,MUTAGEN:S->A: Abolishes phosphorylation. No migration in response to chemokine CXCL12/SDF-1-alpha stimulation; when associated with A-2077 and A-2087.,MUTAGEN:S->A: Abolishes phosphorylation. No migration in response to chemokine CXCL12/SDF-1-alpha stimulation; when associated with A-2082 and A-2087.,MUTAGEN:S->E: Phosphomimetic mutant. Enhances migration in response to chemokine CXCL12/SDF-1-alpha stimulation and reduces interaction with LRCH1; when associated with E-2077 and E-2082.,MUTAGEN:S->E: Phosphomimetic mutant. Enhances migration in response to chemokine CXCL12/SDF-1-alpha stimulation and reduces interaction with LRCH1; when associated with E-2077 and E-2087.,MUTAGEN:S->E: Phosphomimetic mutant. Enhances migration in response to chemokine CXCL12/SDF-1-alpha stimulation and reduces interaction with LRCH1; when associated with E-2082 and E-2087.,
DHRS7	dehydrogenase/reductase 7(DHRS7)	Homo sapiens			GO:0042572~retinol metabolic process,	GO:0005789~endoplasmic reticulum membrane,GO:0016020~membrane,	GO:0004090~carbonyl reductase (NADPH) activity,GO:0005515~protein binding,GO:0016491~oxidoreductase activity,GO:0016616~oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor,GO:0052650~NADP-retinol dehydrogenase activity,	IPR002347:SDR_fam,IPR020904:Sc_DH/Rdtase_CS,IPR036291:NAD(P)-bd_dom_sf,						KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0732~Signal,	KW-0520~NAD,KW-0521~NADP,	KW-0560~Oxidoreductase,		ACT_SITE:Proton acceptor,
DENR	density regulated re-initiation and release factor(DENR)	Homo sapiens			GO:0001731~formation of translation preinitiation complex,GO:0002188~translation reinitiation,GO:0032790~ribosome disassembly,GO:0075522~IRES-dependent viral translational initiation,		GO:0003729~mRNA binding,GO:0003743~translation initiation factor activity,GO:0005515~protein binding,	IPR001950:SUI1,IPR005873:DENR_eukaryotes,IPR036877:SUI1_dom_sf,IPR046447:DENR_C,IPR048517:DENR_N,					KW-0648~Protein biosynthesis,					KW-0396~Initiation factor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:SUI1,REGION:Disordered,
DCK	deoxycytidine kinase(DCK)	Homo sapiens			GO:0006220~pyrimidine nucleotide metabolic process,GO:0009224~CMP biosynthetic process,GO:0016310~phosphorylation,GO:1901135~carbohydrate derivative metabolic process,GO:1901293~nucleoside phosphate biosynthetic process,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,	GO:0004136~deoxyadenosine kinase activity,GO:0004137~deoxycytidine kinase activity,GO:0004138~deoxyguanosine kinase activity,GO:0005524~ATP binding,GO:0019136~deoxynucleoside kinase activity,GO:0042803~protein homodimerization activity,GO:0043771~cytidine kinase activity,	IPR002624:DCK/DGK,IPR027417:P-loop_NTPase,IPR031314:DNK_dom,	hsa00230:Purine metabolism,hsa00240:Pyrimidine metabolism,hsa01100:Metabolic pathways,hsa01232:Nucleotide metabolism,		PIRSF000705:DNK,			KW-0539~Nucleus,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,DOMAIN:Deoxynucleoside kinase,MUTAGEN:A->V: Strongly increased catalytic efficiency towards deoxycytidine; when associated with M-104 and A-133.,MUTAGEN:D->A: Strongly increased catalytic efficiency towards deoxycytidine; when associated with V-100 and M-104. Strongly increased catalytic efficiency towards deoxythymidine; when associated with L-104.,MUTAGEN:R->L: Strongly increased catalytic efficiency towards deoxythymidine; when associated with A-133.,MUTAGEN:R->M: Strongly increased catalytic efficiency towards deoxycytidine; when associated with V-100 and A-133.,MUTAGEN:S->A: 4.5-fold increase in Km.,REGION:Disordered,
DGUOK	deoxyguanosine kinase(DGUOK)	Homo sapiens			GO:0008617~guanosine metabolic process,GO:0010977~negative regulation of neuron projection development,GO:0016310~phosphorylation,GO:0042775~mitochondrial ATP synthesis coupled electron transport,GO:0046070~dGTP metabolic process,GO:0046122~purine deoxyribonucleoside metabolic process,GO:1901135~carbohydrate derivative metabolic process,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0005829~cytosol,	GO:0004136~deoxyadenosine kinase activity,GO:0004138~deoxyguanosine kinase activity,GO:0005524~ATP binding,GO:0016301~kinase activity,GO:0019136~deoxynucleoside kinase activity,	IPR002624:DCK/DGK,IPR027417:P-loop_NTPase,IPR031314:DNK_dom,	hsa00230:Purine metabolism,hsa01100:Metabolic pathways,hsa01232:Nucleotide metabolism,	251880~Mitochondrial DNA depletion syndrome 3 (hepatocerebral type),617070~Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 4,Portal hypertension, noncirrhotic, 1 617068~Portal hypertension, noncirrhotic, 1 617068,	PIRSF000705:DNK,			KW-0496~Mitochondrion,	KW-0225~Disease variant,KW-0622~Neuropathy,KW-0935~Progressive external ophthalmoplegia,KW-1274~Primary mitochondrial disease,	KW-0809~Transit peptide,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0808~Transferase,	KW-0007~Acetylation,	ACT_SITE:Proton acceptor,DOMAIN:Deoxynucleoside kinase,REGION:Disordered,TRANSIT:Mitochondrion,
DNTTIP2	deoxynucleotidyltransferase terminal interacting protein 2(DNTTIP2)	Homo sapiens			GO:0006396~RNA processing,GO:0042274~ribosomal small subunit biogenesis,	GO:0005654~nucleoplasm,GO:0005694~chromosome,GO:0005730~nucleolus,GO:0032040~small-subunit processome,	GO:0003723~RNA binding,GO:0005515~protein binding,	IPR014810:Fcf2_C,IPR039883:Fcf2/DNTTIP2,					KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0175~Coiled coil,			KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),REGION:Disordered,REGION:TdBR region; mediates interaction with DNTT,
DUT	deoxyuridine triphosphatase(DUT)	Homo sapiens		h_PparaPathway:Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha),	GO:0001889~liver development,GO:0006139~nucleobase-containing compound metabolic process,GO:0006226~dUMP biosynthetic process,GO:0006231~dTMP biosynthetic process,GO:0006260~DNA replication,GO:0014070~response to organic cyclic compound,GO:0043254~regulation of protein complex assembly,GO:0046081~dUTP catabolic process,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005739~mitochondrion,GO:0070062~extracellular exosome,	GO:0000287~magnesium ion binding,GO:0003723~RNA binding,GO:0004170~dUTP diphosphatase activity,GO:0005515~protein binding,GO:0030547~receptor inhibitor activity,GO:0032556~pyrimidine deoxyribonucleotide binding,GO:0042802~identical protein binding,GO:0042975~peroxisome proliferator activated receptor binding,	IPR008181:dUTPase,IPR029054:dUTPase-like,IPR033704:dUTPase_trimeric,IPR036157:dUTPase-like_sf,	hsa00240:Pyrimidine metabolism,hsa00983:Drug metabolism - other enzymes,hsa01100:Metabolic pathways,hsa01232:Nucleotide metabolism,	620044~Bone marrow failure and diabetes mellitus syndrome,			KW-0546~Nucleotide metabolism,	KW-0496~Mitochondrion,KW-0539~Nucleus,	KW-0219~Diabetes mellitus,KW-0225~Disease variant,	KW-0809~Transit peptide,	KW-0460~Magnesium,KW-0479~Metal-binding,	KW-0378~Hydrolase,	KW-0597~Phosphoprotein,	DOMAIN:dUTPase-like,MUTAGEN:S->A: Loss of phosphorylation.,REGION:Disordered,TRANSIT:Mitochondrion,
DERL2	derlin 2(DERL2)	Homo sapiens			GO:0001967~suckling behavior,GO:0006950~response to stress,GO:0008284~positive regulation of cell proliferation,GO:0010498~proteasomal protein catabolic process,GO:0030307~positive regulation of cell growth,GO:0030433~ubiquitin-dependent ERAD pathway,GO:0030968~endoplasmic reticulum unfolded protein response,GO:0030970~retrograde protein transport, ER to cytosol,GO:0036503~ERAD pathway,GO:1904153~negative regulation of retrograde protein transport, ER to cytosol,	GO:0000839~Hrd1p ubiquitin ligase ERAD-L complex,GO:0005769~early endosome,GO:0005770~late endosome,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0016020~membrane,	GO:0005047~signal recognition particle binding,GO:0005515~protein binding,GO:0044877~macromolecular complex binding,GO:0051787~misfolded protein binding,GO:1990381~ubiquitin-specific protease binding,	IPR007599:DER1,IPR035952:Rhomboid-like_sf,	hsa04141:Protein processing in endoplasmic reticulum,				KW-0834~Unfolded protein response,KW-0945~Host-virus interaction,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,
DESI2	desumoylating isopeptidase 2(DESI2)	Homo sapiens			GO:0006508~proteolysis,GO:0016579~protein deubiquitination,	GO:0005737~cytoplasm,	GO:0004843~thiol-dependent ubiquitin-specific protease activity,GO:0005515~protein binding,GO:0008233~peptidase activity,GO:0052816~long-chain acyl-CoA hydrolase activity,GO:0061578~Lys63-specific deubiquitinase activity,GO:0101005~ubiquitinyl hydrolase activity,GO:1990380~Lys48-specific deubiquitinase activity,	IPR008580:PPPDE_dom,IPR042266:PPPDE_sf,				SM01179:DUF862,	KW-0833~Ubl conjugation pathway,	KW-0963~Cytoplasm,				KW-0378~Hydrolase,KW-0645~Protease,		DOMAIN:PPPDE,MUTAGEN:C->S: Loss of deubiquitination activity.,REGION:Disordered,
DRG1	developmentally regulated GTP binding protein 1(DRG1)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0031116~positive regulation of microtubule polymerization,GO:1901673~regulation of mitotic spindle assembly,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005844~polysome,GO:0016020~membrane,GO:0016604~nuclear body,	GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0008017~microtubule binding,GO:0030955~potassium ion binding,GO:0042802~identical protein binding,	IPR004095:TGS,IPR005225:Small_GTP-bd_dom,IPR006073:GTP-bd,IPR006074:GTP1-OBG_CS,IPR012675:Beta-grasp_dom_sf,IPR012676:TGS-like,IPR027417:P-loop_NTPase,IPR031167:G_OBG,IPR031662:GTP-binding_2,IPR045001:DRG,		620641~Tan-Almurshedi syndrome,				KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0342~GTP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,	KW-0007~Acetylation,KW-0379~Hydroxylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	DOMAIN:OBG-type G,DOMAIN:TGS,MUTAGEN:K->A: Impairs JMJD7-mediated hydroxylation.,MUTAGEN:T->D: Reduces the GTPase activity.,REGION:Disordered,REGION:Required for interaction with STK16,
DIABLO	diablo IAP-binding mitochondrial protein(DIABLO)	Homo sapiens	126.Apoptosis-Bcl-2,127.Mito-stress,81.Structure_of_Caps_and_SMACs,	h_mitochondriaPathway:Role of Mitochondria in Apoptotic Signaling,	GO:0006915~apoptotic process,GO:0006919~activation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0008625~extrinsic apoptotic signaling pathway via death domain receptors,GO:0008631~intrinsic apoptotic signaling pathway in response to oxidative stress,GO:0008635~activation of cysteine-type endopeptidase activity involved in apoptotic process by cytochrome c,GO:0043065~positive regulation of apoptotic process,GO:0051402~neuron apoptotic process,GO:0097193~intrinsic apoptotic signaling pathway,	GO:0005739~mitochondrion,GO:0005758~mitochondrial intermembrane space,GO:0005829~cytosol,GO:0009898~cytoplasmic side of plasma membrane,GO:0016020~membrane,GO:0035631~CD40 receptor complex,	GO:0005515~protein binding,	IPR009062:Smac/DIABLO-like_sf,IPR015142:Smac_DIABLO,	hsa04210:Apoptosis,hsa04215:Apoptosis - multiple species,	614152~Deafness, autosomal dominant 64,			KW-0053~Apoptosis,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0963~Cytoplasm,	KW-0209~Deafness,KW-0225~Disease variant,KW-1010~Non-syndromic deafness,	KW-0732~Signal,KW-0809~Transit peptide,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0832~Ubl conjugation,	MOTIF:IAP-binding,REGION:Disordered,SITE:Cleavage; by PARL,TRANSIT:Mitochondrion,TRANSMEM:Helical,
DGKA	diacylglycerol kinase alpha(DGKA)	Homo sapiens			GO:0006654~phosphatidic acid biosynthetic process,GO:0007205~protein kinase C-activating G-protein coupled receptor signaling pathway,GO:0016310~phosphorylation,GO:0030168~platelet activation,GO:0035556~intracellular signal transduction,GO:0046339~diacylglycerol metabolic process,GO:0046486~glycerolipid metabolic process,GO:0046834~lipid phosphorylation,	GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016020~membrane,	GO:0004143~diacylglycerol kinase activity,GO:0005509~calcium ion binding,GO:0005524~ATP binding,GO:0005543~phospholipid binding,GO:0008289~lipid binding,GO:0016301~kinase activity,GO:0046872~metal ion binding,GO:0047649~alkylglycerol kinase activity,	IPR000756:Diacylglycerol_kin_accessory,IPR001206:Diacylglycerol_kinase_cat_dom,IPR002048:EF_hand_dom,IPR002219:PE/DAG-bd,IPR011992:EF-hand-dom_pair,IPR016064:NAD/diacylglycerol_kinase_sf,IPR017438:ATP-NAD_kinase_N,IPR018247:EF_Hand_1_Ca_BS,IPR029477:DAG_kinase_typeI_N,IPR037607:DGK,IPR038199:DGK_typeI_N_sf,IPR046349:C1-like_sf,IPR047469:C1_DGKalpha_rpt2,	hsa00561:Glycerolipid metabolism,hsa00564:Glycerophospholipid metabolism,hsa01100:Metabolic pathways,hsa04070:Phosphatidylinositol signaling system,hsa04072:Phospholipase D signaling pathway,hsa05231:Choline metabolism in cancer,			SM00045:DAGKa,SM00046:DAGKc,SM00054:EFh,SM00109:C1,	KW-0443~Lipid metabolism,	KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0067~ATP-binding,KW-0106~Calcium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,KW-0862~Zinc,	KW-0418~Kinase,KW-0808~Transferase,	KW-0007~Acetylation,	DOMAIN:DAGKc,DOMAIN:Diacylglycerol kinase type I N-terminal,DOMAIN:EF-hand,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,DOMAIN:Phorbol-ester/DAG-type,MUTAGEN:E->Q: Binds calcium but with decreased affinity.,MUTAGEN:E->Q: Loss of calcium-binding.,ZN_FING:Phorbol-ester/DAG-type 1,ZN_FING:Phorbol-ester/DAG-type 2,
DBI	diazepam binding inhibitor, acyl-CoA binding protein(DBI)	Homo sapiens			GO:0006631~fatty acid metabolic process,GO:0036151~phosphatidylcholine acyl-chain remodeling,GO:1903060~negative regulation of protein lipidation,GO:1905920~positive regulation of CoA-transferase activity,GO:2001140~positive regulation of phospholipid transport,	GO:0005783~endoplasmic reticulum,GO:0005788~endoplasmic reticulum lumen,GO:0005794~Golgi apparatus,GO:0032994~protein-lipid complex,GO:0070062~extracellular exosome,GO:0097038~perinuclear endoplasmic reticulum,	GO:0000062~fatty-acyl-CoA binding,GO:0030156~benzodiazepine receptor binding,GO:0036042~long-chain fatty acyl-CoA binding,GO:0042802~identical protein binding,	IPR000582:Acyl-CoA-binding_protein,IPR014352:FERM/acyl-CoA-bd_prot_sf,IPR022408:Acyl-CoA-binding_prot_CS,IPR035984:Acyl-CoA-binding_sf,	hsa03320:PPAR signaling pathway,				KW-0813~Transport,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,			KW-0446~Lipid-binding,KW-0711~Selenium,		KW-0007~Acetylation,KW-0379~Hydroxylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:ACB,NON_STD:Selenocysteine,REGION:Disordered,
DLST	dihydrolipoamide S-succinyltransferase(DLST)	Homo sapiens			GO:0006091~generation of precursor metabolites and energy,GO:0006099~tricarboxylic acid cycle,GO:0006103~2-oxoglutarate metabolic process,GO:0006104~succinyl-CoA metabolic process,GO:0033512~L-lysine catabolic process to acetyl-CoA via saccharopine,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0005829~cytosol,GO:0016020~membrane,GO:0045252~oxoglutarate dehydrogenase complex,GO:1990204~oxidoreductase complex,	GO:0004149~dihydrolipoyllysine-residue succinyltransferase activity,GO:0005515~protein binding,GO:0016740~transferase activity,GO:0016746~transferase activity, transferring acyl groups,	IPR000089:Biotin_lipoyl,IPR001078:2-oxoacid_DH_actylTfrase,IPR003016:2-oxoA_DH_lipoyl-BS,IPR006255:SucB,IPR011053:Single_hybrid_motif,IPR023213:CAT-like_dom_sf,	hsa00020:Citrate cycle (TCA cycle),hsa00310:Lysine degradation,hsa00380:Tryptophan metabolism,hsa00785:Lipoic acid metabolism,hsa01100:Metabolic pathways,hsa01200:Carbon metabolism,hsa01210:2-Oxocarboxylic acid metabolism,	618475~Pheochromocytoma/paraganglioma syndrome 7,			KW-0816~Tricarboxylic acid cycle,	KW-0496~Mitochondrion,KW-0539~Nucleus,	KW-0225~Disease variant,	KW-0450~Lipoyl,KW-0809~Transit peptide,		KW-0012~Acyltransferase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:2-oxoacid dehydrogenase acyltransferase catalytic,DOMAIN:Lipoyl-binding,MUTAGEN:H->A: Loss of dihydrolipoyllysine-residue succinyltransferase activity.,MUTAGEN:REK->AEA: Reduced nuclear localization of the 2-oxoglutarate dehydrogenase complex. Reduced histone succinylation.,REGION:Disordered,TRANSIT:Mitochondrion,
DPP7	dipeptidyl peptidase 7(DPP7)	Homo sapiens			GO:0006508~proteolysis,GO:1905146~lysosomal protein catabolic process,	GO:0005576~extracellular region,GO:0005794~Golgi apparatus,GO:0031982~vesicle,GO:0035578~azurophil granule lumen,GO:0043231~intracellular membrane-bounded organelle,GO:0070062~extracellular exosome,	GO:0004177~aminopeptidase activity,GO:0008236~serine-type peptidase activity,GO:0008239~dipeptidyl-peptidase activity,GO:0016787~hydrolase activity,GO:0070008~serine-type exopeptidase activity,	IPR008758:Peptidase_S28,IPR029058:AB_hydrolase,IPR042269:Ser_carbopepase_S28_SKS,						KW-0458~Lysosome,KW-0964~Secreted,KW-0968~Cytoplasmic vesicle,		KW-0732~Signal,		KW-0031~Aminopeptidase,KW-0378~Hydrolase,KW-0645~Protease,KW-0720~Serine protease,	KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-0865~Zymogen,	ACT_SITE:Charge relay system,CARBOHYD:N-linked (GlcNAc...) asparagine,REGION:Disordered,
DPH3	diphthamide biosynthesis 3(DPH3)	Homo sapiens			GO:0002926~tRNA wobble base 5-methoxycarbonylmethyl-2-thiouridine biosynthesis.,GO:0017183~peptidyl-diphthamide biosynthetic process from peptidyl-histidine,GO:0050709~negative regulation of protein secretion,GO:0051099~positive regulation of binding,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0005515~protein binding,GO:0008198~ferrous iron binding,GO:0034986~iron chaperone activity,	IPR007872:DPH_MB_dom,IPR036671:DPH_MB_sf,IPR044248:DPH3/4-like,						KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0408~Iron,KW-0479~Metal-binding,			DOMAIN:DPH-type MB,
DOK2	docking protein 2(DOK2)	Homo sapiens			GO:0007165~signal transduction,GO:0007166~cell surface receptor signaling pathway,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0007265~Ras protein signal transduction,GO:0016310~phosphorylation,GO:0043410~positive regulation of MAPK cascade,	GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0005068~transmembrane receptor protein tyrosine kinase adaptor activity,GO:0005515~protein binding,GO:0016301~kinase activity,	IPR001849:PH_domain,IPR002404:IRS_PTB,IPR011993:PH-like_dom_sf,IPR037751:Dok1/2/3_PTB,				SM00233:PH,SM00310:PTBI,SM01244:IRS,	KW-0945~Host-virus interaction,					KW-0418~Kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	COMPBIAS:Pro residues,DOMAIN:IRS-type PTB,DOMAIN:PH,REGION:Disordered,
DDOST	dolichyl-diphosphooligosaccharide--protein glycosyltransferase non-catalytic subunit(DDOST)	Homo sapiens			GO:0006486~protein glycosylation,GO:0006487~protein N-linked glycosylation,GO:0018279~protein N-linked glycosylation via asparagine,GO:0031647~regulation of protein stability,GO:0034097~response to cytokine,GO:0042110~T cell activation,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0008250~oligosaccharyltransferase complex,GO:0016020~membrane,GO:0035577~azurophil granule membrane,GO:0043231~intracellular membrane-bounded organelle,	GO:0005515~protein binding,GO:0008047~enzyme activator activity,	IPR005013:DDOST_48_kDa_subunit,	hsa00510:N-Glycan biosynthesis,hsa00513:Various types of N-glycan biosynthesis,hsa01100:Metabolic pathways,hsa04141:Protein processing in endoplasmic reticulum,	614507~Congenital disorder of glycosylation, type Ir,				KW-0256~Endoplasmic reticulum,KW-0472~Membrane,	KW-0225~Disease variant,KW-0900~Congenital disorder of glycosylation,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,				TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
DR1	down-regulator of transcription 1(DR1)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0045995~regulation of embryonic development,GO:0051123~RNA polymerase II transcriptional preinitiation complex assembly,GO:0051302~regulation of cell division,GO:0051726~regulation of cell cycle,GO:0090043~regulation of tubulin deacetylation,	GO:0005654~nucleoplasm,GO:0017054~negative cofactor 2 complex,GO:0072686~mitotic spindle,GO:0090575~RNA polymerase II transcription factor complex,	GO:0003677~DNA binding,GO:0005515~protein binding,GO:0017025~TBP-class protein binding,GO:0046982~protein heterodimerization activity,	IPR003958:CBFA_NFYB_domain,IPR009072:Histone-fold,IPR042225:Ncb2,					KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0238~DNA-binding,KW-0678~Repressor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Histone-fold,DOMAIN:Transcription factor CBF/NF-Y/archaeal histone,MOTIF:Nuclear localization signal,REGION:Disordered,
DPY30	dpy-30 histone methyltransferase complex regulatory subunit(DPY30)	Homo sapiens			GO:0016197~endosomal transport,GO:0045815~positive regulation of gene expression, epigenetic,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005794~Golgi apparatus,GO:0005802~trans-Golgi network,GO:0035097~histone methyltransferase complex,GO:0044665~MLL1/2 complex,GO:0044666~MLL3/4 complex,GO:0048188~Set1C/COMPASS complex,GO:0071339~MLL1 complex,	GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,	IPR007858:Dpy-30_motif,IPR037856:Sdc1/DPY30,					KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0333~Golgi apparatus,KW-0539~Nucleus,				KW-0156~Chromatin regulator,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,REGION:Disordered,
DBNL	drebrin like(DBNL)	Homo sapiens			GO:0002250~adaptive immune response,GO:0006897~endocytosis,GO:0007416~synapse assembly,GO:0016601~Rac protein signal transduction,GO:0048812~neuron projection morphogenesis,GO:0061024~membrane organization,GO:0071800~podosome assembly,GO:0098974~postsynaptic actin cytoskeleton organization,	GO:0000139~Golgi membrane,GO:0001726~ruffle,GO:0002102~podosome,GO:0005576~extracellular region,GO:0005737~cytoplasm,GO:0005769~early endosome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005938~cell cortex,GO:0014069~postsynaptic density,GO:0016020~membrane,GO:0030027~lamellipodium,GO:0030425~dendrite,GO:0030665~clathrin-coated vesicle membrane,GO:0034774~secretory granule lumen,GO:0043204~perikaryon,GO:0043231~intracellular membrane-bounded organelle,GO:0070062~extracellular exosome,GO:0070161~anchoring junction,GO:0098793~presynapse,GO:0098978~glutamatergic synapse,GO:1904724~tertiary granule lumen,GO:1904813~ficolin-1-rich granule lumen,	GO:0003779~actin binding,GO:0005515~protein binding,GO:0008047~enzyme activator activity,GO:0019904~protein domain specific binding,GO:0045296~cadherin binding,GO:0051015~actin filament binding,GO:0098973~structural constituent of postsynaptic actin cytoskeleton,	IPR001452:SH3_domain,IPR002108:ADF-H,IPR029006:ADF-H/Gelsolin-like_dom_sf,IPR035717:Drebrin-like_SH3,IPR036028:SH3-like_dom_sf,				SM00102:ADF,SM00326:SH3,	KW-0254~Endocytosis,KW-0391~Immunity,KW-0813~Transport,KW-1064~Adaptive immunity,	KW-0206~Cytoskeleton,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0770~Synapse,KW-0963~Cytoplasm,KW-0965~Cell junction,KW-0966~Cell projection,KW-0967~Endosome,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,		KW-0175~Coiled coil,KW-0728~SH3 domain,		KW-0009~Actin-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:ADF-H,DOMAIN:SH3,MUTAGEN:D->A: Abolishes cleavage by caspase-3.,REGION:Disordered,SITE:Cleavage; by caspase-3,
DUSP1	dual specificity phosphatase 1(DUSP1)	Homo sapiens		h_cd40Pathway:CD40L Signaling Pathway,h_dspPathway:Regulation of MAP Kinase Pathways Through Dual Specificity Phosphatases,h_nthiPathway:NFkB activation by Nontypeable Hemophilus influenzae,h_PparaPathway:Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha),h_tnfr2Pathway:TNFR2 Signaling Pathway,	GO:0001706~endoderm formation,GO:0007049~cell cycle,GO:0007162~negative regulation of cell adhesion,GO:0008285~negative regulation of cell proliferation,GO:0016311~dephosphorylation,GO:0035335~peptidyl-tyrosine dephosphorylation,GO:0035970~peptidyl-threonine dephosphorylation,GO:0043407~negative regulation of MAP kinase activity,GO:0043409~negative regulation of MAPK cascade,GO:0051447~negative regulation of meiotic cell cycle,GO:0070262~peptidyl-serine dephosphorylation,GO:0090027~negative regulation of monocyte chemotaxis,GO:0090266~regulation of mitotic cell cycle spindle assembly checkpoint,GO:1903753~negative regulation of p38MAPK cascade,GO:1990869~cellular response to chemokine,	GO:0005634~nucleus,GO:0005737~cytoplasm,	GO:0004722~protein serine/threonine phosphatase activity,GO:0004725~protein tyrosine phosphatase activity,GO:0005515~protein binding,GO:0008138~protein tyrosine/serine/threonine phosphatase activity,GO:0008330~protein tyrosine/threonine phosphatase activity,GO:0017017~MAP kinase tyrosine/serine/threonine phosphatase activity,GO:0017018~myosin phosphatase activity,GO:0033550~MAP kinase tyrosine phosphatase activity,GO:0051019~mitogen-activated protein kinase binding,	IPR000340:Dual-sp_phosphatase_cat-dom,IPR000387:Tyr_Pase_dom,IPR001763:Rhodanese-like_dom,IPR003595:Tyr_Pase_cat,IPR008343:MKP,IPR016130:Tyr_Pase_AS,IPR020422:TYR_PHOSPHATASE_DUAL_dom,IPR029021:Prot-tyrosine_phosphatase-like,IPR036873:Rhodanese-like_dom_sf,	hsa04010:MAPK signaling pathway,hsa04726:Serotonergic synapse,hsa05012:Parkinson disease,hsa05418:Fluid shear stress and atherosclerosis,		PIRSF000939:MAPK_Ptase,	SM00195:DSPc,SM00404:PTPc_motif,SM00450:RHOD,	KW-0131~Cell cycle,KW-0346~Stress response,	KW-0539~Nucleus,				KW-0378~Hydrolase,KW-0904~Protein phosphatase,	KW-0597~Phosphoprotein,	ACT_SITE:Phosphocysteine intermediate,DOMAIN:Rhodanese,DOMAIN:Tyrosine specific protein phosphatases,DOMAIN:Tyrosine-protein phosphatase,MUTAGEN:C->S: Loss of phosphatase activity.,
DUSP12	dual specificity phosphatase 12(DUSP12)	Homo sapiens			GO:0006470~protein dephosphorylation,GO:0016311~dephosphorylation,GO:0036211~protein modification process,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0004725~protein tyrosine phosphatase activity,GO:0005515~protein binding,GO:0008138~protein tyrosine/serine/threonine phosphatase activity,GO:0008270~zinc ion binding,GO:0016791~phosphatase activity,GO:0017018~myosin phosphatase activity,GO:0019900~kinase binding,	IPR000340:Dual-sp_phosphatase_cat-dom,IPR000387:Tyr_Pase_dom,IPR013087:Znf_C2H2_type,IPR016278:DUSP12,IPR020422:TYR_PHOSPHATASE_DUAL_dom,IPR029021:Prot-tyrosine_phosphatase-like,			PIRSF000941:DUSP12,	SM00195:DSPc,		KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0479~Metal-binding,KW-0862~Zinc,	KW-0378~Hydrolase,KW-0904~Protein phosphatase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Phosphocysteine intermediate,DOMAIN:Tyrosine-protein phosphatase,
DUSP16	dual specificity phosphatase 16(DUSP16)	Homo sapiens			GO:0006470~protein dephosphorylation,GO:0016311~dephosphorylation,GO:0035335~peptidyl-tyrosine dephosphorylation,GO:0043409~negative regulation of MAPK cascade,GO:0043508~negative regulation of JUN kinase activity,GO:0045204~MAPK export from nucleus,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0031410~cytoplasmic vesicle,	GO:0004721~phosphoprotein phosphatase activity,GO:0005515~protein binding,GO:0008330~protein tyrosine/threonine phosphatase activity,GO:0008432~JUN kinase binding,GO:0016791~phosphatase activity,GO:0017017~MAP kinase tyrosine/serine/threonine phosphatase activity,GO:0017018~myosin phosphatase activity,GO:0033550~MAP kinase tyrosine phosphatase activity,GO:0048273~mitogen-activated protein kinase p38 binding,GO:0051019~mitogen-activated protein kinase binding,	IPR000340:Dual-sp_phosphatase_cat-dom,IPR000387:Tyr_Pase_dom,IPR001763:Rhodanese-like_dom,IPR008343:MKP,IPR016130:Tyr_Pase_AS,IPR020422:TYR_PHOSPHATASE_DUAL_dom,IPR029021:Prot-tyrosine_phosphatase-like,IPR036873:Rhodanese-like_dom_sf,	hsa04010:MAPK signaling pathway,hsa04148:Efferocytosis,			SM00195:DSPc,SM00450:RHOD,		KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,				KW-0378~Hydrolase,KW-0904~Protein phosphatase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Phosphocysteine intermediate,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Rhodanese,DOMAIN:Tyrosine specific protein phosphatases,DOMAIN:Tyrosine-protein phosphatase,REGION:Disordered,
DUSP2	dual specificity phosphatase 2(DUSP2)	Homo sapiens		h_dspPathway:Regulation of MAP Kinase Pathways Through Dual Specificity Phosphatases,	GO:0001706~endoderm formation,GO:0006470~protein dephosphorylation,GO:0035335~peptidyl-tyrosine dephosphorylation,GO:0043409~negative regulation of MAPK cascade,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0031965~nuclear membrane,	GO:0004725~protein tyrosine phosphatase activity,GO:0005515~protein binding,GO:0008330~protein tyrosine/threonine phosphatase activity,GO:0017017~MAP kinase tyrosine/serine/threonine phosphatase activity,GO:0017018~myosin phosphatase activity,GO:0033550~MAP kinase tyrosine phosphatase activity,GO:0051019~mitogen-activated protein kinase binding,	IPR000340:Dual-sp_phosphatase_cat-dom,IPR000387:Tyr_Pase_dom,IPR001763:Rhodanese-like_dom,IPR003595:Tyr_Pase_cat,IPR008343:MKP,IPR016130:Tyr_Pase_AS,IPR020422:TYR_PHOSPHATASE_DUAL_dom,IPR029021:Prot-tyrosine_phosphatase-like,IPR036873:Rhodanese-like_dom_sf,	hsa04010:MAPK signaling pathway,hsa04148:Efferocytosis,		PIRSF000939:MAPK_Ptase,	SM00195:DSPc,SM00404:PTPc_motif,SM00450:RHOD,		KW-0539~Nucleus,				KW-0378~Hydrolase,KW-0904~Protein phosphatase,		ACT_SITE:Phosphocysteine intermediate,DOMAIN:Rhodanese,DOMAIN:Tyrosine-protein phosphatase,MUTAGEN:C->S: Loss of tyrosine phosphatase activity.,
DCTN1	dynactin subunit 1(DCTN1)	Homo sapiens		h_Lis1Pathway:Lissencephaly gene (LIS1) in neuronal migration and development,	GO:0000132~establishment of mitotic spindle orientation,GO:0000278~mitotic cell cycle,GO:0007097~nuclear migration,GO:0007399~nervous system development,GO:0007528~neuromuscular junction development,GO:0010457~centriole-centriole cohesion,GO:0021517~ventral spinal cord development,GO:0031116~positive regulation of microtubule polymerization,GO:0032402~melanosome transport,GO:0034454~microtubule anchoring at centrosome,GO:0042147~retrograde transport, endosome to Golgi,GO:0050905~neuromuscular process,GO:0051081~nuclear envelope disassembly,GO:0051301~cell division,GO:0060236~regulation of mitotic spindle organization,GO:0061744~motor behavior,GO:0070050~neuron cellular homeostasis,GO:0090063~positive regulation of microtubule nucleation,GO:0099558~maintenance of synapse structure,GO:1904398~positive regulation of neuromuscular junction development,GO:1905515~non-motile cilium assembly,GO:1990535~neuron projection maintenance,	GO:0000776~kinetochore,GO:0000922~spindle pole,GO:0005635~nuclear envelope,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005814~centriole,GO:0005819~spindle,GO:0005829~cytosol,GO:0005874~microtubule,GO:0005875~microtubule associated complex,GO:0005938~cell cortex,GO:0015630~microtubule cytoskeleton,GO:0016020~membrane,GO:0030286~dynein complex,GO:0030424~axon,GO:0030904~retromer complex,GO:0031252~cell leading edge,GO:0035371~microtubule plus-end,GO:0036064~ciliary basal body,GO:0043005~neuron projection,GO:0043025~neuronal cell body,GO:0045171~intercellular bridge,GO:0072686~mitotic spindle,GO:0099738~cell cortex region,	GO:0005515~protein binding,GO:0008017~microtubule binding,GO:0015631~tubulin binding,GO:0019901~protein kinase binding,GO:0048156~tau protein binding,	IPR000938:CAP-Gly_domain,IPR022157:Dynactin,IPR036859:CAP-Gly_dom_sf,	hsa04814:Motor proteins,hsa04962:Vasopressin-regulated water reabsorption,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05132:Salmonella infection,	105400~Amyotrophic lateral sclerosis, susceptibility to,168605~Perry syndrome,607641~Neuronopathy, distal hereditary motor, autosomal dominant 14,		SM01052:CAP_GLY,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,KW-0813~Transport,	KW-0206~Cytoskeleton,KW-0243~Dynein,KW-0493~Microtubule,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0036~Amyotrophic lateral sclerosis,KW-0523~Neurodegeneration,KW-0622~Neuropathy,KW-0908~Parkinsonism,	KW-0175~Coiled coil,			KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,DOMAIN:CAP-Gly,MUTAGEN:K->A: Abolishes interaction with CLIP1.,MUTAGEN:R->E: Abolishes interaction with CLIP1.,MUTAGEN:S->A: No effect on its interaction with CLIP1 and PLK1.,MUTAGEN:S->A: Non-phosphorylatable by PLK1. Decreased nuclear envelope localization. No loss of microtubule-binding. No effect on its interaction with CLIP1.,MUTAGEN:S->D: No loss of localization to nuclear envelope. Decrease in microtubule-binding. No effect on its interaction with CLIP1.,MUTAGEN:T->A: Affects centrosomal localization; when associated with A-145 and A-146.,MUTAGEN:T->A: Affects centrosomal localization; when associated with A-145 and A-147.,MUTAGEN:T->A: Affects centrosomal localization; when associated with A-146 and A-147.,REGION:Disordered,REGION:Interaction with HPS6,
DCTN3	dynactin subunit 3(DCTN3)	Homo sapiens		h_Lis1Pathway:Lissencephaly gene (LIS1) in neuronal migration and development,	GO:0000278~mitotic cell cycle,GO:0007017~microtubule-based process,GO:0061640~cytoskeleton-dependent cytokinesis,	GO:0000776~kinetochore,GO:0005730~nucleolus,GO:0005813~centrosome,GO:0005819~spindle,GO:0005829~cytosol,GO:0005869~dynactin complex,GO:0030496~midbody,GO:0032154~cleavage furrow,GO:0048471~perinuclear region of cytoplasm,	GO:0005198~structural molecule activity,GO:0005515~protein binding,	IPR009991:DCTN3,	hsa04814:Motor proteins,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05132:Salmonella infection,				KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,	KW-0137~Centromere,KW-0158~Chromosome,KW-0206~Cytoskeleton,KW-0963~Cytoplasm,KW-0995~Kinetochore,		KW-0175~Coiled coil,			KW-0007~Acetylation,
DNAAF2	dynein axonemal assembly factor 2(DNAAF2)	Homo sapiens			GO:0001701~in utero embryonic development,GO:0003351~epithelial cilium movement,GO:0032526~response to retinoic acid,GO:0036158~outer dynein arm assembly,GO:0036159~inner dynein arm assembly,GO:0050821~protein stabilization,GO:0051649~establishment of localization in cell,GO:0060285~cilium-dependent cell motility,GO:0070286~axonemal dynein complex assembly,	GO:0005576~extracellular region,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0101031~chaperone complex,	GO:0005515~protein binding,	IPR012981:PIH1_N,IPR034727:Kintoun,IPR041442:PIH1D1/2/3_CS-like,		612518~Ciliary dyskinesia, primary, 10,				KW-0963~Cytoplasm,	KW-0990~Primary ciliary dyskinesia,KW-1012~Kartagener syndrome,KW-1186~Ciliopathy,				KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,REGION:Disordered,
DYNC1H1	dynein cytoplasmic 1 heavy chain 1(DYNC1H1)	Homo sapiens			GO:0007018~microtubule-based movement,GO:0007052~mitotic spindle organization,GO:0007097~nuclear migration,GO:0008090~retrograde axonal transport,GO:0031122~cytoplasmic microtubule organization,GO:0032388~positive regulation of intracellular transport,GO:0033962~cytoplasmic mRNA processing body assembly,GO:0034063~stress granule assembly,GO:0051293~establishment of spindle localization,GO:0051301~cell division,GO:0060236~regulation of mitotic spindle organization,GO:0090235~regulation of metaphase plate congression,GO:1905832~positive regulation of spindle assembly,	GO:0005576~extracellular region,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005829~cytosol,GO:0005868~cytoplasmic dynein complex,GO:0005874~microtubule,GO:0005881~cytoplasmic microtubule,GO:0005938~cell cortex,GO:0016020~membrane,GO:0030175~filopodium,GO:0030286~dynein complex,GO:0035578~azurophil granule lumen,GO:0070062~extracellular exosome,GO:1904115~axon cytoplasm,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008569~ATP-dependent microtubule motor activity, minus-end-directed,GO:0016887~ATPase activity,GO:0045505~dynein intermediate chain binding,GO:0051959~dynein light intermediate chain binding,	IPR003593:AAA+_ATPase,IPR004273:Dynein_heavy_D6_P-loop,IPR013594:Dynein_heavy_tail,IPR013602:Dynein_heavy_linker,IPR024317:Dynein_heavy_chain_D4_dom,IPR024743:Dynein_HC_stalk,IPR026983:DHC_fam,IPR027417:P-loop_NTPase,IPR035699:AAA_6,IPR035706:AAA_9,IPR041228:Dynein_C,IPR041466:Dynein_AAA5_ext,IPR041658:AAA_lid_11,IPR042219:AAA_lid_11_sf,IPR042222:Dynein_2_N,IPR042228:Dynein_linker_3,IPR043157:Dynein_AAA1S,IPR043160:Dynein_C_barrel,	hsa04145:Phagosome,hsa04814:Motor proteins,hsa04962:Vasopressin-regulated water reabsorption,hsa05132:Salmonella infection,	158600~Spinal muscular atrophy, lower extremity-predominant 1, AD,614228~Charcot-Marie-Tooth disease, axonal, type 2O,614563~Cortical dysplasia, complex, with other brain malformations 13,		SM00382:AAA,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,KW-0813~Transport,	KW-0206~Cytoskeleton,KW-0243~Dynein,KW-0493~Microtubule,KW-0963~Cytoplasm,	KW-0144~Charcot-Marie-Tooth disease,KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0622~Neuropathy,KW-0991~Intellectual disability,	KW-0175~Coiled coil,KW-0677~Repeat,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0505~Motor protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:AAA+ ATPase,DOMAIN:Dynein heavy chain C-terminal,DOMAIN:Dynein heavy chain hydrolytic ATP-binding dynein motor region,DOMAIN:Dynein heavy chain linker,DOMAIN:Dynein heavy chain tail,REGION:AAA 1,REGION:AAA 2,REGION:AAA 3,REGION:AAA 4,REGION:AAA 5,REGION:AAA 6,REGION:Disordered,REGION:Interaction with DYNC1I2,REGION:Interaction with DYNC1LI2,REGION:Stalk,REGION:Stem,
DYNLL1	dynein light chain LC8-type 1(DYNLL1)	Homo sapiens		h_Lis1Pathway:Lissencephaly gene (LIS1) in neuronal migration and development,	GO:0006915~apoptotic process,GO:0007017~microtubule-based process,GO:0007286~spermatid development,GO:0021762~substantia nigra development,GO:0035721~intraciliary retrograde transport,GO:0035774~positive regulation of insulin secretion involved in cellular response to glucose stimulus,GO:0042326~negative regulation of phosphorylation,GO:0044458~motile cilium assembly,GO:0045019~negative regulation of nitric oxide biosynthetic process,GO:0051881~regulation of mitochondrial membrane potential,GO:1902857~positive regulation of non-motile cilium assembly,	GO:0000776~kinetochore,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005813~centrosome,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005868~cytoplasmic dynein complex,GO:0005874~microtubule,GO:0005886~plasma membrane,GO:0005929~cilium,GO:0008180~COP9 signalosome,GO:0016020~membrane,GO:0030141~secretory granule,GO:0030286~dynein complex,GO:0070821~tertiary granule membrane,GO:0072686~mitotic spindle,GO:0097542~ciliary tip,GO:0101003~ficolin-1-rich granule membrane,GO:1904115~axon cytoplasm,	GO:0004857~enzyme inhibitor activity,GO:0005515~protein binding,GO:0019899~enzyme binding,GO:0019904~protein domain specific binding,GO:0030235~nitric-oxide synthase regulator activity,GO:0042802~identical protein binding,GO:0044877~macromolecular complex binding,GO:0045505~dynein intermediate chain binding,GO:0097110~scaffold protein binding,	IPR001372:Dynein_light_chain_typ-1/2,IPR019763:Dynein_light_1/2_CS,IPR037177:DLC_sf,	hsa04814:Motor proteins,hsa04962:Vasopressin-regulated water reabsorption,hsa05132:Salmonella infection,			SM01375:Dynein_light,	KW-0053~Apoptosis,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0813~Transport,KW-0945~Host-virus interaction,	KW-0206~Cytoskeleton,KW-0243~Dynein,KW-0493~Microtubule,KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0010~Activator,KW-0505~Motor protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),MUTAGEN:S->A: Abolishes growth factor-mediated phosphorylation. Increases BCL2L11 protein level and promotes apoptosis.,MUTAGEN:S->E: Abolishes homodimerization. Abolishes interaction with BCL2L11 isoform 1 and isoform 2.,MUTAGEN:T->A: Abolishes interaction with PAK1.,REGION:Interaction with ESR1,
DYNLT3	dynein light chain Tctex-type 3(DYNLT3)	Homo sapiens			GO:0007018~microtubule-based movement,GO:0007049~cell cycle,GO:0007346~regulation of mitotic cell cycle,GO:0045931~positive regulation of mitotic cell cycle,GO:0051301~cell division,	GO:0000776~kinetochore,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005868~cytoplasmic dynein complex,GO:0061673~mitotic spindle astral microtubule,	GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0045505~dynein intermediate chain binding,	IPR005334:Tctex-1-like,IPR038586:Tctex-1-like_sf,	hsa04814:Motor proteins,hsa05132:Salmonella infection,				KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,KW-0813~Transport,	KW-0137~Centromere,KW-0158~Chromosome,KW-0206~Cytoskeleton,KW-0243~Dynein,KW-0493~Microtubule,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0995~Kinetochore,		KW-0732~Signal,		KW-0505~Motor protein,	KW-0944~Nitration,
EVI2A	ecotropic viral integration site 2A(EVI2A)	Homo sapiens				GO:0016020~membrane,	GO:0004888~transmembrane signaling receptor activity,GO:0005515~protein binding,	IPR008608:Ectropic_vir_integratn_site_2A,			PIRSF019625:EVI_S2A,			KW-0472~Membrane,	KW-0656~Proto-oncogene,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
EVI2B	ecotropic viral integration site 2B(EVI2B)	Homo sapiens			GO:0030854~positive regulation of granulocyte differentiation,GO:0043066~negative regulation of apoptotic process,GO:0045660~positive regulation of neutrophil differentiation,GO:0051726~regulation of cell cycle,GO:0061515~myeloid cell development,GO:2000035~regulation of stem cell division,	GO:0005886~plasma membrane,GO:0016020~membrane,		IPR033239:EVI2B,						KW-0472~Membrane,	KW-0656~Proto-oncogene,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
ETFA	electron transfer flavoprotein subunit alpha(ETFA)	Homo sapiens			GO:0009063~cellular amino acid catabolic process,GO:0022904~respiratory electron transport chain,GO:0033539~fatty acid beta-oxidation using acyl-CoA dehydrogenase,	GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0045251~electron transfer flavoprotein complex,	GO:0005515~protein binding,GO:0009055~electron carrier activity,GO:0016491~oxidoreductase activity,GO:0050660~flavin adenine dinucleotide binding,	IPR001308:ETF_a/FixB,IPR014729:Rossmann-like_a/b/a_fold,IPR014730:ETF_a/b_N,IPR014731:ETF_asu_C,IPR018206:ETF_asu_C_CS,IPR029035:DHS-like_NAD/FAD-binding_dom,IPR033947:ETF_alpha_N,		231680~Glutaric acidemia IIA,	PIRSF000089:Electra_flavoP_a,	SM00893:ETF,	KW-0249~Electron transport,KW-0813~Transport,	KW-0496~Mitochondrion,	KW-0225~Disease variant,KW-0316~Glutaricaciduria,	KW-0809~Transit peptide,	KW-0274~FAD,KW-0285~Flavoprotein,		KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:Electron transfer flavoprotein alpha subunit C-terminal,DOMAIN:Electron transfer flavoprotein alpha/beta-subunit N-terminal,MUTAGEN:R->A: Loss of electron transfer activity.,REGION:Disordered,REGION:Domain I,REGION:Domain II,TRANSIT:Mitochondrion,
ELP5	elongator acetyltransferase complex subunit 5(ELP5)	Homo sapiens			GO:0002098~tRNA wobble uridine modification,GO:0006400~tRNA modification,GO:0006417~regulation of translation,GO:0030335~positive regulation of cell migration,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0033588~Elongator holoenzyme complex,	GO:0000049~tRNA binding,GO:0005515~protein binding,	IPR019519:Elp5,					KW-0819~tRNA processing,	KW-0539~Nucleus,KW-0963~Cytoplasm,					KW-0597~Phosphoprotein,	REGION:Disordered,
EMB	embigin(EMB)	Homo sapiens			GO:0007155~cell adhesion,GO:0007156~homophilic cell adhesion via plasma membrane adhesion molecules,GO:0007411~axon guidance,GO:0035879~plasma membrane lactate transport,GO:0070593~dendrite self-avoidance,	GO:0005886~plasma membrane,GO:0030424~axon,GO:0045202~synapse,	GO:0098632~protein binding involved in cell-cell adhesion,	IPR003599:Ig_sub,IPR007110:Ig-like_dom,IPR013098:Ig_I-set,IPR013783:Ig-like_fold,IPR036179:Ig-like_dom_sf,IPR043204:Basigin-like,				SM00409:IG,		KW-0472~Membrane,KW-0770~Synapse,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like,DOMAIN:Ig-like V-type 1,DOMAIN:Ig-like V-type 2,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
EED	embryonic ectoderm development(EED)	Homo sapiens		h_prc2Pathway:The PRC2 Complex Sets Long-term Gene Silencing Through Modification of Histone Tails,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006338~chromatin remodeling,GO:0021510~spinal cord development,GO:0045892~negative regulation of transcription, DNA-templated,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005694~chromosome,GO:0005829~cytosol,GO:0016020~membrane,GO:0035098~ESC/E(Z) complex,	GO:0001222~transcription corepressor binding,GO:0003682~chromatin binding,GO:0005515~protein binding,GO:0008047~enzyme activator activity,GO:0031491~nucleosome binding,GO:0042054~histone methyltransferase activity,GO:0042802~identical protein binding,	IPR001680:WD40_rpt,IPR015943:WD40/YVTN_repeat-like_dom_sf,IPR019775:WD40_repeat_CS,IPR036322:WD40_repeat_dom_sf,	hsa03083:Polycomb repressive complex,	617561~Cohen-Gibson syndrome,		SM00320:WD40,	KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0158~Chromosome,KW-0472~Membrane,KW-0539~Nucleus,	KW-0225~Disease variant,	KW-0677~Repeat,KW-0812~Transmembrane,KW-0853~WD repeat,KW-1133~Transmembrane helix,		KW-0156~Chromatin regulator,KW-0678~Repressor,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,MUTAGEN:F->A: Abolishes binding to H3K27me3.,MUTAGEN:HRNY->AAAA: Impairs interaction with the matrix protein MA of HIV-1.,MUTAGEN:I->N: Impairs interaction with EZH2.,MUTAGEN:L->P: Impairs interaction with EZH2.,MUTAGEN:ST->AA: Impairs interaction with the matrix protein MA of HIV-1.,MUTAGEN:W->A: Abolishes binding to H3K27me3.,MUTAGEN:W->L: Abolishes binding to H3K27me3.,MUTAGEN:Y->A: Abolishes binding to H3K27me3.,REGION:Disordered,REGION:Interaction with EZH2,REGION:Required for interaction with the matrix protein MA of HIV-1,REPEAT:WD,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,REPEAT:WD 7,TRANSMEM:Helical,
EMD	emerin(EMD)	Homo sapiens			GO:0006936~muscle contraction,GO:0007517~muscle organ development,GO:0035914~skeletal muscle cell differentiation,GO:0046827~positive regulation of protein export from nucleus,GO:0048147~negative regulation of fibroblast proliferation,GO:0060828~regulation of canonical Wnt signaling pathway,GO:0071363~cellular response to growth factor stimulus,GO:0071763~nuclear membrane organization,GO:0090090~negative regulation of canonical Wnt signaling pathway,	GO:0005635~nuclear envelope,GO:0005637~nuclear inner membrane,GO:0005640~nuclear outer membrane,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005819~spindle,GO:0005829~cytosol,GO:0005874~microtubule,GO:0016020~membrane,GO:0031616~spindle pole centrosome,GO:0031965~nuclear membrane,GO:0032541~cortical endoplasmic reticulum,	GO:0003779~actin binding,GO:0005515~protein binding,GO:0045296~cadherin binding,GO:0048487~beta-tubulin binding,	IPR003887:LEM_dom,IPR011015:LEM/LEM-like_dom_sf,IPR034989:LEM_emerin,IPR035004:Emerin,	hsa05410:Hypertrophic cardiomyopathy,hsa05412:Arrhythmogenic right ventricular cardiomyopathy,hsa05414:Dilated cardiomyopathy,	310300~Emery-Dreifuss muscular dystrophy 1, X-linked,		SM00540:LEM,		KW-0472~Membrane,KW-0493~Microtubule,KW-0539~Nucleus,	KW-0122~Cardiomyopathy,KW-0225~Disease variant,KW-1067~Emery-Dreifuss muscular dystrophy,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0009~Actin-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:LEM,MUTAGEN:S->A: Abolishes phosphorylation. No effect on targeting to nuclear envelope nor on interaction with LMNA.,MUTAGEN:S->A: No loss of binding to F-actin; when associated with A-196.,MUTAGEN:S->A: No loss of binding to F-actin; when associated with A-197.,MUTAGEN:S->E: Mimics phosphorylation. No effect on targeting to nuclear envelope nor on interaction with LMNA.,REGION:Disordered,REGION:Interaction with CTNNB1,REGION:Interaction with F-actin,TRANSMEM:Helical,
ERLEC1	endoplasmic reticulum lectin 1(ERLEC1)	Homo sapiens			GO:0030433~ubiquitin-dependent ERAD pathway,GO:0030968~endoplasmic reticulum unfolded protein response,GO:0030970~retrograde protein transport, ER to cytosol,GO:0036503~ERAD pathway,GO:1904153~negative regulation of retrograde protein transport, ER to cytosol,	GO:0005788~endoplasmic reticulum lumen,GO:0044322~endoplasmic reticulum quality control compartment,	GO:0005515~protein binding,GO:0030246~carbohydrate binding,GO:0051082~unfolded protein binding,	IPR009011:Man6P_isomerase_rcpt-bd_dom_sf,IPR012913:OS9-like_dom,IPR044865:MRH_dom,IPR045149:OS-9-like,	hsa04141:Protein processing in endoplasmic reticulum,					KW-0256~Endoplasmic reticulum,		KW-0175~Coiled coil,KW-0677~Repeat,KW-0732~Signal,	KW-0430~Lectin,		KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,DOMAIN:MRH,DOMAIN:MRH 1,DOMAIN:MRH 2,DOMAIN:Protein OS9-like,MUTAGEN:G->S: Abolishes binding to KREMEN2.,MUTAGEN:R->A: Abolishes interaction with SEL1L.,REGION:Disordered,
ERP29	endoplasmic reticulum protein 29(ERP29)	Homo sapiens			GO:0001934~positive regulation of protein phosphorylation,GO:0006457~protein folding,GO:0006886~intracellular protein transport,GO:0009306~protein secretion,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0043335~protein unfolding,GO:0043406~positive regulation of MAP kinase activity,GO:0050709~negative regulation of protein secretion,GO:1902235~regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway,	GO:0005783~endoplasmic reticulum,GO:0005788~endoplasmic reticulum lumen,GO:0005790~smooth endoplasmic reticulum,GO:0009986~cell surface,GO:0016020~membrane,GO:0030133~transport vesicle,GO:0042470~melanosome,	GO:0005515~protein binding,GO:0042803~protein homodimerization activity,GO:0051087~chaperone binding,	IPR011679:ERp29_C,IPR012883:ERp29_N,IPR016855:ERp29,IPR036249:Thioredoxin-like_sf,IPR036356:ERp29_C_sf,	hsa04141:Protein processing in endoplasmic reticulum,		PIRSF027352:ER_p29,			KW-0256~Endoplasmic reticulum,		KW-0732~Signal,			KW-0597~Phosphoprotein,	DOMAIN:ERp29 N-terminal,DOMAIN:Endoplasmic reticulum resident protein 29 C-terminal,MOTIF:Prevents secretion from ER,
ERP44	endoplasmic reticulum protein 44(ERP44)	Homo sapiens			GO:0006457~protein folding,GO:0006986~response to unfolded protein,GO:0009100~glycoprotein metabolic process,GO:0034976~response to endoplasmic reticulum stress,GO:0045454~cell redox homeostasis,	GO:0005576~extracellular region,GO:0005788~endoplasmic reticulum lumen,GO:0005789~endoplasmic reticulum membrane,GO:0005793~endoplasmic reticulum-Golgi intermediate compartment,GO:0009986~cell surface,GO:0035580~specific granule lumen,GO:0070062~extracellular exosome,	GO:0003756~protein disulfide isomerase activity,GO:0005515~protein binding,	IPR013766:Thioredoxin_domain,IPR036249:Thioredoxin-like_sf,IPR041862:ERp44_PDI_b,IPR041870:ERp44_PDI_b,					KW-0346~Stress response,	KW-0256~Endoplasmic reticulum,		KW-0732~Signal,		KW-0143~Chaperone,	KW-1015~Disulfide bond,	COMPBIAS:Polar residues,DISULFID:Interchain (with ERO1A),DOMAIN:Thioredoxin,MOTIF:Prevents secretion from ER,REGION:Disordered,REGION:Interaction with ITPR1,
ERN1	endoplasmic reticulum to nucleus signaling 1(ERN1)	Homo sapiens			GO:0001935~endothelial cell proliferation,GO:0006402~mRNA catabolic process,GO:0006468~protein phosphorylation,GO:0010468~regulation of gene expression,GO:0016241~regulation of macroautophagy,GO:0030968~endoplasmic reticulum unfolded protein response,GO:0033120~positive regulation of RNA splicing,GO:0034620~cellular response to unfolded protein,GO:0034976~response to endoplasmic reticulum stress,GO:0035924~cellular response to vascular endothelial growth factor stimulus,GO:0036289~peptidyl-serine autophosphorylation,GO:0036498~IRE1-mediated unfolded protein response,GO:0043507~positive regulation of JUN kinase activity,GO:0046777~protein autophosphorylation,GO:0051252~regulation of RNA metabolic process,GO:0070054~mRNA splicing, via endonucleolytic cleavage and ligation,GO:0070059~intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress,GO:0070301~cellular response to hydrogen peroxide,GO:0071333~cellular response to glucose stimulus,GO:1900103~positive regulation of endoplasmic reticulum unfolded protein response,GO:1901142~insulin metabolic process,GO:1904707~positive regulation of vascular smooth muscle cell proliferation,GO:1990579~peptidyl-serine trans-autophosphorylation,	GO:0005637~nuclear inner membrane,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:1990332~Ire1 complex,GO:1990597~AIP1-IRE1 complex,GO:1990604~IRE1-TRAF2-ASK1 complex,GO:1990630~IRE1-RACK1-PP2A complex,	GO:0000287~magnesium ion binding,GO:0004521~endoribonuclease activity,GO:0004674~protein serine/threonine kinase activity,GO:0005161~platelet-derived growth factor receptor binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0019899~enzyme binding,GO:0030544~Hsp70 protein binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0043531~ADP binding,GO:0051082~unfolded protein binding,GO:0051879~Hsp90 protein binding,	IPR000719:Prot_kinase_dom,IPR008271:Ser/Thr_kinase_AS,IPR010513:KEN_dom,IPR011009:Kinase-like_dom_sf,IPR011047:Quinoprotein_ADH-like_supfam,IPR015943:WD40/YVTN_repeat-like_dom_sf,IPR018391:PQQ_beta_propeller_repeat,IPR038357:KEN_sf,IPR045133:IRE1/2-like,	hsa04140:Autophagy - animal,hsa04141:Protein processing in endoplasmic reticulum,hsa04210:Apoptosis,hsa04932:Non-alcoholic fatty liver disease,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05017:Spinocerebellar ataxia,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05417:Lipid and atherosclerosis,			SM00220:S_TKc,SM00564:PQQ,SM00580:PUG,	KW-0053~Apoptosis,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0834~Unfolded protein response,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,KW-0418~Kinase,KW-0511~Multifunctional enzyme,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0013~ADP-ribosylation,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	ACT_SITE:Proton acceptor,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:KEN,DOMAIN:Protein kinase,MUTAGEN:C->S: No effect on dimerization. No effect on interaction with P4HB; when associated with S-148 and S-332.,MUTAGEN:C->S: No effect on dimerization. Weakens dimer; when associated with S-148. No effect on interaction with P4HB; when associated with S-109 and S-148.,MUTAGEN:C->S: No effect on dimerization. Weakens dimer; when associated with S-332. Abolishes interaction with PDIA6. Prolonged splicing of XBP1, probably due to prolonged activation of PDIA6. Inhibits formation of oxidized multimeric forms of ERN1 in response to ER stress. No effect on interaction with P4HB; when associated with S-109 and S-332.,MUTAGEN:D->P: Abolishes ability to homodimerize.,MUTAGEN:K->A: Loss of autophosphorylation and of endoribonuclease activity. Inhibition of growth arrest.,MUTAGEN:Q->E: Impaired ability to homodimerize.,MUTAGEN:W->A: Abolishes ability to homodimerize.,REGION:Disordered,REGION:Interacts with hydroxy-aryl-aldehyde inhibitors,SITE:Interacts with hydroxy-aryl-aldehyde inhibitors,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
ELMO1	engulfment and cell motility 1(ELMO1)	Homo sapiens			GO:0006909~phagocytosis,GO:0006911~phagocytosis, engulfment,GO:0006915~apoptotic process,GO:0007015~actin filament organization,GO:0016601~Rac protein signal transduction,GO:0030029~actin filament-based process,GO:0030036~actin cytoskeleton organization,GO:0048870~cell motility,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0032045~guanyl-nucleotide exchange factor complex,	GO:0005085~guanyl-nucleotide exchange factor activity,GO:0005515~protein binding,GO:0017124~SH3 domain binding,	IPR001849:PH_domain,IPR006816:ELMO_dom,IPR011989:ARM-like,IPR011993:PH-like_dom_sf,IPR016024:ARM-type_fold,IPR024574:ELMO_ARM,	hsa04062:Chemokine signaling pathway,hsa04148:Efferocytosis,hsa05100:Bacterial invasion of epithelial cells,hsa05131:Shigellosis,hsa05132:Salmonella infection,hsa05135:Yersinia infection,				KW-0053~Apoptosis,KW-0581~Phagocytosis,	KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0729~SH3-binding,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:ELMO,DOMAIN:ELMO armadillo-like helical,DOMAIN:PH,MOTIF:SH3-binding,
ECHS1	enoyl-CoA hydratase, short chain 1(ECHS1)	Homo sapiens			GO:0006635~fatty acid beta-oxidation,GO:0009083~branched-chain amino acid catabolic process,	GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,	GO:0003824~catalytic activity,GO:0004165~dodecenoyl-CoA delta-isomerase activity,GO:0004300~enoyl-CoA hydratase activity,GO:0005515~protein binding,GO:0043956~3-hydroxypropionyl-CoA dehydratase activity,	IPR001753:Enoyl-CoA_hydra/iso,IPR014748:Enoyl-CoA_hydra_C,IPR018376:Enoyl-CoA_hyd/isom_CS,IPR029045:ClpP/crotonase-like_dom_sf,	hsa00062:Fatty acid elongation,hsa00071:Fatty acid degradation,hsa00280:Valine, leucine and isoleucine degradation,hsa00310:Lysine degradation,hsa00380:Tryptophan metabolism,hsa00410:beta-Alanine metabolism,hsa00640:Propanoate metabolism,hsa00650:Butanoate metabolism,hsa01100:Metabolic pathways,hsa01200:Carbon metabolism,hsa01212:Fatty acid metabolism,	616277~Mitochondrial short-chain enoyl-CoA hydratase 1 deficiency,			KW-0276~Fatty acid metabolism,KW-0443~Lipid metabolism,	KW-0496~Mitochondrion,	KW-0225~Disease variant,KW-0523~Neurodegeneration,	KW-0809~Transit peptide,		KW-0413~Isomerase,KW-0456~Lyase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	SITE:Important for catalytic activity,TRANSIT:Mitochondrion,
EPS15	epidermal growth factor receptor pathway substrate 15(EPS15)	Homo sapiens		h_ndkDynaminPathway:Endocytotic role of NDK, Phosphins and Dynamin,	GO:0001921~positive regulation of receptor recycling,GO:0006895~Golgi to endosome transport,GO:0006897~endocytosis,GO:0015031~protein transport,GO:0016050~vesicle organization,GO:0016197~endosomal transport,GO:0019065~receptor-mediated endocytosis of virus by host cell,GO:0032456~endocytic recycling,GO:0042127~regulation of cell proliferation,GO:0046718~viral entry into host cell,GO:0048268~clathrin coat assembly,GO:0098884~postsynaptic neurotransmitter receptor internalization,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005905~clathrin-coated pit,GO:0009925~basal plasma membrane,GO:0016020~membrane,GO:0016235~aggresome,GO:0016324~apical plasma membrane,GO:0030132~clathrin coat of coated pit,GO:0031901~early endosome membrane,GO:0043231~intracellular membrane-bounded organelle,GO:0098794~postsynapse,GO:0098978~glutamatergic synapse,	GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0017124~SH3 domain binding,GO:0031593~polyubiquitin binding,GO:0045296~cadherin binding,	IPR000261:EH_dom,IPR002048:EF_hand_dom,IPR003903:UIM_dom,IPR011992:EF-hand-dom_pair,IPR018247:EF_Hand_1_Ca_BS,	hsa04144:Endocytosis,			SM00027:EH,SM00054:EFh,SM00726:UIM,	KW-0254~Endocytosis,KW-0653~Protein transport,KW-0813~Transport,KW-0945~Host-virus interaction,	KW-0168~Coated pit,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0967~Endosome,KW-1003~Cell membrane,	KW-0656~Proto-oncogene,	KW-0175~Coiled coil,KW-0677~Repeat,KW-0729~SH3-binding,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0675~Receptor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:EF-hand,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,DOMAIN:EF-hand 3,DOMAIN:EF-hand 4,DOMAIN:EH,DOMAIN:EH 1,DOMAIN:EH 2,DOMAIN:EH 3,DOMAIN:UIM 1,DOMAIN:UIM 2,MOTIF:SH3-binding,MUTAGEN:V->E: Loss of interaction with STON2 NPF motifs.,MUTAGEN:W->A: Loss of interaction with STON2 NPF motifs.,REGION:15 X 3 AA repeats of D-P-F,REGION:Disordered,REGION:Interaction with DAB2,REPEAT:1,REPEAT:10,REPEAT:11,REPEAT:12,REPEAT:13,REPEAT:14,REPEAT:15,REPEAT:2,REPEAT:3,REPEAT:4,REPEAT:5,REPEAT:6,REPEAT:7,REPEAT:8,REPEAT:9,
EPN1	epsin 1(EPN1)	Homo sapiens		h_ndkDynaminPathway:Endocytotic role of NDK, Phosphins and Dynamin,	GO:0001701~in utero embryonic development,GO:0006897~endocytosis,GO:0007219~Notch signaling pathway,GO:0007565~female pregnancy,GO:0048568~embryonic organ development,GO:1903671~negative regulation of sprouting angiogenesis,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005768~endosome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005905~clathrin-coated pit,GO:0030125~clathrin vesicle coat,	GO:0005515~protein binding,GO:0005543~phospholipid binding,GO:0008289~lipid binding,GO:0030276~clathrin binding,	IPR003903:UIM_dom,IPR008942:ENTH_VHS,IPR013809:ENTH,	hsa04144:Endocytosis,			SM00273:ENTH,SM00726:UIM,	KW-0254~Endocytosis,	KW-0168~Coated pit,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0677~Repeat,	KW-0446~Lipid-binding,		KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Pro residues,DOMAIN:ENTH,DOMAIN:UIM 1,DOMAIN:UIM 2,DOMAIN:UIM 3,MOTIF:[DE]-X(1,2)-F-X-X-[FL]-X-X-X-R motif,MUTAGEN:F->A: Reduces interaction with AP2B1.,MUTAGEN:S->A: Abolishes phosphorylation by CDK1.,MUTAGEN:S->D: Abolishes phosphorylation by CDK1 and reduces REPS2 binding.,REGION:3 X 3 AA repeats of N-P-F,REGION:8 X 3 AA repeats of [ED]-P-W,REGION:Disordered,REPEAT:1,REPEAT:2,REPEAT:3,REPEAT:4,REPEAT:5,REPEAT:6,REPEAT:7,REPEAT:8,
EPB41	erythrocyte membrane protein band 4.1(EPB41)	Homo sapiens		h_PDZsPathway:Synaptic Proteins at the Synaptic Junction,	GO:0007049~cell cycle,GO:0030036~actin cytoskeleton organization,GO:0030866~cortical actin cytoskeleton organization,GO:0031032~actomyosin structure organization,GO:0032092~positive regulation of protein binding,GO:0051301~cell division,GO:0051924~regulation of calcium ion transport,GO:0065003~macromolecular complex assembly,GO:1904478~regulation of intestinal absorption,GO:1904778~positive regulation of protein localization to cell cortex,	GO:0005634~nucleus,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0005938~cell cortex,GO:0009898~cytoplasmic side of plasma membrane,GO:0014731~spectrin-associated cytoskeleton,GO:0016020~membrane,GO:0016323~basolateral plasma membrane,GO:0016604~nuclear body,GO:0030054~cell junction,GO:0030863~cortical cytoskeleton,GO:0032991~macromolecular complex,GO:0045171~intercellular bridge,GO:0072686~mitotic spindle,	GO:0003779~actin binding,GO:0005198~structural molecule activity,GO:0005200~structural constituent of cytoskeleton,GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0005545~1-phosphatidylinositol binding,GO:0008092~cytoskeletal protein binding,GO:0030507~spectrin binding,GO:0051219~phosphoprotein binding,	IPR000299:FERM_domain,IPR000798:Ez/rad/moesin-like,IPR007477:SAB_dom,IPR008379:Band_4.1_C,IPR011993:PH-like_dom_sf,IPR014352:FERM/acyl-CoA-bd_prot_sf,IPR014847:FA,IPR018979:FERM_N,IPR018980:FERM_PH-like_C,IPR019747:FERM_CS,IPR019748:FERM_central,IPR019749:Band_41_domain,IPR021187:EPB4.1_FERM_F1,IPR029071:Ubiquitin-like_domsf,IPR035963:FERM_2,		611804~Elliptocytosis-1,	PIRSF002304:Membrane_skeletal_4_1,	SM00295:B41,SM01195:FA,SM01196:FERM_C,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,KW-0813~Transport,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0250~Elliptocytosis,KW-0360~Hereditary hemolytic anemia,KW-0668~Pyropoikilocytosis,	KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0009~Actin-binding,KW-0112~Calmodulin-binding,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:FERM,DOMAIN:SAB,MUTAGEN:S->A: Loss of CDK1-mediated phosphorylation. Abolishes targeting onto the mitotic spindle; when associated with A-60.,MUTAGEN:T->A: Loss of CDK1-mediated phosphorylation. Abolishes targeting onto the mitotic spindle; when associated with A-712.,REGION:C-terminal (CTD),REGION:Disordered,REGION:Hydrophilic,REGION:Spectrin--actin-binding,TRANSMEM:Helical,
ESCO1	establishment of sister chromatid cohesion N-acetyltransferase 1(ESCO1)	Homo sapiens			GO:0006275~regulation of DNA replication,GO:0007062~sister chromatid cohesion,GO:0007064~mitotic sister chromatid cohesion,GO:0018394~peptidyl-lysine acetylation,GO:0034421~post-translational protein acetylation,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005694~chromosome,	GO:0008080~N-acetyltransferase activity,GO:0008270~zinc ion binding,GO:0016407~acetyltransferase activity,GO:0042802~identical protein binding,GO:0061733~peptide-lysine-N-acetyltransferase activity,	IPR028005:AcTrfase_ESCO_Znf_dom,IPR028009:ESCO_Acetyltransf_dom,	hsa04110:Cell cycle,				KW-0131~Cell cycle,	KW-0158~Chromosome,KW-0539~Nucleus,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0012~Acyltransferase,KW-0808~Transferase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:N-acetyltransferase ESCO acetyl-transferase,MUTAGEN:C->G: No effect on association with chromosomes.,MUTAGEN:D->N: Strongly decreased enzyme activity.,MUTAGEN:E->A: Reduced autoacetylation.,MUTAGEN:E->A: Strongly decreased enzyme activity.,MUTAGEN:F->A: Strongly decreased enzyme activity.,MUTAGEN:G->D: Loss of autoacetylation.,MUTAGEN:G->R: Strongly decreased enzyme activity. No effect on thermal stability.,MUTAGEN:K->A: Strongly reduced autoacetylation.,MUTAGEN:KI->EV: Significant reduction in autoacetylation.,MUTAGEN:Q->A: Strongly decreased enzyme activity.,MUTAGEN:R->A: Nearly abolishes autoacetylation.,MUTAGEN:R->A: Strongly decreased enzyme activity.,MUTAGEN:R->C: Decreased thermal stability. Strongly decreased enzyme activity.,MUTAGEN:RR->GG: Significant reduction in autoacetylation.,MUTAGEN:S->A: Strongly decreased enzyme activity.,MUTAGEN:W->A: Strongly decreased enzyme activity.,MUTAGEN:W->G: Decreased thermal stability.Strongly decreased enzyme activity.,REGION:Disordered,ZN_FING:CCHH-type,
ETNK1	ethanolamine kinase 1(ETNK1)	Homo sapiens			GO:0006646~phosphatidylethanolamine biosynthetic process,GO:0016310~phosphorylation,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016020~membrane,	GO:0004305~ethanolamine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016301~kinase activity,	IPR011009:Kinase-like_dom_sf,	hsa00564:Glycerophospholipid metabolism,hsa01100:Metabolic pathways,				KW-0443~Lipid metabolism,KW-0444~Lipid biosynthesis,KW-0594~Phospholipid biosynthesis,KW-1208~Phospholipid metabolism,	KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0808~Transferase,		REGION:Disordered,
EEF1A1	eukaryotic translation elongation factor 1 alpha 1(EEF1A1)	Homo sapiens		h_WNVpathway:West Nile Virus,	GO:0006412~translation,GO:0006414~translational elongation,GO:0044829~positive regulation by host of viral genome replication,GO:0071364~cellular response to epidermal growth factor stimulus,GO:1900022~regulation of D-erythro-sphingosine kinase activity,GO:1904714~regulation of chaperone-mediated autophagy,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005840~ribosome,GO:0005853~eukaryotic translation elongation factor 1 complex,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0022626~cytosolic ribosome,GO:0030864~cortical actin cytoskeleton,GO:0032587~ruffle membrane,GO:0034774~secretory granule lumen,GO:0070062~extracellular exosome,GO:0098574~cytoplasmic side of lysosomal membrane,GO:1904813~ficolin-1-rich granule lumen,	GO:0000049~tRNA binding,GO:0003723~RNA binding,GO:0003746~translation elongation factor activity,GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0019900~kinase binding,GO:0019901~protein kinase binding,GO:0060090~binding, bridging,	IPR000795:T_Tr_GTP-bd_dom,IPR004160:Transl_elong_EFTu/EF1A_C,IPR004161:EFTu-like_2,IPR004539:Transl_elong_EF1A_euk/arc,IPR009000:Transl_B-barrel_sf,IPR009001:Transl_elong_EF1A/Init_IF2_C,IPR027417:P-loop_NTPase,IPR031157:G_TR_CS,	hsa03013:Nucleocytoplasmic transport,hsa05134:Legionellosis,hsa05140:Leishmaniasis,				KW-0648~Protein biosynthesis,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,			KW-0342~GTP-binding,KW-0547~Nucleotide-binding,	KW-0251~Elongation factor,KW-0378~Hydrolase,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:Tr-type G,DOMAIN:Translation elongation factor EFTu-like,DOMAIN:Translation elongation factor EFTu/EF1A C-terminal,DOMAIN:tr-type G,MUTAGEN:A->V: Resistant to inhibition by plitidepsin and ternatin-4. No effect on SARS-CoV-2 proteins translation.,MUTAGEN:K->A: Abolishes methylation by EEF1AKMT3.,MUTAGEN:K->R: Abolishes methylation by EEF1AKMT2.,MUTAGEN:K->R: Impaired ubiquitination in response to ribosome stalling caused by ternatin-4.,MUTAGEN:K->R: No effect on methylation by EEF1AKMT2.,MUTAGEN:K->R: No effect on methylation by EEF1AKMT2. Abolishes EEF1AKMT4-mediated methylation.,MUTAGEN:K->R: No effect on methylation by EEF1AKMT2. Abolishes methylation by METTL13.,MUTAGEN:T->A: Abolishes phosphorylation by PASK.,REGION:Disordered,REGION:G1,REGION:G2,REGION:G3,REGION:G4,REGION:G5,
EEF1B2	eukaryotic translation elongation factor 1 beta 2(EEF1B2)	Homo sapiens			GO:0006414~translational elongation,	GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0005853~eukaryotic translation elongation factor 1 complex,	GO:0003746~translation elongation factor activity,GO:0005085~guanyl-nucleotide exchange factor activity,GO:0005515~protein binding,	IPR001326:Transl_elong_EF1B_B/D_CS,IPR014038:EF1B_bsu/dsu_GNE,IPR014717:Transl_elong_EF1B/ribsomal_bS6,IPR018940:EF-1_beta_acid_region_euk,IPR036219:eEF-1beta-like_sf,IPR036282:Glutathione-S-Trfase_C_sf,				SM00888:EF1_GNE,SM01182:EF-1_beta_acid,	KW-0648~Protein biosynthesis,			KW-0175~Coiled coil,		KW-0251~Elongation factor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Elongation factor 1 beta central acidic region eukaryote,DOMAIN:GST C-terminal,DOMAIN:Translation elongation factor EF1B beta/delta subunit guanine nucleotide exchange,REGION:Disordered,
EEF1D	eukaryotic translation elongation factor 1 delta(EEF1D)	Homo sapiens			GO:0002182~cytoplasmic translational elongation,GO:0006414~translational elongation,GO:0034605~cellular response to heat,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0071479~cellular response to ionizing radiation,	GO:0001650~fibrillar center,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0005853~eukaryotic translation elongation factor 1 complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0003677~DNA binding,GO:0003746~translation elongation factor activity,GO:0005085~guanyl-nucleotide exchange factor activity,GO:0005515~protein binding,GO:0008135~translation factor activity, RNA binding,GO:0031072~heat shock protein binding,GO:0045296~cadherin binding,	IPR001326:Transl_elong_EF1B_B/D_CS,IPR014038:EF1B_bsu/dsu_GNE,IPR014717:Transl_elong_EF1B/ribsomal_bS6,IPR018940:EF-1_beta_acid_region_euk,IPR036219:eEF-1beta-like_sf,				SM00888:EF1_GNE,SM01182:EF-1_beta_acid,	KW-0648~Protein biosynthesis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0175~Coiled coil,		KW-0238~DNA-binding,KW-0251~Elongation factor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,DOMAIN:Elongation factor 1 beta central acidic region eukaryote,DOMAIN:Translation elongation factor EF1B beta/delta subunit guanine nucleotide exchange,REGION:Catalytic (GEF),REGION:Disordered,REGION:Leucine-zipper,
EEF1G	eukaryotic translation elongation factor 1 gamma(EEF1G)	Homo sapiens			GO:0006414~translational elongation,GO:0009615~response to virus,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0016020~membrane,GO:0070062~extracellular exosome,	GO:0003746~translation elongation factor activity,GO:0005515~protein binding,GO:0045296~cadherin binding,	IPR001662:EF1B_G_C,IPR004045:Glutathione_S-Trfase_N,IPR004046:GST_C,IPR010987:Glutathione-S-Trfase_C-like,IPR036249:Thioredoxin-like_sf,IPR036282:Glutathione-S-Trfase_C_sf,IPR036433:EF1B_G_C_sf,IPR040079:Glutathione_S-Trfase,	hsa05134:Legionellosis,			SM01183:EF1G,	KW-0648~Protein biosynthesis,					KW-0251~Elongation factor,	KW-0007~Acetylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:EF-1-gamma C-terminal,DOMAIN:GST C-terminal,DOMAIN:GST N-terminal,REGION:Disordered,
EEF2	eukaryotic translation elongation factor 2(EEF2)	Homo sapiens	104.Insulin_signaling,	h_eifPathway:Eukaryotic protein translation,	GO:0002244~hematopoietic progenitor cell differentiation,GO:0006414~translational elongation,GO:0010467~gene expression,GO:0045727~positive regulation of translation,	GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005840~ribosome,GO:0005844~polysome,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016235~aggresome,GO:0034774~secretory granule lumen,GO:0045202~synapse,GO:0070062~extracellular exosome,GO:1904813~ficolin-1-rich granule lumen,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003746~translation elongation factor activity,GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0019901~protein kinase binding,GO:0043022~ribosome binding,GO:0045296~cadherin binding,	IPR000640:EFG_V-like,IPR000795:T_Tr_GTP-bd_dom,IPR004161:EFTu-like_2,IPR005225:Small_GTP-bd_dom,IPR005517:Transl_elong_EFG/EF2_IV,IPR009000:Transl_B-barrel_sf,IPR014721:Ribsml_uS5_D2-typ_fold_subgr,IPR020568:Ribosomal_Su5_D2-typ_SF,IPR027417:P-loop_NTPase,IPR031157:G_TR_CS,IPR035647:EFG_III/V,IPR041095:EFG_II,	hsa04152:AMPK signaling pathway,hsa04921:Oxytocin signaling pathway,	609306~Spinocerebellar ataxia 26,		SM00838:EFG_C,SM00889:EFG_IV,	KW-0648~Protein biosynthesis,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0950~Spinocerebellar ataxia,		KW-0342~GTP-binding,KW-0547~Nucleotide-binding,	KW-0251~Elongation factor,KW-0378~Hydrolase,	KW-0007~Acetylation,KW-0013~ADP-ribosylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,DOMAIN:Tr-type G,DOMAIN:tr-type G,MUTAGEN:H->L,M,N,Q: Confers resistance to diphtheria toxin.,MUTAGEN:H->P: Strongly reduced phosphorylation at Thr-57.,MUTAGEN:S->A: Strongly reduced phosphorylation at Thr-57.,SITE:Cleavage,
EIF1B	eukaryotic translation initiation factor 1B(EIF1B)	Homo sapiens			GO:0006413~translational initiation,GO:0006446~regulation of translational initiation,	GO:0016282~eukaryotic 43S preinitiation complex,	GO:0003723~RNA binding,GO:0003743~translation initiation factor activity,GO:0005515~protein binding,GO:0043024~ribosomal small subunit binding,	IPR001950:SUI1,IPR005874:SUI1_euk,IPR036877:SUI1_dom_sf,			PIRSF004499:SUI1_euk,		KW-0648~Protein biosynthesis,					KW-0396~Initiation factor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:SUI1,
EIF2S2	eukaryotic translation initiation factor 2 subunit beta(EIF2S2)	Homo sapiens		h_eif2Pathway:Regulation of eIF2,h_eifPathway:Eukaryotic protein translation,h_igf1mtorPathway:Skeletal muscle hypertrophy is regulated via AKT/mTOR pathway,h_rnaPathway:Double Stranded RNA Induced Gene Expression,h_vegfPathway:VEGF, Hypoxia, and Angiogenesis,	GO:0001701~in utero embryonic development,GO:0001731~formation of translation preinitiation complex,GO:0001732~formation of cytoplasmic translation initiation complex,GO:0002176~male germ cell proliferation,GO:0002183~cytoplasmic translational initiation,GO:0006413~translational initiation,GO:0008584~male gonad development,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005850~eukaryotic translation initiation factor 2 complex,GO:0045202~synapse,	GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0003743~translation initiation factor activity,GO:0005515~protein binding,GO:0008135~translation factor activity, RNA binding,GO:0031369~translation initiation factor binding,GO:0046872~metal ion binding,	IPR002735:Transl_init_fac_IF2/IF5_dom,IPR016189:Transl_init_fac_IF2/IF5_N,IPR016190:Transl_init_fac_IF2/IF5_Zn-bd,IPR045196:IF2/IF5,				SM00653:eIF2B_5,	KW-0648~Protein biosynthesis,KW-0945~Host-virus interaction,	KW-0963~Cytoplasm,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0396~Initiation factor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Translation initiation factor IF2/IF5,REGION:Disordered,ZN_FING:C4-type,
EIF3A	eukaryotic translation initiation factor 3 subunit A(EIF3A)	Homo sapiens		h_eifPathway:Eukaryotic protein translation,h_iresPathway:Internal Ribosome entry pathway,h_mtorPathway:mTOR Signaling Pathway,	GO:0001732~formation of cytoplasmic translation initiation complex,GO:0002188~translation reinitiation,GO:0006413~translational initiation,GO:0075522~IRES-dependent viral translational initiation,GO:0075525~viral translational termination-reinitiation,	GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005852~eukaryotic translation initiation factor 3 complex,GO:0014069~postsynaptic density,GO:0016020~membrane,GO:0016282~eukaryotic 43S preinitiation complex,GO:0033290~eukaryotic 48S preinitiation complex,GO:0043614~multi-eIF complex,GO:0071540~eukaryotic translation initiation factor 3 complex, eIF3e,GO:0071541~eukaryotic translation initiation factor 3 complex, eIF3m,	GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0003743~translation initiation factor activity,GO:0005198~structural molecule activity,GO:0005515~protein binding,	IPR000717:PCI_dom,IPR027512:EIF3A,				SM00088:PINT,	KW-0648~Protein biosynthesis,KW-0945~Host-virus interaction,	KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0677~Repeat,		KW-0396~Initiation factor,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:PCI,REGION:25 X 10 AA approximate tandem repeats of [DE]-[DE]-[DE]-R-[SEVGFPILV]-[HPSN]-[RSW]-[RL]-[DRGTIHN]-[EPMANLGDT],REGION:Disordered,REGION:Interaction with EIF3B,REPEAT:1,REPEAT:10,REPEAT:11,REPEAT:12,REPEAT:13,REPEAT:14,REPEAT:15,REPEAT:16,REPEAT:17,REPEAT:18,REPEAT:19,REPEAT:20,REPEAT:21,REPEAT:22,REPEAT:23; truncated,REPEAT:24,REPEAT:25; approximate,REPEAT:2; truncated,REPEAT:3,REPEAT:4,REPEAT:5,REPEAT:6,REPEAT:7,REPEAT:8,REPEAT:9,
EIF3D	eukaryotic translation initiation factor 3 subunit D(EIF3D)	Homo sapiens			GO:0001732~formation of cytoplasmic translation initiation complex,GO:0002191~cap-dependent translational initiation,GO:0006413~translational initiation,GO:0045727~positive regulation of translation,GO:0075522~IRES-dependent viral translational initiation,GO:0075525~viral translational termination-reinitiation,GO:1902416~positive regulation of mRNA binding,	GO:0005829~cytosol,GO:0005852~eukaryotic translation initiation factor 3 complex,GO:0016020~membrane,GO:0016282~eukaryotic 43S preinitiation complex,GO:0033290~eukaryotic 48S preinitiation complex,GO:0045202~synapse,GO:0071541~eukaryotic translation initiation factor 3 complex, eIF3m,	GO:0003723~RNA binding,GO:0003743~translation initiation factor activity,GO:0005515~protein binding,GO:0098808~mRNA cap binding,	IPR007783:eIF3d,			PIRSF016281:EIF-3_zeta,		KW-0648~Protein biosynthesis,KW-0945~Host-virus interaction,	KW-0963~Cytoplasm,				KW-0396~Initiation factor,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,MUTAGEN:D->Q: Reduced binding to JUN mRNA; when associated with 262-I-A-263.,MUTAGEN:TYINH->EYENA: Reduced binding to JUN mRNA.,MUTAGEN:VY->IA: Reduced binding to JUN mRNA; when associated with Q-249.,REGION:Disordered,REGION:RNA gate,
EIF3E	eukaryotic translation initiation factor 3 subunit E(EIF3E)	Homo sapiens			GO:0000184~nuclear-transcribed mRNA catabolic process, nonsense-mediated decay,GO:0001732~formation of cytoplasmic translation initiation complex,GO:0006413~translational initiation,GO:0006446~regulation of translational initiation,GO:0045727~positive regulation of translation,GO:0045947~negative regulation of translational initiation,GO:1902416~positive regulation of mRNA binding,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005852~eukaryotic translation initiation factor 3 complex,GO:0014069~postsynaptic density,GO:0016020~membrane,GO:0016282~eukaryotic 43S preinitiation complex,GO:0016605~PML body,GO:0033290~eukaryotic 48S preinitiation complex,GO:0070062~extracellular exosome,GO:0071540~eukaryotic translation initiation factor 3 complex, eIF3e,	GO:0003723~RNA binding,GO:0003743~translation initiation factor activity,GO:0005515~protein binding,GO:0045296~cadherin binding,	IPR000717:PCI_dom,IPR016650:eIF3e,IPR019010:eIF3e_N,IPR036390:WH_DNA-bd_sf,	hsa05160:Hepatitis C,		PIRSF016255:eIF3e_su6,	SM00088:PINT,SM01186:eIF3_N,	KW-0648~Protein biosynthesis,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0396~Initiation factor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:Eukaryotic translation initiation factor 3 subunit E N-terminal,DOMAIN:PCI,MUTAGEN:L->D: Promotes nuclear accumulation.,REGION:Disordered,REGION:Sufficient for interaction with EPAS1,REGION:Sufficient for interaction with MCM7,REGION:Sufficient for interaction with TRIM27,TRANSMEM:Helical,
EIF3F	eukaryotic translation initiation factor 3 subunit F(EIF3F)	Homo sapiens			GO:0001732~formation of cytoplasmic translation initiation complex,GO:0006413~translational initiation,GO:0006508~proteolysis,GO:0016579~protein deubiquitination,GO:0075522~IRES-dependent viral translational initiation,	GO:0005829~cytosol,GO:0005852~eukaryotic translation initiation factor 3 complex,GO:0016020~membrane,GO:0016282~eukaryotic 43S preinitiation complex,GO:0033290~eukaryotic 48S preinitiation complex,GO:0045202~synapse,GO:0071541~eukaryotic translation initiation factor 3 complex, eIF3m,	GO:0003743~translation initiation factor activity,GO:0004843~thiol-dependent ubiquitin-specific protease activity,GO:0005515~protein binding,GO:0008237~metallopeptidase activity,GO:0031369~translation initiation factor binding,GO:0042802~identical protein binding,	IPR000555:JAMM/MPN+_dom,IPR024969:EIF3F/CSN6-like_C,IPR027531:eIF3f,IPR037518:MPN,		618295~Intellectual developmental disorder, autosomal recessive 67,		SM00232:JAB_MPN,	KW-0648~Protein biosynthesis,KW-0833~Ubl conjugation pathway,	KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0991~Intellectual disability,			KW-0378~Hydrolase,KW-0396~Initiation factor,KW-0645~Protease,KW-0788~Thiol protease,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Pro residues,DOMAIN:JAB1/MPN/MOV34 metalloenzyme,DOMAIN:MPN,REGION:Disordered,
EIF3G	eukaryotic translation initiation factor 3 subunit G(EIF3G)	Homo sapiens			GO:0001732~formation of cytoplasmic translation initiation complex,GO:0006413~translational initiation,GO:0075525~viral translational termination-reinitiation,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005852~eukaryotic translation initiation factor 3 complex,GO:0016282~eukaryotic 43S preinitiation complex,GO:0033290~eukaryotic 48S preinitiation complex,GO:0048471~perinuclear region of cytoplasm,	GO:0003723~RNA binding,GO:0003743~translation initiation factor activity,GO:0005515~protein binding,	IPR000504:RRM_dom,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR017334:eIF3_g,IPR024675:eIF3g_N,IPR034240:eIF3G_RRM,IPR035979:RBD_domain_sf,			PIRSF037949:Transl_init_eIF-3_RNA-bind,	SM00360:RRM,	KW-0648~Protein biosynthesis,	KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0396~Initiation factor,KW-0694~RNA-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:Eukaryotic translation initiation factor 3 subunit G N-terminal,DOMAIN:RRM,REGION:Disordered,
EIF3H	eukaryotic translation initiation factor 3 subunit H(EIF3H)	Homo sapiens			GO:0001732~formation of cytoplasmic translation initiation complex,GO:0006413~translational initiation,GO:0006446~regulation of translational initiation,GO:0032435~negative regulation of proteasomal ubiquitin-dependent protein catabolic process,	GO:0005829~cytosol,GO:0005852~eukaryotic translation initiation factor 3 complex,GO:0016020~membrane,GO:0016282~eukaryotic 43S preinitiation complex,GO:0033290~eukaryotic 48S preinitiation complex,GO:0042788~polysomal ribosome,GO:0070062~extracellular exosome,GO:0071541~eukaryotic translation initiation factor 3 complex, eIF3m,	GO:0003723~RNA binding,GO:0003743~translation initiation factor activity,GO:0005515~protein binding,GO:0008237~metallopeptidase activity,	IPR000555:JAMM/MPN+_dom,IPR027524:eIF3h,IPR037518:MPN,IPR045810:eIF3h_C,	hsa05162:Measles,			SM00232:JAB_MPN,	KW-0648~Protein biosynthesis,	KW-0963~Cytoplasm,				KW-0396~Initiation factor,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:JAB1/MPN/MOV34 metalloenzyme,DOMAIN:MPN,REGION:Disordered,
EIF3I	eukaryotic translation initiation factor 3 subunit I(EIF3I)	Homo sapiens			GO:0001732~formation of cytoplasmic translation initiation complex,GO:0002183~cytoplasmic translational initiation,GO:0006413~translational initiation,	GO:0005829~cytosol,GO:0005852~eukaryotic translation initiation factor 3 complex,GO:0016282~eukaryotic 43S preinitiation complex,GO:0033290~eukaryotic 48S preinitiation complex,GO:0045202~synapse,GO:0070062~extracellular exosome,GO:0071541~eukaryotic translation initiation factor 3 complex, eIF3m,	GO:0003723~RNA binding,GO:0003743~translation initiation factor activity,GO:0005515~protein binding,	IPR001680:WD40_rpt,IPR015943:WD40/YVTN_repeat-like_dom_sf,IPR019775:WD40_repeat_CS,IPR024977:Apc4-like_WD40_dom,IPR027525:eIF3i,IPR036322:WD40_repeat_dom_sf,				SM00320:WD40,	KW-0648~Protein biosynthesis,	KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0853~WD repeat,		KW-0396~Initiation factor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:Anaphase-promoting complex subunit 4-like WD40,REGION:Disordered,REPEAT:WD,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,REPEAT:WD 7,
EIF3J	eukaryotic translation initiation factor 3 subunit J(EIF3J)	Homo sapiens			GO:0001732~formation of cytoplasmic translation initiation complex,GO:0006413~translational initiation,	GO:0005829~cytosol,GO:0005852~eukaryotic translation initiation factor 3 complex,GO:0016282~eukaryotic 43S preinitiation complex,GO:0033290~eukaryotic 48S preinitiation complex,	GO:0003743~translation initiation factor activity,GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR013906:eIF3j,IPR023194:eIF3-like_dom_sf,					KW-0648~Protein biosynthesis,	KW-0963~Cytoplasm,		KW-0175~Coiled coil,		KW-0396~Initiation factor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),REGION:Disordered,REGION:Promotes stable association with the 40S ribosome,REGION:Sufficient for interaction with EIF3B,
EIF3K	eukaryotic translation initiation factor 3 subunit K(EIF3K)	Homo sapiens			GO:0001732~formation of cytoplasmic translation initiation complex,GO:0006413~translational initiation,GO:0006446~regulation of translational initiation,	GO:0005634~nucleus,GO:0005829~cytosol,GO:0005852~eukaryotic translation initiation factor 3 complex,GO:0016020~membrane,GO:0016282~eukaryotic 43S preinitiation complex,GO:0033290~eukaryotic 48S preinitiation complex,	GO:0003723~RNA binding,GO:0003743~translation initiation factor activity,GO:0005515~protein binding,GO:0043022~ribosome binding,	IPR000717:PCI_dom,IPR009374:eIF3k,IPR016020:Transl_init_fac_sub12_N_euk,IPR016024:ARM-type_fold,IPR033464:CSN8_PSD8_EIF3K,IPR036388:WH-like_DNA-bd_sf,IPR036390:WH_DNA-bd_sf,					KW-0648~Protein biosynthesis,	KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0396~Initiation factor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:PCI,
EIF3L	eukaryotic translation initiation factor 3 subunit L(EIF3L)	Homo sapiens			GO:0001732~formation of cytoplasmic translation initiation complex,GO:0006413~translational initiation,GO:0075525~viral translational termination-reinitiation,	GO:0001650~fibrillar center,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0005852~eukaryotic translation initiation factor 3 complex,GO:0016020~membrane,GO:0016282~eukaryotic 43S preinitiation complex,GO:0033290~eukaryotic 48S preinitiation complex,GO:0045202~synapse,	GO:0003723~RNA binding,GO:0003743~translation initiation factor activity,GO:0005515~protein binding,	IPR000717:PCI_dom,IPR011990:TPR-like_helical_dom_sf,IPR019382:eIF3l,					KW-0648~Protein biosynthesis,	KW-0963~Cytoplasm,				KW-0396~Initiation factor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:PCI,REGION:Disordered,
EIF3M	eukaryotic translation initiation factor 3 subunit M(EIF3M)	Homo sapiens			GO:0001732~formation of cytoplasmic translation initiation complex,GO:0002183~cytoplasmic translational initiation,GO:0006413~translational initiation,	GO:0005829~cytosol,GO:0005852~eukaryotic translation initiation factor 3 complex,GO:0016282~eukaryotic 43S preinitiation complex,GO:0032991~macromolecular complex,GO:0033290~eukaryotic 48S preinitiation complex,GO:0071541~eukaryotic translation initiation factor 3 complex, eIF3m,	GO:0003743~translation initiation factor activity,GO:0005515~protein binding,GO:0031369~translation initiation factor binding,	IPR000717:PCI_dom,IPR016024:ARM-type_fold,IPR027528:eIF3m,IPR036390:WH_DNA-bd_sf,IPR040750:eIF3m_C_helix,IPR045237:COPS7/eIF3m,				SM00088:PINT,	KW-0648~Protein biosynthesis,KW-0945~Host-virus interaction,	KW-0963~Cytoplasm,				KW-0396~Initiation factor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:PCI,MUTAGEN:L->P: Reduces HSV binding and entry.,MUTAGEN:V->P: Reduces HSV binding and entry.,REGION:Interaction with HSV-1 and HSV-2,
EIF4G1	eukaryotic translation initiation factor 4 gamma 1(EIF4G1)	Homo sapiens		h_eif4Pathway:Regulation of eIF4e and p70 S6 Kinase,h_eifPathway:Eukaryotic protein translation,h_iresPathway:Internal Ribosome entry pathway,h_mtorPathway:mTOR Signaling Pathway,	GO:0001662~behavioral fear response,GO:0002191~cap-dependent translational initiation,GO:0006412~translation,GO:0006413~translational initiation,GO:0006446~regulation of translational initiation,GO:0009059~macromolecule biosynthetic process,GO:0010507~negative regulation of autophagy,GO:0010801~negative regulation of peptidyl-threonine phosphorylation,GO:0030182~neuron differentiation,GO:0030307~positive regulation of cell growth,GO:0030324~lung development,GO:0031669~cellular response to nutrient levels,GO:0033138~positive regulation of peptidyl-serine phosphorylation,GO:0035278~miRNA mediated inhibition of translation,GO:0036493~positive regulation of translation in response to endoplasmic reticulum stress,GO:0045471~response to ethanol,GO:0045666~positive regulation of neuron differentiation,GO:0051247~positive regulation of protein metabolic process,GO:0080135~regulation of cellular response to stress,GO:0097009~energy homeostasis,GO:1900087~positive regulation of G1/S transition of mitotic cell cycle,GO:1904377~positive regulation of protein localization to cell periphery,GO:1905537~positive regulation of eukaryotic translation initiation factor 4F complex assembly,GO:1905606~regulation of presynapse assembly,GO:1905612~positive regulation of mRNA cap binding,GO:1905696~regulation of polysome binding,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005840~ribosome,GO:0005844~polysome,GO:0010494~cytoplasmic stress granule,GO:0016020~membrane,GO:0016281~eukaryotic translation initiation factor 4F complex,GO:0098794~postsynapse,	GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0003743~translation initiation factor activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008135~translation factor activity, RNA binding,GO:0008190~eukaryotic initiation factor 4E binding,GO:0031369~translation initiation factor binding,GO:0042802~identical protein binding,GO:0060090~binding, bridging,	IPR003307:W2_domain,IPR003890:MIF4G-like_typ-3,IPR003891:Initiation_fac_eIF4g_MI,IPR016024:ARM-type_fold,IPR045208:IF4G,	hsa05416:Viral myocarditis,	614251~Parkinson disease 18,		SM00515:eIF5C,SM00543:MIF4G,SM00544:MA3,	KW-0648~Protein biosynthesis,KW-0810~Translation regulation,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0907~Parkinson disease,KW-0908~Parkinsonism,			KW-0396~Initiation factor,KW-0694~RNA-binding,KW-1155~Translational shunt,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:MI,DOMAIN:MIF4G,DOMAIN:W2,MUTAGEN:DPNQ->AAAA: Loss of PABPC1 binding; when associated with 174-AAAAA-178.,MUTAGEN:F->A: Abolishes binding to EIF4A; when associated with A-767 and A-770.,MUTAGEN:F->A: Abolishes binding to EIF4A; when associated with A-973.,MUTAGEN:FE->AK: Abolishes binding to EIF4A; when associated with A-841 and A-842.,MUTAGEN:G->A,V,W,R,E: Reduced cleavage by protease 2A from human rhinovirus 2.,MUTAGEN:I->A: Abolishes binding to EIF4A; when associated with A-895 and A-95.,MUTAGEN:I->A: Loss of PABPC1 binding.,MUTAGEN:KRERK->AAAAA: Loss of PABPC1 binding; when associated with 184-AAAA-187.,MUTAGEN:L->A: Abolishes binding to EIF4A; when associated with A-767 and A-775.,MUTAGEN:L->A: Abolishes binding to EIF4A; when associated with A-770 and A-775.,MUTAGEN:L->A: Abolishes binding to EIF4A; when associated with A-895 and A-92.,MUTAGEN:L->A: Abolishes binding to EIF4A; when associated with A-92 and A-95.,MUTAGEN:L->A: Slightly reduced binding to EIF4A; when associated with A-989.,MUTAGEN:LL->AA: Abolishes binding to EIF4A; when associated with A-850 and K-851.,MUTAGEN:LL->AA: Abolishes binding to EIF4E.,MUTAGEN:R->A: Abolishes binding to EIF4A; when associated with A-976.,MUTAGEN:W->A: Slightly reduced binding to EIF4A; when associated with A-984.,MUTAGEN:Y->A,F: Abolishes binding to EIF4E.,REGION:Disordered,REGION:EIF4A-binding,REGION:EIF4E-binding,REGION:Necessary but not sufficient for MKNK1-binding,REGION:PABPC1-binding,REGION:eIF3/EIF4A-binding,SITE:Cleavage; by enterovirus/rhinovirus protease 2A,SITE:Cleavage; by foot-and-mouth disease virus leader protease,
EIF4A1	eukaryotic translation initiation factor 4A1(EIF4A1)	Homo sapiens		h_eif4Pathway:Regulation of eIF4e and p70 S6 Kinase,h_eifPathway:Eukaryotic protein translation,h_iresPathway:Internal Ribosome entry pathway,h_mtorPathway:mTOR Signaling Pathway,	GO:0002183~cytoplasmic translational initiation,GO:0006413~translational initiation,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016020~membrane,GO:0016281~eukaryotic translation initiation factor 4F complex,GO:0070062~extracellular exosome,	GO:0000339~RNA cap binding,GO:0003676~nucleic acid binding,GO:0003723~RNA binding,GO:0003724~RNA helicase activity,GO:0003725~double-stranded RNA binding,GO:0003729~mRNA binding,GO:0003743~translation initiation factor activity,GO:0004386~helicase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008135~translation factor activity, RNA binding,GO:0016787~hydrolase activity,GO:0016887~ATPase activity,	IPR000629:RNA-helicase_DEAD-box_CS,IPR001650:Helicase_C,IPR011545:DEAD/DEAH_box_helicase_dom,IPR014001:Helicase_ATP-bd,IPR014014:RNA_helicase_DEAD_Q_motif,IPR027417:P-loop_NTPase,IPR044728:EIF4A_DEADc,				SM00487:DEXDc,SM00490:HELICc,	KW-0648~Protein biosynthesis,KW-0945~Host-virus interaction,				KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0347~Helicase,KW-0378~Hydrolase,KW-0396~Initiation factor,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:DEAD-box RNA helicase Q,DOMAIN:Helicase ATP-binding,DOMAIN:Helicase C-terminal,MOTIF:DEAD box,MOTIF:Q motif,REGION:Disordered,
EIF4A2	eukaryotic translation initiation factor 4A2(EIF4A2)	Homo sapiens		h_eif4Pathway:Regulation of eIF4e and p70 S6 Kinase,h_eifPathway:Eukaryotic protein translation,h_iresPathway:Internal Ribosome entry pathway,h_mtorPathway:mTOR Signaling Pathway,	GO:0002183~cytoplasmic translational initiation,GO:0006413~translational initiation,GO:0006446~regulation of translational initiation,GO:1900260~negative regulation of RNA-directed 5'-3' RNA polymerase activity,GO:1990830~cellular response to leukemia inhibitory factor,	GO:0005829~cytosol,GO:0016281~eukaryotic translation initiation factor 4F complex,GO:0048471~perinuclear region of cytoplasm,	GO:0003723~RNA binding,GO:0003724~RNA helicase activity,GO:0003743~translation initiation factor activity,GO:0004386~helicase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016787~hydrolase activity,GO:0016887~ATPase activity,	IPR000629:RNA-helicase_DEAD-box_CS,IPR001650:Helicase_C,IPR011545:DEAD/DEAH_box_helicase_dom,IPR014001:Helicase_ATP-bd,IPR014014:RNA_helicase_DEAD_Q_motif,IPR027417:P-loop_NTPase,IPR044728:EIF4A_DEADc,		620455~Neurodevelopmental disorder with hypotonia and speech delay, with or without seizures,		SM00487:DEXDc,SM00490:HELICc,	KW-0648~Protein biosynthesis,KW-0945~Host-virus interaction,				KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0347~Helicase,KW-0378~Hydrolase,KW-0396~Initiation factor,KW-0694~RNA-binding,	KW-0597~Phosphoprotein,	DOMAIN:DEAD-box RNA helicase Q,DOMAIN:Helicase ATP-binding,DOMAIN:Helicase C-terminal,MOTIF:DEAD box,MOTIF:Q motif,REGION:Disordered,
EIF4A3	eukaryotic translation initiation factor 4A3(EIF4A3)	Homo sapiens			GO:0000184~nuclear-transcribed mRNA catabolic process, nonsense-mediated decay,GO:0000398~mRNA splicing, via spliceosome,GO:0006364~rRNA processing,GO:0006406~mRNA export from nucleus,GO:0008306~associative learning,GO:0014070~response to organic cyclic compound,GO:0017148~negative regulation of translation,GO:0035640~exploration behavior,GO:0045727~positive regulation of translation,GO:0048701~embryonic cranial skeleton morphogenesis,GO:0072715~cellular response to selenite ion,GO:0090394~negative regulation of excitatory postsynaptic potential,GO:0099578~regulation of translation at postsynapse, modulating synaptic transmission,GO:1904570~negative regulation of selenocysteine incorporation,GO:1990416~cellular response to brain-derived neurotrophic factor stimulus,GO:2000622~regulation of nuclear-transcribed mRNA catabolic process, nonsense-mediated decay,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016020~membrane,GO:0016607~nuclear speck,GO:0030425~dendrite,GO:0035145~exon-exon junction complex,GO:0043025~neuronal cell body,GO:0071006~U2-type catalytic step 1 spliceosome,GO:0071013~catalytic step 2 spliceosome,GO:0098794~postsynapse,GO:0098978~glutamatergic synapse,	GO:0003676~nucleic acid binding,GO:0003723~RNA binding,GO:0003724~RNA helicase activity,GO:0003729~mRNA binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008143~poly(A) binding,GO:0016787~hydrolase activity,GO:0016887~ATPase activity,GO:0035368~selenocysteine insertion sequence binding,GO:0035613~RNA stem-loop binding,GO:0043021~ribonucleoprotein complex binding,	IPR000629:RNA-helicase_DEAD-box_CS,IPR001650:Helicase_C,IPR011545:DEAD/DEAH_box_helicase_dom,IPR014001:Helicase_ATP-bd,IPR014014:RNA_helicase_DEAD_Q_motif,IPR027417:P-loop_NTPase,	hsa03013:Nucleocytoplasmic transport,hsa03015:mRNA surveillance pathway,hsa03040:Spliceosome,	268305~Robin sequence with cleft mandible and limb anomalies,		SM00487:DEXDc,SM00490:HELICc,	KW-0507~mRNA processing,KW-0508~mRNA splicing,KW-0509~mRNA transport,KW-0698~rRNA processing,KW-0810~Translation regulation,KW-0813~Transport,KW-0866~Nonsense-mediated mRNA decay,	KW-0539~Nucleus,KW-0747~Spliceosome,KW-0963~Cytoplasm,	KW-0225~Disease variant,		KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0347~Helicase,KW-0378~Hydrolase,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:DEAD-box RNA helicase Q,DOMAIN:Helicase ATP-binding,DOMAIN:Helicase C-terminal,MOTIF:DEAD box,MOTIF:Q motif,MUTAGEN:AN->RD: Decreased interaction with CWC22.,MUTAGEN:C->Q: No effect on interaction with CWC22.,MUTAGEN:D->K: Loss of CWC22-binding and loss of incorporation into EJCs; when associated with K-270.,MUTAGEN:D->K: Loss of CWC22-binding and loss of incorporation into EJCs; when associated with K-273.,MUTAGEN:D->K: Loss of incorporation into EJCs; when associated with R-402.,MUTAGEN:E->R: Loss of incorporation into EJCs; when associated with K-401.,MUTAGEN:K->A: ATPase activity is not increased by the presence of CASC3. Does not prevent EJC formation. Prevents the EJC disassembly.,MUTAGEN:NFT->LAG: Loss of CWC22-binding and loss of incorporation into EJCs.,MUTAGEN:T->V: Reduced incorporation into EJCs.,MUTAGEN:TI->GD: Loss of CWC22-binding and loss of incorporation into EJCs.,
EIF4B	eukaryotic translation initiation factor 4B(EIF4B)	Homo sapiens		h_mtorPathway:mTOR Signaling Pathway,	GO:0006413~translational initiation,GO:0006446~regulation of translational initiation,	GO:0005829~cytosol,GO:0016281~eukaryotic translation initiation factor 4F complex,	GO:0003723~RNA binding,GO:0003743~translation initiation factor activity,GO:0005515~protein binding,	IPR000504:RRM_dom,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR033107:EIF-4B_RRM,IPR035979:RBD_domain_sf,	hsa04150:mTOR signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa05205:Proteoglycans in cancer,			SM00360:RRM,	KW-0648~Protein biosynthesis,					KW-0396~Initiation factor,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:RRM,MUTAGEN:S->A: Non-phosphorylatable mutant whose expression results in reduced SLC4A7 protein levels in TSC2-deficient cells accompanied by decrease in the bicarbonate-dependent flux into nucleotide synthesis.,REGION:Disordered,
EIF4EBP2	eukaryotic translation initiation factor 4E binding protein 2(EIF4EBP2)	Homo sapiens			GO:0006412~translation,GO:0007613~memory,GO:0008286~insulin receptor signaling pathway,GO:0031929~TOR signaling,GO:0035176~social behavior,GO:0045947~negative regulation of translational initiation,GO:0048167~regulation of synaptic plasticity,GO:0050804~modulation of synaptic transmission,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0043232~intracellular non-membrane-bounded organelle,GO:0071598~neuronal ribonucleoprotein granule,GO:0098794~postsynapse,	GO:0003743~translation initiation factor activity,GO:0005515~protein binding,GO:0008190~eukaryotic initiation factor 4E binding,GO:0030371~translation repressor activity,	IPR008606:EIF4EBP,	hsa04213:Longevity regulating pathway - multiple species,				KW-0648~Protein biosynthesis,KW-0810~Translation regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0396~Initiation factor,KW-0652~Protein synthesis inhibitor,	KW-0597~Phosphoprotein,	MOTIF:Secondary EIF4E binding site,MOTIF:TOS motif,MOTIF:YXXXXLphi motif,MUTAGEN:G->V: Abolishes folding of the intrinsically disordered protein without affecting greatly affinity for EIF4E even when the protein is fully phosphorylated; when associated with V-39.,MUTAGEN:G->V: Abolishes folding of the intrinsically disordered protein without affecting greatly affinity for EIF4E even when the protein is fully phosphorylated; when associated with V-48.,MUTAGEN:IPGVT->AAAAA: Impaired binding to EIF4E.,MUTAGEN:T->D,E: Acidic residues do not mimic phosphorylation state. Does not induce folding of the intrinsically disordered protein; when associated with D-37 or E-37.,MUTAGEN:T->D,E: Acidic residues do not mimic phosphorylation state. Does not induce folding of the intrinsically disordered protein; when associated with D-46 or E-46.,MUTAGEN:YDRKFLL->AAAAAAA: Impaired binding to EIF4E.,REGION:Disordered,
EIF4H	eukaryotic translation initiation factor 4H(EIF4H)	Homo sapiens			GO:0006413~translational initiation,GO:0006446~regulation of translational initiation,GO:0019953~sexual reproduction,GO:0048589~developmental growth,	GO:0005829~cytosol,GO:0005844~polysome,GO:0016020~membrane,GO:0016281~eukaryotic translation initiation factor 4F complex,GO:0048471~perinuclear region of cytoplasm,	GO:0003723~RNA binding,GO:0003743~translation initiation factor activity,GO:0005515~protein binding,GO:0008135~translation factor activity, RNA binding,GO:0045296~cadherin binding,	IPR000504:RRM_dom,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR034229:eIF4H_RRM,IPR035979:RBD_domain_sf,				SM00360:RRM,	KW-0648~Protein biosynthesis,KW-0945~Host-virus interaction,	KW-0963~Cytoplasm,	KW-0856~Williams-Beuren syndrome,			KW-0396~Initiation factor,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:RRM,REGION:Disordered,REGION:HHV-1 Vhs binding site,
EIF5A	eukaryotic translation initiation factor 5A(EIF5A)	Homo sapiens			GO:0006414~translational elongation,GO:0033209~tumor necrosis factor-mediated signaling pathway,GO:0045901~positive regulation of translational elongation,GO:0045905~positive regulation of translational termination,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0098586~cellular response to virus,GO:1902255~positive regulation of intrinsic apoptotic signaling pathway by p53 class mediator,	GO:0005634~nucleus,GO:0005642~annulate lamellae,GO:0005643~nuclear pore,GO:0005737~cytoplasm,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0016020~membrane,	GO:0003723~RNA binding,GO:0003746~translation elongation factor activity,GO:0005515~protein binding,GO:0017070~U6 snRNA binding,GO:0043022~ribosome binding,	IPR001884:IF5A-like,IPR008991:Translation_prot_SH3-like_sf,IPR012340:NA-bd_OB-fold,IPR014722:Rib_uL2_dom2,IPR019769:Trans_elong_IF5A_hypusine_site,IPR020189:Transl_elong_IF5A_C,IPR048670:IF5A-like_N,		619376~Faundes-Banka syndrome,	PIRSF003025:eIF5A,	SM01376:eIF-5a,	KW-0648~Protein biosynthesis,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,			KW-0251~Elongation factor,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0385~Hypusine,	DOMAIN:Translation elongation factor IF5A C-terminal,MUTAGEN:G->A: Causes total inactivation of eIF5A in supporting yeast growth.,MUTAGEN:K->A,R: Abolishes acetylation.,MUTAGEN:K->A: Causes total inactivation of eIF5A in supporting yeast growth.,MUTAGEN:K->A: Decreases significantly the acetylation at position K-47 and causes total inactivation of eIF5A in supporting yeast growth.,MUTAGEN:K->D: Causes total inactivation of eIF5A in supporting yeast growth.,MUTAGEN:K->I,D,R: Causes total inactivation of eIF5A in supporting yeast growth.,MUTAGEN:V->G: Leads to temperature sensitivity when expressed in yeast cells.,REGION:Interaction with DOHH,
EXOSC3	exosome component 3(EXOSC3)	Homo sapiens			GO:0000467~exonucleolytic trimming to generate mature 3'-end of 5.8S rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA),GO:0006364~rRNA processing,GO:0006396~RNA processing,GO:0006401~RNA catabolic process,GO:0034427~nuclear-transcribed mRNA catabolic process, exonucleolytic, 3'-5',GO:0034475~U4 snRNA 3'-end processing,GO:0043928~exonucleolytic nuclear-transcribed mRNA catabolic process involved in deadenylation-dependent decay,GO:0045006~DNA deamination,GO:0045190~isotype switching,GO:0045830~positive regulation of isotype switching,GO:0071034~CUT catabolic process,GO:0071035~nuclear polyadenylation-dependent rRNA catabolic process,GO:0071038~nuclear polyadenylation-dependent tRNA catabolic process,GO:0071051~polyadenylation-dependent snoRNA 3'-end processing,	GO:0000176~nuclear exosome (RNase complex),GO:0000177~cytoplasmic exosome (RNase complex),GO:0000178~exosome (RNase complex),GO:0000791~euchromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0101019~nucleolar exosome (RNase complex),	GO:0000175~3'-5'-exoribonuclease activity,GO:0003723~RNA binding,GO:0005515~protein binding,	IPR004088:KH_dom_type_1,IPR012340:NA-bd_OB-fold,IPR026699:Exosome_RNA_bind1/RRP40/RRP4,IPR036612:KH_dom_type_1_sf,IPR037319:Rrp40_S1,IPR048541:RRP40_N,	hsa03018:RNA degradation,	614678~Pontocerebellar hypoplasia, type 1B,			KW-0698~rRNA processing,	KW-0271~Exosome,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0523~Neurodegeneration,			KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:K Homology,
FIP1L1	factor interacting with PAPOLA and CPSF1(FIP1L1)	Homo sapiens			GO:0006397~mRNA processing,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0005847~mRNA cleavage and polyadenylation specificity factor complex,	GO:0003723~RNA binding,GO:0005515~protein binding,	IPR007854:Fip1_dom,	hsa03015:mRNA surveillance pathway,				KW-0507~mRNA processing,	KW-0539~Nucleus,				KW-0694~RNA-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Pre-mRNA polyadenylation factor Fip1,REGION:Arg/Asp/Glu-rich domain,REGION:Disordered,REGION:Necessary for stimulating PAPOLA activity,REGION:Sufficient for interaction with CPSF1 and CSTF3,REGION:Sufficient for interaction with CPSF4,REGION:Sufficient for interaction with PAPOLA,SITE:Breakpoint for interstitial deletion to form the FIP1L1-PDGFRA fusion protein,
FAM107B	family with sequence similarity 107 member B(FAM107B)	Homo sapiens						IPR009533:FAM107,								KW-0175~Coiled coil,			KW-0007~Acetylation,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,
FAM118A	family with sequence similarity 118 member A(FAM118A)	Homo sapiens				GO:0016020~membrane,	GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR038916:FAM118,IPR039444:SIR2-like,						KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,REGION:Disordered,TRANSMEM:Helical,
FAM133B	family with sequence similarity 133 member B(FAM133B)	Homo sapiens					GO:0003723~RNA binding,	IPR026766:Fam133,											KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,REGION:Disordered,
FAM136A	family with sequence similarity 136 member A(FAM136A)	Homo sapiens				GO:0005737~cytoplasm,	GO:0005515~protein binding,	IPR008560:DUF842_euk,											KW-0007~Acetylation,KW-0597~Phosphoprotein,	REGION:Disordered,
FAM162A	family with sequence similarity 162 member A(FAM162A)	Homo sapiens			GO:0006919~activation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0043065~positive regulation of apoptotic process,GO:0051402~neuron apoptotic process,GO:0071456~cellular response to hypoxia,GO:0090200~positive regulation of release of cytochrome c from mitochondria,	GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0016020~membrane,GO:0031966~mitochondrial membrane,	GO:0005515~protein binding,	IPR009432:DUF1075,					KW-0053~Apoptosis,	KW-0472~Membrane,KW-0496~Mitochondrion,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				REGION:Disordered,REGION:Required for proapoptotic activity,TRANSMEM:Helical,
FAM177A1	family with sequence similarity 177 member A1(FAM177A1)	Homo sapiens						IPR028260:FAM177,								KW-0175~Coiled coil,KW-0732~Signal,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,REGION:Disordered,
FAM204A	family with sequence similarity 204 member A(FAM204A)	Homo sapiens					GO:0005515~protein binding,	IPR037690:FAM204A,								KW-0175~Coiled coil,				COMPBIAS:Basic and acidic residues,REGION:Disordered,
FAM32A	family with sequence similarity 32 member A(FAM32A)	Homo sapiens			GO:0006915~apoptotic process,GO:0007049~cell cycle,	GO:0005654~nucleoplasm,GO:0005730~nucleolus,	GO:0003723~RNA binding,GO:0005515~protein binding,	IPR013865:FAM32A,					KW-0053~Apoptosis,KW-0131~Cell cycle,	KW-0539~Nucleus,						COMPBIAS:Basic and acidic residues,REGION:Disordered,
FAM50A	family with sequence similarity 50 member A(FAM50A)	Homo sapiens			GO:0006325~chromatin organization,GO:0006397~mRNA processing,GO:0007283~spermatogenesis,GO:0008380~RNA splicing,GO:0043484~regulation of RNA splicing,	GO:0005634~nucleus,GO:0005654~nucleoplasm,	GO:0003723~RNA binding,GO:0005515~protein binding,	IPR007005:XAP5,IPR048337:FAM50A/XAP5_C,		300261~Intellectual developmental disorder, X-linked syndromic, Armfield type,			KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-0991~Intellectual disability,	KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:FAM50A/XAP5 C-terminal,MOTIF:Nuclear localization signal,REGION:Disordered,
FNTA	farnesyltransferase, CAAX box, alpha(FNTA)	Homo sapiens			GO:0007179~transforming growth factor beta receptor signaling pathway,GO:0018343~protein farnesylation,GO:0018344~protein geranylgeranylation,GO:0035022~positive regulation of Rac protein signal transduction,GO:0071340~skeletal muscle acetylcholine-gated channel clustering,GO:0090044~positive regulation of tubulin deacetylation,GO:0090045~positive regulation of deacetylase activity,GO:1904395~positive regulation of skeletal muscle acetylcholine-gated channel clustering,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005875~microtubule associated complex,GO:0005886~plasma membrane,GO:0005953~CAAX-protein geranylgeranyltransferase complex,GO:0005965~protein farnesyltransferase complex,	GO:0004660~protein farnesyltransferase activity,GO:0004661~protein geranylgeranyltransferase activity,GO:0004662~CAAX-protein geranylgeranyltransferase activity,GO:0004663~Rab geranylgeranyltransferase activity,GO:0005515~protein binding,GO:0008017~microtubule binding,GO:0008318~protein prenyltransferase activity,GO:0030971~receptor tyrosine kinase binding,GO:0043014~alpha-tubulin binding,GO:0060090~binding, bridging,	IPR002088:Prenyl_trans_a,	hsa00900:Terpenoid backbone biosynthesis,							KW-0175~Coiled coil,KW-0677~Repeat,	KW-0460~Magnesium,	KW-0637~Prenyltransferase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Pro residues,MUTAGEN:K->N: Reduced activity.,MUTAGEN:N->K: Reduced catalytic efficiency.,REGION:Disordered,REPEAT:PFTA 1,REPEAT:PFTA 2,REPEAT:PFTA 3,REPEAT:PFTA 4,REPEAT:PFTA 5,
FDX1	ferredoxin 1(FDX1)	Homo sapiens			GO:0006694~steroid biosynthetic process,GO:0008203~cholesterol metabolic process,GO:0022900~electron transport chain,GO:0042446~hormone biosynthetic process,GO:0071320~cellular response to cAMP,GO:1904322~cellular response to forskolin,	GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,	GO:0005506~iron ion binding,GO:0009055~electron carrier activity,GO:0051537~2 iron, 2 sulfur cluster binding,	IPR001041:2Fe-2S_ferredoxin-type,IPR001055:Adrenodoxin,IPR012675:Beta-grasp_dom_sf,IPR018298:Adrenodoxin_Fe-S_BS,IPR036010:2Fe-2S_ferredoxin-like_sf,					KW-0153~Cholesterol metabolism,KW-0249~Electron transport,KW-0443~Lipid metabolism,KW-0753~Steroid metabolism,KW-0755~Steroidogenesis,KW-0813~Transport,KW-1207~Sterol metabolism,	KW-0496~Mitochondrion,		KW-0809~Transit peptide,	KW-0001~2Fe-2S,KW-0408~Iron,KW-0411~Iron-sulfur,KW-0479~Metal-binding,		KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:2Fe-2S ferredoxin-type,REGION:Disordered,TRANSIT:Mitochondrion,
FTH1	ferritin heavy chain 1(FTH1)	Homo sapiens			GO:0006826~iron ion transport,GO:0006879~cellular iron ion homeostasis,GO:0006880~intracellular sequestering of iron ion,GO:0006955~immune response,GO:0008285~negative regulation of cell proliferation,GO:0048147~negative regulation of fibroblast proliferation,	GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0008043~intracellular ferritin complex,GO:0016020~membrane,GO:0044754~autolysosome,GO:0070062~extracellular exosome,GO:1904724~tertiary granule lumen,GO:1904813~ficolin-1-rich granule lumen,	GO:0004322~ferroxidase activity,GO:0005506~iron ion binding,GO:0005515~protein binding,GO:0008198~ferrous iron binding,GO:0008199~ferric iron binding,GO:0042802~identical protein binding,	IPR001519:Ferritin,IPR008331:Ferritin_DPS_dom,IPR009040:Ferritin-like_diiron,IPR009078:Ferritin-like_SF,IPR012347:Ferritin-like,IPR014034:Ferritin_CS,	hsa04216:Ferroptosis,hsa04217:Necroptosis,hsa04978:Mineral absorption,	615517~Hemochromatosis, type 5,620669~Neurodegeneration with brain iron accumulation 9,			KW-0409~Iron storage,	KW-0472~Membrane,KW-0963~Cytoplasm,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0408~Iron,KW-0479~Metal-binding,	KW-0560~Oxidoreductase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:Ferritin-like diiron,MUTAGEN:E->A: No effect on iron binding but the oxidation rate is severely reduced; when associated with Q-87.,MUTAGEN:E->A: Reduces iron binding and oxidation rate; when associated with Q-87.,MUTAGEN:K->Q: Reduces iron binding and oxidation rate; when associated with A-28. No effect on iron binding but the oxidation rate is severely reduced; when associated with A-108.,REGION:Disordered,TRANSMEM:Helical,
FBL	fibrillarin(FBL)	Homo sapiens		h_SARSpathway:SARS Coronavirus Protease,	GO:0000494~box C/D snoRNA 3'-end processing,GO:0001649~osteoblast differentiation,GO:0006338~chromatin remodeling,GO:0006364~rRNA processing,GO:0031167~rRNA methylation,GO:0032259~methylation,GO:0042274~ribosomal small subunit biogenesis,GO:0048254~snoRNA localization,	GO:0001650~fibrillar center,GO:0001652~granular component,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0015030~Cajal body,GO:0016020~membrane,GO:0031428~box C/D snoRNP complex,GO:0032040~small-subunit processome,GO:0070062~extracellular exosome,GO:1990904~ribonucleoprotein complex,	GO:0001094~TFIID-class transcription factor binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0008649~rRNA methyltransferase activity,GO:0008757~S-adenosylmethionine-dependent methyltransferase activity,GO:0051117~ATPase binding,GO:1990259~histone-glutamine methyltransferase activity,	IPR000692:Fibrillarin,IPR020813:Fibrillarin_CS,IPR029063:SAM-dependent_MTases_sf,	hsa03008:Ribosome biogenesis in eukaryotes,		PIRSF006540:Nop17p,	SM01206:Fibrillarin,	KW-0698~rRNA processing,	KW-0539~Nucleus,			KW-0949~S-adenosyl-L-methionine,	KW-0489~Methyltransferase,KW-0687~Ribonucleoprotein,KW-0694~RNA-binding,KW-0808~Transferase,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),MUTAGEN:K->Q: Mimics acetylation; impaired ability to methylate histone H2A; when associated with Q-102 and 205-Q-Q-206.,MUTAGEN:K->Q: Mimics acetylation; impaired ability to methylate histone H2A; when associated with Q-121 and 205-Q-Q-206.,MUTAGEN:K->R: Decreased acetylation; restores ability to methylate histone H2A; when associated with R-102 and 205-R-R-206.,MUTAGEN:K->R: Decreased acetylation; restores ability to methylate histone H2A; when associated with R-121 and 205-R-R-206.,MUTAGEN:KK->QQ: Mimics acetylation; impaired ability to methylate histone H2A; when associated with Q-102 and Q-121.,MUTAGEN:KK->RR: Decreased acetylation; restores ability to methylate histone H2A; when associated with R-102 and R-121.,REGION:Disordered,REGION:Helical,
FLNA	filamin A(FLNA)	Homo sapiens			GO:0001525~angiogenesis,GO:0001837~epithelial to mesenchymal transition,GO:0001974~blood vessel remodeling,GO:0003007~heart morphogenesis,GO:0007195~adenylate cyclase-inhibiting dopamine receptor signaling pathway,GO:0007597~blood coagulation, intrinsic pathway,GO:0010572~positive regulation of platelet activation,GO:0010977~negative regulation of neuron projection development,GO:0016479~negative regulation of transcription from RNA polymerase I promoter,GO:0021943~formation of radial glial scaffolds,GO:0021987~cerebral cortex development,GO:0030036~actin cytoskeleton organization,GO:0030334~regulation of cell migration,GO:0032233~positive regulation of actin filament bundle assembly,GO:0034394~protein localization to cell surface,GO:0035855~megakaryocyte development,GO:0042177~negative regulation of protein catabolic process,GO:0042307~positive regulation of protein import into nucleus,GO:0042789~mRNA transcription from RNA polymerase II promoter,GO:0043066~negative regulation of apoptotic process,GO:0043113~receptor clustering,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043433~negative regulation of sequence-specific DNA binding transcription factor activity,GO:0044319~wound healing, spreading of cells,GO:0045022~early endosome to late endosome transport,GO:0045184~establishment of protein localization,GO:0045216~cell-cell junction organization,GO:0048680~positive regulation of axon regeneration,GO:0050808~synapse organization,GO:0050821~protein stabilization,GO:0051209~release of sequestered calcium ion into cytosol,GO:0051220~cytoplasmic sequestering of protein,GO:0051764~actin crosslink formation,GO:0060271~cilium assembly,GO:0070527~platelet aggregation,GO:0071526~semaphorin-plexin signaling pathway,GO:0072659~protein localization to plasma membrane,GO:0090042~tubulin deacetylation,GO:0090307~mitotic spindle assembly,GO:0097368~establishment of Sertoli cell barrier,GO:1900026~positive regulation of substrate adhesion-dependent cell spreading,GO:1901381~positive regulation of potassium ion transmembrane transport,GO:1902396~protein localization to bicellular tight junction,GO:1905000~regulation of membrane repolarization during atrial cardiac muscle cell action potential,GO:1905031~regulation of membrane repolarization during cardiac muscle cell action potential,GO:2000179~positive regulation of neural precursor cell proliferation,GO:2001046~positive regulation of integrin-mediated signaling pathway,GO:2001224~positive regulation of neuron migration,	GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005802~trans-Golgi network,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005884~actin filament,GO:0005886~plasma membrane,GO:0005903~brush border,GO:0005911~cell-cell junction,GO:0005925~focal adhesion,GO:0015629~actin cytoskeleton,GO:0016020~membrane,GO:0030018~Z disc,GO:0030863~cortical cytoskeleton,GO:0031523~Myb complex,GO:0032432~actin filament bundle,GO:0043198~dendritic shaft,GO:0043204~perikaryon,GO:0044295~axonal growth cone,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,GO:0097440~apical dendrite,GO:0098794~postsynapse,GO:0098978~glutamatergic synapse,GO:1990779~glycoprotein Ib-IX-V complex,	GO:0001664~G-protein coupled receptor binding,GO:0003723~RNA binding,GO:0005080~protein kinase C binding,GO:0005515~protein binding,GO:0015459~potassium channel regulator activity,GO:0019900~kinase binding,GO:0031267~small GTPase binding,GO:0034988~Fc-gamma receptor I complex binding,GO:0042803~protein homodimerization activity,GO:0044325~ion channel binding,GO:0045296~cadherin binding,GO:0046332~SMAD binding,GO:0051015~actin filament binding,GO:0051020~GTPase binding,	IPR001298:Filamin/ABP280_rpt,IPR001589:Actinin_actin-bd_CS,IPR001715:CH_dom,IPR013783:Ig-like_fold,IPR014756:Ig_E-set,IPR017868:Filamin/ABP280_repeat-like,IPR036872:CH_dom_sf,IPR044801:Filamin,	hsa04010:MAPK signaling pathway,hsa04510:Focal adhesion,hsa05132:Salmonella infection,hsa05205:Proteoglycans in cancer,	300048~Congenital short bowel syndrome,300048~Intestinal pseudoobstruction, neuronal,300049~Heterotopia, periventricular, 1,300244~Terminal osseous dysplasia,300321~FG syndrome 2,304120~Otopalatodigital syndrome, type II,305620~Frontometaphyseal dysplasia 1,309350~Melnick-Needles syndrome,311300~Otopalatodigital syndrome, type I,314400~Cardiac valvular dysplasia, X-linked,		SM00033:CH,SM00557:IG_FLMN,	KW-0970~Cilium biogenesis/degradation,	KW-0206~Cytoskeleton,KW-0963~Cytoplasm,KW-0966~Cell projection,	KW-0209~Deafness,KW-0225~Disease variant,	KW-0677~Repeat,		KW-0009~Actin-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:Calponin-homology (CH),DOMAIN:Calponin-homology (CH) 1,DOMAIN:Calponin-homology (CH) 2,MUTAGEN:K->R: Abrogates ASB2alpha-mediated degradation without altering ASB2alpha binding; when associated with R-42 and R-135.,MUTAGEN:K->R: Abrogates ASB2alpha-mediated degradation without altering ASB2alpha binding; when associated with R-42 and R-43.,MUTAGEN:K->R: Abrogates ASB2alpha-mediated degradation without altering ASB2alpha binding; when associated with R-43 and R-135.,REGION:Actin-binding,REGION:Disordered,REGION:Hinge 1,REGION:Hinge 2,REGION:Interaction with furin,REGION:Self-association site, tail,REPEAT:Filamin,REPEAT:Filamin 1,REPEAT:Filamin 10,REPEAT:Filamin 11,REPEAT:Filamin 12,REPEAT:Filamin 13,REPEAT:Filamin 14,REPEAT:Filamin 15,REPEAT:Filamin 16,REPEAT:Filamin 17,REPEAT:Filamin 18,REPEAT:Filamin 19,REPEAT:Filamin 2,REPEAT:Filamin 20,REPEAT:Filamin 21,REPEAT:Filamin 22,REPEAT:Filamin 23,REPEAT:Filamin 24,REPEAT:Filamin 3,REPEAT:Filamin 4,REPEAT:Filamin 5,REPEAT:Filamin 6,REPEAT:Filamin 7,REPEAT:Filamin 8,REPEAT:Filamin 9,SITE:Cleavage; by calpain,
FIS1	fission, mitochondrial 1(FIS1)	Homo sapiens			GO:0000266~mitochondrial fission,GO:0000422~mitophagy,GO:0001836~release of cytochrome c from mitochondria,GO:0006626~protein targeting to mitochondrion,GO:0007005~mitochondrion organization,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0008053~mitochondrial fusion,GO:0010821~regulation of mitochondrion organization,GO:0016559~peroxisome fission,GO:0032471~negative regulation of endoplasmic reticulum calcium ion concentration,GO:0035584~calcium-mediated signaling using intracellular calcium source,GO:0043280~positive regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0043653~mitochondrial fragmentation involved in apoptotic process,GO:0051561~positive regulation of mitochondrial calcium ion concentration,GO:0070584~mitochondrion morphogenesis,GO:0090141~positive regulation of mitochondrial fission,GO:0090314~positive regulation of protein targeting to membrane,GO:1903579~negative regulation of ATP metabolic process,GO:2000192~negative regulation of fatty acid transport,GO:2001244~positive regulation of intrinsic apoptotic signaling pathway,	GO:0005739~mitochondrion,GO:0005741~mitochondrial outer membrane,GO:0005777~peroxisome,GO:0005778~peroxisomal membrane,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0016020~membrane,GO:0032991~macromolecular complex,	GO:0005515~protein binding,GO:0008289~lipid binding,GO:0042802~identical protein binding,GO:0060090~binding, bridging,	IPR011990:TPR-like_helical_dom_sf,IPR016543:Fis1,IPR028058:Fis1_TPR_N,IPR028061:Fis1_TPR_C,IPR033745:Fis1_cytosol,	hsa04137:Mitophagy - animal,		PIRSF008835:TPR_repeat_11_Fis1,		KW-0053~Apoptosis,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0576~Peroxisome,KW-1000~Mitochondrion outer membrane,		KW-0802~TPR repeat,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,MUTAGEN:K->A: Protein localizes to both mitochondrion and endoplasmic reticulum. Protein localizes to endoplasmic reticulum only; when associated with A-149.,MUTAGEN:K->A: Protein localizes to both mitochondrion and endoplasmic reticulum. Protein localizes to endoplasmic reticulum only; when associated with A-151.,MUTAGEN:L->P: Approximately 40% of cells display fragmented mitochondria.,MUTAGEN:L->P: Approximately 40% of cells display fragmented mitochondria. No change in binding to DNM1L.,MUTAGEN:L->P: Less than 15% of cells display fragmented mitochondria.,MUTAGEN:L->P: Less than 15% of cells display fragmented mitochondria. Shows greatly reduced binding to DNM1L.,REGION:Disordered,REPEAT:TPR,TOPO_DOM:Cytoplasmic,TOPO_DOM:Mitochondrial intermembrane,TRANSMEM:Helical,
FOXN3	forkhead box N3(FOXN3)	Homo sapiens			GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007049~cell cycle,GO:0007095~mitotic G2 DNA damage checkpoint,GO:0045892~negative regulation of transcription, DNA-templated,GO:0097094~craniofacial suture morphogenesis,	GO:0000785~chromatin,GO:0005634~nucleus,	GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0000987~core promoter proximal region sequence-specific DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0043565~sequence-specific DNA binding,	IPR001766:Fork_head_dom,IPR018122:TF_fork_head_CS_1,IPR030456:TF_fork_head_CS_2,IPR036388:WH-like_DNA-bd_sf,IPR036390:WH_DNA-bd_sf,IPR047119:FOXN2-4-like,IPR047404:FH_FOXN3,				SM00339:FH,	KW-0131~Cell cycle,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0238~DNA-binding,KW-0678~Repressor,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DNA_BIND:Fork-head,DOMAIN:Fork-head,REGION:Disordered,
FNBP1	formin binding protein 1(FNBP1)	Homo sapiens			GO:0006897~endocytosis,GO:0007165~signal transduction,	GO:0005737~cytoplasm,GO:0005764~lysosome,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0005905~clathrin-coated pit,GO:0005938~cell cortex,GO:0031410~cytoplasmic vesicle,GO:0043231~intracellular membrane-bounded organelle,	GO:0005515~protein binding,GO:0008289~lipid binding,GO:0042802~identical protein binding,	IPR001060:FCH_dom,IPR001452:SH3_domain,IPR011072:HR1_rho-bd,IPR027267:AH/BAR_dom_sf,IPR031160:F_BAR,IPR035492:FNBP1_SH3,IPR036028:SH3-like_dom_sf,IPR037449:FNBP1_F-BAR,	hsa05131:Shigellosis,			SM00055:FCH,SM00326:SH3,	KW-0254~Endocytosis,	KW-0168~Coated pit,KW-0206~Cytoskeleton,KW-0458~Lysosome,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,		KW-0175~Coiled coil,KW-0728~SH3 domain,	KW-0446~Lipid-binding,		KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:F-BAR,DOMAIN:REM-1,DOMAIN:SH3,MUTAGEN:D->A,N,R: No significant effect.,MUTAGEN:D->A: Impairs interaction with TNKS; when associated with A-515.,MUTAGEN:K->A: Abolishes membrane invagination.,MUTAGEN:K->E: Abolishes membrane invagination.,MUTAGEN:K->Q: Impairs lipid-binding and induction of membrane tubulation; when associated with Q-35.,MUTAGEN:KK->QQ: Impairs lipid-binding and induction of membrane tubulation.,MUTAGEN:L->E: Impairs membrane tubulation but does not affect lipid-binding.,MUTAGEN:Missing: Abrogates interaction with TNKS.,MUTAGEN:P->A: Disrupts helix kink and moderately increases diameter of the induced tubular membrane.,MUTAGEN:P->L: Abrogates interaction with DNM1, DNM2 and DNM3.,MUTAGEN:R->A: Impairs interaction with TNKS.,MUTAGEN:R->Q: Impairs lipid-binding and induction of membrane tubulation; when associated with Q-33.,MUTAGEN:RK->QQ: Impairs lipid-binding and induction of membrane tubulation.,MUTAGEN:T->A: Abolishes membrane invagination.,REGION:Disordered,REGION:Interaction with ARHGAP17, DAAM1, DIAPH1 and DIAPH2,REGION:Interaction with DNM1 and DNM3,REGION:Interaction with DNM2 and WASL,REGION:Interaction with FASLG,REGION:Interaction with PDE6G,REGION:Interaction with RND2,REGION:Interaction with microtubules,REGION:Required for interaction with TNKS,REGION:Required for self-association and induction of membrane tubulation,SITE:Mediates end-to-end attachment of dimers,
FNBP4	formin binding protein 4(FNBP4)	Homo sapiens				GO:0005654~nucleoplasm,	GO:0005515~protein binding,	IPR001202:WW_dom,IPR036020:WW_dom_sf,				SM00456:WW,				KW-0677~Repeat,			KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:WW,DOMAIN:WW 1,DOMAIN:WW 2,REGION:Disordered,
FMNL1	formin like 1(FMNL1)	Homo sapiens			GO:0007010~cytoskeleton organization,GO:0008360~regulation of cell shape,GO:0016477~cell migration,GO:0022604~regulation of cell morphogenesis,GO:0030866~cortical actin cytoskeleton organization,GO:0051014~actin filament severing,	GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005938~cell cortex,GO:0016020~membrane,GO:0032059~bleb,GO:0045335~phagocytic vesicle,GO:0070062~extracellular exosome,	GO:0003779~actin binding,GO:0005515~protein binding,GO:0031267~small GTPase binding,GO:0032794~GTPase activating protein binding,GO:0051015~actin filament binding,	IPR010472:FH3_dom,IPR010473:GTPase-bd,IPR011989:ARM-like,IPR014767:DAD_dom,IPR014768:GBD/FH3_dom,IPR015425:FH2_Formin,IPR016024:ARM-type_fold,IPR042201:FH2_Formin_sf,IPR043592:FMNL_animal,				SM00498:FH2,SM01139:Drf_FH3,SM01140:Drf_GBD,		KW-0472~Membrane,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0449~Lipoprotein,KW-0519~Myristate,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,DOMAIN:DAD,DOMAIN:FH2,DOMAIN:GBD/FH3,LIPID:N-myristoyl glycine,REGION:Disordered,TRANSMEM:Helical,
FYTTD1	forty-two-three domain containing 1(FYTTD1)	Homo sapiens			GO:0006406~mRNA export from nucleus,	GO:0005654~nucleoplasm,GO:0016607~nuclear speck,	GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0005515~protein binding,	IPR009782:FYTTD1,					KW-0509~mRNA transport,KW-0813~Transport,	KW-0539~Nucleus,				KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),MOTIF:UAP56-binding motif,REGION:Disordered,
GALM	galactose mutarotase(GALM)	Homo sapiens			GO:0005975~carbohydrate metabolic process,GO:0006006~glucose metabolic process,GO:0006012~galactose metabolic process,GO:0033499~galactose catabolic process via UDP-galactose,	GO:0005737~cytoplasm,GO:0070062~extracellular exosome,	GO:0004034~aldose 1-epimerase activity,GO:0030246~carbohydrate binding,	IPR008183:Aldose_1/G6P_1-epimerase,IPR011013:Gal_mutarotase_sf_dom,IPR014718:GH-type_carb-bd,IPR015443:Aldose_1-epimerase,IPR018052:Ald1_epimerase_CS,IPR047215:Galactose_mutarotase-like,	hsa00010:Glycolysis / Gluconeogenesis,hsa00052:Galactose metabolism,hsa01100:Metabolic pathways,	618881~Galactosemia IV,	PIRSF005096:GALM,		KW-0119~Carbohydrate metabolism,	KW-0963~Cytoplasm,	KW-0225~Disease variant,			KW-0413~Isomerase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,ACT_SITE:Proton donor,MUTAGEN:E->A: Loss of activity.,MUTAGEN:H->A: Decreased activity by 300-fold.,MUTAGEN:H->A: Decreased activity by 5-fold.,
GLA	galactosidase alpha(GLA)	Homo sapiens			GO:0005975~carbohydrate metabolic process,GO:0006629~lipid metabolic process,GO:0009311~oligosaccharide metabolic process,GO:0016139~glycoside catabolic process,GO:0045019~negative regulation of nitric oxide biosynthetic process,GO:0046477~glycosylceramide catabolic process,GO:0046479~glycosphingolipid catabolic process,GO:0051001~negative regulation of nitric-oxide synthase activity,	GO:0005576~extracellular region,GO:0005737~cytoplasm,GO:0005764~lysosome,GO:0005794~Golgi apparatus,GO:0035578~azurophil granule lumen,GO:0043202~lysosomal lumen,GO:0070062~extracellular exosome,	GO:0003824~catalytic activity,GO:0004553~hydrolase activity, hydrolyzing O-glycosyl compounds,GO:0004557~alpha-galactosidase activity,GO:0005102~receptor binding,GO:0005515~protein binding,GO:0016787~hydrolase activity,GO:0016936~galactoside binding,GO:0042803~protein homodimerization activity,	IPR000111:Glyco_hydro_27/36_CS,IPR002241:Glyco_hydro_27,IPR013780:Glyco_hydro_b,IPR013785:Aldolase_TIM,IPR017853:Glycoside_hydrolase_SF,IPR035373:Melibiase/NAGA_C,	hsa00052:Galactose metabolism,hsa00561:Glycerolipid metabolism,hsa00600:Sphingolipid metabolism,hsa00603:Glycosphingolipid biosynthesis - globo and isoglobo series,hsa01100:Metabolic pathways,hsa04142:Lysosome,	301500~Fabry disease,301500~Fabry disease, cardiac variant,			KW-0443~Lipid metabolism,	KW-0458~Lysosome,	KW-0225~Disease variant,	KW-0732~Signal,		KW-0326~Glycosidase,KW-0378~Hydrolase,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	ACT_SITE:Nucleophile,ACT_SITE:Proton donor,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Alpha galactosidase A C-terminal beta-sandwich,
GLB1	galactosidase beta 1(GLB1)	Homo sapiens			GO:0005975~carbohydrate metabolic process,GO:0006687~glycosphingolipid metabolic process,GO:0008152~metabolic process,GO:0019388~galactose catabolic process,GO:0030200~heparan sulfate proteoglycan catabolic process,GO:0042340~keratan sulfate catabolic process,GO:0046479~glycosphingolipid catabolic process,GO:0051413~response to cortisone,GO:1904016~response to Thyroglobulin triiodothyronine,	GO:0005576~extracellular region,GO:0005737~cytoplasm,GO:0005773~vacuole,GO:0005794~Golgi apparatus,GO:0035578~azurophil granule lumen,GO:0043202~lysosomal lumen,GO:0043231~intracellular membrane-bounded organelle,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,GO:1904813~ficolin-1-rich granule lumen,	GO:0004553~hydrolase activity, hydrolyzing O-glycosyl compounds,GO:0004565~beta-galactosidase activity,GO:0005515~protein binding,GO:0016936~galactoside binding,GO:0042803~protein homodimerization activity,	IPR001944:Glycoside_Hdrlase_35,IPR008979:Galactose-bd-like_sf,IPR017853:Glycoside_hydrolase_SF,IPR019801:Glyco_hydro_35_CS,IPR026283:B-gal_1-like,IPR031330:Gly_Hdrlase_35_cat,IPR048912:BetaGal1-like_ABD1,IPR048913:BetaGal_gal-bd,	hsa00052:Galactose metabolism,hsa00511:Other glycan degradation,hsa00531:Glycosaminoglycan degradation,hsa00600:Sphingolipid metabolism,hsa00604:Glycosphingolipid biosynthesis - ganglio series,hsa01100:Metabolic pathways,hsa04142:Lysosome,	230500~GM1-gangliosidosis, type I,230600~GM1-gangliosidosis, type II,230650~GM1-gangliosidosis, type III,253010~Mucopolysaccharidosis type IVB (Morquio),	PIRSF006336:B-gal,			KW-0458~Lysosome,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0331~Gangliosidosis,KW-0510~Mucopolysaccharidosis,	KW-0732~Signal,		KW-0326~Glycosidase,KW-0378~Hydrolase,	KW-0325~Glycoprotein,KW-0865~Zymogen,KW-1015~Disulfide bond,	ACT_SITE:Nucleophile,ACT_SITE:Proton donor,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Beta-galactosidase 1-like first all-beta,DOMAIN:Beta-galactosidase galactose-binding,DOMAIN:Glycoside hydrolase 35 catalytic,REGION:Disordered,
LGALS1	galectin 1(LGALS1)	Homo sapiens			GO:0002317~plasma cell differentiation,GO:0006915~apoptotic process,GO:0031295~T cell costimulation,GO:0042981~regulation of apoptotic process,GO:0043065~positive regulation of apoptotic process,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0045445~myoblast differentiation,GO:0046598~positive regulation of viral entry into host cell,GO:0050729~positive regulation of inflammatory response,GO:0098609~cell-cell adhesion,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0005788~endoplasmic reticulum lumen,GO:0005829~cytosol,GO:0070062~extracellular exosome,GO:1990724~galectin complex,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0030246~carbohydrate binding,GO:0030395~lactose binding,GO:0043236~laminin binding,	IPR001079:Galectin_CRD,IPR013320:ConA-like_dom_sf,IPR044156:Galectin-like,				SM00276:GLECT,SM00908:Gal-bind_lectin,	KW-0053~Apoptosis,	KW-0272~Extracellular matrix,KW-0963~Cytoplasm,KW-0964~Secreted,			KW-0430~Lectin,		KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:Galectin,REGION:Disordered,
LGALS3	galectin 3(LGALS3)	Homo sapiens			GO:0002548~monocyte chemotaxis,GO:0006397~mRNA processing,GO:0008380~RNA splicing,GO:0030593~neutrophil chemotaxis,GO:0030855~epithelial cell differentiation,GO:0031334~positive regulation of protein complex assembly,GO:0042129~regulation of T cell proliferation,GO:0045087~innate immune response,GO:0045806~negative regulation of endocytosis,GO:0048245~eosinophil chemotaxis,GO:0048246~macrophage chemotaxis,GO:0050860~negative regulation of T cell receptor signaling pathway,GO:0050918~positive chemotaxis,GO:0070232~regulation of T cell apoptotic process,GO:0071674~mononuclear cell migration,GO:0071677~positive regulation of mononuclear cell migration,GO:0090280~positive regulation of calcium ion import,GO:1902041~regulation of extrinsic apoptotic signaling pathway via death domain receptors,GO:1903078~positive regulation of protein localization to plasma membrane,GO:1903614~negative regulation of protein tyrosine phosphatase activity,GO:2000521~negative regulation of immunological synapse formation,GO:2001189~negative regulation of T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell,GO:2001237~negative regulation of extrinsic apoptotic signaling pathway,	GO:0001772~immunological synapse,GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005681~spliceosomal complex,GO:0005737~cytoplasm,GO:0005743~mitochondrial inner membrane,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,GO:0030667~secretory granule membrane,GO:0070062~extracellular exosome,GO:0101003~ficolin-1-rich granule membrane,	GO:0003723~RNA binding,GO:0004864~protein phosphatase inhibitor activity,GO:0005515~protein binding,GO:0019863~IgE binding,GO:0019903~protein phosphatase binding,GO:0030246~carbohydrate binding,GO:0042056~chemoattractant activity,GO:0043236~laminin binding,GO:0048030~disaccharide binding,	IPR001079:Galectin_CRD,IPR013320:ConA-like_dom_sf,IPR044156:Galectin-like,				SM00276:GLECT,SM00908:Gal-bind_lectin,	KW-0221~Differentiation,KW-0391~Immunity,KW-0399~Innate immunity,KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,KW-0747~Spliceosome,KW-0963~Cytoplasm,KW-0964~Secreted,		KW-0677~Repeat,	KW-0430~Lectin,	KW-0389~IgE-binding protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,DISULFID:Interchain,DOMAIN:Galectin,MOTIF:Nuclear export signal,REGION:8 X 9 AA tandem repeats of Y-P-G-X(3)-P-G-A,REGION:Disordered,REPEAT:1,REPEAT:2,REPEAT:3,REPEAT:4; approximate,REPEAT:5,REPEAT:6; approximate,REPEAT:7; approximate,REPEAT:8; approximate,
GGNBP2	gametogenetin binding protein 2(GGNBP2)	Homo sapiens			GO:0007283~spermatogenesis,GO:0008285~negative regulation of cell proliferation,GO:0010629~negative regulation of gene expression,GO:0030154~cell differentiation,GO:0033140~negative regulation of peptidyl-serine phosphorylation of STAT protein,GO:0042532~negative regulation of tyrosine phosphorylation of STAT protein,GO:0060716~labyrinthine layer blood vessel development,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0031410~cytoplasmic vesicle,		IPR026073:GGNBP2,					KW-0221~Differentiation,KW-0744~Spermatogenesis,	KW-0968~Cytoplasmic vesicle,		KW-0175~Coiled coil,		KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,	REGION:Disordered,
GSDMD	gasdermin D(GSDMD)	Homo sapiens			GO:0006954~inflammatory response,GO:0009306~protein secretion,GO:0012501~programmed cell death,GO:0031668~cellular response to extracellular stimulus,GO:0032731~positive regulation of interleukin-1 beta production,GO:0042742~defense response to bacterium,GO:0045087~innate immune response,GO:0046931~pore complex assembly,GO:0050729~positive regulation of inflammatory response,GO:0050829~defense response to Gram-negative bacterium,GO:0050830~defense response to Gram-positive bacterium,GO:0051260~protein homooligomerization,GO:0055085~transmembrane transport,GO:0070269~pyroptosis,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0031966~mitochondrial membrane,GO:0035580~specific granule lumen,GO:0072559~NLRP3 inflammasome complex,GO:1904724~tertiary granule lumen,GO:1904813~ficolin-1-rich granule lumen,	GO:0001786~phosphatidylserine binding,GO:0005515~protein binding,GO:0005546~phosphatidylinositol-4,5-bisphosphate binding,GO:0022829~wide pore channel activity,GO:0070273~phosphatidylinositol-4-phosphate binding,GO:0070300~phosphatidic acid binding,GO:1901612~cardiolipin binding,	IPR007677:Gasdermin,IPR040460:Gasdermin_pore,IPR041263:Gasdermin_PUB,	hsa04613:Neutrophil extracellular trap formation,hsa04621:NOD-like receptor signaling pathway,hsa04623:Cytosolic DNA-sensing pathway,hsa05132:Salmonella infection,				KW-0391~Immunity,KW-0395~Inflammatory response,KW-0399~Innate immunity,KW-0804~Transcription,KW-0805~Transcription regulation,KW-1210~Necrosis,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0964~Secreted,KW-1003~Cell membrane,KW-1271~Inflammasome,		KW-0812~Transmembrane,KW-1134~Transmembrane beta strand,	KW-0446~Lipid-binding,		KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,DOMAIN:Gasdermin PUB,DOMAIN:Gasdermin pore forming,MUTAGEN:A->D: Spontaneous pyroptosis-inducing activity.,MUTAGEN:D->A: Loss of cleavage by CASP1 and CASP4 and of LPS-induced pyroptosis. Does not affect interaction with CASP1 and CASP4.,MUTAGEN:D->K: Does not affect ability to induce pyroptosis.,MUTAGEN:DGQIQGSVE->AGQIQGSVA: In AP2; promotes ability to release of interleukin-1 (IL1B and IL18) precursors.,MUTAGEN:DILEPDAAEPD->AILAPDAAAPA: In AP1; promotes ability to release of interleukin-1 (IL1B and IL18) precursors.,MUTAGEN:E->K: No spontaneous pyroptosis-inducing activity; when associated with D-192.,MUTAGEN:F->A,R: Constitutively active mutant; promotes activation of pyroptosis.,MUTAGEN:F->D: Abolished ability to induce pyroptosis.,MUTAGEN:F->Y: No effect.,MUTAGEN:FLT->AAA: Does not affect interaction with CASP4.,MUTAGEN:I->N: Decreased effectiveness in pore formation and pyroptosis induction. No effect on cleavage by CASP1.,MUTAGEN:K->D: Does not affect ability to induce pyroptosis.,MUTAGEN:K->E: Reduced ability to form a pore.,MUTAGEN:L->D: Decreased induction of pyroptosis and defects in liposome-binding. No spontaneous pyroptosis-inducing activity; when associated with K-15.,MUTAGEN:L->D: Spontaneous pyroptosis-inducing activity.,MUTAGEN:LDHGGEF->VSGSRGD: Abolished ubiquitination by S.flexneri IpaH7.8.,MUTAGEN:LDREL->ADREA: Impairs interaction with CASP1 and CASP4 and subsequent cleavage.,MUTAGEN:P->D: Does not affect ability to induce pyroptosis.,MUTAGEN:Q->A: Abolished cleavage by enterovirus 71 (EV71) Protease 3C and human coronavirus SARS-CoV-2 3C-like proteinase nsp5.,MUTAGEN:Q->A: Does not affect cleavage by enterovirus 71 (EV71) Protease 3C.,MUTAGEN:Q->D: Does not affect ability to induce pyroptosis.,MUTAGEN:QGLR->AAA: Abolished generation of the Gasdermin-D, p40 chain and ability to promote secretion of IL33.,MUTAGEN:R->D: Does not affect ability to induce pyroptosis.,MUTAGEN:R->E: Reduced ability to form a pore.,MUTAGEN:RKPSSSWFWKPR->EEPSSSWFWEPE: Abolished ability to form a pore.,MUTAGEN:RVVRR->AVVAA: Impaired pore-formation.,MUTAGEN:T->D: Abolished ability to induce pyroptosis.,MUTAGEN:VPAEGAFTEDFQGLRAEVET->SGGGS: Constitutively active mutant; promotes activation of pyroptosis.,MUTAGEN:VPEL->APEA: Impairs interaction with CASP1 and CASP4 and subsequent cleavage.,MUTAGEN:WFW->GFG: Abolished ability to form a pore.,MUTAGEN:Y->D: Spontaneous pyroptosis-inducing activity.,REGION:Disordered,REGION:Linker helix loop,SITE:Cleavage; by CASP3 or CASP7,SITE:Cleavage; by caspases CASP1, CASP4, CASP5 and CASP8,SITE:Cleavage; by enterovirus 71 (EV71) Protease 3C and coronavirus SARS-CoV-2 proteinase nsp5,SITE:Cleavage; by papain,TRANSMEM:Beta stranded,
GTF2A2	general transcription factor IIA subunit 2(GTF2A2)	Homo sapiens			GO:0006366~transcription from RNA polymerase II promoter,GO:0006367~transcription initiation from RNA polymerase II promoter,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051123~RNA polymerase II transcriptional preinitiation complex assembly,GO:0060261~positive regulation of transcription initiation from RNA polymerase II promoter,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005669~transcription factor TFIID complex,GO:0005672~transcription factor TFIIA complex,GO:0030054~cell junction,	GO:0001091~RNA polymerase II basal transcription factor binding,GO:0005515~protein binding,GO:0017025~TBP-class protein binding,GO:0042803~protein homodimerization activity,GO:0046982~protein heterodimerization activity,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,	IPR003194:TFIIA_gsu,IPR009083:TFIIA_a-hlx,IPR009088:TFIIA_b-brl,IPR015871:TFIIA_gsu_C,IPR015872:TFIIA_gsu_N,	hsa03022:Basal transcription factors,hsa05203:Viral carcinogenesis,		PIRSF009415:Hum_TFIIA_gamma,		KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0539~Nucleus,						DOMAIN:Transcription initiation factor IIA gamma subunit C-terminal,DOMAIN:Transcription initiation factor IIA gamma subunit N-terminal,
GTF2B	general transcription factor IIB(GTF2B)	Homo sapiens		h_hSWI-SNFpathway:Chromatin Remodeling by hSWI/SNF ATP-dependent Complexes,h_rarrxrPathway:Nuclear receptors coordinate the activities of chromatin remodeling complexes and coactivators to facilitate initiation of transcription in carcinoma cells,	GO:0001174~transcriptional start site selection at RNA polymerase II promoter,GO:0006338~chromatin remodeling,GO:0006366~transcription from RNA polymerase II promoter,GO:0006367~transcription initiation from RNA polymerase II promoter,GO:0006473~protein acetylation,GO:0019083~viral transcription,GO:0051123~RNA polymerase II transcriptional preinitiation complex assembly,GO:0051177~meiotic sister chromatid cohesion,GO:0051225~spindle assembly,GO:0070897~DNA-templated transcriptional preinitiation complex assembly,GO:1904798~positive regulation of core promoter binding,GO:1990114~RNA Polymerase II core complex assembly,	GO:0000776~kinetochore,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005669~transcription factor TFIID complex,GO:0005694~chromosome,GO:0016604~nuclear body,GO:0032153~cell division site,GO:0032993~protein-DNA complex,GO:0042585~germinal vesicle,GO:0090575~RNA polymerase II transcription factor complex,GO:0097550~transcriptional preinitiation complex,	GO:0000979~RNA polymerase II core promoter sequence-specific DNA binding,GO:0000993~RNA polymerase II core binding,GO:0004402~histone acetyltransferase activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0016407~acetyltransferase activity,GO:0017025~TBP-class protein binding,GO:0046966~thyroid hormone receptor binding,GO:1990841~promoter-specific chromatin binding,	IPR000812:TFIIB,IPR013137:Znf_TFIIB,IPR013150:TFIIB_cyclin,IPR013763:Cyclin-like_dom,IPR023486:TFIIB_CS,IPR036915:Cyclin-like_sf,	hsa03022:Basal transcription factors,hsa05017:Spinocerebellar ataxia,hsa05203:Viral carcinogenesis,			SM00385:CYCLIN,	KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0158~Chromosome,KW-0539~Nucleus,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0012~Acyltransferase,KW-0238~DNA-binding,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:TFIIB-type,MUTAGEN:C->S: Does not inhibit interaction with TBP. Inhibits the recruitment of RNA polymerase II into the initiation complex.,MUTAGEN:E->R,A,D: Defects in transcription start site selection. Supports a level of transcription equivalent to wild-type.,MUTAGEN:EWRTFS->AWRTFA: Partial loss of HIV-1 Vpr binding.,MUTAGEN:F->A: Partial loss of HIV-1 Vpr binding.,MUTAGEN:G->Q: Decreases BREd-dependent pre-initiation complex formation.,MUTAGEN:G->V: Inhibits interaction with TBP.,MUTAGEN:K->A: Abolishes autoacetylation, represses transcription activity, does not inhibit its association with chromatin to promoter-specific regions and decreases the association of GTF2F1 with chromatin to promoter-specific regions.,MUTAGEN:K->E: Inhibits interaction with SSU72; when associated with E-193. Reduces interaction with SSU72; when associated with E-200. Inhibits interaction with VP16; when associated with E-200. Inhibits RNA pol II transcription activation induced by VP16 but does not affect basal transcription; when associated with E-200.,MUTAGEN:K->E: Reduces interaction with SSU72; when associated with E-185 or E-189. Inhibits interaction with VP16; when associated with E-189. Inhibits RNA pol II transcription activation induced by VP16 but does not affect basal transcription; when associated with E-189.,MUTAGEN:K->KGSGS: Reduces the formation of the TATA box-bound TBP ternary complex.,MUTAGEN:K->L: Reduces interaction with VP16; when associated with L-185.,MUTAGEN:K->L: Reduces interaction with VP16; when associated with L-196.,MUTAGEN:K->L: Reduces interaction with VP16; when associated with L-200.,MUTAGEN:KALETSVDL->GSGS: Reduces the formation of the TATA box-bound TBP ternary complex.,MUTAGEN:L->LGSGS: Does not inhibit the formation of the TATA box-bound TBP ternary complex.,MUTAGEN:R->A,E,K: Defects in transcription start site selection. Supports a level of transcription equivalent to wild-type.,MUTAGEN:R->A: Reduces DNA-binding.,MUTAGEN:R->E: Inhibits interaction with RNA polymerase II; when associated with E-286 and E-290.,MUTAGEN:R->E: Inhibits interaction with RNA polymerase II; when associated with E-286 and E-295.,MUTAGEN:R->E: Inhibits interaction with RNA polymerase II; when associated with E-290 and E-295.,MUTAGEN:R->E: Inhibits interaction with SSU72; when associated with E-185 or E-189. Inhibits interaction with VP16; when associated with E-185. Inhibits RNA pol II transcription activation induced by VP16 but does not affect basal transcription; when associated with E-185.,MUTAGEN:R->E: Reduces interaction with SSU72; when associated with E-193 or E-200. Inhibits interaction with VP16; when associated with E-193. Inhibits RNA pol II transcription activation induced by VP16 but does not affect basal transcription; when associated with E-193.,MUTAGEN:R->L: Reduces interaction with VP16; when associated with L-189.,MUTAGEN:RT->AA: Partial loss of HIV-1 Vpr binding.,MUTAGEN:V->A: Reduces DNA-binding.,MUTAGEN:W->A: Partial loss of HIV-1 Vpr binding.,REGION:Core promoter DNA-binding,REGION:Disordered,REGION:Necessary for TATA box-bound TBP complex formation,REPEAT:1,REPEAT:2,ZN_FING:TFIIB-type,
GTF2E2	general transcription factor IIE subunit 2(GTF2E2)	Homo sapiens			GO:0006366~transcription from RNA polymerase II promoter,GO:0006367~transcription initiation from RNA polymerase II promoter,	GO:0005654~nucleoplasm,GO:0005669~transcription factor TFIID complex,GO:0005673~transcription factor TFIIE complex,GO:0005829~cytosol,	GO:0001097~TFIIH-class transcription factor binding,GO:0003677~DNA binding,GO:0003723~RNA binding,GO:0005515~protein binding,	IPR003166:TFIIE_bsu_DNA-bd,IPR016656:TFIIE-bsu,IPR036388:WH-like_DNA-bd_sf,IPR036390:WH_DNA-bd_sf,IPR040501:TFA2_Winged_2,	hsa03022:Basal transcription factors,hsa05203:Viral carcinogenesis,	616943~Trichothiodystrophy 6, nonphotosensitive,	PIRSF016398:TFIIE-beta,		KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,			KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,DNA_BIND:TFIIE beta,DOMAIN:TFIIE beta,REGION:Disordered,
GTF3A	general transcription factor IIIA(GTF3A)	Homo sapiens			GO:0006383~transcription from RNA polymerase III promoter,GO:0009303~rRNA transcription,GO:0042273~ribosomal large subunit biogenesis,	GO:0005634~nucleus,GO:0005654~nucleoplasm,	GO:0003677~DNA binding,GO:0008097~5S rRNA binding,GO:0046872~metal ion binding,	IPR013087:Znf_C2H2_type,IPR036236:Znf_C2H2_sf,				SM00355:ZnF_C2H2,	KW-0690~Ribosome biogenesis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,KW-0694~RNA-binding,		DOMAIN:C2H2-type,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4; atypical,ZN_FING:C2H2-type 5,ZN_FING:C2H2-type 6,ZN_FING:C2H2-type 7,ZN_FING:C2H2-type 8,ZN_FING:C2H2-type 9,
GMCL1	germ cell-less 1, spermatogenesis associated(GMCL1)	Homo sapiens			GO:0007281~germ cell development,GO:0007283~spermatogenesis,	GO:0005634~nucleus,GO:0016363~nuclear matrix,	GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR000210:BTB/POZ_dom,IPR011333:SKP1/BTB/POZ_sf,IPR011705:BACK,IPR043380:Gcl-like,				SM00225:BTB,SM00875:BACK,	KW-0221~Differentiation,KW-0744~Spermatogenesis,	KW-0539~Nucleus,				KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,	DOMAIN:BACK,DOMAIN:BTB,MOTIF:Nuclear localization signal,REGION:Disordered,
GMFG	glia maturation factor gamma(GMFG)	Homo sapiens			GO:0006468~protein phosphorylation,GO:0007165~signal transduction,GO:0034316~negative regulation of Arp2/3 complex-mediated actin nucleation,GO:0071846~actin filament debranching,	GO:0005576~extracellular region,GO:0034774~secretory granule lumen,GO:1904813~ficolin-1-rich granule lumen,	GO:0003779~actin binding,GO:0004860~protein kinase inhibitor activity,GO:0008047~enzyme activator activity,GO:0008083~growth factor activity,GO:0071933~Arp2/3 complex binding,	IPR002108:ADF-H,IPR011171:GMF,IPR029006:ADF-H/Gelsolin-like_dom_sf,			PIRSF001788:GMF-beta,	SM00102:ADF,						KW-0339~Growth factor,	KW-0007~Acetylation,	DOMAIN:ADF-H,
G6PD	glucose-6-phosphate dehydrogenase(G6PD)	Homo sapiens			GO:0006006~glucose metabolic process,GO:0006098~pentose-phosphate shunt,GO:0006629~lipid metabolic process,GO:0006695~cholesterol biosynthetic process,GO:0006739~NADP metabolic process,GO:0006740~NADPH regeneration,GO:0006749~glutathione metabolic process,GO:0009051~pentose-phosphate shunt, oxidative branch,GO:0010041~response to iron(III) ion,GO:0010734~negative regulation of protein glutathionylation,GO:0014070~response to organic cyclic compound,GO:0019322~pentose biosynthetic process,GO:0021762~substantia nigra development,GO:0032094~response to food,GO:0034599~cellular response to oxidative stress,GO:0043249~erythrocyte maturation,GO:0043523~regulation of neuron apoptotic process,GO:0045471~response to ethanol,GO:0046390~ribose phosphate biosynthetic process,GO:0051156~glucose 6-phosphate metabolic process,GO:0061052~negative regulation of cell growth involved in cardiac muscle cell development,GO:1904879~positive regulation of calcium ion transmembrane transport via high voltage-gated calcium channel,GO:2000378~negative regulation of reactive oxygen species metabolic process,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0009898~cytoplasmic side of plasma membrane,GO:0016020~membrane,GO:0034451~centriolar satellite,GO:0043231~intracellular membrane-bounded organelle,GO:0070062~extracellular exosome,	GO:0004345~glucose-6-phosphate dehydrogenase activity,GO:0005515~protein binding,GO:0005536~glucose binding,GO:0016614~oxidoreductase activity, acting on CH-OH group of donors,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0050661~NADP binding,	IPR001282:G6P_DH,IPR019796:G6P_DH_AS,IPR022674:G6P_DH_NAD-bd,IPR022675:G6P_DH_C,IPR036291:NAD(P)-bd_dom_sf,	hsa00030:Pentose phosphate pathway,hsa00480:Glutathione metabolism,hsa01100:Metabolic pathways,hsa01200:Carbon metabolism,hsa05230:Central carbon metabolism in cancer,hsa05415:Diabetic cardiomyopathy,	300908~Hemolytic anemia, G6PD deficient (favism),611162~Resistance to malaria due to G6PD deficiency,	PIRSF000110:G6PD,		KW-0119~Carbohydrate metabolism,KW-0313~Glucose metabolism,	KW-0472~Membrane,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0360~Hereditary hemolytic anemia,		KW-0521~NADP,	KW-0560~Oxidoreductase,	KW-0007~Acetylation,KW-0379~Hydroxylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,DOMAIN:Glucose-6-phosphate dehydrogenase C-terminal,DOMAIN:Glucose-6-phosphate dehydrogenase NAD-binding,MUTAGEN:K->Q: Impairs dimerization and reduces catalytic activity in cells under oxidative stress.,MUTAGEN:K->Q: Impairs dimerization and reduces catalytic activity.,MUTAGEN:K->Q: Inhibits catalytic activity. Does not impair dimerization.,MUTAGEN:K->R: Does not impair dimerization and catalytic activity.,MUTAGEN:K->R: Inhibits catalytic activity. Does not impair dimerization.,REGION:Disordered,
GPI	glucose-6-phosphate isomerase(GPI)	Homo sapiens		h_glycolysisPathway:Glycolysis Pathway,	GO:0001701~in utero embryonic development,GO:0001707~mesoderm formation,GO:0002639~positive regulation of immunoglobulin production,GO:0005975~carbohydrate metabolic process,GO:0006094~gluconeogenesis,GO:0006096~glycolytic process,GO:0006959~humoral immune response,GO:0007165~signal transduction,GO:0007599~hemostasis,GO:0007611~learning or memory,GO:0010595~positive regulation of endothelial cell migration,GO:0032355~response to estradiol,GO:0032570~response to progesterone,GO:0033574~response to testosterone,GO:0034101~erythrocyte homeostasis,GO:0035902~response to immobilization stress,GO:0035994~response to muscle stretch,GO:0042593~glucose homeostasis,GO:0043524~negative regulation of neuron apoptotic process,GO:0046686~response to cadmium ion,GO:0051156~glucose 6-phosphate metabolic process,GO:1901135~carbohydrate derivative metabolic process,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005829~cytosol,GO:0016020~membrane,GO:0034774~secretory granule lumen,GO:0060170~ciliary membrane,GO:0070062~extracellular exosome,GO:1904813~ficolin-1-rich granule lumen,	GO:0004347~glucose-6-phosphate isomerase activity,GO:0005125~cytokine activity,GO:0005515~protein binding,GO:0008083~growth factor activity,GO:0031625~ubiquitin protein ligase binding,GO:0048029~monosaccharide binding,GO:0097367~carbohydrate derivative binding,	IPR001672:G6P_Isomerase,IPR018189:Phosphoglucose_isomerase_CS,IPR023096:G6P_Isomerase_C,IPR035476:SIS_PGI_1,IPR035482:SIS_PGI_2,IPR046348:SIS_dom_sf,	hsa00010:Glycolysis / Gluconeogenesis,hsa00030:Pentose phosphate pathway,hsa00500:Starch and sucrose metabolism,hsa00520:Amino sugar and nucleotide sugar metabolism,hsa01100:Metabolic pathways,hsa01200:Carbon metabolism,hsa01250:Biosynthesis of nucleotide sugars,	613470~Hemolytic anemia, nonspherocytic, due to glucose phosphate isomerase deficiency,			KW-0312~Gluconeogenesis,KW-0324~Glycolysis,	KW-0963~Cytoplasm,KW-0964~Secreted,	KW-0225~Disease variant,KW-0360~Hereditary hemolytic anemia,			KW-0202~Cytokine,KW-0339~Growth factor,KW-0413~Isomerase,	KW-0007~Acetylation,KW-0379~Hydroxylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	ACT_SITE:Proton donor,MUTAGEN:S->A: Retained full enzymatic activity.,MUTAGEN:S->E: Decreased enzymatic activity.,REGION:Disordered,
GUSB	glucuronidase beta(GUSB)	Homo sapiens			GO:0005975~carbohydrate metabolic process,GO:0006027~glycosaminoglycan catabolic process,GO:0019391~glucuronoside catabolic process,GO:0030200~heparan sulfate proteoglycan catabolic process,GO:0030207~chondroitin sulfate catabolic process,GO:0030214~hyaluronan catabolic process,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005764~lysosome,GO:0016020~membrane,GO:0035578~azurophil granule lumen,GO:0043202~lysosomal lumen,GO:0043231~intracellular membrane-bounded organelle,GO:0070062~extracellular exosome,GO:1904813~ficolin-1-rich granule lumen,	GO:0004553~hydrolase activity, hydrolyzing O-glycosyl compounds,GO:0004566~beta-glucuronidase activity,GO:0005102~receptor binding,GO:0019904~protein domain specific binding,GO:0030246~carbohydrate binding,	IPR006101:Glyco_hydro_2,IPR006102:Glyco_hydro_2_Ig-like,IPR006103:Glyco_hydro_2_cat,IPR006104:Glyco_hydro_2_N,IPR008979:Galactose-bd-like_sf,IPR013783:Ig-like_fold,IPR017853:Glycoside_hydrolase_SF,IPR023230:Glyco_hydro_2_CS,IPR023232:Glyco_hydro_2_AS,IPR036156:Beta-gal/glucu_dom_sf,	hsa00040:Pentose and glucuronate interconversions,hsa00053:Ascorbate and aldarate metabolism,hsa00531:Glycosaminoglycan degradation,hsa00860:Porphyrin metabolism,hsa00983:Drug metabolism - other enzymes,hsa01100:Metabolic pathways,hsa01240:Biosynthesis of cofactors,hsa04142:Lysosome,	253220~Mucopolysaccharidosis VII,				KW-0458~Lysosome,	KW-0225~Disease variant,KW-0510~Mucopolysaccharidosis,	KW-0732~Signal,		KW-0326~Glycosidase,KW-0378~Hydrolase,	KW-0325~Glycoprotein,	ACT_SITE:Proton donor,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Glycoside hydrolase family 2 catalytic,DOMAIN:Glycoside hydrolase family 2 immunoglobulin-like beta-sandwich,DOMAIN:Glycosyl hydrolases family 2 sugar binding,
GLUD1	glutamate dehydrogenase 1(GLUD1)	Homo sapiens		h_argininecPathway:Catabolic Pathways for Arginine , Histidine, Glutamate, Glutamine, and Proline,	GO:0006520~cellular amino acid metabolic process,GO:0006537~glutamate biosynthetic process,GO:0006538~glutamate catabolic process,GO:0006541~glutamine metabolic process,GO:0021762~substantia nigra development,GO:0032024~positive regulation of insulin secretion,GO:0072350~tricarboxylic acid metabolic process,	GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0005783~endoplasmic reticulum,	GO:0000166~nucleotide binding,GO:0004352~glutamate dehydrogenase (NAD+) activity,GO:0004353~glutamate dehydrogenase [NAD(P)+] activity,GO:0004354~glutamate dehydrogenase (NADP+) activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0005525~GTP binding,GO:0016491~oxidoreductase activity,GO:0016639~oxidoreductase activity, acting on the CH-NH2 group of donors, NAD or NADP as acceptor,GO:0042803~protein homodimerization activity,GO:0043531~ADP binding,GO:0070403~NAD+ binding,GO:0070728~leucine binding,	IPR006095:Glu/Leu/Phe/Val/Trp_DH,IPR006096:Glu/Leu/Phe/Val/Trp_DH_C,IPR006097:Glu/Leu/Phe/Val/Trp_DH_dimer,IPR014362:Glu_DH,IPR033524:Glu/Leu/Phe/Val_DH_AS,IPR033922:NAD_bind_Glu_DH,IPR036291:NAD(P)-bd_dom_sf,IPR046346:Aminoacid_DH-like_N_sf,	hsa00220:Arginine biosynthesis,hsa00250:Alanine, aspartate and glutamate metabolism,hsa00910:Nitrogen metabolism,hsa01100:Metabolic pathways,hsa01200:Carbon metabolism,hsa04217:Necroptosis,hsa04964:Proximal tubule bicarbonate reclamation,	606762~Hyperinsulinism-hyperammonemia syndrome,	PIRSF000185:Glu_DH,	SM00839:ELFV_dehydrog,		KW-0256~Endoplasmic reticulum,KW-0496~Mitochondrion,	KW-0225~Disease variant,	KW-0809~Transit peptide,	KW-0067~ATP-binding,KW-0342~GTP-binding,KW-0520~NAD,KW-0521~NADP,KW-0547~Nucleotide-binding,	KW-0560~Oxidoreductase,	KW-0007~Acetylation,KW-0013~ADP-ribosylation,KW-0379~Hydroxylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton donor,DOMAIN:Glutamate/phenylalanine/leucine/valine/L-tryptophan dehydrogenase C-terminal,DOMAIN:Glutamate/phenylalanine/leucine/valine/L-tryptophan dehydrogenase dimerisation,MUTAGEN:R->A: Abolishes activation by ADP.,MUTAGEN:S->A: Reduces activity and inhibition by GTP.,SITE:Important for catalysis,TRANSIT:Mitochondrion,
ERICH1	glutamate rich 1(ERICH1)	Homo sapiens					GO:0005515~protein binding,	IPR026719:ERICH1,											KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,REGION:Disordered,
GRWD1	glutamate rich WD repeat containing 1(GRWD1)	Homo sapiens			GO:0006260~DNA replication,GO:0006334~nucleosome assembly,GO:0006337~nucleosome disassembly,GO:0042254~ribosome biogenesis,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005694~chromosome,GO:0005730~nucleolus,GO:0005829~cytosol,GO:0032991~macromolecular complex,	GO:0003682~chromatin binding,GO:0003688~DNA replication origin binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0042393~histone binding,	IPR001680:WD40_rpt,IPR015943:WD40/YVTN_repeat-like_dom_sf,IPR019775:WD40_repeat_CS,IPR020472:G-protein_beta_WD-40_rep,IPR022052:Histone-bd_RBBP4_N,IPR036322:WD40_repeat_dom_sf,				SM00320:WD40,	KW-0235~DNA replication,	KW-0158~Chromosome,KW-0539~Nucleus,		KW-0677~Repeat,KW-0853~WD repeat,			KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Histone-binding protein RBBP4 N-terminal,REGION:Disordered,REPEAT:WD,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,REPEAT:WD 7,
GLUL	glutamate-ammonia ligase(GLUL)	Homo sapiens			GO:0001525~angiogenesis,GO:0006538~glutamate catabolic process,GO:0006542~glutamine biosynthetic process,GO:0008283~cell proliferation,GO:0009267~cellular response to starvation,GO:0009749~response to glucose,GO:0010594~regulation of endothelial cell migration,GO:0018345~protein palmitoylation,GO:0042254~ribosome biogenesis,GO:1903670~regulation of sprouting angiogenesis,GO:1904749~regulation of protein localization to nucleolus,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0044297~cell body,GO:0070062~extracellular exosome,GO:0097386~glial cell projection,	GO:0004356~glutamate-ammonia ligase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0019706~protein-cysteine S-palmitoyltransferase activity,GO:0042802~identical protein binding,GO:0046872~metal ion binding,	IPR008146:Gln_synth_cat_dom,IPR008147:Gln_synt_N,IPR014746:Gln_synth/guanido_kin_cat_dom,IPR027302:Gln_synth_N_conserv_site,IPR027303:Gln_synth_gly_rich_site,IPR036651:Gln_synt_N_sf,	hsa00220:Arginine biosynthesis,hsa00250:Alanine, aspartate and glutamate metabolism,hsa00630:Glyoxylate and dicarboxylate metabolism,hsa00910:Nitrogen metabolism,hsa01100:Metabolic pathways,hsa01230:Biosynthesis of amino acids,hsa04217:Necroptosis,hsa04724:Glutamatergic synapse,hsa04727:GABAergic synapse,	610015~Glutamine deficiency, congenital,		SM01230:Gln-synt_C,	KW-0037~Angiogenesis,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0492~Microsome,KW-0496~Mitochondrion,KW-0963~Cytoplasm,KW-1003~Cell membrane,	KW-0225~Disease variant,		KW-0067~ATP-binding,KW-0460~Magnesium,KW-0464~Manganese,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0436~Ligase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Basic and acidic residues,DOMAIN:GS beta-grasp,DOMAIN:GS catalytic,MUTAGEN:C->A: Reduced ability to mediate autopalmitoylation.,MUTAGEN:R->A,C: Decreases ribolosomal 40S subunit synthesis. Loss of nucleolar location of BYSL.,REGION:Disordered,
GCLM	glutamate-cysteine ligase modifier subunit(GCLM)	Homo sapiens			GO:0006534~cysteine metabolic process,GO:0006536~glutamate metabolic process,GO:0006750~glutathione biosynthetic process,GO:0006979~response to oxidative stress,GO:0007584~response to nutrient,GO:0008637~apoptotic mitochondrial changes,GO:0009410~response to xenobiotic stimulus,GO:0014823~response to activity,GO:0035229~positive regulation of glutamate-cysteine ligase activity,GO:0035729~cellular response to hepatocyte growth factor stimulus,GO:0035733~hepatic stellate cell activation,GO:0043524~negative regulation of neuron apoptotic process,GO:0044344~cellular response to fibroblast growth factor stimulus,GO:0044752~response to human chorionic gonadotropin,GO:0051409~response to nitrosative stress,GO:0051900~regulation of mitochondrial depolarization,GO:0071333~cellular response to glucose stimulus,GO:0071372~cellular response to follicle-stimulating hormone stimulus,GO:0097069~cellular response to thyroxine stimulus,GO:0097746~regulation of blood vessel diameter,GO:1990830~cellular response to leukemia inhibitory factor,GO:2001237~negative regulation of extrinsic apoptotic signaling pathway,	GO:0005829~cytosol,GO:0017109~glutamate-cysteine ligase complex,	GO:0004357~glutamate-cysteine ligase activity,GO:0005515~protein binding,GO:0030234~enzyme regulator activity,GO:0035226~glutamate-cysteine ligase catalytic subunit binding,GO:0044877~macromolecular complex binding,	IPR023210:NADP_OxRdtase_dom,IPR032963:Gclm,IPR036812:NADP_OxRdtase_dom_sf,	hsa00270:Cysteine and methionine metabolism,hsa00480:Glutathione metabolism,hsa01100:Metabolic pathways,hsa01240:Biosynthesis of cofactors,hsa04216:Ferroptosis,	608446~Myocardial infarction, susceptibility to,			KW-0317~Glutathione biosynthesis,						KW-0007~Acetylation,
GOT2	glutamic-oxaloacetic transaminase 2(GOT2)	Homo sapiens			GO:0006103~2-oxoglutarate metabolic process,GO:0006107~oxaloacetate metabolic process,GO:0006520~cellular amino acid metabolic process,GO:0006531~aspartate metabolic process,GO:0006532~aspartate biosynthetic process,GO:0006533~aspartate catabolic process,GO:0006536~glutamate metabolic process,GO:0009058~biosynthetic process,GO:0015908~fatty acid transport,GO:0019470~4-hydroxyproline catabolic process,GO:0019550~glutamate catabolic process to aspartate,GO:0019551~glutamate catabolic process to 2-oxoglutarate,GO:0045471~response to ethanol,GO:0097052~L-kynurenine metabolic process,	GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0005886~plasma membrane,GO:0070062~extracellular exosome,	GO:0003723~RNA binding,GO:0004069~L-aspartate:2-oxoglutarate aminotransferase activity,GO:0016212~kynurenine-oxoglutarate transaminase activity,GO:0030170~pyridoxal phosphate binding,	IPR000796:Asp_trans,IPR004838:NHTrfase_class1_PyrdxlP-BS,IPR004839:Aminotransferase_I/II,IPR015421:PyrdxlP-dep_Trfase_major,IPR015422:PyrdxlP-dep_Trfase_small,IPR015424:PyrdxlP-dep_Trfase,	hsa00220:Arginine biosynthesis,hsa00250:Alanine, aspartate and glutamate metabolism,hsa00270:Cysteine and methionine metabolism,hsa00330:Arginine and proline metabolism,hsa00350:Tyrosine metabolism,hsa00360:Phenylalanine metabolism,hsa00400:Phenylalanine, tyrosine and tryptophan biosynthesis,hsa01100:Metabolic pathways,hsa01200:Carbon metabolism,hsa01210:2-Oxocarboxylic acid metabolism,hsa01230:Biosynthesis of amino acids,hsa04975:Fat digestion and absorption,	618721~Developmental and epileptic encephalopathy 82,			KW-0445~Lipid transport,KW-0813~Transport,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0887~Epilepsy,	KW-0809~Transit peptide,	KW-0663~Pyridoxal phosphate,	KW-0032~Aminotransferase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0944~Nitration,	DOMAIN:Aminotransferase class I/classII,TRANSIT:Mitochondrion,
GLS	glutaminase(GLS)	Homo sapiens		h_argininecPathway:Catabolic Pathways for Arginine , Histidine, Glutamate, Glutamine, and Proline,	GO:0001967~suckling behavior,GO:0002087~regulation of respiratory gaseous exchange by neurological system process,GO:0006537~glutamate biosynthetic process,GO:0006541~glutamine metabolic process,GO:0006543~glutamine catabolic process,GO:0007268~chemical synaptic transmission,GO:0051289~protein homotetramerization,GO:0090461~glutamate homeostasis,	GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0005829~cytosol,GO:0045202~synapse,	GO:0004359~glutaminase activity,GO:0005515~protein binding,	IPR002110:Ankyrin_rpt,IPR012338:Beta-lactam/transpept-like,IPR015868:Glutaminase,IPR036770:Ankyrin_rpt-contain_sf,IPR041541:Glutaminase_EF-hand,	hsa00220:Arginine biosynthesis,hsa00250:Alanine, aspartate and glutamate metabolism,hsa00470:D-Amino acid metabolism,hsa01100:Metabolic pathways,hsa04724:Glutamatergic synapse,hsa04727:GABAergic synapse,hsa04964:Proximal tubule bicarbonate reclamation,hsa05206:MicroRNAs in cancer,hsa05230:Central carbon metabolism in cancer,	618328~Developmental and epileptic encephalopathy 71,618339~Infantile cataract, skin abnormalities, glutamate excess, and impaired intellectual development,618412~Global developmental delay, progressive ataxia, and elevated glutamine,		SM00248:ANK,		KW-0496~Mitochondrion,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0887~Epilepsy,KW-0898~Cataract,	KW-0040~ANK repeat,KW-0677~Repeat,KW-0809~Transit peptide,		KW-0378~Hydrolase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:Glutaminase EF-hand,MUTAGEN:F->S: No effect on catalytic activity. Loss of inhibition by BPTES; when associated with Y-318.,MUTAGEN:F->Y: No effect on catalytic activity. Loss of inhibition by BPTES; when associated with S-322.,MUTAGEN:K->A: Loss of enzyme activity.,MUTAGEN:L->A: Decreased enzyme activity.,MUTAGEN:S->A: Loss of enzyme activity.,MUTAGEN:Y->A: Decreased enzyme activity.,MUTAGEN:Y->A: Loss of enzyme activity.,MUTAGEN:Y->L: No effect on catalytic activity. Loss of inhibition by BPTES.,REGION:Disordered,REGION:Highly mobile activation loop,REPEAT:ANK,REPEAT:ANK 1,REPEAT:ANK 2,SITE:Cleavage; by MPP,TRANSIT:Mitochondrion,
QRICH1	glutamine rich 1(QRICH1)	Homo sapiens			GO:0030968~endoplasmic reticulum unfolded protein response,GO:0034976~response to endoplasmic reticulum stress,GO:0036499~PERK-mediated unfolded protein response,GO:0042981~regulation of apoptotic process,GO:0043065~positive regulation of apoptotic process,GO:0045893~positive regulation of transcription, DNA-templated,GO:0070059~intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005886~plasma membrane,	GO:0003677~DNA binding,GO:0005515~protein binding,	IPR001315:CARD,IPR011029:DEATH-like_dom_sf,IPR021893:DUF3504,		617982~Ververi-Brady syndrome,			KW-0804~Transcription,KW-0805~Transcription regulation,KW-0834~Unfolded protein response,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0991~Intellectual disability,				KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:CARD,DOMAIN:DUF3504,REGION:Disordered,
GLRX3	glutaredoxin 3(GLRX3)	Homo sapiens			GO:0002026~regulation of the force of heart contraction,GO:0006879~cellular iron ion homeostasis,GO:0010614~negative regulation of cardiac muscle hypertrophy,GO:0016226~iron-sulfur cluster assembly,GO:0044571~[2Fe-2S] cluster assembly,GO:0045454~cell redox homeostasis,GO:0097428~protein maturation by iron-sulfur cluster transfer,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005938~cell cortex,GO:0030018~Z disc,GO:0030425~dendrite,GO:1990229~iron-sulfur cluster assembly complex,	GO:0003723~RNA binding,GO:0005080~protein kinase C binding,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0046872~metal ion binding,GO:0051536~iron-sulfur cluster binding,	IPR002109:Glutaredoxin,IPR004480:Monothiol_GRX-rel,IPR013766:Thioredoxin_domain,IPR033658:GRX_PICOT-like,IPR036249:Thioredoxin-like_sf,						KW-0963~Cytoplasm,		KW-0677~Repeat,	KW-0408~Iron,KW-0411~Iron-sulfur,KW-0479~Metal-binding,		KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:Glutaredoxin 1,DOMAIN:Glutaredoxin 2,DOMAIN:Thioredoxin,MUTAGEN:C->S: Loss of 2Fe-2S-binding; when associated with S-159. Loss of 2Fe-2S-binding and interaction with BOLA2; when associated with 299-D-A-300.,MUTAGEN:C->S: Loss of 2Fe-2S-binding; when associated with S-261. Loss of 2Fe-2S-binding and interaction with BOLA2; when associated with 197-D-A-198.,MUTAGEN:WP->DA: Loss of 2Fe-2S-binding and interaction with BOLA2; when associated with S-159.,MUTAGEN:WP->DA: Loss of 2Fe-2S-binding and interaction with BOLA2; when associated with S-261.,
GLRX	glutaredoxin(GLRX)	Homo sapiens			GO:0015949~nucleobase-containing small molecule interconversion,GO:0045838~positive regulation of membrane potential,	GO:0005634~nucleus,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0015038~glutathione disulfide oxidoreductase activity,GO:0017080~sodium channel regulator activity,	IPR002109:Glutaredoxin,IPR011767:GLR_AS,IPR011899:Glutaredoxin_euk/vir,IPR014025:Glutaredoxin_subgr,IPR036249:Thioredoxin-like_sf,IPR047185:GLRX1,					KW-0249~Electron transport,KW-0813~Transport,	KW-0963~Cytoplasm,		KW-0676~Redox-active center,			KW-0007~Acetylation,KW-1015~Disulfide bond,	DISULFID:Redox-active,DOMAIN:Glutaredoxin,
GSTK1	glutathione S-transferase kappa 1(GSTK1)	Homo sapiens			GO:0006749~glutathione metabolic process,GO:0030855~epithelial cell differentiation,GO:0098869~cellular oxidant detoxification,	GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0005777~peroxisome,GO:0005782~peroxisomal matrix,GO:0005829~cytosol,GO:0016020~membrane,GO:0070062~extracellular exosome,	GO:0004364~glutathione transferase activity,GO:0004602~glutathione peroxidase activity,GO:0005515~protein binding,GO:0016491~oxidoreductase activity,	IPR001853:DSBA-like_thioredoxin_dom,IPR014440:HCCAis_GSTk,IPR036249:Thioredoxin-like_sf,IPR044088:GSTK,	hsa00480:Glutathione metabolism,hsa00980:Metabolism of xenobiotics by cytochrome P450,hsa00982:Drug metabolism - cytochrome P450,hsa01100:Metabolic pathways,hsa04146:Peroxisome,hsa05204:Chemical carcinogenesis - DNA adducts,		PIRSF006386:HCCAis_GSTk,			KW-0576~Peroxisome,				KW-0808~Transferase,	KW-0007~Acetylation,	ACT_SITE:Nucleophile,DOMAIN:DSBA-like thioredoxin,
GSTO1	glutathione S-transferase omega 1(GSTO1)	Homo sapiens			GO:0006749~glutathione metabolic process,GO:0010880~regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum,GO:0010881~regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion,GO:0014810~positive regulation of skeletal muscle contraction by regulation of release of sequestered calcium ion,GO:0019852~L-ascorbic acid metabolic process,GO:0042178~xenobiotic catabolic process,GO:0060315~negative regulation of ryanodine-sensitive calcium-release channel activity,GO:0060316~positive regulation of ryanodine-sensitive calcium-release channel activity,GO:0071243~cellular response to arsenic-containing substance,GO:0098869~cellular oxidant detoxification,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0004364~glutathione transferase activity,GO:0005515~protein binding,GO:0016491~oxidoreductase activity,GO:0045174~glutathione dehydrogenase (ascorbate) activity,GO:0050610~methylarsonate reductase activity,	IPR004045:Glutathione_S-Trfase_N,IPR004046:GST_C,IPR005442:GST_omega,IPR010987:Glutathione-S-Trfase_C-like,IPR036249:Thioredoxin-like_sf,IPR036282:Glutathione-S-Trfase_C_sf,IPR040079:Glutathione_S-Trfase,IPR045073:Omega/Tau-like,	hsa00480:Glutathione metabolism,hsa00980:Metabolism of xenobiotics by cytochrome P450,hsa00982:Drug metabolism - cytochrome P450,hsa00983:Drug metabolism - other enzymes,hsa01100:Metabolic pathways,hsa01524:Platinum drug resistance,hsa05200:Pathways in cancer,hsa05204:Chemical carcinogenesis - DNA adducts,hsa05207:Chemical carcinogenesis - receptor activation,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05225:Hepatocellular carcinoma,hsa05418:Fluid shear stress and atherosclerosis,					KW-0963~Cytoplasm,				KW-0560~Oxidoreductase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Nucleophile,DOMAIN:GST C-terminal,DOMAIN:GST N-terminal,MUTAGEN:C->A: Loss of activity.,
GPX4	glutathione peroxidase 4(GPX4)	Homo sapiens			GO:0006325~chromatin organization,GO:0006644~phospholipid metabolic process,GO:0006749~glutathione metabolic process,GO:0006979~response to oxidative stress,GO:0007283~spermatogenesis,GO:0019369~arachidonic acid metabolic process,GO:0019372~lipoxygenase pathway,GO:0032355~response to estradiol,GO:0042759~long-chain fatty acid biosynthetic process,GO:0051258~protein polymerization,GO:0098869~cellular oxidant detoxification,	GO:0005634~nucleus,GO:0005635~nuclear envelope,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0032991~macromolecular complex,GO:0070062~extracellular exosome,	GO:0004601~peroxidase activity,GO:0004602~glutathione peroxidase activity,GO:0005515~protein binding,GO:0008430~selenium binding,GO:0042802~identical protein binding,GO:0047066~phospholipid-hydroperoxide glutathione peroxidase activity,	IPR000889:Glutathione_peroxidase,IPR029759:GPX_AS,IPR029760:GPX_CS,IPR036249:Thioredoxin-like_sf,	hsa00480:Glutathione metabolism,hsa00590:Arachidonic acid metabolism,hsa01100:Metabolic pathways,hsa04216:Ferroptosis,	250220~Spondylometaphyseal dysplasia, Sedaghatian type,	PIRSF000303:Glutathion_perox,		KW-0443~Lipid metabolism,	KW-0496~Mitochondrion,KW-0963~Cytoplasm,	KW-0242~Dwarfism,	KW-0732~Signal,KW-0809~Transit peptide,		KW-0217~Developmental protein,KW-0560~Oxidoreductase,KW-0575~Peroxidase,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,MUTAGEN:U->A: Loss of enzyme activity.,MUTAGEN:U->C: Almost complete loss of enzyme activity.,NON_STD:Selenocysteine,REGION:Disordered,TRANSIT:Mitochondrion,
GK	glycerol kinase(GK)	Homo sapiens			GO:0005975~carbohydrate metabolic process,GO:0006071~glycerol metabolic process,GO:0006072~glycerol-3-phosphate metabolic process,GO:0006641~triglyceride metabolic process,GO:0016310~phosphorylation,GO:0019432~triglyceride biosynthetic process,GO:0019563~glycerol catabolic process,GO:0046167~glycerol-3-phosphate biosynthetic process,GO:0046380~N-acetylneuraminate biosynthetic process,	GO:0005634~nucleus,GO:0005739~mitochondrion,GO:0005741~mitochondrial outer membrane,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0004370~glycerol kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016301~kinase activity,GO:0046872~metal ion binding,	IPR000577:Carb_kinase_FGGY,IPR005999:Glycerol_kin,IPR018483:Carb_kinase_FGGY_CS,IPR018484:FGGY_N,IPR018485:FGGY_C,IPR042018:GK1-3_metazoa,IPR043129:ATPase_NBD,	hsa00561:Glycerolipid metabolism,hsa01100:Metabolic pathways,hsa03320:PPAR signaling pathway,	307030~Glycerol kinase deficiency,	PIRSF000538:GlpK,		KW-0319~Glycerol metabolism,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1000~Mitochondrion outer membrane,	KW-0225~Disease variant,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,KW-0862~Zinc,	KW-0418~Kinase,KW-0808~Transferase,		DOMAIN:Carbohydrate kinase FGGY C-terminal,DOMAIN:Carbohydrate kinase FGGY N-terminal,TRANSMEM:Helical,
GDE1	glycerophosphodiester phosphodiesterase 1(GDE1)	Homo sapiens			GO:0006580~ethanolamine metabolic process,GO:0006629~lipid metabolic process,GO:0006644~phospholipid metabolic process,GO:0046475~glycerophospholipid catabolic process,GO:0070291~N-acylethanolamine metabolic process,	GO:0005886~plasma membrane,GO:0016020~membrane,GO:0030659~cytoplasmic vesicle membrane,	GO:0004622~lysophospholipase activity,GO:0005515~protein binding,GO:0008081~phosphoric diester hydrolase activity,GO:0008889~glycerophosphodiester phosphodiesterase activity,GO:0046872~metal ion binding,GO:0047395~glycerophosphoinositol glycerophosphodiesterase activity,	IPR017946:PLC-like_Pdiesterase_TIM-brl,IPR030395:GP_PDE_dom,					KW-0443~Lipid metabolism,	KW-0472~Membrane,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0460~Magnesium,KW-0479~Metal-binding,	KW-0378~Hydrolase,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:GP-PDE,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
GYG1	glycogenin 1(GYG1)	Homo sapiens			GO:0005978~glycogen biosynthetic process,	GO:0005576~extracellular region,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016020~membrane,GO:0034774~secretory granule lumen,GO:0043202~lysosomal lumen,GO:1904813~ficolin-1-rich granule lumen,	GO:0005515~protein binding,GO:0008194~UDP-glycosyltransferase activity,GO:0008466~glycogenin glucosyltransferase activity,GO:0016757~transferase activity, transferring glycosyl groups,GO:0030145~manganese ion binding,GO:0042803~protein homodimerization activity,	IPR002495:Glyco_trans_8,IPR029044:Nucleotide-diphossugar_trans,	hsa00500:Starch and sucrose metabolism,hsa01100:Metabolic pathways,	613507~Glycogen storage disease XV,616199~Polyglucosan body myopathy 2,			KW-0320~Glycogen biosynthesis,		KW-0225~Disease variant,KW-0322~Glycogen storage disease,		KW-0464~Manganese,KW-0479~Metal-binding,	KW-0808~Transferase,	KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:O-linked (Glc...) tyrosine,MUTAGEN:Y->F: Loss of glucosylation.,REGION:Interaction with GYS1,SITE:Important for catalytic activity,
GLTP	glycolipid transfer protein(GLTP)	Homo sapiens			GO:0006687~glycosphingolipid metabolic process,GO:0006688~glycosphingolipid biosynthetic process,GO:0035621~ER to Golgi ceramide transport,GO:0035627~ceramide transport,GO:0035902~response to immobilization stress,GO:0046836~glycolipid transport,GO:1902389~ceramide 1-phosphate transport,	GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0005515~protein binding,GO:0008289~lipid binding,GO:0017089~glycolipid transporter activity,GO:0042802~identical protein binding,GO:0051861~glycolipid binding,GO:1902387~ceramide 1-phosphate binding,GO:1902388~ceramide 1-phosphate transporter activity,	IPR014830:Glycolipid_transfer_prot_dom,IPR036497:GLTP_sf,					KW-0445~Lipid transport,KW-0813~Transport,	KW-0963~Cytoplasm,		KW-0677~Repeat,			KW-0007~Acetylation,	DOMAIN:Glycolipid transfer protein,MUTAGEN:D->V: Significant inactivation; 15% residual activity.,MUTAGEN:F->S: About 25% decrease in activity.,MUTAGEN:F->S: About 50% decrease in activity.,MUTAGEN:F->S: No loss of activity; 90% residual activity.,MUTAGEN:H->L: Almost complete inactivation; 1-3% residual activity.,MUTAGEN:I->N: 18% decrease in activity.,MUTAGEN:K->I: No loss of activity; 90-97% residual activity.,MUTAGEN:L->R: 46% decrease in activity.,MUTAGEN:L->R: Significant inactivation; 5% residual acti vity.,MUTAGEN:N->I: Significant inactivation; 15% residual activity.,MUTAGEN:W->A: Almost complete inactivation; 1-3% residual activity. No effect on autophagy.,MUTAGEN:W->F: Partial inactivation; 63% residual activity.,MUTAGEN:Y->L: No loss of activity; 90-97% residual activity.,REGION:2 X 12 AA approximate tandem repeats,REGION:Disordered,REPEAT:1,REPEAT:2,
GYPC	glycophorin C (Gerbich blood group)(GYPC)	Homo sapiens				GO:0005886~plasma membrane,GO:0016020~membrane,GO:0030863~cortical cytoskeleton,	GO:0005515~protein binding,	IPR001195:Glycophorin,IPR003585:Neurexin-like,IPR042192:Glycophorin-C,	hsa05144:Malaria,	611162~Malaria, resistance to,616089~Blood group, Gerbich,	PIRSF002466:Glycophorin,	SM00294:4.1m,		KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0730~Sialic acid,	KW-0095~Blood group antigen,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (GalNAc...) serine,CARBOHYD:O-linked (GalNAc...) threonine,COMPBIAS:Polar residues,DOMAIN:Neurexin/syndecan/glycophorin C,REGION:Disordered,SITE:Not glycosylated; in variant Webb antigen,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type III membrane protein,
GINM1	glycosylated integral membrane protein 1(GINM1)	Homo sapiens				GO:0016020~membrane,	GO:0005515~protein binding,	IPR042319:GINM1,						KW-0472~Membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
GPAA1	glycosylphosphatidylinositol anchor attachment 1(GPAA1)	Homo sapiens			GO:0006621~protein retention in ER lumen,GO:0016255~attachment of GPI anchor to protein,GO:0065003~macromolecular complex assembly,	GO:0005739~mitochondrion,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005813~centrosome,GO:0005829~cytosol,GO:0016020~membrane,GO:0042765~GPI-anchor transamidase complex,	GO:0003923~GPI-anchor transamidase activity,GO:0005515~protein binding,GO:0015631~tubulin binding,GO:0034235~GPI anchor binding,	IPR007246:Gaa1,	hsa00563:Glycosylphosphatidylinositol (GPI)-anchor biosynthesis,hsa01100:Metabolic pathways,	617810~Glycosylphosphatidylinositol biosynthesis defect 15,	PIRSF036762:GAA1,		KW-0337~GPI-anchor biosynthesis,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,	KW-0225~Disease variant,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,MUTAGEN:D->A: Decreased function in GPI-anchor attachment to protein.,MUTAGEN:D->A: No effect on function in GPI-anchor attachment to protein.,MUTAGEN:E->A: No effect on function in GPI-anchor attachment to protein.,MUTAGEN:EH->AA: No effect on function in GPI-anchor attachment to protein.,MUTAGEN:ER->AA: No effect on function in GPI-anchor attachment to protein.,MUTAGEN:F->A: No effect on function in GPI-anchor attachment to protein.,MUTAGEN:K->A: No effect on function in GPI-anchor attachment to protein.,MUTAGEN:N->Q: No effect on function in GPI-anchor attachment to protein.,MUTAGEN:R->A: No effect on function in GPI-anchor attachment to protein.,MUTAGEN:Y->A: No effect on function in GPI-anchor attachment to protein.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
GLO1	glyoxalase I(GLO1)	Homo sapiens			GO:0005975~carbohydrate metabolic process,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006749~glutathione metabolic process,GO:0009438~methylglyoxal metabolic process,GO:0030316~osteoclast differentiation,GO:0043066~negative regulation of apoptotic process,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0070062~extracellular exosome,	GO:0004462~lactoylglutathione lyase activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0046872~metal ion binding,	IPR004360:Glyas_Fos-R_dOase_dom,IPR004361:Glyoxalase_1,IPR018146:Glyoxalase_1_CS,IPR029068:Glyas_Bleomycin-R_OHBP_Dase,IPR037523:VOC,	hsa00620:Pyruvate metabolism,hsa01100:Metabolic pathways,								KW-0479~Metal-binding,KW-0862~Zinc,	KW-0456~Lyase,	KW-0007~Acetylation,KW-0318~Glutathionylation,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	ACT_SITE:Proton donor/acceptor,BINDING:in other chain,DISULFID:Alternate,DOMAIN:VOC,MUTAGEN:C->A: Impaired NO-mediated modification. Loss of NO-mediated modification; when associated with A-19 or A-20.,MUTAGEN:C->A: No effect on NO-mediated modification.,MUTAGEN:C->A: No effect on NO-mediated modification. Impaired NO-mediated modification; when associated with A-19. Loss of NO-mediated modification; when associated with A-139.,MUTAGEN:C->A: No effect on NO-mediated modification. Impaired NO-mediated modification; when associated with A-20. Loss of NO-mediated modification; when associated with A-139.,MUTAGEN:E->Q: Abolishes enzyme activity.,MUTAGEN:E->Q: Reduces enzyme activity by over 99%.,MUTAGEN:Q->E: Reduces enzyme activity by 99%.,MUTAGEN:S->A: No effect on phosphorylation.,MUTAGEN:T->A: Loss of phosphorylation.,MUTAGEN:T->A: No effect on phosphorylation.,
GLOD4	glyoxalase domain containing 4(GLOD4)	Homo sapiens				GO:0005739~mitochondrion,GO:0070062~extracellular exosome,	GO:0045296~cadherin binding,	IPR004360:Glyas_Fos-R_dOase_dom,IPR029068:Glyas_Bleomycin-R_OHBP_Dase,IPR037523:VOC,IPR043193:GLOD4,IPR043194:GLOD4_C,						KW-0496~Mitochondrion,		KW-0677~Repeat,			KW-0597~Phosphoprotein,	DOMAIN:VOC,DOMAIN:VOC 1,DOMAIN:VOC 2,
GRHPR	glyoxylate and hydroxypyruvate reductase(GRHPR)	Homo sapiens			GO:0019752~carboxylic acid metabolic process,GO:0043648~dicarboxylic acid metabolic process,GO:0046487~glyoxylate metabolic process,	GO:0005737~cytoplasm,GO:0005782~peroxisomal matrix,GO:0005829~cytosol,GO:0070062~extracellular exosome,GO:1902494~catalytic complex,	GO:0005515~protein binding,GO:0008465~glycerate dehydrogenase activity,GO:0016616~oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor,GO:0016618~hydroxypyruvate reductase activity,GO:0030267~glyoxylate reductase (NADP) activity,GO:0031406~carboxylic acid binding,GO:0042803~protein homodimerization activity,GO:0050661~NADP binding,GO:0051287~NAD binding,GO:0070402~NADPH binding,	IPR006139:D-isomer_2_OHA_DH_cat_dom,IPR006140:D-isomer_DH_NAD-bd,IPR029753:D-isomer_DH_CS,IPR036291:NAD(P)-bd_dom_sf,	hsa00260:Glycine, serine and threonine metabolism,hsa00620:Pyruvate metabolism,hsa00630:Glyoxylate and dicarboxylate metabolism,hsa01100:Metabolic pathways,	260000~Hyperoxaluria, primary, type II,							KW-0521~NADP,	KW-0560~Oxidoreductase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton donor,DOMAIN:D-isomer specific 2-hydroxyacid dehydrogenase NAD-binding,DOMAIN:D-isomer specific 2-hydroxyacid dehydrogenase catalytic,SITE:Raises pKa of active site His,
GGA2	golgi associated, gamma adaptin ear containing, ARF binding protein 2(GGA2)	Homo sapiens			GO:0006886~intracellular protein transport,GO:0006893~Golgi to plasma membrane transport,GO:0034394~protein localization to cell surface,GO:0043001~Golgi to plasma membrane protein transport,	GO:0005794~Golgi apparatus,GO:0005802~trans-Golgi network,GO:0010008~endosome membrane,GO:0030136~clathrin-coated vesicle,GO:0031901~early endosome membrane,	GO:0005515~protein binding,GO:0031267~small GTPase binding,GO:0035091~phosphatidylinositol binding,GO:0043130~ubiquitin binding,	IPR002014:VHS_dom,IPR004152:GAT_dom,IPR008152:Clathrin_a/b/g-adaptin_app_Ig,IPR008153:GAE_dom,IPR008942:ENTH_VHS,IPR013041:Clathrin_app_Ig-like_sf,IPR027422:GGA1-3,IPR038425:GAT_sf,IPR041198:GGA_N-GAT,	hsa04142:Lysosome,			SM00288:VHS,SM00809:Alpha_adaptinC2,	KW-0653~Protein transport,KW-0813~Transport,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0967~Endosome,					KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,DOMAIN:GAE,DOMAIN:GAT,DOMAIN:VHS,MUTAGEN:LIDLE->AADAA: Partial loss of clathrin-binding.,REGION:Disordered,REGION:Unstructured hinge,
GLG1	golgi glycoprotein 1(GLG1)	Homo sapiens			GO:0007179~transforming growth factor beta receptor signaling pathway,GO:0010955~negative regulation of protein processing,GO:0016485~protein processing,GO:0030512~negative regulation of transforming growth factor beta receptor signaling pathway,GO:0032330~regulation of chondrocyte differentiation,GO:0060349~bone morphogenesis,	GO:0000139~Golgi membrane,GO:0005794~Golgi apparatus,GO:0005815~microtubule organizing center,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0031012~extracellular matrix,GO:0070062~extracellular exosome,	GO:0005102~receptor binding,GO:0017134~fibroblast growth factor binding,	IPR001893:Cys-rich_GLG1_repeat,IPR017873:Cys-rich_GLG1_repeat_euk,IPR039728:GLG1,	hsa04514:Cell adhesion molecules,					KW-0206~Cytoskeleton,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0730~Sialic acid,		KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,REGION:Disordered,REPEAT:Cys-rich GLG1,REPEAT:Cys-rich GLG1 1,REPEAT:Cys-rich GLG1 10,REPEAT:Cys-rich GLG1 11,REPEAT:Cys-rich GLG1 12,REPEAT:Cys-rich GLG1 13,REPEAT:Cys-rich GLG1 14,REPEAT:Cys-rich GLG1 15,REPEAT:Cys-rich GLG1 16,REPEAT:Cys-rich GLG1 2,REPEAT:Cys-rich GLG1 3,REPEAT:Cys-rich GLG1 4,REPEAT:Cys-rich GLG1 5,REPEAT:Cys-rich GLG1 6,REPEAT:Cys-rich GLG1 7,REPEAT:Cys-rich GLG1 8,REPEAT:Cys-rich GLG1 9,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
GORASP2	golgi reassembly stacking protein 2(GORASP2)	Homo sapiens			GO:0006996~organelle organization,GO:0007030~Golgi organization,GO:0007283~spermatogenesis,GO:0030154~cell differentiation,GO:0034976~response to endoplasmic reticulum stress,GO:0070925~organelle assembly,	GO:0000139~Golgi membrane,GO:0005789~endoplasmic reticulum membrane,GO:0005794~Golgi apparatus,GO:0005801~cis-Golgi network,GO:0016020~membrane,	GO:0005515~protein binding,	IPR007583:GRASP55_65,IPR024958:GRASP_PDZ,IPR036034:PDZ_sf,	hsa04140:Autophagy - animal,				KW-0221~Differentiation,KW-0744~Spermatogenesis,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,		KW-0677~Repeat,			KW-0449~Lipoprotein,KW-0488~Methylation,KW-0519~Myristate,KW-0564~Palmitate,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:PDZ GRASP-type,DOMAIN:PDZ GRASP-type 1,DOMAIN:PDZ GRASP-type 2,LIPID:N-myristoyl glycine,MUTAGEN:D->N: Enhances homodimerization. Loss of ER stress-induced relocalization from Golgi to ER.,MUTAGEN:G->A: Abolishes myristoylation. Loss of its ability to mediate unconventional (ER/Golgi-independent) trafficking of CFTR to the cell membrane. No effect on ER stress-induced relocalization from Golgi to ER.,MUTAGEN:I->S: Abolishes organelle clustering; when associated with A-59.,MUTAGEN:L->A: Abolishes organelle clustering; when associated with S-100.,MUTAGEN:S->A: Loss of phosphorylation and its ability to mediate unconventional (ER/Golgi-independent) trafficking of CFTR to the cell membrane. Inhibits ER stress-mediated disruption of homodimerization. Loss of ER stress-induced relocalization from Golgi to ER.,MUTAGEN:S->A: Loss of phosphorylation. Does not inhibit ER stress-mediated disruption of homodimerization.,MUTAGEN:S->D: Phosphomimetic mutant. No disruption of homodimerization.,MUTAGEN:S->D: Phosphomimetic mutant. No loss of its ability to mediate unconventional (ER/Golgi-independent) trafficking of CFTR to the cell membrane. Disrupts homodimerization. No loss of ER stress-induced relocalization from Golgi to ER.,MUTAGEN:S->D: Phosphomimetic mutant. Partial disruption of homodimerization.,MUTAGEN:S->D: Phosphomimetic mutation that decreases the ability to promote organelle clustering.,MUTAGEN:T->A: Abolishes mitotic phosphorylation; when associated with A-222.,MUTAGEN:T->A: Abolishes mitotic phosphorylation; when associated with A-225.,REGION:Disordered,REGION:GRASP,REGION:Important for membrane binding,
GOLT1B	golgi transport 1B(GOLT1B)	Homo sapiens			GO:0006888~ER to Golgi vesicle-mediated transport,GO:0015031~protein transport,GO:0042147~retrograde transport, endosome to Golgi,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,	GO:0000139~Golgi membrane,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0016020~membrane,GO:0032991~macromolecular complex,	GO:0005515~protein binding,	IPR007305:Vesicle_transpt_Got1/SFT2,IPR045176:Got1,					KW-0653~Protein transport,KW-0813~Transport,	KW-0333~Golgi apparatus,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,	TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,
GOLGA4	golgin A4(GOLGA4)	Homo sapiens			GO:0016192~vesicle-mediated transport,GO:0043001~Golgi to plasma membrane protein transport,GO:0045773~positive regulation of axon extension,GO:0048193~Golgi vesicle transport,	GO:0000139~Golgi membrane,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005802~trans-Golgi network,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0031267~small GTPase binding,GO:0051020~GTPase binding,	IPR000237:GRIP_dom,				SM00755:Grip,		KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0963~Cytoplasm,		KW-0175~Coiled coil,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:GRIP,MUTAGEN:F->A: Abolishes Golgi localization.,MUTAGEN:F->A: Loss of TBC1D23-binding.,MUTAGEN:I->A: Abolishes Golgi localization.,MUTAGEN:L->A: Abolishes Golgi localization.,MUTAGEN:M->A: Abolishes Golgi localization.,MUTAGEN:T->A: Abolishes Golgi localization.,MUTAGEN:V->A: Abolishes Golgi localization.,MUTAGEN:Y->A: Loss of localization at the Golgi apparatus.,MUTAGEN:Y->A: Loss of localization at the Golgi apparatus. Loss of ARL1-binding.,MUTAGEN:Y->F: No effect on localization at the Golgi apparatus.,REGION:Disordered,REGION:Interaction with MACF1,
GOLGA7	golgin A7(GOLGA7)	Homo sapiens			GO:0006612~protein targeting to membrane,GO:0006893~Golgi to plasma membrane transport,GO:0018230~peptidyl-L-cysteine S-palmitoylation,GO:0043001~Golgi to plasma membrane protein transport,GO:0050821~protein stabilization,	GO:0000139~Golgi membrane,GO:0002178~palmitoyltransferase complex,GO:0005576~extracellular region,GO:0005795~Golgi stack,GO:0016020~membrane,GO:0070062~extracellular exosome,GO:1904724~tertiary granule lumen,	GO:0005515~protein binding,	IPR019383:Golgin_A_7/ERF4,						KW-0333~Golgi apparatus,KW-0472~Membrane,					KW-0449~Lipoprotein,KW-0564~Palmitate,	DOMAIN:Golgin subfamily A member 7/ERF4,LIPID:S-palmitoyl cysteine,MUTAGEN:C->A: Slightly reduces palmitoylation.,MUTAGEN:C->A: Strongly reduces palmitoylation. Abolishes palmitoylation and Golgi localization; when associated with A-69.,MUTAGEN:C->A: Strongly reduces palmitoylation. Abolishes palmitoylation and Golgi localization; when associated with A-72.,
GON4L	gon-4 like(GON4L)	Homo sapiens			GO:0006355~regulation of transcription, DNA-templated,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0016604~nuclear body,	GO:0003712~transcription cofactor activity,	IPR001005:SANT/Myb,IPR003822:PAH,IPR009057:Homeobox-like_sf,IPR036600:PAH_sf,IPR049257:Gon4l/CASP8AP2_myb-like,					KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0677~Repeat,		KW-0678~Repressor,	KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,DOMAIN:Myb-like,DOMAIN:PAH 1,DOMAIN:PAH 2,REGION:Disordered,REGION:Required for interaction with YY1, SIN3A and HDAC1, and transcriptional repression activity,
GZMA	granzyme A(GZMA)	Homo sapiens		h_setPathway:Granzyme A mediated Apoptosis Pathway,	GO:0006915~apoptotic process,GO:0006955~immune response,GO:0009617~response to bacterium,GO:0031640~killing of cells of other organism,GO:0032078~negative regulation of endodeoxyribonuclease activity,GO:0043065~positive regulation of apoptotic process,GO:0043392~negative regulation of DNA binding,GO:0051354~negative regulation of oxidoreductase activity,GO:0051603~proteolysis involved in cellular protein catabolic process,GO:0051604~protein maturation,GO:0070269~pyroptosis,GO:1902483~cytotoxic T cell apoptotic process,	GO:0001772~immunological synapse,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005737~cytoplasm,	GO:0004252~serine-type endopeptidase activity,GO:0005515~protein binding,GO:0042803~protein homodimerization activity,	IPR001254:Trypsin_dom,IPR001314:Peptidase_S1A,IPR009003:Peptidase_S1_PA,IPR018114:TRYPSIN_HIS,IPR033116:TRYPSIN_SER,IPR043504:Peptidase_S1_PA_chymotrypsin,	hsa04080:Neuroactive ligand-receptor interaction,			SM00020:Tryp_SPc,	KW-0204~Cytolysis,	KW-0964~Secreted,		KW-0732~Signal,		KW-0378~Hydrolase,KW-0645~Protease,KW-0720~Serine protease,	KW-0325~Glycoprotein,KW-0865~Zymogen,KW-1015~Disulfide bond,	ACT_SITE:Charge relay system,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Peptidase S1,MUTAGEN:S->A: Abolished protease activity.,PROPEP:Activation peptide,
GZMB	granzyme B(GZMB)	Homo sapiens		h_caspasePathway:Caspase Cascade in Apoptosis,h_ctlPathway:CTL mediated immune response against target cells ,h_d4gdiPathway:D4-GDI Signaling Pathway,h_DNAfragmentPathway:Apoptotic DNA fragmentation and tissue homeostasis,h_setPathway:Granzyme A mediated Apoptosis Pathway,	GO:0006508~proteolysis,GO:0006915~apoptotic process,GO:0017148~negative regulation of translation,GO:0031640~killing of cells of other organism,GO:0042267~natural killer cell mediated cytotoxicity,GO:0051603~proteolysis involved in cellular protein catabolic process,GO:0051604~protein maturation,GO:0070269~pyroptosis,GO:1900740~positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway,	GO:0001772~immunological synapse,GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0016020~membrane,GO:0043231~intracellular membrane-bounded organelle,GO:0044194~cytolytic granule,	GO:0004252~serine-type endopeptidase activity,GO:0005515~protein binding,GO:0008236~serine-type peptidase activity,	IPR001254:Trypsin_dom,IPR001314:Peptidase_S1A,IPR009003:Peptidase_S1_PA,IPR018114:TRYPSIN_HIS,IPR033116:TRYPSIN_SER,IPR043504:Peptidase_S1_PA_chymotrypsin,	hsa04210:Apoptosis,hsa04650:Natural killer cell mediated cytotoxicity,hsa04940:Type I diabetes mellitus,hsa05202:Transcriptional misregulation in cancer,hsa05320:Autoimmune thyroid disease,hsa05330:Allograft rejection,hsa05332:Graft-versus-host disease,			SM00020:Tryp_SPc,	KW-0053~Apoptosis,KW-0204~Cytolysis,	KW-0458~Lysosome,KW-0964~Secreted,		KW-0732~Signal,		KW-0378~Hydrolase,KW-0645~Protease,KW-0720~Serine protease,	KW-0325~Glycoprotein,KW-0865~Zymogen,KW-1015~Disulfide bond,	ACT_SITE:Charge relay system,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Peptidase S1,PROPEP:Activation peptide,SITE:Mediates preference for Asp-containing substrates,
GZMK	granzyme K(GZMK)	Homo sapiens			GO:0006508~proteolysis,	GO:0005576~extracellular region,GO:0030141~secretory granule,	GO:0004252~serine-type endopeptidase activity,GO:0005515~protein binding,GO:0008236~serine-type peptidase activity,	IPR001254:Trypsin_dom,IPR001314:Peptidase_S1A,IPR009003:Peptidase_S1_PA,IPR018114:TRYPSIN_HIS,IPR033116:TRYPSIN_SER,IPR043504:Peptidase_S1_PA_chymotrypsin,				SM00020:Tryp_SPc,		KW-0964~Secreted,		KW-0732~Signal,		KW-0378~Hydrolase,KW-0645~Protease,KW-0720~Serine protease,	KW-0865~Zymogen,KW-1015~Disulfide bond,	ACT_SITE:Charge relay system,DOMAIN:Peptidase S1,PROPEP:Activation peptide,
GADD45A	growth arrest and DNA damage inducible alpha(GADD45A)	Homo sapiens		h_atmPathway:ATM Signaling Pathway,h_g2Pathway:Cell Cycle: G2/M Checkpoint,h_p53hypoxiaPathway:Hypoxia and p53 in the Cardiovascular system,h_p53Pathway:p53 Signaling Pathway,	GO:0000079~regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006281~DNA repair,GO:0006915~apoptotic process,GO:0007098~centrosome cycle,GO:0016525~negative regulation of angiogenesis,GO:0033140~negative regulation of peptidyl-serine phosphorylation of STAT protein,GO:0042770~signal transduction in response to DNA damage,GO:0043065~positive regulation of apoptotic process,GO:0043537~negative regulation of blood vessel endothelial cell migration,GO:0046330~positive regulation of JNK cascade,GO:0051726~regulation of cell cycle,GO:0071260~cellular response to mechanical stimulus,GO:0071479~cellular response to ionizing radiation,GO:0071901~negative regulation of protein serine/threonine kinase activity,GO:1900745~positive regulation of p38MAPK cascade,GO:2000379~positive regulation of reactive oxygen species metabolic process,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0016607~nuclear speck,	GO:0005515~protein binding,GO:0019900~kinase binding,GO:0042803~protein homodimerization activity,GO:0046982~protein heterodimerization activity,GO:1990841~promoter-specific chromatin binding,	IPR004038:Ribosomal_eL8/eL30/eS12/Gad45,IPR024824:GADD45,IPR029064:Ribosomal_eL30-like_sf,	hsa04010:MAPK signaling pathway,hsa04064:NF-kappa B signaling pathway,hsa04068:FoxO signaling pathway,hsa04110:Cell cycle,hsa04115:p53 signaling pathway,hsa04210:Apoptosis,hsa04218:Cellular senescence,hsa05169:Epstein-Barr virus infection,hsa05200:Pathways in cancer,hsa05202:Transcriptional misregulation in cancer,hsa05210:Colorectal cancer,hsa05212:Pancreatic cancer,hsa05213:Endometrial cancer,hsa05214:Glioma,hsa05216:Thyroid cancer,hsa05217:Basal cell carcinoma,hsa05218:Melanoma,hsa05220:Chronic myeloid leukemia,hsa05222:Small cell lung cancer,hsa05223:Non-small cell lung cancer,hsa05224:Breast cancer,hsa05225:Hepatocellular carcinoma,hsa05226:Gastric cancer,				KW-0131~Cell cycle,KW-0227~DNA damage,KW-0338~Growth arrest,	KW-0539~Nucleus,					KW-0597~Phosphoprotein,	DOMAIN:Ribosomal protein eL8/eL30/eS12/Gadd45,MUTAGEN:L->E: Abolishes dimerization.,
GRB2	growth factor receptor bound protein 2(GRB2)	Homo sapiens	104.Insulin_signaling,108.Regulating_glucose_transport,	h_at1rPathway:Angiotensin II mediated activation of JNK Pathway via Pyk2 dependent signaling,h_bcrPathway:BCR Signaling Pathway,h_biopeptidesPathway:Bioactive Peptide Induced Signaling Pathway,h_cblPathway:CBL mediated ligand-induced downregulation of EGF receptors,h_crebPathway:Transcription factor CREB and its extracellular signals,h_ctla4Pathway:The Co-Stimulatory Signal During T-cell Activation,h_egfPathway:EGF Signaling Pathway,h_epoPathway:EPO Signaling Pathway,h_erk5Pathway:Role of Erk5 in Neuronal Survival,h_erkPathway:Erk1/Erk2 Mapk Signaling pathway,h_fcer1Pathway:Fc Epsilon Receptor I Signaling in Mast Cells,h_ghPathway:Growth Hormone Signaling Pathway,h_gleevecPathway:Inhibition of Cellular Proliferation by Gleevec,h_hbxPathway:Calcium Signaling by HBx of Hepatitis B virus,h_her2Pathway:Role of ERBB2 in Signal Transduction and Oncology,h_igf1Pathway:IGF-1 Signaling Pathway,h_igf1rPathway:Multiple antiapoptotic pathways from IGF-1R signaling lead to BAD phosphorylation,h_il2Pathway:IL 2 signaling pathway,h_il2rbPathway:IL-2 Receptor Beta Chain in T cell Activation,h_il3Pathway:IL 3 signaling pathway,h_il4Pathway:IL 4 signaling pathway,h_il6Pathway:IL 6 signaling pathway,h_insulinPathway:Insulin Signaling Pathway,h_integrinPathway:Integrin Signaling Pathway,h_mapkPathway:MAPKinase Signaling Pathway,h_metPathway:Signaling of Hepatocyte Growth Factor Receptor,h_ngfPathway:Nerve growth factor pathway (NGF),h_p38mapkPathway:p38 MAPK Signaling Pathway ,h_pdgfPathway:PDGF Signaling Pathway,h_ptenPathway:PTEN dependent cell cycle arrest and apoptosis,h_pyk2Pathway:Links between Pyk2 and Map Kinases,h_spryPathway:Sprouty regulation of tyrosine kinase signals,h_srcRPTPPathway:Activation of Src by Protein-tyrosine phosphatase alpha,h_tcrPathway:T Cell Receptor Signaling Pathway,h_tffPathway:Trefoil Factors Initiate  Mucosal Healing,h_tpoPathway:TPO Signaling Pathway,h_trkaPathway:Trka Receptor Signaling Pathway,	GO:0007165~signal transduction,GO:0007173~epidermal growth factor receptor signaling pathway,GO:0007265~Ras protein signal transduction,GO:0008286~insulin receptor signaling pathway,GO:0008543~fibroblast growth factor receptor signaling pathway,GO:0014044~Schwann cell development,GO:0030036~actin cytoskeleton organization,GO:0030838~positive regulation of actin filament polymerization,GO:0031623~receptor internalization,GO:0035987~endodermal cell differentiation,GO:0042552~myelination,GO:0042770~signal transduction in response to DNA damage,GO:0043408~regulation of MAPK cascade,GO:0048009~insulin-like growth factor receptor signaling pathway,GO:0050853~B cell receptor signaling pathway,GO:0060670~branching involved in labyrinthine layer morphogenesis,GO:0071479~cellular response to ionizing radiation,GO:2000379~positive regulation of reactive oxygen species metabolic process,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005768~endosome,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005911~cell-cell junction,GO:0005938~cell cortex,GO:0008180~COP9 signalosome,GO:0012506~vesicle membrane,GO:0070062~extracellular exosome,GO:0070436~Grb2-EGFR complex,	GO:0001784~phosphotyrosine binding,GO:0003723~RNA binding,GO:0005068~transmembrane receptor protein tyrosine kinase adaptor activity,GO:0005091~guanyl-nucleotide exchange factor adaptor activity,GO:0005154~epidermal growth factor receptor binding,GO:0005168~neurotrophin TRKA receptor binding,GO:0005515~protein binding,GO:0017124~SH3 domain binding,GO:0019901~protein kinase binding,GO:0019903~protein phosphatase binding,GO:0019904~protein domain specific binding,GO:0042802~identical protein binding,GO:0043560~insulin receptor substrate binding,GO:0046875~ephrin receptor binding,	IPR000980:SH2,IPR001452:SH3_domain,IPR035641:GRB2_N_SH3,IPR035643:GRB2_C_SH3,IPR036028:SH3-like_dom_sf,IPR036860:SH2_dom_sf,IPR043539:Grb2-like,	hsa01521:EGFR tyrosine kinase inhibitor resistance,hsa01522:Endocrine resistance,hsa04010:MAPK signaling pathway,hsa04012:ErbB signaling pathway,hsa04014:Ras signaling pathway,hsa04062:Chemokine signaling pathway,hsa04068:FoxO signaling pathway,hsa04072:Phospholipase D signaling pathway,hsa04150:mTOR signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04380:Osteoclast differentiation,hsa04510:Focal adhesion,hsa04540:Gap junction,hsa04550:Signaling pathways regulating pluripotency of stem cells,hsa04630:JAK-STAT signaling pathway,hsa04650:Natural killer cell mediated cytotoxicity,hsa04660:T cell receptor signaling pathway,hsa04662:B cell receptor signaling pathway,hsa04664:Fc epsilon RI signaling pathway,hsa04714:Thermogenesis,hsa04722:Neurotrophin signaling pathway,hsa04910:Insulin signaling pathway,hsa04912:GnRH signaling pathway,hsa04915:Estrogen signaling pathway,hsa04917:Prolactin signaling pathway,hsa04926:Relaxin signaling pathway,hsa04935:Growth hormone synthesis, secretion and action,hsa05034:Alcoholism,hsa05160:Hepatitis C,hsa05161:Hepatitis B,hsa05163:Human cytomegalovirus infection,hsa05165:Human papillomavirus infection,hsa05200:Pathways in cancer,hsa05203:Viral carcinogenesis,hsa05205:Proteoglycans in cancer,hsa05206:MicroRNAs in cancer,hsa05207:Chemical carcinogenesis - receptor activation,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05210:Colorectal cancer,hsa05211:Renal cell carcinoma,hsa05213:Endometrial cancer,hsa05214:Glioma,hsa05215:Prostate cancer,hsa05220:Chronic myeloid leukemia,hsa05221:Acute myeloid leukemia,hsa05223:Non-small cell lung cancer,hsa05224:Breast cancer,hsa05225:Hepatocellular carcinoma,hsa05226:Gastric cancer,hsa05231:Choline metabolism in cancer,			SM00252:SH2,SM00326:SH3,	KW-0945~Host-virus interaction,	KW-0333~Golgi apparatus,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0967~Endosome,		KW-0677~Repeat,KW-0727~SH2 domain,KW-0728~SH3 domain,		KW-0675~Receptor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:SH2,DOMAIN:SH3,DOMAIN:SH3 1,DOMAIN:SH3 2,MUTAGEN:E->K: No effect on the interaction with SOS1.,MUTAGEN:G->R: Ineffective in DNA synthesis. Abolishes interaction with SOS1.,MUTAGEN:P->L: Abolishes interaction with SHB; when associated with L-49.,MUTAGEN:P->L: Ineffective in DNA synthesis. Abolishes interaction with SHB; when associated with L-206. Abolishes interaction with SOS1.,MUTAGEN:S->N: No effect on the interaction with SOS1.,
GFER	growth factor, augmenter of liver regeneration(GFER)	Homo sapiens			GO:0001889~liver development,GO:0007165~signal transduction,GO:0043066~negative regulation of apoptotic process,GO:0045953~negative regulation of natural killer cell mediated cytotoxicity,GO:0071222~cellular response to lipopolysaccharide,GO:0071356~cellular response to tumor necrosis factor,GO:0072717~cellular response to actinomycin D,GO:0097237~cellular response to toxic substance,GO:0097421~liver regeneration,GO:2000573~positive regulation of DNA biosynthetic process,	GO:0005615~extracellular space,GO:0005739~mitochondrion,GO:0005758~mitochondrial intermembrane space,GO:0005829~cytosol,	GO:0005515~protein binding,GO:0008083~growth factor activity,GO:0015035~protein disulfide oxidoreductase activity,GO:0016971~flavin-linked sulfhydryl oxidase activity,GO:0050660~flavin adenine dinucleotide binding,	IPR017905:ERV/ALR_sulphydryl_oxidase,IPR036774:ERV/ALR_sulphydryl_oxid_sf,IPR039799:ALR/ERV,		613076~Myopathy, mitochondrial progressive, with congenital cataract and developmental delay,				KW-0496~Mitochondrion,KW-0963~Cytoplasm,KW-0964~Secreted,	KW-0209~Deafness,KW-0225~Disease variant,KW-0898~Cataract,KW-1274~Primary mitochondrial disease,		KW-0274~FAD,KW-0285~Flavoprotein,	KW-0339~Growth factor,KW-0560~Oxidoreductase,	KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	DISULFID:Interchain (with C-204),DISULFID:Interchain (with C-95),DISULFID:Redox-active,DOMAIN:ERV/ALR sulfhydryl oxidase,REGION:Disordered,
GHITM	growth hormone inducible transmembrane protein(GHITM)	Homo sapiens			GO:0006816~calcium ion transport,GO:0006851~mitochondrial calcium ion transport,GO:0006915~apoptotic process,GO:0007007~inner mitochondrial membrane organization,GO:0090201~negative regulation of release of cytochrome c from mitochondria,GO:0099093~mitochondrial calcium release,GO:1902600~hydrogen ion transmembrane transport,GO:1905448~positive regulation of mitochondrial ATP synthesis coupled electron transport,	GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0016020~membrane,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0015369~calcium:proton antiporter activity,	IPR006214:Bax_inhibitor_1-related,IPR035871:GHITM,					KW-0053~Apoptosis,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,		KW-0809~Transit peptide,KW-0812~Transmembrane,KW-1133~Transmembrane helix,				TOPO_DOM:Mitochondrial intermembrane,TOPO_DOM:Mitochondrial matrix,TRANSIT:Mitochondrion,TRANSMEM:Helical,
GBP2	guanylate binding protein 2(GBP2)	Homo sapiens			GO:0002218~activation of innate immune response,GO:0006955~immune response,GO:0034504~protein localization to nucleus,GO:0042742~defense response to bacterium,GO:0042832~defense response to protozoan,GO:0045087~innate immune response,GO:0050830~defense response to Gram-positive bacterium,GO:0051607~defense response to virus,GO:0051715~cytolysis in other organism,GO:0071222~cellular response to lipopolysaccharide,GO:0071346~cellular response to interferon-gamma,GO:0071347~cellular response to interleukin-1,GO:0071356~cellular response to tumor necrosis factor,	GO:0000139~Golgi membrane,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0030659~cytoplasmic vesicle membrane,GO:0031410~cytoplasmic vesicle,GO:0048471~perinuclear region of cytoplasm,	GO:0003924~GTPase activity,GO:0004866~endopeptidase inhibitor activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,	IPR003191:Guanylate-bd/ATL_C,IPR015894:Guanylate-bd_N,IPR027417:P-loop_NTPase,IPR030386:G_GB1_RHD3_dom,IPR036543:Guanylate-bd_C_sf,IPR037684:GBP_C,	hsa04621:NOD-like receptor signaling pathway,				KW-0391~Immunity,KW-0399~Innate immunity,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,			KW-0342~GTP-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,KW-0929~Antimicrobial,	KW-0449~Lipoprotein,KW-0488~Methylation,KW-0636~Prenylation,KW-0832~Ubl conjugation,	DOMAIN:GB1/RHD3-type G,LIPID:S-geranylgeranyl cysteine,MUTAGEN:C->A: Loss of isoprenylation and of localization at the Golgi apparatus.,MUTAGEN:Missing: No effect on subcellular location by confocal microscopy, but loss of membrane-association by subcellular fractionation.,PROPEP:Removed in mature form,REGION:GTPase domain (Globular),
GBP4	guanylate binding protein 4(GBP4)	Homo sapiens			GO:0042832~defense response to protozoan,GO:0050830~defense response to Gram-positive bacterium,GO:0071346~cellular response to interferon-gamma,	GO:0000139~Golgi membrane,GO:0005634~nucleus,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0031410~cytoplasmic vesicle,GO:0048471~perinuclear region of cytoplasm,	GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,	IPR003191:Guanylate-bd/ATL_C,IPR015894:Guanylate-bd_N,IPR027417:P-loop_NTPase,IPR030386:G_GB1_RHD3_dom,IPR036543:Guanylate-bd_C_sf,IPR037684:GBP_C,	hsa04621:NOD-like receptor signaling pathway,				KW-0391~Immunity,KW-0399~Innate immunity,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,	KW-0342~GTP-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,	KW-0832~Ubl conjugation,	DOMAIN:GB1/RHD3-type G,REGION:GTPase domain (Globular),
GBP5	guanylate binding protein 5(GBP5)	Homo sapiens			GO:0002218~activation of innate immune response,GO:0006605~protein targeting,GO:0006954~inflammatory response,GO:0032731~positive regulation of interleukin-1 beta production,GO:0032741~positive regulation of interleukin-18 production,GO:0034067~protein localization to Golgi apparatus,GO:0042742~defense response to bacterium,GO:0045087~innate immune response,GO:0045089~positive regulation of innate immune response,GO:0051289~protein homotetramerization,GO:0051607~defense response to virus,GO:0051715~cytolysis in other organism,GO:0071222~cellular response to lipopolysaccharide,GO:0071346~cellular response to interferon-gamma,GO:1900017~positive regulation of cytokine production involved in inflammatory response,GO:1900227~positive regulation of NLRP3 inflammasome complex assembly,	GO:0000139~Golgi membrane,GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0016020~membrane,GO:0030659~cytoplasmic vesicle membrane,GO:0031410~cytoplasmic vesicle,GO:0048471~perinuclear region of cytoplasm,GO:0098552~side of membrane,	GO:0003924~GTPase activity,GO:0004866~endopeptidase inhibitor activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,	IPR003191:Guanylate-bd/ATL_C,IPR015894:Guanylate-bd_N,IPR027417:P-loop_NTPase,IPR030386:G_GB1_RHD3_dom,IPR036543:Guanylate-bd_C_sf,IPR037684:GBP_C,	hsa04621:NOD-like receptor signaling pathway,				KW-0391~Immunity,KW-0395~Inflammatory response,KW-0399~Innate immunity,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,			KW-0342~GTP-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,KW-0929~Antimicrobial,	KW-0325~Glycoprotein,KW-0336~GPI-anchor,KW-0449~Lipoprotein,KW-0488~Methylation,KW-0636~Prenylation,	DOMAIN:GB1/RHD3-type G,LIPID:S-geranylgeranyl cysteine,MUTAGEN:C->A: Loss of isoprenylation and of localization at the Golgi apparatus. Impaired ability to restrict HIV-1.,MUTAGEN:D->N: Decreased nucleotide-binding, without affecting ability to inhibit HIV-1 infectivity.,MUTAGEN:EEAVK->AEAVA: In MMMD mutant; abolished dimerization and ability to restrict HIV-1; when associated with 464-A--A-476.,MUTAGEN:GAIDL->QAIDQ: Promotes ubiquitination and degradation by S. flexneri IpaH9.8.,MUTAGEN:KS->AA: Loss of GTPase activity. No effect on tetramerization. Does not affect ability to inhibit HIV-1 infectivity.,MUTAGEN:KSKESVSHAILQT->AAAEAASAAILAA: In MMMD mutant; abolished dimerization and ability to restrict HIV-1; when associated with 417-A--A-421.,MUTAGEN:Missing: Loss of isoprenylation and of localization at the Golgi apparatus.,MUTAGEN:R->A: No effect.,MUTAGEN:S->A: Does not affect GTPase activity.,MUTAGEN:T->S: Abolished GTPase activity, without affecting ability to inhibit HIV-1 infectivity.,PROPEP:Removed in mature form,REGION:GTPase domain (Globular),REGION:NLRP3-binding,REGION:Required for tetramerization, but not for dimerization,
GUK1	guanylate kinase 1(GUK1)	Homo sapiens		h_PDZsPathway:Synaptic Proteins at the Synaptic Junction,	GO:0006163~purine nucleotide metabolic process,GO:0006185~dGDP biosynthetic process,GO:0006805~xenobiotic metabolic process,GO:0015949~nucleobase-containing small molecule interconversion,GO:0016310~phosphorylation,GO:0019673~GDP-mannose metabolic process,GO:0034436~glycoprotein transport,GO:0046037~GMP metabolic process,GO:0046054~dGMP metabolic process,GO:0046060~dATP metabolic process,GO:0046710~GDP metabolic process,GO:0046711~GDP biosynthetic process,	GO:0001917~photoreceptor inner segment,GO:0005829~cytosol,	GO:0004385~guanylate kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,	IPR008144:Guanylate_kin-like_dom,IPR008145:GK/Ca_channel_bsu,IPR017665:Guanylate_kinase,IPR020590:Guanylate_kinase_CS,IPR027417:P-loop_NTPase,	hsa00230:Purine metabolism,hsa01100:Metabolic pathways,hsa01232:Nucleotide metabolism,			SM00072:GuKc,		KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0808~Transferase,	KW-0007~Acetylation,	COMPBIAS:Polar residues,DOMAIN:Guanylate kinase-like,MUTAGEN:G->A: Increases in kcat with GMP as substrate.,MUTAGEN:L->P: Leads to aggregation. Increases in kcat with GMP as substrate.,MUTAGEN:R->H: Increases in kcat with GMP as substrate.,MUTAGEN:R->Q: Increases in kcat with GMP as substrate.,MUTAGEN:S->F: Increases in kcat with GMP as substrate.,MUTAGEN:S->L: Increases in kcat with GMP as substrate.,MUTAGEN:S->Y: Increases in kcat with GMP as substrate.,MUTAGEN:V->M: Increases in kcat with GMP as substrate.,REGION:Disordered,
GET4	guided entry of tail-anchored proteins factor 4(GET4)	Homo sapiens			GO:0006511~ubiquitin-dependent protein catabolic process,GO:0006620~posttranslational protein targeting to membrane,GO:0031647~regulation of protein stability,GO:0036503~ERAD pathway,GO:0036506~maintenance of unfolded protein,GO:0045048~protein insertion into ER membrane,GO:0051220~cytoplasmic sequestering of protein,GO:0071816~tail-anchored membrane protein insertion into ER membrane,GO:1904378~maintenance of unfolded protein involved in ERAD pathway,	GO:0005654~nucleoplasm,GO:0005694~chromosome,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0071818~BAT3 complex,	GO:0005515~protein binding,GO:0051087~chaperone binding,	IPR007317:GET4,IPR011990:TPR-like_helical_dom_sf,	hsa03060:Protein export,	620200~Congenital disorder of glycosylation, type IIy,			KW-0813~Transport,	KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0900~Congenital disorder of glycosylation,				KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Acidic residues,MUTAGEN:C->A: No effect on interaction with BAG6.,MUTAGEN:D->K: Reduces tail-anchored protein delivery.,MUTAGEN:F->A: No effect on interaction with BAG6.,MUTAGEN:L->A: No effect on interaction with BAG6.,MUTAGEN:V->A: No effect on interaction with BAG6.,MUTAGEN:W->A: No effect on interaction with BAG6.,MUTAGEN:Y->A: Inhibits interaction with BAG6.,MUTAGEN:Y->A: No effect on interaction with BAG6.,REGION:Disordered,REGION:Interacts with BAG6,
HSP90AA1	heat shock protein 90 alpha family class A member 1(HSP90AA1)	Homo sapiens		h_acrPathway:Ahr Signal Transduction Pathway,h_aktPathway:AKT Signaling Pathway,h_gcrpathway:Corticosteroids and cardioprotection,h_hifPathway:Hypoxia-Inducible Factor in the Cardiovascular System,h_no1Pathway:Actions of Nitric Oxide in the Heart,h_p53hypoxiaPathway:Hypoxia and p53 in the Cardiovascular system,h_PparaPathway:Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha),h_telPathway:Telomeres, Telomerase, Cellular Aging, and  Immortality,	GO:0001764~neuron migration,GO:0001934~positive regulation of protein phosphorylation,GO:0002218~activation of innate immune response,GO:0002230~positive regulation of defense response to virus by host,GO:0003009~skeletal muscle contraction,GO:0006457~protein folding,GO:0006839~mitochondrial transport,GO:0006986~response to unfolded protein,GO:0007004~telomere maintenance via telomerase,GO:0009408~response to heat,GO:0009409~response to cold,GO:0009410~response to xenobiotic stimulus,GO:0009651~response to salt stress,GO:0010592~positive regulation of lamellipodium assembly,GO:0010659~cardiac muscle cell apoptotic process,GO:0031396~regulation of protein ubiquitination,GO:0032273~positive regulation of protein polymerization,GO:0032728~positive regulation of interferon-beta production,GO:0032880~regulation of protein localization,GO:0034605~cellular response to heat,GO:0042026~protein refolding,GO:0042220~response to cocaine,GO:0042307~positive regulation of protein import into nucleus,GO:0042981~regulation of apoptotic process,GO:0043254~regulation of protein complex assembly,GO:0043335~protein unfolding,GO:0043627~response to estrogen,GO:0045040~protein import into mitochondrial outer membrane,GO:0045429~positive regulation of nitric oxide biosynthetic process,GO:0045732~positive regulation of protein catabolic process,GO:0045793~positive regulation of cell size,GO:0046677~response to antibiotic,GO:0050821~protein stabilization,GO:0051131~chaperone-mediated protein complex assembly,GO:0051171~regulation of nitrogen compound metabolic process,GO:0051973~positive regulation of telomerase activity,GO:0060255~regulation of macromolecule metabolic process,GO:0060452~positive regulation of cardiac muscle contraction,GO:0061684~chaperone-mediated autophagy,GO:0080090~regulation of primary metabolic process,GO:0098586~cellular response to virus,GO:0099072~regulation of postsynaptic specialization membrane neurotransmitter receptor levels,GO:1902949~positive regulation of tau-protein kinase activity,GO:1905323~telomerase holoenzyme complex assembly,	GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,GO:0016323~basolateral plasma membrane,GO:0016324~apical plasma membrane,GO:0031526~brush border membrane,GO:0032991~macromolecular complex,GO:0034774~secretory granule lumen,GO:0042470~melanosome,GO:0043025~neuronal cell body,GO:0043202~lysosomal lumen,GO:0043209~myelin sheath,GO:0044294~dendritic growth cone,GO:0044295~axonal growth cone,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,GO:0071682~endocytic vesicle lumen,GO:0097226~sperm mitochondrial sheath,GO:0097524~sperm plasma membrane,GO:1904813~ficolin-1-rich granule lumen,	GO:0002134~UTP binding,GO:0002135~CTP binding,GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0005525~GTP binding,GO:0016887~ATPase activity,GO:0017098~sulfonylurea receptor binding,GO:0019903~protein phosphatase binding,GO:0023026~MHC class II protein complex binding,GO:0030235~nitric-oxide synthase regulator activity,GO:0030911~TPR domain binding,GO:0031625~ubiquitin protein ligase binding,GO:0032564~dATP binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0042826~histone deacetylase binding,GO:0044325~ion channel binding,GO:0048156~tau protein binding,GO:0051020~GTPase binding,GO:0051022~Rho GDP-dissociation inhibitor binding,GO:0051082~unfolded protein binding,GO:0070182~DNA polymerase binding,GO:0097110~scaffold protein binding,GO:0097718~disordered domain specific binding,GO:1990782~protein tyrosine kinase binding,	IPR001404:Hsp90_fam,IPR003594:HATPase_C,IPR019805:Heat_shock_protein_90_CS,IPR020568:Ribosomal_Su5_D2-typ_SF,IPR020575:Hsp90_N,IPR036890:HATPase_C_sf,IPR037196:HSP90_C,	hsa04141:Protein processing in endoplasmic reticulum,hsa04151:PI3K-Akt signaling pathway,hsa04217:Necroptosis,hsa04612:Antigen processing and presentation,hsa04621:NOD-like receptor signaling pathway,hsa04657:IL-17 signaling pathway,hsa04659:Th17 cell differentiation,hsa04914:Progesterone-mediated oocyte maturation,hsa04915:Estrogen signaling pathway,hsa05132:Salmonella infection,hsa05200:Pathways in cancer,hsa05207:Chemical carcinogenesis - receptor activation,hsa05215:Prostate cancer,hsa05417:Lipid and atherosclerosis,hsa05418:Fluid shear stress and atherosclerosis,		PIRSF002583:Hsp90,	SM00387:HATPase_c,	KW-0346~Stress response,KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0143~Chaperone,KW-0378~Hydrolase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0702~S-nitrosylation,KW-0832~Ubl conjugation,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,DOMAIN:Histidine kinase/HSP90-like ATPase,MOTIF:TPR repeat-binding,MUTAGEN:C->A,N,D: Reduces ATPase activity and client protein activation.,MUTAGEN:C->S: Loss of S-nitrosylation.,MUTAGEN:D->A: Impaired ATP-binding. Strong interaction with HIF1A, MET, KEAP1 and RHOBTB2. Loss of interaction with HSF1 and ERBB2. Los of interaction with TSC1.,MUTAGEN:E->A: Strong ATP-binding. Strong interaction with HSF1, HIF1A, ERBB2, MET, KEAP1 and RHOBTB2. No effect on interaction with TSC1.,MUTAGEN:G->D: Abolishes ATPase activity.,MUTAGEN:MEEVD->AAAA: Loss of interaction with TOMM70. No effect on interaction with IRF3.,MUTAGEN:Missing: Loss of interaction with TOMM70.,MUTAGEN:Missing: Loss of interaction with TSC1.,MUTAGEN:VD->AA: Loss of interaction with TOMM70. No effect on interaction with IRF3.,MUTAGEN:Y->E: Loss of interaction with TSC1 and increases interaction with AHSA1.,MUTAGEN:Y->F: No deffect on the interaction with TSC1.,REGION:Disordered,REGION:Essential for interaction with SGTA and TTC1,REGION:Essential for interaction with SMYD3, TSC1 and STIP1/HOP,REGION:Interaction with FLCN and FNIP1,REGION:Interaction with FNIP2 and TSC1,REGION:Interaction with NR1D1,REGION:Interaction with NR3C1,REGION:Required for homodimerization,
HSP90AB1	heat shock protein 90 alpha family class B member 1(HSP90AB1)	Homo sapiens			GO:0001890~placenta development,GO:0006457~protein folding,GO:0006986~response to unfolded protein,GO:0007004~telomere maintenance via telomerase,GO:0019062~virion attachment to host cell,GO:0030511~positive regulation of transforming growth factor beta receptor signaling pathway,GO:0031396~regulation of protein ubiquitination,GO:0032435~negative regulation of proteasomal ubiquitin-dependent protein catabolic process,GO:0032516~positive regulation of phosphoprotein phosphatase activity,GO:0032880~regulation of protein localization,GO:0034605~cellular response to heat,GO:0043066~negative regulation of apoptotic process,GO:0045429~positive regulation of nitric oxide biosynthetic process,GO:0045597~positive regulation of cell differentiation,GO:0050821~protein stabilization,GO:0051131~chaperone-mediated protein complex assembly,GO:0051171~regulation of nitrogen compound metabolic process,GO:0051248~negative regulation of protein metabolic process,GO:0051726~regulation of cell cycle,GO:0051973~positive regulation of telomerase activity,GO:0060255~regulation of macromolecule metabolic process,GO:0071353~cellular response to interleukin-4,GO:0080090~regulation of primary metabolic process,GO:0097435~supramolecular fiber organization,GO:1901389~negative regulation of transforming growth factor beta activation,GO:1901799~negative regulation of proteasomal protein catabolic process,GO:1902949~positive regulation of tau-protein kinase activity,GO:1904031~positive regulation of cyclin-dependent protein kinase activity,GO:1905323~telomerase holoenzyme complex assembly,GO:2000010~positive regulation of protein localization to cell surface,	GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0008180~COP9 signalosome,GO:0009986~cell surface,GO:0016020~membrane,GO:0032991~macromolecular complex,GO:0034751~aryl hydrocarbon receptor complex,GO:0034774~secretory granule lumen,GO:0042470~melanosome,GO:0043025~neuronal cell body,GO:0044294~dendritic growth cone,GO:0044295~axonal growth cone,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,GO:1904813~ficolin-1-rich granule lumen,GO:1990565~HSP90-CDC37 chaperone complex,	GO:0003723~RNA binding,GO:0003725~double-stranded RNA binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016887~ATPase activity,GO:0019887~protein kinase regulator activity,GO:0019900~kinase binding,GO:0019901~protein kinase binding,GO:0023026~MHC class II protein complex binding,GO:0030235~nitric-oxide synthase regulator activity,GO:0030911~TPR domain binding,GO:0031072~heat shock protein binding,GO:0031625~ubiquitin protein ligase binding,GO:0042277~peptide binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0042826~histone deacetylase binding,GO:0043008~ATP-dependent protein binding,GO:0045296~cadherin binding,GO:0046983~protein dimerization activity,GO:0048156~tau protein binding,GO:0051082~unfolded protein binding,GO:0070182~DNA polymerase binding,GO:0097718~disordered domain specific binding,GO:1990226~histone methyltransferase binding,	IPR001404:Hsp90_fam,IPR003594:HATPase_C,IPR019805:Heat_shock_protein_90_CS,IPR020568:Ribosomal_Su5_D2-typ_SF,IPR020575:Hsp90_N,IPR036890:HATPase_C_sf,IPR037196:HSP90_C,	hsa04141:Protein processing in endoplasmic reticulum,hsa04151:PI3K-Akt signaling pathway,hsa04217:Necroptosis,hsa04612:Antigen processing and presentation,hsa04621:NOD-like receptor signaling pathway,hsa04657:IL-17 signaling pathway,hsa04659:Th17 cell differentiation,hsa04914:Progesterone-mediated oocyte maturation,hsa04915:Estrogen signaling pathway,hsa05132:Salmonella infection,hsa05200:Pathways in cancer,hsa05207:Chemical carcinogenesis - receptor activation,hsa05215:Prostate cancer,hsa05417:Lipid and atherosclerosis,hsa05418:Fluid shear stress and atherosclerosis,		PIRSF002583:Hsp90,	SM00387:HATPase_c,	KW-0346~Stress response,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0964~Secreted,KW-1003~Cell membrane,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0143~Chaperone,	KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0702~S-nitrosylation,KW-0832~Ubl conjugation,	CARBOHYD:O-linked (GlcNAc) serine,COMPBIAS:Basic and acidic residues,DOMAIN:Histidine kinase/HSP90-like ATPase,MOTIF:TPR repeat-binding,MUTAGEN:C->A,N,D: Reduced ATPase activity and client protein activation.,MUTAGEN:D->A: Impaired ATP-binding. Strong interaction with HIF1A, MET, KEAP1 and RHOBTB2. Loss of interaction with HSF1 and ERBB2.,MUTAGEN:E->A: Strong ATP-binding. Strong interaction with HSF1, HIF1A, ERBB2, MET, KEAP1 and RHOBTB2.,MUTAGEN:K->A: Decreases the signal of SMYD2-dependent HSP90AB1 methylation. Highly decreases the signal of SMYD2-dependent HSP90AB1 methylation; when associated with A-531. Diminishes dimerized form; when associated with A-531. Reduces interaction with STIP1 or CDC37; when associated with A-531.,MUTAGEN:K->A: Highly decreases the signal of SMYD2-dependent HSP90AB1 methylation; when associated with A-574. Diminishes dimerized form; when associated with A-574. Reduces interaction with STIP1 or CDC37; when associated with A-574.,MUTAGEN:S->A: Increases the binding affinity for AHR; when associated with A-226. Increases AHR transcription activity; when associated with A-226.,MUTAGEN:S->A: Increases the binding affinity for AHR; when associated with A-255. Increases AHR transcription activity; when associated with A-255.,MUTAGEN:S->E: No effect on the interaction with AHR; when associated with E-226.,MUTAGEN:S->E: No effect on the interaction with AHR; when associated with E-255.,MUTAGEN:Y->F: Decreases interaction with NOS3 and SRC. impairs resists LPS-induced tyrosine phosphorylation. Does not block LPS-induced pp60src phosphorylation.,REGION:Disordered,REGION:Interaction with AHSA1,REGION:Interaction with BIRC2,REGION:Interaction with NR1D1,REGION:Interaction with NR3C1,REGION:Interaction with TP53,SITE:Cleaved under oxidative stress,
HSPA1B	heat shock protein family A (Hsp70) member 1B(HSPA1B)	Homo sapiens	114.Genomic_reformatting_Brain_Ischemia,		GO:0006402~mRNA catabolic process,GO:0008285~negative regulation of cell proliferation,GO:0010628~positive regulation of gene expression,GO:0030308~negative regulation of cell growth,GO:0031396~regulation of protein ubiquitination,GO:0031397~negative regulation of protein ubiquitination,GO:0032436~positive regulation of proteasomal ubiquitin-dependent protein catabolic process,GO:0032757~positive regulation of interleukin-8 production,GO:0034599~cellular response to oxidative stress,GO:0034605~cellular response to heat,GO:0042026~protein refolding,GO:0043066~negative regulation of apoptotic process,GO:0045648~positive regulation of erythrocyte differentiation,GO:0046034~ATP metabolic process,GO:0046718~viral entry into host cell,GO:0050821~protein stabilization,GO:0051085~chaperone mediated protein folding requiring cofactor,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0070370~cellular heat acclimation,GO:0070434~positive regulation of nucleotide-binding oligomerization domain containing 2 signaling pathway,GO:0071383~cellular response to steroid hormone stimulus,GO:0090063~positive regulation of microtubule nucleation,GO:0090084~negative regulation of inclusion body assembly,GO:1901673~regulation of mitotic spindle assembly,GO:1903265~positive regulation of tumor necrosis factor-mediated signaling pathway,GO:2001240~negative regulation of extrinsic apoptotic signaling pathway in absence of ligand,	GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005783~endoplasmic reticulum,GO:0005813~centrosome,GO:0005814~centriole,GO:0005829~cytosol,GO:0005925~focal adhesion,GO:0016234~inclusion body,GO:0016235~aggresome,GO:0016607~nuclear speck,GO:0031982~vesicle,GO:0032991~macromolecular complex,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,GO:0072562~blood microparticle,GO:1904813~ficolin-1-rich granule lumen,GO:1990904~ribonucleoprotein complex,	GO:0001618~virus receptor activity,GO:0001664~G-protein coupled receptor binding,GO:0003723~RNA binding,GO:0005102~receptor binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016887~ATPase activity,GO:0019899~enzyme binding,GO:0031072~heat shock protein binding,GO:0031625~ubiquitin protein ligase binding,GO:0042826~histone deacetylase binding,GO:0044183~protein binding involved in protein folding,GO:0051082~unfolded protein binding,GO:0055131~C3HC4-type RING finger domain binding,	IPR013126:Hsp_70_fam,IPR018181:Heat_shock_70_CS,IPR029047:HSP70_peptide-bd_sf,IPR029048:HSP70_C_sf,IPR043129:ATPase_NBD,	hsa03040:Spliceosome,hsa04010:MAPK signaling pathway,hsa04141:Protein processing in endoplasmic reticulum,hsa04144:Endocytosis,hsa04213:Longevity regulating pathway - multiple species,hsa04612:Antigen processing and presentation,hsa04915:Estrogen signaling pathway,hsa05020:Prion disease,hsa05134:Legionellosis,hsa05145:Toxoplasmosis,hsa05162:Measles,hsa05417:Lipid and atherosclerosis,				KW-0346~Stress response,KW-0945~Host-virus interaction,	KW-0206~Cytoskeleton,KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0143~Chaperone,KW-0675~Receptor,KW-1183~Host cell receptor for virus entry,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	MUTAGEN:D->A: Reduces affinity for ADP.,MUTAGEN:K->Q: No loss of acetylation and ATPase activity. Exhibits normal protein refolding activity during the early phase but exhibits defects in ubiquitin-mediated protein degradation during the later phase.,MUTAGEN:K->R: Complete loss of in vitro methylation by METTL21A.,MUTAGEN:K->R: Significant loss of acetylation and ATPase activity. Decreased binding to HOPX and HSP90 and increased binding to STUB1 and NAA10. Impaired capacity for protein refolding during the early phase after stress but shows normal protein degradation activity in the late phase.,REGION:Disordered,REGION:Nucleotide-binding domain (NBD),REGION:Substrate-binding domain (SBD),
HSPA4	heat shock protein family A (Hsp70) member 4(HSPA4)	Homo sapiens			GO:0006457~protein folding,GO:0006986~response to unfolded protein,GO:0045040~protein import into mitochondrial outer membrane,GO:0051131~chaperone-mediated protein complex assembly,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0000774~adenyl-nucleotide exchange factor activity,GO:0005515~protein binding,GO:0005524~ATP binding,	IPR013126:Hsp_70_fam,IPR018181:Heat_shock_70_CS,IPR029047:HSP70_peptide-bd_sf,IPR029048:HSP70_C_sf,IPR042052:HSPA4_NBD,IPR043129:ATPase_NBD,	hsa04530:Tight junction,hsa04612:Antigen processing and presentation,hsa05417:Lipid and atherosclerosis,				KW-0346~Stress response,	KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,		KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,REGION:Disordered,
HSPA5	heat shock protein family A (Hsp70) member 5(HSPA5)	Homo sapiens		h_prionPathway:Prion Pathway,h_stathminPathway:Stathmin and breast cancer resistance to antimicrotubule agents,	GO:0006983~ER overload response,GO:0021589~cerebellum structural organization,GO:0021680~cerebellar Purkinje cell layer development,GO:0021762~substantia nigra development,GO:0030335~positive regulation of cell migration,GO:0030433~ubiquitin-dependent ERAD pathway,GO:0030512~negative regulation of transforming growth factor beta receptor signaling pathway,GO:0030968~endoplasmic reticulum unfolded protein response,GO:0031204~posttranslational protein targeting to membrane, translocation,GO:0031333~negative regulation of protein complex assembly,GO:0031398~positive regulation of protein ubiquitination,GO:0034975~protein folding in endoplasmic reticulum,GO:0034976~response to endoplasmic reticulum stress,GO:0035437~maintenance of protein localization in endoplasmic reticulum,GO:0036503~ERAD pathway,GO:0042026~protein refolding,GO:0042149~cellular response to glucose starvation,GO:0043066~negative regulation of apoptotic process,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051085~chaperone mediated protein folding requiring cofactor,GO:0051603~proteolysis involved in cellular protein catabolic process,GO:0060904~regulation of protein folding in endoplasmic reticulum,GO:0071353~cellular response to interleukin-4,GO:1903891~regulation of ATF6-mediated unfolded protein response,GO:1903894~regulation of IRE1-mediated unfolded protein response,GO:1903895~negative regulation of IRE1-mediated unfolded protein response,GO:1903897~regulation of PERK-mediated unfolded protein response,GO:1990440~positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005783~endoplasmic reticulum,GO:0005788~endoplasmic reticulum lumen,GO:0005789~endoplasmic reticulum membrane,GO:0005793~endoplasmic reticulum-Golgi intermediate compartment,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0008180~COP9 signalosome,GO:0009986~cell surface,GO:0016020~membrane,GO:0030496~midbody,GO:0032991~macromolecular complex,GO:0034663~endoplasmic reticulum chaperone complex,GO:0042470~melanosome,GO:0043231~intracellular membrane-bounded organelle,GO:0070062~extracellular exosome,	GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016887~ATPase activity,GO:0019899~enzyme binding,GO:0019904~protein domain specific binding,GO:0031072~heat shock protein binding,GO:0031625~ubiquitin protein ligase binding,GO:0043022~ribosome binding,GO:0044183~protein binding involved in protein folding,GO:0045296~cadherin binding,GO:0051082~unfolded protein binding,GO:0051087~chaperone binding,GO:0051787~misfolded protein binding,	IPR013126:Hsp_70_fam,IPR018181:Heat_shock_70_CS,IPR029047:HSP70_peptide-bd_sf,IPR029048:HSP70_C_sf,IPR042050:BIP_NBD,IPR043129:ATPase_NBD,	hsa03060:Protein export,hsa04141:Protein processing in endoplasmic reticulum,hsa04612:Antigen processing and presentation,hsa04918:Thyroid hormone synthesis,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05417:Lipid and atherosclerosis,				KW-0945~Host-virus interaction,	KW-0256~Endoplasmic reticulum,KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0732~Signal,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0143~Chaperone,KW-0378~Hydrolase,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-0944~Nitration,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),MOTIF:Prevents secretion from ER,MUTAGEN:K->R: Complete loss of in vitro methylation by METTL21A.,MUTAGEN:T->A: Impaired ATPase activity.,REGION:Disordered,REGION:Interdomain linker,REGION:Nucleotide-binding (NBD),REGION:Required for interaction with KIAA1324,REGION:Substrate-binding (SBD),
HSPA8	heat shock protein family A (Hsp70) member 8(HSPA8)	Homo sapiens			GO:0000398~mRNA splicing, via spliceosome,GO:0006457~protein folding,GO:0006986~response to unfolded protein,GO:0009267~cellular response to starvation,GO:0031647~regulation of protein stability,GO:0042026~protein refolding,GO:0043254~regulation of protein complex assembly,GO:0045892~negative regulation of transcription, DNA-templated,GO:0046034~ATP metabolic process,GO:0051085~chaperone mediated protein folding requiring cofactor,GO:0061024~membrane organization,GO:0061635~regulation of protein complex stability,GO:0061684~chaperone-mediated autophagy,GO:0061738~late endosomal microautophagy,GO:0061740~protein targeting to lysosome involved in chaperone-mediated autophagy,GO:0071383~cellular response to steroid hormone stimulus,GO:0072318~clathrin coat disassembly,GO:1900226~negative regulation of NLRP3 inflammasome complex assembly,GO:1902904~negative regulation of supramolecular fiber organization,GO:1904589~regulation of protein import,GO:1904764~chaperone-mediated autophagy translocation complex disassembly,GO:1990832~slow axonal transport,	GO:0000974~Prp19 complex,GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005681~spliceosomal complex,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005764~lysosome,GO:0005765~lysosomal membrane,GO:0005776~autophagosome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0016020~membrane,GO:0030425~dendrite,GO:0034774~secretory granule lumen,GO:0042470~melanosome,GO:0043195~terminal bouton,GO:0043202~lysosomal lumen,GO:0061202~clathrin-sculpted gamma-aminobutyric acid transport vesicle membrane,GO:0070062~extracellular exosome,GO:0072562~blood microparticle,GO:0098575~lumenal side of lysosomal membrane,GO:0099523~presynaptic cytosol,GO:0099524~postsynaptic cytosol,GO:0101031~chaperone complex,GO:1904813~ficolin-1-rich granule lumen,GO:1990904~ribonucleoprotein complex,	GO:0001664~G-protein coupled receptor binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016887~ATPase activity,GO:0019899~enzyme binding,GO:0023026~MHC class II protein complex binding,GO:0030674~protein binding, bridging,GO:0031072~heat shock protein binding,GO:0031625~ubiquitin protein ligase binding,GO:0044183~protein binding involved in protein folding,GO:0045296~cadherin binding,GO:0051082~unfolded protein binding,GO:0051087~chaperone binding,GO:0055131~C3HC4-type RING finger domain binding,GO:1990833~clathrin-uncoating ATPase activity,	IPR013126:Hsp_70_fam,IPR018181:Heat_shock_70_CS,IPR029047:HSP70_peptide-bd_sf,IPR029048:HSP70_C_sf,IPR043129:ATPase_NBD,	hsa03040:Spliceosome,hsa04010:MAPK signaling pathway,hsa04141:Protein processing in endoplasmic reticulum,hsa04144:Endocytosis,hsa04213:Longevity regulating pathway - multiple species,hsa04612:Antigen processing and presentation,hsa04915:Estrogen signaling pathway,hsa05020:Prion disease,hsa05134:Legionellosis,hsa05145:Toxoplasmosis,hsa05162:Measles,hsa05417:Lipid and atherosclerosis,				KW-0072~Autophagy,KW-0346~Stress response,KW-0507~mRNA processing,KW-0508~mRNA splicing,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0458~Lysosome,KW-0472~Membrane,KW-0539~Nucleus,KW-0747~Spliceosome,KW-0963~Cytoplasm,KW-1003~Cell membrane,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0143~Chaperone,KW-0378~Hydrolase,KW-0678~Repressor,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,MUTAGEN:K->R: Complete loss of in vitro methylation by METTL21A.,REGION:Disordered,REGION:Interaction with BAG1,REGION:Nucleotide-binding domain (NBD),REGION:Substrate-binding domain (SBD),
HSPA9	heat shock protein family A (Hsp70) member 9(HSPA9)	Homo sapiens			GO:0006611~protein export from nucleus,GO:0006886~intracellular protein transport,GO:0007007~inner mitochondrial membrane organization,GO:0016226~iron-sulfur cluster assembly,GO:0030218~erythrocyte differentiation,GO:0042026~protein refolding,GO:0043066~negative regulation of apoptotic process,GO:0045646~regulation of erythrocyte differentiation,GO:0045647~negative regulation of erythrocyte differentiation,GO:0051085~chaperone mediated protein folding requiring cofactor,GO:1902037~negative regulation of hematopoietic stem cell differentiation,GO:1903707~negative regulation of hemopoiesis,	GO:0001401~mitochondrial sorting and assembly machinery complex,GO:0005634~nucleus,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005744~mitochondrial inner membrane presequence translocase complex,GO:0005759~mitochondrial matrix,GO:0005925~focal adhesion,GO:0042645~mitochondrial nucleoid,GO:0070062~extracellular exosome,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016887~ATPase activity,GO:0019899~enzyme binding,GO:0031072~heat shock protein binding,GO:0031625~ubiquitin protein ligase binding,GO:0044183~protein binding involved in protein folding,GO:0051082~unfolded protein binding,	IPR012725:Chaperone_DnaK,IPR013126:Hsp_70_fam,IPR018181:Heat_shock_70_CS,IPR029047:HSP70_peptide-bd_sf,IPR029048:HSP70_C_sf,IPR043129:ATPase_NBD,	hsa03018:RNA degradation,hsa05152:Tuberculosis,	182170~Anemia, sideroblastic, 4,616854~Even-plus syndrome,			KW-0346~Stress response,	KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0242~Dwarfism,	KW-0175~Coiled coil,KW-0732~Signal,KW-0809~Transit peptide,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0143~Chaperone,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,MUTAGEN:G->E: Significant loss of interaction with FXN and ISCU. Significant increase in interaction with NFS1.,MUTAGEN:I->A: Abolishes interaction with UBXN2A.,MUTAGEN:K->A: Reduces interaction with UBXN2A.,MUTAGEN:P->A: Abolishes interaction with UBXN2A.,MUTAGEN:T->A: No effect on interaction with UBXN2A.,REGION:Disordered,REGION:Interaction with FXN and ISCU,REGION:Interaction with NFS1,TRANSIT:Mitochondrion,
HSPB1	heat shock protein family B (small) member 1(HSPB1)	Homo sapiens	114.Genomic_reformatting_Brain_Ischemia,	h_hsp27Pathway:Stress Induction of HSP Regulation,h_mta3Pathway:Downregulated of MTA-3 in ER-negative Breast Tumors,h_p38mapkPathway:p38 MAPK Signaling Pathway ,	GO:0001932~regulation of protein phosphorylation,GO:0006446~regulation of translational initiation,GO:0006469~negative regulation of protein kinase activity,GO:0006986~response to unfolded protein,GO:0009408~response to heat,GO:0009615~response to virus,GO:0010506~regulation of autophagy,GO:0032731~positive regulation of interleukin-1 beta production,GO:0032760~positive regulation of tumor necrosis factor production,GO:0035556~intracellular signal transduction,GO:0035924~cellular response to vascular endothelial growth factor stimulus,GO:0038033~positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway,GO:0042026~protein refolding,GO:0043066~negative regulation of apoptotic process,GO:0043122~regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043536~positive regulation of blood vessel endothelial cell migration,GO:0045766~positive regulation of angiogenesis,GO:0061077~chaperone-mediated protein folding,GO:0070527~platelet aggregation,GO:0099641~anterograde axonal protein transport,GO:1902176~negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway,GO:2001028~positive regulation of endothelial cell chemotaxis,	GO:0000502~proteasome complex,GO:0001533~cornified envelope,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005819~spindle,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005925~focal adhesion,GO:0030018~Z disc,GO:0070062~extracellular exosome,GO:1904115~axon cytoplasm,	GO:0003723~RNA binding,GO:0005080~protein kinase C binding,GO:0005515~protein binding,GO:0008426~protein kinase C inhibitor activity,GO:0019901~protein kinase binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0043130~ubiquitin binding,GO:0044183~protein binding involved in protein folding,GO:0051082~unfolded protein binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,	IPR001436:Alpha-crystallin/sHSP_animal,IPR002068:A-crystallin/Hsp20_dom,IPR008978:HSP20-like_chaperone,IPR037876:ACD_HspB1,	hsa04010:MAPK signaling pathway,hsa04370:VEGF signaling pathway,hsa05146:Amoebiasis,	606595~Charcot-Marie-Tooth disease, axonal, type 2F,608634~Neuronopathy, distal hereditary motor, autosomal dominant 3,			KW-0346~Stress response,KW-0945~Host-virus interaction,	KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0144~Charcot-Marie-Tooth disease,KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0622~Neuropathy,			KW-0143~Chaperone,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:SHSP,DOMAIN:sHSP,MUTAGEN:S->D: Mimicks phosphorylation state, leading to dreased ability to act as molecular chaperones; when associated with D-15 and D-78.,MUTAGEN:S->D: Mimicks phosphorylation state, leading to dreased ability to act as molecular chaperones; when associated with D-15 and D-82.,MUTAGEN:S->D: Mimicks phosphorylation state, leading to dreased ability to act as molecular chaperones; when associated with D-78 and D-82.,REGION:Disordered,REGION:Interaction with TGFB1I1,
HSPD1	heat shock protein family D (Hsp60) member 1(HSPD1)	Homo sapiens			GO:0002755~MyD88-dependent toll-like receptor signaling pathway,GO:0002842~positive regulation of T cell mediated immune response to tumor cell,GO:0006457~protein folding,GO:0006458~'de novo' protein folding,GO:0006919~activation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0006986~response to unfolded protein,GO:0008637~apoptotic mitochondrial changes,GO:0009409~response to cold,GO:0032727~positive regulation of interferon-alpha production,GO:0032729~positive regulation of interferon-gamma production,GO:0032733~positive regulation of interleukin-10 production,GO:0032735~positive regulation of interleukin-12 production,GO:0032755~positive regulation of interleukin-6 production,GO:0034514~mitochondrial unfolded protein response,GO:0042026~protein refolding,GO:0042100~B cell proliferation,GO:0042110~T cell activation,GO:0042113~B cell activation,GO:0043032~positive regulation of macrophage activation,GO:0043065~positive regulation of apoptotic process,GO:0043066~negative regulation of apoptotic process,GO:0045041~protein import into mitochondrial intermembrane space,GO:0048291~isotype switching to IgG isotypes,GO:0050821~protein stabilization,GO:0050870~positive regulation of T cell activation,GO:0051131~chaperone-mediated protein complex assembly,GO:0051604~protein maturation,GO:0051702~interaction with symbiont,GO:0098761~cellular response to interleukin-7,	GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005759~mitochondrial matrix,GO:0005769~early endosome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005905~clathrin-coated pit,GO:0009986~cell surface,GO:0016020~membrane,GO:0030135~coated vesicle,GO:0030141~secretory granule,GO:0032991~macromolecular complex,GO:0046696~lipopolysaccharide receptor complex,GO:0070062~extracellular exosome,GO:0097225~sperm midpiece,GO:0097524~sperm plasma membrane,	GO:0001530~lipopolysaccharide binding,GO:0002039~p53 binding,GO:0003688~DNA replication origin binding,GO:0003697~single-stranded DNA binding,GO:0003723~RNA binding,GO:0003725~double-stranded RNA binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008035~high-density lipoprotein particle binding,GO:0016853~isomerase activity,GO:0016887~ATPase activity,GO:0019899~enzyme binding,GO:0031625~ubiquitin protein ligase binding,GO:0034185~apolipoprotein binding,GO:0034186~apolipoprotein A-I binding,GO:0051082~unfolded protein binding,GO:0051087~chaperone binding,	IPR001844:Cpn60/GroEL,IPR002423:Cpn60/GroEL/TCP-1,IPR017998:Chaperone_TCP-1,IPR018370:Chaperonin_Cpn60_CS,IPR027409:GroEL-like_apical_dom_sf,IPR027410:TCP-1-like_intermed_sf,IPR027413:GROEL-like_equatorial_sf,	hsa03018:RNA degradation,hsa04940:Type I diabetes mellitus,hsa05134:Legionellosis,hsa05152:Tuberculosis,hsa05417:Lipid and atherosclerosis,	605280~Spastic paraplegia 13, autosomal dominant,612233~Leukodystrophy, hypomyelinating, 4,			KW-0346~Stress response,KW-0945~Host-virus interaction,	KW-0496~Mitochondrion,	KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0890~Hereditary spastic paraplegia,KW-1026~Leukodystrophy,	KW-0809~Transit peptide,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0143~Chaperone,KW-0413~Isomerase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),TRANSIT:Mitochondrion,
HSPE1	heat shock protein family E (Hsp10) member 1(HSPE1)	Homo sapiens			GO:0001649~osteoblast differentiation,GO:0006457~protein folding,GO:0006919~activation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0006986~response to unfolded protein,GO:0051085~chaperone mediated protein folding requiring cofactor,	GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0016020~membrane,GO:0070062~extracellular exosome,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0044183~protein binding involved in protein folding,GO:0046872~metal ion binding,GO:0051082~unfolded protein binding,GO:0051087~chaperone binding,	IPR011032:GroES-like_sf,IPR018369:Chaprnonin_Cpn10_CS,IPR020818:Chaperonin_GroES,IPR037124:Chaperonin_GroES_sf,				SM00883:Cpn10,	KW-0346~Stress response,	KW-0496~Mitochondrion,				KW-0143~Chaperone,	KW-0007~Acetylation,KW-0597~Phosphoprotein,
HSPH1	heat shock protein family H (Hsp110) member 1(HSPH1)	Homo sapiens			GO:0006457~protein folding,GO:0006986~response to unfolded protein,GO:0045345~positive regulation of MHC class I biosynthetic process,GO:0051085~chaperone mediated protein folding requiring cofactor,GO:0051135~positive regulation of NK T cell activation,	GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005874~microtubule,GO:0032991~macromolecular complex,GO:0070062~extracellular exosome,GO:0071682~endocytic vesicle lumen,	GO:0000774~adenyl-nucleotide exchange factor activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0043014~alpha-tubulin binding,	IPR013126:Hsp_70_fam,IPR018181:Heat_shock_70_CS,IPR029047:HSP70_peptide-bd_sf,IPR029048:HSP70_C_sf,IPR042053:HSPH1_NBD,IPR043129:ATPase_NBD,	hsa04141:Protein processing in endoplasmic reticulum,				KW-0346~Stress response,	KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,		KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,
HSF1	heat shock transcription factor 1(HSF1)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0000165~MAPK cascade,GO:0006281~DNA repair,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006397~mRNA processing,GO:0006952~defense response,GO:0007584~response to nutrient,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0010667~negative regulation of cardiac muscle cell apoptotic process,GO:0014823~response to activity,GO:0031333~negative regulation of protein complex assembly,GO:0033574~response to testosterone,GO:0034605~cellular response to heat,GO:0034620~cellular response to unfolded protein,GO:0035865~cellular response to potassium ion,GO:0042531~positive regulation of tyrosine phosphorylation of STAT protein,GO:0045651~positive regulation of macrophage differentiation,GO:0045931~positive regulation of mitotic cell cycle,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051028~mRNA transport,GO:0051091~positive regulation of sequence-specific DNA binding transcription factor activity,GO:0065003~macromolecular complex assembly,GO:0070301~cellular response to hydrogen peroxide,GO:0071222~cellular response to lipopolysaccharide,GO:0071276~cellular response to cadmium ion,GO:0071280~cellular response to copper ion,GO:0071392~cellular response to estradiol stimulus,GO:0071466~cellular response to xenobiotic stimulus,GO:0071480~cellular response to gamma radiation,GO:0072738~cellular response to diamide,GO:0090084~negative regulation of inclusion body assembly,GO:0090261~positive regulation of inclusion body assembly,GO:1900034~regulation of cellular response to heat,GO:1902512~positive regulation of apoptotic DNA fragmentation,GO:1903936~cellular response to sodium arsenite,GO:1904385~cellular response to angiotensin,GO:1904843~cellular response to nitroglycerin,GO:1904845~cellular response to L-glutamine,GO:1990910~response to hypobaric hypoxia,GO:1990911~response to psychosocial stress,GO:2001033~negative regulation of double-strand break repair via nonhomologous end joining,	GO:0000776~kinetochore,GO:0000785~chromatin,GO:0000791~euchromatin,GO:0000792~heterochromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005829~cytosol,GO:0016605~PML body,GO:0048471~perinuclear region of cytoplasm,GO:0097165~nuclear stress granule,GO:0097431~mitotic spindle pole,GO:0101031~chaperone complex,GO:1990904~ribonucleoprotein complex,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001162~RNA polymerase II intronic transcription regulatory region sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0019901~protein kinase binding,GO:0031072~heat shock protein binding,GO:0031490~chromatin DNA binding,GO:0042802~identical protein binding,GO:0043565~sequence-specific DNA binding,GO:0043621~protein self-association,GO:0046982~protein heterodimerization activity,GO:0051879~Hsp90 protein binding,GO:0061770~translation elongation factor binding,GO:0097677~STAT family protein binding,GO:0098847~sequence-specific single stranded DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,GO:1990841~promoter-specific chromatin binding,	IPR000232:HSF_DNA-bd,IPR010542:Vert_HSTF_C,IPR027725:HSF_fam,IPR036388:WH-like_DNA-bd_sf,IPR036390:WH_DNA-bd_sf,	hsa05134:Legionellosis,			SM00415:HSF,	KW-0227~DNA damage,KW-0234~DNA repair,KW-0346~Stress response,KW-0507~mRNA processing,KW-0509~mRNA transport,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0813~Transport,KW-0945~Host-virus interaction,	KW-0137~Centromere,KW-0158~Chromosome,KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0995~Kinetochore,				KW-0010~Activator,KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:HSF-type DNA-binding,DOMAIN:Vertebrate heat shock transcription factor C-terminal,MOTIF:9aaTAD,MUTAGEN:E->A: Induces derepression of transcriptional activity at control temperature.,MUTAGEN:E->A: No effect neither on repression of transcriptional activity at control temperature nor on transcriptional activation upon heat shock.,MUTAGEN:E->A: No effect on repression of transcriptional activity at control temperature.,MUTAGEN:K->A: Induces derepression of transcriptional activity at control temperature.,MUTAGEN:K->Q: Loss of nuclear stress bodies localization. Loss of DNA-binding and transcriptional activities upon heat shock. No change in homotrimerization upon heat shock.,MUTAGEN:K->Q: Loss of nuclear stress bodies localization. No change in protein abundance.,MUTAGEN:K->Q: No change in nuclear stress bodies localization. Increased protein abundance.,MUTAGEN:K->R: Abolishes sumoylation. No effect on phosphorylation of S-303 nor of S-307. No change in subcellular location to nuclear stress granules upon heat shock. Loss of colocalization with SUMO1 to nuclear stress granules upon heat shock. Does not change interaction with XRCC5 and XRCC6. No effect on binding to HSE nor on transactivation of HSP70. Increases transcriptional activity in a DAXX-dependent manner. No change in protein abundance.,MUTAGEN:K->R: Does not change interaction with XRCC5 and XRCC6. Loss of nuclear stress bodies localization. Decreased nuclear stress bodies localization. Loss of DNA-binding and transcriptional activities upon heat shock.,MUTAGEN:K->R: No change in nuclear stress bodies localization.,MUTAGEN:K->R: No change in nuclear stress bodies localization. No change in protein abundance.,MUTAGEN:K->R: No effect on sumoylation.,MUTAGEN:L->A: Does not lead to constitutive homotrimerization and DNA-binding activities at 20 degrees Celsius. Leads to constitutive homotrimerization and DNA-binding activities at 30 degrees Celsius. No effect on DNA-binding activity at 37 degrees Celsius.,MUTAGEN:L->A: Inhibits HSE DNA-binding activity and transcriptional activation.,MUTAGEN:L->E: Leads to constitutive DNA-binding and homotrimerization activities at 20 degrees Celsius. No effect on DNA-binding activity at 37 degrees Celsius.,MUTAGEN:L->E: Leads to constitutive homotrimerization and DNA-binding activities at 20 degrees Celsius. Decreased DNA-binding activity at 37 degrees Celsius.,MUTAGEN:L->E: Leads to constitutive homotrimerization, DNA-binding and transactivation activities at 20 degrees Celsius. Decreased DNA-binding activity at 37 degrees Celsius.,MUTAGEN:L->K: Leads to constitutive DNA-binding and homotrimerization activities at 20 degrees Celsius. No effect on DNA-binding activity at 37 degrees Celsius.,MUTAGEN:L->K: Leads to constitutive homotrimerization and DNA-binding activities at 20 degrees Celsius. Does not lead to constitutive transactivation activity at 20 degrees Celsius. Decreased DNA-binding activity at 37 degrees Celsius.,MUTAGEN:L->K: Leads to constitutive homotrimerization and DNA-binding activities at 20 degrees Celsius. Loss of DNA-binding activity at 37 degrees Celsius.,MUTAGEN:L->K: Leads to constitutive homotrimerization and DNA-binding activities at 20 degrees Celsius. No effect on DNA-binding activity at 37 degrees Celsius.,MUTAGEN:M->A: Does not lead to constitutive DNA-binding activity at 20 degrees Celsius. Leads to weak constitutive DNA-binding and homotrimerization activities at 30 degrees Celsius. Decreased DNA-binding activity at 37 degrees Celsius.,MUTAGEN:M->A: Leads to constitutive homotrimerization and DNA-binding activities at 20 degrees Celsius. Does not lead to constitutive transactivation activity at 20 degrees Celsius. No effect on DNA-binding activity at 37 degrees Celsius.,MUTAGEN:M->E: Does not lead to constitutive homotrimerization and DNA-binding activities at 20 degrees Celsius. Loss of DNA-binding activity at 37 degrees Celsius.,MUTAGEN:M->E: Leads to constitutive DNA-binding and homotrimerization activities at 20 degrees Celsius. Does not lead to constitutive transactivation activity at 20 degrees Celsius. No effect on DNA-binding activity at 37 degrees Celsius.,MUTAGEN:M->K: Does not lead to constitutive homotrimerization and DNA-binding activities at 20 degrees Celsius. Loss of DNA-binding activity at 37 degrees Celsius.,MUTAGEN:M->K: Leads to constitutive DNA-binding and homotrimerization activities at 20 degrees Celsius. No effect on DNA-binding activity at 37 degrees Celsius.,MUTAGEN:R->A: No effect neither on repression of transcriptional activity at control temperature nor on transcriptional activation upon heat shock.,MUTAGEN:R->A: No effect on repression of transcriptional activity at control temperature.,MUTAGEN:S->A: Decreased nuclear localization and transcriptional activity upon heat shock.,MUTAGEN:S->A: Decreases MAPK8-induced phosphorylation and does not negatively regulates transactivating activity upon heat shock. No effect on sumoylation.,MUTAGEN:S->A: Does not change interaction with XRCC5 and XRCC6. Decreased nuclear localization upon heat shock. Strongly decreases PLK1-induced phosphorylation. No change in PLK1-induced phosphorylation in mitosis.,MUTAGEN:S->A: Does not change interaction with XRCC5 and XRCC6. No PLK1-induced phosphorylation in mitosis. Inhibits PLK1-stimulated ubiquitinylation. Increased protein stability.,MUTAGEN:S->A: Increased binding HSE and transcriptional activity. Greatly reduced binding to HSP90AA1. No effect on MAPKAPK2 binding.,MUTAGEN:S->A: No change in binding HSE nor on transcriptional activity. Decreased binding HSE; when associated with A-527.,MUTAGEN:S->A: No effect on binding HSE nor on transcriptional activity.,MUTAGEN:S->A: No phosphorylation nor sumoylation. No change in nuclear stress granules subcellular location upon heat shock. Loss of colocalization with SUMO1 to nuclear stress granules upon heat shock. Slight decrease in transcriptional activity on heat treatment. No change in PLK1-induced phosphorylation in mitosis, induces derepression of transcription activation at control temperature, abolishes sumoylation and induces 2.5-fold increase in transcriptional activity on heat treatment; when associated with A-307.,MUTAGEN:S->A: No phosphorylation. Does not reduce Ser-303 phosphorylation. 1.5% increase in transcriptional activity on heat-treatment. No change in PLK1-induced phosphorylation in mitosis, induces derepression of transcription activation at control temperature, abolishes sumoylation and induces 2.5-fold increase in transcriptional activity on heat treatment; when associated with A-303.,MUTAGEN:S->A: No phosphorylation. Increased nuclear localization upon heat shock. No effect on oligomerization, DNA-binding activities and nuclear localization. Significant decrease in transcriptional activity by heat shock. Decreases transcriptional activity in a DAXX-dependent manner. Does not change interaction with XRCC5 and XRCC6. Weak decreased PLK1-induced phosphorylation.,MUTAGEN:S->A: No phosphorylation. No change in PLK1-induced phosphorylation in mitosis. No change in DNA-binding activity upon heat shock. Decreased transcriptional activity upon heat shock.,MUTAGEN:S->A: Reduced increase in heat-induced transcriptional activity.,MUTAGEN:S->A: Weak decreased PLK1-induced phosphorylation.,MUTAGEN:S->A: Weak decreased PLK1-induced phosphorylation. Increased nuclear localization upon heat shock.,MUTAGEN:S->D: 5-fold derepression of transcriptional activity at control temperature; when associated with D-303. Decreased HSF1-induced expression of HSPA1A mRNA in a IER5-dependent manner; when associated with D-121; D-314; D-323 and D-367.,MUTAGEN:S->D: Decreased HSF1-induced expression of HSPA1A mRNA in a IER5-dependent manner; when associated with D-121; D-307; D-323 and D-367.,MUTAGEN:S->D: Increased nuclear localization and transcriptional activity upon heat shock.,MUTAGEN:S->D: Mimics phosphorylation. No effect on in vitro sumoylation. Greatly increased transcriptional activity on heat induction. 5-fold derepression of transcriptional activity at control temperature; when associated with D-307.,MUTAGEN:S->D: Mimics phosphorylation. No effect on transcriptional activity upon heat shock.,MUTAGEN:S->D: Some inhibition of binding HSE and transcriptional activity. No change in binding HSP90AA1. Inhibits MAPKAPK2 binding. Decreased HSF1-induced expression of HSPA1A mRNA in a IER5-dependent manner; when associated with D-307; D-314; D-323 and D-367.,MUTAGEN:S->E: Does not change interaction with XRCC5 and XRCC6.,MUTAGEN:S->E: Does not change interaction with XRCC5 and XRCC6. No change in spindle pole localization. Increases weakly PLK1-stimulated ubiquitinylation. No change in protein stability. Increased interaction with BTRC.,MUTAGEN:S->G: Leads to constitutive transactivation activity at room temperature. Inhibits interaction with YWHAE and increases cytoplasmic localization; when associated with G-303.,MUTAGEN:S->G: Leads to constitutive transactivation activity at room temperature. Inhibits interaction with YWHAE and increases cytoplasmic localization; when associated with G-307.,MUTAGEN:S->G: Leads to weak constitutive transactivation activity at room temperature.,MUTAGEN:S->N: Decreased spindle pole localization. Decreased interaction with BTRC. Increased protein stability.,MUTAGEN:T->A: No change in binding HSE nor on transcriptional activity. Decreased binding HSE; when associated with A-529.,MUTAGEN:T->A: No effect on binding HSE nor on transcriptional activity.,MUTAGEN:T->A: Reduced promoter activity by about 90%. Almost no transcriptional activity when coexpressed with CK2.,MUTAGEN:T->D: Decreased HSF1-induced expression of HSPA1A mRNA in a IER5-dependent manner; when associated with D-121; D-307; D-314 and D-323.,MUTAGEN:T->D: Decreased HSF1-induced expression of HSPA1A mRNA in a IER5-dependent manner; when associated with D-121; D-307; D-314 and D-367.,MUTAGEN:V->A: Slight effect on derepression of transcriptional activity at control temperature and on transcriptional activation upon heat shock.,REGION:D domain,REGION:DNA-binding domain,REGION:Disordered,REGION:Hydrophobic repeat HR-A/B,REGION:Hydrophobic repeat HR-C,REGION:Regulatory domain,REGION:Transactivation domain,
HELZ	helicase with zinc finger(HELZ)	Homo sapiens			GO:0035194~posttranscriptional gene silencing by RNA,	GO:0005634~nucleus,GO:0005829~cytosol,GO:0016020~membrane,GO:0043186~P granule,	GO:0003723~RNA binding,GO:0004386~helicase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016787~hydrolase activity,GO:0046872~metal ion binding,	IPR000571:Znf_CCCH,IPR006935:Helicase/UvrB_N,IPR011990:TPR-like_helical_dom_sf,IPR014016:UvrD-like_ATP-bd,IPR027417:P-loop_NTPase,IPR036855:Znf_CCCH_sf,IPR041677:DNA2/NAM7_AAA_11,IPR041679:DNA2/NAM7-like_C,IPR045055:DNA2/NAM7-like,IPR047187:SF1_C_Upf1,				SM00356:ZnF_C3H1,	KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-0539~Nucleus,		KW-0812~Transmembrane,KW-0863~Zinc-finger,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,KW-0862~Zinc,	KW-0347~Helicase,KW-0378~Hydrolase,	KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic residues,COMPBIAS:Polar residues,DOMAIN:C3H1-type,MOTIF:DEAA box,REGION:Disordered,TRANSMEM:Helical,ZN_FING:C3H1-type,
HCST	hematopoietic cell signal transducer(HCST)	Homo sapiens			GO:0006468~protein phosphorylation,GO:0050776~regulation of immune response,GO:0051897~positive regulation of protein kinase B signaling,	GO:0005886~plasma membrane,GO:0009986~cell surface,	GO:0005102~receptor binding,GO:0005515~protein binding,GO:0043548~phosphatidylinositol 3-kinase binding,	IPR009861:HCST,	hsa04650:Natural killer cell mediated cytotoxicity,					KW-0472~Membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	MUTAGEN:D->A: Abolishes stable interaction with KLRK1.,MUTAGEN:M->Q: Abrogates cell killing and interaction with PIK3R1. No effect on interaction with GRB2.,MUTAGEN:N->Q: Abrogates cell killing and interaction with GRB2. No effect on interaction with PIK3R1.,REGION:GRB2 binding site,REGION:PIK3R1 binding site,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
HCLS1	hematopoietic cell-specific Lyn substrate 1(HCLS1)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006355~regulation of transcription, DNA-templated,GO:0007015~actin filament organization,GO:0007165~signal transduction,GO:0008284~positive regulation of cell proliferation,GO:0009725~response to hormone,GO:0030218~erythrocyte differentiation,GO:0030833~regulation of actin filament polymerization,GO:0030854~positive regulation of granulocyte differentiation,GO:0035556~intracellular signal transduction,GO:0038158~granulocyte colony-stimulating factor signaling pathway,GO:0042307~positive regulation of protein import into nucleus,GO:0042531~positive regulation of tyrosine phosphorylation of STAT protein,GO:0045651~positive regulation of macrophage differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0050731~positive regulation of peptidyl-tyrosine phosphorylation,GO:0051169~nuclear transport,GO:0051897~positive regulation of protein kinase B signaling,GO:0071345~cellular response to cytokine stimulus,GO:2000107~negative regulation of leukocyte apoptotic process,	GO:0005634~nucleus,GO:0005667~transcription factor complex,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0030139~endocytic vesicle,	GO:0005515~protein binding,GO:0017124~SH3 domain binding,GO:0019901~protein kinase binding,GO:0035591~signaling adaptor activity,GO:0051015~actin filament binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,	IPR001452:SH3_domain,IPR003134:Hs1_Cortactin,IPR036028:SH3-like_dom_sf,	hsa04530:Tight junction,hsa05100:Bacterial invasion of epithelial cells,hsa05130:Pathogenic Escherichia coli infection,hsa05131:Shigellosis,hsa05205:Proteoglycans in cancer,			SM00326:SH3,		KW-0472~Membrane,KW-0496~Mitochondrion,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0728~SH3 domain,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,DOMAIN:SH3,REGION:Disordered,REGION:Involved in HAX-1 binding,REPEAT:Cortactin 1,REPEAT:Cortactin 2,REPEAT:Cortactin 3,REPEAT:Cortactin 4; truncated,
HGS	hepatocyte growth factor-regulated tyrosine kinase substrate(HGS)	Homo sapiens		h_eea1Pathway:The role of FYVE-finger proteins in vesicle transport,	GO:0006622~protein targeting to lysosome,GO:0007165~signal transduction,GO:0008285~negative regulation of cell proliferation,GO:0010324~membrane invagination,GO:0010628~positive regulation of gene expression,GO:0010642~negative regulation of platelet-derived growth factor receptor signaling pathway,GO:0015031~protein transport,GO:0016197~endosomal transport,GO:0016236~macroautophagy,GO:0016310~phosphorylation,GO:0016525~negative regulation of angiogenesis,GO:0030948~negative regulation of vascular endothelial growth factor receptor signaling pathway,GO:0031623~receptor internalization,GO:0032456~endocytic recycling,GO:0036258~multivesicular body assembly,GO:0042176~regulation of protein catabolic process,GO:0043328~protein targeting to vacuole involved in ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway,GO:0043405~regulation of MAP kinase activity,GO:0046426~negative regulation of JAK-STAT cascade,GO:0072657~protein localization to membrane,GO:0090148~membrane fission,GO:1903543~positive regulation of exosomal secretion,	GO:0005764~lysosome,GO:0005768~endosome,GO:0005769~early endosome,GO:0005829~cytosol,GO:0031901~early endosome membrane,GO:0032585~multivesicular body membrane,GO:0033565~ESCRT-0 complex,GO:0070062~extracellular exosome,GO:0097013~phagocytic vesicle lumen,	GO:0005515~protein binding,GO:0016301~kinase activity,GO:0019904~protein domain specific binding,GO:0035091~phosphatidylinositol binding,GO:0043130~ubiquitin binding,GO:0044389~ubiquitin-like protein ligase binding,GO:0046872~metal ion binding,	IPR000306:Znf_FYVE,IPR002014:VHS_dom,IPR003903:UIM_dom,IPR008942:ENTH_VHS,IPR011011:Znf_FYVE_PHD,IPR013083:Znf_RING/FYVE/PHD,IPR017073:HGS/VPS27,IPR017455:Znf_FYVE-rel,IPR024641:HRS_helical,	hsa03250:Viral life cycle - HIV-1,hsa04144:Endocytosis,hsa04145:Phagosome,		PIRSF036956:Hrs_Vps27,	SM00064:FYVE,SM00288:VHS,	KW-0653~Protein transport,KW-0813~Transport,	KW-0472~Membrane,KW-0963~Cytoplasm,KW-0967~Endosome,		KW-0175~Coiled coil,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0418~Kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Basic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:FYVE-type,DOMAIN:Hepatocyte growth factor-regulated tyrosine kinase substrate helical,DOMAIN:UIM,DOMAIN:VHS,MUTAGEN:A->Q: Strongly reduced ubiquitin-binding. Reduced degradation of ubiquitinated EGFR.,REGION:Disordered,REGION:Interaction with NF2,REGION:Interaction with SNAP25 and TRAK2,REGION:Interaction with SNX1,REGION:Interaction with STAM,ZN_FING:FYVE-type,
HP1BP3	heterochromatin protein 1 binding protein 3(HP1BP3)	Homo sapiens			GO:0006334~nucleosome assembly,GO:0006355~regulation of transcription, DNA-templated,GO:0042127~regulation of cell proliferation,GO:0070828~heterochromatin organization,GO:0071456~cellular response to hypoxia,GO:0097298~regulation of nucleus size,	GO:0000786~nucleosome,GO:0005634~nucleus,GO:0005694~chromosome,GO:0016607~nuclear speck,	GO:0003677~DNA binding,GO:0005515~protein binding,GO:0030527~structural constituent of chromatin,GO:0031491~nucleosome binding,	IPR005818:Histone_H1/H5_H15,IPR005819:H1/H5,IPR036388:WH-like_DNA-bd_sf,IPR036390:WH_DNA-bd_sf,				SM00526:H15,		KW-0158~Chromosome,KW-0539~Nucleus,		KW-0677~Repeat,		KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0164~Citrullination,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:H15,DOMAIN:H15 1,DOMAIN:H15 2,DOMAIN:H15 3,MOTIF:PxVxL motif,REGION:Disordered,
HNRNPD	heterogeneous nuclear ribonucleoprotein D(HNRNPD)	Homo sapiens			GO:0001889~liver development,GO:0006355~regulation of transcription, DNA-templated,GO:0006396~RNA processing,GO:0006401~RNA catabolic process,GO:0010468~regulation of gene expression,GO:0010557~positive regulation of macromolecule biosynthetic process,GO:0010629~negative regulation of gene expression,GO:0021549~cerebellum development,GO:0032204~regulation of telomere maintenance,GO:0042752~regulation of circadian rhythm,GO:0042789~mRNA transcription from RNA polymerase II promoter,GO:0045727~positive regulation of translation,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051592~response to calcium ion,GO:0051602~response to electrical stimulus,GO:0061158~3'-UTR-mediated mRNA destabilization,GO:0070934~CRD-mediated mRNA stabilization,GO:0071230~cellular response to amino acid stimulus,GO:0071392~cellular response to estradiol stimulus,GO:0071732~cellular response to nitric oxide,GO:0097167~circadian regulation of translation,GO:1900152~negative regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay,GO:1901355~response to rapamycin,GO:1904355~positive regulation of telomere capping,GO:1904383~response to sodium phosphate,GO:1904586~cellular response to putrescine,GO:1905663~positive regulation of telomerase RNA reverse transcriptase activity,GO:1990828~hepatocyte dedifferentiation,GO:2000767~positive regulation of cytoplasmic translation,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0014069~postsynaptic density,GO:0098978~glutamatergic synapse,GO:1990904~ribonucleoprotein complex,	GO:0003680~AT DNA binding,GO:0003682~chromatin binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0035925~mRNA 3'-UTR AU-rich region binding,GO:0042162~telomeric DNA binding,GO:0042826~histone deacetylase binding,	IPR000504:RRM_dom,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR012956:CARG-binding_factor_N,IPR035979:RBD_domain_sf,				SM00360:RRM,	KW-0090~Biological rhythms,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,		KW-0238~DNA-binding,KW-0687~Ribonucleoprotein,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:CARG-binding factor N-terminal,DOMAIN:RRM,DOMAIN:RRM 1,DOMAIN:RRM 2,REGION:Disordered,
HNRNPF	heterogeneous nuclear ribonucleoprotein F(HNRNPF)	Homo sapiens			GO:0000398~mRNA splicing, via spliceosome,GO:0006396~RNA processing,GO:0043484~regulation of RNA splicing,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0045202~synapse,GO:0071013~catalytic step 2 spliceosome,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003727~single-stranded RNA binding,GO:0005515~protein binding,	IPR000504:RRM_dom,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR012996:Znf_CHHC,IPR035979:RBD_domain_sf,				SM00360:RRM,	KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,KW-0747~Spliceosome,		KW-0677~Repeat,		KW-0687~Ribonucleoprotein,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:RRM,DOMAIN:RRM 1,DOMAIN:RRM 2,DOMAIN:RRM 3,MUTAGEN:E->A: Decreases affinity for RNA oligonucleotide 100-fold.,MUTAGEN:E->A: Loss of RNA-binding.,MUTAGEN:F->A: Drastically effects folding of RRM2.,MUTAGEN:F->A: Little disruption of binding RNA. Decreases affinity for RNA oligonucleotide 100-fold. Abrogates RNA-binding; when associated with A-180.,MUTAGEN:F->A: Minimal effect on affinity for RNA oligonucleotide.,MUTAGEN:H->A: Little disruption of binding RNA.,MUTAGEN:K->A: Minimal effect on affinity for RNA oligonucleotide.,MUTAGEN:K->A: No effect on affinity for RNA oligonucleotide.,MUTAGEN:R->A: Decreases affinity for RNA oligonucleotide 100-fold.,MUTAGEN:W->A: Loss of RNA-binding.,MUTAGEN:Y->A: Decreases affinity for RNA oligonucleotide 10-fold. Abrogates RNA-binding; when associated with A-120.,REGION:Interaction with RNA,SITE:Interaction with RNA,
HNRNPH1	heterogeneous nuclear ribonucleoprotein H1(HNRNPH1)	Homo sapiens			GO:0000398~mRNA splicing, via spliceosome,GO:0006396~RNA processing,GO:0043484~regulation of RNA splicing,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0016020~membrane,GO:0071013~catalytic step 2 spliceosome,GO:1990904~ribonucleoprotein complex,	GO:0003676~nucleic acid binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0008266~poly(U) RNA binding,GO:0042802~identical protein binding,	IPR000504:RRM_dom,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR012996:Znf_CHHC,IPR035979:RBD_domain_sf,		620083~Neurodevelopmental disorder with craniofacial dysmorphism and skeletal defects,		SM00360:RRM,	KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,KW-0747~Spliceosome,	KW-0225~Disease variant,KW-0991~Intellectual disability,	KW-0677~Repeat,		KW-0687~Ribonucleoprotein,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:RRM,DOMAIN:RRM 1,DOMAIN:RRM 2,DOMAIN:RRM 3,REGION:2 X 16 AA Gly-rich approximate repeats,REGION:2 X 19 AA perfect repeats,REGION:Disordered,REPEAT:1-1,REPEAT:1-2,REPEAT:2-1,REPEAT:2-2,
HNRNPH3	heterogeneous nuclear ribonucleoprotein H3(HNRNPH3)	Homo sapiens			GO:0000398~mRNA splicing, via spliceosome,GO:0006396~RNA processing,GO:0008380~RNA splicing,GO:0030855~epithelial cell differentiation,GO:0043484~regulation of RNA splicing,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005681~spliceosomal complex,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0005515~protein binding,	IPR000504:RRM_dom,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR034969:hnRNPH3_RRM3,IPR034970:hnRNPH3_RRM2,IPR035979:RBD_domain_sf,				SM00360:RRM,	KW-0507~mRNA processing,	KW-0539~Nucleus,		KW-0677~Repeat,		KW-0687~Ribonucleoprotein,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:RRM,DOMAIN:RRM 1,DOMAIN:RRM 2,
HNRNPLL	heterogeneous nuclear ribonucleoprotein L like(HNRNPLL)	Homo sapiens			GO:0006397~mRNA processing,GO:0033120~positive regulation of RNA splicing,GO:0043484~regulation of RNA splicing,	GO:0005634~nucleus,GO:0016020~membrane,GO:0045202~synapse,GO:1990904~ribonucleoprotein complex,	GO:0003676~nucleic acid binding,GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0005515~protein binding,	IPR000504:RRM_dom,IPR006536:HnRNP-L/PTB,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR021790:PTBP1-like_RRM2,IPR034983:hnRPLL_RRM3,IPR034985:hnRPLL_RRM1,IPR034986:hnRPLL_RRM2,IPR034987:hnRPLL_RRM4,IPR035979:RBD_domain_sf,				SM00360:RRM,				KW-0677~Repeat,		KW-0687~Ribonucleoprotein,KW-0694~RNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:RRM,DOMAIN:RRM 1,DOMAIN:RRM 2,DOMAIN:RRM 3,REGION:Disordered,
HNRNPL	heterogeneous nuclear ribonucleoprotein L(HNRNPL)	Homo sapiens			GO:0000381~regulation of alternative mRNA splicing, via spliceosome,GO:0006396~RNA processing,GO:0006397~mRNA processing,GO:0043484~regulation of RNA splicing,GO:0045892~negative regulation of transcription, DNA-templated,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0016020~membrane,GO:0035770~ribonucleoprotein granule,GO:0070062~extracellular exosome,GO:1990904~ribonucleoprotein complex,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0005515~protein binding,GO:0097157~pre-mRNA intronic binding,	IPR000504:RRM_dom,IPR006536:HnRNP-L/PTB,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR021790:PTBP1-like_RRM2,IPR034816:hnRNP-L_RRM3,IPR034817:hnRNPL_RRM4,IPR035005:hnRNPL_RRM1,IPR035008:hnRNPL_RRM2,IPR035979:RBD_domain_sf,				SM00360:RRM,		KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,		KW-0687~Ribonucleoprotein,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:RRM,DOMAIN:RRM 1,DOMAIN:RRM 2,DOMAIN:RRM 3,DOMAIN:RRM 4,MUTAGEN:F->A: Significant decrease in RNA-binding affinity.,MUTAGEN:H->A: 6-fold decrease in RNA-binding affinity.,MUTAGEN:H->A: Significant decrease in RNA-binding affinity.,MUTAGEN:L->A: 15-fold decrease in RNA-binding affinity; when associated with A-174.,MUTAGEN:N->A: 1-fold increase in RNA-binding affinity.,MUTAGEN:S->A: 15-fold decrease in RNA-binding affinity; when associated with A-174.,MUTAGEN:V->A: 4-fold increase in RNA-binding affinity.,REGION:Disordered,
HNRNPUL1	heterogeneous nuclear ribonucleoprotein U like 1(HNRNPUL1)	Homo sapiens			GO:0000380~alternative mRNA splicing, via spliceosome,GO:0006396~RNA processing,GO:0009615~response to virus,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0045202~synapse,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0019899~enzyme binding,	IPR001870:B30.2/SPRY,IPR003034:SAP_dom,IPR003877:SPRY_dom,IPR013320:ConA-like_dom_sf,IPR027417:P-loop_NTPase,IPR035778:SPRY_hnRNP_U,IPR036361:SAP_dom_sf,IPR043136:B30.2/SPRY_sf,	hsa05164:Influenza A,			SM00449:SPRY,SM00513:SAP,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0677~Repeat,		KW-0010~Activator,KW-0678~Repressor,KW-0687~Ribonucleoprotein,KW-0694~RNA-binding,	KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:B30.2/SPRY,DOMAIN:SAP,REGION:5 X 3 AA repeats of R-G-G,REGION:Disordered,REGION:Necessary for interaction with BRD7 and transcriptional activation,REGION:Necessary for interaction with HRMT1L1,REGION:Necessary for interaction with TP53,REGION:Necessary for transcription repression,REPEAT:1-1,REPEAT:1-2,REPEAT:1-3,REPEAT:1-4,REPEAT:1-5,
HNRNPU	heterogeneous nuclear ribonucleoprotein U(HNRNPU)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0000380~alternative mRNA splicing, via spliceosome,GO:0000381~regulation of alternative mRNA splicing, via spliceosome,GO:0000398~mRNA splicing, via spliceosome,GO:0001649~osteoblast differentiation,GO:0006325~chromatin organization,GO:0006396~RNA processing,GO:0007049~cell cycle,GO:0007346~regulation of mitotic cell cycle,GO:0009048~dosage compensation by inactivation of X chromosome,GO:0032211~negative regulation of telomere maintenance via telomerase,GO:0032922~circadian regulation of gene expression,GO:0033673~negative regulation of kinase activity,GO:0034244~negative regulation of transcription elongation from RNA polymerase II promoter,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048255~mRNA stabilization,GO:0051301~cell division,GO:0051457~maintenance of protein location in nucleus,GO:0055013~cardiac muscle cell development,GO:0070934~CRD-mediated mRNA stabilization,GO:0071385~cellular response to glucocorticoid stimulus,GO:0090336~positive regulation of brown fat cell differentiation,GO:0098963~dendritic transport of messenger ribonucleoprotein complex,GO:1900152~negative regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay,GO:1901673~regulation of mitotic spindle assembly,GO:1902275~regulation of chromatin organization,GO:1902425~positive regulation of attachment of mitotic spindle microtubules to kinetochore,GO:1902889~protein localization to spindle microtubule,GO:1990280~RNA localization to chromatin,GO:1990830~cellular response to leukemia inhibitory factor,GO:1990845~adaptive thermogenesis,GO:2000373~positive regulation of DNA topoisomerase (ATP-hydrolyzing) activity,GO:2000648~positive regulation of stem cell proliferation,GO:2000737~negative regulation of stem cell differentiation,GO:2000767~positive regulation of cytoplasmic translation,	GO:0000228~nuclear chromosome,GO:0000776~kinetochore,GO:0000922~spindle pole,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005697~telomerase holoenzyme complex,GO:0005813~centrosome,GO:0005829~cytosol,GO:0009986~cell surface,GO:0016020~membrane,GO:0016363~nuclear matrix,GO:0016607~nuclear speck,GO:0030496~midbody,GO:0032839~dendrite cytoplasm,GO:0032991~macromolecular complex,GO:0036464~cytoplasmic ribonucleoprotein granule,GO:0070937~CRD-mediated mRNA stability complex,GO:0071013~catalytic step 2 spliceosome,GO:0072686~mitotic spindle,GO:0090575~RNA polymerase II transcription factor complex,GO:0098577~inactive sex chromosome,GO:1990023~mitotic spindle midzone,GO:1990498~mitotic spindle microtubule,GO:1990904~ribonucleoprotein complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000993~RNA polymerase II core binding,GO:0001097~TFIIH-class transcription factor binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003690~double-stranded DNA binding,GO:0003697~single-stranded DNA binding,GO:0003714~transcription corepressor activity,GO:0003723~RNA binding,GO:0003725~double-stranded RNA binding,GO:0003727~single-stranded RNA binding,GO:0003730~mRNA 3'-UTR binding,GO:0003779~actin binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008143~poly(A) binding,GO:0017069~snRNA binding,GO:0017130~poly(C) RNA binding,GO:0031490~chromatin DNA binding,GO:0034046~poly(G) binding,GO:0036002~pre-mRNA binding,GO:0042802~identical protein binding,GO:0043021~ribonucleoprotein complex binding,GO:0044877~macromolecular complex binding,GO:0070034~telomerase RNA binding,GO:0099122~RNA polymerase II C-terminal domain binding,GO:1990837~sequence-specific double-stranded DNA binding,GO:1990841~promoter-specific chromatin binding,	IPR001870:B30.2/SPRY,IPR003034:SAP_dom,IPR003877:SPRY_dom,IPR013320:ConA-like_dom_sf,IPR027417:P-loop_NTPase,IPR035778:SPRY_hnRNP_U,IPR036361:SAP_dom_sf,IPR043136:B30.2/SPRY_sf,	hsa03040:Spliceosome,	617391~Developmental and epileptic encephalopathy 54,		SM00449:SPRY,SM00513:SAP,	KW-0090~Biological rhythms,KW-0131~Cell cycle,KW-0132~Cell division,KW-0221~Differentiation,KW-0498~Mitosis,KW-0507~mRNA processing,KW-0508~mRNA splicing,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0137~Centromere,KW-0158~Chromosome,KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0539~Nucleus,KW-0747~Spliceosome,KW-0963~Cytoplasm,KW-0995~Kinetochore,	KW-0225~Disease variant,KW-0887~Epilepsy,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0010~Activator,KW-0156~Chromatin regulator,KW-0217~Developmental protein,KW-0238~DNA-binding,KW-0678~Repressor,KW-0687~Ribonucleoprotein,KW-0694~RNA-binding,KW-9996~Developmental protein,	KW-0007~Acetylation,KW-0013~ADP-ribosylation,KW-0164~Citrullination,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:B30.2/SPRY,DOMAIN:SAP,MUTAGEN:D->A: No cleavage by caspases during apoptosis. Inhibits CASP3-induced cleavage in vitro.,MUTAGEN:RTQKK->ATQAA: Loss of actin-binding.,MUTAGEN:S->A: No change in interaction with AURKA, PLK1 and TPX2. Increases mitotic chromosome misalignment and chromosome segregation defects and time required to progress through mitosis.,MUTAGEN:S->E: Increases mitotic chromosome misalignment and chromosome segregation defects and decreases time required to progress through mitosis.,REGION:ATPase domain,REGION:Actin-binding,REGION:Disordered,REGION:RNA-binding RGG-box,SITE:Cleavage; by CASP3,TRANSMEM:Helical,
HDLBP	high density lipoprotein binding protein(HDLBP)	Homo sapiens			GO:0006869~lipid transport,GO:0008203~cholesterol metabolic process,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005844~polysome,GO:0005886~plasma membrane,GO:0034364~high-density lipoprotein particle,	GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0005515~protein binding,GO:0008289~lipid binding,GO:0045296~cadherin binding,	IPR004087:KH_dom,IPR004088:KH_dom_type_1,IPR036612:KH_dom_type_1_sf,				SM00322:KH,	KW-0153~Cholesterol metabolism,KW-0443~Lipid metabolism,KW-0445~Lipid transport,KW-0753~Steroid metabolism,KW-0813~Transport,KW-1207~Sterol metabolism,	KW-0345~HDL,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0677~Repeat,		KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0449~Lipoprotein,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:K Homology,DOMAIN:KH 1,DOMAIN:KH 10,DOMAIN:KH 11,DOMAIN:KH 12,DOMAIN:KH 13,DOMAIN:KH 14,DOMAIN:KH 2,DOMAIN:KH 3,DOMAIN:KH 4,DOMAIN:KH 5,DOMAIN:KH 6,DOMAIN:KH 7,DOMAIN:KH 8,DOMAIN:KH 9,REGION:Disordered,
HMGN2	high mobility group nucleosomal binding domain 2(HMGN2)	Homo sapiens			GO:0006325~chromatin organization,GO:0031640~killing of cells of other organism,GO:0061844~antimicrobial humoral immune response mediated by antimicrobial peptide,	GO:0000785~chromatin,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005737~cytoplasm,	GO:0003682~chromatin binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0031492~nucleosomal DNA binding,	IPR000079:HMGN_fam,				SM00527:HMG17,		KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0013~ADP-ribosylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,REGION:Disordered,
HMGN3	high mobility group nucleosomal binding domain 3(HMGN3)	Homo sapiens			GO:0006325~chromatin organization,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,	GO:0003682~chromatin binding,GO:0005515~protein binding,GO:0031492~nucleosomal DNA binding,GO:0046966~thyroid hormone receptor binding,	IPR000079:HMGN_fam,				SM00527:HMG17,		KW-0539~Nucleus,				KW-0156~Chromatin regulator,KW-0238~DNA-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,
HMGN4	high mobility group nucleosomal binding domain 4(HMGN4)	Homo sapiens			GO:0006325~chromatin organization,	GO:0000785~chromatin,GO:0005634~nucleus,	GO:0003682~chromatin binding,GO:0005515~protein binding,GO:0031492~nucleosomal DNA binding,	IPR000079:HMGN_fam,				SM00527:HMG17,		KW-0539~Nucleus,				KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0013~ADP-ribosylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,
HINT1	histidine triad nucleotide binding protein 1(HINT1)	Homo sapiens			GO:0006355~regulation of transcription, DNA-templated,GO:0006508~proteolysis,GO:0007165~signal transduction,GO:0009154~purine ribonucleotide catabolic process,GO:0016926~protein desumoylation,GO:0050850~positive regulation of calcium-mediated signaling,GO:0072332~intrinsic apoptotic signaling pathway by p53 class mediator,	GO:0000118~histone deacetylase complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0070062~extracellular exosome,	GO:0000166~nucleotide binding,GO:0003824~catalytic activity,GO:0005080~protein kinase C binding,GO:0005515~protein binding,GO:0016787~hydrolase activity,GO:0016929~SUMO-specific protease activity,GO:0043530~adenosine 5'-monophosphoramidase activity,	IPR001310:Histidine_triad_HIT,IPR011146:HIT-like,IPR019808:Histidine_triad_CS,IPR036265:HIT-like_sf,		137200~Neuromyotonia and axonal neuropathy, autosomal recessive,			KW-0053~Apoptosis,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0622~Neuropathy,		KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,KW-0645~Protease,KW-0788~Thiol protease,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Tele-AMP-histidine intermediate,DOMAIN:HIT,MOTIF:Histidine triad motif,MUTAGEN:C->R: No effect on SUMO-specific isopeptidase activity.,MUTAGEN:D->N: Approximately 50-fold increased affinity for tryptamine adenosine phosphoramidate.,MUTAGEN:E->K: Reduced SUMO-specific isopeptidase activity.,MUTAGEN:F->S: Loss of SUMO-specific isopeptidase activity.,MUTAGEN:G->A: Reduces adenosine 5'-monophosphoramidase activity.,MUTAGEN:H->A: Nearly abolishes adenosine 5'-monophosphoramidase activity. A 3-fold increased affinity for 3-indolepropionic acyl-adenylate and a 2-fold increased affinity for tryptamine adenosine phosphoramidate monoester.,MUTAGEN:H->A: No effect on affinity for 3-indolepropionic acyl-adenylate but a 13.8-fold increased affinity for tryptamine adenosine phosphoramidate monoester.,MUTAGEN:H->A: No significant effect on affinity for 3-indolepropionic acyl-adenylate and tryptamine adenosine phosphoramidate monoester.,MUTAGEN:H->R: Loss of SUMO-specific isopeptidase activity.,MUTAGEN:I->F: Approximately 10-fold increased affinity for tryptamine adenosine phosphoramidate.,MUTAGEN:I->W: Approximately 30-fold increased affinity for tryptamine adenosine phosphoramidate.,MUTAGEN:K->N: Loss of SUMO-specific isopeptidase activity.,MUTAGEN:S->A: Reduces adenosine 5'-monophosphoramidase activity.,MUTAGEN:V->D: Loss of dimerization. Strongly reduced adenosine 5'-monophosphoramidase activity. A 110-fold increased affinity for 3-indolepropionic acyl-adenylate and a 100-fold increased affinity for tryptamine adenosine phosphoramidate monoester.,MUTAGEN:V->E: Loss of dimerization. Strongly reduced adenosine 5'-monophosphoramidase activity. A 128-fold increased affinity for 3-indolepropionic acyl-adenylate and a 1000-fold increased affinity for tryptamine adenosine phosphoramidate monoester.,MUTAGEN:V->M: Loss of SUMO-specific isopeptidase activity.,MUTAGEN:W->A: Nearly abolishes adenosine 5'-monophosphoramidase activity.,
HDAC1	histone deacetylase 1(HDAC1)	Homo sapiens		h_carm-erPathway:CARM1 and Regulation of the Estrogen Receptor,h_g1Pathway:Cell Cycle: G1/S Check Point ,h_huntingtonPathway:Inhibition of Huntington's disease neurodegeneration by histone deacetylase inhibitors,h_mef2dPathway:Role of MEF2D in T-cell Apoptosis,h_mta3Pathway:Downregulated of MTA-3 in ER-negative Breast Tumors,h_pitx2Pathway:Multi-step Regulation of Transcription by Pitx2,h_prc2Pathway:The PRC2 Complex Sets Long-term Gene Silencing Through Modification of Histone Tails,h_ranbp2Pathway:Sumoylation by RanBP2 Regulates Transcriptional Repression,h_tertPathway:Overview of telomerase protein component gene hTert Transcriptional Regulation ,h_vdrPathway:Control of Gene Expression by Vitamin D Receptor,h_wntPathway:WNT Signaling Pathway,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006325~chromatin organization,GO:0006338~chromatin remodeling,GO:0006346~methylation-dependent chromatin silencing,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006476~protein deacetylation,GO:0007492~endoderm development,GO:0008284~positive regulation of cell proliferation,GO:0009913~epidermal cell differentiation,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0021766~hippocampus development,GO:0030182~neuron differentiation,GO:0030336~negative regulation of cell migration,GO:0030512~negative regulation of transforming growth factor beta receptor signaling pathway,GO:0032922~circadian regulation of gene expression,GO:0036120~cellular response to platelet-derived growth factor stimulus,GO:0042475~odontogenesis of dentin-containing tooth,GO:0042659~regulation of cell fate specification,GO:0042733~embryonic digit morphogenesis,GO:0043066~negative regulation of apoptotic process,GO:0043124~negative regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043922~negative regulation by host of viral transcription,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048661~positive regulation of smooth muscle cell proliferation,GO:0048709~oligodendrocyte differentiation,GO:0048714~positive regulation of oligodendrocyte differentiation,GO:0052548~regulation of endopeptidase activity,GO:0060766~negative regulation of androgen receptor signaling pathway,GO:0060789~hair follicle placode formation,GO:0061029~eyelid development in camera-type eye,GO:0061198~fungiform papilla formation,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:1900221~regulation of beta-amyloid clearance,GO:1902455~negative regulation of stem cell population maintenance,GO:1902459~positive regulation of stem cell population maintenance,GO:2000273~positive regulation of receptor activity,GO:2000736~regulation of stem cell differentiation,GO:2001243~negative regulation of intrinsic apoptotic signaling pathway,	GO:0000118~histone deacetylase complex,GO:0000785~chromatin,GO:0000792~heterochromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016580~Sin3 complex,GO:0016581~NuRD complex,GO:0017053~transcriptional repressor complex,GO:0032991~macromolecular complex,GO:0043025~neuronal cell body,GO:0070822~Sin3-type complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000979~RNA polymerase II core promoter sequence-specific DNA binding,GO:0001046~core promoter sequence-specific DNA binding,GO:0001222~transcription corepressor binding,GO:0002039~p53 binding,GO:0003714~transcription corepressor activity,GO:0004407~histone deacetylase activity,GO:0005515~protein binding,GO:0019899~enzyme binding,GO:0031492~nucleosomal DNA binding,GO:0033558~protein deacetylase activity,GO:0035851~Krueppel-associated box domain binding,GO:0042826~histone deacetylase binding,GO:0046872~metal ion binding,GO:0051059~NF-kappaB binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:0070888~E-box binding,GO:1990841~promoter-specific chromatin binding,	IPR000286:His_deacetylse,IPR003084:His_deacetylse_1,IPR023696:Ureohydrolase_dom_sf,IPR023801:His_deacetylse_dom,IPR037138:His_deacetylse_dom_sf,	hsa03082:ATP-dependent chromatin remodeling,hsa03083:Polycomb repressive complex,hsa04110:Cell cycle,hsa04213:Longevity regulating pathway - multiple species,hsa04330:Notch signaling pathway,hsa04350:TGF-beta signaling pathway,hsa04613:Neutrophil extracellular trap formation,hsa04919:Thyroid hormone signaling pathway,hsa05016:Huntington disease,hsa05031:Amphetamine addiction,hsa05034:Alcoholism,hsa05165:Human papillomavirus infection,hsa05169:Epstein-Barr virus infection,hsa05200:Pathways in cancer,hsa05202:Transcriptional misregulation in cancer,hsa05203:Viral carcinogenesis,hsa05206:MicroRNAs in cancer,hsa05220:Chronic myeloid leukemia,		PIRSF037913:His_deacetylse_1,		KW-0090~Biological rhythms,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,			KW-0479~Metal-binding,	KW-0156~Chromatin regulator,KW-0378~Hydrolase,KW-0678~Repressor,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0702~S-nitrosylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	ACT_SITE:Proton acceptor,COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:Histone deacetylase,MUTAGEN:AGG->VRPP: Impaired protein deacetylase activity without affecting the protein decrotonylase activity.,MUTAGEN:E->A: Decreases deacetylase activity, and disrupts interaction with NuRD and SIN3 complexes.,MUTAGEN:E->A: No effect on deacetylase activity, no effect on interaction with NuRD and SIN3 complexes.,MUTAGEN:E->A: Slightly decreases deacetylase activity, no effect on interaction with NuRD and SIN3 complexes.,MUTAGEN:EEE->AEA: Abolished histone deacetylase and decrotonylase activities.,MUTAGEN:F->Y: Abolishes interaction with CHFR; when associated with I-297.,MUTAGEN:H->A: Abolishes histone deacetylase and decrotonylase activities.,MUTAGEN:M->I: Abolishes interaction with CHFR; when associated with Y-287.,MUTAGEN:Missing: Strongly decreases deacetylase activity, and disrupts interaction with NuRD and SIN3 complexes.,MUTAGEN:S->A: Strongly decreases deacetylase activity, and disrupts interaction with NuRD and SIN3 complexes.,MUTAGEN:S->D,E: Decreases deacetylase activity.,MUTAGEN:S->D,E: Slightly decreases deacetylase activity.,REGION:Disordered,REGION:Histone deacetylase,
HOXB2	homeobox B2(HOXB2)	Homo sapiens			GO:0002011~morphogenesis of an epithelial sheet,GO:0007399~nervous system development,GO:0009952~anterior/posterior pattern specification,GO:0009953~dorsal/ventral pattern formation,GO:0021569~rhombomere 3 development,GO:0021570~rhombomere 4 development,GO:0021612~facial nerve structural organization,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048704~embryonic skeletal system morphogenesis,GO:0048857~neural nucleus development,	GO:0000785~chromatin,GO:0005654~nucleoplasm,	GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0005515~protein binding,GO:0043565~sequence-specific DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeobox_dom,IPR001827:Homeobox_Antennapedia_CS,IPR009057:Homeobox-like_sf,IPR017970:Homeobox_CS,IPR020479:Homeobox_metazoa,				SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,	COMPBIAS:Pro residues,DNA_BIND:Homeobox,MOTIF:Antp-type hexapeptide,REGION:Disordered,
HERPUD1	homocysteine inducible ER protein with ubiquitin like domain 1(HERPUD1)	Homo sapiens			GO:0006511~ubiquitin-dependent protein catabolic process,GO:0006986~response to unfolded protein,GO:0030433~ubiquitin-dependent ERAD pathway,GO:0030968~endoplasmic reticulum unfolded protein response,GO:0030970~retrograde protein transport, ER to cytosol,GO:0031396~regulation of protein ubiquitination,GO:0032469~endoplasmic reticulum calcium ion homeostasis,GO:0034976~response to endoplasmic reticulum stress,GO:0036503~ERAD pathway,GO:0045047~protein targeting to ER,GO:1902236~negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway,GO:1903069~regulation of ER-associated ubiquitin-dependent protein catabolic process,GO:1903071~positive regulation of ER-associated ubiquitin-dependent protein catabolic process,GO:1904292~regulation of ERAD pathway,GO:1904294~positive regulation of ERAD pathway,GO:2000060~positive regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process,GO:2001243~negative regulation of intrinsic apoptotic signaling pathway,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0016020~membrane,GO:0044322~endoplasmic reticulum quality control compartment,GO:1990037~Lewy body core,	GO:0005515~protein binding,GO:0044325~ion channel binding,GO:1990756~protein binding, bridging involved in substrate recognition for ubiquitination,	IPR000626:Ubiquitin-like_dom,IPR029071:Ubiquitin-like_domsf,IPR039751:HERPUD1/2,	hsa04141:Protein processing in endoplasmic reticulum,			SM00213:UBQ,	KW-0834~Unfolded protein response,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Ubiquitin-like,REGION:Disordered,REGION:Interaction with SYVN1,REGION:Interaction with UBQLN1,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
HOOK3	hook microtubule tethering protein 3(HOOK3)	Homo sapiens			GO:0001678~cellular glucose homeostasis,GO:0006002~fructose 6-phosphate metabolic process,GO:0006006~glucose metabolic process,GO:0006096~glycolytic process,GO:0007032~endosome organization,GO:0007040~lysosome organization,GO:0008333~endosome to lysosome transport,GO:0015031~protein transport,GO:0019318~hexose metabolic process,GO:0022027~interkinetic nuclear migration,GO:0030705~cytoskeleton-dependent intracellular transport,GO:0031122~cytoplasmic microtubule organization,GO:0034454~microtubule anchoring at centrosome,GO:0045022~early endosome to late endosome transport,GO:0046835~carbohydrate phosphorylation,GO:0050768~negative regulation of neurogenesis,GO:0051156~glucose 6-phosphate metabolic process,GO:0051645~Golgi localization,GO:0061621~canonical glycolysis,GO:0071539~protein localization to centrosome,GO:0097150~neuronal stem cell population maintenance,GO:1905719~protein localization to perinuclear region of cytoplasm,	GO:0000242~pericentriolar material,GO:0005576~extracellular region,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005801~cis-Golgi network,GO:0005813~centrosome,GO:0005829~cytosol,GO:0005874~microtubule,GO:0030897~HOPS complex,GO:0034451~centriolar satellite,GO:0034774~secretory granule lumen,GO:0070695~FHF complex,GO:1904813~ficolin-1-rich granule lumen,	GO:0004340~glucokinase activity,GO:0004396~hexokinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0005536~glucose binding,GO:0008017~microtubule binding,GO:0008865~fructokinase activity,GO:0034452~dynactin binding,GO:0042802~identical protein binding,GO:0045503~dynein light chain binding,GO:0045505~dynein intermediate chain binding,GO:0051959~dynein light intermediate chain binding,	IPR001312:Hexokinase,IPR001715:CH_dom,IPR008636:Hook_C,IPR019807:Hexokinase_BS,IPR022672:Hexokinase_N,IPR022673:Hexokinase_C,IPR036872:CH_dom_sf,IPR043129:ATPase_NBD,IPR043936:HOOK_N,	hsa04814:Motor proteins,				KW-0324~Glycolysis,KW-0653~Protein transport,KW-0813~Transport,	KW-0206~Cytoskeleton,KW-0333~Golgi apparatus,KW-0493~Microtubule,KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0677~Repeat,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0021~Allosteric enzyme,KW-0418~Kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:Calponin-homology (CH),DOMAIN:Hexokinase 1,DOMAIN:Hexokinase 2,DOMAIN:Hexokinase C-terminal,DOMAIN:Hexokinase N-terminal,DOMAIN:Hook C-terminal,REGION:Disordered,REGION:Hexokinase large subdomain 1,REGION:Hexokinase large subdomain 2,REGION:Hexokinase small subdomain 1,REGION:Hexokinase small subdomain 2,REGION:Required for association with Golgi,REGION:Required for interaction with MSR1,REGION:Sufficient for interaction with microtubules,
HCFC1R1	host cell factor C1 regulator 1(HCFC1R1)	Homo sapiens				GO:0005654~nucleoplasm,GO:0005737~cytoplasm,		IPR029195:HCFC1R1,						KW-0539~Nucleus,KW-0963~Cytoplasm,						MOTIF:Nuclear export signal,MUTAGEN:DHPY->AAPA: Loss of interaction with HCFC1.,MUTAGEN:LRL->ARA: Reduces nuclear export.,REGION:Interaction with HCFC1,
HADHA	hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha(HADHA)	Homo sapiens			GO:0006631~fatty acid metabolic process,GO:0006635~fatty acid beta-oxidation,GO:0009410~response to xenobiotic stimulus,GO:0032868~response to insulin,GO:0035965~cardiolipin acyl-chain remodeling,	GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0016507~mitochondrial fatty acid beta-oxidation multienzyme complex,GO:0042645~mitochondrial nucleoid,	GO:0000062~fatty-acyl-CoA binding,GO:0003824~catalytic activity,GO:0003857~3-hydroxyacyl-CoA dehydrogenase activity,GO:0003985~acetyl-CoA C-acetyltransferase activity,GO:0003988~acetyl-CoA C-acyltransferase activity,GO:0004300~enoyl-CoA hydratase activity,GO:0005515~protein binding,GO:0016509~long-chain-3-hydroxyacyl-CoA dehydrogenase activity,GO:0018812~3-hydroxyacyl-CoA dehydratase activity,GO:0044877~macromolecular complex binding,GO:0070403~NAD+ binding,	IPR001753:Enoyl-CoA_hydra/iso,IPR006108:3HC_DH_C,IPR006176:3-OHacyl-CoA_DH_NAD-bd,IPR006180:3-OHacyl-CoA_DH_CS,IPR008927:6-PGluconate_DH-like_C_sf,IPR012803:Fa_ox_alpha_mit,IPR018376:Enoyl-CoA_hyd/isom_CS,IPR029045:ClpP/crotonase-like_dom_sf,IPR036291:NAD(P)-bd_dom_sf,	hsa00062:Fatty acid elongation,hsa00071:Fatty acid degradation,hsa00280:Valine, leucine and isoleucine degradation,hsa00310:Lysine degradation,hsa00380:Tryptophan metabolism,hsa00410:beta-Alanine metabolism,hsa00640:Propanoate metabolism,hsa00650:Butanoate metabolism,hsa01100:Metabolic pathways,hsa01212:Fatty acid metabolism,	609015~Mitochondrial trifunctional protein deficiency 1,609016~Fatty liver, acute, of pregnancy,609016~HELLP syndrome, maternal, of pregnancy,609016~LCHAD deficiency,			KW-0276~Fatty acid metabolism,KW-0443~Lipid metabolism,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,	KW-0225~Disease variant,	KW-0809~Transit peptide,	KW-0520~NAD,	KW-0456~Lyase,KW-0511~Multifunctional enzyme,KW-0560~Oxidoreductase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	ACT_SITE:For hydroxyacyl-coenzyme A dehydrogenase activity,DOMAIN:3-hydroxyacyl-CoA dehydrogenase C-terminal,DOMAIN:3-hydroxyacyl-CoA dehydrogenase NAD binding,SITE:Important for hydroxyacyl-coenzyme A dehydrogenase activity,SITE:Important for long-chain enoyl-CoA hydratase activity,TRANSIT:Mitochondrion,
HADHB	hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta(HADHB)	Homo sapiens			GO:0006635~fatty acid beta-oxidation,GO:0010467~gene expression,GO:0071222~cellular response to lipopolysaccharide,	GO:0005739~mitochondrion,GO:0005740~mitochondrial envelope,GO:0005741~mitochondrial outer membrane,GO:0005743~mitochondrial inner membrane,GO:0005783~endoplasmic reticulum,GO:0016507~mitochondrial fatty acid beta-oxidation multienzyme complex,GO:0042645~mitochondrial nucleoid,	GO:0003723~RNA binding,GO:0003857~3-hydroxyacyl-CoA dehydrogenase activity,GO:0003985~acetyl-CoA C-acetyltransferase activity,GO:0003988~acetyl-CoA C-acyltransferase activity,GO:0004300~enoyl-CoA hydratase activity,GO:0005515~protein binding,GO:0016747~transferase activity, transferring acyl groups other than amino-acyl groups,GO:0050633~acetyl-CoA C-myristoyltransferase activity,	IPR002155:Thiolase,IPR016039:Thiolase-like,IPR020610:Thiolase_AS,IPR020613:Thiolase_CS,IPR020615:Thiolase_acyl_enz_int_AS,IPR020616:Thiolase_N,IPR020617:Thiolase_C,	hsa00062:Fatty acid elongation,hsa00071:Fatty acid degradation,hsa00280:Valine, leucine and isoleucine degradation,hsa01100:Metabolic pathways,hsa01212:Fatty acid metabolism,	620300~Mitochondrial trifunctional protein deficiency 2,	PIRSF000429:Ac-CoA_Ac_transf,		KW-0276~Fatty acid metabolism,KW-0443~Lipid metabolism,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,KW-1000~Mitochondrion outer membrane,	KW-0225~Disease variant,	KW-0809~Transit peptide,		KW-0012~Acyltransferase,KW-0808~Transferase,	KW-0007~Acetylation,	ACT_SITE:Acyl-thioester intermediate,ACT_SITE:Proton donor/acceptor,DOMAIN:Thiolase C-terminal,DOMAIN:Thiolase N-terminal,SITE:Increases nucleophilicity of active site Cys,TRANSIT:Mitochondrion,
HAGH	hydroxyacylglutathione hydrolase(HAGH)	Homo sapiens			GO:0006749~glutathione metabolic process,GO:0006750~glutathione biosynthetic process,GO:0019243~methylglyoxal catabolic process to D-lactate via S-lactoyl-glutathione,	GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0005829~cytosol,	GO:0004416~hydroxyacylglutathione hydrolase activity,GO:0005515~protein binding,GO:0016787~hydrolase activity,GO:0046872~metal ion binding,	IPR001279:Metallo-B-lactamas,IPR017782:Hydroxyacylglutathione_Hdrlase,IPR032282:HAGH_C,IPR035680:Clx_II_MBL,IPR036866:RibonucZ/Hydroxyglut_hydro,	hsa00620:Pyruvate metabolism,hsa01100:Metabolic pathways,	614033~Glyoxalase II deficiency,	PIRSF005457:Glx,	SM00849:Lactamase_B,		KW-0496~Mitochondrion,KW-0963~Cytoplasm,		KW-0809~Transit peptide,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0378~Hydrolase,	KW-0007~Acetylation,	COMPBIAS:Basic and acidic residues,DOMAIN:Hydroxyacylglutathione hydrolase C-terminal,DOMAIN:Metallo-beta-lactamase,REGION:Disordered,TRANSIT:Mitochondrion,
HSD17B10	hydroxysteroid 17-beta dehydrogenase 10(HSD17B10)	Homo sapiens			GO:0006550~isoleucine catabolic process,GO:0006629~lipid metabolic process,GO:0006631~fatty acid metabolic process,GO:0006635~fatty acid beta-oxidation,GO:0006699~bile acid biosynthetic process,GO:0007005~mitochondrion organization,GO:0008207~C21-steroid hormone metabolic process,GO:0008209~androgen metabolic process,GO:0008210~estrogen metabolic process,GO:0051289~protein homotetramerization,GO:0070901~mitochondrial tRNA methylation,GO:0097745~mitochondrial tRNA 5'-end processing,GO:1990180~mitochondrial tRNA 3'-end processing,	GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0005886~plasma membrane,GO:0030678~mitochondrial ribonuclease P complex,GO:0042645~mitochondrial nucleoid,GO:0043527~tRNA methyltransferase complex,	GO:0000049~tRNA binding,GO:0003723~RNA binding,GO:0003857~3-hydroxyacyl-CoA dehydrogenase activity,GO:0004303~estradiol 17-beta-dehydrogenase activity,GO:0005515~protein binding,GO:0008709~cholate 7-alpha-dehydrogenase activity,GO:0016491~oxidoreductase activity,GO:0030283~testosterone dehydrogenase [NAD(P)] activity,GO:0044594~17-beta-hydroxysteroid dehydrogenase (NAD+) activity,GO:0047015~3-hydroxy-2-methylbutyryl-CoA dehydrogenase activity,GO:0047035~testosterone dehydrogenase (NAD+) activity,GO:0047044~androstan-3-alpha,17-beta-diol dehydrogenase activity,	IPR002347:SDR_fam,IPR020904:Sc_DH/Rdtase_CS,IPR036291:NAD(P)-bd_dom_sf,	hsa00280:Valine, leucine and isoleucine degradation,hsa01100:Metabolic pathways,hsa05010:Alzheimer disease,hsa05022:Pathways of neurodegeneration - multiple diseases,	300438~HSD10 mitochondrial disease,		SM00822:PKS_KR,	KW-0276~Fatty acid metabolism,KW-0443~Lipid metabolism,KW-0753~Steroid metabolism,KW-0819~tRNA processing,	KW-0496~Mitochondrion,KW-1135~Mitochondrion nucleoid,	KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0991~Intellectual disability,		KW-0520~NAD,	KW-0560~Oxidoreductase,	KW-0007~Acetylation,	ACT_SITE:Proton acceptor,MUTAGEN:K->A: Abolishes dehydrogenase activity. Does not affect mitochondrial tRNA 5'-end processing. Does not affect tRNA methylation. Does not affect homotetramerization.,MUTAGEN:S->F: Decreased dehydrogenase activity. Does not affect mitochondrial tRNA 5'-end processing. Does not affect tRNA methylation.,REGION:Disordered,
HPRT1	hypoxanthine phosphoribosyltransferase 1(HPRT1)	Homo sapiens			GO:0001913~T cell mediated cytotoxicity,GO:0001975~response to amphetamine,GO:0006164~purine nucleotide biosynthetic process,GO:0006166~purine ribonucleoside salvage,GO:0006178~guanine salvage,GO:0007625~grooming behavior,GO:0007626~locomotory behavior,GO:0021756~striatum development,GO:0021895~cerebral cortex neuron differentiation,GO:0021954~central nervous system neuron development,GO:0032263~GMP salvage,GO:0032264~IMP salvage,GO:0042417~dopamine metabolic process,GO:0043103~hypoxanthine salvage,GO:0044209~AMP salvage,GO:0045964~positive regulation of dopamine metabolic process,GO:0046038~GMP catabolic process,GO:0046040~IMP metabolic process,GO:0046083~adenine metabolic process,GO:0046100~hypoxanthine metabolic process,GO:0046651~lymphocyte proliferation,GO:0048813~dendrite morphogenesis,GO:0051289~protein homotetramerization,GO:0071542~dopaminergic neuron differentiation,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0000166~nucleotide binding,GO:0000287~magnesium ion binding,GO:0004422~hypoxanthine phosphoribosyltransferase activity,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0046872~metal ion binding,GO:0052657~guanine phosphoribosyltransferase activity,	IPR000836:PRibTrfase_dom,IPR005904:Hxn_phspho_trans,IPR029057:PRTase-like,	hsa00230:Purine metabolism,hsa00983:Drug metabolism - other enzymes,hsa01100:Metabolic pathways,hsa01232:Nucleotide metabolism,	300322~Lesch-Nyhan syndrome,300323~Hyperuricemia, HRPT-related,			KW-0660~Purine salvage,	KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0335~Gout,		KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0328~Glycosyltransferase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	ACT_SITE:Proton acceptor,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:Phosphoribosyltransferase,MUTAGEN:K->A: Reduced affinity for hypoxanthine, phosphoribosylpyrophosphate and IMP. Reduced catalytic activity.,
HIF1A	hypoxia inducible factor 1 subunit alpha(HIF1A)	Homo sapiens		h_eponfkbPathway:Erythropoietin mediated neuroprotection through NF-kB,h_hifPathway:Hypoxia-Inducible Factor in the Cardiovascular System,h_p53hypoxiaPathway:Hypoxia and p53 in the Cardiovascular system,h_vegfPathway:VEGF, Hypoxia, and Angiogenesis,	GO:0000302~response to reactive oxygen species,GO:0001525~angiogenesis,GO:0001666~response to hypoxia,GO:0001678~cellular glucose homeostasis,GO:0001755~neural crest cell migration,GO:0001837~epithelial to mesenchymal transition,GO:0001892~embryonic placenta development,GO:0001922~B-1 B cell homeostasis,GO:0001938~positive regulation of endothelial cell proliferation,GO:0001947~heart looping,GO:0002052~positive regulation of neuroblast proliferation,GO:0002062~chondrocyte differentiation,GO:0002071~glandular epithelial cell maturation,GO:0002248~connective tissue replacement involved in inflammatory response wound healing,GO:0003151~outflow tract morphogenesis,GO:0003208~cardiac ventricle morphogenesis,GO:0006089~lactate metabolic process,GO:0006110~regulation of glycolytic process,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006879~cellular iron ion homeostasis,GO:0007165~signal transduction,GO:0007405~neuroblast proliferation,GO:0007595~lactation,GO:0008542~visual learning,GO:0010039~response to iron ion,GO:0010468~regulation of gene expression,GO:0010573~vascular endothelial growth factor production,GO:0010575~positive regulation of vascular endothelial growth factor production,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0010634~positive regulation of epithelial cell migration,GO:0014850~response to muscle activity,GO:0016239~positive regulation of macroautophagy,GO:0019896~axonal transport of mitochondrion,GO:0021502~neural fold elevation formation,GO:0021987~cerebral cortex development,GO:0030282~bone mineralization,GO:0030502~negative regulation of bone mineralization,GO:0030949~positive regulation of vascular endothelial growth factor receptor signaling pathway,GO:0031929~TOR signaling,GO:0032007~negative regulation of TOR signaling,GO:0032364~oxygen homeostasis,GO:0032722~positive regulation of chemokine production,GO:0032909~regulation of transforming growth factor beta2 production,GO:0032963~collagen metabolic process,GO:0034599~cellular response to oxidative stress,GO:0035162~embryonic hemopoiesis,GO:0035773~insulin secretion involved in cellular response to glucose stimulus,GO:0035774~positive regulation of insulin secretion involved in cellular response to glucose stimulus,GO:0042541~hemoglobin biosynthetic process,GO:0043524~negative regulation of neuron apoptotic process,GO:0043536~positive regulation of blood vessel endothelial cell migration,GO:0043619~regulation of transcription from RNA polymerase II promoter in response to oxidative stress,GO:0045648~positive regulation of erythrocyte differentiation,GO:0045766~positive regulation of angiogenesis,GO:0045821~positive regulation of glycolytic process,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045926~negative regulation of growth,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046716~muscle cell cellular homeostasis,GO:0046886~positive regulation of hormone biosynthetic process,GO:0048546~digestive tract morphogenesis,GO:0051000~positive regulation of nitric-oxide synthase activity,GO:0051402~neuron apoptotic process,GO:0051541~elastin metabolic process,GO:0060574~intestinal epithelial cell maturation,GO:0061030~epithelial cell differentiation involved in mammary gland alveolus development,GO:0061072~iris morphogenesis,GO:0061298~retina vasculature development in camera-type eye,GO:0070101~positive regulation of chemokine-mediated signaling pathway,GO:0070244~negative regulation of thymocyte apoptotic process,GO:0071347~cellular response to interleukin-1,GO:0071456~cellular response to hypoxia,GO:0071542~dopaminergic neuron differentiation,GO:0097152~mesenchymal cell apoptotic process,GO:0097411~hypoxia-inducible factor-1alpha signaling pathway,GO:0098586~cellular response to virus,GO:1900017~positive regulation of cytokine production involved in inflammatory response,GO:1901526~positive regulation of macromitophagy,GO:1902894~negative regulation of pri-miRNA transcription from RNA polymerase II promoter,GO:1902895~positive regulation of pri-miRNA transcription from RNA polymerase II promoter,GO:1903377~negative regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway,GO:1903599~positive regulation of mitophagy,GO:1903715~regulation of aerobic respiration,GO:2000273~positive regulation of receptor activity,GO:2000378~negative regulation of reactive oxygen species metabolic process,GO:2000434~regulation of protein neddylation,GO:2001054~negative regulation of mesenchymal cell apoptotic process,	GO:0000785~chromatin,GO:0000791~euchromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016604~nuclear body,GO:0016607~nuclear speck,GO:0031514~motile cilium,GO:0032991~macromolecular complex,GO:0090575~RNA polymerase II transcription factor complex,GO:1904115~axon cytoplasm,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0000987~core promoter proximal region sequence-specific DNA binding,GO:0001216~bacterial-type RNA polymerase transcriptional activator activity, sequence-specific DNA binding,GO:0001217~bacterial-type RNA polymerase transcriptional repressor activity, sequence-specific DNA binding,GO:0001223~transcription coactivator binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0002039~p53 binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0016922~ligand-dependent nuclear receptor binding,GO:0019899~enzyme binding,GO:0019901~protein kinase binding,GO:0019904~protein domain specific binding,GO:0031625~ubiquitin protein ligase binding,GO:0042826~histone deacetylase binding,GO:0043565~sequence-specific DNA binding,GO:0046982~protein heterodimerization activity,GO:0046983~protein dimerization activity,GO:0051879~Hsp90 protein binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:0070888~E-box binding,	IPR000014:PAS,IPR001321:HIF-1_alpha,IPR001610:PAC,IPR011598:bHLH_dom,IPR013655:PAS_fold_3,IPR013767:PAS_fold,IPR014887:HIF-1_CTAD,IPR021537:HIF_alpha-like,IPR035965:PAS-like_dom_sf,IPR036638:HLH_DNA-bd_sf,	hsa04066:HIF-1 signaling pathway,hsa04137:Mitophagy - animal,hsa04140:Autophagy - animal,hsa04148:Efferocytosis,hsa04659:Th17 cell differentiation,hsa04919:Thyroid hormone signaling pathway,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05200:Pathways in cancer,hsa05205:Proteoglycans in cancer,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05211:Renal cell carcinoma,hsa05230:Central carbon metabolism in cancer,hsa05231:Choline metabolism in cancer,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,			SM00086:PAC,SM00091:PAS,SM00353:HLH,	KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,		KW-0010~Activator,KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0379~Hydroxylation,KW-0597~Phosphoprotein,KW-0702~S-nitrosylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CARBOHYD:(Microbial infection) N-beta-linked (GlcNAc) arginine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:BHLH,DOMAIN:PAC,DOMAIN:PAS,DOMAIN:PAS 1,DOMAIN:PAS 2,DOMAIN:bHLH,MOTIF:Nuclear localization signal,MUTAGEN:C->A: Blocks increase in transcriptional activation caused by nitrosylation.,MUTAGEN:C->S: Abolishes hypoxia-inducible transcriptional activation of ctaD.,MUTAGEN:K->R: Abolishes 1 sumoylation. Abolishes 1 sumoylation; when associated with R-532. Abolishes 2 sumoylations; when associated with R-477. No change in HIF1A protein turnover rate but increased transcriptional activity; when associated with R-377; R-477 and R-532.,MUTAGEN:K->R: Abolishes 1 sumoylation. Abolishes 2 sumoylations; when associated with R-391. No change in HIF1A protein turnover rate but increased transcriptional activity; when associated with R-377; R-391 and R-532.,MUTAGEN:K->R: Abolishes SIRT2-mediated deacetylation, increases HIF1A instability and reduces HIF1A-induced target gene transcriptional activation. Increases interaction with EGLN1.,MUTAGEN:K->R: No change in HIF1A protein turnover rate but increased transcriptional activity; when associated with R-391; R-477 and R-532.,MUTAGEN:K->R: No change in sumoylation nor in ARD1-mediated acetylation.,MUTAGEN:K->R: No change in sumoylation, but reduced ubiquitination. Complete loss of ubiquitination, but no change in VHL binding; when associated with K-532 and K-538.,MUTAGEN:K->R: No change in sumoylation, but reduced ubiquitination. Complete loss of ubiquitination, but no change in VHL binding; when associated with K-532 and K-547.,MUTAGEN:K->R: No change in sumoylation.,MUTAGEN:K->R: Reduced ubiquitination. No change in sumoylation nor on interaction with NAA10. No change in HIF1A protein turnover rate but increased transcriptional activity; when associated with R-377; R-391 and R-477. Complete loss of ubiquitination, but no change in VHL binding; when associated with K-538 and K-547.,MUTAGEN:K->T: Dramatic reduction of accumulation in the nucleus in response to hypoxia.,MUTAGEN:L->A: Abolishes VHLE3-dependent ubiquitination; when associated with A-397.,MUTAGEN:L->A: Abolishes VHLE3-dependent ubiquitination; when associated with A-400.,MUTAGEN:L->A: Inhibits interaction with EP300 and transactivation activity.,MUTAGEN:N->A: Recruits CREBBP. No enhancement of CREBBP by Clioquinol in the presence of FIH1. No change in nuclear location nor on repression of transcriptional activity in the presence of histone deacetylase inhibitor.,MUTAGEN:P->A: Abolishes in VHLE3-dependent ubiquitination, abolishes oxygen-dependent regulation of VP16, partially reduced VHLE target site ubiquitination and no interaction with VHL. No VHLE target site ubiquitination; when associated with G-564. Increases HIF1A instability and reduces HIF1A-induced target gene transcriptional activation; when associated with A-564.,MUTAGEN:P->A: Increases HIF1A instability and reduces HIF1A-induced target gene transcriptional activation; when associated with A-402.,MUTAGEN:P->A: No change in VHLE3-dependent ubiquitination.,MUTAGEN:P->G: No change in VHL-dependent ubiquitination. Partially reduced VHLE target site ubiquitination. No VHLE target site ubiquitination; when associated with A-402.,MUTAGEN:R->K: Strongly reduced GlcNAcylation by E.coli NleB1.,MUTAGEN:S->A: Constitutive kinase activity.,MUTAGEN:S->A: Induces stabilization of the protein.,MUTAGEN:S->D: Impaired kinase activity.,MUTAGEN:S->G: Constitutive expression under nonhypoxic conditions by decreasing ubiquitination.,MUTAGEN:T->A: Constitutive expression under nonhypoxic conditions by decreasing ubiquitination.,REGION:C-terminal VHL recognition site,REGION:CTAD,REGION:DNA-binding,REGION:Disordered,REGION:ID,REGION:Interaction with TSGA10,REGION:N-terminal VHL recognition site,REGION:NTAD,REGION:ODD,REGION:Required for heterodimer formation with ARNT,
IDS	iduronate 2-sulfatase(IDS)	Homo sapiens			GO:0006027~glycosaminoglycan catabolic process,GO:0030200~heparan sulfate proteoglycan catabolic process,GO:0030209~dermatan sulfate catabolic process,	GO:0005737~cytoplasm,GO:0005764~lysosome,GO:0043202~lysosomal lumen,	GO:0004423~iduronate-2-sulfatase activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0008484~sulfuric ester hydrolase activity,GO:0046872~metal ion binding,	IPR000917:Sulfatase_N,IPR017850:Alkaline_phosphatase_core_sf,IPR024607:Sulfatase_CS,IPR035874:IDS,	hsa00531:Glycosaminoglycan degradation,hsa01100:Metabolic pathways,hsa04142:Lysosome,	309900~Mucopolysaccharidosis II,				KW-0458~Lysosome,	KW-0225~Disease variant,KW-0510~Mucopolysaccharidosis,	KW-0732~Signal,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0378~Hydrolase,	KW-0325~Glycoprotein,KW-0865~Zymogen,KW-1015~Disulfide bond,	ACT_SITE:Nucleophile,BINDING:via 3-oxoalanine,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Sulfatase N-terminal,REGION:Disordered,
IER2	immediate early response 2(IER2)	Homo sapiens			GO:0030182~neuron differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048870~cell motility,GO:0071774~response to fibroblast growth factor,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,	GO:0003677~DNA binding,GO:0005515~protein binding,	IPR008653:IER,						KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0238~DNA-binding,	KW-0007~Acetylation,	COMPBIAS:Basic and acidic residues,REGION:Disordered,
IPO7	importin 7(IPO7)	Homo sapiens			GO:0006606~protein import into nucleus,GO:0006886~intracellular protein transport,GO:0045087~innate immune response,GO:0045668~negative regulation of osteoblast differentiation,GO:0045736~negative regulation of cyclin-dependent protein serine/threonine kinase activity,GO:1900182~positive regulation of protein localization to nucleus,GO:1901331~positive regulation of odontoblast differentiation,	GO:0005635~nuclear envelope,GO:0005643~nuclear pore,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016020~membrane,	GO:0005515~protein binding,GO:0030695~GTPase regulator activity,GO:0031267~small GTPase binding,GO:0042393~histone binding,GO:0046332~SMAD binding,	IPR001494:Importin-beta_N,IPR011989:ARM-like,IPR013713:XPO2_central,IPR016024:ARM-type_fold,	hsa03013:Nucleocytoplasmic transport,			SM00913:IBN_N,	KW-0653~Protein transport,KW-0813~Transport,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0963~Cytoplasm,					KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,DOMAIN:Importin N-terminal,MUTAGEN:K->A,D: Lowered affinity for RanGTP-binding.,REGION:Disordered,
ICOS	inducible T cell costimulator(ICOS)	Homo sapiens		h_ctla4Pathway:The Co-Stimulatory Signal During T-cell Activation,	GO:0002517~T cell tolerance induction,GO:0006955~immune response,GO:0031295~T cell costimulation,GO:0098609~cell-cell adhesion,	GO:0005576~extracellular region,GO:0005886~plasma membrane,GO:0016020~membrane,	GO:0005515~protein binding,	IPR013106:Ig_V-set,IPR013783:Ig-like_fold,IPR039943:ICOS,	hsa04514:Cell adhesion molecules,hsa04660:T cell receptor signaling pathway,hsa04672:Intestinal immune network for IgA production,hsa05340:Primary immunodeficiency,	607594~Immunodeficiency, common variable, 1,				KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like V-type,DOMAIN:Immunoglobulin V-set,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
IVNS1ABP	influenza virus NS1A binding protein(IVNS1ABP)	Homo sapiens			GO:0006383~transcription from RNA polymerase III promoter,GO:0008380~RNA splicing,GO:0009615~response to virus,GO:0031397~negative regulation of protein ubiquitination,GO:0097193~intrinsic apoptotic signaling pathway,GO:2001243~negative regulation of intrinsic apoptotic signaling pathway,	GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005681~spliceosomal complex,GO:0005829~cytosol,GO:0005856~cytoskeleton,	GO:0005515~protein binding,	IPR000210:BTB/POZ_dom,IPR006652:Kelch_1,IPR011333:SKP1/BTB/POZ_sf,IPR011705:BACK,IPR015915:Kelch-typ_b-propeller,IPR017096:BTB-kelch_protein,		618969~Immunodeficiency 70,	PIRSF037037:Kelch-like_protein_gigaxonin,	SM00225:BTB,SM00612:Kelch,SM00875:BACK,	KW-0945~Host-virus interaction,	KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0880~Kelch repeat,			KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:BACK,DOMAIN:BTB,MUTAGEN:E->K: Significant inhibition of interaction with AHR; partial decrease of AHR signaling induced by IVNS1ABP.,MUTAGEN:V->M: Significant inhibition of interaction with AHR; partial decrease of AHR signaling induced by IVNS1ABP.,REGION:Disordered,REGION:Sufficient for AHR interaction and signaling,REPEAT:Kelch 1,REPEAT:Kelch 2,REPEAT:Kelch 3,REPEAT:Kelch 4,REPEAT:Kelch 5,REPEAT:Kelch 6,
IKBKG	inhibitor of nuclear factor kappa B kinase regulatory subunit gamma(IKBKG)	Homo sapiens		h_aktPathway:AKT Signaling Pathway,h_cd40Pathway:CD40L Signaling Pathway,h_nfkbPathway:NF-kB Signaling Pathway,h_raccycdPathway:Influence of Ras and Rho proteins on G1 to S Transition,h_relaPathway:Acetylation and Deacetylation of RelA in The Nucleus,h_stressPathway:TNF/Stress Related Signaling,h_tnfr2Pathway:TNFR2 Signaling Pathway,h_tollPathway:Toll-Like Receptor Pathway,	GO:0006915~apoptotic process,GO:0006954~inflammatory response,GO:0006955~immune response,GO:0006974~cellular response to DNA damage stimulus,GO:0007249~I-kappaB kinase/NF-kappaB signaling,GO:0009615~response to virus,GO:0016239~positive regulation of macroautophagy,GO:0016310~phosphorylation,GO:0042742~defense response to bacterium,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043276~anoikis,GO:0045087~innate immune response,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0050852~T cell receptor signaling pathway,GO:0050862~positive regulation of T cell receptor signaling pathway,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0051650~establishment of vesicle localization,GO:0065003~macromolecular complex assembly,GO:2000060~positive regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process,	GO:0000151~ubiquitin ligase complex,GO:0000922~spindle pole,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0008385~IkappaB kinase complex,GO:0032991~macromolecular complex,GO:0072686~mitotic spindle,	GO:0005515~protein binding,GO:0016301~kinase activity,GO:0019904~protein domain specific binding,GO:0031593~polyubiquitin binding,GO:0031625~ubiquitin protein ligase binding,GO:0035591~signaling adaptor activity,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0046872~metal ion binding,GO:0046982~protein heterodimerization activity,GO:0070530~K63-linked polyubiquitin binding,GO:1990450~linear polyubiquitin binding,GO:1990459~transferrin receptor binding,	IPR021063:NEMO_N,IPR032419:CC2-LZ_dom,IPR034735:NEMO_ZF,	hsa01523:Antifolate resistance,hsa04010:MAPK signaling pathway,hsa04014:Ras signaling pathway,hsa04062:Chemokine signaling pathway,hsa04064:NF-kappa B signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04210:Apoptosis,hsa04380:Osteoclast differentiation,hsa04620:Toll-like receptor signaling pathway,hsa04621:NOD-like receptor signaling pathway,hsa04622:RIG-I-like receptor signaling pathway,hsa04623:Cytosolic DNA-sensing pathway,hsa04625:C-type lectin receptor signaling pathway,hsa04657:IL-17 signaling pathway,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04660:T cell receptor signaling pathway,hsa04662:B cell receptor signaling pathway,hsa04668:TNF signaling pathway,hsa04920:Adipocytokine signaling pathway,hsa04936:Alcoholic liver disease,hsa05010:Alzheimer disease,hsa05120:Epithelial cell signaling in Helicobacter pylori infection,hsa05130:Pathogenic Escherichia coli infection,hsa05131:Shigellosis,hsa05132:Salmonella infection,hsa05135:Yersinia infection,hsa05142:Chagas disease,hsa05145:Toxoplasmosis,hsa05160:Hepatitis C,hsa05161:Hepatitis B,hsa05162:Measles,hsa05163:Human cytomegalovirus infection,hsa05164:Influenza A,hsa05165:Human papillomavirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05171:Coronavirus disease - COVID-19,hsa05200:Pathways in cancer,hsa05203:Viral carcinogenesis,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05212:Pancreatic cancer,hsa05215:Prostate cancer,hsa05220:Chronic myeloid leukemia,hsa05221:Acute myeloid leukemia,hsa05222:Small cell lung cancer,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,hsa05340:Primary immunodeficiency,hsa05417:Lipid and atherosclerosis,hsa05418:Fluid shear stress and atherosclerosis,	300291~Ectodermal dysplasia and immunodeficiency 1,300636~Immunodeficiency 33,301081~Autoinflammatory disease, systemic, X-linked,308300~Incontinentia pigmenti,			KW-0227~DNA damage,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0038~Ectodermal dysplasia,KW-0225~Disease variant,KW-0987~Osteopetrosis,	KW-0175~Coiled coil,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0418~Kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin and interchain with MARCHF2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin); alternate,DISULFID:Interchain,DOMAIN:CCHC NOA-type,DOMAIN:NF-kappa-B essential modulator NEMO N-terminal,MUTAGEN:A->D: Greatly impairs tandem ubiquitin binding.,MUTAGEN:E->A: No effet on oligomerization,impairs binding of 'Lys-63'-linked ubiuitin and linear tetra-ubiquitin, impairs TNF-induced NF-kappa-B activation.,MUTAGEN:E->Q: Greatly impairs tandem ubiquitin binding.,MUTAGEN:F->A: Greatly impairs tandem ubiquitin binding,impairs oligomerization, impairs TNF-induced NF-kappa-B activation.,MUTAGEN:F->W: MNo effet on oligomerization, preferentially binds tri-ubiquitin chains ('Lys-48' or 'Lys-63'-linked).,MUTAGEN:F->Y: Impairs tandem ubiquitin binding.,MUTAGEN:I->N: Greatly impairs tandem ubiquitin binding.,MUTAGEN:K->A: Partial abolition of sumoylation. Abolishes sumoylation and IKK activation; when associated with A-277. No effect on MARCH2F-mediated K48-linked ubiquitination.,MUTAGEN:K->A: Partial abolition of sumoylation. Abolishes sumoylation and IKK activation; when associated with A-309.,MUTAGEN:K->R: Abolishes BCL10-mediated but not RIPK2-mediated ubiquitination. Important decrease in the ubiquitination level; when associated with R-285. No change in the ubiquitination level; when associated with R-115 or R-224.,MUTAGEN:K->R: Abolishes MARCH2F-mediated K48-linked ubiquitination and subsequent suppression of antiviral and antibacterial innate immune response.,MUTAGEN:K->R: Decreased ability to activate NF-kappa-B. Important decrease in the ubiquitination level; when associated with R-399.,MUTAGEN:K->R: No change in the ubiquitination level; when associated with R-399.,MUTAGEN:K->R: No effect on MARCH2F-mediated K48-linked ubiquitination.,MUTAGEN:L->A: Impairs oligomerization, impairs binding of 'Lys-63'-linked ubiuitin, impairs TNF-induced NF-kappa-B activation; when associated with A-329.,MUTAGEN:L->A: Impairs oligomerization, impairs binding of 'Lys-63'-linked ubiuitin, impairs TNF-induced NF-kappa-B activation; when associated with A-336.,MUTAGEN:L->A: Impairs tandem ubiquitin binding.,MUTAGEN:L->P: Abolished ubiquitin-binding.,MUTAGEN:M->S: Impairs binding to polyubiquitin.,MUTAGEN:Q->A,W: Greatly impairs tandem ubiquitin binding.,MUTAGEN:Q->A: Complete loss of cleavage by HAV protease 3c.,MUTAGEN:Q->A: Impairs tandem ubiquitin binding.,MUTAGEN:S->A: Decreases ubiquitination and abolishes nuclear export.,MUTAGEN:S->A: Increases formation of homodimers.,MUTAGEN:S->E: Abolishes interaction with IKBKB; abolishes TNF-alpha induced NF-kappa-B activity.,MUTAGEN:V->D: Greatly impairs tandem ubiquitin binding.,MUTAGEN:V->S: Abolishes binding to polyubiquitin.,MUTAGEN:Y->A: Greatly impairs tandem ubiquitin binding.,REGION:Disordered,REGION:Interaction with CHUK/IKBKB,REGION:Interaction with CYLD,REGION:Interaction with TANK,REGION:Leucine-zipper,REGION:Required for interaction with TNFAIP3,REGION:Required for interaction with and ubiquitination by MARCHF2,REGION:Self-association,REGION:Ubiquitin-binding (UBAN),ZN_FING:CCHC NOA-type,
PPA1	inorganic pyrophosphatase 1(PPA1)	Homo sapiens			GO:0006796~phosphate-containing compound metabolic process,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0000287~magnesium ion binding,GO:0004427~inorganic diphosphatase activity,	IPR008162:Pyrophosphatase,IPR036649:Pyrophosphatase_sf,	hsa00190:Oxidative phosphorylation,					KW-0963~Cytoplasm,			KW-0460~Magnesium,KW-0479~Metal-binding,	KW-0378~Hydrolase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,
IMPDH2	inosine monophosphate dehydrogenase 2(IMPDH2)	Homo sapiens			GO:0006164~purine nucleotide biosynthetic process,GO:0006177~GMP biosynthetic process,GO:0006183~GTP biosynthetic process,GO:0007623~circadian rhythm,GO:0046651~lymphocyte proliferation,GO:0071353~cellular response to interleukin-4,GO:0097294~'de novo' XMP biosynthetic process,	GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005778~peroxisomal membrane,GO:0005829~cytosol,GO:0016020~membrane,GO:0034774~secretory granule lumen,GO:0070062~extracellular exosome,GO:1904813~ficolin-1-rich granule lumen,	GO:0000166~nucleotide binding,GO:0003677~DNA binding,GO:0003723~RNA binding,GO:0003938~IMP dehydrogenase activity,GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR000644:CBS_dom,IPR001093:IMP_DH_GMPRt,IPR005990:IMP_DH,IPR013785:Aldolase_TIM,IPR015875:IMP_DH/GMP_Rdtase_CS,IPR046342:CBS_dom_sf,	hsa00230:Purine metabolism,hsa00983:Drug metabolism - other enzymes,hsa01100:Metabolic pathways,hsa01232:Nucleotide metabolism,	617995~IMPDH2 enzyme activity, variation in,	PIRSF000130:IMPDH,	SM00116:CBS,SM01240:IMPDH,	KW-0332~GMP biosynthesis,KW-0658~Purine biosynthesis,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0129~CBS domain,KW-0677~Repeat,	KW-0479~Metal-binding,KW-0520~NAD,KW-0630~Potassium,	KW-0238~DNA-binding,KW-0560~Oxidoreductase,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	ACT_SITE:Proton acceptor,ACT_SITE:Thioimidate intermediate,BINDING:in other chain,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:CBS,DOMAIN:CBS 1,DOMAIN:CBS 2,DOMAIN:IMP dehydrogenase/GMP reductase,
ITPR1	inositol 1,4,5-trisphosphate receptor type 1(ITPR1)	Homo sapiens			GO:0000902~cell morphogenesis,GO:0001666~response to hypoxia,GO:0006816~calcium ion transport,GO:0007165~signal transduction,GO:0007207~phospholipase C-activating G-protein coupled acetylcholine receptor signaling pathway,GO:0009791~post-embryonic development,GO:0010506~regulation of autophagy,GO:0019722~calcium-mediated signaling,GO:0032024~positive regulation of insulin secretion,GO:0032469~endoplasmic reticulum calcium ion homeostasis,GO:0042045~epithelial fluid transport,GO:0050849~negative regulation of calcium-mediated signaling,GO:0050882~voluntary musculoskeletal movement,GO:0051209~release of sequestered calcium ion into cytosol,GO:0070059~intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress,GO:0099105~ion channel modulating, G-protein coupled receptor signaling pathway,GO:0099566~regulation of postsynaptic cytosolic calcium ion concentration,	GO:0005637~nuclear inner membrane,GO:0005730~nucleolus,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0005955~calcineurin complex,GO:0014069~postsynaptic density,GO:0016020~membrane,GO:0016529~sarcoplasmic reticulum,GO:0030658~transport vesicle membrane,GO:0030667~secretory granule membrane,GO:0031088~platelet dense granule membrane,GO:0031094~platelet dense tubular network,GO:0031095~platelet dense tubular network membrane,GO:0048471~perinuclear region of cytoplasm,GO:0098685~Schaffer collateral - CA1 synapse,	GO:0005216~ion channel activity,GO:0005220~inositol 1,4,5-trisphosphate-sensitive calcium-release channel activity,GO:0005262~calcium channel activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0015085~calcium ion transmembrane transporter activity,GO:0015278~calcium-release channel activity,GO:0019855~calcium channel inhibitor activity,GO:0019904~protein domain specific binding,GO:0035091~phosphatidylinositol binding,GO:0070679~inositol 1,4,5 trisphosphate binding,	IPR000493:InsP3_rcpt,IPR000699:RIH_dom,IPR005821:Ion_trans_dom,IPR013662:RIH_assoc-dom,IPR014821:Ins145_P3_rcpt,IPR015925:Ryanodine_IP3_receptor,IPR016024:ARM-type_fold,IPR016093:MIR_motif,IPR035910:RyR/IP3R_RIH_dom_sf,IPR036300:MIR_dom_sf,	hsa04020:Calcium signaling pathway,hsa04022:cGMP-PKG signaling pathway,hsa04070:Phosphatidylinositol signaling system,hsa04114:Oocyte meiosis,hsa04140:Autophagy - animal,hsa04210:Apoptosis,hsa04218:Cellular senescence,hsa04270:Vascular smooth muscle contraction,hsa04371:Apelin signaling pathway,hsa04380:Osteoclast differentiation,hsa04540:Gap junction,hsa04611:Platelet activation,hsa04621:NOD-like receptor signaling pathway,hsa04625:C-type lectin receptor signaling pathway,hsa04713:Circadian entrainment,hsa04720:Long-term potentiation,hsa04723:Retrograde endocannabinoid signaling,hsa04724:Glutamatergic synapse,hsa04725:Cholinergic synapse,hsa04726:Serotonergic synapse,hsa04728:Dopaminergic synapse,hsa04730:Long-term depression,hsa04750:Inflammatory mediator regulation of TRP channels,hsa04912:GnRH signaling pathway,hsa04915:Estrogen signaling pathway,hsa04918:Thyroid hormone synthesis,hsa04921:Oxytocin signaling pathway,hsa04922:Glucagon signaling pathway,hsa04924:Renin secretion,hsa04925:Aldosterone synthesis and secretion,hsa04927:Cortisol synthesis and secretion,hsa04928:Parathyroid hormone synthesis, secretion and action,hsa04929:GnRH secretion,hsa04934:Cushing syndrome,hsa04935:Growth hormone synthesis, secretion and action,hsa04970:Salivary secretion,hsa04971:Gastric acid secretion,hsa04972:Pancreatic secretion,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05016:Huntington disease,hsa05017:Spinocerebellar ataxia,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05131:Shigellosis,hsa05163:Human cytomegalovirus infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05205:Proteoglycans in cancer,hsa05417:Lipid and atherosclerosis,	117360~Spinocerebellar ataxia 29, congenital nonprogressive,206700~Gillespie syndrome,606658~Spinocerebellar ataxia 15,		SM00472:MIR,	KW-0053~Apoptosis,KW-0109~Calcium transport,KW-0406~Ion transport,KW-0813~Transport,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,	KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0950~Spinocerebellar ataxia,KW-0991~Intellectual disability,	KW-0175~Coiled coil,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,	KW-0107~Calcium channel,KW-0407~Ion channel,KW-0675~Receptor,KW-1071~Ligand-gated ion channel,	KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:Ion transport,DOMAIN:MIR,DOMAIN:MIR 1,DOMAIN:MIR 2,DOMAIN:MIR 3,DOMAIN:MIR 4,DOMAIN:MIR 5,DOMAIN:RIH,DOMAIN:RyR/IP3R Homology associated,LIPID:S-palmitoyl cysteine,MUTAGEN:K->A: Abolishes interaction with AHCYL1.,MUTAGEN:K->Q: Abolishes interaction with AHCYL1.,MUTAGEN:P->L: Creates a dileucine motif and recruits clathrin.,MUTAGEN:R->A: Abolishes interaction with AHCYL1.,MUTAGEN:R->Q: Abolishes interaction with AHCYL1.,MUTAGEN:R->Q: No effect on interaction with AHCYL1.,MUTAGEN:T->A: No effect on interaction with AHCYL1.,MUTAGEN:Y->A: Abolishes interaction with AHCYL1.,REGION:Disordered,REGION:Interaction with ERP44,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
IP6K1	inositol hexakisphosphate kinase 1(IP6K1)	Homo sapiens			GO:0016310~phosphorylation,GO:0032958~inositol phosphate biosynthetic process,GO:0043647~inositol phosphate metabolic process,GO:0046854~phosphatidylinositol phosphorylation,	GO:0001650~fibrillar center,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0000827~inositol-1,3,4,5,6-pentakisphosphate kinase activity,GO:0000828~inositol hexakisphosphate kinase activity,GO:0000829~inositol heptakisphosphate kinase activity,GO:0000832~inositol hexakisphosphate 5-kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016301~kinase activity,GO:0052723~inositol hexakisphosphate 1-kinase activity,GO:0052724~inositol hexakisphosphate 3-kinase activity,GO:0052836~inositol 5-diphosphate pentakisphosphate 5-kinase activity,GO:0052839~inositol diphosphate tetrakisphosphate kinase activity,	IPR005522:IPK,IPR038286:IPK_sf,	hsa04070:Phosphatidylinositol signaling system,					KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,
INPP5D	inositol polyphosphate-5-phosphatase D(INPP5D)	Homo sapiens			GO:0006661~phosphatidylinositol biosynthetic process,GO:0006796~phosphate-containing compound metabolic process,GO:0006915~apoptotic process,GO:0007165~signal transduction,GO:0008340~determination of adult lifespan,GO:0009968~negative regulation of signal transduction,GO:0016064~immunoglobulin mediated immune response,GO:0030889~negative regulation of B cell proliferation,GO:0032715~negative regulation of interleukin-6 production,GO:0035556~intracellular signal transduction,GO:0043065~positive regulation of apoptotic process,GO:0045579~positive regulation of B cell differentiation,GO:0045648~positive regulation of erythrocyte differentiation,GO:0045656~negative regulation of monocyte differentiation,GO:0045659~negative regulation of neutrophil differentiation,GO:0045671~negative regulation of osteoclast differentiation,GO:0045779~negative regulation of bone resorption,GO:0046856~phosphatidylinositol dephosphorylation,GO:0050776~regulation of immune response,GO:0050777~negative regulation of immune response,GO:0050852~T cell receptor signaling pathway,	GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0045121~membrane raft,	GO:0004439~phosphatidylinositol-4,5-bisphosphate 5-phosphatase activity,GO:0004445~inositol-polyphosphate 5-phosphatase activity,GO:0005515~protein binding,GO:0016314~phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase activity,GO:0016791~phosphatase activity,GO:0017124~SH3 domain binding,GO:0034485~phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase activity,GO:0052658~inositol-1,4,5-trisphosphate 5-phosphatase activity,GO:0052659~inositol-1,3,4,5-tetrakisphosphate 5-phosphatase activity,	IPR000300:IPPc,IPR000980:SH2,IPR036691:Endo/exonu/phosph_ase_sf,IPR036860:SH2_dom_sf,	hsa00562:Inositol phosphate metabolism,hsa01100:Metabolic pathways,hsa04070:Phosphatidylinositol signaling system,hsa04662:B cell receptor signaling pathway,hsa04664:Fc epsilon RI signaling pathway,hsa04666:Fc gamma R-mediated phagocytosis,			SM00128:IPPc,SM00252:SH2,	KW-0053~Apoptosis,KW-0391~Immunity,KW-0443~Lipid metabolism,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0727~SH2 domain,KW-0729~SH3-binding,		KW-0378~Hydrolase,	KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Inositol polyphosphate-related phosphatase,DOMAIN:SH2,MOTIF:NPXY motif 1,MOTIF:NPXY motif 2,MOTIF:SH3-binding 1,MOTIF:SH3-binding 2,MOTIF:SH3-binding 3,REGION:Disordered,REGION:Interaction with DAB2,
INPP5K	inositol polyphosphate-5-phosphatase K(INPP5K)	Homo sapiens			GO:0001701~in utero embryonic development,GO:0001933~negative regulation of protein phosphorylation,GO:0005979~regulation of glycogen biosynthetic process,GO:0006469~negative regulation of protein kinase activity,GO:0006661~phosphatidylinositol biosynthetic process,GO:0007186~G-protein coupled receptor signaling pathway,GO:0010801~negative regulation of peptidyl-threonine phosphorylation,GO:0010829~negative regulation of glucose transport,GO:0016311~dephosphorylation,GO:0030036~actin cytoskeleton organization,GO:0032869~cellular response to insulin stimulus,GO:0032870~cellular response to hormone stimulus,GO:0033137~negative regulation of peptidyl-serine phosphorylation,GO:0035305~negative regulation of dephosphorylation,GO:0035810~positive regulation of urine volume,GO:0042593~glucose homeostasis,GO:0043407~negative regulation of MAP kinase activity,GO:0043922~negative regulation by host of viral transcription,GO:0045719~negative regulation of glycogen biosynthetic process,GO:0045869~negative regulation of single stranded viral RNA replication via double stranded DNA intermediate,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0046627~negative regulation of insulin receptor signaling pathway,GO:0046856~phosphatidylinositol dephosphorylation,GO:0051497~negative regulation of stress fiber assembly,GO:0051898~negative regulation of protein kinase B signaling,GO:0051926~negative regulation of calcium ion transport,GO:0071320~cellular response to cAMP,GO:0071356~cellular response to tumor necrosis factor,GO:0071364~cellular response to epidermal growth factor stimulus,GO:0072659~protein localization to plasma membrane,GO:0090315~negative regulation of protein targeting to membrane,GO:0097178~ruffle assembly,GO:2000466~negative regulation of glycogen (starch) synthase activity,GO:2001153~positive regulation of renal water transport,	GO:0001726~ruffle,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005802~trans-Golgi network,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0032587~ruffle membrane,GO:0043005~neuron projection,GO:0048471~perinuclear region of cytoplasm,	GO:0004439~phosphatidylinositol-4,5-bisphosphate 5-phosphatase activity,GO:0004445~inositol-polyphosphate 5-phosphatase activity,GO:0005000~vasopressin receptor activity,GO:0005515~protein binding,GO:0016312~inositol bisphosphate phosphatase activity,GO:0016791~phosphatase activity,GO:0034485~phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase activity,GO:0034594~phosphatidylinositol trisphosphate phosphatase activity,GO:0034595~phosphatidylinositol phosphate 5-phosphatase activity,GO:0042577~lipid phosphatase activity,GO:0046030~inositol trisphosphate phosphatase activity,GO:0052658~inositol-1,4,5-trisphosphate 5-phosphatase activity,GO:0052659~inositol-1,3,4,5-tetrakisphosphate 5-phosphatase activity,	IPR000300:IPPc,IPR036691:Endo/exonu/phosph_ase_sf,IPR041611:SKICH,IPR046985:IP5,	hsa00562:Inositol phosphate metabolism,hsa01100:Metabolic pathways,	617404~Muscular dystrophy, congenital, with cataracts and intellectual disability,		SM00128:IPPc,	KW-0443~Lipid metabolism,	KW-0256~Endoplasmic reticulum,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0898~Cataract,KW-0912~Congenital muscular dystrophy,KW-0991~Intellectual disability,			KW-0378~Hydrolase,		DOMAIN:Inositol polyphosphate-related phosphatase,DOMAIN:SKICH,MUTAGEN:D->A: Significant decrease in EGF-induced ruffle localization.,MUTAGEN:D->G: No phosphatidylinositol-4,5-bisphosphate 5-phosphatase activity.,MUTAGEN:W->A: Significant decrease in EGF-induced ruffle localization.,MUTAGEN:Y->A,F: No effect on EGF-induced ruffle localization.,REGION:Catalytic,REGION:Disordered,REGION:Required for interaction with GPR78 and PAK1,REGION:Required for ruffle localization,
INSIG1	insulin induced gene 1(INSIG1)	Homo sapiens			GO:0006641~triglyceride metabolic process,GO:0006695~cholesterol biosynthetic process,GO:0008203~cholesterol metabolic process,GO:0010894~negative regulation of steroid biosynthetic process,GO:0032869~cellular response to insulin stimulus,GO:0032933~SREBP signaling pathway,GO:0036315~cellular response to sterol,GO:0036316~SREBP-SCAP complex retention in endoplasmic reticulum,GO:0042472~inner ear morphogenesis,GO:0042474~middle ear morphogenesis,GO:0042632~cholesterol homeostasis,GO:0045599~negative regulation of fat cell differentiation,GO:0045717~negative regulation of fatty acid biosynthetic process,GO:0060021~palate development,GO:0060363~cranial suture morphogenesis,GO:0070862~negative regulation of protein exit from endoplasmic reticulum,GO:1901303~negative regulation of cargo loading into COPII-coated vesicle,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0032937~SREBP-SCAP-Insig complex,	GO:0005515~protein binding,GO:0008142~oxysterol binding,	IPR025929:INSIG_fam,					KW-0153~Cholesterol metabolism,KW-0443~Lipid metabolism,KW-0753~Steroid metabolism,KW-1207~Sterol metabolism,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0446~Lipid-binding,		KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),MOTIF:KxHxx,MUTAGEN:D->A: Loss of ability to suppress the cleavage of SREBP2 and to accelerate the degradation of HMGCR.,MUTAGEN:K->R: Loss of ubiquitination and degradation.,MUTAGEN:S->A: Abolished phosphorylation by PCK1, does not affect oxysterol-binding, does not affect the interaction with SCAP.,MUTAGEN:S->E: Phosphomimetic mutant, reduced binding to oxysterol.,REGION:Disordered,SITE:Required for the recognition of 25-hydroxycholesterol,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,
ITM2A	integral membrane protein 2A(ITM2A)	Homo sapiens			GO:0002317~plasma cell differentiation,GO:0042985~negative regulation of amyloid precursor protein biosynthetic process,	GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,	GO:0001540~beta-amyloid binding,GO:0005515~protein binding,	IPR007084:BRICHOS_dom,IPR040145:ITM2,				SM01039:BRICHOS,		KW-0472~Membrane,KW-1003~Cell membrane,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:BRICHOS,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
ITM2B	integral membrane protein 2B(ITM2B)	Homo sapiens			GO:0007399~nervous system development,GO:0042985~negative regulation of amyloid precursor protein biosynthetic process,	GO:0000139~Golgi membrane,GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0010008~endosome membrane,GO:0016020~membrane,GO:0030660~Golgi-associated vesicle membrane,GO:0031090~organelle membrane,GO:0043231~intracellular membrane-bounded organelle,GO:0070062~extracellular exosome,	GO:0001540~beta-amyloid binding,GO:0005515~protein binding,GO:0005524~ATP binding,	IPR007084:BRICHOS_dom,IPR040145:ITM2,		117300~Dementia, familial Danish,176500~Dementia, familial British,616079~Retinal dystrophy with inner retinal dysfunction and ganglion cell abnormalities,		SM01039:BRICHOS,		KW-0034~Amyloid,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0964~Secreted,KW-0967~Endosome,KW-1003~Cell membrane,	KW-0209~Deafness,KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-1008~Amyloidosis,	KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DISULFID:Interchain,DISULFID:Interchain (between ADan peptide variants),DOMAIN:BRICHOS,MUTAGEN:G->V: Strongly reduces intramembrane cleavage by SPPL2B.,MUTAGEN:N->A: Accumulates in intracellular compartments. Does not inhibit furin, ADAM10 and SPPL2A extracellular proteolytic processing activity.,MUTAGEN:RE->AA: Inhibits cleavage by furin. Does not prevent ADAM10 shedding.,PEPTIDE:Bri23 peptide,REGION:Disordered,REGION:Necessary for interaction with APP and inhibitor effects on APP processing,SITE:Cleavage; by furin,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
ITM2C	integral membrane protein 2C(ITM2C)	Homo sapiens			GO:0010977~negative regulation of neuron projection development,GO:0030182~neuron differentiation,GO:0042985~negative regulation of amyloid precursor protein biosynthetic process,GO:2001238~positive regulation of extrinsic apoptotic signaling pathway,	GO:0005764~lysosome,GO:0005765~lysosomal membrane,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,	GO:0001540~beta-amyloid binding,GO:0005515~protein binding,GO:0005524~ATP binding,	IPR007084:BRICHOS_dom,IPR040145:ITM2,				SM01039:BRICHOS,		KW-0458~Lysosome,KW-0472~Membrane,KW-1003~Cell membrane,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:BRICHOS,MUTAGEN:KR->AA: Completely abrogates proteolytic processing.,PEPTIDE:CT-BRI3,SITE:Cleavage; by furin,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
INTS10	integrator complex subunit 10(INTS10)	Homo sapiens			GO:0016180~snRNA processing,GO:0034243~regulation of transcription elongation from RNA polymerase II promoter,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0032039~integrator complex,	GO:0005515~protein binding,	IPR026164:Int_cplx_su10,						KW-0539~Nucleus,					KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),REGION:Disordered,
ILK	integrin linked kinase(ILK)	Homo sapiens	66.Prot_Interac_w_integrin_domains,	h_ptenPathway:PTEN dependent cell cycle arrest and apoptosis,	GO:0000902~cell morphogenesis,GO:0001658~branching involved in ureteric bud morphogenesis,GO:0001934~positive regulation of protein phosphorylation,GO:0003151~outflow tract morphogenesis,GO:0006468~protein phosphorylation,GO:0007160~cell-matrix adhesion,GO:0007229~integrin-mediated signaling pathway,GO:0008284~positive regulation of cell proliferation,GO:0009967~positive regulation of signal transduction,GO:0010761~fibroblast migration,GO:0021675~nerve development,GO:0022011~myelination in peripheral nervous system,GO:0030030~cell projection organization,GO:0030513~positive regulation of BMP signaling pathway,GO:0033209~tumor necrosis factor-mediated signaling pathway,GO:0034446~substrate adhesion-dependent cell spreading,GO:0042327~positive regulation of phosphorylation,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043491~protein kinase B signaling,GO:0045197~establishment or maintenance of epithelial cell apical/basal polarity,GO:0045669~positive regulation of osteoblast differentiation,GO:0045893~positive regulation of transcription, DNA-templated,GO:0061351~neural precursor cell proliferation,GO:0070527~platelet aggregation,GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:1900026~positive regulation of substrate adhesion-dependent cell spreading,GO:2000178~negative regulation of neural precursor cell proliferation,	GO:0001725~stress fiber,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0016020~membrane,GO:0030017~sarcomere,GO:0030027~lamellipodium,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0019901~protein kinase binding,	IPR000719:Prot_kinase_dom,IPR001245:Ser-Thr/Tyr_kinase_cat_dom,IPR002110:Ankyrin_rpt,IPR011009:Kinase-like_dom_sf,IPR035692:PK_ILK,IPR036770:Ankyrin_rpt-contain_sf,	hsa03320:PPAR signaling pathway,hsa04360:Axon guidance,hsa04510:Focal adhesion,hsa05100:Bacterial invasion of epithelial cells,hsa05131:Shigellosis,hsa05213:Endometrial cancer,		PIRSF000654:Integrin-linked_kinase,	SM00248:ANK,		KW-0472~Membrane,KW-0963~Cytoplasm,KW-0965~Cell junction,KW-0966~Cell projection,KW-1003~Cell membrane,		KW-0040~ANK repeat,KW-0677~Repeat,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:Protein kinase,MUTAGEN:E->K: Inactivation of ILK.,MUTAGEN:H->D: Alters interaction with LIMS1.,REGION:Interaction with LIMS1,REGION:PH-like; mediates interaction with TGFB1I1,REPEAT:ANK,REPEAT:ANK 1,REPEAT:ANK 2,REPEAT:ANK 3,REPEAT:ANK 4,REPEAT:ANK 5,
ITGAE	integrin subunit alpha E(ITGAE)	Homo sapiens			GO:0007160~cell-matrix adhesion,GO:0007229~integrin-mediated signaling pathway,GO:0033627~cell adhesion mediated by integrin,GO:0098609~cell-cell adhesion,	GO:0005886~plasma membrane,GO:0008305~integrin complex,GO:0009897~external side of plasma membrane,	GO:0005178~integrin binding,GO:0046872~metal ion binding,	IPR000413:Integrin_alpha,IPR002035:VWF_A,IPR013517:FG-GAP,IPR013519:Int_alpha_beta-p,IPR018184:Integrin_alpha_C_CS,IPR028994:Integrin_alpha_N,IPR032695:Integrin_dom_sf,IPR036465:vWFA_dom_sf,IPR048285:Integrin_alpha_Ig-like_2,	hsa04810:Regulation of actin cytoskeleton,			SM00191:Int_alpha,SM00327:VWA,	KW-0130~Cell adhesion,	KW-0472~Membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0460~Magnesium,KW-0479~Metal-binding,	KW-0401~Integrin,KW-0675~Receptor,	KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,DOMAIN:Integrin alpha second immunoglobulin-like,DOMAIN:VWFA,MOTIF:GFFKR motif,MUTAGEN:D->A: Loss of E-cadherin binding.,MUTAGEN:F->A: Loss of E-cadherin binding.,REGION:Disordered,REGION:X-domain (extra domain),REPEAT:FG-GAP 1,REPEAT:FG-GAP 2,REPEAT:FG-GAP 3,REPEAT:FG-GAP 4,REPEAT:FG-GAP 5,REPEAT:FG-GAP 6,REPEAT:FG-GAP 7,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
ITGAL	integrin subunit alpha L(ITGAL)	Homo sapiens		h_blymphocytePathway:B Lymphocyte Cell Surface Molecules,h_ctlPathway:CTL mediated immune response against target cells ,h_granulocytesPathway:Adhesion and Diapedesis of Granulocytes,h_LairPathway:Cells and Molecules involved in local acute inflammatory response,h_lymPathway:Adhesion and Diapedesis of Lymphocytes,h_lymphocytePathway:Adhesion Molecules on Lymphocyte,h_monocytePathway:Monocyte and its Surface Molecules,h_neutrophilPathway:Neutrophil and Its Surface Molecules,h_tcytotoxicPathway:T Cytotoxic Cell Surface Molecules,h_thelperPathway:T Helper Cell Surface Molecules,	GO:0002291~T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell,GO:0006909~phagocytosis,GO:0006954~inflammatory response,GO:0007155~cell adhesion,GO:0007157~heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules,GO:0007159~leukocyte cell-cell adhesion,GO:0007160~cell-matrix adhesion,GO:0007165~signal transduction,GO:0007229~integrin-mediated signaling pathway,GO:0033627~cell adhesion mediated by integrin,GO:0035683~memory T cell extravasation,GO:0043113~receptor clustering,GO:0098609~cell-cell adhesion,	GO:0005886~plasma membrane,GO:0008305~integrin complex,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,GO:0034687~integrin alphaL-beta2 complex,GO:0035579~specific granule membrane,GO:0070062~extracellular exosome,	GO:0005178~integrin binding,GO:0005515~protein binding,GO:0030369~ICAM-3 receptor activity,GO:0046872~metal ion binding,GO:0050839~cell adhesion molecule binding,	IPR000413:Integrin_alpha,IPR002035:VWF_A,IPR013517:FG-GAP,IPR013519:Int_alpha_beta-p,IPR013649:Integrin_alpha_Ig-like_1,IPR018184:Integrin_alpha_C_CS,IPR028994:Integrin_alpha_N,IPR032695:Integrin_dom_sf,IPR036465:vWFA_dom_sf,IPR048285:Integrin_alpha_Ig-like_2,	hsa04015:Rap1 signaling pathway,hsa04514:Cell adhesion molecules,hsa04613:Neutrophil extracellular trap formation,hsa04650:Natural killer cell mediated cytotoxicity,hsa04670:Leukocyte transendothelial migration,hsa04810:Regulation of actin cytoskeleton,hsa05144:Malaria,hsa05150:Staphylococcus aureus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05323:Rheumatoid arthritis,hsa05416:Viral myocarditis,			SM00191:Int_alpha,SM00327:VWA,	KW-0130~Cell adhesion,KW-0581~Phagocytosis,KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0460~Magnesium,KW-0479~Metal-binding,	KW-0401~Integrin,KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Integrin alpha second immunoglobulin-like,DOMAIN:VWFA,MOTIF:GFFKR motif,MUTAGEN:S->A: Abolishes phosphorylation and MEM-83-activated T-cell adhesion to ICAM1. Abolishes integrin alpha-L/beta-2 activation by CXCL12 and TERF2IP/RAP1. Does not affect heterodimerization of cell surface expression. Does not affect TCR- or phorbol ester-activated T-cell adhesion to ICAM1.,REGION:Disordered,REPEAT:FG-GAP,REPEAT:FG-GAP 1,REPEAT:FG-GAP 2,REPEAT:FG-GAP 3,REPEAT:FG-GAP 4,REPEAT:FG-GAP 5,REPEAT:FG-GAP 6,REPEAT:FG-GAP 7,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
ITGB1BP1	integrin subunit beta 1 binding protein 1(ITGB1BP1)	Homo sapiens	66.Prot_Interac_w_integrin_domains,		GO:0002043~blood vessel endothelial cell proliferation involved in sprouting angiogenesis,GO:0006469~negative regulation of protein kinase activity,GO:0006933~negative regulation of cell adhesion involved in substrate-bound cell migration,GO:0007160~cell-matrix adhesion,GO:0007219~Notch signaling pathway,GO:0007229~integrin-mediated signaling pathway,GO:0008284~positive regulation of cell proliferation,GO:0008285~negative regulation of cell proliferation,GO:0010595~positive regulation of endothelial cell migration,GO:0010764~negative regulation of fibroblast migration,GO:0016477~cell migration,GO:0030154~cell differentiation,GO:0031214~biomineral tissue development,GO:0032091~negative regulation of protein binding,GO:0032148~activation of protein kinase B activity,GO:0033622~integrin activation,GO:0033628~regulation of cell adhesion mediated by integrin,GO:0035148~tube formation,GO:0035556~intracellular signal transduction,GO:0035924~cellular response to vascular endothelial growth factor stimulus,GO:0043087~regulation of GTPase activity,GO:0043113~receptor clustering,GO:0044344~cellular response to fibroblast growth factor stimulus,GO:0045747~positive regulation of Notch signaling pathway,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051451~myoblast migration,GO:0051496~positive regulation of stress fiber assembly,GO:0051781~positive regulation of cell division,GO:0051894~positive regulation of focal adhesion assembly,GO:0051895~negative regulation of focal adhesion assembly,GO:0051897~positive regulation of protein kinase B signaling,GO:0070373~negative regulation of ERK1 and ERK2 cascade,GO:0072659~protein localization to plasma membrane,GO:0090051~negative regulation of cell migration involved in sprouting angiogenesis,GO:0090314~positive regulation of protein targeting to membrane,GO:0090315~negative regulation of protein targeting to membrane,GO:0097746~regulation of blood vessel diameter,GO:1900025~negative regulation of substrate adhesion-dependent cell spreading,GO:2001044~regulation of integrin-mediated signaling pathway,	GO:0001726~ruffle,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016604~nuclear body,GO:0030027~lamellipodium,GO:0034451~centriolar satellite,GO:0048471~perinuclear region of cytoplasm,GO:0071944~cell periphery,	GO:0005092~GDP-dissociation inhibitor activity,GO:0005178~integrin binding,GO:0005515~protein binding,GO:0019901~protein kinase binding,	IPR006020:PTB/PI_dom,IPR011993:PH-like_dom_sf,IPR019517:Integrin-bd_ICAP-1,				SM00462:PTB,	KW-0037~Angiogenesis,KW-0091~Biomineralization,KW-0130~Cell adhesion,KW-0221~Differentiation,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0914~Notch signaling pathway,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-1003~Cell membrane,				KW-0401~Integrin,KW-0497~Mitogen,	KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:PID,MOTIF:Nuclear localization signal,MUTAGEN:C->D: Reduces KRIT1 and ITGB1 binding.,MUTAGEN:D->A: Abolishes KRIT1 binding; when associated with A-96.,MUTAGEN:I->A: Abolishes ITGB1 binding.,MUTAGEN:I->R: Reduces KRIT1 binding. No effect on ITGB1 binding.,MUTAGEN:KK->AA: Abolishes nuclear import and transcriptional activity.,MUTAGEN:L->A: Abolishes ITGB1 binding.,MUTAGEN:L->A: Reduces ITGB1 binding.,MUTAGEN:L->Q: No effect on ITGB1 binding.,MUTAGEN:LYLII->AYAA: Reduces KRIT1 and ITGB1 binding.,MUTAGEN:Q->A: Abolishes KRIT1 binding; when associated with A-93.,MUTAGEN:T->A: Stimulates cell spreading on fibronectin to a similar extent as inhibition of CaMKII.,MUTAGEN:T->D: Changes in cell spreading.,MUTAGEN:T->D: Strong defect in cell spreading.,MUTAGEN:Y->T: Abolishes ITGB1 binding.,REGION:Disordered,REGION:Interaction with ITGB1,REGION:Interaction with KRIT1,
ITGB2	integrin subunit beta 2(ITGB2)	Homo sapiens	125.T_Cells_CNS-APCs,55.Allergen_recognition_by_Th2_or_Th0_cell,60.IL-15_rheumatoid-arthritis_synovitis,78.B_Cell_Development,81.Structure_of_Caps_and_SMACs,	h_blymphocytePathway:B Lymphocyte Cell Surface Molecules,h_ctlPathway:CTL mediated immune response against target cells ,h_granulocytesPathway:Adhesion and Diapedesis of Granulocytes,h_LairPathway:Cells and Molecules involved in local acute inflammatory response,h_lymPathway:Adhesion and Diapedesis of Lymphocytes,h_lymphocytePathway:Adhesion Molecules on Lymphocyte,h_monocytePathway:Monocyte and its Surface Molecules,h_neutrophilPathway:Neutrophil and Its Surface Molecules,h_tcytotoxicPathway:T Cytotoxic Cell Surface Molecules,h_thelperPathway:T Helper Cell Surface Molecules,	GO:0001774~microglial cell activation,GO:0002523~leukocyte migration involved in inflammatory response,GO:0006898~receptor-mediated endocytosis,GO:0006909~phagocytosis,GO:0006911~phagocytosis, engulfment,GO:0006915~apoptotic process,GO:0006954~inflammatory response,GO:0007155~cell adhesion,GO:0007159~leukocyte cell-cell adhesion,GO:0007160~cell-matrix adhesion,GO:0007229~integrin-mediated signaling pathway,GO:0007267~cell-cell signaling,GO:0008360~regulation of cell shape,GO:0030593~neutrophil chemotaxis,GO:0031623~receptor internalization,GO:0032930~positive regulation of superoxide anion generation,GO:0033627~cell adhesion mediated by integrin,GO:0034113~heterotypic cell-cell adhesion,GO:0035987~endodermal cell differentiation,GO:0043113~receptor clustering,GO:0043315~positive regulation of neutrophil degranulation,GO:0043542~endothelial cell migration,GO:0045123~cellular extravasation,GO:0045429~positive regulation of nitric oxide biosynthetic process,GO:0045766~positive regulation of angiogenesis,GO:0045963~negative regulation of dopamine metabolic process,GO:0050730~regulation of peptidyl-tyrosine phosphorylation,GO:0071404~cellular response to low-density lipoprotein particle stimulus,GO:0090314~positive regulation of protein targeting to membrane,GO:0097242~beta-amyloid clearance,GO:0098609~cell-cell adhesion,GO:0098742~cell-cell adhesion via plasma-membrane adhesion molecules,GO:1904996~positive regulation of leukocyte adhesion to vascular endothelial cell,GO:1990266~neutrophil migration,GO:2000363~positive regulation of prostaglandin-E synthase activity,	GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0008305~integrin complex,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,GO:0034687~integrin alphaL-beta2 complex,GO:0034688~integrin alphaM-beta2 complex,GO:0034689~integrin alphaX-beta2 complex,GO:0035579~specific granule membrane,GO:0043235~receptor complex,GO:0044853~plasma membrane raft,GO:0045121~membrane raft,GO:0070062~extracellular exosome,GO:0070821~tertiary granule membrane,GO:0101003~ficolin-1-rich granule membrane,GO:1903561~extracellular vesicle,	GO:0001540~beta-amyloid binding,GO:0001851~complement component C3b binding,GO:0005178~integrin binding,GO:0005515~protein binding,GO:0019901~protein kinase binding,GO:0030369~ICAM-3 receptor activity,GO:0031072~heat shock protein binding,GO:0038024~cargo receptor activity,GO:0044877~macromolecular complex binding,GO:0046872~metal ion binding,GO:0050839~cell adhesion molecule binding,	IPR002369:Integrin_bsu_VWA,IPR012896:Integrin_bsu_tail,IPR013111:EGF_extracell,IPR014836:Integrin_bsu_cyt_dom,IPR015439:Integrin_b-2_sf,IPR015812:Integrin_bsu,IPR016201:PSI,IPR032695:Integrin_dom_sf,IPR033760:Integrin_beta_N,IPR036349:Integrin_bsu_tail_dom_sf,IPR036465:vWFA_dom_sf,	hsa04015:Rap1 signaling pathway,hsa04145:Phagosome,hsa04390:Hippo signaling pathway,hsa04514:Cell adhesion molecules,hsa04610:Complement and coagulation cascades,hsa04613:Neutrophil extracellular trap formation,hsa04650:Natural killer cell mediated cytotoxicity,hsa04670:Leukocyte transendothelial migration,hsa04810:Regulation of actin cytoskeleton,hsa05133:Pertussis,hsa05134:Legionellosis,hsa05140:Leishmaniasis,hsa05144:Malaria,hsa05146:Amoebiasis,hsa05150:Staphylococcus aureus infection,hsa05152:Tuberculosis,hsa05166:Human T-cell leukemia virus 1 infection,hsa05323:Rheumatoid arthritis,hsa05416:Viral myocarditis,	116920~Leukocyte adhesion deficiency,	PIRSF002512:Integrin_B,	SM00187:INB,SM00423:PSI,SM01241:Integrin_b_cyt,SM01242:Integrin_B_tail,	KW-0130~Cell adhesion,KW-0581~Phagocytosis,	KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0245~EGF-like domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0460~Magnesium,KW-0479~Metal-binding,	KW-0401~Integrin,KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0873~Pyrrolidone carboxylic acid,KW-1015~Disulfide bond,	BINDING:in ADMIDAS binding site,BINDING:in ADMIDAS binding site and liganded-open conformation,BINDING:in ADMIDAS binding site and unliganded-closed conformation,BINDING:in LIMBS binding site,BINDING:in MIDAS binding site,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:EGF-like,DOMAIN:EGF-like 1,DOMAIN:EGF-like 2,DOMAIN:EGF-like 3,DOMAIN:EGF-like 4,DOMAIN:Integrin beta N-terminal,DOMAIN:Integrin beta subunit VWA,DOMAIN:Integrin beta subunit cytoplasmic,DOMAIN:Integrin beta subunit tail,DOMAIN:PSI,DOMAIN:VWFA,MOTIF:Cell attachment site,MUTAGEN:T->A: Abolishes phosphorylation. Reduces COS cell adhesion to ICAM1.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
IWS1	interacts with SUPT6H, CTD assembly factor 1(IWS1)	Homo sapiens			GO:0006338~chromatin remodeling,GO:0006397~mRNA processing,GO:0008380~RNA splicing,GO:0010793~regulation of mRNA export from nucleus,GO:0016973~poly(A)+ mRNA export from nucleus,GO:0050684~regulation of mRNA processing,	GO:0005634~nucleus,GO:0005654~nucleoplasm,	GO:0005515~protein binding,	IPR017923:TFIIS_N,IPR035441:TFIIS/LEDGF_dom_sf,					KW-0507~mRNA processing,KW-0508~mRNA splicing,KW-0509~mRNA transport,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0813~Transport,	KW-0539~Nucleus,		KW-0677~Repeat,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,DOMAIN:TFIIS N-terminal,MOTIF:Integrase domain-binding motif (IBM),MUTAGEN:F->A: Loss of interaction with PSIP1; when associated with A-476.,MUTAGEN:I->A: Loss of interaction with PSIP1; when associated with A-477.,MUTAGEN:S->D: Phosphomimetic mutant. Moderate increase in interaction with PSIP1.,REGION:3 X approximate tandem repeats,REGION:Disordered,REGION:Interaction with SUPT6H and ALYREF,REPEAT:1,REPEAT:2,REPEAT:3; half-length,
ICAM3	intercellular adhesion molecule 3(ICAM3)	Homo sapiens			GO:0006909~phagocytosis,GO:0007155~cell adhesion,GO:0098609~cell-cell adhesion,	GO:0005886~plasma membrane,GO:0016020~membrane,GO:0070062~extracellular exosome,	GO:0005102~receptor binding,GO:0005178~integrin binding,GO:0005515~protein binding,	IPR003599:Ig_sub,IPR003987:ICAM_VCAM_N,IPR003988:ICAM,IPR007110:Ig-like_dom,IPR013768:ICAM_N,IPR013783:Ig-like_fold,IPR036179:Ig-like_dom_sf,IPR047012:ICAM_VCAM,IPR048679:ICAM1_3_5_D2,	hsa04514:Cell adhesion molecules,			SM00409:IG,	KW-0130~Cell adhesion,KW-0581~Phagocytosis,	KW-0472~Membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,DOMAIN:Ig-like C2-type 3,DOMAIN:Ig-like C2-type 4,DOMAIN:Ig-like C2-type 5,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
IFNAR1	interferon alpha and beta receptor subunit 1(IFNAR1)	Homo sapiens		h_ifnaPathway:IFN alpha signaling pathway,h_ranklPathway:Bone Remodelling,	GO:0007259~JAK-STAT cascade,GO:0009615~response to virus,GO:0032496~response to lipopolysaccharide,GO:0035457~cellular response to interferon-alpha,GO:0035458~cellular response to interferon-beta,GO:0046425~regulation of JAK-STAT cascade,GO:0060337~type I interferon signaling pathway,GO:0098586~cellular response to virus,GO:1901857~positive regulation of cellular respiration,	GO:0005764~lysosome,GO:0005770~late endosome,GO:0005886~plasma membrane,GO:0016020~membrane,	GO:0004905~type I interferon receptor activity,GO:0005515~protein binding,GO:0008269~JAK pathway signal transduction adaptor activity,GO:0019955~cytokine binding,GO:0019962~type I interferon binding,	IPR003961:FN3_dom,IPR013783:Ig-like_fold,IPR015373:Interferon/interleukin_rcp_dom,IPR016669:Interferon_alpha/beta_rcpt-1,IPR036116:FN3_sf,	hsa04060:Cytokine-cytokine receptor interaction,hsa04151:PI3K-Akt signaling pathway,hsa04217:Necroptosis,hsa04380:Osteoclast differentiation,hsa04620:Toll-like receptor signaling pathway,hsa04621:NOD-like receptor signaling pathway,hsa04630:JAK-STAT signaling pathway,hsa04650:Natural killer cell mediated cytotoxicity,hsa05160:Hepatitis C,hsa05161:Hepatitis B,hsa05162:Measles,hsa05164:Influenza A,hsa05165:Human papillomavirus infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05171:Coronavirus disease - COVID-19,hsa05200:Pathways in cancer,	619935~Immunodeficiency 106, susceptibility to viral infections,	PIRSF016567:IFN_alpha/beta_recept-1,			KW-0458~Lysosome,KW-0472~Membrane,KW-0967~Endosome,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,KW-1017~Isopeptide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:Fibronectin type-III,DOMAIN:Fibronectin type-III 1,DOMAIN:Fibronectin type-III 2,DOMAIN:Fibronectin type-III 3,DOMAIN:Fibronectin type-III 4,DOMAIN:Interferon/interleukin receptor,LIPID:S-palmitoyl cysteine,MUTAGEN:E->A: Impairs interaction with TYK2.,MUTAGEN:EE->AA: Impairs interaction with TYK2.,MUTAGEN:K->R: Mildly reduces ubiquitination. Nearly abolishes ubiquitination and subsequent degradation; when associated with 525-R-R-526.,MUTAGEN:KK->RR: Reduces ubiquitination. Nearly abolishes ubiquitination and subsequent degradation; when associated with R-501.,MUTAGEN:LL->AA: Impairs interaction with TYK2.,MUTAGEN:S->A: Abolishes interaction with FBXW11 and decreases ubiquitination.,MUTAGEN:S->A: Abolishes phosphorylation at this site and interaction with SHMT2.,MUTAGEN:Y->F: Impairs internalization in response to interferon.,REGION:Disordered,REGION:Important for interaction with TYK2,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
IFNAR2	interferon alpha and beta receptor subunit 2(IFNAR2)	Homo sapiens		h_ifnaPathway:IFN alpha signaling pathway,h_ranklPathway:Bone Remodelling,	GO:0007166~cell surface receptor signaling pathway,GO:0007259~JAK-STAT cascade,GO:0009615~response to virus,GO:0035455~response to interferon-alpha,GO:0035456~response to interferon-beta,GO:0035458~cellular response to interferon-beta,GO:0046425~regulation of JAK-STAT cascade,GO:0051607~defense response to virus,GO:0060337~type I interferon signaling pathway,GO:0098586~cellular response to virus,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0016020~membrane,	GO:0004905~type I interferon receptor activity,GO:0005515~protein binding,GO:0008269~JAK pathway signal transduction adaptor activity,GO:0019901~protein kinase binding,GO:0019955~cytokine binding,GO:0019962~type I interferon binding,GO:0042018~interleukin-22 receptor activity,	IPR003961:FN3_dom,IPR013783:Ig-like_fold,IPR015373:Interferon/interleukin_rcp_dom,IPR036116:FN3_sf,	hsa04060:Cytokine-cytokine receptor interaction,hsa04151:PI3K-Akt signaling pathway,hsa04217:Necroptosis,hsa04380:Osteoclast differentiation,hsa04620:Toll-like receptor signaling pathway,hsa04621:NOD-like receptor signaling pathway,hsa04630:JAK-STAT signaling pathway,hsa04650:Natural killer cell mediated cytotoxicity,hsa05160:Hepatitis C,hsa05162:Measles,hsa05164:Influenza A,hsa05165:Human papillomavirus infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05171:Coronavirus disease - COVID-19,hsa05200:Pathways in cancer,	610424~Hepatitis B virus, susceptibility to,616669~Immunodeficiency 45,				KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:Fibronectin type-III,DOMAIN:Interferon/interleukin receptor,MUTAGEN:Y->F: Does not inhibit STAT1, STAT2 and STAT3 activation by IFN. Inhibits STAT1, STAT2 and STAT3 activation by IFN; when associated with F-269; F-306; F-316; F-318; F-337 and F-411. Inhibits STAT1, STAT2 and STAT3 activation by IFN; when associated with F-269; F-306; F-316; F-318 and F-411. Does not inhibit STAT1, STAT2 and STAT3 activation by IFN; when associated with F-411.,MUTAGEN:Y->F: Does not inhibit STAT1, STAT2 and STAT3 activation by IFN. Inhibits STAT1, STAT2 and STAT3 activation by IFN; when associated with F-269; F-306; F-316; F-318; F-337 and F-512. Inhibits STAT1, STAT2 and STAT3 activation by IFN; when associated with F-269; F-306; F-316; F-318 and F-512. Does not inhibit STAT1, STAT2 and STAT3 activation by IFN; when associated with F-512.,MUTAGEN:Y->F: Does not inhibit STAT1, STAT2 and STAT3 activation by IFN. Inhibits STAT1, STAT2 and STAT3 activation by IFN; when associated with F-269; F-306; F-316; F-318; F-411 and F-512. Does not inhibit STAT1, STAT2 and STAT3 activation by IFN; when associated with F-512. Does not inhibit STAT1, STAT2 and STAT3 activation by IFN; when associated with F-269; F-306; F-316 and F-318.,MUTAGEN:Y->F: Does not inhibit STAT1, STAT2 and STAT3 activation by IFN. Inhibits STAT1, STAT2 and STAT3 activation by IFN; when associated with F-269; F-306; F-316; F-337; F-411 and F-512. Inhibits STAT1, STAT2 and STAT3 activation by IFN; when associated with F-269; F-306; F-316; F-411 and F-512. Does not inhibit STAT1, STAT2 and STAT3 activation by IFN; when associated with F-512. Does not inhibit STAT1, STAT2 and STAT3 activation by IFN; when associated with F-269; F-306; F-316 and F-337.,MUTAGEN:Y->F: Does not inhibit STAT1, STAT2 and STAT3 activation by IFN. Inhibits STAT1, STAT2 and STAT3 activation by IFN; when associated with F-269; F-306; F-318; F-337; F-411 and F-512. Inhibits STAT1, STAT2 and STAT3 activation by IFN; when associated with F-269; F-306; F-318; F-411 and F-512. Does not inhibit STAT1, STAT2 and STAT3 activation by IFN; when associated with F-512. Does not inhibit STAT1, STAT2 and STAT3 activation by IFN; when associated with F-269; F-306; F-318 and F-337.,MUTAGEN:Y->F: Does not inhibit STAT1, STAT2 and STAT3 activation by IFN. Inhibits STAT1, STAT2 and STAT3 activation by IFN; when associated with F-269; F-316; F-318; F-337; F-411 and F-512. Inhibits STAT1, STAT2 and STAT3 activation by IFN; when associated with F-269; F-316; F-318; F-411 and F-512. Does not inhibit STAT1, STAT2 and STAT3 activation by IFN; when associated with F-512. Does not inhibit STAT1, STAT2 and STAT3 activation by IFN; when associated with F-269; F-316; F-318 and F-337.,MUTAGEN:Y->F: Does not inhibit STAT1, STAT2 and STAT3 activation by IFN. Inhibits STAT1, STAT2 and STAT3 activation by IFN; when associated with F-306; F-316; F-318; F-337; F-411 and F-512. Inhibits STAT1, STAT2 and STAT3 activation by IFN; when associated with F-306; F-316; F-318; F-411 and F-512. Does not inhibit STAT1, STAT2 and STAT3 activation by IFN; when associated with F-306; F-316; F-318 and F-337.,REGION:Disordered,REGION:Mediates interaction with STAT2 (and required for the recruitment of USP18),TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
IFI6	interferon alpha inducible protein 6(IFI6)	Homo sapiens			GO:0001836~release of cytochrome c from mitochondria,GO:0006915~apoptotic process,GO:0006955~immune response,GO:0042058~regulation of epidermal growth factor receptor signaling pathway,GO:0043066~negative regulation of apoptotic process,GO:0043154~negative regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0045087~innate immune response,GO:0051607~defense response to virus,GO:0051902~negative regulation of mitochondrial depolarization,GO:0072593~reactive oxygen species metabolic process,GO:0097190~apoptotic signaling pathway,GO:0097193~intrinsic apoptotic signaling pathway,GO:0098586~cellular response to virus,GO:2001240~negative regulation of extrinsic apoptotic signaling pathway in absence of ligand,	GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0031966~mitochondrial membrane,	GO:0005515~protein binding,	IPR009311:IFI6/IFI27-like,IPR038213:IFI6/IFI27-like_sf,					KW-0051~Antiviral defense,KW-0053~Apoptosis,KW-0391~Immunity,KW-0399~Innate immunity,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,				TRANSMEM:Helical,
IFI16	interferon gamma inducible protein 16(IFI16)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001819~positive regulation of cytokine production,GO:0002218~activation of innate immune response,GO:0006914~autophagy,GO:0006954~inflammatory response,GO:0010506~regulation of autophagy,GO:0030099~myeloid cell differentiation,GO:0030224~monocyte differentiation,GO:0032731~positive regulation of interleukin-1 beta production,GO:0035458~cellular response to interferon-beta,GO:0042149~cellular response to glucose starvation,GO:0042771~intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator,GO:0043392~negative regulation of DNA binding,GO:0045071~negative regulation of viral genome replication,GO:0045087~innate immune response,GO:0045814~negative regulation of gene expression, epigenetic,GO:0045824~negative regulation of innate immune response,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051607~defense response to virus,GO:0071479~cellular response to ionizing radiation,GO:0072332~intrinsic apoptotic signaling pathway by p53 class mediator,GO:0097202~activation of cysteine-type endopeptidase activity,GO:2000117~negative regulation of cysteine-type endopeptidase activity,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016020~membrane,GO:0016607~nuclear speck,	GO:0003690~double-stranded DNA binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:0042802~identical protein binding,	IPR004020:DAPIN,IPR004021:HIN200/IF120x,IPR011029:DEATH-like_dom_sf,IPR012340:NA-bd_OB-fold,IPR040205:HIN-200,	hsa04621:NOD-like receptor signaling pathway,hsa04623:Cytosolic DNA-sensing pathway,			SM01289:PYRIN,	KW-0053~Apoptosis,KW-0072~Autophagy,KW-0391~Immunity,KW-0395~Inflammatory response,KW-0399~Innate immunity,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,		KW-0010~Activator,KW-0238~DNA-binding,KW-0678~Repressor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:HIN-200,DOMAIN:HIN-200 1,DOMAIN:HIN-200 2,DOMAIN:Pyrin,MOTIF:Nuclear localization signal,MUTAGEN:E->A: Abolishes TP53-mediated transcriptional activation; when associated with A-222.,MUTAGEN:E->A: Abolishes TP53-mediated transcriptional activation; when associated with A-272.,MUTAGEN:K->A: Impairs DNA binding; when associated with A-627; A-663; A-667; A-670; A- 674; A-732 and A-734.,MUTAGEN:K->A: Impairs DNA binding; when associated with A-627; A-663; A-667; A-670; A- 674; A-732 and A-759.,MUTAGEN:K->A: Impairs DNA binding; when associated with A-627; A-663; A-667; A-670; A- 674; A-734 and A-759.,MUTAGEN:K->A: Impairs DNA binding; when associated with A-627; A-663; A-667; A-670; A-732; A-734 and A-759.,MUTAGEN:K->A: Impairs DNA binding; when associated with A-627; A-667; A-670; A-674; A-732; A-734 and A-759.,MUTAGEN:K->A: Impairs DNA binding; when associated with A-663; A-667; A-670; A-674; A-732; A-734 and A-759.,MUTAGEN:K->Q: Predominant cytoplasmic, reduces nuclear localization (mimics non-acetylated state).,MUTAGEN:K->R: Minor effect on nuclear localization (mimics acetylated state).,MUTAGEN:Missing: Mostly nuclear, minor cytoplasmic localization.,MUTAGEN:Missing: Predominant cytoplasmic localization.,MUTAGEN:Missing: Predominant nuclear, some cytoplasmic localization.,MUTAGEN:R->A: Impairs DNA binding; when associated with A-627; A-663; A-670; A-674; A-732; A-734 and A-759.,MUTAGEN:S->A: Impairs DNA binding; when associated with A-627; A-663; A-667; A-674; A-732; A-734 and A-759.,MUTAGEN:Y->A: Abolishes TP53-mediated transcriptional activation; when associated with A-218.,MUTAGEN:Y->A: Abolishes TP53-mediated transcriptional activation; when associated with A-267.,REGION:Disordered,REGION:Interaction with TP53 C-terminus,REGION:Interaction with TP53 core domain,
IFNGR1	interferon gamma receptor 1(IFNGR1)	Homo sapiens		h_ifngPathway:IFN gamma signaling pathway ,h_nktPathway:Selective expression of chemokine receptors during T-cell polarization,h_th1th2Pathway:Th1/Th2 Differentiation,h_tidPathway:Chaperones modulate interferon Signaling Pathway,	GO:0001774~microglial cell activation,GO:0007165~signal transduction,GO:0009615~response to virus,GO:0010628~positive regulation of gene expression,GO:0019221~cytokine-mediated signaling pathway,GO:0032760~positive regulation of tumor necrosis factor production,GO:0038196~type III interferon signaling pathway,GO:0048143~astrocyte activation,GO:0060333~interferon-gamma-mediated signaling pathway,GO:0098586~cellular response to virus,GO:1900222~negative regulation of beta-amyloid clearance,GO:1902004~positive regulation of beta-amyloid formation,	GO:0005886~plasma membrane,GO:0016020~membrane,	GO:0004896~cytokine receptor activity,GO:0004906~interferon-gamma receptor activity,GO:0005515~protein binding,GO:0019955~cytokine binding,	IPR003961:FN3_dom,IPR008355:Interferon_gamma_rcpt_asu,IPR013783:Ig-like_fold,IPR021126:IFN_gamma_rc_D2_pox/mammal,IPR036116:FN3_sf,	hsa04060:Cytokine-cytokine receptor interaction,hsa04066:HIF-1 signaling pathway,hsa04217:Necroptosis,hsa04380:Osteoclast differentiation,hsa04630:JAK-STAT signaling pathway,hsa04650:Natural killer cell mediated cytotoxicity,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa05140:Leishmaniasis,hsa05142:Chagas disease,hsa05145:Toxoplasmosis,hsa05152:Tuberculosis,hsa05164:Influenza A,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05200:Pathways in cancer,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,hsa05321:Inflammatory bowel disease,	209950~Immunodeficiency 27A, mycobacteriosis, AR,600263~H. pylori infection, susceptibility to,607948~Tuberculosis infection, protection against,607948~Tuberculosis, susceptibility to,610424~Hepatitis B virus infection, susceptibility to,615978~Immunodeficiency 27B, mycobacteriosis, AD,				KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0393~Immunoglobulin domain,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:Fibronectin type-III,DOMAIN:Interferon gamma receptor D2,MUTAGEN:K->R: Strong decreased level of ubiquitination; when associated with R-277 and R-279.,MUTAGEN:K->R: Strong decreased level of ubiquitination; when associated with R-277 and R-285.,MUTAGEN:K->R: Strong decreased level of ubiquitination; when associated with R-279 and R-285.,MUTAGEN:V->Q: Loss of function in the interferon-gamma-mediated signaling pathway.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
IFI35	interferon induced protein 35(IFI35)	Homo sapiens			GO:0002281~macrophage activation involved in immune response,GO:0008285~negative regulation of cell proliferation,GO:0034145~positive regulation of toll-like receptor 4 signaling pathway,GO:0045087~innate immune response,GO:0045089~positive regulation of innate immune response,GO:0050729~positive regulation of inflammatory response,GO:1901223~negative regulation of NIK/NF-kappaB signaling,GO:1901224~positive regulation of NIK/NF-kappaB signaling,	GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016020~membrane,	GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR009909:Nmi/IFP35_dom,IPR009938:Nmi/IFP35_N,IPR012677:Nucleotide-bd_a/b_plait_sf,					KW-0391~Immunity,KW-0399~Innate immunity,	KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0964~Secreted,					KW-0597~Phosphoprotein,	DOMAIN:NID 1,DOMAIN:NID 2,REGION:Leucine-zipper,
IFITM1	interferon induced transmembrane protein 1(IFITM1)	Homo sapiens			GO:0001503~ossification,GO:0007166~cell surface receptor signaling pathway,GO:0008285~negative regulation of cell proliferation,GO:0009615~response to virus,GO:0030336~negative regulation of cell migration,GO:0034341~response to interferon-gamma,GO:0035455~response to interferon-alpha,GO:0035456~response to interferon-beta,GO:0045071~negative regulation of viral genome replication,GO:0045669~positive regulation of osteoblast differentiation,GO:0046597~negative regulation of viral entry into host cell,GO:0051607~defense response to virus,GO:0060337~type I interferon signaling pathway,	GO:0005765~lysosomal membrane,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0032991~macromolecular complex,	GO:0005515~protein binding,	IPR007593:CD225/Dispanin_fam,	hsa04662:B cell receptor signaling pathway,				KW-0051~Antiviral defense,KW-0391~Immunity,KW-0399~Innate immunity,KW-0892~Osteogenesis,	KW-0458~Lysosome,KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,	INTRAMEM:Helical,LIPID:S-palmitoyl cysteine,MUTAGEN:C->A: Loss of anti-HCV activity. Only localizes at the lysosome.,MUTAGEN:CC->AA: No effect on anti-HCV activity. Only localizes at the lysosome.,REGION:Interaction with CAV1,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
IRF1	interferon regulatory factor 1(IRF1)	Homo sapiens		h_pcafPathway:The information-processing pathway at the IFN-beta enhancer,	GO:0002376~immune system process,GO:0002819~regulation of adaptive immune response,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0006915~apoptotic process,GO:0008285~negative regulation of cell proliferation,GO:0032481~positive regulation of type I interferon production,GO:0032728~positive regulation of interferon-beta production,GO:0032735~positive regulation of interleukin-12 production,GO:0034124~regulation of MyD88-dependent toll-like receptor signaling pathway,GO:0035458~cellular response to interferon-beta,GO:0043374~CD8-positive, alpha-beta T cell differentiation,GO:0045088~regulation of innate immune response,GO:0045590~negative regulation of regulatory T cell differentiation,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051607~defense response to virus,GO:0051726~regulation of cell cycle,GO:0060333~interferon-gamma-mediated signaling pathway,GO:0071260~cellular response to mechanical stimulus,GO:2000564~regulation of CD8-positive, alpha-beta T cell proliferation,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,	IPR001346:Interferon_reg_fact_DNA-bd_dom,IPR017431:IRF1/IRF2,IPR019817:Interferon_reg_fac_CS,IPR036388:WH-like_DNA-bd_sf,IPR036390:WH_DNA-bd_sf,	hsa04625:C-type lectin receptor signaling pathway,hsa04668:TNF signaling pathway,hsa04917:Prolactin signaling pathway,hsa05133:Pertussis,hsa05165:Human papillomavirus infection,	211980~Nonsmall cell lung cancer, somatic,613659~Gastric cancer, somatic,620668~Immunodeficiency 117, mycobacteriosis, autosomal recessive,	PIRSF038196:IFN_RF1/2,	SM00348:IRF,	KW-0051~Antiviral defense,KW-0391~Immunity,KW-0399~Innate immunity,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0043~Tumor suppressor,KW-0225~Disease variant,			KW-0010~Activator,KW-0238~DNA-binding,KW-0678~Repressor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO),DNA_BIND:IRF tryptophan pentad repeat,DOMAIN:IRF tryptophan pentad repeat,MUTAGEN:K->R: Large loss of sumoylation. Abolishes sumoylation, diminished ubiquitination, higher resistance to degradation, and increased apoptotic activity; when associated with R-275.,MUTAGEN:K->R: Loss of acetylation. Partial loss of DNA-binding and transcriptional activity.,MUTAGEN:K->R: Some loss of sumoylation. Partial inhibition of acetylation and activity. Abolishes sumoylation, diminished ubiquitination, higher resistance to degradation, and increased apoptotic activity; when associated with R-299.,REGION:Disordered,
IRF2BP2	interferon regulatory factor 2 binding protein 2(IRF2BP2)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0002327~immature B cell differentiation,GO:0006357~regulation of transcription from RNA polymerase II promoter,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,	GO:0003714~transcription corepressor activity,GO:0046872~metal ion binding,	IPR022750:Interferon_reg_fac2-bd1_2_Znf,IPR044882:I2BP1/2_C3HC4-RING_sf,		617765~Immunodeficiency, common variable, 14,			KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,	KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0678~Repressor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),MOTIF:Nuclear localization signal,REGION:Cys-rich,REGION:Disordered,ZN_FING:RING-type; degenerate,
IRF2	interferon regulatory factor 2(IRF2)	Homo sapiens		h_pcafPathway:The information-processing pathway at the IFN-beta enhancer,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0002376~immune system process,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0008283~cell proliferation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051607~defense response to virus,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0005925~focal adhesion,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001346:Interferon_reg_fact_DNA-bd_dom,IPR017431:IRF1/IRF2,IPR019817:Interferon_reg_fac_CS,IPR036388:WH-like_DNA-bd_sf,IPR036390:WH_DNA-bd_sf,			PIRSF038196:IFN_RF1/2,	SM00348:IRF,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0010~Activator,KW-0238~DNA-binding,KW-0678~Repressor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DNA_BIND:IRF tryptophan pentad repeat,DOMAIN:IRF tryptophan pentad repeat,MUTAGEN:K->R: Diminished acetylation by both CREBBP/p300 and PCAF. Greatly reduced enhancement of H4 promoter activity.,MUTAGEN:K->R: Greatly diminished acetylation by PCAF. Lesser loss of acetylation by CREBBP/p300. Loss of DNA binding and no enhancement of H4 promoter activity.,MUTAGEN:K->R: Little loss of sumoylation. Increases IRF2-mediation activation of ISRE and H4 promoters. Increased inhibition of IRF1-mediated transcription. Greater loss of sumoylation; when associated with R-137. Further loss of sumoylation; when associated with R-293. Abolishes sumoylation. Greatly increased activation of ISRE and H4 promoters and further increased ability to inhibit IRF1-mediated transcription; when associated with R-137 and R-293.,MUTAGEN:K->R: Some loss of sumoylation. Increases IRF2-mediation activation of ISRE and H4 promoters. Increased inhibition of IRF1-mediated transcription. Additional small loss of sumoylation; when associated with R-166. Great loss of sumoylation; when associated with R-296. Abolishes sumoylation. Greatly increased activation of ISRE and H4 promoters and further increased ability to inhibit IRF1-mediated transcription; when associated with R-166 and R-293.,MUTAGEN:K->R: Some loss of sumoylation. Increases IRF2-mediation activation of ISRE and H4 promoters. Increased inhibition of IRF1-mediated transcription. Further small loss of sumoylation; when associated with R-166. Great loss of sumoylation; when associated with R-137. Abolishes sumoylation. Greatly increased activation of ISRE and H4 promoters and further increased ability to inhibit IRF1-mediated transcription; when associated with R-166 and R-293.,REGION:Disordered,
IRF7	interferon regulatory factor 7(IRF7)	Homo sapiens		h_pcafPathway:The information-processing pathway at the IFN-beta enhancer,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0002376~immune system process,GO:0002753~cytoplasmic pattern recognition receptor signaling pathway,GO:0002819~regulation of adaptive immune response,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006974~cellular response to DNA damage stimulus,GO:0009615~response to virus,GO:0016064~immunoglobulin mediated immune response,GO:0019043~establishment of viral latency,GO:0032479~regulation of type I interferon production,GO:0032481~positive regulation of type I interferon production,GO:0032727~positive regulation of interferon-alpha production,GO:0032728~positive regulation of interferon-beta production,GO:0034124~regulation of MyD88-dependent toll-like receptor signaling pathway,GO:0034127~regulation of MyD88-independent toll-like receptor signaling pathway,GO:0039530~MDA-5 signaling pathway,GO:0045087~innate immune response,GO:0045655~regulation of monocyte differentiation,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0050776~regulation of immune response,GO:0051607~defense response to virus,GO:0060337~type I interferon signaling pathway,GO:0060340~positive regulation of type I interferon-mediated signaling pathway,GO:2000110~negative regulation of macrophage apoptotic process,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0010008~endosome membrane,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001346:Interferon_reg_fact_DNA-bd_dom,IPR008984:SMAD_FHA_dom_sf,IPR017855:SMAD-like_dom_sf,IPR019471:Interferon_reg_factor-3,IPR019817:Interferon_reg_fac_CS,IPR036388:WH-like_DNA-bd_sf,IPR036390:WH_DNA-bd_sf,	hsa04620:Toll-like receptor signaling pathway,hsa04621:NOD-like receptor signaling pathway,hsa04622:RIG-I-like receptor signaling pathway,hsa04623:Cytosolic DNA-sensing pathway,hsa05160:Hepatitis C,hsa05161:Hepatitis B,hsa05162:Measles,hsa05164:Influenza A,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05203:Viral carcinogenesis,hsa05417:Lipid and atherosclerosis,	616345~Immunodeficiency 39,		SM00348:IRF,SM01243:IRF-3,	KW-0051~Antiviral defense,KW-0391~Immunity,KW-0399~Innate immunity,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,			KW-0010~Activator,KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DNA_BIND:IRF tryptophan pentad repeat,DOMAIN:IRF tryptophan pentad repeat,DOMAIN:Interferon regulatory factor-3,MUTAGEN:G->T: Loss of acetylation, increased DNA-binding and activity; when associated with R-93.,MUTAGEN:K->R: Loss of NEURL3-mediated ubiquitination.,MUTAGEN:K->R: Loss of acetylation, DNA-binding and activity.,MUTAGEN:Q->A: Complete loss of cleavage by enterovirus 71.,MUTAGEN:Q->A: Complete loss of inactivation of IFN-I production; when associated with R-189.,MUTAGEN:Q->A: No effect on cleavage by enterovirus 71.,MUTAGEN:Q->R: Complete loss of inactivation of IFN-I production; when associated with A-167.,MUTAGEN:SLS->ALA: Complete loss of TBK1 and IKKE phosphorylation.,MUTAGEN:T->R: Loss of acetylation, increased DNA-binding and activity; when associated with T-90.,REGION:Disordered,REGION:Necessary for the interaction with NMI,SITE:(Microbial infection) Cleavage; by viral EV 71 protease 3C and EV68 protease 3C,SITE:(Microbial infection) Cleavage; by viral EV68 protease 3C,
IFRD1	interferon related developmental regulator 1(IFRD1)	Homo sapiens			GO:0007518~myoblast fate determination,GO:0014706~striated muscle tissue development,GO:0030517~negative regulation of axon extension,GO:0042692~muscle cell differentiation,GO:0043403~skeletal muscle tissue regeneration,GO:0048671~negative regulation of collateral sprouting,	GO:0005634~nucleus,GO:0016528~sarcoplasm,		IPR006921:Interferon-rel_develop_reg_C,IPR007701:Interferon-rel_develop_reg_N,IPR011989:ARM-like,IPR016024:ARM-type_fold,IPR039777:IFRD,					KW-0221~Differentiation,					KW-0217~Developmental protein,KW-9996~Developmental protein,		COMPBIAS:Polar residues,DOMAIN:Interferon-related developmental regulator C-terminal,DOMAIN:Interferon-related developmental regulator N-terminal,REGION:Disordered,
ISG20L2	interferon stimulated exonuclease gene 20 like 2(ISG20L2)	Homo sapiens			GO:0042254~ribosome biogenesis,	GO:0005634~nucleus,GO:0005730~nucleolus,	GO:0000175~3'-5'-exoribonuclease activity,GO:0003723~RNA binding,GO:0004527~exonuclease activity,GO:0005515~protein binding,	IPR012337:RNaseH-like_sf,IPR013520:Exonuclease_RNaseT/DNA_pol3,IPR036397:RNaseH_sf,IPR037433:ISG20_DEDDh,IPR047021:REXO1/3/4-like,				SM00479:EXOIII,	KW-0690~Ribosome biogenesis,	KW-0539~Nucleus,				KW-0269~Exonuclease,KW-0378~Hydrolase,KW-0540~Nuclease,		COMPBIAS:Polar residues,DOMAIN:Exonuclease,REGION:Disordered,
ISG20	interferon stimulated exonuclease gene 20(ISG20)	Homo sapiens			GO:0006308~DNA catabolic process,GO:0006364~rRNA processing,GO:0006401~RNA catabolic process,GO:0009615~response to virus,GO:0045071~negative regulation of viral genome replication,GO:0045087~innate immune response,GO:0051607~defense response to virus,	GO:0000932~P-body,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0015030~Cajal body,GO:0016605~PML body,	GO:0000175~3'-5'-exoribonuclease activity,GO:0003676~nucleic acid binding,GO:0004527~exonuclease activity,GO:0008310~single-stranded DNA 3'-5' exodeoxyribonuclease activity,GO:0008859~exoribonuclease II activity,GO:0030619~U1 snRNA binding,GO:0030620~U2 snRNA binding,GO:0034511~U3 snoRNA binding,GO:0046872~metal ion binding,	IPR012337:RNaseH-like_sf,IPR013520:Exonuclease_RNaseT/DNA_pol3,IPR036397:RNaseH_sf,IPR047021:REXO1/3/4-like,				SM00479:EXOIII,	KW-0051~Antiviral defense,KW-0391~Immunity,KW-0399~Innate immunity,KW-0698~rRNA processing,	KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0464~Manganese,KW-0479~Metal-binding,	KW-0269~Exonuclease,KW-0378~Hydrolase,KW-0540~Nuclease,KW-0694~RNA-binding,		DOMAIN:Exonuclease,
IL10RA	interleukin 10 receptor subunit alpha(IL10RA)	Homo sapiens		h_il10Pathway:IL-10 Anti-inflammatory Signaling Pathway,h_il22bpPathway:IL22 Soluble Receptor Signaling Pathway ,	GO:0010507~negative regulation of autophagy,GO:0019221~cytokine-mediated signaling pathway,GO:0032496~response to lipopolysaccharide,GO:0046427~positive regulation of JAK-STAT cascade,GO:0050728~negative regulation of inflammatory response,GO:0050807~regulation of synapse organization,GO:0060729~intestinal epithelial structure maintenance,GO:0070086~ubiquitin-dependent endocytosis,	GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016324~apical plasma membrane,	GO:0004920~interleukin-10 receptor activity,GO:0005515~protein binding,GO:0019969~interleukin-10 binding,GO:0038023~signaling receptor activity,	IPR003961:FN3_dom,IPR013783:Ig-like_fold,IPR036116:FN3_sf,	hsa04060:Cytokine-cytokine receptor interaction,hsa04061:Viral protein interaction with cytokine and cytokine receptor,hsa04630:JAK-STAT signaling pathway,hsa05145:Toxoplasmosis,hsa05152:Tuberculosis,hsa05163:Human cytomegalovirus infection,	613148~Inflammatory bowel disease 28, early onset, autosomal recessive,				KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:Fibronectin type-III,MOTIF:BTRC recognition motif,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
IL16	interleukin 16(IL16)	Homo sapiens		h_cytokinePathway:Cytokine Network,	GO:0006935~chemotaxis,GO:0006955~immune response,GO:0007165~signal transduction,GO:0030595~leukocyte chemotaxis,GO:0032730~positive regulation of interleukin-1 alpha production,GO:0032735~positive regulation of interleukin-12 production,GO:0032755~positive regulation of interleukin-6 production,GO:0050729~positive regulation of inflammatory response,GO:0050930~induction of positive chemotaxis,GO:0051924~regulation of calcium ion transport,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0016607~nuclear speck,GO:0090543~Flemming body,	GO:0005125~cytokine activity,GO:0042609~CD4 receptor binding,	IPR001478:PDZ,IPR020450:IL-16,IPR036034:PDZ_sf,	hsa04060:Cytokine-cytokine receptor interaction,			SM00228:PDZ,	KW-0145~Chemotaxis,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0964~Secreted,		KW-0677~Repeat,		KW-0202~Cytokine,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:PDZ,DOMAIN:PDZ 1,DOMAIN:PDZ 2,DOMAIN:PDZ 3,DOMAIN:PDZ 4,MUTAGEN:D->A: Abolishes proteolytic cleavage.,MUTAGEN:KGLRNR->AGLANA: Reduces nuclear localization of pro-interleukin-16; when associated with 780-AA-781.,MUTAGEN:KK->AA: Reduces nuclear localization of pro-interleukin-16; when associated with 797-AGLANA-802.,MUTAGEN:S->A: Reduces phosphorylation and nuclear localization.,MUTAGEN:T->A: Reduces phosphorylation. Enhances nuclear localization.,REGION:Disordered,REGION:Interaction with GRIN2A,REGION:Interaction with HTLV-1 tax,REGION:Interaction with PPP1R12A, PPP1R12B and PPP1R12C,
IL2RB	interleukin 2 receptor subunit beta(IL2RB)	Homo sapiens		h_il2Pathway:IL 2 signaling pathway,h_il2rbPathway:IL-2 Receptor Beta Chain in T cell Activation,	GO:0007165~signal transduction,GO:0016064~immunoglobulin mediated immune response,GO:0019221~cytokine-mediated signaling pathway,GO:0035723~interleukin-15-mediated signaling pathway,GO:0038110~interleukin-2-mediated signaling pathway,GO:0043066~negative regulation of apoptotic process,GO:0050766~positive regulation of phagocytosis,GO:0065003~macromolecular complex assembly,	GO:0005768~endosome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005893~interleukin-2 receptor complex,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,	GO:0004896~cytokine receptor activity,GO:0004911~interleukin-2 receptor activity,GO:0005515~protein binding,GO:0015026~coreceptor activity,GO:0019976~interleukin-2 binding,GO:0042010~interleukin-15 receptor activity,	IPR003531:Hempt_rcpt_S_F1_CS,IPR003961:FN3_dom,IPR013783:Ig-like_fold,IPR036116:FN3_sf,IPR040951:IL2RB_N1,	hsa04060:Cytokine-cytokine receptor interaction,hsa04061:Viral protein interaction with cytokine and cytokine receptor,hsa04144:Endocytosis,hsa04151:PI3K-Akt signaling pathway,hsa04630:JAK-STAT signaling pathway,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa05162:Measles,hsa05166:Human T-cell leukemia virus 1 infection,hsa05200:Pathways in cancer,hsa05202:Transcriptional misregulation in cancer,	618495~Immunodeficiency 63 with lymphoproliferation and autoimmunity,		SM00060:FN3,	KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Pro residues,DOMAIN:Fibronectin type-III,DOMAIN:Interleukin-2 receptor subunit beta N-terminal,MOTIF:Box 1 motif,MOTIF:WSXWS motif,MUTAGEN:Y->F: Partial loss of interaction with SHB; when associated with F-418.,MUTAGEN:Y->F: Partial loss of interaction with SHB; when associated with F-536.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
IL2RG	interleukin 2 receptor subunit gamma(IL2RG)	Homo sapiens		h_il2Pathway:IL 2 signaling pathway,h_il2rbPathway:IL-2 Receptor Beta Chain in T cell Activation,h_il4Pathway:IL 4 signaling pathway,h_il7Pathway:IL-7 Signal Transduction,	GO:0002335~mature B cell differentiation,GO:0002361~CD4-positive, CD25-positive, alpha-beta regulatory T cell differentiation,GO:0006955~immune response,GO:0007165~signal transduction,GO:0010467~gene expression,GO:0010628~positive regulation of gene expression,GO:0019221~cytokine-mediated signaling pathway,GO:0032831~positive regulation of CD4-positive, CD25-positive, alpha-beta regulatory T cell differentiation,GO:0033077~T cell differentiation in thymus,GO:0033089~positive regulation of T cell differentiation in thymus,GO:0035723~interleukin-15-mediated signaling pathway,GO:0035771~interleukin-4-mediated signaling pathway,GO:0038110~interleukin-2-mediated signaling pathway,GO:0038111~interleukin-7-mediated signaling pathway,GO:0038113~interleukin-9-mediated signaling pathway,GO:0045579~positive regulation of B cell differentiation,GO:0050766~positive regulation of phagocytosis,	GO:0005654~nucleoplasm,GO:0005768~endosome,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,GO:0043235~receptor complex,	GO:0004896~cytokine receptor activity,GO:0004911~interleukin-2 receptor activity,GO:0004913~interleukin-4 receptor activity,GO:0004917~interleukin-7 receptor activity,GO:0005515~protein binding,GO:0015026~coreceptor activity,GO:0019955~cytokine binding,GO:0019976~interleukin-2 binding,GO:0042010~interleukin-15 receptor activity,	IPR003531:Hempt_rcpt_S_F1_CS,IPR003961:FN3_dom,IPR013783:Ig-like_fold,IPR036116:FN3_sf,IPR048648:CRLF2-like_D2,IPR048651:CRLF2_D1,	hsa04060:Cytokine-cytokine receptor interaction,hsa04061:Viral protein interaction with cytokine and cytokine receptor,hsa04144:Endocytosis,hsa04151:PI3K-Akt signaling pathway,hsa04630:JAK-STAT signaling pathway,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa05162:Measles,hsa05166:Human T-cell leukemia virus 1 infection,hsa05200:Pathways in cancer,hsa05321:Inflammatory bowel disease,hsa05340:Primary immunodeficiency,	300400~Severe combined immunodeficiency, X-linked,312863~Combined immunodeficiency, X-linked, moderate,			KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0705~SCID,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Cytokine receptor-like factor 2-like D1,DOMAIN:Fibronectin type-III,MOTIF:Box 1 motif,MOTIF:WSXWS motif,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
IL21R	interleukin 21 receptor(IL21R)	Homo sapiens			GO:0016064~immunoglobulin mediated immune response,GO:0019221~cytokine-mediated signaling pathway,GO:0030101~natural killer cell activation,GO:0038114~interleukin-21-mediated signaling pathway,	GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0016020~membrane,	GO:0001532~interleukin-21 receptor activity,GO:0004888~transmembrane signaling receptor activity,GO:0004896~cytokine receptor activity,GO:0005515~protein binding,	IPR003531:Hempt_rcpt_S_F1_CS,IPR003961:FN3_dom,IPR013783:Ig-like_fold,IPR036116:FN3_sf,	hsa04060:Cytokine-cytokine receptor interaction,hsa04630:JAK-STAT signaling pathway,hsa04659:Th17 cell differentiation,hsa05321:Inflammatory bowel disease,	615207~Immunodeficiency 56,				KW-0472~Membrane,	KW-0225~Disease variant,	KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:C-linked (Man) tryptophan,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Fibronectin type-III,DOMAIN:Fibronectin type-III 1,DOMAIN:Fibronectin type-III 2,MOTIF:Box 1 motif,MOTIF:WSXWS motif,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
IL27RA	interleukin 27 receptor subunit alpha(IL27RA)	Homo sapiens			GO:0002827~positive regulation of T-helper 1 type immune response,GO:0002829~negative regulation of type 2 immune response,GO:0006955~immune response,GO:0007166~cell surface receptor signaling pathway,GO:0019221~cytokine-mediated signaling pathway,GO:0032700~negative regulation of interleukin-17 production,GO:0032715~negative regulation of interleukin-6 production,GO:0032720~negative regulation of tumor necrosis factor production,GO:0032729~positive regulation of interferon-gamma production,GO:0043524~negative regulation of neuron apoptotic process,GO:0048302~regulation of isotype switching to IgG isotypes,GO:0050830~defense response to Gram-positive bacterium,GO:0070106~interleukin-27-mediated signaling pathway,GO:2000317~negative regulation of T-helper 17 type immune response,GO:2000408~negative regulation of T cell extravasation,	GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0043235~receptor complex,	GO:0004888~transmembrane signaling receptor activity,GO:0005515~protein binding,GO:0019955~cytokine binding,GO:0045509~interleukin-27 receptor activity,	IPR003961:FN3_dom,IPR013783:Ig-like_fold,IPR036116:FN3_sf,	hsa04060:Cytokine-cytokine receptor interaction,hsa04630:JAK-STAT signaling pathway,hsa04659:Th17 cell differentiation,			SM00060:FN3,		KW-0472~Membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Fibronectin type-III 1,DOMAIN:Fibronectin type-III 2,DOMAIN:Fibronectin type-III 3,MOTIF:Box 1 motif,MOTIF:WSXWS motif,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
IL32	interleukin 32(IL32)	Homo sapiens			GO:0006952~defense response,GO:0006955~immune response,GO:0007155~cell adhesion,GO:0007165~signal transduction,GO:0010628~positive regulation of gene expression,GO:0034346~positive regulation of type III interferon production,GO:1903901~negative regulation of viral life cycle,GO:1905636~positive regulation of RNA polymerase II regulatory region sequence-specific DNA binding,	GO:0005615~extracellular space,GO:0005829~cytosol,GO:0016020~membrane,	GO:0005125~cytokine activity,GO:0005515~protein binding,	IPR028067:IL-32,	hsa04060:Cytokine-cytokine receptor interaction,					KW-0964~Secreted,		KW-0732~Signal,		KW-0202~Cytokine,		COMPBIAS:Basic and acidic residues,REGION:Disordered,
IL4R	interleukin 4 receptor(IL4R)	Homo sapiens	55.Allergen_recognition_by_Th2_or_Th0_cell,80.T_cell_Activation,	h_il4Pathway:IL 4 signaling pathway,h_nktPathway:Selective expression of chemokine receptors during T-cell polarization,h_th1th2Pathway:Th1/Th2 Differentiation,	GO:0002532~production of molecular mediator involved in inflammatory response,GO:0002639~positive regulation of immunoglobulin production,GO:0006955~immune response,GO:0007165~signal transduction,GO:0016064~immunoglobulin mediated immune response,GO:0019221~cytokine-mediated signaling pathway,GO:0032722~positive regulation of chemokine production,GO:0035771~interleukin-4-mediated signaling pathway,GO:0042832~defense response to protozoan,GO:0043032~positive regulation of macrophage activation,GO:0043306~positive regulation of mast cell degranulation,GO:0045063~T-helper 1 cell differentiation,GO:0045064~T-helper 2 cell differentiation,GO:0045626~negative regulation of T-helper 1 cell differentiation,GO:0045630~positive regulation of T-helper 2 cell differentiation,GO:1901741~positive regulation of myoblast fusion,	GO:0005576~extracellular region,GO:0005654~nucleoplasm,GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0016020~membrane,GO:0034451~centriolar satellite,GO:0043235~receptor complex,	GO:0004896~cytokine receptor activity,GO:0004913~interleukin-4 receptor activity,GO:0005515~protein binding,	IPR003531:Hempt_rcpt_S_F1_CS,IPR003961:FN3_dom,IPR013783:Ig-like_fold,IPR015319:IL-4_rcpt-alpha_N,IPR036116:FN3_sf,	hsa04060:Cytokine-cytokine receptor interaction,hsa04151:PI3K-Akt signaling pathway,hsa04630:JAK-STAT signaling pathway,hsa04640:Hematopoietic cell lineage,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa05200:Pathways in cancer,hsa05321:Inflammatory bowel disease,				KW-0391~Immunity,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Fibronectin type-III,DOMAIN:Interleukin-4 receptor alpha N-terminal,MOTIF:Box 1 motif,MOTIF:ITIM motif,MOTIF:WSXWS motif,MUTAGEN:D->A,N: >150-fold reduction in IL4 binding.,MUTAGEN:D->A: 50-fold reduction in IL4 binding.,MUTAGEN:D->A: Little effect on IL4 binding.,MUTAGEN:E->A: No effect on IL4 binding.,MUTAGEN:F->A: 45-fold reduction in IL4 binding.,MUTAGEN:K->A: Little effect on IL4 binding.,MUTAGEN:L->A: 100-fold reduction in IL4 binding.,MUTAGEN:L->A: Little effect on IL4 binding.,MUTAGEN:L->A: No effect on IL4 binding.,MUTAGEN:M->A: No effect on IL4 binding.,MUTAGEN:N->A: Little effect on IL4 binding.,MUTAGEN:N->A: No effect on IL4 binding.,MUTAGEN:P->A: Little effect on IL4 binding.,MUTAGEN:S->A: No effect on IL4 binding.,MUTAGEN:V->A: 35-fold reduction in IL4 binding.,MUTAGEN:V->A: Little effect on IL4 binding.,MUTAGEN:Y->A: 10-fold reduction in IL4 binding.,MUTAGEN:Y->A: 40-fold reduction in IL4 binding.,MUTAGEN:Y->A: 500-fold reduction in IL4 binding.,MUTAGEN:Y->A: 700-fold reduction in IL4 binding.,MUTAGEN:Y->A: Little effect on IL4 binding.,MUTAGEN:Y->F: 200-fold reduction in IL4 binding.,MUTAGEN:Y->F: 25-fold reduction in IL4 binding.,MUTAGEN:Y->F: Abolishes IRS1 tyrosine phosphorylation. No cell proliferation.,MUTAGEN:Y->F: Increased IL4-induced cell proliferation and STAT6 activation.,MUTAGEN:Y->F: Loss of CD23 gene induction; when associated with F-575 and F-603.,MUTAGEN:Y->F: Loss of CD23 gene induction; when associated with F-575 and F-631.,MUTAGEN:Y->F: Loss of CD23 gene induction; when associated with F-603 and F-631.,MUTAGEN:Y->F: No effect on IL4 binding.,REGION:Disordered,REGION:Required for IL4-induced gene expression,REGION:Required for IRS1 activation and IL4-induced cell growth,SITE:Major IL4 binding determinant,SITE:Minor IL4 binding determinant,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
IL6ST	interleukin 6 cytokine family signal transducer(IL6ST)	Homo sapiens	11.IL-6_gp130-Jak-STAT,12.IL-6_type_cytok-signal-transduct,	h_her2Pathway:Role of ERBB2 in Signal Transduction and Oncology,h_il6Pathway:IL 6 signaling pathway,	GO:0002675~positive regulation of acute inflammatory response,GO:0002821~positive regulation of adaptive immune response,GO:0005977~glycogen metabolic process,GO:0008284~positive regulation of cell proliferation,GO:0010575~positive regulation of vascular endothelial growth factor production,GO:0010613~positive regulation of cardiac muscle hypertrophy,GO:0019221~cytokine-mediated signaling pathway,GO:0034097~response to cytokine,GO:0038154~interleukin-11-mediated signaling pathway,GO:0038165~oncostatin-M-mediated signaling pathway,GO:0042102~positive regulation of T cell proliferation,GO:0042531~positive regulation of tyrosine phosphorylation of STAT protein,GO:0043066~negative regulation of apoptotic process,GO:0043524~negative regulation of neuron apoptotic process,GO:0045669~positive regulation of osteoblast differentiation,GO:0045747~positive regulation of Notch signaling pathway,GO:0048711~positive regulation of astrocyte differentiation,GO:0048861~leukemia inhibitory factor signaling pathway,GO:0060576~intestinal epithelial cell development,GO:0070102~interleukin-6-mediated signaling pathway,GO:0070104~negative regulation of interleukin-6-mediated signaling pathway,GO:0070106~interleukin-27-mediated signaling pathway,GO:0070120~ciliary neurotrophic factor-mediated signaling pathway,GO:0072540~T-helper 17 cell lineage commitment,GO:1901731~positive regulation of platelet aggregation,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0005896~interleukin-6 receptor complex,GO:0005900~oncostatin-M receptor complex,GO:0009897~external side of plasma membrane,GO:0016020~membrane,GO:0030425~dendrite,GO:0043025~neuronal cell body,GO:0043235~receptor complex,GO:0045121~membrane raft,GO:0070062~extracellular exosome,GO:0070110~ciliary neurotrophic factor receptor complex,	GO:0004896~cytokine receptor activity,GO:0004897~ciliary neurotrophic factor receptor activity,GO:0004915~interleukin-6 receptor activity,GO:0004921~interleukin-11 receptor activity,GO:0004923~leukemia inhibitory factor receptor activity,GO:0004924~oncostatin-M receptor activity,GO:0005127~ciliary neurotrophic factor receptor binding,GO:0005138~interleukin-6 receptor binding,GO:0005515~protein binding,GO:0015026~coreceptor activity,GO:0019838~growth factor binding,GO:0019955~cytokine binding,GO:0019970~interleukin-11 binding,GO:0019981~interleukin-6 binding,GO:0030296~protein tyrosine kinase activator activity,GO:0042802~identical protein binding,GO:0045509~interleukin-27 receptor activity,GO:0097110~scaffold protein binding,	IPR003529:Hematopoietin_rcpt_Gp130_CS,IPR003961:FN3_dom,IPR010457:IgC2-like_lig-bd,IPR013783:Ig-like_fold,IPR015321:TypeI_recpt_CBD,IPR036116:FN3_sf,IPR036179:Ig-like_dom_sf,	hsa04060:Cytokine-cytokine receptor interaction,hsa04061:Viral protein interaction with cytokine and cytokine receptor,hsa04550:Signaling pathways regulating pluripotency of stem cells,hsa04630:JAK-STAT signaling pathway,hsa04659:Th17 cell differentiation,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05171:Coronavirus disease - COVID-19,hsa05200:Pathways in cancer,hsa05203:Viral carcinogenesis,	618523~Hyper-IgE syndrome 4B, autosomal recessive, with recurrent infections,619750~Immunodeficiency 94 with autoinflammation and dysmorphic facies,619751~Stuve-Wiedemann syndrome 2,619752~Hyper-IgE syndrome 4A, autosomal dominant, with recurrent infections,		SM00060:FN3,	KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) (complex) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:Fibronectin type-III,DOMAIN:Fibronectin type-III 1,DOMAIN:Fibronectin type-III 2,DOMAIN:Fibronectin type-III 3,DOMAIN:Fibronectin type-III 4,DOMAIN:Fibronectin type-III 5,DOMAIN:Ig-like C2-type,DOMAIN:Immunoglobulin C2-set-like ligand-binding,MOTIF:Box 1 motif,MOTIF:WSXWS motif,MUTAGEN:C->S: Induces ligand-independent activation.,MUTAGEN:D->G: Induces ligand-independent activation.,MUTAGEN:Missing: Induces ligand-independent activation.,MUTAGEN:Missing: Results in impaired cytokine-mediated signaling pathway with loss of response to IL-6 and IL-11. Weak response to IL-27, OSM and LIF.,MUTAGEN:S->A: Increases cell surface expression.,MUTAGEN:V->G: Does not induce ligand-independent activation.,MUTAGEN:V->G: Induces ligand-independent activation.,MUTAGEN:Y->F: Refractory to inhibition by SOCS3.,MUTAGEN:Y->G: Does not induce ligand-independent activation.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
ILF3	interleukin enhancer binding factor 3(ILF3)	Homo sapiens			GO:0006468~protein phosphorylation,GO:0017148~negative regulation of translation,GO:0045071~negative regulation of viral genome replication,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0046718~viral entry into host cell,GO:0051607~defense response to virus,	GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0016020~membrane,GO:1990904~ribonucleoprotein complex,	GO:0001618~virus receptor activity,GO:0003677~DNA binding,GO:0003723~RNA binding,GO:0003725~double-stranded RNA binding,GO:0003727~single-stranded RNA binding,GO:0005515~protein binding,GO:0035925~mRNA 3'-UTR AU-rich region binding,	IPR006561:DZF_dom,IPR014720:dsRBD_dom,IPR033099:DSRM1_ILF3,IPR043519:NT_sf,IPR049401:DZF_dom_N,IPR049402:DZF_dom_C,				SM00358:DSRM,SM00572:DZF,	KW-0051~Antiviral defense,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,		KW-0238~DNA-binding,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:DRBM,DOMAIN:DRBM 1,DOMAIN:DRBM 2,DOMAIN:DZF,MOTIF:Bipartite nuclear localization signal,REGION:Disordered,REGION:Interaction with PRMT1,
ITSN2	intersectin 2(ITSN2)	Homo sapiens			GO:0006897~endocytosis,GO:0016197~endosomal transport,GO:0030154~cell differentiation,GO:1903861~positive regulation of dendrite extension,	GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0042734~presynaptic membrane,GO:0070062~extracellular exosome,GO:0097708~intracellular vesicle,	GO:0005085~guanyl-nucleotide exchange factor activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0060090~binding, bridging,	IPR000008:C2_dom,IPR000219:DH-domain,IPR000261:EH_dom,IPR001452:SH3_domain,IPR001849:PH_domain,IPR002048:EF_hand_dom,IPR011992:EF-hand-dom_pair,IPR011993:PH-like_dom_sf,IPR018247:EF_Hand_1_Ca_BS,IPR035737:Intersectin-2_SH3_1,IPR035738:Intersectin-2_SH3_2,IPR035739:Intersectin-2_SH3_3,IPR035740:Intersectin-2_SH3_4,IPR035741:Intersectin-2_SH3_5,IPR035892:C2_domain_sf,IPR035899:DBL_dom_sf,IPR036028:SH3-like_dom_sf,				SM00027:EH,SM00054:EFh,SM00233:PH,SM00239:C2,SM00325:RhoGEF,SM00326:SH3,	KW-0221~Differentiation,KW-0254~Endocytosis,KW-0945~Host-virus interaction,	KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0677~Repeat,KW-0728~SH3 domain,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:C2,DOMAIN:DH,DOMAIN:EF-hand,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,DOMAIN:EH,DOMAIN:EH 1,DOMAIN:EH 2,DOMAIN:PH,DOMAIN:SH3,DOMAIN:SH3 1,DOMAIN:SH3 2,DOMAIN:SH3 3,DOMAIN:SH3 4,DOMAIN:SH3 5,REGION:Disordered,
IFT20	intraflagellar transport 20(IFT20)	Homo sapiens			GO:0001736~establishment of planar polarity,GO:0001822~kidney development,GO:0007224~smoothened signaling pathway,GO:0007283~spermatogenesis,GO:0008542~visual learning,GO:0034067~protein localization to Golgi apparatus,GO:0035720~intraciliary anterograde transport,GO:0035845~photoreceptor cell outer segment organization,GO:0036372~opsin transport,GO:0042073~intraciliary transport,GO:0045198~establishment of epithelial cell apical/basal polarity,GO:0045724~positive regulation of cilium assembly,GO:0051642~centrosome localization,GO:0055007~cardiac muscle cell differentiation,GO:0060122~inner ear receptor stereocilium organization,GO:0060271~cilium assembly,GO:0060828~regulation of canonical Wnt signaling pathway,GO:0061351~neural precursor cell proliferation,GO:0061512~protein localization to cilium,GO:0072659~protein localization to plasma membrane,GO:0090102~cochlea development,GO:1902017~regulation of cilium assembly,GO:2000583~regulation of platelet-derived growth factor receptor-alpha signaling pathway,GO:2000785~regulation of autophagosome assembly,	GO:0000139~Golgi membrane,GO:0001669~acrosomal vesicle,GO:0001750~photoreceptor outer segment,GO:0002177~manchette,GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005801~cis-Golgi network,GO:0005813~centrosome,GO:0005814~centriole,GO:0005902~microvillus,GO:0005929~cilium,GO:0030992~intraciliary transport particle B,GO:0031514~motile cilium,GO:0032391~photoreceptor connecting cilium,GO:0032420~stereocilium,GO:0036064~ciliary basal body,GO:0044292~dendrite terminus,GO:0097542~ciliary tip,GO:0097546~ciliary base,GO:1902636~kinociliary basal body,	GO:0002046~opsin binding,GO:0005515~protein binding,GO:0031267~small GTPase binding,	IPR028172:FT20,					KW-0221~Differentiation,KW-0744~Spermatogenesis,KW-0970~Cilium biogenesis/degradation,	KW-0206~Cytoskeleton,KW-0282~Flagellum,KW-0333~Golgi apparatus,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-0968~Cytoplasmic vesicle,KW-0969~Cilium,		KW-0175~Coiled coil,				REGION:Disordered,REGION:IFT57-binding,
ISCA1	iron-sulfur cluster assembly 1(ISCA1)	Homo sapiens			GO:0016226~iron-sulfur cluster assembly,GO:0097428~protein maturation by iron-sulfur cluster transfer,	GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,	GO:0005515~protein binding,GO:0046872~metal ion binding,GO:0051536~iron-sulfur cluster binding,GO:0051537~2 iron, 2 sulfur cluster binding,	IPR000361:FeS_biogenesis,IPR016092:FeS_cluster_insertion,IPR017870:FeS_cluster_insertion_CS,IPR035903:HesB-like_dom_sf,		617613~Multiple mitochondrial dysfunctions syndrome 5,				KW-0496~Mitochondrion,	KW-0225~Disease variant,	KW-0809~Transit peptide,	KW-0408~Iron,KW-0411~Iron-sulfur,KW-0479~Metal-binding,			DOMAIN:FeS cluster biogenesis,TRANSIT:Mitochondrion,
ISCU	iron-sulfur cluster assembly enzyme(ISCU)	Homo sapiens			GO:0006879~cellular iron ion homeostasis,GO:0016226~iron-sulfur cluster assembly,GO:0044571~[2Fe-2S] cluster assembly,GO:0044572~[4Fe-4S] cluster assembly,GO:1902958~positive regulation of mitochondrial electron transport, NADH to ubiquinone,GO:1904234~positive regulation of aconitate hydratase activity,GO:1904439~negative regulation of ferrous iron import across plasma membrane,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0005829~cytosol,GO:0099128~mitochondrial iron-sulfur cluster assembly complex,GO:1990229~iron-sulfur cluster assembly complex,	GO:0005506~iron ion binding,GO:0005515~protein binding,GO:0008198~ferrous iron binding,GO:0008270~zinc ion binding,GO:0042803~protein homodimerization activity,GO:0051536~iron-sulfur cluster binding,GO:0051537~2 iron, 2 sulfur cluster binding,GO:0060090~binding, bridging,	IPR002871:NIF_FeS_clus_asmbl_NifU_N,IPR011339:ISCU,		255125~Myopathy with lactic acidosis, hereditary,				KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0809~Transit peptide,	KW-0408~Iron,KW-0479~Metal-binding,		KW-0597~Phosphoprotein,	ACT_SITE:Cysteine persulfide intermediate,DOMAIN:NIF system FeS cluster assembly NifU N-terminal,MUTAGEN:C->A: Does not affect ISC complex formation. Does not affect the unstimulated cysteine desulfurase activity in the absence of FXN. Does not affect the cysteine desulfurase activity in the presence of FXN. Slightly decreases the cysteine desulfurase activity in the presence of FXN; when associated with A-95. Does not affect iron based stimulation of the cysteine desulfurase activity in the presence of FXN. Does not affect iron based stimulation of the cysteine desulfurase activity in the presence of FXN; when associated with A-95. Loss of the [2Fe-2S] cluster formation.,MUTAGEN:C->A: Does not affect ISC complex formation. Does not affect the unstimulated cysteine desulfurase activity in the absence of FXN. Does not affect the cysteine desulfurase activity in the presence of FXN. Slightly decreases the cysteine desulfurase activity in the presence of FXN; when associated with A-95. Does not affect iron based stimulation of the cysteine desulfurase activity in the presence of FXN. Does not affect iron based stimulation of the cysteine desulfurase activity in the presence of FXN; when associated with A.69. Loss of the [2Fe-2S] cluster formation.,MUTAGEN:C->A: Does not affect ISC complex formation. Does not affect the unstimulated cysteine desulfurase activity in the absence of FXN. Loss of iron-based stimulation of the cysteine desulfurase activity in the presence of FXN. Loss of the [2Fe-2S] cluster formation.,MUTAGEN:C->S: Does not affect the cysteine desulfurase activity in the presence of FXN. Does not affect iron based stimulation of the cysteine desulfurase activity in the presence of FXN.,MUTAGEN:C->S: Does not affect the unstimulated cysteine desulfurase activity in the absence of FXN. Does not affect the cysteine desulfurase activity in the presence of FXN. Does not affect iron based stimulation of the cysteine desulfurase activity in the presence of FXN. Does not affect the [2Fe-2S] cluster assembly.,MUTAGEN:C->S: Loss of iron-based stimulation of the cysteine desulfurase activity in the presence of FXN.,MUTAGEN:C->S: Slightly decrease the cysteine desulfurase activity in the presence of FXN. Does not affect iron based stimulation of the cysteine desulfurase activity in the presence of FXN.,MUTAGEN:D->A: Stabilizes the D-state.,MUTAGEN:D->V: Stabilizes the S-state.,MUTAGEN:H->A: Stabilizes the D-state.,MUTAGEN:M->I: Does not affect the SDA complex formation. Abolishes desulfurase activity of SDA complex when zinc ion is bound. Activated by FXN when component of SDAU complex.,MUTAGEN:M->L: Does not affect the SDA complex formation. Abolishes desulfurase activity of SDA complex when zinc ion is bound. Activated by FXN when component of SDAU complex.,MUTAGEN:M->V: Does not affect the SDA complex formation. Abolishes desulfurase activity of SDA complex when zinc ion is bound. Activated by FXN when component of SDAU complex.,MUTAGEN:N->A: Stabilizes the S-state.,MUTAGEN:S->A: Loss of phosphorylation. Does not affect phosphorylation.,MUTAGEN:Y->A: Does not affect mitochondrial localization. Loss of iron-sulfur cluster biogenesis. Does not affect reductive cleavage of the ISCU2-bound-persulfide by FDX2.,SITE:Mediates ISCU dimerization and de novo [2Fe-2S] cluster assembly,TRANSIT:Mitochondrion,
ISOC1	isochorismatase domain containing 1(ISOC1)	Homo sapiens				GO:0005737~cytoplasm,GO:0005777~peroxisome,	GO:0005515~protein binding,	IPR000868:Isochorismatase-like,IPR036380:Isochorismatase-like_sf,											KW-0597~Phosphoprotein,	DOMAIN:Isochorismatase-like,
IDH3B	isocitrate dehydrogenase (NAD(+)) 3 non-catalytic subunit beta(IDH3B)	Homo sapiens			GO:0006099~tricarboxylic acid cycle,GO:0006102~isocitrate metabolic process,GO:0022900~electron transport chain,	GO:0005634~nucleus,GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0005962~mitochondrial isocitrate dehydrogenase complex (NAD+),	GO:0000287~magnesium ion binding,GO:0004449~isocitrate dehydrogenase (NAD+) activity,GO:0009055~electron carrier activity,GO:0016616~oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor,GO:0051287~NAD binding,	IPR004434:Isocitrate_DH_NAD,IPR019818:IsoCit/isopropylmalate_DH_CS,IPR024084:IsoPropMal-DH-like_dom,	hsa00020:Citrate cycle (TCA cycle),hsa01100:Metabolic pathways,hsa01200:Carbon metabolism,hsa01210:2-Oxocarboxylic acid metabolism,hsa01230:Biosynthesis of amino acids,	612572~Retinitis pigmentosa 46,		SM01329:Iso_dh,	KW-0816~Tricarboxylic acid cycle,	KW-0496~Mitochondrion,	KW-0225~Disease variant,KW-0682~Retinitis pigmentosa,	KW-0809~Transit peptide,			KW-0007~Acetylation,	DOMAIN:Isopropylmalate dehydrogenase-like,TRANSIT:Mitochondrion,
IDH3G	isocitrate dehydrogenase (NAD(+)) 3 non-catalytic subunit gamma(IDH3G)	Homo sapiens			GO:0005975~carbohydrate metabolic process,GO:0006099~tricarboxylic acid cycle,GO:0006102~isocitrate metabolic process,	GO:0005730~nucleolus,GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0005962~mitochondrial isocitrate dehydrogenase complex (NAD+),	GO:0000287~magnesium ion binding,GO:0004449~isocitrate dehydrogenase (NAD+) activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016616~oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor,GO:0051287~NAD binding,	IPR004434:Isocitrate_DH_NAD,IPR019818:IsoCit/isopropylmalate_DH_CS,IPR024084:IsoPropMal-DH-like_dom,	hsa00020:Citrate cycle (TCA cycle),hsa01100:Metabolic pathways,hsa01200:Carbon metabolism,hsa01210:2-Oxocarboxylic acid metabolism,hsa01230:Biosynthesis of amino acids,			SM01329:Iso_dh,	KW-0816~Tricarboxylic acid cycle,	KW-0496~Mitochondrion,		KW-0809~Transit peptide,	KW-0067~ATP-binding,KW-0460~Magnesium,KW-0464~Manganese,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,			DOMAIN:Isopropylmalate dehydrogenase-like,MUTAGEN:D->A: Significantly impairs the activation of the heterodimer composed of IDH3A and IDH3G subunits by citrate and ADP.,MUTAGEN:E->A: No effect on the activation of the heterodimer composed of IDH3A and IDH3G subunits by citrate and ADP.,MUTAGEN:K->A: Complete loss of the activation of the heterotetramer and the heterodimer composed of IDH3A and IDH3G subunits by citrate and ADP.,MUTAGEN:K->A: No significant effect on the activation of the heterodimer composed of IDH3A and IDH3G subunits by ADP.,MUTAGEN:N->A: Complete loss of the activation of the heterodimer composed of IDH3A and IDH3G subunits by ADP.,MUTAGEN:N->A: No effect on the activation of the heterodimer composed of IDH3A and IDH3G subunits by citrate.,MUTAGEN:N->A: Significantly impairs the activation of the heterodimer composed of IDH3A and IDH3G subunits by ADP.,MUTAGEN:N->A: Significantly impairs the activation of the heterodimer composed of IDH3A and IDH3G subunits by citrate.,MUTAGEN:R->A: Significantly impairs the activation of the heterodimer composed of IDH3A and IDH3G subunits by citrate.,MUTAGEN:S->A: No significant effect on the activation of the heterodimer composed of IDH3A and IDH3G subunits by citrate.,MUTAGEN:T->A: Significantly impairs the activation of the heterodimer composed of IDH3A and IDH3G subunits by ADP.,MUTAGEN:T->A: Significantly impairs the activation of the heterodimer composed of IDH3A and IDH3G subunits by citrate.,MUTAGEN:Y->F: Significantly impairs the activation of the heterodimer composed of IDH3A and IDH3G subunits by citrate and ADP.,MUTAGEN:Y->F: Significantly impairs the activation of the heterodimer composed of IDH3A and IDH3G subunits by citrate.,TRANSIT:Mitochondrion,
IDI1	isopentenyl-diphosphate delta isomerase 1(IDI1)	Homo sapiens			GO:0006695~cholesterol biosynthetic process,GO:0008299~isoprenoid biosynthetic process,GO:0009240~isopentenyl diphosphate biosynthetic process,GO:0050992~dimethylallyl diphosphate biosynthetic process,	GO:0005737~cytoplasm,GO:0005777~peroxisome,GO:0005829~cytosol,	GO:0000287~magnesium ion binding,GO:0004452~isopentenyl-diphosphate delta-isomerase activity,GO:0030145~manganese ion binding,GO:0046872~metal ion binding,	IPR000086:NUDIX_hydrolase_dom,IPR011876:IsopentenylPP_isomerase_typ1,IPR015797:NUDIX_hydrolase-like_dom_sf,	hsa00900:Terpenoid backbone biosynthesis,hsa01100:Metabolic pathways,		PIRSF018427:Isopntndiph_ism,		KW-0152~Cholesterol biosynthesis,KW-0153~Cholesterol metabolism,KW-0414~Isoprene biosynthesis,KW-0443~Lipid metabolism,KW-0444~Lipid biosynthesis,KW-0752~Steroid biosynthesis,KW-0753~Steroid metabolism,KW-0756~Sterol biosynthesis,KW-1207~Sterol metabolism,	KW-0576~Peroxisome,			KW-0460~Magnesium,KW-0479~Metal-binding,	KW-0413~Isomerase,	KW-0007~Acetylation,	DOMAIN:Nudix hydrolase,MOTIF:Microbody targeting signal,
JAGN1	jagunal homolog 1(JAGN1)	Homo sapiens			GO:0002446~neutrophil mediated immunity,GO:0006887~exocytosis,GO:0007029~endoplasmic reticulum organization,GO:0015031~protein transport,GO:0016192~vesicle-mediated transport,GO:0030223~neutrophil differentiation,GO:0038158~granulocyte colony-stimulating factor signaling pathway,GO:0050832~defense response to fungus,GO:0061179~negative regulation of insulin secretion involved in cellular response to glucose stimulus,GO:1990266~neutrophil migration,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,	GO:0005515~protein binding,	IPR009787:Jagunal,		616022~Neutropenia, severe congenital, 6, autosomal recessive,			KW-0391~Immunity,KW-0653~Protein transport,KW-0813~Transport,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,	KW-0225~Disease variant,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,	TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
JARID2	jumonji and AT-rich interaction domain containing 2(JARID2)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001889~liver development,GO:0006338~chromatin remodeling,GO:0007417~central nervous system development,GO:0010468~regulation of gene expression,GO:0010614~negative regulation of cardiac muscle hypertrophy,GO:0048536~spleen development,GO:0048538~thymus development,GO:0048863~stem cell differentiation,GO:0060038~cardiac muscle cell proliferation,GO:0060044~negative regulation of cardiac muscle cell proliferation,GO:0060816~random inactivation of X chromosome,GO:1902682~protein localization to nuclear pericentric heterochromatin,GO:1990830~cellular response to leukemia inhibitory factor,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005739~mitochondrion,GO:0035097~histone methyltransferase complex,GO:0035098~ESC/E(Z) complex,	GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0043130~ubiquitin binding,GO:0046976~histone methyltransferase activity (H3-K27 specific),GO:0061649~ubiquitinated histone binding,	IPR001606:ARID_dom,IPR003347:JmjC_dom,IPR003349:JmjN,IPR004198:Znf_C5HC2,IPR036431:ARID_dom_sf,	hsa03083:Polycomb repressive complex,hsa04550:Signaling pathways regulating pluripotency of stem cells,	620098~Developmental delay with variable intellectual disability and dysmorphic facies,		SM00501:BRIGHT,SM00545:JmjN,SM00558:JmjC,SM01014:ARID,	KW-0221~Differentiation,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0991~Intellectual disability,			KW-0156~Chromatin regulator,KW-0217~Developmental protein,KW-0678~Repressor,KW-9996~Developmental protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:ARID,DOMAIN:JmjC,DOMAIN:JmjN,MOTIF:GSGFP motif,MOTIF:Nuclear localization signal,MUTAGEN:KPK->EPE,APA: Abolishes nucleosome binding activity of a minimal SUZ12-RBBP4-AEBP2-JARID2 PRC2 complex.,MUTAGEN:KR->DE,AA: Abolishes nucleosome binding activity of a minimal SUZ12-RBBP4-AEBP2-JARID2 PRC2 complex.,REGION:Disordered,REGION:Sufficient for interaction with the PRC2 complex,
JMJD1C	jumonji domain containing 1C(JMJD1C)	Homo sapiens			GO:0006338~chromatin remodeling,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007596~blood coagulation,	GO:0000118~histone deacetylase complex,GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,	GO:0003712~transcription cofactor activity,GO:0005515~protein binding,GO:0031490~chromatin DNA binding,GO:0032454~histone demethylase activity (H3-K9 specific),GO:0046872~metal ion binding,GO:0046966~thyroid hormone receptor binding,GO:0051213~dioxygenase activity,	IPR003347:JmjC_dom,IPR045109:JHDM2-like,	hsa05202:Transcriptional misregulation in cancer,			SM00558:JmjC,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0863~Zinc-finger,	KW-0408~Iron,KW-0479~Metal-binding,KW-0862~Zinc,	KW-0156~Chromatin regulator,KW-0223~Dioxygenase,KW-0560~Oxidoreductase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:JmjC,MOTIF:LXXLL motif,REGION:Disordered,ZN_FING:C6-type,
JMJD6	jumonji domain containing 6, arginine demethylase and lysine hydroxylase(JMJD6)	Homo sapiens			GO:0001822~kidney development,GO:0002040~sprouting angiogenesis,GO:0006338~chromatin remodeling,GO:0006397~mRNA processing,GO:0006909~phagocytosis,GO:0007166~cell surface receptor signaling pathway,GO:0007507~heart development,GO:0008380~RNA splicing,GO:0018395~peptidyl-lysine hydroxylation to 5-hydroxy-L-lysine,GO:0030324~lung development,GO:0032259~methylation,GO:0032463~negative regulation of protein homooligomerization,GO:0033077~T cell differentiation in thymus,GO:0035513~oxidative RNA demethylation,GO:0042116~macrophage activation,GO:0043654~recognition of apoptotic cell,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048024~regulation of mRNA splicing, via spliceosome,GO:0048821~erythrocyte development,GO:0051260~protein homooligomerization,GO:0060041~retina development in camera-type eye,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003727~single-stranded RNA binding,GO:0005506~iron ion binding,GO:0005515~protein binding,GO:0008168~methyltransferase activity,GO:0032452~histone demethylase activity,GO:0033746~histone demethylase activity (H3-R2 specific),GO:0033749~histone demethylase activity (H4-R3 specific),GO:0035515~oxidative RNA demethylase activity,GO:0038023~signaling receptor activity,GO:0042802~identical protein binding,GO:0070815~peptidyl-lysine 5-dioxygenase activity,	IPR003347:JmjC_dom,				SM00558:JmjC,	KW-0221~Differentiation,KW-0507~mRNA processing,KW-0508~mRNA splicing,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0408~Iron,KW-0479~Metal-binding,	KW-0156~Chromatin regulator,KW-0217~Developmental protein,KW-0223~Dioxygenase,KW-0489~Methyltransferase,KW-0560~Oxidoreductase,KW-0675~Receptor,KW-0694~RNA-binding,KW-0808~Transferase,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:JmjC,MOTIF:Nuclear localization signal 1,MOTIF:Nuclear localization signal 2,MOTIF:Nuclear localization signal 3,MOTIF:Nuclear localization signal 4,MOTIF:Nuclear localization signal 5,MUTAGEN:D->A: Loss of arginine demethylase and a lysyl-hydroxylase activities; when associated with A-187 and A-273.,MUTAGEN:E->A: Impairs both hydroxylation activity and 2-oxoglutarate turnover assays.,MUTAGEN:H->A: Loss of arginine demethylase and a lysyl-hydroxylase activities; when associated with A-187 and A-189.,MUTAGEN:H->A: Loss of histone arginine demethylase and lysyl-hydroxylase activities. Abolishes homooligomerisation. Loss of arginine demethylase and a lysyl-hydroxylase activities; when associated with A-189 and A-273.,MUTAGEN:K->A: Impairs enzyme activity without affecting 2-oxoglutarate-binding.,MUTAGEN:K->A: Nearly abolishes the interaction with the NET domain of BRD4.,MUTAGEN:L->A: Nearly abolishes the interaction with the NET domain of BRD4.,MUTAGEN:N->A: Impairs enzyme activity.,MUTAGEN:R->A: Nearly abolishes the interaction with the NET domain of BRD4.,MUTAGEN:T->A: Impairs enzyme activity and 2-oxoglutarate-binding.,MUTAGEN:W->A: Decreases interaction with the NET domain of BRD4.,MUTAGEN:Y->F: Abolishes 2-oxoglutarate-binding and enzyme activity.,REGION:Disordered,
JTB	jumping translocation breakpoint(JTB)	Homo sapiens			GO:0000278~mitotic cell cycle,GO:0000281~mitotic cytokinesis,GO:0008637~apoptotic mitochondrial changes,GO:0042127~regulation of cell proliferation,GO:0045860~positive regulation of protein kinase activity,	GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005813~centrosome,GO:0005819~spindle,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0030496~midbody,	GO:0019901~protein kinase binding,	IPR008657:JTB,					KW-0053~Apoptosis,KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0496~Mitochondrion,KW-0963~Cytoplasm,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,				TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
JAML	junction adhesion molecule like(JAML)	Homo sapiens			GO:0007157~heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules,GO:0030593~neutrophil chemotaxis,GO:0035696~monocyte extravasation,GO:0046629~gamma-delta T cell activation,GO:0060054~positive regulation of epithelial cell proliferation involved in wound healing,GO:0072672~neutrophil extravasation,	GO:0005654~nucleoplasm,GO:0005886~plasma membrane,GO:0005923~bicellular tight junction,GO:0016020~membrane,	GO:0005178~integrin binding,GO:0042803~protein homodimerization activity,GO:0050839~cell adhesion molecule binding,	IPR000920:Myelin_P0-rel,IPR003599:Ig_sub,IPR007110:Ig-like_dom,IPR013106:Ig_V-set,IPR013783:Ig-like_fold,IPR036179:Ig-like_dom_sf,				SM00409:IG,	KW-0130~Cell adhesion,KW-0391~Immunity,	KW-0472~Membrane,KW-0965~Cell junction,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like,DOMAIN:Ig-like V-type 1,DOMAIN:Ig-like V-type 2,DOMAIN:Immunoglobulin V-set,MUTAGEN:K->E: Loss of the ability to homodimerize, loss of interaction with CXADR and loss of function in cell-cell adhesion.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
KPNA1	karyopherin subunit alpha 1(KPNA1)	Homo sapiens			GO:0000018~regulation of DNA recombination,GO:0006606~protein import into nucleus,GO:0006607~NLS-bearing protein import into nucleus,GO:0014841~skeletal muscle satellite cell proliferation,GO:0014901~satellite cell activation involved in skeletal muscle regeneration,GO:0042981~regulation of apoptotic process,GO:0060828~regulation of canonical Wnt signaling pathway,GO:0099527~postsynapse to nucleus signaling pathway,	GO:0005634~nucleus,GO:0005643~nuclear pore,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0014069~postsynaptic density,GO:0030425~dendrite,GO:0042564~NLS-dependent protein nuclear import complex,GO:0098978~glutamatergic synapse,	GO:0005515~protein binding,GO:0008139~nuclear localization sequence binding,GO:0061608~nuclear import signal receptor activity,	IPR000225:Armadillo,IPR002652:Importin-a_IBB,IPR011989:ARM-like,IPR016024:ARM-type_fold,IPR024931:Importin_alpha,IPR032413:Arm_3,IPR036975:Importin-a_IBB_sf,	hsa03013:Nucleocytoplasmic transport,hsa05132:Salmonella infection,hsa05164:Influenza A,hsa05207:Chemical carcinogenesis - receptor activation,		PIRSF005673:Importin_alpha,	SM00185:ARM,	KW-0653~Protein transport,KW-0813~Transport,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0732~Signal,			KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Basic and acidic residues,DOMAIN:IBB,MOTIF:Nuclear localization signal,REGION:Binding to RAG1,REGION:Disordered,REGION:NLS binding site (major),REGION:NLS binding site (minor),REPEAT:ARM,REPEAT:ARM 10; atypical,REPEAT:ARM 1; truncated,REPEAT:ARM 2,REPEAT:ARM 3,REPEAT:ARM 4,REPEAT:ARM 5,REPEAT:ARM 6,REPEAT:ARM 7,REPEAT:ARM 8,REPEAT:ARM 9,
KPNA4	karyopherin subunit alpha 4(KPNA4)	Homo sapiens			GO:0006606~protein import into nucleus,GO:0006607~NLS-bearing protein import into nucleus,GO:0010467~gene expression,GO:0014046~dopamine secretion,	GO:0005634~nucleus,GO:0005643~nuclear pore,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016020~membrane,GO:0031965~nuclear membrane,GO:0042564~NLS-dependent protein nuclear import complex,	GO:0005515~protein binding,GO:0008139~nuclear localization sequence binding,GO:0061608~nuclear import signal receptor activity,	IPR000225:Armadillo,IPR002652:Importin-a_IBB,IPR011989:ARM-like,IPR016024:ARM-type_fold,IPR024931:Importin_alpha,IPR032413:Arm_3,IPR036975:Importin-a_IBB_sf,	hsa03013:Nucleocytoplasmic transport,hsa05132:Salmonella infection,hsa05207:Chemical carcinogenesis - receptor activation,		PIRSF005673:Importin_alpha,	SM00185:ARM,	KW-0653~Protein transport,KW-0813~Transport,KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:IBB,MOTIF:Nuclear localization signal,REGION:Disordered,REGION:NLS binding site (major),REGION:NLS binding site (minor),REPEAT:ARM,REPEAT:ARM 10; atypical,REPEAT:ARM 1; truncated,REPEAT:ARM 2,REPEAT:ARM 3,REPEAT:ARM 4,REPEAT:ARM 5,REPEAT:ARM 6,REPEAT:ARM 7,REPEAT:ARM 8,REPEAT:ARM 9,TRANSMEM:Helical,
KPNB1	karyopherin subunit beta 1(KPNB1)	Homo sapiens		h_npcPathway:Mechanism of Protein Import into the Nucleus,h_ranMSPathway:Role of Ran in mitotic spindle regulation,	GO:0006404~RNA import into nucleus,GO:0006606~protein import into nucleus,GO:0006607~NLS-bearing protein import into nucleus,GO:0006610~ribosomal protein import into nucleus,GO:0007079~mitotic chromosome movement towards spindle pole,GO:0007080~mitotic metaphase plate congression,GO:0030953~astral microtubule organization,GO:0031291~Ran protein signal transduction,GO:0040001~establishment of mitotic spindle localization,GO:0045184~establishment of protein localization,GO:0090307~mitotic spindle assembly,	GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005635~nuclear envelope,GO:0005643~nuclear pore,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0010494~cytoplasmic stress granule,GO:0016020~membrane,GO:0031965~nuclear membrane,GO:0035580~specific granule lumen,GO:0042564~NLS-dependent protein nuclear import complex,GO:0070062~extracellular exosome,GO:0071782~endoplasmic reticulum tubular network,GO:1904813~ficolin-1-rich granule lumen,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0008139~nuclear localization sequence binding,GO:0008270~zinc ion binding,GO:0019899~enzyme binding,GO:0019904~protein domain specific binding,GO:0031267~small GTPase binding,GO:0051879~Hsp90 protein binding,GO:0061608~nuclear import signal receptor activity,GO:0061676~importin-alpha family protein binding,	IPR000225:Armadillo,IPR001494:Importin-beta_N,IPR011989:ARM-like,IPR016024:ARM-type_fold,IPR021133:HEAT_type_2,IPR040122:Importin_beta,	hsa03013:Nucleocytoplasmic transport,hsa05207:Chemical carcinogenesis - receptor activation,			SM00185:ARM,SM00913:IBN_N,	KW-0653~Protein transport,KW-0813~Transport,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,			KW-0007~Acetylation,KW-0013~ADP-ribosylation,KW-0597~Phosphoprotein,	DOMAIN:Importin N-terminal,MUTAGEN:I->A: Largely reduced binding to FxFG repeats and reduced nuclear import.,MUTAGEN:I->F,D: Loss of binding to FxFG repeats and reduced nuclear import.,REGION:Disordered,REGION:Essential for high affinity interaction with RPL23A,REGION:IAB-binding,REGION:Ran-GTP binding,REPEAT:HEAT,REPEAT:HEAT 1,REPEAT:HEAT 10,REPEAT:HEAT 11,REPEAT:HEAT 12,REPEAT:HEAT 13,REPEAT:HEAT 14,REPEAT:HEAT 15,REPEAT:HEAT 16,REPEAT:HEAT 17,REPEAT:HEAT 18,REPEAT:HEAT 19,REPEAT:HEAT 2,REPEAT:HEAT 3,REPEAT:HEAT 4,REPEAT:HEAT 5,REPEAT:HEAT 6,REPEAT:HEAT 7,REPEAT:HEAT 8,REPEAT:HEAT 9,
KLHDC3	kelch domain containing 3(KLHDC3)	Homo sapiens			GO:0007131~reciprocal meiotic recombination,GO:0016567~protein ubiquitination,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,	GO:0000785~chromatin,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0031462~Cul2-RING ubiquitin ligase complex,	GO:0003682~chromatin binding,GO:0005515~protein binding,GO:1990756~protein binding, bridging involved in substrate recognition for ubiquitination,	IPR006652:Kelch_1,IPR011498:Kelch_2,IPR015915:Kelch-typ_b-propeller,					KW-0469~Meiosis,KW-0833~Ubl conjugation pathway,	KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0880~Kelch repeat,				REPEAT:Kelch 1,REPEAT:Kelch 2,REPEAT:Kelch 3,REPEAT:Kelch 4,REPEAT:Kelch 5,
KEAP1	kelch like ECH associated protein 1(KEAP1)	Homo sapiens		h_arenrf2Pathway:Oxidative Stress Induced Gene Expression Via Nrf2,	GO:0001701~in utero embryonic development,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0010506~regulation of autophagy,GO:0016567~protein ubiquitination,GO:0032436~positive regulation of proteasomal ubiquitin-dependent protein catabolic process,GO:0034599~cellular response to oxidative stress,GO:0043433~negative regulation of sequence-specific DNA binding transcription factor activity,GO:0045604~regulation of epidermal cell differentiation,GO:0071353~cellular response to interleukin-4,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0005884~actin filament,GO:0016234~inclusion body,GO:0030496~midbody,GO:0031463~Cul3-RING ubiquitin ligase complex,GO:0034451~centriolar satellite,	GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:0042802~identical protein binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:0097718~disordered domain specific binding,GO:1990756~protein binding, bridging involved in substrate recognition for ubiquitination,	IPR000210:BTB/POZ_dom,IPR006652:Kelch_1,IPR011333:SKP1/BTB/POZ_sf,IPR011705:BACK,IPR015915:Kelch-typ_b-propeller,IPR017096:BTB-kelch_protein,IPR030563:KEAP1_BTB_POZ_dom,IPR045887:SAGL1-like,IPR047098:KEAP1_BACK,	hsa04120:Ubiquitin mediated proteolysis,hsa05012:Parkinson disease,hsa05200:Pathways in cancer,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05225:Hepatocellular carcinoma,hsa05418:Fluid shear stress and atherosclerosis,		PIRSF037037:Kelch-like_protein_gigaxonin,	SM00225:BTB,SM00612:Kelch,SM00875:BACK,	KW-0833~Ubl conjugation pathway,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0880~Kelch repeat,			KW-0702~S-nitrosylation,KW-0832~Ubl conjugation,	COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,CROSSLNK:N5-[4-(S-L-cysteinyl)-5-methyl-1H-imidazol-2-yl]-L-ornithine (Arg-Cys) (interchain with C-151 in KEAP1),CROSSLNK:N5-[4-(S-L-cysteinyl)-5-methyl-1H-imidazol-2-yl]-L-ornithine (Cys-Arg) (interchain with R-135 in KEAP1),DOMAIN:BACK,DOMAIN:BTB,MUTAGEN:C->S,N,D,L: Substitution with a small side chain that prevents covalent modification by an electrophile; promotes constitutive ubiquitination of NFE2L2/NRF2 and subsequent repression of phase 2 detoxifying enzymes. Resistance of ubiquitination of PGAM5 to inhibition by oxidative stress and sulforaphane. Impaired interaction with CUL3. Reduced formation of a high-molecular mass KEAP1 molecule when methylglyoxal accumulates.,MUTAGEN:C->S: Abolishes repression of NFE2L2/NRF2-dependent gene expression. Slows down degradation of NFE2L2/NRF2.,MUTAGEN:C->W,Y: Substitution with a bulky side chain that mimicks covalent modification by an electrophile; prevents ubiquitination and degradation of NFE2L2/NRF2, leading to constitutive activation of NFE2L2/NRF2 and subsequent expression of phase 2 detoxifying enzymes.,MUTAGEN:F->A: Abolishes repression of NFE2L2/NRF2-dependent gene expression.,MUTAGEN:H->A: Loss of interaction with NFE2L2/NRF2. Abolishes repression of NFE2L2/NRF2-dependent gene expression. Does not affect interaction with SQSTM1/p62.,MUTAGEN:IEG->AAA: Increases ubiquitination and proteolytic degradation.,MUTAGEN:L->A: Loss of export from nucleus; when associated with A-308.,MUTAGEN:L->A: Loss of export from nucleus; when associated with A-310.,MUTAGEN:MY->AA: Abolished interaction with NFE2L2/NRF2; when associated with 123-A--A-127.,MUTAGEN:N->A: Loss of interaction with NFE2L2/NRF2. Strongly reduces repression of NFE2L2/NRF2-dependent gene expression. Impaired interaction with SQSTM1/p62.,MUTAGEN:R->A: Loss of interaction with NFE2L2/NRF2. Abolishes repression of NFE2L2/NRF2-dependent gene expression. Impaired interaction with SQSTM1/p62.,MUTAGEN:R->A: Loss of interaction with NFE2L2/NRF2. Abolishes repression of NFE2L2/NRF2-dependent gene expression. Loss of interaction with PGAM5. Does not affect interaction with SQSTM1/p62.,MUTAGEN:R->A: Reduced formation of a high-molecular mass KEAP1 molecule when methylglyoxal accumulates.,MUTAGEN:VSIEG->ASAEA: Abolished interaction with NFE2L2/NRF2; when associated with 161-A-A-162.,MUTAGEN:Y->A: Loss of interaction with NFE2L2/NRF2. Strongly reduces repression of NFE2L2/NRF2-dependent gene expression. Abolishes interaction with SQSTM1/p62.,MUTAGEN:Y->A: Loss of interaction with NFE2L2/NRF2. Strongly reduces repression of NFE2L2/NRF2-dependent gene expression. Loss of interaction with PGAM5.,MUTAGEN:Y->A: Loss of interaction with NFE2L2/NRF2. Strongly reduces repression of NFE2L2/NRF2-dependent gene expression. Loss of interaction with PGAM5. Abolishes interaction with SQSTM1/p62.,MUTAGEN:YQI->AAA: Increases ubiquitination and proteolytic degradation.,REGION:Disordered,REPEAT:Kelch 1,REPEAT:Kelch 2,REPEAT:Kelch 3,REPEAT:Kelch 4,REPEAT:Kelch 5,REPEAT:Kelch 6,SITE:Sensor for electrophilic agents,
KLHL28	kelch like family member 28(KLHL28)	Homo sapiens						IPR000210:BTB/POZ_dom,IPR006652:Kelch_1,IPR011043:Gal_Oxase/kelch_b-propeller,IPR011333:SKP1/BTB/POZ_sf,IPR011705:BACK,IPR015915:Kelch-typ_b-propeller,IPR017096:BTB-kelch_protein,			PIRSF037037:Kelch-like_protein_gigaxonin,	SM00225:BTB,SM00612:Kelch,SM00875:BACK,				KW-0677~Repeat,KW-0880~Kelch repeat,				DOMAIN:BTB,REPEAT:Kelch 1,REPEAT:Kelch 2,REPEAT:Kelch 3,REPEAT:Kelch 4,REPEAT:Kelch 5,REPEAT:Kelch 6,
KRTCAP2	keratinocyte associated protein 2(KRTCAP2)	Homo sapiens			GO:0006487~protein N-linked glycosylation,GO:0042543~protein N-linked glycosylation via arginine,	GO:0008250~oligosaccharyltransferase complex,GO:0016020~membrane,	GO:0008047~enzyme activator activity,	IPR018614:KRTCAP2,						KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,	MOTIF:Prevents secretion from ER,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
KIF22	kinesin family member 22(KIF22)	Homo sapiens			GO:0000278~mitotic cell cycle,GO:0006281~DNA repair,GO:0007018~microtubule-based movement,GO:0007062~sister chromatid cohesion,GO:0007080~mitotic metaphase plate congression,GO:0051310~metaphase plate congression,	GO:0000776~kinetochore,GO:0000785~chromatin,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005871~kinesin complex,GO:0005874~microtubule,GO:0016607~nuclear speck,GO:0072686~mitotic spindle,	GO:0003677~DNA binding,GO:0003777~microtubule motor activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008017~microtubule binding,GO:0016887~ATPase activity,	IPR001752:Kinesin_motor_dom,IPR003583:Hlx-hairpin-Hlx_DNA-bd_motif,IPR010994:RuvA_2-like,IPR019821:Kinesin_motor_CS,IPR027417:P-loop_NTPase,IPR027640:Kinesin-like_fam,IPR036961:Kinesin_motor_dom_sf,IPR047149:KIF11-like,	hsa04814:Motor proteins,hsa04914:Progesterone-mediated oocyte maturation,	603546~Spondyloepimetaphyseal dysplasia with joint laxity, type 2,		SM00129:KISc,SM00278:HhH1,		KW-0206~Cytoskeleton,KW-0493~Microtubule,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0242~Dwarfism,	KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0238~DNA-binding,KW-0505~Motor protein,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Kinesin motor,REGION:Disordered,
KIF2A	kinesin family member 2A(KIF2A)	Homo sapiens	28.KLFs_cytoplas_dynein_cargo_nerve_axons,30.Kinesin_superfamily_proteins,		GO:0000226~microtubule cytoskeleton organization,GO:0007018~microtubule-based movement,GO:0007019~microtubule depolymerization,GO:0007052~mitotic spindle organization,GO:0007399~nervous system development,GO:0030154~cell differentiation,GO:0030334~regulation of cell migration,GO:0051301~cell division,GO:0090307~mitotic spindle assembly,	GO:0000922~spindle pole,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005814~centriole,GO:0005819~spindle,GO:0005829~cytosol,GO:0005871~kinesin complex,GO:0005874~microtubule,GO:0005876~spindle microtubule,GO:0016020~membrane,GO:0016604~nuclear body,	GO:0003774~motor activity,GO:0003777~microtubule motor activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008017~microtubule binding,GO:0016887~ATPase activity,	IPR001752:Kinesin_motor_dom,IPR019821:Kinesin_motor_CS,IPR027417:P-loop_NTPase,IPR027640:Kinesin-like_fam,IPR036961:Kinesin_motor_dom_sf,	hsa04814:Motor proteins,	615411~Cortical dysplasia, complex, with other brain malformations 3,		SM00129:KISc,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0221~Differentiation,KW-0498~Mitosis,KW-0524~Neurogenesis,	KW-0206~Cytoskeleton,KW-0493~Microtubule,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0451~Lissencephaly,	KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0217~Developmental protein,KW-0505~Motor protein,KW-9996~Developmental protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Kinesin motor,REGION:Disordered,REGION:Globular,
KIF5B	kinesin family member 5B(KIF5B)	Homo sapiens			GO:0007018~microtubule-based movement,GO:0007028~cytoplasm organization,GO:0007411~axon guidance,GO:0032230~positive regulation of synaptic transmission, GABAergic,GO:0032418~lysosome localization,GO:0035617~stress granule disassembly,GO:0042267~natural killer cell mediated cytotoxicity,GO:0042391~regulation of membrane potential,GO:0043268~positive regulation of potassium ion transport,GO:0047496~vesicle transport along microtubule,GO:0047497~mitochondrion transport along microtubule,GO:0048489~synaptic vesicle transport,GO:0051642~centrosome localization,GO:0071346~cellular response to interferon-gamma,GO:0072383~plus-end-directed vesicle transport along microtubule,GO:0098971~anterograde dendritic transport of neurotransmitter receptor complex,GO:0099641~anterograde axonal protein transport,GO:1903078~positive regulation of protein localization to plasma membrane,GO:1990048~anterograde neuronal dense core vesicle transport,GO:1990049~retrograde neuronal dense core vesicle transport,	GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0005871~kinesin complex,GO:0005874~microtubule,GO:0016020~membrane,GO:0031982~vesicle,GO:0032839~dendrite cytoplasm,GO:0034451~centriolar satellite,GO:0035253~ciliary rootlet,GO:0043005~neuron projection,GO:0045335~phagocytic vesicle,GO:0048471~perinuclear region of cytoplasm,GO:0101004~cytolytic granule membrane,GO:1904115~axon cytoplasm,	GO:0003777~microtubule motor activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008017~microtubule binding,GO:0008574~ATP-dependent microtubule motor activity, plus-end-directed,GO:0016887~ATPase activity,GO:0042802~identical protein binding,GO:0044877~macromolecular complex binding,GO:0045296~cadherin binding,	IPR001752:Kinesin_motor_dom,IPR019821:Kinesin_motor_CS,IPR027417:P-loop_NTPase,IPR027640:Kinesin-like_fam,IPR036961:Kinesin_motor_dom_sf,	hsa04144:Endocytosis,hsa04728:Dopaminergic synapse,hsa04814:Motor proteins,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05132:Salmonella infection,hsa05223:Non-small cell lung cancer,			SM00129:KISc,		KW-0206~Cytoskeleton,KW-0458~Lysosome,KW-0472~Membrane,KW-0493~Microtubule,KW-0963~Cytoplasm,		KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0505~Motor protein,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Kinesin motor,REGION:Disordered,REGION:Globular,
LDHB	lactate dehydrogenase B(LDHB)	Homo sapiens		h_SARSpathway:SARS Coronavirus Protease,	GO:0006089~lactate metabolic process,GO:0006090~pyruvate metabolic process,GO:0019674~NAD metabolic process,GO:0019752~carboxylic acid metabolic process,	GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005829~cytosol,GO:0016020~membrane,GO:0045121~membrane raft,GO:0070062~extracellular exosome,GO:1990204~oxidoreductase complex,	GO:0004459~L-lactate dehydrogenase activity,GO:0005515~protein binding,GO:0016616~oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor,GO:0019900~kinase binding,GO:0042802~identical protein binding,GO:0051287~NAD binding,	IPR001236:Lactate/malate_DH_N,IPR001557:L-lactate/malate_DH,IPR011304:L-lactate_DH,IPR015955:Lactate_DH/Glyco_Ohase_4_C,IPR018177:L-lactate_DH_AS,IPR022383:Lactate/malate_DH_C,IPR036291:NAD(P)-bd_dom_sf,	hsa00010:Glycolysis / Gluconeogenesis,hsa00270:Cysteine and methionine metabolism,hsa00620:Pyruvate metabolism,hsa00640:Propanoate metabolism,hsa01100:Metabolic pathways,hsa04066:HIF-1 signaling pathway,hsa04922:Glucagon signaling pathway,hsa05230:Central carbon metabolism in cancer,	614128~Lactate dehydrogenase-B deficiency,	PIRSF000102:Lac_mal_DH,			KW-0472~Membrane,KW-0496~Mitochondrion,KW-0963~Cytoplasm,KW-0999~Mitochondrion inner membrane,	KW-0225~Disease variant,		KW-0520~NAD,	KW-0560~Oxidoreductase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,DOMAIN:Lactate/malate dehydrogenase C-terminal,DOMAIN:Lactate/malate dehydrogenase N-terminal,MUTAGEN:D->A: Abolishes interaction with MP31.,MUTAGEN:R->A: Abolishes interaction with MP31.,
LBR	lamin B receptor(LBR)	Homo sapiens			GO:0006695~cholesterol biosynthetic process,GO:0030223~neutrophil differentiation,	GO:0005634~nucleus,GO:0005635~nuclear envelope,GO:0005637~nuclear inner membrane,GO:0005737~cytoplasm,GO:0005789~endoplasmic reticulum membrane,GO:0016020~membrane,GO:0031965~nuclear membrane,	GO:0003677~DNA binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0005521~lamin binding,GO:0050613~delta14-sterol reductase activity,GO:0070087~chromo shadow domain binding,GO:0070402~NADPH binding,	IPR001171:ERG24_DHCR-like,IPR002999:Tudor,IPR018083:Sterol_reductase_CS,IPR019023:Lamin-B_rcpt_of_tudor,	hsa00100:Steroid biosynthesis,hsa01100:Metabolic pathways,	169400~Pelger-Huet anomaly,215140~Greenberg skeletal dysplasia,613471~Reynolds syndrome,618019~Rhizomelic skeletal dysplasia with or without Pelger-Huet anomaly,		SM00333:TUDOR,	KW-0152~Cholesterol biosynthesis,KW-0153~Cholesterol metabolism,KW-0443~Lipid metabolism,KW-0444~Lipid biosynthesis,KW-0752~Steroid biosynthesis,KW-0753~Steroid metabolism,KW-0756~Sterol biosynthesis,KW-1207~Sterol metabolism,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0242~Dwarfism,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0238~DNA-binding,KW-0560~Oxidoreductase,KW-0675~Receptor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,DOMAIN:Lamin-B receptor of TUDOR,DOMAIN:Tudor,REGION:Disordered,TOPO_DOM:Nuclear,TRANSMEM:Helical,
LMNB1	lamin B1(LMNB1)	Homo sapiens		h_caspasePathway:Caspase Cascade in Apoptosis,h_fasPathway:FAS signaling pathway ( CD95 ),h_hivnefPathway:HIV-I Nef: negative effector of Fas and TNF,h_tnfr1Pathway:TNFR1 Signaling Pathway,	GO:0006998~nuclear envelope organization,GO:0007010~cytoskeleton organization,GO:0007097~nuclear migration,GO:0031507~heterochromatin assembly,GO:0051664~nuclear pore localization,GO:0090435~protein localization to nuclear envelope,	GO:0005634~nucleus,GO:0005635~nuclear envelope,GO:0005637~nuclear inner membrane,GO:0005638~lamin filament,GO:0005652~nuclear lamina,GO:0005654~nucleoplasm,GO:0005882~intermediate filament,GO:0016020~membrane,GO:0016363~nuclear matrix,GO:0031965~nuclear membrane,	GO:0005198~structural molecule activity,GO:0005200~structural constituent of cytoskeleton,GO:0005515~protein binding,GO:0043274~phospholipase binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001322:Lamin_tail_dom,IPR018039:IF_conserved,IPR036415:Lamin_tail_dom_sf,IPR039008:IF_rod_dom,	hsa04210:Apoptosis,	169500~Leukodystrophy, adult-onset, autosomal dominant,619179~Microcephaly 26, primary, autosomal dominant,		SM01391:Filament,		KW-0403~Intermediate filament,KW-0539~Nucleus,	KW-0225~Disease variant,KW-0905~Primary microcephaly,KW-0991~Intellectual disability,KW-1026~Leukodystrophy,	KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0449~Lipoprotein,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0636~Prenylation,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DISULFID:Interchain,DOMAIN:IF rod,DOMAIN:LTD,LIPID:S-farnesyl cysteine,MOTIF:Nuclear localization signal,PROPEP:Removed in mature form,REGION:Coil 1A,REGION:Coil 1B,REGION:Coil 2,REGION:Disordered,REGION:Head,REGION:Linker 1,REGION:Linker 2,REGION:Tail,
LAMTOR1	late endosomal/lysosomal adaptor, MAPK and MTOR activator 1(LAMTOR1)	Homo sapiens			GO:0001558~regulation of cell growth,GO:0001919~regulation of receptor recycling,GO:0007032~endosome organization,GO:0007040~lysosome organization,GO:0008104~protein localization,GO:0010874~regulation of cholesterol efflux,GO:0016197~endosomal transport,GO:0031669~cellular response to nutrient levels,GO:0032008~positive regulation of TOR signaling,GO:0032418~lysosome localization,GO:0038202~TORC1 signaling,GO:0042632~cholesterol homeostasis,GO:0043410~positive regulation of MAPK cascade,GO:0060620~regulation of cholesterol import,GO:0071230~cellular response to amino acid stimulus,GO:0072657~protein localization to membrane,GO:1904263~positive regulation of TORC1 signaling,	GO:0005764~lysosome,GO:0005765~lysosomal membrane,GO:0005886~plasma membrane,GO:0031902~late endosome membrane,GO:0035577~azurophil granule membrane,GO:0035579~specific granule membrane,GO:0045121~membrane raft,GO:0070062~extracellular exosome,GO:0071986~Ragulator complex,GO:0101003~ficolin-1-rich granule membrane,GO:1990877~Lst4-Lst7 complex,	GO:0005085~guanyl-nucleotide exchange factor activity,GO:0005515~protein binding,GO:0043495~protein anchor,GO:0051020~GTPase binding,GO:0060090~binding, bridging,	IPR028209:LAMTOR1/MEH1,	hsa04150:mTOR signaling pathway,			SM01262:LAMTOR,		KW-0458~Lysosome,KW-0472~Membrane,KW-0967~Endosome,					KW-0449~Lipoprotein,KW-0519~Myristate,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),LIPID:N-myristoyl glycine,LIPID:S-palmitoyl cysteine,MUTAGEN:C->A: Decreased palmitoylation.,MUTAGEN:C->S: Does not affect interaction with ZDHHC3.,MUTAGEN:CC->SS: Abolished palmitoylation and recruitment to lysosomes, leading to impaired activation of the mTORC1 complex.,MUTAGEN:G->A: Abolished N-myristoylation and subsequent palmitoylation.,MUTAGEN:KEE->AAA: Impaired recruiment of Rag GTPases (RRAGA and RRAGC) to the lysosomal membrane.,MUTAGEN:L->R: Impaired assembly of the Ragulator complex.,MUTAGEN:LVV->AAA: Impaired recruiment of Rag GTPases (RRAGA and RRAGC) to the lysosomal membrane.,MUTAGEN:LVVQF->DDDQD: Does not affect interaction with RRAGA and RRAGC in vitro.,MUTAGEN:V->D: Impaired assembly of the Ragulator complex.,MUTAGEN:VD->AA: Impaired assembly of the Ragulator complex.,REGION:Disordered,REGION:Interaction with LAMTOR2 and LAMTOR3,
LAMTOR2	late endosomal/lysosomal adaptor, MAPK and MTOR activator 2(LAMTOR2)	Homo sapiens			GO:0001558~regulation of cell growth,GO:0008104~protein localization,GO:0010761~fibroblast migration,GO:0032008~positive regulation of TOR signaling,GO:0038202~TORC1 signaling,GO:0043410~positive regulation of MAPK cascade,GO:0071230~cellular response to amino acid stimulus,GO:1902414~protein localization to cell junction,GO:1904263~positive regulation of TORC1 signaling,	GO:0005765~lysosomal membrane,GO:0005770~late endosome,GO:0005886~plasma membrane,GO:0010008~endosome membrane,GO:0031902~late endosome membrane,GO:0035579~specific granule membrane,GO:0070821~tertiary granule membrane,GO:0071986~Ragulator complex,GO:1990877~Lst4-Lst7 complex,	GO:0005085~guanyl-nucleotide exchange factor activity,GO:0005515~protein binding,GO:0060090~binding, bridging,	IPR004942:Roadblock/LAMTOR2_dom,IPR037587:LAMTOR2-like,	hsa04150:mTOR signaling pathway,	610798~Immunodeficiency due to defect in MAPBP-interacting protein,		SM00960:Robl_LC7,		KW-0458~Lysosome,KW-0472~Membrane,KW-0967~Endosome,						MUTAGEN:DAR->AAA: In M6 mutant; impaired assembly of the Ragulator complex.,MUTAGEN:VTAA->DTAD: In M7 mutant; impaired association with Rag GTPases.,REGION:Required for location at endosomes,
LAMTOR3	late endosomal/lysosomal adaptor, MAPK and MTOR activator 3(LAMTOR3)	Homo sapiens			GO:0008104~protein localization,GO:0016310~phosphorylation,GO:0032006~regulation of TOR signaling,GO:0032008~positive regulation of TOR signaling,GO:0038202~TORC1 signaling,GO:0043410~positive regulation of MAPK cascade,GO:0071230~cellular response to amino acid stimulus,GO:1902414~protein localization to cell junction,GO:1904263~positive regulation of TORC1 signaling,	GO:0005765~lysosomal membrane,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0010008~endosome membrane,GO:0031902~late endosome membrane,GO:0035579~specific granule membrane,GO:0070062~extracellular exosome,GO:0070821~tertiary granule membrane,GO:0071986~Ragulator complex,GO:1990877~Lst4-Lst7 complex,	GO:0005085~guanyl-nucleotide exchange factor activity,GO:0005515~protein binding,GO:0016301~kinase activity,GO:0019209~kinase activator activity,GO:0060090~binding, bridging,	IPR015019:LAMTOR3,	hsa04010:MAPK signaling pathway,hsa04150:mTOR signaling pathway,			SM01278:MAPKK1_Int,		KW-0472~Membrane,KW-0967~Endosome,				KW-0418~Kinase,KW-0808~Transferase,		MUTAGEN:QGSK->AGSD: In M5 mutant; impaired association with Rag GTPases.,REGION:Required for interaction with LAMTOR2,
LMAN1	lectin, mannose binding 1(LMAN1)	Homo sapiens			GO:0006457~protein folding,GO:0006888~ER to Golgi vesicle-mediated transport,GO:0007029~endoplasmic reticulum organization,GO:0007030~Golgi organization,GO:0007596~blood coagulation,GO:0010638~positive regulation of organelle organization,GO:0015031~protein transport,GO:1903215~negative regulation of protein targeting to mitochondrion,	GO:0000139~Golgi membrane,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005793~endoplasmic reticulum-Golgi intermediate compartment,GO:0012507~ER to Golgi transport vesicle membrane,GO:0016020~membrane,GO:0030017~sarcomere,GO:0030134~ER to Golgi transport vesicle,GO:0033116~endoplasmic reticulum-Golgi intermediate compartment membrane,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0005537~mannose binding,GO:0030246~carbohydrate binding,GO:0046872~metal ion binding,GO:0051082~unfolded protein binding,	IPR005052:Lectin_leg,IPR013320:ConA-like_dom_sf,	hsa04141:Protein processing in endoplasmic reticulum,	227300~Combined factor V and VIII deficiency,			KW-0653~Protein transport,KW-0813~Transport,KW-0931~ER-Golgi transport,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,		KW-0175~Coiled coil,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0430~Lectin,KW-0479~Metal-binding,		KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	COMPBIAS:Basic and acidic residues,DISULFID:Interchain,DOMAIN:L-type lectin-like,MOTIF:ER export motif,REGION:Disordered,REGION:Mediates interaction with RAB3GAP1, RAB3GAP2 and UBXN6,SITE:Required for ER export,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
LMAN2	lectin, mannose binding 2(LMAN2)	Homo sapiens			GO:0006888~ER to Golgi vesicle-mediated transport,GO:0006890~retrograde vesicle-mediated transport, Golgi to ER,GO:0015031~protein transport,GO:0050766~positive regulation of phagocytosis,	GO:0000139~Golgi membrane,GO:0005615~extracellular space,GO:0005789~endoplasmic reticulum membrane,GO:0005793~endoplasmic reticulum-Golgi intermediate compartment,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,GO:0030134~ER to Golgi transport vesicle,GO:0033116~endoplasmic reticulum-Golgi intermediate compartment membrane,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0005537~mannose binding,GO:0030246~carbohydrate binding,GO:0031072~heat shock protein binding,GO:0046872~metal ion binding,	IPR005052:Lectin_leg,IPR013320:ConA-like_dom_sf,IPR035664:VIP36_lectin,	hsa04141:Protein processing in endoplasmic reticulum,				KW-0653~Protein transport,KW-0813~Transport,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0430~Lectin,KW-0479~Metal-binding,		KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:L-type lectin-like,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
LEPROTL1	leptin receptor overlapping transcript like 1(LEPROTL1)	Homo sapiens			GO:0032511~late endosome to vacuole transport via multivesicular body sorting pathway,GO:0060400~negative regulation of growth hormone receptor signaling pathway,	GO:0005768~endosome,GO:0016020~membrane,	GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR007262:Vps55/LEPROT,						KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,		REGION:Disordered,TRANSMEM:Helical,
LAP3	leucine aminopeptidase 3(LAP3)	Homo sapiens			GO:0006508~proteolysis,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005925~focal adhesion,GO:0070062~extracellular exosome,	GO:0004177~aminopeptidase activity,GO:0004180~carboxypeptidase activity,GO:0005515~protein binding,GO:0008233~peptidase activity,GO:0008235~metalloexopeptidase activity,GO:0030145~manganese ion binding,GO:0070006~metalloaminopeptidase activity,	IPR000819:Peptidase_M17_C,IPR008283:Peptidase_M17_N,IPR011356:Leucine_aapep/pepB,IPR023042:Peptidase_M17_leu_NH2_pept,IPR043472:Macro_dom-like,	hsa00330:Arginine and proline metabolism,hsa00480:Glutathione metabolism,hsa01100:Metabolic pathways,					KW-0963~Cytoplasm,			KW-0460~Magnesium,KW-0464~Manganese,KW-0479~Metal-binding,KW-0862~Zinc,	KW-0031~Aminopeptidase,KW-0378~Hydrolase,KW-0645~Protease,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:Cytosol aminopeptidase,
LCMT1	leucine carboxyl methyltransferase 1(LCMT1)	Homo sapiens			GO:0000086~G2/M transition of mitotic cell cycle,GO:0006479~protein methylation,GO:0006481~C-terminal protein methylation,GO:0010906~regulation of glucose metabolic process,GO:0031333~negative regulation of protein complex assembly,GO:0032259~methylation,GO:0036211~protein modification process,GO:0042981~regulation of apoptotic process,GO:0090266~regulation of mitotic cell cycle spindle assembly checkpoint,	GO:0005654~nucleoplasm,GO:0005829~cytosol,	GO:0003880~protein C-terminal carboxyl O-methyltransferase activity,GO:0005515~protein binding,GO:0008757~S-adenosylmethionine-dependent methyltransferase activity,GO:0018423~protein C-terminal leucine carboxyl O-methyltransferase activity,	IPR007213:Ppm1/Ppm2/Tcmp,IPR016651:PPM1,IPR029063:SAM-dependent_MTases_sf,			PIRSF016305:LCM_mtfrase,						KW-0949~S-adenosyl-L-methionine,	KW-0489~Methyltransferase,KW-0808~Transferase,
LRRC41	leucine rich repeat containing 41(LRRC41)	Homo sapiens			GO:0016567~protein ubiquitination,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016020~membrane,	GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR026137:Leu_rpt_41,IPR032675:LRR_dom_sf,				SM00368:LRR_RI,	KW-0833~Ubl conjugation pathway,			KW-0433~Leucine-rich repeat,KW-0677~Repeat,			KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,REGION:Disordered,REGION:Interaction with Elongin BC complex,REPEAT:LRR 1,REPEAT:LRR 2,REPEAT:LRR 3,REPEAT:LRR 4,REPEAT:LRR 5,REPEAT:LRR 6,REPEAT:LRR 7,
LRRC59	leucine rich repeat containing 59(LRRC59)	Homo sapiens			GO:0006470~protein dephosphorylation,GO:0007165~signal transduction,	GO:0005635~nuclear envelope,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0016020~membrane,GO:0042645~mitochondrial nucleoid,GO:0043231~intracellular membrane-bounded organelle,	GO:0003723~RNA binding,GO:0004722~protein serine/threonine phosphatase activity,GO:0005515~protein binding,GO:0045296~cadherin binding,	IPR001611:Leu-rich_rpt,IPR003591:Leu-rich_rpt_typical-subtyp,IPR032675:LRR_dom_sf,				SM00369:LRR_TYP,		KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0492~Microsome,KW-0539~Nucleus,		KW-0175~Coiled coil,KW-0433~Leucine-rich repeat,KW-0677~Repeat,KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,REGION:Disordered,REPEAT:LRR 1,REPEAT:LRR 2,REPEAT:LRR 3,REPEAT:LRR 4,REPEAT:LRR 5,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
LUZP1	leucine zipper protein 1(LUZP1)	Homo sapiens			GO:0003281~ventricular septum development,GO:0021503~neural fold bending,GO:0060840~artery development,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0016020~membrane,GO:0070062~extracellular exosome,	GO:0005515~protein binding,							KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,
LNPEP	leucyl and cystinyl aminopeptidase(LNPEP)	Homo sapiens			GO:0000209~protein polyubiquitination,GO:0002480~antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent,GO:0006508~proteolysis,GO:0007165~signal transduction,GO:0007267~cell-cell signaling,GO:0007565~female pregnancy,GO:0008217~regulation of blood pressure,GO:0030163~protein catabolic process,GO:0043171~peptide catabolic process,GO:0060395~SMAD protein signal transduction,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0005765~lysosomal membrane,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0030659~cytoplasmic vesicle membrane,GO:0031905~early endosome lumen,GO:0048471~perinuclear region of cytoplasm,	GO:0004177~aminopeptidase activity,GO:0005515~protein binding,GO:0008237~metallopeptidase activity,GO:0008270~zinc ion binding,GO:0042277~peptide binding,GO:0070006~metalloaminopeptidase activity,	IPR001930:Peptidase_M1,IPR014782:Peptidase_M1_dom,IPR024571:ERAP1-like_C_dom,IPR027268:Peptidase_M4/M1_CTD_sf,IPR034016:M1_APN-typ,IPR042097:Aminopeptidase_N-like_N_sf,IPR045357:Aminopeptidase_N-like_N,	hsa04614:Renin-angiotensin system,					KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0031~Aminopeptidase,KW-0378~Hydrolase,KW-0482~Metalloprotease,KW-0645~Protease,	KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Aminopeptidase N-like N-terminal,DOMAIN:ERAP1-like C-terminal,DOMAIN:Peptidase M1 membrane alanine aminopeptidase,MOTIF:Dileucine internalization motif,REGION:Tankyrase binding,SITE:Cleavage; to produce pregnancy serum form,SITE:Transition state stabilizer,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
LTA4H	leukotriene A4 hydrolase(LTA4H)	Homo sapiens			GO:0006508~proteolysis,GO:0006629~lipid metabolic process,GO:0010043~response to zinc ion,GO:0019370~leukotriene biosynthetic process,GO:0019538~protein metabolic process,GO:0043171~peptide catabolic process,GO:0043434~response to peptide hormone,GO:0060509~Type I pneumocyte differentiation,	GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0070062~extracellular exosome,GO:1904724~tertiary granule lumen,GO:1904813~ficolin-1-rich granule lumen,	GO:0003723~RNA binding,GO:0004177~aminopeptidase activity,GO:0004301~epoxide hydrolase activity,GO:0004463~leukotriene-A4 hydrolase activity,GO:0005515~protein binding,GO:0008233~peptidase activity,GO:0008237~metallopeptidase activity,GO:0008270~zinc ion binding,GO:0016787~hydrolase activity,GO:0045148~tripeptide aminopeptidase activity,GO:0070006~metalloaminopeptidase activity,	IPR001930:Peptidase_M1,IPR012777:LTA4H,IPR014782:Peptidase_M1_dom,IPR015211:Peptidase_M1_C,IPR016024:ARM-type_fold,IPR027268:Peptidase_M4/M1_CTD_sf,IPR034015:M1_LTA4H,IPR038502:M1_LTA-4_hydro/amino_C_sf,IPR042097:Aminopeptidase_N-like_N_sf,IPR045357:Aminopeptidase_N-like_N,	hsa00590:Arachidonic acid metabolism,hsa01100:Metabolic pathways,			SM01263:Leuk-A4-hydro_C,	KW-0434~Leukotriene biosynthesis,KW-0443~Lipid metabolism,	KW-0963~Cytoplasm,			KW-0479~Metal-binding,KW-0862~Zinc,	KW-0378~Hydrolase,KW-0482~Metalloprotease,KW-0645~Protease,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,ACT_SITE:Proton donor,DOMAIN:Peptidase M1 leukotriene A4 hydrolase/aminopeptidase C-terminal,MUTAGEN:D->A: Strongly reduced hydrolysis of peptides starting with Arg. Small effect on hydrolysis of peptides starting with Ala. Abolishes epoxide hydrolase activity.,MUTAGEN:D->E: Strongly reduced aminopeptidase activity. Abolishes epoxide hydrolase activity.,MUTAGEN:D->N: Abolishes aminopeptidase activity. Decreased epoxide hydrolase activity.,MUTAGEN:D->N: No loss of activity.,MUTAGEN:E->A,D: Complete loss of epoxide hydrolase activity and aminopeptidase activity.,MUTAGEN:E->A: Complete loss of LTA4 hydrolase and peptidase enzyme activities.,MUTAGEN:E->A: Loss of epoxide hydrolase and aminopeptidase activities.,MUTAGEN:E->K: Loss of epoxide hydrolase and aminopeptidase activities.,MUTAGEN:E->Q: Loss of LTA4 hydrolase activity, and aminopeptidase activity strongly impaired.,MUTAGEN:E->Q: Loss of aminopeptidase activity, but keeps LTA4 hydrolase activity.,MUTAGEN:E->Q: Reduced aminopeptidase activity. Minor effect on epoxide hydrolase activity.,MUTAGEN:G->A: No loss of activity.,MUTAGEN:H->L: Complete loss of LTA4 hydrolase and peptidase enzyme activities.,MUTAGEN:H->Q: Aminopeptidase activity almost absent, but keeps LTA4 activity.,MUTAGEN:H->Y: Complete loss of LTA4 hydrolase and peptidase enzyme activities.,MUTAGEN:K->A,M: Strongly reduced affinity for peptide substrates. Reduced epoxide hydrolase and aminopeptidase activity.,MUTAGEN:K->R: No effect on epoxide hydrolase and aminopeptidase activity.,MUTAGEN:M->L: No loss of activity.,MUTAGEN:N->A: No loss of epoxide hydrolase activity and aminopeptidase activity.,MUTAGEN:Q->A,L: Srongly increased epoxide hydrolase activity.,MUTAGEN:Q->A: No loss of activity.,MUTAGEN:Q->A: Strongly reduced aminopeptidase activity. Strongly decreased affinity for leukotriene. Abolishes epoxide hydrolase activity.,MUTAGEN:Q->L: Aminopeptidase activity strongly impaired, but keeps LTA4 activity.,MUTAGEN:Q->N: Aminopeptidase activity almost absent, but keeps LTA4 activity.,MUTAGEN:R->A,K,M: Abolishes epoxide hydrolase activity. Reduced aminopeptidase activity.,SITE:Covalently modified during suicide inhibition by leukotrienes,SITE:Essential for epoxide hydrolase activity, but not for aminopeptidase activity,SITE:Pro-Gly-Pro binding,
LPXN	leupaxin(LPXN)	Homo sapiens			GO:0007155~cell adhesion,GO:0007162~negative regulation of cell adhesion,GO:0007165~signal transduction,GO:0007179~transforming growth factor beta receptor signaling pathway,GO:0033628~regulation of cell adhesion mediated by integrin,GO:0034446~substrate adhesion-dependent cell spreading,GO:0043542~endothelial cell migration,GO:0050859~negative regulation of B cell receptor signaling pathway,GO:0065003~macromolecular complex assembly,	GO:0002102~podosome,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0016020~membrane,GO:0016607~nuclear speck,GO:0042995~cell projection,GO:0048471~perinuclear region of cytoplasm,	GO:0003712~transcription cofactor activity,GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR001781:Znf_LIM,IPR017305:Tgfb1i1/Leupaxin/TGFB1I1,			PIRSF037881:Leupaxin,	SM00132:LIM,	KW-0130~Cell adhesion,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0965~Cell junction,KW-0966~Cell projection,KW-1003~Cell membrane,		KW-0440~LIM domain,KW-0677~Repeat,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:LIM zinc-binding,DOMAIN:LIM zinc-binding 1,DOMAIN:LIM zinc-binding 2,DOMAIN:LIM zinc-binding 3,DOMAIN:LIM zinc-binding 4,MOTIF:LD motif 1,MOTIF:LD motif 2,MOTIF:LD motif 3,REGION:Disordered,
LRIF1	ligand dependent nuclear receptor interacting factor 1(LRIF1)	Homo sapiens			GO:0006355~regulation of transcription, DNA-templated,GO:0009048~dosage compensation by inactivation of X chromosome,	GO:0000781~chromosome, telomeric region,GO:0001740~Barr body,GO:0005654~nucleoplasm,GO:0016363~nuclear matrix,GO:0034451~centriolar satellite,	GO:0005515~protein binding,GO:0042974~retinoic acid receptor binding,	IPR026191:LRIF1,		619477~Facioscapulohumeral muscular dystrophy 3, digenic,			KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0158~Chromosome,KW-0539~Nucleus,		KW-0175~Coiled coil,		KW-0678~Repressor,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),MOTIF:Nuclear localization signal,MOTIF:PxVxL motif,MUTAGEN:KKR->AAA: Abolishes nuclear localization.,MUTAGEN:KKR->AAA: Slightly reduces nuclear localization.,MUTAGEN:VCL->DCE: Abolishes interaction with HP1 (CBX1/HP1-beta, CBX3/HP1-gamma and CBX5/HP1-alpha).,REGION:Disordered,
LIX1L	limb and CNS expressed 1 like(LIX1L)	Homo sapiens			GO:0097352~autophagosome maturation,	GO:0005737~cytoplasm,		IPR029270:LIX1,												COMPBIAS:Pro residues,REGION:Disordered,
LMBR1L	limb development membrane protein 1 like(LMBR1L)	Homo sapiens			GO:0006898~receptor-mediated endocytosis,GO:0007165~signal transduction,GO:0016055~Wnt signaling pathway,GO:0030217~T cell differentiation,GO:0042098~T cell proliferation,GO:0060218~hematopoietic stem cell differentiation,GO:0070231~T cell apoptotic process,GO:0090090~negative regulation of canonical Wnt signaling pathway,	GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0016020~membrane,	GO:0004888~transmembrane signaling receptor activity,GO:0005515~protein binding,	IPR006876:LMBR1-like_membr_prot,IPR008075:LIMR,					KW-0254~Endocytosis,KW-0879~Wnt signaling pathway,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,		REGION:Disordered,REGION:Interaction with LGB,REGION:LCN1-binding,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
LMBR1	limb development membrane protein 1(LMBR1)	Homo sapiens			GO:0007165~signal transduction,GO:0042733~embryonic digit morphogenesis,	GO:0016020~membrane,	GO:0004888~transmembrane signaling receptor activity,GO:0005515~protein binding,	IPR006876:LMBR1-like_membr_prot,IPR008075:LIMR,		135750~Laurin-Sandrow syndrome,186200~Syndactyly, type IV,190605~Triphalangeal thumb-polysyndactyly syndrome,200500~Acheiropody,				KW-0472~Membrane,		KW-0175~Coiled coil,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,		COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
LAT	linker for activation of T cells(LAT)	Homo sapiens	63.LAT_couples_T-cell_receptor,	h_nkcellsPathway:Ras-Independent pathway in NK cell-mediated cytotoxicity,h_tcrPathway:T Cell Receptor Signaling Pathway,	GO:0002250~adaptive immune response,GO:0002260~lymphocyte homeostasis,GO:0006954~inflammatory response,GO:0006955~immune response,GO:0007165~signal transduction,GO:0007229~integrin-mediated signaling pathway,GO:0007265~Ras protein signal transduction,GO:0010467~gene expression,GO:0019722~calcium-mediated signaling,GO:0035556~intracellular signal transduction,GO:0042110~T cell activation,GO:0043303~mast cell degranulation,GO:0045860~positive regulation of protein kinase activity,GO:0050852~T cell receptor signaling pathway,GO:0050863~regulation of T cell activation,	GO:0001772~immunological synapse,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0005911~cell-cell junction,GO:0008180~COP9 signalosome,GO:0016020~membrane,GO:0045121~membrane raft,	GO:0005515~protein binding,GO:0019901~protein kinase binding,GO:0030159~receptor signaling complex scaffold activity,	IPR008359:Linker_for_activat_Tcells_prot,	hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04064:NF-kappa B signaling pathway,hsa04650:Natural killer cell mediated cytotoxicity,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04660:T cell receptor signaling pathway,hsa04664:Fc epsilon RI signaling pathway,hsa04666:Fc gamma R-mediated phagocytosis,hsa05135:Yersinia infection,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,	617514~Immunodeficiency 52,			KW-0391~Immunity,KW-0467~Mast cell degranulation,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,LIPID:S-palmitoyl cysteine,MUTAGEN:C->A: Reduces palmitoylation; abolishes localization to lipid rafts.,MUTAGEN:C->A: Reduces palmitoylation; impairs localization to lipid rafts.,MUTAGEN:Y->F: Abolishes interaction with GRB2 and PIK3R1; when associated with F-200.,MUTAGEN:Y->F: Abolishes interaction with GRB2 and PIK3R1; when associated with F-220.,MUTAGEN:Y->F: Abolishes interaction with PLCG1.,REGION:Disordered,REGION:Interaction with GRB2, GRAP2 and PIK3R1,REGION:Interaction with PLCG1,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical; Signal-anchor for type III membrane protein,
LMF2	lipase maturation factor 2(LMF2)	Homo sapiens			GO:0051604~protein maturation,	GO:0005789~endoplasmic reticulum membrane,GO:0016020~membrane,	GO:0005515~protein binding,	IPR009613:LMF,						KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,REGION:Disordered,TRANSMEM:Helical,
LITAF	lipopolysaccharide induced TNF factor(LITAF)	Homo sapiens			GO:0001817~regulation of cytokine production,GO:0010935~regulation of macrophage cytokine production,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0071222~cellular response to lipopolysaccharide,GO:1901223~negative regulation of NIK/NF-kappaB signaling,	GO:0000139~Golgi membrane,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005765~lysosomal membrane,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0009898~cytoplasmic side of plasma membrane,GO:0043231~intracellular membrane-bounded organelle,GO:0098559~cytoplasmic side of early endosome membrane,GO:0098560~cytoplasmic side of late endosome membrane,GO:0098574~cytoplasmic side of lysosomal membrane,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0042802~identical protein binding,GO:0046872~metal ion binding,GO:0050699~WW domain binding,	IPR006629:LITAF,IPR037519:LITAF_fam,	hsa04142:Lysosome,	601098~Charcot-Marie-Tooth disease, type 1C,		SM00714:LITAF,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0333~Golgi apparatus,KW-0458~Lysosome,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0967~Endosome,KW-1003~Cell membrane,	KW-0144~Charcot-Marie-Tooth disease,KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0622~Neuropathy,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:LITAF,MOTIF:PPxY motif,MOTIF:PSAP motif; important for interaction with TSG101,MUTAGEN:C->A: Abolishes association with cytoplasmic vesicle membranes.,MUTAGEN:P->T: Decreases protein stability and association with early endosome membranes. Impaired function in targeting endocytosed proteins for lysosomal degradation.,MUTAGEN:PSA->AGG: Abolishes interaction with TSG101.,MUTAGEN:PSAP->ASAA: Impaired function in targeting endocytosed proteins for lysosomal degradation.,MUTAGEN:V->M: No effect on location at endosomes, but impairs protein stability.,MUTAGEN:Y->A: Abolishes interaction with NEDD4.,MUTAGEN:Y->A: Abolishes interaction with WWOX. Abolishes interaction with NEDD4. Abolishes interaction with NEDD4 and impairs location at endosomes; when associated with A-61.,MUTAGEN:Y->A: No effect on interaction with WWOX. No effect on interaction with NEDD4. Abolishes interaction with NEDD4 and impairs location at endosomes; when associated with A-23.,REGION:Disordered,REGION:Membrane-binding amphipathic helix,TRANSMEM:Helical,
LDLRAD4	low density lipoprotein receptor class A domain containing 4(LDLRAD4)	Homo sapiens			GO:0010719~negative regulation of epithelial to mesenchymal transition,GO:0030336~negative regulation of cell migration,GO:0030512~negative regulation of transforming growth factor beta receptor signaling pathway,GO:0060392~negative regulation of SMAD protein import into nucleus,	GO:0000139~Golgi membrane,GO:0016020~membrane,GO:0031901~early endosome membrane,GO:0043231~intracellular membrane-bounded organelle,	GO:0070412~R-SMAD binding,	IPR002172:LDrepeatLR_classA_rpt,IPR023415:LDLR_class-A_CS,IPR036055:LDL_receptor-like_sf,IPR043445:TMEPAI/LRAD4,				SM00192:LDLa,		KW-0472~Membrane,KW-0967~Endosome,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0734~Signal transduction inhibitor,	KW-1015~Disulfide bond,	DOMAIN:LDL-receptor class A,MOTIF:PPxY motif 1,MOTIF:PPxY motif 2,MOTIF:SMAD interaction motif (SIM),REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
LY6E	lymphocyte antigen 6 family member E(LY6E)	Homo sapiens			GO:0007166~cell surface receptor signaling pathway,GO:0046597~negative regulation of viral entry into host cell,	GO:0005576~extracellular region,GO:0005886~plasma membrane,GO:0098552~side of membrane,	GO:0005515~protein binding,GO:0030550~acetylcholine receptor inhibitor activity,	IPR016054:LY6_UPA_recep-like,IPR035076:Toxin/TOLIP,IPR045860:Snake_toxin-like_sf,				SM00134:LU,	KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0732~Signal,			KW-0325~Glycoprotein,KW-0336~GPI-anchor,KW-0449~Lipoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Snake toxin/toxin-like,DOMAIN:UPAR/Ly6,LIPID:GPI-anchor amidated serine,MUTAGEN:I->A: About 50% loss of viral entry enhancement.,MUTAGEN:L->A: Complete loss of viral entry enhancement. Abolishes inhibition of human coronaviruses entry.,MUTAGEN:N->A: Abolishes inhibition of human coronaviruses entry.,PROPEP:Removed in mature form,
LCP1	lymphocyte cytosolic protein 1(LCP1)	Homo sapiens			GO:0002286~T cell activation involved in immune response,GO:0010737~protein kinase A signaling,GO:0016477~cell migration,GO:0022617~extracellular matrix disassembly,GO:0030866~cortical actin cytoskeleton organization,GO:0031100~animal organ regeneration,GO:0033157~regulation of intracellular protein transport,GO:0051017~actin filament bundle assembly,GO:0051639~actin filament network formation,GO:0051764~actin crosslink formation,GO:0071803~positive regulation of podosome assembly,	GO:0001725~stress fiber,GO:0001726~ruffle,GO:0001891~phagocytic cup,GO:0002102~podosome,GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005884~actin filament,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0015629~actin cytoskeleton,GO:0030054~cell junction,GO:0030175~filopodium,GO:0032432~actin filament bundle,GO:0032587~ruffle membrane,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,GO:0097386~glial cell projection,	GO:0003779~actin binding,GO:0005178~integrin binding,GO:0005509~calcium ion binding,GO:0051015~actin filament binding,GO:0051020~GTPase binding,	IPR001589:Actinin_actin-bd_CS,IPR001715:CH_dom,IPR002048:EF_hand_dom,IPR011992:EF-hand-dom_pair,IPR018247:EF_Hand_1_Ca_BS,IPR036872:CH_dom_sf,IPR039959:Fimbrin/Plastin,				SM00033:CH,SM00054:EFh,		KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0965~Cell junction,KW-0966~Cell projection,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0677~Repeat,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0009~Actin-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:Calponin-homology (CH),DOMAIN:Calponin-homology (CH) 1,DOMAIN:Calponin-homology (CH) 2,DOMAIN:Calponin-homology (CH) 3,DOMAIN:Calponin-homology (CH) 4,DOMAIN:EF-hand,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,MUTAGEN:S->A: Abolishes phosphorylation and reduces the cell surface expression of CD69 and IL2RA. Reduces association with the actin cytoskeleton.,MUTAGEN:S->E: Promotes association with the actin cytoskeleton.,REGION:Actin-binding 1,REGION:Actin-binding 2,
LSP1	lymphocyte specific protein 1(LSP1)	Homo sapiens			GO:0006935~chemotaxis,GO:0006968~cellular defense response,GO:0007165~signal transduction,GO:0098761~cellular response to interleukin-7,	GO:0005886~plasma membrane,GO:0015629~actin cytoskeleton,GO:0016020~membrane,GO:0070062~extracellular exosome,	GO:0003779~actin binding,GO:0005515~protein binding,GO:0008092~cytoskeletal protein binding,	IPR002211:Lymphspecific,IPR006018:Caldesmon_LSP,	hsa04625:C-type lectin receptor signaling pathway,hsa05152:Tuberculosis,					KW-0472~Membrane,KW-1003~Cell membrane,					KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,
LTB	lymphotoxin beta(LTB)	Homo sapiens			GO:0006955~immune response,GO:0007165~signal transduction,GO:0007267~cell-cell signaling,GO:0010467~gene expression,GO:0032735~positive regulation of interleukin-12 production,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043588~skin development,GO:0048535~lymph node development,GO:2001238~positive regulation of extrinsic apoptotic signaling pathway,	GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0016020~membrane,	GO:0005102~receptor binding,GO:0005125~cytokine activity,GO:0005164~tumor necrosis factor receptor binding,	IPR002961:TNF_C,IPR006052:TNF_dom,IPR006053:TNF,IPR008983:Tumour_necrosis_fac-like_dom,IPR021184:TNF_CS,	hsa04060:Cytokine-cytokine receptor interaction,hsa04064:NF-kappa B signaling pathway,hsa05323:Rheumatoid arthritis,			SM00207:TNF,		KW-0472~Membrane,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0202~Cytokine,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:TNF family profile,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
KAT6A	lysine acetyltransferase 6A(KAT6A)	Homo sapiens			GO:0006334~nucleosome assembly,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006473~protein acetylation,GO:0010628~positive regulation of gene expression,GO:0030099~myeloid cell differentiation,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0050793~regulation of developmental process,GO:0051276~chromosome organization,GO:0090398~cellular senescence,GO:1901796~regulation of signal transduction by p53 class mediator,GO:1903706~regulation of hemopoiesis,	GO:0000123~histone acetyltransferase complex,GO:0000786~nucleosome,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005829~cytosol,GO:0016605~PML body,GO:0016607~nuclear speck,GO:0070776~MOZ/MORF histone acetyltransferase complex,	GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003712~transcription cofactor activity,GO:0003713~transcription coactivator activity,GO:0004402~histone acetyltransferase activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0010484~H3 histone acetyltransferase activity,GO:0016407~acetyltransferase activity,GO:0036408~histone acetyltransferase activity (H3-K14 specific),GO:0043995~histone acetyltransferase activity (H4-K5 specific),GO:0043996~histone acetyltransferase activity (H4-K8 specific),GO:0043997~histone acetyltransferase activity (H4-K12 specific),GO:0046872~metal ion binding,GO:0046972~histone acetyltransferase activity (H4-K16 specific),	IPR001965:Znf_PHD,IPR002717:HAT_MYST-type,IPR005818:Histone_H1/H5_H15,IPR011011:Znf_FYVE_PHD,IPR013083:Znf_RING/FYVE/PHD,IPR016181:Acyl_CoA_acyltransferase,IPR019787:Znf_PHD-finger,IPR036388:WH-like_DNA-bd_sf,IPR036390:WH_DNA-bd_sf,IPR040706:Zf-MYST,IPR048589:SAMD1-like_WH,	hsa04550:Signaling pathways regulating pluripotency of stem cells,	616268~Arboleda-Tham syndrome,		SM00249:PHD,SM00526:H15,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0656~Proto-oncogene,KW-0991~Intellectual disability,	KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0012~Acyltransferase,KW-0156~Chromatin regulator,KW-0678~Repressor,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	ACT_SITE:Proton donor/acceptor,COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:H15,DOMAIN:MYST-type HAT,DOMAIN:PHD-type,DOMAIN:SAMD1-like winged helix (WH),MUTAGEN:C->G: Abrogates HAT activity.,MUTAGEN:G->E: Abrogates HAT activity.,MUTAGEN:H->D: Reduced affinity for DNA.,MUTAGEN:I->E: Slightly reduced affinity for DNA.,MUTAGEN:K->A: Reduced affinity for DNA.,REGION:Catalytic,REGION:Disordered,REGION:Interaction with PML,REGION:Interaction with RUNX1-1,REGION:Interaction with RUNX1-2,REGION:Mediates interaction with BRPF1, required for histone H3 acetyltransferase activity,REGION:Required for activation of RUNX1-1,REGION:Required for activation of RUNX1-2,REGION:Required for nuclear localization,SITE:Breakpoint for translocation to form KAT6A-ASXL2,SITE:Breakpoint for translocation to form KAT6A-CREBBP,SITE:Breakpoint for translocation to form KAT6A-EP300 and KAT6A-NCOA2,ZN_FING:C2HC MYST-type,ZN_FING:PHD-type 1,ZN_FING:PHD-type 2,
KAT6B	lysine acetyltransferase 6B(KAT6B)	Homo sapiens			GO:0006334~nucleosome assembly,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0050793~regulation of developmental process,GO:1903706~regulation of hemopoiesis,	GO:0000123~histone acetyltransferase complex,GO:0000786~nucleosome,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0070776~MOZ/MORF histone acetyltransferase complex,	GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003712~transcription cofactor activity,GO:0003713~transcription coactivator activity,GO:0004402~histone acetyltransferase activity,GO:0005515~protein binding,GO:0010484~H3 histone acetyltransferase activity,GO:0036408~histone acetyltransferase activity (H3-K14 specific),GO:0044877~macromolecular complex binding,GO:0046872~metal ion binding,GO:0061733~peptide-lysine-N-acetyltransferase activity,	IPR001965:Znf_PHD,IPR002717:HAT_MYST-type,IPR005818:Histone_H1/H5_H15,IPR011011:Znf_FYVE_PHD,IPR013083:Znf_RING/FYVE/PHD,IPR016024:ARM-type_fold,IPR016181:Acyl_CoA_acyltransferase,IPR019787:Znf_PHD-finger,IPR036388:WH-like_DNA-bd_sf,IPR036390:WH_DNA-bd_sf,IPR040706:Zf-MYST,IPR048589:SAMD1-like_WH,		603736~SBBYSS syndrome,606170~Genitopatellar syndrome,		SM00249:PHD,SM00526:H15,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0175~Coiled coil,KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0012~Acyltransferase,KW-0156~Chromatin regulator,KW-0678~Repressor,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	ACT_SITE:Proton donor/acceptor,COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:H15,DOMAIN:MYST-type HAT,DOMAIN:PHD-type,DOMAIN:SAM,DOMAIN:SAMD1-like winged helix (WH),REGION:Catalytic,REGION:Disordered,REGION:Interaction with BRPF1,REGION:Interaction with RUNX1 and RUNX2,REGION:Negatively regulates HAT activity,SITE:Breakpoint for translocation to form KAT6B-CREBBP,ZN_FING:C2HC MYST-type,ZN_FING:PHD-type 1,ZN_FING:PHD-type 2,
KDM2A	lysine demethylase 2A(KDM2A)	Homo sapiens			GO:0006303~double-strand break repair via nonhomologous end joining,GO:0006338~chromatin remodeling,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006482~protein demethylation,GO:0010944~negative regulation of transcription by competitive promoter binding,GO:0032259~methylation,GO:0032922~circadian regulation of gene expression,GO:0042752~regulation of circadian rhythm,	GO:0005654~nucleoplasm,GO:0005694~chromosome,	GO:0003712~transcription cofactor activity,GO:0005515~protein binding,GO:0008168~methyltransferase activity,GO:0008270~zinc ion binding,GO:0032452~histone demethylase activity,GO:0045322~unmethylated CpG binding,GO:0051213~dioxygenase activity,GO:0051864~histone demethylase activity (H3-K36 specific),	IPR001810:F-box_dom,IPR001965:Znf_PHD,IPR002857:Znf_CXXC,IPR003347:JmjC_dom,IPR006553:Leu-rich_rpt_Cys-con_subtyp,IPR011011:Znf_FYVE_PHD,IPR013083:Znf_RING/FYVE/PHD,IPR019786:Zinc_finger_PHD-type_CS,IPR019787:Znf_PHD-finger,IPR032675:LRR_dom_sf,IPR041070:JHD,	hsa03083:Polycomb repressive complex,			SM00249:PHD,SM00367:LRR_CC,SM00558:JmjC,	KW-0090~Biological rhythms,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0833~Ubl conjugation pathway,	KW-0158~Chromosome,KW-0539~Nucleus,		KW-0433~Leucine-rich repeat,KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0408~Iron,KW-0479~Metal-binding,KW-0862~Zinc,	KW-0156~Chromatin regulator,KW-0223~Dioxygenase,KW-0238~DNA-binding,KW-0489~Methyltransferase,KW-0560~Oxidoreductase,KW-0678~Repressor,KW-0808~Transferase,	KW-0013~ADP-ribosylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:CXXC-type,DOMAIN:F-box,DOMAIN:JmjC,DOMAIN:PHD-type,MUTAGEN:C->A: Abolishes association with centromeric heterochromatin; when associated with A-571 and A-574. Loss of its ability to repress the transcriptional activator activity of the CLOCK-BMAL1 heterodimer; when associated with A-574.,MUTAGEN:C->A: Abolishes association with centromeric heterochromatin; when associated with A-571 and A-577. Loss of its ability to repress the transcriptional activator activity of the CLOCK-BMAL1 heterodimer; when associated with A-577.,MUTAGEN:C->A: Abolishes association with centromeric heterochromatin; when associated with A-574 and A-577.,MUTAGEN:C->A: No loss of its ability to repress the transcriptional activator activity of the CLOCK-BMAL1 heterodimer; when associated with A-620.,MUTAGEN:C->A: No loss of its ability to repress the transcriptional activator activity of the CLOCK-BMAL1 heterodimer; when associated with A-623.,MUTAGEN:H->A: Abolishes histone demethylase activity. No loss of its ability to repress the transcriptional activator activity of the CLOCK-BMAL1 heterodimer.,MUTAGEN:HVD->AVA: Abolishes lysine-specific histone demethylase activity.,MUTAGEN:W->V: Reduced interaction with UBB.,REGION:Disordered,REPEAT:LRR 1,REPEAT:LRR 2,REPEAT:LRR 3,REPEAT:LRR 4,REPEAT:LRR 5,REPEAT:LRR 6,ZN_FING:CXXC-type,ZN_FING:PHD-type,
KDM2B	lysine demethylase 2B(KDM2B)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006338~chromatin remodeling,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006482~protein demethylation,GO:0007283~spermatogenesis,GO:0021555~midbrain-hindbrain boundary morphogenesis,GO:0021592~fourth ventricle development,GO:0021670~lateral ventricle development,GO:0021678~third ventricle development,GO:0021993~initiation of neural tube closure,GO:0030307~positive regulation of cell growth,GO:0030900~forebrain development,GO:0030901~midbrain development,GO:0030902~hindbrain development,GO:0043524~negative regulation of neuron apoptotic process,GO:0048596~embryonic camera-type eye morphogenesis,GO:1902459~positive regulation of stem cell population maintenance,GO:2000178~negative regulation of neural precursor cell proliferation,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005694~chromosome,GO:0005730~nucleolus,GO:0031519~PcG protein complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0003677~DNA binding,GO:0003712~transcription cofactor activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0019843~rRNA binding,GO:0032452~histone demethylase activity,GO:0045322~unmethylated CpG binding,GO:0046872~metal ion binding,GO:0051213~dioxygenase activity,GO:0051864~histone demethylase activity (H3-K36 specific),	IPR001810:F-box_dom,IPR001965:Znf_PHD,IPR002857:Znf_CXXC,IPR003347:JmjC_dom,IPR006553:Leu-rich_rpt_Cys-con_subtyp,IPR011011:Znf_FYVE_PHD,IPR013083:Znf_RING/FYVE/PHD,IPR019787:Znf_PHD-finger,IPR032675:LRR_dom_sf,IPR041070:JHD,IPR041667:Cupin_8,	hsa03083:Polycomb repressive complex,			SM00249:PHD,SM00367:LRR_CC,SM00558:JmjC,	KW-0804~Transcription,KW-0805~Transcription regulation,KW-0833~Ubl conjugation pathway,	KW-0158~Chromosome,KW-0539~Nucleus,		KW-0175~Coiled coil,KW-0433~Leucine-rich repeat,KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0408~Iron,KW-0479~Metal-binding,KW-0862~Zinc,	KW-0156~Chromatin regulator,KW-0223~Dioxygenase,KW-0238~DNA-binding,KW-0560~Oxidoreductase,KW-0678~Repressor,KW-0694~RNA-binding,KW-0699~rRNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:CXXC-type,DOMAIN:F-box,DOMAIN:JmjC,DOMAIN:Jumonji helical,DOMAIN:PHD-type,MUTAGEN:A->Y: Increased interaction with UBB.,MUTAGEN:V->A: Decreased ininteraction with UBB.,MUTAGEN:V->W: Increased interaction with UBB.,REGION:Disordered,REPEAT:LRR 1,REPEAT:LRR 2,REPEAT:LRR 3,REPEAT:LRR 4,REPEAT:LRR 5,REPEAT:LRR 6,REPEAT:LRR 7,ZN_FING:CXXC-type,ZN_FING:PHD-type,
KDM5A	lysine demethylase 5A(KDM5A)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006338~chromatin remodeling,GO:0006355~regulation of transcription, DNA-templated,GO:0032259~methylation,GO:0032922~circadian regulation of gene expression,GO:0045893~positive regulation of transcription, DNA-templated,GO:0051090~regulation of sequence-specific DNA binding transcription factor activity,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0003677~DNA binding,GO:0003713~transcription coactivator activity,GO:0004857~enzyme inhibitor activity,GO:0005515~protein binding,GO:0008168~methyltransferase activity,GO:0008270~zinc ion binding,GO:0031490~chromatin DNA binding,GO:0032452~histone demethylase activity,GO:0034647~histone demethylase activity (H3-trimethyl-K4 specific),GO:0035064~methylated histone binding,GO:0042393~histone binding,	IPR001606:ARID_dom,IPR001965:Znf_PHD,IPR003347:JmjC_dom,IPR003349:JmjN,IPR004198:Znf_C5HC2,IPR011011:Znf_FYVE_PHD,IPR013083:Znf_RING/FYVE/PHD,IPR013637:Lys_sp_deMease-like_dom,IPR019786:Zinc_finger_PHD-type_CS,IPR019787:Znf_PHD-finger,IPR036431:ARID_dom_sf,IPR047970:KDM5A_PHD2,IPR047972:KDM5A_PHD3,IPR047973:KDM5A_PHD1,IPR047974:KDM5A_ARID,IPR048615:KDM5_C-hel,				SM00249:PHD,SM00501:BRIGHT,SM00545:JmjN,SM00558:JmjC,SM01014:ARID,	KW-0090~Biological rhythms,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0408~Iron,KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0156~Chromatin regulator,KW-0217~Developmental protein,KW-0223~Dioxygenase,KW-0489~Methyltransferase,KW-0560~Oxidoreductase,KW-0808~Transferase,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:ARID,DOMAIN:JmjC,DOMAIN:JmjN,DOMAIN:Lysine-specific demethylase-like,MOTIF:GSGFP motif,MUTAGEN:C->S: No effect on lysine-specific histone demethylase activity; when associated with S-626.,MUTAGEN:C->S: No effect on lysine-specific histone demethylase activity; when associated with S-636.,MUTAGEN:EW->AA: Abolishes interaction with histone H3 di- and trimethylated at 'Lys-4'.,MUTAGEN:K->E: Abolishes DNA-binding.,MUTAGEN:L->E: Decreases DNA-binding.,MUTAGEN:R->E: Decreases DNA-binding.,MUTAGEN:S->D: Decreases DNA-binding.,MUTAGEN:V->G: No effect on interaction with histone H3 di- and trimethylated at 'Lys-4'.,MUTAGEN:W->A: Abolishes interaction with histone H3 di- and trimethylated at 'Lys-4'.,REGION:Disordered,REGION:Interaction with LMO2,SITE:Breakpoint for translocation to form the NUP98-KDM5A fusion protein,ZN_FING:C5HC2,ZN_FING:PHD-type 1,ZN_FING:PHD-type 2,ZN_FING:PHD-type 3,
KDM6B	lysine demethylase 6B(KDM6B)	Homo sapiens			GO:0002437~inflammatory response to antigenic stimulus,GO:0006338~chromatin remodeling,GO:0007507~heart development,GO:0010468~regulation of gene expression,GO:0014823~response to activity,GO:0021766~hippocampus development,GO:0045165~cell fate commitment,GO:0045446~endothelial cell differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048333~mesodermal cell differentiation,GO:0055007~cardiac muscle cell differentiation,GO:0060992~response to fungicide,GO:0070301~cellular response to hydrogen peroxide,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0044666~MLL3/4 complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0005515~protein binding,GO:0008013~beta-catenin binding,GO:0031490~chromatin DNA binding,GO:0032452~histone demethylase activity,GO:0046872~metal ion binding,GO:0071558~histone demethylase activity (H3-K27 specific),	IPR003347:JmjC_dom,IPR046941:KDM6_GATAL_sf,IPR048560:KDM6A_B-like_GATAL,IPR048562:KDM6A_B-like_C-hel,		618505~Stolerman neurodevelopmental syndrome,		SM00558:JmjC,	KW-0395~Inflammatory response,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-0991~Intellectual disability,		KW-0408~Iron,KW-0479~Metal-binding,KW-0862~Zinc,	KW-0156~Chromatin regulator,KW-0223~Dioxygenase,KW-0560~Oxidoreductase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:JmjC,MUTAGEN:HQE->AQA: Abolishes lysine-specific histone demethylase activity.,REGION:Disordered,
KMT2A	lysine methyltransferase 2A(KMT2A)	Homo sapiens			GO:0006306~DNA methylation,GO:0006355~regulation of transcription, DNA-templated,GO:0006508~proteolysis,GO:0006915~apoptotic process,GO:0007221~positive regulation of transcription of Notch receptor target,GO:0008542~visual learning,GO:0009791~post-embryonic development,GO:0009952~anterior/posterior pattern specification,GO:0032259~methylation,GO:0032922~circadian regulation of gene expression,GO:0035162~embryonic hemopoiesis,GO:0035640~exploration behavior,GO:0035864~response to potassium ion,GO:0036211~protein modification process,GO:0040029~regulation of gene expression, epigenetic,GO:0045064~T-helper 2 cell differentiation,GO:0045815~positive regulation of gene expression, epigenetic,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048144~fibroblast proliferation,GO:0048147~negative regulation of fibroblast proliferation,GO:0048172~regulation of short-term neuronal synaptic plasticity,GO:0048536~spleen development,GO:0048873~homeostasis of number of cells within a tissue,GO:0051899~membrane depolarization,GO:0060216~definitive hemopoiesis,GO:0065003~macromolecular complex assembly,GO:0071560~cellular response to transforming growth factor beta stimulus,GO:0090310~negative regulation of methylation-dependent chromatin silencing,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0035097~histone methyltransferase complex,GO:0071339~MLL1 complex,	GO:0003677~DNA binding,GO:0003680~AT DNA binding,GO:0003682~chromatin binding,GO:0003713~transcription coactivator activity,GO:0004197~cysteine-type endopeptidase activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0042800~histone methyltransferase activity (H3-K4 specific),GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0045322~unmethylated CpG binding,GO:0046872~metal ion binding,GO:0070577~lysine-acetylated histone binding,	IPR001214:SET_dom,IPR001487:Bromodomain,IPR001965:Znf_PHD,IPR002857:Znf_CXXC,IPR003616:Post-SET_dom,IPR003888:FYrich_N,IPR003889:FYrich_C,IPR005314:Peptidase_C50,IPR011011:Znf_FYVE_PHD,IPR013083:Znf_RING/FYVE/PHD,IPR016569:MeTrfase_trithorax,IPR019786:Zinc_finger_PHD-type_CS,IPR019787:Znf_PHD-finger,IPR034732:EPHD,IPR036427:Bromodomain-like_sf,IPR041958:KMT2A_ePHD,IPR042023:KMT2A_PHD1,IPR042025:KMT2A_PHD2,IPR044133:KMT2A_PHD3,IPR046341:SET_dom_sf,IPR046369:MAML1-3,IPR047219:KMT2A_2B_SET,	hsa00310:Lysine degradation,hsa01100:Metabolic pathways,hsa04934:Cushing syndrome,hsa05202:Transcriptional misregulation in cancer,	605130~Wiedemann-Steiner syndrome,	PIRSF010354:Methyltransferase_trithorax,	SM00249:PHD,SM00297:BROMO,SM00317:SET,SM00508:PostSET,SM00541:FYRN,SM00542:FYRC,	KW-0053~Apoptosis,KW-0090~Biological rhythms,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0539~Nucleus,	KW-0656~Proto-oncogene,	KW-0103~Bromodomain,KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,KW-0949~S-adenosyl-L-methionine,	KW-0156~Chromatin regulator,KW-0238~DNA-binding,KW-0489~Methyltransferase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DNA_BIND:A.T hook 1,DNA_BIND:A.T hook 2,DNA_BIND:A.T hook 3,DOMAIN:Bromo,DOMAIN:Bromo; divergent,DOMAIN:CXXC-type,DOMAIN:FYR C-terminal,DOMAIN:FYR N-terminal,DOMAIN:PHD-type,DOMAIN:Post-SET,DOMAIN:SET,MOTIF:9aaTAD,MOTIF:Integrase domain-binding motif 1 (IBM1),MOTIF:Integrase domain-binding motif 2 (IBM2),MOTIF:Menin-binding motif (MBM),MOTIF:WDR5 interaction motif (WIN),MUTAGEN:A->R: Reduced interaction with MEN1.,MUTAGEN:C->A,S: Abolished auto-methylation.,MUTAGEN:C->A: Abolishes zinc-binding and stability of the CXXC-type zinc finger and causes loss of DNA-binding.,MUTAGEN:C->A: Impairs zinc-binding and stability of the CXXC-type zinc finger and causes loss of DNA-binding.,MUTAGEN:C->A: No effect on stability or DNA-binding.,MUTAGEN:C->D: Abolishes DNA-binding and increases CpG methylation of the HOXA9 promoter region. Does not lead to the development of leukemia when overexpressed in mice as gene fusion with MLLT3.,MUTAGEN:D->A: Abolishes zinc-binding and stability of the CXXC-type zinc finger and causes loss of DNA-binding.,MUTAGEN:D->A: Does not affect methyltransferase activity of the enzyme alone or in complex; when associated with A-3872.,MUTAGEN:D->A: Impairs DNA-binding.,MUTAGEN:DG->AA: Reduces cleavage without abolishing it. Abolishes cleavage by TASP1; when associated with 2718-A--A-2720.,MUTAGEN:DGV->AAA: Abolishes cleavage by TASP1; when associated with 2666-A-A-2667.,MUTAGEN:E->A: Does not affect methyltransferase activity of the enzyme alone or in complex; when associated with A-3869.,MUTAGEN:E->Q: Loss of interaction with PSIP1; when associated with Q-144 and A-148.,MUTAGEN:E->Q: Loss of interaction with PSIP1; when associated with Q-146 and A-148.,MUTAGEN:F->A: Impairs DNA-binding.,MUTAGEN:F->A: Loss of interaction with MEN1.,MUTAGEN:F->A: Reduced interaction with PSIP1.,MUTAGEN:F->A: Reduced interaction with PSIP1. Loss of interaction with PSIP1; when associated with A-149 or Q-144 and Q-146.,MUTAGEN:F->A: Reduced interaction with PSIP1; when associated with A-129 or A-132.,MUTAGEN:F->A: Weakly affects interaction with PSIP1 whereas significantly decreases interaction of KMT2A-MEN1 complex with PSIP1. Reduced interaction with PSIP1; when associated with A-133.,MUTAGEN:F->H,Y: Reduced interaction with MEN1.,MUTAGEN:H->A,F: Slight decrease in interaction with WDR5.,MUTAGEN:H->Y: Increased interaction with WDR5.,MUTAGEN:K->A: Affects methyltransferase activity of the enzyme alone, while it does not affect methyltransferase activity in complex; when associated with A-3874.,MUTAGEN:K->A: Impairs DNA-binding.,MUTAGEN:KFGG->AAAA: Abolishes zinc-binding and stability of the CXXC-type zinc finger and causes loss of DNA-binding.,MUTAGEN:L->A: Loss of interaction with PSIP1; when associated with A-148.,MUTAGEN:L->A: Mildly decreases DNA-binding.,MUTAGEN:M->A: No effect on DNA-binding.,MUTAGEN:N->A: Impairs DNA-binding.,MUTAGEN:N->A: Loss of the histone H3 methyltransferase activity. Abolishes interaction with S-adenosyl-L-methionine.,MUTAGEN:N->A: No effect on stability or DNA-binding.,MUTAGEN:N->I: Leads to stable interaction with ASH2L and RBBP5 in the absence of WDR5; when associated with L-3867.,MUTAGEN:N->T: Leads to stable interaction with ASH2L and RBBP5 in the absence of WDR5; when associated with V-3867.,MUTAGEN:P->A: Reduced interaction with MEN1.,MUTAGEN:Q->A: Decreases affinity for histone H3K4me3.,MUTAGEN:Q->A: Impairs DNA-binding.,MUTAGEN:Q->A: No effect on stability or DNA-binding.,MUTAGEN:Q->A: Slightly affects methyltransferase activity of the enzyme alone, while it impairs methyltransferase activity in complex; when associated with A-3871.,MUTAGEN:Q->L: Leads to stable interaction with ASH2L and RBBP5 in the absence of WDR5; when associated with I-3861.,MUTAGEN:Q->V: Leads to stable interaction with ASH2L and RBBP5 in the absence of WDR5; when associated with T-3861.,MUTAGEN:R->A: Abolishes zinc-binding and stability of the CXXC-type zinc finger and causes loss of DNA-binding.,MUTAGEN:R->A: Disrupts interaction with ASH2L and RBBP5 and nearly abolishes histone methyltransferase activity.,MUTAGEN:R->A: Impairs DNA-binding.,MUTAGEN:R->A: Loss of interaction with the WRAD complex and WDR5.,MUTAGEN:R->A: No effect on stability or DNA-binding.,MUTAGEN:R->A: Reduced interaction with MEN1.,MUTAGEN:R->A: Slightly affects methyltransferase activity of the enzyme alone, while it impairs methyltransferase activity in complex; when associated with A-3867.,MUTAGEN:R->E: Reduced interaction with MEN1; when associated with E-24.,MUTAGEN:R->E: Reduced interaction with MEN1; when associated with E-25.,MUTAGEN:S->A: Increased interaction with WDR5.,MUTAGEN:S->D: Phosphomimetic mutant. Significant increase in interaction with PSIP1; when associated with D-136.,MUTAGEN:S->D: Phosphomimetic mutant. Significant increase in interaction with PSIP1; when associated with D-142.,MUTAGEN:V->A: Decreases binding affinity for PPIE.,MUTAGEN:V->A: Reduced interaction with PSIP1; when associated with A-133.,MUTAGEN:W->A: Abolishes interaction with histone H3K4me3.,MUTAGEN:W->A: Reduced interaction with MEN1.,MUTAGEN:W->E: Decreases affinity for histone H3K4me3.,MUTAGEN:Y->A,F: Impairs methyltransferase activity toward unmodified or monomethylated H3K4me.,MUTAGEN:Y->A: Affects methyltransferase activity of the enzyme alone, while it does not affect methyltransferase activity in complex; when associated with A-3878.,MUTAGEN:Y->A: Decreases affinity for histone H3K4me3.,MUTAGEN:Y->A: Impairs methyltransferase activity toward unmodified or monomethylated H3K4me.,MUTAGEN:Y->A: May perturb protein folding and thereby decrease binding affinity for PPIE.,MUTAGEN:Y->F: Shifts from a specific monomethyltransferase to a di- and trimethyltransferase activity.,MUTAGEN:Y->F: Slightly affects methyltransferase activity toward unmodified or monomethylated H3K4me.,REGION:Disordered,REGION:Interaction with histone H3K4me3,SITE:Breakpoint for translocation to form KMT2A-AF3P21 and KMT2A-KNL1 oncogenes,SITE:Breakpoint for translocation to form KMT2A-AFF4 fusion protein,SITE:Breakpoint for translocation to form KMT2A-CENPK oncogene,SITE:Breakpoint for translocation to form KMT2A-FRYL fusion protein,SITE:Breakpoint for translocation to form KMT2A-GAS7 oncogene,SITE:Breakpoint for translocation to form KMT2A-LPP,SITE:Breakpoint for translocation to form KMT2A-ZFYVE19 oncogene,SITE:Cleavage; by TASP1, site 1,SITE:Cleavage; by TASP1, site 2,SITE:Important for WDR5-recognition and binding,ZN_FING:C2HC pre-PHD-type,ZN_FING:CXXC-type,ZN_FING:PHD-type 1,ZN_FING:PHD-type 2,ZN_FING:PHD-type 3,ZN_FING:PHD-type 4,
KMT2C	lysine methyltransferase 2C(KMT2C)	Homo sapiens			GO:0006325~chromatin organization,GO:0006338~chromatin remodeling,GO:0006355~regulation of transcription, DNA-templated,GO:0032259~methylation,GO:0043933~macromolecular complex subunit organization,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051602~response to electrical stimulus,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0035097~histone methyltransferase complex,GO:0044666~MLL3/4 complex,	GO:0003677~DNA binding,GO:0003713~transcription coactivator activity,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0008168~methyltransferase activity,GO:0016746~transferase activity, transferring acyl groups,GO:0042054~histone methyltransferase activity,GO:0042393~histone binding,GO:0042800~histone methyltransferase activity (H3-K4 specific),GO:0046872~metal ion binding,	IPR000637:HMGI/Y_DNA-bd_CS,IPR001214:SET_dom,IPR001841:Znf_RING,IPR001965:Znf_PHD,IPR002219:PE/DAG-bd,IPR003616:Post-SET_dom,IPR003888:FYrich_N,IPR003889:FYrich_C,IPR009071:HMG_box_dom,IPR011011:Znf_FYVE_PHD,IPR013083:Znf_RING/FYVE/PHD,IPR019786:Zinc_finger_PHD-type_CS,IPR019787:Znf_PHD-finger,IPR034732:EPHD,IPR036910:HMG_box_dom_sf,IPR037877:PHD3_KMT2C,IPR041967:KMT2C_ePHD1,IPR041968:KMT2C_ePHD2,IPR046341:SET_dom_sf,IPR047003:KMT2C_PHD4,IPR047004:KMT2C_PHD2,IPR047005:KMT2C_PHD6,	hsa00310:Lysine degradation,hsa01100:Metabolic pathways,	617768~Kleefstra syndrome 2,		SM00184:RING,SM00249:PHD,SM00317:SET,SM00398:HMG,SM00508:PostSET,SM00541:FYRN,SM00542:FYRC,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-0991~Intellectual disability,	KW-0175~Coiled coil,KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,KW-0949~S-adenosyl-L-methionine,	KW-0010~Activator,KW-0012~Acyltransferase,KW-0156~Chromatin regulator,KW-0238~DNA-binding,KW-0489~Methyltransferase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0449~Lipoprotein,KW-0488~Methylation,KW-0564~Palmitate,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DNA_BIND:A.T hook,DOMAIN:DHHC,DOMAIN:FYR C-terminal,DOMAIN:FYR N-terminal,DOMAIN:HMG box,DOMAIN:PHD-type,DOMAIN:Phorbol-ester/DAG-type,DOMAIN:Post-SET,DOMAIN:RING-type,DOMAIN:SET,MOTIF:WDR5 interaction motif (WIN),MUTAGEN:H->N: Confers a WRAD-dependent gain-of-function histone H3 dimethylation activity. Converts H3K4me1 into H3K4me2.,MUTAGEN:N->A: Abolishes interaction with S-adenosyl-L-methionine.,MUTAGEN:Q->Y: Confers a WRAD-dependent gain-of-function histone H3 dimethylation activity. Converts H3K4me1 into H3K4me2.,MUTAGEN:R->P: Confers a WRAD-dependent gain-of-function histone H3 dimethylation activity. Converts H3K4me1 into H3K4me2.,MUTAGEN:Y->F: Confers a WRAD-dependent gain-of-function histone H3 dimethylation activity. Converts H3K4me1 into H3K4me2.,REGION:Disordered,ZN_FING:C2HC pre-PHD-type 1; degenerate,ZN_FING:C2HC pre-PHD-type 2,ZN_FING:PHD-type 1,ZN_FING:PHD-type 2,ZN_FING:PHD-type 3,ZN_FING:PHD-type 4,ZN_FING:PHD-type 5,ZN_FING:PHD-type 6,ZN_FING:PHD-type 7,ZN_FING:PHD-type 8,ZN_FING:RING-type,
KMT2E	lysine methyltransferase 2E (inactive)(KMT2E)	Homo sapiens			GO:0002446~neutrophil mediated immunity,GO:0006306~DNA methylation,GO:0006325~chromatin organization,GO:0006355~regulation of transcription, DNA-templated,GO:0007049~cell cycle,GO:0030218~erythrocyte differentiation,GO:0042119~neutrophil activation,GO:0045893~positive regulation of transcription, DNA-templated,GO:1900087~positive regulation of G1/S transition of mitotic cell cycle,	GO:0000785~chromatin,GO:0000791~euchromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016604~nuclear body,GO:0016607~nuclear speck,GO:0032991~macromolecular complex,GO:0034967~Set3 complex,GO:0070210~Rpd3L-Expanded complex,	GO:0003713~transcription coactivator activity,GO:0005515~protein binding,GO:0019899~enzyme binding,GO:0035064~methylated histone binding,GO:0046872~metal ion binding,	IPR001214:SET_dom,IPR001965:Znf_PHD,IPR011011:Znf_FYVE_PHD,IPR013083:Znf_RING/FYVE/PHD,IPR019786:Zinc_finger_PHD-type_CS,IPR019787:Znf_PHD-finger,IPR044434:KMT2E_SET,IPR046341:SET_dom_sf,	hsa00310:Lysine degradation,hsa01100:Metabolic pathways,	618512~O'Donnell-Luria-Rodan syndrome,		SM00249:PHD,SM00317:SET,	KW-0131~Cell cycle,KW-0338~Growth arrest,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0158~Chromosome,KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0991~Intellectual disability,	KW-0175~Coiled coil,KW-0812~Transmembrane,KW-0863~Zinc-finger,KW-1133~Transmembrane helix,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0156~Chromatin regulator,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	CARBOHYD:O-linked (GlcNAc) serine,CARBOHYD:O-linked (GlcNAc) threonine,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:PHD-type,DOMAIN:SET,MOTIF:HCFC1-binding motif (HBM),MUTAGEN:C->A: Fails to activate the cell cycle regulated element (CCRE) in the cyclin A promoter.,MUTAGEN:D->K: Severe reduction in the binding to tri-methylated 'Lys-4' of histone H3 (H3K4me3).,MUTAGEN:DHNY->AAAA: Abolishes interaction with HCFC1.,MUTAGEN:F->A: No effect on binding to tri-methylated 'Lys-4' of histone H3 (H3K4me3).,MUTAGEN:W->A: Loss of binding to tri-methylated 'Lys-4' of histone H3 (H3K4me3).,MUTAGEN:Y->A,K: Severe reduction in the binding to tri-methylated 'Lys-4' of histone H3 (H3K4me3).,REGION:Disordered,TRANSMEM:Helical,ZN_FING:PHD-type,
KRCC1	lysine rich coiled-coil 1(KRCC1)	Homo sapiens					GO:0005515~protein binding,									KW-0175~Coiled coil,				COMPBIAS:Basic and acidic residues,REGION:Disordered,
LPCAT3	lysophosphatidylcholine acyltransferase 3(LPCAT3)	Homo sapiens			GO:0006656~phosphatidylcholine biosynthetic process,GO:0030258~lipid modification,GO:0034378~chylomicron assembly,GO:0034379~very-low-density lipoprotein particle assembly,GO:0036150~phosphatidylserine acyl-chain remodeling,GO:0036151~phosphatidylcholine acyl-chain remodeling,GO:0036152~phosphatidylethanolamine acyl-chain remodeling,GO:0036335~intestinal stem cell homeostasis,GO:0045540~regulation of cholesterol biosynthetic process,GO:0045797~positive regulation of intestinal cholesterol absorption,GO:0050728~negative regulation of inflammatory response,GO:0090158~endoplasmic reticulum membrane organization,GO:1903573~negative regulation of response to endoplasmic reticulum stress,GO:1905885~positive regulation of triglyceride transport,	GO:0005789~endoplasmic reticulum membrane,GO:0016020~membrane,	GO:0003841~1-acylglycerol-3-phosphate O-acyltransferase activity,GO:0016746~transferase activity, transferring acyl groups,GO:0047144~2-acylglycerol-3-phosphate O-acyltransferase activity,GO:0047184~1-acylglycerophosphocholine O-acyltransferase activity,GO:0071617~lysophospholipid acyltransferase activity,	IPR004299:MBOAT_fam,	hsa00564:Glycerophospholipid metabolism,hsa04216:Ferroptosis,				KW-0443~Lipid metabolism,KW-0444~Lipid biosynthesis,KW-0594~Phospholipid biosynthesis,KW-1208~Phospholipid metabolism,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0012~Acyltransferase,KW-0808~Transferase,	KW-0007~Acetylation,	MOTIF:Di-lysine motif,TRANSMEM:Helical,
LYPLA1	lysophospholipase 1(LYPLA1)	Homo sapiens			GO:0002084~protein depalmitoylation,GO:0006631~fatty acid metabolic process,GO:0015908~fatty acid transport,GO:0042997~negative regulation of Golgi to plasma membrane protein transport,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,GO:0031965~nuclear membrane,GO:0070062~extracellular exosome,	GO:0004620~phospholipase activity,GO:0004622~lysophospholipase activity,GO:0005515~protein binding,GO:0008474~palmitoyl-(protein) hydrolase activity,GO:0016298~lipase activity,GO:0016787~hydrolase activity,GO:0052689~carboxylic ester hydrolase activity,	IPR003140:PLipase/COase/thioEstase,IPR029058:AB_hydrolase,	hsa00564:Glycerophospholipid metabolism,hsa05231:Choline metabolism in cancer,				KW-0276~Fatty acid metabolism,KW-0443~Lipid metabolism,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0378~Hydrolase,	KW-0007~Acetylation,	ACT_SITE:Charge relay system,DOMAIN:Phospholipase/carboxylesterase/thioesterase,MUTAGEN:S->A: Loss of thioesterase and lysophospholipase activity.,TRANSMEM:Helical,
LYPLA2	lysophospholipase 2(LYPLA2)	Homo sapiens			GO:0002084~protein depalmitoylation,GO:0006631~fatty acid metabolic process,GO:0007411~axon guidance,GO:0046464~acylglycerol catabolic process,GO:1905344~prostaglandin catabolic process,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005795~Golgi stack,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0004622~lysophospholipase activity,GO:0005515~protein binding,GO:0008474~palmitoyl-(protein) hydrolase activity,GO:0016787~hydrolase activity,GO:0045296~cadherin binding,GO:0052689~carboxylic ester hydrolase activity,	IPR003140:PLipase/COase/thioEstase,IPR029058:AB_hydrolase,	hsa00564:Glycerophospholipid metabolism,				KW-0276~Fatty acid metabolism,KW-0443~Lipid metabolism,	KW-0963~Cytoplasm,				KW-0378~Hydrolase,	KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,	ACT_SITE:Charge relay system,DOMAIN:Phospholipase/carboxylesterase/thioesterase,LIPID:S-palmitoyl cysteine,MUTAGEN:C->A: Abolishes palmitoylation.,MUTAGEN:S->A: Abolishes ability to mediate depalmitoylation of ZDHHC6.,REGION:Disordered,
LAMP1	lysosomal associated membrane protein 1(LAMP1)	Homo sapiens	57.Post-Golgi&endo_trans_MHC_class_II,		GO:0007042~lysosomal lumen acidification,GO:0043323~positive regulation of natural killer cell degranulation,GO:0045954~positive regulation of natural killer cell mediated cytotoxicity,GO:0046718~viral entry into host cell,GO:0050821~protein stabilization,GO:0072594~establishment of protein localization to organelle,GO:0090160~Golgi to lysosome transport,GO:1902513~regulation of organelle transport along microtubule,	GO:0000421~autophagosome membrane,GO:0005737~cytoplasm,GO:0005764~lysosome,GO:0005765~lysosomal membrane,GO:0005770~late endosome,GO:0005771~multivesicular body,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0008021~synaptic vesicle,GO:0009897~external side of plasma membrane,GO:0010008~endosome membrane,GO:0016020~membrane,GO:0031902~late endosome membrane,GO:0035577~azurophil granule membrane,GO:0042383~sarcolemma,GO:0042470~melanosome,GO:0044754~autolysosome,GO:0048471~perinuclear region of cytoplasm,GO:0061474~phagolysosome membrane,GO:0070062~extracellular exosome,GO:0101003~ficolin-1-rich granule membrane,GO:0101004~cytolytic granule membrane,	GO:0001618~virus receptor activity,GO:0005515~protein binding,GO:0008200~ion channel inhibitor activity,GO:0019899~enzyme binding,GO:0019904~protein domain specific binding,	IPR002000:Lysosome-assoc_membr_glycop,IPR018134:LAMP_CS,IPR048524:Lamp2-like_TM,IPR048528:Lamp2-like_luminal,	hsa04140:Autophagy - animal,hsa04142:Lysosome,hsa04145:Phagosome,hsa05152:Tuberculosis,				KW-0945~Host-virus interaction,	KW-0458~Lysosome,KW-0472~Membrane,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,KW-1183~Host cell receptor for virus entry,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) (polylactosaminoglycan) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (GalNAc...) serine,CARBOHYD:O-linked (GalNAc...) serine; partial,CARBOHYD:O-linked (GalNAc...) threonine,COMPBIAS:Pro residues,DOMAIN:Lysosome-associated membrane glycoprotein 2-like luminal,DOMAIN:Lysosome-associated membrane glycoprotein 2-like transmembrane,MUTAGEN:N->S: Complete loss of interaction with Lassa virus protein GPC.,REGION:Disordered,REGION:First lumenal domain,REGION:Hinge,REGION:Second lumenal domain,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
LAMP2	lysosomal associated membrane protein 2(LAMP2)	Homo sapiens			GO:0006605~protein targeting,GO:0007042~lysosomal lumen acidification,GO:0009267~cellular response to starvation,GO:0017038~protein import,GO:0030163~protein catabolic process,GO:0031333~negative regulation of protein complex assembly,GO:0031647~regulation of protein stability,GO:0046716~muscle cell cellular homeostasis,GO:0050821~protein stabilization,GO:0061684~chaperone-mediated autophagy,GO:0061740~protein targeting to lysosome involved in chaperone-mediated autophagy,GO:0097352~autophagosome maturation,GO:1900226~negative regulation of NLRP3 inflammasome complex assembly,GO:1905146~lysosomal protein catabolic process,	GO:0000421~autophagosome membrane,GO:0005615~extracellular space,GO:0005764~lysosome,GO:0005765~lysosomal membrane,GO:0005770~late endosome,GO:0005802~trans-Golgi network,GO:0005886~plasma membrane,GO:0010008~endosome membrane,GO:0016020~membrane,GO:0030670~phagocytic vesicle membrane,GO:0031088~platelet dense granule membrane,GO:0031902~late endosome membrane,GO:0035577~azurophil granule membrane,GO:0043202~lysosomal lumen,GO:0043231~intracellular membrane-bounded organelle,GO:0044754~autolysosome,GO:0048471~perinuclear region of cytoplasm,GO:0061742~chaperone-mediated autophagy translocation complex,GO:0070062~extracellular exosome,GO:0098857~membrane microdomain,GO:0101003~ficolin-1-rich granule membrane,	GO:0005515~protein binding,GO:0008200~ion channel inhibitor activity,GO:0019899~enzyme binding,GO:0019904~protein domain specific binding,GO:0035591~signaling adaptor activity,	IPR002000:Lysosome-assoc_membr_glycop,IPR018134:LAMP_CS,IPR048524:Lamp2-like_TM,IPR048528:Lamp2-like_luminal,	hsa04140:Autophagy - animal,hsa04142:Lysosome,hsa04145:Phagosome,hsa05152:Tuberculosis,	300257~Danon disease,			KW-0072~Autophagy,	KW-0458~Lysosome,KW-0472~Membrane,KW-0967~Endosome,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0322~Glycogen storage disease,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) (polylactosaminoglycan) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (GalNAc...) serine,CARBOHYD:O-linked (GalNAc...) serine; partial,CARBOHYD:O-linked (GalNAc...) threonine,CARBOHYD:O-linked (GalNAc...) threonine; partial,COMPBIAS:Polar residues,DOMAIN:Lysosome-associated membrane glycoprotein 2-like luminal,DOMAIN:Lysosome-associated membrane glycoprotein 2-like transmembrane,MUTAGEN:KHHH->AAAA: Impairs binding and subsequent lysosomal degradation of target proteins, such as GAPDH.,REGION:Disordered,REGION:First lumenal domain,REGION:Hinge,REGION:Important for binding and subsequent lysosomal degradation of target proteins,REGION:Second lumenal domain,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
LAPTM4A	lysosomal protein transmembrane 4 alpha(LAPTM4A)	Homo sapiens				GO:0005765~lysosomal membrane,GO:0005794~Golgi apparatus,GO:0016020~membrane,GO:0031902~late endosome membrane,	GO:0005515~protein binding,	IPR004687:LAPTM4/5,IPR018396:LAPTM_4A/5,	hsa04142:Lysosome,				KW-0813~Transport,	KW-0472~Membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,	TRANSMEM:Helical,
LAPTM5	lysosomal protein transmembrane 5(LAPTM5)	Homo sapiens			GO:0002357~defense response to tumor cell,GO:0002720~positive regulation of cytokine production involved in immune response,GO:0006622~protein targeting to lysosome,GO:0006886~intracellular protein transport,GO:0006919~activation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0012502~induction of programmed cell death,GO:0031398~positive regulation of protein ubiquitination,GO:0032689~negative regulation of interferon-gamma production,GO:0032703~negative regulation of interleukin-2 production,GO:0032735~positive regulation of interleukin-12 production,GO:0043410~positive regulation of MAPK cascade,GO:0050860~negative regulation of T cell receptor signaling pathway,GO:0050868~negative regulation of T cell activation,GO:0050869~negative regulation of B cell activation,GO:0060907~positive regulation of macrophage cytokine production,GO:0090160~Golgi to lysosome transport,GO:0097214~positive regulation of lysosomal membrane permeability,GO:1901224~positive regulation of NIK/NF-kappaB signaling,GO:1903265~positive regulation of tumor necrosis factor-mediated signaling pathway,GO:1904093~negative regulation of autophagic cell death,GO:2000060~positive regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process,GO:2000646~positive regulation of receptor catabolic process,	GO:0005764~lysosome,GO:0005765~lysosomal membrane,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0030133~transport vesicle,GO:0031410~cytoplasmic vesicle,GO:0032991~macromolecular complex,GO:0048471~perinuclear region of cytoplasm,	GO:0005515~protein binding,GO:0031625~ubiquitin protein ligase binding,	IPR004687:LAPTM4/5,IPR018396:LAPTM_4A/5,	hsa04142:Lysosome,				KW-0813~Transport,	KW-0458~Lysosome,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,	TRANSMEM:Helical,
LYST	lysosomal trafficking regulator(LYST)	Homo sapiens			GO:0006909~phagocytosis,GO:0008104~protein localization,GO:0015031~protein transport,GO:0030595~leukocyte chemotaxis,GO:0032438~melanosome organization,GO:0032510~endosome to lysosome transport via multivesicular body sorting pathway,GO:0033364~mast cell secretory granule organization,GO:0042267~natural killer cell mediated cytotoxicity,GO:0042742~defense response to bacterium,GO:0042832~defense response to protozoan,GO:0043473~pigmentation,GO:0051607~defense response to virus,	GO:0005829~cytosol,GO:0015630~microtubule cytoskeleton,GO:0016020~membrane,	GO:0005515~protein binding,GO:0019901~protein kinase binding,	IPR000409:BEACH_dom,IPR001680:WD40_rpt,IPR011993:PH-like_dom_sf,IPR015943:WD40/YVTN_repeat-like_dom_sf,IPR016024:ARM-type_fold,IPR019775:WD40_repeat_CS,IPR023362:PH-BEACH_dom,IPR036322:WD40_repeat_dom_sf,IPR036372:BEACH_dom_sf,		214500~Chediak-Higashi syndrome,		SM00320:WD40,SM01026:Beach,	KW-0581~Phagocytosis,KW-0653~Protein transport,KW-0813~Transport,	KW-0963~Cytoplasm,	KW-0225~Disease variant,	KW-0677~Repeat,KW-0732~Signal,KW-0853~WD repeat,			KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:BEACH,DOMAIN:BEACH-type PH,REGION:Disordered,REPEAT:WD,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,REPEAT:WD 7,
MAEA	macrophage erythroblast attacher, E3 ubiquitin ligase(MAEA)	Homo sapiens			GO:0007010~cytoskeleton organization,GO:0007049~cell cycle,GO:0007155~cell adhesion,GO:0007346~regulation of mitotic cell cycle,GO:0033033~negative regulation of myeloid cell apoptotic process,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0043249~erythrocyte maturation,GO:0048822~enucleate erythrocyte development,GO:0051301~cell division,	GO:0000151~ubiquitin ligase complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005819~spindle,GO:0005826~actomyosin contractile ring,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0016363~nuclear matrix,GO:0034657~GID complex,	GO:0003779~actin binding,GO:0004842~ubiquitin-protein transferase activity,GO:0046872~metal ion binding,GO:0061630~ubiquitin protein ligase activity,	IPR006594:LisH,IPR006595:CTLH_C,IPR013144:CRA_dom,IPR024964:CTLH/CRA,IPR027370:Znf-RING_euk,IPR044063:ZF_RING_GID,IPR045098:Fyv10_fam,				SM00667:LisH,SM00668:CTLH,SM00757:CRA,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0265~Erythrocyte maturation,KW-0833~Ubl conjugation pathway,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0009~Actin-binding,KW-0808~Transferase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	DOMAIN:CTLH,DOMAIN:LisH,DOMAIN:RING-Gid-type,REGION:Disordered,REGION:Extracellular and involved in cell to cell contact,SITE:Essential for ubiquitin ligase activity,ZN_FING:RING-Gid-type,
MFSD10	major facilitator superfamily domain containing 10(MFSD10)	Homo sapiens			GO:0006915~apoptotic process,GO:0015904~tetracycline transport,GO:0043252~sodium-independent organic anion transport,	GO:0005637~nuclear inner membrane,GO:0016020~membrane,GO:0030659~cytoplasmic vesicle membrane,GO:0031526~brush border membrane,	GO:0005515~protein binding,GO:0008493~tetracycline transporter activity,GO:0008514~organic anion transmembrane transporter activity,GO:0022857~transmembrane transporter activity,	IPR011701:MFS,IPR020846:MFS_dom,IPR036259:MFS_trans_sf,					KW-0053~Apoptosis,KW-0813~Transport,	KW-0472~Membrane,KW-0539~Nucleus,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				DOMAIN:Major facilitator superfamily (MFS) profile,REGION:Disordered,TRANSMEM:Helical,
MFSD11	major facilitator superfamily domain containing 11(MFSD11)	Homo sapiens				GO:0016020~membrane,	GO:0005515~protein binding,	IPR010291:Ion_channel_UNC-93,IPR036259:MFS_trans_sf,						KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,TRANSMEM:Helical,
MFSD14A	major facilitator superfamily domain containing 14A(MFSD14A)	Homo sapiens			GO:0001675~acrosome assembly,GO:0007289~spermatid nucleus differentiation,GO:0030382~sperm mitochondrion organization,GO:0055085~transmembrane transport,	GO:0016020~membrane,	GO:0022857~transmembrane transporter activity,	IPR001958:Tet-R_TetA/multi-R_MdtG-like,IPR005829:Sugar_transporter_CS,IPR011701:MFS,IPR020846:MFS_dom,IPR036259:MFS_trans_sf,					KW-0813~Transport,	KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Major facilitator superfamily (MFS) profile,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=10,TRANSMEM:Helical; Name=11,TRANSMEM:Helical; Name=12,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,TRANSMEM:Helical; Name=8,TRANSMEM:Helical; Name=9,
MFSD5	major facilitator superfamily domain containing 5(MFSD5)	Homo sapiens			GO:0006811~ion transport,GO:0015689~molybdate ion transport,	GO:0005886~plasma membrane,GO:0016020~membrane,	GO:0005515~protein binding,GO:0015098~molybdate ion transmembrane transporter activity,	IPR008509:MOT2/MFSD5,IPR036259:MFS_trans_sf,					KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				TRANSMEM:Helical,
HLA-A	major histocompatibility complex, class I, A(HLA-A)	Homo sapiens	70.Signal_peptides_(MHC)_class_I_molecules,	h_ctlPathway:CTL mediated immune response against target cells ,h_mhcPathway:Antigen Processing and Presentation,h_nkcellsPathway:Ras-Independent pathway in NK cell-mediated cytotoxicity,	GO:0001913~T cell mediated cytotoxicity,GO:0001916~positive regulation of T cell mediated cytotoxicity,GO:0002250~adaptive immune response,GO:0002419~T cell mediated cytotoxicity directed against tumor cell target,GO:0002476~antigen processing and presentation of endogenous peptide antigen via MHC class Ib,GO:0002485~antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-dependent,GO:0002486~antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent,GO:0002502~peptide antigen assembly with MHC class I protein complex,GO:0002504~antigen processing and presentation of peptide or polysaccharide antigen via MHC class II,GO:0002726~positive regulation of T cell cytokine production,GO:0006955~immune response,GO:0016045~detection of bacterium,GO:0019731~antibacterial humoral response,GO:0019882~antigen processing and presentation,GO:0019885~antigen processing and presentation of endogenous peptide antigen via MHC class I,GO:0032729~positive regulation of interferon-gamma production,GO:0036037~CD8-positive, alpha-beta T cell activation,GO:0042270~protection from natural killer cell mediated cytotoxicity,GO:0042590~antigen processing and presentation of exogenous peptide antigen via MHC class I,GO:0045087~innate immune response,GO:0050830~defense response to Gram-positive bacterium,GO:0050852~T cell receptor signaling pathway,GO:2000566~positive regulation of CD8-positive, alpha-beta T cell proliferation,GO:2000568~positive regulation of memory T cell activation,GO:2001187~positive regulation of CD8-positive, alpha-beta T cell activation,	GO:0000139~Golgi membrane,GO:0005615~extracellular space,GO:0005765~lysosomal membrane,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005794~Golgi apparatus,GO:0005797~Golgi medial cisterna,GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0010008~endosome membrane,GO:0012507~ER to Golgi transport vesicle membrane,GO:0016020~membrane,GO:0030670~phagocytic vesicle membrane,GO:0031901~early endosome membrane,GO:0042612~MHC class I protein complex,GO:0042613~MHC class II protein complex,GO:0042824~MHC class I peptide loading complex,GO:0055038~recycling endosome membrane,GO:0070062~extracellular exosome,GO:0070971~endoplasmic reticulum exit site,GO:0098553~lumenal side of endoplasmic reticulum membrane,	GO:0003723~RNA binding,GO:0005102~receptor binding,GO:0005515~protein binding,GO:0030881~beta-2-microglobulin binding,GO:0042605~peptide antigen binding,GO:0042608~T cell receptor binding,GO:0042610~CD8 receptor binding,GO:0046977~TAP binding,	IPR000353:MHC_II_b_N,IPR001039:MHC_I_a_a1/a2,IPR003006:Ig/MHC_CS,IPR003597:Ig_C1-set,IPR007110:Ig-like_dom,IPR010579:MHC_I_a_C,IPR011161:MHC_I-like_Ag-recog,IPR011162:MHC_I/II-like_Ag-recog,IPR013783:Ig-like_fold,IPR014745:MHC_II_a/b_N,IPR036179:Ig-like_dom_sf,IPR037055:MHC_I-like_Ag-recog_sf,	hsa04144:Endocytosis,hsa04145:Phagosome,hsa04218:Cellular senescence,hsa04514:Cell adhesion molecules,hsa04612:Antigen processing and presentation,hsa04940:Type I diabetes mellitus,hsa05163:Human cytomegalovirus infection,hsa05165:Human papillomavirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05203:Viral carcinogenesis,hsa05320:Autoimmune thyroid disease,hsa05330:Allograft rejection,hsa05332:Graft-versus-host disease,hsa05416:Viral myocarditis,	608579~Hypersensitivity syndrome, carbamazepine-induced, susceptibility to,		SM00407:IGc1,SM00921:MHC_II_beta,	KW-0391~Immunity,KW-0399~Innate immunity,KW-0945~Host-virus interaction,KW-1064~Adaptive immunity,	KW-0256~Endoplasmic reticulum,KW-0458~Lysosome,KW-0472~Membrane,KW-0490~MHC I,KW-0491~MHC II,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0765~Sulfation,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,DOMAIN:Ig-like,DOMAIN:Ig-like C1-type,DOMAIN:Immunoglobulin C1-set,DOMAIN:MHC class I alpha chain C-terminal,DOMAIN:MHC class I-like antigen recognition-like,DOMAIN:MHC class II beta chain N-terminal,MUTAGEN:N->Q: Impairs the recruitment of HLA-A*02 in the peptide-loading complex.,MUTAGEN:S->C: Impairs the maturation of a peptide-receptive HLA-A*02-B2M complex.,MUTAGEN:T->K: Impairs binding to TAP1-TAP2 transporter, resulting in impaired presentation of intracellular peptides.,REGION:Alpha-1,REGION:Alpha-2,REGION:Alpha-3,REGION:Connecting peptide,REGION:Disordered,REGION:VL9 epitope,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,UNSURE:I or L,
HLA-B	major histocompatibility complex, class I, B(HLA-B)	Homo sapiens	70.Signal_peptides_(MHC)_class_I_molecules,		GO:0001916~positive regulation of T cell mediated cytotoxicity,GO:0002250~adaptive immune response,GO:0002476~antigen processing and presentation of endogenous peptide antigen via MHC class Ib,GO:0002486~antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent,GO:0002504~antigen processing and presentation of peptide or polysaccharide antigen via MHC class II,GO:0002667~regulation of T cell anergy,GO:0006952~defense response,GO:0006955~immune response,GO:0016045~detection of bacterium,GO:0019882~antigen processing and presentation,GO:0032655~regulation of interleukin-12 production,GO:0032675~regulation of interleukin-6 production,GO:0042270~protection from natural killer cell mediated cytotoxicity,GO:0045087~innate immune response,GO:2001198~regulation of dendritic cell differentiation,	GO:0000139~Golgi membrane,GO:0005615~extracellular space,GO:0005765~lysosomal membrane,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0010008~endosome membrane,GO:0012507~ER to Golgi transport vesicle membrane,GO:0016020~membrane,GO:0030667~secretory granule membrane,GO:0030670~phagocytic vesicle membrane,GO:0031901~early endosome membrane,GO:0042612~MHC class I protein complex,GO:0042613~MHC class II protein complex,GO:0055038~recycling endosome membrane,GO:0070062~extracellular exosome,GO:0098553~lumenal side of endoplasmic reticulum membrane,	GO:0005102~receptor binding,GO:0005515~protein binding,GO:0042605~peptide antigen binding,GO:0046977~TAP binding,GO:0051087~chaperone binding,	IPR000353:MHC_II_b_N,IPR001039:MHC_I_a_a1/a2,IPR003006:Ig/MHC_CS,IPR003597:Ig_C1-set,IPR007110:Ig-like_dom,IPR010579:MHC_I_a_C,IPR011161:MHC_I-like_Ag-recog,IPR011162:MHC_I/II-like_Ag-recog,IPR013783:Ig-like_fold,IPR014745:MHC_II_a/b_N,IPR036179:Ig-like_dom_sf,IPR037055:MHC_I-like_Ag-recog_sf,	hsa04144:Endocytosis,hsa04145:Phagosome,hsa04218:Cellular senescence,hsa04514:Cell adhesion molecules,hsa04612:Antigen processing and presentation,hsa04940:Type I diabetes mellitus,hsa05163:Human cytomegalovirus infection,hsa05165:Human papillomavirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05203:Viral carcinogenesis,hsa05320:Autoimmune thyroid disease,hsa05330:Allograft rejection,hsa05332:Graft-versus-host disease,hsa05416:Viral myocarditis,	106300~Spondyloarthropathy, susceptibility to, 1,608579~Stevens-Johnson syndrome, susceptibility to,608579~Toxic epidermal necrolysis, susceptibility to,Abacavir hypersensitivity, susceptibility to~Abacavir hypersensitivity, susceptibility to,Drug-induced liver injury due to flucloxacillin~Drug-induced liver injury due to flucloxacillin,Synovitis, chronic, susceptibility to~Synovitis, chronic, susceptibility to,		SM00407:IGc1,SM00921:MHC_II_beta,	KW-0391~Immunity,KW-0399~Innate immunity,KW-0945~Host-virus interaction,KW-1064~Adaptive immunity,	KW-0256~Endoplasmic reticulum,KW-0458~Lysosome,KW-0472~Membrane,KW-0490~MHC I,KW-0491~MHC II,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,DOMAIN:Ig-like,DOMAIN:Ig-like C1-type,DOMAIN:Immunoglobulin C1-set,DOMAIN:MHC class I alpha chain C-terminal,DOMAIN:MHC class I-like antigen recognition-like,MOTIF:Bw6 motif,REGION:Alpha-1,REGION:Alpha-2,REGION:Alpha-3,REGION:Connecting peptide,REGION:Disordered,REGION:VL9 epitope,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,UNSURE:D or N,
HLA-C	major histocompatibility complex, class I, C(HLA-C)	Homo sapiens	70.Signal_peptides_(MHC)_class_I_molecules,		GO:0001916~positive regulation of T cell mediated cytotoxicity,GO:0002250~adaptive immune response,GO:0002476~antigen processing and presentation of endogenous peptide antigen via MHC class Ib,GO:0002486~antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent,GO:0006955~immune response,GO:0019882~antigen processing and presentation,GO:0045087~innate immune response,	GO:0000139~Golgi membrane,GO:0005615~extracellular space,GO:0005783~endoplasmic reticulum,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0012507~ER to Golgi transport vesicle membrane,GO:0016020~membrane,GO:0030667~secretory granule membrane,GO:0030670~phagocytic vesicle membrane,GO:0031901~early endosome membrane,GO:0042612~MHC class I protein complex,GO:0042613~MHC class II protein complex,GO:0055038~recycling endosome membrane,GO:0070062~extracellular exosome,GO:0098553~lumenal side of endoplasmic reticulum membrane,	GO:0005102~receptor binding,GO:0005515~protein binding,GO:0032395~MHC class II receptor activity,GO:0042605~peptide antigen binding,GO:0046977~TAP binding,	IPR000353:MHC_II_b_N,IPR001039:MHC_I_a_a1/a2,IPR003006:Ig/MHC_CS,IPR003597:Ig_C1-set,IPR007110:Ig-like_dom,IPR010579:MHC_I_a_C,IPR011161:MHC_I-like_Ag-recog,IPR011162:MHC_I/II-like_Ag-recog,IPR013783:Ig-like_fold,IPR014745:MHC_II_a/b_N,IPR036179:Ig-like_dom_sf,IPR037055:MHC_I-like_Ag-recog_sf,	hsa04144:Endocytosis,hsa04145:Phagosome,hsa04218:Cellular senescence,hsa04514:Cell adhesion molecules,hsa04612:Antigen processing and presentation,hsa04940:Type I diabetes mellitus,hsa05163:Human cytomegalovirus infection,hsa05165:Human papillomavirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05203:Viral carcinogenesis,hsa05320:Autoimmune thyroid disease,hsa05330:Allograft rejection,hsa05332:Graft-versus-host disease,hsa05416:Viral myocarditis,	177900~Psoriasis susceptibility 1,609423~HIV-1 viremia, susceptibility to,		SM00407:IGc1,SM00921:MHC_II_beta,	KW-0391~Immunity,KW-0399~Innate immunity,KW-0945~Host-virus interaction,KW-1064~Adaptive immunity,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0490~MHC I,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Ig-like,DOMAIN:Ig-like C1-type,DOMAIN:Immunoglobulin C1-set,DOMAIN:MHC class I alpha chain C-terminal,DOMAIN:MHC class I-like antigen recognition-like,DOMAIN:MHC class II beta chain N-terminal,MUTAGEN:S->G: Impairs N-linked glycosylation resulting in impaired interaction with CANX and CALR chaperones as well as TAPBPL.,REGION:Alpha-1,REGION:Alpha-2,REGION:Alpha-3,REGION:Connecting peptide,REGION:Disordered,REGION:VL9 epitope,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
HLA-E	major histocompatibility complex, class I, E(HLA-E)	Homo sapiens	70.Signal_peptides_(MHC)_class_I_molecules,		GO:0001815~positive regulation of antibody-dependent cellular cytotoxicity,GO:0001916~positive regulation of T cell mediated cytotoxicity,GO:0002250~adaptive immune response,GO:0002476~antigen processing and presentation of endogenous peptide antigen via MHC class Ib,GO:0002477~antigen processing and presentation of exogenous peptide antigen via MHC class Ib,GO:0002486~antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent,GO:0002519~natural killer cell tolerance induction,GO:0002639~positive regulation of immunoglobulin production,GO:0002715~regulation of natural killer cell mediated immunity,GO:0002717~positive regulation of natural killer cell mediated immunity,GO:0002729~positive regulation of natural killer cell cytokine production,GO:0006955~immune response,GO:0019731~antibacterial humoral response,GO:0019882~antigen processing and presentation,GO:0032736~positive regulation of interleukin-13 production,GO:0032753~positive regulation of interleukin-4 production,GO:0032759~positive regulation of TRAIL production,GO:0032760~positive regulation of tumor necrosis factor production,GO:0032815~negative regulation of natural killer cell activation,GO:0032816~positive regulation of natural killer cell activation,GO:0032819~positive regulation of natural killer cell proliferation,GO:0036037~CD8-positive, alpha-beta T cell activation,GO:0042130~negative regulation of T cell proliferation,GO:0042270~protection from natural killer cell mediated cytotoxicity,GO:0045087~innate immune response,GO:0045953~negative regulation of natural killer cell mediated cytotoxicity,GO:0045954~positive regulation of natural killer cell mediated cytotoxicity,GO:0050830~defense response to Gram-positive bacterium,GO:2000566~positive regulation of CD8-positive, alpha-beta T cell proliferation,GO:2001187~positive regulation of CD8-positive, alpha-beta T cell activation,	GO:0000139~Golgi membrane,GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0012507~ER to Golgi transport vesicle membrane,GO:0016020~membrane,GO:0030670~phagocytic vesicle membrane,GO:0031901~early endosome membrane,GO:0032398~MHC class Ib protein complex,GO:0042612~MHC class I protein complex,GO:0055038~recycling endosome membrane,GO:0070062~extracellular exosome,GO:0098553~lumenal side of endoplasmic reticulum membrane,	GO:0005102~receptor binding,GO:0005515~protein binding,GO:0030881~beta-2-microglobulin binding,GO:0042288~MHC class I protein binding,GO:0042605~peptide antigen binding,GO:0042608~T cell receptor binding,GO:0046703~natural killer cell lectin-like receptor binding,	IPR001039:MHC_I_a_a1/a2,IPR003006:Ig/MHC_CS,IPR003597:Ig_C1-set,IPR007110:Ig-like_dom,IPR010579:MHC_I_a_C,IPR011161:MHC_I-like_Ag-recog,IPR011162:MHC_I/II-like_Ag-recog,IPR013783:Ig-like_fold,IPR036179:Ig-like_dom_sf,IPR037055:MHC_I-like_Ag-recog_sf,	hsa04144:Endocytosis,hsa04145:Phagosome,hsa04218:Cellular senescence,hsa04514:Cell adhesion molecules,hsa04612:Antigen processing and presentation,hsa04940:Type I diabetes mellitus,hsa05163:Human cytomegalovirus infection,hsa05165:Human papillomavirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05203:Viral carcinogenesis,hsa05320:Autoimmune thyroid disease,hsa05330:Allograft rejection,hsa05332:Graft-versus-host disease,hsa05416:Viral myocarditis,			SM00407:IGc1,	KW-0391~Immunity,KW-0399~Innate immunity,KW-0945~Host-virus interaction,KW-1064~Adaptive immunity,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0490~MHC I,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Ig-like,DOMAIN:Ig-like C1-type,DOMAIN:Immunoglobulin C1-set,DOMAIN:MHC class I-like antigen recognition-like,MUTAGEN:D->A: Has no impact on the affinity for KLRD1-KLRC1.,MUTAGEN:D->A: Impairs the recognition by KLRD1-KLRC1.,MUTAGEN:E->A: Has no impact on the affinity for KLRD1-KLRC1.,MUTAGEN:E->A: Impairs the recognition by KLRD1-KLRC1.,MUTAGEN:E->A: Reduces the affinity for KLRD1-KLRC1.,MUTAGEN:H->A: Has no impact on the affinity for KLRD1-KLRC1.,MUTAGEN:K->A: Impairs folding.,MUTAGEN:Q->A: Impairs the recognition by KLRD1-KLRC1.,MUTAGEN:R->A: Abolishes the recognition by KLRD1-KLRC1.,MUTAGEN:R->A: Has no impact on the affinity for KLRD1-KLRC1.,MUTAGEN:R->A: Reduces the affinity for KLRD1-KLRC1.,MUTAGEN:T->A: Has no impact on the affinity for KLRD1-KLRC1.,MUTAGEN:V->A: Impairs the recognition by KLRD1-KLRC1.,REGION:Alpha-1,REGION:Alpha-2,REGION:Alpha-3,REGION:Connecting peptide,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
HLA-F	major histocompatibility complex, class I, F(HLA-F)	Homo sapiens			GO:0001916~positive regulation of T cell mediated cytotoxicity,GO:0002476~antigen processing and presentation of endogenous peptide antigen via MHC class Ib,GO:0002477~antigen processing and presentation of exogenous peptide antigen via MHC class Ib,GO:0002486~antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent,GO:0002725~negative regulation of T cell cytokine production,GO:0002728~negative regulation of natural killer cell cytokine production,GO:0002729~positive regulation of natural killer cell cytokine production,GO:0006955~immune response,GO:0019882~antigen processing and presentation,GO:0043322~negative regulation of natural killer cell degranulation,GO:0043323~positive regulation of natural killer cell degranulation,GO:0045953~negative regulation of natural killer cell mediated cytotoxicity,	GO:0000139~Golgi membrane,GO:0005615~extracellular space,GO:0005765~lysosomal membrane,GO:0005783~endoplasmic reticulum,GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0012507~ER to Golgi transport vesicle membrane,GO:0016020~membrane,GO:0030670~phagocytic vesicle membrane,GO:0031901~early endosome membrane,GO:0032398~MHC class Ib protein complex,GO:0042612~MHC class I protein complex,GO:0055038~recycling endosome membrane,GO:0098553~lumenal side of endoplasmic reticulum membrane,	GO:0005102~receptor binding,GO:0005515~protein binding,GO:0030881~beta-2-microglobulin binding,GO:0042605~peptide antigen binding,GO:0046978~TAP1 binding,GO:0046979~TAP2 binding,GO:0071889~14-3-3 protein binding,	IPR001039:MHC_I_a_a1/a2,IPR003006:Ig/MHC_CS,IPR003597:Ig_C1-set,IPR007110:Ig-like_dom,IPR010579:MHC_I_a_C,IPR011161:MHC_I-like_Ag-recog,IPR011162:MHC_I/II-like_Ag-recog,IPR013783:Ig-like_fold,IPR036179:Ig-like_dom_sf,IPR037055:MHC_I-like_Ag-recog_sf,	hsa04144:Endocytosis,hsa04145:Phagosome,hsa04218:Cellular senescence,hsa04514:Cell adhesion molecules,hsa04612:Antigen processing and presentation,hsa04940:Type I diabetes mellitus,hsa05163:Human cytomegalovirus infection,hsa05165:Human papillomavirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05203:Viral carcinogenesis,hsa05320:Autoimmune thyroid disease,hsa05330:Allograft rejection,hsa05332:Graft-versus-host disease,hsa05416:Viral myocarditis,			SM00407:IGc1,	KW-0391~Immunity,	KW-0458~Lysosome,KW-0472~Membrane,KW-0490~MHC I,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like,DOMAIN:Ig-like C1-type,DOMAIN:MHC class I-like antigen recognition-like,MOTIF:Sorting signal sequence; Golgi-retention signal; ER-retention signal,MUTAGEN:Missing: Impairs the interaction with coat protein complex II; impairs the anterograde ER-to-Golgi transport.,MUTAGEN:RNR->AAA: Impairs the interaction with 14-3-3 proteins.,MUTAGEN:RNR->GKG: Impairs the anterograde ER-to-Golgi transport.,MUTAGEN:V->S: Impairs the anterograde ER-to-Golgi transport.,MUTAGEN:W->R: Impairs peptide binding.,REGION:Alpha-1,REGION:Alpha-2,REGION:Alpha-3,REGION:Connecting peptide,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
HLA-DMA	major histocompatibility complex, class II, DM alpha(HLA-DMA)	Homo sapiens			GO:0002250~adaptive immune response,GO:0002503~peptide antigen assembly with MHC class II protein complex,GO:0002504~antigen processing and presentation of peptide or polysaccharide antigen via MHC class II,GO:0006955~immune response,GO:0019882~antigen processing and presentation,GO:0019886~antigen processing and presentation of exogenous peptide antigen via MHC class II,GO:0050778~positive regulation of immune response,GO:0050870~positive regulation of T cell activation,	GO:0005765~lysosomal membrane,GO:0009986~cell surface,GO:0010008~endosome membrane,GO:0016020~membrane,GO:0031902~late endosome membrane,GO:0042613~MHC class II protein complex,GO:0043231~intracellular membrane-bounded organelle,	GO:0005515~protein binding,GO:0023026~MHC class II protein complex binding,GO:0032395~MHC class II receptor activity,GO:0042605~peptide antigen binding,	IPR001003:MHC_II_a_N,IPR003006:Ig/MHC_CS,IPR003597:Ig_C1-set,IPR007110:Ig-like_dom,IPR011162:MHC_I/II-like_Ag-recog,IPR013783:Ig-like_fold,IPR014745:MHC_II_a/b_N,IPR036179:Ig-like_dom_sf,	hsa04145:Phagosome,hsa04514:Cell adhesion molecules,hsa04612:Antigen processing and presentation,hsa04640:Hematopoietic cell lineage,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04672:Intestinal immune network for IgA production,hsa04940:Type I diabetes mellitus,hsa05140:Leishmaniasis,hsa05145:Toxoplasmosis,hsa05150:Staphylococcus aureus infection,hsa05152:Tuberculosis,hsa05164:Influenza A,hsa05166:Human T-cell leukemia virus 1 infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05310:Asthma,hsa05320:Autoimmune thyroid disease,hsa05321:Inflammatory bowel disease,hsa05322:Systemic lupus erythematosus,hsa05323:Rheumatoid arthritis,hsa05330:Allograft rejection,hsa05332:Graft-versus-host disease,hsa05416:Viral myocarditis,			SM00407:IGc1,SM00920:MHC_II_alpha,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0458~Lysosome,KW-0472~Membrane,KW-0491~MHC II,KW-0967~Endosome,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like,DOMAIN:Ig-like C1-type,DOMAIN:Immunoglobulin C1-set,DOMAIN:MHC class II alpha chain N-terminal,MUTAGEN:F->A: Decreases the interaction with MHCII and peptide exchange.,MUTAGEN:I->N: Decreases the interaction with MHCII and peptide exchange.,MUTAGEN:N->A,R: Abrogates the interaction with MHCII and peptide exchange.,MUTAGEN:R->A: Decreases the interaction with MHCII and peptide exchange; when associated with A-124.,MUTAGEN:R->A: Decreases the interaction with MHCII and peptide exchange; when associated with A-220.,REGION:Alpha-1,REGION:Alpha-2,REGION:Connecting peptide,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
HLA-DPA1	major histocompatibility complex, class II, DP alpha 1(HLA-DPA1)	Homo sapiens			GO:0002250~adaptive immune response,GO:0002503~peptide antigen assembly with MHC class II protein complex,GO:0002504~antigen processing and presentation of peptide or polysaccharide antigen via MHC class II,GO:0006955~immune response,GO:0019882~antigen processing and presentation,GO:0019886~antigen processing and presentation of exogenous peptide antigen via MHC class II,GO:0032729~positive regulation of interferon-gamma production,GO:0042102~positive regulation of T cell proliferation,GO:0050778~positive regulation of immune response,GO:0050870~positive regulation of T cell activation,GO:0071346~cellular response to interferon-gamma,	GO:0000139~Golgi membrane,GO:0005765~lysosomal membrane,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0010008~endosome membrane,GO:0012507~ER to Golgi transport vesicle membrane,GO:0016020~membrane,GO:0030658~transport vesicle membrane,GO:0030666~endocytic vesicle membrane,GO:0030669~clathrin-coated endocytic vesicle membrane,GO:0031902~late endosome membrane,GO:0032588~trans-Golgi network membrane,GO:0042613~MHC class II protein complex,GO:0043231~intracellular membrane-bounded organelle,GO:0098553~lumenal side of endoplasmic reticulum membrane,	GO:0023026~MHC class II protein complex binding,GO:0032395~MHC class II receptor activity,GO:0042605~peptide antigen binding,	IPR001003:MHC_II_a_N,IPR003006:Ig/MHC_CS,IPR003597:Ig_C1-set,IPR007110:Ig-like_dom,IPR011162:MHC_I/II-like_Ag-recog,IPR013783:Ig-like_fold,IPR014745:MHC_II_a/b_N,IPR036179:Ig-like_dom_sf,	hsa04145:Phagosome,hsa04514:Cell adhesion molecules,hsa04612:Antigen processing and presentation,hsa04640:Hematopoietic cell lineage,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04672:Intestinal immune network for IgA production,hsa04940:Type I diabetes mellitus,hsa05140:Leishmaniasis,hsa05145:Toxoplasmosis,hsa05150:Staphylococcus aureus infection,hsa05152:Tuberculosis,hsa05164:Influenza A,hsa05166:Human T-cell leukemia virus 1 infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05310:Asthma,hsa05320:Autoimmune thyroid disease,hsa05321:Inflammatory bowel disease,hsa05322:Systemic lupus erythematosus,hsa05323:Rheumatoid arthritis,hsa05330:Allograft rejection,hsa05332:Graft-versus-host disease,hsa05416:Viral myocarditis,			SM00407:IGc1,SM00920:MHC_II_alpha,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0458~Lysosome,KW-0472~Membrane,KW-0491~MHC II,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like,DOMAIN:Ig-like C1-type,DOMAIN:Immunoglobulin C1-set,DOMAIN:MHC class II alpha chain N-terminal,REGION:Alpha-1,REGION:Alpha-2,REGION:Connecting peptide,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
HLA-DPB1	major histocompatibility complex, class II, DP beta 1(HLA-DPB1)	Homo sapiens			GO:0002250~adaptive immune response,GO:0002503~peptide antigen assembly with MHC class II protein complex,GO:0002504~antigen processing and presentation of peptide or polysaccharide antigen via MHC class II,GO:0006955~immune response,GO:0019882~antigen processing and presentation,GO:0019886~antigen processing and presentation of exogenous peptide antigen via MHC class II,GO:0032729~positive regulation of interferon-gamma production,GO:0042102~positive regulation of T cell proliferation,GO:0050778~positive regulation of immune response,GO:0050852~T cell receptor signaling pathway,GO:0050870~positive regulation of T cell activation,	GO:0000139~Golgi membrane,GO:0005765~lysosomal membrane,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0010008~endosome membrane,GO:0012507~ER to Golgi transport vesicle membrane,GO:0016020~membrane,GO:0030658~transport vesicle membrane,GO:0030666~endocytic vesicle membrane,GO:0030669~clathrin-coated endocytic vesicle membrane,GO:0030670~phagocytic vesicle membrane,GO:0031901~early endosome membrane,GO:0031902~late endosome membrane,GO:0032588~trans-Golgi network membrane,GO:0042613~MHC class II protein complex,GO:0055038~recycling endosome membrane,GO:0098553~lumenal side of endoplasmic reticulum membrane,	GO:0005515~protein binding,GO:0023026~MHC class II protein complex binding,GO:0032395~MHC class II receptor activity,GO:0042605~peptide antigen binding,	IPR000353:MHC_II_b_N,IPR001003:MHC_II_a_N,IPR001039:MHC_I_a_a1/a2,IPR003006:Ig/MHC_CS,IPR003597:Ig_C1-set,IPR007110:Ig-like_dom,IPR010579:MHC_I_a_C,IPR011161:MHC_I-like_Ag-recog,IPR011162:MHC_I/II-like_Ag-recog,IPR013783:Ig-like_fold,IPR014745:MHC_II_a/b_N,IPR036179:Ig-like_dom_sf,IPR037055:MHC_I-like_Ag-recog_sf,	hsa04145:Phagosome,hsa04514:Cell adhesion molecules,hsa04612:Antigen processing and presentation,hsa04640:Hematopoietic cell lineage,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04672:Intestinal immune network for IgA production,hsa04940:Type I diabetes mellitus,hsa05140:Leishmaniasis,hsa05145:Toxoplasmosis,hsa05150:Staphylococcus aureus infection,hsa05152:Tuberculosis,hsa05164:Influenza A,hsa05166:Human T-cell leukemia virus 1 infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05310:Asthma,hsa05320:Autoimmune thyroid disease,hsa05321:Inflammatory bowel disease,hsa05322:Systemic lupus erythematosus,hsa05323:Rheumatoid arthritis,hsa05330:Allograft rejection,hsa05332:Graft-versus-host disease,hsa05416:Viral myocarditis,	Beryllium disease, chronic, susceptibility to~Beryllium disease, chronic, susceptibility to,		SM00407:IGc1,SM00920:MHC_II_alpha,SM00921:MHC_II_beta,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0458~Lysosome,KW-0472~Membrane,KW-0491~MHC II,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:Ig-like,DOMAIN:Ig-like C1-type,DOMAIN:MHC class II beta chain N-terminal,REGION:Beta-1,REGION:Beta-2,REGION:Connecting peptide,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
HLA-DQA1	major histocompatibility complex, class II, DQ alpha 1(HLA-DQA1)	Homo sapiens			GO:0002250~adaptive immune response,GO:0002503~peptide antigen assembly with MHC class II protein complex,GO:0002504~antigen processing and presentation of peptide or polysaccharide antigen via MHC class II,GO:0006955~immune response,GO:0019882~antigen processing and presentation,GO:0019886~antigen processing and presentation of exogenous peptide antigen via MHC class II,GO:0050778~positive regulation of immune response,GO:0050870~positive regulation of T cell activation,	GO:0000139~Golgi membrane,GO:0005765~lysosomal membrane,GO:0005886~plasma membrane,GO:0010008~endosome membrane,GO:0012507~ER to Golgi transport vesicle membrane,GO:0016020~membrane,GO:0030658~transport vesicle membrane,GO:0030666~endocytic vesicle membrane,GO:0030669~clathrin-coated endocytic vesicle membrane,GO:0031902~late endosome membrane,GO:0032588~trans-Golgi network membrane,GO:0042613~MHC class II protein complex,GO:0098553~lumenal side of endoplasmic reticulum membrane,	GO:0005515~protein binding,GO:0023026~MHC class II protein complex binding,GO:0032395~MHC class II receptor activity,GO:0042605~peptide antigen binding,GO:0046872~metal ion binding,	IPR001003:MHC_II_a_N,IPR003006:Ig/MHC_CS,IPR003597:Ig_C1-set,IPR007110:Ig-like_dom,IPR011162:MHC_I/II-like_Ag-recog,IPR013783:Ig-like_fold,IPR014745:MHC_II_a/b_N,IPR036179:Ig-like_dom_sf,	hsa04145:Phagosome,hsa04514:Cell adhesion molecules,hsa04612:Antigen processing and presentation,hsa04640:Hematopoietic cell lineage,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04672:Intestinal immune network for IgA production,hsa04940:Type I diabetes mellitus,hsa05140:Leishmaniasis,hsa05145:Toxoplasmosis,hsa05150:Staphylococcus aureus infection,hsa05152:Tuberculosis,hsa05164:Influenza A,hsa05166:Human T-cell leukemia virus 1 infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05310:Asthma,hsa05320:Autoimmune thyroid disease,hsa05321:Inflammatory bowel disease,hsa05322:Systemic lupus erythematosus,hsa05323:Rheumatoid arthritis,hsa05330:Allograft rejection,hsa05332:Graft-versus-host disease,hsa05416:Viral myocarditis,	212750~Celiac disease, susceptibility to,		SM00407:IGc1,SM00920:MHC_II_alpha,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0458~Lysosome,KW-0472~Membrane,KW-0491~MHC II,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like,DOMAIN:Ig-like C1-type,DOMAIN:Immunoglobulin C1-set,DOMAIN:MHC class II alpha chain N-terminal,REGION:Alpha-1,REGION:Alpha-2,REGION:Connecting peptide,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
HLA-DQB1	major histocompatibility complex, class II, DQ beta 1(HLA-DQB1)	Homo sapiens			GO:0002250~adaptive immune response,GO:0002503~peptide antigen assembly with MHC class II protein complex,GO:0002504~antigen processing and presentation of peptide or polysaccharide antigen via MHC class II,GO:0006955~immune response,GO:0006959~humoral immune response,GO:0019882~antigen processing and presentation,GO:0019886~antigen processing and presentation of exogenous peptide antigen via MHC class II,GO:0050778~positive regulation of immune response,GO:0050852~T cell receptor signaling pathway,GO:0050870~positive regulation of T cell activation,	GO:0000139~Golgi membrane,GO:0005765~lysosomal membrane,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0010008~endosome membrane,GO:0012507~ER to Golgi transport vesicle membrane,GO:0016020~membrane,GO:0030658~transport vesicle membrane,GO:0030666~endocytic vesicle membrane,GO:0030669~clathrin-coated endocytic vesicle membrane,GO:0030670~phagocytic vesicle membrane,GO:0031901~early endosome membrane,GO:0031902~late endosome membrane,GO:0032588~trans-Golgi network membrane,GO:0042613~MHC class II protein complex,GO:0055038~recycling endosome membrane,GO:0098553~lumenal side of endoplasmic reticulum membrane,	GO:0005515~protein binding,GO:0023026~MHC class II protein complex binding,GO:0032395~MHC class II receptor activity,GO:0042605~peptide antigen binding,GO:0046872~metal ion binding,	IPR000353:MHC_II_b_N,IPR001039:MHC_I_a_a1/a2,IPR003006:Ig/MHC_CS,IPR003597:Ig_C1-set,IPR007110:Ig-like_dom,IPR010579:MHC_I_a_C,IPR011161:MHC_I-like_Ag-recog,IPR011162:MHC_I/II-like_Ag-recog,IPR013783:Ig-like_fold,IPR014745:MHC_II_a/b_N,IPR036179:Ig-like_dom_sf,IPR037055:MHC_I-like_Ag-recog_sf,	hsa04145:Phagosome,hsa04514:Cell adhesion molecules,hsa04612:Antigen processing and presentation,hsa04640:Hematopoietic cell lineage,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04672:Intestinal immune network for IgA production,hsa04940:Type I diabetes mellitus,hsa05140:Leishmaniasis,hsa05145:Toxoplasmosis,hsa05150:Staphylococcus aureus infection,hsa05152:Tuberculosis,hsa05164:Influenza A,hsa05166:Human T-cell leukemia virus 1 infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05310:Asthma,hsa05320:Autoimmune thyroid disease,hsa05321:Inflammatory bowel disease,hsa05322:Systemic lupus erythematosus,hsa05323:Rheumatoid arthritis,hsa05330:Allograft rejection,hsa05332:Graft-versus-host disease,hsa05416:Viral myocarditis,	123400~Creutzfeldt-Jakob disease, variant, resistance to,126200~Multiple sclerosis, susceptibility to, 1,212750~Celiac disease, susceptibility to,		SM00407:IGc1,SM00921:MHC_II_beta,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0458~Lysosome,KW-0472~Membrane,KW-0491~MHC II,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:Ig-like,DOMAIN:Ig-like C1-type,DOMAIN:Immunoglobulin C1-set,DOMAIN:MHC class II beta chain N-terminal,REGION:Beta-1,REGION:Beta-2,REGION:Connecting peptide,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,UNSURE:E or Q,
HLA-DRA	major histocompatibility complex, class II, DR alpha(HLA-DRA)	Homo sapiens		h_asbcellPathway:Antigen Dependent B Cell Activation,h_bbcellPathway:Bystander B Cell Activation,h_blymphocytePathway:B Lymphocyte Cell Surface Molecules,h_cskPathway:Activation of Csk by cAMP-dependent Protein Kinase Inhibits Signaling through the T Cell Receptor,h_ctla4Pathway:The Co-Stimulatory Signal During T-cell Activation,h_eosinophilsPathway:The Role of Eosinophils in the Chemokine Network of Allergy,h_il5Pathway:IL 5 Signaling Pathway,h_inflamPathway:Cytokines and Inflammatory Response,h_mhcPathway:Antigen Processing and Presentation,h_tcraPathway:Lck and Fyn tyrosine kinases in initiation of TCR Activation,h_th1th2Pathway:Th1/Th2 Differentiation,	GO:0001916~positive regulation of T cell mediated cytotoxicity,GO:0002250~adaptive immune response,GO:0002469~myeloid dendritic cell antigen processing and presentation,GO:0002491~antigen processing and presentation of endogenous peptide antigen via MHC class II,GO:0002503~peptide antigen assembly with MHC class II protein complex,GO:0002504~antigen processing and presentation of peptide or polysaccharide antigen via MHC class II,GO:0006955~immune response,GO:0019882~antigen processing and presentation,GO:0019886~antigen processing and presentation of exogenous peptide antigen via MHC class II,GO:0032831~positive regulation of CD4-positive, CD25-positive, alpha-beta regulatory T cell differentiation,GO:0043382~positive regulation of memory T cell differentiation,GO:0045622~regulation of T-helper cell differentiation,GO:0050778~positive regulation of immune response,GO:0050870~positive regulation of T cell activation,GO:0050890~cognition,GO:2000516~positive regulation of CD4-positive, alpha-beta T cell activation,	GO:0000139~Golgi membrane,GO:0001772~immunological synapse,GO:0005764~lysosome,GO:0005765~lysosomal membrane,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0010008~endosome membrane,GO:0012507~ER to Golgi transport vesicle membrane,GO:0016020~membrane,GO:0030658~transport vesicle membrane,GO:0030666~endocytic vesicle membrane,GO:0030669~clathrin-coated endocytic vesicle membrane,GO:0031901~early endosome membrane,GO:0031902~late endosome membrane,GO:0032588~trans-Golgi network membrane,GO:0042613~MHC class II protein complex,GO:0070062~extracellular exosome,GO:0098553~lumenal side of endoplasmic reticulum membrane,	GO:0005515~protein binding,GO:0023026~MHC class II protein complex binding,GO:0030247~polysaccharide binding,GO:0032395~MHC class II receptor activity,GO:0042605~peptide antigen binding,GO:0042608~T cell receptor binding,	IPR001003:MHC_II_a_N,IPR003006:Ig/MHC_CS,IPR003597:Ig_C1-set,IPR007110:Ig-like_dom,IPR011162:MHC_I/II-like_Ag-recog,IPR013783:Ig-like_fold,IPR014745:MHC_II_a/b_N,IPR036179:Ig-like_dom_sf,	hsa04145:Phagosome,hsa04514:Cell adhesion molecules,hsa04612:Antigen processing and presentation,hsa04640:Hematopoietic cell lineage,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04672:Intestinal immune network for IgA production,hsa04940:Type I diabetes mellitus,hsa05140:Leishmaniasis,hsa05145:Toxoplasmosis,hsa05150:Staphylococcus aureus infection,hsa05152:Tuberculosis,hsa05164:Influenza A,hsa05166:Human T-cell leukemia virus 1 infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05310:Asthma,hsa05320:Autoimmune thyroid disease,hsa05321:Inflammatory bowel disease,hsa05322:Systemic lupus erythematosus,hsa05323:Rheumatoid arthritis,hsa05330:Allograft rejection,hsa05332:Graft-versus-host disease,hsa05416:Viral myocarditis,			SM00407:IGc1,SM00920:MHC_II_alpha,	KW-0391~Immunity,KW-0945~Host-virus interaction,KW-1064~Adaptive immunity,	KW-0256~Endoplasmic reticulum,KW-0458~Lysosome,KW-0472~Membrane,KW-0491~MHC II,KW-0967~Endosome,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,KW-1017~Isopeptide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:Ig-like,DOMAIN:Ig-like C1-type,DOMAIN:Immunoglobulin C1-set,DOMAIN:MHC class II alpha chain N-terminal,MUTAGEN:A->L: Decreases the affinity of the interaction with TCR by more than five-fold.,MUTAGEN:E->A: Increases the interaction with HLA-DM complex and peptide exchange. Decreases the affinity of the interaction with TCR by more than five-fold.,MUTAGEN:E->K: Impairs the interaction with HLA-DM complex, CLIP dissociation and peptide exchange.,MUTAGEN:F->A,C: Increases the interaction with HLA-DM complex and peptide exchange.,MUTAGEN:F->A,S,V,L: Impairs the interaction with HLA-DM complex, CLIP dissociation and peptide exchange.,MUTAGEN:F->W: Increases the interaction with HLA-DM complex and peptide exchange.,MUTAGEN:G->S: Increases the interaction with HLA-DM complex and peptide exchange.,MUTAGEN:K->R: Almost no change in down-regulation of MHCII. No ubiquitination and complete loss of down-regulation of MHCII; when associated with 'R-254' of HLA-DRB.,MUTAGEN:L->R: Decreases the interaction with CD4.,MUTAGEN:P->S: Decreases the interaction with HLA-DM complex and peptide exchange.,MUTAGEN:Q->A: Decreases the interaction with HLA-DM complex and peptide exchange.,MUTAGEN:R->A: Impairs the interaction with HLA-DM complex and peptide exchange.,MUTAGEN:S->D,H: Decreases the interaction with HLA-DM complex and peptide exchange.,MUTAGEN:T->R: Decreases the interaction with CD4.,MUTAGEN:W->F: Decreases the interaction with HLA-DM complex and peptide exchange.,REGION:Alpha-1,REGION:Alpha-2,REGION:Connecting peptide,SITE:Pathogen-derived peptide antigen,SITE:Self- and pathogen-derived peptide antigen,SITE:Self-peptide antigen,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
HLA-DRB1	major histocompatibility complex, class II, DR beta 1(HLA-DRB1)	Homo sapiens		h_asbcellPathway:Antigen Dependent B Cell Activation,h_bbcellPathway:Bystander B Cell Activation,h_blymphocytePathway:B Lymphocyte Cell Surface Molecules,h_cskPathway:Activation of Csk by cAMP-dependent Protein Kinase Inhibits Signaling through the T Cell Receptor,h_ctla4Pathway:The Co-Stimulatory Signal During T-cell Activation,h_eosinophilsPathway:The Role of Eosinophils in the Chemokine Network of Allergy,h_il5Pathway:IL 5 Signaling Pathway,h_inflamPathway:Cytokines and Inflammatory Response,h_mhcPathway:Antigen Processing and Presentation,h_tcraPathway:Lck and Fyn tyrosine kinases in initiation of TCR Activation,h_th1th2Pathway:Th1/Th2 Differentiation,	GO:0001916~positive regulation of T cell mediated cytotoxicity,GO:0001934~positive regulation of protein phosphorylation,GO:0002250~adaptive immune response,GO:0002437~inflammatory response to antigenic stimulus,GO:0002469~myeloid dendritic cell antigen processing and presentation,GO:0002491~antigen processing and presentation of endogenous peptide antigen via MHC class II,GO:0002503~peptide antigen assembly with MHC class II protein complex,GO:0002504~antigen processing and presentation of peptide or polysaccharide antigen via MHC class II,GO:0002842~positive regulation of T cell mediated immune response to tumor cell,GO:0002862~negative regulation of inflammatory response to antigenic stimulus,GO:0006955~immune response,GO:0006959~humoral immune response,GO:0007010~cytoskeleton organization,GO:0007165~signal transduction,GO:0008544~epidermis development,GO:0016045~detection of bacterium,GO:0019882~antigen processing and presentation,GO:0019886~antigen processing and presentation of exogenous peptide antigen via MHC class II,GO:0030225~macrophage differentiation,GO:0032653~regulation of interleukin-10 production,GO:0032673~regulation of interleukin-4 production,GO:0032689~negative regulation of interferon-gamma production,GO:0032831~positive regulation of CD4-positive, CD25-positive, alpha-beta regulatory T cell differentiation,GO:0033674~positive regulation of kinase activity,GO:0035774~positive regulation of insulin secretion involved in cellular response to glucose stimulus,GO:0042088~T-helper 1 type immune response,GO:0042130~negative regulation of T cell proliferation,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043382~positive regulation of memory T cell differentiation,GO:0043410~positive regulation of MAPK cascade,GO:0045622~regulation of T-helper cell differentiation,GO:0045657~positive regulation of monocyte differentiation,GO:0045893~positive regulation of transcription, DNA-templated,GO:0046598~positive regulation of viral entry into host cell,GO:0050778~positive regulation of immune response,GO:0050852~T cell receptor signaling pathway,GO:0050870~positive regulation of T cell activation,GO:0051262~protein tetramerization,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:2000516~positive regulation of CD4-positive, alpha-beta T cell activation,	GO:0000139~Golgi membrane,GO:0001772~immunological synapse,GO:0005615~extracellular space,GO:0005765~lysosomal membrane,GO:0005882~intermediate filament,GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0010008~endosome membrane,GO:0012507~ER to Golgi transport vesicle membrane,GO:0016020~membrane,GO:0030658~transport vesicle membrane,GO:0030666~endocytic vesicle membrane,GO:0030669~clathrin-coated endocytic vesicle membrane,GO:0031902~late endosome membrane,GO:0032588~trans-Golgi network membrane,GO:0042613~MHC class II protein complex,GO:0070062~extracellular exosome,GO:0098553~lumenal side of endoplasmic reticulum membrane,	GO:0005200~structural constituent of cytoskeleton,GO:0005515~protein binding,GO:0023026~MHC class II protein complex binding,GO:0030247~polysaccharide binding,GO:0032395~MHC class II receptor activity,GO:0042605~peptide antigen binding,GO:0042608~T cell receptor binding,GO:0042609~CD4 receptor binding,	IPR000353:MHC_II_b_N,IPR001039:MHC_I_a_a1/a2,IPR003006:Ig/MHC_CS,IPR003597:Ig_C1-set,IPR007110:Ig-like_dom,IPR011161:MHC_I-like_Ag-recog,IPR011162:MHC_I/II-like_Ag-recog,IPR013783:Ig-like_fold,IPR014745:MHC_II_a/b_N,IPR036179:Ig-like_dom_sf,IPR037055:MHC_I-like_Ag-recog_sf,	hsa04145:Phagosome,hsa04514:Cell adhesion molecules,hsa04612:Antigen processing and presentation,hsa04640:Hematopoietic cell lineage,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04672:Intestinal immune network for IgA production,hsa04940:Type I diabetes mellitus,hsa05140:Leishmaniasis,hsa05145:Toxoplasmosis,hsa05150:Staphylococcus aureus infection,hsa05152:Tuberculosis,hsa05164:Influenza A,hsa05166:Human T-cell leukemia virus 1 infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05310:Asthma,hsa05320:Autoimmune thyroid disease,hsa05321:Inflammatory bowel disease,hsa05322:Systemic lupus erythematosus,hsa05323:Rheumatoid arthritis,hsa05330:Allograft rejection,hsa05332:Graft-versus-host disease,hsa05416:Viral myocarditis,	126200~Multiple sclerosis, susceptibility to, 1,181000~Sarcoidosis, susceptibility to, 1,		SM00407:IGc1,SM00921:MHC_II_beta,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0256~Endoplasmic reticulum,KW-0458~Lysosome,KW-0472~Membrane,KW-0491~MHC II,KW-0967~Endosome,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,KW-1017~Isopeptide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:Ig-like,DOMAIN:Ig-like C1-type,DOMAIN:Immunoglobulin C1-set,DOMAIN:MHC class I-like antigen recognition-like,DOMAIN:MHC class II beta chain N-terminal,MUTAGEN:D->N: Reduces the interaction with HLA-DM complex that results in impaired dissociation of CLIP from MHCII.,MUTAGEN:E->A: Decreases the interaction with CD4; when assocated with A-172.,MUTAGEN:E->K: Reduces the interaction with HLA-DM complex that results in impaired dissociation of CLIP from MHCII.,MUTAGEN:I->R: Decreases the interaction with CD4.,MUTAGEN:K->A: Impairs MARCHF1-dependent down-regulation through ubiquitination.,MUTAGEN:L->H: Reduces the interaction with HLA-DM complex that results in impaired dissociation of CLIP from MHCII.,MUTAGEN:L->R: Decreases the interaction with CD4.,MUTAGEN:V->A: Decreases the interaction with CD4; when assocated with A-166.,REGION:Beta-1,REGION:Beta-2,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
MVP	major vault protein(MVP)	Homo sapiens			GO:0015031~protein transport,GO:0031953~negative regulation of protein autophosphorylation,GO:0038127~ERBB signaling pathway,GO:0042059~negative regulation of epidermal growth factor receptor signaling pathway,GO:0051028~mRNA transport,GO:0061099~negative regulation of protein tyrosine kinase activity,	GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005643~nuclear pore,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0016020~membrane,GO:0034774~secretory granule lumen,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,GO:1904813~ficolin-1-rich granule lumen,GO:1990904~ribonucleoprotein complex,	GO:0005515~protein binding,GO:0019901~protein kinase binding,GO:0019903~protein phosphatase binding,GO:0042802~identical protein binding,	IPR002499:Vault_N,IPR021870:MVP_shoulder,IPR036013:Band_7/SPFH_dom_sf,IPR039059:MVP,IPR040989:Vault_3,IPR041134:Vault_2,IPR041136:Vault_4,IPR041139:MVP_rep_dom,IPR043023:MVP_rep_sf,IPR043179:Vault_2_sf,					KW-0509~mRNA transport,KW-0653~Protein transport,KW-0811~Translocation,KW-0813~Transport,	KW-0539~Nucleus,KW-0906~Nuclear pore complex,KW-0963~Cytoplasm,		KW-0677~Repeat,		KW-0687~Ribonucleoprotein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Major vault protein repeat,DOMAIN:Major vault protein shoulder,REGION:Disordered,REPEAT:MVP,REPEAT:MVP 1,REPEAT:MVP 2,REPEAT:MVP 3,REPEAT:MVP 4,REPEAT:MVP 5,REPEAT:MVP 6,REPEAT:MVP 7,REPEAT:MVP 8,REPEAT:MVP 9,
MEA1	male-enhanced antigen 1(MEA1)	Homo sapiens			GO:0007283~spermatogenesis,GO:0008584~male gonad development,GO:0030154~cell differentiation,	GO:0005737~cytoplasm,	GO:0005515~protein binding,	IPR009685:MEA1,					KW-0221~Differentiation,KW-0744~Spermatogenesis,					KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,	REGION:Disordered,
MLEC	malectin(MLEC)	Homo sapiens			GO:0005975~carbohydrate metabolic process,GO:0006487~protein N-linked glycosylation,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0008250~oligosaccharyltransferase complex,GO:0016020~membrane,GO:0035579~specific granule membrane,	GO:0005515~protein binding,GO:0019899~enzyme binding,GO:0030246~carbohydrate binding,	IPR021720:Malectin_dom,IPR039155:MLEC,					KW-0119~Carbohydrate metabolism,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:Malectin,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
M6PR	mannose-6-phosphate receptor, cation dependent(M6PR)	Homo sapiens			GO:0006622~protein targeting to lysosome,GO:0006898~receptor-mediated endocytosis,GO:0007041~lysosomal transport,GO:0008333~endosome to lysosome transport,GO:0033299~secretion of lysosomal enzymes,GO:0046479~glycosphingolipid catabolic process,	GO:0005765~lysosomal membrane,GO:0005768~endosome,GO:0005770~late endosome,GO:0005794~Golgi apparatus,GO:0005802~trans-Golgi network,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0030133~transport vesicle,GO:0030669~clathrin-coated endocytic vesicle membrane,GO:0032588~trans-Golgi network membrane,GO:0048471~perinuclear region of cytoplasm,	GO:0004888~transmembrane signaling receptor activity,GO:0005515~protein binding,GO:0019904~protein domain specific binding,GO:1905394~retromer complex binding,	IPR000296:Man-6-P_rcpt_cation_dep,IPR009011:Man6P_isomerase_rcpt-bd_dom_sf,IPR028927:Man-6-P_rcpt,IPR044865:MRH_dom,	hsa04142:Lysosome,hsa04145:Phagosome,hsa05132:Salmonella infection,				KW-0813~Transport,	KW-0458~Lysosome,KW-0472~Membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:MRH,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
MAN2B1	mannosidase alpha class 2B member 1(MAN2B1)	Homo sapiens		h_aMANpathway:Steps in the Glycosylation of Mammalian N-linked Oligosaccarides,h_eradPathway:ERï¿½associated degradation (ERAD) Pathway,	GO:0005975~carbohydrate metabolic process,GO:0006013~mannose metabolic process,GO:0006517~protein deglycosylation,GO:0007611~learning or memory,GO:0009313~oligosaccharide catabolic process,GO:0036211~protein modification process,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005654~nucleoplasm,GO:0005764~lysosome,GO:0035578~azurophil granule lumen,GO:0043202~lysosomal lumen,GO:0043231~intracellular membrane-bounded organelle,GO:0070062~extracellular exosome,	GO:0003824~catalytic activity,GO:0004559~alpha-mannosidase activity,GO:0030246~carbohydrate binding,GO:0046872~metal ion binding,	IPR000602:Glyco_hydro_38_N,IPR011013:Gal_mutarotase_sf_dom,IPR011330:Glyco_hydro/deAcase_b/a-brl,IPR011682:Glyco_hydro_38_C,IPR013780:Glyco_hydro_b,IPR015341:Glyco_hydro_38_cen,IPR027291:Glyco_hydro_38_N_sf,IPR028995:Glyco_hydro_57/38_cen_sf,IPR037094:Glyco_hydro_38_cen_sf,IPR048534:Man2a1-like_dom,	hsa00511:Other glycan degradation,hsa04142:Lysosome,	248500~Mannosidosis, alpha-, types I and II,		SM00872:Alpha-mann_mid,		KW-0458~Lysosome,	KW-0225~Disease variant,	KW-0732~Signal,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0326~Glycosidase,KW-0378~Hydrolase,	KW-0325~Glycoprotein,KW-0865~Zymogen,KW-1015~Disulfide bond,	ACT_SITE:Nucleophile,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Glycoside hydrolase family 38 N-terminal,DOMAIN:Glycoside hydrolase family 38 central,DOMAIN:Lysosomal alpha-mannosidase-like central,REGION:Disordered,
MED10	mediator complex subunit 10(MED10)	Homo sapiens			GO:0016567~protein ubiquitination,GO:0032968~positive regulation of transcription elongation from RNA polymerase II promoter,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051123~RNA polymerase II transcriptional preinitiation complex assembly,GO:0060261~positive regulation of transcription initiation from RNA polymerase II promoter,	GO:0000151~ubiquitin ligase complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0016592~mediator complex,GO:0070847~core mediator complex,	GO:0003712~transcription cofactor activity,GO:0005515~protein binding,GO:0061630~ubiquitin protein ligase activity,	IPR019145:Mediator_Med10,					KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0010~Activator,
MED17	mediator complex subunit 17(MED17)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006367~transcription initiation from RNA polymerase II promoter,GO:0016567~protein ubiquitination,GO:0032968~positive regulation of transcription elongation from RNA polymerase II promoter,GO:0035019~somatic stem cell population maintenance,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051123~RNA polymerase II transcriptional preinitiation complex assembly,GO:0060261~positive regulation of transcription initiation from RNA polymerase II promoter,	GO:0000151~ubiquitin ligase complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0016020~membrane,GO:0016592~mediator complex,GO:0070847~core mediator complex,	GO:0003712~transcription cofactor activity,GO:0003713~transcription coactivator activity,GO:0005515~protein binding,GO:0030374~ligand-dependent nuclear receptor transcription coactivator activity,GO:0042809~vitamin D receptor binding,GO:0046966~thyroid hormone receptor binding,GO:0061630~ubiquitin protein ligase activity,	IPR019313:Mediator_Med17,	hsa04919:Thyroid hormone signaling pathway,	613668~Microcephaly, postnatal progressive, with seizures and brain atrophy,			KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,			KW-0010~Activator,		COMPBIAS:Acidic residues,REGION:Disordered,
MED19	mediator complex subunit 19(MED19)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0032968~positive regulation of transcription elongation from RNA polymerase II promoter,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051123~RNA polymerase II transcriptional preinitiation complex assembly,GO:0060261~positive regulation of transcription initiation from RNA polymerase II promoter,	GO:0005634~nucleus,GO:0016592~mediator complex,GO:0070847~core mediator complex,	GO:0003712~transcription cofactor activity,GO:0005515~protein binding,GO:0008134~transcription factor binding,	IPR019403:Mediator_Med19_met,					KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0010~Activator,	KW-0597~Phosphoprotein,	COMPBIAS:Basic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,REGION:Disordered,
MED21	mediator complex subunit 21(MED21)	Homo sapiens			GO:0001824~blastocyst development,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0016567~protein ubiquitination,GO:0032968~positive regulation of transcription elongation from RNA polymerase II promoter,GO:0035019~somatic stem cell population maintenance,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051123~RNA polymerase II transcriptional preinitiation complex assembly,GO:0060261~positive regulation of transcription initiation from RNA polymerase II promoter,	GO:0000151~ubiquitin ligase complex,GO:0005634~nucleus,GO:0016592~mediator complex,GO:0070847~core mediator complex,	GO:0003712~transcription cofactor activity,GO:0003713~transcription coactivator activity,GO:0003899~DNA-directed 5'-3' RNA polymerase activity,GO:0005515~protein binding,GO:0061630~ubiquitin protein ligase activity,	IPR021384:Mediator_Med21,IPR037212:Med7/Med21-like,					KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0010~Activator,
MED28	mediator complex subunit 28(MED28)	Homo sapiens			GO:0032968~positive regulation of transcription elongation from RNA polymerase II promoter,GO:0035019~somatic stem cell population maintenance,GO:0051123~RNA polymerase II transcriptional preinitiation complex assembly,GO:0051151~negative regulation of smooth muscle cell differentiation,GO:0060261~positive regulation of transcription initiation from RNA polymerase II promoter,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0016020~membrane,GO:0016592~mediator complex,GO:0030864~cortical actin cytoskeleton,GO:0070847~core mediator complex,	GO:0003779~actin binding,GO:0005515~protein binding,	IPR021640:Mediator_Med28,					KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,		KW-0009~Actin-binding,KW-0010~Activator,		REGION:Disordered,
MED29	mediator complex subunit 29(MED29)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0032968~positive regulation of transcription elongation from RNA polymerase II promoter,GO:0051123~RNA polymerase II transcriptional preinitiation complex assembly,GO:0060261~positive regulation of transcription initiation from RNA polymerase II promoter,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0016592~mediator complex,GO:0070847~core mediator complex,	GO:0003712~transcription cofactor activity,GO:0005515~protein binding,GO:0008134~transcription factor binding,	IPR021018:Mediator_Med29_met,					KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0010~Activator,	KW-0007~Acetylation,	COMPBIAS:Polar residues,REGION:Disordered,
MED31	mediator complex subunit 31(MED31)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0016567~protein ubiquitination,GO:0032968~positive regulation of transcription elongation from RNA polymerase II promoter,GO:0048147~negative regulation of fibroblast proliferation,GO:0051123~RNA polymerase II transcriptional preinitiation complex assembly,GO:0060173~limb development,GO:0060261~positive regulation of transcription initiation from RNA polymerase II promoter,	GO:0000151~ubiquitin ligase complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0016592~mediator complex,GO:0070847~core mediator complex,	GO:0003712~transcription cofactor activity,GO:0005515~protein binding,GO:0061630~ubiquitin protein ligase activity,	IPR008831:Mediator_Med31,IPR038089:Med31_sf,					KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0010~Activator,	KW-0007~Acetylation,
MED8	mediator complex subunit 8(MED8)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0016567~protein ubiquitination,GO:0032968~positive regulation of transcription elongation from RNA polymerase II promoter,GO:0051123~RNA polymerase II transcriptional preinitiation complex assembly,GO:0060261~positive regulation of transcription initiation from RNA polymerase II promoter,	GO:0000151~ubiquitin ligase complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0016592~mediator complex,GO:0070847~core mediator complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0003712~transcription cofactor activity,GO:0005515~protein binding,GO:0061630~ubiquitin protein ligase activity,	IPR019364:Mediatior_Med8_fun/met,					KW-0804~Transcription,KW-0805~Transcription regulation,KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,		KW-0175~Coiled coil,		KW-0010~Activator,	KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,MUTAGEN:C->F: Impairs interaction with the Elongin BC complex; when associated with P-143.,MUTAGEN:L->P: Impairs interaction with the Elongin BC complex; when associated with F-147.,REGION:Disordered,REGION:Interaction with the Elongin BC complex,
MBTPS1	membrane bound transcription factor peptidase, site 1(MBTPS1)	Homo sapiens		h_s1pPathway:SREBP control of lipid synthesis,	GO:0006508~proteolysis,GO:0007040~lysosome organization,GO:0007095~mitotic G2 DNA damage checkpoint,GO:0008203~cholesterol metabolic process,GO:0016485~protein processing,GO:0030968~endoplasmic reticulum unfolded protein response,GO:0031293~membrane protein intracellular domain proteolysis,GO:0034976~response to endoplasmic reticulum stress,GO:0036500~ATF6-mediated unfolded protein response,GO:0045540~regulation of cholesterol biosynthetic process,GO:0051604~protein maturation,GO:0060627~regulation of vesicle-mediated transport,	GO:0000139~Golgi membrane,GO:0005788~endoplasmic reticulum lumen,GO:0005789~endoplasmic reticulum membrane,GO:0005794~Golgi apparatus,GO:0005795~Golgi stack,GO:0016020~membrane,	GO:0004252~serine-type endopeptidase activity,GO:0005515~protein binding,	IPR000209:Peptidase_S8/S53_dom,IPR015500:Peptidase_S8_subtilisin-rel,IPR022398:Peptidase_S8_His-AS,IPR023828:Peptidase_S8_Ser-AS,IPR034185:Site-1_peptidase_cat_dom,IPR036852:Peptidase_S8/S53_dom_sf,	hsa04141:Protein processing in endoplasmic reticulum,	618392~Spondyloepiphyseal dysplasia, Kondo-Fu type,			KW-0153~Cholesterol metabolism,KW-0443~Lipid metabolism,KW-0753~Steroid metabolism,KW-1207~Sterol metabolism,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,	KW-0225~Disease variant,KW-0242~Dwarfism,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,	KW-0378~Hydrolase,KW-0645~Protease,KW-0720~Serine protease,	KW-0068~Autocatalytic cleavage,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0865~Zymogen,	ACT_SITE:Charge relay system,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:Peptidase S8,DOMAIN:Peptidase S8/S53,MUTAGEN:H->A: Abolishes serine protease activity.,MUTAGEN:S->A: Abolishes serine protease activity. Does not promote FAM20C kinase activity.,REGION:Disordered,SITE:Cleavage; by autolysis,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
MANF	mesencephalic astrocyte derived neurotrophic factor(MANF)	Homo sapiens			GO:0002014~vasoconstriction of artery involved in ischemic response to lowering of systemic arterial blood pressure,GO:0006986~response to unfolded protein,GO:0007165~signal transduction,GO:0031175~neuron projection development,GO:0071542~dopaminergic neuron differentiation,GO:1905897~regulation of response to endoplasmic reticulum stress,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005783~endoplasmic reticulum,GO:0005788~endoplasmic reticulum lumen,GO:0005829~cytosol,GO:0033018~sarcoplasmic reticulum lumen,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0008083~growth factor activity,	IPR019345:ARMET_C,IPR036361:SAP_dom_sf,IPR045332:ARMET_N,IPR045333:ARMET-like,		620651~Diabetes, deafness, developmental delay, and short stature syndrome,			KW-0346~Stress response,KW-0834~Unfolded protein response,	KW-0256~Endoplasmic reticulum,KW-0703~Sarcoplasmic reticulum,KW-0964~Secreted,		KW-0732~Signal,	KW-0446~Lipid-binding,KW-0730~Sialic acid,	KW-0339~Growth factor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	DOMAIN:ARMET C-terminal,DOMAIN:ARMET N-terminal,MUTAGEN:K->L: Reduced sulfatide binding and uptake by target cells. Reduces cytoprotective effect of the wild-type protein. Attenuates stress granule formation in response to endoplasmic reticulum stress.,MUTAGEN:Missing: Two-fold increase in secretion.,MUTAGEN:R->K: 14-fold decrease in secretion.,
MTDH	metadherin(MTDH)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0010508~positive regulation of autophagy,GO:0031663~lipopolysaccharide-mediated signaling pathway,GO:0043066~negative regulation of apoptotic process,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0045766~positive regulation of angiogenesis,GO:0045893~positive regulation of transcription, DNA-templated,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0051897~positive regulation of protein kinase B signaling,	GO:0001650~fibrillar center,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005923~bicellular tight junction,GO:0016020~membrane,GO:0016324~apical plasma membrane,GO:0016604~nuclear body,GO:0031965~nuclear membrane,GO:0046581~intercellular canaliculus,GO:0048471~perinuclear region of cytoplasm,	GO:0003712~transcription cofactor activity,GO:0003713~transcription coactivator activity,GO:0003723~RNA binding,GO:0003725~double-stranded RNA binding,GO:0005515~protein binding,GO:0051059~NF-kappaB binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,	IPR031402:LYRIC,						KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0539~Nucleus,KW-0796~Tight junction,KW-0963~Cytoplasm,KW-0965~Cell junction,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Activation of NF-kappa-B,REGION:Disordered,REGION:Interaction with BCCIP,REGION:Interaction with RELA,REGION:Lung-homing for mammary tumors,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
MTF2	metal response element binding transcription factor 2(MTF2)	Homo sapiens			GO:0006325~chromatin organization,GO:0006355~regulation of transcription, DNA-templated,GO:0007379~segment specification,GO:0019827~stem cell population maintenance,GO:0040029~regulation of gene expression, epigenetic,GO:0048863~stem cell differentiation,GO:1990830~cellular response to leukemia inhibitory factor,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0035098~ESC/E(Z) complex,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0001222~transcription corepressor binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0035064~methylated histone binding,GO:0046872~metal ion binding,	IPR001965:Znf_PHD,IPR002999:Tudor,IPR011011:Znf_FYVE_PHD,IPR013083:Znf_RING/FYVE/PHD,IPR019786:Zinc_finger_PHD-type_CS,IPR019787:Znf_PHD-finger,IPR025894:Mtf2_C_dom,IPR040477:KDM4-like_Tudor,IPR042014:MTF2_PHD1,IPR042015:MTF2_PHD2,	hsa03083:Polycomb repressive complex,			SM00249:PHD,SM00333:TUDOR,		KW-0539~Nucleus,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0156~Chromatin regulator,KW-0238~DNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:PHD-type,DOMAIN:Tudor,MUTAGEN:KK->AA: Abolishes chromatin binding activity of the PRC2.1 complex.,MUTAGEN:Missing: Reduced chromatin binding activity of the PRC2.1 complex, probably due to loss of dimer stability.,REGION:Disordered,ZN_FING:PHD-type 1,ZN_FING:PHD-type 2,
MAT2B	methionine adenosyltransferase 2 non-catalytic beta subunit(MAT2B)	Homo sapiens			GO:0006556~S-adenosylmethionine biosynthetic process,GO:0006730~one-carbon metabolic process,	GO:0005634~nucleus,GO:0005829~cytosol,GO:0048269~methionine adenosyltransferase complex,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0016740~transferase activity,GO:0019899~enzyme binding,GO:0048270~methionine adenosyltransferase regulator activity,	IPR005913:dTDP_dehydrorham_reduct,IPR029903:RmlD-like-bd,IPR036291:NAD(P)-bd_dom_sf,	hsa00270:Cysteine and methionine metabolism,hsa01100:Metabolic pathways,hsa01230:Biosynthesis of amino acids,hsa01240:Biosynthesis of cofactors,				KW-0554~One-carbon metabolism,				KW-0521~NADP,	KW-0808~Transferase,	KW-0597~Phosphoprotein,	DOMAIN:RmlD-like substrate binding,REGION:Required for interaction with MAT2A,
MAT2A	methionine adenosyltransferase 2A(MAT2A)	Homo sapiens			GO:0006556~S-adenosylmethionine biosynthetic process,GO:0006730~one-carbon metabolic process,GO:0034214~protein hexamerization,GO:0051291~protein heterooligomerization,GO:1990830~cellular response to leukemia inhibitory factor,	GO:0005829~cytosol,GO:0048269~methionine adenosyltransferase complex,	GO:0004478~methionine adenosyltransferase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0036094~small molecule binding,GO:0042802~identical protein binding,GO:0046872~metal ion binding,	IPR002133:S-AdoMet_synthetase,IPR022628:S-AdoMet_synt_N,IPR022629:S-AdoMet_synt_central,IPR022630:S-AdoMet_synt_C,IPR022631:ADOMET_SYNTHASE_CS,IPR022636:S-AdoMet_synthetase_sfam,	hsa00270:Cysteine and methionine metabolism,hsa01100:Metabolic pathways,hsa01230:Biosynthesis of amino acids,hsa01240:Biosynthesis of cofactors,		PIRSF000497:MAT,		KW-0554~One-carbon metabolism,				KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,KW-0630~Potassium,	KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	BINDING:in other chain,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:S-adenosylmethionine synthetase C-terminal,DOMAIN:S-adenosylmethionine synthetase N-terminal,DOMAIN:S-adenosylmethionine synthetase central,REGION:Flexible loop,
METAP2	methionyl aminopeptidase 2(METAP2)	Homo sapiens			GO:0006508~proteolysis,GO:0016485~protein processing,GO:0018206~peptidyl-methionine modification,GO:0031365~N-terminal protein amino acid modification,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,	GO:0003723~RNA binding,GO:0004177~aminopeptidase activity,GO:0005515~protein binding,GO:0008235~metalloexopeptidase activity,GO:0046872~metal ion binding,GO:0070006~metalloaminopeptidase activity,	IPR000994:Pept_M24,IPR001714:Pept_M24_MAP,IPR002468:Pept_M24A_MAP2,IPR018349:Pept_M24A_MAP2_BS,IPR036005:Creatinase/aminopeptidase-like,IPR036388:WH-like_DNA-bd_sf,IPR036390:WH_DNA-bd_sf,						KW-0963~Cytoplasm,			KW-0479~Metal-binding,	KW-0031~Aminopeptidase,KW-0378~Hydrolase,KW-0645~Protease,	KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:O-linked (GlcNAc) serine; alternate,COMPBIAS:Basic and acidic residues,DOMAIN:Peptidase M24,REGION:Disordered,
MBD4	methyl-CpG binding domain 4, DNA glycosylase(MBD4)	Homo sapiens			GO:0006281~DNA repair,GO:0032355~response to estradiol,GO:0045008~depyrimidination,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0016607~nuclear speck,	GO:0003677~DNA binding,GO:0003696~satellite DNA binding,GO:0004520~endodeoxyribonuclease activity,GO:0005515~protein binding,GO:0008263~pyrimidine-specific mismatch base pair DNA N-glycosylase activity,GO:0019104~DNA N-glycosylase activity,	IPR001739:Methyl_CpG_DNA-bd,IPR011257:DNA_glycosylase,IPR016177:DNA-bd_dom_sf,IPR017352:MBD4,IPR045138:MeCP2/MBD4,	hsa03410:Base excision repair,	606660~Uveal melanoma, susceptibility to, 1,619975~Tumor predisposition syndrome 2,	PIRSF038005:Methyl_CpG_bd_MBD4,	SM00391:MBD,	KW-0227~DNA damage,KW-0234~DNA repair,	KW-0539~Nucleus,	KW-0225~Disease variant,			KW-0238~DNA-binding,KW-0378~Hydrolase,	KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:MBD,MUTAGEN:D->A: Loss of DNA N-glycosylase activity.,REGION:Disordered,
MECP2	methyl-CpG binding protein 2(MECP2)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001662~behavioral fear response,GO:0001666~response to hypoxia,GO:0001964~startle response,GO:0001976~neurological system process involved in regulation of systemic arterial blood pressure,GO:0002087~regulation of respiratory gaseous exchange by neurological system process,GO:0006020~inositol metabolic process,GO:0006541~glutamine metabolic process,GO:0006576~cellular biogenic amine metabolic process,GO:0007219~Notch signaling pathway,GO:0007416~synapse assembly,GO:0007507~heart development,GO:0007585~respiratory gaseous exchange,GO:0007616~long-term memory,GO:0008104~protein localization,GO:0008211~glucocorticoid metabolic process,GO:0008344~adult locomotory behavior,GO:0008542~visual learning,GO:0009791~post-embryonic development,GO:0010212~response to ionizing radiation,GO:0010288~response to lead ion,GO:0010467~gene expression,GO:0010629~negative regulation of gene expression,GO:0014003~oligodendrocyte development,GO:0014009~glial cell proliferation,GO:0016358~dendrite development,GO:0016525~negative regulation of angiogenesis,GO:0019230~proprioception,GO:0019233~sensory perception of pain,GO:0021510~spinal cord development,GO:0021549~cerebellum development,GO:0021591~ventricular system development,GO:0021740~principal sensory nucleus of trigeminal nerve development,GO:0021756~striatum development,GO:0021766~hippocampus development,GO:0021772~olfactory bulb development,GO:0021794~thalamus development,GO:0021987~cerebral cortex development,GO:0031507~heterochromatin assembly,GO:0031915~positive regulation of synaptic plasticity,GO:0032048~cardiolipin metabolic process,GO:0032355~response to estradiol,GO:0035176~social behavior,GO:0035865~cellular response to potassium ion,GO:0042220~response to cocaine,GO:0042551~neuron maturation,GO:0043524~negative regulation of neuron apoptotic process,GO:0043537~negative regulation of blood vessel endothelial cell migration,GO:0044030~regulation of DNA methylation,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046470~phosphatidylcholine metabolic process,GO:0048286~lung alveolus development,GO:0048712~negative regulation of astrocyte differentiation,GO:0050432~catecholamine secretion,GO:0050807~regulation of synapse organization,GO:0051151~negative regulation of smooth muscle cell differentiation,GO:0051570~regulation of histone H3-K9 methylation,GO:0051707~response to other organism,GO:0060079~excitatory postsynaptic potential,GO:0060252~positive regulation of glial cell proliferation,GO:0060291~long-term synaptic potentiation,GO:0060999~positive regulation of dendritic spine development,GO:0061000~negative regulation of dendritic spine development,GO:0071317~cellular response to isoquinoline alkaloid,GO:0071514~genetic imprinting,GO:0090063~positive regulation of microtubule nucleation,GO:0090327~negative regulation of locomotion involved in locomotory behavior,GO:0099611~regulation of action potential firing threshold,GO:1901953~positive regulation of anterograde dense core granule transport,GO:1901956~positive regulation of retrograde dense core granule transport,GO:1903860~negative regulation of dendrite extension,GO:1903861~positive regulation of dendrite extension,GO:1903941~negative regulation of respiratory gaseous exchange,GO:1905492~positive regulation of branching morphogenesis of a nerve,GO:1905643~positive regulation of DNA methylation,GO:2000635~negative regulation of primary miRNA processing,	GO:0000792~heterochromatin,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005813~centrosome,GO:0005829~cytosol,GO:0098794~postsynapse,GO:0098978~glutamatergic synapse,	GO:0000400~four-way junction DNA binding,GO:0003676~nucleic acid binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003714~transcription corepressor activity,GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0005515~protein binding,GO:0008327~methyl-CpG binding,GO:0010385~double-stranded methylated DNA binding,GO:0019904~protein domain specific binding,GO:0031490~chromatin DNA binding,GO:0035197~siRNA binding,GO:0042802~identical protein binding,GO:0042826~histone deacetylase binding,GO:0045322~unmethylated CpG binding,GO:0060090~binding, bridging,GO:1990841~promoter-specific chromatin binding,	IPR001739:Methyl_CpG_DNA-bd,IPR016177:DNA-bd_dom_sf,IPR017353:Me_CpG-bd_MeCP2,IPR045138:MeCP2/MBD4,		300055~Intellectual developmental disorder, X-linked syndromic 13,300260~Intellectual developmental disorder, X-linked syndromic, Lubs type,300496~Autism susceptibility, X-linked 3,300673~Encephalopathy, neonatal severe,312750~Rett syndrome,312750~Rett syndrome, atypical,312750~Rett syndrome, preserved speech variant,	PIRSF038006:Methyl_CpG_bd_MeCP2,	SM00391:MBD,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-0991~Intellectual disability,KW-1268~Autism spectrum disorder,KW-1269~Autism,	KW-0677~Repeat,		KW-0238~DNA-binding,KW-0678~Repressor,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,DNA_BIND:A.T hook 1,DNA_BIND:A.T hook 2,DOMAIN:MBD,REGION:Disordered,REGION:Interaction with NCOR2,REGION:Interaction with TBL1XR1,
MTHFD2	methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase(MTHFD2)	Homo sapiens			GO:0006730~one-carbon metabolic process,GO:0035999~tetrahydrofolate interconversion,GO:0046653~tetrahydrofolate metabolic process,GO:0046655~folic acid metabolic process,	GO:0005615~extracellular space,GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,	GO:0000287~magnesium ion binding,GO:0004477~methenyltetrahydrofolate cyclohydrolase activity,GO:0004487~methylenetetrahydrofolate dehydrogenase (NAD+) activity,GO:0004488~methylenetetrahydrofolate dehydrogenase (NADP+) activity,GO:0005515~protein binding,GO:0042301~phosphate ion binding,	IPR000672:THF_DH/CycHdrlase,IPR020630:THF_DH/CycHdrlase_cat_dom,IPR020631:THF_DH/CycHdrlase_NAD-bd_dom,IPR020867:THF_DH/CycHdrlase_CS,IPR036291:NAD(P)-bd_dom_sf,IPR046346:Aminoacid_DH-like_N_sf,	hsa00670:One carbon pool by folate,hsa01100:Metabolic pathways,hsa01240:Biosynthesis of cofactors,				KW-0554~One-carbon metabolism,	KW-0496~Mitochondrion,		KW-0809~Transit peptide,	KW-0460~Magnesium,KW-0520~NAD,KW-0521~NADP,	KW-0378~Hydrolase,KW-0511~Multifunctional enzyme,KW-0560~Oxidoreductase,	KW-0007~Acetylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:Tetrahydrofolate dehydrogenase/cyclohydrolase NAD(P)-binding,DOMAIN:Tetrahydrofolate dehydrogenase/cyclohydrolase catalytic,MUTAGEN:D->A,S,E: Complete loss of NAD and NADP-dependent dehydrogenase specific activity.,MUTAGEN:D->A: Significant loss of NAD and NADP-dependent dehydrogenase specific activity.,MUTAGEN:D->E: Complete loss of NAD and NADP-dependent dehydrogenase specific activity.,MUTAGEN:D->N: 80% decrease in NAD-dependent dehydrogenase specific activity. 18% decrease in NADP-dependent dehydrogenase specific activity. Reduced affinity for magnesium.,MUTAGEN:D->N: 84% decrease in NAD-dependent dehydrogenase specific activity. 36% increase in NADP-dependent dehydrogenase specific activity. Reduced affinity for magnesium.,MUTAGEN:D->S: 82% decrease in NAD-dependent dehydrogenase specific activity. 65% decrease in NADP-dependent dehydrogenase specific activity. Reduced affinity for magnesium.,MUTAGEN:R->A,S,K: Complete loss of NAD and NADP-dependent dehydrogenase specific activity.,MUTAGEN:R->A: Significant loss of NAD and NADP-dependent dehydrogenase specific activity.,MUTAGEN:R->K: 50% decrease in NAD and NADP-dependent dehydrogenase specific activity. Reduced affinity for magnesium.,MUTAGEN:R->S: Almost complete loss of NAD-dependent dehydrogenase specific activity. 50% decrease in NADP-dependent dehydrogenase specific activity.,TRANSIT:Mitochondrion,
METTL5	methyltransferase 5, N6-adenosine(METTL5)	Homo sapiens			GO:0006807~nitrogen compound metabolic process,GO:0031167~rRNA methylation,GO:0043414~macromolecule methylation,GO:0044238~primary metabolic process,GO:0045727~positive regulation of translation,GO:0048863~stem cell differentiation,	GO:0001650~fibrillar center,GO:0005634~nucleus,GO:0005730~nucleolus,GO:0005829~cytosol,GO:0042995~cell projection,GO:0098793~presynapse,GO:0098794~postsynapse,	GO:0003676~nucleic acid binding,GO:0005515~protein binding,GO:0008757~S-adenosylmethionine-dependent methyltransferase activity,GO:0008988~rRNA (adenine-N6-)-methyltransferase activity,GO:1904047~S-adenosyl-L-methionine binding,	IPR002052:DNA_methylase_N6_adenine_CS,IPR007848:Small_mtfrase_dom,IPR029063:SAM-dependent_MTases_sf,		618665~Intellectual developmental disorder, autosomal recessive 72,				KW-0539~Nucleus,KW-0770~Synapse,KW-0966~Cell projection,	KW-0991~Intellectual disability,		KW-0949~S-adenosyl-L-methionine,	KW-0489~Methyltransferase,KW-0808~Transferase,		DOMAIN:Methyltransferase small,MUTAGEN:NPP->AAA: In METTL5-3A; abolished methyltransferase activity.,
METTL9	methyltransferase 9, His-X-His N1(pi)-histidine(METTL9)	Homo sapiens			GO:0032259~methylation,	GO:0005739~mitochondrion,GO:0005783~endoplasmic reticulum,	GO:0005515~protein binding,	IPR007884:METL9,IPR029063:SAM-dependent_MTases_sf,						KW-0256~Endoplasmic reticulum,KW-0496~Mitochondrion,		KW-0732~Signal,		KW-0489~Methyltransferase,KW-0808~Transferase,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,MUTAGEN:E->A: Abolished protein-L-histidine N-pros-methyltransferase activity.,
METTL17	methyltransferase like 17(METTL17)	Homo sapiens			GO:0006412~translation,GO:0032259~methylation,GO:0042274~ribosomal small subunit biogenesis,	GO:0005654~nucleoplasm,GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,	GO:0005515~protein binding,GO:0008168~methyltransferase activity,GO:0008757~S-adenosylmethionine-dependent methyltransferase activity,GO:1904047~S-adenosyl-L-methionine binding,	IPR015324:Ribosomal_Rsm22-like,IPR029063:SAM-dependent_MTases_sf,						KW-0496~Mitochondrion,		KW-0732~Signal,KW-0809~Transit peptide,	KW-0949~S-adenosyl-L-methionine,	KW-0489~Methyltransferase,KW-0808~Transferase,		TRANSIT:Mitochondrion,
MVD	mevalonate diphosphate decarboxylase(MVD)	Homo sapiens			GO:0006695~cholesterol biosynthetic process,GO:0008284~positive regulation of cell proliferation,GO:0008299~isoprenoid biosynthetic process,GO:0019287~isopentenyl diphosphate biosynthetic process, mevalonate pathway,	GO:0005829~cytosol,	GO:0004163~diphosphomevalonate decarboxylase activity,GO:0005524~ATP binding,GO:0016831~carboxy-lyase activity,GO:0030544~Hsp70 protein binding,GO:0042803~protein homodimerization activity,	IPR005935:Mev_decarb,IPR006204:GHMP_kinase_N_dom,IPR014721:Ribsml_uS5_D2-typ_fold_subgr,IPR020568:Ribosomal_Su5_D2-typ_SF,IPR029765:Mev_diP_decarb,IPR036554:GHMP_kinase_C_sf,IPR041431:Mvd1_C,	hsa00900:Terpenoid backbone biosynthesis,hsa01100:Metabolic pathways,	614714~Porokeratosis 7, multiple types,	PIRSF015950:Mev_P_decrbx,		KW-0152~Cholesterol biosynthesis,KW-0153~Cholesterol metabolism,KW-0443~Lipid metabolism,KW-0444~Lipid biosynthesis,KW-0752~Steroid biosynthesis,KW-0753~Steroid metabolism,KW-0756~Sterol biosynthesis,KW-1207~Sterol metabolism,	KW-0963~Cytoplasm,	KW-0225~Disease variant,		KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0456~Lyase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:GHMP kinase N-terminal,DOMAIN:Mvd1 C-terminal,MUTAGEN:N->A: 15-fold inflation in KM for mevalonate diphosphate.,
MGST3	microsomal glutathione S-transferase 3(MGST3)	Homo sapiens			GO:0006629~lipid metabolic process,GO:0006692~prostanoid metabolic process,GO:0019369~arachidonic acid metabolic process,GO:0019370~leukotriene biosynthetic process,GO:0098869~cellular oxidant detoxification,	GO:0005635~nuclear envelope,GO:0005741~mitochondrial outer membrane,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0016020~membrane,GO:0043231~intracellular membrane-bounded organelle,	GO:0004364~glutathione transferase activity,GO:0004464~leukotriene-C4 synthase activity,GO:0004602~glutathione peroxidase activity,GO:0005515~protein binding,GO:0016740~transferase activity,GO:0042802~identical protein binding,	IPR001129:Membr-assoc_MAPEG,IPR023352:MAPEG-like_dom_sf,	hsa00480:Glutathione metabolism,hsa00980:Metabolism of xenobiotics by cytochrome P450,hsa00982:Drug metabolism - cytochrome P450,hsa00983:Drug metabolism - other enzymes,hsa01100:Metabolic pathways,hsa01524:Platinum drug resistance,hsa05200:Pathways in cancer,hsa05204:Chemical carcinogenesis - DNA adducts,hsa05207:Chemical carcinogenesis - receptor activation,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05225:Hepatocellular carcinoma,hsa05418:Fluid shear stress and atherosclerosis,				KW-0443~Lipid metabolism,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-1000~Mitochondrion outer membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0456~Lyase,KW-0560~Oxidoreductase,KW-0808~Transferase,	KW-0449~Lipoprotein,KW-0564~Palmitate,	LIPID:S-palmitoyl cysteine,MUTAGEN:C->S: Abolishes S-acylation; when associated with S-150.,MUTAGEN:C->S: Abolishes S-acylation; when associated with S-151.,TOPO_DOM:Cytoplasmic,TOPO_DOM:Mitochondrial intermembrane,TRANSMEM:Helical,
MCRS1	microspherule protein 1(MCRS1)	Homo sapiens			GO:0000723~telomere maintenance,GO:0006275~regulation of DNA replication,GO:0006281~DNA repair,GO:0006282~regulation of DNA repair,GO:0006310~DNA recombination,GO:0006338~chromatin remodeling,GO:0033044~regulation of chromosome organization,GO:0036211~protein modification process,GO:0045739~positive regulation of DNA repair,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0045995~regulation of embryonic development,GO:0051571~positive regulation of histone H3-K4 methylation,GO:0051726~regulation of cell cycle,GO:0051974~negative regulation of telomerase activity,GO:0060382~regulation of DNA strand elongation,GO:1904357~negative regulation of telomere maintenance via telomere lengthening,GO:1904507~positive regulation of telomere maintenance in response to DNA damage,GO:1904751~positive regulation of protein localization to nucleolus,	GO:0000123~histone acetyltransferase complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005844~polysome,GO:0030425~dendrite,GO:0031011~Ino80 complex,GO:0043204~perikaryon,GO:0044545~NSL complex,GO:0071339~MLL1 complex,	GO:0002151~G-quadruplex RNA binding,GO:0005515~protein binding,GO:0008266~poly(U) RNA binding,GO:0010521~telomerase inhibitor activity,GO:0034046~poly(G) binding,	IPR000253:FHA_dom,IPR008984:SMAD_FHA_dom_sf,IPR025999:MCRS_N,IPR037912:MCRS1,	hsa03082:ATP-dependent chromatin remodeling,			SM00240:FHA,	KW-0227~DNA damage,KW-0233~DNA recombination,KW-0234~DNA repair,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,		KW-0156~Chromatin regulator,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:FHA,DOMAIN:Microspherule protein N-terminal,MOTIF:Nuclear localization signal,REGION:Disordered,
MACF1	microtubule actin crosslinking factor 1(MACF1)	Homo sapiens			GO:0010632~regulation of epithelial cell migration,GO:0016055~Wnt signaling pathway,GO:0030177~positive regulation of Wnt signaling pathway,GO:0030334~regulation of cell migration,GO:0032886~regulation of microtubule-based process,GO:0042060~wound healing,GO:0043001~Golgi to plasma membrane protein transport,GO:0045104~intermediate filament cytoskeleton organization,GO:0045773~positive regulation of axon extension,GO:0051893~regulation of focal adhesion assembly,	GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005856~cytoskeleton,GO:0005874~microtubule,GO:0005882~intermediate filament,GO:0005886~plasma membrane,GO:0015629~actin cytoskeleton,GO:0016020~membrane,GO:0030054~cell junction,GO:0032587~ruffle membrane,GO:0042995~cell projection,	GO:0003723~RNA binding,GO:0003779~actin binding,GO:0005198~structural molecule activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0008017~microtubule binding,GO:0045296~cadherin binding,GO:0051011~microtubule minus-end binding,GO:0051015~actin filament binding,	IPR001101:Plectin_repeat,IPR001452:SH3_domain,IPR001589:Actinin_actin-bd_CS,IPR001715:CH_dom,IPR002017:Spectrin_repeat,IPR002048:EF_hand_dom,IPR003108:GAR_dom,IPR011992:EF-hand-dom_pair,IPR018159:Spectrin/alpha-actinin,IPR018247:EF_Hand_1_Ca_BS,IPR035915:Plakin_repeat_sf,IPR036534:GAR_dom_sf,IPR036872:CH_dom_sf,IPR037727:MCAF1-like,IPR041573:Desmoplakin_Spectrin-like,IPR041615:Desmoplakin_SH3,IPR043197:Plakin,		618325~Lissencephaly 9 with complex brainstem malformation,		SM00033:CH,SM00054:EFh,SM00150:SPEC,SM00243:GAS2,SM00250:PLEC,SM01129:DELLA,	KW-0879~Wnt signaling pathway,	KW-0206~Cytoskeleton,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0493~Microtubule,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0451~Lissencephaly,	KW-0175~Coiled coil,KW-0433~Leucine-rich repeat,KW-0677~Repeat,KW-0728~SH3 domain,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0009~Actin-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Calponin-homology (CH),DOMAIN:Calponin-homology (CH) 1,DOMAIN:Calponin-homology (CH) 2,DOMAIN:EF-hand,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,DOMAIN:GAR,DOMAIN:SH3,REGION:13 X 13 AA approximate tandem repeat of P-T-S-P-A-A-A-V-P-T-P-E-E,REGION:4 X 4 AA tandem repeats of [GS]-S-R-[AR],REGION:Actin-binding,REGION:C-terminal tail,REGION:Disordered,REPEAT:1,REPEAT:10,REPEAT:11,REPEAT:12,REPEAT:13,REPEAT:2,REPEAT:3,REPEAT:4,REPEAT:5,REPEAT:6,REPEAT:7,REPEAT:8,REPEAT:9,REPEAT:LRR 1,REPEAT:LRR 10,REPEAT:LRR 11,REPEAT:LRR 12,REPEAT:LRR 13,REPEAT:LRR 14,REPEAT:LRR 15,REPEAT:LRR 16,REPEAT:LRR 17,REPEAT:LRR 18,REPEAT:LRR 19,REPEAT:LRR 2,REPEAT:LRR 20,REPEAT:LRR 21,REPEAT:LRR 22,REPEAT:LRR 23,REPEAT:LRR 24,REPEAT:LRR 3,REPEAT:LRR 4,REPEAT:LRR 5,REPEAT:LRR 6,REPEAT:LRR 7,REPEAT:LRR 8,REPEAT:LRR 9,REPEAT:Plectin 1,REPEAT:Plectin 10,REPEAT:Plectin 11,REPEAT:Plectin 2,REPEAT:Plectin 3,REPEAT:Plectin 4,REPEAT:Plectin 5,REPEAT:Plectin 6,REPEAT:Plectin 7,REPEAT:Plectin 8,REPEAT:Plectin 9,REPEAT:Spectrin 1,REPEAT:Spectrin 10,REPEAT:Spectrin 11,REPEAT:Spectrin 12,REPEAT:Spectrin 13,REPEAT:Spectrin 14,REPEAT:Spectrin 15,REPEAT:Spectrin 16,REPEAT:Spectrin 17,REPEAT:Spectrin 2,REPEAT:Spectrin 3,REPEAT:Spectrin 4,REPEAT:Spectrin 5,REPEAT:Spectrin 6,REPEAT:Spectrin 7,REPEAT:Spectrin 8,REPEAT:Spectrin 9,TRANSMEM:Helical,
MAP1LC3A	microtubule associated protein 1 light chain 3 alpha(MAP1LC3A)	Homo sapiens			GO:0000045~autophagosome assembly,GO:0000422~mitophagy,GO:0006995~cellular response to nitrogen starvation,GO:0007254~JNK cascade,GO:0009267~cellular response to starvation,GO:0010040~response to iron(II) ion,GO:0010288~response to lead ion,GO:0016236~macroautophagy,GO:0034198~cellular response to amino acid starvation,GO:0038066~p38MAPK cascade,GO:0060395~SMAD protein signal transduction,GO:0070301~cellular response to hydrogen peroxide,GO:0071280~cellular response to copper ion,GO:0090650~cellular response to oxygen-glucose deprivation,GO:0097352~autophagosome maturation,	GO:0000421~autophagosome membrane,GO:0005770~late endosome,GO:0005776~autophagosome,GO:0005829~cytosol,GO:0005874~microtubule,GO:0031090~organelle membrane,GO:0043231~intracellular membrane-bounded organelle,GO:0044754~autolysosome,GO:0098978~glutamatergic synapse,	GO:0005515~protein binding,GO:0005543~phospholipid binding,GO:0008017~microtubule binding,GO:0008429~phosphatidylethanolamine binding,GO:0031625~ubiquitin protein ligase binding,	IPR004241:Atg8-like,IPR029071:Ubiquitin-like_domsf,	hsa04137:Mitophagy - animal,hsa04140:Autophagy - animal,hsa04216:Ferroptosis,hsa04371:Apelin signaling pathway,hsa04621:NOD-like receptor signaling pathway,hsa05014:Amyotrophic lateral sclerosis,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05131:Shigellosis,hsa05167:Kaposi sarcoma-associated herpesvirus infection,				KW-0072~Autophagy,KW-0833~Ubl conjugation pathway,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0493~Microtubule,KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,					KW-0449~Lipoprotein,KW-0597~Phosphoprotein,	LIPID:Phosphatidylethanolamine amidated glycine; alternate,LIPID:Phosphatidylserine amidated glycine; alternate,MUTAGEN:E->A: Abolished deconjugation of phosphatidylethanolamine (PE) by Legionella RavZ, without affecting deconjugation by ATG4B.,MUTAGEN:F->A: Abolished deconjugation of phosphatidylethanolamine (PE) by both Legionella RavZ and ATG4B.,MUTAGEN:G->A: No processing of precursor.,MUTAGEN:H->D: Enhances binding to RETREG1.,MUTAGEN:H->Y: Enhances binding to RETREG1.,MUTAGEN:K->A: Decreases interaction with ATG13 and strongly reduces autophagosome formation.,MUTAGEN:K->A: Increases interaction with ATG13 and strongly reduces autophagosome formation.,MUTAGEN:K->F: Enhances binding to RETREG1.,MUTAGEN:K->R: Enhances binding to RETREG1.,MUTAGEN:L->A: Decreases interaction with ATG13.,MUTAGEN:Missing: Abolished deconjugation of phosphatidylethanolamine (PE) by both Legionella RavZ and ATG4B.,MUTAGEN:Q->A: Abolished deconjugation of phosphatidylethanolamine (PE) by ATG4B, without affecting deconjugation by Legionella RavZ.,MUTAGEN:QE->AA: Abolished deconjugation of phosphatidylethanolamine (PE) by ATG4B, without affecting deconjugation by Legionella RavZ.,MUTAGEN:QET->AAA: Abolished deconjugation of phosphatidylethanolamine (PE) by both Legionella RavZ and ATG4B.,MUTAGEN:QETF->AAAA: Abolished deconjugation of phosphatidylethanolamine (PE) by both Legionella RavZ and ATG4B.,MUTAGEN:T->A: Does not affect deconjugation of phosphatidylethanolamine (PE).,PROPEP:Removed in mature form,REGION:Important for interaction with ATG13 and for autophagosome formation,SITE:Cleavage; by ATG4B,
MAP1LC3B2	microtubule associated protein 1 light chain 3 beta 2(MAP1LC3B2)	Homo sapiens			GO:0000045~autophagosome assembly,GO:0000422~mitophagy,GO:0006995~cellular response to nitrogen starvation,GO:0016236~macroautophagy,GO:0097352~autophagosome maturation,	GO:0000421~autophagosome membrane,GO:0005776~autophagosome,GO:0005829~cytosol,GO:0005874~microtubule,GO:0012505~endomembrane system,GO:0031410~cytoplasmic vesicle,GO:0043231~intracellular membrane-bounded organelle,	GO:0008017~microtubule binding,GO:0008429~phosphatidylethanolamine binding,GO:0031625~ubiquitin protein ligase binding,	IPR004241:Atg8-like,IPR029071:Ubiquitin-like_domsf,	hsa04137:Mitophagy - animal,hsa04140:Autophagy - animal,hsa04216:Ferroptosis,hsa04371:Apelin signaling pathway,hsa04621:NOD-like receptor signaling pathway,hsa05014:Amyotrophic lateral sclerosis,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05131:Shigellosis,hsa05167:Kaposi sarcoma-associated herpesvirus infection,				KW-0072~Autophagy,KW-0833~Ubl conjugation pathway,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0493~Microtubule,KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,					KW-0449~Lipoprotein,	LIPID:Phosphatidylethanolamine amidated glycine; alternate,LIPID:Phosphatidylserine amidated glycine; alternate,PROPEP:Removed in mature form,SITE:Cleavage; by ATG4B,
MAP1LC3B	microtubule associated protein 1 light chain 3 beta(MAP1LC3B)	Homo sapiens			GO:0000045~autophagosome assembly,GO:0000422~mitophagy,GO:0000423~macromitophagy,GO:0006914~autophagy,GO:0006995~cellular response to nitrogen starvation,GO:0009267~cellular response to starvation,GO:0016236~macroautophagy,GO:0097352~autophagosome maturation,	GO:0000421~autophagosome membrane,GO:0005739~mitochondrion,GO:0005776~autophagosome,GO:0005829~cytosol,GO:0005874~microtubule,GO:0005930~axoneme,GO:0012505~endomembrane system,GO:0016020~membrane,GO:0031090~organelle membrane,GO:0031410~cytoplasmic vesicle,GO:0031966~mitochondrial membrane,GO:0043231~intracellular membrane-bounded organelle,	GO:0005515~protein binding,GO:0008017~microtubule binding,GO:0008429~phosphatidylethanolamine binding,GO:0031625~ubiquitin protein ligase binding,GO:0097001~ceramide binding,	IPR004241:Atg8-like,IPR029071:Ubiquitin-like_domsf,	hsa04137:Mitophagy - animal,hsa04140:Autophagy - animal,hsa04216:Ferroptosis,hsa04371:Apelin signaling pathway,hsa04621:NOD-like receptor signaling pathway,hsa05014:Amyotrophic lateral sclerosis,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05131:Shigellosis,hsa05167:Kaposi sarcoma-associated herpesvirus infection,				KW-0072~Autophagy,KW-0833~Ubl conjugation pathway,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0493~Microtubule,KW-0496~Mitochondrion,KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,					KW-0449~Lipoprotein,KW-0597~Phosphoprotein,	LIPID:Phosphatidylethanolamine amidated glycine; alternate,LIPID:Phosphatidylserine amidated glycine; alternate,MUTAGEN:F->A: Decreases C18 ceramide binding.,MUTAGEN:F->A: Impaired localization to autophagosomes.,MUTAGEN:FL->AA: No effect on interaction with TECPR2.,MUTAGEN:FLL->ALA: Impaired localization to autophagosomes.,MUTAGEN:G->A: No processing of precursor. No lipidation. Decreases C18 ceramide binding.,MUTAGEN:H->A: Decreased interaction with Legionella effector RavZ.,MUTAGEN:H->D: Increased interaction with WDFY3/ALFY, no effect on SQSTM1-binding; when associated with K-26 and Y-27.,MUTAGEN:H->Y: Increased interaction with WDFY3/ALFY, no effect on SQSTM1-binding; when associated with K-26 and D-57.,MUTAGEN:I->A: Decreases C18 ceramide binding.,MUTAGEN:K->A: No effect on processing of precursor.,MUTAGEN:Q->K: Increased interaction with WDFY3/ALFY, no effect on SQSTM1-binding; when associated with Y-27 and D-57.,MUTAGEN:Q->P: Abolished delipidation by ATG4 family proteins.,MUTAGEN:R->A: Abolishes interaction with TECPR2.,MUTAGEN:R->A: Impairs cleavage by ATG4B.,PROPEP:Removed in mature form,REGION:Disordered,SITE:Cleavage; by ATG4B,
MAP4	microtubule associated protein 4(MAP4)	Homo sapiens			GO:0000226~microtubule cytoskeleton organization,GO:0007052~mitotic spindle organization,GO:0031175~neuron projection development,GO:0046785~microtubule polymerization,GO:0051012~microtubule sliding,GO:0051294~establishment of spindle orientation,GO:0051301~cell division,GO:0061523~cilium disassembly,GO:1902856~negative regulation of non-motile cilium assembly,	GO:0005737~cytoplasm,GO:0005815~microtubule organizing center,GO:0005829~cytosol,GO:0005874~microtubule,GO:0005875~microtubule associated complex,GO:0005886~plasma membrane,GO:0005930~axoneme,GO:0015630~microtubule cytoskeleton,GO:0030424~axon,GO:0043005~neuron projection,GO:0072686~mitotic spindle,	GO:0003723~RNA binding,GO:0005198~structural molecule activity,GO:0005515~protein binding,GO:0008017~microtubule binding,	IPR001084:MAP_tubulin-bd_rpt,IPR027324:MAP2/MAP4/Tau,						KW-0206~Cytoskeleton,KW-0493~Microtubule,KW-0963~Cytoplasm,		KW-0677~Repeat,			KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),MUTAGEN:S->E: No change in microtubule binding; no change in microtubule polymerization activity.,MUTAGEN:S->E: No change in microtubule binding; reduced microtubule polymerization activity.,REGION:17 X 14 AA tandem repeats,REGION:Disordered,REPEAT:1,REPEAT:10,REPEAT:11,REPEAT:12,REPEAT:13,REPEAT:14,REPEAT:15,REPEAT:16,REPEAT:17,REPEAT:2,REPEAT:26 residues 1,REPEAT:26 residues 2,REPEAT:3,REPEAT:4,REPEAT:5,REPEAT:6,REPEAT:7,REPEAT:8; truncated,REPEAT:9,REPEAT:Tau/MAP 1,REPEAT:Tau/MAP 2,REPEAT:Tau/MAP 3,REPEAT:Tau/MAP 4,
MAPRE1	microtubule associated protein RP/EB family member 1(MAPRE1)	Homo sapiens			GO:0000132~establishment of mitotic spindle orientation,GO:0001578~microtubule bundle formation,GO:0008104~protein localization,GO:0016477~cell migration,GO:0031110~regulation of microtubule polymerization or depolymerization,GO:0031115~negative regulation of microtubule polymerization,GO:0031116~positive regulation of microtubule polymerization,GO:0035372~protein localization to microtubule,GO:0046785~microtubule polymerization,GO:0051225~spindle assembly,GO:0051301~cell division,GO:0051315~attachment of mitotic spindle microtubules to kinetochore,GO:0071539~protein localization to centrosome,GO:1902888~protein localization to astral microtubule,GO:1905515~non-motile cilium assembly,	GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005813~centrosome,GO:0005815~microtubule organizing center,GO:0005819~spindle,GO:0005829~cytosol,GO:0005874~microtubule,GO:0005881~cytoplasmic microtubule,GO:0005925~focal adhesion,GO:0030981~cortical microtubule cytoskeleton,GO:0031253~cell projection membrane,GO:0035371~microtubule plus-end,GO:0036064~ciliary basal body,GO:0051233~spindle midzone,GO:0097431~mitotic spindle pole,GO:1905721~mitotic spindle astral microtubule end,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0008017~microtubule binding,GO:0019901~protein kinase binding,GO:0042802~identical protein binding,GO:0045296~cadherin binding,GO:0051010~microtubule plus-end binding,GO:0060090~binding, bridging,	IPR001715:CH_dom,IPR004953:EB1_C,IPR027328:MAPRE,IPR036133:EB1_C_sf,IPR036872:CH_dom_sf,					KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,	KW-0206~Cytoskeleton,KW-0333~Golgi apparatus,KW-0493~Microtubule,KW-0963~Cytoplasm,					KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:Calponin-homology (CH),DOMAIN:EB1 C-terminal,MUTAGEN:K->E: Loss of binding to microtubules.,MUTAGEN:K->R: Abolished acetylation by KAT2B/PCAF, impairing kinetochore-microtubule interactions during mitosis.,MUTAGEN:K->R: Abolished crotonylation by KAT5.,MUTAGEN:KK->EE: No effect.,REGION:APC-binding,REGION:DCTN1-binding,REGION:Disordered,REGION:Interaction with APC,REGION:Interaction with CDK5RAP2,REGION:Interaction with MTUS2/TIP150,
MAPRE2	microtubule associated protein RP/EB family member 2(MAPRE2)	Homo sapiens			GO:0031110~regulation of microtubule polymerization or depolymerization,GO:0032014~positive regulation of ARF protein signal transduction,GO:0035372~protein localization to microtubule,GO:0043547~positive regulation of GTPase activity,GO:0051225~spindle assembly,GO:0051301~cell division,GO:0051549~positive regulation of keratinocyte migration,	GO:0005737~cytoplasm,GO:0005815~microtubule organizing center,GO:0005881~cytoplasmic microtubule,GO:0005925~focal adhesion,GO:0015630~microtubule cytoskeleton,GO:0035371~microtubule plus-end,GO:0051233~spindle midzone,	GO:0005515~protein binding,GO:0008017~microtubule binding,GO:0019901~protein kinase binding,GO:0042802~identical protein binding,GO:0051010~microtubule plus-end binding,	IPR001715:CH_dom,IPR004953:EB1_C,IPR027328:MAPRE,IPR036133:EB1_C_sf,IPR036872:CH_dom_sf,		616734~Symmetric circumferential skin creases, congenital, 2,			KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,	KW-0206~Cytoskeleton,KW-0493~Microtubule,KW-0963~Cytoplasm,					KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:Calponin-homology (CH),DOMAIN:EB1 C-terminal,REGION:APC-binding,REGION:DCTN1-binding,REGION:Disordered,
MITD1	microtubule interacting and trafficking domain containing 1(MITD1)	Homo sapiens			GO:0000281~mitotic cytokinesis,GO:0032091~negative regulation of protein binding,	GO:0016020~membrane,GO:0030496~midbody,GO:0031902~late endosome membrane,GO:0043231~intracellular membrane-bounded organelle,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0019904~protein domain specific binding,GO:0035091~phosphatidylinositol binding,GO:0042802~identical protein binding,	IPR007330:MIT_dom,IPR032341:MITD1_C,IPR036181:MIT_dom_sf,IPR038113:MITD1_C_sf,IPR045331:MITD1_N,				SM00745:MIT,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0813~Transport,	KW-0472~Membrane,KW-0967~Endosome,						DOMAIN:MIT,MUTAGEN:E->A: Abolishes interaction with CHMP1A, CHMP1B and CHMP2A. Abolishes location at the midbody.,MUTAGEN:F->A: Abolishes homodimerization; when associated with A-132 and A-225.,MUTAGEN:M->D: Abolishes interaction with CHMP1A, CHMP1B and CHMP2A.,MUTAGEN:R->E: Strongly reduces binding to membranes; when associated with E-168 and E-231.,MUTAGEN:R->E: Strongly reduces binding to membranes; when associated with E-221 and E-220.,MUTAGEN:R->E: Strongly reduces binding to membranes; when associated with E-221 and E-231.,MUTAGEN:Y->A: Abolishes homodimerization; when associated with A-132 and A-221.,MUTAGEN:Y->A: Abolishes homodimerization; when associated with A-221 and A-225.,REGION:Important for association with membranes,
MIEN1	migration and invasion enhancer 1(MIEN1)	Homo sapiens			GO:0006915~apoptotic process,GO:0030335~positive regulation of cell migration,GO:0043066~negative regulation of apoptotic process,GO:0051491~positive regulation of filopodium assembly,	GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0009898~cytoplasmic side of plasma membrane,	GO:0005515~protein binding,	IPR011893:Selenoprotein_Rdx-typ,IPR036249:Thioredoxin-like_sf,					KW-0053~Apoptosis,	KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0676~Redox-active center,			KW-0007~Acetylation,KW-0449~Lipoprotein,KW-0636~Prenylation,KW-1015~Disulfide bond,	DISULFID:Redox-active,LIPID:S-geranylgeranyl cysteine,MUTAGEN:C->S: Abolishes prenylation. Predominantly cysolic with little plasma membrane-associated expression. Reduces cell migration by affecting filopodia formation.,MUTAGEN:Missing: No effect on subcellular location. Low protein abundance, suggesting that stability is affected.,PROPEP:Removed in mature form,REGION:Disordered,
MUL1	mitochondrial E3 ubiquitin protein ligase 1(MUL1)	Homo sapiens			GO:0000209~protein polyubiquitination,GO:0000266~mitochondrial fission,GO:0006915~apoptotic process,GO:0006919~activation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0006996~organelle organization,GO:0010637~negative regulation of mitochondrial fusion,GO:0010821~regulation of mitochondrion organization,GO:0016567~protein ubiquitination,GO:0016925~protein sumoylation,GO:0030308~negative regulation of cell growth,GO:0031648~protein destabilization,GO:0033235~positive regulation of protein sumoylation,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0045824~negative regulation of innate immune response,GO:0050689~negative regulation of defense response to virus by host,GO:0050821~protein stabilization,GO:0051646~mitochondrion localization,GO:0051881~regulation of mitochondrial membrane potential,GO:0051898~negative regulation of protein kinase B signaling,GO:0060339~negative regulation of type I interferon-mediated signaling pathway,GO:0071360~cellular response to exogenous dsRNA,GO:0071650~negative regulation of chemokine (C-C motif) ligand 5 production,GO:0090141~positive regulation of mitochondrial fission,GO:1901028~regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway,GO:1903861~positive regulation of dendrite extension,GO:1904925~positive regulation of mitophagy in response to mitochondrial depolarization,	GO:0005739~mitochondrion,GO:0005741~mitochondrial outer membrane,GO:0005777~peroxisome,GO:0016020~membrane,GO:0030424~axon,GO:0043025~neuronal cell body,	GO:0002039~p53 binding,GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0019789~SUMO transferase activity,GO:0031625~ubiquitin protein ligase binding,GO:0042802~identical protein binding,GO:0046872~metal ion binding,GO:0061630~ubiquitin protein ligase activity,	IPR001841:Znf_RING,IPR013083:Znf_RING/FYVE/PHD,IPR022170:MUL1-like,	hsa04137:Mitophagy - animal,				KW-0053~Apoptosis,KW-0833~Ubl conjugation pathway,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0576~Peroxisome,KW-1000~Mitochondrion outer membrane,		KW-0812~Transmembrane,KW-0863~Zinc-finger,KW-1133~Transmembrane helix,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0808~Transferase,	KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:RING-type,MUTAGEN:C->A: Abolishes ligase activity.,MUTAGEN:C->S: Failure to reduce TP53 levels and abolishes ligase activity; when associated with S-302.,MUTAGEN:C->S: Failure to reduce TP53 levels and abolishes ligase activity; when associated with S-305.,MUTAGEN:H->A: Abolishes ligase activity. No effect on mitochondrial localization.,MUTAGEN:K->A: Protein is targeted to the ER; when associated with A-260.,MUTAGEN:R->A: Protein is targeted to the ER; when associated with A-261.,TOPO_DOM:Cytoplasmic,TOPO_DOM:Mitochondrial intermembrane,TRANSMEM:Helical,ZN_FING:RING-type,
MALSU1	mitochondrial assembly of ribosomal large subunit 1(MALSU1)	Homo sapiens			GO:0017148~negative regulation of translation,GO:0042273~ribosomal large subunit biogenesis,GO:0070130~negative regulation of mitochondrial translation,GO:0090071~negative regulation of ribosome biogenesis,	GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0005829~cytosol,	GO:0005515~protein binding,GO:0043023~ribosomal large subunit binding,	IPR004394:Iojap/RsfS/C7orf30,IPR043519:NT_sf,					KW-0690~Ribosome biogenesis,	KW-0496~Mitochondrion,						REGION:Disordered,
MFF	mitochondrial fission factor(MFF)	Homo sapiens			GO:0000266~mitochondrial fission,GO:0001836~release of cytochrome c from mitochondria,GO:0006626~protein targeting to mitochondrion,GO:0007005~mitochondrion organization,GO:0008053~mitochondrial fusion,GO:0010821~regulation of mitochondrion organization,GO:0016559~peroxisome fission,GO:0043653~mitochondrial fragmentation involved in apoptotic process,GO:0070584~mitochondrion morphogenesis,GO:0090141~positive regulation of mitochondrial fission,GO:0090200~positive regulation of release of cytochrome c from mitochondria,GO:0090314~positive regulation of protein targeting to membrane,GO:1900063~regulation of peroxisome organization,	GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005741~mitochondrial outer membrane,GO:0005777~peroxisome,GO:0008021~synaptic vesicle,GO:0016020~membrane,GO:0031966~mitochondrial membrane,GO:0032991~macromolecular complex,GO:0043231~intracellular membrane-bounded organelle,	GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,	IPR008518:Mff/Tango-11,IPR039433:Mff-like_dom,		617086~Encephalopathy due to defective mitochondrial and peroxisomal fission 2,				KW-0472~Membrane,KW-0496~Mitochondrion,KW-0576~Peroxisome,KW-0770~Synapse,KW-0968~Cytoplasmic vesicle,KW-1000~Mitochondrion outer membrane,		KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Mff-like,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Mitochondrial intermembrane,TRANSMEM:Helical,TRANSMEM:Helical; Anchor for type IV membrane protein,
MRPL27	mitochondrial ribosomal protein L27(MRPL27)	Homo sapiens			GO:0006412~translation,GO:0032543~mitochondrial translation,	GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005762~mitochondrial large ribosomal subunit,GO:0005840~ribosome,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,	IPR001684:Ribosomal_bL27,	hsa03010:Ribosome,					KW-0496~Mitochondrion,		KW-0809~Transit peptide,		KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,		REGION:Disordered,TRANSIT:Mitochondrion,
MRPL28	mitochondrial ribosomal protein L28(MRPL28)	Homo sapiens			GO:0006412~translation,GO:0032543~mitochondrial translation,	GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005761~mitochondrial ribosome,GO:0005762~mitochondrial large ribosomal subunit,GO:0005829~cytosol,GO:0005840~ribosome,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,	IPR026569:Ribosomal_bL28,IPR034704:Ribosomal_bL28/bL31-like_sf,IPR037147:Ribosomal_bL28_sf,	hsa03010:Ribosome,					KW-0496~Mitochondrion,		KW-0809~Transit peptide,		KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,		TRANSIT:Mitochondrion,
MRPL32	mitochondrial ribosomal protein L32(MRPL32)	Homo sapiens			GO:0006412~translation,GO:0032543~mitochondrial translation,	GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005761~mitochondrial ribosome,GO:0005762~mitochondrial large ribosomal subunit,GO:0005840~ribosome,GO:0015934~large ribosomal subunit,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,	IPR002677:Ribosomal_bL32,IPR011332:Ribosomal_zn-bd,	hsa03010:Ribosome,					KW-0496~Mitochondrion,		KW-0732~Signal,KW-0809~Transit peptide,		KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,		COMPBIAS:Basic and acidic residues,REGION:Disordered,TRANSIT:Mitochondrion,
MRPL43	mitochondrial ribosomal protein L43(MRPL43)	Homo sapiens			GO:0006412~translation,GO:0032543~mitochondrial translation,	GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005761~mitochondrial ribosome,GO:0005762~mitochondrial large ribosomal subunit,GO:0005840~ribosome,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,	IPR007741:Ribosomal_mL43/mS25/NADH_DH,IPR036249:Thioredoxin-like_sf,IPR039927:Ribosomal_mL43,				SM00916:L51_S25_CI-B8,		KW-0496~Mitochondrion,		KW-0809~Transit peptide,		KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,		DOMAIN:Ribosomal protein/NADH dehydrogenase,REGION:Disordered,TRANSIT:Mitochondrion,
MRPL49	mitochondrial ribosomal protein L49(MRPL49)	Homo sapiens			GO:0006412~translation,GO:0032543~mitochondrial translation,	GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005761~mitochondrial ribosome,GO:0005762~mitochondrial large ribosomal subunit,GO:0005840~ribosome,GO:1990904~ribonucleoprotein complex,	GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,	IPR007740:Ribosomal_mL49,						KW-0496~Mitochondrion,				KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,		COMPBIAS:Pro residues,REGION:Disordered,
MRPL54	mitochondrial ribosomal protein L54(MRPL54)	Homo sapiens			GO:0032543~mitochondrial translation,	GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005762~mitochondrial large ribosomal subunit,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,	IPR013870:Ribosomal_mL54,						KW-0496~Mitochondrion,		KW-0809~Transit peptide,		KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,		TRANSIT:Mitochondrion,
MRPS16	mitochondrial ribosomal protein S16(MRPS16)	Homo sapiens			GO:0006412~translation,GO:0032543~mitochondrial translation,	GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005763~mitochondrial small ribosomal subunit,GO:0005829~cytosol,GO:0005840~ribosome,GO:1990904~ribonucleoprotein complex,	GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,	IPR000307:Ribosomal_bS16,IPR023803:Ribosomal_bS16_dom_sf,	hsa03010:Ribosome,	610498~Combined oxidative phosphorylation deficiency 2,				KW-0496~Mitochondrion,	KW-1274~Primary mitochondrial disease,	KW-0809~Transit peptide,		KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0597~Phosphoprotein,	TRANSIT:Mitochondrion,
MRPS23	mitochondrial ribosomal protein S23(MRPS23)	Homo sapiens			GO:0006412~translation,GO:0032543~mitochondrial translation,	GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005763~mitochondrial small ribosomal subunit,GO:0005840~ribosome,GO:0031965~nuclear membrane,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,	IPR019520:Ribosomal_mS23_met,IPR023611:Ribosomal_mS23_dom,		618952~Combined oxidative phosphorylation deficiency 46,				KW-0496~Mitochondrion,	KW-0225~Disease variant,KW-1274~Primary mitochondrial disease,			KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0007~Acetylation,	COMPBIAS:Basic and acidic residues,DOMAIN:Small ribosomal subunit protein mS23 conserved,REGION:Disordered,
MRPS26	mitochondrial ribosomal protein S26(MRPS26)	Homo sapiens			GO:0032543~mitochondrial translation,	GO:0005654~nucleoplasm,GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005763~mitochondrial small ribosomal subunit,	GO:0003723~RNA binding,	IPR026140:Ribosomal_mS26,						KW-0496~Mitochondrion,		KW-0809~Transit peptide,		KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,		TRANSIT:Mitochondrion,
MRPS7	mitochondrial ribosomal protein S7(MRPS7)	Homo sapiens			GO:0000028~ribosomal small subunit assembly,GO:0006412~translation,GO:0032543~mitochondrial translation,	GO:0005743~mitochondrial inner membrane,GO:0005763~mitochondrial small ribosomal subunit,GO:0005840~ribosome,GO:0015935~small ribosomal subunit,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0003735~structural constituent of ribosome,GO:0019843~rRNA binding,	IPR000235:Ribosomal_uS7,IPR023798:Ribosomal_uS7_dom,IPR036823:Ribosomal_uS7_dom_sf,	hsa03010:Ribosome,	617872~Combined oxidative phosphorylation deficiency 34,	PIRSF002122:RPS7p_RPS7a_RPS5e_RPS7o,			KW-0496~Mitochondrion,	KW-0225~Disease variant,KW-1274~Primary mitochondrial disease,	KW-0809~Transit peptide,		KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0007~Acetylation,	DOMAIN:Small ribosomal subunit protein uS7,TRANSIT:Mitochondrion,
MT-ATP6	mitochondrially encoded ATP synthase 6(MT-ATP6)	Homo sapiens			GO:0006754~ATP biosynthetic process,GO:0015986~ATP synthesis coupled proton transport,GO:0042776~mitochondrial ATP synthesis coupled proton transport,GO:0055093~response to hyperoxia,GO:1902600~hydrogen ion transmembrane transport,	GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005753~mitochondrial proton-transporting ATP synthase complex,GO:0016020~membrane,GO:0045263~proton-transporting ATP synthase complex, coupling factor F(o),	GO:0005515~protein binding,GO:0015078~hydrogen ion transmembrane transporter activity,GO:0046933~proton-transporting ATP synthase activity, rotational mechanism,	IPR000568:ATP_synth_F0_asu,IPR023011:ATP_synth_F0_asu_AS,IPR035908:F0_ATP_A_sf,IPR045083:ATP_synth_F0_asu_bact/mt,	hsa00190:Oxidative phosphorylation,hsa01100:Metabolic pathways,hsa04714:Thermogenesis,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05415:Diabetic cardiomyopathy,				KW-0066~ATP synthesis,KW-0375~Hydrogen ion transport,KW-0406~Ion transport,KW-0813~Transport,	KW-0138~CF(0),KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,	KW-0122~Cardiomyopathy,KW-0225~Disease variant,KW-0429~Leber hereditary optic neuropathy,KW-0431~Leigh syndrome,KW-0622~Neuropathy,KW-0682~Retinitis pigmentosa,KW-1274~Primary mitochondrial disease,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,				TRANSMEM:Helical,
MT-ATP8	mitochondrially encoded ATP synthase 8(MT-ATP8)	Homo sapiens			GO:0015986~ATP synthesis coupled proton transport,GO:0042776~mitochondrial ATP synthesis coupled proton transport,GO:1902600~hydrogen ion transmembrane transport,	GO:0000276~mitochondrial proton-transporting ATP synthase complex, coupling factor F(o),GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005753~mitochondrial proton-transporting ATP synthase complex,	GO:0005515~protein binding,GO:0015078~hydrogen ion transmembrane transporter activity,GO:0046933~proton-transporting ATP synthase activity, rotational mechanism,	IPR001421:ATP8_metazoa,IPR039017:ATP8_mammal,	hsa00190:Oxidative phosphorylation,hsa01100:Metabolic pathways,hsa04714:Thermogenesis,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05415:Diabetic cardiomyopathy,				KW-0066~ATP synthesis,KW-0375~Hydrogen ion transport,KW-0406~Ion transport,KW-0813~Transport,	KW-0138~CF(0),KW-0472~Membrane,KW-0496~Mitochondrion,	KW-0122~Cardiomyopathy,KW-0225~Disease variant,KW-1274~Primary mitochondrial disease,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,	REGION:Disordered,TRANSMEM:Helical,
MT-ND4L	mitochondrially encoded NADH 4L dehydrogenase(MT-ND4L)	Homo sapiens			GO:0006120~mitochondrial electron transport, NADH to ubiquinone,GO:0009060~aerobic respiration,GO:0042773~ATP synthesis coupled electron transport,GO:0042776~mitochondrial ATP synthesis coupled proton transport,	GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005747~mitochondrial respiratory chain complex I,GO:0016020~membrane,GO:0070469~respiratory chain,	GO:0008137~NADH dehydrogenase (ubiquinone) activity,GO:0016491~oxidoreductase activity,GO:0016651~oxidoreductase activity, acting on NAD(P)H,	IPR001133:NADH_UbQ_OxRdtase_chain4L/K,IPR039428:NUOK/Mnh_C1-like,	hsa00190:Oxidative phosphorylation,hsa01100:Metabolic pathways,hsa04714:Thermogenesis,hsa04723:Retrograde endocannabinoid signaling,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05415:Diabetic cardiomyopathy,				KW-0249~Electron transport,KW-0679~Respiratory chain,KW-0813~Transport,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,	KW-0225~Disease variant,KW-0429~Leber hereditary optic neuropathy,KW-1274~Primary mitochondrial disease,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0520~NAD,KW-0830~Ubiquinone,	KW-0560~Oxidoreductase,KW-1278~Translocase,		TRANSMEM:Helical,
MT-ND1	mitochondrially encoded NADH dehydrogenase 1(MT-ND1)	Homo sapiens			GO:0001666~response to hypoxia,GO:0006120~mitochondrial electron transport, NADH to ubiquinone,GO:0009060~aerobic respiration,GO:0009410~response to xenobiotic stimulus,GO:0014070~response to organic cyclic compound,GO:0032981~mitochondrial respiratory chain complex I assembly,GO:0033194~response to hydroperoxide,GO:0042776~mitochondrial ATP synthesis coupled proton transport,	GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005747~mitochondrial respiratory chain complex I,GO:0016020~membrane,GO:0030425~dendrite,GO:0031966~mitochondrial membrane,GO:0043025~neuronal cell body,GO:0070469~respiratory chain,	GO:0003954~NADH dehydrogenase activity,GO:0005515~protein binding,GO:0008137~NADH dehydrogenase (ubiquinone) activity,GO:0016491~oxidoreductase activity,	IPR001694:NADH_UbQ_OxRdtase_su1/FPO,IPR018086:NADH_UbQ_OxRdtase_su1_CS,	hsa00190:Oxidative phosphorylation,hsa01100:Metabolic pathways,hsa04714:Thermogenesis,hsa04723:Retrograde endocannabinoid signaling,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05415:Diabetic cardiomyopathy,				KW-0249~Electron transport,KW-0679~Respiratory chain,KW-0813~Transport,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,	KW-0026~Alzheimer disease,KW-0219~Diabetes mellitus,KW-0225~Disease variant,KW-0429~Leber hereditary optic neuropathy,KW-0523~Neurodegeneration,KW-0867~MELAS syndrome,KW-0887~Epilepsy,KW-1008~Amyloidosis,KW-1274~Primary mitochondrial disease,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0520~NAD,KW-0830~Ubiquinone,	KW-0560~Oxidoreductase,KW-1278~Translocase,		TRANSMEM:Helical,UNSURE:I or L,
MT-ND2	mitochondrially encoded NADH dehydrogenase 2(MT-ND2)	Homo sapiens			GO:0001666~response to hypoxia,GO:0006120~mitochondrial electron transport, NADH to ubiquinone,GO:0009060~aerobic respiration,GO:0032981~mitochondrial respiratory chain complex I assembly,GO:0042776~mitochondrial ATP synthesis coupled proton transport,GO:0072593~reactive oxygen species metabolic process,	GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005747~mitochondrial respiratory chain complex I,GO:0016020~membrane,GO:0070469~respiratory chain,	GO:0005515~protein binding,GO:0008137~NADH dehydrogenase (ubiquinone) activity,GO:0019901~protein kinase binding,GO:0035255~ionotropic glutamate receptor binding,	IPR001750:ND/Mrp_mem,IPR003917:NADH_UbQ_OxRdtase_chain2,IPR010933:NADH_DH_su2_C,	hsa00190:Oxidative phosphorylation,hsa01100:Metabolic pathways,hsa04714:Thermogenesis,hsa04723:Retrograde endocannabinoid signaling,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05415:Diabetic cardiomyopathy,				KW-0249~Electron transport,KW-0679~Respiratory chain,KW-0813~Transport,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,	KW-0026~Alzheimer disease,KW-0225~Disease variant,KW-0429~Leber hereditary optic neuropathy,KW-0431~Leigh syndrome,KW-0523~Neurodegeneration,KW-1008~Amyloidosis,KW-1274~Primary mitochondrial disease,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0520~NAD,KW-0830~Ubiquinone,	KW-0560~Oxidoreductase,KW-1278~Translocase,		DOMAIN:NADH dehydrogenase subunit 2 C-terminal,DOMAIN:NADH:quinone oxidoreductase/Mrp antiporter membrane subunit,TRANSMEM:Helical,UNSURE:I or L,
MT-ND3	mitochondrially encoded NADH dehydrogenase 3(MT-ND3)	Homo sapiens			GO:0006120~mitochondrial electron transport, NADH to ubiquinone,GO:0006979~response to oxidative stress,GO:0009060~aerobic respiration,GO:0009642~response to light intensity,GO:0042776~mitochondrial ATP synthesis coupled proton transport,GO:0071385~cellular response to glucocorticoid stimulus,	GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005747~mitochondrial respiratory chain complex I,GO:0016020~membrane,GO:0031966~mitochondrial membrane,GO:0070469~respiratory chain,	GO:0005515~protein binding,GO:0008137~NADH dehydrogenase (ubiquinone) activity,	IPR000440:NADH_UbQ/plastoQ_OxRdtase_su3,IPR038430:NDAH_ubi_oxred_su3_sf,	hsa00190:Oxidative phosphorylation,hsa01100:Metabolic pathways,hsa04714:Thermogenesis,hsa04723:Retrograde endocannabinoid signaling,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05415:Diabetic cardiomyopathy,				KW-0249~Electron transport,KW-0679~Respiratory chain,KW-0813~Transport,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,	KW-0225~Disease variant,KW-0431~Leigh syndrome,KW-1274~Primary mitochondrial disease,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0520~NAD,KW-0830~Ubiquinone,	KW-0560~Oxidoreductase,KW-1278~Translocase,		TRANSMEM:Helical,
MT-ND4	mitochondrially encoded NADH dehydrogenase 4(MT-ND4)	Homo sapiens			GO:0001666~response to hypoxia,GO:0001701~in utero embryonic development,GO:0006120~mitochondrial electron transport, NADH to ubiquinone,GO:0009060~aerobic respiration,GO:0015990~electron transport coupled proton transport,GO:0021549~cerebellum development,GO:0032981~mitochondrial respiratory chain complex I assembly,GO:0035094~response to nicotine,GO:0042773~ATP synthesis coupled electron transport,GO:0042776~mitochondrial ATP synthesis coupled proton transport,GO:0045471~response to ethanol,	GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005747~mitochondrial respiratory chain complex I,GO:0016020~membrane,GO:0031966~mitochondrial membrane,GO:0070469~respiratory chain,	GO:0003954~NADH dehydrogenase activity,GO:0008137~NADH dehydrogenase (ubiquinone) activity,GO:0016491~oxidoreductase activity,GO:0048039~ubiquinone binding,	IPR000260:NADH4_N,IPR001750:ND/Mrp_mem,IPR003918:NADH_UbQ_OxRdtase,IPR010227:NADH_Q_OxRdtase_chainM/4,	hsa00190:Oxidative phosphorylation,hsa01100:Metabolic pathways,hsa04714:Thermogenesis,hsa04723:Retrograde endocannabinoid signaling,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05415:Diabetic cardiomyopathy,				KW-0249~Electron transport,KW-0679~Respiratory chain,KW-0813~Transport,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,	KW-0225~Disease variant,KW-0429~Leber hereditary optic neuropathy,KW-0867~MELAS syndrome,KW-1023~Dystonia,KW-1274~Primary mitochondrial disease,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0520~NAD,KW-0830~Ubiquinone,	KW-0560~Oxidoreductase,KW-1278~Translocase,		DOMAIN:NADH:quinone oxidoreductase/Mrp antiporter membrane subunit,DOMAIN:NADH:ubiquinone oxidoreductase chain 4 N-terminal,TRANSMEM:Helical,
MT-CYB	mitochondrially encoded cytochrome b(MT-CYB)	Homo sapiens			GO:0001666~response to hypoxia,GO:0006119~oxidative phosphorylation,GO:0006122~mitochondrial electron transport, ubiquinol to cytochrome c,GO:0009410~response to xenobiotic stimulus,GO:0009636~response to toxic substance,GO:0015990~electron transport coupled proton transport,GO:0022904~respiratory electron transport chain,GO:0031100~animal organ regeneration,GO:0033590~response to cobalamin,GO:0033762~response to glucagon,GO:0045333~cellular respiration,GO:0045471~response to ethanol,GO:0046686~response to cadmium ion,GO:0046688~response to copper ion,GO:0046689~response to mercury ion,GO:0051592~response to calcium ion,GO:0055093~response to hyperoxia,	GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005750~mitochondrial respiratory chain complex III,GO:0016020~membrane,GO:0045275~respiratory chain complex III,GO:0070469~respiratory chain,	GO:0004129~cytochrome-c oxidase activity,GO:0008121~ubiquinol-cytochrome-c reductase activity,GO:0009055~electron carrier activity,GO:0020037~heme binding,GO:0044877~macromolecular complex binding,GO:0046872~metal ion binding,	IPR000883:Cyt_C_Oxase_1,IPR005797:Cyt_b/b6_N,IPR005798:Cyt_b/b6_C,IPR016174:Di-haem_cyt_TM,IPR023616:Cyt_c_oxase-like_su1_dom,IPR027387:Cytb/b6-like_sf,IPR030689:Cytochrome_b,IPR036150:Cyt_b/b6_C_sf,IPR036927:Cyt_c_oxase-like_su1_sf,IPR048259:Cytochrome_b_N_euk/bac,IPR048260:Cytochrome_b_C_euk/bac,	hsa00190:Oxidative phosphorylation,hsa01100:Metabolic pathways,hsa04260:Cardiac muscle contraction,hsa04714:Thermogenesis,hsa04932:Non-alcoholic fatty liver disease,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05415:Diabetic cardiomyopathy,		PIRSF000032:Cytochrome_b6,PIRSF038885:COB,		KW-0249~Electron transport,KW-0679~Respiratory chain,KW-0813~Transport,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,	KW-0122~Cardiomyopathy,KW-0209~Deafness,KW-0225~Disease variant,KW-0429~Leber hereditary optic neuropathy,KW-0898~Cataract,KW-1274~Primary mitochondrial disease,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0186~Copper,KW-0349~Heme,KW-0408~Iron,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0830~Ubiquinone,KW-0915~Sodium,	KW-0560~Oxidoreductase,		BINDING:axial binding residue,DOMAIN:Cytochrome b/b6 C-terminal region profile,DOMAIN:Cytochrome b/b6 N-terminal region profile,DOMAIN:Cytochrome oxidase subunit I profile,TRANSMEM:Helical,
MT-CO1	mitochondrially encoded cytochrome c oxidase I(MT-CO1)	Homo sapiens			GO:0001666~response to hypoxia,GO:0006119~oxidative phosphorylation,GO:0006123~mitochondrial electron transport, cytochrome c to oxygen,GO:0006979~response to oxidative stress,GO:0015990~electron transport coupled proton transport,GO:0021549~cerebellum development,GO:0045333~cellular respiration,GO:0046688~response to copper ion,GO:0051602~response to electrical stimulus,	GO:0005743~mitochondrial inner membrane,GO:0005750~mitochondrial respiratory chain complex III,GO:0005751~mitochondrial respiratory chain complex IV,GO:0031966~mitochondrial membrane,GO:0045277~respiratory chain complex IV,GO:0070469~respiratory chain,	GO:0004129~cytochrome-c oxidase activity,GO:0005515~protein binding,GO:0008137~NADH dehydrogenase (ubiquinone) activity,GO:0020037~heme binding,GO:0046872~metal ion binding,	IPR000883:Cyt_C_Oxase_1,IPR001457:NADH_UbQ/plastoQ_OxRdtase_su6,IPR023615:Cyt_c_Oxase_su1_BS,IPR023616:Cyt_c_oxase-like_su1_dom,IPR033944:Cyt_c_oxase_su1_dom,IPR036927:Cyt_c_oxase-like_su1_sf,	hsa00190:Oxidative phosphorylation,hsa01100:Metabolic pathways,hsa04260:Cardiac muscle contraction,hsa04714:Thermogenesis,hsa04932:Non-alcoholic fatty liver disease,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05415:Diabetic cardiomyopathy,				KW-0249~Electron transport,KW-0679~Respiratory chain,KW-0813~Transport,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,	KW-0209~Deafness,KW-0225~Disease variant,KW-0429~Leber hereditary optic neuropathy,KW-1010~Non-syndromic deafness,KW-1274~Primary mitochondrial disease,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0186~Copper,KW-0349~Heme,KW-0408~Iron,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0520~NAD,KW-0830~Ubiquinone,KW-0915~Sodium,	KW-1278~Translocase,		BINDING:axial binding residue,CROSSLNK:1'-histidyl-3'-tyrosine (His-Tyr),DOMAIN:Cytochrome oxidase subunit I profile,TOPO_DOM:Mitochondrial intermembrane,TOPO_DOM:Mitochondrial matrix,TRANSMEM:Helical,TRANSMEM:Helical; Name=I,TRANSMEM:Helical; Name=II,TRANSMEM:Helical; Name=III,TRANSMEM:Helical; Name=IV,TRANSMEM:Helical; Name=IX,TRANSMEM:Helical; Name=V,TRANSMEM:Helical; Name=VI,TRANSMEM:Helical; Name=VII,TRANSMEM:Helical; Name=VIII,TRANSMEM:Helical; Name=X,TRANSMEM:Helical; Name=XI,TRANSMEM:Helical; Name=XII,UNSURE:D or N,UNSURE:I or L,
MT-CO2	mitochondrially encoded cytochrome c oxidase II(MT-CO2)	Homo sapiens			GO:0001666~response to hypoxia,GO:0006123~mitochondrial electron transport, cytochrome c to oxygen,GO:0007595~lactation,GO:0042773~ATP synthesis coupled electron transport,GO:0045333~cellular respiration,GO:1902600~hydrogen ion transmembrane transport,	GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005751~mitochondrial respiratory chain complex IV,GO:0016020~membrane,GO:0031966~mitochondrial membrane,GO:0045277~respiratory chain complex IV,GO:0070469~respiratory chain,	GO:0004129~cytochrome-c oxidase activity,GO:0005507~copper ion binding,GO:0005515~protein binding,	IPR001505:Copper_CuA,IPR002429:CcO_II-like_C,IPR008972:Cupredoxin,IPR011759:Cyt_c_oxidase_su2_TM_dom,IPR014222:Cyt_c_oxidase_su2,IPR034210:CcO_II_C,IPR036257:Cyt_c_oxidase_su2_TM_sf,IPR045187:CcO_II,	hsa00190:Oxidative phosphorylation,hsa01100:Metabolic pathways,hsa04260:Cardiac muscle contraction,hsa04714:Thermogenesis,hsa04932:Non-alcoholic fatty liver disease,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05415:Diabetic cardiomyopathy,				KW-0249~Electron transport,KW-0679~Respiratory chain,KW-0813~Transport,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,	KW-0225~Disease variant,KW-1274~Primary mitochondrial disease,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0186~Copper,KW-0460~Magnesium,KW-0479~Metal-binding,	KW-1278~Translocase,		DOMAIN:Cytochrome oxidase subunit II copper A binding,DOMAIN:Cytochrome oxidase subunit II transmembrane region profile,TOPO_DOM:Mitochondrial intermembrane,TOPO_DOM:Mitochondrial matrix,TRANSMEM:Helical,TRANSMEM:Helical; Name=I,TRANSMEM:Helical; Name=II,UNSURE:D or N,
MT-CO3	mitochondrially encoded cytochrome c oxidase III(MT-CO3)	Homo sapiens			GO:0006123~mitochondrial electron transport, cytochrome c to oxygen,GO:0008535~respiratory chain complex IV assembly,GO:0019646~aerobic electron transport chain,GO:0045333~cellular respiration,GO:1902600~hydrogen ion transmembrane transport,	GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005751~mitochondrial respiratory chain complex IV,GO:0016020~membrane,GO:0031966~mitochondrial membrane,GO:0045277~respiratory chain complex IV,	GO:0004129~cytochrome-c oxidase activity,GO:0005515~protein binding,	IPR000298:Cyt_c_oxidase-like_su3,IPR013833:Cyt_c_oxidase_su3_a-hlx,IPR024791:Cyt_c/ubiquinol_Oxase_su3,IPR033945:Cyt_c_oxase_su3_dom,IPR035973:Cyt_c_oxidase_su3-like_sf,	hsa00190:Oxidative phosphorylation,hsa01100:Metabolic pathways,hsa04260:Cardiac muscle contraction,hsa04714:Thermogenesis,hsa04932:Non-alcoholic fatty liver disease,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05415:Diabetic cardiomyopathy,					KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,	KW-0225~Disease variant,KW-0429~Leber hereditary optic neuropathy,KW-1274~Primary mitochondrial disease,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-1278~Translocase,		DOMAIN:Heme-copper oxidase subunit III family profile,REGION:Disordered,TOPO_DOM:Mitochondrial intermembrane,TOPO_DOM:Mitochondrial matrix,TRANSMEM:Helical,TRANSMEM:Helical; Name=I,TRANSMEM:Helical; Name=II,TRANSMEM:Helical; Name=III,TRANSMEM:Helical; Name=IV,TRANSMEM:Helical; Name=V,TRANSMEM:Helical; Name=VI,TRANSMEM:Helical; Name=VII,UNSURE:I or L,
MAP2K1	mitogen-activated protein kinase kinase 1(MAP2K1)	Homo sapiens	100.MAPK_signaling_cascades,67.Ikaros_and_signaling_inhibitors,	h_AnthraxPathway:Anthrax Toxin Mechanism of Action,h_at1rPathway:Angiotensin II mediated activation of JNK Pathway via Pyk2 dependent signaling,h_bArr-mapkPathway:Role of ï¿½-arrestins in the activation and targeting of MAP kinases,h_bArrestin-srcPathway:Roles of ï¿½-arrestin-dependent Recruitment of Src Kinases in GPCR Signaling,h_bcrPathway:BCR Signaling Pathway,h_biopeptidesPathway:Bioactive Peptide Induced Signaling Pathway,h_ccr3Pathway:CCR3 signaling in Eosinophils,h_cdk5Pathway:Phosphorylation of MEK1 by cdk5/p35 down regulates the MAP kinase pathway,h_cdmacPathway:Cadmium induces DNA synthesis and proliferation in macrophages,h_ceramidePathway:Ceramide Signaling Pathway,h_cxcr4Pathway:CXCR4 Signaling Pathway,h_ecmPathway:Erk and PI-3 Kinase Are Necessary for Collagen Binding in Corneal Epithelia,h_egfPathway:EGF Signaling Pathway,h_egfr_smrtePathway:Map Kinase Inactivation of SMRT Corepressor,h_epoPathway:EPO Signaling Pathway,h_erkPathway:Erk1/Erk2 Mapk Signaling pathway,h_fcer1Pathway:Fc Epsilon Receptor I Signaling in Mast Cells,h_fmlpPathway:fMLP induced chemokine gene expression in HMC-1 cells,h_ghPathway:Growth Hormone Signaling Pathway,h_gleevecPathway:Inhibition of Cellular Proliferation by Gleevec,h_gpcrPathway:Signaling Pathway from G-Protein Families,h_hcmvPathway:Human Cytomegalovirus and Map Kinase Pathways,h_her2Pathway:Role of ERBB2 in Signal Transduction and Oncology,h_igf1Pathway:IGF-1 Signaling Pathway,h_igf1rPathway:Multiple antiapoptotic pathways from IGF-1R signaling lead to BAD phosphorylation,h_il2Pathway:IL 2 signaling pathway,h_il3Pathway:IL 3 signaling pathway,h_il6Pathway:IL 6 signaling pathway,h_insulinPathway:Insulin Signaling Pathway,h_integrinPathway:Integrin Signaling Pathway,h_keratinocytePathway:Keratinocyte Differentiation,h_malPathway:Role of MAL in Rho-Mediated Activation of SRF,h_mapkPathway:MAPKinase Signaling Pathway,h_metPathway:Signaling of Hepatocyte Growth Factor Receptor,h_nfatPathway:NFAT and Hypertrophy of the heart (Transcription in the broken heart),h_ngfPathway:Nerve growth factor pathway (NGF),h_nkcellsPathway:Ras-Independent pathway in NK cell-mediated cytotoxicity,h_pdgfPathway:PDGF Signaling Pathway,h_pyk2Pathway:Links between Pyk2 and Map Kinases,h_rasPathway:Ras Signaling Pathway,h_sppaPathway:Aspirin Blocks Signaling Pathway Involved in Platelet Activation,h_spryPathway:Sprouty regulation of tyrosine kinase signals,h_tcrPathway:T Cell Receptor Signaling Pathway,h_tgfbPathway:TGF beta signaling pathway,h_tpoPathway:TPO Signaling Pathway,	GO:0000165~MAPK cascade,GO:0006468~protein phosphorylation,GO:0006935~chemotaxis,GO:0007165~signal transduction,GO:0007507~heart development,GO:0008285~negative regulation of cell proliferation,GO:0010628~positive regulation of gene expression,GO:0014044~Schwann cell development,GO:0016310~phosphorylation,GO:0021697~cerebellar cortex formation,GO:0030182~neuron differentiation,GO:0030216~keratinocyte differentiation,GO:0030878~thyroid gland development,GO:0032872~regulation of stress-activated MAPK cascade,GO:0035987~endodermal cell differentiation,GO:0038133~ERBB2-ERBB3 signaling pathway,GO:0042552~myelination,GO:0043410~positive regulation of MAPK cascade,GO:0044342~type B pancreatic cell proliferation,GO:0045893~positive regulation of transcription, DNA-templated,GO:0048009~insulin-like growth factor receptor signaling pathway,GO:0048538~thymus development,GO:0048679~regulation of axon regeneration,GO:0048870~cell motility,GO:0050772~positive regulation of axonogenesis,GO:0060020~Bergmann glial cell differentiation,GO:0060324~face development,GO:0060440~trachea formation,GO:0060502~epithelial cell proliferation involved in lung morphogenesis,GO:0060674~placenta blood vessel development,GO:0060711~labyrinthine layer development,GO:0070371~ERK1 and ERK2 cascade,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0071902~positive regulation of protein serine/threonine kinase activity,GO:0090170~regulation of Golgi inheritance,GO:0090398~cellular senescence,GO:1903226~positive regulation of endodermal cell differentiation,GO:2000641~regulation of early endosome to late endosome transport,	GO:0005634~nucleus,GO:0005739~mitochondrion,GO:0005769~early endosome,GO:0005770~late endosome,GO:0005783~endoplasmic reticulum,GO:0005794~Golgi apparatus,GO:0005813~centrosome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005925~focal adhesion,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004708~MAP kinase kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0004713~protein tyrosine kinase activity,GO:0005078~MAP-kinase scaffold activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0030295~protein kinase activator activity,GO:0043539~protein serine/threonine kinase activator activity,GO:0097110~scaffold protein binding,	IPR000719:Prot_kinase_dom,IPR008271:Ser/Thr_kinase_AS,IPR011009:Kinase-like_dom_sf,IPR017441:Protein_kinase_ATP_BS,	hsa01521:EGFR tyrosine kinase inhibitor resistance,hsa01522:Endocrine resistance,hsa04010:MAPK signaling pathway,hsa04012:ErbB signaling pathway,hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04022:cGMP-PKG signaling pathway,hsa04024:cAMP signaling pathway,hsa04062:Chemokine signaling pathway,hsa04066:HIF-1 signaling pathway,hsa04068:FoxO signaling pathway,hsa04071:Sphingolipid signaling pathway,hsa04072:Phospholipase D signaling pathway,hsa04114:Oocyte meiosis,hsa04140:Autophagy - animal,hsa04148:Efferocytosis,hsa04150:mTOR signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04210:Apoptosis,hsa04218:Cellular senescence,hsa04270:Vascular smooth muscle contraction,hsa04370:VEGF signaling pathway,hsa04371:Apelin signaling pathway,hsa04380:Osteoclast differentiation,hsa04510:Focal adhesion,hsa04540:Gap junction,hsa04550:Signaling pathways regulating pluripotency of stem cells,hsa04613:Neutrophil extracellular trap formation,hsa04620:Toll-like receptor signaling pathway,hsa04650:Natural killer cell mediated cytotoxicity,hsa04660:T cell receptor signaling pathway,hsa04662:B cell receptor signaling pathway,hsa04664:Fc epsilon RI signaling pathway,hsa04666:Fc gamma R-mediated phagocytosis,hsa04668:TNF signaling pathway,hsa04720:Long-term potentiation,hsa04722:Neurotrophin signaling pathway,hsa04725:Cholinergic synapse,hsa04726:Serotonergic synapse,hsa04730:Long-term depression,hsa04810:Regulation of actin cytoskeleton,hsa04910:Insulin signaling pathway,hsa04912:GnRH signaling pathway,hsa04914:Progesterone-mediated oocyte maturation,hsa04915:Estrogen signaling pathway,hsa04916:Melanogenesis,hsa04917:Prolactin signaling pathway,hsa04919:Thyroid hormone signaling pathway,hsa04921:Oxytocin signaling pathway,hsa04926:Relaxin signaling pathway,hsa04928:Parathyroid hormone synthesis, secretion and action,hsa04929:GnRH secretion,hsa04934:Cushing syndrome,hsa04935:Growth hormone synthesis, secretion and action,hsa05010:Alzheimer disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05034:Alcoholism,hsa05132:Salmonella infection,hsa05135:Yersinia infection,hsa05160:Hepatitis C,hsa05161:Hepatitis B,hsa05163:Human cytomegalovirus infection,hsa05164:Influenza A,hsa05165:Human papillomavirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05200:Pathways in cancer,hsa05205:Proteoglycans in cancer,hsa05206:MicroRNAs in cancer,hsa05207:Chemical carcinogenesis - receptor activation,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05210:Colorectal cancer,hsa05211:Renal cell carcinoma,hsa05212:Pancreatic cancer,hsa05213:Endometrial cancer,hsa05214:Glioma,hsa05215:Prostate cancer,hsa05216:Thyroid cancer,hsa05218:Melanoma,hsa05219:Bladder cancer,hsa05220:Chronic myeloid leukemia,hsa05221:Acute myeloid leukemia,hsa05223:Non-small cell lung cancer,hsa05224:Breast cancer,hsa05225:Hepatocellular carcinoma,hsa05226:Gastric cancer,hsa05230:Central carbon metabolism in cancer,hsa05231:Choline metabolism in cancer,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,	155950~Melorheostosis, isolated, somatic mosaic,615279~Cardiofaciocutaneous syndrome 3,		SM00220:S_TKc,		KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0038~Ectodermal dysplasia,KW-0122~Cardiomyopathy,KW-0225~Disease variant,KW-0991~Intellectual disability,	KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,KW-0829~Tyrosine-protein kinase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,COMPBIAS:Polar residues,DOMAIN:Protein kinase,MUTAGEN:A->L: Increases interaction with KSR1 and BRAF; when associated with w-219.,MUTAGEN:F->S: Loss of interaction with BRAF and KSR1. Loss of BRAF-KSR1 dimerization.,MUTAGEN:K->A: Loss of catalytic activity. Strongly reduces phosphorylation upon UV irradiation.,MUTAGEN:K->R: Loss of catalytic activity. No effect on BRAF-KSR1 or BRAF-KSR2 dimerization.,MUTAGEN:M->V: Increases interaction with KSR1 and BRAF.,MUTAGEN:M->W: Increases interaction with KSR1 and BRAF; when associated with L-220.,MUTAGEN:N->Y: Increases interaction with KSR1 and BRAF.,MUTAGEN:S->A: Loss of catalytic activity. No effect on BRAF-KSR1 dimerization; when associated with A-218.,MUTAGEN:S->A: Loss of catalytic activity. No effect on BRAF-KSR1 dimerization; when associated with A-222.,MUTAGEN:S->A: No loss of activity.,MUTAGEN:S->D: No effect on BRAF-KSR1 dimerization; when associated with D-218.,MUTAGEN:S->D: No effect on BRAF-KSR1 dimerization; when associated with D-222.,REGION:Disordered,REGION:RAF1-binding,SITE:Cleavage; by anthrax lethal factor,
MAP2K3	mitogen-activated protein kinase kinase 3(MAP2K3)	Homo sapiens	100.MAPK_signaling_cascades,	h_fmlpPathway:fMLP induced chemokine gene expression in HMC-1 cells,h_gata3Pathway:GATA3 participate in activating the Th2 cytokine genes expression,h_hcmvPathway:Human Cytomegalovirus and Map Kinase Pathways,h_il1rPathway:Signal transduction through IL1R,h_keratinocytePathway:Keratinocyte Differentiation,h_mapkPathway:MAPKinase Signaling Pathway,h_nthiPathway:NFkB activation by Nontypeable Hemophilus influenzae,h_pyk2Pathway:Links between Pyk2 and Map Kinases,h_stressPathway:TNF/Stress Related Signaling,h_tollPathway:Toll-Like Receptor Pathway,	GO:0000165~MAPK cascade,GO:0001817~regulation of cytokine production,GO:0001934~positive regulation of protein phosphorylation,GO:0002931~response to ischemia,GO:0006954~inflammatory response,GO:0007165~signal transduction,GO:0007507~heart development,GO:0016310~phosphorylation,GO:0031098~stress-activated protein kinase signaling cascade,GO:0035331~negative regulation of hippo signaling,GO:0035924~cellular response to vascular endothelial growth factor stimulus,GO:0038066~p38MAPK cascade,GO:0043410~positive regulation of MAPK cascade,GO:0043536~positive regulation of blood vessel endothelial cell migration,GO:0045860~positive regulation of protein kinase activity,GO:0045893~positive regulation of transcription, DNA-templated,GO:0051770~positive regulation of nitric-oxide synthase biosynthetic process,GO:0060048~cardiac muscle contraction,GO:0071222~cellular response to lipopolysaccharide,GO:0072709~cellular response to sorbitol,GO:0090398~cellular senescence,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016020~membrane,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004708~MAP kinase kinase activity,GO:0004713~protein tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0019901~protein kinase binding,	IPR000719:Prot_kinase_dom,IPR008271:Ser/Thr_kinase_AS,IPR011009:Kinase-like_dom_sf,IPR017441:Protein_kinase_ATP_BS,	hsa04010:MAPK signaling pathway,hsa04015:Rap1 signaling pathway,hsa04218:Cellular senescence,hsa04620:Toll-like receptor signaling pathway,hsa04664:Fc epsilon RI signaling pathway,hsa04668:TNF signaling pathway,hsa04714:Thermogenesis,hsa04750:Inflammatory mediator regulation of TRP channels,hsa04912:GnRH signaling pathway,hsa04935:Growth hormone synthesis, secretion and action,hsa04936:Alcoholic liver disease,hsa05014:Amyotrophic lateral sclerosis,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05132:Salmonella infection,hsa05135:Yersinia infection,hsa05145:Toxoplasmosis,hsa05161:Hepatitis B,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,hsa05417:Lipid and atherosclerosis,			SM00220:S_TKc,			KW-0225~Disease variant,		KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,KW-0829~Tyrosine-protein kinase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,COMPBIAS:Polar residues,DOMAIN:Protein kinase,MUTAGEN:S->A: Inactivation.,MUTAGEN:S->E: Constitutive activation.,MUTAGEN:T->A: Inactivation.,MUTAGEN:T->E: Constitutive activation.,REGION:Disordered,
MAP3K11	mitogen-activated protein kinase kinase kinase 11(MAP3K11)	Homo sapiens	100.MAPK_signaling_cascades,	h_mapkPathway:MAPKinase Signaling Pathway,	GO:0000165~MAPK cascade,GO:0006468~protein phosphorylation,GO:0007017~microtubule-based process,GO:0007254~JNK cascade,GO:0016310~phosphorylation,GO:0043065~positive regulation of apoptotic process,GO:0043507~positive regulation of JUN kinase activity,GO:0043525~positive regulation of neuron apoptotic process,GO:0044843~cell cycle G1/S phase transition,GO:0046330~positive regulation of JNK cascade,GO:0046777~protein autophosphorylation,	GO:0005813~centrosome,GO:0005829~cytosol,GO:0005874~microtubule,GO:0016020~membrane,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004706~JUN kinase kinase kinase activity,GO:0004709~MAP kinase kinase kinase activity,GO:0004713~protein tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016301~kinase activity,GO:0031267~small GTPase binding,GO:0031434~mitogen-activated protein kinase kinase binding,GO:0031435~mitogen-activated protein kinase kinase kinase binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,	IPR000719:Prot_kinase_dom,IPR001245:Ser-Thr/Tyr_kinase_cat_dom,IPR001452:SH3_domain,IPR008271:Ser/Thr_kinase_AS,IPR011009:Kinase-like_dom_sf,IPR016231:MLK1-4,IPR017441:Protein_kinase_ATP_BS,IPR020635:Tyr_kinase_cat_dom,IPR035779:MLK1-3_SH3,IPR036028:SH3-like_dom_sf,	hsa04010:MAPK signaling pathway,hsa04932:Non-alcoholic fatty liver disease,		PIRSF000556:MAPKKK9_11,	SM00219:TyrKc,SM00220:S_TKc,SM00326:SH3,		KW-0206~Cytoskeleton,KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0677~Repeat,KW-0728~SH3 domain,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,DOMAIN:Protein kinase,DOMAIN:SH3,MUTAGEN:E->A: Greatly reduced autophosphorylation activity.,MUTAGEN:K->A: Greatly reduced autophosphorylation activity.,MUTAGEN:K->R: Loss of kinase activity. Prevents activation of SAPK and MAPK14.,MUTAGEN:S->A: Reduced autophosphorylation activity. Reduced activation of SAPK and MAPK14.,MUTAGEN:S->E: No effect on SAPK activation.,MUTAGEN:T->A: No effect on autophosphorylation activity or activation of SAPK and MAPK14.,MUTAGEN:T->A: Severely reduced autophosphorylation activity. Prevents phosphorylation of SAPK and MAPK14.,MUTAGEN:T->E: No effect on SAPK activation.,REGION:Disordered,REGION:Leucine-zipper 1,REGION:Leucine-zipper 2,
MAP3K2	mitogen-activated protein kinase kinase kinase 2(MAP3K2)	Homo sapiens	100.MAPK_signaling_cascades,	h_mapkPathway:MAPKinase Signaling Pathway,	GO:0000165~MAPK cascade,GO:0016310~phosphorylation,GO:0035556~intracellular signal transduction,GO:0071260~cellular response to mechanical stimulus,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004709~MAP kinase kinase kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0019901~protein kinase binding,GO:0046872~metal ion binding,	IPR000270:PB1_dom,IPR000719:Prot_kinase_dom,IPR011009:Kinase-like_dom_sf,IPR017441:Protein_kinase_ATP_BS,IPR034879:PB1_MEKK2/3,	hsa04010:MAPK signaling pathway,hsa04540:Gap junction,hsa04912:GnRH signaling pathway,			SM00220:S_TKc,SM00666:PB1,		KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	ACT_SITE:Proton acceptor,COMPBIAS:Polar residues,DOMAIN:PB1,DOMAIN:Protein kinase,REGION:Disordered,
MAP3K8	mitogen-activated protein kinase kinase kinase 8(MAP3K8)	Homo sapiens		h_mapkPathway:MAPKinase Signaling Pathway,	GO:0000165~MAPK cascade,GO:0006468~protein phosphorylation,GO:0007049~cell cycle,GO:0016310~phosphorylation,GO:0031295~T cell costimulation,	GO:0005829~cytosol,	GO:0000287~magnesium ion binding,GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004709~MAP kinase kinase kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,	IPR000719:Prot_kinase_dom,IPR008271:Ser/Thr_kinase_AS,IPR011009:Kinase-like_dom_sf,IPR017424:MAPKKK8,	hsa04010:MAPK signaling pathway,hsa04620:Toll-like receptor signaling pathway,hsa04660:T cell receptor signaling pathway,hsa04668:TNF signaling pathway,	211980~Lung cancer, somatic,	PIRSF038171:MAPKKK8,	SM00220:S_TKc,	KW-0131~Cell cycle,KW-0391~Immunity,	KW-0963~Cytoplasm,	KW-0656~Proto-oncogene,		KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,DOMAIN:Protein kinase,MUTAGEN:T->A: Loss of MEK phosphorylation activity and almost abolished autophosphorylation activity. Loss of IL1-stimulated MEK phosphorylation activity but not of IL1-stimulated autophosphorylation activity. No effect on KSR2 binding.,MUTAGEN:T->D: Impaired MEK phosphorylation and autophosphorylation activities. No effect on KSR2 binding.,MUTAGEN:T->E: Loss of MEK phosphorylation activity and almost abolished autophosphorylation activity. No effect on KSR2 binding.,
MSN	moesin(MSN)	Homo sapiens			GO:0001771~immunological synapse formation,GO:0007010~cytoskeleton organization,GO:0007159~leukocyte cell-cell adhesion,GO:0008360~regulation of cell shape,GO:0008361~regulation of cell size,GO:0010628~positive regulation of gene expression,GO:0022612~gland morphogenesis,GO:0022614~membrane to membrane docking,GO:0042098~T cell proliferation,GO:0045198~establishment of epithelial cell apical/basal polarity,GO:0045732~positive regulation of protein catabolic process,GO:0050900~leukocyte migration,GO:0061028~establishment of endothelial barrier,GO:0070489~T cell aggregation,GO:0071394~cellular response to testosterone stimulus,GO:0071803~positive regulation of podosome assembly,GO:0072678~T cell migration,GO:1902115~regulation of organelle assembly,GO:1902966~positive regulation of protein localization to early endosome,GO:2000401~regulation of lymphocyte migration,GO:2000643~positive regulation of early endosome to late endosome transport,	GO:0001931~uropod,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0005902~microvillus,GO:0005912~adherens junction,GO:0005925~focal adhesion,GO:0009986~cell surface,GO:0016323~basolateral plasma membrane,GO:0016324~apical plasma membrane,GO:0030175~filopodium,GO:0031143~pseudopodium,GO:0031528~microvillus membrane,GO:0031982~vesicle,GO:0042995~cell projection,GO:0045177~apical part of cell,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,GO:0071944~cell periphery,GO:0072562~blood microparticle,	GO:0003725~double-stranded RNA binding,GO:0003779~actin binding,GO:0005102~receptor binding,GO:0005200~structural constituent of cytoskeleton,GO:0005515~protein binding,GO:0019899~enzyme binding,GO:0019901~protein kinase binding,GO:0050839~cell adhesion molecule binding,	IPR000299:FERM_domain,IPR000798:Ez/rad/moesin-like,IPR008954:Moesin_tail_sf,IPR011174:ERM,IPR011259:ERM_C_dom,IPR011993:PH-like_dom_sf,IPR014352:FERM/acyl-CoA-bd_prot_sf,IPR018979:FERM_N,IPR018980:FERM_PH-like_C,IPR019747:FERM_CS,IPR019748:FERM_central,IPR019749:Band_41_domain,IPR029071:Ubiquitin-like_domsf,IPR035963:FERM_2,IPR041789:ERM_FERM_C,IPR046810:ERM_helical,	hsa04530:Tight junction,hsa04670:Leukocyte transendothelial migration,hsa04810:Regulation of actin cytoskeleton,hsa05162:Measles,hsa05205:Proteoglycans in cancer,	300988~Immunodeficiency 50,	PIRSF002305:ERM,	SM00295:B41,SM01196:FERM_C,	KW-0945~Host-virus interaction,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-1003~Cell membrane,	KW-0225~Disease variant,				KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0702~S-nitrosylation,	COMPBIAS:Basic and acidic residues,DOMAIN:FERM,MOTIF:[IL]-x-C-x-x-[DE] motif,MUTAGEN:E->M: Inhibits S-nitrosylation of Cys-117; when associated with M-115.,MUTAGEN:I->M: Inhibits S-nitrosylation of Cys-117; when associated with M-120.,MUTAGEN:T->A: Abolishes phosphorylation by STK10.,MUTAGEN:T->D: Completely abolishes the interaction between N- and C-terminal domains.,MUTAGEN:T->D: Phosphomimetic mutant.,MUTAGEN:Y->R: Impairs phosphorylation by STK10.,REGION:Disordered,
MORF4L1	mortality factor 4 like 1(MORF4L1)	Homo sapiens			GO:0000724~double-strand break repair via homologous recombination,GO:0006325~chromatin organization,GO:0006355~regulation of transcription, DNA-templated,GO:0042981~regulation of apoptotic process,GO:0045893~positive regulation of transcription, DNA-templated,GO:0048144~fibroblast proliferation,GO:0051726~regulation of cell cycle,GO:1905168~positive regulation of double-strand break repair via homologous recombination,GO:2000779~regulation of double-strand break repair,	GO:0000786~nucleosome,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0016580~Sin3 complex,GO:0016607~nuclear speck,GO:0035267~NuA4 histone acetyltransferase complex,GO:0070822~Sin3-type complex,	GO:0003682~chromatin binding,GO:0005515~protein binding,	IPR000953:Chromo/chromo_shadow_dom,IPR008676:MRG,IPR016197:Chromo-like_dom_sf,IPR025995:Tudor-knot,IPR026541:MRG_dom,IPR038217:MRG_C_sf,	hsa03082:ATP-dependent chromatin remodeling,		PIRSF038133:HAT_Nua4_EAF3/MRG15,	SM00298:CHROMO,	KW-0227~DNA damage,KW-0233~DNA recombination,KW-0234~DNA repair,KW-0341~Growth regulation,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0156~Chromatin regulator,	KW-0007~Acetylation,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Chromo,DOMAIN:MRG,DOMAIN:Tudor-knot,MOTIF:Nuclear localization signal,MUTAGEN:E->R: No effect on MRFAP1 binding.,MUTAGEN:N->C: Reduces binding to MRFAP1.,MUTAGEN:V->E: Abolishes binding to MRFAP1.,MUTAGEN:Y->A: No effect on MRFAP1 binding.,REGION:Disordered,REGION:Interaction with KAT8,REGION:Interaction with RB1-1,REGION:Interaction with RB1-2,REGION:Sufficient for interaction with PHF12,REGION:Sufficient for interaction with SIN3A,
MORF4L2	mortality factor 4 like 2(MORF4L2)	Homo sapiens			GO:0006281~DNA repair,GO:0006325~chromatin organization,GO:0006355~regulation of transcription, DNA-templated,GO:0042981~regulation of apoptotic process,GO:0045893~positive regulation of transcription, DNA-templated,GO:0051726~regulation of cell cycle,GO:1905168~positive regulation of double-strand break repair via homologous recombination,GO:2000779~regulation of double-strand break repair,	GO:0000786~nucleosome,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005886~plasma membrane,GO:0035267~NuA4 histone acetyltransferase complex,	GO:0005515~protein binding,	IPR008676:MRG,IPR026541:MRG_dom,IPR038217:MRG_C_sf,	hsa03082:ATP-dependent chromatin remodeling,				KW-0227~DNA damage,KW-0234~DNA repair,KW-0341~Growth regulation,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0156~Chromatin regulator,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:MRG,MUTAGEN:L->A: Abrogates both transcriptional activation and repression by MORF4L2.,MUTAGEN:Missing: Abrogates both transcriptional activation and repression by MORF4L2.,REGION:Disordered,
MSI2	musashi RNA binding protein 2(MSI2)	Homo sapiens			GO:0006417~regulation of translation,GO:0007417~central nervous system development,GO:0048864~stem cell development,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005844~polysome,GO:0043231~intracellular membrane-bounded organelle,	GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0005515~protein binding,GO:0008266~poly(U) RNA binding,GO:0042802~identical protein binding,	IPR000504:RRM_dom,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR034126:MSI_RRM2,IPR035979:RBD_domain_sf,	hsa03015:mRNA surveillance pathway,			SM00360:RRM,		KW-0963~Cytoplasm,		KW-0677~Repeat,		KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:RRM,DOMAIN:RRM 1,DOMAIN:RRM 2,REGION:Disordered,SITE:Breakpoint for translocation to form MSI2/HOXA9 fusion protein,
MBNL1	muscleblind like splicing regulator 1(MBNL1)	Homo sapiens			GO:0001701~in utero embryonic development,GO:0006397~mRNA processing,GO:0007399~nervous system development,GO:0008380~RNA splicing,GO:0030326~embryonic limb morphogenesis,GO:0043484~regulation of RNA splicing,GO:0045445~myoblast differentiation,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0010494~cytoplasmic stress granule,	GO:0001069~regulatory region RNA binding,GO:0003723~RNA binding,GO:0003725~double-stranded RNA binding,GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR000571:Znf_CCCH,				SM00356:ZnF_C3H1,	KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-1212~Corneal dystrophy,	KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0694~RNA-binding,	KW-0597~Phosphoprotein,	DOMAIN:C3H1-type,ZN_FING:C3H1-type,ZN_FING:C3H1-type 1,ZN_FING:C3H1-type 2,ZN_FING:C3H1-type 3,ZN_FING:C3H1-type 4,
MBP	myelin basic protein(MBP)	Homo sapiens			GO:0000165~MAPK cascade,GO:0006955~immune response,GO:0007268~chemical synaptic transmission,GO:0007417~central nervous system development,GO:0007605~sensory perception of sound,GO:0008366~axon ensheathment,GO:0009636~response to toxic substance,GO:0021762~substantia nigra development,GO:0032755~positive regulation of interleukin-6 production,GO:0034115~negative regulation of heterotypic cell-cell adhesion,GO:0035633~maintenance of permeability of blood-brain barrier,GO:0042552~myelination,GO:0061024~membrane organization,GO:1904685~positive regulation of metalloendopeptidase activity,GO:2000343~positive regulation of chemokine (C-X-C motif) ligand 2 production,	GO:0005634~nucleus,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0032991~macromolecular complex,GO:0033269~internode region of axon,GO:0043025~neuronal cell body,GO:0043209~myelin sheath,GO:0043218~compact myelin,GO:0045202~synapse,GO:0071944~cell periphery,	GO:0002020~protease binding,GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0008289~lipid binding,GO:0019911~structural constituent of myelin sheath,	IPR000548:Myelin_BP,						KW-0472~Membrane,KW-0539~Nucleus,KW-1003~Cell membrane,	KW-0069~Autoimmune encephalomyelitis,				KW-0007~Acetylation,KW-0164~Citrullination,KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,REGION:Induces experimental autoimmune encephalomyelitis (EAE) 1,REGION:Induces experimental autoimmune encephalomyelitis (EAE) 2,SITE:Cleavage; by CTSG,
MYADM	myeloid associated differentiation marker(MYADM)	Homo sapiens			GO:0001933~negative regulation of protein phosphorylation,GO:0010629~negative regulation of gene expression,GO:0030335~positive regulation of cell migration,GO:0030837~negative regulation of actin filament polymerization,GO:0031579~membrane raft organization,GO:0034115~negative regulation of heterotypic cell-cell adhesion,GO:0044860~protein localization to plasma membrane raft,GO:0061028~establishment of endothelial barrier,GO:0090038~negative regulation of protein kinase C signaling,GO:1900026~positive regulation of substrate adhesion-dependent cell spreading,	GO:0001726~ruffle,GO:0005886~plasma membrane,GO:0005911~cell-cell junction,GO:0016020~membrane,GO:0030864~cortical actin cytoskeleton,GO:0045121~membrane raft,	GO:0005515~protein binding,	IPR008253:Marvel,IPR047123:MYADM-like,						KW-0472~Membrane,		KW-0677~Repeat,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,	DOMAIN:MARVEL,DOMAIN:MARVEL 1,DOMAIN:MARVEL 2,REGION:Disordered,TRANSMEM:Helical,
MLF2	myeloid leukemia factor 2(MLF2)	Homo sapiens			GO:0006355~regulation of transcription, DNA-templated,GO:0009887~animal organ morphogenesis,GO:0009888~tissue development,GO:0016322~neuron remodeling,GO:0016477~cell migration,GO:0034446~substrate adhesion-dependent cell spreading,GO:0060668~regulation of branching involved in salivary gland morphogenesis by extracellular matrix-epithelial cell signaling,GO:0070831~basement membrane assembly,	GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0043256~laminin complex,	GO:0005515~protein binding,GO:0043237~laminin-1 binding,	IPR001134:Netrin_domain,IPR002049:LE_dom,IPR008211:Laminin_N,IPR008993:TIMP-like_OB-fold,IPR018933:Netrin_module_non-TIMP,IPR019376:Myeloid_leukemia_factor,IPR035811:Netrin-4_NTR,				SM00136:LamNT,SM00180:EGF_Lam,SM00643:C345C,		KW-0084~Basement membrane,KW-0272~Extracellular matrix,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0964~Secreted,		KW-0424~Laminin EGF-like domain,KW-0677~Repeat,KW-0732~Signal,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:Laminin EGF-like,DOMAIN:Laminin EGF-like 1,DOMAIN:Laminin EGF-like 2,DOMAIN:Laminin EGF-like 3,DOMAIN:Laminin N-terminal,DOMAIN:NTR,REGION:Disordered,
MEF2D	myocyte enhancer factor 2D(MEF2D)	Homo sapiens		h_at1rPathway:Angiotensin II mediated activation of JNK Pathway via Pyk2 dependent signaling,h_erk5Pathway:Role of Erk5 in Neuronal Survival,h_hdacPathway:Control of skeletal myogenesis by HDAC & calcium/calmodulin-dependent kinase (CaMK),h_mapkPathway:MAPKinase Signaling Pathway,h_mef2dPathway:Role of MEF2D in T-cell Apoptosis,h_mitrPathway:Signal Dependent Regulation of Myogenesis by Corepressor MITR,h_p38mapkPathway:p38 MAPK Signaling Pathway ,h_pgc1aPathway:Regulation of PGC-1a,	GO:0001649~osteoblast differentiation,GO:0001958~endochondral ossification,GO:0002062~chondrocyte differentiation,GO:0006915~apoptotic process,GO:0007399~nervous system development,GO:0007512~adult heart development,GO:0007517~muscle organ development,GO:0030154~cell differentiation,GO:0035914~skeletal muscle cell differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048513~animal organ development,GO:1904707~positive regulation of vascular smooth muscle cell proliferation,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0043231~intracellular membrane-bounded organelle,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0042803~protein homodimerization activity,GO:0042826~histone deacetylase binding,GO:0046982~protein heterodimerization activity,GO:0046983~protein dimerization activity,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR002100:TF_MADSbox,IPR022102:HJURP_C,IPR033896:MADS_MEF2-like,IPR036879:TF_MADSbox_sf,	hsa04022:cGMP-PKG signaling pathway,hsa04371:Apelin signaling pathway,hsa04928:Parathyroid hormone synthesis, secretion and action,			SM00432:MADS,	KW-0053~Apoptosis,KW-0221~Differentiation,KW-0524~Neurogenesis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0010~Activator,KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO); alternate,DNA_BIND:Mef2-type,DOMAIN:MADS-box,MUTAGEN:D->A: Abolishes cleavage by caspase 7.,MUTAGEN:D->N: Abolishes transcriptional activity; when associated with Q-287 and N-288.,MUTAGEN:D->N: Abolishes transcriptional activity; when associated with Q-287 and N-291.,MUTAGEN:E->Q: Abolishes transcriptional activity; when associated with N-288 and N-291.,MUTAGEN:H->A: Same transcriptional activity as for isoforms with beta domain.,MUTAGEN:I->A: Abolishes K-439 sumoylation.,MUTAGEN:K->R: Abolishes sumoylation and acetylation.,MUTAGEN:S->A: Abolishes K-439 sumoylation. Reduced neurotoxin-induced apoptosis of neuronal cells. More resistant to degradation.,MUTAGEN:S->A: Abolishes MAPK7- and EGF-mediated transcriptional activation.,MUTAGEN:S->A: No effect on MAPK7- or EGF-mediated transcriptional activity.,MUTAGEN:S->E: No effect on K-439 sumoylation.,MUTAGEN:T->A: Same transcriptional activity as for isoforms with beta domain.,REGION:Beta domain,REGION:Disordered,SITE:Cleavage,
MYH9	myosin heavy chain 9(MYH9)	Homo sapiens			GO:0000212~meiotic spindle organization,GO:0001525~angiogenesis,GO:0001701~in utero embryonic development,GO:0001768~establishment of T cell polarity,GO:0001778~plasma membrane repair,GO:0006509~membrane protein ectodomain proteolysis,GO:0006911~phagocytosis, engulfment,GO:0007229~integrin-mediated signaling pathway,GO:0007520~myoblast fusion,GO:0008360~regulation of cell shape,GO:0015031~protein transport,GO:0030036~actin cytoskeleton organization,GO:0030048~actin filament-based movement,GO:0030220~platelet formation,GO:0030224~monocyte differentiation,GO:0031032~actomyosin structure organization,GO:0032418~lysosome localization,GO:0032506~cytokinetic process,GO:0032796~uropod organization,GO:0035987~endodermal cell differentiation,GO:0043534~blood vessel endothelial cell migration,GO:0045055~regulated exocytosis,GO:0050900~leukocyte migration,GO:0051295~establishment of meiotic spindle localization,GO:0060471~cortical granule exocytosis,GO:0070527~platelet aggregation,GO:1903919~negative regulation of actin filament severing,GO:1903923~positive regulation of protein processing in phagocytic vesicle,GO:1905684~regulation of plasma membrane repair,	GO:0001725~stress fiber,GO:0001726~ruffle,GO:0001772~immunological synapse,GO:0001931~uropod,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005819~spindle,GO:0005826~actomyosin contractile ring,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005903~brush border,GO:0005912~adherens junction,GO:0005925~focal adhesion,GO:0008180~COP9 signalosome,GO:0009898~cytoplasmic side of plasma membrane,GO:0015629~actin cytoskeleton,GO:0016020~membrane,GO:0016459~myosin complex,GO:0016460~myosin II complex,GO:0016604~nuclear body,GO:0031252~cell leading edge,GO:0031594~neuromuscular junction,GO:0032154~cleavage furrow,GO:0032982~myosin filament,GO:0032991~macromolecular complex,GO:0042641~actomyosin,GO:0060473~cortical granule,GO:0070062~extracellular exosome,GO:0097513~myosin II filament,	GO:0000146~microfilament motor activity,GO:0003723~RNA binding,GO:0003774~motor activity,GO:0003779~actin binding,GO:0005178~integrin binding,GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0005524~ATP binding,GO:0019904~protein domain specific binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0043495~protein anchor,GO:0043531~ADP binding,GO:0045296~cadherin binding,GO:0051015~actin filament binding,	IPR000048:IQ_motif_EF-hand-BS,IPR001609:Myosin_head_motor_dom,IPR002928:Myosin_tail,IPR004009:Myosin_N,IPR008989:Myosin_S1_N,IPR027417:P-loop_NTPase,IPR036305:RGS_sf,IPR036961:Kinesin_motor_dom_sf,	hsa04270:Vascular smooth muscle contraction,hsa04530:Tight junction,hsa04810:Regulation of actin cytoskeleton,hsa04814:Motor proteins,hsa05130:Pathogenic Escherichia coli infection,	155100~Macrothrombocytopenia and granulocyte inclusions with or without nephritis or sensorineural hearing loss,603622~Deafness, autosomal dominant 17,		SM00015:IQ,SM00242:MYSc,	KW-0130~Cell adhesion,KW-0133~Cell shape,	KW-0206~Cytoskeleton,KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,	KW-0023~Alport syndrome,KW-0209~Deafness,KW-0225~Disease variant,KW-0898~Cataract,KW-1010~Non-syndromic deafness,	KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0009~Actin-binding,KW-0112~Calmodulin-binding,KW-0505~Motor protein,KW-0518~Myosin,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Basic and acidic residues,DOMAIN:IQ,DOMAIN:Myosin N-terminal SH3-like,DOMAIN:Myosin motor,DOMAIN:Myosin tail,REGION:Actin-binding,REGION:Disordered,REGION:Mediates interaction with LIMCH1,
MYL12A	myosin light chain 12A(MYL12A)	Homo sapiens			GO:0008360~regulation of cell shape,GO:0070527~platelet aggregation,GO:0072659~protein localization to plasma membrane,	GO:0001725~stress fiber,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016460~myosin II complex,GO:0030018~Z disc,GO:0070062~extracellular exosome,	GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0035254~glutamate receptor binding,GO:0051020~GTPase binding,	IPR002048:EF_hand_dom,IPR011992:EF-hand-dom_pair,IPR015070:EF_hand_DJBP,IPR018247:EF_Hand_1_Ca_BS,	hsa04360:Axon guidance,hsa04510:Focal adhesion,hsa04520:Adherens junction,hsa04530:Tight junction,hsa04611:Platelet activation,hsa04670:Leukocyte transendothelial migration,hsa04810:Regulation of actin cytoskeleton,hsa04814:Motor proteins,hsa05131:Shigellosis,hsa05132:Salmonella infection,			SM00054:EFh,				KW-0677~Repeat,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0505~Motor protein,KW-0514~Muscle protein,KW-0518~Myosin,	KW-0597~Phosphoprotein,	DOMAIN:EF-hand,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,DOMAIN:EF-hand 3,REGION:Disordered,
MYL6	myosin light chain 6(MYL6)	Homo sapiens			GO:0006936~muscle contraction,GO:0007519~skeletal muscle tissue development,GO:0030049~muscle filament sliding,	GO:0005829~cytosol,GO:0005903~brush border,GO:0016020~membrane,GO:0016459~myosin complex,GO:0016460~myosin II complex,GO:0016461~unconventional myosin complex,GO:0031982~vesicle,GO:0070062~extracellular exosome,	GO:0000146~microfilament motor activity,GO:0003774~motor activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0008307~structural constituent of muscle,	IPR002048:EF_hand_dom,IPR011992:EF-hand-dom_pair,	hsa04270:Vascular smooth muscle contraction,hsa04530:Tight junction,hsa04814:Motor proteins,hsa04921:Oxytocin signaling pathway,			SM00054:EFh,				KW-0677~Repeat,		KW-0505~Motor protein,KW-0514~Muscle protein,KW-0518~Myosin,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:EF-hand,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,DOMAIN:EF-hand 3,REGION:Disordered,
MTPN	myotrophin(MTPN)	Homo sapiens			GO:0006417~regulation of translation,GO:0006584~catecholamine metabolic process,GO:0008361~regulation of cell size,GO:0010557~positive regulation of macromolecule biosynthetic process,GO:0010613~positive regulation of cardiac muscle hypertrophy,GO:0016202~regulation of striated muscle tissue development,GO:0021707~cerebellar granule cell differentiation,GO:0030182~neuron differentiation,GO:0030307~positive regulation of cell growth,GO:0043403~skeletal muscle tissue regeneration,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0051146~striated muscle cell differentiation,GO:0051247~positive regulation of protein metabolic process,GO:0071260~cellular response to mechanical stimulus,GO:2000812~regulation of barbed-end actin filament capping,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0008290~F-actin capping protein complex,GO:0030424~axon,GO:0048471~perinuclear region of cytoplasm,	GO:0043565~sequence-specific DNA binding,	IPR002110:Ankyrin_rpt,IPR036770:Ankyrin_rpt-contain_sf,				SM00248:ANK,		KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0040~ANK repeat,KW-0677~Repeat,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	REPEAT:ANK,REPEAT:ANK 1,REPEAT:ANK 2,REPEAT:ANK 3,
MTMR14	myotubularin related protein 14(MTMR14)	Homo sapiens			GO:0006661~phosphatidylinositol biosynthetic process,GO:0016236~macroautophagy,GO:0016311~dephosphorylation,	GO:0001726~ruffle,GO:0005829~cytosol,GO:0048471~perinuclear region of cytoplasm,	GO:0004438~phosphatidylinositol-3-phosphatase activity,GO:0004722~protein serine/threonine phosphatase activity,GO:0005515~protein binding,GO:0052629~phosphatidylinositol-3,5-bisphosphate 3-phosphatase activity,	IPR016130:Tyr_Pase_AS,IPR029021:Prot-tyrosine_phosphatase-like,IPR039802:MTMR14,IPR039803:MTMR14_PH-GRAM,	hsa00562:Inositol phosphate metabolism,hsa01100:Metabolic pathways,hsa04070:Phosphatidylinositol signaling system,hsa04140:Autophagy - animal,	160150~Centronuclear myopathy, autosomal, modifier of,				KW-0963~Cytoplasm,	KW-0225~Disease variant,	KW-0732~Signal,		KW-0378~Hydrolase,	KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0488~Methylation,KW-0597~Phosphoprotein,	ACT_SITE:Phosphocysteine intermediate,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,MUTAGEN:C->S: Drastically reduced enzymatic activity.,REGION:Disordered,
MTMR6	myotubularin related protein 6(MTMR6)	Homo sapiens			GO:0006470~protein dephosphorylation,GO:0006661~phosphatidylinositol biosynthetic process,GO:0006897~endocytosis,GO:0016311~dephosphorylation,GO:0046488~phosphatidylinositol metabolic process,GO:0046856~phosphatidylinositol dephosphorylation,	GO:0005635~nuclear envelope,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005793~endoplasmic reticulum-Golgi intermediate compartment,GO:0005829~cytosol,GO:0032587~ruffle membrane,GO:0048471~perinuclear region of cytoplasm,	GO:0004438~phosphatidylinositol-3-phosphatase activity,GO:0004722~protein serine/threonine phosphatase activity,GO:0004725~protein tyrosine phosphatase activity,GO:0005515~protein binding,GO:0052629~phosphatidylinositol-3,5-bisphosphate 3-phosphatase activity,	IPR003595:Tyr_Pase_cat,IPR010569:Myotubularin-like_Pase_dom,IPR011993:PH-like_dom_sf,IPR016130:Tyr_Pase_AS,IPR029021:Prot-tyrosine_phosphatase-like,IPR030564:Myotubularin_fam,IPR035998:MTMR6_PH-GRAM,	hsa00562:Inositol phosphate metabolism,hsa01100:Metabolic pathways,hsa04070:Phosphatidylinositol signaling system,			SM00404:PTPc_motif,	KW-0254~Endocytosis,KW-0443~Lipid metabolism,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-1003~Cell membrane,		KW-0175~Coiled coil,		KW-0378~Hydrolase,	KW-0597~Phosphoprotein,	ACT_SITE:Phosphocysteine intermediate,DOMAIN:GRAM,DOMAIN:Myotubularin phosphatase,REGION:Interaction with RAB1B,
NRDC	nardilysin convertase(NRDC)	Homo sapiens			GO:0006508~proteolysis,GO:0031643~positive regulation of myelination,GO:0050772~positive regulation of axonogenesis,GO:0051044~positive regulation of membrane protein ectodomain proteolysis,GO:0052548~regulation of endopeptidase activity,	GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0009986~cell surface,GO:0030425~dendrite,	GO:0004222~metalloendopeptidase activity,GO:0005515~protein binding,GO:0008237~metallopeptidase activity,GO:0046872~metal ion binding,GO:0048408~epidermal growth factor binding,	IPR001431:Pept_M16_Zn_BS,IPR007863:Peptidase_M16_C,IPR011249:Metalloenz_LuxS/M16,IPR011765:Pept_M16_N,IPR032632:Peptidase_M16_M,						KW-0496~Mitochondrion,KW-0966~Cell projection,		KW-0732~Signal,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0378~Hydrolase,KW-0482~Metalloprotease,KW-0645~Protease,	KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Peptidase M16 C-terminal,DOMAIN:Peptidase M16 N-terminal,DOMAIN:Peptidase M16 middle/third,REGION:Disordered,
NACA	nascent polypeptide associated complex subunit alpha(NACA)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0003231~cardiac ventricle development,GO:0006412~translation,GO:0006612~protein targeting to membrane,GO:0010664~negative regulation of striated muscle cell apoptotic process,GO:0015031~protein transport,GO:0042060~wound healing,GO:0043403~skeletal muscle tissue regeneration,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048633~positive regulation of skeletal muscle tissue growth,GO:0048742~regulation of skeletal muscle fiber development,GO:0061384~heart trabecula morphogenesis,GO:1905551~negative regulation of protein localization to endoplasmic reticulum,GO:2000138~positive regulation of cell proliferation involved in heart morphogenesis,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005854~nascent polypeptide-associated complex,GO:0070062~extracellular exosome,	GO:0003677~DNA binding,GO:0003713~transcription coactivator activity,GO:0051082~unfolded protein binding,	IPR002715:Nas_poly-pep-assoc_cplx_dom,IPR016641:EGD2/NACA,IPR038187:NAC_A/B_dom_sf,IPR044034:NAC-like_UBA,	hsa04928:Parathyroid hormone synthesis, secretion and action,		PIRSF015901:NAC_alpha,	SM01407:NAC,	KW-0653~Protein transport,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0813~Transport,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0020~Allergen,	KW-0677~Repeat,		KW-0010~Activator,KW-0143~Chaperone,KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:NAC-A/B,DOMAIN:UBA,MOTIF:PXLXP,REGION:Disordered,REGION:RNA/DNA-binding,REGION:Required for DNA-binding,
NKG7	natural killer cell granule protein 7(NKG7)	Homo sapiens			GO:0002420~natural killer cell mediated cytotoxicity directed against tumor cell target,GO:0006954~inflammatory response,GO:0031640~killing of cells of other organism,GO:0035710~CD4-positive, alpha-beta T cell activation,GO:0042267~natural killer cell mediated cytotoxicity,GO:0042832~defense response to protozoan,GO:0043320~natural killer cell degranulation,GO:0050729~positive regulation of inflammatory response,	GO:0005886~plasma membrane,GO:0016020~membrane,GO:0044194~cytolytic granule,GO:0101004~cytolytic granule membrane,	GO:0005515~protein binding,	IPR004031:PMP22/EMP/MP20/Claudin,IPR004032:PMP22_EMP_MP20,					KW-0204~Cytolysis,KW-0395~Inflammatory response,	KW-0458~Lysosome,KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				REGION:Disordered,TRANSMEM:Helical,
NELFA	negative elongation factor complex member A(NELFA)	Homo sapiens			GO:0031401~positive regulation of protein modification process,GO:0034244~negative regulation of transcription elongation from RNA polymerase II promoter,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0016604~nuclear body,GO:0032021~NELF complex,	GO:0003682~chromatin binding,GO:0005515~protein binding,GO:0060090~binding, bridging,	IPR037517:HDAG_dom,	hsa03250:Viral life cycle - HIV-1,				KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0678~Repressor,	KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:HDAg,REGION:Disordered,REGION:NELF-C/D-binding,REGION:RNAPII-binding,
NELFCD	negative elongation factor complex member C/D(NELFCD)	Homo sapiens			GO:0034244~negative regulation of transcription elongation from RNA polymerase II promoter,GO:0045892~negative regulation of transcription, DNA-templated,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0016020~membrane,GO:0032021~NELF complex,	GO:0003723~RNA binding,GO:0005515~protein binding,	IPR006942:TH1,	hsa03250:Viral life cycle - HIV-1,				KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0678~Repressor,KW-0694~RNA-binding,		COMPBIAS:Acidic residues,MUTAGEN:K->M: Reduces RNA binding; when associated with Q-291, M-315, M-371, M-372, M-374, M-384, Q-419 and Q-506.,MUTAGEN:K->M: Reduces RNA binding; when associated with Q-291, M-315, M-371, M-372, M-374, M-388, Q-419 and Q-506.,MUTAGEN:K->M: Reduces RNA binding; when associated with Q-291, M-315, M-371, M-372, M-384, M-388, Q-419 and Q-506.,MUTAGEN:K->M: Reduces RNA binding; when associated with Q-291, M-315, M-371, M-374, M-384, M-388, Q-419 and Q-506.,MUTAGEN:K->M: Reduces RNA binding; when associated with Q-291, M-315, M-372, M-374, M-384, M-388, Q-419 and Q-506.,MUTAGEN:K->M: Reduces RNA binding; when associated with Q-291, M-371, M-372, M-374, M-384, M-388, Q-419 and Q-506.,MUTAGEN:R->Q: Reduces RNA binding; when associated with M-315, M-371, M-372, M-374, M-384, M-388, Q-419 and Q-506.,MUTAGEN:R->Q: Reduces RNA binding; when associated with Q-291, M-315, M-371, M-372, M-374, M-384, M-388 and Q-419.,MUTAGEN:R->Q: Reduces RNA binding; when associated with Q-291, M-315, M-371, M-372, M-374, M-384, M-388 and Q-506.,REGION:Disordered,
NELFE	negative elongation factor complex member E(NELFE)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006355~regulation of transcription, DNA-templated,GO:0031401~positive regulation of protein modification process,GO:0034244~negative regulation of transcription elongation from RNA polymerase II promoter,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051179~localization,GO:0070374~positive regulation of ERK1 and ERK2 cascade,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005694~chromosome,GO:0005886~plasma membrane,GO:0016604~nuclear body,GO:0032021~NELF complex,	GO:0003682~chromatin binding,GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0005515~protein binding,	IPR000504:RRM_dom,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR033102:NELFE,IPR034637:NELFE_RRM,IPR035979:RBD_domain_sf,	hsa03250:Viral life cycle - HIV-1,			SM00360:RRM,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0158~Chromosome,KW-0539~Nucleus,		KW-0175~Coiled coil,KW-0677~Repeat,		KW-0678~Repressor,KW-0694~RNA-binding,	KW-0013~ADP-ribosylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:RRM,MUTAGEN:E->Q: Abolished poly-ADP-ribosylation by PARP1; when associated with Q-122; Q-151 and Q-172.,MUTAGEN:E->Q: Abolished poly-ADP-ribosylation by PARP1; when associated with Q-122; Q-151 and Q-374.,MUTAGEN:E->Q: Abolished poly-ADP-ribosylation by PARP1; when associated with Q-122; Q-172 and Q-374.,MUTAGEN:E->Q: Abolished poly-ADP-ribosylation by PARP1; when associated with Q-151; Q-172 and Q-374.,MUTAGEN:RNCAF->EQMAT: Abolishes interaction with RNA but not the interaction with other proteins of the NELF complex.,MUTAGEN:SPPRSRSRDRS->APPRARARDRA: Decreased phosphorylation.,MUTAGEN:SPPRSRSRDRS->EPPRERERDRE: Mimics phosphorylation, promoting its release from chromatin.,REGION:30 X 2 AA approximate tandem repeats of R-[DSNE],REGION:Disordered,REPEAT:1,REPEAT:10,REPEAT:11,REPEAT:12,REPEAT:13,REPEAT:14,REPEAT:15,REPEAT:16,REPEAT:17,REPEAT:18,REPEAT:19,REPEAT:2,REPEAT:20,REPEAT:21,REPEAT:22,REPEAT:23,REPEAT:24,REPEAT:25,REPEAT:26,REPEAT:27,REPEAT:28,REPEAT:29,REPEAT:3,REPEAT:30,REPEAT:4,REPEAT:5; approximate,REPEAT:6,REPEAT:7,REPEAT:8,REPEAT:9,
NEU1	neuraminidase 1(NEU1)	Homo sapiens			GO:0006689~ganglioside catabolic process,GO:0009313~oligosaccharide catabolic process,GO:0016042~lipid catabolic process,	GO:0005576~extracellular region,GO:0005737~cytoplasm,GO:0005764~lysosome,GO:0005765~lysosomal membrane,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0030054~cell junction,GO:0035580~specific granule lumen,GO:0043202~lysosomal lumen,GO:0043231~intracellular membrane-bounded organelle,GO:0070062~extracellular exosome,	GO:0004308~exo-alpha-sialidase activity,GO:0005515~protein binding,GO:0016997~alpha-sialidase activity,GO:0052794~exo-alpha-(2->3)-sialidase activity,GO:0052795~exo-alpha-(2->6)-sialidase activity,GO:0052796~exo-alpha-(2->8)-sialidase activity,	IPR011040:Sialidase,IPR026856:Sialidase_fam,IPR036278:Sialidase_sf,	hsa00511:Other glycan degradation,hsa00600:Sphingolipid metabolism,hsa01100:Metabolic pathways,hsa04142:Lysosome,	256550~Sialidosis, type I,256550~Sialidosis, type II,			KW-0119~Carbohydrate metabolism,KW-0442~Lipid degradation,KW-0443~Lipid metabolism,	KW-0458~Lysosome,KW-0472~Membrane,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0326~Glycosidase,KW-0378~Hydrolase,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	ACT_SITE:Nucleophile,ACT_SITE:Proton acceptor,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Sialidase,MOTIF:FRIP motif,MOTIF:Internalization signal,MUTAGEN:G->A: Correct sorting to the plasma membrane but no endocytosis and internalization.,MUTAGEN:L->A: Correct sorting to the plasma membrane but no endocytosis and internalization.,MUTAGEN:Y->A: Correct sorting to the plasma membrane but no endocytosis and internalization.,REGION:Disordered,REPEAT:BNR 1,REPEAT:BNR 2,REPEAT:BNR 3,REPEAT:BNR 4,TRANSMEM:Helical,
NCDN	neurochondrin(NCDN)	Homo sapiens			GO:0031175~neuron projection development,GO:0045453~bone resorption,GO:0048168~regulation of neuronal synaptic plasticity,	GO:0005829~cytosol,GO:0010008~endosome membrane,GO:0016020~membrane,GO:0030425~dendrite,GO:0043025~neuronal cell body,GO:0043204~perikaryon,GO:0098794~postsynapse,	GO:0005515~protein binding,	IPR008709:Neurochondrin,IPR016024:ARM-type_fold,		619373~Neurodevelopmental disorder with infantile epileptic spasms,				KW-0472~Membrane,KW-0770~Synapse,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-0967~Endosome,	KW-0225~Disease variant,KW-0887~Epilepsy,KW-0991~Intellectual disability,				KW-0007~Acetylation,KW-0449~Lipoprotein,KW-0488~Methylation,KW-0564~Palmitate,KW-0597~Phosphoprotein,	LIPID:S-palmitoyl cysteine,
NGDN	neuroguidin(NGDN)	Homo sapiens			GO:0000462~maturation of SSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA),GO:0042274~ribosomal small subunit biogenesis,	GO:0000775~chromosome, centromeric region,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005739~mitochondrion,GO:0030175~filopodium,GO:0030424~axon,GO:0030425~dendrite,GO:0032040~small-subunit processome,GO:0098794~postsynapse,GO:0098978~glutamatergic synapse,	GO:0003723~RNA binding,GO:0005515~protein binding,	IPR007146:Sas10/Utp3/C1D,					KW-0810~Translation regulation,	KW-0137~Centromere,KW-0158~Chromosome,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0966~Cell projection,		KW-0175~Coiled coil,		KW-0678~Repressor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic residues,REGION:Disordered,REGION:Necessary for interaction with EIF4E,
NMB	neuromedin B(NMB)	Homo sapiens			GO:0007165~signal transduction,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0007218~neuropeptide signaling pathway,GO:0007267~cell-cell signaling,GO:0032715~negative regulation of interleukin-6 production,GO:0032727~positive regulation of interferon-alpha production,GO:0046887~positive regulation of hormone secretion,GO:0046888~negative regulation of hormone secretion,GO:0050482~arachidonic acid secretion,GO:0090290~positive regulation of osteoclast proliferation,GO:1903942~positive regulation of respiratory gaseous exchange,GO:2000845~positive regulation of testosterone secretion,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0043005~neuron projection,	GO:0005179~hormone activity,GO:0005184~neuropeptide hormone activity,GO:0005515~protein binding,GO:0031710~neuromedin B receptor binding,	IPR000874:Bombesin,	hsa04080:Neuroactive ligand-receptor interaction,				KW-0391~Immunity,KW-0399~Innate immunity,	KW-0964~Secreted,KW-0966~Cell projection,		KW-0732~Signal,			KW-0027~Amidation,KW-0165~Cleavage on pair of basic residues,	PEPTIDE:Neuromedin-B,PEPTIDE:Neuromedin-B-32,
NPTN	neuroplastin(NPTN)	Homo sapiens			GO:0001818~negative regulation of cytokine production,GO:0001934~positive regulation of protein phosphorylation,GO:0006874~cellular calcium ion homeostasis,GO:0007156~homophilic cell adhesion via plasma membrane adhesion molecules,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0010976~positive regulation of neuron projection development,GO:0045743~positive regulation of fibroblast growth factor receptor signaling pathway,GO:0048170~positive regulation of long-term neuronal synaptic plasticity,GO:0060291~long-term synaptic potentiation,GO:1902683~regulation of receptor localization to synapse,GO:1904861~excitatory synapse assembly,	GO:0001772~immunological synapse,GO:0009986~cell surface,GO:0014069~postsynaptic density,GO:0016020~membrane,GO:0042734~presynaptic membrane,	GO:0005105~type 1 fibroblast growth factor receptor binding,GO:0005515~protein binding,GO:0050839~cell adhesion molecule binding,	IPR003598:Ig_sub2,IPR003599:Ig_sub,IPR007110:Ig-like_dom,IPR013783:Ig-like_fold,IPR036179:Ig-like_dom_sf,IPR037448:Zig-8,			PIRSF000615:TyrPK_CSF1-R,	SM00408:IGc2,SM00409:IG,	KW-0130~Cell adhesion,KW-0524~Neurogenesis,	KW-0472~Membrane,KW-0770~Synapse,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like,DOMAIN:Ig-like 1,DOMAIN:Ig-like 2,DOMAIN:Ig-like 3,REGION:Disordered,REGION:Narpin; mediates binding with FGFR1 and has antidepressant-like activity,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
NCF4	neutrophil cytosolic factor 4(NCF4)	Homo sapiens			GO:0006909~phagocytosis,GO:0042554~superoxide anion generation,GO:0045730~respiratory burst,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0010008~endosome membrane,GO:0016020~membrane,GO:0032010~phagolysosome,GO:0043020~NADPH oxidase complex,	GO:0005515~protein binding,GO:0016176~superoxide-generating NADPH oxidase activator activity,GO:0032266~phosphatidylinositol-3-phosphate binding,GO:0035091~phosphatidylinositol binding,	IPR000270:PB1_dom,IPR000919:p40phox,IPR001452:SH3_domain,IPR001683:PX_dom,IPR034853:PB1_P40,IPR034912:PX_p40phox,IPR035541:p40phox_SH3,IPR036028:SH3-like_dom_sf,IPR036871:PX_dom_sf,	hsa04145:Phagosome,hsa04380:Osteoclast differentiation,hsa04613:Neutrophil extracellular trap formation,hsa04670:Leukocyte transendothelial migration,hsa05020:Prion disease,hsa05140:Leishmaniasis,hsa05415:Diabetic cardiomyopathy,hsa05417:Lipid and atherosclerosis,	613960~Chronic granulomatous disease 3, autosomal recessive,		SM00312:PX,SM00326:SH3,SM00666:PB1,		KW-0472~Membrane,KW-0963~Cytoplasm,KW-0967~Endosome,	KW-0161~Chronic granulomatous disease,KW-0225~Disease variant,	KW-0728~SH3 domain,	KW-0446~Lipid-binding,		KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:PB1,DOMAIN:PX,DOMAIN:SH3,MUTAGEN:K->A: Abolishes interaction with membranes enriched in phosphatidylinositol 3-phosphate.,MUTAGEN:R->A: Abolishes interaction with membranes enriched in phosphatidylinositol 3-phosphate.,MUTAGEN:R->A: Strongly reduces interaction with membranes enriched in phosphatidylinositol 3-phosphate.,MUTAGEN:R->Q: Abolishes interaction with membranes enriched in phosphatidylinositol 3-phosphate.,MUTAGEN:S->A: Reduces phosphorylation.,MUTAGEN:T->A: No effect on phosphorylation.,MUTAGEN:T->A: Reduces phosphorylation.,MUTAGEN:Y->A: Slightly reduces interaction with membranes enriched in phosphatidylinositol 3-phosphate.,REGION:Disordered,
NAMPT	nicotinamide phosphoribosyltransferase(NAMPT)	Homo sapiens			GO:0007165~signal transduction,GO:0007267~cell-cell signaling,GO:0008284~positive regulation of cell proliferation,GO:0009435~NAD biosynthetic process,GO:0032922~circadian regulation of gene expression,GO:0034356~NAD biosynthesis via nicotinamide riboside salvage pathway,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051770~positive regulation of nitric-oxide synthase biosynthetic process,	GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016607~nuclear speck,GO:0030054~cell junction,GO:0070062~extracellular exosome,	GO:0005125~cytokine activity,GO:0005515~protein binding,GO:0016740~transferase activity,GO:0016757~transferase activity, transferring glycosyl groups,GO:0042802~identical protein binding,GO:0047280~nicotinamide phosphoribosyltransferase activity,	IPR013785:Aldolase_TIM,IPR016471:Nicotinamide_PRibTrfase,IPR036068:Nicotinate_pribotase-like_C,IPR041525:N/Namide_PRibTrfase,IPR041529:DUF5598,	hsa00760:Nicotinate and nicotinamide metabolism,hsa01100:Metabolic pathways,hsa04621:NOD-like receptor signaling pathway,		PIRSF005943:NMPRT,		KW-0090~Biological rhythms,KW-0662~Pyridine nucleotide biosynthesis,	KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0964~Secreted,				KW-0202~Cytokine,KW-0328~Glycosyltransferase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:Nicotinamide phosphoribosyltransferase N-terminal,DOMAIN:Nicotinate/nicotinamide phosphoribosyltransferase,MUTAGEN:D->N,S: No effect on activity towards nicotinamide. Alters specificity, so that the enzyme acquires activity towards nicotinic acid.,MUTAGEN:H->A: Reduces activity towards nicotinamide.,MUTAGEN:R->D: Reduces activity towards nicotinamide.,
NONO	non-POU domain containing octamer binding(NONO)	Homo sapiens		h_antisensePathway:RNA polymerase III transcription,	GO:0002218~activation of innate immune response,GO:0006281~DNA repair,GO:0006310~DNA recombination,GO:0006355~regulation of transcription, DNA-templated,GO:0006397~mRNA processing,GO:0007623~circadian rhythm,GO:0008380~RNA splicing,GO:0042752~regulation of circadian rhythm,GO:0043066~negative regulation of apoptotic process,GO:0045087~innate immune response,GO:0045892~negative regulation of transcription, DNA-templated,GO:0048511~rhythmic process,GO:0071456~cellular response to hypoxia,GO:1903377~negative regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway,GO:1904385~cellular response to angiotensin,	GO:0001650~fibrillar center,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005694~chromosome,GO:0016020~membrane,GO:0016363~nuclear matrix,GO:0016607~nuclear speck,GO:0042382~paraspeckles,GO:0090575~RNA polymerase II transcription factor complex,	GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR000504:RRM_dom,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR012975:NOPS,IPR034552:p54nrb_RRM1,IPR034558:p54nrb_RRM2,IPR035979:RBD_domain_sf,		300967~Intellectual developmental disorder, X-linked syndromic 34,		SM00360:RRM,	KW-0090~Biological rhythms,KW-0227~DNA damage,KW-0233~DNA recombination,KW-0234~DNA repair,KW-0391~Immunity,KW-0399~Innate immunity,KW-0507~mRNA processing,KW-0508~mRNA splicing,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0158~Chromosome,KW-0539~Nucleus,	KW-0991~Intellectual disability,	KW-0175~Coiled coil,KW-0677~Repeat,		KW-0010~Activator,KW-0238~DNA-binding,KW-0678~Repressor,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:RRM,DOMAIN:RRM 1,DOMAIN:RRM 2,MUTAGEN:W->A: Abolishes interaction with PSPC1 and localization in nuclear paraspeckles; when associated with A-267.,MUTAGEN:Y->A: Abolishes interaction with PSPC1 and localization in nuclear paraspeckles; when associated with A-271.,REGION:DBHS,REGION:Disordered,SITE:Breakpoint for translocation to form NONO-TFE3,
NUFIP2	nuclear FMR1 interacting protein 2(NUFIP2)	Homo sapiens				GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005840~ribosome,GO:0010494~cytoplasmic stress granule,GO:0016020~membrane,GO:0016604~nuclear body,GO:0042788~polysomal ribosome,	GO:0003723~RNA binding,GO:0005515~protein binding,	IPR032747:NUFIP2,						KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0694~RNA-binding,	KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),REGION:Disordered,
NASP	nuclear autoantigenic sperm protein(NASP)	Homo sapiens			GO:0001824~blastocyst development,GO:0006260~DNA replication,GO:0006334~nucleosome assembly,GO:0006335~DNA replication-dependent nucleosome assembly,GO:0007049~cell cycle,GO:0008584~male gonad development,GO:0015031~protein transport,GO:0033574~response to testosterone,GO:0034080~CENP-A containing nucleosome assembly,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0032991~macromolecular complex,	GO:0005515~protein binding,GO:0042393~histone binding,GO:0044877~macromolecular complex binding,	IPR011990:TPR-like_helical_dom_sf,IPR019544:Tetratricopeptide_SHNi-TPR_dom,IPR019734:TPR_repeat,				SM00028:TPR,	KW-0131~Cell cycle,KW-0235~DNA replication,KW-0653~Protein transport,KW-0813~Transport,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0677~Repeat,KW-0802~TPR repeat,			KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1),DOMAIN:Tetratricopeptide SHNi-TPR,MOTIF:Nuclear localization signal,REGION:Disordered,REGION:Histone-binding,REPEAT:TPR,REPEAT:TPR 1,REPEAT:TPR 2,REPEAT:TPR 3,
NCBP3	nuclear cap binding subunit 3(NCBP3)	Homo sapiens			GO:0006370~7-methylguanosine mRNA capping,GO:0006406~mRNA export from nucleus,GO:0006408~snRNA export from nucleus,GO:0035194~posttranscriptional gene silencing by RNA,GO:0042789~mRNA transcription from RNA polymerase II promoter,GO:0051607~defense response to virus,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005845~mRNA cap binding complex,GO:0005846~nuclear cap binding complex,GO:0016607~nuclear speck,GO:0034518~RNA cap binding complex,	GO:0000339~RNA cap binding,GO:0000340~RNA 7-methylguanosine cap binding,GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0005515~protein binding,	IPR012677:Nucleotide-bd_a/b_plait_sf,IPR019416:NCBP3,					KW-0051~Antiviral defense,KW-0506~mRNA capping,KW-0507~mRNA processing,KW-0509~mRNA transport,KW-0813~Transport,	KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0694~RNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),MOTIF:WLDD motif; essential for 7-methylguanosine-containing mRNA cap binding,MUTAGEN:D->A: Minor loss of 7-methylguanosine-containing mRNA cap binding.,MUTAGEN:WLDD->ALAA: Complete loss of 7-methylguanosine-containing mRNA cap binding.,REGION:Disordered,REGION:RNA recognition motif (RRM) domain,
NEMF	nuclear export mediator factor(NEMF)	Homo sapiens			GO:0051168~nuclear export,GO:0065003~macromolecular complex assembly,GO:0072344~rescue of stalled ribosome,GO:1990116~ribosome-associated ubiquitin-dependent protein catabolic process,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0022626~cytosolic ribosome,GO:1990112~RQC complex,	GO:0000049~tRNA binding,GO:0043023~ribosomal large subunit binding,GO:1904678~alpha-aminoacyl-tRNA binding,	IPR008532:NFACT_RNA-bd,IPR021846:NFACT-C,		619099~Intellectual developmental disorder with speech delay and axonal peripheral neuropathy,				KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0622~Neuropathy,KW-0991~Intellectual disability,	KW-0175~Coiled coil,			KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,DOMAIN:NFACT RNA-binding,DOMAIN:NFACT protein C-terminal,MUTAGEN:D->A: Abolished ability to mediate CAT tailing.,MUTAGEN:DR->AA: Abolished ability to mediate CAT tailing.,REGION:Disordered,
NFKB1	nuclear factor kappa B subunit 1(NFKB1)	Homo sapiens	138.Fig1AB_Eukaryotic_transcriptional_control,139.Fig1CD_Eukaryotic_transcriptional_control,150.caspase_and_NFKB_activation,151.pro-apoptotic_actions_of_altered_APP&PS1,17.Activators-CAM,40.Deg_of_Chrom_DNA_TNF-ind_apoptosis,44.Sig_Trans_TNFR1-DR3-DR4_DR5,51.CD40_and_EBV,72.IAP_interaction_with_cell_death_pathways,77.IkBa_Kinase_JNK_MEKK1,79.B_cell_Activation,90.IB_and-cat-Arm_processing_of_Ci,92.Ancient_Host_Defense_Pathways,99.NF-kB_activation,	h_41BBPathway:The 4-1BB-dependent immune response,h_aktPathway:AKT Signaling Pathway,h_atmPathway:ATM Signaling Pathway,h_cardiacEGFPathway:Role of EGF Receptor Transactivation by GPCRs in Cardiac Hypertrophy,h_cd40Pathway:CD40L Signaling Pathway,h_cdmacPathway:Cadmium induces DNA synthesis and proliferation in macrophages,h_ceramidePathway:Ceramide Signaling Pathway,h_cxcr4Pathway:CXCR4 Signaling Pathway,h_deathPathway:Induction of apoptosis through DR3 and DR4/5 Death Receptors ,h_eponfkbPathway:Erythropoietin mediated neuroprotection through NF-kB,h_fmlpPathway:fMLP induced chemokine gene expression in HMC-1 cells,h_freePathway:Free Radical Induced Apoptosis,h_gcrpathway:Corticosteroids and cardioprotection,H_gsk3Pathway:Inactivation of Gsk3 by AKT causes accumulation of b-catenin in Alveolar Macrophages,h_hcmvPathway:Human Cytomegalovirus and Map Kinase Pathways,h_hivnefPathway:HIV-I Nef: negative effector of Fas and TNF,h_il1rPathway:Signal transduction through IL1R,h_keratinocytePathway:Keratinocyte Differentiation,h_mapkPathway:MAPKinase Signaling Pathway,h_nfkbPathway:NF-kB Signaling Pathway,h_nthiPathway:NFkB activation by Nontypeable Hemophilus influenzae,h_pcafPathway:The information-processing pathway at the IFN-beta enhancer,h_pkcPathway:Activation of PKC through G protein coupled receptor,h_raccycdPathway:Influence of Ras and Rho proteins on G1 to S Transition,h_ranklPathway:Bone Remodelling,h_rasPathway:Ras Signaling Pathway,h_relaPathway:Acetylation and Deacetylation of RelA in The Nucleus,h_rnaPathway:Double Stranded RNA Induced Gene Expression,h_stressPathway:TNF/Stress Related Signaling,h_tall1Pathway:TACI and BCMA stimulation of B cell immune responses.,h_tcrPathway:T Cell Receptor Signaling Pathway,h_tidPathway:Chaperones modulate interferon Signaling Pathway,h_tnfr2Pathway:TNFR2 Signaling Pathway,h_tollPathway:Toll-Like Receptor Pathway,h_vipPathway:Neuropeptides VIP and PACAP inhibit the apoptosis of activated T cells,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0006915~apoptotic process,GO:0006954~inflammatory response,GO:0007165~signal transduction,GO:0007249~I-kappaB kinase/NF-kappaB signaling,GO:0007254~JNK cascade,GO:0010629~negative regulation of gene expression,GO:0010744~positive regulation of macrophage derived foam cell differentiation,GO:0010884~positive regulation of lipid storage,GO:0010956~negative regulation of calcidiol 1-monooxygenase activity,GO:0010957~negative regulation of vitamin D biosynthetic process,GO:0032375~negative regulation of cholesterol transport,GO:0032695~negative regulation of interleukin-12 production,GO:0033554~cellular response to stress,GO:0034097~response to cytokine,GO:0035994~response to muscle stretch,GO:0038061~NIK/NF-kappaB signaling,GO:0043066~negative regulation of apoptotic process,GO:0045087~innate immune response,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0050728~negative regulation of inflammatory response,GO:0050853~B cell receptor signaling pathway,GO:0051248~negative regulation of protein metabolic process,GO:0060056~mammary gland involution,GO:0060261~positive regulation of transcription initiation from RNA polymerase II promoter,GO:0071222~cellular response to lipopolysaccharide,GO:0071260~cellular response to mechanical stimulus,GO:0071316~cellular response to nicotine,GO:0071347~cellular response to interleukin-1,GO:0071354~cellular response to interleukin-6,GO:0071356~cellular response to tumor necrosis factor,GO:0071359~cellular response to dsRNA,GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:0097398~cellular response to interleukin-17,GO:0098586~cellular response to virus,GO:1900127~positive regulation of hyaluronan biosynthetic process,GO:1904385~cellular response to angiotensin,GO:2000630~positive regulation of miRNA metabolic process,	GO:0000785~chromatin,GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0033256~I-kappaB/NF-kappaB complex,GO:0034774~secretory granule lumen,GO:0035525~NF-kappaB p50/p65 complex,GO:0035580~specific granule lumen,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0003712~transcription cofactor activity,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0042805~actinin binding,	IPR000451:NFkB/Dor,IPR000488:Death_domain,IPR002110:Ankyrin_rpt,IPR002909:IPT_dom,IPR008967:p53-like_TF_DNA-bd_sf,IPR011029:DEATH-like_dom_sf,IPR011539:RHD_DNA_bind_dom,IPR013783:Ig-like_fold,IPR014756:Ig_E-set,IPR030492:RHD_CS,IPR030503:NF-kB_p105_RHD_N,IPR032397:RHD_dimer,IPR033926:IPT_NFkappaB,IPR036770:Ankyrin_rpt-contain_sf,IPR037059:RHD_DNA_bind_dom_sf,IPR047096:NF-kB_p105_DD,	hsa01523:Antifolate resistance,hsa04010:MAPK signaling pathway,hsa04014:Ras signaling pathway,hsa04024:cAMP signaling pathway,hsa04062:Chemokine signaling pathway,hsa04064:NF-kappa B signaling pathway,hsa04066:HIF-1 signaling pathway,hsa04071:Sphingolipid signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04210:Apoptosis,hsa04211:Longevity regulating pathway,hsa04218:Cellular senescence,hsa04380:Osteoclast differentiation,hsa04613:Neutrophil extracellular trap formation,hsa04620:Toll-like receptor signaling pathway,hsa04621:NOD-like receptor signaling pathway,hsa04622:RIG-I-like receptor signaling pathway,hsa04623:Cytosolic DNA-sensing pathway,hsa04625:C-type lectin receptor signaling pathway,hsa04657:IL-17 signaling pathway,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04660:T cell receptor signaling pathway,hsa04662:B cell receptor signaling pathway,hsa04668:TNF signaling pathway,hsa04722:Neurotrophin signaling pathway,hsa04917:Prolactin signaling pathway,hsa04920:Adipocytokine signaling pathway,hsa04926:Relaxin signaling pathway,hsa04931:Insulin resistance,hsa04932:Non-alcoholic fatty liver disease,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa04936:Alcoholic liver disease,hsa05010:Alzheimer disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05030:Cocaine addiction,hsa05120:Epithelial cell signaling in Helicobacter pylori infection,hsa05130:Pathogenic Escherichia coli infection,hsa05131:Shigellosis,hsa05132:Salmonella infection,hsa05133:Pertussis,hsa05134:Legionellosis,hsa05135:Yersinia infection,hsa05140:Leishmaniasis,hsa05142:Chagas disease,hsa05145:Toxoplasmosis,hsa05146:Amoebiasis,hsa05152:Tuberculosis,hsa05160:Hepatitis C,hsa05161:Hepatitis B,hsa05162:Measles,hsa05163:Human cytomegalovirus infection,hsa05164:Influenza A,hsa05165:Human papillomavirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05171:Coronavirus disease - COVID-19,hsa05200:Pathways in cancer,hsa05202:Transcriptional misregulation in cancer,hsa05203:Viral carcinogenesis,hsa05206:MicroRNAs in cancer,hsa05207:Chemical carcinogenesis - receptor activation,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05212:Pancreatic cancer,hsa05215:Prostate cancer,hsa05220:Chronic myeloid leukemia,hsa05221:Acute myeloid leukemia,hsa05222:Small cell lung cancer,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,hsa05321:Inflammatory bowel disease,hsa05415:Diabetic cardiomyopathy,hsa05417:Lipid and atherosclerosis,hsa05418:Fluid shear stress and atherosclerosis,	616576~Immunodeficiency, common variable, 12,		SM00005:DEATH,SM00248:ANK,SM00429:IPT,	KW-0053~Apoptosis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0040~ANK repeat,KW-0677~Repeat,		KW-0010~Activator,KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0379~Hydroxylation,KW-0449~Lipoprotein,KW-0597~Phosphoprotein,KW-0702~S-nitrosylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Death,DOMAIN:RHD,LIPID:S-(15-deoxy-Delta12,14-prostaglandin J2-9-yl)cysteine; alternate,MOTIF:Nuclear localization signal,MUTAGEN:C->S: Suppresses S-nitrosylation-induced inhibition of DNA-binding activity. Loss of S-(15-deoxy-Delta12,14-prostaglandin J2-9-yl)cysteine-induced inhibition of DNA-binding activity.,MUTAGEN:N->A: Fails to promote HIF1AN-dependent 2-oxoglutarate decarboxylation.,MUTAGEN:S->A: Decrease in stimuli-induced phosphorylation. Loss of phosphorylation; when associated with A-921 and A-923.,MUTAGEN:S->A: Decrease in stimuli-induced phosphorylation. Loss of phosphorylation; when associated with A-921 and A-932.,MUTAGEN:S->A: Decrease in stimuli-induced phosphorylation. Loss of phosphorylation; when associated with A-923 and A-932.,MUTAGEN:S->A: Decreased phosphorylation by IKBKB/IKKB and decreased generation of the NF-kappa-B p50 subunit from p105.,MUTAGEN:S->A: Prevents p105 proteolysis in response to TNF-alpha.,REGION:Disordered,REGION:Essential for interaction with HIF1AN,REGION:GRR,REGION:Interaction with CFLAR,REPEAT:ANK,REPEAT:ANK 1,REPEAT:ANK 2,REPEAT:ANK 3,REPEAT:ANK 4,REPEAT:ANK 5,REPEAT:ANK 6,REPEAT:ANK 7,SITE:Cleavage (when cotranslationally processed),
NFKB2	nuclear factor kappa B subunit 2(NFKB2)	Homo sapiens			GO:0002268~follicular dendritic cell differentiation,GO:0002467~germinal center formation,GO:0006355~regulation of transcription, DNA-templated,GO:0006954~inflammatory response,GO:0007165~signal transduction,GO:0007249~I-kappaB kinase/NF-kappaB signaling,GO:0030198~extracellular matrix organization,GO:0032496~response to lipopolysaccharide,GO:0033554~cellular response to stress,GO:0034097~response to cytokine,GO:0038061~NIK/NF-kappaB signaling,GO:0045087~innate immune response,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048511~rhythmic process,GO:0048536~spleen development,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0033257~Bcl3/NF-kappaB2 complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000451:NFkB/Dor,IPR000488:Death_domain,IPR002110:Ankyrin_rpt,IPR002909:IPT_dom,IPR008967:p53-like_TF_DNA-bd_sf,IPR011029:DEATH-like_dom_sf,IPR011539:RHD_DNA_bind_dom,IPR013783:Ig-like_fold,IPR014756:Ig_E-set,IPR030492:RHD_CS,IPR030497:NFkB_p100_RHD_N,IPR032397:RHD_dimer,IPR033926:IPT_NFkappaB,IPR036770:Ankyrin_rpt-contain_sf,IPR037059:RHD_DNA_bind_dom_sf,	hsa04010:MAPK signaling pathway,hsa04064:NF-kappa B signaling pathway,hsa04380:Osteoclast differentiation,hsa04625:C-type lectin receptor signaling pathway,hsa05134:Legionellosis,hsa05166:Human T-cell leukemia virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05200:Pathways in cancer,hsa05203:Viral carcinogenesis,hsa05224:Breast cancer,	615577~Immunodeficiency, common variable, 10,		SM00005:DEATH,SM00248:ANK,SM00429:IPT,	KW-0090~Biological rhythms,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0656~Proto-oncogene,	KW-0040~ANK repeat,KW-0677~Repeat,		KW-0010~Activator,KW-0238~DNA-binding,KW-0678~Repressor,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:Death,DOMAIN:RHD,MOTIF:Nuclear localization signal,MUTAGEN:A->P: No change in cleavage rate or products.,MUTAGEN:G->A: No change in cleavage rate or products.,MUTAGEN:P->A: No change in cleavage rate or products.,MUTAGEN:Q->N: No change in cleavage rate or products.,MUTAGEN:S->A: Decrease in MAP3K14-induced phosphorylation; no inducible processing occurs; when associated with A-865.,MUTAGEN:S->A: Decrease in MAP3K14-induced phosphorylation; no inducible processing occurs; when associated with A-869.,MUTAGEN:S->A: Loss of phosphorylation; when associated with G-713 and A-715.,MUTAGEN:S->A: Loss of phosphorylation; when associated with G-713 and A-717.,MUTAGEN:S->G: Loss of phosphorylation; when associated with A-715 and A-717.,MUTAGEN:YLL->AAA: Two-fold reduction in heterodimerization with RelA.,REGION:Disordered,REGION:GRR,REPEAT:ANK,REPEAT:ANK 1,REPEAT:ANK 2,REPEAT:ANK 3,REPEAT:ANK 4,REPEAT:ANK 5,REPEAT:ANK 6,REPEAT:ANK 7,SITE:Breakpoint for translocation to form NFKB2-IGHA1 oncogene,SITE:Cleavage (when cotranslationally processed),
NFATC2	nuclear factor of activated T cells 2(NFATC2)	Homo sapiens	67.Ikaros_and_signaling_inhibitors,	h_bcrPathway:BCR Signaling Pathway,h_calcineurinPathway:Effects of calcineurin in Keratinocyte Differentiation,h_fcer1Pathway:Fc Epsilon Receptor I Signaling in Mast Cells,h_fmlpPathway:fMLP induced chemokine gene expression in HMC-1 cells,h_gata3Pathway:GATA3 participate in activating the Th2 cytokine genes expression,h_gpcrPathway:Signaling Pathway from G-Protein Families,h_hdacPathway:Control of skeletal myogenesis by HDAC & calcium/calmodulin-dependent kinase (CaMK),h_mef2dPathway:Role of MEF2D in T-cell Apoptosis,h_nfatPathway:NFAT and Hypertrophy of the heart (Transcription in the broken heart),h_tcrPathway:T Cell Receptor Signaling Pathway,h_vipPathway:Neuropeptides VIP and PACAP inhibit the apoptosis of activated T cells,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001816~cytokine production,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0006974~cellular response to DNA damage stimulus,GO:0009410~response to xenobiotic stimulus,GO:0010628~positive regulation of gene expression,GO:0014904~myotube cell development,GO:0016477~cell migration,GO:0030890~positive regulation of B cell proliferation,GO:0033173~calcineurin-NFAT signaling cascade,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0050853~B cell receptor signaling pathway,GO:0051216~cartilage development,GO:0071277~cellular response to calcium ion,GO:0098781~ncRNA transcription,GO:1901741~positive regulation of myoblast fusion,GO:1905064~negative regulation of vascular smooth muscle cell differentiation,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0035976~transcription factor AP-1 complex,GO:1990904~ribonucleoprotein complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:0019902~phosphatase binding,GO:0060090~binding, bridging,GO:0071889~14-3-3 protein binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR002909:IPT_dom,IPR008366:NFAT,IPR008967:p53-like_TF_DNA-bd_sf,IPR011539:RHD_DNA_bind_dom,IPR013783:Ig-like_fold,IPR014756:Ig_E-set,IPR032397:RHD_dimer,IPR037059:RHD_DNA_bind_dom_sf,	hsa04020:Calcium signaling pathway,hsa04022:cGMP-PKG signaling pathway,hsa04148:Efferocytosis,hsa04218:Cellular senescence,hsa04310:Wnt signaling pathway,hsa04360:Axon guidance,hsa04370:VEGF signaling pathway,hsa04380:Osteoclast differentiation,hsa04625:C-type lectin receptor signaling pathway,hsa04650:Natural killer cell mediated cytotoxicity,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04660:T cell receptor signaling pathway,hsa04662:B cell receptor signaling pathway,hsa04921:Oxytocin signaling pathway,hsa05135:Yersinia infection,hsa05161:Hepatitis B,hsa05163:Human cytomegalovirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,hsa05417:Lipid and atherosclerosis,	620232~Joint contracture, osteochondromas, and B-cell lymphoma,		SM00429:IPT,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,		KW-0010~Activator,KW-0238~DNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,DOMAIN:RHD,MOTIF:9aaTAD,MOTIF:Nuclear export signal,MOTIF:Nuclear localization signal,REGION:3 X approximate SP repeats,REGION:Calcineurin-binding,REGION:Disordered,REGION:Required for cytoplasmic retention of the phosphorylated form,REGION:Transactivation domain A (TAD-A),REPEAT:1,REPEAT:2,REPEAT:3; approximate,
NFATC3	nuclear factor of activated T cells 3(NFATC3)	Homo sapiens	80.T_cell_Activation,	h_bcrPathway:BCR Signaling Pathway,h_calcineurinPathway:Effects of calcineurin in Keratinocyte Differentiation,h_fcer1Pathway:Fc Epsilon Receptor I Signaling in Mast Cells,h_fmlpPathway:fMLP induced chemokine gene expression in HMC-1 cells,h_gpcrPathway:Signaling Pathway from G-Protein Families,h_nfatPathway:NFAT and Hypertrophy of the heart (Transcription in the broken heart),h_tcrPathway:T Cell Receptor Signaling Pathway,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001816~cytokine production,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006954~inflammatory response,GO:0033173~calcineurin-NFAT signaling cascade,GO:0045059~positive thymic T cell selection,GO:0045429~positive regulation of nitric oxide biosynthetic process,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:1902894~negative regulation of pri-miRNA transcription from RNA polymerase II promoter,GO:1904157~DN4 thymocyte differentiation,GO:1905064~negative regulation of vascular smooth muscle cell differentiation,GO:1905653~positive regulation of artery morphogenesis,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR002909:IPT_dom,IPR008366:NFAT,IPR008967:p53-like_TF_DNA-bd_sf,IPR011539:RHD_DNA_bind_dom,IPR013783:Ig-like_fold,IPR014756:Ig_E-set,IPR032397:RHD_dimer,IPR037059:RHD_DNA_bind_dom_sf,	hsa04010:MAPK signaling pathway,hsa04020:Calcium signaling pathway,hsa04022:cGMP-PKG signaling pathway,hsa04148:Efferocytosis,hsa04218:Cellular senescence,hsa04310:Wnt signaling pathway,hsa04360:Axon guidance,hsa04625:C-type lectin receptor signaling pathway,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04660:T cell receptor signaling pathway,hsa04662:B cell receptor signaling pathway,hsa04921:Oxytocin signaling pathway,hsa05135:Yersinia infection,hsa05161:Hepatitis B,hsa05163:Human cytomegalovirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,hsa05417:Lipid and atherosclerosis,			SM00429:IPT,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,		KW-0010~Activator,KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:RHD,MOTIF:Nuclear export signal,MOTIF:Nuclear localization signal,REGION:3 X SP repeats,REGION:Calcineurin-binding,REGION:Disordered,REPEAT:1,REPEAT:2,REPEAT:3,
NFAT5	nuclear factor of activated T cells 5(NFAT5)	Homo sapiens			GO:0001816~cytokine production,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0006974~cellular response to DNA damage stimulus,GO:0007165~signal transduction,GO:0010628~positive regulation of gene expression,GO:0033173~calcineurin-NFAT signaling cascade,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0070884~regulation of calcineurin-NFAT signaling cascade,GO:0071345~cellular response to cytokine stimulus,GO:0071474~cellular hyperosmotic response,GO:1904996~positive regulation of leukocyte adhesion to vascular endothelial cell,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005829~cytosol,GO:0016020~membrane,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR002909:IPT_dom,IPR008366:NFAT,IPR008967:p53-like_TF_DNA-bd_sf,IPR011539:RHD_DNA_bind_dom,IPR013783:Ig-like_fold,IPR014756:Ig_E-set,IPR015646:NFAT5_RHD_DNA-bd,IPR032397:RHD_dimer,IPR037059:RHD_DNA_bind_dom_sf,				SM00429:IPT,	KW-0227~DNA damage,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0158~Chromosome,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0010~Activator,KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0013~ADP-ribosylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:RHD,MUTAGEN:S->A: Increased nuclear localization.,MUTAGEN:S->A: Normal nuclear localization.,MUTAGEN:S->A: Reduced nuclear localization.,MUTAGEN:T->A: Reduced nuclear localization.,REGION:Disordered,TRANSMEM:Helical,
NEAT1	nuclear paraspeckle assembly transcript 1(NEAT1)	Homo sapiens			GO:0010793~regulation of mRNA export from nucleus,GO:0030575~nuclear body organization,GO:0035195~gene silencing by miRNA,GO:0050729~positive regulation of inflammatory response,GO:1901647~positive regulation of synoviocyte proliferation,GO:2000627~positive regulation of miRNA catabolic process,	GO:0016442~RISC complex,GO:0042382~paraspeckles,	GO:0005515~protein binding,GO:0035198~miRNA binding,GO:1905172~RISC complex binding,
NSD1	nuclear receptor binding SET domain protein 1(NSD1)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006338~chromatin remodeling,GO:0006355~regulation of transcription, DNA-templated,GO:0032259~methylation,GO:0033135~regulation of peptidyl-serine phosphorylation,GO:0045893~positive regulation of transcription, DNA-templated,GO:1903025~regulation of RNA polymerase II regulatory region sequence-specific DNA binding,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0003682~chromatin binding,GO:0003712~transcription cofactor activity,GO:0003714~transcription corepressor activity,GO:0005515~protein binding,GO:0008168~methyltransferase activity,GO:0008270~zinc ion binding,GO:0030331~estrogen receptor binding,GO:0042799~histone methyltransferase activity (H4-K20 specific),GO:0042974~retinoic acid receptor binding,GO:0046872~metal ion binding,GO:0046965~retinoid X receptor binding,GO:0046966~thyroid hormone receptor binding,GO:0046975~histone methyltransferase activity (H3-K36 specific),GO:0050681~androgen receptor binding,	IPR000313:PWWP_dom,IPR001214:SET_dom,IPR001965:Znf_PHD,IPR003616:Post-SET_dom,IPR006560:AWS_dom,IPR011011:Znf_FYVE_PHD,IPR013083:Znf_RING/FYVE/PHD,IPR019786:Zinc_finger_PHD-type_CS,IPR019787:Znf_PHD-finger,IPR041306:C5HCH,IPR046341:SET_dom_sf,IPR047423:PWWP_NSD1_rpt2,IPR047426:PHD1_NSD1_2,IPR047428:PHD2_NSD1,IPR047429:PHD3_NSD1,IPR047430:PHD4_NSD1,IPR047432:PHD5_NSD1,IPR047433:SET_NSD1,	hsa00310:Lysine degradation,hsa01100:Metabolic pathways,	117550~Sotos syndrome,		SM00249:PHD,SM00293:PWWP,SM00317:SET,SM00508:PostSET,SM00570:AWS,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0158~Chromosome,KW-0539~Nucleus,	KW-0225~Disease variant,KW-0656~Proto-oncogene,	KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,KW-0949~S-adenosyl-L-methionine,	KW-0010~Activator,KW-0156~Chromatin regulator,KW-0489~Methyltransferase,KW-0675~Receptor,KW-0678~Repressor,KW-0808~Transferase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:AWS,DOMAIN:NSD Cys-His rich,DOMAIN:PHD-type,DOMAIN:PWWP,DOMAIN:PWWP 1,DOMAIN:PWWP 2,DOMAIN:Post-SET,DOMAIN:SET,MUTAGEN:R->C: Reduced enzyme activity.,MUTAGEN:R->W: Nearly abolished enzyme activity.,REGION:Disordered,REGION:Inhibits enzyme activity in the absence of bound histone,ZN_FING:PHD-type 1,ZN_FING:PHD-type 2,ZN_FING:PHD-type 3,ZN_FING:PHD-type 4; atypical,
NRBF2	nuclear receptor binding factor 2(NRBF2)	Homo sapiens			GO:0006914~autophagy,GO:0034976~response to endoplasmic reticulum stress,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005776~autophagosome,GO:0031410~cytoplasmic vesicle,GO:0035032~phosphatidylinositol 3-kinase complex, class III,	GO:0005515~protein binding,	IPR015056:NRBF2_C,IPR033393:NRBF2_MIT,IPR039679:NRBF2,	hsa04140:Autophagy - animal,hsa05010:Alzheimer disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05017:Spinocerebellar ataxia,hsa05022:Pathways of neurodegeneration - multiple diseases,				KW-0072~Autophagy,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,		KW-0175~Coiled coil,			KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,MOTIF:Nuclear receptor interaction motif,MUTAGEN:LL->AA: Decreased interaction with nuclear receptors.,REGION:Disordered,
NCOA4	nuclear receptor coactivator 4(NCOA4)	Homo sapiens			GO:0006622~protein targeting to lysosome,GO:0006879~cellular iron ion homeostasis,GO:0008584~male gonad development,GO:0009725~response to hormone,GO:0030520~intracellular estrogen receptor signaling pathway,GO:0045893~positive regulation of transcription, DNA-templated,GO:0071391~cellular response to estrogen stimulus,GO:0071394~cellular response to testosterone stimulus,	GO:0005634~nucleus,GO:0044754~autolysosome,	GO:0003713~transcription coactivator activity,	IPR022174:ARA70,IPR039947:NCoA-4,	hsa04216:Ferroptosis,hsa05200:Pathways in cancer,hsa05216:Thyroid cancer,				KW-0804~Transcription,KW-0805~Transcription regulation,		KW-0656~Proto-oncogene,			KW-0010~Activator,KW-0675~Receptor,		DOMAIN:Nuclear coactivator,MUTAGEN:LL->AA: Decreased interaction with PPAR and RXR.,REGION:Disordered,SITE:Breakpoint for rearrangement to form RET/PTC3 oncogene,
NCOR1	nuclear receptor corepressor 1(NCOR1)	Homo sapiens		h_PparaPathway:Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha),h_vdrPathway:Control of Gene Expression by Vitamin D Receptor,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006325~chromatin organization,GO:0045475~locomotor rhythm,GO:0045820~negative regulation of glycolytic process,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045922~negative regulation of fatty acid metabolic process,GO:0046329~negative regulation of JNK cascade,GO:0051225~spindle assembly,GO:0060766~negative regulation of androgen receptor signaling pathway,GO:1902894~negative regulation of pri-miRNA transcription from RNA polymerase II promoter,	GO:0000118~histone deacetylase complex,GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0016020~membrane,GO:0017053~transcriptional repressor complex,GO:0072686~mitotic spindle,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0003714~transcription corepressor activity,GO:0005515~protein binding,GO:0016922~ligand-dependent nuclear receptor binding,GO:0042826~histone deacetylase binding,GO:0046966~thyroid hormone receptor binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,	IPR001005:SANT/Myb,IPR009057:Homeobox-like_sf,IPR017884:SANT_dom,IPR017930:Myb_dom,IPR031557:N-CoR_GPS2_interact,	hsa01522:Endocrine resistance,hsa04350:TGF-beta signaling pathway,hsa04919:Thyroid hormone signaling pathway,hsa05202:Transcriptional misregulation in cancer,			SM00717:SANT,	KW-0090~Biological rhythms,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0175~Coiled coil,KW-0677~Repeat,		KW-0156~Chromatin regulator,KW-0238~DNA-binding,KW-0675~Receptor,KW-0678~Repressor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:HTH myb-type,DOMAIN:Myb-like,DOMAIN:N-CoR GPS2-interacting,DOMAIN:SANT,DOMAIN:SANT 1,DOMAIN:SANT 2,MOTIF:CORNR box 1,MOTIF:CORNR box 2,MOTIF:CORNR box 3,REGION:Disordered,REGION:ID1,REGION:ID2,REGION:Interaction with C1D,REGION:Interaction with ETO,REGION:Interaction with SIN3A/B,REGION:Interaction with ZBTB33 and HEXIM1,REGION:Required for interaction with RARA in the absence of its ligand,
NR1H2	nuclear receptor subfamily 1 group H member 2(NR1H2)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006629~lipid metabolic process,GO:0009755~hormone-mediated signaling pathway,GO:0010745~negative regulation of macrophage derived foam cell differentiation,GO:0010867~positive regulation of triglyceride biosynthetic process,GO:0010875~positive regulation of cholesterol efflux,GO:0010884~positive regulation of lipid storage,GO:0010887~negative regulation of cholesterol storage,GO:0030154~cell differentiation,GO:0030522~intracellular receptor signaling pathway,GO:0032369~negative regulation of lipid transport,GO:0032376~positive regulation of cholesterol transport,GO:0036151~phosphatidylcholine acyl-chain remodeling,GO:0042632~cholesterol homeostasis,GO:0042789~mRNA transcription from RNA polymerase II promoter,GO:0045723~positive regulation of fatty acid biosynthetic process,GO:0045861~negative regulation of proteolysis,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048550~negative regulation of pinocytosis,GO:0051006~positive regulation of lipoprotein lipase activity,GO:0051247~positive regulation of protein metabolic process,GO:0060336~negative regulation of interferon-gamma-mediated signaling pathway,GO:0090108~positive regulation of high-density lipoprotein particle assembly,GO:0090187~positive regulation of pancreatic juice secretion,GO:0090340~positive regulation of secretion of lysosomal enzymes,GO:1902895~positive regulation of pri-miRNA transcription from RNA polymerase II promoter,GO:1903573~negative regulation of response to endoplasmic reticulum stress,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0090575~RNA polymerase II transcription factor complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0004879~RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0031490~chromatin DNA binding,GO:0034191~apolipoprotein A-I receptor binding,GO:0043565~sequence-specific DNA binding,GO:0046965~retinoid X receptor binding,GO:0051117~ATPase binding,	IPR000536:Nucl_hrmn_rcpt_lig-bd,IPR001628:Znf_hrmn_rcpt,IPR001723:Nuclear_hrmn_rcpt,IPR013088:Znf_NHR/GATA,IPR023257:Liver_X_rcpt,IPR035500:NHR-like_dom_sf,	hsa04148:Efferocytosis,hsa04931:Insulin resistance,			SM00399:ZnF_C4,SM00430:HOLI,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0238~DNA-binding,KW-0675~Receptor,	KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DNA_BIND:Nuclear receptor,DOMAIN:NR LBD,DOMAIN:Nuclear receptor,MUTAGEN:K->R: Impaired ability to act as an anti-inflammatory role during the hepatic acute phase response; when associated with R-409.,MUTAGEN:K->R: Impaired ability to act as an anti-inflammatory role during the hepatic acute phase response; when associated with R-447.,REGION:Disordered,REGION:Transactivation AF-1; required for ligand-independent transactivation function,REGION:Transactivation AF-2; required for ligand-dependent transactivation function; mediates interaction with CCAR2,ZN_FING:NR C4-type,
NR3C1	nuclear receptor subfamily 3 group C member 1(NR3C1)	Homo sapiens		h_gcrpathway:Corticosteroids and cardioprotection,h_hSWI-SNFpathway:Chromatin Remodeling by hSWI/SNF ATP-dependent Complexes,h_nthiPathway:NFkB activation by Nontypeable Hemophilus influenzae,h_vobesityPathway:Visceral Fat Deposits and the Metabolic Syndrome,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006111~regulation of gluconeogenesis,GO:0006325~chromatin organization,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006915~apoptotic process,GO:0007059~chromosome segregation,GO:0007165~signal transduction,GO:0008211~glucocorticoid metabolic process,GO:0010467~gene expression,GO:0014004~microglia differentiation,GO:0030325~adrenal gland development,GO:0030518~intracellular steroid hormone receptor signaling pathway,GO:0031946~regulation of glucocorticoid biosynthetic process,GO:0035249~synaptic transmission, glutamatergic,GO:0042711~maternal behavior,GO:0042921~glucocorticoid receptor signaling pathway,GO:0043402~glucocorticoid mediated signaling pathway,GO:0043525~positive regulation of neuron apoptotic process,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048708~astrocyte differentiation,GO:0051301~cell division,GO:0051647~nucleus localization,GO:0060603~mammary gland duct morphogenesis,GO:0061744~motor behavior,GO:0071383~cellular response to steroid hormone stimulus,GO:0071385~cellular response to glucocorticoid stimulus,GO:0071549~cellular response to dexamethasone stimulus,GO:0071560~cellular response to transforming growth factor beta stimulus,GO:1902895~positive regulation of pri-miRNA transcription from RNA polymerase II promoter,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0005813~centrosome,GO:0005819~spindle,GO:0005829~cytosol,GO:0016020~membrane,GO:0016607~nuclear speck,GO:0032991~macromolecular complex,GO:0045202~synapse,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001046~core promoter sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0003723~RNA binding,GO:0004879~RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding,GO:0004883~glucocorticoid receptor activity,GO:0005496~steroid binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0017025~TBP-class protein binding,GO:0019901~protein kinase binding,GO:0034056~estrogen response element binding,GO:0042802~identical protein binding,GO:0043565~sequence-specific DNA binding,GO:0051879~Hsp90 protein binding,GO:1990239~steroid hormone binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000536:Nucl_hrmn_rcpt_lig-bd,IPR001409:Glcrtcd_rcpt,IPR001628:Znf_hrmn_rcpt,IPR001723:Nuclear_hrmn_rcpt,IPR013088:Znf_NHR/GATA,IPR035500:NHR-like_dom_sf,	hsa04080:Neuroactive ligand-receptor interaction,	615962~Glucocorticoid resistance,		SM00399:ZnF_C4,SM00430:HOLI,	KW-0053~Apoptosis,KW-0131~Cell cycle,KW-0132~Cell division,KW-0159~Chromosome partition,KW-0498~Mitosis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0206~Cytoskeleton,KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0657~Pseudohermaphroditism,KW-9991~Pseudohermaphroditism,	KW-0863~Zinc-finger,	KW-0446~Lipid-binding,KW-0479~Metal-binding,KW-0754~Steroid-binding,KW-0862~Zinc,	KW-0156~Chromatin regulator,KW-0238~DNA-binding,KW-0675~Receptor,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DNA_BIND:Nuclear receptor,DOMAIN:NR LBD,DOMAIN:Nuclear receptor,MUTAGEN:D->A: Reduces activation mediated by ligand binding domain; when associated with A-585.,MUTAGEN:D->A: Reduces transcription activation activity of isoform Alpha-C3 by half.,MUTAGEN:D->K: Reduces transcription activation activity of isoform Alpha-C3 by half. Suppresses apoptosis-inducing activity of isoform Alpha-C3. Impairs recruitment of selected coregulators onto DNA binding sites.,MUTAGEN:F->D: Reduces transactivation by the ADA complex.,MUTAGEN:F->L: Strongly reduces transactivation by the ADA complex; when associated with V-236.,MUTAGEN:F->S: Increases solubility. No effect on transactivation by dexamethasone.,MUTAGEN:I->A: Decreases dimerization and transactivation by dexamethasone; when associated with S-602.,MUTAGEN:I->D: Reduces transactivation by the ADA complex.,MUTAGEN:K->A: Decrease in acetylation and in repression of its transcriptional activity by CLOCK-BMAL1 heterodimer. Complete loss in acetylation and in repression of its transcriptional activity by CLOCK-BMAL1 heterodimer; when associated with A-480; A-494 and A-495.,MUTAGEN:K->A: Decrease in acetylation and in repression of its transcriptional activity by CLOCK-BMAL1 heterodimer. Complete loss in acetylation and in repression of its transcriptional activity by CLOCK-BMAL1 heterodimer; when associated with A-492; A-494 and A-495.,MUTAGEN:K->A: Decrease in acetylation and in repression of its transcriptional activity by CLOCK-BMAL1 heterodimer; when associated with A-494. Complete loss in acetylation and in repression of its transcriptional activity by CLOCK-BMAL1 heterodimer; when associated with A-480; A-492 and A-494.,MUTAGEN:K->A: Decrease in acetylation and in repression of its transcriptional activity by CLOCK-BMAL1 heterodimer; when associated with A-495. Complete loss in acetylation and in repression of its transcriptional activity by CLOCK-BMAL1 heterodimer; when associated with A-480; A-492 and A-495.,MUTAGEN:K->R: Slightly reduces sumoylation. Inhibits the stimulatory effect of RWDD3 on its transcriptional activity.,MUTAGEN:K->R: Strongly reduces sumoylation. Almost complete loss of sumoylation; when associated with R-277.,MUTAGEN:K->R: Strongly reduces sumoylation. Almost complete loss of sumoylation; when associated with R-293.,MUTAGEN:L->A: Strongly reduces transactivation by the ADA complex; when associated with V-224 and F-225.,MUTAGEN:L->E: Reduces transactivation by the ADA complex.,MUTAGEN:L->F: Strongly reduces transactivation by the ADA complex; when associated with A-194 and V-224.,MUTAGEN:L->V: Strongly reduces transactivation by the ADA complex; when associated with A-194 and F-225.,MUTAGEN:L->V: Strongly reduces transactivation by the ADA complex; when associated with L-235.,MUTAGEN:M->I: Abolishes expression of C-type isoforms; when associated with I-86 and I-90.,MUTAGEN:M->I: Abolishes expression of C-type isoforms; when associated with I-86 and I-98.,MUTAGEN:M->I: Abolishes expression of C-type isoforms; when associated with I-90 and I-98.,MUTAGEN:M->I: Abolishes expression of D-type isoforms; when associated with I-316 and I-331.,MUTAGEN:M->I: Abolishes expression of D-type isoforms; when associated with I-316 and I-336.,MUTAGEN:M->I: Abolishes expression of D-type isoforms; when associated with I-331 and I-336.,MUTAGEN:M->T: Abolishes expression of A-type isoforms.,MUTAGEN:M->T: Abolishes expression of B-type isoforms.,MUTAGEN:P->A: Decreases transactivation by dexamethasone by 95%.,MUTAGEN:QQ->LL: Reduces activity of isoform Alpha-C3 by half.,MUTAGEN:R->A: Reduces activation mediated by ligand binding domain; when associated with A-590.,MUTAGEN:S->A: Abolishes phosphorylation and enhances transcriptional activation.,MUTAGEN:S->A: Abolishes phosphorylation. Does not affect translocation to the nucleus following ligand stimulation. Increases protein half-life and transcriptional repressor activity. Alters repertoire of regulated genes. Increases cell death.,MUTAGEN:S->A: Reduces expression of target genes IGFBP1 and IRF8.,MUTAGEN:S->D: Does not affect translocation to the nucleus following ligand stimulation.,MUTAGEN:SS->AA: Does not affect the activity of isoform Alpha-C3.,MUTAGEN:W->A: Strongly reduces transactivation by the ADA complex.,REGION:Disordered,REGION:Hinge,REGION:Interaction with CLOCK,REGION:Interaction with CRY1,REGION:Modulating,REGION:Required for high transcriptional activity of isoform Alpha-C3,ZN_FING:NR C4-type,
NFYC	nuclear transcription factor Y subunit gamma(NFYC)	Homo sapiens		h_tercPathway:Overview of telomerase RNA component gene hTerc Transcriptional Regulation,	GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006457~protein folding,GO:0035065~regulation of histone acetylation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0016602~CCAAT-binding factor complex,GO:0032993~protein-DNA complex,GO:0043229~intracellular organelle,GO:0090575~RNA polymerase II transcription factor complex,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0046982~protein heterodimerization activity,	IPR007125:Histone_H2A/H2B/H3,IPR009072:Histone-fold,	hsa04612:Antigen processing and presentation,hsa05152:Tuberculosis,				KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0010~Activator,KW-0238~DNA-binding,		COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Histone H2A/H2B/H3,REGION:Disordered,
NXT1	nuclear transport factor 2 like export factor 1(NXT1)	Homo sapiens			GO:0006406~mRNA export from nucleus,GO:0006611~protein export from nucleus,GO:0016973~poly(A)+ mRNA export from nucleus,	GO:0005634~nucleus,GO:0005643~nuclear pore,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016607~nuclear speck,GO:0042272~nuclear RNA export factor complex,GO:0044613~nuclear pore central transport channel,	GO:0005515~protein binding,GO:0031267~small GTPase binding,	IPR002075:NTF2_dom,IPR018222:Nuclear_transport_factor_2_euk,IPR032710:NTF2-like_dom_sf,IPR045875:NTF2,	hsa03008:Ribosome biogenesis in eukaryotes,hsa03013:Nucleocytoplasmic transport,hsa03015:mRNA surveillance pathway,hsa05014:Amyotrophic lateral sclerosis,hsa05164:Influenza A,				KW-0653~Protein transport,KW-0813~Transport,	KW-0539~Nucleus,KW-0963~Cytoplasm,					KW-0007~Acetylation,	DOMAIN:NTF2,MUTAGEN:I->R: 70% reduction in mRNA export activity.,MUTAGEN:R->D: 57% reduction in mRNA export activity and loss of nuclear rim staining.,
NUTF2	nuclear transport factor 2(NUTF2)	Homo sapiens		h_npcPathway:Mechanism of Protein Import into the Nucleus,	GO:0006606~protein import into nucleus,GO:0006611~protein export from nucleus,GO:0006913~nucleocytoplasmic transport,GO:0015031~protein transport,GO:0051028~mRNA transport,GO:0090204~protein localization to nuclear pore,	GO:0005634~nucleus,GO:0005637~nuclear inner membrane,GO:0005640~nuclear outer membrane,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0031965~nuclear membrane,GO:0044613~nuclear pore central transport channel,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0017056~structural constituent of nuclear pore,GO:0031267~small GTPase binding,GO:0042802~identical protein binding,GO:0061608~nuclear import signal receptor activity,	IPR002075:NTF2_dom,IPR018222:Nuclear_transport_factor_2_euk,IPR032710:NTF2-like_dom_sf,IPR045875:NTF2,					KW-0509~mRNA transport,KW-0653~Protein transport,KW-0811~Translocation,KW-0813~Transport,	KW-0472~Membrane,KW-0539~Nucleus,KW-0906~Nuclear pore complex,KW-0963~Cytoplasm,					KW-0007~Acetylation,	DOMAIN:NTF2,MUTAGEN:E->K: No effect on localization to the nucleoplasm.,MUTAGEN:Missing: No effect on localization to the nucleoplasm.,REGION:Disordered,
NABP1	nucleic acid binding protein 1(NABP1)	Homo sapiens			GO:0000724~double-strand break repair via homologous recombination,GO:0006281~DNA repair,GO:0006974~cellular response to DNA damage stimulus,GO:0007093~mitotic cell cycle checkpoint,GO:0010212~response to ionizing radiation,GO:0044818~mitotic G2/M transition checkpoint,	GO:0000781~chromosome, telomeric region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0035861~site of double-strand break,GO:0070876~SOSS complex,	GO:0003677~DNA binding,GO:0003697~single-stranded DNA binding,GO:0003723~RNA binding,GO:0005515~protein binding,	IPR012340:NA-bd_OB-fold,IPR048970:Ssb-like_OB,					KW-0227~DNA damage,KW-0234~DNA repair,	KW-0539~Nucleus,				KW-0238~DNA-binding,		COMPBIAS:Polar residues,DNA_BIND:OB,DOMAIN:Single-stranded DNA binding protein Ssb-like OB fold,REGION:Disordered,
NOLC1	nucleolar and coiled-body phosphoprotein 1(NOLC1)	Homo sapiens	1.RBphosphoE2F,158.14-3-3_signal_transduction,		GO:0000278~mitotic cell cycle,GO:0006364~rRNA processing,GO:0006417~regulation of translation,GO:0007000~nucleolus organization,GO:0007409~axonogenesis,GO:0014029~neural crest formation,GO:0014032~neural crest cell development,GO:0048167~regulation of synaptic plasticity,	GO:0001650~fibrillar center,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0015030~Cajal body,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0005525~GTP binding,GO:0030674~protein binding, bridging,GO:0046982~protein heterodimerization activity,	IPR006594:LisH,IPR007718:Srp40_C,						KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,	KW-0067~ATP-binding,KW-0342~GTP-binding,KW-0547~Nucleotide-binding,		KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:LisH,DOMAIN:Srp40 C-terminal,REGION:11 X 12 AA approximate repeats of an acidic serine cluster,REGION:Disordered,REGION:Interaction with RPA194,REPEAT:Acidic serine cluster 1,REPEAT:Acidic serine cluster 10,REPEAT:Acidic serine cluster 11,REPEAT:Acidic serine cluster 2,REPEAT:Acidic serine cluster 3,REPEAT:Acidic serine cluster 4,REPEAT:Acidic serine cluster 5,REPEAT:Acidic serine cluster 6,REPEAT:Acidic serine cluster 7,REPEAT:Acidic serine cluster 8,REPEAT:Acidic serine cluster 9,
NIFK	nucleolar protein interacting with the FHA domain of MKI67(NIFK)	Homo sapiens			GO:0000463~maturation of LSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA),GO:0009303~rRNA transcription,GO:0016072~rRNA metabolic process,GO:0065003~macromolecular complex assembly,	GO:0000794~condensed nuclear chromosome,GO:0005654~nucleoplasm,GO:0005694~chromosome,GO:0005730~nucleolus,GO:0005737~cytoplasm,	GO:0003723~RNA binding,GO:0005515~protein binding,	IPR000504:RRM_dom,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR021043:NIFK_FHA_Ki67-binding,IPR035979:RBD_domain_sf,				SM00360:RRM,		KW-0158~Chromosome,KW-0539~Nucleus,				KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:MKI67 FHA,DOMAIN:RRM,MUTAGEN:P->A: Reduces phosphorylation at T-234 and T-238.,MUTAGEN:P->A: Reduces phosphorylation at T-234.,MUTAGEN:S->A: Loss of phosphorylation site.,MUTAGEN:T->A: Loss of phosphorylation site. Abrogates interaction with MKI67.,REGION:Disordered,REGION:Interaction with MKI67,
NCL	nucleolin(NCL)	Homo sapiens		h_SARSpathway:SARS Coronavirus Protease,	GO:0001525~angiogenesis,GO:0017148~negative regulation of translation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046627~negative regulation of insulin receptor signaling pathway,GO:0048026~positive regulation of mRNA splicing, via spliceosome,GO:0050730~regulation of peptidyl-tyrosine phosphorylation,GO:0071364~cellular response to epidermal growth factor stimulus,GO:1901838~positive regulation of transcription of nuclear large rRNA transcript from RNA polymerase I promoter,GO:1990830~cellular response to leukemia inhibitory factor,	GO:0001533~cornified envelope,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005681~spliceosomal complex,GO:0005694~chromosome,GO:0005730~nucleolus,GO:0005938~cell cortex,GO:0016020~membrane,GO:0036464~cytoplasmic ribonucleoprotein granule,GO:0070062~extracellular exosome,GO:1990904~ribonucleoprotein complex,	GO:0003677~DNA binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0042162~telomeric DNA binding,GO:0042731~PH domain binding,GO:0042802~identical protein binding,GO:0043560~insulin receptor substrate binding,GO:0044547~DNA topoisomerase binding,GO:0048027~mRNA 5'-UTR binding,	IPR000504:RRM_dom,IPR003954:RRM_dom_euk,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR034230:Nucleolin_RRM1,IPR034233:Nucleolin_RRM2,IPR034234:Nucleolin_RRM3,IPR034235:Nucleolin_RRM4,IPR035979:RBD_domain_sf,	hsa05130:Pathogenic Escherichia coli infection,			SM00360:RRM,SM00361:RRM_1,		KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,		KW-0238~DNA-binding,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:RRM,DOMAIN:RRM 1,DOMAIN:RRM 2,DOMAIN:RRM 3,DOMAIN:RRM 4,REGION:8 X 8 AA tandem repeats of X-T-P-X-K-K-X-X,REGION:Disordered,REPEAT:1,REPEAT:2,REPEAT:3,REPEAT:4,REPEAT:5; truncated,REPEAT:6,REPEAT:7,REPEAT:8,
NPM1	nucleophosmin 1(NPM1)	Homo sapiens			GO:0000054~ribosomal subunit export from nucleus,GO:0000055~ribosomal large subunit export from nucleus,GO:0000056~ribosomal small subunit export from nucleus,GO:0001558~regulation of cell growth,GO:0006281~DNA repair,GO:0006334~nucleosome assembly,GO:0006338~chromatin remodeling,GO:0006407~rRNA export from nucleus,GO:0006884~cell volume homeostasis,GO:0006886~intracellular protein transport,GO:0006913~nucleocytoplasmic transport,GO:0007098~centrosome cycle,GO:0007165~signal transduction,GO:0008104~protein localization,GO:0008284~positive regulation of cell proliferation,GO:0008285~negative regulation of cell proliferation,GO:0010608~posttranscriptional regulation of gene expression,GO:0010824~regulation of centrosome duplication,GO:0010825~positive regulation of centrosome duplication,GO:0010826~negative regulation of centrosome duplication,GO:0031398~positive regulation of protein ubiquitination,GO:0032071~regulation of endodeoxyribonuclease activity,GO:0034644~cellular response to UV,GO:0042255~ribosome assembly,GO:0042273~ribosomal large subunit biogenesis,GO:0042274~ribosomal small subunit biogenesis,GO:0043066~negative regulation of apoptotic process,GO:0043516~regulation of DNA damage response, signal transduction by p53 class mediator,GO:0044387~negative regulation of protein kinase activity by regulation of protein phosphorylation,GO:0045727~positive regulation of translation,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046599~regulation of centriole replication,GO:0048025~negative regulation of mRNA splicing, via spliceosome,GO:0050821~protein stabilization,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0060699~regulation of endoribonuclease activity,GO:0060735~regulation of eIF2 alpha phosphorylation by dsRNA,GO:0090398~cellular senescence,GO:1902629~regulation of mRNA stability involved in cellular response to UV,GO:1902751~positive regulation of cell cycle G2/M phase transition,GO:1904751~positive regulation of protein localization to nucleolus,	GO:0001652~granular component,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005829~cytosol,GO:0005925~focal adhesion,GO:0015934~large ribosomal subunit,GO:0015935~small ribosomal subunit,GO:0016020~membrane,GO:0016607~nuclear speck,GO:0031616~spindle pole centrosome,GO:0032991~macromolecular complex,GO:0032993~protein-DNA complex,GO:1990904~ribonucleoprotein complex,	GO:0001046~core promoter sequence-specific DNA binding,GO:0003676~nucleic acid binding,GO:0003682~chromatin binding,GO:0003713~transcription coactivator activity,GO:0003723~RNA binding,GO:0004860~protein kinase inhibitor activity,GO:0005515~protein binding,GO:0019843~rRNA binding,GO:0019901~protein kinase binding,GO:0030957~Tat protein binding,GO:0042393~histone binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0043023~ribosomal large subunit binding,GO:0043024~ribosomal small subunit binding,GO:0051059~NF-kappaB binding,GO:0051082~unfolded protein binding,	IPR004301:Nucleoplasmin,IPR024057:Nucleoplasmin_core_dom,IPR032569:NPM1_C,IPR036824:Nucleoplasmin_core_dom_sf,		601626~Leukemia, acute myeloid, somatic,			KW-0945~Host-virus interaction,	KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0656~Proto-oncogene,			KW-0143~Chaperone,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0013~ADP-ribosylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:Nucleophosmin C-terminal,DOMAIN:Nucleoplasmin core,MOTIF:Nuclear localization signal,MUTAGEN:F->A: Complete destabilization of the structure and loss of nucleolus localization; when associated with A-268.,MUTAGEN:F->A: Complete destabilization of the structure and loss of nucleolus localization; when associated with A-276.,MUTAGEN:K->A: Increase in the stabilization of the structure and complete delocalization to the nucleoplasm. Complete delocalization to the nucleoplasm; when associated with A-263.,MUTAGEN:K->A: Increase in the stabilization of the structure and partial delocalization to the nucleoplasm. Complete delocalization to the nucleoplasm; when associated with A-267.,MUTAGEN:K->A: Increase in the stabilization of the structure.,MUTAGEN:K->A: Partial destabilization of the structure.,MUTAGEN:K->R: No change in the sumoylation level.,MUTAGEN:S->A: Abolishes phosphorylation by PLK2 and impairs centriole duplication.,MUTAGEN:S->A: Does not affect phosphorylation by PLK2.,MUTAGEN:S->D,E: Mimicks phosphorylation state, inducing accumulation of centrioles.,MUTAGEN:T->A: Does not affect phosphorylation by PLK2.,MUTAGEN:T->A: Partial loss of phosphorylation.,MUTAGEN:T->A: Partial loss of phosphorylation. Does not affect phosphorylation by PLK2.,MUTAGEN:T->A: Partial loss of phosphorylation; when associated with A-237.,MUTAGEN:W->A: Complete destabilization of the structure; when associated with A-290.,MUTAGEN:W->A: Partial destabilization of the structure. Complete destabilization of the structure; when associated with A-288.,REGION:Disordered,REGION:Necessary for interaction with APEX1,REGION:Required for interaction with SENP3,REGION:Required for nucleolar localization,SITE:Breakpoint for translocation to form NPM1-MLF1,SITE:Interaction between pentamers,
NUP62	nucleoporin 62(NUP62)	Homo sapiens		h_npcPathway:Mechanism of Protein Import into the Nucleus,	GO:0006405~RNA export from nucleus,GO:0006606~protein import into nucleus,GO:0006913~nucleocytoplasmic transport,GO:0007080~mitotic metaphase plate congression,GO:0007098~centrosome cycle,GO:0007100~mitotic centrosome separation,GO:0007166~cell surface receptor signaling pathway,GO:0008285~negative regulation of cell proliferation,GO:0009966~regulation of signal transduction,GO:0015031~protein transport,GO:0042059~negative regulation of epidermal growth factor receptor signaling pathway,GO:0043066~negative regulation of apoptotic process,GO:0043069~negative regulation of programmed cell death,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0045742~positive regulation of epidermal growth factor receptor signaling pathway,GO:0045840~positive regulation of mitotic nuclear division,GO:0045893~positive regulation of transcription, DNA-templated,GO:0046578~regulation of Ras protein signal transduction,GO:0046580~negative regulation of Ras protein signal transduction,GO:0046601~positive regulation of centriole replication,GO:0051028~mRNA transport,GO:0060236~regulation of mitotic spindle organization,GO:0090398~cellular senescence,GO:0098534~centriole assembly,GO:1903438~positive regulation of mitotic cytokinetic process,GO:1904781~positive regulation of protein localization to centrosome,	GO:0000922~spindle pole,GO:0005635~nuclear envelope,GO:0005643~nuclear pore,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0031965~nuclear membrane,GO:0044613~nuclear pore central transport channel,GO:0072686~mitotic spindle,GO:0090543~Flemming body,GO:1990904~ribonucleoprotein complex,	GO:0003682~chromatin binding,GO:0005515~protein binding,GO:0005543~phospholipid binding,GO:0017056~structural constituent of nuclear pore,GO:0030159~receptor signaling complex scaffold activity,GO:0030544~Hsp70 protein binding,GO:0042169~SH2 domain binding,GO:0043130~ubiquitin binding,GO:0051425~PTB domain binding,GO:0051879~Hsp90 protein binding,	IPR007758:Nucleoporin_NSP1_C,IPR026010:NSP1/NUP62,	hsa03013:Nucleocytoplasmic transport,hsa05014:Amyotrophic lateral sclerosis,	271930~Striatonigral degeneration, infantile,			KW-0509~mRNA transport,KW-0653~Protein transport,KW-0811~Translocation,KW-0813~Transport,KW-0945~Host-virus interaction,	KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0906~Nuclear pore complex,KW-0963~Cytoplasm,	KW-0225~Disease variant,	KW-0175~Coiled coil,KW-0677~Repeat,			KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:O-linked (GlcNAc) serine,CARBOHYD:O-linked (GlcNAc) threonine,COMPBIAS:Polar residues,DISULFID:Interchain (with NUP155),DOMAIN:Nucleoporin NSP1-like C-terminal,REGION:5 X 2 AA repeats of F-G,REGION:Disordered,REGION:Required for centrosome localization,REPEAT:1,REPEAT:2,REPEAT:3,REPEAT:4,REPEAT:5,
NAP1L1	nucleosome assembly protein 1 like 1(NAP1L1)	Homo sapiens			GO:0006260~DNA replication,GO:0006334~nucleosome assembly,GO:0007399~nervous system development,GO:0008284~positive regulation of cell proliferation,GO:0050769~positive regulation of neurogenesis,GO:2000179~positive regulation of neural precursor cell proliferation,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0016020~membrane,GO:0042470~melanosome,	GO:0003682~chromatin binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0042393~histone binding,	IPR002164:NAP_family,IPR037231:NAP-like_sf,					KW-0524~Neurogenesis,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0449~Lipoprotein,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0636~Prenylation,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,LIPID:S-farnesyl cysteine,MOTIF:NAP1L motif,MOTIF:Nuclear localization signal,MUTAGEN:E->A: Impaired binding to histones and ability to mediate histone chaperone activity.,MUTAGEN:W->A: Impaired binding to histones and ability to mediate histone chaperone activity.,PROPEP:Removed in mature form,REGION:Disordered,
NAP1L4	nucleosome assembly protein 1 like 4(NAP1L4)	Homo sapiens			GO:0006334~nucleosome assembly,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005737~cytoplasm,	GO:0003682~chromatin binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0031491~nucleosome binding,GO:0042393~histone binding,GO:0051082~unfolded protein binding,	IPR002164:NAP_family,IPR024309:NUT_N,IPR024310:NUT,IPR037231:NAP-like_sf,						KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0143~Chaperone,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Nuclear Testis protein N-terminal,MOTIF:Nuclear localization signal,REGION:Disordered,
NDEL1	nudE neurodevelopment protein 1 like 1(NDEL1)	Homo sapiens		h_Lis1Pathway:Lissencephaly gene (LIS1) in neuronal migration and development,	GO:0000132~establishment of mitotic spindle orientation,GO:0001833~inner cell mass cell proliferation,GO:0007020~microtubule nucleation,GO:0007059~chromosome segregation,GO:0007100~mitotic centrosome separation,GO:0008090~retrograde axonal transport,GO:0008286~insulin receptor signaling pathway,GO:0010975~regulation of neuron projection development,GO:0016477~cell migration,GO:0021799~cerebral cortex radially oriented cell migration,GO:0021955~central nervous system neuron axonogenesis,GO:0030154~cell differentiation,GO:0032418~lysosome localization,GO:0033157~regulation of intracellular protein transport,GO:0043547~positive regulation of GTPase activity,GO:0047496~vesicle transport along microtubule,GO:0051303~establishment of chromosome localization,GO:0051642~centrosome localization,GO:0060052~neurofilament cytoskeleton organization,GO:1900029~positive regulation of ruffle assembly,GO:1990138~neuron projection extension,	GO:0000776~kinetochore,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005819~spindle,GO:0005829~cytosol,GO:0005871~kinesin complex,GO:0005874~microtubule,GO:0008021~synaptic vesicle,GO:0031252~cell leading edge,GO:0043203~axon hillock,GO:0060053~neurofilament cytoskeleton,GO:1904115~axon cytoplasm,	GO:0005515~protein binding,GO:0008017~microtubule binding,GO:0042802~identical protein binding,GO:0043014~alpha-tubulin binding,GO:0048487~beta-tubulin binding,	IPR006964:NUDE_dom,IPR033494:NUDE,					KW-0221~Differentiation,KW-0524~Neurogenesis,KW-0813~Transport,	KW-0137~Centromere,KW-0158~Chromosome,KW-0206~Cytoskeleton,KW-0493~Microtubule,KW-0963~Cytoplasm,KW-0995~Kinetochore,		KW-0175~Coiled coil,		KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:NUDE,LIPID:S-palmitoyl cysteine; by ZDHHC2, ZDHHC3 and ZDHHC7,MUTAGEN:C->A: Abolishes oligopeptidase activity.,MUTAGEN:E->A: Abolishes interaction with DISC1; when associated with A-266.,MUTAGEN:L->A: Abolishes interaction with DISC1; when associated with A-267.,MUTAGEN:S->A: Abrogates mitotic phosphorylation; when associated with A-198; V-219; A-231 and V-245.,MUTAGEN:S->A: Abrogates mitotic phosphorylation; when associated with A-198; V-219; A-242 and V-245. Abrogates phosphorylation by CDK5; when associated with A-198 and A-219.,MUTAGEN:S->A: Abrogates mitotic phosphorylation; when associated with V-219; A-231; A-242 and V-245. Abrogates phosphorylation by CDK5; when associated with A-219 and A-231.,MUTAGEN:S->E: Enhances interaction with PAFAH1B1 and impairs centrosomal localization; when associated with E-198; E-219; E-231 and E-245.,MUTAGEN:S->E: Enhances interaction with PAFAH1B1 and impairs centrosomal localization; when associated with E-198; E-219; E-242 and E-245.,MUTAGEN:S->E: Enhances interaction with PAFAH1B1 and impairs centrosomal localization; when associated with E-219; E-231; E-242 and E-245.,MUTAGEN:T->A: Abrogates phosphorylation by CDK5; when associated with A-198 and A-231.,MUTAGEN:T->E: Enhances interaction with PAFAH1B1 and impairs centrosomal localization; when associated with E-198; E-219; E-231 and E-242.,MUTAGEN:T->E: Enhances interaction with PAFAH1B1 and impairs centrosomal localization; when associated with E-198; E-231; E-242 and E-245.,MUTAGEN:T->V: Abrogates mitotic phosphorylation; when associated with A-198; A-231; A-242 and V-245.,MUTAGEN:T->V: Abrogates mitotic phosphorylation; when associated with A-198; V-219; A-231 and A-242.,REGION:Disordered,REGION:Interaction with CENPF,REGION:Interaction with DISC1,REGION:Interaction with KATNA1,REGION:Interaction with KATNB1,REGION:Interaction with NEFL,REGION:Interaction with YWHAE,REGION:Required for interaction with PAFAH1B1,REGION:Required for localization to the centrosome and interaction with dynein, dynactin, tubulin gamma, PCM1 and PCNT,REGION:Self-association,
NDE1	nudE neurodevelopment protein 1(NDE1)	Homo sapiens			GO:0000132~establishment of mitotic spindle orientation,GO:0001764~neuron migration,GO:0007020~microtubule nucleation,GO:0007059~chromosome segregation,GO:0007100~mitotic centrosome separation,GO:0007405~neuroblast proliferation,GO:0016477~cell migration,GO:0021987~cerebral cortex development,GO:0030154~cell differentiation,GO:0047496~vesicle transport along microtubule,GO:0051298~centrosome duplication,GO:0051301~cell division,GO:0051303~establishment of chromosome localization,GO:0051642~centrosome localization,	GO:0000776~kinetochore,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005819~spindle,GO:0005829~cytosol,GO:0005871~kinesin complex,GO:0005874~microtubule,GO:0016020~membrane,GO:0031616~spindle pole centrosome,GO:0032154~cleavage furrow,GO:0045202~synapse,	GO:0005515~protein binding,GO:0008017~microtubule binding,GO:0042802~identical protein binding,	IPR006964:NUDE_dom,IPR033494:NUDE,		605013~Microhydranencephaly,614019~Lissencephaly 4 (with microcephaly),			KW-0131~Cell cycle,KW-0132~Cell division,KW-0221~Differentiation,KW-0498~Mitosis,KW-0524~Neurogenesis,	KW-0137~Centromere,KW-0158~Chromosome,KW-0206~Cytoskeleton,KW-0493~Microtubule,KW-0963~Cytoplasm,KW-0995~Kinetochore,	KW-0451~Lissencephaly,	KW-0175~Coiled coil,		KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:NUDE,LIPID:S-palmitoyl cysteine; by ZDHHC2, ZDHHC3 and ZDHHC7,MUTAGEN:S->A: Retained on spindle poles during mitosis, no loss of phosphorylation in vivo and increased ZNF365-binding; when associated with V-191; V-215; V-228; V-243 and V-246.,MUTAGEN:S->E: Loss of centrosomal localization and reduced ZNF365-binding; when associated with E-191; E-215; E-228; E-243 and E-246.,MUTAGEN:T->E: Loss of centrosomal localization and reduced ZNF365-binding; when associated with E-191; E-215; E-228; E-243 and E-282.,MUTAGEN:T->E: Loss of centrosomal localization and reduced ZNF365-binding; when associated with E-191; E-215; E-228; E-246 and E-282.,MUTAGEN:T->E: Loss of centrosomal localization and reduced ZNF365-binding; when associated with E-191; E-215; E-243; E-246 and E-282.,MUTAGEN:T->E: Loss of centrosomal localization and reduced ZNF365-binding; when associated with E-191; E-228; E-243; E-246 and E-282.,MUTAGEN:T->E: Loss of centrosomal localization and reduced ZNF365-binding; when associated with E-215; E-228; E-243; E-246 and E-282.,MUTAGEN:T->V: Retained on spindle poles during mitosis, no loss of phosphorylation in vivo and increased ZNF365-binding; when associated with V-191; V-215; V-228; V-243 and A-282.,MUTAGEN:T->V: Retained on spindle poles during mitosis, no loss of phosphorylation in vivo and increased ZNF365-binding; when associated with V-191; V-215; V-228; V-246 and A-282.,MUTAGEN:T->V: Retained on spindle poles during mitosis, no loss of phosphorylation in vivo and increased ZNF365-binding; when associated with V-191; V-215; V-243; V-246 and A-282.,MUTAGEN:T->V: Retained on spindle poles during mitosis, no loss of phosphorylation in vivo and increased ZNF365-binding; when associated with V-191; V-228; V-243; V-246 and A-282.,MUTAGEN:T->V: Retained on spindle poles during mitosis, no loss of phosphorylation in vivo and increased ZNF365-binding; when associated with V-215; V-228; V-243; V-246 and A-282.,REGION:Disordered,REGION:Interaction with CENPF,REGION:Interaction with PAFAH1B1,REGION:Self-association,
NUDT21	nudix hydrolase 21(NUDT21)	Homo sapiens			GO:0006378~mRNA polyadenylation,GO:0006397~mRNA processing,GO:0010608~posttranscriptional regulation of gene expression,GO:0030154~cell differentiation,GO:0031124~mRNA 3'-end processing,GO:0051262~protein tetramerization,GO:0051290~protein heterotetramerization,GO:1990120~messenger ribonucleoprotein complex assembly,GO:2000738~positive regulation of stem cell differentiation,GO:2000975~positive regulation of pro-B cell differentiation,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005847~mRNA cleavage and polyadenylation specificity factor complex,GO:0005849~mRNA cleavage factor complex,GO:0016604~nuclear body,GO:0034451~centriolar satellite,GO:0042382~paraspeckles,	GO:0003682~chromatin binding,GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0005515~protein binding,GO:0035925~mRNA 3'-UTR AU-rich region binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0042826~histone deacetylase binding,	IPR000086:NUDIX_hydrolase_dom,IPR015797:NUDIX_hydrolase-like_dom_sf,IPR016706:Cleav_polyA_spec_factor_su5,	hsa03015:mRNA surveillance pathway,		PIRSF017888:CPSF-25,		KW-0221~Differentiation,KW-0507~mRNA processing,	KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	DOMAIN:Nudix hydrolase,MOTIF:Nudix box,MUTAGEN:E->A: Reduces affinity for UGUA RNA by 12%.,MUTAGEN:E->A: Reduces affinity for UGUA RNA by 50%.,MUTAGEN:E->A: Reduces affinity for UGUA RNA by 88%.,MUTAGEN:F->A: Reduces affinity for UGUA RNA by 99%.,MUTAGEN:F->W: Reduces affinity for UGUA RNA by over 90%.,MUTAGEN:K->R: Abolishes acetylation.,MUTAGEN:K->R: No effect on acetylation.,MUTAGEN:L->R: Reduces interactions with CPSF6 and CPSF7 and decreases mRNA 3'-processing activity.,MUTAGEN:R->S: Reduces affinity for UGUA RNA by 99%.,MUTAGEN:Y->A: Abolishes interaction with CPSF6; when associated with A-158.,MUTAGEN:Y->A: Abolishes interaction with CPSF6; when associated with A-160.,REGION:Interaction with RNA,REGION:Necessary for RNA-binding,REGION:Necessary for interactions with PAPOLA and PABPN1,SITE:Interaction with RNA,
NUDT4	nudix hydrolase 4(NUDT4)	Homo sapiens			GO:0019722~calcium-mediated signaling,GO:0019935~cyclic-nucleotide-mediated signaling,GO:0035556~intracellular signal transduction,GO:0071543~diphosphoinositol polyphosphate metabolic process,GO:1901907~diadenosine pentaphosphate catabolic process,GO:1901909~diadenosine hexaphosphate catabolic process,GO:1901911~adenosine 5'-(hexahydrogen pentaphosphate) catabolic process,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0000298~endopolyphosphatase activity,GO:0005515~protein binding,GO:0008486~diphosphoinositol-polyphosphate diphosphatase activity,GO:0016462~pyrophosphatase activity,GO:0030515~snoRNA binding,GO:0034431~bis(5'-adenosyl)-hexaphosphatase activity,GO:0034432~bis(5'-adenosyl)-pentaphosphatase activity,GO:0046872~metal ion binding,GO:0052845~inositol-5-diphosphate-1,2,3,4,6-pentakisphosphate diphosphatase activity,GO:0052848~inositol-3,5-bisdiphosphate-2,3,4,6-tetrakisphosphate 5-diphosphatase activity,	IPR000086:NUDIX_hydrolase_dom,IPR015797:NUDIX_hydrolase-like_dom_sf,IPR020084:NUDIX_hydrolase_CS,IPR047198:DDP-like_NUDIX,						KW-0963~Cytoplasm,			KW-0460~Magnesium,KW-0464~Manganese,KW-0479~Metal-binding,	KW-0378~Hydrolase,KW-0694~RNA-binding,	KW-0007~Acetylation,	ACT_SITE:Proton acceptor,DOMAIN:Nudix hydrolase,MOTIF:Nudix box,
NUDT5	nudix hydrolase 5(NUDT5)	Homo sapiens			GO:0006338~chromatin remodeling,GO:0006753~nucleoside phosphate metabolic process,GO:0009117~nucleotide metabolic process,GO:0009191~ribonucleoside diphosphate catabolic process,GO:0019303~D-ribose catabolic process,GO:0019693~ribose phosphate metabolic process,GO:0055086~nucleobase-containing small molecule metabolic process,GO:1990966~ATP generation from poly-ADP-D-ribose,	GO:0005634~nucleus,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0000287~magnesium ion binding,GO:0005515~protein binding,GO:0016779~nucleotidyltransferase activity,GO:0016787~hydrolase activity,GO:0019144~ADP-sugar diphosphatase activity,GO:0030515~snoRNA binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0044715~8-oxo-dGDP phosphatase activity,GO:0044716~8-oxo-GDP phosphatase activity,GO:0047631~ADP-ribose diphosphatase activity,	IPR000086:NUDIX_hydrolase_dom,IPR015797:NUDIX_hydrolase-like_dom_sf,IPR020084:NUDIX_hydrolase_CS,IPR020476:Nudix_hydrolase,	hsa00230:Purine metabolism,hsa01100:Metabolic pathways,					KW-0539~Nucleus,			KW-0460~Magnesium,KW-0479~Metal-binding,	KW-0378~Hydrolase,KW-0694~RNA-binding,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	BINDING:in other chain,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Nudix hydrolase,MOTIF:Nudix box,MUTAGEN:E->Q: Catalytic inactive mutant for both ADP-sugar pyrophosphatase and nuclear ATP-synthesis activities. Reduces catalytic rate 6300-fold.,MUTAGEN:E->Q: Reduces catalytic rate 120-fold.,MUTAGEN:E->Q: Reduces catalytic rate 2000-fold.,MUTAGEN:L->A: Reduces affinity for substrate about 6-fold.,MUTAGEN:R->Q: Reduces affinity for substrate about 15-fold and reduces catalytic rate about 17-fold.,MUTAGEN:R->Q: Reduces affinity for substrate about 5-fold and reduces catalytic rate 67-fold.,MUTAGEN:T->A: Impaired phosphorylation; generates ATP in the presence of diphosphate.,MUTAGEN:T->D: Phosphomimetic mutant; unable to generate ATP in the presence of diphosphate.,MUTAGEN:W->A: Reduces affinity for substrate about 6-fold. Strongly reduced catalytic activity and strongly reduced affinity for substrate; when associated with A-28.,MUTAGEN:W->A: Reduces affinity for substrate about 8-fold. Strongly reduced catalytic activity and strongly reduced affinity for substrate; when associated with A-46.,
OGFR	opioid growth factor receptor(OGFR)	Homo sapiens			GO:0001558~regulation of cell growth,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0016020~membrane,	GO:0005515~protein binding,	IPR006757:OGF_rcpt,IPR006770:OGF_rcpt_rpt,IPR039574:OGFr,					KW-0341~Growth regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,		KW-0675~Receptor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Pro residues,DOMAIN:Opioid growth factor receptor (OGFr) conserved,MOTIF:Bipartite nuclear localization signal,REGION:7 X 20 AA approximate tandem repeats of [ST]-P-S-E-T-P-G-P-[SR]-P-A-G-P-[AT]-[GR]-D-E-P-A-[EK],REGION:Disordered,REPEAT:1,REPEAT:2,REPEAT:3,REPEAT:4,REPEAT:5,REPEAT:6,REPEAT:7,
OPTN	optineurin(OPTN)	Homo sapiens			GO:0001920~negative regulation of receptor recycling,GO:0006914~autophagy,GO:0007030~Golgi organization,GO:0007165~signal transduction,GO:0008219~cell death,GO:0010508~positive regulation of autophagy,GO:0034067~protein localization to Golgi apparatus,GO:0034620~cellular response to unfolded protein,GO:0043001~Golgi to plasma membrane protein transport,GO:0043122~regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043124~negative regulation of I-kappaB kinase/NF-kappaB signaling,GO:0045087~innate immune response,GO:0050829~defense response to Gram-negative bacterium,GO:0061734~parkin-mediated stimulation of mitophagy in response to mitochondrial depolarization,GO:0090161~Golgi ribbon formation,GO:1904417~positive regulation of xenophagy,	GO:0000139~Golgi membrane,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005776~autophagosome,GO:0005794~Golgi apparatus,GO:0005802~trans-Golgi network,GO:0005829~cytosol,GO:0048471~perinuclear region of cytoplasm,GO:0055037~recycling endosome,GO:0055038~recycling endosome membrane,	GO:0005515~protein binding,GO:0030674~protein binding, bridging,GO:0031593~polyubiquitin binding,GO:0042802~identical protein binding,GO:0046872~metal ion binding,GO:0070530~K63-linked polyubiquitin binding,	IPR021063:NEMO_N,IPR032419:CC2-LZ_dom,IPR034735:NEMO_ZF,	hsa04137:Mitophagy - animal,hsa04140:Autophagy - animal,hsa05014:Amyotrophic lateral sclerosis,hsa05022:Pathways of neurodegeneration - multiple diseases,	137760~Glaucoma 1, open angle, E,606657~Glaucoma, normal tension, susceptibility to,613435~Amyotrophic lateral sclerosis 12 with or without frontotemporal dementia,			KW-0072~Autophagy,KW-0391~Immunity,KW-0399~Innate immunity,KW-0945~Host-virus interaction,	KW-0333~Golgi apparatus,KW-0963~Cytoplasm,KW-0967~Endosome,KW-0968~Cytoplasmic vesicle,	KW-0036~Amyotrophic lateral sclerosis,KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0955~Glaucoma,	KW-0175~Coiled coil,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:CCHC NOA-type,DOMAIN:NF-kappa-B essential modulator NEMO N-terminal,MOTIF:LIR,MOTIF:UBAN,MUTAGEN:D->N: No effect on retinal ganglion cell death, drastically decreased interaction with TFRC, loss of localization to recycling endosomes, loss of ubiquitin-binding; when associated with K-50.,MUTAGEN:D->N: Significant reduction in ubiquitin binding, decreased interaction with TBK1, loss of localization to recycling endosomes, disruption of interaction with TFRC, loss of inhibition of IFNB activation in response to TLR3 or RIG-I signaling, no effect on retinal ganglion cell death.,MUTAGEN:DF->NA: Abolishes colocalization with cytosolic Salmonella.,MUTAGEN:E->K: No effect on retinal ganglion cell death, decreased interaction with TFRC, loss of localization to recycling endosomes, loss of ubiquitin-binding; when associated with N-474.,MUTAGEN:F->A: Abolishes interaction with MAP1LC3A and GABARAPL1, no effect on binding to linear ubiquitin.,MUTAGEN:F->W: Increases interaction with MAP1LC3B.,REGION:Disordered,REGION:Interaction with HD,REGION:Interaction with MYO6,REGION:Interaction with Rab8,ZN_FING:CCHC NOA-type,
OAT	ornithine aminotransferase(OAT)	Homo sapiens		h_argininecPathway:Catabolic Pathways for Arginine , Histidine, Glutamate, Glutamine, and Proline,	GO:0007601~visual perception,GO:0010121~arginine catabolic process to proline via ornithine,GO:0019544~arginine catabolic process to glutamate,GO:0055129~L-proline biosynthetic process,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,	GO:0004587~ornithine-oxo-acid transaminase activity,GO:0005515~protein binding,GO:0030170~pyridoxal phosphate binding,GO:0042802~identical protein binding,	IPR005814:Aminotrans_3,IPR010164:Orn_aminotrans,IPR015421:PyrdxlP-dep_Trfase_major,IPR015422:PyrdxlP-dep_Trfase_small,IPR015424:PyrdxlP-dep_Trfase,	hsa00330:Arginine and proline metabolism,hsa01100:Metabolic pathways,	258870~Gyrate atrophy of choroid and retina with or without ornithinemia,	PIRSF000521:Transaminase_4ab_Lys_Orn,			KW-0496~Mitochondrion,	KW-0225~Disease variant,	KW-0809~Transit peptide,	KW-0663~Pyridoxal phosphate,	KW-0032~Aminotransferase,KW-0808~Transferase,	KW-0007~Acetylation,	TRANSIT:Mitochondrion; in hepatic form,TRANSIT:Mitochondrion; in renal form,
ODC1	ornithine decarboxylase 1(ODC1)	Homo sapiens	61.Myc_network,		GO:0001822~kidney development,GO:0006595~polyamine metabolic process,GO:0006596~polyamine biosynthetic process,GO:0008283~cell proliferation,GO:0008284~positive regulation of cell proliferation,GO:0009615~response to virus,GO:0033387~putrescine biosynthetic process from ornithine,GO:0042176~regulation of protein catabolic process,	GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0003824~catalytic activity,GO:0004586~ornithine decarboxylase activity,GO:0005515~protein binding,GO:0042803~protein homodimerization activity,	IPR000183:Orn/DAP/Arg_de-COase,IPR002433:Orn_de-COase,IPR009006:Ala_racemase/Decarboxylase_C,IPR022643:De-COase2_C,IPR022644:De-COase2_N,IPR022653:De-COase2_pyr-phos_BS,IPR022657:De-COase2_CS,IPR029066:PLP-binding_barrel,	hsa00330:Arginine and proline metabolism,hsa00480:Glutathione metabolism,hsa01100:Metabolic pathways,hsa04148:Efferocytosis,	619075~Bachmann-Bupp syndrome,			KW-0620~Polyamine biosynthesis,		KW-0225~Disease variant,KW-1063~Hypotrichosis,		KW-0663~Pyridoxal phosphate,	KW-0210~Decarboxylase,KW-0456~Lyase,	KW-0597~Phosphoprotein,KW-0702~S-nitrosylation,	ACT_SITE:Proton donor; shared with dimeric partner,BINDING:in other chain,DOMAIN:Orn/DAP/Arg decarboxylase 2 C-terminal,DOMAIN:Orn/DAP/Arg decarboxylase 2 N-terminal,MUTAGEN:C->A: 25% decrease of in vitro nitrosylation level.,SITE:Stacks against the aromatic ring of pyridoxal phosphate and stabilizes reaction intermediates,
OAZ1	ornithine decarboxylase antizyme 1(OAZ1)	Homo sapiens			GO:0006596~polyamine biosynthetic process,GO:0045732~positive regulation of protein catabolic process,GO:0090316~positive regulation of intracellular protein transport,GO:1902268~negative regulation of polyamine transmembrane transport,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0005515~protein binding,GO:0008073~ornithine decarboxylase inhibitor activity,	IPR002993:ODC_AZ,IPR016181:Acyl_CoA_acyltransferase,IPR038581:ODC_AZ_sf,					KW-0620~Polyamine biosynthesis,KW-0813~Transport,							COMPBIAS:Polar residues,REGION:Disordered,
OSTF1	osteoclast stimulating factor 1(OSTF1)	Homo sapiens			GO:0001503~ossification,GO:0007165~signal transduction,	GO:0005576~extracellular region,GO:0034774~secretory granule lumen,GO:1904813~ficolin-1-rich granule lumen,	GO:0005515~protein binding,GO:0017124~SH3 domain binding,	IPR001452:SH3_domain,IPR002110:Ankyrin_rpt,IPR036028:SH3-like_dom_sf,IPR036770:Ankyrin_rpt-contain_sf,				SM00248:ANK,SM00326:SH3,		KW-0963~Cytoplasm,		KW-0040~ANK repeat,KW-0677~Repeat,KW-0728~SH3 domain,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:SH3,REPEAT:ANK,REPEAT:ANK 1,REPEAT:ANK 2,REPEAT:ANK 3,
OXSR1	oxidative stress responsive kinase 1(OXSR1)	Homo sapiens			GO:0006468~protein phosphorylation,GO:0006884~cell volume homeostasis,GO:0006979~response to oxidative stress,GO:0007165~signal transduction,GO:0007231~osmosensory signaling pathway,GO:0009410~response to xenobiotic stimulus,GO:0010820~positive regulation of T cell chemotaxis,GO:0016310~phosphorylation,GO:0018107~peptidyl-threonine phosphorylation,GO:0035556~intracellular signal transduction,GO:0038116~chemokine (C-C motif) ligand 21 signaling pathway,GO:0038146~chemokine (C-X-C motif) ligand 12 signaling pathway,GO:0046777~protein autophosphorylation,GO:0070294~renal sodium ion absorption,GO:0071474~cellular hyperosmotic response,GO:0071476~cellular hypotonic response,GO:1901017~negative regulation of potassium ion transmembrane transporter activity,GO:1901380~negative regulation of potassium ion transmembrane transport,GO:1990869~cellular response to chemokine,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0000287~magnesium ion binding,GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0019901~protein kinase binding,GO:0042802~identical protein binding,	IPR000719:Prot_kinase_dom,IPR011009:Kinase-like_dom_sf,IPR017441:Protein_kinase_ATP_BS,IPR024678:Kinase_OSR1/WNK_CCT,				SM00220:S_TKc,		KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,COMPBIAS:Basic and acidic residues,DOMAIN:Protein kinase,MUTAGEN:A->L: Decreased interaction with WNK4.,MUTAGEN:D->A: Abolished interaction with SLC12A2/NKCC1 and WNK4.,MUTAGEN:D->A: Decreased interaction with WNK4.,MUTAGEN:E->A: Abolished interaction with WNK4.,MUTAGEN:E->A: Decreased interaction with WNK4.,MUTAGEN:I->A: Abolished interaction with WNK4.,MUTAGEN:K->A: Loss of autophosphorylation and kinase activity.,MUTAGEN:K->M: Loss of RELT, RELL1 and RELL2 phosphorylation. Retention of some autophosphorylation activity may be due to complex formation with other endogenous kinases in the assay.,MUTAGEN:L->A: Abolished interaction with SLC12A2/NKCC1 and WNK4.,MUTAGEN:L->F: Abolished interaction with WNK4.,MUTAGEN:N->A: Decreased interaction with WNK4.,MUTAGEN:R->A: Decreased interaction with WNK4.,MUTAGEN:S->A: Does not affect activation by WNK kinases.,MUTAGEN:S->E,D: Mimics phosphorylation; slighlty promoting kinase activity independently of WNK kinases.,MUTAGEN:T->A: Prevents phosphorylation and activation by WNK kinases.,MUTAGEN:T->E,D: Mimics phosphorylation; promoting kinase activity independently of WNK kinases.,REGION:Disordered,
OGDH	oxoglutarate dehydrogenase(OGDH)	Homo sapiens			GO:0006091~generation of precursor metabolites and energy,GO:0006096~glycolytic process,GO:0006099~tricarboxylic acid cycle,GO:0006103~2-oxoglutarate metabolic process,GO:0006104~succinyl-CoA metabolic process,GO:0021695~cerebellar cortex development,GO:0021756~striatum development,GO:0021766~hippocampus development,GO:0021794~thalamus development,GO:0021860~pyramidal neuron development,GO:0022028~tangential migration from the subventricular zone to the olfactory bulb,GO:0061034~olfactory bulb mitral cell layer development,	GO:0005634~nucleus,GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0031966~mitochondrial membrane,GO:0045252~oxoglutarate dehydrogenase complex,	GO:0004591~oxoglutarate dehydrogenase (succinyl-transferring) activity,GO:0005515~protein binding,GO:0030976~thiamine pyrophosphate binding,GO:0034602~oxoglutarate dehydrogenase (NAD+) activity,GO:0046872~metal ion binding,	IPR001017:DH_E1,IPR005475:Transketolase-like_Pyr-bd,IPR011603:2oxoglutarate_DH_E1,IPR029061:THDP-binding,IPR031717:KGD_C,IPR032106:2-oxogl_dehyd_N,IPR042179:KGD_C_sf,	hsa00020:Citrate cycle (TCA cycle),hsa00785:Lipoic acid metabolism,hsa01100:Metabolic pathways,hsa01200:Carbon metabolism,hsa01210:2-Oxocarboxylic acid metabolism,	203740~Oxoglutarate dehydrogenase deficiency,	PIRSF000157:Oxoglu_dh_E1,	SM00861:Transket_pyr,	KW-0324~Glycolysis,	KW-0496~Mitochondrion,KW-0539~Nucleus,		KW-0809~Transit peptide,	KW-0106~Calcium,KW-0479~Metal-binding,KW-0786~Thiamine pyrophosphate,	KW-0560~Oxidoreductase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:2-oxoglutarate dehydrogenase E1 component N-terminal,DOMAIN:Dehydrogenase E1 component,DOMAIN:Transketolase-like pyrimidine-binding,MUTAGEN:D->A: Six-fold decrease in sensitivity for calcium.,MUTAGEN:PY->AA: Abolished enzyme activity and ability to promote histone succinylation.,REGION:Disordered,TRANSIT:Mitochondrion,
OSBPL8	oxysterol binding protein like 8(OSBPL8)	Homo sapiens			GO:0006869~lipid transport,GO:0010891~negative regulation of sequestering of triglyceride,GO:0015914~phospholipid transport,GO:0015918~sterol transport,GO:0030336~negative regulation of cell migration,GO:0036150~phosphatidylserine acyl-chain remodeling,GO:0045444~fat cell differentiation,GO:0046326~positive regulation of glucose import,GO:0046628~positive regulation of insulin receptor signaling pathway,GO:0051897~positive regulation of protein kinase B signaling,GO:0090204~protein localization to nuclear pore,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0016020~membrane,GO:0031965~nuclear membrane,GO:0032541~cortical endoplasmic reticulum,GO:0043231~intracellular membrane-bounded organelle,	GO:0001786~phosphatidylserine binding,GO:0005515~protein binding,GO:0005548~phospholipid transporter activity,GO:0008289~lipid binding,GO:0015248~sterol transporter activity,GO:0015485~cholesterol binding,GO:0070273~phosphatidylinositol-4-phosphate binding,	IPR000648:Oxysterol-bd,IPR001849:PH_domain,IPR011993:PH-like_dom_sf,IPR018494:Oxysterol-bd_CS,IPR037239:OSBP_sf,				SM00233:PH,	KW-0445~Lipid transport,KW-0813~Transport,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0539~Nucleus,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0446~Lipid-binding,		KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,DOMAIN:PH,MUTAGEN:HH->AA: Impaired lipid countertransport between the endoplasmic reticulum and the plasma membrane.,REGION:Disordered,TRANSMEM:Helical,
PERP	p53 apoptosis effector related to PMP22(PERP)	Homo sapiens			GO:0002934~desmosome organization,GO:0007219~Notch signaling pathway,GO:0034113~heterotypic cell-cell adhesion,GO:0045862~positive regulation of proteolysis,GO:0072332~intrinsic apoptotic signaling pathway by p53 class mediator,GO:0097186~amelogenesis,GO:0097202~activation of cysteine-type endopeptidase activity,GO:0098609~cell-cell adhesion,	GO:0005739~mitochondrion,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0005911~cell-cell junction,GO:0030057~desmosome,	GO:0005515~protein binding,	IPR004031:PMP22/EMP/MP20/Claudin,IPR015664:P53_induced,	hsa04115:p53 signaling pathway,	619208~Olmsted syndrome 2,619209~Erythrokeratodermia variabilis et progressiva 7,			KW-0053~Apoptosis,KW-0130~Cell adhesion,	KW-0472~Membrane,KW-0965~Cell junction,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-1007~Palmoplantar keratoderma,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,				TRANSMEM:Helical,
PPT1	palmitoyl-protein thioesterase 1(PPT1)	Homo sapiens			GO:0002084~protein depalmitoylation,GO:0006898~receptor-mediated endocytosis,GO:0006907~pinocytosis,GO:0007042~lysosomal lumen acidification,GO:0007269~neurotransmitter secretion,GO:0007399~nervous system development,GO:0007420~brain development,GO:0007601~visual perception,GO:0007625~grooming behavior,GO:0008306~associative learning,GO:0008344~adult locomotory behavior,GO:0015031~protein transport,GO:0016042~lipid catabolic process,GO:0030149~sphingolipid catabolic process,GO:0030163~protein catabolic process,GO:0030308~negative regulation of cell growth,GO:0031579~membrane raft organization,GO:0043066~negative regulation of apoptotic process,GO:0043524~negative regulation of neuron apoptotic process,GO:0046949~fatty-acyl-CoA biosynthetic process,GO:0048260~positive regulation of receptor-mediated endocytosis,GO:0048549~positive regulation of pinocytosis,GO:0048666~neuron development,GO:0050803~regulation of synapse structure or activity,GO:0050896~response to stimulus,	GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005764~lysosome,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0008021~synaptic vesicle,GO:0016020~membrane,GO:0030424~axon,GO:0030425~dendrite,GO:0043025~neuronal cell body,GO:0043202~lysosomal lumen,GO:0043231~intracellular membrane-bounded organelle,GO:0045121~membrane raft,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0008474~palmitoyl-(protein) hydrolase activity,GO:0016290~palmitoyl-CoA hydrolase activity,GO:0035727~lysophosphatidic acid binding,GO:0052816~long-chain acyl-CoA hydrolase activity,	IPR002472:Palm_thioest,IPR029058:AB_hydrolase,	hsa00062:Fatty acid elongation,hsa01100:Metabolic pathways,hsa01212:Fatty acid metabolism,hsa04142:Lysosome,	256730~Ceroid lipofuscinosis, neuronal, 1,			KW-0716~Sensory transduction,KW-0844~Vision,	KW-0458~Lysosome,KW-0964~Secreted,	KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0525~Neuronal ceroid lipofuscinosis,	KW-0732~Signal,		KW-0378~Hydrolase,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,
PANK2	pantothenate kinase 2(PANK2)	Homo sapiens			GO:0001525~angiogenesis,GO:0007005~mitochondrion organization,GO:0007286~spermatid development,GO:0009060~aerobic respiration,GO:0015937~coenzyme A biosynthetic process,GO:0015939~pantothenate metabolic process,GO:0016310~phosphorylation,GO:0019217~regulation of fatty acid metabolic process,GO:0051881~regulation of mitochondrial membrane potential,GO:0070584~mitochondrion morphogenesis,GO:0090207~regulation of triglyceride metabolic process,GO:1904251~regulation of bile acid metabolic process,	GO:0005634~nucleus,GO:0005739~mitochondrion,GO:0005758~mitochondrial intermembrane space,GO:0005829~cytosol,GO:0016020~membrane,	GO:0004594~pantothenate kinase activity,GO:0005524~ATP binding,	IPR004567:Type_II_PanK,IPR043129:ATPase_NBD,	hsa00770:Pantothenate and CoA biosynthesis,hsa01100:Metabolic pathways,hsa01240:Biosynthesis of cofactors,	234200~Neurodegeneration with brain iron accumulation 1,607236~HARP syndrome,			KW-0037~Angiogenesis,KW-0173~Coenzyme A biosynthesis,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0523~Neurodegeneration,	KW-0732~Signal,KW-0809~Transit peptide,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,MOTIF:Nuclear export signal,MOTIF:Nucleolar localization signal,MUTAGEN:LELKDLTL->AEAKDATA: Loss of export from nucleus.,MUTAGEN:RWRNGRGGRPRAR->AWANGAGGAPAAA: Loss of nuclear localization.,REGION:Disordered,SITE:Cleavage; by MPP,TRANSIT:Mitochondrion,TRANSMEM:Helical,
PSPC1	paraspeckle component 1(PSPC1)	Homo sapiens			GO:0002218~activation of innate immune response,GO:0006355~regulation of transcription, DNA-templated,GO:0042752~regulation of circadian rhythm,GO:0045087~innate immune response,GO:0045892~negative regulation of transcription, DNA-templated,GO:0048511~rhythmic process,	GO:0001650~fibrillar center,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0016363~nuclear matrix,GO:0016607~nuclear speck,GO:0042382~paraspeckles,	GO:0003723~RNA binding,GO:0005515~protein binding,	IPR000504:RRM_dom,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR012975:NOPS,IPR034522:PSP1_RRM1,IPR034523:PSP1_RRM2,IPR035979:RBD_domain_sf,				SM00360:RRM,	KW-0090~Biological rhythms,KW-0391~Immunity,KW-0399~Innate immunity,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0677~Repeat,		KW-0010~Activator,KW-0678~Repressor,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:RRM,DOMAIN:RRM 1,DOMAIN:RRM 2,MUTAGEN:F->A: Abolishes accumulation in paraspeckles, but not in perinucleolar caps; when associated with A-119; A-121 and A-198.,MUTAGEN:F->A: Abolishes accumulation in paraspeckles, but not in perinucleolar caps; when associated with A-119; A-198 and A-200.,MUTAGEN:F->A: Abolishes accumulation in paraspeckles, but not in perinucleolar caps; when associated with A-121; A-198 and A-200.,MUTAGEN:K->A: Abolishes accumulation in paraspeckles, but not in perinucleolar caps; when associated with A-119; A-121 and A-200.,MUTAGEN:W->A: Abolishes interaction with NONO and localization in nuclear paraspeckles; when associated with A-275.,MUTAGEN:Y->A: Abolishes interaction with NONO and localization in nuclear paraspeckles; when associated with A-279.,REGION:Disordered,REGION:Sufficient for paraspeckles localization,REGION:Sufficient for perinucleolar caps localization and interaction with NONO,
PTMS	parathymosin(PTMS)	Homo sapiens			GO:0002376~immune system process,GO:0006260~DNA replication,GO:0043066~negative regulation of apoptotic process,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,	GO:0005634~nucleus,	GO:0042393~histone binding,	IPR004931:Pro/parathymosin,					KW-0391~Immunity,						KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,REGION:Disordered,
PNPLA8	patatin like phospholipase domain containing 8(PNPLA8)	Homo sapiens			GO:0001516~prostaglandin biosynthetic process,GO:0006631~fatty acid metabolic process,GO:0016042~lipid catabolic process,GO:0019369~arachidonic acid metabolic process,GO:0032048~cardiolipin metabolic process,GO:0034638~phosphatidylcholine catabolic process,GO:0035556~intracellular signal transduction,GO:0043651~linoleic acid metabolic process,GO:0046338~phosphatidylethanolamine catabolic process,GO:0050482~arachidonic acid secretion,GO:0055088~lipid homeostasis,GO:0070328~triglyceride homeostasis,GO:1900407~regulation of cellular response to oxidative stress,	GO:0005739~mitochondrion,GO:0005777~peroxisome,GO:0005778~peroxisomal membrane,GO:0005789~endoplasmic reticulum membrane,GO:0016020~membrane,GO:0031966~mitochondrial membrane,	GO:0004620~phospholipase activity,GO:0004622~lysophospholipase activity,GO:0005524~ATP binding,GO:0008970~phosphatidylcholine 1-acylhydrolase activity,GO:0047499~calcium-independent phospholipase A2 activity,	IPR002641:PNPLA_dom,IPR016035:Acyl_Trfase/lysoPLipase,IPR045217:PNPLA8-like,		251950~Mitochondrial myopathy with lactic acidosis,			KW-0442~Lipid degradation,KW-0443~Lipid metabolism,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0496~Mitochondrion,KW-0576~Peroxisome,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0378~Hydrolase,	KW-0325~Glycoprotein,	ACT_SITE:Nucleophile,ACT_SITE:Proton acceptor,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,DOMAIN:PNPLA,MOTIF:DGA/G,MOTIF:GXGXXG,MOTIF:GXSXG,REGION:Disordered,TRANSMEM:Helical,
PELI1	pellino E3 ubiquitin protein ligase 1(PELI1)	Homo sapiens			GO:0001819~positive regulation of cytokine production,GO:0008592~regulation of Toll signaling pathway,GO:0030890~positive regulation of B cell proliferation,GO:0031398~positive regulation of protein ubiquitination,GO:0032496~response to lipopolysaccharide,GO:0034141~positive regulation of toll-like receptor 3 signaling pathway,GO:0034145~positive regulation of toll-like receptor 4 signaling pathway,GO:0042098~T cell proliferation,GO:0042130~negative regulation of T cell proliferation,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0043331~response to dsRNA,GO:0060544~regulation of necroptotic process,GO:0060546~negative regulation of necroptotic process,GO:0070534~protein K63-linked ubiquitination,GO:0070936~protein K48-linked ubiquitination,	GO:0005634~nucleus,GO:0005829~cytosol,	GO:0005515~protein binding,GO:0034450~ubiquitin-ubiquitin ligase activity,GO:0061630~ubiquitin protein ligase activity,	IPR006800:Pellino_fam,IPR048334:Pellino_FHA,IPR048335:Pellino_RING,			PIRSF038886:Pellino,		KW-0833~Ubl conjugation pathway,					KW-0808~Transferase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	DOMAIN:FHA; atypical,DOMAIN:Pellino FHA,DOMAIN:Pellino RING,MUTAGEN:C->A: Loss of ability to ubiquitinate RIPK3. No loss of interaction with RIPK3.,MUTAGEN:H->A: Loss of ability to ubiquitinate RIPK3. No loss of interaction with RIPK3.,MUTAGEN:R->A: Loss of ability to ubiquitinate RIPK3. Loss of interaction with RIPK1, IRAK1 and RIPK3.,REGION:Ring-like domain; necessary for ubiqitination of RIPK3,
PEF1	penta-EF-hand domain containing 1(PEF1)	Homo sapiens			GO:0006888~ER to Golgi vesicle-mediated transport,GO:0014029~neural crest formation,GO:0014032~neural crest cell development,GO:0048208~COPII vesicle coating,GO:0051592~response to calcium ion,GO:1902527~positive regulation of protein monoubiquitination,	GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0030127~COPII vesicle coat,GO:0031463~Cul3-RING ubiquitin ligase complex,GO:0070062~extracellular exosome,	GO:0003723~RNA binding,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0046982~protein heterodimerization activity,GO:0046983~protein dimerization activity,GO:0048306~calcium-dependent protein binding,GO:1990756~protein binding, bridging involved in substrate recognition for ubiquitination,	IPR002048:EF_hand_dom,IPR011992:EF-hand-dom_pair,IPR018247:EF_Hand_1_Ca_BS,				SM00054:EFh,		KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,		KW-0677~Repeat,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:EF-hand,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,DOMAIN:EF-hand 3,DOMAIN:EF-hand 4,DOMAIN:EF-hand 5,MUTAGEN:K->R: Decreased ubiquitination by the BCR(KLHL12) E3 ubiquitin ligase complex.,MUTAGEN:K->R: Does not affect ubiquitination by the BCR(KLHL12) E3 ubiquitin ligase complex.,REGION:9 X 9 AA approximate tandem repeat of [AP]-P-G-G-P-Y-G-G-P-P,REGION:Disordered,REGION:Required for interaction with PDCD6,REPEAT:1,REPEAT:2,REPEAT:3,REPEAT:4,REPEAT:5,REPEAT:6,REPEAT:7,REPEAT:8,REPEAT:9,
PIN1	peptidylprolyl cis/trans isomerase, NIMA-interacting 1(PIN1)	Homo sapiens		h_mPRPathway:How Progesterone Initiates the Oocyte Maturation,	GO:0000413~protein peptidyl-prolyl isomerization,GO:0001666~response to hypoxia,GO:0001932~regulation of protein phosphorylation,GO:0001934~positive regulation of protein phosphorylation,GO:0007049~cell cycle,GO:0007088~regulation of mitotic nuclear division,GO:0010468~regulation of gene expression,GO:0030182~neuron differentiation,GO:0030512~negative regulation of transforming growth factor beta receptor signaling pathway,GO:0031647~regulation of protein stability,GO:0032091~negative regulation of protein binding,GO:0032092~positive regulation of protein binding,GO:0032465~regulation of cytokinesis,GO:0035307~positive regulation of protein dephosphorylation,GO:0042177~negative regulation of protein catabolic process,GO:0043547~positive regulation of GTPase activity,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0050808~synapse organization,GO:0050821~protein stabilization,GO:0051171~regulation of nitrogen compound metabolic process,GO:0060255~regulation of macromolecule metabolic process,GO:0060392~negative regulation of SMAD protein import into nucleus,GO:0070373~negative regulation of ERK1 and ERK2 cascade,GO:0080090~regulation of primary metabolic process,GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:1900180~regulation of protein localization to nucleus,GO:1902430~negative regulation of beta-amyloid formation,GO:2000146~negative regulation of cell motility,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016607~nuclear speck,GO:0030496~midbody,GO:0036064~ciliary basal body,GO:0098978~glutamatergic synapse,GO:0099524~postsynaptic cytosol,	GO:0003755~peptidyl-prolyl cis-trans isomerase activity,GO:0003774~motor activity,GO:0005515~protein binding,GO:0008013~beta-catenin binding,GO:0016853~isomerase activity,GO:0016859~cis-trans isomerase activity,GO:0031434~mitogen-activated protein kinase kinase binding,GO:0032794~GTPase activating protein binding,GO:0048156~tau protein binding,GO:0050815~phosphoserine binding,GO:0050816~phosphothreonine binding,GO:0051219~phosphoprotein binding,GO:1990757~ubiquitin ligase activator activity,	IPR000297:PPIase_PpiC,IPR001202:WW_dom,IPR023058:PPIase_PpiC_CS,IPR036020:WW_dom_sf,IPR046357:PPIase_dom_sf,	hsa03250:Viral life cycle - HIV-1,hsa04622:RIG-I-like receptor signaling pathway,			SM00456:WW,	KW-0131~Cell cycle,	KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0413~Isomerase,KW-0697~Rotamase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:PpiC,DOMAIN:WW,MUTAGEN:C->A: Loss of peptidyl-prolyl cis/trans isomerase activity; decrease in DNA repair of double-strand breaks by homologous recombination slightly less efficient than that observed with wild-type protein. No effect on RBBP8/CtIP.,MUTAGEN:K->A: Loss of peptidyl-prolyl cis/trans isomerase activity. No effect on the interaction with IRAK3/IRAK-M. Abolishes IL33-mediated increase of IRAK3/IRAK-M protein levels.,MUTAGEN:S->D,E: Loss of peptidyl-prolyl cis/trans isomerase activity, nuclear localization and cellular function.,MUTAGEN:W->A: Loss of binding to phosphorylated target proteins, including to phosphorylated RBBP8/CtIP; decrease in DNA repair of double-strand breaks by homologous recombination less efficient than that observed with wild-type protein. Abolishes interaction with IRAK3/IRAK-M. Abolishes IL33-mediated increase of IRAK3/IRAK-M protein levels.,MUTAGEN:Y->A: Reduced affinity for KIF20B.,REGION:Disordered,
PPIB	peptidylprolyl isomerase B(PPIB)	Homo sapiens			GO:0000413~protein peptidyl-prolyl isomerization,GO:0006457~protein folding,GO:0030593~neutrophil chemotaxis,GO:0040018~positive regulation of multicellular organism growth,GO:0044794~positive regulation by host of viral process,GO:0044829~positive regulation by host of viral genome replication,GO:0050821~protein stabilization,GO:0060348~bone development,GO:0061077~chaperone-mediated protein folding,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005788~endoplasmic reticulum lumen,GO:0005790~smooth endoplasmic reticulum,GO:0005829~cytosol,GO:0005925~focal adhesion,GO:0016020~membrane,GO:0032991~macromolecular complex,GO:0034663~endoplasmic reticulum chaperone complex,GO:0042470~melanosome,GO:0043231~intracellular membrane-bounded organelle,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,	GO:0003723~RNA binding,GO:0003755~peptidyl-prolyl cis-trans isomerase activity,GO:0005515~protein binding,GO:0005518~collagen binding,GO:0016018~cyclosporin A binding,GO:0051082~unfolded protein binding,GO:0070063~RNA polymerase binding,	IPR002130:Cyclophilin-type_PPIase_dom,IPR020892:Cyclophilin-type_PPIase_CS,IPR024936:Cyclophilin-type_PPIase,IPR029000:Cyclophilin-like_dom_sf,		259440~Osteogenesis imperfecta, type IX,	PIRSF001467:Peptidylpro_ismrse,			KW-0256~Endoplasmic reticulum,KW-0946~Virion,	KW-0225~Disease variant,KW-0242~Dwarfism,KW-1065~Osteogenesis imperfecta,	KW-0732~Signal,		KW-0413~Isomerase,KW-0697~Rotamase,	KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0702~S-nitrosylation,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:PPIase cyclophilin-type,MOTIF:Prevents secretion from ER,MUTAGEN:K->A: Impairs interaction with CLGN and CANX.,
PPID	peptidylprolyl isomerase D(PPID)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0000413~protein peptidyl-prolyl isomerization,GO:0006457~protein folding,GO:0006915~apoptotic process,GO:0015031~protein transport,GO:0019076~viral release from host cell,GO:0034389~lipid particle organization,GO:0043065~positive regulation of apoptotic process,GO:0045070~positive regulation of viral genome replication,GO:0050714~positive regulation of protein secretion,GO:0061077~chaperone-mediated protein folding,GO:0065003~macromolecular complex assembly,GO:0071492~cellular response to UV-A,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0003755~peptidyl-prolyl cis-trans isomerase activity,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:0016018~cyclosporin A binding,GO:0030331~estrogen receptor binding,GO:0030544~Hsp70 protein binding,GO:0031072~heat shock protein binding,GO:0051879~Hsp90 protein binding,	IPR002130:Cyclophilin-type_PPIase_dom,IPR011990:TPR-like_helical_dom_sf,IPR019734:TPR_repeat,IPR020892:Cyclophilin-type_PPIase_CS,IPR024936:Cyclophilin-type_PPIase,IPR029000:Cyclophilin-like_dom_sf,	hsa04217:Necroptosis,hsa04218:Cellular senescence,hsa05010:Alzheimer disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05131:Shigellosis,		PIRSF001467:Peptidylpro_ismrse,	SM00028:TPR,	KW-0053~Apoptosis,KW-0653~Protein transport,KW-0813~Transport,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0802~TPR repeat,		KW-0143~Chaperone,KW-0413~Isomerase,KW-0697~Rotamase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:PPIase cyclophilin-type,MUTAGEN:D->A: Impairs interaction with HSP90AB1.,MUTAGEN:F->A: Impairs interaction with HSP90AB1 and HSPA8.,MUTAGEN:K->A: Abolishes interaction with HSP90AB1 and impairs interaction with HSPA8.,MUTAGEN:K->A: Impairs interaction with HSP90AB1 and HSPA8.,MUTAGEN:L->A: Impairs interaction with HSP90AB1 and HSPA8.,MUTAGEN:N->A: Abolishes interaction with HSP90AB1 and impairs interaction with HSPA8.,MUTAGEN:N->A: Abolishes interaction with HSP90AB1.,MUTAGEN:R->A: Abolishes interaction with HSP90AB1 and impairs interaction with HSPA8.,MUTAGEN:S->L: Impairs interaction with HSP90AB1 and HSPA8.,REGION:Chaperone activity,REGION:Interaction with HSP90AB1,REPEAT:TPR,REPEAT:TPR 1,REPEAT:TPR 2,REPEAT:TPR 3,
PPIE	peptidylprolyl isomerase E(PPIE)	Homo sapiens			GO:0000398~mRNA splicing, via spliceosome,GO:0000413~protein peptidyl-prolyl isomerization,GO:0006355~regulation of transcription, DNA-templated,GO:0006457~protein folding,GO:0045070~positive regulation of viral genome replication,	GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016607~nuclear speck,GO:0034774~secretory granule lumen,GO:0043231~intracellular membrane-bounded organelle,GO:0071007~U2-type catalytic step 2 spliceosome,GO:0071013~catalytic step 2 spliceosome,GO:1904813~ficolin-1-rich granule lumen,	GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0003755~peptidyl-prolyl cis-trans isomerase activity,GO:0005515~protein binding,GO:0008143~poly(A) binding,GO:0016018~cyclosporin A binding,	IPR000504:RRM_dom,IPR002130:Cyclophilin-type_PPIase_dom,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR016304:PPIE,IPR020892:Cyclophilin-type_PPIase_CS,IPR029000:Cyclophilin-like_dom_sf,IPR034168:PPIE_RRM,IPR035979:RBD_domain_sf,	hsa03040:Spliceosome,		PIRSF001475:PPI_cyclophilin_E,	SM00360:RRM,	KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,KW-0747~Spliceosome,				KW-0413~Isomerase,KW-0694~RNA-binding,KW-0697~Rotamase,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:PPIase cyclophilin-type,DOMAIN:RRM,MUTAGEN:E->A: Slightly decreased affinity for KMT2A.,MUTAGEN:F->A: Expected to disrupt proline isomerase activity. Abolishes inhibition of KMT2A activity; when associated with A-191.,MUTAGEN:F->A: Impairs protein folding.,MUTAGEN:F->A: Strongly decreased affinity for KMT2A. Decreased affinity for RNA.,MUTAGEN:F->D: Abolishes interaction with KMT2A. Abolishes inhibition of KMT2A activity.,MUTAGEN:FM->EE: Expected to disrupt peptidylproline binding. Decreases interaction with KMT2A. Abolishes inhibition of KMT2A activity.,MUTAGEN:K->A: No effect on interaction with KMT2A.,MUTAGEN:L->A: Decreased affinity for KMT2A.,MUTAGEN:Missing: Abolishes interaction with KMT2A.,MUTAGEN:R->A: Expected to disrupt proline isomerase activity. Abolishes inhibition of KMT2A activity; when associated with A-196.,MUTAGEN:R->A: No effect on interaction with KMT2A.,MUTAGEN:Y->A: Decreased affinity for RNA.,REGION:Disordered,
PPIH	peptidylprolyl isomerase H(PPIH)	Homo sapiens			GO:0000398~mRNA splicing, via spliceosome,GO:0000413~protein peptidyl-prolyl isomerization,GO:0006457~protein folding,GO:0045070~positive regulation of viral genome replication,GO:0065003~macromolecular complex assembly,	GO:0005654~nucleoplasm,GO:0005681~spliceosomal complex,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016607~nuclear speck,GO:0043231~intracellular membrane-bounded organelle,GO:0046540~U4/U6 x U5 tri-snRNP complex,GO:0071001~U4/U6 snRNP,	GO:0003755~peptidyl-prolyl cis-trans isomerase activity,GO:0005515~protein binding,GO:0016018~cyclosporin A binding,GO:0043021~ribonucleoprotein complex binding,	IPR002130:Cyclophilin-type_PPIase_dom,IPR020892:Cyclophilin-type_PPIase_CS,IPR024936:Cyclophilin-type_PPIase,IPR029000:Cyclophilin-like_dom_sf,	hsa03040:Spliceosome,		PIRSF001467:Peptidylpro_ismrse,		KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,KW-0747~Spliceosome,KW-0963~Cytoplasm,				KW-0143~Chaperone,KW-0413~Isomerase,KW-0697~Rotamase,	KW-0007~Acetylation,	DOMAIN:PPIase cyclophilin-type,MUTAGEN:W->F: Abolishes inhibition by cyclosporin A.,
PPWD1	peptidylprolyl isomerase domain and WD repeat containing 1(PPWD1)	Homo sapiens			GO:0000398~mRNA splicing, via spliceosome,GO:0000413~protein peptidyl-prolyl isomerization,	GO:0005654~nucleoplasm,GO:0016604~nuclear body,GO:0071013~catalytic step 2 spliceosome,	GO:0003755~peptidyl-prolyl cis-trans isomerase activity,GO:0016018~cyclosporin A binding,	IPR001680:WD40_rpt,IPR002130:Cyclophilin-type_PPIase_dom,IPR015943:WD40/YVTN_repeat-like_dom_sf,IPR029000:Cyclophilin-like_dom_sf,IPR036322:WD40_repeat_dom_sf,IPR044666:Cyclophilin_A-like,				SM00320:WD40,	KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,KW-0747~Spliceosome,		KW-0677~Repeat,KW-0853~WD repeat,		KW-0413~Isomerase,KW-0697~Rotamase,	KW-0007~Acetylation,	COMPBIAS:Basic and acidic residues,DOMAIN:PPIase cyclophilin-type,REGION:Disordered,REPEAT:WD,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,REPEAT:WD 7,
PRF1	perforin 1(PRF1)	Homo sapiens		h_caspasePathway:Caspase Cascade in Apoptosis,h_ctlPathway:CTL mediated immune response against target cells ,h_d4gdiPathway:D4-GDI Signaling Pathway,h_setPathway:Granzyme A mediated Apoptosis Pathway,	GO:0001771~immunological synapse formation,GO:0001909~leukocyte mediated cytotoxicity,GO:0001913~T cell mediated cytotoxicity,GO:0002357~defense response to tumor cell,GO:0002418~immune response to tumor cell,GO:0006915~apoptotic process,GO:0006968~cellular defense response,GO:0009306~protein secretion,GO:0017038~protein import,GO:0031640~killing of cells of other organism,GO:0051260~protein homooligomerization,GO:0051607~defense response to virus,GO:0051712~positive regulation of killing of cells of other organism,GO:0071806~protein transmembrane transport,	GO:0001772~immunological synapse,GO:0005576~extracellular region,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0031904~endosome lumen,GO:0044194~cytolytic granule,	GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0022829~wide pore channel activity,GO:0042802~identical protein binding,	IPR000008:C2_dom,IPR020863:MACPF_CS,IPR020864:MACPF,IPR035892:C2_domain_sf,IPR037300:Perforin-1_C2,	hsa04210:Apoptosis,hsa04650:Natural killer cell mediated cytotoxicity,hsa04940:Type I diabetes mellitus,hsa05320:Autoimmune thyroid disease,hsa05330:Allograft rejection,hsa05332:Graft-versus-host disease,hsa05416:Viral myocarditis,	603553~Hemophagocytic lymphohistiocytosis, familial, 2,605027~Lymphoma, non-Hodgkin,609135~Aplastic anemia,		SM00239:C2,SM00457:MACPF,	KW-0204~Cytolysis,	KW-0458~Lysosome,KW-0472~Membrane,KW-0964~Secreted,KW-0967~Endosome,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0951~Familial hemophagocytic lymphohistiocytosis,	KW-0245~EGF-like domain,KW-0732~Signal,KW-0812~Transmembrane,KW-1134~Transmembrane beta strand,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:C2,DOMAIN:EGF-like,DOMAIN:MACPF,SITE:Important for oligomerization,TRANSMEM:Beta stranded; Name=CH1,TRANSMEM:Beta stranded; Name=CH2,
PLIN2	perilipin 2(PLIN2)	Homo sapiens			GO:0009410~response to xenobiotic stimulus,GO:0010890~positive regulation of sequestering of triglyceride,GO:0014070~response to organic cyclic compound,GO:0015909~long-chain fatty acid transport,GO:0019915~lipid storage,GO:0042149~cellular response to glucose starvation,GO:1905691~lipid particle disassembly,	GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005783~endoplasmic reticulum,GO:0005811~lipid particle,GO:0005829~cytosol,GO:0005886~plasma membrane,	GO:0005515~protein binding,	IPR004279:Perilipin,	hsa03320:PPAR signaling pathway,		PIRSF036881:PAT,			KW-0472~Membrane,KW-0551~Lipid droplet,					KW-0007~Acetylation,KW-0449~Lipoprotein,KW-0597~Phosphoprotein,	MUTAGEN:Y->F: Abolished phosphorylation at Tyr-232 by isoform 1 of CHKA (CHKalpha2).,REGION:Disordered,
PRDX3	peroxiredoxin 3(PRDX3)	Homo sapiens			GO:0001893~maternal placenta development,GO:0006979~response to oxidative stress,GO:0007005~mitochondrion organization,GO:0008284~positive regulation of cell proliferation,GO:0018171~peptidyl-cysteine oxidation,GO:0030099~myeloid cell differentiation,GO:0032496~response to lipopolysaccharide,GO:0033554~cellular response to stress,GO:0033673~negative regulation of kinase activity,GO:0034599~cellular response to oxidative stress,GO:0034614~cellular response to reactive oxygen species,GO:0042542~response to hydrogen peroxide,GO:0042744~hydrogen peroxide catabolic process,GO:0043066~negative regulation of apoptotic process,GO:0045454~cell redox homeostasis,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0051881~regulation of mitochondrial membrane potential,GO:0098869~cellular oxidant detoxification,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0005769~early endosome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0032991~macromolecular complex,GO:0043231~intracellular membrane-bounded organelle,	GO:0005515~protein binding,GO:0008379~thioredoxin peroxidase activity,GO:0008785~alkyl hydroperoxide reductase activity,GO:0019901~protein kinase binding,GO:0042802~identical protein binding,GO:0043027~cysteine-type endopeptidase inhibitor activity involved in apoptotic process,GO:0051920~peroxiredoxin activity,	IPR000866:AhpC/TSA,IPR013766:Thioredoxin_domain,IPR019479:Peroxiredoxin_C,IPR036249:Thioredoxin-like_sf,		619862~Spinocerebellar ataxia, autosomal recessive 32,619871~Corneal dystrophy, punctiform and polychromatic pre-Descemet,				KW-0496~Mitochondrion,KW-0963~Cytoplasm,KW-0967~Endosome,	KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-1212~Corneal dystrophy,	KW-0676~Redox-active center,KW-0809~Transit peptide,		KW-0049~Antioxidant,KW-0560~Oxidoreductase,KW-0575~Peroxidase,	KW-0007~Acetylation,KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	ACT_SITE:Cysteine sulfenic acid (-SOH) intermediate,DISULFID:Interchain (with C-108); in linked form,DISULFID:Interchain (with C-229); in linked form,DOMAIN:Thioredoxin,MUTAGEN:S->C: Forms predominantly dodecamer rings.,MUTAGEN:S->E: Forms obligate homodimers under reducing and oxidizing conditions; does not form dodecamer rings under reducing conditions.,MUTAGEN:T->A: Impairs phosphorylation.,TRANSIT:Mitochondrion,
PRDX6	peroxiredoxin 6(PRDX6)	Homo sapiens			GO:0006979~response to oxidative stress,GO:0016042~lipid catabolic process,GO:0045454~cell redox homeostasis,GO:0046475~glycerophospholipid catabolic process,GO:0048026~positive regulation of mRNA splicing, via spliceosome,GO:0098869~cellular oxidant detoxification,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0016020~membrane,GO:0035578~azurophil granule lumen,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,	GO:0004602~glutathione peroxidase activity,GO:0004623~phospholipase A2 activity,GO:0005515~protein binding,GO:0031625~ubiquitin protein ligase binding,GO:0042802~identical protein binding,GO:0045296~cadherin binding,GO:0047184~1-acylglycerophosphocholine O-acyltransferase activity,GO:0047499~calcium-independent phospholipase A2 activity,GO:0051920~peroxiredoxin activity,	IPR000866:AhpC/TSA,IPR013766:Thioredoxin_domain,IPR019479:Peroxiredoxin_C,IPR024706:Peroxiredoxin_AhpC-typ,IPR036249:Thioredoxin-like_sf,IPR045020:PRX_1cys,	hsa00480:Glutathione metabolism,hsa01100:Metabolic pathways,		PIRSF000239:AHPC,		KW-0442~Lipid degradation,KW-0443~Lipid metabolism,	KW-0458~Lysosome,KW-0963~Cytoplasm,		KW-0676~Redox-active center,		KW-0049~Antioxidant,KW-0378~Hydrolase,KW-0511~Multifunctional enzyme,KW-0560~Oxidoreductase,KW-0575~Peroxidase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Cysteine sulfenic acid (-SOH) intermediate; for peroxidase activity,ACT_SITE:For phospholipase activity,DOMAIN:Thioredoxin,MUTAGEN:C->S: Loss of peroxidase activity, but no effect on phospholipase activity.,MUTAGEN:S->A: Loss of phospholipase activity, but no effect on peroxidase activity.,REGION:Required and sufficient for targeting to lysosomes and lamellar bodies,SITE:Important for phospholipase activity,
PEX16	peroxisomal biogenesis factor 16(PEX16)	Homo sapiens			GO:0006625~protein targeting to peroxisome,GO:0007031~peroxisome organization,GO:0016557~peroxisome membrane biogenesis,GO:0016558~protein import into peroxisome matrix,GO:0022615~protein to membrane docking,GO:0032581~ER-dependent peroxisome organization,GO:0045046~protein import into peroxisome membrane,	GO:0005777~peroxisome,GO:0005778~peroxisomal membrane,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0016020~membrane,	GO:0005515~protein binding,	IPR013919:Pex16,	hsa04146:Peroxisome,	614876~Peroxisome biogenesis disorder 8A (Zellweger),614877~Peroxisome biogenesis disorder 8B,			KW-0962~Peroxisome biogenesis,	KW-0472~Membrane,KW-0576~Peroxisome,	KW-0225~Disease variant,KW-0861~Zellweger syndrome,KW-0958~Peroxisome biogenesis disorder,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,				REGION:Disordered,REGION:Interaction with PEX19,REGION:Required for peroxisomal location,TOPO_DOM:Cytoplasmic,TOPO_DOM:Peroxisomal,TRANSMEM:Helical,
FARSA	phenylalanyl-tRNA synthetase subunit alpha(FARSA)	Homo sapiens			GO:0006432~phenylalanyl-tRNA aminoacylation,GO:0043039~tRNA aminoacylation,GO:0051290~protein heterotetramerization,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0009328~phenylalanine-tRNA ligase complex,GO:0016020~membrane,	GO:0000049~tRNA binding,GO:0000287~magnesium ion binding,GO:0003723~RNA binding,GO:0004812~aminoacyl-tRNA ligase activity,GO:0004826~phenylalanine-tRNA ligase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0046872~metal ion binding,	IPR002319:Phenylalanyl-tRNA_Synthase,IPR004529:Phe-tRNA-synth_IIc_asu,IPR006195:aa-tRNA-synth_II,IPR036390:WH_DNA-bd_sf,IPR040586:PheRS_DBD2,IPR040724:PheRS_DBD1,IPR040725:PheRS_DBD3,IPR045864:aa-tRNA-synth_II/BPL/LPL,	hsa00970:Aminoacyl-tRNA biosynthesis,	619013~Rajab interstitial lung disease with brain calcifications 2,			KW-0648~Protein biosynthesis,	KW-0963~Cytoplasm,	KW-0225~Disease variant,		KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0030~Aminoacyl-tRNA synthetase,KW-0436~Ligase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:Aminoacyl-transfer RNA synthetases class-II family profile,DOMAIN:PheRS DNA binding,DOMAIN:Phenylalanyl-tRNA synthetase,REGION:Disordered,
PMAIP1	phorbol-12-myristate-13-acetate-induced protein 1(PMAIP1)	Homo sapiens			GO:0001836~release of cytochrome c from mitochondria,GO:0006915~apoptotic process,GO:0006974~cellular response to DNA damage stimulus,GO:0010498~proteasomal protein catabolic process,GO:0010907~positive regulation of glucose metabolic process,GO:0010917~negative regulation of mitochondrial membrane potential,GO:0042149~cellular response to glucose starvation,GO:0043029~T cell homeostasis,GO:0043065~positive regulation of apoptotic process,GO:0043280~positive regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0043331~response to dsRNA,GO:0043517~positive regulation of DNA damage response, signal transduction by p53 class mediator,GO:0046902~regulation of mitochondrial membrane permeability,GO:0051607~defense response to virus,GO:0071456~cellular response to hypoxia,GO:0072332~intrinsic apoptotic signaling pathway by p53 class mediator,GO:0072593~reactive oxygen species metabolic process,GO:0090200~positive regulation of release of cytochrome c from mitochondria,GO:0097193~intrinsic apoptotic signaling pathway,GO:1902043~positive regulation of extrinsic apoptotic signaling pathway via death domain receptors,GO:1902237~positive regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway,GO:2001244~positive regulation of intrinsic apoptotic signaling pathway,	GO:0005634~nucleus,GO:0005739~mitochondrion,GO:0005741~mitochondrial outer membrane,GO:0005829~cytosol,GO:0097136~Bcl-2 family protein complex,	GO:0005515~protein binding,	IPR024140:Noxa,	hsa01524:Platinum drug resistance,hsa04115:p53 signaling pathway,hsa04210:Apoptosis,hsa04215:Apoptosis - multiple species,hsa05200:Pathways in cancer,hsa05203:Viral carcinogenesis,hsa05210:Colorectal cancer,				KW-0053~Apoptosis,	KW-0496~Mitochondrion,						MOTIF:BH3,MUTAGEN:F->E: Loss of interaction with MCL1 and of increased MCL1 degradation; when associated with E-29 and E-36.,MUTAGEN:F->I: Alters specificity of protein interaction and enhances pro-apoptotic activity; when associated with E-35.,MUTAGEN:K->E: Alters specificity of protein interaction and enhances pro-apoptotic activity; when associated with I-32.,MUTAGEN:L->A: Reduced interaction with BAX.,MUTAGEN:L->E: Loss of interaction with MCL1 and of increased MCL1 degradation; when associated with E-29 and E-32.,MUTAGEN:L->E: Loss of interaction with MCL1 and of increased MCL1 degradation; when associated with E-32 and E-32.,REGION:Disordered,REGION:Required for mitochondrial location,
PDCL3	phosducin like 3(PDCL3)	Homo sapiens			GO:0001525~angiogenesis,GO:0001938~positive regulation of endothelial cell proliferation,GO:0006457~protein folding,GO:0006915~apoptotic process,GO:0010628~positive regulation of gene expression,GO:0030036~actin cytoskeleton organization,GO:0045766~positive regulation of angiogenesis,GO:0050730~regulation of peptidyl-tyrosine phosphorylation,GO:0050821~protein stabilization,GO:0061077~chaperone-mediated protein folding,GO:1903645~negative regulation of chaperone-mediated protein folding,GO:2000059~negative regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0032991~macromolecular complex,GO:0048471~perinuclear region of cytoplasm,GO:0097356~perinucleolar compartment,	GO:0005515~protein binding,GO:0043184~vascular endothelial growth factor receptor 2 binding,GO:0044183~protein binding involved in protein folding,	IPR024253:Phosducin_thioredoxin-like_dom,IPR036249:Thioredoxin-like_sf,					KW-0037~Angiogenesis,KW-0053~Apoptosis,	KW-0256~Endoplasmic reticulum,KW-0963~Cytoplasm,				KW-0143~Chaperone,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:Phosducin thioredoxin-like,MUTAGEN:Missing: Loss of acetylation. Increases protein stability.,REGION:Interaction with XIAP,REGION:Thioredoxin fold,
PI4KB	phosphatidylinositol 4-kinase beta(PI4KB)	Homo sapiens			GO:0006661~phosphatidylinositol biosynthetic process,GO:0006898~receptor-mediated endocytosis,GO:0007040~lysosome organization,GO:0007165~signal transduction,GO:0016310~phosphorylation,GO:0046854~phosphatidylinositol phosphorylation,GO:0048015~phosphatidylinositol-mediated signaling,GO:0048839~inner ear development,	GO:0000139~Golgi membrane,GO:0005737~cytoplasm,GO:0005741~mitochondrial outer membrane,GO:0005768~endosome,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0016020~membrane,GO:0030867~rough endoplasmic reticulum membrane,GO:0048471~perinuclear region of cytoplasm,	GO:0004430~1-phosphatidylinositol 4-kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016301~kinase activity,GO:0071889~14-3-3 protein binding,	IPR000403:PI3/4_kinase_cat_dom,IPR001263:PI3K_accessory_dom,IPR011009:Kinase-like_dom_sf,IPR015433:PI_Kinase,IPR018936:PI3/4_kinase_CS,IPR036940:PI3/4_kinase_cat_sf,IPR049160:PI4KB-PIK1_PIK,	hsa00562:Inositol phosphate metabolism,hsa01100:Metabolic pathways,hsa04070:Phosphatidylinositol signaling system,	620281~Deafness, autosomal dominant 87,		SM00146:PI3Kc,	KW-0443~Lipid metabolism,KW-0945~Host-virus interaction,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0496~Mitochondrion,KW-0963~Cytoplasm,KW-1000~Mitochondrion outer membrane,	KW-0209~Deafness,KW-0225~Disease variant,KW-1010~Non-syndromic deafness,		KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:PI3K/PI4K catalytic,DOMAIN:PIK helical,MUTAGEN:C->A: No effect on ACBD3-, ARMH3-, nor RAB11B-binding.,MUTAGEN:D->A: Loss of interaction with ACBD3.,MUTAGEN:EKV->AAA: No effect on ACBD3-, ARMH3-, nor RAB11B-binding.,MUTAGEN:EV->AA: No effect on ACBD3-, ARMH3-, nor RAB11B-binding.,MUTAGEN:I->A: Loss of interaction with ACBD3.,MUTAGEN:IDP->AAA: Drastically decreased ACBD3-binding. No effect on ARMH3-, nor RAB11B-binding.,MUTAGEN:L->A: Loss of interaction with ACBD3.,MUTAGEN:LSV->AAA: Small decrease in ARMH3-binding. No effect on ACBD3-, nor RAB11B-binding.,MUTAGEN:QE->AA: Drastically decreased ARMH3- and RAB11B-binding. 6-fold increase in ACBD3-binding.,MUTAGEN:QK->AA: No effect on ACBD3-, ARMH3-, nor RAB11B-binding.,MUTAGEN:V->A: Loss of interaction with ACBD3.,MUTAGEN:V->A: No loss of interaction with ACBD3.,MUTAGEN:VL->AA: Drastically decreased ACBD3-binding. No effect on ARMH3-, nor RAB11B-binding.,REGION:Activation loop,REGION:Catalytic loop,REGION:Disordered,REGION:G-loop,REGION:Interaction with ACBD3,
PITPNB	phosphatidylinositol transfer protein beta(PITPNB)	Homo sapiens			GO:0006629~lipid metabolic process,GO:0006890~retrograde vesicle-mediated transport, Golgi to ER,GO:0006997~nucleus organization,GO:0015914~phospholipid transport,	GO:0000139~Golgi membrane,GO:0005737~cytoplasm,GO:0005789~endoplasmic reticulum membrane,GO:0005794~Golgi apparatus,	GO:0005515~protein binding,GO:0008525~phosphatidylcholine transporter activity,GO:0008526~phosphatidylinositol transporter activity,GO:0031210~phosphatidylcholine binding,GO:0035091~phosphatidylinositol binding,	IPR001666:PI_transfer,IPR023393:START-like_dom_sf,					KW-0445~Lipid transport,KW-0813~Transport,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,			KW-0446~Lipid-binding,		KW-0007~Acetylation,KW-0597~Phosphoprotein,	MUTAGEN:C->A: No effect on phosphatidylinositol transfer activity.,MUTAGEN:C->T,A: Loss of phosphatidylcholine transfer activity but no effect on phosphatidylinositol transfer activity. Not inhibited by N-ethylmaleimide. Fails to rescue the retrograde transport defect from the Golgi to endoplasmic reticulum in PITPNB-deficient cells.,MUTAGEN:K->A: Loss of phosphatidylinositol transfer activity but no effect on phosphatidylcholine transfer activity. Fails to rescue the retrograde transport defect from the Golgi to endoplasmic reticulum in PITPNB-deficient cells.,MUTAGEN:N->F: Loss of phosphatidylinositol transfer activity but no effect on phosphatidylcholine transfer activity. Fails to rescue the retrograde transport defect from the Golgi to endoplasmic reticulum in PITPNB-deficient cells.,MUTAGEN:WW->AA: Loss of phosphatidylinositol transfer activity. Fails to rescue the retrograde transport defect from the Golgi to endoplasmic reticulum in PITPNB-deficient cells.,
PITPNC1	phosphatidylinositol transfer protein cytoplasmic 1(PITPNC1)	Homo sapiens			GO:0007165~signal transduction,GO:0015914~phospholipid transport,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0005515~protein binding,GO:0008526~phosphatidylinositol transporter activity,GO:0035091~phosphatidylinositol binding,GO:0070300~phosphatidic acid binding,GO:1901611~phosphatidylglycerol binding,GO:1990050~phosphatidic acid transporter activity,	IPR001666:PI_transfer,IPR023393:START-like_dom_sf,					KW-0445~Lipid transport,KW-0813~Transport,	KW-0963~Cytoplasm,			KW-0446~Lipid-binding,		KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,
PTDSS1	phosphatidylserine synthase 1(PTDSS1)	Homo sapiens			GO:0006659~phosphatidylserine biosynthetic process,	GO:0005789~endoplasmic reticulum membrane,GO:0016020~membrane,	GO:0016740~transferase activity,	IPR004277:PSS,	hsa00564:Glycerophospholipid metabolism,hsa01100:Metabolic pathways,	151050~Lenz-Majewski hyperostotic dwarfism,			KW-0443~Lipid metabolism,KW-0444~Lipid biosynthesis,KW-0594~Phospholipid biosynthesis,KW-1208~Phospholipid metabolism,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,	KW-0225~Disease variant,KW-0242~Dwarfism,KW-0991~Intellectual disability,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
PDE3B	phosphodiesterase 3B(PDE3B)	Homo sapiens		h_no1Pathway:Actions of Nitric Oxide in the Heart,	GO:0001525~angiogenesis,GO:0007162~negative regulation of cell adhesion,GO:0007165~signal transduction,GO:0007186~G-protein coupled receptor signaling pathway,GO:0016525~negative regulation of angiogenesis,GO:0019933~cAMP-mediated signaling,GO:0032869~cellular response to insulin stimulus,GO:0033629~negative regulation of cell adhesion mediated by integrin,GO:0043951~negative regulation of cAMP-mediated signaling,GO:0045765~regulation of angiogenesis,GO:0050995~negative regulation of lipid catabolic process,GO:0051896~regulation of protein kinase B signaling,	GO:0005783~endoplasmic reticulum,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0016020~membrane,GO:0032045~guanyl-nucleotide exchange factor complex,	GO:0004114~3',5'-cyclic-nucleotide phosphodiesterase activity,GO:0004115~3',5'-cyclic-AMP phosphodiesterase activity,GO:0004119~cGMP-inhibited cyclic-nucleotide phosphodiesterase activity,GO:0005515~protein binding,GO:0043422~protein kinase B binding,GO:0046872~metal ion binding,GO:0047555~3',5'-cyclic-GMP phosphodiesterase activity,	IPR002073:PDEase_catalytic_dom,IPR003607:HD/PDEase_dom,IPR023174:PDEase_CS,IPR036971:PDEase_catalytic_dom_sf,	hsa00230:Purine metabolism,hsa01100:Metabolic pathways,hsa04022:cGMP-PKG signaling pathway,hsa04024:cAMP signaling pathway,hsa04371:Apelin signaling pathway,hsa04910:Insulin signaling pathway,hsa04914:Progesterone-mediated oocyte maturation,hsa04922:Glucagon signaling pathway,hsa04923:Regulation of lipolysis in adipocytes,hsa04924:Renin secretion,hsa05032:Morphine addiction,			SM00471:HDc,	KW-0037~Angiogenesis,	KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0114~cAMP,KW-0140~cGMP,KW-0460~Magnesium,KW-0479~Metal-binding,	KW-0378~Hydrolase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton donor,COMPBIAS:Acidic residues,COMPBIAS:Polar residues,DOMAIN:PDEase,MUTAGEN:A->D: Loss of interaction with RAPGEF3.,MUTAGEN:K->A: Loss of interaction with RAPGEF3.,MUTAGEN:P->A: Loss of interaction with PIK3R6.,MUTAGEN:R->A: Loss of interaction with PIK3R6.,MUTAGEN:R->A: Loss of interaction with RAPGEF3.,MUTAGEN:S->A: Loss of interaction with PIK3R6.,REGION:Disordered,REGION:Interaction with PIK3R6,REGION:Interaction with RAPGEF3,TRANSMEM:Helical,
PDE4D	phosphodiesterase 4D(PDE4D)	Homo sapiens			GO:0002027~regulation of heart rate,GO:0006198~cAMP catabolic process,GO:0007165~signal transduction,GO:0010460~positive regulation of heart rate,GO:0010880~regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum,GO:0019933~cAMP-mediated signaling,GO:0032729~positive regulation of interferon-gamma production,GO:0032743~positive regulation of interleukin-2 production,GO:0032754~positive regulation of interleukin-5 production,GO:0033137~negative regulation of peptidyl-serine phosphorylation,GO:0043951~negative regulation of cAMP-mediated signaling,GO:0045822~negative regulation of heart contraction,GO:0050852~T cell receptor signaling pathway,GO:0061028~establishment of endothelial barrier,GO:0071320~cellular response to cAMP,GO:0071872~cellular response to epinephrine stimulus,GO:0071875~adrenergic receptor signaling pathway,GO:0086004~regulation of cardiac muscle cell contraction,GO:1901844~regulation of cell communication by electrical coupling involved in cardiac conduction,GO:1901898~negative regulation of relaxation of cardiac muscle,GO:1902514~regulation of calcium ion transmembrane transport via high voltage-gated calcium channel,	GO:0005634~nucleus,GO:0005813~centrosome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005891~voltage-gated calcium channel complex,GO:0016020~membrane,GO:0016324~apical plasma membrane,GO:0034704~calcium channel complex,GO:0048471~perinuclear region of cytoplasm,	GO:0004114~3',5'-cyclic-nucleotide phosphodiesterase activity,GO:0004115~3',5'-cyclic-AMP phosphodiesterase activity,GO:0005246~calcium channel regulator activity,GO:0005515~protein binding,GO:0019899~enzyme binding,GO:0030545~receptor regulator activity,GO:0030552~cAMP binding,GO:0031698~beta-2 adrenergic receptor binding,GO:0044325~ion channel binding,GO:0046872~metal ion binding,GO:0047555~3',5'-cyclic-GMP phosphodiesterase activity,GO:0051117~ATPase binding,GO:0097110~scaffold protein binding,GO:1901363~heterocyclic compound binding,	IPR002073:PDEase_catalytic_dom,IPR003607:HD/PDEase_dom,IPR023088:PDEase,IPR023174:PDEase_CS,IPR036971:PDEase_catalytic_dom_sf,IPR040844:PDE4_UCR,	hsa00230:Purine metabolism,hsa01100:Metabolic pathways,hsa04024:cAMP signaling pathway,hsa04928:Parathyroid hormone synthesis, secretion and action,hsa05032:Morphine addiction,	614613~Acrodysostosis 2, with or without hormone resistance,				KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,	KW-0225~Disease variant,		KW-0114~cAMP,KW-0464~Manganese,KW-0479~Metal-binding,KW-0862~Zinc,	KW-0378~Hydrolase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	ACT_SITE:Proton donor,COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO),DOMAIN:PDEase,MUTAGEN:D->N: Decreased 3',5'-cyclic-AMP phosphodiesterase activity. Loss of Mg2(+)-binding.,MUTAGEN:D->R: Abolishes homodimerization.,MUTAGEN:R->D: Abolishes homodimerization.,REGION:Disordered,
PGD	phosphogluconate dehydrogenase(PGD)	Homo sapiens			GO:0006098~pentose-phosphate shunt,GO:0009051~pentose-phosphate shunt, oxidative branch,GO:0019322~pentose biosynthetic process,GO:0019521~D-gluconate metabolic process,GO:0046177~D-gluconate catabolic process,	GO:0005634~nucleus,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0004616~phosphogluconate dehydrogenase (decarboxylating) activity,GO:0050661~NADP binding,	IPR006113:6PGDH_Gnd/GntZ,IPR006114:6PGDH_C,IPR006115:6PGDH_NADP-bd,IPR006183:Pgluconate_DH,IPR006184:6PGdom_BS,IPR008927:6-PGluconate_DH-like_C_sf,IPR013328:6PGD_dom2,IPR036291:NAD(P)-bd_dom_sf,	hsa00030:Pentose phosphate pathway,hsa00480:Glutathione metabolism,hsa01100:Metabolic pathways,hsa01200:Carbon metabolism,		PIRSF000109:6PGD,	SM01350:6PGD,	KW-0311~Gluconate utilization,KW-0570~Pentose shunt,	KW-0963~Cytoplasm,			KW-0521~NADP,	KW-0560~Oxidoreductase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,ACT_SITE:Proton donor,BINDING:in other chain,DOMAIN:6-phosphogluconate dehydrogenase C-terminal,DOMAIN:6-phosphogluconate dehydrogenase NADP-binding,
PGAM1	phosphoglycerate mutase 1(PGAM1)	Homo sapiens		h_glycolysisPathway:Glycolysis Pathway,	GO:0006094~gluconeogenesis,GO:0006096~glycolytic process,GO:0006110~regulation of glycolytic process,GO:0043456~regulation of pentose-phosphate shunt,GO:0045730~respiratory burst,GO:0061621~canonical glycolysis,	GO:0005576~extracellular region,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016020~membrane,GO:0034774~secretory granule lumen,GO:0070062~extracellular exosome,GO:1904813~ficolin-1-rich granule lumen,	GO:0004082~bisphosphoglycerate mutase activity,GO:0004619~phosphoglycerate mutase activity,GO:0005515~protein binding,GO:0016787~hydrolase activity,GO:0016868~intramolecular transferase activity, phosphotransferases,GO:0019901~protein kinase binding,GO:0046538~2,3-bisphosphoglycerate-dependent phosphoglycerate mutase activity,	IPR001345:PG/BPGM_mutase_AS,IPR005952:Phosphogly_mut1,IPR013078:His_Pase_superF_clade-1,IPR029033:His_PPase_superfam,	hsa00010:Glycolysis / Gluconeogenesis,hsa00260:Glycine, serine and threonine metabolism,hsa01100:Metabolic pathways,hsa01200:Carbon metabolism,hsa01230:Biosynthesis of amino acids,hsa04922:Glucagon signaling pathway,hsa05230:Central carbon metabolism in cancer,		PIRSF000709:6PFK_2-Ptase,	SM00855:PGAM,	KW-0324~Glycolysis,					KW-0378~Hydrolase,KW-0413~Isomerase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton donor/acceptor,ACT_SITE:Tele-phosphohistidine intermediate,SITE:Transition state stabilizer,
PHPT1	phosphohistidine phosphatase 1(PHPT1)	Homo sapiens			GO:0006470~protein dephosphorylation,GO:0030036~actin cytoskeleton organization,GO:0035971~peptidyl-histidine dephosphorylation,GO:0050860~negative regulation of T cell receptor signaling pathway,GO:0051350~negative regulation of lyase activity,GO:0097581~lamellipodium organization,GO:2000147~positive regulation of cell motility,GO:2000984~negative regulation of ATP citrate synthase activity,	GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016604~nuclear body,GO:0061851~leading edge of lamellipodium,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0019855~calcium channel inhibitor activity,GO:0044325~ion channel binding,GO:0051015~actin filament binding,GO:0101006~protein histidine phosphatase activity,	IPR007702:Janus,IPR038596:Janus_sf,						KW-0963~Cytoplasm,				KW-0378~Hydrolase,KW-0904~Protein phosphatase,	KW-0007~Acetylation,	ACT_SITE:Proton acceptor,MUTAGEN:H->A: Decreased affinity for substrate and slightly reduced catalytic activity.,MUTAGEN:H->A: Loss of activity.,MUTAGEN:K->A: Decreased affinity for substrate and strongly reduced catalytic activity.,MUTAGEN:R->A: Decreased affinity for substrate and reduced catalytic activity.,MUTAGEN:R->A: Slightly decreased affinity for substrate, but no effect on catalytic activity.,MUTAGEN:S->A: Decreased affinity for substrate and strongly reduced catalytic activity.,
PIK3IP1	phosphoinositide-3-kinase interacting protein 1(PIK3IP1)	Homo sapiens			GO:0051898~negative regulation of protein kinase B signaling,	GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0016020~membrane,	GO:0004175~endopeptidase activity,GO:0005102~receptor binding,GO:0005515~protein binding,GO:0036313~phosphatidylinositol 3-kinase catalytic subunit binding,	IPR000001:Kringle,IPR013806:Kringle-like,IPR018056:Kringle_CS,IPR038178:Kringle_sf,				SM00130:KR,		KW-0472~Membrane,KW-1003~Cell membrane,		KW-0420~Kringle,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) (complex) asparagine,CARBOHYD:O-linked (GalNAc...) serine,DOMAIN:Kringle,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
PIK3R1	phosphoinositide-3-kinase regulatory subunit 1(PIK3R1)	Homo sapiens	104.Insulin_signaling,105.Signaling_glucose_uptake,106.Glycogen_synthase-synthesis,107.mRNA_translation-protein_synthesis,2.Cytokine_Receptors,37.Akt-PKB_Effector_of_P13K_in_Vivo,63.LAT_couples_T-cell_receptor,	h_achPathway:Role of nicotinic acetylcholine receptors in the regulation of apoptosis,h_aktPathway:AKT Signaling Pathway,h_arfPathway:Tumor Suppressor Arf Inhibits Ribosomal Biogenesis,h_badPathway:Regulation of BAD phosphorylation,h_bcellsurvivalPathway:B Cell Survival Pathway,h_cdc42racPathway:Role of PI3K subunit p85 in regulation of Actin Organization and Cell Migration,h_crebPathway:Transcription factor CREB and its extracellular signals,h_ctcfPathway:CTCF: First Multivalent Nuclear Factor,h_ctla4Pathway:The Co-Stimulatory Signal During T-cell Activation,h_cxcr4Pathway:CXCR4 Signaling Pathway,h_ecmPathway:Erk and PI-3 Kinase Are Necessary for Collagen Binding in Corneal Epithelia,h_edg1Pathway:Phospholipids as signalling intermediaries,h_egfPathway:EGF Signaling Pathway,h_eif4Pathway:Regulation of eIF4e and p70 S6 Kinase,h_erk5Pathway:Role of Erk5 in Neuronal Survival,h_fcer1Pathway:Fc Epsilon Receptor I Signaling in Mast Cells,h_gcrpathway:Corticosteroids and cardioprotection,h_ghPathway:Growth Hormone Signaling Pathway,h_gleevecPathway:Inhibition of Cellular Proliferation by Gleevec,H_gsk3Pathway:Inactivation of Gsk3 by AKT causes accumulation of b-catenin in Alveolar Macrophages,h_hcmvPathway:Human Cytomegalovirus and Map Kinase Pathways,h_hdacPathway:Control of skeletal myogenesis by HDAC & calcium/calmodulin-dependent kinase (CaMK),h_her2Pathway:Role of ERBB2 in Signal Transduction and Oncology,h_igf1mtorPathway:Skeletal muscle hypertrophy is regulated via AKT/mTOR pathway,h_igf1Pathway:IGF-1 Signaling Pathway,h_igf1rPathway:Multiple antiapoptotic pathways from IGF-1R signaling lead to BAD phosphorylation,h_il2rbPathway:IL-2 Receptor Beta Chain in T cell Activation,h_il7Pathway:IL-7 Signal Transduction,h_insulinPathway:Insulin Signaling Pathway,h_longevityPathway:The IGF-1 Receptor and Longevity,h_metPathway:Signaling of Hepatocyte Growth Factor Receptor,h_mtorPathway:mTOR Signaling Pathway,h_nfatPathway:NFAT and Hypertrophy of the heart (Transcription in the broken heart),h_ngfPathway:Nerve growth factor pathway (NGF),h_nkcellsPathway:Ras-Independent pathway in NK cell-mediated cytotoxicity,h_par1pathway:Thrombin signaling and protease-activated receptors,h_pdgfPathway:PDGF Signaling Pathway,h_plcPathway:Phospholipase C Signaling Pathway,h_PparaPathway:Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha),h_ptenPathway:PTEN dependent cell cycle arrest and apoptosis,h_rac1Pathway:Rac 1 cell motility signaling pathway,h_raccycdPathway:Influence of Ras and Rho proteins on G1 to S Transition,h_rasPathway:Ras Signaling Pathway,h_tcrPathway:T Cell Receptor Signaling Pathway,h_tffPathway:Trefoil Factors Initiate  Mucosal Healing,h_tpoPathway:TPO Signaling Pathway,h_trkaPathway:Trka Receptor Signaling Pathway,h_vegfPathway:VEGF, Hypoxia, and Angiogenesis,	GO:0001678~cellular glucose homeostasis,GO:0001953~negative regulation of cell-matrix adhesion,GO:0002687~positive regulation of leukocyte migration,GO:0006366~transcription from RNA polymerase II promoter,GO:0006606~protein import into nucleus,GO:0006955~immune response,GO:0007165~signal transduction,GO:0008286~insulin receptor signaling pathway,GO:0008625~extrinsic apoptotic signaling pathway via death domain receptors,GO:0008630~intrinsic apoptotic signaling pathway in response to DNA damage,GO:0010592~positive regulation of lamellipodium assembly,GO:0015031~protein transport,GO:0016310~phosphorylation,GO:0019221~cytokine-mediated signaling pathway,GO:0030183~B cell differentiation,GO:0030217~T cell differentiation,GO:0030316~osteoclast differentiation,GO:0032760~positive regulation of tumor necrosis factor production,GO:0032869~cellular response to insulin stimulus,GO:0033120~positive regulation of RNA splicing,GO:0034143~regulation of toll-like receptor 4 signaling pathway,GO:0034446~substrate adhesion-dependent cell spreading,GO:0034644~cellular response to UV,GO:0034976~response to endoplasmic reticulum stress,GO:0035655~interleukin-18-mediated signaling pathway,GO:0042307~positive regulation of protein import into nucleus,GO:0043066~negative regulation of apoptotic process,GO:0043491~protein kinase B signaling,GO:0045671~negative regulation of osteoclast differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046326~positive regulation of glucose import,GO:0046854~phosphatidylinositol phosphorylation,GO:0048009~insulin-like growth factor receptor signaling pathway,GO:0048661~positive regulation of smooth muscle cell proliferation,GO:0050821~protein stabilization,GO:0051491~positive regulation of filopodium assembly,GO:0051497~negative regulation of stress fiber assembly,GO:0060396~growth hormone receptor signaling pathway,GO:0097529~myeloid leukocyte migration,GO:1900103~positive regulation of endoplasmic reticulum unfolded protein response,GO:1903076~regulation of protein localization to plasma membrane,GO:1903078~positive regulation of protein localization to plasma membrane,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005801~cis-Golgi network,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005911~cell-cell junction,GO:0005942~phosphatidylinositol 3-kinase complex,GO:0005943~phosphatidylinositol 3-kinase complex, class IA,GO:0016020~membrane,GO:0048471~perinuclear region of cytoplasm,GO:1990578~perinuclear endoplasmic reticulum membrane,	GO:0001784~phosphotyrosine binding,GO:0003677~DNA binding,GO:0004879~RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding,GO:0005068~transmembrane receptor protein tyrosine kinase adaptor activity,GO:0005158~insulin receptor binding,GO:0005159~insulin-like growth factor receptor binding,GO:0005168~neurotrophin TRKA receptor binding,GO:0005515~protein binding,GO:0016301~kinase activity,GO:0019209~kinase activator activity,GO:0019903~protein phosphatase binding,GO:0035014~phosphatidylinositol 3-kinase regulator activity,GO:0036312~phosphatidylinositol 3-kinase regulatory subunit binding,GO:0043125~ErbB-3 class receptor binding,GO:0043548~phosphatidylinositol 3-kinase binding,GO:0043559~insulin binding,GO:0043560~insulin receptor substrate binding,GO:0046935~1-phosphatidylinositol-3-kinase regulator activity,GO:0046982~protein heterodimerization activity,GO:0052742~phosphatidylinositol kinase activity,	IPR000198:RhoGAP_dom,IPR000980:SH2,IPR001452:SH3_domain,IPR003070:NR4A1-3,IPR008936:Rho_GTPase_activation_prot,IPR032498:PI3K_P85_iSH2,IPR035020:PI3kinase_P85_cSH2,IPR035022:PI3kinase_P85_nSH2,IPR035591:PI3K_p85alpha_SH3,IPR036028:SH3-like_dom_sf,IPR036860:SH2_dom_sf,IPR044124:ISH2_PIK3R1,	hsa01521:EGFR tyrosine kinase inhibitor resistance,hsa01522:Endocrine resistance,hsa01524:Platinum drug resistance,hsa04012:ErbB signaling pathway,hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04024:cAMP signaling pathway,hsa04062:Chemokine signaling pathway,hsa04066:HIF-1 signaling pathway,hsa04068:FoxO signaling pathway,hsa04070:Phosphatidylinositol signaling system,hsa04071:Sphingolipid signaling pathway,hsa04072:Phospholipase D signaling pathway,hsa04140:Autophagy - animal,hsa04150:mTOR signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04152:AMPK signaling pathway,hsa04210:Apoptosis,hsa04211:Longevity regulating pathway,hsa04213:Longevity regulating pathway - multiple species,hsa04218:Cellular senescence,hsa04360:Axon guidance,hsa04370:VEGF signaling pathway,hsa04380:Osteoclast differentiation,hsa04510:Focal adhesion,hsa04550:Signaling pathways regulating pluripotency of stem cells,hsa04611:Platelet activation,hsa04613:Neutrophil extracellular trap formation,hsa04620:Toll-like receptor signaling pathway,hsa04625:C-type lectin receptor signaling pathway,hsa04630:JAK-STAT signaling pathway,hsa04650:Natural killer cell mediated cytotoxicity,hsa04660:T cell receptor signaling pathway,hsa04662:B cell receptor signaling pathway,hsa04664:Fc epsilon RI signaling pathway,hsa04666:Fc gamma R-mediated phagocytosis,hsa04668:TNF signaling pathway,hsa04670:Leukocyte transendothelial migration,hsa04722:Neurotrophin signaling pathway,hsa04725:Cholinergic synapse,hsa04750:Inflammatory mediator regulation of TRP channels,hsa04810:Regulation of actin cytoskeleton,hsa04910:Insulin signaling pathway,hsa04914:Progesterone-mediated oocyte maturation,hsa04915:Estrogen signaling pathway,hsa04917:Prolactin signaling pathway,hsa04919:Thyroid hormone signaling pathway,hsa04923:Regulation of lipolysis in adipocytes,hsa04926:Relaxin signaling pathway,hsa04929:GnRH secretion,hsa04930:Type II diabetes mellitus,hsa04931:Insulin resistance,hsa04932:Non-alcoholic fatty liver disease,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa04935:Growth hormone synthesis, secretion and action,hsa04960:Aldosterone-regulated sodium reabsorption,hsa04973:Carbohydrate digestion and absorption,hsa05010:Alzheimer disease,hsa05017:Spinocerebellar ataxia,hsa05020:Prion disease,hsa05100:Bacterial invasion of epithelial cells,hsa05131:Shigellosis,hsa05135:Yersinia infection,hsa05142:Chagas disease,hsa05146:Amoebiasis,hsa05160:Hepatitis C,hsa05161:Hepatitis B,hsa05162:Measles,hsa05163:Human cytomegalovirus infection,hsa05164:Influenza A,hsa05165:Human papillomavirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05171:Coronavirus disease - COVID-19,hsa05200:Pathways in cancer,hsa05203:Viral carcinogenesis,hsa05205:Proteoglycans in cancer,hsa05206:MicroRNAs in cancer,hsa05207:Chemical carcinogenesis - receptor activation,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05210:Colorectal cancer,hsa05211:Renal cell carcinoma,hsa05212:Pancreatic cancer,hsa05213:Endometrial cancer,hsa05214:Glioma,hsa05215:Prostate cancer,hsa05218:Melanoma,hsa05220:Chronic myeloid leukemia,hsa05221:Acute myeloid leukemia,hsa05222:Small cell lung cancer,hsa05223:Non-small cell lung cancer,hsa05224:Breast cancer,hsa05225:Hepatocellular carcinoma,hsa05226:Gastric cancer,hsa05230:Central carbon metabolism in cancer,hsa05231:Choline metabolism in cancer,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,hsa05415:Diabetic cardiomyopathy,hsa05417:Lipid and atherosclerosis,hsa05418:Fluid shear stress and atherosclerosis,	269880~SHORT syndrome,615214~Agammaglobulinemia 7, autosomal recessive,616005~Immunodeficiency 36,		SM00252:SH2,SM00324:RhoGAP,SM00326:SH3,	KW-0346~Stress response,KW-0653~Protein transport,KW-0813~Transport,KW-0945~Host-virus interaction,		KW-0225~Disease variant,KW-0242~Dwarfism,	KW-0175~Coiled coil,KW-0677~Repeat,KW-0727~SH2 domain,KW-0728~SH3 domain,		KW-0418~Kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Pro residues,DOMAIN:Rho-GAP,DOMAIN:SH2,DOMAIN:SH2 1,DOMAIN:SH2 2,DOMAIN:SH3,REGION:Disordered,
PLD3	phospholipase D family member 3(PLD3)	Homo sapiens		h_cb1rPathway:Metabolism of Anandamide, an Endogenous Cannabinoid,	GO:0002376~immune system process,GO:0006259~DNA metabolic process,GO:0006954~inflammatory response,GO:0014902~myotube differentiation,GO:0016042~lipid catabolic process,GO:1900015~regulation of cytokine production involved in inflammatory response,	GO:0000139~Golgi membrane,GO:0005765~lysosomal membrane,GO:0005789~endoplasmic reticulum membrane,GO:0016020~membrane,GO:0031901~early endosome membrane,GO:0031902~late endosome membrane,GO:0043202~lysosomal lumen,GO:0070062~extracellular exosome,	GO:0003824~catalytic activity,GO:0004630~phospholipase D activity,GO:0005515~protein binding,GO:0045145~single-stranded DNA 5'-3' exodeoxyribonuclease activity,	IPR001736:PLipase_D/transphosphatidylase,IPR025202:PLD-like_dom,IPR032803:PLDc_3,	hsa00564:Glycerophospholipid metabolism,hsa00565:Ether lipid metabolism,hsa01100:Metabolic pathways,	617770~Spinocerebellar ataxia 46,		SM00155:PLDc,	KW-0391~Immunity,KW-0395~Inflammatory response,KW-0442~Lipid degradation,KW-0443~Lipid metabolism,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0458~Lysosome,KW-0472~Membrane,KW-0967~Endosome,	KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0950~Spinocerebellar ataxia,	KW-0677~Repeat,KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0269~Exonuclease,KW-0378~Hydrolase,KW-0540~Nuclease,	KW-0325~Glycoprotein,KW-0832~Ubl conjugation,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:PLD phosphodiesterase,DOMAIN:PLD phosphodiesterase 1,DOMAIN:PLD phosphodiesterase 2,DOMAIN:Phospholipase D-like,MUTAGEN:K->R: Impairs myotube formation.,MUTAGEN:Y->A: Slightly increased plasma membrane localization, does not affect delivery to lysosomes.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
PMVK	phosphomevalonate kinase(PMVK)	Homo sapiens			GO:0006695~cholesterol biosynthetic process,GO:0016126~sterol biosynthetic process,GO:0016310~phosphorylation,GO:0019287~isopentenyl diphosphate biosynthetic process, mevalonate pathway,GO:0070723~response to cholesterol,	GO:0005777~peroxisome,GO:0005829~cytosol,GO:0016020~membrane,GO:0070062~extracellular exosome,	GO:0004631~phosphomevalonate kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,	IPR005919:Pmev_kin_anim,IPR027417:P-loop_NTPase,	hsa00900:Terpenoid backbone biosynthesis,hsa01100:Metabolic pathways,hsa04146:Peroxisome,	175800~Porokeratosis 1, multiple types,	PIRSF036639:PMK_anim,		KW-0152~Cholesterol biosynthesis,KW-0153~Cholesterol metabolism,KW-0443~Lipid metabolism,KW-0444~Lipid biosynthesis,KW-0752~Steroid biosynthesis,KW-0753~Steroid metabolism,KW-0756~Sterol biosynthesis,KW-1207~Sterol metabolism,	KW-0963~Cytoplasm,	KW-0225~Disease variant,		KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0808~Transferase,		MUTAGEN:D->N: Approximately 7-fold decrease in Vmax for MgATP and R-MVP. Approximately 10-fold increase in KM for MgATP and 5-fold increase in KM for R-MVP.,MUTAGEN:K->M: Approximately 100000-fold decrease in Vmax for MgATP.,MUTAGEN:K->M: Approximately 1400-fold decrease in Vmax for MgATP and R-MVP. Approximately 3-fold increase in KM for MgATP and R-MVP.,MUTAGEN:K->M: Approximately 500-fold decrease in Vmax for MgATP and R-MVP. Approximately 3-fold increase in KM for MgATP and R-MVP.,MUTAGEN:K->M: Approximately 8-fold decrease in Vmax for MgATP and R-MVP. Approximately 5-fold increase in KM for MgATP and R-MVP.,MUTAGEN:K->M: Approximately 9-fold decrease in Vmax for MgATP and R-MVP. Approximately 10-fold increase in KM for MgATP and R-MVP.,MUTAGEN:R->M: Almost no change in KM and Vmax for MgATP and R-MVP.,MUTAGEN:R->M: Approximately 10-fold decrease in Vmax for MgATP and R-MVP. Approximately 3-fold increase in KM for MgATP and 50-fold increase in KM for R-MVP.,MUTAGEN:R->M: Approximately 15-fold decrease in Vmax for MgATP and R-MVP. Approximately 50-fold increase in KM for MgATP and approximately 7-fold in KM for R-MVP.,MUTAGEN:R->M: Approximately 20000-fold decrease in Vmax for MgATP.,MUTAGEN:R->M: Approximately 3-fold decrease in Vmax for MgATP and R-MVP. Approximately 5-fold increase in KM for MgATP and no change in KM for R-MVP.,MUTAGEN:R->M: Approximately 3000-fold decrease in Vmax for MgATP and R-MVP. No change in KM for MgATP and approximately 3-fold increase in KM for R-MVP.,MUTAGEN:R->M: Approximately 4-fold decrease in Vmax for MgATP and R-MVP. Approximately 3-fold increase in KM for MgATP and R-MVP.,MUTAGEN:R->M: Approximately 65-fold decrease in Vmax for MgATP and R-MVP. Approximately 8-fold increase in KM for MgATP and 60-fold increase in KM for R-MVP.,MUTAGEN:R->Q: Approximately 85-fold decrease in Vmax for MgATP and R-MVP. Approximately 5-fold increase in KM for MgATP and R-MVP.,
PPCS	phosphopantothenoylcysteine synthetase(PPCS)	Homo sapiens			GO:0003015~heart process,GO:0006085~acetyl-CoA biosynthetic process,GO:0015937~coenzyme A biosynthetic process,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0003824~catalytic activity,GO:0004632~phosphopantothenate--cysteine ligase activity,GO:0005524~ATP binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,	IPR007085:DNA/pantothenate-metab_flavo_C,IPR035929:CoaB-like_sf,	hsa00770:Pantothenate and CoA biosynthesis,hsa01100:Metabolic pathways,hsa01240:Biosynthesis of cofactors,	618189~Cardiomyopathy, dilated, 2C,					KW-0122~Cardiomyopathy,KW-0225~Disease variant,		KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0436~Ligase,	KW-0007~Acetylation,	DOMAIN:DNA/pantothenate metabolism flavoprotein C-terminal,
PAG1	phosphoprotein membrane anchor with glycosphingolipid microdomains 1(PAG1)	Homo sapiens			GO:0002250~adaptive immune response,GO:0007165~signal transduction,GO:0035556~intracellular signal transduction,GO:0050863~regulation of T cell activation,GO:0050868~negative regulation of T cell activation,	GO:0005886~plasma membrane,GO:0045121~membrane raft,	GO:0005515~protein binding,GO:0035591~signaling adaptor activity,GO:0042169~SH2 domain binding,	IPR032748:PAG,					KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,LIPID:S-palmitoyl cysteine,MUTAGEN:Y->F: No effect on interaction with FYN or CSK.,MUTAGEN:Y->F: No effect on interaction with FYN. Abolishes interaction with CSK.,REGION:Disordered,REGION:Interaction with CSK,REGION:Interaction with NHERF1,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical; Signal-anchor for type III membrane protein,
PRPS1	phosphoribosyl pyrophosphate synthetase 1(PRPS1)	Homo sapiens			GO:0006015~5-phosphoribose 1-diphosphate biosynthetic process,GO:0006144~purine nucleobase metabolic process,GO:0006164~purine nucleotide biosynthetic process,GO:0006221~pyrimidine nucleotide biosynthetic process,GO:0007399~nervous system development,GO:0009156~ribonucleoside monophosphate biosynthetic process,GO:0009165~nucleotide biosynthetic process,GO:0016310~phosphorylation,GO:0034418~urate biosynthetic process,GO:0046101~hypoxanthine biosynthetic process,	GO:0002189~ribose phosphate diphosphokinase complex,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016020~membrane,	GO:0000287~magnesium ion binding,GO:0004749~ribose phosphate diphosphokinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016301~kinase activity,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,	IPR000836:PRibTrfase_dom,IPR000842:PRib_PP_synth_CS,IPR005946:Rib-P_diPkinase,IPR029057:PRTase-like,IPR029099:Pribosyltran_N,IPR037515:Rib-P_diPkinase_bac,	hsa00030:Pentose phosphate pathway,hsa00230:Purine metabolism,hsa01100:Metabolic pathways,hsa01200:Carbon metabolism,hsa01230:Biosynthesis of amino acids,	300661~Gout, PRPS-related,300661~Phosphoribosylpyrophosphate synthetase superactivity,301835~Arts syndrome,304500~Deafness, X-linked 1,311070~Charcot-Marie-Tooth disease, X-linked recessive, 5,		SM01400:Pribosyltran_N,	KW-0545~Nucleotide biosynthesis,	KW-0472~Membrane,	KW-0144~Charcot-Marie-Tooth disease,KW-0209~Deafness,KW-0225~Disease variant,KW-0335~Gout,KW-0523~Neurodegeneration,KW-0622~Neuropathy,KW-0682~Retinitis pigmentosa,KW-0991~Intellectual disability,KW-1010~Non-syndromic deafness,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0808~Transferase,		DOMAIN:Phosphoribosyltransferase,DOMAIN:Ribose-phosphate pyrophosphokinase N-terminal,MUTAGEN:N->H: No effect on catalytic activity.,MUTAGEN:S->A: Reduces catalytic activity.,MUTAGEN:S->F: No effect on catalytic activity.,MUTAGEN:Y->F: No effect on catalytic activity.,MUTAGEN:Y->M: Reduces catalytic activity.,REGION:Binding of phosphoribosylpyrophosphate,REGION:Disordered,TRANSMEM:Helical,
PRPSAP1	phosphoribosyl pyrophosphate synthetase associated protein 1(PRPSAP1)	Homo sapiens			GO:0006015~5-phosphoribose 1-diphosphate biosynthetic process,GO:0006139~nucleobase-containing compound metabolic process,GO:0006164~purine nucleotide biosynthetic process,GO:0009165~nucleotide biosynthetic process,	GO:0002189~ribose phosphate diphosphokinase complex,GO:0005737~cytoplasm,	GO:0000287~magnesium ion binding,GO:0004749~ribose phosphate diphosphokinase activity,GO:0004857~enzyme inhibitor activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0042802~identical protein binding,	IPR005946:Rib-P_diPkinase,IPR029057:PRTase-like,IPR029099:Pribosyltran_N,				SM01400:Pribosyltran_N,	KW-0545~Nucleotide biosynthesis,						KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:Ribose-phosphate pyrophosphokinase N-terminal,REGION:Disordered,
GART	phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase(GART)	Homo sapiens			GO:0003360~brainstem development,GO:0006164~purine nucleotide biosynthetic process,GO:0006177~GMP biosynthetic process,GO:0006189~'de novo' IMP biosynthetic process,GO:0006544~glycine metabolic process,GO:0009113~purine nucleobase biosynthetic process,GO:0009168~purine ribonucleoside monophosphate biosynthetic process,GO:0010033~response to organic substance,GO:0010035~response to inorganic substance,GO:0021549~cerebellum development,GO:0021987~cerebral cortex development,GO:0044208~'de novo' AMP biosynthetic process,GO:0046084~adenine biosynthetic process,GO:0046654~tetrahydrofolate biosynthetic process,GO:0097294~'de novo' XMP biosynthetic process,	GO:0005829~cytosol,GO:0016020~membrane,GO:0070062~extracellular exosome,	GO:0004637~phosphoribosylamine-glycine ligase activity,GO:0004641~phosphoribosylformylglycinamidine cyclo-ligase activity,GO:0004644~phosphoribosylglycinamide formyltransferase activity,GO:0005524~ATP binding,GO:0016740~transferase activity,GO:0046872~metal ion binding,	IPR000115:PRibGlycinamide_synth,IPR001555:GART_AS,IPR002376:Formyl_transf_N,IPR004607:GART,IPR004733:PurM_cligase,IPR010918:PurM-like_C_dom,IPR011054:Rudment_hybrid_motif,IPR011761:ATP-grasp,IPR013815:ATP_grasp_subdomain_1,IPR016185:PreATP-grasp_dom_sf,IPR016188:PurM-like_N,IPR020559:PRibGlycinamide_synth_CS,IPR020560:PRibGlycinamide_synth_C-dom,IPR020561:PRibGlycinamid_synth_ATP-grasp,IPR020562:PRibGlycinamide_synth_N,IPR036477:Formyl_transf_N_sf,IPR036676:PurM-like_C_sf,IPR036921:PurM-like_N_sf,IPR037123:PRibGlycinamide_synth_C_sf,	hsa00230:Purine metabolism,hsa00670:One carbon pool by folate,hsa01100:Metabolic pathways,hsa01523:Antifolate resistance,			SM01209:GARS_A,SM01210:GARS_C,	KW-0658~Purine biosynthesis,	KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0460~Magnesium,KW-0464~Manganese,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0436~Ligase,KW-0511~Multifunctional enzyme,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton donor,DOMAIN:ATP-grasp,DOMAIN:Formyl transferase N-terminal,DOMAIN:Phosphoribosylglycinamide synthetase ATP-grasp (A),DOMAIN:Phosphoribosylglycinamide synthetase N-terminal,DOMAIN:PurM-like N-terminal,REGION:AIRS domain,REGION:GART domain,SITE:Raises pKa of active site His,TRANSMEM:Helical,
PCIF1	phosphorylated CTD interacting factor 1(PCIF1)	Homo sapiens			GO:0017148~negative regulation of translation,GO:0045727~positive regulation of translation,GO:0080009~mRNA methylation,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0015630~microtubule cytoskeleton,GO:0045171~intercellular bridge,	GO:0016422~mRNA (2'-O-methyladenosine-N6-)-methyltransferase activity,GO:0099122~RNA polymerase II C-terminal domain binding,GO:1904047~S-adenosyl-L-methionine binding,GO:1990269~RNA polymerase II C-terminal domain phosphoserine binding,	IPR001202:WW_dom,IPR022035:PCIF1_WW,IPR029048:HSP70_C_sf,IPR036020:WW_dom_sf,IPR039881:PCIF1-like,				SM00456:WW,		KW-0539~Nucleus,				KW-0489~Methyltransferase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:PCIF1 WW,DOMAIN:WW,MOTIF:Nuclear localization signal,MUTAGEN:F->G: Strongly reduced formation of N(6),2'-O-dimethyladenosine cap (m6A(m)).,MUTAGEN:N->A: Strongly reduced formation of N(6),2'-O-dimethyladenosine cap (m6A(m)).,MUTAGEN:NPPF->APPA,SPPG: Abolishes formation of N(6),2'-O-dimethyladenosine cap (m6A(m)).,REGION:Disordered,
PAFAH1B1	platelet activating factor acetylhydrolase 1b regulatory subunit 1(PAFAH1B1)	Homo sapiens		h_Lis1Pathway:Lissencephaly gene (LIS1) in neuronal migration and development,	GO:0000132~establishment of mitotic spindle orientation,GO:0000226~microtubule cytoskeleton organization,GO:0001667~ameboidal-type cell migration,GO:0001675~acrosome assembly,GO:0001764~neuron migration,GO:0001961~positive regulation of cytokine-mediated signaling pathway,GO:0007017~microtubule-based process,GO:0007049~cell cycle,GO:0007097~nuclear migration,GO:0007254~JNK cascade,GO:0007268~chemical synaptic transmission,GO:0007281~germ cell development,GO:0007399~nervous system development,GO:0007405~neuroblast proliferation,GO:0007611~learning or memory,GO:0008090~retrograde axonal transport,GO:0008344~adult locomotory behavior,GO:0009306~protein secretion,GO:0010977~negative regulation of neuron projection development,GO:0016042~lipid catabolic process,GO:0017145~stem cell division,GO:0019226~transmission of nerve impulse,GO:0021540~corpus callosum morphogenesis,GO:0021766~hippocampus development,GO:0021819~layer formation in cerebral cortex,GO:0021895~cerebral cortex neuron differentiation,GO:0021987~cerebral cortex development,GO:0030036~actin cytoskeleton organization,GO:0030154~cell differentiation,GO:0031023~microtubule organizing center organization,GO:0036035~osteoclast development,GO:0038026~reelin-mediated signaling pathway,GO:0040019~positive regulation of embryonic development,GO:0042249~establishment of planar polarity of embryonic epithelium,GO:0043622~cortical microtubule organization,GO:0045773~positive regulation of axon extension,GO:0045931~positive regulation of mitotic cell cycle,GO:0046329~negative regulation of JNK cascade,GO:0046469~platelet activating factor metabolic process,GO:0047496~vesicle transport along microtubule,GO:0048854~brain morphogenesis,GO:0050804~modulation of synaptic transmission,GO:0050885~neuromuscular process controlling balance,GO:0051012~microtubule sliding,GO:0051081~nuclear envelope disassembly,GO:0051301~cell division,GO:0051660~establishment of centrosome localization,GO:0051661~maintenance of centrosome location,GO:0060117~auditory receptor cell development,GO:0061003~positive regulation of dendritic spine morphogenesis,GO:0070507~regulation of microtubule cytoskeleton organization,GO:0090102~cochlea development,GO:0090176~microtubule cytoskeleton organization involved in establishment of planar polarity,GO:0097529~myeloid leukocyte migration,GO:1904936~interneuron migration,	GO:0000235~astral microtubule,GO:0000776~kinetochore,GO:0005635~nuclear envelope,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005819~spindle,GO:0005829~cytosol,GO:0005871~kinesin complex,GO:0005874~microtubule,GO:0005875~microtubule associated complex,GO:0005881~cytoplasmic microtubule,GO:0005938~cell cortex,GO:0008247~1-alkyl-2-acetylglycerophosphocholine esterase complex,GO:0031252~cell leading edge,GO:0031514~motile cilium,GO:0031965~nuclear membrane,GO:0032420~stereocilium,GO:0043005~neuron projection,GO:0043025~neuronal cell body,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,GO:0090724~central region of growth cone,GO:0098685~Schaffer collateral - CA1 synapse,GO:0098978~glutamatergic synapse,GO:1904115~axon cytoplasm,	GO:0005515~protein binding,GO:0008017~microtubule binding,GO:0008201~heparin binding,GO:0034452~dynactin binding,GO:0042802~identical protein binding,GO:0043274~phospholipase binding,GO:0045505~dynein intermediate chain binding,GO:0046982~protein heterodimerization activity,GO:0051010~microtubule plus-end binding,GO:0051219~phosphoprotein binding,GO:0070840~dynein complex binding,	IPR001680:WD40_rpt,IPR006594:LisH,IPR015943:WD40/YVTN_repeat-like_dom_sf,IPR017252:Dynein_regulator_LIS1,IPR019775:WD40_repeat_CS,IPR020472:G-protein_beta_WD-40_rep,IPR036322:WD40_repeat_dom_sf,IPR037190:LIS1_N,	hsa00565:Ether lipid metabolism,hsa01100:Metabolic pathways,	607432~Lissencephaly 1,607432~Subcortical laminar heterotopia,	PIRSF037647:Dynein_regulator_Lis1,	SM00320:WD40,SM00667:LisH,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0221~Differentiation,KW-0442~Lipid degradation,KW-0443~Lipid metabolism,KW-0498~Mitosis,KW-0524~Neurogenesis,KW-0813~Transport,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0493~Microtubule,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0451~Lissencephaly,	KW-0175~Coiled coil,KW-0677~Repeat,KW-0853~WD repeat,		KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:LisH,REGION:Disordered,REGION:Interaction with DCX,REGION:Interaction with NDE1,REGION:Interaction with NDEL1,REGION:Interaction with dynein and dynactin,REGION:Required for self-association and interaction with PAFAH1B2 and PAFAH1B3,REPEAT:WD,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,REPEAT:WD 7,
PLEKHA2	pleckstrin homology domain containing A2(PLEKHA2)	Homo sapiens			GO:0001954~positive regulation of cell-matrix adhesion,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0032991~macromolecular complex,	GO:0001968~fibronectin binding,GO:0005515~protein binding,GO:0008289~lipid binding,GO:0030165~PDZ domain binding,GO:0043236~laminin binding,GO:0043325~phosphatidylinositol-3,4-bisphosphate binding,	IPR001849:PH_domain,IPR011993:PH-like_dom_sf,				SM00233:PH,		KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0677~Repeat,	KW-0446~Lipid-binding,		KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:PH,DOMAIN:PH 1,DOMAIN:PH 2,REGION:Disordered,
PLEKHJ1	pleckstrin homology domain containing J1(PLEKHJ1)	Homo sapiens			GO:0001881~receptor recycling,GO:0007032~endosome organization,GO:0042147~retrograde transport, endosome to Golgi,	GO:0005769~early endosome,GO:0005802~trans-Golgi network,GO:0005829~cytosol,GO:0030136~clathrin-coated vesicle,GO:0055037~recycling endosome,	GO:0005515~protein binding,	IPR001849:PH_domain,IPR011993:PH-like_dom_sf,IPR045188:Boi1/Boi2-like,				SM00233:PH,		KW-0333~Golgi apparatus,KW-0967~Endosome,KW-0968~Cytoplasmic vesicle,					KW-0597~Phosphoprotein,	DOMAIN:PH,REGION:Disordered,
PHIP	pleckstrin homology domain interacting protein(PHIP)	Homo sapiens			GO:0001932~regulation of protein phosphorylation,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007010~cytoskeleton organization,GO:0008284~positive regulation of cell proliferation,GO:0008286~insulin receptor signaling pathway,GO:0008360~regulation of cell shape,GO:0022604~regulation of cell morphogenesis,GO:0043066~negative regulation of apoptotic process,GO:0043568~positive regulation of insulin-like growth factor receptor signaling pathway,GO:0045840~positive regulation of mitotic nuclear division,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:2001237~negative regulation of extrinsic apoptotic signaling pathway,	GO:0005634~nucleus,	GO:0005158~insulin receptor binding,GO:0005515~protein binding,GO:0070577~lysine-acetylated histone binding,	IPR001487:Bromodomain,IPR001680:WD40_rpt,IPR015943:WD40/YVTN_repeat-like_dom_sf,IPR018359:Bromodomain_CS,IPR019775:WD40_repeat_CS,IPR020472:G-protein_beta_WD-40_rep,IPR036322:WD40_repeat_dom_sf,IPR036427:Bromodomain-like_sf,		617991~Chung-Jansen syndrome,		SM00297:BROMO,SM00320:WD40,		KW-0539~Nucleus,	KW-0225~Disease variant,KW-0991~Intellectual disability,	KW-0103~Bromodomain,KW-0677~Repeat,KW-0853~WD repeat,			KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:Bromo,DOMAIN:Bromo 1,DOMAIN:Bromo 2,REGION:Disordered,REGION:Mediates interaction with IRS1,REPEAT:WD,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,REPEAT:WD 7,REPEAT:WD 8,
PLRG1	pleiotropic regulator 1(PLRG1)	Homo sapiens			GO:0000398~mRNA splicing, via spliceosome,GO:0034504~protein localization to nucleus,GO:1900087~positive regulation of G1/S transition of mitotic cell cycle,	GO:0000974~Prp19 complex,GO:0001650~fibrillar center,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005662~DNA replication factor A complex,GO:0005681~spliceosomal complex,GO:0016020~membrane,GO:0016607~nuclear speck,GO:0031965~nuclear membrane,GO:0071007~U2-type catalytic step 2 spliceosome,GO:0071013~catalytic step 2 spliceosome,	GO:0005515~protein binding,	IPR001680:WD40_rpt,IPR015943:WD40/YVTN_repeat-like_dom_sf,IPR019775:WD40_repeat_CS,IPR020472:G-protein_beta_WD-40_rep,IPR036322:WD40_repeat_dom_sf,IPR045241:Prp46/PLRG1-like,	hsa03040:Spliceosome,			SM00320:WD40,	KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0472~Membrane,KW-0539~Nucleus,KW-0747~Spliceosome,		KW-0677~Repeat,KW-0812~Transmembrane,KW-0853~WD repeat,KW-1133~Transmembrane helix,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	REGION:Disordered,REPEAT:WD,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,REPEAT:WD 7,TRANSMEM:Helical,
POGZ	pogo transposable element derived with ZNF domain(POGZ)	Homo sapiens			GO:0000724~double-strand break repair via homologous recombination,GO:0007064~mitotic sister chromatid cohesion,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051301~cell division,GO:0051382~kinetochore assembly,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0003676~nucleic acid binding,GO:0003677~DNA binding,GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR004875:DDE_SF_endonuclease_dom,IPR006600:HTH_CenpB_DNA-bd_dom,IPR009057:Homeobox-like_sf,IPR013087:Znf_C2H2_type,IPR036236:Znf_C2H2_sf,		616364~White-Sutton syndrome,		SM00355:ZnF_C2H2,SM00674:CENPB,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0227~DNA damage,KW-0233~DNA recombination,KW-0234~DNA repair,	KW-0158~Chromosome,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0991~Intellectual disability,KW-1268~Autism spectrum disorder,	KW-0175~Coiled coil,KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:C2H2-type,DOMAIN:DDE-1,DOMAIN:HTH CENPB-type,MOTIF:Integrase domain-binding motif (IBM),MUTAGEN:C->A: Abolishes interaction with CBX1, CBX3 and CBX5; when associated with when associated with A-817; A-833 and A-840.,MUTAGEN:C->A: Diminishes interaction with CBX5 and abolishes interaction with CBX1 and CBX5; when associated with A-820; A-833 and A-840.,MUTAGEN:H->A: Abolishes interaction with CBX1, CBX3 and CBX5; when associated with A-817; A-820 and A-833.,MUTAGEN:H->A: Abolishes interaction with CBX1, CBX3 and CBX5; when associated with A-817; A-820 and A-840.,MUTAGEN:S->A: Loss of phosphorylation. Loss of interaction with PSIP1; when associated with A-1392.,MUTAGEN:S->A: Loss of phosphorylation. Loss of interaction with PSIP1; when associated with A-1396.,MUTAGEN:S->D: Phosphomimetic mutant. Significant increase in interaction with PSIP1; when associated with D-1392.,MUTAGEN:S->D: Phosphomimetic mutant. Significant increase in interaction with PSIP1; when associated with D-1396.,REGION:Disordered,REGION:Required for interaction with CBX5,ZN_FING:C2H2-type 1; atypical,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4,ZN_FING:C2H2-type 5,ZN_FING:C2H2-type 6,ZN_FING:C2H2-type 7,ZN_FING:C2H2-type 8,ZN_FING:C2H2-type 9,
PAIP1	poly(A) binding protein interacting protein 1(PAIP1)	Homo sapiens			GO:0006413~translational initiation,GO:0006446~regulation of translational initiation,GO:0019081~viral translation,GO:0044794~positive regulation by host of viral process,GO:0048255~mRNA stabilization,GO:0070934~CRD-mediated mRNA stabilization,GO:1900152~negative regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay,GO:2000767~positive regulation of cytoplasmic translation,	GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0008494~translation activator activity,	IPR003890:MIF4G-like_typ-3,IPR009818:Ataxin-2_C,IPR016024:ARM-type_fold,				SM00543:MIF4G,	KW-0810~Translation regulation,KW-0945~Host-virus interaction,	KW-0963~Cytoplasm,					KW-0007~Acetylation,KW-0488~Methylation,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Ataxin-2 C-terminal,DOMAIN:MIF4G,REGION:Disordered,REGION:PABPC1-interacting motif-1 (PAM1),REGION:PABPC1-interacting motif-2 (PAM2),REGION:PAIP1 middle domain (PAIP1M),
PAIP2	poly(A) binding protein interacting protein 2(PAIP2)	Homo sapiens			GO:0006412~translation,GO:0007283~spermatogenesis,GO:0007613~memory,GO:0017148~negative regulation of translation,GO:0045947~negative regulation of translational initiation,GO:1900271~regulation of long-term synaptic potentiation,	GO:0005737~cytoplasm,	GO:0000900~translation repressor activity, nucleic acid binding,GO:0003729~mRNA binding,GO:0005515~protein binding,GO:0030371~translation repressor activity,	IPR009818:Ataxin-2_C,IPR040396:PAIP2-like,					KW-0810~Translation regulation,	KW-0963~Cytoplasm,					KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,DOMAIN:Ataxin-2 C-terminal,REGION:Disordered,REGION:PABPC1-interacting motif-1 (PAM1),REGION:PABPC1-interacting motif-2 (PAM2),
PABPN1	poly(A) binding protein nuclear 1(PABPN1)	Homo sapiens		h_cpsfPathway:Polyadenylation of mRNA,	GO:0000165~MAPK cascade,GO:0006396~RNA processing,GO:0006397~mRNA processing,GO:0006936~muscle contraction,GO:0016973~poly(A)+ mRNA export from nucleus,GO:0071222~cellular response to lipopolysaccharide,GO:1904247~positive regulation of polynucleotide adenylyltransferase activity,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0016607~nuclear speck,GO:0042405~nuclear inclusion body,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0008143~poly(A) binding,GO:0070063~RNA polymerase binding,	IPR000504:RRM_dom,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR035979:RBD_domain_sf,	hsa03015:mRNA surveillance pathway,hsa05164:Influenza A,	164300~Oculopharyngeal muscular dystrophy,		SM00360:RRM,	KW-0507~mRNA processing,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,	KW-0175~Coiled coil,		KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,DOMAIN:RRM,MUTAGEN:Missing: Abolishes self-association, protein aggregation and cell death.,REGION:Disordered,REGION:Interaction with PAPOLA,REGION:Interaction with SKIP,REGION:Necessary for homooligomerization,REGION:Stimulates PAPOLA,
PAPOLA	poly(A) polymerase alpha(PAPOLA)	Homo sapiens		h_cpsfPathway:Polyadenylation of mRNA,	GO:0006378~mRNA polyadenylation,GO:0006397~mRNA processing,GO:0031123~RNA 3'-end processing,GO:0031124~mRNA 3'-end processing,GO:0031440~regulation of mRNA 3'-end processing,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0016020~membrane,	GO:0000287~magnesium ion binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0030145~manganese ion binding,GO:0046872~metal ion binding,GO:1990817~RNA adenylyltransferase activity,	IPR007010:PolA_pol_RNA-bd_dom,IPR007012:PolA_pol_cen_dom,IPR011068:NuclTrfase_I-like_C,IPR014492:PolyA_polymerase,IPR043519:NT_sf,IPR048840:PolA_pol_NTPase,	hsa03015:mRNA surveillance pathway,		PIRSF018425:PolyA_polymerase,		KW-0507~mRNA processing,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0460~Magnesium,KW-0464~Manganese,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0694~RNA-binding,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO); alternate,DOMAIN:Poly(A) polymerase RNA-binding,DOMAIN:Poly(A) polymerase central,DOMAIN:Poly(A) polymerase nucleotidyltransferase,MOTIF:Nuclear localization signal 1,MOTIF:Nuclear localization signal 2,REGION:Disordered,REGION:Required for interaction with NUDT21,REGION:Ser/Thr-rich,SITE:Interaction with RNA,TRANSMEM:Helical,
PARP1	poly(ADP-ribose) polymerase 1(PARP1)	Homo sapiens	39.Deg_of_Chromosomal_DNA,	h_aifPathway:Opposing roles of AIF in Apoptosis and Cell Survival,h_caspasePathway:Caspase Cascade in Apoptosis,h_chemicalPathway:Apoptotic Signaling in Response to DNA Damage,h_d4gdiPathway:D4-GDI Signaling Pathway,h_fasPathway:FAS signaling pathway ( CD95 ),h_hivnefPathway:HIV-I Nef: negative effector of Fas and TNF,h_tnfr1Pathway:TNFR1 Signaling Pathway,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0000723~telomere maintenance,GO:0006281~DNA repair,GO:0006302~double-strand break repair,GO:0006366~transcription from RNA polymerase II promoter,GO:0006915~apoptotic process,GO:0006974~cellular response to DNA damage stimulus,GO:0007005~mitochondrion organization,GO:0007179~transforming growth factor beta receptor signaling pathway,GO:0010332~response to gamma radiation,GO:0010613~positive regulation of cardiac muscle hypertrophy,GO:0016051~carbohydrate biosynthetic process,GO:0016540~protein autoprocessing,GO:0023019~signal transduction involved in regulation of gene expression,GO:0030225~macrophage differentiation,GO:0030592~DNA ADP-ribosylation,GO:0032042~mitochondrial DNA metabolic process,GO:0032786~positive regulation of DNA-templated transcription, elongation,GO:0032869~cellular response to insulin stimulus,GO:0032880~regulation of protein localization,GO:0033148~positive regulation of intracellular estrogen receptor signaling pathway,GO:0034244~negative regulation of transcription elongation from RNA polymerase II promoter,GO:0034599~cellular response to oxidative stress,GO:0034644~cellular response to UV,GO:0036211~protein modification process,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043504~mitochondrial DNA repair,GO:0044030~regulation of DNA methylation,GO:0045087~innate immune response,GO:0045188~regulation of circadian sleep/wake cycle, non-REM sleep,GO:0045824~negative regulation of innate immune response,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046697~decidualization,GO:0050790~regulation of catalytic activity,GO:0051052~regulation of DNA metabolic process,GO:0051901~positive regulation of mitochondrial depolarization,GO:0060391~positive regulation of SMAD protein import into nucleus,GO:0060545~positive regulation of necroptotic process,GO:0070212~protein poly-ADP-ribosylation,GO:0070213~protein auto-ADP-ribosylation,GO:0071168~protein localization to chromatin,GO:0071294~cellular response to zinc ion,GO:0071932~replication fork reversal,GO:1900182~positive regulation of protein localization to nucleus,GO:1903376~regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway,GO:1903518~positive regulation of single strand break repair,GO:1904044~response to aldosterone,GO:1904178~negative regulation of adipose tissue development,GO:1904357~negative regulation of telomere maintenance via telomere lengthening,GO:1904646~cellular response to beta-amyloid,GO:1904762~positive regulation of myofibroblast differentiation,GO:1905051~regulation of base-excision repair,GO:1905168~positive regulation of double-strand break repair via homologous recombination,GO:1990090~cellular response to nerve growth factor stimulus,GO:1990966~ATP generation from poly-ADP-D-ribose,GO:2001170~negative regulation of ATP biosynthetic process,	GO:0000781~chromosome, telomeric region,GO:0000785~chromatin,GO:0005634~nucleus,GO:0005635~nuclear envelope,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005694~chromosome,GO:0005730~nucleolus,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0016020~membrane,GO:0016604~nuclear body,GO:0032991~macromolecular complex,GO:0032993~protein-DNA complex,GO:0035861~site of double-strand break,GO:0043596~nuclear replication fork,GO:0090734~site of DNA damage,	GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003684~damaged DNA binding,GO:0003723~RNA binding,GO:0003950~NAD+ ADP-ribosyltransferase activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0016779~nucleotidyltransferase activity,GO:0019899~enzyme binding,GO:0019901~protein kinase binding,GO:0030331~estrogen receptor binding,GO:0031491~nucleosome binding,GO:0031625~ubiquitin protein ligase binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0042826~histone deacetylase binding,GO:0051287~NAD binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:0070412~R-SMAD binding,GO:1990404~protein ADP-ribosylase activity,	IPR001357:BRCT_dom,IPR001510:Znf_PARP,IPR004102:Poly(ADP-ribose)pol_reg_dom,IPR008288:PARP,IPR008893:WGR_domain,IPR012317:Poly(ADP-ribose)pol_cat_dom,IPR012982:PARP1-like_PADR1_Zn_ribbon,IPR036420:BRCT_dom_sf,IPR036616:Poly(ADP-ribose)pol_reg_dom_sf,IPR036930:WGR_dom_sf,IPR036957:Znf_PARP_sf,IPR038650:PADR1_C_dom_sf,IPR049296:PARP1-like_PADR1_N,	hsa03410:Base excision repair,hsa04064:NF-kappa B signaling pathway,hsa04210:Apoptosis,hsa04217:Necroptosis,hsa05415:Diabetic cardiomyopathy,		PIRSF000489:NAD_ADPRT,	SM00292:BRCT,SM00773:WGR,SM01335:PADR1,SM01336:zf-PARP,	KW-0053~Apoptosis,KW-0227~DNA damage,KW-0234~DNA repair,KW-0391~Immunity,KW-0399~Innate immunity,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0158~Chromosome,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0520~NAD,KW-0862~Zinc,	KW-0021~Allosteric enzyme,KW-0238~DNA-binding,KW-0328~Glycosyltransferase,KW-0548~Nucleotidyltransferase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0013~ADP-ribosylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	ACT_SITE:For poly [ADP-ribose] polymerase activity,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:BRCT,DOMAIN:PADR1 zinc-binding,DOMAIN:PARP alpha-helical,DOMAIN:PARP catalytic,DOMAIN:PARP-type,DOMAIN:WGR,MOTIF:Nuclear localization signal,MUTAGEN:A->G: Does not affect auto-poly-ADP-ribosylation.,MUTAGEN:A->S,L: Increased DNA-independent poly-ADP-ribosyltransferase activity.,MUTAGEN:C->A: Decreased stability leading to impaired oly-ADP-ribosyltransferase activity.,MUTAGEN:C->R: <0.5% of wild-type activity.,MUTAGEN:D->A: Does not affect DNA-binding. Decreased poly-ADP-ribosyltransferase activity.,MUTAGEN:D->A: Does not affect auto-poly-ADP-ribosylation.,MUTAGEN:D->G: Abolished interaction with TIMELESS.,MUTAGEN:D->N: 0.6% of wild-type activity.,MUTAGEN:D->N: Abolished cleavage by caspase-7 (CASP7).,MUTAGEN:DNLLD->ANLLA: Able to bind EB-47 or BAD inhibitors in absence of DNA. Released from DNA strand break independently of EB-47 or BAD inhibitors.,MUTAGEN:E->A,D,Q,K: Poly-ADP-ribosyltransferase activity is inhibited while mono-ADP-ribosyltransferase activity is not affected; only monomers are added. Disrupts interaction with CHD1L and ability to recruit PARP2 to DNA damage sites.,MUTAGEN:E->Q: Does not affect ADP-ribosyltransferase activity.,MUTAGEN:EAPVT->ASSVA: Does not affect DNA-independent poly-ADP-ribosyltransferase activity.,MUTAGEN:EMLDNLLD->AMLANLLA: Able to bind BAD inhibitor in absence of DNA.,MUTAGEN:F->A: Abolished DNA-binding.,MUTAGEN:F->D: Strongly decreased homodimerization.,MUTAGEN:F->S: 10% of wild-type activity.,MUTAGEN:F->Y: Does not affect auto-poly-ADP-ribosylation.,MUTAGEN:FDGKV->ADGKA: Abolished DNA-binding.,MUTAGEN:G->L: Increased DNA-independent poly-ADP-ribosyltransferase activity.,MUTAGEN:G->S: Does not affect DNA-independent poly-ADP-ribosyltransferase activity.,MUTAGEN:H->A: Poly-ADP-ribosyltransferase activity is impaired while mono-ADP-ribosyltransferase activity is not affected; produces a mixture of short and mono ADP-ribose chains.,MUTAGEN:H->A: Strongly reduced serine ADP-ribosylation, caused by abolished interaction with HPF1.,MUTAGEN:H->E: Decreased polymerase activity, leading to the production of short poly-ADP-ribose chains.,MUTAGEN:K->A: Decreased poly-ADP-ribosyltransferase activity upon binding to damaged DNA.,MUTAGEN:K->A: Does not affect auto-poly-ADP-ribosylation.,MUTAGEN:K->I: Abolishes enzymatic activity.,MUTAGEN:K->Q: Strongly decreased ability of the BRCT domain to bind intact DNA; when associated with Q-394.,MUTAGEN:K->Q: Strongly decreased ability of the BRCT domain to bind intact DNA; when associated with Q-418.,MUTAGEN:KDEVK->QDEVQ: Strongly decreased ability of the BRCT domain to bind intact DNA.,MUTAGEN:KK->QQ: Strongly decreased ability of the BRCT domain to bind intact DNA.,MUTAGEN:KLTGTANK->QLTGTANQ: Strongly decreased ability of the BRCT domain to bind intact DNA.,MUTAGEN:L->A: Increased auto-poly-ADP-ribosylation.,MUTAGEN:L->F: 1.5% of wild-type activity.,MUTAGEN:L->F: Leads to constitutive activity in absence of DNA damage due to unfolding of the PARP alpha-helical domain, relieving autoinhibition.,MUTAGEN:L->P: 1.5% of wild-type activity.,MUTAGEN:LGKL->AGKA: Increased auto-poly-ADP-ribosylation.,MUTAGEN:LGMI->AGMA: Abolished DNA-binding.,MUTAGEN:LKV->DKD: Does not affect auto-poly-ADP-ribosylation.,MUTAGEN:LW->EE: Strongly reduced serine ADP-ribosylation, caused by abolished interaction with HPF1.,MUTAGEN:M->A: No effect.,MUTAGEN:M->D: Strongly decreased homodimerization.,MUTAGEN:M->V: <0.5% of wild-type activity.,MUTAGEN:Missing: Abolished interaction with TIMELESS.,MUTAGEN:Missing: Abolished prolonged residence (trapping) to chromatin.,MUTAGEN:N->A: Decreased poly-ADP-ribosyltransferase activity upon binding to damaged DNA.,MUTAGEN:N->S: 4% of wild-type activity.,MUTAGEN:P->G,S: Does not affect DNA-independent poly-ADP-ribosyltransferase activity.,MUTAGEN:P->G: Does not affect DNA-independent poly-ADP-ribosyltransferase activity.,MUTAGEN:P->G: No effect.,MUTAGEN:PP->GG: Does not affect auto-poly-ADP-ribosylation.,MUTAGEN:Q->A: Does not affect DNA-binding.,MUTAGEN:Q->L: Does not affect auto-poly-ADP-ribosylation.,MUTAGEN:R->A: Abolished DNA-binding.,MUTAGEN:R->A: Decreased poly-ADP-ribosyltransferase activity upon binding to damaged DNA.,MUTAGEN:R->A: Increased affinity for DNA damage sites.,MUTAGEN:R->A: Strongly decreased DNA-binding.,MUTAGEN:R->E: Abolished binding to DNA strand breaks.,MUTAGEN:S->A: Abolishes automodification on serine following interaction with HPF1, leading to delay dissociation from chromatin; when associated with A-499 and A-507.,MUTAGEN:S->A: Abolishes automodification on serine following interaction with HPF1, leading to delay dissociation from chromatin; when associated with A-499 and A-519.,MUTAGEN:S->A: Abolishes automodification on serine following interaction with HPF1, leading to delay dissociation from chromatin; when associated with A-507 and A-519.,MUTAGEN:S->A: Does not affect translocation into the cytosol.,MUTAGEN:S->A: No effect.,MUTAGEN:T->A: Abolished phosphorylation by PRKDC, inhibiting translocation into the cytosol.,MUTAGEN:T->A: Does not affect auto-poly-ADP-ribosylation.,MUTAGEN:T->A: Does not affect translocation into the cytosol.,MUTAGEN:T->A: Strongly reduced poly-ADP-ribosyltransferase and ability to regulate chromatin compaction.,MUTAGEN:V->A: Does not affect auto-poly-ADP-ribosylation.,MUTAGEN:VEVV->GEVQ: Strongly reduced interaction with TIMELESS.,MUTAGEN:W->A,R,E: Strongly reduced poly-ADP-ribosyltransferase activity. Able to bind damaged DNA, however, defects in the interdomain communication prevent unfolding of the PARP alpha-helical domain, blocking catalytic activation.,MUTAGEN:W->A: Decreased poly-ADP-ribosyltransferase activity upon binding to damaged DNA.,MUTAGEN:W->A: Decreased poly-ADP-ribosyltransferase activity upon binding to damaged DNA. Abolished ability to mediate DNA intrastrand transfer (named 'monkey-bar mechanism').,MUTAGEN:W->F: Does not affect auto-poly-ADP-ribosylation.,MUTAGEN:Y->H: 14% of wild-type activity and increased branching 15-fold.,REGION:Automodification domain,REGION:Disordered,REGION:Zinc ribbon,SITE:Cleavage; by caspase-3 and caspase-7,ZN_FING:PARP-type 1,ZN_FING:PARP-type 2,
PARP14	poly(ADP-ribose) polymerase family member 14(PARP14)	Homo sapiens			GO:0010629~negative regulation of gene expression,GO:0042531~positive regulation of tyrosine phosphorylation of STAT protein,GO:0042532~negative regulation of tyrosine phosphorylation of STAT protein,GO:0045087~innate immune response,GO:0045892~negative regulation of transcription, DNA-templated,GO:0060336~negative regulation of interferon-gamma-mediated signaling pathway,GO:0070212~protein poly-ADP-ribosylation,GO:1902216~positive regulation of interleukin-4-mediated signaling pathway,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016020~membrane,	GO:0003714~transcription corepressor activity,GO:0003950~NAD+ ADP-ribosyltransferase activity,GO:0005515~protein binding,GO:0016779~nucleotidyltransferase activity,GO:0019899~enzyme binding,GO:0070403~NAD+ binding,GO:1990404~protein ADP-ribosylase activity,	IPR002589:Macro_dom,IPR004170:WWE-dom,IPR012317:Poly(ADP-ribose)pol_cat_dom,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR034517:PAR14_RRM2,IPR037197:WWE_dom_sf,IPR043472:Macro_dom-like,				SM00506:A1pp,	KW-0391~Immunity,KW-0399~Innate immunity,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0677~Repeat,	KW-0520~NAD,	KW-0328~Glycosyltransferase,KW-0548~Nucleotidyltransferase,KW-0808~Transferase,	KW-0013~ADP-ribosylation,KW-0597~Phosphoprotein,	DOMAIN:Macro,DOMAIN:Macro 1,DOMAIN:Macro 2,DOMAIN:Macro 3,DOMAIN:PARP catalytic,DOMAIN:WWE,MUTAGEN:G->E: Abolishes interaction with PARP10.,REGION:Disordered,
PUF60	poly(U) binding splicing factor 60(PUF60)	Homo sapiens			GO:0000380~alternative mRNA splicing, via spliceosome,GO:0000381~regulation of alternative mRNA splicing, via spliceosome,GO:0006376~mRNA splice site selection,GO:0006397~mRNA processing,GO:0006915~apoptotic process,GO:0008380~RNA splicing,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0030054~cell junction,GO:1990904~ribonucleoprotein complex,	GO:0003677~DNA binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0045296~cadherin binding,	IPR000504:RRM_dom,IPR003954:RRM_dom_euk,IPR006532:PUF60-like,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR034209:PUF60_RRM1,IPR034211:PUF60_RRM2,IPR034212:PUF60_RRM3,IPR035979:RBD_domain_sf,	hsa03040:Spliceosome,	615583~Verheij syndrome,		SM00360:RRM,SM00361:RRM_1,	KW-0053~Apoptosis,KW-0507~mRNA processing,KW-0508~mRNA splicing,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,	KW-0677~Repeat,		KW-0238~DNA-binding,KW-0678~Repressor,KW-0687~Ribonucleoprotein,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:RRM,DOMAIN:RRM 1,DOMAIN:RRM 2,DOMAIN:RRM 3; atypical,REGION:Disordered,REGION:Inhibits homodimerization,REGION:Inhibits transcriptional repression, interaction with ERCC3 and apoptosis induction,
PCBP1	poly(rC) binding protein 1(PCBP1)	Homo sapiens			GO:0039694~viral RNA genome replication,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0014069~postsynaptic density,GO:0016020~membrane,GO:0016607~nuclear speck,GO:0036464~cytoplasmic ribonucleoprotein granule,GO:0070062~extracellular exosome,GO:1990904~ribonucleoprotein complex,	GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003697~single-stranded DNA binding,GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0005515~protein binding,GO:0045296~cadherin binding,GO:0098847~sequence-specific single stranded DNA binding,	IPR004087:KH_dom,IPR004088:KH_dom_type_1,IPR036612:KH_dom_type_1_sf,	hsa03040:Spliceosome,hsa04216:Ferroptosis,hsa04623:Cytosolic DNA-sensing pathway,			SM00322:KH,	KW-0693~Viral RNA replication,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,		KW-0238~DNA-binding,KW-0687~Ribonucleoprotein,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:K Homology,DOMAIN:KH 1,DOMAIN:KH 2,DOMAIN:KH 3,
PCBP2	poly(rC) binding protein 2(PCBP2)	Homo sapiens			GO:0010468~regulation of gene expression,GO:0016071~mRNA metabolic process,GO:0039694~viral RNA genome replication,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0045087~innate immune response,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0050687~negative regulation of defense response to virus,GO:0051252~regulation of RNA metabolic process,GO:0051607~defense response to virus,GO:0075522~IRES-dependent viral translational initiation,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005925~focal adhesion,GO:0014069~postsynaptic density,GO:0016020~membrane,GO:0070062~extracellular exosome,GO:1990904~ribonucleoprotein complex,	GO:0003697~single-stranded DNA binding,GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0005515~protein binding,GO:0019899~enzyme binding,GO:0031625~ubiquitin protein ligase binding,GO:1990829~C-rich single-stranded DNA binding,	IPR004087:KH_dom,IPR004088:KH_dom_type_1,IPR036612:KH_dom_type_1_sf,	hsa04216:Ferroptosis,			SM00322:KH,	KW-0051~Antiviral defense,KW-0391~Immunity,KW-0399~Innate immunity,KW-0693~Viral RNA replication,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,		KW-0238~DNA-binding,KW-0687~Ribonucleoprotein,KW-0694~RNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:K Homology,DOMAIN:KH 1,DOMAIN:KH 2,DOMAIN:KH 3,REGION:Disordered,SITE:Cleavage, by viral proteinase 3CD,
PCGF5	polycomb group ring finger 5(PCGF5)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0060816~random inactivation of X chromosome,GO:0060818~inactivation of paternal X chromosome by genetic imprinting,	GO:0000805~X chromosome,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005794~Golgi apparatus,GO:0005813~centrosome,GO:0031519~PcG protein complex,GO:0035102~PRC1 complex,	GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR001841:Znf_RING,IPR013083:Znf_RING/FYVE/PHD,IPR017907:Znf_RING_CS,IPR032443:RAWUL,	hsa03083:Polycomb repressive complex,hsa04550:Signaling pathways regulating pluripotency of stem cells,			SM00184:RING,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0678~Repressor,		COMPBIAS:Basic and acidic residues,REGION:Disordered,ZN_FING:RING-type,
PQBP1	polyglutamine binding protein 1(PQBP1)	Homo sapiens			GO:0000380~alternative mRNA splicing, via spliceosome,GO:0002218~activation of innate immune response,GO:0002230~positive regulation of defense response to virus by host,GO:0006355~regulation of transcription, DNA-templated,GO:0031175~neuron projection development,GO:0032481~positive regulation of type I interferon production,GO:0043484~regulation of RNA splicing,GO:0045087~innate immune response,GO:0045893~positive regulation of transcription, DNA-templated,GO:0048814~regulation of dendrite morphogenesis,GO:0051607~defense response to virus,GO:0071360~cellular response to exogenous dsRNA,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0010494~cytoplasmic stress granule,GO:0016604~nuclear body,GO:0016607~nuclear speck,GO:0071598~neuronal ribonucleoprotein granule,	GO:0003677~DNA binding,GO:0003690~double-stranded DNA binding,GO:0003713~transcription coactivator activity,GO:0005515~protein binding,GO:0043021~ribonucleoprotein complex binding,	IPR001202:WW_dom,IPR036020:WW_dom_sf,	hsa03040:Spliceosome,	309500~Renpenning syndrome,		SM00456:WW,	KW-0391~Immunity,KW-0399~Innate immunity,KW-0507~mRNA processing,KW-0508~mRNA splicing,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0991~Intellectual disability,	KW-0677~Repeat,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:WW,MUTAGEN:L->D: Abolishes interaction with TXNL4A.,MUTAGEN:N->D: Strongly reduces affinity for TXNL4A.,MUTAGEN:P->D: Abolishes interaction with TXNL4A.,MUTAGEN:P->G: No effect on transcriptional activation.,MUTAGEN:R->D: Strongly reduces affinity for TXNL4A.,MUTAGEN:V->D: Abolishes interaction with TXNL4A.,MUTAGEN:W->A: Enhances transcriptional activation. Reduces transcriptional activation; when associated with A-75. Markedly reduced transcriptional activation; when associated with A-64; A-65 and A-66. Abolishes transcriptional activation; when associated with A-64; A-65; A-66 and A-75.,MUTAGEN:W->A: No effect on transcriptional activation. Reduces transcriptional activation; when associated with A-52. Abolishes transcriptional activation; when associated with A-52; A-64; A-65 and A-66.,MUTAGEN:W->A: No effect on transcriptional activation; when associated with A-64 and A-65. Markedly reduced transcriptional activation; when associated with A-52; A-64 and A-65. Abolishes transcriptional activation; when associated with A-52; A-64; A-65 and A-75.,MUTAGEN:Y->A: No effect on transcriptional activation; when associated with A-64 and A-66. Markedly reduced transcriptional activation; when associated with A-52; A-64 and A-66. Abolishes transcriptional activation; when associated with A-52; A-64; A-66 and A-75.,MUTAGEN:Y->A: No effect on transcriptional activation; when associated with A-65 and A-66. Markedly reduced transcriptional activation; when associated with A-52; A-65 and A-66. Abolishes transcriptional activation; when associated with A-52; A-65; A-66 and A-75.,MUTAGEN:Y->D: Abolishes interaction with TXNL4A.,REGION:3 X 2 AA tandem repeats of [DE]-R,REGION:5 X 7 AA approximate tandem repeats of D-R-[SG]-H-D-K-S,REGION:7 X 2 AA tandem repeats of [DE]-R,REGION:Disordered,REGION:Important for interaction with TXNL4A,REPEAT:1-1,REPEAT:1-2,REPEAT:1-3,REPEAT:1-4,REPEAT:1-5,REPEAT:2-1,REPEAT:2-2,REPEAT:2-3,REPEAT:3-1,REPEAT:3-2,REPEAT:3-3,REPEAT:3-4,REPEAT:3-5,REPEAT:3-6,REPEAT:3-7,
PHC3	polyhomeotic homolog 3(PHC3)	Homo sapiens			GO:0045892~negative regulation of transcription, DNA-templated,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0031519~PcG protein complex,GO:0032991~macromolecular complex,GO:0035102~PRC1 complex,	GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0042393~histone binding,	IPR001660:SAM,IPR012313:Znf_FCS,IPR013761:SAM/pointed_sf,IPR038603:Znf_FCS_sf,	hsa03083:Polycomb repressive complex,			SM00454:SAM,		KW-0539~Nucleus,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:FCS-type,DOMAIN:SAM,MOTIF:HD1,REGION:Disordered,ZN_FING:FCS-type,
PTBP1	polypyrimidine tract binding protein 1(PTBP1)	Homo sapiens			GO:0000381~regulation of alternative mRNA splicing, via spliceosome,GO:0006397~mRNA processing,GO:0008380~RNA splicing,GO:0022008~neurogenesis,GO:0033119~negative regulation of RNA splicing,GO:0035307~positive regulation of protein dephosphorylation,GO:0043484~regulation of RNA splicing,GO:0045595~regulation of cell differentiation,GO:0045665~negative regulation of neuron differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048025~negative regulation of mRNA splicing, via spliceosome,GO:0051148~negative regulation of muscle cell differentiation,GO:0070886~positive regulation of calcineurin-NFAT signaling cascade,GO:0075522~IRES-dependent viral translational initiation,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0016020~membrane,GO:0070062~extracellular exosome,	GO:0003676~nucleic acid binding,GO:0003677~DNA binding,GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0005515~protein binding,GO:0008187~poly-pyrimidine tract binding,GO:0036002~pre-mRNA binding,	IPR000504:RRM_dom,IPR006536:HnRNP-L/PTB,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR021790:PTBP1-like_RRM2,IPR035000:PTBP1_RRM1,IPR035001:PTBP1_RRM3,IPR035979:RBD_domain_sf,				SM00360:RRM,	KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,		KW-0677~Repeat,		KW-0010~Activator,KW-0678~Repressor,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:RRM,DOMAIN:RRM 1,DOMAIN:RRM 2,DOMAIN:RRM 3,DOMAIN:RRM 4,REGION:Disordered,
PTBP3	polypyrimidine tract binding protein 3(PTBP3)	Homo sapiens			GO:0006397~mRNA processing,GO:0008380~RNA splicing,GO:0009653~anatomical structure morphogenesis,GO:0033119~negative regulation of RNA splicing,GO:0043249~erythrocyte maturation,GO:0043484~regulation of RNA splicing,GO:0045595~regulation of cell differentiation,	GO:0005634~nucleus,	GO:0003723~RNA binding,GO:0003729~mRNA binding,	IPR000504:RRM_dom,IPR006536:HnRNP-L/PTB,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR021790:PTBP1-like_RRM2,IPR033110:PTBP3_RRM4,IPR034326:ROD1_RRM1,IPR035979:RBD_domain_sf,				SM00360:RRM,	KW-0221~Differentiation,KW-0265~Erythrocyte maturation,KW-0507~mRNA processing,KW-0508~mRNA splicing,			KW-0677~Repeat,		KW-0678~Repressor,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:RRM,DOMAIN:RRM 1,DOMAIN:RRM 2,DOMAIN:RRM 3,DOMAIN:RRM 4,REGION:Disordered,
PBDC1	polysaccharide biosynthesis domain containing 1(PBDC1)	Homo sapiens					GO:0005515~protein binding,	IPR008476:PBDC1_metazoa/fungi,IPR023139:PBDC1-like_dom_sf,											KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,REGION:Disordered,
KCTD20	potassium channel tetramerization domain containing 20(KCTD20)	Homo sapiens			GO:0042327~positive regulation of phosphorylation,	GO:0005737~cytoplasm,GO:0016020~membrane,		IPR000210:BTB/POZ_dom,IPR011333:SKP1/BTB/POZ_sf,IPR039885:BTBD10/KCTD20_BTB/POZ,IPR039886:BTBD10/KCTD20,				SM00225:BTB,		KW-0472~Membrane,KW-0963~Cytoplasm,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				DOMAIN:BTB,REGION:Disordered,TRANSMEM:Helical,
PRPF19	pre-mRNA processing factor 19(PRPF19)	Homo sapiens			GO:0000077~DNA damage checkpoint,GO:0000209~protein polyubiquitination,GO:0000244~spliceosomal tri-snRNP complex assembly,GO:0000245~spliceosomal complex assembly,GO:0000398~mRNA splicing, via spliceosome,GO:0006281~DNA repair,GO:0006303~double-strand break repair via nonhomologous end joining,GO:0008104~protein localization,GO:0008610~lipid biosynthetic process,GO:0010498~proteasomal protein catabolic process,GO:0048026~positive regulation of mRNA splicing, via spliceosome,GO:0070534~protein K63-linked ubiquitination,	GO:0000974~Prp19 complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005662~DNA replication factor A complex,GO:0005681~spliceosomal complex,GO:0005737~cytoplasm,GO:0005811~lipid particle,GO:0005819~spindle,GO:0016020~membrane,GO:0016607~nuclear speck,GO:0035861~site of double-strand break,GO:0071006~U2-type catalytic step 1 spliceosome,GO:0071007~U2-type catalytic step 2 spliceosome,GO:0071013~catalytic step 2 spliceosome,	GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0034450~ubiquitin-ubiquitin ligase activity,GO:0042802~identical protein binding,GO:0061630~ubiquitin protein ligase activity,	IPR001680:WD40_rpt,IPR003613:Ubox_domain,IPR013083:Znf_RING/FYVE/PHD,IPR013915:Pre-mRNA_splic_Prp19,IPR015943:WD40/YVTN_repeat-like_dom_sf,IPR019775:WD40_repeat_CS,IPR020472:G-protein_beta_WD-40_rep,IPR036322:WD40_repeat_dom_sf,IPR038959:Prp19,	hsa03040:Spliceosome,hsa04120:Ubiquitin mediated proteolysis,			SM00320:WD40,SM00504:Ubox,	KW-0227~DNA damage,KW-0234~DNA repair,KW-0507~mRNA processing,KW-0508~mRNA splicing,KW-0833~Ubl conjugation pathway,	KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0551~Lipid droplet,KW-0747~Spliceosome,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0853~WD repeat,		KW-0808~Transferase,	KW-0007~Acetylation,	DOMAIN:Pre-mRNA-splicing factor 19,DOMAIN:U-box,MUTAGEN:Y->A: Loss of interaction with the RPA complex and loss of recruitment to sites of DNA damage.,REGION:May mediate interaction with PSMC5,REPEAT:WD,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,REPEAT:WD 7,
PRPF38B	pre-mRNA processing factor 38B(PRPF38B)	Homo sapiens			GO:0000398~mRNA splicing, via spliceosome,GO:0001558~regulation of cell growth,GO:0006397~mRNA processing,GO:0007165~signal transduction,GO:0008380~RNA splicing,GO:0035025~positive regulation of Rho protein signal transduction,GO:0035556~intracellular signal transduction,GO:0043065~positive regulation of apoptotic process,GO:0043547~positive regulation of GTPase activity,GO:0051056~regulation of small GTPase mediated signal transduction,GO:0051451~myoblast migration,GO:0070301~cellular response to hydrogen peroxide,GO:0071479~cellular response to ionizing radiation,	GO:0005634~nucleus,GO:0005829~cytosol,GO:0071011~precatalytic spliceosome,	GO:0003723~RNA binding,GO:0005085~guanyl-nucleotide exchange factor activity,	IPR000219:DH-domain,IPR001331:GDS_CDC24_CS,IPR001849:PH_domain,IPR005037:PRP38,IPR011993:PH-like_dom_sf,IPR035899:DBL_dom_sf,IPR037853:Net1_PH,	hsa03040:Spliceosome,			SM00233:PH,SM00325:RhoGEF,	KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,KW-0747~Spliceosome,KW-0963~Cytoplasm,	KW-0656~Proto-oncogene,	KW-0175~Coiled coil,		KW-0344~Guanine-nucleotide releasing factor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,DOMAIN:DH,DOMAIN:PH,MOTIF:Nuclear localization signal,REGION:Disordered,REGION:Necessary for nuclear localization,
PRPF40A	pre-mRNA processing factor 40 homolog A(PRPF40A)	Homo sapiens			GO:0000398~mRNA splicing, via spliceosome,GO:0007010~cytoskeleton organization,GO:0007049~cell cycle,GO:0008360~regulation of cell shape,GO:0016477~cell migration,GO:0032465~regulation of cytokinesis,GO:0045292~mRNA cis splicing, via spliceosome,GO:0051301~cell division,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005685~U1 snRNP,GO:0016020~membrane,GO:0016363~nuclear matrix,GO:0016607~nuclear speck,GO:0071004~U2-type prespliceosome,	GO:0003712~transcription cofactor activity,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0070063~RNA polymerase binding,	IPR001202:WW_dom,IPR002713:FF_domain,IPR036020:WW_dom_sf,IPR036517:FF_domain_sf,IPR039726:Prp40-like,IPR045148:TCRG1-like,	hsa03040:Spliceosome,			SM00441:FF,SM00456:WW,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,		KW-0175~Coiled coil,KW-0677~Repeat,			KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:FF,DOMAIN:FF 1,DOMAIN:FF 2,DOMAIN:FF 3,DOMAIN:FF 4,DOMAIN:FF 5,DOMAIN:FF 6,DOMAIN:WW,DOMAIN:WW 1,DOMAIN:WW 2,REGION:Disordered,
PRPF6	pre-mRNA processing factor 6(PRPF6)	Homo sapiens			GO:0000244~spliceosomal tri-snRNP complex assembly,GO:0000245~spliceosomal complex assembly,GO:0000375~RNA splicing, via transesterification reactions,GO:0000398~mRNA splicing, via spliceosome,GO:0006403~RNA localization,GO:0008380~RNA splicing,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005681~spliceosomal complex,GO:0005682~U5 snRNP,GO:0016020~membrane,GO:0016607~nuclear speck,GO:0046540~U4/U6 x U5 tri-snRNP complex,GO:0071005~U2-type precatalytic spliceosome,GO:0071013~catalytic step 2 spliceosome,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0043021~ribonucleoprotein complex binding,	IPR003107:HAT,IPR010491:PRP1_N,IPR011990:TPR-like_helical_dom_sf,IPR019734:TPR_repeat,IPR045075:Syf1-like,	hsa03040:Spliceosome,	613983~Retinitis pigmentosa 60,		SM00028:TPR,SM00386:HAT,	KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,KW-0747~Spliceosome,	KW-0225~Disease variant,KW-0682~Retinitis pigmentosa,	KW-0677~Repeat,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,REGION:Disordered,REPEAT:HAT 1,REPEAT:HAT 2,REPEAT:HAT 3,REPEAT:HAT 4,REPEAT:HAT 5,REPEAT:HAT 6,REPEAT:HAT 7,REPEAT:HAT 8,REPEAT:HAT 9,
PFDN4	prefoldin subunit 4(PFDN4)	Homo sapiens			GO:0006457~protein folding,GO:0061077~chaperone-mediated protein folding,GO:1905907~negative regulation of amyloid fibril formation,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0016020~membrane,GO:0016272~prefoldin complex,	GO:0001540~beta-amyloid binding,GO:0005515~protein binding,GO:0051082~unfolded protein binding,GO:0051087~chaperone binding,	IPR002777:PFD_beta-like,IPR009053:Prefoldin,IPR016661:PFDN4,			PIRSF016477:Prefoldin_subunit_4,			KW-0472~Membrane,KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0143~Chaperone,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	TRANSMEM:Helical,
PFDN6	prefoldin subunit 6(PFDN6)	Homo sapiens			GO:0006457~protein folding,GO:0050821~protein stabilization,GO:0051131~chaperone-mediated protein complex assembly,GO:0061077~chaperone-mediated protein folding,GO:1905907~negative regulation of amyloid fibril formation,	GO:0005737~cytoplasm,GO:0016272~prefoldin complex,GO:0101031~chaperone complex,GO:1990062~RPAP3/R2TP/prefoldin-like complex,	GO:0001540~beta-amyloid binding,GO:0005515~protein binding,GO:0051082~unfolded protein binding,GO:0051087~chaperone binding,	IPR002777:PFD_beta-like,IPR009053:Prefoldin,								KW-0175~Coiled coil,		KW-0143~Chaperone,	KW-0007~Acetylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,
PDCD2	programmed cell death 2(PDCD2)	Homo sapiens			GO:0006915~apoptotic process,GO:0006919~activation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0043065~positive regulation of apoptotic process,GO:1901532~regulation of hematopoietic progenitor cell differentiation,GO:1902035~positive regulation of hematopoietic stem cell proliferation,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0070062~extracellular exosome,	GO:0003677~DNA binding,GO:0005515~protein binding,GO:0019899~enzyme binding,GO:0046872~metal ion binding,	IPR002893:Znf_MYND,IPR007320:PDCD2_C,					KW-0053~Apoptosis,	KW-0539~Nucleus,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,	KW-0832~Ubl conjugation,	DOMAIN:MYND-type,ZN_FING:MYND-type; atypical,
PDCD5	programmed cell death 5(PDCD5)	Homo sapiens			GO:0006915~apoptotic process,GO:0008285~negative regulation of cell proliferation,GO:0010628~positive regulation of gene expression,GO:0043065~positive regulation of apoptotic process,GO:0043280~positive regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0071560~cellular response to transforming growth factor beta stimulus,GO:0090200~positive regulation of release of cytochrome c from mitochondria,GO:1903638~positive regulation of protein import into mitochondrial outer membrane,GO:1903645~negative regulation of chaperone-mediated protein folding,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0003677~DNA binding,GO:0005515~protein binding,GO:0008201~heparin binding,GO:0010698~acetyltransferase activator activity,GO:0048487~beta-tubulin binding,	IPR002836:PDCD5-like,IPR036883:PDCD5-like_sf,			PIRSF015730:TFAR19,		KW-0053~Apoptosis,						KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,
PDCD6IP	programmed cell death 6 interacting protein(PDCD6IP)	Homo sapiens			GO:0000281~mitotic cytokinesis,GO:0000915~actomyosin contractile ring assembly,GO:0006915~apoptotic process,GO:0010824~regulation of centrosome duplication,GO:0015031~protein transport,GO:0016236~macroautophagy,GO:0036258~multivesicular body assembly,GO:0039702~viral budding via host ESCRT complex,GO:0045199~maintenance of epithelial cell apical/basal polarity,GO:0046755~viral budding,GO:0051260~protein homooligomerization,GO:0070830~bicellular tight junction assembly,GO:0071985~multivesicular body sorting pathway,GO:0090559~regulation of membrane permeability,GO:0090611~ubiquitin-independent protein catabolic process via the multivesicular body sorting pathway,GO:0097734~extracellular exosome biogenesis,GO:1903543~positive regulation of exosomal secretion,GO:1903551~regulation of extracellular exosome assembly,GO:1903553~positive regulation of extracellular exosome assembly,	GO:0001772~immunological synapse,GO:0005768~endosome,GO:0005813~centrosome,GO:0005829~cytosol,GO:0005923~bicellular tight junction,GO:0005925~focal adhesion,GO:0016020~membrane,GO:0042470~melanosome,GO:0042641~actomyosin,GO:0070062~extracellular exosome,GO:0070971~endoplasmic reticulum exit site,GO:0090543~Flemming body,GO:1903561~extracellular vesicle,	GO:0005515~protein binding,GO:0031871~proteinase activated receptor binding,GO:0042803~protein homodimerization activity,GO:0048306~calcium-dependent protein binding,	IPR004328:BRO1_dom,IPR025304:ALIX_V_dom,IPR038499:BRO1_sf,	hsa03250:Viral life cycle - HIV-1,hsa04144:Endocytosis,	620047~Microcephaly 29, primary, autosomal recessive,		SM01041:BRO1,	KW-0053~Apoptosis,KW-0131~Cell cycle,KW-0132~Cell division,KW-0653~Protein transport,KW-0813~Transport,KW-0945~Host-virus interaction,	KW-0206~Cytoskeleton,KW-0796~Tight junction,KW-0963~Cytoplasm,KW-0964~Secreted,KW-0965~Cell junction,	KW-0905~Primary microcephaly,KW-0991~Intellectual disability,	KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:BRO1,MUTAGEN:C->A: No effect on interaction with HIV-1 p6; impairs rescue of PTAP-type L domain-deficient HIV-1 p6.,MUTAGEN:F->A: Diminishes rescue of PTAP-type L domain-deficient HIV-1 p6.,MUTAGEN:F->A: Loss of interaction with SDCBP.,MUTAGEN:F->D: Abolishes interaction with HIV-1 p6 and EIAV p9; abolishes rescue of PTAP-type L domain-deficient HIV-1 p6; no effect on cytokinesis, nor on midbody formation.,MUTAGEN:F->D: Does not support cytokinesis; loss of normal midbody formation; loss of CHMP4A-, CHMP4B- and CHMP4C-binding in a yeast two-hybrid assay; no effect on localization to the midbody; abolishes rescue of PTAP-type L domain-deficient HIV-1 p6.,MUTAGEN:F->D: Impairs rescue of PTAP-type L domain-deficient HIV-1 p6.,MUTAGEN:GPP->AAA: Abolishes interaction with CEP55; inhibits support of cytokinesis.,MUTAGEN:I->A: Greatly diminishes rescue of PTAP-type L domain--deficient HIV-1 p6.,MUTAGEN:I->A: No effect on interaction with HIV-1 p6.,MUTAGEN:I->D: Does not support cytokinesis; loss of normal midbody formation; loss of CHMP4A-, CHMP4B- and CHMP4C-binding in a yeast two-hybrid assay; impairs rescue of PTAP-type L domain-deficient HIV-1 p6; no effect on localization to the midbody.,MUTAGEN:I->D: Reduces interaction with HIV-1 p6 and EIAV p9; abolishes rescue of PTAP-type L domain-deficient HIV-1 p6.,MUTAGEN:L->D: Abolishes interaction with CHMP4B and abolishes rescue of PTAP-type L domain-deficient HIV-1 p6.,MUTAGEN:L->D: Impairs rescue of PTAP-type L domain-deficient HIV-1 p6.,MUTAGEN:Missing: Does not support the formation of normal midbodies; loss of localization to the midbody; loss of CD2AP-, CEP55-, SH3GL2-, SH3KBP1-, TSG101-binding in a yeast two-hybrid assay.,MUTAGEN:P->A: Decreased interaction with CEP55.,MUTAGEN:P->L: Abolishes interaction with TSG101; no effect on rescue of PTAP-type L domain-deficient HIV-1 p6.,MUTAGEN:PP->VD: Loss of midbody localization; does not support cytokinesis; loss of CEP55-binding in a yeast two-hybrid assay; no effect on HIV-1 release.,MUTAGEN:PR->VD: No effect on midbody formation; loss of CD2AP- and SH3KBP1-binding in a yeast two-hybrid assay; no effect on HIV-1 release.,MUTAGEN:PSAP->AAAA: No effect on midbody formation, nor on cytokinesis; reduced TSG101-binding; no effect on HIV-1 release. Almost complete loss of TSG101-binding and impaired cytokinesis; when associated with 852-A--A-855.,MUTAGEN:PSYP->ASAA: Loss of homoologimerization and reduced TSG101-binding; decreased HIV-1 release; no effect on cytokinesis. Almost complete loss of TSG101-binding and impaired cytokinesis; when associated with 717-A--A-720.,MUTAGEN:RP->AA: Abolishes interaction with SH3GL1 and SH3GL2; no effect on rescue of PTAP-type L domain-deficient HIV-1 p6.,MUTAGEN:RPP->GAA: No effect on midbody formation; loss of SH3GL2-binding in a yeast two-hybrid assay.,MUTAGEN:TY->VD: Loss of CEP55-binding in a yeast two-hybrid assay.,MUTAGEN:V->D: Abolishes interaction with HIV-1 p6; impairs rescue of PTAP-type L domain-deficient HIV-1 p6.,MUTAGEN:V->D: Reduces interaction with HIV-1 p6 and EIAV p9; abolishes rescue of PTAP-type L domain-deficient HIV-1 p6.,MUTAGEN:Y->A: Abolishes interaction with CEP55.,MUTAGEN:Y->A: Greatly diminishes rescue of PTAP-type L domain-deficient HIV-1 p6.,MUTAGEN:Y->F: No effect on rescue of PTAP-type L domain-deficient HIV-1 p6.,MUTAGEN:YP->VD: No effect on CEP55-binding in a yeast two-hybrid assay.,MUTAGEN:YY->AA: Loss of homooligomerization; reduced TSG101-binding; impaired HIV-1 release.,REGION:Disordered,REGION:Essential to promote virus budding,REGION:Interaction with CEP55,REGION:Interaction with CHMP4A, CHMP4B and CHMP4C,REGION:Interaction with EIAV p9,REGION:Interaction with SDCBP,REGION:Interaction with TSG101,REGION:Self-association,
PDCD6	programmed cell death 6(PDCD6)	Homo sapiens			GO:0001525~angiogenesis,GO:0001938~positive regulation of endothelial cell proliferation,GO:0006886~intracellular protein transport,GO:0006888~ER to Golgi vesicle-mediated transport,GO:0010595~positive regulation of endothelial cell migration,GO:0014029~neural crest formation,GO:0014032~neural crest cell development,GO:0030948~negative regulation of vascular endothelial growth factor receptor signaling pathway,GO:0032007~negative regulation of TOR signaling,GO:0034605~cellular response to heat,GO:0036324~vascular endothelial growth factor receptor-2 signaling pathway,GO:0043280~positive regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0045766~positive regulation of angiogenesis,GO:0048208~COPII vesicle coating,GO:0051592~response to calcium ion,GO:0051898~negative regulation of protein kinase B signaling,GO:0097190~apoptotic signaling pathway,GO:1902527~positive regulation of protein monoubiquitination,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005768~endosome,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0030127~COPII vesicle coat,GO:0031410~cytoplasmic vesicle,GO:0031463~Cul3-RING ubiquitin ligase complex,GO:0070062~extracellular exosome,GO:0070971~endoplasmic reticulum exit site,	GO:0000287~magnesium ion binding,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0030674~protein binding, bridging,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0043495~protein anchor,GO:0046983~protein dimerization activity,GO:0048306~calcium-dependent protein binding,GO:1990756~protein binding, bridging involved in substrate recognition for ubiquitination,	IPR002048:EF_hand_dom,IPR011992:EF-hand-dom_pair,IPR018247:EF_Hand_1_Ca_BS,				SM00054:EFh,	KW-0037~Angiogenesis,KW-0053~Apoptosis,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0967~Endosome,KW-0968~Cytoplasmic vesicle,		KW-0677~Repeat,	KW-0106~Calcium,KW-0460~Magnesium,KW-0479~Metal-binding,		KW-0007~Acetylation,	DOMAIN:EF-hand,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,DOMAIN:EF-hand 3,DOMAIN:EF-hand 4,DOMAIN:EF-hand 5,MUTAGEN:E->A: Loss of interaction with SEC31A and PLSCR3, and loss of localization to the endoplasmic reticulum; when associated with A-114.,MUTAGEN:E->A: Loss of interaction with SEC31A and PLSCR3, and loss of localization to the endoplasmic reticulum; when associated with A-47.,MUTAGEN:F->A: Abolishes the interaction with SEC31A, PDCD6IP, ANXA7 and ANXA11.,MUTAGEN:F->A: Increases interaction with PDCD6IP and ANXA7. Impairs interaction with ANXA11. Augments stauroporine-induced cell death.,MUTAGEN:F->A: Strongly impaired interaction with SEC31A and TFG. Does not affect interaction with PDCD6IP.,MUTAGEN:F->G: Increases interaction with PDCD6IP. Impairs interaction with ANXA11.,MUTAGEN:F->S: Increases interaction with PDCD6IP. Impairs interaction with ANAX7 and ANXA11.,MUTAGEN:F->S: Slightly reduced interaction with SEC31A. Does not affect interaction with PDCD6IP.,MUTAGEN:F->W: Impairs interaction with ANXA11.,MUTAGEN:I->A: Does not affect interaction with SEC31A. Does not affect interaction with PDCD6IP.,MUTAGEN:L->A: Strongly impaired interaction with SEC31A. Slightly reduced interaction with PDCD6IP.,MUTAGEN:S->G: Slightly reduced interaction with SEC31A. Does not affect interaction with PDCD6IP.,MUTAGEN:W->A: Abolishes the interaction with PDCD6IP, ANXA7 and ANXA11.,MUTAGEN:W->A: Does not affect interaction with SEC31A. Does not affect interaction with PDCD6IP.,MUTAGEN:W->A: Does not affect interaction with SEC31A. Reduces the interaction with HEBP2, PDCD6IP and ANXA7.,MUTAGEN:Y->A: Abolishes the interaction with PDCD6IP, ANXA7 and ANXA11.,MUTAGEN:Y->A: Abolishes the interaction with PDCD6IP, TSG101, ANXA7 and ANXA11. Does not affect interaction with TFG and SEC31A.,REGION:Disordered,
PHB2	prohibitin 2(PHB2)	Homo sapiens		h_carm-erPathway:CARM1 and Regulation of the Estrogen Receptor,	GO:0000423~macromitophagy,GO:0002639~positive regulation of immunoglobulin production,GO:0006606~protein import into nucleus,GO:0007005~mitochondrion organization,GO:0007062~sister chromatid cohesion,GO:0007202~activation of phospholipase C activity,GO:0016477~cell migration,GO:0023035~CD40 signaling pathway,GO:0030520~intracellular estrogen receptor signaling pathway,GO:0031536~positive regulation of exit from mitosis,GO:0033147~negative regulation of intracellular estrogen receptor signaling pathway,GO:0033598~mammary gland epithelial cell proliferation,GO:0033600~negative regulation of mammary gland epithelial cell proliferation,GO:0039529~RIG-I signaling pathway,GO:0042113~B cell activation,GO:0043066~negative regulation of apoptotic process,GO:0043433~negative regulation of sequence-specific DNA binding transcription factor activity,GO:0045892~negative regulation of transcription, DNA-templated,GO:0050821~protein stabilization,GO:0051091~positive regulation of sequence-specific DNA binding transcription factor activity,GO:0060744~mammary gland branching involved in thelarche,GO:0060749~mammary gland alveolus development,GO:0060762~regulation of branching involved in mammary gland duct morphogenesis,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0071300~cellular response to retinoic acid,GO:0071456~cellular response to hypoxia,GO:1900208~regulation of cardiolipin metabolic process,GO:1901224~positive regulation of NIK/NF-kappaB signaling,GO:1902808~positive regulation of cell cycle G1/S phase transition,GO:1904959~regulation of cytochrome-c oxidase activity,GO:1990051~activation of protein kinase C activity,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005741~mitochondrial outer membrane,GO:0005743~mitochondrial inner membrane,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0014069~postsynaptic density,GO:0016363~nuclear matrix,GO:0030424~axon,GO:0032991~macromolecular complex,GO:0035632~mitochondrial prohibitin complex,GO:0048786~presynaptic active zone,GO:0071944~cell periphery,GO:0098978~glutamatergic synapse,GO:0098982~GABA-ergic synapse,	GO:0005515~protein binding,GO:0030331~estrogen receptor binding,GO:0033218~amide binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0046625~sphingolipid binding,GO:0046982~protein heterodimerization activity,	IPR000163:Prohibitin,IPR001107:Band_7,IPR036013:Band_7/SPFH_dom_sf,	hsa04137:Mitophagy - animal,			SM00244:PHB,	KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0999~Mitochondrion inner membrane,KW-1003~Cell membrane,		KW-0175~Coiled coil,		KW-0675~Receptor,KW-0678~Repressor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:Band 7,MUTAGEN:EGEAE->KGKAK: No effect on homodimerization or interaction with PHB. Decreases mitochondrial dynamics. Disrupts mitochondrial-mediated antiviral innate immune response.,MUTAGEN:FSLI->ASLA: Decreases interaction with MAP1LC3B.,MUTAGEN:I->P: Reduces helicity. Decreases homodimerization and interaction with PHB. Disrupts mitochondrial dynamics. Disrupts mitochondrial-mediated antiviral innate immune response.,MUTAGEN:Y->K: No effect on interaction with MAP1LC3B.,MUTAGEN:YQRL->AQRA: Abolishes interaction with MAP1LC3B. No effect on interaction with PHB. No effect on mitochondrial location. Abolishes rescue of Parkin-mediated mitophagy.,REGION:LC3-interaction region,REGION:Necessary for transcriptional repression,
PA2G4	proliferation-associated 2G4(PA2G4)	Homo sapiens			GO:0006364~rRNA processing,GO:0006417~regulation of translation,GO:0043066~negative regulation of apoptotic process,GO:0045597~positive regulation of cell differentiation,GO:0045892~negative regulation of transcription, DNA-templated,	GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0016020~membrane,GO:0035578~azurophil granule lumen,GO:0070062~extracellular exosome,GO:1990904~ribonucleoprotein complex,	GO:0003676~nucleic acid binding,GO:0003714~transcription corepressor activity,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0031625~ubiquitin protein ligase binding,	IPR000994:Pept_M24,IPR004545:PA2G4,IPR018349:Pept_M24A_MAP2_BS,IPR036005:Creatinase/aminopeptidase-like,IPR036388:WH-like_DNA-bd_sf,IPR036390:WH_DNA-bd_sf,IPR047113:PA2G4/ARX1,					KW-0698~rRNA processing,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0810~Translation regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0732~Signal,		KW-0678~Repressor,KW-0687~Ribonucleoprotein,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Peptidase M24,MUTAGEN:KYK->AYA: Loss of nucleolar localization.,MUTAGEN:RK->AA: Only partial nucleolar localization.,MUTAGEN:S->A: Loss of phosphorylation and interaction with ERBB3 and HUWE1.,MUTAGEN:S->A: No effect on in vitro phosphorylation by PKC.,MUTAGEN:S->D: No effect on phosphorylation and loss of nucleolar localization.,MUTAGEN:T->A: Decreases in vitro phosphorylation by PKC.,REGION:Disordered,REGION:Interaction with RNA,REGION:Necessary for nucleolar localization,REGION:RNA-binding,
PRR14	proline rich 14(PRR14)	Homo sapiens			GO:0007517~muscle organ development,	GO:0005652~nuclear lamina,GO:0005654~nucleoplasm,GO:0005694~chromosome,	GO:0005515~protein binding,	IPR026320:PRR14,IPR028149:Tantalus-like,					KW-0517~Myogenesis,	KW-0158~Chromosome,KW-0539~Nucleus,					KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Tantalus-like,MUTAGEN:E->K: Increased binding to GRB2 and enhanced cell proliferation.,MUTAGEN:S->C: Increased binding to GRB2 and enhanced cell proliferation.,MUTAGEN:VV->AA: Loss of heterochromatin association. Loss of interaction with CBX5.,MUTAGEN:VV->EE: Loss of heterochromatin association during interphase and loss of chromatin association during anaphase.,REGION:Disordered,REGION:Required for nuclear lamina association,REGION:Required for nuclear localization,REGION:Required for the interaction with GRB2 and sufficient to promote the phosphorylation of AKT and cell proliferation,REGION:Sufficient for heterochromatin association in interphase and chromatin association in anaphase,
PRRC2A	proline rich coiled-coil 2A(PRRC2A)	Homo sapiens			GO:0030154~cell differentiation,	GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0070062~extracellular exosome,	GO:0003723~RNA binding,GO:0005515~protein binding,	IPR009738:BAT2_N,IPR033184:PRRC2,						KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,			KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:BAT2 N-terminal,REGION:2 X type B repeats,REGION:3 X 50 AA type C repeats,REGION:4 X 57 AA type A repeats,REGION:Disordered,REPEAT:1-1,REPEAT:1-2,REPEAT:1-3,REPEAT:1-4,REPEAT:2-1,REPEAT:2-2,REPEAT:3-1,REPEAT:3-2,REPEAT:3-3,
PRRC2B	proline rich coiled-coil 2B(PRRC2B)	Homo sapiens			GO:0030154~cell differentiation,		GO:0003723~RNA binding,GO:0005515~protein binding,	IPR009738:BAT2_N,IPR033184:PRRC2,								KW-0175~Coiled coil,			KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:BAT2 N-terminal,REGION:Disordered,
PRRC2C	proline rich coiled-coil 2C(PRRC2C)	Homo sapiens			GO:0002244~hematopoietic progenitor cell differentiation,GO:0034063~stress granule assembly,	GO:0005829~cytosol,GO:0010494~cytoplasmic stress granule,GO:0016020~membrane,	GO:0003723~RNA binding,GO:0005515~protein binding,	IPR009738:BAT2_N,IPR033184:PRRC2,						KW-0963~Cytoplasm,		KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:BAT2 N-terminal,REGION:Disordered,
PRCC	proline rich mitotic checkpoint control factor(PRCC)	Homo sapiens			GO:0007049~cell cycle,GO:0051726~regulation of cell cycle,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0016607~nuclear speck,	GO:0005515~protein binding,	IPR018800:PRCC,	hsa05202:Transcriptional misregulation in cancer,hsa05211:Renal cell carcinoma,	605074~Renal cell carcinoma, papillary,			KW-0131~Cell cycle,	KW-0539~Nucleus,	KW-0656~Proto-oncogene,				KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,REGION:Disordered,REGION:Mediates interaction with MAD2L2,
PNRC1	proline rich nuclear receptor coactivator 1(PNRC1)	Homo sapiens			GO:0000184~nuclear-transcribed mRNA catabolic process, nonsense-mediated decay,	GO:0000932~P-body,GO:0005634~nucleus,	GO:0005515~protein binding,	IPR026780:PNRC1/2,					KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0010~Activator,		COMPBIAS:Polar residues,MOTIF:Nuclear localization signal,MOTIF:SH3-binding,MUTAGEN:P->A: Abolishes the interaction with the nuclear receptors; when associated with A-287.,MUTAGEN:P->A: Abolishes the interaction with the nuclear receptors; when associated with A-290.,REGION:Disordered,
PSTPIP1	proline-serine-threonine phosphatase interacting protein 1(PSTPIP1)	Homo sapiens			GO:0006897~endocytosis,GO:0006954~inflammatory response,GO:0007155~cell adhesion,GO:0007165~signal transduction,GO:0030041~actin filament polymerization,GO:0045087~innate immune response,	GO:0001931~uropod,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005884~actin filament,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0030027~lamellipodium,GO:0032154~cleavage furrow,GO:0048471~perinuclear region of cytoplasm,	GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0051015~actin filament binding,	IPR001060:FCH_dom,IPR001452:SH3_domain,IPR027267:AH/BAR_dom_sf,IPR030777:PSTPIP1_SH3,IPR031160:F_BAR,IPR036028:SH3-like_dom_sf,	hsa04621:NOD-like receptor signaling pathway,	604416~Pyogenic sterile arthritis, pyoderma gangrenosum, and acne,		SM00055:FCH,SM00326:SH3,	KW-0130~Cell adhesion,KW-0254~Endocytosis,KW-0391~Immunity,KW-0395~Inflammatory response,KW-0399~Innate immunity,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0175~Coiled coil,KW-0728~SH3 domain,			KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:F-BAR,DOMAIN:SH3,MUTAGEN:D->N: No effect on filament formation.,MUTAGEN:W->A: Abolishes binding to MEFV. Cytoplasmic filaments are finer with fewer branches.,MUTAGEN:Y->F: Decreases binding to MEFV.,REGION:Disordered,
PREP	prolyl endopeptidase(PREP)	Homo sapiens			GO:0006508~proteolysis,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016020~membrane,	GO:0004252~serine-type endopeptidase activity,GO:0005515~protein binding,GO:0008236~serine-type peptidase activity,GO:0070012~oligopeptidase activity,	IPR001375:Peptidase_S9,IPR002470:Peptidase_S9A,IPR002471:Pept_S9_AS,IPR023302:Pept_S9A_N,IPR029058:AB_hydrolase,	hsa04614:Renin-angiotensin system,					KW-0963~Cytoplasm,				KW-0378~Hydrolase,KW-0645~Protease,KW-0720~Serine protease,	KW-0007~Acetylation,	ACT_SITE:Charge relay system,DOMAIN:Peptidase S9 prolyl oligopeptidase catalytic,DOMAIN:Peptidase S9A N-terminal,
PSAP	prosaposin(PSAP)	Homo sapiens			GO:0006665~sphingolipid metabolic process,GO:0007041~lysosomal transport,GO:0007193~adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway,GO:0010506~regulation of autophagy,GO:0019216~regulation of lipid metabolic process,GO:0060736~prostate gland growth,GO:0060742~epithelial cell differentiation involved in prostate gland development,GO:1903771~positive regulation of beta-galactosidase activity,GO:1905572~ganglioside GM1 transport to membrane,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005764~lysosome,GO:0005765~lysosomal membrane,GO:0005770~late endosome,GO:0005886~plasma membrane,GO:0035577~azurophil granule membrane,GO:0043202~lysosomal lumen,GO:0043231~intracellular membrane-bounded organelle,GO:0070062~extracellular exosome,	GO:0002020~protease binding,GO:0005515~protein binding,GO:0005543~phospholipid binding,GO:0008047~enzyme activator activity,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0097110~scaffold protein binding,GO:1905573~ganglioside GM1 binding,GO:1905574~ganglioside GM2 binding,GO:1905575~ganglioside GM3 binding,GO:1905576~ganglioside GT1b binding,GO:1905577~ganglioside GP1c binding,	IPR003119:SAP_A,IPR007856:SapB_1,IPR008138:SapB_2,IPR008139:SaposinB_dom,IPR008373:Saposin,IPR011001:Saposin-like,IPR021165:Saposin_chordata,	hsa00600:Sphingolipid metabolism,hsa04142:Lysosome,	249900~Metachromatic leukodystrophy due to SAP-b deficiency,610539~Gaucher disease, atypical,611721~Combined SAP deficiency,611722~Krabbe disease, atypical,619491~Parkinson disease 24, autosomal dominant, susceptibility to,	PIRSF002431:Saposin,	SM00162:SAPA,SM00741:SapB,	KW-0443~Lipid metabolism,KW-0746~Sphingolipid metabolism,	KW-0458~Lysosome,KW-0964~Secreted,	KW-0225~Disease variant,KW-0307~Gaucher disease,KW-0331~Gangliosidosis,KW-0478~Metachromatic leukodystrophy,KW-0523~Neurodegeneration,KW-0907~Parkinson disease,KW-0908~Parkinsonism,KW-1026~Leukodystrophy,	KW-0677~Repeat,KW-0732~Signal,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) (complex) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Saposin A-type,DOMAIN:Saposin A-type 1,DOMAIN:Saposin A-type 2,DOMAIN:Saposin B-type,DOMAIN:Saposin B-type 1,DOMAIN:Saposin B-type 2,DOMAIN:Saposin B-type 3,DOMAIN:Saposin B-type 4,MUTAGEN:I->C: Strongly decreases stimulation of cerebroside sulfate hydrolysis.,SITE:Not glycosylated; in variant MLDSAPB Ile-217,
PSMA3	proteasome 20S subunit alpha 3(PSMA3)	Homo sapiens			GO:0006511~ubiquitin-dependent protein catabolic process,GO:0010498~proteasomal protein catabolic process,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0051603~proteolysis involved in cellular protein catabolic process,GO:0052548~regulation of endopeptidase activity,	GO:0000502~proteasome complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005839~proteasome core complex,GO:0019773~proteasome core complex, alpha-subunit complex,GO:0045202~synapse,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0031625~ubiquitin protein ligase binding,	IPR000426:Proteasome_asu_N,IPR001353:Proteasome_sua/b,IPR023332:Proteasome_alpha-type,IPR029055:Ntn_hydrolases_N,	hsa03050:Proteasome,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05017:Spinocerebellar ataxia,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,			SM00948:Proteasome_A_N,	KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0647~Proteasome,KW-0963~Cytoplasm,					KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:Proteasome alpha-type subunits,
PSMB1	proteasome 20S subunit beta 1(PSMB1)	Homo sapiens			GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0051603~proteolysis involved in cellular protein catabolic process,	GO:0000502~proteasome complex,GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005839~proteasome core complex,GO:0019774~proteasome core complex, beta-subunit complex,GO:0034774~secretory granule lumen,GO:0070062~extracellular exosome,GO:1904813~ficolin-1-rich granule lumen,	GO:0005515~protein binding,	IPR001353:Proteasome_sua/b,IPR016050:Proteasome_bsu_CS,IPR023333:Proteasome_suB-type,IPR029055:Ntn_hydrolases_N,	hsa03050:Proteasome,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05017:Spinocerebellar ataxia,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,	620038~Neurodevelopmental disorder with microcephaly, hypotonia, and absent language,			KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0647~Proteasome,KW-0963~Cytoplasm,	KW-0209~Deafness,KW-0991~Intellectual disability,				KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:O-linked (GlcNAc) serine,
PSMB3	proteasome 20S subunit beta 3(PSMB3)	Homo sapiens			GO:0010498~proteasomal protein catabolic process,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0051603~proteolysis involved in cellular protein catabolic process,	GO:0000502~proteasome complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005839~proteasome core complex,GO:0019774~proteasome core complex, beta-subunit complex,GO:0070062~extracellular exosome,	GO:0005515~protein binding,	IPR001353:Proteasome_sua/b,IPR016050:Proteasome_bsu_CS,IPR023333:Proteasome_suB-type,IPR029055:Ntn_hydrolases_N,IPR033811:Proteasome_beta_3,	hsa03050:Proteasome,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05017:Spinocerebellar ataxia,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,				KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0647~Proteasome,KW-0963~Cytoplasm,					KW-0007~Acetylation,
PSMB8	proteasome 20S subunit beta 8(PSMB8)	Homo sapiens		h_mhcPathway:Antigen Processing and Presentation,	GO:0010498~proteasomal protein catabolic process,GO:0019882~antigen processing and presentation,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0045444~fat cell differentiation,GO:0051603~proteolysis involved in cellular protein catabolic process,GO:0052548~regulation of endopeptidase activity,	GO:0000502~proteasome complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005839~proteasome core complex,GO:0019774~proteasome core complex, beta-subunit complex,GO:0070062~extracellular exosome,GO:1990111~spermatoproteasome complex,	GO:0004175~endopeptidase activity,GO:0004298~threonine-type endopeptidase activity,GO:0005515~protein binding,	IPR000243:Pept_T1A_subB,IPR001353:Proteasome_sua/b,IPR016050:Proteasome_bsu_CS,IPR023333:Proteasome_suB-type,IPR029055:Ntn_hydrolases_N,	hsa03050:Proteasome,	256040~Proteasome-associated autoinflammatory syndrome 1 and digenic forms,			KW-0221~Differentiation,KW-0391~Immunity,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0647~Proteasome,KW-0963~Cytoplasm,	KW-0225~Disease variant,			KW-0378~Hydrolase,KW-0645~Protease,KW-0888~Threonine protease,	KW-0597~Phosphoprotein,KW-0865~Zymogen,	ACT_SITE:Nucleophile,PROPEP:Removed in mature form,REGION:Disordered,SITE:Cleavage; by autolysis,
PSMB9	proteasome 20S subunit beta 9(PSMB9)	Homo sapiens		h_mhcPathway:Antigen Processing and Presentation,	GO:0002376~immune system process,GO:0010498~proteasomal protein catabolic process,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0051603~proteolysis involved in cellular protein catabolic process,GO:2000116~regulation of cysteine-type endopeptidase activity,	GO:0000502~proteasome complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005839~proteasome core complex,GO:0019774~proteasome core complex, beta-subunit complex,GO:0070062~extracellular exosome,GO:1990111~spermatoproteasome complex,	GO:0004175~endopeptidase activity,GO:0004298~threonine-type endopeptidase activity,GO:0005515~protein binding,	IPR000243:Pept_T1A_subB,IPR001353:Proteasome_sua/b,IPR016050:Proteasome_bsu_CS,IPR023333:Proteasome_suB-type,IPR029055:Ntn_hydrolases_N,	hsa03050:Proteasome,	617591~Proteasome-associated autoinflammatory syndrome 3, digenic,			KW-0391~Immunity,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0647~Proteasome,KW-0963~Cytoplasm,				KW-0378~Hydrolase,KW-0645~Protease,KW-0888~Threonine protease,	KW-0007~Acetylation,KW-0865~Zymogen,	ACT_SITE:Nucleophile,MUTAGEN:G->A: Impairs correct processing at the consensus site.,MUTAGEN:K->A: Impairs correct processing at the consensus site.,MUTAGEN:T->A: Impairs correct processing at the consensus site.,PROPEP:Removed in mature form,SITE:Cleavage; by autolysis,
PSMC1	proteasome 26S subunit, ATPase 1(PSMC1)	Homo sapiens			GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:1901800~positive regulation of proteasomal protein catabolic process,	GO:0000502~proteasome complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0005838~proteasome regulatory particle,GO:0008540~proteasome regulatory particle, base subcomplex,GO:0016020~membrane,GO:0022624~proteasome accessory complex,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016887~ATPase activity,GO:0036402~proteasome-activating ATPase activity,	IPR003593:AAA+_ATPase,IPR003959:ATPase_AAA_core,IPR003960:ATPase_AAA_CS,IPR012340:NA-bd_OB-fold,IPR027417:P-loop_NTPase,IPR032501:Prot_ATP_ID_OB_2nd,IPR041569:AAA_lid_3,	hsa03050:Proteasome,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05017:Spinocerebellar ataxia,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05165:Human papillomavirus infection,hsa05169:Epstein-Barr virus infection,hsa05203:Viral carcinogenesis,	620071~Birk-Aharoni syndrome,		SM00382:AAA,		KW-0472~Membrane,KW-0539~Nucleus,KW-0647~Proteasome,KW-0963~Cytoplasm,	KW-0209~Deafness,KW-0991~Intellectual disability,		KW-0067~ATP-binding,KW-0547~Nucleotide-binding,		KW-0007~Acetylation,KW-0449~Lipoprotein,KW-0519~Myristate,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:AAA+ ATPase,DOMAIN:ATPase AAA-type core,LIPID:N-myristoyl glycine,REGION:Disordered,
PSMC3	proteasome 26S subunit, ATPase 3(PSMC3)	Homo sapiens			GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0043921~modulation by host of viral transcription,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:1901800~positive regulation of proteasomal protein catabolic process,	GO:0000502~proteasome complex,GO:0000932~P-body,GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0008540~proteasome regulatory particle, base subcomplex,GO:0016020~membrane,GO:0022624~proteasome accessory complex,GO:0034774~secretory granule lumen,GO:1904813~ficolin-1-rich granule lumen,	GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016887~ATPase activity,GO:0036402~proteasome-activating ATPase activity,GO:0042802~identical protein binding,	IPR003593:AAA+_ATPase,IPR003959:ATPase_AAA_core,IPR003960:ATPase_AAA_CS,IPR012340:NA-bd_OB-fold,IPR027417:P-loop_NTPase,IPR032501:Prot_ATP_ID_OB_2nd,IPR041569:AAA_lid_3,	hsa03050:Proteasome,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05017:Spinocerebellar ataxia,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05169:Epstein-Barr virus infection,	619354~Deafness, cataract, impaired intellectual development, and polyneuropathy,		SM00382:AAA,	KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0647~Proteasome,KW-0963~Cytoplasm,	KW-0209~Deafness,KW-0622~Neuropathy,KW-0898~Cataract,KW-0991~Intellectual disability,		KW-0067~ATP-binding,KW-0547~Nucleotide-binding,		KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	DOMAIN:AAA+ ATPase,DOMAIN:ATPase AAA-type core,DOMAIN:Proteasomal ATPase second OB,REGION:Disordered,
PSMC5	proteasome 26S subunit, ATPase 5(PSMC5)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0043069~negative regulation of programmed cell death,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:1901800~positive regulation of proteasomal protein catabolic process,	GO:0000502~proteasome complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005838~proteasome regulatory particle,GO:0008540~proteasome regulatory particle, base subcomplex,GO:0016020~membrane,GO:0022624~proteasome accessory complex,GO:0031410~cytoplasmic vesicle,GO:0070062~extracellular exosome,GO:0072562~blood microparticle,	GO:0005102~receptor binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008134~transcription factor binding,GO:0016887~ATPase activity,GO:0031531~thyrotropin-releasing hormone receptor binding,GO:0036402~proteasome-activating ATPase activity,	IPR003593:AAA+_ATPase,IPR003959:ATPase_AAA_core,IPR003960:ATPase_AAA_CS,IPR012340:NA-bd_OB-fold,IPR027417:P-loop_NTPase,IPR032501:Prot_ATP_ID_OB_2nd,IPR041569:AAA_lid_3,	hsa03050:Proteasome,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05017:Spinocerebellar ataxia,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05169:Epstein-Barr virus infection,			SM00382:AAA,		KW-0539~Nucleus,KW-0647~Proteasome,KW-0963~Cytoplasm,		KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,		KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:AAA+ ATPase,DOMAIN:ATPase AAA-type core,DOMAIN:Proteasomal ATPase second OB,REGION:Disordered,REGION:May mediate interaction with PRPF9,
PSMD11	proteasome 26S subunit, non-ATPase 11(PSMD11)	Homo sapiens			GO:0006511~ubiquitin-dependent protein catabolic process,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0043248~proteasome assembly,GO:0048863~stem cell differentiation,	GO:0000502~proteasome complex,GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0008541~proteasome regulatory particle, lid subcomplex,GO:0016020~membrane,GO:0022624~proteasome accessory complex,GO:0034774~secretory granule lumen,GO:1904813~ficolin-1-rich granule lumen,	GO:0005198~structural molecule activity,GO:0005515~protein binding,	IPR000717:PCI_dom,IPR011990:TPR-like_helical_dom_sf,IPR036390:WH_DNA-bd_sf,IPR040773:Rpn6_N,IPR040780:Rpn6_C_helix,	hsa03050:Proteasome,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05017:Spinocerebellar ataxia,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05169:Epstein-Barr virus infection,			SM00088:PINT,SM00753:PAM,		KW-0539~Nucleus,KW-0647~Proteasome,KW-0963~Cytoplasm,					KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:26S proteasome regulatory subunit Rpn6 N-terminal,DOMAIN:PCI,MUTAGEN:S->A: Does not affect phosphorylation by AMPK; when associated with A-14 and A-272.,MUTAGEN:S->A: Does not affect phosphorylation by AMPK; when associated with A-79 and A-272.,MUTAGEN:S->A: Does not affect phosphorylation by AMPK; when associated with A14- and A-79.,
PSMD14	proteasome 26S subunit, non-ATPase 14(PSMD14)	Homo sapiens			GO:0000724~double-strand break repair via homologous recombination,GO:0006303~double-strand break repair via nonhomologous end joining,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0016579~protein deubiquitination,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0045471~response to ethanol,GO:0061136~regulation of proteasomal protein catabolic process,GO:0070536~protein K63-linked deubiquitination,	GO:0000502~proteasome complex,GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0008541~proteasome regulatory particle, lid subcomplex,GO:0022624~proteasome accessory complex,GO:0031597~cytosolic proteasome complex,GO:0034774~secretory granule lumen,GO:1904813~ficolin-1-rich granule lumen,	GO:0005515~protein binding,GO:0008237~metallopeptidase activity,GO:0046872~metal ion binding,GO:0061133~endopeptidase activator activity,GO:0061578~Lys63-specific deubiquitinase activity,GO:0070628~proteasome binding,	IPR000555:JAMM/MPN+_dom,IPR037518:MPN,	hsa03050:Proteasome,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05017:Spinocerebellar ataxia,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05169:Epstein-Barr virus infection,			SM00232:JAB_MPN,	KW-0227~DNA damage,KW-0234~DNA repair,KW-0833~Ubl conjugation pathway,	KW-0647~Proteasome,			KW-0479~Metal-binding,KW-0862~Zinc,	KW-0378~Hydrolase,KW-0482~Metalloprotease,KW-0645~Protease,	KW-0597~Phosphoprotein,	DOMAIN:MPN,MOTIF:JAMM motif,MUTAGEN:HSH->ASA: Abolishes ubiquitin thioesterase activity, leading to prevent maintenance of JMJD2A/KDM4A on chromatin.,REGION:Disordered,
PSMD3	proteasome 26S subunit, non-ATPase 3(PSMD3)	Homo sapiens			GO:0006511~ubiquitin-dependent protein catabolic process,GO:0042176~regulation of protein catabolic process,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,	GO:0000502~proteasome complex,GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0008541~proteasome regulatory particle, lid subcomplex,GO:0016020~membrane,GO:0022624~proteasome accessory complex,GO:0034774~secretory granule lumen,GO:0070062~extracellular exosome,GO:1904813~ficolin-1-rich granule lumen,	GO:0005515~protein binding,GO:0030234~enzyme regulator activity,	IPR000717:PCI_dom,IPR011990:TPR-like_helical_dom_sf,IPR013586:26S_Psome_reg_C,IPR036390:WH_DNA-bd_sf,	hsa03050:Proteasome,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05017:Spinocerebellar ataxia,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05169:Epstein-Barr virus infection,			SM00088:PINT,SM00753:PAM,		KW-0647~Proteasome,					KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:PCI,REGION:Disordered,
PSMD8	proteasome 26S subunit, non-ATPase 8(PSMD8)	Homo sapiens			GO:0006508~proteolysis,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,	GO:0000502~proteasome complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0005838~proteasome regulatory particle,GO:0008541~proteasome regulatory particle, lid subcomplex,GO:0022624~proteasome accessory complex,	GO:0005515~protein binding,	IPR000717:PCI_dom,IPR006746:26S_Psome_Rpn12,IPR033464:CSN8_PSD8_EIF3K,	hsa03050:Proteasome,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05017:Spinocerebellar ataxia,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05169:Epstein-Barr virus infection,					KW-0647~Proteasome,					KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:CSN8/PSMD8/EIF3K,DOMAIN:PCI,REGION:Disordered,
PSMD9	proteasome 26S subunit, non-ATPase 9(PSMD9)	Homo sapiens			GO:0006508~proteolysis,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0032024~positive regulation of insulin secretion,GO:0045893~positive regulation of transcription, DNA-templated,GO:0046676~negative regulation of insulin secretion,GO:0070682~proteasome regulatory particle assembly,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005838~proteasome regulatory particle,GO:0008540~proteasome regulatory particle, base subcomplex,	GO:0003713~transcription coactivator activity,GO:0005515~protein binding,GO:0043425~bHLH transcription factor binding,	IPR001478:PDZ,IPR035269:PSMD9,IPR036034:PDZ_sf,IPR040815:Nas2_N,IPR041489:PDZ_6,	hsa03050:Proteasome,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05017:Spinocerebellar ataxia,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,			SM00228:PDZ,						KW-0143~Chaperone,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Nas2 N-terminal,DOMAIN:PDZ,REGION:Disordered,
PSME3	proteasome activator subunit 3(PSME3)	Homo sapiens			GO:0006915~apoptotic process,GO:0007049~cell cycle,GO:0010950~positive regulation of endopeptidase activity,GO:0061136~regulation of proteasomal protein catabolic process,GO:2000045~regulation of G1/S transition of mitotic cell cycle,GO:2001237~negative regulation of extrinsic apoptotic signaling pathway,	GO:0000502~proteasome complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0008537~proteasome activator complex,GO:0016020~membrane,	GO:0002039~p53 binding,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0061133~endopeptidase activator activity,GO:0097371~MDM2/MDM4 family protein binding,	IPR003185:Proteasome_activ_PA28_N,IPR003186:PA28_C,IPR009077:Proteasome_activ_PA28,IPR036252:Proteasome_activ_sf,IPR036996:PA28_N_sf,IPR036997:PA28_C_sf,	hsa03050:Proteasome,hsa04612:Antigen processing and presentation,hsa05160:Hepatitis C,				KW-0053~Apoptosis,KW-0131~Cell cycle,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0647~Proteasome,KW-0963~Cytoplasm,					KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:Proteasome activator PA28 C-terminal,DOMAIN:Proteasome activator PA28 N-terminal,MUTAGEN:K->E,D,A,C,N,Q,H,F,S,I,P: Assembles into less stable hexamers/heptamers and therefore impairs specificity of activation of trypsin-like subunits of the proteasome.,REGION:Disordered,
PSMG2	proteasome assembly chaperone 2(PSMG2)	Homo sapiens			GO:0007094~mitotic spindle assembly checkpoint,GO:0043066~negative regulation of apoptotic process,GO:0043248~proteasome assembly,GO:0051131~chaperone-mediated protein complex assembly,	GO:0005634~nucleus,GO:0005829~cytosol,GO:0101031~chaperone complex,	GO:0005515~protein binding,GO:0060090~binding, bridging,	IPR016562:Proteasome_assmbl_chp_2_euk,IPR019151:Proteasome_assmbl_chaperone_2,IPR038389:PSMG2_sf,		619183~Proteasome-associated autoinflammatory syndrome 4,	PIRSF010044:UCP010044,			KW-0539~Nucleus,				KW-0143~Chaperone,	KW-0597~Phosphoprotein,
POMP	proteasome maturation protein(POMP)	Homo sapiens			GO:0043248~proteasome assembly,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0016020~membrane,GO:0016607~nuclear speck,	GO:0005515~protein binding,	IPR008012:Ump1,	hsa03050:Proteasome,	601952~Keratosis linearis with ichthyosis congenita and sclerosing keratoderma,618048~Proteasome-associated autoinflammatory syndrome 2,				KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0492~Microsome,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0977~Ichthyosis,KW-1007~Palmoplantar keratoderma,			KW-0143~Chaperone,	KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),MOTIF:High-affinity association with the preproteasome,
PRKRA	protein activator of interferon induced protein kinase EIF2AK2(PRKRA)	Homo sapiens			GO:0006955~immune response,GO:0008285~negative regulation of cell proliferation,GO:0009615~response to virus,GO:0016310~phosphorylation,GO:0030422~production of siRNA involved in RNA interference,GO:0031054~pre-miRNA processing,GO:0034599~cellular response to oxidative stress,GO:0035196~production of miRNAs involved in gene silencing by miRNA,GO:0042473~outer ear morphogenesis,GO:0042474~middle ear morphogenesis,GO:0048705~skeletal system morphogenesis,GO:0050821~protein stabilization,GO:0070920~regulation of production of small RNA involved in gene silencing by RNA,GO:0070922~small RNA loading onto RISC,GO:2001244~positive regulation of intrinsic apoptotic signaling pathway,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016020~membrane,GO:0016442~RISC complex,GO:0048471~perinuclear region of cytoplasm,GO:0070578~RISC-loading complex,	GO:0003723~RNA binding,GO:0003725~double-stranded RNA binding,GO:0005515~protein binding,GO:0008047~enzyme activator activity,GO:0016301~kinase activity,GO:0019899~enzyme binding,GO:0035197~siRNA binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0070883~pre-miRNA binding,	IPR014720:dsRBD_dom,IPR044465:PRKRA_DSRM_1,IPR044466:PRKRA_DSRM_2,IPR044467:PRKRA_DSRM_3,		612067~Dystonia 16,		SM00358:DSRM,	KW-0943~RNA-mediated gene silencing,KW-0945~Host-virus interaction,	KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0908~Parkinsonism,KW-1023~Dystonia,	KW-0677~Repeat,		KW-0418~Kinase,KW-0694~RNA-binding,KW-0808~Transferase,	KW-0597~Phosphoprotein,	DOMAIN:DRBM,DOMAIN:DRBM 1,DOMAIN:DRBM 2,DOMAIN:DRBM 3,MUTAGEN:AA->KK: Abrogates interaction with DICER1 but does not affect interaction with AGO2.,MUTAGEN:C->A: Abrogates apoptosis induction under conditions of stress.,MUTAGEN:D->A: Abrogates apoptosis induction under conditions of stress.,MUTAGEN:G->A: Abrogates apoptosis induction under conditions of stress.,MUTAGEN:Q->A: Abrogates apoptosis induction under conditions of stress.,MUTAGEN:S->A: Abrogates apoptosis induction under conditions of stress and binding to EIF2AK2. Prevents activation of EIF2AK2 in stressed cells; when associated with A-287.,MUTAGEN:S->A: Abrogates apoptosis induction under conditions of stress.,MUTAGEN:S->A: Abrogates apoptosis induction under conditions of stress. Prevents activation of EIF2AK2 in stressed cells; when associated with A-246.,MUTAGEN:S->A: No effect on apoptosis induction under conditions of stress.,MUTAGEN:S->D: Does not induce apoptosis.,MUTAGEN:S->D: Induces activation of EIF2AK2 and apoptosis in unstressed cells; when associated with D-246.,MUTAGEN:S->D: Induces activation of EIF2AK2 and apoptosis in unstressed cells; when associated with D-287.,REGION:Disordered,REGION:Sufficient for self-association and interaction with TARBP2,
PRMT1	protein arginine methyltransferase 1(PRMT1)	Homo sapiens		h_btg2Pathway:BTG family proteins and cell cycle regulation,h_vdrPathway:Control of Gene Expression by Vitamin D Receptor,	GO:0001701~in utero embryonic development,GO:0006338~chromatin remodeling,GO:0006479~protein methylation,GO:0007166~cell surface receptor signaling pathway,GO:0008284~positive regulation of cell proliferation,GO:0008380~RNA splicing,GO:0018216~peptidyl-arginine methylation,GO:0019082~viral protein processing,GO:0030510~regulation of BMP signaling pathway,GO:0031175~neuron projection development,GO:0032259~methylation,GO:0045648~positive regulation of erythrocyte differentiation,GO:0045652~regulation of megakaryocyte differentiation,GO:0045653~negative regulation of megakaryocyte differentiation,GO:0045727~positive regulation of translation,GO:0046329~negative regulation of JNK cascade,GO:0046985~positive regulation of hemoglobin biosynthetic process,GO:0048738~cardiac muscle tissue development,GO:0051260~protein homooligomerization,GO:1900745~positive regulation of p38MAPK cascade,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0034709~methylosome,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0008168~methyltransferase activity,GO:0008170~N-methyltransferase activity,GO:0008276~protein methyltransferase activity,GO:0008327~methyl-CpG binding,GO:0016274~protein-arginine N-methyltransferase activity,GO:0019899~enzyme binding,GO:0035241~protein-arginine omega-N monomethyltransferase activity,GO:0035242~protein-arginine omega-N asymmetric methyltransferase activity,GO:0042054~histone methyltransferase activity,GO:0042802~identical protein binding,GO:0044020~histone methyltransferase activity (H4-R3 specific),GO:0048273~mitogen-activated protein kinase p38 binding,GO:1904047~S-adenosyl-L-methionine binding,	IPR025799:Arg_MeTrfase,IPR029063:SAM-dependent_MTases_sf,IPR041698:Methyltransf_25,	hsa04068:FoxO signaling pathway,hsa04922:Glucagon signaling pathway,					KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0949~S-adenosyl-L-methionine,	KW-0489~Methyltransferase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:Methyltransferase,DOMAIN:SAM-dependent MTase PRMT-type,MUTAGEN:D->A: Loss of FOXO1 methylation, its nuclear retention, and transcriptional activity.,MUTAGEN:L->A: Loss of FOXO1 methylation, its nuclear retention, and transcriptional activity.,MUTAGEN:L->A: No effect on S-adenosyl-L-methionine binding but reduced EWS protein methylation; when associated with A-280 and A-322. No effect on homodimerization but loss of homooligomerization; when associated with A-280 and A-322.,MUTAGEN:V->A: Loss of FOXO1 methylation, its nuclear retention, and transcriptional activity.,MUTAGEN:Y->A: No effect on S-adenosyl-L-methionine binding but reduced EWS protein methylation; when associated with A-280 and A-359. No effect on homodimerization but loss of homooligomerization; when associated with A-280 and A-359.,MUTAGEN:Y->A: No effect on S-adenosyl-L-methionine binding but reduced EWS protein methylation; when associated with A-322 and A-359. No effect on homodimerization but loss of homooligomerization; when associated with A-322 and A-359.,REGION:Disordered,
PRMT2	protein arginine methyltransferase 2(PRMT2)	Homo sapiens			GO:0006338~chromatin remodeling,GO:0006479~protein methylation,GO:0007165~signal transduction,GO:0032088~negative regulation of NF-kappaB transcription factor activity,GO:0032259~methylation,GO:0043065~positive regulation of apoptotic process,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0048588~developmental cell growth,GO:0060765~regulation of androgen receptor signaling pathway,GO:2000134~negative regulation of G1/S transition of mitotic cell cycle,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0003713~transcription coactivator activity,GO:0005515~protein binding,GO:0008168~methyltransferase activity,GO:0016274~protein-arginine N-methyltransferase activity,GO:0030331~estrogen receptor binding,GO:0033142~progesterone receptor binding,GO:0035242~protein-arginine omega-N asymmetric methyltransferase activity,GO:0042054~histone methyltransferase activity,GO:0042803~protein homodimerization activity,GO:0042974~retinoic acid receptor binding,GO:0042975~peroxisome proliferator activated receptor binding,GO:0044877~macromolecular complex binding,GO:0046966~thyroid hormone receptor binding,GO:0050681~androgen receptor binding,	IPR001452:SH3_domain,IPR007848:Small_mtfrase_dom,IPR025799:Arg_MeTrfase,IPR029063:SAM-dependent_MTases_sf,IPR036028:SH3-like_dom_sf,				SM00326:SH3,		KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0728~SH3 domain,	KW-0949~S-adenosyl-L-methionine,	KW-0489~Methyltransferase,KW-0808~Transferase,	KW-0488~Methylation,	DOMAIN:Methyltransferase small,DOMAIN:SAM-dependent MTase PRMT-type,DOMAIN:SH3,REGION:Disordered,REGION:Interaction with ESR1,REGION:Interaction with RB1,
PDIA3	protein disulfide isomerase family A member 3(PDIA3)	Homo sapiens			GO:0002250~adaptive immune response,GO:0002502~peptide antigen assembly with MHC class I protein complex,GO:0006457~protein folding,GO:0034975~protein folding in endoplasmic reticulum,GO:0034976~response to endoplasmic reticulum stress,GO:0070527~platelet aggregation,GO:0097191~extrinsic apoptotic signaling pathway,GO:0098761~cellular response to interleukin-7,GO:2001238~positive regulation of extrinsic apoptotic signaling pathway,	GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005783~endoplasmic reticulum,GO:0005788~endoplasmic reticulum lumen,GO:0005925~focal adhesion,GO:0009986~cell surface,GO:0042470~melanosome,GO:0042824~MHC class I peptide loading complex,GO:0045335~phagocytic vesicle,GO:0055038~recycling endosome membrane,GO:0061779~Tapasin-ERp57 complex,GO:0070062~extracellular exosome,	GO:0003723~RNA binding,GO:0003756~protein disulfide isomerase activity,GO:0004197~cysteine-type endopeptidase activity,GO:0004629~phospholipase C activity,GO:0005515~protein binding,GO:0015035~protein disulfide oxidoreductase activity,GO:0015036~disulfide oxidoreductase activity,GO:0042802~identical protein binding,	IPR005788:PDI_thioredoxin-like_dom,IPR005792:Prot_disulphide_isomerase,IPR013766:Thioredoxin_domain,IPR017937:Thioredoxin_CS,IPR036249:Thioredoxin-like_sf,IPR041868:PDIA3_PDI_b,IPR044569:PDIA6-like,	hsa04141:Protein processing in endoplasmic reticulum,hsa04612:Antigen processing and presentation,hsa05163:Human cytomegalovirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,				KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0256~Endoplasmic reticulum,		KW-0676~Redox-active center,KW-0677~Repeat,KW-0732~Signal,		KW-0413~Isomerase,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	ACT_SITE:Nucleophile,COMPBIAS:Basic and acidic residues,DISULFID:Interchain (with C-115 in TAPBP); in linked form; reversible,DISULFID:Redox-active,DISULFID:Redox-active; reversible,DOMAIN:Thioredoxin,DOMAIN:Thioredoxin 1,DOMAIN:Thioredoxin 2,MOTIF:Prevents secretion from ER,MUTAGEN:C->A: No effect on disulfide bond with TAPBP.,MUTAGEN:C->A: No loss of activity. No loss of activity; when associated with A-406.,MUTAGEN:C->A: No loss of activity. No loss of activity; when associated with A-57.,MUTAGEN:C->A: Trapped via disulfide bond with TAPBP.,MUTAGEN:C->S: Activity changed to serine protease.,MUTAGEN:C->S: Activity changed to serine protease; when associated with S-409.,MUTAGEN:C->S: Activity changed to serine protease; when associated with S-60.,REGION:Disordered,SITE:Contributes to redox potential value,SITE:Lowers pKa of C-terminal Cys of first active site,SITE:Lowers pKa of C-terminal Cys of second active site,
PDIA4	protein disulfide isomerase family A member 4(PDIA4)	Homo sapiens			GO:0006457~protein folding,GO:0009306~protein secretion,GO:0034976~response to endoplasmic reticulum stress,GO:0061077~chaperone-mediated protein folding,	GO:0005615~extracellular space,GO:0005783~endoplasmic reticulum,GO:0005788~endoplasmic reticulum lumen,GO:0009986~cell surface,GO:0042470~melanosome,	GO:0003723~RNA binding,GO:0003756~protein disulfide isomerase activity,GO:0005515~protein binding,GO:0015035~protein disulfide oxidoreductase activity,	IPR005788:PDI_thioredoxin-like_dom,IPR005792:Prot_disulphide_isomerase,IPR013766:Thioredoxin_domain,IPR017068:Protein_diS-isomerase_A4,IPR017937:Thioredoxin_CS,IPR036249:Thioredoxin-like_sf,IPR041866:PDIA4_PDI_b,	hsa04141:Protein processing in endoplasmic reticulum,hsa04918:Thyroid hormone synthesis,hsa05110:Vibrio cholerae infection,		PIRSF036862:Disulphide_isom_A4,			KW-0256~Endoplasmic reticulum,		KW-0676~Redox-active center,KW-0677~Repeat,KW-0732~Signal,		KW-0413~Isomerase,	KW-0007~Acetylation,KW-1015~Disulfide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,DISULFID:Redox-active,DOMAIN:Thioredoxin,DOMAIN:Thioredoxin 1,DOMAIN:Thioredoxin 2,DOMAIN:Thioredoxin 3,MOTIF:CXXC,MOTIF:Prevents secretion from ER,REGION:Disordered,
PDIA6	protein disulfide isomerase family A member 6(PDIA6)	Homo sapiens	84.Ubiquitination_Pathways_Cell_Cycle,		GO:0006457~protein folding,GO:0034976~response to endoplasmic reticulum stress,	GO:0005615~extracellular space,GO:0005783~endoplasmic reticulum,GO:0005788~endoplasmic reticulum lumen,GO:0005789~endoplasmic reticulum membrane,GO:0005793~endoplasmic reticulum-Golgi intermediate compartment,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0034663~endoplasmic reticulum chaperone complex,GO:0042470~melanosome,GO:0070062~extracellular exosome,	GO:0003756~protein disulfide isomerase activity,GO:0005515~protein binding,GO:0015035~protein disulfide oxidoreductase activity,	IPR005788:PDI_thioredoxin-like_dom,IPR013766:Thioredoxin_domain,IPR017937:Thioredoxin_CS,IPR036249:Thioredoxin-like_sf,IPR044569:PDIA6-like,	hsa04141:Protein processing in endoplasmic reticulum,					KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-1003~Cell membrane,		KW-0676~Redox-active center,KW-0677~Repeat,KW-0732~Signal,		KW-0143~Chaperone,KW-0413~Isomerase,	KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	ACT_SITE:Nucleophile,DISULFID:Redox-active,DOMAIN:Thioredoxin,DOMAIN:Thioredoxin 1,DOMAIN:Thioredoxin 2,MOTIF:Prevents secretion from ER,MUTAGEN:C->A: Accelerates dephosphorylation of ERN1; when associated with A-193.,MUTAGEN:C->A: Accelerates dephosphorylation of ERN1; when associated with A-58.,MUTAGEN:C->S: 25% decrease in enzyme activity; when associated with S-193. Abolishes enzyme activity; when associated with S-55; S-58 and S-193.,MUTAGEN:C->S: 50% decrease in enzyme activity; when associated with S-55. 90% decrease in enzyme activity; when associated with S-193. Abolishes enzyme activity; when associated with S-55; S-190 and S-193.,MUTAGEN:C->S: 50% decrease in enzyme activity; when associated with S-58. Abolishes enzyme activity; when associated with S-58; S-190 and S-193.,MUTAGEN:C->S: 90% decrease in enzyme activity; when associated with S-58. 25% decrease in enzyme activity; when associated with S-190. Abolishes enzyme activity; when associated with S-55; S-58 and S-190.,REGION:Disordered,SITE:Contributes to redox potential value,SITE:Lowers pKa of C-terminal Cys of first active site,SITE:Lowers pKa of C-terminal Cys of second active site,
PRKCH	protein kinase C eta(PRKCH)	Homo sapiens		h_keratinocytePathway:Keratinocyte Differentiation,	GO:0006468~protein phosphorylation,GO:0007165~signal transduction,GO:0010744~positive regulation of macrophage derived foam cell differentiation,GO:0016310~phosphorylation,GO:0017148~negative regulation of translation,GO:0018105~peptidyl-serine phosphorylation,GO:0030154~cell differentiation,GO:0032056~positive regulation of translation in response to stress,GO:0034198~cellular response to amino acid starvation,GO:0034351~negative regulation of glial cell apoptotic process,GO:0035556~intracellular signal transduction,GO:0036211~protein modification process,GO:0045618~positive regulation of keratinocyte differentiation,GO:0050861~positive regulation of B cell receptor signaling pathway,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0060252~positive regulation of glial cell proliferation,GO:0070528~protein kinase C signaling,GO:0071901~negative regulation of protein serine/threonine kinase activity,GO:0080090~regulation of primary metabolic process,GO:1903078~positive regulation of protein localization to plasma membrane,GO:2000810~regulation of bicellular tight junction assembly,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005911~cell-cell junction,GO:0016020~membrane,GO:0070062~extracellular exosome,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004697~protein kinase C activity,GO:0004699~calcium-independent protein kinase C activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0019899~enzyme binding,GO:0030291~protein serine/threonine kinase inhibitor activity,GO:0031267~small GTPase binding,GO:0045182~translation regulator activity,GO:0046872~metal ion binding,	IPR000008:C2_dom,IPR000719:Prot_kinase_dom,IPR000961:AGC-kinase_C,IPR002219:PE/DAG-bd,IPR008271:Ser/Thr_kinase_AS,IPR011009:Kinase-like_dom_sf,IPR014376:Prot_kin_PKC_delta,IPR015727:Protein_Kinase_C_mu-related,IPR017441:Protein_kinase_ATP_BS,IPR017892:Pkinase_C,IPR020454:DAG/PE-bd,IPR027431:PKC_eta,IPR034665:nPKC_eta,IPR035892:C2_domain_sf,IPR046349:C1-like_sf,	hsa04270:Vascular smooth muscle contraction,hsa04750:Inflammatory mediator regulation of TRP channels,	601367~Cerebral infarction, susceptibility to,	PIRSF000551:PKC_delta,PIRSF501107:Protein_kin_C_eta,	SM00109:C1,SM00133:S_TK_X,SM00220:S_TKc,SM00239:C2,	KW-0221~Differentiation,KW-0346~Stress response,KW-0810~Translation regulation,	KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0067~ATP-binding,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,KW-0862~Zinc,	KW-0418~Kinase,KW-0649~Protein kinase inhibitor,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,DOMAIN:AGC-kinase C-terminal,DOMAIN:C2,DOMAIN:Phorbol-ester/DAG-type,DOMAIN:Protein kinase,MUTAGEN:A->S,T: Abolishes kinase inhibitor activity and converts peptide to a substrate for PRKCH and PRKCE but not for PRKCA.,REGION:Disordered,ZN_FING:Phorbol-ester/DAG-type 1,ZN_FING:Phorbol-ester/DAG-type 2,
PRKCQ	protein kinase C theta(PRKCQ)	Homo sapiens		h_keratinocytePathway:Keratinocyte Differentiation,	GO:0001558~regulation of cell growth,GO:0006355~regulation of transcription, DNA-templated,GO:0006468~protein phosphorylation,GO:0006509~membrane protein ectodomain proteolysis,GO:0006954~inflammatory response,GO:0007411~axon guidance,GO:0018105~peptidyl-serine phosphorylation,GO:0032212~positive regulation of telomere maintenance via telomerase,GO:0032740~positive regulation of interleukin-17 production,GO:0032743~positive regulation of interleukin-2 production,GO:0032753~positive regulation of interleukin-4 production,GO:0035556~intracellular signal transduction,GO:0035739~CD4-positive, alpha-beta T cell proliferation,GO:0038095~Fc-epsilon receptor signaling pathway,GO:0046627~negative regulation of insulin receptor signaling pathway,GO:0050870~positive regulation of T cell activation,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0051973~positive regulation of telomerase activity,GO:0060326~cell chemotaxis,GO:0070233~negative regulation of T cell apoptotic process,GO:0090330~regulation of platelet aggregation,GO:1904355~positive regulation of telomere capping,GO:2000318~positive regulation of T-helper 17 type immune response,GO:2000563~positive regulation of CD4-positive, alpha-beta T cell proliferation,GO:2000570~positive regulation of T-helper 2 cell activation,	GO:0001772~immunological synapse,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016235~aggresome,GO:0034451~centriolar satellite,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004697~protein kinase C activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0046872~metal ion binding,	IPR000008:C2_dom,IPR000719:Prot_kinase_dom,IPR000961:AGC-kinase_C,IPR002219:PE/DAG-bd,IPR008271:Ser/Thr_kinase_AS,IPR011009:Kinase-like_dom_sf,IPR014376:Prot_kin_PKC_delta,IPR017441:Protein_kinase_ATP_BS,IPR017892:Pkinase_C,IPR020454:DAG/PE-bd,IPR027264:PKC_theta,IPR034668:nPKC_theta,IPR035892:C2_domain_sf,IPR046349:C1-like_sf,	hsa04064:NF-kappa B signaling pathway,hsa04140:Autophagy - animal,hsa04270:Vascular smooth muscle contraction,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04660:T cell receptor signaling pathway,hsa04750:Inflammatory mediator regulation of TRP channels,hsa04920:Adipocytokine signaling pathway,hsa04931:Insulin resistance,hsa05131:Shigellosis,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,		PIRSF000551:PKC_delta,PIRSF501105:Protein_kin_C_theta,	SM00109:C1,SM00133:S_TK_X,SM00220:S_TKc,	KW-0391~Immunity,KW-0395~Inflammatory response,	KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,KW-0862~Zinc,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,DOMAIN:AGC-kinase C-terminal,DOMAIN:C2,DOMAIN:Protein kinase,MUTAGEN:A->E: Constitutively active form.,MUTAGEN:K->A,E: Loss of kinase activity.,MUTAGEN:S->A: Reduction in kinase activity.,MUTAGEN:T->A: Loss of kinase activity.,MUTAGEN:T->A: Loss of transactivation of the IL2 promoter and translocation to the plasma membrane. No effect on kinase activity.,MUTAGEN:Y->F: Loss of function in T-cells proliferation. No effect on kinase activity.,ZN_FING:Phorbol-ester/DAG-type 1,ZN_FING:Phorbol-ester/DAG-type 2,
PRKAR1A	protein kinase cAMP-dependent type I regulatory subunit alpha(PRKAR1A)	Homo sapiens		h_agpcrPathway:Attenuation of GPCR Signaling,h_badPathway:Regulation of BAD phosphorylation,h_carm1Pathway:Transcription Regulation by Methyltransferase of CARM1,h_cftrPathway:Cystic fibrosis transmembrane conductance regulator (CFTR) and beta 2 adrenergic receptor (b2AR) pathway,h_chrebpPathway:ChREBP regulation by carbohydrates and cAMP,h_ck1Pathway:Regulation of ck1/cdk5 by type 1 glutamate receptors,h_crebPathway:Transcription factor CREB and its extracellular signals,h_cskPathway:Activation of Csk by cAMP-dependent Protein Kinase Inhibits Signaling through the T Cell Receptor,h_dreamPathway:Repression of Pain Sensation by the Transcriptional Regulator DREAM,h_gata3Pathway:GATA3 participate in activating the Th2 cytokine genes expression,h_gpcrPathway:Signaling Pathway from G-Protein Families,h_gsPathway:Activation of cAMP-dependent protein kinase, PKA,h_igf1rPathway:Multiple antiapoptotic pathways from IGF-1R signaling lead to BAD phosphorylation,h_mCalpainPathway:mCalpain and friends in Cell motility,h_mPRPathway:How Progesterone Initiates the Oocyte Maturation,h_nfatPathway:NFAT and Hypertrophy of the heart (Transcription in the broken heart),h_no1Pathway:Actions of Nitric Oxide in the Heart,h_nos1Pathway:Nitric Oxide Signaling Pathway,h_plcePathway:Phospholipase C-epsilon pathway,h_PparaPathway:Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha),h_shhPathway:Sonic Hedgehog (Shh) Pathway,h_stathminPathway:Stathmin and breast cancer resistance to antimicrotubule agents,h_vipPathway:Neuropeptides VIP and PACAP inhibit the apoptosis of activated T cells,	GO:0001707~mesoderm formation,GO:0001932~regulation of protein phosphorylation,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007189~adenylate cyclase-activating G-protein coupled receptor signaling pathway,GO:0010629~negative regulation of gene expression,GO:0016310~phosphorylation,GO:0032024~positive regulation of insulin secretion,GO:0035556~intracellular signal transduction,GO:0045214~sarcomere organization,GO:0046007~negative regulation of activated T cell proliferation,GO:0060038~cardiac muscle cell proliferation,GO:0071377~cellular response to glucagon stimulus,GO:2000480~negative regulation of cAMP-dependent protein kinase activity,	GO:0001772~immunological synapse,GO:0005737~cytoplasm,GO:0005771~multivesicular body,GO:0005813~centrosome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005930~axoneme,GO:0005952~cAMP-dependent protein kinase complex,GO:0016020~membrane,GO:0031588~nucleotide-activated protein kinase complex,GO:0031594~neuromuscular junction,GO:0032991~macromolecular complex,GO:0044853~plasma membrane raft,GO:0097224~sperm connecting piece,GO:0097546~ciliary base,GO:0098978~glutamatergic synapse,	GO:0004862~cAMP-dependent protein kinase inhibitor activity,GO:0005515~protein binding,GO:0008603~cAMP-dependent protein kinase regulator activity,GO:0016301~kinase activity,GO:0019904~protein domain specific binding,GO:0030552~cAMP binding,GO:0031625~ubiquitin protein ligase binding,GO:0034236~protein kinase A catalytic subunit binding,	IPR000595:cNMP-bd_dom,IPR003117:cAMP_dep_PK_reg_su_I/II_a/b,IPR012198:cAMP_dep_PK_reg_su,IPR014710:RmlC-like_jellyroll,IPR018488:cNMP-bd_CS,IPR018490:cNMP-bd_dom_sf,	hsa04910:Insulin signaling pathway,	101800~Acrodysostosis 1, with or without hormone resistance,160980~Carney complex, type 1,255960~Myxoma, intracardiac,610489~Pigmented nodular adrenocortical disease, primary, 1,Adrenocortical tumor, somatic,~Adrenocortical tumor, somatic,,	PIRSF000548:PK_regulatory,	SM00100:cNMP,SM00394:RIIa,		KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-1062~Cushing syndrome,	KW-0677~Repeat,	KW-0114~cAMP,KW-0116~cAMP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	DISULFID:Interchain (with C-18),DISULFID:Interchain (with C-39),DOMAIN:Cyclic nucleotide-binding,DOMAIN:RIIa,MOTIF:Pseudophosphorylation motif,MUTAGEN:Y->A: Impairs response of PKA to c-AMP.,REGION:Dimerization and phosphorylation,REGION:Disordered,
PRKAR2A	protein kinase cAMP-dependent type II regulatory subunit alpha(PRKAR2A)	Homo sapiens		h_agpcrPathway:Attenuation of GPCR Signaling,h_akap13Pathway:Rho-Selective Guanine Exchange Factor AKAP13 Mediates Stress Fiber Formation,h_akap95Pathway:AKAP95 role in mitosis and chromosome dynamics,h_akapcentrosomePathway:Protein Kinase A at the Centrosome,h_badPathway:Regulation of BAD phosphorylation,h_carm1Pathway:Transcription Regulation by Methyltransferase of CARM1,h_cftrPathway:Cystic fibrosis transmembrane conductance regulator (CFTR) and beta 2 adrenergic receptor (b2AR) pathway,h_chrebpPathway:ChREBP regulation by carbohydrates and cAMP,h_ck1Pathway:Regulation of ck1/cdk5 by type 1 glutamate receptors,h_crebPathway:Transcription factor CREB and its extracellular signals,h_cskPathway:Activation of Csk by cAMP-dependent Protein Kinase Inhibits Signaling through the T Cell Receptor,h_dreamPathway:Repression of Pain Sensation by the Transcriptional Regulator DREAM,h_gata3Pathway:GATA3 participate in activating the Th2 cytokine genes expression,h_gpcrPathway:Signaling Pathway from G-Protein Families,h_igf1rPathway:Multiple antiapoptotic pathways from IGF-1R signaling lead to BAD phosphorylation,h_mCalpainPathway:mCalpain and friends in Cell motility,h_mPRPathway:How Progesterone Initiates the Oocyte Maturation,h_nfatPathway:NFAT and Hypertrophy of the heart (Transcription in the broken heart),h_no1Pathway:Actions of Nitric Oxide in the Heart,h_nos1Pathway:Nitric Oxide Signaling Pathway,h_plcePathway:Phospholipase C-epsilon pathway,h_PparaPathway:Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha),h_shhPathway:Sonic Hedgehog (Shh) Pathway,h_stathminPathway:Stathmin and breast cancer resistance to antimicrotubule agents,h_vipPathway:Neuropeptides VIP and PACAP inhibit the apoptosis of activated T cells,	GO:0001932~regulation of protein phosphorylation,GO:0007339~binding of sperm to zona pellucida,GO:0016310~phosphorylation,GO:0035556~intracellular signal transduction,GO:2000480~negative regulation of cAMP-dependent protein kinase activity,	GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0005930~axoneme,GO:0005952~cAMP-dependent protein kinase complex,GO:0016020~membrane,GO:0031588~nucleotide-activated protein kinase complex,GO:0032991~macromolecular complex,GO:0044853~plasma membrane raft,GO:0070062~extracellular exosome,GO:0097546~ciliary base,	GO:0004862~cAMP-dependent protein kinase inhibitor activity,GO:0005515~protein binding,GO:0008603~cAMP-dependent protein kinase regulator activity,GO:0016301~kinase activity,GO:0019904~protein domain specific binding,GO:0030552~cAMP binding,GO:0031625~ubiquitin protein ligase binding,GO:0034236~protein kinase A catalytic subunit binding,	IPR000595:cNMP-bd_dom,IPR003117:cAMP_dep_PK_reg_su_I/II_a/b,IPR012105:Sp17,IPR012198:cAMP_dep_PK_reg_su,IPR014710:RmlC-like_jellyroll,IPR018488:cNMP-bd_CS,IPR018490:cNMP-bd_dom_sf,	hsa04910:Insulin signaling pathway,		PIRSF000548:PK_regulatory,PIRSF016533:Sp17,	SM00100:cNMP,SM00394:RIIa,		KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0677~Repeat,	KW-0114~cAMP,KW-0116~cAMP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,DOMAIN:Cyclic nucleotide-binding,DOMAIN:RIIa,REGION:Dimerization and phosphorylation,REGION:Disordered,
PRKDC	protein kinase, DNA-activated, catalytic subunit(PRKDC)	Homo sapiens		h_fasPathway:FAS signaling pathway ( CD95 ),h_g2Pathway:Cell Cycle: G2/M Checkpoint,h_hivnefPathway:HIV-I Nef: negative effector of Fas and TNF,h_tnfr1Pathway:TNFR1 Signaling Pathway,	GO:0000460~maturation of 5.8S rRNA,GO:0000723~telomere maintenance,GO:0001756~somitogenesis,GO:0001933~negative regulation of protein phosphorylation,GO:0002218~activation of innate immune response,GO:0002326~B cell lineage commitment,GO:0002327~immature B cell differentiation,GO:0002328~pro-B cell differentiation,GO:0002360~T cell lineage commitment,GO:0006302~double-strand break repair,GO:0006303~double-strand break repair via nonhomologous end joining,GO:0006338~chromatin remodeling,GO:0006468~protein phosphorylation,GO:0006974~cellular response to DNA damage stimulus,GO:0007420~brain development,GO:0007507~heart development,GO:0008630~intrinsic apoptotic signaling pathway in response to DNA damage,GO:0010332~response to gamma radiation,GO:0016233~telomere capping,GO:0016310~phosphorylation,GO:0018105~peptidyl-serine phosphorylation,GO:0018107~peptidyl-threonine phosphorylation,GO:0031571~mitotic G1 DNA damage checkpoint,GO:0031648~protein destabilization,GO:0032869~cellular response to insulin stimulus,GO:0033077~T cell differentiation in thymus,GO:0033152~immunoglobulin V(D)J recombination,GO:0033153~T cell receptor V(D)J recombination,GO:0034462~small-subunit processome assembly,GO:0035234~ectopic germ cell programmed cell death,GO:0036211~protein modification process,GO:0042752~regulation of circadian rhythm,GO:0043065~positive regulation of apoptotic process,GO:0043066~negative regulation of apoptotic process,GO:0045087~innate immune response,GO:0045621~positive regulation of lymphocyte differentiation,GO:0045648~positive regulation of erythrocyte differentiation,GO:0045727~positive regulation of translation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048511~rhythmic process,GO:0048584~positive regulation of response to stimulus,GO:0048660~regulation of smooth muscle cell proliferation,GO:0050678~regulation of epithelial cell proliferation,GO:0051171~regulation of nitrogen compound metabolic process,GO:0060255~regulation of macromolecule metabolic process,GO:0080090~regulation of primary metabolic process,GO:0080135~regulation of cellular response to stress,GO:0097681~double-strand break repair via alternative nonhomologous end joining,GO:1902036~regulation of hematopoietic stem cell differentiation,GO:1905221~positive regulation of platelet formation,GO:2001034~positive regulation of double-strand break repair via nonhomologous end joining,	GO:0000781~chromosome, telomeric region,GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005730~nucleolus,GO:0005829~cytosol,GO:0005958~DNA-dependent protein kinase-DNA ligase 4 complex,GO:0016020~membrane,GO:0032040~small-subunit processome,GO:0032991~macromolecular complex,GO:0032993~protein-DNA complex,GO:0070418~DNA-dependent protein kinase complex,GO:0070419~nonhomologous end joining complex,	GO:0003690~double-stranded DNA binding,GO:0003723~RNA binding,GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004677~DNA-dependent protein kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016301~kinase activity,GO:0019899~enzyme binding,GO:0019904~protein domain specific binding,GO:0034511~U3 snoRNA binding,GO:0035979~histone kinase activity (H2A-S139 specific),GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,	IPR000403:PI3/4_kinase_cat_dom,IPR003151:PIK-rel_kinase_FAT,IPR003152:FATC_dom,IPR011009:Kinase-like_dom_sf,IPR011989:ARM-like,IPR012582:DNAPKcs_CC3,IPR014009:PIK_FAT,IPR016024:ARM-type_fold,IPR018936:PI3/4_kinase_CS,IPR036940:PI3/4_kinase_cat_sf,IPR037706:DNA-PK_dom,IPR045581:DNAPKcs_CC5,IPR046803:DNAPKcs_CC1-2,IPR046804:DNA-PKcs_N,	hsa03450:Non-homologous end-joining,hsa04110:Cell cycle,	615966~Immunodeficiency 26, with or without neurologic abnormalities,		SM00146:PI3Kc,SM01343:FATC,SM01344:NUC194,	KW-0090~Biological rhythms,KW-0227~DNA damage,KW-0233~DNA recombination,KW-0234~DNA repair,KW-0391~Immunity,KW-0399~Innate immunity,KW-0690~Ribosome biogenesis,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-0705~SCID,	KW-0677~Repeat,KW-0802~TPR repeat,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0238~DNA-binding,KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	DOMAIN:DNA-PKcs N-terminal,DOMAIN:FAT,DOMAIN:FATC,DOMAIN:PI3K/PI4K catalytic,MUTAGEN:EL->PD: Loss of interaction with C1D.,MUTAGEN:L->P: Loss of interaction with C1D.,MUTAGEN:S->A: Reduced phosphorylation; when associated with A-2609.,MUTAGEN:T->A: Alleviates phosphorylation, leaves a fully active enzyme with compromised cellular resistance to ionizing radiation without affecting DNA end joining; when associated with A-2638.,MUTAGEN:T->A: Alleviates phosphorylation, leaves a fully active enzyme with compromised cellular resistance to ionizing radiation without affecting DNA end joining; when associated with A-2647.,MUTAGEN:T->A: Leads to radiation sensitivity and impaired DSB joining. Gives rise to reduced phosphorylation; when associated with A-2612.,REGION:Activation loop,REGION:Catalytic loop,REGION:Disordered,REGION:G-loop,REGION:Interaction with C1D,REGION:KIP-binding,REGION:Leucine-zipper,REGION:May split the end of the DNA molecule, with the two strands separating around the region,REPEAT:HEAT 1,REPEAT:HEAT 2,REPEAT:TPR 1,REPEAT:TPR 2,REPEAT:TPR 3,SITE:Cleavage; by caspase-3,
PPP1CA	protein phosphatase 1 catalytic subunit alpha(PPP1CA)	Homo sapiens		h_akap95Pathway:AKAP95 role in mitosis and chromosome dynamics,h_akapcentrosomePathway:Protein Kinase A at the Centrosome,h_ck1Pathway:Regulation of ck1/cdk5 by type 1 glutamate receptors,h_eif2Pathway:Regulation of eIF2,	GO:0005977~glycogen metabolic process,GO:0005979~regulation of glycogen biosynthetic process,GO:0005981~regulation of glycogen catabolic process,GO:0006446~regulation of translational initiation,GO:0006470~protein dephosphorylation,GO:0007049~cell cycle,GO:0010288~response to lead ion,GO:0016311~dephosphorylation,GO:0030324~lung development,GO:0032091~negative regulation of protein binding,GO:0032922~circadian regulation of gene expression,GO:0035970~peptidyl-threonine dephosphorylation,GO:0036496~regulation of translational initiation by eIF2 alpha dephosphorylation,GO:0042752~regulation of circadian rhythm,GO:0043153~entrainment of circadian clock by photoperiod,GO:0048754~branching morphogenesis of an epithelial tube,GO:0051301~cell division,GO:0060828~regulation of canonical Wnt signaling pathway,GO:0070262~peptidyl-serine dephosphorylation,GO:0098609~cell-cell adhesion,GO:1904886~beta-catenin destruction complex disassembly,GO:2001241~positive regulation of extrinsic apoptotic signaling pathway in absence of ligand,	GO:0000781~chromosome, telomeric region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005912~adherens junction,GO:0042587~glycogen granule,GO:0043197~dendritic spine,GO:0043204~perikaryon,GO:0070062~extracellular exosome,GO:0072357~PTW/PP1 phosphatase complex,GO:0098793~presynapse,GO:0098978~glutamatergic synapse,	GO:0004721~phosphoprotein phosphatase activity,GO:0004722~protein serine/threonine phosphatase activity,GO:0005515~protein binding,GO:0008157~protein phosphatase 1 binding,GO:0016791~phosphatase activity,GO:0017018~myosin phosphatase activity,GO:0043021~ribonucleoprotein complex binding,GO:0046872~metal ion binding,GO:0098641~cadherin binding involved in cell-cell adhesion,	IPR004843:Calcineurin-like_PHP_ApaH,IPR006186:Ser/Thr-sp_prot-phosphatase,IPR029052:Metallo-depent_PP-like,IPR031675:STPPase_N,	hsa03015:mRNA surveillance pathway,hsa04022:cGMP-PKG signaling pathway,hsa04024:cAMP signaling pathway,hsa04114:Oocyte meiosis,hsa04218:Cellular senescence,hsa04261:Adrenergic signaling in cardiomyocytes,hsa04270:Vascular smooth muscle contraction,hsa04390:Hippo signaling pathway,hsa04510:Focal adhesion,hsa04611:Platelet activation,hsa04720:Long-term potentiation,hsa04728:Dopaminergic synapse,hsa04750:Inflammatory mediator regulation of TRP channels,hsa04810:Regulation of actin cytoskeleton,hsa04910:Insulin signaling pathway,hsa04921:Oxytocin signaling pathway,hsa04931:Insulin resistance,hsa05031:Amphetamine addiction,hsa05034:Alcoholism,hsa05168:Herpes simplex virus 1 infection,hsa05205:Proteoglycans in cancer,hsa05415:Diabetic cardiomyopathy,			SM00156:PP2Ac,	KW-0119~Carbohydrate metabolism,KW-0131~Cell cycle,KW-0132~Cell division,KW-0321~Glycogen metabolism,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0464~Manganese,KW-0479~Metal-binding,	KW-0378~Hydrolase,KW-0904~Protein phosphatase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton donor,DOMAIN:Serine/threonine specific protein phosphatases,REGION:Disordered,
PPP1CB	protein phosphatase 1 catalytic subunit beta(PPP1CB)	Homo sapiens			GO:0000165~MAPK cascade,GO:0005977~glycogen metabolic process,GO:0006470~protein dephosphorylation,GO:0007049~cell cycle,GO:0030155~regulation of cell adhesion,GO:0032922~circadian regulation of gene expression,GO:0042752~regulation of circadian rhythm,GO:0043153~entrainment of circadian clock by photoperiod,GO:0051301~cell division,	GO:0000781~chromosome, telomeric region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005925~focal adhesion,GO:0070062~extracellular exosome,GO:0072357~PTW/PP1 phosphatase complex,	GO:0004721~phosphoprotein phosphatase activity,GO:0004722~protein serine/threonine phosphatase activity,GO:0005515~protein binding,GO:0016791~phosphatase activity,GO:0017018~myosin phosphatase activity,GO:0019901~protein kinase binding,GO:0046872~metal ion binding,GO:0050115~myosin-light-chain-phosphatase activity,	IPR004843:Calcineurin-like_PHP_ApaH,IPR006186:Ser/Thr-sp_prot-phosphatase,IPR029052:Metallo-depent_PP-like,IPR031675:STPPase_N,	hsa03015:mRNA surveillance pathway,hsa04022:cGMP-PKG signaling pathway,hsa04024:cAMP signaling pathway,hsa04114:Oocyte meiosis,hsa04218:Cellular senescence,hsa04261:Adrenergic signaling in cardiomyocytes,hsa04270:Vascular smooth muscle contraction,hsa04390:Hippo signaling pathway,hsa04510:Focal adhesion,hsa04611:Platelet activation,hsa04720:Long-term potentiation,hsa04728:Dopaminergic synapse,hsa04750:Inflammatory mediator regulation of TRP channels,hsa04810:Regulation of actin cytoskeleton,hsa04910:Insulin signaling pathway,hsa04921:Oxytocin signaling pathway,hsa04931:Insulin resistance,hsa05031:Amphetamine addiction,hsa05034:Alcoholism,hsa05168:Herpes simplex virus 1 infection,hsa05205:Proteoglycans in cancer,hsa05415:Diabetic cardiomyopathy,	617506~Noonan syndrome-like disorder with loose anagen hair 2,		SM00156:PP2Ac,	KW-0090~Biological rhythms,KW-0119~Carbohydrate metabolism,KW-0131~Cell cycle,KW-0132~Cell division,KW-0321~Glycogen metabolism,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,		KW-0464~Manganese,KW-0479~Metal-binding,	KW-0378~Hydrolase,KW-0904~Protein phosphatase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton donor,DOMAIN:Serine-threonine protein phosphatase N-terminal,DOMAIN:Serine/threonine specific protein phosphatases,REGION:Disordered,
PPP1CC	protein phosphatase 1 catalytic subunit gamma(PPP1CC)	Homo sapiens			GO:0000165~MAPK cascade,GO:0001824~blastocyst development,GO:0005977~glycogen metabolic process,GO:0006470~protein dephosphorylation,GO:0007049~cell cycle,GO:0007283~spermatogenesis,GO:0030182~neuron differentiation,GO:0032922~circadian regulation of gene expression,GO:0042752~regulation of circadian rhythm,GO:0043153~entrainment of circadian clock by photoperiod,GO:0046822~regulation of nucleocytoplasmic transport,GO:0051301~cell division,GO:0060252~positive regulation of glial cell proliferation,	GO:0000776~kinetochore,GO:0000781~chromosome, telomeric region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005741~mitochondrial outer membrane,GO:0005815~microtubule organizing center,GO:0005829~cytosol,GO:0005925~focal adhesion,GO:0016607~nuclear speck,GO:0030496~midbody,GO:0032154~cleavage furrow,GO:0032991~macromolecular complex,GO:0043197~dendritic spine,GO:0072357~PTW/PP1 phosphatase complex,GO:0098793~presynapse,GO:0098978~glutamatergic synapse,	GO:0003723~RNA binding,GO:0004721~phosphoprotein phosphatase activity,GO:0004722~protein serine/threonine phosphatase activity,GO:0005515~protein binding,GO:0005521~lamin binding,GO:0008157~protein phosphatase 1 binding,GO:0016791~phosphatase activity,GO:0017018~myosin phosphatase activity,GO:0019901~protein kinase binding,GO:0019904~protein domain specific binding,GO:0044877~macromolecular complex binding,GO:0046872~metal ion binding,	IPR004843:Calcineurin-like_PHP_ApaH,IPR006186:Ser/Thr-sp_prot-phosphatase,IPR029052:Metallo-depent_PP-like,IPR031675:STPPase_N,	hsa03015:mRNA surveillance pathway,hsa04022:cGMP-PKG signaling pathway,hsa04024:cAMP signaling pathway,hsa04114:Oocyte meiosis,hsa04218:Cellular senescence,hsa04261:Adrenergic signaling in cardiomyocytes,hsa04270:Vascular smooth muscle contraction,hsa04390:Hippo signaling pathway,hsa04510:Focal adhesion,hsa04611:Platelet activation,hsa04720:Long-term potentiation,hsa04728:Dopaminergic synapse,hsa04750:Inflammatory mediator regulation of TRP channels,hsa04810:Regulation of actin cytoskeleton,hsa04910:Insulin signaling pathway,hsa04921:Oxytocin signaling pathway,hsa04931:Insulin resistance,hsa05031:Amphetamine addiction,hsa05034:Alcoholism,hsa05168:Herpes simplex virus 1 infection,hsa05205:Proteoglycans in cancer,hsa05415:Diabetic cardiomyopathy,			SM00156:PP2Ac,	KW-0090~Biological rhythms,KW-0119~Carbohydrate metabolism,KW-0131~Cell cycle,KW-0132~Cell division,KW-0321~Glycogen metabolism,	KW-0137~Centromere,KW-0158~Chromosome,KW-0206~Cytoskeleton,KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0995~Kinetochore,		KW-0732~Signal,	KW-0464~Manganese,KW-0479~Metal-binding,	KW-0378~Hydrolase,KW-0904~Protein phosphatase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	ACT_SITE:Proton donor,DOMAIN:Calcineurin-like phosphoesterase,DOMAIN:Serine/threonine specific protein phosphatases,MUTAGEN:C->A,S,L: Abolishes interaction with microcystin toxin.,MUTAGEN:H->A: Loss of activity.,REGION:Disordered,SITE:Inhibition by microcystin toxin binding,
PPP1R11	protein phosphatase 1 regulatory inhibitor subunit 11(PPP1R11)	Homo sapiens			GO:0001818~negative regulation of cytokine production,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0016567~protein ubiquitination,GO:0050830~defense response to Gram-positive bacterium,	GO:0005634~nucleus,GO:0005737~cytoplasm,	GO:0004864~protein phosphatase inhibitor activity,GO:0004865~protein serine/threonine phosphatase inhibitor activity,GO:0005515~protein binding,GO:0008157~protein phosphatase 1 binding,GO:0019902~phosphatase binding,GO:0061630~ubiquitin protein ligase activity,	IPR011107:PPI_Ypi1,					KW-0833~Ubl conjugation pathway,					KW-0650~Protein phosphatase inhibitor,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,MUTAGEN:C->S: Loss of function in inducing TLR2 degradation.,MUTAGEN:CCC->SSS: Loss of function in inducing TLR2 degradation.,MUTAGEN:H->A: Loss of function in inducing TLR2 degradation.,MUTAGEN:HC->AS: Loss of function in inducing TLR2 degradation.,REGION:Atypical RING finger domain 1,REGION:Atypical RING finger domain 2,REGION:Disordered,
PPP1R2	protein phosphatase 1 regulatory inhibitor subunit 2(PPP1R2)	Homo sapiens			GO:0005977~glycogen metabolic process,GO:0006091~generation of precursor metabolites and energy,GO:0009966~regulation of signal transduction,GO:0043666~regulation of phosphoprotein phosphatase activity,		GO:0004864~protein phosphatase inhibitor activity,GO:0004865~protein serine/threonine phosphatase inhibitor activity,GO:0005515~protein binding,	IPR007062:PPI-2,					KW-0119~Carbohydrate metabolism,KW-0321~Glycogen metabolism,					KW-0650~Protein phosphatase inhibitor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Polar residues,REGION:Disordered,REGION:Required for binding PPP1CC,REGION:Required for binding PPP1CC catalytic center, displacing metal ions and inhibition of PPP1CC catalytic activity,
PPP1R10	protein phosphatase 1 regulatory subunit 10(PPP1R10)	Homo sapiens			GO:0006606~protein import into nucleus,GO:0010667~negative regulation of cardiac muscle cell apoptotic process,GO:0032206~positive regulation of telomere maintenance,GO:1904290~negative regulation of mitotic DNA damage checkpoint,	GO:0000781~chromosome, telomeric region,GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0016604~nuclear body,GO:0072357~PTW/PP1 phosphatase complex,	GO:0003677~DNA binding,GO:0003723~RNA binding,GO:0004864~protein phosphatase inhibitor activity,GO:0005515~protein binding,GO:0008157~protein phosphatase 1 binding,GO:0046872~metal ion binding,	IPR000571:Znf_CCCH,IPR003617:TFIIS/CRSP70_N_sub,IPR017923:TFIIS_N,IPR035441:TFIIS/LEDGF_dom_sf,IPR036855:Znf_CCCH_sf,				SM00356:ZnF_C3H1,SM00509:TFS2N,		KW-0539~Nucleus,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,KW-0650~Protein phosphatase inhibitor,KW-0694~RNA-binding,	KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:C3H1-type,DOMAIN:TFIIS N-terminal,MOTIF:PP1-binding motif,REGION:Disordered,REGION:Essential for PPP1CA inhibition,REGION:Interaction with TOX4,REGION:Interaction with WDR82,REGION:Necessary for interaction with PPP1CA,REGION:Necessary for interaction with PPP1CC,ZN_FING:C3H1-type,
PPP1R15A	protein phosphatase 1 regulatory subunit 15A(PPP1R15A)	Homo sapiens			GO:0006915~apoptotic process,GO:0006974~cellular response to DNA damage stimulus,GO:0031400~negative regulation of protein modification process,GO:0032058~positive regulation of translational initiation in response to stress,GO:0032515~negative regulation of phosphoprotein phosphatase activity,GO:0032516~positive regulation of phosphoprotein phosphatase activity,GO:0034976~response to endoplasmic reticulum stress,GO:0035308~negative regulation of protein dephosphorylation,GO:0036496~regulation of translational initiation by eIF2 alpha dephosphorylation,GO:0045936~negative regulation of phosphate metabolic process,GO:0051726~regulation of cell cycle,GO:0070059~intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress,GO:0070972~protein localization to endoplasmic reticulum,GO:1902310~positive regulation of peptidyl-serine dephosphorylation,GO:1903898~negative regulation of PERK-mediated unfolded protein response,GO:1903917~positive regulation of endoplasmic reticulum stress-induced eIF2 alpha dephosphorylation,	GO:0000164~protein phosphatase type 1 complex,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005741~mitochondrial outer membrane,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0016020~membrane,	GO:0005515~protein binding,GO:0008157~protein phosphatase 1 binding,GO:0019888~protein phosphatase regulator activity,GO:0019901~protein kinase binding,GO:0072542~protein phosphatase activator activity,	IPR019523:Prot_Pase1_reg-su15A/B_C,	hsa04141:Protein processing in endoplasmic reticulum,				KW-0053~Apoptosis,KW-0346~Stress response,KW-0810~Translation regulation,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0496~Mitochondrion,KW-1000~Mitochondrion outer membrane,		KW-0677~Repeat,			KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Protein phosphatase 1 regulatory subunit 15A/B C-terminal,INTRAMEM:Helical,MUTAGEN:KVRF->AAAA: Reduces interaction with SMARCB1.,MUTAGEN:L->R: Localizes to cytoplasm.,MUTAGEN:R->D: Reduces PP1-binding.,MUTAGEN:R->K: Reduces PP1-binding; when associated with K-612.,MUTAGEN:R->K: Reduces PP1-binding; when associated with K-614.,MUTAGEN:V->R: Localizes to cytoplasm, degraded more slowly.,MUTAGEN:VRF->ARA: Impairs PP1 activation.,MUTAGEN:Y->F: Significantly reduced turnover.,REGION:4 X 34 AA approximate repeats,REGION:Disordered,REGION:Interaction with KMT2A/MLL1,REGION:Interaction with SMAD7,REGION:Interaction with SMARCB1,REGION:Required for localization in the endoplasmic reticulum,REPEAT:1,REPEAT:2,REPEAT:3,REPEAT:4,TOPO_DOM:Cytoplasmic,
PPP1R16B	protein phosphatase 1 regulatory subunit 16B(PPP1R16B)	Homo sapiens			GO:0001938~positive regulation of endothelial cell proliferation,GO:0035304~regulation of protein dephosphorylation,GO:0035307~positive regulation of protein dephosphorylation,GO:0035308~negative regulation of protein dephosphorylation,GO:0051489~regulation of filopodium assembly,GO:0051896~regulation of protein kinase B signaling,GO:0061028~establishment of endothelial barrier,GO:1902309~negative regulation of peptidyl-serine dephosphorylation,GO:1903589~positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis,GO:1903670~regulation of sprouting angiogenesis,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0016607~nuclear speck,GO:0042995~cell projection,GO:0048471~perinuclear region of cytoplasm,	GO:0004857~enzyme inhibitor activity,GO:0005515~protein binding,GO:0017020~myosin phosphatase regulator activity,GO:0019888~protein phosphatase regulator activity,	IPR002110:Ankyrin_rpt,IPR017417:Pase-1_reg_su_16AB,IPR036770:Ankyrin_rpt-contain_sf,			PIRSF038159:PP1_16AB_vert,	SM00248:ANK,		KW-0472~Membrane,KW-0539~Nucleus,KW-0966~Cell projection,KW-1003~Cell membrane,		KW-0040~ANK repeat,KW-0175~Coiled coil,KW-0677~Repeat,			KW-0449~Lipoprotein,KW-0488~Methylation,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-0636~Prenylation,	COMPBIAS:Basic and acidic residues,LIPID:S-farnesyl cysteine,LIPID:S-palmitoyl cysteine,MUTAGEN:G->A: Strongly decreased interaction with EEF1A1.,PROPEP:Removed in mature form,REGION:Disordered,REPEAT:ANK 1,REPEAT:ANK 2,REPEAT:ANK 3,REPEAT:ANK 4,REPEAT:ANK 5,
PPP1R18	protein phosphatase 1 regulatory subunit 18(PPP1R18)	Homo sapiens				GO:0005737~cytoplasm,GO:0005856~cytoskeleton,	GO:0003779~actin binding,GO:0005515~protein binding,GO:0019902~phosphatase binding,	IPR025903:Phostensin/Taperin_N_dom,IPR025907:Phostensin/Taperin_PP1-bd_dom,IPR026671:PPP1R18/Tprn,						KW-0206~Cytoskeleton,KW-0963~Cytoplasm,				KW-0009~Actin-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Phostensin/Taperin N-terminal,DOMAIN:Phostensin/Taperin PP1-binding,MUTAGEN:F->G: Decrease binding to PP1. Decrease binding to PP1. Complete inhibition of PP1 binding; when associated with G-540.,MUTAGEN:I->G: Decrease binding to PP1. Complete inhibition of PP1 binding; when associated with G-542.,REGION:Disordered,
PPP1R7	protein phosphatase 1 regulatory subunit 7(PPP1R7)	Homo sapiens			GO:0000398~mRNA splicing, via spliceosome,GO:0035307~positive regulation of protein dephosphorylation,	GO:0005634~nucleus,GO:0005694~chromosome,GO:0005737~cytoplasm,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0019888~protein phosphatase regulator activity,GO:0030234~enzyme regulator activity,GO:0030620~U2 snRNA binding,	IPR001611:Leu-rich_rpt,IPR003591:Leu-rich_rpt_typical-subtyp,IPR003603:U2A'_phosphoprotein32A_C,IPR025875:Leu-rich_rpt_4,IPR032675:LRR_dom_sf,IPR044640:RU2A,				SM00365:LRR_SD22,SM00369:LRR_TYP,SM00446:LRRcap,		KW-0539~Nucleus,		KW-0433~Leucine-rich repeat,KW-0677~Repeat,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:LRRCT,DOMAIN:U2A'/phosphoprotein 32 family A C-terminal,MUTAGEN:D->A: Severely impairs the binding of protein phosphatase 1.,MUTAGEN:D->V: Completely abolishes the interaction with protein phosphatase 1.,MUTAGEN:E->A: Completely abolishes the interaction with protein phosphatase 1.,MUTAGEN:F->A: Completely abolishes the interaction with protein phosphatase 1.,MUTAGEN:F->A: Severely impaired the binding of protein phosphatase 1.,MUTAGEN:W->A: Completely abolishes the interaction with protein phosphatase 1.,MUTAGEN:Y->A: Completely abolishes the interaction with protein phosphatase 1.,REGION:Disordered,REPEAT:LRR 1,REPEAT:LRR 10,REPEAT:LRR 11,REPEAT:LRR 2,REPEAT:LRR 3,REPEAT:LRR 4,REPEAT:LRR 5,REPEAT:LRR 6,REPEAT:LRR 7,REPEAT:LRR 8,REPEAT:LRR 9,
PPP2CA	protein phosphatase 2 catalytic subunit alpha(PPP2CA)	Homo sapiens		h_akap95Pathway:AKAP95 role in mitosis and chromosome dynamics,h_akapcentrosomePathway:Protein Kinase A at the Centrosome,h_aktPathway:AKT Signaling Pathway,h_chrebpPathway:ChREBP regulation by carbohydrates and cAMP,h_ck1Pathway:Regulation of ck1/cdk5 by type 1 glutamate receptors,h_ctcfPathway:CTCF: First Multivalent Nuclear Factor,h_erkPathway:Erk1/Erk2 Mapk Signaling pathway,H_gsk3Pathway:Inactivation of Gsk3 by AKT causes accumulation of b-catenin in Alveolar Macrophages,h_igf1mtorPathway:Skeletal muscle hypertrophy is regulated via AKT/mTOR pathway,h_keratinocytePathway:Keratinocyte Differentiation,h_mtorPathway:mTOR Signaling Pathway,h_p35AlzheimersPathway:Deregulation of CDK5 in Alzheimers Disease,h_telPathway:Telomeres, Telomerase, Cellular Aging, and  Immortality,h_wntPathway:WNT Signaling Pathway,	GO:0000278~mitotic cell cycle,GO:0001932~regulation of protein phosphorylation,GO:0006275~regulation of DNA replication,GO:0006355~regulation of transcription, DNA-templated,GO:0006470~protein dephosphorylation,GO:0006672~ceramide metabolic process,GO:0006915~apoptotic process,GO:0007498~mesoderm development,GO:0008380~RNA splicing,GO:0010033~response to organic substance,GO:0010288~response to lead ion,GO:0010719~negative regulation of epithelial to mesenchymal transition,GO:0019932~second-messenger-mediated signaling,GO:0030111~regulation of Wnt signaling pathway,GO:0030155~regulation of cell adhesion,GO:0030308~negative regulation of cell growth,GO:0035970~peptidyl-threonine dephosphorylation,GO:0040008~regulation of growth,GO:0042532~negative regulation of tyrosine phosphorylation of STAT protein,GO:0043029~T cell homeostasis,GO:0045595~regulation of cell differentiation,GO:0051321~meiotic cell cycle,GO:0051898~negative regulation of protein kinase B signaling,GO:0070262~peptidyl-serine dephosphorylation,GO:0071902~positive regulation of protein serine/threonine kinase activity,GO:1900227~positive regulation of NLRP3 inflammasome complex assembly,GO:1904526~regulation of microtubule binding,GO:1904528~positive regulation of microtubule binding,GO:1904539~negative regulation of glycolytic process through fructose-6-phosphate,GO:2000045~regulation of G1/S transition of mitotic cell cycle,	GO:0000159~protein phosphatase type 2A complex,GO:0000775~chromosome, centromeric region,GO:0000922~spindle pole,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0015630~microtubule cytoskeleton,GO:0016020~membrane,GO:0045121~membrane raft,GO:0045202~synapse,GO:0070062~extracellular exosome,	GO:0004721~phosphoprotein phosphatase activity,GO:0004722~protein serine/threonine phosphatase activity,GO:0004725~protein tyrosine phosphatase activity,GO:0005515~protein binding,GO:0017018~myosin phosphatase activity,GO:0046872~metal ion binding,GO:0046982~protein heterodimerization activity,GO:0048156~tau protein binding,GO:0050811~GABA receptor binding,	IPR004843:Calcineurin-like_PHP_ApaH,IPR006186:Ser/Thr-sp_prot-phosphatase,IPR029052:Metallo-depent_PP-like,IPR047129:PPA2-like,	hsa03015:mRNA surveillance pathway,hsa04071:Sphingolipid signaling pathway,hsa04110:Cell cycle,hsa04114:Oocyte meiosis,hsa04136:Autophagy - other,hsa04140:Autophagy - animal,hsa04151:PI3K-Akt signaling pathway,hsa04152:AMPK signaling pathway,hsa04261:Adrenergic signaling in cardiomyocytes,hsa04350:TGF-beta signaling pathway,hsa04390:Hippo signaling pathway,hsa04530:Tight junction,hsa04660:T cell receptor signaling pathway,hsa04728:Dopaminergic synapse,hsa04730:Long-term depression,hsa05142:Chagas disease,hsa05160:Hepatitis C,hsa05165:Human papillomavirus infection,	618354~Houge-Janssens syndrome 3,		SM00156:PP2Ac,	KW-0469~Meiosis,	KW-0137~Centromere,KW-0158~Chromosome,KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0991~Intellectual disability,		KW-0464~Manganese,KW-0479~Metal-binding,	KW-0378~Hydrolase,KW-0904~Protein phosphatase,	KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	ACT_SITE:Proton donor,DOMAIN:Serine/threonine specific protein phosphatases,MUTAGEN:D->N: Loss of phosphatase activity.,MUTAGEN:L->A: Loss of binding to PP2A B-alpha regulatory subunit.,
PPP2R3C	protein phosphatase 2 regulatory subunit B''gamma(PPP2R3C)	Homo sapiens			GO:0000226~microtubule cytoskeleton organization,GO:0001782~B cell homeostasis,GO:0002759~regulation of antimicrobial humoral response,GO:0030865~cortical cytoskeleton organization,GO:0035303~regulation of dephosphorylation,GO:0043029~T cell homeostasis,GO:0045579~positive regulation of B cell differentiation,GO:0048536~spleen development,GO:0051900~regulation of mitochondrial depolarization,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005794~Golgi apparatus,GO:0005813~centrosome,GO:0005829~cytosol,	GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR011992:EF-hand-dom_pair,IPR018247:EF_Hand_1_Ca_BS,IPR039865:PPP2R3C,IPR041534:EF-hand_13,	hsa03015:mRNA surveillance pathway,hsa04071:Sphingolipid signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04152:AMPK signaling pathway,hsa04261:Adrenergic signaling in cardiomyocytes,hsa04660:T cell receptor signaling pathway,hsa04728:Dopaminergic synapse,hsa05165:Human papillomavirus infection,	618419~Myoectodermal gonadal dysgenesis syndrome,618420~Spermatogenic failure 36,				KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0182~Cone-rod dystrophy,KW-0209~Deafness,KW-0225~Disease variant,	KW-0677~Repeat,	KW-0106~Calcium,KW-0479~Metal-binding,			DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,DOMAIN:PP2A regulatory subunit B'' EF-hand,
PPP2R5E	protein phosphatase 2 regulatory subunit B'epsilon(PPP2R5E)	Homo sapiens			GO:0006470~protein dephosphorylation,GO:0007165~signal transduction,	GO:0000159~protein phosphatase type 2A complex,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0005515~protein binding,GO:0019888~protein phosphatase regulator activity,GO:0072542~protein phosphatase activator activity,	IPR002554:PP2A_B56,IPR011989:ARM-like,IPR016024:ARM-type_fold,	hsa03015:mRNA surveillance pathway,hsa04071:Sphingolipid signaling pathway,hsa04110:Cell cycle,hsa04114:Oocyte meiosis,hsa04151:PI3K-Akt signaling pathway,hsa04152:AMPK signaling pathway,hsa04261:Adrenergic signaling in cardiomyocytes,hsa04660:T cell receptor signaling pathway,hsa04728:Dopaminergic synapse,hsa05165:Human papillomavirus infection,		PIRSF028043:PP2A_B56,			KW-0963~Cytoplasm,					KW-0007~Acetylation,KW-0597~Phosphoprotein,	REGION:Disordered,
PPP2R2A	protein phosphatase 2 regulatory subunit Balpha(PPP2R2A)	Homo sapiens			GO:0006470~protein dephosphorylation,GO:0043278~response to morphine,	GO:0000159~protein phosphatase type 2A complex,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0098978~glutamatergic synapse,	GO:0005515~protein binding,GO:0019888~protein phosphatase regulator activity,	IPR000009:PP2A_PR55,IPR001680:WD40_rpt,IPR015943:WD40/YVTN_repeat-like_dom_sf,IPR018067:PP2A_PR55_CS,IPR036322:WD40_repeat_dom_sf,	hsa03015:mRNA surveillance pathway,hsa04071:Sphingolipid signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04152:AMPK signaling pathway,hsa04261:Adrenergic signaling in cardiomyocytes,hsa04390:Hippo signaling pathway,hsa04530:Tight junction,hsa04660:T cell receptor signaling pathway,hsa04728:Dopaminergic synapse,hsa05142:Chagas disease,hsa05160:Hepatitis C,hsa05165:Human papillomavirus infection,		PIRSF037309:PP2A_PR55,	SM00320:WD40,				KW-0677~Repeat,KW-0853~WD repeat,			KW-0007~Acetylation,	REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,REPEAT:WD 7,
PPP2R1A	protein phosphatase 2 scaffold subunit Aalpha(PPP2R1A)	Homo sapiens			GO:0006275~regulation of DNA replication,GO:0006355~regulation of transcription, DNA-templated,GO:0006470~protein dephosphorylation,GO:0006672~ceramide metabolic process,GO:0006915~apoptotic process,GO:0007059~chromosome segregation,GO:0007143~female meiotic division,GO:0008380~RNA splicing,GO:0010033~response to organic substance,GO:0019932~second-messenger-mediated signaling,GO:0030111~regulation of Wnt signaling pathway,GO:0030155~regulation of cell adhesion,GO:0030308~negative regulation of cell growth,GO:0040008~regulation of growth,GO:0042532~negative regulation of tyrosine phosphorylation of STAT protein,GO:0043029~T cell homeostasis,GO:0043409~negative regulation of MAPK cascade,GO:0045595~regulation of cell differentiation,GO:0051232~meiotic spindle elongation,GO:0051306~mitotic sister chromatid separation,GO:0051754~meiotic sister chromatid cohesion, centromeric,GO:0051898~negative regulation of protein kinase B signaling,GO:0065003~macromolecular complex assembly,GO:1903538~regulation of meiotic cell cycle process involved in oocyte maturation,GO:2001241~positive regulation of extrinsic apoptotic signaling pathway in absence of ligand,	GO:0000159~protein phosphatase type 2A complex,GO:0000775~chromosome, centromeric region,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0015630~microtubule cytoskeleton,GO:0016020~membrane,GO:0016328~lateral plasma membrane,GO:0030425~dendrite,GO:0043005~neuron projection,GO:0043025~neuronal cell body,GO:0070062~extracellular exosome,GO:0098978~glutamatergic synapse,	GO:0004722~protein serine/threonine phosphatase activity,GO:0005515~protein binding,GO:0019888~protein phosphatase regulator activity,GO:0046982~protein heterodimerization activity,GO:1990405~protein antigen binding,	IPR000357:HEAT,IPR011989:ARM-like,IPR016024:ARM-type_fold,IPR021133:HEAT_type_2,	hsa03015:mRNA surveillance pathway,hsa04071:Sphingolipid signaling pathway,hsa04110:Cell cycle,hsa04114:Oocyte meiosis,hsa04151:PI3K-Akt signaling pathway,hsa04152:AMPK signaling pathway,hsa04261:Adrenergic signaling in cardiomyocytes,hsa04350:TGF-beta signaling pathway,hsa04390:Hippo signaling pathway,hsa04530:Tight junction,hsa04660:T cell receptor signaling pathway,hsa04728:Dopaminergic synapse,hsa04730:Long-term depression,hsa05142:Chagas disease,hsa05160:Hepatitis C,hsa05165:Human papillomavirus infection,	616362~Houge-Janssens syndrome 2,			KW-0159~Chromosome partition,KW-0945~Host-virus interaction,	KW-0137~Centromere,KW-0158~Chromosome,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0991~Intellectual disability,	KW-0677~Repeat,			KW-0007~Acetylation,	COMPBIAS:Polar residues,REGION:Disordered,REGION:PP2A subunit B binding,REGION:PP2A subunit C binding,REGION:Polyoma small and medium T antigens Binding,REGION:SV40 small T antigen binding,REPEAT:HEAT,REPEAT:HEAT 1,REPEAT:HEAT 10,REPEAT:HEAT 11,REPEAT:HEAT 12,REPEAT:HEAT 13,REPEAT:HEAT 14,REPEAT:HEAT 15,REPEAT:HEAT 2,REPEAT:HEAT 3,REPEAT:HEAT 4,REPEAT:HEAT 5,REPEAT:HEAT 6,REPEAT:HEAT 7,REPEAT:HEAT 8,REPEAT:HEAT 9,
PPP3CC	protein phosphatase 3 catalytic subunit gamma(PPP3CC)	Homo sapiens		h_bcrPathway:BCR Signaling Pathway,h_calcineurinPathway:Effects of calcineurin in Keratinocyte Differentiation,h_fcer1Pathway:Fc Epsilon Receptor I Signaling in Mast Cells,h_fmlpPathway:fMLP induced chemokine gene expression in HMC-1 cells,h_gpcrPathway:Signaling Pathway from G-Protein Families,h_hdacPathway:Control of skeletal myogenesis by HDAC & calcium/calmodulin-dependent kinase (CaMK),h_mef2dPathway:Role of MEF2D in T-cell Apoptosis,h_ndkDynaminPathway:Endocytotic role of NDK, Phosphins and Dynamin,h_nfatPathway:NFAT and Hypertrophy of the heart (Transcription in the broken heart),h_nos1Pathway:Nitric Oxide Signaling Pathway,h_pgc1aPathway:Regulation of PGC-1a,h_tcrPathway:T Cell Receptor Signaling Pathway,h_vipPathway:Neuropeptides VIP and PACAP inhibit the apoptosis of activated T cells,	GO:0006470~protein dephosphorylation,GO:0033173~calcineurin-NFAT signaling cascade,GO:0070886~positive regulation of calcineurin-NFAT signaling cascade,GO:0097720~calcineurin-mediated signaling,GO:1900244~positive regulation of synaptic vesicle endocytosis,GO:1905665~positive regulation of calcium ion import across plasma membrane,GO:1905949~negative regulation of calcium ion import across plasma membrane,	GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0005955~calcineurin complex,GO:0008287~protein serine/threonine phosphatase complex,GO:0098793~presynapse,GO:0098978~glutamatergic synapse,	GO:0004723~calcium-dependent protein serine/threonine phosphatase activity,GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0017018~myosin phosphatase activity,GO:0033192~calmodulin-dependent protein phosphatase activity,GO:0046872~metal ion binding,	IPR004843:Calcineurin-like_PHP_ApaH,IPR006186:Ser/Thr-sp_prot-phosphatase,IPR029052:Metallo-depent_PP-like,IPR041751:MPP_PP2B,IPR043360:PP2B,	hsa04010:MAPK signaling pathway,hsa04020:Calcium signaling pathway,hsa04022:cGMP-PKG signaling pathway,hsa04114:Oocyte meiosis,hsa04218:Cellular senescence,hsa04310:Wnt signaling pathway,hsa04360:Axon guidance,hsa04370:VEGF signaling pathway,hsa04380:Osteoclast differentiation,hsa04625:C-type lectin receptor signaling pathway,hsa04650:Natural killer cell mediated cytotoxicity,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04660:T cell receptor signaling pathway,hsa04662:B cell receptor signaling pathway,hsa04720:Long-term potentiation,hsa04724:Glutamatergic synapse,hsa04728:Dopaminergic synapse,hsa04921:Oxytocin signaling pathway,hsa04922:Glucagon signaling pathway,hsa04924:Renin secretion,hsa05010:Alzheimer disease,hsa05014:Amyotrophic lateral sclerosis,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05031:Amphetamine addiction,hsa05152:Tuberculosis,hsa05163:Human cytomegalovirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,hsa05417:Lipid and atherosclerosis,			SM00156:PP2Ac,		KW-0496~Mitochondrion,			KW-0408~Iron,KW-0479~Metal-binding,KW-0862~Zinc,	KW-0112~Calmodulin-binding,KW-0378~Hydrolase,KW-0904~Protein phosphatase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton donor,DOMAIN:Calcineurin-like phosphoesterase,DOMAIN:Serine/threonine specific protein phosphatases,MOTIF:SAPNY motif,REGION:Autoinhibitory domain,REGION:Autoinhibitory segment,REGION:Calcineurin B binding,REGION:Calmodulin-binding,REGION:Catalytic,REGION:Disordered,
PPP4C	protein phosphatase 4 catalytic subunit(PPP4C)	Homo sapiens			GO:0000724~double-strand break repair via homologous recombination,GO:0010569~regulation of double-strand break repair via homologous recombination,GO:2000779~regulation of double-strand break repair,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0030289~protein phosphatase 4 complex,	GO:0004704~NF-kappaB-inducing kinase activity,GO:0004722~protein serine/threonine phosphatase activity,GO:0005515~protein binding,GO:0017018~myosin phosphatase activity,GO:0046872~metal ion binding,	IPR004843:Calcineurin-like_PHP_ApaH,IPR006186:Ser/Thr-sp_prot-phosphatase,IPR029052:Metallo-depent_PP-like,IPR047129:PPA2-like,	hsa04922:Glucagon signaling pathway,			SM00156:PP2Ac,		KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0464~Manganese,KW-0479~Metal-binding,	KW-0378~Hydrolase,KW-0904~Protein phosphatase,	KW-0007~Acetylation,KW-0488~Methylation,	ACT_SITE:Proton donor,DOMAIN:Serine/threonine specific protein phosphatases,MUTAGEN:D->A: Loss of activity.,MUTAGEN:E->K: Abolishes interaction with PPP4R4.,MUTAGEN:E->K: Abolishes interaction with PPP4R4; no effect on interaction with PPP4R1 and PPP4R2.,MUTAGEN:E->K: Diminishes interaction with PPP4R4.,MUTAGEN:L->A: Unable to dephosphorylate 53BP1 and KAR1, loss of DSB repair activity.,MUTAGEN:N->D: Diminishes interaction with PPP4R4.,MUTAGEN:R->E: Diminishes interaction with PPP4R4.,
PPP4R2	protein phosphatase 4 regulatory subunit 2(PPP4R2)	Homo sapiens			GO:0006397~mRNA processing,GO:0008380~RNA splicing,GO:0010569~regulation of double-strand break repair via homologous recombination,GO:0036211~protein modification process,GO:2000779~regulation of double-strand break repair,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0030289~protein phosphatase 4 complex,	GO:0005515~protein binding,GO:0019888~protein phosphatase regulator activity,GO:0030674~protein binding, bridging,	IPR015267:PPP4R2,					KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,					KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,MUTAGEN:E->A: No effect on RPA2-binding, nor on PPP4C-binding.,MUTAGEN:F->A: No effect on RPA2-binding; decrease in PPP4C-binding.,MUTAGEN:R->A: No effect on RPA2-binding; loss of PPP4C-binding.,REGION:Disordered,
PPP4R3A	protein phosphatase 4 regulatory subunit 3A(PPP4R3A)	Homo sapiens			GO:0006470~protein dephosphorylation,GO:0006974~cellular response to DNA damage stimulus,	GO:0005654~nucleoplasm,GO:0005813~centrosome,GO:0005829~cytosol,GO:0016607~nuclear speck,GO:0030289~protein phosphatase 4 complex,	GO:0072542~protein phosphatase activator activity,	IPR000697:WH1/EVH1_dom,IPR006887:P4R3-like_central_dom,IPR011989:ARM-like,IPR011993:PH-like_dom_sf,IPR016024:ARM-type_fold,	hsa04922:Glucagon signaling pathway,					KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,					KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Serine/threonine-protein phosphatase 4 regulatory subunit 3-like central,DOMAIN:WH1,REGION:Disordered,
PPP4R3B	protein phosphatase 4 regulatory subunit 3B(PPP4R3B)	Homo sapiens			GO:0006094~gluconeogenesis,GO:0006470~protein dephosphorylation,GO:0006974~cellular response to DNA damage stimulus,GO:0045722~positive regulation of gluconeogenesis,GO:2000779~regulation of double-strand break repair,	GO:0000785~chromatin,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0016607~nuclear speck,GO:0030289~protein phosphatase 4 complex,	GO:0072542~protein phosphatase activator activity,	IPR000697:WH1/EVH1_dom,IPR006887:P4R3-like_central_dom,IPR011993:PH-like_dom_sf,IPR016024:ARM-type_fold,	hsa04922:Glucagon signaling pathway,					KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,					KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:WH1,REGION:Disordered,
PPP6C	protein phosphatase 6 catalytic subunit(PPP6C)	Homo sapiens			GO:0000082~G1/S transition of mitotic cell cycle,GO:0006470~protein dephosphorylation,GO:0045087~innate immune response,GO:0048208~COPII vesicle coating,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,	GO:0004722~protein serine/threonine phosphatase activity,GO:0005515~protein binding,GO:0017018~myosin phosphatase activity,GO:0046872~metal ion binding,	IPR004843:Calcineurin-like_PHP_ApaH,IPR006186:Ser/Thr-sp_prot-phosphatase,IPR029052:Metallo-depent_PP-like,IPR047129:PPA2-like,				SM00156:PP2Ac,	KW-0131~Cell cycle,KW-0391~Immunity,KW-0399~Innate immunity,	KW-0496~Mitochondrion,KW-0963~Cytoplasm,			KW-0464~Manganese,KW-0479~Metal-binding,	KW-0378~Hydrolase,KW-0904~Protein phosphatase,	KW-0007~Acetylation,	ACT_SITE:Proton donor,DOMAIN:Serine/threonine specific protein phosphatases,
PPP6R3	protein phosphatase 6 regulatory subunit 3(PPP6R3)	Homo sapiens			GO:0006516~glycoprotein catabolic process,GO:0043666~regulation of phosphoprotein phosphatase activity,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,	GO:0005515~protein binding,GO:0019888~protein phosphatase regulator activity,GO:0019903~protein phosphatase binding,	IPR006588:Peptide_N_glycanase_PAW_dom,IPR007587:SAPS,IPR016024:ARM-type_fold,						KW-0539~Nucleus,KW-0963~Cytoplasm,					KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:PAW,REGION:Disordered,
PPM1G	protein phosphatase, Mg2+/Mn2+ dependent 1G(PPM1G)	Homo sapiens			GO:0006470~protein dephosphorylation,GO:0035970~peptidyl-threonine dephosphorylation,GO:0051726~regulation of cell cycle,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0016020~membrane,	GO:0004722~protein serine/threonine phosphatase activity,GO:0005515~protein binding,GO:0017018~myosin phosphatase activity,GO:0046872~metal ion binding,	IPR000222:PP2C_BS,IPR001932:PPM-type_phosphatase-like_dom,IPR015655:PP2C,IPR036457:PPM-type-like_dom_sf,				SM00332:PP2Cc,		KW-0472~Membrane,KW-0963~Cytoplasm,		KW-0677~Repeat,	KW-0460~Magnesium,KW-0464~Manganese,KW-0479~Metal-binding,	KW-0378~Hydrolase,KW-0904~Protein phosphatase,	KW-0007~Acetylation,KW-0449~Lipoprotein,KW-0488~Methylation,KW-0519~Myristate,KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:PPM-type phosphatase,LIPID:N-myristoyl glycine,REGION:Disordered,
PPM1K	protein phosphatase, Mg2+/Mn2+ dependent 1K(PPM1K)	Homo sapiens			GO:0009083~branched-chain amino acid catabolic process,GO:0035970~peptidyl-threonine dephosphorylation,GO:1902108~regulation of mitochondrial membrane permeability involved in apoptotic process,	GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,	GO:0004721~phosphoprotein phosphatase activity,GO:0004722~protein serine/threonine phosphatase activity,GO:0005515~protein binding,GO:0017018~myosin phosphatase activity,GO:0030145~manganese ion binding,GO:0043169~cation binding,GO:0046872~metal ion binding,	IPR000222:PP2C_BS,IPR001932:PPM-type_phosphatase-like_dom,IPR015655:PP2C,IPR036457:PPM-type-like_dom_sf,		615135~Maple syrup urine disease, mild variant,		SM00331:PP2C_SIG,SM00332:PP2Cc,		KW-0496~Mitochondrion,		KW-0809~Transit peptide,	KW-0460~Magnesium,KW-0464~Manganese,KW-0479~Metal-binding,	KW-0378~Hydrolase,KW-0904~Protein phosphatase,	KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:PPM-type phosphatase,MUTAGEN:D->A: Loss of serine/threonine phosphatase activity toward BCKDHA.,MUTAGEN:D->A: Loss of serine/threonine phosphatase activity toward BCKDHA. Does not affect the interaction with DBT.,MUTAGEN:H->A: Slightly decreases the catalytic efficiency toward BCKDHA. Does not affect the interaction with DBT.,MUTAGEN:R->A: Decreases the affinity toward BCKDHA by 61-fold. Decreases the catalytic efficiency toward BCKDHA down to 2%.,MUTAGEN:R->G: Complete loss of serine/threonine phosphatase activity toward BCKDHA. Does not affect the interaction with DBT.,REGION:Critical for association with the BCKDH complex,REGION:Disordered,TRANSIT:Mitochondrion,
PTP4A2	protein tyrosine phosphatase 4A2(PTP4A2)	Homo sapiens			GO:0016311~dephosphorylation,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005769~early endosome,GO:0005829~cytosol,GO:0005886~plasma membrane,	GO:0004725~protein tyrosine phosphatase activity,GO:0004727~prenylated protein tyrosine phosphatase activity,GO:0005515~protein binding,GO:0008138~protein tyrosine/serine/threonine phosphatase activity,	IPR000242:PTP_cat,IPR000387:Tyr_Pase_dom,IPR003595:Tyr_Pase_cat,IPR020422:TYR_PHOSPHATASE_DUAL_dom,IPR029021:Prot-tyrosine_phosphatase-like,				SM00404:PTPc_motif,		KW-0472~Membrane,KW-0963~Cytoplasm,KW-0967~Endosome,KW-1003~Cell membrane,				KW-0378~Hydrolase,KW-0904~Protein phosphatase,	KW-0449~Lipoprotein,KW-0488~Methylation,KW-0636~Prenylation,KW-1015~Disulfide bond,	ACT_SITE:Phosphocysteine intermediate,ACT_SITE:Proton donor,DOMAIN:Tyrosine-protein phosphatase,LIPID:S-farnesyl cysteine,MUTAGEN:C->S: No effect on interaction with RABGGTB.,MUTAGEN:Missing: Locates in the nucleus and cytosol. No interaction with RABGGTB.,PROPEP:Removed in mature form,
PTPN1	protein tyrosine phosphatase non-receptor type 1(PTPN1)	Homo sapiens			GO:0006470~protein dephosphorylation,GO:0008286~insulin receptor signaling pathway,GO:0009966~regulation of signal transduction,GO:0009968~negative regulation of signal transduction,GO:0016311~dephosphorylation,GO:0030036~actin cytoskeleton organization,GO:0030100~regulation of endocytosis,GO:0030948~negative regulation of vascular endothelial growth factor receptor signaling pathway,GO:0030968~endoplasmic reticulum unfolded protein response,GO:0033157~regulation of intracellular protein transport,GO:0034620~cellular response to unfolded protein,GO:0035335~peptidyl-tyrosine dephosphorylation,GO:0035791~platelet-derived growth factor receptor-beta signaling pathway,GO:0036498~IRE1-mediated unfolded protein response,GO:0038020~insulin receptor recycling,GO:0043407~negative regulation of MAP kinase activity,GO:0043507~positive regulation of JUN kinase activity,GO:0046627~negative regulation of insulin receptor signaling pathway,GO:0060338~regulation of type I interferon-mediated signaling pathway,GO:0060397~JAK-STAT cascade involved in growth hormone signaling pathway,GO:0061098~positive regulation of protein tyrosine kinase activity,GO:0070373~negative regulation of ERK1 and ERK2 cascade,GO:1902202~regulation of hepatocyte growth factor receptor signaling pathway,GO:1902236~negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway,GO:1903896~positive regulation of IRE1-mediated unfolded protein response,GO:1903898~negative regulation of PERK-mediated unfolded protein response,GO:1990264~peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activity,GO:2000646~positive regulation of receptor catabolic process,	GO:0005737~cytoplasm,GO:0005759~mitochondrial matrix,GO:0005769~early endosome,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0030061~mitochondrial crista,GO:0031904~endosome lumen,GO:0032991~macromolecular complex,GO:0097443~sorting endosome,GO:0098554~cytoplasmic side of endoplasmic reticulum membrane,	GO:0003723~RNA binding,GO:0004725~protein tyrosine phosphatase activity,GO:0004726~non-membrane spanning protein tyrosine phosphatase activity,GO:0005158~insulin receptor binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0019899~enzyme binding,GO:0019901~protein kinase binding,GO:0030971~receptor tyrosine kinase binding,GO:0045296~cadherin binding,GO:0046875~ephrin receptor binding,GO:0051721~protein phosphatase 2A binding,	IPR000242:PTP_cat,IPR000387:Tyr_Pase_dom,IPR003595:Tyr_Pase_cat,IPR012265:Ptpn1/Ptpn2,IPR016130:Tyr_Pase_AS,IPR029021:Prot-tyrosine_phosphatase-like,	hsa04520:Adherens junction,hsa04910:Insulin signaling pathway,hsa04931:Insulin resistance,hsa05208:Chemical carcinogenesis - reactive oxygen species,	125853~Insulin resistance, susceptibility to,	PIRSF000926:Tyr-Ptase_nr1,	SM00194:PTPc,SM00404:PTPc_motif,		KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0378~Hydrolase,KW-0675~Receptor,KW-0904~Protein phosphatase,	KW-0007~Acetylation,KW-0558~Oxidation,KW-0597~Phosphoprotein,KW-0702~S-nitrosylation,	ACT_SITE:Phosphocysteine intermediate,CROSSLNK:N,N-(cysteine-1,S-diyl)serine (Cys-Ser); in inhibited form,DOMAIN:Tyrosine specific protein phosphatases,DOMAIN:Tyrosine-protein phosphatase,MUTAGEN:C->S: Catalytically inactive mutant; abolishes sulfhydration.,MUTAGEN:D->A: Substrate-trapping mutant.,MUTAGEN:S->A,D: No phosphorylation.,REGION:Disordered,TRANSMEM:Helical,
PTPN2	protein tyrosine phosphatase non-receptor type 2(PTPN2)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0008285~negative regulation of cell proliferation,GO:0008286~insulin receptor signaling pathway,GO:0010804~negative regulation of tumor necrosis factor-mediated signaling pathway,GO:0010888~negative regulation of lipid storage,GO:0016311~dephosphorylation,GO:0030183~B cell differentiation,GO:0030217~T cell differentiation,GO:0030218~erythrocyte differentiation,GO:0035335~peptidyl-tyrosine dephosphorylation,GO:0038020~insulin receptor recycling,GO:0042059~negative regulation of epidermal growth factor receptor signaling pathway,GO:0042532~negative regulation of tyrosine phosphorylation of STAT protein,GO:0042593~glucose homeostasis,GO:0045650~negative regulation of macrophage differentiation,GO:0045722~positive regulation of gluconeogenesis,GO:0046426~negative regulation of JAK-STAT cascade,GO:0046627~negative regulation of insulin receptor signaling pathway,GO:0050728~negative regulation of inflammatory response,GO:0050860~negative regulation of T cell receptor signaling pathway,GO:0050922~negative regulation of chemotaxis,GO:0060334~regulation of interferon-gamma-mediated signaling pathway,GO:0060336~negative regulation of interferon-gamma-mediated signaling pathway,GO:0060339~negative regulation of type I interferon-mediated signaling pathway,GO:0070104~negative regulation of interleukin-6-mediated signaling pathway,GO:0070373~negative regulation of ERK1 and ERK2 cascade,GO:1902202~regulation of hepatocyte growth factor receptor signaling pathway,GO:1902206~negative regulation of interleukin-2-mediated signaling pathway,GO:1902215~negative regulation of interleukin-4-mediated signaling pathway,GO:1902227~negative regulation of macrophage colony-stimulating factor signaling pathway,GO:1902233~negative regulation of positive thymic T cell selection,GO:1902237~positive regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway,GO:1903899~positive regulation of PERK-mediated unfolded protein response,GO:2000587~negative regulation of platelet-derived growth factor receptor-beta signaling pathway,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005793~endoplasmic reticulum-Golgi intermediate compartment,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0031904~endosome lumen,	GO:0004725~protein tyrosine phosphatase activity,GO:0004726~non-membrane spanning protein tyrosine phosphatase activity,GO:0005178~integrin binding,GO:0005515~protein binding,GO:0019901~protein kinase binding,GO:0019905~syntaxin binding,GO:0030971~receptor tyrosine kinase binding,GO:0097677~STAT family protein binding,	IPR000242:PTP_cat,IPR000387:Tyr_Pase_dom,IPR003595:Tyr_Pase_cat,IPR012265:Ptpn1/Ptpn2,IPR016130:Tyr_Pase_AS,IPR029021:Prot-tyrosine_phosphatase-like,	hsa04630:JAK-STAT signaling pathway,		PIRSF000926:Tyr-Ptase_nr1,	SM00194:PTPc,SM00404:PTPc_motif,		KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0378~Hydrolase,KW-0675~Receptor,KW-0904~Protein phosphatase,	KW-0597~Phosphoprotein,KW-0702~S-nitrosylation,	ACT_SITE:Phosphocysteine intermediate,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,DOMAIN:Tyrosine specific protein phosphatases,DOMAIN:Tyrosine-protein phosphatase,MUTAGEN:D->A: Substrate-trapping mutant; catalytically inactive it forms a stable complex with physiological substrates including INSR and EGFR. Accumulates in the cytoplasm upon stimulation by insulin or EGF; isoform 2.,MUTAGEN:K->Q: Prevents location to the nucleus; isoform 2.,MUTAGEN:R->M: Impairs phosphatase activity.,MUTAGEN:RKR->QQQ: Alters location to the endoplasmic reticulum; isoform 1.,MUTAGEN:S->A: Alters phosphorylation by cyclin-dependent kinases of isoform 2 but has no effect on its phosphatase activity.,REGION:Disordered,REGION:Endoplasmic reticulum location,REGION:Mediates interaction with STX17,TRANSMEM:Helical,
PTPN22	protein tyrosine phosphatase non-receptor type 22(PTPN22)	Homo sapiens			GO:0002230~positive regulation of defense response to virus by host,GO:0002685~regulation of leukocyte migration,GO:0006470~protein dephosphorylation,GO:0006629~lipid metabolic process,GO:0006914~autophagy,GO:0010507~negative regulation of autophagy,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0016311~dephosphorylation,GO:0030217~T cell differentiation,GO:0031663~lipopolysaccharide-mediated signaling pathway,GO:0032481~positive regulation of type I interferon production,GO:0032496~response to lipopolysaccharide,GO:0032715~negative regulation of interleukin-6 production,GO:0032717~negative regulation of interleukin-8 production,GO:0032720~negative regulation of tumor necrosis factor production,GO:0032727~positive regulation of interferon-alpha production,GO:0032728~positive regulation of interferon-beta production,GO:0032729~positive regulation of interferon-gamma production,GO:0032817~regulation of natural killer cell proliferation,GO:0034141~positive regulation of toll-like receptor 3 signaling pathway,GO:0034145~positive regulation of toll-like receptor 4 signaling pathway,GO:0034157~positive regulation of toll-like receptor 7 signaling pathway,GO:0034165~positive regulation of toll-like receptor 9 signaling pathway,GO:0035644~phosphoanandamide dephosphorylation,GO:0042307~positive regulation of protein import into nucleus,GO:0043508~negative regulation of JUN kinase activity,GO:0045088~regulation of innate immune response,GO:0050730~regulation of peptidyl-tyrosine phosphorylation,GO:0050852~T cell receptor signaling pathway,GO:0050855~regulation of B cell receptor signaling pathway,GO:0050856~regulation of T cell receptor signaling pathway,GO:0050860~negative regulation of T cell receptor signaling pathway,GO:0050868~negative regulation of T cell activation,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0070433~negative regulation of nucleotide-binding oligomerization domain containing 2 signaling pathway,GO:0071225~cellular response to muramyl dipeptide,GO:0071663~positive regulation of granzyme B production,GO:1900227~positive regulation of NLRP3 inflammasome complex assembly,GO:1901222~regulation of NIK/NF-kappaB signaling,GO:1902523~positive regulation of protein K63-linked ubiquitination,GO:1903169~regulation of calcium ion transmembrane transport,GO:1903753~negative regulation of p38MAPK cascade,GO:2000566~positive regulation of CD8-positive, alpha-beta T cell proliferation,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0009898~cytoplasmic side of plasma membrane,GO:0043229~intracellular organelle,GO:0048471~perinuclear region of cytoplasm,	GO:0004725~protein tyrosine phosphatase activity,GO:0004726~non-membrane spanning protein tyrosine phosphatase activity,GO:0005515~protein binding,GO:0016791~phosphatase activity,GO:0017124~SH3 domain binding,GO:0019900~kinase binding,GO:0031625~ubiquitin protein ligase binding,GO:1990782~protein tyrosine kinase binding,	IPR000242:PTP_cat,IPR000387:Tyr_Pase_dom,IPR003595:Tyr_Pase_cat,IPR016130:Tyr_Pase_AS,IPR016276:PTPN22,IPR029021:Prot-tyrosine_phosphatase-like,IPR047170:PTN12/18/22,IPR047253:PTN22_cat,		152700~Systemic lupus erythematosus susceptibility to,180300~Rheumatoid arthritis, susceptibility to,222100~Diabetes, type 1, susceptibility to,	PIRSF000930:PTPN8_PTPN22,	SM00194:PTPc,SM00404:PTPc_motif,	KW-0072~Autophagy,KW-0391~Immunity,KW-0443~Lipid metabolism,	KW-0963~Cytoplasm,	KW-0219~Diabetes mellitus,KW-0225~Disease variant,KW-0772~Systemic lupus erythematosus,			KW-0378~Hydrolase,KW-0675~Receptor,KW-0904~Protein phosphatase,	KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	ACT_SITE:Phosphocysteine intermediate,DOMAIN:Tyrosine specific protein phosphatases,DOMAIN:Tyrosine-protein phosphatase,MUTAGEN:C->S: Decreases activity 2 fold.,MUTAGEN:C->S: Decreases activity 7 fold.,MUTAGEN:S->E: Loss of phosphorylation by PKC/PRKCD.,MUTAGEN:T->E: No effect on phosphorylation by PKC/PRKCD.,REGION:Disordered,
PTPN4	protein tyrosine phosphatase non-receptor type 4(PTPN4)	Homo sapiens			GO:0006470~protein dephosphorylation,GO:0016311~dephosphorylation,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0009898~cytoplasmic side of plasma membrane,	GO:0004725~protein tyrosine phosphatase activity,GO:0004726~non-membrane spanning protein tyrosine phosphatase activity,GO:0005515~protein binding,GO:0008092~cytoskeletal protein binding,GO:0016787~hydrolase activity,GO:0035254~glutamate receptor binding,	IPR000242:PTP_cat,IPR000299:FERM_domain,IPR000387:Tyr_Pase_dom,IPR000798:Ez/rad/moesin-like,IPR001478:PDZ,IPR003595:Tyr_Pase_cat,IPR011993:PH-like_dom_sf,IPR012151:Tyr_Pase_non-rcpt_typ-3/4,IPR014352:FERM/acyl-CoA-bd_prot_sf,IPR014847:FA,IPR016130:Tyr_Pase_AS,IPR018979:FERM_N,IPR018980:FERM_PH-like_C,IPR019747:FERM_CS,IPR019748:FERM_central,IPR019749:Band_41_domain,IPR029021:Prot-tyrosine_phosphatase-like,IPR029071:Ubiquitin-like_domsf,IPR035963:FERM_2,IPR036034:PDZ_sf,IPR041783:PTPN3/4_FERM_C,			PIRSF000927:Tyr-Ptase_nr3,	SM00194:PTPc,SM00228:PDZ,SM00295:B41,SM00404:PTPc_motif,SM01195:FA,SM01196:FERM_C,		KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,				KW-0378~Hydrolase,KW-0904~Protein phosphatase,	KW-0597~Phosphoprotein,	ACT_SITE:Phosphocysteine intermediate,COMPBIAS:Polar residues,DOMAIN:FERM,DOMAIN:PDZ,DOMAIN:Tyrosine specific protein phosphatases,DOMAIN:Tyrosine-protein phosphatase,REGION:Disordered,
PTPN7	protein tyrosine phosphatase non-receptor type 7(PTPN7)	Homo sapiens		h_tcrPathway:T Cell Receptor Signaling Pathway,	GO:0000165~MAPK cascade,GO:0006470~protein dephosphorylation,GO:0016311~dephosphorylation,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0009898~cytoplasmic side of plasma membrane,GO:0015630~microtubule cytoskeleton,GO:0072686~mitotic spindle,	GO:0004725~protein tyrosine phosphatase activity,GO:0004726~non-membrane spanning protein tyrosine phosphatase activity,GO:0005515~protein binding,	IPR000242:PTP_cat,IPR000387:Tyr_Pase_dom,IPR003595:Tyr_Pase_cat,IPR008356:Tyr_Pase_KIM-con,IPR016130:Tyr_Pase_AS,IPR029021:Prot-tyrosine_phosphatase-like,	hsa04010:MAPK signaling pathway,			SM00194:PTPc,SM00404:PTPc_motif,		KW-0206~Cytoskeleton,KW-0963~Cytoplasm,				KW-0378~Hydrolase,KW-0675~Receptor,KW-0904~Protein phosphatase,	KW-0558~Oxidation,KW-0597~Phosphoprotein,	ACT_SITE:Phosphocysteine intermediate,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Tyrosine specific protein phosphatases,DOMAIN:Tyrosine-protein phosphatase,MUTAGEN:C->S: Loss of catalytic activity.,MUTAGEN:D->A: Loss of catalytic activity.,MUTAGEN:Q->A: Reduced catalytic activity.,MUTAGEN:S->A: Prevents dissociation of bound MAP kinase and enhances their dephosphorylation.,MUTAGEN:S->A: Prevents dissociation of bound MAP kinase and enhances their dephosphorylation; when associated with A-66.,MUTAGEN:S->D: Reduces binding of MAP kinase.,MUTAGEN:T->A: Prevents dissociation of bound MAP kinase and enhances their dephosphorylation; when associated with A-93.,MUTAGEN:Y->A: Strongly reduced catalytic activity.,REGION:Disordered,REGION:Interaction with MAP kinases,
PTPRCAP	protein tyrosine phosphatase receptor type C associated protein(PTPRCAP)	Homo sapiens			GO:0006952~defense response,	GO:0005886~plasma membrane,	GO:0005515~protein binding,	IPR016553:PTPRCAP,			PIRSF009325:PTPRC-associated_protein,			KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,	REGION:Disordered,TRANSMEM:Helical,
PLP2	proteolipid protein 2(PLP2)	Homo sapiens			GO:0006811~ion transport,GO:0006935~chemotaxis,GO:0019221~cytokine-mediated signaling pathway,GO:0034220~ion transmembrane transport,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0016020~membrane,	GO:0005515~protein binding,GO:0015075~ion transmembrane transporter activity,GO:0019956~chemokine binding,	IPR008253:Marvel,						KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:MARVEL,TRANSMEM:Helical,
PTMA	prothymosin alpha(PTMA)	Homo sapiens	61.Myc_network,		GO:0006351~transcription, DNA-templated,GO:0043066~negative regulation of apoptotic process,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,	GO:0005515~protein binding,GO:0042393~histone binding,GO:0043167~ion binding,	IPR004931:Pro/parathymosin,						KW-0539~Nucleus,					KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,PEPTIDE:Thymosin alpha-1,REGION:Disordered,
PUM1	pumilio RNA binding family member 1(PUM1)	Homo sapiens			GO:0006417~regulation of translation,GO:0007283~spermatogenesis,GO:0008344~adult locomotory behavior,GO:0010608~posttranscriptional regulation of gene expression,GO:0016441~posttranscriptional gene silencing,GO:0035196~production of miRNAs involved in gene silencing by miRNA,GO:0043488~regulation of mRNA stability,GO:0048863~stem cell differentiation,GO:0051726~regulation of cell cycle,GO:0051983~regulation of chromosome segregation,GO:0060964~regulation of gene silencing by miRNA,GO:0061157~mRNA destabilization,GO:0061158~3'-UTR-mediated mRNA destabilization,GO:1900246~positive regulation of RIG-I signaling pathway,GO:2000637~positive regulation of gene silencing by miRNA,	GO:0000932~P-body,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0010494~cytoplasmic stress granule,GO:0030424~axon,	GO:0003723~RNA binding,GO:0003730~mRNA 3'-UTR binding,GO:0005515~protein binding,GO:0035198~miRNA binding,	IPR001313:Pumilio_RNA-bd_rpt,IPR011989:ARM-like,IPR016024:ARM-type_fold,IPR033133:PUM-HD,IPR033712:Pumilio_RNA-bd,	hsa05017:Spinocerebellar ataxia,	617931~Spinocerebellar ataxia 47,620719~Neurodevelopmental disorder with motor abnormalities, seizures, and facial dysmorphism,		SM00025:Pumilio,	KW-0221~Differentiation,KW-0744~Spermatogenesis,KW-0810~Translation regulation,	KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0950~Spinocerebellar ataxia,	KW-0677~Repeat,		KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:PUM-HD,MUTAGEN:C->N: Specifically binds uracil-nucleotide in RNA target.,MUTAGEN:CRVIQ->GRVIR,ARVIR,SRVIR,TRVIR,CRVIR: Specifically binds cytosine-nucleotide in RNA target.,MUTAGEN:CRVIQ->GRVIR: Specifically binds cytosine-nucleotide in RNA target.,MUTAGEN:CRVIQ->SRVIE: Specifically binds guanine-nucleotide in RNA target.,MUTAGEN:NHVVQ->GHVVR: Specifically binds cytosine-nucleotide in RNA target.,MUTAGEN:NY->SN: Changes the specificity for RNA; when associated with E-1047.,MUTAGEN:NYVIQ->GYVIR: Specifically binds cytosine-nucleotide in RNA target.,MUTAGEN:NYVVQ->GYVVR: Specifically binds cytosine-nucleotide in RNA target.,MUTAGEN:Q->E: Changes the specificity for RNA; when associated with 1043-SN-1044.,MUTAGEN:S->A: Decreased RNA-binding activity.,MUTAGEN:S->A: Does not affect RNA-binding activity.,MUTAGEN:S->E: Phospho-mimic mutant; persistent RNA-binding activity in quiescent cells.,MUTAGEN:SNVVE->GNVVR: Specifically binds cytosine-nucleotide in RNA target.,MUTAGEN:SRFIQ->GRFIR: B and inds cytosine-nucleotide in RNA target.,REGION:Adenine-nucleotide binding in RNA target,REGION:Disordered,REGION:Guanine-nucleotide binding in RNA target,REGION:Non-specific-nucleotide binding in RNA target,REGION:Uracil-nucleotide binding in RNA target,REPEAT:Pumilio,REPEAT:Pumilio 1,REPEAT:Pumilio 2,REPEAT:Pumilio 3,REPEAT:Pumilio 4,REPEAT:Pumilio 5,REPEAT:Pumilio 6,REPEAT:Pumilio 7,REPEAT:Pumilio 8,
PUM2	pumilio RNA binding family member 2(PUM2)	Homo sapiens			GO:0001501~skeletal system development,GO:0001942~hair follicle development,GO:0006417~regulation of translation,GO:0007005~mitochondrion organization,GO:0010608~posttranscriptional regulation of gene expression,GO:0022904~respiratory electron transport chain,GO:0034063~stress granule assembly,GO:0035196~production of miRNAs involved in gene silencing by miRNA,GO:0043488~regulation of mRNA stability,GO:0048687~positive regulation of sprouting of injured axon,GO:0051276~chromosome organization,GO:0051983~regulation of chromosome segregation,GO:0060612~adipose tissue development,GO:0060964~regulation of gene silencing by miRNA,GO:0061158~3'-UTR-mediated mRNA destabilization,GO:1900246~positive regulation of RIG-I signaling pathway,GO:1904580~regulation of intracellular mRNA localization,GO:2000637~positive regulation of gene silencing by miRNA,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0010494~cytoplasmic stress granule,GO:0031965~nuclear membrane,GO:0043025~neuronal cell body,GO:0048471~perinuclear region of cytoplasm,	GO:0003723~RNA binding,GO:0003730~mRNA 3'-UTR binding,GO:0005515~protein binding,GO:0035198~miRNA binding,	IPR001313:Pumilio_RNA-bd_rpt,IPR011989:ARM-like,IPR016024:ARM-type_fold,IPR033133:PUM-HD,IPR033712:Pumilio_RNA-bd,	hsa05017:Spinocerebellar ataxia,			SM00025:Pumilio,	KW-0810~Translation regulation,	KW-0963~Cytoplasm,		KW-0677~Repeat,		KW-0694~RNA-binding,	KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:PUM-HD,REGION:Adenine-nucleotide binding in RNA target,REGION:Disordered,REGION:Guanine-nucleotide binding in RNA target,REGION:Interaction with SNAPIN,REGION:Non-specific-nucleotide binding in RNA target,REGION:Uracil-nucleotide binding in RNA target,REPEAT:Pumilio,REPEAT:Pumilio 1,REPEAT:Pumilio 2,REPEAT:Pumilio 3,REPEAT:Pumilio 4,REPEAT:Pumilio 5,REPEAT:Pumilio 6,REPEAT:Pumilio 7,REPEAT:Pumilio 8,
PNP	purine nucleoside phosphorylase(PNP)	Homo sapiens			GO:0000255~allantoin metabolic process,GO:0006139~nucleobase-containing compound metabolic process,GO:0006148~inosine catabolic process,GO:0006149~deoxyinosine catabolic process,GO:0006157~deoxyadenosine catabolic process,GO:0006166~purine ribonucleoside salvage,GO:0006204~IMP catabolic process,GO:0006738~nicotinamide riboside catabolic process,GO:0006955~immune response,GO:0009116~nucleoside metabolic process,GO:0009165~nucleotide biosynthetic process,GO:0009410~response to xenobiotic stimulus,GO:0032743~positive regulation of interleukin-2 production,GO:0034418~urate biosynthetic process,GO:0042102~positive regulation of T cell proliferation,GO:0043101~purine-containing compound salvage,GO:0046059~dAMP catabolic process,GO:0046638~positive regulation of alpha-beta T cell differentiation,	GO:0005576~extracellular region,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0034774~secretory granule lumen,GO:0070062~extracellular exosome,GO:1904813~ficolin-1-rich granule lumen,	GO:0001882~nucleoside binding,GO:0002060~purine nucleobase binding,GO:0004731~purine-nucleoside phosphorylase activity,GO:0005515~protein binding,GO:0042301~phosphate ion binding,GO:0042802~identical protein binding,GO:0047975~guanosine phosphorylase activity,	IPR000845:Nucleoside_phosphorylase_d,IPR011268:Purine_phosphorylase,IPR011270:Pur_Nuc_Pase_Ino/Guo-sp,IPR018099:Purine_phosphorylase-2_CS,IPR035994:Nucleoside_phosphorylase_sf,	hsa00230:Purine metabolism,hsa00760:Nicotinate and nicotinamide metabolism,hsa01100:Metabolic pathways,hsa01232:Nucleotide metabolism,	613179~Immunodeficiency due to purine nucleoside phosphorylase deficiency,	PIRSF000477:PurNPase,		KW-0660~Purine salvage,	KW-0963~Cytoplasm,	KW-0225~Disease variant,			KW-0328~Glycosyltransferase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:Nucleoside phosphorylase,MUTAGEN:E->A,Q: Severe loss of catalytic activity.,MUTAGEN:H->W: Reduces catalytic activity towards inosine.,MUTAGEN:N->A: Reduces catalytic activity.,MUTAGEN:N->D: Reduces catalytic activity towards inosine, hypoxanthine, guanosine and guanine. Increases catalytic activity towards adenosine and adenine.,REGION:Disordered,SITE:Important for substrate specificity,
PHTF2	putative homeodomain transcription factor 2(PHTF2)	Homo sapiens				GO:0005783~endoplasmic reticulum,GO:0016020~membrane,		IPR021980:PHTF1/2_N,IPR039775:PHTF1/2,						KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:PHTF,REGION:Disordered,TRANSMEM:Helical,
PDXDC1	pyridoxal dependent decarboxylase domain containing 1(PDXDC1)	Homo sapiens			GO:0019752~carboxylic acid metabolic process,	GO:0005794~Golgi apparatus,GO:0043231~intracellular membrane-bounded organelle,	GO:0016830~carbon-carbon lyase activity,GO:0016831~carboxy-lyase activity,GO:0030170~pyridoxal phosphate binding,GO:0045296~cadherin binding,	IPR002129:PyrdxlP-dep_de-COase,IPR015421:PyrdxlP-dep_Trfase_major,IPR015424:PyrdxlP-dep_Trfase,									KW-0663~Pyridoxal phosphate,	KW-0210~Decarboxylase,KW-0456~Lyase,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,
PYHIN1	pyrin and HIN domain family member 1(PYHIN1)	Homo sapiens			GO:0002218~activation of innate immune response,GO:0007049~cell cycle,GO:0031648~protein destabilization,GO:0035457~cellular response to interferon-alpha,GO:0035458~cellular response to interferon-beta,GO:0043388~positive regulation of DNA binding,GO:0045893~positive regulation of transcription, DNA-templated,GO:0050821~protein stabilization,GO:1900182~positive regulation of protein localization to nucleus,GO:1902164~positive regulation of DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator,GO:2000060~positive regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process,	GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005829~cytosol,GO:0016607~nuclear speck,GO:0032991~macromolecular complex,	GO:0003690~double-stranded DNA binding,GO:0031625~ubiquitin protein ligase binding,	IPR004020:DAPIN,IPR004021:HIN200/IF120x,IPR011029:DEATH-like_dom_sf,IPR012340:NA-bd_OB-fold,IPR040205:HIN-200,				SM01289:PYRIN,	KW-0131~Cell cycle,	KW-0539~Nucleus,	KW-0043~Tumor suppressor,					COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:HIN-200,DOMAIN:Pyrin,REGION:Disordered,
PDHA1	pyruvate dehydrogenase E1 subunit alpha 1(PDHA1)	Homo sapiens		h_malatexPathway:Shuttle for transfer of acetyl groups from mitochondria to the cytosol,	GO:0006006~glucose metabolic process,GO:0006086~acetyl-CoA biosynthetic process from pyruvate,GO:0006099~tricarboxylic acid cycle,	GO:0005634~nucleus,GO:0005730~nucleolus,GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0005967~mitochondrial pyruvate dehydrogenase complex,GO:0045254~pyruvate dehydrogenase complex,	GO:0004739~pyruvate dehydrogenase (acetyl-transferring) activity,GO:0005515~protein binding,GO:0016624~oxidoreductase activity, acting on the aldehyde or oxo group of donors, disulfide as acceptor,GO:0034604~pyruvate dehydrogenase (NAD+) activity,	IPR001017:DH_E1,IPR017597:Pyrv_DH_E1_asu_subgrp-y,IPR029061:THDP-binding,	hsa00010:Glycolysis / Gluconeogenesis,hsa00020:Citrate cycle (TCA cycle),hsa00620:Pyruvate metabolism,hsa00785:Lipoic acid metabolism,hsa01100:Metabolic pathways,hsa01200:Carbon metabolism,hsa01210:2-Oxocarboxylic acid metabolism,hsa04066:HIF-1 signaling pathway,hsa04922:Glucagon signaling pathway,hsa05230:Central carbon metabolism in cancer,hsa05415:Diabetic cardiomyopathy,	312170~Pyruvate dehydrogenase E1-alpha deficiency,			KW-0119~Carbohydrate metabolism,KW-0313~Glucose metabolism,KW-0816~Tricarboxylic acid cycle,	KW-0496~Mitochondrion,	KW-0225~Disease variant,KW-0431~Leigh syndrome,KW-1274~Primary mitochondrial disease,	KW-0809~Transit peptide,	KW-0670~Pyruvate,KW-0786~Thiamine pyrophosphate,	KW-0560~Oxidoreductase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:Dehydrogenase E1 component,MUTAGEN:S->A: Abolishes inactivation by phosphorylation; when associated with A-232 and A-293.,MUTAGEN:S->A: Abolishes inactivation by phosphorylation; when associated with A-293 and A-300.,MUTAGEN:S->A: Reduces enzyme activity. Abolishes inactivation by phosphorylation; when associated with A-232 and A-300.,MUTAGEN:S->E: Interferes with substrate binding.,TRANSIT:Mitochondrion,
PDHB	pyruvate dehydrogenase E1 subunit beta(PDHB)	Homo sapiens			GO:0006006~glucose metabolic process,GO:0006086~acetyl-CoA biosynthetic process from pyruvate,GO:0006099~tricarboxylic acid cycle,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0005967~mitochondrial pyruvate dehydrogenase complex,GO:0045254~pyruvate dehydrogenase complex,	GO:0004739~pyruvate dehydrogenase (acetyl-transferring) activity,GO:0005515~protein binding,GO:0034604~pyruvate dehydrogenase (NAD+) activity,	IPR005475:Transketolase-like_Pyr-bd,IPR009014:Transketo_C/PFOR_II,IPR027110:PDHB,IPR029061:THDP-binding,IPR033248:Transketolase_C,	hsa00010:Glycolysis / Gluconeogenesis,hsa00020:Citrate cycle (TCA cycle),hsa00620:Pyruvate metabolism,hsa00785:Lipoic acid metabolism,hsa01100:Metabolic pathways,hsa01200:Carbon metabolism,hsa01210:2-Oxocarboxylic acid metabolism,hsa04066:HIF-1 signaling pathway,hsa04922:Glucagon signaling pathway,hsa05230:Central carbon metabolism in cancer,hsa05415:Diabetic cardiomyopathy,	614111~Pyruvate dehydrogenase E1-beta deficiency,		SM00861:Transket_pyr,	KW-0119~Carbohydrate metabolism,KW-0313~Glucose metabolism,KW-0816~Tricarboxylic acid cycle,	KW-0496~Mitochondrion,	KW-0225~Disease variant,	KW-0809~Transit peptide,	KW-0670~Pyruvate,KW-0786~Thiamine pyrophosphate,	KW-0560~Oxidoreductase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:Transketolase-like pyrimidine-binding,MUTAGEN:D->A: Inhibits interaction with DLAT. Does not affect pyruvate decarboxylase activity. Loss of multienzyme pyruvate dehydrogenase complex activity.,MUTAGEN:D->N: Reduces interaction with DLAT. Reduces multienzyme pyruvate dehydrogenase complex activity. Does not affect pyruvate decarboxylase activity.,MUTAGEN:E->A,Q: Does not affect interaction with DLAT.,MUTAGEN:I->A: Reduces pyruvate decarboxylase and multienzyme pyruvate dehydrogenase complex activity. Does not affect interaction with DLAT.,MUTAGEN:Missing: Reduces pyruvate decarboxylase and multienzyme pyruvate dehydrogenase complex activity. Does not affect interaction with DLAT.,SITE:Important for interaction with DLAT,TRANSIT:Mitochondrion,
RFTN1	raftlin, lipid raft linker 1(RFTN1)	Homo sapiens			GO:0001765~membrane raft assembly,GO:0002457~T cell antigen processing and presentation,GO:0032596~protein transport into membrane raft,GO:0032740~positive regulation of interleukin-17 production,GO:0033227~dsRNA transport,GO:0034138~toll-like receptor 3 signaling pathway,GO:0040010~positive regulation of growth rate,GO:0043330~response to exogenous dsRNA,GO:0050852~T cell receptor signaling pathway,GO:0050853~B cell receptor signaling pathway,GO:1903044~protein localization to membrane raft,	GO:0005737~cytoplasm,GO:0005768~endosome,GO:0005769~early endosome,GO:0005886~plasma membrane,GO:0032991~macromolecular complex,GO:0045121~membrane raft,GO:0070062~extracellular exosome,	GO:0003725~double-stranded RNA binding,	IPR028169:Raftlin,						KW-0472~Membrane,KW-0963~Cytoplasm,KW-0967~Endosome,KW-1003~Cell membrane,					KW-0449~Lipoprotein,KW-0519~Myristate,KW-0564~Palmitate,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,LIPID:N-myristoyl glycine,LIPID:S-palmitoyl cysteine,MUTAGEN:C->S: Partially affects association with membranes. Loss of association with membranes; when associated with A-2.,MUTAGEN:G->A: Loss of association with membranes. Same effect; when associated with S-3.,REGION:Disordered,
RHOA	ras homolog family member A(RHOA)	Homo sapiens	102.Cholesterol_Stress_Response,	h_akap13Pathway:Rho-Selective Guanine Exchange Factor AKAP13 Mediates Stress Fiber Formation,h_akapcentrosomePathway:Protein Kinase A at the Centrosome,h_cardiacEGFPathway:Role of EGF Receptor Transactivation by GPCRs in Cardiac Hypertrophy,h_ccr3Pathway:CCR3 signaling in Eosinophils,h_cdc42racPathway:Role of PI3K subunit p85 in regulation of Actin Organization and Cell Migration,h_ecmPathway:Erk and PI-3 Kinase Are Necessary for Collagen Binding in Corneal Epithelia,h_edg1Pathway:Phospholipids as signalling intermediaries,h_integrinPathway:Integrin Signaling Pathway,h_malPathway:Role of MAL in Rho-Mediated Activation of SRF,h_par1pathway:Thrombin signaling and protease-activated receptors,h_raccycdPathway:Influence of Ras and Rho proteins on G1 to S Transition,h_rasPathway:Ras Signaling Pathway,h_rhoPathway:Rho cell motility signaling pathway,h_tffPathway:Trefoil Factors Initiate  Mucosal Healing,h_uCalpainPathway:uCalpain and friends in Cell spread,	GO:0000281~mitotic cytokinesis,GO:0000902~cell morphogenesis,GO:0001764~neuron migration,GO:0001822~kidney development,GO:0001998~angiotensin-mediated vasoconstriction involved in regulation of systemic arterial blood pressure,GO:0002363~alpha-beta T cell lineage commitment,GO:0003100~regulation of systemic arterial blood pressure by endothelin,GO:0003189~aortic valve formation,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007015~actin filament organization,GO:0007160~cell-matrix adhesion,GO:0007165~signal transduction,GO:0007264~small GTPase mediated signal transduction,GO:0007266~Rho protein signal transduction,GO:0007519~skeletal muscle tissue development,GO:0010812~negative regulation of cell-substrate adhesion,GO:0010975~regulation of neuron projection development,GO:0016477~cell migration,GO:0021762~substantia nigra development,GO:0021795~cerebral cortex cell migration,GO:0021861~forebrain radial glial cell differentiation,GO:0030036~actin cytoskeleton organization,GO:0030334~regulation of cell migration,GO:0030335~positive regulation of cell migration,GO:0030521~androgen receptor signaling pathway,GO:0031122~cytoplasmic microtubule organization,GO:0031334~positive regulation of protein complex assembly,GO:0032467~positive regulation of cytokinesis,GO:0032956~regulation of actin cytoskeleton organization,GO:0033144~negative regulation of intracellular steroid hormone receptor signaling pathway,GO:0033688~regulation of osteoblast proliferation,GO:0034329~cell junction assembly,GO:0034446~substrate adhesion-dependent cell spreading,GO:0035385~Roundabout signaling pathway,GO:0036089~cleavage furrow formation,GO:0038027~apolipoprotein A-I-mediated signaling pathway,GO:0042476~odontogenesis,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043149~stress fiber assembly,GO:0043297~apical junction assembly,GO:0043366~beta selection,GO:0043542~endothelial cell migration,GO:0043931~ossification involved in bone maturation,GO:0044319~wound healing, spreading of cells,GO:0045198~establishment of epithelial cell apical/basal polarity,GO:0045666~positive regulation of neuron differentiation,GO:0045792~negative regulation of cell size,GO:0046638~positive regulation of alpha-beta T cell differentiation,GO:0050919~negative chemotaxis,GO:0051496~positive regulation of stress fiber assembly,GO:0051893~regulation of focal adhesion assembly,GO:0060071~Wnt signaling pathway, planar cell polarity pathway,GO:0060193~positive regulation of lipase activity,GO:0061430~bone trabecula morphogenesis,GO:0070507~regulation of microtubule cytoskeleton organization,GO:0071222~cellular response to lipopolysaccharide,GO:0071345~cellular response to cytokine stimulus,GO:0071526~semaphorin-plexin signaling pathway,GO:0071803~positive regulation of podosome assembly,GO:0071902~positive regulation of protein serine/threonine kinase activity,GO:0090051~negative regulation of cell migration involved in sprouting angiogenesis,GO:0090307~mitotic spindle assembly,GO:0090324~negative regulation of oxidative phosphorylation,GO:0097049~motor neuron apoptotic process,GO:0097498~endothelial tube lumen extension,GO:1901224~positive regulation of NIK/NF-kappaB signaling,GO:1902766~skeletal muscle satellite cell migration,GO:1903427~negative regulation of reactive oxygen species biosynthetic process,GO:1903673~mitotic cleavage furrow formation,GO:1904695~positive regulation of vascular smooth muscle contraction,GO:1904996~positive regulation of leukocyte adhesion to vascular endothelial cell,GO:1905274~regulation of modification of postsynaptic actin cytoskeleton,GO:1990869~cellular response to chemokine,GO:2000177~regulation of neural precursor cell proliferation,GO:2000406~positive regulation of T cell migration,GO:2000672~negative regulation of motor neuron apoptotic process,	GO:0005634~nucleus,GO:0005768~endosome,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0005938~cell cortex,GO:0009898~cytoplasmic side of plasma membrane,GO:0030027~lamellipodium,GO:0030054~cell junction,GO:0030496~midbody,GO:0030667~secretory granule membrane,GO:0031982~vesicle,GO:0032154~cleavage furrow,GO:0032420~stereocilium,GO:0032587~ruffle membrane,GO:0043005~neuron projection,GO:0043197~dendritic spine,GO:0043296~apical junction complex,GO:0070062~extracellular exosome,GO:0071944~cell periphery,GO:0098794~postsynapse,GO:0098978~glutamatergic synapse,GO:0101003~ficolin-1-rich granule membrane,	GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0017022~myosin binding,GO:0019901~protein kinase binding,	IPR001806:Small_GTPase,IPR003578:Small_GTPase_Rho,IPR005225:Small_GTP-bd_dom,IPR027417:P-loop_NTPase,	hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04022:cGMP-PKG signaling pathway,hsa04024:cAMP signaling pathway,hsa04062:Chemokine signaling pathway,hsa04071:Sphingolipid signaling pathway,hsa04072:Phospholipase D signaling pathway,hsa04144:Endocytosis,hsa04150:mTOR signaling pathway,hsa04270:Vascular smooth muscle contraction,hsa04310:Wnt signaling pathway,hsa04350:TGF-beta signaling pathway,hsa04360:Axon guidance,hsa04510:Focal adhesion,hsa04520:Adherens junction,hsa04530:Tight junction,hsa04611:Platelet activation,hsa04621:NOD-like receptor signaling pathway,hsa04625:C-type lectin receptor signaling pathway,hsa04660:T cell receptor signaling pathway,hsa04670:Leukocyte transendothelial migration,hsa04722:Neurotrophin signaling pathway,hsa04810:Regulation of actin cytoskeleton,hsa04921:Oxytocin signaling pathway,hsa04928:Parathyroid hormone synthesis, secretion and action,hsa04972:Pancreatic secretion,hsa05100:Bacterial invasion of epithelial cells,hsa05130:Pathogenic Escherichia coli infection,hsa05131:Shigellosis,hsa05132:Salmonella infection,hsa05133:Pertussis,hsa05135:Yersinia infection,hsa05152:Tuberculosis,hsa05163:Human cytomegalovirus infection,hsa05200:Pathways in cancer,hsa05203:Viral carcinogenesis,hsa05205:Proteoglycans in cancer,hsa05206:MicroRNAs in cancer,hsa05210:Colorectal cancer,hsa05417:Lipid and atherosclerosis,hsa05418:Fluid shear stress and atherosclerosis,	618727~Ectodermal dysplasia with facial dysmorphism and acral, ocular, and brain anomalies, somatic mosaic,		SM00173:RAS,SM00174:RHO,SM00175:RAB,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0945~Host-virus interaction,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-1003~Cell membrane,	KW-0038~Ectodermal dysplasia,KW-0225~Disease variant,KW-0656~Proto-oncogene,		KW-0342~GTP-binding,KW-0460~Magnesium,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,	KW-0013~ADP-ribosylation,KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0636~Prenylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CARBOHYD:(Microbial infection) O-alpha-linked (GlcNAc) threonine; by C.novyi toxin TcdA; alternate,CARBOHYD:(Microbial infection) O-linked (Glc) threonine; by C.difficile toxins TcdA and TcdB,CARBOHYD:(Microbial infection) O-linked (Glc) threonine; by C.difficile toxins TcdA and TcdB; alternate,CARBOHYD:(Microbial infection) O-linked (GlcNAc) tyrosine; by Photorhabdus PAU_02230; alternate,CARBOHYD:O-linked (GlcNAc) tyrosine; by Photorhabdus PAU_02230,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),LIPID:(Microbial infection) N6-stearoyl lysine,LIPID:S-geranylgeranyl cysteine,MOTIF:Effector region,MUTAGEN:G->V: Increased Rho protein signal transduction. Constitutively active.,MUTAGEN:K->R: Reduced FBXL19-mediated ubiquitination and subsequent degradation.,MUTAGEN:KKK->RRR: In 3KR mutant; abolished stearoylation in response to S.flexneri infection.,MUTAGEN:L->M: Converts geranyl-geranylation to farnesylation; does not prevent the cleavage by yopT.,MUTAGEN:Q->L: Causes constitutive activation.,MUTAGEN:T->A: Abolished monoglucosylation by C.difficile toxin TcdA. Abolished O-GlcNAcylation by C.novyi toxin TcdA.,MUTAGEN:T->N: Decreased Rho protein signal transduction. Decreased substrate adhesion-dependent cell spreading. Decreased stress fibers assembly. Decreased cytoplasmic microtubule organization.,MUTAGEN:Y->A: Abolishes interaction with DGKQ.,MUTAGEN:Y->F: Abolishes AMPylation by Haemophilus IbpA.,PROPEP:Removed in mature form,REGION:Switch II region; involved in RAP1GDS1 isoform 2 binding,SITE:(Microbial infection) Cleavage; by yopT,
RHOF	ras homolog family member F, filopodia associated(RHOF)	Homo sapiens			GO:0007015~actin filament organization,GO:0007165~signal transduction,GO:0007264~small GTPase mediated signal transduction,GO:0016477~cell migration,GO:0032956~regulation of actin cytoskeleton organization,GO:0051056~regulation of small GTPase mediated signal transduction,	GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0030667~secretory granule membrane,GO:0070062~extracellular exosome,	GO:0003924~GTPase activity,GO:0005085~guanyl-nucleotide exchange factor activity,GO:0005525~GTP binding,GO:0019901~protein kinase binding,	IPR001806:Small_GTPase,IPR003578:Small_GTPase_Rho,IPR005225:Small_GTP-bd_dom,IPR027417:P-loop_NTPase,				SM00173:RAS,SM00174:RHO,SM00175:RAB,SM00176:RAN,		KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,			KW-0342~GTP-binding,KW-0547~Nucleotide-binding,		KW-0007~Acetylation,KW-0449~Lipoprotein,KW-0488~Methylation,KW-0636~Prenylation,	LIPID:S-geranylgeranyl cysteine,MOTIF:Effector region,PROPEP:Removed in mature form,
RHOG	ras homolog family member G(RHOG)	Homo sapiens			GO:0007015~actin filament organization,GO:0007163~establishment or maintenance of cell polarity,GO:0007264~small GTPase mediated signal transduction,GO:0007266~Rho protein signal transduction,GO:0008284~positive regulation of cell proliferation,GO:0008360~regulation of cell shape,GO:0016601~Rac protein signal transduction,GO:0030036~actin cytoskeleton organization,GO:0030865~cortical cytoskeleton organization,GO:0032956~regulation of actin cytoskeleton organization,GO:0045893~positive regulation of transcription, DNA-templated,GO:0060326~cell chemotaxis,GO:0090630~activation of GTPase activity,GO:1900027~regulation of ruffle assembly,GO:1903078~positive regulation of protein localization to plasma membrane,	GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0030667~secretory granule membrane,GO:0031410~cytoplasmic vesicle,GO:0042995~cell projection,GO:0070062~extracellular exosome,	GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0019901~protein kinase binding,	IPR001806:Small_GTPase,IPR003578:Small_GTPase_Rho,IPR005225:Small_GTP-bd_dom,IPR027417:P-loop_NTPase,IPR042734:RhoG,	hsa05100:Bacterial invasion of epithelial cells,hsa05132:Salmonella infection,hsa05135:Yersinia infection,			SM00173:RAS,SM00174:RHO,SM00175:RAB,SM00176:RAN,		KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,		KW-0342~GTP-binding,KW-0547~Nucleotide-binding,		KW-0013~ADP-ribosylation,KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0636~Prenylation,	CARBOHYD:(Microbial infection) O-alpha-linked (GlcNAc) threonine; by C.novyi toxin TcdA; alternate,CARBOHYD:(Microbial infection) O-linked (Glc) threonine; by C.difficile toxin TcdB; alternate,LIPID:S-geranylgeranyl cysteine,MOTIF:Effector region,PROPEP:Removed in mature form,
RHOH	ras homolog family member H(RHOH)	Homo sapiens			GO:0006355~regulation of transcription, DNA-templated,GO:0007015~actin filament organization,GO:0007165~signal transduction,GO:0007264~small GTPase mediated signal transduction,GO:0030217~T cell differentiation,GO:0043124~negative regulation of I-kappaB kinase/NF-kappaB signaling,GO:0045576~mast cell activation,GO:0045582~positive regulation of T cell differentiation,	GO:0001772~immunological synapse,GO:0005737~cytoplasm,GO:0005886~plasma membrane,	GO:0003924~GTPase activity,GO:0005095~GTPase inhibitor activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0019210~kinase inhibitor activity,GO:0019901~protein kinase binding,GO:0031267~small GTPase binding,	IPR001806:Small_GTPase,IPR003578:Small_GTPase_Rho,IPR005225:Small_GTP-bd_dom,IPR027417:P-loop_NTPase,	hsa04670:Leukocyte transendothelial migration,hsa05132:Salmonella infection,	618307~Epidermodysplasia verruciformis, susceptibility to, 4,		SM00173:RAS,SM00174:RHO,SM00175:RAB,		KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,	KW-0225~Disease variant,		KW-0342~GTP-binding,KW-0547~Nucleotide-binding,		KW-0449~Lipoprotein,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0636~Prenylation,	LIPID:S-geranylgeranyl cysteine,MOTIF:Effector region,PROPEP:Removed in mature form,REGION:Interaction with ZAP70,
ROMO1	reactive oxygen species modulator 1(ROMO1)	Homo sapiens			GO:0006886~intracellular protein transport,GO:0008284~positive regulation of cell proliferation,GO:0030150~protein import into mitochondrial matrix,GO:0031640~killing of cells of other organism,GO:0034614~cellular response to reactive oxygen species,GO:0042742~defense response to bacterium,GO:0045039~protein import into mitochondrial inner membrane,GO:0050829~defense response to Gram-negative bacterium,GO:0050830~defense response to Gram-positive bacterium,GO:0051838~cytolysis by host of symbiont cells,GO:0061844~antimicrobial humoral immune response mediated by antimicrobial peptide,GO:0090399~replicative senescence,GO:2000379~positive regulation of reactive oxygen species metabolic process,	GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005744~mitochondrial inner membrane presequence translocase complex,	GO:0005515~protein binding,	IPR018450:Romo1/Mgr2,				SM01378:Romo1,		KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0044~Antibiotic,KW-0929~Antimicrobial,		REGION:Sufficient for antibacterial activity,TRANSMEM:Helical,
REEP5	receptor accessory protein 5(REEP5)	Homo sapiens			GO:0007029~endoplasmic reticulum organization,GO:0032386~regulation of intracellular transport,GO:0090158~endoplasmic reticulum membrane organization,	GO:0005783~endoplasmic reticulum,GO:0016020~membrane,GO:0033017~sarcoplasmic reticulum membrane,GO:0071782~endoplasmic reticulum tubular network,	GO:0005515~protein binding,	IPR004345:TB2_DP1_HVA22,						KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0703~Sarcoplasmic reticulum,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,		REGION:Required for dimerization and maintaining endoplasmic reticulum morphology,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
RGS1	regulator of G protein signaling 1(RGS1)	Homo sapiens			GO:0006955~immune response,GO:0007165~signal transduction,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007193~adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway,GO:0009617~response to bacterium,GO:0009968~negative regulation of signal transduction,GO:0043547~positive regulation of GTPase activity,GO:0061737~leukotriene signaling pathway,	GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0009898~cytoplasmic side of plasma membrane,	GO:0001965~G-protein alpha-subunit binding,GO:0003924~GTPase activity,GO:0005096~GTPase activator activity,GO:0005516~calmodulin binding,	IPR016137:RGS,IPR024066:RGS_subdom1/3,IPR036305:RGS_sf,IPR044926:RGS_subdomain_2,				SM00315:RGS,		KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,				KW-0343~GTPase activation,KW-0734~Signal transduction inhibitor,		DOMAIN:RGS,
RGS10	regulator of G protein signaling 10(RGS10)	Homo sapiens			GO:0007186~G-protein coupled receptor signaling pathway,GO:0007213~G-protein coupled acetylcholine receptor signaling pathway,GO:0008277~regulation of G-protein coupled receptor protein signaling pathway,GO:0009968~negative regulation of signal transduction,GO:0043547~positive regulation of GTPase activity,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016604~nuclear body,GO:0045202~synapse,	GO:0001965~G-protein alpha-subunit binding,GO:0003924~GTPase activity,GO:0005096~GTPase activator activity,GO:0005515~protein binding,	IPR016137:RGS,IPR024066:RGS_subdom1/3,IPR036305:RGS_sf,IPR037879:RGS10_RGS,IPR044926:RGS_subdomain_2,IPR046995:RGS10/12/14-like,				SM00315:RGS,		KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0343~GTPase activation,KW-0734~Signal transduction inhibitor,	KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,	DOMAIN:RGS,LIPID:S-palmitoyl cysteine,MUTAGEN:S->A: Abolishes phosphorylation site and leads to strongly reduced overall phosphorylation.,REGION:Disordered,
RGS2	regulator of G protein signaling 2(RGS2)	Homo sapiens			GO:0001975~response to amphetamine,GO:0007049~cell cycle,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007283~spermatogenesis,GO:0008277~regulation of G-protein coupled receptor protein signaling pathway,GO:0010519~negative regulation of phospholipase activity,GO:0010614~negative regulation of cardiac muscle hypertrophy,GO:0010976~positive regulation of neuron projection development,GO:0017148~negative regulation of translation,GO:0043407~negative regulation of MAP kinase activity,GO:0045471~response to ethanol,GO:0045744~negative regulation of G-protein coupled receptor protein signaling pathway,GO:0050873~brown fat cell differentiation,GO:0055119~relaxation of cardiac muscle,GO:0060087~relaxation of vascular smooth muscle,GO:0060135~maternal process involved in female pregnancy,GO:0060452~positive regulation of cardiac muscle contraction,GO:0061052~negative regulation of cell growth involved in cardiac muscle cell development,GO:0071877~regulation of adrenergic receptor signaling pathway,GO:1900924~negative regulation of glycine import,	GO:0005634~nucleus,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0009898~cytoplasmic side of plasma membrane,	GO:0001965~G-protein alpha-subunit binding,GO:0003924~GTPase activity,GO:0005096~GTPase activator activity,GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0010855~adenylate cyclase inhibitor activity,GO:0048487~beta-tubulin binding,	IPR016137:RGS,IPR024066:RGS_subdom1/3,IPR034947:RGS2_RGS,IPR036305:RGS_sf,IPR044926:RGS_subdomain_2,	hsa04022:cGMP-PKG signaling pathway,hsa04740:Olfactory transduction,hsa04921:Oxytocin signaling pathway,			SM00315:RGS,	KW-0131~Cell cycle,KW-0810~Translation regulation,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,				KW-0343~GTPase activation,KW-0734~Signal transduction inhibitor,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:RGS,MUTAGEN:C->S: Changes specificity and confers GNAI1 binding; when associated with D-184. Strongly increases affinity for GNAI1 and GNAI3; when associated with D-184 and K-191.,MUTAGEN:E->A: Near loss of EIF2B5 binding and inhibition of in vitro translation; when associated with L-79; E-86; L-87; S-90; K-102; F-105; I-110 and L-114.,MUTAGEN:E->A: Near loss of EIF2B5 binding and inhibition of in vitro translation; when associated with L-79; L-87; S-90; K-102; F-105; I-110; E-111 and L-114.,MUTAGEN:E->K: Strongly increases affinity for GNAI1 and GNAI3; when associated with S-106 and D-184.,MUTAGEN:F->A: Near loss of EIF2B5 binding and inhibition of in vitro translation; when associated with L-79; E-86; L-87; S-90; K-102; I-110; E-111 and L-114.,MUTAGEN:F->D: Impairs association with plasma membrane.,MUTAGEN:I->A: Near loss of EIF2B5 binding and inhibition of in vitro translation; when associated with L-79; E-86; L-87; S-90; K-102; F-105; E-111 and L-114.,MUTAGEN:K->A: Near loss of EIF2B5 binding and inhibition of in vitro translation; when associated with L-79; E-86; L-87; S-90; F-105; I-110; E-111 and L-114.,MUTAGEN:L->A: Near loss of EIF2B5 binding and inhibition of in vitro translation; when associated with E-86; L-87; S-90; K-102; F-105; I-110; E-111 and L-114.,MUTAGEN:L->A: Near loss of EIF2B5 binding and inhibition of in vitro translation; when associated with L-79; E-86; L-87; S-90; K-102; F-105; I-110 and E-111.,MUTAGEN:L->A: Near loss of EIF2B5 binding and inhibition of in vitro translation; when associated with L-79; E-86; S-90; K-102; F-105; I-110; E-111 and L-114.,MUTAGEN:L->D: Impairs association with plasma membrane.,MUTAGEN:M->L: Loss of isoform 1 expression.,MUTAGEN:M->L: Loss of isoform 2 expression.,MUTAGEN:M->L: Loss of isoform 3 expression.,MUTAGEN:M->L: Loss of isoform 4 expression.,MUTAGEN:N->A: Decreases GTPase accelerating function but has no effect on translation inhibitory activity, suggesting that its role in translation is independent of its effects on G proteins.,MUTAGEN:N->D: Changes specificity and confers GNAI1 binding; when associated with D-184. Strongly increases affinity for GNAI1 and GNAI3; when associated with S-106 and K-191.,MUTAGEN:S->A: Near loss of EIF2B5 binding and inhibition of in vitro translation; when associated with L-79; E-86; L-87; K-102; F-105; I-110; E-111 and L-114.,MUTAGEN:W->D: Impairs association with plasma membrane.,REGION:Disordered,REGION:Necessary for membrane association,REGION:Necessary to inhibit protein synthesis,
RGCC	regulator of cell cycle(RGCC)	Homo sapiens			GO:0001100~negative regulation of exit from mitosis,GO:0001818~negative regulation of cytokine production,GO:0001819~positive regulation of cytokine production,GO:0001937~negative regulation of endothelial cell proliferation,GO:0003331~positive regulation of extracellular matrix constituent secretion,GO:0006956~complement activation,GO:0007049~cell cycle,GO:0008285~negative regulation of cell proliferation,GO:0010628~positive regulation of gene expression,GO:0010718~positive regulation of epithelial to mesenchymal transition,GO:0016525~negative regulation of angiogenesis,GO:0032967~positive regulation of collagen biosynthetic process,GO:0043537~negative regulation of blood vessel endothelial cell migration,GO:0045737~positive regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0045840~positive regulation of mitotic nuclear division,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051091~positive regulation of sequence-specific DNA binding transcription factor activity,GO:0051496~positive regulation of stress fiber assembly,GO:0071456~cellular response to hypoxia,GO:0072537~fibroblast activation,GO:0090272~negative regulation of fibroblast growth factor production,GO:1900087~positive regulation of G1/S transition of mitotic cell cycle,GO:1901203~positive regulation of extracellular matrix assembly,GO:1901991~negative regulation of mitotic cell cycle phase transition,GO:2000048~negative regulation of cell-cell adhesion mediated by cadherin,GO:2000353~positive regulation of endothelial cell apoptotic process,GO:2000573~positive regulation of DNA biosynthetic process,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005829~cytosol,	GO:0005515~protein binding,GO:0019901~protein kinase binding,GO:0030295~protein kinase activator activity,GO:0070412~R-SMAD binding,	IPR029252:RGCC,	hsa04810:Regulation of actin cytoskeleton,				KW-0131~Cell cycle,	KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,					KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,MUTAGEN:T->A: Loss of phosphorylation. Reduced stimulation of CDK1 activity.,REGION:Disordered,
RSF1	remodeling and spacing factor 1(RSF1)	Homo sapiens			GO:0006325~chromatin organization,GO:0006334~nucleosome assembly,GO:0006338~chromatin remodeling,GO:0006352~DNA-templated transcription, initiation,GO:0006355~regulation of transcription, DNA-templated,GO:0043392~negative regulation of DNA binding,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0050434~positive regulation of viral transcription,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0031213~RSF complex,	GO:0005515~protein binding,GO:0042393~histone binding,GO:0046872~metal ion binding,	IPR001965:Znf_PHD,IPR011011:Znf_FYVE_PHD,IPR013083:Znf_RING/FYVE/PHD,IPR019786:Zinc_finger_PHD-type_CS,IPR019787:Znf_PHD-finger,IPR028938:Rsf1-like,IPR028942:WHIM1_dom,	hsa03082:ATP-dependent chromatin remodeling,			SM00249:PHD,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0175~Coiled coil,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0156~Chromatin regulator,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:DDT,DOMAIN:PHD-type,DOMAIN:WHIM1,REGION:Disordered,ZN_FING:PHD-type,
RFC1	replication factor C subunit 1(RFC1)	Homo sapiens		h_alkPathway:ALK in cardiac myocytes,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006260~DNA replication,GO:0006261~DNA-dependent DNA replication,GO:0006281~DNA repair,GO:0007004~telomere maintenance via telomerase,GO:0045893~positive regulation of transcription, DNA-templated,GO:0090618~DNA clamp unloading,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005663~DNA replication factor C complex,GO:0031391~Elg1 RFC-like complex,GO:0070062~extracellular exosome,	GO:0003677~DNA binding,GO:0003689~DNA clamp loader activity,GO:0003690~double-stranded DNA binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008047~enzyme activator activity,GO:0016887~ATPase activity,GO:0019904~protein domain specific binding,GO:0043565~sequence-specific DNA binding,	IPR001357:BRCT_dom,IPR003593:AAA+_ATPase,IPR003959:ATPase_AAA_core,IPR008921:DNA_pol3_clamp-load_cplx_C,IPR012178:RFC1,IPR013725:DNA_replication_fac_RFC1_C,IPR027417:P-loop_NTPase,IPR036420:BRCT_dom_sf,IPR047854:RFC_lid,	hsa03030:DNA replication,hsa03410:Base excision repair,hsa03420:Nucleotide excision repair,hsa03430:Mismatch repair,	614575~Cerebellar ataxia, neuropathy, and vestibular areflexia syndrome,	PIRSF036578:RFC1,	SM00292:BRCT,SM00382:AAA,	KW-0235~DNA replication,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0622~Neuropathy,		KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0010~Activator,KW-0238~DNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:BRCT,DOMAIN:DNA replication factor RFC1 C-terminal,MOTIF:Nuclear localization signal,REGION:Disordered,
RPA1	replication protein A1(RPA1)	Homo sapiens		h_p53hypoxiaPathway:Hypoxia and p53 in the Cardiovascular system,	GO:0000723~telomere maintenance,GO:0000724~double-strand break repair via homologous recombination,GO:0006260~DNA replication,GO:0006261~DNA-dependent DNA replication,GO:0006281~DNA repair,GO:0006284~base-excision repair,GO:0006289~nucleotide-excision repair,GO:0006298~mismatch repair,GO:0006310~DNA recombination,GO:0006325~chromatin organization,GO:0006974~cellular response to DNA damage stimulus,GO:0007004~telomere maintenance via telomerase,GO:0034502~protein localization to chromosome,GO:0051321~meiotic cell cycle,GO:1990166~protein localization to site of double-strand break,	GO:0000781~chromosome, telomeric region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005662~DNA replication factor A complex,GO:0016605~PML body,GO:0035861~site of double-strand break,GO:0090734~site of DNA damage,	GO:0003677~DNA binding,GO:0003684~damaged DNA binding,GO:0003697~single-stranded DNA binding,GO:0005515~protein binding,GO:0043047~single-stranded telomeric DNA binding,GO:0046872~metal ion binding,GO:0098505~G-rich strand telomeric DNA binding,	IPR004365:NA-bd_OB_tRNA,IPR004591:Rfa1,IPR007199:Rep_factor-A_N,IPR012340:NA-bd_OB-fold,IPR013955:Rep_factor-A_C,IPR031657:REPA_OB_2,IPR047192:Euk_RPA1_DBD_C,	hsa03030:DNA replication,hsa03420:Nucleotide excision repair,hsa03430:Mismatch repair,hsa03440:Homologous recombination,hsa03460:Fanconi anemia pathway,	619767~Pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 6,			KW-0227~DNA damage,KW-0233~DNA recombination,KW-0234~DNA repair,KW-0235~DNA replication,	KW-0539~Nucleus,	KW-0225~Disease variant,	KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0013~ADP-ribosylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin); alternate,DNA_BIND:OB,DOMAIN:Replication factor A C-terminal,DOMAIN:Replication factor-A protein 1 N-terminal,DOMAIN:Replication protein A OB,MUTAGEN:C->S: Loss of function in DNA replication and mismatch repair without effect on DNA-binding activity; when associated with S-500.,MUTAGEN:C->S: Loss of function in DNA replication and mismatch repair without effect on DNA-binding activity; when associated with S-503.,MUTAGEN:K->R: Significant reduction of sumoylation. Loss of sumoylation; when associated with R-577.,MUTAGEN:K->R: Slight sumoylation decrease. Loss of sumoylation; when associated with R-449.,MUTAGEN:R->E: Loss of HELB-binding; when associated with E-41.,MUTAGEN:R->E: Loss of HELB-binding; when associated with E-43.,REGION:Disordered,ZN_FING:C4-type,
RPA3	replication protein A3(RPA3)	Homo sapiens			GO:0000723~telomere maintenance,GO:0000724~double-strand break repair via homologous recombination,GO:0006260~DNA replication,GO:0006281~DNA repair,GO:0006284~base-excision repair,GO:0006289~nucleotide-excision repair,GO:0006298~mismatch repair,GO:0006310~DNA recombination,GO:0007346~regulation of mitotic cell cycle,GO:0042127~regulation of cell proliferation,	GO:0005654~nucleoplasm,GO:0005662~DNA replication factor A complex,GO:0031981~nuclear lumen,GO:0035861~site of double-strand break,	GO:0003677~DNA binding,GO:0003684~damaged DNA binding,GO:0003697~single-stranded DNA binding,GO:0005515~protein binding,	IPR012340:NA-bd_OB-fold,IPR013970:Rfa2,	hsa03030:DNA replication,hsa03420:Nucleotide excision repair,hsa03430:Mismatch repair,hsa03440:Homologous recombination,hsa03460:Fanconi anemia pathway,				KW-0227~DNA damage,KW-0233~DNA recombination,KW-0234~DNA repair,KW-0235~DNA replication,	KW-0539~Nucleus,					KW-0007~Acetylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),
RIF1	replication timing regulatory factor 1(RIF1)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0000723~telomere maintenance,GO:0006281~DNA repair,GO:0006974~cellular response to DNA damage stimulus,GO:0007049~cell cycle,GO:0031509~telomeric heterochromatin assembly,GO:0035019~somatic stem cell population maintenance,GO:0043247~telomere maintenance in response to DNA damage,GO:0045814~negative regulation of gene expression, epigenetic,GO:0045830~positive regulation of isotype switching,GO:1990830~cellular response to leukemia inhibitory factor,GO:2000042~negative regulation of double-strand break repair via homologous recombination,GO:2001034~positive regulation of double-strand break repair via nonhomologous end joining,	GO:0000781~chromosome, telomeric region,GO:0000785~chromatin,GO:0000793~condensed chromosome,GO:0001939~female pronucleus,GO:0001940~male pronucleus,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0031965~nuclear membrane,GO:0035861~site of double-strand break,GO:0051233~spindle midzone,	GO:0005515~protein binding,	IPR011989:ARM-like,IPR016024:ARM-type_fold,IPR022031:Rif1_N,	hsa04550:Signaling pathways regulating pluripotency of stem cells,				KW-0131~Cell cycle,KW-0227~DNA damage,KW-0234~DNA repair,	KW-0158~Chromosome,KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0779~Telomere,KW-0963~Cytoplasm,					KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Telomere-associated protein Rif1 N-terminal,REGION:Disordered,REGION:Interaction with ERCC6,REGION:Interaction with condensed chromosomes in telophase,
RCN2	reticulocalbin 2(RCN2)	Homo sapiens				GO:0005730~nucleolus,GO:0005783~endoplasmic reticulum,GO:0005788~endoplasmic reticulum lumen,	GO:0005509~calcium ion binding,GO:0005515~protein binding,	IPR002048:EF_hand_dom,IPR011992:EF-hand-dom_pair,IPR018247:EF_Hand_1_Ca_BS,				SM00054:EFh,		KW-0256~Endoplasmic reticulum,		KW-0677~Repeat,KW-0732~Signal,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-0597~Phosphoprotein,	DOMAIN:EF-hand,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,DOMAIN:EF-hand 3,DOMAIN:EF-hand 4,DOMAIN:EF-hand 5,DOMAIN:EF-hand 6,MOTIF:Prevents secretion from ER,
RTN3	reticulon 3(RTN3)	Homo sapiens			GO:0006915~apoptotic process,GO:0007420~brain development,GO:0016192~vesicle-mediated transport,GO:0030182~neuron differentiation,GO:0071786~endoplasmic reticulum tubular network organization,GO:0071787~endoplasmic reticulum tubular network formation,GO:1902430~negative regulation of beta-amyloid formation,	GO:0000139~Golgi membrane,GO:0005615~extracellular space,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0014069~postsynaptic density,GO:0043005~neuron projection,	GO:0005515~protein binding,	IPR003388:Reticulon,IPR046964:RTN1-4,	hsa05010:Alzheimer disease,				KW-0053~Apoptosis,KW-0346~Stress response,KW-0813~Transport,KW-0931~ER-Golgi transport,KW-0945~Host-virus interaction,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Reticulon,INTRAMEM:Helical,REGION:Disordered,REGION:Interaction with BACE1,REGION:Interaction with FADD,TOPO_DOM:Cytoplasmic,TRANSMEM:Helical,
RTN4	reticulon 4(RTN4)	Homo sapiens			GO:0001825~blastocyst formation,GO:0002523~leukocyte migration involved in inflammatory response,GO:0006915~apoptotic process,GO:0007029~endoplasmic reticulum organization,GO:0007413~axonal fasciculation,GO:0007420~brain development,GO:0010634~positive regulation of epithelial cell migration,GO:0021801~cerebral cortex radial glia guided migration,GO:0022009~central nervous system vasculogenesis,GO:0030182~neuron differentiation,GO:0030308~negative regulation of cell growth,GO:0030334~regulation of cell migration,GO:0030517~negative regulation of axon extension,GO:0033601~positive regulation of mammary gland epithelial cell proliferation,GO:0034165~positive regulation of toll-like receptor 9 signaling pathway,GO:0035022~positive regulation of Rac protein signal transduction,GO:0035441~cell migration involved in vasculogenesis,GO:0042981~regulation of apoptotic process,GO:0045766~positive regulation of angiogenesis,GO:0050804~modulation of synaptic transmission,GO:0050821~protein stabilization,GO:0051292~nuclear pore complex assembly,GO:0051897~positive regulation of protein kinase B signaling,GO:0060317~cardiac epithelial to mesenchymal transition,GO:0060907~positive regulation of macrophage cytokine production,GO:0061462~protein localization to lysosome,GO:0071456~cellular response to hypoxia,GO:0071786~endoplasmic reticulum tubular network organization,GO:0071787~endoplasmic reticulum tubular network formation,GO:0090156~cellular sphingolipid homeostasis,GO:1902430~negative regulation of beta-amyloid formation,GO:1902624~positive regulation of neutrophil migration,GO:1905523~positive regulation of macrophage migration,GO:1905552~positive regulation of protein localization to endoplasmic reticulum,GO:1905580~positive regulation of ERBB3 signaling pathway,GO:1905653~positive regulation of artery morphogenesis,GO:1990809~endoplasmic reticulum tubular network membrane organization,GO:2000172~regulation of branching morphogenesis of a nerve,GO:2000347~positive regulation of hepatocyte proliferation,GO:2001213~negative regulation of vasculogenesis,	GO:0005635~nuclear envelope,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0014069~postsynaptic density,GO:0030054~cell junction,GO:0043005~neuron projection,GO:0045202~synapse,GO:0070161~anchoring junction,GO:0071782~endoplasmic reticulum tubular network,GO:0098826~endoplasmic reticulum tubular network membrane,GO:0098978~glutamatergic synapse,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0031625~ubiquitin protein ligase binding,GO:0042803~protein homodimerization activity,GO:0045296~cadherin binding,GO:0046872~metal ion binding,	IPR003388:Reticulon,IPR046964:RTN1-4,	hsa05010:Alzheimer disease,				KW-0524~Neurogenesis,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0770~Synapse,KW-0965~Cell junction,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Reticulon,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
RARA	retinoic acid receptor alpha(RARA)	Homo sapiens		h_carm1Pathway:Transcription Regulation by Methyltransferase of CARM1,h_egfr_smrtePathway:Map Kinase Inactivation of SMRT Corepressor,h_nuclearRsPathway:Nuclear Receptors in Lipid Metabolism and Toxicity,h_pmlPathway:Regulation of transcriptional activity by PML,h_rarPathway:Degradation of the RAR and RXR by the proteasome,h_rarrxrPathway:Nuclear receptors coordinate the activities of chromatin remodeling complexes and coactivators to facilitate initiation of transcription in carcinoma cells,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001657~ureteric bud development,GO:0001843~neural tube closure,GO:0001889~liver development,GO:0002068~glandular epithelial cell development,GO:0003417~growth plate cartilage development,GO:0006468~protein phosphorylation,GO:0007281~germ cell development,GO:0007565~female pregnancy,GO:0008284~positive regulation of cell proliferation,GO:0008285~negative regulation of cell proliferation,GO:0009755~hormone-mediated signaling pathway,GO:0010628~positive regulation of gene expression,GO:0017148~negative regulation of translation,GO:0021766~hippocampus development,GO:0030154~cell differentiation,GO:0030850~prostate gland development,GO:0030852~regulation of granulocyte differentiation,GO:0030853~negative regulation of granulocyte differentiation,GO:0031076~embryonic camera-type eye development,GO:0031641~regulation of myelination,GO:0032355~response to estradiol,GO:0032526~response to retinoic acid,GO:0032689~negative regulation of interferon-gamma production,GO:0032720~negative regulation of tumor necrosis factor production,GO:0032736~positive regulation of interleukin-13 production,GO:0032753~positive regulation of interleukin-4 production,GO:0032754~positive regulation of interleukin-5 production,GO:0033189~response to vitamin A,GO:0034097~response to cytokine,GO:0035264~multicellular organism growth,GO:0042789~mRNA transcription from RNA polymerase II promoter,GO:0042981~regulation of apoptotic process,GO:0043277~apoptotic cell clearance,GO:0045471~response to ethanol,GO:0045596~negative regulation of cell differentiation,GO:0045630~positive regulation of T-helper 2 cell differentiation,GO:0045666~positive regulation of neuron differentiation,GO:0045787~positive regulation of cell cycle,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048167~regulation of synaptic plasticity,GO:0048384~retinoic acid receptor signaling pathway,GO:0051099~positive regulation of binding,GO:0055012~ventricular cardiac muscle cell differentiation,GO:0060010~Sertoli cell fate commitment,GO:0060173~limb development,GO:0060324~face development,GO:0060534~trachea cartilage development,GO:0060591~chondroblast differentiation,GO:0061037~negative regulation of cartilage development,GO:0071222~cellular response to lipopolysaccharide,GO:0071300~cellular response to retinoic acid,GO:0071391~cellular response to estrogen stimulus,GO:1901532~regulation of hematopoietic progenitor cell differentiation,GO:1902894~negative regulation of pri-miRNA transcription from RNA polymerase II promoter,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0015629~actin cytoskeleton,GO:0030425~dendrite,GO:0032991~macromolecular complex,GO:0048471~perinuclear region of cytoplasm,GO:0090575~RNA polymerase II transcription factor complex,	GO:0000900~translation repressor activity, nucleic acid binding,GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001217~bacterial-type RNA polymerase transcriptional repressor activity, sequence-specific DNA binding,GO:0001223~transcription coactivator binding,GO:0001972~retinoic acid binding,GO:0003682~chromatin binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0004879~RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding,GO:0005102~receptor binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0019899~enzyme binding,GO:0019904~protein domain specific binding,GO:0031490~chromatin DNA binding,GO:0042826~histone deacetylase binding,GO:0043422~protein kinase B binding,GO:0043565~sequence-specific DNA binding,GO:0044323~retinoic acid-responsive element binding,GO:0048027~mRNA 5'-UTR binding,GO:0051018~protein kinase A binding,GO:0051393~alpha-actinin binding,GO:1901363~heterocyclic compound binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000536:Nucl_hrmn_rcpt_lig-bd,IPR001628:Znf_hrmn_rcpt,IPR001723:Nuclear_hrmn_rcpt,IPR003078:Retinoic_acid_rcpt,IPR013088:Znf_NHR/GATA,IPR035500:NHR-like_dom_sf,IPR047158:NR_LBD_RAR,IPR047159:NR_DBD_RAR,	hsa04659:Th17 cell differentiation,hsa04915:Estrogen signaling pathway,hsa05200:Pathways in cancer,hsa05202:Transcriptional misregulation in cancer,hsa05221:Acute myeloid leukemia,	612376~Leukemia, acute promyelocytic,		SM00399:ZnF_C4,SM00430:HOLI,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0656~Proto-oncogene,	KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,KW-0675~Receptor,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO),DNA_BIND:Nuclear receptor,DOMAIN:NR LBD,DOMAIN:Nuclear receptor,MOTIF:9aaTAD,MUTAGEN:E->Q: Impairs interaction with ASXL1 and NCOA1; when associated with Q-412.,MUTAGEN:E->Q: Impairs interaction with ASXL1 and NCOA1; when associated with Q-415.,MUTAGEN:I->E: Abrogates interaction with NCOR1 or NCOR2. Increased affinity for NCOR1 and NCOR2 in the presence of BMS493. Increased transcriptional activity in the presence of agonist and decreased activity in the presence of neutral antagonist.,MUTAGEN:K->R: Abrogates sumoylation in the presence or absence of ATRA and primarily nuclear localization and enhanced ATRA-mediated transcriptional activity; when associated with R-166; R-171 and R-399.,MUTAGEN:K->R: Cytoplasmic in the absence of ATRA and reduced transcriptional activity in the presence of ATRA. Low sumoylation levels in the presence of ATRA; when associated with R-399. Nuclear localization and enhanced transcriptional activity; when associated with R-166 and R-399. Primarily nuclear localization and enhanced ATRA-mediated transcriptional activity; when associated with R-147; R-166 and R-399.,MUTAGEN:K->R: Cytoplasmic in the absence of ATRA and reduced transcriptional activity in the presence of ATRA. Low sumoylation levels in the presence of ATRA; when associated with R-399. Nuclear localization and enhanced transcriptional activity; when associated with R-171 and R-399. Primarily nuclear localization and enhanced ATRA-mediated transcriptional activity; when associated with R-147; R-171 and R-399.,MUTAGEN:K->R: In the absence of ATRA, abolishes sumoylation and is mainly nuclear. In the presence of ATRA, some sumoylation, cytoplasmic location, reduced transcriptional activity and no SENP6 binding. Low sumoylation levels in the presence of ATRA and nuclear location in the absence of ATRA; when associated with R-166 or with R-171. Primarily nuclear localization and enhanced ATRA-mediated transcriptional activity; when associated with R-147; R-166 and R-171.,MUTAGEN:LI->AA: Abolishes interaction with ASXL1 and NCOA1.,MUTAGEN:ML->AA: Abolishes interaction with ASXL1 and NCOA1.,MUTAGEN:S->A: Abolishes PKB/AKT1-mediated phosphorylation. Repressed transactivation.,MUTAGEN:S->A: No effect on PKB/AKT1-mediated phosphorylation. No repression of transactivation.,MUTAGEN:S->A: No effect on PKB/AKT1-mediated phosphorylation. Repressed transactivation.,MUTAGEN:S->A: No effect on heterodimerization with RARA. On ATRA treatment, localizes to the nucleus, and increased protein levels; when associated with A-219.,MUTAGEN:S->A: No effect on heterodimerization with RARA. On ATRA treatment, localizes to the nucleus, and increased protein levels; when associated with A-369.,MUTAGEN:S->E: No effect on heterodimerization with RARA. On ATRA treatment, localizes to both nucleus and cytoplasm, no increase in protein levels, and decrease in RARA-mediated transcriptional activity; when associated with E-369.,MUTAGEN:S->E: Some inhibition of heterodimerization with RARA. On ATRA treatment, localizes to both nucleus and cytoplasm, increase in protein levels, and decrease in RARA-mediated transcriptional activity; when associated with E-219.,REGION:Disordered,REGION:Hinge,REGION:Modulating,REGION:Required for binding corepressor NCOR1,SITE:Breakpoint for translocation to form PLZF-RAR-alpha, RAR-alpha1-PLZF and PML-RAR-alpha oncogenes,ZN_FING:NR C4-type,
RDH11	retinol dehydrogenase 11(RDH11)	Homo sapiens			GO:0001523~retinoid metabolic process,GO:0007601~visual perception,GO:0016062~adaptation of rhodopsin mediated signaling,GO:0042572~retinol metabolic process,GO:0042574~retinal metabolic process,	GO:0001917~photoreceptor inner segment,GO:0005789~endoplasmic reticulum membrane,	GO:0004745~retinol dehydrogenase activity,GO:0005515~protein binding,GO:0016616~oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor,GO:0033721~aldehyde dehydrogenase (NADP+) activity,GO:0052650~NADP-retinol dehydrogenase activity,	IPR002347:SDR_fam,IPR036291:NAD(P)-bd_dom_sf,	hsa00830:Retinol metabolism,hsa01100:Metabolic pathways,hsa01240:Biosynthesis of cofactors,	616108~Retinal dystrophy, juvenile cataracts, and short stature syndrome,			KW-0443~Lipid metabolism,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,	KW-0242~Dwarfism,KW-0898~Cataract,	KW-0732~Signal,KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0521~NADP,	KW-0560~Oxidoreductase,	KW-0007~Acetylation,	ACT_SITE:Proton acceptor,REGION:Disordered,TOPO_DOM:Cytoplasmic,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
RNASEH2C	ribonuclease H2 subunit C(RNASEH2C)	Homo sapiens			GO:0006298~mismatch repair,GO:0006401~RNA catabolic process,	GO:0005634~nucleus,GO:0032299~ribonuclease H2 complex,	GO:0005515~protein binding,	IPR013924:RNase_H2_suC,	hsa03030:DNA replication,	610329~Aicardi-Goutieres syndrome 3,				KW-0539~Nucleus,	KW-0225~Disease variant,KW-0948~Aicardi-Goutieres syndrome,				KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,REGION:Disordered,
RPP21	ribonuclease P/MRP subunit p21(RPP21)	Homo sapiens			GO:0001682~tRNA 5'-leader removal,GO:0008033~tRNA processing,GO:0009410~response to xenobiotic stimulus,GO:0034470~ncRNA processing,	GO:0005654~nucleoplasm,GO:0005655~nucleolar ribonuclease P complex,GO:0030681~multimeric ribonuclease P complex,GO:1902555~endoribonuclease complex,GO:1990904~ribonucleoprotein complex,	GO:0004526~ribonuclease P activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0033204~ribonuclease P RNA binding,GO:0046872~metal ion binding,	IPR000315:Znf_B-box,IPR001841:Znf_RING,IPR001870:B30.2/SPRY,IPR003879:Butyrophylin_SPRY,IPR006574:PRY,IPR007175:Rpr2/Snm1/Rpp21,IPR013083:Znf_RING/FYVE/PHD,IPR013320:ConA-like_dom_sf,IPR017907:Znf_RING_CS,IPR043136:B30.2/SPRY_sf,				SM00184:RING,SM00336:BBOX,SM00589:PRY,	KW-0819~tRNA processing,	KW-0539~Nucleus,		KW-0175~Coiled coil,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0694~RNA-binding,	KW-0007~Acetylation,	COMPBIAS:Polar residues,DOMAIN:B box-type,DOMAIN:B30.2/SPRY,DOMAIN:RING-type,REGION:Disordered,
RNASET2	ribonuclease T2(RNASET2)	Homo sapiens			GO:0006401~RNA catabolic process,GO:0045087~innate immune response,GO:0071704~organic substance metabolic process,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005758~mitochondrial intermembrane space,GO:0005764~lysosome,GO:0005788~endoplasmic reticulum lumen,GO:0035578~azurophil granule lumen,GO:0043202~lysosomal lumen,GO:0070062~extracellular exosome,	GO:0003723~RNA binding,GO:0004521~endoribonuclease activity,GO:0004540~ribonuclease activity,GO:0033897~ribonuclease T2 activity,	IPR001568:RNase_T2-like,IPR018188:RNase_T2_His_AS_1,IPR033130:RNase_T2_His_AS_2,IPR033697:Ribonuclease_T2_eukaryotic,IPR036430:RNase_T2-like_sf,		612951~Leukoencephalopathy, cystic, without megalencephaly,			KW-0391~Immunity,KW-0399~Innate immunity,	KW-0256~Endoplasmic reticulum,KW-0458~Lysosome,KW-0496~Mitochondrion,KW-0964~Secreted,	KW-0225~Disease variant,	KW-0732~Signal,		KW-0255~Endonuclease,KW-0378~Hydrolase,KW-0456~Lyase,KW-0540~Nuclease,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,MUTAGEN:H->Y: Abolishes the effect on degradation of mitochondrion-associated cytosolic rRNAs.,
RAE1	ribonucleic acid export 1(RAE1)	Homo sapiens			GO:0000972~transcription-dependent tethering of RNA polymerase II gene DNA at nuclear periphery,GO:0006405~RNA export from nucleus,GO:0006406~mRNA export from nucleus,GO:0006913~nucleocytoplasmic transport,GO:0007049~cell cycle,GO:0051301~cell division,GO:0060236~regulation of mitotic spindle organization,GO:0071407~cellular response to organic cyclic compound,	GO:0001650~fibrillar center,GO:0005634~nucleus,GO:0005635~nuclear envelope,GO:0005643~nuclear pore,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0097431~mitotic spindle pole,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0008017~microtubule binding,GO:0043130~ubiquitin binding,	IPR001680:WD40_rpt,IPR015943:WD40/YVTN_repeat-like_dom_sf,IPR019775:WD40_repeat_CS,IPR020472:G-protein_beta_WD-40_rep,IPR036322:WD40_repeat_dom_sf,	hsa03013:Nucleocytoplasmic transport,hsa05014:Amyotrophic lateral sclerosis,hsa05164:Influenza A,			SM00320:WD40,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,KW-0813~Transport,KW-0945~Host-virus interaction,	KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0732~Signal,KW-0853~WD repeat,			KW-0597~Phosphoprotein,	REGION:Disordered,REPEAT:WD,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,REPEAT:WD 7,
RPN1	ribophorin I(RPN1)	Homo sapiens			GO:0006486~protein glycosylation,GO:0006487~protein N-linked glycosylation,GO:0018279~protein N-linked glycosylation via asparagine,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005791~rough endoplasmic reticulum,GO:0005829~cytosol,GO:0008250~oligosaccharyltransferase complex,GO:0016020~membrane,GO:0042470~melanosome,	GO:0003723~RNA binding,GO:0004579~dolichyl-diphosphooligosaccharide-protein glycotransferase activity,GO:0005515~protein binding,GO:0016740~transferase activity,	IPR007676:Ribophorin_I,	hsa00510:N-Glycan biosynthesis,hsa00513:Various types of N-glycan biosynthesis,hsa01100:Metabolic pathways,hsa04141:Protein processing in endoplasmic reticulum,					KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0175~Coiled coil,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0808~Transferase,	KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
RPN2	ribophorin II(RPN2)	Homo sapiens			GO:0006487~protein N-linked glycosylation,GO:0018279~protein N-linked glycosylation via asparagine,GO:0036211~protein modification process,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0008250~oligosaccharyltransferase complex,GO:0016020~membrane,GO:0016604~nuclear body,	GO:0004579~dolichyl-diphosphooligosaccharide-protein glycotransferase activity,GO:0005515~protein binding,	IPR008814:Swp1,	hsa00510:N-Glycan biosynthesis,hsa00513:Various types of N-glycan biosynthesis,hsa01100:Metabolic pathways,hsa04141:Protein processing in endoplasmic reticulum,					KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
RSL24D1	ribosomal L24 domain containing 1(RSL24D1)	Homo sapiens			GO:0006412~translation,GO:0042273~ribosomal large subunit biogenesis,	GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005840~ribosome,	GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,	IPR000988:Ribosomal_eL24-rel,IPR011017:TRASH_dom,IPR023438:Ribosomal_eL24,IPR023442:Ribosomal_eL24_CS,IPR038630:L24e/L24_sf,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,			SM00746:TRASH,	KW-0690~Ribosome biogenesis,	KW-0539~Nucleus,						DOMAIN:TRASH,
RRP7A	ribosomal RNA processing 7 homolog A(RRP7A)	Homo sapiens			GO:0000028~ribosomal small subunit assembly,GO:0001825~blastocyst formation,GO:0006364~rRNA processing,GO:0042254~ribosome biogenesis,GO:0042274~ribosomal small subunit biogenesis,GO:0061523~cilium disassembly,GO:1902570~protein localization to nucleolus,	GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005929~cilium,GO:0032040~small-subunit processome,GO:0032545~CURI complex,GO:0034456~UTP-C complex,	GO:0003723~RNA binding,GO:0005515~protein binding,	IPR012677:Nucleotide-bd_a/b_plait_sf,IPR024326:RRP7_C,IPR034890:Rrp7A_RRM,IPR035979:RBD_domain_sf,IPR040446:RRP7,IPR040447:RRM_Rrp7,	hsa03008:Ribosome biogenesis in eukaryotes,	619453~Microcephaly 28, primary, autosomal recessive,				KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0966~Cell projection,	KW-0225~Disease variant,KW-0905~Primary microcephaly,KW-0991~Intellectual disability,			KW-0694~RNA-binding,	KW-0597~Phosphoprotein,	DOMAIN:RRM,
RPL10	ribosomal protein L10(RPL10)	Homo sapiens			GO:0000027~ribosomal large subunit assembly,GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0002181~cytoplasmic translation,GO:0006412~translation,GO:0006417~regulation of translation,GO:0043066~negative regulation of apoptotic process,GO:1990403~embryonic brain development,	GO:0005634~nucleus,GO:0005783~endoplasmic reticulum,GO:0005790~smooth endoplasmic reticulum,GO:0005829~cytosol,GO:0005840~ribosome,GO:0015934~large ribosomal subunit,GO:0016020~membrane,GO:0022625~cytosolic large ribosomal subunit,GO:0022626~cytosolic ribosome,GO:0032991~macromolecular complex,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,GO:0045182~translation regulator activity,	IPR001197:Ribosomal_uL16_euk_arch,IPR016180:Ribosomal_uL16_dom,IPR018255:Ribosomal_uL16_CS_euk_arc,IPR036920:Ribosomal_uL16_sf,IPR047873:Ribosomal_uL16,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,	300847~Autism, susceptibility to, X-linked 5,300998~Intellectual developmental disorder, X-linked syndromic 35,	PIRSF005590:Ribosomal_L10,		KW-0810~Translation regulation,	KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0991~Intellectual disability,KW-1268~Autism spectrum disorder,KW-1269~Autism,			KW-0217~Developmental protein,KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,KW-9996~Developmental protein,	KW-0164~Citrullination,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),REGION:Disordered,
RPL10A	ribosomal protein L10a(RPL10A)	Homo sapiens			GO:0000470~maturation of LSU-rRNA,GO:0002181~cytoplasmic translation,GO:0006412~translation,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005925~focal adhesion,GO:0015934~large ribosomal subunit,GO:0016020~membrane,GO:0022625~cytosolic large ribosomal subunit,GO:0022626~cytosolic ribosome,GO:0042788~polysomal ribosome,GO:0070062~extracellular exosome,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,	IPR002143:Ribosomal_uL1,IPR016095:Ribosomal_uL1_3-a/b-sand,IPR023673:Ribosomal_uL1_CS,IPR023674:Ribosomal_uL1-like,IPR028364:Ribosomal_uL1/biogenesis,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,		PIRSF002155:Ribosomal_L1,			KW-0963~Cytoplasm,				KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,
RPL11	ribosomal protein L11(RPL11)	Homo sapiens			GO:0000027~ribosomal large subunit assembly,GO:0002181~cytoplasmic translation,GO:0006364~rRNA processing,GO:0006412~translation,GO:0006605~protein targeting,GO:0010628~positive regulation of gene expression,GO:0032092~positive regulation of protein binding,GO:0032435~negative regulation of proteasomal ubiquitin-dependent protein catabolic process,GO:0034504~protein localization to nucleus,GO:0042273~ribosomal large subunit biogenesis,GO:0050821~protein stabilization,GO:1901796~regulation of signal transduction by p53 class mediator,GO:1901798~positive regulation of signal transduction by p53 class mediator,GO:1902255~positive regulation of intrinsic apoptotic signaling pathway by p53 class mediator,GO:1904667~negative regulation of ubiquitin protein ligase activity,GO:2000059~negative regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process,GO:2000435~negative regulation of protein neddylation,	GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005840~ribosome,GO:0016020~membrane,GO:0022625~cytosolic large ribosomal subunit,GO:0022626~cytosolic ribosome,GO:0032991~macromolecular complex,GO:0042788~polysomal ribosome,GO:0070062~extracellular exosome,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,GO:0008097~5S rRNA binding,GO:0031625~ubiquitin protein ligase binding,GO:1990948~ubiquitin ligase inhibitor activity,	IPR002132:Ribosomal_uL5,IPR020929:Ribosomal_uL5_CS,IPR022803:Ribosomal_uL5_dom_sf,IPR031309:Ribosomal_uL5_C,IPR031310:Ribosomal_uL5_N,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,	612562~Diamond-Blackfan anemia 7,	PIRSF002161:Ribosomal_L5,			KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-1024~Diamond-Blackfan anemia,			KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,KW-0694~RNA-binding,KW-0699~rRNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:Large ribosomal subunit protein uL5 C-terminal,DOMAIN:Large ribosomal subunit protein uL5 N-terminal,
RPL12	ribosomal protein L12(RPL12)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0006412~translation,	GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005840~ribosome,GO:0005925~focal adhesion,GO:0014069~postsynaptic density,GO:0016020~membrane,GO:0022625~cytosolic large ribosomal subunit,GO:0022626~cytosolic ribosome,GO:0070062~extracellular exosome,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,GO:0070180~large ribosomal subunit rRNA binding,	IPR000911:Ribosomal_uL11,IPR020783:Ribosomal_uL11_C,IPR020784:Ribosomal_uL11_N,IPR020785:Ribosomal_uL11_CS,IPR036769:Ribosomal_uL11_C_sf,IPR036796:Ribosomal_uL11_N_sf,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,			SM00649:RL11,						KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:Large ribosomal subunit protein uL11 C-terminal,DOMAIN:Large ribosomal subunit protein uL11 N-terminal,
RPL13	ribosomal protein L13(RPL13)	Homo sapiens			GO:0001824~blastocyst development,GO:0002181~cytoplasmic translation,GO:0006412~translation,GO:0060348~bone development,	GO:0005634~nucleus,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0005840~ribosome,GO:0016020~membrane,GO:0022625~cytosolic large ribosomal subunit,GO:0022626~cytosolic ribosome,GO:0045202~synapse,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,	IPR001380:Ribosomal_eL13,IPR018256:Ribosomal_eL13_CS,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,	618728~Spondyloepimetaphyseal dysplasia, Isidor-Toutain type,				KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0242~Dwarfism,			KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,REGION:Disordered,
RPL13A	ribosomal protein L13a(RPL13A)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0006412~translation,GO:0006417~regulation of translation,GO:0017148~negative regulation of translation,GO:0032496~response to lipopolysaccharide,GO:0042592~homeostatic process,GO:0048246~macrophage chemotaxis,GO:0060425~lung morphogenesis,GO:0071346~cellular response to interferon-gamma,GO:1901194~negative regulation of formation of translation preinitiation complex,	GO:0005634~nucleus,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005840~ribosome,GO:0005925~focal adhesion,GO:0015934~large ribosomal subunit,GO:0016020~membrane,GO:0022625~cytosolic large ribosomal subunit,GO:0022626~cytosolic ribosome,GO:0045202~synapse,GO:0097452~GAIT complex,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0003735~structural constituent of ribosome,	IPR005755:Ribosomal_uL13_euk/arc,IPR005822:Ribosomal_uL13,IPR023563:Ribosomal_uL13_CS,IPR036899:Ribosomal_uL13_sf,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,				KW-0810~Translation regulation,	KW-0963~Cytoplasm,				KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0007~Acetylation,KW-0164~Citrullination,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,MUTAGEN:S->A: Loss of interferon-gamma induced phosphorylation.,REGION:Disordered,
RPL14	ribosomal protein L14(RPL14)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0006364~rRNA processing,GO:0006412~translation,GO:0042273~ribosomal large subunit biogenesis,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005840~ribosome,GO:0014069~postsynaptic density,GO:0016020~membrane,GO:0022625~cytosolic large ribosomal subunit,GO:0022626~cytosolic ribosome,GO:0070062~extracellular exosome,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,GO:0045296~cadherin binding,	IPR002784:Ribosomal_eL14_dom,IPR005824:KOW,IPR008991:Translation_prot_SH3-like_sf,IPR014722:Rib_uL2_dom2,IPR039660:Ribosomal_eL14,IPR041985:Ribosomal_eL14_KOW,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,					KW-0963~Cytoplasm,		KW-0677~Repeat,		KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:KOW,DOMAIN:Large ribosomal subunit protein eL14,REGION:2 X 3 AA tandem repeats of K-[GA]-Q,REGION:4 X 5 AA tandem repeats of Q-K-A-[PAS]-X,REGION:Disordered,REPEAT:1-1,REPEAT:1-2,REPEAT:1-3,REPEAT:1-4,REPEAT:2-1,REPEAT:2-2,
RPL15	ribosomal protein L15(RPL15)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0006412~translation,GO:0045471~response to ethanol,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005840~ribosome,GO:0022625~cytosolic large ribosomal subunit,GO:0022626~cytosolic ribosome,GO:0031672~A band,GO:0044391~ribosomal subunit,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,GO:0045296~cadherin binding,	IPR000439:Ribosomal_eL15,IPR012678:Ribosomal_uL23/eL15/eS24_sf,IPR020925:Ribosomal_eL15_CS,IPR024794:Rbsml_eL15_core_dom_sf,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,	615550~Diamond-Blackfan anemia 12,		SM01384:Ribosomal_L15e,		KW-0963~Cytoplasm,	KW-1024~Diamond-Blackfan anemia,			KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0449~Lipoprotein,KW-0519~Myristate,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),LIPID:N-myristoyl glycine,REGION:Disordered,
RPL17	ribosomal protein L17(RPL17)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0006412~translation,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0015934~large ribosomal subunit,GO:0022625~cytosolic large ribosomal subunit,GO:0022626~cytosolic ribosome,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,	IPR001063:Ribosomal_uL22,IPR005721:Ribosomal_uL22_euk/arc,IPR018260:Ribosomal_uL22_CS,IPR036394:Ribosomal_uL22_sf,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,					KW-0963~Cytoplasm,				KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,		COMPBIAS:Basic residues,REGION:Disordered,
RPL18	ribosomal protein L18(RPL18)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0006412~translation,	GO:0005634~nucleus,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005791~rough endoplasmic reticulum,GO:0005829~cytosol,GO:0005840~ribosome,GO:0005925~focal adhesion,GO:0016020~membrane,GO:0022625~cytosolic large ribosomal subunit,GO:0022626~cytosolic ribosome,GO:0042788~polysomal ribosome,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,	IPR000039:Ribosomal_eL18,IPR021131:Ribosomal_uL15/eL18,IPR021132:Ribosomal_eL18/eL18-A/B/_CS,IPR036227:Ribosomal_uL15/eL18_sf,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,	618310~Diamond-Blackfan anemia 18,				KW-0256~Endoplasmic reticulum,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-1024~Diamond-Blackfan anemia,			KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Large ribosomal subunit protein uL15/eL18,REGION:Disordered,
RPL18A	ribosomal protein L18a(RPL18A)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0006412~translation,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005840~ribosome,GO:0016020~membrane,GO:0022625~cytosolic large ribosomal subunit,GO:0022626~cytosolic ribosome,GO:0042788~polysomal ribosome,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,	IPR021138:Ribosomal_eL20_eukaryotes,IPR023573:Ribosomal_eL20_dom,IPR028877:Ribosomal_eL20,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,		PIRSF002190:Ribosomal_L18a,			KW-0963~Cytoplasm,				KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Large ribosomal subunit protein eL20,
RPL19	ribosomal protein L19(RPL19)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0006412~translation,	GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005925~focal adhesion,GO:0016020~membrane,GO:0022625~cytosolic large ribosomal subunit,GO:0022626~cytosolic ribosome,GO:0042788~polysomal ribosome,GO:0045202~synapse,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,	IPR000196:Ribosomal_eL19_dom,IPR015972:Ribosomal_eL19_dom1,IPR023638:Ribosomal_eL19_CS,IPR033935:Ribosomal_eL19_euk,IPR035970:60S_ribosomal_eL19_sf,IPR039547:Ribosomal_eL19,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,			SM01416:Ribosomal_L19e,		KW-0963~Cytoplasm,				KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0164~Citrullination,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1),DOMAIN:Large ribosomal subunit protein eL19,REGION:Disordered,
RPL21	ribosomal protein L21(RPL21)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0006412~translation,	GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0005840~ribosome,GO:0016020~membrane,GO:0022625~cytosolic large ribosomal subunit,GO:0022626~cytosolic ribosome,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,	IPR001147:Ribosomal_eL21,IPR008991:Translation_prot_SH3-like_sf,IPR018259:Ribosomal_eL21_CS,IPR036948:Ribosomal_eL21_sf,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,	615885~Hypotrichosis 12,				KW-0256~Endoplasmic reticulum,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-1063~Hypotrichosis,			KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,		REGION:Disordered,
RPL22L1	ribosomal protein L22 like 1(RPL22L1)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0006412~translation,	GO:0005840~ribosome,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,	IPR002671:Ribosomal_eL22,IPR038526:Ribosomal_eL22_sf,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,									KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0597~Phosphoprotein,
RPL23	ribosomal protein L23(RPL23)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0002181~cytoplasmic translation,GO:0006412~translation,GO:0006610~ribosomal protein import into nucleus,GO:0008284~positive regulation of cell proliferation,GO:0010628~positive regulation of gene expression,GO:0032986~protein-DNA complex disassembly,GO:0050821~protein stabilization,GO:0070314~G1 to G0 transition,GO:0072717~cellular response to actinomycin D,GO:1901798~positive regulation of signal transduction by p53 class mediator,GO:1903450~regulation of G1 to G0 transition,GO:1904667~negative regulation of ubiquitin protein ligase activity,GO:2000059~negative regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process,	GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005840~ribosome,GO:0005925~focal adhesion,GO:0016020~membrane,GO:0022625~cytosolic large ribosomal subunit,GO:0022626~cytosolic ribosome,GO:0032991~macromolecular complex,GO:0045202~synapse,GO:0070062~extracellular exosome,GO:1990904~ribonucleoprotein complex,	GO:0001223~transcription coactivator binding,GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,GO:0031625~ubiquitin protein ligase binding,GO:0070180~large ribosomal subunit rRNA binding,GO:1990948~ubiquitin ligase inhibitor activity,	IPR000218:Ribosomal_uL14,IPR019972:Ribosomal_uL14_CS,IPR036853:Ribosomal_uL14_sf,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,			SM01374:Ribosomal_L14,		KW-0963~Cytoplasm,				KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0597~Phosphoprotein,
RPL23A	ribosomal protein L23a(RPL23A)	Homo sapiens			GO:0000027~ribosomal large subunit assembly,GO:0002181~cytoplasmic translation,GO:0006412~translation,	GO:0005634~nucleus,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0022625~cytosolic large ribosomal subunit,GO:0022626~cytosolic ribosome,GO:0044391~ribosomal subunit,GO:0045202~synapse,GO:0070062~extracellular exosome,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,GO:0019843~rRNA binding,GO:0045296~cadherin binding,GO:1904841~TORC2 complex binding,	IPR001014:Ribosomal_uL23_CS,IPR005633:Ribosomal_uL23_N,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR012678:Ribosomal_uL23/eL15/eS24_sf,IPR013025:Ribosomal_uL23-like,IPR019985:Ribosomal_uL23,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,					KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,KW-0694~RNA-binding,KW-0699~rRNA-binding,	KW-0007~Acetylation,KW-0164~Citrullination,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Large ribosomal subunit protein uL23 N-terminal,REGION:Beta-like import receptor binding (BIB) domain,REGION:Disordered,
RPL24	ribosomal protein L24(RPL24)	Homo sapiens			GO:0000027~ribosomal large subunit assembly,GO:0002181~cytoplasmic translation,GO:0006412~translation,GO:0010458~exit from mitosis,GO:0021554~optic nerve development,GO:0031290~retinal ganglion cell axon guidance,GO:0060041~retina development in camera-type eye,	GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0005840~ribosome,GO:0016020~membrane,GO:0022625~cytosolic large ribosomal subunit,GO:0022626~cytosolic ribosome,GO:0042788~polysomal ribosome,GO:0045202~synapse,GO:0070062~extracellular exosome,	GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,GO:0045296~cadherin binding,	IPR000988:Ribosomal_eL24-rel,IPR011017:TRASH_dom,IPR023442:Ribosomal_eL24_CS,IPR038630:L24e/L24_sf,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,			SM00746:TRASH,		KW-0963~Cytoplasm,				KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0007~Acetylation,KW-0013~ADP-ribosylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:TRASH,MUTAGEN:E->Q: Abolished mono-ADP-ribosylation by PARP16, leading to increased protein synthesis.,REGION:Disordered,
RPL26	ribosomal protein L26(RPL26)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0006364~rRNA processing,GO:0006412~translation,GO:0006977~DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest,GO:0034644~cellular response to UV,GO:0042273~ribosomal large subunit biogenesis,GO:0045727~positive regulation of translation,GO:0071480~cellular response to gamma radiation,GO:1902164~positive regulation of DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator,GO:1902167~positive regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator,GO:1904803~regulation of translation involved in cellular response to UV,	GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0015934~large ribosomal subunit,GO:0016020~membrane,GO:0022625~cytosolic large ribosomal subunit,GO:0022626~cytosolic ribosome,GO:0045202~synapse,GO:0070062~extracellular exosome,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,GO:0048027~mRNA 5'-UTR binding,	IPR005756:Ribosomal_uL24_euk/arc,IPR005824:KOW,IPR005825:Ribosomal_uL24_CS,IPR008991:Translation_prot_SH3-like_sf,IPR014722:Rib_uL2_dom2,IPR041988:Ribosomal_uL24_KOW,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,	614900~Diamond-Blackfan anemia 11,		SM00739:KOW,		KW-0963~Cytoplasm,	KW-1024~Diamond-Blackfan anemia,			KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:KOW,REGION:Disordered,
RPL27	ribosomal protein L27(RPL27)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0006364~rRNA processing,GO:0006412~translation,GO:1904044~response to aldosterone,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005791~rough endoplasmic reticulum,GO:0005829~cytosol,GO:0005840~ribosome,GO:0005925~focal adhesion,GO:0016020~membrane,GO:0022625~cytosolic large ribosomal subunit,GO:0022626~cytosolic ribosome,GO:0045202~synapse,GO:0070062~extracellular exosome,GO:0098556~cytoplasmic side of rough endoplasmic reticulum membrane,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,	IPR001141:Ribosomal_eL27,IPR005824:KOW,IPR008991:Translation_prot_SH3-like_sf,IPR018262:Ribosomal_eL27_CS,IPR038655:Ribosomal_eL27_sf,IPR041991:Ribosomal_eL27_KOW,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,	617408~Diamond-Blackfan anemia 16,		SM00739:KOW,		KW-0256~Endoplasmic reticulum,KW-0963~Cytoplasm,	KW-1024~Diamond-Blackfan anemia,			KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0007~Acetylation,	DOMAIN:KOW,
RPL27A	ribosomal protein L27a(RPL27A)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0006412~translation,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0005840~ribosome,GO:0015934~large ribosomal subunit,GO:0016020~membrane,GO:0022625~cytosolic large ribosomal subunit,GO:0022626~cytosolic ribosome,GO:0045202~synapse,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,	IPR001196:Ribosomal_uL15_CS,IPR021131:Ribosomal_uL15/eL18,IPR027386:Rbsml_uL15_N,IPR030878:Ribosomal_uL15,IPR036227:Ribosomal_uL15/eL18_sf,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,					KW-0963~Cytoplasm,				KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0007~Acetylation,KW-0379~Hydroxylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic residues,DOMAIN:Large ribosomal subunit protein uL15/eL18,REGION:Disordered,
RPL28	ribosomal protein L28(RPL28)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0006412~translation,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005840~ribosome,GO:0016020~membrane,GO:0022625~cytosolic large ribosomal subunit,GO:0022626~cytosolic ribosome,GO:0030425~dendrite,GO:0036464~cytoplasmic ribonucleoprotein granule,GO:0044297~cell body,GO:0045202~synapse,GO:0070062~extracellular exosome,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,	IPR002672:Ribosomal_eL28,IPR029004:Ribosomal_eL28/Mak16,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,					KW-0963~Cytoplasm,				KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Ribosomal eL28/Mak16,REGION:Disordered,
RPL29	ribosomal protein L29(RPL29)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0006412~translation,GO:0007566~embryo implantation,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005840~ribosome,GO:0016020~membrane,GO:0022625~cytosolic large ribosomal subunit,GO:0022626~cytosolic ribosome,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0008201~heparin binding,GO:0045296~cadherin binding,	IPR002673:Ribosomal_eL29,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,					KW-0963~Cytoplasm,		KW-0677~Repeat,		KW-0358~Heparin-binding,KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,REGION:Disordered,
RPL3	ribosomal protein L3(RPL3)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0006412~translation,GO:0071353~cellular response to interleukin-4,	GO:0005634~nucleus,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005840~ribosome,GO:0005925~focal adhesion,GO:0022625~cytosolic large ribosomal subunit,GO:0022626~cytosolic ribosome,GO:0032991~macromolecular complex,GO:0070062~extracellular exosome,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,	IPR000597:Ribosomal_uL3,IPR009000:Transl_B-barrel_sf,IPR019926:Ribosomal_uL3_CS,IPR044892:Ribosomal_L3_dom_3_arc_sf,IPR045077:L3_arc_euk,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,					KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,MUTAGEN:RGLR->AGLA: No effect on methylation by METTL18.,REGION:Disordered,
RPL30	ribosomal protein L30(RPL30)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0006412~translation,GO:0031640~killing of cells of other organism,GO:0050829~defense response to Gram-negative bacterium,GO:0061844~antimicrobial humoral immune response mediated by antimicrobial peptide,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005840~ribosome,GO:0005925~focal adhesion,GO:0014069~postsynaptic density,GO:0016020~membrane,GO:0022625~cytosolic large ribosomal subunit,GO:0022626~cytosolic ribosome,GO:0042788~polysomal ribosome,GO:0070062~extracellular exosome,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,	IPR000231:Ribosomal_eL30,IPR004038:Ribosomal_eL8/eL30/eS12/Gad45,IPR022991:Ribosomal_eL30_CS,IPR029064:Ribosomal_eL30-like_sf,IPR039109:Ribosomal_eL30-like,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,					KW-0963~Cytoplasm,				KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:Ribosomal protein eL8/eL30/eS12/Gadd45,
RPL31	ribosomal protein L31(RPL31)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0006412~translation,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005840~ribosome,GO:0005925~focal adhesion,GO:0016020~membrane,GO:0022625~cytosolic large ribosomal subunit,GO:0022626~cytosolic ribosome,GO:0042788~polysomal ribosome,GO:0070062~extracellular exosome,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,	IPR000054:Ribosomal_eL31,IPR020052:Ribosomal_eL31_CS,IPR023621:Ribosomal_eL31_dom_sf,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,			SM01380:Ribosomal_L31e,		KW-0963~Cytoplasm,				KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,
RPL32	ribosomal protein L32(RPL32)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0006412~translation,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005840~ribosome,GO:0016020~membrane,GO:0022625~cytosolic large ribosomal subunit,GO:0022626~cytosolic ribosome,GO:0042788~polysomal ribosome,GO:0045202~synapse,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,	IPR001515:Ribosomal_eL32,IPR018263:Ribosomal_eL32_CS,IPR036351:Ribosomal_eL32_sf,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,			SM01393:Ribosomal_L32e,		KW-0963~Cytoplasm,				KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),
RPL34	ribosomal protein L34(RPL34)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0006412~translation,	GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0022625~cytosolic large ribosomal subunit,GO:0022626~cytosolic ribosome,GO:0045202~synapse,GO:0070062~extracellular exosome,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,GO:0045296~cadherin binding,	IPR008195:Ribosomal_eL34,IPR018065:Ribosomal_eL34_CS,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,					KW-0256~Endoplasmic reticulum,KW-0963~Cytoplasm,				KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),
RPL35	ribosomal protein L35(RPL35)	Homo sapiens			GO:0000463~maturation of LSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA),GO:0002181~cytoplasmic translation,GO:0006412~translation,	GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016020~membrane,GO:0022625~cytosolic large ribosomal subunit,GO:0022626~cytosolic ribosome,	GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0003735~structural constituent of ribosome,	IPR001854:Ribosomal_uL29,IPR018254:Ribosomal_uL29_CS,IPR036049:Ribosomal_uL29_sf,IPR045059:Ribosomal_uL29_euk,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,	618312~Diamond-Blackfan anemia 19,				KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-1024~Diamond-Blackfan anemia,			KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),REGION:Disordered,
RPL35A	ribosomal protein L35a(RPL35A)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0006364~rRNA processing,GO:0006412~translation,GO:0042273~ribosomal large subunit biogenesis,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005840~ribosome,GO:0016020~membrane,GO:0022625~cytosolic large ribosomal subunit,GO:0022626~cytosolic ribosome,GO:0045202~synapse,GO:0070062~extracellular exosome,GO:1990904~ribonucleoprotein complex,	GO:0000049~tRNA binding,GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,	IPR001780:Ribosomal_eL33,IPR009000:Transl_B-barrel_sf,IPR018266:Ribosomal_eL33_CS,IPR038661:Ribosomal_eL33_sf,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,	612528~Diamond-Blackfan anemia 5,				KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-1024~Diamond-Blackfan anemia,			KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,KW-0694~RNA-binding,KW-0820~tRNA-binding,	KW-0007~Acetylation,
RPL36	ribosomal protein L36(RPL36)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0006412~translation,	GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005840~ribosome,GO:0016020~membrane,GO:0022625~cytosolic large ribosomal subunit,GO:0022626~cytosolic ribosome,GO:0042788~polysomal ribosome,GO:0045202~synapse,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,	IPR000509:Ribosomal_eL36,IPR038097:Ribosomal_eL36_sf,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,					KW-0963~Cytoplasm,				KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0007~Acetylation,	REGION:Disordered,
RPL36AL	ribosomal protein L36a like(RPL36AL)	Homo sapiens			GO:0006412~translation,	GO:0005634~nucleus,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0005840~ribosome,GO:0005886~plasma membrane,GO:0022625~cytosolic large ribosomal subunit,GO:1990904~ribonucleoprotein complex,	GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,	IPR000552:Ribosomal_eL44,IPR011332:Ribosomal_zn-bd,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,					KW-0963~Cytoplasm,				KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0488~Methylation,	COMPBIAS:Basic and acidic residues,REGION:Disordered,
RPL36A	ribosomal protein L36a(RPL36A)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0006412~translation,	GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0005840~ribosome,GO:0005886~plasma membrane,GO:0022625~cytosolic large ribosomal subunit,GO:0022626~cytosolic ribosome,GO:0042788~polysomal ribosome,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,	IPR000552:Ribosomal_eL44,IPR011332:Ribosomal_zn-bd,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,					KW-0963~Cytoplasm,				KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,		COMPBIAS:Basic and acidic residues,REGION:Disordered,
RPL37	ribosomal protein L37(RPL37)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0006412~translation,GO:1901798~positive regulation of signal transduction by p53 class mediator,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0022625~cytosolic large ribosomal subunit,GO:0022626~cytosolic ribosome,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0019843~rRNA binding,GO:0046872~metal ion binding,GO:0097371~MDM2/MDM4 family protein binding,GO:1990948~ubiquitin ligase inhibitor activity,	IPR001569:Ribosomal_eL37,IPR011331:Ribosomal_eL37/eL43,IPR011332:Ribosomal_zn-bd,IPR018267:Ribosomal_eL37_CS,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,					KW-0963~Cytoplasm,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,KW-0694~RNA-binding,KW-0699~rRNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ZN_FING:C4-type,
RPL37A	ribosomal protein L37a(RPL37A)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0006412~translation,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005925~focal adhesion,GO:0022625~cytosolic large ribosomal subunit,GO:0022626~cytosolic ribosome,GO:0045202~synapse,GO:0070062~extracellular exosome,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR002674:Ribosomal_eL43,IPR011331:Ribosomal_eL37/eL43,IPR011332:Ribosomal_zn-bd,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,					KW-0963~Cytoplasm,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,		ZN_FING:C4-type,
RPL38	ribosomal protein L38(RPL38)	Homo sapiens			GO:0001501~skeletal system development,GO:0001503~ossification,GO:0002181~cytoplasmic translation,GO:0006412~translation,GO:0006417~regulation of translation,GO:0007605~sensory perception of sound,GO:0022618~ribonucleoprotein complex assembly,GO:0034463~90S preribosome assembly,GO:0042474~middle ear morphogenesis,GO:0048318~axial mesoderm development,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005840~ribosome,GO:0005925~focal adhesion,GO:0014069~postsynaptic density,GO:0022625~cytosolic large ribosomal subunit,GO:0022626~cytosolic ribosome,GO:0033291~eukaryotic 80S initiation complex,GO:0042788~polysomal ribosome,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,	IPR002675:Ribosomal_eL38,IPR038464:Ribosomal_eL38_sf,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,					KW-0963~Cytoplasm,				KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0007~Acetylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,
RPL39	ribosomal protein L39(RPL39)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0002227~innate immune response in mucosa,GO:0006412~translation,GO:0019731~antibacterial humoral response,GO:0050830~defense response to Gram-positive bacterium,GO:0061844~antimicrobial humoral immune response mediated by antimicrobial peptide,	GO:0005615~extracellular space,GO:0005829~cytosol,GO:0022625~cytosolic large ribosomal subunit,GO:0022626~cytosolic ribosome,GO:0042788~polysomal ribosome,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,	IPR000077:Ribosomal_eL39,IPR020083:Ribosomal_eL39_CS,IPR023626:Ribosomal_eL39_dom_sf,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,					KW-0963~Cytoplasm,				KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,
RPL4	ribosomal protein L4(RPL4)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0006412~translation,	GO:0005634~nucleus,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005791~rough endoplasmic reticulum,GO:0005829~cytosol,GO:0005840~ribosome,GO:0005925~focal adhesion,GO:0016020~membrane,GO:0022625~cytosolic large ribosomal subunit,GO:0022626~cytosolic ribosome,GO:0070062~extracellular exosome,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,	IPR002136:Ribosomal_uL4,IPR013000:Ribosomal_uL4_euk/arc_CS,IPR023574:Ribosomal_uL4_dom_sf,IPR025755:Ribos_uL4_C_dom,IPR045240:Ribosomal_uL4_euk/arch,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,					KW-0963~Cytoplasm,				KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0007~Acetylation,KW-0164~Citrullination,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Large ribosomal subunit protein uL4 C-terminal,REGION:Disordered,
RPL41	ribosomal protein L41(RPL41)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0006412~translation,	GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0005840~ribosome,GO:0022625~cytosolic large ribosomal subunit,GO:0042788~polysomal ribosome,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003730~mRNA 3'-UTR binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,GO:0048027~mRNA 5'-UTR binding,	IPR007836:Ribosomal_eL41,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,					KW-0963~Cytoplasm,				KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,		REGION:Disordered,
RPL5	ribosomal protein L5(RPL5)	Homo sapiens			GO:0000027~ribosomal large subunit assembly,GO:0002181~cytoplasmic translation,GO:0006364~rRNA processing,GO:0006412~translation,GO:0010628~positive regulation of gene expression,GO:0042273~ribosomal large subunit biogenesis,GO:0045727~positive regulation of translation,GO:0050821~protein stabilization,GO:1901796~regulation of signal transduction by p53 class mediator,GO:1904667~negative regulation of ubiquitin protein ligase activity,GO:2000059~negative regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process,GO:2000435~negative regulation of protein neddylation,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0005840~ribosome,GO:0005925~focal adhesion,GO:0016020~membrane,GO:0022625~cytosolic large ribosomal subunit,GO:0022626~cytosolic ribosome,GO:0032991~macromolecular complex,GO:0070062~extracellular exosome,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003730~mRNA 3'-UTR binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,GO:0008097~5S rRNA binding,GO:0031625~ubiquitin protein ligase binding,GO:0048027~mRNA 5'-UTR binding,GO:1990948~ubiquitin ligase inhibitor activity,	IPR005485:Rbsml_uL18_euk/arc,IPR025607:Ribosomal_uL18_C_euk,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,	612561~Diamond-Blackfan anemia 6,				KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-1024~Diamond-Blackfan anemia,			KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,KW-0694~RNA-binding,KW-0699~rRNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:Large ribosomal subunit protein uL18 C-terminal eukaryotes,REGION:Disordered,
RPL6	ribosomal protein L6(RPL6)	Homo sapiens			GO:0000027~ribosomal large subunit assembly,GO:0002181~cytoplasmic translation,GO:0006355~regulation of transcription, DNA-templated,GO:0006412~translation,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005791~rough endoplasmic reticulum,GO:0005829~cytosol,GO:0005840~ribosome,GO:0005925~focal adhesion,GO:0014069~postsynaptic density,GO:0016020~membrane,GO:0022625~cytosolic large ribosomal subunit,GO:0022626~cytosolic ribosome,GO:0036464~cytoplasmic ribonucleoprotein granule,GO:0042788~polysomal ribosome,GO:1990904~ribonucleoprotein complex,	GO:0003677~DNA binding,GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,GO:0045296~cadherin binding,	IPR000915:60S_ribosomal_eL6,IPR005568:Ribosomal_uL6_N,IPR008991:Translation_prot_SH3-like_sf,IPR014722:Rib_uL2_dom2,IPR041997:Ribosomal_eL6_KOW,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,					KW-0256~Endoplasmic reticulum,KW-0963~Cytoplasm,				KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Large ribosomal subunit protein uL6 N-terminal,REGION:Disordered,
RPL7L1	ribosomal protein L7 like 1(RPL7L1)	Homo sapiens			GO:0000463~maturation of LSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA),GO:0001825~blastocyst formation,	GO:0005730~nucleolus,GO:0022625~cytosolic large ribosomal subunit,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,	IPR005998:Ribosomal_uL30_euk,IPR012988:Ribosomal_uL30_N_euk,IPR016082:Ribosomal_uL30_ferredoxin-like,IPR018038:Ribosomal_uL30_CS,IPR035808:Ribosomal_uL30_euk_arc,IPR036919:Ribo_uL30_ferredoxin-like_sf,IPR039699:Ribosomal_uL30,										KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:Large ribosomal subunit protein uL30 N-terminal eukaryotes,DOMAIN:Large ribosomal subunit protein uL30-like ferredoxin-like fold,REGION:Disordered,
RPL7	ribosomal protein L7(RPL7)	Homo sapiens			GO:0000463~maturation of LSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA),GO:0002181~cytoplasmic translation,GO:0006364~rRNA processing,GO:0006412~translation,GO:0042273~ribosomal large subunit biogenesis,	GO:0005634~nucleus,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005925~focal adhesion,GO:0014069~postsynaptic density,GO:0016020~membrane,GO:0022625~cytosolic large ribosomal subunit,GO:0022626~cytosolic ribosome,GO:1990904~ribonucleoprotein complex,	GO:0003677~DNA binding,GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR005998:Ribosomal_uL30_euk,IPR012988:Ribosomal_uL30_N_euk,IPR016082:Ribosomal_uL30_ferredoxin-like,IPR018038:Ribosomal_uL30_CS,IPR035808:Ribosomal_uL30_euk_arc,IPR036919:Ribo_uL30_ferredoxin-like_sf,IPR039699:Ribosomal_uL30,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,					KW-0963~Cytoplasm,		KW-0677~Repeat,		KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:Large ribosomal subunit protein uL30 N-terminal eukaryotes,DOMAIN:Large ribosomal subunit protein uL30-like ferredoxin-like fold,REGION:4 X 12 AA tandem repeats,REPEAT:1,REPEAT:2,REPEAT:3,REPEAT:4,
RPL7A	ribosomal protein L7a(RPL7A)	Homo sapiens			GO:0000470~maturation of LSU-rRNA,GO:0002181~cytoplasmic translation,GO:0006412~translation,GO:0042254~ribosome biogenesis,	GO:0005634~nucleus,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005840~ribosome,GO:0005925~focal adhesion,GO:0016020~membrane,GO:0022625~cytosolic large ribosomal subunit,GO:0022626~cytosolic ribosome,GO:0042788~polysomal ribosome,GO:0045202~synapse,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,GO:0045296~cadherin binding,	IPR001921:Ribosomal_eL8,IPR004037:Ribosomal_eL8-like_CS,IPR004038:Ribosomal_eL8/eL30/eS12/Gad45,IPR018492:Ribosomal_eL8/Nhp2,IPR029064:Ribosomal_eL30-like_sf,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,					KW-0963~Cytoplasm,				KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0007~Acetylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:Ribosomal protein eL8/eL30/eS12/Gadd45,
RPL8	ribosomal protein L8(RPL8)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0006412~translation,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005840~ribosome,GO:0005925~focal adhesion,GO:0014069~postsynaptic density,GO:0016020~membrane,GO:0022625~cytosolic large ribosomal subunit,GO:0022626~cytosolic ribosome,GO:0042788~polysomal ribosome,GO:0098794~postsynapse,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,GO:0019843~rRNA binding,	IPR002171:Ribosomal_uL2,IPR008991:Translation_prot_SH3-like_sf,IPR012340:NA-bd_OB-fold,IPR014722:Rib_uL2_dom2,IPR014726:Ribosomal_uL2_dom3,IPR022666:Ribosomal_uL2_RNA-bd_dom,IPR022669:Ribosomal_uL2_C,IPR022671:Ribosomal_uL2_CS,IPR023672:Ribosomal_uL2_arc,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,		PIRSF002158:Ribosomal_L2,	SM01382:Ribosomal_L2_C,SM01383:Ribosomal_L2,		KW-0963~Cytoplasm,				KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,KW-0694~RNA-binding,KW-0699~rRNA-binding,	KW-0379~Hydroxylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Large ribosomal subunit protein uL2 C-terminal,MUTAGEN:H->A,G: No incorporation into translating E.coli polysomes; ribosomes assembled normally. Significantly reduced translational activity.,REGION:Disordered,
RPL9	ribosomal protein L9(RPL9)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0006412~translation,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005840~ribosome,GO:0005925~focal adhesion,GO:0016020~membrane,GO:0022625~cytosolic large ribosomal subunit,GO:0022626~cytosolic ribosome,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,GO:0019843~rRNA binding,	IPR000702:Ribosomal_uL6-like,IPR002359:Ribosomal_uL6_CS2,IPR020040:Ribosomal_uL6_a/b-dom,IPR036789:Ribosomal_uL6-like_a/b-dom_sf,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,		PIRSF002162:Ribosomal_L6,			KW-0472~Membrane,KW-0963~Cytoplasm,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0007~Acetylation,	DOMAIN:Large ribosomal subunit protein uL6 alpha-beta,TRANSMEM:Helical,
RPS10	ribosomal protein S10(RPS10)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0006412~translation,	GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005840~ribosome,GO:0005925~focal adhesion,GO:0016020~membrane,GO:0022626~cytosolic ribosome,GO:0022627~cytosolic small ribosomal subunit,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,	IPR005326:Plectin_eS10_N,IPR036388:WH-like_DNA-bd_sf,IPR037447:Ribosomal_eS10,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,	613308~Diamond-Blackfan anemia 9,				KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-1024~Diamond-Blackfan anemia,			KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:Plectin/eS10 N-terminal,MUTAGEN:KK->RR: Abolishes monoubiquitination by ZNF598, leading to enhanced readthrough on the poly(A)-stall sequences.,MUTAGEN:R->K: Weakly methylated. Complete loss of methylation; inefficient assembly into ribosomes; instability; increased degradation by the proteasomal pathway; decreased interaction with NPM1; absence of localization in the granular component (GC) region of the nucleolus; when associated with K-158.,MUTAGEN:R->K: Weakly methylated. Complete loss of methylation; inefficient assembly into ribosomes; instability; increased degradation by the proteasomal pathway; decreased interaction with NPM1; absence of localization in the granular component (GC) region of the nucleolus; when associated with K-160.,REGION:Disordered,
RPS11	ribosomal protein S11(RPS11)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0006412~translation,GO:0042274~ribosomal small subunit biogenesis,	GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005840~ribosome,GO:0005925~focal adhesion,GO:0016020~membrane,GO:0022626~cytosolic ribosome,GO:0022627~cytosolic small ribosomal subunit,GO:0032040~small-subunit processome,GO:0045202~synapse,GO:0070062~extracellular exosome,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,GO:0019843~rRNA binding,	IPR000266:Ribosomal_uS17,IPR012340:NA-bd_OB-fold,IPR019979:Ribosomal_uS17_CS,IPR028333:Ribosomal_uS17_arc/euk,IPR032440:Ribosomal_uS17_N,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,					KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,KW-0694~RNA-binding,KW-0699~rRNA-binding,	KW-0007~Acetylation,KW-0164~Citrullination,KW-0449~Lipoprotein,KW-0488~Methylation,KW-0564~Palmitate,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:Small ribosomal subunit protein uS17 N-terminal,LIPID:S-palmitoyl cysteine,MUTAGEN:C->S: Abolishes S-acylation.,REGION:Disordered,
RPS12	ribosomal protein S12(RPS12)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0006412~translation,GO:0042274~ribosomal small subunit biogenesis,GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:1990145~maintenance of translational fidelity,	GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0016020~membrane,GO:0022626~cytosolic ribosome,GO:0022627~cytosolic small ribosomal subunit,GO:0032040~small-subunit processome,GO:0043231~intracellular membrane-bounded organelle,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,	IPR000530:Ribosomal_eS12,IPR004038:Ribosomal_eL8/eL30/eS12/Gad45,IPR029064:Ribosomal_eL30-like_sf,IPR047860:Ribosomal_eS12_CS,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,					KW-0539~Nucleus,				KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0007~Acetylation,
RPS13	ribosomal protein S13(RPS13)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0006412~translation,GO:0033119~negative regulation of RNA splicing,GO:0042274~ribosomal small subunit biogenesis,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005840~ribosome,GO:0005925~focal adhesion,GO:0014069~postsynaptic density,GO:0016020~membrane,GO:0022626~cytosolic ribosome,GO:0022627~cytosolic small ribosomal subunit,GO:0032040~small-subunit processome,GO:0070062~extracellular exosome,	GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,GO:0048027~mRNA 5'-UTR binding,GO:0070181~small ribosomal subunit rRNA binding,	IPR000589:Ribosomal_uS15,IPR009068:uS15_NS1_RNA-bd_sf,IPR012606:Ribosomal_uS15_N,IPR023029:Ribosomal_uS15_arc_euk,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,			SM01386:Ribosomal_S13_N,SM01387:Ribosomal_S15,		KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:Small ribosomal subunit protein uS15 N-terminal,
RPS14	ribosomal protein S14(RPS14)	Homo sapiens			GO:0000028~ribosomal small subunit assembly,GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0002181~cytoplasmic translation,GO:0006412~translation,GO:0006417~regulation of translation,GO:0030218~erythrocyte differentiation,GO:0030490~maturation of SSU-rRNA,GO:0042274~ribosomal small subunit biogenesis,	GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005840~ribosome,GO:0005925~focal adhesion,GO:0014069~postsynaptic density,GO:0015935~small ribosomal subunit,GO:0016020~membrane,GO:0022626~cytosolic ribosome,GO:0022627~cytosolic small ribosomal subunit,GO:0032040~small-subunit processome,GO:0070062~extracellular exosome,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,GO:0045182~translation regulator activity,GO:0048027~mRNA 5'-UTR binding,	IPR001971:Ribosomal_uS11,IPR018102:Ribosomal_uS11_CS,IPR036967:Ribosomal_uS11_sf,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,	153550~Macrocytic anemia, refractory, due to 5q deletion, somatic,	PIRSF002131:Ribosomal_S11,			KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),REGION:Disordered,TRANSMEM:Helical,
RPS15	ribosomal protein S15(RPS15)	Homo sapiens			GO:0000028~ribosomal small subunit assembly,GO:0000056~ribosomal small subunit export from nucleus,GO:0001649~osteoblast differentiation,GO:0002181~cytoplasmic translation,GO:0006364~rRNA processing,GO:0006412~translation,GO:0042274~ribosomal small subunit biogenesis,GO:0097421~liver regeneration,GO:1901798~positive regulation of signal transduction by p53 class mediator,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005840~ribosome,GO:0005925~focal adhesion,GO:0015935~small ribosomal subunit,GO:0016020~membrane,GO:0022626~cytosolic ribosome,GO:0022627~cytosolic small ribosomal subunit,GO:0045202~synapse,GO:1990904~ribonucleoprotein complex,	GO:0003677~DNA binding,GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,GO:0097371~MDM2/MDM4 family protein binding,GO:1990948~ubiquitin ligase inhibitor activity,	IPR002222:Ribosomal_uS19,IPR005713:Ribosomal_uS19_euk/arc,IPR020934:Ribosomal_uS19_CS,IPR023575:Ribosomal_uS19_SF,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,		PIRSF002144:Ribosomal_S19,			KW-0963~Cytoplasm,				KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0007~Acetylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),REGION:Disordered,
RPS15A	ribosomal protein S15a(RPS15A)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0006412~translation,GO:0008284~positive regulation of cell proliferation,GO:0009615~response to virus,GO:0042274~ribosomal small subunit biogenesis,GO:0045787~positive regulation of cell cycle,	GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005840~ribosome,GO:0016020~membrane,GO:0022626~cytosolic ribosome,GO:0022627~cytosolic small ribosomal subunit,GO:0032040~small-subunit processome,GO:0045202~synapse,GO:0070062~extracellular exosome,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,	IPR000630:Ribosomal_uS8,IPR035987:Ribosomal_uS8_sf,IPR047863:Ribosomal_uS8_CS,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,	618313~Diamond-Blackfan anemia 20,				KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-1024~Diamond-Blackfan anemia,			KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,
RPS17	ribosomal protein S17(RPS17)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0006364~rRNA processing,GO:0006412~translation,GO:0006413~translational initiation,GO:0034101~erythrocyte homeostasis,GO:0042274~ribosomal small subunit biogenesis,	GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005840~ribosome,GO:0005925~focal adhesion,GO:0016020~membrane,GO:0022626~cytosolic ribosome,GO:0022627~cytosolic small ribosomal subunit,GO:0032040~small-subunit processome,GO:0045202~synapse,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,	IPR001210:Ribosomal_eS17,IPR018273:Ribosomal_eS17_CS,IPR036401:Ribosomal_eS17_sf,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,	612527~Diamond-Blackfan anemia 4,				KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-1024~Diamond-Blackfan anemia,			KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,
RPS18	ribosomal protein S18(RPS18)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0006412~translation,	GO:0005581~collagen trimer,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005840~ribosome,GO:0005925~focal adhesion,GO:0014069~postsynaptic density,GO:0015935~small ribosomal subunit,GO:0016020~membrane,GO:0022626~cytosolic ribosome,GO:0022627~cytosolic small ribosomal subunit,GO:0070062~extracellular exosome,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,GO:0019843~rRNA binding,	IPR001892:Ribosomal_uS13,IPR010979:Ribosomal_uS13-like_H2TH,IPR018269:Ribosomal_uS13_CS,IPR027437:Rbsml_uS13_C,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,		PIRSF002134:Ribosomal_S13,			KW-0963~Cytoplasm,		KW-0176~Collagen,		KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,KW-0694~RNA-binding,KW-0699~rRNA-binding,	KW-0007~Acetylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,
RPS19BP1	ribosomal protein S19 binding protein 1(RPS19BP1)	Homo sapiens			GO:0042274~ribosomal small subunit biogenesis,	GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005829~cytosol,GO:0032040~small-subunit processome,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0019899~enzyme binding,	IPR023262:AROS,						KW-0539~Nucleus,					KW-0164~Citrullination,KW-0597~Phosphoprotein,	REGION:Disordered,
RPS2	ribosomal protein S2(RPS2)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0006412~translation,GO:0051443~positive regulation of ubiquitin-protein transferase activity,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005840~ribosome,GO:0005925~focal adhesion,GO:0015935~small ribosomal subunit,GO:0016020~membrane,GO:0022626~cytosolic ribosome,GO:0022627~cytosolic small ribosomal subunit,GO:0070062~extracellular exosome,	GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,GO:0017134~fibroblast growth factor binding,GO:0019899~enzyme binding,GO:0045296~cadherin binding,	IPR000851:Ribosomal_uS5,IPR005324:Ribosomal_uS5_C,IPR005711:Ribosomal_uS5_euk/arc,IPR013810:Ribosomal_uS5_N,IPR014721:Ribsml_uS5_D2-typ_fold_subgr,IPR018192:Ribosomal_uS5_N_CS,IPR020568:Ribosomal_Su5_D2-typ_SF,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,					KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,		KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0007~Acetylation,KW-0164~Citrullination,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin); alternate,DOMAIN:S5 DRBM,DOMAIN:Small ribosomal subunit protein uS5 C-terminal,MUTAGEN:K->R: Does not affect readthrough on the poly(A)-stall sequences; when associated with R-275.,MUTAGEN:K->R: Does not affect readthrough on the poly(A)-stall sequences; when associated with R-58.,MUTAGEN:KAEDK->RAEDR: Abolished ubiquitination and degradation by RNF10.,REGION:Disordered,
RPS20	ribosomal protein S20(RPS20)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0006412~translation,GO:1901798~positive regulation of signal transduction by p53 class mediator,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005840~ribosome,GO:0015935~small ribosomal subunit,GO:0016020~membrane,GO:0022626~cytosolic ribosome,GO:0022627~cytosolic small ribosomal subunit,GO:0045202~synapse,GO:0070062~extracellular exosome,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,GO:0097371~MDM2/MDM4 family protein binding,GO:1990948~ubiquitin ligase inhibitor activity,	IPR001848:Ribosomal_uS10,IPR005729:Ribosomal_uS10_euk/arc,IPR018268:Ribosomal_uS10_CS,IPR027486:Ribosomal_uS10_dom,IPR036838:Ribosomal_uS10_dom_sf,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,			SM01403:Ribosomal_S10,		KW-0963~Cytoplasm,				KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin); alternate,DOMAIN:Small ribosomal subunit protein uS10,MUTAGEN:K->R: Enhanced readthrough on the poly(A)-stall sequences; when associated with R-4.,MUTAGEN:K->R: Enhanced readthrough on the poly(A)-stall sequences; when associated with R-8.,
RPS21	ribosomal protein S21(RPS21)	Homo sapiens			GO:0000447~endonucleolytic cleavage in ITS1 to separate SSU-rRNA from 5.8S rRNA and LSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA),GO:0000461~endonucleolytic cleavage to generate mature 3'-end of SSU-rRNA from (SSU-rRNA, 5.8S rRNA, LSU-rRNA),GO:0002181~cytoplasmic translation,GO:0006412~translation,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005791~rough endoplasmic reticulum,GO:0005829~cytosol,GO:0005840~ribosome,GO:0015935~small ribosomal subunit,GO:0022626~cytosolic ribosome,GO:0022627~cytosolic small ribosomal subunit,GO:0042788~polysomal ribosome,GO:0045202~synapse,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,	IPR001931:Ribosomal_eS21,IPR018279:Ribosomal_eS21_CS,IPR038579:Ribosomal_eS21_sf,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,		PIRSF002148:Ribosomal_S21e,			KW-0256~Endoplasmic reticulum,KW-0963~Cytoplasm,				KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0007~Acetylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),
RPS23	ribosomal protein S23(RPS23)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0006412~translation,GO:0034063~stress granule assembly,GO:0042274~ribosomal small subunit biogenesis,GO:1990145~maintenance of translational fidelity,	GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005791~rough endoplasmic reticulum,GO:0005829~cytosol,GO:0005840~ribosome,GO:0015935~small ribosomal subunit,GO:0016020~membrane,GO:0022626~cytosolic ribosome,GO:0022627~cytosolic small ribosomal subunit,GO:0032040~small-subunit processome,GO:0042788~polysomal ribosome,GO:0045202~synapse,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,	IPR005680:Ribosomal_uS12_euk/arc,IPR006032:Ribosomal_uS12,IPR012340:NA-bd_OB-fold,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,	617412~Brachycephaly, trichomegaly, and developmental delay,	PIRSF002133:Ribosomal_S12/S23,			KW-0256~Endoplasmic reticulum,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0209~Deafness,KW-0225~Disease variant,KW-0242~Dwarfism,			KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0007~Acetylation,KW-0379~Hydroxylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),REGION:Disordered,
RPS24	ribosomal protein S24(RPS24)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0006364~rRNA processing,GO:0006412~translation,GO:0034101~erythrocyte homeostasis,GO:0042274~ribosomal small subunit biogenesis,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0015935~small ribosomal subunit,GO:0016020~membrane,GO:0022626~cytosolic ribosome,GO:0022627~cytosolic small ribosomal subunit,GO:0032040~small-subunit processome,GO:0044391~ribosomal subunit,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0031369~translation initiation factor binding,	IPR001976:Ribosomal_eS24,IPR012678:Ribosomal_uL23/eL15/eS24_sf,IPR018098:Ribosomal_eS24_CS,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,	610629~Diamond-blackfan anemia 3,				KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-1024~Diamond-Blackfan anemia,			KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),REGION:Disordered,
RPS25	ribosomal protein S25(RPS25)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0006364~rRNA processing,GO:0006412~translation,GO:0042274~ribosomal small subunit biogenesis,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005840~ribosome,GO:0014069~postsynaptic density,GO:0015935~small ribosomal subunit,GO:0022626~cytosolic ribosome,GO:0022627~cytosolic small ribosomal subunit,GO:0070062~extracellular exosome,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,	IPR004977:Ribosomal_eS25,IPR036388:WH-like_DNA-bd_sf,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,					KW-0963~Cytoplasm,				KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0007~Acetylation,	COMPBIAS:Basic and acidic residues,REGION:Disordered,
RPS26	ribosomal protein S26(RPS26)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0006412~translation,GO:0033119~negative regulation of RNA splicing,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005840~ribosome,GO:0015935~small ribosomal subunit,GO:0016020~membrane,GO:0022627~cytosolic small ribosomal subunit,GO:0042788~polysomal ribosome,GO:0045202~synapse,GO:0070062~extracellular exosome,GO:0098556~cytoplasmic side of rough endoplasmic reticulum membrane,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,GO:0045296~cadherin binding,	IPR000892:Ribosomal_eS26,IPR038551:Ribosomal_eS26_sf,IPR047864:Ribosomal_eS26_CS,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,	613309~Diamond-Blackfan anemia 10,				KW-0256~Endoplasmic reticulum,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-1024~Diamond-Blackfan anemia,			KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,REGION:Disordered,
RPS27L	ribosomal protein S27 like(RPS27L)	Homo sapiens			GO:0000028~ribosomal small subunit assembly,GO:0006412~translation,GO:0006919~activation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0006978~DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator,GO:0031571~mitotic G1 DNA damage checkpoint,GO:0042771~intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator,GO:0045727~positive regulation of translation,	GO:0005634~nucleus,GO:0005840~ribosome,GO:0022627~cytosolic small ribosomal subunit,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,GO:0008494~translation activator activity,GO:0008656~cysteine-type endopeptidase activator activity involved in apoptotic process,GO:0046872~metal ion binding,	IPR000592:Ribosomal_eS27,IPR011332:Ribosomal_zn-bd,IPR023407:Ribosomal_eS27_Zn-bd_dom_sf,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,							KW-0732~Signal,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,		REGION:Disordered,ZN_FING:C4-type,
RPS27	ribosomal protein S27(RPS27)	Homo sapiens			GO:0000028~ribosomal small subunit assembly,GO:0002181~cytoplasmic translation,GO:0006364~rRNA processing,GO:0006412~translation,GO:0006919~activation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0006978~DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator,GO:0031571~mitotic G1 DNA damage checkpoint,GO:0042274~ribosomal small subunit biogenesis,GO:0042771~intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator,GO:0045727~positive regulation of translation,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005829~cytosol,GO:0005840~ribosome,GO:0014069~postsynaptic density,GO:0022626~cytosolic ribosome,GO:0022627~cytosolic small ribosomal subunit,GO:0032040~small-subunit processome,GO:1990904~ribonucleoprotein complex,	GO:0003677~DNA binding,GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0008494~translation activator activity,GO:0008656~cysteine-type endopeptidase activator activity involved in apoptotic process,GO:0046872~metal ion binding,	IPR000592:Ribosomal_eS27,IPR011332:Ribosomal_zn-bd,IPR023407:Ribosomal_eS27_Zn-bd_dom_sf,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,	617409~Diamond-Blackfan anemia 17,				KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-1024~Diamond-Blackfan anemia,	KW-0732~Signal,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,REGION:Disordered,ZN_FING:C4-type,
RPS28	ribosomal protein S28(RPS28)	Homo sapiens			GO:0000028~ribosomal small subunit assembly,GO:0002181~cytoplasmic translation,GO:0006364~rRNA processing,GO:0006412~translation,GO:0030490~maturation of SSU-rRNA,GO:0042254~ribosome biogenesis,GO:0042274~ribosomal small subunit biogenesis,	GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005840~ribosome,GO:0015935~small ribosomal subunit,GO:0022627~cytosolic small ribosomal subunit,GO:0032040~small-subunit processome,GO:0042788~polysomal ribosome,GO:0045202~synapse,GO:0070062~extracellular exosome,GO:0098556~cytoplasmic side of rough endoplasmic reticulum membrane,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,	IPR000289:Ribosomal_eS28,IPR012340:NA-bd_OB-fold,IPR028626:Ribosomal_eS28_CS,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,	606164~Diamond Blackfan anemia 15 with mandibulofacial dysostosis,				KW-0256~Endoplasmic reticulum,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-1024~Diamond-Blackfan anemia,			KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,
RPS29	ribosomal protein S29(RPS29)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0006412~translation,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005840~ribosome,GO:0005925~focal adhesion,GO:0015935~small ribosomal subunit,GO:0022627~cytosolic small ribosomal subunit,GO:0042788~polysomal ribosome,GO:0070062~extracellular exosome,GO:0098556~cytoplasmic side of rough endoplasmic reticulum membrane,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0008270~zinc ion binding,	IPR001209:Ribosomal_uS14,IPR018271:Ribosomal_uS14_CS,IPR023676:Ribosomal_uS14_arc,IPR039744:RIbosomal_uS14_euk_arc,IPR043140:Ribosomal_uS14_sf,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,	615909~Diamond-Blackfan anemia 13,				KW-0256~Endoplasmic reticulum,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-1024~Diamond-Blackfan anemia,		KW-0479~Metal-binding,KW-0862~Zinc,	KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,
RPS3	ribosomal protein S3(RPS3)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0006281~DNA repair,GO:0006284~base-excision repair,GO:0006412~translation,GO:0006413~translational initiation,GO:0006417~regulation of translation,GO:0006915~apoptotic process,GO:0006974~cellular response to DNA damage stimulus,GO:0007059~chromosome segregation,GO:0010628~positive regulation of gene expression,GO:0017148~negative regulation of translation,GO:0031116~positive regulation of microtubule polymerization,GO:0031334~positive regulation of protein complex assembly,GO:0031397~negative regulation of protein ubiquitination,GO:0032079~positive regulation of endodeoxyribonuclease activity,GO:0032743~positive regulation of interleukin-2 production,GO:0034614~cellular response to reactive oxygen species,GO:0042104~positive regulation of activated T cell proliferation,GO:0042981~regulation of apoptotic process,GO:0043507~positive regulation of JUN kinase activity,GO:0045738~negative regulation of DNA repair,GO:0045739~positive regulation of DNA repair,GO:0050862~positive regulation of T cell receptor signaling pathway,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0051225~spindle assembly,GO:0051301~cell division,GO:0061481~response to TNF agonist,GO:0070301~cellular response to hydrogen peroxide,GO:0071356~cellular response to tumor necrosis factor,GO:1901224~positive regulation of NIK/NF-kappaB signaling,GO:1902231~positive regulation of intrinsic apoptotic signaling pathway in response to DNA damage,GO:1905053~positive regulation of base-excision repair,GO:2001235~positive regulation of apoptotic signaling pathway,GO:2001272~positive regulation of cysteine-type endopeptidase activity involved in execution phase of apoptosis,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005743~mitochondrial inner membrane,GO:0005759~mitochondrial matrix,GO:0005783~endoplasmic reticulum,GO:0005819~spindle,GO:0005829~cytosol,GO:0005840~ribosome,GO:0005844~polysome,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0014069~postsynaptic density,GO:0015935~small ribosomal subunit,GO:0016020~membrane,GO:0022626~cytosolic ribosome,GO:0022627~cytosolic small ribosomal subunit,GO:0032587~ruffle membrane,GO:0070062~extracellular exosome,GO:0071159~NF-kappaB complex,GO:0072686~mitotic spindle,GO:1990904~ribonucleoprotein complex,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0003677~DNA binding,GO:0003684~damaged DNA binding,GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0003735~structural constituent of ribosome,GO:0003906~DNA-(apurinic or apyrimidinic site) lyase activity,GO:0004520~endodeoxyribonuclease activity,GO:0005515~protein binding,GO:0008017~microtubule binding,GO:0015631~tubulin binding,GO:0019899~enzyme binding,GO:0019900~kinase binding,GO:0019901~protein kinase binding,GO:0030544~Hsp70 protein binding,GO:0032357~oxidized purine DNA binding,GO:0032358~oxidized pyrimidine DNA binding,GO:0044390~ubiquitin-like protein conjugating enzyme binding,GO:0044877~macromolecular complex binding,GO:0051018~protein kinase A binding,GO:0051536~iron-sulfur cluster binding,GO:0051879~Hsp90 protein binding,GO:0070181~small ribosomal subunit rRNA binding,GO:0097100~supercoiled DNA binding,	IPR001351:Ribosomal_uS3_C,IPR004044:KH_dom_type_2,IPR005703:Ribosomal_uS3_euk/arc,IPR009019:KH_sf_prok-type,IPR015946:KH_dom-like_a/b,IPR018280:Ribosomal_uS3_CS,IPR036419:Ribosomal_S3_C_sf,	hsa03010:Ribosome,hsa05130:Pathogenic Escherichia coli infection,hsa05132:Salmonella infection,hsa05171:Coronavirus disease - COVID-19,				KW-0053~Apoptosis,KW-0131~Cell cycle,KW-0132~Cell division,KW-0227~DNA damage,KW-0234~DNA repair,KW-0498~Mitosis,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0810~Translation regulation,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0999~Mitochondrion inner membrane,				KW-0238~DNA-binding,KW-0456~Lyase,KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin); alternate,DOMAIN:KH type-2,DOMAIN:Small ribosomal subunit protein uS3 C-terminal,MUTAGEN:K->A: Does not affect ability to cleave DNA but abolishes binding to 8-oxoG.,MUTAGEN:K->R: Does not affect ubiquitination in response to ribosome stalling.,MUTAGEN:K->R: No effect on sumoylation. Abolishes sumoylation; when associated with R-18 and R-214. Does not affect ubiquitination in response to ribosome stalling.,MUTAGEN:K->R: No effect on sumoylation. Abolishes sumoylation; when associated with R-18 and R-230. Abolished ubiquitination by RNF10 in response to ribosome stalling and deubiquitination by USP10.,MUTAGEN:K->R: No effect on sumoylation. Abolishes sumoylation; when associated with R-214 and R-230.,MUTAGEN:S->A: No effect on phosphorylation by CDK1. Greatly reduced phosphorylation by PRKCD. Abolishes phosphorylation by PRKCD; when associated with A-221.,MUTAGEN:S->A: No effect on phosphorylation by PRKCD.,MUTAGEN:S->A: Reduced phosphorylation by IKKB.,MUTAGEN:T->A: Abolishes phosphorylation by MAPK and translocation to the nucleus following exposure of cells to hydrogen peroxide. No effect on phosphorylation by CDK1 or PRKCD.,MUTAGEN:T->A: No effect on phosphorylation by MAPK. Significantly reduces phosphorylation by CDK1 and nuclear accumulation. Greatly reduced phosphorylation by PRKCD. Abolishes phosphorylation by PRKCD; when associated with A-6.,MUTAGEN:T->A: No effect on phosphorylation by PRKCD.,MUTAGEN:T->A: No effect on phosphorylation by PRKCD. Abolishes phosphorylation by PKB.,MUTAGEN:T->D,E,R: Abolishes phosphorylation by PKB.,MUTAGEN:T->D: Phosphomimetic mutant which is detected exclusively in the nucleus.,REGION:Disordered,
RPS3A	ribosomal protein S3A(RPS3A)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0006412~translation,GO:0006413~translational initiation,GO:0030154~cell differentiation,GO:0042274~ribosomal small subunit biogenesis,GO:0043066~negative regulation of apoptotic process,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0005840~ribosome,GO:0005925~focal adhesion,GO:0022626~cytosolic ribosome,GO:0022627~cytosolic small ribosomal subunit,GO:0032040~small-subunit processome,GO:0045202~synapse,GO:0070062~extracellular exosome,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,GO:0048027~mRNA 5'-UTR binding,	IPR001593:Ribosomal_eS1,IPR018281:Ribosomal_eS1_CS,IPR027500:Ribosomal_eS1_euk,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,			SM01397:Ribosomal_S3Ae,	KW-0221~Differentiation,	KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0007~Acetylation,KW-0013~ADP-ribosylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,MUTAGEN:Y->F: Decreased ADP-ribosylation.,REGION:Disordered,
RPS4X	ribosomal protein S4 X-linked(RPS4X)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0006412~translation,GO:0008284~positive regulation of cell proliferation,GO:0042274~ribosomal small subunit biogenesis,GO:0045727~positive regulation of translation,	GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005829~cytosol,GO:0005840~ribosome,GO:0005844~polysome,GO:0005925~focal adhesion,GO:0015935~small ribosomal subunit,GO:0016020~membrane,GO:0022626~cytosolic ribosome,GO:0022627~cytosolic small ribosomal subunit,GO:0032040~small-subunit processome,GO:0036464~cytoplasmic ribonucleoprotein granule,GO:0045202~synapse,GO:0070062~extracellular exosome,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,GO:0019843~rRNA binding,	IPR000876:Ribosomal_eS4,IPR002942:S4_RNA-bd,IPR005824:KOW,IPR013843:Ribosomal_eS4_N,IPR013845:Ribosomal_eS4_central_region,IPR014722:Rib_uL2_dom2,IPR018199:Ribosomal_eS4_N_CS,IPR032277:Ribosomal_eS4_C,IPR036986:S4_RNA-bd_sf,IPR038237:Ribosomal_eS4_central_sf,IPR041982:Ribosomal_eS4_KOW,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,		PIRSF002116:Ribosomal_S4,	SM00363:S4,		KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,KW-0694~RNA-binding,KW-0699~rRNA-binding,	KW-0007~Acetylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:RNA-binding S4,DOMAIN:S4 RNA-binding,
RPS4Y1	ribosomal protein S4 Y-linked 1(RPS4Y1)	Homo sapiens			GO:0006412~translation,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0005840~ribosome,GO:0005844~polysome,GO:0016020~membrane,GO:0022627~cytosolic small ribosomal subunit,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0019843~rRNA binding,	IPR000876:Ribosomal_eS4,IPR002942:S4_RNA-bd,IPR005824:KOW,IPR013843:Ribosomal_eS4_N,IPR013845:Ribosomal_eS4_central_region,IPR014722:Rib_uL2_dom2,IPR018199:Ribosomal_eS4_N_CS,IPR032277:Ribosomal_eS4_C,IPR036986:S4_RNA-bd_sf,IPR038237:Ribosomal_eS4_central_sf,IPR041982:Ribosomal_eS4_KOW,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,		PIRSF002116:Ribosomal_S4,	SM00363:S4,						KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,KW-0694~RNA-binding,KW-0699~rRNA-binding,		DOMAIN:RNA-binding S4,DOMAIN:S4 RNA-binding,
RPS5	ribosomal protein S5(RPS5)	Homo sapiens			GO:0000028~ribosomal small subunit assembly,GO:0002181~cytoplasmic translation,GO:0006412~translation,GO:0006413~translational initiation,GO:0006450~regulation of translational fidelity,GO:0042274~ribosomal small subunit biogenesis,	GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005840~ribosome,GO:0005925~focal adhesion,GO:0015935~small ribosomal subunit,GO:0016020~membrane,GO:0022626~cytosolic ribosome,GO:0022627~cytosolic small ribosomal subunit,GO:0032040~small-subunit processome,GO:0045202~synapse,GO:0070062~extracellular exosome,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,GO:0019843~rRNA binding,	IPR000235:Ribosomal_uS7,IPR005716:Ribosomal_uS7_euk/arc,IPR020606:Ribosomal_uS7_CS,IPR023798:Ribosomal_uS7_dom,IPR036823:Ribosomal_uS7_dom_sf,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,		PIRSF002122:RPS7p_RPS7a_RPS5e_RPS7o,			KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:Small ribosomal subunit protein uS7,
RPS6KB2	ribosomal protein S6 kinase B2(RPS6KB2)	Homo sapiens	67.Ikaros_and_signaling_inhibitors,	h_mapkPathway:MAPKinase Signaling Pathway,	GO:0006412~translation,GO:0007165~signal transduction,GO:0016310~phosphorylation,GO:0018105~peptidyl-serine phosphorylation,GO:0031929~TOR signaling,GO:0043491~protein kinase B signaling,GO:0045948~positive regulation of translational initiation,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004711~ribosomal protein S6 kinase activity,GO:0005524~ATP binding,GO:0042277~peptide binding,	IPR000719:Prot_kinase_dom,IPR000961:AGC-kinase_C,IPR008271:Ser/Thr_kinase_AS,IPR011009:Kinase-like_dom_sf,IPR016238:Ribosomal_S6_kinase,IPR017441:Protein_kinase_ATP_BS,IPR017892:Pkinase_C,	hsa01521:EGFR tyrosine kinase inhibitor resistance,hsa01522:Endocrine resistance,hsa04012:ErbB signaling pathway,hsa04066:HIF-1 signaling pathway,hsa04140:Autophagy - animal,hsa04150:mTOR signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04152:AMPK signaling pathway,hsa04211:Longevity regulating pathway,hsa04213:Longevity regulating pathway - multiple species,hsa04350:TGF-beta signaling pathway,hsa04371:Apelin signaling pathway,hsa04666:Fc gamma R-mediated phagocytosis,hsa04714:Thermogenesis,hsa04910:Insulin signaling pathway,hsa04931:Insulin resistance,hsa05131:Shigellosis,hsa05163:Human cytomegalovirus infection,hsa05165:Human papillomavirus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05200:Pathways in cancer,hsa05205:Proteoglycans in cancer,hsa05207:Chemical carcinogenesis - receptor activation,hsa05210:Colorectal cancer,hsa05212:Pancreatic cancer,hsa05221:Acute myeloid leukemia,hsa05224:Breast cancer,hsa05225:Hepatocellular carcinoma,hsa05226:Gastric cancer,hsa05231:Choline metabolism in cancer,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,		PIRSF000605:Ribsml_S6_kin_1,	SM00133:S_TK_X,SM00220:S_TKc,		KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,COMPBIAS:Pro residues,DOMAIN:AGC-kinase C-terminal,DOMAIN:Protein kinase,MOTIF:Nuclear localization signal,REGION:Disordered,
RPS7	ribosomal protein S7(RPS7)	Homo sapiens			GO:0001843~neural tube closure,GO:0002181~cytoplasmic translation,GO:0006364~rRNA processing,GO:0006412~translation,GO:0010628~positive regulation of gene expression,GO:0014033~neural crest cell differentiation,GO:0042274~ribosomal small subunit biogenesis,GO:0050821~protein stabilization,GO:1902255~positive regulation of intrinsic apoptotic signaling pathway by p53 class mediator,GO:1904667~negative regulation of ubiquitin protein ligase activity,GO:2000059~negative regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005813~centrosome,GO:0005829~cytosol,GO:0005840~ribosome,GO:0005925~focal adhesion,GO:0016020~membrane,GO:0022626~cytosolic ribosome,GO:0022627~cytosolic small ribosomal subunit,GO:0032040~small-subunit processome,GO:0032991~macromolecular complex,GO:0045202~synapse,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003730~mRNA 3'-UTR binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,GO:0019901~protein kinase binding,GO:0048027~mRNA 5'-UTR binding,GO:1990948~ubiquitin ligase inhibitor activity,	IPR000554:Ribosomal_eS7,IPR047861:Ribosomal_eS7_CS,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,	612563~Diamond-Blackfan anemia 8,				KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-1024~Diamond-Blackfan anemia,			KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0007~Acetylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,
RPS8	ribosomal protein S8(RPS8)	Homo sapiens			GO:0000462~maturation of SSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA),GO:0002181~cytoplasmic translation,GO:0006412~translation,GO:0042274~ribosomal small subunit biogenesis,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0005840~ribosome,GO:0005925~focal adhesion,GO:0016020~membrane,GO:0022626~cytosolic ribosome,GO:0022627~cytosolic small ribosomal subunit,GO:0032040~small-subunit processome,GO:0070062~extracellular exosome,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,	IPR001047:Ribosomal_eS8,IPR018283:Ribosomal_eS8_CS,IPR022309:Ribosomal_Se8/biogenesis_NSA2,IPR042563:Ribosomal_protein_eS8_euk,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,					KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0007~Acetylation,KW-0449~Lipoprotein,KW-0519~Myristate,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),LIPID:N-myristoyl glycine,REGION:Disordered,
RPS9	ribosomal protein S9(RPS9)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0006412~translation,GO:0006417~regulation of translation,GO:0008284~positive regulation of cell proliferation,GO:0042274~ribosomal small subunit biogenesis,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005840~ribosome,GO:0005925~focal adhesion,GO:0015935~small ribosomal subunit,GO:0016020~membrane,GO:0022626~cytosolic ribosome,GO:0022627~cytosolic small ribosomal subunit,GO:0032040~small-subunit processome,GO:0045202~synapse,GO:0070062~extracellular exosome,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,GO:0019843~rRNA binding,GO:0045182~translation regulator activity,	IPR001912:Ribosomal_uS4_N,IPR002942:S4_RNA-bd,IPR005710:Ribosomal_uS4_euk/arc,IPR018079:Ribosomal_uS4_CS,IPR022801:Ribosomal_uS4,IPR036986:S4_RNA-bd_sf,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,			SM00363:S4,SM01390:Ribosomal_S4,		KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,KW-0694~RNA-binding,KW-0699~rRNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:RNA-binding S4,DOMAIN:S4 RNA-binding,DOMAIN:Small ribosomal subunit protein uS4 N-terminal,REGION:Disordered,
RPLP0	ribosomal protein lateral stalk subunit P0(RPLP0)	Homo sapiens			GO:0000027~ribosomal large subunit assembly,GO:0002181~cytoplasmic translation,GO:0006412~translation,GO:0042254~ribosome biogenesis,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0005840~ribosome,GO:0005925~focal adhesion,GO:0014069~postsynaptic density,GO:0016020~membrane,GO:0022625~cytosolic large ribosomal subunit,GO:0022626~cytosolic ribosome,GO:0036464~cytoplasmic ribonucleoprotein granule,GO:0070062~extracellular exosome,GO:0098794~postsynapse,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,GO:0070180~large ribosomal subunit rRNA binding,	IPR001790:Ribosomal_uL10,IPR030670:uL10_eukaryotes,IPR040637:Ribosomal_uL10-like_insert,IPR043141:Ribosomal_uL10-like_sf,IPR043164:Ribosomal_uL10-like_insert_sf,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,		PIRSF039087:L10E,			KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:Large ribosomal subunit protein uL10-like insertion,REGION:Disordered,
RPLP1	ribosomal protein lateral stalk subunit P1(RPLP1)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0006412~translation,GO:0006414~translational elongation,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005840~ribosome,GO:0005925~focal adhesion,GO:0022625~cytosolic large ribosomal subunit,GO:0022626~cytosolic ribosome,GO:1990904~ribonucleoprotein complex,	GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,GO:0030295~protein kinase activator activity,GO:0043021~ribonucleoprotein complex binding,	IPR027534:Ribosomal_P1/P2,IPR038716:P1/P2_N_sf,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,									KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),REGION:Disordered,
RPLP2	ribosomal protein lateral stalk subunit P2(RPLP2)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0002182~cytoplasmic translational elongation,GO:0006412~translation,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005925~focal adhesion,GO:0016020~membrane,GO:0022625~cytosolic large ribosomal subunit,GO:0070062~extracellular exosome,	GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,	IPR027534:Ribosomal_P1/P2,IPR038716:P1/P2_N_sf,IPR044076:Ribosomal_P2,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,									KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	REGION:Disordered,
RING1	ring finger protein 1(RING1)	Homo sapiens		h_prc2Pathway:The PRC2 Complex Sets Long-term Gene Silencing Through Modification of Histone Tails,	GO:0006325~chromatin organization,GO:0006338~chromatin remodeling,GO:0009952~anterior/posterior pattern specification,GO:0016567~protein ubiquitination,GO:0045892~negative regulation of transcription, DNA-templated,GO:0048593~camera-type eye morphogenesis,	GO:0000151~ubiquitin ligase complex,GO:0001739~sex chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0016604~nuclear body,GO:0016607~nuclear speck,GO:0031519~PcG protein complex,GO:0035102~PRC1 complex,	GO:0003682~chromatin binding,GO:0005515~protein binding,GO:0046872~metal ion binding,GO:0061630~ubiquitin protein ligase activity,GO:0097027~ubiquitin-protein transferase activator activity,	IPR001841:Znf_RING,IPR013083:Znf_RING/FYVE/PHD,IPR017907:Znf_RING_CS,IPR032443:RAWUL,IPR043540:RING1/RING2,	hsa03083:Polycomb repressive complex,			SM00184:RING,	KW-0804~Transcription,KW-0805~Transcription regulation,KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0156~Chromatin regulator,KW-0678~Repressor,KW-0808~Transferase,	KW-0597~Phosphoprotein,	DOMAIN:RING-type,MOTIF:Nuclear localization signal,REGION:Disordered,REGION:Necessary for interaction with CBX2,REGION:Necessary for transcriptional repression,ZN_FING:RING-type,
RNF10	ring finger protein 10(RNF10)	Homo sapiens			GO:0006513~protein monoubiquitination,GO:0010626~negative regulation of Schwann cell proliferation,GO:0031643~positive regulation of myelination,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051865~protein autoubiquitination,GO:0099527~postsynapse to nucleus signaling pathway,GO:1990116~ribosome-associated ubiquitin-dependent protein catabolic process,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0022626~cytosolic ribosome,GO:0098978~glutamatergic synapse,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0005515~protein binding,GO:0046872~metal ion binding,GO:0061630~ubiquitin protein ligase activity,	IPR001841:Znf_RING,IPR013083:Znf_RING/FYVE/PHD,IPR017907:Znf_RING_CS,IPR027370:Znf-RING_euk,IPR039739:MAG2/RNF10,				SM00184:RING,	KW-0804~Transcription,KW-0805~Transcription regulation,KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,KW-0808~Transferase,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:RING-type,MUTAGEN:C->S: Abolished E3 ubiquitin-protein ligase activity and ability to monoubiquitinate RPS2/us5 and RPS3/us3.,MUTAGEN:CPIC->SPIS: Abolished E3 ubiquitin-protein ligase activity and ability to monoubiquitinate RPS2/us5 and RPS3/us3.,REGION:Disordered,REGION:Interaction with MEOX2,ZN_FING:RING-type,
RNF113A	ring finger protein 113A(RNF113A)	Homo sapiens			GO:0000398~mRNA splicing, via spliceosome,GO:0006281~DNA repair,GO:0016567~protein ubiquitination,GO:0034247~snoRNA splicing,GO:0070100~negative regulation of chemokine-mediated signaling pathway,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005684~U2-type spliceosomal complex,GO:0016607~nuclear speck,GO:0071005~U2-type precatalytic spliceosome,	GO:0005515~protein binding,GO:0046872~metal ion binding,GO:0061630~ubiquitin protein ligase activity,	IPR000571:Znf_CCCH,IPR001841:Znf_RING,IPR013083:Znf_RING/FYVE/PHD,IPR017907:Znf_RING_CS,IPR036855:Znf_CCCH_sf,IPR039971:CWC24-like,		300953~Trichothiodystrophy 5, nonphotosensitive,		SM00184:RING,SM00356:ZnF_C3H1,	KW-0227~DNA damage,KW-0234~DNA repair,KW-0507~mRNA processing,KW-0508~mRNA splicing,KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,KW-0747~Spliceosome,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,MUTAGEN:C->A: Loss of E3 ubiquitin ligase activity.,MUTAGEN:I->A: Strongly reduced E3 ubiquitin ligase activity.,MUTAGEN:Missing: Cells are hypersensitive to DNA damage by alkylating agents.,MUTAGEN:Missing: Strongly decreased interaction with CXCR4. Abolishes the ability to promote CXCR4 degradation.,MUTAGEN:Missing: Strongly decreased interaction with SNRNP200/BRR2.,REGION:Disordered,REGION:Important for interaction with CXCR4,REGION:Important for interaction with SNRNP200/BRR2,ZN_FING:C3H1-type,ZN_FING:RING-type,
RNF114	ring finger protein 114(RNF114)	Homo sapiens			GO:0000209~protein polyubiquitination,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0007283~spermatogenesis,GO:0016567~protein ubiquitination,GO:0030154~cell differentiation,	GO:0005634~nucleus,GO:0005829~cytosol,GO:0005886~plasma membrane,	GO:0005515~protein binding,GO:0046872~metal ion binding,GO:0061630~ubiquitin protein ligase activity,	IPR001841:Znf_RING,IPR008598:Di19_Zn-bd,IPR013083:Znf_RING/FYVE/PHD,IPR017907:Znf_RING_CS,IPR027370:Znf-RING_euk,IPR034734:ZF_C2HC_RNF,IPR042716:RNF114_RING-HC,				SM00184:RING,	KW-0221~Differentiation,KW-0744~Spermatogenesis,KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0217~Developmental protein,KW-0808~Transferase,KW-9996~Developmental protein,	KW-0007~Acetylation,KW-0832~Ubl conjugation,	DOMAIN:C2HC RNF-type,DOMAIN:RING-type,DOMAIN:Zinc finger RING-type eukaryotic,ZN_FING:C2HC RNF-type,ZN_FING:RING-type,
RNF115	ring finger protein 115(RNF115)	Homo sapiens			GO:0016567~protein ubiquitination,GO:0042059~negative regulation of epidermal growth factor receptor signaling pathway,GO:0043162~ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway,GO:0051865~protein autoubiquitination,GO:0070534~protein K63-linked ubiquitination,GO:0070936~protein K48-linked ubiquitination,	GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0046872~metal ion binding,GO:0061630~ubiquitin protein ligase activity,	IPR001841:Znf_RING,IPR013083:Znf_RING/FYVE/PHD,				SM00184:RING,	KW-0833~Ubl conjugation pathway,	KW-0963~Cytoplasm,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0808~Transferase,	KW-0007~Acetylation,KW-0832~Ubl conjugation,	MUTAGEN:C->A: Loss of autoubiquitination.,MUTAGEN:K->R: Loss of autoubiquitination; when associated with R-26.,MUTAGEN:K->R: Loss of autoubiquitination; when associated with R-32.,REGION:Disordered,ZN_FING:RING-type,
RNF125	ring finger protein 125(RNF125)	Homo sapiens			GO:0000209~protein polyubiquitination,GO:0002250~adaptive immune response,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0032480~negative regulation of type I interferon production,GO:0039536~negative regulation of RIG-I signaling pathway,GO:1990830~cellular response to leukemia inhibitory factor,	GO:0000139~Golgi membrane,GO:0034098~VCP-NPL4-UFD1 AAA ATPase complex,GO:0043231~intracellular membrane-bounded organelle,	GO:0002039~p53 binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0031624~ubiquitin conjugating enzyme binding,GO:0061630~ubiquitin protein ligase activity,	IPR001841:Znf_RING,IPR008598:Di19_Zn-bd,IPR013083:Znf_RING/FYVE/PHD,IPR017907:Znf_RING_CS,IPR034734:ZF_C2HC_RNF,	hsa04622:RIG-I-like receptor signaling pathway,	616260~Tenorio syndrome,		SM00184:RING,	KW-0391~Immunity,KW-0833~Ubl conjugation pathway,KW-1064~Adaptive immunity,	KW-0333~Golgi apparatus,KW-0472~Membrane,	KW-0225~Disease variant,KW-0991~Intellectual disability,	KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0808~Transferase,	KW-0449~Lipoprotein,KW-0519~Myristate,KW-0832~Ubl conjugation,	LIPID:N-myristoyl glycine,MUTAGEN:C->A: Abolishes ability to regulate T-cell activation and E3 ligase activity in vitro; when associated with A-37.,MUTAGEN:C->A: Abolishes ability to regulate T-cell activation and E3 ligase activity in vitro; when associated with A-40.,MUTAGEN:C->A: Abolishes ability to regulate T-cell activation and E3 ligase activity in vitro; when associated with A-54.,MUTAGEN:C->A: Abolishes ability to regulate T-cell activation and E3 ligase activity in vitro; when associated with A-72.,MUTAGEN:C->A: Abolishes ability to regulate T-cell activation and E3 ligase activity in vitro; when associated with A-75.,MUTAGEN:CAEC->AAEA: Abolished E3 ubiquitin-protein ligase activity in vitro.,MUTAGEN:G->A: Abolishes ability to regulate T-cell activation but not E3 ligase activity in vitro. Also abolishes myristoylation and membrane localization.,MUTAGEN:H->A: Abolishes ability to regulate T-cell activation and E3 ligase activity in vitro; when associated with A-57.,MUTAGEN:LSEMR->ASEAA: Abolished E3 ubiquitin-protein ligase activity in vitro.,MUTAGEN:S->Q: Reduced ubiquitination and reduced binding to ubiquitinated proteins; when associated with P-217.,MUTAGEN:V->P: Reduced ubiquitination and reduced binding to ubiquitinated proteins; when associated with Q-221.,REGION:Disordered,REGION:Interaction with the C2HC RNF-type zinc finger,REGION:Interaction with the RING-type zinc finger,REGION:Linker region,REGION:Required for interaction with ubiquitin and for autoubiquitination,ZN_FING:C2HC RNF-type,ZN_FING:RING-type,
RNF126	ring finger protein 126(RNF126)	Homo sapiens			GO:0006511~ubiquitin-dependent protein catabolic process,GO:0006513~protein monoubiquitination,GO:0016567~protein ubiquitination,GO:0042059~negative regulation of epidermal growth factor receptor signaling pathway,GO:0042127~regulation of cell proliferation,GO:0042147~retrograde transport, endosome to Golgi,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0043162~ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway,GO:0070534~protein K63-linked ubiquitination,GO:0070936~protein K48-linked ubiquitination,GO:0071629~ubiquitin-dependent catabolism of misfolded proteins by cytoplasm-associated proteasome,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0005154~epidermal growth factor receptor binding,GO:0005515~protein binding,GO:0046872~metal ion binding,GO:0061630~ubiquitin protein ligase activity,	IPR001841:Znf_RING,IPR013083:Znf_RING/FYVE/PHD,IPR039525:RNF126-like_zinc-ribbon,				SM00184:RING,	KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:E3 ubiquitin-protein ligase RNF126-like zinc-ribbon,DOMAIN:RING-type,MUTAGEN:C->A: Loss of E3 ligase activity; when associated with A-229.,MUTAGEN:C->A: Loss of E3 ligase activity; when associated with A-232.,MUTAGEN:EE->RR: Impaired interaction with BAG6.,MUTAGEN:F->A: Impaired interaction with BAG6.,MUTAGEN:H->A: Impaired interaction with BAG6.,REGION:Disordered,REGION:Required for interaction with BAG6,REGION:Sufficient for interaction with AICDA,ZN_FING:C4-type,ZN_FING:RING-type,
RNF13	ring finger protein 13(RNF13)	Homo sapiens			GO:0006511~ubiquitin-dependent protein catabolic process,GO:0016567~protein ubiquitination,GO:0051640~organelle localization,GO:0051865~protein autoubiquitination,GO:0070304~positive regulation of stress-activated protein kinase signaling cascade,	GO:0005637~nuclear inner membrane,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005765~lysosomal membrane,GO:0005768~endosome,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0016020~membrane,GO:0031902~late endosome membrane,GO:0043231~intracellular membrane-bounded organelle,	GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0008432~JUN kinase binding,GO:0046872~metal ion binding,GO:0061630~ubiquitin protein ligase activity,	IPR001841:Znf_RING,IPR003137:PA_domain,IPR013083:Znf_RING/FYVE/PHD,IPR044744:ZNRF4/RNF13/RNF167_PA,IPR046450:PA_dom_sf,		618379~Developmental and epileptic encephalopathy 73,		SM00184:RING,	KW-0833~Ubl conjugation pathway,	KW-0256~Endoplasmic reticulum,KW-0458~Lysosome,KW-0472~Membrane,KW-0539~Nucleus,KW-0967~Endosome,	KW-0225~Disease variant,KW-0887~Epilepsy,	KW-0732~Signal,KW-0812~Transmembrane,KW-0863~Zinc-finger,KW-1133~Transmembrane helix,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0808~Transferase,	KW-0325~Glycoprotein,KW-0832~Ubl conjugation,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Acidic residues,COMPBIAS:Polar residues,DOMAIN:PA,DOMAIN:RING-type,MUTAGEN:C->A: Complete loss of E3 ligase activity; when associated with A-260.,MUTAGEN:C->W: Abolishes ER stress-induced JNK activation and apoptosis. Abolishes interaction with ERN1. Does not affect localization to endoplasmic reticulum.,MUTAGEN:H->A: Complete loss of E3 ligase activity; when associated with A-258.,MUTAGEN:Missing: Abolishes ER stress-induced JNK activation and apoptosis.,MUTAGEN:Missing: Abolishes ER stress-induced JNK activation and apoptosis. Disrupts localization to endoplasmic reticulum.,MUTAGEN:Missing: No effect on ER stress-induced JNK activation and apoptosis.,MUTAGEN:Missing: No effect on ER stress-induced JNK activation and apoptosis. No effect on interaction with ERN1.,MUTAGEN:N->A: Loss of glycosylation.,MUTAGEN:N->A: No effect on glycosylation.,MUTAGEN:W->A: Drastically reduces E3 ligase activity.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,ZN_FING:RING-type; atypical,
RNF145	ring finger protein 145(RNF145)	Homo sapiens			GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0012505~endomembrane system,GO:0016020~membrane,	GO:0008270~zinc ion binding,GO:0016740~transferase activity,GO:0061630~ubiquitin protein ligase activity,	IPR001841:Znf_RING,IPR011016:Znf_RING-CH,IPR013083:Znf_RING/FYVE/PHD,IPR025754:TRC8_N_dom,IPR047823:RNF145_RING-H2,				SM00184:RING,SM00744:RINGv,	KW-0833~Ubl conjugation pathway,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0812~Transmembrane,KW-0863~Zinc-finger,KW-1133~Transmembrane helix,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0808~Transferase,		COMPBIAS:Basic and acidic residues,DOMAIN:RING-type,MOTIF:YLYF motif,REGION:Disordered,TRANSMEM:Helical,ZN_FING:RING-type; atypical,
RNF149	ring finger protein 149(RNF149)	Homo sapiens			GO:0006511~ubiquitin-dependent protein catabolic process,GO:0016567~protein ubiquitination,GO:0031647~regulation of protein stability,GO:0043409~negative regulation of MAPK cascade,GO:0071466~cellular response to xenobiotic stimulus,	GO:0005737~cytoplasm,GO:0005770~late endosome,GO:0005783~endoplasmic reticulum,GO:0005794~Golgi apparatus,GO:0016020~membrane,	GO:0046872~metal ion binding,GO:0061630~ubiquitin protein ligase activity,	IPR001841:Znf_RING,IPR003137:PA_domain,IPR013083:Znf_RING/FYVE/PHD,IPR042712:RNF149_RING-H2,IPR046450:PA_dom_sf,				SM00184:RING,	KW-0833~Ubl conjugation pathway,	KW-0472~Membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-0863~Zinc-finger,KW-1133~Transmembrane helix,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0808~Transferase,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:PA,DOMAIN:RING-type,REGION:Disordered,TRANSMEM:Helical,ZN_FING:RING-type; atypical,
RNF166	ring finger protein 166(RNF166)	Homo sapiens			GO:0000209~protein polyubiquitination,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0006914~autophagy,GO:0016567~protein ubiquitination,GO:0045087~innate immune response,	GO:0005737~cytoplasm,	GO:0005515~protein binding,GO:0046872~metal ion binding,GO:0061630~ubiquitin protein ligase activity,	IPR001841:Znf_RING,IPR008598:Di19_Zn-bd,IPR013083:Znf_RING/FYVE/PHD,IPR017907:Znf_RING_CS,IPR027370:Znf-RING_euk,IPR034734:ZF_C2HC_RNF,				SM00184:RING,	KW-0072~Autophagy,KW-0391~Immunity,KW-0399~Innate immunity,KW-0833~Ubl conjugation pathway,	KW-0963~Cytoplasm,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0808~Transferase,		DOMAIN:C2HC RNF-type,DOMAIN:Drought induced 19 protein type zinc-binding,DOMAIN:RING-type,DOMAIN:UIM,MUTAGEN:C->A: Complete loss of SQSTM1 ubiquitination; in association with A-33.,MUTAGEN:C->A: Complete loss of SQSTM1 ubiquitination; in association with A-36.,ZN_FING:C2HC RNF-type,ZN_FING:RING-type,
RNF167	ring finger protein 167(RNF167)	Homo sapiens			GO:0000209~protein polyubiquitination,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0016567~protein ubiquitination,GO:0032418~lysosome localization,GO:0035519~protein K29-linked ubiquitination,GO:0045786~negative regulation of cell cycle,GO:0051640~organelle localization,GO:0051966~regulation of synaptic transmission, glutamatergic,GO:0070534~protein K63-linked ubiquitination,GO:1904262~negative regulation of TORC1 signaling,GO:1904263~positive regulation of TORC1 signaling,GO:1990253~cellular response to leucine starvation,	GO:0005737~cytoplasm,GO:0005764~lysosome,GO:0005765~lysosomal membrane,GO:0005768~endosome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0036020~endolysosome membrane,	GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0046872~metal ion binding,GO:0061630~ubiquitin protein ligase activity,	IPR001841:Znf_RING,IPR003137:PA_domain,IPR011016:Znf_RING-CH,IPR013083:Znf_RING/FYVE/PHD,IPR044744:ZNRF4/RNF13/RNF167_PA,IPR046450:PA_dom_sf,				SM00184:RING,SM00744:RINGv,	KW-0833~Ubl conjugation pathway,	KW-0458~Lysosome,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-0863~Zinc-finger,KW-1133~Transmembrane helix,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0808~Transferase,	KW-0325~Glycoprotein,KW-0832~Ubl conjugation,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Pro residues,DOMAIN:PA,DOMAIN:RING-type,MUTAGEN:C->S: Abolished E3 ubiquitin-protein ligase activity.,MUTAGEN:HAYH->WAYW: Abolished E3 ubiquitin-protein ligase activity.,MUTAGEN:I->A: Drastically increased stability; reduction in auto-ubiquitination activity; loss of cell delay/arrest in G1.,MUTAGEN:N->Q: Reduced N-glycosylation. Abolished N-glycosylation; when associated with Q-33.,MUTAGEN:N->Q: Reduced N-glycosylation. Abolished N-glycosylation; when associated with Q-79.,MUTAGEN:W->A: Drastically increased stability; reduction in auto-ubiquitination activity; loss of cell delay/arrest in G1.,REGION:Disordered,TRANSMEM:Helical,ZN_FING:RING-type; atypical,
RNF168	ring finger protein 168(RNF168)	Homo sapiens			GO:0006302~double-strand break repair,GO:0006303~double-strand break repair via nonhomologous end joining,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0006974~cellular response to DNA damage stimulus,GO:0010212~response to ionizing radiation,GO:0016567~protein ubiquitination,GO:0034244~negative regulation of transcription elongation from RNA polymerase II promoter,GO:0036297~interstrand cross-link repair,GO:0040029~regulation of gene expression, epigenetic,GO:0045190~isotype switching,GO:0045739~positive regulation of DNA repair,GO:0070534~protein K63-linked ubiquitination,GO:0097680~double-strand break repair via classical nonhomologous end joining,	GO:0000151~ubiquitin ligase complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0032991~macromolecular complex,GO:0035861~site of double-strand break,	GO:0003682~chromatin binding,GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0031491~nucleosome binding,GO:0042393~histone binding,GO:0043130~ubiquitin binding,GO:0046872~metal ion binding,GO:0070530~K63-linked polyubiquitin binding,	IPR001841:Znf_RING,IPR013083:Znf_RING/FYVE/PHD,IPR018957:Znf_C3HC4_RING-type,IPR034725:RNF168,		611943~RIDDLE syndrome,		SM00184:RING,	KW-0227~DNA damage,KW-0234~DNA repair,KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0156~Chromatin regulator,KW-0808~Transferase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:RING-type,MOTIF:LR motif 1,MOTIF:LR motif 2,MOTIF:MIU motif 1,MOTIF:MIU motif 2,MOTIF:UMI motif,MUTAGEN:A->G: Impairs ability to form foci following ionizing radiation and impaired binding to 'Lys-63'-linked ubiquitin.,MUTAGEN:A->G: Still able to bind 'Lys-63'-linked ubiquitin.,MUTAGEN:C->S: Does not affect ability to bind ubiquitin and localization to DSBs sites, while it abolishes E3 ligase activity; when associated with S-16.,MUTAGEN:C->S: Does not affect ability to bind ubiquitin and localization to DSBs sites, while it abolishes E3 ligase activity; when associated with S-19.,MUTAGEN:I->A: Abolishes ability to ubiquitinate KDM4A.,MUTAGEN:LL->AA: Impaired ability to bind ubiquitin.,MUTAGEN:LR->AA: Does not affect ubiquitin-binding but impairs recruitment to DSBs.,MUTAGEN:R->D: Does not affect the monomeric structure but abolishes ability to monoubiquitinate H2A in nucleosomes.,REGION:Disordered,ZN_FING:RING-type,
RNF181	ring finger protein 181(RNF181)	Homo sapiens			GO:0016567~protein ubiquitination,GO:0051865~protein autoubiquitination,	GO:0005737~cytoplasm,	GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0046872~metal ion binding,GO:0061630~ubiquitin protein ligase activity,	IPR001841:Znf_RING,IPR013083:Znf_RING/FYVE/PHD,				SM00184:RING,	KW-0833~Ubl conjugation pathway,			KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0808~Transferase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Basic and acidic residues,DOMAIN:RING-type,REGION:Disordered,ZN_FING:RING-type; atypical,
RNF19A	ring finger protein 19A, RBR E3 ubiquitin protein ligase(RNF19A)	Homo sapiens			GO:0000209~protein polyubiquitination,GO:0000226~microtubule cytoskeleton organization,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0032436~positive regulation of proteasomal ubiquitin-dependent protein catabolic process,GO:0099576~regulation of protein catabolic process at postsynapse, modulating synaptic transmission,	GO:0000151~ubiquitin ligase complex,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005829~cytosol,GO:0016020~membrane,GO:0098686~hippocampal mossy fiber to CA3 synapse,GO:0098794~postsynapse,GO:0098978~glutamatergic synapse,	GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0031624~ubiquitin conjugating enzyme binding,GO:0061630~ubiquitin protein ligase activity,	IPR001841:Znf_RING,IPR002867:IBR_dom,IPR013083:Znf_RING/FYVE/PHD,IPR031127:E3_UB_ligase_RBR,IPR044066:TRIAD_supradom,				SM00184:RING,SM00647:IBR,	KW-0833~Ubl conjugation pathway,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0812~Transmembrane,KW-0863~Zinc-finger,KW-1133~Transmembrane helix,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0808~Transferase,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,MUTAGEN:C->S: Abolishes interaction with VCP and E3 ligase activity toward mutant SOD1; when associated with S-132.,MUTAGEN:C->S: Abolishes interaction with VCP and E3 ligase activity toward mutant SOD1; when associated with S-135.,REGION:Disordered,REGION:Interaction with CASR,REGION:TRIAD supradomain,TRANSMEM:Helical,ZN_FING:IBR-type,ZN_FING:RING-type 1,ZN_FING:RING-type 2; atypical,
RNF213	ring finger protein 213(RNF213)	Homo sapiens			GO:0001525~angiogenesis,GO:0002040~sprouting angiogenesis,GO:0002376~immune system process,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0016567~protein ubiquitination,GO:0019216~regulation of lipid metabolic process,GO:0042742~defense response to bacterium,GO:0051865~protein autoubiquitination,GO:0070534~protein K63-linked ubiquitination,GO:0098792~xenophagy,GO:2000051~negative regulation of non-canonical Wnt signaling pathway,	GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005811~lipid particle,GO:0005829~cytosol,GO:0016020~membrane,	GO:0004842~ubiquitin-protein transferase activity,GO:0005524~ATP binding,GO:0016887~ATPase activity,GO:0046872~metal ion binding,GO:0061630~ubiquitin protein ligase activity,	IPR001841:Znf_RING,IPR003593:AAA+_ATPase,IPR013083:Znf_RING/FYVE/PHD,IPR018957:Znf_C3HC4_RING-type,IPR027417:P-loop_NTPase,IPR031248:RNF213,IPR046439:ZF_RZ_dom,		607151~Moyamoya disease 2, susceptibility to,		SM00184:RING,SM00382:AAA,	KW-0037~Angiogenesis,KW-0391~Immunity,KW-0443~Lipid metabolism,KW-0833~Ubl conjugation pathway,	KW-0551~Lipid droplet,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0656~Proto-oncogene,	KW-0175~Coiled coil,KW-0863~Zinc-finger,	KW-0067~ATP-binding,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,KW-0862~Zinc,	KW-0378~Hydrolase,KW-0511~Multifunctional enzyme,KW-0808~Transferase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	ACT_SITE:Nucleophile; for E3 ubiquitin-lipopolysaccharide ligase activity,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:RING-type,DOMAIN:RZ-type,MUTAGEN:E->A: Decreased ATPase activity; abolished ubiquitination of lipopolysaccharide. In mutant B1B2; abolished ATPase activity and localization to lipid droplets; when associated with A-2488.,MUTAGEN:E->A: Decreased ATPase activity; abolished ubiquitination of lipopolysaccharide. In mutant B1B2; abolished ATPase activity and localization to lipid droplets; when associated with A-2845.,MUTAGEN:E->Q: Loss of ATPase hydrolysis.,MUTAGEN:H->A: Abolished ability to ubiquitinate lipopolysaccharide.,MUTAGEN:H->N: Abolished E3 ubiquitin-protein ligase activity; does not affect ubiquitination of lipopolysaccharide.,MUTAGEN:K->A: Impaired ATP-binding leading to decreased ATPase activity; abolished ubiquitination of lipopolysaccharide. In mutant A1A2; abolished ATP-binding and localization to lipid droplets; when associated with A-2426.,MUTAGEN:K->A: Impaired ATP-binding leading to decreased ATPase activity; abolished ubiquitination of lipopolysaccharide. In mutant A1A2; abolished ATP-binding and localization to lipid droplets; when associated with A-2775.,MUTAGEN:W->R: Abolished E3 ubiquitin-protein ligase activity; does not affect ubiquitination of lipopolysaccharide.,REGION:Disordered,ZN_FING:RING-type,ZN_FING:RZ-type,
RNF34	ring finger protein 34(RNF34)	Homo sapiens			GO:0006511~ubiquitin-dependent protein catabolic process,GO:0006915~apoptotic process,GO:0016567~protein ubiquitination,GO:0035872~nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0070417~cellular response to cold,GO:0070936~protein K48-linked ubiquitination,GO:1901796~regulation of signal transduction by p53 class mediator,GO:1901797~negative regulation of signal transduction by p53 class mediator,GO:1902042~negative regulation of extrinsic apoptotic signaling pathway via death domain receptors,GO:2000374~regulation of oxygen metabolic process,GO:2001271~negative regulation of cysteine-type endopeptidase activity involved in execution phase of apoptosis,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0012505~endomembrane system,GO:0016604~nuclear body,GO:0016607~nuclear speck,	GO:0002039~p53 binding,GO:0005515~protein binding,GO:0031625~ubiquitin protein ligase binding,GO:0046872~metal ion binding,GO:0061630~ubiquitin protein ligase activity,GO:1901981~phosphatidylinositol phosphate binding,	IPR001841:Znf_RING,IPR011011:Znf_FYVE_PHD,IPR013083:Znf_RING/FYVE/PHD,IPR036361:SAP_dom_sf,IPR049320:CARP1_2_FYVE,IPR049323:CARP1_FYVE,				SM00184:RING,	KW-0053~Apoptosis,KW-0833~Ubl conjugation pathway,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0808~Transferase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Acidic residues,COMPBIAS:Polar residues,DOMAIN:E3 ubiquitin-protein ligase CARP1/2 FYVE/PHD zinc finger,DOMAIN:RING-type,DOMAIN:SAP 1,DOMAIN:SAP 2,MUTAGEN:C->A: Loss of E3 ubiquitin protein ligase activity.,MUTAGEN:H->A: Loss of E3 ubiquitin protein ligase activity.,REGION:Disordered,SITE:Cleavage; by caspase-3,ZN_FING:FYVE-type,ZN_FING:RING-type,
RNF4	ring finger protein 4(RNF4)	Homo sapiens			GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046685~response to arsenic-containing substance,GO:0051865~protein autoubiquitination,GO:0070534~protein K63-linked ubiquitination,GO:0070936~protein K48-linked ubiquitination,GO:0070979~protein K11-linked ubiquitination,GO:0085020~protein K6-linked ubiquitination,GO:0090169~regulation of spindle assembly,GO:0090234~regulation of kinetochore assembly,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0016604~nuclear body,GO:0016605~PML body,GO:1990752~microtubule end,	GO:0003677~DNA binding,GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:0008270~zinc ion binding,GO:0016740~transferase activity,GO:0030374~ligand-dependent nuclear receptor transcription coactivator activity,GO:0031491~nucleosome binding,GO:0032184~SUMO polymer binding,GO:0042802~identical protein binding,GO:0061630~ubiquitin protein ligase activity,	IPR001841:Znf_RING,IPR013083:Znf_RING/FYVE/PHD,IPR017907:Znf_RING_CS,IPR043295:RING-HC_RNF4,IPR047134:RNF4-like,				SM00184:RING,	KW-0804~Transcription,KW-0805~Transcription regulation,KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0238~DNA-binding,KW-0808~Transferase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,DOMAIN:RING-type,MOTIF:SUMO interaction motif 1,MOTIF:SUMO interaction motif 2,MOTIF:SUMO interaction motif 3,MOTIF:SUMO interaction motif 4,MUTAGEN:H->A: Abolished E3 ubiquitin-protein ligase activity.,MUTAGEN:M->S: Dominant-negative E2-binding mutant, leads to increased trapping of PARP1 to chromatin; when associated with A-177.,MUTAGEN:R->A: Dominant-negative E2-binding mutant, leads to increased trapping of PARP1 to chromatin; when associated with S-136.,REGION:Disordered,REGION:Mediates interaction with TRPS1,REGION:Required for ubiquitination activity,ZN_FING:RING-type,
RNF40	ring finger protein 40(RNF40)	Homo sapiens			GO:0006325~chromatin organization,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0016567~protein ubiquitination,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,	GO:0000151~ubiquitin ligase complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0016020~membrane,GO:0033503~HULC complex,GO:0043005~neuron projection,	GO:0003730~mRNA 3'-UTR binding,GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0031625~ubiquitin protein ligase binding,GO:0042803~protein homodimerization activity,GO:0046872~metal ion binding,GO:0061630~ubiquitin protein ligase activity,	IPR001841:Znf_RING,IPR013083:Znf_RING/FYVE/PHD,IPR013956:E3_ubiquit_lig_Bre1,IPR017907:Znf_RING_CS,IPR018957:Znf_C3HC4_RING-type,				SM00184:RING,	KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,		KW-0175~Coiled coil,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0156~Chromatin regulator,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:RING-type,MUTAGEN:C->M: Abolishes interaction with RB1.,MUTAGEN:E->Q: Abolishes interaction with RB1.,MUTAGEN:L->S: Abolishes interaction with RB1.,REGION:Disordered,ZN_FING:RING-type,
RNF41	ring finger protein 41(RNF41)	Homo sapiens			GO:0000209~protein polyubiquitination,GO:0006914~autophagy,GO:0008285~negative regulation of cell proliferation,GO:0010498~proteasomal protein catabolic process,GO:0016567~protein ubiquitination,GO:0030336~negative regulation of cell migration,GO:0043408~regulation of MAPK cascade,GO:0045619~regulation of lymphocyte differentiation,GO:0045637~regulation of myeloid cell differentiation,GO:0045732~positive regulation of protein catabolic process,GO:0051865~protein autoubiquitination,GO:0051896~regulation of protein kinase B signaling,GO:0097191~extrinsic apoptotic signaling pathway,GO:1901525~negative regulation of macromitophagy,GO:2000377~regulation of reactive oxygen species metabolic process,GO:2000379~positive regulation of reactive oxygen species metabolic process,	GO:0005829~cytosol,GO:0048471~perinuclear region of cytoplasm,GO:0071782~endoplasmic reticulum tubular network,	GO:0004842~ubiquitin-protein transferase activity,GO:0005128~erythropoietin receptor binding,GO:0005135~interleukin-3 receptor binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0019904~protein domain specific binding,GO:0030971~receptor tyrosine kinase binding,GO:0031267~small GTPase binding,GO:0042802~identical protein binding,GO:0061630~ubiquitin protein ligase activity,	IPR001841:Znf_RING,IPR013010:Znf_SIAH,IPR013083:Znf_RING/FYVE/PHD,IPR015036:NRDP1,IPR017907:Znf_RING_CS,IPR037255:NRDP1_C,	hsa04144:Endocytosis,			SM00184:RING,	KW-0053~Apoptosis,KW-0072~Autophagy,KW-0833~Ubl conjugation pathway,			KW-0175~Coiled coil,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0808~Transferase,	KW-0832~Ubl conjugation,	DOMAIN:RING-type,DOMAIN:SIAH-type,MUTAGEN:C->S: Loss of activity; when associated with Q-36.,MUTAGEN:D->V: Loss of activity.,MUTAGEN:H->Q: Loss of activity; when associated with S-34.,REGION:Disordered,ZN_FING:RING-type; degenerate,ZN_FING:SIAH-type; degenerate,
RNF5	ring finger protein 5(RNF5)	Homo sapiens			GO:0006511~ubiquitin-dependent protein catabolic process,GO:0009617~response to bacterium,GO:0010507~negative regulation of autophagy,GO:0016567~protein ubiquitination,GO:0030163~protein catabolic process,GO:0030433~ubiquitin-dependent ERAD pathway,GO:0031648~protein destabilization,GO:0036503~ERAD pathway,GO:0055085~transmembrane transport,GO:0070534~protein K63-linked ubiquitination,GO:0070936~protein K48-linked ubiquitination,GO:0071712~ER-associated misfolded protein catabolic process,GO:2000785~regulation of autophagosome assembly,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0031966~mitochondrial membrane,	GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0016874~ligase activity,GO:0042802~identical protein binding,GO:0044390~ubiquitin-like protein conjugating enzyme binding,GO:0044877~macromolecular complex binding,GO:0046872~metal ion binding,GO:0061630~ubiquitin protein ligase activity,	IPR001841:Znf_RING,IPR013083:Znf_RING/FYVE/PHD,IPR017907:Znf_RING_CS,IPR045103:RNF5/RNF185-like,	hsa04141:Protein processing in endoplasmic reticulum,			SM00184:RING,	KW-0833~Ubl conjugation pathway,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0496~Mitochondrion,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-0863~Zinc-finger,KW-1133~Transmembrane helix,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0436~Ligase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:RING-type,MUTAGEN:C->S: Loss of E3 ubiquitin-protein ligase activity.,REGION:Disordered,TRANSMEM:Helical,ZN_FING:RING-type,
RBX1	ring-box 1(RBX1)	Homo sapiens	84.Ubiquitination_Pathways_Cell_Cycle,	h_eradPathway:ERï¿½associated degradation (ERAD) Pathway,h_p27Pathway:Regulation of p27 Phosphorylation during Cell Cycle Progression,	GO:0000165~MAPK cascade,GO:0000209~protein polyubiquitination,GO:0006281~DNA repair,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0006513~protein monoubiquitination,GO:0006974~cellular response to DNA damage stimulus,GO:0007283~spermatogenesis,GO:0016567~protein ubiquitination,GO:0031146~SCF-dependent proteasomal ubiquitin-dependent protein catabolic process,GO:0032436~positive regulation of proteasomal ubiquitin-dependent protein catabolic process,GO:0032480~negative regulation of type I interferon production,GO:0034644~cellular response to UV,GO:0042110~T cell activation,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0043687~post-translational protein modification,GO:0045116~protein neddylation,GO:0045732~positive regulation of protein catabolic process,GO:0070936~protein K48-linked ubiquitination,GO:0071230~cellular response to amino acid stimulus,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:1902499~positive regulation of protein autoubiquitination,GO:1904263~positive regulation of TORC1 signaling,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0019005~SCF ubiquitin ligase complex,GO:0031461~cullin-RING ubiquitin ligase complex,GO:0031462~Cul2-RING ubiquitin ligase complex,GO:0031463~Cul3-RING ubiquitin ligase complex,GO:0031464~Cul4A-RING E3 ubiquitin ligase complex,GO:0031465~Cul4B-RING E3 ubiquitin ligase complex,GO:0031466~Cul5-RING ubiquitin ligase complex,GO:0031467~Cul7-RING ubiquitin ligase complex,	GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0019788~NEDD8 transferase activity,GO:0031625~ubiquitin protein ligase binding,GO:0034450~ubiquitin-ubiquitin ligase activity,GO:0060090~binding, bridging,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:0061630~ubiquitin protein ligase activity,GO:0061663~NEDD8 ligase activity,GO:0097602~cullin family protein binding,	IPR001841:Znf_RING,IPR013083:Znf_RING/FYVE/PHD,IPR024766:Znf_RING_H2,	hsa03420:Nucleotide excision repair,hsa04066:HIF-1 signaling pathway,hsa04110:Cell cycle,hsa04114:Oocyte meiosis,hsa04120:Ubiquitin mediated proteolysis,hsa04141:Protein processing in endoplasmic reticulum,hsa04310:Wnt signaling pathway,hsa04350:TGF-beta signaling pathway,hsa04710:Circadian rhythm,hsa05131:Shigellosis,hsa05170:Human immunodeficiency virus 1 infection,hsa05200:Pathways in cancer,hsa05211:Renal cell carcinoma,				KW-0227~DNA damage,KW-0234~DNA repair,KW-0833~Ubl conjugation pathway,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	MUTAGEN:C->A: Strong reduction in ligase activity; when associated with A-53.,MUTAGEN:C->A: Strong reduction in ligase activity; when associated with A-56.,MUTAGEN:C->A: Strong reduction in ligase activity; when associated with A-77.,MUTAGEN:H->A: Strong reduction in ligase activity; when associated with A-75.,ZN_FING:RING-type,
RSBN1	round spermatid basic protein 1(RSBN1)	Homo sapiens			GO:0006338~chromatin remodeling,	GO:0005634~nucleus,GO:0005783~endoplasmic reticulum,	GO:0035575~histone demethylase activity (H4-K20 specific),GO:0046872~metal ion binding,GO:0051213~dioxygenase activity,	IPR026306:RSBN1/Dpy-21,IPR039775:PHTF1/2,						KW-0539~Nucleus,			KW-0408~Iron,KW-0479~Metal-binding,	KW-0156~Chromatin regulator,KW-0223~Dioxygenase,KW-0560~Oxidoreductase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),MOTIF:Nuclear localization signal,REGION:Disordered,
SLMAP	sarcolemma associated protein(SLMAP)	Homo sapiens			GO:0006936~muscle contraction,GO:0072659~protein localization to plasma membrane,GO:1900825~regulation of membrane depolarization during cardiac muscle cell action potential,GO:1902305~regulation of sodium ion transmembrane transport,GO:1905150~regulation of voltage-gated sodium channel activity,	GO:0005790~smooth endoplasmic reticulum,GO:0005813~centrosome,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0042383~sarcolemma,	GO:0005515~protein binding,GO:0031267~small GTPase binding,	IPR000253:FHA_dom,IPR008984:SMAD_FHA_dom_sf,				SM00240:FHA,		KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:FHA,REGION:Disordered,REGION:Necessary for targeting to centrosomes,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Anchor for type IV membrane protein,
SAFB	scaffold attachment factor B(SAFB)	Homo sapiens			GO:0006325~chromatin organization,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0030520~intracellular estrogen receptor signaling pathway,GO:0050684~regulation of mRNA processing,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0030496~midbody,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0003682~chromatin binding,GO:0003690~double-stranded DNA binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0043565~sequence-specific DNA binding,	IPR000504:RRM_dom,IPR003034:SAP_dom,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR034781:SAFB1_2_RBD,IPR035979:RBD_domain_sf,IPR036361:SAP_dom_sf,				SM00360:RRM,SM00513:SAP,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0175~Coiled coil,		KW-0238~DNA-binding,KW-0678~Repressor,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:RRM,DOMAIN:SAP,MOTIF:Nuclear localization signal,REGION:Disordered,REGION:Interaction with POLR2A. Interaction with SFRS1; SFRS9 and SFRS10,REGION:Interaction with SAFB2,
SAFB2	scaffold attachment factor B2(SAFB2)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0050684~regulation of mRNA processing,GO:0060008~Sertoli cell differentiation,GO:0060765~regulation of androgen receptor signaling pathway,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0016604~nuclear body,GO:0043231~intracellular membrane-bounded organelle,GO:0070062~extracellular exosome,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0043565~sequence-specific DNA binding,	IPR000504:RRM_dom,IPR003034:SAP_dom,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR034781:SAFB1_2_RBD,IPR035979:RBD_domain_sf,IPR036361:SAP_dom_sf,				SM00360:RRM,SM00513:SAP,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0238~DNA-binding,KW-0678~Repressor,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:RRM,DOMAIN:SAP,MOTIF:Nuclear localization signal,REGION:Disordered,REGION:Interaction with SAFB1,
SLFN12L	schlafen family member 12 like(SLFN12L)	Homo sapiens				GO:0016020~membrane,		IPR007421:Schlafen_AlbA_2_dom,IPR029684:Schlafen,IPR031450:Poxin-SLFN/SLFN_N,IPR038461:Schlafen_AlbA_2_dom_sf,IPR048729:SLFN_GTPase-like,						KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				DOMAIN:Poxin-Schlafen/Schlafen-like N-terminal,DOMAIN:Schlafen AlbA-2,DOMAIN:Schlafen GTPase-like,TRANSMEM:Helical,
SAR1B	secretion associated Ras related GTPase 1B(SAR1B)	Homo sapiens			GO:0002474~antigen processing and presentation of peptide antigen via MHC class I,GO:0003400~regulation of COPII vesicle coating,GO:0006886~intracellular protein transport,GO:0006888~ER to Golgi vesicle-mediated transport,GO:0016050~vesicle organization,GO:0016192~vesicle-mediated transport,GO:0032368~regulation of lipid transport,GO:0042953~lipoprotein transport,GO:0055088~lipid homeostasis,GO:0061024~membrane organization,GO:0070863~positive regulation of protein exit from endoplasmic reticulum,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0012507~ER to Golgi transport vesicle membrane,GO:0030127~COPII vesicle coat,GO:0032580~Golgi cisterna membrane,GO:0070971~endoplasmic reticulum exit site,	GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0046872~metal ion binding,	IPR005225:Small_GTP-bd_dom,IPR006687:Small_GTPase_SAR1,IPR006689:Small_GTPase_ARF/SAR,IPR027417:P-loop_NTPase,	hsa04141:Protein processing in endoplasmic reticulum,hsa05134:Legionellosis,	246700~Chylomicron retention disease,		SM00177:ARF,SM00178:SAR,	KW-0653~Protein transport,KW-0813~Transport,KW-0931~ER-Golgi transport,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,	KW-0225~Disease variant,		KW-0342~GTP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,		KW-0597~Phosphoprotein,
SCAMP2	secretory carrier membrane protein 2(SCAMP2)	Homo sapiens			GO:0006892~post-Golgi vesicle-mediated transport,GO:0015031~protein transport,	GO:0005794~Golgi apparatus,GO:0016020~membrane,GO:0032588~trans-Golgi network membrane,GO:0043231~intracellular membrane-bounded organelle,GO:0055038~recycling endosome membrane,GO:0070062~extracellular exosome,	GO:0005515~protein binding,	IPR007273:SCAMP,					KW-0653~Protein transport,KW-0813~Transport,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0967~Endosome,		KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,REGION:Disordered,REGION:Interaction with SLC9A7,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
SCAMP3	secretory carrier membrane protein 3(SCAMP3)	Homo sapiens			GO:0006892~post-Golgi vesicle-mediated transport,GO:0015031~protein transport,	GO:0016020~membrane,GO:0032588~trans-Golgi network membrane,GO:0043231~intracellular membrane-bounded organelle,GO:0055038~recycling endosome membrane,GO:0070062~extracellular exosome,	GO:0031625~ubiquitin protein ligase binding,	IPR007273:SCAMP,					KW-0653~Protein transport,KW-0813~Transport,	KW-0472~Membrane,		KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1),MUTAGEN:P->L: Abolishes interaction with TSG101.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TRANSMEM:Helical,
SELPLG	selectin P ligand(SELPLG)	Homo sapiens	16.Chemokines-rec-T-cells,	h_granulocytesPathway:Adhesion and Diapedesis of Granulocytes,h_LairPathway:Cells and Molecules involved in local acute inflammatory response,	GO:0007155~cell adhesion,GO:0046718~viral entry into host cell,GO:0050900~leukocyte migration,GO:0050901~leukocyte tethering or rolling,GO:0050902~leukocyte adhesive activation,GO:0071354~cellular response to interleukin-6,	GO:0001931~uropod,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0044853~plasma membrane raft,	GO:0001618~virus receptor activity,GO:0005102~receptor binding,GO:0005515~protein binding,	IPR026195:PSGL-1,	hsa04514:Cell adhesion molecules,hsa04613:Neutrophil extracellular trap formation,hsa05150:Staphylococcus aureus infection,				KW-0130~Cell adhesion,KW-0945~Host-virus interaction,	KW-0472~Membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0730~Sialic acid,	KW-0675~Receptor,KW-1183~Host cell receptor for virus entry,	KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0765~Sulfation,KW-0873~Pyrrolidone carboxylic acid,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (GalNAc...) threonine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DISULFID:Interchain,MUTAGEN:C->A,S: No dimer formation. No effect on P-selectin binding.,MUTAGEN:T->A: No E- nor P-selectin binding, and very little neutrophil rolling. Binding of L-selectin reduced by 91%; when associated with F-46; F-48 and F-51.,MUTAGEN:T->A: No effect on L-selectin binding nor neutrophil rolling.,MUTAGEN:Y->F: Binding L-selectin reduced by 20%, neutrophil recruitment reduced by 30%, and lymphocyte rolling reduced by 32%; when associated with F-46. Binding L-lectin reduced by 31%, neutrophil recruitment reduced by 52%, and lymphocyte rolling reduced by 52%; when associated with F-51. Binding L-selectin reduced by 89%, and neutrophil recruitment reduced by 90%; when associated with F-46 and F-51. Binding of L-selectin reduced by 91%; when associated with F-46; F-51 and A-57.,MUTAGEN:Y->F: Binding L-selectin reduced by 20%, neutrophil recruitment reduced by 30%, and lymphocyte rolling reduced by 32%; when associated with F-48. Binding L-selectin reduced by 86%, neutrophil recruitment reduced by 75%, and lymphocyte rolling reduced by 69%; when associated with F-51. Binding L-selectin reduced by 89%, and neutrophil recruitment reduced by 90%; when associated with F-48 and F-51. Binding of L-selectin reduced by 91%; when associated with F-48; F-51 and A-57.,MUTAGEN:Y->F: Binding L-selectin reduced by 86%, neutrophil recruitment reduced by 75% and, lymphocyte rolling reduced by 69%; when associated with F-46. Binding L-selectin reduced by 31%, neutrophil recruitment reduced by 52%, and lymphocyte rolling reduced by 52%; when associated with F-48; Binding L-selectin reduced by 89%, and neutrophil recruitment reduced by 90%; when associated with F-46 and F-48. Binding of L-selectin reduced by 91%; when associated with F-46; F-48 and A-57.,MUTAGEN:YEYLDY->FEFLDF: No sulfation. Almost complete loss of P-selectin binding. No effect on E-selectin binding.,MUTAGEN:YEYLDYD->FEFLDFE: No sulfation. Almost complete loss of P-selectin binding. No effect on E-selectin binding.,REGION:12 X 10 AA tandem repeats,REGION:Disordered,REPEAT:1,REPEAT:10,REPEAT:11,REPEAT:12,REPEAT:2,REPEAT:3,REPEAT:4,REPEAT:5,REPEAT:6,REPEAT:7,REPEAT:8,REPEAT:9,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SEPHS2	selenophosphate synthetase 2(SEPHS2)	Homo sapiens			GO:0001887~selenium compound metabolic process,GO:0016259~selenocysteine metabolic process,GO:0016260~selenocysteine biosynthetic process,GO:0016310~phosphorylation,	GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0004756~selenide, water dikinase activity,GO:0005524~ATP binding,GO:0046872~metal ion binding,	IPR004536:SPS/SelD,IPR010918:PurM-like_C_dom,IPR016188:PurM-like_N,IPR036676:PurM-like_C_sf,IPR036921:PurM-like_N_sf,	hsa00450:Selenocompound metabolism,hsa01100:Metabolic pathways,		PIRSF036407:Selenphspht_syn,						KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,KW-0711~Selenium,	KW-0418~Kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	BINDING:in other chain,DOMAIN:PurM-like C-terminal,DOMAIN:PurM-like N-terminal,NON_STD:Selenocysteine,REGION:Disordered,SITE:Important for catalytic activity,
SEMA4D	semaphorin 4D(SEMA4D)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001755~neural crest cell migration,GO:0001934~positive regulation of protein phosphorylation,GO:0006955~immune response,GO:0007155~cell adhesion,GO:0007162~negative regulation of cell adhesion,GO:0007165~signal transduction,GO:0007399~nervous system development,GO:0007411~axon guidance,GO:0008360~regulation of cell shape,GO:0030154~cell differentiation,GO:0030335~positive regulation of cell migration,GO:0031344~regulation of cell projection organization,GO:0035025~positive regulation of Rho protein signal transduction,GO:0043066~negative regulation of apoptotic process,GO:0043547~positive regulation of GTPase activity,GO:0043931~ossification involved in bone maturation,GO:0045668~negative regulation of osteoblast differentiation,GO:0048672~positive regulation of collateral sprouting,GO:0048814~regulation of dendrite morphogenesis,GO:0048843~negative regulation of axon extension involved in axon guidance,GO:0050731~positive regulation of peptidyl-tyrosine phosphorylation,GO:0050732~negative regulation of peptidyl-tyrosine phosphorylation,GO:0050919~negative chemotaxis,GO:0051897~positive regulation of protein kinase B signaling,GO:0061430~bone trabecula morphogenesis,GO:0070486~leukocyte aggregation,GO:0071526~semaphorin-plexin signaling pathway,GO:1905704~positive regulation of inhibitory synapse assembly,	GO:0002116~semaphorin receptor complex,GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0016020~membrane,	GO:0004888~transmembrane signaling receptor activity,GO:0005102~receptor binding,GO:0005515~protein binding,GO:0030215~semaphorin receptor binding,GO:0038023~signaling receptor activity,GO:0042802~identical protein binding,GO:0045499~chemorepellent activity,GO:0048018~receptor agonist activity,	IPR001627:Semap_dom,IPR002165:Plexin_repeat,IPR003598:Ig_sub2,IPR003599:Ig_sub,IPR007110:Ig-like_dom,IPR013151:Immunoglobulin,IPR013783:Ig-like_fold,IPR015943:WD40/YVTN_repeat-like_dom_sf,IPR016201:PSI,IPR027231:Semaphorin,IPR036179:Ig-like_dom_sf,IPR036352:Semap_dom_sf,	hsa04360:Axon guidance,			SM00408:IGc2,SM00409:IG,SM00423:PSI,SM00630:Sema,	KW-0221~Differentiation,KW-0524~Neurogenesis,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0217~Developmental protein,KW-0675~Receptor,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type,DOMAIN:PSI,DOMAIN:Sema,MUTAGEN:F->N: Abolishes homodimerization, abolishes collapse of growth cones and reduces PLXNB1 binding; when associated with S-246.,MUTAGEN:F->S: Abolishes homodimerization, abolishes collapse of growth cones and reduces PLXNB1 binding; when associated with N-244.,MUTAGEN:FL->ER: Abolishes PLXNB1 binding.,MUTAGEN:K->E: Strongly reduces PLXNB1 binding.,MUTAGEN:KG->DT: Abolishes PLXNB1 binding.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SETX	senataxin(SETX)	Homo sapiens			GO:0000165~MAPK cascade,GO:0006302~double-strand break repair,GO:0006310~DNA recombination,GO:0006353~DNA-templated transcription, termination,GO:0006369~termination of RNA polymerase II transcription,GO:0006376~mRNA splice site selection,GO:0006396~RNA processing,GO:0006974~cellular response to DNA damage stimulus,GO:0007283~spermatogenesis,GO:0007399~nervous system development,GO:0007623~circadian rhythm,GO:0008543~fibroblast growth factor receptor signaling pathway,GO:0010976~positive regulation of neuron projection development,GO:0030154~cell differentiation,GO:0032508~DNA duplex unwinding,GO:0033120~positive regulation of RNA splicing,GO:0034599~cellular response to oxidative stress,GO:0043066~negative regulation of apoptotic process,GO:0043491~protein kinase B signaling,GO:0044344~cellular response to fibroblast growth factor stimulus,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0060566~positive regulation of DNA-templated transcription, termination,GO:0070301~cellular response to hydrogen peroxide,GO:0071300~cellular response to retinoic acid,GO:2000144~positive regulation of DNA-templated transcription, initiation,GO:2000806~positive regulation of termination of RNA polymerase II transcription, poly(A)-coupled,	GO:0000228~nuclear chromosome,GO:0000781~chromosome, telomeric region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0016604~nuclear body,GO:0030424~axon,GO:0030426~growth cone,GO:0045171~intercellular bridge,	GO:0001147~transcription termination site sequence-specific DNA binding,GO:0003677~DNA binding,GO:0003678~DNA helicase activity,GO:0003723~RNA binding,GO:0004386~helicase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016787~hydrolase activity,GO:0042802~identical protein binding,	IPR027417:P-loop_NTPase,IPR041677:DNA2/NAM7_AAA_11,IPR041679:DNA2/NAM7-like_C,IPR045055:DNA2/NAM7-like,IPR047187:SF1_C_Upf1,	hsa05014:Amyotrophic lateral sclerosis,	602433~Amyotrophic lateral sclerosis 4, juvenile,606002~Spinocerebellar ataxia, autosomal recessive, with axonal neuropathy 2,			KW-0090~Biological rhythms,KW-0221~Differentiation,KW-0227~DNA damage,KW-0233~DNA recombination,KW-0234~DNA repair,KW-0524~Neurogenesis,KW-0744~Spermatogenesis,	KW-0158~Chromosome,KW-0539~Nucleus,KW-0779~Telomere,KW-0963~Cytoplasm,KW-0966~Cell projection,	KW-0036~Amyotrophic lateral sclerosis,KW-0225~Disease variant,KW-0523~Neurodegeneration,	KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0347~Helicase,KW-0378~Hydrolase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:DNA2/NAM7 helicase helicase,DOMAIN:DNA2/NAM7 helicase-like C-terminal,MOTIF:Bipartite nuclear localization signal,MUTAGEN:E->K: Abolishes interaction with EXOSC9 and UBE2I and decreases sumoylation.,REGION:Disordered,REGION:Necessary for nuclear localization,
SRSF11	serine and arginine rich splicing factor 11(SRSF11)	Homo sapiens			GO:0006397~mRNA processing,GO:0008380~RNA splicing,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0016607~nuclear speck,	GO:0003676~nucleic acid binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR000504:RRM_dom,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR034447:RRM_SRSF11,IPR035979:RBD_domain_sf,				SM00360:RRM,	KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,		KW-0677~Repeat,		KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:RRM,REGION:10 X 8 AA approximate repeats of R-R-S-R-S-R-S-R,REGION:Disordered,REPEAT:1,REPEAT:10,REPEAT:2,REPEAT:3,REPEAT:4,REPEAT:5,REPEAT:6,REPEAT:7,REPEAT:8,REPEAT:9,
SRSF3	serine and arginine rich splicing factor 3(SRSF3)	Homo sapiens			GO:0000398~mRNA splicing, via spliceosome,GO:0006406~mRNA export from nucleus,GO:0031053~primary miRNA processing,GO:0048024~regulation of mRNA splicing, via spliceosome,GO:1990830~cellular response to leukemia inhibitory factor,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0016607~nuclear speck,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0043274~phospholipase binding,GO:0070878~primary miRNA binding,	IPR000504:RRM_dom,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR035979:RBD_domain_sf,	hsa03040:Spliceosome,hsa05014:Amyotrophic lateral sclerosis,hsa05168:Herpes simplex virus 1 infection,			SM00360:RRM,	KW-0507~mRNA processing,KW-0508~mRNA splicing,KW-0509~mRNA transport,KW-0813~Transport,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,		KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,DOMAIN:RRM,MUTAGEN:R->E: Abolishes interaction with NXF1.,REGION:2 X approximate repeats, basic,REGION:Disordered,REGION:Sufficient for interaction with NXF1,REPEAT:B-1,REPEAT:B-2,
SRSF4	serine and arginine rich splicing factor 4(SRSF4)	Homo sapiens			GO:0000375~RNA splicing, via transesterification reactions,GO:0000398~mRNA splicing, via spliceosome,GO:0006397~mRNA processing,GO:0008380~RNA splicing,GO:0032868~response to insulin,GO:0048025~negative regulation of mRNA splicing, via spliceosome,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0016607~nuclear speck,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:1990825~sequence-specific mRNA binding,	IPR000504:RRM_dom,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR035979:RBD_domain_sf,IPR047190:RRM2_SRSF4-like,	hsa03040:Spliceosome,hsa05168:Herpes simplex virus 1 infection,			SM00360:RRM,	KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,		KW-0677~Repeat,		KW-0678~Repressor,KW-0694~RNA-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,DOMAIN:RRM,DOMAIN:RRM 1,DOMAIN:RRM 2,REGION:Disordered,
SRSF5	serine and arginine rich splicing factor 5(SRSF5)	Homo sapiens			GO:0000398~mRNA splicing, via spliceosome,GO:0006376~mRNA splice site selection,GO:0006397~mRNA processing,	GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005829~cytosol,GO:0016607~nuclear speck,	GO:0003723~RNA binding,GO:0005515~protein binding,	IPR000504:RRM_dom,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR035979:RBD_domain_sf,	hsa03040:Spliceosome,hsa05168:Herpes simplex virus 1 infection,			SM00360:RRM,	KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,		KW-0677~Repeat,		KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,DOMAIN:RRM,DOMAIN:RRM 1,DOMAIN:RRM 2,REGION:Disordered,
SRSF6	serine and arginine rich splicing factor 6(SRSF6)	Homo sapiens			GO:0000380~alternative mRNA splicing, via spliceosome,GO:0000381~regulation of alternative mRNA splicing, via spliceosome,GO:0000398~mRNA splicing, via spliceosome,GO:0006376~mRNA splice site selection,GO:0010837~regulation of keratinocyte proliferation,GO:0032868~response to insulin,GO:0045617~negative regulation of keratinocyte differentiation,GO:0048025~negative regulation of mRNA splicing, via spliceosome,GO:0060501~positive regulation of epithelial cell proliferation involved in lung morphogenesis,GO:0061041~regulation of wound healing,GO:2000675~negative regulation of type B pancreatic cell apoptotic process,	GO:0005654~nucleoplasm,GO:0016607~nuclear speck,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0036002~pre-mRNA binding,	IPR000504:RRM_dom,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR034511:SRSF6_RRM1,IPR035979:RBD_domain_sf,	hsa03040:Spliceosome,hsa05168:Herpes simplex virus 1 infection,			SM00360:RRM,	KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,		KW-0677~Repeat,		KW-0678~Repressor,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:RRM,DOMAIN:RRM 1,DOMAIN:RRM 2,MUTAGEN:S->A: Abolishes regulatory effect of DYRK1A on alternative splicing of MAPT/Tau exon 10.,MUTAGEN:S->A: No effect on regulation of alternative splicing of MAPT/Tau exon 10 by DYRK1A.,REGION:Disordered,
SRSF7	serine and arginine rich splicing factor 7(SRSF7)	Homo sapiens			GO:0000398~mRNA splicing, via spliceosome,GO:0006397~mRNA processing,GO:0008380~RNA splicing,GO:0048025~negative regulation of mRNA splicing, via spliceosome,GO:0051028~mRNA transport,GO:1990830~cellular response to leukemia inhibitory factor,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0016607~nuclear speck,GO:0070062~extracellular exosome,	GO:0003676~nucleic acid binding,GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0019904~protein domain specific binding,	IPR000504:RRM_dom,IPR001878:Znf_CCHC,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR034651:SRSF7_RRM,IPR035979:RBD_domain_sf,IPR036875:Znf_CCHC_sf,	hsa03040:Spliceosome,hsa05014:Amyotrophic lateral sclerosis,hsa05168:Herpes simplex virus 1 infection,			SM00360:RRM,	KW-0507~mRNA processing,KW-0508~mRNA splicing,KW-0509~mRNA transport,KW-0813~Transport,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0678~Repressor,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:CCHC-type,DOMAIN:RRM,MUTAGEN:RR->EE: Abolishes interaction with NXF1.,REGION:6 X 8 AA repeats of R-R-S-R-S-X-S-X,REGION:Disordered,REGION:Sufficient for interaction with NXF1,REPEAT:1,REPEAT:2,REPEAT:3,REPEAT:4,REPEAT:5; approximate,REPEAT:6; approximate,ZN_FING:CCHC-type,
SRSF9	serine and arginine rich splicing factor 9(SRSF9)	Homo sapiens			GO:0000380~alternative mRNA splicing, via spliceosome,GO:0006376~mRNA splice site selection,GO:0006397~mRNA processing,GO:0009636~response to toxic substance,GO:0043279~response to alkaloid,GO:0048025~negative regulation of mRNA splicing, via spliceosome,	GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0016607~nuclear speck,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0019904~protein domain specific binding,	IPR000504:RRM_dom,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR034503:SRSF9_RRM1,IPR034995:SRSF9_RRM2,IPR035979:RBD_domain_sf,	hsa03040:Spliceosome,hsa05168:Herpes simplex virus 1 infection,			SM00360:RRM,	KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,		KW-0677~Repeat,		KW-0678~Repressor,KW-0694~RNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:RRM,DOMAIN:RRM 1,DOMAIN:RRM 2,REGION:Disordered,REGION:Interaction with SAFB1,
SERINC1	serine incorporator 1(SERINC1)	Homo sapiens			GO:0006658~phosphatidylserine metabolic process,GO:0006665~sphingolipid metabolic process,GO:0008654~phospholipid biosynthetic process,GO:0044091~membrane biogenesis,GO:1904219~positive regulation of CDP-diacylglycerol-serine O-phosphatidyltransferase activity,GO:1904222~positive regulation of serine C-palmitoyltransferase activity,	GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0016020~membrane,	GO:0005515~protein binding,GO:0030674~protein binding, bridging,	IPR005016:TDE1/TMS,					KW-0443~Lipid metabolism,KW-0444~Lipid biosynthesis,KW-0594~Phospholipid biosynthesis,KW-1208~Phospholipid metabolism,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0519~Myristate,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,LIPID:N-myristoyl glycine,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
SERINC3	serine incorporator 3(SERINC3)	Homo sapiens			GO:0006564~L-serine biosynthetic process,GO:0009597~detection of virus,GO:0015825~L-serine transport,GO:0045087~innate immune response,GO:0051607~defense response to virus,GO:1902237~positive regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway,	GO:0000139~Golgi membrane,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0048471~perinuclear region of cytoplasm,	GO:0005515~protein binding,GO:0015194~L-serine transmembrane transporter activity,	IPR005016:TDE1/TMS,	hsa03250:Viral life cycle - HIV-1,				KW-0051~Antiviral defense,KW-0391~Immunity,KW-0399~Innate immunity,KW-0945~Host-virus interaction,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SERINC5	serine incorporator 5(SERINC5)	Homo sapiens			GO:0006564~L-serine biosynthetic process,GO:0006658~phosphatidylserine metabolic process,GO:0008654~phospholipid biosynthetic process,GO:0009597~detection of virus,GO:0015825~L-serine transport,GO:0042552~myelination,GO:0045087~innate immune response,GO:0051607~defense response to virus,GO:1904219~positive regulation of CDP-diacylglycerol-serine O-phosphatidyltransferase activity,GO:1904222~positive regulation of serine C-palmitoyltransferase activity,	GO:0005794~Golgi apparatus,GO:0005813~centrosome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0043209~myelin sheath,GO:0043231~intracellular membrane-bounded organelle,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,	GO:0015194~L-serine transmembrane transporter activity,	IPR005016:TDE1/TMS,	hsa03250:Viral life cycle - HIV-1,				KW-0051~Antiviral defense,KW-0391~Immunity,KW-0399~Innate immunity,KW-0443~Lipid metabolism,KW-0444~Lipid biosynthesis,KW-0594~Phospholipid biosynthesis,KW-0945~Host-virus interaction,KW-1208~Phospholipid metabolism,	KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SRRM2	serine/arginine repetitive matrix 2(SRRM2)	Homo sapiens			GO:0000398~mRNA splicing, via spliceosome,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0015030~Cajal body,GO:0016607~nuclear speck,GO:0071005~U2-type precatalytic spliceosome,GO:0071007~U2-type catalytic step 2 spliceosome,GO:0071013~catalytic step 2 spliceosome,	GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0005515~protein binding,GO:0070742~C2H2 zinc finger domain binding,	IPR013170:mRNA_splic_Cwf21_dom,IPR024945:Spt5_C_dom,IPR047490:SRRM2_cwf21,		620439~Intellectual developmental disorder, autosomal dominant 72,		SM01104:CTD,SM01115:cwf21,	KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,KW-0747~Spliceosome,		KW-0175~Coiled coil,		KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:CWF21,DOMAIN:Spt5 C-terminal,REGION:Disordered,REGION:Sufficient for RNA-binding,
STK10	serine/threonine kinase 10(STK10)	Homo sapiens			GO:0006468~protein phosphorylation,GO:0007049~cell cycle,GO:0046777~protein autophosphorylation,GO:0071593~lymphocyte aggregation,GO:2000401~regulation of lymphocyte migration,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0035579~specific granule membrane,GO:0070062~extracellular exosome,	GO:0004674~protein serine/threonine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,	IPR000719:Prot_kinase_dom,IPR008271:Ser/Thr_kinase_AS,IPR011009:Kinase-like_dom_sf,IPR017441:Protein_kinase_ATP_BS,IPR022165:PKK,IPR042743:STK10_STKc,	hsa04914:Progesterone-mediated oocyte maturation,			SM00220:S_TKc,	KW-0131~Cell cycle,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Protein kinase,MUTAGEN:K->I: Loss of kinase activity.,REGION:Activation segment,REGION:Disordered,
STK17A	serine/threonine kinase 17a(STK17A)	Homo sapiens			GO:0006468~protein phosphorylation,GO:0006915~apoptotic process,GO:0035556~intracellular signal transduction,GO:0043065~positive regulation of apoptotic process,GO:2000271~positive regulation of fibroblast apoptotic process,GO:2000377~regulation of reactive oxygen species metabolic process,	GO:0005634~nucleus,GO:0005886~plasma membrane,GO:0016607~nuclear speck,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0005524~ATP binding,	IPR000719:Prot_kinase_dom,IPR008271:Ser/Thr_kinase_AS,IPR011009:Kinase-like_dom_sf,IPR017441:Protein_kinase_ATP_BS,IPR042704:DRAK1_STKc,				SM00220:S_TKc,	KW-0053~Apoptosis,	KW-0539~Nucleus,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,DOMAIN:Protein kinase,MUTAGEN:K->A: Loss of activity and of apoptotic function.,REGION:Disordered,
STK17B	serine/threonine kinase 17b(STK17B)	Homo sapiens			GO:0006468~protein phosphorylation,GO:0006915~apoptotic process,GO:0016310~phosphorylation,GO:0035556~intracellular signal transduction,GO:0043065~positive regulation of apoptotic process,GO:0046777~protein autophosphorylation,GO:2000271~positive regulation of fibroblast apoptotic process,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005793~endoplasmic reticulum-Golgi intermediate compartment,GO:0005886~plasma membrane,GO:0015629~actin cytoskeleton,GO:0090543~Flemming body,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0005524~ATP binding,	IPR000719:Prot_kinase_dom,IPR008271:Ser/Thr_kinase_AS,IPR011009:Kinase-like_dom_sf,IPR017441:Protein_kinase_ATP_BS,IPR042763:ST17B_STKc,				SM00220:S_TKc,	KW-0053~Apoptosis,	KW-0472~Membrane,KW-0539~Nucleus,KW-1003~Cell membrane,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,COMPBIAS:Basic and acidic residues,DOMAIN:Protein kinase,MUTAGEN:K->A: Loss of activity and of apoptotic function.,REGION:Disordered,
STK38	serine/threonine kinase 38(STK38)	Homo sapiens			GO:0006468~protein phosphorylation,GO:0016310~phosphorylation,GO:0018105~peptidyl-serine phosphorylation,GO:0035556~intracellular signal transduction,GO:0036211~protein modification process,GO:0043407~negative regulation of MAP kinase activity,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0098978~glutamatergic synapse,	GO:0000287~magnesium ion binding,GO:0004674~protein serine/threonine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0031435~mitogen-activated protein kinase kinase kinase binding,GO:0045296~cadherin binding,	IPR000719:Prot_kinase_dom,IPR000961:AGC-kinase_C,IPR008271:Ser/Thr_kinase_AS,IPR011009:Kinase-like_dom_sf,IPR017441:Protein_kinase_ATP_BS,IPR017892:Pkinase_C,				SM00133:S_TK_X,SM00220:S_TKc,		KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	ACT_SITE:Proton acceptor,DOMAIN:AGC-kinase C-terminal,DOMAIN:Protein kinase,MUTAGEN:K->A: Loss of autophosphorylation and kinase activity.,MUTAGEN:S->A: Loss of autophosphorylation and kinase activity.,MUTAGEN:T->A: Decreases autophosphorylation and kinase activity.,MUTAGEN:T->A: Decreases autophosphorylation and kinase activity. Reduced binding of S100B.,REGION:Interaction with S100B,
STRAP	serine/threonine kinase receptor associated protein(STRAP)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0000380~alternative mRNA splicing, via spliceosome,GO:0000387~spliceosomal snRNP assembly,GO:0030182~neuron differentiation,GO:0030277~maintenance of gastrointestinal epithelium,GO:0030512~negative regulation of transforming growth factor beta receptor signaling pathway,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0032797~SMN complex,GO:0034719~SMN-Sm protein complex,	GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0005102~receptor binding,GO:0005515~protein binding,GO:1990447~U2 snRNP binding,	IPR001680:WD40_rpt,IPR011047:Quinoprotein_ADH-like_supfam,IPR015943:WD40/YVTN_repeat-like_dom_sf,IPR020472:G-protein_beta_WD-40_rep,IPR036322:WD40_repeat_dom_sf,				SM00320:WD40,	KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0853~WD repeat,			KW-0597~Phosphoprotein,	REPEAT:WD,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,REPEAT:WD 7,
SERPINB1	serpin family B member 1(SERPINB1)	Homo sapiens			GO:0010951~negative regulation of endopeptidase activity,GO:0032691~negative regulation of interleukin-1 beta production,GO:0044342~type B pancreatic cell proliferation,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005769~early endosome,GO:0016020~membrane,GO:0034774~secretory granule lumen,GO:0036464~cytoplasmic ribonucleoprotein granule,GO:0044194~cytolytic granule,GO:0070062~extracellular exosome,	GO:0004867~serine-type endopeptidase inhibitor activity,GO:0005515~protein binding,GO:0030414~peptidase inhibitor activity,	IPR000215:Serpin_fam,IPR023795:Serpin_CS,IPR023796:Serpin_dom,IPR036186:Serpin_sf,IPR042178:Serpin_sf_1,IPR042185:Serpin_sf_2,				SM00093:SERPIN,		KW-0458~Lysosome,KW-0963~Cytoplasm,KW-0964~Secreted,KW-0967~Endosome,				KW-0646~Protease inhibitor,KW-0722~Serine protease inhibitor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:Serpin,MUTAGEN:C->A: Loss of proteinase-3-binding activity but caspase-binding activity remains unaffected; in association with A-343.,MUTAGEN:F->A: Loss of proteinase-3-binding activity but caspase-binding activity remains unaffected; in association with A-344.,REGION:CARD-binding motif (CBM),SITE:Reactive bond 1,SITE:Reactive bond 2,
SERPINB9	serpin family B member 9(SERPINB9)	Homo sapiens			GO:0002448~mast cell mediated immunity,GO:0006955~immune response,GO:0010951~negative regulation of endopeptidase activity,GO:0042270~protection from natural killer cell mediated cytotoxicity,GO:0043066~negative regulation of apoptotic process,GO:0071391~cellular response to estrogen stimulus,	GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0016020~membrane,GO:0070062~extracellular exosome,	GO:0002020~protease binding,GO:0004867~serine-type endopeptidase inhibitor activity,GO:0005515~protein binding,GO:0043027~cysteine-type endopeptidase inhibitor activity involved in apoptotic process,	IPR000215:Serpin_fam,IPR000240:Serpin_B9/Maspin,IPR023795:Serpin_CS,IPR023796:Serpin_dom,IPR036186:Serpin_sf,IPR042178:Serpin_sf_1,IPR042185:Serpin_sf_2,	hsa05146:Amoebiasis,			SM00093:SERPIN,		KW-0963~Cytoplasm,				KW-0646~Protease inhibitor,KW-0722~Serine protease inhibitor,	KW-0007~Acetylation,	SITE:Reactive bond,
SHISA5	shisa family member 5(SHISA5)	Homo sapiens			GO:0042771~intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,	GO:0005783~endoplasmic reticulum,GO:0005788~endoplasmic reticulum lumen,GO:0005789~endoplasmic reticulum membrane,GO:0016020~membrane,GO:0031965~nuclear membrane,	GO:0005515~protein binding,GO:0050699~WW domain binding,	IPR026910:Shisa,	hsa04115:p53 signaling pathway,				KW-0053~Apoptosis,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0539~Nucleus,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,				REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SPN	sialophorin(SPN)	Homo sapiens			GO:0001562~response to protozoan,GO:0001808~negative regulation of type IV hypersensitivity,GO:0001934~positive regulation of protein phosphorylation,GO:0002296~T-helper 1 cell lineage commitment,GO:0006935~chemotaxis,GO:0006955~immune response,GO:0006968~cellular defense response,GO:0007162~negative regulation of cell adhesion,GO:0007163~establishment or maintenance of cell polarity,GO:0007165~signal transduction,GO:0007166~cell surface receptor signaling pathway,GO:0031295~T cell costimulation,GO:0032760~positive regulation of tumor necrosis factor production,GO:0042098~T cell proliferation,GO:0042102~positive regulation of T cell proliferation,GO:0042130~negative regulation of T cell proliferation,GO:0042742~defense response to bacterium,GO:0045060~negative thymic T cell selection,GO:0050688~regulation of defense response to virus,GO:0050776~regulation of immune response,GO:0050863~regulation of T cell activation,GO:0050901~leukocyte tethering or rolling,GO:0097190~apoptotic signaling pathway,GO:2000404~regulation of T cell migration,GO:2000406~positive regulation of T cell migration,	GO:0001931~uropod,GO:0005604~basement membrane,GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0005902~microvillus,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,GO:0016605~PML body,GO:0070062~extracellular exosome,	GO:0004888~transmembrane signaling receptor activity,GO:0005515~protein binding,GO:0030544~Hsp70 protein binding,GO:0031072~heat shock protein binding,	IPR038829:Leukosialin,	hsa04514:Cell adhesion molecules,					KW-0472~Membrane,KW-0539~Nucleus,KW-0966~Cell projection,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (GalNAc...) serine,CARBOHYD:O-linked (GalNAc...) threonine,COMPBIAS:Polar residues,MOTIF:Nuclear localization signal,MUTAGEN:KR->PG: Reduced nuclear localization. Loss of nuclear localization; when associated with 282-P-G-283.,MUTAGEN:KR->PG: Reduced nuclear localization. Loss of nuclear localization; when associated with 295-P-G-296.,REGION:Disordered,REGION:Required for interaction with EZR, MSN and RDX and for co-localization to microvilli,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SIPA1L1	signal induced proliferation associated 1 like 1(SIPA1L1)	Homo sapiens			GO:0030036~actin cytoskeleton organization,GO:0043087~regulation of GTPase activity,GO:0048013~ephrin receptor signaling pathway,GO:0048167~regulation of synaptic plasticity,GO:0050770~regulation of axonogenesis,GO:0051056~regulation of small GTPase mediated signal transduction,GO:0061001~regulation of dendritic spine morphogenesis,GO:0090630~activation of GTPase activity,	GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0014069~postsynaptic density,GO:0015629~actin cytoskeleton,GO:0043197~dendritic spine,	GO:0005096~GTPase activator activity,GO:0005515~protein binding,GO:0046875~ephrin receptor binding,	IPR000331:Rap/Ran_GAP_dom,IPR001478:PDZ,IPR021818:SIPA1L_C,IPR035974:Rap/Ran-GAP_sf,IPR036034:PDZ_sf,	hsa04015:Rap1 signaling pathway,			SM00228:PDZ,		KW-0206~Cytoskeleton,KW-0770~Synapse,KW-0771~Synaptosome,KW-0963~Cytoplasm,		KW-0175~Coiled coil,		KW-0343~GTPase activation,	KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:PDZ,DOMAIN:Rap-GAP,REGION:Disordered,
SPCS1	signal peptidase complex subunit 1(SPCS1)	Homo sapiens			GO:0006465~signal peptide processing,GO:0006508~proteolysis,GO:0019068~virion assembly,GO:0019082~viral protein processing,GO:0045047~protein targeting to ER,	GO:0005787~signal peptidase complex,GO:0005789~endoplasmic reticulum membrane,	GO:0005515~protein binding,GO:0043022~ribosome binding,	IPR009542:Spc1/SPCS1,	hsa03060:Protein export,					KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,	REGION:(Microbial infection) Interaction with HCV NS2 and HCV E2,REGION:(Microbial infection) Interaction with JEV NS2B,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
SPCS2	signal peptidase complex subunit 2(SPCS2)	Homo sapiens			GO:0006465~signal peptide processing,GO:0045047~protein targeting to ER,	GO:0005787~signal peptidase complex,GO:0005789~endoplasmic reticulum membrane,	GO:0005515~protein binding,GO:0008233~peptidase activity,	IPR009582:Spc2/SPCS2,	hsa03060:Protein export,					KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,	REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
SPPL2A	signal peptide peptidase like 2A(SPPL2A)	Homo sapiens			GO:0006509~membrane protein ectodomain proteolysis,GO:0010803~regulation of tumor necrosis factor-mediated signaling pathway,GO:0031293~membrane protein intracellular domain proteolysis,GO:0033619~membrane protein proteolysis,GO:0050776~regulation of immune response,	GO:0005765~lysosomal membrane,GO:0005770~late endosome,GO:0005886~plasma membrane,GO:0010008~endosome membrane,GO:0016020~membrane,GO:0030660~Golgi-associated vesicle membrane,GO:0031902~late endosome membrane,GO:0043231~intracellular membrane-bounded organelle,GO:0070062~extracellular exosome,GO:0098553~lumenal side of endoplasmic reticulum membrane,GO:0098554~cytoplasmic side of endoplasmic reticulum membrane,	GO:0005515~protein binding,GO:0042500~aspartic endopeptidase activity, intramembrane cleaving,GO:0042803~protein homodimerization activity,	IPR003137:PA_domain,IPR006639:Preselin/SPP,IPR007369:Peptidase_A22B_SPP,IPR046450:PA_dom_sf,		619549~Immunodeficiency 86, mycobacteriosis,		SM00730:PSN,		KW-0458~Lysosome,KW-0472~Membrane,KW-0967~Endosome,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0378~Hydrolase,KW-0645~Protease,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) (complex) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:PA,MOTIF:PAL,MOTIF:YXXo lysosomal targeting motif,MUTAGEN:D->A: Loss of intramembrane-cleaving activity toward FASLG, ITM2B, TNF and the simian foamy virus envelope glycoprotein gp130.,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
SRP9	signal recognition particle 9(SRP9)	Homo sapiens			GO:0006614~SRP-dependent cotranslational protein targeting to membrane,GO:0045900~negative regulation of translational elongation,	GO:0005785~signal recognition particle receptor complex,GO:0005786~signal recognition particle, endoplasmic reticulum targeting,GO:0005829~cytosol,	GO:0003723~RNA binding,GO:0005047~signal recognition particle binding,GO:0005515~protein binding,GO:0008312~7S RNA binding,	IPR008832:SRP9,IPR009018:Signal_recog_particle_SRP9/14,IPR039432:SRP9_dom,IPR039914:SRP9-like,	hsa03060:Protein export,		PIRSF017029:Signal_recog_particle_SRP9,			KW-0733~Signal recognition particle,KW-0963~Cytoplasm,				KW-0687~Ribonucleoprotein,KW-0694~RNA-binding,	KW-0007~Acetylation,	DOMAIN:SRP9,
SSR1	signal sequence receptor subunit 1(SSR1)	Homo sapiens			GO:0006613~cotranslational protein targeting to membrane,GO:0008284~positive regulation of cell proliferation,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0016020~membrane,	GO:0005515~protein binding,	IPR005595:TRAP_alpha,	hsa04141:Protein processing in endoplasmic reticulum,					KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,	KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
SSR2	signal sequence receptor subunit 2(SSR2)	Homo sapiens			GO:0006613~cotranslational protein targeting to membrane,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0016020~membrane,	GO:0005515~protein binding,	IPR008856:TRAP_beta,	hsa04141:Protein processing in endoplasmic reticulum,		PIRSF016400:TRAP_beta,			KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
SSR3	signal sequence receptor subunit 3(SSR3)	Homo sapiens			GO:0006614~SRP-dependent cotranslational protein targeting to membrane,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,	GO:0005515~protein binding,	IPR009779:SSR3,	hsa04141:Protein processing in endoplasmic reticulum,					KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
STAT1	signal transducer and activator of transcription 1(STAT1)	Homo sapiens	11.IL-6_gp130-Jak-STAT,12.IL-6_type_cytok-signal-transduct,17.Activators-CAM,2.Cytokine_Receptors,48.mice_minus_JAKs_and_STATs,75.Stats_activators_of_Apoptosis,	h_biopeptidesPathway:Bioactive Peptide Induced Signaling Pathway,h_chemicalPathway:Apoptotic Signaling in Response to DNA Damage,h_egfPathway:EGF Signaling Pathway,h_gleevecPathway:Inhibition of Cellular Proliferation by Gleevec,h_ifnaPathway:IFN alpha signaling pathway,h_ifngPathway:IFN gamma signaling pathway ,h_il10Pathway:IL-10 Anti-inflammatory Signaling Pathway,h_il22bpPathway:IL22 Soluble Receptor Signaling Pathway ,h_mapkPathway:MAPKinase Signaling Pathway,h_p38mapkPathway:p38 MAPK Signaling Pathway ,h_pdgfPathway:PDGF Signaling Pathway,h_tpoPathway:TPO Signaling Pathway,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001937~negative regulation of endothelial cell proliferation,GO:0002053~positive regulation of mesenchymal cell proliferation,GO:0002230~positive regulation of defense response to virus by host,GO:0003340~negative regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006952~defense response,GO:0007165~signal transduction,GO:0007166~cell surface receptor signaling pathway,GO:0007259~JAK-STAT cascade,GO:0007584~response to nutrient,GO:0008015~blood circulation,GO:0009410~response to xenobiotic stimulus,GO:0009612~response to mechanical stimulus,GO:0010742~macrophage derived foam cell differentiation,GO:0016525~negative regulation of angiogenesis,GO:0032727~positive regulation of interferon-alpha production,GO:0032869~cellular response to insulin stimulus,GO:0033209~tumor necrosis factor-mediated signaling pathway,GO:0034097~response to cytokine,GO:0034341~response to interferon-gamma,GO:0035456~response to interferon-beta,GO:0035458~cellular response to interferon-beta,GO:0038113~interleukin-9-mediated signaling pathway,GO:0042127~regulation of cell proliferation,GO:0042542~response to hydrogen peroxide,GO:0042981~regulation of apoptotic process,GO:0043124~negative regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043434~response to peptide hormone,GO:0045648~positive regulation of erythrocyte differentiation,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046725~negative regulation by virus of viral protein levels in host cell,GO:0048661~positive regulation of smooth muscle cell proliferation,GO:0051591~response to cAMP,GO:0051607~defense response to virus,GO:0051770~positive regulation of nitric-oxide synthase biosynthetic process,GO:0060333~interferon-gamma-mediated signaling pathway,GO:0060337~type I interferon signaling pathway,GO:0061326~renal tubule development,GO:0070106~interleukin-27-mediated signaling pathway,GO:0071310~cellular response to organic substance,GO:0071346~cellular response to interferon-gamma,GO:0071407~cellular response to organic cyclic compound,GO:0072136~metanephric mesenchymal cell proliferation involved in metanephros development,GO:0072162~metanephric mesenchymal cell differentiation,GO:0072308~negative regulation of metanephric nephron tubule epithelial cell differentiation,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0030424~axon,GO:0030425~dendrite,GO:0032991~macromolecular complex,GO:0048471~perinuclear region of cytoplasm,GO:0070721~ISGF3 complex,GO:0090575~RNA polymerase II transcription factor complex,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000979~RNA polymerase II core promoter sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001222~transcription corepressor binding,GO:0001223~transcription coactivator binding,GO:0003677~DNA binding,GO:0003690~double-stranded DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005164~tumor necrosis factor receptor binding,GO:0005515~protein binding,GO:0016922~ligand-dependent nuclear receptor binding,GO:0019899~enzyme binding,GO:0031730~CCR5 chemokine receptor binding,GO:0035035~histone acetyltransferase binding,GO:0042393~histone binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0044389~ubiquitin-like protein ligase binding,GO:0045296~cadherin binding,GO:0051721~protein phosphatase 2A binding,GO:1990841~promoter-specific chromatin binding,	IPR000980:SH2,IPR001217:STAT,IPR008967:p53-like_TF_DNA-bd_sf,IPR012345:STAT_TF_DNA-bd_N,IPR013799:STAT_TF_prot_interaction,IPR013800:STAT_TF_alpha,IPR013801:STAT_TF_DNA-bd,IPR015988:STAT_TF_coiled-coil,IPR022752:STAT1_TAZ2-bd_C,IPR035859:STAT1_SH2,IPR036535:STAT_N_sf,IPR036860:SH2_dom_sf,IPR038295:STAT1_C_sf,IPR048988:STAT_linker,	hsa04062:Chemokine signaling pathway,hsa04217:Necroptosis,hsa04380:Osteoclast differentiation,hsa04620:Toll-like receptor signaling pathway,hsa04621:NOD-like receptor signaling pathway,hsa04625:C-type lectin receptor signaling pathway,hsa04630:JAK-STAT signaling pathway,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04917:Prolactin signaling pathway,hsa04919:Thyroid hormone signaling pathway,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa04935:Growth hormone synthesis, secretion and action,hsa05140:Leishmaniasis,hsa05145:Toxoplasmosis,hsa05152:Tuberculosis,hsa05160:Hepatitis C,hsa05161:Hepatitis B,hsa05162:Measles,hsa05164:Influenza A,hsa05165:Human papillomavirus infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05171:Coronavirus disease - COVID-19,hsa05200:Pathways in cancer,hsa05212:Pancreatic cancer,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,hsa05321:Inflammatory bowel disease,	613796~Immunodeficiency 31B, mycobacterial and viral infections, autosomal recessive,614162~Immunodeficiency 31C, chronic mucocutaneous candidiasis, autosomal dominant,614892~Immunodeficiency 31A, mycobacteriosis, autosomal dominant,		SM00964:STAT_int,	KW-0051~Antiviral defense,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,	KW-0175~Coiled coil,KW-0727~SH2 domain,		KW-0010~Activator,KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0013~ADP-ribosylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:SH2,DOMAIN:STAT transcription factor protein interaction,MUTAGEN:AEN->CEC: Enhances STAT1 nuclear translocation and interferon (IFN)-stimulated gene (ISG) expression in response to IFN-beta stimulation. Reduces viral load in infected cultured cells.,MUTAGEN:E->Q: Loss of ADP-ribosylation and increased Tyr-701 phosphorylation; when associated with Q-657.,MUTAGEN:E->Q: Loss of ADP-ribosylation and increased Tyr-701 phosphorylation; when associated with Q-705.,MUTAGEN:K->A: No effect on IFN-alpha-induced STAT1 phosphorylation and nuclear translocation.,MUTAGEN:K->A: Strongly reduced IFN-alpha-induced STAT1 phosphorylation and nuclear translocation. Does not affect ability to homodimerize.,MUTAGEN:K->R: Abolishes sumoylation by SUMO1. Increased IFN-gamma-mediated transactivation.,MUTAGEN:K->R: Sumoylated.,MUTAGEN:KK->AA: No effect on IFN-alpha-induced STAT1 phosphorylation and nuclear translocation.,MUTAGEN:L->A: Impaired phosphorylation at S-727.,MUTAGEN:S->A: Decreased transcriptional activation. No effect on basal sumoylation. No enhancement of sumoylation on MAPK stimulation. No PRKCD-induced apoptosis. Upon IFNB induction, phosphorylated at Y-701 but not at S-708.,MUTAGEN:S->A: Phosphorylated at Y-701 upon IFNB induction.,MUTAGEN:S->D: No change in enhancement of MAPK-induced sumoylation. Basal interaction with PIAS1. Interaction with PIAS1 increased on MAPK stimulation.,MUTAGEN:S->D: Not phosphorylated at Y-701 upon IFNB induction.,MUTAGEN:S->E: No change in enhancement of MAPK-induced sumoylation.,MUTAGEN:Y->E: Not phosphorylated at S-708 upon IFNB induction.,MUTAGEN:Y->F: No effect on basal sumoylation. Enhances sumoylation in the presence of MAPK stimulation. Phosphorylated at S-708 upon IFNB induction.,SITE:Required for recruitment of EP300/p300,
STAT3	signal transducer and activator of transcription 3(STAT3)	Homo sapiens	11.IL-6_gp130-Jak-STAT,12.IL-6_type_cytok-signal-transduct,48.mice_minus_JAKs_and_STATs,	h_biopeptidesPathway:Bioactive Peptide Induced Signaling Pathway,h_egfPathway:EGF Signaling Pathway,h_erkPathway:Erk1/Erk2 Mapk Signaling pathway,h_her2Pathway:Role of ERBB2 in Signal Transduction and Oncology,h_il10Pathway:IL-10 Anti-inflammatory Signaling Pathway,h_il22bpPathway:IL22 Soluble Receptor Signaling Pathway ,h_il6Pathway:IL 6 signaling pathway,h_metPathway:Signaling of Hepatocyte Growth Factor Receptor,h_pdgfPathway:PDGF Signaling Pathway,h_stat3Pathway:Stat3 Signaling Pathway,h_tpoPathway:TPO Signaling Pathway,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001659~temperature homeostasis,GO:0001754~eye photoreceptor cell differentiation,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006606~protein import into nucleus,GO:0006952~defense response,GO:0006954~inflammatory response,GO:0007165~signal transduction,GO:0007166~cell surface receptor signaling pathway,GO:0007179~transforming growth factor beta receptor signaling pathway,GO:0007259~JAK-STAT cascade,GO:0007399~nervous system development,GO:0008283~cell proliferation,GO:0008285~negative regulation of cell proliferation,GO:0010507~negative regulation of autophagy,GO:0010575~positive regulation of vascular endothelial growth factor production,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0016310~phosphorylation,GO:0019221~cytokine-mediated signaling pathway,GO:0019953~sexual reproduction,GO:0030154~cell differentiation,GO:0030335~positive regulation of cell migration,GO:0030522~intracellular receptor signaling pathway,GO:0032355~response to estradiol,GO:0032731~positive regulation of interleukin-1 beta production,GO:0032733~positive regulation of interleukin-10 production,GO:0032755~positive regulation of interleukin-6 production,GO:0032757~positive regulation of interleukin-8 production,GO:0032760~positive regulation of tumor necrosis factor production,GO:0032870~cellular response to hormone stimulus,GO:0033210~leptin-mediated signaling pathway,GO:0035019~somatic stem cell population maintenance,GO:0035723~interleukin-15-mediated signaling pathway,GO:0038110~interleukin-2-mediated signaling pathway,GO:0038113~interleukin-9-mediated signaling pathway,GO:0038154~interleukin-11-mediated signaling pathway,GO:0040014~regulation of multicellular organism growth,GO:0042127~regulation of cell proliferation,GO:0042593~glucose homeostasis,GO:0042755~eating behavior,GO:0042789~mRNA transcription from RNA polymerase II promoter,GO:0043434~response to peptide hormone,GO:0043491~protein kinase B signaling,GO:0044320~cellular response to leptin stimulus,GO:0044321~response to leptin,GO:0045648~positive regulation of erythrocyte differentiation,GO:0045747~positive regulation of Notch signaling pathway,GO:0045766~positive regulation of angiogenesis,GO:0045820~negative regulation of glycolytic process,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048708~astrocyte differentiation,GO:0050728~negative regulation of inflammatory response,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0051726~regulation of cell cycle,GO:0060019~radial glial cell differentiation,GO:0060221~retinal rod cell differentiation,GO:0060259~regulation of feeding behavior,GO:0060396~growth hormone receptor signaling pathway,GO:0060397~JAK-STAT cascade involved in growth hormone signaling pathway,GO:0070102~interleukin-6-mediated signaling pathway,GO:0071310~cellular response to organic substance,GO:0072538~T-helper 17 type immune response,GO:0072540~T-helper 17 cell lineage commitment,GO:0097009~energy homeostasis,GO:0097398~cellular response to interleukin-17,GO:0097696~STAT cascade,GO:1900017~positive regulation of cytokine production involved in inflammatory response,GO:1902895~positive regulation of pri-miRNA transcription from RNA polymerase II promoter,GO:1904685~positive regulation of metalloendopeptidase activity,GO:1905564~positive regulation of vascular endothelial cell proliferation,GO:2000635~negative regulation of primary miRNA processing,GO:2000737~negative regulation of stem cell differentiation,GO:2001223~negative regulation of neuron migration,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0090575~RNA polymerase II transcription factor complex,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0004879~RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding,GO:0005102~receptor binding,GO:0005515~protein binding,GO:0019901~protein kinase binding,GO:0019903~protein phosphatase binding,GO:0031490~chromatin DNA binding,GO:0035591~signaling adaptor activity,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0046983~protein dimerization activity,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:0070878~primary miRNA binding,	IPR000980:SH2,IPR001217:STAT,IPR008967:p53-like_TF_DNA-bd_sf,IPR012345:STAT_TF_DNA-bd_N,IPR013799:STAT_TF_prot_interaction,IPR013800:STAT_TF_alpha,IPR013801:STAT_TF_DNA-bd,IPR015988:STAT_TF_coiled-coil,IPR035855:STAT3_SH2,IPR036535:STAT_N_sf,IPR036860:SH2_dom_sf,IPR048988:STAT_linker,	hsa01521:EGFR tyrosine kinase inhibitor resistance,hsa04062:Chemokine signaling pathway,hsa04066:HIF-1 signaling pathway,hsa04068:FoxO signaling pathway,hsa04217:Necroptosis,hsa04550:Signaling pathways regulating pluripotency of stem cells,hsa04630:JAK-STAT signaling pathway,hsa04659:Th17 cell differentiation,hsa04917:Prolactin signaling pathway,hsa04920:Adipocytokine signaling pathway,hsa04931:Insulin resistance,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa04935:Growth hormone synthesis, secretion and action,hsa05145:Toxoplasmosis,hsa05160:Hepatitis C,hsa05161:Hepatitis B,hsa05162:Measles,hsa05163:Human cytomegalovirus infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05169:Epstein-Barr virus infection,hsa05171:Coronavirus disease - COVID-19,hsa05200:Pathways in cancer,hsa05203:Viral carcinogenesis,hsa05205:Proteoglycans in cancer,hsa05206:MicroRNAs in cancer,hsa05207:Chemical carcinogenesis - receptor activation,hsa05212:Pancreatic cancer,hsa05221:Acute myeloid leukemia,hsa05223:Non-small cell lung cancer,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,hsa05321:Inflammatory bowel disease,hsa05417:Lipid and atherosclerosis,	147060~Hyper-IgE syndrome 1, autosomal dominant, with recurrent infections,615952~Autoimmune disease, multisystem, infantile-onset, 1,		SM00964:STAT_int,	KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0219~Diabetes mellitus,KW-0225~Disease variant,KW-0242~Dwarfism,	KW-0175~Coiled coil,KW-0727~SH2 domain,KW-0732~Signal,		KW-0010~Activator,KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:SH2,DOMAIN:STAT transcription factor protein interaction,MOTIF:Essential for nuclear import,MUTAGEN:EE->AA: Inhibits leptin-mediated transactivation of CCND1 promoter. No effect on interaction with INPP5F.,MUTAGEN:Y->F: Inhibits leptin-mediated transactivation of CCND1 promoter. Abolished phosphorylation by isoform M2 of PKM (PKM2).,REGION:Disordered,
STAT4	signal transducer and activator of transcription 4(STAT4)	Homo sapiens	48.mice_minus_JAKs_and_STATs,80.T_cell_Activation,	h_il12Pathway:IL12 and Stat4 Dependent Signaling Pathway in Th1 Development,h_no2il12Pathway:NO2-dependent IL 12 Pathway in NK cells,	GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006952~defense response,GO:0007165~signal transduction,GO:0007166~cell surface receptor signaling pathway,GO:0007259~JAK-STAT cascade,GO:0019221~cytokine-mediated signaling pathway,GO:0035722~interleukin-12-mediated signaling pathway,GO:0042127~regulation of cell proliferation,GO:0043434~response to peptide hormone,GO:0045063~T-helper 1 cell differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0071310~cellular response to organic substance,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0090575~RNA polymerase II transcription factor complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR000980:SH2,IPR001217:STAT,IPR008967:p53-like_TF_DNA-bd_sf,IPR012345:STAT_TF_DNA-bd_N,IPR013799:STAT_TF_prot_interaction,IPR013800:STAT_TF_alpha,IPR013801:STAT_TF_DNA-bd,IPR015155:PFU,IPR015988:STAT_TF_coiled-coil,IPR029839:STAT4_DBD,IPR035856:STAT4_SH2,IPR036535:STAT_N_sf,IPR036860:SH2_dom_sf,IPR046991:STAT4_CCD,IPR048988:STAT_linker,	hsa04217:Necroptosis,hsa04630:JAK-STAT signaling pathway,hsa04658:Th1 and Th2 cell differentiation,hsa05161:Hepatitis B,hsa05200:Pathways in cancer,hsa05321:Inflammatory bowel disease,	612253~Systemic lupus erythematosus, susceptibility to, 11,620443~Disabling pansclerotic morphea of childhood,		SM00964:STAT_int,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0772~Systemic lupus erythematosus,	KW-0175~Coiled coil,KW-0727~SH2 domain,		KW-0010~Activator,KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:PFU,DOMAIN:SH2,DOMAIN:STAT transcription factor protein interaction,DOMAIN:Signal transducer and activator of transcription linker,MUTAGEN:S->A: About 50% loss of transcriptional activity.,MUTAGEN:Y->A: Abrogates phosphorylation and transcriptional activity.,
STAT5A	signal transducer and activator of transcription 5A(STAT5A)	Homo sapiens	48.mice_minus_JAKs_and_STATs,	h_biopeptidesPathway:Bioactive Peptide Induced Signaling Pathway,h_egfPathway:EGF Signaling Pathway,h_epoPathway:EPO Signaling Pathway,h_ghPathway:Growth Hormone Signaling Pathway,h_gleevecPathway:Inhibition of Cellular Proliferation by Gleevec,h_il10Pathway:IL-10 Anti-inflammatory Signaling Pathway,h_il22bpPathway:IL22 Soluble Receptor Signaling Pathway ,h_il2Pathway:IL 2 signaling pathway,h_il2rbPathway:IL-2 Receptor Beta Chain in T cell Activation,h_il3Pathway:IL 3 signaling pathway,h_il7Pathway:IL-7 Signal Transduction,h_pdgfPathway:PDGF Signaling Pathway,h_PparaPathway:Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha),h_tpoPathway:TPO Signaling Pathway,	GO:0000278~mitotic cell cycle,GO:0001553~luteinization,GO:0001779~natural killer cell differentiation,GO:0001787~natural killer cell proliferation,GO:0001938~positive regulation of endothelial cell proliferation,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0006952~defense response,GO:0007165~signal transduction,GO:0007166~cell surface receptor signaling pathway,GO:0007259~JAK-STAT cascade,GO:0007565~female pregnancy,GO:0007595~lactation,GO:0019218~regulation of steroid metabolic process,GO:0019221~cytokine-mediated signaling pathway,GO:0019530~taurine metabolic process,GO:0019915~lipid storage,GO:0030183~B cell differentiation,GO:0030218~erythrocyte differentiation,GO:0030222~eosinophil differentiation,GO:0030856~regulation of epithelial cell differentiation,GO:0032355~response to estradiol,GO:0032743~positive regulation of interleukin-2 production,GO:0032819~positive regulation of natural killer cell proliferation,GO:0032825~positive regulation of natural killer cell differentiation,GO:0032870~cellular response to hormone stimulus,GO:0033028~myeloid cell apoptotic process,GO:0033033~negative regulation of myeloid cell apoptotic process,GO:0033077~T cell differentiation in thymus,GO:0035723~interleukin-15-mediated signaling pathway,GO:0035771~interleukin-4-mediated signaling pathway,GO:0038026~reelin-mediated signaling pathway,GO:0038043~interleukin-5-mediated signaling pathway,GO:0038110~interleukin-2-mediated signaling pathway,GO:0038113~interleukin-9-mediated signaling pathway,GO:0038156~interleukin-3-mediated signaling pathway,GO:0040014~regulation of multicellular organism growth,GO:0040018~positive regulation of multicellular organism growth,GO:0042104~positive regulation of activated T cell proliferation,GO:0042127~regulation of cell proliferation,GO:0042267~natural killer cell mediated cytotoxicity,GO:0042448~progesterone metabolic process,GO:0042492~gamma-delta T cell differentiation,GO:0043029~T cell homeostasis,GO:0043434~response to peptide hormone,GO:0043536~positive regulation of blood vessel endothelial cell migration,GO:0045579~positive regulation of B cell differentiation,GO:0045588~positive regulation of gamma-delta T cell differentiation,GO:0045647~negative regulation of erythrocyte differentiation,GO:0045648~positive regulation of erythrocyte differentiation,GO:0045931~positive regulation of mitotic cell cycle,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0045954~positive regulation of natural killer cell mediated cytotoxicity,GO:0046543~development of secondary female sexual characteristics,GO:0046544~development of secondary male sexual characteristics,GO:0048541~Peyer's patch development,GO:0050729~positive regulation of inflammatory response,GO:0050798~activated T cell proliferation,GO:0060397~JAK-STAT cascade involved in growth hormone signaling pathway,GO:0070669~response to interleukin-2,GO:0070670~response to interleukin-4,GO:0070672~response to interleukin-15,GO:0071310~cellular response to organic substance,GO:0071363~cellular response to growth factor stimulus,GO:0071364~cellular response to epidermal growth factor stimulus,GO:0097531~mast cell migration,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0090575~RNA polymerase II transcription factor complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0035259~glucocorticoid receptor binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0046983~protein dimerization activity,	IPR000980:SH2,IPR001217:STAT,IPR008967:p53-like_TF_DNA-bd_sf,IPR012345:STAT_TF_DNA-bd_N,IPR013799:STAT_TF_prot_interaction,IPR013800:STAT_TF_alpha,IPR013801:STAT_TF_DNA-bd,IPR015988:STAT_TF_coiled-coil,IPR035858:STAT5a/5b_DBD,IPR035886:STAT5b_SH2,IPR036535:STAT_N_sf,IPR036860:SH2_dom_sf,IPR046994:STAT5_CCD,IPR048988:STAT_linker,	hsa04012:ErbB signaling pathway,hsa04217:Necroptosis,hsa04630:JAK-STAT signaling pathway,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04917:Prolactin signaling pathway,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa04935:Growth hormone synthesis, secretion and action,hsa05161:Hepatitis B,hsa05162:Measles,hsa05166:Human T-cell leukemia virus 1 infection,hsa05200:Pathways in cancer,hsa05203:Viral carcinogenesis,hsa05207:Chemical carcinogenesis - receptor activation,hsa05220:Chronic myeloid leukemia,hsa05221:Acute myeloid leukemia,hsa05223:Non-small cell lung cancer,			SM00252:SH2,SM00964:STAT_int,	KW-0421~Lactation,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0242~Dwarfism,	KW-0727~SH2 domain,		KW-0010~Activator,KW-0238~DNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	DOMAIN:SH2,DOMAIN:STAT transcription factor protein interaction,MUTAGEN:T->A: Abolishes interaction with INSR.,MUTAGEN:Y->F: Abolishes phosphorylation by HCK.,REGION:Disordered,REGION:Required for interaction with NMI,
STAT5B	signal transducer and activator of transcription 5B(STAT5B)	Homo sapiens	48.mice_minus_JAKs_and_STATs,	h_epoPathway:EPO Signaling Pathway,h_ghPathway:Growth Hormone Signaling Pathway,h_gleevecPathway:Inhibition of Cellular Proliferation by Gleevec,h_il22bpPathway:IL22 Soluble Receptor Signaling Pathway ,h_il2Pathway:IL 2 signaling pathway,h_il2rbPathway:IL-2 Receptor Beta Chain in T cell Activation,h_il3Pathway:IL 3 signaling pathway,h_il7Pathway:IL-7 Signal Transduction,h_PparaPathway:Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha),h_tpoPathway:TPO Signaling Pathway,	GO:0000278~mitotic cell cycle,GO:0001553~luteinization,GO:0001779~natural killer cell differentiation,GO:0001787~natural killer cell proliferation,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0006952~defense response,GO:0007165~signal transduction,GO:0007166~cell surface receptor signaling pathway,GO:0007259~JAK-STAT cascade,GO:0007565~female pregnancy,GO:0007595~lactation,GO:0019218~regulation of steroid metabolic process,GO:0019221~cytokine-mediated signaling pathway,GO:0019530~taurine metabolic process,GO:0019915~lipid storage,GO:0030183~B cell differentiation,GO:0030218~erythrocyte differentiation,GO:0030856~regulation of epithelial cell differentiation,GO:0032355~response to estradiol,GO:0032743~positive regulation of interleukin-2 production,GO:0032819~positive regulation of natural killer cell proliferation,GO:0032825~positive regulation of natural killer cell differentiation,GO:0032870~cellular response to hormone stimulus,GO:0033028~myeloid cell apoptotic process,GO:0033033~negative regulation of myeloid cell apoptotic process,GO:0033077~T cell differentiation in thymus,GO:0040014~regulation of multicellular organism growth,GO:0040018~positive regulation of multicellular organism growth,GO:0042104~positive regulation of activated T cell proliferation,GO:0042127~regulation of cell proliferation,GO:0042267~natural killer cell mediated cytotoxicity,GO:0042448~progesterone metabolic process,GO:0042492~gamma-delta T cell differentiation,GO:0043029~T cell homeostasis,GO:0043434~response to peptide hormone,GO:0045579~positive regulation of B cell differentiation,GO:0045588~positive regulation of gamma-delta T cell differentiation,GO:0045647~negative regulation of erythrocyte differentiation,GO:0045648~positive regulation of erythrocyte differentiation,GO:0045931~positive regulation of mitotic cell cycle,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0045954~positive regulation of natural killer cell mediated cytotoxicity,GO:0046543~development of secondary female sexual characteristics,GO:0046544~development of secondary male sexual characteristics,GO:0048541~Peyer's patch development,GO:0050729~positive regulation of inflammatory response,GO:0050798~activated T cell proliferation,GO:0060397~JAK-STAT cascade involved in growth hormone signaling pathway,GO:0070669~response to interleukin-2,GO:0070670~response to interleukin-4,GO:0070672~response to interleukin-15,GO:0071310~cellular response to organic substance,GO:0071363~cellular response to growth factor stimulus,GO:0071364~cellular response to epidermal growth factor stimulus,GO:0097531~mast cell migration,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0090575~RNA polymerase II transcription factor complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0035259~glucocorticoid receptor binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0046983~protein dimerization activity,	IPR000980:SH2,IPR001217:STAT,IPR008967:p53-like_TF_DNA-bd_sf,IPR012345:STAT_TF_DNA-bd_N,IPR013799:STAT_TF_prot_interaction,IPR013800:STAT_TF_alpha,IPR013801:STAT_TF_DNA-bd,IPR015988:STAT_TF_coiled-coil,IPR035858:STAT5a/5b_DBD,IPR035886:STAT5b_SH2,IPR036535:STAT_N_sf,IPR036860:SH2_dom_sf,IPR046994:STAT5_CCD,IPR048988:STAT_linker,	hsa04012:ErbB signaling pathway,hsa04062:Chemokine signaling pathway,hsa04217:Necroptosis,hsa04630:JAK-STAT signaling pathway,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04917:Prolactin signaling pathway,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa04935:Growth hormone synthesis, secretion and action,hsa05161:Hepatitis B,hsa05162:Measles,hsa05166:Human T-cell leukemia virus 1 infection,hsa05200:Pathways in cancer,hsa05203:Viral carcinogenesis,hsa05207:Chemical carcinogenesis - receptor activation,hsa05220:Chronic myeloid leukemia,hsa05221:Acute myeloid leukemia,hsa05223:Non-small cell lung cancer,	102578~Leukemia, acute promyelocytic, somatic,245590~Growth hormone insensitivity with immune dysregulation 1, autosomal recessive,618985~Growth hormone insensitivity with immune dysregulation 2, autosomal dominant,		SM00252:SH2,SM00964:STAT_int,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0242~Dwarfism,	KW-0727~SH2 domain,		KW-0010~Activator,KW-0238~DNA-binding,	KW-0597~Phosphoprotein,	DOMAIN:SH2,DOMAIN:STAT transcription factor protein interaction,MUTAGEN:T->A: Abolishes interaction with INSR.,MUTAGEN:Y->F: Abolishes phosphorylation by HCK.,REGION:Required for interaction with NMI,
STAM	signal transducing adaptor molecule(STAM)	Homo sapiens			GO:0007165~signal transduction,GO:0015031~protein transport,GO:0016236~macroautophagy,GO:0036258~multivesicular body assembly,GO:0043328~protein targeting to vacuole involved in ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway,GO:0090148~membrane fission,GO:1903543~positive regulation of exosomal secretion,GO:1903551~regulation of extracellular exosome assembly,	GO:0005829~cytosol,GO:0031901~early endosome membrane,GO:0033565~ESCRT-0 complex,GO:0043231~intracellular membrane-bounded organelle,	GO:0005515~protein binding,GO:0035091~phosphatidylinositol binding,GO:0043130~ubiquitin binding,GO:0044389~ubiquitin-like protein ligase binding,	IPR001452:SH3_domain,IPR002014:VHS_dom,IPR003903:UIM_dom,IPR008942:ENTH_VHS,IPR035657:STAM1_SH3,IPR036028:SH3-like_dom_sf,IPR047492:GAT_STAM1,IPR047528:VHS_STAM1,	hsa04144:Endocytosis,hsa04630:JAK-STAT signaling pathway,			SM00288:VHS,SM00326:SH3,	KW-0653~Protein transport,KW-0813~Transport,	KW-0472~Membrane,KW-0963~Cytoplasm,KW-0967~Endosome,		KW-0728~SH3 domain,			KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:ITAM,DOMAIN:SH3,DOMAIN:UIM,DOMAIN:VHS,REGION:Disordered,
SIGIRR	single Ig and TIR domain containing(SIGIRR)	Homo sapiens			GO:0001960~negative regulation of cytokine-mediated signaling pathway,GO:0006953~acute-phase response,GO:0007165~signal transduction,GO:0031665~negative regulation of lipopolysaccharide-mediated signaling pathway,GO:0032682~negative regulation of chemokine production,GO:0043433~negative regulation of sequence-specific DNA binding transcription factor activity,	GO:0005886~plasma membrane,GO:0016020~membrane,	GO:0005515~protein binding,	IPR000157:TIR_dom,IPR007110:Ig-like_dom,IPR013783:Ig-like_fold,IPR015621:IL-1_rcpt_fam,IPR035897:Toll_tir_struct_dom_sf,IPR036179:Ig-like_dom_sf,				SM00255:TIR,		KW-0472~Membrane,		KW-0393~Immunoglobulin domain,KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type,DOMAIN:TIR,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type III membrane protein,
SSBP1	single stranded DNA binding protein 1(SSBP1)	Homo sapiens			GO:0006260~DNA replication,GO:0006264~mitochondrial DNA replication,GO:0006268~DNA unwinding involved in DNA replication,GO:0051096~positive regulation of helicase activity,GO:0051289~protein homotetramerization,GO:0070584~mitochondrion morphogenesis,GO:0090297~positive regulation of mitochondrial DNA replication,	GO:0005634~nucleus,GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0042645~mitochondrial nucleoid,GO:0070062~extracellular exosome,	GO:0003682~chromatin binding,GO:0003697~single-stranded DNA binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,	IPR000424:Primosome_PriB/ssb,IPR011344:ssDNA-bd,IPR012340:NA-bd_OB-fold,	hsa03030:DNA replication,hsa03430:Mismatch repair,hsa03440:Homologous recombination,	165510~Optic atrophy 13 with retinal and foveal abnormalities,	PIRSF002070:SSB,		KW-0235~DNA replication,	KW-0496~Mitochondrion,KW-1135~Mitochondrion nucleoid,	KW-0225~Disease variant,	KW-0809~Transit peptide,		KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:SSB,MUTAGEN:EGK->AAA: In mtSSBloop12; decreased unwinding of double-stranded DNA by the helicase TWNK and increased binding to single-stranded DNA, in vitro.,MUTAGEN:KNN->AAA: In mtSSB45-2; decreased unwinding of double-stranded DNA by the helicase TWNK, in vitro.,MUTAGEN:Missing: In mtSSBloop23; reduced ability to open template DNA and decreased POLG polymerase activity, in vitro. Also displays decreased unwinding of double-stranded DNA by the helicase TWNK and increased binding to single-stranded DNA.,MUTAGEN:YGE->AAA: In mtSSB45-1; decreased POLG polymerase activity and increased unwinding of double-stranded DNA by the helicase TWNK, in vitro.,MUTAGEN:YQ->AA: In mtSSBalpha1; decreased POLG polymerase activity, in vitro. No effect on unwinding of double-stranded DNA by the helicase TWNK.,TRANSIT:Mitochondrion,
SMDT1	single-pass membrane protein with aspartate rich tail 1(SMDT1)	Homo sapiens			GO:0006851~mitochondrial calcium ion transport,GO:0036444~mitochondrial calcium uptake,GO:0051560~mitochondrial calcium ion homeostasis,	GO:0005654~nucleoplasm,GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005759~mitochondrial matrix,GO:1990246~uniplex complex,	GO:0005515~protein binding,	IPR018782:MCU_reg,					KW-0109~Calcium transport,KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,		KW-0809~Transit peptide,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,			MOTIF:GXXXX[G/A/S],MUTAGEN:EDDDDDD->QNNNNNN: Abolishes regulation of calcium uptake into mitochondria.,MUTAGEN:G->W: Abolishes calcium uptake into mitochondria.,MUTAGEN:S->W: Abolishes calcium uptake into mitochondria.,REGION:Interaction with MAIP1,TOPO_DOM:Mitochondrial intermembrane,TOPO_DOM:Mitochondrial matrix,TRANSIT:Mitochondrion,TRANSMEM:Helical,
SIRT2	sirtuin 2(SIRT2)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0000183~chromatin silencing at rDNA,GO:0006476~protein deacetylation,GO:0006914~autophagy,GO:0007084~mitotic nuclear envelope reassembly,GO:0007096~regulation of exit from mitosis,GO:0010507~negative regulation of autophagy,GO:0010801~negative regulation of peptidyl-threonine phosphorylation,GO:0016575~histone deacetylation,GO:0021762~substantia nigra development,GO:0022011~myelination in peripheral nervous system,GO:0031507~heterochromatin assembly,GO:0031509~telomeric heterochromatin assembly,GO:0031641~regulation of myelination,GO:0032436~positive regulation of proteasomal ubiquitin-dependent protein catabolic process,GO:0034599~cellular response to oxidative stress,GO:0034983~peptidyl-lysine deacetylation,GO:0040029~regulation of gene expression, epigenetic,GO:0042177~negative regulation of protein catabolic process,GO:0042325~regulation of phosphorylation,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0043388~positive regulation of DNA binding,GO:0044242~cellular lipid catabolic process,GO:0044546~NLRP3 inflammasome complex assembly,GO:0045087~innate immune response,GO:0045599~negative regulation of fat cell differentiation,GO:0045723~positive regulation of fatty acid biosynthetic process,GO:0045836~positive regulation of meiotic nuclear division,GO:0045843~negative regulation of striated muscle tissue development,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051301~cell division,GO:0051321~meiotic cell cycle,GO:0051726~regulation of cell cycle,GO:0051775~response to redox state,GO:0051781~positive regulation of cell division,GO:0051987~positive regulation of attachment of spindle microtubules to kinetochore,GO:0061428~negative regulation of transcription from RNA polymerase II promoter in response to hypoxia,GO:0061433~cellular response to caloric restriction,GO:0070446~negative regulation of oligodendrocyte progenitor proliferation,GO:0071456~cellular response to hypoxia,GO:0071872~cellular response to epinephrine stimulus,GO:0090042~tubulin deacetylation,GO:1900119~positive regulation of execution phase of apoptosis,GO:1900195~positive regulation of oocyte maturation,GO:1900226~negative regulation of NLRP3 inflammasome complex assembly,GO:2000378~negative regulation of reactive oxygen species metabolic process,	GO:0000781~chromosome, telomeric region,GO:0000792~heterochromatin,GO:0005634~nucleus,GO:0005677~chromatin silencing complex,GO:0005694~chromosome,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005813~centrosome,GO:0005814~centriole,GO:0005819~spindle,GO:0005829~cytosol,GO:0005874~microtubule,GO:0005886~plasma membrane,GO:0030426~growth cone,GO:0030496~midbody,GO:0033010~paranodal junction,GO:0033270~paranode region of axon,GO:0043204~perikaryon,GO:0043209~myelin sheath,GO:0043219~lateral loop,GO:0043220~Schmidt-Lanterman incisure,GO:0044224~juxtaparanode region of axon,GO:0048471~perinuclear region of cytoplasm,GO:0072686~mitotic spindle,GO:0072687~meiotic spindle,GO:0097386~glial cell projection,	GO:0003682~chromatin binding,GO:0003950~NAD+ ADP-ribosyltransferase activity,GO:0004407~histone deacetylase activity,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:0008270~zinc ion binding,GO:0016740~transferase activity,GO:0017136~NAD-dependent histone deacetylase activity,GO:0033558~protein deacetylase activity,GO:0034979~NAD-dependent protein deacetylase activity,GO:0035035~histone acetyltransferase binding,GO:0042826~histone deacetylase binding,GO:0042903~tubulin deacetylase activity,GO:0043130~ubiquitin binding,GO:0046872~metal ion binding,GO:0046970~NAD-dependent histone deacetylase activity (H4-K16 specific),GO:0070403~NAD+ binding,	IPR003000:Sirtuin,IPR017328:Sirtuin_class_I,IPR026590:Ssirtuin_cat_dom,IPR026591:Sirtuin_cat_small_dom_sf,IPR029035:DHS-like_NAD/FAD-binding_dom,	hsa00760:Nicotinate and nicotinamide metabolism,hsa01100:Metabolic pathways,		PIRSF037938:SIR2_euk,		KW-0072~Autophagy,KW-0131~Cell cycle,KW-0132~Cell division,KW-0221~Differentiation,KW-0391~Immunity,KW-0399~Innate immunity,KW-0469~Meiosis,KW-0498~Mitosis,KW-0524~Neurogenesis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0158~Chromosome,KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0493~Microtubule,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-1003~Cell membrane,	KW-0523~Neurodegeneration,		KW-0479~Metal-binding,KW-0520~NAD,KW-0862~Zinc,	KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	ACT_SITE:Proton acceptor,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Deacetylase sirtuin-type,MOTIF:Nuclear export signal,MUTAGEN:D->A,N: Reduces deacetylase activity.,MUTAGEN:D->A: Reduces binding for the peptide inhibitor S2iL5.,MUTAGEN:E->A: Reduces binding for the peptide inhibitor S2iL5.,MUTAGEN:F->A: Strongly reduces binding for the peptide inhibitor S2iL5.,MUTAGEN:H->Y,A: Inhibits deacetylase activity toward histone, alpha-tubulin, FZR1 and CDC20. No effect on CDK2-dependent phosphorylation. Does not inhibit interaction with alpha-tubulin, HDAC6, HIF1A and the cyclin E-CDK2 complex. Inhibits interaction with BEX4 and KMT5A. Abolishes deacetylation, dimeric formation and enzymatic activity increase of G6PD. Prevents histone H4 methylation at 'Lys-20'(H4K20me1) in metaphase chromosomes. Inhibits the block of entry to chromosome condensation and subsequent hyperploidy cell formation in response to mitotic stress; when associated with A-167 and A-168. Strongly reduced activity toward long-chain fatty acyl groups.,MUTAGEN:N->A: Abolishes deacetylation of alpha-tubulin. Inhibits deacetylation of histone H3 at 'Lys-18'. Inhibits the block of entry to chromosome condensation and subsequent hyperploidy cell formation in response to mitotic stress; when associated with A-167 and A-187.,MUTAGEN:Q->A: Reduces binding for the peptide inhibitor S2iL5.,MUTAGEN:Q->A: Reduces deacetylase activity. Inhibits the block of entry to chromosome condensation and subsequent hyperploidy cell formation in response to mitotic stress; when associated with A-168 and A-187.,MUTAGEN:R->A: No effect on deacetylase activity.,MUTAGEN:S->A: Abolishes CDK2-dependent phosphorylation.,MUTAGEN:S->A: Does not affect deacetylase activity. Abolishes CDK2-dependent phosphorylation. Inhibits cellular proliferation delay in the early metaphase to prevent chromosomal instability. Does not inhibit interaction with a cyclin E-CDK2 complex. Does not inhibit interaction with HDAC6 and ubiquitination. Inhibits cell adhesion and migration and neurite outgrowth. Inhibits deacetylase activity; when associated with A-372.,MUTAGEN:S->A: Inhibits deacetylase activity.,MUTAGEN:S->A: Reduces binding for the peptide inhibitor S2iL5.,MUTAGEN:S->A: Reduces deacetylase activity.,MUTAGEN:S->A: Reduces phosphorylation. Does not inhibit interaction with HDAC6, ubiquitination and deacetylase activity. Inhibits deacetylase activity; when associated with A-368.,MUTAGEN:S->D: Abolishes CDK2-dependent phosphorylation. Inhibits interaction with a cyclin E-CDK2 complex. Reduces strongly histone deacetylation activity.,MUTAGEN:S->E: Abolishes CDK2-dependent phosphorylation.,MUTAGEN:T->A: Reduces deacetylase activity.,MUTAGEN:Y->A: Reduces deacetylase activity.,REGION:Disordered,
SMAP1	small ArfGAP 1(SMAP1)	Homo sapiens			GO:0045648~positive regulation of erythrocyte differentiation,GO:2000369~regulation of clathrin-dependent endocytosis,	GO:0005737~cytoplasm,GO:0005886~plasma membrane,	GO:0005096~GTPase activator activity,GO:0030276~clathrin binding,GO:0046872~metal ion binding,	IPR001164:ArfGAP_dom,IPR037278:ARFGAP/RecO,IPR038508:ArfGAP_dom_sf,IPR044732:ArfGAP_SMAP1-like,	hsa04144:Endocytosis,			SM00105:ArfGap,		KW-0472~Membrane,KW-1003~Cell membrane,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0343~GTPase activation,		COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Arf-GAP,MOTIF:Interaction with clathrin heavy chains,REGION:Disordered,ZN_FING:C4-type,
SMAP2	small ArfGAP2(SMAP2)	Homo sapiens				GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0005096~GTPase activator activity,GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR001164:ArfGAP_dom,IPR037278:ARFGAP/RecO,IPR038508:ArfGAP_dom_sf,	hsa04144:Endocytosis,			SM00105:ArfGap,		KW-0963~Cytoplasm,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0343~GTPase activation,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:Arf-GAP,REGION:Disordered,REGION:Interaction with PICALM,REGION:Interaction with clathrin heavy chains,ZN_FING:C4-type,
SVIP	small VCP interacting protein(SVIP)	Homo sapiens			GO:0010508~positive regulation of autophagy,GO:0031333~negative regulation of protein complex assembly,GO:1903061~positive regulation of protein lipidation,GO:1903070~negative regulation of ER-associated ubiquitin-dependent protein catabolic process,GO:1904153~negative regulation of retrograde protein transport, ER to cytosol,GO:1904240~negative regulation of VCP-NPL4-UFD1 AAA ATPase complex assembly,GO:1904293~negative regulation of ERAD pathway,	GO:0000139~Golgi membrane,GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0030667~secretory granule membrane,GO:0030868~smooth endoplasmic reticulum membrane,GO:0070062~extracellular exosome,GO:0070821~tertiary granule membrane,	GO:0005515~protein binding,GO:0043621~protein self-association,GO:0051117~ATPase binding,	IPR031632:SVIP,	hsa04141:Protein processing in endoplasmic reticulum,					KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-1003~Cell membrane,					KW-0449~Lipoprotein,KW-0519~Myristate,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,LIPID:N-myristoyl glycine,REGION:Disordered,REGION:VCP/p97-interacting motif (VIM),
SGTA	small glutamine rich tetratricopeptide repeat co-chaperone alpha(SGTA)	Homo sapiens			GO:0006620~posttranslational protein targeting to membrane,GO:0030433~ubiquitin-dependent ERAD pathway,GO:0036503~ERAD pathway,GO:0071816~tail-anchored membrane protein insertion into ER membrane,GO:1903070~negative regulation of ER-associated ubiquitin-dependent protein catabolic process,GO:1903071~positive regulation of ER-associated ubiquitin-dependent protein catabolic process,GO:1904293~negative regulation of ERAD pathway,GO:1904294~positive regulation of ERAD pathway,GO:2000059~negative regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process,GO:2000060~positive regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016020~membrane,GO:0072380~TRC complex,	GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0043621~protein self-association,GO:0060090~binding, bridging,GO:1904288~BAT3 complex binding,	IPR001440:TPR_1,IPR011990:TPR-like_helical_dom_sf,IPR019734:TPR_repeat,IPR032374:SGTA_dimer,IPR047150:SGT,	hsa03060:Protein export,			SM00028:TPR,	KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0802~TPR repeat,		KW-0143~Chaperone,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:SGTA homodimerisation,MUTAGEN:C->A: Reduces tail-anchored proteins transfer.,REGION:Disordered,REPEAT:TPR,REPEAT:TPR 1,REPEAT:TPR 2,REPEAT:TPR 3,
SNRNP27	small nuclear ribonucleoprotein U4/U6.U5 subunit 27(SNRNP27)	Homo sapiens			GO:0000398~mRNA splicing, via spliceosome,GO:0006397~mRNA processing,GO:0008380~RNA splicing,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0046540~U4/U6 x U5 tri-snRNP complex,	GO:0003676~nucleic acid binding,GO:0005515~protein binding,	IPR013957:SNRNP27,	hsa03040:Spliceosome,				KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,					KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,DOMAIN:U4/U6.U5 small nuclear ribonucleoprotein 27kDa protein,REGION:Disordered,
SNRNP200	small nuclear ribonucleoprotein U5 subunit 200(SNRNP200)	Homo sapiens			GO:0000354~cis assembly of pre-catalytic spliceosome,GO:0000388~spliceosome conformational change to release U4 (or U4atac) and U1 (or U11),GO:0000398~mRNA splicing, via spliceosome,GO:0001649~osteoblast differentiation,GO:0006397~mRNA processing,GO:0010467~gene expression,GO:0071840~cellular component organization or biogenesis,GO:0090304~nucleic acid metabolic process,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005681~spliceosomal complex,GO:0005682~U5 snRNP,GO:0016020~membrane,GO:0046540~U4/U6 x U5 tri-snRNP complex,GO:0071005~U2-type precatalytic spliceosome,GO:0071006~U2-type catalytic step 1 spliceosome,GO:0071013~catalytic step 2 spliceosome,	GO:0003676~nucleic acid binding,GO:0003723~RNA binding,GO:0003724~RNA helicase activity,GO:0004386~helicase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016787~hydrolase activity,GO:0016887~ATPase activity,GO:0042802~identical protein binding,	IPR001650:Helicase_C,IPR004179:Sec63-dom,IPR011545:DEAD/DEAH_box_helicase_dom,IPR014001:Helicase_ATP-bd,IPR014756:Ig_E-set,IPR027417:P-loop_NTPase,IPR035892:C2_domain_sf,IPR036388:WH-like_DNA-bd_sf,IPR036390:WH_DNA-bd_sf,IPR041094:Brr2_helicase_PWI,IPR048863:BRR2_plug,	hsa03040:Spliceosome,	610359~Retinitis pigmentosa 33,	PIRSF039073:BRR2,	SM00487:DEXDc,SM00490:HELICc,SM00973:Sec63,	KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,KW-0747~Spliceosome,	KW-0225~Disease variant,KW-0682~Retinitis pigmentosa,	KW-0175~Coiled coil,KW-0677~Repeat,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0347~Helicase,KW-0378~Hydrolase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Helicase ATP-binding,DOMAIN:Helicase ATP-binding 1,DOMAIN:Helicase ATP-binding 2,DOMAIN:Helicase C-terminal,DOMAIN:Helicase C-terminal 1,DOMAIN:Helicase C-terminal 2,DOMAIN:SEC63,DOMAIN:SEC63 1,DOMAIN:SEC63 2,MOTIF:DEIH box,MOTIF:DEVH box,MUTAGEN:H->A: Strongly decreases ATP-dependent RNA helicase activity.,MUTAGEN:K->A: Decreases ATP-dependent RNA helicase activity.,MUTAGEN:R->A: Strongly decreases ATP-dependent RNA helicase activity.,MUTAGEN:T->A: Decreases ATP-dependent RNA helicase activity.,REGION:Disordered,REGION:Interaction with C9orf78 and WBP4,REGION:Interaction with TSSC4,
SNRNP40	small nuclear ribonucleoprotein U5 subunit 40(SNRNP40)	Homo sapiens			GO:0000375~RNA splicing, via transesterification reactions,GO:0000398~mRNA splicing, via spliceosome,GO:0006396~RNA processing,GO:0008380~RNA splicing,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005682~U5 snRNP,GO:0005732~small nucleolar ribonucleoprotein complex,GO:0005829~cytosol,GO:0016020~membrane,GO:0016607~nuclear speck,GO:0046540~U4/U6 x U5 tri-snRNP complex,GO:0071007~U2-type catalytic step 2 spliceosome,GO:0071013~catalytic step 2 spliceosome,	GO:0003723~RNA binding,GO:0005515~protein binding,	IPR001680:WD40_rpt,IPR015943:WD40/YVTN_repeat-like_dom_sf,IPR019775:WD40_repeat_CS,IPR020472:G-protein_beta_WD-40_rep,IPR036322:WD40_repeat_dom_sf,	hsa03040:Spliceosome,			SM00320:WD40,	KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0472~Membrane,KW-0539~Nucleus,KW-0747~Spliceosome,		KW-0677~Repeat,KW-0812~Transmembrane,KW-0853~WD repeat,KW-1133~Transmembrane helix,			KW-0488~Methylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),REPEAT:WD,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,REPEAT:WD 7,TRANSMEM:Helical,
SNHG12	small nucleolar RNA host gene 12(SNHG12)	Homo sapiens			GO:0006396~RNA processing,	GO:0005730~nucleolus,
SUMO3	small ubiquitin like modifier 3(SUMO3)	Homo sapiens		h_sumoPathway:Basic Mechanisms of SUMOylation,	GO:0016925~protein sumoylation,GO:0043392~negative regulation of DNA binding,GO:1900180~regulation of protein localization to nucleus,	GO:0000776~kinetochore,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0016605~PML body,	GO:0005515~protein binding,GO:0031386~protein tag,GO:0044389~ubiquitin-like protein ligase binding,	IPR000626:Ubiquitin-like_dom,IPR022617:Rad60/SUMO-like_dom,IPR029071:Ubiquitin-like_domsf,	hsa03013:Nucleocytoplasmic transport,hsa05418:Fluid shear stress and atherosclerosis,			SM00213:UBQ,	KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,KW-0963~Cytoplasm,					KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Gly-Lys) (interchain with K-? in acceptor proteins),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:Ubiquitin-like,MUTAGEN:I->A: Impaired interaction with USP25; when associated with A-34.,MUTAGEN:K->A: Impaired interaction with USP25; when associated with A-33.,MUTAGEN:K->R: Abolishes the formation of poly(SUMO) chains.,
SCNM1	sodium channel modifier 1(SCNM1)	Homo sapiens			GO:0000380~alternative mRNA splicing, via spliceosome,GO:0008380~RNA splicing,	GO:0005634~nucleus,GO:0005681~spliceosomal complex,GO:0016607~nuclear speck,	GO:0005515~protein binding,GO:0019899~enzyme binding,GO:0046872~metal ion binding,	IPR031622:Znf-SCNM1,IPR031625:SCNM1_acidic,IPR033570:SCNM1,		620107~Orofaciodigital syndrome XIX,			KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,KW-0747~Spliceosome,	KW-0225~Disease variant,KW-1186~Ciliopathy,	KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),MOTIF:Bipartite nuclear localization signal,REGION:Disordered,REGION:Required for interaction with LUC7L2,ZN_FING:Matrin-type,
SLC1A4	solute carrier family 1 member 4(SLC1A4)	Homo sapiens			GO:0006865~amino acid transport,GO:0006868~glutamine transport,GO:0015808~L-alanine transport,GO:0015811~L-cystine transport,GO:0015813~L-glutamate transport,GO:0015824~proline transport,GO:0015825~L-serine transport,GO:0015826~threonine transport,GO:0034589~hydroxyproline transport,GO:0035249~synaptic transmission, glutamatergic,GO:0035524~proline transmembrane transport,GO:0050890~cognition,GO:1902476~chloride transmembrane transport,GO:1903812~L-serine import into cell,GO:1904273~L-alanine import across plasma membrane,	GO:0005813~centrosome,GO:0005882~intermediate filament,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,GO:0042470~melanosome,GO:0045202~synapse,GO:0070062~extracellular exosome,	GO:0005254~chloride channel activity,GO:0015171~amino acid transmembrane transporter activity,GO:0015179~L-amino acid transmembrane transporter activity,GO:0015180~L-alanine transmembrane transporter activity,GO:0015183~L-aspartate transmembrane transporter activity,GO:0015184~L-cystine transmembrane transporter activity,GO:0015186~L-glutamine transmembrane transporter activity,GO:0015193~L-proline transmembrane transporter activity,GO:0015194~L-serine transmembrane transporter activity,GO:0015195~L-threonine transmembrane transporter activity,GO:0015293~symporter activity,GO:0034590~L-hydroxyproline transmembrane transporter activity,	IPR001991:Na-dicarboxylate_symporter,IPR018107:Na-dicarboxylate_symporter_CS,IPR036458:Na:dicarbo_symporter_sf,		616657~Spastic tetraplegia, thin corpus callosum, and progressive microcephaly,			KW-0769~Symport,KW-0813~Transport,	KW-0472~Membrane,	KW-0225~Disease variant,KW-0887~Epilepsy,KW-0991~Intellectual disability,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SLC10A3	solute carrier family 10 member 3(SLC10A3)	Homo sapiens			GO:0015721~bile acid and bile salt transport,GO:0032526~response to retinoic acid,GO:0055085~transmembrane transport,	GO:0016020~membrane,	GO:0008508~bile acid:sodium symporter activity,GO:0015293~symporter activity,	IPR002657:BilAc:Na_symport/Acr3,IPR004710:Bilac:Na_transpt,IPR038770:Na+/solute_symporter_sf,					KW-0769~Symport,KW-0813~Transport,	KW-0472~Membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,				COMPBIAS:Polar residues,REGION:Disordered,TRANSMEM:Helical,
SLC16A3	solute carrier family 16 member 3(SLC16A3)	Homo sapiens			GO:0015718~monocarboxylic acid transport,GO:0030163~protein catabolic process,GO:0035873~lactate transmembrane transport,GO:0042867~pyruvate catabolic process,GO:1901475~pyruvate transmembrane transport,	GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016323~basolateral plasma membrane,GO:0016324~apical plasma membrane,GO:0016328~lateral plasma membrane,GO:0031965~nuclear membrane,GO:0045202~synapse,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0008028~monocarboxylic acid transmembrane transporter activity,GO:0015650~lactate:proton symporter activity,GO:0022857~transmembrane transporter activity,GO:0050833~pyruvate transmembrane transporter activity,	IPR004743:MCT,IPR011701:MFS,IPR020846:MFS_dom,IPR036259:MFS_trans_sf,	hsa05230:Central carbon metabolism in cancer,				KW-0769~Symport,KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,	DOMAIN:Major facilitator superfamily (MFS) profile,MUTAGEN:E->A: Affects subcellular localization leading to apical localization. Affects subcellular localization leading to apical localization; when associated with A-425 and A-426.,MUTAGEN:E->A: Affects subcellular localization leading to apical localization. Affects subcellular localization leading to apical localization; when associated with A-426 and A-427.,MUTAGEN:E->A: Leads to a nonpolar expression pattern. Affects subcellular localization leading to apical localization; when associated with A-425 and A-427.,MUTAGEN:P->A: Does not affect basolateral plasma membrane localization. Intracellular accumulation. Affects subcellular localization leading to apical localization; when associated with A-432.,MUTAGEN:P->A: Does not affect basolateral plasma membrane localization. Intracellular accumulation. Affects subcellular localization leading to apical localization; when associated with A-433.,MUTAGEN:R->Q,K: Abolishes lactate transmembrane transporter activity. Does not affect cell membrane localization.,MUTAGEN:R->Q: Does not affect lactate transmembrane transporter activity.,REGION:Basolateral sorting signal,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SLC2A3	solute carrier family 2 member 3(SLC2A3)	Homo sapiens	105.Signaling_glucose_uptake,	h_vitCBPathway:Vitamin C in the Brain,	GO:0005975~carbohydrate metabolic process,GO:0015757~galactose transport,GO:0019852~L-ascorbic acid metabolic process,GO:0046323~glucose import,GO:0070837~dehydroascorbic acid transport,GO:0098708~glucose import across plasma membrane,GO:1904659~glucose transmembrane transport,	GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016235~aggresome,GO:0030667~secretory granule membrane,GO:0035579~specific granule membrane,GO:0042995~cell projection,GO:0043204~perikaryon,GO:0070062~extracellular exosome,GO:0070821~tertiary granule membrane,GO:0101003~ficolin-1-rich granule membrane,	GO:0005354~galactose transmembrane transporter activity,GO:0005355~glucose transmembrane transporter activity,GO:0005515~protein binding,GO:0005536~glucose binding,GO:0022857~transmembrane transporter activity,GO:0033300~dehydroascorbic acid transporter activity,GO:0055056~D-glucose transmembrane transporter activity,	IPR002945:Glc_transpt_3,IPR003663:Sugar/inositol_transpt,IPR005828:MFS_sugar_transport-like,IPR005829:Sugar_transporter_CS,IPR020846:MFS_dom,IPR036259:MFS_trans_sf,IPR045263:GLUT,					KW-0762~Sugar transport,KW-0813~Transport,	KW-0472~Membrane,KW-0966~Cell projection,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Major facilitator superfamily (MFS) profile,MUTAGEN:QLS->HVA: Confers moderate fructose transport activity.,REGION:Important for selectivity against fructose,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=10,TRANSMEM:Helical; Name=11,TRANSMEM:Helical; Name=12,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,TRANSMEM:Helical; Name=8,TRANSMEM:Helical; Name=9,
SLC20A1	solute carrier family 20 member 1(SLC20A1)	Homo sapiens			GO:0006796~phosphate-containing compound metabolic process,GO:0006811~ion transport,GO:0006817~phosphate ion transport,GO:0008283~cell proliferation,GO:0031214~biomineral tissue development,GO:0035435~phosphate ion transmembrane transport,GO:0035725~sodium ion transmembrane transport,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,	GO:0005886~plasma membrane,GO:0016020~membrane,	GO:0005315~inorganic phosphate transmembrane transporter activity,GO:0005316~high-affinity inorganic phosphate:sodium symporter activity,GO:0005436~sodium:phosphate symporter activity,GO:0015293~symporter activity,GO:0038023~signaling receptor activity,	IPR001204:Phos_transporter,					KW-0592~Phosphate transport,KW-0769~Symport,KW-0813~Transport,KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0597~Phosphoprotein,	MUTAGEN:D->K: Drastic reduction of virus infectibility, but conserved virus binding ability.,MUTAGEN:DTGDVSSKV->KQEASTKA: Loss of virus infectibility.,MUTAGEN:Missing: Loss of virus infectibility.,MUTAGEN:S->A: Loss of sodium-dependent phosphate transporter activity. Able to restore cell proliferation in SLC20A1-deficient HeLa cells to a level identical to that observed in their wild-type counterpart. No effect on its localization to the cell membrane.,REGION:A,TRANSMEM:Helical,
SLC25A5	solute carrier family 25 member 5(SLC25A5)	Homo sapiens			GO:0007059~chromosome segregation,GO:0008284~positive regulation of cell proliferation,GO:0015853~adenine transport,GO:0030183~B cell differentiation,GO:0030218~erythrocyte differentiation,GO:0046902~regulation of mitochondrial membrane permeability,GO:0051503~adenine nucleotide transport,GO:1901029~negative regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway,GO:1901526~positive regulation of macromitophagy,GO:1902600~hydrogen ion transmembrane transport,GO:1990544~mitochondrial ATP transmembrane transport,GO:1990830~cellular response to leukemia inhibitory factor,GO:1990845~adaptive thermogenesis,	GO:0005634~nucleus,GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005757~mitochondrial permeability transition pore complex,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0042645~mitochondrial nucleoid,GO:0071817~MMXD complex,	GO:0000295~adenine nucleotide transmembrane transporter activity,GO:0003723~RNA binding,GO:0005471~ATP:ADP antiporter activity,GO:0005515~protein binding,GO:0015078~hydrogen ion transmembrane transporter activity,GO:0015207~adenine transmembrane transporter activity,GO:0017077~oxidative phosphorylation uncoupler activity,GO:0031625~ubiquitin protein ligase binding,	IPR002067:Mit_carrier,IPR002113:ADT_euk_type,IPR018108:Mitochondrial_sb/sol_carrier,IPR023395:Mt_carrier_dom_sf,	hsa04020:Calcium signaling pathway,hsa04022:cGMP-PKG signaling pathway,hsa04217:Necroptosis,hsa04218:Cellular senescence,hsa04613:Neutrophil extracellular trap formation,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05016:Huntington disease,hsa05017:Spinocerebellar ataxia,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05164:Influenza A,hsa05166:Human T-cell leukemia virus 1 infection,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05415:Diabetic cardiomyopathy,				KW-0050~Antiport,KW-0159~Chromosome partition,KW-0813~Transport,KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,		KW-0677~Repeat,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	MOTIF:Nucleotide carrier signature motif,REGION:Important for transport activity,REPEAT:Solcar,REPEAT:Solcar 1,REPEAT:Solcar 2,REPEAT:Solcar 3,TOPO_DOM:Mitochondrial intermembrane,TOPO_DOM:Mitochondrial matrix,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,
SLC25A6	solute carrier family 25 member 6(SLC25A6)	Homo sapiens		h_etcPathway:Electron Transport Reaction in Mitochondria,	GO:0006915~apoptotic process,GO:1901029~negative regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway,GO:1990544~mitochondrial ATP transmembrane transport,	GO:0005634~nucleus,GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005744~mitochondrial inner membrane presequence translocase complex,GO:0016020~membrane,	GO:0005471~ATP:ADP antiporter activity,GO:0005515~protein binding,	IPR002067:Mit_carrier,IPR002113:ADT_euk_type,IPR018108:Mitochondrial_sb/sol_carrier,IPR023395:Mt_carrier_dom_sf,	hsa04020:Calcium signaling pathway,hsa04022:cGMP-PKG signaling pathway,hsa04217:Necroptosis,hsa04218:Cellular senescence,hsa04613:Neutrophil extracellular trap formation,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05016:Huntington disease,hsa05017:Spinocerebellar ataxia,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05164:Influenza A,hsa05166:Human T-cell leukemia virus 1 infection,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05415:Diabetic cardiomyopathy,				KW-0050~Antiport,KW-0053~Apoptosis,KW-0813~Transport,KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,		KW-0677~Repeat,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,KW-0488~Methylation,	MOTIF:Nucleotide carrier signature motif,REGION:Important for transport activity,REPEAT:Solcar,REPEAT:Solcar 1,REPEAT:Solcar 2,REPEAT:Solcar 3,TOPO_DOM:Mitochondrial intermembrane,TOPO_DOM:Mitochondrial matrix,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,
SLC30A5	solute carrier family 30 member 5(SLC30A5)	Homo sapiens			GO:0006506~GPI anchor biosynthetic process,GO:0006824~cobalt ion transport,GO:0006829~zinc II ion transport,GO:0006882~cellular zinc ion homeostasis,GO:0010043~response to zinc ion,GO:0030070~insulin processing,GO:0071577~zinc II ion transmembrane transport,GO:0071578~zinc II ion transmembrane import,GO:1904257~zinc II ion import across Golgi membrane,	GO:0000139~Golgi membrane,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005789~endoplasmic reticulum membrane,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0012507~ER to Golgi transport vesicle membrane,GO:0016020~membrane,GO:0016324~apical plasma membrane,GO:0030141~secretory granule,GO:0030667~secretory granule membrane,GO:0031410~cytoplasmic vesicle,GO:0032588~trans-Golgi network membrane,GO:1990674~Golgi cis cisterna membrane,	GO:0005385~zinc ion transmembrane transporter activity,GO:0005515~protein binding,GO:0015297~antiporter activity,GO:0022883~zinc efflux transmembrane transporter activity,GO:0046872~metal ion binding,	IPR002524:Cation_efflux,IPR027469:Cation_efflux_TMD_sf,IPR045316:Msc2-like,					KW-0050~Antiport,KW-0406~Ion transport,KW-0813~Transport,KW-0864~Zinc transport,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0007~Acetylation,	MUTAGEN:D->A: Loss of zinc transporter activity. No effect on localization to the trans-Golgi network.,MUTAGEN:D->E: No effect on zinc transporter activity. No effect on localization to the trans-Golgi network.,MUTAGEN:H->A: Loss of zinc transporter activity.,MUTAGEN:H->D: No effect on zinc ion transmembrane transporter activity. No effect on zinc ion import into Golgi. Loss of specificity for zinc ions as it can also transport cadmium ions.,REGION:Disordered,REGION:His-rich loop; required for zinc transport,REGION:Mediates homodimerization with SLC30A6,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
SLC35B1	solute carrier family 35 member B1(SLC35B1)	Homo sapiens			GO:0015786~UDP-glucose transport,GO:0015866~ADP transport,GO:0015867~ATP transport,GO:0055085~transmembrane transport,GO:0072334~UDP-galactose transmembrane transport,	GO:0005789~endoplasmic reticulum membrane,GO:0016020~membrane,GO:0043231~intracellular membrane-bounded organelle,	GO:0005459~UDP-galactose transmembrane transporter activity,GO:0005460~UDP-glucose transmembrane transporter activity,GO:0005471~ATP:ADP antiporter activity,GO:0005515~protein binding,	IPR013657:SCL35B1-4/HUT1,					KW-0050~Antiport,KW-0813~Transport,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,	MOTIF:Di-lysine motif,MUTAGEN:K->A: Loss of ATP:ADP antiporter activity.,MUTAGEN:R->A: Loss of ATP:ADP antiporter activity.,TRANSMEM:Helical,
SLC38A1	solute carrier family 38 member 1(SLC38A1)	Homo sapiens			GO:0001504~neurotransmitter uptake,GO:0003333~amino acid transmembrane transport,GO:0006541~glutamine metabolic process,GO:0006814~sodium ion transport,GO:0006865~amino acid transport,GO:0006868~glutamine transport,GO:0007565~female pregnancy,GO:0009449~gamma-aminobutyric acid biosynthetic process,GO:0015804~neutral amino acid transport,GO:0015816~glycine transport,GO:0032228~regulation of synaptic transmission, GABAergic,GO:0032328~alanine transport,GO:0043090~amino acid import,GO:0048167~regulation of synaptic plasticity,GO:1901036~positive regulation of L-glutamine import,GO:1902475~L-alpha-amino acid transmembrane transport,	GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016323~basolateral plasma membrane,GO:0030424~axon,GO:0043025~neuronal cell body,GO:0070062~extracellular exosome,GO:0098591~external side of apical plasma membrane,	GO:0005283~sodium:amino acid symporter activity,GO:0005295~neutral amino acid:sodium symporter activity,GO:0005298~proline:sodium symporter activity,GO:0005515~protein binding,GO:0015171~amino acid transmembrane transporter activity,GO:0015175~neutral amino acid transmembrane transporter activity,GO:0015179~L-amino acid transmembrane transporter activity,GO:0015186~L-glutamine transmembrane transporter activity,GO:0015375~glycine:sodium symporter activity,GO:0015655~alanine:sodium symporter activity,	IPR013057:AA_transpt_TM,	hsa04724:Glutamatergic synapse,hsa04727:GABAergic synapse,				KW-0029~Amino-acid transport,KW-0406~Ion transport,KW-0739~Sodium transport,KW-0769~Symport,KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0915~Sodium,		KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:Amino acid transporter transmembrane,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SLC38A10	solute carrier family 38 member 10(SLC38A10)	Homo sapiens			GO:0003333~amino acid transmembrane transport,GO:0060348~bone development,GO:1902475~L-alpha-amino acid transmembrane transport,	GO:0005794~Golgi apparatus,GO:0016020~membrane,	GO:0015179~L-amino acid transmembrane transporter activity,	IPR013057:AA_transpt_TM,					KW-0029~Amino-acid transport,KW-0813~Transport,	KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Amino acid transporter transmembrane,REGION:Disordered,TRANSMEM:Helical,
SLC38A2	solute carrier family 38 member 2(SLC38A2)	Homo sapiens			GO:0003333~amino acid transmembrane transport,GO:0006814~sodium ion transport,GO:0006836~neurotransmitter transport,GO:0006865~amino acid transport,GO:0006868~glutamine transport,GO:0007565~female pregnancy,GO:0010628~positive regulation of gene expression,GO:0014850~response to muscle activity,GO:0015800~acidic amino acid transport,GO:0015804~neutral amino acid transport,GO:0015824~proline transport,GO:0015825~L-serine transport,GO:0021987~cerebral cortex development,GO:0031460~glycine betaine transport,GO:0032328~alanine transport,GO:0033120~positive regulation of RNA splicing,GO:0034198~cellular response to amino acid starvation,GO:0043090~amino acid import,GO:0071260~cellular response to mechanical stimulus,GO:0080135~regulation of cellular response to stress,GO:1903294~regulation of glutamate secretion, neurotransmission,GO:1903803~L-glutamine import into cell,GO:1903812~L-serine import into cell,GO:1903841~cellular response to arsenite(3-),GO:1904271~L-proline import across plasma membrane,	GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0005903~brush border,GO:0016020~membrane,GO:0030424~axon,GO:0030425~dendrite,GO:0042383~sarcolemma,GO:0043025~neuronal cell body,	GO:0005283~sodium:amino acid symporter activity,GO:0005295~neutral amino acid:sodium symporter activity,GO:0005298~proline:sodium symporter activity,GO:0005515~protein binding,GO:0015171~amino acid transmembrane transporter activity,GO:0015172~acidic amino acid transmembrane transporter activity,GO:0015186~L-glutamine transmembrane transporter activity,GO:0015194~L-serine transmembrane transporter activity,GO:0015655~alanine:sodium symporter activity,	IPR013057:AA_transpt_TM,	hsa04724:Glutamatergic synapse,hsa04727:GABAergic synapse,hsa04974:Protein digestion and absorption,				KW-0029~Amino-acid transport,KW-0406~Ion transport,KW-0739~Sodium transport,KW-0769~Symport,KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0915~Sodium,		KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Amino acid transporter transmembrane,REGION:Disordered,REGION:Regulates protein turnover upon amino acid deprivation,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SLC39A8	solute carrier family 39 member 8(SLC39A8)	Homo sapiens			GO:0006351~transcription, DNA-templated,GO:0006355~regulation of transcription, DNA-templated,GO:0006487~protein N-linked glycosylation,GO:0006525~arginine metabolic process,GO:0006824~cobalt ion transport,GO:0006829~zinc II ion transport,GO:0006882~cellular zinc ion homeostasis,GO:0015694~mercury ion transport,GO:0015701~bicarbonate transport,GO:0030026~cellular manganese ion homeostasis,GO:0030198~extracellular matrix organization,GO:0042391~regulation of membrane potential,GO:0043124~negative regulation of I-kappaB kinase/NF-kappaB signaling,GO:0050728~negative regulation of inflammatory response,GO:0061757~leukocyte adhesion to arterial endothelial cell,GO:0070574~cadmium ion transmembrane transport,GO:0071421~manganese ion transmembrane transport,GO:0071577~zinc II ion transmembrane transport,GO:0071578~zinc II ion transmembrane import,GO:0097080~plasma membrane selenite transport,GO:0098711~iron ion import across plasma membrane,GO:0098849~cellular detoxification of cadmium ion,GO:1990079~cartilage homeostasis,GO:1990540~mitochondrial manganese ion transmembrane transport,	GO:0005765~lysosomal membrane,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016323~basolateral plasma membrane,GO:0016324~apical plasma membrane,GO:0031090~organelle membrane,	GO:0005385~zinc ion transmembrane transporter activity,GO:0046873~metal ion transmembrane transporter activity,	IPR003689:ZIP,	hsa04216:Ferroptosis,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,	616721~Congenital disorder of glycosylation, type IIn,			KW-0406~Ion transport,KW-0769~Symport,KW-0813~Transport,KW-0864~Zinc transport,	KW-0458~Lysosome,KW-0472~Membrane,KW-1003~Cell membrane,	KW-0900~Congenital disorder of glycosylation,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0862~Zinc,		KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,MOTIF:XEXPHE-motif,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SLC5A3	solute carrier family 5 member 3(SLC5A3)	Homo sapiens			GO:0006020~inositol metabolic process,GO:0007422~peripheral nervous system development,GO:0015750~pentose transport,GO:0015756~fucose transport,GO:0015791~polyol transport,GO:0015798~myo-inositol transport,GO:0035725~sodium ion transmembrane transport,GO:0043085~positive regulation of catalytic activity,GO:0043576~regulation of respiratory gaseous exchange,GO:1903428~positive regulation of reactive oxygen species biosynthetic process,GO:1904659~glucose transmembrane transport,GO:1904679~myo-inositol import across plasma membrane,GO:1905477~positive regulation of protein localization to membrane,	GO:0005886~plasma membrane,GO:0008076~voltage-gated potassium channel complex,GO:0016020~membrane,GO:0016323~basolateral plasma membrane,GO:0016324~apical plasma membrane,GO:0048471~perinuclear region of cytoplasm,	GO:0005365~myo-inositol transmembrane transporter activity,GO:0005367~myo-inositol:sodium symporter activity,GO:0005412~glucose:sodium symporter activity,GO:0005515~protein binding,GO:0015146~pentose transmembrane transporter activity,GO:0015150~fucose transmembrane transporter activity,GO:0015166~polyol transmembrane transporter activity,GO:0015459~potassium channel regulator activity,GO:0044325~ion channel binding,	IPR001734:Na/solute_symporter,IPR018212:Na/solute_symporter_CS,IPR038377:Na/Glc_symporter_sf,IPR042731:SMIT,					KW-0406~Ion transport,KW-0739~Sodium transport,KW-0769~Symport,KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0915~Sodium,		KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,SITE:Implicated in sodium coupling,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SLC52A2	solute carrier family 52 member 2(SLC52A2)	Homo sapiens			GO:0006771~riboflavin metabolic process,GO:0032218~riboflavin transport,GO:0046718~viral entry into host cell,GO:0072388~flavin adenine dinucleotide biosynthetic process,	GO:0005886~plasma membrane,	GO:0001618~virus receptor activity,GO:0005515~protein binding,GO:0032217~riboflavin transporter activity,	IPR009357:Riboflavin_transptr,		614707~Brown-Vialetto-Van Laere syndrome 2,			KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,	KW-0209~Deafness,KW-0225~Disease variant,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,KW-1183~Host cell receptor for virus entry,		REGION:Disordered,TRANSMEM:Helical,
SLC7A5	solute carrier family 7 member 5(SLC7A5)	Homo sapiens			GO:0002720~positive regulation of cytokine production involved in immune response,GO:0003333~amino acid transmembrane transport,GO:0010507~negative regulation of autophagy,GO:0010629~negative regulation of gene expression,GO:0014850~response to muscle activity,GO:0015804~neutral amino acid transport,GO:0015818~isoleucine transport,GO:0015820~leucine transport,GO:0015821~methionine transport,GO:0015823~phenylalanine transport,GO:0015824~proline transport,GO:0015827~tryptophan transport,GO:0015828~tyrosine transport,GO:0015829~valine transport,GO:0032328~alanine transport,GO:0032729~positive regulation of interferon-gamma production,GO:0032740~positive regulation of interleukin-17 production,GO:0032753~positive regulation of interleukin-4 production,GO:0042149~cellular response to glucose starvation,GO:0042908~xenobiotic transport,GO:0055093~response to hyperoxia,GO:0060252~positive regulation of glial cell proliferation,GO:0070327~thyroid hormone transport,GO:0071222~cellular response to lipopolysaccharide,GO:0089718~amino acid import across plasma membrane,GO:0097421~liver regeneration,GO:0098713~leucine import across plasma membrane,GO:1902024~L-histidine transport,GO:1903577~cellular response to L-arginine,GO:1903801~L-leucine import into cell,GO:1904556~L-tryptophan transmembrane transport,GO:1905460~negative regulation of vascular associated smooth muscle cell apoptotic process,GO:1905534~positive regulation of leucine import across plasma membrane,	GO:0005765~lysosomal membrane,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0009925~basal plasma membrane,GO:0016020~membrane,GO:0016323~basolateral plasma membrane,GO:0016324~apical plasma membrane,GO:0031528~microvillus membrane,GO:0043231~intracellular membrane-bounded organelle,GO:0070062~extracellular exosome,GO:0098591~external side of apical plasma membrane,GO:1990184~amino acid transport complex,	GO:0005515~protein binding,GO:0015171~amino acid transmembrane transporter activity,GO:0015173~aromatic amino acid transmembrane transporter activity,GO:0015175~neutral amino acid transmembrane transporter activity,GO:0015179~L-amino acid transmembrane transporter activity,GO:0015190~L-leucine transmembrane transporter activity,GO:0015196~L-tryptophan transmembrane transporter activity,GO:0015297~antiporter activity,GO:0015349~thyroid hormone transmembrane transporter activity,GO:0022857~transmembrane transporter activity,GO:0042605~peptide antigen binding,	IPR002293:AA/rel_permease1,IPR004760:L_AA_transporter,	hsa04150:mTOR signaling pathway,hsa05230:Central carbon metabolism in cancer,		PIRSF006060:AA_transporter,		KW-0029~Amino-acid transport,KW-0813~Transport,	KW-0458~Lysosome,KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DISULFID:Interchain (with C-210 in SLC3A2),MUTAGEN:A->V: Nearly abolishes leucine transport activity.,MUTAGEN:E->K: Decreased leucine transport activity.,MUTAGEN:F->A: Nearly abolishes leucine transport activity.,MUTAGEN:Missing: Nearly abolishes leucine transport activity.,MUTAGEN:N->A: Decreased leucine transport activity.,MUTAGEN:N->D: Nearly abolishes leucine transport activity.,MUTAGEN:P->L: Nearly abolishes leucine transport activity.,MUTAGEN:W->A: Nearly abolishes leucine transport activity.,MUTAGEN:Y->A: Strongly decreased leucine transport activity.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SNX1	sorting nexin 1(SNX1)	Homo sapiens			GO:0006886~intracellular protein transport,GO:0015031~protein transport,GO:0031623~receptor internalization,GO:0034498~early endosome to Golgi transport,GO:0042147~retrograde transport, endosome to Golgi,GO:0072673~lamellipodium morphogenesis,	GO:0005737~cytoplasm,GO:0005764~lysosome,GO:0005768~endosome,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0010008~endosome membrane,GO:0016020~membrane,GO:0030027~lamellipodium,GO:0030904~retromer complex,GO:0030905~retromer, tubulation complex,GO:0031410~cytoplasmic vesicle,GO:0031901~early endosome membrane,GO:0031982~vesicle,GO:0032991~macromolecular complex,GO:0043231~intracellular membrane-bounded organelle,	GO:0005154~epidermal growth factor receptor binding,GO:0005158~insulin receptor binding,GO:0005515~protein binding,GO:0035091~phosphatidylinositol binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0045296~cadherin binding,GO:0046982~protein heterodimerization activity,GO:1990459~transferrin receptor binding,GO:1990460~leptin receptor binding,	IPR001683:PX_dom,IPR005329:Sorting_nexin_N,IPR015404:Vps5_C,IPR027267:AH/BAR_dom_sf,IPR028660:SNX1_BAR,IPR034901:PX_SNX1,IPR036871:PX_dom_sf,	hsa04144:Endocytosis,			SM00312:PX,	KW-0653~Protein transport,KW-0813~Transport,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0966~Cell projection,KW-0967~Endosome,			KW-0446~Lipid-binding,		KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:BAR,DOMAIN:PX,DOMAIN:Sorting nexin N-terminal,DOMAIN:Sorting nexin/Vps5-like C-terminal,MUTAGEN:K->A: Abolishes phosphatidylinositol phosphate binding. Abolishes endosomal location.,MUTAGEN:K->A: No effect on membrane remodeling and membrane binding; when associated with A-442.,MUTAGEN:K->A: No effect on membrane remodeling and membrane binding; when associated with A-445.,MUTAGEN:KKR->EEE: Loss of endosomal location.,MUTAGEN:MF->EE: Abolishes membrane remodeling capacity; no effect on dimerization.,REGION:Disordered,REGION:Membrane-binding amphipathic helix,
SNX17	sorting nexin 17(SNX17)	Homo sapiens			GO:0001822~kidney development,GO:0003279~cardiac septum development,GO:0006707~cholesterol catabolic process,GO:0006886~intracellular protein transport,GO:0006898~receptor-mediated endocytosis,GO:0007165~signal transduction,GO:0016192~vesicle-mediated transport,GO:0016197~endosomal transport,GO:0030100~regulation of endocytosis,GO:0032456~endocytic recycling,GO:0035904~aorta development,GO:0060976~coronary vasculature development,	GO:0005768~endosome,GO:0005769~early endosome,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0010008~endosome membrane,GO:0016020~membrane,GO:0030659~cytoplasmic vesicle membrane,GO:0031410~cytoplasmic vesicle,GO:0032991~macromolecular complex,GO:0043231~intracellular membrane-bounded organelle,	GO:0005102~receptor binding,GO:0005515~protein binding,GO:0035091~phosphatidylinositol binding,GO:0050750~low-density lipoprotein particle receptor binding,	IPR000159:RA_dom,IPR001683:PX_dom,IPR011993:PH-like_dom_sf,IPR028666:SNX17_FERM_N,IPR036871:PX_dom_sf,IPR037831:SNX17/27/31,IPR037836:SNX17_FERM-like_dom,IPR040842:SNX17/31_FERM,IPR048763:SNX17-31_FERM_F1,IPR048767:SNX17-31_FERM_F2,				SM00312:PX,	KW-0653~Protein transport,KW-0813~Transport,	KW-0472~Membrane,KW-0963~Cytoplasm,KW-0967~Endosome,KW-0968~Cytoplasmic vesicle,			KW-0446~Lipid-binding,		KW-0597~Phosphoprotein,	DOMAIN:PX,DOMAIN:Ras-associating,DOMAIN:Sortin nexin 17/31 FERM,DOMAIN:Sorting nexin-17/31 FERM,MUTAGEN:D->K: Slightly decreases interaction with CCDC22, CCDC93, VPS26C and VPS35L.,MUTAGEN:G->V: Slightly decreases interaction with CCDC22, CCDC93, VPS26C and VPS35L.,MUTAGEN:K->A: No association with endosomes.,MUTAGEN:L->A: No effect on interaction with CCDC22, CCDC93, VPS26C and VPS35L.,MUTAGEN:L->G: Strongly decreases interaction with CCDC22, CCDC93, VPS26C and VPS35L. No effect on endosomal location.,MUTAGEN:Missing: Strongly decreases interaction with CCDC22, CCDC93, VPS26C and VPS35L. No effect on endosomal location.,MUTAGEN:S->D: No effect on interaction with CCDC22, CCDC93, VPS26C and VPS35L.,REGION:Disordered,REGION:FERM-like,REGION:PTB-like F3 module,
SNX2	sorting nexin 2(SNX2)	Homo sapiens			GO:0006886~intracellular protein transport,GO:0034498~early endosome to Golgi transport,GO:0042147~retrograde transport, endosome to Golgi,GO:0072673~lamellipodium morphogenesis,	GO:0005737~cytoplasm,GO:0005764~lysosome,GO:0005768~endosome,GO:0005829~cytosol,GO:0010008~endosome membrane,GO:0016020~membrane,GO:0030027~lamellipodium,GO:0030904~retromer complex,GO:0030905~retromer, tubulation complex,GO:0031901~early endosome membrane,GO:0032991~macromolecular complex,	GO:0005154~epidermal growth factor receptor binding,GO:0005158~insulin receptor binding,GO:0005515~protein binding,GO:0035091~phosphatidylinositol binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0045296~cadherin binding,GO:0046982~protein heterodimerization activity,GO:1990459~transferrin receptor binding,GO:1990460~leptin receptor binding,	IPR001683:PX_dom,IPR005329:Sorting_nexin_N,IPR015404:Vps5_C,IPR027267:AH/BAR_dom_sf,IPR036871:PX_dom_sf,IPR037918:SNX2_PX,	hsa04144:Endocytosis,			SM00312:PX,	KW-0653~Protein transport,KW-0813~Transport,	KW-0472~Membrane,KW-0966~Cell projection,KW-0967~Endosome,		KW-0175~Coiled coil,	KW-0446~Lipid-binding,		KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:BAR,DOMAIN:PX,DOMAIN:Sorting nexin N-terminal,MUTAGEN:K->A: Abolishes phosphatidylinositol phosphate binding. Abolishes endosomal location.,MUTAGEN:K->A: Decreases KALRN-dependent lamellipodium formation; no effect on interaction with KALRN; when associated with A-428.,MUTAGEN:R->A: Decreases KALRN-dependent lamellipodium formation; no effect on interaction with KALRN; when associated with A-426.,MUTAGEN:RRF->AAA: Decreases KALRN-dependent lamellipodium formation; no effect on interaction with KALRN.,REGION:Disordered,REGION:Interaction with RhoG,REGION:Membrane-binding amphipathic helix,
SNX20	sorting nexin 20(SNX20)	Homo sapiens			GO:0015031~protein transport,	GO:0005654~nucleoplasm,GO:0005886~plasma membrane,GO:0031901~early endosome membrane,	GO:0005515~protein binding,GO:0005546~phosphatidylinositol-4,5-bisphosphate binding,GO:0032266~phosphatidylinositol-3-phosphate binding,GO:1901981~phosphatidylinositol phosphate binding,	IPR001683:PX_dom,IPR036871:PX_dom_sf,IPR039937:SNX20/SNX21,				SM00312:PX,	KW-0653~Protein transport,KW-0813~Transport,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0967~Endosome,KW-1003~Cell membrane,			KW-0446~Lipid-binding,		KW-0597~Phosphoprotein,	DOMAIN:PX,MUTAGEN:R->Q: Decreased binding activity to all phospholipids.,REGION:Disordered,
SNX5	sorting nexin 5(SNX5)	Homo sapiens			GO:0006886~intracellular protein transport,GO:0006907~pinocytosis,GO:0015031~protein transport,GO:0016241~regulation of macroautophagy,GO:0042147~retrograde transport, endosome to Golgi,GO:0045893~positive regulation of transcription, DNA-templated,GO:0046628~positive regulation of insulin receptor signaling pathway,	GO:0001726~ruffle,GO:0001891~phagocytic cup,GO:0005768~endosome,GO:0005829~cytosol,GO:0009898~cytoplasmic side of plasma membrane,GO:0030904~retromer complex,GO:0030905~retromer, tubulation complex,GO:0031410~cytoplasmic vesicle,GO:0043231~intracellular membrane-bounded organelle,GO:0048471~perinuclear region of cytoplasm,GO:0070685~macropinocytic cup,GO:0097422~tubular endosome,GO:0098559~cytoplasmic side of early endosome membrane,	GO:0005515~protein binding,GO:0034452~dynactin binding,GO:0035091~phosphatidylinositol binding,GO:0045296~cadherin binding,	IPR001683:PX_dom,IPR014637:SNX5/SNX6/SNX32,IPR015404:Vps5_C,IPR027267:AH/BAR_dom_sf,IPR028654:BAR_SNX5,IPR036871:PX_dom_sf,IPR042135:PX_SNX5,	hsa04144:Endocytosis,		PIRSF036924:Snx5_Snx6,		KW-0254~Endocytosis,KW-0653~Protein transport,KW-0813~Transport,KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-0967~Endosome,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,			KW-0446~Lipid-binding,		KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:BAR,DOMAIN:PX,DOMAIN:Sorting nexin/Vps5-like C-terminal,MUTAGEN:E->A: Enables homodimerization; when associated with A-280.,MUTAGEN:E->A: Enables homodimerization; when associated with A-383.,MUTAGEN:FF->EE: No effect on dimerization.,MUTAGEN:K->E: Decreaes phosphoinositide binding, including PtdIns(3,4)P2 and PtdIns(3P); when associated with E-224, E-235, E-324 and E-330.,MUTAGEN:K->E: Decreaes phosphoinositide binding, including PtdIns(3,4)P2 and PtdIns(3P); when associated with E-224, E-235, E-328 and E-330.,MUTAGEN:K->E: Decreaes phosphoinositide binding, including PtdIns(3,4)P2 and PtdIns(3P); when associated with E-235, E-324, E-328 and E-330.,MUTAGEN:R->E: Decreaes phosphoinositide binding, including PtdIns(3,4)P2 and PtdIns(3P); when associated with E-224, E-235, E-324 and E-328.,MUTAGEN:R->E: Decreaes phosphoinositide binding, including PtdIns(3,4)P2 and PtdIns(3P); when associated with E-224, E-324, E-328 and E-330.,REGION:Disordered,REGION:Interaction with DOCK1,REGION:Membrane-binding amphipathic helix,
SNX9	sorting nexin 9(SNX9)	Homo sapiens			GO:0000281~mitotic cytokinesis,GO:0006886~intracellular protein transport,GO:0006897~endocytosis,GO:0006898~receptor-mediated endocytosis,GO:0016197~endosomal transport,GO:0030838~positive regulation of actin filament polymerization,GO:0036089~cleavage furrow formation,GO:0043547~positive regulation of GTPase activity,GO:0045860~positive regulation of protein kinase activity,GO:0051044~positive regulation of membrane protein ectodomain proteolysis,GO:0060988~lipid tube assembly,GO:0065003~macromolecular complex assembly,GO:0097320~plasma membrane tubulation,GO:1900242~regulation of synaptic vesicle endocytosis,	GO:0001726~ruffle,GO:0005737~cytoplasm,GO:0005802~trans-Golgi network,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005905~clathrin-coated pit,GO:0030136~clathrin-coated vesicle,GO:0030659~cytoplasmic vesicle membrane,GO:0031410~cytoplasmic vesicle,GO:0032437~cuticular plate,GO:0070062~extracellular exosome,GO:0098793~presynapse,	GO:0005515~protein binding,GO:0005545~1-phosphatidylinositol binding,GO:0031625~ubiquitin protein ligase binding,GO:0035091~phosphatidylinositol binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0045296~cadherin binding,GO:0071933~Arp2/3 complex binding,	IPR001452:SH3_domain,IPR001683:PX_dom,IPR014536:Snx9_fam,IPR019497:Sorting_nexin_WASP-bd-dom,IPR027267:AH/BAR_dom_sf,IPR035558:SNX9_SH3,IPR036028:SH3-like_dom_sf,IPR036871:PX_dom_sf,IPR037425:SNX9_BAR,IPR037426:SNX9_PX,	hsa05132:Salmonella infection,		PIRSF027744:Snx9,	SM00312:PX,SM00326:SH3,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0254~Endocytosis,KW-0498~Mitosis,KW-0653~Protein transport,KW-0813~Transport,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,		KW-0728~SH3 domain,	KW-0446~Lipid-binding,		KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,DOMAIN:BAR,DOMAIN:PX,DOMAIN:SH3,DOMAIN:Sorting nexin protein WASP-binding,MUTAGEN:K->A: Abolishes binding to phosphatidylinositol 3-phosphate, but not to phosphatidylinositol 4,5-bisphosphate; when associated with A-287.,MUTAGEN:K->E: Abolishes membrane tubulation activity; when associated with E-522.,MUTAGEN:K->E: Abolishes membrane tubulation activity; when associated with E-528.,MUTAGEN:K->E: Strongly reduced membrane binding.,MUTAGEN:KR->EE: Loss of membrane binding.,MUTAGEN:Y->A: Abolishes membrane tubulation activity. Abolishes binding to phosphatidylinositol 3-phosphate, but not to phosphatidylinositol 4,5-bisphosphate; when associated with A-313.,REGION:Critical for tubulation activity,REGION:Disordered,
SPOP	speckle type BTB/POZ protein(SPOP)	Homo sapiens			GO:0000209~protein polyubiquitination,GO:0016567~protein ubiquitination,GO:0030162~regulation of proteolysis,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0051179~localization,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0016607~nuclear speck,GO:0031463~Cul3-RING ubiquitin ligase complex,	GO:0005515~protein binding,GO:0031625~ubiquitin protein ligase binding,	IPR000210:BTB/POZ_dom,IPR002083:MATH/TRAF_dom,IPR008974:TRAF-like,IPR011333:SKP1/BTB/POZ_sf,IPR034089:SPOP_C,	hsa04340:Hedgehog signaling pathway,	618828~Nabais Sa-de Vries syndrome, type 1,618829~Nabais Sa-de Vries syndrome, type 2,		SM00061:MATH,SM00225:BTB,	KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,	KW-0991~Intellectual disability,					DOMAIN:BTB,DOMAIN:MATH,MUTAGEN:D->A: Strongly reduced affinity for substrate proteins.,MUTAGEN:F->A: Strongly reduced affinity for substrate proteins.,MUTAGEN:I->K: Strongly reduced homodimerization. Reduces the activity of the cullin-RING-based BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex.,MUTAGEN:L->D: Strongly reduced homodimerization. Reduces the activity of the cullin-RING-based BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex.,MUTAGEN:W->A: Strongly reduced affinity for substrate proteins.,MUTAGEN:Y->A: Strongly reduced affinity for substrate proteins.,REGION:Important for binding substrate proteins,REGION:Important for homodimerization,REGION:Required for nuclear localization,
SPTAN1	spectrin alpha, non-erythrocytic 1(SPTAN1)	Homo sapiens		h_deathPathway:Induction of apoptosis through DR3 and DR4/5 Death Receptors ,h_fasPathway:FAS signaling pathway ( CD95 ),h_hivnefPathway:HIV-I Nef: negative effector of Fas and TNF,h_PDZsPathway:Synaptic Proteins at the Synaptic Junction,h_tnfr1Pathway:TNFR1 Signaling Pathway,h_uCalpainPathway:uCalpain and friends in Cell spread,	GO:0030036~actin cytoskeleton organization,GO:0051693~actin filament capping,	GO:0005576~extracellular region,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005938~cell cortex,GO:0008091~spectrin,GO:0015629~actin cytoskeleton,GO:0015630~microtubule cytoskeleton,GO:0016020~membrane,GO:0030054~cell junction,GO:0030864~cortical actin cytoskeleton,GO:0035580~specific granule lumen,GO:0042995~cell projection,GO:0043231~intracellular membrane-bounded organelle,GO:0070062~extracellular exosome,GO:1903561~extracellular vesicle,GO:1904724~tertiary granule lumen,	GO:0003779~actin binding,GO:0005200~structural constituent of cytoskeleton,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0008092~cytoskeletal protein binding,GO:0045296~cadherin binding,GO:0051015~actin filament binding,	IPR001452:SH3_domain,IPR002017:Spectrin_repeat,IPR002048:EF_hand_dom,IPR011992:EF-hand-dom_pair,IPR014837:EF-hand_Ca_insen,IPR018159:Spectrin/alpha-actinin,IPR018247:EF_Hand_1_Ca_BS,IPR035825:Alpha_Spectrin_SH3,IPR036028:SH3-like_dom_sf,	hsa04210:Apoptosis,	613477~Developmental and epileptic encephalopathy 5,620528~Neuronopathy, distal hereditary motor, autosomal dominant 11,620538~Spastic paraplegia 91, autosomal dominant, with or without cerebellar ataxia,620540~Developmental delay with or without epilepsy,		SM00054:EFh,SM00150:SPEC,SM00326:SH3,SM01184:efhand_Ca_insen,		KW-0206~Cytoskeleton,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0887~Epilepsy,KW-0991~Intellectual disability,	KW-0175~Coiled coil,KW-0677~Repeat,KW-0728~SH3 domain,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0009~Actin-binding,KW-0112~Calmodulin-binding,KW-0117~Actin capping,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:EF-hand,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,DOMAIN:EF-hand 3,DOMAIN:SH3,REGION:Disordered,REPEAT:Spectrin 1,REPEAT:Spectrin 10,REPEAT:Spectrin 11,REPEAT:Spectrin 12,REPEAT:Spectrin 13,REPEAT:Spectrin 14,REPEAT:Spectrin 15,REPEAT:Spectrin 16,REPEAT:Spectrin 17,REPEAT:Spectrin 18,REPEAT:Spectrin 19,REPEAT:Spectrin 2,REPEAT:Spectrin 20,REPEAT:Spectrin 3,REPEAT:Spectrin 4,REPEAT:Spectrin 5,REPEAT:Spectrin 6,REPEAT:Spectrin 7,REPEAT:Spectrin 8,REPEAT:Spectrin 9,SITE:Cleavage; by mu-calpain,
SYNE1	spectrin repeat containing nuclear envelope protein 1(SYNE1)	Homo sapiens			GO:0002053~positive regulation of mesenchymal cell proliferation,GO:0006997~nucleus organization,GO:0007030~Golgi organization,GO:0007283~spermatogenesis,GO:0009416~response to light stimulus,GO:0042692~muscle cell differentiation,GO:0048260~positive regulation of receptor-mediated endocytosis,GO:0048814~regulation of dendrite morphogenesis,GO:0051641~cellular localization,GO:0055007~cardiac muscle cell differentiation,GO:0090292~nuclear matrix anchoring at nuclear membrane,GO:1903353~regulation of nucleus organization,GO:2001054~negative regulation of mesenchymal cell apoptotic process,	GO:0000932~P-body,GO:0005634~nucleus,GO:0005635~nuclear envelope,GO:0005640~nuclear outer membrane,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005856~cytoskeleton,GO:0016020~membrane,GO:0030017~sarcomere,GO:0030496~midbody,GO:0031965~nuclear membrane,GO:0034993~LINC complex,GO:0044327~dendritic spine head,GO:0045211~postsynaptic membrane,GO:0048471~perinuclear region of cytoplasm,	GO:0003723~RNA binding,GO:0003779~actin binding,GO:0005102~receptor binding,GO:0005515~protein binding,GO:0005521~lamin binding,GO:0019899~enzyme binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0051015~actin filament binding,	IPR001589:Actinin_actin-bd_CS,IPR001715:CH_dom,IPR002017:Spectrin_repeat,IPR012315:KASH,IPR018159:Spectrin/alpha-actinin,IPR036872:CH_dom_sf,IPR047290:CH_SYNE1_rpt1,IPR047291:CH_SYNE1_rpt2,		610743~Spinocerebellar ataxia, autosomal recessive 8,612998~Emery-Dreifuss muscular dystrophy 4, autosomal dominant,618484~Arthrogryposis multiplex congenita 3, myogenic type,		SM00033:CH,SM00150:SPEC,SM01249:KASH,	KW-0221~Differentiation,KW-0744~Spermatogenesis,	KW-0206~Cytoskeleton,KW-0261~Viral envelope protein,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0539~Nucleus,KW-0946~Virion,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-1067~Emery-Dreifuss muscular dystrophy,	KW-0175~Coiled coil,KW-0677~Repeat,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0009~Actin-binding,	KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	COMPBIAS:Polar residues,DISULFID:Interchain (C-563 in SUN2); alternate,DISULFID:Interchain (with C-657 in SUN1); alternate,DOMAIN:Calponin-homology (CH),DOMAIN:Calponin-homology (CH) 1,DOMAIN:Calponin-homology (CH) 2,DOMAIN:KASH,MUTAGEN:Missing: Abolishes the nuclear envelope targeting, induces a cytoplasmic localization.,REGION:Actin-binding,REGION:Disordered,REPEAT:Spectrin 1,REPEAT:Spectrin 10,REPEAT:Spectrin 11,REPEAT:Spectrin 12,REPEAT:Spectrin 13,REPEAT:Spectrin 14,REPEAT:Spectrin 15,REPEAT:Spectrin 16,REPEAT:Spectrin 17,REPEAT:Spectrin 18,REPEAT:Spectrin 19,REPEAT:Spectrin 2,REPEAT:Spectrin 20,REPEAT:Spectrin 21,REPEAT:Spectrin 22,REPEAT:Spectrin 23,REPEAT:Spectrin 24,REPEAT:Spectrin 25,REPEAT:Spectrin 26,REPEAT:Spectrin 27,REPEAT:Spectrin 28,REPEAT:Spectrin 29,REPEAT:Spectrin 3,REPEAT:Spectrin 30,REPEAT:Spectrin 31,REPEAT:Spectrin 32,REPEAT:Spectrin 33,REPEAT:Spectrin 34,REPEAT:Spectrin 35,REPEAT:Spectrin 36,REPEAT:Spectrin 37,REPEAT:Spectrin 38,REPEAT:Spectrin 39,REPEAT:Spectrin 4,REPEAT:Spectrin 40,REPEAT:Spectrin 41,REPEAT:Spectrin 42,REPEAT:Spectrin 43,REPEAT:Spectrin 44,REPEAT:Spectrin 45,REPEAT:Spectrin 46,REPEAT:Spectrin 47,REPEAT:Spectrin 48,REPEAT:Spectrin 49,REPEAT:Spectrin 5,REPEAT:Spectrin 50,REPEAT:Spectrin 51,REPEAT:Spectrin 52,REPEAT:Spectrin 53,REPEAT:Spectrin 54,REPEAT:Spectrin 55,REPEAT:Spectrin 56,REPEAT:Spectrin 57,REPEAT:Spectrin 58,REPEAT:Spectrin 59,REPEAT:Spectrin 6,REPEAT:Spectrin 60,REPEAT:Spectrin 61,REPEAT:Spectrin 62,REPEAT:Spectrin 63,REPEAT:Spectrin 64,REPEAT:Spectrin 65,REPEAT:Spectrin 66,REPEAT:Spectrin 67,REPEAT:Spectrin 68,REPEAT:Spectrin 69,REPEAT:Spectrin 7,REPEAT:Spectrin 70,REPEAT:Spectrin 71,REPEAT:Spectrin 72,REPEAT:Spectrin 73,REPEAT:Spectrin 74,REPEAT:Spectrin 8,REPEAT:Spectrin 9,TOPO_DOM:Cytoplasmic,TOPO_DOM:Perinuclear space,TRANSMEM:Helical; Anchor for type IV membrane protein,
SYNE2	spectrin repeat containing nuclear envelope protein 2(SYNE2)	Homo sapiens			GO:0007097~nuclear migration,GO:0021817~nucleokinesis involved in cell motility in cerebral cortex radial glia guided migration,GO:0030335~positive regulation of cell migration,GO:0031022~nuclear migration along microfilament,GO:0051642~centrosome localization,GO:1902017~regulation of cilium assembly,	GO:0005634~nucleus,GO:0005635~nuclear envelope,GO:0005640~nuclear outer membrane,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005925~focal adhesion,GO:0016020~membrane,GO:0016529~sarcoplasmic reticulum,GO:0030018~Z disc,GO:0031258~lamellipodium membrane,GO:0031527~filopodium membrane,GO:0031965~nuclear membrane,GO:0031981~nuclear lumen,GO:0033017~sarcoplasmic reticulum membrane,GO:0034993~LINC complex,GO:0045111~intermediate filament cytoskeleton,GO:0070062~extracellular exosome,	GO:0003779~actin binding,GO:0005515~protein binding,	IPR001589:Actinin_actin-bd_CS,IPR001715:CH_dom,IPR002017:Spectrin_repeat,IPR012315:KASH,IPR018159:Spectrin/alpha-actinin,IPR036872:CH_dom_sf,IPR039906:Anc-1-like,		612999~Emery-Dreifuss muscular dystrophy 5, autosomal dominant,		SM00033:CH,SM00150:SPEC,SM01249:KASH,		KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0703~Sarcoplasmic reticulum,KW-0963~Cytoplasm,KW-0965~Cell junction,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-1067~Emery-Dreifuss muscular dystrophy,	KW-0175~Coiled coil,KW-0677~Repeat,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0009~Actin-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DISULFID:Interchain (with C-563 in SUN2),DOMAIN:Calponin-homology (CH),DOMAIN:Calponin-homology (CH) 1,DOMAIN:Calponin-homology (CH) 2,DOMAIN:KASH,MUTAGEN:L->A: Disrupts interaction with SUN2.,MUTAGEN:P->A: Disrupts interaction with SUN2.,MUTAGEN:Y->A: Disrupts interaction with SUN2.,REGION:Actin-binding,REGION:Disordered,REGION:Sufficient for interaction with SUN2,REPEAT:Spectrin 1,REPEAT:Spectrin 10,REPEAT:Spectrin 11,REPEAT:Spectrin 12,REPEAT:Spectrin 13,REPEAT:Spectrin 14,REPEAT:Spectrin 15,REPEAT:Spectrin 16,REPEAT:Spectrin 17,REPEAT:Spectrin 18,REPEAT:Spectrin 19,REPEAT:Spectrin 2,REPEAT:Spectrin 20,REPEAT:Spectrin 21,REPEAT:Spectrin 22,REPEAT:Spectrin 23,REPEAT:Spectrin 24,REPEAT:Spectrin 25,REPEAT:Spectrin 26,REPEAT:Spectrin 27,REPEAT:Spectrin 28,REPEAT:Spectrin 29,REPEAT:Spectrin 3,REPEAT:Spectrin 30,REPEAT:Spectrin 31,REPEAT:Spectrin 32,REPEAT:Spectrin 33,REPEAT:Spectrin 34,REPEAT:Spectrin 35,REPEAT:Spectrin 36,REPEAT:Spectrin 37,REPEAT:Spectrin 38,REPEAT:Spectrin 39,REPEAT:Spectrin 4,REPEAT:Spectrin 40,REPEAT:Spectrin 41,REPEAT:Spectrin 42,REPEAT:Spectrin 43,REPEAT:Spectrin 44,REPEAT:Spectrin 45,REPEAT:Spectrin 46,REPEAT:Spectrin 47,REPEAT:Spectrin 48,REPEAT:Spectrin 49,REPEAT:Spectrin 5,REPEAT:Spectrin 50,REPEAT:Spectrin 51,REPEAT:Spectrin 52,REPEAT:Spectrin 53,REPEAT:Spectrin 54,REPEAT:Spectrin 55,REPEAT:Spectrin 56,REPEAT:Spectrin 6,REPEAT:Spectrin 7,REPEAT:Spectrin 8,REPEAT:Spectrin 9,TOPO_DOM:Cytoplasmic,TOPO_DOM:Perinuclear space,TRANSMEM:Helical; Anchor for type IV membrane protein,
SPAG7	sperm associated antigen 7(SPAG7)	Homo sapiens				GO:0005634~nucleus,	GO:0003676~nucleic acid binding,GO:0005515~protein binding,	IPR001374:R3H_dom,IPR017330:SPAG7,IPR034068:R3H_sperm-antigen,IPR036867:R3H_dom_sf,			PIRSF037943:Sperm-assoc_antigen_PAG7,	SM00393:R3H,		KW-0539~Nucleus,					KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:R3H,MOTIF:Nuclear localization signal,REGION:Disordered,
SPAG9	sperm associated antigen 9(SPAG9)	Homo sapiens			GO:0001933~negative regulation of protein phosphorylation,GO:0016192~vesicle-mediated transport,GO:0030335~positive regulation of cell migration,GO:0032418~lysosome localization,GO:0042147~retrograde transport, endosome to Golgi,GO:0043410~positive regulation of MAPK cascade,GO:0045665~negative regulation of neuron differentiation,GO:0045666~positive regulation of neuron differentiation,GO:0051146~striated muscle cell differentiation,GO:1903860~negative regulation of dendrite extension,	GO:0001669~acrosomal vesicle,GO:0005737~cytoplasm,GO:0005765~lysosomal membrane,GO:0005829~cytosol,GO:0016020~membrane,GO:0034451~centriolar satellite,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,	GO:0005078~MAP-kinase scaffold activity,GO:0005515~protein binding,GO:0008432~JUN kinase binding,GO:0019894~kinesin binding,GO:0030159~receptor signaling complex scaffold activity,GO:0042802~identical protein binding,	IPR015943:WD40/YVTN_repeat-like_dom_sf,IPR019143:JNK/Rab-associated_protein-1_N,IPR032486:JIP_LZII,IPR034743:RH1,IPR034744:RH2,IPR036322:WD40_repeat_dom_sf,IPR039911:JIP3/JIP4,						KW-0458~Lysosome,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,		KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:JNK-interacting protein leucine zipper II,DOMAIN:RH1,DOMAIN:RH2,REGION:Disordered,TRANSMEM:Helical,
SAT2	spermidine/spermine N1-acetyltransferase family member 2(SAT2)	Homo sapiens			GO:0032918~spermidine acetylation,GO:0032919~spermine acetylation,GO:0032920~putrescine acetylation,GO:0046204~nor-spermidine metabolic process,	GO:0005737~cytoplasm,GO:0070062~extracellular exosome,	GO:0004145~diamine N-acetyltransferase activity,GO:0005515~protein binding,GO:0008080~N-acetyltransferase activity,GO:0016747~transferase activity, transferring acyl groups other than amino-acyl groups,GO:0042802~identical protein binding,	IPR000182:GNAT_dom,IPR016181:Acyl_CoA_acyltransferase,	hsa00330:Arginine and proline metabolism,hsa01100:Metabolic pathways,hsa04216:Ferroptosis,					KW-0963~Cytoplasm,				KW-0012~Acyltransferase,KW-0808~Transferase,	KW-0007~Acetylation,	ACT_SITE:Proton donor,COMPBIAS:Pro residues,DOMAIN:N-acetyltransferase,REGION:Disordered,
SMS	spermine synthase(SMS)	Homo sapiens			GO:0006555~methionine metabolic process,GO:0006595~polyamine metabolic process,GO:0006597~spermine biosynthetic process,	GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0008757~S-adenosylmethionine-dependent methyltransferase activity,GO:0016768~spermine synthase activity,	IPR015576:Spermine_synthase_animal,IPR029063:SAM-dependent_MTases_sf,IPR030373:PABS_CS,IPR030374:PABS,IPR035246:Spermidine_synt_N,IPR037163:Spermidine_synt_N_sf,IPR040900:SpmSyn_N,	hsa00270:Cysteine and methionine metabolism,hsa00330:Arginine and proline metabolism,hsa00480:Glutathione metabolism,hsa01100:Metabolic pathways,	309583~Intellectual developmental disorder, X-linked syndromic, Snyder-Robinson type,			KW-0620~Polyamine biosynthesis,		KW-0991~Intellectual disability,			KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,DOMAIN:PABS,MUTAGEN:D->A,N: 100,000-fold decrease in catalytic efficiency.,MUTAGEN:D->N: 200,000-fold decrease in catalytic efficiency.,MUTAGEN:E->Q: 800-fold decrease in catalytic efficiency.,REGION:Disordered,
S1PR1	sphingosine-1-phosphate receptor 1(S1PR1)	Homo sapiens		h_edg1Pathway:Phospholipids as signalling intermediaries,	GO:0001525~angiogenesis,GO:0001955~blood vessel maturation,GO:0003245~cardiac muscle tissue growth involved in heart morphogenesis,GO:0003376~sphingosine-1-phosphate signaling pathway,GO:0006935~chemotaxis,GO:0007155~cell adhesion,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007189~adenylate cyclase-activating G-protein coupled receptor signaling pathway,GO:0007193~adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway,GO:0007200~phospholipase C-activating G-protein coupled receptor signaling pathway,GO:0007420~brain development,GO:0008283~cell proliferation,GO:0016477~cell migration,GO:0019222~regulation of metabolic process,GO:0019226~transmission of nerve impulse,GO:0030032~lamellipodium assembly,GO:0030036~actin cytoskeleton organization,GO:0030155~regulation of cell adhesion,GO:0030182~neuron differentiation,GO:0030335~positive regulation of cell migration,GO:0030500~regulation of bone mineralization,GO:0030595~leukocyte chemotaxis,GO:0045124~regulation of bone resorption,GO:0045446~endothelial cell differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048661~positive regulation of smooth muscle cell proliferation,GO:0050927~positive regulation of positive chemotaxis,GO:0051497~negative regulation of stress fiber assembly,GO:0061384~heart trabecula morphogenesis,GO:0072678~T cell migration,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005768~endosome,GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0043231~intracellular membrane-bounded organelle,GO:0045121~membrane raft,	GO:0001664~G-protein coupled receptor binding,GO:0004930~G-protein coupled receptor activity,GO:0005515~protein binding,GO:0038036~sphingosine-1-phosphate receptor activity,GO:0046625~sphingolipid binding,	IPR000276:GPCR_Rhodpsn,IPR000987:EDG1,IPR004061:S1P_rcpt,IPR017452:GPCR_Rhodpsn_7TM,	hsa04068:FoxO signaling pathway,hsa04071:Sphingolipid signaling pathway,hsa04080:Neuroactive ligand-receptor interaction,hsa04148:Efferocytosis,			SM01381:7TM_GPCR_Srsx,	KW-0037~Angiogenesis,KW-0145~Chemotaxis,	KW-0472~Membrane,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:G-protein coupled receptors family 1 profile,LIPID:S-palmitoyl cysteine,MUTAGEN:E->A: Drastically reduced affinity for sphingosine 1-phosphate.,MUTAGEN:E->Q: Slight activation of the receptor at maximal ligand concentration.,MUTAGEN:F->L: Impairs sphingosine 1-phosphate binding and signaling.,MUTAGEN:R->A,V: Drastically reduced affinity for sphingosine 1-phosphate.,MUTAGEN:R->A: Drastically reduced affinity for sphingosine 1-phosphate.,MUTAGEN:T->A: Acts as a dominant negative GPCR and inhibits S1P-induced Rac activation, chemotaxis, and angiogenesis.,MUTAGEN:W->F,L: Impairs sphingosine 1-phosphate binding and signaling.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
S1PR4	sphingosine-1-phosphate receptor 4(S1PR4)	Homo sapiens			GO:0003376~sphingosine-1-phosphate signaling pathway,GO:0006955~immune response,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007189~adenylate cyclase-activating G-protein coupled receptor signaling pathway,GO:0007202~activation of phospholipase C activity,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0019222~regulation of metabolic process,	GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005886~plasma membrane,	GO:0004930~G-protein coupled receptor activity,GO:0005515~protein binding,GO:0008289~lipid binding,GO:0038036~sphingosine-1-phosphate receptor activity,	IPR000276:GPCR_Rhodpsn,IPR004061:S1P_rcpt,IPR004064:EDG6_rcpt,IPR017452:GPCR_Rhodpsn_7TM,	hsa04068:FoxO signaling pathway,hsa04071:Sphingolipid signaling pathway,hsa04080:Neuroactive ligand-receptor interaction,					KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0564~Palmitate,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:G-protein coupled receptors family 1 profile,LIPID:S-palmitoyl cysteine,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
SPSB3	splA/ryanodine receptor domain and SOCS box containing 3(SPSB3)	Homo sapiens			GO:0016567~protein ubiquitination,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,	GO:0005829~cytosol,GO:0019005~SCF ubiquitin ligase complex,	GO:0005515~protein binding,	IPR001496:SOCS_box,IPR001870:B30.2/SPRY,IPR003877:SPRY_dom,IPR013320:ConA-like_dom_sf,IPR035754:SPRY_SPSB3,IPR043136:B30.2/SPRY_sf,				SM00449:SPRY,SM00969:SOCS_box,						KW-0675~Receptor,		DOMAIN:B30.2/SPRY,DOMAIN:SOCS box,REGION:Disordered,
SART3	spliceosome associated factor 3, U4/U6 recycling protein(SART3)	Homo sapiens			GO:0000244~spliceosomal tri-snRNP complex assembly,GO:0000387~spliceosomal snRNP assembly,GO:0000398~mRNA splicing, via spliceosome,GO:0000902~cell morphogenesis,GO:0006334~nucleosome assembly,GO:0006396~RNA processing,GO:0010468~regulation of gene expression,GO:0048872~homeostasis of number of cells,GO:0071425~hematopoietic stem cell proliferation,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005691~U6atac snRNP,GO:0005737~cytoplasm,GO:0015030~Cajal body,GO:0016607~nuclear speck,GO:0061574~ASAP complex,GO:0071001~U4/U6 snRNP,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0017070~U6 snRNA binding,GO:0030621~U4 snRNA binding,GO:0030624~U6atac snRNA binding,GO:0042393~histone binding,GO:1990381~ubiquitin-specific protease binding,	IPR000504:RRM_dom,IPR003107:HAT,IPR008669:LSM_interact,IPR011990:TPR-like_helical_dom_sf,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR034217:SART3_RRM1,IPR034218:SART3_RRM2,IPR035979:RBD_domain_sf,				SM00360:RRM,SM00386:HAT,	KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0677~Repeat,		KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:RRM,DOMAIN:RRM 1,DOMAIN:RRM 2,MOTIF:Nuclear localization signal,REGION:Disordered,REGION:Mediates interaction with PRPF3,REGION:Necessary and sufficient for U6 snRNA binding,REGION:Required for interaction with USP4,REGION:Required for nuclear localization,REPEAT:HAT 1,REPEAT:HAT 2,REPEAT:HAT 3,REPEAT:HAT 4,REPEAT:HAT 5,REPEAT:HAT 6,REPEAT:HAT 7,REPEAT:HAT 8,
SF3A2	splicing factor 3a subunit 2(SF3A2)	Homo sapiens			GO:0000245~spliceosomal complex assembly,GO:0000389~mRNA 3'-splice site recognition,GO:0000398~mRNA splicing, via spliceosome,GO:0006397~mRNA processing,GO:0008380~RNA splicing,GO:0010976~positive regulation of neuron projection development,GO:1903241~U2-type prespliceosome assembly,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005681~spliceosomal complex,GO:0005684~U2-type spliceosomal complex,GO:0005686~U2 snRNP,GO:0016607~nuclear speck,GO:0071004~U2-type prespliceosome,GO:0071005~U2-type precatalytic spliceosome,GO:0071013~catalytic step 2 spliceosome,	GO:0003676~nucleic acid binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,	IPR000690:Matrin/U1-C_Znf_C2H2,IPR003604:Matrin/U1-like-C_Znf_C2H2,IPR013087:Znf_C2H2_type,IPR031781:SF3A2_dom,IPR036236:Znf_C2H2_sf,	hsa03040:Spliceosome,			SM00451:ZnF_U1,SM01050:CactinC_cactus,	KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,KW-0747~Spliceosome,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Pro residues,DOMAIN:Matrin-type,REGION:Disordered,ZN_FING:Matrin-type,
SF3A3	splicing factor 3a subunit 3(SF3A3)	Homo sapiens			GO:0000375~RNA splicing, via transesterification reactions,GO:0000389~mRNA 3'-splice site recognition,GO:0000398~mRNA splicing, via spliceosome,GO:0006397~mRNA processing,GO:1903241~U2-type prespliceosome assembly,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005681~spliceosomal complex,GO:0005684~U2-type spliceosomal complex,GO:0005686~U2 snRNP,GO:0016607~nuclear speck,GO:0071005~U2-type precatalytic spliceosome,GO:0071013~catalytic step 2 spliceosome,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,	IPR000690:Matrin/U1-C_Znf_C2H2,IPR021966:SF3a60_bindingd,IPR024598:SF3a60/Prp9_C,IPR025086:SDE2-like_C_dom,IPR031774:SF3A3_dom,	hsa03040:Spliceosome,				KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,KW-0747~Spliceosome,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,DOMAIN:Matrin-type,MOTIF:Nuclear localization signal,MUTAGEN:Missing: Loss of nuclear location.,REGION:Disordered,ZN_FING:Matrin-type,
SF3B2	splicing factor 3b subunit 2(SF3B2)	Homo sapiens			GO:0000398~mRNA splicing, via spliceosome,GO:0006397~mRNA processing,GO:0008380~RNA splicing,GO:1903241~U2-type prespliceosome assembly,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005681~spliceosomal complex,GO:0005684~U2-type spliceosomal complex,GO:0005686~U2 snRNP,GO:0005689~U12-type spliceosomal complex,GO:0016607~nuclear speck,GO:0071005~U2-type precatalytic spliceosome,GO:0071011~precatalytic spliceosome,GO:0071013~catalytic step 2 spliceosome,	GO:0003723~RNA binding,GO:0005515~protein binding,	IPR003034:SAP_dom,IPR006568:PSP_pro-rich,IPR007180:DUF382,	hsa03040:Spliceosome,	164210~Craniofacial microsomia,		SM00513:SAP,SM00581:PSP,	KW-0507~mRNA processing,KW-0508~mRNA splicing,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0747~Spliceosome,	KW-0225~Disease variant,	KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:PSP proline-rich,DOMAIN:SAP,MUTAGEN:F->A: Does not affect methylation by PRMT9; when associated with A-510.,MUTAGEN:K->A: Moderately diminished formation of omega-N monomethylarginine but greatly reduced formation of symmetrical dimethylarginine; when associated with A-507.,MUTAGEN:K->A: Moderately diminished formation of omega-N monomethylarginine but greatly reduced formation of symmetrical dimethylarginine; when associated with A-509.,MUTAGEN:K->R: Moderately diminished formation of omega-N monomethylarginine but greatly reduced formation of symmetrical dimethylarginine; when associated with R-507. Abolishes formation of omega-N monomethylarginine and formation of symmetrical dimethylarginine; when associated with K-508 and R-507.,MUTAGEN:K->R: Moderately diminished formation of omega-N monomethylarginine but greatly reduced formation of symmetrical dimethylarginine; when associated with R-509. Abolishes formation of omega-N monomethylarginine and formation of symmetrical dimethylarginine; when associated with R-508. Abolishes formation of omega-N monomethylarginine and formation of symmetrical dimethylarginine; when associated with K-508 and R-509.,MUTAGEN:R->K: Abolishes interaction with SMN1; Abolishes methylation by PRMT9. Abolishes formation of omega-N monomethylarginine and formation of symmetrical dimethylarginine; when associated with R-507. Abolishes formation of omega-N monomethylarginine and formation of symmetrical dimethylarginine; when associated with R-507. Abolishes formation of omega-N monomethylarginine and formation of symmetrical dimethylarginine; when associated with R-507 and R-509.,MUTAGEN:R->K: Does not affect methylation by PRMT9.,MUTAGEN:Y->A: Does not affect methylation by PRMT9; when associated with A-506.,REGION:Disordered,REGION:Required for interaction with PRMT9,
SF3B6	splicing factor 3b subunit 6(SF3B6)	Homo sapiens			GO:0000398~mRNA splicing, via spliceosome,GO:0001825~blastocyst formation,GO:1903241~U2-type prespliceosome assembly,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005681~spliceosomal complex,GO:0005684~U2-type spliceosomal complex,GO:0005686~U2 snRNP,GO:0005689~U12-type spliceosomal complex,GO:0071011~precatalytic spliceosome,GO:0071013~catalytic step 2 spliceosome,	GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0005515~protein binding,	IPR000504:RRM_dom,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR034150:SF3B6_RRM,IPR035979:RBD_domain_sf,	hsa03040:Spliceosome,			SM00360:RRM,	KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,KW-0747~Spliceosome,				KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:RRM,REGION:Interaction with pre-mRNA branch site,
SKAP1	src kinase associated phosphoprotein 1(SKAP1)	Homo sapiens			GO:0001954~positive regulation of cell-matrix adhesion,GO:0002250~adaptive immune response,GO:0002821~positive regulation of adaptive immune response,GO:0033625~positive regulation of integrin activation,GO:0033634~positive regulation of cell-cell adhesion mediated by integrin,GO:0034116~positive regulation of heterotypic cell-cell adhesion,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0050852~T cell receptor signaling pathway,GO:0072659~protein localization to plasma membrane,GO:1903039~positive regulation of leukocyte cell-cell adhesion,	GO:0001772~immunological synapse,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005911~cell-cell junction,GO:0042101~T cell receptor complex,GO:0044853~plasma membrane raft,	GO:0005515~protein binding,GO:0017124~SH3 domain binding,GO:0019901~protein kinase binding,GO:0019903~protein phosphatase binding,GO:0042169~SH2 domain binding,	IPR001452:SH3_domain,IPR001849:PH_domain,IPR011993:PH-like_dom_sf,IPR035765:SKAP1_SH3,IPR036028:SH3-like_dom_sf,IPR037781:SKAP_fam,	hsa04015:Rap1 signaling pathway,			SM00233:PH,SM00326:SH3,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0728~SH3 domain,			KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Polar residues,DOMAIN:PH,DOMAIN:SH3,MUTAGEN:W->R: Abolishes homodimerization, interaction with FYB1 and activation of the MAP kinase pathway.,MUTAGEN:Y->F: Abolishes FYB1-dependent activation of ITGAL clustering.,MUTAGEN:Y->F: Abolishes interaction with PTPRC, translocation to cell membrane upon T-cell stimulation and activation of the MAP kinase pathway. No effect on interaction with FYN or GRB2.,MUTAGEN:Y->F: Impairs interaction with FYB1.,MUTAGEN:Y->F: Impairs interaction with PTPRC. No effect on interaction with FYN or GRB2.,MUTAGEN:Y->F: No effect on interaction with PTPRC and translocation to cell membrane upon T-cell stimulation. Abolishes interaction with FYN and GRB2 and activation of the MAP kinase pathway.,REGION:Disordered,REGION:Interaction with FYB1,
STMN1	stathmin 1(STMN1)	Homo sapiens		h_stathminPathway:Stathmin and breast cancer resistance to antimicrotubule agents,	GO:0000281~mitotic cytokinesis,GO:0007019~microtubule depolymerization,GO:0007052~mitotic spindle organization,GO:0007165~signal transduction,GO:0007409~axonogenesis,GO:0009615~response to virus,GO:0030334~regulation of cell migration,GO:0031110~regulation of microtubule polymerization or depolymerization,GO:0031115~negative regulation of microtubule polymerization,GO:0031175~neuron projection development,GO:0035024~negative regulation of Rho protein signal transduction,GO:0035556~intracellular signal transduction,GO:0048012~hepatocyte growth factor receptor signaling pathway,GO:0051497~negative regulation of stress fiber assembly,GO:0061436~establishment of skin barrier,GO:0070495~negative regulation of thrombin-activated receptor signaling pathway,GO:1905098~negative regulation of guanyl-nucleotide exchange factor activity,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005874~microtubule,GO:0016020~membrane,GO:0043005~neuron projection,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0015631~tubulin binding,	IPR000956:Stathmin_fam,IPR030514:Stathmin_CS,IPR036002:Stathmin_sf,	hsa04010:MAPK signaling pathway,hsa05206:MicroRNAs in cancer,		PIRSF002285:Stathmin,		KW-0221~Differentiation,KW-0524~Neurogenesis,	KW-0206~Cytoskeleton,KW-0493~Microtubule,KW-0963~Cytoplasm,		KW-0175~Coiled coil,		KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	DOMAIN:SLD,REGION:Disordered,
SLBP	stem-loop histone mRNA binding protein(SLBP)	Homo sapiens			GO:0002191~cap-dependent translational initiation,GO:0006398~mRNA 3'-end processing by stem-loop binding and cleavage,GO:0051028~mRNA transport,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0071204~histone pre-mRNA 3'end processing complex,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0071207~histone pre-mRNA stem-loop binding,GO:0071208~histone pre-mRNA DCP binding,	IPR026502:SLBP1/SLBP2,IPR029344:SLBP_RNA_bind,IPR038294:SLBP_RNA_bind_sf,					KW-0507~mRNA processing,	KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0687~Ribonucleoprotein,KW-0694~RNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Histone RNA hairpin-binding protein RNA-binding,MOTIF:Nuclear localization signal NLS1,MOTIF:Nuclear localization signal NLS2,MUTAGEN:KRKL->AAAA: Increases its stability at the end of the S phase and through G2 and mitosis. Inhibits phosphorylation of T-62. Localizes in the nucleus. Reduces interaction with the importin alpha/importin beta receptor. Abolishes interaction with the importin alpha/importin beta receptor; when associated with A-31; A-32; A-33 and A-34 or with A-241; A-242; A-243 and A-244.,MUTAGEN:KVRH->AAAA: Reduces interaction with the importin alpha/importin beta receptor. Abolishes interaction with the importin alpha/importin beta receptor; when associated with A-31; A-32; A-33 and A-34 or with A-96; A-97; A-98 and A-99.,MUTAGEN:Missing: Decrease in 3'-end processing efficiency.,MUTAGEN:P->A: Increases its stability at the end of the S phase and through G2 and mitosis.,MUTAGEN:R->A: Inhibits histone RNA-binding and localization to the cytoplasm.,MUTAGEN:RKRR->AAAA: Reduces interaction with the importin alpha/importin beta receptor. Abolishes interaction with the importin alpha/importin beta receptor; when associated with A-96; A-97; A-98 and A-99 or with A-241; A-242; A-243 and A-244.,MUTAGEN:S->A: Does not increase its stability at the end of the S phase and through G2 and mitosis.,MUTAGEN:SFTTP->AAAA: Does not increase its stability at the end of the S phase and through G2 and mitosis.,MUTAGEN:T->A: Increases its stability at the end of the S phase and through G2 and mitosis.,MUTAGEN:T->A: Increases its stability at the end of the S phase and through G2 and mitosis. Active in histone pre-mRNA processing during the G2 phase.,REGION:Disordered,REGION:RNA-binding,
SAMD9	sterile alpha motif domain containing 9(SAMD9)	Homo sapiens			GO:0034058~endosomal vesicle fusion,GO:0045087~innate immune response,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0043231~intracellular membrane-bounded organelle,	GO:0005515~protein binding,	IPR001660:SAM,IPR013761:SAM/pointed_sf,IPR027417:P-loop_NTPase,		610455~Tumoral calcinosis, familial, normophosphatemic,617053~MIRAGE syndrome,619041~Monosomy 7 myelodysplasia and leukemia syndrome 2,		SM00454:SAM,	KW-0391~Immunity,KW-0399~Innate immunity,	KW-0963~Cytoplasm,	KW-0225~Disease variant,					COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:SAM,MUTAGEN:K->E: No defect in double-stranded nucleic acid binding but defective at inhibiting viral replication.,REGION:Disordered,
SCP2	sterol carrier protein 2(SCP2)	Homo sapiens			GO:0006635~fatty acid beta-oxidation,GO:0006694~steroid biosynthetic process,GO:0006699~bile acid biosynthetic process,GO:0006701~progesterone biosynthetic process,GO:0006869~lipid transport,GO:0008206~bile acid metabolic process,GO:0015914~phospholipid transport,GO:0032367~intracellular cholesterol transport,GO:0032385~positive regulation of intracellular cholesterol transport,GO:0032959~inositol trisphosphate biosynthetic process,GO:0033540~fatty acid beta-oxidation using acyl-CoA oxidase,GO:0036109~alpha-linolenic acid metabolic process,GO:0045940~positive regulation of steroid metabolic process,GO:0071071~regulation of phospholipid biosynthetic process,GO:0072659~protein localization to plasma membrane,GO:1901373~lipid hydroperoxide transport,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005777~peroxisome,GO:0005782~peroxisomal matrix,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0016020~membrane,GO:0032991~macromolecular complex,	GO:0000062~fatty-acyl-CoA binding,GO:0003988~acetyl-CoA C-acyltransferase activity,GO:0005102~receptor binding,GO:0005515~protein binding,GO:0008289~lipid binding,GO:0008526~phosphatidylinositol transporter activity,GO:0015485~cholesterol binding,GO:0016747~transferase activity, transferring acyl groups other than amino-acyl groups,GO:0033814~propanoyl-CoA C-acyltransferase activity,GO:0036042~long-chain fatty acyl-CoA binding,GO:0050632~propionyl-CoA C2-trimethyltridecanoyltransferase activity,GO:0050633~acetyl-CoA C-myristoyltransferase activity,GO:0070538~oleic acid binding,	IPR002155:Thiolase,IPR003033:SCP2_sterol-bd_dom,IPR016039:Thiolase-like,IPR020613:Thiolase_CS,IPR020615:Thiolase_acyl_enz_int_AS,IPR020616:Thiolase_N,IPR020617:Thiolase_C,IPR036527:SCP2_sterol-bd_dom_sf,IPR039543:POX18/UbiT/NSL-TP1,	hsa00120:Primary bile acid biosynthesis,hsa01040:Biosynthesis of unsaturated fatty acids,hsa01100:Metabolic pathways,hsa01212:Fatty acid metabolism,hsa03320:PPAR signaling pathway,hsa04146:Peroxisome,	613724~Leukoencephalopathy with dystonia and motor neuropathy,	PIRSF000429:Ac-CoA_Ac_transf,		KW-0443~Lipid metabolism,KW-0445~Lipid transport,KW-0813~Transport,	KW-0256~Endoplasmic reticulum,KW-0496~Mitochondrion,KW-0576~Peroxisome,KW-0963~Cytoplasm,		KW-0809~Transit peptide,	KW-0446~Lipid-binding,	KW-0012~Acyltransferase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:SCP2,DOMAIN:Thiolase C-terminal,DOMAIN:Thiolase N-terminal,MOTIF:Microbody targeting signal,MUTAGEN:G->D: Strongly reduces sterol carrier and phosphatidylcholine transfer activity; when associated with D-528.,MUTAGEN:N->D: Strongly reduces sterol carrier and phosphatidylcholine transfer activity; when associated with D-530.,MUTAGEN:N->I: Strongly reduces sterol carrier and phosphatidylcholine transfer activity.,REGION:Disordered,SITE:Cleavage,
STOML2	stomatin like 2(STOML2)	Homo sapiens			GO:0006874~cellular calcium ion homeostasis,GO:0007005~mitochondrion organization,GO:0010876~lipid localization,GO:0032743~positive regulation of interleukin-2 production,GO:0034982~mitochondrial protein processing,GO:0035710~CD4-positive, alpha-beta T cell activation,GO:0042776~mitochondrial ATP synthesis coupled proton transport,GO:0050852~T cell receptor signaling pathway,GO:0051259~protein oligomerization,GO:1990046~stress-induced mitochondrial fusion,	GO:0001772~immunological synapse,GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005758~mitochondrial intermembrane space,GO:0005886~plasma membrane,GO:0015629~actin cytoskeleton,GO:0045121~membrane raft,	GO:0005515~protein binding,GO:0042608~T cell receptor binding,GO:0051020~GTPase binding,GO:1901612~cardiolipin binding,	IPR001107:Band_7,IPR001972:Stomatin_HflK_fam,IPR032435:STML2-like_C,IPR036013:Band_7/SPFH_dom_sf,				SM00244:PHB,		KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0496~Mitochondrion,KW-0963~Cytoplasm,KW-0999~Mitochondrion inner membrane,KW-1003~Cell membrane,		KW-0175~Coiled coil,KW-0809~Transit peptide,	KW-0446~Lipid-binding,		KW-0007~Acetylation,KW-0449~Lipoprotein,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Band 7,REGION:Disordered,TRANSIT:Mitochondrion,
SBNO1	strawberry notch homolog 1(SBNO1)	Homo sapiens			GO:0006355~regulation of transcription, DNA-templated,GO:0048583~regulation of response to stimulus,	GO:0005634~nucleus,	GO:0031490~chromatin DNA binding,GO:0042393~histone binding,	IPR026741:SNO,IPR026937:SBNO_Helicase_C_dom,IPR027417:P-loop_NTPase,IPR039187:SNO_AAA,								KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,
SERP1	stress associated endoplasmic reticulum protein 1(SERP1)	Homo sapiens			GO:0001501~skeletal system development,GO:0006006~glucose metabolic process,GO:0006486~protein glycosylation,GO:0007009~plasma membrane organization,GO:0009791~post-embryonic development,GO:0015031~protein transport,GO:0030073~insulin secretion,GO:0030968~endoplasmic reticulum unfolded protein response,GO:0032024~positive regulation of insulin secretion,GO:0036211~protein modification process,GO:0045727~positive regulation of translation,GO:0046622~positive regulation of organ growth,GO:0048644~muscle organ morphogenesis,GO:0060124~positive regulation of growth hormone secretion,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0005840~ribosome,GO:0005881~cytoplasmic microtubule,	GO:0005515~protein binding,	IPR010580:ER_stress-assoc,					KW-0653~Protein transport,KW-0811~Translocation,KW-0813~Transport,KW-0834~Unfolded protein response,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				REGION:Disordered,TRANSMEM:Helical,
STIP1	stress induced phosphoprotein 1(STIP1)	Homo sapiens			GO:0098761~cellular response to interleukin-7,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0032991~macromolecular complex,GO:0101031~chaperone complex,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0051879~Hsp90 protein binding,	IPR001440:TPR_1,IPR006636:STI1_HS-bd,IPR011990:TPR-like_helical_dom_sf,IPR013105:TPR_2,IPR019734:TPR_repeat,IPR041243:STI1/HOP_DP,	hsa05020:Prion disease,			SM00028:TPR,SM00727:STI1,		KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0802~TPR repeat,			KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:STI1,DOMAIN:STI1 1,DOMAIN:STI1 2,DOMAIN:STI1/HOP DP,MOTIF:Bipartite nuclear localization signal,REGION:Disordered,REPEAT:TPR,REPEAT:TPR 1,REPEAT:TPR 2,REPEAT:TPR 3,REPEAT:TPR 4,REPEAT:TPR 5,REPEAT:TPR 6,REPEAT:TPR 7,REPEAT:TPR 8,REPEAT:TPR 9,
SDF2L1	stromal cell derived factor 2 like 1(SDF2L1)	Homo sapiens			GO:0036503~ERAD pathway,GO:0042981~regulation of apoptotic process,GO:0051085~chaperone mediated protein folding requiring cofactor,GO:0071712~ER-associated misfolded protein catabolic process,	GO:0005783~endoplasmic reticulum,GO:0005788~endoplasmic reticulum lumen,GO:0016020~membrane,GO:0034663~endoplasmic reticulum chaperone complex,GO:0101031~chaperone complex,	GO:0005515~protein binding,GO:0051087~chaperone binding,GO:0051117~ATPase binding,GO:0051787~misfolded protein binding,	IPR016093:MIR_motif,IPR036300:MIR_dom_sf,				SM00472:MIR,		KW-0256~Endoplasmic reticulum,		KW-0677~Repeat,KW-0732~Signal,			KW-0597~Phosphoprotein,	DOMAIN:MIR 1,DOMAIN:MIR 2,DOMAIN:MIR 3,MOTIF:Prevents secretion from ER,
SDF2	stromal cell derived factor 2(SDF2)	Homo sapiens			GO:0051085~chaperone mediated protein folding requiring cofactor,	GO:0005783~endoplasmic reticulum,GO:0101031~chaperone complex,	GO:0051787~misfolded protein binding,	IPR016093:MIR_motif,IPR036300:MIR_dom_sf,				SM00472:MIR,		KW-0964~Secreted,		KW-0677~Repeat,KW-0732~Signal,				COMPBIAS:Polar residues,DOMAIN:MIR,DOMAIN:MIR 1,DOMAIN:MIR 2,DOMAIN:MIR 3,REGION:Disordered,
SDF4	stromal cell derived factor 4(SDF4)	Homo sapiens			GO:0009650~UV protection,GO:0017156~calcium ion regulated exocytosis,GO:0021549~cerebellum development,GO:0045444~fat cell differentiation,GO:0045471~response to ethanol,GO:0070625~zymogen granule exocytosis,GO:0099558~maintenance of synapse structure,	GO:0005737~cytoplasm,GO:0005770~late endosome,GO:0005783~endoplasmic reticulum,GO:0005794~Golgi apparatus,GO:0005796~Golgi lumen,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0032059~bleb,GO:0070062~extracellular exosome,	GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR002048:EF_hand_dom,IPR011992:EF-hand-dom_pair,IPR018247:EF_Hand_1_Ca_BS,IPR027240:CAB45_EFh,				SM00054:EFh,	KW-0268~Exocytosis,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0732~Signal,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:EF-hand,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,DOMAIN:EF-hand 3,DOMAIN:EF-hand 4,DOMAIN:EF-hand 5,DOMAIN:EF-hand 6,MUTAGEN:E->Q: Does not affect calcium-binding.,MUTAGEN:E->Q: Inhibits calcium-binding.,REGION:Disordered,REGION:Necessary for intracellular retention in Golgi apparatus lumen,
SMC4	structural maintenance of chromosomes 4(SMC4)	Homo sapiens			GO:0000070~mitotic sister chromatid segregation,GO:0007049~cell cycle,GO:0007076~mitotic chromosome condensation,GO:0010032~meiotic chromosome condensation,GO:0045132~meiotic chromosome segregation,GO:0051276~chromosome organization,GO:0051301~cell division,GO:0051383~kinetochore organization,GO:0051984~positive regulation of chromosome segregation,GO:1905820~positive regulation of chromosome separation,GO:1905821~positive regulation of chromosome condensation,	GO:0000775~chromosome, centromeric region,GO:0000794~condensed nuclear chromosome,GO:0000796~condensin complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005694~chromosome,GO:0005829~cytosol,GO:0016607~nuclear speck,	GO:0003682~chromatin binding,GO:0003697~single-stranded DNA binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016887~ATPase activity,	IPR003395:RecF/RecN/SMC_N,IPR010935:SMC_hinge,IPR024704:SMC,IPR027417:P-loop_NTPase,IPR036277:SMC_hinge_sf,			PIRSF005719:SMC,	SM00968:SMC_hinge,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0226~DNA condensation,KW-0498~Mitosis,	KW-0158~Chromosome,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,		KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,DOMAIN:RecF/RecN/SMC N-terminal,DOMAIN:SMC hinge,REGION:Disordered,
SMC5	structural maintenance of chromosomes 5(SMC5)	Homo sapiens			GO:0000722~telomere maintenance via recombination,GO:0000724~double-strand break repair via homologous recombination,GO:0006974~cellular response to DNA damage stimulus,GO:0007059~chromosome segregation,GO:0016925~protein sumoylation,GO:0019827~stem cell population maintenance,GO:0030261~chromosome condensation,GO:0032204~regulation of telomere maintenance,GO:0034184~positive regulation of maintenance of mitotic sister chromatid cohesion,GO:0044772~mitotic cell cycle phase transition,GO:0044828~negative regulation by host of viral genome replication,GO:0051301~cell division,GO:0051984~positive regulation of chromosome segregation,GO:0071459~protein localization to chromosome, centromeric region,GO:0090398~cellular senescence,	GO:0000775~chromosome, centromeric region,GO:0000781~chromosome, telomeric region,GO:0000803~sex chromosome,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0016605~PML body,GO:0016607~nuclear speck,GO:0030054~cell junction,GO:0030915~Smc5-Smc6 complex,GO:0035061~interchromatin granule,GO:0035861~site of double-strand break,	GO:0000217~DNA secondary structure binding,GO:0003697~single-stranded DNA binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016887~ATPase activity,	IPR003395:RecF/RecN/SMC_N,IPR027131:SMC5,IPR027417:P-loop_NTPase,IPR038729:Rad50/SbcC_AAA,		620185~Atelis syndrome 2,			KW-0131~Cell cycle,KW-0132~Cell division,KW-0227~DNA damage,KW-0233~DNA recombination,KW-0234~DNA repair,KW-0498~Mitosis,	KW-0158~Chromosome,KW-0539~Nucleus,KW-0779~Telomere,	KW-0225~Disease variant,	KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,		KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,DOMAIN:Rad50/SbcC-type AAA,REGION:Disordered,REGION:Flexible hinge,
SMCHD1	structural maintenance of chromosomes flexible hinge domain containing 1(SMCHD1)	Homo sapiens			GO:0006302~double-strand break repair,GO:0009048~dosage compensation by inactivation of X chromosome,GO:0010424~DNA methylation on cytosine within a CG sequence,GO:0043584~nose development,GO:0045739~positive regulation of DNA repair,GO:0051276~chromosome organization,GO:0060818~inactivation of paternal X chromosome by genetic imprinting,GO:2000042~negative regulation of double-strand break repair via homologous recombination,GO:2001034~positive regulation of double-strand break repair via nonhomologous end joining,	GO:0000781~chromosome, telomeric region,GO:0001740~Barr body,GO:0005634~nucleus,GO:0005694~chromosome,GO:0016020~membrane,GO:0035861~site of double-strand break,	GO:0003677~DNA binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016887~ATPase activity,GO:0042803~protein homodimerization activity,	IPR010935:SMC_hinge,IPR036277:SMC_hinge_sf,IPR036890:HATPase_C_sf,IPR038892:SMCHD1,		158901~Fascioscapulohumeral muscular dystrophy 2, digenic,603457~Bosma arhinia microphthalmia syndrome,		SM00968:SMC_hinge,	KW-0227~DNA damage,KW-0234~DNA repair,	KW-0158~Chromosome,KW-0472~Membrane,	KW-0225~Disease variant,KW-0956~Kallmann syndrome,KW-1013~Microphthalmia,KW-1016~Hypogonadotropic hypogonadism,	KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0156~Chromatin regulator,KW-0238~DNA-binding,KW-0378~Hydrolase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:SMC hinge,REGION:ATPase activity domain,REGION:Disordered,TRANSMEM:Helical,
SDHC	succinate dehydrogenase complex subunit C(SDHC)	Homo sapiens		h_etcPathway:Electron Transport Reaction in Mitochondria,	GO:0006099~tricarboxylic acid cycle,GO:0006121~mitochondrial electron transport, succinate to ubiquinone,GO:0009060~aerobic respiration,GO:0042776~mitochondrial ATP synthesis coupled proton transport,	GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005749~mitochondrial respiratory chain complex II, succinate dehydrogenase complex (ubiquinone),GO:0016020~membrane,GO:0045257~succinate dehydrogenase complex (ubiquinone),GO:0045281~succinate dehydrogenase complex,	GO:0000104~succinate dehydrogenase activity,GO:0005515~protein binding,GO:0009055~electron carrier activity,GO:0016627~oxidoreductase activity, acting on the CH-CH group of donors,GO:0020037~heme binding,GO:0046872~metal ion binding,	IPR000701:SuccDH_FuR_B_TM-su,IPR014314:Succ_DH_cytb556,IPR018495:Succ_DH_cyt_bsu_CS,IPR034804:SQR/QFR_C/D,	hsa00020:Citrate cycle (TCA cycle),hsa00190:Oxidative phosphorylation,hsa01100:Metabolic pathways,hsa01200:Carbon metabolism,hsa04714:Thermogenesis,hsa04932:Non-alcoholic fatty liver disease,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05415:Diabetic cardiomyopathy,	605373~Pheochromocytoma/paraganglioma syndrome 3,606764~Gastrointestinal stromal tumor,606864~Paraganglioma and gastric stromal sarcoma,	PIRSF000178:SDH_cyt_b560,		KW-0249~Electron transport,KW-0813~Transport,KW-0816~Tricarboxylic acid cycle,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,		KW-0732~Signal,KW-0809~Transit peptide,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0349~Heme,KW-0408~Iron,KW-0479~Metal-binding,			BINDING:axial binding residue,TOPO_DOM:Mitochondrial intermembrane,TOPO_DOM:Mitochondrial matrix,TRANSIT:Mitochondrion,TRANSMEM:Helical,
SDHD	succinate dehydrogenase complex subunit D(SDHD)	Homo sapiens		h_etcPathway:Electron Transport Reaction in Mitochondria,	GO:0006099~tricarboxylic acid cycle,GO:0006121~mitochondrial electron transport, succinate to ubiquinone,GO:0042776~mitochondrial ATP synthesis coupled proton transport,GO:0050433~regulation of catecholamine secretion,GO:0071456~cellular response to hypoxia,	GO:0005739~mitochondrion,GO:0005740~mitochondrial envelope,GO:0005743~mitochondrial inner membrane,GO:0005749~mitochondrial respiratory chain complex II, succinate dehydrogenase complex (ubiquinone),GO:0045257~succinate dehydrogenase complex (ubiquinone),	GO:0005515~protein binding,GO:0008177~succinate dehydrogenase (ubiquinone) activity,GO:0009055~electron carrier activity,GO:0020037~heme binding,GO:0046872~metal ion binding,GO:0048039~ubiquinone binding,	IPR007992:CybS,IPR034804:SQR/QFR_C/D,	hsa00020:Citrate cycle (TCA cycle),hsa00190:Oxidative phosphorylation,hsa01100:Metabolic pathways,hsa01200:Carbon metabolism,hsa04714:Thermogenesis,hsa04932:Non-alcoholic fatty liver disease,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05415:Diabetic cardiomyopathy,	168000~Pheochromocytoma/paraganglioma syndrome 1,606864~Paraganglioma and gastric stromal sarcoma,619167~Mitochondrial complex II deficiency, nuclear type 3,			KW-0249~Electron transport,KW-0813~Transport,KW-0816~Tricarboxylic acid cycle,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,	KW-0225~Disease variant,KW-1274~Primary mitochondrial disease,	KW-0732~Signal,KW-0809~Transit peptide,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0349~Heme,KW-0408~Iron,KW-0479~Metal-binding,			BINDING:axial binding residue,TOPO_DOM:Mitochondrial intermembrane,TOPO_DOM:Mitochondrial matrix,TRANSIT:Mitochondrion,TRANSMEM:Helical,
SUCLG1	succinate-CoA ligase GDP/ADP-forming subunit alpha(SUCLG1)	Homo sapiens			GO:0006099~tricarboxylic acid cycle,GO:1901289~succinyl-CoA catabolic process,	GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0009361~succinate-CoA ligase complex (ADP-forming),GO:0045244~succinate-CoA ligase complex (GDP-forming),	GO:0000166~nucleotide binding,GO:0003723~RNA binding,GO:0004775~succinate-CoA ligase (ADP-forming) activity,GO:0004776~succinate-CoA ligase (GDP-forming) activity,GO:0005515~protein binding,	IPR003781:CoA-bd,IPR005810:CoA_lig_alpha,IPR005811:CoA_ligase,IPR016102:Succinyl-CoA_synth-like,IPR017440:Cit_synth/succinyl-CoA_lig_AS,IPR033847:Citrt_syn/SCS-alpha_CS,IPR036291:NAD(P)-bd_dom_sf,	hsa00020:Citrate cycle (TCA cycle),hsa00640:Propanoate metabolism,hsa01100:Metabolic pathways,hsa01200:Carbon metabolism,	245400~Mitochondrial DNA depletion syndrome 9 (encephalomyopathic type with methylmalonic aciduria),	PIRSF001553:SucCS_alpha,	SM00881:CoA_binding,	KW-0816~Tricarboxylic acid cycle,	KW-0496~Mitochondrion,	KW-0225~Disease variant,KW-1274~Primary mitochondrial disease,	KW-0809~Transit peptide,	KW-0547~Nucleotide-binding,	KW-0436~Ligase,	KW-0007~Acetylation,	ACT_SITE:Tele-phosphohistidine intermediate,DOMAIN:CoA-binding,TRANSIT:Mitochondrion,
SUMF2	sulfatase modifying factor 2(SUMF2)	Homo sapiens				GO:0005783~endoplasmic reticulum,GO:0005788~endoplasmic reticulum lumen,	GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0046872~metal ion binding,	IPR005532:SUMF_dom,IPR016187:CTDL_fold,IPR042095:SUMF_sf,						KW-0256~Endoplasmic reticulum,		KW-0732~Signal,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:Sulfatase-modifying factor enzyme,MOTIF:Non-canonical ER retention motif,MUTAGEN:C->A: Abolishes interaction with and inhibition of SUMF1. Can still form homodimers.,MUTAGEN:Missing: Abolishes endoplasmic reticulum retention.,MUTAGEN:P->S: Does not affect endoplasmic reticulum retention.,MUTAGEN:PG->KD: Does not affect endoplasmic reticulum retention.,REGION:Disordered,
SOD1	superoxide dismutase 1(SOD1)	Homo sapiens	6.CD23_engagement,	h_FlumazenilPathway:Cardiac Protection Against ROS ,h_freePathway:Free Radical Induced Apoptosis,h_longevityPathway:The IGF-1 Receptor and Longevity,	GO:0000303~response to superoxide,GO:0001541~ovarian follicle development,GO:0001819~positive regulation of cytokine production,GO:0001890~placenta development,GO:0001895~retina homeostasis,GO:0002262~myeloid cell homeostasis,GO:0006749~glutathione metabolic process,GO:0006801~superoxide metabolic process,GO:0006879~cellular iron ion homeostasis,GO:0006915~apoptotic process,GO:0007283~spermatogenesis,GO:0007566~embryo implantation,GO:0007605~sensory perception of sound,GO:0007626~locomotory behavior,GO:0008089~anterograde axonal transport,GO:0008090~retrograde axonal transport,GO:0008217~regulation of blood pressure,GO:0008340~determination of adult lifespan,GO:0009408~response to heat,GO:0009410~response to xenobiotic stimulus,GO:0010033~response to organic substance,GO:0010467~gene expression,GO:0019226~transmission of nerve impulse,GO:0019228~neuronal action potential,GO:0019430~removal of superoxide radicals,GO:0032287~peripheral nervous system myelin maintenance,GO:0032930~positive regulation of superoxide anion generation,GO:0033081~regulation of T cell differentiation in thymus,GO:0035234~ectopic germ cell programmed cell death,GO:0040014~regulation of multicellular organism growth,GO:0042542~response to hydrogen peroxide,GO:0042554~superoxide anion generation,GO:0043065~positive regulation of apoptotic process,GO:0043085~positive regulation of catalytic activity,GO:0043087~regulation of GTPase activity,GO:0043410~positive regulation of MAPK cascade,GO:0043524~negative regulation of neuron apoptotic process,GO:0045471~response to ethanol,GO:0045541~negative regulation of cholesterol biosynthetic process,GO:0045859~regulation of protein kinase activity,GO:0046620~regulation of organ growth,GO:0046716~muscle cell cellular homeostasis,GO:0048538~thymus development,GO:0048678~response to axon injury,GO:0050665~hydrogen peroxide biosynthetic process,GO:0050728~negative regulation of inflammatory response,GO:0050766~positive regulation of phagocytosis,GO:0051093~negative regulation of developmental process,GO:0051881~regulation of mitochondrial membrane potential,GO:0060047~heart contraction,GO:0060052~neurofilament cytoskeleton organization,GO:0060087~relaxation of vascular smooth muscle,GO:0060088~auditory receptor cell stereocilium organization,GO:0072593~reactive oxygen species metabolic process,GO:0099610~action potential initiation,GO:1902177~positive regulation of oxidative stress-induced intrinsic apoptotic signaling pathway,GO:2000242~negative regulation of reproductive process,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005758~mitochondrial intermembrane space,GO:0005759~mitochondrial matrix,GO:0005777~peroxisome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0031410~cytoplasmic vesicle,GO:0032839~dendrite cytoplasm,GO:0032991~macromolecular complex,GO:0043025~neuronal cell body,GO:0070062~extracellular exosome,GO:1904115~axon cytoplasm,	GO:0004784~superoxide dismutase activity,GO:0005507~copper ion binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0030346~protein phosphatase 2B binding,GO:0031267~small GTPase binding,GO:0042802~identical protein binding,GO:0046872~metal ion binding,GO:0051087~chaperone binding,	IPR001424:SOD_Cu_Zn_dom,IPR018152:SOD_Cu/Zn_BS,IPR024134:SOD_Cu/Zn_/chaperone,IPR036423:SOD-like_Cu/Zn_dom_sf,	hsa04146:Peroxisome,hsa04213:Longevity regulating pathway - multiple species,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05208:Chemical carcinogenesis - reactive oxygen species,	105400~Amyotrophic lateral sclerosis 1,618598~Spastic tetraplegia and axial hypotonia, progressive,				KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0036~Amyotrophic lateral sclerosis,KW-0225~Disease variant,KW-0523~Neurodegeneration,		KW-0186~Copper,KW-0479~Metal-binding,KW-0862~Zinc,	KW-0049~Antioxidant,KW-0560~Oxidoreductase,	KW-0007~Acetylation,KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,	CROSSLNK:1-(tryptophan-3-yl)-tryptophan (Trp-Trp) (interchain with W-33),DOMAIN:Superoxide dismutase copper/zinc binding,LIPID:S-palmitoyl cysteine,MUTAGEN:C->A: Exhibits very slow copper acquisition.,MUTAGEN:C->S: Enhances formation of fibrillar aggregates in the absence of bound zinc; when associated with S-58; S-112 and S-147.,MUTAGEN:C->S: Enhances formation of fibrillar aggregates in the absence of bound zinc; when associated with S-7; S-112 and S-147.,MUTAGEN:C->S: Enhances formation of fibrillar aggregates in the absence of bound zinc; when associated with S-7; S-58 and S-112.,MUTAGEN:C->S: Enhances formation of fibrillar aggregates in the absence of bound zinc; when associated with S-7; S-58 and S-147.,MUTAGEN:C->S: No palmitoylation, reduced nuclear targeting.,MUTAGEN:D->A: Loss of zinc binding and enhanced tendency to form aggregates; when associated with A-81.,MUTAGEN:D->S: Destabilization of dimer and loss of zinc binding; when associated with S-81.,MUTAGEN:E->Q: Abolishes dimerization; when associated with E-50 and E-51.,MUTAGEN:FG->EE: Abolishes dimerization; when associated with Q-134.,MUTAGEN:H->A: Loss of zinc binding and enhanced tendency to form aggregates; when associated with A-84.,MUTAGEN:H->S: Destabilization of dimer and loss of zinc binding; when associated with S-84.,MUTAGEN:K->A: Decreased succinylation.,MUTAGEN:K->E: Mimicks constitutive succinylation state; decreased activity.,REGION:Disordered,
SOCS1	suppressor of cytokine signaling 1(SOCS1)	Homo sapiens	12.IL-6_type_cytok-signal-transduct,	h_ghPathway:Growth Hormone Signaling Pathway,h_il2rbPathway:IL-2 Receptor Beta Chain in T cell Activation,	GO:0001817~regulation of cytokine production,GO:0001932~regulation of protein phosphorylation,GO:0007259~JAK-STAT cascade,GO:0016567~protein ubiquitination,GO:0019221~cytokine-mediated signaling pathway,GO:0030225~macrophage differentiation,GO:0035556~intracellular signal transduction,GO:0042532~negative regulation of tyrosine phosphorylation of STAT protein,GO:0043372~positive regulation of CD4-positive, alpha-beta T cell differentiation,GO:0043377~negative regulation of CD8-positive, alpha-beta T cell differentiation,GO:0045444~fat cell differentiation,GO:0045591~positive regulation of regulatory T cell differentiation,GO:0046426~negative regulation of JAK-STAT cascade,GO:0046627~negative regulation of insulin receptor signaling pathway,GO:0046854~phosphatidylinositol phosphorylation,GO:0071230~cellular response to amino acid stimulus,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005942~phosphatidylinositol 3-kinase complex,GO:0031410~cytoplasmic vesicle,GO:0036464~cytoplasmic ribonucleoprotein granule,	GO:0004860~protein kinase inhibitor activity,GO:0005159~insulin-like growth factor receptor binding,GO:0005515~protein binding,GO:0019210~kinase inhibitor activity,GO:0019901~protein kinase binding,GO:0046935~1-phosphatidylinositol-3-kinase regulator activity,	IPR000980:SH2,IPR001496:SOCS_box,IPR035861:SOCS1_SH2,IPR036036:SOCS_box-like_dom_sf,IPR036860:SH2_dom_sf,	hsa04120:Ubiquitin mediated proteolysis,hsa04380:Osteoclast differentiation,hsa04630:JAK-STAT signaling pathway,hsa04910:Insulin signaling pathway,hsa04917:Prolactin signaling pathway,hsa04930:Type II diabetes mellitus,hsa04935:Growth hormone synthesis, secretion and action,hsa05145:Toxoplasmosis,hsa05206:MicroRNAs in cancer,	619375~Autoinflammatory syndrome, familial, with or without immunodeficiency,		SM00252:SH2,SM00253:SOCS,SM00969:SOCS_box,	KW-0341~Growth regulation,KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,KW-0968~Cytoplasmic vesicle,	KW-0225~Disease variant,	KW-0727~SH2 domain,		KW-0734~Signal transduction inhibitor,		COMPBIAS:Polar residues,DOMAIN:SH2,DOMAIN:SOCS box,REGION:Disordered,REGION:Extended SH2 subdomain (ESS),REGION:Interaction with Elongin BC complex,REGION:Kinase inhibitory region (KIR),
SYAP1	synapse associated protein 1(SYAP1)	Homo sapiens			GO:0030154~cell differentiation,GO:0032869~cellular response to insulin stimulus,GO:0036120~cellular response to platelet-derived growth factor stimulus,GO:0038203~TORC2 signaling,GO:0045600~positive regulation of fat cell differentiation,GO:0048172~regulation of short-term neuronal synaptic plasticity,GO:0071364~cellular response to epidermal growth factor stimulus,GO:0071902~positive regulation of protein serine/threonine kinase activity,GO:1990314~cellular response to insulin-like growth factor stimulus,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0009898~cytoplasmic side of plasma membrane,GO:0030424~axon,GO:0030425~dendrite,GO:0030426~growth cone,GO:0042734~presynaptic membrane,GO:0043204~perikaryon,GO:0045202~synapse,GO:0045211~postsynaptic membrane,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,	GO:0005515~protein binding,	IPR005607:BSD_dom,IPR035925:BSD_dom_sf,				SM00751:BSD,	KW-0221~Differentiation,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0628~Postsynaptic cell membrane,KW-0770~Synapse,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-1003~Cell membrane,		KW-0175~Coiled coil,			KW-0597~Phosphoprotein,	DOMAIN:BSD,MUTAGEN:FW->AA: Inhibits interaction with AKT1, mTORC2-mediated phosphorylation of AKT1 at 'Ser-473' and adipocyte differentiation.,REGION:Disordered,
SYNGR2	synaptogyrin 2(SYNGR2)	Homo sapiens			GO:0045055~regulated exocytosis,GO:0048499~synaptic vesicle membrane organization,	GO:0005811~lipid particle,GO:0016020~membrane,GO:0030672~synaptic vesicle membrane,GO:0031594~neuromuscular junction,GO:0070062~extracellular exosome,	GO:0005515~protein binding,	IPR008253:Marvel,IPR016579:Synaptogyrin,			PIRSF011282:Synaptogyrin,		KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-0551~Lipid droplet,KW-0770~Synapse,KW-0968~Cytoplasmic vesicle,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:MARVEL,REGION:Disordered,TRANSMEM:Helical,
SNAP29	synaptosome associated protein 29(SNAP29)	Homo sapiens			GO:0006887~exocytosis,GO:0006903~vesicle targeting,GO:0015031~protein transport,GO:0016082~synaptic vesicle priming,GO:0016240~autophagosome docking,GO:0031629~synaptic vesicle fusion to presynaptic active zone membrane,GO:0060271~cilium assembly,GO:0061025~membrane fusion,GO:0097352~autophagosome maturation,	GO:0000139~Golgi membrane,GO:0000421~autophagosome membrane,GO:0005737~cytoplasm,GO:0005776~autophagosome,GO:0005813~centrosome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0020018~ciliary pocket membrane,GO:0031201~SNARE complex,GO:0035577~azurophil granule membrane,GO:0098793~presynapse,	GO:0005484~SNAP receptor activity,GO:0005515~protein binding,GO:0019905~syntaxin binding,	IPR000727:T_SNARE_dom,	hsa04130:SNARE interactions in vesicular transport,hsa04140:Autophagy - animal,	609528~Cerebral dysgenesis, neuropathy, ichthyosis, and palmoplantar keratoderma syndrome,		SM00397:t_SNARE,	KW-0072~Autophagy,KW-0653~Protein transport,KW-0813~Transport,KW-0970~Cilium biogenesis/degradation,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-0968~Cytoplasmic vesicle,KW-0969~Cilium,KW-1003~Cell membrane,	KW-0622~Neuropathy,KW-0977~Ichthyosis,KW-1007~Palmoplantar keratoderma,	KW-0175~Coiled coil,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:T-SNARE coiled-coil homology,DOMAIN:t-SNARE coiled-coil homology,REGION:Disordered,
SYNCRIP	synaptotagmin binding cytoplasmic RNA interacting protein(SYNCRIP)	Homo sapiens			GO:0000398~mRNA splicing, via spliceosome,GO:0001649~osteoblast differentiation,GO:0006396~RNA processing,GO:0008380~RNA splicing,GO:0016556~mRNA modification,GO:0017148~negative regulation of translation,GO:0070934~CRD-mediated mRNA stabilization,GO:0071346~cellular response to interferon-gamma,GO:1900152~negative regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay,GO:1901537~positive regulation of DNA demethylation,GO:2000623~negative regulation of nuclear-transcribed mRNA catabolic process, nonsense-mediated decay,GO:2000767~positive regulation of cytoplasmic translation,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0016020~membrane,GO:0045293~mRNA editing complex,GO:0070937~CRD-mediated mRNA stability complex,GO:0071013~catalytic step 2 spliceosome,GO:0071204~histone pre-mRNA 3'end processing complex,GO:0097452~GAIT complex,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0048027~mRNA 5'-UTR binding,	IPR000504:RRM_dom,IPR006535:HnRNP_R/Q_splicing_fac,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR034544:hnRNPQ_RRM1,IPR034548:hnRNPQ_RRM2,IPR035979:RBD_domain_sf,IPR041337:hnRNP_Q_AcD,				SM00360:RRM,	KW-0507~mRNA processing,KW-0508~mRNA splicing,KW-0810~Translation regulation,KW-0945~Host-virus interaction,	KW-0256~Endoplasmic reticulum,KW-0492~Microsome,KW-0539~Nucleus,KW-0747~Spliceosome,KW-0963~Cytoplasm,		KW-0677~Repeat,		KW-0687~Ribonucleoprotein,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Heterogeneous nuclear ribonucleoprotein Q acidic,DOMAIN:RRM,DOMAIN:RRM 1,DOMAIN:RRM 2,DOMAIN:RRM 3,MOTIF:Bipartite nuclear localization signal,REGION:3 X 4 AA repeats of Y-Y-G-Y,REGION:8 X 3 AA repeats of R-G-G,REGION:Disordered,REGION:Interaction with APOBEC1,REGION:Interaction with SMN,REPEAT:1-1,REPEAT:1-2,REPEAT:1-3,REPEAT:1-4,REPEAT:1-5,REPEAT:1-6,REPEAT:1-7,REPEAT:1-8,REPEAT:2-1,REPEAT:2-2,REPEAT:2-3,
SYTL2	synaptotagmin like 2(SYTL2)	Homo sapiens			GO:0006886~intracellular protein transport,GO:0006887~exocytosis,GO:0006904~vesicle docking involved in exocytosis,GO:0016192~vesicle-mediated transport,	GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0042470~melanosome,GO:0070382~exocytic vesicle,	GO:0001786~phosphatidylserine binding,GO:0005515~protein binding,GO:0005546~phosphatidylinositol-4,5-bisphosphate binding,GO:0019902~phosphatase binding,GO:0031267~small GTPase binding,GO:0042043~neurexin family protein binding,	IPR000008:C2_dom,IPR001565:Synaptotagmin,IPR010911:Rab_BD,IPR035892:C2_domain_sf,IPR041282:FYVE_2,IPR043567:SYTL1-5_C2B,				SM00239:C2,	KW-0268~Exocytosis,	KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0677~Repeat,				COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:C2,DOMAIN:C2 1,DOMAIN:C2 2,DOMAIN:RabBD,MUTAGEN:E->A: Abolishes interaction with RAB27A.,MUTAGEN:R->A: Abolishes interaction with RAB27A.,REGION:Disordered,
SYTL3	synaptotagmin like 3(SYTL3)	Homo sapiens			GO:0006886~intracellular protein transport,GO:0006887~exocytosis,	GO:0005886~plasma membrane,GO:0070382~exocytic vesicle,	GO:0005515~protein binding,GO:0005544~calcium-dependent phospholipid binding,GO:0031267~small GTPase binding,GO:0042043~neurexin family protein binding,	IPR000008:C2_dom,IPR010911:Rab_BD,IPR011011:Znf_FYVE_PHD,IPR013083:Znf_RING/FYVE/PHD,IPR035892:C2_domain_sf,IPR041282:FYVE_2,IPR043567:SYTL1-5_C2B,				SM00239:C2,		KW-0472~Membrane,		KW-0677~Repeat,				COMPBIAS:Polar residues,DOMAIN:C2,DOMAIN:C2 1,DOMAIN:C2 2,DOMAIN:RabBD,REGION:Disordered,
SDCBP	syndecan binding protein(SDCBP)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0002091~negative regulation of receptor internalization,GO:0006508~proteolysis,GO:0006612~protein targeting to membrane,GO:0006930~substrate-dependent cell migration, cell extension,GO:0007265~Ras protein signal transduction,GO:0007268~chemical synaptic transmission,GO:0007346~regulation of mitotic cell cycle,GO:0008284~positive regulation of cell proliferation,GO:0010718~positive regulation of epithelial to mesenchymal transition,GO:0030036~actin cytoskeleton organization,GO:0030307~positive regulation of cell growth,GO:0030335~positive regulation of cell migration,GO:0030511~positive regulation of transforming growth factor beta receptor signaling pathway,GO:0035556~intracellular signal transduction,GO:0042327~positive regulation of phosphorylation,GO:0046330~positive regulation of JNK cascade,GO:0099054~presynapse assembly,GO:1903543~positive regulation of exosomal secretion,GO:1903553~positive regulation of extracellular exosome assembly,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0005895~interleukin-5 receptor complex,GO:0005912~adherens junction,GO:0005925~focal adhesion,GO:0016020~membrane,GO:0031965~nuclear membrane,GO:0035578~azurophil granule lumen,GO:0042470~melanosome,GO:0045121~membrane raft,GO:0070062~extracellular exosome,GO:0072562~blood microparticle,GO:0098793~presynapse,GO:1903561~extracellular vesicle,	GO:0005109~frizzled binding,GO:0005137~interleukin-5 receptor binding,GO:0005515~protein binding,GO:0005546~phosphatidylinositol-4,5-bisphosphate binding,GO:0008093~cytoskeletal adaptor activity,GO:0019838~growth factor binding,GO:0035255~ionotropic glutamate receptor binding,GO:0042043~neurexin family protein binding,GO:0042802~identical protein binding,GO:0044877~macromolecular complex binding,GO:0045545~syndecan binding,GO:0046875~ephrin receptor binding,GO:0046982~protein heterodimerization activity,GO:0050839~cell adhesion molecule binding,	IPR001478:PDZ,IPR036034:PDZ_sf,IPR041489:PDZ_6,				SM00228:PDZ,		KW-0206~Cytoskeleton,KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0964~Secreted,KW-0965~Cell junction,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0446~Lipid-binding,		KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:PDZ,DOMAIN:PDZ 1,DOMAIN:PDZ 2,MOTIF:LYPX(n)L motif 1,MOTIF:LYPX(n)L motif 2,MOTIF:LYPX(n)L motif 3,MUTAGEN:K->A: Disruption of the cooperative binding of C-terminal peptides from FZD7 and phosphatidylinositol-4,5-bisphosphate. Impaired interaction with FZD7 and disruption of the cooperative binding of C-terminal peptides from FZD7 and phosphatidylinositol-4,5-bisphosphate; when associated with A-214.,MUTAGEN:K->A: Disruption of the cooperative binding of C-terminal peptides from FZD7 and phosphatidylinositol-4,5-bisphosphate. Impaired interaction with FZD7 and disruption of the cooperative binding of C-terminal peptides from FZD7 and phosphatidylinositol-4,5-bisphosphate; when associated with A-250.,MUTAGEN:N->D: Disruption of the cooperative binding of C-terminal peptides from FZD7 and phosphatidylinositol-4,5-bisphosphate.,REGION:Interaction with PDCD6IP,TRANSMEM:Helical,
STX12	syntaxin 12(STX12)	Homo sapiens			GO:0000045~autophagosome assembly,GO:0006886~intracellular protein transport,GO:0006906~vesicle fusion,GO:0016192~vesicle-mediated transport,GO:0032456~endocytic recycling,GO:0033344~cholesterol efflux,GO:0048278~vesicle docking,GO:0050821~protein stabilization,	GO:0000139~Golgi membrane,GO:0000407~pre-autophagosomal structure,GO:0005654~nucleoplasm,GO:0005794~Golgi apparatus,GO:0008021~synaptic vesicle,GO:0012505~endomembrane system,GO:0016020~membrane,GO:0031083~BLOC-1 complex,GO:0031201~SNARE complex,GO:0031901~early endosome membrane,GO:0031982~vesicle,GO:0043231~intracellular membrane-bounded organelle,GO:0045121~membrane raft,GO:0045335~phagocytic vesicle,GO:0055037~recycling endosome,GO:0055038~recycling endosome membrane,GO:0098837~postsynaptic recycling endosome,	GO:0000149~SNARE binding,GO:0005484~SNAP receptor activity,GO:0005515~protein binding,	IPR000727:T_SNARE_dom,IPR006011:Syntaxin_N,IPR006012:Syntaxin/epimorphin_CS,IPR010989:SNARE,IPR045242:Syntaxin,	hsa04145:Phagosome,			SM00397:t_SNARE,SM00503:SynN,	KW-0653~Protein transport,KW-0813~Transport,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0967~Endosome,		KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:Syntaxin N-terminal,DOMAIN:T-SNARE coiled-coil homology,DOMAIN:t-SNARE coiled-coil homology,TOPO_DOM:Cytoplasmic,TOPO_DOM:Vesicular,TRANSMEM:Helical,TRANSMEM:Helical; Anchor for type IV membrane protein,
TRNAU1AP	tRNA selenocysteine 1 associated protein 1(TRNAU1AP)	Homo sapiens			GO:0001514~selenocysteine incorporation,	GO:0005634~nucleus,GO:0005737~cytoplasm,	GO:0000049~tRNA binding,GO:0003723~RNA binding,GO:0005515~protein binding,	IPR000504:RRM_dom,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR034510:SECp43_RRM2,IPR035979:RBD_domain_sf,IPR040434:TSAP1,IPR041085:TSAP1_C,				SM00360:RRM,	KW-0648~Protein biosynthesis,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,		KW-0694~RNA-binding,		DOMAIN:RRM 1,DOMAIN:RRM 2,
TSEN34	tRNA splicing endonuclease subunit 34(TSEN34)	Homo sapiens			GO:0000379~tRNA-type intron splice site recognition and cleavage,GO:0006397~mRNA processing,	GO:0000214~tRNA-intron endonuclease complex,GO:0005654~nucleoplasm,GO:0005730~nucleolus,	GO:0000213~tRNA-intron endonuclease activity,GO:0003676~nucleic acid binding,GO:0016829~lyase activity,	IPR006676:tRNA_splic,IPR006677:tRNA_intron_Endonuc_cat-like,IPR011856:tRNA_endonuc-like_dom_sf,IPR016690:tRNA_splic_SEN34,IPR036167:tRNA_intron_Endo_cat-like_sf,		612390~Pontocerebellar hypoplasia type 2C,	PIRSF017250:tRNA_splic_SEN34,		KW-0507~mRNA processing,KW-0819~tRNA processing,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-1021~Pontocerebellar hypoplasia,			KW-0255~Endonuclease,KW-0378~Hydrolase,KW-0456~Lyase,KW-0540~Nuclease,		COMPBIAS:Polar residues,DOMAIN:tRNA intron endonuclease catalytic,REGION:Disordered,
TSEN54	tRNA splicing endonuclease subunit 54(TSEN54)	Homo sapiens			GO:0000379~tRNA-type intron splice site recognition and cleavage,GO:0006388~tRNA splicing, via endonucleolytic cleavage and ligation,GO:0006397~mRNA processing,GO:0008033~tRNA processing,	GO:0000214~tRNA-intron endonuclease complex,GO:0005654~nucleoplasm,GO:0005730~nucleolus,	GO:0005515~protein binding,	IPR024336:tRNA_splic_suSen54_N,IPR024337:tRNA_splic_suSen54,		225753~Pontocerebellar hypoplasia type 4,277470~Pontocerebellar hypoplasia type 2A,610204~Pontocerebellar hypoplasia type 5,			KW-0507~mRNA processing,KW-0819~tRNA processing,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-1021~Pontocerebellar hypoplasia,	KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:tRNA-splicing endonuclease subunit Sen54 N-terminal,REGION:Disordered,
TLN1	talin 1(TLN1)	Homo sapiens		h_chemicalPathway:Apoptotic Signaling in Response to DNA Damage,h_ecmPathway:Erk and PI-3 Kinase Are Necessary for Collagen Binding in Corneal Epithelia,h_integrinPathway:Integrin Signaling Pathway,h_mCalpainPathway:mCalpain and friends in Cell motility,h_rhoPathway:Rho cell motility signaling pathway,h_uCalpainPathway:uCalpain and friends in Cell spread,	GO:0007043~cell-cell junction assembly,GO:0007044~cell-substrate junction assembly,GO:0007229~integrin-mediated signaling pathway,GO:0030866~cortical actin cytoskeleton organization,GO:0033622~integrin activation,GO:0051893~regulation of focal adhesion assembly,GO:0070527~platelet aggregation,GO:0098609~cell-cell adhesion,	GO:0001726~ruffle,GO:0005576~extracellular region,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0005912~adherens junction,GO:0005925~focal adhesion,GO:0009986~cell surface,GO:0032587~ruffle membrane,GO:0070062~extracellular exosome,	GO:0001786~phosphatidylserine binding,GO:0005178~integrin binding,GO:0005200~structural constituent of cytoskeleton,GO:0005515~protein binding,GO:0017166~vinculin binding,GO:0030274~LIM domain binding,GO:0035091~phosphatidylinositol binding,GO:0045296~cadherin binding,GO:0051015~actin filament binding,	IPR000299:FERM_domain,IPR002558:ILWEQ_dom,IPR011993:PH-like_dom_sf,IPR014352:FERM/acyl-CoA-bd_prot_sf,IPR015009:Vinculin-bd_dom,IPR015224:Talin_cent,IPR019747:FERM_CS,IPR019748:FERM_central,IPR019749:Band_41_domain,IPR029071:Ubiquitin-like_domsf,IPR032425:FERM_f0,IPR035963:FERM_2,IPR035964:I/LWEQ_dom_sf,IPR036476:Talin_cent_sf,IPR036723:Alpha-catenin/vinculin-like_sf,IPR037438:Talin1/2-RS,IPR049108:Talin_R4,	hsa04015:Rap1 signaling pathway,hsa04510:Focal adhesion,hsa04611:Platelet activation,hsa05131:Shigellosis,hsa05166:Human T-cell leukemia virus 1 infection,			SM00295:B41,SM00307:ILWEQ,SM01244:IRS,	KW-0945~Host-virus interaction,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0965~Cell junction,KW-0966~Cell projection,KW-1003~Cell membrane,					KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:FERM,DOMAIN:I/LWEQ,REGION:Helical bundle R1,REGION:Helical bundle R10,REGION:Helical bundle R11,REGION:Helical bundle R12,REGION:Helical bundle R13,REGION:Helical bundle R2,REGION:Helical bundle R3,REGION:Helical bundle R4,REGION:Helical bundle R5,REGION:Helical bundle R6,REGION:Helical bundle R7A,REGION:Helical bundle R7B,REGION:Helical bundle R8,REGION:Helical bundle R9,REGION:Interaction with LAYN,REGION:Interaction with SYNM,REGION:Interaction with VCL and F-actin,
TNKS2	tankyrase 2(TNKS2)	Homo sapiens			GO:0000209~protein polyubiquitination,GO:0016055~Wnt signaling pathway,GO:0032212~positive regulation of telomere maintenance via telomerase,GO:0070198~protein localization to chromosome, telomeric region,GO:0070212~protein poly-ADP-ribosylation,GO:0070213~protein auto-ADP-ribosylation,GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:1904355~positive regulation of telomere capping,GO:1904357~negative regulation of telomere maintenance via telomere lengthening,	GO:0000139~Golgi membrane,GO:0000242~pericentriolar material,GO:0000781~chromosome, telomeric region,GO:0005634~nucleus,GO:0005635~nuclear envelope,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0048471~perinuclear region of cytoplasm,	GO:0003950~NAD+ ADP-ribosyltransferase activity,GO:0005515~protein binding,GO:0016779~nucleotidyltransferase activity,GO:0019899~enzyme binding,GO:0046872~metal ion binding,GO:1990404~protein ADP-ribosylase activity,	IPR001660:SAM,IPR002110:Ankyrin_rpt,IPR012317:Poly(ADP-ribose)pol_cat_dom,IPR013761:SAM/pointed_sf,IPR036770:Ankyrin_rpt-contain_sf,				SM00248:ANK,SM00454:SAM,	KW-0879~Wnt signaling pathway,	KW-0158~Chromosome,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0539~Nucleus,KW-0779~Telomere,KW-0963~Cytoplasm,		KW-0040~ANK repeat,KW-0677~Repeat,	KW-0479~Metal-binding,KW-0520~NAD,KW-0862~Zinc,	KW-0328~Glycosyltransferase,KW-0548~Nucleotidyltransferase,KW-0808~Transferase,	KW-0013~ADP-ribosylation,KW-0379~Hydroxylation,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,DOMAIN:PARP catalytic,DOMAIN:SAM,MUTAGEN:H->D: Enhanced hydroxylation by HIF1AN.,MUTAGEN:H->N: Enhanced hydroxylation by HIF1AN.,MUTAGEN:M->V: Loss of activity.,REGION:Disordered,REGION:HIF1AN-binding,REPEAT:ANK 1,REPEAT:ANK 10,REPEAT:ANK 11,REPEAT:ANK 12,REPEAT:ANK 13,REPEAT:ANK 14,REPEAT:ANK 15,REPEAT:ANK 2,REPEAT:ANK 3,REPEAT:ANK 4,REPEAT:ANK 5,REPEAT:ANK 6,REPEAT:ANK 7,REPEAT:ANK 8,REPEAT:ANK 9,
TOM1	target of myb1 membrane trafficking protein(TOM1)	Homo sapiens			GO:0006897~endocytosis,GO:0007165~signal transduction,GO:0015031~protein transport,GO:0016197~endosomal transport,GO:0061753~substrate localization to autophagosome,GO:1901098~positive regulation of autophagosome maturation,GO:1904978~regulation of endosome organization,	GO:0005737~cytoplasm,GO:0005768~endosome,GO:0005769~early endosome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0010008~endosome membrane,GO:0016020~membrane,GO:0031901~early endosome membrane,GO:0035577~azurophil granule membrane,GO:0035579~specific granule membrane,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0010314~phosphatidylinositol-5-phosphate binding,GO:0030276~clathrin binding,GO:0031593~polyubiquitin binding,GO:0032050~clathrin heavy chain binding,GO:0035091~phosphatidylinositol binding,GO:0043130~ubiquitin binding,GO:0070853~myosin VI binding,	IPR002014:VHS_dom,IPR004152:GAT_dom,IPR008942:ENTH_VHS,IPR014645:TOM1,IPR038425:GAT_sf,		619510~Immunodeficiency 85 and autoimmunity,	PIRSF036948:TOM1,	SM00288:VHS,	KW-0653~Protein transport,KW-0813~Transport,	KW-0472~Membrane,KW-0963~Cytoplasm,KW-0967~Endosome,	KW-0225~Disease variant,				KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:GAT,DOMAIN:VHS,MOTIF:KRKK,MUTAGEN:D->G,R: Reduced interaction with UBC/ubiquitin.,MUTAGEN:E->A: Reduced interaction with TOLLIP.,MUTAGEN:E->N: Reduced interaction with UBC/ubiquitin.,MUTAGEN:KDALRAVKKR->ADALAAVA: Reduced binding to phosphatidylinositol monophosphates.,MUTAGEN:L->A: Reduced interaction with TOLLIP.,MUTAGEN:L->R,S: Reduced interaction with UBC/ubiquitin.,MUTAGEN:LED->AEA: Reduced interaction with clathrin heavy chain.,MUTAGEN:M->A: Reduced interaction with TOLLIP.,MUTAGEN:Missing: Fails to interact with clathrin heavy chain. Diffuse localization throughout the cell.,MUTAGEN:N->A: Reduced interaction with TOLLIP. Reduced localization to endosomal vesicles.,MUTAGEN:R->A: Reduced interaction with TOLLIP.,MUTAGEN:V->A: Reduced interaction with TOLLIP.,REGION:Clathrin box,REGION:Disordered,REGION:Interaction with MYO6,
TERF1	telomeric repeat binding factor 1(TERF1)	Homo sapiens		h_telPathway:Telomeres, Telomerase, Cellular Aging, and  Immortality,	GO:0000723~telomere maintenance,GO:0007004~telomere maintenance via telomerase,GO:0007049~cell cycle,GO:0008156~negative regulation of DNA replication,GO:0016233~telomere capping,GO:0032206~positive regulation of telomere maintenance,GO:0032211~negative regulation of telomere maintenance via telomerase,GO:0032214~negative regulation of telomere maintenance via semi-conservative replication,GO:0045141~meiotic telomere clustering,GO:0051301~cell division,GO:0051974~negative regulation of telomerase activity,GO:0061820~telomeric D-loop disassembly,GO:0090656~t-circle formation,GO:1904357~negative regulation of telomere maintenance via telomere lengthening,GO:1904792~positive regulation of shelterin complex assembly,GO:1904850~negative regulation of establishment of protein localization to telomere,GO:1904911~negative regulation of establishment of RNA localization to telomere,GO:1904914~negative regulation of establishment of macromolecular complex localization to telomere,GO:1905778~negative regulation of exonuclease activity,GO:1905839~negative regulation of telomeric D-loop disassembly,	GO:0000781~chromosome, telomeric region,GO:0000783~nuclear telomere cap complex,GO:0001650~fibrillar center,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005819~spindle,GO:0016604~nuclear body,GO:0070187~shelterin complex,	GO:0003677~DNA binding,GO:0003691~double-stranded telomeric DNA binding,GO:0003720~telomerase activity,GO:0005515~protein binding,GO:0008017~microtubule binding,GO:0008301~DNA binding, bending,GO:0042162~telomeric DNA binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0060090~binding, bridging,GO:0071532~ankyrin repeat binding,GO:0098505~G-rich strand telomeric DNA binding,	IPR001005:SANT/Myb,IPR009057:Homeobox-like_sf,IPR013867:Telomere_rpt-bd_fac_dimer_dom,IPR017357:TERF1/2,IPR017930:Myb_dom,IPR036507:Telomere_rpt-bd_fac_dimer_sf,			PIRSF038016:Telomere_bd-1_Pin2,	SM00717:SANT,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,	KW-0158~Chromosome,KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0779~Telomere,KW-0963~Cytoplasm,				KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0013~ADP-ribosylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DNA_BIND:H-T-H motif,DOMAIN:HTH myb-type,DOMAIN:Myb-like,DOMAIN:Telomere repeat-binding factor dimerisation,MOTIF:Nuclear localization signal,MUTAGEN:A->D: Abolishes dimerization and telomere binding; when associated with P-75.,MUTAGEN:A->P: Abolishes dimerization and telomere binding; when associated with D-74.,MUTAGEN:F->P: Abolishes telomere binding.,MUTAGEN:F->P: Diminishes telomere binding.,MUTAGEN:L->R: Loss of interaction with FBXO4.,MUTAGEN:S->A: Loss of phosphorylation; induction of mitotic entry and apoptosis and increased radiation hypersensitivity of ataxia-telangiectasia cells.,MUTAGEN:S->D,E: Fails to induce apoptosis and decreases radiation hypersensitivity of ataxia-telangiectasia cells (phospho-mimicking mutants).,MUTAGEN:W->P: Abolishes telomere binding.,REGION:Disordered,REGION:Interaction with RLIM,REGION:TRFH mediates dimerization,
TESC	tescalcin(TESC)	Homo sapiens			GO:0008285~negative regulation of cell proliferation,GO:0010628~positive regulation of gene expression,GO:0015031~protein transport,GO:0030154~cell differentiation,GO:0030854~positive regulation of granulocyte differentiation,GO:0032417~positive regulation of sodium:proton antiporter activity,GO:0033628~regulation of cell adhesion mediated by integrin,GO:0045654~positive regulation of megakaryocyte differentiation,GO:0045893~positive regulation of transcription, DNA-templated,GO:0050821~protein stabilization,GO:0051604~protein maturation,GO:0071300~cellular response to retinoic acid,GO:0072659~protein localization to plasma membrane,	GO:0001726~ruffle,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0030027~lamellipodium,GO:0032587~ruffle membrane,	GO:0000287~magnesium ion binding,GO:0004860~protein kinase inhibitor activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0019212~phosphatase inhibitor activity,GO:0042803~protein homodimerization activity,	IPR002048:EF_hand_dom,IPR011992:EF-hand-dom_pair,IPR018247:EF_Hand_1_Ca_BS,				SM00054:EFh,	KW-0221~Differentiation,KW-0653~Protein transport,KW-0813~Transport,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-1003~Cell membrane,			KW-0106~Calcium,KW-0479~Metal-binding,	KW-0649~Protein kinase inhibitor,	KW-0449~Lipoprotein,KW-0519~Myristate,KW-1015~Disulfide bond,	COMPBIAS:Basic and acidic residues,DOMAIN:EF-hand,LIPID:N-myristoyl glycine,REGION:Disordered,
TTC1	tetratricopeptide repeat domain 1(TTC1)	Homo sapiens			GO:0006457~protein folding,	GO:0005778~peroxisomal membrane,GO:0005829~cytosol,	GO:0005515~protein binding,GO:0051082~unfolded protein binding,	IPR001440:TPR_1,IPR011990:TPR-like_helical_dom_sf,IPR019734:TPR_repeat,				SM00028:TPR,				KW-0677~Repeat,KW-0802~TPR repeat,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,REGION:Disordered,REPEAT:TPR,REPEAT:TPR 1,REPEAT:TPR 2,REPEAT:TPR 3,
TTC3	tetratricopeptide repeat domain 3(TTC3)	Homo sapiens			GO:0006511~ubiquitin-dependent protein catabolic process,GO:0016567~protein ubiquitination,GO:0070936~protein K48-linked ubiquitination,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0016020~membrane,	GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR001841:Znf_RING,IPR011029:DEATH-like_dom_sf,IPR011990:TPR-like_helical_dom_sf,IPR013083:Znf_RING/FYVE/PHD,IPR019734:TPR_repeat,IPR043866:TTC3/DZIP3_dom,				SM00028:TPR,SM00184:RING,	KW-0833~Ubl conjugation pathway,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0677~Repeat,KW-0802~TPR repeat,KW-0812~Transmembrane,KW-0863~Zinc-finger,KW-1133~Transmembrane helix,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0808~Transferase,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:E3 ubiquitin-protein ligase TTC3/DZIP3,DOMAIN:RING-type,MUTAGEN:S->A: Abolishes phosphorylation by Akt and impairs ubiquitin ligase activity on Akt.,REGION:Disordered,REGION:Interaction with POLG,REPEAT:TPR,REPEAT:TPR 1,REPEAT:TPR 2,REPEAT:TPR 3,REPEAT:TPR 4,TRANSMEM:Helical,ZN_FING:RING-type,
TTC39C	tetratricopeptide repeat domain 39C(TTC39C)	Homo sapiens			GO:0032474~otolith morphogenesis,GO:0060271~cilium assembly,			IPR011990:TPR-like_helical_dom_sf,IPR019412:Iml2/TPR_39,								KW-0677~Repeat,KW-0732~Signal,KW-0802~TPR repeat,				COMPBIAS:Basic and acidic residues,REGION:Disordered,REPEAT:TPR 1,REPEAT:TPR 2,REPEAT:TPR 3,
TXN2	thioredoxin 2(TXN2)	Homo sapiens			GO:0001666~response to hypoxia,GO:0006979~response to oxidative stress,GO:0009410~response to xenobiotic stimulus,GO:0009725~response to hormone,GO:0009749~response to glucose,GO:0014070~response to organic cyclic compound,GO:0031669~cellular response to nutrient levels,GO:0045454~cell redox homeostasis,GO:0048678~response to axon injury,	GO:0005730~nucleolus,GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0030425~dendrite,GO:0043025~neuronal cell body,	GO:0005515~protein binding,GO:0008113~peptide-methionine (S)-S-oxide reductase activity,GO:0015035~protein disulfide oxidoreductase activity,GO:0033743~peptide-methionine (R)-S-oxide reductase activity,GO:0044877~macromolecular complex binding,	IPR005746:Thioredoxin,IPR013766:Thioredoxin_domain,IPR017937:Thioredoxin_CS,IPR036249:Thioredoxin-like_sf,	hsa04621:NOD-like receptor signaling pathway,hsa05012:Parkinson disease,hsa05132:Salmonella infection,hsa05418:Fluid shear stress and atherosclerosis,	616811~Combined oxidative phosphorylation deficiency 29,			KW-0249~Electron transport,KW-0813~Transport,	KW-0496~Mitochondrion,	KW-0523~Neurodegeneration,KW-1274~Primary mitochondrial disease,	KW-0676~Redox-active center,KW-0809~Transit peptide,			KW-0007~Acetylation,KW-1015~Disulfide bond,	ACT_SITE:Nucleophile,DISULFID:Redox-active,DOMAIN:Thioredoxin,REGION:Disordered,SITE:Contributes to redox potential value,SITE:Deprotonates C-terminal active site Cys,TRANSIT:Mitochondrion,
TXNDC12	thioredoxin domain containing 12(TXNDC12)	Homo sapiens			GO:1902236~negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway,	GO:0005783~endoplasmic reticulum,GO:0005788~endoplasmic reticulum lumen,	GO:0005515~protein binding,GO:0015035~protein disulfide oxidoreductase activity,GO:0019153~protein-disulfide reductase (glutathione) activity,	IPR013766:Thioredoxin_domain,IPR017937:Thioredoxin_CS,IPR036249:Thioredoxin-like_sf,IPR037462:ERp19,	hsa00480:Glutathione metabolism,hsa01100:Metabolic pathways,					KW-0256~Endoplasmic reticulum,		KW-0676~Redox-active center,KW-0732~Signal,		KW-0560~Oxidoreductase,	KW-1015~Disulfide bond,	DISULFID:Redox-active,DOMAIN:Thioredoxin,MOTIF:Prevents secretion from ER,MUTAGEN:C->S: Loss of protein-disulfide reductase (glutathione) activity. Loss of the formation of disulfide bonds in substrate.,
TXNDC17	thioredoxin domain containing 17(TXNDC17)	Homo sapiens			GO:0033209~tumor necrosis factor-mediated signaling pathway,GO:0098869~cellular oxidant detoxification,	GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0004601~peroxidase activity,GO:0005515~protein binding,GO:0047134~protein-disulfide reductase activity,	IPR010357:TXNDC17_dom,IPR036249:Thioredoxin-like_sf,IPR045108:TXNDC17-like,						KW-0963~Cytoplasm,		KW-0676~Redox-active center,			KW-0007~Acetylation,KW-1015~Disulfide bond,	ACT_SITE:Nucleophile,DISULFID:Redox-active,DOMAIN:Thioredoxin,MUTAGEN:C->S: Loss of peroxidase activity.,SITE:Contributes to redox potential value,
TXNDC9	thioredoxin domain containing 9(TXNDC9)	Homo sapiens			GO:0000226~microtubule cytoskeleton organization,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005829~cytosol,GO:0030496~midbody,	GO:0005515~protein binding,GO:0045296~cadherin binding,	IPR013766:Thioredoxin_domain,IPR036249:Thioredoxin-like_sf,						KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,					KW-0597~Phosphoprotein,	DOMAIN:Thioredoxin,
TXNL1	thioredoxin like 1(TXNL1)	Homo sapiens				GO:0000502~proteasome complex,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0015035~protein disulfide oxidoreductase activity,GO:0015036~disulfide oxidoreductase activity,	IPR008979:Galactose-bd-like_sf,IPR010400:PITH_dom,IPR013766:Thioredoxin_domain,IPR017937:Thioredoxin_CS,IPR036249:Thioredoxin-like_sf,IPR037047:PITH_dom_sf,					KW-0249~Electron transport,KW-0813~Transport,	KW-0539~Nucleus,KW-0647~Proteasome,KW-0963~Cytoplasm,		KW-0676~Redox-active center,			KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	DISULFID:Redox-active,DOMAIN:PITH,DOMAIN:Thioredoxin,REGION:Disordered,
TXNRD1	thioredoxin reductase 1(TXNRD1)	Homo sapiens			GO:0001707~mesoderm formation,GO:0006979~response to oxidative stress,GO:0007165~signal transduction,GO:0008283~cell proliferation,GO:0010035~response to inorganic substance,GO:0045454~cell redox homeostasis,GO:0098869~cellular oxidant detoxification,	GO:0001650~fibrillar center,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0004791~thioredoxin-disulfide reductase activity,GO:0005515~protein binding,GO:0016491~oxidoreductase activity,GO:0016668~oxidoreductase activity, acting on a sulfur group of donors, NAD(P) as acceptor,GO:0042802~identical protein binding,GO:0050137~NADPH peroxidase activity,GO:0050660~flavin adenine dinucleotide binding,GO:0071949~FAD binding,	IPR001100:Pyr_nuc-diS_OxRdtase,IPR002109:Glutaredoxin,IPR004099:Pyr_nucl-diS_OxRdtase_dimer,IPR006338:Thioredoxin/glutathione_Rdtase,IPR012999:Pyr_OxRdtase_I_AS,IPR016156:FAD/NAD-linked_Rdtase_dimer_sf,IPR023753:FAD/NAD-binding_dom,IPR036188:FAD/NAD-bd_sf,IPR036249:Thioredoxin-like_sf,IPR046952:GSHR/TRXR-like,	hsa00450:Selenocompound metabolism,hsa05200:Pathways in cancer,hsa05225:Hepatocellular carcinoma,		PIRSF000350:Mercury_reductase_MerA,		KW-0249~Electron transport,KW-0813~Transport,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0676~Redox-active center,	KW-0274~FAD,KW-0285~Flavoprotein,KW-0520~NAD,KW-0521~NADP,KW-0547~Nucleotide-binding,	KW-0560~Oxidoreductase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,	ACT_SITE:Proton acceptor,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Cysteinyl-selenocysteine (Cys-Sec),DISULFID:Redox-active,DOMAIN:FAD/NAD(P)-binding,DOMAIN:Glutaredoxin,DOMAIN:Pyridine nucleotide-disulphide oxidoreductase dimerisation,NON_STD:Selenocysteine,REGION:Disordered,REGION:Required for interaction with ESR1 and ESR2,
TMX1	thioredoxin related transmembrane protein 1(TMX1)	Homo sapiens			GO:0010868~negative regulation of triglyceride biosynthetic process,GO:0034976~response to endoplasmic reticulum stress,GO:0051924~regulation of calcium ion transport,GO:0090331~negative regulation of platelet aggregation,GO:1904294~positive regulation of ERAD pathway,	GO:0005576~extracellular region,GO:0005789~endoplasmic reticulum membrane,GO:0012505~endomembrane system,GO:0031966~mitochondrial membrane,GO:0044233~ER-mitochondrion membrane contact site,	GO:0003756~protein disulfide isomerase activity,GO:0004857~enzyme inhibitor activity,GO:0005515~protein binding,GO:0015035~protein disulfide oxidoreductase activity,GO:0015036~disulfide oxidoreductase activity,	IPR013766:Thioredoxin_domain,IPR017937:Thioredoxin_CS,IPR036249:Thioredoxin-like_sf,					KW-0249~Electron transport,KW-0813~Transport,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0496~Mitochondrion,KW-0964~Secreted,		KW-0676~Redox-active center,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0413~Isomerase,	KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	ACT_SITE:Nucleophile,COMPBIAS:Polar residues,DISULFID:Redox-active,DOMAIN:Thioredoxin,LIPID:S-palmitoyl cysteine,MUTAGEN:C->S: Loss of reductase activity and ability to inhibit TMEM68/DIESL; when associated with S-56.,MUTAGEN:C->S: Loss of reductase activity and ability to inhibit TMEM68/DIESL; when associated with S-59.,MUTAGEN:CLC->ALA: Abolished palmitoylation, leading to decreased localization to mitochondria-associated endoplasmic reticulum membrane (MAM).,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
TMX2	thioredoxin related transmembrane protein 2(TMX2)	Homo sapiens			GO:0007420~brain development,	GO:0005739~mitochondrion,GO:0005789~endoplasmic reticulum membrane,GO:0016020~membrane,GO:0031966~mitochondrial membrane,GO:0043227~membrane-bounded organelle,GO:0044233~ER-mitochondrion membrane contact site,	GO:0005515~protein binding,GO:0015036~disulfide oxidoreductase activity,GO:0042802~identical protein binding,	IPR013766:Thioredoxin_domain,IPR036249:Thioredoxin-like_sf,IPR037463:TMX2_thioredoxin_dom,IPR039101:TMX2,		618730~Neurodevelopmental disorder with microcephaly, cortical malformations, and spasticity,				KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0496~Mitochondrion,	KW-0225~Disease variant,KW-0451~Lissencephaly,KW-0523~Neurodegeneration,KW-0991~Intellectual disability,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	DOMAIN:Thioredoxin,MOTIF:Di-lysine motif,MUTAGEN:C->G: Increased homodimerization even in absence of oxidative stress.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
TMX3	thioredoxin related transmembrane protein 3(TMX3)	Homo sapiens			GO:0018171~peptidyl-cysteine oxidation,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,GO:0031092~platelet alpha granule membrane,	GO:0003756~protein disulfide isomerase activity,GO:0005515~protein binding,GO:0015035~protein disulfide oxidoreductase activity,GO:0016853~isomerase activity,	IPR013766:Thioredoxin_domain,IPR017937:Thioredoxin_CS,IPR036249:Thioredoxin-like_sf,						KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0676~Redox-active center,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0413~Isomerase,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	ACT_SITE:Nucleophile,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,DISULFID:Redox-active,DOMAIN:Thioredoxin,MOTIF:Di-lysine motif,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
TMX4	thioredoxin related transmembrane protein 4(TMX4)	Homo sapiens				GO:0005637~nuclear inner membrane,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0012505~endomembrane system,GO:0016020~membrane,	GO:0015036~disulfide oxidoreductase activity,	IPR013766:Thioredoxin_domain,IPR017937:Thioredoxin_CS,IPR036249:Thioredoxin-like_sf,					KW-0249~Electron transport,KW-0813~Transport,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0539~Nucleus,		KW-0676~Redox-active center,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	ACT_SITE:Nucleophile,COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,DISULFID:Redox-active,DOMAIN:Thioredoxin,REGION:Disordered,TRANSMEM:Helical,
TYMP	thymidine phosphorylase(TYMP)	Homo sapiens			GO:0000002~mitochondrial genome maintenance,GO:0001525~angiogenesis,GO:0006206~pyrimidine nucleobase metabolic process,GO:0006213~pyrimidine nucleoside metabolic process,GO:0006935~chemotaxis,GO:0007165~signal transduction,GO:0030154~cell differentiation,GO:0031641~regulation of myelination,GO:0046074~dTMP catabolic process,GO:0051969~regulation of transmission of nerve impulse,GO:1905333~regulation of gastric motility,	GO:0005829~cytosol,	GO:0004645~phosphorylase activity,GO:0005515~protein binding,GO:0008083~growth factor activity,GO:0009032~thymidine phosphorylase activity,GO:0016154~pyrimidine-nucleoside phosphorylase activity,GO:0016763~transferase activity, transferring pentosyl groups,GO:0042803~protein homodimerization activity,	IPR000053:Thymidine/pyrmidine_PPase,IPR000312:Glycosyl_Trfase_fam3,IPR013102:PYNP_C,IPR017459:Glycosyl_Trfase_fam3_N_dom,IPR017872:Pyrmidine_PPase_CS,IPR018090:Pyrmidine_PPas_bac/euk,IPR035902:Nuc_phospho_transferase,IPR036320:Glycosyl_Trfase_fam3_N_dom_sf,IPR036566:PYNP-like_C_sf,	hsa00240:Pyrimidine metabolism,hsa00983:Drug metabolism - other enzymes,hsa01100:Metabolic pathways,hsa01232:Nucleotide metabolism,hsa05219:Bladder cancer,	603041~Mitochondrial DNA depletion syndrome 1 (MNGIE type),	PIRSF000478:TP_PyNP,	SM00941:PYNP_C,	KW-0037~Angiogenesis,KW-0145~Chemotaxis,KW-0221~Differentiation,		KW-0225~Disease variant,KW-0622~Neuropathy,KW-0935~Progressive external ophthalmoplegia,KW-1274~Primary mitochondrial disease,	KW-0677~Repeat,		KW-0217~Developmental protein,KW-0328~Glycosyltransferase,KW-0339~Growth factor,KW-0808~Transferase,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,	DOMAIN:Glycosyl transferase family 3,DOMAIN:Glycosyl transferase family 3 N-terminal,DOMAIN:Pyrimidine nucleoside phosphorylase C-terminal,MUTAGEN:Y->A: Abolishes catalytic activity.,MUTAGEN:Y->F: Reduced catalytic activity.,MUTAGEN:Y->L: Reduced catalytic activity.,REGION:Disordered,REPEAT:R-A-L-X-X-A-L-V-L,REPEAT:R-V-A-A-A-L-X(5,6)-L-G-R,
THYN1	thymocyte nuclear protein 1(THYN1)	Homo sapiens				GO:0005634~nucleus,		IPR002740:EVE_domain,IPR015947:PUA-like_sf,IPR047197:THYN1-like_EVE,						KW-0539~Nucleus,					KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,MOTIF:Nuclear localization signal,REGION:Disordered,
TRIP12	thyroid hormone receptor interactor 12(TRIP12)	Homo sapiens			GO:0000209~protein polyubiquitination,GO:0006281~DNA repair,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0006974~cellular response to DNA damage stimulus,GO:0016567~protein ubiquitination,GO:0033696~negative regulation of extent of heterochromatin assembly,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0045995~regulation of embryonic development,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0016607~nuclear speck,	GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0046966~thyroid hormone receptor binding,GO:0061630~ubiquitin protein ligase activity,	IPR000569:HECT_dom,IPR004170:WWE-dom,IPR011989:ARM-like,IPR016024:ARM-type_fold,IPR018123:WWE-dom_subgr,IPR035983:Hect_E3_ubiquitin_ligase,IPR037197:WWE_dom_sf,IPR045322:HECTD1/TRIP12-like,	hsa04120:Ubiquitin mediated proteolysis,	617752~Intellectual developmental disorder, autosomal dominant 49,		SM00119:HECTc,SM00678:WWE,	KW-0227~DNA damage,KW-0234~DNA repair,KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-0991~Intellectual disability,KW-1268~Autism spectrum disorder,			KW-0675~Receptor,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Glycyl thioester intermediate,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:HECT,DOMAIN:WWE,MUTAGEN:C->A: Abolishes E3 ubiquitin-protein ligase activity.,REGION:Disordered,REGION:K-box,
TOLLIP	toll interacting protein(TOLLIP)	Homo sapiens		H_gsk3Pathway:Inactivation of Gsk3 by AKT causes accumulation of b-catenin in Alveolar Macrophages,h_il1rPathway:Signal transduction through IL1R,h_tollPathway:Toll-Like Receptor Pathway,	GO:0006511~ubiquitin-dependent protein catabolic process,GO:0006914~autophagy,GO:0006954~inflammatory response,GO:0007165~signal transduction,GO:0016310~phosphorylation,GO:0030855~epithelial cell differentiation,GO:0033235~positive regulation of protein sumoylation,GO:0036010~protein localization to endosome,GO:0045087~innate immune response,GO:0045321~leukocyte activation,GO:0070498~interleukin-1-mediated signaling pathway,	GO:0005576~extracellular region,GO:0005737~cytoplasm,GO:0005769~early endosome,GO:0005829~cytosol,GO:0016604~nuclear body,GO:0019897~extrinsic component of plasma membrane,GO:0032991~macromolecular complex,GO:0035578~azurophil granule lumen,GO:0035580~specific granule lumen,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,	GO:0005150~interleukin-1, Type I receptor binding,GO:0005515~protein binding,GO:0019900~kinase binding,GO:0031624~ubiquitin conjugating enzyme binding,GO:0031625~ubiquitin protein ligase binding,GO:0032183~SUMO binding,GO:0035325~Toll-like receptor binding,GO:0043130~ubiquitin binding,GO:0060090~binding, bridging,	IPR000008:C2_dom,IPR003892:CUE,IPR009060:UBA-like_sf,IPR035892:C2_domain_sf,IPR037301:Tollip_C2,IPR041799:TOLIP_CUE,	hsa04620:Toll-like receptor signaling pathway,			SM00239:C2,SM00546:CUE,	KW-0072~Autophagy,KW-0391~Immunity,KW-0395~Inflammatory response,KW-0399~Innate immunity,	KW-0963~Cytoplasm,KW-0967~Endosome,		KW-0677~Repeat,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:C2,DOMAIN:CUE,MOTIF:AIM1,MOTIF:AIM2,MUTAGEN:D->A: Reduced interaction with TOM1; when associated with Ala-23.,MUTAGEN:F->A: Reduced interaction with TOM1.,MUTAGEN:R->A: Reduced interaction with TOM1; when associated with Ala-12.,MUTAGEN:R->A: Reduced interaction with TOM1; when associated with Ala-20.,MUTAGEN:V->A: Reduced interaction with TOM1; when associated with Ala-9.,
TOR1AIP1	torsin 1A interacting protein 1(TOR1AIP1)	Homo sapiens			GO:0032781~positive regulation of ATPase activity,GO:0034504~protein localization to nucleus,GO:0071763~nuclear membrane organization,GO:0090435~protein localization to nuclear envelope,	GO:0005634~nucleus,GO:0005635~nuclear envelope,GO:0005637~nuclear inner membrane,GO:0031965~nuclear membrane,	GO:0001671~ATPase activator activity,GO:0005515~protein binding,GO:0005521~lamin binding,GO:0008092~cytoskeletal protein binding,GO:0051117~ATPase binding,	IPR008662:TOIP1/2,IPR038599:LAP1C-like_C_sf,IPR046753:TOIP1/2_C,IPR046754:TOIP1/2_N,		617072~Muscular dystrophy, autosomal recessive, with rigid spine and distal joint contractures,				KW-0472~Membrane,KW-0539~Nucleus,	KW-0947~Limb-girdle muscular dystrophy,	KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0558~Oxidation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Torsin-1A-interacting protein 1/2 AAA+ activator,DOMAIN:Torsin-1A-interacting protein 1/2 N-terminal,REGION:Disordered,REGION:Interaction with TOR1A,TOPO_DOM:Nuclear,TOPO_DOM:Perinuclear space,TRANSMEM:Helical,
TOR1A	torsin family 1 member A(TOR1A)	Homo sapiens			GO:0000338~protein deneddylation,GO:0006979~response to oxidative stress,GO:0006996~organelle organization,GO:0006998~nuclear envelope organization,GO:0007155~cell adhesion,GO:0031175~neuron projection development,GO:0034504~protein localization to nucleus,GO:0036503~ERAD pathway,GO:0044319~wound healing, spreading of cells,GO:0045104~intermediate filament cytoskeleton organization,GO:0048489~synaptic vesicle transport,GO:0048499~synaptic vesicle membrane organization,GO:0051085~chaperone mediated protein folding requiring cofactor,GO:0051584~regulation of dopamine uptake involved in synaptic transmission,GO:0061077~chaperone-mediated protein folding,GO:0071712~ER-associated misfolded protein catabolic process,GO:0071763~nuclear membrane organization,GO:1900244~positive regulation of synaptic vesicle endocytosis,GO:2000008~regulation of protein localization to cell surface,	GO:0005635~nuclear envelope,GO:0005783~endoplasmic reticulum,GO:0005788~endoplasmic reticulum lumen,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0008021~synaptic vesicle,GO:0016020~membrane,GO:0030141~secretory granule,GO:0030426~growth cone,GO:0030659~cytoplasmic vesicle membrane,GO:0031965~nuclear membrane,GO:0043231~intracellular membrane-bounded organelle,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008092~cytoskeletal protein binding,GO:0016887~ATPase activity,GO:0019894~kinesin binding,GO:0042802~identical protein binding,GO:0051082~unfolded protein binding,GO:0051787~misfolded protein binding,	IPR010448:Torsin,IPR017378:Torsin_1/2,IPR027417:P-loop_NTPase,IPR049337:TOR1A_C,		128100~Dystonia-1, torsion,618947~Arthrogryposis multiplex congenita 5,Dystonia-1, modifier of~Dystonia-1, modifier of,	PIRSF038079:Torsin_2A,			KW-0206~Cytoskeleton,KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0539~Nucleus,KW-0770~Synapse,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-0968~Cytoplasmic vesicle,	KW-0225~Disease variant,KW-1023~Dystonia,	KW-0732~Signal,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0143~Chaperone,KW-0378~Hydrolase,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) (high mannose) asparagine,DOMAIN:Torsin-1A C-terminal,MUTAGEN:A->F: Inhibits sequence signal cleavage.,MUTAGEN:E->Q: Loss of ATP hydrolysis. Loss of interaction with KLHL14. Localizes in the nuclear envelope. No effect on interaction with TOR1AIP1.,MUTAGEN:K->A: Loss of ATP-binding. No effect on interaction with KLHL14. Increases interaction with TOR1AIP1 and TOR1AIP2. Abolishes interaction with SLC6A3.,MUTAGEN:N->Q: Reduces N-glycosylation.,MUTAGEN:V->F: Inhibits sequence signal cleavage.,MUTAGEN:V->N: N-glycosylated.,REGION:Interaction with KLC1,REGION:Interaction with SNAPIN,REGION:Interaction with SYNE3,
TOR3A	torsin family 3 member A(TOR3A)	Homo sapiens				GO:0005635~nuclear envelope,GO:0005783~endoplasmic reticulum,GO:0005788~endoplasmic reticulum lumen,GO:0070062~extracellular exosome,	GO:0005524~ATP binding,GO:0016887~ATPase activity,	IPR010448:Torsin,IPR027417:P-loop_NTPase,IPR049337:TOR1A_C,						KW-0256~Endoplasmic reticulum,KW-0963~Cytoplasm,		KW-0732~Signal,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,		KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Torsin-1A C-terminal,MUTAGEN:E->Q: No effect on subcellular location.,
TLK1	tousled like kinase 1(TLK1)	Homo sapiens			GO:0006325~chromatin organization,GO:0006468~protein phosphorylation,GO:0006886~intracellular protein transport,GO:0006974~cellular response to DNA damage stimulus,GO:0007059~chromosome segregation,GO:0016310~phosphorylation,GO:0018105~peptidyl-serine phosphorylation,GO:0035556~intracellular signal transduction,GO:1902275~regulation of chromatin organization,	GO:0005634~nucleus,GO:0005654~nucleoplasm,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016301~kinase activity,	IPR000719:Prot_kinase_dom,IPR008271:Ser/Thr_kinase_AS,IPR011009:Kinase-like_dom_sf,IPR017441:Protein_kinase_ATP_BS,				SM00220:S_TKc,	KW-0131~Cell cycle,KW-0227~DNA damage,	KW-0539~Nucleus,		KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0156~Chromatin regulator,KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Protein kinase,MUTAGEN:D->A: Loss of kinase activity.,MUTAGEN:S->A: Loss of kinase inhibition in response to DNA damage.,MUTAGEN:S->D: Loss of kinase inhibition in response to DNA damage.,MUTAGEN:S->E: Loss of kinase inhibition in response to DNA damage.,REGION:Disordered,
TFG	trafficking from ER to golgi regulator(TFG)	Homo sapiens			GO:0006888~ER to Golgi vesicle-mediated transport,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0048208~COPII vesicle coating,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0043231~intracellular membrane-bounded organelle,GO:0070971~endoplasmic reticulum exit site,	GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR000270:PB1_dom,IPR033512:TFG,IPR034857:PB1_TFG,	hsa05200:Pathways in cancer,hsa05216:Thyroid cancer,	604484~Hereditary motor and sensory neuropathy, Okinawa type,615658~Spastic paraplegia 57, autosomal recessive,		SM00666:PB1,	KW-0813~Transport,KW-0931~ER-Golgi transport,	KW-0256~Endoplasmic reticulum,	KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0622~Neuropathy,KW-0656~Proto-oncogene,KW-0890~Hereditary spastic paraplegia,	KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:PB1,REGION:Disordered,SITE:Breakpoint for translocation to form TRK-T3,
TRAPPC2L	trafficking protein particle complex subunit 2L(TRAPPC2L)	Homo sapiens			GO:0006888~ER to Golgi vesicle-mediated transport,GO:0006901~vesicle coating,GO:0048208~COPII vesicle coating,GO:0099022~vesicle tethering,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0030008~TRAPP complex,GO:0043231~intracellular membrane-bounded organelle,GO:0048471~perinuclear region of cytoplasm,GO:1990071~TRAPPII protein complex,GO:1990072~TRAPPIII protein complex,	GO:0005515~protein binding,	IPR006722:Sedlin,IPR011012:Longin-like_dom_sf,IPR044760:TRAPPC2L,		618331~Encephalopathy, progressive, early-onset, with episodic rhabdomyolysis,			KW-0813~Transport,KW-0931~ER-Golgi transport,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0887~Epilepsy,
TRAPPC4	trafficking protein particle complex subunit 4(TRAPPC4)	Homo sapiens			GO:0006888~ER to Golgi vesicle-mediated transport,GO:0006901~vesicle coating,GO:0006914~autophagy,GO:0016358~dendrite development,GO:0048208~COPII vesicle coating,GO:0099022~vesicle tethering,	GO:0000139~Golgi membrane,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005794~Golgi apparatus,GO:0005795~Golgi stack,GO:0005829~cytosol,GO:0008021~synaptic vesicle,GO:0030008~TRAPP complex,GO:0030425~dendrite,GO:0045202~synapse,GO:0045211~postsynaptic membrane,GO:1990071~TRAPPII protein complex,GO:1990072~TRAPPIII protein complex,	GO:0005515~protein binding,	IPR007233:TRAPPC,IPR011012:Longin-like_dom_sf,		618741~Neurodevelopmental disorder with epilepsy, spasticity, and brain atrophy,		SM01399:Sybindin,	KW-0813~Transport,KW-0931~ER-Golgi transport,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0628~Postsynaptic cell membrane,KW-0770~Synapse,KW-1003~Cell membrane,
TGOLN2	trans-golgi network protein 2(TGOLN2)	Homo sapiens				GO:0005654~nucleoplasm,GO:0005768~endosome,GO:0005788~endoplasmic reticulum lumen,GO:0005794~Golgi apparatus,GO:0005802~trans-Golgi network,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0030133~transport vesicle,GO:0030140~trans-Golgi network transport vesicle,GO:0030669~clathrin-coated endocytic vesicle membrane,	GO:0005515~protein binding,							KW-0333~Golgi apparatus,KW-0472~Membrane,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,MOTIF:Endocytosis signal; in isoform TGN46 and isoform TGN48,MOTIF:Endocytosis signal; in isoform TGN51,MUTAGEN:Y->A: Loss of relocalization to the trans-Golgi.,REGION:14 X 14 AA tandem repeats,REGION:Disordered,REPEAT:1,REPEAT:10,REPEAT:11,REPEAT:12,REPEAT:13,REPEAT:14,REPEAT:2,REPEAT:3,REPEAT:4,REPEAT:5,REPEAT:6,REPEAT:7,REPEAT:8,REPEAT:9,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
TVP23B	trans-golgi network vesicle protein 23 homolog B(TVP23B)	Homo sapiens			GO:0009306~protein secretion,GO:0016192~vesicle-mediated transport,	GO:0016020~membrane,	GO:0005515~protein binding,	IPR008564:TVP23-like,						KW-0472~Membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,	REGION:Disordered,TRANSMEM:Helical,
TALDO1	transaldolase 1(TALDO1)	Homo sapiens			GO:0005975~carbohydrate metabolic process,GO:0006002~fructose 6-phosphate metabolic process,GO:0006098~pentose-phosphate shunt,GO:0009052~pentose-phosphate shunt, non-oxidative branch,GO:0019682~glyceraldehyde-3-phosphate metabolic process,	GO:0005622~intracellular,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0004801~sedoheptulose-7-phosphate:D-glyceraldehyde-3-phosphate glyceronetransferase activity,GO:0005515~protein binding,GO:0048029~monosaccharide binding,	IPR001585:TAL/FSA,IPR004730:Transaldolase_1,IPR013785:Aldolase_TIM,IPR018225:Transaldolase_AS,	hsa00030:Pentose phosphate pathway,hsa01100:Metabolic pathways,hsa01200:Carbon metabolism,hsa01230:Biosynthesis of amino acids,	606003~Transaldolase deficiency,			KW-0570~Pentose shunt,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,		KW-0704~Schiff base,	KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Schiff-base intermediate with substrate,MOTIF:Nuclear localization signal,MUTAGEN:F->Y: Confers fructose-6-phosphate aldolase activity.,REGION:Disordered,
TCERG1	transcription elongation regulator 1(TCERG1)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006397~mRNA processing,GO:0008380~RNA splicing,GO:0032968~positive regulation of transcription elongation from RNA polymerase II promoter,GO:0034244~negative regulation of transcription elongation from RNA polymerase II promoter,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0016607~nuclear speck,	GO:0003712~transcription cofactor activity,GO:0003713~transcription coactivator activity,GO:0003714~transcription corepressor activity,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0044390~ubiquitin-like protein conjugating enzyme binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:0070063~RNA polymerase binding,GO:0070064~proline-rich region binding,	IPR001202:WW_dom,IPR002713:FF_domain,IPR036020:WW_dom_sf,IPR036517:FF_domain_sf,IPR045148:TCRG1-like,	hsa03040:Spliceosome,			SM00441:FF,SM00456:WW,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0175~Coiled coil,KW-0677~Repeat,		KW-0010~Activator,KW-0678~Repressor,	KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:FF,DOMAIN:FF 1,DOMAIN:FF 2,DOMAIN:FF 3,DOMAIN:FF 4,DOMAIN:FF 5,DOMAIN:FF 6,DOMAIN:WW,DOMAIN:WW 1,DOMAIN:WW 2,DOMAIN:WW 3,MOTIF:Nuclear localization signal,MUTAGEN:FFY->AAA: No effect.,MUTAGEN:YYY->AAA: Loss of interaction with SF1. Reduces repression of transcription by 35%. Reduces repression of transcription by 63%; when associated with 148-AAA-150.,MUTAGEN:YYY->AAA: Reduces repression of transcription by 35%. Reduces repression of transcription by 63%; when associated with 446-AAA-448.,REGION:Disordered,
TCF25	transcription factor 25(TCF25)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0007507~heart development,GO:0072344~rescue of stalled ribosome,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:1990112~RQC complex,	GO:0003677~DNA binding,GO:0003714~transcription corepressor activity,GO:0005515~protein binding,	IPR006994:TCF25/Rqc1,IPR011990:TPR-like_helical_dom_sf,					KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0238~DNA-binding,KW-0678~Repressor,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,REGION:Disordered,
TFAM	transcription factor A, mitochondrial(TFAM)	Homo sapiens			GO:0001666~response to hypoxia,GO:0006390~transcription from mitochondrial promoter,GO:0006391~transcription initiation from mitochondrial promoter,GO:0007584~response to nutrient,GO:0033108~mitochondrial respiratory chain complex assembly,GO:0045893~positive regulation of transcription, DNA-templated,	GO:0005634~nucleus,GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0005829~cytosol,GO:0032991~macromolecular complex,GO:0042645~mitochondrial nucleoid,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0001018~mitochondrial RNA polymerase regulatory region DNA binding,GO:0001223~transcription coactivator binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0031072~heat shock protein binding,GO:0034246~mitochondrial RNA polymerase binding promoter specificity activity,GO:0043565~sequence-specific DNA binding,	IPR009071:HMG_box_dom,IPR036910:HMG_box_dom_sf,	hsa04371:Apelin signaling pathway,hsa05016:Huntington disease,	617156~Mitochondrial DNA depletion syndrome 15 (hepatocerebral type),		SM00398:HMG,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0496~Mitochondrion,KW-0539~Nucleus,KW-1135~Mitochondrion nucleoid,	KW-0225~Disease variant,KW-1274~Primary mitochondrial disease,	KW-0677~Repeat,KW-0732~Signal,KW-0809~Transit peptide,		KW-0010~Activator,KW-0238~DNA-binding,	KW-0597~Phosphoprotein,	DNA_BIND:HMG box,DNA_BIND:HMG box 1,DNA_BIND:HMG box 2,DOMAIN:HMG box,MUTAGEN:T->A: Moderate reduction in DNA bending.,MUTAGEN:Y->A: Moderate reduction in DNA bending.,SITE:Intercalates between bases and promotes DNA bending,TRANSIT:Mitochondrion,
TADA3	transcriptional adaptor 3(TADA3)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0000278~mitotic cell cycle,GO:0001932~regulation of protein phosphorylation,GO:0006282~regulation of DNA repair,GO:0006325~chromatin organization,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0010628~positive regulation of gene expression,GO:0030520~intracellular estrogen receptor signaling pathway,GO:0031647~regulation of protein stability,GO:0043484~regulation of RNA splicing,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045995~regulation of embryonic development,GO:0051302~regulation of cell division,GO:0051726~regulation of cell cycle,GO:0090043~regulation of tubulin deacetylation,	GO:0000124~SAGA complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0033276~transcription factor TFTC complex,GO:0072686~mitotic spindle,	GO:0003713~transcription coactivator activity,GO:0005515~protein binding,GO:0016922~ligand-dependent nuclear receptor binding,GO:0019904~protein domain specific binding,GO:0030374~ligand-dependent nuclear receptor transcription coactivator activity,	IPR019340:Histone_AcTrfase_su3,	hsa05165:Human papillomavirus infection,				KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),REGION:Disordered,
TOB1	transducer of ERBB2, 1(TOB1)	Homo sapiens		h_tob1Pathway:Role of Tob in T-cell activation,	GO:0008285~negative regulation of cell proliferation,GO:0010468~regulation of gene expression,GO:0017148~negative regulation of translation,GO:0030514~negative regulation of BMP signaling pathway,GO:0045668~negative regulation of osteoblast differentiation,GO:0045892~negative regulation of transcription, DNA-templated,GO:0060212~negative regulation of nuclear-transcribed mRNA poly(A) tail shortening,GO:0060213~positive regulation of nuclear-transcribed mRNA poly(A) tail shortening,GO:0060390~regulation of SMAD protein import into nucleus,GO:1900153~positive regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0030014~CCR4-NOT complex,	GO:0003714~transcription corepressor activity,GO:0005515~protein binding,GO:0030971~receptor tyrosine kinase binding,GO:0046332~SMAD binding,	IPR002087:Anti_prolifrtn,IPR015676:Tob1/2,IPR036054:BTG-like_sf,	hsa03018:RNA degradation,			SM00099:btg1,		KW-0539~Nucleus,KW-0963~Cytoplasm,					KW-0597~Phosphoprotein,	COMPBIAS:Pro residues,DOMAIN:Anti-proliferative protein,MOTIF:Bipartite nuclear localization signal,MOTIF:Nuclear export signal,MUTAGEN:D->A: Impairs interaction with CNOT7 and CNOT8.,MUTAGEN:F->A: Impairs interaction with CNOT7 and CNOT8.,MUTAGEN:W->A: Impairs interaction with CNOT7 and CNOT8.,MUTAGEN:Y->A: Impairs interaction with CNOT7 and CNOT8.,REGION:Disordered,REGION:Important for nuclear localization,REGION:Required for interaction with CPEB3,
TRA2B	transformer 2 beta homolog(TRA2B)	Homo sapiens			GO:0000375~RNA splicing, via transesterification reactions,GO:0000381~regulation of alternative mRNA splicing, via spliceosome,GO:0000398~mRNA splicing, via spliceosome,GO:0021796~cerebral cortex regionalization,GO:0043484~regulation of RNA splicing,GO:0048026~positive regulation of mRNA splicing, via spliceosome,GO:0071333~cellular response to glucose stimulus,GO:1990403~embryonic brain development,	GO:0005634~nucleus,GO:0005637~nuclear inner membrane,GO:0005654~nucleoplasm,GO:0005681~spliceosomal complex,GO:0032991~macromolecular complex,	GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0005515~protein binding,GO:0019904~protein domain specific binding,GO:0036002~pre-mRNA binding,GO:0042802~identical protein binding,	IPR000504:RRM_dom,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR035979:RBD_domain_sf,	hsa03040:Spliceosome,hsa04936:Alcoholic liver disease,			SM00360:RRM,	KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,				KW-0010~Activator,KW-0678~Repressor,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:RRM,REGION:Disordered,REGION:Linker,
TGFB1	transforming growth factor beta 1(TGFB1)	Homo sapiens	124.GH-IGF1_thymopoiesis,125.T_Cells_CNS-APCs,18.Cytokine_astocytes,19.Cytokine_microglia,20.Cytokine_oligodendrocytes,21.Cytokine_neurons,41.E2A-HLF_action_in_pro-B_lympocytes,5.B7_CD40_B-cell_activa,	h_alkPathway:ALK in cardiac myocytes,h_ctcfPathway:CTCF: First Multivalent Nuclear Factor,h_erythPathway:Erythrocyte Differentiation Pathway,h_g1Pathway:Cell Cycle: G1/S Check Point ,h_il1rPathway:Signal transduction through IL1R,h_inflamPathway:Cytokines and Inflammatory Response,h_mapkPathway:MAPKinase Signaling Pathway,h_nktPathway:Selective expression of chemokine receptors during T-cell polarization,h_p38mapkPathway:p38 MAPK Signaling Pathway ,h_slrp2Pathway:Function of SLRP in Bone: An Integrated View,h_tgfbPathway:TGF beta signaling pathway,h_tob1Pathway:Role of Tob in T-cell activation,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0000902~cell morphogenesis,GO:0001570~vasculogenesis,GO:0001657~ureteric bud development,GO:0001666~response to hypoxia,GO:0001837~epithelial to mesenchymal transition,GO:0001843~neural tube closure,GO:0001933~negative regulation of protein phosphorylation,GO:0002028~regulation of sodium ion transport,GO:0002040~sprouting angiogenesis,GO:0002062~chondrocyte differentiation,GO:0002069~columnar/cuboidal epithelial cell maturation,GO:0002244~hematopoietic progenitor cell differentiation,GO:0002248~connective tissue replacement involved in inflammatory response wound healing,GO:0002460~adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains,GO:0002513~tolerance induction to self antigen,GO:0002859~negative regulation of natural killer cell mediated cytotoxicity directed against tumor cell target,GO:0003179~heart valve morphogenesis,GO:0003180~aortic valve morphogenesis,GO:0006611~protein export from nucleus,GO:0006754~ATP biosynthetic process,GO:0006796~phosphate-containing compound metabolic process,GO:0006874~cellular calcium ion homeostasis,GO:0006954~inflammatory response,GO:0007179~transforming growth factor beta receptor signaling pathway,GO:0007219~Notch signaling pathway,GO:0007406~negative regulation of neuroblast proliferation,GO:0007435~salivary gland morphogenesis,GO:0007492~endoderm development,GO:0007507~heart development,GO:0007565~female pregnancy,GO:0008284~positive regulation of cell proliferation,GO:0008285~negative regulation of cell proliferation,GO:0008354~germ cell migration,GO:0009410~response to xenobiotic stimulus,GO:0009611~response to wounding,GO:0009749~response to glucose,GO:0010467~gene expression,GO:0010575~positive regulation of vascular endothelial growth factor production,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0010716~negative regulation of extracellular matrix disassembly,GO:0010718~positive regulation of epithelial to mesenchymal transition,GO:0010742~macrophage derived foam cell differentiation,GO:0010763~positive regulation of fibroblast migration,GO:0010936~negative regulation of macrophage cytokine production,GO:0014003~oligodendrocyte development,GO:0014008~positive regulation of microglia differentiation,GO:0016202~regulation of striated muscle tissue development,GO:0017015~regulation of transforming growth factor beta receptor signaling pathway,GO:0021915~neural tube development,GO:0022408~negative regulation of cell-cell adhesion,GO:0030214~hyaluronan catabolic process,GO:0030279~negative regulation of ossification,GO:0030308~negative regulation of cell growth,GO:0030316~osteoclast differentiation,GO:0030334~regulation of cell migration,GO:0030335~positive regulation of cell migration,GO:0031065~positive regulation of histone deacetylation,GO:0031293~membrane protein intracellular domain proteolysis,GO:0031334~positive regulation of protein complex assembly,GO:0031536~positive regulation of exit from mitosis,GO:0032355~response to estradiol,GO:0032570~response to progesterone,GO:0032667~regulation of interleukin-23 production,GO:0032700~negative regulation of interleukin-17 production,GO:0032740~positive regulation of interleukin-17 production,GO:0032755~positive regulation of interleukin-6 production,GO:0032760~positive regulation of tumor necrosis factor production,GO:0032801~receptor catabolic process,GO:0032930~positive regulation of superoxide anion generation,GO:0032956~regulation of actin cytoskeleton organization,GO:0032967~positive regulation of collagen biosynthetic process,GO:0033280~response to vitamin D,GO:0034616~response to laminar fluid shear stress,GO:0035066~positive regulation of histone acetylation,GO:0035307~positive regulation of protein dephosphorylation,GO:0035902~response to immobilization stress,GO:0036446~myofibroblast differentiation,GO:0042098~T cell proliferation,GO:0042127~regulation of cell proliferation,GO:0042130~negative regulation of T cell proliferation,GO:0042306~regulation of protein import into nucleus,GO:0042307~positive regulation of protein import into nucleus,GO:0042475~odontogenesis of dentin-containing tooth,GO:0042482~positive regulation of odontogenesis,GO:0042552~myelination,GO:0043029~T cell homeostasis,GO:0043065~positive regulation of apoptotic process,GO:0043117~positive regulation of vascular permeability,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043129~surfactant homeostasis,GO:0043410~positive regulation of MAPK cascade,GO:0043536~positive regulation of blood vessel endothelial cell migration,GO:0043537~negative regulation of blood vessel endothelial cell migration,GO:0045066~regulatory T cell differentiation,GO:0045216~cell-cell junction organization,GO:0045591~positive regulation of regulatory T cell differentiation,GO:0045596~negative regulation of cell differentiation,GO:0045599~negative regulation of fat cell differentiation,GO:0045662~negative regulation of myoblast differentiation,GO:0045742~positive regulation of epidermal growth factor receptor signaling pathway,GO:0045786~negative regulation of cell cycle,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046716~muscle cell cellular homeostasis,GO:0048146~positive regulation of fibroblast proliferation,GO:0048286~lung alveolus development,GO:0048298~positive regulation of isotype switching to IgA isotypes,GO:0048535~lymph node development,GO:0048565~digestive tract development,GO:0048642~negative regulation of skeletal muscle tissue development,GO:0048661~positive regulation of smooth muscle cell proliferation,GO:0048839~inner ear development,GO:0050673~epithelial cell proliferation,GO:0050679~positive regulation of epithelial cell proliferation,GO:0050680~negative regulation of epithelial cell proliferation,GO:0050714~positive regulation of protein secretion,GO:0050729~positive regulation of inflammatory response,GO:0050731~positive regulation of peptidyl-tyrosine phosphorylation,GO:0050765~negative regulation of phagocytosis,GO:0050832~defense response to fungus,GO:0050921~positive regulation of chemotaxis,GO:0051152~positive regulation of smooth muscle cell differentiation,GO:0051247~positive regulation of protein metabolic process,GO:0051280~negative regulation of release of sequestered calcium ion into cytosol,GO:0051402~neuron apoptotic process,GO:0051781~positive regulation of cell division,GO:0051897~positive regulation of protein kinase B signaling,GO:0055010~ventricular cardiac muscle tissue morphogenesis,GO:0055091~phospholipid homeostasis,GO:0060070~canonical Wnt signaling pathway,GO:0060312~regulation of blood vessel remodeling,GO:0060325~face morphogenesis,GO:0060364~frontal suture morphogenesis,GO:0060391~positive regulation of SMAD protein import into nucleus,GO:0060435~bronchiole development,GO:0060744~mammary gland branching involved in thelarche,GO:0060751~branch elongation involved in mammary gland duct branching,GO:0060762~regulation of branching involved in mammary gland duct morphogenesis,GO:0061035~regulation of cartilage development,GO:0061298~retina vasculature development in camera-type eye,GO:0061448~connective tissue development,GO:0061520~Langerhans cell differentiation,GO:0070168~negative regulation of biomineral tissue development,GO:0070173~regulation of enamel mineralization,GO:0070306~lens fiber cell differentiation,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0070723~response to cholesterol,GO:0071260~cellular response to mechanical stimulus,GO:0071404~cellular response to low-density lipoprotein particle stimulus,GO:0071456~cellular response to hypoxia,GO:0071479~cellular response to ionizing radiation,GO:0071549~cellular response to dexamethasone stimulus,GO:0071560~cellular response to transforming growth factor beta stimulus,GO:0071677~positive regulation of mononuclear cell migration,GO:0071895~odontoblast differentiation,GO:0072089~stem cell proliferation,GO:0085029~extracellular matrix assembly,GO:0090190~positive regulation of branching involved in ureteric bud morphogenesis,GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:0097191~extrinsic apoptotic signaling pathway,GO:0097421~liver regeneration,GO:0098586~cellular response to virus,GO:1900126~negative regulation of hyaluronan biosynthetic process,GO:1900182~positive regulation of protein localization to nucleus,GO:1901203~positive regulation of extracellular matrix assembly,GO:1902074~response to salt,GO:1902462~positive regulation of mesenchymal stem cell proliferation,GO:1902894~negative regulation of pri-miRNA transcription from RNA polymerase II promoter,GO:1902895~positive regulation of pri-miRNA transcription from RNA polymerase II promoter,GO:1903077~negative regulation of protein localization to plasma membrane,GO:1904018~positive regulation of vasculature development,GO:1904894~positive regulation of STAT cascade,GO:1990314~cellular response to insulin-like growth factor stimulus,GO:1990402~embryonic liver development,GO:2000343~positive regulation of chemokine (C-X-C motif) ligand 2 production,GO:2000353~positive regulation of endothelial cell apoptotic process,GO:2000636~positive regulation of primary miRNA processing,GO:2000648~positive regulation of stem cell proliferation,GO:2000727~positive regulation of cardiac muscle cell differentiation,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005796~Golgi lumen,GO:0005886~plasma membrane,GO:0005902~microvillus,GO:0009986~cell surface,GO:0030141~secretory granule,GO:0030424~axon,GO:0031012~extracellular matrix,GO:0031093~platelet alpha granule lumen,GO:0043025~neuronal cell body,GO:0072562~blood microparticle,	GO:0003823~antigen binding,GO:0005114~type II transforming growth factor beta receptor binding,GO:0005125~cytokine activity,GO:0005160~transforming growth factor beta receptor binding,GO:0005515~protein binding,GO:0008083~growth factor activity,GO:0019899~enzyme binding,GO:0034713~type I transforming growth factor beta receptor binding,GO:0034714~type III transforming growth factor beta receptor binding,GO:0035800~deubiquitinase activator activity,GO:0042802~identical protein binding,GO:0043539~protein serine/threonine kinase activator activity,GO:0044877~macromolecular complex binding,	IPR001111:TGF-b_propeptide,IPR001839:TGF-b_C,IPR003939:TGFb1,IPR015615:TGF-beta-rel,IPR016319:TGF-beta,IPR017948:TGFb_CS,IPR029034:Cystine-knot_cytokine,	hsa04010:MAPK signaling pathway,hsa04060:Cytokine-cytokine receptor interaction,hsa04068:FoxO signaling pathway,hsa04110:Cell cycle,hsa04148:Efferocytosis,hsa04218:Cellular senescence,hsa04350:TGF-beta signaling pathway,hsa04380:Osteoclast differentiation,hsa04390:Hippo signaling pathway,hsa04659:Th17 cell differentiation,hsa04672:Intestinal immune network for IgA production,hsa04926:Relaxin signaling pathway,hsa04932:Non-alcoholic fatty liver disease,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa05140:Leishmaniasis,hsa05142:Chagas disease,hsa05144:Malaria,hsa05145:Toxoplasmosis,hsa05146:Amoebiasis,hsa05152:Tuberculosis,hsa05161:Hepatitis B,hsa05166:Human T-cell leukemia virus 1 infection,hsa05200:Pathways in cancer,hsa05205:Proteoglycans in cancer,hsa05210:Colorectal cancer,hsa05211:Renal cell carcinoma,hsa05212:Pancreatic cancer,hsa05220:Chronic myeloid leukemia,hsa05225:Hepatocellular carcinoma,hsa05226:Gastric cancer,hsa05321:Inflammatory bowel disease,hsa05323:Rheumatoid arthritis,hsa05410:Hypertrophic cardiomyopathy,hsa05414:Dilated cardiomyopathy,hsa05415:Diabetic cardiomyopathy,	131300~Camurati-Engelmann disease,219700~Cystic fibrosis lung disease, modifier of,618213~Inflammatory bowel disease, immunodeficiency, and encephalopathy,	PIRSF001787:TGF-beta,	SM00204:TGFB,		KW-0272~Extracellular matrix,KW-0964~Secreted,	KW-0225~Disease variant,	KW-0732~Signal,		KW-0339~Growth factor,KW-0497~Mitogen,	KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DISULFID:Interchain,DISULFID:Interchain (with C-1359 or C-1384 in LTBP1); in inactive form,DISULFID:Interchain (with C-223),DISULFID:Interchain (with C-225),DOMAIN:TGF-beta family profile,DOMAIN:TGF-beta propeptide,MOTIF:Cell attachment site,MUTAGEN:C->S: Abolishes interchain disulfide bond with LTBP1 and/or LRRC32, and subsequent regulation of activation of TGF-beta-1.,MUTAGEN:E->A: Does not affect integrin-binding or activation of TGF-beta-1.,MUTAGEN:FLLL->GLLG: Strongly inhibits integrin-binding and activation of TGF-beta-1.,MUTAGEN:L->A,R: Does not affect integrin-binding or activation of TGF-beta-1.,MUTAGEN:L->A: Does not affect integrin-binding or activation of TGF-beta-1.,MUTAGEN:LQVDI->GQGDG: Strongly inhibits integrin-binding and activation of TGF-beta-1.,MUTAGEN:N->A: Does not affect integrin-binding or activation of TGF-beta-1.,MUTAGEN:P->A,R: Does not affect integrin-binding or activation of TGF-beta-1.,MUTAGEN:R->A: Prevents cleavage and subsequent maturation of the protein. Generated in order to mimic the structure of the Transforming growth factor beta-1 proprotein.,MUTAGEN:VDI->GDG: Strongly inhibits integrin-binding and activation of TGF-beta-1.,REGION:Arm domain,REGION:Bowtie tail,REGION:Disordered,REGION:Straightjacket domain,SITE:Cleavage; by FURIN,
TGFBR2	transforming growth factor beta receptor 2(TGFBR2)	Homo sapiens		h_alkPathway:ALK in cardiac myocytes,h_ctcfPathway:CTCF: First Multivalent Nuclear Factor,h_nthiPathway:NFkB activation by Nontypeable Hemophilus influenzae,h_tgfbPathway:TGF beta signaling pathway,h_tob1Pathway:Role of Tob in T-cell activation,	GO:0001568~blood vessel development,GO:0001569~branching involved in blood vessel morphogenesis,GO:0001570~vasculogenesis,GO:0001701~in utero embryonic development,GO:0001837~epithelial to mesenchymal transition,GO:0001947~heart looping,GO:0002053~positive regulation of mesenchymal cell proliferation,GO:0002088~lens development in camera-type eye,GO:0002651~positive regulation of tolerance induction to self antigen,GO:0002663~positive regulation of B cell tolerance induction,GO:0002666~positive regulation of T cell tolerance induction,GO:0003148~outflow tract septum morphogenesis,GO:0003149~membranous septum morphogenesis,GO:0003151~outflow tract morphogenesis,GO:0003180~aortic valve morphogenesis,GO:0003181~atrioventricular valve morphogenesis,GO:0003186~tricuspid valve morphogenesis,GO:0003214~cardiac left ventricle morphogenesis,GO:0003274~endocardial cushion fusion,GO:0003430~growth plate cartilage chondrocyte growth,GO:0006468~protein phosphorylation,GO:0006915~apoptotic process,GO:0007179~transforming growth factor beta receptor signaling pathway,GO:0007219~Notch signaling pathway,GO:0007224~smoothened signaling pathway,GO:0007369~gastrulation,GO:0007420~brain development,GO:0007507~heart development,GO:0008284~positive regulation of cell proliferation,GO:0009410~response to xenobiotic stimulus,GO:0009893~positive regulation of metabolic process,GO:0010468~regulation of gene expression,GO:0010634~positive regulation of epithelial cell migration,GO:0010718~positive regulation of epithelial to mesenchymal transition,GO:0016310~phosphorylation,GO:0019222~regulation of metabolic process,GO:0030154~cell differentiation,GO:0032147~activation of protein kinase activity,GO:0032924~activin receptor signaling pathway,GO:0035162~embryonic hemopoiesis,GO:0035909~aorta morphogenesis,GO:0042127~regulation of cell proliferation,GO:0043011~myeloid dendritic cell differentiation,GO:0045766~positive regulation of angiogenesis,GO:0048701~embryonic cranial skeleton morphogenesis,GO:0048844~artery morphogenesis,GO:0051138~positive regulation of NK T cell differentiation,GO:0051239~regulation of multicellular organismal process,GO:0060021~palate development,GO:0060391~positive regulation of SMAD protein import into nucleus,GO:0060395~SMAD protein signal transduction,GO:0060412~ventricular septum morphogenesis,GO:0060434~bronchus morphogenesis,GO:0060440~trachea formation,GO:0060443~mammary gland morphogenesis,GO:0060463~lung lobe morphogenesis,GO:0061520~Langerhans cell differentiation,GO:0070723~response to cholesterol,GO:0071363~cellular response to growth factor stimulus,GO:0072091~regulation of stem cell proliferation,GO:1905007~positive regulation of epithelial to mesenchymal transition involved in endocardial cushion formation,GO:1905317~inferior endocardial cushion morphogenesis,GO:1990086~lens fiber cell apoptotic process,GO:1990428~miRNA transport,GO:2000379~positive regulation of reactive oxygen species metabolic process,GO:2000563~positive regulation of CD4-positive, alpha-beta T cell proliferation,GO:2000736~regulation of stem cell differentiation,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005901~caveola,GO:0009897~external side of plasma membrane,GO:0016020~membrane,GO:0043235~receptor complex,GO:0045121~membrane raft,GO:0070021~transforming growth factor beta1-type II receptor-type I receptor complex,	GO:0004675~transmembrane receptor protein serine/threonine kinase activity,GO:0005024~transforming growth factor beta-activated receptor activity,GO:0005026~transforming growth factor beta receptor activity, type II,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0005539~glycosaminoglycan binding,GO:0017002~activin-activated receptor activity,GO:0019209~kinase activator activity,GO:0034713~type I transforming growth factor beta receptor binding,GO:0034714~type III transforming growth factor beta receptor binding,GO:0046332~SMAD binding,GO:0046872~metal ion binding,GO:0048185~activin binding,GO:0050431~transforming growth factor beta binding,GO:0060090~binding, bridging,	IPR000333:TGFB_receptor,IPR000719:Prot_kinase_dom,IPR001245:Ser-Thr/Tyr_kinase_cat_dom,IPR008271:Ser/Thr_kinase_AS,IPR011009:Kinase-like_dom_sf,IPR015013:Transforming_GF_b_rcpt_2_ecto,IPR017194:Transform_growth_fac-b_typ-2,IPR017441:Protein_kinase_ATP_BS,IPR045860:Snake_toxin-like_sf,	hsa04010:MAPK signaling pathway,hsa04060:Cytokine-cytokine receptor interaction,hsa04068:FoxO signaling pathway,hsa04144:Endocytosis,hsa04218:Cellular senescence,hsa04350:TGF-beta signaling pathway,hsa04380:Osteoclast differentiation,hsa04390:Hippo signaling pathway,hsa04520:Adherens junction,hsa04659:Th17 cell differentiation,hsa04926:Relaxin signaling pathway,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa05142:Chagas disease,hsa05161:Hepatitis B,hsa05166:Human T-cell leukemia virus 1 infection,hsa05200:Pathways in cancer,hsa05202:Transcriptional misregulation in cancer,hsa05210:Colorectal cancer,hsa05212:Pancreatic cancer,hsa05220:Chronic myeloid leukemia,hsa05225:Hepatocellular carcinoma,hsa05226:Gastric cancer,hsa05415:Diabetic cardiomyopathy,	133239~Esophageal cancer, somatic,610168~Loeys-Dietz syndrome 2,614331~Colorectal cancer, hereditary nonpolyposis, type 6,	PIRSF037393:TGFRII,	SM00220:S_TKc,	KW-0053~Apoptosis,KW-0221~Differentiation,KW-0341~Growth regulation,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0362~Hereditary nonpolyposis colorectal cancer,KW-0989~Craniosynostosis,KW-0993~Aortic aneurysm,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0460~Magnesium,KW-0464~Manganese,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0675~Receptor,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	ACT_SITE:Proton acceptor,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Protein kinase,DOMAIN:Transforming growth factor beta receptor 2 ectodomain,MUTAGEN:K->R: Abolishes kinase activity, TGF-beta signaling and interaction with DAXX.,REGION:Sufficient for interaction with CLU,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
TBRG4	transforming growth factor beta regulator 4(TBRG4)	Homo sapiens			GO:0000963~mitochondrial RNA processing,GO:0008284~positive regulation of cell proliferation,GO:0016071~mRNA metabolic process,GO:0044528~regulation of mitochondrial mRNA stability,GO:0051726~regulation of cell cycle,GO:0090615~mitochondrial mRNA processing,	GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0035770~ribonucleoprotein granule,	GO:0003723~RNA binding,GO:0005515~protein binding,	IPR010622:FAST_Leu-rich,IPR013579:FAST_2,IPR013584:RAP,				SM00952:RAP,		KW-0496~Mitochondrion,		KW-0809~Transit peptide,			KW-0597~Phosphoprotein,	DOMAIN:FAST kinase leucine-rich,DOMAIN:FAST kinase-like protein subdomain 2,DOMAIN:RAP,MUTAGEN:D->A: Does not affect location in mitochondria; fails to rescue the increased accumulation of the level of mature MT-ND3, MT-CO3, MT-CYB or MT-ND5 mRNA in TBRG4-deficient cells; does not abolish the accumulation of the MT-ND5-CYB precursor RNA in a TBRG4-deficient cell line.,TRANSIT:Mitochondrion,
TRPC4AP	transient receptor potential cation channel subfamily C member 4 associated protein(TRPC4AP)	Homo sapiens			GO:0006511~ubiquitin-dependent protein catabolic process,GO:0016567~protein ubiquitination,GO:0048820~hair follicle maturation,GO:0070588~calcium ion transmembrane transport,	GO:0005886~plasma membrane,GO:0031464~Cul4A-RING E3 ubiquitin ligase complex,GO:0048471~perinuclear region of cytoplasm,GO:0080008~Cul4-RING E3 ubiquitin ligase complex,	GO:0005262~calcium channel activity,GO:0005515~protein binding,GO:0019902~phosphatase binding,GO:1990756~protein binding, bridging involved in substrate recognition for ubiquitination,	IPR016024:ARM-type_fold,IPR022162:TRPC4AP,					KW-0833~Ubl conjugation pathway,KW-0945~Host-virus interaction,	KW-0963~Cytoplasm,				KW-0675~Receptor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Basic and acidic residues,REGION:Disordered,REGION:Interaction with TNFRSF1A,
TRPM7	transient receptor potential cation channel subfamily M member 7(TRPM7)	Homo sapiens			GO:0006816~calcium ion transport,GO:0016310~phosphorylation,GO:0016340~calcium-dependent cell-matrix adhesion,GO:0031032~actomyosin structure organization,GO:0051262~protein tetramerization,GO:0070266~necroptotic process,GO:0070588~calcium ion transmembrane transport,GO:0098655~cation transmembrane transport,	GO:0001726~ruffle,GO:0005886~plasma membrane,GO:0016020~membrane,	GO:0003779~actin binding,GO:0004674~protein serine/threonine kinase activity,GO:0005262~calcium channel activity,GO:0005524~ATP binding,GO:0017022~myosin binding,GO:0046872~metal ion binding,	IPR004166:a-kinase_dom,IPR005821:Ion_trans_dom,IPR011009:Kinase-like_dom_sf,IPR029601:TRPM7_a-kinase_dom,IPR032415:TRPM_tetra,IPR037162:TRPM_tetra_sf,IPR041491:TRPM_SLOG,	hsa04217:Necroptosis,hsa04218:Cellular senescence,hsa04621:NOD-like receptor signaling pathway,hsa04978:Mineral absorption,	105500~Amyotrophic lateral sclerosis-parkinsonism/dementia complex, susceptibility to,		SM00811:Alpha_kinase,	KW-0109~Calcium transport,KW-0406~Ion transport,KW-0813~Transport,KW-1210~Necrosis,	KW-0472~Membrane,	KW-0036~Amyotrophic lateral sclerosis,KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0908~Parkinsonism,	KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0106~Calcium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,KW-0862~Zinc,	KW-0107~Calcium channel,KW-0407~Ion channel,KW-0418~Kinase,KW-0675~Receptor,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,COMPBIAS:Polar residues,DOMAIN:Alpha-type protein kinase,INTRAMEM:Pore-forming,MUTAGEN:G->D: Loss of kinase activity.,MUTAGEN:K->R: Loss of kinase activity.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
TKT	transketolase(TKT)	Homo sapiens			GO:0006098~pentose-phosphate shunt,GO:0009052~pentose-phosphate shunt, non-oxidative branch,GO:0040008~regulation of growth,GO:0046166~glyceraldehyde-3-phosphate biosynthetic process,GO:1901159~xylulose 5-phosphate biosynthetic process,	GO:0005654~nucleoplasm,GO:0005777~peroxisome,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0016604~nuclear body,GO:0031982~vesicle,GO:0070062~extracellular exosome,	GO:0000287~magnesium ion binding,GO:0004802~transketolase activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0016740~transferase activity,GO:0030976~thiamine pyrophosphate binding,GO:0042803~protein homodimerization activity,GO:0046872~metal ion binding,	IPR005474:Transketolase_N,IPR005475:Transketolase-like_Pyr-bd,IPR009014:Transketo_C/PFOR_II,IPR020826:Transketolase_BS,IPR029061:THDP-binding,IPR033248:Transketolase_C,	hsa00030:Pentose phosphate pathway,hsa01100:Metabolic pathways,hsa01200:Carbon metabolism,hsa01230:Biosynthesis of amino acids,	617044~Short stature, developmental delay, and congenital heart defects,		SM00861:Transket_pyr,			KW-0225~Disease variant,KW-0242~Dwarfism,		KW-0106~Calcium,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0786~Thiamine pyrophosphate,	KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	ACT_SITE:Proton donor,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Transketolase signature 1,REGION:Disordered,SITE:Important for catalytic activity,
TMA7	translation machinery associated 7 homolog(TMA7)	Homo sapiens						IPR015157:TMA7,								KW-0175~Coiled coil,			KW-0013~ADP-ribosylation,	COMPBIAS:Basic and acidic residues,REGION:Disordered,
TSN	translin(TSN)	Homo sapiens	15.T-cell_polarization-chemokine_receptors,		GO:0006310~DNA recombination,GO:0016070~RNA metabolic process,GO:0030422~production of siRNA involved in RNA interference,GO:0035194~posttranscriptional gene silencing by RNA,	GO:0001673~male germ cell nucleus,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:1902555~endoribonuclease complex,	GO:0003677~DNA binding,GO:0003697~single-stranded DNA binding,GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0004519~endonuclease activity,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0043565~sequence-specific DNA binding,GO:0046872~metal ion binding,	IPR002848:Translin_fam,IPR016068:Translin_N,IPR016069:Translin_C,IPR033956:Translin,IPR036081:Translin_sf,						KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0460~Magnesium,KW-0479~Metal-binding,	KW-0238~DNA-binding,KW-0255~Endonuclease,KW-0378~Hydrolase,KW-0540~Nuclease,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	REGION:DNA/RNA binding,REGION:Leucine-zipper,
TIMM8B	translocase of inner mitochondrial membrane 8 homolog B(TIMM8B)	Homo sapiens			GO:0006626~protein targeting to mitochondrion,GO:0007605~sensory perception of sound,GO:0015031~protein transport,GO:0045039~protein import into mitochondrial inner membrane,	GO:0005615~extracellular space,GO:0005743~mitochondrial inner membrane,GO:0005758~mitochondrial intermembrane space,GO:0042719~mitochondrial intermembrane space protein transporter complex,	GO:0008270~zinc ion binding,	IPR004217:Tim10-like,IPR035427:Tim10-like_dom_sf,					KW-0653~Protein transport,KW-0811~Translocation,KW-0813~Transport,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,			KW-0479~Metal-binding,KW-0862~Zinc,	KW-0143~Chaperone,	KW-0007~Acetylation,KW-1015~Disulfide bond,	DOMAIN:Tim10-like,MOTIF:Twin CX3C motif,
TIMMDC1	translocase of inner mitochondrial membrane domain containing 1(TIMMDC1)	Homo sapiens				GO:0005654~nucleoplasm,GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0016020~membrane,	GO:0005515~protein binding,			618251~Mitochondrial complex I deficiency, nuclear type 31,				KW-0472~Membrane,KW-0496~Mitochondrion,	KW-1274~Primary mitochondrial disease,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0143~Chaperone,	KW-0597~Phosphoprotein,	TRANSMEM:Helical,
TOMM5	translocase of outer mitochondrial membrane 5(TOMM5)	Homo sapiens			GO:0006626~protein targeting to mitochondrion,GO:0045040~protein import into mitochondrial outer membrane,	GO:0005739~mitochondrion,GO:0005741~mitochondrial outer membrane,GO:0005742~mitochondrial outer membrane translocase complex,		IPR019603:Tom5,IPR029179:TOMM5_metazoa,					KW-0653~Protein transport,KW-0813~Transport,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-1000~Mitochondrion outer membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),TRANSMEM:Helical,
TOMM7	translocase of outer mitochondrial membrane 7(TOMM7)	Homo sapiens			GO:0006626~protein targeting to mitochondrion,GO:0030150~protein import into mitochondrial matrix,GO:0031647~regulation of protein stability,GO:0045040~protein import into mitochondrial outer membrane,GO:0098779~positive regulation of macromitophagy in response to mitochondrial depolarization,GO:1903955~positive regulation of protein targeting to mitochondrion,	GO:0005739~mitochondrion,GO:0005741~mitochondrial outer membrane,GO:0005742~mitochondrial outer membrane translocase complex,	GO:0005515~protein binding,GO:0008320~protein transmembrane transporter activity,	IPR012621:Tom7,	hsa04137:Mitophagy - animal,	620601~Garg-Mishra progeroid syndrome,			KW-0653~Protein transport,KW-0813~Transport,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-1000~Mitochondrion outer membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,				TOPO_DOM:Cytoplasmic,TOPO_DOM:Mitochondrial intermembrane,TRANSMEM:Helical,
TPR	translocated promoter region, nuclear basket protein(TPR)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006404~RNA import into nucleus,GO:0006405~RNA export from nucleus,GO:0006406~mRNA export from nucleus,GO:0006606~protein import into nucleus,GO:0006913~nucleocytoplasmic transport,GO:0006999~nuclear pore organization,GO:0007094~mitotic spindle assembly checkpoint,GO:0010965~regulation of mitotic sister chromatid separation,GO:0031453~positive regulation of heterochromatin assembly,GO:0031990~mRNA export from nucleus in response to heat stress,GO:0032880~regulation of protein localization,GO:0034605~cellular response to heat,GO:0035457~cellular response to interferon-alpha,GO:0042307~positive regulation of protein import into nucleus,GO:0045947~negative regulation of translational initiation,GO:0046827~positive regulation of protein export from nucleus,GO:0046832~negative regulation of RNA export from nucleus,GO:0051301~cell division,GO:0070849~response to epidermal growth factor,GO:0090267~positive regulation of mitotic cell cycle spindle assembly checkpoint,GO:0090316~positive regulation of intracellular protein transport,GO:1901673~regulation of mitotic spindle assembly,	GO:0000776~kinetochore,GO:0005634~nucleus,GO:0005635~nuclear envelope,GO:0005643~nuclear pore,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005868~cytoplasmic dynein complex,GO:0031965~nuclear membrane,GO:0034399~nuclear periphery,GO:0042405~nuclear inclusion body,GO:0044615~nuclear pore nuclear basket,GO:0072686~mitotic spindle,	GO:0003682~chromatin binding,GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0005515~protein binding,GO:0015631~tubulin binding,GO:0017056~structural constituent of nuclear pore,GO:0031072~heat shock protein binding,GO:0042803~protein homodimerization activity,GO:0051019~mitogen-activated protein kinase binding,GO:0070840~dynein complex binding,	IPR012929:TPR/MLP1,	hsa03013:Nucleocytoplasmic transport,hsa05014:Amyotrophic lateral sclerosis,hsa05200:Pathways in cancer,hsa05216:Thyroid cancer,	620393~Intellectual developmental disorder, autosomal recessive 79,			KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,KW-0509~mRNA transport,KW-0653~Protein transport,KW-0811~Translocation,KW-0813~Transport,	KW-0137~Centromere,KW-0158~Chromosome,KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0539~Nucleus,KW-0906~Nuclear pore complex,KW-0963~Cytoplasm,KW-0995~Kinetochore,	KW-0225~Disease variant,KW-0656~Proto-oncogene,KW-0991~Intellectual disability,	KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,MUTAGEN:L->P: Diminishes association to NPC but not homodimerization. Inhibits association to NPC, interaction with NUP153 and nuclear membrane localization but not homodimerization; when associated with P-489.,MUTAGEN:M->P: Diminishes association to NPC but not homodimerization. Inhibits association to NPC, interaction with NUP153 and nuclear membrane localization but not homodimerization; when associated with P-458.,REGION:Disordered,REGION:Necessary for association to the NPC,REGION:Necessary for interaction with HSF1,REGION:Sufficient and essential for mediating its nuclear import,REGION:Sufficient for interaction with TPR,SITE:Breakpoint for translocation to form TRK-T1,
TRAM1	translocation associated membrane protein 1(TRAM1)	Homo sapiens			GO:0006613~cotranslational protein targeting to membrane,GO:0006616~SRP-dependent cotranslational protein targeting to membrane, translocation,GO:0006986~response to unfolded protein,GO:0045048~protein insertion into ER membrane,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0016020~membrane,	GO:0005515~protein binding,GO:0038023~signaling receptor activity,	IPR006634:TLC-dom,IPR016447:Translocation_assoc_membrane,	hsa04141:Protein processing in endoplasmic reticulum,		PIRSF005449:Translocation_assoc_membrane,	SM00724:TLC,	KW-0653~Protein transport,KW-0811~Translocation,KW-0813~Transport,KW-0834~Unfolded protein response,KW-0945~Host-virus interaction,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:TLC,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
TSPO	translocator protein(TSPO)	Homo sapiens			GO:0006626~protein targeting to mitochondrion,GO:0006700~C21-steroid hormone biosynthetic process,GO:0006783~heme biosynthetic process,GO:0006820~anion transport,GO:0006821~chloride transport,GO:0008202~steroid metabolic process,GO:0008347~glial cell migration,GO:0009410~response to xenobiotic stimulus,GO:0010042~response to manganese ion,GO:0010266~response to vitamin B1,GO:0014012~peripheral nervous system axon regeneration,GO:0015918~sterol transport,GO:0030325~adrenal gland development,GO:0031397~negative regulation of protein ubiquitination,GO:0032374~regulation of cholesterol transport,GO:0032570~response to progesterone,GO:0032720~negative regulation of tumor necrosis factor production,GO:0033574~response to testosterone,GO:0042127~regulation of cell proliferation,GO:0042632~cholesterol homeostasis,GO:0043065~positive regulation of apoptotic process,GO:0045019~negative regulation of nitric oxide biosynthetic process,GO:0048266~behavioral response to pain,GO:0050810~regulation of steroid biosynthetic process,GO:0051901~positive regulation of mitochondrial depolarization,GO:0051928~positive regulation of calcium ion transport,GO:0060242~contact inhibition,GO:0060252~positive regulation of glial cell proliferation,GO:0060253~negative regulation of glial cell proliferation,GO:0071222~cellular response to lipopolysaccharide,GO:0071294~cellular response to zinc ion,GO:0071476~cellular hypotonic response,GO:0072656~maintenance of protein location in mitochondrion,GO:1901525~negative regulation of macromitophagy,GO:1903147~negative regulation of mitophagy,GO:1903579~negative regulation of ATP metabolic process,GO:1905144~response to acetylcholine,GO:2000379~positive regulation of reactive oxygen species metabolic process,GO:2000853~negative regulation of corticosterone secretion,	GO:0005739~mitochondrion,GO:0005741~mitochondrial outer membrane,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0016020~membrane,GO:0043231~intracellular membrane-bounded organelle,GO:0070062~extracellular exosome,	GO:0005497~androgen binding,GO:0005515~protein binding,GO:0008503~benzodiazepine receptor activity,GO:0015485~cholesterol binding,GO:0044325~ion channel binding,	IPR004307:TspO_MBR,IPR038330:TspO/MBR-related_sf,	hsa04080:Neuroactive ligand-receptor interaction,hsa04979:Cholesterol metabolism,hsa05166:Human T-cell leukemia virus 1 infection,		PIRSF005859:PBR,		KW-0445~Lipid transport,KW-0813~Transport,	KW-0472~Membrane,KW-0496~Mitochondrion,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,		TOPO_DOM:Cytoplasmic,TOPO_DOM:Mitochondrial intermembrane,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,
TM9SF2	transmembrane 9 superfamily member 2(TM9SF2)	Homo sapiens			GO:0006672~ceramide metabolic process,GO:0006688~glycosphingolipid biosynthetic process,GO:0010908~regulation of heparan sulfate proteoglycan biosynthetic process,GO:0072657~protein localization to membrane,	GO:0005768~endosome,GO:0005794~Golgi apparatus,GO:0005815~microtubule organizing center,GO:0005886~plasma membrane,GO:0010008~endosome membrane,GO:0016020~membrane,GO:0070062~extracellular exosome,		IPR004240:EMP70,						KW-0206~Cytoskeleton,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0967~Endosome,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,				TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
TMBIM1	transmembrane BAX inhibitor motif containing 1(TMBIM1)	Homo sapiens			GO:0043086~negative regulation of catalytic activity,GO:1902042~negative regulation of extrinsic apoptotic signaling pathway via death domain receptors,GO:1902045~negative regulation of Fas signaling pathway,GO:1903077~negative regulation of protein localization to plasma membrane,GO:2000504~positive regulation of blood vessel remodeling,GO:2001234~negative regulation of apoptotic signaling pathway,	GO:0005765~lysosomal membrane,GO:0005783~endoplasmic reticulum,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0010008~endosome membrane,GO:0016020~membrane,GO:0035579~specific granule membrane,GO:0043231~intracellular membrane-bounded organelle,GO:0070062~extracellular exosome,	GO:0005123~death receptor binding,GO:0005515~protein binding,	IPR006214:Bax_inhibitor_1-related,						KW-0458~Lysosome,KW-0472~Membrane,KW-0967~Endosome,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,REGION:Disordered,TRANSMEM:Helical,
TMBIM6	transmembrane BAX inhibitor motif containing 6(TMBIM6)	Homo sapiens			GO:0002638~negative regulation of immunoglobulin production,GO:0006914~autophagy,GO:0006986~response to unfolded protein,GO:0010523~negative regulation of calcium ion transport into cytosol,GO:0032091~negative regulation of protein binding,GO:0032469~endoplasmic reticulum calcium ion homeostasis,GO:0033119~negative regulation of RNA splicing,GO:0034620~cellular response to unfolded protein,GO:0036483~neuron intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress,GO:0043066~negative regulation of apoptotic process,GO:0060702~negative regulation of endoribonuclease activity,GO:1902065~response to L-glutamate,GO:1902236~negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway,GO:1903298~negative regulation of hypoxia-induced intrinsic apoptotic signaling pathway,GO:1990441~negative regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress,GO:2001234~negative regulation of apoptotic signaling pathway,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0031966~mitochondrial membrane,	GO:0005515~protein binding,GO:0019899~enzyme binding,GO:0031625~ubiquitin protein ligase binding,GO:0060698~endoribonuclease inhibitor activity,	IPR006213:Bax_inhbtr1_CS,IPR006214:Bax_inhibitor_1-related,	hsa05130:Pathogenic Escherichia coli infection,				KW-0053~Apoptosis,KW-0072~Autophagy,KW-0834~Unfolded protein response,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,		KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),INTRAMEM:Helical,MUTAGEN:D->A: Abolishes calcium flux properties.,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
TMCO1	transmembrane and coiled-coil domains 1(TMCO1)	Homo sapiens			GO:0006983~ER overload response,GO:0032469~endoplasmic reticulum calcium ion homeostasis,GO:0070588~calcium ion transmembrane transport,	GO:0000139~Golgi membrane,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0016020~membrane,	GO:0005262~calcium channel activity,GO:0005515~protein binding,GO:0043022~ribosome binding,	IPR002809:EMC3/TMCO1,IPR008559:TMCO1,		213980~Craniofacial dysmorphism, skeletal anomalies, and impaired intellectual development 1,	PIRSF023322:DUF841_euk,	SM01415:DUF106,	KW-0109~Calcium transport,KW-0406~Ion transport,KW-0813~Transport,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,	KW-0225~Disease variant,KW-0955~Glaucoma,KW-0991~Intellectual disability,	KW-0175~Coiled coil,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,	KW-0107~Calcium channel,KW-0407~Ion channel,	KW-0597~Phosphoprotein,	MUTAGEN:D->A: Abolishes the calcium channel activity.,MUTAGEN:D->E: Retains some of the calcium channel activity.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
TMUB1	transmembrane and ubiquitin like domain containing 1(TMUB1)	Homo sapiens			GO:0030433~ubiquitin-dependent ERAD pathway,GO:0036503~ERAD pathway,	GO:0005730~nucleolus,GO:0005813~centrosome,GO:0016020~membrane,GO:0045211~postsynaptic membrane,GO:0055037~recycling endosome,	GO:0005515~protein binding,	IPR000626:Ubiquitin-like_dom,IPR029071:Ubiquitin-like_domsf,IPR040352:TMUB1/2,						KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0539~Nucleus,KW-0628~Postsynaptic cell membrane,KW-0770~Synapse,KW-0963~Cytoplasm,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,	DOMAIN:Ubiquitin-like,REGION:Disordered,REGION:Required to release iHOPS from membranes,TRANSMEM:Helical,
TMED10	transmembrane p24 trafficking protein 10(TMED10)	Homo sapiens			GO:0006886~intracellular protein transport,GO:0006888~ER to Golgi vesicle-mediated transport,GO:0006890~retrograde vesicle-mediated transport, Golgi to ER,GO:0007030~Golgi organization,GO:0032732~positive regulation of interleukin-1 production,GO:0035459~cargo loading into vesicle,GO:0035964~COPI-coated vesicle budding,GO:0045055~regulated exocytosis,GO:0048199~vesicle targeting, to, from or within Golgi,GO:0048205~COPI coating of Golgi vesicle,GO:0048208~COPII vesicle coating,GO:0050714~positive regulation of protein secretion,GO:0071806~protein transmembrane transport,GO:1902003~regulation of beta-amyloid formation,	GO:0000139~Golgi membrane,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005793~endoplasmic reticulum-Golgi intermediate compartment,GO:0005794~Golgi apparatus,GO:0005801~cis-Golgi network,GO:0005886~plasma membrane,GO:0012507~ER to Golgi transport vesicle membrane,GO:0016020~membrane,GO:0030133~transport vesicle,GO:0030134~ER to Golgi transport vesicle,GO:0030137~COPI-coated vesicle,GO:0030140~trans-Golgi network transport vesicle,GO:0030667~secretory granule membrane,GO:0033116~endoplasmic reticulum-Golgi intermediate compartment membrane,GO:0042470~melanosome,GO:0042589~zymogen granule membrane,GO:0070765~gamma-secretase complex,	GO:0005515~protein binding,GO:0008320~protein transmembrane transporter activity,GO:0019905~syntaxin binding,GO:0038024~cargo receptor activity,	IPR009038:GOLD_dom,IPR015720:Emp24-like,	hsa05130:Pathogenic Escherichia coli infection,			SM01190:EMP24_GP25L,	KW-0653~Protein transport,KW-0813~Transport,KW-0931~ER-Golgi transport,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0488~Methylation,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:GOLD,MOTIF:COPI vesicle coat-binding,MOTIF:COPII vesicle coat-binding,MUTAGEN:FF->AA: Disrupts interaction with COPG1 and association with coatomer; when associated with 215-A-A-216.,MUTAGEN:FF->AA: No decrease in binding to COPG1. Disrupts interaction with SEC23A.,MUTAGEN:KK->AA: Disrupts interaction with COPG1 and association with coatomer; when associated with 211-A-A-212.,MUTAGEN:KK->AA: Significant reduction in binding to COPG1.,REGION:Interaction with ARF1 and IL1B,REGION:Interaction with COPG1,REGION:Required for TMED10 and TMED2 cis-Golgi network localization,REGION:Required for interaction with STX17,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
TMED5	transmembrane p24 trafficking protein 5(TMED5)	Homo sapiens			GO:0006886~intracellular protein transport,GO:0006888~ER to Golgi vesicle-mediated transport,GO:0015031~protein transport,GO:0090161~Golgi ribbon formation,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005793~endoplasmic reticulum-Golgi intermediate compartment,GO:0005794~Golgi apparatus,GO:0005801~cis-Golgi network,GO:0016020~membrane,GO:0030134~ER to Golgi transport vesicle,GO:0033116~endoplasmic reticulum-Golgi intermediate compartment membrane,GO:0070971~endoplasmic reticulum exit site,	GO:0005515~protein binding,GO:0038024~cargo receptor activity,	IPR009038:GOLD_dom,IPR015720:Emp24-like,IPR036598:GOLD_dom_sf,				SM01190:EMP24_GP25L,	KW-0653~Protein transport,KW-0813~Transport,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,				DOMAIN:GOLD,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
TMEM109	transmembrane protein 109(TMEM109)	Homo sapiens			GO:0042771~intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator,GO:0043069~negative regulation of programmed cell death,GO:0071480~cellular response to gamma radiation,GO:0098655~cation transmembrane transport,	GO:0005640~nuclear outer membrane,GO:0016020~membrane,GO:0033017~sarcoplasmic reticulum membrane,GO:0034702~ion channel complex,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0022843~voltage-gated cation channel activity,	IPR039492:TMEM109,					KW-0406~Ion transport,KW-0813~Transport,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0539~Nucleus,KW-0703~Sarcoplasmic reticulum,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0407~Ion channel,KW-0851~Voltage-gated channel,		TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
TMEM11	transmembrane protein 11(TMEM11)	Homo sapiens			GO:0007005~mitochondrion organization,GO:0007007~inner mitochondrial membrane organization,	GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005886~plasma membrane,	GO:0005515~protein binding,	IPR026120:TMEM11,						KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				REGION:Disordered,TRANSMEM:Helical,
TMEM115	transmembrane protein 115(TMEM115)	Homo sapiens			GO:0006890~retrograde vesicle-mediated transport, Golgi to ER,GO:0008285~negative regulation of cell proliferation,GO:0015031~protein transport,	GO:0000139~Golgi membrane,GO:0005634~nucleus,GO:0005794~Golgi apparatus,GO:0016020~membrane,GO:0017119~Golgi transport complex,GO:0032580~Golgi cisterna membrane,	GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR013861:TMEM115/Pdh1/Rbl19,IPR035952:Rhomboid-like_sf,				SM01160:DUF1751,	KW-0653~Protein transport,KW-0813~Transport,	KW-0333~Golgi apparatus,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,	REGION:Disordered,REGION:Mediates homooligomerization,REGION:Mediates localization to the Golgi,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,
TMEM123	transmembrane protein 123(TMEM123)	Homo sapiens				GO:0009897~external side of plasma membrane,GO:0016020~membrane,GO:0031410~cytoplasmic vesicle,	GO:0005515~protein binding,GO:0038023~signaling receptor activity,	IPR007947:CD164_MGC24,						KW-0472~Membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
TMEM14C	transmembrane protein 14C(TMEM14C)	Homo sapiens			GO:0006783~heme biosynthetic process,GO:0006839~mitochondrial transport,GO:0030218~erythrocyte differentiation,GO:0070453~regulation of heme biosynthetic process,GO:0071702~organic substance transport,GO:0071705~nitrogen compound transport,	GO:0005743~mitochondrial inner membrane,GO:0016020~membrane,GO:0031966~mitochondrial membrane,	GO:0005515~protein binding,	IPR005349:TMEM14,IPR044890:TMEM14_sf,					KW-0350~Heme biosynthesis,	KW-0472~Membrane,KW-0496~Mitochondrion,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				TRANSMEM:Helical,
TMEM167A	transmembrane protein 167A(TMEM167A)	Homo sapiens			GO:0009306~protein secretion,GO:0045054~constitutive secretory pathway,GO:0046907~intracellular transport,	GO:0000139~Golgi membrane,GO:0005794~Golgi apparatus,	GO:0005515~protein binding,	IPR009653:Ksh1,						KW-0333~Golgi apparatus,KW-0472~Membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
TMEM167B	transmembrane protein 167B(TMEM167B)	Homo sapiens			GO:0045054~constitutive secretory pathway,	GO:0000139~Golgi membrane,GO:0005794~Golgi apparatus,	GO:0005515~protein binding,	IPR009653:Ksh1,IPR042863:Kish-B,						KW-0333~Golgi apparatus,KW-0472~Membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,				REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
TMEM170A	transmembrane protein 170A(TMEM170A)	Homo sapiens			GO:0006998~nuclear envelope organization,GO:0051292~nuclear pore complex assembly,GO:0071786~endoplasmic reticulum tubular network organization,	GO:0005635~nuclear envelope,GO:0005789~endoplasmic reticulum membrane,GO:0016020~membrane,	GO:0005515~protein binding,	IPR019334:Transmembrane_pr_170,						KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0539~Nucleus,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
TMEM183A	transmembrane protein 183A(TMEM183A)	Homo sapiens			GO:0031647~regulation of protein stability,	GO:0016020~membrane,GO:0019005~SCF ubiquitin ligase complex,	GO:0005515~protein binding,	IPR026509:TMEM183,IPR036047:F-box-like_dom_sf,						KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				REGION:Disordered,TRANSMEM:Helical,
TMEM216	transmembrane protein 216(TMEM216)	Homo sapiens			GO:0060271~cilium assembly,GO:1905515~non-motile cilium assembly,	GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005929~cilium,GO:0016020~membrane,GO:0035869~ciliary transition zone,GO:0036038~MKS complex,GO:0042995~cell projection,	GO:0005515~protein binding,	IPR019184:Uncharacterised_TM-17,		603194~Meckel syndrome 2,608091~Joubert syndrome 2,			KW-0970~Cilium biogenesis/degradation,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0966~Cell projection,	KW-0225~Disease variant,KW-0979~Joubert syndrome,KW-0981~Meckel syndrome,KW-1186~Ciliopathy,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,				TRANSMEM:Helical,
TMEM230	transmembrane protein 230(TMEM230)	Homo sapiens			GO:0048489~synaptic vesicle transport,	GO:0005769~early endosome,GO:0005770~late endosome,GO:0005776~autophagosome,GO:0005783~endoplasmic reticulum,GO:0005802~trans-Golgi network,GO:0008021~synaptic vesicle,GO:0012505~endomembrane system,GO:0016020~membrane,GO:0055037~recycling endosome,		IPR008590:TMEM_230/134,IPR044234:TMEM230,						KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0770~Synapse,KW-0967~Endosome,KW-0968~Cytoplasmic vesicle,	KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0907~Parkinson disease,KW-0908~Parkinsonism,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,REGION:Disordered,TRANSMEM:Helical,
TMEM243	transmembrane protein 243(TMEM243)	Homo sapiens				GO:0016020~membrane,	GO:0005515~protein binding,	IPR022564:DUF2678,						KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,	TRANSMEM:Helical,
TMEM256	transmembrane protein 256(TMEM256)	Homo sapiens				GO:0016020~membrane,GO:0070062~extracellular exosome,		IPR006696:DUF423,						KW-0472~Membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,	TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
TMEM258	transmembrane protein 258(TMEM258)	Homo sapiens			GO:0006487~protein N-linked glycosylation,GO:0006954~inflammatory response,GO:0034976~response to endoplasmic reticulum stress,GO:1904019~epithelial cell apoptotic process,	GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0008250~oligosaccharyltransferase complex,GO:0016020~membrane,GO:0032991~macromolecular complex,GO:0034998~oligosaccharyltransferase I complex,GO:0043227~membrane-bounded organelle,	GO:0005515~protein binding,	IPR007915:TMEM258/Ost5,	hsa00510:N-Glycan biosynthesis,hsa00513:Various types of N-glycan biosynthesis,hsa04141:Protein processing in endoplasmic reticulum,					KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0963~Cytoplasm,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,	TRANSMEM:Helical,
TMEM263	transmembrane protein 263(TMEM263)	Homo sapiens				GO:0016020~membrane,		IPR028153:UPF0444,						KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,REGION:Disordered,TRANSMEM:Helical,
TMEM39A	transmembrane protein 39A(TMEM39A)	Homo sapiens			GO:0006914~autophagy,GO:0045070~positive regulation of viral genome replication,GO:1901097~negative regulation of autophagosome maturation,GO:1902902~negative regulation of autophagosome assembly,	GO:0005789~endoplasmic reticulum membrane,GO:0016020~membrane,	GO:0005515~protein binding,	IPR019397:Uncharacterised_TMEM39,					KW-0072~Autophagy,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,REGION:Disordered,TRANSMEM:Helical,
TMEM50B	transmembrane protein 50B(TMEM50B)	Homo sapiens			GO:0032511~late endosome to vacuole transport via multivesicular body sorting pathway,	GO:0000139~Golgi membrane,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0016020~membrane,	GO:0005515~protein binding,	IPR007919:UPF0220,						KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,	TRANSMEM:Helical,
TMEM70	transmembrane protein 70(TMEM70)	Homo sapiens			GO:0033615~mitochondrial proton-transporting ATP synthase complex assembly,GO:0051259~protein oligomerization,GO:0051260~protein homooligomerization,	GO:0005654~nucleoplasm,GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0030061~mitochondrial crista,GO:0031966~mitochondrial membrane,	GO:0005515~protein binding,	IPR009724:TMEM70,IPR045325:TMEM70/TMEM186/TMEM223,		614052~Mitochondrial complex V (ATP synthase) deficiency, nuclear type 2,				KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,	KW-1274~Primary mitochondrial disease,	KW-0809~Transit peptide,KW-0812~Transmembrane,KW-1133~Transmembrane helix,				COMPBIAS:Polar residues,REGION:Disordered,TOPO_DOM:Mitochondrial intermembrane,TOPO_DOM:Mitochondrial matrix,TRANSIT:Mitochondrion,TRANSMEM:Helical,
TMEM87A	transmembrane protein 87A(TMEM87A)	Homo sapiens			GO:0042147~retrograde transport, endosome to Golgi,GO:0071260~cellular response to mechanical stimulus,	GO:0000139~Golgi membrane,GO:0001726~ruffle,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0032580~Golgi cisterna membrane,		IPR009637:GPR107/GPR108-like,						KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0966~Cell projection,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,MUTAGEN:G->N: Reduced mechanosensitive channel activity in Tmem87a-expressing cells.,MUTAGEN:L->F: Reduced mechanosensitive channel activity in Tmem87a-expressing cells.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
TPRA1	transmembrane protein adipocyte associated 1(TPRA1)	Homo sapiens			GO:0006629~lipid metabolic process,GO:0007186~G-protein coupled receptor signaling pathway,GO:0040016~embryonic cleavage,GO:1901991~negative regulation of mitotic cell cycle phase transition,	GO:0005886~plasma membrane,GO:0016020~membrane,	GO:0004930~G-protein coupled receptor activity,GO:0005515~protein binding,	IPR018781:TPRA1/CAND2/CAND8,						KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
TAP1	transporter 1, ATP binding cassette subfamily B member(TAP1)	Homo sapiens		h_mhcPathway:Antigen Processing and Presentation,	GO:0002250~adaptive immune response,GO:0006952~defense response,GO:0015031~protein transport,GO:0015833~peptide transport,GO:0019885~antigen processing and presentation of endogenous peptide antigen via MHC class I,GO:0046967~cytosol to ER transport,GO:0055085~transmembrane transport,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0030670~phagocytic vesicle membrane,GO:0033116~endoplasmic reticulum-Golgi intermediate compartment membrane,GO:0034451~centriolar satellite,GO:0042824~MHC class I peptide loading complex,GO:0042825~TAP complex,	GO:0005515~protein binding,GO:0005524~ATP binding,GO:0015433~peptide antigen-transporting ATPase activity,GO:0016887~ATPase activity,GO:0023029~MHC class Ib protein binding,GO:0042288~MHC class I protein binding,GO:0042605~peptide antigen binding,GO:0042803~protein homodimerization activity,GO:0043531~ADP binding,GO:0046872~metal ion binding,GO:0046978~TAP1 binding,GO:0046979~TAP2 binding,GO:1904680~peptide transmembrane transporter activity,	IPR003439:ABC_transporter-like_ATP-bd,IPR003593:AAA+_ATPase,IPR011527:ABC1_TM_dom,IPR013305:ABC_Tap-like,IPR017871:ABC_transporter-like_CS,IPR027417:P-loop_NTPase,IPR036640:ABC1_TM_sf,IPR039421:Type_1_exporter,	hsa02010:ABC transporters,hsa04145:Phagosome,hsa04612:Antigen processing and presentation,hsa05163:Human cytomegalovirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05340:Primary immunodeficiency,	604571~Bare lymphocyte syndrome, type I,	PIRSF002773:ABC_prm/ATPase_B,	SM00382:AAA,	KW-0391~Immunity,KW-0571~Peptide transport,KW-0653~Protein transport,KW-0813~Transport,KW-0945~Host-virus interaction,KW-1064~Adaptive immunity,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-1278~Translocase,		COMPBIAS:Basic and acidic residues,DOMAIN:ABC transmembrane type-1,DOMAIN:ABC transporter,MUTAGEN:D->A: Impairs allosteric coupling of peptide transport to ATP hydrolysis, converting the unidirectional active pump into a passive bidirectional nucleotide-gated facilitator. Inactive in peptide transport when associated with 'A-638' of TAP2.,MUTAGEN:D->K: Complete loss of interaction with TAPBP, resulting in impaired PLC assembly and antigen presentation.,REGION:Disordered,REGION:Part of the peptide-binding site,SITE:Inter-subunit salt bridge with TAPBP,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=10,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,TRANSMEM:Helical; Name=8,TRANSMEM:Helical; Name=9,
TNPO1	transportin 1(TNPO1)	Homo sapiens			GO:0006606~protein import into nucleus,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005929~cilium,GO:0070062~extracellular exosome,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0008139~nuclear localization sequence binding,GO:0031267~small GTPase binding,GO:0061608~nuclear import signal receptor activity,	IPR000357:HEAT,IPR001494:Importin-beta_N,IPR011989:ARM-like,IPR016024:ARM-type_fold,IPR040122:Importin_beta,	hsa03013:Nucleocytoplasmic transport,			SM00913:IBN_N,	KW-0653~Protein transport,KW-0813~Transport,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,			KW-0007~Acetylation,	COMPBIAS:Acidic residues,DOMAIN:Importin N-terminal,MUTAGEN:W->A: Abolishes interaction with the ADAR nuclear localization signal. Abolishes ADAR nuclear import.,REGION:Disordered,REPEAT:HEAT 1,REPEAT:HEAT 10,REPEAT:HEAT 11,REPEAT:HEAT 12,REPEAT:HEAT 13,REPEAT:HEAT 14,REPEAT:HEAT 15,REPEAT:HEAT 16,REPEAT:HEAT 17,REPEAT:HEAT 18,REPEAT:HEAT 19,REPEAT:HEAT 2,REPEAT:HEAT 20,REPEAT:HEAT 3,REPEAT:HEAT 4,REPEAT:HEAT 5,REPEAT:HEAT 6,REPEAT:HEAT 7,REPEAT:HEAT 8,REPEAT:HEAT 9,SITE:Important for interaction with cargo nuclear localization signals,
TGS1	trimethylguanosine synthase 1(TGS1)	Homo sapiens			GO:0000387~spliceosomal snRNP assembly,GO:0001510~RNA methylation,GO:0009452~7-methylguanosine RNA capping,GO:0022613~ribonucleoprotein complex biogenesis,GO:0036261~7-methylguanosine cap hypermethylation,	GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0015030~Cajal body,GO:0030532~small nuclear ribonucleoprotein complex,	GO:0005515~protein binding,GO:0008173~RNA methyltransferase activity,GO:0008757~S-adenosylmethionine-dependent methyltransferase activity,GO:0071164~RNA trimethylguanosine synthase activity,	IPR019012:RNA_cap_Gua-N2-MeTrfase,IPR029063:SAM-dependent_MTases_sf,					KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0949~S-adenosyl-L-methionine,	KW-0489~Methyltransferase,KW-0675~Receptor,KW-0808~Transferase,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,MUTAGEN:D->A: Loss of catalytic activity.,MUTAGEN:F->A: Loss of catalytic activity.,MUTAGEN:N->A: Decreases catalytic activity to 11 percent of wild type.,MUTAGEN:N->A: Decreases catalytic activity to 4 percent of wild type.,MUTAGEN:N->A: Decreases catalytic activity to 5 percent of wild type.,MUTAGEN:R->A: Decreases catalytic activity to 6 percent of wild type.,MUTAGEN:S->A: Decreases catalytic activity to 26 percent of wild type.,MUTAGEN:T->A: Decreases catalytic activity to 13 percent of wild type.,MUTAGEN:W->A: Loss of catalytic activity.,REGION:Disordered,REGION:Sufficient for catalytic activity,
TNRC6B	trinucleotide repeat containing adaptor 6B(TNRC6B)	Homo sapiens			GO:0031047~gene silencing by RNA,GO:0035195~gene silencing by miRNA,GO:0035278~miRNA mediated inhibition of translation,GO:0060213~positive regulation of nuclear-transcribed mRNA poly(A) tail shortening,GO:1900153~positive regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay,	GO:0000932~P-body,GO:0005654~nucleoplasm,GO:0005829~cytosol,	GO:0003676~nucleic acid binding,GO:0003723~RNA binding,GO:0005515~protein binding,	IPR012677:Nucleotide-bd_a/b_plait_sf,IPR019486:Argonaute_hook_dom,IPR032226:TNRC6_PABC-bd,IPR034925:TNRC6B_RRM,IPR035979:RBD_domain_sf,		619243~Global developmental delay with speech and behavioral abnormalities,			KW-0810~Translation regulation,KW-0943~RNA-mediated gene silencing,	KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0991~Intellectual disability,KW-1268~Autism spectrum disorder,	KW-0175~Coiled coil,		KW-0694~RNA-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Argonaute hook,DOMAIN:RRM,DOMAIN:TNRC6 PABC binding,REGION:Disordered,REGION:Interaction with argonaute proteins,REGION:PABPC1-interacting motif-2 (PAM2),REGION:Silencing domain; interaction with CNOT1 and PAN3,
TRIM11	tripartite motif containing 11(TRIM11)	Homo sapiens			GO:0010468~regulation of gene expression,GO:0016567~protein ubiquitination,GO:0032897~negative regulation of viral transcription,GO:0044790~negative regulation by host of viral release from host cell,GO:0045087~innate immune response,GO:0045892~negative regulation of transcription, DNA-templated,GO:0046597~negative regulation of viral entry into host cell,GO:0046598~positive regulation of viral entry into host cell,GO:0050768~negative regulation of neurogenesis,GO:0051865~protein autoubiquitination,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0019904~protein domain specific binding,GO:0030674~protein binding, bridging,GO:0061630~ubiquitin protein ligase activity,	IPR000315:Znf_B-box,IPR001841:Znf_RING,IPR001870:B30.2/SPRY,IPR003877:SPRY_dom,IPR003879:Butyrophylin_SPRY,IPR006574:PRY,IPR013083:Znf_RING/FYVE/PHD,IPR013320:ConA-like_dom_sf,IPR017907:Znf_RING_CS,IPR043136:B30.2/SPRY_sf,				SM00184:RING,SM00336:BBOX,SM00449:SPRY,SM00589:PRY,	KW-0051~Antiviral defense,KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0808~Transferase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:B30.2/SPRY,MUTAGEN:C->A: Abolished E3 ubiquitin-protein ligase activity.,MUTAGEN:K->R: Does not affect autoubiquitination.,MUTAGEN:K->R: Reduced autoubiquitination, leading to abolish interaction with SQSTM1/p62.,ZN_FING:B box-type,ZN_FING:RING-type,
TRIM22	tripartite motif containing 22(TRIM22)	Homo sapiens			GO:0000209~protein polyubiquitination,GO:0002230~positive regulation of defense response to virus by host,GO:0006355~regulation of transcription, DNA-templated,GO:0006955~immune response,GO:0009615~response to virus,GO:0010508~positive regulation of autophagy,GO:0032880~regulation of protein localization,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0045087~innate immune response,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0046596~regulation of viral entry into host cell,GO:0051091~positive regulation of sequence-specific DNA binding transcription factor activity,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0051607~defense response to virus,GO:0070534~protein K63-linked ubiquitination,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0015030~Cajal body,GO:0016604~nuclear body,GO:0016607~nuclear speck,	GO:0003713~transcription coactivator activity,GO:0003714~transcription corepressor activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0019901~protein kinase binding,GO:0030674~protein binding, bridging,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0061630~ubiquitin protein ligase activity,	IPR000315:Znf_B-box,IPR001841:Znf_RING,IPR001870:B30.2/SPRY,IPR003877:SPRY_dom,IPR003879:Butyrophylin_SPRY,IPR013083:Znf_RING/FYVE/PHD,IPR013320:ConA-like_dom_sf,IPR017907:Znf_RING_CS,IPR027370:Znf-RING_euk,IPR035827:PRY/SPRY_TRIM22,IPR043136:B30.2/SPRY_sf,				SM00184:RING,SM00336:BBOX,SM00449:SPRY,	KW-0051~Antiviral defense,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0833~Ubl conjugation pathway,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0678~Repressor,KW-0808~Transferase,	KW-0832~Ubl conjugation,	DOMAIN:B box-type,DOMAIN:B30.2/SPRY,DOMAIN:RING-type,MOTIF:Nuclear localization signal,MUTAGEN:C->A: Loss of E3 ubiquitin-protein ligase activity, reduces auto-ubiquitination and not affect nuclear bodies formation. Loss of antiviral activity; when associated with A-18.,MUTAGEN:C->A: Loss of antiviral activity and not affect nuclear bodies formation; when associated with A-15.,MUTAGEN:VC->AA: Reduces formation of regular nuclear bodies.,ZN_FING:B box-type,ZN_FING:RING-type,
TRIM26	tripartite motif containing 26(TRIM26)	Homo sapiens			GO:0016567~protein ubiquitination,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0044790~negative regulation by host of viral release from host cell,GO:0045087~innate immune response,GO:0046597~negative regulation of viral entry into host cell,GO:0051091~positive regulation of sequence-specific DNA binding transcription factor activity,GO:0070979~protein K11-linked ubiquitination,GO:1901224~positive regulation of NIK/NF-kappaB signaling,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0003677~DNA binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0046872~metal ion binding,GO:0061630~ubiquitin protein ligase activity,	IPR000315:Znf_B-box,IPR001841:Znf_RING,IPR001870:B30.2/SPRY,IPR003877:SPRY_dom,IPR003879:Butyrophylin_SPRY,IPR006574:PRY,IPR013083:Znf_RING/FYVE/PHD,IPR013320:ConA-like_dom_sf,IPR020457:Znf_B-box_chordata,IPR043136:B30.2/SPRY_sf,				SM00184:RING,SM00336:BBOX,SM00449:SPRY,SM00589:PRY,	KW-0391~Immunity,KW-0399~Innate immunity,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0808~Transferase,	KW-0832~Ubl conjugation,	COMPBIAS:Acidic residues,DOMAIN:B box-type,DOMAIN:B30.2/SPRY,DOMAIN:RING-type,MUTAGEN:C->A: Strong loss of ubiquitination activity.,REGION:Disordered,ZN_FING:B box-type,ZN_FING:RING-type,
TRIM27	tripartite motif containing 27(TRIM27)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0002820~negative regulation of adaptive immune response,GO:0006469~negative regulation of protein kinase activity,GO:0007283~spermatogenesis,GO:0010507~negative regulation of autophagy,GO:0016925~protein sumoylation,GO:0032480~negative regulation of type I interferon production,GO:0032703~negative regulation of interleukin-2 production,GO:0032720~negative regulation of tumor necrosis factor production,GO:0032729~positive regulation of interferon-gamma production,GO:0032897~negative regulation of viral transcription,GO:0034314~Arp2/3 complex-mediated actin nucleation,GO:0042147~retrograde transport, endosome to Golgi,GO:0044790~negative regulation by host of viral release from host cell,GO:0045087~innate immune response,GO:0045814~negative regulation of gene expression, epigenetic,GO:0045893~positive regulation of transcription, DNA-templated,GO:0051091~positive regulation of sequence-specific DNA binding transcription factor activity,GO:0051127~positive regulation of actin nucleation,GO:0070534~protein K63-linked ubiquitination,GO:0090281~negative regulation of calcium ion import,	GO:0001650~fibrillar center,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005768~endosome,GO:0005769~early endosome,GO:0005829~cytosol,GO:0016605~PML body,GO:0030904~retromer complex,GO:0031965~nuclear membrane,	GO:0003676~nucleic acid binding,GO:0003677~DNA binding,GO:0003713~transcription coactivator activity,GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0019789~SUMO transferase activity,GO:0042802~identical protein binding,GO:0046872~metal ion binding,GO:0061630~ubiquitin protein ligase activity,	IPR000315:Znf_B-box,IPR001841:Znf_RING,IPR001870:B30.2/SPRY,IPR003877:SPRY_dom,IPR003879:Butyrophylin_SPRY,IPR006574:PRY,IPR013083:Znf_RING/FYVE/PHD,IPR013320:ConA-like_dom_sf,IPR017907:Znf_RING_CS,IPR020457:Znf_B-box_chordata,IPR035791:SPRY/PRY_TRIM27,IPR043136:B30.2/SPRY_sf,				SM00184:RING,SM00336:BBOX,SM00449:SPRY,SM00589:PRY,	KW-0804~Transcription,KW-0805~Transcription regulation,KW-0813~Transport,KW-0833~Ubl conjugation pathway,	KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0967~Endosome,	KW-0656~Proto-oncogene,	KW-0175~Coiled coil,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,KW-0678~Repressor,KW-0808~Transferase,		DOMAIN:B box-type,DOMAIN:B30.2/SPRY,DOMAIN:RING-type,DOMAIN:SPRY-associated,MUTAGEN:C->A: Abolished E3 ubiquitin-protein ligase activity; when associated with A-16.,MUTAGEN:C->A: Abolished E3 ubiquitin-protein ligase activity; when associated with A-31.,SITE:Breakpoint for translocation to form the TRIM27/RET oncogene,ZN_FING:B box-type,ZN_FING:RING-type,
TRIM4	tripartite motif containing 4(TRIM4)	Homo sapiens			GO:0010468~regulation of gene expression,GO:0016567~protein ubiquitination,GO:0045087~innate immune response,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,	GO:0004842~ubiquitin-protein transferase activity,GO:0008270~zinc ion binding,GO:0042802~identical protein binding,GO:0061630~ubiquitin protein ligase activity,	IPR000315:Znf_B-box,IPR001841:Znf_RING,IPR001870:B30.2/SPRY,IPR003877:SPRY_dom,IPR003879:Butyrophylin_SPRY,IPR013083:Znf_RING/FYVE/PHD,IPR013320:ConA-like_dom_sf,IPR017907:Znf_RING_CS,IPR035829:PRY/SPRY_TRIM4,IPR043136:B30.2/SPRY_sf,				SM00184:RING,SM00336:BBOX,SM00449:SPRY,	KW-0391~Immunity,KW-0399~Innate immunity,KW-0833~Ubl conjugation pathway,	KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0808~Transferase,		DOMAIN:B box-type,DOMAIN:B30.2/SPRY,DOMAIN:RING-type,MUTAGEN:C->S: Abolishes ligase activity.,ZN_FING:B box-type,ZN_FING:RING-type,
TRIM69	tripartite motif containing 69(TRIM69)	Homo sapiens			GO:0006915~apoptotic process,GO:0016567~protein ubiquitination,GO:0071539~protein localization to centrosome,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005829~cytosol,GO:0016607~nuclear speck,	GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0046872~metal ion binding,GO:0061630~ubiquitin protein ligase activity,	IPR001841:Znf_RING,IPR001870:B30.2/SPRY,IPR003877:SPRY_dom,IPR003879:Butyrophylin_SPRY,IPR006574:PRY,IPR013083:Znf_RING/FYVE/PHD,IPR013320:ConA-like_dom_sf,IPR017907:Znf_RING_CS,IPR043136:B30.2/SPRY_sf,				SM00184:RING,SM00449:SPRY,SM00589:PRY,	KW-0053~Apoptosis,KW-0833~Ubl conjugation pathway,	KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0808~Transferase,	KW-0597~Phosphoprotein,	DOMAIN:B30.2/SPRY,DOMAIN:RING-type,MUTAGEN:C->A: Loss of E3 ubiquitin-protein ligase activity; when associated with A-61.,MUTAGEN:C->A: Loss of E3 ubiquitin-protein ligase activity; when associated with A-64.,MUTAGEN:L->A: Loss of antiviral activity; able to form dimers but not higher-order multimers.,MUTAGEN:L->A: Loss of antiviral activity; able to form dimers but not higher-order multimers; when associated with A-91.,MUTAGEN:V->A: Loss of antiviral activity; able to form dimers but not higher-order multimers; when associated with A-96.,REGION:Necessary for nuclear localization,ZN_FING:RING-type,
TPP1	tripeptidyl peptidase 1(TPP1)	Homo sapiens			GO:0006508~proteolysis,GO:0006629~lipid metabolic process,GO:0007040~lysosome organization,GO:0007399~nervous system development,GO:0007417~central nervous system development,GO:0030163~protein catabolic process,GO:0030855~epithelial cell differentiation,GO:0043171~peptide catabolic process,GO:0045453~bone resorption,GO:0050885~neuromuscular process controlling balance,GO:0070198~protein localization to chromosome, telomeric region,GO:1905146~lysosomal protein catabolic process,	GO:0005764~lysosome,GO:0005794~Golgi apparatus,GO:0042470~melanosome,GO:0043202~lysosomal lumen,GO:0045121~membrane raft,GO:0055037~recycling endosome,GO:0070062~extracellular exosome,	GO:0004175~endopeptidase activity,GO:0004252~serine-type endopeptidase activity,GO:0005515~protein binding,GO:0008233~peptidase activity,GO:0008236~serine-type peptidase activity,GO:0008240~tripeptidyl-peptidase activity,GO:0035727~lysophosphatidic acid binding,GO:0042277~peptide binding,GO:0046872~metal ion binding,	IPR000209:Peptidase_S8/S53_dom,IPR015366:S53_propep,IPR030400:Sedolisin_dom,IPR036852:Peptidase_S8/S53_dom_sf,	hsa04142:Lysosome,	204500~Ceroid lipofuscinosis, neuronal, 2,609270~Spinocerebellar ataxia, autosomal recessive 7,		SM00944:Pro-kuma_activ,		KW-0458~Lysosome,	KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0525~Neuronal ceroid lipofuscinosis,KW-0887~Epilepsy,KW-0950~Spinocerebellar ataxia,	KW-0732~Signal,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0378~Hydrolase,KW-0645~Protease,KW-0720~Serine protease,	KW-0068~Autocatalytic cleavage,KW-0325~Glycoprotein,KW-0865~Zymogen,KW-1015~Disulfide bond,	ACT_SITE:Charge relay system,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Peptidase S53,DOMAIN:Peptidase S53 activation,MUTAGEN:D->A: Inactive. Impaired processing.,MUTAGEN:H->A: No effect.,MUTAGEN:S->A: Inactive. Impaired processing.,PROPEP:Removed in mature form,REGION:Disordered,
TPP2	tripeptidyl peptidase 2(TPP2)	Homo sapiens			GO:0000209~protein polyubiquitination,GO:0006508~proteolysis,GO:0080144~amino acid homeostasis,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016604~nuclear body,	GO:0004175~endopeptidase activity,GO:0004177~aminopeptidase activity,GO:0004252~serine-type endopeptidase activity,GO:0005515~protein binding,GO:0008240~tripeptidyl-peptidase activity,GO:0042802~identical protein binding,	IPR000209:Peptidase_S8/S53_dom,IPR015500:Peptidase_S8_subtilisin-rel,IPR022229:TPPII_Ig-like-2,IPR022232:TPPII_C_art,IPR022398:Peptidase_S8_His-AS,IPR023828:Peptidase_S8_Ser-AS,IPR034051:TPP_II_domain,IPR036852:Peptidase_S8/S53_dom_sf,IPR046939:TPPII_C_sf,IPR046940:TPPII_Ig-like_sf,IPR048383:TPPII_Ig-like-1,IPR048384:TPPII_GBD,		619220~Immunodeficiency 78 with autoimmunity and developmental delay,				KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,			KW-0031~Aminopeptidase,KW-0378~Hydrolase,KW-0645~Protease,KW-0720~Serine protease,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Charge relay system,COMPBIAS:Basic and acidic residues,DOMAIN:Peptidase S8,DOMAIN:Peptidase S8/S53,DOMAIN:Tripeptidyl peptidase II C-terminal,DOMAIN:Tripeptidyl peptidase II second Ig-like,DOMAIN:Tripeptidyl-peptidase II first Ig-like,DOMAIN:Tripeptidyl-peptidase II galactose-binding,REGION:Disordered,
TPM4	tropomyosin 4(TPM4)	Homo sapiens			GO:0001649~osteoblast differentiation,GO:0006936~muscle contraction,GO:0007015~actin filament organization,	GO:0001725~stress fiber,GO:0002102~podosome,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005862~muscle thin filament tropomyosin,GO:0005884~actin filament,GO:0005925~focal adhesion,GO:0016020~membrane,GO:0030863~cortical cytoskeleton,GO:0070062~extracellular exosome,	GO:0003779~actin binding,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0008307~structural constituent of muscle,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0046982~protein heterodimerization activity,GO:0051015~actin filament binding,	IPR000533:Tropomyosin,IPR014751:XRCC4-like_C,	hsa04260:Cardiac muscle contraction,hsa04261:Adrenergic signaling in cardiomyocytes,hsa04814:Motor proteins,hsa05410:Hypertrophic cardiomyopathy,hsa05414:Dilated cardiomyopathy,	620486~Bleeding disorder, platelet-type, 25,				KW-0206~Cytoskeleton,KW-0963~Cytoplasm,		KW-0175~Coiled coil,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0009~Actin-binding,KW-0514~Muscle protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,REGION:Disordered,
TUBA1C	tubulin alpha 1c(TUBA1C)	Homo sapiens			GO:0000226~microtubule cytoskeleton organization,GO:0000278~mitotic cell cycle,GO:0007017~microtubule-based process,GO:0030705~cytoskeleton-dependent intracellular transport,GO:0051301~cell division,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005874~microtubule,GO:0005881~cytoplasmic microtubule,GO:0015630~microtubule cytoskeleton,GO:0031982~vesicle,	GO:0005198~structural molecule activity,GO:0005200~structural constituent of cytoskeleton,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0016787~hydrolase activity,GO:0046872~metal ion binding,	IPR000217:Tubulin,IPR002452:Alpha_tubulin,IPR003008:Tubulin_FtsZ_GTPase,IPR008280:Tub_FtsZ_C,IPR017975:Tubulin_CS,IPR018316:Tubulin/FtsZ_2-layer-sand-dom,IPR023123:Tubulin_C,IPR036525:Tubulin/FtsZ_GTPase_sf,IPR037103:Tubulin/FtsZ-like_C,	hsa04145:Phagosome,hsa04210:Apoptosis,hsa04530:Tight junction,hsa04540:Gap junction,hsa04814:Motor proteins,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05130:Pathogenic Escherichia coli infection,hsa05132:Salmonella infection,			SM00864:Tubulin,SM00865:Tubulin_C,		KW-0206~Cytoskeleton,KW-0493~Microtubule,KW-0963~Cytoplasm,			KW-0342~GTP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0944~Nitration,	DOMAIN:Tubulin/FtsZ 2-layer sandwich,DOMAIN:Tubulin/FtsZ GTPase,MOTIF:MREC motif,REGION:Disordered,SITE:Involved in polymerization,
TBCB	tubulin folding cofactor B(TBCB)	Homo sapiens			GO:0007021~tubulin complex assembly,GO:0007023~post-chaperonin tubulin folding pathway,GO:0007399~nervous system development,GO:0030154~cell differentiation,GO:0031122~cytoplasmic microtubule organization,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005938~cell cortex,GO:0015630~microtubule cytoskeleton,GO:0035371~microtubule plus-end,	GO:0005515~protein binding,GO:0043014~alpha-tubulin binding,GO:0051010~microtubule plus-end binding,	IPR000626:Ubiquitin-like_dom,IPR000938:CAP-Gly_domain,IPR029071:Ubiquitin-like_domsf,IPR036859:CAP-Gly_dom_sf,IPR045172:TBCB_Ubl,				SM01052:CAP_GLY,	KW-0221~Differentiation,KW-0524~Neurogenesis,	KW-0206~Cytoskeleton,KW-0493~Microtubule,KW-0963~Cytoplasm,				KW-0143~Chaperone,KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Basic and acidic residues,DOMAIN:CAP-Gly,DOMAIN:Ubiquitin-like,MUTAGEN:S->A: Reduced phosphorylation by PAK1. Reduced microtubule polymerization and loss of phosphorylation by PAK1; when associated with A-128.,MUTAGEN:S->A: Reduced phosphorylation by PAK1. Reduced microtubule polymerization and loss of phosphorylation by PAK1; when associated with A-65.,REGION:Disordered,
TBCC	tubulin folding cofactor C(TBCC)	Homo sapiens			GO:0006457~protein folding,GO:0007021~tubulin complex assembly,GO:0007023~post-chaperonin tubulin folding pathway,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005874~microtubule,GO:0032391~photoreceptor connecting cilium,	GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0015631~tubulin binding,GO:0051087~chaperone binding,	IPR006599:CARP_motif,IPR012945:Tubulin-bd_cofactor_C_dom,IPR016098:CAP/MinC_C,IPR017901:C-CAP_CF_C-like,IPR027684:TBCC,IPR031925:TBCC_N,IPR038397:TBCC_N_sf,				SM00673:CARP,		KW-0963~Cytoplasm,				KW-0143~Chaperone,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:C-CAP/cofactor C-like,MUTAGEN:R->A: Inhibits stimulation of tubulin GTPase activity.,REGION:Disordered,
TPT1	tumor protein, translationally-controlled 1(TPT1)	Homo sapiens			GO:0006816~calcium ion transport,GO:0006874~cellular calcium ion homeostasis,GO:0009615~response to virus,GO:0019827~stem cell population maintenance,GO:0042981~regulation of apoptotic process,GO:0043066~negative regulation of apoptotic process,GO:1902230~negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage,GO:2000384~negative regulation of ectoderm development,	GO:0000922~spindle pole,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005771~multivesicular body,GO:0005829~cytosol,GO:0005881~cytoplasmic microtubule,GO:0070062~extracellular exosome,	GO:0003723~RNA binding,GO:0005509~calcium ion binding,GO:0005515~protein binding,	IPR011057:Mss4-like_sf,IPR011323:Mss4/transl-control_tumour,IPR018103:Translation_control_tumour_CS,IPR018105:Translational_control_tumour_p,IPR034737:TCTP,						KW-0963~Cytoplasm,			KW-0106~Calcium,		KW-0597~Phosphoprotein,	DOMAIN:TCTP,REGION:Required for reduction of TSC22D1 protein stability,
TUSC2	tumor suppressor 2, mitochondrial calcium regulator(TUSC2)	Homo sapiens			GO:0001779~natural killer cell differentiation,GO:0006909~phagocytosis,GO:0006954~inflammatory response,GO:0007049~cell cycle,GO:0032700~negative regulation of interleukin-17 production,GO:0032733~positive regulation of interleukin-10 production,GO:0048469~cell maturation,GO:0051881~regulation of mitochondrial membrane potential,GO:0070945~neutrophil mediated killing of gram-negative bacterium,GO:2000377~regulation of reactive oxygen species metabolic process,	GO:0005739~mitochondrion,	GO:0005515~protein binding,	IPR029393:FUS1,					KW-0131~Cell cycle,		KW-0043~Tumor suppressor,				KW-0449~Lipoprotein,KW-0519~Myristate,KW-0597~Phosphoprotein,	LIPID:N-myristoyl glycine,
TWF1	twinfilin actin binding protein 1(TWF1)	Homo sapiens			GO:0010591~regulation of lamellipodium assembly,GO:0010613~positive regulation of cardiac muscle hypertrophy,GO:0010976~positive regulation of neuron projection development,GO:0030042~actin filament depolymerization,GO:0030837~negative regulation of actin filament polymerization,GO:0042989~sequestering of actin monomers,GO:0043538~regulation of actin phosphorylation,GO:0051016~barbed-end actin filament capping,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005884~actin filament,GO:0005911~cell-cell junction,GO:0005925~focal adhesion,GO:0015629~actin cytoskeleton,GO:0030016~myofibril,GO:0030175~filopodium,GO:0032587~ruffle membrane,GO:0048471~perinuclear region of cytoplasm,	GO:0003779~actin binding,GO:0003785~actin monomer binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0005546~phosphatidylinositol-4,5-bisphosphate binding,GO:0045296~cadherin binding,GO:0051015~actin filament binding,	IPR002108:ADF-H,IPR028458:Twinfilin,IPR029006:ADF-H/Gelsolin-like_dom_sf,				SM00102:ADF,		KW-0206~Cytoskeleton,KW-0963~Cytoplasm,	KW-0225~Disease variant,	KW-0677~Repeat,		KW-0009~Actin-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:ADF-H,DOMAIN:ADF-H 1,DOMAIN:ADF-H 2,REGION:Disordered,
TWF2	twinfilin actin binding protein 2(TWF2)	Homo sapiens			GO:0010591~regulation of lamellipodium assembly,GO:0010592~positive regulation of lamellipodium assembly,GO:0010976~positive regulation of neuron projection development,GO:0030030~cell projection organization,GO:0030042~actin filament depolymerization,GO:0030837~negative regulation of actin filament polymerization,GO:0032532~regulation of microvillus length,GO:0032956~regulation of actin cytoskeleton organization,GO:0042989~sequestering of actin monomers,GO:0045773~positive regulation of axon extension,GO:0051016~barbed-end actin filament capping,GO:0071300~cellular response to retinoic acid,GO:0071363~cellular response to growth factor stimulus,	GO:0005737~cytoplasm,GO:0005856~cytoskeleton,GO:0005884~actin filament,GO:0030016~myofibril,GO:0030027~lamellipodium,GO:0030175~filopodium,GO:0030426~growth cone,GO:0032420~stereocilium,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,	GO:0003723~RNA binding,GO:0003779~actin binding,GO:0003785~actin monomer binding,GO:0005080~protein kinase C binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0005546~phosphatidylinositol-4,5-bisphosphate binding,GO:0045296~cadherin binding,GO:0051015~actin filament binding,	IPR002108:ADF-H,IPR028458:Twinfilin,IPR029006:ADF-H/Gelsolin-like_dom_sf,				SM00102:ADF,	KW-0970~Cilium biogenesis/degradation,	KW-0206~Cytoskeleton,KW-0963~Cytoplasm,KW-0966~Cell projection,		KW-0677~Repeat,		KW-0009~Actin-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:ADF-H,DOMAIN:ADF-H 1,DOMAIN:ADF-H 2,REGION:Disordered,
YWHAE	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein epsilon(YWHAE)	Homo sapiens			GO:0000165~MAPK cascade,GO:0001764~neuron migration,GO:0002753~cytoplasmic pattern recognition receptor signaling pathway,GO:0003064~regulation of heart rate by hormone,GO:0006605~protein targeting,GO:0007165~signal transduction,GO:0007346~regulation of mitotic cell cycle,GO:0021762~substantia nigra development,GO:0021766~hippocampus development,GO:0021987~cerebral cortex development,GO:0034504~protein localization to nucleus,GO:0034605~cellular response to heat,GO:0035308~negative regulation of protein dephosphorylation,GO:0035556~intracellular signal transduction,GO:0046827~positive regulation of protein export from nucleus,GO:0051480~regulation of cytosolic calcium ion concentration,GO:0060306~regulation of membrane repolarization,GO:0086013~membrane repolarization during cardiac muscle cell action potential,GO:0086091~regulation of heart rate by cardiac conduction,GO:1901016~regulation of potassium ion transmembrane transporter activity,GO:1901020~negative regulation of calcium ion transmembrane transporter activity,GO:1902309~negative regulation of peptidyl-serine dephosphorylation,GO:1905913~negative regulation of calcium ion export from cell,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0016020~membrane,GO:0031966~mitochondrial membrane,GO:0042470~melanosome,GO:0070062~extracellular exosome,	GO:0003723~RNA binding,GO:0005246~calcium channel regulator activity,GO:0005515~protein binding,GO:0015459~potassium channel regulator activity,GO:0019899~enzyme binding,GO:0019903~protein phosphatase binding,GO:0019904~protein domain specific binding,GO:0023026~MHC class II protein complex binding,GO:0031625~ubiquitin protein ligase binding,GO:0035591~signaling adaptor activity,GO:0042802~identical protein binding,GO:0042826~histone deacetylase binding,GO:0044325~ion channel binding,GO:0045296~cadherin binding,GO:0046982~protein heterodimerization activity,GO:0050815~phosphoserine binding,GO:0051219~phosphoprotein binding,GO:0097110~scaffold protein binding,	IPR000308:14-3-3,IPR023409:14-3-3_CS,IPR023410:14-3-3_domain,IPR036815:14-3-3_dom_sf,	hsa04110:Cell cycle,hsa04114:Oocyte meiosis,hsa04151:PI3K-Akt signaling pathway,hsa04390:Hippo signaling pathway,hsa04621:NOD-like receptor signaling pathway,hsa04722:Neurotrophin signaling pathway,hsa05160:Hepatitis C,hsa05203:Viral carcinogenesis,		PIRSF000868:14-3-3,	SM00101:14_3_3,	KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0963~Cytoplasm,					KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:14-3-3,MUTAGEN:Q->A: Complete loss of cleavage by poliovirus protease 3C.,REGION:Disordered,SITE:(Microbial infection) Cleavage; by poliovirus protease 3C,SITE:Interaction with phosphoserine on interacting protein,
YWHAQ	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein theta(YWHAQ)	Homo sapiens		h_g2Pathway:Cell Cycle: G2/M Checkpoint,	GO:0006605~protein targeting,GO:0007165~signal transduction,GO:0007264~small GTPase mediated signal transduction,GO:0021762~substantia nigra development,GO:0034766~negative regulation of ion transmembrane transport,GO:0045892~negative regulation of transcription, DNA-templated,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005925~focal adhesion,GO:0016020~membrane,GO:0032991~macromolecular complex,GO:0045202~synapse,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0019904~protein domain specific binding,GO:0042802~identical protein binding,GO:0044325~ion channel binding,GO:0071889~14-3-3 protein binding,	IPR000308:14-3-3,IPR023409:14-3-3_CS,IPR023410:14-3-3_domain,IPR036815:14-3-3_dom_sf,IPR042584:14-3-3_theta,	hsa04110:Cell cycle,hsa04114:Oocyte meiosis,hsa04151:PI3K-Akt signaling pathway,hsa04390:Hippo signaling pathway,hsa05160:Hepatitis C,hsa05161:Hepatitis B,hsa05203:Viral carcinogenesis,		PIRSF000868:14-3-3,	SM00101:14_3_3,		KW-0963~Cytoplasm,					KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-0944~Nitration,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:14-3-3,SITE:Interaction with phosphoserine on interacting protein,
YWHAZ	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta(YWHAZ)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006468~protein phosphorylation,GO:0007165~signal transduction,GO:0016310~phosphorylation,GO:0042149~cellular response to glucose starvation,GO:0043066~negative regulation of apoptotic process,GO:0045824~negative regulation of innate immune response,GO:0051683~establishment of Golgi localization,GO:0070372~regulation of ERK1 and ERK2 cascade,GO:0090128~regulation of synapse maturation,GO:0090168~Golgi reassembly,GO:1900181~negative regulation of protein localization to nucleus,GO:1904262~negative regulation of TORC1 signaling,	GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005925~focal adhesion,GO:0031982~vesicle,GO:0042470~melanosome,GO:0070062~extracellular exosome,GO:0072562~blood microparticle,GO:0098978~glutamatergic synapse,	GO:0003723~RNA binding,GO:0004497~monooxygenase activity,GO:0005515~protein binding,GO:0016301~kinase activity,GO:0019901~protein kinase binding,GO:0031625~ubiquitin protein ligase binding,GO:0042802~identical protein binding,GO:0044325~ion channel binding,GO:0045296~cadherin binding,GO:0050815~phosphoserine binding,	IPR000308:14-3-3,IPR023409:14-3-3_CS,IPR023410:14-3-3_domain,IPR036815:14-3-3_dom_sf,	hsa04110:Cell cycle,hsa04114:Oocyte meiosis,hsa04151:PI3K-Akt signaling pathway,hsa04390:Hippo signaling pathway,hsa05160:Hepatitis C,hsa05161:Hepatitis B,hsa05203:Viral carcinogenesis,		PIRSF000868:14-3-3,	SM00101:14_3_3,	KW-0945~Host-virus interaction,	KW-0963~Cytoplasm,	KW-0225~Disease variant,	KW-0175~Coiled coil,		KW-0418~Kinase,KW-0503~Monooxygenase,KW-0560~Oxidoreductase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:14-3-3,MUTAGEN:K->E: Loss of interaction with NOXA1.,MUTAGEN:RSSWR->ASSWA: Abolishes lamellipodia formation and induces filopodia formation.,MUTAGEN:S->A: Loss of sphingosine-activated PKA phosphorylation. Promotes homodimerization and heterodimerization with YWHAE. Enhanced transcriptional activity of P53.,MUTAGEN:S->A: On DNA damage, loss of MAPK8-mediated phosphorylation. Loss of binding ABL1. Attenuates ABL1-mediated apoptosis. No loss of interaction with BAX under stress conditions. Inhibits translocation of BAX to mitochondria.,MUTAGEN:S->E: Loss of homodimerization. Reduced dimerization with YWHAE. Significantly reduced interaction with P53. No enhancement of P53 transcriptional activity.,MUTAGEN:T->A: Loss of phosphorylation by CK1.,SITE:Interaction with phosphoserine on interacting protein,
TDP2	tyrosyl-DNA phosphodiesterase 2(TDP2)	Homo sapiens			GO:0006302~double-strand break repair,GO:0007166~cell surface receptor signaling pathway,GO:0045892~negative regulation of transcription, DNA-templated,GO:0048666~neuron development,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0016235~aggresome,GO:0016604~nuclear body,GO:0016605~PML body,	GO:0000287~magnesium ion binding,GO:0003697~single-stranded DNA binding,GO:0003714~transcription corepressor activity,GO:0003824~catalytic activity,GO:0004518~nuclease activity,GO:0005515~protein binding,GO:0030145~manganese ion binding,GO:0036317~tyrosyl-RNA phosphodiesterase activity,GO:0070260~5'-tyrosyl-DNA phosphodiesterase activity,	IPR005135:Endo/exonuclease/phosphatase,IPR009060:UBA-like_sf,IPR036691:Endo/exonu/phosph_ase_sf,		616949~Spinocerebellar ataxia, autosomal recessive 23,			KW-0227~DNA damage,KW-0234~DNA repair,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0523~Neurodegeneration,KW-0950~Spinocerebellar ataxia,KW-0991~Intellectual disability,	KW-0732~Signal,	KW-0460~Magnesium,KW-0479~Metal-binding,	KW-0378~Hydrolase,KW-0540~Nuclease,KW-0675~Receptor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	ACT_SITE:Proton donor/acceptor,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Endonuclease/exonuclease/phosphatase,MUTAGEN:D->A: Loss of phosphodiesterase activity.,MUTAGEN:D->H,L,M: Loss of phosphodiesterase activity.,MUTAGEN:D->N: Strongly decreased phosphodiesterase activity.,MUTAGEN:E->A: Loss of phosphodiesterase activity.,MUTAGEN:H->A: Loss of phosphodiesterase activity.,MUTAGEN:H->Q: Loss of phosphodiesterase activity.,MUTAGEN:L->A,F,W: Decreased phosphodiesterase activity.,MUTAGEN:N->A: Strongly reduced phosphodiesterase activity.,MUTAGEN:R->A,K: Loss of phosphodiesterase activity.,MUTAGEN:T->A: Abolishes function, but retains ability to interact with SMAD3; when associated with A-88.,MUTAGEN:T->A: Abolishes function, but retains ability to interact with SMAD3; when associated with A-92.,MUTAGEN:Y->F,W: Strongly decreased phosphodiesterase activity.,REGION:Disordered,REGION:Interaction with 5' end of substrate DNA,SITE:Interaction with 5' end of substrate DNA,
UBQLN1	ubiquilin 1(UBQLN1)	Homo sapiens		h_gabaPathway:Gamma-aminobutyric Acid Receptor Life Cycle,	GO:0000045~autophagosome assembly,GO:0016236~macroautophagy,GO:0016241~regulation of macroautophagy,GO:0030433~ubiquitin-dependent ERAD pathway,GO:0031396~regulation of protein ubiquitination,GO:0031398~positive regulation of protein ubiquitination,GO:0032434~regulation of proteasomal ubiquitin-dependent protein catabolic process,GO:0033554~cellular response to stress,GO:0034140~negative regulation of toll-like receptor 3 signaling pathway,GO:0034976~response to endoplasmic reticulum stress,GO:0035973~aggrephagy,GO:0036503~ERAD pathway,GO:0071456~cellular response to hypoxia,GO:0097352~autophagosome maturation,GO:1901340~negative regulation of store-operated calcium channel activity,GO:1902175~regulation of oxidative stress-induced intrinsic apoptotic signaling pathway,GO:1903071~positive regulation of ER-associated ubiquitin-dependent protein catabolic process,GO:1904294~positive regulation of ERAD pathway,	GO:0000502~proteasome complex,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005776~autophagosome,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016235~aggresome,GO:0031410~cytoplasmic vesicle,GO:0032991~macromolecular complex,GO:0048471~perinuclear region of cytoplasm,	GO:0005515~protein binding,GO:0019900~kinase binding,GO:0031593~polyubiquitin binding,GO:0042802~identical protein binding,	IPR000626:Ubiquitin-like_dom,IPR006636:STI1_HS-bd,IPR009060:UBA-like_sf,IPR015496:Ubiquilin,IPR015940:UBA,IPR029071:Ubiquitin-like_domsf,	hsa04141:Protein processing in endoplasmic reticulum,hsa05014:Amyotrophic lateral sclerosis,			SM00165:UBA,SM00213:UBQ,SM00727:STI1,	KW-0072~Autophagy,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0539~Nucleus,KW-0647~Proteasome,KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,					KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,DOMAIN:STI1,DOMAIN:STI1 1,DOMAIN:STI1 2,DOMAIN:STI1 3,DOMAIN:STI1 4,DOMAIN:UBA,DOMAIN:Ubiquitin-like,REGION:Disordered,REGION:Interaction with UBXN4,
UQCRC1	ubiquinol-cytochrome c reductase core protein 1(UQCRC1)	Homo sapiens		h_etcPathway:Electron Transport Reaction in Mitochondria,	GO:0006119~oxidative phosphorylation,GO:0006122~mitochondrial electron transport, ubiquinol to cytochrome c,GO:0009060~aerobic respiration,GO:0014823~response to activity,GO:0043279~response to alkaloid,GO:0045333~cellular respiration,GO:1902600~hydrogen ion transmembrane transport,	GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0005746~mitochondrial respiratory chain,GO:0005750~mitochondrial respiratory chain complex III,	GO:0005515~protein binding,GO:0008121~ubiquinol-cytochrome-c reductase activity,GO:0031625~ubiquitin protein ligase binding,GO:0044877~macromolecular complex binding,GO:0046872~metal ion binding,	IPR007863:Peptidase_M16_C,IPR011249:Metalloenz_LuxS/M16,IPR011765:Pept_M16_N,	hsa00190:Oxidative phosphorylation,hsa01100:Metabolic pathways,hsa04260:Cardiac muscle contraction,hsa04714:Thermogenesis,hsa04932:Non-alcoholic fatty liver disease,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05415:Diabetic cardiomyopathy,	619279~Parkinsonism with polyneuropathy,			KW-0249~Electron transport,KW-0679~Respiratory chain,KW-0813~Transport,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,	KW-0225~Disease variant,KW-0622~Neuropathy,KW-0908~Parkinsonism,	KW-0809~Transit peptide,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	TRANSIT:Mitochondrion,
UQCR10	ubiquinol-cytochrome c reductase, complex III subunit X(UQCR10)	Homo sapiens			GO:0006122~mitochondrial electron transport, ubiquinol to cytochrome c,GO:0045333~cellular respiration,GO:1902600~hydrogen ion transmembrane transport,	GO:0005743~mitochondrial inner membrane,GO:0005750~mitochondrial respiratory chain complex III,	GO:0005515~protein binding,GO:0008121~ubiquinol-cytochrome-c reductase activity,	IPR008027:QCR9,IPR036656:QCR9_sf,	hsa00190:Oxidative phosphorylation,hsa01100:Metabolic pathways,hsa04260:Cardiac muscle contraction,hsa04714:Thermogenesis,hsa04932:Non-alcoholic fatty liver disease,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05415:Diabetic cardiomyopathy,				KW-0249~Electron transport,KW-0679~Respiratory chain,KW-0813~Transport,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				TOPO_DOM:Mitochondrial intermembrane,TOPO_DOM:Mitochondrial matrix,TRANSMEM:Helical,
UQCR11	ubiquinol-cytochrome c reductase, complex III subunit XI(UQCR11)	Homo sapiens			GO:0006091~generation of precursor metabolites and energy,GO:0006122~mitochondrial electron transport, ubiquinol to cytochrome c,GO:0045333~cellular respiration,	GO:0005743~mitochondrial inner membrane,GO:0005750~mitochondrial respiratory chain complex III,	GO:0009055~electron carrier activity,	IPR015089:UQCR,IPR029027:Single_a-helix_sf,	hsa00190:Oxidative phosphorylation,hsa01100:Metabolic pathways,hsa04260:Cardiac muscle contraction,hsa04714:Thermogenesis,hsa04932:Non-alcoholic fatty liver disease,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05415:Diabetic cardiomyopathy,				KW-0249~Electron transport,KW-0679~Respiratory chain,KW-0813~Transport,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				TOPO_DOM:Mitochondrial intermembrane,TOPO_DOM:Mitochondrial matrix,TRANSMEM:Helical,
UBA52	ubiquitin A-52 residue ribosomal protein fusion product 1(UBA52)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0006412~translation,GO:0016567~protein ubiquitination,GO:0019941~modification-dependent protein catabolic process,GO:0036211~protein modification process,	GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005741~mitochondrial outer membrane,GO:0005765~lysosomal membrane,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0005840~ribosome,GO:0005886~plasma membrane,GO:0010008~endosome membrane,GO:0022625~cytosolic large ribosomal subunit,GO:0022626~cytosolic ribosome,GO:0022627~cytosolic small ribosomal subunit,GO:0030666~endocytic vesicle membrane,GO:0031982~vesicle,GO:0070062~extracellular exosome,GO:1990904~ribonucleoprotein complex,	GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,GO:0031386~protein tag,GO:0031625~ubiquitin protein ligase binding,	IPR000626:Ubiquitin-like_dom,IPR001975:Ribosomal_eL40_dom,IPR011332:Ribosomal_zn-bd,IPR019954:Ubiquitin_CS,IPR019956:Ubiquitin_dom,IPR029071:Ubiquitin-like_domsf,IPR038587:Ribosomal_eL40_sf,	hsa03010:Ribosome,hsa04120:Ubiquitin mediated proteolysis,hsa04137:Mitophagy - animal,hsa04140:Autophagy - animal,hsa05012:Parkinson disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05131:Shigellosis,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05171:Coronavirus disease - COVID-19,			SM00213:UBQ,SM01377:Ribosomal_L40e,		KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,	KW-0013~ADP-ribosylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Gly-Lys) (interchain with K-? in acceptor proteins),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:Ubiquitin-like,MUTAGEN:G->A: Loss of ADP-ribosylation.,MUTAGEN:H->G: Loss of DTX3L-mediated polyubiquitination of histone H3 and H4.,MUTAGEN:K->R: Abolishes HLTF-mediated polyubiquitination of PCNA.,MUTAGEN:K->R: No effect on HLTF-mediated polyubiquitination of PCNA.,MUTAGEN:R->G: No effect on ADP-ribosylation.,MUTAGEN:R->K: No effect on ADP-ribosylation, when associated with K-72.,MUTAGEN:R->K: No effect on ADP-ribosylation, when associated with K-74.,MUTAGEN:S->A: Prevents phosphorylation in case of mitophagy. Impaired translocation of PRKN to mitochondria.,MUTAGEN:S->D: Phosphomimetic mutant that binds and activates PRKN.,MUTAGEN:S->G: Phosphomimetic mutant that can recruit PRKN to mitochondria.,SITE:Essential for function,SITE:Interacts with activating enzyme,
UBAP1	ubiquitin associated protein 1(UBAP1)	Homo sapiens			GO:0036258~multivesicular body assembly,GO:0043162~ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway,GO:0043328~protein targeting to vacuole involved in ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway,GO:0090148~membrane fission,	GO:0000813~ESCRT I complex,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0010008~endosome membrane,GO:0043231~intracellular membrane-bounded organelle,	GO:0005515~protein binding,GO:0043130~ubiquitin binding,	IPR009060:UBA-like_sf,IPR015940:UBA,IPR023340:UMA,IPR038870:UBAP1,IPR042575:UBAP1_C,		618418~Spastic paraplegia 80, autosomal dominant,			KW-0653~Protein transport,KW-0813~Transport,	KW-0963~Cytoplasm,KW-0967~Endosome,	KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0890~Hereditary spastic paraplegia,	KW-0677~Repeat,			KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:UBA,DOMAIN:UBA 1,DOMAIN:UBA 2,DOMAIN:UMA,MUTAGEN:E->G: Abolishes association with the ESCRT-I complex.,MUTAGEN:F->A: Strongly reduced interaction with ubiquitinated proteins.,MUTAGEN:F->S: Abolished interaction with PTPN23.,MUTAGEN:L->A: Does not affect interaction with PTPN23.,MUTAGEN:LDD->AAA: Abolishes association with the ESCRT-I complex.,MUTAGEN:P->A: Abolishes association with the ESCRT-I complex.,MUTAGEN:P->A: Does not affect interaction with PTPN23.,MUTAGEN:VPF->AAA: Abolishes association with the ESCRT-I complex.,MUTAGEN:Y->A: Strongly reduced interaction with ubiquitinated proteins.,REGION:Disordered,REGION:Interaction with ESCRT-I,REGION:Interaction with PTPN23,
UBE2A	ubiquitin conjugating enzyme E2 A(UBE2A)	Homo sapiens			GO:0000086~G2/M transition of mitotic cell cycle,GO:0000209~protein polyubiquitination,GO:0006281~DNA repair,GO:0006301~postreplication repair,GO:0006338~chromatin remodeling,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0009411~response to UV,GO:0032446~protein modification by small protein conjugation,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0070936~protein K48-linked ubiquitination,GO:0070979~protein K11-linked ubiquitination,	GO:0000785~chromatin,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0033503~HULC complex,	GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0019787~ubiquitin-like protein transferase activity,GO:0031625~ubiquitin protein ligase binding,GO:0043130~ubiquitin binding,GO:0061631~ubiquitin conjugating enzyme activity,	IPR000608:UBQ-conjugat_E2,IPR016135:UBQ-conjugating_enzyme/RWD,IPR023313:UBQ-conjugating_AS,	hsa04120:Ubiquitin mediated proteolysis,	300860~Intellectual developmental disorder, X-linked syndromic, Nascimento type,		SM00212:UBCc,	KW-0227~DNA damage,KW-0234~DNA repair,KW-0833~Ubl conjugation pathway,		KW-0225~Disease variant,KW-0991~Intellectual disability,		KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0156~Chromatin regulator,KW-0808~Transferase,	KW-0597~Phosphoprotein,	ACT_SITE:Glycyl thioester intermediate,COMPBIAS:Polar residues,DOMAIN:UBC core,REGION:Disordered,
UBE2B	ubiquitin conjugating enzyme E2 B(UBE2B)	Homo sapiens			GO:0000209~protein polyubiquitination,GO:0001701~in utero embryonic development,GO:0006281~DNA repair,GO:0006301~postreplication repair,GO:0006325~chromatin organization,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0006915~apoptotic process,GO:0006974~cellular response to DNA damage stimulus,GO:0007283~spermatogenesis,GO:0007288~sperm axoneme assembly,GO:0009410~response to xenobiotic stimulus,GO:0009411~response to UV,GO:0010845~positive regulation of reciprocal meiotic recombination,GO:0016567~protein ubiquitination,GO:0032446~protein modification by small protein conjugation,GO:0035234~ectopic germ cell programmed cell death,GO:0043066~negative regulation of apoptotic process,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0043951~negative regulation of cAMP-mediated signaling,GO:0045141~meiotic telomere clustering,GO:0050821~protein stabilization,GO:0051026~chiasma assembly,GO:0051093~negative regulation of developmental process,GO:0051865~protein autoubiquitination,GO:0070193~synaptonemal complex organization,GO:0070534~protein K63-linked ubiquitination,GO:0070936~protein K48-linked ubiquitination,GO:0070979~protein K11-linked ubiquitination,GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:1901874~negative regulation of post-translational protein modification,GO:2000242~negative regulation of reproductive process,	GO:0000785~chromatin,GO:0001741~XY body,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005657~replication fork,GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0033503~HULC complex,	GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0019787~ubiquitin-like protein transferase activity,GO:0031625~ubiquitin protein ligase binding,GO:0061631~ubiquitin conjugating enzyme activity,	IPR000608:UBQ-conjugat_E2,IPR016135:UBQ-conjugating_enzyme/RWD,IPR023313:UBQ-conjugating_AS,	hsa04120:Ubiquitin mediated proteolysis,			SM00212:UBCc,	KW-0227~DNA damage,KW-0234~DNA repair,KW-0833~Ubl conjugation pathway,	KW-0472~Membrane,KW-0539~Nucleus,KW-1003~Cell membrane,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0808~Transferase,		ACT_SITE:Glycyl thioester intermediate,DOMAIN:UBC core,REGION:Disordered,
UBE2D2	ubiquitin conjugating enzyme E2 D2(UBE2D2)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0000209~protein polyubiquitination,GO:0006281~DNA repair,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0006513~protein monoubiquitination,GO:0006915~apoptotic process,GO:0016567~protein ubiquitination,GO:0030514~negative regulation of BMP signaling pathway,GO:0032446~protein modification by small protein conjugation,GO:0036211~protein modification process,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0051865~protein autoubiquitination,GO:0070936~protein K48-linked ubiquitination,GO:0070979~protein K11-linked ubiquitination,GO:0085020~protein K6-linked ubiquitination,GO:1903955~positive regulation of protein targeting to mitochondrion,	GO:0000151~ubiquitin ligase complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0010008~endosome membrane,GO:0032991~macromolecular complex,GO:0070062~extracellular exosome,	GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0019787~ubiquitin-like protein transferase activity,GO:0031625~ubiquitin protein ligase binding,GO:0061630~ubiquitin protein ligase activity,GO:0061631~ubiquitin conjugating enzyme activity,	IPR000608:UBQ-conjugat_E2,IPR016135:UBQ-conjugating_enzyme/RWD,IPR023313:UBQ-conjugating_AS,	hsa03083:Polycomb repressive complex,hsa04120:Ubiquitin mediated proteolysis,hsa04141:Protein processing in endoplasmic reticulum,hsa05131:Shigellosis,			SM00212:UBCc,	KW-0053~Apoptosis,KW-0227~DNA damage,KW-0234~DNA repair,KW-0833~Ubl conjugation pathway,	KW-0472~Membrane,KW-0967~Endosome,KW-1003~Cell membrane,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0808~Transferase,	KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	ACT_SITE:Glycyl thioester intermediate,DOMAIN:UBC core,MUTAGEN:C->A: Catalytically inactive. Loss of ability to promote FBXW2-mediated GCM1 ubiquitination. Inhibition of TNF-alpha-induced degradation of NFKBIA.,MUTAGEN:C->A: Loss of function.,MUTAGEN:D->E,P: Has intermediate lysine reactivity.,MUTAGEN:D->H: Strongly impairs lysine reactivity but retains some ability to transfer ubiquitin to BRCA1.,MUTAGEN:D->K: Abolishes affect lysine reactivity.,MUTAGEN:D->N: Does not affect lysine reactivity.,MUTAGEN:K->A,E: Strongly reduced interaction with CNTO4.,MUTAGEN:N->S: Activity is restricted HECT-type and not RING-containing E3 ubiquitin-protein ligases. Exhibits ubiquitin transfer with ARIH1 and PRKN.,REGION:Disordered,
UBE2I	ubiquitin conjugating enzyme E2 I(UBE2I)	Homo sapiens		h_ctbp1Pathway:SUMOylation as a mechanism to modulate CtBP-dependent gene responses,h_eradPathway:ERï¿½associated degradation (ERAD) Pathway,h_sumoPathway:Basic Mechanisms of SUMOylation,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0007059~chromosome segregation,GO:0007084~mitotic nuclear envelope reassembly,GO:0016925~protein sumoylation,GO:0030335~positive regulation of cell migration,GO:0032446~protein modification by small protein conjugation,GO:0036211~protein modification process,GO:0045892~negative regulation of transcription, DNA-templated,GO:0051168~nuclear export,GO:0051301~cell division,GO:1903755~positive regulation of SUMO transferase activity,	GO:0000795~synaptonemal complex,GO:0005634~nucleus,GO:0005635~nuclear envelope,GO:0005643~nuclear pore,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016605~PML body,GO:0048471~perinuclear region of cytoplasm,GO:1990234~transferase complex,	GO:0001221~transcription cofactor binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008134~transcription factor binding,GO:0019787~ubiquitin-like protein transferase activity,GO:0019789~SUMO transferase activity,GO:0019899~enzyme binding,GO:0044388~small protein activating enzyme binding,GO:0061656~SUMO conjugating enzyme activity,GO:0071535~RING-like zinc finger domain binding,	IPR000608:UBQ-conjugat_E2,IPR016135:UBQ-conjugating_enzyme/RWD,IPR023313:UBQ-conjugating_AS,	hsa03013:Nucleocytoplasmic transport,hsa04064:NF-kappa B signaling pathway,hsa04120:Ubiquitin mediated proteolysis,hsa05206:MicroRNAs in cancer,			SM00212:UBCc,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0159~Chromosome partition,KW-0498~Mitosis,KW-0833~Ubl conjugation pathway,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	ACT_SITE:Glycyl thioester intermediate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin); alternate,DOMAIN:UBC core,MUTAGEN:C->S: Loss of enhancement of sumoylation by RWDD3. No effect on RWDD3 protein levels.,MUTAGEN:D->A: Impairs catalytic activity.,MUTAGEN:D->S: No effect on catalytic activity.,MUTAGEN:DK->AA: Impairs catalytic activity.,MUTAGEN:E->A: Slightly impairs binding to RANBP2.,MUTAGEN:F->A: Impairs binding to RANBP2.,MUTAGEN:K->A: Impairs binding to RANBP2.,MUTAGEN:K->A: Slightly impairs binding to RANBP2.,MUTAGEN:L->A: Impairs binding to RANBP2.,MUTAGEN:N->Q: Impairs catalytic activity.,MUTAGEN:R->A: Slightly impairs binding to RANBP2.,MUTAGEN:RK->AA: Impairs binding to SUMO1 and catalytic activity.,MUTAGEN:V->A: Impairs binding to RANBP2.,MUTAGEN:Y->A: Impairs catalytic activity.,REGION:Disordered,REGION:Interaction with SUMO1,SITE:Interaction with RANBP2,SITE:Substrate binding,
UBE2J2	ubiquitin conjugating enzyme E2 J2(UBE2J2)	Homo sapiens			GO:0000209~protein polyubiquitination,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0006986~response to unfolded protein,GO:0030433~ubiquitin-dependent ERAD pathway,GO:0036503~ERAD pathway,GO:0085020~protein K6-linked ubiquitination,GO:1903955~positive regulation of protein targeting to mitochondrion,	GO:0000151~ubiquitin ligase complex,GO:0005634~nucleus,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0016020~membrane,	GO:0005515~protein binding,GO:0005524~ATP binding,GO:0031625~ubiquitin protein ligase binding,GO:0061631~ubiquitin conjugating enzyme activity,	IPR000608:UBQ-conjugat_E2,IPR016135:UBQ-conjugating_enzyme/RWD,	hsa04120:Ubiquitin mediated proteolysis,hsa04141:Protein processing in endoplasmic reticulum,hsa05012:Parkinson disease,hsa05022:Pathways of neurodegeneration - multiple diseases,			SM00212:UBCc,	KW-0833~Ubl conjugation pathway,KW-0834~Unfolded protein response,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0808~Transferase,	KW-0832~Ubl conjugation,	ACT_SITE:Glycyl thioester intermediate,COMPBIAS:Polar residues,DOMAIN:UBC core,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,TRANSMEM:Helical; Anchor for type IV membrane protein,
UBE2L3	ubiquitin conjugating enzyme E2 L3(UBE2L3)	Homo sapiens		h_parkinPathway:Role of Parkin in the Ubiquitin-Proteasomal Pathway,	GO:0000209~protein polyubiquitination,GO:0006355~regulation of transcription, DNA-templated,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0008283~cell proliferation,GO:0016567~protein ubiquitination,GO:0031398~positive regulation of protein ubiquitination,GO:0032446~protein modification by small protein conjugation,GO:0036211~protein modification process,GO:0044770~cell cycle phase transition,GO:0045893~positive regulation of transcription, DNA-templated,GO:0051443~positive regulation of ubiquitin-protein transferase activity,GO:0070979~protein K11-linked ubiquitination,GO:0071383~cellular response to steroid hormone stimulus,GO:0071385~cellular response to glucocorticoid stimulus,GO:1903955~positive regulation of protein targeting to mitochondrion,	GO:0000151~ubiquitin ligase complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0003713~transcription coactivator activity,GO:0003723~RNA binding,GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0019787~ubiquitin-like protein transferase activity,GO:0019899~enzyme binding,GO:0031625~ubiquitin protein ligase binding,GO:0061631~ubiquitin conjugating enzyme activity,GO:0097027~ubiquitin-protein transferase activator activity,	IPR000608:UBQ-conjugat_E2,IPR016135:UBQ-conjugating_enzyme/RWD,IPR023313:UBQ-conjugating_AS,	hsa04120:Ubiquitin mediated proteolysis,hsa05012:Parkinson disease,hsa05022:Pathways of neurodegeneration - multiple diseases,			SM00212:UBCc,	KW-0804~Transcription,KW-0805~Transcription regulation,KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0808~Transferase,	KW-0007~Acetylation,KW-0832~Ubl conjugation,	ACT_SITE:Glycyl thioester intermediate,DOMAIN:UBC core,MUTAGEN:C->S: Loss of catalytic activity. Prevents ubiquitin-dependent proteasomal degradation of UBE2L3.,MUTAGEN:E->R: Decrease in autoubiquitination.,MUTAGEN:F->A: Decrease in autoubiquitination.,MUTAGEN:H->D: Does not convert into a lysine reactive E2; when associated with D-88.,MUTAGEN:K->E: Decrease in autoubiquitination.,MUTAGEN:K->E: Marked decrease in autoubiquitination.,MUTAGEN:P->D: Does not convert into a lysine reactive E2; when associated with D-119.,
UBE2V2	ubiquitin conjugating enzyme E2 V2(UBE2V2)	Homo sapiens			GO:0000209~protein polyubiquitination,GO:0000729~DNA double-strand break processing,GO:0006282~regulation of DNA repair,GO:0006301~postreplication repair,GO:0016567~protein ubiquitination,GO:0042275~error-free postreplication DNA repair,GO:0070534~protein K63-linked ubiquitination,GO:1902523~positive regulation of protein K63-linked ubiquitination,GO:2000781~positive regulation of double-strand break repair,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0031372~UBC13-MMS2 complex,GO:0070062~extracellular exosome,	GO:0005515~protein binding,	IPR000608:UBQ-conjugat_E2,IPR016135:UBQ-conjugating_enzyme/RWD,	hsa05131:Shigellosis,			SM00212:UBCc,	KW-0833~Ubl conjugation pathway,						KW-0007~Acetylation,	DOMAIN:UBC core,
UFM1	ubiquitin fold modifier 1(UFM1)	Homo sapiens			GO:0007420~brain development,GO:0033146~regulation of intracellular estrogen receptor signaling pathway,GO:0034976~response to endoplasmic reticulum stress,GO:0042308~negative regulation of protein import into nucleus,GO:0043066~negative regulation of apoptotic process,GO:0061709~reticulophagy,GO:0071569~protein ufmylation,GO:1990592~protein K69-linked ufmylation,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,	GO:0005515~protein binding,	IPR005375:UFM1,IPR029071:Ubiquitin-like_domsf,		617899~Leukodystrophy, hypomyelinating, 14,	PIRSF038027:Ubiquitin-like_Ufm1,		KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-1026~Leukodystrophy,				KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Gly-Lys) (interchain with K-? in acceptor proteins),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in UFM1),MUTAGEN:A->F,Q: Abolished ability to be activated by UBA5.,MUTAGEN:E->A: Abolished ability to be activated by UBA5.,MUTAGEN:G->A: Confers resistance to cleavage.,MUTAGEN:L->A: Abolished ability to be activated by UBA5.,MUTAGEN:R->A: Slightly reduced interaction with UFM1.,PROPEP:Removed in mature form,
UIMC1	ubiquitin interaction motif containing 1(UIMC1)	Homo sapiens			GO:0006282~regulation of DNA repair,GO:0006302~double-strand break repair,GO:0006325~chromatin organization,GO:0007095~mitotic G2 DNA damage checkpoint,GO:0010212~response to ionizing radiation,GO:0044818~mitotic G2/M transition checkpoint,GO:0045739~positive regulation of DNA repair,GO:0045892~negative regulation of transcription, DNA-templated,GO:0070537~histone H2A K63-linked deubiquitination,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0016604~nuclear body,GO:0035861~site of double-strand break,GO:0070531~BRCA1-A complex,	GO:0003677~DNA binding,GO:0005515~protein binding,GO:0042393~histone binding,GO:0046872~metal ion binding,GO:0061649~ubiquitinated histone binding,GO:0070530~K63-linked polyubiquitin binding,	IPR003903:UIM_dom,IPR006642:Rad18_UBZ4,IPR038868:RAP80,IPR040714:RAP80_UIM,	hsa03440:Homologous recombination,			SM00726:UIM,	KW-0227~DNA damage,KW-0234~DNA repair,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0156~Chromatin regulator,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:RAP80 N-terminal,DOMAIN:UIM 1,DOMAIN:UIM 2,MOTIF:LR motif,MUTAGEN:A->G,S: Impairs localization to DNA damages sites; when associated with A-92; S-113 and A-117.,MUTAGEN:A->G,S: Impairs ubiquitin-binding and localization to DNA damages sites; when associated with S-88; A-92 and A-117.,MUTAGEN:C->A: Abolishes interaction with histone monoubiquitinated H2B without affecting the interaction with H2A.,MUTAGEN:K->A: Does not affect symoylation; when associated with A-19; A-31; A-52 and A-61.,MUTAGEN:K->A: Does not affect symoylation; when associated with A-9; A-19; A-31 and A-52.,MUTAGEN:K->A: Does not affect symoylation; when associated with A-9; A-19; A-31 and A-61.,MUTAGEN:K->A: Does not affect symoylation; when associated with A-9; A-19; A-52 and A-61.,MUTAGEN:K->A: Does not affect symoylation; when associated with A-9; A-31; A-52 and A-61.,MUTAGEN:Missing: Strongly reduces ubiquitin binding via UIM 1.,MUTAGEN:REVNSQE->AA: Impairs the selectivity for 'K-63'-linked ubiquitin.,MUTAGEN:REVNSQE->AAAAAAA: Increases the selectivity for 'K-63'-linked ubiquitin.,MUTAGEN:REVNSQE->AAAAAAAAA: Impairs the selectivity for 'K-63'-linked ubiquitin.,MUTAGEN:S->A,E: Slightly impairs the selectivity for 'K-63'-linked ubiquitin.,MUTAGEN:S->A: Impairs localization to DNA damages sites; when associated with S-88; S-113 and A-117.,MUTAGEN:S->A: Impairs ubiquitin-binding and localization to DNA damages sites; when associated with S-88; A-92 and S-113.,MUTAGEN:S->G: Abolishes phosphorylation at this position.,REGION:AIR,REGION:Disordered,REGION:Necessary for interaction with NR6A1 C-terminus,REGION:Necessary for interaction with NR6A1 N-terminus,REGION:Necessary for transcriptional repression,REGION:UIM-linker,REGION:Zinc-finger-like region,ZN_FING:UBZ4-type,
UBL5	ubiquitin like 5(UBL5)	Homo sapiens			GO:0000398~mRNA splicing, via spliceosome,GO:0036211~protein modification process,GO:1903955~positive regulation of protein targeting to mitochondrion,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0015030~Cajal body,	GO:0005515~protein binding,GO:0031386~protein tag,	IPR000626:Ubiquitin-like_dom,IPR029071:Ubiquitin-like_domsf,IPR039732:Hub1/Ubl5,					KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,KW-0963~Cytoplasm,						DOMAIN:Ubiquitin-like,MUTAGEN:D->A: Does not impair binding to SART1 nor its pre-mRNA splicing function.,
UBL7	ubiquitin like 7(UBL7)	Homo sapiens			GO:0006511~ubiquitin-dependent protein catabolic process,GO:0045087~innate immune response,GO:0051607~defense response to virus,	GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0005515~protein binding,GO:0031593~polyubiquitin binding,GO:0060090~binding, bridging,	IPR000626:Ubiquitin-like_dom,IPR009060:UBA-like_sf,IPR015496:Ubiquilin,IPR015940:UBA,IPR029071:Ubiquitin-like_domsf,IPR047877:UBL7_Ubl,IPR047878:UBL7_UBA,				SM00165:UBA,SM00213:UBQ,	KW-0051~Antiviral defense,KW-0391~Immunity,KW-0399~Innate immunity,KW-0833~Ubl conjugation pathway,						KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:UBA,DOMAIN:Ubiquitin-like,REGION:Disordered,
UBA2	ubiquitin like modifier activating enzyme 2(UBA2)	Homo sapiens		h_ctbp1Pathway:SUMOylation as a mechanism to modulate CtBP-dependent gene responses,h_eradPathway:ERï¿½associated degradation (ERAD) Pathway,h_sumoPathway:Basic Mechanisms of SUMOylation,	GO:0016925~protein sumoylation,GO:0033235~positive regulation of protein sumoylation,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0031510~SUMO activating enzyme complex,	GO:0000287~magnesium ion binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008641~small protein activating enzyme activity,GO:0016740~transferase activity,GO:0019948~SUMO activating enzyme activity,GO:0032183~SUMO binding,GO:0044388~small protein activating enzyme binding,GO:0044390~ubiquitin-like protein conjugating enzyme binding,GO:0046872~metal ion binding,GO:0046982~protein heterodimerization activity,	IPR000594:ThiF_NAD_FAD-bd,IPR018074:UBQ-activ_enz_E1_CS,IPR023318:Ub_act_enz_dom_a_sf,IPR028077:UAE_UbL_dom,IPR030661:Uba2,IPR032426:UBA2_C,IPR033127:UBQ-activ_enz_E1_Cys_AS,IPR035985:Ubiquitin-activating_enz,IPR042449:Ub-E1_IAD_1,IPR045886:ThiF/MoeB/HesA,	hsa04120:Ubiquitin mediated proteolysis,	619959~ACCES syndrome,	PIRSF039133:SUMO_E1B,		KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0038~Ectodermal dysplasia,KW-0225~Disease variant,		KW-0067~ATP-binding,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,KW-0862~Zinc,	KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	ACT_SITE:Glycyl thioester intermediate,COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:SUMO-activating enzyme subunit 2 C-terminal,DOMAIN:THIF-type NAD/FAD binding fold,DOMAIN:Ubiquitin/SUMO-activating enzyme ubiquitin-like,MUTAGEN:C->A: Loss of enzyme activity.,MUTAGEN:D->A: Abolishes ATP-dependent activation of SUMO proteins.,MUTAGEN:G->GGGG: Strongly reduced interaction with UBE2I.,MUTAGEN:H->Q: No effect on enzyme activity.,MUTAGEN:I->A: Strongly reduced interaction with UBE2I; when associated with A-235.,MUTAGEN:I->A: Strongly reduced interaction with UBE2I; when associated with A-238.,MUTAGEN:K->A: Abolishes ATP-dependent activation of SUMO proteins.,MUTAGEN:L->A: Strongly reduces ATP-dependent activation of SUMO proteins.,MUTAGEN:Missing: Strongly reduced interaction with UBE2I.,MUTAGEN:N->A: Abolishes ATP-dependent activation of SUMO proteins.,MUTAGEN:R->A: Strongly reduces ATP-dependent activation of SUMO proteins.,MUTAGEN:T->A: Slightly reduced enzyme activity.,REGION:Disordered,
UHRF2	ubiquitin like with PHD and ring finger domains 2(UHRF2)	Homo sapiens			GO:0007049~cell cycle,GO:0016567~protein ubiquitination,GO:0016925~protein sumoylation,GO:0030154~cell differentiation,GO:0051726~regulation of cell cycle,GO:0051865~protein autoubiquitination,	GO:0000792~heterochromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005721~pericentric heterochromatin,	GO:0003677~DNA binding,GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0019789~SUMO transferase activity,GO:0042393~histone binding,GO:0046872~metal ion binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:0061630~ubiquitin protein ligase activity,	IPR000626:Ubiquitin-like_dom,IPR001841:Znf_RING,IPR001965:Znf_PHD,IPR003105:SRA_YDG,IPR011011:Znf_FYVE_PHD,IPR013083:Znf_RING/FYVE/PHD,IPR014722:Rib_uL2_dom2,IPR015947:PUA-like_sf,IPR017907:Znf_RING_CS,IPR019787:Znf_PHD-finger,IPR021991:TTD_dom,IPR029071:Ubiquitin-like_domsf,IPR036987:SRA-YDG_sf,IPR045134:UHRF1/2-like,IPR047407:Tudor_UHRF2_rpt1,IPR047466:RING-HC_UHRF2,IPR047467:PHD_UHRF2,IPR047468:Ubl_UHRF2,				SM00184:RING,SM00213:UBQ,SM00249:PHD,SM00466:SRA,	KW-0131~Cell cycle,KW-0833~Ubl conjugation pathway,	KW-0158~Chromosome,KW-0539~Nucleus,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,KW-0808~Transferase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,	COMPBIAS:Polar residues,DISULFID:Interchain,DOMAIN:UHRF1 tandem tudor,DOMAIN:Ubiquitin-like,DOMAIN:YDG,MUTAGEN:C->S: No effect on autosumoylation, nor on ZNF131 sumoylation.,MUTAGEN:K->R: No effect on autosumoylation.,REGION:Disordered,REGION:Interaction with PCNP,REGION:Methyl-CpG binding and interaction with HDAC1,REGION:Required for interaction with histone H3,ZN_FING:PHD-type,ZN_FING:RING-type,
UBR2	ubiquitin protein ligase E3 component n-recognin 2(UBR2)	Homo sapiens			GO:0007131~reciprocal meiotic recombination,GO:0007140~male meiosis,GO:0007141~male meiosis I,GO:0007283~spermatogenesis,GO:0010526~negative regulation of transposition, RNA-mediated,GO:0016567~protein ubiquitination,GO:0031507~heterochromatin assembly,GO:0032007~negative regulation of TOR signaling,GO:0071233~cellular response to leucine,GO:0071596~ubiquitin-dependent protein catabolic process via the N-end rule pathway,	GO:0000151~ubiquitin ligase complex,GO:0000785~chromatin,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0016874~ligase activity,GO:0061630~ubiquitin protein ligase activity,GO:0070728~leucine binding,	IPR003126:Znf_UBR,IPR003769:ClpS_core,IPR014719:Ribosomal_bL12_C/ClpS-like,IPR036390:WH_DNA-bd_sf,IPR039164:UBR1-like,IPR042065:E3_ELL-like,IPR044046:E3_ligase_UBR-like_C,IPR047508:UBR-box_UBR2,				SM00396:ZnF_UBR1,	KW-0833~Ubl conjugation pathway,	KW-0158~Chromosome,KW-0539~Nucleus,		KW-0175~Coiled coil,KW-0732~Signal,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0436~Ligase,KW-0808~Transferase,	KW-0007~Acetylation,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:E3 ubiquitin-protein ligase UBR-like C-terminal,REGION:Disordered,ZN_FING:RING-type; atypical,ZN_FING:UBR-type,
URM1	ubiquitin related modifier 1(URM1)	Homo sapiens			GO:0002098~tRNA wobble uridine modification,GO:0032447~protein urmylation,GO:0034227~tRNA thio-modification,	GO:0005634~nucleus,GO:0005829~cytosol,	GO:0005515~protein binding,GO:0031386~protein tag,GO:0097163~sulfur carrier activity,	IPR012675:Beta-grasp_dom_sf,IPR015221:Urm1,IPR016155:Mopterin_synth/thiamin_S_b,	hsa04122:Sulfur relay system,		PIRSF037379:Ubiquitin-related_modifier_1,		KW-0819~tRNA processing,KW-0833~Ubl conjugation pathway,	KW-0963~Cytoplasm,					KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Gly-Lys) (interchain with K-? in acceptor proteins),
USP11	ubiquitin specific peptidase 11(USP11)	Homo sapiens			GO:0006508~proteolysis,GO:0016579~protein deubiquitination,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005694~chromosome,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0001222~transcription corepressor binding,GO:0004197~cysteine-type endopeptidase activity,GO:0004843~thiol-dependent ubiquitin-specific protease activity,GO:0005515~protein binding,	IPR001394:Peptidase_C19_UCH,IPR006615:Pept_C19_DUSP,IPR018200:USP_CS,IPR028135:Ub_USP-typ,IPR028889:USP_dom,IPR029346:USP_C,IPR035927:DUSP-like_sf,IPR038765:Papain-like_cys_pep_sf,				SM00695:DUSP,	KW-0833~Ubl conjugation pathway,KW-0945~Host-virus interaction,	KW-0158~Chromosome,KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0378~Hydrolase,KW-0645~Protease,KW-0788~Thiol protease,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Nucleophile,ACT_SITE:Proton acceptor,COMPBIAS:Acidic residues,COMPBIAS:Polar residues,DOMAIN:DUSP,DOMAIN:USP,MUTAGEN:C->S: Loss of deubiquitinase activity.,REGION:Disordered,
USP14	ubiquitin specific peptidase 14(USP14)	Homo sapiens			GO:0007268~chemical synaptic transmission,GO:0016579~protein deubiquitination,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0045087~innate immune response,GO:0050920~regulation of chemotaxis,GO:0061136~regulation of proteasomal protein catabolic process,GO:1903070~negative regulation of ER-associated ubiquitin-dependent protein catabolic process,GO:1904293~negative regulation of ERAD pathway,GO:2000059~negative regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process,	GO:0000502~proteasome complex,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0031410~cytoplasmic vesicle,GO:0045202~synapse,GO:0070062~extracellular exosome,	GO:0004197~cysteine-type endopeptidase activity,GO:0004843~thiol-dependent ubiquitin-specific protease activity,GO:0004866~endopeptidase inhibitor activity,GO:0005515~protein binding,GO:0061578~Lys63-specific deubiquitinase activity,GO:0070628~proteasome binding,GO:0101005~ubiquitinyl hydrolase activity,	IPR000626:Ubiquitin-like_dom,IPR001394:Peptidase_C19_UCH,IPR018200:USP_CS,IPR019954:Ubiquitin_CS,IPR028889:USP_dom,IPR029071:Ubiquitin-like_domsf,IPR038765:Papain-like_cys_pep_sf,IPR044635:UBP14-like,				SM00213:UBQ,	KW-0391~Immunity,KW-0399~Innate immunity,KW-0833~Ubl conjugation pathway,	KW-0472~Membrane,KW-0647~Proteasome,KW-0963~Cytoplasm,KW-1003~Cell membrane,				KW-0378~Hydrolase,KW-0645~Protease,KW-0788~Thiol protease,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Nucleophile,ACT_SITE:Proton acceptor,DOMAIN:USP,DOMAIN:Ubiquitin-like,
USP15	ubiquitin specific peptidase 15(USP15)	Homo sapiens			GO:0006508~proteolysis,GO:0007179~transforming growth factor beta receptor signaling pathway,GO:0016579~protein deubiquitination,GO:0030509~BMP signaling pathway,GO:0030512~negative regulation of transforming growth factor beta receptor signaling pathway,GO:0035520~monoubiquitinated protein deubiquitination,GO:1900246~positive regulation of RIG-I signaling pathway,GO:1902238~regulation of intrinsic apoptotic signaling pathway in response to osmotic stress by p53 class mediator,GO:1905035~negative regulation of antifungal innate immune response,GO:1990167~protein K27-linked deubiquitination,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0016604~nuclear body,	GO:0004197~cysteine-type endopeptidase activity,GO:0004843~thiol-dependent ubiquitin-specific protease activity,GO:0005160~transforming growth factor beta receptor binding,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0046332~SMAD binding,GO:0061649~ubiquitinated histone binding,GO:0101005~ubiquitinyl hydrolase activity,GO:1990380~Lys48-specific deubiquitinase activity,	IPR001394:Peptidase_C19_UCH,IPR006615:Pept_C19_DUSP,IPR013792:RNA3'P_cycl/enolpyr_Trfase_a/b,IPR018200:USP_CS,IPR028135:Ub_USP-typ,IPR028889:USP_dom,IPR029071:Ubiquitin-like_domsf,IPR029346:USP_C,IPR035927:DUSP-like_sf,IPR038765:Papain-like_cys_pep_sf,	hsa04137:Mitophagy - animal,			SM00695:DUSP,	KW-0833~Ubl conjugation pathway,KW-0945~Host-virus interaction,	KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0378~Hydrolase,KW-0645~Protease,KW-0788~Thiol protease,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	ACT_SITE:Nucleophile,ACT_SITE:Proton acceptor,COMPBIAS:Acidic residues,COMPBIAS:Polar residues,DOMAIN:DUSP,DOMAIN:USP,DOMAIN:Ubiquitin-like,MUTAGEN:C->A: Loss of activity towards polyubiquitin.,MUTAGEN:C->A: Loss of enzyme activity.,REGION:Disordered,REGION:Mediates interaction with SART3,
USP22	ubiquitin specific peptidase 22(USP22)	Homo sapiens			GO:0006282~regulation of DNA repair,GO:0006338~chromatin remodeling,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006508~proteolysis,GO:0007049~cell cycle,GO:0009792~embryo development ending in birth or egg hatching,GO:0016579~protein deubiquitination,GO:0043484~regulation of RNA splicing,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045931~positive regulation of mitotic cell cycle,	GO:0000124~SAGA complex,GO:0005654~nucleoplasm,GO:0033276~transcription factor TFTC complex,	GO:0003713~transcription coactivator activity,GO:0004843~thiol-dependent ubiquitin-specific protease activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0010485~H4 histone acetyltransferase activity,GO:0019899~enzyme binding,GO:0030374~ligand-dependent nuclear receptor transcription coactivator activity,	IPR001394:Peptidase_C19_UCH,IPR001607:Znf_UBP,IPR013083:Znf_RING/FYVE/PHD,IPR018200:USP_CS,IPR028889:USP_dom,IPR038765:Papain-like_cys_pep_sf,					KW-0131~Cell cycle,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0156~Chromatin regulator,KW-0378~Hydrolase,KW-0645~Protease,KW-0788~Thiol protease,	KW-0007~Acetylation,	ACT_SITE:Nucleophile,ACT_SITE:Proton acceptor,COMPBIAS:Polar residues,DOMAIN:UBP-type,DOMAIN:USP,MUTAGEN:H->A: Impairs its function as a positive modulator of androgen receptor transactivation; when associated with A-471.,MUTAGEN:H->A: Impairs its function as a positive modulator of androgen receptor transactivation; when associated with A-479.,REGION:Disordered,ZN_FING:UBP-type,
USP33	ubiquitin specific peptidase 33(USP33)	Homo sapiens			GO:0006511~ubiquitin-dependent protein catabolic process,GO:0006807~nitrogen compound metabolic process,GO:0006897~endocytosis,GO:0007411~axon guidance,GO:0008277~regulation of G-protein coupled receptor protein signaling pathway,GO:0009267~cellular response to starvation,GO:0010506~regulation of autophagy,GO:0016477~cell migration,GO:0016579~protein deubiquitination,GO:0032091~negative regulation of protein binding,GO:0032092~positive regulation of protein binding,GO:0043170~macromolecule metabolic process,GO:0044238~primary metabolic process,GO:0050821~protein stabilization,GO:0051298~centrosome duplication,GO:0070536~protein K63-linked deubiquitination,GO:0071108~protein K48-linked deubiquitination,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005813~centrosome,GO:0005829~cytosol,GO:0005925~focal adhesion,GO:0030891~VCB complex,GO:0043025~neuronal cell body,GO:0048471~perinuclear region of cytoplasm,	GO:0001664~G-protein coupled receptor binding,GO:0004197~cysteine-type endopeptidase activity,GO:0004843~thiol-dependent ubiquitin-specific protease activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0031267~small GTPase binding,	IPR001394:Peptidase_C19_UCH,IPR001607:Znf_UBP,IPR006615:Pept_C19_DUSP,IPR013083:Znf_RING/FYVE/PHD,IPR018200:USP_CS,IPR028889:USP_dom,IPR035927:DUSP-like_sf,IPR038765:Papain-like_cys_pep_sf,				SM00290:ZnF_UBP,SM00695:DUSP,	KW-0254~Endocytosis,KW-0833~Ubl conjugation pathway,	KW-0206~Cytoskeleton,KW-0333~Golgi apparatus,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0378~Hydrolase,KW-0645~Protease,KW-0788~Thiol protease,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	ACT_SITE:Nucleophile,ACT_SITE:Proton acceptor,COMPBIAS:Polar residues,DOMAIN:DUSP,DOMAIN:DUSP 1,DOMAIN:DUSP 2,DOMAIN:UBP-type,DOMAIN:USP,MUTAGEN:C->S: Abolishes deubiquitinating activity. Does not inhibit lysosomal trafficking of ADRB2; when associated with Q-673.,MUTAGEN:H->Q: Abolishes deubiquitinating activity. Does not inhibit lysosomal trafficking of ADRB2; when associated with S-194.,REGION:Disordered,ZN_FING:UBP-type,
USP34	ubiquitin specific peptidase 34(USP34)	Homo sapiens			GO:0006508~proteolysis,GO:0016055~Wnt signaling pathway,GO:0016579~protein deubiquitination,GO:0071108~protein K48-linked deubiquitination,GO:0090263~positive regulation of canonical Wnt signaling pathway,	GO:0005634~nucleus,GO:0005829~cytosol,	GO:0004197~cysteine-type endopeptidase activity,GO:0004843~thiol-dependent ubiquitin-specific protease activity,GO:0005515~protein binding,	IPR001394:Peptidase_C19_UCH,IPR016024:ARM-type_fold,IPR018200:USP_CS,IPR021905:DUF3517,IPR028889:USP_dom,IPR038765:Papain-like_cys_pep_sf,					KW-0833~Ubl conjugation pathway,KW-0879~Wnt signaling pathway,					KW-0378~Hydrolase,KW-0645~Protease,KW-0788~Thiol protease,	KW-0597~Phosphoprotein,	ACT_SITE:Nucleophile,ACT_SITE:Proton acceptor,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:DUF3517,DOMAIN:USP,MUTAGEN:C->S: Loss of function.,REGION:Disordered,
USP36	ubiquitin specific peptidase 36(USP36)	Homo sapiens			GO:0006325~chromatin organization,GO:0006338~chromatin remodeling,GO:0006508~proteolysis,GO:0007000~nucleolus organization,GO:0016242~negative regulation of macroautophagy,GO:0016579~protein deubiquitination,GO:0031647~regulation of protein stability,GO:0042981~regulation of apoptotic process,GO:0050821~protein stabilization,GO:1901524~regulation of macromitophagy,GO:1903146~regulation of mitophagy,GO:1903955~positive regulation of protein targeting to mitochondrion,GO:2000232~regulation of rRNA processing,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016607~nuclear speck,	GO:0003723~RNA binding,GO:0004843~thiol-dependent ubiquitin-specific protease activity,GO:0005515~protein binding,GO:0016740~transferase activity,GO:1990380~Lys48-specific deubiquitinase activity,	IPR001394:Peptidase_C19_UCH,IPR018200:USP_CS,IPR028889:USP_dom,IPR038765:Papain-like_cys_pep_sf,					KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0378~Hydrolase,KW-0645~Protease,KW-0694~RNA-binding,KW-0788~Thiol protease,KW-0808~Transferase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	ACT_SITE:Nucleophile,ACT_SITE:Proton acceptor,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:USP,MUTAGEN:C->A,S: Abolishes deubiquitinase activity. No effect on NTRK1 ubiquitination levels.,REGION:Disordered,
USP4	ubiquitin specific peptidase 4(USP4)	Homo sapiens			GO:0000244~spliceosomal tri-snRNP complex assembly,GO:0006508~proteolysis,GO:0016579~protein deubiquitination,GO:0031397~negative regulation of protein ubiquitination,GO:0031647~regulation of protein stability,GO:0034394~protein localization to cell surface,GO:1904263~positive regulation of TORC1 signaling,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005764~lysosome,GO:0005829~cytosol,GO:0005886~plasma membrane,	GO:0004843~thiol-dependent ubiquitin-specific protease activity,GO:0005515~protein binding,GO:0031685~adenosine receptor binding,GO:0042802~identical protein binding,GO:0046872~metal ion binding,	IPR001394:Peptidase_C19_UCH,IPR006615:Pept_C19_DUSP,IPR018200:USP_CS,IPR028135:Ub_USP-typ,IPR028889:USP_dom,IPR033362:SSNA1_fam,IPR035927:DUSP-like_sf,IPR038765:Papain-like_cys_pep_sf,				SM00695:DUSP,	KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0656~Proto-oncogene,	KW-0175~Coiled coil,KW-0677~Repeat,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0378~Hydrolase,KW-0645~Protease,KW-0788~Thiol protease,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	ACT_SITE:Nucleophile,ACT_SITE:Proton acceptor,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:DUSP,DOMAIN:USP,DOMAIN:Ubiquitin-like 1,DOMAIN:Ubiquitin-like 2,MOTIF:Nuclear export signal,MOTIF:Nuclear localization signal,MUTAGEN:C->A: Loss of thiol-dependent deubiquitinase activity. Its ubiquitination by TRIM21 is enhanced. Does affect interaction with HAS2. Does not deubiquitinate HAS2.,MUTAGEN:D->G: Severe reduction in thiol-dependent deubiquitinase activity.,MUTAGEN:D->R: Severe reduction in thiol-dependent deubiquitinase activity.,MUTAGEN:E->A: Moderate reduction in thiol-dependent deubiquitinase activity.,MUTAGEN:E->A: Severe reduction in thiol-dependent deubiquitinase activity.,MUTAGEN:E->Q: Reduces the interaction with RB1.,MUTAGEN:F->D: Moderate reduction in thiol-dependent deubiquitinase activity.,MUTAGEN:F->G: Lowers affinity for ubiquitin characterized by a 10-fold increase in ubiquitin release and a slight reduction in ubiquitin binding.,MUTAGEN:I->P: Severe reduction in thiol-dependent deubiquitinase activity.,MUTAGEN:I->R: Moderate reduction in thiol-dependent deubiquitinase activity.,MUTAGEN:L->E: Moderate reduction in thiol-dependent deubiquitinase activity.,MUTAGEN:LVCPE->AVRPH: Reduces the interaction with RB1.,MUTAGEN:M->D: Moderate reduction in thiol-dependent deubiquitinase activity.,MUTAGEN:PQ->AV: Severe reduction in thiol-dependent deubiquitinase activity.,MUTAGEN:R->E: Moderate reduction in thiol-dependent deubiquitinase activity.,MUTAGEN:S->A: Abolished phosphorylation by PKB/AKT1 in response to EGF signaling.,MUTAGEN:S->D: Mimics phosphorylation; promoting association with RHEB.,MUTAGEN:Y->A: Severe reduction in thiol-dependent deubiquitinase activity.,REGION:Disordered,REGION:Interacts with DUSP and ubiquitin-like 1 domains and is required for USP4 activation,REGION:Necessary for interaction with RB1 and RBL2,REGION:Necessary for interaction with RBL2,REGION:Necessary for interaction with SART3,REGION:Regulates ubiquitin dissociation,REGION:Required for USP4 activation by providing conformational flexibility between the DUSP and catalytic domains,
USP47	ubiquitin specific peptidase 47(USP47)	Homo sapiens			GO:0006284~base-excision repair,GO:0006508~proteolysis,GO:0006974~cellular response to DNA damage stimulus,GO:0008630~intrinsic apoptotic signaling pathway in response to DNA damage,GO:0009410~response to xenobiotic stimulus,GO:0010972~negative regulation of G2/M transition of mitotic cell cycle,GO:0016579~protein deubiquitination,GO:0030307~positive regulation of cell growth,GO:0034644~cellular response to UV,GO:0035520~monoubiquitinated protein deubiquitination,GO:0043066~negative regulation of apoptotic process,GO:0043154~negative regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0045892~negative regulation of transcription, DNA-templated,GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:1902230~negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0019005~SCF ubiquitin ligase complex,	GO:0004843~thiol-dependent ubiquitin-specific protease activity,GO:0005515~protein binding,GO:0071987~WD40-repeat domain binding,GO:0101005~ubiquitinyl hydrolase activity,	IPR001394:Peptidase_C19_UCH,IPR018200:USP_CS,IPR028889:USP_dom,IPR029071:Ubiquitin-like_domsf,IPR038765:Papain-like_cys_pep_sf,IPR045578:USP47_C,					KW-0227~DNA damage,KW-0234~DNA repair,KW-0833~Ubl conjugation pathway,	KW-0963~Cytoplasm,				KW-0378~Hydrolase,KW-0645~Protease,KW-0788~Thiol protease,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Nucleophile,ACT_SITE:Proton acceptor,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:USP,DOMAIN:Ubiquitin carboxyl-terminal hydrolase 47 C-terminal,REGION:Disordered,
USP48	ubiquitin specific peptidase 48(USP48)	Homo sapiens			GO:0006508~proteolysis,GO:0009062~fatty acid catabolic process,GO:0016579~protein deubiquitination,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,	GO:0004197~cysteine-type endopeptidase activity,GO:0004843~thiol-dependent ubiquitin-specific protease activity,GO:0005515~protein binding,GO:0008670~2,4-dienoyl-CoA reductase (NADPH) activity,GO:0101005~ubiquitinyl hydrolase activity,	IPR000626:Ubiquitin-like_dom,IPR001394:Peptidase_C19_UCH,IPR006615:Pept_C19_DUSP,IPR018200:USP_CS,IPR028889:USP_dom,IPR029071:Ubiquitin-like_domsf,IPR033841:USP48,IPR035927:DUSP-like_sf,IPR038765:Papain-like_cys_pep_sf,IPR044743:Ubl_USP48,IPR045017:DECR2-like,		620227~Deafness, autosomal dominant 85,			KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0209~Deafness,KW-1010~Non-syndromic deafness,	KW-0677~Repeat,	KW-0521~NADP,	KW-0378~Hydrolase,KW-0560~Oxidoreductase,KW-0645~Protease,KW-0788~Thiol protease,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Nucleophile,ACT_SITE:Proton acceptor,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:DUSP,DOMAIN:DUSP 1,DOMAIN:DUSP 2,DOMAIN:DUSP 3,DOMAIN:USP,DOMAIN:Ubiquitin-like,MUTAGEN:C->S: Loss of deubiquitinase activity.,MUTAGEN:Missing: Loss of deubiquitinase activity.,REGION:Disordered,
USP8	ubiquitin specific peptidase 8(USP8)	Homo sapiens			GO:0000281~mitotic cytokinesis,GO:0006508~proteolysis,GO:0007032~endosome organization,GO:0007265~Ras protein signal transduction,GO:0016579~protein deubiquitination,GO:0031647~regulation of protein stability,GO:0032880~regulation of protein localization,GO:0070536~protein K63-linked deubiquitination,GO:0071108~protein K48-linked deubiquitination,GO:0071549~cellular response to dexamethasone stimulus,GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:0099576~regulation of protein catabolic process at postsynapse, modulating synaptic transmission,GO:1905166~negative regulation of lysosomal protein catabolic process,GO:1905908~positive regulation of amyloid fibril formation,GO:1990090~cellular response to nerve growth factor stimulus,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005769~early endosome,GO:0005829~cytosol,GO:0010008~endosome membrane,GO:0014069~postsynaptic density,GO:0019897~extrinsic component of plasma membrane,GO:0030496~midbody,GO:0043197~dendritic spine,GO:0098978~glutamatergic synapse,	GO:0004197~cysteine-type endopeptidase activity,GO:0004843~thiol-dependent ubiquitin-specific protease activity,GO:0005515~protein binding,GO:0017124~SH3 domain binding,GO:0045296~cadherin binding,GO:0061578~Lys63-specific deubiquitinase activity,GO:1990380~Lys48-specific deubiquitinase activity,	IPR001394:Peptidase_C19_UCH,IPR001763:Rhodanese-like_dom,IPR015063:USP8_dimer,IPR018200:USP_CS,IPR028889:USP_dom,IPR036873:Rhodanese-like_dom_sf,IPR038765:Papain-like_cys_pep_sf,IPR048498:WW_USP8,	hsa04137:Mitophagy - animal,hsa04144:Endocytosis,hsa04934:Cushing syndrome,	219090~Pituitary adenoma 4, ACTH-secreting, somatic,			KW-0131~Cell cycle,KW-0833~Ubl conjugation pathway,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0967~Endosome,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-1062~Cushing syndrome,	KW-0175~Coiled coil,KW-0729~SH3-binding,		KW-0378~Hydrolase,KW-0645~Protease,KW-0788~Thiol protease,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	ACT_SITE:Nucleophile,ACT_SITE:Proton acceptor,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:MIT,DOMAIN:Rhodanese,DOMAIN:USP,DOMAIN:USP8 dimerisation,MOTIF:SH3-binding,MUTAGEN:C->S: Impairs deubiquitination activity and leads to endosome membrane accumulation.,REGION:Disordered,
USP9X	ubiquitin specific peptidase 9 X-linked(USP9X)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001764~neuron migration,GO:0007059~chromosome segregation,GO:0007179~transforming growth factor beta receptor signaling pathway,GO:0007292~female gamete generation,GO:0008104~protein localization,GO:0016477~cell migration,GO:0016562~protein import into peroxisome matrix, receptor recycling,GO:0016567~protein ubiquitination,GO:0016579~protein deubiquitination,GO:0030509~BMP signaling pathway,GO:0032092~positive regulation of protein binding,GO:0032435~negative regulation of proteasomal ubiquitin-dependent protein catabolic process,GO:0035520~monoubiquitinated protein deubiquitination,GO:0042752~regulation of circadian rhythm,GO:0048511~rhythmic process,GO:0048675~axon extension,GO:0050821~protein stabilization,GO:0051301~cell division,GO:0060271~cilium assembly,GO:0061824~cytosolic ciliogenesis,GO:0070536~protein K63-linked deubiquitination,GO:0071947~protein deubiquitination involved in ubiquitin-dependent protein catabolic process,GO:1901537~positive regulation of DNA demethylation,GO:1904515~positive regulation of TORC2 signaling,GO:1990000~amyloid fibril formation,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005929~cilium,GO:0016020~membrane,GO:0030426~growth cone,	GO:0004197~cysteine-type endopeptidase activity,GO:0004843~thiol-dependent ubiquitin-specific protease activity,GO:0005515~protein binding,GO:0008234~cysteine-type peptidase activity,GO:0061578~Lys63-specific deubiquitinase activity,GO:0070410~co-SMAD binding,GO:0101005~ubiquitinyl hydrolase activity,GO:1990380~Lys48-specific deubiquitinase activity,	IPR001394:Peptidase_C19_UCH,IPR016024:ARM-type_fold,IPR018200:USP_CS,IPR021905:DUF3517,IPR028889:USP_dom,IPR038765:Papain-like_cys_pep_sf,		300919~Intellectual developmental disorder, X-linked 99,300968~Intellectual developmental disorder, X-linked 99, syndromic, female-restricted,			KW-0090~Biological rhythms,KW-0131~Cell cycle,KW-0132~Cell division,KW-0159~Chromosome partition,KW-0498~Mitosis,KW-0833~Ubl conjugation pathway,	KW-0206~Cytoskeleton,KW-0963~Cytoplasm,KW-0966~Cell projection,	KW-0225~Disease variant,KW-0991~Intellectual disability,			KW-0378~Hydrolase,KW-0645~Protease,KW-0788~Thiol protease,	KW-0597~Phosphoprotein,	ACT_SITE:Nucleophile,ACT_SITE:Proton acceptor,COMPBIAS:Polar residues,DOMAIN:DUF3517,DOMAIN:USP,MUTAGEN:C->A: Does not restore RICTOR expression levels when introduced into cells where endogenous USP9X has been silenced.,REGION:Disordered,
UFC1	ubiquitin-fold modifier conjugating enzyme 1(UFC1)	Homo sapiens			GO:0007420~brain development,GO:0034976~response to endoplasmic reticulum stress,GO:0061709~reticulophagy,GO:0071569~protein ufmylation,GO:1990592~protein K69-linked ufmylation,	GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0061657~UFM1 conjugating enzyme activity,GO:0071568~UFM1 transferase activity,	IPR014806:Ufc1,IPR016135:UBQ-conjugating_enzyme/RWD,		618076~Neurodevelopmental disorder with spasticity and poor growth,	PIRSF008716:DUF1782,		KW-0833~Ubl conjugation pathway,		KW-0225~Disease variant,					ACT_SITE:Glycyl thioester intermediate,MUTAGEN:C->S: Instead of the formation of an intermediate complex with a thiol ester bond between UFC1 (E2-like enzyme) and UFM1 (substrate), a stable complex with an O-ester bond is formed.,MUTAGEN:K->A: Impairs binding to UBA5 and thioester formation with UFM1.,MUTAGEN:Q->A: Does not affect neither UBA5-binding nor thioester formation with UFM1.,
UXT	ubiquitously expressed prefoldin like chaperone(UXT)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0000226~microtubule cytoskeleton organization,GO:0006915~apoptotic process,GO:0007098~centrosome cycle,GO:0047497~mitochondrion transport along microtubule,GO:0050821~protein stabilization,	GO:0000922~spindle pole,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005856~cytoskeleton,GO:0101031~chaperone complex,GO:1990062~RPAP3/R2TP/prefoldin-like complex,	GO:0003682~chromatin binding,GO:0003714~transcription corepressor activity,GO:0005515~protein binding,GO:0008017~microtubule binding,GO:0048487~beta-tubulin binding,	IPR003994:UXT,IPR004127:Prefoldin_subunit_alpha,IPR009053:Prefoldin,					KW-0053~Apoptosis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0010~Activator,KW-0143~Chaperone,KW-0678~Repressor,	KW-0832~Ubl conjugation,	MUTAGEN:L->P: Causes dislocation from the centrosome; when associated with L-50.,MUTAGEN:L->P: Causes dislocation from the centrosome; when associated with L-59.,
UNC45A	unc-45 myosin chaperone A(UNC45A)	Homo sapiens			GO:0007517~muscle organ development,GO:0030154~cell differentiation,GO:0061077~chaperone-mediated protein folding,	GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0016607~nuclear speck,GO:0048471~perinuclear region of cytoplasm,	GO:0005515~protein binding,GO:0045296~cadherin binding,GO:0051879~Hsp90 protein binding,	IPR011989:ARM-like,IPR011990:TPR-like_helical_dom_sf,IPR016024:ARM-type_fold,IPR019734:TPR_repeat,IPR024660:UCS_central_dom,		619377~Osteootohepatoenteric syndrome,		SM00028:TPR,	KW-0221~Differentiation,KW-0517~Myogenesis,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0209~Deafness,	KW-0677~Repeat,KW-0732~Signal,KW-0802~TPR repeat,		KW-0143~Chaperone,KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:UNC-45/Cro1/She4 central,MUTAGEN:A->D: Abolishes interaction with HSP90AB1; when associated with E-33. No effect on interaction with PGR.,MUTAGEN:A->D: Abolishes interaction with HSP90AB1; when associated with E-70. No effect on interaction with PGR.,MUTAGEN:K->E: Abolishes interaction with HSP90AB1; when associated with D-40. No effect on interaction with PGR.,MUTAGEN:K->E: Abolishes interaction with HSP90AB1; when associated with D-77. No effect on interaction with PGR.,REGION:Disordered,REPEAT:TPR,REPEAT:TPR 1,REPEAT:TPR 2,REPEAT:TPR 3,
UCP2	uncoupling protein 2(UCP2)	Homo sapiens			GO:0000266~mitochondrial fission,GO:0000303~response to superoxide,GO:0001666~response to hypoxia,GO:0006096~glycolytic process,GO:0006541~glutamine metabolic process,GO:0006839~mitochondrial transport,GO:0007565~female pregnancy,GO:0009409~response to cold,GO:0015740~C4-dicarboxylate transport,GO:0030225~macrophage differentiation,GO:0032869~cellular response to insulin stimulus,GO:0034198~cellular response to amino acid starvation,GO:0035435~phosphate ion transmembrane transport,GO:0043524~negative regulation of neuron apoptotic process,GO:0051881~regulation of mitochondrial membrane potential,GO:0061179~negative regulation of insulin secretion involved in cellular response to glucose stimulus,GO:0070542~response to fatty acid,GO:0070778~L-aspartate transport,GO:0071284~cellular response to lead ion,GO:0071333~cellular response to glucose stimulus,GO:0071423~malate transmembrane transport,GO:0071548~response to dexamethasone,GO:0072593~reactive oxygen species metabolic process,GO:0097421~liver regeneration,GO:1902356~oxaloacetate(2-) transmembrane transport,GO:1902358~sulfate transmembrane transport,GO:1902476~chloride transmembrane transport,GO:1902600~hydrogen ion transmembrane transport,GO:1990542~mitochondrial transmembrane transport,GO:1990845~adaptive thermogenesis,	GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0016020~membrane,	GO:0005515~protein binding,GO:0008271~secondary active sulfate transmembrane transporter activity,GO:0015078~hydrogen ion transmembrane transporter activity,GO:0015108~chloride transmembrane transporter activity,GO:0015131~oxaloacetate transmembrane transporter activity,GO:0015140~malate transmembrane transporter activity,GO:0015183~L-aspartate transmembrane transporter activity,GO:0015297~antiporter activity,GO:0017077~oxidative phosphorylation uncoupler activity,GO:0042803~protein homodimerization activity,	IPR002030:Mit_uncoupling_UCP-like,IPR018108:Mitochondrial_sb/sol_carrier,IPR023395:Mt_carrier_dom_sf,		607447~Obesity, susceptibility to, BMIQ4,			KW-0813~Transport,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,		KW-0677~Repeat,KW-0812~Transmembrane,KW-1133~Transmembrane helix,				REGION:Purine nucleotide binding,REPEAT:Solcar,REPEAT:Solcar 1,REPEAT:Solcar 2,REPEAT:Solcar 3,TOPO_DOM:Mitochondrial intermembrane,TOPO_DOM:Mitochondrial matrix,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,
UBTF	upstream binding transcription factor(UBTF)	Homo sapiens			GO:0001188~RNA polymerase I transcriptional preinitiation complex assembly,GO:0006360~transcription from RNA polymerase I promoter,GO:0006361~transcription initiation from RNA polymerase I promoter,GO:0045943~positive regulation of transcription from RNA polymerase I promoter,	GO:0001650~fibrillar center,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,	GO:0001164~RNA polymerase I CORE element sequence-specific DNA binding,GO:0001165~RNA polymerase I upstream control element sequence-specific DNA binding,GO:0001181~transcription factor activity, core RNA polymerase I binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0097110~scaffold protein binding,	IPR009071:HMG_box_dom,IPR029215:HMG_box_5,IPR036910:HMG_box_dom_sf,		617672~Neurodegeneration, childhood-onset, with brain atrophy,		SM00398:HMG,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0991~Intellectual disability,	KW-0677~Repeat,		KW-0010~Activator,KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Polar residues,DNA_BIND:HMG box,DNA_BIND:HMG box 1,DNA_BIND:HMG box 2,DNA_BIND:HMG box 3,DNA_BIND:HMG box 4,DNA_BIND:HMG box 5,DNA_BIND:HMG box 6,DOMAIN:HMG box,REGION:Disordered,
UTRN	utrophin(UTRN)	Homo sapiens		h_agrPathway:Agrin in Postsynaptic Differentiation,	GO:0001954~positive regulation of cell-matrix adhesion,GO:0006936~muscle contraction,GO:0007517~muscle organ development,GO:0099536~synaptic signaling,GO:2000649~regulation of sodium ion transmembrane transporter activity,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0016010~dystrophin-associated glycoprotein complex,GO:0016020~membrane,GO:0030175~filopodium,GO:0031527~filopodium membrane,GO:0031594~neuromuscular junction,GO:0032991~macromolecular complex,GO:0042383~sarcolemma,GO:0045202~synapse,GO:0045211~postsynaptic membrane,GO:0070062~extracellular exosome,GO:0070938~contractile ring,	GO:0003779~actin binding,GO:0005178~integrin binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0017166~vinculin binding,GO:0019901~protein kinase binding,	IPR000433:Znf_ZZ,IPR001202:WW_dom,IPR001589:Actinin_actin-bd_CS,IPR001715:CH_dom,IPR002017:Spectrin_repeat,IPR011992:EF-hand-dom_pair,IPR015153:EF-hand_dom_typ1,IPR015154:EF-hand_dom_typ2,IPR018159:Spectrin/alpha-actinin,IPR035436:Dystrophin/utrophin,IPR036020:WW_dom_sf,IPR036872:CH_dom_sf,IPR043145:Znf_ZZ_sf,			PIRSF002341:Dystrophin/utrophin,	SM00033:CH,SM00150:SPEC,SM00291:ZnF_ZZ,SM00456:WW,		KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0628~Postsynaptic cell membrane,KW-0770~Synapse,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0175~Coiled coil,KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0106~Calcium,KW-0479~Metal-binding,KW-0862~Zinc,	KW-0009~Actin-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Calponin-homology (CH),DOMAIN:Calponin-homology (CH) 1,DOMAIN:Calponin-homology (CH) 2,DOMAIN:WW,DOMAIN:ZZ-type,REGION:Actin-binding,REGION:Disordered,REGION:Interaction with SYNM,REPEAT:Spectrin 1,REPEAT:Spectrin 10,REPEAT:Spectrin 11,REPEAT:Spectrin 12,REPEAT:Spectrin 13,REPEAT:Spectrin 14,REPEAT:Spectrin 15,REPEAT:Spectrin 16,REPEAT:Spectrin 17,REPEAT:Spectrin 18,REPEAT:Spectrin 19,REPEAT:Spectrin 2,REPEAT:Spectrin 20,REPEAT:Spectrin 21,REPEAT:Spectrin 22,REPEAT:Spectrin 3,REPEAT:Spectrin 4,REPEAT:Spectrin 5,REPEAT:Spectrin 6,REPEAT:Spectrin 7,REPEAT:Spectrin 8,REPEAT:Spectrin 9,ZN_FING:ZZ-type; degenerate,
VMA21	vacuolar ATPase assembly factor VMA21(VMA21)	Homo sapiens			GO:0043462~regulation of ATPase activity,GO:0070072~vacuolar proton-transporting V-type ATPase complex assembly,	GO:0005764~lysosome,GO:0005789~endoplasmic reticulum membrane,GO:0012507~ER to Golgi transport vesicle membrane,GO:0033116~endoplasmic reticulum-Golgi intermediate compartment membrane,	GO:0005515~protein binding,	IPR019013:Vma21,		310440~Myopathy, X-linked, with excessive autophagy,				KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0968~Cytoplasmic vesicle,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
VPS13C	vacuolar protein sorting 13 homolog C(VPS13C)	Homo sapiens			GO:0006623~protein targeting to vacuole,GO:0006869~lipid transport,GO:0006895~Golgi to endosome transport,GO:0007005~mitochondrion organization,GO:0032868~response to insulin,GO:0045053~protein retention in Golgi apparatus,GO:1905090~negative regulation of parkin-mediated stimulation of mitophagy in response to mitochondrial depolarization,	GO:0005737~cytoplasm,GO:0005741~mitochondrial outer membrane,GO:0005764~lysosome,GO:0005765~lysosomal membrane,GO:0005770~late endosome,GO:0005789~endoplasmic reticulum membrane,GO:0005811~lipid particle,GO:0005829~cytosol,GO:0019898~extrinsic component of membrane,GO:0031902~late endosome membrane,GO:0032127~dense core granule membrane,GO:0070062~extracellular exosome,		IPR009543:VPS13_VAB,IPR015412:Atg2/VPS13_C,IPR026847:VPS13,IPR026854:VPS13-like_N,IPR031642:VPS13_mid_RBG,IPR031645:VPS13_DH-like,IPR031646:VPS13_extend_chorein,IPR037197:WWE_dom_sf,IPR049424:VPS13_C,		616840~Parkinson disease 23, autosomal recessive, early onset,			KW-0445~Lipid transport,KW-0813~Transport,	KW-0256~Endoplasmic reticulum,KW-0458~Lysosome,KW-0472~Membrane,KW-0496~Mitochondrion,KW-0551~Lipid droplet,KW-0967~Endosome,KW-1000~Mitochondrion outer membrane,	KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0907~Parkinson disease,KW-0908~Parkinsonism,				KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic residues,DOMAIN:Atg2/VPS13 C-terminal,DOMAIN:Chorein N-terminal,DOMAIN:Intermembrane lipid transfer protein VPS13 C-terminal,DOMAIN:SHR-BD,DOMAIN:VPS13 middle RBG modules,DOMAIN:Vacuolar protein sorting-associated protein 13 DH-like,DOMAIN:Vacuolar protein sorting-associated protein 13 VPS13 adaptor binding,MOTIF:FFAT,MUTAGEN:YF->SL: Abnormal localization to the cytosol.,REGION:Disordered,REGION:Required for late endosome/lysosome localization,REGION:Required for lipid droplet localization,
VPS4A	vacuolar protein sorting 4 homolog A(VPS4A)	Homo sapiens			GO:0000916~actomyosin contractile ring contraction,GO:0001778~plasma membrane repair,GO:0006622~protein targeting to lysosome,GO:0006900~membrane budding,GO:0006914~autophagy,GO:0006996~organelle organization,GO:0006997~nucleus organization,GO:0006998~nuclear envelope organization,GO:0007033~vacuole organization,GO:0007049~cell cycle,GO:0007080~mitotic metaphase plate congression,GO:0007084~mitotic nuclear envelope reassembly,GO:0009838~abscission,GO:0015031~protein transport,GO:0016192~vesicle-mediated transport,GO:0016197~endosomal transport,GO:0016236~macroautophagy,GO:0019076~viral release from host cell,GO:0031468~nuclear envelope reassembly,GO:0032367~intracellular cholesterol transport,GO:0032466~negative regulation of cytokinesis,GO:0032880~regulation of protein localization,GO:0034058~endosomal vesicle fusion,GO:0036258~multivesicular body assembly,GO:0039702~viral budding via host ESCRT complex,GO:0043162~ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway,GO:0044878~mitotic cytokinesis checkpoint,GO:0046761~viral budding from plasma membrane,GO:0051301~cell division,GO:0061640~cytoskeleton-dependent cytokinesis,GO:0061738~late endosomal microautophagy,GO:0061764~late endosome to lysosome transport via multivesicular body sorting pathway,GO:0071985~multivesicular body sorting pathway,GO:0072319~vesicle uncoating,GO:0090148~membrane fission,GO:0090611~ubiquitin-independent protein catabolic process via the multivesicular body sorting pathway,GO:0097352~autophagosome maturation,GO:1903076~regulation of protein localization to plasma membrane,GO:1903543~positive regulation of exosomal secretion,GO:1903774~positive regulation of viral budding via host ESCRT complex,GO:1904896~ESCRT complex disassembly,GO:1904903~ESCRT III complex disassembly,	GO:0000922~spindle pole,GO:0005634~nucleus,GO:0005643~nuclear pore,GO:0005737~cytoplasm,GO:0005764~lysosome,GO:0005768~endosome,GO:0005769~early endosome,GO:0005770~late endosome,GO:0005774~vacuolar membrane,GO:0005813~centrosome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0010008~endosome membrane,GO:0030496~midbody,GO:0031902~late endosome membrane,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,GO:0090543~Flemming body,GO:1904949~ATPase complex,	GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016887~ATPase activity,GO:0044877~macromolecular complex binding,	IPR003593:AAA+_ATPase,IPR003959:ATPase_AAA_core,IPR003960:ATPase_AAA_CS,IPR007330:MIT_dom,IPR015415:Spast_Vps4_C,IPR027417:P-loop_NTPase,IPR036181:MIT_dom_sf,IPR041569:AAA_lid_3,IPR045253:VPS4_MIT,	hsa03250:Viral life cycle - HIV-1,hsa04144:Endocytosis,hsa04217:Necroptosis,	619273~CIMDAG syndrome,		SM00382:AAA,SM00745:MIT,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0653~Protein transport,KW-0813~Transport,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0967~Endosome,	KW-0225~Disease variant,KW-0360~Hereditary hemolytic anemia,KW-0898~Cataract,KW-0991~Intellectual disability,KW-1055~Congenital dyserythropoietic anemia,		KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:AAA+ ATPase,DOMAIN:MIT,DOMAIN:Spastin/Vps4 C-terminal,MUTAGEN:E->D: Diminishes interaction with CHMP1B.,MUTAGEN:E->Q: Defective in ATP-hydrolysis. Causes membrane association. Induces vacuolation of endosomal compartments and impairs cholesterol and protein sorting. Inhibits HIV-1 release. Increases binding to CHMP1.,MUTAGEN:G->A: Impairs HIV-1 release.,MUTAGEN:K->Q: Defective in ATP-binding. Causes membrane association. Induces vacuolation of endosomal compartments and impairs cholesterol sorting. Inhibits HIV-1 release. Greatly diminishes localization to punctate class E compartments and partially restores HIV-1 release; when associated with D-64. Greatly diminishes localization to punctate class E compartments; when associated with D-173.,MUTAGEN:L->A,D: Abolishes interaction with CHMP1B; diminishes interaction with IST1.,MUTAGEN:L->D: Greatly diminishes localization to punctate class E compartments and partially restores HIV-1 release; when associated with Q-173.,MUTAGEN:L->D: Modestly reduces interaction with CHMP6.,MUTAGEN:V->A,D: Diminishes interaction with IST1.,MUTAGEN:V->D: Abolishes interaction with CHMP6, no effect on interaction with CHMP1A.,MUTAGEN:V->D: Greatly diminishes localization to punctate class E compartments; when associated with Q-173.,MUTAGEN:WL->AA: Strongly impairs HIV-1 release.,REGION:Disordered,REGION:Interaction with CHMP1B,
VPS4B	vacuolar protein sorting 4 homolog B(VPS4B)	Homo sapiens			GO:0001525~angiogenesis,GO:0001778~plasma membrane repair,GO:0006813~potassium ion transport,GO:0006914~autophagy,GO:0006997~nucleus organization,GO:0007033~vacuole organization,GO:0007049~cell cycle,GO:0007080~mitotic metaphase plate congression,GO:0010824~regulation of centrosome duplication,GO:0010971~positive regulation of G2/M transition of mitotic cell cycle,GO:0015031~protein transport,GO:0016197~endosomal transport,GO:0016236~macroautophagy,GO:0030301~cholesterol transport,GO:0031468~nuclear envelope reassembly,GO:0032510~endosome to lysosome transport via multivesicular body sorting pathway,GO:0033993~response to lipid,GO:0036258~multivesicular body assembly,GO:0039702~viral budding via host ESCRT complex,GO:0043162~ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway,GO:0046761~viral budding from plasma membrane,GO:0051261~protein depolymerization,GO:0051301~cell division,GO:0060070~canonical Wnt signaling pathway,GO:0060856~establishment of blood-brain barrier,GO:0061738~late endosomal microautophagy,GO:0061764~late endosome to lysosome transport via multivesicular body sorting pathway,GO:0071985~multivesicular body sorting pathway,GO:0090148~membrane fission,GO:0090611~ubiquitin-independent protein catabolic process via the multivesicular body sorting pathway,GO:0097352~autophagosome maturation,GO:1901673~regulation of mitotic spindle assembly,GO:1903542~negative regulation of exosomal secretion,GO:1903543~positive regulation of exosomal secretion,GO:1903724~positive regulation of centriole elongation,GO:1904903~ESCRT III complex disassembly,	GO:0000922~spindle pole,GO:0005634~nucleus,GO:0005643~nuclear pore,GO:0005737~cytoplasm,GO:0005768~endosome,GO:0005813~centrosome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0010008~endosome membrane,GO:0030496~midbody,GO:0031902~late endosome membrane,GO:0070062~extracellular exosome,GO:0090543~Flemming body,GO:1904949~ATPase complex,	GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016887~ATPase activity,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0044877~macromolecular complex binding,	IPR003593:AAA+_ATPase,IPR003959:ATPase_AAA_core,IPR003960:ATPase_AAA_CS,IPR007330:MIT_dom,IPR015415:Spast_Vps4_C,IPR027417:P-loop_NTPase,IPR036181:MIT_dom_sf,IPR041569:AAA_lid_3,IPR045253:VPS4_MIT,	hsa03250:Viral life cycle - HIV-1,hsa04144:Endocytosis,hsa04217:Necroptosis,			SM00382:AAA,SM00745:MIT,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0653~Protein transport,KW-0813~Transport,	KW-0472~Membrane,KW-0967~Endosome,		KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:AAA+ ATPase,DOMAIN:MIT,MUTAGEN:A->D: Reduces HIV-1 release 10-fold; when associated with D-66.,MUTAGEN:A->D: Reduces HIV-1 release 2-fold.,MUTAGEN:E->Q: Defective in vacuolar protein sorting.,MUTAGEN:G->A: Impairs HIV-1 release.,MUTAGEN:L->D: Reduces HIV-1 release 10-fold; when associated with D-15.,MUTAGEN:L->D: Reduces HIV-1 release 3-fold.,MUTAGEN:Missing: Abolishes interaction with VTA1.,MUTAGEN:WL->AA: Strongly impairs HIV-1 release.,REGION:Disordered,
VMP1	vacuole membrane protein 1(VMP1)	Homo sapiens			GO:0000045~autophagosome assembly,GO:0006914~autophagy,GO:0007030~Golgi organization,GO:0007566~embryo implantation,GO:0016240~autophagosome docking,GO:0017121~phospholipid scrambling,GO:0034329~cell junction assembly,GO:0042953~lipoprotein transport,GO:0098609~cell-cell adhesion,GO:1901896~positive regulation of calcium-transporting ATPase activity,GO:1990456~mitochondrion-ER tethering,	GO:0000407~pre-autophagosomal structure,GO:0000421~autophagosome membrane,GO:0005730~nucleolus,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0012505~endomembrane system,GO:0016020~membrane,GO:0033116~endoplasmic reticulum-Golgi intermediate compartment membrane,	GO:0005515~protein binding,GO:0017128~phospholipid scramblase activity,	IPR032816:VTT_dom,	hsa04140:Autophagy - animal,				KW-0072~Autophagy,KW-0130~Cell adhesion,KW-0445~Lipid transport,KW-0813~Transport,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0926~Vacuole,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,	DOMAIN:VTT,MUTAGEN:G->E: Decreases interaction with ATP2A2.,MUTAGEN:G->R: Decreases interaction with ATP2A2.,REGION:Disordered,REGION:VTT domain,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
VEZF1	vascular endothelial zinc finger 1(VEZF1)	Homo sapiens			GO:0001525~angiogenesis,GO:0001885~endothelial cell development,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006968~cellular defense response,GO:0045603~positive regulation of endothelial cell differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,	GO:0005634~nucleus,GO:0005654~nucleoplasm,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR013087:Znf_C2H2_type,IPR036236:Znf_C2H2_sf,		620247~Cardiomyopathy, dilated, 1OO,		SM00355:ZnF_C2H2,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0122~Cardiomyopathy,KW-0225~Disease variant,	KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0238~DNA-binding,	KW-0007~Acetylation,	COMPBIAS:Polar residues,DOMAIN:C2H2-type,REGION:4 X 7 AA repeats of P-[LV]-T-[IL]-T-[ST]-P,REGION:Disordered,REPEAT:1,REPEAT:2,REPEAT:3,REPEAT:4,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4,ZN_FING:C2H2-type 5,ZN_FING:C2H2-type 6,
VAMP5	vesicle associated membrane protein 5(VAMP5)	Homo sapiens			GO:0007517~muscle organ development,GO:0007519~skeletal muscle tissue development,GO:0030154~cell differentiation,GO:0043001~Golgi to plasma membrane protein transport,	GO:0005770~late endosome,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0014704~intercalated disc,GO:0030659~cytoplasmic vesicle membrane,GO:0031090~organelle membrane,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,	GO:0005515~protein binding,	IPR001388:Synaptobrevin-like,IPR042166:Vamp5,IPR042581:VAMP5_R-SNARE,IPR042855:V_SNARE_CC,	hsa04130:SNARE interactions in vesicular transport,				KW-0221~Differentiation,KW-0517~Myogenesis,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-1003~Cell membrane,		KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,	DOMAIN:V-SNARE coiled-coil homology,DOMAIN:v-SNARE coiled-coil homology,REGION:Disordered,SITE:(Microbial infection) Cleavage; by C.botulinum neurotoxin type X (BoNT/X),TOPO_DOM:Cytoplasmic,TOPO_DOM:Vesicular,TRANSMEM:Helical,TRANSMEM:Helical; Anchor for type IV membrane protein,
VAMP7	vesicle associated membrane protein 7(VAMP7)	Homo sapiens			GO:0006887~exocytosis,GO:0006888~ER to Golgi vesicle-mediated transport,GO:0006906~vesicle fusion,GO:0006911~phagocytosis, engulfment,GO:0008333~endosome to lysosome transport,GO:0015031~protein transport,GO:0016192~vesicle-mediated transport,GO:0017156~calcium ion regulated exocytosis,GO:0043308~eosinophil degranulation,GO:0043312~neutrophil degranulation,GO:0043320~natural killer cell degranulation,GO:1903595~positive regulation of histamine secretion by mast cell,	GO:0005737~cytoplasm,GO:0005765~lysosomal membrane,GO:0005789~endoplasmic reticulum membrane,GO:0005802~trans-Golgi network,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0030027~lamellipodium,GO:0030141~secretory granule,GO:0030658~transport vesicle membrane,GO:0030667~secretory granule membrane,GO:0030669~clathrin-coated endocytic vesicle membrane,GO:0030670~phagocytic vesicle membrane,GO:0031091~platelet alpha granule,GO:0031143~pseudopodium,GO:0031201~SNARE complex,GO:0031902~late endosome membrane,GO:0035577~azurophil granule membrane,GO:0043005~neuron projection,GO:0043231~intracellular membrane-bounded organelle,GO:0045202~synapse,GO:0045335~phagocytic vesicle,GO:0070062~extracellular exosome,	GO:0000149~SNARE binding,GO:0005484~SNAP receptor activity,GO:0005515~protein binding,	IPR001388:Synaptobrevin-like,IPR010908:Longin_dom,IPR011012:Longin-like_dom_sf,IPR042855:V_SNARE_CC,	hsa04130:SNARE interactions in vesicular transport,			SM01270:Longin,	KW-0268~Exocytosis,KW-0653~Protein transport,KW-0813~Transport,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0458~Lysosome,KW-0472~Membrane,KW-0770~Synapse,KW-0771~Synaptosome,KW-0967~Endosome,KW-0968~Cytoplasmic vesicle,		KW-0175~Coiled coil,KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:Longin,DOMAIN:V-SNARE coiled-coil homology,DOMAIN:v-SNARE coiled-coil homology,TOPO_DOM:Cytoplasmic,TOPO_DOM:Vesicular,TRANSMEM:Helical,TRANSMEM:Helical; Anchor for type IV membrane protein,
VAMP8	vesicle associated membrane protein 8(VAMP8)	Homo sapiens			GO:0006906~vesicle fusion,GO:0015031~protein transport,GO:0016192~vesicle-mediated transport,GO:0016240~autophagosome docking,GO:0035493~SNARE complex assembly,GO:0046718~viral entry into host cell,GO:0051607~defense response to virus,GO:0070254~mucus secretion,GO:0097352~autophagosome maturation,GO:1903076~regulation of protein localization to plasma membrane,GO:1903531~negative regulation of secretion by cell,GO:1903595~positive regulation of histamine secretion by mast cell,	GO:0005737~cytoplasm,GO:0005765~lysosomal membrane,GO:0005769~early endosome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0030667~secretory granule membrane,GO:0030669~clathrin-coated endocytic vesicle membrane,GO:0030670~phagocytic vesicle membrane,GO:0031201~SNARE complex,GO:0031901~early endosome membrane,GO:0031902~late endosome membrane,GO:0031982~vesicle,GO:0035577~azurophil granule membrane,GO:0035579~specific granule membrane,GO:0042589~zymogen granule membrane,GO:0048471~perinuclear region of cytoplasm,GO:0055037~recycling endosome,GO:0055038~recycling endosome membrane,GO:0070062~extracellular exosome,GO:0070821~tertiary granule membrane,GO:0098594~mucin granule,	GO:0005484~SNAP receptor activity,GO:0005515~protein binding,GO:0019869~chloride channel inhibitor activity,GO:0019905~syntaxin binding,	IPR001388:Synaptobrevin-like,IPR016444:Synaptobrevin/VAMP,IPR042855:V_SNARE_CC,	hsa04130:SNARE interactions in vesicular transport,hsa04140:Autophagy - animal,hsa04611:Platelet activation,		PIRSF005409:Synaptobrevin_euk,		KW-0051~Antiviral defense,KW-0072~Autophagy,KW-0653~Protein transport,KW-0813~Transport,	KW-0458~Lysosome,KW-0472~Membrane,KW-0967~Endosome,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,		KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,KW-0449~Lipoprotein,KW-0597~Phosphoprotein,	DOMAIN:V-SNARE coiled-coil homology,DOMAIN:v-SNARE coiled-coil homology,LIPID:(Microbial infection) N6-stearoyl lysine,MUTAGEN:K->R: Does not affect stearoylation in response to S.flexneri infection.,MUTAGEN:KVARK->RVARR: Abolished stearoylation in response to S.flexneri infection.,SITE:Interaction with STX8,TOPO_DOM:Cytoplasmic,TOPO_DOM:Vesicular,TRANSMEM:Helical,TRANSMEM:Helical; Anchor for type IV membrane protein,
VTA1	vesicle trafficking 1(VTA1)	Homo sapiens			GO:0015031~protein transport,GO:0016236~macroautophagy,GO:0032511~late endosome to vacuole transport via multivesicular body sorting pathway,GO:0036258~multivesicular body assembly,GO:0071985~multivesicular body sorting pathway,GO:1904903~ESCRT III complex disassembly,	GO:0005654~nucleoplasm,GO:0005771~multivesicular body,GO:0005829~cytosol,GO:0010008~endosome membrane,GO:0043231~intracellular membrane-bounded organelle,GO:0070062~extracellular exosome,	GO:0005515~protein binding,	IPR023175:Vta1/CALS_N_sf,IPR039431:Vta1/CALS_N,IPR041212:Vta1_C,IPR044538:Vta1-like,	hsa04144:Endocytosis,				KW-0653~Protein transport,KW-0813~Transport,	KW-0472~Membrane,KW-0963~Cytoplasm,KW-0967~Endosome,					KW-0007~Acetylation,	COMPBIAS:Polar residues,DOMAIN:Vta1 C-terminal,DOMAIN:Vta1/callose synthase N-terminal,REGION:Disordered,REGION:Interaction with CHMP5,REGION:Interaction with IST1,REGION:Interaction with VPS4B,
VTI1B	vesicle transport through interaction with t-SNAREs 1B(VTI1B)	Homo sapiens			GO:0006886~intracellular protein transport,GO:0006891~intra-Golgi vesicle-mediated transport,GO:0006896~Golgi to vacuole transport,GO:0006904~vesicle docking involved in exocytosis,GO:0015031~protein transport,GO:0016192~vesicle-mediated transport,GO:0016236~macroautophagy,GO:0042147~retrograde transport, endosome to Golgi,GO:0048280~vesicle fusion with Golgi apparatus,GO:0061025~membrane fusion,GO:1903076~regulation of protein localization to plasma membrane,	GO:0005576~extracellular region,GO:0005737~cytoplasm,GO:0005765~lysosomal membrane,GO:0005789~endoplasmic reticulum membrane,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0008021~synaptic vesicle,GO:0012507~ER to Golgi transport vesicle membrane,GO:0016020~membrane,GO:0031093~platelet alpha granule lumen,GO:0031201~SNARE complex,GO:0031901~early endosome membrane,GO:0031902~late endosome membrane,GO:0031982~vesicle,GO:0043025~neuronal cell body,GO:0043231~intracellular membrane-bounded organelle,GO:0048471~perinuclear region of cytoplasm,GO:0055037~recycling endosome,GO:0055038~recycling endosome membrane,	GO:0000149~SNARE binding,GO:0005484~SNAP receptor activity,GO:0005515~protein binding,GO:0019869~chloride channel inhibitor activity,	IPR000727:T_SNARE_dom,IPR007705:Vesicle_trsprt_v-SNARE_N,IPR010989:SNARE,IPR038407:v-SNARE_N_sf,	hsa04130:SNARE interactions in vesicular transport,			SM00397:t_SNARE,	KW-0653~Protein transport,KW-0813~Transport,	KW-0458~Lysosome,KW-0472~Membrane,KW-0967~Endosome,		KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:T-SNARE coiled-coil homology,MUTAGEN:E->A: Abolished binding to CLINT1. Abnormal subcellular localization restricted to late endosomes and lysosomes.,MUTAGEN:E->R: Abolished binding to CLINT1. Rescued binding to CLINT1 E-146 mutant.,MUTAGEN:E->W: Abolished binding to CLINT1.,MUTAGEN:F->S: Abolished binding to CLINT1. Abnormal subcellular localization restricted to late endosomes and lysosomes.,MUTAGEN:I->S: Normal binding to CLINT1.,MUTAGEN:M->S: Normal binding to CLINT1.,MUTAGEN:P->S: Reduced binding to CLINT1.,MUTAGEN:S->W: Abolished binding to CLINT1.,REGION:Disordered,REGION:Interaction with CLINT1,TOPO_DOM:Cytoplasmic,TOPO_DOM:Vesicular,TRANSMEM:Helical,TRANSMEM:Helical; Anchor for type IV membrane protein,
VEZT	vezatin, adherens junctions transmembrane protein(VEZT)	Homo sapiens			GO:0098609~cell-cell adhesion,	GO:0001669~acrosomal vesicle,GO:0002142~stereocilia ankle link complex,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005912~adherens junction,GO:0016020~membrane,GO:0060171~stereocilium membrane,	GO:0017022~myosin binding,	IPR026858:Vezatin,IPR026859:Myosin-bd,						KW-0472~Membrane,KW-0539~Nucleus,KW-0965~Cell junction,KW-0966~Cell projection,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,		KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,				COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Myosin-binding,REGION:Disordered,TRANSMEM:Helical,
VIM	vimentin(VIM)	Homo sapiens			GO:0010628~positive regulation of gene expression,GO:0010977~negative regulation of neuron projection development,GO:0014002~astrocyte development,GO:0031175~neuron projection development,GO:0032967~positive regulation of collagen biosynthetic process,GO:0043488~regulation of mRNA stability,GO:0045109~intermediate filament organization,GO:0045727~positive regulation of translation,GO:0060020~Bergmann glial cell differentiation,GO:0060395~SMAD protein signal transduction,GO:0070307~lens fiber cell development,GO:0071222~cellular response to lipopolysaccharide,GO:0071225~cellular response to muramyl dipeptide,GO:0071346~cellular response to interferon-gamma,	GO:0005737~cytoplasm,GO:0005777~peroxisome,GO:0005815~microtubule organizing center,GO:0005829~cytosol,GO:0005844~polysome,GO:0005856~cytoskeleton,GO:0005882~intermediate filament,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0016363~nuclear matrix,GO:0030424~axon,GO:0031252~cell leading edge,GO:0043005~neuron projection,GO:0045111~intermediate filament cytoskeleton,GO:0045335~phagocytic vesicle,GO:0070062~extracellular exosome,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003725~double-stranded RNA binding,GO:0005200~structural constituent of cytoskeleton,GO:0005212~structural constituent of eye lens,GO:0005515~protein binding,GO:0019904~protein domain specific binding,GO:0042802~identical protein binding,GO:0060090~binding, bridging,GO:0097110~scaffold protein binding,GO:1990254~keratin filament binding,	IPR006821:Intermed_filament_DNA-bd,IPR018039:IF_conserved,IPR039008:IF_rod_dom,	hsa05169:Epstein-Barr virus infection,hsa05206:MicroRNAs in cancer,	116300~Cataract 30, pulverulent,		SM01391:Filament,	KW-0945~Host-virus interaction,	KW-0206~Cytoskeleton,KW-0403~Intermediate filament,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0898~Cataract,	KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0702~S-nitrosylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CARBOHYD:O-linked (GlcNAc) serine; alternate,CARBOHYD:O-linked (GlcNAc) threonine,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:IF rod,DOMAIN:Intermediate filament head DNA-binding,MOTIF:[IL]-x-C-x-x-[DE] motif,REGION:Coil 1A,REGION:Coil 1B,REGION:Coil 2,REGION:Disordered,REGION:Head,REGION:Linker 1,REGION:Linker 12,REGION:Tail,SITE:Stutter,
VDAC1	voltage dependent anion channel 1(VDAC1)	Homo sapiens			GO:0001662~behavioral fear response,GO:0006090~pyruvate metabolic process,GO:0006820~anion transport,GO:0006915~apoptotic process,GO:0007270~neuron-neuron synaptic transmission,GO:0007612~learning,GO:0030855~epithelial cell differentiation,GO:0043066~negative regulation of apoptotic process,GO:0098656~anion transmembrane transport,GO:1903146~regulation of mitophagy,GO:1905091~positive regulation of parkin-mediated stimulation of mitophagy in response to mitochondrial depolarization,GO:2000378~negative regulation of reactive oxygen species metabolic process,	GO:0005634~nucleus,GO:0005739~mitochondrion,GO:0005741~mitochondrial outer membrane,GO:0005757~mitochondrial permeability transition pore complex,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0031966~mitochondrial membrane,GO:0042645~mitochondrial nucleoid,GO:0045121~membrane raft,GO:0045202~synapse,GO:0046930~pore complex,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0008142~oxysterol binding,GO:0008308~voltage-gated anion channel activity,GO:0015288~porin activity,GO:0015485~cholesterol binding,GO:0019901~protein kinase binding,GO:0031210~phosphatidylcholine binding,GO:0042802~identical protein binding,GO:0044325~ion channel binding,GO:0097001~ceramide binding,	IPR001925:Porin_Euk,IPR023614:Porin_dom_sf,IPR027246:Porin_Euk/Tom40,	hsa04020:Calcium signaling pathway,hsa04022:cGMP-PKG signaling pathway,hsa04217:Necroptosis,hsa04218:Cellular senescence,hsa04613:Neutrophil extracellular trap formation,hsa04621:NOD-like receptor signaling pathway,hsa04979:Cholesterol metabolism,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05017:Spinocerebellar ataxia,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05131:Shigellosis,hsa05164:Influenza A,hsa05166:Human T-cell leukemia virus 1 infection,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05415:Diabetic cardiomyopathy,				KW-0053~Apoptosis,KW-0406~Ion transport,KW-0813~Transport,KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-1000~Mitochondrion outer membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1134~Transmembrane beta strand,	KW-0446~Lipid-binding,	KW-0626~Porin,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin); alternate,MUTAGEN:E->Q: Abolishes ceramide and phosphatidylcholine binding.,MUTAGEN:K->R: Loss of PRKN-dependent monoubiquitination increases mitochondria calcium uptake, and ultimately increased apoptosis. Consequently, mitochondria are swelled with defective cristae structures. PRKN-dependent polyubiquitination is unaffected.,MUTAGEN:K->R: PRKN-dependent polybiquitination is decreased, whereas PRKN-dependent monoubiquitination, mitochondrial calcium uptake and apoptosis are unaffected; when associated with R-12; R-20 and 109-R-R-110.,MUTAGEN:K->R: PRKN-dependent polybiquitination is decreased, whereas PRKN-dependent monoubiquitination, mitochondrial calcium uptake and apoptosis are unaffected; when associated with R-12; R-53 and 109-R-R-110.,MUTAGEN:K->R: PRKN-dependent polybiquitination is decreased, whereas PRKN-dependent monoubiquitination, mitochondrial calcium uptake and apoptosis are unaffected; when associated with R-20; R-53 and 109-R-R-110.,MUTAGEN:KK->RR: PRKN-dependent polybiquitination is decreased, whereas PRKN-dependent monoubiquitination, mitochondrial calcium uptake and apoptosis are unaffected; when associated with R-12; R-20 and R-53.,MUTAGEN:S->A: Conformation remains open and constitutively allows cytochrome c efflux.,MUTAGEN:S->E: Conformation remains closed and prevents cytochrome c leakage.,SITE:Involved in ceramide and phosphatidylcholine binding. Critical for channel structural stability and gating,TRANSMEM:Beta stranded,
VHL	von Hippel-Lindau tumor suppressor(VHL)	Homo sapiens		h_hifPathway:Hypoxia-Inducible Factor in the Cardiovascular System,h_vegfPathway:VEGF, Hypoxia, and Angiogenesis,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0000902~cell morphogenesis,GO:0006355~regulation of transcription, DNA-templated,GO:0006508~proteolysis,GO:0008285~negative regulation of cell proliferation,GO:0009968~negative regulation of signal transduction,GO:0010468~regulation of gene expression,GO:0010507~negative regulation of autophagy,GO:0010629~negative regulation of gene expression,GO:0016567~protein ubiquitination,GO:0034244~negative regulation of transcription elongation from RNA polymerase II promoter,GO:0043066~negative regulation of apoptotic process,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0045597~positive regulation of cell differentiation,GO:0045893~positive regulation of transcription, DNA-templated,GO:0046426~negative regulation of JAK-STAT cascade,GO:0050821~protein stabilization,GO:0061428~negative regulation of transcription from RNA polymerase II promoter in response to hypoxia,GO:0071456~cellular response to hypoxia,GO:1900037~regulation of cellular response to hypoxia,GO:1904262~negative regulation of TORC1 signaling,GO:1990000~amyloid fibril formation,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005739~mitochondrion,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0043232~intracellular non-membrane-bounded organelle,	GO:0003714~transcription corepressor activity,GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0019899~enzyme binding,GO:0060090~binding, bridging,GO:1990756~protein binding, bridging involved in substrate recognition for ubiquitination,	IPR022772:VHL_tumour_suppress_b/a_dom,IPR024048:VHL_alpha_dom,IPR024053:VHL_beta_dom,IPR036208:VHL_sf,IPR037139:VHL_alpha_dom_sf,IPR037140:VHL_beta_dom_sf,	hsa04066:HIF-1 signaling pathway,hsa04120:Ubiquitin mediated proteolysis,hsa05200:Pathways in cancer,hsa05211:Renal cell carcinoma,	144700~Renal cell carcinoma, somatic,171300~Pheochromocytoma,193300~von Hippel-Lindau syndrome,263400~Erythrocytosis, familial, 2,Hemangioblastoma, cerebellar, somatic~Hemangioblastoma, cerebellar, somatic,			KW-0833~Ubl conjugation pathway,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,	KW-0043~Tumor suppressor,KW-0225~Disease variant,KW-0985~Congenital erythrocytosis,	KW-0677~Repeat,				COMPBIAS:Acidic residues,COMPBIAS:Polar residues,DOMAIN:von Hippel-Lindau disease tumour suppressor alpha,DOMAIN:von Hippel-Lindau disease tumour suppressor beta,MUTAGEN:Y->N: No interaction with HIF1A. No HIF1A degradation.,REGION:8 X 5 AA tandem repeats of G-[PAVG]-E-E-[DAYSLE],REGION:Disordered,REGION:Interaction with Elongin BC complex,REGION:Involved in binding to CCT complex,REPEAT:1,REPEAT:2,REPEAT:3,REPEAT:4,REPEAT:5,REPEAT:6,REPEAT:7,REPEAT:8,
YPEL5	yippee like 5(YPEL5)	Homo sapiens			GO:0008283~cell proliferation,	GO:0000151~ubiquitin ligase complex,GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005813~centrosome,GO:0030496~midbody,GO:0097431~mitotic spindle pole,GO:1904724~tertiary granule lumen,GO:1904813~ficolin-1-rich granule lumen,	GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR004910:Yippee/Mis18/Cereblon,IPR034751:Yippee,IPR039058:Yippee_fam,						KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0479~Metal-binding,KW-0862~Zinc,		KW-0597~Phosphoprotein,	DOMAIN:Yippee,
ZAP70	zeta chain of T cell receptor associated protein kinase 70(ZAP70)	Homo sapiens	3.T_cell_receptor,54.T-cell_anergy,63.LAT_couples_T-cell_receptor,82.TCR_and_Cap_or_SMAC,	h_cskPathway:Activation of Csk by cAMP-dependent Protein Kinase Inhibits Signaling through the T Cell Receptor,h_tcraPathway:Lck and Fyn tyrosine kinases in initiation of TCR Activation,h_tcrPathway:T Cell Receptor Signaling Pathway,	GO:0002250~adaptive immune response,GO:0006468~protein phosphorylation,GO:0006955~immune response,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0018108~peptidyl-tyrosine phosphorylation,GO:0019722~calcium-mediated signaling,GO:0030154~cell differentiation,GO:0030217~T cell differentiation,GO:0035556~intracellular signal transduction,GO:0042110~T cell activation,GO:0042113~B cell activation,GO:0043366~beta selection,GO:0045059~positive thymic T cell selection,GO:0045060~negative thymic T cell selection,GO:0045087~innate immune response,GO:0045582~positive regulation of T cell differentiation,GO:0046638~positive regulation of alpha-beta T cell differentiation,GO:0046641~positive regulation of alpha-beta T cell proliferation,GO:0050850~positive regulation of calcium-mediated signaling,GO:0050852~T cell receptor signaling pathway,GO:0070489~T cell aggregation,GO:0072678~T cell migration,	GO:0001772~immunological synapse,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005911~cell-cell junction,GO:0031234~extrinsic component of cytoplasmic side of plasma membrane,GO:0042101~T cell receptor complex,GO:0045121~membrane raft,	GO:0001784~phosphotyrosine binding,GO:0004713~protein tyrosine kinase activity,GO:0004715~non-membrane spanning protein tyrosine kinase activity,GO:0005102~receptor binding,GO:0005515~protein binding,GO:0005524~ATP binding,	IPR000719:Prot_kinase_dom,IPR000980:SH2,IPR001245:Ser-Thr/Tyr_kinase_cat_dom,IPR008266:Tyr_kinase_AS,IPR011009:Kinase-like_dom_sf,IPR012234:Tyr_kinase_non-rcpt_SYK/ZAP70,IPR017441:Protein_kinase_ATP_BS,IPR020635:Tyr_kinase_cat_dom,IPR023420:Kinase_SYK/ZAP-70_inter-SH2_sf,IPR035838:SYK/ZAP-70_N_SH2,IPR036860:SH2_dom_sf,	hsa04014:Ras signaling pathway,hsa04064:NF-kappa B signaling pathway,hsa04650:Natural killer cell mediated cytotoxicity,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04660:T cell receptor signaling pathway,hsa05135:Yersinia infection,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,hsa05340:Primary immunodeficiency,	269840~Immunodeficiency 48,617006~Autoimmune disease, multisystem, infantile-onset, 2,	PIRSF000604:TyrPK_SYK,	SM00219:TyrKc,SM00252:SH2,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0705~SCID,	KW-0677~Repeat,KW-0727~SH2 domain,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0808~Transferase,KW-0829~Tyrosine-protein kinase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	ACT_SITE:Proton acceptor,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:Protein kinase,DOMAIN:SH2 1,DOMAIN:SH2 2,MUTAGEN:A->E: Increased constitutive kinase activity.,MUTAGEN:D->N: Abolishes kinase activity.,MUTAGEN:D->P: Increases constitutive kinase activity on LAT phosphorylation, strongly increases subcellular localization of CD69 at the cell surface and decreases autoinhibition conformation.,MUTAGEN:K->E: Increases constitutive kinase activity on LAT phosphorylation, strongly increases subcellular localization of CD69 at the cell surface and decreases autoinhibition conformation.,MUTAGEN:K->R: No effect on ubiquitination.,MUTAGEN:K->R: Strongly decreased ubiquitination.,MUTAGEN:L->A: Increased constitutive kinase activity.,MUTAGEN:P->A: Increased kinase activity after activation by LCK.,MUTAGEN:Q->A: Increased kinase activity after activation by LCK.,MUTAGEN:R->K: Decreases interaction with phosphorylated CD247; when associated with K-190.,MUTAGEN:R->K: Decreases interaction with phosphorylated CD247; when associated with K-37.,MUTAGEN:S->A: Increased kinase activity after activation by LCK.,MUTAGEN:V->A: Increased constitutive kinase activity.,MUTAGEN:W->A: Increased constitutive kinase activity.,MUTAGEN:Y->A: Increased constitutive kinase activity; when associated with F-315.,MUTAGEN:Y->A: Increased constitutive kinase activity; when associated with F-319.,MUTAGEN:Y->A: Increased kinase activity after activation by LCK.,MUTAGEN:Y->F: Impairs kinase activity.,MUTAGEN:Y->F: Increased constitutive kinase activity; when associated with F-315. About 80% loss of TCR-induced NFAT activation.,MUTAGEN:Y->F: Increased constitutive kinase activity; when associated with F-319. About 75% loss of CD247/CD3Z-binding in stimulated TCR and complete loss of VAV1 interaction.,MUTAGEN:Y->F: Increases kinase activity.,MUTAGEN:Y->F: Induces constitutive TCR stimulation-independent NFAT induction.,MUTAGEN:YESPY->AESPA: Increases strongly constitutive kinase activity on LAT phosphorylation.,REGION:Disordered,REGION:Interdomain A,REGION:Interdomain B,
ZFAND2A	zinc finger AN1-type containing 2A(ZFAND2A)	Homo sapiens			GO:0032436~positive regulation of proteasomal ubiquitin-dependent protein catabolic process,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0045047~protein targeting to ER,GO:0071243~cellular response to arsenic-containing substance,	GO:0000502~proteasome complex,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,	GO:0005515~protein binding,GO:0008270~zinc ion binding,	IPR000058:Znf_AN1,IPR035896:AN1-like_Znf,				SM00154:ZnF_AN1,		KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,			DOMAIN:AN1-type,REGION:Disordered,ZN_FING:AN1-type 1,ZN_FING:AN1-type 2,
ZFAND2B	zinc finger AN1-type containing 2B(ZFAND2B)	Homo sapiens			GO:0006616~SRP-dependent cotranslational protein targeting to membrane, translocation,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0043567~regulation of insulin-like growth factor receptor signaling pathway,GO:0045047~protein targeting to ER,	GO:0000502~proteasome complex,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0016020~membrane,	GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0036435~K48-linked polyubiquitin binding,GO:0043130~ubiquitin binding,	IPR000058:Znf_AN1,IPR003903:UIM_dom,IPR035896:AN1-like_Znf,				SM00154:ZnF_AN1,SM00726:UIM,		KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0449~Lipoprotein,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0636~Prenylation,	COMPBIAS:Basic and acidic residues,DOMAIN:AN1-type,DOMAIN:UIM 1,DOMAIN:UIM 2,LIPID:S-geranylgeranyl cysteine,MOTIF:CAAX motif,PROPEP:Removed in mature form,REGION:Disordered,REGION:VCP/p97-interacting motif (VIM),ZN_FING:AN1-type 1,ZN_FING:AN1-type 2,
ZFAND3	zinc finger AN1-type containing 3(ZFAND3)	Homo sapiens					GO:0003677~DNA binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,	IPR000058:Znf_AN1,IPR002653:Znf_A20,IPR035896:AN1-like_Znf,				SM00154:ZnF_AN1,SM00259:ZnF_A20,				KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,			COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:A20-type,DOMAIN:AN1-type,REGION:Disordered,ZN_FING:A20-type,ZN_FING:AN1-type,
ZFAND5	zinc finger AN1-type containing 5(ZFAND5)	Homo sapiens			GO:0001701~in utero embryonic development,GO:0001944~vasculature development,GO:0003016~respiratory system process,GO:0010761~fibroblast migration,GO:0048008~platelet-derived growth factor receptor signaling pathway,GO:0048705~skeletal system morphogenesis,GO:0048745~smooth muscle tissue development,GO:0060324~face development,	GO:0005737~cytoplasm,	GO:0003677~DNA binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,	IPR000058:Znf_AN1,IPR002653:Znf_A20,IPR035896:AN1-like_Znf,				SM00154:ZnF_AN1,SM00259:ZnF_A20,	KW-0833~Ubl conjugation pathway,	KW-0963~Cytoplasm,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:A20-type,REGION:Disordered,ZN_FING:A20-type,ZN_FING:AN1-type,
ZFAND6	zinc finger AN1-type containing 6(ZFAND6)	Homo sapiens			GO:0006625~protein targeting to peroxisome,GO:0006915~apoptotic process,GO:0015031~protein transport,GO:0043066~negative regulation of apoptotic process,GO:0043122~regulation of I-kappaB kinase/NF-kappaB signaling,GO:0071356~cellular response to tumor necrosis factor,	GO:0005829~cytosol,	GO:0003677~DNA binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0031593~polyubiquitin binding,	IPR000058:Znf_AN1,IPR002653:Znf_A20,IPR035896:AN1-like_Znf,				SM00154:ZnF_AN1,SM00259:ZnF_A20,	KW-0053~Apoptosis,KW-0653~Protein transport,KW-0813~Transport,	KW-0963~Cytoplasm,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:A20-type,DOMAIN:AN1-type,REGION:Disordered,ZN_FING:A20-type,ZN_FING:AN1-type,
ZFC3H1	zinc finger C3H1-type containing(ZFC3H1)	Homo sapiens			GO:0006396~RNA processing,	GO:0000178~exosome (RNase complex),GO:0005615~extracellular space,GO:0005634~nucleus,	GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR003107:HAT,IPR011990:TPR-like_helical_dom_sf,IPR019607:Putative_zinc-finger_domain,IPR039278:Red1,				SM00386:HAT,		KW-0539~Nucleus,		KW-0175~Coiled coil,KW-0677~Repeat,KW-0802~TPR repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,REGION:Disordered,REPEAT:TPR 1,REPEAT:TPR 2,REPEAT:TPR 3,REPEAT:TPR 4,REPEAT:TPR 5,REPEAT:TPR 6,REPEAT:TPR 7,ZN_FING:C3H1-type,
ZGPAT	zinc finger CCCH-type and G-patch domain containing(ZGPAT)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0007175~negative regulation of epidermal growth factor-activated receptor activity,GO:0045892~negative regulation of transcription, DNA-templated,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005886~plasma membrane,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003676~nucleic acid binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0043565~sequence-specific DNA binding,GO:0046872~metal ion binding,	IPR000467:G_patch_dom,IPR000571:Znf_CCCH,IPR036855:Znf_CCCH_sf,IPR041367:Znf-CCCH_4,IPR043560:ZGPAT,				SM00356:ZnF_C3H1,SM00443:G_patch,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,KW-0678~Repressor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Basic and acidic residues,DOMAIN:C3H1-type,DOMAIN:G-patch,REGION:Disordered,ZN_FING:C3H1-type,
ZC3H11A	zinc finger CCCH-type containing 11A(ZC3H11A)	Homo sapiens			GO:0016973~poly(A)+ mRNA export from nucleus,	GO:0000346~transcription export complex,GO:0005654~nucleoplasm,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR000571:Znf_CCCH,IPR036855:Znf_CCCH_sf,IPR041686:Znf-CCCH_3,				SM00356:ZnF_C3H1,	KW-0509~mRNA transport,KW-0813~Transport,	KW-0539~Nucleus,		KW-0175~Coiled coil,KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:C3H1-type,DOMAIN:Zinc-finger CCCH,REGION:Disordered,ZN_FING:C3H1-type,ZN_FING:C3H1-type 1,ZN_FING:C3H1-type 2,ZN_FING:C3H1-type 3,
ZC3H12A	zinc finger CCCH-type containing 12A(ZC3H12A)	Homo sapiens			GO:0000184~nuclear-transcribed mRNA catabolic process, nonsense-mediated decay,GO:0001525~angiogenesis,GO:0001933~negative regulation of protein phosphorylation,GO:0002230~positive regulation of defense response to virus by host,GO:0002757~immune response-activating signal transduction,GO:0006915~apoptotic process,GO:0006954~inflammatory response,GO:0006974~cellular response to DNA damage stimulus,GO:0007399~nervous system development,GO:0010468~regulation of gene expression,GO:0010508~positive regulation of autophagy,GO:0010587~miRNA catabolic process,GO:0010595~positive regulation of endothelial cell migration,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0010656~negative regulation of muscle cell apoptotic process,GO:0010884~positive regulation of lipid storage,GO:0016579~protein deubiquitination,GO:0030154~cell differentiation,GO:0032088~negative regulation of NF-kappaB transcription factor activity,GO:0032689~negative regulation of interferon-gamma production,GO:0032691~negative regulation of interleukin-1 beta production,GO:0032715~negative regulation of interleukin-6 production,GO:0032720~negative regulation of tumor necrosis factor production,GO:0034599~cellular response to oxidative stress,GO:0042149~cellular response to glucose starvation,GO:0042307~positive regulation of protein import into nucleus,GO:0043031~negative regulation of macrophage activation,GO:0043124~negative regulation of I-kappaB kinase/NF-kappaB signaling,GO:0044828~negative regulation by host of viral genome replication,GO:0045019~negative regulation of nitric oxide biosynthetic process,GO:0045600~positive regulation of fat cell differentiation,GO:0045766~positive regulation of angiogenesis,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0050852~T cell receptor signaling pathway,GO:0051259~protein oligomerization,GO:0051607~defense response to virus,GO:0055118~negative regulation of cardiac muscle contraction,GO:0061014~positive regulation of mRNA catabolic process,GO:0061158~3'-UTR-mediated mRNA destabilization,GO:0071222~cellular response to lipopolysaccharide,GO:0071347~cellular response to interleukin-1,GO:0071356~cellular response to tumor necrosis factor,GO:0098586~cellular response to virus,GO:1900016~negative regulation of cytokine production involved in inflammatory response,GO:1900119~positive regulation of execution phase of apoptosis,GO:1900745~positive regulation of p38MAPK cascade,GO:1901223~negative regulation of NIK/NF-kappaB signaling,GO:1903003~positive regulation of protein deubiquitination,GO:1903936~cellular response to sodium arsenite,GO:1904637~cellular response to ionomycin,GO:1990869~cellular response to chemokine,GO:2000320~negative regulation of T-helper 17 cell differentiation,GO:2000379~positive regulation of reactive oxygen species metabolic process,GO:2000627~positive regulation of miRNA catabolic process,	GO:0000932~P-body,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005856~cytoskeleton,GO:0030867~rough endoplasmic reticulum membrane,GO:0032991~macromolecular complex,GO:0036464~cytoplasmic ribonucleoprotein granule,	GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0003730~mRNA 3'-UTR binding,GO:0004519~endonuclease activity,GO:0004521~endoribonuclease activity,GO:0004532~exoribonuclease activity,GO:0004540~ribonuclease activity,GO:0004843~thiol-dependent ubiquitin-specific protease activity,GO:0005515~protein binding,GO:0016787~hydrolase activity,GO:0035198~miRNA binding,GO:0035613~RNA stem-loop binding,GO:0035925~mRNA 3'-UTR AU-rich region binding,GO:0043022~ribosome binding,GO:0046872~metal ion binding,	IPR021869:RNase_Zc3h12_NYN,IPR040546:Rege-1_UBA-like,IPR040757:Regnase_1/ZC3H12_C,					KW-0037~Angiogenesis,KW-0051~Antiviral defense,KW-0053~Apoptosis,KW-0221~Differentiation,KW-0227~DNA damage,KW-0346~Stress response,KW-0391~Immunity,KW-0395~Inflammatory response,KW-0524~Neurogenesis,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0863~Zinc-finger,	KW-0460~Magnesium,KW-0479~Metal-binding,KW-0862~Zinc,	KW-0217~Developmental protein,KW-0238~DNA-binding,KW-0255~Endonuclease,KW-0378~Hydrolase,KW-0540~Nuclease,KW-0678~Repressor,KW-0694~RNA-binding,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,DOMAIN:Endoribonuclease Regnase 1/ZC3H12 C-terminal,DOMAIN:RNase NYN,DOMAIN:Rege-1 UBA-like,MUTAGEN:C->A: Does not inhibit antiviral effects.,MUTAGEN:C->G: Inhibits transcriptional activity; when associated with G-311.,MUTAGEN:C->G: Inhibits transcriptional activity; when associated with G-317.,MUTAGEN:C->R: Loss of interleukin IL17A mRNA instability. Reduces weakly pre-miRNA RNase activity. Attenuates miRNA silencing activity. Does not inhibit binding to Japanese encephalitis virus (JEV) and dengue virus (DEN) RNAs and weakly attenuates antiviral effects. Loss of HIV-1 antiviral activity.,MUTAGEN:D->A: Loss of pre-miRNA RNase activity, IL17A mRNA instability and antiviral effects; when associated with A-225. Loss of IL1B mRNA instability; when associated with N-141.,MUTAGEN:D->A: Loss of pre-miRNA RNase activity, IL17A mRNA instability and antiviral effects; when associated with A-226.,MUTAGEN:D->N: Abolishes RNase activity.,MUTAGEN:D->N: Loss of pre-miRNA RNase activity. Attenuates strongly miRNA silencing activity. Loss of interleukin IL17A and IL6 mRNA instabilities. Reduces angiogenic differentiation. Loss of RNase activity on JEV and DEN viral RNAs and antiviral effects. Loss of HIV-1 antiviral activity. Loss of IL1B mRNA instability; when associated with A-226.,MUTAGEN:K->G: Inhibits transcriptional activity; when associated with G-312.,MUTAGEN:K->G: Inhibits transcriptional activity; when associated with G-318.,MUTAGEN:N->A: No change in RNase activity.,MUTAGEN:R->A: Abolishes RNase activity.,REGION:Disordered,REGION:Necessary for interaction with TANK,REGION:Necessary for interaction with ZC3H12D,REGION:RNA binding,REGION:RNase,REGION:Ubiquitin association domain,ZN_FING:C3H1-type,
ZC3H15	zinc finger CCCH-type containing 15(ZC3H15)	Homo sapiens			GO:0002181~cytoplasmic translation,GO:0019221~cytokine-mediated signaling pathway,GO:0043547~positive regulation of GTPase activity,	GO:0005634~nucleus,GO:0005829~cytosol,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0045296~cadherin binding,GO:0046872~metal ion binding,	IPR000571:Znf_CCCH,IPR032378:ZC3H15/TMA46_C,IPR036855:Znf_CCCH_sf,				SM00356:ZnF_C3H1,		KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:C3H1-type,REGION:Disordered,REGION:Required for interaction with DRG1,ZN_FING:C3H1-type,ZN_FING:C3H1-type 1,ZN_FING:C3H1-type 2,
ZC3H18	zinc finger CCCH-type containing 18(ZC3H18)	Homo sapiens			GO:0050779~RNA destabilization,	GO:0016607~nuclear speck,GO:0032991~macromolecular complex,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0030674~protein binding, bridging,GO:0046872~metal ion binding,	IPR000571:Znf_CCCH,IPR036855:Znf_CCCH_sf,IPR041367:Znf-CCCH_4,				SM00356:ZnF_C3H1,		KW-0539~Nucleus,		KW-0175~Coiled coil,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:C3H1-type,DOMAIN:E3 ligase CCCH-type zinc finger,REGION:Disordered,ZN_FING:C3H1-type,
ZC3HAV1	zinc finger CCCH-type containing, antiviral 1(ZC3HAV1)	Homo sapiens			GO:0009615~response to virus,GO:0032481~positive regulation of type I interferon production,GO:0032727~positive regulation of interferon-alpha production,GO:0032728~positive regulation of interferon-beta production,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0045071~negative regulation of viral genome replication,GO:0045087~innate immune response,GO:0051607~defense response to virus,GO:0061014~positive regulation of mRNA catabolic process,GO:1900246~positive regulation of RIG-I signaling pathway,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0003723~RNA binding,GO:0003950~NAD+ ADP-ribosyltransferase activity,GO:0005515~protein binding,GO:0045296~cadherin binding,GO:0046872~metal ion binding,	IPR000571:Znf_CCCH,IPR004170:WWE-dom,IPR012317:Poly(ADP-ribose)pol_cat_dom,IPR036388:WH-like_DNA-bd_sf,IPR037197:WWE_dom_sf,IPR040954:Znf-CCCH_8,IPR041360:ZAP_HTH,					KW-0051~Antiviral defense,KW-0391~Immunity,KW-0399~Innate immunity,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:C3H1-type,DOMAIN:PARP catalytic,DOMAIN:WWE,MOTIF:Nuclear export signal,MOTIF:Nuclear localization signal,MUTAGEN:H->N: No effect on the structural inability to bind NAD(+); when associated with Y-830.,MUTAGEN:N->Y: No effect on the structural inability to bind NAD(+); when associated with N-810.,REGION:Binding to EXOSC5,REGION:Disordered,REGION:N-terminal domain,ZN_FING:C3H1-type,ZN_FING:C3H1-type 1,ZN_FING:C3H1-type 2,ZN_FING:C3H1-type 3,ZN_FING:C3H1-type 4,
ZDHHC3	zinc finger DHHC-type palmitoyltransferase 3(ZDHHC3)	Homo sapiens			GO:0006612~protein targeting to membrane,GO:0008277~regulation of G-protein coupled receptor protein signaling pathway,GO:0018230~peptidyl-L-cysteine S-palmitoylation,GO:0018345~protein palmitoylation,GO:0032230~positive regulation of synaptic transmission, GABAergic,GO:0036462~TRAIL-activated apoptotic signaling pathway,GO:0044873~lipoprotein localization to membrane,GO:0072657~protein localization to membrane,GO:0072659~protein localization to plasma membrane,GO:1902685~positive regulation of receptor localization to synapse,GO:1903546~protein localization to photoreceptor outer segment,	GO:0000139~Golgi membrane,GO:0005783~endoplasmic reticulum,GO:0005794~Golgi apparatus,GO:0016020~membrane,	GO:0016409~palmitoyltransferase activity,GO:0019705~protein-cysteine S-myristoyltransferase activity,GO:0019706~protein-cysteine S-palmitoyltransferase activity,GO:0042803~protein homodimerization activity,	IPR001594:Palmitoyltrfase_DHHC,						KW-0333~Golgi apparatus,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0012~Acyltransferase,KW-0808~Transferase,	KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,	ACT_SITE:S-palmitoyl cysteine intermediate,COMPBIAS:Acidic residues,DOMAIN:DHHC,DOMAIN:Palmitoyltransferase DHHC,LIPID:S-palmitoyl cysteine,MUTAGEN:C->S: Probable loss of protein-cysteine S-palmitoyltransferase activity. Loss of function in the TRAIL-activated apoptotic signaling pathway. No effect on binding of the TNFRSF10A substrate.,MUTAGEN:H->A: Probable loss of protein-cysteine S-palmitoyltransferase activity. Loss of function in the TRAIL-activated apoptotic signaling pathway.,MUTAGEN:V->VEKKNR,VKKKEK,VKGKRD: Impaired localization leading to localization to the endoplasmic reticulum.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
ZEB1	zinc finger E-box binding homeobox 1(ZEB1)	Homo sapiens		h_ctbp1Pathway:SUMOylation as a mechanism to modulate CtBP-dependent gene responses,	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007389~pattern specification process,GO:0010464~regulation of mesenchymal cell proliferation,GO:0010839~negative regulation of keratinocyte proliferation,GO:0014823~response to activity,GO:0017015~regulation of transforming growth factor beta receptor signaling pathway,GO:0030154~cell differentiation,GO:0030857~negative regulation of epithelial cell differentiation,GO:0030900~forebrain development,GO:0031667~response to nutrient levels,GO:0033081~regulation of T cell differentiation in thymus,GO:0043616~keratinocyte proliferation,GO:0045602~negative regulation of endothelial cell differentiation,GO:0045666~positive regulation of neuron differentiation,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048596~embryonic camera-type eye morphogenesis,GO:0048704~embryonic skeletal system morphogenesis,GO:0048752~semicircular canal morphogenesis,GO:0048856~anatomical structure development,GO:0051150~regulation of smooth muscle cell differentiation,GO:0051216~cartilage development,GO:0071230~cellular response to amino acid stimulus,GO:0071560~cellular response to transforming growth factor beta stimulus,GO:0090103~cochlea morphogenesis,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0070888~E-box binding,	IPR001356:Homeobox_dom,IPR008598:Di19_Zn-bd,IPR009057:Homeobox-like_sf,IPR013087:Znf_C2H2_type,IPR036236:Znf_C2H2_sf,	hsa05202:Transcriptional misregulation in cancer,hsa05206:MicroRNAs in cancer,hsa05215:Prostate cancer,	609141~Corneal dystrophy, posterior polymorphous, 3,613270~Corneal dystrophy, Fuchs endothelial, 6,		SM00355:ZnF_C2H2,SM00389:HOX,	KW-0221~Differentiation,KW-0524~Neurogenesis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-1212~Corneal dystrophy,	KW-0371~Homeobox,KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0238~DNA-binding,KW-0678~Repressor,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DNA_BIND:Homeobox; atypical,DOMAIN:C2H2-type,REGION:Disordered,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4; atypical,ZN_FING:C2H2-type 5,ZN_FING:C2H2-type 6,ZN_FING:C2H2-type 7; atypical,
ZNHIT3	zinc finger HIT-type containing 3(ZNHIT3)	Homo sapiens			GO:0000463~maturation of LSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA),GO:0000492~box C/D snoRNP assembly,GO:0006355~regulation of transcription, DNA-templated,GO:0048254~snoRNA localization,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0070761~pre-snoRNP complex,	GO:0005515~protein binding,GO:0046872~metal ion binding,GO:0046966~thyroid hormone receptor binding,	IPR007529:Znf_HIT,IPR013083:Znf_RING/FYVE/PHD,IPR048371:ZNHIT3_C,		260565~PEHO syndrome,				KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0887~Epilepsy,KW-0991~Intellectual disability,	KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0597~Phosphoprotein,	DOMAIN:HIT-type,DOMAIN:Zinc finger HIT,ZN_FING:HIT-type,
ZMYM2	zinc finger MYM-type containing 2(ZMYM2)	Homo sapiens			GO:0045892~negative regulation of transcription, DNA-templated,	GO:0005634~nucleus,GO:0005829~cytosol,GO:0016605~PML body,	GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0031624~ubiquitin conjugating enzyme binding,	IPR010507:Znf_MYM,IPR011017:TRASH_dom,IPR021893:DUF3504,		619522~Neurodevelopmental-craniofacial syndrome with variable renal and cardiac abnormalities,		SM00746:TRASH,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-0991~Intellectual disability,	KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:MYM-type,DOMAIN:TRASH,REGION:Disordered,SITE:Breakpoint for translocation to form ZMYM2-FGFR1,ZN_FING:MYM-type 1,ZN_FING:MYM-type 2,ZN_FING:MYM-type 3,ZN_FING:MYM-type 4,ZN_FING:MYM-type 5,ZN_FING:MYM-type 6,ZN_FING:MYM-type 7,ZN_FING:MYM-type 8,
ZMYM5	zinc finger MYM-type containing 5(ZMYM5)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,	GO:0005634~nucleus,	GO:0005515~protein binding,GO:0008270~zinc ion binding,	IPR010507:Znf_MYM,IPR011017:TRASH_dom,				SM00746:TRASH,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),MUTAGEN:D->G: Increases repression activity.,MUTAGEN:N->H: Abolishes interaction with ETV5. Abolished repression activity.,MUTAGEN:S->G: Abolishes interaction with ETV5. No effect on repression activity.,MUTAGEN:T->A: No effect on repression activity.,ZN_FING:MYM-type 1,ZN_FING:MYM-type 2,ZN_FING:MYM-type 3,ZN_FING:MYM-type 4,
ZRANB2	zinc finger RANBP2-type containing 2(ZRANB2)	Homo sapiens			GO:0006397~mRNA processing,GO:0008380~RNA splicing,	GO:0005654~nucleoplasm,	GO:0001530~lipopolysaccharide binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR001876:Znf_RanBP2,IPR017337:ZRANB2,IPR036443:Znf_RanBP2_sf,			PIRSF037956:UCP037956_ZnF_Ran,	SM00547:ZnF_RBZ,	KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,REGION:Disordered,REGION:Required for nuclear targeting,ZN_FING:RanBP2-type 1,ZN_FING:RanBP2-type 2,
ZFR	zinc finger RNA binding protein(ZFR)	Homo sapiens				GO:0005634~nucleus,GO:0005694~chromosome,GO:0005737~cytoplasm,	GO:0003676~nucleic acid binding,GO:0003677~DNA binding,GO:0003723~RNA binding,GO:0003725~double-stranded RNA binding,GO:0003727~single-stranded RNA binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,	IPR003604:Matrin/U1-like-C_Znf_C2H2,IPR006561:DZF_dom,IPR013087:Znf_C2H2_type,IPR036236:Znf_C2H2_sf,IPR043519:NT_sf,IPR049401:DZF_dom_N,IPR049402:DZF_dom_C,				SM00355:ZnF_C2H2,SM00451:ZnF_U1,SM00572:DZF,		KW-0158~Chromosome,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-0694~RNA-binding,KW-9996~Developmental protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:DZF,REGION:Disordered,
ZBTB1	zinc finger and BTB domain containing 1(ZBTB1)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001817~regulation of cytokine production,GO:0002682~regulation of immune system process,GO:0002711~positive regulation of T cell mediated immunity,GO:0006281~DNA repair,GO:0006338~chromatin remodeling,GO:0006974~cellular response to DNA damage stimulus,GO:0019985~translesion synthesis,GO:0030183~B cell differentiation,GO:0032825~positive regulation of natural killer cell differentiation,GO:0033077~T cell differentiation in thymus,GO:0034644~cellular response to UV,GO:0042789~mRNA transcription from RNA polymerase II promoter,GO:0045087~innate immune response,GO:0045582~positive regulation of T cell differentiation,GO:0048538~thymus development,GO:0051260~protein homooligomerization,GO:2000176~positive regulation of pro-T cell differentiation,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0016604~nuclear body,GO:0031965~nuclear membrane,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0005515~protein binding,GO:0042803~protein homodimerization activity,GO:0046872~metal ion binding,GO:0046982~protein heterodimerization activity,GO:0070530~K63-linked polyubiquitin binding,	IPR000210:BTB/POZ_dom,IPR011333:SKP1/BTB/POZ_sf,IPR013087:Znf_C2H2_type,IPR036236:Znf_C2H2_sf,				SM00225:BTB,SM00355:ZnF_C2H2,	KW-0221~Differentiation,KW-0227~DNA damage,KW-0234~DNA repair,KW-0391~Immunity,KW-0399~Innate immunity,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,KW-0678~Repressor,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:BTB,DOMAIN:C2H2-type,MUTAGEN:C->A: Abolishes binding to ubiquitin; Abolishes recruitment to DNA lesion sites.,MUTAGEN:I->N: Reduces sumoylation of Lys-328.,MUTAGEN:I->S: Reduces sumoylation of Lys-328.,MUTAGEN:K->R: Reduces sumoylation. Does not reduce transcriptional repressive activity. Inhibits sumoylation but does not reduce transcriptional repressive activity; when associated with R-265.,MUTAGEN:K->R: Reduces sumoylation. Inhibits transcriptional repressive activity. Inhibits sumoylation and reduces transcriptional repressive activity; when associated with R-328.,REGION:Disordered,ZN_FING:C2H2-type 1; atypical,ZN_FING:C2H2-type 2; atypical,ZN_FING:C2H2-type 4,ZN_FING:C2H2-type 5,ZN_FING:C2H2-type 6,ZN_FING:C2H2-type 7,ZN_FING:C2H2-type 8,ZN_FING:UBZ-type,
ZBTB38	zinc finger and BTB domain containing 38(ZBTB38)	Homo sapiens			GO:0006275~regulation of DNA replication,GO:0006355~regulation of transcription, DNA-templated,GO:0006974~cellular response to DNA damage stimulus,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005694~chromosome,GO:0072562~blood microparticle,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0008327~methyl-CpG binding,GO:0042803~protein homodimerization activity,GO:0046872~metal ion binding,	IPR000210:BTB/POZ_dom,IPR011333:SKP1/BTB/POZ_sf,IPR013087:Znf_C2H2_type,IPR036236:Znf_C2H2_sf,				SM00225:BTB,SM00355:ZnF_C2H2,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0158~Chromosome,KW-0539~Nucleus,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0238~DNA-binding,KW-0678~Repressor,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:BTB,DOMAIN:C2H2-type,REGION:Disordered,REGION:Interaction with CBFA2T3,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 10,ZN_FING:C2H2-type 2; degenerate,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4,ZN_FING:C2H2-type 5,ZN_FING:C2H2-type 6,ZN_FING:C2H2-type 7,ZN_FING:C2H2-type 8,ZN_FING:C2H2-type 9,
ZBTB8OS	zinc finger and BTB domain containing 8 opposite strand(ZBTB8OS)	Homo sapiens			GO:0006388~tRNA splicing, via endonucleolytic cleavage and ligation,GO:0008033~tRNA processing,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0072669~tRNA-splicing ligase complex,	GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR002804:Archease,IPR023572:Archease_dom,IPR036820:Archease_dom_sf,					KW-0819~tRNA processing,				KW-0106~Calcium,KW-0479~Metal-binding,		KW-0007~Acetylation,	DOMAIN:Archease,MUTAGEN:D->A: Abolishes ability to activate tRNA ligase activity of RTCB.,MUTAGEN:K->A: Abolishes ability to activate tRNA ligase activity of RTCB.,
ZMAT2	zinc finger matrin-type 2(ZMAT2)	Homo sapiens			GO:0000398~mRNA splicing, via spliceosome,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005681~spliceosomal complex,GO:0046540~U4/U6 x U5 tri-snRNP complex,GO:0071005~U2-type precatalytic spliceosome,	GO:0003676~nucleic acid binding,GO:0003677~DNA binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,	IPR003604:Matrin/U1-like-C_Znf_C2H2,IPR013087:Znf_C2H2_type,IPR022755:Znf_C2H2_jaz,IPR036236:Znf_C2H2_sf,IPR040107:Snu23,	hsa03040:Spliceosome,			SM00451:ZnF_U1,	KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,KW-0747~Spliceosome,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:U1-type,REGION:Disordered,ZN_FING:Matrin-type,
ZNF106	zinc finger protein 106(ZNF106)	Homo sapiens			GO:0008286~insulin receptor signaling pathway,	GO:0005730~nucleolus,GO:0005829~cytosol,GO:0016020~membrane,GO:0016607~nuclear speck,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0017124~SH3 domain binding,GO:0046872~metal ion binding,	IPR001680:WD40_rpt,IPR013087:Znf_C2H2_type,IPR015943:WD40/YVTN_repeat-like_dom_sf,IPR036236:Znf_C2H2_sf,IPR036322:WD40_repeat_dom_sf,IPR042622:Znf106,				SM00320:WD40,SM00355:ZnF_C2H2,		KW-0539~Nucleus,		KW-0677~Repeat,KW-0853~WD repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:C2H2-type,REGION:Disordered,REPEAT:WD,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,ZN_FING:C2H2-type 1; atypical,ZN_FING:C2H2-type 2; atypical,
ZNF131	zinc finger protein 131(ZNF131)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001817~regulation of cytokine production,GO:0002682~regulation of immune system process,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,	GO:0005654~nucleoplasm,GO:0045111~intermediate filament cytoskeleton,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0046872~metal ion binding,	IPR000210:BTB/POZ_dom,IPR011333:SKP1/BTB/POZ_sf,IPR013087:Znf_C2H2_type,IPR036236:Znf_C2H2_sf,				SM00225:BTB,SM00355:ZnF_C2H2,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,KW-0678~Repressor,	KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:BTB,DOMAIN:C2H2-type,MOTIF:Nuclear localization signal 1,MOTIF:Nuclear localization signal 2,MUTAGEN:K->R: No effect on sumoylation. Complete loss of CBX4 sumoylation; when associated with R-477 and R-601.,MUTAGEN:K->R: No effect on sumoylation; when associated with R-242 and R-281.,MUTAGEN:K->R: No effect on sumoylation; when associated with R-281 and R-289.,MUTAGEN:K->R: Significant loss of sumoylation. Complete loss of CBX4 sumoylation; when associated with R-477 and R-610.,MUTAGEN:K->R: Small loss of sumoylation. Complete loss of CBX4 sumoylation; when associated with R-601 and R-610.,REGION:Disordered,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4; degenerate,ZN_FING:C2H2-type 5,ZN_FING:C2H2-type 6,
ZNF146	zinc finger protein 146(ZNF146)	Homo sapiens			GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,	GO:0005634~nucleus,GO:0005730~nucleolus,GO:0005829~cytosol,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003677~DNA binding,GO:0005515~protein binding,GO:0008201~heparin binding,GO:0008270~zinc ion binding,	IPR013087:Znf_C2H2_type,IPR036236:Znf_C2H2_sf,				SM00355:ZnF_C2H2,		KW-0539~Nucleus,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,	KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),MUTAGEN:K->R: Induces a decrease in sumoylation. Induces a strong decrease but does not abolish sumoylation; when associated with R-157.,MUTAGEN:K->R: Induces a decrease in sumoylation. Induces a strong decrease but does not abolish sumoylation; when associated with R-169.,REGION:Interaction with TERF2IP,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 10,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4,ZN_FING:C2H2-type 5,ZN_FING:C2H2-type 6,ZN_FING:C2H2-type 7,ZN_FING:C2H2-type 8,ZN_FING:C2H2-type 9,
ZNF148	zinc finger protein 148(ZNF148)	Homo sapiens			GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006968~cellular defense response,GO:0007276~gamete generation,GO:0010629~negative regulation of gene expression,GO:0021762~substantia nigra development,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,	GO:0005654~nucleoplasm,GO:0005794~Golgi apparatus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0043565~sequence-specific DNA binding,GO:0046872~metal ion binding,	IPR013087:Znf_C2H2_type,IPR036236:Znf_C2H2_sf,		617260~Global developmental delay, absent or hypoplastic corpus callosum, and dysmorphic facies,		SM00355:ZnF_C2H2,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0242~Dwarfism,KW-0991~Intellectual disability,	KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,KW-0678~Repressor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:C2H2-type,REGION:Disordered,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4,
ZNF207	zinc finger protein 207(ZNF207)	Homo sapiens			GO:0000070~mitotic sister chromatid segregation,GO:0001578~microtubule bundle formation,GO:0007094~mitotic spindle assembly checkpoint,GO:0008608~attachment of spindle microtubules to kinetochore,GO:0046785~microtubule polymerization,GO:0050821~protein stabilization,GO:0051301~cell division,GO:0051983~regulation of chromosome segregation,GO:0090307~mitotic spindle assembly,	GO:0000776~kinetochore,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005819~spindle,GO:0005874~microtubule,GO:1990047~spindle matrix,	GO:0003677~DNA binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0008017~microtubule binding,GO:0008201~heparin binding,GO:0046872~metal ion binding,	IPR013087:Znf_C2H2_type,				SM00355:ZnF_C2H2,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0159~Chromosome partition,KW-0498~Mitosis,	KW-0137~Centromere,KW-0158~Chromosome,KW-0206~Cytoskeleton,KW-0493~Microtubule,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0995~Kinetochore,		KW-0677~Repeat,KW-0732~Signal,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,		COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:C2H2-type,MUTAGEN:EE->AA: In BuGZAA: Abolishes interaction with BUB3.,REGION:Disordered,REGION:GLEBS,REGION:Microtubule-binding region,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 2,
ZNF24	zinc finger protein 24(ZNF24)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0042552~myelination,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,	GO:0005634~nucleus,GO:0005654~nucleoplasm,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0043565~sequence-specific DNA binding,GO:0046872~metal ion binding,	IPR003309:SCAN_dom,IPR013087:Znf_C2H2_type,IPR036236:Znf_C2H2_sf,IPR038269:SCAN_sf,				SM00355:ZnF_C2H2,SM00431:SCAN,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,KW-0678~Repressor,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:SCAN box,MUTAGEN:K->A: Partial cytoplasmic accumulation.,MUTAGEN:R->A: Partial cytoplasmic accumulation.,REGION:Necessary and sufficient for nuclear localization,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4,
ZNF267	zinc finger protein 267(ZNF267)	Homo sapiens			GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,	GO:0005634~nucleus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0046872~metal ion binding,	IPR001909:KRAB,IPR013087:Znf_C2H2_type,IPR036051:KRAB_dom_sf,IPR036236:Znf_C2H2_sf,	hsa05168:Herpes simplex virus 1 infection,			SM00349:KRAB,SM00355:ZnF_C2H2,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,	KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:KRAB,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 10,ZN_FING:C2H2-type 11,ZN_FING:C2H2-type 12,ZN_FING:C2H2-type 13,ZN_FING:C2H2-type 14,ZN_FING:C2H2-type 15,ZN_FING:C2H2-type 2; atypical,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4,ZN_FING:C2H2-type 5,ZN_FING:C2H2-type 6,ZN_FING:C2H2-type 7,ZN_FING:C2H2-type 8,ZN_FING:C2H2-type 9,
ZNF292	zinc finger protein 292(ZNF292)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,	GO:0005634~nucleus,	GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0046872~metal ion binding,	IPR013087:Znf_C2H2_type,IPR036236:Znf_C2H2_sf,		619188~Intellectual developmental disorder, autosomal dominant 64,		SM00355:ZnF_C2H2,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-0991~Intellectual disability,KW-1268~Autism spectrum disorder,	KW-0175~Coiled coil,KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,DOMAIN:C2H2-type,REGION:Disordered,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 10,ZN_FING:C2H2-type 11,ZN_FING:C2H2-type 12,ZN_FING:C2H2-type 13,ZN_FING:C2H2-type 14,ZN_FING:C2H2-type 15,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4,ZN_FING:C2H2-type 5,ZN_FING:C2H2-type 6,ZN_FING:C2H2-type 7,ZN_FING:C2H2-type 8; degenerate,ZN_FING:C2H2-type 9,
ZNF331	zinc finger protein 331(ZNF331)	Homo sapiens			GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,	GO:0005634~nucleus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0008270~zinc ion binding,GO:0046872~metal ion binding,	IPR001909:KRAB,IPR013087:Znf_C2H2_type,IPR036051:KRAB_dom_sf,IPR036236:Znf_C2H2_sf,	hsa05168:Herpes simplex virus 1 infection,			SM00349:KRAB,SM00355:ZnF_C2H2,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,	KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:C2H2-type,DOMAIN:KRAB,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 10,ZN_FING:C2H2-type 11,ZN_FING:C2H2-type 12,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4,ZN_FING:C2H2-type 5,ZN_FING:C2H2-type 6,ZN_FING:C2H2-type 7,ZN_FING:C2H2-type 8,ZN_FING:C2H2-type 9,
ZNF384	zinc finger protein 384(ZNF384)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,	GO:0005634~nucleus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0046872~metal ion binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR013087:Znf_C2H2_type,IPR036236:Znf_C2H2_sf,				SM00355:ZnF_C2H2,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:C2H2-type,REGION:Disordered,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4,ZN_FING:C2H2-type 5,ZN_FING:C2H2-type 6,ZN_FING:C2H2-type 7,ZN_FING:C2H2-type 8,
ZNF394	zinc finger protein 394(ZNF394)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,	GO:0005634~nucleus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR001909:KRAB,IPR003309:SCAN_dom,IPR013087:Znf_C2H2_type,IPR036051:KRAB_dom_sf,IPR036236:Znf_C2H2_sf,IPR038269:SCAN_sf,				SM00349:KRAB,SM00355:ZnF_C2H2,SM00431:SCAN,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:KRAB,DOMAIN:SCAN box,REGION:Disordered,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4,ZN_FING:C2H2-type 5,ZN_FING:C2H2-type 6,ZN_FING:C2H2-type 7,
ZNF428	zinc finger protein 428(ZNF428)	Homo sapiens					GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR013087:Znf_C2H2_type,IPR038977:ZNF428,								KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:C2H2-type,REGION:Disordered,ZN_FING:C2H2-type,
ZNF581	zinc finger protein 581(ZNF581)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,	GO:0005634~nucleus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR013087:Znf_C2H2_type,IPR036236:Znf_C2H2_sf,				SM00355:ZnF_C2H2,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,		COMPBIAS:Polar residues,DOMAIN:C2H2-type,REGION:Disordered,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4,
ZNF622	zinc finger protein 622(ZNF622)	Homo sapiens			GO:0008631~intrinsic apoptotic signaling pathway in response to oxidative stress,GO:0033674~positive regulation of kinase activity,GO:0042273~ribosomal large subunit biogenesis,GO:0043065~positive regulation of apoptotic process,GO:0043410~positive regulation of MAPK cascade,GO:0046330~positive regulation of JNK cascade,	GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0030687~preribosome, large subunit precursor,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:1990275~preribosome binding,	IPR003604:Matrin/U1-like-C_Znf_C2H2,IPR013087:Znf_C2H2_type,IPR022755:Znf_C2H2_jaz,IPR036236:Znf_C2H2_sf,IPR040025:Znf622/Rei1/Reh1,IPR041661:ZN622/Rei1/Reh1_Znf-C2H2,				SM00355:ZnF_C2H2,SM00451:ZnF_U1,	KW-0690~Ribosome biogenesis,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Acidic residues,REGION:Disordered,ZN_FING:U1-type 1,ZN_FING:U1-type 2,
ZNF638	zinc finger protein 638(ZNF638)	Homo sapiens			GO:0008380~RNA splicing,GO:0043484~regulation of RNA splicing,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0016607~nuclear speck,GO:0043231~intracellular membrane-bounded organelle,	GO:0003676~nucleic acid binding,GO:0003690~double-stranded DNA binding,GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0008270~zinc ion binding,	IPR000504:RRM_dom,IPR000690:Matrin/U1-C_Znf_C2H2,IPR003604:Matrin/U1-like-C_Znf_C2H2,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR013087:Znf_C2H2_type,IPR022755:Znf_C2H2_jaz,IPR033096:ZNF638_RRM1/2,IPR035979:RBD_domain_sf,IPR036236:Znf_C2H2_sf,				SM00355:ZnF_C2H2,SM00360:RRM,SM00451:ZnF_U1,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0238~DNA-binding,KW-0678~Repressor,KW-0694~RNA-binding,	KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Matrin-type,DOMAIN:RRM,DOMAIN:RRM 1,DOMAIN:RRM 2,REGION:Disordered,REGION:Involved in localization to nuclear speckles,ZN_FING:Matrin-type,
ZNF644	zinc finger protein 644(ZNF644)	Homo sapiens			GO:0006357~regulation of transcription from RNA polymerase II promoter,	GO:0005634~nucleus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001222~transcription corepressor binding,GO:0046872~metal ion binding,	IPR013087:Znf_C2H2_type,IPR036236:Znf_C2H2_sf,		614167~Myopia 21, autosomal dominant,		SM00355:ZnF_C2H2,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,	KW-0175~Coiled coil,KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:C2H2-type,REGION:Disordered,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4,ZN_FING:C2H2-type 5,ZN_FING:C2H2-type 6,ZN_FING:C2H2-type 7,
ZNF706	zinc finger protein 706(ZNF706)	Homo sapiens			GO:0006417~regulation of translation,GO:0045892~negative regulation of transcription, DNA-templated,GO:1902455~negative regulation of stem cell population maintenance,	GO:0005634~nucleus,GO:0005737~cytoplasm,	GO:0046872~metal ion binding,	IPR007513:SERF-like_N,IPR013087:Znf_C2H2_type,IPR026939:ZNF706/At2g23090_sf,IPR045230:MBS1/2-like,					KW-0810~Translation regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0678~Repressor,		COMPBIAS:Polar residues,DOMAIN:C2H2-type,DOMAIN:Small EDRK-rich factor-like N-terminal,REGION:Disordered,ZN_FING:C2H2-type,
ZNF800	zinc finger protein 800(ZNF800)	Homo sapiens			GO:0006355~regulation of transcription, DNA-templated,GO:0031018~endocrine pancreas development,GO:0090425~acinar cell differentiation,	GO:0005634~nucleus,	GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0046872~metal ion binding,	IPR013087:Znf_C2H2_type,IPR036236:Znf_C2H2_sf,IPR039149:ZNF800/341,IPR041697:Znf-C2H2_11,				SM00355:ZnF_C2H2,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:C2H2-type,REGION:Disordered,ZN_FING:C2H2-type 1; degenerate,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4,ZN_FING:C2H2-type 5,ZN_FING:C2H2-type 6,ZN_FING:C2H2-type 7,
ZMPSTE24	zinc metallopeptidase STE24(ZMPSTE24)	Homo sapiens			GO:0001889~liver development,GO:0001942~hair follicle development,GO:0003007~heart morphogenesis,GO:0003229~ventricular cardiac muscle tissue development,GO:0003231~cardiac ventricle development,GO:0003417~growth plate cartilage development,GO:0006281~DNA repair,GO:0006508~proteolysis,GO:0006925~inflammatory cell apoptotic process,GO:0006998~nuclear envelope organization,GO:0007628~adult walking behavior,GO:0008340~determination of adult lifespan,GO:0008360~regulation of cell shape,GO:0010506~regulation of autophagy,GO:0010906~regulation of glucose metabolic process,GO:0019216~regulation of lipid metabolic process,GO:0030282~bone mineralization,GO:0030327~prenylated protein catabolic process,GO:0030500~regulation of bone mineralization,GO:0032006~regulation of TOR signaling,GO:0032350~regulation of hormone metabolic process,GO:0035264~multicellular organism growth,GO:0040014~regulation of multicellular organism growth,GO:0043007~maintenance of rDNA,GO:0043516~regulation of DNA damage response, signal transduction by p53 class mediator,GO:0044029~hypomethylation of CpG island,GO:0044030~regulation of DNA methylation,GO:0044255~cellular lipid metabolic process,GO:0048145~regulation of fibroblast proliferation,GO:0048538~thymus development,GO:0050688~regulation of defense response to virus,GO:0050905~neuromuscular process,GO:0055013~cardiac muscle cell development,GO:0060307~regulation of ventricular cardiac muscle cell membrane repolarization,GO:0060993~kidney morphogenesis,GO:0061337~cardiac conduction,GO:0061762~CAMKK-AMPK signaling cascade,GO:0070302~regulation of stress-activated protein kinase signaling cascade,GO:0071480~cellular response to gamma radiation,GO:0071586~CAAX-box protein processing,GO:0072423~response to DNA damage checkpoint signaling,GO:1903463~regulation of mitotic cell cycle DNA replication,GO:1903799~negative regulation of production of miRNAs involved in gene silencing by miRNA,GO:1990036~calcium ion import into sarcoplasmic reticulum,GO:2000730~regulation of termination of RNA polymerase I transcription,GO:2000772~regulation of cellular senescence,	GO:0005637~nuclear inner membrane,GO:0005789~endoplasmic reticulum membrane,GO:0016020~membrane,GO:0031901~early endosome membrane,GO:0031902~late endosome membrane,GO:0032991~macromolecular complex,GO:0070062~extracellular exosome,	GO:0003690~double-stranded DNA binding,GO:0004222~metalloendopeptidase activity,GO:0005515~protein binding,GO:0008235~metalloexopeptidase activity,GO:0046872~metal ion binding,	IPR001915:Peptidase_M48,IPR027057:CAXX_Prtase_1,IPR032456:Peptidase_M48_N,	hsa00900:Terpenoid backbone biosynthesis,	275210~Restrictive dermopathy 1,608612~Mandibuloacral dysplasia with type B lipodystrophy,				KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0539~Nucleus,KW-0967~Endosome,	KW-0225~Disease variant,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0378~Hydrolase,KW-0482~Metalloprotease,KW-0645~Protease,KW-0930~Antiviral protein,		DOMAIN:CAAX prenyl protease 1 N-terminal,MUTAGEN:E->A: Loss of catalytic activity but not viral restriction.,MUTAGEN:H->A: Loss of catalytic activity but not viral restriction.,TOPO_DOM:Lumenal,TOPO_DOM:Nuclear,TRANSMEM:Helical,
